data_1i18_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1i18 _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.541 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.3 t . . . . . 0 N--CA 1.495 1.804 0 CA-C-O 121.682 0.753 . . . . 0.0 111.026 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -59.98 -40.02 87.7 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.574 -0.704 . . . . 0.0 110.56 174.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.541 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -170.66 -176.95 40.37 Favored Glycine 0 N--CA 1.495 2.588 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.118 -174.634 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.48 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 21.4 p -117.58 169.83 9.24 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.872 -1.37 . . . . 0.0 111.13 -175.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.525 ' CB ' ' CG1' ' A' ' 82' ' ' VAL . . . -135.13 147.8 49.58 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.684 -0.635 . . . . 0.0 109.356 -179.033 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 34.0 tttt -103.57 115.74 31.07 Favored 'General case' 0 C--N 1.293 -1.856 0 O-C-N 121.046 -1.034 . . . . 0.0 110.269 -179.583 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.518 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 12.0 tp -59.87 126.45 27.62 Favored 'General case' 0 C--N 1.298 -1.653 0 O-C-N 120.892 -1.13 . . . . 0.0 108.823 172.736 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.601 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -126.91 -29.02 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 O-C-N 121.438 -0.789 . . . . 0.0 110.017 -179.094 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.04 141.91 26.88 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 119.058 -1.057 . . . . 0.0 111.606 -178.748 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.584 HG12 ' CD2' ' A' ' 24' ' ' HIS . 14.2 mt -109.08 130.52 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.052 -1.03 . . . . 0.0 110.206 170.786 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.479 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 81.6 m-20 -107.71 115.46 30.19 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.291 -0.88 . . . . 0.0 109.963 174.121 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -104.21 114.4 28.61 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.969 -1.082 . . . . 0.0 110.591 -176.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.472 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.0 OUTLIER -113.67 128.97 25.14 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.141 -0.974 . . . . 0.0 109.203 175.343 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.1 Cg_endo -52.37 -18.37 7.84 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 O-C-N 123.831 1.437 . . . . 0.0 110.944 -179.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.587 ' ND2' ' N ' ' A' ' 20' ' ' ASN . 0.3 OUTLIER -92.3 -33.54 14.58 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.135 -0.978 . . . . 0.0 108.939 178.309 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.545 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 84.1 m-85 -156.16 150.24 25.33 Favored 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.358 0.599 . . . . 0.0 110.14 179.792 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.452 ' NH1' ' CD2' ' A' ' 68' ' ' LEU . 60.1 ttt180 -90.89 144.24 25.89 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 120.744 -1.223 . . . . 0.0 109.775 175.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.479 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 85.0 m -129.17 137.69 51.31 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.472 -0.767 . . . . 0.0 109.822 -177.09 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.584 ' CD2' HG12 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.25 137.04 49.81 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 120.967 -1.083 . . . . 0.0 111.141 179.394 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.525 ' CG2' ' OG ' ' A' ' 60' ' ' SER . 15.6 t -119.05 134.91 61.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.037 -1.039 . . . . 0.0 110.641 -177.279 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.465 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 16.9 m -117.13 170.93 6.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 CA-C-O 121.088 0.47 . . . . 0.0 110.112 177.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.574 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 8.7 tt0 -107.42 116.58 32.18 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.486 ' N ' ' ND2' ' A' ' 57' ' ' ASN . 9.3 tp -81.36 128.59 69.59 Favored Pre-proline 0 C--N 1.295 -1.766 0 O-C-N 121.307 -0.87 . . . . 0.0 109.978 -171.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.478 ' HD2' HD12 ' A' ' 28' ' ' LEU . 33.6 Cg_endo -68.0 176.83 4.9 Favored 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.903 1.475 . . . . 0.0 110.88 -179.376 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -60.02 -40.02 87.85 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.255 -0.903 . . . . 0.0 111.261 -174.251 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.568 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.85 0.83 56.81 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.75 -1.219 . . . . 0.0 110.936 -173.912 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.568 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.9 mmm -113.23 -9.63 13.44 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 120.839 -1.163 . . . . 0.0 110.074 170.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.523 ' CD2' ' HB2' ' A' ' 57' ' ' ASN . 19.9 mt -70.02 -23.18 63.08 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.169 -0.957 . . . . 0.0 110.052 176.263 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -94.47 129.94 41.04 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.469 -0.769 . . . . 0.0 110.478 -177.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.98 -43.53 1.71 Allowed Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.909 -1.139 . . . . 0.0 110.396 174.126 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.479 HD11 HD22 ' A' ' 28' ' ' LEU . 7.1 tt -69.94 149.16 48.07 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.836 -1.391 . . . . 0.0 110.855 -174.221 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 19.3 pt-20 -150.42 170.02 20.06 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.512 -0.742 . . . . 0.0 109.682 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.532 ' CG2' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -65.82 153.51 41.7 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.024 -1.048 . . . . 0.0 110.235 179.779 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.41 -2.15 63.32 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -178.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.46 ' HB2' HG23 ' A' ' 51' ' ' VAL . . . -78.3 158.07 28.98 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.254 -1.145 . . . . 0.0 109.552 176.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -100.31 107.74 19.61 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.026 -1.07 . . . . 0.0 109.876 175.653 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.58 HG13 ' CE1' ' A' ' 44' ' ' HIS . 2.1 t -93.65 133.23 35.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 121.321 -0.862 . . . . 0.0 108.896 173.305 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.467 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -97.98 120.0 37.59 Favored 'General case' 0 C--N 1.295 -1.763 0 C-N-CA 119.109 -1.036 . . . . 0.0 109.107 172.174 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.58 ' CE1' HG13 ' A' ' 42' ' ' VAL . 0.4 OUTLIER -89.7 106.99 18.83 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 178.929 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 54.01 14.12 0.66 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.444 -0.785 . . . . 0.0 111.048 -168.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.483 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 117.87 2.83 16.37 Favored Glycine 0 N--CA 1.489 2.178 0 C-N-CA 119.527 -1.32 . . . . 0.0 110.798 172.559 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.488 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 33.2 t -98.65 109.9 22.58 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.521 -1.576 . . . . 0.0 109.47 174.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.449 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 31.0 p -76.8 130.26 37.41 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.978 -1.076 . . . . 0.0 111.182 -170.251 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.529 ' CD1' ' HB3' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -146.54 161.23 40.93 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.573 -0.704 . . . . 0.0 109.333 173.123 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.411 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 22.9 m -100.81 153.02 19.82 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.587 -1.321 . . . . 0.0 111.105 -171.199 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.551 ' CG1' HG13 ' A' ' 59' ' ' VAL . 24.6 t -76.68 113.77 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.839 -0.538 . . . . 0.0 110.186 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.54 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 27.7 p -70.26 -41.55 73.3 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.24 -0.912 . . . . 0.0 109.518 174.146 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.51 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 20.4 pt-20 -160.12 160.09 32.59 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 119.543 -0.863 . . . . 0.0 110.813 176.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.532 HD11 ' CG2' ' A' ' 38' ' ' THR . 8.9 mt -110.58 130.05 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.268 -0.895 . . . . 0.0 109.962 173.653 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.462 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 3.2 m-80 -103.33 63.22 0.8 Allowed 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 120.071 -0.652 . . . . 0.0 109.509 179.25 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.36 -117.43 4.79 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 108.961 -1.655 . . . . 0.0 108.961 -173.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.523 ' HB2' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -77.14 -20.63 55.29 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 120.965 -1.314 . . . . 0.0 108.803 175.45 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.601 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 9.1 m170 -75.56 158.7 32.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.28 -0.888 . . . . 0.0 110.141 -177.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.64 ' CG1' ' CZ ' ' A' ' 61' ' ' PHE . 55.1 t -140.41 123.82 17.26 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 C-N-CA 119.143 -1.023 . . . . 0.0 110.674 171.478 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.525 ' OG ' ' CG2' ' A' ' 25' ' ' VAL . 1.1 t -89.82 134.17 34.33 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.391 -0.818 . . . . 0.0 109.381 175.505 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.64 ' CZ ' ' CG1' ' A' ' 59' ' ' VAL . 89.1 m-85 -115.67 159.87 20.79 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.224 -0.922 . . . . 0.0 110.277 175.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.54 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 28.3 p-10 -93.02 149.09 21.46 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.187 -0.945 . . . . 0.0 111.129 178.542 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.541 HD21 ' CD1' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -154.18 117.69 4.61 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -175.127 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.515 ' HB2' ' CB ' ' A' ' 67' ' ' THR . 54.1 mtp -70.33 139.38 52.0 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.911 -1.118 . . . . 0.0 109.981 179.149 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.481 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 45.0 tptt -59.93 -49.91 75.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.163 -0.961 . . . . 0.0 110.274 -179.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.441 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.5 tt0 -64.97 -39.99 94.31 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.753 -1.217 . . . . 0.0 109.859 177.245 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.515 ' CB ' ' HB2' ' A' ' 64' ' ' MET . 85.5 m -59.87 -35.67 75.3 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.934 -1.104 . . . . 0.0 109.397 173.066 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.522 HD11 ' CD2' ' A' ' 63' ' ' LEU . 20.0 tp -62.84 -46.71 86.63 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.186 -0.946 . . . . 0.0 109.756 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 71.5 ttt-85 -69.98 -39.17 76.11 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.484 -0.76 . . . . 0.0 110.136 178.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.51 HG22 HG22 ' A' ' 71' ' ' THR . 1.1 tt -66.81 -40.02 84.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.366 -0.833 . . . . 0.0 109.337 -179.24 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.51 HG22 HG22 ' A' ' 70' ' ' ILE . 65.0 p -86.26 -173.65 4.66 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 174.244 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.4 t30 -104.18 25.04 10.53 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 170.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.541 ' CD1' HD21 ' A' ' 63' ' ' LEU . 87.9 mt -69.96 -40.0 75.69 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.027 -1.046 . . . . 0.0 110.008 177.298 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.513 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -47.7 -21.93 1.65 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.5 p-10 -67.11 -17.83 65.04 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.938 -1.33 . . . . 0.0 110.823 -174.221 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.0 mt -60.01 142.96 53.02 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.118 -0.989 . . . . 0.0 111.068 -175.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.485 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 54.6 mttp -140.03 139.23 35.93 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.709 -0.619 . . . . 0.0 109.762 174.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.562 ' CG2' HG13 ' A' ' 15' ' ' ILE . 15.8 t -61.02 153.08 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.862 -1.149 . . . . 0.0 110.351 -178.286 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.02 -15.03 58.99 Favored Glycine 0 N--CA 1.483 1.801 0 N-CA-C 108.716 -1.753 . . . . 0.0 108.716 -177.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.417 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 25.1 t0 -96.21 169.5 9.9 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.428 -1.042 . . . . 0.0 109.601 176.478 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.5 m95 -115.97 164.32 14.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.913 -1.117 . . . . 0.0 110.351 175.244 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.525 ' CG1' ' CB ' ' A' ' 10' ' ' ALA . 1.7 p -129.62 144.39 38.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.564 -0.71 . . . . 0.0 109.949 -176.518 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.482 ' HB2' ' HB3' ' B' ' 72' ' ' ASN . 2.6 m-20 -70.95 105.24 3.21 Favored 'General case' 0 C--N 1.293 -1.862 0 O-C-N 121.077 -1.014 . . . . 0.0 109.266 170.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.48 ' CG2' ' C ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -108.89 138.92 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 120.535 -1.353 . . . . 0.0 111.153 -176.063 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -137.15 147.02 45.68 Favored 'General case' 0 N--CA 1.495 1.82 0 C-N-CA 120.293 -0.563 . . . . 0.0 110.193 179.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 73.9 ttt-85 -85.22 130.65 34.56 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.232 -0.917 . . . . 0.0 111.309 -174.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 1.653 0 O-C-N 121.274 -0.891 . . . . 0.0 110.047 175.803 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.542 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.3 t . . . . . 0 N--CA 1.494 1.748 0 CA-C-O 121.646 0.736 . . . . 0.0 111.093 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -59.95 -39.91 87.18 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.59 -0.693 . . . . 0.0 110.62 174.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.542 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -170.88 -177.2 40.65 Favored Glycine 0 N--CA 1.495 2.616 0 C-N-CA 119.201 -1.476 . . . . 0.0 110.222 -174.534 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.487 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 21.4 p -117.48 169.8 9.24 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.896 -1.355 . . . . 0.0 111.207 -175.611 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.53 ' CB ' ' CG1' ' B' ' 82' ' ' VAL . . . -135.04 147.96 49.77 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 -179.066 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.588 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 34.0 tttt -103.78 115.84 31.22 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 121.15 -0.969 . . . . 0.0 110.16 -179.535 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.514 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 12.0 tp -59.99 126.31 27.05 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 120.96 -1.088 . . . . 0.0 108.843 172.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.604 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -126.67 -29.15 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.03 -179.087 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.02 141.83 26.82 Favored 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.25 -0.98 . . . . 0.0 111.568 -178.623 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.583 HG12 ' CD2' ' B' ' 24' ' ' HIS . 14.2 mt -108.96 130.64 61.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.046 -1.034 . . . . 0.0 110.232 170.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.49 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 81.0 m-20 -107.98 115.6 30.42 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.369 -0.832 . . . . 0.0 109.746 174.239 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -104.18 114.42 28.65 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.042 -1.037 . . . . 0.0 110.547 -176.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . 0.466 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.0 OUTLIER -113.75 128.9 25.23 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.358 -0.839 . . . . 0.0 109.183 175.353 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.1 Cg_endo -52.37 -18.42 7.93 Favored 'Trans proline' 0 C--N 1.304 -1.809 0 O-C-N 123.858 1.451 . . . . 0.0 110.906 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.564 ' ND2' ' N ' ' B' ' 20' ' ' ASN . 0.3 OUTLIER -92.22 -33.9 14.49 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.06 -1.025 . . . . 0.0 108.769 178.413 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.548 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 84.2 m-85 -155.89 150.25 25.76 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.196 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . 0.453 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 60.0 ttt180 -90.87 144.14 26.0 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.909 -1.12 . . . . 0.0 109.797 175.639 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.49 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 82.7 m -129.14 137.74 51.37 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.539 -0.726 . . . . 0.0 109.826 -177.135 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.583 ' CD2' HG12 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.18 136.94 49.8 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.029 -1.045 . . . . 0.0 111.054 179.573 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.531 ' CG2' ' OG ' ' B' ' 60' ' ' SER . 15.6 t -118.98 135.09 60.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.116 -0.99 . . . . 0.0 110.734 -177.404 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.476 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 17.2 m -117.42 170.91 6.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 C-N-CA 120.444 -0.502 . . . . 0.0 109.99 178.072 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.573 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 8.7 tt0 -107.36 116.53 32.1 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.594 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.485 ' N ' ' ND2' ' B' ' 57' ' ' ASN . 9.3 tp -81.2 128.49 70.4 Favored Pre-proline 0 C--N 1.295 -1.781 0 O-C-N 121.228 -0.92 . . . . 0.0 110.05 -171.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.467 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 33.8 Cg_endo -67.99 176.82 4.9 Favored 'Trans proline' 0 C--N 1.308 -1.567 0 O-C-N 123.9 1.474 . . . . 0.0 110.87 -179.392 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.414 ' HA ' HD11 ' B' ' 33' ' ' LEU . 96.1 m-20 -60.02 -39.99 87.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.314 -0.866 . . . . 0.0 111.255 -174.211 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.574 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.82 0.84 56.78 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.733 -1.229 . . . . 0.0 110.974 -173.949 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.574 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.8 mmm -113.28 -9.57 13.41 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.824 -1.172 . . . . 0.0 110.143 170.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.506 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 20.0 mt -69.98 -23.33 63.14 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.232 -0.918 . . . . 0.0 109.994 176.189 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 94.3 m-20 -94.44 129.89 41.01 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.383 -0.823 . . . . 0.0 110.57 -177.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.96 -43.47 1.73 Allowed Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.885 -1.15 . . . . 0.0 110.48 174.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . 0.505 HD21 ' N ' ' B' ' 37' ' ' GLU . 7.2 tt -70.09 149.15 47.92 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.926 -1.338 . . . . 0.0 110.81 -174.216 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . 0.505 ' N ' HD21 ' B' ' 36' ' ' LEU . 19.3 pt-20 -150.39 170.01 20.07 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.515 -0.741 . . . . 0.0 109.738 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.52 ' CG2' HD13 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -65.8 153.38 42.02 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.992 -1.068 . . . . 0.0 110.236 179.832 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.41 -2.06 63.62 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.468 ' HB1' ' O ' ' B' ' 37' ' ' GLU . . . -78.42 157.89 28.87 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.259 -1.142 . . . . 0.0 109.558 176.713 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 41' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -99.97 107.67 19.7 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.894 -1.128 . . . . 0.0 109.994 175.625 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.571 ' HB ' ' CE2' ' B' ' 61' ' ' PHE . 2.1 t -93.66 133.31 35.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.358 -0.839 . . . . 0.0 108.874 173.322 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.465 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -97.99 120.05 37.69 Favored 'General case' 0 C--N 1.296 -1.738 0 C-N-CA 119.162 -1.015 . . . . 0.0 109.055 172.184 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.564 ' CE1' HG12 ' B' ' 42' ' ' VAL . 0.4 OUTLIER -89.75 106.78 18.69 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.427 -0.796 . . . . 0.0 108.994 178.876 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 54.13 14.21 0.7 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.396 -0.815 . . . . 0.0 111.043 -168.537 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.483 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 117.65 3.21 16.58 Favored Glycine 0 N--CA 1.488 2.142 0 C-N-CA 119.545 -1.312 . . . . 0.0 110.823 172.452 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.487 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 33.5 t -98.82 110.02 22.69 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.521 -1.576 . . . . 0.0 109.397 174.702 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . 0.449 ' O ' ' SG ' ' B' ' 48' ' ' CYS . 31.2 p -76.82 130.35 37.51 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.032 -1.043 . . . . 0.0 111.184 -170.32 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.528 ' CD1' ' HB3' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -146.7 161.17 41.15 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.62 -0.675 . . . . 0.0 109.304 173.105 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 50' ' ' THR . . . . . 0.424 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 22.9 m -100.69 153.13 19.69 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.722 -1.236 . . . . 0.0 111.06 -171.099 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.553 ' CG1' HG13 ' B' ' 59' ' ' VAL . 24.8 t -76.8 113.74 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.694 -0.629 . . . . 0.0 110.268 -179.55 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.535 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 28.0 p -70.25 -41.55 73.35 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.196 -0.94 . . . . 0.0 109.524 174.262 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.518 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 20.5 pt-20 -160.18 160.04 32.36 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.325 -0.859 . . . . 0.0 110.805 176.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.52 HD13 ' CG2' ' B' ' 38' ' ' THR . 9.0 mt -110.52 130.02 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.307 -0.87 . . . . 0.0 109.945 173.773 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.477 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 3.2 m-80 -103.33 63.13 0.79 Allowed 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 120.018 -0.673 . . . . 0.0 109.524 179.274 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.55 -117.53 4.79 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 108.884 -1.686 . . . . 0.0 108.884 -173.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.506 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -77.04 -20.79 55.47 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.1 -1.235 . . . . 0.0 108.814 175.471 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.604 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 9.2 m170 -75.33 158.51 32.69 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.423 -0.798 . . . . 0.0 110.223 -178.099 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.633 ' CG1' ' CZ ' ' B' ' 61' ' ' PHE . 54.9 t -140.33 123.7 17.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 C-N-CA 119.126 -1.029 . . . . 0.0 110.677 171.593 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.531 ' OG ' ' CG2' ' B' ' 25' ' ' VAL . 1.1 t -89.76 134.31 34.24 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.448 -0.783 . . . . 0.0 109.406 175.501 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.633 ' CZ ' ' CG1' ' B' ' 59' ' ' VAL . 89.2 m-85 -115.74 159.89 20.81 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.213 175.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.535 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 28.3 p-10 -92.96 149.15 21.43 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.163 -0.961 . . . . 0.0 111.059 178.539 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.528 HD21 ' CD1' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -154.28 117.77 4.59 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -175.23 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.523 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 54.3 mtp -70.4 139.42 51.87 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.989 -1.07 . . . . 0.0 110.042 179.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.479 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 45.1 tptt -59.92 -49.88 75.95 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.188 -0.945 . . . . 0.0 110.328 -179.567 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . 0.453 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 86.5 tt0 -64.88 -40.0 94.43 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.868 -1.145 . . . . 0.0 109.953 177.17 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.523 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 85.0 m -60.05 -35.79 75.9 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.942 -1.099 . . . . 0.0 109.328 173.172 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.525 HD13 ' CD2' ' B' ' 63' ' ' LEU . 19.8 tp -62.61 -46.64 87.36 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.226 -0.921 . . . . 0.0 109.85 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 71.5 ttt-85 -70.07 -39.24 75.74 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.474 -0.766 . . . . 0.0 110.075 178.156 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.488 HG23 HG23 ' B' ' 71' ' ' THR . 1.1 tt -66.78 -40.04 85.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.466 -0.771 . . . . 0.0 109.302 -179.228 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.488 HG23 HG23 ' B' ' 70' ' ' ILE . 65.9 p -86.21 -173.53 4.6 Favored 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 120.035 -0.666 . . . . 0.0 109.324 174.265 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.482 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 4.4 t30 -104.32 25.21 10.41 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 170.244 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.528 ' CD1' HD21 ' B' ' 63' ' ' LEU . 87.6 mt -70.06 -39.97 75.36 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.02 -1.05 . . . . 0.0 109.985 177.223 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.499 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -47.92 -21.68 1.73 Allowed Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 -179.408 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.6 p-10 -67.18 -17.8 64.99 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.911 -1.347 . . . . 0.0 110.792 -174.279 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.507 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 97.0 mt -59.97 142.9 53.01 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.139 -0.976 . . . . 0.0 111.045 -175.596 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.486 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 54.6 mttp -140.01 139.28 35.97 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.652 -0.655 . . . . 0.0 109.768 174.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.555 ' CG2' HG13 ' B' ' 15' ' ' ILE . 15.9 t -61.13 153.06 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.964 -1.085 . . . . 0.0 110.322 -178.176 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.01 -14.82 59.54 Favored Glycine 0 N--CA 1.484 1.88 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.425 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 25.0 t0 -96.31 169.4 9.96 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.463 -1.022 . . . . 0.0 109.626 176.326 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.588 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.5 m95 -116.05 164.18 14.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.996 -1.065 . . . . 0.0 110.327 175.33 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.53 ' CG1' ' CB ' ' B' ' 10' ' ' ALA . 1.6 p -129.46 144.49 37.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.613 -0.679 . . . . 0.0 110.031 -176.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.449 ' HB2' ' HB3' ' A' ' 72' ' ' ASN . 2.5 m-20 -70.91 105.08 3.14 Favored 'General case' 0 C--N 1.292 -1.892 0 O-C-N 121.164 -0.96 . . . . 0.0 109.301 170.512 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.487 ' CG2' ' C ' ' B' ' 9' ' ' THR . 0.0 OUTLIER -108.84 138.93 33.52 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 120.614 -1.304 . . . . 0.0 111.099 -175.972 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -137.15 147.05 45.7 Favored 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.19 179.385 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 74.0 ttt-85 -85.16 130.7 34.56 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.175 -0.953 . . . . 0.0 111.278 -174.619 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 1.761 0 O-C-N 121.376 -0.827 . . . . 0.0 110.001 175.76 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.53 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 1.3 t . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 121.531 0.682 . . . . 0.0 110.061 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.508 ' OE1' ' NH1' ' A' ' 86' ' ' ARG . 97.2 mt-30 -70.24 -30.03 66.98 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.492 -0.755 . . . . 0.0 111.405 -178.495 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.53 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -148.44 176.13 27.39 Favored Glycine 0 N--CA 1.495 2.579 0 C-N-CA 118.687 -1.721 . . . . 0.0 110.271 -173.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.463 ' O ' ' HG3' ' A' ' 29' ' ' PRO . 2.9 p -123.28 171.3 9.49 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.153 -1.204 . . . . 0.0 110.574 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.536 ' CB ' HG12 ' A' ' 82' ' ' VAL . . . -141.11 150.07 42.37 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.46 -0.775 . . . . 0.0 109.401 -175.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 26.3 tttt -111.53 116.23 30.52 Favored 'General case' 0 C--N 1.297 -1.704 0 O-C-N 121.059 -1.025 . . . . 0.0 110.334 179.875 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.5 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 9.9 tp -58.43 124.78 20.74 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.013 -1.054 . . . . 0.0 108.931 173.1 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.633 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.0 OUTLIER -118.24 -29.29 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 O-C-N 121.359 -0.838 . . . . 0.0 109.597 178.751 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.43 149.96 27.37 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.057 -1.057 . . . . 0.0 111.639 -178.381 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.583 HG12 ' CD2' ' A' ' 24' ' ' HIS . 19.5 mt -112.09 132.24 61.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.158 -0.964 . . . . 0.0 109.998 172.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.494 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 86.3 m-20 -108.65 116.12 31.38 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.305 -0.872 . . . . 0.0 109.861 174.786 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -106.13 108.73 20.4 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.064 -1.023 . . . . 0.0 110.534 -176.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.469 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -102.14 128.55 28.24 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.069 -1.019 . . . . 0.0 108.924 172.66 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_endo -50.47 -29.61 24.86 Favored 'Trans proline' 0 C--N 1.303 -1.865 0 O-C-N 123.834 1.439 . . . . 0.0 110.453 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.482 ' C ' ' CG ' ' A' ' 21' ' ' PHE . 12.8 m-80 -77.87 -39.99 41.54 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.181 -0.949 . . . . 0.0 110.021 176.069 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.482 ' CG ' ' C ' ' A' ' 20' ' ' ASN . 51.0 m-85 -151.18 150.23 30.38 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.342 -0.849 . . . . 0.0 109.925 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.464 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 60.0 ttt180 -90.42 145.24 25.09 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.714 -1.241 . . . . 0.0 110.012 176.823 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.494 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 91.5 m -129.64 138.19 51.08 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.429 -0.794 . . . . 0.0 109.941 -177.251 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.583 ' CD2' HG12 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -128.99 136.44 50.34 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 120.91 -1.119 . . . . 0.0 111.085 178.934 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.479 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 8.2 t -120.08 132.63 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.922 -1.111 . . . . 0.0 110.77 -176.55 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.592 HG12 ' CE1' ' A' ' 61' ' ' PHE . 23.2 m -116.9 173.31 4.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 CA-C-O 121.27 0.557 . . . . 0.0 110.341 178.575 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.553 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 9.9 tt0 -106.2 117.91 35.25 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.464 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.526 HD22 ' CD1' ' A' ' 36' ' ' LEU . 9.2 tp -85.54 125.69 68.71 Favored Pre-proline 0 C--N 1.299 -1.624 0 O-C-N 121.403 -0.81 . . . . 0.0 110.3 -171.209 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.47 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 22.2 Cg_endo -66.17 176.37 3.97 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.878 1.462 . . . . 0.0 111.245 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.418 ' OD1' ' O ' ' A' ' 30' ' ' ASP . 47.8 t0 -60.06 -39.9 87.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.336 -0.853 . . . . 0.0 111.183 -175.421 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.585 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.03 0.0 57.35 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.844 -1.16 . . . . 0.0 110.663 -174.937 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.585 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.8 mmm -112.26 -12.34 13.61 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.958 -1.089 . . . . 0.0 109.704 171.502 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.532 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 17.9 mt -69.25 -36.89 77.63 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.4 -0.813 . . . . 0.0 110.069 175.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -82.7 138.9 33.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.438 -0.789 . . . . 0.0 110.778 -177.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.44 -40.73 2.83 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 110.194 -1.163 . . . . 0.0 110.194 174.553 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.526 ' CD1' HD22 ' A' ' 28' ' ' LEU . 8.3 tt -73.28 145.93 45.72 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.053 -1.263 . . . . 0.0 110.631 -176.171 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.46 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 20.9 pt-20 -150.35 167.0 28.33 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.488 -0.757 . . . . 0.0 109.687 179.765 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.532 ' CG2' HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -65.2 152.18 44.28 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.033 -1.042 . . . . 0.0 110.237 -178.123 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.63 -3.87 62.28 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -176.18 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.46 ' HB3' ' O ' ' A' ' 37' ' ' GLU . . . -77.32 155.42 32.01 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.141 -1.211 . . . . 0.0 109.467 176.336 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.469 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -96.82 104.36 16.36 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 119.036 -1.066 . . . . 0.0 109.82 176.831 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.575 HG11 ' CE1' ' A' ' 44' ' ' HIS . 2.1 t -86.06 132.0 33.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 O-C-N 121.24 -0.913 . . . . 0.0 109.139 174.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.523 ' CB ' ' CG ' ' A' ' 85' ' ' GLU . . . -98.78 120.29 38.98 Favored 'General case' 0 C--N 1.296 -1.742 0 C-N-CA 119.408 -0.917 . . . . 0.0 109.262 173.479 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.575 ' CE1' HG11 ' A' ' 42' ' ' VAL . 1.5 m80 -93.08 104.08 16.32 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.593 -0.692 . . . . 0.0 109.268 179.503 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.514 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.3 t-20 55.64 11.29 0.62 Allowed 'General case' 0 C--N 1.298 -1.633 0 O-C-N 121.622 -0.674 . . . . 0.0 111.094 -169.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.494 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.61 1.95 10.73 Favored Glycine 0 N--CA 1.488 2.166 0 C-N-CA 119.796 -1.193 . . . . 0.0 110.818 174.209 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.484 ' HB2' ' OD1' ' B' ' 45' ' ' ASN . 8.6 t -97.22 113.26 24.85 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 120.361 -1.67 . . . . 0.0 109.545 175.494 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.408 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 26.4 p -79.86 124.25 28.48 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.119 -0.988 . . . . 0.0 111.191 -170.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.618 ' CD1' ' CD2' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -141.36 163.21 33.55 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.385 -0.822 . . . . 0.0 109.661 172.861 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 57.5 m -102.96 152.08 21.72 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.689 -1.257 . . . . 0.0 111.019 -172.122 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.527 HG13 ' CG1' ' A' ' 59' ' ' VAL . 14.0 t -78.38 114.69 19.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.751 -0.593 . . . . 0.0 110.272 -178.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.52 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 46.1 p -71.29 -44.51 65.07 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.194 -0.941 . . . . 0.0 109.868 175.644 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.52 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -158.33 153.89 26.17 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.199 -0.938 . . . . 0.0 110.336 178.126 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.532 HD12 ' CG2' ' A' ' 38' ' ' THR . 8.0 mt -105.37 130.37 56.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.161 -0.962 . . . . 0.0 109.818 175.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.474 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 12.4 m-80 -102.4 64.25 0.9 Allowed 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.565 -0.71 . . . . 0.0 109.612 179.828 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.54 -113.08 3.93 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -173.029 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.532 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.05 -21.31 43.59 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.066 -1.255 . . . . 0.0 109.293 175.568 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.633 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 9.8 m170 -74.88 159.53 31.76 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.352 -0.842 . . . . 0.0 110.102 -177.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.527 ' CG1' HG13 ' A' ' 51' ' ' VAL . 53.9 t -140.04 122.16 16.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 C-N-CA 119.023 -1.071 . . . . 0.0 110.916 172.162 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.479 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 60.2 p -91.06 129.09 37.09 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.724 -0.61 . . . . 0.0 109.689 177.772 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.618 ' CD2' ' CD1' ' A' ' 49' ' ' LEU . 1.3 p90 -123.14 156.89 34.12 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.964 -1.085 . . . . 0.0 110.61 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.52 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 32.6 p-10 -91.33 152.06 20.61 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.184 -0.948 . . . . 0.0 111.329 -172.658 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.486 ' CD2' HD12 ' A' ' 68' ' ' LEU . 0.1 OUTLIER -155.72 111.84 3.1 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 -175.771 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.505 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 84.2 mmm -65.71 139.86 58.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.877 -1.14 . . . . 0.0 109.232 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.451 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 58.0 tptt -60.0 -44.41 94.56 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.958 -1.089 . . . . 0.0 109.981 -176.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.417 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.0 tt0 -69.01 -40.0 78.97 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.122 -0.986 . . . . 0.0 110.385 178.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.505 ' HB ' ' HB2' ' A' ' 64' ' ' MET . 89.9 m -60.98 -39.99 91.76 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.937 -1.102 . . . . 0.0 109.085 173.25 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.534 ' CD1' ' HA2' ' A' ' 74' ' ' GLY . 5.1 tp -60.01 -46.24 90.15 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.494 -0.753 . . . . 0.0 109.66 178.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 32.5 tpt180 -67.4 -40.11 85.58 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.548 -0.72 . . . . 0.0 110.519 177.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.449 HG22 HG22 ' A' ' 71' ' ' THR . 1.3 tt -69.96 -41.56 79.46 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.247 -0.908 . . . . 0.0 109.491 -176.457 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.471 HG22 ' O ' ' A' ' 67' ' ' THR . 61.1 p -84.65 -173.22 4.6 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 178.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.484 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.6 t30 -101.76 23.08 11.84 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 170.834 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.464 ' CD1' HD23 ' A' ' 63' ' ' LEU . 94.1 mt -70.04 -42.31 73.07 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.036 -1.04 . . . . 0.0 109.992 176.114 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.534 ' HA2' ' CD1' ' A' ' 68' ' ' LEU . . . -52.28 -18.93 5.31 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -178.029 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 23.7 p-10 -64.67 -18.32 64.86 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.085 -1.244 . . . . 0.0 110.469 -176.193 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 88.6 mt -59.97 143.23 52.23 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.257 -0.902 . . . . 0.0 110.836 -176.246 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.473 ' O ' HD23 ' A' ' 12' ' ' LEU . 54.6 mttt -142.58 141.25 31.96 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.734 -0.604 . . . . 0.0 109.597 175.658 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.55 ' CG2' HG13 ' A' ' 15' ' ' ILE . 16.9 t -60.75 151.25 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 120.784 -1.198 . . . . 0.0 110.601 -174.51 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.65 -10.97 65.42 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -177.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 47.4 t0 -96.38 163.18 13.17 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.268 -1.137 . . . . 0.0 109.622 176.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.0 m95 -113.41 161.64 17.06 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.072 -1.018 . . . . 0.0 110.263 176.877 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.536 HG12 ' CB ' ' A' ' 10' ' ' ALA . 1.5 p -131.24 149.76 33.66 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 O-C-N 121.522 -0.736 . . . . 0.0 109.847 -176.324 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.527 ' CA ' HG12 ' A' ' 6' ' ' VAL . 2.6 m-20 -75.43 108.02 7.95 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 121.24 -0.912 . . . . 0.0 109.188 170.613 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.467 HG11 ' HB1' ' A' ' 10' ' ' ALA . 0.2 OUTLIER -111.71 145.11 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.52 -1.363 . . . . 0.0 111.501 -175.229 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.523 ' CG ' ' CB ' ' A' ' 43' ' ' ALA . 25.9 pt-20 -144.52 160.02 41.81 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.652 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . 0.508 ' NH1' ' OE1' ' A' ' 7' ' ' GLN . 31.5 ptt-85 -98.27 132.91 43.36 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.024 -1.048 . . . . 0.0 110.979 -174.319 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.469 ' O ' ' OG ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.46 -0.775 . . . . 0.0 109.845 177.192 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.534 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 1.3 t . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.578 0.704 . . . . 0.0 110.003 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.514 ' OE1' ' NH1' ' B' ' 86' ' ' ARG . 97.2 mt-30 -70.2 -29.93 66.91 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.497 -0.752 . . . . 0.0 111.483 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.534 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -148.62 175.9 27.67 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 118.91 -1.614 . . . . 0.0 110.386 -173.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.472 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 2.9 p -123.25 171.17 9.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -1.164 . . . . 0.0 110.591 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.544 ' CB ' HG11 ' B' ' 82' ' ' VAL . . . -140.94 150.16 42.78 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.515 -0.741 . . . . 0.0 109.39 -175.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.589 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 26.4 tttt -111.62 116.44 30.81 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.122 -0.986 . . . . 0.0 110.275 179.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.511 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 10.0 tp -58.65 124.87 21.16 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.136 -0.978 . . . . 0.0 108.911 173.133 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.637 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.0 OUTLIER -118.3 -29.08 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 C-N-CA 119.549 -0.86 . . . . 0.0 109.674 178.744 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.58 149.99 27.25 Favored 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 119.115 -1.034 . . . . 0.0 111.539 -178.416 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.586 HG12 ' CD2' ' B' ' 24' ' ' HIS . 19.5 mt -112.1 132.16 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.307 -0.87 . . . . 0.0 110.098 172.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.503 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 86.1 m-20 -108.71 116.23 31.59 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.386 -0.821 . . . . 0.0 109.776 174.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -106.21 108.54 20.1 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.001 -1.062 . . . . 0.0 110.537 -176.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . 0.463 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -102.01 128.48 28.51 Favored Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.167 -0.958 . . . . 0.0 109.022 172.647 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_endo -50.49 -29.63 25.05 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 O-C-N 123.841 1.443 . . . . 0.0 110.465 -179.463 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.473 ' C ' ' CG ' ' B' ' 21' ' ' PHE . 12.6 m-80 -77.7 -40.32 41.73 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.236 -0.915 . . . . 0.0 110.016 176.037 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.473 ' CG ' ' C ' ' B' ' 20' ' ' ASN . 51.4 m-85 -150.94 150.19 30.53 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.409 -0.807 . . . . 0.0 109.9 -179.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . 0.456 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 60.0 ttt180 -90.43 145.12 25.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.74 -1.225 . . . . 0.0 110.063 176.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.503 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 92.0 m -129.49 138.36 51.34 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.569 -0.707 . . . . 0.0 109.843 -177.185 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.587 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -129.09 136.57 50.41 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.042 -1.037 . . . . 0.0 110.977 178.901 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.502 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 8.5 t -120.04 132.78 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.119 -0.988 . . . . 0.0 110.711 -176.499 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.583 HG12 ' CE1' ' B' ' 61' ' ' PHE . 23.7 m -117.07 173.25 4.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.815 -0.553 . . . . 0.0 110.318 178.605 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.558 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 9.8 tt0 -105.98 117.89 35.19 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 -179.645 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.475 HD23 ' HA ' ' B' ' 33' ' ' LEU . 9.2 tp -85.58 125.67 68.68 Favored Pre-proline 0 C--N 1.298 -1.666 0 O-C-N 121.318 -0.864 . . . . 0.0 110.251 -171.226 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.475 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 22.1 Cg_endo -66.08 176.36 3.92 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 O-C-N 123.889 1.468 . . . . 0.0 111.196 -179.512 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.415 ' OD1' ' O ' ' B' ' 30' ' ' ASP . 47.8 t0 -60.07 -39.98 87.93 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.338 -0.851 . . . . 0.0 111.135 -175.476 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.574 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.99 0.15 57.26 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.877 -1.139 . . . . 0.0 110.734 -174.928 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.574 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.7 mmm -112.33 -12.38 13.57 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.957 -1.09 . . . . 0.0 109.708 171.552 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.544 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 17.7 mt -69.28 -36.91 77.55 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.346 -0.847 . . . . 0.0 110.032 175.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 72.9 m-20 -82.71 138.96 33.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.438 -0.789 . . . . 0.0 110.8 -177.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.34 -40.61 2.86 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 174.621 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . 0.449 HD12 ' CG2' ' B' ' 42' ' ' VAL . 8.2 tt -73.37 145.95 45.53 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.997 -1.296 . . . . 0.0 110.556 -176.187 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . 0.466 ' O ' ' HB3' ' B' ' 40' ' ' ALA . 20.9 pt-20 -150.34 167.04 28.2 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.44 -0.787 . . . . 0.0 109.674 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.524 ' CG2' HD13 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -65.24 152.16 44.38 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.994 -1.066 . . . . 0.0 110.323 -178.156 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.62 -3.94 62.02 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -176.054 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.466 ' HB3' ' O ' ' B' ' 37' ' ' GLU . . . -77.36 155.2 32.09 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.212 -1.17 . . . . 0.0 109.521 176.262 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 41' ' ' SER . . . . . 0.465 ' OG ' ' O ' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -96.54 104.25 16.22 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.893 -1.13 . . . . 0.0 109.873 176.858 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.575 ' CG1' ' CE1' ' B' ' 44' ' ' HIS . 2.1 t -86.07 131.97 33.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.224 -0.923 . . . . 0.0 109.178 174.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.52 ' CB ' ' CG ' ' B' ' 85' ' ' GLU . . . -98.67 120.33 38.92 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 121.227 -0.921 . . . . 0.0 109.288 173.473 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.575 ' CE1' ' CG1' ' B' ' 42' ' ' VAL . 1.4 m80 -93.1 103.75 16.01 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.502 -0.749 . . . . 0.0 109.365 179.482 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.514 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.3 t-20 55.9 11.48 0.71 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.557 -0.714 . . . . 0.0 110.972 -169.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.494 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.41 2.24 10.84 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 119.755 -1.212 . . . . 0.0 110.8 174.048 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.463 ' O ' ' HA ' ' B' ' 43' ' ' ALA . 8.7 t -97.47 113.32 24.99 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 120.327 -1.69 . . . . 0.0 109.543 175.384 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . 0.41 ' O ' ' SG ' ' B' ' 48' ' ' CYS . 26.4 p -79.8 124.3 28.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.044 -1.035 . . . . 0.0 111.145 -170.723 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.619 ' CD1' ' CD2' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -141.51 163.34 33.2 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.538 -0.726 . . . . 0.0 109.618 172.77 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 50' ' ' THR . . . . . 0.404 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 57.4 m -102.92 152.18 21.59 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.78 -1.2 . . . . 0.0 110.991 -172.032 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.531 HG13 ' CG1' ' B' ' 59' ' ' VAL . 14.1 t -78.54 114.72 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.749 -0.594 . . . . 0.0 110.323 -178.644 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.519 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 47.0 p -71.32 -44.56 64.9 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.09 -1.006 . . . . 0.0 109.821 175.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.516 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -158.25 153.92 26.38 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.241 -0.912 . . . . 0.0 110.272 178.176 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.524 HD13 ' CG2' ' B' ' 38' ' ' THR . 7.9 mt -105.34 130.32 56.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.117 -0.989 . . . . 0.0 109.825 176.028 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.484 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 12.3 m-80 -102.54 64.32 0.89 Allowed 'General case' 0 C--N 1.297 -1.675 0 C-N-CA 119.865 -0.734 . . . . 0.0 109.608 179.844 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.68 -113.0 3.88 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 108.659 -1.776 . . . . 0.0 108.659 -173.139 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.544 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.1 -21.53 43.19 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.045 -1.268 . . . . 0.0 109.225 175.609 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.637 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 9.9 m170 -74.72 159.46 31.99 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.317 -0.864 . . . . 0.0 110.155 -177.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.531 ' CG1' HG13 ' B' ' 51' ' ' VAL . 54.5 t -140.06 122.19 16.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 C-N-CA 118.903 -1.119 . . . . 0.0 110.867 172.303 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.502 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 60.1 p -91.16 129.23 37.18 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.734 -0.604 . . . . 0.0 109.682 177.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.619 ' CD2' ' CD1' ' B' ' 49' ' ' LEU . 1.3 p90 -123.2 156.94 34.12 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.072 -1.018 . . . . 0.0 110.555 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.519 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 32.7 p-10 -91.28 152.22 20.58 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.097 -1.002 . . . . 0.0 111.224 -172.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.493 ' CD2' HD12 ' B' ' 68' ' ' LEU . 0.1 OUTLIER -155.81 111.91 3.09 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -175.88 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.489 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 84.1 mmm -65.8 139.82 58.35 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.871 -1.143 . . . . 0.0 109.186 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.45 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 57.9 tptt -60.03 -44.27 94.73 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.11 -0.994 . . . . 0.0 109.987 -176.685 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . 0.42 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 85.9 tt0 -69.15 -39.96 78.48 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.171 -0.955 . . . . 0.0 110.302 178.626 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.489 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 90.5 m -61.05 -40.07 92.22 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.899 -1.126 . . . . 0.0 109.019 173.288 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.527 ' CD1' ' HA2' ' B' ' 74' ' ' GLY . 5.1 tp -59.94 -46.08 90.55 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.512 -0.742 . . . . 0.0 109.747 178.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 32.5 tpt180 -67.6 -39.98 84.75 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.612 -0.68 . . . . 0.0 110.506 177.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.465 HG23 HG21 ' B' ' 71' ' ' THR . 1.3 tt -70.0 -41.47 79.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 O-C-N 121.328 -0.858 . . . . 0.0 109.593 -176.544 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.48 HG21 ' O ' ' B' ' 67' ' ' THR . 60.2 p -84.65 -173.16 4.57 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 120.177 -0.609 . . . . 0.0 109.517 178.563 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.48 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 4.5 t30 -101.65 22.98 11.9 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 170.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.463 ' CD1' HD23 ' B' ' 63' ' ' LEU . 94.2 mt -69.96 -42.31 73.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.022 -1.049 . . . . 0.0 110.02 176.096 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.527 ' HA2' ' CD1' ' B' ' 68' ' ' LEU . . . -52.34 -18.82 5.31 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -178.025 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 23.7 p-10 -64.78 -18.29 64.95 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.054 -1.262 . . . . 0.0 110.436 -176.217 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.516 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 88.7 mt -59.99 143.24 52.27 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.23 -0.919 . . . . 0.0 110.844 -176.297 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.446 ' O ' HD22 ' B' ' 12' ' ' LEU . 54.6 mttt -142.61 141.22 31.91 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.652 -0.655 . . . . 0.0 109.62 175.723 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.549 ' CG2' HG13 ' B' ' 15' ' ' ILE . 17.2 t -60.85 151.15 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 120.844 -1.16 . . . . 0.0 110.555 -174.408 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.68 -10.82 66.03 Favored Glycine 0 N--CA 1.487 2.07 0 N-CA-C 109.02 -1.632 . . . . 0.0 109.02 -177.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.502 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 47.0 t0 -96.45 163.11 13.19 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.348 -1.089 . . . . 0.0 109.695 176.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.589 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.0 m95 -113.38 161.58 17.1 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.056 -1.028 . . . . 0.0 110.284 176.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.555 HG22 ' CD2' ' B' ' 44' ' ' HIS . 1.5 p -131.27 149.92 33.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.575 -0.703 . . . . 0.0 109.801 -176.479 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.529 ' CA ' HG12 ' B' ' 6' ' ' VAL . 2.5 m-20 -75.34 107.79 7.69 Favored 'General case' 0 C--N 1.294 -1.806 0 O-C-N 121.205 -0.934 . . . . 0.0 109.282 170.633 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.474 ' CG1' ' HB1' ' B' ' 10' ' ' ALA . 0.2 OUTLIER -111.65 145.2 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 120.522 -1.361 . . . . 0.0 111.501 -175.121 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . 0.52 ' CG ' ' CB ' ' B' ' 43' ' ' ALA . 25.9 pt-20 -144.6 159.98 41.91 Favored 'General case' 0 N--CA 1.494 1.773 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.691 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . 0.514 ' NH1' ' OE1' ' B' ' 7' ' ' GLN . 31.5 ptt-85 -98.1 132.88 43.25 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.869 -1.145 . . . . 0.0 110.963 -174.28 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.465 ' O ' ' OG ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.763 0 O-C-N 121.401 -0.812 . . . . 0.0 109.79 177.134 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.515 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 1.4 t . . . . . 0 N--CA 1.492 1.674 0 CA-C-O 121.537 0.684 . . . . 0.0 110.418 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -69.94 -33.65 72.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.51 -0.744 . . . . 0.0 111.051 178.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.515 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -155.66 172.85 33.77 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.871 -1.633 . . . . 0.0 109.909 -173.675 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.483 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 0.6 OUTLIER -115.2 168.8 9.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.143 -1.21 . . . . 0.0 110.48 -179.496 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.523 ' CB ' HG13 ' A' ' 82' ' ' VAL . . . -135.59 147.82 48.83 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.547 -0.721 . . . . 0.0 109.472 -179.142 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.581 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 29.1 tttt -105.98 115.86 30.96 Favored 'General case' 0 C--N 1.294 -1.829 0 O-C-N 121.121 -0.987 . . . . 0.0 110.247 178.835 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.517 ' CG ' ' HA ' ' A' ' 78' ' ' VAL . 12.1 tp -59.71 128.09 35.24 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 120.89 -1.131 . . . . 0.0 108.653 172.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.632 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -128.2 -31.52 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 C-N-CA 119.553 -0.859 . . . . 0.0 110.085 -177.719 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.91 144.71 30.35 Favored 'General case' 0 N--CA 1.495 1.786 0 C-N-CA 118.859 -1.136 . . . . 0.0 111.293 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.573 ' CG1' ' CG2' ' A' ' 78' ' ' VAL . 12.5 mt -109.44 132.99 56.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.245 -0.91 . . . . 0.0 110.351 173.177 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.477 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 79.8 m-20 -110.15 116.22 31.14 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.307 -0.871 . . . . 0.0 109.98 173.125 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -106.54 114.45 28.57 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.007 -1.058 . . . . 0.0 110.567 -178.216 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.467 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.7 mtmt -110.74 132.94 21.35 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.248 -0.907 . . . . 0.0 109.138 175.492 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -50.07 -34.54 38.83 Favored 'Trans proline' 0 C--N 1.301 -1.93 0 O-C-N 123.857 1.451 . . . . 0.0 110.692 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.465 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 12.3 m-80 -74.6 -39.71 62.02 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.149 -0.97 . . . . 0.0 110.076 177.304 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.467 ' O ' ' HB2' ' A' ' 18' ' ' LYS . 96.1 m-85 -154.35 150.16 27.65 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.345 -0.847 . . . . 0.0 110.128 -178.471 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.481 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 59.5 ttt180 -91.71 146.29 23.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.751 -1.218 . . . . 0.0 110.121 176.684 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.477 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 90.4 m -130.0 140.04 50.95 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.408 -0.807 . . . . 0.0 109.927 -175.608 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.561 ' CD2' HG12 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -129.15 136.43 50.18 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.9 -1.125 . . . . 0.0 111.148 177.565 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.508 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 5.8 t -115.78 132.46 65.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.075 -1.016 . . . . 0.0 110.7 -177.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 12.5 m -116.1 170.19 6.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-O 121.111 0.482 . . . . 0.0 110.124 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.453 ' HA ' ' CD2' ' A' ' 58' ' ' HIS . 2.7 tm-20 -101.55 117.8 35.65 Favored 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.322 -0.861 . . . . 0.0 109.23 179.068 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.472 HD21 ' HA ' ' A' ' 33' ' ' LEU . 9.3 tp -82.71 127.27 70.81 Favored Pre-proline 0 C--N 1.298 -1.661 0 O-C-N 121.485 -0.759 . . . . 0.0 110.003 -174.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.47 ' HD2' HD13 ' A' ' 28' ' ' LEU . 25.3 Cg_endo -66.5 -178.5 1.21 Allowed 'Trans proline' 0 C--N 1.308 -1.561 0 O-C-N 123.88 1.463 . . . . 0.0 111.008 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.502 ' OD1' ' N ' ' A' ' 30' ' ' ASP . 22.6 p-10 -65.66 -39.98 91.96 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.413 -0.804 . . . . 0.0 111.016 -177.18 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.581 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.0 0.36 57.15 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.905 -1.122 . . . . 0.0 110.924 -174.557 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.581 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.8 mmm -110.14 -16.02 13.88 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.949 -1.094 . . . . 0.0 109.692 171.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.55 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 13.4 mt -66.13 -32.04 73.25 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.515 -0.74 . . . . 0.0 110.41 178.163 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.419 ' OD1' ' N ' ' A' ' 35' ' ' GLY . 63.7 t0 -80.26 142.93 34.11 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.222 -0.924 . . . . 0.0 110.864 -176.7 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.419 ' N ' ' OD1' ' A' ' 34' ' ' ASP . . . 85.94 -31.77 3.92 Favored Glycine 0 N--CA 1.493 2.443 0 C-N-CA 119.99 -1.1 . . . . 0.0 111.096 170.702 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.422 ' HA ' HD12 ' A' ' 36' ' ' LEU . 57.7 tp -77.45 155.09 31.98 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.708 -1.466 . . . . 0.0 111.111 -173.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.461 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 20.0 pt-20 -153.57 167.84 28.18 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.531 -0.731 . . . . 0.0 109.644 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.529 ' CG2' ' HA ' ' A' ' 53' ' ' GLU . 0.0 OUTLIER -67.8 154.5 41.39 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.876 -1.14 . . . . 0.0 110.111 178.142 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.59 0.3 58.2 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -174.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.461 ' HB3' ' O ' ' A' ' 37' ' ' GLU . . . -79.99 160.22 25.98 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.173 -1.193 . . . . 0.0 109.041 174.407 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.525 ' O ' ' CB ' ' A' ' 87' ' ' ALA . 1.6 p -103.33 118.87 37.74 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 118.294 -1.362 . . . . 0.0 109.692 175.081 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.577 HG13 ' CE1' ' A' ' 44' ' ' HIS . 1.6 t -101.67 125.87 55.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 175.188 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.468 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -87.89 118.58 27.52 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 119.269 -0.972 . . . . 0.0 109.154 174.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.577 ' CE1' HG13 ' A' ' 42' ' ' VAL . 0.7 OUTLIER -91.43 106.08 18.24 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 176.378 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.489 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.6 t-20 55.44 13.41 0.92 Allowed 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.452 -0.78 . . . . 0.0 111.257 -168.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.476 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.56 -6.25 10.63 Favored Glycine 0 N--CA 1.49 2.243 0 C-N-CA 119.459 -1.353 . . . . 0.0 110.999 171.25 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.468 ' O ' ' HA ' ' A' ' 43' ' ' ALA . 32.6 t -89.7 107.58 19.18 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.51 -1.583 . . . . 0.0 109.457 175.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.422 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 26.7 p -74.07 123.44 24.39 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.122 -0.986 . . . . 0.0 110.531 -174.13 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.538 ' CD1' ' HB3' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -138.96 156.53 47.17 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.405 -0.809 . . . . 0.0 109.411 175.196 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.41 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 26.8 m -94.76 156.42 16.39 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 120.489 -1.382 . . . . 0.0 111.315 -169.184 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.544 ' CG1' HG13 ' A' ' 59' ' ' VAL . 16.8 t -82.24 116.06 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.859 -0.525 . . . . 0.0 110.332 -178.055 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.553 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 59.8 p -69.85 -40.03 76.04 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.177 -0.952 . . . . 0.0 109.453 172.561 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.529 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 51.8 tp10 -162.55 156.29 20.69 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.221 -0.992 . . . . 0.0 110.839 -177.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.513 HD12 ' N ' ' A' ' 38' ' ' THR . 7.5 mt -109.98 130.03 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.087 -1.008 . . . . 0.0 109.545 170.699 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.472 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 46.5 m-80 -104.2 62.94 0.74 Allowed 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.603 -0.686 . . . . 0.0 109.493 178.632 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.49 -114.77 4.1 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.809 -1.717 . . . . 0.0 108.809 -172.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.55 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.08 -19.72 46.81 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.042 -1.27 . . . . 0.0 109.038 175.967 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.632 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 9.7 m170 -76.91 159.14 30.24 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.279 -0.888 . . . . 0.0 110.233 -177.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.639 ' CG1' ' CE1' ' A' ' 61' ' ' PHE . 54.0 t -140.42 120.34 12.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.027 -1.046 . . . . 0.0 110.948 173.403 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.508 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 21.3 m -86.02 128.72 34.92 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.57 -0.706 . . . . 0.0 109.729 177.257 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.639 ' CE1' ' CG1' ' A' ' 59' ' ' VAL . 60.2 m-85 -111.37 160.02 17.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.907 -1.12 . . . . 0.0 110.341 178.808 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.553 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 31.8 p-10 -93.36 146.89 23.4 Favored 'General case' 0 N--CA 1.497 1.917 0 CA-C-O 122.099 0.952 . . . . 0.0 111.436 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.553 ' CD2' ' CD1' ' A' ' 68' ' ' LEU . 0.0 OUTLIER -157.39 113.37 2.88 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.459 -176.967 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.487 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 57.0 ttm -69.27 142.39 54.15 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.847 -1.158 . . . . 0.0 109.572 179.116 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.474 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 47.6 tptt -60.05 -46.13 90.57 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.013 -1.054 . . . . 0.0 110.284 -175.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 87.8 tt0 -69.73 -40.09 76.43 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.92 -1.113 . . . . 0.0 110.201 179.358 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.487 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 86.5 m -60.29 -38.34 83.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.931 -1.106 . . . . 0.0 109.228 172.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.553 ' CD1' ' CD2' ' A' ' 63' ' ' LEU . 11.0 tp -60.05 -44.0 94.99 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.368 -0.832 . . . . 0.0 109.375 -179.618 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -68.11 -39.82 82.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.346 -0.846 . . . . 0.0 110.695 174.336 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.468 HG23 HG23 ' A' ' 71' ' ' THR . 1.4 tt -66.3 -41.64 89.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.275 -0.891 . . . . 0.0 109.626 -175.063 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.468 HG23 HG23 ' A' ' 70' ' ' ILE . 50.7 p -83.53 -168.58 2.17 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.709 -0.62 . . . . 0.0 109.606 177.679 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.488 ' HB3' ' HB2' ' B' ' 83' ' ' ASN . 7.1 t30 -104.92 19.6 20.28 Favored 'General case' 0 C--N 1.293 -1.87 0 O-C-N 121.245 -0.909 . . . . 0.0 108.559 168.054 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.457 ' HB3' HD23 ' A' ' 63' ' ' LEU . 81.8 mt -69.98 -40.06 75.55 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.092 -1.005 . . . . 0.0 109.997 175.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.488 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -47.14 -22.68 1.43 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 178.208 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 22.2 p-10 -62.62 -16.25 55.69 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.959 -1.318 . . . . 0.0 110.391 -175.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.518 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 84.4 mt -63.07 146.21 53.75 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.252 -0.905 . . . . 0.0 111.037 -175.129 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.496 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 96.6 mttt -149.21 138.17 21.29 Favored 'General case' 0 N--CA 1.493 1.698 0 CA-C-O 121.461 0.648 . . . . 0.0 109.684 174.182 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.573 ' CG2' ' CG1' ' A' ' 15' ' ' ILE . 17.5 t -61.52 151.86 6.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.843 -1.161 . . . . 0.0 110.51 -175.112 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.03 -14.51 60.38 Favored Glycine 0 N--CA 1.484 1.835 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 -175.279 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.428 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 25.7 t0 -97.82 168.4 10.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.267 -1.137 . . . . 0.0 109.625 176.22 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.581 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.2 m95 -116.64 169.12 9.59 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.079 -1.013 . . . . 0.0 110.045 177.112 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.523 HG13 ' CB ' ' A' ' 10' ' ' ALA . 1.5 p -136.34 147.98 27.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.329 -0.857 . . . . 0.0 109.965 -177.148 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.489 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 2.9 m-20 -73.11 104.36 4.16 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.078 -1.014 . . . . 0.0 109.197 170.06 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.504 HG12 ' CE1' ' A' ' 44' ' ' HIS . 0.1 OUTLIER -107.96 140.26 27.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 120.786 -1.197 . . . . 0.0 111.183 -176.841 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -142.19 140.83 32.49 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.783 -0.573 . . . . 0.0 110.235 -176.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 95.2 mtt180 -60.19 131.62 51.39 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.045 -1.035 . . . . 0.0 109.777 178.648 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.525 ' CB ' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.238 -0.914 . . . . 0.0 109.984 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.531 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 1.5 t . . . . . 0 N--CA 1.494 1.725 0 CA-C-O 121.548 0.69 . . . . 0.0 110.336 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -70.07 -33.5 72.01 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.525 -0.734 . . . . 0.0 111.096 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.531 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -155.79 172.71 33.84 Favored Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.029 -1.558 . . . . 0.0 110.025 -173.684 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.489 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 0.6 OUTLIER -115.18 168.67 9.74 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.203 -1.175 . . . . 0.0 110.537 -179.499 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.501 ' CB ' HG12 ' B' ' 82' ' ' VAL . . . -135.47 148.03 49.09 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.535 -0.728 . . . . 0.0 109.426 -179.245 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.58 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 29.1 tttt -106.13 115.92 31.05 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.163 -0.961 . . . . 0.0 110.191 178.876 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.527 ' CG ' ' HA ' ' B' ' 78' ' ' VAL . 12.1 tp -59.81 128.07 35.11 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.002 -1.061 . . . . 0.0 108.701 172.843 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.627 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -128.08 -31.68 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 C-N-CA 119.586 -0.845 . . . . 0.0 110.141 -177.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.74 144.65 30.47 Favored 'General case' 0 N--CA 1.493 1.687 0 C-N-CA 119.069 -1.052 . . . . 0.0 111.44 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.577 HG13 ' CG2' ' B' ' 78' ' ' VAL . 12.3 mt -109.27 133.03 55.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.19 -0.944 . . . . 0.0 110.479 173.125 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.487 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 79.6 m-20 -110.29 116.34 31.29 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.36 -0.837 . . . . 0.0 109.901 173.18 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -106.57 114.48 28.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.935 -1.103 . . . . 0.0 110.62 -178.269 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.7 mtmt -110.71 132.92 21.35 Favored Pre-proline 0 N--CA 1.493 1.719 0 O-C-N 121.297 -0.877 . . . . 0.0 109.192 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -50.19 -34.53 39.83 Favored 'Trans proline' 0 C--N 1.301 -1.927 0 O-C-N 123.8 1.421 . . . . 0.0 110.703 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.467 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 12.4 m-80 -74.5 -40.13 61.99 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.129 -0.982 . . . . 0.0 109.973 177.259 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.467 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 96.2 m-85 -153.89 150.2 28.13 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.371 -0.831 . . . . 0.0 110.182 -178.428 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . 0.477 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 59.5 ttt180 -91.65 146.22 23.96 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.899 -1.125 . . . . 0.0 110.159 176.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.487 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 91.2 m -129.93 140.0 51.02 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.416 -0.802 . . . . 0.0 110.023 -175.717 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.552 ' CD2' HG12 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -129.03 136.56 50.46 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.998 -1.064 . . . . 0.0 111.16 177.603 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.53 HG21 ' CB ' ' B' ' 60' ' ' SER . 5.7 t -115.76 132.49 65.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.185 -0.947 . . . . 0.0 110.755 -177.373 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 13.0 m -116.3 170.31 6.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.025 179.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.455 ' HA ' ' CD2' ' B' ' 58' ' ' HIS . 2.7 tm-20 -101.57 117.81 35.68 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 121.298 -0.876 . . . . 0.0 109.244 179.071 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.467 HD21 ' HA ' ' B' ' 33' ' ' LEU . 9.3 tp -82.65 127.28 70.9 Favored Pre-proline 0 C--N 1.299 -1.623 0 O-C-N 121.435 -0.791 . . . . 0.0 110.115 -174.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.465 ' HD2' ' HB2' ' B' ' 32' ' ' MET . 24.9 Cg_endo -66.55 -178.53 1.23 Allowed 'Trans proline' 0 C--N 1.307 -1.658 0 O-C-N 123.932 1.491 . . . . 0.0 110.917 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.503 ' HA ' HD12 ' B' ' 33' ' ' LEU . 22.7 p-10 -65.56 -40.01 92.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.335 -0.853 . . . . 0.0 111.089 -177.271 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.567 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.02 0.38 57.14 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.913 -1.117 . . . . 0.0 110.983 -174.641 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.567 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.8 mmm -110.15 -15.98 13.88 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.978 -1.076 . . . . 0.0 109.756 171.593 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.553 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 13.5 mt -66.09 -32.08 73.33 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.462 -0.774 . . . . 0.0 110.453 178.071 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . 0.426 ' OD1' ' N ' ' B' ' 35' ' ' GLY . 63.7 t0 -80.2 142.93 34.23 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.282 -0.887 . . . . 0.0 110.894 -176.741 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . 0.426 ' N ' ' OD1' ' B' ' 34' ' ' ASP . . . 85.9 -31.91 3.88 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 119.92 -1.133 . . . . 0.0 111.092 170.726 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . 0.456 HD22 HD22 ' B' ' 28' ' ' LEU . 57.8 tp -77.39 155.12 32.08 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.669 -1.489 . . . . 0.0 111.131 -173.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . 0.469 ' O ' ' HB2' ' B' ' 40' ' ' ALA . 20.0 pt-20 -153.57 167.92 27.89 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.558 -0.714 . . . . 0.0 109.665 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.528 ' CG2' ' HA ' ' B' ' 53' ' ' GLU . 0.0 OUTLIER -67.96 154.51 41.46 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.953 -1.092 . . . . 0.0 110.157 178.15 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.65 0.31 58.52 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -174.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.469 ' HB2' ' O ' ' B' ' 37' ' ' GLU . . . -80.07 159.96 25.96 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.202 -1.175 . . . . 0.0 109.074 174.271 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 41' ' ' SER . . . . . 0.54 ' O ' ' CB ' ' B' ' 87' ' ' ALA . 1.6 p -102.86 118.83 37.7 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.559 -1.338 . . . . 0.0 109.818 175.076 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.575 HG13 ' CE1' ' B' ' 44' ' ' HIS . 1.6 t -101.88 125.98 55.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 175.198 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.459 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -87.99 118.62 27.67 Favored 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.196 -1.002 . . . . 0.0 109.155 174.532 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.575 ' CE1' HG13 ' B' ' 42' ' ' VAL . 0.7 OUTLIER -91.39 105.9 18.11 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 176.374 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.489 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.6 t-20 55.49 13.57 0.98 Allowed 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.423 -0.798 . . . . 0.0 111.266 -169.023 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.476 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.47 -6.1 10.73 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 119.379 -1.391 . . . . 0.0 110.961 171.081 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.459 ' O ' ' HA ' ' B' ' 43' ' ' ALA . 33.0 t -89.82 107.54 19.16 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.549 -1.559 . . . . 0.0 109.413 175.577 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . 0.417 ' O ' ' SG ' ' B' ' 48' ' ' CYS . 26.5 p -74.04 123.68 24.82 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.14 -0.975 . . . . 0.0 110.452 -174.129 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.542 ' CD1' ' HB3' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -139.15 156.54 47.05 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.42 -0.8 . . . . 0.0 109.344 175.141 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 50' ' ' THR . . . . . 0.411 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 26.8 m -94.63 156.44 16.42 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 120.608 -1.308 . . . . 0.0 111.266 -169.107 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.544 ' CG1' HG13 ' B' ' 59' ' ' VAL . 17.0 t -82.35 116.1 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.831 -0.543 . . . . 0.0 110.389 -178.151 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.542 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 60.1 p -69.85 -40.06 76.02 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.133 -0.98 . . . . 0.0 109.458 172.631 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.528 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 51.8 tp10 -162.58 156.25 20.58 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.384 -0.926 . . . . 0.0 110.827 -177.589 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.497 HD12 ' N ' ' B' ' 38' ' ' THR . 7.5 mt -110.0 129.98 63.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.14 -0.975 . . . . 0.0 109.535 170.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.487 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 46.5 m-80 -104.2 62.85 0.74 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.624 -0.673 . . . . 0.0 109.539 178.672 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.6 -114.74 4.08 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 -172.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.553 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.06 -19.76 46.79 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.948 -1.325 . . . . 0.0 109.102 175.947 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.627 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 9.7 m170 -76.91 158.97 30.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.337 -0.852 . . . . 0.0 110.263 -177.784 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.633 ' CG1' ' CE1' ' B' ' 61' ' ' PHE . 53.9 t -140.35 120.36 13.02 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 C-N-CA 119.104 -1.038 . . . . 0.0 110.921 173.542 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.53 ' CB ' HG21 ' B' ' 25' ' ' VAL . 21.8 m -85.99 128.83 34.93 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.648 -0.658 . . . . 0.0 109.751 177.293 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.633 ' CE1' ' CG1' ' B' ' 59' ' ' VAL . 60.4 m-85 -111.45 160.05 17.49 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.931 -1.106 . . . . 0.0 110.343 178.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.542 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 31.6 p-10 -93.44 146.89 23.43 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.08 -1.012 . . . . 0.0 111.317 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.557 ' CD2' ' CD1' ' B' ' 68' ' ' LEU . 0.0 OUTLIER -157.37 113.44 2.89 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 -177.033 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.49 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 56.9 ttm -69.25 142.37 54.19 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.877 -1.139 . . . . 0.0 109.61 179.012 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.474 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 47.6 tptt -59.91 -46.19 90.13 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.107 -0.995 . . . . 0.0 110.341 -175.771 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 87.8 tt0 -69.81 -40.04 76.18 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.971 -1.08 . . . . 0.0 110.123 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.49 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 87.1 m -60.29 -38.46 83.66 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.915 -1.115 . . . . 0.0 109.191 173.026 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.557 ' CD1' ' CD2' ' B' ' 63' ' ' LEU . 11.1 tp -60.04 -43.71 95.15 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.52 -0.738 . . . . 0.0 109.45 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -68.31 -39.81 81.91 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.304 -0.872 . . . . 0.0 110.598 174.314 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.485 HG21 ' N ' ' B' ' 71' ' ' THR . 1.4 tt -66.38 -41.56 89.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.571 -174.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.485 ' N ' HG21 ' B' ' 70' ' ' ILE . 51.3 p -83.51 -168.5 2.13 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.113 -0.635 . . . . 0.0 109.634 177.703 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.462 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 7.2 t30 -104.93 19.59 20.29 Favored 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 168.042 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.471 ' HB3' HD22 ' B' ' 63' ' ' LEU . 81.5 mt -69.96 -40.07 75.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.005 -1.059 . . . . 0.0 109.931 175.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.486 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -47.28 -22.58 1.52 Allowed Glycine 0 N--CA 1.487 2.051 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 178.354 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 22.3 p-10 -62.64 -16.24 55.82 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.045 -1.268 . . . . 0.0 110.349 -175.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.516 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 84.2 mt -63.22 146.14 54.02 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.309 -0.87 . . . . 0.0 111.046 -175.085 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.498 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 96.6 mttt -149.03 138.34 21.61 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.781 -0.575 . . . . 0.0 109.647 174.172 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.577 ' CG2' HG13 ' B' ' 15' ' ' ILE . 17.3 t -61.56 151.92 6.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.051 -1.031 . . . . 0.0 110.479 -175.127 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.89 -14.24 60.86 Favored Glycine 0 N--CA 1.483 1.777 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 -175.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.408 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 25.5 t0 -97.89 168.41 10.32 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.413 -1.051 . . . . 0.0 109.645 176.056 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.58 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.3 m95 -116.64 168.91 9.76 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.973 -1.079 . . . . 0.0 110.144 177.119 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.501 HG12 ' CB ' ' B' ' 10' ' ' ALA . 1.5 p -136.25 148.06 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.494 -0.754 . . . . 0.0 110.006 -177.295 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.488 ' HB2' ' HB3' ' A' ' 72' ' ' ASN . 2.8 m-20 -73.08 104.2 4.09 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.082 -1.011 . . . . 0.0 109.243 170.106 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.496 HG12 ' CE1' ' B' ' 44' ' ' HIS . 0.1 OUTLIER -107.81 140.6 25.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 120.843 -1.161 . . . . 0.0 110.99 -176.664 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -142.49 140.81 32.0 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.762 -0.586 . . . . 0.0 110.183 -176.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 95.3 mtt180 -60.29 131.69 51.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.113 -0.992 . . . . 0.0 109.77 178.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.54 ' CB ' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.331 -0.856 . . . . 0.0 110.114 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.535 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 3.7 t . . . . . 0 N--CA 1.492 1.637 0 CA-C-O 121.683 0.754 . . . . 0.0 110.817 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 94.3 mm-40 -69.94 -33.2 71.81 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.603 -0.686 . . . . 0.0 110.556 175.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -168.87 174.52 43.45 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.104 -1.522 . . . . 0.0 109.87 -176.58 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.493 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 41.5 p -114.58 170.01 8.63 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.065 -1.256 . . . . 0.0 110.772 -177.598 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.516 ' CB ' HG13 ' A' ' 82' ' ' VAL . . . -135.53 149.93 49.6 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.572 -0.705 . . . . 0.0 109.577 -175.721 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.59 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.0 tttt -105.71 116.77 32.51 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.142 -0.974 . . . . 0.0 110.337 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.501 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 11.5 tp -60.02 127.12 30.33 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 120.898 -1.126 . . . . 0.0 108.825 172.383 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.636 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -125.57 -31.45 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.876 0 O-C-N 121.405 -0.81 . . . . 0.0 109.983 -179.495 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.2 144.6 29.04 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.027 -1.069 . . . . 0.0 111.237 -179.243 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.578 HG23 ' CD2' ' A' ' 24' ' ' HIS . 13.4 mt -108.53 135.64 46.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.162 -0.961 . . . . 0.0 110.032 172.027 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.486 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 84.0 m-20 -109.35 114.88 28.93 Favored 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.289 -0.882 . . . . 0.0 109.867 174.732 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -105.67 114.25 28.3 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.994 -1.067 . . . . 0.0 110.587 -175.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.448 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.1 mtmt -111.46 127.78 26.37 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.18 -0.95 . . . . 0.0 108.993 174.285 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -50.99 -24.06 13.31 Favored 'Trans proline' 0 C--N 1.303 -1.859 0 O-C-N 123.824 1.434 . . . . 0.0 110.254 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.543 ' C ' ' CD2' ' A' ' 21' ' ' PHE . 11.4 m-80 -80.15 -42.5 23.33 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.251 -0.905 . . . . 0.0 109.985 175.243 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.543 ' CD2' ' C ' ' A' ' 20' ' ' ASN . 97.5 m-85 -153.97 150.32 28.18 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.4 -0.812 . . . . 0.0 109.977 -178.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.466 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 62.0 ttt180 -90.58 145.29 24.98 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.878 -1.139 . . . . 0.0 110.167 178.581 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.486 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 87.4 m -131.75 141.75 49.6 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.511 -0.743 . . . . 0.0 109.846 -175.409 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.584 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -131.03 143.91 51.07 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 120.97 -1.081 . . . . 0.0 111.475 -179.466 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.512 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 6.6 t -125.34 133.94 68.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.128 -0.982 . . . . 0.0 110.975 -178.309 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 29.5 m -116.88 174.59 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 CA-C-O 121.24 0.543 . . . . 0.0 110.319 178.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.48 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 11.8 tt0 -104.59 118.46 36.65 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 177.7 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.599 ' CD1' ' CB ' ' A' ' 32' ' ' MET 0.266 0.2 OUTLIER -87.32 123.08 70.41 Favored Pre-proline 0 C--N 1.297 -1.704 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -172.649 . . . . . . . . 4 4 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.498 ' HD2' HD11 ' A' ' 28' ' ' LEU . 17.8 Cg_endo -66.29 172.81 8.34 Favored 'Trans proline' 0 C--N 1.309 -1.51 0 O-C-N 123.551 1.29 . . . . 0.0 111.094 -178.266 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -59.99 -40.05 87.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.568 -0.708 . . . . 0.0 111.196 -174.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.518 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.02 -0.0 57.35 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.672 -1.267 . . . . 0.0 110.659 -171.479 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.599 ' CB ' ' CD1' ' A' ' 28' ' ' LEU . 97.8 mmm -113.52 -14.87 12.65 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.908 -1.12 . . . . 0.0 109.715 169.128 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.463 HD11 ' O ' ' A' ' 28' ' ' LEU . 14.0 mt -62.32 -40.02 94.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.087 -1.008 . . . . 0.0 109.59 176.585 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -69.93 129.95 40.9 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.469 -0.769 . . . . 0.0 110.278 178.036 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.0 -44.25 1.66 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 176.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.459 HD22 ' HG ' ' A' ' 28' ' ' LEU . 66.0 tp -63.61 145.13 56.29 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.05 -1.265 . . . . 0.0 110.946 -176.442 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.454 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 21.6 pt-20 -153.09 160.02 42.87 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.507 -0.745 . . . . 0.0 109.316 175.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.539 ' CG2' ' HA ' ' A' ' 53' ' ' GLU . 0.0 OUTLIER -62.81 148.76 45.98 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.93 -1.107 . . . . 0.0 110.058 -179.296 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.52 -6.45 68.94 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 -175.035 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.454 ' HB3' ' O ' ' A' ' 37' ' ' GLU . . . -72.86 155.73 39.61 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.178 -1.189 . . . . 0.0 109.543 176.479 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -100.03 99.75 10.53 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 119.05 -1.06 . . . . 0.0 109.698 176.762 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.581 HG12 ' CE1' ' A' ' 44' ' ' HIS . 2.2 t -85.58 131.74 33.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.347 -0.846 . . . . 0.0 109.355 176.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.466 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -95.03 119.98 34.47 Favored 'General case' 0 C--N 1.294 -1.83 0 O-C-N 121.059 -1.025 . . . . 0.0 109.272 170.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.581 ' CE1' HG12 ' A' ' 42' ' ' VAL . 0.3 OUTLIER -89.51 108.2 19.52 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 176.579 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.491 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.0 t-20 51.83 16.34 0.49 Allowed 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.235 -0.916 . . . . 0.0 111.056 -168.218 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.477 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 117.09 -1.53 19.33 Favored Glycine 0 N--CA 1.49 2.235 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.915 172.356 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.517 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 18.9 t -93.84 107.13 19.05 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.505 -1.585 . . . . 0.0 109.304 174.621 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.437 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 32.1 p -75.19 130.01 38.45 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.003 -1.061 . . . . 0.0 111.019 -171.584 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.641 ' CD1' ' CD2' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -144.75 161.22 39.77 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.526 -0.734 . . . . 0.0 109.524 174.518 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.434 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 10.7 m -100.22 149.97 23.02 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.757 -1.214 . . . . 0.0 111.043 -171.012 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.532 ' CG1' HG13 ' A' ' 59' ' ' VAL . 36.7 t -80.03 115.33 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.773 -0.579 . . . . 0.0 110.432 -178.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.532 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 30.5 p -70.09 -39.99 75.22 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.175 -0.953 . . . . 0.0 109.871 175.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.539 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 87.7 tt0 -161.3 154.2 20.88 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.262 -0.899 . . . . 0.0 110.333 179.059 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.529 HD13 ' CG2' ' A' ' 38' ' ' THR . 5.8 mt -102.48 132.73 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.983 -1.073 . . . . 0.0 109.909 174.472 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.502 ' CB ' ' HB2' ' A' ' 58' ' ' HIS . 2.5 m-80 -103.89 65.25 0.81 Allowed 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.569 -0.707 . . . . 0.0 109.869 179.334 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.94 -118.55 5.69 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 108.719 -1.752 . . . . 0.0 108.719 -173.091 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.48 ' O ' ' HB2' ' A' ' 28' ' ' LEU . 0.0 OUTLIER -75.02 -21.46 59.07 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 120.903 -1.351 . . . . 0.0 108.764 173.818 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.636 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 12.8 m170 -72.89 159.96 32.9 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.242 -0.912 . . . . 0.0 110.17 -177.37 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.532 HG13 ' CG1' ' A' ' 51' ' ' VAL . 52.8 t -140.1 125.57 20.72 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 O-C-N 121.04 -1.037 . . . . 0.0 110.662 171.536 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.512 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 54.3 p -96.09 125.82 40.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.723 -0.611 . . . . 0.0 109.742 179.641 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.641 ' CD2' ' CD1' ' A' ' 49' ' ' LEU . 4.3 p90 -118.45 155.26 31.08 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.016 -1.052 . . . . 0.0 110.296 179.806 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.532 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 35.1 p-10 -87.87 152.81 21.81 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.075 -1.016 . . . . 0.0 111.244 -173.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.531 ' CD2' ' CD1' ' A' ' 68' ' ' LEU . 0.0 OUTLIER -157.96 114.36 2.84 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 -176.518 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.486 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 57.6 ttm -71.92 142.33 49.48 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.009 -1.057 . . . . 0.0 109.624 -178.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.461 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 71.3 tttt -59.98 -50.01 75.41 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.075 -1.016 . . . . 0.0 110.505 -175.285 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -65.58 -39.96 92.2 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.996 -1.065 . . . . 0.0 109.914 178.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.486 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 93.0 m -61.11 -40.04 92.27 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.978 -1.076 . . . . 0.0 109.289 174.05 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.531 ' CD1' ' CD2' ' A' ' 63' ' ' LEU . 18.0 tp -59.95 -43.01 95.28 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.319 -0.863 . . . . 0.0 109.466 178.368 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -67.64 -39.98 84.59 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.554 -0.716 . . . . 0.0 110.138 176.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.47 HG22 HG21 ' A' ' 71' ' ' THR . 1.2 tt -68.23 -40.02 82.04 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.357 -0.84 . . . . 0.0 109.301 -177.055 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.47 HG21 HG22 ' A' ' 70' ' ' ILE . 60.1 p -84.61 -172.73 4.33 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 120.261 -0.576 . . . . 0.0 109.483 177.779 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.48 ' N ' ' OD1' ' B' ' 83' ' ' ASN . 5.9 t30 -102.32 22.45 13.33 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 169.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.529 ' CD1' HD22 ' A' ' 63' ' ' LEU . 88.2 mt -70.02 -39.92 75.51 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.01 -1.056 . . . . 0.0 109.757 174.794 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.495 ' HA2' HD12 ' A' ' 68' ' ' LEU . . . -44.56 -23.96 0.6 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.396 -1.082 . . . . 0.0 110.396 178.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 23.0 p-10 -69.97 -19.16 63.36 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.913 -1.346 . . . . 0.0 110.603 -174.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.519 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 98.4 mt -59.92 140.41 56.7 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.085 -1.01 . . . . 0.0 110.714 -176.682 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.487 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 92.3 mttt -143.6 138.97 29.43 Favored 'General case' 0 C--N 1.297 -1.712 0 CA-C-O 121.427 0.632 . . . . 0.0 109.83 177.301 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.569 ' CG2' HG13 ' A' ' 15' ' ' ILE . 16.4 t -60.33 152.2 5.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 120.983 -1.073 . . . . 0.0 110.48 -175.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.37 -14.46 59.43 Favored Glycine 0 N--CA 1.483 1.776 0 N-CA-C 108.906 -1.678 . . . . 0.0 108.906 -176.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 49.6 t0 -96.27 166.37 11.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.33 -1.1 . . . . 0.0 109.627 176.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.59 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.1 m95 -115.43 165.99 12.37 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.963 -1.086 . . . . 0.0 110.157 175.53 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.516 HG13 ' CB ' ' A' ' 10' ' ' ALA . 0.9 OUTLIER -129.96 158.4 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.339 -0.851 . . . . 0.0 110.081 -177.532 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.483 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 0.1 OUTLIER -80.0 107.5 12.83 Favored 'General case' 0 C--N 1.297 -1.674 0 O-C-N 121.006 -1.058 . . . . 0.0 109.14 167.029 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.513 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -108.85 138.13 37.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 120.596 -1.315 . . . . 0.0 111.194 -176.356 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -140.92 146.51 37.5 Favored 'General case' 0 N--CA 1.492 1.661 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.043 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 58.0 ttp180 -83.21 130.02 35.06 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.027 -1.045 . . . . 0.0 111.038 -176.41 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.464 ' O ' ' OG ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 110.031 174.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.535 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 3.7 t . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.532 0.682 . . . . 0.0 110.856 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 94.3 mm-40 -69.99 -32.97 71.44 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.735 -0.603 . . . . 0.0 110.635 175.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -169.13 174.4 43.61 Favored Glycine 0 N--CA 1.495 2.576 0 C-N-CA 119.175 -1.488 . . . . 0.0 109.935 -176.626 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.488 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 41.6 p -114.52 170.03 8.61 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.0 -1.294 . . . . 0.0 110.778 -177.475 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.525 ' CB ' HG11 ' B' ' 82' ' ' VAL . . . -135.61 150.04 49.54 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.614 -0.679 . . . . 0.0 109.523 -175.742 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 30.1 tttt -105.84 116.83 32.61 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.101 -0.999 . . . . 0.0 110.262 179.134 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.517 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 11.5 tp -60.0 127.13 30.36 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 120.96 -1.088 . . . . 0.0 108.9 172.334 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.641 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -125.53 -31.61 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.856 0 O-C-N 121.383 -0.823 . . . . 0.0 110.009 -179.479 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.02 144.59 29.25 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.273 -0.971 . . . . 0.0 111.351 -179.281 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.574 HG22 ' CD2' ' B' ' 24' ' ' HIS . 13.5 mt -108.58 135.67 46.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.217 -0.927 . . . . 0.0 109.994 172.058 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.499 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.6 m-20 -109.48 115.0 29.11 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 121.367 -0.833 . . . . 0.0 109.788 174.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -105.62 114.18 28.19 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.012 -1.055 . . . . 0.0 110.619 -175.388 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.0 OUTLIER -111.46 127.77 26.39 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.233 -0.917 . . . . 0.0 109.049 174.226 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_endo -51.16 -23.97 13.96 Favored 'Trans proline' 0 C--N 1.303 -1.834 0 O-C-N 123.827 1.435 . . . . 0.0 110.238 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.54 ' C ' ' CD2' ' B' ' 21' ' ' PHE . 11.2 m-80 -79.94 -43.0 22.91 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.106 -0.996 . . . . 0.0 109.884 175.15 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.54 ' CD2' ' C ' ' B' ' 20' ' ' ASN . 97.4 m-85 -153.69 150.37 28.5 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.54 -0.725 . . . . 0.0 109.993 -178.745 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . 0.461 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 62.1 ttt180 -90.54 145.2 25.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.934 -1.104 . . . . 0.0 110.108 178.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.499 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 87.0 m -131.63 141.84 49.72 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.541 -0.725 . . . . 0.0 109.852 -175.535 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.584 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -131.05 144.08 51.18 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 120.926 -1.109 . . . . 0.0 111.336 -179.431 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.516 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 6.6 t -125.43 134.07 67.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.15 -0.969 . . . . 0.0 110.93 -178.271 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 30.3 m -117.14 174.59 3.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.812 -0.555 . . . . 0.0 110.304 179.102 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.484 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 12.0 tt0 -104.57 118.51 36.77 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 177.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.586 ' CD1' ' CB ' ' B' ' 32' ' ' MET 0.266 0.2 OUTLIER -87.35 123.07 70.38 Favored Pre-proline 0 C--N 1.296 -1.728 0 O-C-N 121.403 -0.811 . . . . 0.0 108.968 -172.769 . . . . . . . . 4 4 . 1 . 004 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.497 ' HD2' HD12 ' B' ' 28' ' ' LEU . 18.1 Cg_endo -66.27 172.84 8.27 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 O-C-N 123.6 1.316 . . . . 0.0 111.114 -178.213 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -60.07 -40.04 88.15 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.579 -0.701 . . . . 0.0 111.135 -174.647 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.516 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.94 -0.03 57.34 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.743 -1.223 . . . . 0.0 110.72 -171.514 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.586 ' CB ' ' CD1' ' B' ' 28' ' ' LEU . 98.0 mmm -113.48 -14.87 12.67 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.975 -1.078 . . . . 0.0 109.729 169.148 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.464 ' CD2' ' HB3' ' B' ' 28' ' ' LEU . 14.0 mt -62.32 -39.93 94.66 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.071 -1.018 . . . . 0.0 109.652 176.572 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -70.02 130.07 41.16 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.486 -0.759 . . . . 0.0 110.29 177.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.88 -44.13 1.69 Allowed Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.179 -1.169 . . . . 0.0 110.179 176.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . 0.429 HD22 ' HG ' ' B' ' 28' ' ' LEU . 66.4 tp -63.78 145.13 56.36 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.012 -1.287 . . . . 0.0 110.891 -176.441 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . 0.465 ' O ' ' HB2' ' B' ' 40' ' ' ALA . 21.6 pt-20 -153.07 159.97 42.89 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.52 -0.737 . . . . 0.0 109.334 175.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.542 ' CG2' HD13 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -62.87 148.65 46.54 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.944 -1.098 . . . . 0.0 110.151 -179.303 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.67 -6.51 69.26 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 -174.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.465 ' HB2' ' O ' ' B' ' 37' ' ' GLU . . . -72.99 155.61 39.67 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.206 -1.173 . . . . 0.0 109.509 176.489 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 41' ' ' SER . . . . . 0.463 ' O ' ' CB ' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -99.7 99.61 10.46 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 120.926 -1.109 . . . . 0.0 109.799 176.725 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.58 HG12 ' CE1' ' B' ' 44' ' ' HIS . 2.2 t -85.62 131.87 33.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.332 -0.855 . . . . 0.0 109.319 176.183 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.467 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -95.12 120.06 34.69 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.037 -1.039 . . . . 0.0 109.292 170.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.58 ' CE1' HG12 ' B' ' 42' ' ' VAL . 0.3 OUTLIER -89.58 107.97 19.39 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.32 -0.863 . . . . 0.0 108.916 176.639 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.491 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.0 t-20 51.95 16.54 0.53 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.218 -0.926 . . . . 0.0 110.972 -168.204 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.477 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 116.92 -1.27 19.71 Favored Glycine 0 N--CA 1.489 2.227 0 C-N-CA 119.543 -1.313 . . . . 0.0 110.917 172.199 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.511 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 18.9 t -93.99 107.07 19.01 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.49 -1.594 . . . . 0.0 109.316 174.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . 0.433 ' O ' ' SG ' ' B' ' 48' ' ' CYS . 32.1 p -75.04 129.99 38.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.037 -1.039 . . . . 0.0 111.089 -171.626 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.64 ' CD1' ' CD2' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -144.81 161.19 39.89 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.526 -0.734 . . . . 0.0 109.507 174.503 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 50' ' ' THR . . . . . 0.436 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 10.5 m -100.06 150.15 22.75 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.749 -1.219 . . . . 0.0 111.069 -171.024 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.523 HG13 ' CG1' ' B' ' 59' ' ' VAL . 37.7 t -80.27 115.36 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.639 -0.663 . . . . 0.0 110.434 -178.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 30.5 p -70.07 -39.98 75.32 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.14 -0.975 . . . . 0.0 109.91 175.474 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.524 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 87.7 tt0 -161.36 154.25 20.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.267 -0.895 . . . . 0.0 110.297 179.079 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.542 HD13 ' CG2' ' B' ' 38' ' ' THR . 5.8 mt -102.5 132.75 47.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.11 -0.994 . . . . 0.0 109.927 174.535 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.489 ' CB ' ' HB2' ' B' ' 58' ' ' HIS . 2.5 m-80 -104.04 65.36 0.8 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.528 -0.733 . . . . 0.0 109.758 179.415 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.02 -118.48 5.64 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.655 -1.778 . . . . 0.0 108.655 -173.224 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.482 ' O ' ' HB2' ' B' ' 28' ' ' LEU . 0.0 OUTLIER -75.0 -21.66 59.0 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.928 -1.336 . . . . 0.0 108.777 173.796 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.641 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 12.8 m170 -72.7 159.76 33.3 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.345 -0.847 . . . . 0.0 110.192 -177.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.523 ' CG1' HG13 ' B' ' 51' ' ' VAL . 53.1 t -140.03 125.52 20.87 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.093 -1.005 . . . . 0.0 110.748 171.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.516 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 54.4 p -96.04 126.06 41.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.651 -0.656 . . . . 0.0 109.818 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.64 ' CD2' ' CD1' ' B' ' 49' ' ' LEU . 4.3 p90 -118.6 155.2 31.37 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.963 -1.086 . . . . 0.0 110.344 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.533 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 34.9 p-10 -87.76 152.73 21.9 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.097 -1.002 . . . . 0.0 111.305 -173.226 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.542 ' CD2' ' CD1' ' B' ' 68' ' ' LEU . 0.0 OUTLIER -157.79 114.53 2.91 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -176.662 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.5 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 57.7 ttm -72.08 142.41 49.22 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.931 -1.105 . . . . 0.0 109.574 -178.801 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.46 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 71.2 tttt -60.11 -49.91 75.77 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.988 -1.07 . . . . 0.0 110.441 -175.117 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -65.6 -40.02 92.2 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.969 -1.082 . . . . 0.0 109.906 178.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.5 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 93.1 m -61.2 -39.94 92.1 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.974 -1.079 . . . . 0.0 109.219 174.13 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.542 ' CD1' ' CD2' ' B' ' 63' ' ' LEU . 17.9 tp -59.98 -42.95 95.3 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.439 -0.788 . . . . 0.0 109.522 178.334 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -67.52 -39.99 85.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.581 -0.7 . . . . 0.0 110.269 176.476 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.466 HG22 HG22 ' B' ' 71' ' ' THR . 1.2 tt -68.19 -40.08 82.22 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 CA-C-O 121.904 0.859 . . . . 0.0 109.295 -177.115 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.467 HG22 ' O ' ' B' ' 67' ' ' THR . 59.2 p -84.52 -172.52 4.22 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 120.083 -0.647 . . . . 0.0 109.546 177.782 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.47 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 5.8 t30 -102.42 22.56 13.23 Favored 'General case' 0 C--N 1.296 -1.754 0 O-C-N 121.218 -0.927 . . . . 0.0 108.51 169.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.535 ' CD1' HD22 ' B' ' 63' ' ' LEU . 88.1 mt -70.09 -39.95 75.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.013 -1.054 . . . . 0.0 109.713 174.71 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.492 ' HA2' HD13 ' B' ' 68' ' ' LEU . . . -44.56 -23.82 0.58 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 178.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 23.2 p-10 -70.04 -19.07 63.31 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.932 -1.334 . . . . 0.0 110.648 -175.021 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.519 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.3 mt -60.03 140.41 56.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.121 -0.987 . . . . 0.0 110.67 -176.662 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.489 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 92.2 mttt -143.6 139.05 29.46 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 121.363 0.601 . . . . 0.0 109.853 177.297 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.561 ' CG2' HG13 ' B' ' 15' ' ' ILE . 16.5 t -60.56 152.24 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 120.937 -1.102 . . . . 0.0 110.42 -175.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.29 -14.22 59.89 Favored Glycine 0 N--CA 1.485 1.932 0 N-CA-C 108.927 -1.669 . . . . 0.0 108.927 -176.067 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.508 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 49.4 t0 -96.37 166.31 11.77 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.387 -1.066 . . . . 0.0 109.572 176.469 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.1 m95 -115.38 165.93 12.43 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.03 -1.044 . . . . 0.0 110.225 175.493 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.525 HG11 ' CB ' ' B' ' 10' ' ' ALA . 0.9 OUTLIER -129.95 158.5 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.387 -0.821 . . . . 0.0 110.081 -177.628 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.48 ' OD1' ' N ' ' A' ' 72' ' ' ASN . 0.1 OUTLIER -79.96 107.29 12.63 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 120.987 -1.07 . . . . 0.0 109.179 167.043 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.503 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -108.67 138.34 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 120.668 -1.27 . . . . 0.0 111.061 -176.196 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -141.34 146.57 36.87 Favored 'General case' 0 N--CA 1.492 1.659 0 C-N-CA 120.397 -0.521 . . . . 0.0 109.933 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 58.0 ttp180 -83.07 129.97 35.08 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.027 -1.046 . . . . 0.0 110.996 -176.288 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.463 ' CB ' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.492 1.642 0 O-C-N 121.258 -0.901 . . . . 0.0 110.023 174.486 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.537 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 1.8 t . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 121.799 0.809 . . . . 0.0 111.047 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 30.3 mm100 -69.91 -36.25 75.23 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.716 -0.615 . . . . 0.0 110.836 178.033 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.537 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -154.36 170.78 32.84 Favored Glycine 0 N--CA 1.493 2.448 0 C-N-CA 119.156 -1.497 . . . . 0.0 109.986 -172.492 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.445 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 4.2 p -114.4 173.86 6.24 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.927 -1.337 . . . . 0.0 111.173 -175.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.51 ' CB ' HG11 ' A' ' 82' ' ' VAL . . . -142.2 149.8 40.16 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.676 -0.64 . . . . 0.0 109.347 -177.502 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.594 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 38.3 tttt -107.29 116.72 32.42 Favored 'General case' 0 C--N 1.295 -1.766 0 O-C-N 121.003 -1.061 . . . . 0.0 110.269 177.908 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.531 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 11.9 tp -60.02 126.95 29.53 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.848 -1.157 . . . . 0.0 108.827 171.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.623 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.3 p -122.79 -31.65 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 O-C-N 121.395 -0.816 . . . . 0.0 109.881 -179.481 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.94 146.59 27.92 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 118.984 -1.086 . . . . 0.0 111.473 -179.324 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.573 HG13 ' CG2' ' A' ' 78' ' ' VAL . 7.6 mt -108.45 138.06 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.026 -1.046 . . . . 0.0 110.238 171.207 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.475 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.9 m-20 -109.22 115.72 30.55 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.196 -0.94 . . . . 0.0 109.765 171.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -104.56 112.27 25.28 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.019 -1.05 . . . . 0.0 110.379 -175.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 20.4 mmmt -115.64 129.27 25.28 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.17 -0.956 . . . . 0.0 109.125 177.33 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -51.03 -31.34 34.46 Favored 'Trans proline' 0 C--N 1.303 -1.841 0 O-C-N 123.775 1.408 . . . . 0.0 110.264 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 11.6 m-80 -74.42 -39.99 62.27 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.232 -0.917 . . . . 0.0 110.09 175.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 83.7 m-85 -156.35 150.46 25.27 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.328 -0.858 . . . . 0.0 110.308 -177.623 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.48 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 59.0 ttt180 -92.05 141.81 28.21 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.921 -1.112 . . . . 0.0 109.94 176.579 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.475 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.6 m -130.08 139.95 50.89 Favored 'General case' 0 C--N 1.294 -1.819 0 O-C-N 121.675 -0.641 . . . . 0.0 109.912 -173.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.57 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -131.12 141.41 50.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.905 -1.122 . . . . 0.0 111.068 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.499 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 6.8 t -122.51 133.17 69.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.053 -1.03 . . . . 0.0 110.677 -178.823 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.573 HG11 ' CE1' ' A' ' 61' ' ' PHE . 30.1 m -116.19 173.33 3.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.808 -0.557 . . . . 0.0 110.22 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.508 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 8.4 tt0 -104.44 116.44 32.13 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.434 -0.791 . . . . 0.0 108.942 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.473 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.6 tp -83.55 124.35 75.56 Favored Pre-proline 0 C--N 1.298 -1.649 0 O-C-N 121.475 -0.766 . . . . 0.0 110.059 -173.159 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.471 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 26.2 Cg_endo -66.42 176.61 3.92 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 123.923 1.486 . . . . 0.0 111.104 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 30' ' ' ASP . 47.4 t0 -60.09 -39.88 87.67 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.328 -0.858 . . . . 0.0 111.13 -175.467 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.573 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.64 0.06 57.19 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.756 -1.215 . . . . 0.0 110.576 -174.548 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.573 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.7 mmm -111.43 -14.1 13.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.037 -1.04 . . . . 0.0 109.813 170.291 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.544 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 17.5 mt -69.81 -39.97 76.21 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.271 -0.893 . . . . 0.0 110.308 177.648 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -78.06 129.37 35.15 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.919 . . . . 0.0 110.337 -178.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.88 -42.96 1.87 Allowed Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.865 -1.159 . . . . 0.0 110.374 174.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.47 ' CD1' HD22 ' A' ' 28' ' ' LEU . 7.1 tt -66.79 146.65 54.2 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.932 -1.334 . . . . 0.0 110.508 -175.012 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.464 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 14.7 pt-20 -149.97 164.38 35.63 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.556 -0.715 . . . . 0.0 109.672 -178.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.53 ' CG2' ' HA ' ' A' ' 53' ' ' GLU . 0.0 OUTLIER -66.5 150.06 49.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.99 -1.069 . . . . 0.0 109.949 179.335 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.7 -4.81 63.39 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -173.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.464 ' HB3' ' O ' ' A' ' 37' ' ' GLU . . . -76.62 153.54 35.18 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.225 -1.162 . . . . 0.0 109.519 177.145 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.468 ' HB2' ' HB3' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -97.82 109.23 22.02 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 121.016 -1.052 . . . . 0.0 110.086 178.153 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.575 HG12 ' CE1' ' A' ' 44' ' ' HIS . 2.2 t -95.37 133.1 37.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.224 -0.923 . . . . 0.0 109.129 173.737 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.471 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -95.9 119.9 35.22 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.112 -0.993 . . . . 0.0 109.071 171.417 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.575 ' CE1' HG12 ' A' ' 42' ' ' VAL . 0.3 OUTLIER -88.81 104.85 17.3 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.433 -0.792 . . . . 0.0 108.884 177.636 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.5 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 54.82 12.86 0.64 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.361 -0.837 . . . . 0.0 111.258 -168.513 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.472 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.34 -1.22 11.46 Favored Glycine 0 N--CA 1.49 2.283 0 C-N-CA 119.603 -1.284 . . . . 0.0 110.769 172.804 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.503 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 36.1 t -93.85 109.71 21.4 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 120.531 -1.57 . . . . 0.0 109.517 175.275 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.7 p -74.44 128.26 35.1 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.113 -0.992 . . . . 0.0 110.984 -171.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.622 ' CD1' ' CD2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -144.3 159.18 43.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.506 -0.746 . . . . 0.0 109.421 174.177 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 65.3 m -102.34 151.26 22.46 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.718 -1.239 . . . . 0.0 111.148 -172.022 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.539 ' CG1' HG11 ' A' ' 59' ' ' VAL . 21.3 t -78.44 119.77 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.728 -0.608 . . . . 0.0 110.641 -177.329 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.52 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 43.2 p -73.25 -43.84 60.46 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.242 -0.911 . . . . 0.0 110.15 174.481 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.53 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -159.32 151.22 20.67 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.319 -0.863 . . . . 0.0 110.468 -178.244 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.527 HD13 ' CG2' ' A' ' 38' ' ' THR . 6.3 mt -102.87 133.13 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.172 -0.955 . . . . 0.0 109.953 174.724 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.467 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 44.9 m-80 -108.04 65.72 0.64 Allowed 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.492 -0.755 . . . . 0.0 109.703 178.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.93 -116.28 4.77 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -174.091 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.544 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.35 -20.89 50.38 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.02 -1.282 . . . . 0.0 109.059 175.028 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.623 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 10.4 m170 -74.45 160.03 31.5 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.358 -0.839 . . . . 0.0 110.096 -177.109 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.539 HG11 ' CG1' ' A' ' 51' ' ' VAL . 54.9 t -140.37 122.88 16.14 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 O-C-N 121.006 -1.059 . . . . 0.0 110.808 171.117 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.499 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 3.0 m -89.46 128.96 36.02 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.643 -0.661 . . . . 0.0 109.586 177.162 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.622 ' CD2' ' CD1' ' A' ' 49' ' ' LEU . 3.1 p90 -123.23 155.5 37.01 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.026 -1.046 . . . . 0.0 110.082 178.643 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.52 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 29.6 p-10 -90.03 154.41 19.83 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.946 -1.096 . . . . 0.0 111.594 -170.377 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.528 HD23 ' CD1' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -158.85 123.96 4.23 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 -175.753 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.494 ' HB2' ' CB ' ' A' ' 67' ' ' THR . 96.0 mtp -79.65 146.72 32.33 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.677 -1.264 . . . . 0.0 109.714 178.077 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.469 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 27.8 ttpt -60.01 -47.63 85.06 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.082 -1.011 . . . . 0.0 109.626 178.477 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.99 -40.03 75.55 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.214 -0.928 . . . . 0.0 110.833 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.494 ' CB ' ' HB2' ' A' ' 64' ' ' MET . 23.6 m -65.51 -33.95 77.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.681 -1.262 . . . . 0.0 109.103 175.22 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.532 ' CD1' ' HA2' ' A' ' 74' ' ' GLY . 4.3 tp -60.04 -45.96 91.1 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.546 -0.721 . . . . 0.0 109.705 177.009 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 31.7 tpt180 -69.78 -40.05 76.27 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.304 -0.872 . . . . 0.0 110.54 178.477 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.496 ' CG2' HG21 ' A' ' 71' ' ' THR . 1.5 tt -63.94 -42.78 96.87 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 O-C-N 121.18 -0.95 . . . . 0.0 109.288 -178.681 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.496 HG21 ' CG2' ' A' ' 70' ' ' ILE . 20.9 p -83.59 -173.29 4.63 Favored 'General case' 0 C--N 1.298 -1.63 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 174.678 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 3.4 t30 -104.64 25.66 10.04 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 169.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.528 ' CD1' HD23 ' A' ' 63' ' ' LEU . 90.4 mt -68.07 -39.95 82.85 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.239 -0.913 . . . . 0.0 109.671 175.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.532 ' HA2' ' CD1' ' A' ' 68' ' ' LEU . . . -49.87 -23.7 5.51 Favored Glycine 0 N--CA 1.486 1.977 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.06 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 23.7 p-10 -64.52 -17.26 63.74 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.941 -1.329 . . . . 0.0 110.188 -176.202 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.518 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.7 mt -60.52 144.96 50.25 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.314 -0.866 . . . . 0.0 110.484 -178.454 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.498 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 66.2 mttt -150.12 138.65 20.64 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 121.725 -0.609 . . . . 0.0 109.669 178.11 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.573 ' CG2' HG13 ' A' ' 15' ' ' ILE . 62.1 t -63.54 147.3 12.28 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 120.884 -1.135 . . . . 0.0 110.152 -175.516 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.98 -11.43 70.72 Favored Glycine 0 N--CA 1.483 1.805 0 N-CA-C 108.779 -1.729 . . . . 0.0 108.779 -172.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.505 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 41.7 t0 -100.88 162.25 13.03 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.392 -1.063 . . . . 0.0 109.722 176.408 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.594 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.4 m95 -114.09 159.9 19.52 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.144 -0.972 . . . . 0.0 109.976 177.268 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.51 HG11 ' CB ' ' A' ' 10' ' ' ALA . 0.9 OUTLIER -126.81 156.97 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.973 -177.516 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.527 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 2.4 m-20 -82.14 104.93 12.83 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.202 -0.936 . . . . 0.0 109.263 169.552 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.469 HG11 HG23 ' A' ' 82' ' ' VAL . 0.1 OUTLIER -107.22 138.58 32.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 120.574 -1.329 . . . . 0.0 111.542 -175.564 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -131.63 147.55 52.53 Favored 'General case' 0 N--CA 1.494 1.738 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.994 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . 0.471 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 38.2 ptt180 -87.92 131.77 34.47 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.135 -0.978 . . . . 0.0 110.627 -178.595 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.468 ' HB3' ' HB2' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.594 0 O-C-N 121.202 -0.936 . . . . 0.0 110.239 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.54 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 1.7 t . . . . . 0 N--CA 1.492 1.629 0 CA-C-O 121.737 0.78 . . . . 0.0 111.074 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 30.3 mm100 -69.94 -35.95 74.91 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.834 -0.541 . . . . 0.0 110.938 178.085 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.54 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -154.53 170.68 32.94 Favored Glycine 0 N--CA 1.495 2.596 0 C-N-CA 119.232 -1.461 . . . . 0.0 110.13 -172.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.447 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 4.2 p -114.43 173.82 6.27 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.992 -1.299 . . . . 0.0 111.246 -175.317 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.52 ' CB ' HG11 ' B' ' 82' ' ' VAL . . . -142.13 150.01 40.55 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -177.534 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.59 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 38.3 tttt -107.52 116.78 32.56 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.109 -0.994 . . . . 0.0 110.126 177.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.519 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 11.9 tp -60.06 126.82 28.99 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.872 -1.142 . . . . 0.0 108.916 171.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.626 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.3 p -122.68 -31.74 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.849 0 O-C-N 121.387 -0.821 . . . . 0.0 109.859 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.84 146.67 28.07 Favored 'General case' 0 N--CA 1.493 1.706 0 C-N-CA 119.16 -1.016 . . . . 0.0 111.474 -179.333 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.576 HG13 ' CG2' ' B' ' 78' ' ' VAL . 7.6 mt -108.47 138.06 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.067 -1.021 . . . . 0.0 110.291 171.152 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.489 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 78.1 m-20 -109.32 115.7 30.47 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.46 -0.775 . . . . 0.0 109.754 172.054 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -104.51 112.28 25.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.097 -1.002 . . . . 0.0 110.312 -175.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 20.1 mmmt -115.64 129.29 25.26 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.325 -0.859 . . . . 0.0 109.161 177.247 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -51.17 -31.25 35.46 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.721 1.379 . . . . 0.0 110.216 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.552 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 11.9 m-80 -74.42 -40.27 62.08 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.2 -0.937 . . . . 0.0 109.94 175.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.552 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 83.8 m-85 -156.07 150.4 25.64 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.289 -0.882 . . . . 0.0 110.357 -177.513 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . 0.48 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 58.8 ttt180 -91.97 141.69 28.35 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.989 -1.069 . . . . 0.0 110.016 176.525 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.489 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 94.6 m -129.95 139.98 51.0 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 121.67 -0.644 . . . . 0.0 109.951 -173.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.571 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -131.06 141.4 50.18 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.021 -1.049 . . . . 0.0 111.046 -179.586 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.519 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 6.7 t -122.47 133.3 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.157 -0.964 . . . . 0.0 110.744 -178.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.569 HG12 ' CE1' ' B' ' 61' ' ' PHE . 30.7 m -116.37 173.26 4.07 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.766 -0.583 . . . . 0.0 110.101 178.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.509 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 8.4 tt0 -104.32 116.56 32.37 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 179.685 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.468 ' N ' ' ND2' ' B' ' 57' ' ' ASN . 9.6 tp -83.57 124.32 75.56 Favored Pre-proline 0 C--N 1.299 -1.629 0 O-C-N 121.338 -0.851 . . . . 0.0 110.095 -173.164 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.468 ' HD2' HD11 ' B' ' 28' ' ' LEU . 26.0 Cg_endo -66.41 176.6 3.93 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 O-C-N 123.858 1.452 . . . . 0.0 111.104 -179.483 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.435 ' HA ' HD11 ' B' ' 33' ' ' LEU . 47.4 t0 -60.0 -40.03 87.78 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.341 -0.849 . . . . 0.0 111.104 -175.49 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.567 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.56 0.1 57.14 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.753 -1.217 . . . . 0.0 110.658 -174.57 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.567 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.7 mmm -111.43 -14.11 13.78 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.055 -1.028 . . . . 0.0 109.828 170.266 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.544 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 17.8 mt -69.7 -40.06 76.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.358 -0.839 . . . . 0.0 110.338 177.628 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 55.8 t0 -78.01 129.38 35.2 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.886 . . . . 0.0 110.432 -178.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.95 -43.08 1.85 Allowed Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.854 -1.165 . . . . 0.0 110.304 174.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . 0.463 ' CD1' HD22 ' B' ' 28' ' ' LEU . 7.0 tt -66.81 146.68 54.17 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.866 -1.373 . . . . 0.0 110.533 -174.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . 0.454 ' O ' ' HB2' ' B' ' 40' ' ' ALA . 14.7 pt-20 -150.04 164.35 35.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.4 -0.812 . . . . 0.0 109.618 -178.664 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.534 ' CG2' HD13 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.49 149.94 49.7 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.031 -1.043 . . . . 0.0 109.962 179.369 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.85 -4.83 63.93 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 -174.048 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.454 ' HB2' ' O ' ' B' ' 37' ' ' GLU . . . -76.63 153.35 35.32 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.293 -1.122 . . . . 0.0 109.592 177.024 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 41' ' ' SER . . . . . 0.465 ' HB2' ' HB2' ' B' ' 87' ' ' ALA . 0.1 OUTLIER -97.53 109.05 21.88 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 120.951 -1.093 . . . . 0.0 110.195 178.096 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.569 HG12 ' CE1' ' B' ' 44' ' ' HIS . 2.2 t -95.29 133.13 37.35 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 O-C-N 121.253 -0.904 . . . . 0.0 109.154 173.723 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.468 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -95.89 119.87 35.16 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 119.204 -0.999 . . . . 0.0 109.181 171.284 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.569 ' CE1' HG12 ' B' ' 42' ' ' VAL . 0.3 OUTLIER -88.79 104.66 17.11 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.302 -0.874 . . . . 0.0 108.966 177.696 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.5 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 55.01 12.88 0.67 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.54 -0.725 . . . . 0.0 111.291 -168.491 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.472 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.15 -0.79 11.63 Favored Glycine 0 N--CA 1.491 2.346 0 C-N-CA 119.662 -1.256 . . . . 0.0 110.75 172.687 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.508 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 36.0 t -94.03 109.68 21.42 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.45 -1.617 . . . . 0.0 109.54 175.134 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 18.7 p -74.4 128.41 35.47 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.095 -1.003 . . . . 0.0 110.965 -171.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.638 ' CD1' ' CD2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -144.5 159.1 43.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.541 -0.724 . . . . 0.0 109.387 174.129 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 64.9 m -102.22 151.38 22.28 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.705 -1.247 . . . . 0.0 111.112 -171.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.539 ' CG1' HG11 ' B' ' 59' ' ' VAL . 21.4 t -78.65 119.94 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.727 -0.608 . . . . 0.0 110.584 -177.27 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.523 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 43.3 p -73.32 -43.93 59.93 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.17 -0.956 . . . . 0.0 110.159 174.576 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.526 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -159.24 151.36 20.99 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.331 -0.856 . . . . 0.0 110.455 -178.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.534 HD13 ' CG2' ' B' ' 38' ' ' THR . 6.3 mt -103.0 133.0 48.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.102 -0.999 . . . . 0.0 109.933 174.789 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.485 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 44.8 m-80 -108.0 65.74 0.64 Allowed 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 119.972 -0.691 . . . . 0.0 109.679 179.014 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.08 -116.31 4.74 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 -174.22 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.544 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.31 -21.09 50.17 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 120.983 -1.304 . . . . 0.0 109.049 175.069 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.626 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 10.6 m170 -74.17 159.77 32.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.474 -0.766 . . . . 0.0 110.252 -177.239 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.539 HG11 ' CG1' ' B' ' 51' ' ' VAL . 55.8 t -140.24 122.87 16.46 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 C-N-CA 119.094 -1.042 . . . . 0.0 110.877 171.177 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.519 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 3.0 m -89.61 128.97 36.12 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.751 -0.593 . . . . 0.0 109.556 177.304 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.638 ' CD2' ' CD1' ' B' ' 49' ' ' LEU . 3.1 p90 -123.21 155.56 36.88 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.113 -0.992 . . . . 0.0 110.07 178.71 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.523 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 29.7 p-10 -90.1 154.4 19.81 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.818 -1.176 . . . . 0.0 111.554 -170.273 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.515 HD22 ' CD1' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -158.78 124.04 4.3 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 -175.764 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.5 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 96.0 mtp -79.74 146.68 32.23 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.631 -1.293 . . . . 0.0 109.706 178.029 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.467 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 27.9 ttpt -60.07 -47.61 85.15 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.195 -0.941 . . . . 0.0 109.542 178.562 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.95 -40.01 75.71 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.186 -0.946 . . . . 0.0 110.896 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.5 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 23.7 m -65.48 -34.14 77.57 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.649 -1.282 . . . . 0.0 109.021 175.204 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.534 ' CD1' ' HA2' ' B' ' 74' ' ' GLY . 4.3 tp -60.04 -45.67 92.08 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.571 -0.706 . . . . 0.0 109.844 177.039 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 31.6 tpt180 -70.01 -39.99 75.5 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.278 -0.889 . . . . 0.0 110.498 178.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.515 ' CG2' HG22 ' B' ' 71' ' ' THR . 1.5 tt -63.85 -42.7 96.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.221 -0.924 . . . . 0.0 109.332 -178.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.515 HG22 ' CG2' ' B' ' 70' ' ' ILE . 21.3 p -83.71 -173.08 4.51 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 174.84 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.498 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 3.4 t30 -104.79 25.59 10.21 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 169.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.515 ' CD1' HD22 ' B' ' 63' ' ' LEU . 90.1 mt -68.07 -40.02 82.83 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.149 -0.97 . . . . 0.0 109.636 176.032 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.534 ' HA2' ' CD1' ' B' ' 68' ' ' LEU . . . -49.82 -23.74 5.46 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 -179.061 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 23.3 p-10 -64.46 -17.22 63.63 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.07 -1.253 . . . . 0.0 110.218 -176.227 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.519 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 97.7 mt -60.51 144.93 50.26 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.262 -0.899 . . . . 0.0 110.441 -178.47 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.499 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 66.1 mttt -150.09 138.62 20.65 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.626 -0.671 . . . . 0.0 109.696 178.077 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.576 ' CG2' HG13 ' B' ' 15' ' ' ILE . 62.0 t -63.56 147.26 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.042 -1.036 . . . . 0.0 110.178 -175.513 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.0 -11.15 71.6 Favored Glycine 0 N--CA 1.484 1.85 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 -172.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 41.5 t0 -101.08 162.09 13.14 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.333 -1.098 . . . . 0.0 109.695 176.408 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.59 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.4 m95 -114.0 159.79 19.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.195 -0.941 . . . . 0.0 110.031 177.282 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.52 HG11 ' CB ' ' B' ' 10' ' ' ALA . 0.8 OUTLIER -126.77 157.12 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.402 -0.811 . . . . 0.0 109.896 -177.611 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.513 ' HB3' ' CG2' ' B' ' 6' ' ' VAL . 2.3 m-20 -82.17 104.86 12.81 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.277 -0.89 . . . . 0.0 109.29 169.601 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.471 ' O ' HG13 ' B' ' 6' ' ' VAL . 0.1 OUTLIER -107.13 138.77 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 120.665 -1.272 . . . . 0.0 111.453 -175.426 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -131.84 147.62 52.49 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.983 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . 0.47 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 38.2 ptt180 -87.89 131.84 34.42 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.166 -0.959 . . . . 0.0 110.568 -178.525 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.465 ' HB2' ' HB2' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.495 1.78 0 O-C-N 121.335 -0.853 . . . . 0.0 110.214 179.368 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.538 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.3 t . . . . . 0 N--CA 1.494 1.768 0 CA-C-O 121.791 0.805 . . . . 0.0 110.919 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 -70.04 -31.79 69.6 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.867 -0.521 . . . . 0.0 111.021 179.197 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.538 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -156.38 -177.97 30.06 Favored Glycine 0 N--CA 1.499 2.862 0 C-N-CA 118.541 -1.79 . . . . 0.0 110.795 -170.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.498 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.0 p -129.08 167.25 17.81 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.792 -1.417 . . . . 0.0 110.95 -178.435 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.518 ' CB ' HG11 ' A' ' 82' ' ' VAL . . . -139.97 149.84 43.75 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.597 -0.69 . . . . 0.0 109.201 -175.021 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.581 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 34.5 tttt -109.24 115.77 30.63 Favored 'General case' 0 C--N 1.294 -1.816 0 O-C-N 121.013 -1.055 . . . . 0.0 110.362 -179.12 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.521 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 11.5 tp -59.98 127.68 33.08 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.916 -1.115 . . . . 0.0 108.863 172.622 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.629 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.6 p -127.01 -29.32 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 C-N-CA 119.6 -0.84 . . . . 0.0 109.932 -179.045 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.75 144.15 24.11 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 118.959 -1.096 . . . . 0.0 111.243 179.23 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.571 HG12 ' CD2' ' A' ' 24' ' ' HIS . 8.8 mt -107.9 141.03 24.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.187 -0.946 . . . . 0.0 110.233 174.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.483 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 79.7 m-20 -109.79 113.87 26.97 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.238 -0.914 . . . . 0.0 109.972 172.247 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -101.24 113.13 25.89 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.109 -0.995 . . . . 0.0 110.427 -178.099 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.47 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -109.77 134.4 20.64 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.197 -0.939 . . . . 0.0 109.499 176.005 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.64 -16.65 11.4 Favored 'Trans proline' 0 C--N 1.303 -1.854 0 O-C-N 123.973 1.512 . . . . 0.0 110.652 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.572 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 4.9 m-80 -100.8 -26.57 13.73 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.129 -0.982 . . . . 0.0 110.035 179.23 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.572 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 92.9 m-85 -157.81 150.2 22.48 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.437 -0.789 . . . . 0.0 109.857 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.474 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 57.1 ttt180 -93.54 141.16 28.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.6 -1.312 . . . . 0.0 110.026 174.196 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.483 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.3 m -129.97 141.03 50.82 Favored 'General case' 0 C--N 1.294 -1.814 0 O-C-N 121.698 -0.626 . . . . 0.0 109.835 -173.703 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.579 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -129.98 143.6 50.88 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.012 -1.055 . . . . 0.0 111.612 -179.156 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.529 ' CG2' ' OG ' ' A' ' 60' ' ' SER . 6.4 t -123.34 132.88 70.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.11 -0.994 . . . . 0.0 110.613 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.549 HG13 ' CE1' ' A' ' 61' ' ' PHE . 26.0 m -114.9 174.48 2.93 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.326 178.509 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.506 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 12.8 tt0 -104.38 118.61 37.03 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.473 HD22 ' O ' ' A' ' 32' ' ' MET . 9.5 tp -81.21 122.57 81.52 Favored Pre-proline 0 C--N 1.297 -1.708 0 O-C-N 121.7 -0.625 . . . . 0.0 109.626 -174.75 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.466 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 18.3 Cg_endo -63.44 174.07 3.79 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 123.907 1.477 . . . . 0.0 110.572 -179.307 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.415 ' HA ' HD11 ' A' ' 33' ' ' LEU . 53.4 t0 -60.01 -39.47 85.91 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.412 -0.805 . . . . 0.0 110.611 -177.011 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.581 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.95 -0.1 57.39 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.843 -1.161 . . . . 0.0 110.894 -175.012 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.581 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 95.9 mmm -109.71 -11.73 14.7 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.87 -1.143 . . . . 0.0 109.824 170.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.544 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 15.3 mt -69.23 -40.1 78.13 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.323 -0.861 . . . . 0.0 110.312 179.225 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -79.98 123.89 28.21 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.349 -0.844 . . . . 0.0 110.527 -177.06 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.12 -47.09 1.08 Allowed Glycine 0 N--CA 1.492 2.377 0 C-N-CA 119.829 -1.177 . . . . 0.0 110.401 175.128 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.426 ' C ' HD23 ' A' ' 36' ' ' LEU . 8.2 tt -67.34 147.37 53.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.985 -1.303 . . . . 0.0 110.727 -175.068 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.47 ' HA ' HD12 ' A' ' 54' ' ' ILE . 21.3 pt-20 -149.96 169.07 22.04 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.378 -0.826 . . . . 0.0 109.656 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.545 ' CG2' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -66.81 148.92 51.29 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.986 -1.071 . . . . 0.0 110.087 -179.985 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.9 -10.05 58.43 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 -175.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.469 ' HB3' ' O ' ' A' ' 37' ' ' GLU . . . -71.25 157.87 37.37 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.245 -1.15 . . . . 0.0 109.272 174.706 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.529 ' O ' ' CB ' ' A' ' 87' ' ' ALA . 1.6 p -105.34 116.82 32.59 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 118.533 -1.267 . . . . 0.0 109.754 176.012 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.58 HG12 ' CE1' ' A' ' 44' ' ' HIS . 1.6 t -99.63 126.38 53.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 121.333 -0.854 . . . . 0.0 109.006 175.353 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.474 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -88.31 119.53 28.81 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.234 -0.986 . . . . 0.0 109.089 173.374 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.58 ' CE1' HG12 ' A' ' 42' ' ' VAL . 0.4 OUTLIER -89.75 105.43 17.8 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 119.729 -0.788 . . . . 0.0 108.939 177.955 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.8 t-20 56.84 9.87 0.67 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.527 -0.733 . . . . 0.0 111.514 -170.316 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 126.57 -2.15 7.55 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.553 -1.308 . . . . 0.0 110.86 173.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.516 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 50.2 t -98.63 104.86 16.93 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.521 -1.576 . . . . 0.0 109.756 176.236 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 43' ' ' ALA . 25.5 p -71.36 128.91 37.44 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.176 -0.952 . . . . 0.0 110.727 -174.453 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.632 ' CD1' ' CD2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -141.41 159.98 41.08 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.445 -0.785 . . . . 0.0 109.262 173.942 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 23.9 m -99.88 150.05 22.78 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 120.45 -1.406 . . . . 0.0 111.347 -170.252 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.575 ' CG1' HG12 ' A' ' 59' ' ' VAL . 34.9 t -76.25 116.44 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.941 -0.475 . . . . 0.0 110.318 -179.182 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.541 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 28.3 p -71.91 -39.96 69.15 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.365 -0.835 . . . . 0.0 109.789 174.186 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.532 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -163.27 152.9 15.21 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.272 -0.893 . . . . 0.0 110.362 -179.031 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.545 HD11 ' CG2' ' A' ' 38' ' ' THR . 7.6 mt -105.52 132.14 53.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.193 -0.942 . . . . 0.0 109.965 175.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.463 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 26.6 m-80 -104.92 64.78 0.73 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.63 -0.669 . . . . 0.0 109.594 179.229 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.65 -116.95 5.3 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 -173.126 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.544 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -77.0 -20.74 55.68 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.015 -1.285 . . . . 0.0 109.153 175.727 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.629 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 11.2 m80 -75.64 159.98 30.59 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.33 -0.856 . . . . 0.0 110.192 -177.593 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.575 HG12 ' CG1' ' A' ' 51' ' ' VAL . 53.6 t -140.69 123.07 15.55 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 C-N-CA 119.133 -1.027 . . . . 0.0 110.74 173.208 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.529 ' OG ' ' CG2' ' A' ' 25' ' ' VAL . 1.3 t -90.71 134.61 34.29 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.48 -0.762 . . . . 0.0 109.416 177.329 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.632 ' CD2' ' CD1' ' A' ' 49' ' ' LEU . 2.7 p90 -126.75 151.17 48.56 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.366 -0.833 . . . . 0.0 110.318 176.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.541 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 38.2 p-10 -86.66 154.87 20.67 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.084 -1.01 . . . . 0.0 111.422 -171.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.596 ' CD2' ' CD1' ' A' ' 68' ' ' LEU . 0.0 OUTLIER -161.9 100.42 1.12 Allowed 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.754 -0.591 . . . . 0.0 109.546 -175.49 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.46 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 33.0 ttp -60.68 140.06 57.63 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.883 -1.135 . . . . 0.0 109.52 -178.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.475 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 29.4 tptp -60.07 -48.31 82.23 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.891 -1.13 . . . . 0.0 110.473 -172.69 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -63.21 -39.99 96.19 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.714 -1.241 . . . . 0.0 109.806 177.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.46 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 55.2 m -60.05 -39.98 87.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.052 -1.03 . . . . 0.0 109.602 172.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.596 ' CD1' ' CD2' ' A' ' 63' ' ' LEU . 27.0 tp -61.64 -40.8 96.16 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.446 -0.784 . . . . 0.0 109.816 -179.592 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 15.5 ttm180 -69.92 -40.12 75.75 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.275 -0.891 . . . . 0.0 110.441 177.086 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.475 HG23 HG23 ' A' ' 71' ' ' THR . 1.2 tt -64.78 -44.58 96.42 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.285 -0.884 . . . . 0.0 109.602 -176.569 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.475 HG23 HG23 ' A' ' 70' ' ' ILE . 30.5 p -79.99 -174.98 4.73 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.561 -0.712 . . . . 0.0 109.25 175.258 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.499 ' CB ' ' N ' ' B' ' 83' ' ' ASN . 4.1 t30 -99.97 23.34 9.95 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.013 -1.054 . . . . 0.0 108.459 169.32 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.524 ' CD1' HD21 ' A' ' 63' ' ' LEU . 87.7 mt -69.18 -40.02 78.37 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.071 -1.018 . . . . 0.0 109.799 174.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.531 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -46.81 -22.44 1.15 Allowed Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.619 -0.993 . . . . 0.0 110.619 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.3 p-10 -68.98 -17.01 63.87 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.958 -1.319 . . . . 0.0 110.534 -174.668 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.503 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 98.4 mt -59.93 141.18 55.98 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.226 -0.921 . . . . 0.0 111.042 -176.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.481 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 24.9 mttm -142.38 143.04 32.51 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.734 -0.604 . . . . 0.0 109.762 173.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.54 ' CG2' HG13 ' A' ' 15' ' ' ILE . 32.2 t -63.15 150.09 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.914 -1.116 . . . . 0.0 110.391 -177.209 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.46 -14.82 60.17 Favored Glycine 0 N--CA 1.485 1.916 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 -175.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.494 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 41.9 t0 -94.28 167.7 11.37 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.328 -1.101 . . . . 0.0 109.637 175.839 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.581 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.2 m95 -116.67 158.8 23.2 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.976 -1.077 . . . . 0.0 110.036 175.038 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.572 HG21 ' CG ' ' A' ' 44' ' ' HIS . 1.1 p -121.28 155.27 25.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.389 -0.82 . . . . 0.0 109.917 179.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.513 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 0.2 OUTLIER -78.51 105.56 9.86 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 120.993 -1.067 . . . . 0.0 109.003 168.06 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.498 ' CG2' ' C ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -106.64 137.84 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 120.548 -1.345 . . . . 0.0 111.048 -176.96 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -138.98 140.09 38.11 Favored 'General case' 0 N--CA 1.492 1.629 0 C-N-CA 120.291 -0.564 . . . . 0.0 109.991 -177.319 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 53.0 ttt85 -60.06 127.05 29.97 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.155 -0.966 . . . . 0.0 110.293 -179.508 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.529 ' CB ' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.489 1.497 0 O-C-N 121.341 -0.849 . . . . 0.0 109.554 176.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.549 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.3 t . . . . . 0 N--CA 1.493 1.69 0 CA-C-O 121.773 0.797 . . . . 0.0 110.945 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 99.5 mt-30 -69.98 -31.72 69.55 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.785 -0.572 . . . . 0.0 111.025 179.27 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.549 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -156.49 -178.09 30.28 Favored Glycine 0 N--CA 1.499 2.895 0 C-N-CA 118.632 -1.747 . . . . 0.0 110.857 -170.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.503 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.0 p -129.03 167.13 17.94 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.913 -1.345 . . . . 0.0 111.028 -178.426 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.514 ' CB ' HG12 ' B' ' 82' ' ' VAL . . . -139.88 150.04 44.13 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 -175.179 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.583 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 34.5 tttt -109.3 115.81 30.68 Favored 'General case' 0 C--N 1.295 -1.772 0 O-C-N 121.028 -1.045 . . . . 0.0 110.294 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.507 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 11.5 tp -60.24 127.61 32.64 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 120.945 -1.097 . . . . 0.0 108.905 172.62 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.627 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -126.84 -29.38 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.874 0 O-C-N 121.345 -0.847 . . . . 0.0 110.034 -178.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.67 144.11 24.14 Favored 'General case' 0 C--N 1.297 -1.681 0 C-N-CA 119.225 -0.99 . . . . 0.0 111.243 179.224 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.564 HG12 ' CD2' ' B' ' 24' ' ' HIS . 8.9 mt -107.88 141.1 23.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.292 -0.88 . . . . 0.0 110.242 174.617 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.473 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 79.5 m-20 -109.92 113.98 27.15 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.364 -0.835 . . . . 0.0 109.961 172.243 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -101.22 113.08 25.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.155 -0.966 . . . . 0.0 110.444 -178.06 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . 0.47 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.0 OUTLIER -109.87 134.36 20.68 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.311 -0.868 . . . . 0.0 109.442 176.043 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.71 -16.66 11.62 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 O-C-N 123.971 1.511 . . . . 0.0 110.662 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 4.8 m-80 -100.51 -27.16 13.57 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.087 -1.008 . . . . 0.0 109.939 179.111 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 93.0 m-85 -157.37 150.33 23.44 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.416 -0.802 . . . . 0.0 109.814 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . 0.464 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 57.0 ttt180 -93.62 141.16 28.79 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.67 -1.269 . . . . 0.0 110.036 174.137 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.473 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 94.7 m -129.95 141.07 50.82 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.579 -0.701 . . . . 0.0 109.767 -173.683 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.586 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -129.93 143.78 50.98 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.989 -1.069 . . . . 0.0 111.472 -179.161 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.538 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 6.4 t -123.38 132.93 70.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.161 -0.962 . . . . 0.0 110.709 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.556 HG13 ' CE1' ' B' ' 61' ' ' PHE . 26.7 m -115.08 174.44 3.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 121.688 -0.633 . . . . 0.0 110.226 178.677 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.513 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 12.8 tt0 -104.28 118.65 37.13 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.455 -0.778 . . . . 0.0 108.972 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.469 HD21 ' O ' ' B' ' 32' ' ' MET . 9.5 tp -81.13 122.58 81.69 Favored Pre-proline 0 C--N 1.296 -1.738 0 O-C-N 121.573 -0.704 . . . . 0.0 109.651 -174.818 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.479 ' HD2' ' HB2' ' B' ' 32' ' ' MET . 18.2 Cg_endo -63.43 174.01 3.84 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.842 1.443 . . . . 0.0 110.564 -179.35 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -60.02 -39.46 85.93 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.501 -0.749 . . . . 0.0 110.56 -176.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.578 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.03 0.05 57.32 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.932 -1.105 . . . . 0.0 110.848 -174.974 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.578 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 95.8 mmm -109.73 -11.75 14.7 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.83 -1.169 . . . . 0.0 109.846 170.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.541 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 15.3 mt -69.26 -40.02 78.09 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.32 -0.863 . . . . 0.0 110.305 179.272 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -80.06 123.91 28.27 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.266 -0.896 . . . . 0.0 110.463 -177.054 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.11 -47.1 1.08 Allowed Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.784 -1.198 . . . . 0.0 110.391 175.116 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . 0.428 HD22 ' N ' ' B' ' 37' ' ' GLU . 8.2 tt -67.26 147.3 53.19 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.001 -1.294 . . . . 0.0 110.805 -175.093 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . 0.468 ' O ' ' HB2' ' B' ' 40' ' ' ALA . 21.3 pt-20 -150.02 168.94 22.41 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.432 -0.792 . . . . 0.0 109.677 -179.617 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.548 ' CG2' HD11 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -66.77 148.86 51.37 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.95 -1.094 . . . . 0.0 110.106 -179.912 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.0 -10.09 58.78 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -175.509 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.468 ' HB2' ' O ' ' B' ' 37' ' ' GLU . . . -71.33 157.76 37.53 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.17 -1.194 . . . . 0.0 109.102 174.669 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 41' ' ' SER . . . . . 0.526 ' O ' ' CB ' ' B' ' 87' ' ' ALA . 1.7 p -105.02 116.44 31.96 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 118.844 -1.142 . . . . 0.0 109.968 175.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.59 HG13 ' CE1' ' B' ' 44' ' ' HIS . 1.5 t -99.9 126.4 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.472 -0.768 . . . . 0.0 108.971 175.432 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.474 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -88.23 119.43 28.63 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.094 -1.004 . . . . 0.0 109.16 173.401 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.59 ' CE1' HG13 ' B' ' 42' ' ' VAL . 0.4 OUTLIER -89.7 105.26 17.68 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.369 -0.832 . . . . 0.0 109.019 177.934 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.8 t-20 57.13 9.77 0.72 Allowed 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.515 -0.74 . . . . 0.0 111.464 -170.427 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 126.55 -1.93 7.55 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.504 -1.332 . . . . 0.0 110.84 173.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.519 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 50.1 t -98.85 104.79 16.87 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.534 -1.568 . . . . 0.0 109.707 176.257 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . 0.435 ' HA ' ' HA ' ' B' ' 43' ' ' ALA . 25.1 p -71.17 129.07 37.99 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.124 -0.985 . . . . 0.0 110.667 -174.489 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.638 ' CD1' ' CD2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -141.65 159.85 41.37 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.348 -0.845 . . . . 0.0 109.239 173.857 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 23.7 m -99.69 150.02 22.72 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.588 -1.32 . . . . 0.0 111.412 -170.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.469 ' HB ' ' HA ' ' B' ' 38' ' ' THR . 32.6 t -76.23 116.47 19.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.855 -0.528 . . . . 0.0 110.382 -179.225 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.537 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 28.6 p -71.92 -40.04 69.07 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.297 -0.877 . . . . 0.0 109.722 174.29 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.532 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -163.21 152.83 15.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.342 -0.849 . . . . 0.0 110.421 -178.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.548 HD11 ' CG2' ' B' ' 38' ' ' THR . 7.6 mt -105.51 132.03 53.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.295 -0.878 . . . . 0.0 110.012 175.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.482 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 26.5 m-80 -104.87 64.82 0.73 Allowed 'General case' 0 C--N 1.297 -1.698 0 C-N-CA 120.048 -0.661 . . . . 0.0 109.562 179.285 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.72 -117.0 5.3 Favored Glycine 0 N--CA 1.487 2.063 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 -173.182 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.541 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -76.97 -20.9 55.54 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.076 -1.249 . . . . 0.0 109.164 175.73 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.627 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 11.2 m80 -75.59 159.79 30.83 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.338 -0.851 . . . . 0.0 110.285 -177.683 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.472 HG21 ' O ' ' B' ' 58' ' ' HIS . 56.7 t -140.46 123.1 16.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.76 173.361 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.538 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 1.3 t -90.67 134.67 34.24 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.481 -0.762 . . . . 0.0 109.54 177.278 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.638 ' CD2' ' CD1' ' B' ' 49' ' ' LEU . 2.7 p90 -126.93 151.05 49.0 Favored 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.314 176.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.537 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 38.2 p-10 -86.39 154.81 20.9 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.927 -1.108 . . . . 0.0 111.442 -171.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.593 ' CD2' ' CD1' ' B' ' 68' ' ' LEU . 0.0 OUTLIER -161.94 100.42 1.12 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.76 -0.588 . . . . 0.0 109.608 -175.614 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.475 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 33.0 ttp -60.67 139.99 57.64 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.836 -1.165 . . . . 0.0 109.53 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.474 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 29.5 tptp -59.94 -48.41 81.81 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.946 -1.096 . . . . 0.0 110.469 -172.69 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -63.24 -40.02 96.25 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.792 -1.193 . . . . 0.0 109.792 177.467 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.475 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 55.5 m -60.01 -39.88 87.36 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.188 -0.945 . . . . 0.0 109.657 172.691 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.593 ' CD1' ' CD2' ' B' ' 63' ' ' LEU . 27.1 tp -61.73 -40.66 95.84 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.504 -0.748 . . . . 0.0 109.892 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 15.6 ttm180 -69.96 -40.01 75.66 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.34 -0.85 . . . . 0.0 110.52 176.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.46 ' CG2' ' N ' ' B' ' 71' ' ' THR . 1.2 tt -64.87 -44.47 96.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.296 -0.877 . . . . 0.0 109.623 -176.618 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.47 HG23 ' O ' ' B' ' 67' ' ' THR . 30.4 p -80.18 -174.89 4.76 Favored 'General case' 0 C--N 1.301 -1.538 0 C-N-CA 119.84 -0.744 . . . . 0.0 109.294 175.247 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.5 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 3.9 t30 -99.97 23.41 9.87 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.069 -1.02 . . . . 0.0 108.406 169.458 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.533 ' CD1' HD23 ' B' ' 63' ' ' LEU . 87.7 mt -69.25 -40.03 78.11 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.09 -1.006 . . . . 0.0 109.768 174.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.531 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -46.81 -22.38 1.14 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -179.365 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.3 p-10 -69.08 -16.9 63.79 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.905 -1.35 . . . . 0.0 110.488 -174.62 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.503 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.3 mt -60.1 141.29 56.04 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.229 -0.92 . . . . 0.0 111.06 -176.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.477 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 24.9 mttm -142.47 143.07 32.42 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.725 -0.61 . . . . 0.0 109.694 174.073 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.552 ' CG2' HG13 ' B' ' 15' ' ' ILE . 32.7 t -63.19 150.05 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.924 -1.11 . . . . 0.0 110.317 -177.188 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.38 -14.7 60.4 Favored Glycine 0 N--CA 1.486 1.974 0 N-CA-C 108.777 -1.729 . . . . 0.0 108.777 -175.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.488 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 41.8 t0 -94.43 167.68 11.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.426 -1.044 . . . . 0.0 109.635 175.749 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.583 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.1 m95 -116.64 158.83 23.12 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.074 -1.016 . . . . 0.0 110.068 175.088 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.575 HG21 ' CG ' ' B' ' 44' ' ' HIS . 1.0 OUTLIER -121.32 155.33 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.419 -0.801 . . . . 0.0 109.887 179.457 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.499 ' N ' ' CB ' ' A' ' 72' ' ' ASN . 0.2 OUTLIER -78.39 105.29 9.55 Favored 'General case' 0 C--N 1.297 -1.674 0 O-C-N 121.105 -0.997 . . . . 0.0 109.147 168.007 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.503 ' CG2' ' C ' ' B' ' 9' ' ' THR . 0.0 OUTLIER -106.49 138.12 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 120.596 -1.315 . . . . 0.0 110.894 -176.821 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -139.29 140.21 37.55 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 120.268 -0.573 . . . . 0.0 109.914 -177.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 53.0 ttt85 -59.99 127.04 29.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.176 -0.953 . . . . 0.0 110.267 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.526 ' CB ' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.442 -0.786 . . . . 0.0 109.444 176.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.529 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.2 t . . . . . 0 N--CA 1.493 1.717 0 CA-C-O 121.529 0.68 . . . . 0.0 110.399 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -95.21 -22.06 18.06 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.493 -0.755 . . . . 0.0 110.75 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.529 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -144.43 175.59 24.1 Favored Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.081 -1.533 . . . . 0.0 109.968 -176.209 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.434 ' C ' HG22 ' A' ' 84' ' ' VAL . 6.2 p -127.51 166.04 18.72 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.06 -1.259 . . . . 0.0 110.625 179.227 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.516 ' CB ' ' CG1' ' A' ' 82' ' ' VAL . . . -133.94 148.84 51.23 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.598 -0.689 . . . . 0.0 109.258 -178.681 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 23.5 tttt -107.66 116.89 32.76 Favored 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.113 -0.992 . . . . 0.0 110.147 179.353 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.515 HD22 ' N ' ' A' ' 78' ' ' VAL . 12.2 tp -59.92 126.32 27.08 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 120.876 -1.14 . . . . 0.0 108.914 173.333 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.595 HG13 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -124.95 -30.8 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 C-N-CA 119.744 -0.782 . . . . 0.0 109.718 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.59 142.36 27.89 Favored 'General case' 0 N--CA 1.492 1.653 0 C-N-CA 119.214 -0.995 . . . . 0.0 111.127 -178.098 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.582 HG12 ' CD2' ' A' ' 24' ' ' HIS . 10.6 mt -108.62 130.19 61.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.113 -0.992 . . . . 0.0 110.314 172.4 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.479 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 74.1 m-20 -104.49 117.76 34.95 Favored 'General case' 0 C--N 1.295 -1.769 0 O-C-N 121.376 -0.827 . . . . 0.0 109.809 172.755 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -107.4 105.31 15.18 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.146 -0.971 . . . . 0.0 110.176 -177.518 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.472 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 2.1 mmmt -102.2 130.56 23.98 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.347 -0.846 . . . . 0.0 109.282 179.219 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -51.5 -19.43 7.12 Favored 'Trans proline' 0 C--N 1.303 -1.856 0 O-C-N 123.913 1.481 . . . . 0.0 110.573 -179.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.573 ' O ' ' CD1' ' A' ' 21' ' ' PHE . 0.3 OUTLIER -90.54 -38.37 13.24 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.169 -0.957 . . . . 0.0 109.102 177.268 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.573 ' CD1' ' O ' ' A' ' 20' ' ' ASN . 64.6 m-85 -153.15 150.18 28.8 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.833 -0.542 . . . . 0.0 110.148 -177.651 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.472 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 63.4 ttt180 -88.43 145.03 26.01 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.6 -1.313 . . . . 0.0 109.941 174.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.479 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 84.8 m -133.08 140.82 47.87 Favored 'General case' 0 C--N 1.296 -1.752 0 O-C-N 121.407 -0.808 . . . . 0.0 109.946 -174.173 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.582 ' CD2' HG12 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.03 131.96 46.04 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.767 -1.208 . . . . 0.0 111.561 -179.669 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 4.0 t -109.85 132.28 58.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.184 -0.947 . . . . 0.0 110.537 -178.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.469 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 15.5 m -117.44 169.85 7.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 120.359 -0.537 . . . . 0.0 110.343 -179.111 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.479 ' HG3' ' NE2' ' A' ' 58' ' ' HIS . 13.1 tt0 -103.22 118.31 36.5 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.215 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.513 ' CD2' ' O ' ' A' ' 32' ' ' MET . 9.5 tp -84.14 126.37 70.05 Favored Pre-proline 0 C--N 1.298 -1.667 0 O-C-N 121.327 -0.858 . . . . 0.0 109.759 -175.073 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.46 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 17.7 Cg_endo -64.27 176.84 2.37 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 123.903 1.475 . . . . 0.0 110.927 -179.192 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 77.4 m-20 -60.06 -39.94 87.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.427 -0.796 . . . . 0.0 110.997 -176.37 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.557 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.13 2.57 55.15 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.797 -1.19 . . . . 0.0 110.744 -174.457 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.557 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 89.1 mmm -113.07 -11.89 13.27 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.912 -1.118 . . . . 0.0 109.991 170.364 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.525 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 18.1 mt -69.97 -40.1 75.58 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.321 -0.862 . . . . 0.0 110.378 178.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -82.68 115.76 21.76 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.905 . . . . 0.0 110.505 -176.384 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.61 -52.75 0.69 Allowed Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.81 -1.186 . . . . 0.0 110.376 175.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.48 HD11 ' CB ' ' A' ' 40' ' ' ALA . 42.6 tp -61.52 151.34 33.23 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.955 -1.321 . . . . 0.0 110.851 -173.471 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.471 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 20.9 pt-20 -149.95 168.33 24.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.468 -0.77 . . . . 0.0 109.484 178.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.528 ' CG2' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -66.09 152.84 43.82 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.885 -1.134 . . . . 0.0 109.982 -178.985 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.31 -4.72 66.31 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -176.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.48 ' CB ' HD11 ' A' ' 36' ' ' LEU . . . -77.26 156.64 31.27 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.291 -1.123 . . . . 0.0 109.668 176.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.468 ' HB2' ' HB3' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -100.61 108.24 20.09 Favored 'General case' 0 C--N 1.306 -1.286 0 O-C-N 121.103 -0.998 . . . . 0.0 110.087 178.629 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.581 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 2.2 t -94.24 129.45 44.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.224 -0.923 . . . . 0.0 109.125 174.203 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.453 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -93.33 119.54 32.59 Favored 'General case' 0 C--N 1.296 -1.724 0 C-N-CA 119.258 -0.977 . . . . 0.0 109.07 171.572 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.575 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.3 OUTLIER -89.17 102.6 15.26 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.64 -0.824 . . . . 0.0 108.94 178.463 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.497 ' N ' ' O ' ' A' ' 83' ' ' ASN . 1.7 t-20 58.22 11.49 1.58 Allowed 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.449 -0.782 . . . . 0.0 110.772 -169.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.491 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.16 -2.29 11.56 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.777 -1.201 . . . . 0.0 110.891 172.672 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.491 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 43.0 t -92.16 109.17 20.53 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.39 -1.653 . . . . 0.0 109.389 174.352 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 15.8 p -74.89 128.43 35.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.099 -1.001 . . . . 0.0 110.844 -171.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.52 ' CD1' ' HB3' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -146.96 157.0 43.5 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.347 -0.846 . . . . 0.0 109.499 173.741 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 23.9 m -97.5 159.0 15.18 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.735 -1.228 . . . . 0.0 111.296 -170.6 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.556 ' CG1' HG12 ' A' ' 59' ' ' VAL . 22.4 t -83.26 116.63 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.832 -0.542 . . . . 0.0 110.43 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.529 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 39.4 p -70.0 -39.91 75.6 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.241 -0.912 . . . . 0.0 109.715 172.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.515 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.9 tt0 -160.95 154.83 22.5 Favored 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 119.357 -0.937 . . . . 0.0 111.204 -175.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.528 HD11 ' CG2' ' A' ' 38' ' ' THR . 6.4 mt -110.06 129.99 64.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.091 -1.006 . . . . 0.0 110.044 169.497 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.453 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 27.7 m-80 -103.7 65.12 0.82 Allowed 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.592 -0.692 . . . . 0.0 109.514 176.648 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.49 -113.4 3.82 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.812 -1.715 . . . . 0.0 108.812 -173.263 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.525 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -79.99 -21.07 44.09 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.05 -1.265 . . . . 0.0 109.168 175.405 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.595 ' CD2' HG13 ' A' ' 13' ' ' VAL . 8.5 m170 -77.65 159.99 28.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.246 -0.909 . . . . 0.0 110.112 -176.488 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.624 ' CG1' ' CZ ' ' A' ' 61' ' ' PHE . 97.7 t -144.4 115.43 2.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 C-N-CA 119.309 -0.957 . . . . 0.0 110.891 177.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.532 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 13.7 m -81.74 130.15 34.96 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.677 -0.639 . . . . 0.0 109.849 178.465 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.624 ' CZ ' ' CG1' ' A' ' 59' ' ' VAL . 96.4 m-85 -115.19 159.98 20.28 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.952 -1.092 . . . . 0.0 110.235 178.037 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.529 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 25.7 p-10 -95.2 147.81 23.07 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.163 -0.961 . . . . 0.0 111.335 -177.019 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.524 HD21 ' CD1' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -159.14 116.47 2.75 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.718 -0.614 . . . . 0.0 109.559 -175.729 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.464 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 57.9 ttm -75.27 146.97 40.63 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.863 -1.148 . . . . 0.0 109.852 179.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.466 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 39.0 ttpt -60.07 -49.75 76.4 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.078 -1.014 . . . . 0.0 110.305 -177.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -63.95 -42.46 97.3 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.895 -1.128 . . . . 0.0 110.17 178.574 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.492 ' O ' HG21 ' A' ' 71' ' ' THR . 69.4 m -60.31 -40.04 89.12 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.932 -1.105 . . . . 0.0 109.606 174.332 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.526 ' HG ' ' CA ' ' A' ' 74' ' ' GLY . 11.7 tp -59.99 -43.16 95.33 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.288 -0.882 . . . . 0.0 109.582 177.756 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 16.4 mmm180 -70.0 -40.07 75.52 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.57 -0.706 . . . . 0.0 110.608 177.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.478 ' CG2' ' N ' ' A' ' 71' ' ' THR . 1.5 tt -66.15 -43.72 91.95 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.209 -0.932 . . . . 0.0 109.329 -177.169 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.492 HG21 ' O ' ' A' ' 67' ' ' THR . 32.9 p -84.7 -171.01 3.4 Favored 'General case' 0 C--N 1.297 -1.68 0 CA-C-O 121.361 0.601 . . . . 0.0 109.673 178.013 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.519 ' CB ' ' N ' ' B' ' 83' ' ' ASN . 1.6 t30 -103.2 21.84 15.14 Favored 'General case' 0 C--N 1.293 -1.862 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 170.477 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.524 ' CD1' HD21 ' A' ' 63' ' ' LEU . 91.5 mt -66.26 -40.0 89.84 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.939 -1.101 . . . . 0.0 109.787 173.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.526 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -49.79 -25.17 6.75 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -178.543 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 24.0 p-10 -65.99 -16.63 64.06 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.001 -1.294 . . . . 0.0 110.508 -174.816 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 96.2 mt -60.01 140.17 56.96 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.151 -0.968 . . . . 0.0 110.65 -176.805 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.487 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 26.0 mttt -144.07 140.33 29.43 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-O 121.346 0.593 . . . . 0.0 109.688 176.01 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.571 ' CG2' HG13 ' A' ' 15' ' ' ILE . 18.8 t -61.77 150.17 8.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 120.686 -1.259 . . . . 0.0 110.524 -173.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.61 -13.63 63.57 Favored Glycine 0 N--CA 1.482 1.733 0 N-CA-C 108.855 -1.698 . . . . 0.0 108.855 -176.463 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.408 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 34.8 t0 -95.36 169.94 9.72 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.324 -1.104 . . . . 0.0 109.459 175.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.584 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.3 m95 -117.47 168.31 10.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.908 -1.12 . . . . 0.0 110.245 175.785 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.575 HG21 ' CG ' ' A' ' 44' ' ' HIS . 1.4 p -130.17 153.05 38.37 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.491 -0.756 . . . . 0.0 109.696 179.369 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.533 ' N ' ' CB ' ' B' ' 72' ' ' ASN . 2.2 m-20 -79.77 106.02 11.5 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 120.89 -1.131 . . . . 0.0 109.043 170.019 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.459 HG11 HG23 ' A' ' 82' ' ' VAL . 0.1 OUTLIER -106.23 139.98 25.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 120.481 -1.387 . . . . 0.0 111.37 -175.042 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.467 ' HB2' HG23 ' A' ' 6' ' ' VAL . 86.5 tt0 -131.02 142.6 50.34 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.037 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 39.6 ttm180 -81.24 121.07 25.7 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 110.481 -178.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.468 ' HB3' ' HB2' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.23 -0.919 . . . . 0.0 110.124 176.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.528 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.2 t . . . . . 0 N--CA 1.493 1.691 0 CA-C-O 121.474 0.654 . . . . 0.0 110.398 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -95.35 -21.78 18.17 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.483 -0.76 . . . . 0.0 110.788 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.528 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -144.63 175.4 24.35 Favored Glycine 0 N--CA 1.493 2.459 0 C-N-CA 119.273 -1.441 . . . . 0.0 110.141 -176.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.442 ' C ' HG22 ' B' ' 84' ' ' VAL . 6.1 p -127.45 166.09 18.58 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.118 -1.225 . . . . 0.0 110.589 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.514 ' CB ' ' CG1' ' B' ' 82' ' ' VAL . . . -133.9 148.98 51.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.631 -0.668 . . . . 0.0 109.254 -178.75 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.581 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 23.6 tttt -107.79 116.91 32.81 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.121 -0.987 . . . . 0.0 110.109 179.326 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.505 HD21 ' N ' ' B' ' 78' ' ' VAL . 12.2 tp -59.96 126.3 27.02 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.963 -1.086 . . . . 0.0 108.98 173.308 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.595 HG12 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -124.93 -30.86 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 O-C-N 121.451 -0.781 . . . . 0.0 109.724 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.56 142.45 28.01 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.37 -0.932 . . . . 0.0 111.098 -178.135 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.574 HG12 ' CD2' ' B' ' 24' ' ' HIS . 10.7 mt -108.68 130.24 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.176 -0.952 . . . . 0.0 110.315 172.4 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.489 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 73.5 m-20 -104.71 117.88 35.18 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.287 -0.883 . . . . 0.0 109.662 172.892 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -107.4 105.37 15.26 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.105 -0.997 . . . . 0.0 110.157 -177.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . 0.473 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 2.1 mmmt -102.23 130.5 24.08 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.427 -0.796 . . . . 0.0 109.276 179.189 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -51.55 -19.33 7.11 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 123.889 1.468 . . . . 0.0 110.606 -179.491 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.587 ' ND2' ' N ' ' B' ' 20' ' ' ASN . 0.3 OUTLIER -90.43 -38.94 12.95 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.176 -0.952 . . . . 0.0 108.941 177.272 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' B' ' 20' ' ' ASN . 64.8 m-85 -152.71 150.27 29.26 Favored 'General case' 0 N--CA 1.494 1.765 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.15 -177.562 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . 0.471 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 63.5 ttt180 -88.47 144.89 26.07 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.701 -1.249 . . . . 0.0 109.889 174.421 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.489 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 84.9 m -132.96 140.84 48.01 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.55 -0.719 . . . . 0.0 109.927 -174.213 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.574 ' CD2' HG12 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -129.98 132.1 46.17 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.941 -1.099 . . . . 0.0 111.454 -179.654 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.528 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 4.0 t -109.89 132.44 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.349 -0.844 . . . . 0.0 110.571 -178.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.479 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 16.0 m -117.61 169.78 7.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 CA-C-O 121.304 0.573 . . . . 0.0 110.215 -178.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.469 ' HG3' ' NE2' ' B' ' 58' ' ' HIS . 13.1 tt0 -103.09 118.48 36.89 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.102 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.519 ' CD2' ' O ' ' B' ' 32' ' ' MET . 9.5 tp -84.2 126.31 70.09 Favored Pre-proline 0 C--N 1.297 -1.711 0 O-C-N 121.254 -0.904 . . . . 0.0 109.749 -175.122 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.472 ' HD2' HD12 ' B' ' 28' ' ' LEU . 17.7 Cg_endo -64.27 176.8 2.39 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 O-C-N 123.865 1.455 . . . . 0.0 110.869 -179.191 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 77.3 m-20 -60.04 -40.0 87.88 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.413 -0.805 . . . . 0.0 111.007 -176.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.559 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.96 2.49 55.04 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.863 -1.148 . . . . 0.0 110.847 -174.552 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.559 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 89.2 mmm -113.06 -11.94 13.27 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.894 -1.129 . . . . 0.0 110.012 170.373 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.519 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 18.1 mt -69.96 -40.05 75.64 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.245 -0.91 . . . . 0.0 110.404 178.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -82.67 115.78 21.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.201 -0.937 . . . . 0.0 110.48 -176.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.62 -52.74 0.69 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.81 -1.185 . . . . 0.0 110.4 175.378 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 42.8 tp -61.65 151.42 33.61 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.919 -1.342 . . . . 0.0 110.795 -173.41 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . 0.478 ' HA ' HD13 ' B' ' 54' ' ' ILE . 20.9 pt-20 -149.96 168.37 24.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.531 -0.731 . . . . 0.0 109.452 178.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.518 ' CG2' HD12 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.2 152.68 44.32 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.882 -1.136 . . . . 0.0 109.995 -178.921 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.52 -4.73 67.13 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 -176.388 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.478 ' HB2' ' O ' ' B' ' 37' ' ' GLU . . . -77.4 156.48 31.15 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.299 -1.118 . . . . 0.0 109.616 176.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 41' ' ' SER . . . . . 0.461 ' HB2' ' HB2' ' B' ' 87' ' ' ALA . 0.1 OUTLIER -100.26 108.1 20.09 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.059 -1.026 . . . . 0.0 110.173 178.616 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.582 ' HB ' ' CE1' ' B' ' 61' ' ' PHE . 2.2 t -94.37 129.52 44.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.263 -0.898 . . . . 0.0 109.147 174.178 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.449 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -93.27 119.58 32.59 Favored 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 119.231 -0.988 . . . . 0.0 109.042 171.635 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.581 ' CE1' HG11 ' B' ' 42' ' ' VAL . 0.3 OUTLIER -89.21 102.55 15.21 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.319 -0.863 . . . . 0.0 108.946 178.434 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.488 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.8 t-20 58.38 11.47 1.66 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.511 -0.743 . . . . 0.0 110.68 -170.007 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.491 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.07 -2.13 11.65 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.888 172.662 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.481 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 43.4 t -92.35 109.18 20.56 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.428 -1.631 . . . . 0.0 109.355 174.319 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 15.9 p -74.78 128.57 35.88 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.161 -0.962 . . . . 0.0 110.744 -171.736 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.519 ' CD1' ' HB3' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -147.2 156.85 43.31 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.448 -0.782 . . . . 0.0 109.477 173.649 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 23.8 m -97.26 159.09 15.12 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.737 -1.227 . . . . 0.0 111.281 -170.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.55 ' CG1' HG12 ' B' ' 59' ' ' VAL . 22.7 t -83.39 116.72 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.679 -0.638 . . . . 0.0 110.437 -178.524 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.523 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 39.8 p -70.01 -39.96 75.51 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.159 -0.963 . . . . 0.0 109.664 172.843 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.517 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.9 tt0 -160.93 154.76 22.43 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.409 -0.916 . . . . 0.0 111.172 -175.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.518 HD12 ' CG2' ' B' ' 38' ' ' THR . 6.4 mt -109.97 129.99 63.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.115 -0.991 . . . . 0.0 110.03 169.525 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.458 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 27.6 m-80 -103.74 65.1 0.81 Allowed 'General case' 0 C--N 1.299 -1.615 0 C-N-CA 119.862 -0.735 . . . . 0.0 109.564 176.608 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.68 -113.43 3.81 Favored Glycine 0 N--CA 1.486 2.012 0 N-CA-C 108.715 -1.754 . . . . 0.0 108.715 -173.279 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.519 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.02 -21.1 43.93 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.061 -1.258 . . . . 0.0 109.152 175.45 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.595 ' CD2' HG12 ' B' ' 13' ' ' VAL . 8.5 m170 -77.54 159.81 29.05 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.186 -0.947 . . . . 0.0 110.108 -176.535 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.63 ' CG1' ' CZ ' ' B' ' 61' ' ' PHE . 97.1 t -144.31 115.47 2.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 C-N-CA 119.284 -0.967 . . . . 0.0 110.912 177.71 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.528 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 13.7 m -81.83 130.28 35.02 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.751 -0.593 . . . . 0.0 109.931 178.494 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.63 ' CZ ' ' CG1' ' B' ' 59' ' ' VAL . 96.4 m-85 -115.27 160.02 20.29 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.977 -1.077 . . . . 0.0 110.275 178.107 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.523 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 25.7 p-10 -95.2 147.77 23.11 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.012 -1.055 . . . . 0.0 111.273 -176.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.526 HD22 ' CD1' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.16 116.43 2.73 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.788 -0.57 . . . . 0.0 109.538 -175.744 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.454 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 58.0 ttm -75.25 146.99 40.66 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.867 -1.146 . . . . 0.0 109.851 179.275 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.463 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 39.0 ttpt -60.04 -49.88 75.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.041 -1.037 . . . . 0.0 110.249 -177.63 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -63.94 -42.4 97.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.888 -1.132 . . . . 0.0 110.241 178.64 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.454 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 71.3 m -60.27 -40.07 89.08 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.003 -1.061 . . . . 0.0 109.671 174.258 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.532 ' CD1' ' HA2' ' B' ' 74' ' ' GLY . 11.7 tp -59.94 -43.18 95.13 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.438 -0.789 . . . . 0.0 109.559 177.733 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 16.4 mmm180 -69.98 -39.93 75.65 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.562 -0.711 . . . . 0.0 110.665 177.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.472 ' CG2' ' N ' ' B' ' 71' ' ' THR . 1.5 tt -66.22 -43.69 91.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 CA-C-O 121.922 0.868 . . . . 0.0 109.363 -177.195 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.472 ' N ' ' CG2' ' B' ' 70' ' ' ILE . 33.0 p -84.6 -170.77 3.28 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 121.44 0.638 . . . . 0.0 109.708 177.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.533 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 1.6 t30 -103.39 21.82 15.31 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 170.531 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.526 ' CD1' HD22 ' B' ' 63' ' ' LEU . 91.7 mt -66.22 -40.02 89.99 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.917 -1.114 . . . . 0.0 109.736 173.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.532 ' HA2' ' CD1' ' B' ' 68' ' ' LEU . . . -49.78 -25.18 6.75 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 110.429 -1.068 . . . . 0.0 110.429 -178.496 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 24.2 p-10 -66.02 -16.64 64.08 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.995 -1.297 . . . . 0.0 110.433 -174.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.517 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 96.2 mt -59.98 140.21 56.91 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.155 -0.965 . . . . 0.0 110.639 -176.784 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.482 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 26.0 mttt -144.13 140.4 29.39 Favored 'General case' 0 C--N 1.296 -1.737 0 O-C-N 121.796 -0.565 . . . . 0.0 109.675 175.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.567 ' CG2' HG13 ' B' ' 15' ' ' ILE . 19.0 t -61.82 150.25 8.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 120.942 -1.099 . . . . 0.0 110.536 -173.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.47 -13.49 63.73 Favored Glycine 0 N--CA 1.483 1.778 0 N-CA-C 108.959 -1.656 . . . . 0.0 108.959 -176.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.413 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 34.4 t0 -95.35 169.95 9.71 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.366 -1.079 . . . . 0.0 109.51 175.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.581 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.3 m95 -117.52 168.19 10.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.951 -1.093 . . . . 0.0 110.261 175.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.572 HG22 ' CG ' ' B' ' 44' ' ' HIS . 1.4 p -130.15 153.14 38.49 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.465 -0.772 . . . . 0.0 109.63 179.307 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.519 ' N ' ' CB ' ' A' ' 72' ' ' ASN . 2.1 m-20 -79.77 105.72 11.27 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 120.97 -1.081 . . . . 0.0 109.158 170.023 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.444 HG11 HG21 ' B' ' 82' ' ' VAL . 0.1 OUTLIER -106.06 140.0 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.45 -1.406 . . . . 0.0 111.331 -174.873 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -131.01 142.69 50.35 Favored 'General case' 0 N--CA 1.492 1.675 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.059 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 39.5 ttm180 -81.31 121.2 25.9 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.36 -0.838 . . . . 0.0 110.351 -178.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.461 ' HB2' ' HB2' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.612 0 O-C-N 121.275 -0.891 . . . . 0.0 110.158 176.491 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.539 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 1.5 t . . . . . 0 N--CA 1.493 1.689 0 CA-C-O 121.676 0.75 . . . . 0.0 110.568 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -69.98 -33.6 72.27 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.669 -0.644 . . . . 0.0 110.708 -178.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.539 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -153.42 174.75 32.02 Favored Glycine 0 N--CA 1.495 2.585 0 C-N-CA 118.957 -1.592 . . . . 0.0 110.395 -172.645 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.497 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 17.9 p -120.61 169.0 10.78 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.991 -1.3 . . . . 0.0 111.008 -177.263 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.482 ' O ' ' HA ' ' A' ' 81' ' ' TRP . . . -138.07 149.5 46.05 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.6 -0.687 . . . . 0.0 109.432 -175.337 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 19.1 tttt -106.47 117.3 33.7 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.076 -1.015 . . . . 0.0 110.216 179.088 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.515 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 12.0 tp -59.93 128.52 37.27 Favored 'General case' 0 C--N 1.298 -1.643 0 O-C-N 120.885 -1.135 . . . . 0.0 108.737 172.523 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.601 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.58 -28.81 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 O-C-N 121.369 -0.832 . . . . 0.0 110.055 -178.152 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.53 140.2 24.77 Favored 'General case' 0 N--CA 1.494 1.757 0 C-N-CA 119.14 -1.024 . . . . 0.0 111.385 -178.766 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.577 HG13 ' CG2' ' A' ' 78' ' ' VAL . 7.0 mt -107.01 133.16 52.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.002 -1.061 . . . . 0.0 110.043 169.845 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.471 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 86.9 m-20 -109.98 114.51 28.09 Favored 'General case' 0 C--N 1.294 -1.832 0 O-C-N 121.443 -0.786 . . . . 0.0 109.987 173.795 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -103.9 116.6 32.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.047 -1.033 . . . . 0.0 110.388 -177.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.418 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -111.67 135.1 21.13 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.298 -0.876 . . . . 0.0 109.344 178.205 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -51.8 -18.44 6.52 Favored 'Trans proline' 0 C--N 1.303 -1.829 0 O-C-N 123.906 1.477 . . . . 0.0 110.774 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.575 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 4.9 m-80 -97.2 -32.6 11.85 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.027 -1.046 . . . . 0.0 110.423 178.59 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.575 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 83.2 m-85 -158.03 150.41 22.28 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.272 -0.893 . . . . 0.0 110.208 -177.394 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.468 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 65.8 ttt180 -90.72 144.11 26.06 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.7 -1.25 . . . . 0.0 110.03 176.648 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.471 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 96.8 m -129.84 139.96 51.1 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.607 -0.683 . . . . 0.0 109.746 -175.278 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.576 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.21 139.72 50.79 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.972 -1.08 . . . . 0.0 111.164 179.766 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.486 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 4.0 t -120.51 132.52 69.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 O-C-N 121.051 -1.031 . . . . 0.0 110.468 -178.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 31.7 m -115.88 171.37 5.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.862 -0.524 . . . . 0.0 110.026 179.411 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.563 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 10.4 tt0 -108.54 115.7 30.59 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.516 ' CD2' ' O ' ' A' ' 32' ' ' MET . 8.7 tp -86.8 127.97 58.05 Favored Pre-proline 0 C--N 1.296 -1.725 0 O-C-N 121.206 -0.934 . . . . 0.0 110.285 -172.109 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.472 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 28.9 Cg_endo -66.72 177.1 3.68 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 O-C-N 123.941 1.496 . . . . 0.0 111.05 -179.401 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -60.07 -40.06 88.21 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.23 -0.919 . . . . 0.0 111.083 -174.251 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.574 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.02 0.86 56.88 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.814 -1.178 . . . . 0.0 110.959 -174.655 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.574 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.8 mmm -112.59 -12.03 13.49 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.958 -1.089 . . . . 0.0 109.964 172.282 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.544 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 19.8 mt -70.07 -39.97 75.33 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.408 -0.807 . . . . 0.0 110.186 177.832 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -73.91 143.13 45.9 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.419 -0.801 . . . . 0.0 110.583 -178.147 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.5 -39.02 3.01 Favored Glycine 0 N--CA 1.492 2.409 0 C-N-CA 119.925 -1.131 . . . . 0.0 110.555 173.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.439 HD22 HD23 ' A' ' 28' ' ' LEU . 50.3 tp -77.54 147.93 35.5 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.896 -1.355 . . . . 0.0 110.892 -174.108 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.469 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 21.3 pt-20 -149.07 166.58 28.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.409 -0.807 . . . . 0.0 109.511 177.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.534 ' CG2' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -64.99 147.78 52.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.825 -1.172 . . . . 0.0 109.862 179.376 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.94 -7.68 62.3 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -175.412 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.469 ' HB1' ' O ' ' A' ' 37' ' ' GLU . . . -74.99 153.18 38.64 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.277 -1.131 . . . . 0.0 109.645 177.319 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.548 ' HB2' ' HB3' ' A' ' 87' ' ' ALA . 0.0 OUTLIER -96.58 110.12 22.59 Favored 'General case' 0 C--N 1.309 -1.19 0 O-C-N 120.76 -1.212 . . . . 0.0 109.955 175.474 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.587 HG11 ' CE1' ' A' ' 44' ' ' HIS . 2.0 t -92.91 130.09 42.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 173.321 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.523 ' HB3' ' CG ' ' A' ' 85' ' ' GLU . . . -93.47 119.69 32.85 Favored 'General case' 0 C--N 1.293 -1.848 0 C-N-CA 119.001 -1.079 . . . . 0.0 109.071 173.12 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.587 ' CE1' HG11 ' A' ' 42' ' ' VAL . 0.3 OUTLIER -90.31 106.02 18.21 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 177.727 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.0 t-20 58.27 7.85 0.73 Allowed 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.341 -0.849 . . . . 0.0 111.547 -169.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.61 -3.2 8.13 Favored Glycine 0 N--CA 1.49 2.292 0 O-C-N 120.703 -1.248 . . . . 0.0 110.549 174.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.48 ' O ' ' HA ' ' A' ' 43' ' ' ALA . 32.6 t -94.37 108.26 20.17 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.59 -1.535 . . . . 0.0 109.812 176.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 19.5 p -70.29 128.54 36.57 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.163 -0.961 . . . . 0.0 110.895 -175.434 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.504 ' CD1' ' HB2' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -143.29 158.03 43.98 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.365 -0.834 . . . . 0.0 109.344 172.347 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 65.0 m -99.51 149.33 23.34 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.559 -1.338 . . . . 0.0 111.403 -170.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.491 ' HB ' ' HA ' ' A' ' 38' ' ' THR . 20.4 t -76.88 114.74 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 CA-C-O 121.01 0.433 . . . . 0.0 110.406 -178.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.518 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 52.6 p -69.32 -40.07 77.84 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.184 -0.947 . . . . 0.0 109.602 173.781 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.527 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 89.3 tt0 -161.49 156.4 23.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.428 -0.795 . . . . 0.0 110.157 -178.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.534 HD11 ' CG2' ' A' ' 38' ' ' THR . 8.2 mt -108.9 129.3 63.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.075 -1.015 . . . . 0.0 109.987 174.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.513 ' CB ' ' HB2' ' A' ' 58' ' ' HIS . 8.6 m-80 -102.39 62.95 0.87 Allowed 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.537 -0.727 . . . . 0.0 109.88 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.67 -117.99 5.33 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.768 -1.733 . . . . 0.0 108.768 -173.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.544 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -74.9 -19.87 59.95 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 120.902 -1.352 . . . . 0.0 108.768 174.216 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.601 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 10.3 m170 -75.61 159.77 30.84 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.424 -0.798 . . . . 0.0 110.129 -177.177 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.466 HG13 HG12 ' A' ' 51' ' ' VAL . 53.6 t -140.55 123.0 15.81 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 121.039 -1.038 . . . . 0.0 110.641 171.092 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.486 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 17.0 m -89.65 128.72 36.11 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.609 -0.682 . . . . 0.0 109.478 177.682 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.58 ' N ' ' CD1' ' A' ' 61' ' ' PHE . 2.4 p90 -124.14 152.38 42.86 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.98 -1.075 . . . . 0.0 110.182 179.002 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.518 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 33.1 p-10 -89.38 156.12 18.9 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 120.986 -1.071 . . . . 0.0 111.708 -171.216 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.526 ' CD2' HD11 ' A' ' 68' ' ' LEU . 0.2 OUTLIER -160.64 101.4 1.33 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.691 -0.631 . . . . 0.0 109.613 -173.416 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.491 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 57.2 ttm -61.53 139.56 58.23 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.57 -1.331 . . . . 0.0 109.174 178.491 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.469 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 78.7 tttt -59.96 -47.87 84.01 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.723 -1.236 . . . . 0.0 110.38 -173.574 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -64.49 -39.95 94.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.876 -1.14 . . . . 0.0 109.87 177.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.491 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 94.6 m -61.38 -39.93 92.45 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.898 -1.126 . . . . 0.0 109.526 173.13 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.531 ' HG ' ' CA ' ' A' ' 74' ' ' GLY . 16.3 tp -59.99 -41.14 91.42 Favored 'General case' 0 C--N 1.3 -1.587 0 O-C-N 121.352 -0.843 . . . . 0.0 109.269 178.378 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -67.02 -39.99 87.17 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.475 -0.766 . . . . 0.0 110.491 173.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.473 HG23 ' O ' ' A' ' 67' ' ' THR . 0.8 OUTLIER -65.64 -43.39 93.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.139 -0.975 . . . . 0.0 109.359 -175.538 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.471 HG23 HG23 ' A' ' 70' ' ' ILE . 24.7 p -84.25 -174.43 5.27 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 175.035 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.4 t30 -101.45 23.48 11.02 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 171.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.507 ' CD1' HD22 ' A' ' 63' ' ' LEU . 91.6 mt -70.05 -39.96 75.4 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.132 -0.98 . . . . 0.0 110.009 176.049 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.531 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -47.53 -22.56 1.74 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 -178.816 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.508 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.3 p-10 -68.69 -17.15 64.02 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.066 -1.255 . . . . 0.0 110.612 -174.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.508 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 89.3 mt -62.38 143.04 57.49 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.243 -0.911 . . . . 0.0 110.909 -177.627 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.495 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 89.8 mttt -141.5 144.61 34.43 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 109.327 -0.619 . . . . 0.0 109.327 174.789 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.577 ' CG2' HG13 ' A' ' 15' ' ' ILE . 47.3 t -64.95 147.28 12.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 120.752 -1.217 . . . . 0.0 110.07 -176.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.55 -14.14 62.14 Favored Glycine 0 N--CA 1.483 1.807 0 N-CA-C 108.616 -1.794 . . . . 0.0 108.616 -173.039 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 39.6 t0 -96.09 166.85 11.55 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.387 -1.067 . . . . 0.0 109.504 175.648 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.584 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.2 m95 -117.64 166.92 11.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.044 -1.035 . . . . 0.0 110.199 177.311 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.481 HG12 ' HB2' ' A' ' 10' ' ' ALA . 1.3 p -132.39 156.57 42.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.382 -0.824 . . . . 0.0 109.984 -178.294 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.511 ' HB2' ' HB3' ' B' ' 72' ' ' ASN . 2.2 m-20 -79.53 105.63 10.97 Favored 'General case' 0 C--N 1.296 -1.752 0 O-C-N 121.03 -1.044 . . . . 0.0 109.097 169.096 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.497 ' CG2' ' C ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -110.24 141.92 24.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 120.382 -1.449 . . . . 0.0 110.873 -176.56 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.523 ' CG ' ' HB3' ' A' ' 43' ' ' ALA . 19.9 pt-20 -149.06 153.83 38.41 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 119.748 -0.781 . . . . 0.0 110.162 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 63.1 ttt180 -68.2 130.03 41.7 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.228 -0.92 . . . . 0.0 110.385 -178.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.548 ' HB3' ' HB2' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.489 1.516 0 O-C-N 121.371 -0.831 . . . . 0.0 109.489 176.494 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.542 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 1.5 t . . . . . 0 N--CA 1.493 1.714 0 CA-C-O 121.731 0.777 . . . . 0.0 110.527 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 88.2 mt-30 -69.97 -33.37 71.99 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.672 -0.642 . . . . 0.0 110.792 -178.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.542 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -153.62 174.52 32.2 Favored Glycine 0 N--CA 1.498 2.767 0 C-N-CA 119.073 -1.537 . . . . 0.0 110.441 -172.583 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.499 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 18.1 p -120.49 168.85 10.9 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.049 -1.265 . . . . 0.0 111.053 -177.254 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.483 ' O ' ' HA ' ' B' ' 81' ' ' TRP . . . -137.96 149.64 46.32 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.549 -0.719 . . . . 0.0 109.396 -175.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.58 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 19.1 tttt -106.54 117.37 33.86 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.105 -0.997 . . . . 0.0 110.194 179.102 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.505 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 12.0 tp -60.02 128.38 36.55 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.0 -1.063 . . . . 0.0 108.818 172.532 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.603 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.45 -28.84 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.926 0 C-N-CA 119.684 -0.806 . . . . 0.0 110.136 -178.148 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.46 140.22 24.86 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.304 -0.958 . . . . 0.0 111.459 -178.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.571 HG23 ' CD2' ' B' ' 24' ' ' HIS . 6.7 mt -106.87 133.12 52.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.922 -1.111 . . . . 0.0 110.145 169.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.486 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 86.9 m-20 -110.04 114.53 28.13 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.555 -0.716 . . . . 0.0 110.026 173.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -103.85 116.52 32.44 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.096 -1.002 . . . . 0.0 110.379 -176.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . 0.42 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -111.59 134.99 21.11 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.285 -0.884 . . . . 0.0 109.35 178.208 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_endo -51.85 -18.44 6.62 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 O-C-N 123.861 1.453 . . . . 0.0 110.734 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.573 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 4.9 m-80 -96.91 -33.32 11.65 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.095 -1.003 . . . . 0.0 110.263 178.62 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.573 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 83.7 m-85 -157.52 150.43 23.25 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.293 -0.879 . . . . 0.0 110.215 -177.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . 0.487 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 65.9 ttt180 -90.61 144.06 26.13 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.926 -1.109 . . . . 0.0 110.074 176.569 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.486 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 96.0 m -129.77 140.03 51.15 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.684 -0.635 . . . . 0.0 109.728 -175.33 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.571 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.18 139.77 50.82 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.007 -1.058 . . . . 0.0 111.118 179.802 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.532 HG22 ' CB ' ' B' ' 60' ' ' SER . 3.9 t -120.51 132.55 69.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.197 -0.939 . . . . 0.0 110.436 -178.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.502 HG13 ' CE1' ' B' ' 61' ' ' PHE . 32.4 m -116.03 171.38 5.1 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 121.691 -0.631 . . . . 0.0 109.922 179.462 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.57 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 10.4 tt0 -108.48 115.71 30.62 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 -179.537 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.519 ' CD2' ' O ' ' B' ' 32' ' ' MET . 8.7 tp -86.69 127.94 58.41 Favored Pre-proline 0 C--N 1.296 -1.732 0 O-C-N 121.148 -0.97 . . . . 0.0 110.28 -172.098 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.478 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 29.1 Cg_endo -66.79 177.12 3.71 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 O-C-N 123.924 1.486 . . . . 0.0 111.056 -179.435 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.421 ' HA ' HD12 ' B' ' 33' ' ' LEU . 96.1 m-20 -60.09 -39.95 87.9 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.273 -0.892 . . . . 0.0 111.159 -174.233 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.579 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.05 0.73 56.97 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.79 -1.194 . . . . 0.0 110.862 -174.671 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.579 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.7 mmm -112.58 -11.86 13.52 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.981 -1.074 . . . . 0.0 109.971 172.255 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.538 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 19.9 mt -70.14 -39.9 75.12 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.354 -0.841 . . . . 0.0 110.185 177.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -73.98 143.11 45.75 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.499 -0.751 . . . . 0.0 110.532 -178.083 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.51 -39.01 3.01 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 119.954 -1.117 . . . . 0.0 110.505 173.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . 0.474 HD21 HD22 ' B' ' 28' ' ' LEU . 50.5 tp -77.47 147.91 35.66 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.86 -1.377 . . . . 0.0 110.826 -174.056 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . 0.469 ' O ' ' HB1' ' B' ' 40' ' ' ALA . 21.4 pt-20 -149.12 166.59 28.31 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.454 -0.779 . . . . 0.0 109.5 177.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.526 ' CG2' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -64.98 147.7 52.96 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.85 -1.156 . . . . 0.0 109.942 179.366 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.06 -7.76 62.43 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -175.393 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.469 ' HB1' ' O ' ' B' ' 37' ' ' GLU . . . -75.02 152.89 38.67 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.336 -1.096 . . . . 0.0 109.64 177.254 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 41' ' ' SER . . . . . 0.536 ' HB2' ' HB3' ' B' ' 87' ' ' ALA . 0.0 OUTLIER -96.09 110.03 22.35 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 120.882 -1.137 . . . . 0.0 110.059 175.39 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.58 HG12 ' CE1' ' B' ' 44' ' ' HIS . 2.0 t -93.08 130.01 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 173.301 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.517 ' HB1' ' CG ' ' B' ' 85' ' ' GLU . . . -93.38 119.67 32.77 Favored 'General case' 0 C--N 1.295 -1.789 0 C-N-CA 118.993 -1.083 . . . . 0.0 109.167 173.075 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.58 ' CE1' HG12 ' B' ' 42' ' ' VAL . 0.3 OUTLIER -90.26 105.62 17.93 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 177.712 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.0 t-20 58.81 7.77 0.83 Allowed 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.375 -0.828 . . . . 0.0 111.379 -170.08 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.45 -2.82 8.22 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.749 -1.215 . . . . 0.0 110.638 174.57 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.474 ' O ' ' HA ' ' B' ' 43' ' ' ALA . 32.7 t -94.56 108.08 20.05 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.597 -1.531 . . . . 0.0 109.867 176.732 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 18.2 p -70.07 128.68 37.14 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.133 -0.979 . . . . 0.0 110.842 -175.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.502 ' CD1' ' HB2' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -143.42 158.08 43.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.335 -0.853 . . . . 0.0 109.263 172.239 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 65.1 m -99.46 149.42 23.22 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.523 -1.361 . . . . 0.0 111.411 -170.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.519 ' CG1' HG11 ' B' ' 59' ' ' VAL . 20.7 t -77.19 114.82 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.839 -0.538 . . . . 0.0 110.434 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 53.7 p -69.38 -40.02 77.66 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.176 -0.953 . . . . 0.0 109.601 173.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.525 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 89.3 tt0 -161.51 156.38 23.38 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.77 -0.772 . . . . 0.0 110.128 -178.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.526 HD11 ' CG2' ' B' ' 38' ' ' THR . 8.3 mt -108.85 129.16 63.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.096 -1.003 . . . . 0.0 110.088 175.05 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.518 ' HB2' ' CB ' ' B' ' 58' ' ' HIS . 8.5 m-80 -102.45 63.12 0.86 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.626 -0.671 . . . . 0.0 109.782 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.67 -118.0 5.34 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.695 -1.762 . . . . 0.0 108.695 -173.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.538 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -74.87 -20.01 59.92 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 120.988 -1.301 . . . . 0.0 108.78 174.249 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.603 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 10.3 m170 -75.52 159.59 31.11 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.469 -0.769 . . . . 0.0 110.234 -177.219 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.519 HG11 ' CG1' ' B' ' 51' ' ' VAL . 54.3 t -140.46 123.09 16.15 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 O-C-N 121.063 -1.023 . . . . 0.0 110.55 171.247 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.532 ' CB ' HG22 ' B' ' 25' ' ' VAL . 17.4 m -89.69 128.78 36.14 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.586 -0.696 . . . . 0.0 109.519 177.675 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.58 ' N ' ' CD1' ' B' ' 61' ' ' PHE . 2.4 p90 -124.21 152.37 43.0 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.965 -1.085 . . . . 0.0 110.186 178.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.533 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 33.0 p-10 -89.32 156.09 18.94 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 120.834 -1.166 . . . . 0.0 111.588 -171.119 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.527 HD21 ' CD1' ' B' ' 73' ' ' LEU . 0.2 OUTLIER -160.66 101.52 1.32 Allowed 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.696 -0.628 . . . . 0.0 109.656 -173.526 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.48 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 57.1 ttm -61.59 139.45 58.27 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.612 -1.305 . . . . 0.0 109.163 178.527 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.468 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 78.6 tttt -59.94 -47.81 84.26 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.86 -1.15 . . . . 0.0 110.384 -173.506 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -64.5 -40.0 94.83 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.943 -1.098 . . . . 0.0 109.843 177.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.48 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 94.2 m -61.24 -40.08 92.7 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.96 -1.087 . . . . 0.0 109.564 173.117 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.527 ' HG ' ' CA ' ' B' ' 74' ' ' GLY . 16.3 tp -59.92 -41.08 90.94 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.339 -0.851 . . . . 0.0 109.35 178.352 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -67.04 -40.07 87.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.415 -0.803 . . . . 0.0 110.449 173.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.474 HG23 ' O ' ' B' ' 67' ' ' THR . 0.8 OUTLIER -65.51 -43.32 94.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.24 -0.913 . . . . 0.0 109.426 -175.599 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.471 HG23 HG23 ' B' ' 70' ' ' ILE . 25.1 p -84.36 -174.17 5.13 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.006 -0.678 . . . . 0.0 109.195 175.171 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.511 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 4.1 t30 -101.62 23.47 11.17 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 171.708 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.527 ' CD1' HD21 ' B' ' 63' ' ' LEU . 91.6 mt -70.04 -39.99 75.39 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.133 -0.979 . . . . 0.0 109.996 176.013 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.527 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -47.42 -22.7 1.69 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -178.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.4 p-10 -68.65 -17.08 64.03 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.057 -1.261 . . . . 0.0 110.647 -174.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 89.5 mt -62.32 143.08 57.39 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.2 -0.937 . . . . 0.0 110.912 -177.702 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.501 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 89.8 mttt -141.64 144.58 34.23 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 174.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.57 ' CG2' HG13 ' B' ' 15' ' ' ILE . 47.2 t -64.9 147.31 12.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.885 -1.134 . . . . 0.0 110.062 -176.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.49 -14.07 62.23 Favored Glycine 0 N--CA 1.484 1.875 0 N-CA-C 108.67 -1.772 . . . . 0.0 108.67 -173.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 39.2 t0 -96.12 166.76 11.6 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.472 -1.016 . . . . 0.0 109.483 175.564 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.58 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.3 m95 -117.64 166.84 11.93 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.057 -1.027 . . . . 0.0 110.136 177.388 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.476 HG13 ' CB ' ' B' ' 10' ' ' ALA . 1.3 p -132.36 156.66 42.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.429 -0.794 . . . . 0.0 109.963 -178.427 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.498 ' CA ' HG12 ' B' ' 6' ' ' VAL . 2.1 m-20 -79.44 105.53 10.82 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.116 -0.99 . . . . 0.0 109.203 169.117 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.499 ' CG2' ' C ' ' B' ' 9' ' ' THR . 0.0 OUTLIER -110.2 142.21 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 120.419 -1.425 . . . . 0.0 110.765 -176.399 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . 0.517 ' CG ' ' HB1' ' B' ' 43' ' ' ALA . 19.9 pt-20 -149.38 153.84 38.0 Favored 'General case' 0 N--CA 1.492 1.64 0 C-N-CA 119.779 -0.768 . . . . 0.0 110.05 179.249 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 63.2 ttt180 -68.14 129.97 41.51 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.181 -0.95 . . . . 0.0 110.432 -178.045 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.536 ' HB3' ' HB2' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.411 -0.806 . . . . 0.0 109.502 176.509 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.544 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.0 t . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.704 0.764 . . . . 0.0 110.835 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -70.06 -34.83 73.71 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.86 -0.525 . . . . 0.0 111.036 178.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.544 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -154.76 174.44 33.05 Favored Glycine 0 N--CA 1.496 2.641 0 C-N-CA 118.933 -1.603 . . . . 0.0 110.191 -172.1 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.441 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.3 p -119.99 170.45 9.26 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.944 -1.327 . . . . 0.0 111.2 -176.14 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.516 ' CB ' HG11 ' A' ' 82' ' ' VAL . . . -139.46 150.1 44.79 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -178.005 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 21.6 tttt -108.9 117.68 34.83 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.045 -1.034 . . . . 0.0 110.375 -179.552 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.529 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 12.0 tp -59.41 128.85 39.15 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.892 -1.13 . . . . 0.0 108.947 173.531 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.632 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.99 -28.82 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 C-N-CA 119.512 -0.875 . . . . 0.0 110.101 -178.802 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.93 140.56 23.5 Favored 'General case' 0 N--CA 1.493 1.696 0 C-N-CA 119.089 -1.045 . . . . 0.0 111.445 -178.375 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.571 HG12 ' CD2' ' A' ' 24' ' ' HIS . 14.1 mt -109.96 133.39 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.116 -0.99 . . . . 0.0 110.279 172.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.47 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 76.6 m-20 -108.54 116.12 31.37 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.335 -0.853 . . . . 0.0 109.883 172.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -107.64 115.33 29.95 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.948 -1.095 . . . . 0.0 110.735 -175.473 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.48 130.27 24.45 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.21 -0.931 . . . . 0.0 109.209 176.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -52.1 -19.79 9.51 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.792 1.417 . . . . 0.0 110.275 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.574 ' ND2' ' N ' ' A' ' 20' ' ' ASN . 0.4 OUTLIER -83.54 -42.57 16.67 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.186 -0.946 . . . . 0.0 108.991 176.554 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.57 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 89.5 m-85 -156.98 150.32 24.14 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-O 121.307 0.575 . . . . 0.0 110.044 -177.674 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.508 ' NH1' HD23 ' A' ' 68' ' ' LEU . 60.2 ttt180 -89.49 143.59 26.7 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.898 -1.126 . . . . 0.0 110.116 177.673 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.47 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.3 m -128.74 135.04 48.67 Favored 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.548 -0.72 . . . . 0.0 109.827 -176.358 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.585 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -127.78 141.36 51.6 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.813 -1.18 . . . . 0.0 111.594 -179.449 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.53 ' CG2' ' OG ' ' A' ' 60' ' ' SER . 6.3 t -123.26 133.48 69.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.172 -0.955 . . . . 0.0 110.667 -179.397 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 36.0 m -117.66 172.47 5.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-O 121.233 0.539 . . . . 0.0 110.274 179.533 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.51 ' CB ' ' HB3' ' A' ' 11' ' ' LYS . 7.2 tt0 -100.22 116.96 33.44 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.313 -0.867 . . . . 0.0 109.071 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.6 ' CD1' ' CB ' ' A' ' 32' ' ' MET 0.256 0.1 OUTLIER -86.81 114.82 59.99 Favored Pre-proline 0 C--N 1.295 -1.777 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -176.818 . . . . . . . . 4 4 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.49 ' HD2' HD11 ' A' ' 28' ' ' LEU . 18.9 Cg_endo -63.3 174.48 3.33 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.779 1.41 . . . . 0.0 111.187 -178.299 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.527 ' OD1' ' N ' ' A' ' 31' ' ' HIS . 1.9 p30 -63.22 -35.54 80.65 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.452 -0.78 . . . . 0.0 111.269 -174.219 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.527 ' N ' ' OD1' ' A' ' 30' ' ' ASP . 0.0 OUTLIER -91.0 -0.19 57.69 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.728 -1.232 . . . . 0.0 111.057 -173.551 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.6 ' CB ' ' CD1' ' A' ' 28' ' ' LEU . 96.2 mmm -114.48 -14.32 12.15 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 120.925 -1.109 . . . . 0.0 109.815 168.89 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.522 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 12.4 mt -64.3 -40.04 95.14 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.163 -0.961 . . . . 0.0 109.932 177.653 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -63.98 131.53 47.93 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.32 -0.862 . . . . 0.0 110.484 -178.104 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.39 -39.26 3.08 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 175.149 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.514 ' CD2' ' HG ' ' A' ' 28' ' ' LEU . 60.8 tp -62.38 144.52 55.7 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.963 -1.316 . . . . 0.0 110.85 -175.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.467 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 19.2 pt-20 -151.49 164.78 36.02 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.728 -0.607 . . . . 0.0 109.452 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.534 ' CG2' HD13 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -66.92 150.48 49.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.849 -1.157 . . . . 0.0 109.763 178.376 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.63 -0.06 62.0 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 -174.572 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.467 ' HB1' ' O ' ' A' ' 37' ' ' GLU . . . -75.38 158.99 31.92 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.228 -1.16 . . . . 0.0 109.279 175.358 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.488 ' CB ' ' HB2' ' A' ' 87' ' ' ALA . 0.6 OUTLIER -100.39 110.89 23.12 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 118.854 -1.138 . . . . 0.0 109.829 176.025 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.582 HG13 ' CE1' ' A' ' 44' ' ' HIS . 1.8 t -100.1 125.67 53.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.457 -0.777 . . . . 0.0 109.041 175.688 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.454 ' HA ' ' HA ' ' A' ' 48' ' ' CYS . . . -92.0 119.78 32.03 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 119.041 -1.064 . . . . 0.0 109.242 172.401 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.582 ' CE1' HG13 ' A' ' 42' ' ' VAL . 0.6 OUTLIER -87.98 103.02 15.3 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 177.922 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.5 t-20 57.16 11.17 0.98 Allowed 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.455 -0.778 . . . . 0.0 111.141 -170.474 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 123.84 -0.21 9.17 Favored Glycine 0 N--CA 1.489 2.233 0 C-N-CA 119.584 -1.293 . . . . 0.0 110.605 174.621 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.499 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 16.7 t -98.74 105.39 17.53 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.41 -1.641 . . . . 0.0 109.535 175.604 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.454 ' HA ' ' HA ' ' A' ' 43' ' ' ALA . 15.9 p -74.05 129.0 36.99 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.983 -1.073 . . . . 0.0 110.855 -172.368 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.634 ' CD1' ' CD1' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -142.95 160.84 39.59 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.377 -0.827 . . . . 0.0 109.605 173.739 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 6.6 m -100.43 148.1 25.12 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.552 -1.342 . . . . 0.0 111.237 -170.09 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.528 ' CG1' HG13 ' A' ' 59' ' ' VAL . 21.0 t -76.21 115.32 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.892 -0.505 . . . . 0.0 110.475 -179.361 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.53 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 30.4 p -70.46 -40.02 73.93 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.247 -0.908 . . . . 0.0 109.789 173.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.531 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -162.64 154.49 18.36 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.288 -0.882 . . . . 0.0 110.313 -179.479 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.534 HD13 ' CG2' ' A' ' 38' ' ' THR . 7.6 mt -105.72 130.52 57.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.159 -0.963 . . . . 0.0 110.088 176.367 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.469 ' HB2' ' CB ' ' A' ' 58' ' ' HIS . 4.7 m-80 -102.51 64.39 0.9 Allowed 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.61 -0.681 . . . . 0.0 109.822 179.027 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.2 -119.5 5.9 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.774 -1.73 . . . . 0.0 108.774 -173.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.522 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -73.12 -22.1 60.61 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 120.878 -1.366 . . . . 0.0 108.643 174.315 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.632 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 12.3 m80 -74.02 159.97 31.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.283 -0.885 . . . . 0.0 110.431 -176.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.528 HG13 ' CG1' ' A' ' 51' ' ' VAL . 51.4 t -139.98 125.38 20.77 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 121.084 -1.01 . . . . 0.0 110.706 170.526 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.53 ' OG ' ' CG2' ' A' ' 25' ' ' VAL . 1.7 t -91.6 135.08 34.13 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.444 -0.785 . . . . 0.0 109.274 175.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.634 ' CD1' ' CD1' ' A' ' 49' ' ' LEU . 8.8 p90 -128.35 154.39 46.02 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 121.304 -0.872 . . . . 0.0 110.483 177.141 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.53 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 28.9 p-10 -89.67 150.85 22.16 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.157 -0.965 . . . . 0.0 111.332 -171.616 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.523 HD23 ' CD1' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -155.6 117.6 4.09 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -176.079 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.508 ' HB2' ' CB ' ' A' ' 67' ' ' THR . 52.6 mtt -68.46 142.33 55.37 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.786 -1.196 . . . . 0.0 109.518 177.425 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.465 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 86.0 tttt -59.97 -44.59 94.36 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 120.991 -1.068 . . . . 0.0 109.715 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 52.5 tp10 -70.04 -39.93 75.43 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.189 -0.944 . . . . 0.0 110.235 178.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.508 ' CB ' ' HB2' ' A' ' 64' ' ' MET . 89.5 m -61.41 -37.81 84.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.795 -1.191 . . . . 0.0 109.084 172.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.508 HD23 ' NH1' ' A' ' 22' ' ' ARG . 7.1 tp -60.07 -44.32 94.84 Favored 'General case' 0 C--N 1.297 -1.69 0 O-C-N 121.143 -0.973 . . . . 0.0 109.193 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 52.0 ttt85 -70.08 -39.91 75.3 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.456 -0.777 . . . . 0.0 110.52 175.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.466 HG23 ' O ' ' A' ' 67' ' ' THR . 1.3 tt -62.72 -41.38 92.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.176 -0.953 . . . . 0.0 109.072 -177.719 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.481 HG23 ' O ' ' A' ' 67' ' ' THR . 31.2 p -88.93 -176.76 5.29 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 175.765 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.481 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 2.4 t30 -100.18 25.08 7.87 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 172.112 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.523 ' CD1' HD23 ' A' ' 63' ' ' LEU . 55.7 mt -69.85 -39.99 76.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.941 -1.099 . . . . 0.0 109.861 174.556 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.474 ' HA2' HD13 ' A' ' 68' ' ' LEU . . . -48.12 -22.76 2.38 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 -179.034 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.0 p-10 -64.89 -17.38 64.26 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.151 -1.205 . . . . 0.0 110.5 -176.369 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 90.3 mt -62.06 144.02 55.8 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.299 -0.875 . . . . 0.0 110.889 -176.724 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.491 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 35.0 mttp -143.83 143.86 31.51 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.747 -0.596 . . . . 0.0 109.41 174.13 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.552 ' CG2' HG13 ' A' ' 15' ' ' ILE . 14.9 t -61.77 150.06 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 120.637 -1.289 . . . . 0.0 110.107 -176.722 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.35 -12.15 61.48 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 108.927 -1.669 . . . . 0.0 108.927 -176.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 48.7 t0 -95.77 166.27 11.89 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.312 -1.111 . . . . 0.0 109.496 176.236 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.6 m95 -117.43 156.63 27.62 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.987 -1.071 . . . . 0.0 110.524 178.728 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.516 HG11 ' CB ' ' A' ' 10' ' ' ALA . 1.1 p -120.05 150.88 22.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.516 -0.74 . . . . 0.0 109.874 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.522 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 0.3 OUTLIER -76.82 106.28 8.4 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.072 -1.018 . . . . 0.0 108.951 168.966 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.455 HG13 HG21 ' A' ' 82' ' ' VAL . 0.1 OUTLIER -105.97 138.52 30.89 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 120.425 -1.422 . . . . 0.0 111.5 -175.223 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -133.3 140.67 47.58 Favored 'General case' 0 N--CA 1.496 1.829 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.178 -179.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 71.6 ttt-85 -80.31 134.17 36.04 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.195 -0.94 . . . . 0.0 111.148 -175.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.488 ' HB2' ' CB ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.734 0 O-C-N 121.409 -0.807 . . . . 0.0 110.28 179.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.542 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.0 t . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 121.739 0.78 . . . . 0.0 110.798 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -70.01 -34.71 73.65 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.79 -0.569 . . . . 0.0 111.063 178.342 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.542 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -154.96 174.33 33.2 Favored Glycine 0 N--CA 1.495 2.58 0 C-N-CA 118.902 -1.618 . . . . 0.0 110.248 -172.03 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.446 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.5 p -119.9 170.42 9.27 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.892 -1.358 . . . . 0.0 111.173 -176.016 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.517 ' CB ' HG11 ' B' ' 82' ' ' VAL . . . -139.53 150.17 44.78 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -178.157 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.574 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 21.6 tttt -108.82 117.83 35.22 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.115 -0.991 . . . . 0.0 110.346 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.507 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 12.0 tp -59.68 128.74 38.47 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 120.936 -1.102 . . . . 0.0 109.019 173.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.627 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.81 -28.9 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 O-C-N 121.33 -0.856 . . . . 0.0 110.139 -178.719 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.91 140.66 23.59 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.294 -0.962 . . . . 0.0 111.401 -178.371 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.573 HG12 ' CD2' ' B' ' 24' ' ' HIS . 14.1 mt -109.99 133.38 55.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.177 -0.952 . . . . 0.0 110.244 172.695 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.486 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 76.2 m-20 -108.61 116.23 31.58 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.344 -0.847 . . . . 0.0 109.706 173.01 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 99.9 mt-10 -107.72 115.37 30.03 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.917 -1.114 . . . . 0.0 110.717 -175.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.55 130.27 24.46 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.269 -0.894 . . . . 0.0 109.294 176.82 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -52.32 -19.77 10.13 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.731 1.385 . . . . 0.0 110.21 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.569 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 0.4 OUTLIER -83.28 -43.16 16.34 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.26 -0.9 . . . . 0.0 108.867 176.508 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.569 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 89.6 m-85 -156.54 150.36 24.87 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.813 -0.555 . . . . 0.0 110.028 -177.535 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . 0.513 ' NH1' HD23 ' B' ' 68' ' ' LEU . 60.2 ttt180 -89.37 143.52 26.76 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.942 -1.098 . . . . 0.0 110.152 177.585 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.486 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 94.3 m -128.64 135.04 48.77 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.648 -0.657 . . . . 0.0 109.89 -176.517 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.585 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -127.61 141.54 51.6 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.824 -1.173 . . . . 0.0 111.534 -179.466 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.54 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 6.2 t -123.32 133.63 68.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.189 -0.945 . . . . 0.0 110.654 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 35.2 m -118.03 172.29 5.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.798 -0.564 . . . . 0.0 110.227 179.581 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.509 ' CB ' ' HB3' ' B' ' 11' ' ' LYS . 7.2 tt0 -99.99 117.06 33.47 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.321 -0.862 . . . . 0.0 109.058 179.184 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.59 ' CD1' ' CB ' ' B' ' 32' ' ' MET 0.255 0.1 OUTLIER -86.83 114.84 60.1 Favored Pre-proline 0 C--N 1.296 -1.723 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 -176.922 . . . . . . . . 4 4 . 1 . 009 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.491 ' HD2' HD11 ' B' ' 28' ' ' LEU . 19.0 Cg_endo -63.3 174.6 3.23 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.744 1.392 . . . . 0.0 111.267 -178.306 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' B' ' 31' ' ' HIS . 1.9 p30 -63.35 -35.56 80.81 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.484 -0.76 . . . . 0.0 111.169 -174.206 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.521 ' N ' ' OD1' ' B' ' 30' ' ' ASP . 0.0 OUTLIER -91.05 -0.02 57.64 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.738 -1.226 . . . . 0.0 110.997 -173.51 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.59 ' CB ' ' CD1' ' B' ' 28' ' ' LEU . 96.2 mmm -114.48 -14.34 12.15 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 120.881 -1.137 . . . . 0.0 109.806 168.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.526 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 12.4 mt -64.35 -39.96 94.93 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.184 -0.948 . . . . 0.0 109.989 177.642 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -64.02 131.51 47.82 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.307 -0.87 . . . . 0.0 110.497 -178.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.47 -39.31 3.07 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.329 -1.109 . . . . 0.0 110.329 175.207 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . 0.518 ' CD2' ' HG ' ' B' ' 28' ' ' LEU . 60.7 tp -62.37 144.57 55.62 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.872 -1.37 . . . . 0.0 110.883 -175.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . 0.466 ' O ' ' HB1' ' B' ' 40' ' ' ALA . 19.2 pt-20 -151.57 164.78 36.09 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.658 -0.651 . . . . 0.0 109.36 -179.629 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.528 ' CG2' ' HA ' ' B' ' 53' ' ' GLU . 0.0 OUTLIER -66.92 150.48 49.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.784 -1.198 . . . . 0.0 109.827 178.332 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.61 -0.01 62.03 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -174.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.466 ' HB1' ' O ' ' B' ' 37' ' ' GLU . . . -75.51 158.97 31.82 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.191 -1.182 . . . . 0.0 109.23 175.293 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 41' ' ' SER . . . . . 0.495 ' CB ' ' HB2' ' B' ' 87' ' ' ALA . 0.7 OUTLIER -100.21 110.64 22.9 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.977 -1.077 . . . . 0.0 109.901 176.018 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.587 HG13 ' CE1' ' B' ' 44' ' ' HIS . 1.8 t -99.95 125.69 53.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.427 -0.796 . . . . 0.0 109.081 175.627 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.459 ' HA ' ' HA ' ' B' ' 48' ' ' CYS . . . -91.98 119.73 31.97 Favored 'General case' 0 C--N 1.297 -1.712 0 C-N-CA 119.056 -1.058 . . . . 0.0 109.274 172.349 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.587 ' CE1' HG13 ' B' ' 42' ' ' VAL . 0.6 OUTLIER -87.94 102.95 15.22 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.417 -0.802 . . . . 0.0 108.968 177.887 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.6 t-20 57.32 11.11 1.04 Allowed 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.439 -0.788 . . . . 0.0 111.113 -170.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 123.77 0.2 9.17 Favored Glycine 0 N--CA 1.489 2.225 0 C-N-CA 119.653 -1.261 . . . . 0.0 110.609 174.509 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.489 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 16.9 t -98.99 105.49 17.64 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.465 -1.609 . . . . 0.0 109.464 175.488 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . 0.459 ' HA ' ' HA ' ' B' ' 43' ' ' ALA . 15.9 p -74.06 129.02 37.03 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.012 -1.055 . . . . 0.0 110.802 -172.39 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.633 ' CD1' ' CD1' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -143.05 160.79 39.71 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.396 -0.815 . . . . 0.0 109.484 173.751 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 6.6 m -100.27 148.22 24.89 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 120.647 -1.283 . . . . 0.0 111.255 -170.128 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.527 ' CG1' HG13 ' B' ' 59' ' ' VAL . 21.2 t -76.46 115.24 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.716 -0.615 . . . . 0.0 110.479 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.536 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 30.3 p -70.39 -40.01 74.2 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.213 -0.929 . . . . 0.0 109.818 173.722 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.528 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -162.63 154.48 18.37 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.406 -0.809 . . . . 0.0 110.265 -179.525 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.527 HD13 ' CG2' ' B' ' 38' ' ' THR . 7.6 mt -105.6 130.46 56.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.11 -0.994 . . . . 0.0 110.173 176.323 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.473 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 4.6 m-80 -102.53 64.41 0.89 Allowed 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.659 -0.651 . . . . 0.0 109.737 179.082 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.32 -119.52 5.87 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 108.739 -1.744 . . . . 0.0 108.739 -173.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.526 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -73.08 -22.09 60.65 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.894 -1.357 . . . . 0.0 108.753 174.216 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.627 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 12.4 m80 -74.07 160.05 31.81 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.257 -0.902 . . . . 0.0 110.421 -176.588 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.527 HG13 ' CG1' ' B' ' 51' ' ' VAL . 50.7 t -140.14 125.35 20.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 C-N-CA 119.107 -1.037 . . . . 0.0 110.595 170.692 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.54 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 1.7 t -91.57 135.25 34.0 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.5 -0.75 . . . . 0.0 109.284 175.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.633 ' CD1' ' CD1' ' B' ' 49' ' ' LEU . 8.7 p90 -128.46 154.46 46.05 Favored 'General case' 0 N--CA 1.496 1.828 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.417 177.099 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.536 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 29.2 p-10 -89.75 150.83 22.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.059 -1.026 . . . . 0.0 111.246 -171.554 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.525 HD21 ' CD1' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -155.57 117.6 4.09 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -176.125 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.511 ' HB2' ' HB ' ' B' ' 67' ' ' THR . 52.9 mtt -68.38 142.32 55.47 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.889 -1.132 . . . . 0.0 109.463 177.538 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.464 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 86.0 tttt -60.06 -44.54 94.64 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.072 -1.017 . . . . 0.0 109.635 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 52.5 tp10 -69.99 -39.92 75.62 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.148 -0.97 . . . . 0.0 110.328 178.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.511 ' HB ' ' HB2' ' B' ' 64' ' ' MET . 89.2 m -61.38 -38.04 85.59 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.776 -1.203 . . . . 0.0 108.99 172.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.513 HD23 ' NH1' ' B' ' 22' ' ' ARG . 7.0 tp -59.99 -44.23 94.66 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.235 -0.916 . . . . 0.0 109.289 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 52.0 ttt85 -70.03 -39.93 75.48 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.38 -0.825 . . . . 0.0 110.563 175.429 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.471 HG23 ' O ' ' B' ' 67' ' ' THR . 1.3 tt -62.73 -41.28 91.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 CA-C-O 121.917 0.865 . . . . 0.0 109.07 -177.743 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.474 HG22 ' O ' ' B' ' 67' ' ' THR . 31.5 p -89.0 -176.63 5.23 Favored 'General case' 0 C--N 1.3 -1.565 0 C-N-CA 120.2 -0.6 . . . . 0.0 109.394 175.859 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.48 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 2.3 t30 -100.17 25.11 7.83 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 172.144 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.525 ' CD1' HD21 ' B' ' 63' ' ' LEU . 54.8 mt -69.89 -40.0 75.92 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.894 -1.129 . . . . 0.0 109.848 174.569 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.467 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -48.16 -22.63 2.36 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 -179.021 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.5 p-10 -64.89 -17.51 64.39 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.189 -1.183 . . . . 0.0 110.438 -176.392 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 90.2 mt -62.08 143.95 55.93 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.256 -0.902 . . . . 0.0 110.871 -176.601 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.48 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 35.0 mttp -143.76 143.95 31.6 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.637 -0.664 . . . . 0.0 109.395 174.123 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.547 ' CG2' HG13 ' B' ' 15' ' ' ILE . 15.3 t -61.78 150.05 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.666 -1.271 . . . . 0.0 110.057 -176.634 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.2 -11.95 61.67 Favored Glycine 0 N--CA 1.484 1.868 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -176.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 48.5 t0 -95.81 166.25 11.9 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.386 -1.067 . . . . 0.0 109.458 176.051 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.574 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.6 m95 -117.4 156.62 27.6 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.051 -1.03 . . . . 0.0 110.516 178.759 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.546 HG22 ' CG ' ' B' ' 44' ' ' HIS . 1.1 p -120.14 150.94 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.569 -0.707 . . . . 0.0 109.807 179.683 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.503 ' HB3' ' CG2' ' B' ' 6' ' ' VAL . 0.3 OUTLIER -76.79 106.14 8.29 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.037 -1.039 . . . . 0.0 109.014 168.971 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.454 HG11 HG21 ' B' ' 82' ' ' VAL . 0.1 OUTLIER -105.9 138.71 29.91 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 120.476 -1.39 . . . . 0.0 111.454 -175.118 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -133.42 140.69 47.46 Favored 'General case' 0 N--CA 1.495 1.824 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.191 -179.364 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 71.7 ttt-85 -80.33 134.29 36.04 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.16 -0.962 . . . . 0.0 111.029 -175.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.495 ' HB2' ' CB ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.744 0 O-C-N 121.267 -0.896 . . . . 0.0 110.271 179.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.533 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 1.7 t . . . . . 0 N--CA 1.493 1.725 0 CA-C-O 121.332 0.587 . . . . 0.0 110.287 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -81.23 -26.29 35.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.427 -0.796 . . . . 0.0 110.891 -179.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.533 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -153.92 176.71 31.74 Favored Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.288 -1.434 . . . . 0.0 109.922 -176.086 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.472 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 18.4 p -123.34 170.01 10.75 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.942 -1.328 . . . . 0.0 110.839 -178.444 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.522 ' CB ' HG13 ' A' ' 82' ' ' VAL . . . -137.36 149.89 47.31 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.557 -0.715 . . . . 0.0 109.65 -177.076 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.585 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 36.9 tttt -104.07 117.86 35.28 Favored 'General case' 0 C--N 1.296 -1.731 0 O-C-N 120.901 -1.124 . . . . 0.0 110.355 178.673 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.5 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 12.1 tp -61.44 126.14 26.29 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.861 -1.15 . . . . 0.0 108.749 171.482 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.593 HG12 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.38 -28.86 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.934 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.004 -178.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -148.76 141.02 24.06 Favored 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 118.964 -1.094 . . . . 0.0 111.225 178.824 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.567 HG13 ' CG2' ' A' ' 78' ' ' VAL . 13.6 mt -105.54 138.22 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.007 -1.058 . . . . 0.0 110.062 171.372 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.486 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 83.7 m-20 -110.83 114.66 28.18 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.25 -0.906 . . . . 0.0 109.932 173.789 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -103.35 112.65 25.63 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.017 -1.052 . . . . 0.0 110.374 -178.008 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.467 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 19.7 mtmt -107.02 132.77 20.65 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.296 -0.877 . . . . 0.0 109.282 177.338 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.9 Cg_endo -51.84 -18.9 7.2 Favored 'Trans proline' 0 C--N 1.303 -1.851 0 O-C-N 123.879 1.462 . . . . 0.0 110.745 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.57 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 7.8 m-80 -95.77 -33.06 12.42 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.125 -0.984 . . . . 0.0 110.204 178.298 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.57 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 98.2 m-85 -157.46 150.29 23.23 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.363 -0.836 . . . . 0.0 110.318 -177.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -87.76 145.88 25.91 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.898 -1.126 . . . . 0.0 110.108 177.318 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.486 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 92.5 m -133.89 145.37 49.56 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.455 -0.778 . . . . 0.0 109.748 -176.418 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.56 ' CD2' HG21 ' A' ' 15' ' ' ILE . 0.4 OUTLIER -135.35 135.27 40.59 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.781 -1.199 . . . . 0.0 111.476 -177.879 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.517 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 9.7 t -114.43 132.77 62.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.092 -1.005 . . . . 0.0 110.814 -179.127 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.426 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 17.4 m -118.11 170.92 6.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 CA-C-O 121.177 0.513 . . . . 0.0 110.106 179.217 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.487 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 13.5 tt0 -102.64 118.92 37.91 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.329 -0.857 . . . . 0.0 109.096 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.485 ' HB3' ' CD2' ' A' ' 33' ' ' LEU . 10.2 tp -83.59 123.77 76.1 Favored Pre-proline 0 C--N 1.3 -1.567 0 C-N-CA 119.969 -0.692 . . . . 0.0 109.739 -175.345 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.47 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 25.9 Cg_endo -66.18 175.31 4.97 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 O-C-N 123.843 1.444 . . . . 0.0 111.035 -179.298 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.427 ' HA ' HD13 ' A' ' 33' ' ' LEU . 57.8 t0 -59.86 -39.77 86.34 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.387 -0.821 . . . . 0.0 110.831 -175.714 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.579 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -88.76 1.08 55.82 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.941 -1.1 . . . . 0.0 110.633 -175.004 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.579 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 93.5 mmm -112.17 -14.16 13.42 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.989 -1.069 . . . . 0.0 109.916 170.683 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.537 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 19.6 mt -69.96 -39.92 75.72 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.454 -0.779 . . . . 0.0 110.516 178.422 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -82.26 113.57 20.16 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.281 -0.887 . . . . 0.0 110.437 -176.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.8 -52.62 0.7 Allowed Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.835 -1.174 . . . . 0.0 110.415 175.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.1 tt -66.37 152.21 45.51 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.93 -1.335 . . . . 0.0 110.756 -173.396 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.463 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 11.3 pt-20 -150.76 169.96 20.39 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.477 -0.764 . . . . 0.0 109.752 -177.271 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.526 ' CG2' HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -65.43 158.4 26.84 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.951 -1.093 . . . . 0.0 110.38 -178.27 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 71.51 2.71 51.1 Favored Glycine 0 N--CA 1.495 2.57 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 -178.229 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.471 ' HB2' HG22 ' A' ' 51' ' ' VAL . . . -82.52 163.73 21.35 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.227 -1.161 . . . . 0.0 109.768 177.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.471 ' CB ' ' HB2' ' A' ' 87' ' ' ALA . 1.0 OUTLIER -104.52 112.77 25.97 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.982 -1.074 . . . . 0.0 109.985 176.491 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.586 HG12 ' CE1' ' A' ' 44' ' ' HIS . 2.0 t -102.83 130.96 52.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.377 -0.827 . . . . 0.0 108.931 173.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.464 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -91.45 120.05 31.95 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.214 -0.995 . . . . 0.0 109.092 172.272 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.586 ' CE1' HG12 ' A' ' 42' ' ' VAL . 0.3 OUTLIER -90.3 107.9 19.43 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 177.112 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.1 t-20 52.98 13.09 0.33 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.47 -0.769 . . . . 0.0 111.688 -167.149 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 121.22 -2.59 11.48 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.441 -1.362 . . . . 0.0 110.855 172.257 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.47 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 35.5 t -94.25 109.0 20.84 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.402 -1.646 . . . . 0.0 109.448 174.829 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.3 p -76.99 124.65 28.08 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.105 -0.997 . . . . 0.0 110.836 -172.443 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.51 ' CD1' ' HB3' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -140.02 159.98 40.95 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.507 -0.745 . . . . 0.0 109.145 173.805 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.448 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 28.5 m -97.03 160.84 14.11 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.654 -1.278 . . . . 0.0 111.179 -170.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.558 ' CG1' HG12 ' A' ' 59' ' ' VAL . 18.8 t -84.69 116.39 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.854 -0.529 . . . . 0.0 110.372 -177.376 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.55 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 77.4 p -70.02 -40.02 75.47 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.252 -0.905 . . . . 0.0 109.667 173.793 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.502 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 54.4 tp10 -164.86 157.9 16.77 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.576 -176.364 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.526 HD12 ' CG2' ' A' ' 38' ' ' THR . 8.7 mt -110.44 129.93 64.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.173 -0.954 . . . . 0.0 109.807 172.608 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.475 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 29.0 m-80 -102.35 64.05 0.9 Allowed 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.738 -0.601 . . . . 0.0 109.474 179.037 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.87 -114.28 4.3 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -172.18 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.537 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.82 -22.43 46.21 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 120.94 -1.33 . . . . 0.0 109.3 175.314 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.593 ' CD2' HG12 ' A' ' 13' ' ' VAL . 9.4 m170 -74.43 159.94 31.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.271 -0.893 . . . . 0.0 110.052 -177.489 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.577 HG13 ' CE2' ' A' ' 61' ' ' PHE . 78.4 t -140.0 120.04 13.38 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 O-C-N 121.103 -0.998 . . . . 0.0 110.693 173.317 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.517 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 6.5 t -83.13 138.02 33.84 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.424 -0.798 . . . . 0.0 109.531 176.055 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.577 ' CE2' HG13 ' A' ' 59' ' ' VAL . 87.0 m-85 -120.2 160.52 22.75 Favored 'General case' 0 C--N 1.295 -1.788 0 O-C-N 121.336 -0.853 . . . . 0.0 110.543 177.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.55 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 32.9 p-10 -95.46 148.2 22.73 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.247 -0.908 . . . . 0.0 111.1 179.21 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.519 HD22 ' CD1' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -157.23 121.92 4.43 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -176.762 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.489 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 26.8 ttt -82.19 141.87 32.66 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.983 -1.073 . . . . 0.0 109.669 -178.141 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.472 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 83.3 tttt -60.0 -48.26 82.44 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.094 -1.003 . . . . 0.0 110.611 -173.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.2 tp10 -68.08 -40.06 82.77 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 120.793 -1.192 . . . . 0.0 109.94 179.014 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.489 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 87.4 m -60.01 -39.02 84.37 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.976 -1.078 . . . . 0.0 109.257 173.007 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.523 ' CD1' ' HA2' ' A' ' 74' ' ' GLY . 2.0 tp -59.98 -45.38 92.9 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.23 -0.919 . . . . 0.0 109.706 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -67.05 -39.96 87.04 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.329 -0.857 . . . . 0.0 110.363 176.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.484 HG21 HG21 ' A' ' 71' ' ' THR . 1.1 tt -66.04 -40.14 86.43 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.294 -0.879 . . . . 0.0 109.258 -176.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.484 HG21 HG21 ' A' ' 70' ' ' ILE . 52.3 p -84.92 -169.77 2.81 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 121.362 0.601 . . . . 0.0 109.524 175.28 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.475 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 7.1 t30 -105.97 22.92 14.83 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 170.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.519 ' CD1' HD22 ' A' ' 63' ' ' LEU . 88.5 mt -69.95 -40.03 75.69 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.199 -0.938 . . . . 0.0 110.219 178.289 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.523 ' HA2' ' CD1' ' A' ' 68' ' ' LEU . . . -50.16 -21.6 4.21 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -177.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.4 p-10 -69.19 -17.45 63.8 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.98 -1.306 . . . . 0.0 110.753 -173.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.513 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 95.9 mt -60.01 141.02 56.38 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.105 -0.997 . . . . 0.0 110.709 -176.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.493 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 66.4 mttm -140.0 139.07 35.94 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 121.514 0.674 . . . . 0.0 109.88 175.651 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.567 ' CG2' HG13 ' A' ' 15' ' ' ILE . 22.0 t -61.08 152.77 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 120.906 -1.122 . . . . 0.0 110.376 -176.393 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.83 -16.08 57.61 Favored Glycine 0 N--CA 1.482 1.725 0 N-CA-C 108.729 -1.748 . . . . 0.0 108.729 -176.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.9 t0 -97.39 169.72 9.56 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.344 -1.091 . . . . 0.0 109.544 175.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.585 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.2 m95 -117.26 166.57 12.12 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.03 -1.044 . . . . 0.0 110.045 177.306 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.522 HG13 ' CB ' ' A' ' 10' ' ' ALA . 1.3 p -128.69 157.47 41.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.283 -0.886 . . . . 0.0 110.03 -177.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.497 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 2.2 m-20 -83.54 104.71 13.89 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.177 -0.952 . . . . 0.0 109.083 170.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.474 HG13 ' CE1' ' A' ' 44' ' ' HIS . 0.1 OUTLIER -107.54 139.27 30.0 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.781 0 O-C-N 120.444 -1.41 . . . . 0.0 111.287 -174.826 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -139.58 138.48 36.25 Favored 'General case' 0 N--CA 1.492 1.674 0 C-N-CA 120.355 -0.538 . . . . 0.0 109.837 -178.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . 0.468 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 39.0 ptt180 -73.02 137.72 45.55 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.983 -1.073 . . . . 0.0 110.664 -174.151 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.471 ' HB2' ' CB ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.254 -0.904 . . . . 0.0 109.923 173.788 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.536 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 1.7 t . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.398 0.618 . . . . 0.0 110.291 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -81.43 -25.96 35.74 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.38 -0.825 . . . . 0.0 110.887 -178.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.536 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -154.09 176.58 31.92 Favored Glycine 0 N--CA 1.494 2.559 0 C-N-CA 119.423 -1.37 . . . . 0.0 109.958 -176.1 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.468 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 18.4 p -123.32 170.05 10.69 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.951 -1.323 . . . . 0.0 110.838 -178.432 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.522 ' CB ' HG13 ' B' ' 82' ' ' VAL . . . -137.39 149.9 47.29 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.582 -0.699 . . . . 0.0 109.607 -177.143 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.577 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 36.9 tttt -104.13 117.98 35.55 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.961 -1.087 . . . . 0.0 110.304 178.615 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.506 ' CG ' ' HA ' ' B' ' 78' ' ' VAL . 12.1 tp -61.58 126.04 25.94 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.018 -1.051 . . . . 0.0 108.804 171.48 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.596 HG12 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.1 -29.12 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.979 0 O-C-N 121.371 -0.831 . . . . 0.0 110.054 -178.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -148.67 141.0 24.15 Favored 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 119.263 -0.975 . . . . 0.0 111.357 178.834 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.562 HG13 ' CG2' ' B' ' 78' ' ' VAL . 13.6 mt -105.6 138.32 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.996 -1.065 . . . . 0.0 110.082 171.373 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.499 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.6 m-20 -110.89 114.79 28.4 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.317 -0.865 . . . . 0.0 109.842 173.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -103.44 112.54 25.48 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.002 -1.061 . . . . 0.0 110.363 -177.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . 0.463 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 19.6 mtmt -107.0 132.72 20.68 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.382 -0.823 . . . . 0.0 109.317 177.34 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -51.92 -18.79 7.3 Favored 'Trans proline' 0 C--N 1.304 -1.782 0 O-C-N 123.832 1.438 . . . . 0.0 110.716 -179.527 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.57 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 7.9 m-80 -95.64 -33.68 12.26 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.107 -0.996 . . . . 0.0 110.068 178.291 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.57 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 98.2 m-85 -157.0 150.29 24.09 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.352 -0.843 . . . . 0.0 110.412 -177.82 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -87.68 145.73 26.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.042 -1.036 . . . . 0.0 110.196 177.265 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.499 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 92.7 m -133.85 145.39 49.65 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.386 -0.821 . . . . 0.0 109.755 -176.483 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.55 ' CD2' HG22 ' B' ' 15' ' ' ILE . 0.4 OUTLIER -135.24 135.41 40.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.927 -1.108 . . . . 0.0 111.447 -177.804 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 9.8 t -114.48 133.01 61.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 110.789 -179.119 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 17.7 m -118.45 170.85 7.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 CA-C-O 121.237 0.541 . . . . 0.0 109.988 179.357 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.488 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 13.5 tt0 -102.55 119.03 38.13 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.365 -0.834 . . . . 0.0 109.122 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.492 ' HB3' ' CD2' ' B' ' 33' ' ' LEU . 10.3 tp -83.68 123.75 75.94 Favored Pre-proline 0 C--N 1.299 -1.589 0 O-C-N 121.443 -0.786 . . . . 0.0 109.76 -175.358 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.478 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 25.8 Cg_endo -66.17 175.44 4.84 Favored 'Trans proline' 0 C--N 1.309 -1.538 0 O-C-N 123.851 1.448 . . . . 0.0 111.049 -179.221 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -60.07 -39.68 86.89 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.368 -0.833 . . . . 0.0 110.8 -175.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.583 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -88.78 1.08 55.83 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.819 -1.176 . . . . 0.0 110.695 -175.073 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.583 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 93.5 mmm -112.14 -14.13 13.44 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.961 -1.087 . . . . 0.0 109.92 170.628 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.547 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 19.7 mt -70.04 -39.91 75.46 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.366 -0.834 . . . . 0.0 110.511 178.442 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -82.2 113.56 20.12 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.296 -0.878 . . . . 0.0 110.436 -176.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.79 -52.64 0.7 Allowed Glycine 0 N--CA 1.491 2.335 0 C-N-CA 119.834 -1.174 . . . . 0.0 110.422 175.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 5.2 tt -66.39 152.2 45.57 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.916 -1.344 . . . . 0.0 110.807 -173.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . 0.464 ' HA ' HD12 ' B' ' 54' ' ' ILE . 11.3 pt-20 -150.69 169.99 20.27 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.402 -0.811 . . . . 0.0 109.733 -177.249 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.531 ' CG2' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -65.41 158.36 26.9 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.958 -1.089 . . . . 0.0 110.425 -178.303 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 71.54 2.64 50.83 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.966 -1.253 . . . . 0.0 109.966 -178.233 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.471 ' HB2' HG21 ' B' ' 51' ' ' VAL . . . -82.54 163.47 21.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.226 -1.161 . . . . 0.0 109.817 177.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 41' ' ' SER . . . . . 0.469 ' HB2' ' HB1' ' B' ' 87' ' ' ALA . 1.0 OUTLIER -104.21 112.59 25.67 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.893 -1.129 . . . . 0.0 110.078 176.546 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.575 HG12 ' CE1' ' B' ' 44' ' ' HIS . 2.0 t -102.78 131.01 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.389 -0.819 . . . . 0.0 108.947 173.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.462 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -91.44 119.98 31.88 Favored 'General case' 0 C--N 1.296 -1.718 0 O-C-N 121.128 -0.983 . . . . 0.0 109.196 172.149 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.575 ' CE1' HG12 ' B' ' 42' ' ' VAL . 0.3 OUTLIER -90.23 107.55 19.2 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 177.138 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.1 t-20 53.29 13.16 0.39 Allowed 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.445 -0.784 . . . . 0.0 111.515 -167.252 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 121.17 -2.44 11.54 Favored Glycine 0 N--CA 1.491 2.311 0 C-N-CA 119.474 -1.346 . . . . 0.0 110.784 172.14 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.469 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 35.6 t -94.32 109.04 20.9 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.411 -1.64 . . . . 0.0 109.434 174.808 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 16.7 p -76.99 124.77 28.26 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.054 -1.029 . . . . 0.0 110.814 -172.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.518 ' CD1' ' HB3' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -140.21 159.96 41.02 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.553 -0.717 . . . . 0.0 109.086 173.773 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 50' ' ' THR . . . . . 0.454 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 28.5 m -96.79 160.95 14.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.686 -1.259 . . . . 0.0 111.214 -170.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.561 ' CG1' HG13 ' B' ' 59' ' ' VAL . 19.0 t -84.99 116.35 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.787 -0.57 . . . . 0.0 110.426 -177.42 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.537 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 77.3 p -69.96 -39.93 75.72 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.154 -0.966 . . . . 0.0 109.716 173.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.511 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 54.4 tp10 -164.94 157.8 16.46 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.589 -176.392 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.531 HD11 ' CG2' ' B' ' 38' ' ' THR . 8.7 mt -110.32 129.89 64.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.194 -0.941 . . . . 0.0 109.854 172.667 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.486 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 28.7 m-80 -102.46 64.07 0.89 Allowed 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 120.103 -0.639 . . . . 0.0 109.42 179.101 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.02 -114.35 4.29 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 108.666 -1.774 . . . . 0.0 108.666 -172.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.547 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.65 -22.73 46.43 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.032 -1.275 . . . . 0.0 109.358 175.244 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.596 ' CD2' HG12 ' B' ' 13' ' ' VAL . 9.5 m170 -74.21 159.8 32.02 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.386 -0.821 . . . . 0.0 110.097 -177.515 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.581 HG11 ' CE2' ' B' ' 61' ' ' PHE . 78.4 t -139.99 120.02 13.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 C-N-CA 119.017 -1.073 . . . . 0.0 110.574 173.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.533 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 6.4 t -83.16 137.98 33.84 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.426 -0.796 . . . . 0.0 109.578 176.044 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.581 ' CE2' HG11 ' B' ' 59' ' ' VAL . 86.4 m-85 -120.25 160.63 22.58 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.351 -0.843 . . . . 0.0 110.471 177.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.537 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 32.9 p-10 -95.48 148.24 22.69 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.113 -0.992 . . . . 0.0 110.945 179.388 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.527 HD21 ' CD1' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -157.21 121.93 4.44 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -176.829 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.496 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 26.9 ttt -82.21 141.87 32.64 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.067 -1.02 . . . . 0.0 109.722 -178.183 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.471 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 83.3 tttt -59.95 -48.39 81.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.066 -1.021 . . . . 0.0 110.53 -173.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 54.1 tp10 -68.0 -40.05 83.08 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.915 -1.116 . . . . 0.0 109.966 179.088 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.496 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 87.6 m -59.98 -39.1 84.54 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.004 -1.06 . . . . 0.0 109.278 173.017 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.526 ' CD1' ' HA2' ' B' ' 74' ' ' GLY . 2.0 tp -60.02 -45.2 93.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.314 -0.866 . . . . 0.0 109.734 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -67.06 -39.95 86.97 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.451 -0.781 . . . . 0.0 110.384 176.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.483 HG22 ' N ' ' B' ' 71' ' ' THR . 1.2 tt -66.1 -40.11 86.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.289 -0.882 . . . . 0.0 109.212 -176.809 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.483 ' N ' HG22 ' B' ' 70' ' ' ILE . 52.3 p -84.84 -169.43 2.64 Favored 'General case' 0 C--N 1.301 -1.543 0 C-N-CA 120.17 -0.612 . . . . 0.0 109.577 175.241 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.476 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 7.0 t30 -106.16 22.75 15.19 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 170.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.527 ' CD1' HD21 ' B' ' 63' ' ' LEU . 88.7 mt -69.91 -40.0 75.87 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.308 -0.87 . . . . 0.0 110.182 178.361 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.526 ' HA2' ' CD1' ' B' ' 68' ' ' LEU . . . -50.16 -21.67 4.27 Favored Glycine 0 N--CA 1.487 2.071 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -177.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.1 p-10 -69.22 -17.4 63.77 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.014 -1.286 . . . . 0.0 110.736 -173.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.507 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 95.8 mt -59.99 141.0 56.39 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.139 -0.975 . . . . 0.0 110.8 -176.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.493 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 66.4 mttm -140.03 139.06 35.9 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 121.611 -0.681 . . . . 0.0 109.912 175.673 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.562 ' CG2' HG13 ' B' ' 15' ' ' ILE . 22.1 t -61.11 152.76 5.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.036 -1.04 . . . . 0.0 110.43 -176.348 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.64 -15.83 57.95 Favored Glycine 0 N--CA 1.484 1.837 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 -176.072 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -97.49 169.63 9.6 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.345 -1.091 . . . . 0.0 109.582 175.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.577 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.3 m95 -117.23 166.52 12.16 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.104 -0.998 . . . . 0.0 110.05 177.389 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.522 HG13 ' CB ' ' B' ' 10' ' ' ALA . 1.3 p -128.65 157.54 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.41 -0.806 . . . . 0.0 110.054 -177.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.473 ' HB3' ' CG2' ' B' ' 6' ' ' VAL . 2.1 m-20 -83.48 104.53 13.7 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.307 -0.87 . . . . 0.0 109.263 170.775 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.494 HG11 ' CE1' ' B' ' 44' ' ' HIS . 0.1 OUTLIER -107.38 139.55 28.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.468 -1.395 . . . . 0.0 111.17 -174.637 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -139.92 138.44 35.63 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 120.389 -0.525 . . . . 0.0 109.789 -178.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . 0.455 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 39.0 ptt180 -72.95 137.71 45.67 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.06 -1.025 . . . . 0.0 110.608 -174.09 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.469 ' HB1' ' HB2' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.162 -0.962 . . . . 0.0 109.825 173.764 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.532 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 3.4 t . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 121.624 0.726 . . . . 0.0 110.583 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 28.2 mm100 -98.48 -15.19 19.69 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.554 -0.716 . . . . 0.0 110.783 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.532 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -141.0 165.4 26.25 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.247 -1.454 . . . . 0.0 109.749 -177.595 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.488 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 0.7 OUTLIER -124.83 169.99 11.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.95 -1.324 . . . . 0.0 110.504 178.746 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.531 ' CB ' HG12 ' A' ' 82' ' ' VAL . . . -141.26 149.27 41.1 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.471 -0.768 . . . . 0.0 109.245 -176.525 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.579 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 32.1 tttt -109.65 114.13 27.48 Favored 'General case' 0 C--N 1.294 -1.839 0 O-C-N 121.091 -1.005 . . . . 0.0 110.175 178.852 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.528 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 11.6 tp -59.69 127.86 34.11 Favored 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.061 -1.024 . . . . 0.0 108.903 175.137 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.59 HG12 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -128.31 -30.65 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.868 0 O-C-N 121.339 -0.851 . . . . 0.0 110.062 -178.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.35 141.97 30.08 Favored 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 119.088 -1.045 . . . . 0.0 111.284 -178.158 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.589 ' CG1' ' CG2' ' A' ' 78' ' ' VAL . 8.4 mt -110.04 132.89 57.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.098 -1.001 . . . . 0.0 110.362 172.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.486 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 88.5 m-20 -109.8 114.97 28.98 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.41 -0.806 . . . . 0.0 110.038 175.353 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -102.62 109.61 21.28 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.01 -1.056 . . . . 0.0 110.471 -177.402 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.3 OUTLIER -101.71 135.96 19.66 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.243 -0.91 . . . . 0.0 109.557 175.884 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -53.97 -16.92 9.83 Favored 'Trans proline' 0 C--N 1.302 -1.877 0 O-C-N 123.956 1.503 . . . . 0.0 110.853 -179.631 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.555 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 6.0 m-80 -102.7 -26.56 13.13 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.063 -1.023 . . . . 0.0 109.953 179.744 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.555 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 87.6 m-85 -156.69 150.24 24.52 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.428 -0.795 . . . . 0.0 109.919 -178.549 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.474 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 61.3 ttt180 -92.36 141.74 28.21 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.665 -1.272 . . . . 0.0 109.844 174.799 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.486 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 89.1 m -129.94 140.05 51.0 Favored 'General case' 0 C--N 1.295 -1.799 0 O-C-N 121.495 -0.753 . . . . 0.0 109.824 -172.677 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.584 ' CD2' HG21 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -130.09 142.47 50.6 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 120.986 -1.071 . . . . 0.0 111.413 -179.286 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.523 ' CG2' ' OG ' ' A' ' 60' ' ' SER . 16.6 t -119.66 134.31 63.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.111 -0.993 . . . . 0.0 110.418 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.565 HG13 ' CE1' ' A' ' 61' ' ' PHE . 32.9 m -116.82 170.76 6.02 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 O-C-N 121.912 -0.492 . . . . 0.0 110.113 178.894 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.518 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 9.4 tt0 -102.65 116.64 33.0 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 179.401 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.489 ' CD2' ' O ' ' A' ' 32' ' ' MET . 8.7 tp -80.56 121.63 81.54 Favored Pre-proline 0 C--N 1.295 -1.771 0 O-C-N 121.493 -0.755 . . . . 0.0 109.653 -173.74 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.464 ' HD2' ' HB2' ' A' ' 32' ' ' MET . 18.5 Cg_endo -63.42 178.84 1.07 Allowed 'Trans proline' 0 C--N 1.308 -1.583 0 O-C-N 123.874 1.46 . . . . 0.0 111.004 -179.112 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -60.32 -39.91 88.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.373 -0.83 . . . . 0.0 111.102 -175.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.583 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.17 0.26 57.27 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.833 -1.167 . . . . 0.0 110.93 -175.553 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.583 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.1 mmm -109.12 -12.84 14.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.923 -1.11 . . . . 0.0 110.006 171.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.54 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 19.2 mt -68.8 -31.35 70.29 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.284 -0.885 . . . . 0.0 110.221 178.098 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 52.6 t0 -94.06 122.94 37.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.282 -0.886 . . . . 0.0 110.319 -178.315 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 111.42 -50.6 0.76 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 177.172 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.427 HD11 HD22 ' A' ' 28' ' ' LEU . 6.7 tt -67.0 140.03 57.7 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.087 -1.243 . . . . 0.0 110.296 -176.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.466 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 19.7 pt-20 -147.42 168.5 21.71 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.383 -0.823 . . . . 0.0 109.451 176.767 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.532 ' CG2' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -63.24 151.65 39.87 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.975 -1.078 . . . . 0.0 110.265 -175.885 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.52 -0.44 60.58 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -174.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.466 ' HB3' ' O ' ' A' ' 37' ' ' GLU . . . -79.99 159.37 26.29 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.162 -1.199 . . . . 0.0 109.392 175.861 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.454 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.5 OUTLIER -103.19 117.54 34.77 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 118.849 -1.141 . . . . 0.0 110.155 177.068 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.578 HG11 ' CE1' ' A' ' 44' ' ' HIS . 1.6 t -102.37 128.28 55.21 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 121.335 -0.853 . . . . 0.0 108.907 172.476 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.47 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -92.88 119.68 32.44 Favored 'General case' 0 C--N 1.297 -1.689 0 C-N-CA 119.214 -0.995 . . . . 0.0 109.096 172.644 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.578 ' CE1' HG11 ' A' ' 42' ' ' VAL . 0.4 OUTLIER -87.62 102.63 14.8 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 119.729 -0.789 . . . . 0.0 108.982 179.194 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.8 t-20 59.6 6.29 0.8 Allowed 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.685 -0.634 . . . . 0.0 111.681 -170.642 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.428 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 128.58 -1.04 6.42 Favored Glycine 0 N--CA 1.489 2.181 0 C-N-CA 119.525 -1.321 . . . . 0.0 110.655 174.352 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.475 ' O ' HD23 ' A' ' 49' ' ' LEU . 34.8 t -98.51 108.67 21.42 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.438 -1.624 . . . . 0.0 109.55 175.74 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 22.7 p -74.3 130.17 39.18 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.087 -1.008 . . . . 0.0 111.074 -171.351 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.56 ' CD1' ' CD2' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -147.02 153.82 40.48 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.429 -0.794 . . . . 0.0 109.356 173.901 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 92.5 m -95.83 160.11 14.64 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.527 -1.358 . . . . 0.0 111.558 -169.118 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.531 ' CG1' HG13 ' A' ' 59' ' ' VAL . 15.8 t -82.08 114.72 23.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.847 -0.533 . . . . 0.0 110.358 -178.804 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.521 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 30.2 p -70.9 -39.94 72.47 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.322 -0.861 . . . . 0.0 109.977 175.137 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.53 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -166.19 154.2 10.47 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.31 -0.869 . . . . 0.0 110.177 179.677 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.532 HD11 ' CG2' ' A' ' 38' ' ' THR . 9.8 mt -108.31 134.91 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.1 -1.0 . . . . 0.0 110.138 177.699 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.468 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 47.4 m-80 -108.81 66.23 0.63 Allowed 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.601 -0.687 . . . . 0.0 109.512 177.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.2 -116.84 5.11 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 -173.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.54 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.43 -20.19 51.57 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.055 -1.262 . . . . 0.0 109.116 177.012 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.59 ' CD2' HG12 ' A' ' 13' ' ' VAL . 9.9 m170 -76.61 158.92 30.72 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.241 -0.912 . . . . 0.0 110.044 -178.35 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.531 HG13 ' CG1' ' A' ' 51' ' ' VAL . 55.6 t -140.78 123.06 15.31 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 O-C-N 121.055 -1.028 . . . . 0.0 110.591 171.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.523 ' OG ' ' CG2' ' A' ' 25' ' ' VAL . 0.9 OUTLIER -87.5 133.32 33.78 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.47 -0.769 . . . . 0.0 109.13 175.264 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.587 ' N ' ' CD1' ' A' ' 61' ' ' PHE . 1.8 p90 -125.96 156.01 40.46 Favored 'General case' 0 C--N 1.295 -1.79 0 O-C-N 121.378 -0.826 . . . . 0.0 110.185 178.038 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.521 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 36.7 p-10 -90.78 151.16 21.31 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.089 -1.007 . . . . 0.0 111.398 -170.161 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.532 HD23 ' CD1' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -159.82 111.54 2.03 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 -175.574 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.501 ' HB2' ' CB ' ' A' ' 67' ' ' THR . 28.4 mtm -66.17 140.02 58.16 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.819 -1.176 . . . . 0.0 109.825 -179.848 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.483 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 49.3 tptt -60.11 -49.8 76.23 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.209 -0.932 . . . . 0.0 110.251 -178.411 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -65.2 -40.01 93.58 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.875 -1.141 . . . . 0.0 109.76 176.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.501 ' CB ' ' HB2' ' A' ' 64' ' ' MET . 94.3 m -60.05 -39.7 86.89 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.02 -1.05 . . . . 0.0 109.452 173.289 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.534 ' HG ' ' CA ' ' A' ' 74' ' ' GLY . 7.8 tp -59.95 -43.57 94.95 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.308 -0.87 . . . . 0.0 109.65 179.723 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -68.16 -40.01 82.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.38 -0.825 . . . . 0.0 110.579 176.042 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.467 HG22 ' O ' ' A' ' 67' ' ' THR . 1.3 tt -64.9 -43.25 96.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.17 -0.956 . . . . 0.0 109.328 -177.108 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.458 HG23 HG22 ' A' ' 70' ' ' ILE . 29.9 p -86.68 -174.63 5.07 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.727 -0.608 . . . . 0.0 109.667 176.751 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.479 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 6.1 t30 -98.78 22.59 9.87 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.167 -0.958 . . . . 0.0 108.686 171.469 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.532 ' CD1' HD23 ' A' ' 63' ' ' LEU . 91.8 mt -68.73 -39.98 80.12 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.095 -1.003 . . . . 0.0 109.975 176.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.534 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -50.44 -23.9 6.78 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -178.351 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.5 p-10 -62.12 -18.01 59.53 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.089 -1.242 . . . . 0.0 110.233 -175.764 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.9 mt -63.62 142.09 58.53 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.319 -0.863 . . . . 0.0 110.961 -177.69 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.464 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 42.8 mttt -143.54 144.84 32.13 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-O 121.311 0.577 . . . . 0.0 109.731 175.106 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.589 ' CG2' ' CG1' ' A' ' 15' ' ' ILE . 21.9 t -64.52 149.93 10.7 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 120.843 -1.161 . . . . 0.0 110.479 -175.327 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.97 -13.63 60.78 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -175.144 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 46.6 t0 -94.61 163.3 13.44 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.337 -1.096 . . . . 0.0 109.585 176.021 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.579 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 13.9 m95 -113.28 154.79 26.23 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 120.964 -1.085 . . . . 0.0 110.155 175.829 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.531 HG12 ' CB ' ' A' ' 10' ' ' ALA . 1.4 p -119.99 153.03 22.82 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.437 -0.789 . . . . 0.0 109.852 -179.019 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.486 ' N ' HG22 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -77.73 107.34 10.16 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.171 -0.955 . . . . 0.0 109.02 168.475 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.488 ' CG2' ' C ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -109.4 138.85 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 120.474 -1.391 . . . . 0.0 111.364 -176.724 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -131.49 139.59 49.35 Favored 'General case' 0 N--CA 1.494 1.749 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.131 -179.369 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -81.37 133.62 35.44 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.091 -1.006 . . . . 0.0 110.94 -175.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.454 ' O ' ' OG ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.736 0 O-C-N 121.28 -0.888 . . . . 0.0 110.639 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.529 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 3.4 t . . . . . 0 N--CA 1.489 1.491 0 CA-C-O 121.54 0.686 . . . . 0.0 110.583 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 28.2 mm100 -98.55 -14.83 19.77 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.54 -0.725 . . . . 0.0 110.854 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.529 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -141.28 165.14 26.42 Favored Glycine 0 N--CA 1.493 2.458 0 C-N-CA 119.338 -1.41 . . . . 0.0 109.868 -177.536 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.487 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 0.7 OUTLIER -124.74 169.99 11.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.123 -1.221 . . . . 0.0 110.556 178.821 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.534 ' CB ' HG11 ' B' ' 82' ' ' VAL . . . -141.31 149.34 41.1 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.507 -0.745 . . . . 0.0 109.235 -176.617 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.589 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 32.0 tttt -109.7 114.34 27.86 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.151 -0.968 . . . . 0.0 110.014 178.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.515 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 11.7 tp -60.02 127.78 33.57 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.104 -0.998 . . . . 0.0 108.939 175.106 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.593 HG12 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.96 -31.04 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 O-C-N 121.393 -0.817 . . . . 0.0 110.1 -178.651 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.08 141.9 30.32 Favored 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.328 -178.082 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.586 ' CG1' ' CG2' ' B' ' 78' ' ' VAL . 8.4 mt -109.91 132.96 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.128 -0.982 . . . . 0.0 110.377 172.917 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.494 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 88.2 m-20 -109.99 114.98 28.95 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.416 -0.803 . . . . 0.0 109.995 175.388 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -102.59 109.67 21.36 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.982 -1.074 . . . . 0.0 110.497 -177.399 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . 0.466 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.3 OUTLIER -101.87 135.95 19.62 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.274 -0.892 . . . . 0.0 109.541 175.943 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.05 -16.85 9.97 Favored 'Trans proline' 0 C--N 1.303 -1.837 0 O-C-N 123.934 1.492 . . . . 0.0 110.856 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.547 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 6.0 m-80 -102.56 -26.98 13.03 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.107 -0.996 . . . . 0.0 109.874 179.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.547 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 87.5 m-85 -156.3 150.22 25.08 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.432 -0.793 . . . . 0.0 109.972 -178.426 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . 0.476 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 61.2 ttt180 -92.31 141.67 28.3 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.701 -1.25 . . . . 0.0 109.806 174.786 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.494 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 88.4 m -129.96 140.12 50.97 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 121.617 -0.677 . . . . 0.0 109.798 -172.715 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.573 ' CD2' HG21 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -130.05 142.45 50.61 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 120.964 -1.085 . . . . 0.0 111.338 -179.158 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.526 ' CG2' ' OG ' ' B' ' 60' ' ' SER . 16.3 t -119.51 134.41 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.264 -0.898 . . . . 0.0 110.435 179.55 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.579 HG13 ' CE1' ' B' ' 61' ' ' PHE . 33.1 m -117.09 170.76 6.21 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 CA-C-O 121.263 0.554 . . . . 0.0 109.955 178.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.519 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 9.3 tt0 -102.56 116.68 33.08 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.345 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.495 ' CD2' ' O ' ' B' ' 32' ' ' MET . 8.7 tp -80.54 121.62 81.56 Favored Pre-proline 0 C--N 1.297 -1.703 0 O-C-N 121.433 -0.792 . . . . 0.0 109.716 -173.805 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.47 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 18.5 Cg_endo -63.4 178.86 1.06 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 O-C-N 123.91 1.479 . . . . 0.0 111.007 -179.09 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -60.29 -39.98 88.85 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.356 -0.84 . . . . 0.0 111.118 -175.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.566 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.11 0.28 57.23 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.87 -1.144 . . . . 0.0 110.945 -175.609 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.566 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.1 mmm -109.16 -12.81 14.77 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.87 -1.144 . . . . 0.0 109.93 171.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.53 ' CD2' ' HB2' ' B' ' 57' ' ' ASN . 19.2 mt -68.88 -31.32 70.17 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.226 -0.921 . . . . 0.0 110.22 178.054 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -93.99 122.95 37.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.381 -0.824 . . . . 0.0 110.363 -178.38 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 111.43 -50.65 0.75 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.061 -1.215 . . . . 0.0 110.061 177.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . 0.525 HD21 ' N ' ' B' ' 37' ' ' GLU . 6.7 tt -66.97 140.02 57.72 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.051 -1.264 . . . . 0.0 110.299 -176.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . 0.525 ' N ' HD21 ' B' ' 36' ' ' LEU . 19.7 pt-20 -147.38 168.55 21.54 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.401 -0.812 . . . . 0.0 109.41 176.673 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.533 ' CG2' ' HA ' ' B' ' 53' ' ' GLU . 0.0 OUTLIER -63.33 151.51 40.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.995 -1.066 . . . . 0.0 110.382 -175.949 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.73 -0.48 61.32 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -174.658 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.456 ' CB ' ' O ' ' B' ' 37' ' ' GLU . . . -80.07 159.34 26.18 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.141 -1.211 . . . . 0.0 109.382 175.816 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 41' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' B' ' 87' ' ' ALA . 0.5 OUTLIER -102.99 117.33 34.36 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.782 -1.199 . . . . 0.0 110.309 177.03 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.582 HG11 ' CE1' ' B' ' 44' ' ' HIS . 1.7 t -102.27 128.43 54.93 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 121.357 -0.839 . . . . 0.0 108.868 172.5 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.466 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -92.97 119.74 32.55 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 119.227 -0.989 . . . . 0.0 108.988 172.617 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.582 ' CE1' HG11 ' B' ' 42' ' ' VAL . 0.4 OUTLIER -87.72 102.45 14.65 Favored 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.54 -0.864 . . . . 0.0 109.098 179.106 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 59.84 6.38 0.89 Allowed 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.554 -0.716 . . . . 0.0 111.549 -170.688 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.436 ' HA3' ' O ' ' A' ' 45' ' ' ASN . . . 128.38 -0.62 6.46 Favored Glycine 0 N--CA 1.489 2.218 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.714 174.228 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.466 ' O ' ' HA ' ' B' ' 43' ' ' ALA . 34.6 t -98.63 108.61 21.34 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.502 -1.587 . . . . 0.0 109.537 175.552 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 22.9 p -74.19 130.19 39.27 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.058 -1.026 . . . . 0.0 111.043 -171.429 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.558 ' CD1' ' CD2' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -147.11 153.92 40.5 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.527 -0.733 . . . . 0.0 109.359 173.726 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 92.9 m -95.9 160.41 14.48 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 120.527 -1.358 . . . . 0.0 111.556 -169.085 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.534 ' CG1' HG13 ' B' ' 59' ' ' VAL . 16.1 t -82.44 114.65 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.84 -0.538 . . . . 0.0 110.433 -178.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 30.2 p -70.71 -40.03 73.07 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.272 -0.893 . . . . 0.0 109.918 175.339 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.533 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -166.21 154.11 10.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.202 -0.936 . . . . 0.0 110.208 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.532 HD11 ' CG2' ' B' ' 38' ' ' THR . 9.8 mt -108.31 134.89 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.114 -0.991 . . . . 0.0 110.206 177.684 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.477 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 47.1 m-80 -108.84 66.14 0.63 Allowed 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.64 -0.662 . . . . 0.0 109.522 177.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.32 -116.81 5.08 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 108.861 -1.696 . . . . 0.0 108.861 -173.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.53 ' HB2' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.44 -20.29 51.35 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.075 -1.25 . . . . 0.0 109.151 177.054 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.593 ' CD2' HG12 ' B' ' 13' ' ' VAL . 9.9 m170 -76.5 158.79 30.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.347 -0.846 . . . . 0.0 110.097 -178.375 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.534 HG13 ' CG1' ' B' ' 51' ' ' VAL . 55.8 t -140.76 123.15 15.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 C-N-CA 119.076 -1.05 . . . . 0.0 110.519 171.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.526 ' OG ' ' CG2' ' B' ' 25' ' ' VAL . 0.9 OUTLIER -87.52 133.3 33.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.441 -0.787 . . . . 0.0 109.204 175.225 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.589 ' N ' ' CD1' ' B' ' 61' ' ' PHE . 1.8 p90 -125.98 155.99 40.53 Favored 'General case' 0 N--CA 1.494 1.773 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.177 178.033 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 36.6 p-10 -90.67 151.19 21.37 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.0 -1.062 . . . . 0.0 111.381 -170.115 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.534 HD22 ' CD1' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.82 111.53 2.03 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -175.638 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.505 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 28.5 mtm -66.22 139.96 58.13 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.888 -1.133 . . . . 0.0 109.824 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.485 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 49.3 tptt -59.92 -49.87 76.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.131 -0.98 . . . . 0.0 110.3 -178.439 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -65.24 -39.99 93.42 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.913 -1.117 . . . . 0.0 109.765 176.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.505 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 94.5 m -60.01 -39.83 87.19 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.988 -1.07 . . . . 0.0 109.342 173.29 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.523 ' HG ' ' CA ' ' B' ' 74' ' ' GLY . 7.8 tp -59.94 -43.45 94.97 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.293 -0.879 . . . . 0.0 109.707 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 78.5 ttt180 -68.21 -40.08 82.21 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.293 -0.879 . . . . 0.0 110.603 175.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.459 HG21 HG21 ' B' ' 71' ' ' THR . 1.3 tt -64.75 -43.24 96.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.195 -0.941 . . . . 0.0 109.434 -177.213 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.466 HG21 ' O ' ' B' ' 67' ' ' THR . 30.0 p -86.65 -174.56 5.04 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 120.231 -0.588 . . . . 0.0 109.658 176.774 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.484 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 6.0 t30 -98.71 22.57 9.84 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.19 -0.944 . . . . 0.0 108.78 171.393 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.534 ' CD1' HD22 ' B' ' 63' ' ' LEU . 91.4 mt -68.71 -40.0 80.17 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.075 -1.015 . . . . 0.0 110.05 176.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.523 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -50.46 -23.87 6.78 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 -178.384 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.0 p-10 -62.1 -17.94 59.23 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.062 -1.258 . . . . 0.0 110.295 -175.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.513 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.1 mt -63.68 142.22 58.48 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.287 -0.883 . . . . 0.0 110.929 -177.746 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.478 ' O ' HD22 ' B' ' 12' ' ' LEU . 42.8 mttt -143.67 144.95 32.1 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.627 -0.671 . . . . 0.0 109.665 175.13 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.586 ' CG2' ' CG1' ' B' ' 15' ' ' ILE . 22.2 t -64.73 150.03 10.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 O-C-N 120.856 -1.153 . . . . 0.0 110.341 -175.182 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.8 -13.45 60.89 Favored Glycine 0 N--CA 1.484 1.84 0 N-CA-C 108.848 -1.701 . . . . 0.0 108.848 -175.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.499 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 46.2 t0 -94.62 163.23 13.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.319 -1.106 . . . . 0.0 109.59 175.832 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.589 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 13.9 m95 -113.31 154.73 26.37 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.97 -1.081 . . . . 0.0 110.215 175.782 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.534 HG11 ' CB ' ' B' ' 10' ' ' ALA . 1.4 p -119.98 153.1 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.579 -0.701 . . . . 0.0 109.881 -179.082 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.483 ' N ' HG23 ' B' ' 82' ' ' VAL . 0.3 OUTLIER -77.72 107.27 10.09 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.178 -0.951 . . . . 0.0 109.018 168.569 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.487 ' CG2' ' C ' ' B' ' 9' ' ' THR . 0.0 OUTLIER -109.32 138.96 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 120.462 -1.399 . . . . 0.0 111.211 -176.533 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -131.58 139.68 49.25 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.883 -0.511 . . . . 0.0 110.144 -179.569 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -81.35 133.69 35.46 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.117 -0.99 . . . . 0.0 110.916 -175.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.457 ' O ' ' OG ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.496 1.844 0 O-C-N 121.403 -0.81 . . . . 0.0 110.647 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.527 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.5 t . . . . . 0 N--CA 1.493 1.708 0 CA-C-O 121.557 0.694 . . . . 0.0 110.638 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 20.1 pt20 -89.64 -16.15 31.13 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.453 -0.779 . . . . 0.0 110.829 -178.426 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -158.45 177.12 35.25 Favored Glycine 0 N--CA 1.493 2.484 0 C-N-CA 119.129 -1.51 . . . . 0.0 110.083 -177.522 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.487 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 1.4 p -125.87 167.97 14.51 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.069 -1.254 . . . . 0.0 110.472 178.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.533 ' CB ' HG13 ' A' ' 82' ' ' VAL . . . -139.93 149.64 43.57 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.346 -0.846 . . . . 0.0 109.903 -174.283 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 31.2 tttt -106.26 116.01 31.21 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.126 -0.984 . . . . 0.0 110.169 179.255 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.515 HD22 ' N ' ' A' ' 78' ' ' VAL . 13.1 tp -59.93 128.03 34.84 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.793 -1.192 . . . . 0.0 108.582 171.676 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.637 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.7 p -131.34 -31.01 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 O-C-N 121.262 -0.898 . . . . 0.0 110.316 -176.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -144.34 139.68 28.65 Favored 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 118.936 -1.106 . . . . 0.0 111.39 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.573 HG13 ' CG2' ' A' ' 78' ' ' VAL . 9.9 mt -109.16 137.0 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.052 -1.03 . . . . 0.0 110.08 171.366 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.458 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 78.7 m-20 -111.86 114.35 27.25 Favored 'General case' 0 C--N 1.295 -1.79 0 O-C-N 121.415 -0.803 . . . . 0.0 110.182 173.028 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -105.04 118.61 36.97 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.033 -1.042 . . . . 0.0 110.492 -177.443 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.453 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.9 mtpp -118.26 140.18 27.74 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.256 -0.902 . . . . 0.0 109.779 178.876 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -55.1 -15.2 10.03 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 O-C-N 124.067 1.562 . . . . 0.0 110.964 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.586 ' ND2' ' N ' ' A' ' 20' ' ' ASN . 0.1 OUTLIER -107.61 -25.25 11.42 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.999 -1.063 . . . . 0.0 109.308 -177.892 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.568 ' CD1' ' O ' ' A' ' 20' ' ' ASN . 75.8 m-85 -157.74 150.3 22.71 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.622 -0.674 . . . . 0.0 110.105 179.337 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.466 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 63.6 ttt180 -96.77 143.32 27.8 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 120.815 -1.178 . . . . 0.0 110.012 172.614 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.458 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 54.4 m -130.91 140.18 50.17 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.488 -0.758 . . . . 0.0 110.145 -173.414 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.576 ' HB3' ' CE1' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -130.14 143.86 51.03 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 120.94 -1.1 . . . . 0.0 111.604 178.805 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.536 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 8.3 t -125.77 136.1 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.158 -0.964 . . . . 0.0 110.651 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.48 HG11 ' CE2' ' A' ' 61' ' ' PHE . 35.4 m -117.67 171.74 5.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 121.783 -0.573 . . . . 0.0 110.211 178.228 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.569 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 3.6 tt0 -104.25 117.31 33.92 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.218 -0.926 . . . . 0.0 109.247 -178.772 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.505 ' CD2' ' O ' ' A' ' 32' ' ' MET . 9.6 tp -82.81 125.87 74.4 Favored Pre-proline 0 C--N 1.299 -1.621 0 O-C-N 121.585 -0.697 . . . . 0.0 110.106 -173.641 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.478 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 28.2 Cg_endo -67.04 176.94 4.01 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 123.886 1.466 . . . . 0.0 111.069 -179.627 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.444 ' HA ' HD12 ' A' ' 33' ' ' LEU . 92.6 m-20 -60.03 -40.0 87.84 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.239 -0.913 . . . . 0.0 111.306 -174.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.573 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.99 0.64 56.99 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.751 -1.218 . . . . 0.0 110.907 -174.472 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.573 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.8 mmm -112.17 -8.57 13.99 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.875 -1.141 . . . . 0.0 110.006 170.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.548 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 16.0 mt -70.03 -40.01 75.42 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.224 -0.922 . . . . 0.0 109.915 177.065 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -81.74 128.81 34.38 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.594 -0.691 . . . . 0.0 110.486 -178.246 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.47 -46.18 1.21 Allowed Glycine 0 N--CA 1.493 2.445 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.256 174.795 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.486 HD21 ' N ' ' A' ' 37' ' ' GLU . 6.8 tt -69.7 148.84 48.71 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.93 -1.335 . . . . 0.0 110.445 -175.365 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.486 ' N ' HD21 ' A' ' 36' ' ' LEU . 21.3 pt-20 -150.62 170.02 20.16 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.367 -0.833 . . . . 0.0 109.397 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.539 ' CG2' ' HA ' ' A' ' 53' ' ' GLU . 0.0 OUTLIER -70.06 151.15 45.84 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.058 -1.026 . . . . 0.0 110.228 -178.919 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.09 -3.3 66.2 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -174.183 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.472 ' HB2' ' O ' ' A' ' 37' ' ' GLU . . . -77.99 161.48 27.46 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.27 -1.135 . . . . 0.0 109.661 177.612 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.476 ' CB ' ' HB1' ' A' ' 87' ' ' ALA . 0.6 OUTLIER -101.64 114.95 29.46 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.016 -1.052 . . . . 0.0 110.104 177.354 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.537 ' CG1' ' CE1' ' A' ' 44' ' ' HIS . 1.8 t -103.16 128.88 55.76 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.323 -0.861 . . . . 0.0 109.157 174.06 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.466 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -94.8 120.08 34.43 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.269 -0.972 . . . . 0.0 109.265 173.043 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.567 ' CD2' HG23 ' A' ' 82' ' ' VAL . 1.4 m80 -90.71 106.19 18.34 Favored 'General case' 0 C--N 1.301 -1.503 0 C-N-CA 119.676 -0.81 . . . . 0.0 109.054 177.568 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.494 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.8 t-20 53.92 14.81 0.72 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.338 -0.851 . . . . 0.0 110.925 -167.02 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.493 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 117.78 -0.5 17.73 Favored Glycine 0 N--CA 1.489 2.17 0 C-N-CA 119.623 -1.275 . . . . 0.0 110.978 170.559 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.526 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 43.4 t -92.35 106.84 18.76 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.49 -1.594 . . . . 0.0 109.151 173.525 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.8 p -75.49 128.66 35.8 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.15 -0.969 . . . . 0.0 110.749 -170.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.6 HD12 ' CG ' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -143.14 159.66 41.88 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.442 -0.786 . . . . 0.0 109.714 175.296 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.406 HG21 ' N ' ' A' ' 51' ' ' VAL . 28.9 m -100.16 149.82 23.14 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.576 -1.328 . . . . 0.0 111.409 -170.781 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.538 ' CG1' HG11 ' A' ' 59' ' ' VAL . 15.1 t -78.06 118.39 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 CA-C-O 121.155 0.502 . . . . 0.0 110.617 -178.002 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.53 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 42.9 p -73.89 -39.94 63.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.126 -0.984 . . . . 0.0 110.031 174.494 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.539 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.6 tt0 -163.4 149.85 12.07 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.35 -0.844 . . . . 0.0 110.214 -178.007 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.532 HD11 ' CG2' ' A' ' 38' ' ' THR . 5.7 mt -101.51 134.9 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.09 -1.007 . . . . 0.0 109.955 176.148 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.457 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 49.9 m-80 -110.45 65.78 0.62 Allowed 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.571 -0.705 . . . . 0.0 109.913 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.19 -118.68 4.99 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.879 -1.688 . . . . 0.0 108.879 -175.236 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.548 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.62 -16.39 57.41 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 120.949 -1.324 . . . . 0.0 108.816 174.307 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.637 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 11.8 m170 -76.6 159.81 29.96 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.37 -0.831 . . . . 0.0 110.39 -178.192 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.538 HG11 ' CG1' ' A' ' 51' ' ' VAL . 52.2 t -140.3 127.02 22.42 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 O-C-N 121.02 -1.05 . . . . 0.0 110.596 170.036 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.536 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 2.7 t -95.8 136.74 35.83 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.474 -0.767 . . . . 0.0 109.564 178.382 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.6 ' CG ' HD12 ' A' ' 49' ' ' LEU . 2.0 p90 -128.06 157.78 39.76 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.864 173.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.53 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 25.0 p-10 -89.48 157.64 18.02 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.31 -0.869 . . . . 0.0 111.129 -171.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.528 ' CD2' HD12 ' A' ' 68' ' ' LEU . 0.1 OUTLIER -159.94 102.57 1.47 Allowed 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 120.035 -0.666 . . . . 0.0 109.461 -175.441 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.491 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 56.3 ttm -59.75 140.4 56.54 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.002 -1.062 . . . . 0.0 109.364 -179.557 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.45 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 39.4 ttpt -60.01 -43.32 95.31 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.022 -1.049 . . . . 0.0 110.285 -175.159 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.74 -39.99 76.43 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.02 -1.05 . . . . 0.0 110.067 178.279 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.504 ' O ' HG21 ' A' ' 71' ' ' THR . 92.2 m -60.56 -39.96 89.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.978 -1.076 . . . . 0.0 109.184 172.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.528 HD12 ' CD2' ' A' ' 63' ' ' LEU . 7.3 tp -59.94 -45.4 92.74 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.285 -0.885 . . . . 0.0 109.782 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.405 ' HD3' ' HA ' ' A' ' 69' ' ' ARG . 15.0 tpp180 -69.21 -39.59 78.51 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.529 -0.732 . . . . 0.0 110.47 177.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.473 ' CG2' ' N ' ' A' ' 71' ' ' THR . 1.4 tt -63.68 -43.98 98.27 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.13 -0.982 . . . . 0.0 109.368 -177.47 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.504 HG21 ' O ' ' A' ' 67' ' ' THR . 37.8 p -83.55 -170.51 3.1 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.404 0.621 . . . . 0.0 109.703 178.611 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.5 t30 -103.28 22.63 13.79 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 170.187 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.499 ' CD1' HD23 ' A' ' 63' ' ' LEU . 89.4 mt -69.54 -41.23 76.22 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.158 -0.964 . . . . 0.0 109.999 176.731 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.494 ' HA2' ' CD1' ' A' ' 68' ' ' LEU . . . -51.01 -20.81 4.75 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 -178.163 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.1 p-10 -67.43 -18.5 65.12 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.927 -1.337 . . . . 0.0 110.673 -174.003 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.517 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 90.2 mt -60.89 142.86 55.92 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.166 -0.959 . . . . 0.0 110.983 -175.476 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.478 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 98.7 mttt -140.34 139.53 35.43 Favored 'General case' 0 N--CA 1.493 1.695 0 CA-C-O 121.537 0.684 . . . . 0.0 109.955 173.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.573 ' CG2' HG13 ' A' ' 15' ' ' ILE . 15.4 t -63.19 153.47 6.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 120.868 -1.145 . . . . 0.0 110.636 -174.45 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.0 -16.93 55.83 Favored Glycine 0 N--CA 1.485 1.928 0 N-CA-C 108.645 -1.782 . . . . 0.0 108.645 -175.134 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -95.14 170.09 9.64 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.402 -1.058 . . . . 0.0 109.743 175.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.5 m95 -116.97 169.51 9.35 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.965 -1.085 . . . . 0.0 110.17 176.013 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.567 HG23 ' CD2' ' A' ' 44' ' ' HIS . 1.4 p -134.09 155.63 39.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 121.438 -0.789 . . . . 0.0 109.808 -176.669 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.487 ' HB2' ' HB3' ' B' ' 72' ' ' ASN . 2.1 m-20 -79.57 109.12 13.66 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.006 -1.059 . . . . 0.0 109.134 168.668 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.49 ' O ' HG12 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -110.78 138.59 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 120.43 -1.419 . . . . 0.0 111.275 -175.546 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -134.35 145.03 48.62 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.864 -0.522 . . . . 0.0 110.292 -177.244 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 36.1 ttm180 -83.49 130.65 35.02 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.311 -0.868 . . . . 0.0 111.027 -176.679 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.476 ' HB1' ' CB ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.25 -0.906 . . . . 0.0 110.023 174.737 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.525 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.5 t . . . . . 0 N--CA 1.493 1.685 0 CA-C-O 121.477 0.656 . . . . 0.0 110.727 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 20.1 pt20 -89.72 -15.84 31.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.374 -0.828 . . . . 0.0 110.887 -178.418 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.525 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -158.8 177.0 35.59 Favored Glycine 0 N--CA 1.494 2.552 0 C-N-CA 119.143 -1.503 . . . . 0.0 110.113 -177.495 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.486 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 1.4 p -125.88 167.92 14.58 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.088 -1.243 . . . . 0.0 110.42 179.103 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.534 ' CB ' HG11 ' B' ' 82' ' ' VAL . . . -139.84 149.77 43.85 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.278 -0.889 . . . . 0.0 109.88 -174.399 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.589 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 31.2 tttt -106.35 116.04 31.25 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.081 -1.012 . . . . 0.0 110.141 179.201 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.514 HD23 ' N ' ' B' ' 78' ' ' VAL . 13.1 tp -60.06 128.03 34.82 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.828 -1.17 . . . . 0.0 108.671 171.634 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.642 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.7 p -131.41 -30.86 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.31 -176.711 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -144.46 139.8 28.55 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.12 -1.032 . . . . 0.0 111.348 179.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.575 HG13 ' CG2' ' B' ' 78' ' ' VAL . 10.3 mt -109.32 136.98 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.078 -1.013 . . . . 0.0 110.06 171.4 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.473 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 78.6 m-20 -111.97 114.5 27.44 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 121.44 -0.787 . . . . 0.0 110.159 173.039 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -104.96 118.74 37.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.188 -0.945 . . . . 0.0 110.493 -177.435 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . 0.449 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.9 mtpp -118.39 140.3 27.99 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.29 -0.881 . . . . 0.0 109.771 178.838 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -55.39 -15.11 10.81 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 124.008 1.53 . . . . 0.0 110.967 -179.785 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.571 ' O ' ' CD1' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -107.28 -25.9 11.28 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.01 -1.056 . . . . 0.0 109.214 -177.946 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.571 ' CD1' ' O ' ' B' ' 20' ' ' ASN . 75.3 m-85 -157.2 150.36 23.79 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.534 -0.729 . . . . 0.0 110.195 179.499 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . 0.457 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 63.7 ttt180 -96.8 143.21 27.93 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.914 -1.117 . . . . 0.0 109.944 172.616 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.473 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 54.0 m -130.76 140.21 50.29 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.638 -0.664 . . . . 0.0 110.134 -173.492 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.574 ' HB3' ' CE1' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -130.04 143.94 51.06 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.005 -1.06 . . . . 0.0 111.492 178.806 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.541 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 8.2 t -125.7 136.3 61.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.317 -0.864 . . . . 0.0 110.764 179.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.478 HG13 ' CE2' ' B' ' 61' ' ' PHE . 35.6 m -117.91 171.78 5.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.744 -0.598 . . . . 0.0 110.126 178.355 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.574 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 3.6 tt0 -104.18 117.45 34.28 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.274 -0.891 . . . . 0.0 109.199 -178.786 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.514 ' N ' ' ND2' ' B' ' 57' ' ' ASN . 9.6 tp -82.9 125.8 74.37 Favored Pre-proline 0 C--N 1.299 -1.613 0 O-C-N 121.545 -0.722 . . . . 0.0 110.129 -173.724 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.479 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 28.1 Cg_endo -67.01 176.96 3.97 Favored 'Trans proline' 0 C--N 1.31 -1.491 0 O-C-N 123.919 1.484 . . . . 0.0 110.934 -179.583 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -60.01 -39.99 87.72 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.309 -0.869 . . . . 0.0 111.35 -174.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.567 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.01 0.63 57.0 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.761 -1.212 . . . . 0.0 110.844 -174.434 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.567 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.8 mmm -112.19 -8.58 13.98 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.856 -1.153 . . . . 0.0 110.006 170.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.546 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 16.0 mt -70.0 -40.04 75.52 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.268 -0.895 . . . . 0.0 109.888 177.07 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -81.7 128.93 34.49 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.597 -0.689 . . . . 0.0 110.508 -178.273 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.35 -46.15 1.21 Allowed Glycine 0 N--CA 1.492 2.414 0 C-N-CA 119.868 -1.158 . . . . 0.0 110.328 174.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . 0.452 HD11 HD21 ' B' ' 28' ' ' LEU . 6.8 tt -69.66 148.89 48.71 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.95 -1.324 . . . . 0.0 110.43 -175.402 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . 0.47 ' O ' ' HB3' ' B' ' 40' ' ' ALA . 21.4 pt-20 -150.68 169.95 20.36 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.347 -0.845 . . . . 0.0 109.51 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.543 ' CG2' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -69.99 151.12 45.94 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.038 -1.039 . . . . 0.0 110.252 -178.855 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.17 -3.5 65.96 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 -174.209 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.47 ' HB3' ' O ' ' B' ' 37' ' ' GLU . . . -77.91 161.36 27.62 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.297 -1.119 . . . . 0.0 109.701 177.521 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 41' ' ' SER . . . . . 0.481 ' CB ' ' HB3' ' B' ' 87' ' ' ALA . 0.6 OUTLIER -101.43 114.82 29.17 Favored 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 119.096 -1.042 . . . . 0.0 110.18 177.35 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.537 ' CG1' ' CE1' ' B' ' 44' ' ' HIS . 1.8 t -103.12 129.01 55.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.379 -0.826 . . . . 0.0 109.141 174.068 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.463 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -94.87 120.05 34.45 Favored 'General case' 0 C--N 1.298 -1.651 0 C-N-CA 119.245 -0.982 . . . . 0.0 109.214 173.044 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.579 ' CD2' HG23 ' B' ' 82' ' ' VAL . 1.4 m80 -90.69 106.15 18.31 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.403 -0.811 . . . . 0.0 109.074 177.478 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.494 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.8 t-20 54.01 14.84 0.75 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.368 -0.833 . . . . 0.0 110.858 -167.157 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.493 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 117.66 -0.3 17.98 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.715 -1.231 . . . . 0.0 111.031 170.438 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.52 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 43.1 t -92.38 106.9 18.8 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.411 -1.641 . . . . 0.0 109.134 173.395 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 17.8 p -75.45 128.75 36.04 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.097 -1.002 . . . . 0.0 110.684 -170.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.57 ' CD1' ' CG ' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -143.29 159.64 41.97 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.416 -0.803 . . . . 0.0 109.61 175.259 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 29.4 m -100.02 150.01 22.88 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.673 -1.267 . . . . 0.0 111.329 -170.74 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.537 ' CG1' HG12 ' B' ' 59' ' ' VAL . 15.4 t -78.38 118.46 25.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.827 -0.546 . . . . 0.0 110.607 -178.027 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.531 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 43.0 p -73.89 -40.01 63.49 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.201 -0.937 . . . . 0.0 110.037 174.629 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.531 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.6 tt0 -163.32 149.83 12.19 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.336 -0.852 . . . . 0.0 110.206 -177.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.543 HD11 ' CG2' ' B' ' 38' ' ' THR . 5.7 mt -101.52 134.79 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.096 -1.002 . . . . 0.0 109.993 176.148 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.474 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 49.7 m-80 -110.41 65.78 0.62 Allowed 'General case' 0 C--N 1.298 -1.634 0 C-N-CA 119.857 -0.737 . . . . 0.0 109.907 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.31 -118.75 4.99 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 108.809 -1.717 . . . . 0.0 108.809 -175.26 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.546 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.55 -16.54 57.32 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.969 -1.312 . . . . 0.0 108.901 174.302 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.642 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 11.8 m170 -76.51 159.63 30.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.491 -0.756 . . . . 0.0 110.347 -178.2 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.537 HG12 ' CG1' ' B' ' 51' ' ' VAL . 52.1 t -140.15 127.1 23.14 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 C-N-CA 119.042 -1.063 . . . . 0.0 110.554 170.054 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.541 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 2.7 t -95.81 136.85 35.69 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.575 -0.703 . . . . 0.0 109.616 178.307 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.574 ' CE1' ' HB3' ' B' ' 24' ' ' HIS . 2.0 p90 -128.11 157.63 40.2 Favored 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 119.054 -1.058 . . . . 0.0 110.876 174.065 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.531 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 25.3 p-10 -89.47 157.76 17.98 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.297 -0.877 . . . . 0.0 111.056 -171.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.524 HD22 ' CD1' ' B' ' 68' ' ' LEU . 0.1 OUTLIER -159.96 102.54 1.47 Allowed 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.958 -0.697 . . . . 0.0 109.445 -175.428 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.487 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 56.1 ttm -59.77 140.36 56.58 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.117 -0.989 . . . . 0.0 109.381 -179.501 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.45 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 39.4 ttpt -59.98 -43.38 95.15 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.042 -1.036 . . . . 0.0 110.242 -175.094 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.72 -40.04 76.47 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.049 -1.032 . . . . 0.0 110.083 178.297 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.487 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 92.2 m -60.58 -39.97 90.02 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.95 -1.094 . . . . 0.0 109.14 173.016 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.524 ' CD1' HD22 ' B' ' 63' ' ' LEU . 7.3 tp -60.0 -45.17 93.61 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.375 -0.828 . . . . 0.0 109.892 179.3 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 15.0 tpp180 -69.33 -39.41 78.21 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.547 -0.72 . . . . 0.0 110.493 177.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.47 HG22 ' O ' ' B' ' 67' ' ' THR . 1.4 tt -63.85 -43.88 97.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.177 -0.952 . . . . 0.0 109.365 -177.427 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.478 HG22 ' O ' ' B' ' 67' ' ' THR . 37.3 p -83.44 -170.42 3.04 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 121.433 0.635 . . . . 0.0 109.805 178.529 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.487 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 4.3 t30 -103.33 22.58 13.91 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 170.176 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.5 ' CD1' HD23 ' B' ' 63' ' ' LEU . 89.3 mt -69.55 -41.16 76.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.228 -0.92 . . . . 0.0 110.091 176.689 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.503 ' HA2' ' CD1' ' B' ' 68' ' ' LEU . . . -51.01 -20.8 4.73 Favored Glycine 0 N--CA 1.487 2.099 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -178.23 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.1 p-10 -67.55 -18.41 65.01 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.998 -1.295 . . . . 0.0 110.706 -173.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.514 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 90.3 mt -60.92 142.82 56.07 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.077 -1.015 . . . . 0.0 110.947 -175.513 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.483 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 98.7 mttt -140.32 139.74 35.49 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.682 -0.636 . . . . 0.0 109.854 173.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.575 ' CG2' HG13 ' B' ' 15' ' ' ILE . 16.2 t -63.4 153.45 7.01 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.12 -0.987 . . . . 0.0 110.625 -174.399 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.02 -16.68 56.48 Favored Glycine 0 N--CA 1.484 1.874 0 N-CA-C 108.687 -1.765 . . . . 0.0 108.687 -175.285 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 24.9 t0 -95.13 169.95 9.74 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.374 -1.074 . . . . 0.0 109.808 175.615 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.589 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.5 m95 -116.98 169.42 9.42 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.034 -1.041 . . . . 0.0 110.139 176.022 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.579 HG23 ' CD2' ' B' ' 44' ' ' HIS . 1.4 p -133.96 155.7 40.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.539 -0.726 . . . . 0.0 109.908 -176.824 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.485 ' N ' HG21 ' B' ' 82' ' ' VAL . 2.0 m-20 -79.5 108.91 13.39 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.074 -1.016 . . . . 0.0 109.245 168.692 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.486 ' CG2' ' C ' ' B' ' 9' ' ' THR . 0.0 OUTLIER -110.45 138.87 36.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 120.458 -1.401 . . . . 0.0 111.183 -175.393 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -134.73 145.08 48.13 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.856 -0.527 . . . . 0.0 110.128 -177.364 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 36.2 ttm180 -83.43 130.67 35.04 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.26 -0.9 . . . . 0.0 110.987 -176.675 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.481 ' HB3' ' CB ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.493 1.715 0 O-C-N 121.279 -0.888 . . . . 0.0 109.965 174.666 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.527 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 4.0 t . . . . . 0 N--CA 1.493 1.696 0 CA-C-O 121.803 0.811 . . . . 0.0 111.3 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -69.99 -34.08 72.88 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.695 -0.628 . . . . 0.0 110.632 175.369 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -163.34 171.43 39.05 Favored Glycine 0 N--CA 1.494 2.555 0 C-N-CA 118.729 -1.7 . . . . 0.0 110.394 -174.518 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.497 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 11.7 p -112.81 168.35 9.75 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.031 -1.276 . . . . 0.0 110.699 -178.729 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.519 ' CB ' HG11 ' A' ' 82' ' ' VAL . . . -133.46 148.87 51.76 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -178.022 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.578 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 22.5 tttt -104.25 112.64 25.74 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 120.972 -1.08 . . . . 0.0 110.15 178.109 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.544 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 10.9 tp -57.14 126.88 29.2 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 121.146 -0.971 . . . . 0.0 108.803 173.598 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.64 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.21 -31.35 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 O-C-N 121.349 -0.844 . . . . 0.0 110.046 -178.237 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -142.86 144.18 32.39 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.147 -1.021 . . . . 0.0 111.582 -179.454 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.585 HG13 ' CG2' ' A' ' 78' ' ' VAL . 8.1 mt -110.94 130.37 64.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 120.995 -1.065 . . . . 0.0 110.21 168.749 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.487 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 76.0 m-20 -108.86 115.49 30.19 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.364 -0.835 . . . . 0.0 109.889 172.331 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -103.91 110.28 22.35 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 120.888 -1.132 . . . . 0.0 110.495 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.467 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.9 OUTLIER -102.61 131.87 21.91 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.177 -0.952 . . . . 0.0 108.88 173.76 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -50.52 -34.21 41.43 Favored 'Trans proline' 0 C--N 1.302 -1.91 0 O-C-N 123.828 1.436 . . . . 0.0 110.383 -179.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.55 ' HB3' ' CE2' ' A' ' 21' ' ' PHE . 10.4 m-80 -74.19 -39.33 63.25 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.244 -0.91 . . . . 0.0 110.32 175.899 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.55 ' CE2' ' HB3' ' A' ' 20' ' ' ASN . 49.9 m-85 -152.53 150.14 29.26 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.271 -0.893 . . . . 0.0 110.106 -176.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.425 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 50.7 ttt180 -88.73 144.96 25.91 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.914 -1.116 . . . . 0.0 109.999 175.065 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.487 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.8 m -130.07 140.06 50.89 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.437 -0.79 . . . . 0.0 110.099 -177.876 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.591 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -129.59 144.61 51.35 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.967 -1.083 . . . . 0.0 111.107 177.333 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.48 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 6.9 t -124.06 133.37 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.034 -1.041 . . . . 0.0 110.508 179.229 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.568 HG11 ' CE1' ' A' ' 61' ' ' PHE . 13.1 m -112.88 172.31 3.26 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 121.737 -0.602 . . . . 0.0 109.954 177.403 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.573 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 8.1 tt0 -106.95 116.3 31.69 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.357 -0.839 . . . . 0.0 108.794 178.128 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.53 ' N ' ' ND2' ' A' ' 57' ' ' ASN . 9.2 tp -80.09 123.98 83.13 Favored Pre-proline 0 C--N 1.296 -1.753 0 O-C-N 121.548 -0.72 . . . . 0.0 109.977 -172.569 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.471 ' HG3' ' O ' ' A' ' 9' ' ' THR . 27.7 Cg_endo -66.35 -178.54 1.18 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 O-C-N 123.822 1.433 . . . . 0.0 110.977 -179.521 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.47 ' HA ' HD12 ' A' ' 33' ' ' LEU . 61.6 t0 -62.55 -40.97 98.52 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 111.027 -174.667 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.578 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.03 1.14 56.66 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.811 -1.181 . . . . 0.0 111.014 -174.664 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.578 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.4 mmm -108.56 -15.37 14.45 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.784 -1.198 . . . . 0.0 109.844 169.829 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.532 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 21.0 mt -69.51 -22.04 63.62 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.217 -0.927 . . . . 0.0 109.997 177.699 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -95.16 115.6 27.65 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.364 -0.835 . . . . 0.0 110.473 -178.59 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.34 -50.52 0.78 Allowed Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.764 -1.207 . . . . 0.0 110.556 173.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.459 HD21 HG21 ' A' ' 59' ' ' VAL . 9.8 tt -60.98 159.33 11.67 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.886 -1.361 . . . . 0.0 111.123 -172.319 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.466 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 22.0 pt-20 -157.52 163.46 38.39 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.53 ' N ' HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -69.9 151.57 45.51 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.845 -1.159 . . . . 0.0 109.921 -177.474 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.09 -4.66 65.68 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 -172.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.466 ' HB3' ' O ' ' A' ' 37' ' ' GLU . . . -74.33 160.12 31.48 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.293 -1.122 . . . . 0.0 109.683 176.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.486 ' O ' ' CB ' ' A' ' 87' ' ' ALA . 0.7 OUTLIER -100.98 103.25 14.39 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.068 -1.02 . . . . 0.0 110.12 178.298 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.5 HG13 ' CE1' ' A' ' 44' ' ' HIS . 2.2 t -88.12 131.46 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.201 -0.937 . . . . 0.0 109.489 175.489 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.484 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -98.17 120.97 39.51 Favored 'General case' 0 C--N 1.296 -1.755 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.418 170.862 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.5 ' CE1' HG13 ' A' ' 42' ' ' VAL . 1.0 OUTLIER -88.74 105.83 17.96 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 119.583 -0.847 . . . . 0.0 108.987 177.525 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.1 t-20 52.96 11.92 0.24 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.463 -0.773 . . . . 0.0 111.525 -166.482 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 127.73 -6.8 6.97 Favored Glycine 0 N--CA 1.489 2.233 0 C-N-CA 119.224 -1.465 . . . . 0.0 111.169 172.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.535 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 13.8 t -92.49 105.99 18.06 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.192 -1.77 . . . . 0.0 109.471 177.027 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.434 ' HA ' ' HA ' ' A' ' 43' ' ' ALA . 16.2 p -75.24 129.52 37.6 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.14 -0.975 . . . . 0.0 111.122 -171.138 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.558 ' CD1' ' CD2' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -141.97 159.98 41.13 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.595 -0.691 . . . . 0.0 109.276 174.91 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.437 HG22 ' N ' ' A' ' 51' ' ' VAL . 51.7 m -94.79 148.24 22.5 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.613 -1.305 . . . . 0.0 111.279 -170.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.496 HG13 HG13 ' A' ' 59' ' ' VAL . 19.3 t -77.27 122.03 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.651 -0.656 . . . . 0.0 110.265 178.849 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.527 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 19.3 p -77.54 -44.49 28.41 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.257 -0.902 . . . . 0.0 110.138 175.204 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.502 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.1 tt0 -157.47 150.13 23.04 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.113 -0.992 . . . . 0.0 110.348 178.023 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.53 HD12 ' N ' ' A' ' 38' ' ' THR . 1.4 mp -97.79 137.0 26.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.07 -1.019 . . . . 0.0 109.728 173.237 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.453 ' O ' ' HB2' ' A' ' 58' ' ' HIS . 33.4 m-80 -110.03 70.43 0.72 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.595 -0.691 . . . . 0.0 109.698 178.147 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 72.04 -120.12 7.75 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 -172.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.532 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -75.51 -21.17 58.21 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 120.995 -1.297 . . . . 0.0 109.04 175.543 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.64 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 10.7 m170 -72.41 160.48 32.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.28 -0.887 . . . . 0.0 110.234 -178.395 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.496 HG13 HG13 ' A' ' 51' ' ' VAL . 53.1 t -140.07 124.54 19.18 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 C-N-CA 119.127 -1.029 . . . . 0.0 110.536 170.679 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 53.1 p -95.08 128.56 42.01 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.476 -0.765 . . . . 0.0 109.553 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.591 ' CZ ' ' HB3' ' A' ' 24' ' ' HIS . 1.8 p90 -124.01 157.35 34.65 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 120.995 -1.066 . . . . 0.0 110.254 -179.118 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.527 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 30.4 p-10 -93.27 152.79 18.96 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 122.09 0.947 . . . . 0.0 111.127 -172.794 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.48 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -152.21 120.03 6.15 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -175.894 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.496 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 63.5 tpp -77.16 139.58 39.96 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.983 -1.073 . . . . 0.0 109.848 -179.64 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.466 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 74.9 tttt -59.93 -49.85 76.07 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.12 -0.987 . . . . 0.0 110.578 -173.49 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -66.27 -39.96 89.79 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.828 -1.17 . . . . 0.0 109.996 178.223 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.496 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 90.9 m -60.0 -39.57 86.21 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.002 -1.061 . . . . 0.0 109.197 173.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.505 ' HG ' ' CA ' ' A' ' 74' ' ' GLY . 2.1 tp -59.97 -45.28 93.18 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.319 -0.863 . . . . 0.0 109.852 179.339 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 tpt85 -69.39 -38.32 77.93 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.386 -0.821 . . . . 0.0 110.079 177.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.509 HG21 ' N ' ' A' ' 71' ' ' THR . 1.3 tt -67.75 -39.9 82.84 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 O-C-N 121.333 -0.855 . . . . 0.0 109.191 -177.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.509 ' N ' HG21 ' A' ' 70' ' ' ILE . 49.4 p -88.77 -176.41 5.22 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 175.572 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.467 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 8.8 t30 -98.22 21.18 11.26 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.244 -0.91 . . . . 0.0 108.903 173.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.48 ' HB3' HD21 ' A' ' 63' ' ' LEU . 34.4 mt -70.04 -39.99 75.42 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.912 -1.118 . . . . 0.0 110.444 179.609 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.505 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -52.54 -19.33 6.19 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -176.34 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 27.1 p-10 -69.98 -18.21 63.33 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.111 -1.229 . . . . 0.0 110.965 -174.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 85.5 mt -59.99 146.49 42.41 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.088 -1.008 . . . . 0.0 111.026 -174.54 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.465 ' O ' HD22 ' A' ' 12' ' ' LEU . 67.4 mttt -139.88 141.75 36.57 Favored 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 121.537 0.684 . . . . 0.0 109.906 176.68 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.585 ' CG2' HG13 ' A' ' 15' ' ' ILE . 46.2 t -66.44 150.06 11.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 120.888 -1.133 . . . . 0.0 110.466 -177.329 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.96 -14.99 60.46 Favored Glycine 0 N--CA 1.482 1.743 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 -174.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.478 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 13.9 t0 -96.65 168.27 10.62 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.409 -1.053 . . . . 0.0 109.576 174.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.578 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.4 m95 -115.83 156.09 26.71 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.04 -1.037 . . . . 0.0 110.304 177.72 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.519 HG11 ' CB ' ' A' ' 10' ' ' ALA . 1.1 p -120.07 150.0 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.262 -0.899 . . . . 0.0 110.1 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.497 ' N ' ' HB2' ' B' ' 72' ' ' ASN . 0.4 OUTLIER -70.79 104.53 2.92 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.044 -1.035 . . . . 0.0 108.887 166.785 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.508 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -104.35 139.42 25.37 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 120.51 -1.369 . . . . 0.0 110.987 -176.839 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.467 ' OE2' HG22 ' A' ' 6' ' ' VAL . 85.2 mt-10 -125.47 146.62 49.56 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.918 -0.488 . . . . 0.0 110.15 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . 0.52 ' HB3' ' CZ ' ' A' ' 86' ' ' ARG . 18.3 mtp-105 -90.26 114.77 26.87 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.513 -0.742 . . . . 0.0 110.033 177.494 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.486 ' CB ' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.061 -1.024 . . . . 0.0 110.524 -178.254 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.54 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 4.0 t . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.783 0.802 . . . . 0.0 111.367 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -70.05 -33.75 72.36 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.745 -0.597 . . . . 0.0 110.685 175.449 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.54 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -163.66 171.35 39.29 Favored Glycine 0 N--CA 1.495 2.628 0 C-N-CA 118.91 -1.614 . . . . 0.0 110.52 -174.52 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.498 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 11.7 p -112.9 168.29 9.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.06 -1.259 . . . . 0.0 110.739 -178.632 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.526 ' HB3' ' CG1' ' B' ' 84' ' ' VAL . . . -133.38 149.01 51.85 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 -178.017 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.573 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 22.7 tttt -104.36 112.79 25.97 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 120.982 -1.074 . . . . 0.0 110.047 178.115 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.53 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 11.0 tp -57.35 126.84 29.06 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.193 -0.942 . . . . 0.0 108.761 173.592 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.639 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.18 -31.24 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.784 0 O-C-N 121.339 -0.851 . . . . 0.0 110.089 -178.211 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -142.99 144.17 32.21 Favored 'General case' 0 N--CA 1.493 1.716 0 C-N-CA 119.234 -0.986 . . . . 0.0 111.553 -179.478 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.581 HG13 ' CG2' ' B' ' 78' ' ' VAL . 8.0 mt -110.85 130.47 64.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 120.992 -1.068 . . . . 0.0 110.193 168.836 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.494 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 75.5 m-20 -109.12 115.59 30.33 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.353 -0.842 . . . . 0.0 109.767 172.389 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -103.92 110.31 22.39 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.019 -1.05 . . . . 0.0 110.443 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . 0.459 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.9 OUTLIER -102.7 131.92 21.82 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.347 -0.846 . . . . 0.0 108.874 173.763 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -50.62 -34.19 42.29 Favored 'Trans proline' 0 C--N 1.301 -1.95 0 O-C-N 123.825 1.434 . . . . 0.0 110.295 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.561 ' HB3' ' CE2' ' B' ' 21' ' ' PHE . 10.5 m-80 -73.98 -39.96 63.31 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.224 -0.922 . . . . 0.0 110.165 175.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.561 ' CE2' ' HB3' ' B' ' 20' ' ' ASN . 49.4 m-85 -152.06 150.18 29.66 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.381 -0.824 . . . . 0.0 110.183 -176.757 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . 0.413 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 50.5 ttt180 -88.65 144.91 25.98 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.916 -1.115 . . . . 0.0 109.924 175.033 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.494 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 95.0 m -130.09 140.08 50.87 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.511 -0.743 . . . . 0.0 110.147 -178.003 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.588 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -129.57 144.58 51.33 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.095 -1.003 . . . . 0.0 110.994 177.476 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.519 HG22 ' CB ' ' B' ' 60' ' ' SER . 6.8 t -123.99 133.48 69.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.142 -0.974 . . . . 0.0 110.573 179.113 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.574 HG11 ' CE1' ' B' ' 61' ' ' PHE . 13.3 m -112.96 172.3 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.698 -0.626 . . . . 0.0 109.876 177.485 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.579 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 8.1 tt0 -106.86 116.24 31.58 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.444 -0.785 . . . . 0.0 108.923 177.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.541 ' N ' ' ND2' ' B' ' 57' ' ' ASN . 9.3 tp -80.01 123.98 83.26 Favored Pre-proline 0 C--N 1.296 -1.747 0 O-C-N 121.434 -0.791 . . . . 0.0 110.028 -172.587 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.466 ' HD2' ' HB2' ' B' ' 32' ' ' MET . 27.7 Cg_endo -66.3 -178.42 1.13 Allowed 'Trans proline' 0 C--N 1.31 -1.489 0 O-C-N 123.831 1.437 . . . . 0.0 110.96 -179.523 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 61.7 t0 -62.67 -40.91 98.55 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.386 -0.821 . . . . 0.0 111.027 -174.698 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.576 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.01 1.11 56.68 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.867 -1.145 . . . . 0.0 111.01 -174.631 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.576 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.4 mmm -108.61 -15.25 14.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.752 -1.218 . . . . 0.0 109.813 169.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.53 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 20.8 mt -69.69 -21.93 63.47 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.269 -0.894 . . . . 0.0 109.982 177.722 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -95.22 115.68 27.75 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.348 -0.845 . . . . 0.0 110.408 -178.606 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.18 -50.43 0.78 Allowed Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.823 -1.179 . . . . 0.0 110.543 173.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . 0.456 HD21 HG23 ' B' ' 59' ' ' VAL . 9.8 tt -61.01 159.29 11.81 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.843 -1.386 . . . . 0.0 111.132 -172.362 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . 0.475 ' O ' ' HB1' ' B' ' 40' ' ' ALA . 21.9 pt-20 -157.51 163.36 38.51 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.544 HG22 ' CD1' ' B' ' 54' ' ' ILE . 0.0 OUTLIER -69.85 151.59 45.53 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.862 -1.149 . . . . 0.0 109.965 -177.531 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.98 -4.47 66.05 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -172.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.475 ' HB1' ' O ' ' B' ' 37' ' ' GLU . . . -74.37 160.02 31.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.199 -1.177 . . . . 0.0 109.653 176.68 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 41' ' ' SER . . . . . 0.485 ' O ' ' CB ' ' B' ' 87' ' ' ALA . 0.6 OUTLIER -100.82 103.12 14.32 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.969 -1.082 . . . . 0.0 110.139 178.291 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.512 HG11 ' CE1' ' B' ' 44' ' ' HIS . 2.2 t -88.1 131.59 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.284 -0.885 . . . . 0.0 109.486 175.432 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.477 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -98.25 121.0 39.64 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 120.961 -1.087 . . . . 0.0 109.441 170.716 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.544 ' CG ' HG21 ' B' ' 82' ' ' VAL . 1.0 OUTLIER -88.78 105.58 17.8 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.245 -0.91 . . . . 0.0 109.1 177.494 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.1 t-20 53.23 11.94 0.28 Allowed 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.462 -0.774 . . . . 0.0 111.409 -166.565 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 127.55 -6.36 7.07 Favored Glycine 0 N--CA 1.49 2.251 0 C-N-CA 119.231 -1.461 . . . . 0.0 111.082 172.03 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.524 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 13.9 t -92.66 106.04 18.09 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.059 -1.847 . . . . 0.0 109.439 176.825 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . 0.42 ' HA ' ' HA ' ' B' ' 43' ' ' ALA . 16.1 p -75.21 129.57 37.7 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.086 -1.009 . . . . 0.0 111.145 -171.19 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.551 ' CD1' ' CD2' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -142.01 159.93 41.23 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 174.925 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 52.1 m -94.69 148.21 22.52 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.514 -1.366 . . . . 0.0 111.244 -170.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.486 HG12 HG13 ' B' ' 59' ' ' VAL . 18.6 t -77.23 122.06 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.647 -0.658 . . . . 0.0 110.281 178.796 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.525 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 19.7 p -77.66 -44.55 27.73 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.213 -0.93 . . . . 0.0 110.029 175.33 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.504 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.3 tt0 -157.43 150.18 23.17 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.101 -0.999 . . . . 0.0 110.348 178.031 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.544 ' CD1' HG22 ' B' ' 38' ' ' THR . 1.4 mp -97.82 136.94 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.175 -0.953 . . . . 0.0 109.729 173.282 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.469 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 33.5 m-80 -109.95 70.29 0.72 Allowed 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.545 -0.722 . . . . 0.0 109.676 178.219 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 72.09 -120.11 7.71 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 108.713 -1.755 . . . . 0.0 108.713 -172.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.541 ' ND2' ' N ' ' B' ' 28' ' ' LEU . 0.0 OUTLIER -75.41 -21.28 58.35 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.054 -1.262 . . . . 0.0 109.12 175.468 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.639 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 10.8 m170 -72.43 160.27 32.61 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.407 -0.808 . . . . 0.0 110.362 -178.404 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.486 HG13 HG12 ' B' ' 51' ' ' VAL . 53.6 t -139.89 124.62 19.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 119.061 -1.056 . . . . 0.0 110.415 170.853 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.519 ' CB ' HG22 ' B' ' 25' ' ' VAL . 53.4 p -95.08 128.82 42.21 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.619 -0.675 . . . . 0.0 109.509 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.588 ' CZ ' ' HB3' ' B' ' 24' ' ' HIS . 1.8 p90 -124.26 157.29 35.21 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.002 -1.061 . . . . 0.0 110.218 -179.148 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.525 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 30.5 p-10 -93.2 152.74 19.03 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.136 -0.978 . . . . 0.0 111.192 -172.753 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.462 HD21 HD13 ' B' ' 68' ' ' LEU . 0.0 OUTLIER -152.06 119.97 6.19 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 -175.883 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.503 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 63.6 tpp -77.19 139.57 39.93 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.976 -1.078 . . . . 0.0 109.845 -179.61 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.475 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 74.9 tttt -60.03 -49.73 76.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.166 -0.959 . . . . 0.0 110.492 -173.362 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . 0.4 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 88.4 tt0 -66.35 -40.0 89.53 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.794 -1.191 . . . . 0.0 109.946 178.326 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.503 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 90.3 m -60.05 -39.55 86.32 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.031 -1.043 . . . . 0.0 109.145 174.008 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.506 ' HG ' ' CA ' ' B' ' 74' ' ' GLY . 2.1 tp -60.01 -45.14 93.73 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.388 -0.82 . . . . 0.0 109.962 179.278 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 tpt85 -69.35 -38.52 78.14 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.409 -0.807 . . . . 0.0 110.079 177.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.487 HG21 HG21 ' B' ' 71' ' ' THR . 1.3 tt -67.55 -39.95 83.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 CA-C-O 121.73 0.776 . . . . 0.0 109.238 -178.032 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.487 HG21 HG21 ' B' ' 70' ' ' ILE . 49.6 p -88.74 -176.24 5.18 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 175.674 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.497 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 8.7 t30 -98.3 21.19 11.33 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 121.182 -0.948 . . . . 0.0 108.733 173.881 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.461 ' HB3' HD23 ' B' ' 63' ' ' LEU . 34.1 mt -70.01 -40.03 75.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.954 -1.091 . . . . 0.0 110.458 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.506 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -52.49 -19.31 6.09 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -176.324 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.504 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 27.2 p-10 -70.05 -18.25 63.28 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.083 -1.245 . . . . 0.0 110.946 -174.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.504 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 85.7 mt -59.95 146.43 42.45 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.188 -0.945 . . . . 0.0 111.012 -174.547 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.47 ' O ' HD22 ' B' ' 12' ' ' LEU . 67.4 mttt -139.89 141.78 36.54 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.626 -0.671 . . . . 0.0 109.888 176.658 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.581 ' CG2' HG13 ' B' ' 15' ' ' ILE . 46.2 t -66.49 150.01 11.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.04 -1.038 . . . . 0.0 110.498 -177.274 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.01 -14.94 60.65 Favored Glycine 0 N--CA 1.483 1.824 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -174.712 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 13.8 t0 -96.73 168.13 10.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.359 -1.083 . . . . 0.0 109.582 174.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.573 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.4 m95 -115.76 156.0 26.8 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.06 -1.025 . . . . 0.0 110.325 177.788 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.544 HG21 ' CG ' ' B' ' 44' ' ' HIS . 1.1 p -120.01 150.06 22.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.427 -0.795 . . . . 0.0 110.173 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.479 ' HB3' ' CG2' ' B' ' 6' ' ' VAL . 0.4 OUTLIER -70.68 104.32 2.81 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.001 -1.062 . . . . 0.0 109.053 166.705 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.526 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -104.22 139.59 24.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 120.464 -1.398 . . . . 0.0 110.905 -176.61 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . 0.462 ' OE2' HG22 ' B' ' 6' ' ' VAL . 85.0 mt-10 -125.73 146.57 49.7 Favored 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.193 0.521 . . . . 0.0 110.064 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . 0.526 ' HB3' ' CZ ' ' B' ' 86' ' ' ARG . 18.3 mtp-105 -90.26 114.84 26.95 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.35 -0.844 . . . . 0.0 109.957 177.566 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.485 ' CB ' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.624 0 O-C-N 121.256 -0.903 . . . . 0.0 110.57 -178.292 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.537 HG11 ' CA ' ' A' ' 83' ' ' ASN . 1.6 t . . . . . 0 N--CA 1.49 1.562 0 CA-C-O 121.836 0.827 . . . . 0.0 110.871 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -71.04 -33.09 69.98 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.866 -0.521 . . . . 0.0 111.182 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.533 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -150.35 171.92 30.2 Favored Glycine 0 N--CA 1.495 2.582 0 C-N-CA 119.054 -1.546 . . . . 0.0 110.133 -171.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.495 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 3.1 p -119.23 172.34 7.66 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.893 -1.357 . . . . 0.0 111.214 -176.453 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.528 ' CB ' HG11 ' A' ' 82' ' ' VAL . . . -142.64 150.0 39.66 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 -176.362 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.589 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.1 tttt -110.83 115.15 29.03 Favored 'General case' 0 C--N 1.295 -1.803 0 O-C-N 121.097 -1.002 . . . . 0.0 110.276 179.54 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.542 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 10.9 tp -59.74 127.71 33.32 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.015 -1.053 . . . . 0.0 109.079 174.362 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.64 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -122.2 -28.9 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 C-N-CA 119.641 -0.824 . . . . 0.0 109.648 179.2 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.71 147.54 26.83 Favored 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 119.05 -1.06 . . . . 0.0 111.551 -179.155 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.576 HG12 ' CD2' ' A' ' 24' ' ' HIS . 11.7 mt -109.59 138.61 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.212 -0.93 . . . . 0.0 110.03 172.415 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.478 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.7 m-20 -109.58 114.62 28.4 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.283 -0.885 . . . . 0.0 109.924 173.52 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -100.35 112.15 24.47 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.13 -0.981 . . . . 0.0 110.369 -176.484 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.469 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.2 OUTLIER -112.76 132.76 22.12 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.203 -0.935 . . . . 0.0 108.94 175.492 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -49.57 -40.39 45.88 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 O-C-N 123.855 1.45 . . . . 0.0 110.754 -179.204 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.445 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 12.0 m-80 -70.59 -39.37 73.89 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.124 -0.985 . . . . 0.0 110.259 177.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.469 ' O ' ' HB2' ' A' ' 18' ' ' LYS . 95.7 m-85 -152.55 150.3 29.42 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.289 -0.882 . . . . 0.0 110.526 -174.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.475 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 60.7 ttt180 -91.28 143.54 26.54 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 120.835 -1.166 . . . . 0.0 109.909 175.006 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.478 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 97.1 m -129.57 140.77 51.12 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.597 -0.69 . . . . 0.0 109.738 -174.663 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.577 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -132.65 137.27 46.92 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 120.948 -1.095 . . . . 0.0 111.142 -177.95 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.517 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 4.8 t -120.16 131.72 71.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.115 -0.991 . . . . 0.0 110.677 -178.379 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.581 HG13 ' CE1' ' A' ' 61' ' ' PHE . 18.9 m -111.9 175.74 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 CA-C-O 121.212 0.529 . . . . 0.0 110.265 178.007 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.573 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 7.9 tt0 -107.02 117.05 33.03 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.387 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.513 ' CD2' ' O ' ' A' ' 32' ' ' MET . 10.7 tp -80.45 126.74 77.97 Favored Pre-proline 0 C--N 1.296 -1.724 0 O-C-N 121.428 -0.795 . . . . 0.0 109.827 -173.53 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.462 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 18.7 Cg_endo -63.78 173.67 4.47 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.886 1.466 . . . . 0.0 110.654 -179.362 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -59.99 -38.06 81.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.372 -0.83 . . . . 0.0 110.676 -176.159 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.57 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.18 0.06 57.37 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.959 -1.088 . . . . 0.0 110.947 -175.734 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.57 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 94.5 mmm -110.43 -12.01 14.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.854 -1.154 . . . . 0.0 109.948 170.176 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.531 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 15.8 mt -63.04 -31.38 72.5 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.299 -0.875 . . . . 0.0 110.15 176.817 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -93.23 139.99 30.02 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.339 -0.851 . . . . 0.0 110.536 -176.335 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.08 -41.42 2.34 Favored Glycine 0 N--CA 1.491 2.335 0 C-N-CA 119.892 -1.147 . . . . 0.0 110.387 174.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.468 HD23 HG21 ' A' ' 59' ' ' VAL . 9.1 tt -76.1 149.28 37.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.926 -1.338 . . . . 0.0 111.054 -174.394 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.467 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 15.8 pt-20 -151.59 169.25 22.56 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.464 -0.772 . . . . 0.0 109.58 177.289 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.531 ' N ' ' CD1' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -61.32 151.64 31.47 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.936 -1.102 . . . . 0.0 109.876 179.107 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.73 -5.81 60.36 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -178.647 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.469 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -73.28 156.15 38.77 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.228 -1.16 . . . . 0.0 109.649 177.266 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.456 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -99.8 106.2 18.06 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.958 -1.089 . . . . 0.0 109.749 176.296 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.578 HG11 ' CE1' ' A' ' 44' ' ' HIS . 2.2 t -93.3 129.89 43.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 121.21 -0.931 . . . . 0.0 109.122 174.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.464 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -93.38 120.02 33.17 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.3 -0.96 . . . . 0.0 109.117 172.336 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.578 ' CE1' HG11 ' A' ' 42' ' ' VAL . 0.4 OUTLIER -91.22 104.79 17.3 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.698 -0.801 . . . . 0.0 108.886 177.98 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.496 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.6 t-20 55.34 14.09 1.03 Allowed 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.314 -0.866 . . . . 0.0 110.896 -168.704 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 120.33 -5.16 12.12 Favored Glycine 0 N--CA 1.49 2.255 0 C-N-CA 119.58 -1.295 . . . . 0.0 110.919 172.132 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.529 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 25.1 t -90.58 110.32 21.46 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.336 -1.685 . . . . 0.0 109.495 176.634 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.9 p -74.47 127.93 34.29 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.959 -1.088 . . . . 0.0 110.789 -171.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.603 ' CD1' ' CD2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -143.21 160.06 41.16 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.323 -0.861 . . . . 0.0 109.707 174.825 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.431 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 3.6 m -102.22 151.56 22.06 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.773 -1.205 . . . . 0.0 111.083 -172.526 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.518 HG13 HG23 ' A' ' 38' ' ' THR . 14.6 t -78.22 118.39 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.752 -0.593 . . . . 0.0 110.489 -177.341 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.523 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 43.9 p -72.32 -40.03 67.77 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.367 -0.833 . . . . 0.0 110.065 174.128 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.483 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -164.48 153.5 13.22 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.272 -0.893 . . . . 0.0 110.2 -176.956 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.531 ' CD1' ' N ' ' A' ' 38' ' ' THR . 6.8 mt -109.56 130.02 63.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.107 -0.996 . . . . 0.0 109.958 176.118 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.464 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 4.5 m-80 -102.56 63.28 0.86 Allowed 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.682 -0.636 . . . . 0.0 109.725 179.427 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.11 -114.06 4.06 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.781 -1.728 . . . . 0.0 108.781 -174.086 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.531 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.53 -22.31 47.5 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 120.953 -1.322 . . . . 0.0 108.82 175.001 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.64 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 11.8 m80 -74.46 159.44 32.27 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.331 -0.856 . . . . 0.0 110.229 -177.651 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.489 HG13 HG12 ' A' ' 51' ' ' VAL . 54.1 t -141.62 122.58 12.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 C-N-CA 119.163 -1.015 . . . . 0.0 110.81 172.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.517 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 1.4 t -88.26 134.9 33.68 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.454 -0.779 . . . . 0.0 109.705 175.366 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.609 ' N ' ' CD1' ' A' ' 61' ' ' PHE . 2.1 p90 -127.26 154.66 44.6 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.374 -0.829 . . . . 0.0 110.292 176.66 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.523 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 35.8 p-10 -88.95 152.29 21.8 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.149 -0.969 . . . . 0.0 111.329 -171.136 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.531 HD23 ' CD1' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -157.77 100.25 1.75 Allowed 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.598 -0.689 . . . . 0.0 109.369 -174.178 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.477 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 60.7 ttm -60.23 139.89 57.32 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.058 -1.026 . . . . 0.0 109.669 -177.307 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.48 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 5.1 ttpm? -59.94 -43.31 95.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.138 -0.977 . . . . 0.0 110.409 -175.36 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.33 -40.03 77.84 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.833 -1.167 . . . . 0.0 109.842 178.056 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.477 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 94.2 m -59.98 -37.64 80.24 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.05 -1.031 . . . . 0.0 109.474 172.231 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.53 ' CD1' ' HA2' ' A' ' 74' ' ' GLY . 14.2 tp -59.96 -45.81 91.45 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.273 -0.892 . . . . 0.0 109.428 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 55.2 ttt85 -69.96 -39.94 75.71 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.382 -0.824 . . . . 0.0 110.739 176.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.459 HG23 HG23 ' A' ' 71' ' ' THR . 1.5 tt -67.27 -42.82 88.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.233 -0.917 . . . . 0.0 109.445 -175.779 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.461 HG23 ' O ' ' A' ' 67' ' ' THR . 40.3 p -83.84 -173.87 4.96 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 174.678 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.499 ' HB3' ' HB2' ' B' ' 83' ' ' ASN . 3.1 t30 -102.71 23.63 11.77 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 169.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.531 ' CD1' HD23 ' A' ' 63' ' ' LEU . 86.9 mt -68.42 -40.07 81.36 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.089 -1.007 . . . . 0.0 110.015 176.768 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.53 ' HA2' ' CD1' ' A' ' 68' ' ' LEU . . . -47.88 -22.36 1.98 Allowed Glycine 0 N--CA 1.487 2.086 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.694 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.2 p-10 -62.83 -18.69 63.19 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.163 -1.198 . . . . 0.0 110.405 -176.303 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.513 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.8 mt -60.0 143.16 52.52 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.202 -0.936 . . . . 0.0 110.516 -177.752 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.459 ' O ' HD21 ' A' ' 12' ' ' LEU . 23.3 mttm -145.82 146.87 31.32 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.584 -0.698 . . . . 0.0 109.381 176.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.568 ' CG2' HG13 ' A' ' 15' ' ' ILE . 22.4 t -68.25 148.59 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.677 -1.265 . . . . 0.0 110.176 -175.625 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.14 -11.17 63.61 Favored Glycine 0 N--CA 1.483 1.813 0 N-CA-C 108.743 -1.743 . . . . 0.0 108.743 -174.167 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.487 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 45.5 t0 -95.68 162.63 13.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.344 -1.092 . . . . 0.0 109.694 176.785 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.589 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.0 m95 -114.76 149.35 37.07 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.124 -0.985 . . . . 0.0 110.005 176.778 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.55 HG22 ' CD2' ' A' ' 44' ' ' HIS . 1.2 p -115.21 153.79 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.498 -0.751 . . . . 0.0 109.971 -179.581 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.537 ' CA ' HG11 ' A' ' 6' ' ' VAL . 2.6 m-20 -78.19 106.11 9.87 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.143 -0.973 . . . . 0.0 109.125 168.607 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.521 HG11 ' CE1' ' A' ' 44' ' ' HIS . 0.0 OUTLIER -108.4 139.88 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 120.665 -1.272 . . . . 0.0 111.177 -176.643 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.42 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.4 tt0 -136.92 144.02 43.23 Favored 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 120.217 -0.593 . . . . 0.0 110.201 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 66.5 ttp85 -79.58 129.92 34.91 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.279 -0.888 . . . . 0.0 111.011 -176.552 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.456 ' O ' ' OG ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.61 0 O-C-N 121.351 -0.843 . . . . 0.0 110.134 175.815 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.543 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 1.6 t . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 121.85 0.833 . . . . 0.0 110.921 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -71.11 -32.79 69.46 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.814 -0.554 . . . . 0.0 111.221 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.543 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -150.64 171.78 30.42 Favored Glycine 0 N--CA 1.495 2.63 0 C-N-CA 119.105 -1.522 . . . . 0.0 110.153 -171.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.499 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 3.1 p -119.23 172.26 7.72 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.937 -1.331 . . . . 0.0 111.238 -176.31 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.513 ' CB ' HG11 ' B' ' 82' ' ' VAL . . . -142.58 150.13 39.95 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 -176.417 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.588 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 30.1 tttt -110.9 115.25 29.19 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.102 -0.999 . . . . 0.0 110.224 179.585 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.54 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 10.9 tp -59.95 127.68 33.08 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.085 -1.009 . . . . 0.0 109.068 174.41 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.644 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -122.03 -29.16 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.662 179.295 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.67 147.6 26.92 Favored 'General case' 0 N--CA 1.493 1.678 0 C-N-CA 119.188 -1.005 . . . . 0.0 111.473 -179.137 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.572 HG12 ' CD2' ' B' ' 24' ' ' HIS . 11.8 mt -109.59 138.71 35.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.305 -0.872 . . . . 0.0 110.041 172.404 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.483 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 77.4 m-20 -109.72 114.61 28.34 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 121.31 -0.869 . . . . 0.0 109.863 173.638 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.31 112.18 24.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.16 -0.963 . . . . 0.0 110.311 -176.449 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . 0.466 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.2 OUTLIER -112.83 132.74 22.16 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.173 -0.954 . . . . 0.0 109.005 175.393 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -49.67 -40.35 46.85 Favored 'Trans proline' 0 C--N 1.303 -1.852 0 O-C-N 123.91 1.479 . . . . 0.0 110.705 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.438 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 12.1 m-80 -70.35 -40.07 74.3 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.141 -0.974 . . . . 0.0 110.108 177.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.466 ' O ' ' HB2' ' B' ' 18' ' ' LYS . 96.0 m-85 -152.03 150.36 29.87 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.314 -0.867 . . . . 0.0 110.542 -174.848 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . 0.464 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 60.6 ttt180 -91.31 143.42 26.66 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.893 -1.129 . . . . 0.0 109.965 174.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.483 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 97.2 m -129.41 140.69 51.25 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.659 -0.651 . . . . 0.0 109.718 -174.591 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.572 ' CD2' HG12 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -132.52 137.5 47.19 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.069 -1.019 . . . . 0.0 111.094 -178.088 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.536 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 4.8 t -120.13 131.95 71.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.119 -0.988 . . . . 0.0 110.662 -178.379 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.583 HG11 ' CE1' ' B' ' 61' ' ' PHE . 19.0 m -112.24 175.64 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 121.751 -0.593 . . . . 0.0 110.171 178.067 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.578 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 7.9 tt0 -106.76 117.09 33.12 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 178.31 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.517 ' CD2' ' O ' ' B' ' 32' ' ' MET . 10.8 tp -80.42 126.67 78.22 Favored Pre-proline 0 C--N 1.295 -1.763 0 O-C-N 121.235 -0.916 . . . . 0.0 109.83 -173.554 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.474 ' HD2' ' HB2' ' B' ' 32' ' ' MET . 18.6 Cg_endo -63.67 173.65 4.38 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 O-C-N 123.946 1.498 . . . . 0.0 110.699 -179.427 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -59.97 -38.05 81.39 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 110.739 -176.265 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.567 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.16 -0.05 57.42 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.922 -1.112 . . . . 0.0 110.902 -175.72 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.567 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 94.6 mmm -110.35 -11.98 14.47 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.867 -1.146 . . . . 0.0 109.913 170.182 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.531 ' CD2' ' HB2' ' B' ' 57' ' ' ASN . 15.8 mt -63.0 -31.43 72.57 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.341 -0.849 . . . . 0.0 110.133 176.818 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -93.22 139.99 30.02 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.347 -0.846 . . . . 0.0 110.538 -176.277 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.06 -41.32 2.35 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 174.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 9.0 tt -76.09 149.25 37.47 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.973 -1.31 . . . . 0.0 111.034 -174.399 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . 0.465 ' HA ' HD11 ' B' ' 54' ' ' ILE . 15.8 pt-20 -151.52 169.3 22.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.52 -0.737 . . . . 0.0 109.645 177.194 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.539 ' CG2' HD13 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -61.34 151.66 31.52 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.026 -1.046 . . . . 0.0 109.969 179.059 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.79 -5.94 60.17 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 -178.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.461 ' HB1' ' O ' ' B' ' 37' ' ' GLU . . . -73.26 155.96 38.98 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.24 -1.153 . . . . 0.0 109.668 177.234 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 41' ' ' SER . . . . . 0.454 ' OG ' ' O ' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -99.52 106.05 18.02 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.86 -1.15 . . . . 0.0 109.87 176.252 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.587 HG11 ' CE1' ' B' ' 44' ' ' HIS . 2.2 t -93.3 130.01 42.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.311 -0.868 . . . . 0.0 109.071 174.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.458 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -93.31 120.02 33.11 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 119.274 -0.971 . . . . 0.0 109.225 172.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.587 ' CE1' HG11 ' B' ' 42' ' ' VAL . 0.4 OUTLIER -91.22 104.67 17.2 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.578 -0.849 . . . . 0.0 108.939 177.977 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.496 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.6 t-20 55.4 14.2 1.08 Allowed 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.378 -0.826 . . . . 0.0 110.864 -168.692 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 120.21 -4.92 12.34 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.622 -1.275 . . . . 0.0 110.916 171.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.528 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 25.0 t -90.68 110.31 21.49 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.365 -1.668 . . . . 0.0 109.478 176.547 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 19.1 p -74.32 128.02 34.48 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.074 -1.016 . . . . 0.0 110.803 -171.556 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.603 ' CD1' ' CD2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -143.36 159.98 41.38 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.41 -0.806 . . . . 0.0 109.709 174.78 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 50' ' ' THR . . . . . 0.434 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 3.6 m -102.07 151.66 21.89 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.803 -1.185 . . . . 0.0 111.019 -172.473 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.578 ' CG1' HG12 ' B' ' 59' ' ' VAL . 15.9 t -78.41 118.35 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.599 -0.688 . . . . 0.0 110.549 -177.39 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.527 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 43.9 p -72.26 -40.11 67.91 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.336 -0.853 . . . . 0.0 110.061 174.222 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.486 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -164.44 153.5 13.3 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.193 -0.942 . . . . 0.0 110.21 -176.956 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.539 HD13 ' CG2' ' B' ' 38' ' ' THR . 6.9 mt -109.48 129.97 63.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.149 -0.97 . . . . 0.0 110.016 176.118 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.476 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 4.5 m-80 -102.68 63.3 0.85 Allowed 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.598 -0.689 . . . . 0.0 109.732 179.433 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.29 -114.11 4.05 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 108.758 -1.737 . . . . 0.0 108.758 -174.162 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.531 ' HB2' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.36 -22.57 47.76 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.01 -1.288 . . . . 0.0 108.903 174.89 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.644 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 12.0 m80 -74.27 159.23 32.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.475 -0.766 . . . . 0.0 110.249 -177.638 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.578 HG12 ' CG1' ' B' ' 51' ' ' VAL . 54.3 t -141.48 122.56 12.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.756 173.104 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.536 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 1.4 t -88.34 135.13 33.61 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.464 -0.772 . . . . 0.0 109.655 175.418 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.608 ' N ' ' CD1' ' B' ' 61' ' ' PHE . 2.1 p90 -127.46 154.62 44.85 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.692 -0.803 . . . . 0.0 110.263 176.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.527 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 36.3 p-10 -88.89 152.29 21.83 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.035 -1.041 . . . . 0.0 111.275 -171.041 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.528 HD21 ' CD1' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -157.79 100.24 1.74 Allowed 'General case' 0 C--N 1.3 -1.562 0 C-N-CA 120.065 -0.654 . . . . 0.0 109.298 -174.186 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.488 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 60.8 ttm -60.14 139.84 57.28 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.066 -1.021 . . . . 0.0 109.737 -177.391 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.483 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 5.1 ttpm? -59.98 -43.28 95.23 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.131 -0.981 . . . . 0.0 110.399 -175.353 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.36 -40.01 77.74 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.914 -1.116 . . . . 0.0 109.883 178.044 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.488 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 94.4 m -60.01 -37.68 80.43 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.075 -1.015 . . . . 0.0 109.434 172.26 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.529 ' CD1' ' HA2' ' B' ' 74' ' ' GLY . 14.2 tp -60.01 -45.59 92.26 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.302 -0.874 . . . . 0.0 109.482 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 55.2 ttt85 -70.01 -40.03 75.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.465 -0.772 . . . . 0.0 110.732 176.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.457 HG23 HG23 ' B' ' 71' ' ' THR . 1.5 tt -67.2 -42.78 88.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.289 -0.882 . . . . 0.0 109.438 -175.802 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.47 HG23 ' O ' ' B' ' 67' ' ' THR . 40.2 p -83.84 -173.69 4.86 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 174.759 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.501 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 3.2 t30 -102.8 23.71 11.71 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.172 -1.048 . . . . 0.0 108.172 169.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.528 ' CD1' HD21 ' B' ' 63' ' ' LEU . 86.2 mt -68.6 -39.95 80.68 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.141 -0.975 . . . . 0.0 109.938 176.832 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.529 ' HA2' ' CD1' ' B' ' 68' ' ' LEU . . . -47.96 -22.28 2.02 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.646 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.3 p-10 -62.86 -18.69 63.27 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.092 -1.24 . . . . 0.0 110.434 -176.335 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.517 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.0 mt -60.02 143.26 52.31 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.269 -0.894 . . . . 0.0 110.496 -177.738 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.477 ' O ' HD22 ' B' ' 12' ' ' LEU . 23.3 mttm -145.99 146.71 31.1 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.681 -0.637 . . . . 0.0 109.351 177.02 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.552 ' CG2' HG13 ' B' ' 15' ' ' ILE . 22.1 t -68.05 148.69 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 120.865 -1.147 . . . . 0.0 110.303 -175.669 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 85.96 -10.94 63.83 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.86 -1.696 . . . . 0.0 108.86 -174.125 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.48 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 45.2 t0 -95.74 162.48 13.58 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.303 -1.116 . . . . 0.0 109.687 176.658 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.588 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.0 m95 -114.73 149.41 36.88 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.174 -0.954 . . . . 0.0 109.999 176.833 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.546 HG21 ' CD2' ' B' ' 44' ' ' HIS . 1.2 p -115.37 153.95 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.422 -0.799 . . . . 0.0 109.857 -179.574 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.536 ' CA ' HG11 ' B' ' 6' ' ' VAL . 2.5 m-20 -78.27 106.09 9.94 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.138 -0.976 . . . . 0.0 109.197 168.616 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.505 HG11 ' CE1' ' B' ' 44' ' ' HIS . 0.0 OUTLIER -108.36 140.04 28.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 120.726 -1.234 . . . . 0.0 111.014 -176.446 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . 0.416 ' HB2' HG21 ' B' ' 6' ' ' VAL . 86.5 tt0 -137.18 143.98 42.66 Favored 'General case' 0 N--CA 1.492 1.633 0 C-N-CA 120.282 -0.567 . . . . 0.0 110.205 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 66.5 ttp85 -79.36 130.03 35.04 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.219 -0.926 . . . . 0.0 110.946 -176.515 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.454 ' O ' ' OG ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.757 0 O-C-N 121.302 -0.874 . . . . 0.0 110.045 175.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.53 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.3 t . . . . . 0 N--CA 1.496 1.84 0 CA-C-O 121.781 0.801 . . . . 0.0 110.892 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 -69.43 -35.0 75.28 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.773 -0.579 . . . . 0.0 110.621 177.107 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.53 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -162.68 173.9 38.98 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 118.896 -1.621 . . . . 0.0 110.094 -174.114 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.464 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.5 p -114.69 174.76 5.8 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.154 -1.204 . . . . 0.0 110.836 -177.701 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.487 ' HB1' HG12 ' A' ' 82' ' ' VAL . . . -142.61 149.04 38.45 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.622 -0.674 . . . . 0.0 109.541 -177.718 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.0 tttt -103.95 118.62 37.1 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 120.95 -1.094 . . . . 0.0 110.2 178.134 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.515 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 12.2 tp -60.7 127.55 32.21 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 120.795 -1.191 . . . . 0.0 108.569 171.005 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.637 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.7 p -130.45 -31.17 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.874 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.229 -177.126 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -143.84 139.83 29.49 Favored 'General case' 0 C--N 1.296 -1.719 0 C-N-CA 119.079 -1.048 . . . . 0.0 111.272 -178.634 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.574 HG13 ' CG2' ' A' ' 78' ' ' VAL . 11.2 mt -110.02 130.81 62.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.034 -1.041 . . . . 0.0 110.198 171.201 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.484 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 81.6 m-20 -108.07 114.64 28.7 Favored 'General case' 0 C--N 1.294 -1.843 0 O-C-N 121.443 -0.786 . . . . 0.0 109.962 173.195 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.4 110.77 22.98 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.002 -1.061 . . . . 0.0 110.592 -176.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.468 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -110.29 128.12 25.89 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.133 -0.979 . . . . 0.0 108.917 174.09 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -50.61 -33.42 39.28 Favored 'Trans proline' 0 C--N 1.303 -1.851 0 O-C-N 123.767 1.404 . . . . 0.0 110.314 -179.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.474 ' C ' ' CD2' ' A' ' 21' ' ' PHE . 12.4 m-80 -72.27 -40.0 67.95 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.149 -0.97 . . . . 0.0 109.938 175.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.474 ' CD2' ' C ' ' A' ' 20' ' ' ASN . 91.0 m-85 -152.51 150.25 29.39 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.374 -0.829 . . . . 0.0 110.197 -178.4 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.463 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 57.5 ttt180 -88.31 139.95 29.97 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 120.734 -1.229 . . . . 0.0 109.7 173.074 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.484 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 95.0 m -124.97 131.73 53.38 Favored 'General case' 0 C--N 1.294 -1.847 0 O-C-N 121.597 -0.689 . . . . 0.0 109.901 -176.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.578 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -126.21 138.89 53.68 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.905 -1.122 . . . . 0.0 111.303 -179.7 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.524 HG22 ' CB ' ' A' ' 60' ' ' SER . 5.7 t -120.83 134.26 64.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.135 -0.978 . . . . 0.0 110.861 -176.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.55 HG13 ' CE1' ' A' ' 61' ' ' PHE . 35.9 m -114.79 172.17 4.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 O-C-N 121.804 -0.56 . . . . 0.0 110.09 178.243 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.478 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 9.2 tt0 -104.21 117.91 35.37 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.376 -0.827 . . . . 0.0 108.788 177.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.475 HD23 ' O ' ' A' ' 32' ' ' MET . 7.5 tp -85.83 127.93 60.48 Favored Pre-proline 0 C--N 1.297 -1.703 0 O-C-N 121.562 -0.711 . . . . 0.0 109.943 -171.128 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.468 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 20.6 Cg_endo -66.02 178.69 2.25 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.881 1.464 . . . . 0.0 110.743 -179.363 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.49 ' OD1' ' N ' ' A' ' 31' ' ' HIS . 33.9 p-10 -62.65 -40.1 95.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.349 -0.844 . . . . 0.0 110.999 -175.542 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.585 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.93 -0.0 57.33 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.837 -1.164 . . . . 0.0 110.823 -174.367 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.585 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.0 mmm -108.11 -16.98 14.15 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.87 -1.144 . . . . 0.0 109.638 170.772 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.548 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 24.7 mt -66.2 -25.77 67.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.363 -0.835 . . . . 0.0 109.721 174.736 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -92.26 131.33 37.56 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.474 -0.766 . . . . 0.0 110.56 -178.094 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.79 -41.75 2.71 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 176.601 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.467 HD13 HD23 ' A' ' 28' ' ' LEU . 5.1 tt -70.84 148.2 48.09 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.076 -1.249 . . . . 0.0 110.335 -177.226 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.47 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 19.9 pt-20 -156.75 166.36 33.61 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.322 -0.862 . . . . 0.0 109.599 -177.66 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.536 ' CG2' ' HA ' ' A' ' 53' ' ' GLU . 0.1 OUTLIER -65.57 148.5 51.63 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.886 -1.134 . . . . 0.0 110.051 -178.886 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.67 -3.47 68.76 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.234 -1.546 . . . . 0.0 109.234 -174.369 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.47 ' HB3' ' O ' ' A' ' 37' ' ' GLU . . . -78.22 160.03 28.19 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.263 -1.14 . . . . 0.0 109.445 176.108 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.471 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -101.64 114.31 28.24 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 118.799 -1.16 . . . . 0.0 110.097 177.107 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.577 HG13 ' CE1' ' A' ' 44' ' ' HIS . 1.7 t -99.11 128.75 50.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.278 -0.889 . . . . 0.0 108.94 173.277 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.473 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -94.99 119.48 33.58 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 119.156 -1.017 . . . . 0.0 109.074 172.295 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.577 ' CE1' HG13 ' A' ' 42' ' ' VAL . 0.6 OUTLIER -87.32 103.14 15.19 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.415 -0.803 . . . . 0.0 108.958 178.41 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.498 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 57.83 8.9 0.77 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.441 -0.787 . . . . 0.0 111.309 -170.312 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.482 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 124.11 2.26 8.51 Favored Glycine 0 N--CA 1.489 2.168 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.858 174.846 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.526 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 42.7 t -98.45 107.33 19.77 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.461 -1.611 . . . . 0.0 109.485 174.706 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 26.2 p -75.1 129.9 38.35 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.237 -0.914 . . . . 0.0 111.211 -170.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.637 ' CD1' ' CD2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -145.27 160.63 41.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.443 -0.786 . . . . 0.0 109.637 173.552 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 57.9 m -100.95 151.17 22.08 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.737 -1.227 . . . . 0.0 110.923 -171.719 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.545 ' CG1' HG12 ' A' ' 59' ' ' VAL . 38.6 t -78.48 116.85 22.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.655 -0.653 . . . . 0.0 110.487 -178.358 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 37.7 p -70.03 -40.01 75.42 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.205 -0.934 . . . . 0.0 109.893 174.092 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.536 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -163.47 153.39 15.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.298 -0.876 . . . . 0.0 110.194 -177.676 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.529 HD12 ' CG2' ' A' ' 38' ' ' THR . 5.9 mt -104.49 133.63 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.018 -1.051 . . . . 0.0 109.885 175.044 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.468 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 31.4 m-80 -107.72 66.94 0.67 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.507 -0.745 . . . . 0.0 109.823 179.154 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.27 -116.06 4.83 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.816 -1.714 . . . . 0.0 108.816 -174.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.548 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -79.21 -19.13 51.53 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.055 -1.262 . . . . 0.0 108.764 174.545 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.637 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 11.2 m170 -74.73 160.66 30.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.467 -0.77 . . . . 0.0 110.343 -178.236 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.545 HG12 ' CG1' ' A' ' 51' ' ' VAL . 62.9 t -141.25 123.21 14.27 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 O-C-N 121.229 -0.92 . . . . 0.0 110.433 171.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.524 ' CB ' HG22 ' A' ' 25' ' ' VAL . 13.3 m -91.32 130.53 37.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.573 -0.704 . . . . 0.0 109.535 178.283 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.637 ' CD2' ' CD1' ' A' ' 49' ' ' LEU . 4.0 p90 -124.69 153.66 42.0 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.096 -1.002 . . . . 0.0 110.333 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 27.2 p-10 -88.73 152.22 21.93 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.091 -1.006 . . . . 0.0 111.37 -170.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.53 HD21 ' CD1' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -155.73 114.33 3.46 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -176.128 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.501 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 7.1 ttp -71.64 140.0 49.52 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.803 -1.186 . . . . 0.0 109.685 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.483 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 37.5 ttpt -60.04 -46.03 90.86 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.075 -1.015 . . . . 0.0 110.532 -174.05 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -70.0 -40.05 75.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.659 -1.275 . . . . 0.0 110.003 178.522 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.501 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 33.4 m -61.88 -34.9 76.87 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.053 -1.029 . . . . 0.0 109.462 173.805 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.509 ' HG ' ' CA ' ' A' ' 74' ' ' GLY . 7.6 tp -59.96 -45.81 91.47 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.244 -0.91 . . . . 0.0 109.151 178.205 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 71.8 ttt-85 -66.46 -39.98 89.15 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.284 -0.885 . . . . 0.0 110.682 175.115 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.466 HG21 HG21 ' A' ' 71' ' ' THR . 1.3 tt -66.72 -44.24 89.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.173 -0.954 . . . . 0.0 109.584 -175.549 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.466 HG21 HG21 ' A' ' 70' ' ' ILE . 31.2 p -83.17 -175.13 5.68 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 120.199 -0.6 . . . . 0.0 109.437 175.5 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 3.7 t30 -99.48 23.59 9.21 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 171.216 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.53 ' CD1' HD21 ' A' ' 63' ' ' LEU . 90.9 mt -70.0 -39.96 75.55 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.12 -0.987 . . . . 0.0 110.117 176.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.509 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -53.75 -18.1 7.71 Favored Glycine 0 N--CA 1.486 1.987 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 -177.137 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.2 p-10 -69.99 -19.03 63.35 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.953 -1.322 . . . . 0.0 110.575 -175.567 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.518 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 87.9 mt -62.13 141.92 57.88 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.233 -0.917 . . . . 0.0 110.815 -176.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.487 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 43.5 mtmt -141.49 141.74 33.62 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 121.63 -0.669 . . . . 0.0 109.776 174.32 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.574 ' CG2' HG13 ' A' ' 15' ' ' ILE . 16.6 t -60.32 152.6 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 120.926 -1.109 . . . . 0.0 110.451 -174.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.43 -15.9 57.45 Favored Glycine 0 N--CA 1.482 1.722 0 N-CA-C 108.762 -1.735 . . . . 0.0 108.762 -176.348 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 37.8 t0 -95.76 166.8 11.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.312 -1.111 . . . . 0.0 109.664 175.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.3 m95 -116.82 160.49 20.74 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.083 -1.011 . . . . 0.0 110.171 178.014 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.487 HG12 ' HB1' ' A' ' 10' ' ' ALA . 1.1 p -125.55 155.21 34.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.339 -0.851 . . . . 0.0 110.034 -177.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.489 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 0.2 OUTLIER -79.97 105.04 10.96 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.964 -1.085 . . . . 0.0 109.059 168.229 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.464 ' CG2' ' C ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -105.56 138.01 32.68 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 O-C-N 120.546 -1.346 . . . . 0.0 111.118 -176.539 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -133.53 140.03 46.96 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 120.298 -0.561 . . . . 0.0 110.028 -178.023 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . 0.517 ' NH1' ' HB2' ' A' ' 86' ' ' ARG . 26.7 ttm105 -78.31 126.91 31.45 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.258 -0.901 . . . . 0.0 110.701 -176.053 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.471 ' O ' ' OG ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.392 -0.817 . . . . 0.0 110.076 176.289 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.524 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.3 t . . . . . 0 N--CA 1.495 1.793 0 CA-C-O 121.719 0.771 . . . . 0.0 110.984 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 90.8 mm-40 -69.51 -34.74 74.72 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.685 -0.635 . . . . 0.0 110.665 177.167 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.524 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -163.03 173.72 39.26 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.065 -1.541 . . . . 0.0 110.177 -174.111 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.468 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.4 p -114.68 174.63 5.87 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.156 -1.203 . . . . 0.0 110.841 -177.543 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.472 ' CB ' HG12 ' B' ' 82' ' ' VAL . . . -142.45 149.24 39.0 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.704 -0.622 . . . . 0.0 109.462 -177.802 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 29.9 tttt -103.97 118.68 37.24 Favored 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.051 -1.03 . . . . 0.0 110.154 178.065 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.516 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 12.1 tp -60.86 127.42 31.5 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 120.952 -1.092 . . . . 0.0 108.624 170.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.635 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.7 p -130.2 -31.53 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.836 0 O-C-N 121.265 -0.897 . . . . 0.0 110.267 -177.008 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -143.7 139.89 29.75 Favored 'General case' 0 C--N 1.295 -1.772 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.311 -178.649 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.576 HG13 ' CG2' ' B' ' 78' ' ' VAL . 11.2 mt -109.92 130.84 62.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.048 -1.032 . . . . 0.0 110.149 171.259 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.495 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 81.2 m-20 -108.2 114.79 28.95 Favored 'General case' 0 C--N 1.296 -1.722 0 O-C-N 121.42 -0.8 . . . . 0.0 109.912 173.127 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.38 110.79 23.01 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.119 -0.988 . . . . 0.0 110.503 -176.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . 0.465 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -110.34 128.1 25.91 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.158 -0.964 . . . . 0.0 109.016 173.971 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -50.8 -33.27 40.2 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 O-C-N 123.758 1.399 . . . . 0.0 110.253 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.471 ' C ' ' CD2' ' B' ' 21' ' ' PHE . 12.3 m-80 -72.32 -40.17 67.66 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.203 -0.935 . . . . 0.0 109.902 175.713 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.471 ' CD2' ' C ' ' B' ' 20' ' ' ASN . 91.1 m-85 -152.33 150.23 29.5 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.393 -0.817 . . . . 0.0 110.233 -178.423 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . 0.476 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 57.5 ttt180 -88.13 139.89 30.05 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.777 -1.202 . . . . 0.0 109.706 173.063 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.495 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 95.6 m -124.96 131.75 53.38 Favored 'General case' 0 C--N 1.295 -1.781 0 O-C-N 121.676 -0.64 . . . . 0.0 109.908 -176.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.571 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -126.18 138.97 53.7 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.011 -1.056 . . . . 0.0 111.241 -179.635 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.521 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 5.7 t -120.78 134.44 64.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.224 -0.923 . . . . 0.0 110.834 -176.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.474 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 35.8 m -115.04 172.08 4.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.773 -0.579 . . . . 0.0 110.021 178.28 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.482 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 9.2 tt0 -104.1 118.05 35.73 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 177.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.503 ' CD2' HD13 ' B' ' 36' ' ' LEU . 7.5 tp -85.84 127.8 60.96 Favored Pre-proline 0 C--N 1.296 -1.735 0 O-C-N 121.338 -0.851 . . . . 0.0 110.0 -171.209 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.46 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 20.9 Cg_endo -65.95 178.63 2.25 Favored 'Trans proline' 0 C--N 1.308 -1.604 0 O-C-N 123.828 1.436 . . . . 0.0 110.799 -179.365 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' B' ' 31' ' ' HIS . 33.8 p-10 -62.74 -39.94 95.68 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.322 -0.861 . . . . 0.0 110.984 -175.47 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.571 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.0 0.0 57.34 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.851 -1.156 . . . . 0.0 110.797 -174.363 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.571 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.0 mmm -108.16 -16.87 14.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.84 -1.162 . . . . 0.0 109.62 170.833 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.533 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 24.6 mt -66.36 -25.69 66.92 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.369 -0.832 . . . . 0.0 109.714 174.739 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -92.28 131.31 37.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.48 -0.762 . . . . 0.0 110.525 -178.129 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.76 -41.64 2.72 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 176.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . 0.503 HD13 ' CD2' ' B' ' 28' ' ' LEU . 5.1 tt -70.81 148.26 48.05 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.033 -1.275 . . . . 0.0 110.267 -177.222 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . 0.474 ' N ' HD23 ' B' ' 36' ' ' LEU . 19.9 pt-20 -156.8 166.39 33.51 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.366 -0.834 . . . . 0.0 109.576 -177.702 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.537 ' CG2' HD12 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -65.65 148.46 51.72 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.927 -1.108 . . . . 0.0 110.064 -178.886 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.59 -3.33 68.94 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.319 -1.512 . . . . 0.0 109.319 -174.272 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.466 ' CB ' ' O ' ' B' ' 37' ' ' GLU . . . -78.41 159.99 28.01 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.286 -1.126 . . . . 0.0 109.33 176.021 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 41' ' ' SER . . . . . 0.465 ' OG ' ' O ' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -101.56 114.18 27.97 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 120.86 -1.15 . . . . 0.0 110.116 177.177 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.583 HG13 ' CE1' ' B' ' 44' ' ' HIS . 1.7 t -99.24 128.77 50.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.319 -0.863 . . . . 0.0 108.923 173.329 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.472 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -94.86 119.47 33.47 Favored 'General case' 0 C--N 1.297 -1.707 0 O-C-N 121.083 -1.011 . . . . 0.0 109.135 172.294 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.583 ' CE1' HG13 ' B' ' 42' ' ' VAL . 0.6 OUTLIER -87.42 102.99 15.08 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.376 -0.828 . . . . 0.0 108.975 178.403 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.498 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 58.12 8.9 0.85 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.49 -0.756 . . . . 0.0 111.25 -170.459 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.482 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 123.87 2.73 8.57 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.789 -1.196 . . . . 0.0 110.802 174.709 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.524 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 42.7 t -98.62 107.26 19.66 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 120.378 -1.66 . . . . 0.0 109.44 174.535 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 26.2 p -74.97 130.04 38.68 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.114 -0.991 . . . . 0.0 111.142 -171.026 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.645 ' CD1' ' CD2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -145.43 160.41 41.62 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.484 -0.76 . . . . 0.0 109.717 173.462 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 57.7 m -100.7 151.35 21.76 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.781 -1.199 . . . . 0.0 110.982 -171.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.496 ' CG1' HG11 ' B' ' 59' ' ' VAL . 38.2 t -78.67 116.92 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.644 -0.66 . . . . 0.0 110.472 -178.358 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.517 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 38.8 p -70.07 -40.06 75.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.201 -0.937 . . . . 0.0 109.884 174.224 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.529 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -163.36 153.44 15.6 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.341 -0.849 . . . . 0.0 110.226 -177.683 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.537 HD12 ' CG2' ' B' ' 38' ' ' THR . 5.9 mt -104.52 133.65 48.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.151 -0.968 . . . . 0.0 109.937 174.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.48 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 31.3 m-80 -107.82 66.99 0.67 Allowed 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.572 -0.705 . . . . 0.0 109.762 179.194 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.41 -116.08 4.81 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 108.743 -1.743 . . . . 0.0 108.743 -174.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.533 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -79.18 -19.22 51.42 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 120.974 -1.309 . . . . 0.0 108.832 174.478 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.635 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 11.1 m170 -74.65 160.53 30.69 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.443 -0.785 . . . . 0.0 110.361 -178.301 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.496 HG11 ' CG1' ' B' ' 51' ' ' VAL . 62.9 t -141.06 123.22 14.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 O-C-N 121.208 -0.932 . . . . 0.0 110.453 171.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.521 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 13.4 m -91.43 130.87 37.21 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.632 -0.667 . . . . 0.0 109.553 178.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.645 ' CD2' ' CD1' ' B' ' 49' ' ' LEU . 3.9 p90 -124.96 153.43 42.76 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.188 -0.945 . . . . 0.0 110.255 -179.721 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.517 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 27.4 p-10 -88.58 152.21 21.99 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.976 -1.077 . . . . 0.0 111.466 -170.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.519 HD22 ' CD1' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -155.71 114.4 3.48 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 -176.154 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.495 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 7.1 ttp -71.62 139.97 49.54 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.867 -1.146 . . . . 0.0 109.799 -178.076 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.485 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 37.5 ttpt -60.06 -45.98 91.06 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.128 -0.982 . . . . 0.0 110.477 -173.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -70.06 -39.98 75.36 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.806 -1.184 . . . . 0.0 110.023 178.591 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.495 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 34.4 m -61.94 -34.98 77.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.035 -1.041 . . . . 0.0 109.342 173.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.503 ' CD1' ' HA2' ' B' ' 74' ' ' GLY . 7.6 tp -60.05 -45.47 92.74 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.312 -0.867 . . . . 0.0 109.243 178.26 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 71.8 ttt-85 -66.7 -39.96 88.27 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.356 -0.84 . . . . 0.0 110.652 175.051 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.469 HG21 HG21 ' B' ' 71' ' ' THR . 1.3 tt -66.71 -44.23 89.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.144 -0.973 . . . . 0.0 109.595 -175.602 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.469 HG21 ' O ' ' B' ' 67' ' ' THR . 31.2 p -83.05 -175.02 5.63 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 120.114 -0.634 . . . . 0.0 109.477 175.518 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.489 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 3.7 t30 -99.56 23.68 9.16 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 171.125 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.519 ' CD1' HD22 ' B' ' 63' ' ' LEU . 90.7 mt -70.05 -39.96 75.4 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.123 -0.985 . . . . 0.0 110.089 176.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.503 ' HA2' ' CD1' ' B' ' 68' ' ' LEU . . . -53.79 -18.0 7.7 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 -177.11 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.4 p-10 -70.06 -18.99 63.3 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.039 -1.271 . . . . 0.0 110.578 -175.556 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.511 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 88.1 mt -62.14 141.89 57.91 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.231 -0.918 . . . . 0.0 110.828 -177.025 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.49 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 43.4 mtmt -141.52 141.72 33.58 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.666 -0.646 . . . . 0.0 109.787 174.321 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.576 ' CG2' HG13 ' B' ' 15' ' ' ILE . 16.7 t -60.31 152.51 5.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.957 -1.09 . . . . 0.0 110.43 -174.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.38 -15.59 58.16 Favored Glycine 0 N--CA 1.484 1.846 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -176.415 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 38.0 t0 -95.97 166.68 11.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.422 -1.046 . . . . 0.0 109.655 175.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.4 m95 -116.76 160.53 20.66 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.15 -0.968 . . . . 0.0 110.176 178.076 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.506 HG23 ' CG ' ' B' ' 44' ' ' HIS . 1.1 p -125.56 155.35 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.407 -0.808 . . . . 0.0 109.979 -178.056 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.475 ' OD1' ' N ' ' A' ' 72' ' ' ASN . 0.2 OUTLIER -80.01 104.89 10.89 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.093 -1.004 . . . . 0.0 109.003 168.296 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.468 ' CG2' ' C ' ' B' ' 9' ' ' THR . 0.0 OUTLIER -105.54 138.18 31.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 120.559 -1.338 . . . . 0.0 111.075 -176.491 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -133.71 140.08 46.79 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 120.335 -0.546 . . . . 0.0 110.05 -178.103 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . 0.516 ' NH1' ' HB2' ' B' ' 86' ' ' ARG . 26.8 ttm105 -78.34 126.92 31.46 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.213 -0.929 . . . . 0.0 110.642 -176.014 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.465 ' O ' ' OG ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.766 0 O-C-N 121.334 -0.854 . . . . 0.0 110.015 176.286 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.528 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 1.7 t . . . . . 0 N--CA 1.493 1.707 0 CA-C-O 121.726 0.774 . . . . 0.0 110.784 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 79.2 mm-40 -69.97 -34.84 73.91 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.64 -0.663 . . . . 0.0 110.843 178.275 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.528 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -158.28 179.19 34.15 Favored Glycine 0 N--CA 1.494 2.527 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.235 -173.167 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.47 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 1.0 OUTLIER -118.54 170.0 9.32 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.117 -1.226 . . . . 0.0 110.956 -177.962 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.582 ' CB ' ' CG1' ' A' ' 82' ' ' VAL . . . -136.55 149.7 48.23 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.667 -0.646 . . . . 0.0 109.448 -179.237 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.587 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 39.6 tttt -110.57 117.87 34.69 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.024 -1.048 . . . . 0.0 110.455 -179.44 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.504 ' CG ' ' HA ' ' A' ' 78' ' ' VAL . 10.9 tp -60.04 126.26 26.83 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.882 -1.136 . . . . 0.0 108.979 172.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.591 HG12 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -125.76 -31.67 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 O-C-N 121.471 -0.768 . . . . 0.0 109.545 179.252 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.09 143.12 30.24 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.453 -0.899 . . . . 0.0 111.103 -179.648 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.58 HG12 ' CD2' ' A' ' 24' ' ' HIS . 18.0 mt -106.71 134.98 46.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.038 -1.039 . . . . 0.0 110.0 171.027 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.502 ' CB ' ' HB ' ' A' ' 23' ' ' THR . 56.0 m-20 -107.53 115.81 30.83 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.274 -0.891 . . . . 0.0 109.851 174.067 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -107.06 111.88 24.55 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.057 -1.027 . . . . 0.0 110.467 -176.448 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 8.2 mtmm -109.09 131.28 21.9 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.217 -0.927 . . . . 0.0 109.262 175.686 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -51.13 -22.88 11.69 Favored 'Trans proline' 0 C--N 1.304 -1.78 0 O-C-N 123.954 1.502 . . . . 0.0 111.052 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.582 ' O ' ' CD1' ' A' ' 21' ' ' PHE . 7.4 m-80 -92.78 -33.61 14.21 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.085 -1.009 . . . . 0.0 109.983 177.833 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.582 ' CD1' ' O ' ' A' ' 20' ' ' ASN . 36.3 m-85 -148.2 150.17 33.27 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.488 -0.758 . . . . 0.0 110.026 -177.516 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.468 ' NH1' HD23 ' A' ' 68' ' ' LEU . 60.4 ttt180 -95.76 143.5 26.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.668 -1.27 . . . . 0.0 109.964 173.739 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.502 ' HB ' ' CB ' ' A' ' 16' ' ' ASP . 56.3 m -132.61 145.65 51.27 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.494 -0.754 . . . . 0.0 109.955 -176.095 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.58 ' CD2' HG12 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -134.2 134.06 41.64 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.943 -1.098 . . . . 0.0 111.327 -179.666 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.517 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 5.3 t -113.62 132.75 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.071 -1.018 . . . . 0.0 110.856 -177.32 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.461 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 12.9 m -118.79 170.93 7.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 CA-C-O 121.317 0.579 . . . . 0.0 110.331 -179.17 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.436 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 15.3 tt0 -100.08 116.65 32.6 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 177.789 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.559 ' CD1' ' CB ' ' A' ' 32' ' ' MET . 0.0 OUTLIER -86.15 118.5 70.51 Favored Pre-proline 0 C--N 1.295 -1.798 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -175.36 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.498 ' HD2' ' CD1' ' A' ' 28' ' ' LEU . 19.6 Cg_endo -63.25 170.78 7.34 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 O-C-N 123.801 1.422 . . . . 0.0 110.976 -178.527 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.504 ' OD1' ' N ' ' A' ' 31' ' ' HIS . 34.1 p-10 -61.26 -35.85 78.42 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.477 -0.765 . . . . 0.0 110.83 -175.713 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.578 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.69 -0.49 57.71 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.828 -1.17 . . . . 0.0 110.874 -173.486 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.578 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.9 mmm -116.69 -11.17 11.01 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.984 -1.072 . . . . 0.0 109.933 169.499 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.528 ' CD2' ' HB3' ' A' ' 28' ' ' LEU . 13.2 mt -65.67 -37.95 87.93 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.07 -1.019 . . . . 0.0 109.599 175.168 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -69.04 132.25 46.34 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.486 -0.759 . . . . 0.0 110.746 -177.402 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.12 -40.12 2.8 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 173.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.518 ' CD2' HD21 ' A' ' 28' ' ' LEU . 59.1 tp -69.2 145.44 53.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.03 -1.277 . . . . 0.0 110.688 -175.262 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.474 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 16.8 pt-20 -148.01 169.1 20.64 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.591 -0.693 . . . . 0.0 109.408 177.445 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.542 ' CG2' HD12 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -64.53 148.56 50.45 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.9 -1.125 . . . . 0.0 109.83 178.291 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.42 -4.66 62.85 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -176.45 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.474 ' HB2' ' O ' ' A' ' 37' ' ' GLU . . . -74.45 159.13 32.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.257 -1.143 . . . . 0.0 109.499 176.568 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.47 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -100.51 117.42 34.63 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 118.909 -1.116 . . . . 0.0 109.885 176.642 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.577 HG13 ' CE1' ' A' ' 44' ' ' HIS . 2.1 t -105.97 126.25 61.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.333 -0.855 . . . . 0.0 109.079 175.262 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.469 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -89.72 118.62 29.46 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.185 -1.006 . . . . 0.0 109.191 172.282 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.577 ' CE1' HG13 ' A' ' 42' ' ' VAL . 0.4 OUTLIER -88.8 100.99 13.58 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 177.054 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.491 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 59.59 8.79 1.35 Allowed 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.486 -0.759 . . . . 0.0 111.143 -168.514 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.468 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 128.76 -12.69 6.18 Favored Glycine 0 N--CA 1.489 2.197 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.8 174.167 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 43' ' ' ALA . 42.8 t -85.97 110.05 19.2 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.356 -1.673 . . . . 0.0 109.779 179.196 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 19.6 p -77.65 113.4 15.46 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.304 -0.872 . . . . 0.0 110.984 -172.376 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.459 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -130.33 161.18 31.86 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.436 -0.79 . . . . 0.0 109.119 172.628 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 57.2 m -103.93 155.08 18.93 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.492 -1.38 . . . . 0.0 111.356 -168.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.55 ' CG1' HG13 ' A' ' 59' ' ' VAL . 21.2 t -77.44 112.79 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.677 -0.64 . . . . 0.0 110.379 -179.51 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 17.6 p -69.95 -40.0 75.72 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.211 -0.931 . . . . 0.0 109.493 172.193 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.45 ' HA ' HG23 ' A' ' 38' ' ' THR . 86.0 tt0 -158.46 153.9 25.96 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 119.322 -0.951 . . . . 0.0 110.845 -177.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.542 HD12 ' CG2' ' A' ' 38' ' ' THR . 13.6 mt -110.37 130.06 64.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.181 -0.95 . . . . 0.0 109.887 172.713 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.452 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 9.7 m-80 -103.73 63.67 0.78 Allowed 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.542 -0.724 . . . . 0.0 109.723 178.899 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.69 -112.51 3.55 Favored Glycine 0 N--CA 1.487 2.07 0 N-CA-C 108.691 -1.764 . . . . 0.0 108.691 -173.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.49 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.1 -22.49 42.14 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.988 -1.301 . . . . 0.0 108.846 174.201 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.591 ' CD2' HG12 ' A' ' 13' ' ' VAL . 8.9 m170 -74.58 158.69 33.27 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.123 -0.985 . . . . 0.0 110.218 -176.211 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.582 ' CG1' ' CZ ' ' A' ' 61' ' ' PHE . 80.2 t -141.31 119.68 9.72 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 C-N-CA 119.312 -0.955 . . . . 0.0 110.923 175.693 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.517 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 15.9 m -88.65 126.21 35.19 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.627 -0.671 . . . . 0.0 109.739 178.672 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.582 ' CZ ' ' CG1' ' A' ' 59' ' ' VAL . 98.0 m-85 -109.9 156.53 20.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.788 -1.195 . . . . 0.0 110.396 179.52 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 19.8 p-10 -89.8 148.22 23.34 Favored 'General case' 0 N--CA 1.494 1.738 0 CA-C-O 122.045 0.926 . . . . 0.0 110.878 178.856 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.516 HD21 ' CD1' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -155.53 116.6 3.91 Favored 'General case' 0 C--N 1.296 -1.759 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -176.483 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.51 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 93.2 mmm -69.97 141.72 52.96 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 119.109 -1.037 . . . . 0.0 109.518 179.738 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.414 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 46.8 tttp -60.0 -45.15 93.69 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.103 -0.998 . . . . 0.0 110.195 -176.849 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.432 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.4 tt0 -69.44 -40.04 77.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.984 -1.072 . . . . 0.0 110.283 177.642 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.51 ' HB ' ' HB2' ' A' ' 64' ' ' MET . 89.8 m -61.69 -39.38 91.24 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.927 -1.108 . . . . 0.0 109.278 174.091 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.489 ' HG ' ' CA ' ' A' ' 74' ' ' GLY . 7.7 tp -60.09 -43.57 95.42 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.325 -0.86 . . . . 0.0 109.364 178.022 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 92.6 mtt180 -69.86 -39.97 76.05 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.545 -0.722 . . . . 0.0 110.692 176.03 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.473 HG22 HG22 ' A' ' 71' ' ' THR . 1.3 tt -69.94 -41.61 79.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.246 -0.909 . . . . 0.0 109.404 -176.078 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.473 HG22 HG22 ' A' ' 70' ' ' ILE . 65.3 p -83.59 -173.94 5.0 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 178.072 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 3.0 t30 -100.73 22.62 11.68 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 170.883 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.516 ' CD1' HD21 ' A' ' 63' ' ' LEU . 96.6 mt -69.91 -40.2 75.75 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.013 -1.054 . . . . 0.0 110.053 174.653 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.489 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -52.99 -24.27 19.48 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 -176.095 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 25.9 p-10 -64.98 -19.67 66.1 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.043 -1.269 . . . . 0.0 110.634 -174.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.52 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 95.8 mt -60.01 140.25 56.9 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.216 -0.928 . . . . 0.0 110.923 -177.056 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.467 ' O ' HD23 ' A' ' 12' ' ' LEU . 75.9 mttt -140.92 144.1 35.0 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 173.606 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.548 ' CG2' HG13 ' A' ' 15' ' ' ILE . 12.0 t -59.32 152.0 4.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 120.731 -1.231 . . . . 0.0 110.304 -173.538 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.15 -15.81 57.27 Favored Glycine 0 N--CA 1.484 1.847 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 -177.37 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 52.7 t0 -93.41 164.58 13.15 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.284 -1.127 . . . . 0.0 109.684 176.104 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.587 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.3 m95 -115.4 168.15 10.24 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.062 -1.023 . . . . 0.0 110.253 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.582 ' CG1' ' CB ' ' A' ' 10' ' ' ALA . 1.5 p -131.97 155.56 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.518 -0.739 . . . . 0.0 110.039 -178.878 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.53 ' N ' ' CB ' ' B' ' 72' ' ' ASN . 2.6 m-20 -80.57 109.86 15.49 Favored 'General case' 0 C--N 1.296 -1.75 0 O-C-N 121.007 -1.058 . . . . 0.0 109.12 167.725 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.47 ' CG2' ' C ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -109.76 138.62 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.577 -1.327 . . . . 0.0 111.232 -175.301 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -137.02 138.53 40.57 Favored 'General case' 0 N--CA 1.494 1.741 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.801 -178.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . 0.446 ' HG3' ' HE1' ' A' ' 32' ' ' MET . 83.9 mtm180 -78.41 142.33 37.67 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.958 -1.089 . . . . 0.0 110.951 -176.14 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.47 ' O ' ' OG ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.492 1.663 0 O-C-N 121.387 -0.82 . . . . 0.0 110.133 176.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.53 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 1.7 t . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.658 0.742 . . . . 0.0 110.78 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 79.3 mm-40 -70.05 -34.63 73.46 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.79 -0.569 . . . . 0.0 110.842 178.284 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.53 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -158.56 179.01 34.53 Favored Glycine 0 N--CA 1.494 2.553 0 C-N-CA 119.048 -1.548 . . . . 0.0 110.227 -173.101 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.469 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 1.0 OUTLIER -118.45 170.03 9.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.094 -1.239 . . . . 0.0 110.976 -177.851 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.575 ' CB ' ' CG1' ' B' ' 82' ' ' VAL . . . -136.55 149.85 48.31 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.671 -0.643 . . . . 0.0 109.381 -179.329 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.588 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 39.8 tttt -110.65 117.98 34.96 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.048 -1.033 . . . . 0.0 110.39 -179.439 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.509 ' CG ' ' HA ' ' B' ' 78' ' ' VAL . 10.9 tp -60.33 126.13 26.32 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.037 -1.039 . . . . 0.0 109.085 172.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.594 HG12 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -125.65 -31.54 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 O-C-N 121.442 -0.786 . . . . 0.0 109.684 179.488 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.23 143.15 30.11 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 119.516 -0.874 . . . . 0.0 111.092 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.571 HG12 ' CD2' ' B' ' 24' ' ' HIS . 17.8 mt -106.67 134.88 47.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.005 -1.06 . . . . 0.0 110.03 171.046 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.499 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 55.7 m-20 -107.54 115.88 30.94 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.28 -0.888 . . . . 0.0 109.898 174.079 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -107.05 111.78 24.41 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.035 -1.04 . . . . 0.0 110.428 -176.342 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . 0.465 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 8.2 mtmm -109.02 131.27 21.9 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.259 -0.901 . . . . 0.0 109.288 175.623 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -51.11 -23.02 11.86 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 O-C-N 123.868 1.457 . . . . 0.0 111.061 -179.209 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.571 ' O ' ' CD1' ' B' ' 21' ' ' PHE . 7.4 m-80 -92.46 -34.22 14.2 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.065 -1.022 . . . . 0.0 109.879 177.827 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.571 ' CD1' ' O ' ' B' ' 20' ' ' ASN . 36.3 m-85 -147.7 150.23 33.93 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.431 -0.793 . . . . 0.0 110.026 -177.36 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . 0.489 ' NH1' HD21 ' B' ' 68' ' ' LEU . 60.3 ttt180 -95.74 143.53 26.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.756 -1.215 . . . . 0.0 110.058 173.559 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.499 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 55.9 m -132.59 145.61 51.24 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.503 -0.748 . . . . 0.0 110.029 -176.135 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.571 ' CD2' HG12 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -134.04 134.09 41.98 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.085 -1.009 . . . . 0.0 111.197 -179.517 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.53 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 5.4 t -113.68 133.0 61.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.207 -0.933 . . . . 0.0 110.778 -177.41 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 13.2 m -119.05 170.94 7.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-O 121.232 0.539 . . . . 0.0 110.268 -179.067 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.451 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 15.3 tt0 -100.03 116.71 32.71 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 177.714 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.567 ' CD1' ' CB ' ' B' ' 32' ' ' MET . 0.0 OUTLIER -86.11 118.35 70.28 Favored Pre-proline 0 C--N 1.295 -1.804 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 -175.422 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.49 ' HD2' ' CD1' ' B' ' 28' ' ' LEU . 19.5 Cg_endo -63.13 170.75 7.22 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 O-C-N 123.802 1.422 . . . . 0.0 110.96 -178.525 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.499 ' OD1' ' N ' ' B' ' 31' ' ' HIS . 34.1 p-10 -61.28 -35.74 78.15 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.47 -0.769 . . . . 0.0 110.873 -175.741 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.572 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.74 -0.48 57.72 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.783 -1.198 . . . . 0.0 110.839 -173.487 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.572 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.9 mmm -116.64 -11.22 11.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.857 -1.152 . . . . 0.0 109.984 169.509 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.538 ' CD2' ' HB3' ' B' ' 28' ' ' LEU . 13.2 mt -65.68 -38.02 88.1 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.013 -1.054 . . . . 0.0 109.626 175.165 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -68.99 132.27 46.39 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.549 -0.719 . . . . 0.0 110.792 -177.404 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.1 -40.16 2.8 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 110.346 -1.102 . . . . 0.0 110.346 174.061 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . 0.459 ' CD2' HD21 ' B' ' 28' ' ' LEU . 59.0 tp -69.13 145.49 53.3 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.045 -1.268 . . . . 0.0 110.726 -175.302 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . 0.468 ' O ' ' HB2' ' B' ' 40' ' ' ALA . 16.8 pt-20 -147.98 169.1 20.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.506 -0.746 . . . . 0.0 109.423 177.473 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.534 ' CG2' HD12 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -64.66 148.48 50.89 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.939 -1.101 . . . . 0.0 109.859 178.298 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.57 -4.67 63.44 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -176.464 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.468 ' HB2' ' O ' ' B' ' 37' ' ' GLU . . . -74.49 158.98 32.86 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.121 -1.223 . . . . 0.0 109.492 176.474 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 41' ' ' SER . . . . . 0.477 ' CB ' ' HB2' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -100.37 117.21 34.09 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 120.94 -1.1 . . . . 0.0 110.029 176.584 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.57 HG13 ' CE1' ' B' ' 44' ' ' HIS . 2.1 t -105.96 126.28 61.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.383 -0.823 . . . . 0.0 109.105 175.316 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.474 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -89.7 118.64 29.46 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 119.133 -1.027 . . . . 0.0 109.114 172.351 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.57 ' CE1' HG13 ' B' ' 42' ' ' VAL . 0.4 OUTLIER -88.77 100.72 13.36 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 176.994 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.536 ' N ' ' O ' ' B' ' 83' ' ' ASN . 1.9 t-20 59.88 8.79 1.49 Allowed 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.53 -0.731 . . . . 0.0 110.987 -168.642 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.468 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 128.68 -12.65 6.21 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.583 -1.294 . . . . 0.0 110.818 174.151 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.474 ' O ' ' HA ' ' B' ' 43' ' ' ALA . 41.7 t -85.97 109.94 19.12 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.259 -1.73 . . . . 0.0 109.757 179.151 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 19.4 p -77.54 113.44 15.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.227 -0.92 . . . . 0.0 110.969 -172.465 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.468 ' CD2' ' O ' ' B' ' 47' ' ' CYS . 0.2 OUTLIER -130.46 161.1 32.17 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.355 -0.841 . . . . 0.0 109.129 172.521 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 50' ' ' THR . . . . . 0.483 HG22 ' N ' ' B' ' 51' ' ' VAL . 57.5 m -103.76 155.2 18.78 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.545 -1.347 . . . . 0.0 111.277 -168.841 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.552 ' CG1' HG12 ' B' ' 59' ' ' VAL . 21.2 t -77.62 112.79 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.606 -0.683 . . . . 0.0 110.415 -179.525 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.538 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 17.7 p -69.93 -40.05 75.77 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.16 -0.963 . . . . 0.0 109.512 172.339 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.468 ' HA ' HG22 ' B' ' 38' ' ' THR . 86.0 tt0 -158.5 153.74 25.61 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.757 -177.753 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.534 HD12 ' CG2' ' B' ' 38' ' ' THR . 13.7 mt -110.23 130.03 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.205 -0.934 . . . . 0.0 109.908 172.738 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.466 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 9.6 m-80 -103.73 63.64 0.78 Allowed 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.943 -0.703 . . . . 0.0 109.692 178.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.77 -112.5 3.55 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 108.638 -1.785 . . . . 0.0 108.638 -173.625 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.487 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.07 -22.64 42.04 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.865 -1.373 . . . . 0.0 108.873 174.206 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.594 ' CD2' HG12 ' B' ' 13' ' ' VAL . 9.0 m170 -74.42 158.53 33.72 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.175 -0.953 . . . . 0.0 110.263 -176.278 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.587 ' CG1' ' CZ ' ' B' ' 61' ' ' PHE . 79.9 t -141.26 119.72 9.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 C-N-CA 119.158 -1.017 . . . . 0.0 110.817 175.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.53 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 15.9 m -88.69 126.4 35.29 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.617 -0.677 . . . . 0.0 109.73 178.679 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.587 ' CZ ' ' CG1' ' B' ' 59' ' ' VAL . 98.0 m-85 -110.08 156.49 20.49 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.867 -1.146 . . . . 0.0 110.374 179.554 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.538 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 19.8 p-10 -89.72 148.2 23.41 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.209 -0.932 . . . . 0.0 110.9 178.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.528 HD22 ' CD1' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -155.51 116.72 3.94 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -176.585 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.497 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 93.1 mmm -70.04 141.67 52.84 Favored 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 119.119 -1.032 . . . . 0.0 109.552 179.683 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.409 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 46.8 tttp -60.06 -45.08 94.05 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.172 -0.955 . . . . 0.0 110.119 -176.7 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . 0.441 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 86.5 tt0 -69.38 -40.0 77.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.102 -0.999 . . . . 0.0 110.333 177.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.497 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 89.2 m -61.73 -39.6 92.13 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.959 -1.088 . . . . 0.0 109.16 174.148 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.497 ' HG ' ' CA ' ' B' ' 74' ' ' GLY . 7.7 tp -59.98 -43.41 95.15 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.562 -0.711 . . . . 0.0 109.47 178.077 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 92.7 mtt180 -69.96 -39.98 75.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.449 -0.782 . . . . 0.0 110.67 175.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.467 HG22 HG22 ' B' ' 71' ' ' THR . 1.3 tt -70.06 -41.35 79.17 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.278 -0.889 . . . . 0.0 109.52 -176.131 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.469 HG22 ' O ' ' B' ' 67' ' ' THR . 65.5 p -83.56 -173.81 4.93 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 177.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.53 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 3.1 t30 -100.78 22.66 11.68 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 170.827 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.528 ' CD1' HD22 ' B' ' 63' ' ' LEU . 96.9 mt -69.96 -40.09 75.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.116 -0.99 . . . . 0.0 110.071 174.665 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.497 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -53.01 -24.34 19.93 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 110.409 -1.077 . . . . 0.0 110.409 -176.127 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.1 p-10 -64.97 -19.65 66.09 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.116 -1.226 . . . . 0.0 110.632 -174.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.521 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 95.8 mt -60.02 140.19 56.95 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.187 -0.946 . . . . 0.0 110.901 -177.065 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.463 ' O ' HD23 ' B' ' 12' ' ' LEU . 76.0 mttt -140.92 144.1 34.99 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 173.607 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.554 ' CG2' HG13 ' B' ' 15' ' ' ILE . 12.1 t -59.34 151.95 4.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 120.76 -1.213 . . . . 0.0 110.335 -173.519 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.18 -15.72 57.54 Favored Glycine 0 N--CA 1.484 1.847 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 -177.396 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 52.6 t0 -93.47 164.4 13.21 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.432 -1.04 . . . . 0.0 109.675 176.043 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.588 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.2 m95 -115.28 168.16 10.21 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.132 -0.98 . . . . 0.0 110.373 178.312 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.575 ' CG1' ' CB ' ' B' ' 10' ' ' ALA . 1.5 p -132.04 155.55 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.547 -0.721 . . . . 0.0 109.965 -178.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.536 ' O ' ' N ' ' B' ' 45' ' ' ASN . 2.5 m-20 -80.4 109.67 15.12 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.009 -1.057 . . . . 0.0 109.174 167.729 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.469 ' CG2' ' C ' ' B' ' 9' ' ' THR . 0.0 OUTLIER -109.45 138.95 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 120.66 -1.275 . . . . 0.0 111.138 -175.233 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -137.48 138.51 39.8 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.894 -0.504 . . . . 0.0 109.724 -179.056 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 83.9 mtm180 -78.35 142.44 37.68 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.042 -1.036 . . . . 0.0 110.917 -176.062 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.477 ' HB2' ' CB ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.493 1.685 0 O-C-N 121.359 -0.838 . . . . 0.0 110.103 176.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.538 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.4 t . . . . . 0 N--CA 1.494 1.736 0 CA-C-O 121.508 0.671 . . . . 0.0 110.611 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.436 ' OE1' ' HG2' ' A' ' 86' ' ' ARG . 18.2 pt20 -93.34 -23.81 18.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.55 -0.719 . . . . 0.0 110.787 179.266 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.538 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -150.52 173.99 29.98 Favored Glycine 0 N--CA 1.493 2.487 0 C-N-CA 119.328 -1.415 . . . . 0.0 109.758 -175.485 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.478 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 2.2 p -123.37 170.83 9.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.845 -1.386 . . . . 0.0 110.981 -177.436 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.52 ' CB ' HG13 ' A' ' 82' ' ' VAL . . . -139.33 149.46 44.22 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.562 -0.711 . . . . 0.0 109.259 -179.649 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.578 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 33.3 tttt -106.73 115.43 30.19 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 120.908 -1.12 . . . . 0.0 110.254 179.535 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.523 ' CG ' ' HA ' ' A' ' 78' ' ' VAL . 12.2 tp -58.55 127.19 30.91 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 120.82 -1.175 . . . . 0.0 108.688 173.329 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.613 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.6 p -130.05 -30.14 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.898 0 O-C-N 121.345 -0.847 . . . . 0.0 109.946 -177.844 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -145.1 140.44 28.04 Favored 'General case' 0 N--CA 1.494 1.735 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.974 -179.439 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.576 HG13 ' CG2' ' A' ' 78' ' ' VAL . 13.9 mt -107.53 131.11 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 120.991 -1.068 . . . . 0.0 110.185 172.339 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.486 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.7 m-20 -108.53 114.87 29.04 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.384 -0.823 . . . . 0.0 109.873 174.692 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -107.11 112.38 25.27 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.002 -1.061 . . . . 0.0 110.522 -176.129 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.472 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 6.1 mtmt -107.94 129.93 23.48 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.219 -0.926 . . . . 0.0 109.177 175.24 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_endo -51.85 -24.47 18.73 Favored 'Trans proline' 0 C--N 1.303 -1.864 0 O-C-N 123.779 1.41 . . . . 0.0 110.279 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 10.7 m-80 -81.2 -39.74 24.95 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.24 -0.913 . . . . 0.0 110.182 175.417 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 95.1 m-85 -156.68 150.22 24.52 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.433 -0.792 . . . . 0.0 109.971 -178.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.48 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 59.6 ttt180 -91.93 145.13 24.79 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.807 -1.183 . . . . 0.0 110.327 178.771 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.486 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 74.9 m -129.98 140.02 50.97 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.583 -0.698 . . . . 0.0 109.718 -176.156 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.576 ' CD2' HG22 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -128.74 128.32 43.79 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.858 -1.152 . . . . 0.0 111.324 178.184 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.529 ' CG2' ' OG ' ' A' ' 60' ' ' SER . 4.3 t -104.95 131.42 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.283 -0.886 . . . . 0.0 110.695 -178.108 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.466 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 33.4 m -115.91 168.16 7.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 O-C-N 121.962 -0.461 . . . . 0.0 109.963 179.427 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.458 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 2.5 tm-20 -101.11 115.31 30.19 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.305 -0.872 . . . . 0.0 109.409 178.538 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.517 HD21 ' CD1' ' A' ' 36' ' ' LEU . 9.8 tp -79.15 125.33 83.74 Favored Pre-proline 0 C--N 1.295 -1.804 0 O-C-N 121.617 -0.677 . . . . 0.0 109.868 -176.543 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.467 ' HG3' ' O ' ' A' ' 9' ' ' THR . 27.7 Cg_endo -67.5 -179.16 1.79 Allowed 'Trans proline' 0 C--N 1.309 -1.552 0 O-C-N 123.894 1.471 . . . . 0.0 110.826 -179.54 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.502 ' OD1' ' N ' ' A' ' 31' ' ' HIS . 32.3 p-10 -64.85 -40.02 94.5 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.322 -0.861 . . . . 0.0 110.952 -175.56 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.574 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.01 1.32 56.44 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.939 -1.101 . . . . 0.0 110.987 -174.037 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.574 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 98.7 mmm -112.17 -14.14 13.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.854 -1.154 . . . . 0.0 109.871 171.411 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.53 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 19.2 mt -69.93 -20.38 63.34 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.39 -0.818 . . . . 0.0 110.437 176.203 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -61.0 123.05 16.5 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.088 -1.007 . . . . 0.0 111.286 -171.276 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 48.92 54.72 13.29 Favored Glycine 0 N--CA 1.493 2.498 0 C-N-CA 120.339 -0.934 . . . . 0.0 111.015 169.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.517 ' CD1' HD21 ' A' ' 28' ' ' LEU . 6.4 tt -113.25 155.44 25.07 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.83 -1.394 . . . . 0.0 110.181 174.131 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 21.3 pt-20 -149.95 167.85 25.48 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.221 -0.924 . . . . 0.0 110.139 -178.207 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.543 ' CG2' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -68.09 155.27 39.92 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.212 -0.93 . . . . 0.0 109.754 177.539 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.56 -8.86 63.63 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.744 -1.343 . . . . 0.0 109.744 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.42 ' HB2' HG23 ' A' ' 51' ' ' VAL . . . -75.37 159.91 30.88 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.11 -1.229 . . . . 0.0 109.753 178.126 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.468 ' HB2' ' HB2' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -105.2 120.2 40.95 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.831 -1.168 . . . . 0.0 110.309 -179.416 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.581 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 1.6 t -109.95 132.51 58.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.328 -0.858 . . . . 0.0 109.193 172.74 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.467 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -92.38 119.95 32.42 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.145 -0.972 . . . . 0.0 109.337 172.59 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.575 ' CE1' HG12 ' A' ' 42' ' ' VAL . 0.4 OUTLIER -89.83 106.92 18.79 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.402 -0.811 . . . . 0.0 109.109 177.865 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.493 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.6 t-20 52.57 17.59 0.82 Allowed 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.39 -0.819 . . . . 0.0 110.503 -166.5 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.49 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 116.35 -4.81 19.77 Favored Glycine 0 N--CA 1.487 2.084 0 C-N-CA 119.64 -1.267 . . . . 0.0 110.831 170.219 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.525 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 17.3 t -90.08 109.84 20.87 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.345 -1.679 . . . . 0.0 109.084 174.491 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 43' ' ' ALA . 27.5 p -77.68 124.89 28.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.996 -1.065 . . . . 0.0 110.691 -172.397 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.525 ' CD2' ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -136.85 166.38 23.74 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.353 -0.842 . . . . 0.0 108.945 172.128 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.457 ' O ' ' OD1' ' A' ' 62' ' ' ASP . 54.9 m -103.13 154.18 19.56 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.574 -1.329 . . . . 0.0 111.146 -169.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.554 ' CG1' HG11 ' A' ' 59' ' ' VAL . 7.0 t -74.67 113.26 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.899 -0.5 . . . . 0.0 110.034 -179.294 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.579 ' CG2' ' N ' ' A' ' 62' ' ' ASP . 19.0 p -75.3 -43.59 50.21 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.365 -0.835 . . . . 0.0 109.57 176.209 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.433 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -158.36 150.53 21.77 Favored 'General case' 0 N--CA 1.491 1.621 0 C-N-CA 119.576 -0.85 . . . . 0.0 110.335 179.246 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.543 HD11 ' CG2' ' A' ' 38' ' ' THR . 2.5 mp -108.18 132.3 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.225 -0.922 . . . . 0.0 110.304 175.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.451 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 54.9 m-80 -108.26 66.24 0.65 Allowed 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.662 -0.649 . . . . 0.0 109.541 177.824 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.44 -119.36 5.79 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 108.794 -1.722 . . . . 0.0 108.794 -173.112 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.53 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -77.12 -17.71 58.46 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.016 -1.285 . . . . 0.0 109.009 176.084 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.613 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 9.1 m170 -77.57 160.09 28.82 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.312 -0.867 . . . . 0.0 110.419 -178.447 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.589 HG12 ' CE2' ' A' ' 61' ' ' PHE . 94.1 t -145.16 117.83 2.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 C-N-CA 119.379 -0.928 . . . . 0.0 110.879 175.423 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.529 ' OG ' ' CG2' ' A' ' 25' ' ' VAL . 19.6 m -81.92 125.3 30.58 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.529 -0.732 . . . . 0.0 109.592 175.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.589 ' CE2' HG12 ' A' ' 59' ' ' VAL . 82.9 m-85 -110.03 154.78 22.73 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.898 -1.127 . . . . 0.0 110.23 178.73 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.579 ' N ' ' CG2' ' A' ' 52' ' ' THR . 9.1 p-10 -89.54 148.18 23.53 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.132 -0.98 . . . . 0.0 111.265 -176.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.548 ' CD2' ' CD1' ' A' ' 68' ' ' LEU . 0.0 OUTLIER -159.16 102.2 1.6 Allowed 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.705 -0.622 . . . . 0.0 109.485 -175.363 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.486 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 54.5 ttm -59.98 140.16 56.93 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.892 -1.13 . . . . 0.0 109.47 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.473 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 22.0 tptm -60.05 -43.45 95.38 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.027 -1.046 . . . . 0.0 110.315 -174.472 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.68 -39.96 76.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.974 -1.079 . . . . 0.0 110.012 177.695 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.486 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 93.7 m -60.95 -38.39 85.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.996 -1.065 . . . . 0.0 109.294 173.135 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.548 ' CD1' ' CD2' ' A' ' 63' ' ' LEU . 7.1 tp -59.96 -45.71 91.8 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.325 -0.859 . . . . 0.0 109.746 178.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 76.5 ttt-85 -69.32 -39.67 78.07 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.428 -0.795 . . . . 0.0 110.438 177.739 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.467 HG21 HG22 ' A' ' 71' ' ' THR . 1.3 tt -64.65 -41.57 92.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.171 -0.955 . . . . 0.0 109.434 -176.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.473 HG22 ' O ' ' A' ' 67' ' ' THR . 42.0 p -85.25 -174.62 5.33 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 175.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.481 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 2.6 t30 -101.11 21.82 13.29 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 171.624 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.464 HD13 HD23 ' A' ' 63' ' ' LEU . 41.9 mt -69.99 -40.05 75.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.012 -1.055 . . . . 0.0 110.304 175.122 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.525 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -48.62 -22.29 2.6 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 -178.548 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.4 p-10 -66.11 -16.49 64.0 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.137 -1.213 . . . . 0.0 110.588 -174.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 94.7 mt -59.99 141.44 55.61 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.276 -0.89 . . . . 0.0 110.763 -176.232 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.484 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 95.1 mttt -140.0 139.77 36.1 Favored 'General case' 0 N--CA 1.493 1.678 0 CA-C-O 121.337 0.589 . . . . 0.0 109.444 174.202 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.576 ' CG2' HG13 ' A' ' 15' ' ' ILE . 16.4 t -60.51 152.45 5.39 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 120.788 -1.195 . . . . 0.0 110.383 -176.225 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.0 -15.56 57.66 Favored Glycine 0 N--CA 1.484 1.86 0 N-CA-C 108.811 -1.716 . . . . 0.0 108.811 -176.045 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 9.2 t0 -95.28 165.51 12.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.347 -1.09 . . . . 0.0 109.689 175.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.578 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.5 m95 -114.55 157.2 23.33 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.058 -1.027 . . . . 0.0 110.202 177.504 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.52 HG13 ' CB ' ' A' ' 10' ' ' ALA . 1.3 p -120.04 149.34 22.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.429 -0.795 . . . . 0.0 109.843 -179.18 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.484 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 0.2 OUTLIER -75.79 104.36 6.3 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.021 -1.049 . . . . 0.0 109.43 169.286 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.517 ' CG1' ' CE1' ' A' ' 44' ' ' HIS . 0.0 OUTLIER -106.21 137.76 34.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 120.459 -1.401 . . . . 0.0 111.392 -176.943 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -130.06 144.86 51.57 Favored 'General case' 0 N--CA 1.495 1.78 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.986 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . 0.441 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 34.0 ptt180 -81.45 133.67 35.44 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.261 -0.899 . . . . 0.0 111.024 -176.235 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.468 ' HB2' ' HB2' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.492 1.672 0 O-C-N 121.429 -0.794 . . . . 0.0 110.176 175.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.536 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.4 t . . . . . 0 N--CA 1.494 1.734 0 CA-C-O 121.544 0.688 . . . . 0.0 110.628 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.433 ' OE1' ' HG2' ' B' ' 86' ' ' ARG . 18.2 pt20 -93.48 -23.61 18.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.508 -0.745 . . . . 0.0 110.834 179.264 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.536 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -150.62 173.87 30.09 Favored Glycine 0 N--CA 1.493 2.498 0 C-N-CA 119.396 -1.383 . . . . 0.0 109.911 -175.553 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.479 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 2.2 p -123.3 170.83 9.9 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.001 -1.293 . . . . 0.0 110.932 -177.386 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.521 ' CB ' HG13 ' B' ' 82' ' ' VAL . . . -139.33 149.54 44.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.592 -0.693 . . . . 0.0 109.165 -179.634 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 33.4 tttt -106.82 115.58 30.43 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.045 -1.034 . . . . 0.0 110.139 179.554 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.53 ' CG ' ' HA ' ' B' ' 78' ' ' VAL . 12.2 tp -58.84 127.09 30.47 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.013 -1.054 . . . . 0.0 108.721 173.351 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.605 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.6 p -129.83 -30.27 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.983 0 O-C-N 121.421 -0.8 . . . . 0.0 110.031 -177.783 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -145.14 140.46 28.0 Favored 'General case' 0 C--N 1.297 -1.676 0 C-N-CA 119.499 -0.881 . . . . 0.0 110.979 -179.46 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.574 HG13 ' CG2' ' B' ' 78' ' ' VAL . 13.9 mt -107.51 131.01 58.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 120.918 -1.114 . . . . 0.0 110.266 172.357 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.493 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 77.6 m-20 -108.63 114.94 29.15 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.451 -0.781 . . . . 0.0 109.919 174.728 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 87.1 tt0 -107.0 112.31 25.2 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.1 -1.0 . . . . 0.0 110.524 -176.04 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . 0.468 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 6.1 mtmt -107.86 129.94 23.47 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.229 -0.919 . . . . 0.0 109.241 175.143 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -51.9 -24.44 18.9 Favored 'Trans proline' 0 C--N 1.303 -1.833 0 O-C-N 123.73 1.384 . . . . 0.0 110.187 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.554 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 10.6 m-80 -81.18 -40.03 24.54 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.206 -0.934 . . . . 0.0 110.127 175.411 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.554 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 95.2 m-85 -156.41 150.33 25.04 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.456 -0.778 . . . . 0.0 109.964 -178.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . 0.471 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 59.6 ttt180 -91.95 145.07 24.83 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.884 -1.135 . . . . 0.0 110.327 178.754 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.493 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 78.3 m -130.02 139.98 50.94 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.677 -0.64 . . . . 0.0 109.757 -176.183 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.562 ' CD2' HG12 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -128.54 128.34 44.11 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.94 -1.1 . . . . 0.0 111.322 178.319 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.519 ' CG2' ' OG ' ' B' ' 60' ' ' SER . 4.3 t -104.94 131.65 53.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.384 -0.822 . . . . 0.0 110.638 -178.135 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.479 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 33.5 m -116.22 168.09 8.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.973 -0.455 . . . . 0.0 109.788 179.546 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.455 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 2.5 tm-20 -101.05 115.42 30.45 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.27 -0.894 . . . . 0.0 109.409 178.468 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.531 ' HB3' ' CD2' ' B' ' 33' ' ' LEU . 9.8 tp -79.2 125.3 83.68 Favored Pre-proline 0 C--N 1.296 -1.753 0 O-C-N 121.538 -0.727 . . . . 0.0 109.878 -176.546 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.467 ' HD2' HD11 ' B' ' 28' ' ' LEU . 27.9 Cg_endo -67.49 -179.23 1.83 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.788 1.415 . . . . 0.0 110.806 -179.538 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.493 ' OD1' ' N ' ' B' ' 31' ' ' HIS . 32.2 p-10 -64.85 -39.97 94.41 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.384 -0.823 . . . . 0.0 110.94 -175.49 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.576 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.99 1.25 56.51 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.886 -1.134 . . . . 0.0 110.954 -174.01 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.576 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 98.6 mmm -112.19 -14.12 13.42 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.902 -1.124 . . . . 0.0 109.881 171.479 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.541 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 19.6 mt -69.96 -20.31 63.33 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.398 -0.814 . . . . 0.0 110.484 176.17 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -61.03 123.0 16.37 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.117 -0.989 . . . . 0.0 111.263 -171.262 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 48.95 54.84 12.89 Favored Glycine 0 N--CA 1.493 2.448 0 O-C-N 121.208 -0.932 . . . . 0.0 110.927 169.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . 0.529 ' CD1' HD23 ' B' ' 28' ' ' LEU . 6.4 tt -113.34 155.52 25.03 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.728 -1.454 . . . . 0.0 110.091 174.15 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . . . . . . . . . 21.3 pt-20 -150.06 167.77 25.82 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.106 -0.996 . . . . 0.0 110.203 -178.211 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.53 ' CG2' HD11 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -67.99 155.15 40.1 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.309 -0.869 . . . . 0.0 109.811 177.55 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.62 -8.82 64.0 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.549 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.407 ' HB1' HG21 ' B' ' 51' ' ' VAL . . . -75.57 159.81 30.84 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.144 -1.21 . . . . 0.0 109.762 178.101 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 41' ' ' SER . . . . . 0.466 ' HB2' ' HB1' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -104.97 119.93 40.22 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.882 -1.136 . . . . 0.0 110.467 -179.357 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.572 ' HB ' ' CE1' ' B' ' 61' ' ' PHE . 1.6 t -109.94 132.6 57.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.424 -0.797 . . . . 0.0 109.219 172.754 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.47 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -92.34 120.04 32.49 Favored 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.133 -0.98 . . . . 0.0 109.407 172.532 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.578 ' CG ' HG23 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -89.85 107.03 18.86 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.382 -0.824 . . . . 0.0 109.074 177.832 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.493 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.6 t-20 52.5 17.63 0.81 Allowed 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.348 -0.845 . . . . 0.0 110.535 -166.558 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.49 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 116.26 -4.69 19.98 Favored Glycine 0 N--CA 1.488 2.127 0 C-N-CA 119.626 -1.273 . . . . 0.0 110.864 170.192 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.534 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 17.2 t -90.09 109.78 20.82 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.294 -1.709 . . . . 0.0 109.13 174.423 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . 0.449 ' HA ' ' HA ' ' B' ' 43' ' ' ALA . 27.6 p -77.6 124.93 28.57 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.937 -1.102 . . . . 0.0 110.742 -172.473 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.534 ' CD2' ' O ' ' B' ' 47' ' ' CYS . 0.2 OUTLIER -136.92 166.27 24.02 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.381 -0.825 . . . . 0.0 108.943 172.114 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 50' ' ' THR . . . . . 0.456 ' O ' ' OD1' ' B' ' 62' ' ' ASP . 55.5 m -102.94 154.33 19.33 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.633 -1.292 . . . . 0.0 111.201 -169.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.55 ' CG1' HG11 ' B' ' 59' ' ' VAL . 7.1 t -74.88 113.29 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 CA-C-O 121.249 0.547 . . . . 0.0 110.053 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.578 ' CG2' ' N ' ' B' ' 62' ' ' ASP . 19.0 p -75.29 -43.49 50.78 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.292 -0.88 . . . . 0.0 109.599 176.258 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.444 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -158.5 150.46 21.45 Favored 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.391 179.204 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.53 HD11 ' CG2' ' B' ' 38' ' ' THR . 2.5 mp -108.14 132.33 56.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.209 -0.932 . . . . 0.0 110.295 176.087 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.469 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 54.7 m-80 -108.33 66.19 0.64 Allowed 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 120.168 -0.613 . . . . 0.0 109.495 177.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.57 -119.31 5.74 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 -173.127 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.541 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -77.17 -17.85 58.26 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.965 -1.315 . . . . 0.0 108.946 176.112 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.605 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 9.1 m170 -77.49 160.02 28.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.468 -0.77 . . . . 0.0 110.436 -178.453 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.587 HG12 ' CE2' ' B' ' 61' ' ' PHE . 94.3 t -145.1 117.79 2.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 C-N-CA 119.329 -0.949 . . . . 0.0 110.874 175.527 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.519 ' OG ' ' CG2' ' B' ' 25' ' ' VAL . 19.7 m -82.03 125.36 30.72 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.618 -0.676 . . . . 0.0 109.622 176.037 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.587 ' CE2' HG12 ' B' ' 59' ' ' VAL . 83.0 m-85 -110.0 154.88 22.55 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 120.915 -1.116 . . . . 0.0 110.25 178.708 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.578 ' N ' ' CG2' ' B' ' 52' ' ' THR . 9.1 p-10 -89.57 148.29 23.46 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 120.984 -1.072 . . . . 0.0 111.192 -176.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.546 ' CD2' ' CD1' ' B' ' 68' ' ' LEU . 0.0 OUTLIER -159.22 102.11 1.59 Allowed 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 -175.361 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.484 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 54.5 ttm -59.99 140.15 56.95 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.968 -1.082 . . . . 0.0 109.476 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.471 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 22.0 tptm -60.04 -43.37 95.39 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.118 -0.989 . . . . 0.0 110.4 -174.456 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.67 -39.97 76.69 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.034 -1.041 . . . . 0.0 110.149 177.612 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.491 ' O ' HG22 ' B' ' 71' ' ' THR . 93.1 m -60.77 -38.6 85.81 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.97 -1.081 . . . . 0.0 109.329 173.002 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.546 ' CD1' ' CD2' ' B' ' 63' ' ' LEU . 7.1 tp -59.95 -45.45 92.59 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.324 -0.86 . . . . 0.0 109.89 178.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 76.5 ttt-85 -69.41 -39.63 77.8 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.526 -0.734 . . . . 0.0 110.451 177.66 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.484 HG23 HG22 ' B' ' 71' ' ' THR . 1.3 tt -64.72 -41.48 92.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.302 -0.873 . . . . 0.0 109.486 -176.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.491 HG22 ' O ' ' B' ' 67' ' ' THR . 40.7 p -85.1 -174.52 5.3 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.279 175.813 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.47 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 2.7 t30 -101.1 21.8 13.31 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 171.482 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.464 ' HB3' HD22 ' B' ' 63' ' ' LEU . 41.3 mt -70.06 -39.95 75.36 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.07 -1.019 . . . . 0.0 110.232 175.239 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.521 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -48.7 -22.36 2.72 Favored Glycine 0 N--CA 1.486 1.98 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -178.505 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.2 p-10 -65.93 -16.52 63.94 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.161 -1.199 . . . . 0.0 110.624 -174.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 94.2 mt -60.01 141.4 55.73 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.126 -0.984 . . . . 0.0 110.829 -176.217 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.486 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 95.1 mttt -139.96 139.82 36.18 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.734 -0.604 . . . . 0.0 109.397 174.196 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.574 ' CG2' HG13 ' B' ' 15' ' ' ILE . 16.4 t -60.55 152.46 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.989 -1.069 . . . . 0.0 110.357 -176.205 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.88 -15.25 58.19 Favored Glycine 0 N--CA 1.484 1.846 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 -176.088 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.481 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 9.1 t0 -95.44 165.32 12.42 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.402 -1.058 . . . . 0.0 109.706 175.768 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.6 m95 -114.46 157.24 23.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.147 -0.971 . . . . 0.0 110.288 177.441 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.578 HG23 ' CG ' ' B' ' 44' ' ' HIS . 1.3 p -120.06 149.34 22.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.688 -0.632 . . . . 0.0 109.871 -179.181 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.479 ' OD1' ' N ' ' A' ' 72' ' ' ASN . 0.2 OUTLIER -75.78 104.18 6.21 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.084 -1.01 . . . . 0.0 109.526 169.26 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.523 ' CG1' ' CE1' ' B' ' 44' ' ' HIS . 0.0 OUTLIER -106.09 137.83 34.41 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.459 -1.401 . . . . 0.0 111.38 -176.812 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -130.2 144.92 51.64 Favored 'General case' 0 N--CA 1.493 1.712 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.005 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . 0.443 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 34.1 ptt180 -81.53 133.72 35.42 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.206 -0.934 . . . . 0.0 110.93 -176.11 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.466 ' HB1' ' HB2' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.746 0 O-C-N 121.355 -0.841 . . . . 0.0 110.08 175.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.527 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.0 t . . . . . 0 N--CA 1.493 1.699 0 CA-C-O 121.83 0.824 . . . . 0.0 111.108 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 27.8 mm100 -70.0 -36.32 75.04 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.793 -0.567 . . . . 0.0 110.686 177.254 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -155.24 169.11 33.19 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.029 -1.558 . . . . 0.0 110.187 -173.569 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.437 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 0.7 OUTLIER -108.91 172.39 6.87 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.081 -1.246 . . . . 0.0 111.104 -176.167 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.483 ' O ' ' HA ' ' A' ' 81' ' ' TRP . . . -139.46 148.54 42.87 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -178.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.588 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 20.8 tttt -106.42 117.01 32.92 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 120.993 -1.067 . . . . 0.0 110.149 178.759 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.526 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 12.0 tp -59.81 127.65 33.02 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 120.831 -1.168 . . . . 0.0 108.756 172.563 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.601 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -126.72 -30.85 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 C-N-CA 119.596 -0.842 . . . . 0.0 110.032 -178.215 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.13 142.56 27.48 Favored 'General case' 0 N--CA 1.494 1.762 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.361 -178.403 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.578 HG13 ' CG2' ' A' ' 78' ' ' VAL . 10.3 mt -109.46 133.78 53.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.186 -0.946 . . . . 0.0 110.191 172.92 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.483 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 83.8 m-20 -109.88 114.29 27.72 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.377 -0.827 . . . . 0.0 110.129 176.072 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.25 112.69 25.03 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.018 -1.051 . . . . 0.0 110.556 -177.284 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.469 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.0 OUTLIER -107.43 133.22 20.46 Favored Pre-proline 0 N--CA 1.492 1.661 0 O-C-N 121.186 -0.946 . . . . 0.0 109.372 174.915 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -51.99 -25.1 21.12 Favored 'Trans proline' 0 C--N 1.302 -1.869 0 O-C-N 123.859 1.452 . . . . 0.0 110.35 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.567 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 8.8 m-80 -86.2 -35.76 19.87 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.25 -0.906 . . . . 0.0 110.272 177.708 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.567 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 95.4 m-85 -157.17 150.24 23.71 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.407 -0.808 . . . . 0.0 110.244 -176.382 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.473 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 61.6 ttt180 -86.2 144.26 27.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.783 -1.198 . . . . 0.0 110.085 175.218 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.483 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 85.3 m -130.6 140.01 50.42 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.499 -0.751 . . . . 0.0 109.668 -175.676 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.583 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -130.98 141.27 50.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.776 -1.203 . . . . 0.0 111.546 -178.433 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.528 ' CG2' ' OG ' ' A' ' 60' ' ' SER . 12.8 t -120.98 135.05 62.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.118 -0.989 . . . . 0.0 110.656 -179.152 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.579 HG12 ' CE1' ' A' ' 61' ' ' PHE . 21.4 m -117.46 171.96 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.738 -0.601 . . . . 0.0 110.246 178.16 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.48 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 12.8 tt0 -106.3 116.87 32.67 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.922 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.582 ' CD2' ' CD2' ' A' ' 36' ' ' LEU . 9.6 tp -90.73 130.93 39.19 Favored Pre-proline 0 C--N 1.296 -1.747 0 O-C-N 121.203 -0.936 . . . . 0.0 110.521 -171.295 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.475 ' HD2' HD11 ' A' ' 28' ' ' LEU . 30.7 Cg_endo -68.05 176.91 4.84 Favored 'Trans proline' 0 C--N 1.308 -1.605 0 O-C-N 124.015 1.534 . . . . 0.0 111.053 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -60.55 -39.92 89.71 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.429 -0.795 . . . . 0.0 111.401 -175.187 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.578 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.89 0.03 57.29 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.8 -1.188 . . . . 0.0 110.755 -174.078 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.578 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.9 mmm -110.67 -16.14 13.69 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.95 -1.094 . . . . 0.0 109.638 169.793 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.538 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 29.6 mt -71.2 -24.86 62.3 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.313 -0.867 . . . . 0.0 109.863 174.386 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . 0.476 ' O ' ' N ' ' A' ' 36' ' ' LEU . 38.6 p-10 -71.16 162.25 29.74 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.467 -0.771 . . . . 0.0 110.94 -173.104 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.428 ' C ' ' O ' ' A' ' 34' ' ' ASP . . . 37.54 27.69 0.03 OUTLIER Glycine 0 N--CA 1.494 2.522 0 O-C-N 121.504 -0.747 . . . . 0.0 111.605 174.295 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.582 ' CD2' ' CD2' ' A' ' 28' ' ' LEU . 60.8 tp -101.21 158.45 16.02 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 120.537 -1.566 . . . . 0.0 110.919 179.025 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.422 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 21.5 pt-20 -160.04 161.09 33.9 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.566 -0.709 . . . . 0.0 109.428 177.49 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.541 ' CG2' ' HA ' ' A' ' 53' ' ' GLU . 0.0 OUTLIER -66.84 154.42 40.96 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.043 -1.035 . . . . 0.0 109.526 175.779 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.39 -9.45 61.43 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.257 -1.537 . . . . 0.0 109.257 -176.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.47 ' O ' HG21 ' A' ' 51' ' ' VAL . . . -69.87 153.21 43.6 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.135 -1.215 . . . . 0.0 109.627 177.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.471 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -97.35 104.53 16.56 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 120.966 -1.084 . . . . 0.0 109.906 178.117 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 1.6 t -87.87 137.54 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.239 -0.913 . . . . 0.0 109.027 174.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.45 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -102.96 120.12 40.06 Favored 'General case' 0 C--N 1.295 -1.781 0 O-C-N 120.865 -1.147 . . . . 0.0 109.535 170.167 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.582 ' CD2' HG23 ' A' ' 82' ' ' VAL . 1.2 m80 -87.45 101.02 13.19 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 176.12 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.0 t-20 58.55 8.88 0.95 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.575 -0.703 . . . . 0.0 111.399 -169.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 124.62 -3.19 8.73 Favored Glycine 0 N--CA 1.489 2.167 0 C-N-CA 119.674 -1.25 . . . . 0.0 110.617 174.344 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.526 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 19.7 t -90.34 107.39 19.12 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.334 -1.686 . . . . 0.0 109.2 174.623 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 23.5 p -78.12 125.55 29.51 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.127 -0.983 . . . . 0.0 110.768 -170.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.552 ' CD1' ' CD2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -142.57 160.16 40.83 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.508 -0.745 . . . . 0.0 109.592 176.051 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 27.6 m -99.51 149.15 23.53 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.715 -1.24 . . . . 0.0 111.378 -169.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.52 HG12 ' CG1' ' A' ' 59' ' ' VAL . 16.9 t -75.16 114.62 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.739 -0.6 . . . . 0.0 110.273 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.52 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 47.3 p -70.29 -40.0 74.55 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.299 -0.875 . . . . 0.0 109.947 174.214 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.541 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -162.78 154.5 18.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.344 -0.847 . . . . 0.0 110.23 -179.344 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.537 HD11 ' CG2' ' A' ' 38' ' ' THR . 5.5 mt -105.55 130.01 57.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.012 -1.055 . . . . 0.0 109.888 175.201 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.5 ' HB2' ' CB ' ' A' ' 58' ' ' HIS . 9.6 m-80 -101.66 61.94 0.91 Allowed 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.614 -0.678 . . . . 0.0 109.691 178.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.79 -114.72 4.16 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 108.743 -1.743 . . . . 0.0 108.743 -173.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.538 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.54 -19.97 51.72 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.024 -1.28 . . . . 0.0 108.807 174.374 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.601 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 9.3 m170 -75.29 160.04 30.79 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.459 -0.776 . . . . 0.0 110.116 -177.222 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.52 ' CG1' HG12 ' A' ' 51' ' ' VAL . 54.6 t -140.14 121.99 15.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 O-C-N 120.957 -1.089 . . . . 0.0 110.711 171.059 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.528 ' OG ' ' CG2' ' A' ' 25' ' ' VAL . 1.1 t -87.75 133.69 33.81 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.522 -0.736 . . . . 0.0 109.287 174.729 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.624 ' N ' ' CD1' ' A' ' 61' ' ' PHE . 1.3 p90 -126.85 154.07 44.85 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 121.43 -0.793 . . . . 0.0 110.225 178.554 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.52 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 31.4 p-10 -88.72 147.77 24.32 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.004 -1.06 . . . . 0.0 111.399 -170.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.588 ' CD2' ' CD1' ' A' ' 68' ' ' LEU . 0.0 OUTLIER -154.47 113.66 3.69 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 -176.186 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.514 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 56.9 ttm -69.96 140.61 53.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.794 -1.191 . . . . 0.0 109.449 -179.382 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.473 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 36.4 tptt -60.01 -49.23 78.5 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.995 -1.066 . . . . 0.0 110.299 -175.1 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -65.48 -40.01 92.62 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.901 -1.124 . . . . 0.0 110.129 178.162 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.514 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 60.8 m -62.76 -38.13 89.34 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.902 -1.124 . . . . 0.0 109.426 174.238 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.588 ' CD1' ' CD2' ' A' ' 63' ' ' LEU . 14.7 tp -60.05 -41.58 92.61 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.14 -0.975 . . . . 0.0 109.225 177.325 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.526 ' NH1' ' HB3' ' A' ' 69' ' ' ARG . 6.4 mmm180 -69.96 -38.85 76.24 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.466 -0.771 . . . . 0.0 110.433 174.012 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.471 HG23 ' O ' ' A' ' 67' ' ' THR . 1.1 tt -67.97 -40.43 83.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.327 -0.858 . . . . 0.0 109.412 -176.574 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.465 HG22 ' O ' ' A' ' 67' ' ' THR . 59.1 p -87.49 -171.56 3.51 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.339 0.59 . . . . 0.0 109.764 179.083 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.467 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 8.3 t30 -99.92 18.75 17.6 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.338 -0.852 . . . . 0.0 108.865 170.194 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.542 ' CD1' HD23 ' A' ' 63' ' ' LEU . 70.2 mt -68.33 -40.02 81.77 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.931 -1.106 . . . . 0.0 109.749 174.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.502 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -47.06 -22.55 1.3 Allowed Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 -179.702 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.3 p-10 -67.91 -17.18 64.39 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.975 -1.309 . . . . 0.0 110.419 -175.351 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 95.5 mt -63.51 142.11 58.51 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.223 -0.923 . . . . 0.0 110.917 -176.243 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.473 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 46.1 mttt -142.65 142.73 32.12 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.733 -0.604 . . . . 0.0 109.495 174.561 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.578 ' CG2' HG13 ' A' ' 15' ' ' ILE . 21.3 t -63.61 150.04 10.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.587 0 O-C-N 120.843 -1.16 . . . . 0.0 110.36 -176.707 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.78 -13.6 62.35 Favored Glycine 0 N--CA 1.483 1.797 0 N-CA-C 108.793 -1.723 . . . . 0.0 108.793 -175.21 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 44.9 t0 -95.2 166.31 11.97 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.267 -1.137 . . . . 0.0 109.55 176.1 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.588 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.8 m95 -117.22 159.04 23.28 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.006 -1.059 . . . . 0.0 110.118 176.563 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.582 HG23 ' CD2' ' A' ' 44' ' ' HIS . 1.0 OUTLIER -125.38 155.02 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.441 -0.787 . . . . 0.0 109.891 -179.124 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.522 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 0.3 OUTLIER -78.16 105.29 9.28 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.17 -0.956 . . . . 0.0 108.965 168.093 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.47 ' O ' HG12 ' A' ' 6' ' ' VAL . 0.1 OUTLIER -106.19 140.46 24.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 120.535 -1.353 . . . . 0.0 111.478 -176.312 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -134.27 157.09 47.19 Favored 'General case' 0 N--CA 1.496 1.855 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.948 -179.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 47.5 ptt85 -100.23 133.37 44.74 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.114 -0.991 . . . . 0.0 110.992 -176.232 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.471 ' O ' ' OG ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.492 1.665 0 O-C-N 121.344 -0.848 . . . . 0.0 110.126 179.598 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.534 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.0 t . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.701 0.762 . . . . 0.0 111.11 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 27.8 mm100 -69.98 -36.08 74.93 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.836 -0.54 . . . . 0.0 110.81 177.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.534 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -155.42 168.96 33.27 Favored Glycine 0 N--CA 1.495 2.631 0 C-N-CA 119.086 -1.53 . . . . 0.0 110.269 -173.563 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.44 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 0.7 OUTLIER -108.87 172.17 7.0 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.127 -1.219 . . . . 0.0 111.177 -176.128 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.488 ' O ' ' HA ' ' B' ' 81' ' ' TRP . . . -139.24 148.79 43.55 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 -179.145 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 20.8 tttt -106.59 117.11 33.18 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.091 -1.006 . . . . 0.0 110.055 178.787 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.519 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 12.0 tp -59.98 127.54 32.43 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.977 -1.077 . . . . 0.0 108.814 172.583 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.605 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -126.51 -31.0 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.837 0 O-C-N 121.312 -0.868 . . . . 0.0 110.061 -178.115 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.09 142.55 27.51 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.229 -0.988 . . . . 0.0 111.391 -178.358 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.579 HG13 ' CG2' ' B' ' 78' ' ' VAL . 10.3 mt -109.42 133.85 53.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.169 -0.957 . . . . 0.0 110.241 172.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.486 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.6 m-20 -110.0 114.44 27.98 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.387 -0.821 . . . . 0.0 110.077 176.059 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -100.24 112.66 24.99 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.101 -1.0 . . . . 0.0 110.612 -177.358 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . 0.473 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.0 OUTLIER -107.47 133.3 20.44 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.27 -0.894 . . . . 0.0 109.4 174.904 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -52.12 -24.99 21.57 Favored 'Trans proline' 0 C--N 1.303 -1.855 0 O-C-N 123.873 1.46 . . . . 0.0 110.32 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.572 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 9.2 m-80 -86.12 -36.35 19.64 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.305 -0.872 . . . . 0.0 110.06 177.804 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.572 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 95.5 m-85 -156.71 150.27 24.52 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.43 -0.794 . . . . 0.0 110.296 -176.285 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . 0.459 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 61.5 ttt180 -86.18 144.15 27.62 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.783 -1.198 . . . . 0.0 110.072 175.165 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.486 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 85.2 m -130.44 140.07 50.56 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.504 -0.747 . . . . 0.0 109.745 -175.76 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.585 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -130.92 141.29 50.28 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.859 -1.151 . . . . 0.0 111.505 -178.358 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.525 ' CG2' ' OG ' ' B' ' 60' ' ' SER . 12.6 t -120.9 135.21 61.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.313 -0.867 . . . . 0.0 110.648 -179.164 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.586 HG12 ' CE1' ' B' ' 61' ' ' PHE . 21.7 m -117.72 171.94 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.757 -0.589 . . . . 0.0 110.19 178.171 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.488 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 12.8 tt0 -106.19 116.82 32.59 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.583 ' CD2' ' CD2' ' B' ' 36' ' ' LEU . 9.5 tp -90.59 130.9 39.57 Favored Pre-proline 0 C--N 1.295 -1.773 0 O-C-N 121.16 -0.962 . . . . 0.0 110.547 -171.298 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.471 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 30.6 Cg_endo -68.13 176.92 4.89 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 O-C-N 123.98 1.516 . . . . 0.0 111.005 -179.505 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -60.51 -40.02 89.89 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.454 -0.779 . . . . 0.0 111.355 -175.143 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.574 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.87 0.06 57.27 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.738 -1.226 . . . . 0.0 110.707 -174.008 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.574 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.9 mmm -110.71 -16.03 13.7 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.848 -1.157 . . . . 0.0 109.665 169.765 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.545 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 29.4 mt -71.31 -24.92 62.22 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.298 -0.876 . . . . 0.0 109.779 174.408 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . 0.488 ' O ' ' N ' ' B' ' 36' ' ' LEU . 38.6 p-10 -71.11 162.18 29.86 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.443 -0.786 . . . . 0.0 110.955 -173.088 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' B' ' 34' ' ' ASP . . . 37.53 27.74 0.03 OUTLIER Glycine 0 N--CA 1.496 2.694 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.564 174.343 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . 0.583 ' CD2' ' CD2' ' B' ' 28' ' ' LEU . 60.8 tp -101.28 158.43 16.05 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.572 -1.546 . . . . 0.0 110.925 178.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . 0.442 ' O ' ' HB1' ' B' ' 40' ' ' ALA . 21.5 pt-20 -159.97 161.17 34.09 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.561 -0.712 . . . . 0.0 109.421 177.525 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.544 ' CG2' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.97 154.43 41.14 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.007 -1.058 . . . . 0.0 109.49 175.794 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.38 -9.37 61.63 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -176.577 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.442 ' HB1' ' O ' ' B' ' 37' ' ' GLU . . . -70.01 152.98 43.79 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.265 -1.138 . . . . 0.0 109.612 177.885 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 41' ' ' SER . . . . . 0.468 ' OG ' ' O ' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -97.08 104.28 16.28 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.947 -1.096 . . . . 0.0 110.037 178.103 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.404 ' CG1' ' HD1' ' B' ' 44' ' ' HIS . 1.6 t -87.81 137.54 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.247 -0.908 . . . . 0.0 109.108 174.554 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.445 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -103.02 120.19 40.2 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 120.931 -1.106 . . . . 0.0 109.482 170.239 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.577 ' CD2' HG23 ' B' ' 82' ' ' VAL . 1.2 m80 -87.51 100.89 13.11 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.67 -0.812 . . . . 0.0 108.925 176.099 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.0 t-20 58.87 8.86 1.03 Allowed 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.5 -0.75 . . . . 0.0 111.256 -170.12 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 124.5 -2.9 8.82 Favored Glycine 0 N--CA 1.488 2.123 0 C-N-CA 119.699 -1.239 . . . . 0.0 110.601 174.173 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.517 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 19.7 t -90.44 107.33 19.09 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.3 -1.706 . . . . 0.0 109.266 174.492 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 23.3 p -78.05 125.55 29.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.128 -0.983 . . . . 0.0 110.774 -170.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.562 ' CD1' ' CD2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -142.59 160.08 41.0 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.596 -0.69 . . . . 0.0 109.632 176.05 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 27.7 m -99.25 149.3 23.25 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.676 -1.265 . . . . 0.0 111.357 -169.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.533 ' CG1' HG11 ' B' ' 59' ' ' VAL . 17.1 t -75.42 114.55 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.675 -0.641 . . . . 0.0 110.342 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.523 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 48.3 p -70.32 -39.96 74.46 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.178 -0.952 . . . . 0.0 109.865 174.433 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.531 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -162.74 154.6 18.26 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.388 -0.82 . . . . 0.0 110.214 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.544 HD11 ' CG2' ' B' ' 38' ' ' THR . 5.5 mt -105.63 129.9 57.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.12 -0.987 . . . . 0.0 109.925 175.215 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.505 ' HB2' ' CB ' ' B' ' 58' ' ' HIS . 9.6 m-80 -101.58 61.9 0.92 Allowed 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.658 -0.651 . . . . 0.0 109.748 178.867 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.78 -114.66 4.15 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 -173.655 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.545 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.41 -20.2 51.61 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.004 -1.292 . . . . 0.0 108.815 174.34 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.605 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 9.4 m170 -75.21 159.87 31.06 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.442 -0.786 . . . . 0.0 110.144 -177.203 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.533 HG11 ' CG1' ' B' ' 51' ' ' VAL . 54.7 t -140.04 122.16 16.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 C-N-CA 118.926 -1.11 . . . . 0.0 110.662 171.133 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.525 ' OG ' ' CG2' ' B' ' 25' ' ' VAL . 1.1 t -87.86 133.83 33.82 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.457 -0.777 . . . . 0.0 109.371 174.746 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.62 ' N ' ' CD1' ' B' ' 61' ' ' PHE . 1.3 p90 -126.98 154.07 45.05 Favored 'General case' 0 N--CA 1.498 1.929 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.109 178.681 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.523 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 31.1 p-10 -88.7 147.77 24.34 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.939 -1.1 . . . . 0.0 111.352 -170.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.583 ' CD2' ' CD1' ' B' ' 68' ' ' LEU . 0.0 OUTLIER -154.38 113.76 3.73 Favored 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 -176.309 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.505 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 56.8 ttm -70.05 140.53 52.82 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.744 -1.222 . . . . 0.0 109.402 -179.386 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.474 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 36.5 tptt -59.99 -49.1 78.99 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.023 -1.048 . . . . 0.0 110.347 -175.117 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -65.54 -40.03 92.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.948 -1.095 . . . . 0.0 110.098 178.22 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.505 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 61.0 m -62.7 -38.23 89.6 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.905 -1.122 . . . . 0.0 109.426 174.242 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.583 ' CD1' ' CD2' ' B' ' 63' ' ' LEU . 14.7 tp -60.01 -41.46 92.21 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.292 -0.88 . . . . 0.0 109.264 177.312 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . 0.53 ' NH1' ' HB3' ' B' ' 69' ' ' ARG . 6.4 mmm180 -70.0 -38.99 76.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.558 -0.714 . . . . 0.0 110.386 174.03 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.466 HG23 HG22 ' B' ' 71' ' ' THR . 1.1 tt -67.88 -40.39 83.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.526 -176.641 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.466 HG22 HG23 ' B' ' 70' ' ' ILE . 59.2 p -87.37 -171.43 3.47 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-O 121.296 0.57 . . . . 0.0 109.863 178.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.501 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 8.4 t30 -99.92 18.74 17.62 Favored 'General case' 0 C--N 1.297 -1.703 0 O-C-N 121.384 -0.823 . . . . 0.0 108.814 170.195 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.538 ' CD1' HD23 ' B' ' 63' ' ' LEU . 69.4 mt -68.41 -39.98 81.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.023 -1.048 . . . . 0.0 109.716 174.811 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.5 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -47.02 -22.64 1.3 Allowed Glycine 0 N--CA 1.489 2.2 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -179.71 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.4 p-10 -67.94 -17.14 64.36 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.08 -1.247 . . . . 0.0 110.492 -175.321 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 95.5 mt -63.44 142.1 58.52 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.17 -0.956 . . . . 0.0 110.92 -176.334 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.477 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 46.1 mttt -142.84 142.84 31.91 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.71 -0.619 . . . . 0.0 109.391 174.507 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.579 ' CG2' HG13 ' B' ' 15' ' ' ILE . 21.5 t -63.61 149.99 10.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 120.903 -1.123 . . . . 0.0 110.422 -176.568 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.67 -13.34 62.8 Favored Glycine 0 N--CA 1.483 1.804 0 N-CA-C 108.885 -1.686 . . . . 0.0 108.885 -175.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 44.5 t0 -95.28 166.22 12.0 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.392 -1.064 . . . . 0.0 109.545 175.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.0 m95 -117.16 159.08 23.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.019 -1.051 . . . . 0.0 110.183 176.479 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.577 HG23 ' CD2' ' B' ' 44' ' ' HIS . 1.0 OUTLIER -125.45 155.15 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.5 -0.75 . . . . 0.0 109.936 -179.289 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.515 ' N ' HG21 ' B' ' 82' ' ' VAL . 0.3 OUTLIER -78.25 105.15 9.29 Favored 'General case' 0 C--N 1.297 -1.69 0 O-C-N 121.123 -0.986 . . . . 0.0 109.025 168.203 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.461 ' O ' HG11 ' B' ' 6' ' ' VAL . 0.1 OUTLIER -106.07 140.61 23.62 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 120.631 -1.293 . . . . 0.0 111.361 -176.047 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -134.54 157.06 47.52 Favored 'General case' 0 N--CA 1.495 1.785 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.888 -179.649 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 47.6 ptt85 -100.12 133.46 44.48 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.079 -1.013 . . . . 0.0 110.919 -176.12 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.468 ' O ' ' OG ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.767 0 O-C-N 121.401 -0.812 . . . . 0.0 110.08 179.603 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.535 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.2 t . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 121.743 0.783 . . . . 0.0 111.09 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -69.95 -35.11 74.24 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.778 -0.576 . . . . 0.0 111.072 176.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -156.24 172.97 34.14 Favored Glycine 0 N--CA 1.495 2.609 0 C-N-CA 118.747 -1.692 . . . . 0.0 110.513 -172.526 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.449 ' O ' ' HG3' ' A' ' 29' ' ' PRO . 12.6 p -117.75 172.35 7.43 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.031 -1.276 . . . . 0.0 111.017 -176.814 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.533 ' CB ' HG13 ' A' ' 82' ' ' VAL . . . -140.01 148.53 41.99 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.562 -0.711 . . . . 0.0 109.609 -178.726 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.581 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 37.6 tttt -107.18 115.3 29.93 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.047 -1.033 . . . . 0.0 110.321 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.532 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 11.3 tp -59.91 126.74 28.73 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.038 -1.039 . . . . 0.0 108.896 173.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.592 HG13 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -125.32 -29.32 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.838 0 C-N-CA 119.583 -0.847 . . . . 0.0 109.909 -179.417 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.93 142.4 24.37 Favored 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 118.942 -1.103 . . . . 0.0 111.523 179.735 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.574 HG12 ' CD2' ' A' ' 24' ' ' HIS . 12.0 mt -105.55 137.13 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.155 -0.966 . . . . 0.0 110.185 171.569 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.493 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 86.7 m-20 -112.95 115.99 29.28 Favored 'General case' 0 C--N 1.297 -1.703 0 O-C-N 121.344 -0.847 . . . . 0.0 109.937 173.512 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -105.9 115.24 29.9 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.897 -1.127 . . . . 0.0 110.799 -176.477 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.475 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 4.1 mtmt -110.4 127.58 26.77 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.121 -0.987 . . . . 0.0 108.935 171.703 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -52.27 -18.73 8.13 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.848 1.446 . . . . 0.0 110.812 -179.367 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.577 ' ND2' ' N ' ' A' ' 20' ' ' ASN . 0.3 OUTLIER -90.18 -35.84 15.13 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.139 -0.975 . . . . 0.0 108.741 177.077 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.501 ' CD2' ' HB2' ' A' ' 20' ' ' ASN . 81.9 m-85 -151.07 150.15 30.37 Favored 'General case' 0 N--CA 1.491 1.623 0 CA-C-O 121.192 0.52 . . . . 0.0 109.748 179.183 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.469 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 62.4 ttt180 -97.69 143.83 27.95 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.589 -1.32 . . . . 0.0 110.021 176.504 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.493 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 96.5 m -129.98 140.09 50.96 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.412 -0.805 . . . . 0.0 110.126 -173.304 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.574 ' CD2' HG12 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.22 135.77 48.5 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.984 -1.073 . . . . 0.0 111.207 179.216 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.512 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 15.8 t -115.53 134.25 59.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.002 -1.061 . . . . 0.0 110.767 -178.276 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.445 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 29.5 m -119.67 170.02 9.88 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.062 -179.703 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.504 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 7.5 tt0 -103.55 116.97 33.36 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -179.383 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.469 HD21 ' O ' ' A' ' 32' ' ' MET . 8.9 tp -82.01 119.73 75.78 Favored Pre-proline 0 C--N 1.295 -1.798 0 O-C-N 121.502 -0.748 . . . . 0.0 109.815 -173.719 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.449 ' HG3' ' O ' ' A' ' 9' ' ' THR . 22.6 Cg_endo -65.33 179.22 1.66 Allowed 'Trans proline' 0 C--N 1.308 -1.554 0 O-C-N 123.85 1.447 . . . . 0.0 111.047 -179.378 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.417 ' OD1' ' C ' ' A' ' 30' ' ' ASP . 50.5 t0 -60.1 -41.28 92.18 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.415 -0.803 . . . . 0.0 111.098 -175.319 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.55 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.39 1.47 56.57 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.87 -1.144 . . . . 0.0 110.763 -174.156 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.55 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 96.4 mmm -111.07 -15.82 13.63 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.036 -1.04 . . . . 0.0 109.82 171.835 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.532 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 16.5 mt -68.18 -30.39 69.48 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.33 -0.856 . . . . 0.0 109.999 178.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 57.4 t0 -91.72 127.02 37.01 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.328 -0.858 . . . . 0.0 110.266 -179.648 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.28 -48.06 1.0 Allowed Glycine 0 N--CA 1.492 2.403 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 177.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.479 HD12 ' CG2' ' A' ' 42' ' ' VAL . 7.4 tt -70.02 145.81 51.49 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.141 -1.211 . . . . 0.0 110.664 -175.762 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.464 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 20.7 pt-20 -150.43 170.01 20.09 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.427 -0.796 . . . . 0.0 109.622 -179.512 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.528 ' CG2' HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -67.23 151.15 48.05 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.91 -1.119 . . . . 0.0 110.13 179.972 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.62 0.0 62.15 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 -176.226 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.464 ' HB1' ' O ' ' A' ' 37' ' ' GLU . . . -79.79 159.0 26.71 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.242 -1.152 . . . . 0.0 109.7 177.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.451 ' HB2' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -101.06 113.23 26.05 Favored 'General case' 0 N--CA 1.486 1.345 0 O-C-N 121.126 -0.984 . . . . 0.0 110.04 176.72 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.573 HG11 ' CE1' ' A' ' 44' ' ' HIS . 2.0 t -104.74 130.0 56.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.278 -0.889 . . . . 0.0 109.172 174.718 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.478 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -93.31 119.53 32.56 Favored 'General case' 0 C--N 1.297 -1.708 0 C-N-CA 119.146 -1.022 . . . . 0.0 109.149 172.257 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.573 ' CE1' HG11 ' A' ' 42' ' ' VAL . 0.3 OUTLIER -88.0 107.15 18.58 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 178.52 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.51 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.1 t-20 50.29 16.28 0.25 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.487 -0.758 . . . . 0.0 111.283 -166.457 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.474 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 120.92 0.85 11.75 Favored Glycine 0 N--CA 1.489 2.221 0 C-N-CA 119.444 -1.36 . . . . 0.0 111.164 171.292 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.524 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 34.8 t -98.71 108.46 21.15 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.137 -1.802 . . . . 0.0 109.492 175.082 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 21.2 p -75.7 126.74 31.59 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.015 -1.053 . . . . 0.0 111.084 -171.116 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.526 ' CD1' ' HB3' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -141.35 162.74 34.76 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.505 -0.747 . . . . 0.0 109.466 172.712 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.418 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 55.0 m -102.47 152.88 20.61 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 120.637 -1.29 . . . . 0.0 111.074 -171.13 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.542 ' CG1' HG11 ' A' ' 59' ' ' VAL . 34.5 t -76.82 117.73 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.62 -0.675 . . . . 0.0 110.458 -177.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.542 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 41.2 p -70.21 -39.99 74.81 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.122 -0.986 . . . . 0.0 109.669 172.253 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.521 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 52.3 tp10 -164.72 156.12 15.26 Favored 'General case' 0 N--CA 1.492 1.642 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.819 -177.349 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.528 HD12 ' CG2' ' A' ' 38' ' ' THR . 8.8 mt -110.47 130.07 64.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.083 -1.011 . . . . 0.0 109.986 172.794 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.463 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 63.8 m-80 -104.7 65.62 0.76 Allowed 'General case' 0 C--N 1.297 -1.678 0 CA-C-O 121.532 0.682 . . . . 0.0 109.54 177.703 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.91 -115.09 4.24 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 -174.158 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.532 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.0 -21.08 44.04 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.121 -1.223 . . . . 0.0 109.162 176.609 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.592 ' CD2' HG13 ' A' ' 13' ' ' VAL . 9.5 m170 -77.05 159.38 29.91 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.186 -0.946 . . . . 0.0 109.791 -178.024 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.582 HG12 ' CE2' ' A' ' 61' ' ' PHE . 59.9 t -140.9 121.48 13.27 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 C-N-CA 119.078 -1.049 . . . . 0.0 110.522 171.707 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.512 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 1.2 t -84.35 135.35 34.33 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.434 -0.791 . . . . 0.0 109.264 175.885 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.582 ' CE2' HG12 ' A' ' 59' ' ' VAL . 58.9 m-85 -115.55 158.5 22.53 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.319 -0.863 . . . . 0.0 110.199 178.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.542 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 25.1 p-10 -92.12 147.47 22.91 Favored 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 122.106 0.955 . . . . 0.0 110.842 178.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.523 HD22 ' CD1' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -159.71 125.0 4.08 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 -176.864 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.518 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 56.1 ttm -84.85 146.44 27.31 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.931 -1.106 . . . . 0.0 109.434 -177.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.42 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 71.4 tttt -60.06 -49.13 78.88 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.014 -1.053 . . . . 0.0 109.99 -177.231 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 53.4 tp10 -69.59 -40.02 76.95 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.147 -0.97 . . . . 0.0 110.397 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.518 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 37.7 m -62.25 -38.66 90.11 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.823 -1.173 . . . . 0.0 109.085 174.427 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.528 ' CD1' ' HA2' ' A' ' 74' ' ' GLY . 1.0 OUTLIER -60.05 -47.37 86.16 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.233 -0.917 . . . . 0.0 109.709 177.419 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 74.9 ttt-85 -65.76 -40.05 91.65 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.467 -0.771 . . . . 0.0 110.481 178.192 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.503 HG21 ' N ' ' A' ' 71' ' ' THR . 1.4 tt -64.19 -41.28 91.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.234 -0.917 . . . . 0.0 109.093 -179.323 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.503 ' N ' HG21 ' A' ' 70' ' ' ILE . 20.1 p -89.72 -177.01 5.16 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 175.626 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.479 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 3.4 t30 -100.01 25.16 7.67 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.07 -1.019 . . . . 0.0 108.332 172.414 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.523 ' CD1' HD22 ' A' ' 63' ' ' LEU . 86.8 mt -67.66 -39.96 84.52 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.996 -1.065 . . . . 0.0 109.933 176.551 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.528 ' HA2' ' CD1' ' A' ' 68' ' ' LEU . . . -54.88 -23.98 32.41 Favored Glycine 0 N--CA 1.485 1.909 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -177.52 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 21.9 p-10 -64.12 -17.02 63.05 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.962 -1.317 . . . . 0.0 110.32 -175.335 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.52 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 96.0 mt -60.08 141.48 55.7 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.262 -0.898 . . . . 0.0 110.476 -177.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.472 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 59.8 mmtt -140.02 143.28 36.34 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-O 121.814 0.816 . . . . 0.0 110.4 175.807 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.564 ' CG2' HG13 ' A' ' 15' ' ' ILE . 35.9 t -63.08 149.51 10.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.252 -0.905 . . . . 0.0 110.235 -176.199 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.54 -13.79 63.05 Favored Glycine 0 N--CA 1.484 1.849 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 -175.338 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 46.3 t0 -96.23 163.13 13.22 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.346 -1.091 . . . . 0.0 109.587 176.167 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.581 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 13.7 m95 -113.89 162.15 16.73 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.062 -1.024 . . . . 0.0 110.201 176.52 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.533 HG13 ' CB ' ' A' ' 10' ' ' ALA . 1.6 p -130.8 140.24 49.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 O-C-N 121.514 -0.741 . . . . 0.0 110.16 -175.625 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.461 ' HB3' HG22 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -66.95 103.89 1.25 Allowed 'General case' 0 C--N 1.295 -1.795 0 O-C-N 121.095 -1.003 . . . . 0.0 109.46 169.07 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.474 HG13 ' ND1' ' A' ' 44' ' ' HIS . 0.1 OUTLIER -106.58 137.63 36.2 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.816 0 O-C-N 120.537 -1.352 . . . . 0.0 111.414 -178.885 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -132.73 131.66 41.46 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.072 179.703 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 75.9 ttt180 -72.18 139.2 48.11 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.151 -0.968 . . . . 0.0 110.972 -175.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.451 ' HB3' ' HB2' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.493 1.716 0 O-C-N 121.436 -0.79 . . . . 0.0 109.814 176.654 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.528 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.2 t . . . . . 0 N--CA 1.495 1.793 0 CA-C-O 121.731 0.777 . . . . 0.0 111.124 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 -70.02 -34.73 73.66 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.715 -0.615 . . . . 0.0 111.137 176.826 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.528 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -156.56 172.81 34.33 Favored Glycine 0 N--CA 1.498 2.767 0 C-N-CA 118.814 -1.66 . . . . 0.0 110.599 -172.555 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.452 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 12.5 p -117.7 172.35 7.42 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.074 -1.251 . . . . 0.0 111.01 -176.763 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.529 ' CB ' HG11 ' B' ' 82' ' ' VAL . . . -139.95 148.68 42.3 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.654 -0.653 . . . . 0.0 109.518 -178.791 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 37.6 tttt -107.38 115.42 30.12 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.146 -0.971 . . . . 0.0 110.246 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.522 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 11.2 tp -60.03 126.67 28.44 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.058 -1.026 . . . . 0.0 108.956 173.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.587 HG13 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -125.14 -29.51 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.827 0 O-C-N 121.347 -0.846 . . . . 0.0 109.974 -179.366 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.88 142.27 24.29 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 119.089 -1.044 . . . . 0.0 111.52 179.819 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.574 HG12 ' CD2' ' B' ' 24' ' ' HIS . 11.8 mt -105.41 137.15 36.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.065 -1.022 . . . . 0.0 110.137 171.606 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.499 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 86.4 m-20 -113.09 115.99 29.18 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.398 -0.814 . . . . 0.0 109.854 173.536 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -105.83 115.24 29.9 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.895 -1.128 . . . . 0.0 110.754 -176.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . 0.47 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 4.1 mtmt -110.45 127.67 26.62 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.188 -0.945 . . . . 0.0 108.925 171.636 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -52.34 -18.78 8.4 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.763 1.402 . . . . 0.0 110.744 -179.3 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.57 ' ND2' ' N ' ' B' ' 20' ' ' ASN . 0.3 OUTLIER -90.01 -36.22 15.06 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.174 -0.954 . . . . 0.0 108.659 177.044 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.499 ' CD2' ' HB2' ' B' ' 20' ' ' ASN . 81.7 m-85 -150.71 150.2 30.77 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.886 -0.509 . . . . 0.0 109.801 179.263 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . 0.456 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 62.4 ttt180 -97.76 143.85 27.97 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.733 -1.229 . . . . 0.0 109.994 176.499 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.499 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 97.3 m -130.03 140.12 50.91 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.579 -0.7 . . . . 0.0 110.04 -173.335 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.574 ' CD2' HG12 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -129.99 135.94 48.86 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.045 -1.035 . . . . 0.0 111.186 179.179 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.53 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 15.7 t -115.54 134.44 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.09 -1.006 . . . . 0.0 110.687 -178.379 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 30.2 m -119.97 170.02 10.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 C-N-CA 120.46 -0.496 . . . . 0.0 109.957 -179.711 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.502 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 7.6 tt0 -103.51 117.13 33.74 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 121.455 -0.778 . . . . 0.0 108.968 -179.347 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.473 HD21 ' HA ' ' B' ' 33' ' ' LEU . 8.9 tp -82.05 119.77 75.86 Favored Pre-proline 0 C--N 1.294 -1.81 0 O-C-N 121.449 -0.782 . . . . 0.0 109.815 -173.678 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.474 ' HD2' ' HB2' ' B' ' 32' ' ' MET . 22.1 Cg_endo -65.42 179.08 1.75 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 O-C-N 123.829 1.437 . . . . 0.0 111.032 -179.327 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.419 ' OD1' ' C ' ' B' ' 30' ' ' ASP . 50.5 t0 -60.01 -41.26 91.78 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.413 -0.804 . . . . 0.0 111.134 -175.338 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.551 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.36 1.5 56.52 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.971 -1.08 . . . . 0.0 110.804 -174.236 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.551 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 96.4 mmm -110.97 -15.98 13.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.049 -1.032 . . . . 0.0 109.839 171.818 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.532 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 16.6 mt -68.01 -30.49 69.75 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.412 -0.805 . . . . 0.0 110.043 178.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -91.72 127.02 37.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.331 -0.856 . . . . 0.0 110.238 -179.635 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.3 -47.98 1.0 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 177.673 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . 0.443 HD11 HD23 ' B' ' 28' ' ' LEU . 7.4 tt -69.97 145.74 51.62 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.022 -1.281 . . . . 0.0 110.649 -175.758 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . 0.476 ' O ' ' HB3' ' B' ' 40' ' ' ALA . 20.7 pt-20 -150.44 169.99 20.14 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.505 -0.747 . . . . 0.0 109.608 -179.529 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.524 ' CG2' ' HA ' ' B' ' 53' ' ' GLU . 0.0 OUTLIER -67.25 151.09 48.13 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.883 -1.136 . . . . 0.0 110.115 179.996 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.74 -0.09 62.4 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -176.211 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.476 ' HB3' ' O ' ' B' ' 37' ' ' GLU . . . -79.85 158.94 26.63 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.281 -1.129 . . . . 0.0 109.656 177.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 41' ' ' SER . . . . . 0.461 ' HB2' ' HB2' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -100.94 113.24 26.02 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.993 -1.067 . . . . 0.0 110.075 176.7 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.581 ' HB ' ' CE1' ' B' ' 61' ' ' PHE . 2.0 t -104.89 130.02 56.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 121.285 -0.884 . . . . 0.0 109.111 174.764 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.48 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -93.22 119.53 32.5 Favored 'General case' 0 C--N 1.298 -1.645 0 C-N-CA 119.085 -1.046 . . . . 0.0 109.278 172.155 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.567 ' CE1' HG11 ' B' ' 42' ' ' VAL . 0.3 OUTLIER -88.0 107.03 18.53 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.416 -0.802 . . . . 0.0 109.066 178.503 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.51 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.1 t-20 50.44 16.23 0.27 Allowed 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.469 -0.77 . . . . 0.0 111.222 -166.506 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.474 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 120.82 1.23 11.81 Favored Glycine 0 N--CA 1.49 2.298 0 C-N-CA 119.407 -1.378 . . . . 0.0 111.086 171.158 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.538 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 35.1 t -98.92 108.44 21.12 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.188 -1.772 . . . . 0.0 109.379 175.02 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 21.0 p -75.58 126.84 31.8 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.113 -0.992 . . . . 0.0 111.011 -171.172 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.538 ' CD2' ' O ' ' B' ' 47' ' ' CYS . 0.4 OUTLIER -141.44 162.74 34.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.458 -0.776 . . . . 0.0 109.461 172.637 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 50' ' ' THR . . . . . 0.43 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 55.0 m -102.44 152.97 20.5 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 120.612 -1.305 . . . . 0.0 111.037 -171.14 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.541 ' CG1' HG11 ' B' ' 59' ' ' VAL . 34.0 t -76.91 117.55 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.509 -0.745 . . . . 0.0 110.488 -177.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.539 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 40.9 p -70.02 -40.11 75.42 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.087 -1.008 . . . . 0.0 109.691 172.271 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.524 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 52.3 tp10 -164.68 156.14 15.39 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.252 -0.905 . . . . 0.0 110.838 -177.328 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.52 HD11 ' CG2' ' B' ' 38' ' ' THR . 9.0 mt -110.44 130.02 64.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.236 -0.915 . . . . 0.0 110.029 172.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.482 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 63.7 m-80 -104.74 65.45 0.75 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-O 121.445 0.641 . . . . 0.0 109.482 177.823 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.13 -115.04 4.21 Favored Glycine 0 N--CA 1.486 2.005 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 -174.213 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.532 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.01 -21.22 43.85 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.035 -1.273 . . . . 0.0 109.183 176.596 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.587 ' CD2' HG13 ' B' ' 13' ' ' VAL . 9.6 m170 -76.95 159.23 30.12 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.155 -0.966 . . . . 0.0 109.758 -178.036 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.584 HG12 ' CE2' ' B' ' 61' ' ' PHE . 59.5 t -140.83 121.52 13.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 C-N-CA 119.008 -1.077 . . . . 0.0 110.469 171.796 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.53 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 1.2 t -84.42 135.35 34.3 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.468 -0.77 . . . . 0.0 109.368 175.876 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.584 ' CE2' HG12 ' B' ' 59' ' ' VAL . 58.7 m-85 -115.47 158.72 22.15 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.287 -0.883 . . . . 0.0 110.165 179.012 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.539 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 25.1 p-10 -92.25 147.48 22.89 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.08 -1.013 . . . . 0.0 110.876 178.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.523 HD22 ' CD1' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.69 125.09 4.12 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -176.885 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.512 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 56.1 ttm -84.92 146.4 27.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.966 -1.084 . . . . 0.0 109.388 -177.811 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.421 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 71.3 tttt -60.03 -49.14 78.84 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.104 -0.998 . . . . 0.0 109.977 -177.205 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -69.6 -39.99 76.91 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.149 -0.969 . . . . 0.0 110.444 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.512 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 38.5 m -62.26 -38.83 90.8 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.935 -1.103 . . . . 0.0 108.98 174.449 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.518 ' CD1' ' HA2' ' B' ' 74' ' ' GLY . 1.0 OUTLIER -59.9 -47.28 86.43 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.436 -0.79 . . . . 0.0 109.8 177.398 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 74.9 ttt-85 -65.83 -39.99 91.36 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.54 -0.725 . . . . 0.0 110.513 178.173 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.496 HG23 ' N ' ' B' ' 71' ' ' THR . 1.3 tt -64.2 -41.19 91.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.285 -0.885 . . . . 0.0 109.13 -179.381 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.496 ' N ' HG23 ' B' ' 70' ' ' ILE . 20.4 p -89.7 -176.85 5.11 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 120.236 -0.586 . . . . 0.0 109.433 175.602 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.478 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 3.5 t30 -100.0 25.09 7.73 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.079 -1.013 . . . . 0.0 108.307 172.336 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.523 ' CD1' HD22 ' B' ' 63' ' ' LEU . 86.6 mt -67.69 -39.94 84.38 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.995 -1.066 . . . . 0.0 109.945 176.609 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.518 ' HA2' ' CD1' ' B' ' 68' ' ' LEU . . . -54.86 -23.95 32.12 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 110.321 -1.112 . . . . 0.0 110.321 -177.527 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 21.5 p-10 -64.1 -17.02 63.02 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.006 -1.29 . . . . 0.0 110.349 -175.381 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 96.1 mt -60.0 141.41 55.68 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.252 -0.905 . . . . 0.0 110.484 -177.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.472 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 59.8 mmtt -139.93 143.29 36.53 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 121.555 0.693 . . . . 0.0 110.446 175.771 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.565 ' CG2' HG13 ' B' ' 15' ' ' ILE . 36.5 t -63.19 149.47 10.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.22 -176.152 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.48 -13.53 63.64 Favored Glycine 0 N--CA 1.483 1.808 0 N-CA-C 108.818 -1.713 . . . . 0.0 108.818 -175.3 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 46.0 t0 -96.27 162.99 13.27 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.27 -1.135 . . . . 0.0 109.629 175.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 13.6 m95 -113.9 162.05 16.86 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.09 -1.007 . . . . 0.0 110.178 176.598 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.565 HG21 ' CG ' ' B' ' 44' ' ' HIS . 1.5 p -130.78 140.31 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.545 -0.722 . . . . 0.0 110.179 -175.78 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.447 ' OD1' ' N ' ' A' ' 72' ' ' ASN . 0.2 OUTLIER -66.87 103.78 1.21 Allowed 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.115 -0.991 . . . . 0.0 109.549 169.089 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.485 HG11 ' ND1' ' B' ' 44' ' ' HIS . 0.1 OUTLIER -106.48 137.92 34.58 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 120.589 -1.319 . . . . 0.0 111.28 -178.692 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . 0.44 ' HB2' HG22 ' B' ' 6' ' ' VAL . 84.3 tt0 -133.03 131.64 40.91 Favored 'General case' 0 N--CA 1.493 1.7 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.036 179.681 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 75.9 ttt180 -72.11 139.17 48.24 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.25 -0.906 . . . . 0.0 110.955 -175.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.461 ' HB2' ' HB2' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.496 1.847 0 O-C-N 121.389 -0.82 . . . . 0.0 109.749 176.623 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.523 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.9 t . . . . . 0 N--CA 1.493 1.697 0 CA-C-O 121.656 0.741 . . . . 0.0 111.408 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . 0.433 ' HG2' ' HG3' ' A' ' 85' ' ' GLU . 89.5 mm-40 -70.02 -38.59 75.95 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.662 -0.649 . . . . 0.0 110.294 173.349 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.523 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -168.3 -176.52 38.76 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 119.404 -1.379 . . . . 0.0 109.816 -176.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.472 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 1.1 p -120.78 171.83 8.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.96 -1.317 . . . . 0.0 110.859 -177.431 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.537 ' CB ' HG13 ' A' ' 82' ' ' VAL . . . -140.3 149.92 43.38 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.556 -0.715 . . . . 0.0 109.531 -178.221 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.585 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 35.2 tttt -105.52 116.02 31.24 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 120.922 -1.111 . . . . 0.0 110.138 178.597 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.519 ' CG ' ' HA ' ' A' ' 78' ' ' VAL . 12.9 tp -59.83 128.48 37.14 Favored 'General case' 0 C--N 1.297 -1.703 0 O-C-N 120.863 -1.148 . . . . 0.0 108.69 172.558 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.629 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.6 p -129.41 -29.3 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.291 -177.839 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.68 142.36 26.66 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 118.948 -1.101 . . . . 0.0 111.534 179.368 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.578 HG13 ' CG2' ' A' ' 78' ' ' VAL . 10.9 mt -107.81 135.71 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.037 -1.039 . . . . 0.0 110.174 171.653 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.47 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 83.5 m-20 -110.14 114.56 28.15 Favored 'General case' 0 C--N 1.295 -1.769 0 O-C-N 121.308 -0.87 . . . . 0.0 110.272 173.909 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -101.91 109.6 21.38 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.175 -0.953 . . . . 0.0 110.421 -178.231 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.472 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.4 mtpt -103.87 134.54 19.67 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.056 -1.028 . . . . 0.0 109.424 175.272 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.58 -18.31 8.26 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 O-C-N 123.995 1.524 . . . . 0.0 110.802 -179.616 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.575 ' O ' ' CD1' ' A' ' 21' ' ' PHE . 0.3 OUTLIER -99.28 -32.77 11.03 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.143 -0.973 . . . . 0.0 109.138 -179.906 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.575 ' CD1' ' O ' ' A' ' 20' ' ' ASN . 56.3 m-85 -150.48 150.21 31.0 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.835 -0.54 . . . . 0.0 110.144 -175.747 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.461 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 56.1 ttt180 -94.02 143.33 26.45 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.639 -1.288 . . . . 0.0 110.055 173.14 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.47 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 44.5 m -129.99 139.22 51.09 Favored 'General case' 0 C--N 1.296 -1.743 0 O-C-N 121.564 -0.71 . . . . 0.0 109.818 -175.315 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.545 ' CD2' HG12 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.0 135.46 48.32 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.862 -1.149 . . . . 0.0 111.312 179.377 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.521 ' CG2' ' OG ' ' A' ' 60' ' ' SER . 4.8 t -117.47 131.91 68.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.085 -1.01 . . . . 0.0 110.731 -176.791 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 7.0 m -113.63 172.32 3.52 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.94 -0.475 . . . . 0.0 110.061 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.552 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 7.1 tt0 -105.34 117.27 33.59 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.427 -0.795 . . . . 0.0 108.948 178.567 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.519 ' HB3' ' CD2' ' A' ' 33' ' ' LEU . 9.0 tp -83.55 121.05 76.32 Favored Pre-proline 0 C--N 1.296 -1.751 0 O-C-N 121.632 -0.668 . . . . 0.0 109.943 -172.888 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.464 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 25.1 Cg_endo -66.27 176.0 4.4 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 O-C-N 123.9 1.474 . . . . 0.0 111.007 -179.372 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.441 ' HA ' HD12 ' A' ' 33' ' ' LEU . 51.2 t0 -60.07 -39.97 87.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.424 -0.798 . . . . 0.0 111.049 -175.177 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.578 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.08 0.35 57.18 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.939 -1.1 . . . . 0.0 110.785 -174.917 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.578 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 98.0 mmm -113.06 -11.03 13.4 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.959 -1.088 . . . . 0.0 110.053 172.328 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.53 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 15.7 mt -69.98 -32.32 70.46 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.304 -0.872 . . . . 0.0 109.923 177.629 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -79.91 139.91 36.92 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.512 -0.742 . . . . 0.0 111.009 -176.156 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.01 -38.43 3.17 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 120.024 -1.084 . . . . 0.0 110.645 171.786 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 64.7 tp -77.99 147.72 34.74 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.787 -1.42 . . . . 0.0 111.102 -174.015 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.464 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 20.6 pt-20 -149.23 170.04 19.39 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.459 -0.775 . . . . 0.0 109.322 175.216 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.533 ' CG2' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -62.96 151.94 38.1 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.931 -1.106 . . . . 0.0 110.027 -178.688 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.24 -3.48 62.11 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -176.225 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.464 ' HB1' ' O ' ' A' ' 37' ' ' GLU . . . -77.1 158.72 30.3 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.242 -1.152 . . . . 0.0 109.491 176.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.47 ' HB2' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -100.97 110.05 22.04 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.901 -1.124 . . . . 0.0 110.045 178.567 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.583 HG13 ' CE1' ' A' ' 44' ' ' HIS . 2.0 t -98.99 129.94 48.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 121.212 -0.93 . . . . 0.0 109.155 174.782 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.478 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -95.51 119.95 34.9 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 119.244 -0.982 . . . . 0.0 109.227 172.093 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.583 ' CE1' HG13 ' A' ' 42' ' ' VAL . 0.6 OUTLIER -88.25 106.97 18.56 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 177.789 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.495 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 55.33 13.76 0.96 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.329 -0.857 . . . . 0.0 110.91 -167.326 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 117.56 -0.5 18.23 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 119.508 -1.329 . . . . 0.0 110.615 172.797 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.524 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 36.6 t -93.54 105.59 17.63 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.477 -1.602 . . . . 0.0 109.423 175.728 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 25.0 p -73.73 129.44 37.92 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.193 -0.942 . . . . 0.0 111.183 -170.747 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.536 ' CD1' ' HB3' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -145.39 160.57 41.36 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 172.841 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 21.3 m -96.3 152.95 18.1 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.534 -1.354 . . . . 0.0 111.175 -170.095 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.551 ' CG1' HG12 ' A' ' 59' ' ' VAL . 21.2 t -76.96 112.11 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.775 -0.578 . . . . 0.0 110.037 178.695 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.543 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 33.9 p -69.39 -40.05 77.61 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.119 -0.988 . . . . 0.0 109.556 173.757 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.511 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -160.59 156.13 25.21 Favored 'General case' 0 N--CA 1.49 1.557 0 C-N-CA 119.383 -0.927 . . . . 0.0 110.895 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.533 HD11 ' CG2' ' A' ' 38' ' ' THR . 7.8 mt -109.97 130.47 63.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.211 -0.931 . . . . 0.0 109.73 172.598 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.47 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 46.6 m-80 -104.45 65.03 0.76 Allowed 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 119.822 -0.751 . . . . 0.0 109.567 178.13 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.46 -114.91 4.42 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 -173.609 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.53 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.02 -19.74 47.0 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.078 -1.248 . . . . 0.0 109.119 176.645 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.629 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 9.8 m170 -76.61 159.0 30.66 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.256 -0.903 . . . . 0.0 110.061 -178.663 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.637 ' CG1' ' CZ ' ' A' ' 61' ' ' PHE . 54.0 t -141.45 122.52 12.97 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 O-C-N 121.01 -1.056 . . . . 0.0 111.029 173.655 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.521 ' OG ' ' CG2' ' A' ' 25' ' ' VAL . 17.4 m -91.83 127.48 37.31 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.655 -0.653 . . . . 0.0 109.897 179.581 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.637 ' CZ ' ' CG1' ' A' ' 59' ' ' VAL . 54.4 m-85 -111.59 160.81 16.85 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.869 -1.145 . . . . 0.0 110.243 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.543 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 38.1 p-10 -92.01 148.63 22.05 Favored 'General case' 0 N--CA 1.496 1.858 0 CA-C-O 122.065 0.936 . . . . 0.0 111.321 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.527 ' CD2' HD12 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -156.01 118.55 4.13 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 -177.304 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.508 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 74.3 mmm -73.0 142.73 47.74 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.937 -1.102 . . . . 0.0 109.514 179.088 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.474 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 38.5 tttp -60.0 -44.9 94.24 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.007 -1.058 . . . . 0.0 110.091 -177.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.449 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.6 tt0 -70.04 -39.95 75.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.01 -1.056 . . . . 0.0 110.105 179.109 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.508 ' HB ' ' HB2' ' A' ' 64' ' ' MET . 93.8 m -60.05 -39.37 85.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.923 -1.111 . . . . 0.0 109.286 172.31 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.535 ' CD1' ' HA2' ' A' ' 74' ' ' GLY . 9.3 tp -59.95 -44.95 94.07 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.199 -0.938 . . . . 0.0 109.348 -179.638 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 61.0 ttt180 -69.93 -39.92 75.83 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.517 -0.739 . . . . 0.0 110.686 175.528 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.452 HG23 HG22 ' A' ' 71' ' ' THR . 1.4 tt -66.85 -42.61 89.35 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 O-C-N 121.164 -0.96 . . . . 0.0 109.386 -176.289 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.472 HG22 ' O ' ' A' ' 67' ' ' THR . 43.6 p -84.74 -174.1 5.09 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 175.642 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.472 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 6.7 t30 -102.17 24.02 10.78 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 170.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.451 HD11 ' SG ' ' A' ' 47' ' ' CYS . 98.0 mt -69.98 -40.04 75.57 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.136 -0.978 . . . . 0.0 109.734 176.455 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.535 ' HA2' ' CD1' ' A' ' 68' ' ' LEU . . . -49.55 -22.91 4.24 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.381 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 25.6 p-10 -63.61 -19.33 64.76 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.014 -1.286 . . . . 0.0 110.357 -175.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.514 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.4 mt -61.33 140.43 58.0 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.148 -0.97 . . . . 0.0 110.962 -176.769 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.497 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 22.8 mttm -141.44 139.35 33.36 Favored 'General case' 0 C--N 1.296 -1.726 0 CA-C-O 121.479 0.657 . . . . 0.0 109.559 174.356 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.578 ' CG2' HG13 ' A' ' 15' ' ' ILE . 44.0 t -60.93 151.46 6.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 O-C-N 120.924 -1.11 . . . . 0.0 110.327 -176.338 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.97 -14.66 61.35 Favored Glycine 0 N--CA 1.482 1.746 0 N-CA-C 108.751 -1.739 . . . . 0.0 108.751 -175.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -98.16 167.12 11.07 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.31 -1.112 . . . . 0.0 109.626 175.311 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.585 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.5 m95 -115.37 156.72 25.02 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.104 -0.997 . . . . 0.0 110.134 177.092 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.537 HG13 ' CB ' ' A' ' 10' ' ' ALA . 0.9 OUTLIER -120.13 155.15 23.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 O-C-N 121.527 -0.733 . . . . 0.0 109.892 -178.124 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.516 ' N ' HG23 ' A' ' 82' ' ' VAL . 2.5 m-20 -80.02 106.75 12.27 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.21 -0.931 . . . . 0.0 108.988 168.793 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.472 ' CG2' ' C ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -107.25 138.6 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.55 -1.344 . . . . 0.0 111.039 -175.223 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.433 ' HG3' ' HG2' ' A' ' 7' ' ' GLN . 86.4 tt0 -136.83 135.34 37.84 Favored 'General case' 0 N--CA 1.492 1.632 0 C-N-CA 120.381 -0.528 . . . . 0.0 109.752 -178.355 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -78.67 129.92 35.27 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.055 -1.028 . . . . 0.0 110.618 -176.212 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.47 ' HB3' ' HB2' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.567 0 O-C-N 121.401 -0.812 . . . . 0.0 110.199 178.298 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.522 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.9 t . . . . . 0 N--CA 1.493 1.725 0 CA-C-O 121.681 0.753 . . . . 0.0 111.42 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . 0.442 ' HG2' ' HG3' ' B' ' 85' ' ' GLU . 89.6 mm-40 -70.02 -38.31 75.86 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.694 -0.629 . . . . 0.0 110.371 173.437 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.522 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -168.6 -176.65 39.02 Favored Glycine 0 N--CA 1.494 2.556 0 C-N-CA 119.478 -1.344 . . . . 0.0 109.854 -177.013 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.48 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 1.1 p -120.73 171.83 8.32 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.039 -1.271 . . . . 0.0 110.918 -177.401 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.537 ' CB ' HG11 ' B' ' 82' ' ' VAL . . . -140.29 149.94 43.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.533 -0.729 . . . . 0.0 109.444 -178.18 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.587 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 35.3 tttt -105.51 116.13 31.42 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.057 -1.027 . . . . 0.0 110.087 178.531 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.526 ' CG ' ' HA ' ' B' ' 78' ' ' VAL . 12.9 tp -60.03 128.31 36.21 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.971 -1.081 . . . . 0.0 108.781 172.461 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.632 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.6 p -129.12 -29.53 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 C-N-CA 119.565 -0.854 . . . . 0.0 110.296 -177.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.57 142.33 26.74 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 119.072 -1.051 . . . . 0.0 111.501 179.454 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.57 HG13 ' CG2' ' B' ' 78' ' ' VAL . 10.9 mt -107.76 135.84 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.116 -0.99 . . . . 0.0 110.207 171.606 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.483 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.2 m-20 -110.33 114.69 28.35 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.443 -0.785 . . . . 0.0 110.184 173.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -101.91 109.53 21.29 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.099 -1.001 . . . . 0.0 110.443 -178.25 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . 0.467 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.4 mtpt -103.88 134.6 19.63 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.218 -0.926 . . . . 0.0 109.546 175.196 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -52.73 -18.2 8.48 Favored 'Trans proline' 0 C--N 1.303 -1.868 0 O-C-N 123.952 1.501 . . . . 0.0 110.747 -179.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.574 ' O ' ' CD1' ' B' ' 21' ' ' PHE . 0.3 OUTLIER -99.04 -33.46 10.8 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.154 -0.966 . . . . 0.0 109.044 -179.966 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.574 ' CD1' ' O ' ' B' ' 20' ' ' ASN . 56.2 m-85 -149.96 150.31 31.64 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 120.327 -0.549 . . . . 0.0 110.176 -175.634 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . 0.466 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 56.1 ttt180 -94.01 143.42 26.37 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.757 -1.214 . . . . 0.0 110.008 173.101 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.483 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 42.9 m -130.09 139.3 50.97 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.745 -0.597 . . . . 0.0 109.736 -175.367 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.55 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.02 135.64 48.5 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.984 -1.073 . . . . 0.0 111.227 179.347 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.53 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 4.8 t -117.42 131.99 68.52 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.262 -0.899 . . . . 0.0 110.769 -176.822 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.473 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 7.2 m -113.79 172.24 3.62 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 O-C-N 121.909 -0.495 . . . . 0.0 110.025 179.234 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.555 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 7.0 tt0 -105.09 117.32 33.7 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.466 -0.771 . . . . 0.0 109.118 178.413 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.526 ' HB3' ' CD2' ' B' ' 33' ' ' LEU . 8.9 tp -83.51 120.99 76.35 Favored Pre-proline 0 C--N 1.295 -1.779 0 O-C-N 121.555 -0.716 . . . . 0.0 110.028 -172.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.454 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 25.6 Cg_endo -66.16 175.97 4.33 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 O-C-N 123.856 1.45 . . . . 0.0 111.005 -179.41 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.403 ' OD1' ' C ' ' B' ' 30' ' ' ASP . 51.3 t0 -60.02 -40.07 88.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.448 -0.783 . . . . 0.0 111.061 -175.27 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.583 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.02 0.34 57.16 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.884 -1.135 . . . . 0.0 110.851 -174.925 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.583 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 98.0 mmm -113.05 -11.2 13.39 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.105 -0.997 . . . . 0.0 110.053 172.377 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.543 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 15.8 mt -69.89 -32.21 70.41 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.35 -0.844 . . . . 0.0 110.022 177.628 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -80.11 139.96 36.64 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.545 -0.722 . . . . 0.0 110.927 -176.16 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.92 -38.4 3.17 Favored Glycine 0 N--CA 1.493 2.442 0 C-N-CA 119.965 -1.112 . . . . 0.0 110.581 171.799 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . 0.502 ' CD2' HD23 ' B' ' 28' ' ' LEU . 64.5 tp -77.97 147.68 34.8 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.93 -1.335 . . . . 0.0 111.146 -174.101 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . 0.46 ' O ' ' HB1' ' B' ' 40' ' ' ALA . 20.6 pt-20 -149.13 170.03 19.35 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.466 -0.771 . . . . 0.0 109.323 175.269 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.534 ' CG2' HD12 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -62.99 151.79 38.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.932 -1.105 . . . . 0.0 110.071 -178.8 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.34 -3.51 62.37 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -176.159 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.46 ' HB1' ' O ' ' B' ' 37' ' ' GLU . . . -77.18 158.58 30.27 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.184 -1.186 . . . . 0.0 109.446 176.764 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 41' ' ' SER . . . . . 0.462 ' OG ' ' O ' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -100.65 109.84 21.93 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 120.904 -1.123 . . . . 0.0 110.14 178.537 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.572 HG11 ' CE1' ' B' ' 44' ' ' HIS . 2.0 t -99.0 129.9 48.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.284 -0.885 . . . . 0.0 109.171 174.713 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.475 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -95.44 120.01 34.94 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 119.204 -0.999 . . . . 0.0 109.199 172.06 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.572 ' CE1' HG11 ' B' ' 42' ' ' VAL . 0.6 OUTLIER -88.29 106.79 18.45 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.408 -0.807 . . . . 0.0 108.915 177.691 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.495 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 55.5 13.88 1.05 Allowed 'General case' 0 C--N 1.299 -1.597 0 O-C-N 121.333 -0.854 . . . . 0.0 110.888 -167.346 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 117.46 -0.32 18.44 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.513 -1.327 . . . . 0.0 110.612 172.671 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.519 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 36.7 t -93.66 105.59 17.62 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.536 -1.567 . . . . 0.0 109.439 175.67 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 25.1 p -73.65 129.56 38.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.084 -1.01 . . . . 0.0 111.079 -170.707 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.519 ' CD2' ' O ' ' B' ' 47' ' ' CYS . 0.2 OUTLIER -145.61 160.54 41.52 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 172.714 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 21.3 m -96.14 153.05 18.0 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.703 -1.248 . . . . 0.0 111.181 -170.021 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.543 ' CG1' HG11 ' B' ' 59' ' ' VAL . 21.2 t -77.06 112.05 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.652 -0.655 . . . . 0.0 110.126 178.598 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.544 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 34.5 p -69.54 -39.91 77.18 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.168 -0.958 . . . . 0.0 109.462 173.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.511 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -160.64 156.1 25.05 Favored 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.861 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.534 HD12 ' CG2' ' B' ' 38' ' ' THR . 7.8 mt -110.01 130.42 63.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.259 -0.901 . . . . 0.0 109.728 172.651 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.482 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 46.6 m-80 -104.55 65.03 0.76 Allowed 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.575 178.151 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.61 -114.94 4.4 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 108.716 -1.754 . . . . 0.0 108.716 -173.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.543 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.03 -19.66 47.15 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.05 -1.265 . . . . 0.0 109.194 176.645 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.632 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 9.9 m170 -76.6 158.78 30.84 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.359 -0.838 . . . . 0.0 110.096 -178.698 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.645 ' CG1' ' CZ ' ' B' ' 61' ' ' PHE . 54.4 t -141.32 122.64 13.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.967 173.735 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.53 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 17.4 m -91.92 127.56 37.43 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.767 -0.583 . . . . 0.0 109.953 179.554 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.645 ' CZ ' ' CG1' ' B' ' 59' ' ' VAL . 54.4 m-85 -111.55 160.81 16.83 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.056 -1.027 . . . . 0.0 110.314 179.258 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.544 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 38.0 p-10 -92.0 148.66 22.03 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.135 -0.978 . . . . 0.0 111.269 179.805 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.524 ' CD2' HD11 ' B' ' 68' ' ' LEU . 0.0 OUTLIER -156.0 118.48 4.12 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -177.354 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.51 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 74.2 mmm -73.01 142.77 47.72 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.907 -1.12 . . . . 0.0 109.481 179.147 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.473 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 38.5 tttp -59.98 -44.92 94.17 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.091 -1.005 . . . . 0.0 110.075 -177.822 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . 0.454 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 86.6 tt0 -69.99 -40.06 75.52 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.047 -1.033 . . . . 0.0 110.062 179.196 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.51 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 94.2 m -59.96 -39.53 85.92 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.923 -1.111 . . . . 0.0 109.144 172.41 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.529 ' CD1' ' HA2' ' B' ' 74' ' ' GLY . 9.4 tp -60.07 -44.71 94.56 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.428 -0.795 . . . . 0.0 109.436 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 61.1 ttt180 -70.04 -39.92 75.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.498 -0.751 . . . . 0.0 110.673 175.372 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.484 HG22 HG23 ' B' ' 71' ' ' THR . 1.4 tt -66.77 -42.52 89.47 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.263 -0.898 . . . . 0.0 109.421 -176.368 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.484 HG23 HG22 ' B' ' 70' ' ' ILE . 43.8 p -84.74 -173.85 4.95 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 175.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.474 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 6.7 t30 -102.31 24.06 10.82 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 170.855 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.467 ' HB3' HD22 ' B' ' 63' ' ' LEU . 98.0 mt -69.99 -40.1 75.53 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.192 -0.942 . . . . 0.0 109.745 176.403 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.529 ' HA2' ' CD1' ' B' ' 68' ' ' LEU . . . -49.59 -22.91 4.31 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 -179.396 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 25.7 p-10 -63.55 -19.38 64.75 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.031 -1.276 . . . . 0.0 110.374 -175.934 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 97.5 mt -61.27 140.47 57.96 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.199 -0.938 . . . . 0.0 110.915 -176.786 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.498 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 22.8 mttm -141.39 139.38 33.47 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-O 121.336 0.589 . . . . 0.0 109.556 174.322 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.57 ' CG2' HG13 ' B' ' 15' ' ' ILE . 44.2 t -60.95 151.33 6.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 120.93 -1.107 . . . . 0.0 110.315 -176.345 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.96 -14.43 61.95 Favored Glycine 0 N--CA 1.482 1.751 0 N-CA-C 108.781 -1.727 . . . . 0.0 108.781 -175.41 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -98.2 167.09 11.08 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.362 -1.081 . . . . 0.0 109.6 175.207 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.587 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.4 m95 -115.42 156.71 25.09 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.177 -0.952 . . . . 0.0 110.13 177.073 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.537 HG11 ' CB ' ' B' ' 10' ' ' ALA . 0.9 OUTLIER -120.12 155.26 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.532 -0.73 . . . . 0.0 109.955 -178.206 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.469 ' ND2' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -80.05 106.43 12.06 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.243 -0.911 . . . . 0.0 109.03 168.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.48 ' CG2' ' C ' ' B' ' 9' ' ' THR . 0.0 OUTLIER -106.94 138.72 31.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 120.588 -1.32 . . . . 0.0 111.061 -175.145 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . 0.442 ' HG3' ' HG2' ' B' ' 7' ' ' GLN . 86.4 tt0 -137.02 135.36 37.51 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.836 -0.54 . . . . 0.0 109.765 -178.461 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -78.6 130.02 35.45 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.015 -1.053 . . . . 0.0 110.543 -176.155 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.462 ' O ' ' OG ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.493 1.704 0 O-C-N 121.525 -0.734 . . . . 0.0 110.144 178.248 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.531 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.5 t . . . . . 0 N--CA 1.495 1.779 0 CA-C-O 121.55 0.691 . . . . 0.0 110.779 . . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -70.0 -32.63 70.9 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.619 -0.676 . . . . 0.0 110.803 177.419 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.531 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -164.96 177.26 40.53 Favored Glycine 0 N--CA 1.494 2.564 0 C-N-CA 118.767 -1.682 . . . . 0.0 110.485 -174.237 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' THR . . . . . 0.506 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 2.9 p -116.34 167.89 10.62 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.131 -1.217 . . . . 0.0 110.886 -177.871 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' ALA . . . . . 0.492 ' O ' ' HA ' ' A' ' 81' ' ' TRP . . . -137.73 148.46 45.64 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 -176.009 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' LYS . . . . . 0.581 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 25.7 tttt -108.88 115.91 30.98 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.022 -1.049 . . . . 0.0 110.379 -179.333 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.517 HD22 ' N ' ' A' ' 78' ' ' VAL . 12.0 tp -58.7 127.37 31.86 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.077 -1.014 . . . . 0.0 108.89 174.284 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.593 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -125.11 -31.48 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 O-C-N 121.352 -0.843 . . . . 0.0 109.932 -179.679 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.54 144.05 28.23 Favored 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.327 -178.054 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.582 HG12 ' CD2' ' A' ' 24' ' ' HIS . 8.6 mt -108.1 130.08 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.214 -0.929 . . . . 0.0 110.181 172.265 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.483 ' CB ' ' HB ' ' A' ' 23' ' ' THR . 67.3 m-20 -105.66 114.24 28.29 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.318 -0.863 . . . . 0.0 109.768 172.895 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -106.59 108.88 20.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.975 -1.078 . . . . 0.0 110.856 -177.511 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' LYS . . . . . 0.464 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -104.26 128.65 26.63 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.198 -0.939 . . . . 0.0 108.888 173.052 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -50.33 -34.06 39.34 Favored 'Trans proline' 0 C--N 1.303 -1.861 0 O-C-N 123.753 1.396 . . . . 0.0 110.496 -179.601 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' ASN . . . . . 0.531 ' C ' ' CD2' ' A' ' 21' ' ' PHE . 12.4 m-80 -71.57 -39.86 70.32 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.201 -0.937 . . . . 0.0 110.039 175.559 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' PHE . . . . . 0.531 ' CD2' ' C ' ' A' ' 20' ' ' ASN . 89.2 m-85 -152.98 150.25 29.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.399 -0.813 . . . . 0.0 109.973 -179.411 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' ARG . . . . . 0.459 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 62.6 ttt180 -93.27 144.95 24.82 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.732 -1.23 . . . . 0.0 110.124 177.046 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.483 ' HB ' ' CB ' ' A' ' 16' ' ' ASP . 56.8 m -130.31 141.56 50.59 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.48 -0.762 . . . . 0.0 110.09 -176.186 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.582 ' CD2' HG12 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -127.89 144.78 51.09 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 120.974 -1.079 . . . . 0.0 111.342 176.75 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.531 ' CG2' ' OG ' ' A' ' 60' ' ' SER . 4.3 t -124.63 133.55 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.183 -0.948 . . . . 0.0 110.703 -179.27 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.456 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 33.4 m -118.5 172.06 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.796 -0.565 . . . . 0.0 110.425 -179.96 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.457 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 12.9 tt0 -101.14 117.51 35.15 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.594 -0.691 . . . . 0.0 109.318 -179.551 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . 0.527 ' HB3' ' CD2' ' A' ' 33' ' ' LEU . 9.4 tp -82.0 121.26 78.91 Favored Pre-proline 0 C--N 1.297 -1.687 0 O-C-N 121.796 -0.565 . . . . 0.0 109.813 -175.302 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.477 ' HD2' ' HB2' ' A' ' 32' ' ' MET . 25.5 Cg_endo -66.23 179.47 1.95 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 O-C-N 123.863 1.454 . . . . 0.0 110.992 -179.42 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.456 ' HA ' HD12 ' A' ' 33' ' ' LEU . 96.0 m-20 -63.41 -40.0 96.0 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.368 -0.833 . . . . 0.0 111.067 -175.646 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' HIS . . . . . 0.414 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.42 1.09 56.97 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.922 -1.111 . . . . 0.0 111.067 -175.31 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' MET . . . . . 0.477 ' HB2' ' HD2' ' A' ' 29' ' ' PRO . 98.4 mmm -113.92 -13.95 12.51 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.998 -1.064 . . . . 0.0 109.801 172.254 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.536 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 14.0 mt -66.19 -39.85 89.99 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.289 -0.882 . . . . 0.0 109.784 176.57 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -77.19 132.35 38.72 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.496 -0.753 . . . . 0.0 110.586 -177.486 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.51 -43.06 1.87 Allowed Glycine 0 N--CA 1.492 2.391 0 C-N-CA 119.903 -1.141 . . . . 0.0 110.258 174.489 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' LEU . . . . . 0.485 HD12 ' CG2' ' A' ' 42' ' ' VAL . 5.7 tt -69.91 145.7 51.76 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.928 -1.337 . . . . 0.0 110.564 -174.94 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.466 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 20.6 pt-20 -149.98 167.63 26.13 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.524 -0.735 . . . . 0.0 109.416 -179.555 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.534 ' CG2' HD13 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -67.95 149.94 49.13 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.85 -1.156 . . . . 0.0 110.201 -178.114 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.33 -3.61 62.03 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 -173.827 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' ALA . . . . . 0.466 ' HB3' ' O ' ' A' ' 37' ' ' GLU . . . -76.55 159.99 29.85 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.236 -1.155 . . . . 0.0 109.122 174.85 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' SER . . . . . 0.53 ' O ' ' CB ' ' A' ' 87' ' ' ALA . 1.1 p -104.21 117.88 35.3 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 118.72 -1.192 . . . . 0.0 109.897 177.184 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.571 ' CG1' ' CE1' ' A' ' 44' ' ' HIS . 0.9 OUTLIER -99.97 120.09 48.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.363 -0.836 . . . . 0.0 108.956 176.943 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.466 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -82.94 117.33 22.7 Favored 'General case' 0 C--N 1.298 -1.641 0 C-N-CA 119.262 -0.975 . . . . 0.0 109.241 174.495 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' HIS . . . . . 0.571 ' CE1' ' CG1' ' A' ' 42' ' ' VAL . 1.5 m80 -87.24 103.42 15.42 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 176.172 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.4 t-20 55.74 12.05 0.77 Allowed 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.548 -0.72 . . . . 0.0 111.335 -169.483 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.469 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 126.85 -6.13 7.39 Favored Glycine 0 N--CA 1.491 2.362 0 C-N-CA 119.605 -1.283 . . . . 0.0 110.825 173.324 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . 0.517 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 44.8 t -93.31 103.64 15.87 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 120.509 -1.583 . . . . 0.0 109.67 176.038 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.432 ' HA ' ' HA ' ' A' ' 43' ' ' ALA . 16.0 p -72.18 121.91 20.13 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.096 -1.003 . . . . 0.0 110.737 -174.444 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' LEU . . . . . 0.637 ' CD1' ' CD1' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -132.04 160.57 35.53 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.364 -0.835 . . . . 0.0 109.341 173.704 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.404 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 37.2 m -97.72 152.52 19.03 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.439 -1.413 . . . . 0.0 111.436 -169.555 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . 0.532 ' CG1' HG12 ' A' ' 59' ' ' VAL . 19.4 t -81.02 114.62 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.917 -0.489 . . . . 0.0 110.396 -178.953 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 52' ' ' THR . . . . . 0.49 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 31.1 p -69.85 -40.08 76.02 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.294 -0.879 . . . . 0.0 109.705 174.416 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 53' ' ' GLU . . . . . 0.528 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.7 tt0 -161.38 155.64 22.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.437 -0.789 . . . . 0.0 109.909 179.686 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.534 HD13 ' CG2' ' A' ' 38' ' ' THR . 7.1 mt -105.15 128.99 58.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.966 -1.084 . . . . 0.0 109.574 174.613 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 55' ' ' ASN . . . . . 0.507 ' CB ' ' HB2' ' A' ' 58' ' ' HIS . 2.2 m-80 -100.6 62.6 1.05 Allowed 'General case' 0 C--N 1.298 -1.653 0 O-C-N 121.58 -0.7 . . . . 0.0 109.585 -179.014 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.04 -120.05 6.58 Favored Glycine 0 N--CA 1.487 2.054 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 -172.638 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.536 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -71.8 -20.22 61.88 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.931 -1.335 . . . . 0.0 108.981 175.094 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' HIS . . . . . 0.593 ' CD2' HG11 ' A' ' 13' ' ' VAL . 11.8 m170 -76.69 161.3 28.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.425 -0.797 . . . . 0.0 110.386 -176.748 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.532 HG12 ' CG1' ' A' ' 51' ' ' VAL . 54.5 t -140.02 125.52 20.9 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 C-N-CA 119.119 -1.032 . . . . 0.0 110.786 170.66 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' SER . . . . . 0.531 ' OG ' ' CG2' ' A' ' 25' ' ' VAL . 24.8 m -97.61 123.16 41.4 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.763 -0.586 . . . . 0.0 109.509 -179.551 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.637 ' CD1' ' CD1' ' A' ' 49' ' ' LEU . 10.1 p90 -118.32 159.67 22.99 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.822 -1.174 . . . . 0.0 110.72 -179.743 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' ASP . . . . . 0.49 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 35.2 p-10 -93.37 156.56 16.72 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.089 -1.007 . . . . 0.0 111.532 -172.004 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' LEU . . . . . 0.564 ' CD2' ' CD1' ' A' ' 68' ' ' LEU . 0.1 OUTLIER -161.19 101.93 1.25 Allowed 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.705 -0.622 . . . . 0.0 109.607 -174.135 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' MET . . . . . 0.484 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 57.7 ttm -59.97 137.71 58.02 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.787 -1.195 . . . . 0.0 109.09 179.351 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.475 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 28.6 tttt -60.03 -45.91 91.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.977 -1.077 . . . . 0.0 110.614 -172.154 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.0 tp10 -66.15 -40.07 90.29 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.702 -1.248 . . . . 0.0 109.866 177.402 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' THR . . . . . 0.484 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 94.1 m -59.92 -40.01 87.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.087 -1.008 . . . . 0.0 109.573 172.683 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' LEU . . . . . 0.564 ' CD1' ' CD2' ' A' ' 63' ' ' LEU . 28.0 tp -60.02 -43.45 95.26 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.299 -0.876 . . . . 0.0 109.764 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 ttt85 -69.99 -39.09 76.12 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.326 -0.859 . . . . 0.0 110.352 177.765 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.534 ' CG2' HG22 ' A' ' 71' ' ' THR . 1.4 tt -64.78 -42.71 95.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.28 -0.887 . . . . 0.0 109.448 -176.816 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' THR . . . . . 0.534 HG22 ' CG2' ' A' ' 70' ' ' ILE . 30.5 p -81.99 -174.9 5.33 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 120.015 -0.674 . . . . 0.0 109.243 175.471 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.483 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 5.2 t30 -99.52 22.25 11.04 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.174 -0.954 . . . . 0.0 108.511 171.062 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' LEU . . . . . 0.526 ' CD1' HD23 ' A' ' 63' ' ' LEU . 70.6 mt -70.12 -39.97 75.12 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.946 -1.096 . . . . 0.0 109.816 175.602 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 74' ' ' GLY . . . . . 0.446 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -49.31 -21.67 3.03 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -177.943 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 75' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.2 p-10 -66.21 -16.46 64.01 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.068 -1.254 . . . . 0.0 110.562 -175.056 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 76' ' ' LEU . . . . . 0.503 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 96.1 mt -62.07 142.34 57.61 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.209 -0.932 . . . . 0.0 111.173 -175.116 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 77' ' ' LYS . . . . . 0.483 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 86.6 mttt -141.48 141.16 33.65 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.647 -0.658 . . . . 0.0 109.558 172.642 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.55 ' CG2' HG13 ' A' ' 15' ' ' ILE . 16.7 t -59.52 151.72 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 120.711 -1.243 . . . . 0.0 110.297 -176.146 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.79 -13.55 60.64 Favored Glycine 0 N--CA 1.484 1.867 0 N-CA-C 108.948 -1.661 . . . . 0.0 108.948 -176.687 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 53.9 t0 -96.41 162.27 13.56 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.409 -1.054 . . . . 0.0 109.666 177.1 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 81' ' ' TRP . . . . . 0.581 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.0 m95 -113.21 153.33 28.51 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.141 -0.974 . . . . 0.0 110.42 177.369 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.482 HG13 ' HB2' ' A' ' 10' ' ' ALA . 0.8 OUTLIER -119.94 149.72 22.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.409 -0.807 . . . . 0.0 109.804 179.675 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 83' ' ' ASN . . . . . 0.515 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 0.2 OUTLIER -69.6 102.58 1.88 Allowed 'General case' 0 C--N 1.3 -1.556 0 O-C-N 120.952 -1.092 . . . . 0.0 109.012 167.8 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . 0.506 ' CG2' ' C ' ' A' ' 9' ' ' THR . 0.1 OUTLIER -104.59 137.96 31.4 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 O-C-N 120.311 -1.493 . . . . 0.0 110.957 -178.772 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -135.83 138.42 42.51 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.923 -0.711 . . . . 0.0 110.235 -176.192 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 76.4 ttt180 -61.3 127.46 31.63 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.24 -0.912 . . . . 0.0 110.044 -179.916 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.53 ' CB ' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.572 0 O-C-N 121.257 -0.902 . . . . 0.0 109.957 179.937 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 6' ' ' VAL . . . . . 0.532 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.5 t . . . . . 0 N--CA 1.494 1.736 0 CA-C-O 121.608 0.718 . . . . 0.0 110.723 . . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -69.98 -32.52 70.78 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.601 -0.687 . . . . 0.0 110.88 177.382 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 8' ' ' GLY . . . . . 0.532 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -165.05 177.16 40.63 Favored Glycine 0 N--CA 1.496 2.641 0 C-N-CA 118.888 -1.625 . . . . 0.0 110.466 -174.184 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 9' ' ' THR . . . . . 0.508 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 3.0 p -116.3 167.82 10.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.105 -1.232 . . . . 0.0 110.953 -177.852 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 10' ' ' ALA . . . . . 0.497 ' O ' ' HA ' ' B' ' 81' ' ' TRP . . . -137.72 148.58 45.77 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -176.099 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 11' ' ' LYS . . . . . 0.581 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 25.9 tttt -108.96 116.08 31.31 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.148 -0.97 . . . . 0.0 110.249 -179.209 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 12' ' ' LEU . . . . . 0.51 HD21 ' N ' ' B' ' 78' ' ' VAL . 12.1 tp -58.97 127.29 31.46 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.124 -0.985 . . . . 0.0 108.976 174.257 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 13' ' ' VAL . . . . . 0.598 HG12 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -124.89 -31.67 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 C-N-CA 119.593 -0.843 . . . . 0.0 109.904 -179.638 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.35 143.98 28.41 Favored 'General case' 0 C--N 1.297 -1.675 0 C-N-CA 119.27 -0.972 . . . . 0.0 111.451 -178.019 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 15' ' ' ILE . . . . . 0.589 HG12 ' CD2' ' B' ' 24' ' ' HIS . 8.2 mt -108.02 130.18 60.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.264 -0.897 . . . . 0.0 110.232 172.246 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 16' ' ' ASP . . . . . 0.495 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 66.8 m-20 -105.94 114.31 28.38 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.369 -0.832 . . . . 0.0 109.724 172.994 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -106.57 108.82 20.52 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.912 -1.118 . . . . 0.0 110.938 -177.532 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 18' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -104.21 128.63 26.7 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.306 -0.871 . . . . 0.0 108.917 173.058 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -50.44 -34.03 40.09 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 O-C-N 123.789 1.415 . . . . 0.0 110.42 -179.508 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 20' ' ' ASN . . . . . 0.54 ' C ' ' CD2' ' B' ' 21' ' ' PHE . 12.4 m-80 -71.41 -40.25 70.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.131 -0.981 . . . . 0.0 109.985 175.524 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 21' ' ' PHE . . . . . 0.54 ' CD2' ' C ' ' B' ' 20' ' ' ASN . 89.3 m-85 -152.65 150.28 29.31 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.417 -0.802 . . . . 0.0 110.004 -179.327 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 22' ' ' ARG . . . . . 0.481 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 62.6 ttt180 -93.16 144.83 24.9 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.872 -1.143 . . . . 0.0 110.197 176.959 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 23' ' ' THR . . . . . 0.495 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 58.2 m -130.27 141.69 50.59 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.596 -0.69 . . . . 0.0 110.043 -176.305 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 24' ' ' HIS . . . . . 0.589 ' CD2' HG12 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -127.81 144.89 51.07 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.066 -1.021 . . . . 0.0 111.233 176.827 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 25' ' ' VAL . . . . . 0.531 ' CG2' ' OG ' ' B' ' 60' ' ' SER . 4.3 t -124.61 133.68 68.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.292 -0.88 . . . . 0.0 110.717 -179.293 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 26' ' ' VAL . . . . . 0.461 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 33.5 m -118.79 172.09 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 CA-C-O 121.27 0.557 . . . . 0.0 110.412 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 27' ' ' GLU . . . . . 0.457 ' HA ' ' CD2' ' B' ' 58' ' ' HIS . 13.1 tt0 -101.1 117.6 35.34 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.603 -0.686 . . . . 0.0 109.235 -179.473 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 28' ' ' LEU . . . . . 0.525 ' HB3' ' CD2' ' B' ' 33' ' ' LEU . 9.4 tp -82.01 121.27 78.89 Favored Pre-proline 0 C--N 1.297 -1.681 0 O-C-N 121.639 -0.663 . . . . 0.0 109.86 -175.401 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 29' ' ' PRO . . . . . 0.469 ' HG3' ' O ' ' B' ' 9' ' ' THR . 25.7 Cg_endo -66.24 179.59 1.9 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 123.913 1.48 . . . . 0.0 110.955 -179.399 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 30' ' ' ASP . . . . . 0.461 ' HA ' HD12 ' B' ' 33' ' ' LEU . 96.0 m-20 -63.48 -40.03 96.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.304 -0.873 . . . . 0.0 111.06 -175.662 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 31' ' ' HIS . . . . . 0.418 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.33 0.95 57.03 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.858 -1.151 . . . . 0.0 111.067 -175.253 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 32' ' ' MET . . . . . 0.469 ' O ' HD21 ' B' ' 28' ' ' LEU . 98.4 mmm -113.87 -13.93 12.54 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.945 -1.097 . . . . 0.0 109.799 172.305 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 33' ' ' LEU . . . . . 0.535 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 14.0 mt -66.15 -39.92 90.18 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.32 -0.862 . . . . 0.0 109.76 176.534 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -77.06 132.4 38.89 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.481 -0.762 . . . . 0.0 110.584 -177.487 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.37 -43.04 1.88 Allowed Glycine 0 N--CA 1.491 2.359 0 N-CA-C 110.306 -1.117 . . . . 0.0 110.306 174.512 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 36' ' ' LEU . . . . . 0.412 HD21 ' N ' ' B' ' 37' ' ' GLU . 5.7 tt -69.91 145.71 51.76 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.942 -1.328 . . . . 0.0 110.557 -174.949 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 37' ' ' GLU . . . . . 0.464 ' HA ' HD13 ' B' ' 54' ' ' ILE . 20.6 pt-20 -150.03 167.6 26.28 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.47 -0.769 . . . . 0.0 109.381 -179.56 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 38' ' ' THR . . . . . 0.54 ' CG2' HD12 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -67.92 149.81 49.33 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.864 -1.148 . . . . 0.0 110.237 -178.125 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.35 -3.46 62.61 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -173.813 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 40' ' ' ALA . . . . . 0.46 ' HB2' ' O ' ' B' ' 37' ' ' GLU . . . -76.74 160.04 29.66 Favored 'General case' 0 N--CA 1.486 1.375 0 O-C-N 121.218 -1.166 . . . . 0.0 109.129 174.742 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 41' ' ' SER . . . . . 0.527 ' O ' ' CB ' ' B' ' 87' ' ' ALA . 1.2 p -103.97 117.72 34.98 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 120.82 -1.175 . . . . 0.0 109.981 177.221 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 42' ' ' VAL . . . . . 0.581 HG12 ' CE1' ' B' ' 44' ' ' HIS . 0.9 OUTLIER -100.03 120.18 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.355 -0.841 . . . . 0.0 108.965 176.934 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 43' ' ' ALA . . . . . 0.474 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -82.89 117.28 22.63 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.247 -0.981 . . . . 0.0 109.316 174.474 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 44' ' ' HIS . . . . . 0.581 ' CE1' HG12 ' B' ' 42' ' ' VAL . 1.4 m80 -87.27 103.19 15.21 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.624 -0.831 . . . . 0.0 108.818 176.232 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.5 t-20 56.07 11.97 0.85 Allowed 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.677 -0.639 . . . . 0.0 111.239 -169.622 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 46' ' ' GLY . . . . . 0.469 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 126.73 -5.74 7.47 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 119.679 -1.248 . . . . 0.0 110.845 173.213 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 47' ' ' CYS . . . . . 0.521 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 44.9 t -93.49 103.63 15.81 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.477 -1.602 . . . . 0.0 109.618 175.922 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 48' ' ' CYS . . . . . 0.433 ' HA ' ' HA ' ' B' ' 43' ' ' ALA . 14.8 p -72.14 122.07 20.37 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.117 -0.989 . . . . 0.0 110.617 -174.449 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 49' ' ' LEU . . . . . 0.638 ' CD1' ' CD1' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -132.21 160.53 35.86 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.461 -0.774 . . . . 0.0 109.283 173.568 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 50' ' ' THR . . . . . 0.411 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 37.5 m -97.53 152.59 18.86 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.42 -1.425 . . . . 0.0 111.464 -169.531 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 51' ' ' VAL . . . . . 0.537 ' CG1' HG13 ' B' ' 59' ' ' VAL . 20.0 t -81.18 114.76 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.795 -0.566 . . . . 0.0 110.389 -178.973 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 52' ' ' THR . . . . . 0.533 HG21 ' HB3' ' B' ' 62' ' ' ASP . 31.4 p -69.97 -40.03 75.63 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.152 -0.967 . . . . 0.0 109.739 174.575 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 53' ' ' GLU . . . . . 0.526 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.6 tt0 -161.49 155.63 22.38 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.416 -0.803 . . . . 0.0 109.804 179.634 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 54' ' ' ILE . . . . . 0.54 HD12 ' CG2' ' B' ' 38' ' ' THR . 7.1 mt -105.11 128.94 58.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.113 -0.992 . . . . 0.0 109.592 174.698 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 55' ' ' ASN . . . . . 0.501 ' CB ' ' HB2' ' B' ' 58' ' ' HIS . 2.2 m-80 -100.57 62.61 1.05 Allowed 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 119.878 -0.729 . . . . 0.0 109.55 -178.988 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.19 -120.08 6.51 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 108.657 -1.777 . . . . 0.0 108.657 -172.716 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 57' ' ' ASN . . . . . 0.535 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -71.8 -20.17 61.89 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 120.97 -1.312 . . . . 0.0 109.109 175.031 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 58' ' ' HIS . . . . . 0.598 ' CD2' HG12 ' B' ' 13' ' ' VAL . 11.8 m170 -76.68 161.22 28.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.421 -0.799 . . . . 0.0 110.432 -176.851 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 59' ' ' VAL . . . . . 0.537 HG13 ' CG1' ' B' ' 51' ' ' VAL . 54.8 t -140.04 125.53 20.82 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 C-N-CA 119.042 -1.063 . . . . 0.0 110.723 170.794 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 60' ' ' SER . . . . . 0.531 ' OG ' ' CG2' ' B' ' 25' ' ' VAL . 24.4 m -97.54 123.42 41.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.75 -0.594 . . . . 0.0 109.513 -179.573 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 61' ' ' PHE . . . . . 0.638 ' CD1' ' CD1' ' B' ' 49' ' ' LEU . 10.0 p90 -118.65 159.65 23.23 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 120.822 -1.174 . . . . 0.0 110.533 -179.655 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 62' ' ' ASP . . . . . 0.533 ' HB3' HG21 ' B' ' 52' ' ' THR . 35.2 p-10 -93.36 156.55 16.72 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.075 -1.016 . . . . 0.0 111.459 -171.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 63' ' ' LEU . . . . . 0.569 ' CD2' ' CD1' ' B' ' 68' ' ' LEU . 0.1 OUTLIER -161.11 102.12 1.26 Allowed 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 120.258 -0.577 . . . . 0.0 109.447 -174.235 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 64' ' ' MET . . . . . 0.486 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 57.6 ttm -60.07 137.64 58.05 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.707 -1.245 . . . . 0.0 109.068 179.266 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 65' ' ' LYS . . . . . 0.474 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 28.6 tttt -59.96 -45.93 91.06 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.91 -1.119 . . . . 0.0 110.63 -172.197 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 54.0 tp10 -66.21 -40.02 90.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.723 -1.236 . . . . 0.0 109.837 177.452 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 67' ' ' THR . . . . . 0.502 ' O ' HG22 ' B' ' 71' ' ' THR . 94.4 m -59.97 -40.03 87.69 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.036 -1.04 . . . . 0.0 109.512 172.657 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 68' ' ' LEU . . . . . 0.569 ' CD1' ' CD2' ' B' ' 63' ' ' LEU . 27.9 tp -60.05 -43.29 95.49 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.374 -0.829 . . . . 0.0 109.823 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 ttt85 -69.99 -39.26 76.02 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.318 -0.864 . . . . 0.0 110.364 177.751 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 70' ' ' ILE . . . . . 0.463 HG21 ' O ' ' B' ' 67' ' ' THR . 1.4 tt -64.56 -42.62 95.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.278 -0.889 . . . . 0.0 109.583 -176.903 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 71' ' ' THR . . . . . 0.502 HG22 ' O ' ' B' ' 67' ' ' THR . 30.5 p -82.06 -174.94 5.37 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.955 -0.698 . . . . 0.0 109.317 175.4 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 72' ' ' ASN . . . . . 0.472 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 5.2 t30 -99.38 22.17 11.03 Favored 'General case' 0 C--N 1.295 -1.77 0 O-C-N 121.141 -0.974 . . . . 0.0 108.534 171.074 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 73' ' ' LEU . . . . . 0.526 ' CD1' HD21 ' B' ' 63' ' ' LEU . 71.5 mt -70.03 -39.99 75.44 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.991 -1.068 . . . . 0.0 109.897 175.62 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 74' ' ' GLY . . . . . 0.454 ' HA2' HD13 ' B' ' 68' ' ' LEU . . . -49.38 -21.6 3.07 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 110.316 -1.113 . . . . 0.0 110.316 -177.954 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.2 p-10 -66.32 -16.31 63.94 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.127 -1.219 . . . . 0.0 110.525 -175.052 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 96.2 mt -62.26 142.36 57.76 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.291 -0.88 . . . . 0.0 111.189 -175.109 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 77' ' ' LYS . . . . . 0.485 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 86.6 mttt -141.46 141.1 33.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.669 -0.645 . . . . 0.0 109.563 172.661 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 78' ' ' VAL . . . . . 0.535 ' CG2' HG13 ' B' ' 15' ' ' ILE . 16.7 t -59.42 151.63 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 120.812 -1.18 . . . . 0.0 110.245 -176.134 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.83 -13.44 60.98 Favored Glycine 0 N--CA 1.484 1.882 0 N-CA-C 108.887 -1.685 . . . . 0.0 108.887 -176.8 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 80' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 53.7 t0 -96.5 162.16 13.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.397 -1.061 . . . . 0.0 109.666 177.029 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 81' ' ' TRP . . . . . 0.581 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.0 m95 -113.13 153.32 28.42 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.103 -0.998 . . . . 0.0 110.372 177.532 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 82' ' ' VAL . . . . . 0.466 HG12 ' HB2' ' B' ' 10' ' ' ALA . 0.8 OUTLIER -120.01 149.75 22.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.553 -0.717 . . . . 0.0 109.858 179.553 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 83' ' ' ASN . . . . . 0.508 ' HB3' ' CG2' ' B' ' 6' ' ' VAL . 0.2 OUTLIER -69.53 102.41 1.82 Allowed 'General case' 0 C--N 1.298 -1.633 0 O-C-N 120.975 -1.078 . . . . 0.0 109.091 167.783 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . 0.508 ' CG2' ' C ' ' B' ' 9' ' ' THR . 0.1 OUTLIER -104.45 138.17 30.31 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 O-C-N 120.422 -1.424 . . . . 0.0 110.862 -178.611 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -136.12 138.38 41.98 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 119.982 -0.687 . . . . 0.0 110.234 -176.277 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 76.5 ttt180 -61.26 127.53 31.98 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.153 -0.967 . . . . 0.0 109.941 -179.8 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 87' ' ' ALA . . . . . 0.527 ' CB ' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.197 -0.939 . . . . 0.0 109.99 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.476 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 32.7 mtt . . . . . 0 N--CA 1.494 1.743 0 CA-C-O 121.063 0.458 . . . . 0.0 110.135 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.586 ' CD2' ' HB2' ' B' ' 87' ' ' ALA . 8.2 p90 179.98 139.5 0.13 Allowed 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 -178.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.528 ' CB ' HG12 ' A' ' 5' ' ' ILE . 14.7 p -126.42 -35.32 2.39 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 120.927 -1.108 . . . . 0.0 109.678 -175.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.494 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 58.38 17.27 31.6 Favored Glycine 0 N--CA 1.485 1.95 0 N-CA-C 108.986 -1.646 . . . . 0.0 108.986 -179.286 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.528 HG12 ' CB ' ' A' ' 3' ' ' THR . 19.2 mm -88.94 134.43 28.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.382 -1.07 . . . . 0.0 109.693 -175.714 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.541 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.3 t -103.5 139.96 23.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 120.969 -1.082 . . . . 0.0 111.026 -168.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -59.98 -40.02 87.7 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.574 -0.704 . . . . 0.0 110.56 174.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.541 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -170.66 -176.95 40.37 Favored Glycine 0 N--CA 1.495 2.588 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.118 -174.634 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.48 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 21.4 p -117.58 169.83 9.24 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.872 -1.37 . . . . 0.0 111.13 -175.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.525 ' CB ' ' CG1' ' A' ' 82' ' ' VAL . . . -135.13 147.8 49.58 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.684 -0.635 . . . . 0.0 109.356 -179.033 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 34.0 tttt -103.57 115.74 31.07 Favored 'General case' 0 C--N 1.293 -1.856 0 O-C-N 121.046 -1.034 . . . . 0.0 110.269 -179.583 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.518 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 12.0 tp -59.87 126.45 27.62 Favored 'General case' 0 C--N 1.298 -1.653 0 O-C-N 120.892 -1.13 . . . . 0.0 108.823 172.736 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.601 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -126.91 -29.02 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 O-C-N 121.438 -0.789 . . . . 0.0 110.017 -179.094 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.04 141.91 26.88 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 119.058 -1.057 . . . . 0.0 111.606 -178.748 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.584 HG12 ' CD2' ' A' ' 24' ' ' HIS . 14.2 mt -109.08 130.52 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.052 -1.03 . . . . 0.0 110.206 170.786 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.479 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 81.6 m-20 -107.71 115.46 30.19 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.291 -0.88 . . . . 0.0 109.963 174.121 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -104.21 114.4 28.61 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.969 -1.082 . . . . 0.0 110.591 -176.412 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.472 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.0 OUTLIER -113.67 128.97 25.14 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.141 -0.974 . . . . 0.0 109.203 175.343 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.1 Cg_endo -52.37 -18.37 7.84 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 O-C-N 123.831 1.437 . . . . 0.0 110.944 -179.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.587 ' ND2' ' N ' ' A' ' 20' ' ' ASN . 0.3 OUTLIER -92.3 -33.54 14.58 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.135 -0.978 . . . . 0.0 108.939 178.309 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.545 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 84.1 m-85 -156.16 150.24 25.33 Favored 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.358 0.599 . . . . 0.0 110.14 179.792 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.452 ' NH1' ' CD2' ' A' ' 68' ' ' LEU . 60.1 ttt180 -90.89 144.24 25.89 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 120.744 -1.223 . . . . 0.0 109.775 175.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.479 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 85.0 m -129.17 137.69 51.31 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.472 -0.767 . . . . 0.0 109.822 -177.09 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.584 ' CD2' HG12 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.25 137.04 49.81 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 120.967 -1.083 . . . . 0.0 111.141 179.394 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.525 ' CG2' ' OG ' ' A' ' 60' ' ' SER . 15.6 t -119.05 134.91 61.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.037 -1.039 . . . . 0.0 110.641 -177.279 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.465 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 16.9 m -117.13 170.93 6.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 CA-C-O 121.088 0.47 . . . . 0.0 110.112 177.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.574 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 8.7 tt0 -107.42 116.58 32.18 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.486 ' N ' ' ND2' ' A' ' 57' ' ' ASN . 9.3 tp -81.36 128.59 69.59 Favored Pre-proline 0 C--N 1.295 -1.766 0 O-C-N 121.307 -0.87 . . . . 0.0 109.978 -171.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.478 ' HD2' HD12 ' A' ' 28' ' ' LEU . 33.6 Cg_endo -68.0 176.83 4.9 Favored 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.903 1.475 . . . . 0.0 110.88 -179.376 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -60.02 -40.02 87.85 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.255 -0.903 . . . . 0.0 111.261 -174.251 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.568 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.85 0.83 56.81 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.75 -1.219 . . . . 0.0 110.936 -173.912 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.568 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.9 mmm -113.23 -9.63 13.44 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 120.839 -1.163 . . . . 0.0 110.074 170.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.523 ' CD2' ' HB2' ' A' ' 57' ' ' ASN . 19.9 mt -70.02 -23.18 63.08 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.169 -0.957 . . . . 0.0 110.052 176.263 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -94.47 129.94 41.04 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.469 -0.769 . . . . 0.0 110.478 -177.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.98 -43.53 1.71 Allowed Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.909 -1.139 . . . . 0.0 110.396 174.126 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.479 HD11 HD22 ' A' ' 28' ' ' LEU . 7.1 tt -69.94 149.16 48.07 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.836 -1.391 . . . . 0.0 110.855 -174.221 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.458 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 19.3 pt-20 -150.42 170.02 20.06 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.512 -0.742 . . . . 0.0 109.682 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.532 ' CG2' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -65.82 153.51 41.7 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.024 -1.048 . . . . 0.0 110.235 179.779 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.41 -2.15 63.32 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -178.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.46 ' HB2' HG23 ' A' ' 51' ' ' VAL . . . -78.3 158.07 28.98 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.254 -1.145 . . . . 0.0 109.552 176.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -100.31 107.74 19.61 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.026 -1.07 . . . . 0.0 109.876 175.653 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.58 HG13 ' CE1' ' A' ' 44' ' ' HIS . 2.1 t -93.65 133.23 35.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 121.321 -0.862 . . . . 0.0 108.896 173.305 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.467 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -97.98 120.0 37.59 Favored 'General case' 0 C--N 1.295 -1.763 0 C-N-CA 119.109 -1.036 . . . . 0.0 109.107 172.174 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.58 ' CE1' HG13 ' A' ' 42' ' ' VAL . 0.4 OUTLIER -89.7 106.99 18.83 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 178.929 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 54.01 14.12 0.66 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.444 -0.785 . . . . 0.0 111.048 -168.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.483 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 117.87 2.83 16.37 Favored Glycine 0 N--CA 1.489 2.178 0 C-N-CA 119.527 -1.32 . . . . 0.0 110.798 172.559 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.488 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 33.2 t -98.65 109.9 22.58 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.521 -1.576 . . . . 0.0 109.47 174.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.455 ' SG ' ' C7 ' ' A' ' 98' ' ' RBF . 31.0 p -76.8 130.26 37.41 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.978 -1.076 . . . . 0.0 111.182 -170.251 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.529 ' CD1' ' HB3' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -146.54 161.23 40.93 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.573 -0.704 . . . . 0.0 109.333 173.123 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.411 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 22.9 m -100.81 153.02 19.82 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.587 -1.321 . . . . 0.0 111.105 -171.199 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.551 ' CG1' HG13 ' A' ' 59' ' ' VAL . 24.6 t -76.68 113.77 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.839 -0.538 . . . . 0.0 110.186 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.54 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 27.7 p -70.26 -41.55 73.3 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.24 -0.912 . . . . 0.0 109.518 174.146 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.51 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 20.4 pt-20 -160.12 160.09 32.59 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 119.543 -0.863 . . . . 0.0 110.813 176.785 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.532 HD11 ' CG2' ' A' ' 38' ' ' THR . 8.9 mt -110.58 130.05 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.268 -0.895 . . . . 0.0 109.962 173.653 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.462 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 3.2 m-80 -103.33 63.22 0.8 Allowed 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 120.071 -0.652 . . . . 0.0 109.509 179.25 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.36 -117.43 4.79 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 108.961 -1.655 . . . . 0.0 108.961 -173.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.523 ' HB2' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -77.14 -20.63 55.29 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 120.965 -1.314 . . . . 0.0 108.803 175.45 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.601 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 9.1 m170 -75.56 158.7 32.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.28 -0.888 . . . . 0.0 110.141 -177.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.64 ' CG1' ' CZ ' ' A' ' 61' ' ' PHE . 55.1 t -140.41 123.82 17.26 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 C-N-CA 119.143 -1.023 . . . . 0.0 110.674 171.478 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.525 ' OG ' ' CG2' ' A' ' 25' ' ' VAL . 1.1 t -89.82 134.17 34.33 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.391 -0.818 . . . . 0.0 109.381 175.505 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.64 ' CZ ' ' CG1' ' A' ' 59' ' ' VAL . 89.1 m-85 -115.67 159.87 20.79 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.224 -0.922 . . . . 0.0 110.277 175.905 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.54 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 28.3 p-10 -93.02 149.09 21.46 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.187 -0.945 . . . . 0.0 111.129 178.542 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.541 HD21 ' CD1' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -154.18 117.69 4.61 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -175.127 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.515 ' HB2' ' CB ' ' A' ' 67' ' ' THR . 54.1 mtp -70.33 139.38 52.0 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.911 -1.118 . . . . 0.0 109.981 179.149 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.481 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 45.0 tptt -59.93 -49.91 75.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.163 -0.961 . . . . 0.0 110.274 -179.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.441 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.5 tt0 -64.97 -39.99 94.31 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.753 -1.217 . . . . 0.0 109.859 177.245 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.515 ' CB ' ' HB2' ' A' ' 64' ' ' MET . 85.5 m -59.87 -35.67 75.3 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.934 -1.104 . . . . 0.0 109.397 173.066 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.522 HD11 ' CD2' ' A' ' 63' ' ' LEU . 20.0 tp -62.84 -46.71 86.63 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.186 -0.946 . . . . 0.0 109.756 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 71.5 ttt-85 -69.98 -39.17 76.11 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.484 -0.76 . . . . 0.0 110.136 178.134 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.51 HG22 HG22 ' A' ' 71' ' ' THR . 1.1 tt -66.81 -40.02 84.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.366 -0.833 . . . . 0.0 109.337 -179.24 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.51 HG22 HG22 ' A' ' 70' ' ' ILE . 65.0 p -86.26 -173.65 4.66 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 174.244 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.4 t30 -104.18 25.04 10.53 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 170.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.541 ' CD1' HD21 ' A' ' 63' ' ' LEU . 87.9 mt -69.96 -40.0 75.69 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.027 -1.046 . . . . 0.0 110.008 177.298 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.513 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -47.7 -21.93 1.65 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.5 p-10 -67.11 -17.83 65.04 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.938 -1.33 . . . . 0.0 110.823 -174.221 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.0 mt -60.01 142.96 53.02 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.118 -0.989 . . . . 0.0 111.068 -175.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.485 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 54.6 mttp -140.03 139.23 35.93 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.709 -0.619 . . . . 0.0 109.762 174.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.562 ' CG2' HG13 ' A' ' 15' ' ' ILE . 15.8 t -61.02 153.08 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.862 -1.149 . . . . 0.0 110.351 -178.286 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.02 -15.03 58.99 Favored Glycine 0 N--CA 1.483 1.801 0 N-CA-C 108.716 -1.753 . . . . 0.0 108.716 -177.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.417 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 25.1 t0 -96.21 169.5 9.9 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.428 -1.042 . . . . 0.0 109.601 176.478 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.5 m95 -115.97 164.32 14.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.913 -1.117 . . . . 0.0 110.351 175.244 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.525 ' CG1' ' CB ' ' A' ' 10' ' ' ALA . 1.7 p -129.62 144.39 38.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.564 -0.71 . . . . 0.0 109.949 -176.518 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.482 ' HB2' ' HB3' ' B' ' 72' ' ' ASN . 2.6 m-20 -70.95 105.24 3.21 Favored 'General case' 0 C--N 1.293 -1.862 0 O-C-N 121.077 -1.014 . . . . 0.0 109.266 170.543 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.48 ' CG2' ' C ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -108.89 138.92 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 120.535 -1.353 . . . . 0.0 111.153 -176.063 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -137.15 147.02 45.68 Favored 'General case' 0 N--CA 1.495 1.82 0 C-N-CA 120.293 -0.563 . . . . 0.0 110.193 179.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 73.9 ttt-85 -85.22 130.65 34.56 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.232 -0.917 . . . . 0.0 111.309 -174.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.501 ' HB2' ' CZ ' ' B' ' 2' ' ' PHE . . . -122.58 149.65 43.67 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.274 -0.891 . . . . 0.0 110.047 175.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -114.67 136.91 52.54 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.287 -0.883 . . . . 0.0 110.935 -178.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 23.6 mmtp -60.01 -40.06 87.93 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.375 -0.828 . . . . 0.0 110.15 -179.248 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 52.7 p90 -146.33 154.6 41.85 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.312 -0.868 . . . . 0.0 110.389 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 52.7 m -139.97 149.99 43.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.324 -0.86 . . . . 0.0 110.386 179.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -62.38 -43.17 99.45 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.277 -0.89 . . . . 0.0 110.209 176.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.46 ' O ' ' HG3' ' A' ' 93' ' ' GLU . 12.9 pt-20 -158.87 55.77 0.43 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.063 -1.023 . . . . 0.0 110.848 -179.14 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.544 ' O ' ' CG2' ' A' ' 94' ' ' ILE . 16.1 mm 53.1 22.85 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 C-N-CA 119.069 -1.052 . . . . 0.0 108.839 177.236 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -67.08 60.07 0.22 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -179.435 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.486 ' N ' ' O ' ' A' ' 94' ' ' ILE . . . -147.0 122.11 1.53 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.448 ' OXT' ' ND1' ' A' ' 97' ' ' HIS . 31.7 p80 . . . . . 0 N--CA 1.492 1.644 0 O-C-N 121.247 -1.149 . . . . 0.0 110.168 179.027 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 1' ' ' MET . . . . . 0.464 ' O ' ' HB3' ' B' ' 2' ' ' PHE . 96.8 mmm . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 121.077 0.465 . . . . 0.0 110.088 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.579 ' CD1' ' O ' ' B' ' 2' ' ' PHE . 8.2 p90 -179.9 139.57 0.13 Allowed 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.71 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.524 ' CB ' HG12 ' B' ' 5' ' ' ILE . 14.7 p -126.48 -35.4 2.37 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 120.94 -1.1 . . . . 0.0 109.67 -176.055 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.479 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 58.3 17.41 31.58 Favored Glycine 0 N--CA 1.485 1.943 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -179.242 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.524 HG12 ' CB ' ' B' ' 3' ' ' THR . 18.8 mm -88.88 134.32 28.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.335 -1.097 . . . . 0.0 109.68 -175.808 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.542 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.3 t -103.46 140.05 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 120.958 -1.089 . . . . 0.0 111.093 -169.008 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -59.95 -39.91 87.18 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.59 -0.693 . . . . 0.0 110.62 174.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.542 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -170.88 -177.2 40.65 Favored Glycine 0 N--CA 1.495 2.616 0 C-N-CA 119.201 -1.476 . . . . 0.0 110.222 -174.534 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.487 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 21.4 p -117.48 169.8 9.24 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.896 -1.355 . . . . 0.0 111.207 -175.611 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.53 ' CB ' ' CG1' ' B' ' 82' ' ' VAL . . . -135.04 147.96 49.77 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 -179.066 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.588 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 34.0 tttt -103.78 115.84 31.22 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 121.15 -0.969 . . . . 0.0 110.16 -179.535 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.514 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 12.0 tp -59.99 126.31 27.05 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 120.96 -1.088 . . . . 0.0 108.843 172.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.604 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -126.67 -29.15 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.03 -179.087 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.02 141.83 26.82 Favored 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.25 -0.98 . . . . 0.0 111.568 -178.623 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.583 HG12 ' CD2' ' B' ' 24' ' ' HIS . 14.2 mt -108.96 130.64 61.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.046 -1.034 . . . . 0.0 110.232 170.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.49 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 81.0 m-20 -107.98 115.6 30.42 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.369 -0.832 . . . . 0.0 109.746 174.239 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -104.18 114.42 28.65 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.042 -1.037 . . . . 0.0 110.547 -176.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.466 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.0 OUTLIER -113.75 128.9 25.23 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.358 -0.839 . . . . 0.0 109.183 175.353 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.1 Cg_endo -52.37 -18.42 7.93 Favored 'Trans proline' 0 C--N 1.304 -1.809 0 O-C-N 123.858 1.451 . . . . 0.0 110.906 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.564 ' ND2' ' N ' ' B' ' 20' ' ' ASN . 0.3 OUTLIER -92.22 -33.9 14.49 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.06 -1.025 . . . . 0.0 108.769 178.413 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.548 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 84.2 m-85 -155.89 150.25 25.76 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.196 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.453 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 60.0 ttt180 -90.87 144.14 26.0 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.909 -1.12 . . . . 0.0 109.797 175.639 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.49 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 82.7 m -129.14 137.74 51.37 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.539 -0.726 . . . . 0.0 109.826 -177.135 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.583 ' CD2' HG12 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.18 136.94 49.8 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.029 -1.045 . . . . 0.0 111.054 179.573 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.531 ' CG2' ' OG ' ' B' ' 60' ' ' SER . 15.6 t -118.98 135.09 60.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.116 -0.99 . . . . 0.0 110.734 -177.404 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.476 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 17.2 m -117.42 170.91 6.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 C-N-CA 120.444 -0.502 . . . . 0.0 109.99 178.072 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.573 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 8.7 tt0 -107.36 116.53 32.1 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.594 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.485 ' N ' ' ND2' ' B' ' 57' ' ' ASN . 9.3 tp -81.2 128.49 70.4 Favored Pre-proline 0 C--N 1.295 -1.781 0 O-C-N 121.228 -0.92 . . . . 0.0 110.05 -171.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.467 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 33.8 Cg_endo -67.99 176.82 4.9 Favored 'Trans proline' 0 C--N 1.308 -1.567 0 O-C-N 123.9 1.474 . . . . 0.0 110.87 -179.392 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.414 ' HA ' HD11 ' B' ' 33' ' ' LEU . 96.1 m-20 -60.02 -39.99 87.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.314 -0.866 . . . . 0.0 111.255 -174.211 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.574 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.82 0.84 56.78 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.733 -1.229 . . . . 0.0 110.974 -173.949 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.574 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.8 mmm -113.28 -9.57 13.41 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.824 -1.172 . . . . 0.0 110.143 170.918 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.506 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 20.0 mt -69.98 -23.33 63.14 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.232 -0.918 . . . . 0.0 109.994 176.189 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 94.3 m-20 -94.44 129.89 41.01 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.383 -0.823 . . . . 0.0 110.57 -177.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.96 -43.47 1.73 Allowed Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.885 -1.15 . . . . 0.0 110.48 174.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . 0.505 HD21 ' N ' ' B' ' 37' ' ' GLU . 7.2 tt -70.09 149.15 47.92 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.926 -1.338 . . . . 0.0 110.81 -174.216 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.505 ' N ' HD21 ' B' ' 36' ' ' LEU . 19.3 pt-20 -150.39 170.01 20.07 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.515 -0.741 . . . . 0.0 109.738 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.52 ' CG2' HD13 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -65.8 153.38 42.02 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.992 -1.068 . . . . 0.0 110.236 179.832 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.41 -2.06 63.62 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.468 ' HB1' ' O ' ' B' ' 37' ' ' GLU . . . -78.42 157.89 28.87 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.259 -1.142 . . . . 0.0 109.558 176.713 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 41' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -99.97 107.67 19.7 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.894 -1.128 . . . . 0.0 109.994 175.625 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.571 ' HB ' ' CE2' ' B' ' 61' ' ' PHE . 2.1 t -93.66 133.31 35.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.358 -0.839 . . . . 0.0 108.874 173.322 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.465 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -97.99 120.05 37.69 Favored 'General case' 0 C--N 1.296 -1.738 0 C-N-CA 119.162 -1.015 . . . . 0.0 109.055 172.184 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.564 ' CE1' HG12 ' B' ' 42' ' ' VAL . 0.4 OUTLIER -89.75 106.78 18.69 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.427 -0.796 . . . . 0.0 108.994 178.876 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 54.13 14.21 0.7 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.396 -0.815 . . . . 0.0 111.043 -168.537 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.494 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 117.65 3.21 16.58 Favored Glycine 0 N--CA 1.488 2.142 0 C-N-CA 119.545 -1.312 . . . . 0.0 110.823 172.452 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.487 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 33.5 t -98.82 110.02 22.69 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.521 -1.576 . . . . 0.0 109.397 174.702 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . 0.456 ' SG ' ' C7 ' ' B' ' 99' ' ' RBF . 31.2 p -76.82 130.35 37.51 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.032 -1.043 . . . . 0.0 111.184 -170.32 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.528 ' CD1' ' HB3' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -146.7 161.17 41.15 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.62 -0.675 . . . . 0.0 109.304 173.105 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 50' ' ' THR . . . . . 0.424 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 22.9 m -100.69 153.13 19.69 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.722 -1.236 . . . . 0.0 111.06 -171.099 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.553 ' CG1' HG13 ' B' ' 59' ' ' VAL . 24.8 t -76.8 113.74 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.694 -0.629 . . . . 0.0 110.268 -179.55 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.535 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 28.0 p -70.25 -41.55 73.35 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.196 -0.94 . . . . 0.0 109.524 174.262 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.518 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 20.5 pt-20 -160.18 160.04 32.36 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.325 -0.859 . . . . 0.0 110.805 176.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.52 HD13 ' CG2' ' B' ' 38' ' ' THR . 9.0 mt -110.52 130.02 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.307 -0.87 . . . . 0.0 109.945 173.773 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.477 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 3.2 m-80 -103.33 63.13 0.79 Allowed 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 120.018 -0.673 . . . . 0.0 109.524 179.274 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.55 -117.53 4.79 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 108.884 -1.686 . . . . 0.0 108.884 -173.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.506 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -77.04 -20.79 55.47 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.1 -1.235 . . . . 0.0 108.814 175.471 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.604 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 9.2 m170 -75.33 158.51 32.69 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.423 -0.798 . . . . 0.0 110.223 -178.099 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.633 ' CG1' ' CZ ' ' B' ' 61' ' ' PHE . 54.9 t -140.33 123.7 17.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 C-N-CA 119.126 -1.029 . . . . 0.0 110.677 171.593 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.531 ' OG ' ' CG2' ' B' ' 25' ' ' VAL . 1.1 t -89.76 134.31 34.24 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.448 -0.783 . . . . 0.0 109.406 175.501 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.633 ' CZ ' ' CG1' ' B' ' 59' ' ' VAL . 89.2 m-85 -115.74 159.89 20.81 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.213 175.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.535 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 28.3 p-10 -92.96 149.15 21.43 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.163 -0.961 . . . . 0.0 111.059 178.539 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.528 HD21 ' CD1' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -154.28 117.77 4.59 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -175.23 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.523 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 54.3 mtp -70.4 139.42 51.87 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.989 -1.07 . . . . 0.0 110.042 179.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.479 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 45.1 tptt -59.92 -49.88 75.95 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.188 -0.945 . . . . 0.0 110.328 -179.567 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . 0.453 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 86.5 tt0 -64.88 -40.0 94.43 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.868 -1.145 . . . . 0.0 109.953 177.17 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.523 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 85.0 m -60.05 -35.79 75.9 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.942 -1.099 . . . . 0.0 109.328 173.172 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.525 HD13 ' CD2' ' B' ' 63' ' ' LEU . 19.8 tp -62.61 -46.64 87.36 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.226 -0.921 . . . . 0.0 109.85 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 71.5 ttt-85 -70.07 -39.24 75.74 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.474 -0.766 . . . . 0.0 110.075 178.156 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.488 HG23 HG23 ' B' ' 71' ' ' THR . 1.1 tt -66.78 -40.04 85.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.466 -0.771 . . . . 0.0 109.302 -179.228 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.488 HG23 HG23 ' B' ' 70' ' ' ILE . 65.9 p -86.21 -173.53 4.6 Favored 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 120.035 -0.666 . . . . 0.0 109.324 174.265 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.482 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 4.4 t30 -104.32 25.21 10.41 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 170.244 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.528 ' CD1' HD21 ' B' ' 63' ' ' LEU . 87.6 mt -70.06 -39.97 75.36 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.02 -1.05 . . . . 0.0 109.985 177.223 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.499 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -47.92 -21.68 1.73 Allowed Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 -179.408 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.6 p-10 -67.18 -17.8 64.99 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.911 -1.347 . . . . 0.0 110.792 -174.279 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.507 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 97.0 mt -59.97 142.9 53.01 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.139 -0.976 . . . . 0.0 111.045 -175.596 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.486 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 54.6 mttp -140.01 139.28 35.97 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.652 -0.655 . . . . 0.0 109.768 174.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.555 ' CG2' HG13 ' B' ' 15' ' ' ILE . 15.9 t -61.13 153.06 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.964 -1.085 . . . . 0.0 110.322 -178.176 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.01 -14.82 59.54 Favored Glycine 0 N--CA 1.484 1.88 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.425 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 25.0 t0 -96.31 169.4 9.96 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.463 -1.022 . . . . 0.0 109.626 176.326 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.588 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.5 m95 -116.05 164.18 14.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.996 -1.065 . . . . 0.0 110.327 175.33 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.53 ' CG1' ' CB ' ' B' ' 10' ' ' ALA . 1.6 p -129.46 144.49 37.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.613 -0.679 . . . . 0.0 110.031 -176.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.449 ' HB2' ' HB3' ' A' ' 72' ' ' ASN . 2.5 m-20 -70.91 105.08 3.14 Favored 'General case' 0 C--N 1.292 -1.892 0 O-C-N 121.164 -0.96 . . . . 0.0 109.301 170.512 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.487 ' CG2' ' C ' ' B' ' 9' ' ' THR . 0.0 OUTLIER -108.84 138.93 33.52 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 120.614 -1.304 . . . . 0.0 111.099 -175.972 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -137.15 147.05 45.7 Favored 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.19 179.385 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 74.0 ttt-85 -85.16 130.7 34.56 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.175 -0.953 . . . . 0.0 111.278 -174.619 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.586 ' HB2' ' CD2' ' A' ' 2' ' ' PHE . . . -122.71 149.81 43.57 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.376 -0.827 . . . . 0.0 110.001 175.76 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -114.92 136.82 52.69 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.287 -0.883 . . . . 0.0 110.869 -177.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 23.7 mmtp -59.98 -40.03 87.74 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.404 -0.81 . . . . 0.0 110.174 -179.179 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 52.8 p90 -146.31 154.56 41.82 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.266 -0.896 . . . . 0.0 110.389 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 91' ' ' SER . . . . . . . . . . . . . 53.1 m -140.02 149.97 43.84 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.43 -0.794 . . . . 0.0 110.402 179.415 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . 0.474 ' O ' ' HB2' ' B' ' 93' ' ' GLU . 96.0 m-20 -62.07 -39.98 94.27 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.214 -0.929 . . . . 0.0 110.02 176.538 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . 0.474 ' HB2' ' O ' ' B' ' 92' ' ' ASP . 98.9 mt-10 55.87 54.55 7.97 Favored 'General case' 0 N--CA 1.506 2.375 0 C-N-CA 120.102 -0.639 . . . . 0.0 110.549 176.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . . . . . . . . . 27.1 mm -60.03 -39.97 81.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.312 -0.868 . . . . 0.0 109.829 175.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 139.88 -69.36 0.47 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 179.039 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . 51.81 -141.91 22.66 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 179.461 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 70.5 t60 . . . . . 0 N--CA 1.492 1.643 0 O-C-N 121.247 -1.149 . . . . 0.0 110.203 -179.56 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.468 HC2' ' HC9' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.479 ' HC9' HC2' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.421 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 74.0 mtm . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.383 0.611 . . . . 0.0 110.61 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.593 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 5.0 p90 -176.32 139.98 0.37 Allowed 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 174.288 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.484 ' HB ' HG12 ' A' ' 5' ' ' ILE . 17.1 p -130.06 -39.56 1.37 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.873 -1.142 . . . . 0.0 108.833 -178.143 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.502 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 55.09 20.1 18.94 Favored Glycine 0 N--CA 1.482 1.753 0 N-CA-C 108.602 -1.799 . . . . 0.0 108.602 -178.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.484 HG12 ' HB ' ' A' ' 3' ' ' THR . 36.7 mm -81.16 114.37 22.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.317 -1.108 . . . . 0.0 110.106 -175.399 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.53 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 1.3 t -79.43 131.61 33.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.252 -0.905 . . . . 0.0 110.061 -176.635 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.508 ' OE1' ' NH1' ' A' ' 86' ' ' ARG . 97.2 mt-30 -70.24 -30.03 66.98 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.492 -0.755 . . . . 0.0 111.405 -178.495 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.53 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -148.44 176.13 27.39 Favored Glycine 0 N--CA 1.495 2.579 0 C-N-CA 118.687 -1.721 . . . . 0.0 110.271 -173.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.463 ' O ' ' HG3' ' A' ' 29' ' ' PRO . 2.9 p -123.28 171.3 9.49 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.153 -1.204 . . . . 0.0 110.574 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.536 ' CB ' HG12 ' A' ' 82' ' ' VAL . . . -141.11 150.07 42.37 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.46 -0.775 . . . . 0.0 109.401 -175.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 26.3 tttt -111.53 116.23 30.52 Favored 'General case' 0 C--N 1.297 -1.704 0 O-C-N 121.059 -1.025 . . . . 0.0 110.334 179.875 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.5 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 9.9 tp -58.43 124.78 20.74 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.013 -1.054 . . . . 0.0 108.931 173.1 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.633 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.0 OUTLIER -118.24 -29.29 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 O-C-N 121.359 -0.838 . . . . 0.0 109.597 178.751 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.43 149.96 27.37 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.057 -1.057 . . . . 0.0 111.639 -178.381 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.583 HG12 ' CD2' ' A' ' 24' ' ' HIS . 19.5 mt -112.09 132.24 61.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.158 -0.964 . . . . 0.0 109.998 172.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.494 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 86.3 m-20 -108.65 116.12 31.38 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.305 -0.872 . . . . 0.0 109.861 174.786 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -106.13 108.73 20.4 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.064 -1.023 . . . . 0.0 110.534 -176.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.469 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -102.14 128.55 28.24 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.069 -1.019 . . . . 0.0 108.924 172.66 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_endo -50.47 -29.61 24.86 Favored 'Trans proline' 0 C--N 1.303 -1.865 0 O-C-N 123.834 1.439 . . . . 0.0 110.453 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.482 ' C ' ' CG ' ' A' ' 21' ' ' PHE . 12.8 m-80 -77.87 -39.99 41.54 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.181 -0.949 . . . . 0.0 110.021 176.069 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.482 ' CG ' ' C ' ' A' ' 20' ' ' ASN . 51.0 m-85 -151.18 150.23 30.38 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.342 -0.849 . . . . 0.0 109.925 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.464 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 60.0 ttt180 -90.42 145.24 25.09 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.714 -1.241 . . . . 0.0 110.012 176.823 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.494 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 91.5 m -129.64 138.19 51.08 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.429 -0.794 . . . . 0.0 109.941 -177.251 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.583 ' CD2' HG12 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -128.99 136.44 50.34 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 120.91 -1.119 . . . . 0.0 111.085 178.934 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.479 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 8.2 t -120.08 132.63 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.922 -1.111 . . . . 0.0 110.77 -176.55 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.592 HG12 ' CE1' ' A' ' 61' ' ' PHE . 23.2 m -116.9 173.31 4.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 CA-C-O 121.27 0.557 . . . . 0.0 110.341 178.575 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.553 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 9.9 tt0 -106.2 117.91 35.25 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.464 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.526 HD22 ' CD1' ' A' ' 36' ' ' LEU . 9.2 tp -85.54 125.69 68.71 Favored Pre-proline 0 C--N 1.299 -1.624 0 O-C-N 121.403 -0.81 . . . . 0.0 110.3 -171.209 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.47 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 22.2 Cg_endo -66.17 176.37 3.97 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.878 1.462 . . . . 0.0 111.245 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.418 ' OD1' ' O ' ' A' ' 30' ' ' ASP . 47.8 t0 -60.06 -39.9 87.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.336 -0.853 . . . . 0.0 111.183 -175.421 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.585 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.03 0.0 57.35 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.844 -1.16 . . . . 0.0 110.663 -174.937 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.585 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.8 mmm -112.26 -12.34 13.61 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.958 -1.089 . . . . 0.0 109.704 171.502 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.532 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 17.9 mt -69.25 -36.89 77.63 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.4 -0.813 . . . . 0.0 110.069 175.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -82.7 138.9 33.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.438 -0.789 . . . . 0.0 110.778 -177.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.44 -40.73 2.83 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 110.194 -1.163 . . . . 0.0 110.194 174.553 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.526 ' CD1' HD22 ' A' ' 28' ' ' LEU . 8.3 tt -73.28 145.93 45.72 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.053 -1.263 . . . . 0.0 110.631 -176.171 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.46 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 20.9 pt-20 -150.35 167.0 28.33 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.488 -0.757 . . . . 0.0 109.687 179.765 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.532 ' CG2' HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -65.2 152.18 44.28 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.033 -1.042 . . . . 0.0 110.237 -178.123 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.63 -3.87 62.28 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -176.18 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.46 ' HB3' ' O ' ' A' ' 37' ' ' GLU . . . -77.32 155.42 32.01 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.141 -1.211 . . . . 0.0 109.467 176.336 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.469 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -96.82 104.36 16.36 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 119.036 -1.066 . . . . 0.0 109.82 176.831 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.575 HG11 ' CE1' ' A' ' 44' ' ' HIS . 2.1 t -86.06 132.0 33.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 O-C-N 121.24 -0.913 . . . . 0.0 109.139 174.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.523 ' CB ' ' CG ' ' A' ' 85' ' ' GLU . . . -98.78 120.29 38.98 Favored 'General case' 0 C--N 1.296 -1.742 0 C-N-CA 119.408 -0.917 . . . . 0.0 109.262 173.479 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.575 ' CE1' HG11 ' A' ' 42' ' ' VAL . 1.5 m80 -93.08 104.08 16.32 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.593 -0.692 . . . . 0.0 109.268 179.503 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.514 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.3 t-20 55.64 11.29 0.62 Allowed 'General case' 0 C--N 1.298 -1.633 0 O-C-N 121.622 -0.674 . . . . 0.0 111.094 -169.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.494 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.61 1.95 10.73 Favored Glycine 0 N--CA 1.488 2.166 0 C-N-CA 119.796 -1.193 . . . . 0.0 110.818 174.209 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.484 ' HB2' ' OD1' ' B' ' 45' ' ' ASN . 8.6 t -97.22 113.26 24.85 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 120.361 -1.67 . . . . 0.0 109.545 175.494 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.446 ' SG ' ' O ' ' B' ' 3' ' ' THR . 26.4 p -79.86 124.25 28.48 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.119 -0.988 . . . . 0.0 111.191 -170.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.618 ' CD1' ' CD2' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -141.36 163.21 33.55 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.385 -0.822 . . . . 0.0 109.661 172.861 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 57.5 m -102.96 152.08 21.72 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.689 -1.257 . . . . 0.0 111.019 -172.122 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.527 HG13 ' CG1' ' A' ' 59' ' ' VAL . 14.0 t -78.38 114.69 19.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.751 -0.593 . . . . 0.0 110.272 -178.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.52 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 46.1 p -71.29 -44.51 65.07 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.194 -0.941 . . . . 0.0 109.868 175.644 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.52 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -158.33 153.89 26.17 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.199 -0.938 . . . . 0.0 110.336 178.126 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.532 HD12 ' CG2' ' A' ' 38' ' ' THR . 8.0 mt -105.37 130.37 56.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.161 -0.962 . . . . 0.0 109.818 175.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.474 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 12.4 m-80 -102.4 64.25 0.9 Allowed 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.565 -0.71 . . . . 0.0 109.612 179.828 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.54 -113.08 3.93 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -173.029 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.532 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.05 -21.31 43.59 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.066 -1.255 . . . . 0.0 109.293 175.568 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.633 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 9.8 m170 -74.88 159.53 31.76 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.352 -0.842 . . . . 0.0 110.102 -177.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.527 ' CG1' HG13 ' A' ' 51' ' ' VAL . 53.9 t -140.04 122.16 16.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 C-N-CA 119.023 -1.071 . . . . 0.0 110.916 172.162 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.479 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 60.2 p -91.06 129.09 37.09 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.724 -0.61 . . . . 0.0 109.689 177.772 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.618 ' CD2' ' CD1' ' A' ' 49' ' ' LEU . 1.3 p90 -123.14 156.89 34.12 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.964 -1.085 . . . . 0.0 110.61 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.52 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 32.6 p-10 -91.33 152.06 20.61 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.184 -0.948 . . . . 0.0 111.329 -172.658 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.486 ' CD2' HD12 ' A' ' 68' ' ' LEU . 0.1 OUTLIER -155.72 111.84 3.1 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 -175.771 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.505 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 84.2 mmm -65.71 139.86 58.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.877 -1.14 . . . . 0.0 109.232 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.451 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 58.0 tptt -60.0 -44.41 94.56 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.958 -1.089 . . . . 0.0 109.981 -176.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.417 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.0 tt0 -69.01 -40.0 78.97 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.122 -0.986 . . . . 0.0 110.385 178.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.505 ' HB ' ' HB2' ' A' ' 64' ' ' MET . 89.9 m -60.98 -39.99 91.76 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.937 -1.102 . . . . 0.0 109.085 173.25 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.534 ' CD1' ' HA2' ' A' ' 74' ' ' GLY . 5.1 tp -60.01 -46.24 90.15 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.494 -0.753 . . . . 0.0 109.66 178.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 32.5 tpt180 -67.4 -40.11 85.58 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.548 -0.72 . . . . 0.0 110.519 177.587 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.449 HG22 HG22 ' A' ' 71' ' ' THR . 1.3 tt -69.96 -41.56 79.46 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.247 -0.908 . . . . 0.0 109.491 -176.457 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.471 HG22 ' O ' ' A' ' 67' ' ' THR . 61.1 p -84.65 -173.22 4.6 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 178.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.484 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.6 t30 -101.76 23.08 11.84 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 170.834 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.464 ' CD1' HD23 ' A' ' 63' ' ' LEU . 94.1 mt -70.04 -42.31 73.07 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.036 -1.04 . . . . 0.0 109.992 176.114 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.534 ' HA2' ' CD1' ' A' ' 68' ' ' LEU . . . -52.28 -18.93 5.31 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -178.029 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 23.7 p-10 -64.67 -18.32 64.86 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.085 -1.244 . . . . 0.0 110.469 -176.193 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 88.6 mt -59.97 143.23 52.23 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.257 -0.902 . . . . 0.0 110.836 -176.246 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.473 ' O ' HD23 ' A' ' 12' ' ' LEU . 54.6 mttt -142.58 141.25 31.96 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.734 -0.604 . . . . 0.0 109.597 175.658 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.55 ' CG2' HG13 ' A' ' 15' ' ' ILE . 16.9 t -60.75 151.25 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 120.784 -1.198 . . . . 0.0 110.601 -174.51 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.65 -10.97 65.42 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -177.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 47.4 t0 -96.38 163.18 13.17 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.268 -1.137 . . . . 0.0 109.622 176.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.0 m95 -113.41 161.64 17.06 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.072 -1.018 . . . . 0.0 110.263 176.877 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.536 HG12 ' CB ' ' A' ' 10' ' ' ALA . 1.5 p -131.24 149.76 33.66 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 O-C-N 121.522 -0.736 . . . . 0.0 109.847 -176.324 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.527 ' CA ' HG12 ' A' ' 6' ' ' VAL . 2.6 m-20 -75.43 108.02 7.95 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 121.24 -0.912 . . . . 0.0 109.188 170.613 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.467 HG11 ' HB1' ' A' ' 10' ' ' ALA . 0.2 OUTLIER -111.71 145.11 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.52 -1.363 . . . . 0.0 111.501 -175.229 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.523 ' CG ' ' CB ' ' A' ' 43' ' ' ALA . 25.9 pt-20 -144.52 160.02 41.81 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.652 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . 0.508 ' NH1' ' OE1' ' A' ' 7' ' ' GLN . 31.5 ptt-85 -98.27 132.91 43.36 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.024 -1.048 . . . . 0.0 110.979 -174.319 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.507 ' HB3' ' CZ ' ' B' ' 2' ' ' PHE . . . -124.25 148.14 47.57 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.46 -0.775 . . . . 0.0 109.845 177.192 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -139.18 153.38 47.91 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.428 -0.795 . . . . 0.0 110.642 -177.355 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 17.2 mttp -60.06 -39.99 87.92 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.358 -0.839 . . . . 0.0 109.925 175.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.2 p90 -130.82 158.3 40.55 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.393 -0.817 . . . . 0.0 109.952 178.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 19.1 t -150.09 165.64 32.19 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.273 -0.892 . . . . 0.0 110.265 -179.307 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.526 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 96.0 m-20 -59.95 -40.07 87.73 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.228 -0.92 . . . . 0.0 110.14 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.526 ' CG ' ' O ' ' A' ' 92' ' ' ASP . 11.2 pt-20 38.59 51.32 1.69 Allowed 'General case' 0 N--CA 1.512 2.651 0 CA-C-O 121.64 0.733 . . . . 0.0 110.337 178.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.405 HD11 ' HA ' ' A' ' 94' ' ' ILE . 40.8 mm -68.25 -40.07 82.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.333 -0.855 . . . . 0.0 110.08 -179.345 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 45.96 65.6 1.97 Allowed Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 179.296 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -69.28 -157.31 1.39 Allowed Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 178.575 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 13.6 p-80 . . . . . 0 N--CA 1.492 1.633 0 O-C-N 121.187 -1.184 . . . . 0.0 110.242 -179.291 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 1' ' ' MET . . . . . 0.445 ' O ' ' HB3' ' B' ' 2' ' ' PHE . 82.5 mtp . . . . . 0 N--CA 1.495 1.801 0 CA-C-O 121.294 0.568 . . . . 0.0 110.642 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.596 ' CD1' ' O ' ' B' ' 2' ' ' PHE . 5.3 p90 -178.5 140.01 0.19 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 174.186 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.509 ' HB ' HG12 ' B' ' 5' ' ' ILE . 17.0 p -129.98 -39.71 1.38 Allowed 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.854 -1.154 . . . . 0.0 108.776 -178.099 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.475 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 55.2 20.01 19.38 Favored Glycine 0 N--CA 1.483 1.791 0 N-CA-C 108.515 -1.834 . . . . 0.0 108.515 -178.703 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.526 HD12 ' C9 ' ' A' ' 98' ' ' RBF . 37.3 mm -81.15 114.38 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.351 -1.088 . . . . 0.0 109.969 -175.268 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.534 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 1.3 t -79.54 131.68 33.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.362 -0.836 . . . . 0.0 110.003 -176.655 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.514 ' OE1' ' NH1' ' B' ' 86' ' ' ARG . 97.2 mt-30 -70.2 -29.93 66.91 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.497 -0.752 . . . . 0.0 111.483 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.534 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -148.62 175.9 27.67 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 118.91 -1.614 . . . . 0.0 110.386 -173.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.472 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 2.9 p -123.25 171.17 9.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -1.164 . . . . 0.0 110.591 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.544 ' CB ' HG11 ' B' ' 82' ' ' VAL . . . -140.94 150.16 42.78 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.515 -0.741 . . . . 0.0 109.39 -175.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.589 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 26.4 tttt -111.62 116.44 30.81 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.122 -0.986 . . . . 0.0 110.275 179.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.511 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 10.0 tp -58.65 124.87 21.16 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.136 -0.978 . . . . 0.0 108.911 173.133 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.637 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.0 OUTLIER -118.3 -29.08 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 C-N-CA 119.549 -0.86 . . . . 0.0 109.674 178.744 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.58 149.99 27.25 Favored 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 119.115 -1.034 . . . . 0.0 111.539 -178.416 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.586 HG12 ' CD2' ' B' ' 24' ' ' HIS . 19.5 mt -112.1 132.16 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.307 -0.87 . . . . 0.0 110.098 172.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.503 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 86.1 m-20 -108.71 116.23 31.59 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.386 -0.821 . . . . 0.0 109.776 174.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -106.21 108.54 20.1 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.001 -1.062 . . . . 0.0 110.537 -176.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.463 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -102.01 128.48 28.51 Favored Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.167 -0.958 . . . . 0.0 109.022 172.647 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_endo -50.49 -29.63 25.05 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 O-C-N 123.841 1.443 . . . . 0.0 110.465 -179.463 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.473 ' C ' ' CG ' ' B' ' 21' ' ' PHE . 12.6 m-80 -77.7 -40.32 41.73 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.236 -0.915 . . . . 0.0 110.016 176.037 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.473 ' CG ' ' C ' ' B' ' 20' ' ' ASN . 51.4 m-85 -150.94 150.19 30.53 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.409 -0.807 . . . . 0.0 109.9 -179.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.456 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 60.0 ttt180 -90.43 145.12 25.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.74 -1.225 . . . . 0.0 110.063 176.841 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.503 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 92.0 m -129.49 138.36 51.34 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.569 -0.707 . . . . 0.0 109.843 -177.185 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.587 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -129.09 136.57 50.41 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.042 -1.037 . . . . 0.0 110.977 178.901 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.502 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 8.5 t -120.04 132.78 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.119 -0.988 . . . . 0.0 110.711 -176.499 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.583 HG12 ' CE1' ' B' ' 61' ' ' PHE . 23.7 m -117.07 173.25 4.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.815 -0.553 . . . . 0.0 110.318 178.605 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.558 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 9.8 tt0 -105.98 117.89 35.19 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 -179.645 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.475 HD23 ' HA ' ' B' ' 33' ' ' LEU . 9.2 tp -85.58 125.67 68.68 Favored Pre-proline 0 C--N 1.298 -1.666 0 O-C-N 121.318 -0.864 . . . . 0.0 110.251 -171.226 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.475 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 22.1 Cg_endo -66.08 176.36 3.92 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 O-C-N 123.889 1.468 . . . . 0.0 111.196 -179.512 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.415 ' OD1' ' O ' ' B' ' 30' ' ' ASP . 47.8 t0 -60.07 -39.98 87.93 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.338 -0.851 . . . . 0.0 111.135 -175.476 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.574 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.99 0.15 57.26 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.877 -1.139 . . . . 0.0 110.734 -174.928 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.574 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.7 mmm -112.33 -12.38 13.57 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.957 -1.09 . . . . 0.0 109.708 171.552 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.544 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 17.7 mt -69.28 -36.91 77.55 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.346 -0.847 . . . . 0.0 110.032 175.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 72.9 m-20 -82.71 138.96 33.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.438 -0.789 . . . . 0.0 110.8 -177.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.34 -40.61 2.86 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 174.621 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . 0.449 HD12 ' CG2' ' B' ' 42' ' ' VAL . 8.2 tt -73.37 145.95 45.53 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.997 -1.296 . . . . 0.0 110.556 -176.187 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.466 ' O ' ' HB3' ' B' ' 40' ' ' ALA . 20.9 pt-20 -150.34 167.04 28.2 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.44 -0.787 . . . . 0.0 109.674 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.524 ' CG2' HD13 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -65.24 152.16 44.38 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.994 -1.066 . . . . 0.0 110.323 -178.156 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.62 -3.94 62.02 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -176.054 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.466 ' HB3' ' O ' ' B' ' 37' ' ' GLU . . . -77.36 155.2 32.09 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.212 -1.17 . . . . 0.0 109.521 176.262 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.465 ' OG ' ' O ' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -96.54 104.25 16.22 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.893 -1.13 . . . . 0.0 109.873 176.858 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.575 ' CG1' ' CE1' ' B' ' 44' ' ' HIS . 2.1 t -86.07 131.97 33.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.224 -0.923 . . . . 0.0 109.178 174.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.52 ' CB ' ' CG ' ' B' ' 85' ' ' GLU . . . -98.67 120.33 38.92 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 121.227 -0.921 . . . . 0.0 109.288 173.473 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.575 ' CE1' ' CG1' ' B' ' 42' ' ' VAL . 1.4 m80 -93.1 103.75 16.01 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.502 -0.749 . . . . 0.0 109.365 179.482 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.514 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.3 t-20 55.9 11.48 0.71 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.557 -0.714 . . . . 0.0 110.972 -169.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.502 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 121.41 2.24 10.84 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 119.755 -1.212 . . . . 0.0 110.8 174.048 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.463 ' O ' ' HA ' ' B' ' 43' ' ' ALA . 8.7 t -97.47 113.32 24.99 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 120.327 -1.69 . . . . 0.0 109.543 175.384 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . 0.434 ' SG ' ' O ' ' A' ' 3' ' ' THR . 26.4 p -79.8 124.3 28.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.044 -1.035 . . . . 0.0 111.145 -170.723 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.619 ' CD1' ' CD2' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -141.51 163.34 33.2 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.538 -0.726 . . . . 0.0 109.618 172.77 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 50' ' ' THR . . . . . 0.404 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 57.4 m -102.92 152.18 21.59 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.78 -1.2 . . . . 0.0 110.991 -172.032 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.531 HG13 ' CG1' ' B' ' 59' ' ' VAL . 14.1 t -78.54 114.72 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.749 -0.594 . . . . 0.0 110.323 -178.644 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.519 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 47.0 p -71.32 -44.56 64.9 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.09 -1.006 . . . . 0.0 109.821 175.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.516 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -158.25 153.92 26.38 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.241 -0.912 . . . . 0.0 110.272 178.176 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.524 HD13 ' CG2' ' B' ' 38' ' ' THR . 7.9 mt -105.34 130.32 56.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.117 -0.989 . . . . 0.0 109.825 176.028 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.484 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 12.3 m-80 -102.54 64.32 0.89 Allowed 'General case' 0 C--N 1.297 -1.675 0 C-N-CA 119.865 -0.734 . . . . 0.0 109.608 179.844 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.68 -113.0 3.88 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 108.659 -1.776 . . . . 0.0 108.659 -173.139 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.544 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.1 -21.53 43.19 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.045 -1.268 . . . . 0.0 109.225 175.609 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.637 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 9.9 m170 -74.72 159.46 31.99 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.317 -0.864 . . . . 0.0 110.155 -177.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.531 ' CG1' HG13 ' B' ' 51' ' ' VAL . 54.5 t -140.06 122.19 16.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 C-N-CA 118.903 -1.119 . . . . 0.0 110.867 172.303 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.502 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 60.1 p -91.16 129.23 37.18 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.734 -0.604 . . . . 0.0 109.682 177.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.619 ' CD2' ' CD1' ' B' ' 49' ' ' LEU . 1.3 p90 -123.2 156.94 34.12 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.072 -1.018 . . . . 0.0 110.555 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.519 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 32.7 p-10 -91.28 152.22 20.58 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.097 -1.002 . . . . 0.0 111.224 -172.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.493 ' CD2' HD12 ' B' ' 68' ' ' LEU . 0.1 OUTLIER -155.81 111.91 3.09 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -175.88 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.489 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 84.1 mmm -65.8 139.82 58.35 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.871 -1.143 . . . . 0.0 109.186 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.45 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 57.9 tptt -60.03 -44.27 94.73 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.11 -0.994 . . . . 0.0 109.987 -176.685 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . 0.42 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 85.9 tt0 -69.15 -39.96 78.48 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.171 -0.955 . . . . 0.0 110.302 178.626 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.489 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 90.5 m -61.05 -40.07 92.22 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.899 -1.126 . . . . 0.0 109.019 173.288 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.527 ' CD1' ' HA2' ' B' ' 74' ' ' GLY . 5.1 tp -59.94 -46.08 90.55 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.512 -0.742 . . . . 0.0 109.747 178.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 32.5 tpt180 -67.6 -39.98 84.75 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.612 -0.68 . . . . 0.0 110.506 177.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.465 HG23 HG21 ' B' ' 71' ' ' THR . 1.3 tt -70.0 -41.47 79.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 O-C-N 121.328 -0.858 . . . . 0.0 109.593 -176.544 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.48 HG21 ' O ' ' B' ' 67' ' ' THR . 60.2 p -84.65 -173.16 4.57 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 120.177 -0.609 . . . . 0.0 109.517 178.563 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.48 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 4.5 t30 -101.65 22.98 11.9 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 170.837 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.463 ' CD1' HD23 ' B' ' 63' ' ' LEU . 94.2 mt -69.96 -42.31 73.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.022 -1.049 . . . . 0.0 110.02 176.096 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.527 ' HA2' ' CD1' ' B' ' 68' ' ' LEU . . . -52.34 -18.82 5.31 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -178.025 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 23.7 p-10 -64.78 -18.29 64.95 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.054 -1.262 . . . . 0.0 110.436 -176.217 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.516 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 88.7 mt -59.99 143.24 52.27 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.23 -0.919 . . . . 0.0 110.844 -176.297 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.446 ' O ' HD22 ' B' ' 12' ' ' LEU . 54.6 mttt -142.61 141.22 31.91 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.652 -0.655 . . . . 0.0 109.62 175.723 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.549 ' CG2' HG13 ' B' ' 15' ' ' ILE . 17.2 t -60.85 151.15 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 120.844 -1.16 . . . . 0.0 110.555 -174.408 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.68 -10.82 66.03 Favored Glycine 0 N--CA 1.487 2.07 0 N-CA-C 109.02 -1.632 . . . . 0.0 109.02 -177.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.502 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 47.0 t0 -96.45 163.11 13.19 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.348 -1.089 . . . . 0.0 109.695 176.761 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.589 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.0 m95 -113.38 161.58 17.1 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.056 -1.028 . . . . 0.0 110.284 176.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.555 HG22 ' CD2' ' B' ' 44' ' ' HIS . 1.5 p -131.27 149.92 33.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.575 -0.703 . . . . 0.0 109.801 -176.479 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.529 ' CA ' HG12 ' B' ' 6' ' ' VAL . 2.5 m-20 -75.34 107.79 7.69 Favored 'General case' 0 C--N 1.294 -1.806 0 O-C-N 121.205 -0.934 . . . . 0.0 109.282 170.633 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.474 ' CG1' ' HB1' ' B' ' 10' ' ' ALA . 0.2 OUTLIER -111.65 145.2 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 120.522 -1.361 . . . . 0.0 111.501 -175.121 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . 0.52 ' CG ' ' CB ' ' B' ' 43' ' ' ALA . 25.9 pt-20 -144.6 159.98 41.91 Favored 'General case' 0 N--CA 1.494 1.773 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.691 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . 0.514 ' NH1' ' OE1' ' B' ' 7' ' ' GLN . 31.5 ptt-85 -98.1 132.88 43.25 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.869 -1.145 . . . . 0.0 110.963 -174.28 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 2' ' ' PHE . . . -124.24 148.14 47.56 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.401 -0.812 . . . . 0.0 109.79 177.134 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -139.32 153.29 47.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.457 -0.777 . . . . 0.0 110.58 -177.309 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 17.1 mttp -60.02 -40.01 87.82 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.427 -0.796 . . . . 0.0 109.977 175.455 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 53.1 p90 -130.82 158.34 40.44 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.322 -0.861 . . . . 0.0 109.942 178.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 91' ' ' SER . . . . . . . . . . . . . 19.3 t -150.08 165.8 31.7 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.266 -0.896 . . . . 0.0 110.259 -179.353 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -60.05 -39.6 86.52 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.908 . . . . 0.0 110.078 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 74.8 mm-40 48.06 54.33 10.3 Favored 'General case' 0 N--CA 1.506 2.335 0 O-C-N 121.249 -0.907 . . . . 0.0 110.045 177.431 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . 0.401 HG23 HD13 ' B' ' 94' ' ' ILE . 26.7 mm -60.24 -39.89 82.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.419 -0.801 . . . . 0.0 110.009 178.716 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 54.55 73.53 0.41 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.331 -1.507 . . . . 0.0 109.331 -179.043 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . 0.406 ' O ' ' C ' ' B' ' 97' ' ' HIS . . . 129.75 50.02 0.12 Allowed Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 -177.476 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . 0.406 ' C ' ' O ' ' B' ' 96' ' ' GLY . 74.9 t60 . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.293 -1.122 . . . . 0.0 110.204 -178.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.545 " C2'" ' HC9' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.543 " C2'" ' HC9' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.464 ' HA ' ' O ' ' B' ' 89' ' ' LYS . 72.2 mtm . . . . . 0 N--CA 1.495 1.788 0 CA-C-O 121.357 0.598 . . . . 0.0 110.34 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.584 ' CD1' ' O ' ' B' ' 88' ' ' ALA . 0.7 OUTLIER -173.22 137.84 0.7 Allowed 'General case' 0 C--N 1.306 -1.322 0 O-C-N 121.318 -0.864 . . . . 0.0 109.008 177.698 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.499 ' HB ' HG13 ' A' ' 5' ' ' ILE . 25.8 p -133.72 -31.78 1.16 Allowed 'General case' 0 C--N 1.297 -1.676 0 O-C-N 120.989 -1.069 . . . . 0.0 110.135 -173.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 3' ' ' THR . . . 45.79 25.1 1.44 Allowed Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.056 -1.618 . . . . 0.0 109.056 -174.687 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.499 HG13 ' HB ' ' A' ' 3' ' ' THR . 57.7 mt -84.01 139.98 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.046 -1.267 . . . . 0.0 110.556 -177.287 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.515 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 1.4 t -94.39 138.62 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.423 -0.798 . . . . 0.0 110.418 -176.195 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -69.94 -33.65 72.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.51 -0.744 . . . . 0.0 111.051 178.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.515 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -155.66 172.85 33.77 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.871 -1.633 . . . . 0.0 109.909 -173.675 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.483 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 0.6 OUTLIER -115.2 168.8 9.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.143 -1.21 . . . . 0.0 110.48 -179.496 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.523 ' CB ' HG13 ' A' ' 82' ' ' VAL . . . -135.59 147.82 48.83 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.547 -0.721 . . . . 0.0 109.472 -179.142 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.581 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 29.1 tttt -105.98 115.86 30.96 Favored 'General case' 0 C--N 1.294 -1.829 0 O-C-N 121.121 -0.987 . . . . 0.0 110.247 178.835 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.517 ' CG ' ' HA ' ' A' ' 78' ' ' VAL . 12.1 tp -59.71 128.09 35.24 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 120.89 -1.131 . . . . 0.0 108.653 172.834 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.632 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -128.2 -31.52 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 C-N-CA 119.553 -0.859 . . . . 0.0 110.085 -177.719 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.91 144.71 30.35 Favored 'General case' 0 N--CA 1.495 1.786 0 C-N-CA 118.859 -1.136 . . . . 0.0 111.293 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.573 ' CG1' ' CG2' ' A' ' 78' ' ' VAL . 12.5 mt -109.44 132.99 56.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.245 -0.91 . . . . 0.0 110.351 173.177 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.477 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 79.8 m-20 -110.15 116.22 31.14 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.307 -0.871 . . . . 0.0 109.98 173.125 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -106.54 114.45 28.57 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.007 -1.058 . . . . 0.0 110.567 -178.216 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.467 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.7 mtmt -110.74 132.94 21.35 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.248 -0.907 . . . . 0.0 109.138 175.492 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -50.07 -34.54 38.83 Favored 'Trans proline' 0 C--N 1.301 -1.93 0 O-C-N 123.857 1.451 . . . . 0.0 110.692 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.465 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 12.3 m-80 -74.6 -39.71 62.02 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.149 -0.97 . . . . 0.0 110.076 177.304 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.467 ' O ' ' HB2' ' A' ' 18' ' ' LYS . 96.1 m-85 -154.35 150.16 27.65 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.345 -0.847 . . . . 0.0 110.128 -178.471 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.481 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 59.5 ttt180 -91.71 146.29 23.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.751 -1.218 . . . . 0.0 110.121 176.684 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.477 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 90.4 m -130.0 140.04 50.95 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.408 -0.807 . . . . 0.0 109.927 -175.608 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.561 ' CD2' HG12 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -129.15 136.43 50.18 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.9 -1.125 . . . . 0.0 111.148 177.565 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.508 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 5.8 t -115.78 132.46 65.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.075 -1.016 . . . . 0.0 110.7 -177.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 12.5 m -116.1 170.19 6.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-O 121.111 0.482 . . . . 0.0 110.124 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.453 ' HA ' ' CD2' ' A' ' 58' ' ' HIS . 2.7 tm-20 -101.55 117.8 35.65 Favored 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.322 -0.861 . . . . 0.0 109.23 179.068 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.472 HD21 ' HA ' ' A' ' 33' ' ' LEU . 9.3 tp -82.71 127.27 70.81 Favored Pre-proline 0 C--N 1.298 -1.661 0 O-C-N 121.485 -0.759 . . . . 0.0 110.003 -174.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.47 ' HD2' HD13 ' A' ' 28' ' ' LEU . 25.3 Cg_endo -66.5 -178.5 1.21 Allowed 'Trans proline' 0 C--N 1.308 -1.561 0 O-C-N 123.88 1.463 . . . . 0.0 111.008 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.502 ' OD1' ' N ' ' A' ' 30' ' ' ASP . 22.6 p-10 -65.66 -39.98 91.96 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.413 -0.804 . . . . 0.0 111.016 -177.18 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.581 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.0 0.36 57.15 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.905 -1.122 . . . . 0.0 110.924 -174.557 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.581 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.8 mmm -110.14 -16.02 13.88 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.949 -1.094 . . . . 0.0 109.692 171.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.55 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 13.4 mt -66.13 -32.04 73.25 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.515 -0.74 . . . . 0.0 110.41 178.163 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.419 ' OD1' ' N ' ' A' ' 35' ' ' GLY . 63.7 t0 -80.26 142.93 34.11 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.222 -0.924 . . . . 0.0 110.864 -176.7 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.419 ' N ' ' OD1' ' A' ' 34' ' ' ASP . . . 85.94 -31.77 3.92 Favored Glycine 0 N--CA 1.493 2.443 0 C-N-CA 119.99 -1.1 . . . . 0.0 111.096 170.702 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.422 ' HA ' HD12 ' A' ' 36' ' ' LEU . 57.7 tp -77.45 155.09 31.98 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.708 -1.466 . . . . 0.0 111.111 -173.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.461 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 20.0 pt-20 -153.57 167.84 28.18 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.531 -0.731 . . . . 0.0 109.644 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.529 ' CG2' ' HA ' ' A' ' 53' ' ' GLU . 0.0 OUTLIER -67.8 154.5 41.39 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.876 -1.14 . . . . 0.0 110.111 178.142 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.59 0.3 58.2 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -174.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.461 ' HB3' ' O ' ' A' ' 37' ' ' GLU . . . -79.99 160.22 25.98 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.173 -1.193 . . . . 0.0 109.041 174.407 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.525 ' O ' ' CB ' ' A' ' 87' ' ' ALA . 1.6 p -103.33 118.87 37.74 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 118.294 -1.362 . . . . 0.0 109.692 175.081 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.577 HG13 ' CE1' ' A' ' 44' ' ' HIS . 1.6 t -101.67 125.87 55.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 175.188 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.468 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -87.89 118.58 27.52 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 119.269 -0.972 . . . . 0.0 109.154 174.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.577 ' CE1' HG13 ' A' ' 42' ' ' VAL . 0.7 OUTLIER -91.43 106.08 18.24 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 176.378 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.489 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.6 t-20 55.44 13.41 0.92 Allowed 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.452 -0.78 . . . . 0.0 111.257 -168.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.476 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.56 -6.25 10.63 Favored Glycine 0 N--CA 1.49 2.243 0 C-N-CA 119.459 -1.353 . . . . 0.0 110.999 171.25 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.468 ' O ' ' HA ' ' A' ' 43' ' ' ALA . 32.6 t -89.7 107.58 19.18 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.51 -1.583 . . . . 0.0 109.457 175.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.443 ' SG ' ' O ' ' B' ' 3' ' ' THR . 26.7 p -74.07 123.44 24.39 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.122 -0.986 . . . . 0.0 110.531 -174.13 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.543 ' CB ' ' O4 ' ' A' ' 98' ' ' RBF . 0.4 OUTLIER -138.96 156.53 47.17 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.405 -0.809 . . . . 0.0 109.411 175.196 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.41 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 26.8 m -94.76 156.42 16.39 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 120.489 -1.382 . . . . 0.0 111.315 -169.184 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.544 ' CG1' HG13 ' A' ' 59' ' ' VAL . 16.8 t -82.24 116.06 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.859 -0.525 . . . . 0.0 110.332 -178.055 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.553 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 59.8 p -69.85 -40.03 76.04 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.177 -0.952 . . . . 0.0 109.453 172.561 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.529 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 51.8 tp10 -162.55 156.29 20.69 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.221 -0.992 . . . . 0.0 110.839 -177.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.513 HD12 ' N ' ' A' ' 38' ' ' THR . 7.5 mt -109.98 130.03 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.087 -1.008 . . . . 0.0 109.545 170.699 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.472 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 46.5 m-80 -104.2 62.94 0.74 Allowed 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.603 -0.686 . . . . 0.0 109.493 178.632 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.49 -114.77 4.1 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.809 -1.717 . . . . 0.0 108.809 -172.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.55 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.08 -19.72 46.81 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.042 -1.27 . . . . 0.0 109.038 175.967 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.632 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 9.7 m170 -76.91 159.14 30.24 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.279 -0.888 . . . . 0.0 110.233 -177.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.639 ' CG1' ' CE1' ' A' ' 61' ' ' PHE . 54.0 t -140.42 120.34 12.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.027 -1.046 . . . . 0.0 110.948 173.403 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.508 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 21.3 m -86.02 128.72 34.92 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.57 -0.706 . . . . 0.0 109.729 177.257 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.639 ' CE1' ' CG1' ' A' ' 59' ' ' VAL . 60.2 m-85 -111.37 160.02 17.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.907 -1.12 . . . . 0.0 110.341 178.808 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.553 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 31.8 p-10 -93.36 146.89 23.4 Favored 'General case' 0 N--CA 1.497 1.917 0 CA-C-O 122.099 0.952 . . . . 0.0 111.436 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.553 ' CD2' ' CD1' ' A' ' 68' ' ' LEU . 0.0 OUTLIER -157.39 113.37 2.88 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.459 -176.967 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.487 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 57.0 ttm -69.27 142.39 54.15 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.847 -1.158 . . . . 0.0 109.572 179.116 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.474 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 47.6 tptt -60.05 -46.13 90.57 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.013 -1.054 . . . . 0.0 110.284 -175.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 87.8 tt0 -69.73 -40.09 76.43 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.92 -1.113 . . . . 0.0 110.201 179.358 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.487 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 86.5 m -60.29 -38.34 83.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.931 -1.106 . . . . 0.0 109.228 172.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.553 ' CD1' ' CD2' ' A' ' 63' ' ' LEU . 11.0 tp -60.05 -44.0 94.99 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.368 -0.832 . . . . 0.0 109.375 -179.618 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -68.11 -39.82 82.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.346 -0.846 . . . . 0.0 110.695 174.336 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.468 HG23 HG23 ' A' ' 71' ' ' THR . 1.4 tt -66.3 -41.64 89.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.275 -0.891 . . . . 0.0 109.626 -175.063 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.468 HG23 HG23 ' A' ' 70' ' ' ILE . 50.7 p -83.53 -168.58 2.17 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.709 -0.62 . . . . 0.0 109.606 177.679 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.488 ' HB3' ' HB2' ' B' ' 83' ' ' ASN . 7.1 t30 -104.92 19.6 20.28 Favored 'General case' 0 C--N 1.293 -1.87 0 O-C-N 121.245 -0.909 . . . . 0.0 108.559 168.054 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.457 ' HB3' HD23 ' A' ' 63' ' ' LEU . 81.8 mt -69.98 -40.06 75.55 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.092 -1.005 . . . . 0.0 109.997 175.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.488 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -47.14 -22.68 1.43 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 178.208 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 22.2 p-10 -62.62 -16.25 55.69 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.959 -1.318 . . . . 0.0 110.391 -175.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.518 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 84.4 mt -63.07 146.21 53.75 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.252 -0.905 . . . . 0.0 111.037 -175.129 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.496 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 96.6 mttt -149.21 138.17 21.29 Favored 'General case' 0 N--CA 1.493 1.698 0 CA-C-O 121.461 0.648 . . . . 0.0 109.684 174.182 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.573 ' CG2' ' CG1' ' A' ' 15' ' ' ILE . 17.5 t -61.52 151.86 6.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.843 -1.161 . . . . 0.0 110.51 -175.112 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.03 -14.51 60.38 Favored Glycine 0 N--CA 1.484 1.835 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 -175.279 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.428 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 25.7 t0 -97.82 168.4 10.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.267 -1.137 . . . . 0.0 109.625 176.22 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.581 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.2 m95 -116.64 169.12 9.59 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.079 -1.013 . . . . 0.0 110.045 177.112 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.523 HG13 ' CB ' ' A' ' 10' ' ' ALA . 1.5 p -136.34 147.98 27.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.329 -0.857 . . . . 0.0 109.965 -177.148 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.489 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 2.9 m-20 -73.11 104.36 4.16 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.078 -1.014 . . . . 0.0 109.197 170.06 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.504 HG12 ' CE1' ' A' ' 44' ' ' HIS . 0.1 OUTLIER -107.96 140.26 27.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 120.786 -1.197 . . . . 0.0 111.183 -176.841 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -142.19 140.83 32.49 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.783 -0.573 . . . . 0.0 110.235 -176.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 95.2 mtt180 -60.19 131.62 51.39 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.045 -1.035 . . . . 0.0 109.777 178.648 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.525 ' CB ' ' O ' ' A' ' 41' ' ' SER . . . -126.02 148.87 49.19 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.238 -0.914 . . . . 0.0 109.984 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.55 ' O ' ' CD1' ' B' ' 2' ' ' PHE . . . -147.13 156.36 42.93 Favored 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 120.005 -0.678 . . . . 0.0 110.883 -177.025 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . 0.493 ' HA ' ' CD1' ' B' ' 2' ' ' PHE . 35.1 mttt -60.01 -40.0 87.73 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.559 -0.713 . . . . 0.0 110.139 175.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -129.8 160.96 31.88 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.326 -0.859 . . . . 0.0 110.138 -177.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 77.3 p -59.72 139.15 57.48 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.24 -0.912 . . . . 0.0 110.718 -174.216 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.528 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 95.6 m-20 -106.31 -6.9 18.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.466 -0.772 . . . . 0.0 110.088 176.143 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.528 ' CG ' ' O ' ' A' ' 92' ' ' ASP . 17.0 pt-20 38.92 52.85 1.99 Allowed 'General case' 0 N--CA 1.509 2.498 0 O-C-N 121.603 -0.685 . . . . 0.0 110.893 176.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 42.2 mm -59.98 -48.91 85.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.007 -1.058 . . . . 0.0 109.74 172.375 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 91.96 -48.96 2.75 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 177.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 154.65 -176.08 32.54 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.302 -1.117 . . . . 0.0 110.223 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 28.3 ptm . . . . . 0 N--CA 1.491 1.618 0 CA-C-O 121.178 0.513 . . . . 0.0 110.218 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.55 ' CD1' ' O ' ' A' ' 88' ' ' ALA . 0.8 OUTLIER -166.07 137.78 3.79 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.187 -0.946 . . . . 0.0 109.145 175.935 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.491 ' O ' HG13 ' B' ' 5' ' ' ILE . 25.8 p -133.53 -31.95 1.18 Allowed 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.039 -1.038 . . . . 0.0 110.194 -174.111 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' B' ' 3' ' ' THR . . . 45.97 24.97 1.52 Allowed Glycine 0 N--CA 1.488 2.13 0 N-CA-C 109.038 -1.625 . . . . 0.0 109.038 -174.664 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.491 HG13 ' O ' ' B' ' 3' ' ' THR . 57.5 mt -83.93 140.0 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.11 -1.23 . . . . 0.0 110.597 -177.306 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.531 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 1.5 t -94.35 138.71 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.402 -0.812 . . . . 0.0 110.336 -176.19 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -70.07 -33.5 72.01 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.525 -0.734 . . . . 0.0 111.096 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.531 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -155.79 172.71 33.84 Favored Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.029 -1.558 . . . . 0.0 110.025 -173.684 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.489 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 0.6 OUTLIER -115.18 168.67 9.74 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.203 -1.175 . . . . 0.0 110.537 -179.499 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.501 ' CB ' HG12 ' B' ' 82' ' ' VAL . . . -135.47 148.03 49.09 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.535 -0.728 . . . . 0.0 109.426 -179.245 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.58 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 29.1 tttt -106.13 115.92 31.05 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.163 -0.961 . . . . 0.0 110.191 178.876 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.527 ' CG ' ' HA ' ' B' ' 78' ' ' VAL . 12.1 tp -59.81 128.07 35.11 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.002 -1.061 . . . . 0.0 108.701 172.843 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.627 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -128.08 -31.68 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 C-N-CA 119.586 -0.845 . . . . 0.0 110.141 -177.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.74 144.65 30.47 Favored 'General case' 0 N--CA 1.493 1.687 0 C-N-CA 119.069 -1.052 . . . . 0.0 111.44 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.577 HG13 ' CG2' ' B' ' 78' ' ' VAL . 12.3 mt -109.27 133.03 55.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.19 -0.944 . . . . 0.0 110.479 173.125 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.487 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 79.6 m-20 -110.29 116.34 31.29 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.36 -0.837 . . . . 0.0 109.901 173.18 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -106.57 114.48 28.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.935 -1.103 . . . . 0.0 110.62 -178.269 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.7 mtmt -110.71 132.92 21.35 Favored Pre-proline 0 N--CA 1.493 1.719 0 O-C-N 121.297 -0.877 . . . . 0.0 109.192 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -50.19 -34.53 39.83 Favored 'Trans proline' 0 C--N 1.301 -1.927 0 O-C-N 123.8 1.421 . . . . 0.0 110.703 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.467 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 12.4 m-80 -74.5 -40.13 61.99 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.129 -0.982 . . . . 0.0 109.973 177.259 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.467 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 96.2 m-85 -153.89 150.2 28.13 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.371 -0.831 . . . . 0.0 110.182 -178.428 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.477 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 59.5 ttt180 -91.65 146.22 23.96 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.899 -1.125 . . . . 0.0 110.159 176.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.487 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 91.2 m -129.93 140.0 51.02 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.416 -0.802 . . . . 0.0 110.023 -175.717 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.552 ' CD2' HG12 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -129.03 136.56 50.46 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.998 -1.064 . . . . 0.0 111.16 177.603 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.53 HG21 ' CB ' ' B' ' 60' ' ' SER . 5.7 t -115.76 132.49 65.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.185 -0.947 . . . . 0.0 110.755 -177.373 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 13.0 m -116.3 170.31 6.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.025 179.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.455 ' HA ' ' CD2' ' B' ' 58' ' ' HIS . 2.7 tm-20 -101.57 117.81 35.68 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 121.298 -0.876 . . . . 0.0 109.244 179.071 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.467 HD21 ' HA ' ' B' ' 33' ' ' LEU . 9.3 tp -82.65 127.28 70.9 Favored Pre-proline 0 C--N 1.299 -1.623 0 O-C-N 121.435 -0.791 . . . . 0.0 110.115 -174.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.465 ' HD2' ' HB2' ' B' ' 32' ' ' MET . 24.9 Cg_endo -66.55 -178.53 1.23 Allowed 'Trans proline' 0 C--N 1.307 -1.658 0 O-C-N 123.932 1.491 . . . . 0.0 110.917 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.503 ' HA ' HD12 ' B' ' 33' ' ' LEU . 22.7 p-10 -65.56 -40.01 92.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.335 -0.853 . . . . 0.0 111.089 -177.271 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.567 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.02 0.38 57.14 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.913 -1.117 . . . . 0.0 110.983 -174.641 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.567 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.8 mmm -110.15 -15.98 13.88 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.978 -1.076 . . . . 0.0 109.756 171.593 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.553 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 13.5 mt -66.09 -32.08 73.33 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.462 -0.774 . . . . 0.0 110.453 178.071 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . 0.426 ' OD1' ' N ' ' B' ' 35' ' ' GLY . 63.7 t0 -80.2 142.93 34.23 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.282 -0.887 . . . . 0.0 110.894 -176.741 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . 0.426 ' N ' ' OD1' ' B' ' 34' ' ' ASP . . . 85.9 -31.91 3.88 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 119.92 -1.133 . . . . 0.0 111.092 170.726 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . 0.456 HD22 HD22 ' B' ' 28' ' ' LEU . 57.8 tp -77.39 155.12 32.08 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.669 -1.489 . . . . 0.0 111.131 -173.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.469 ' O ' ' HB2' ' B' ' 40' ' ' ALA . 20.0 pt-20 -153.57 167.92 27.89 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.558 -0.714 . . . . 0.0 109.665 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.528 ' CG2' ' HA ' ' B' ' 53' ' ' GLU . 0.0 OUTLIER -67.96 154.51 41.46 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.953 -1.092 . . . . 0.0 110.157 178.15 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.65 0.31 58.52 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -174.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.469 ' HB2' ' O ' ' B' ' 37' ' ' GLU . . . -80.07 159.96 25.96 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.202 -1.175 . . . . 0.0 109.074 174.271 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.54 ' O ' ' CB ' ' B' ' 87' ' ' ALA . 1.6 p -102.86 118.83 37.7 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.559 -1.338 . . . . 0.0 109.818 175.076 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.575 HG13 ' CE1' ' B' ' 44' ' ' HIS . 1.6 t -101.88 125.98 55.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 175.198 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.459 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -87.99 118.62 27.67 Favored 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.196 -1.002 . . . . 0.0 109.155 174.532 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.575 ' CE1' HG13 ' B' ' 42' ' ' VAL . 0.7 OUTLIER -91.39 105.9 18.11 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 176.374 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.489 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.6 t-20 55.49 13.57 0.98 Allowed 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.423 -0.798 . . . . 0.0 111.266 -169.023 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.476 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.47 -6.1 10.73 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 119.379 -1.391 . . . . 0.0 110.961 171.081 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.459 ' O ' ' HA ' ' B' ' 43' ' ' ALA . 33.0 t -89.82 107.54 19.16 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.549 -1.559 . . . . 0.0 109.413 175.577 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . 0.461 ' SG ' ' O ' ' A' ' 3' ' ' THR . 26.5 p -74.04 123.68 24.82 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.14 -0.975 . . . . 0.0 110.452 -174.129 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.542 ' CB ' ' O4 ' ' B' ' 99' ' ' RBF . 0.4 OUTLIER -139.15 156.54 47.05 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.42 -0.8 . . . . 0.0 109.344 175.141 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 50' ' ' THR . . . . . 0.411 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 26.8 m -94.63 156.44 16.42 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 120.608 -1.308 . . . . 0.0 111.266 -169.107 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.544 ' CG1' HG13 ' B' ' 59' ' ' VAL . 17.0 t -82.35 116.1 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.831 -0.543 . . . . 0.0 110.389 -178.151 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.542 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 60.1 p -69.85 -40.06 76.02 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.133 -0.98 . . . . 0.0 109.458 172.631 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.528 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 51.8 tp10 -162.58 156.25 20.58 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.384 -0.926 . . . . 0.0 110.827 -177.589 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.497 HD12 ' N ' ' B' ' 38' ' ' THR . 7.5 mt -110.0 129.98 63.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.14 -0.975 . . . . 0.0 109.535 170.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.487 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 46.5 m-80 -104.2 62.85 0.74 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.624 -0.673 . . . . 0.0 109.539 178.672 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.6 -114.74 4.08 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 -172.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.553 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.06 -19.76 46.79 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.948 -1.325 . . . . 0.0 109.102 175.947 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.627 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 9.7 m170 -76.91 158.97 30.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.337 -0.852 . . . . 0.0 110.263 -177.784 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.633 ' CG1' ' CE1' ' B' ' 61' ' ' PHE . 53.9 t -140.35 120.36 13.02 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 C-N-CA 119.104 -1.038 . . . . 0.0 110.921 173.542 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.53 ' CB ' HG21 ' B' ' 25' ' ' VAL . 21.8 m -85.99 128.83 34.93 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.648 -0.658 . . . . 0.0 109.751 177.293 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.633 ' CE1' ' CG1' ' B' ' 59' ' ' VAL . 60.4 m-85 -111.45 160.05 17.49 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.931 -1.106 . . . . 0.0 110.343 178.77 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.542 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 31.6 p-10 -93.44 146.89 23.43 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.08 -1.012 . . . . 0.0 111.317 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.557 ' CD2' ' CD1' ' B' ' 68' ' ' LEU . 0.0 OUTLIER -157.37 113.44 2.89 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 -177.033 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.49 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 56.9 ttm -69.25 142.37 54.19 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.877 -1.139 . . . . 0.0 109.61 179.012 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.474 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 47.6 tptt -59.91 -46.19 90.13 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.107 -0.995 . . . . 0.0 110.341 -175.771 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 87.8 tt0 -69.81 -40.04 76.18 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.971 -1.08 . . . . 0.0 110.123 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.49 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 87.1 m -60.29 -38.46 83.66 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.915 -1.115 . . . . 0.0 109.191 173.026 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.557 ' CD1' ' CD2' ' B' ' 63' ' ' LEU . 11.1 tp -60.04 -43.71 95.15 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.52 -0.738 . . . . 0.0 109.45 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -68.31 -39.81 81.91 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.304 -0.872 . . . . 0.0 110.598 174.314 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.485 HG21 ' N ' ' B' ' 71' ' ' THR . 1.4 tt -66.38 -41.56 89.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.571 -174.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.485 ' N ' HG21 ' B' ' 70' ' ' ILE . 51.3 p -83.51 -168.5 2.13 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.113 -0.635 . . . . 0.0 109.634 177.703 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.462 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 7.2 t30 -104.93 19.59 20.29 Favored 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 168.042 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.471 ' HB3' HD22 ' B' ' 63' ' ' LEU . 81.5 mt -69.96 -40.07 75.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.005 -1.059 . . . . 0.0 109.931 175.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.486 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -47.28 -22.58 1.52 Allowed Glycine 0 N--CA 1.487 2.051 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 178.354 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 22.3 p-10 -62.64 -16.24 55.82 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.045 -1.268 . . . . 0.0 110.349 -175.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.516 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 84.2 mt -63.22 146.14 54.02 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.309 -0.87 . . . . 0.0 111.046 -175.085 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.498 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 96.6 mttt -149.03 138.34 21.61 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.781 -0.575 . . . . 0.0 109.647 174.172 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.577 ' CG2' HG13 ' B' ' 15' ' ' ILE . 17.3 t -61.56 151.92 6.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.051 -1.031 . . . . 0.0 110.479 -175.127 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.89 -14.24 60.86 Favored Glycine 0 N--CA 1.483 1.777 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 -175.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.408 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 25.5 t0 -97.89 168.41 10.32 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.413 -1.051 . . . . 0.0 109.645 176.056 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.58 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.3 m95 -116.64 168.91 9.76 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.973 -1.079 . . . . 0.0 110.144 177.119 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.501 HG12 ' CB ' ' B' ' 10' ' ' ALA . 1.5 p -136.25 148.06 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.494 -0.754 . . . . 0.0 110.006 -177.295 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.488 ' HB2' ' HB3' ' A' ' 72' ' ' ASN . 2.8 m-20 -73.08 104.2 4.09 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.082 -1.011 . . . . 0.0 109.243 170.106 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.496 HG12 ' CE1' ' B' ' 44' ' ' HIS . 0.1 OUTLIER -107.81 140.6 25.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 120.843 -1.161 . . . . 0.0 110.99 -176.664 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -142.49 140.81 32.0 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.762 -0.586 . . . . 0.0 110.183 -176.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 95.3 mtt180 -60.29 131.69 51.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.113 -0.992 . . . . 0.0 109.77 178.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.54 ' CB ' ' O ' ' B' ' 41' ' ' SER . . . -126.0 149.09 49.07 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.331 -0.856 . . . . 0.0 110.114 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . 0.584 ' O ' ' CD1' ' A' ' 2' ' ' PHE . . . -147.5 156.08 42.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.513 -0.742 . . . . 0.0 110.79 -176.66 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . 0.516 ' HA ' ' CD1' ' A' ' 2' ' ' PHE . 35.1 mttt -59.96 -40.03 87.65 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.614 -0.679 . . . . 0.0 110.185 175.64 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -129.74 160.93 31.88 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.26 -0.9 . . . . 0.0 110.087 -177.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 91' ' ' SER . . . . . 0.508 ' OG ' ' CD1' ' B' ' 94' ' ' ILE . 77.3 p -59.72 139.28 57.38 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.19 -0.943 . . . . 0.0 110.672 -174.247 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -106.53 -11.92 15.76 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.347 -0.845 . . . . 0.0 110.084 176.215 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -113.93 54.11 0.76 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.242 -0.911 . . . . 0.0 110.135 -178.016 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . 0.508 ' CD1' ' OG ' ' B' ' 91' ' ' SER . 23.0 mm -60.03 -39.97 81.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.338 -0.851 . . . . 0.0 110.078 178.311 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 49.8 70.85 0.71 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 -176.293 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . 160.39 -179.97 35.56 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 -179.151 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 38.5 m-70 . . . . . 0 N--CA 1.493 1.68 0 O-C-N 121.214 -1.168 . . . . 0.0 110.249 179.603 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.547 " C2'" ' HC9' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.554 " C2'" ' HC9' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.461 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 25.0 ptp . . . . . 0 N--CA 1.494 1.728 0 CA-C-O 121.227 0.537 . . . . 0.0 110.29 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.576 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 5.6 p90 -179.33 138.73 0.14 Allowed 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 179.091 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.475 ' HB ' HG13 ' A' ' 5' ' ' ILE . 20.8 p -125.76 -36.61 2.39 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 120.838 -1.164 . . . . 0.0 110.234 -173.617 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.46 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 57.6 17.7 27.86 Favored Glycine 0 N--CA 1.486 2.011 0 N-CA-C 108.849 -1.7 . . . . 0.0 108.849 -177.155 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.475 HG13 ' HB ' ' A' ' 3' ' ' THR . 26.5 mt -88.6 117.04 31.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.289 -1.124 . . . . 0.0 109.533 -177.376 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.535 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 3.7 t -86.94 144.05 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.116 -0.99 . . . . 0.0 110.817 -172.793 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 94.3 mm-40 -69.94 -33.2 71.81 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.603 -0.686 . . . . 0.0 110.556 175.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -168.87 174.52 43.45 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.104 -1.522 . . . . 0.0 109.87 -176.58 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.493 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 41.5 p -114.58 170.01 8.63 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.065 -1.256 . . . . 0.0 110.772 -177.598 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.516 ' CB ' HG13 ' A' ' 82' ' ' VAL . . . -135.53 149.93 49.6 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.572 -0.705 . . . . 0.0 109.577 -175.721 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.59 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.0 tttt -105.71 116.77 32.51 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.142 -0.974 . . . . 0.0 110.337 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.501 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 11.5 tp -60.02 127.12 30.33 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 120.898 -1.126 . . . . 0.0 108.825 172.383 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.636 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -125.57 -31.45 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.876 0 O-C-N 121.405 -0.81 . . . . 0.0 109.983 -179.495 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.2 144.6 29.04 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.027 -1.069 . . . . 0.0 111.237 -179.243 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.578 HG23 ' CD2' ' A' ' 24' ' ' HIS . 13.4 mt -108.53 135.64 46.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.162 -0.961 . . . . 0.0 110.032 172.027 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.486 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 84.0 m-20 -109.35 114.88 28.93 Favored 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.289 -0.882 . . . . 0.0 109.867 174.732 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -105.67 114.25 28.3 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.994 -1.067 . . . . 0.0 110.587 -175.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.448 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.1 mtmt -111.46 127.78 26.37 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.18 -0.95 . . . . 0.0 108.993 174.285 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -50.99 -24.06 13.31 Favored 'Trans proline' 0 C--N 1.303 -1.859 0 O-C-N 123.824 1.434 . . . . 0.0 110.254 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.543 ' C ' ' CD2' ' A' ' 21' ' ' PHE . 11.4 m-80 -80.15 -42.5 23.33 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.251 -0.905 . . . . 0.0 109.985 175.243 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.543 ' CD2' ' C ' ' A' ' 20' ' ' ASN . 97.5 m-85 -153.97 150.32 28.18 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.4 -0.812 . . . . 0.0 109.977 -178.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.466 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 62.0 ttt180 -90.58 145.29 24.98 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.878 -1.139 . . . . 0.0 110.167 178.581 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.486 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 87.4 m -131.75 141.75 49.6 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.511 -0.743 . . . . 0.0 109.846 -175.409 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.584 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -131.03 143.91 51.07 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 120.97 -1.081 . . . . 0.0 111.475 -179.466 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.512 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 6.6 t -125.34 133.94 68.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.128 -0.982 . . . . 0.0 110.975 -178.309 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.451 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 29.5 m -116.88 174.59 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 CA-C-O 121.24 0.543 . . . . 0.0 110.319 178.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.48 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 11.8 tt0 -104.59 118.46 36.65 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 177.7 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.599 ' CD1' ' CB ' ' A' ' 32' ' ' MET 0.266 0.2 OUTLIER -87.32 123.08 70.41 Favored Pre-proline 0 C--N 1.297 -1.704 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -172.649 . . . . . . . . 4 4 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.498 ' HD2' HD11 ' A' ' 28' ' ' LEU . 17.8 Cg_endo -66.29 172.81 8.34 Favored 'Trans proline' 0 C--N 1.309 -1.51 0 O-C-N 123.551 1.29 . . . . 0.0 111.094 -178.266 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -59.99 -40.05 87.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.568 -0.708 . . . . 0.0 111.196 -174.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.518 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.02 -0.0 57.35 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.672 -1.267 . . . . 0.0 110.659 -171.479 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.599 ' CB ' ' CD1' ' A' ' 28' ' ' LEU . 97.8 mmm -113.52 -14.87 12.65 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.908 -1.12 . . . . 0.0 109.715 169.128 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.463 HD11 ' O ' ' A' ' 28' ' ' LEU . 14.0 mt -62.32 -40.02 94.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.087 -1.008 . . . . 0.0 109.59 176.585 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -69.93 129.95 40.9 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.469 -0.769 . . . . 0.0 110.278 178.036 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.0 -44.25 1.66 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 176.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.459 HD22 ' HG ' ' A' ' 28' ' ' LEU . 66.0 tp -63.61 145.13 56.29 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.05 -1.265 . . . . 0.0 110.946 -176.442 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.454 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 21.6 pt-20 -153.09 160.02 42.87 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.507 -0.745 . . . . 0.0 109.316 175.755 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.539 ' CG2' ' HA ' ' A' ' 53' ' ' GLU . 0.0 OUTLIER -62.81 148.76 45.98 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.93 -1.107 . . . . 0.0 110.058 -179.296 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.52 -6.45 68.94 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 -175.035 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.454 ' HB3' ' O ' ' A' ' 37' ' ' GLU . . . -72.86 155.73 39.61 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.178 -1.189 . . . . 0.0 109.543 176.479 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -100.03 99.75 10.53 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 119.05 -1.06 . . . . 0.0 109.698 176.762 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.581 HG12 ' CE1' ' A' ' 44' ' ' HIS . 2.2 t -85.58 131.74 33.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.347 -0.846 . . . . 0.0 109.355 176.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.466 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -95.03 119.98 34.47 Favored 'General case' 0 C--N 1.294 -1.83 0 O-C-N 121.059 -1.025 . . . . 0.0 109.272 170.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.581 ' CE1' HG12 ' A' ' 42' ' ' VAL . 0.3 OUTLIER -89.51 108.2 19.52 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 176.579 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.491 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.0 t-20 51.83 16.34 0.49 Allowed 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.235 -0.916 . . . . 0.0 111.056 -168.218 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.477 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 117.09 -1.53 19.33 Favored Glycine 0 N--CA 1.49 2.235 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.915 172.356 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.517 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 18.9 t -93.84 107.13 19.05 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.505 -1.585 . . . . 0.0 109.304 174.621 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.437 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 32.1 p -75.19 130.01 38.45 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.003 -1.061 . . . . 0.0 111.019 -171.584 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.641 ' CD1' ' CD2' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -144.75 161.22 39.77 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.526 -0.734 . . . . 0.0 109.524 174.518 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.434 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 10.7 m -100.22 149.97 23.02 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.757 -1.214 . . . . 0.0 111.043 -171.012 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.532 ' CG1' HG13 ' A' ' 59' ' ' VAL . 36.7 t -80.03 115.33 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.773 -0.579 . . . . 0.0 110.432 -178.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.532 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 30.5 p -70.09 -39.99 75.22 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.175 -0.953 . . . . 0.0 109.871 175.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.539 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 87.7 tt0 -161.3 154.2 20.88 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.262 -0.899 . . . . 0.0 110.333 179.059 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.529 HD13 ' CG2' ' A' ' 38' ' ' THR . 5.8 mt -102.48 132.73 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.983 -1.073 . . . . 0.0 109.909 174.472 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.502 ' CB ' ' HB2' ' A' ' 58' ' ' HIS . 2.5 m-80 -103.89 65.25 0.81 Allowed 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.569 -0.707 . . . . 0.0 109.869 179.334 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.94 -118.55 5.69 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 108.719 -1.752 . . . . 0.0 108.719 -173.091 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.48 ' O ' ' HB2' ' A' ' 28' ' ' LEU . 0.0 OUTLIER -75.02 -21.46 59.07 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 120.903 -1.351 . . . . 0.0 108.764 173.818 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.636 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 12.8 m170 -72.89 159.96 32.9 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.242 -0.912 . . . . 0.0 110.17 -177.37 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.532 HG13 ' CG1' ' A' ' 51' ' ' VAL . 52.8 t -140.1 125.57 20.72 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 O-C-N 121.04 -1.037 . . . . 0.0 110.662 171.536 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.512 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 54.3 p -96.09 125.82 40.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.723 -0.611 . . . . 0.0 109.742 179.641 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.641 ' CD2' ' CD1' ' A' ' 49' ' ' LEU . 4.3 p90 -118.45 155.26 31.08 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.016 -1.052 . . . . 0.0 110.296 179.806 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.532 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 35.1 p-10 -87.87 152.81 21.81 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.075 -1.016 . . . . 0.0 111.244 -173.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.531 ' CD2' ' CD1' ' A' ' 68' ' ' LEU . 0.0 OUTLIER -157.96 114.36 2.84 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 -176.518 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.486 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 57.6 ttm -71.92 142.33 49.48 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.009 -1.057 . . . . 0.0 109.624 -178.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.461 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 71.3 tttt -59.98 -50.01 75.41 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.075 -1.016 . . . . 0.0 110.505 -175.285 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -65.58 -39.96 92.2 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.996 -1.065 . . . . 0.0 109.914 178.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.486 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 93.0 m -61.11 -40.04 92.27 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.978 -1.076 . . . . 0.0 109.289 174.05 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.531 ' CD1' ' CD2' ' A' ' 63' ' ' LEU . 18.0 tp -59.95 -43.01 95.28 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.319 -0.863 . . . . 0.0 109.466 178.368 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -67.64 -39.98 84.59 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.554 -0.716 . . . . 0.0 110.138 176.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.47 HG22 HG21 ' A' ' 71' ' ' THR . 1.2 tt -68.23 -40.02 82.04 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.357 -0.84 . . . . 0.0 109.301 -177.055 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.47 HG21 HG22 ' A' ' 70' ' ' ILE . 60.1 p -84.61 -172.73 4.33 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 120.261 -0.576 . . . . 0.0 109.483 177.779 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.48 ' N ' ' OD1' ' B' ' 83' ' ' ASN . 5.9 t30 -102.32 22.45 13.33 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 169.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.529 ' CD1' HD22 ' A' ' 63' ' ' LEU . 88.2 mt -70.02 -39.92 75.51 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.01 -1.056 . . . . 0.0 109.757 174.794 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.495 ' HA2' HD12 ' A' ' 68' ' ' LEU . . . -44.56 -23.96 0.6 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.396 -1.082 . . . . 0.0 110.396 178.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 23.0 p-10 -69.97 -19.16 63.36 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.913 -1.346 . . . . 0.0 110.603 -174.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.519 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 98.4 mt -59.92 140.41 56.7 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.085 -1.01 . . . . 0.0 110.714 -176.682 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.487 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 92.3 mttt -143.6 138.97 29.43 Favored 'General case' 0 C--N 1.297 -1.712 0 CA-C-O 121.427 0.632 . . . . 0.0 109.83 177.301 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.569 ' CG2' HG13 ' A' ' 15' ' ' ILE . 16.4 t -60.33 152.2 5.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 120.983 -1.073 . . . . 0.0 110.48 -175.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.37 -14.46 59.43 Favored Glycine 0 N--CA 1.483 1.776 0 N-CA-C 108.906 -1.678 . . . . 0.0 108.906 -176.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 49.6 t0 -96.27 166.37 11.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.33 -1.1 . . . . 0.0 109.627 176.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.59 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.1 m95 -115.43 165.99 12.37 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.963 -1.086 . . . . 0.0 110.157 175.53 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.516 HG13 ' CB ' ' A' ' 10' ' ' ALA . 0.9 OUTLIER -129.96 158.4 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.339 -0.851 . . . . 0.0 110.081 -177.532 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.483 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 0.1 OUTLIER -80.0 107.5 12.83 Favored 'General case' 0 C--N 1.297 -1.674 0 O-C-N 121.006 -1.058 . . . . 0.0 109.14 167.029 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.513 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -108.85 138.13 37.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 120.596 -1.315 . . . . 0.0 111.194 -176.356 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -140.92 146.51 37.5 Favored 'General case' 0 N--CA 1.492 1.661 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.043 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 58.0 ttp180 -83.21 130.02 35.06 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.027 -1.045 . . . . 0.0 111.038 -176.41 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.56 ' HB3' ' CE2' ' B' ' 2' ' ' PHE . . . -118.01 146.15 44.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 110.031 174.61 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -123.64 138.34 54.56 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.614 -0.679 . . . . 0.0 110.648 -176.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 9.2 mttm -60.07 -39.94 87.78 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.333 -0.854 . . . . 0.0 110.005 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -142.95 156.0 44.8 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.236 -0.915 . . . . 0.0 110.28 178.414 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' SER . . . . . 0.455 ' HB2' HD12 ' A' ' 94' ' ' ILE . 58.7 m -126.82 129.95 49.28 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 109.988 177.253 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -64.78 -45.96 84.11 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.168 -0.958 . . . . 0.0 110.496 -179.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -95.72 44.96 1.08 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.07 -1.018 . . . . 0.0 111.101 -171.163 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.455 HD12 ' HB2' ' A' ' 91' ' ' SER . 20.4 mm -60.64 -40.98 86.4 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 O-C-N 121.268 -0.895 . . . . 0.0 110.132 170.439 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 113.72 -102.05 1.2 Allowed Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 179.279 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.557 ' O ' ' CG ' ' A' ' 97' ' ' HIS . . . 79.99 -178.92 53.58 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -177.361 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.557 ' CG ' ' O ' ' A' ' 96' ' ' GLY . 1.5 m170 . . . . . 0 N--CA 1.493 1.687 0 O-C-N 121.218 -1.166 . . . . 0.0 110.203 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 1' ' ' MET . . . . . 0.425 ' O ' ' HB3' ' B' ' 2' ' ' PHE . 57.2 ttm . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 121.282 0.563 . . . . 0.0 110.199 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.575 ' CD1' ' O ' ' B' ' 2' ' ' PHE . 5.4 p90 -176.92 138.55 0.26 Allowed 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.236 -0.915 . . . . 0.0 108.766 176.464 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.478 ' HB ' ' CD1' ' B' ' 5' ' ' ILE . 21.0 p -125.69 -36.67 2.4 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 120.846 -1.159 . . . . 0.0 110.183 -173.594 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 57.58 17.82 28.18 Favored Glycine 0 N--CA 1.486 1.969 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 -177.116 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.478 ' CD1' ' HB ' ' B' ' 3' ' ' THR . 25.9 mt -88.75 117.02 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.362 -1.081 . . . . 0.0 109.587 -177.412 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.535 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 3.7 t -86.78 144.05 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.121 -0.987 . . . . 0.0 110.856 -172.739 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 94.3 mm-40 -69.99 -32.97 71.44 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.735 -0.603 . . . . 0.0 110.635 175.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -169.13 174.4 43.61 Favored Glycine 0 N--CA 1.495 2.576 0 C-N-CA 119.175 -1.488 . . . . 0.0 109.935 -176.626 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.488 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 41.6 p -114.52 170.03 8.61 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.0 -1.294 . . . . 0.0 110.778 -177.475 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.525 ' CB ' HG11 ' B' ' 82' ' ' VAL . . . -135.61 150.04 49.54 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.614 -0.679 . . . . 0.0 109.523 -175.742 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 30.1 tttt -105.84 116.83 32.61 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.101 -0.999 . . . . 0.0 110.262 179.134 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.517 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 11.5 tp -60.0 127.13 30.36 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 120.96 -1.088 . . . . 0.0 108.9 172.334 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.641 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -125.53 -31.61 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.856 0 O-C-N 121.383 -0.823 . . . . 0.0 110.009 -179.479 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.02 144.59 29.25 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.273 -0.971 . . . . 0.0 111.351 -179.281 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.574 HG22 ' CD2' ' B' ' 24' ' ' HIS . 13.5 mt -108.58 135.67 46.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.217 -0.927 . . . . 0.0 109.994 172.058 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.499 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.6 m-20 -109.48 115.0 29.11 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 121.367 -0.833 . . . . 0.0 109.788 174.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -105.62 114.18 28.19 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.012 -1.055 . . . . 0.0 110.619 -175.388 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.0 OUTLIER -111.46 127.77 26.39 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.233 -0.917 . . . . 0.0 109.049 174.226 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_endo -51.16 -23.97 13.96 Favored 'Trans proline' 0 C--N 1.303 -1.834 0 O-C-N 123.827 1.435 . . . . 0.0 110.238 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.54 ' C ' ' CD2' ' B' ' 21' ' ' PHE . 11.2 m-80 -79.94 -43.0 22.91 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.106 -0.996 . . . . 0.0 109.884 175.15 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.54 ' CD2' ' C ' ' B' ' 20' ' ' ASN . 97.4 m-85 -153.69 150.37 28.5 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.54 -0.725 . . . . 0.0 109.993 -178.745 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.461 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 62.1 ttt180 -90.54 145.2 25.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.934 -1.104 . . . . 0.0 110.108 178.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.499 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 87.0 m -131.63 141.84 49.72 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.541 -0.725 . . . . 0.0 109.852 -175.535 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.584 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -131.05 144.08 51.18 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 120.926 -1.109 . . . . 0.0 111.336 -179.431 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.516 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 6.6 t -125.43 134.07 67.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.15 -0.969 . . . . 0.0 110.93 -178.271 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 30.3 m -117.14 174.59 3.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.812 -0.555 . . . . 0.0 110.304 179.102 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.484 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 12.0 tt0 -104.57 118.51 36.77 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 177.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.586 ' CD1' ' CB ' ' B' ' 32' ' ' MET 0.266 0.2 OUTLIER -87.35 123.07 70.38 Favored Pre-proline 0 C--N 1.296 -1.728 0 O-C-N 121.403 -0.811 . . . . 0.0 108.968 -172.769 . . . . . . . . 4 4 . 1 . 004 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.497 ' HD2' HD12 ' B' ' 28' ' ' LEU . 18.1 Cg_endo -66.27 172.84 8.27 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 O-C-N 123.6 1.316 . . . . 0.0 111.114 -178.213 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -60.07 -40.04 88.15 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.579 -0.701 . . . . 0.0 111.135 -174.647 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.516 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.94 -0.03 57.34 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.743 -1.223 . . . . 0.0 110.72 -171.514 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.586 ' CB ' ' CD1' ' B' ' 28' ' ' LEU . 98.0 mmm -113.48 -14.87 12.67 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.975 -1.078 . . . . 0.0 109.729 169.148 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.464 ' CD2' ' HB3' ' B' ' 28' ' ' LEU . 14.0 mt -62.32 -39.93 94.66 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.071 -1.018 . . . . 0.0 109.652 176.572 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -70.02 130.07 41.16 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.486 -0.759 . . . . 0.0 110.29 177.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.88 -44.13 1.69 Allowed Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.179 -1.169 . . . . 0.0 110.179 176.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . 0.429 HD22 ' HG ' ' B' ' 28' ' ' LEU . 66.4 tp -63.78 145.13 56.36 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.012 -1.287 . . . . 0.0 110.891 -176.441 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.465 ' O ' ' HB2' ' B' ' 40' ' ' ALA . 21.6 pt-20 -153.07 159.97 42.89 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.52 -0.737 . . . . 0.0 109.334 175.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.542 ' CG2' HD13 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -62.87 148.65 46.54 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.944 -1.098 . . . . 0.0 110.151 -179.303 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.67 -6.51 69.26 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 -174.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.465 ' HB2' ' O ' ' B' ' 37' ' ' GLU . . . -72.99 155.61 39.67 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.206 -1.173 . . . . 0.0 109.509 176.489 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.463 ' O ' ' CB ' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -99.7 99.61 10.46 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 120.926 -1.109 . . . . 0.0 109.799 176.725 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.58 HG12 ' CE1' ' B' ' 44' ' ' HIS . 2.2 t -85.62 131.87 33.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.332 -0.855 . . . . 0.0 109.319 176.183 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.467 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -95.12 120.06 34.69 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.037 -1.039 . . . . 0.0 109.292 170.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.58 ' CE1' HG12 ' B' ' 42' ' ' VAL . 0.3 OUTLIER -89.58 107.97 19.39 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.32 -0.863 . . . . 0.0 108.916 176.639 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.491 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.0 t-20 51.95 16.54 0.53 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.218 -0.926 . . . . 0.0 110.972 -168.204 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.477 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 116.92 -1.27 19.71 Favored Glycine 0 N--CA 1.489 2.227 0 C-N-CA 119.543 -1.313 . . . . 0.0 110.917 172.199 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.511 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 18.9 t -93.99 107.07 19.01 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.49 -1.594 . . . . 0.0 109.316 174.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . 0.433 ' O ' ' SG ' ' B' ' 48' ' ' CYS . 32.1 p -75.04 129.99 38.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.037 -1.039 . . . . 0.0 111.089 -171.626 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.64 ' CD1' ' CD2' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -144.81 161.19 39.89 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.526 -0.734 . . . . 0.0 109.507 174.503 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 50' ' ' THR . . . . . 0.436 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 10.5 m -100.06 150.15 22.75 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.749 -1.219 . . . . 0.0 111.069 -171.024 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.523 HG13 ' CG1' ' B' ' 59' ' ' VAL . 37.7 t -80.27 115.36 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.639 -0.663 . . . . 0.0 110.434 -178.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 30.5 p -70.07 -39.98 75.32 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.14 -0.975 . . . . 0.0 109.91 175.474 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.524 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 87.7 tt0 -161.36 154.25 20.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.267 -0.895 . . . . 0.0 110.297 179.079 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.542 HD13 ' CG2' ' B' ' 38' ' ' THR . 5.8 mt -102.5 132.75 47.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.11 -0.994 . . . . 0.0 109.927 174.535 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.489 ' CB ' ' HB2' ' B' ' 58' ' ' HIS . 2.5 m-80 -104.04 65.36 0.8 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.528 -0.733 . . . . 0.0 109.758 179.415 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.02 -118.48 5.64 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.655 -1.778 . . . . 0.0 108.655 -173.224 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.482 ' O ' ' HB2' ' B' ' 28' ' ' LEU . 0.0 OUTLIER -75.0 -21.66 59.0 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.928 -1.336 . . . . 0.0 108.777 173.796 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.641 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 12.8 m170 -72.7 159.76 33.3 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.345 -0.847 . . . . 0.0 110.192 -177.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.523 ' CG1' HG13 ' B' ' 51' ' ' VAL . 53.1 t -140.03 125.52 20.87 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.093 -1.005 . . . . 0.0 110.748 171.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.516 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 54.4 p -96.04 126.06 41.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.651 -0.656 . . . . 0.0 109.818 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.64 ' CD2' ' CD1' ' B' ' 49' ' ' LEU . 4.3 p90 -118.6 155.2 31.37 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.963 -1.086 . . . . 0.0 110.344 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.533 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 34.9 p-10 -87.76 152.73 21.9 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.097 -1.002 . . . . 0.0 111.305 -173.226 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.542 ' CD2' ' CD1' ' B' ' 68' ' ' LEU . 0.0 OUTLIER -157.79 114.53 2.91 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -176.662 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.5 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 57.7 ttm -72.08 142.41 49.22 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.931 -1.105 . . . . 0.0 109.574 -178.801 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.46 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 71.2 tttt -60.11 -49.91 75.77 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.988 -1.07 . . . . 0.0 110.441 -175.117 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -65.6 -40.02 92.2 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.969 -1.082 . . . . 0.0 109.906 178.803 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.5 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 93.1 m -61.2 -39.94 92.1 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.974 -1.079 . . . . 0.0 109.219 174.13 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.542 ' CD1' ' CD2' ' B' ' 63' ' ' LEU . 17.9 tp -59.98 -42.95 95.3 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.439 -0.788 . . . . 0.0 109.522 178.334 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -67.52 -39.99 85.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.581 -0.7 . . . . 0.0 110.269 176.476 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.466 HG22 HG22 ' B' ' 71' ' ' THR . 1.2 tt -68.19 -40.08 82.22 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 CA-C-O 121.904 0.859 . . . . 0.0 109.295 -177.115 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.467 HG22 ' O ' ' B' ' 67' ' ' THR . 59.2 p -84.52 -172.52 4.22 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 120.083 -0.647 . . . . 0.0 109.546 177.782 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.47 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 5.8 t30 -102.42 22.56 13.23 Favored 'General case' 0 C--N 1.296 -1.754 0 O-C-N 121.218 -0.927 . . . . 0.0 108.51 169.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.535 ' CD1' HD22 ' B' ' 63' ' ' LEU . 88.1 mt -70.09 -39.95 75.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.013 -1.054 . . . . 0.0 109.713 174.71 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.492 ' HA2' HD13 ' B' ' 68' ' ' LEU . . . -44.56 -23.82 0.58 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 178.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 23.2 p-10 -70.04 -19.07 63.31 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.932 -1.334 . . . . 0.0 110.648 -175.021 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.519 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.3 mt -60.03 140.41 56.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.121 -0.987 . . . . 0.0 110.67 -176.662 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.489 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 92.2 mttt -143.6 139.05 29.46 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 121.363 0.601 . . . . 0.0 109.853 177.297 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.561 ' CG2' HG13 ' B' ' 15' ' ' ILE . 16.5 t -60.56 152.24 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 120.937 -1.102 . . . . 0.0 110.42 -175.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.29 -14.22 59.89 Favored Glycine 0 N--CA 1.485 1.932 0 N-CA-C 108.927 -1.669 . . . . 0.0 108.927 -176.067 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.508 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 49.4 t0 -96.37 166.31 11.77 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.387 -1.066 . . . . 0.0 109.572 176.469 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.1 m95 -115.38 165.93 12.43 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.03 -1.044 . . . . 0.0 110.225 175.493 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.525 HG11 ' CB ' ' B' ' 10' ' ' ALA . 0.9 OUTLIER -129.95 158.5 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.387 -0.821 . . . . 0.0 110.081 -177.628 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.48 ' OD1' ' N ' ' A' ' 72' ' ' ASN . 0.1 OUTLIER -79.96 107.29 12.63 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 120.987 -1.07 . . . . 0.0 109.179 167.043 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.503 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -108.67 138.34 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 120.668 -1.27 . . . . 0.0 111.061 -176.196 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -141.34 146.57 36.87 Favored 'General case' 0 N--CA 1.492 1.659 0 C-N-CA 120.397 -0.521 . . . . 0.0 109.933 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 58.0 ttp180 -83.07 129.97 35.08 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.027 -1.046 . . . . 0.0 110.996 -176.288 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.573 ' HB2' ' CE2' ' A' ' 2' ' ' PHE . . . -117.97 146.29 44.1 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.258 -0.901 . . . . 0.0 110.023 174.486 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -123.78 138.37 54.52 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.499 -0.751 . . . . 0.0 110.636 -176.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 9.3 mttm -60.08 -39.94 87.86 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.392 -0.818 . . . . 0.0 110.042 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -142.96 156.06 44.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.315 -0.866 . . . . 0.0 110.246 178.365 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 91' ' ' SER . . . . . 0.438 ' OG ' ' CD1' ' B' ' 94' ' ' ILE . 58.8 m -126.83 129.92 49.22 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.349 -0.844 . . . . 0.0 110.011 177.215 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . 0.476 ' O ' ' HB3' ' B' ' 93' ' ' GLU . 54.4 t0 -64.75 -43.46 93.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.267 -0.895 . . . . 0.0 110.387 -179.651 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . 0.476 ' HB3' ' O ' ' B' ' 92' ' ' ASP . 7.3 pt-20 -179.58 48.58 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.69 -0.631 . . . . 0.0 109.899 -175.274 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . 0.44 ' O ' ' C ' ' B' ' 95' ' ' GLY . 58.6 mt -70.44 -44.24 77.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.498 -0.751 . . . . 0.0 110.767 -176.129 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' B' ' 94' ' ' ILE . . . 41.34 61.55 2.06 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 -176.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -103.8 -92.7 2.25 Favored Glycine 0 N--CA 1.492 2.407 0 O-C-N 121.069 -1.254 . . . . 0.0 110.014 -176.372 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 24.1 p80 . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.192 -1.181 . . . . 0.0 110.253 -178.078 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.552 " C2'" ' HC9' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.554 " C2'" ' HC9' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 95.4 mtp . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.132 0.491 . . . . 0.0 110.097 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.594 ' CZ ' ' CB ' ' B' ' 87' ' ' ALA . 7.5 p90 -173.38 153.04 2.3 Favored 'General case' 0 C--N 1.307 -1.275 0 O-C-N 121.129 -0.982 . . . . 0.0 108.899 177.67 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.498 ' HB ' ' CD1' ' A' ' 5' ' ' ILE . 20.9 p -150.49 -39.16 0.13 Allowed 'General case' 0 C--N 1.296 -1.747 0 O-C-N 120.966 -1.084 . . . . 0.0 109.017 175.579 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 48.25 24.04 3.28 Favored Glycine 0 N--CA 1.484 1.862 0 N-CA-C 108.272 -1.931 . . . . 0.0 108.272 -175.369 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.498 ' CD1' ' HB ' ' A' ' 3' ' ' THR . 65.7 mt -81.49 134.45 27.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.371 -1.076 . . . . 0.0 109.857 -176.845 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.537 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 1.8 t -87.86 139.63 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.106 -0.996 . . . . 0.0 111.047 -169.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 30.3 mm100 -69.91 -36.25 75.23 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.716 -0.615 . . . . 0.0 110.836 178.033 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.537 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -154.36 170.78 32.84 Favored Glycine 0 N--CA 1.493 2.448 0 C-N-CA 119.156 -1.497 . . . . 0.0 109.986 -172.492 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.445 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 4.2 p -114.4 173.86 6.24 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.927 -1.337 . . . . 0.0 111.173 -175.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.51 ' CB ' HG11 ' A' ' 82' ' ' VAL . . . -142.2 149.8 40.16 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.676 -0.64 . . . . 0.0 109.347 -177.502 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.594 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 38.3 tttt -107.29 116.72 32.42 Favored 'General case' 0 C--N 1.295 -1.766 0 O-C-N 121.003 -1.061 . . . . 0.0 110.269 177.908 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.531 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 11.9 tp -60.02 126.95 29.53 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.848 -1.157 . . . . 0.0 108.827 171.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.623 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.3 p -122.79 -31.65 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 O-C-N 121.395 -0.816 . . . . 0.0 109.881 -179.481 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.94 146.59 27.92 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 118.984 -1.086 . . . . 0.0 111.473 -179.324 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.573 HG13 ' CG2' ' A' ' 78' ' ' VAL . 7.6 mt -108.45 138.06 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.026 -1.046 . . . . 0.0 110.238 171.207 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.475 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.9 m-20 -109.22 115.72 30.55 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.196 -0.94 . . . . 0.0 109.765 171.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -104.56 112.27 25.28 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.019 -1.05 . . . . 0.0 110.379 -175.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 20.4 mmmt -115.64 129.27 25.28 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.17 -0.956 . . . . 0.0 109.125 177.33 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -51.03 -31.34 34.46 Favored 'Trans proline' 0 C--N 1.303 -1.841 0 O-C-N 123.775 1.408 . . . . 0.0 110.264 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 11.6 m-80 -74.42 -39.99 62.27 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.232 -0.917 . . . . 0.0 110.09 175.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 83.7 m-85 -156.35 150.46 25.27 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.328 -0.858 . . . . 0.0 110.308 -177.623 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.48 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 59.0 ttt180 -92.05 141.81 28.21 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.921 -1.112 . . . . 0.0 109.94 176.579 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.475 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.6 m -130.08 139.95 50.89 Favored 'General case' 0 C--N 1.294 -1.819 0 O-C-N 121.675 -0.641 . . . . 0.0 109.912 -173.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.57 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -131.12 141.41 50.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.905 -1.122 . . . . 0.0 111.068 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.499 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 6.8 t -122.51 133.17 69.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.053 -1.03 . . . . 0.0 110.677 -178.823 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.573 HG11 ' CE1' ' A' ' 61' ' ' PHE . 30.1 m -116.19 173.33 3.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.808 -0.557 . . . . 0.0 110.22 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.508 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 8.4 tt0 -104.44 116.44 32.13 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.434 -0.791 . . . . 0.0 108.942 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.473 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.6 tp -83.55 124.35 75.56 Favored Pre-proline 0 C--N 1.298 -1.649 0 O-C-N 121.475 -0.766 . . . . 0.0 110.059 -173.159 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.471 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 26.2 Cg_endo -66.42 176.61 3.92 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 123.923 1.486 . . . . 0.0 111.104 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' A' ' 30' ' ' ASP . 47.4 t0 -60.09 -39.88 87.67 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.328 -0.858 . . . . 0.0 111.13 -175.467 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.573 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.64 0.06 57.19 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.756 -1.215 . . . . 0.0 110.576 -174.548 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.573 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.7 mmm -111.43 -14.1 13.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.037 -1.04 . . . . 0.0 109.813 170.291 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.544 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 17.5 mt -69.81 -39.97 76.21 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.271 -0.893 . . . . 0.0 110.308 177.648 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -78.06 129.37 35.15 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.919 . . . . 0.0 110.337 -178.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.88 -42.96 1.87 Allowed Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.865 -1.159 . . . . 0.0 110.374 174.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.47 ' CD1' HD22 ' A' ' 28' ' ' LEU . 7.1 tt -66.79 146.65 54.2 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.932 -1.334 . . . . 0.0 110.508 -175.012 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.464 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 14.7 pt-20 -149.97 164.38 35.63 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.556 -0.715 . . . . 0.0 109.672 -178.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.53 ' CG2' ' HA ' ' A' ' 53' ' ' GLU . 0.0 OUTLIER -66.5 150.06 49.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.99 -1.069 . . . . 0.0 109.949 179.335 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.7 -4.81 63.39 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -173.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.464 ' HB3' ' O ' ' A' ' 37' ' ' GLU . . . -76.62 153.54 35.18 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.225 -1.162 . . . . 0.0 109.519 177.145 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.468 ' HB2' ' HB3' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -97.82 109.23 22.02 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 121.016 -1.052 . . . . 0.0 110.086 178.153 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.575 HG12 ' CE1' ' A' ' 44' ' ' HIS . 2.2 t -95.37 133.1 37.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.224 -0.923 . . . . 0.0 109.129 173.737 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.471 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -95.9 119.9 35.22 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.112 -0.993 . . . . 0.0 109.071 171.417 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.575 ' CE1' HG12 ' A' ' 42' ' ' VAL . 0.3 OUTLIER -88.81 104.85 17.3 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.433 -0.792 . . . . 0.0 108.884 177.636 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.5 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 54.82 12.86 0.64 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.361 -0.837 . . . . 0.0 111.258 -168.513 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.472 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.34 -1.22 11.46 Favored Glycine 0 N--CA 1.49 2.283 0 C-N-CA 119.603 -1.284 . . . . 0.0 110.769 172.804 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.503 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 36.1 t -93.85 109.71 21.4 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 120.531 -1.57 . . . . 0.0 109.517 175.275 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.7 p -74.44 128.26 35.1 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.113 -0.992 . . . . 0.0 110.984 -171.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.622 ' CD1' ' CD2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -144.3 159.18 43.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.506 -0.746 . . . . 0.0 109.421 174.177 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 65.3 m -102.34 151.26 22.46 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.718 -1.239 . . . . 0.0 111.148 -172.022 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.539 ' CG1' HG11 ' A' ' 59' ' ' VAL . 21.3 t -78.44 119.77 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.728 -0.608 . . . . 0.0 110.641 -177.329 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.52 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 43.2 p -73.25 -43.84 60.46 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.242 -0.911 . . . . 0.0 110.15 174.481 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.53 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -159.32 151.22 20.67 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.319 -0.863 . . . . 0.0 110.468 -178.244 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.527 HD13 ' CG2' ' A' ' 38' ' ' THR . 6.3 mt -102.87 133.13 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.172 -0.955 . . . . 0.0 109.953 174.724 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.467 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 44.9 m-80 -108.04 65.72 0.64 Allowed 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.492 -0.755 . . . . 0.0 109.703 178.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.93 -116.28 4.77 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -174.091 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.544 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.35 -20.89 50.38 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.02 -1.282 . . . . 0.0 109.059 175.028 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.623 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 10.4 m170 -74.45 160.03 31.5 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.358 -0.839 . . . . 0.0 110.096 -177.109 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.539 HG11 ' CG1' ' A' ' 51' ' ' VAL . 54.9 t -140.37 122.88 16.14 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 O-C-N 121.006 -1.059 . . . . 0.0 110.808 171.117 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.499 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 3.0 m -89.46 128.96 36.02 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.643 -0.661 . . . . 0.0 109.586 177.162 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.622 ' CD2' ' CD1' ' A' ' 49' ' ' LEU . 3.1 p90 -123.23 155.5 37.01 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.026 -1.046 . . . . 0.0 110.082 178.643 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.52 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 29.6 p-10 -90.03 154.41 19.83 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.946 -1.096 . . . . 0.0 111.594 -170.377 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.528 HD23 ' CD1' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -158.85 123.96 4.23 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 -175.753 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.494 ' HB2' ' CB ' ' A' ' 67' ' ' THR . 96.0 mtp -79.65 146.72 32.33 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.677 -1.264 . . . . 0.0 109.714 178.077 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.469 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 27.8 ttpt -60.01 -47.63 85.06 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.082 -1.011 . . . . 0.0 109.626 178.477 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.99 -40.03 75.55 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.214 -0.928 . . . . 0.0 110.833 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.494 ' CB ' ' HB2' ' A' ' 64' ' ' MET . 23.6 m -65.51 -33.95 77.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.681 -1.262 . . . . 0.0 109.103 175.22 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.532 ' CD1' ' HA2' ' A' ' 74' ' ' GLY . 4.3 tp -60.04 -45.96 91.1 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.546 -0.721 . . . . 0.0 109.705 177.009 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 31.7 tpt180 -69.78 -40.05 76.27 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.304 -0.872 . . . . 0.0 110.54 178.477 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.496 ' CG2' HG21 ' A' ' 71' ' ' THR . 1.5 tt -63.94 -42.78 96.87 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 O-C-N 121.18 -0.95 . . . . 0.0 109.288 -178.681 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.496 HG21 ' CG2' ' A' ' 70' ' ' ILE . 20.9 p -83.59 -173.29 4.63 Favored 'General case' 0 C--N 1.298 -1.63 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 174.678 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 3.4 t30 -104.64 25.66 10.04 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 169.827 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.528 ' CD1' HD23 ' A' ' 63' ' ' LEU . 90.4 mt -68.07 -39.95 82.85 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.239 -0.913 . . . . 0.0 109.671 175.966 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.532 ' HA2' ' CD1' ' A' ' 68' ' ' LEU . . . -49.87 -23.7 5.51 Favored Glycine 0 N--CA 1.486 1.977 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.06 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 23.7 p-10 -64.52 -17.26 63.74 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.941 -1.329 . . . . 0.0 110.188 -176.202 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.518 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.7 mt -60.52 144.96 50.25 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.314 -0.866 . . . . 0.0 110.484 -178.454 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.498 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 66.2 mttt -150.12 138.65 20.64 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 121.725 -0.609 . . . . 0.0 109.669 178.11 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.573 ' CG2' HG13 ' A' ' 15' ' ' ILE . 62.1 t -63.54 147.3 12.28 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 120.884 -1.135 . . . . 0.0 110.152 -175.516 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.98 -11.43 70.72 Favored Glycine 0 N--CA 1.483 1.805 0 N-CA-C 108.779 -1.729 . . . . 0.0 108.779 -172.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.505 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 41.7 t0 -100.88 162.25 13.03 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.392 -1.063 . . . . 0.0 109.722 176.408 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.594 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.4 m95 -114.09 159.9 19.52 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.144 -0.972 . . . . 0.0 109.976 177.268 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.51 HG11 ' CB ' ' A' ' 10' ' ' ALA . 0.9 OUTLIER -126.81 156.97 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.973 -177.516 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.527 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 2.4 m-20 -82.14 104.93 12.83 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.202 -0.936 . . . . 0.0 109.263 169.552 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.469 HG11 HG23 ' A' ' 82' ' ' VAL . 0.1 OUTLIER -107.22 138.58 32.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 120.574 -1.329 . . . . 0.0 111.542 -175.564 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -131.63 147.55 52.53 Favored 'General case' 0 N--CA 1.494 1.738 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.994 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . 0.471 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 38.2 ptt180 -87.92 131.77 34.47 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.135 -0.978 . . . . 0.0 110.627 -178.595 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.468 ' HB3' ' HB2' ' A' ' 41' ' ' SER . . . -126.98 145.86 50.55 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.202 -0.936 . . . . 0.0 110.239 179.405 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -136.35 154.21 50.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.71 -0.619 . . . . 0.0 110.549 -178.098 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 28.7 mtpt -59.99 -39.99 87.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.266 -0.896 . . . . 0.0 110.301 179.033 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 42.9 p90 -132.74 161.55 33.74 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.266 -0.896 . . . . 0.0 110.221 -178.291 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 61.1 m -118.26 142.79 47.12 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.285 -0.884 . . . . 0.0 110.552 -176.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.469 ' O ' ' HB2' ' A' ' 93' ' ' GLU . 96.1 m-20 -61.86 -39.56 92.31 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.505 -0.747 . . . . 0.0 110.312 179.353 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.469 ' HB2' ' O ' ' A' ' 92' ' ' ASP . 96.6 mt-10 55.5 50.39 14.73 Favored 'General case' 0 N--CA 1.507 2.402 0 O-C-N 121.289 -0.882 . . . . 0.0 110.301 -179.307 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 61.1 mt -64.56 -41.15 91.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.548 -0.72 . . . . 0.0 110.254 178.391 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 127.71 -84.33 0.33 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -178.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 83.9 -170.45 47.7 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 177.688 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.46 ' CG ' ' OXT' ' A' ' 97' ' ' HIS . 83.2 t60 . . . . . 0 N--CA 1.492 1.653 0 O-C-N 121.305 -1.115 . . . . 0.0 110.151 -179.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 1' ' ' MET . . . . . 0.45 ' O ' ' HG3' ' B' ' 1' ' ' MET . 28.1 ptm . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 121.163 0.506 . . . . 0.0 110.056 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.577 ' CD1' ' O ' ' B' ' 2' ' ' PHE . 7.8 p90 -172.79 153.03 2.59 Favored 'General case' 0 C--N 1.306 -1.291 0 O-C-N 121.211 -0.931 . . . . 0.0 108.856 177.588 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.504 ' HB ' ' CD1' ' B' ' 5' ' ' ILE . 20.7 p -150.46 -39.08 0.13 Allowed 'General case' 0 C--N 1.296 -1.747 0 O-C-N 120.916 -1.115 . . . . 0.0 109.133 175.472 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.459 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 48.45 23.8 3.35 Favored Glycine 0 N--CA 1.484 1.878 0 N-CA-C 108.278 -1.929 . . . . 0.0 108.278 -175.487 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.515 HD12 ' C8M' ' A' ' 98' ' ' RBF . 66.1 mt -81.47 134.47 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.451 -1.029 . . . . 0.0 109.824 -176.67 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.54 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 1.7 t -87.91 139.58 17.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.022 -1.049 . . . . 0.0 111.074 -169.794 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 30.3 mm100 -69.94 -35.95 74.91 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.834 -0.541 . . . . 0.0 110.938 178.085 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.54 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -154.53 170.68 32.94 Favored Glycine 0 N--CA 1.495 2.596 0 C-N-CA 119.232 -1.461 . . . . 0.0 110.13 -172.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.447 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 4.2 p -114.43 173.82 6.27 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.992 -1.299 . . . . 0.0 111.246 -175.317 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.52 ' CB ' HG11 ' B' ' 82' ' ' VAL . . . -142.13 150.01 40.55 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -177.534 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.59 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 38.3 tttt -107.52 116.78 32.56 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.109 -0.994 . . . . 0.0 110.126 177.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.519 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 11.9 tp -60.06 126.82 28.99 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.872 -1.142 . . . . 0.0 108.916 171.951 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.626 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.3 p -122.68 -31.74 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.849 0 O-C-N 121.387 -0.821 . . . . 0.0 109.859 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.84 146.67 28.07 Favored 'General case' 0 N--CA 1.493 1.706 0 C-N-CA 119.16 -1.016 . . . . 0.0 111.474 -179.333 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.576 HG13 ' CG2' ' B' ' 78' ' ' VAL . 7.6 mt -108.47 138.06 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.067 -1.021 . . . . 0.0 110.291 171.152 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.489 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 78.1 m-20 -109.32 115.7 30.47 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.46 -0.775 . . . . 0.0 109.754 172.054 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -104.51 112.28 25.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.097 -1.002 . . . . 0.0 110.312 -175.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.464 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 20.1 mmmt -115.64 129.29 25.26 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.325 -0.859 . . . . 0.0 109.161 177.247 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -51.17 -31.25 35.46 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.721 1.379 . . . . 0.0 110.216 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.552 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 11.9 m-80 -74.42 -40.27 62.08 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.2 -0.937 . . . . 0.0 109.94 175.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.552 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 83.8 m-85 -156.07 150.4 25.64 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.289 -0.882 . . . . 0.0 110.357 -177.513 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.48 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 58.8 ttt180 -91.97 141.69 28.35 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.989 -1.069 . . . . 0.0 110.016 176.525 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.489 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 94.6 m -129.95 139.98 51.0 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 121.67 -0.644 . . . . 0.0 109.951 -173.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.571 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -131.06 141.4 50.18 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.021 -1.049 . . . . 0.0 111.046 -179.586 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.519 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 6.7 t -122.47 133.3 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.157 -0.964 . . . . 0.0 110.744 -178.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.569 HG12 ' CE1' ' B' ' 61' ' ' PHE . 30.7 m -116.37 173.26 4.07 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.766 -0.583 . . . . 0.0 110.101 178.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.509 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 8.4 tt0 -104.32 116.56 32.37 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 179.685 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.468 ' N ' ' ND2' ' B' ' 57' ' ' ASN . 9.6 tp -83.57 124.32 75.56 Favored Pre-proline 0 C--N 1.299 -1.629 0 O-C-N 121.338 -0.851 . . . . 0.0 110.095 -173.164 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.468 ' HD2' HD11 ' B' ' 28' ' ' LEU . 26.0 Cg_endo -66.41 176.6 3.93 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 O-C-N 123.858 1.452 . . . . 0.0 111.104 -179.483 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.435 ' HA ' HD11 ' B' ' 33' ' ' LEU . 47.4 t0 -60.0 -40.03 87.78 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.341 -0.849 . . . . 0.0 111.104 -175.49 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.567 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.56 0.1 57.14 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.753 -1.217 . . . . 0.0 110.658 -174.57 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.567 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.7 mmm -111.43 -14.11 13.78 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.055 -1.028 . . . . 0.0 109.828 170.266 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.544 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 17.8 mt -69.7 -40.06 76.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.358 -0.839 . . . . 0.0 110.338 177.628 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 55.8 t0 -78.01 129.38 35.2 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.886 . . . . 0.0 110.432 -178.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.95 -43.08 1.85 Allowed Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.854 -1.165 . . . . 0.0 110.304 174.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . 0.463 ' CD1' HD22 ' B' ' 28' ' ' LEU . 7.0 tt -66.81 146.68 54.17 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.866 -1.373 . . . . 0.0 110.533 -174.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.454 ' O ' ' HB2' ' B' ' 40' ' ' ALA . 14.7 pt-20 -150.04 164.35 35.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.4 -0.812 . . . . 0.0 109.618 -178.664 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.534 ' CG2' HD13 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.49 149.94 49.7 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.031 -1.043 . . . . 0.0 109.962 179.369 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.85 -4.83 63.93 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 -174.048 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.454 ' HB2' ' O ' ' B' ' 37' ' ' GLU . . . -76.63 153.35 35.32 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.293 -1.122 . . . . 0.0 109.592 177.024 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.465 ' HB2' ' HB2' ' B' ' 87' ' ' ALA . 0.1 OUTLIER -97.53 109.05 21.88 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 120.951 -1.093 . . . . 0.0 110.195 178.096 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.569 HG12 ' CE1' ' B' ' 44' ' ' HIS . 2.2 t -95.29 133.13 37.35 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 O-C-N 121.253 -0.904 . . . . 0.0 109.154 173.723 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.468 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -95.89 119.87 35.16 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 119.204 -0.999 . . . . 0.0 109.181 171.284 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.569 ' CE1' HG12 ' B' ' 42' ' ' VAL . 0.3 OUTLIER -88.79 104.66 17.11 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.302 -0.874 . . . . 0.0 108.966 177.696 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.5 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 55.01 12.88 0.67 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.54 -0.725 . . . . 0.0 111.291 -168.491 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.472 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.15 -0.79 11.63 Favored Glycine 0 N--CA 1.491 2.346 0 C-N-CA 119.662 -1.256 . . . . 0.0 110.75 172.687 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.508 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 36.0 t -94.03 109.68 21.42 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.45 -1.617 . . . . 0.0 109.54 175.134 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 18.7 p -74.4 128.41 35.47 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.095 -1.003 . . . . 0.0 110.965 -171.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.638 ' CD1' ' CD2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -144.5 159.1 43.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.541 -0.724 . . . . 0.0 109.387 174.129 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 64.9 m -102.22 151.38 22.28 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.705 -1.247 . . . . 0.0 111.112 -171.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.539 ' CG1' HG11 ' B' ' 59' ' ' VAL . 21.4 t -78.65 119.94 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.727 -0.608 . . . . 0.0 110.584 -177.27 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.523 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 43.3 p -73.32 -43.93 59.93 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.17 -0.956 . . . . 0.0 110.159 174.576 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.526 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -159.24 151.36 20.99 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.331 -0.856 . . . . 0.0 110.455 -178.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.534 HD13 ' CG2' ' B' ' 38' ' ' THR . 6.3 mt -103.0 133.0 48.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.102 -0.999 . . . . 0.0 109.933 174.789 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.485 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 44.8 m-80 -108.0 65.74 0.64 Allowed 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 119.972 -0.691 . . . . 0.0 109.679 179.014 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.08 -116.31 4.74 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 -174.22 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.544 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.31 -21.09 50.17 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 120.983 -1.304 . . . . 0.0 109.049 175.069 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.626 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 10.6 m170 -74.17 159.77 32.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.474 -0.766 . . . . 0.0 110.252 -177.239 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.539 HG11 ' CG1' ' B' ' 51' ' ' VAL . 55.8 t -140.24 122.87 16.46 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 C-N-CA 119.094 -1.042 . . . . 0.0 110.877 171.177 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.519 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 3.0 m -89.61 128.97 36.12 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.751 -0.593 . . . . 0.0 109.556 177.304 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.638 ' CD2' ' CD1' ' B' ' 49' ' ' LEU . 3.1 p90 -123.21 155.56 36.88 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.113 -0.992 . . . . 0.0 110.07 178.71 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.523 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 29.7 p-10 -90.1 154.4 19.81 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.818 -1.176 . . . . 0.0 111.554 -170.273 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.515 HD22 ' CD1' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -158.78 124.04 4.3 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 -175.764 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.5 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 96.0 mtp -79.74 146.68 32.23 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.631 -1.293 . . . . 0.0 109.706 178.029 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.467 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 27.9 ttpt -60.07 -47.61 85.15 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.195 -0.941 . . . . 0.0 109.542 178.562 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.95 -40.01 75.71 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.186 -0.946 . . . . 0.0 110.896 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.5 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 23.7 m -65.48 -34.14 77.57 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.649 -1.282 . . . . 0.0 109.021 175.204 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.534 ' CD1' ' HA2' ' B' ' 74' ' ' GLY . 4.3 tp -60.04 -45.67 92.08 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.571 -0.706 . . . . 0.0 109.844 177.039 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 31.6 tpt180 -70.01 -39.99 75.5 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.278 -0.889 . . . . 0.0 110.498 178.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.515 ' CG2' HG22 ' B' ' 71' ' ' THR . 1.5 tt -63.85 -42.7 96.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.221 -0.924 . . . . 0.0 109.332 -178.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.515 HG22 ' CG2' ' B' ' 70' ' ' ILE . 21.3 p -83.71 -173.08 4.51 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 174.84 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.498 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 3.4 t30 -104.79 25.59 10.21 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 169.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.515 ' CD1' HD22 ' B' ' 63' ' ' LEU . 90.1 mt -68.07 -40.02 82.83 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.149 -0.97 . . . . 0.0 109.636 176.032 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.534 ' HA2' ' CD1' ' B' ' 68' ' ' LEU . . . -49.82 -23.74 5.46 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 -179.061 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 23.3 p-10 -64.46 -17.22 63.63 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.07 -1.253 . . . . 0.0 110.218 -176.227 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.519 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 97.7 mt -60.51 144.93 50.26 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.262 -0.899 . . . . 0.0 110.441 -178.47 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.499 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 66.1 mttt -150.09 138.62 20.65 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.626 -0.671 . . . . 0.0 109.696 178.077 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.576 ' CG2' HG13 ' B' ' 15' ' ' ILE . 62.0 t -63.56 147.26 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.042 -1.036 . . . . 0.0 110.178 -175.513 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.0 -11.15 71.6 Favored Glycine 0 N--CA 1.484 1.85 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 -172.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 41.5 t0 -101.08 162.09 13.14 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.333 -1.098 . . . . 0.0 109.695 176.408 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.59 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.4 m95 -114.0 159.79 19.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.195 -0.941 . . . . 0.0 110.031 177.282 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.52 HG11 ' CB ' ' B' ' 10' ' ' ALA . 0.8 OUTLIER -126.77 157.12 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.402 -0.811 . . . . 0.0 109.896 -177.611 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.513 ' HB3' ' CG2' ' B' ' 6' ' ' VAL . 2.3 m-20 -82.17 104.86 12.81 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.277 -0.89 . . . . 0.0 109.29 169.601 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.471 ' O ' HG13 ' B' ' 6' ' ' VAL . 0.1 OUTLIER -107.13 138.77 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 120.665 -1.272 . . . . 0.0 111.453 -175.426 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -131.84 147.62 52.49 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.983 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . 0.47 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 38.2 ptt180 -87.89 131.84 34.42 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.166 -0.959 . . . . 0.0 110.568 -178.525 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.594 ' CB ' ' CZ ' ' A' ' 2' ' ' PHE . . . -127.0 145.74 50.6 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.335 -0.853 . . . . 0.0 110.214 179.368 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . 0.403 ' N ' ' CE2' ' A' ' 2' ' ' PHE . . . -136.38 154.2 50.89 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.689 -0.632 . . . . 0.0 110.54 -178.171 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 28.7 mtpt -59.99 -40.0 87.66 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.293 -0.879 . . . . 0.0 110.225 179.189 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 43.0 p90 -132.75 161.43 34.07 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.209 -0.932 . . . . 0.0 110.23 -178.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 91' ' ' SER . . . . . . . . . . . . . 61.0 m -118.2 142.84 47.04 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.307 -0.871 . . . . 0.0 110.553 -176.581 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -62.11 -39.98 94.35 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.36 -0.838 . . . . 0.0 110.278 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . 0.446 ' O ' ' HB ' ' B' ' 94' ' ' ILE . 18.6 pt-20 -138.79 56.44 1.7 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.321 -0.862 . . . . 0.0 110.362 -177.653 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . 0.537 ' O ' ' CG2' ' B' ' 94' ' ' ILE . 16.0 mm 53.37 21.86 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.196 0 O-C-N 121.242 -0.911 . . . . 0.0 109.199 179.027 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.15 65.9 1.55 Allowed Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 178.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -76.82 146.52 32.53 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 58.6 m-70 . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.282 -1.128 . . . . 0.0 110.212 -178.849 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.532 " O2'" ' C9 ' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.526 " O2'" ' C9 ' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 98.6 mmm . . . . . 0 N--CA 1.492 1.641 0 CA-C-O 121.154 0.502 . . . . 0.0 109.973 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.558 ' CD1' ' O ' ' B' ' 88' ' ' ALA . 1.3 p90 -169.9 132.09 1.1 Allowed 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.17 -0.956 . . . . 0.0 109.311 179.589 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.496 ' O ' HG13 ' A' ' 5' ' ' ILE . 34.7 p -128.8 -31.23 2.2 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.061 -1.024 . . . . 0.0 110.212 -178.196 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' B' ' 46' ' ' GLY . . . 45.8 24.44 1.27 Allowed Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 -174.1 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.532 ' CD1' ' C8M' ' B' ' 99' ' ' RBF . 53.0 mt -85.25 144.21 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 120.979 -1.306 . . . . 0.0 110.533 -177.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.538 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.3 t -88.87 144.47 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.345 -0.847 . . . . 0.0 110.919 -175.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 -70.04 -31.79 69.6 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.867 -0.521 . . . . 0.0 111.021 179.197 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.538 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -156.38 -177.97 30.06 Favored Glycine 0 N--CA 1.499 2.862 0 C-N-CA 118.541 -1.79 . . . . 0.0 110.795 -170.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.498 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.0 p -129.08 167.25 17.81 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.792 -1.417 . . . . 0.0 110.95 -178.435 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.518 ' CB ' HG11 ' A' ' 82' ' ' VAL . . . -139.97 149.84 43.75 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.597 -0.69 . . . . 0.0 109.201 -175.021 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.581 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 34.5 tttt -109.24 115.77 30.63 Favored 'General case' 0 C--N 1.294 -1.816 0 O-C-N 121.013 -1.055 . . . . 0.0 110.362 -179.12 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.521 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 11.5 tp -59.98 127.68 33.08 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.916 -1.115 . . . . 0.0 108.863 172.622 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.629 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.6 p -127.01 -29.32 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 C-N-CA 119.6 -0.84 . . . . 0.0 109.932 -179.045 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.75 144.15 24.11 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 118.959 -1.096 . . . . 0.0 111.243 179.23 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.571 HG12 ' CD2' ' A' ' 24' ' ' HIS . 8.8 mt -107.9 141.03 24.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.187 -0.946 . . . . 0.0 110.233 174.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.483 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 79.7 m-20 -109.79 113.87 26.97 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.238 -0.914 . . . . 0.0 109.972 172.247 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -101.24 113.13 25.89 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.109 -0.995 . . . . 0.0 110.427 -178.099 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.47 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -109.77 134.4 20.64 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.197 -0.939 . . . . 0.0 109.499 176.005 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.64 -16.65 11.4 Favored 'Trans proline' 0 C--N 1.303 -1.854 0 O-C-N 123.973 1.512 . . . . 0.0 110.652 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.572 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 4.9 m-80 -100.8 -26.57 13.73 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.129 -0.982 . . . . 0.0 110.035 179.23 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.572 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 92.9 m-85 -157.81 150.2 22.48 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.437 -0.789 . . . . 0.0 109.857 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.474 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 57.1 ttt180 -93.54 141.16 28.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.6 -1.312 . . . . 0.0 110.026 174.196 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.483 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.3 m -129.97 141.03 50.82 Favored 'General case' 0 C--N 1.294 -1.814 0 O-C-N 121.698 -0.626 . . . . 0.0 109.835 -173.703 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.579 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -129.98 143.6 50.88 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.012 -1.055 . . . . 0.0 111.612 -179.156 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.529 ' CG2' ' OG ' ' A' ' 60' ' ' SER . 6.4 t -123.34 132.88 70.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.11 -0.994 . . . . 0.0 110.613 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.549 HG13 ' CE1' ' A' ' 61' ' ' PHE . 26.0 m -114.9 174.48 2.93 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.326 178.509 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.506 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 12.8 tt0 -104.38 118.61 37.03 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.473 HD22 ' O ' ' A' ' 32' ' ' MET . 9.5 tp -81.21 122.57 81.52 Favored Pre-proline 0 C--N 1.297 -1.708 0 O-C-N 121.7 -0.625 . . . . 0.0 109.626 -174.75 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.466 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 18.3 Cg_endo -63.44 174.07 3.79 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 123.907 1.477 . . . . 0.0 110.572 -179.307 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.415 ' HA ' HD11 ' A' ' 33' ' ' LEU . 53.4 t0 -60.01 -39.47 85.91 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.412 -0.805 . . . . 0.0 110.611 -177.011 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.581 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.95 -0.1 57.39 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.843 -1.161 . . . . 0.0 110.894 -175.012 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.581 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 95.9 mmm -109.71 -11.73 14.7 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.87 -1.143 . . . . 0.0 109.824 170.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.544 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 15.3 mt -69.23 -40.1 78.13 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.323 -0.861 . . . . 0.0 110.312 179.225 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -79.98 123.89 28.21 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.349 -0.844 . . . . 0.0 110.527 -177.06 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.12 -47.09 1.08 Allowed Glycine 0 N--CA 1.492 2.377 0 C-N-CA 119.829 -1.177 . . . . 0.0 110.401 175.128 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.426 ' C ' HD23 ' A' ' 36' ' ' LEU . 8.2 tt -67.34 147.37 53.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.985 -1.303 . . . . 0.0 110.727 -175.068 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.47 ' HA ' HD12 ' A' ' 54' ' ' ILE . 21.3 pt-20 -149.96 169.07 22.04 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.378 -0.826 . . . . 0.0 109.656 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.545 ' CG2' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -66.81 148.92 51.29 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.986 -1.071 . . . . 0.0 110.087 -179.985 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.9 -10.05 58.43 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 -175.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.469 ' HB3' ' O ' ' A' ' 37' ' ' GLU . . . -71.25 157.87 37.37 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.245 -1.15 . . . . 0.0 109.272 174.706 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.529 ' O ' ' CB ' ' A' ' 87' ' ' ALA . 1.6 p -105.34 116.82 32.59 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 118.533 -1.267 . . . . 0.0 109.754 176.012 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.58 HG12 ' CE1' ' A' ' 44' ' ' HIS . 1.6 t -99.63 126.38 53.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 121.333 -0.854 . . . . 0.0 109.006 175.353 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.474 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -88.31 119.53 28.81 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.234 -0.986 . . . . 0.0 109.089 173.374 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.58 ' CE1' HG12 ' A' ' 42' ' ' VAL . 0.4 OUTLIER -89.75 105.43 17.8 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 119.729 -0.788 . . . . 0.0 108.939 177.955 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.8 t-20 56.84 9.87 0.67 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.527 -0.733 . . . . 0.0 111.514 -170.316 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' B' ' 4' ' ' GLY . . . 126.57 -2.15 7.55 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.553 -1.308 . . . . 0.0 110.86 173.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.516 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 50.2 t -98.63 104.86 16.93 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.521 -1.576 . . . . 0.0 109.756 176.236 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.45 ' HA ' ' HA ' ' A' ' 43' ' ' ALA . 25.5 p -71.36 128.91 37.44 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.176 -0.952 . . . . 0.0 110.727 -174.453 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.632 ' CD1' ' CD2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -141.41 159.98 41.08 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.445 -0.785 . . . . 0.0 109.262 173.942 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 23.9 m -99.88 150.05 22.78 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 120.45 -1.406 . . . . 0.0 111.347 -170.252 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.575 ' CG1' HG12 ' A' ' 59' ' ' VAL . 34.9 t -76.25 116.44 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.941 -0.475 . . . . 0.0 110.318 -179.182 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.541 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 28.3 p -71.91 -39.96 69.15 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.365 -0.835 . . . . 0.0 109.789 174.186 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.532 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -163.27 152.9 15.21 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.272 -0.893 . . . . 0.0 110.362 -179.031 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.545 HD11 ' CG2' ' A' ' 38' ' ' THR . 7.6 mt -105.52 132.14 53.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.193 -0.942 . . . . 0.0 109.965 175.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.463 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 26.6 m-80 -104.92 64.78 0.73 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.63 -0.669 . . . . 0.0 109.594 179.229 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.65 -116.95 5.3 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 -173.126 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.544 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -77.0 -20.74 55.68 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.015 -1.285 . . . . 0.0 109.153 175.727 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.629 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 11.2 m80 -75.64 159.98 30.59 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.33 -0.856 . . . . 0.0 110.192 -177.593 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.575 HG12 ' CG1' ' A' ' 51' ' ' VAL . 53.6 t -140.69 123.07 15.55 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 C-N-CA 119.133 -1.027 . . . . 0.0 110.74 173.208 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.529 ' OG ' ' CG2' ' A' ' 25' ' ' VAL . 1.3 t -90.71 134.61 34.29 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.48 -0.762 . . . . 0.0 109.416 177.329 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.632 ' CD2' ' CD1' ' A' ' 49' ' ' LEU . 2.7 p90 -126.75 151.17 48.56 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.366 -0.833 . . . . 0.0 110.318 176.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.541 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 38.2 p-10 -86.66 154.87 20.67 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.084 -1.01 . . . . 0.0 111.422 -171.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.596 ' CD2' ' CD1' ' A' ' 68' ' ' LEU . 0.0 OUTLIER -161.9 100.42 1.12 Allowed 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.754 -0.591 . . . . 0.0 109.546 -175.49 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.46 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 33.0 ttp -60.68 140.06 57.63 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.883 -1.135 . . . . 0.0 109.52 -178.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.475 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 29.4 tptp -60.07 -48.31 82.23 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.891 -1.13 . . . . 0.0 110.473 -172.69 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -63.21 -39.99 96.19 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.714 -1.241 . . . . 0.0 109.806 177.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.46 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 55.2 m -60.05 -39.98 87.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.052 -1.03 . . . . 0.0 109.602 172.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.596 ' CD1' ' CD2' ' A' ' 63' ' ' LEU . 27.0 tp -61.64 -40.8 96.16 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.446 -0.784 . . . . 0.0 109.816 -179.592 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 15.5 ttm180 -69.92 -40.12 75.75 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.275 -0.891 . . . . 0.0 110.441 177.086 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.475 HG23 HG23 ' A' ' 71' ' ' THR . 1.2 tt -64.78 -44.58 96.42 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.285 -0.884 . . . . 0.0 109.602 -176.569 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.475 HG23 HG23 ' A' ' 70' ' ' ILE . 30.5 p -79.99 -174.98 4.73 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.561 -0.712 . . . . 0.0 109.25 175.258 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.499 ' CB ' ' N ' ' B' ' 83' ' ' ASN . 4.1 t30 -99.97 23.34 9.95 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.013 -1.054 . . . . 0.0 108.459 169.32 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.524 ' CD1' HD21 ' A' ' 63' ' ' LEU . 87.7 mt -69.18 -40.02 78.37 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.071 -1.018 . . . . 0.0 109.799 174.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.531 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -46.81 -22.44 1.15 Allowed Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.619 -0.993 . . . . 0.0 110.619 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.3 p-10 -68.98 -17.01 63.87 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.958 -1.319 . . . . 0.0 110.534 -174.668 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.503 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 98.4 mt -59.93 141.18 55.98 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.226 -0.921 . . . . 0.0 111.042 -176.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.481 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 24.9 mttm -142.38 143.04 32.51 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.734 -0.604 . . . . 0.0 109.762 173.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.54 ' CG2' HG13 ' A' ' 15' ' ' ILE . 32.2 t -63.15 150.09 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.914 -1.116 . . . . 0.0 110.391 -177.209 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.46 -14.82 60.17 Favored Glycine 0 N--CA 1.485 1.916 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 -175.646 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.494 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 41.9 t0 -94.28 167.7 11.37 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.328 -1.101 . . . . 0.0 109.637 175.839 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.581 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.2 m95 -116.67 158.8 23.2 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.976 -1.077 . . . . 0.0 110.036 175.038 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.572 HG21 ' CG ' ' A' ' 44' ' ' HIS . 1.1 p -121.28 155.27 25.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.389 -0.82 . . . . 0.0 109.917 179.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.513 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 0.2 OUTLIER -78.51 105.56 9.86 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 120.993 -1.067 . . . . 0.0 109.003 168.06 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.498 ' CG2' ' C ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -106.64 137.84 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 120.548 -1.345 . . . . 0.0 111.048 -176.96 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -138.98 140.09 38.11 Favored 'General case' 0 N--CA 1.492 1.629 0 C-N-CA 120.291 -0.564 . . . . 0.0 109.991 -177.319 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 53.0 ttt85 -60.06 127.05 29.97 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.155 -0.966 . . . . 0.0 110.293 -179.508 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.529 ' CB ' ' O ' ' A' ' 41' ' ' SER . . . -121.62 148.38 44.61 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.341 -0.849 . . . . 0.0 109.554 176.57 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.551 ' O ' ' CD1' ' B' ' 2' ' ' PHE . . . -132.72 147.56 52.33 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.255 -0.903 . . . . 0.0 111.401 -174.067 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . 0.554 ' HA ' ' CE1' ' B' ' 2' ' ' PHE . 10.3 pttt -71.87 -16.93 62.15 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.362 -0.836 . . . . 0.0 109.672 171.784 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 44.4 p90 -122.31 161.55 23.14 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.43 -0.794 . . . . 0.0 110.081 178.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' SER . . . . . 0.497 ' HB2' ' CG1' ' A' ' 94' ' ' ILE . 53.3 m -60.0 130.58 47.41 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.229 -0.919 . . . . 0.0 110.498 -176.124 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -69.48 -35.43 75.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.398 -0.814 . . . . 0.0 110.145 178.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -88.29 44.96 1.24 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.154 -0.966 . . . . 0.0 110.272 -179.777 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.51 ' O ' ' N ' ' A' ' 96' ' ' GLY . 15.1 mm -130.19 4.74 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.622 -0.674 . . . . 0.0 110.253 175.268 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -58.55 82.41 0.01 OUTLIER Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -178.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.51 ' N ' ' O ' ' A' ' 94' ' ' ILE . . . 179.98 175.92 47.01 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.346 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.252 -1.146 . . . . 0.0 110.14 179.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 1' ' ' MET . . . . . 0.461 ' O ' ' HG3' ' B' ' 1' ' ' MET . 8.7 ptt? . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 121.239 0.542 . . . . 0.0 110.38 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.554 ' CE1' ' HA ' ' A' ' 89' ' ' LYS . 1.4 p90 -168.42 132.16 1.55 Allowed 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.274 -0.891 . . . . 0.0 109.122 175.551 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.496 ' HB ' HG13 ' B' ' 5' ' ' ILE . 34.7 p -128.84 -31.35 2.18 Favored 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.059 -1.026 . . . . 0.0 110.226 -178.305 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' A' ' 46' ' ' GLY . . . 45.85 24.53 1.32 Allowed Glycine 0 N--CA 1.487 2.06 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -174.114 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.536 ' CD1' ' C8M' ' A' ' 98' ' ' RBF . 53.0 mt -85.25 144.29 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 120.98 -1.306 . . . . 0.0 110.588 -178.062 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.549 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.3 t -88.99 144.41 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.365 -0.834 . . . . 0.0 110.945 -175.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 99.5 mt-30 -69.98 -31.72 69.55 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.785 -0.572 . . . . 0.0 111.025 179.27 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.549 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -156.49 -178.09 30.28 Favored Glycine 0 N--CA 1.499 2.895 0 C-N-CA 118.632 -1.747 . . . . 0.0 110.857 -170.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.503 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.0 p -129.03 167.13 17.94 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.913 -1.345 . . . . 0.0 111.028 -178.426 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.514 ' CB ' HG12 ' B' ' 82' ' ' VAL . . . -139.88 150.04 44.13 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 -175.179 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.583 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 34.5 tttt -109.3 115.81 30.68 Favored 'General case' 0 C--N 1.295 -1.772 0 O-C-N 121.028 -1.045 . . . . 0.0 110.294 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.507 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 11.5 tp -60.24 127.61 32.64 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 120.945 -1.097 . . . . 0.0 108.905 172.62 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.627 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -126.84 -29.38 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.874 0 O-C-N 121.345 -0.847 . . . . 0.0 110.034 -178.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.67 144.11 24.14 Favored 'General case' 0 C--N 1.297 -1.681 0 C-N-CA 119.225 -0.99 . . . . 0.0 111.243 179.224 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.564 HG12 ' CD2' ' B' ' 24' ' ' HIS . 8.9 mt -107.88 141.1 23.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.292 -0.88 . . . . 0.0 110.242 174.617 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.473 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 79.5 m-20 -109.92 113.98 27.15 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.364 -0.835 . . . . 0.0 109.961 172.243 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -101.22 113.08 25.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.155 -0.966 . . . . 0.0 110.444 -178.06 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.47 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.0 OUTLIER -109.87 134.36 20.68 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.311 -0.868 . . . . 0.0 109.442 176.043 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.71 -16.66 11.62 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 O-C-N 123.971 1.511 . . . . 0.0 110.662 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 4.8 m-80 -100.51 -27.16 13.57 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.087 -1.008 . . . . 0.0 109.939 179.111 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 93.0 m-85 -157.37 150.33 23.44 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.416 -0.802 . . . . 0.0 109.814 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.464 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 57.0 ttt180 -93.62 141.16 28.79 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.67 -1.269 . . . . 0.0 110.036 174.137 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.473 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 94.7 m -129.95 141.07 50.82 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.579 -0.701 . . . . 0.0 109.767 -173.683 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.586 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -129.93 143.78 50.98 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.989 -1.069 . . . . 0.0 111.472 -179.161 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.538 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 6.4 t -123.38 132.93 70.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.161 -0.962 . . . . 0.0 110.709 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.556 HG13 ' CE1' ' B' ' 61' ' ' PHE . 26.7 m -115.08 174.44 3.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 121.688 -0.633 . . . . 0.0 110.226 178.677 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.513 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 12.8 tt0 -104.28 118.65 37.13 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.455 -0.778 . . . . 0.0 108.972 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.469 HD21 ' O ' ' B' ' 32' ' ' MET . 9.5 tp -81.13 122.58 81.69 Favored Pre-proline 0 C--N 1.296 -1.738 0 O-C-N 121.573 -0.704 . . . . 0.0 109.651 -174.818 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.479 ' HD2' ' HB2' ' B' ' 32' ' ' MET . 18.2 Cg_endo -63.43 174.01 3.84 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.842 1.443 . . . . 0.0 110.564 -179.35 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -60.02 -39.46 85.93 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.501 -0.749 . . . . 0.0 110.56 -176.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.578 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.03 0.05 57.32 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.932 -1.105 . . . . 0.0 110.848 -174.974 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.578 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 95.8 mmm -109.73 -11.75 14.7 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.83 -1.169 . . . . 0.0 109.846 170.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.541 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 15.3 mt -69.26 -40.02 78.09 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.32 -0.863 . . . . 0.0 110.305 179.272 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -80.06 123.91 28.27 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.266 -0.896 . . . . 0.0 110.463 -177.054 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.11 -47.1 1.08 Allowed Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.784 -1.198 . . . . 0.0 110.391 175.116 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . 0.428 HD22 ' N ' ' B' ' 37' ' ' GLU . 8.2 tt -67.26 147.3 53.19 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.001 -1.294 . . . . 0.0 110.805 -175.093 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.468 ' O ' ' HB2' ' B' ' 40' ' ' ALA . 21.3 pt-20 -150.02 168.94 22.41 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.432 -0.792 . . . . 0.0 109.677 -179.617 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.548 ' CG2' HD11 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -66.77 148.86 51.37 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.95 -1.094 . . . . 0.0 110.106 -179.912 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.0 -10.09 58.78 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -175.509 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.468 ' HB2' ' O ' ' B' ' 37' ' ' GLU . . . -71.33 157.76 37.53 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.17 -1.194 . . . . 0.0 109.102 174.669 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.526 ' O ' ' CB ' ' B' ' 87' ' ' ALA . 1.7 p -105.02 116.44 31.96 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 118.844 -1.142 . . . . 0.0 109.968 175.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.59 HG13 ' CE1' ' B' ' 44' ' ' HIS . 1.5 t -99.9 126.4 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.472 -0.768 . . . . 0.0 108.971 175.432 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.474 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -88.23 119.43 28.63 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.094 -1.004 . . . . 0.0 109.16 173.401 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.59 ' CE1' HG13 ' B' ' 42' ' ' VAL . 0.4 OUTLIER -89.7 105.26 17.68 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.369 -0.832 . . . . 0.0 109.019 177.934 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.8 t-20 57.13 9.77 0.72 Allowed 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.515 -0.74 . . . . 0.0 111.464 -170.427 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 4' ' ' GLY . . . 126.55 -1.93 7.55 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.504 -1.332 . . . . 0.0 110.84 173.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.519 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 50.1 t -98.85 104.79 16.87 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.534 -1.568 . . . . 0.0 109.707 176.257 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . 0.435 ' HA ' ' HA ' ' B' ' 43' ' ' ALA . 25.1 p -71.17 129.07 37.99 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.124 -0.985 . . . . 0.0 110.667 -174.489 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.638 ' CD1' ' CD2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -141.65 159.85 41.37 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.348 -0.845 . . . . 0.0 109.239 173.857 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 23.7 m -99.69 150.02 22.72 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.588 -1.32 . . . . 0.0 111.412 -170.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.469 ' HB ' ' HA ' ' B' ' 38' ' ' THR . 32.6 t -76.23 116.47 19.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.855 -0.528 . . . . 0.0 110.382 -179.225 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.537 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 28.6 p -71.92 -40.04 69.07 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.297 -0.877 . . . . 0.0 109.722 174.29 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.532 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -163.21 152.83 15.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.342 -0.849 . . . . 0.0 110.421 -178.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.548 HD11 ' CG2' ' B' ' 38' ' ' THR . 7.6 mt -105.51 132.03 53.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.295 -0.878 . . . . 0.0 110.012 175.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.482 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 26.5 m-80 -104.87 64.82 0.73 Allowed 'General case' 0 C--N 1.297 -1.698 0 C-N-CA 120.048 -0.661 . . . . 0.0 109.562 179.285 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.72 -117.0 5.3 Favored Glycine 0 N--CA 1.487 2.063 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 -173.182 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.541 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -76.97 -20.9 55.54 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.076 -1.249 . . . . 0.0 109.164 175.73 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.627 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 11.2 m80 -75.59 159.79 30.83 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.338 -0.851 . . . . 0.0 110.285 -177.683 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.472 HG21 ' O ' ' B' ' 58' ' ' HIS . 56.7 t -140.46 123.1 16.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.76 173.361 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.538 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 1.3 t -90.67 134.67 34.24 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.481 -0.762 . . . . 0.0 109.54 177.278 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.638 ' CD2' ' CD1' ' B' ' 49' ' ' LEU . 2.7 p90 -126.93 151.05 49.0 Favored 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.314 176.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.537 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 38.2 p-10 -86.39 154.81 20.9 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.927 -1.108 . . . . 0.0 111.442 -171.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.593 ' CD2' ' CD1' ' B' ' 68' ' ' LEU . 0.0 OUTLIER -161.94 100.42 1.12 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.76 -0.588 . . . . 0.0 109.608 -175.614 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.475 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 33.0 ttp -60.67 139.99 57.64 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.836 -1.165 . . . . 0.0 109.53 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.474 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 29.5 tptp -59.94 -48.41 81.81 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.946 -1.096 . . . . 0.0 110.469 -172.69 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -63.24 -40.02 96.25 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.792 -1.193 . . . . 0.0 109.792 177.467 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.475 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 55.5 m -60.01 -39.88 87.36 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.188 -0.945 . . . . 0.0 109.657 172.691 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.593 ' CD1' ' CD2' ' B' ' 63' ' ' LEU . 27.1 tp -61.73 -40.66 95.84 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.504 -0.748 . . . . 0.0 109.892 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 15.6 ttm180 -69.96 -40.01 75.66 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.34 -0.85 . . . . 0.0 110.52 176.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.463 HG21 " O4'" ' B' ' 99' ' ' RBF . 1.2 tt -64.87 -44.47 96.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.296 -0.877 . . . . 0.0 109.623 -176.618 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.47 HG23 ' O ' ' B' ' 67' ' ' THR . 30.4 p -80.18 -174.89 4.76 Favored 'General case' 0 C--N 1.301 -1.538 0 C-N-CA 119.84 -0.744 . . . . 0.0 109.294 175.247 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.5 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 3.9 t30 -99.97 23.41 9.87 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.069 -1.02 . . . . 0.0 108.406 169.458 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.533 ' CD1' HD23 ' B' ' 63' ' ' LEU . 87.7 mt -69.25 -40.03 78.11 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.09 -1.006 . . . . 0.0 109.768 174.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.531 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -46.81 -22.38 1.14 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -179.365 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.3 p-10 -69.08 -16.9 63.79 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.905 -1.35 . . . . 0.0 110.488 -174.62 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.503 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.3 mt -60.1 141.29 56.04 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.229 -0.92 . . . . 0.0 111.06 -176.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.477 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 24.9 mttm -142.47 143.07 32.42 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.725 -0.61 . . . . 0.0 109.694 174.073 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.552 ' CG2' HG13 ' B' ' 15' ' ' ILE . 32.7 t -63.19 150.05 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.924 -1.11 . . . . 0.0 110.317 -177.188 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.38 -14.7 60.4 Favored Glycine 0 N--CA 1.486 1.974 0 N-CA-C 108.777 -1.729 . . . . 0.0 108.777 -175.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.488 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 41.8 t0 -94.43 167.68 11.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.426 -1.044 . . . . 0.0 109.635 175.749 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.583 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.1 m95 -116.64 158.83 23.12 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.074 -1.016 . . . . 0.0 110.068 175.088 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.575 HG21 ' CG ' ' B' ' 44' ' ' HIS . 1.0 OUTLIER -121.32 155.33 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.419 -0.801 . . . . 0.0 109.887 179.457 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.499 ' N ' ' CB ' ' A' ' 72' ' ' ASN . 0.2 OUTLIER -78.39 105.29 9.55 Favored 'General case' 0 C--N 1.297 -1.674 0 O-C-N 121.105 -0.997 . . . . 0.0 109.147 168.007 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.503 ' CG2' ' C ' ' B' ' 9' ' ' THR . 0.0 OUTLIER -106.49 138.12 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 120.596 -1.315 . . . . 0.0 110.894 -176.821 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -139.29 140.21 37.55 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 120.268 -0.573 . . . . 0.0 109.914 -177.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 53.0 ttt85 -59.99 127.04 29.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.176 -0.953 . . . . 0.0 110.267 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.526 ' CB ' ' O ' ' B' ' 41' ' ' SER . . . -121.28 148.95 43.62 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.442 -0.786 . . . . 0.0 109.444 176.564 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . 0.558 ' O ' ' CD1' ' A' ' 2' ' ' PHE . . . -133.3 147.47 51.89 Favored 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.454 -0.899 . . . . 0.0 111.331 -174.287 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . 0.552 ' HA ' ' CE1' ' A' ' 2' ' ' PHE . 10.3 pttt -71.76 -16.93 62.22 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.42 -0.8 . . . . 0.0 109.657 171.839 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 44.4 p90 -122.4 161.62 23.13 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.475 -0.766 . . . . 0.0 110.009 179.092 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 91' ' ' SER . . . . . 0.522 ' HB3' ' CG1' ' B' ' 94' ' ' ILE . 53.8 m -60.07 130.48 46.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.232 -0.918 . . . . 0.0 110.522 -176.096 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . 0.449 ' O ' ' HG3' ' B' ' 93' ' ' GLU . 96.0 m-20 -69.88 -40.1 75.88 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.419 -0.801 . . . . 0.0 110.39 178.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . 0.449 ' HG3' ' O ' ' B' ' 92' ' ' ASP . 98.8 mt-10 -153.95 54.15 0.71 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.221 -0.925 . . . . 0.0 110.149 -176.051 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . 0.524 ' O ' ' N ' ' B' ' 96' ' ' GLY . 21.5 mm -101.04 6.58 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.309 -0.869 . . . . 0.0 110.354 179.54 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . -49.97 90.48 0.01 OUTLIER Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 -178.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' B' ' 94' ' ' ILE . . . 80.52 12.47 82.94 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 178.011 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 83.5 t60 . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.076 -1.249 . . . . 0.0 110.135 178.225 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.536 ' C8M' ' CD1' ' B' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.532 ' C8M' ' CD1' ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.4 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 96.0 mmm . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 121.192 0.52 . . . . 0.0 110.255 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.602 ' CZ ' ' CB ' ' B' ' 87' ' ' ALA . 12.8 p90 -176.41 154.87 1.36 Allowed 'General case' 0 C--N 1.306 -1.309 0 O-C-N 121.252 -0.905 . . . . 0.0 109.027 179.085 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.534 ' HB ' ' CD1' ' A' ' 5' ' ' ILE . 71.8 p -151.79 -40.26 0.11 Allowed 'General case' 0 C--N 1.297 -1.715 0 O-C-N 120.915 -1.116 . . . . 0.0 109.174 178.348 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.467 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 45.65 24.81 1.27 Allowed Glycine 0 N--CA 1.483 1.796 0 N-CA-C 108.57 -1.812 . . . . 0.0 108.57 -174.224 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.534 ' CD1' ' HB ' ' A' ' 3' ' ' THR . 95.3 mt -76.88 138.61 20.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.228 -1.16 . . . . 0.0 110.296 -176.181 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.529 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.2 t -97.97 147.66 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.353 -0.842 . . . . 0.0 110.399 -175.029 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -95.21 -22.06 18.06 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.493 -0.755 . . . . 0.0 110.75 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.529 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -144.43 175.59 24.1 Favored Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.081 -1.533 . . . . 0.0 109.968 -176.209 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.434 ' C ' HG22 ' A' ' 84' ' ' VAL . 6.2 p -127.51 166.04 18.72 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.06 -1.259 . . . . 0.0 110.625 179.227 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.516 ' CB ' ' CG1' ' A' ' 82' ' ' VAL . . . -133.94 148.84 51.23 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.598 -0.689 . . . . 0.0 109.258 -178.681 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 23.5 tttt -107.66 116.89 32.76 Favored 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.113 -0.992 . . . . 0.0 110.147 179.353 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.515 HD22 ' N ' ' A' ' 78' ' ' VAL . 12.2 tp -59.92 126.32 27.08 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 120.876 -1.14 . . . . 0.0 108.914 173.333 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.595 HG13 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -124.95 -30.8 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 C-N-CA 119.744 -0.782 . . . . 0.0 109.718 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.59 142.36 27.89 Favored 'General case' 0 N--CA 1.492 1.653 0 C-N-CA 119.214 -0.995 . . . . 0.0 111.127 -178.098 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.582 HG12 ' CD2' ' A' ' 24' ' ' HIS . 10.6 mt -108.62 130.19 61.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.113 -0.992 . . . . 0.0 110.314 172.4 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.479 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 74.1 m-20 -104.49 117.76 34.95 Favored 'General case' 0 C--N 1.295 -1.769 0 O-C-N 121.376 -0.827 . . . . 0.0 109.809 172.755 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -107.4 105.31 15.18 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.146 -0.971 . . . . 0.0 110.176 -177.518 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.472 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 2.1 mmmt -102.2 130.56 23.98 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.347 -0.846 . . . . 0.0 109.282 179.219 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -51.5 -19.43 7.12 Favored 'Trans proline' 0 C--N 1.303 -1.856 0 O-C-N 123.913 1.481 . . . . 0.0 110.573 -179.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.573 ' O ' ' CD1' ' A' ' 21' ' ' PHE . 0.3 OUTLIER -90.54 -38.37 13.24 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.169 -0.957 . . . . 0.0 109.102 177.268 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.573 ' CD1' ' O ' ' A' ' 20' ' ' ASN . 64.6 m-85 -153.15 150.18 28.8 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.833 -0.542 . . . . 0.0 110.148 -177.651 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.472 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 63.4 ttt180 -88.43 145.03 26.01 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.6 -1.313 . . . . 0.0 109.941 174.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.479 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 84.8 m -133.08 140.82 47.87 Favored 'General case' 0 C--N 1.296 -1.752 0 O-C-N 121.407 -0.808 . . . . 0.0 109.946 -174.173 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.582 ' CD2' HG12 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.03 131.96 46.04 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.767 -1.208 . . . . 0.0 111.561 -179.669 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 4.0 t -109.85 132.28 58.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.184 -0.947 . . . . 0.0 110.537 -178.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.469 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 15.5 m -117.44 169.85 7.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 120.359 -0.537 . . . . 0.0 110.343 -179.111 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.479 ' HG3' ' NE2' ' A' ' 58' ' ' HIS . 13.1 tt0 -103.22 118.31 36.5 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.215 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.513 ' CD2' ' O ' ' A' ' 32' ' ' MET . 9.5 tp -84.14 126.37 70.05 Favored Pre-proline 0 C--N 1.298 -1.667 0 O-C-N 121.327 -0.858 . . . . 0.0 109.759 -175.073 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.46 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 17.7 Cg_endo -64.27 176.84 2.37 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 123.903 1.475 . . . . 0.0 110.927 -179.192 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 77.4 m-20 -60.06 -39.94 87.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.427 -0.796 . . . . 0.0 110.997 -176.37 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.557 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.13 2.57 55.15 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.797 -1.19 . . . . 0.0 110.744 -174.457 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.557 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 89.1 mmm -113.07 -11.89 13.27 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.912 -1.118 . . . . 0.0 109.991 170.364 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.525 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 18.1 mt -69.97 -40.1 75.58 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.321 -0.862 . . . . 0.0 110.378 178.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -82.68 115.76 21.76 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.905 . . . . 0.0 110.505 -176.384 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.61 -52.75 0.69 Allowed Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.81 -1.186 . . . . 0.0 110.376 175.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.48 HD11 ' CB ' ' A' ' 40' ' ' ALA . 42.6 tp -61.52 151.34 33.23 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.955 -1.321 . . . . 0.0 110.851 -173.471 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.471 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 20.9 pt-20 -149.95 168.33 24.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.468 -0.77 . . . . 0.0 109.484 178.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.528 ' CG2' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -66.09 152.84 43.82 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.885 -1.134 . . . . 0.0 109.982 -178.985 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.31 -4.72 66.31 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -176.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.48 ' CB ' HD11 ' A' ' 36' ' ' LEU . . . -77.26 156.64 31.27 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.291 -1.123 . . . . 0.0 109.668 176.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.468 ' HB2' ' HB3' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -100.61 108.24 20.09 Favored 'General case' 0 C--N 1.306 -1.286 0 O-C-N 121.103 -0.998 . . . . 0.0 110.087 178.629 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.581 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 2.2 t -94.24 129.45 44.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.224 -0.923 . . . . 0.0 109.125 174.203 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.453 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -93.33 119.54 32.59 Favored 'General case' 0 C--N 1.296 -1.724 0 C-N-CA 119.258 -0.977 . . . . 0.0 109.07 171.572 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.575 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.3 OUTLIER -89.17 102.6 15.26 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.64 -0.824 . . . . 0.0 108.94 178.463 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.497 ' N ' ' O ' ' A' ' 83' ' ' ASN . 1.7 t-20 58.22 11.49 1.58 Allowed 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.449 -0.782 . . . . 0.0 110.772 -169.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.491 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.16 -2.29 11.56 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.777 -1.201 . . . . 0.0 110.891 172.672 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.491 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 43.0 t -92.16 109.17 20.53 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.39 -1.653 . . . . 0.0 109.389 174.352 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 15.8 p -74.89 128.43 35.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.099 -1.001 . . . . 0.0 110.844 -171.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.52 ' CB ' ' O4 ' ' A' ' 98' ' ' RBF . 0.4 OUTLIER -146.96 157.0 43.5 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.347 -0.846 . . . . 0.0 109.499 173.741 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 23.9 m -97.5 159.0 15.18 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.735 -1.228 . . . . 0.0 111.296 -170.6 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.556 ' CG1' HG12 ' A' ' 59' ' ' VAL . 22.4 t -83.26 116.63 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.832 -0.542 . . . . 0.0 110.43 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.529 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 39.4 p -70.0 -39.91 75.6 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.241 -0.912 . . . . 0.0 109.715 172.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.515 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.9 tt0 -160.95 154.83 22.5 Favored 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 119.357 -0.937 . . . . 0.0 111.204 -175.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.528 HD11 ' CG2' ' A' ' 38' ' ' THR . 6.4 mt -110.06 129.99 64.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.091 -1.006 . . . . 0.0 110.044 169.497 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.453 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 27.7 m-80 -103.7 65.12 0.82 Allowed 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.592 -0.692 . . . . 0.0 109.514 176.648 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.49 -113.4 3.82 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.812 -1.715 . . . . 0.0 108.812 -173.263 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.525 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -79.99 -21.07 44.09 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.05 -1.265 . . . . 0.0 109.168 175.405 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.595 ' CD2' HG13 ' A' ' 13' ' ' VAL . 8.5 m170 -77.65 159.99 28.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.246 -0.909 . . . . 0.0 110.112 -176.488 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.624 ' CG1' ' CZ ' ' A' ' 61' ' ' PHE . 97.7 t -144.4 115.43 2.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 C-N-CA 119.309 -0.957 . . . . 0.0 110.891 177.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.532 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 13.7 m -81.74 130.15 34.96 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.677 -0.639 . . . . 0.0 109.849 178.465 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.624 ' CZ ' ' CG1' ' A' ' 59' ' ' VAL . 96.4 m-85 -115.19 159.98 20.28 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.952 -1.092 . . . . 0.0 110.235 178.037 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.529 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 25.7 p-10 -95.2 147.81 23.07 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.163 -0.961 . . . . 0.0 111.335 -177.019 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.524 HD21 ' CD1' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -159.14 116.47 2.75 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.718 -0.614 . . . . 0.0 109.559 -175.729 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.464 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 57.9 ttm -75.27 146.97 40.63 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.863 -1.148 . . . . 0.0 109.852 179.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.466 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 39.0 ttpt -60.07 -49.75 76.4 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.078 -1.014 . . . . 0.0 110.305 -177.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -63.95 -42.46 97.3 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.895 -1.128 . . . . 0.0 110.17 178.574 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.492 ' O ' HG21 ' A' ' 71' ' ' THR . 69.4 m -60.31 -40.04 89.12 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.932 -1.105 . . . . 0.0 109.606 174.332 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.526 ' HG ' ' CA ' ' A' ' 74' ' ' GLY . 11.7 tp -59.99 -43.16 95.33 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.288 -0.882 . . . . 0.0 109.582 177.756 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 16.4 mmm180 -70.0 -40.07 75.52 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.57 -0.706 . . . . 0.0 110.608 177.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.478 ' CG2' ' N ' ' A' ' 71' ' ' THR . 1.5 tt -66.15 -43.72 91.95 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.209 -0.932 . . . . 0.0 109.329 -177.169 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.492 HG21 ' O ' ' A' ' 67' ' ' THR . 32.9 p -84.7 -171.01 3.4 Favored 'General case' 0 C--N 1.297 -1.68 0 CA-C-O 121.361 0.601 . . . . 0.0 109.673 178.013 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.519 ' CB ' ' N ' ' B' ' 83' ' ' ASN . 1.6 t30 -103.2 21.84 15.14 Favored 'General case' 0 C--N 1.293 -1.862 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 170.477 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.524 ' CD1' HD21 ' A' ' 63' ' ' LEU . 91.5 mt -66.26 -40.0 89.84 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.939 -1.101 . . . . 0.0 109.787 173.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.526 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -49.79 -25.17 6.75 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -178.543 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 24.0 p-10 -65.99 -16.63 64.06 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.001 -1.294 . . . . 0.0 110.508 -174.816 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 96.2 mt -60.01 140.17 56.96 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.151 -0.968 . . . . 0.0 110.65 -176.805 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.487 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 26.0 mttt -144.07 140.33 29.43 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-O 121.346 0.593 . . . . 0.0 109.688 176.01 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.571 ' CG2' HG13 ' A' ' 15' ' ' ILE . 18.8 t -61.77 150.17 8.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 120.686 -1.259 . . . . 0.0 110.524 -173.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.61 -13.63 63.57 Favored Glycine 0 N--CA 1.482 1.733 0 N-CA-C 108.855 -1.698 . . . . 0.0 108.855 -176.463 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.408 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 34.8 t0 -95.36 169.94 9.72 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.324 -1.104 . . . . 0.0 109.459 175.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.584 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.3 m95 -117.47 168.31 10.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.908 -1.12 . . . . 0.0 110.245 175.785 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.575 HG21 ' CG ' ' A' ' 44' ' ' HIS . 1.4 p -130.17 153.05 38.37 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.491 -0.756 . . . . 0.0 109.696 179.369 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.533 ' N ' ' CB ' ' B' ' 72' ' ' ASN . 2.2 m-20 -79.77 106.02 11.5 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 120.89 -1.131 . . . . 0.0 109.043 170.019 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.459 HG11 HG23 ' A' ' 82' ' ' VAL . 0.1 OUTLIER -106.23 139.98 25.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 120.481 -1.387 . . . . 0.0 111.37 -175.042 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.467 ' HB2' HG23 ' A' ' 6' ' ' VAL . 86.5 tt0 -131.02 142.6 50.34 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.037 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 39.6 ttm180 -81.24 121.07 25.7 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 110.481 -178.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.58 ' CB ' ' CZ ' ' B' ' 2' ' ' PHE . . . -118.04 144.49 45.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.23 -0.919 . . . . 0.0 110.124 176.57 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -126.21 142.13 51.65 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-O 121.48 0.657 . . . . 0.0 110.687 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 28.2 mmtp -60.52 -38.83 85.64 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.531 -0.73 . . . . 0.0 110.157 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.456 ' CD1' ' N ' ' A' ' 90' ' ' PHE . 33.2 p90 -132.44 157.13 45.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.288 -0.882 . . . . 0.0 110.314 -178.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' SER . . . . . 0.463 ' HB2' HG12 ' A' ' 94' ' ' ILE . 87.7 p -85.84 156.95 20.34 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.34 -0.85 . . . . 0.0 110.319 -179.129 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.472 ' O ' ' HG3' ' A' ' 93' ' ' GLU . 95.9 m-20 -70.97 -56.14 6.82 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.195 -0.941 . . . . 0.0 110.363 179.306 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.472 ' HG3' ' O ' ' A' ' 92' ' ' ASP . 98.8 mt-10 -154.97 59.95 0.66 Allowed 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.206 -0.934 . . . . 0.0 111.052 -172.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.463 HG12 ' HB2' ' A' ' 91' ' ' SER . 26.0 mm -64.26 -39.96 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.855 -1.153 . . . . 0.0 109.631 173.651 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 100.51 -47.59 1.24 Allowed Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 178.688 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 68.83 -155.09 53.51 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 24.7 p-80 . . . . . 0 N--CA 1.491 1.593 0 O-C-N 121.242 -1.152 . . . . 0.0 110.184 179.73 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 99.4 mtp . . . . . 0 N--CA 1.496 1.87 0 CA-C-O 122.378 1.085 . . . . 0.0 109.676 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.58 ' CZ ' ' CB ' ' A' ' 87' ' ' ALA . 13.5 p90 -174.68 154.85 2.06 Favored 'General case' 0 C--N 1.281 -2.373 0 CA-C-N 115.283 -0.871 . . . . 0.0 108.88 179.369 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.537 ' HB ' ' CD1' ' B' ' 5' ' ' ILE . 72.4 p -151.74 -40.32 0.11 Allowed 'General case' 0 C--N 1.295 -1.788 0 O-C-N 120.967 -1.083 . . . . 0.0 109.226 178.405 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.458 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 45.74 24.68 1.29 Allowed Glycine 0 N--CA 1.484 1.837 0 N-CA-C 108.616 -1.794 . . . . 0.0 108.616 -174.225 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.537 ' CD1' ' HB ' ' B' ' 3' ' ' THR . 95.6 mt -76.92 138.58 20.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.209 -1.171 . . . . 0.0 110.334 -176.104 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.528 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.2 t -97.87 147.76 6.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.314 -0.866 . . . . 0.0 110.398 -174.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -95.35 -21.78 18.17 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.483 -0.76 . . . . 0.0 110.788 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.528 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -144.63 175.4 24.35 Favored Glycine 0 N--CA 1.493 2.459 0 C-N-CA 119.273 -1.441 . . . . 0.0 110.141 -176.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.442 ' C ' HG22 ' B' ' 84' ' ' VAL . 6.1 p -127.45 166.09 18.58 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.118 -1.225 . . . . 0.0 110.589 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.514 ' CB ' ' CG1' ' B' ' 82' ' ' VAL . . . -133.9 148.98 51.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.631 -0.668 . . . . 0.0 109.254 -178.75 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.581 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 23.6 tttt -107.79 116.91 32.81 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.121 -0.987 . . . . 0.0 110.109 179.326 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.505 HD21 ' N ' ' B' ' 78' ' ' VAL . 12.2 tp -59.96 126.3 27.02 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.963 -1.086 . . . . 0.0 108.98 173.308 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.595 HG12 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -124.93 -30.86 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 O-C-N 121.451 -0.781 . . . . 0.0 109.724 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.56 142.45 28.01 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.37 -0.932 . . . . 0.0 111.098 -178.135 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.574 HG12 ' CD2' ' B' ' 24' ' ' HIS . 10.7 mt -108.68 130.24 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.176 -0.952 . . . . 0.0 110.315 172.4 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.489 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 73.5 m-20 -104.71 117.88 35.18 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.287 -0.883 . . . . 0.0 109.662 172.892 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -107.4 105.37 15.26 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.105 -0.997 . . . . 0.0 110.157 -177.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.473 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 2.1 mmmt -102.23 130.5 24.08 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.427 -0.796 . . . . 0.0 109.276 179.189 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -51.55 -19.33 7.11 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 123.889 1.468 . . . . 0.0 110.606 -179.491 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.587 ' ND2' ' N ' ' B' ' 20' ' ' ASN . 0.3 OUTLIER -90.43 -38.94 12.95 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.176 -0.952 . . . . 0.0 108.941 177.272 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' B' ' 20' ' ' ASN . 64.8 m-85 -152.71 150.27 29.26 Favored 'General case' 0 N--CA 1.494 1.765 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.15 -177.562 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.471 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 63.5 ttt180 -88.47 144.89 26.07 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.701 -1.249 . . . . 0.0 109.889 174.421 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.489 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 84.9 m -132.96 140.84 48.01 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.55 -0.719 . . . . 0.0 109.927 -174.213 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.574 ' CD2' HG12 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -129.98 132.1 46.17 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.941 -1.099 . . . . 0.0 111.454 -179.654 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.528 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 4.0 t -109.89 132.44 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.349 -0.844 . . . . 0.0 110.571 -178.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.479 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 16.0 m -117.61 169.78 7.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 CA-C-O 121.304 0.573 . . . . 0.0 110.215 -178.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.469 ' HG3' ' NE2' ' B' ' 58' ' ' HIS . 13.1 tt0 -103.09 118.48 36.89 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.102 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.519 ' CD2' ' O ' ' B' ' 32' ' ' MET . 9.5 tp -84.2 126.31 70.09 Favored Pre-proline 0 C--N 1.297 -1.711 0 O-C-N 121.254 -0.904 . . . . 0.0 109.749 -175.122 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.472 ' HD2' HD12 ' B' ' 28' ' ' LEU . 17.7 Cg_endo -64.27 176.8 2.39 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 O-C-N 123.865 1.455 . . . . 0.0 110.869 -179.191 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 77.3 m-20 -60.04 -40.0 87.88 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.413 -0.805 . . . . 0.0 111.007 -176.38 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.559 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.96 2.49 55.04 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.863 -1.148 . . . . 0.0 110.847 -174.552 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.559 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 89.2 mmm -113.06 -11.94 13.27 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.894 -1.129 . . . . 0.0 110.012 170.373 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.519 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 18.1 mt -69.96 -40.05 75.64 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.245 -0.91 . . . . 0.0 110.404 178.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -82.67 115.78 21.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.201 -0.937 . . . . 0.0 110.48 -176.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.62 -52.74 0.69 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.81 -1.185 . . . . 0.0 110.4 175.378 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 42.8 tp -61.65 151.42 33.61 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.919 -1.342 . . . . 0.0 110.795 -173.41 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.478 ' HA ' HD13 ' B' ' 54' ' ' ILE . 20.9 pt-20 -149.96 168.37 24.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.531 -0.731 . . . . 0.0 109.452 178.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.518 ' CG2' HD12 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.2 152.68 44.32 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.882 -1.136 . . . . 0.0 109.995 -178.921 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.52 -4.73 67.13 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 -176.388 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.478 ' HB2' ' O ' ' B' ' 37' ' ' GLU . . . -77.4 156.48 31.15 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.299 -1.118 . . . . 0.0 109.616 176.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.461 ' HB2' ' HB2' ' B' ' 87' ' ' ALA . 0.1 OUTLIER -100.26 108.1 20.09 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.059 -1.026 . . . . 0.0 110.173 178.616 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.582 ' HB ' ' CE1' ' B' ' 61' ' ' PHE . 2.2 t -94.37 129.52 44.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.263 -0.898 . . . . 0.0 109.147 174.178 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.449 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -93.27 119.58 32.59 Favored 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 119.231 -0.988 . . . . 0.0 109.042 171.635 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.581 ' CE1' HG11 ' B' ' 42' ' ' VAL . 0.3 OUTLIER -89.21 102.55 15.21 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.319 -0.863 . . . . 0.0 108.946 178.434 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.488 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.8 t-20 58.38 11.47 1.66 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.511 -0.743 . . . . 0.0 110.68 -170.007 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.491 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.07 -2.13 11.65 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.888 172.662 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.481 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 43.4 t -92.35 109.18 20.56 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.428 -1.631 . . . . 0.0 109.355 174.319 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 15.9 p -74.78 128.57 35.88 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.161 -0.962 . . . . 0.0 110.744 -171.736 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.519 ' CD1' ' HB3' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -147.2 156.85 43.31 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.448 -0.782 . . . . 0.0 109.477 173.649 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 23.8 m -97.26 159.09 15.12 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.737 -1.227 . . . . 0.0 111.281 -170.502 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.55 ' CG1' HG12 ' B' ' 59' ' ' VAL . 22.7 t -83.39 116.72 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.679 -0.638 . . . . 0.0 110.437 -178.524 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.523 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 39.8 p -70.01 -39.96 75.51 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.159 -0.963 . . . . 0.0 109.664 172.843 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.517 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.9 tt0 -160.93 154.76 22.43 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.409 -0.916 . . . . 0.0 111.172 -175.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.518 HD12 ' CG2' ' B' ' 38' ' ' THR . 6.4 mt -109.97 129.99 63.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.115 -0.991 . . . . 0.0 110.03 169.525 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.458 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 27.6 m-80 -103.74 65.1 0.81 Allowed 'General case' 0 C--N 1.299 -1.615 0 C-N-CA 119.862 -0.735 . . . . 0.0 109.564 176.608 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.68 -113.43 3.81 Favored Glycine 0 N--CA 1.486 2.012 0 N-CA-C 108.715 -1.754 . . . . 0.0 108.715 -173.279 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.519 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.02 -21.1 43.93 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.061 -1.258 . . . . 0.0 109.152 175.45 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.595 ' CD2' HG12 ' B' ' 13' ' ' VAL . 8.5 m170 -77.54 159.81 29.05 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.186 -0.947 . . . . 0.0 110.108 -176.535 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.63 ' CG1' ' CZ ' ' B' ' 61' ' ' PHE . 97.1 t -144.31 115.47 2.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 C-N-CA 119.284 -0.967 . . . . 0.0 110.912 177.71 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.528 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 13.7 m -81.83 130.28 35.02 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.751 -0.593 . . . . 0.0 109.931 178.494 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.63 ' CZ ' ' CG1' ' B' ' 59' ' ' VAL . 96.4 m-85 -115.27 160.02 20.29 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.977 -1.077 . . . . 0.0 110.275 178.107 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.523 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 25.7 p-10 -95.2 147.77 23.11 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.012 -1.055 . . . . 0.0 111.273 -176.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.526 HD22 ' CD1' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.16 116.43 2.73 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.788 -0.57 . . . . 0.0 109.538 -175.744 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.454 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 58.0 ttm -75.25 146.99 40.66 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.867 -1.146 . . . . 0.0 109.851 179.275 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.463 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 39.0 ttpt -60.04 -49.88 75.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.041 -1.037 . . . . 0.0 110.249 -177.63 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -63.94 -42.4 97.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.888 -1.132 . . . . 0.0 110.241 178.64 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.478 HG21 ' O2 ' ' B' ' 99' ' ' RBF . 71.3 m -60.27 -40.07 89.08 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.003 -1.061 . . . . 0.0 109.671 174.258 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.532 ' CD1' ' HA2' ' B' ' 74' ' ' GLY . 11.7 tp -59.94 -43.18 95.13 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.438 -0.789 . . . . 0.0 109.559 177.733 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 16.4 mmm180 -69.98 -39.93 75.65 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.562 -0.711 . . . . 0.0 110.665 177.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.472 ' CG2' ' N ' ' B' ' 71' ' ' THR . 1.5 tt -66.22 -43.69 91.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 CA-C-O 121.922 0.868 . . . . 0.0 109.363 -177.195 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.472 ' N ' ' CG2' ' B' ' 70' ' ' ILE . 33.0 p -84.6 -170.77 3.28 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 121.44 0.638 . . . . 0.0 109.708 177.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.533 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 1.6 t30 -103.39 21.82 15.31 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 170.531 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.526 ' CD1' HD22 ' B' ' 63' ' ' LEU . 91.7 mt -66.22 -40.02 89.99 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.917 -1.114 . . . . 0.0 109.736 173.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.532 ' HA2' ' CD1' ' B' ' 68' ' ' LEU . . . -49.78 -25.18 6.75 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 110.429 -1.068 . . . . 0.0 110.429 -178.496 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 24.2 p-10 -66.02 -16.64 64.08 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.995 -1.297 . . . . 0.0 110.433 -174.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.517 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 96.2 mt -59.98 140.21 56.91 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.155 -0.965 . . . . 0.0 110.639 -176.784 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.482 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 26.0 mttt -144.13 140.4 29.39 Favored 'General case' 0 C--N 1.296 -1.737 0 O-C-N 121.796 -0.565 . . . . 0.0 109.675 175.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.567 ' CG2' HG13 ' B' ' 15' ' ' ILE . 19.0 t -61.82 150.25 8.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 120.942 -1.099 . . . . 0.0 110.536 -173.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.47 -13.49 63.73 Favored Glycine 0 N--CA 1.483 1.778 0 N-CA-C 108.959 -1.656 . . . . 0.0 108.959 -176.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.413 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 34.4 t0 -95.35 169.95 9.71 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.366 -1.079 . . . . 0.0 109.51 175.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.581 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.3 m95 -117.52 168.19 10.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.951 -1.093 . . . . 0.0 110.261 175.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.572 HG22 ' CG ' ' B' ' 44' ' ' HIS . 1.4 p -130.15 153.14 38.49 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.465 -0.772 . . . . 0.0 109.63 179.307 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.519 ' N ' ' CB ' ' A' ' 72' ' ' ASN . 2.1 m-20 -79.77 105.72 11.27 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 120.97 -1.081 . . . . 0.0 109.158 170.023 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.444 HG11 HG21 ' B' ' 82' ' ' VAL . 0.1 OUTLIER -106.06 140.0 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.45 -1.406 . . . . 0.0 111.331 -174.873 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -131.01 142.69 50.35 Favored 'General case' 0 N--CA 1.492 1.675 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.059 179.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 39.5 ttm180 -81.31 121.2 25.9 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.36 -0.838 . . . . 0.0 110.351 -178.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.602 ' CB ' ' CZ ' ' A' ' 2' ' ' PHE . . . -117.97 144.63 45.35 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.275 -0.891 . . . . 0.0 110.158 176.491 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -126.41 142.05 51.67 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.644 -0.66 . . . . 0.0 110.663 -177.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 28.2 mmtp -60.5 -38.89 85.81 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.481 -0.762 . . . . 0.0 110.102 179.112 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . 0.454 ' CD1' ' N ' ' B' ' 90' ' ' PHE . 33.2 p90 -132.39 157.09 45.43 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.241 -0.912 . . . . 0.0 110.357 -178.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 91' ' ' SER . . . . . 0.516 ' CB ' HD12 ' B' ' 94' ' ' ILE . 87.4 p -85.84 156.78 20.41 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.247 -0.908 . . . . 0.0 110.32 -179.114 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . 0.464 ' O ' ' HB3' ' B' ' 93' ' ' GLU . 96.0 m-20 -70.39 -44.33 68.21 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.138 -0.976 . . . . 0.0 110.229 179.171 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . 0.525 ' O ' ' CG ' ' B' ' 93' ' ' GLU . 4.8 pt-20 -177.28 54.09 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.336 -0.853 . . . . 0.0 110.489 176.287 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . 0.516 HD12 ' CB ' ' B' ' 91' ' ' SER . 57.1 mt -62.29 -40.03 86.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.083 -1.01 . . . . 0.0 110.034 178.7 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 89.53 -41.4 3.01 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.135 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . 95.95 -0.03 62.29 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.646 -1.381 . . . . 0.0 109.646 -178.7 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 1.5 t-80 . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.122 -1.222 . . . . 0.0 110.192 179.559 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.52 ' O4 ' ' CB ' ' A' ' 49' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.517 ' O4 ' ' CB ' ' B' ' 49' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 59.8 ttm . . . . . 0 N--CA 1.496 1.826 0 CA-C-O 121.376 0.607 . . . . 0.0 110.344 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.583 ' CZ ' ' HA ' ' B' ' 88' ' ' ALA . 5.2 p90 -166.0 141.2 4.74 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.407 -0.808 . . . . 0.0 109.231 174.161 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.493 ' HB ' HG13 ' A' ' 5' ' ' ILE . 26.4 p -140.95 -34.94 0.49 Allowed 'General case' 0 C--N 1.296 -1.755 0 O-C-N 121.091 -1.006 . . . . 0.0 110.095 -175.06 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.424 ' O ' ' O ' ' B' ' 46' ' ' GLY . . . 44.81 24.99 0.82 Allowed Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.031 -1.627 . . . . 0.0 109.031 -173.679 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.53 HD13 ' C9 ' ' B' ' 99' ' ' RBF . 51.7 mt -83.21 135.59 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.103 -1.234 . . . . 0.0 110.288 -176.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.539 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 1.5 t -83.09 139.24 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.375 -0.828 . . . . 0.0 110.568 -176.018 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -69.98 -33.6 72.27 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.669 -0.644 . . . . 0.0 110.708 -178.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.539 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -153.42 174.75 32.02 Favored Glycine 0 N--CA 1.495 2.585 0 C-N-CA 118.957 -1.592 . . . . 0.0 110.395 -172.645 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.497 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 17.9 p -120.61 169.0 10.78 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.991 -1.3 . . . . 0.0 111.008 -177.263 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.482 ' O ' ' HA ' ' A' ' 81' ' ' TRP . . . -138.07 149.5 46.05 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.6 -0.687 . . . . 0.0 109.432 -175.337 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 19.1 tttt -106.47 117.3 33.7 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.076 -1.015 . . . . 0.0 110.216 179.088 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.515 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 12.0 tp -59.93 128.52 37.27 Favored 'General case' 0 C--N 1.298 -1.643 0 O-C-N 120.885 -1.135 . . . . 0.0 108.737 172.523 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.601 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.58 -28.81 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 O-C-N 121.369 -0.832 . . . . 0.0 110.055 -178.152 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.53 140.2 24.77 Favored 'General case' 0 N--CA 1.494 1.757 0 C-N-CA 119.14 -1.024 . . . . 0.0 111.385 -178.766 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.577 HG13 ' CG2' ' A' ' 78' ' ' VAL . 7.0 mt -107.01 133.16 52.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.002 -1.061 . . . . 0.0 110.043 169.845 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.471 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 86.9 m-20 -109.98 114.51 28.09 Favored 'General case' 0 C--N 1.294 -1.832 0 O-C-N 121.443 -0.786 . . . . 0.0 109.987 173.795 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -103.9 116.6 32.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.047 -1.033 . . . . 0.0 110.388 -177.016 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.418 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -111.67 135.1 21.13 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.298 -0.876 . . . . 0.0 109.344 178.205 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -51.8 -18.44 6.52 Favored 'Trans proline' 0 C--N 1.303 -1.829 0 O-C-N 123.906 1.477 . . . . 0.0 110.774 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.575 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 4.9 m-80 -97.2 -32.6 11.85 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.027 -1.046 . . . . 0.0 110.423 178.59 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.575 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 83.2 m-85 -158.03 150.41 22.28 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.272 -0.893 . . . . 0.0 110.208 -177.394 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.468 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 65.8 ttt180 -90.72 144.11 26.06 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.7 -1.25 . . . . 0.0 110.03 176.648 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.471 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 96.8 m -129.84 139.96 51.1 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.607 -0.683 . . . . 0.0 109.746 -175.278 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.576 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.21 139.72 50.79 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.972 -1.08 . . . . 0.0 111.164 179.766 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.486 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 4.0 t -120.51 132.52 69.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 O-C-N 121.051 -1.031 . . . . 0.0 110.468 -178.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 31.7 m -115.88 171.37 5.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.862 -0.524 . . . . 0.0 110.026 179.411 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.563 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 10.4 tt0 -108.54 115.7 30.59 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.516 ' CD2' ' O ' ' A' ' 32' ' ' MET . 8.7 tp -86.8 127.97 58.05 Favored Pre-proline 0 C--N 1.296 -1.725 0 O-C-N 121.206 -0.934 . . . . 0.0 110.285 -172.109 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.472 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 28.9 Cg_endo -66.72 177.1 3.68 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 O-C-N 123.941 1.496 . . . . 0.0 111.05 -179.401 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -60.07 -40.06 88.21 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.23 -0.919 . . . . 0.0 111.083 -174.251 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.574 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.02 0.86 56.88 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.814 -1.178 . . . . 0.0 110.959 -174.655 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.574 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.8 mmm -112.59 -12.03 13.49 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.958 -1.089 . . . . 0.0 109.964 172.282 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.544 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 19.8 mt -70.07 -39.97 75.33 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.408 -0.807 . . . . 0.0 110.186 177.832 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -73.91 143.13 45.9 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.419 -0.801 . . . . 0.0 110.583 -178.147 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.5 -39.02 3.01 Favored Glycine 0 N--CA 1.492 2.409 0 C-N-CA 119.925 -1.131 . . . . 0.0 110.555 173.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.439 HD22 HD23 ' A' ' 28' ' ' LEU . 50.3 tp -77.54 147.93 35.5 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.896 -1.355 . . . . 0.0 110.892 -174.108 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.469 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 21.3 pt-20 -149.07 166.58 28.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.409 -0.807 . . . . 0.0 109.511 177.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.534 ' CG2' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -64.99 147.78 52.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.825 -1.172 . . . . 0.0 109.862 179.376 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.94 -7.68 62.3 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -175.412 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.469 ' HB1' ' O ' ' A' ' 37' ' ' GLU . . . -74.99 153.18 38.64 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.277 -1.131 . . . . 0.0 109.645 177.319 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.548 ' HB2' ' HB3' ' A' ' 87' ' ' ALA . 0.0 OUTLIER -96.58 110.12 22.59 Favored 'General case' 0 C--N 1.309 -1.19 0 O-C-N 120.76 -1.212 . . . . 0.0 109.955 175.474 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.587 HG11 ' CE1' ' A' ' 44' ' ' HIS . 2.0 t -92.91 130.09 42.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 173.321 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.523 ' HB3' ' CG ' ' A' ' 85' ' ' GLU . . . -93.47 119.69 32.85 Favored 'General case' 0 C--N 1.293 -1.848 0 C-N-CA 119.001 -1.079 . . . . 0.0 109.071 173.12 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.587 ' CE1' HG11 ' A' ' 42' ' ' VAL . 0.3 OUTLIER -90.31 106.02 18.21 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 177.727 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.0 t-20 58.27 7.85 0.73 Allowed 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.341 -0.849 . . . . 0.0 111.547 -169.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 125.61 -3.2 8.13 Favored Glycine 0 N--CA 1.49 2.292 0 O-C-N 120.703 -1.248 . . . . 0.0 110.549 174.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.48 ' O ' ' HA ' ' A' ' 43' ' ' ALA . 32.6 t -94.37 108.26 20.17 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.59 -1.535 . . . . 0.0 109.812 176.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.43 ' SG ' ' O ' ' B' ' 3' ' ' THR . 19.5 p -70.29 128.54 36.57 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.163 -0.961 . . . . 0.0 110.895 -175.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.526 ' CB ' ' O4 ' ' A' ' 98' ' ' RBF . 0.4 OUTLIER -143.29 158.03 43.98 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.365 -0.834 . . . . 0.0 109.344 172.347 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 65.0 m -99.51 149.33 23.34 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.559 -1.338 . . . . 0.0 111.403 -170.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.491 ' HB ' ' HA ' ' A' ' 38' ' ' THR . 20.4 t -76.88 114.74 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 CA-C-O 121.01 0.433 . . . . 0.0 110.406 -178.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.518 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 52.6 p -69.32 -40.07 77.84 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.184 -0.947 . . . . 0.0 109.602 173.781 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.527 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 89.3 tt0 -161.49 156.4 23.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.428 -0.795 . . . . 0.0 110.157 -178.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.534 HD11 ' CG2' ' A' ' 38' ' ' THR . 8.2 mt -108.9 129.3 63.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.075 -1.015 . . . . 0.0 109.987 174.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.513 ' CB ' ' HB2' ' A' ' 58' ' ' HIS . 8.6 m-80 -102.39 62.95 0.87 Allowed 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.537 -0.727 . . . . 0.0 109.88 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.67 -117.99 5.33 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.768 -1.733 . . . . 0.0 108.768 -173.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.544 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -74.9 -19.87 59.95 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 120.902 -1.352 . . . . 0.0 108.768 174.216 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.601 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 10.3 m170 -75.61 159.77 30.84 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.424 -0.798 . . . . 0.0 110.129 -177.177 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.466 HG13 HG12 ' A' ' 51' ' ' VAL . 53.6 t -140.55 123.0 15.81 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 121.039 -1.038 . . . . 0.0 110.641 171.092 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.486 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 17.0 m -89.65 128.72 36.11 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.609 -0.682 . . . . 0.0 109.478 177.682 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.58 ' N ' ' CD1' ' A' ' 61' ' ' PHE . 2.4 p90 -124.14 152.38 42.86 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.98 -1.075 . . . . 0.0 110.182 179.002 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.518 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 33.1 p-10 -89.38 156.12 18.9 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 120.986 -1.071 . . . . 0.0 111.708 -171.216 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.526 ' CD2' HD11 ' A' ' 68' ' ' LEU . 0.2 OUTLIER -160.64 101.4 1.33 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.691 -0.631 . . . . 0.0 109.613 -173.416 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.491 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 57.2 ttm -61.53 139.56 58.23 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.57 -1.331 . . . . 0.0 109.174 178.491 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.469 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 78.7 tttt -59.96 -47.87 84.01 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.723 -1.236 . . . . 0.0 110.38 -173.574 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -64.49 -39.95 94.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.876 -1.14 . . . . 0.0 109.87 177.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.491 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 94.6 m -61.38 -39.93 92.45 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.898 -1.126 . . . . 0.0 109.526 173.13 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.531 ' HG ' ' CA ' ' A' ' 74' ' ' GLY . 16.3 tp -59.99 -41.14 91.42 Favored 'General case' 0 C--N 1.3 -1.587 0 O-C-N 121.352 -0.843 . . . . 0.0 109.269 178.378 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -67.02 -39.99 87.17 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.475 -0.766 . . . . 0.0 110.491 173.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.473 HG23 ' O ' ' A' ' 67' ' ' THR . 0.8 OUTLIER -65.64 -43.39 93.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.139 -0.975 . . . . 0.0 109.359 -175.538 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.471 HG23 HG23 ' A' ' 70' ' ' ILE . 24.7 p -84.25 -174.43 5.27 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 175.035 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.4 t30 -101.45 23.48 11.02 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 171.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.507 ' CD1' HD22 ' A' ' 63' ' ' LEU . 91.6 mt -70.05 -39.96 75.4 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.132 -0.98 . . . . 0.0 110.009 176.049 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.531 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -47.53 -22.56 1.74 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 -178.816 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.508 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.3 p-10 -68.69 -17.15 64.02 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.066 -1.255 . . . . 0.0 110.612 -174.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.508 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 89.3 mt -62.38 143.04 57.49 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.243 -0.911 . . . . 0.0 110.909 -177.627 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.495 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 89.8 mttt -141.5 144.61 34.43 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 109.327 -0.619 . . . . 0.0 109.327 174.789 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.577 ' CG2' HG13 ' A' ' 15' ' ' ILE . 47.3 t -64.95 147.28 12.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 120.752 -1.217 . . . . 0.0 110.07 -176.86 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.55 -14.14 62.14 Favored Glycine 0 N--CA 1.483 1.807 0 N-CA-C 108.616 -1.794 . . . . 0.0 108.616 -173.039 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 39.6 t0 -96.09 166.85 11.55 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.387 -1.067 . . . . 0.0 109.504 175.648 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.584 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.2 m95 -117.64 166.92 11.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.044 -1.035 . . . . 0.0 110.199 177.311 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.481 HG12 ' HB2' ' A' ' 10' ' ' ALA . 1.3 p -132.39 156.57 42.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.382 -0.824 . . . . 0.0 109.984 -178.294 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.511 ' HB2' ' HB3' ' B' ' 72' ' ' ASN . 2.2 m-20 -79.53 105.63 10.97 Favored 'General case' 0 C--N 1.296 -1.752 0 O-C-N 121.03 -1.044 . . . . 0.0 109.097 169.096 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.497 ' CG2' ' C ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -110.24 141.92 24.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 120.382 -1.449 . . . . 0.0 110.873 -176.56 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.523 ' CG ' ' HB3' ' A' ' 43' ' ' ALA . 19.9 pt-20 -149.06 153.83 38.41 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 119.748 -0.781 . . . . 0.0 110.162 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 63.1 ttt180 -68.2 130.03 41.7 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.228 -0.92 . . . . 0.0 110.385 -178.065 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.548 ' HB3' ' HB2' ' A' ' 41' ' ' SER . . . -128.97 148.24 50.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.371 -0.831 . . . . 0.0 109.489 176.494 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.573 ' HA ' ' CZ ' ' B' ' 2' ' ' PHE . . . 164.61 31.32 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.457 -0.777 . . . . 0.0 111.367 178.756 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . 0.569 ' HB3' ' CD1' ' B' ' 2' ' ' PHE . 0.0 OUTLIER 50.68 28.41 3.53 Favored 'General case' 0 N--CA 1.511 2.609 0 O-C-N 120.923 -1.11 . . . . 0.0 109.835 -179.52 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.432 ' CD2' ' O ' ' A' ' 91' ' ' SER . 42.8 p90 -88.87 165.81 14.39 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.122 -0.986 . . . . 0.0 110.198 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' SER . . . . . 0.513 ' HB2' ' CG1' ' A' ' 94' ' ' ILE . 84.7 p -68.73 149.22 49.29 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.061 -1.024 . . . . 0.0 110.309 -175.237 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.477 ' O ' ' HG3' ' A' ' 93' ' ' GLU . 96.1 m-20 -69.58 -45.23 69.15 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.145 -0.972 . . . . 0.0 110.505 -178.565 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.477 ' HG3' ' O ' ' A' ' 92' ' ' ASP . 43.6 mt-10 -155.04 54.04 0.64 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.0 -1.062 . . . . 0.0 110.68 179.361 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.513 ' CG1' ' HB2' ' A' ' 91' ' ' SER . 35.1 mm -97.02 -13.45 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.16 -0.962 . . . . 0.0 110.346 176.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 113.3 -83.85 0.34 Allowed Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -178.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 64.88 -168.11 29.05 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 178.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.52 ' N ' ' CD2' ' A' ' 97' ' ' HIS . 0.4 OUTLIER . . . . . 0 N--CA 1.493 1.702 0 O-C-N 121.303 -1.116 . . . . 0.0 110.172 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 67.5 mtt . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 121.097 0.475 . . . . 0.0 110.065 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.573 ' CZ ' ' HA ' ' A' ' 88' ' ' ALA . 5.4 p90 -158.52 141.02 14.31 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.11 -0.994 . . . . 0.0 109.068 170.598 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.499 ' HB ' HG13 ' B' ' 5' ' ' ILE . 26.3 p -140.95 -35.09 0.48 Allowed 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.14 -0.975 . . . . 0.0 110.046 -175.059 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.436 ' C ' ' O ' ' B' ' 3' ' ' THR . . . 44.92 24.99 0.85 Allowed Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -173.658 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.505 ' CD1' HC83 ' A' ' 98' ' ' RBF . 51.8 mt -83.29 135.6 24.48 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.09 -1.241 . . . . 0.0 110.268 -176.706 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.542 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 1.5 t -83.12 139.25 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.313 -0.867 . . . . 0.0 110.527 -175.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 88.2 mt-30 -69.97 -33.37 71.99 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.672 -0.642 . . . . 0.0 110.792 -178.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.542 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -153.62 174.52 32.2 Favored Glycine 0 N--CA 1.498 2.767 0 C-N-CA 119.073 -1.537 . . . . 0.0 110.441 -172.583 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.499 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 18.1 p -120.49 168.85 10.9 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.049 -1.265 . . . . 0.0 111.053 -177.254 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.483 ' O ' ' HA ' ' B' ' 81' ' ' TRP . . . -137.96 149.64 46.32 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.549 -0.719 . . . . 0.0 109.396 -175.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.58 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 19.1 tttt -106.54 117.37 33.86 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.105 -0.997 . . . . 0.0 110.194 179.102 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.505 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 12.0 tp -60.02 128.38 36.55 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.0 -1.063 . . . . 0.0 108.818 172.532 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.603 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.45 -28.84 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.926 0 C-N-CA 119.684 -0.806 . . . . 0.0 110.136 -178.148 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.46 140.22 24.86 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.304 -0.958 . . . . 0.0 111.459 -178.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.571 HG23 ' CD2' ' B' ' 24' ' ' HIS . 6.7 mt -106.87 133.12 52.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.922 -1.111 . . . . 0.0 110.145 169.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.486 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 86.9 m-20 -110.04 114.53 28.13 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.555 -0.716 . . . . 0.0 110.026 173.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -103.85 116.52 32.44 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.096 -1.002 . . . . 0.0 110.379 -176.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.42 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -111.59 134.99 21.11 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.285 -0.884 . . . . 0.0 109.35 178.208 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_endo -51.85 -18.44 6.62 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 O-C-N 123.861 1.453 . . . . 0.0 110.734 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.573 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 4.9 m-80 -96.91 -33.32 11.65 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.095 -1.003 . . . . 0.0 110.263 178.62 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.573 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 83.7 m-85 -157.52 150.43 23.25 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.293 -0.879 . . . . 0.0 110.215 -177.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.487 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 65.9 ttt180 -90.61 144.06 26.13 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.926 -1.109 . . . . 0.0 110.074 176.569 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.486 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 96.0 m -129.77 140.03 51.15 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.684 -0.635 . . . . 0.0 109.728 -175.33 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.571 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.18 139.77 50.82 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.007 -1.058 . . . . 0.0 111.118 179.802 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.532 HG22 ' CB ' ' B' ' 60' ' ' SER . 3.9 t -120.51 132.55 69.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.197 -0.939 . . . . 0.0 110.436 -178.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.502 HG13 ' CE1' ' B' ' 61' ' ' PHE . 32.4 m -116.03 171.38 5.1 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 121.691 -0.631 . . . . 0.0 109.922 179.462 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.57 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 10.4 tt0 -108.48 115.71 30.62 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 -179.537 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.519 ' CD2' ' O ' ' B' ' 32' ' ' MET . 8.7 tp -86.69 127.94 58.41 Favored Pre-proline 0 C--N 1.296 -1.732 0 O-C-N 121.148 -0.97 . . . . 0.0 110.28 -172.098 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.478 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 29.1 Cg_endo -66.79 177.12 3.71 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 O-C-N 123.924 1.486 . . . . 0.0 111.056 -179.435 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.421 ' HA ' HD12 ' B' ' 33' ' ' LEU . 96.1 m-20 -60.09 -39.95 87.9 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.273 -0.892 . . . . 0.0 111.159 -174.233 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.579 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.05 0.73 56.97 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.79 -1.194 . . . . 0.0 110.862 -174.671 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.579 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.7 mmm -112.58 -11.86 13.52 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.981 -1.074 . . . . 0.0 109.971 172.255 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.538 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 19.9 mt -70.14 -39.9 75.12 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.354 -0.841 . . . . 0.0 110.185 177.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -73.98 143.11 45.75 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.499 -0.751 . . . . 0.0 110.532 -178.083 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.51 -39.01 3.01 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 119.954 -1.117 . . . . 0.0 110.505 173.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . 0.474 HD21 HD22 ' B' ' 28' ' ' LEU . 50.5 tp -77.47 147.91 35.66 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.86 -1.377 . . . . 0.0 110.826 -174.056 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.469 ' O ' ' HB1' ' B' ' 40' ' ' ALA . 21.4 pt-20 -149.12 166.59 28.31 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.454 -0.779 . . . . 0.0 109.5 177.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.526 ' CG2' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -64.98 147.7 52.96 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.85 -1.156 . . . . 0.0 109.942 179.366 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.06 -7.76 62.43 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -175.393 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.469 ' HB1' ' O ' ' B' ' 37' ' ' GLU . . . -75.02 152.89 38.67 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.336 -1.096 . . . . 0.0 109.64 177.254 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.536 ' HB2' ' HB3' ' B' ' 87' ' ' ALA . 0.0 OUTLIER -96.09 110.03 22.35 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 120.882 -1.137 . . . . 0.0 110.059 175.39 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.58 HG12 ' CE1' ' B' ' 44' ' ' HIS . 2.0 t -93.08 130.01 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 173.301 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.517 ' HB1' ' CG ' ' B' ' 85' ' ' GLU . . . -93.38 119.67 32.77 Favored 'General case' 0 C--N 1.295 -1.789 0 C-N-CA 118.993 -1.083 . . . . 0.0 109.167 173.075 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.58 ' CE1' HG12 ' B' ' 42' ' ' VAL . 0.3 OUTLIER -90.26 105.62 17.93 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 177.712 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.0 t-20 58.81 7.77 0.83 Allowed 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.375 -0.828 . . . . 0.0 111.379 -170.08 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.424 ' O ' ' O ' ' A' ' 4' ' ' GLY . . . 125.45 -2.82 8.22 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.749 -1.215 . . . . 0.0 110.638 174.57 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.474 ' O ' ' HA ' ' B' ' 43' ' ' ALA . 32.7 t -94.56 108.08 20.05 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.597 -1.531 . . . . 0.0 109.867 176.732 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . 0.467 ' SG ' ' O ' ' A' ' 3' ' ' THR . 18.2 p -70.07 128.68 37.14 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.133 -0.979 . . . . 0.0 110.842 -175.414 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.528 ' CB ' ' O4 ' ' B' ' 99' ' ' RBF . 0.4 OUTLIER -143.42 158.08 43.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.335 -0.853 . . . . 0.0 109.263 172.239 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 65.1 m -99.46 149.42 23.22 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.523 -1.361 . . . . 0.0 111.411 -170.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.519 ' CG1' HG11 ' B' ' 59' ' ' VAL . 20.7 t -77.19 114.82 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.839 -0.538 . . . . 0.0 110.434 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 53.7 p -69.38 -40.02 77.66 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.176 -0.953 . . . . 0.0 109.601 173.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.525 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 89.3 tt0 -161.51 156.38 23.38 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.77 -0.772 . . . . 0.0 110.128 -178.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.526 HD11 ' CG2' ' B' ' 38' ' ' THR . 8.3 mt -108.85 129.16 63.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.096 -1.003 . . . . 0.0 110.088 175.05 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.518 ' HB2' ' CB ' ' B' ' 58' ' ' HIS . 8.5 m-80 -102.45 63.12 0.86 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.626 -0.671 . . . . 0.0 109.782 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.67 -118.0 5.34 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.695 -1.762 . . . . 0.0 108.695 -173.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.538 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -74.87 -20.01 59.92 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 120.988 -1.301 . . . . 0.0 108.78 174.249 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.603 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 10.3 m170 -75.52 159.59 31.11 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.469 -0.769 . . . . 0.0 110.234 -177.219 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.519 HG11 ' CG1' ' B' ' 51' ' ' VAL . 54.3 t -140.46 123.09 16.15 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 O-C-N 121.063 -1.023 . . . . 0.0 110.55 171.247 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.532 ' CB ' HG22 ' B' ' 25' ' ' VAL . 17.4 m -89.69 128.78 36.14 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.586 -0.696 . . . . 0.0 109.519 177.675 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.58 ' N ' ' CD1' ' B' ' 61' ' ' PHE . 2.4 p90 -124.21 152.37 43.0 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.965 -1.085 . . . . 0.0 110.186 178.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.533 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 33.0 p-10 -89.32 156.09 18.94 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 120.834 -1.166 . . . . 0.0 111.588 -171.119 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.527 HD21 ' CD1' ' B' ' 73' ' ' LEU . 0.2 OUTLIER -160.66 101.52 1.32 Allowed 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.696 -0.628 . . . . 0.0 109.656 -173.526 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.48 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 57.1 ttm -61.59 139.45 58.27 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.612 -1.305 . . . . 0.0 109.163 178.527 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.468 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 78.6 tttt -59.94 -47.81 84.26 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.86 -1.15 . . . . 0.0 110.384 -173.506 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -64.5 -40.0 94.83 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.943 -1.098 . . . . 0.0 109.843 177.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.48 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 94.2 m -61.24 -40.08 92.7 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.96 -1.087 . . . . 0.0 109.564 173.117 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.527 ' HG ' ' CA ' ' B' ' 74' ' ' GLY . 16.3 tp -59.92 -41.08 90.94 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.339 -0.851 . . . . 0.0 109.35 178.352 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -67.04 -40.07 87.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.415 -0.803 . . . . 0.0 110.449 173.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.474 HG23 ' O ' ' B' ' 67' ' ' THR . 0.8 OUTLIER -65.51 -43.32 94.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.24 -0.913 . . . . 0.0 109.426 -175.599 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.471 HG23 HG23 ' B' ' 70' ' ' ILE . 25.1 p -84.36 -174.17 5.13 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.006 -0.678 . . . . 0.0 109.195 175.171 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.511 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 4.1 t30 -101.62 23.47 11.17 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 171.708 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.527 ' CD1' HD21 ' B' ' 63' ' ' LEU . 91.6 mt -70.04 -39.99 75.39 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.133 -0.979 . . . . 0.0 109.996 176.013 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.527 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -47.42 -22.7 1.69 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -178.856 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.4 p-10 -68.65 -17.08 64.03 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.057 -1.261 . . . . 0.0 110.647 -174.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 89.5 mt -62.32 143.08 57.39 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.2 -0.937 . . . . 0.0 110.912 -177.702 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.501 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 89.8 mttt -141.64 144.58 34.23 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 174.785 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.57 ' CG2' HG13 ' B' ' 15' ' ' ILE . 47.2 t -64.9 147.31 12.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.885 -1.134 . . . . 0.0 110.062 -176.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.49 -14.07 62.23 Favored Glycine 0 N--CA 1.484 1.875 0 N-CA-C 108.67 -1.772 . . . . 0.0 108.67 -173.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 39.2 t0 -96.12 166.76 11.6 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.472 -1.016 . . . . 0.0 109.483 175.564 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.58 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.3 m95 -117.64 166.84 11.93 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.057 -1.027 . . . . 0.0 110.136 177.388 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.476 HG13 ' CB ' ' B' ' 10' ' ' ALA . 1.3 p -132.36 156.66 42.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.429 -0.794 . . . . 0.0 109.963 -178.427 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.498 ' CA ' HG12 ' B' ' 6' ' ' VAL . 2.1 m-20 -79.44 105.53 10.82 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.116 -0.99 . . . . 0.0 109.203 169.117 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.499 ' CG2' ' C ' ' B' ' 9' ' ' THR . 0.0 OUTLIER -110.2 142.21 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 120.419 -1.425 . . . . 0.0 110.765 -176.399 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . 0.517 ' CG ' ' HB1' ' B' ' 43' ' ' ALA . 19.9 pt-20 -149.38 153.84 38.0 Favored 'General case' 0 N--CA 1.492 1.64 0 C-N-CA 119.779 -0.768 . . . . 0.0 110.05 179.249 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 63.2 ttt180 -68.14 129.97 41.51 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.181 -0.95 . . . . 0.0 110.432 -178.045 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.536 ' HB3' ' HB2' ' B' ' 41' ' ' SER . . . -128.68 148.55 50.83 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.411 -0.806 . . . . 0.0 109.502 176.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . 0.583 ' HA ' ' CZ ' ' A' ' 2' ' ' PHE . . . 164.23 31.3 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.158 0 O-C-N 121.418 -0.801 . . . . 0.0 111.346 178.586 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . 0.519 ' O ' ' CG ' ' B' ' 89' ' ' LYS . 0.0 OUTLIER 50.75 28.39 3.58 Favored 'General case' 0 N--CA 1.51 2.537 0 O-C-N 120.951 -1.093 . . . . 0.0 109.892 -179.561 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . 0.44 ' CD2' ' O ' ' B' ' 91' ' ' SER . 42.9 p90 -89.0 165.71 14.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.079 -1.013 . . . . 0.0 110.147 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 91' ' ' SER . . . . . 0.44 ' O ' ' CD2' ' B' ' 90' ' ' PHE . 84.6 p -68.59 149.03 49.65 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.057 -1.027 . . . . 0.0 110.383 -175.25 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . 0.442 ' O ' ' HB3' ' B' ' 93' ' ' GLU . 95.9 m-20 -69.61 -47.41 63.58 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.145 -0.972 . . . . 0.0 110.397 -178.508 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . 0.472 ' O ' ' HG3' ' B' ' 93' ' ' GLU . 21.5 pt-20 -175.92 46.68 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.341 0 CA-C-O 121.751 0.786 . . . . 0.0 110.161 -178.153 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . 0.426 ' HA ' HD12 ' B' ' 94' ' ' ILE . 22.1 mm -65.35 -40.01 87.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.584 -0.698 . . . . 0.0 110.166 178.297 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 115.82 -71.91 0.26 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.358 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -132.54 148.51 19.23 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.456 -1.457 . . . . 0.0 109.456 179.151 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 78.0 t60 . . . . . 0 N--CA 1.493 1.68 0 O-C-N 121.264 -1.139 . . . . 0.0 110.208 -179.378 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.531 " O2'" ' C9 ' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.545 " O2'" ' C9 ' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 29.6 mtp . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.033 0.444 . . . . 0.0 110.081 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.594 ' CZ ' ' CB ' ' B' ' 87' ' ' ALA . 3.9 p90 -169.78 155.17 5.69 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.127 -0.983 . . . . 0.0 108.559 174.523 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.522 ' HB ' ' CD1' ' A' ' 5' ' ' ILE . 30.0 p -150.72 -38.75 0.13 Allowed 'General case' 0 C--N 1.295 -1.771 0 O-C-N 120.942 -1.099 . . . . 0.0 109.284 175.658 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.473 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 48.48 23.98 3.51 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 108.277 -1.929 . . . . 0.0 108.277 -175.309 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.522 ' CD1' ' HB ' ' A' ' 3' ' ' THR . 79.1 mt -79.28 125.44 38.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.437 -1.037 . . . . 0.0 109.732 -178.079 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.544 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.0 t -84.36 139.44 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.191 -0.943 . . . . 0.0 110.835 -170.524 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -70.06 -34.83 73.71 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.86 -0.525 . . . . 0.0 111.036 178.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.544 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -154.76 174.44 33.05 Favored Glycine 0 N--CA 1.496 2.641 0 C-N-CA 118.933 -1.603 . . . . 0.0 110.191 -172.1 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.441 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.3 p -119.99 170.45 9.26 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.944 -1.327 . . . . 0.0 111.2 -176.14 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.516 ' CB ' HG11 ' A' ' 82' ' ' VAL . . . -139.46 150.1 44.79 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -178.005 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 21.6 tttt -108.9 117.68 34.83 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.045 -1.034 . . . . 0.0 110.375 -179.552 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.529 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 12.0 tp -59.41 128.85 39.15 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.892 -1.13 . . . . 0.0 108.947 173.531 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.632 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.99 -28.82 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 C-N-CA 119.512 -0.875 . . . . 0.0 110.101 -178.802 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.93 140.56 23.5 Favored 'General case' 0 N--CA 1.493 1.696 0 C-N-CA 119.089 -1.045 . . . . 0.0 111.445 -178.375 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.571 HG12 ' CD2' ' A' ' 24' ' ' HIS . 14.1 mt -109.96 133.39 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.116 -0.99 . . . . 0.0 110.279 172.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.47 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 76.6 m-20 -108.54 116.12 31.37 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.335 -0.853 . . . . 0.0 109.883 172.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -107.64 115.33 29.95 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.948 -1.095 . . . . 0.0 110.735 -175.473 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.48 130.27 24.45 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.21 -0.931 . . . . 0.0 109.209 176.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -52.1 -19.79 9.51 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.792 1.417 . . . . 0.0 110.275 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.574 ' ND2' ' N ' ' A' ' 20' ' ' ASN . 0.4 OUTLIER -83.54 -42.57 16.67 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.186 -0.946 . . . . 0.0 108.991 176.554 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.57 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 89.5 m-85 -156.98 150.32 24.14 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-O 121.307 0.575 . . . . 0.0 110.044 -177.674 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.508 ' NH1' HD23 ' A' ' 68' ' ' LEU . 60.2 ttt180 -89.49 143.59 26.7 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.898 -1.126 . . . . 0.0 110.116 177.673 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.47 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.3 m -128.74 135.04 48.67 Favored 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.548 -0.72 . . . . 0.0 109.827 -176.358 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.585 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -127.78 141.36 51.6 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.813 -1.18 . . . . 0.0 111.594 -179.449 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.53 ' CG2' ' OG ' ' A' ' 60' ' ' SER . 6.3 t -123.26 133.48 69.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.172 -0.955 . . . . 0.0 110.667 -179.397 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.412 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 36.0 m -117.66 172.47 5.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-O 121.233 0.539 . . . . 0.0 110.274 179.533 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.51 ' CB ' ' HB3' ' A' ' 11' ' ' LYS . 7.2 tt0 -100.22 116.96 33.44 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.313 -0.867 . . . . 0.0 109.071 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.6 ' CD1' ' CB ' ' A' ' 32' ' ' MET 0.256 0.1 OUTLIER -86.81 114.82 59.99 Favored Pre-proline 0 C--N 1.295 -1.777 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -176.818 . . . . . . . . 4 4 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.49 ' HD2' HD11 ' A' ' 28' ' ' LEU . 18.9 Cg_endo -63.3 174.48 3.33 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.779 1.41 . . . . 0.0 111.187 -178.299 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.527 ' OD1' ' N ' ' A' ' 31' ' ' HIS . 1.9 p30 -63.22 -35.54 80.65 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.452 -0.78 . . . . 0.0 111.269 -174.219 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.527 ' N ' ' OD1' ' A' ' 30' ' ' ASP . 0.0 OUTLIER -91.0 -0.19 57.69 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.728 -1.232 . . . . 0.0 111.057 -173.551 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.6 ' CB ' ' CD1' ' A' ' 28' ' ' LEU . 96.2 mmm -114.48 -14.32 12.15 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 120.925 -1.109 . . . . 0.0 109.815 168.89 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.522 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 12.4 mt -64.3 -40.04 95.14 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.163 -0.961 . . . . 0.0 109.932 177.653 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -63.98 131.53 47.93 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.32 -0.862 . . . . 0.0 110.484 -178.104 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.39 -39.26 3.08 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 175.149 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.514 ' CD2' ' HG ' ' A' ' 28' ' ' LEU . 60.8 tp -62.38 144.52 55.7 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.963 -1.316 . . . . 0.0 110.85 -175.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.467 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 19.2 pt-20 -151.49 164.78 36.02 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.728 -0.607 . . . . 0.0 109.452 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.534 ' CG2' HD13 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -66.92 150.48 49.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.849 -1.157 . . . . 0.0 109.763 178.376 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.63 -0.06 62.0 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 -174.572 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.467 ' HB1' ' O ' ' A' ' 37' ' ' GLU . . . -75.38 158.99 31.92 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.228 -1.16 . . . . 0.0 109.279 175.358 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.488 ' CB ' ' HB2' ' A' ' 87' ' ' ALA . 0.6 OUTLIER -100.39 110.89 23.12 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 118.854 -1.138 . . . . 0.0 109.829 176.025 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.582 HG13 ' CE1' ' A' ' 44' ' ' HIS . 1.8 t -100.1 125.67 53.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.457 -0.777 . . . . 0.0 109.041 175.688 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.454 ' HA ' ' HA ' ' A' ' 48' ' ' CYS . . . -92.0 119.78 32.03 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 119.041 -1.064 . . . . 0.0 109.242 172.401 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.582 ' CE1' HG13 ' A' ' 42' ' ' VAL . 0.6 OUTLIER -87.98 103.02 15.3 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 177.922 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.5 t-20 57.16 11.17 0.98 Allowed 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.455 -0.778 . . . . 0.0 111.141 -170.474 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.476 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 123.84 -0.21 9.17 Favored Glycine 0 N--CA 1.489 2.233 0 C-N-CA 119.584 -1.293 . . . . 0.0 110.605 174.621 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.499 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 16.7 t -98.74 105.39 17.53 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.41 -1.641 . . . . 0.0 109.535 175.604 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.454 ' HA ' ' HA ' ' A' ' 43' ' ' ALA . 15.9 p -74.05 129.0 36.99 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.983 -1.073 . . . . 0.0 110.855 -172.368 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.634 ' CD1' ' CD1' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -142.95 160.84 39.59 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.377 -0.827 . . . . 0.0 109.605 173.739 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 6.6 m -100.43 148.1 25.12 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.552 -1.342 . . . . 0.0 111.237 -170.09 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.528 ' CG1' HG13 ' A' ' 59' ' ' VAL . 21.0 t -76.21 115.32 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.892 -0.505 . . . . 0.0 110.475 -179.361 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.53 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 30.4 p -70.46 -40.02 73.93 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.247 -0.908 . . . . 0.0 109.789 173.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.531 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -162.64 154.49 18.36 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.288 -0.882 . . . . 0.0 110.313 -179.479 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.534 HD13 ' CG2' ' A' ' 38' ' ' THR . 7.6 mt -105.72 130.52 57.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.159 -0.963 . . . . 0.0 110.088 176.367 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.469 ' HB2' ' CB ' ' A' ' 58' ' ' HIS . 4.7 m-80 -102.51 64.39 0.9 Allowed 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.61 -0.681 . . . . 0.0 109.822 179.027 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.2 -119.5 5.9 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.774 -1.73 . . . . 0.0 108.774 -173.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.522 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -73.12 -22.1 60.61 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 120.878 -1.366 . . . . 0.0 108.643 174.315 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.632 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 12.3 m80 -74.02 159.97 31.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.283 -0.885 . . . . 0.0 110.431 -176.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.528 HG13 ' CG1' ' A' ' 51' ' ' VAL . 51.4 t -139.98 125.38 20.77 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 121.084 -1.01 . . . . 0.0 110.706 170.526 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.53 ' OG ' ' CG2' ' A' ' 25' ' ' VAL . 1.7 t -91.6 135.08 34.13 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.444 -0.785 . . . . 0.0 109.274 175.972 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.634 ' CD1' ' CD1' ' A' ' 49' ' ' LEU . 8.8 p90 -128.35 154.39 46.02 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 121.304 -0.872 . . . . 0.0 110.483 177.141 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.53 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 28.9 p-10 -89.67 150.85 22.16 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.157 -0.965 . . . . 0.0 111.332 -171.616 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.523 HD23 ' CD1' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -155.6 117.6 4.09 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -176.079 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.508 ' HB2' ' CB ' ' A' ' 67' ' ' THR . 52.6 mtt -68.46 142.33 55.37 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.786 -1.196 . . . . 0.0 109.518 177.425 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.465 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 86.0 tttt -59.97 -44.59 94.36 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 120.991 -1.068 . . . . 0.0 109.715 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 52.5 tp10 -70.04 -39.93 75.43 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.189 -0.944 . . . . 0.0 110.235 178.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.508 ' CB ' ' HB2' ' A' ' 64' ' ' MET . 89.5 m -61.41 -37.81 84.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.795 -1.191 . . . . 0.0 109.084 172.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.508 HD23 ' NH1' ' A' ' 22' ' ' ARG . 7.1 tp -60.07 -44.32 94.84 Favored 'General case' 0 C--N 1.297 -1.69 0 O-C-N 121.143 -0.973 . . . . 0.0 109.193 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 52.0 ttt85 -70.08 -39.91 75.3 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.456 -0.777 . . . . 0.0 110.52 175.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.466 HG23 ' O ' ' A' ' 67' ' ' THR . 1.3 tt -62.72 -41.38 92.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.176 -0.953 . . . . 0.0 109.072 -177.719 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.481 HG23 ' O ' ' A' ' 67' ' ' THR . 31.2 p -88.93 -176.76 5.29 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 175.765 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.481 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 2.4 t30 -100.18 25.08 7.87 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 172.112 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.523 ' CD1' HD23 ' A' ' 63' ' ' LEU . 55.7 mt -69.85 -39.99 76.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.941 -1.099 . . . . 0.0 109.861 174.556 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.474 ' HA2' HD13 ' A' ' 68' ' ' LEU . . . -48.12 -22.76 2.38 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 -179.034 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.0 p-10 -64.89 -17.38 64.26 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.151 -1.205 . . . . 0.0 110.5 -176.369 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 90.3 mt -62.06 144.02 55.8 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.299 -0.875 . . . . 0.0 110.889 -176.724 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.491 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 35.0 mttp -143.83 143.86 31.51 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.747 -0.596 . . . . 0.0 109.41 174.13 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.552 ' CG2' HG13 ' A' ' 15' ' ' ILE . 14.9 t -61.77 150.06 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 120.637 -1.289 . . . . 0.0 110.107 -176.722 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.35 -12.15 61.48 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 108.927 -1.669 . . . . 0.0 108.927 -176.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 48.7 t0 -95.77 166.27 11.89 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.312 -1.111 . . . . 0.0 109.496 176.236 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.6 m95 -117.43 156.63 27.62 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.987 -1.071 . . . . 0.0 110.524 178.728 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.516 HG11 ' CB ' ' A' ' 10' ' ' ALA . 1.1 p -120.05 150.88 22.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.516 -0.74 . . . . 0.0 109.874 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.522 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 0.3 OUTLIER -76.82 106.28 8.4 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.072 -1.018 . . . . 0.0 108.951 168.966 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.455 HG13 HG21 ' A' ' 82' ' ' VAL . 0.1 OUTLIER -105.97 138.52 30.89 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 120.425 -1.422 . . . . 0.0 111.5 -175.223 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -133.3 140.67 47.58 Favored 'General case' 0 N--CA 1.496 1.829 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.178 -179.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 71.6 ttt-85 -80.31 134.17 36.04 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.195 -0.94 . . . . 0.0 111.148 -175.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.582 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -132.15 150.76 52.08 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.409 -0.807 . . . . 0.0 110.28 179.361 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -124.58 156.13 37.93 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.213 -0.929 . . . . 0.0 111.239 -175.019 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 16.3 mmtp -59.96 -46.97 87.69 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.993 -1.067 . . . . 0.0 110.68 -175.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 42.6 p90 -158.62 160.04 36.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.075 -1.016 . . . . 0.0 110.467 178.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' SER . . . . . 0.434 ' HB3' ' CG1' ' A' ' 94' ' ' ILE . 16.8 m -154.51 115.43 4.0 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.468 -0.77 . . . . 0.0 110.229 177.646 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.464 ' O ' ' HG3' ' A' ' 93' ' ' GLU . 96.0 m-20 -69.76 -38.29 76.7 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.214 -0.929 . . . . 0.0 110.331 179.007 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.464 ' HG3' ' O ' ' A' ' 92' ' ' ASP . 93.0 mt-10 -156.38 53.07 0.54 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.369 -0.832 . . . . 0.0 110.16 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.434 ' CG1' ' HB3' ' A' ' 91' ' ' SER . 46.0 mm -92.88 -50.83 12.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.286 -0.884 . . . . 0.0 110.31 -179.548 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 90.83 -43.06 2.86 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.458 ' O ' ' HB2' ' A' ' 97' ' ' HIS . . . 141.11 78.57 0.05 OUTLIER Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.554 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.458 ' HB2' ' O ' ' A' ' 96' ' ' GLY . 72.4 t60 . . . . . 0 N--CA 1.492 1.668 0 O-C-N 121.365 -1.079 . . . . 0.0 110.079 178.411 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 72.1 mtm . . . . . 0 N--CA 1.494 1.756 0 CA-C-O 121.143 0.497 . . . . 0.0 110.071 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.582 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 4.1 p90 -175.33 155.37 1.85 Allowed 'General case' 0 C--N 1.305 -1.358 0 O-C-N 121.216 -0.928 . . . . 0.0 108.715 177.669 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.527 ' HB ' ' CD1' ' B' ' 5' ' ' ILE . 29.9 p -150.71 -38.76 0.13 Allowed 'General case' 0 C--N 1.294 -1.812 0 O-C-N 120.939 -1.101 . . . . 0.0 109.267 175.628 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.476 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 48.48 23.98 3.52 Favored Glycine 0 N--CA 1.483 1.794 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 -175.301 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.527 ' CD1' ' HB ' ' B' ' 3' ' ' THR . 79.0 mt -79.25 125.44 38.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.515 -0.991 . . . . 0.0 109.764 -178.111 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.542 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.0 t -84.35 139.38 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.18 -0.95 . . . . 0.0 110.798 -170.51 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -70.01 -34.71 73.65 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.79 -0.569 . . . . 0.0 111.063 178.342 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.542 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -154.96 174.33 33.2 Favored Glycine 0 N--CA 1.495 2.58 0 C-N-CA 118.902 -1.618 . . . . 0.0 110.248 -172.03 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.446 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.5 p -119.9 170.42 9.27 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.892 -1.358 . . . . 0.0 111.173 -176.016 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.517 ' CB ' HG11 ' B' ' 82' ' ' VAL . . . -139.53 150.17 44.78 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -178.157 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.574 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 21.6 tttt -108.82 117.83 35.22 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.115 -0.991 . . . . 0.0 110.346 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.507 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 12.0 tp -59.68 128.74 38.47 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 120.936 -1.102 . . . . 0.0 109.019 173.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.627 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.81 -28.9 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 O-C-N 121.33 -0.856 . . . . 0.0 110.139 -178.719 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.91 140.66 23.59 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.294 -0.962 . . . . 0.0 111.401 -178.371 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.573 HG12 ' CD2' ' B' ' 24' ' ' HIS . 14.1 mt -109.99 133.38 55.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.177 -0.952 . . . . 0.0 110.244 172.695 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.486 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 76.2 m-20 -108.61 116.23 31.58 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.344 -0.847 . . . . 0.0 109.706 173.01 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 99.9 mt-10 -107.72 115.37 30.03 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.917 -1.114 . . . . 0.0 110.717 -175.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.55 130.27 24.46 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.269 -0.894 . . . . 0.0 109.294 176.82 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -52.32 -19.77 10.13 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.731 1.385 . . . . 0.0 110.21 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.569 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 0.4 OUTLIER -83.28 -43.16 16.34 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.26 -0.9 . . . . 0.0 108.867 176.508 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.569 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 89.6 m-85 -156.54 150.36 24.87 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.813 -0.555 . . . . 0.0 110.028 -177.535 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.513 ' NH1' HD23 ' B' ' 68' ' ' LEU . 60.2 ttt180 -89.37 143.52 26.76 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.942 -1.098 . . . . 0.0 110.152 177.585 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.486 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 94.3 m -128.64 135.04 48.77 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.648 -0.657 . . . . 0.0 109.89 -176.517 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.585 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -127.61 141.54 51.6 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.824 -1.173 . . . . 0.0 111.534 -179.466 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.54 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 6.2 t -123.32 133.63 68.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.189 -0.945 . . . . 0.0 110.654 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 35.2 m -118.03 172.29 5.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.798 -0.564 . . . . 0.0 110.227 179.581 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.509 ' CB ' ' HB3' ' B' ' 11' ' ' LYS . 7.2 tt0 -99.99 117.06 33.47 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.321 -0.862 . . . . 0.0 109.058 179.184 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.59 ' CD1' ' CB ' ' B' ' 32' ' ' MET 0.255 0.1 OUTLIER -86.83 114.84 60.1 Favored Pre-proline 0 C--N 1.296 -1.723 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 -176.922 . . . . . . . . 4 4 . 1 . 009 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.491 ' HD2' HD11 ' B' ' 28' ' ' LEU . 19.0 Cg_endo -63.3 174.6 3.23 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.744 1.392 . . . . 0.0 111.267 -178.306 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' B' ' 31' ' ' HIS . 1.9 p30 -63.35 -35.56 80.81 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.484 -0.76 . . . . 0.0 111.169 -174.206 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.521 ' N ' ' OD1' ' B' ' 30' ' ' ASP . 0.0 OUTLIER -91.05 -0.02 57.64 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.738 -1.226 . . . . 0.0 110.997 -173.51 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.59 ' CB ' ' CD1' ' B' ' 28' ' ' LEU . 96.2 mmm -114.48 -14.34 12.15 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 120.881 -1.137 . . . . 0.0 109.806 168.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.526 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 12.4 mt -64.35 -39.96 94.93 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.184 -0.948 . . . . 0.0 109.989 177.642 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -64.02 131.51 47.82 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.307 -0.87 . . . . 0.0 110.497 -178.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.47 -39.31 3.07 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.329 -1.109 . . . . 0.0 110.329 175.207 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . 0.518 ' CD2' ' HG ' ' B' ' 28' ' ' LEU . 60.7 tp -62.37 144.57 55.62 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.872 -1.37 . . . . 0.0 110.883 -175.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.466 ' O ' ' HB1' ' B' ' 40' ' ' ALA . 19.2 pt-20 -151.57 164.78 36.09 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.658 -0.651 . . . . 0.0 109.36 -179.629 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.528 ' CG2' ' HA ' ' B' ' 53' ' ' GLU . 0.0 OUTLIER -66.92 150.48 49.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.784 -1.198 . . . . 0.0 109.827 178.332 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.61 -0.01 62.03 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -174.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.466 ' HB1' ' O ' ' B' ' 37' ' ' GLU . . . -75.51 158.97 31.82 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.191 -1.182 . . . . 0.0 109.23 175.293 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.495 ' CB ' ' HB2' ' B' ' 87' ' ' ALA . 0.7 OUTLIER -100.21 110.64 22.9 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.977 -1.077 . . . . 0.0 109.901 176.018 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.587 HG13 ' CE1' ' B' ' 44' ' ' HIS . 1.8 t -99.95 125.69 53.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.427 -0.796 . . . . 0.0 109.081 175.627 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.459 ' HA ' ' HA ' ' B' ' 48' ' ' CYS . . . -91.98 119.73 31.97 Favored 'General case' 0 C--N 1.297 -1.712 0 C-N-CA 119.056 -1.058 . . . . 0.0 109.274 172.349 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.587 ' CE1' HG13 ' B' ' 42' ' ' VAL . 0.6 OUTLIER -87.94 102.95 15.22 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.417 -0.802 . . . . 0.0 108.968 177.887 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.6 t-20 57.32 11.11 1.04 Allowed 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.439 -0.788 . . . . 0.0 111.113 -170.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.473 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 123.77 0.2 9.17 Favored Glycine 0 N--CA 1.489 2.225 0 C-N-CA 119.653 -1.261 . . . . 0.0 110.609 174.509 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.489 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 16.9 t -98.99 105.49 17.64 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.465 -1.609 . . . . 0.0 109.464 175.488 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . 0.459 ' HA ' ' HA ' ' B' ' 43' ' ' ALA . 15.9 p -74.06 129.02 37.03 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.012 -1.055 . . . . 0.0 110.802 -172.39 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.633 ' CD1' ' CD1' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -143.05 160.79 39.71 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.396 -0.815 . . . . 0.0 109.484 173.751 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 6.6 m -100.27 148.22 24.89 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 120.647 -1.283 . . . . 0.0 111.255 -170.128 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.527 ' CG1' HG13 ' B' ' 59' ' ' VAL . 21.2 t -76.46 115.24 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.716 -0.615 . . . . 0.0 110.479 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.536 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 30.3 p -70.39 -40.01 74.2 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.213 -0.929 . . . . 0.0 109.818 173.722 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.528 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -162.63 154.48 18.37 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.406 -0.809 . . . . 0.0 110.265 -179.525 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.527 HD13 ' CG2' ' B' ' 38' ' ' THR . 7.6 mt -105.6 130.46 56.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.11 -0.994 . . . . 0.0 110.173 176.323 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.473 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 4.6 m-80 -102.53 64.41 0.89 Allowed 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.659 -0.651 . . . . 0.0 109.737 179.082 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.32 -119.52 5.87 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 108.739 -1.744 . . . . 0.0 108.739 -173.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.526 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -73.08 -22.09 60.65 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.894 -1.357 . . . . 0.0 108.753 174.216 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.627 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 12.4 m80 -74.07 160.05 31.81 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.257 -0.902 . . . . 0.0 110.421 -176.588 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.527 HG13 ' CG1' ' B' ' 51' ' ' VAL . 50.7 t -140.14 125.35 20.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 C-N-CA 119.107 -1.037 . . . . 0.0 110.595 170.692 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.54 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 1.7 t -91.57 135.25 34.0 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.5 -0.75 . . . . 0.0 109.284 175.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.633 ' CD1' ' CD1' ' B' ' 49' ' ' LEU . 8.7 p90 -128.46 154.46 46.05 Favored 'General case' 0 N--CA 1.496 1.828 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.417 177.099 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.536 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 29.2 p-10 -89.75 150.83 22.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.059 -1.026 . . . . 0.0 111.246 -171.554 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.525 HD21 ' CD1' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -155.57 117.6 4.09 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -176.125 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.511 ' HB2' ' HB ' ' B' ' 67' ' ' THR . 52.9 mtt -68.38 142.32 55.47 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.889 -1.132 . . . . 0.0 109.463 177.538 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.464 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 86.0 tttt -60.06 -44.54 94.64 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.072 -1.017 . . . . 0.0 109.635 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 52.5 tp10 -69.99 -39.92 75.62 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.148 -0.97 . . . . 0.0 110.328 178.415 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.511 ' HB ' ' HB2' ' B' ' 64' ' ' MET . 89.2 m -61.38 -38.04 85.59 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.776 -1.203 . . . . 0.0 108.99 172.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.513 HD23 ' NH1' ' B' ' 22' ' ' ARG . 7.0 tp -59.99 -44.23 94.66 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.235 -0.916 . . . . 0.0 109.289 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 52.0 ttt85 -70.03 -39.93 75.48 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.38 -0.825 . . . . 0.0 110.563 175.429 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.471 HG23 ' O ' ' B' ' 67' ' ' THR . 1.3 tt -62.73 -41.28 91.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 CA-C-O 121.917 0.865 . . . . 0.0 109.07 -177.743 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.474 HG22 ' O ' ' B' ' 67' ' ' THR . 31.5 p -89.0 -176.63 5.23 Favored 'General case' 0 C--N 1.3 -1.565 0 C-N-CA 120.2 -0.6 . . . . 0.0 109.394 175.859 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.48 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 2.3 t30 -100.17 25.11 7.83 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 172.144 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.525 ' CD1' HD21 ' B' ' 63' ' ' LEU . 54.8 mt -69.89 -40.0 75.92 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.894 -1.129 . . . . 0.0 109.848 174.569 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.467 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -48.16 -22.63 2.36 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 -179.021 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.5 p-10 -64.89 -17.51 64.39 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.189 -1.183 . . . . 0.0 110.438 -176.392 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 90.2 mt -62.08 143.95 55.93 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.256 -0.902 . . . . 0.0 110.871 -176.601 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.48 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 35.0 mttp -143.76 143.95 31.6 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.637 -0.664 . . . . 0.0 109.395 174.123 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.547 ' CG2' HG13 ' B' ' 15' ' ' ILE . 15.3 t -61.78 150.05 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.666 -1.271 . . . . 0.0 110.057 -176.634 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.2 -11.95 61.67 Favored Glycine 0 N--CA 1.484 1.868 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -176.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 48.5 t0 -95.81 166.25 11.9 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.386 -1.067 . . . . 0.0 109.458 176.051 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.574 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.6 m95 -117.4 156.62 27.6 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.051 -1.03 . . . . 0.0 110.516 178.759 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.546 HG22 ' CG ' ' B' ' 44' ' ' HIS . 1.1 p -120.14 150.94 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.569 -0.707 . . . . 0.0 109.807 179.683 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.503 ' HB3' ' CG2' ' B' ' 6' ' ' VAL . 0.3 OUTLIER -76.79 106.14 8.29 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.037 -1.039 . . . . 0.0 109.014 168.971 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.454 HG11 HG21 ' B' ' 82' ' ' VAL . 0.1 OUTLIER -105.9 138.71 29.91 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 120.476 -1.39 . . . . 0.0 111.454 -175.118 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -133.42 140.69 47.46 Favored 'General case' 0 N--CA 1.495 1.824 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.191 -179.364 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 71.7 ttt-85 -80.33 134.29 36.04 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.16 -0.962 . . . . 0.0 111.029 -175.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.594 ' CB ' ' CZ ' ' A' ' 2' ' ' PHE . . . -132.15 150.93 52.04 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.267 -0.896 . . . . 0.0 110.271 179.372 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -124.88 156.09 38.46 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.241 -0.912 . . . . 0.0 111.104 -174.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 16.3 mmtp -59.99 -46.93 87.85 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.917 -1.115 . . . . 0.0 110.663 -175.667 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 43.0 p90 -158.73 160.01 35.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.099 -1.001 . . . . 0.0 110.451 178.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 91' ' ' SER . . . . . 0.59 ' CB ' ' CD1' ' B' ' 94' ' ' ILE . 17.1 m -154.48 115.43 4.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.433 -0.792 . . . . 0.0 110.246 177.697 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -69.94 -40.25 75.59 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.279 -0.888 . . . . 0.0 110.326 179.071 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -114.54 54.32 0.77 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.182 -0.948 . . . . 0.0 111.02 -174.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . 0.59 ' CD1' ' CB ' ' B' ' 91' ' ' SER . 24.6 mm -60.02 -39.98 81.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.132 -0.98 . . . . 0.0 110.111 173.569 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 98.86 -55.37 1.0 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 178.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -98.55 174.24 28.0 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 56.5 p-80 . . . . . 0 N--CA 1.491 1.614 0 O-C-N 121.27 -1.135 . . . . 0.0 110.124 179.397 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.533 " C2'" ' HC9' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.535 " C2'" ' HC9' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.456 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 77.8 mtm . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.212 0.529 . . . . 0.0 110.069 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.622 ' CZ ' ' CB ' ' B' ' 87' ' ' ALA . 10.6 p90 -179.6 143.44 0.19 Allowed 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.304 -0.872 . . . . 0.0 109.221 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.486 ' HB ' ' CD1' ' A' ' 5' ' ' ILE . 72.1 p -138.5 -40.82 0.5 Allowed 'General case' 0 C--N 1.298 -1.642 0 O-C-N 120.945 -1.097 . . . . 0.0 108.976 -177.4 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.489 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 44.99 25.59 1.01 Allowed Glycine 0 N--CA 1.485 1.92 0 N-CA-C 108.598 -1.801 . . . . 0.0 108.598 -173.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.51 ' CD1' HC82 ' B' ' 99' ' ' RBF . 94.5 mt -77.26 130.55 36.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.166 -1.196 . . . . 0.0 110.374 -176.221 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.533 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 1.7 t -89.06 139.97 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.54 -0.725 . . . . 0.0 110.287 -175.072 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -81.23 -26.29 35.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.427 -0.796 . . . . 0.0 110.891 -179.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.533 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -153.92 176.71 31.74 Favored Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.288 -1.434 . . . . 0.0 109.922 -176.086 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.472 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 18.4 p -123.34 170.01 10.75 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.942 -1.328 . . . . 0.0 110.839 -178.444 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.522 ' CB ' HG13 ' A' ' 82' ' ' VAL . . . -137.36 149.89 47.31 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.557 -0.715 . . . . 0.0 109.65 -177.076 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.585 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 36.9 tttt -104.07 117.86 35.28 Favored 'General case' 0 C--N 1.296 -1.731 0 O-C-N 120.901 -1.124 . . . . 0.0 110.355 178.673 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.5 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 12.1 tp -61.44 126.14 26.29 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.861 -1.15 . . . . 0.0 108.749 171.482 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.593 HG12 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.38 -28.86 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.934 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.004 -178.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -148.76 141.02 24.06 Favored 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 118.964 -1.094 . . . . 0.0 111.225 178.824 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.567 HG13 ' CG2' ' A' ' 78' ' ' VAL . 13.6 mt -105.54 138.22 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.007 -1.058 . . . . 0.0 110.062 171.372 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.486 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 83.7 m-20 -110.83 114.66 28.18 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.25 -0.906 . . . . 0.0 109.932 173.789 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -103.35 112.65 25.63 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.017 -1.052 . . . . 0.0 110.374 -178.008 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.467 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 19.7 mtmt -107.02 132.77 20.65 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.296 -0.877 . . . . 0.0 109.282 177.338 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.9 Cg_endo -51.84 -18.9 7.2 Favored 'Trans proline' 0 C--N 1.303 -1.851 0 O-C-N 123.879 1.462 . . . . 0.0 110.745 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.57 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 7.8 m-80 -95.77 -33.06 12.42 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.125 -0.984 . . . . 0.0 110.204 178.298 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.57 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 98.2 m-85 -157.46 150.29 23.23 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.363 -0.836 . . . . 0.0 110.318 -177.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -87.76 145.88 25.91 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.898 -1.126 . . . . 0.0 110.108 177.318 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.486 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 92.5 m -133.89 145.37 49.56 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.455 -0.778 . . . . 0.0 109.748 -176.418 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.56 ' CD2' HG21 ' A' ' 15' ' ' ILE . 0.4 OUTLIER -135.35 135.27 40.59 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.781 -1.199 . . . . 0.0 111.476 -177.879 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.517 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 9.7 t -114.43 132.77 62.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.092 -1.005 . . . . 0.0 110.814 -179.127 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.426 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 17.4 m -118.11 170.92 6.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 CA-C-O 121.177 0.513 . . . . 0.0 110.106 179.217 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.487 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 13.5 tt0 -102.64 118.92 37.91 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.329 -0.857 . . . . 0.0 109.096 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.485 ' HB3' ' CD2' ' A' ' 33' ' ' LEU . 10.2 tp -83.59 123.77 76.1 Favored Pre-proline 0 C--N 1.3 -1.567 0 C-N-CA 119.969 -0.692 . . . . 0.0 109.739 -175.345 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.47 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 25.9 Cg_endo -66.18 175.31 4.97 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 O-C-N 123.843 1.444 . . . . 0.0 111.035 -179.298 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.427 ' HA ' HD13 ' A' ' 33' ' ' LEU . 57.8 t0 -59.86 -39.77 86.34 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.387 -0.821 . . . . 0.0 110.831 -175.714 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.579 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -88.76 1.08 55.82 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.941 -1.1 . . . . 0.0 110.633 -175.004 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.579 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 93.5 mmm -112.17 -14.16 13.42 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.989 -1.069 . . . . 0.0 109.916 170.683 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.537 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 19.6 mt -69.96 -39.92 75.72 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.454 -0.779 . . . . 0.0 110.516 178.422 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -82.26 113.57 20.16 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.281 -0.887 . . . . 0.0 110.437 -176.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.8 -52.62 0.7 Allowed Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.835 -1.174 . . . . 0.0 110.415 175.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 5.1 tt -66.37 152.21 45.51 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.93 -1.335 . . . . 0.0 110.756 -173.396 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.463 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 11.3 pt-20 -150.76 169.96 20.39 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.477 -0.764 . . . . 0.0 109.752 -177.271 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.526 ' CG2' HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -65.43 158.4 26.84 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.951 -1.093 . . . . 0.0 110.38 -178.27 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 71.51 2.71 51.1 Favored Glycine 0 N--CA 1.495 2.57 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 -178.229 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.471 ' HB2' HG22 ' A' ' 51' ' ' VAL . . . -82.52 163.73 21.35 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.227 -1.161 . . . . 0.0 109.768 177.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.471 ' CB ' ' HB2' ' A' ' 87' ' ' ALA . 1.0 OUTLIER -104.52 112.77 25.97 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.982 -1.074 . . . . 0.0 109.985 176.491 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.586 HG12 ' CE1' ' A' ' 44' ' ' HIS . 2.0 t -102.83 130.96 52.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.377 -0.827 . . . . 0.0 108.931 173.866 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.464 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -91.45 120.05 31.95 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.214 -0.995 . . . . 0.0 109.092 172.272 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.586 ' CE1' HG12 ' A' ' 42' ' ' VAL . 0.3 OUTLIER -90.3 107.9 19.43 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 177.112 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.1 t-20 52.98 13.09 0.33 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.47 -0.769 . . . . 0.0 111.688 -167.149 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.447 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 121.22 -2.59 11.48 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.441 -1.362 . . . . 0.0 110.855 172.257 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.47 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 35.5 t -94.25 109.0 20.84 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.402 -1.646 . . . . 0.0 109.448 174.829 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.52 ' SG ' ' C8 ' ' A' ' 98' ' ' RBF . 17.3 p -76.99 124.65 28.08 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.105 -0.997 . . . . 0.0 110.836 -172.443 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.51 ' CD1' ' HB3' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -140.02 159.98 40.95 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.507 -0.745 . . . . 0.0 109.145 173.805 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.448 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 28.5 m -97.03 160.84 14.11 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.654 -1.278 . . . . 0.0 111.179 -170.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.558 ' CG1' HG12 ' A' ' 59' ' ' VAL . 18.8 t -84.69 116.39 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.854 -0.529 . . . . 0.0 110.372 -177.376 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.55 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 77.4 p -70.02 -40.02 75.47 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.252 -0.905 . . . . 0.0 109.667 173.793 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.502 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 54.4 tp10 -164.86 157.9 16.77 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.576 -176.364 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.526 HD12 ' CG2' ' A' ' 38' ' ' THR . 8.7 mt -110.44 129.93 64.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.173 -0.954 . . . . 0.0 109.807 172.608 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.475 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 29.0 m-80 -102.35 64.05 0.9 Allowed 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.738 -0.601 . . . . 0.0 109.474 179.037 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.87 -114.28 4.3 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -172.18 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.537 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.82 -22.43 46.21 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 120.94 -1.33 . . . . 0.0 109.3 175.314 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.593 ' CD2' HG12 ' A' ' 13' ' ' VAL . 9.4 m170 -74.43 159.94 31.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.271 -0.893 . . . . 0.0 110.052 -177.489 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.577 HG13 ' CE2' ' A' ' 61' ' ' PHE . 78.4 t -140.0 120.04 13.38 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 O-C-N 121.103 -0.998 . . . . 0.0 110.693 173.317 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.517 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 6.5 t -83.13 138.02 33.84 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.424 -0.798 . . . . 0.0 109.531 176.055 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.577 ' CE2' HG13 ' A' ' 59' ' ' VAL . 87.0 m-85 -120.2 160.52 22.75 Favored 'General case' 0 C--N 1.295 -1.788 0 O-C-N 121.336 -0.853 . . . . 0.0 110.543 177.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.55 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 32.9 p-10 -95.46 148.2 22.73 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.247 -0.908 . . . . 0.0 111.1 179.21 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.519 HD22 ' CD1' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -157.23 121.92 4.43 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -176.762 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.489 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 26.8 ttt -82.19 141.87 32.66 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.983 -1.073 . . . . 0.0 109.669 -178.141 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.472 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 83.3 tttt -60.0 -48.26 82.44 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.094 -1.003 . . . . 0.0 110.611 -173.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.2 tp10 -68.08 -40.06 82.77 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 120.793 -1.192 . . . . 0.0 109.94 179.014 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.489 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 87.4 m -60.01 -39.02 84.37 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.976 -1.078 . . . . 0.0 109.257 173.007 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.523 ' CD1' ' HA2' ' A' ' 74' ' ' GLY . 2.0 tp -59.98 -45.38 92.9 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.23 -0.919 . . . . 0.0 109.706 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -67.05 -39.96 87.04 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.329 -0.857 . . . . 0.0 110.363 176.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.484 HG21 HG21 ' A' ' 71' ' ' THR . 1.1 tt -66.04 -40.14 86.43 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.294 -0.879 . . . . 0.0 109.258 -176.907 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.484 HG21 HG21 ' A' ' 70' ' ' ILE . 52.3 p -84.92 -169.77 2.81 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 121.362 0.601 . . . . 0.0 109.524 175.28 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.475 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 7.1 t30 -105.97 22.92 14.83 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 170.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.519 ' CD1' HD22 ' A' ' 63' ' ' LEU . 88.5 mt -69.95 -40.03 75.69 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.199 -0.938 . . . . 0.0 110.219 178.289 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.523 ' HA2' ' CD1' ' A' ' 68' ' ' LEU . . . -50.16 -21.6 4.21 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -177.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.4 p-10 -69.19 -17.45 63.8 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.98 -1.306 . . . . 0.0 110.753 -173.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.513 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 95.9 mt -60.01 141.02 56.38 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.105 -0.997 . . . . 0.0 110.709 -176.818 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.493 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 66.4 mttm -140.0 139.07 35.94 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 121.514 0.674 . . . . 0.0 109.88 175.651 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.567 ' CG2' HG13 ' A' ' 15' ' ' ILE . 22.0 t -61.08 152.77 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 120.906 -1.122 . . . . 0.0 110.376 -176.393 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.83 -16.08 57.61 Favored Glycine 0 N--CA 1.482 1.725 0 N-CA-C 108.729 -1.748 . . . . 0.0 108.729 -176.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.9 t0 -97.39 169.72 9.56 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.344 -1.091 . . . . 0.0 109.544 175.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.585 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.2 m95 -117.26 166.57 12.12 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.03 -1.044 . . . . 0.0 110.045 177.306 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.522 HG13 ' CB ' ' A' ' 10' ' ' ALA . 1.3 p -128.69 157.47 41.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.283 -0.886 . . . . 0.0 110.03 -177.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.497 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 2.2 m-20 -83.54 104.71 13.89 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.177 -0.952 . . . . 0.0 109.083 170.821 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.474 HG13 ' CE1' ' A' ' 44' ' ' HIS . 0.1 OUTLIER -107.54 139.27 30.0 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.781 0 O-C-N 120.444 -1.41 . . . . 0.0 111.287 -174.826 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -139.58 138.48 36.25 Favored 'General case' 0 N--CA 1.492 1.674 0 C-N-CA 120.355 -0.538 . . . . 0.0 109.837 -178.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . 0.468 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 39.0 ptt180 -73.02 137.72 45.55 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.983 -1.073 . . . . 0.0 110.664 -174.151 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.575 ' HB1' ' CZ ' ' B' ' 2' ' ' PHE . . . -128.09 144.18 51.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -0.904 . . . . 0.0 109.923 173.788 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -132.32 148.71 52.44 Favored 'General case' 0 N--CA 1.491 1.622 0 C-N-CA 120.023 -0.671 . . . . 0.0 111.25 -173.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 30.9 mtpt -60.54 -40.0 89.95 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.427 -0.796 . . . . 0.0 109.836 174.011 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.5 p90 -145.79 159.07 43.72 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.354 -0.841 . . . . 0.0 110.243 -179.445 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 58.5 m -133.29 143.85 49.32 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.261 -0.899 . . . . 0.0 110.298 178.415 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -68.88 -38.8 79.92 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.164 -0.96 . . . . 0.0 110.436 179.361 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 50.71 56.6 7.73 Favored 'General case' 0 N--CA 1.507 2.41 0 C-N-CA 119.834 -0.747 . . . . 0.0 110.373 177.163 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.548 ' O ' ' N ' ' A' ' 96' ' ' GLY . 29.8 mm -60.06 -43.75 93.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.142 -0.974 . . . . 0.0 110.219 177.244 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -49.85 88.26 0.01 OUTLIER Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.976 -1.25 . . . . 0.0 109.976 -171.042 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 94' ' ' ILE . . . -171.14 -179.81 42.51 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 5.4 m-70 . . . . . 0 N--CA 1.491 1.612 0 O-C-N 121.287 -1.125 . . . . 0.0 110.192 -179.647 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 96.8 mtp . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.091 0.472 . . . . 0.0 110.093 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.589 ' CD1' ' O ' ' B' ' 2' ' ' PHE . 10.9 p90 -172.49 143.35 1.36 Allowed 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.183 -0.948 . . . . 0.0 109.18 174.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.497 ' HB ' ' CD1' ' B' ' 5' ' ' ILE . 72.8 p -138.57 -40.78 0.5 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 120.95 -1.093 . . . . 0.0 109.0 -177.458 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.447 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 45.24 25.25 1.1 Allowed Glycine 0 N--CA 1.485 1.907 0 N-CA-C 108.623 -1.791 . . . . 0.0 108.623 -174.057 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.497 ' CD1' ' HB ' ' B' ' 3' ' ' THR . 94.4 mt -77.38 130.6 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.209 -1.171 . . . . 0.0 110.422 -176.041 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.536 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 1.7 t -89.08 140.05 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.454 -0.779 . . . . 0.0 110.291 -175.012 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -81.43 -25.96 35.74 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.38 -0.825 . . . . 0.0 110.887 -178.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.536 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -154.09 176.58 31.92 Favored Glycine 0 N--CA 1.494 2.559 0 C-N-CA 119.423 -1.37 . . . . 0.0 109.958 -176.1 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.468 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 18.4 p -123.32 170.05 10.69 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.951 -1.323 . . . . 0.0 110.838 -178.432 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.522 ' CB ' HG13 ' B' ' 82' ' ' VAL . . . -137.39 149.9 47.29 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.582 -0.699 . . . . 0.0 109.607 -177.143 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.577 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 36.9 tttt -104.13 117.98 35.55 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.961 -1.087 . . . . 0.0 110.304 178.615 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.506 ' CG ' ' HA ' ' B' ' 78' ' ' VAL . 12.1 tp -61.58 126.04 25.94 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.018 -1.051 . . . . 0.0 108.804 171.48 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.596 HG12 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.1 -29.12 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.979 0 O-C-N 121.371 -0.831 . . . . 0.0 110.054 -178.892 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -148.67 141.0 24.15 Favored 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 119.263 -0.975 . . . . 0.0 111.357 178.834 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.562 HG13 ' CG2' ' B' ' 78' ' ' VAL . 13.6 mt -105.6 138.32 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.996 -1.065 . . . . 0.0 110.082 171.373 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.499 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.6 m-20 -110.89 114.79 28.4 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.317 -0.865 . . . . 0.0 109.842 173.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -103.44 112.54 25.48 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.002 -1.061 . . . . 0.0 110.363 -177.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.463 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 19.6 mtmt -107.0 132.72 20.68 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.382 -0.823 . . . . 0.0 109.317 177.34 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -51.92 -18.79 7.3 Favored 'Trans proline' 0 C--N 1.304 -1.782 0 O-C-N 123.832 1.438 . . . . 0.0 110.716 -179.527 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.57 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 7.9 m-80 -95.64 -33.68 12.26 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.107 -0.996 . . . . 0.0 110.068 178.291 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.57 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 98.2 m-85 -157.0 150.29 24.09 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.352 -0.843 . . . . 0.0 110.412 -177.82 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -87.68 145.73 26.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.042 -1.036 . . . . 0.0 110.196 177.265 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.499 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 92.7 m -133.85 145.39 49.65 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.386 -0.821 . . . . 0.0 109.755 -176.483 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.55 ' CD2' HG22 ' B' ' 15' ' ' ILE . 0.4 OUTLIER -135.24 135.41 40.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.927 -1.108 . . . . 0.0 111.447 -177.804 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 9.8 t -114.48 133.01 61.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 110.789 -179.119 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 17.7 m -118.45 170.85 7.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 CA-C-O 121.237 0.541 . . . . 0.0 109.988 179.357 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.488 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 13.5 tt0 -102.55 119.03 38.13 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.365 -0.834 . . . . 0.0 109.122 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.492 ' HB3' ' CD2' ' B' ' 33' ' ' LEU . 10.3 tp -83.68 123.75 75.94 Favored Pre-proline 0 C--N 1.299 -1.589 0 O-C-N 121.443 -0.786 . . . . 0.0 109.76 -175.358 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.478 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 25.8 Cg_endo -66.17 175.44 4.84 Favored 'Trans proline' 0 C--N 1.309 -1.538 0 O-C-N 123.851 1.448 . . . . 0.0 111.049 -179.221 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -60.07 -39.68 86.89 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.368 -0.833 . . . . 0.0 110.8 -175.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.583 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -88.78 1.08 55.83 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.819 -1.176 . . . . 0.0 110.695 -175.073 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.583 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 93.5 mmm -112.14 -14.13 13.44 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.961 -1.087 . . . . 0.0 109.92 170.628 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.547 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 19.7 mt -70.04 -39.91 75.46 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.366 -0.834 . . . . 0.0 110.511 178.442 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -82.2 113.56 20.12 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.296 -0.878 . . . . 0.0 110.436 -176.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.79 -52.64 0.7 Allowed Glycine 0 N--CA 1.491 2.335 0 C-N-CA 119.834 -1.174 . . . . 0.0 110.422 175.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 5.2 tt -66.39 152.2 45.57 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.916 -1.344 . . . . 0.0 110.807 -173.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.464 ' HA ' HD12 ' B' ' 54' ' ' ILE . 11.3 pt-20 -150.69 169.99 20.27 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.402 -0.811 . . . . 0.0 109.733 -177.249 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.531 ' CG2' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -65.41 158.36 26.9 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.958 -1.089 . . . . 0.0 110.425 -178.303 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 71.54 2.64 50.83 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.966 -1.253 . . . . 0.0 109.966 -178.233 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.471 ' HB2' HG21 ' B' ' 51' ' ' VAL . . . -82.54 163.47 21.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.226 -1.161 . . . . 0.0 109.817 177.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.469 ' HB2' ' HB1' ' B' ' 87' ' ' ALA . 1.0 OUTLIER -104.21 112.59 25.67 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.893 -1.129 . . . . 0.0 110.078 176.546 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.575 HG12 ' CE1' ' B' ' 44' ' ' HIS . 2.0 t -102.78 131.01 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.389 -0.819 . . . . 0.0 108.947 173.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.462 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -91.44 119.98 31.88 Favored 'General case' 0 C--N 1.296 -1.718 0 O-C-N 121.128 -0.983 . . . . 0.0 109.196 172.149 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.575 ' CE1' HG12 ' B' ' 42' ' ' VAL . 0.3 OUTLIER -90.23 107.55 19.2 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 177.138 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.1 t-20 53.29 13.16 0.39 Allowed 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.445 -0.784 . . . . 0.0 111.515 -167.252 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.489 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 121.17 -2.44 11.54 Favored Glycine 0 N--CA 1.491 2.311 0 C-N-CA 119.474 -1.346 . . . . 0.0 110.784 172.14 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.469 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 35.6 t -94.32 109.04 20.9 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.411 -1.64 . . . . 0.0 109.434 174.808 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . 0.513 ' SG ' ' C8 ' ' B' ' 99' ' ' RBF . 16.7 p -76.99 124.77 28.26 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.054 -1.029 . . . . 0.0 110.814 -172.436 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.518 ' CD1' ' HB3' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -140.21 159.96 41.02 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.553 -0.717 . . . . 0.0 109.086 173.773 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 50' ' ' THR . . . . . 0.454 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 28.5 m -96.79 160.95 14.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.686 -1.259 . . . . 0.0 111.214 -170.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.561 ' CG1' HG13 ' B' ' 59' ' ' VAL . 19.0 t -84.99 116.35 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.787 -0.57 . . . . 0.0 110.426 -177.42 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.537 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 77.3 p -69.96 -39.93 75.72 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.154 -0.966 . . . . 0.0 109.716 173.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.511 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 54.4 tp10 -164.94 157.8 16.46 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.589 -176.392 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.531 HD11 ' CG2' ' B' ' 38' ' ' THR . 8.7 mt -110.32 129.89 64.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.194 -0.941 . . . . 0.0 109.854 172.667 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.486 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 28.7 m-80 -102.46 64.07 0.89 Allowed 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 120.103 -0.639 . . . . 0.0 109.42 179.101 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.02 -114.35 4.29 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 108.666 -1.774 . . . . 0.0 108.666 -172.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.547 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.65 -22.73 46.43 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.032 -1.275 . . . . 0.0 109.358 175.244 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.596 ' CD2' HG12 ' B' ' 13' ' ' VAL . 9.5 m170 -74.21 159.8 32.02 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.386 -0.821 . . . . 0.0 110.097 -177.515 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.581 HG11 ' CE2' ' B' ' 61' ' ' PHE . 78.4 t -139.99 120.02 13.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 C-N-CA 119.017 -1.073 . . . . 0.0 110.574 173.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.533 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 6.4 t -83.16 137.98 33.84 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.426 -0.796 . . . . 0.0 109.578 176.044 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.581 ' CE2' HG11 ' B' ' 59' ' ' VAL . 86.4 m-85 -120.25 160.63 22.58 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.351 -0.843 . . . . 0.0 110.471 177.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.537 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 32.9 p-10 -95.48 148.24 22.69 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.113 -0.992 . . . . 0.0 110.945 179.388 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.527 HD21 ' CD1' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -157.21 121.93 4.44 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -176.829 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.496 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 26.9 ttt -82.21 141.87 32.64 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.067 -1.02 . . . . 0.0 109.722 -178.183 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.471 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 83.3 tttt -59.95 -48.39 81.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.066 -1.021 . . . . 0.0 110.53 -173.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 54.1 tp10 -68.0 -40.05 83.08 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.915 -1.116 . . . . 0.0 109.966 179.088 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.496 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 87.6 m -59.98 -39.1 84.54 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.004 -1.06 . . . . 0.0 109.278 173.017 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.526 ' CD1' ' HA2' ' B' ' 74' ' ' GLY . 2.0 tp -60.02 -45.2 93.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.314 -0.866 . . . . 0.0 109.734 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -67.06 -39.95 86.97 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.451 -0.781 . . . . 0.0 110.384 176.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.483 HG22 ' N ' ' B' ' 71' ' ' THR . 1.2 tt -66.1 -40.11 86.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.289 -0.882 . . . . 0.0 109.212 -176.809 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.483 ' N ' HG22 ' B' ' 70' ' ' ILE . 52.3 p -84.84 -169.43 2.64 Favored 'General case' 0 C--N 1.301 -1.543 0 C-N-CA 120.17 -0.612 . . . . 0.0 109.577 175.241 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.476 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 7.0 t30 -106.16 22.75 15.19 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 170.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.527 ' CD1' HD21 ' B' ' 63' ' ' LEU . 88.7 mt -69.91 -40.0 75.87 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.308 -0.87 . . . . 0.0 110.182 178.361 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.526 ' HA2' ' CD1' ' B' ' 68' ' ' LEU . . . -50.16 -21.67 4.27 Favored Glycine 0 N--CA 1.487 2.071 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -177.953 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.1 p-10 -69.22 -17.4 63.77 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.014 -1.286 . . . . 0.0 110.736 -173.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.507 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 95.8 mt -59.99 141.0 56.39 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.139 -0.975 . . . . 0.0 110.8 -176.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.493 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 66.4 mttm -140.03 139.06 35.9 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 121.611 -0.681 . . . . 0.0 109.912 175.673 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.562 ' CG2' HG13 ' B' ' 15' ' ' ILE . 22.1 t -61.11 152.76 5.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.036 -1.04 . . . . 0.0 110.43 -176.348 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.64 -15.83 57.95 Favored Glycine 0 N--CA 1.484 1.837 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 -176.072 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -97.49 169.63 9.6 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.345 -1.091 . . . . 0.0 109.582 175.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.577 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.3 m95 -117.23 166.52 12.16 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.104 -0.998 . . . . 0.0 110.05 177.389 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.522 HG13 ' CB ' ' B' ' 10' ' ' ALA . 1.3 p -128.65 157.54 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.41 -0.806 . . . . 0.0 110.054 -177.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.473 ' HB3' ' CG2' ' B' ' 6' ' ' VAL . 2.1 m-20 -83.48 104.53 13.7 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.307 -0.87 . . . . 0.0 109.263 170.775 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.494 HG11 ' CE1' ' B' ' 44' ' ' HIS . 0.1 OUTLIER -107.38 139.55 28.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.468 -1.395 . . . . 0.0 111.17 -174.637 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -139.92 138.44 35.63 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 120.389 -0.525 . . . . 0.0 109.789 -178.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . 0.455 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 39.0 ptt180 -72.95 137.71 45.67 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.06 -1.025 . . . . 0.0 110.608 -174.09 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.622 ' CB ' ' CZ ' ' A' ' 2' ' ' PHE . . . -128.01 144.31 51.1 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.162 -0.962 . . . . 0.0 109.825 173.764 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -132.56 148.74 52.38 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.501 -0.75 . . . . 0.0 111.126 -173.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 30.9 mtpt -60.61 -39.9 89.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.349 -0.845 . . . . 0.0 109.923 174.007 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 53.5 p90 -145.83 159.15 43.61 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.282 -0.886 . . . . 0.0 110.332 -179.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 91' ' ' SER . . . . . 0.493 ' HB3' ' CG1' ' B' ' 94' ' ' ILE . 58.6 m -133.45 143.79 49.07 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.211 -0.931 . . . . 0.0 110.238 178.545 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -69.15 -44.71 71.74 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.119 -0.988 . . . . 0.0 110.661 179.47 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 82.5 mm-40 -146.66 52.18 1.11 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.76 -1.212 . . . . 0.0 111.128 -176.241 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . 0.493 ' CG1' ' HB3' ' B' ' 91' ' ' SER . 46.1 mm -104.87 -57.01 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.132 -0.98 . . . . 0.0 110.121 174.276 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . 0.414 ' C ' ' O ' ' B' ' 94' ' ' ILE . . . 40.03 68.38 0.56 Allowed Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.034 -1.226 . . . . 0.0 110.034 177.196 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . 167.63 -153.01 22.06 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 83.7 t60 . . . . . 0 N--CA 1.492 1.636 0 O-C-N 121.216 -1.167 . . . . 0.0 110.158 -179.554 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.52 ' C8 ' ' SG ' ' A' ' 48' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.513 ' C8 ' ' SG ' ' B' ' 48' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.449 ' N ' ' HA ' ' B' ' 89' ' ' LYS . 98.2 mtp . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 121.272 0.558 . . . . 0.0 110.292 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.599 ' CD2' ' HB2' ' B' ' 87' ' ' ALA . 4.6 p90 -170.04 156.43 6.02 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 175.14 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.482 ' HB ' HG13 ' A' ' 5' ' ' ILE . 62.0 p -152.3 -40.83 0.11 Allowed 'General case' 0 C--N 1.293 -1.873 0 O-C-N 120.852 -1.155 . . . . 0.0 108.87 174.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' B' ' 46' ' ' GLY . . . 47.51 23.98 2.39 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 108.162 -1.975 . . . . 0.0 108.162 -174.64 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.482 HG13 ' HB ' ' A' ' 3' ' ' THR . 71.1 mt -81.91 119.77 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.32 -1.106 . . . . 0.0 109.715 -176.945 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.532 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 3.4 t -75.15 149.16 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.362 -0.836 . . . . 0.0 110.583 -173.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 28.2 mm100 -98.48 -15.19 19.69 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.554 -0.716 . . . . 0.0 110.783 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.532 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -141.0 165.4 26.25 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.247 -1.454 . . . . 0.0 109.749 -177.595 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.488 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 0.7 OUTLIER -124.83 169.99 11.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.95 -1.324 . . . . 0.0 110.504 178.746 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.531 ' CB ' HG12 ' A' ' 82' ' ' VAL . . . -141.26 149.27 41.1 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.471 -0.768 . . . . 0.0 109.245 -176.525 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.579 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 32.1 tttt -109.65 114.13 27.48 Favored 'General case' 0 C--N 1.294 -1.839 0 O-C-N 121.091 -1.005 . . . . 0.0 110.175 178.852 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.528 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 11.6 tp -59.69 127.86 34.11 Favored 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.061 -1.024 . . . . 0.0 108.903 175.137 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.59 HG12 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -128.31 -30.65 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.868 0 O-C-N 121.339 -0.851 . . . . 0.0 110.062 -178.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.35 141.97 30.08 Favored 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 119.088 -1.045 . . . . 0.0 111.284 -178.158 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.589 ' CG1' ' CG2' ' A' ' 78' ' ' VAL . 8.4 mt -110.04 132.89 57.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.098 -1.001 . . . . 0.0 110.362 172.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.486 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 88.5 m-20 -109.8 114.97 28.98 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.41 -0.806 . . . . 0.0 110.038 175.353 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -102.62 109.61 21.28 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.01 -1.056 . . . . 0.0 110.471 -177.402 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.3 OUTLIER -101.71 135.96 19.66 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.243 -0.91 . . . . 0.0 109.557 175.884 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -53.97 -16.92 9.83 Favored 'Trans proline' 0 C--N 1.302 -1.877 0 O-C-N 123.956 1.503 . . . . 0.0 110.853 -179.631 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.555 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 6.0 m-80 -102.7 -26.56 13.13 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.063 -1.023 . . . . 0.0 109.953 179.744 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.555 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 87.6 m-85 -156.69 150.24 24.52 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.428 -0.795 . . . . 0.0 109.919 -178.549 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.474 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 61.3 ttt180 -92.36 141.74 28.21 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.665 -1.272 . . . . 0.0 109.844 174.799 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.486 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 89.1 m -129.94 140.05 51.0 Favored 'General case' 0 C--N 1.295 -1.799 0 O-C-N 121.495 -0.753 . . . . 0.0 109.824 -172.677 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.584 ' CD2' HG21 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -130.09 142.47 50.6 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 120.986 -1.071 . . . . 0.0 111.413 -179.286 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.523 ' CG2' ' OG ' ' A' ' 60' ' ' SER . 16.6 t -119.66 134.31 63.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.111 -0.993 . . . . 0.0 110.418 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.565 HG13 ' CE1' ' A' ' 61' ' ' PHE . 32.9 m -116.82 170.76 6.02 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 O-C-N 121.912 -0.492 . . . . 0.0 110.113 178.894 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.518 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 9.4 tt0 -102.65 116.64 33.0 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 179.401 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.489 ' CD2' ' O ' ' A' ' 32' ' ' MET . 8.7 tp -80.56 121.63 81.54 Favored Pre-proline 0 C--N 1.295 -1.771 0 O-C-N 121.493 -0.755 . . . . 0.0 109.653 -173.74 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.464 ' HD2' ' HB2' ' A' ' 32' ' ' MET . 18.5 Cg_endo -63.42 178.84 1.07 Allowed 'Trans proline' 0 C--N 1.308 -1.583 0 O-C-N 123.874 1.46 . . . . 0.0 111.004 -179.112 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -60.32 -39.91 88.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.373 -0.83 . . . . 0.0 111.102 -175.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.583 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.17 0.26 57.27 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.833 -1.167 . . . . 0.0 110.93 -175.553 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.583 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.1 mmm -109.12 -12.84 14.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.923 -1.11 . . . . 0.0 110.006 171.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.54 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 19.2 mt -68.8 -31.35 70.29 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.284 -0.885 . . . . 0.0 110.221 178.098 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 52.6 t0 -94.06 122.94 37.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.282 -0.886 . . . . 0.0 110.319 -178.315 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 111.42 -50.6 0.76 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 177.172 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.427 HD11 HD22 ' A' ' 28' ' ' LEU . 6.7 tt -67.0 140.03 57.7 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.087 -1.243 . . . . 0.0 110.296 -176.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.466 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 19.7 pt-20 -147.42 168.5 21.71 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.383 -0.823 . . . . 0.0 109.451 176.767 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.532 ' CG2' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -63.24 151.65 39.87 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.975 -1.078 . . . . 0.0 110.265 -175.885 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.52 -0.44 60.58 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -174.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.466 ' HB3' ' O ' ' A' ' 37' ' ' GLU . . . -79.99 159.37 26.29 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.162 -1.199 . . . . 0.0 109.392 175.861 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.454 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.5 OUTLIER -103.19 117.54 34.77 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 118.849 -1.141 . . . . 0.0 110.155 177.068 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.578 HG11 ' CE1' ' A' ' 44' ' ' HIS . 1.6 t -102.37 128.28 55.21 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 121.335 -0.853 . . . . 0.0 108.907 172.476 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.47 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -92.88 119.68 32.44 Favored 'General case' 0 C--N 1.297 -1.689 0 C-N-CA 119.214 -0.995 . . . . 0.0 109.096 172.644 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.578 ' CE1' HG11 ' A' ' 42' ' ' VAL . 0.4 OUTLIER -87.62 102.63 14.8 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 119.729 -0.789 . . . . 0.0 108.982 179.194 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.8 t-20 59.6 6.29 0.8 Allowed 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.685 -0.634 . . . . 0.0 111.681 -170.642 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.456 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 128.58 -1.04 6.42 Favored Glycine 0 N--CA 1.489 2.181 0 C-N-CA 119.525 -1.321 . . . . 0.0 110.655 174.352 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.475 ' O ' HD23 ' A' ' 49' ' ' LEU . 34.8 t -98.51 108.67 21.42 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.438 -1.624 . . . . 0.0 109.55 175.74 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 22.7 p -74.3 130.17 39.18 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.087 -1.008 . . . . 0.0 111.074 -171.351 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.56 ' CD1' ' CD2' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -147.02 153.82 40.48 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.429 -0.794 . . . . 0.0 109.356 173.901 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 92.5 m -95.83 160.11 14.64 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.527 -1.358 . . . . 0.0 111.558 -169.118 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.531 ' CG1' HG13 ' A' ' 59' ' ' VAL . 15.8 t -82.08 114.72 23.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.847 -0.533 . . . . 0.0 110.358 -178.804 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.521 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 30.2 p -70.9 -39.94 72.47 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.322 -0.861 . . . . 0.0 109.977 175.137 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.53 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -166.19 154.2 10.47 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.31 -0.869 . . . . 0.0 110.177 179.677 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.532 HD11 ' CG2' ' A' ' 38' ' ' THR . 9.8 mt -108.31 134.91 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.1 -1.0 . . . . 0.0 110.138 177.699 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.468 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 47.4 m-80 -108.81 66.23 0.63 Allowed 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.601 -0.687 . . . . 0.0 109.512 177.87 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.2 -116.84 5.11 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 -173.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.54 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.43 -20.19 51.57 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.055 -1.262 . . . . 0.0 109.116 177.012 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.59 ' CD2' HG12 ' A' ' 13' ' ' VAL . 9.9 m170 -76.61 158.92 30.72 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.241 -0.912 . . . . 0.0 110.044 -178.35 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.531 HG13 ' CG1' ' A' ' 51' ' ' VAL . 55.6 t -140.78 123.06 15.31 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 O-C-N 121.055 -1.028 . . . . 0.0 110.591 171.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.523 ' OG ' ' CG2' ' A' ' 25' ' ' VAL . 0.9 OUTLIER -87.5 133.32 33.78 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.47 -0.769 . . . . 0.0 109.13 175.264 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.587 ' N ' ' CD1' ' A' ' 61' ' ' PHE . 1.8 p90 -125.96 156.01 40.46 Favored 'General case' 0 C--N 1.295 -1.79 0 O-C-N 121.378 -0.826 . . . . 0.0 110.185 178.038 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.521 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 36.7 p-10 -90.78 151.16 21.31 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.089 -1.007 . . . . 0.0 111.398 -170.161 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.532 HD23 ' CD1' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -159.82 111.54 2.03 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 -175.574 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.501 ' HB2' ' CB ' ' A' ' 67' ' ' THR . 28.4 mtm -66.17 140.02 58.16 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.819 -1.176 . . . . 0.0 109.825 -179.848 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.483 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 49.3 tptt -60.11 -49.8 76.23 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.209 -0.932 . . . . 0.0 110.251 -178.411 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -65.2 -40.01 93.58 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.875 -1.141 . . . . 0.0 109.76 176.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.501 ' CB ' ' HB2' ' A' ' 64' ' ' MET . 94.3 m -60.05 -39.7 86.89 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.02 -1.05 . . . . 0.0 109.452 173.289 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.534 ' HG ' ' CA ' ' A' ' 74' ' ' GLY . 7.8 tp -59.95 -43.57 94.95 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.308 -0.87 . . . . 0.0 109.65 179.723 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -68.16 -40.01 82.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.38 -0.825 . . . . 0.0 110.579 176.042 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.467 HG22 ' O ' ' A' ' 67' ' ' THR . 1.3 tt -64.9 -43.25 96.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.17 -0.956 . . . . 0.0 109.328 -177.108 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.458 HG23 HG22 ' A' ' 70' ' ' ILE . 29.9 p -86.68 -174.63 5.07 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.727 -0.608 . . . . 0.0 109.667 176.751 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.479 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 6.1 t30 -98.78 22.59 9.87 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.167 -0.958 . . . . 0.0 108.686 171.469 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.532 ' CD1' HD23 ' A' ' 63' ' ' LEU . 91.8 mt -68.73 -39.98 80.12 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.095 -1.003 . . . . 0.0 109.975 176.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.534 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -50.44 -23.9 6.78 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -178.351 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.5 p-10 -62.12 -18.01 59.53 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.089 -1.242 . . . . 0.0 110.233 -175.764 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.9 mt -63.62 142.09 58.53 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.319 -0.863 . . . . 0.0 110.961 -177.69 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.464 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 42.8 mttt -143.54 144.84 32.13 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-O 121.311 0.577 . . . . 0.0 109.731 175.106 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.589 ' CG2' ' CG1' ' A' ' 15' ' ' ILE . 21.9 t -64.52 149.93 10.7 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 120.843 -1.161 . . . . 0.0 110.479 -175.327 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.97 -13.63 60.78 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -175.144 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 46.6 t0 -94.61 163.3 13.44 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.337 -1.096 . . . . 0.0 109.585 176.021 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.579 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 13.9 m95 -113.28 154.79 26.23 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 120.964 -1.085 . . . . 0.0 110.155 175.829 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.531 HG12 ' CB ' ' A' ' 10' ' ' ALA . 1.4 p -119.99 153.03 22.82 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.437 -0.789 . . . . 0.0 109.852 -179.019 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.486 ' N ' HG22 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -77.73 107.34 10.16 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.171 -0.955 . . . . 0.0 109.02 168.475 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.488 ' CG2' ' C ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -109.4 138.85 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 120.474 -1.391 . . . . 0.0 111.364 -176.724 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -131.49 139.59 49.35 Favored 'General case' 0 N--CA 1.494 1.749 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.131 -179.369 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -81.37 133.62 35.44 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.091 -1.006 . . . . 0.0 110.94 -175.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.577 ' HB2' ' CD2' ' B' ' 2' ' ' PHE . . . -130.69 147.31 52.35 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.28 -0.888 . . . . 0.0 110.639 179.809 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.551 ' HB2' ' CE2' ' A' ' 90' ' ' PHE . . . -151.19 9.07 0.55 Allowed 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.49 -0.756 . . . . 0.0 111.981 -178.168 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . 0.59 ' HG3' ' CE2' ' B' ' 2' ' ' PHE . 20.7 mttm 60.02 19.83 8.96 Favored 'General case' 0 N--CA 1.513 2.698 0 O-C-N 121.373 -0.829 . . . . 0.0 110.781 175.029 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.551 ' CE2' ' HB2' ' A' ' 88' ' ' ALA . 9.6 p90 -154.09 159.65 41.6 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.905 -1.122 . . . . 0.0 110.591 172.68 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' SER . . . . . 0.521 ' HB3' ' CG1' ' A' ' 94' ' ' ILE . 56.7 m -141.78 150.18 41.37 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.493 -0.754 . . . . 0.0 109.831 175.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.466 ' O ' ' HG3' ' A' ' 93' ' ' GLU . 51.8 t0 -69.87 -45.93 66.62 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.107 -0.996 . . . . 0.0 110.313 -178.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.466 ' HG3' ' O ' ' A' ' 92' ' ' ASP . 94.0 mt-10 -157.35 53.96 0.49 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.338 -0.852 . . . . 0.0 110.444 179.198 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.521 ' CG1' ' HB3' ' A' ' 91' ' ' SER . 48.4 mm -98.95 -37.77 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.138 -0.976 . . . . 0.0 110.456 178.661 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 47.11 67.66 1.4 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 -178.635 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' A' ' 97' ' ' HIS . . . -178.59 -170.01 40.07 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -178.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.493 ' CB ' ' O ' ' A' ' 96' ' ' GLY . 0.9 OUTLIER . . . . . 0 N--CA 1.493 1.723 0 O-C-N 121.188 -1.184 . . . . 0.0 110.139 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 1' ' ' MET . . . . . 0.429 ' HB3' ' HE2' ' B' ' 1' ' ' MET . 98.1 mtp . . . . . 0 N--CA 1.492 1.655 0 CA-C-O 121.062 0.458 . . . . 0.0 110.139 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.59 ' CE2' ' HG3' ' A' ' 89' ' ' LYS . 4.6 p90 -165.77 156.24 13.12 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.075 -1.016 . . . . 0.0 108.406 172.725 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.488 ' CG2' ' C ' ' B' ' 2' ' ' PHE . 60.7 p -152.2 -40.9 0.11 Allowed 'General case' 0 C--N 1.292 -1.912 0 O-C-N 120.91 -1.119 . . . . 0.0 108.818 175.01 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.456 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 47.39 24.13 2.33 Favored Glycine 0 N--CA 1.481 1.692 0 N-CA-C 108.213 -1.955 . . . . 0.0 108.213 -174.52 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.481 HG13 ' O ' ' B' ' 3' ' ' THR . 70.8 mt -82.01 119.77 32.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.287 -1.125 . . . . 0.0 109.689 -176.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.529 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 3.4 t -75.1 149.17 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.352 -0.843 . . . . 0.0 110.583 -173.889 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 28.2 mm100 -98.55 -14.83 19.77 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.54 -0.725 . . . . 0.0 110.854 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.529 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -141.28 165.14 26.42 Favored Glycine 0 N--CA 1.493 2.458 0 C-N-CA 119.338 -1.41 . . . . 0.0 109.868 -177.536 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.487 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 0.7 OUTLIER -124.74 169.99 11.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.123 -1.221 . . . . 0.0 110.556 178.821 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.534 ' CB ' HG11 ' B' ' 82' ' ' VAL . . . -141.31 149.34 41.1 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.507 -0.745 . . . . 0.0 109.235 -176.617 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.589 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 32.0 tttt -109.7 114.34 27.86 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.151 -0.968 . . . . 0.0 110.014 178.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.515 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 11.7 tp -60.02 127.78 33.57 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.104 -0.998 . . . . 0.0 108.939 175.106 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.593 HG12 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.96 -31.04 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 O-C-N 121.393 -0.817 . . . . 0.0 110.1 -178.651 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.08 141.9 30.32 Favored 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.328 -178.082 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.586 ' CG1' ' CG2' ' B' ' 78' ' ' VAL . 8.4 mt -109.91 132.96 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.128 -0.982 . . . . 0.0 110.377 172.917 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.494 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 88.2 m-20 -109.99 114.98 28.95 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.416 -0.803 . . . . 0.0 109.995 175.388 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -102.59 109.67 21.36 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.982 -1.074 . . . . 0.0 110.497 -177.399 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.466 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.3 OUTLIER -101.87 135.95 19.62 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.274 -0.892 . . . . 0.0 109.541 175.943 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.05 -16.85 9.97 Favored 'Trans proline' 0 C--N 1.303 -1.837 0 O-C-N 123.934 1.492 . . . . 0.0 110.856 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.547 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 6.0 m-80 -102.56 -26.98 13.03 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.107 -0.996 . . . . 0.0 109.874 179.706 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.547 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 87.5 m-85 -156.3 150.22 25.08 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.432 -0.793 . . . . 0.0 109.972 -178.426 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.476 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 61.2 ttt180 -92.31 141.67 28.3 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.701 -1.25 . . . . 0.0 109.806 174.786 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.494 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 88.4 m -129.96 140.12 50.97 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 121.617 -0.677 . . . . 0.0 109.798 -172.715 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.573 ' CD2' HG21 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -130.05 142.45 50.61 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 120.964 -1.085 . . . . 0.0 111.338 -179.158 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.526 ' CG2' ' OG ' ' B' ' 60' ' ' SER . 16.3 t -119.51 134.41 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.264 -0.898 . . . . 0.0 110.435 179.55 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.579 HG13 ' CE1' ' B' ' 61' ' ' PHE . 33.1 m -117.09 170.76 6.21 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 CA-C-O 121.263 0.554 . . . . 0.0 109.955 178.921 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.519 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 9.3 tt0 -102.56 116.68 33.08 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.345 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.495 ' CD2' ' O ' ' B' ' 32' ' ' MET . 8.7 tp -80.54 121.62 81.56 Favored Pre-proline 0 C--N 1.297 -1.703 0 O-C-N 121.433 -0.792 . . . . 0.0 109.716 -173.805 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.47 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 18.5 Cg_endo -63.4 178.86 1.06 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 O-C-N 123.91 1.479 . . . . 0.0 111.007 -179.09 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -60.29 -39.98 88.85 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.356 -0.84 . . . . 0.0 111.118 -175.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.566 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.11 0.28 57.23 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.87 -1.144 . . . . 0.0 110.945 -175.609 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.566 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.1 mmm -109.16 -12.81 14.77 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.87 -1.144 . . . . 0.0 109.93 171.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.53 ' CD2' ' HB2' ' B' ' 57' ' ' ASN . 19.2 mt -68.88 -31.32 70.17 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.226 -0.921 . . . . 0.0 110.22 178.054 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -93.99 122.95 37.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.381 -0.824 . . . . 0.0 110.363 -178.38 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 111.43 -50.65 0.75 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.061 -1.215 . . . . 0.0 110.061 177.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . 0.525 HD21 ' N ' ' B' ' 37' ' ' GLU . 6.7 tt -66.97 140.02 57.72 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.051 -1.264 . . . . 0.0 110.299 -176.955 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.525 ' N ' HD21 ' B' ' 36' ' ' LEU . 19.7 pt-20 -147.38 168.55 21.54 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.401 -0.812 . . . . 0.0 109.41 176.673 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.533 ' CG2' ' HA ' ' B' ' 53' ' ' GLU . 0.0 OUTLIER -63.33 151.51 40.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.995 -1.066 . . . . 0.0 110.382 -175.949 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.73 -0.48 61.32 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -174.658 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.456 ' CB ' ' O ' ' B' ' 37' ' ' GLU . . . -80.07 159.34 26.18 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.141 -1.211 . . . . 0.0 109.382 175.816 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.457 ' OG ' ' O ' ' B' ' 87' ' ' ALA . 0.5 OUTLIER -102.99 117.33 34.36 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.782 -1.199 . . . . 0.0 110.309 177.03 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.582 HG11 ' CE1' ' B' ' 44' ' ' HIS . 1.7 t -102.27 128.43 54.93 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 121.357 -0.839 . . . . 0.0 108.868 172.5 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.466 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -92.97 119.74 32.55 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 119.227 -0.989 . . . . 0.0 108.988 172.617 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.582 ' CE1' HG11 ' B' ' 42' ' ' VAL . 0.4 OUTLIER -87.72 102.45 14.65 Favored 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.54 -0.864 . . . . 0.0 109.098 179.106 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 59.84 6.38 0.89 Allowed 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.554 -0.716 . . . . 0.0 111.549 -170.688 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' A' ' 4' ' ' GLY . . . 128.38 -0.62 6.46 Favored Glycine 0 N--CA 1.489 2.218 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.714 174.228 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.466 ' O ' ' HA ' ' B' ' 43' ' ' ALA . 34.6 t -98.63 108.61 21.34 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.502 -1.587 . . . . 0.0 109.537 175.552 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 22.9 p -74.19 130.19 39.27 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.058 -1.026 . . . . 0.0 111.043 -171.429 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.558 ' CD1' ' CD2' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -147.11 153.92 40.5 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.527 -0.733 . . . . 0.0 109.359 173.726 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 92.9 m -95.9 160.41 14.48 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 120.527 -1.358 . . . . 0.0 111.556 -169.085 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.534 ' CG1' HG13 ' B' ' 59' ' ' VAL . 16.1 t -82.44 114.65 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.84 -0.538 . . . . 0.0 110.433 -178.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 30.2 p -70.71 -40.03 73.07 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.272 -0.893 . . . . 0.0 109.918 175.339 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.533 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -166.21 154.11 10.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.202 -0.936 . . . . 0.0 110.208 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.532 HD11 ' CG2' ' B' ' 38' ' ' THR . 9.8 mt -108.31 134.89 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.114 -0.991 . . . . 0.0 110.206 177.684 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.477 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 47.1 m-80 -108.84 66.14 0.63 Allowed 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.64 -0.662 . . . . 0.0 109.522 177.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.32 -116.81 5.08 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 108.861 -1.696 . . . . 0.0 108.861 -173.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.53 ' HB2' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.44 -20.29 51.35 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.075 -1.25 . . . . 0.0 109.151 177.054 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.593 ' CD2' HG12 ' B' ' 13' ' ' VAL . 9.9 m170 -76.5 158.79 30.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.347 -0.846 . . . . 0.0 110.097 -178.375 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.534 HG13 ' CG1' ' B' ' 51' ' ' VAL . 55.8 t -140.76 123.15 15.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 C-N-CA 119.076 -1.05 . . . . 0.0 110.519 171.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.526 ' OG ' ' CG2' ' B' ' 25' ' ' VAL . 0.9 OUTLIER -87.52 133.3 33.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.441 -0.787 . . . . 0.0 109.204 175.225 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.589 ' N ' ' CD1' ' B' ' 61' ' ' PHE . 1.8 p90 -125.98 155.99 40.53 Favored 'General case' 0 N--CA 1.494 1.773 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.177 178.033 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 36.6 p-10 -90.67 151.19 21.37 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.0 -1.062 . . . . 0.0 111.381 -170.115 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.534 HD22 ' CD1' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.82 111.53 2.03 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -175.638 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.505 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 28.5 mtm -66.22 139.96 58.13 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.888 -1.133 . . . . 0.0 109.824 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.485 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 49.3 tptt -59.92 -49.87 76.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.131 -0.98 . . . . 0.0 110.3 -178.439 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -65.24 -39.99 93.42 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.913 -1.117 . . . . 0.0 109.765 176.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.505 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 94.5 m -60.01 -39.83 87.19 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.988 -1.07 . . . . 0.0 109.342 173.29 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.523 ' HG ' ' CA ' ' B' ' 74' ' ' GLY . 7.8 tp -59.94 -43.45 94.97 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.293 -0.879 . . . . 0.0 109.707 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 78.5 ttt180 -68.21 -40.08 82.21 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.293 -0.879 . . . . 0.0 110.603 175.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.459 HG21 HG21 ' B' ' 71' ' ' THR . 1.3 tt -64.75 -43.24 96.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.195 -0.941 . . . . 0.0 109.434 -177.213 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.466 HG21 ' O ' ' B' ' 67' ' ' THR . 30.0 p -86.65 -174.56 5.04 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 120.231 -0.588 . . . . 0.0 109.658 176.774 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.484 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 6.0 t30 -98.71 22.57 9.84 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.19 -0.944 . . . . 0.0 108.78 171.393 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.534 ' CD1' HD22 ' B' ' 63' ' ' LEU . 91.4 mt -68.71 -40.0 80.17 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.075 -1.015 . . . . 0.0 110.05 176.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.523 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -50.46 -23.87 6.78 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 -178.384 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.0 p-10 -62.1 -17.94 59.23 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.062 -1.258 . . . . 0.0 110.295 -175.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.513 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.1 mt -63.68 142.22 58.48 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.287 -0.883 . . . . 0.0 110.929 -177.746 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.478 ' O ' HD22 ' B' ' 12' ' ' LEU . 42.8 mttt -143.67 144.95 32.1 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.627 -0.671 . . . . 0.0 109.665 175.13 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.586 ' CG2' ' CG1' ' B' ' 15' ' ' ILE . 22.2 t -64.73 150.03 10.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 O-C-N 120.856 -1.153 . . . . 0.0 110.341 -175.182 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.8 -13.45 60.89 Favored Glycine 0 N--CA 1.484 1.84 0 N-CA-C 108.848 -1.701 . . . . 0.0 108.848 -175.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.499 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 46.2 t0 -94.62 163.23 13.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.319 -1.106 . . . . 0.0 109.59 175.832 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.589 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 13.9 m95 -113.31 154.73 26.37 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.97 -1.081 . . . . 0.0 110.215 175.782 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.534 HG11 ' CB ' ' B' ' 10' ' ' ALA . 1.4 p -119.98 153.1 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.579 -0.701 . . . . 0.0 109.881 -179.082 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.483 ' N ' HG23 ' B' ' 82' ' ' VAL . 0.3 OUTLIER -77.72 107.27 10.09 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.178 -0.951 . . . . 0.0 109.018 168.569 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.487 ' CG2' ' C ' ' B' ' 9' ' ' THR . 0.0 OUTLIER -109.32 138.96 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 120.462 -1.399 . . . . 0.0 111.211 -176.533 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -131.58 139.68 49.25 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.883 -0.511 . . . . 0.0 110.144 -179.569 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -81.35 133.69 35.46 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.117 -0.99 . . . . 0.0 110.916 -175.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.599 ' HB2' ' CD2' ' A' ' 2' ' ' PHE . . . -130.85 147.19 52.47 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.403 -0.81 . . . . 0.0 110.647 179.814 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . 0.551 ' HB3' ' CE2' ' B' ' 90' ' ' PHE . . . -151.22 8.96 0.55 Allowed 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.39 -0.819 . . . . 0.0 112.067 -178.066 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . 0.567 ' HG3' ' CE2' ' A' ' 2' ' ' PHE . 20.6 mttm 59.96 19.98 9.03 Favored 'General case' 0 N--CA 1.512 2.66 0 O-C-N 121.334 -0.854 . . . . 0.0 110.732 175.015 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . 0.551 ' CE2' ' HB3' ' B' ' 88' ' ' ALA . 9.7 p90 -154.1 159.68 41.6 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.872 -1.143 . . . . 0.0 110.685 172.536 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 91' ' ' SER . . . . . 0.478 ' HB3' HG12 ' B' ' 94' ' ' ILE . 56.4 m -141.8 150.28 41.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.476 -0.765 . . . . 0.0 109.787 175.953 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -69.94 -50.29 43.47 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.081 -1.012 . . . . 0.0 110.388 -178.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . 0.432 ' O ' ' HG3' ' B' ' 93' ' ' GLU . 16.6 pt-20 -160.51 63.46 0.32 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.037 -1.039 . . . . 0.0 111.441 -175.589 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . 0.478 HG12 ' HB3' ' B' ' 91' ' ' SER . 20.2 mm -60.04 -42.96 91.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 120.92 -1.113 . . . . 0.0 109.995 174.745 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 114.67 -102.02 1.13 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.489 -1.445 . . . . 0.0 109.489 -177.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -67.28 -41.62 91.41 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -178.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . 0.46 ' OXT' HG21 ' B' ' 94' ' ' ILE . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 O-C-N 121.236 -1.155 . . . . 0.0 110.291 -178.064 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.538 " O2'" ' C9 ' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.53 " O2'" ' C9 ' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.421 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 73.0 mtm . . . . . 0 N--CA 1.493 1.724 0 CA-C-O 121.274 0.559 . . . . 0.0 110.12 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.583 ' CZ ' ' CB ' ' B' ' 87' ' ' ALA . 5.0 p90 -176.83 147.59 0.61 Allowed 'General case' 0 C--N 1.306 -1.322 0 O-C-N 121.148 -0.97 . . . . 0.0 108.815 179.413 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.518 ' CB ' HG12 ' A' ' 5' ' ' ILE . 6.0 p -141.05 -37.98 0.43 Allowed 'General case' 0 C--N 1.296 -1.723 0 O-C-N 120.891 -1.131 . . . . 0.0 109.223 -179.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.461 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 47.64 24.64 2.89 Favored Glycine 0 N--CA 1.485 1.918 0 N-CA-C 108.541 -1.824 . . . . 0.0 108.541 -176.214 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.518 HG12 ' CB ' ' A' ' 3' ' ' THR . 48.4 mm -80.48 124.64 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.294 -1.121 . . . . 0.0 110.032 -175.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.527 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.5 t -84.22 141.82 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.367 -0.833 . . . . 0.0 110.638 -172.606 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 20.1 pt20 -89.64 -16.15 31.13 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.453 -0.779 . . . . 0.0 110.829 -178.426 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -158.45 177.12 35.25 Favored Glycine 0 N--CA 1.493 2.484 0 C-N-CA 119.129 -1.51 . . . . 0.0 110.083 -177.522 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.487 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 1.4 p -125.87 167.97 14.51 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.069 -1.254 . . . . 0.0 110.472 178.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.533 ' CB ' HG13 ' A' ' 82' ' ' VAL . . . -139.93 149.64 43.57 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.346 -0.846 . . . . 0.0 109.903 -174.283 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 31.2 tttt -106.26 116.01 31.21 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.126 -0.984 . . . . 0.0 110.169 179.255 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.515 HD22 ' N ' ' A' ' 78' ' ' VAL . 13.1 tp -59.93 128.03 34.84 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.793 -1.192 . . . . 0.0 108.582 171.676 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.637 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.7 p -131.34 -31.01 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 O-C-N 121.262 -0.898 . . . . 0.0 110.316 -176.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -144.34 139.68 28.65 Favored 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 118.936 -1.106 . . . . 0.0 111.39 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.573 HG13 ' CG2' ' A' ' 78' ' ' VAL . 9.9 mt -109.16 137.0 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.052 -1.03 . . . . 0.0 110.08 171.366 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.458 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 78.7 m-20 -111.86 114.35 27.25 Favored 'General case' 0 C--N 1.295 -1.79 0 O-C-N 121.415 -0.803 . . . . 0.0 110.182 173.028 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -105.04 118.61 36.97 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.033 -1.042 . . . . 0.0 110.492 -177.443 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.453 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.9 mtpp -118.26 140.18 27.74 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.256 -0.902 . . . . 0.0 109.779 178.876 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -55.1 -15.2 10.03 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 O-C-N 124.067 1.562 . . . . 0.0 110.964 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.586 ' ND2' ' N ' ' A' ' 20' ' ' ASN . 0.1 OUTLIER -107.61 -25.25 11.42 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.999 -1.063 . . . . 0.0 109.308 -177.892 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.568 ' CD1' ' O ' ' A' ' 20' ' ' ASN . 75.8 m-85 -157.74 150.3 22.71 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.622 -0.674 . . . . 0.0 110.105 179.337 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.466 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 63.6 ttt180 -96.77 143.32 27.8 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 120.815 -1.178 . . . . 0.0 110.012 172.614 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.458 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 54.4 m -130.91 140.18 50.17 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.488 -0.758 . . . . 0.0 110.145 -173.414 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.576 ' HB3' ' CE1' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -130.14 143.86 51.03 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 120.94 -1.1 . . . . 0.0 111.604 178.805 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.536 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 8.3 t -125.77 136.1 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.158 -0.964 . . . . 0.0 110.651 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.48 HG11 ' CE2' ' A' ' 61' ' ' PHE . 35.4 m -117.67 171.74 5.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 121.783 -0.573 . . . . 0.0 110.211 178.228 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.569 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 3.6 tt0 -104.25 117.31 33.92 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.218 -0.926 . . . . 0.0 109.247 -178.772 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.505 ' CD2' ' O ' ' A' ' 32' ' ' MET . 9.6 tp -82.81 125.87 74.4 Favored Pre-proline 0 C--N 1.299 -1.621 0 O-C-N 121.585 -0.697 . . . . 0.0 110.106 -173.641 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.478 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 28.2 Cg_endo -67.04 176.94 4.01 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 123.886 1.466 . . . . 0.0 111.069 -179.627 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.444 ' HA ' HD12 ' A' ' 33' ' ' LEU . 92.6 m-20 -60.03 -40.0 87.84 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.239 -0.913 . . . . 0.0 111.306 -174.938 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.573 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.99 0.64 56.99 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.751 -1.218 . . . . 0.0 110.907 -174.472 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.573 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.8 mmm -112.17 -8.57 13.99 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.875 -1.141 . . . . 0.0 110.006 170.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.548 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 16.0 mt -70.03 -40.01 75.42 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.224 -0.922 . . . . 0.0 109.915 177.065 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -81.74 128.81 34.38 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.594 -0.691 . . . . 0.0 110.486 -178.246 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.47 -46.18 1.21 Allowed Glycine 0 N--CA 1.493 2.445 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.256 174.795 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.486 HD21 ' N ' ' A' ' 37' ' ' GLU . 6.8 tt -69.7 148.84 48.71 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.93 -1.335 . . . . 0.0 110.445 -175.365 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.486 ' N ' HD21 ' A' ' 36' ' ' LEU . 21.3 pt-20 -150.62 170.02 20.16 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.367 -0.833 . . . . 0.0 109.397 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.539 ' CG2' ' HA ' ' A' ' 53' ' ' GLU . 0.0 OUTLIER -70.06 151.15 45.84 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.058 -1.026 . . . . 0.0 110.228 -178.919 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . 0.412 ' O ' ' NZ ' ' A' ' 89' ' ' LYS . . . 79.09 -3.3 66.2 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -174.183 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.472 ' HB2' ' O ' ' A' ' 37' ' ' GLU . . . -77.99 161.48 27.46 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.27 -1.135 . . . . 0.0 109.661 177.612 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.476 ' CB ' ' HB1' ' A' ' 87' ' ' ALA . 0.6 OUTLIER -101.64 114.95 29.46 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.016 -1.052 . . . . 0.0 110.104 177.354 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.537 ' CG1' ' CE1' ' A' ' 44' ' ' HIS . 1.8 t -103.16 128.88 55.76 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.323 -0.861 . . . . 0.0 109.157 174.06 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.466 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -94.8 120.08 34.43 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.269 -0.972 . . . . 0.0 109.265 173.043 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.567 ' CD2' HG23 ' A' ' 82' ' ' VAL . 1.4 m80 -90.71 106.19 18.34 Favored 'General case' 0 C--N 1.301 -1.503 0 C-N-CA 119.676 -0.81 . . . . 0.0 109.054 177.568 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.494 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.8 t-20 53.92 14.81 0.72 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.338 -0.851 . . . . 0.0 110.925 -167.02 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.493 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 117.78 -0.5 17.73 Favored Glycine 0 N--CA 1.489 2.17 0 C-N-CA 119.623 -1.275 . . . . 0.0 110.978 170.559 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.526 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 43.4 t -92.35 106.84 18.76 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.49 -1.594 . . . . 0.0 109.151 173.525 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.8 p -75.49 128.66 35.8 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.15 -0.969 . . . . 0.0 110.749 -170.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.6 HD12 ' CG ' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -143.14 159.66 41.88 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.442 -0.786 . . . . 0.0 109.714 175.296 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.406 HG21 ' N ' ' A' ' 51' ' ' VAL . 28.9 m -100.16 149.82 23.14 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.576 -1.328 . . . . 0.0 111.409 -170.781 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.538 ' CG1' HG11 ' A' ' 59' ' ' VAL . 15.1 t -78.06 118.39 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 CA-C-O 121.155 0.502 . . . . 0.0 110.617 -178.002 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.53 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 42.9 p -73.89 -39.94 63.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.126 -0.984 . . . . 0.0 110.031 174.494 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.539 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.6 tt0 -163.4 149.85 12.07 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.35 -0.844 . . . . 0.0 110.214 -178.007 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.532 HD11 ' CG2' ' A' ' 38' ' ' THR . 5.7 mt -101.51 134.9 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.09 -1.007 . . . . 0.0 109.955 176.148 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.457 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 49.9 m-80 -110.45 65.78 0.62 Allowed 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.571 -0.705 . . . . 0.0 109.913 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.19 -118.68 4.99 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.879 -1.688 . . . . 0.0 108.879 -175.236 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.548 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.62 -16.39 57.41 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 120.949 -1.324 . . . . 0.0 108.816 174.307 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.637 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 11.8 m170 -76.6 159.81 29.96 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.37 -0.831 . . . . 0.0 110.39 -178.192 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.538 HG11 ' CG1' ' A' ' 51' ' ' VAL . 52.2 t -140.3 127.02 22.42 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 O-C-N 121.02 -1.05 . . . . 0.0 110.596 170.036 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.536 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 2.7 t -95.8 136.74 35.83 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.474 -0.767 . . . . 0.0 109.564 178.382 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.6 ' CG ' HD12 ' A' ' 49' ' ' LEU . 2.0 p90 -128.06 157.78 39.76 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.864 173.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.53 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 25.0 p-10 -89.48 157.64 18.02 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.31 -0.869 . . . . 0.0 111.129 -171.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.528 ' CD2' HD12 ' A' ' 68' ' ' LEU . 0.1 OUTLIER -159.94 102.57 1.47 Allowed 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 120.035 -0.666 . . . . 0.0 109.461 -175.441 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.491 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 56.3 ttm -59.75 140.4 56.54 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.002 -1.062 . . . . 0.0 109.364 -179.557 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.45 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 39.4 ttpt -60.01 -43.32 95.31 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.022 -1.049 . . . . 0.0 110.285 -175.159 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.74 -39.99 76.43 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.02 -1.05 . . . . 0.0 110.067 178.279 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.504 ' O ' HG21 ' A' ' 71' ' ' THR . 92.2 m -60.56 -39.96 89.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.978 -1.076 . . . . 0.0 109.184 172.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.528 HD12 ' CD2' ' A' ' 63' ' ' LEU . 7.3 tp -59.94 -45.4 92.74 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.285 -0.885 . . . . 0.0 109.782 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.405 ' HD3' ' HA ' ' A' ' 69' ' ' ARG . 15.0 tpp180 -69.21 -39.59 78.51 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.529 -0.732 . . . . 0.0 110.47 177.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.473 ' CG2' ' N ' ' A' ' 71' ' ' THR . 1.4 tt -63.68 -43.98 98.27 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.13 -0.982 . . . . 0.0 109.368 -177.47 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.504 HG21 ' O ' ' A' ' 67' ' ' THR . 37.8 p -83.55 -170.51 3.1 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.404 0.621 . . . . 0.0 109.703 178.611 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.5 t30 -103.28 22.63 13.79 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 170.187 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.499 ' CD1' HD23 ' A' ' 63' ' ' LEU . 89.4 mt -69.54 -41.23 76.22 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.158 -0.964 . . . . 0.0 109.999 176.731 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.494 ' HA2' ' CD1' ' A' ' 68' ' ' LEU . . . -51.01 -20.81 4.75 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 -178.163 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.1 p-10 -67.43 -18.5 65.12 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.927 -1.337 . . . . 0.0 110.673 -174.003 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.517 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 90.2 mt -60.89 142.86 55.92 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.166 -0.959 . . . . 0.0 110.983 -175.476 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.478 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 98.7 mttt -140.34 139.53 35.43 Favored 'General case' 0 N--CA 1.493 1.695 0 CA-C-O 121.537 0.684 . . . . 0.0 109.955 173.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.573 ' CG2' HG13 ' A' ' 15' ' ' ILE . 15.4 t -63.19 153.47 6.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 120.868 -1.145 . . . . 0.0 110.636 -174.45 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.0 -16.93 55.83 Favored Glycine 0 N--CA 1.485 1.928 0 N-CA-C 108.645 -1.782 . . . . 0.0 108.645 -175.134 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -95.14 170.09 9.64 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.402 -1.058 . . . . 0.0 109.743 175.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.5 m95 -116.97 169.51 9.35 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.965 -1.085 . . . . 0.0 110.17 176.013 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.567 HG23 ' CD2' ' A' ' 44' ' ' HIS . 1.4 p -134.09 155.63 39.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 121.438 -0.789 . . . . 0.0 109.808 -176.669 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.487 ' HB2' ' HB3' ' B' ' 72' ' ' ASN . 2.1 m-20 -79.57 109.12 13.66 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.006 -1.059 . . . . 0.0 109.134 168.668 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.49 ' O ' HG12 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -110.78 138.59 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 120.43 -1.419 . . . . 0.0 111.275 -175.546 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -134.35 145.03 48.62 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.864 -0.522 . . . . 0.0 110.292 -177.244 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 36.1 ttm180 -83.49 130.65 35.02 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.311 -0.868 . . . . 0.0 111.027 -176.679 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.624 ' CB ' ' CZ ' ' B' ' 2' ' ' PHE . . . -127.66 148.19 50.38 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.25 -0.906 . . . . 0.0 110.023 174.737 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -123.69 141.62 51.84 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.423 -0.798 . . . . 0.0 110.873 -175.723 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . 0.412 ' NZ ' ' O ' ' A' ' 39' ' ' GLY . 15.9 mttp -60.0 -40.03 87.8 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.471 -0.768 . . . . 0.0 110.84 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -159.05 160.0 35.33 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.998 -1.064 . . . . 0.0 111.07 -177.033 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' SER . . . . . 0.587 ' CB ' ' CD1' ' A' ' 94' ' ' ILE . 79.7 p -154.65 161.42 41.58 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.415 -0.803 . . . . 0.0 109.715 173.293 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.509 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 96.0 m-20 -69.96 -40.35 75.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.081 -1.012 . . . . 0.0 110.698 -178.626 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.509 ' CG ' ' O ' ' A' ' 92' ' ' ASP . 59.1 mt-10 -158.11 60.04 0.46 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.949 -1.095 . . . . 0.0 111.323 -172.426 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.587 ' CD1' ' CB ' ' A' ' 91' ' ' SER . 96.7 mt -92.99 25.91 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 120.649 -1.282 . . . . 0.0 109.422 170.613 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 94' ' ' ILE . . . -39.25 -24.7 0.04 OUTLIER Glycine 0 N--CA 1.496 2.643 0 C-N-CA 120.322 -0.942 . . . . 0.0 111.42 -175.196 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 94' ' ' ILE . . . 94.24 171.56 38.27 Favored Glycine 0 N--CA 1.491 2.342 0 O-C-N 120.476 -1.602 . . . . 0.0 109.399 -179.366 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.411 ' ND1' ' N ' ' A' ' 97' ' ' HIS . 30.5 p-80 . . . . . 0 N--CA 1.492 1.633 0 O-C-N 121.289 -1.124 . . . . 0.0 110.161 -179.415 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 58.2 mtm . . . . . 0 N--CA 1.492 1.663 0 CA-C-O 121.115 0.483 . . . . 0.0 110.413 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.624 ' CZ ' ' CB ' ' A' ' 87' ' ' ALA . 5.1 p90 -166.62 147.39 6.08 Favored 'General case' 0 C--N 1.306 -1.308 0 O-C-N 121.184 -0.947 . . . . 0.0 108.653 173.419 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.52 ' CB ' HG12 ' B' ' 5' ' ' ILE . 6.0 p -141.15 -37.96 0.42 Allowed 'General case' 0 C--N 1.298 -1.667 0 O-C-N 120.789 -1.194 . . . . 0.0 109.21 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.404 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 47.67 24.58 2.9 Favored Glycine 0 N--CA 1.485 1.949 0 N-CA-C 108.515 -1.834 . . . . 0.0 108.515 -176.32 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.52 HG12 ' CB ' ' B' ' 3' ' ' THR . 48.3 mm -80.46 124.6 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.357 -1.084 . . . . 0.0 110.056 -175.906 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.525 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.5 t -84.11 141.8 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.367 -0.833 . . . . 0.0 110.727 -172.634 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 20.1 pt20 -89.72 -15.84 31.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.374 -0.828 . . . . 0.0 110.887 -178.418 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.525 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -158.8 177.0 35.59 Favored Glycine 0 N--CA 1.494 2.552 0 C-N-CA 119.143 -1.503 . . . . 0.0 110.113 -177.495 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.486 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 1.4 p -125.88 167.92 14.58 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.088 -1.243 . . . . 0.0 110.42 179.103 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.534 ' CB ' HG11 ' B' ' 82' ' ' VAL . . . -139.84 149.77 43.85 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.278 -0.889 . . . . 0.0 109.88 -174.399 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.589 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 31.2 tttt -106.35 116.04 31.25 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.081 -1.012 . . . . 0.0 110.141 179.201 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.514 HD23 ' N ' ' B' ' 78' ' ' VAL . 13.1 tp -60.06 128.03 34.82 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.828 -1.17 . . . . 0.0 108.671 171.634 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.642 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.7 p -131.41 -30.86 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.31 -176.711 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -144.46 139.8 28.55 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.12 -1.032 . . . . 0.0 111.348 179.913 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.575 HG13 ' CG2' ' B' ' 78' ' ' VAL . 10.3 mt -109.32 136.98 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.078 -1.013 . . . . 0.0 110.06 171.4 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.473 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 78.6 m-20 -111.97 114.5 27.44 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 121.44 -0.787 . . . . 0.0 110.159 173.039 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -104.96 118.74 37.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.188 -0.945 . . . . 0.0 110.493 -177.435 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.449 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.9 mtpp -118.39 140.3 27.99 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.29 -0.881 . . . . 0.0 109.771 178.838 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -55.39 -15.11 10.81 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 124.008 1.53 . . . . 0.0 110.967 -179.785 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.571 ' O ' ' CD1' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -107.28 -25.9 11.28 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.01 -1.056 . . . . 0.0 109.214 -177.946 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.571 ' CD1' ' O ' ' B' ' 20' ' ' ASN . 75.3 m-85 -157.2 150.36 23.79 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.534 -0.729 . . . . 0.0 110.195 179.499 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.457 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 63.7 ttt180 -96.8 143.21 27.93 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.914 -1.117 . . . . 0.0 109.944 172.616 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.473 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 54.0 m -130.76 140.21 50.29 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.638 -0.664 . . . . 0.0 110.134 -173.492 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.574 ' HB3' ' CE1' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -130.04 143.94 51.06 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.005 -1.06 . . . . 0.0 111.492 178.806 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.541 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 8.2 t -125.7 136.3 61.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.317 -0.864 . . . . 0.0 110.764 179.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.478 HG13 ' CE2' ' B' ' 61' ' ' PHE . 35.6 m -117.91 171.78 5.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.744 -0.598 . . . . 0.0 110.126 178.355 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.574 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 3.6 tt0 -104.18 117.45 34.28 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.274 -0.891 . . . . 0.0 109.199 -178.786 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.514 ' N ' ' ND2' ' B' ' 57' ' ' ASN . 9.6 tp -82.9 125.8 74.37 Favored Pre-proline 0 C--N 1.299 -1.613 0 O-C-N 121.545 -0.722 . . . . 0.0 110.129 -173.724 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.479 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 28.1 Cg_endo -67.01 176.96 3.97 Favored 'Trans proline' 0 C--N 1.31 -1.491 0 O-C-N 123.919 1.484 . . . . 0.0 110.934 -179.583 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -60.01 -39.99 87.72 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.309 -0.869 . . . . 0.0 111.35 -174.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.567 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.01 0.63 57.0 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.761 -1.212 . . . . 0.0 110.844 -174.434 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.567 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.8 mmm -112.19 -8.58 13.98 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.856 -1.153 . . . . 0.0 110.006 170.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.546 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 16.0 mt -70.0 -40.04 75.52 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.268 -0.895 . . . . 0.0 109.888 177.07 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -81.7 128.93 34.49 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.597 -0.689 . . . . 0.0 110.508 -178.273 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.35 -46.15 1.21 Allowed Glycine 0 N--CA 1.492 2.414 0 C-N-CA 119.868 -1.158 . . . . 0.0 110.328 174.84 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . 0.452 HD11 HD21 ' B' ' 28' ' ' LEU . 6.8 tt -69.66 148.89 48.71 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.95 -1.324 . . . . 0.0 110.43 -175.402 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.47 ' O ' ' HB3' ' B' ' 40' ' ' ALA . 21.4 pt-20 -150.68 169.95 20.36 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.347 -0.845 . . . . 0.0 109.51 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.543 ' CG2' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -69.99 151.12 45.94 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.038 -1.039 . . . . 0.0 110.252 -178.855 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . 0.409 ' O ' ' NZ ' ' B' ' 89' ' ' LYS . . . 79.17 -3.5 65.96 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 -174.209 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.47 ' HB3' ' O ' ' B' ' 37' ' ' GLU . . . -77.91 161.36 27.62 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.297 -1.119 . . . . 0.0 109.701 177.521 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.481 ' CB ' ' HB3' ' B' ' 87' ' ' ALA . 0.6 OUTLIER -101.43 114.82 29.17 Favored 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 119.096 -1.042 . . . . 0.0 110.18 177.35 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.537 ' CG1' ' CE1' ' B' ' 44' ' ' HIS . 1.8 t -103.12 129.01 55.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.379 -0.826 . . . . 0.0 109.141 174.068 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.463 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -94.87 120.05 34.45 Favored 'General case' 0 C--N 1.298 -1.651 0 C-N-CA 119.245 -0.982 . . . . 0.0 109.214 173.044 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.579 ' CD2' HG23 ' B' ' 82' ' ' VAL . 1.4 m80 -90.69 106.15 18.31 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.403 -0.811 . . . . 0.0 109.074 177.478 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.494 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.8 t-20 54.01 14.84 0.75 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.368 -0.833 . . . . 0.0 110.858 -167.157 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.493 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 117.66 -0.3 17.98 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.715 -1.231 . . . . 0.0 111.031 170.438 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.52 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 43.1 t -92.38 106.9 18.8 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.411 -1.641 . . . . 0.0 109.134 173.395 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 17.8 p -75.45 128.75 36.04 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.097 -1.002 . . . . 0.0 110.684 -170.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.57 ' CD1' ' CG ' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -143.29 159.64 41.97 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.416 -0.803 . . . . 0.0 109.61 175.259 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 29.4 m -100.02 150.01 22.88 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.673 -1.267 . . . . 0.0 111.329 -170.74 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.537 ' CG1' HG12 ' B' ' 59' ' ' VAL . 15.4 t -78.38 118.46 25.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.827 -0.546 . . . . 0.0 110.607 -178.027 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.531 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 43.0 p -73.89 -40.01 63.49 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.201 -0.937 . . . . 0.0 110.037 174.629 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.531 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.6 tt0 -163.32 149.83 12.19 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.336 -0.852 . . . . 0.0 110.206 -177.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.543 HD11 ' CG2' ' B' ' 38' ' ' THR . 5.7 mt -101.52 134.79 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.096 -1.002 . . . . 0.0 109.993 176.148 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.474 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 49.7 m-80 -110.41 65.78 0.62 Allowed 'General case' 0 C--N 1.298 -1.634 0 C-N-CA 119.857 -0.737 . . . . 0.0 109.907 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.31 -118.75 4.99 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 108.809 -1.717 . . . . 0.0 108.809 -175.26 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.546 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.55 -16.54 57.32 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.969 -1.312 . . . . 0.0 108.901 174.302 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.642 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 11.8 m170 -76.51 159.63 30.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.491 -0.756 . . . . 0.0 110.347 -178.2 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.537 HG12 ' CG1' ' B' ' 51' ' ' VAL . 52.1 t -140.15 127.1 23.14 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 C-N-CA 119.042 -1.063 . . . . 0.0 110.554 170.054 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.541 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 2.7 t -95.81 136.85 35.69 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.575 -0.703 . . . . 0.0 109.616 178.307 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.574 ' CE1' ' HB3' ' B' ' 24' ' ' HIS . 2.0 p90 -128.11 157.63 40.2 Favored 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 119.054 -1.058 . . . . 0.0 110.876 174.065 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.531 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 25.3 p-10 -89.47 157.76 17.98 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.297 -0.877 . . . . 0.0 111.056 -171.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.524 HD22 ' CD1' ' B' ' 68' ' ' LEU . 0.1 OUTLIER -159.96 102.54 1.47 Allowed 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.958 -0.697 . . . . 0.0 109.445 -175.428 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.487 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 56.1 ttm -59.77 140.36 56.58 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.117 -0.989 . . . . 0.0 109.381 -179.501 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.45 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 39.4 ttpt -59.98 -43.38 95.15 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.042 -1.036 . . . . 0.0 110.242 -175.094 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.72 -40.04 76.47 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.049 -1.032 . . . . 0.0 110.083 178.297 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.487 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 92.2 m -60.58 -39.97 90.02 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.95 -1.094 . . . . 0.0 109.14 173.016 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.524 ' CD1' HD22 ' B' ' 63' ' ' LEU . 7.3 tp -60.0 -45.17 93.61 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.375 -0.828 . . . . 0.0 109.892 179.3 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 15.0 tpp180 -69.33 -39.41 78.21 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.547 -0.72 . . . . 0.0 110.493 177.912 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.47 HG22 ' O ' ' B' ' 67' ' ' THR . 1.4 tt -63.85 -43.88 97.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.177 -0.952 . . . . 0.0 109.365 -177.427 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.478 HG22 ' O ' ' B' ' 67' ' ' THR . 37.3 p -83.44 -170.42 3.04 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 121.433 0.635 . . . . 0.0 109.805 178.529 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.487 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 4.3 t30 -103.33 22.58 13.91 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 170.176 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.5 ' CD1' HD23 ' B' ' 63' ' ' LEU . 89.3 mt -69.55 -41.16 76.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.228 -0.92 . . . . 0.0 110.091 176.689 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.503 ' HA2' ' CD1' ' B' ' 68' ' ' LEU . . . -51.01 -20.8 4.73 Favored Glycine 0 N--CA 1.487 2.099 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -178.23 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.1 p-10 -67.55 -18.41 65.01 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.998 -1.295 . . . . 0.0 110.706 -173.909 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.514 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 90.3 mt -60.92 142.82 56.07 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.077 -1.015 . . . . 0.0 110.947 -175.513 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.483 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 98.7 mttt -140.32 139.74 35.49 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.682 -0.636 . . . . 0.0 109.854 173.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.575 ' CG2' HG13 ' B' ' 15' ' ' ILE . 16.2 t -63.4 153.45 7.01 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.12 -0.987 . . . . 0.0 110.625 -174.399 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.02 -16.68 56.48 Favored Glycine 0 N--CA 1.484 1.874 0 N-CA-C 108.687 -1.765 . . . . 0.0 108.687 -175.285 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 24.9 t0 -95.13 169.95 9.74 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.374 -1.074 . . . . 0.0 109.808 175.615 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.589 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.5 m95 -116.98 169.42 9.42 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.034 -1.041 . . . . 0.0 110.139 176.022 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.579 HG23 ' CD2' ' B' ' 44' ' ' HIS . 1.4 p -133.96 155.7 40.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.539 -0.726 . . . . 0.0 109.908 -176.824 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.485 ' N ' HG21 ' B' ' 82' ' ' VAL . 2.0 m-20 -79.5 108.91 13.39 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.074 -1.016 . . . . 0.0 109.245 168.692 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.486 ' CG2' ' C ' ' B' ' 9' ' ' THR . 0.0 OUTLIER -110.45 138.87 36.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 120.458 -1.401 . . . . 0.0 111.183 -175.393 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -134.73 145.08 48.13 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.856 -0.527 . . . . 0.0 110.128 -177.364 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 36.2 ttm180 -83.43 130.67 35.04 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.26 -0.9 . . . . 0.0 110.987 -176.675 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.583 ' CB ' ' CZ ' ' A' ' 2' ' ' PHE . . . -127.68 148.29 50.39 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.279 -0.888 . . . . 0.0 109.965 174.666 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -123.88 141.7 51.79 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.305 -0.872 . . . . 0.0 110.779 -175.748 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . 0.409 ' NZ ' ' O ' ' B' ' 39' ' ' GLY . 16.0 mttp -59.96 -40.04 87.67 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.414 -0.804 . . . . 0.0 110.863 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -159.07 160.01 35.28 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.033 -1.042 . . . . 0.0 111.02 -177.039 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 91' ' ' SER . . . . . 0.491 ' O ' HG13 ' B' ' 94' ' ' ILE . 79.6 p -154.5 161.66 41.55 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.373 -0.829 . . . . 0.0 109.727 173.256 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -69.74 -33.34 72.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.955 -1.091 . . . . 0.0 110.491 -178.705 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . 0.571 ' O ' ' CG ' ' B' ' 93' ' ' GLU . 10.8 tt0 -114.74 57.7 0.71 Allowed 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 122.349 1.071 . . . . 0.0 109.465 -178.881 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . 0.512 ' O ' ' N ' ' B' ' 96' ' ' GLY . 66.1 mt -65.99 -40.0 86.13 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 120.539 -1.351 . . . . 0.0 110.341 -178.803 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . 0.439 ' C ' ' O ' ' B' ' 94' ' ' ILE . . . -39.91 93.86 0.01 OUTLIER Glycine 0 N--CA 1.494 2.538 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 -172.488 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' B' ' 94' ' ' ILE . . . -148.31 146.29 15.71 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 177.642 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . 0.417 ' C ' ' O ' ' B' ' 96' ' ' GLY . 32.8 m80 . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.25 -1.147 . . . . 0.0 110.351 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.552 " C2'" ' HC9' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.546 " C2'" ' HC9' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 43.3 tpp . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 121.345 0.593 . . . . 0.0 110.41 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.586 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 13.4 p90 -174.89 143.82 0.75 Allowed 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.237 -0.915 . . . . 0.0 109.262 175.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.522 ' CB ' HG12 ' A' ' 5' ' ' ILE . 5.6 p -139.96 -40.27 0.44 Allowed 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.019 -1.051 . . . . 0.0 108.509 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.494 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 44.1 26.6 0.91 Allowed Glycine 0 N--CA 1.486 2.029 0 N-CA-C 108.685 -1.766 . . . . 0.0 108.685 -174.841 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.522 HG12 ' CB ' ' A' ' 3' ' ' THR . 40.3 mm -79.1 124.33 37.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.445 -1.032 . . . . 0.0 109.52 -178.074 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.527 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 4.0 t -85.58 145.25 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.033 -1.042 . . . . 0.0 111.3 -168.544 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -69.99 -34.08 72.88 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.695 -0.628 . . . . 0.0 110.632 175.369 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -163.34 171.43 39.05 Favored Glycine 0 N--CA 1.494 2.555 0 C-N-CA 118.729 -1.7 . . . . 0.0 110.394 -174.518 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.497 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 11.7 p -112.81 168.35 9.75 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.031 -1.276 . . . . 0.0 110.699 -178.729 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.519 ' CB ' HG11 ' A' ' 82' ' ' VAL . . . -133.46 148.87 51.76 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -178.022 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.578 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 22.5 tttt -104.25 112.64 25.74 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 120.972 -1.08 . . . . 0.0 110.15 178.109 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.544 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 10.9 tp -57.14 126.88 29.2 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 121.146 -0.971 . . . . 0.0 108.803 173.598 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.64 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.21 -31.35 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 O-C-N 121.349 -0.844 . . . . 0.0 110.046 -178.237 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -142.86 144.18 32.39 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.147 -1.021 . . . . 0.0 111.582 -179.454 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.585 HG13 ' CG2' ' A' ' 78' ' ' VAL . 8.1 mt -110.94 130.37 64.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 120.995 -1.065 . . . . 0.0 110.21 168.749 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.487 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 76.0 m-20 -108.86 115.49 30.19 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.364 -0.835 . . . . 0.0 109.889 172.331 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -103.91 110.28 22.35 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 120.888 -1.132 . . . . 0.0 110.495 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.467 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.9 OUTLIER -102.61 131.87 21.91 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.177 -0.952 . . . . 0.0 108.88 173.76 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -50.52 -34.21 41.43 Favored 'Trans proline' 0 C--N 1.302 -1.91 0 O-C-N 123.828 1.436 . . . . 0.0 110.383 -179.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.55 ' HB3' ' CE2' ' A' ' 21' ' ' PHE . 10.4 m-80 -74.19 -39.33 63.25 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.244 -0.91 . . . . 0.0 110.32 175.899 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.55 ' CE2' ' HB3' ' A' ' 20' ' ' ASN . 49.9 m-85 -152.53 150.14 29.26 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.271 -0.893 . . . . 0.0 110.106 -176.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.425 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 50.7 ttt180 -88.73 144.96 25.91 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.914 -1.116 . . . . 0.0 109.999 175.065 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.487 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.8 m -130.07 140.06 50.89 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.437 -0.79 . . . . 0.0 110.099 -177.876 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.591 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -129.59 144.61 51.35 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.967 -1.083 . . . . 0.0 111.107 177.333 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.48 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 6.9 t -124.06 133.37 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.034 -1.041 . . . . 0.0 110.508 179.229 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.568 HG11 ' CE1' ' A' ' 61' ' ' PHE . 13.1 m -112.88 172.31 3.26 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 121.737 -0.602 . . . . 0.0 109.954 177.403 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.573 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 8.1 tt0 -106.95 116.3 31.69 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.357 -0.839 . . . . 0.0 108.794 178.128 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.53 ' N ' ' ND2' ' A' ' 57' ' ' ASN . 9.2 tp -80.09 123.98 83.13 Favored Pre-proline 0 C--N 1.296 -1.753 0 O-C-N 121.548 -0.72 . . . . 0.0 109.977 -172.569 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.471 ' HG3' ' O ' ' A' ' 9' ' ' THR . 27.7 Cg_endo -66.35 -178.54 1.18 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 O-C-N 123.822 1.433 . . . . 0.0 110.977 -179.521 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.47 ' HA ' HD12 ' A' ' 33' ' ' LEU . 61.6 t0 -62.55 -40.97 98.52 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 111.027 -174.667 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.578 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.03 1.14 56.66 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.811 -1.181 . . . . 0.0 111.014 -174.664 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.578 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.4 mmm -108.56 -15.37 14.45 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.784 -1.198 . . . . 0.0 109.844 169.829 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.532 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 21.0 mt -69.51 -22.04 63.62 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.217 -0.927 . . . . 0.0 109.997 177.699 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -95.16 115.6 27.65 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.364 -0.835 . . . . 0.0 110.473 -178.59 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.34 -50.52 0.78 Allowed Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.764 -1.207 . . . . 0.0 110.556 173.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.459 HD21 HG21 ' A' ' 59' ' ' VAL . 9.8 tt -60.98 159.33 11.67 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.886 -1.361 . . . . 0.0 111.123 -172.319 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.466 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 22.0 pt-20 -157.52 163.46 38.39 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.53 ' N ' HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -69.9 151.57 45.51 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.845 -1.159 . . . . 0.0 109.921 -177.474 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.09 -4.66 65.68 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 -172.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.466 ' HB3' ' O ' ' A' ' 37' ' ' GLU . . . -74.33 160.12 31.48 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.293 -1.122 . . . . 0.0 109.683 176.828 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.486 ' O ' ' CB ' ' A' ' 87' ' ' ALA . 0.7 OUTLIER -100.98 103.25 14.39 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.068 -1.02 . . . . 0.0 110.12 178.298 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.5 HG13 ' CE1' ' A' ' 44' ' ' HIS . 2.2 t -88.12 131.46 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.201 -0.937 . . . . 0.0 109.489 175.489 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.484 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -98.17 120.97 39.51 Favored 'General case' 0 C--N 1.296 -1.755 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.418 170.862 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.5 ' CE1' HG13 ' A' ' 42' ' ' VAL . 1.0 OUTLIER -88.74 105.83 17.96 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 119.583 -0.847 . . . . 0.0 108.987 177.525 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.1 t-20 52.96 11.92 0.24 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.463 -0.773 . . . . 0.0 111.525 -166.482 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.474 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 127.73 -6.8 6.97 Favored Glycine 0 N--CA 1.489 2.233 0 C-N-CA 119.224 -1.465 . . . . 0.0 111.169 172.241 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.535 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 13.8 t -92.49 105.99 18.06 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.192 -1.77 . . . . 0.0 109.471 177.027 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.516 ' SG ' ' C8 ' ' A' ' 98' ' ' RBF . 16.2 p -75.24 129.52 37.6 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.14 -0.975 . . . . 0.0 111.122 -171.138 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.558 ' CD1' ' CD2' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -141.97 159.98 41.13 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.595 -0.691 . . . . 0.0 109.276 174.91 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.437 HG22 ' N ' ' A' ' 51' ' ' VAL . 51.7 m -94.79 148.24 22.5 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.613 -1.305 . . . . 0.0 111.279 -170.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.496 HG13 HG13 ' A' ' 59' ' ' VAL . 19.3 t -77.27 122.03 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.651 -0.656 . . . . 0.0 110.265 178.849 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.527 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 19.3 p -77.54 -44.49 28.41 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.257 -0.902 . . . . 0.0 110.138 175.204 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.502 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.1 tt0 -157.47 150.13 23.04 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.113 -0.992 . . . . 0.0 110.348 178.023 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.53 HD12 ' N ' ' A' ' 38' ' ' THR . 1.4 mp -97.79 137.0 26.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.07 -1.019 . . . . 0.0 109.728 173.237 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.453 ' O ' ' HB2' ' A' ' 58' ' ' HIS . 33.4 m-80 -110.03 70.43 0.72 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.595 -0.691 . . . . 0.0 109.698 178.147 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 72.04 -120.12 7.75 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 -172.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.532 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -75.51 -21.17 58.21 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 120.995 -1.297 . . . . 0.0 109.04 175.543 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.64 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 10.7 m170 -72.41 160.48 32.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.28 -0.887 . . . . 0.0 110.234 -178.395 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.496 HG13 HG13 ' A' ' 51' ' ' VAL . 53.1 t -140.07 124.54 19.18 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 C-N-CA 119.127 -1.029 . . . . 0.0 110.536 170.679 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 53.1 p -95.08 128.56 42.01 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.476 -0.765 . . . . 0.0 109.553 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.591 ' CZ ' ' HB3' ' A' ' 24' ' ' HIS . 1.8 p90 -124.01 157.35 34.65 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 120.995 -1.066 . . . . 0.0 110.254 -179.118 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.527 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 30.4 p-10 -93.27 152.79 18.96 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 122.09 0.947 . . . . 0.0 111.127 -172.794 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.48 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -152.21 120.03 6.15 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -175.894 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.496 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 63.5 tpp -77.16 139.58 39.96 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.983 -1.073 . . . . 0.0 109.848 -179.64 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.466 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 74.9 tttt -59.93 -49.85 76.07 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.12 -0.987 . . . . 0.0 110.578 -173.49 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 88.3 tt0 -66.27 -39.96 89.79 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.828 -1.17 . . . . 0.0 109.996 178.223 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.496 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 90.9 m -60.0 -39.57 86.21 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.002 -1.061 . . . . 0.0 109.197 173.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.505 ' HG ' ' CA ' ' A' ' 74' ' ' GLY . 2.1 tp -59.97 -45.28 93.18 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.319 -0.863 . . . . 0.0 109.852 179.339 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 tpt85 -69.39 -38.32 77.93 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.386 -0.821 . . . . 0.0 110.079 177.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.509 HG21 ' N ' ' A' ' 71' ' ' THR . 1.3 tt -67.75 -39.9 82.84 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 O-C-N 121.333 -0.855 . . . . 0.0 109.191 -177.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.509 ' N ' HG21 ' A' ' 70' ' ' ILE . 49.4 p -88.77 -176.41 5.22 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 175.572 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.467 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 8.8 t30 -98.22 21.18 11.26 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.244 -0.91 . . . . 0.0 108.903 173.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.48 ' HB3' HD21 ' A' ' 63' ' ' LEU . 34.4 mt -70.04 -39.99 75.42 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.912 -1.118 . . . . 0.0 110.444 179.609 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.505 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -52.54 -19.33 6.19 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -176.34 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 27.1 p-10 -69.98 -18.21 63.33 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.111 -1.229 . . . . 0.0 110.965 -174.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 85.5 mt -59.99 146.49 42.41 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.088 -1.008 . . . . 0.0 111.026 -174.54 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.465 ' O ' HD22 ' A' ' 12' ' ' LEU . 67.4 mttt -139.88 141.75 36.57 Favored 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 121.537 0.684 . . . . 0.0 109.906 176.68 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.585 ' CG2' HG13 ' A' ' 15' ' ' ILE . 46.2 t -66.44 150.06 11.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 120.888 -1.133 . . . . 0.0 110.466 -177.329 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.96 -14.99 60.46 Favored Glycine 0 N--CA 1.482 1.743 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 -174.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.478 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 13.9 t0 -96.65 168.27 10.62 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.409 -1.053 . . . . 0.0 109.576 174.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.578 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.4 m95 -115.83 156.09 26.71 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.04 -1.037 . . . . 0.0 110.304 177.72 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.519 HG11 ' CB ' ' A' ' 10' ' ' ALA . 1.1 p -120.07 150.0 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.262 -0.899 . . . . 0.0 110.1 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.497 ' N ' ' HB2' ' B' ' 72' ' ' ASN . 0.4 OUTLIER -70.79 104.53 2.92 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.044 -1.035 . . . . 0.0 108.887 166.785 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.508 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -104.35 139.42 25.37 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 120.51 -1.369 . . . . 0.0 110.987 -176.839 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.467 ' OE2' HG22 ' A' ' 6' ' ' VAL . 85.2 mt-10 -125.47 146.62 49.56 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.918 -0.488 . . . . 0.0 110.15 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . 0.52 ' HB3' ' CZ ' ' A' ' 86' ' ' ARG . 18.3 mtp-105 -90.26 114.77 26.87 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.513 -0.742 . . . . 0.0 110.033 177.494 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.486 ' CB ' ' O ' ' A' ' 41' ' ' SER . . . -114.42 147.43 39.25 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.061 -1.024 . . . . 0.0 110.524 -178.254 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -131.45 148.54 52.65 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.609 -0.682 . . . . 0.0 110.862 -176.284 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -59.98 -39.95 87.48 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.435 -0.79 . . . . 0.0 110.185 176.531 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 52.8 p90 -132.36 160.09 37.32 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.279 -0.888 . . . . 0.0 110.253 179.716 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' SER . . . . . 0.408 ' OG ' ' CG1' ' A' ' 94' ' ' ILE . 2.6 p -119.07 135.29 54.71 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.228 -0.92 . . . . 0.0 110.366 -177.746 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 71.7 m-20 -69.83 -40.1 76.05 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.365 -0.834 . . . . 0.0 111.008 -176.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -147.29 71.09 1.2 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.932 -1.105 . . . . 0.0 110.573 -174.448 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.426 ' O ' ' C ' ' A' ' 95' ' ' GLY . 25.5 mm -60.07 -41.06 85.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.191 -0.943 . . . . 0.0 109.725 175.768 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 94' ' ' ILE . . . 40.18 69.99 0.41 Allowed Glycine 0 N--CA 1.494 2.52 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 174.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -109.65 115.08 4.1 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 178.526 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 46.7 p-80 . . . . . 0 N--CA 1.493 1.706 0 O-C-N 121.3 -1.117 . . . . 0.0 110.128 178.873 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 38.3 mtm . . . . . 0 N--CA 1.495 1.797 0 CA-C-O 121.258 0.551 . . . . 0.0 110.177 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.583 ' CD1' ' O ' ' B' ' 2' ' ' PHE . 13.4 p90 -171.72 143.83 1.74 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.11 -0.994 . . . . 0.0 109.248 174.715 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.53 ' CB ' HG12 ' B' ' 5' ' ' ILE . 5.6 p -139.99 -40.28 0.44 Allowed 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.067 -1.021 . . . . 0.0 108.452 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.474 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 44.32 26.33 0.94 Allowed Glycine 0 N--CA 1.486 2.004 0 N-CA-C 108.642 -1.783 . . . . 0.0 108.642 -174.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.53 HG12 ' CB ' ' B' ' 3' ' ' THR . 40.0 mm -79.1 124.37 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.342 -1.093 . . . . 0.0 109.533 -177.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.54 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 4.0 t -85.59 145.25 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.059 -1.025 . . . . 0.0 111.367 -168.56 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -70.05 -33.75 72.36 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.745 -0.597 . . . . 0.0 110.685 175.449 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.54 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -163.66 171.35 39.29 Favored Glycine 0 N--CA 1.495 2.628 0 C-N-CA 118.91 -1.614 . . . . 0.0 110.52 -174.52 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.498 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 11.7 p -112.9 168.29 9.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.06 -1.259 . . . . 0.0 110.739 -178.632 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.526 ' HB3' ' CG1' ' B' ' 84' ' ' VAL . . . -133.38 149.01 51.85 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 -178.017 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.573 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 22.7 tttt -104.36 112.79 25.97 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 120.982 -1.074 . . . . 0.0 110.047 178.115 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.53 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 11.0 tp -57.35 126.84 29.06 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.193 -0.942 . . . . 0.0 108.761 173.592 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.639 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.18 -31.24 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.784 0 O-C-N 121.339 -0.851 . . . . 0.0 110.089 -178.211 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -142.99 144.17 32.21 Favored 'General case' 0 N--CA 1.493 1.716 0 C-N-CA 119.234 -0.986 . . . . 0.0 111.553 -179.478 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.581 HG13 ' CG2' ' B' ' 78' ' ' VAL . 8.0 mt -110.85 130.47 64.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 120.992 -1.068 . . . . 0.0 110.193 168.836 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.494 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 75.5 m-20 -109.12 115.59 30.33 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.353 -0.842 . . . . 0.0 109.767 172.389 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -103.92 110.31 22.39 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.019 -1.05 . . . . 0.0 110.443 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.459 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.9 OUTLIER -102.7 131.92 21.82 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.347 -0.846 . . . . 0.0 108.874 173.763 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -50.62 -34.19 42.29 Favored 'Trans proline' 0 C--N 1.301 -1.95 0 O-C-N 123.825 1.434 . . . . 0.0 110.295 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.561 ' HB3' ' CE2' ' B' ' 21' ' ' PHE . 10.5 m-80 -73.98 -39.96 63.31 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.224 -0.922 . . . . 0.0 110.165 175.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.561 ' CE2' ' HB3' ' B' ' 20' ' ' ASN . 49.4 m-85 -152.06 150.18 29.66 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.381 -0.824 . . . . 0.0 110.183 -176.757 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.413 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 50.5 ttt180 -88.65 144.91 25.98 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.916 -1.115 . . . . 0.0 109.924 175.033 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.494 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 95.0 m -130.09 140.08 50.87 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.511 -0.743 . . . . 0.0 110.147 -178.003 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.588 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -129.57 144.58 51.33 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.095 -1.003 . . . . 0.0 110.994 177.476 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.519 HG22 ' CB ' ' B' ' 60' ' ' SER . 6.8 t -123.99 133.48 69.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.142 -0.974 . . . . 0.0 110.573 179.113 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.574 HG11 ' CE1' ' B' ' 61' ' ' PHE . 13.3 m -112.96 172.3 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.698 -0.626 . . . . 0.0 109.876 177.485 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.579 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 8.1 tt0 -106.86 116.24 31.58 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.444 -0.785 . . . . 0.0 108.923 177.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.541 ' N ' ' ND2' ' B' ' 57' ' ' ASN . 9.3 tp -80.01 123.98 83.26 Favored Pre-proline 0 C--N 1.296 -1.747 0 O-C-N 121.434 -0.791 . . . . 0.0 110.028 -172.587 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.466 ' HD2' ' HB2' ' B' ' 32' ' ' MET . 27.7 Cg_endo -66.3 -178.42 1.13 Allowed 'Trans proline' 0 C--N 1.31 -1.489 0 O-C-N 123.831 1.437 . . . . 0.0 110.96 -179.523 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 61.7 t0 -62.67 -40.91 98.55 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.386 -0.821 . . . . 0.0 111.027 -174.698 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.576 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.01 1.11 56.68 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.867 -1.145 . . . . 0.0 111.01 -174.631 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.576 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.4 mmm -108.61 -15.25 14.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.752 -1.218 . . . . 0.0 109.813 169.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.53 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 20.8 mt -69.69 -21.93 63.47 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.269 -0.894 . . . . 0.0 109.982 177.722 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -95.22 115.68 27.75 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.348 -0.845 . . . . 0.0 110.408 -178.606 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.18 -50.43 0.78 Allowed Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.823 -1.179 . . . . 0.0 110.543 173.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . 0.456 HD21 HG23 ' B' ' 59' ' ' VAL . 9.8 tt -61.01 159.29 11.81 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.843 -1.386 . . . . 0.0 111.132 -172.362 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.475 ' O ' ' HB1' ' B' ' 40' ' ' ALA . 21.9 pt-20 -157.51 163.36 38.51 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.544 HG22 ' CD1' ' B' ' 54' ' ' ILE . 0.0 OUTLIER -69.85 151.59 45.53 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.862 -1.149 . . . . 0.0 109.965 -177.531 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.98 -4.47 66.05 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -172.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.475 ' HB1' ' O ' ' B' ' 37' ' ' GLU . . . -74.37 160.02 31.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.199 -1.177 . . . . 0.0 109.653 176.68 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.485 ' O ' ' CB ' ' B' ' 87' ' ' ALA . 0.6 OUTLIER -100.82 103.12 14.32 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.969 -1.082 . . . . 0.0 110.139 178.291 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.512 HG11 ' CE1' ' B' ' 44' ' ' HIS . 2.2 t -88.1 131.59 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.284 -0.885 . . . . 0.0 109.486 175.432 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.477 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -98.25 121.0 39.64 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 120.961 -1.087 . . . . 0.0 109.441 170.716 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.544 ' CG ' HG21 ' B' ' 82' ' ' VAL . 1.0 OUTLIER -88.78 105.58 17.8 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.245 -0.91 . . . . 0.0 109.1 177.494 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.1 t-20 53.23 11.94 0.28 Allowed 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.462 -0.774 . . . . 0.0 111.409 -166.565 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.494 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 127.55 -6.36 7.07 Favored Glycine 0 N--CA 1.49 2.251 0 C-N-CA 119.231 -1.461 . . . . 0.0 111.082 172.03 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.524 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 13.9 t -92.66 106.04 18.09 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.059 -1.847 . . . . 0.0 109.439 176.825 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . 0.519 ' SG ' ' C8 ' ' B' ' 99' ' ' RBF . 16.1 p -75.21 129.57 37.7 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.086 -1.009 . . . . 0.0 111.145 -171.19 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.551 ' CD1' ' CD2' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -142.01 159.93 41.23 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 174.925 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 52.1 m -94.69 148.21 22.52 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.514 -1.366 . . . . 0.0 111.244 -170.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.486 HG12 HG13 ' B' ' 59' ' ' VAL . 18.6 t -77.23 122.06 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.647 -0.658 . . . . 0.0 110.281 178.796 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.525 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 19.7 p -77.66 -44.55 27.73 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.213 -0.93 . . . . 0.0 110.029 175.33 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.504 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.3 tt0 -157.43 150.18 23.17 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.101 -0.999 . . . . 0.0 110.348 178.031 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.544 ' CD1' HG22 ' B' ' 38' ' ' THR . 1.4 mp -97.82 136.94 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.175 -0.953 . . . . 0.0 109.729 173.282 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.469 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 33.5 m-80 -109.95 70.29 0.72 Allowed 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.545 -0.722 . . . . 0.0 109.676 178.219 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 72.09 -120.11 7.71 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 108.713 -1.755 . . . . 0.0 108.713 -172.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.541 ' ND2' ' N ' ' B' ' 28' ' ' LEU . 0.0 OUTLIER -75.41 -21.28 58.35 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.054 -1.262 . . . . 0.0 109.12 175.468 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.639 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 10.8 m170 -72.43 160.27 32.61 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.407 -0.808 . . . . 0.0 110.362 -178.404 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.486 HG13 HG12 ' B' ' 51' ' ' VAL . 53.6 t -139.89 124.62 19.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 119.061 -1.056 . . . . 0.0 110.415 170.853 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.519 ' CB ' HG22 ' B' ' 25' ' ' VAL . 53.4 p -95.08 128.82 42.21 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.619 -0.675 . . . . 0.0 109.509 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.588 ' CZ ' ' HB3' ' B' ' 24' ' ' HIS . 1.8 p90 -124.26 157.29 35.21 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.002 -1.061 . . . . 0.0 110.218 -179.148 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.525 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 30.5 p-10 -93.2 152.74 19.03 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.136 -0.978 . . . . 0.0 111.192 -172.753 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.462 HD21 HD13 ' B' ' 68' ' ' LEU . 0.0 OUTLIER -152.06 119.97 6.19 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 -175.883 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.503 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 63.6 tpp -77.19 139.57 39.93 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.976 -1.078 . . . . 0.0 109.845 -179.61 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.475 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 74.9 tttt -60.03 -49.73 76.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.166 -0.959 . . . . 0.0 110.492 -173.362 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . 0.4 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 88.4 tt0 -66.35 -40.0 89.53 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.794 -1.191 . . . . 0.0 109.946 178.326 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.503 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 90.3 m -60.05 -39.55 86.32 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.031 -1.043 . . . . 0.0 109.145 174.008 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.506 ' HG ' ' CA ' ' B' ' 74' ' ' GLY . 2.1 tp -60.01 -45.14 93.73 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.388 -0.82 . . . . 0.0 109.962 179.278 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 tpt85 -69.35 -38.52 78.14 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.409 -0.807 . . . . 0.0 110.079 177.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.487 HG21 HG21 ' B' ' 71' ' ' THR . 1.3 tt -67.55 -39.95 83.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 CA-C-O 121.73 0.776 . . . . 0.0 109.238 -178.032 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.487 HG21 HG21 ' B' ' 70' ' ' ILE . 49.6 p -88.74 -176.24 5.18 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 175.674 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.497 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 8.7 t30 -98.3 21.19 11.33 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 121.182 -0.948 . . . . 0.0 108.733 173.881 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.461 ' HB3' HD23 ' B' ' 63' ' ' LEU . 34.1 mt -70.01 -40.03 75.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.954 -1.091 . . . . 0.0 110.458 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.506 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -52.49 -19.31 6.09 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -176.324 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.504 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 27.2 p-10 -70.05 -18.25 63.28 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.083 -1.245 . . . . 0.0 110.946 -174.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.504 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 85.7 mt -59.95 146.43 42.45 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.188 -0.945 . . . . 0.0 111.012 -174.547 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.47 ' O ' HD22 ' B' ' 12' ' ' LEU . 67.4 mttt -139.89 141.78 36.54 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.626 -0.671 . . . . 0.0 109.888 176.658 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.581 ' CG2' HG13 ' B' ' 15' ' ' ILE . 46.2 t -66.49 150.01 11.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.04 -1.038 . . . . 0.0 110.498 -177.274 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.01 -14.94 60.65 Favored Glycine 0 N--CA 1.483 1.824 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -174.712 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 13.8 t0 -96.73 168.13 10.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.359 -1.083 . . . . 0.0 109.582 174.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.573 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.4 m95 -115.76 156.0 26.8 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.06 -1.025 . . . . 0.0 110.325 177.788 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.544 HG21 ' CG ' ' B' ' 44' ' ' HIS . 1.1 p -120.01 150.06 22.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.427 -0.795 . . . . 0.0 110.173 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.479 ' HB3' ' CG2' ' B' ' 6' ' ' VAL . 0.4 OUTLIER -70.68 104.32 2.81 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.001 -1.062 . . . . 0.0 109.053 166.705 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.526 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -104.22 139.59 24.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 120.464 -1.398 . . . . 0.0 110.905 -176.61 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . 0.462 ' OE2' HG22 ' B' ' 6' ' ' VAL . 85.0 mt-10 -125.73 146.57 49.7 Favored 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.193 0.521 . . . . 0.0 110.064 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . 0.526 ' HB3' ' CZ ' ' B' ' 86' ' ' ARG . 18.3 mtp-105 -90.26 114.84 26.95 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.35 -0.844 . . . . 0.0 109.957 177.566 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.535 ' HB3' ' CD2' ' A' ' 2' ' ' PHE . . . -114.48 147.58 39.12 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.256 -0.903 . . . . 0.0 110.57 -178.292 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -131.57 148.65 52.63 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.584 -0.697 . . . . 0.0 110.683 -176.174 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -60.06 -40.01 88.02 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.435 -0.79 . . . . 0.0 110.142 176.49 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -132.41 160.14 37.24 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.329 -0.857 . . . . 0.0 110.171 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 91' ' ' SER . . . . . 0.529 ' OG ' ' CG1' ' B' ' 94' ' ' ILE . 2.6 p -119.04 135.36 54.67 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.258 -0.901 . . . . 0.0 110.382 -177.673 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -69.93 -40.01 75.77 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.41 -0.807 . . . . 0.0 111.025 -176.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 77.1 mm-40 -143.34 68.82 1.29 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.005 -1.059 . . . . 0.0 110.537 -174.251 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . 0.529 ' CG1' ' OG ' ' B' ' 91' ' ' SER . 21.1 mm -59.97 -40.0 81.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.266 -0.896 . . . . 0.0 109.644 175.629 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 47.32 60.96 4.85 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.064 -1.215 . . . . 0.0 110.064 177.261 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -59.94 -40.05 96.38 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.064 -1.614 . . . . 0.0 109.064 176.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 17.6 t60 . . . . . 0 N--CA 1.491 1.613 0 O-C-N 121.331 -1.1 . . . . 0.0 110.122 177.581 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.516 ' C8 ' ' SG ' ' A' ' 48' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.519 ' C8 ' ' SG ' ' B' ' 48' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 17.9 mmm . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.292 0.568 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.6 ' CZ ' ' CB ' ' B' ' 87' ' ' ALA . 8.1 p90 -166.25 155.93 11.84 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.166 -0.959 . . . . 0.0 108.614 172.291 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.522 ' CG2' ' O ' ' A' ' 2' ' ' PHE . 40.3 p -155.77 -39.31 0.08 Allowed 'General case' 0 C--N 1.295 -1.802 0 O-C-N 120.902 -1.124 . . . . 0.0 109.131 177.044 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 45.25 25.25 1.11 Allowed Glycine 0 N--CA 1.484 1.845 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 -173.574 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.468 HG13 ' O ' ' A' ' 3' ' ' THR . 91.4 mt -77.92 135.57 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.323 -1.104 . . . . 0.0 109.777 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.537 HG11 ' CA ' ' A' ' 83' ' ' ASN . 1.6 t -91.42 137.77 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.097 -1.002 . . . . 0.0 110.871 -170.439 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -71.04 -33.09 69.98 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.866 -0.521 . . . . 0.0 111.182 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.533 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -150.35 171.92 30.2 Favored Glycine 0 N--CA 1.495 2.582 0 C-N-CA 119.054 -1.546 . . . . 0.0 110.133 -171.9 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.495 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 3.1 p -119.23 172.34 7.66 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.893 -1.357 . . . . 0.0 111.214 -176.453 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.528 ' CB ' HG11 ' A' ' 82' ' ' VAL . . . -142.64 150.0 39.66 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 -176.362 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.589 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.1 tttt -110.83 115.15 29.03 Favored 'General case' 0 C--N 1.295 -1.803 0 O-C-N 121.097 -1.002 . . . . 0.0 110.276 179.54 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.542 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 10.9 tp -59.74 127.71 33.32 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.015 -1.053 . . . . 0.0 109.079 174.362 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.64 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -122.2 -28.9 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 C-N-CA 119.641 -0.824 . . . . 0.0 109.648 179.2 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.71 147.54 26.83 Favored 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 119.05 -1.06 . . . . 0.0 111.551 -179.155 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.576 HG12 ' CD2' ' A' ' 24' ' ' HIS . 11.7 mt -109.59 138.61 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.212 -0.93 . . . . 0.0 110.03 172.415 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.478 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.7 m-20 -109.58 114.62 28.4 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.283 -0.885 . . . . 0.0 109.924 173.52 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -100.35 112.15 24.47 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.13 -0.981 . . . . 0.0 110.369 -176.484 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.469 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.2 OUTLIER -112.76 132.76 22.12 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.203 -0.935 . . . . 0.0 108.94 175.492 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -49.57 -40.39 45.88 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 O-C-N 123.855 1.45 . . . . 0.0 110.754 -179.204 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.445 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 12.0 m-80 -70.59 -39.37 73.89 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.124 -0.985 . . . . 0.0 110.259 177.962 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.469 ' O ' ' HB2' ' A' ' 18' ' ' LYS . 95.7 m-85 -152.55 150.3 29.42 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.289 -0.882 . . . . 0.0 110.526 -174.978 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.475 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 60.7 ttt180 -91.28 143.54 26.54 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 120.835 -1.166 . . . . 0.0 109.909 175.006 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.478 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 97.1 m -129.57 140.77 51.12 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.597 -0.69 . . . . 0.0 109.738 -174.663 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.577 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -132.65 137.27 46.92 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 120.948 -1.095 . . . . 0.0 111.142 -177.95 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.517 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 4.8 t -120.16 131.72 71.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.115 -0.991 . . . . 0.0 110.677 -178.379 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.581 HG13 ' CE1' ' A' ' 61' ' ' PHE . 18.9 m -111.9 175.74 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 CA-C-O 121.212 0.529 . . . . 0.0 110.265 178.007 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.573 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 7.9 tt0 -107.02 117.05 33.03 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.387 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.513 ' CD2' ' O ' ' A' ' 32' ' ' MET . 10.7 tp -80.45 126.74 77.97 Favored Pre-proline 0 C--N 1.296 -1.724 0 O-C-N 121.428 -0.795 . . . . 0.0 109.827 -173.53 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.462 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 18.7 Cg_endo -63.78 173.67 4.47 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.886 1.466 . . . . 0.0 110.654 -179.362 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -59.99 -38.06 81.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.372 -0.83 . . . . 0.0 110.676 -176.159 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.57 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.18 0.06 57.37 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.959 -1.088 . . . . 0.0 110.947 -175.734 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.57 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 94.5 mmm -110.43 -12.01 14.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.854 -1.154 . . . . 0.0 109.948 170.176 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.531 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 15.8 mt -63.04 -31.38 72.5 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.299 -0.875 . . . . 0.0 110.15 176.817 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -93.23 139.99 30.02 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.339 -0.851 . . . . 0.0 110.536 -176.335 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.08 -41.42 2.34 Favored Glycine 0 N--CA 1.491 2.335 0 C-N-CA 119.892 -1.147 . . . . 0.0 110.387 174.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.468 HD23 HG21 ' A' ' 59' ' ' VAL . 9.1 tt -76.1 149.28 37.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.926 -1.338 . . . . 0.0 111.054 -174.394 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.467 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 15.8 pt-20 -151.59 169.25 22.56 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.464 -0.772 . . . . 0.0 109.58 177.289 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.531 ' N ' ' CD1' ' A' ' 54' ' ' ILE . 0.0 OUTLIER -61.32 151.64 31.47 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.936 -1.102 . . . . 0.0 109.876 179.107 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.73 -5.81 60.36 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -178.647 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.469 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -73.28 156.15 38.77 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.228 -1.16 . . . . 0.0 109.649 177.266 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.456 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -99.8 106.2 18.06 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.958 -1.089 . . . . 0.0 109.749 176.296 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.578 HG11 ' CE1' ' A' ' 44' ' ' HIS . 2.2 t -93.3 129.89 43.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 121.21 -0.931 . . . . 0.0 109.122 174.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.464 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -93.38 120.02 33.17 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.3 -0.96 . . . . 0.0 109.117 172.336 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.578 ' CE1' HG11 ' A' ' 42' ' ' VAL . 0.4 OUTLIER -91.22 104.79 17.3 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.698 -0.801 . . . . 0.0 108.886 177.98 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.496 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.6 t-20 55.34 14.09 1.03 Allowed 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.314 -0.866 . . . . 0.0 110.896 -168.704 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.469 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 120.33 -5.16 12.12 Favored Glycine 0 N--CA 1.49 2.255 0 C-N-CA 119.58 -1.295 . . . . 0.0 110.919 172.132 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.529 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 25.1 t -90.58 110.32 21.46 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.336 -1.685 . . . . 0.0 109.495 176.634 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.9 p -74.47 127.93 34.29 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.959 -1.088 . . . . 0.0 110.789 -171.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.603 ' CD1' ' CD2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -143.21 160.06 41.16 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.323 -0.861 . . . . 0.0 109.707 174.825 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.431 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 3.6 m -102.22 151.56 22.06 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.773 -1.205 . . . . 0.0 111.083 -172.526 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.518 HG13 HG23 ' A' ' 38' ' ' THR . 14.6 t -78.22 118.39 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.752 -0.593 . . . . 0.0 110.489 -177.341 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.523 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 43.9 p -72.32 -40.03 67.77 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.367 -0.833 . . . . 0.0 110.065 174.128 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.483 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -164.48 153.5 13.22 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.272 -0.893 . . . . 0.0 110.2 -176.956 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.531 ' CD1' ' N ' ' A' ' 38' ' ' THR . 6.8 mt -109.56 130.02 63.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.107 -0.996 . . . . 0.0 109.958 176.118 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.464 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 4.5 m-80 -102.56 63.28 0.86 Allowed 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.682 -0.636 . . . . 0.0 109.725 179.427 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.11 -114.06 4.06 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.781 -1.728 . . . . 0.0 108.781 -174.086 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.531 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.53 -22.31 47.5 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 120.953 -1.322 . . . . 0.0 108.82 175.001 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.64 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 11.8 m80 -74.46 159.44 32.27 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.331 -0.856 . . . . 0.0 110.229 -177.651 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.489 HG13 HG12 ' A' ' 51' ' ' VAL . 54.1 t -141.62 122.58 12.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 C-N-CA 119.163 -1.015 . . . . 0.0 110.81 172.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.517 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 1.4 t -88.26 134.9 33.68 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.454 -0.779 . . . . 0.0 109.705 175.366 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.609 ' N ' ' CD1' ' A' ' 61' ' ' PHE . 2.1 p90 -127.26 154.66 44.6 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.374 -0.829 . . . . 0.0 110.292 176.66 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.523 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 35.8 p-10 -88.95 152.29 21.8 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.149 -0.969 . . . . 0.0 111.329 -171.136 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.531 HD23 ' CD1' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -157.77 100.25 1.75 Allowed 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.598 -0.689 . . . . 0.0 109.369 -174.178 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.477 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 60.7 ttm -60.23 139.89 57.32 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.058 -1.026 . . . . 0.0 109.669 -177.307 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.48 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 5.1 ttpm? -59.94 -43.31 95.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.138 -0.977 . . . . 0.0 110.409 -175.36 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.33 -40.03 77.84 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.833 -1.167 . . . . 0.0 109.842 178.056 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.477 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 94.2 m -59.98 -37.64 80.24 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.05 -1.031 . . . . 0.0 109.474 172.231 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.53 ' CD1' ' HA2' ' A' ' 74' ' ' GLY . 14.2 tp -59.96 -45.81 91.45 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.273 -0.892 . . . . 0.0 109.428 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 55.2 ttt85 -69.96 -39.94 75.71 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.382 -0.824 . . . . 0.0 110.739 176.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.459 HG23 HG23 ' A' ' 71' ' ' THR . 1.5 tt -67.27 -42.82 88.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.233 -0.917 . . . . 0.0 109.445 -175.779 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.461 HG23 ' O ' ' A' ' 67' ' ' THR . 40.3 p -83.84 -173.87 4.96 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 174.678 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.499 ' HB3' ' HB2' ' B' ' 83' ' ' ASN . 3.1 t30 -102.71 23.63 11.77 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 169.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.531 ' CD1' HD23 ' A' ' 63' ' ' LEU . 86.9 mt -68.42 -40.07 81.36 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.089 -1.007 . . . . 0.0 110.015 176.768 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.53 ' HA2' ' CD1' ' A' ' 68' ' ' LEU . . . -47.88 -22.36 1.98 Allowed Glycine 0 N--CA 1.487 2.086 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.694 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.2 p-10 -62.83 -18.69 63.19 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.163 -1.198 . . . . 0.0 110.405 -176.303 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.513 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.8 mt -60.0 143.16 52.52 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.202 -0.936 . . . . 0.0 110.516 -177.752 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.459 ' O ' HD21 ' A' ' 12' ' ' LEU . 23.3 mttm -145.82 146.87 31.32 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.584 -0.698 . . . . 0.0 109.381 176.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.568 ' CG2' HG13 ' A' ' 15' ' ' ILE . 22.4 t -68.25 148.59 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.677 -1.265 . . . . 0.0 110.176 -175.625 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.14 -11.17 63.61 Favored Glycine 0 N--CA 1.483 1.813 0 N-CA-C 108.743 -1.743 . . . . 0.0 108.743 -174.167 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.487 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 45.5 t0 -95.68 162.63 13.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.344 -1.092 . . . . 0.0 109.694 176.785 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.589 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.0 m95 -114.76 149.35 37.07 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.124 -0.985 . . . . 0.0 110.005 176.778 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.55 HG22 ' CD2' ' A' ' 44' ' ' HIS . 1.2 p -115.21 153.79 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.498 -0.751 . . . . 0.0 109.971 -179.581 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.537 ' CA ' HG11 ' A' ' 6' ' ' VAL . 2.6 m-20 -78.19 106.11 9.87 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.143 -0.973 . . . . 0.0 109.125 168.607 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.521 HG11 ' CE1' ' A' ' 44' ' ' HIS . 0.0 OUTLIER -108.4 139.88 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 120.665 -1.272 . . . . 0.0 111.177 -176.643 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.42 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.4 tt0 -136.92 144.02 43.23 Favored 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 120.217 -0.593 . . . . 0.0 110.201 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 66.5 ttp85 -79.58 129.92 34.91 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.279 -0.888 . . . . 0.0 111.011 -176.552 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.571 ' HB2' ' CE2' ' B' ' 2' ' ' PHE . . . -125.76 145.92 49.99 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.351 -0.843 . . . . 0.0 110.134 175.815 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -136.37 142.9 43.79 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.668 -0.645 . . . . 0.0 110.457 -177.443 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 26.9 mttt -60.03 -39.9 87.48 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.252 -0.905 . . . . 0.0 109.948 179.774 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -137.83 156.41 47.96 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.364 -0.835 . . . . 0.0 110.04 177.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 48.2 m -133.65 147.18 51.42 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.27 -0.894 . . . . 0.0 110.005 176.243 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.467 ' O ' ' HB2' ' A' ' 93' ' ' GLU . 53.2 t0 -60.05 -37.9 81.2 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.194 -0.941 . . . . 0.0 109.697 177.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.467 ' HB2' ' O ' ' A' ' 92' ' ' ASP . 62.7 mm-40 55.93 50.01 14.76 Favored 'General case' 0 N--CA 1.507 2.402 0 O-C-N 121.574 -0.704 . . . . 0.0 110.512 178.363 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 56.9 mt -60.9 -44.48 97.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.27 -0.894 . . . . 0.0 109.498 172.514 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 79.96 -91.44 1.31 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 178.386 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -169.41 171.06 43.0 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.525 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 . . . . . 0 N--CA 1.491 1.596 0 O-C-N 121.208 -1.172 . . . . 0.0 110.204 -179.556 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 92.3 mmm . . . . . 0 N--CA 1.492 1.645 0 CA-C-O 121.286 0.565 . . . . 0.0 110.487 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.571 ' CE2' ' HB2' ' A' ' 87' ' ' ALA . 8.4 p90 -168.38 155.87 7.97 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 174.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.521 ' CG2' ' O ' ' B' ' 2' ' ' PHE . 40.3 p -155.65 -39.26 0.08 Allowed 'General case' 0 C--N 1.295 -1.795 0 O-C-N 120.85 -1.156 . . . . 0.0 109.174 177.078 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 45.5 24.95 1.2 Allowed Glycine 0 N--CA 1.484 1.86 0 N-CA-C 108.503 -1.839 . . . . 0.0 108.503 -173.69 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.478 HG13 ' HB ' ' B' ' 3' ' ' THR . 91.5 mt -77.91 135.51 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.388 -1.066 . . . . 0.0 109.75 -179.517 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.543 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 1.6 t -91.37 137.76 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.051 -1.031 . . . . 0.0 110.921 -170.45 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -71.11 -32.79 69.46 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.814 -0.554 . . . . 0.0 111.221 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.543 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -150.64 171.78 30.42 Favored Glycine 0 N--CA 1.495 2.63 0 C-N-CA 119.105 -1.522 . . . . 0.0 110.153 -171.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.499 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 3.1 p -119.23 172.26 7.72 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.937 -1.331 . . . . 0.0 111.238 -176.31 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.513 ' CB ' HG11 ' B' ' 82' ' ' VAL . . . -142.58 150.13 39.95 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 -176.417 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.588 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 30.1 tttt -110.9 115.25 29.19 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.102 -0.999 . . . . 0.0 110.224 179.585 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.54 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 10.9 tp -59.95 127.68 33.08 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.085 -1.009 . . . . 0.0 109.068 174.41 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.644 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -122.03 -29.16 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.662 179.295 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.67 147.6 26.92 Favored 'General case' 0 N--CA 1.493 1.678 0 C-N-CA 119.188 -1.005 . . . . 0.0 111.473 -179.137 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.572 HG12 ' CD2' ' B' ' 24' ' ' HIS . 11.8 mt -109.59 138.71 35.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.305 -0.872 . . . . 0.0 110.041 172.404 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.483 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 77.4 m-20 -109.72 114.61 28.34 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 121.31 -0.869 . . . . 0.0 109.863 173.638 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.31 112.18 24.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.16 -0.963 . . . . 0.0 110.311 -176.449 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.466 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.2 OUTLIER -112.83 132.74 22.16 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.173 -0.954 . . . . 0.0 109.005 175.393 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -49.67 -40.35 46.85 Favored 'Trans proline' 0 C--N 1.303 -1.852 0 O-C-N 123.91 1.479 . . . . 0.0 110.705 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.438 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 12.1 m-80 -70.35 -40.07 74.3 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.141 -0.974 . . . . 0.0 110.108 177.897 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.466 ' O ' ' HB2' ' B' ' 18' ' ' LYS . 96.0 m-85 -152.03 150.36 29.87 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.314 -0.867 . . . . 0.0 110.542 -174.848 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.464 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 60.6 ttt180 -91.31 143.42 26.66 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.893 -1.129 . . . . 0.0 109.965 174.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.483 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 97.2 m -129.41 140.69 51.25 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.659 -0.651 . . . . 0.0 109.718 -174.591 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.572 ' CD2' HG12 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -132.52 137.5 47.19 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.069 -1.019 . . . . 0.0 111.094 -178.088 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.536 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 4.8 t -120.13 131.95 71.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.119 -0.988 . . . . 0.0 110.662 -178.379 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.583 HG11 ' CE1' ' B' ' 61' ' ' PHE . 19.0 m -112.24 175.64 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 121.751 -0.593 . . . . 0.0 110.171 178.067 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.578 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 7.9 tt0 -106.76 117.09 33.12 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 178.31 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.517 ' CD2' ' O ' ' B' ' 32' ' ' MET . 10.8 tp -80.42 126.67 78.22 Favored Pre-proline 0 C--N 1.295 -1.763 0 O-C-N 121.235 -0.916 . . . . 0.0 109.83 -173.554 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.474 ' HD2' ' HB2' ' B' ' 32' ' ' MET . 18.6 Cg_endo -63.67 173.65 4.38 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 O-C-N 123.946 1.498 . . . . 0.0 110.699 -179.427 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -59.97 -38.05 81.39 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 110.739 -176.265 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.567 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.16 -0.05 57.42 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.922 -1.112 . . . . 0.0 110.902 -175.72 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.567 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 94.6 mmm -110.35 -11.98 14.47 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.867 -1.146 . . . . 0.0 109.913 170.182 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.531 ' CD2' ' HB2' ' B' ' 57' ' ' ASN . 15.8 mt -63.0 -31.43 72.57 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.341 -0.849 . . . . 0.0 110.133 176.818 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -93.22 139.99 30.02 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.347 -0.846 . . . . 0.0 110.538 -176.277 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.06 -41.32 2.35 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 174.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 9.0 tt -76.09 149.25 37.47 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.973 -1.31 . . . . 0.0 111.034 -174.399 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.465 ' HA ' HD11 ' B' ' 54' ' ' ILE . 15.8 pt-20 -151.52 169.3 22.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.52 -0.737 . . . . 0.0 109.645 177.194 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.539 ' CG2' HD13 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -61.34 151.66 31.52 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.026 -1.046 . . . . 0.0 109.969 179.059 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.79 -5.94 60.17 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 -178.599 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.461 ' HB1' ' O ' ' B' ' 37' ' ' GLU . . . -73.26 155.96 38.98 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.24 -1.153 . . . . 0.0 109.668 177.234 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.454 ' OG ' ' O ' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -99.52 106.05 18.02 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.86 -1.15 . . . . 0.0 109.87 176.252 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.587 HG11 ' CE1' ' B' ' 44' ' ' HIS . 2.2 t -93.3 130.01 42.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.311 -0.868 . . . . 0.0 109.071 174.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.458 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -93.31 120.02 33.11 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 119.274 -0.971 . . . . 0.0 109.225 172.241 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.587 ' CE1' HG11 ' B' ' 42' ' ' VAL . 0.4 OUTLIER -91.22 104.67 17.2 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.578 -0.849 . . . . 0.0 108.939 177.977 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.496 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.6 t-20 55.4 14.2 1.08 Allowed 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.378 -0.826 . . . . 0.0 110.864 -168.692 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.471 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 120.21 -4.92 12.34 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.622 -1.275 . . . . 0.0 110.916 171.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.528 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 25.0 t -90.68 110.31 21.49 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.365 -1.668 . . . . 0.0 109.478 176.547 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 19.1 p -74.32 128.02 34.48 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.074 -1.016 . . . . 0.0 110.803 -171.556 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.603 ' CD1' ' CD2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -143.36 159.98 41.38 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.41 -0.806 . . . . 0.0 109.709 174.78 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 50' ' ' THR . . . . . 0.434 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 3.6 m -102.07 151.66 21.89 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.803 -1.185 . . . . 0.0 111.019 -172.473 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.578 ' CG1' HG12 ' B' ' 59' ' ' VAL . 15.9 t -78.41 118.35 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.599 -0.688 . . . . 0.0 110.549 -177.39 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.527 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 43.9 p -72.26 -40.11 67.91 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.336 -0.853 . . . . 0.0 110.061 174.222 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.486 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -164.44 153.5 13.3 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.193 -0.942 . . . . 0.0 110.21 -176.956 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.539 HD13 ' CG2' ' B' ' 38' ' ' THR . 6.9 mt -109.48 129.97 63.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.149 -0.97 . . . . 0.0 110.016 176.118 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.476 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 4.5 m-80 -102.68 63.3 0.85 Allowed 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.598 -0.689 . . . . 0.0 109.732 179.433 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.29 -114.11 4.05 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 108.758 -1.737 . . . . 0.0 108.758 -174.162 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.531 ' HB2' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.36 -22.57 47.76 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.01 -1.288 . . . . 0.0 108.903 174.89 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.644 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 12.0 m80 -74.27 159.23 32.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.475 -0.766 . . . . 0.0 110.249 -177.638 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.578 HG12 ' CG1' ' B' ' 51' ' ' VAL . 54.3 t -141.48 122.56 12.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.756 173.104 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.536 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 1.4 t -88.34 135.13 33.61 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.464 -0.772 . . . . 0.0 109.655 175.418 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.608 ' N ' ' CD1' ' B' ' 61' ' ' PHE . 2.1 p90 -127.46 154.62 44.85 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.692 -0.803 . . . . 0.0 110.263 176.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.527 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 36.3 p-10 -88.89 152.29 21.83 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.035 -1.041 . . . . 0.0 111.275 -171.041 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.528 HD21 ' CD1' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -157.79 100.24 1.74 Allowed 'General case' 0 C--N 1.3 -1.562 0 C-N-CA 120.065 -0.654 . . . . 0.0 109.298 -174.186 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.488 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 60.8 ttm -60.14 139.84 57.28 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.066 -1.021 . . . . 0.0 109.737 -177.391 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.483 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 5.1 ttpm? -59.98 -43.28 95.23 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.131 -0.981 . . . . 0.0 110.399 -175.353 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.36 -40.01 77.74 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.914 -1.116 . . . . 0.0 109.883 178.044 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.488 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 94.4 m -60.01 -37.68 80.43 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.075 -1.015 . . . . 0.0 109.434 172.26 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.529 ' CD1' ' HA2' ' B' ' 74' ' ' GLY . 14.2 tp -60.01 -45.59 92.26 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.302 -0.874 . . . . 0.0 109.482 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 55.2 ttt85 -70.01 -40.03 75.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.465 -0.772 . . . . 0.0 110.732 176.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.467 HG21 " O5'" ' B' ' 99' ' ' RBF . 1.5 tt -67.2 -42.78 88.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.289 -0.882 . . . . 0.0 109.438 -175.802 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.47 HG23 ' O ' ' B' ' 67' ' ' THR . 40.2 p -83.84 -173.69 4.86 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 174.759 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.501 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 3.2 t30 -102.8 23.71 11.71 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.172 -1.048 . . . . 0.0 108.172 169.937 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.528 ' CD1' HD21 ' B' ' 63' ' ' LEU . 86.2 mt -68.6 -39.95 80.68 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.141 -0.975 . . . . 0.0 109.938 176.832 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.529 ' HA2' ' CD1' ' B' ' 68' ' ' LEU . . . -47.96 -22.28 2.02 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.646 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.3 p-10 -62.86 -18.69 63.27 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.092 -1.24 . . . . 0.0 110.434 -176.335 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.517 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.0 mt -60.02 143.26 52.31 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.269 -0.894 . . . . 0.0 110.496 -177.738 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.477 ' O ' HD22 ' B' ' 12' ' ' LEU . 23.3 mttm -145.99 146.71 31.1 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.681 -0.637 . . . . 0.0 109.351 177.02 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.552 ' CG2' HG13 ' B' ' 15' ' ' ILE . 22.1 t -68.05 148.69 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 120.865 -1.147 . . . . 0.0 110.303 -175.669 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 85.96 -10.94 63.83 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.86 -1.696 . . . . 0.0 108.86 -174.125 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.48 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 45.2 t0 -95.74 162.48 13.58 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.303 -1.116 . . . . 0.0 109.687 176.658 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.588 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.0 m95 -114.73 149.41 36.88 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.174 -0.954 . . . . 0.0 109.999 176.833 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.546 HG21 ' CD2' ' B' ' 44' ' ' HIS . 1.2 p -115.37 153.95 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.422 -0.799 . . . . 0.0 109.857 -179.574 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.536 ' CA ' HG11 ' B' ' 6' ' ' VAL . 2.5 m-20 -78.27 106.09 9.94 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.138 -0.976 . . . . 0.0 109.197 168.616 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.505 HG11 ' CE1' ' B' ' 44' ' ' HIS . 0.0 OUTLIER -108.36 140.04 28.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 120.726 -1.234 . . . . 0.0 111.014 -176.446 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . 0.416 ' HB2' HG21 ' B' ' 6' ' ' VAL . 86.5 tt0 -137.18 143.98 42.66 Favored 'General case' 0 N--CA 1.492 1.633 0 C-N-CA 120.282 -0.567 . . . . 0.0 110.205 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 66.5 ttp85 -79.36 130.03 35.04 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.219 -0.926 . . . . 0.0 110.946 -176.515 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.6 ' CB ' ' CZ ' ' A' ' 2' ' ' PHE . . . -125.87 145.95 50.03 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.302 -0.874 . . . . 0.0 110.045 175.733 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . 0.413 ' N ' ' CE2' ' A' ' 2' ' ' PHE . . . -136.41 142.86 43.72 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.586 -0.696 . . . . 0.0 110.508 -177.5 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 26.8 mttt -59.98 -40.05 87.82 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.899 179.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -137.8 156.5 47.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.377 -0.827 . . . . 0.0 109.949 177.681 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 91' ' ' SER . . . . . 0.469 ' O ' HG13 ' B' ' 94' ' ' ILE . 48.4 m -133.62 147.24 51.46 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.344 -0.848 . . . . 0.0 110.001 176.266 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 52.9 t0 -60.09 -40.03 88.17 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.137 -0.977 . . . . 0.0 109.693 177.679 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 -109.34 51.73 0.74 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.172 -0.955 . . . . 0.0 110.707 -177.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . 0.469 HG13 ' O ' ' B' ' 91' ' ' SER . 59.0 mt -59.98 -41.96 87.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.217 -0.927 . . . . 0.0 109.54 174.725 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 57.83 75.44 0.26 Allowed Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 175.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . 174.37 179.97 45.33 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 178.094 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 93.8 m-70 . . . . . 0 N--CA 1.491 1.61 0 O-C-N 121.331 -1.1 . . . . 0.0 110.143 179.618 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.542 " O2'" ' C9 ' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.537 " O2'" ' C9 ' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.462 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 98.2 mtp . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 121.238 0.542 . . . . 0.0 110.227 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.613 ' CZ ' ' CB ' ' B' ' 87' ' ' ALA . 6.3 p90 -178.26 140.0 0.21 Allowed 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.293 -0.879 . . . . 0.0 108.846 177.642 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.528 ' CB ' HG12 ' A' ' 5' ' ' ILE . 9.9 p -130.99 -36.91 1.31 Allowed 'General case' 0 C--N 1.3 -1.566 0 O-C-N 120.816 -1.177 . . . . 0.0 109.133 -177.11 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.487 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 52.61 22.03 10.53 Favored Glycine 0 N--CA 1.485 1.901 0 N-CA-C 108.584 -1.806 . . . . 0.0 108.584 -178.33 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.528 HG12 ' CB ' ' A' ' 3' ' ' THR . 32.8 mm -80.43 122.82 36.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.429 -1.041 . . . . 0.0 109.789 -176.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.53 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.3 t -82.66 142.84 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.184 -0.947 . . . . 0.0 110.892 -171.702 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 -69.43 -35.0 75.28 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.773 -0.579 . . . . 0.0 110.621 177.107 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.53 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -162.68 173.9 38.98 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 118.896 -1.621 . . . . 0.0 110.094 -174.114 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.464 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.5 p -114.69 174.76 5.8 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.154 -1.204 . . . . 0.0 110.836 -177.701 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.487 ' HB1' HG12 ' A' ' 82' ' ' VAL . . . -142.61 149.04 38.45 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.622 -0.674 . . . . 0.0 109.541 -177.718 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.0 tttt -103.95 118.62 37.1 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 120.95 -1.094 . . . . 0.0 110.2 178.134 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.515 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 12.2 tp -60.7 127.55 32.21 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 120.795 -1.191 . . . . 0.0 108.569 171.005 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.637 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.7 p -130.45 -31.17 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.874 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.229 -177.126 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -143.84 139.83 29.49 Favored 'General case' 0 C--N 1.296 -1.719 0 C-N-CA 119.079 -1.048 . . . . 0.0 111.272 -178.634 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.574 HG13 ' CG2' ' A' ' 78' ' ' VAL . 11.2 mt -110.02 130.81 62.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.034 -1.041 . . . . 0.0 110.198 171.201 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.484 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 81.6 m-20 -108.07 114.64 28.7 Favored 'General case' 0 C--N 1.294 -1.843 0 O-C-N 121.443 -0.786 . . . . 0.0 109.962 173.195 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.4 110.77 22.98 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.002 -1.061 . . . . 0.0 110.592 -176.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.468 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -110.29 128.12 25.89 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.133 -0.979 . . . . 0.0 108.917 174.09 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -50.61 -33.42 39.28 Favored 'Trans proline' 0 C--N 1.303 -1.851 0 O-C-N 123.767 1.404 . . . . 0.0 110.314 -179.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.474 ' C ' ' CD2' ' A' ' 21' ' ' PHE . 12.4 m-80 -72.27 -40.0 67.95 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.149 -0.97 . . . . 0.0 109.938 175.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.474 ' CD2' ' C ' ' A' ' 20' ' ' ASN . 91.0 m-85 -152.51 150.25 29.39 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.374 -0.829 . . . . 0.0 110.197 -178.4 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.463 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 57.5 ttt180 -88.31 139.95 29.97 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 120.734 -1.229 . . . . 0.0 109.7 173.074 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.484 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 95.0 m -124.97 131.73 53.38 Favored 'General case' 0 C--N 1.294 -1.847 0 O-C-N 121.597 -0.689 . . . . 0.0 109.901 -176.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.578 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -126.21 138.89 53.68 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.905 -1.122 . . . . 0.0 111.303 -179.7 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.524 HG22 ' CB ' ' A' ' 60' ' ' SER . 5.7 t -120.83 134.26 64.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.135 -0.978 . . . . 0.0 110.861 -176.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.55 HG13 ' CE1' ' A' ' 61' ' ' PHE . 35.9 m -114.79 172.17 4.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 O-C-N 121.804 -0.56 . . . . 0.0 110.09 178.243 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.478 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 9.2 tt0 -104.21 117.91 35.37 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.376 -0.827 . . . . 0.0 108.788 177.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.475 HD23 ' O ' ' A' ' 32' ' ' MET . 7.5 tp -85.83 127.93 60.48 Favored Pre-proline 0 C--N 1.297 -1.703 0 O-C-N 121.562 -0.711 . . . . 0.0 109.943 -171.128 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.468 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 20.6 Cg_endo -66.02 178.69 2.25 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.881 1.464 . . . . 0.0 110.743 -179.363 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.49 ' OD1' ' N ' ' A' ' 31' ' ' HIS . 33.9 p-10 -62.65 -40.1 95.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.349 -0.844 . . . . 0.0 110.999 -175.542 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.585 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.93 -0.0 57.33 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.837 -1.164 . . . . 0.0 110.823 -174.367 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.585 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.0 mmm -108.11 -16.98 14.15 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.87 -1.144 . . . . 0.0 109.638 170.772 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.548 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 24.7 mt -66.2 -25.77 67.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.363 -0.835 . . . . 0.0 109.721 174.736 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -92.26 131.33 37.56 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.474 -0.766 . . . . 0.0 110.56 -178.094 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.79 -41.75 2.71 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 176.601 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.467 HD13 HD23 ' A' ' 28' ' ' LEU . 5.1 tt -70.84 148.2 48.09 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.076 -1.249 . . . . 0.0 110.335 -177.226 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.47 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 19.9 pt-20 -156.75 166.36 33.61 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.322 -0.862 . . . . 0.0 109.599 -177.66 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.536 ' CG2' ' HA ' ' A' ' 53' ' ' GLU . 0.1 OUTLIER -65.57 148.5 51.63 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.886 -1.134 . . . . 0.0 110.051 -178.886 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.67 -3.47 68.76 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.234 -1.546 . . . . 0.0 109.234 -174.369 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.47 ' HB3' ' O ' ' A' ' 37' ' ' GLU . . . -78.22 160.03 28.19 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.263 -1.14 . . . . 0.0 109.445 176.108 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.471 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -101.64 114.31 28.24 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 118.799 -1.16 . . . . 0.0 110.097 177.107 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.577 HG13 ' CE1' ' A' ' 44' ' ' HIS . 1.7 t -99.11 128.75 50.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.278 -0.889 . . . . 0.0 108.94 173.277 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.473 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -94.99 119.48 33.58 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 119.156 -1.017 . . . . 0.0 109.074 172.295 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.577 ' CE1' HG13 ' A' ' 42' ' ' VAL . 0.6 OUTLIER -87.32 103.14 15.19 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.415 -0.803 . . . . 0.0 108.958 178.41 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.498 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 57.83 8.9 0.77 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.441 -0.787 . . . . 0.0 111.309 -170.312 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.482 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 124.11 2.26 8.51 Favored Glycine 0 N--CA 1.489 2.168 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.858 174.846 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.526 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 42.7 t -98.45 107.33 19.77 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.461 -1.611 . . . . 0.0 109.485 174.706 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.504 ' SG ' ' C7 ' ' A' ' 98' ' ' RBF . 26.2 p -75.1 129.9 38.35 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.237 -0.914 . . . . 0.0 111.211 -170.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.637 ' CD1' ' CD2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -145.27 160.63 41.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.443 -0.786 . . . . 0.0 109.637 173.552 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 57.9 m -100.95 151.17 22.08 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.737 -1.227 . . . . 0.0 110.923 -171.719 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.545 ' CG1' HG12 ' A' ' 59' ' ' VAL . 38.6 t -78.48 116.85 22.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.655 -0.653 . . . . 0.0 110.487 -178.358 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 37.7 p -70.03 -40.01 75.42 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.205 -0.934 . . . . 0.0 109.893 174.092 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.536 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -163.47 153.39 15.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.298 -0.876 . . . . 0.0 110.194 -177.676 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.529 HD12 ' CG2' ' A' ' 38' ' ' THR . 5.9 mt -104.49 133.63 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.018 -1.051 . . . . 0.0 109.885 175.044 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.468 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 31.4 m-80 -107.72 66.94 0.67 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.507 -0.745 . . . . 0.0 109.823 179.154 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.27 -116.06 4.83 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.816 -1.714 . . . . 0.0 108.816 -174.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.548 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -79.21 -19.13 51.53 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.055 -1.262 . . . . 0.0 108.764 174.545 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.637 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 11.2 m170 -74.73 160.66 30.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.467 -0.77 . . . . 0.0 110.343 -178.236 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.545 HG12 ' CG1' ' A' ' 51' ' ' VAL . 62.9 t -141.25 123.21 14.27 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 O-C-N 121.229 -0.92 . . . . 0.0 110.433 171.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.524 ' CB ' HG22 ' A' ' 25' ' ' VAL . 13.3 m -91.32 130.53 37.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.573 -0.704 . . . . 0.0 109.535 178.283 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.637 ' CD2' ' CD1' ' A' ' 49' ' ' LEU . 4.0 p90 -124.69 153.66 42.0 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.096 -1.002 . . . . 0.0 110.333 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 27.2 p-10 -88.73 152.22 21.93 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.091 -1.006 . . . . 0.0 111.37 -170.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.53 HD21 ' CD1' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -155.73 114.33 3.46 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -176.128 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.501 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 7.1 ttp -71.64 140.0 49.52 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.803 -1.186 . . . . 0.0 109.685 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.483 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 37.5 ttpt -60.04 -46.03 90.86 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.075 -1.015 . . . . 0.0 110.532 -174.05 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -70.0 -40.05 75.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.659 -1.275 . . . . 0.0 110.003 178.522 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.501 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 33.4 m -61.88 -34.9 76.87 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.053 -1.029 . . . . 0.0 109.462 173.805 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.509 ' HG ' ' CA ' ' A' ' 74' ' ' GLY . 7.6 tp -59.96 -45.81 91.47 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.244 -0.91 . . . . 0.0 109.151 178.205 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 71.8 ttt-85 -66.46 -39.98 89.15 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.284 -0.885 . . . . 0.0 110.682 175.115 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.466 HG21 HG21 ' A' ' 71' ' ' THR . 1.3 tt -66.72 -44.24 89.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.173 -0.954 . . . . 0.0 109.584 -175.549 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.466 HG21 HG21 ' A' ' 70' ' ' ILE . 31.2 p -83.17 -175.13 5.68 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 120.199 -0.6 . . . . 0.0 109.437 175.5 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 3.7 t30 -99.48 23.59 9.21 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 171.216 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.53 ' CD1' HD21 ' A' ' 63' ' ' LEU . 90.9 mt -70.0 -39.96 75.55 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.12 -0.987 . . . . 0.0 110.117 176.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.509 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -53.75 -18.1 7.71 Favored Glycine 0 N--CA 1.486 1.987 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 -177.137 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.2 p-10 -69.99 -19.03 63.35 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.953 -1.322 . . . . 0.0 110.575 -175.567 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.518 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 87.9 mt -62.13 141.92 57.88 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.233 -0.917 . . . . 0.0 110.815 -176.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.487 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 43.5 mtmt -141.49 141.74 33.62 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 121.63 -0.669 . . . . 0.0 109.776 174.32 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.574 ' CG2' HG13 ' A' ' 15' ' ' ILE . 16.6 t -60.32 152.6 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 120.926 -1.109 . . . . 0.0 110.451 -174.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.43 -15.9 57.45 Favored Glycine 0 N--CA 1.482 1.722 0 N-CA-C 108.762 -1.735 . . . . 0.0 108.762 -176.348 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 37.8 t0 -95.76 166.8 11.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.312 -1.111 . . . . 0.0 109.664 175.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.3 m95 -116.82 160.49 20.74 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.083 -1.011 . . . . 0.0 110.171 178.014 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.487 HG12 ' HB1' ' A' ' 10' ' ' ALA . 1.1 p -125.55 155.21 34.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.339 -0.851 . . . . 0.0 110.034 -177.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.489 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 0.2 OUTLIER -79.97 105.04 10.96 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.964 -1.085 . . . . 0.0 109.059 168.229 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.464 ' CG2' ' C ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -105.56 138.01 32.68 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 O-C-N 120.546 -1.346 . . . . 0.0 111.118 -176.539 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -133.53 140.03 46.96 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 120.298 -0.561 . . . . 0.0 110.028 -178.023 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . 0.517 ' NH1' ' HB2' ' A' ' 86' ' ' ARG . 26.7 ttm105 -78.31 126.91 31.45 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.258 -0.901 . . . . 0.0 110.701 -176.053 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.594 ' CB ' ' CZ ' ' B' ' 2' ' ' PHE . . . -120.51 144.3 48.1 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.392 -0.817 . . . . 0.0 110.076 176.289 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -137.37 157.8 45.8 Favored 'General case' 0 N--CA 1.49 1.533 0 CA-C-O 121.515 0.674 . . . . 0.0 110.727 -176.302 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 40.0 mmtt -66.17 -39.96 90.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.387 -0.82 . . . . 0.0 110.576 179.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 45.7 p90 -108.77 161.45 15.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.085 -1.009 . . . . 0.0 110.499 -175.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 58.4 m -119.93 144.86 47.21 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.438 -0.789 . . . . 0.0 110.323 -178.527 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.42 ' O ' ' OD1' ' A' ' 92' ' ' ASP . 55.0 t0 -69.9 -24.64 63.43 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.41 -0.806 . . . . 0.0 110.696 -178.74 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -92.85 43.19 1.12 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.736 -1.228 . . . . 0.0 110.856 -172.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 57.9 mt -61.44 -45.85 97.78 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 O-C-N 121.35 -0.843 . . . . 0.0 109.765 170.55 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 149.08 -91.44 0.14 Allowed Glycine 0 N--CA 1.488 2.158 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -178.211 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 86.27 -9.94 68.25 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 178.645 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 44.1 m80 . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.202 -1.175 . . . . 0.0 110.174 -178.539 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 1' ' ' MET . . . . . 0.447 ' O ' ' HB3' ' B' ' 2' ' ' PHE . 67.6 mtt . . . . . 0 N--CA 1.492 1.675 0 CA-C-O 121.254 0.549 . . . . 0.0 110.261 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.594 ' CZ ' ' CB ' ' A' ' 87' ' ' ALA . 6.4 p90 -177.94 139.99 0.23 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.304 -0.872 . . . . 0.0 108.748 176.5 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.528 ' CB ' HG12 ' B' ' 5' ' ' ILE . 9.6 p -130.97 -36.88 1.32 Allowed 'General case' 0 C--N 1.301 -1.533 0 O-C-N 120.824 -1.173 . . . . 0.0 109.174 -177.174 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.467 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 52.59 22.01 10.43 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.608 -1.797 . . . . 0.0 108.608 -178.335 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.528 HG12 ' CB ' ' B' ' 3' ' ' THR . 32.9 mm -80.42 122.75 36.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.356 -1.085 . . . . 0.0 109.833 -176.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.524 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.3 t -82.56 142.89 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.166 -0.959 . . . . 0.0 110.984 -171.724 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 90.8 mm-40 -69.51 -34.74 74.72 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.685 -0.635 . . . . 0.0 110.665 177.167 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.524 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -163.03 173.72 39.26 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.065 -1.541 . . . . 0.0 110.177 -174.111 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.468 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.4 p -114.68 174.63 5.87 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.156 -1.203 . . . . 0.0 110.841 -177.543 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.472 ' CB ' HG12 ' B' ' 82' ' ' VAL . . . -142.45 149.24 39.0 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.704 -0.622 . . . . 0.0 109.462 -177.802 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 29.9 tttt -103.97 118.68 37.24 Favored 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.051 -1.03 . . . . 0.0 110.154 178.065 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.516 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 12.1 tp -60.86 127.42 31.5 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 120.952 -1.092 . . . . 0.0 108.624 170.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.635 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.7 p -130.2 -31.53 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.836 0 O-C-N 121.265 -0.897 . . . . 0.0 110.267 -177.008 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -143.7 139.89 29.75 Favored 'General case' 0 C--N 1.295 -1.772 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.311 -178.649 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.576 HG13 ' CG2' ' B' ' 78' ' ' VAL . 11.2 mt -109.92 130.84 62.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.048 -1.032 . . . . 0.0 110.149 171.259 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.495 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 81.2 m-20 -108.2 114.79 28.95 Favored 'General case' 0 C--N 1.296 -1.722 0 O-C-N 121.42 -0.8 . . . . 0.0 109.912 173.127 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.38 110.79 23.01 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.119 -0.988 . . . . 0.0 110.503 -176.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.465 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -110.34 128.1 25.91 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.158 -0.964 . . . . 0.0 109.016 173.971 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -50.8 -33.27 40.2 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 O-C-N 123.758 1.399 . . . . 0.0 110.253 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.471 ' C ' ' CD2' ' B' ' 21' ' ' PHE . 12.3 m-80 -72.32 -40.17 67.66 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.203 -0.935 . . . . 0.0 109.902 175.713 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.471 ' CD2' ' C ' ' B' ' 20' ' ' ASN . 91.1 m-85 -152.33 150.23 29.5 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.393 -0.817 . . . . 0.0 110.233 -178.423 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.476 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 57.5 ttt180 -88.13 139.89 30.05 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.777 -1.202 . . . . 0.0 109.706 173.063 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.495 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 95.6 m -124.96 131.75 53.38 Favored 'General case' 0 C--N 1.295 -1.781 0 O-C-N 121.676 -0.64 . . . . 0.0 109.908 -176.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.571 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -126.18 138.97 53.7 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.011 -1.056 . . . . 0.0 111.241 -179.635 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.521 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 5.7 t -120.78 134.44 64.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.224 -0.923 . . . . 0.0 110.834 -176.971 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.474 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 35.8 m -115.04 172.08 4.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.773 -0.579 . . . . 0.0 110.021 178.28 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.482 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 9.2 tt0 -104.1 118.05 35.73 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 177.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.503 ' CD2' HD13 ' B' ' 36' ' ' LEU . 7.5 tp -85.84 127.8 60.96 Favored Pre-proline 0 C--N 1.296 -1.735 0 O-C-N 121.338 -0.851 . . . . 0.0 110.0 -171.209 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.46 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 20.9 Cg_endo -65.95 178.63 2.25 Favored 'Trans proline' 0 C--N 1.308 -1.604 0 O-C-N 123.828 1.436 . . . . 0.0 110.799 -179.365 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' B' ' 31' ' ' HIS . 33.8 p-10 -62.74 -39.94 95.68 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.322 -0.861 . . . . 0.0 110.984 -175.47 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.571 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.0 0.0 57.34 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.851 -1.156 . . . . 0.0 110.797 -174.363 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.571 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.0 mmm -108.16 -16.87 14.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.84 -1.162 . . . . 0.0 109.62 170.833 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.533 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 24.6 mt -66.36 -25.69 66.92 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.369 -0.832 . . . . 0.0 109.714 174.739 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -92.28 131.31 37.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.48 -0.762 . . . . 0.0 110.525 -178.129 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.76 -41.64 2.72 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 176.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . 0.503 HD13 ' CD2' ' B' ' 28' ' ' LEU . 5.1 tt -70.81 148.26 48.05 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.033 -1.275 . . . . 0.0 110.267 -177.222 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.474 ' N ' HD23 ' B' ' 36' ' ' LEU . 19.9 pt-20 -156.8 166.39 33.51 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.366 -0.834 . . . . 0.0 109.576 -177.702 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.537 ' CG2' HD12 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -65.65 148.46 51.72 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.927 -1.108 . . . . 0.0 110.064 -178.886 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.59 -3.33 68.94 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.319 -1.512 . . . . 0.0 109.319 -174.272 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.466 ' CB ' ' O ' ' B' ' 37' ' ' GLU . . . -78.41 159.99 28.01 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.286 -1.126 . . . . 0.0 109.33 176.021 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.465 ' OG ' ' O ' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -101.56 114.18 27.97 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 120.86 -1.15 . . . . 0.0 110.116 177.177 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.583 HG13 ' CE1' ' B' ' 44' ' ' HIS . 1.7 t -99.24 128.77 50.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.319 -0.863 . . . . 0.0 108.923 173.329 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.472 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -94.86 119.47 33.47 Favored 'General case' 0 C--N 1.297 -1.707 0 O-C-N 121.083 -1.011 . . . . 0.0 109.135 172.294 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.583 ' CE1' HG13 ' B' ' 42' ' ' VAL . 0.6 OUTLIER -87.42 102.99 15.08 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.376 -0.828 . . . . 0.0 108.975 178.403 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.498 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 58.12 8.9 0.85 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.49 -0.756 . . . . 0.0 111.25 -170.459 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.487 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 123.87 2.73 8.57 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.789 -1.196 . . . . 0.0 110.802 174.709 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.524 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 42.7 t -98.62 107.26 19.66 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 120.378 -1.66 . . . . 0.0 109.44 174.535 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . 0.513 ' SG ' ' C7 ' ' B' ' 99' ' ' RBF . 26.2 p -74.97 130.04 38.68 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.114 -0.991 . . . . 0.0 111.142 -171.026 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.645 ' CD1' ' CD2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -145.43 160.41 41.62 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.484 -0.76 . . . . 0.0 109.717 173.462 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 57.7 m -100.7 151.35 21.76 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.781 -1.199 . . . . 0.0 110.982 -171.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.496 ' CG1' HG11 ' B' ' 59' ' ' VAL . 38.2 t -78.67 116.92 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.644 -0.66 . . . . 0.0 110.472 -178.358 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.517 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 38.8 p -70.07 -40.06 75.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.201 -0.937 . . . . 0.0 109.884 174.224 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.529 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -163.36 153.44 15.6 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.341 -0.849 . . . . 0.0 110.226 -177.683 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.537 HD12 ' CG2' ' B' ' 38' ' ' THR . 5.9 mt -104.52 133.65 48.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.151 -0.968 . . . . 0.0 109.937 174.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.48 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 31.3 m-80 -107.82 66.99 0.67 Allowed 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.572 -0.705 . . . . 0.0 109.762 179.194 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.41 -116.08 4.81 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 108.743 -1.743 . . . . 0.0 108.743 -174.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.533 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -79.18 -19.22 51.42 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 120.974 -1.309 . . . . 0.0 108.832 174.478 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.635 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 11.1 m170 -74.65 160.53 30.69 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.443 -0.785 . . . . 0.0 110.361 -178.301 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.496 HG11 ' CG1' ' B' ' 51' ' ' VAL . 62.9 t -141.06 123.22 14.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 O-C-N 121.208 -0.932 . . . . 0.0 110.453 171.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.521 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 13.4 m -91.43 130.87 37.21 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.632 -0.667 . . . . 0.0 109.553 178.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.645 ' CD2' ' CD1' ' B' ' 49' ' ' LEU . 3.9 p90 -124.96 153.43 42.76 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.188 -0.945 . . . . 0.0 110.255 -179.721 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.517 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 27.4 p-10 -88.58 152.21 21.99 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.976 -1.077 . . . . 0.0 111.466 -170.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.519 HD22 ' CD1' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -155.71 114.4 3.48 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 -176.154 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.495 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 7.1 ttp -71.62 139.97 49.54 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.867 -1.146 . . . . 0.0 109.799 -178.076 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.485 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 37.5 ttpt -60.06 -45.98 91.06 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.128 -0.982 . . . . 0.0 110.477 -173.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -70.06 -39.98 75.36 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.806 -1.184 . . . . 0.0 110.023 178.591 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.495 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 34.4 m -61.94 -34.98 77.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.035 -1.041 . . . . 0.0 109.342 173.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.503 ' CD1' ' HA2' ' B' ' 74' ' ' GLY . 7.6 tp -60.05 -45.47 92.74 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.312 -0.867 . . . . 0.0 109.243 178.26 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 71.8 ttt-85 -66.7 -39.96 88.27 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.356 -0.84 . . . . 0.0 110.652 175.051 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.469 HG21 HG21 ' B' ' 71' ' ' THR . 1.3 tt -66.71 -44.23 89.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.144 -0.973 . . . . 0.0 109.595 -175.602 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.469 HG21 ' O ' ' B' ' 67' ' ' THR . 31.2 p -83.05 -175.02 5.63 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 120.114 -0.634 . . . . 0.0 109.477 175.518 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.489 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 3.7 t30 -99.56 23.68 9.16 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 171.125 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.519 ' CD1' HD22 ' B' ' 63' ' ' LEU . 90.7 mt -70.05 -39.96 75.4 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.123 -0.985 . . . . 0.0 110.089 176.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.503 ' HA2' ' CD1' ' B' ' 68' ' ' LEU . . . -53.79 -18.0 7.7 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 -177.11 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.4 p-10 -70.06 -18.99 63.3 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.039 -1.271 . . . . 0.0 110.578 -175.556 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.511 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 88.1 mt -62.14 141.89 57.91 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.231 -0.918 . . . . 0.0 110.828 -177.025 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.49 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 43.4 mtmt -141.52 141.72 33.58 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.666 -0.646 . . . . 0.0 109.787 174.321 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.576 ' CG2' HG13 ' B' ' 15' ' ' ILE . 16.7 t -60.31 152.51 5.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.957 -1.09 . . . . 0.0 110.43 -174.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.38 -15.59 58.16 Favored Glycine 0 N--CA 1.484 1.846 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -176.415 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 38.0 t0 -95.97 166.68 11.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.422 -1.046 . . . . 0.0 109.655 175.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.4 m95 -116.76 160.53 20.66 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.15 -0.968 . . . . 0.0 110.176 178.076 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.506 HG23 ' CG ' ' B' ' 44' ' ' HIS . 1.1 p -125.56 155.35 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.407 -0.808 . . . . 0.0 109.979 -178.056 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.475 ' OD1' ' N ' ' A' ' 72' ' ' ASN . 0.2 OUTLIER -80.01 104.89 10.89 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.093 -1.004 . . . . 0.0 109.003 168.296 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.468 ' CG2' ' C ' ' B' ' 9' ' ' THR . 0.0 OUTLIER -105.54 138.18 31.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 120.559 -1.338 . . . . 0.0 111.075 -176.491 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -133.71 140.08 46.79 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 120.335 -0.546 . . . . 0.0 110.05 -178.103 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . 0.516 ' NH1' ' HB2' ' B' ' 86' ' ' ARG . 26.8 ttm105 -78.34 126.92 31.46 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.213 -0.929 . . . . 0.0 110.642 -176.014 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.613 ' CB ' ' CZ ' ' A' ' 2' ' ' PHE . . . -120.39 144.16 48.06 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.334 -0.854 . . . . 0.0 110.015 176.286 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -137.25 157.89 45.63 Favored 'General case' 0 N--CA 1.49 1.574 0 CA-C-O 121.438 0.637 . . . . 0.0 110.774 -176.473 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 40.0 mmtt -66.26 -39.96 89.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.395 -0.816 . . . . 0.0 110.555 179.799 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 45.8 p90 -108.77 161.53 15.02 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.158 -0.964 . . . . 0.0 110.543 -176.005 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 91' ' ' SER . . . . . . . . . . . . . 58.8 m -119.94 144.94 47.19 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.381 -0.824 . . . . 0.0 110.351 -178.567 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . 0.428 ' O ' ' OD1' ' B' ' 92' ' ' ASP . 55.3 t0 -70.02 -21.19 63.22 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.366 -0.834 . . . . 0.0 110.515 -178.658 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -117.02 55.9 0.82 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.489 -0.757 . . . . 0.0 110.268 -176.077 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . 0.432 ' O ' ' C ' ' B' ' 95' ' ' GLY . 38.7 mm -59.97 -44.72 95.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.276 -0.89 . . . . 0.0 109.64 177.776 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' B' ' 94' ' ' ILE . . . 40.34 65.87 0.91 Allowed Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 177.175 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . 120.32 -126.09 6.52 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.481 -1.447 . . . . 0.0 109.481 -178.65 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . 0.493 ' OXT' ' CD2' ' B' ' 97' ' ' HIS . 30.0 p-80 . . . . . 0 N--CA 1.49 1.573 0 O-C-N 121.203 -1.174 . . . . 0.0 110.266 -179.18 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.528 " O2'" ' C9 ' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.53 " O2'" ' C9 ' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 76.5 mtm . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 121.157 0.503 . . . . 0.0 110.325 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.576 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 10.2 p90 -171.05 143.92 2.04 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.182 -0.949 . . . . 0.0 109.202 177.396 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.523 ' CB ' HG12 ' A' ' 5' ' ' ILE . 6.7 p -140.99 -37.37 0.44 Allowed 'General case' 0 C--N 1.299 -1.604 0 O-C-N 120.984 -1.073 . . . . 0.0 109.087 -178.236 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.491 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 45.99 25.97 1.9 Allowed Glycine 0 N--CA 1.484 1.885 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -176.295 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.523 HG12 ' CB ' ' A' ' 3' ' ' THR . 41.3 mm -76.61 122.8 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.396 -1.061 . . . . 0.0 109.865 -177.294 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.528 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 1.7 t -86.17 139.05 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.256 -0.903 . . . . 0.0 110.784 -170.432 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 79.2 mm-40 -69.97 -34.84 73.91 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.64 -0.663 . . . . 0.0 110.843 178.275 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.528 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -158.28 179.19 34.15 Favored Glycine 0 N--CA 1.494 2.527 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.235 -173.167 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.47 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 1.0 OUTLIER -118.54 170.0 9.32 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.117 -1.226 . . . . 0.0 110.956 -177.962 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.582 ' CB ' ' CG1' ' A' ' 82' ' ' VAL . . . -136.55 149.7 48.23 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.667 -0.646 . . . . 0.0 109.448 -179.237 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.587 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 39.6 tttt -110.57 117.87 34.69 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.024 -1.048 . . . . 0.0 110.455 -179.44 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.504 ' CG ' ' HA ' ' A' ' 78' ' ' VAL . 10.9 tp -60.04 126.26 26.83 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.882 -1.136 . . . . 0.0 108.979 172.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.591 HG12 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -125.76 -31.67 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 O-C-N 121.471 -0.768 . . . . 0.0 109.545 179.252 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.09 143.12 30.24 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.453 -0.899 . . . . 0.0 111.103 -179.648 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.58 HG12 ' CD2' ' A' ' 24' ' ' HIS . 18.0 mt -106.71 134.98 46.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.038 -1.039 . . . . 0.0 110.0 171.027 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.502 ' CB ' ' HB ' ' A' ' 23' ' ' THR . 56.0 m-20 -107.53 115.81 30.83 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.274 -0.891 . . . . 0.0 109.851 174.067 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -107.06 111.88 24.55 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.057 -1.027 . . . . 0.0 110.467 -176.448 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 8.2 mtmm -109.09 131.28 21.9 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.217 -0.927 . . . . 0.0 109.262 175.686 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -51.13 -22.88 11.69 Favored 'Trans proline' 0 C--N 1.304 -1.78 0 O-C-N 123.954 1.502 . . . . 0.0 111.052 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.582 ' O ' ' CD1' ' A' ' 21' ' ' PHE . 7.4 m-80 -92.78 -33.61 14.21 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.085 -1.009 . . . . 0.0 109.983 177.833 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.582 ' CD1' ' O ' ' A' ' 20' ' ' ASN . 36.3 m-85 -148.2 150.17 33.27 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.488 -0.758 . . . . 0.0 110.026 -177.516 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.468 ' NH1' HD23 ' A' ' 68' ' ' LEU . 60.4 ttt180 -95.76 143.5 26.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.668 -1.27 . . . . 0.0 109.964 173.739 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.502 ' HB ' ' CB ' ' A' ' 16' ' ' ASP . 56.3 m -132.61 145.65 51.27 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.494 -0.754 . . . . 0.0 109.955 -176.095 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.58 ' CD2' HG12 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -134.2 134.06 41.64 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.943 -1.098 . . . . 0.0 111.327 -179.666 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.517 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 5.3 t -113.62 132.75 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.071 -1.018 . . . . 0.0 110.856 -177.32 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.461 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 12.9 m -118.79 170.93 7.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 CA-C-O 121.317 0.579 . . . . 0.0 110.331 -179.17 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.436 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 15.3 tt0 -100.08 116.65 32.6 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 177.789 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.559 ' CD1' ' CB ' ' A' ' 32' ' ' MET . 0.0 OUTLIER -86.15 118.5 70.51 Favored Pre-proline 0 C--N 1.295 -1.798 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -175.36 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.498 ' HD2' ' CD1' ' A' ' 28' ' ' LEU . 19.6 Cg_endo -63.25 170.78 7.34 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 O-C-N 123.801 1.422 . . . . 0.0 110.976 -178.527 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.504 ' OD1' ' N ' ' A' ' 31' ' ' HIS . 34.1 p-10 -61.26 -35.85 78.42 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.477 -0.765 . . . . 0.0 110.83 -175.713 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.578 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.69 -0.49 57.71 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.828 -1.17 . . . . 0.0 110.874 -173.486 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.578 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.9 mmm -116.69 -11.17 11.01 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.984 -1.072 . . . . 0.0 109.933 169.499 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.528 ' CD2' ' HB3' ' A' ' 28' ' ' LEU . 13.2 mt -65.67 -37.95 87.93 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.07 -1.019 . . . . 0.0 109.599 175.168 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -69.04 132.25 46.34 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.486 -0.759 . . . . 0.0 110.746 -177.402 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.12 -40.12 2.8 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 173.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.518 ' CD2' HD21 ' A' ' 28' ' ' LEU . 59.1 tp -69.2 145.44 53.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.03 -1.277 . . . . 0.0 110.688 -175.262 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.474 ' O ' ' HB2' ' A' ' 40' ' ' ALA . 16.8 pt-20 -148.01 169.1 20.64 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.591 -0.693 . . . . 0.0 109.408 177.445 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.542 ' CG2' HD12 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -64.53 148.56 50.45 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.9 -1.125 . . . . 0.0 109.83 178.291 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.42 -4.66 62.85 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -176.45 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.474 ' HB2' ' O ' ' A' ' 37' ' ' GLU . . . -74.45 159.13 32.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.257 -1.143 . . . . 0.0 109.499 176.568 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.47 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -100.51 117.42 34.63 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 118.909 -1.116 . . . . 0.0 109.885 176.642 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.577 HG13 ' CE1' ' A' ' 44' ' ' HIS . 2.1 t -105.97 126.25 61.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.333 -0.855 . . . . 0.0 109.079 175.262 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.469 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -89.72 118.62 29.46 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.185 -1.006 . . . . 0.0 109.191 172.282 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.577 ' CE1' HG13 ' A' ' 42' ' ' VAL . 0.4 OUTLIER -88.8 100.99 13.58 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 177.054 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.491 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 59.59 8.79 1.35 Allowed 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.486 -0.759 . . . . 0.0 111.143 -168.514 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.468 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 128.76 -12.69 6.18 Favored Glycine 0 N--CA 1.489 2.197 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.8 174.167 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 43' ' ' ALA . 42.8 t -85.97 110.05 19.2 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.356 -1.673 . . . . 0.0 109.779 179.196 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.477 ' O ' ' C5A' ' A' ' 98' ' ' RBF . 19.6 p -77.65 113.4 15.46 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.304 -0.872 . . . . 0.0 110.984 -172.376 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.459 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -130.33 161.18 31.86 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.436 -0.79 . . . . 0.0 109.119 172.628 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 57.2 m -103.93 155.08 18.93 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.492 -1.38 . . . . 0.0 111.356 -168.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.55 ' CG1' HG13 ' A' ' 59' ' ' VAL . 21.2 t -77.44 112.79 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.677 -0.64 . . . . 0.0 110.379 -179.51 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 17.6 p -69.95 -40.0 75.72 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.211 -0.931 . . . . 0.0 109.493 172.193 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.45 ' HA ' HG23 ' A' ' 38' ' ' THR . 86.0 tt0 -158.46 153.9 25.96 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 119.322 -0.951 . . . . 0.0 110.845 -177.846 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.542 HD12 ' CG2' ' A' ' 38' ' ' THR . 13.6 mt -110.37 130.06 64.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.181 -0.95 . . . . 0.0 109.887 172.713 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.452 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 9.7 m-80 -103.73 63.67 0.78 Allowed 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.542 -0.724 . . . . 0.0 109.723 178.899 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.69 -112.51 3.55 Favored Glycine 0 N--CA 1.487 2.07 0 N-CA-C 108.691 -1.764 . . . . 0.0 108.691 -173.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.49 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.1 -22.49 42.14 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.988 -1.301 . . . . 0.0 108.846 174.201 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.591 ' CD2' HG12 ' A' ' 13' ' ' VAL . 8.9 m170 -74.58 158.69 33.27 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.123 -0.985 . . . . 0.0 110.218 -176.211 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.582 ' CG1' ' CZ ' ' A' ' 61' ' ' PHE . 80.2 t -141.31 119.68 9.72 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 C-N-CA 119.312 -0.955 . . . . 0.0 110.923 175.693 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.517 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 15.9 m -88.65 126.21 35.19 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.627 -0.671 . . . . 0.0 109.739 178.672 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.582 ' CZ ' ' CG1' ' A' ' 59' ' ' VAL . 98.0 m-85 -109.9 156.53 20.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.788 -1.195 . . . . 0.0 110.396 179.52 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 19.8 p-10 -89.8 148.22 23.34 Favored 'General case' 0 N--CA 1.494 1.738 0 CA-C-O 122.045 0.926 . . . . 0.0 110.878 178.856 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.516 HD21 ' CD1' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -155.53 116.6 3.91 Favored 'General case' 0 C--N 1.296 -1.759 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -176.483 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.51 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 93.2 mmm -69.97 141.72 52.96 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 119.109 -1.037 . . . . 0.0 109.518 179.738 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.414 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 46.8 tttp -60.0 -45.15 93.69 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.103 -0.998 . . . . 0.0 110.195 -176.849 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.432 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.4 tt0 -69.44 -40.04 77.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.984 -1.072 . . . . 0.0 110.283 177.642 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.51 ' HB ' ' HB2' ' A' ' 64' ' ' MET . 89.8 m -61.69 -39.38 91.24 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.927 -1.108 . . . . 0.0 109.278 174.091 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.489 ' HG ' ' CA ' ' A' ' 74' ' ' GLY . 7.7 tp -60.09 -43.57 95.42 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.325 -0.86 . . . . 0.0 109.364 178.022 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 92.6 mtt180 -69.86 -39.97 76.05 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.545 -0.722 . . . . 0.0 110.692 176.03 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.473 HG22 HG22 ' A' ' 71' ' ' THR . 1.3 tt -69.94 -41.61 79.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.246 -0.909 . . . . 0.0 109.404 -176.078 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.473 HG22 HG22 ' A' ' 70' ' ' ILE . 65.3 p -83.59 -173.94 5.0 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 178.072 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 3.0 t30 -100.73 22.62 11.68 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 170.883 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.516 ' CD1' HD21 ' A' ' 63' ' ' LEU . 96.6 mt -69.91 -40.2 75.75 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.013 -1.054 . . . . 0.0 110.053 174.653 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.489 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -52.99 -24.27 19.48 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 -176.095 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 25.9 p-10 -64.98 -19.67 66.1 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.043 -1.269 . . . . 0.0 110.634 -174.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.52 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 95.8 mt -60.01 140.25 56.9 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.216 -0.928 . . . . 0.0 110.923 -177.056 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.467 ' O ' HD23 ' A' ' 12' ' ' LEU . 75.9 mttt -140.92 144.1 35.0 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 173.606 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.548 ' CG2' HG13 ' A' ' 15' ' ' ILE . 12.0 t -59.32 152.0 4.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 120.731 -1.231 . . . . 0.0 110.304 -173.538 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.15 -15.81 57.27 Favored Glycine 0 N--CA 1.484 1.847 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 -177.37 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 52.7 t0 -93.41 164.58 13.15 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.284 -1.127 . . . . 0.0 109.684 176.104 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.587 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.3 m95 -115.4 168.15 10.24 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.062 -1.023 . . . . 0.0 110.253 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.582 ' CG1' ' CB ' ' A' ' 10' ' ' ALA . 1.5 p -131.97 155.56 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.518 -0.739 . . . . 0.0 110.039 -178.878 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.53 ' N ' ' CB ' ' B' ' 72' ' ' ASN . 2.6 m-20 -80.57 109.86 15.49 Favored 'General case' 0 C--N 1.296 -1.75 0 O-C-N 121.007 -1.058 . . . . 0.0 109.12 167.725 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.47 ' CG2' ' C ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -109.76 138.62 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.577 -1.327 . . . . 0.0 111.232 -175.301 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -137.02 138.53 40.57 Favored 'General case' 0 N--CA 1.494 1.741 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.801 -178.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . 0.446 ' HG3' ' HE1' ' A' ' 32' ' ' MET . 83.9 mtm180 -78.41 142.33 37.67 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.958 -1.089 . . . . 0.0 110.951 -176.14 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.47 ' O ' ' OG ' ' A' ' 41' ' ' SER . . . -134.43 148.04 50.55 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.387 -0.82 . . . . 0.0 110.133 176.876 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -136.28 148.36 47.96 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.668 -0.645 . . . . 0.0 110.638 -177.307 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . 0.427 ' HE2' ' CE2' ' A' ' 90' ' ' PHE . 0.7 OUTLIER -70.0 -31.14 68.67 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.338 -0.851 . . . . 0.0 110.623 177.966 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.541 ' CD1' ' C ' ' A' ' 90' ' ' PHE . 7.6 p90 -143.11 160.0 41.22 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.908 -1.12 . . . . 0.0 110.343 173.578 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 15.2 t -154.4 150.05 27.49 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.316 -0.865 . . . . 0.0 110.56 179.334 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -68.28 -40.01 81.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.354 -0.842 . . . . 0.0 110.226 176.371 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -104.42 50.19 0.8 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.377 -0.827 . . . . 0.0 110.582 -173.408 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 22.9 mm -59.98 -40.1 82.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.449 -0.782 . . . . 0.0 110.002 175.12 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 110.16 -51.59 0.69 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 177.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 66.33 -142.61 43.01 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.206 -1.173 . . . . 0.0 110.198 -177.833 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 92.9 mmm . . . . . 0 N--CA 1.492 1.642 0 CA-C-O 121.24 0.543 . . . . 0.0 110.219 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.586 ' CD1' ' O ' ' B' ' 2' ' ' PHE . 10.3 p90 -171.52 144.04 1.86 Allowed 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.351 -0.843 . . . . 0.0 109.139 177.504 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.528 ' CB ' HG12 ' B' ' 5' ' ' ILE . 6.7 p -141.03 -37.41 0.44 Allowed 'General case' 0 C--N 1.298 -1.667 0 O-C-N 120.998 -1.064 . . . . 0.0 109.061 -178.198 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.464 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 46.29 25.66 2.01 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 -176.406 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.535 HD11 ' C9 ' ' A' ' 98' ' ' RBF . 41.6 mm -76.66 122.79 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.463 -1.021 . . . . 0.0 109.795 -177.051 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.53 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 1.7 t -86.14 139.07 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.225 -0.922 . . . . 0.0 110.78 -170.431 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 79.3 mm-40 -70.05 -34.63 73.46 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.79 -0.569 . . . . 0.0 110.842 178.284 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.53 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -158.56 179.01 34.53 Favored Glycine 0 N--CA 1.494 2.553 0 C-N-CA 119.048 -1.548 . . . . 0.0 110.227 -173.101 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.469 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 1.0 OUTLIER -118.45 170.03 9.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.094 -1.239 . . . . 0.0 110.976 -177.851 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.575 ' CB ' ' CG1' ' B' ' 82' ' ' VAL . . . -136.55 149.85 48.31 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.671 -0.643 . . . . 0.0 109.381 -179.329 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.588 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 39.8 tttt -110.65 117.98 34.96 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.048 -1.033 . . . . 0.0 110.39 -179.439 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.509 ' CG ' ' HA ' ' B' ' 78' ' ' VAL . 10.9 tp -60.33 126.13 26.32 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.037 -1.039 . . . . 0.0 109.085 172.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.594 HG12 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -125.65 -31.54 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 O-C-N 121.442 -0.786 . . . . 0.0 109.684 179.488 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.23 143.15 30.11 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 119.516 -0.874 . . . . 0.0 111.092 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.571 HG12 ' CD2' ' B' ' 24' ' ' HIS . 17.8 mt -106.67 134.88 47.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.005 -1.06 . . . . 0.0 110.03 171.046 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.499 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 55.7 m-20 -107.54 115.88 30.94 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.28 -0.888 . . . . 0.0 109.898 174.079 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -107.05 111.78 24.41 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.035 -1.04 . . . . 0.0 110.428 -176.342 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.465 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 8.2 mtmm -109.02 131.27 21.9 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.259 -0.901 . . . . 0.0 109.288 175.623 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -51.11 -23.02 11.86 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 O-C-N 123.868 1.457 . . . . 0.0 111.061 -179.209 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.571 ' O ' ' CD1' ' B' ' 21' ' ' PHE . 7.4 m-80 -92.46 -34.22 14.2 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.065 -1.022 . . . . 0.0 109.879 177.827 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.571 ' CD1' ' O ' ' B' ' 20' ' ' ASN . 36.3 m-85 -147.7 150.23 33.93 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.431 -0.793 . . . . 0.0 110.026 -177.36 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.489 ' NH1' HD21 ' B' ' 68' ' ' LEU . 60.3 ttt180 -95.74 143.53 26.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.756 -1.215 . . . . 0.0 110.058 173.559 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.499 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 55.9 m -132.59 145.61 51.24 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.503 -0.748 . . . . 0.0 110.029 -176.135 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.571 ' CD2' HG12 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -134.04 134.09 41.98 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.085 -1.009 . . . . 0.0 111.197 -179.517 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.53 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 5.4 t -113.68 133.0 61.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.207 -0.933 . . . . 0.0 110.778 -177.41 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.471 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 13.2 m -119.05 170.94 7.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-O 121.232 0.539 . . . . 0.0 110.268 -179.067 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.451 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 15.3 tt0 -100.03 116.71 32.71 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 177.714 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.567 ' CD1' ' CB ' ' B' ' 32' ' ' MET . 0.0 OUTLIER -86.11 118.35 70.28 Favored Pre-proline 0 C--N 1.295 -1.804 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 -175.422 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.49 ' HD2' ' CD1' ' B' ' 28' ' ' LEU . 19.5 Cg_endo -63.13 170.75 7.22 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 O-C-N 123.802 1.422 . . . . 0.0 110.96 -178.525 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.499 ' OD1' ' N ' ' B' ' 31' ' ' HIS . 34.1 p-10 -61.28 -35.74 78.15 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.47 -0.769 . . . . 0.0 110.873 -175.741 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.572 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.74 -0.48 57.72 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.783 -1.198 . . . . 0.0 110.839 -173.487 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.572 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.9 mmm -116.64 -11.22 11.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.857 -1.152 . . . . 0.0 109.984 169.509 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.538 ' CD2' ' HB3' ' B' ' 28' ' ' LEU . 13.2 mt -65.68 -38.02 88.1 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.013 -1.054 . . . . 0.0 109.626 175.165 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -68.99 132.27 46.39 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.549 -0.719 . . . . 0.0 110.792 -177.404 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.1 -40.16 2.8 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 110.346 -1.102 . . . . 0.0 110.346 174.061 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . 0.459 ' CD2' HD21 ' B' ' 28' ' ' LEU . 59.0 tp -69.13 145.49 53.3 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.045 -1.268 . . . . 0.0 110.726 -175.302 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.468 ' O ' ' HB2' ' B' ' 40' ' ' ALA . 16.8 pt-20 -147.98 169.1 20.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.506 -0.746 . . . . 0.0 109.423 177.473 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.534 ' CG2' HD12 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -64.66 148.48 50.89 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.939 -1.101 . . . . 0.0 109.859 178.298 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.57 -4.67 63.44 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -176.464 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.468 ' HB2' ' O ' ' B' ' 37' ' ' GLU . . . -74.49 158.98 32.86 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.121 -1.223 . . . . 0.0 109.492 176.474 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.477 ' CB ' ' HB2' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -100.37 117.21 34.09 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 120.94 -1.1 . . . . 0.0 110.029 176.584 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.57 HG13 ' CE1' ' B' ' 44' ' ' HIS . 2.1 t -105.96 126.28 61.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.383 -0.823 . . . . 0.0 109.105 175.316 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.474 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -89.7 118.64 29.46 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 119.133 -1.027 . . . . 0.0 109.114 172.351 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.57 ' CE1' HG13 ' B' ' 42' ' ' VAL . 0.4 OUTLIER -88.77 100.72 13.36 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 176.994 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.536 ' N ' ' O ' ' B' ' 83' ' ' ASN . 1.9 t-20 59.88 8.79 1.49 Allowed 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.53 -0.731 . . . . 0.0 110.987 -168.642 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.491 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 128.68 -12.65 6.21 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.583 -1.294 . . . . 0.0 110.818 174.151 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.474 ' O ' ' HA ' ' B' ' 43' ' ' ALA . 41.7 t -85.97 109.94 19.12 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.259 -1.73 . . . . 0.0 109.757 179.151 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . 0.476 ' O ' ' C5A' ' B' ' 99' ' ' RBF . 19.4 p -77.54 113.44 15.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.227 -0.92 . . . . 0.0 110.969 -172.465 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.468 ' CD2' ' O ' ' B' ' 47' ' ' CYS . 0.2 OUTLIER -130.46 161.1 32.17 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.355 -0.841 . . . . 0.0 109.129 172.521 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 50' ' ' THR . . . . . 0.483 HG22 ' N ' ' B' ' 51' ' ' VAL . 57.5 m -103.76 155.2 18.78 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.545 -1.347 . . . . 0.0 111.277 -168.841 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.552 ' CG1' HG12 ' B' ' 59' ' ' VAL . 21.2 t -77.62 112.79 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.606 -0.683 . . . . 0.0 110.415 -179.525 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.538 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 17.7 p -69.93 -40.05 75.77 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.16 -0.963 . . . . 0.0 109.512 172.339 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.468 ' HA ' HG22 ' B' ' 38' ' ' THR . 86.0 tt0 -158.5 153.74 25.61 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.757 -177.753 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.534 HD12 ' CG2' ' B' ' 38' ' ' THR . 13.7 mt -110.23 130.03 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.205 -0.934 . . . . 0.0 109.908 172.738 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.466 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 9.6 m-80 -103.73 63.64 0.78 Allowed 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.943 -0.703 . . . . 0.0 109.692 178.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.77 -112.5 3.55 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 108.638 -1.785 . . . . 0.0 108.638 -173.625 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.487 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.07 -22.64 42.04 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.865 -1.373 . . . . 0.0 108.873 174.206 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.594 ' CD2' HG12 ' B' ' 13' ' ' VAL . 9.0 m170 -74.42 158.53 33.72 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.175 -0.953 . . . . 0.0 110.263 -176.278 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.587 ' CG1' ' CZ ' ' B' ' 61' ' ' PHE . 79.9 t -141.26 119.72 9.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 C-N-CA 119.158 -1.017 . . . . 0.0 110.817 175.86 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.53 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 15.9 m -88.69 126.4 35.29 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.617 -0.677 . . . . 0.0 109.73 178.679 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.587 ' CZ ' ' CG1' ' B' ' 59' ' ' VAL . 98.0 m-85 -110.08 156.49 20.49 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.867 -1.146 . . . . 0.0 110.374 179.554 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.538 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 19.8 p-10 -89.72 148.2 23.41 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.209 -0.932 . . . . 0.0 110.9 178.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.528 HD22 ' CD1' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -155.51 116.72 3.94 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -176.585 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.497 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 93.1 mmm -70.04 141.67 52.84 Favored 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 119.119 -1.032 . . . . 0.0 109.552 179.683 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.409 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 46.8 tttp -60.06 -45.08 94.05 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.172 -0.955 . . . . 0.0 110.119 -176.7 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . 0.441 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 86.5 tt0 -69.38 -40.0 77.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.102 -0.999 . . . . 0.0 110.333 177.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.497 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 89.2 m -61.73 -39.6 92.13 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.959 -1.088 . . . . 0.0 109.16 174.148 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.497 ' HG ' ' CA ' ' B' ' 74' ' ' GLY . 7.7 tp -59.98 -43.41 95.15 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.562 -0.711 . . . . 0.0 109.47 178.077 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 92.7 mtt180 -69.96 -39.98 75.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.449 -0.782 . . . . 0.0 110.67 175.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.467 HG22 HG22 ' B' ' 71' ' ' THR . 1.3 tt -70.06 -41.35 79.17 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.278 -0.889 . . . . 0.0 109.52 -176.131 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.469 HG22 ' O ' ' B' ' 67' ' ' THR . 65.5 p -83.56 -173.81 4.93 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 177.983 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.53 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 3.1 t30 -100.78 22.66 11.68 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 170.827 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.528 ' CD1' HD22 ' B' ' 63' ' ' LEU . 96.9 mt -69.96 -40.09 75.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.116 -0.99 . . . . 0.0 110.071 174.665 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.497 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -53.01 -24.34 19.93 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 110.409 -1.077 . . . . 0.0 110.409 -176.127 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.1 p-10 -64.97 -19.65 66.09 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.116 -1.226 . . . . 0.0 110.632 -174.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.521 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 95.8 mt -60.02 140.19 56.95 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.187 -0.946 . . . . 0.0 110.901 -177.065 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.463 ' O ' HD23 ' B' ' 12' ' ' LEU . 76.0 mttt -140.92 144.1 34.99 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 173.607 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.554 ' CG2' HG13 ' B' ' 15' ' ' ILE . 12.1 t -59.34 151.95 4.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 120.76 -1.213 . . . . 0.0 110.335 -173.519 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.18 -15.72 57.54 Favored Glycine 0 N--CA 1.484 1.847 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 -177.396 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 52.6 t0 -93.47 164.4 13.21 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.432 -1.04 . . . . 0.0 109.675 176.043 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.588 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.2 m95 -115.28 168.16 10.21 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.132 -0.98 . . . . 0.0 110.373 178.312 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.575 ' CG1' ' CB ' ' B' ' 10' ' ' ALA . 1.5 p -132.04 155.55 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.547 -0.721 . . . . 0.0 109.965 -178.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.536 ' O ' ' N ' ' B' ' 45' ' ' ASN . 2.5 m-20 -80.4 109.67 15.12 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.009 -1.057 . . . . 0.0 109.174 167.729 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.469 ' CG2' ' C ' ' B' ' 9' ' ' THR . 0.0 OUTLIER -109.45 138.95 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 120.66 -1.275 . . . . 0.0 111.138 -175.233 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -137.48 138.51 39.8 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.894 -0.504 . . . . 0.0 109.724 -179.056 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 83.9 mtm180 -78.35 142.44 37.68 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.042 -1.036 . . . . 0.0 110.917 -176.062 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.573 ' HB2' ' CZ ' ' A' ' 2' ' ' PHE . . . -134.49 148.07 50.49 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.359 -0.838 . . . . 0.0 110.103 176.824 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -136.29 148.39 47.95 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.562 -0.711 . . . . 0.0 110.644 -177.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . 0.418 ' HE2' ' CE2' ' B' ' 90' ' ' PHE . 0.7 OUTLIER -70.01 -31.11 68.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.3 -0.875 . . . . 0.0 110.654 177.947 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . 0.541 ' CD1' ' C ' ' B' ' 90' ' ' PHE . 7.6 p90 -143.06 159.98 41.25 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.86 -1.15 . . . . 0.0 110.404 173.621 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 91' ' ' SER . . . . . . . . . . . . . 15.8 t -154.46 150.08 27.46 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.399 -0.813 . . . . 0.0 110.528 179.351 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . 0.497 ' O ' ' CG ' ' B' ' 93' ' ' GLU . 93.6 m-20 -68.32 -35.04 77.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.408 -0.807 . . . . 0.0 110.286 176.352 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . 0.497 ' CG ' ' O ' ' B' ' 92' ' ' ASP . 12.8 pt-20 36.21 52.82 0.92 Allowed 'General case' 0 N--CA 1.515 2.814 0 O-C-N 121.617 -0.677 . . . . 0.0 110.774 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . . . . . . . . . 48.1 mm -69.91 -40.13 78.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.304 -0.873 . . . . 0.0 110.399 -179.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 89.33 -44.84 3.09 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 178.513 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -116.36 -170.89 15.85 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 -179.292 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 84.6 m-70 . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.363 -1.081 . . . . 0.0 110.292 179.615 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.547 " C2'" ' HC9' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.551 " C2'" ' HC9' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.466 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 26.4 ptm . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.105 0.478 . . . . 0.0 110.168 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.644 ' CZ ' ' CB ' ' B' ' 87' ' ' ALA . 8.0 p90 -179.27 143.62 0.21 Allowed 'General case' 0 C--N 1.307 -1.26 0 O-C-N 121.231 -0.918 . . . . 0.0 108.733 176.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.48 ' O ' HG13 ' A' ' 5' ' ' ILE . 73.7 p -135.72 -41.48 0.69 Allowed 'General case' 0 C--N 1.293 -1.853 0 O-C-N 120.959 -1.088 . . . . 0.0 108.55 179.721 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.476 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 49.67 22.77 4.34 Favored Glycine 0 N--CA 1.482 1.718 0 N-CA-C 108.454 -1.858 . . . . 0.0 108.454 -175.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.515 ' CD1' HC82 ' B' ' 99' ' ' RBF . 57.2 mt -84.59 120.26 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.208 -1.172 . . . . 0.0 110.116 -176.647 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.538 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.4 t -72.55 149.97 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.292 -0.88 . . . . 0.0 110.611 -175.426 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.436 ' OE1' ' HG2' ' A' ' 86' ' ' ARG . 18.2 pt20 -93.34 -23.81 18.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.55 -0.719 . . . . 0.0 110.787 179.266 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.538 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -150.52 173.99 29.98 Favored Glycine 0 N--CA 1.493 2.487 0 C-N-CA 119.328 -1.415 . . . . 0.0 109.758 -175.485 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.478 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 2.2 p -123.37 170.83 9.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.845 -1.386 . . . . 0.0 110.981 -177.436 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.52 ' CB ' HG13 ' A' ' 82' ' ' VAL . . . -139.33 149.46 44.22 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.562 -0.711 . . . . 0.0 109.259 -179.649 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.578 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 33.3 tttt -106.73 115.43 30.19 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 120.908 -1.12 . . . . 0.0 110.254 179.535 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.523 ' CG ' ' HA ' ' A' ' 78' ' ' VAL . 12.2 tp -58.55 127.19 30.91 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 120.82 -1.175 . . . . 0.0 108.688 173.329 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.613 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.6 p -130.05 -30.14 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.898 0 O-C-N 121.345 -0.847 . . . . 0.0 109.946 -177.844 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -145.1 140.44 28.04 Favored 'General case' 0 N--CA 1.494 1.735 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.974 -179.439 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.576 HG13 ' CG2' ' A' ' 78' ' ' VAL . 13.9 mt -107.53 131.11 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 120.991 -1.068 . . . . 0.0 110.185 172.339 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.486 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.7 m-20 -108.53 114.87 29.04 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.384 -0.823 . . . . 0.0 109.873 174.692 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -107.11 112.38 25.27 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.002 -1.061 . . . . 0.0 110.522 -176.129 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.472 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 6.1 mtmt -107.94 129.93 23.48 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.219 -0.926 . . . . 0.0 109.177 175.24 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_endo -51.85 -24.47 18.73 Favored 'Trans proline' 0 C--N 1.303 -1.864 0 O-C-N 123.779 1.41 . . . . 0.0 110.279 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 10.7 m-80 -81.2 -39.74 24.95 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.24 -0.913 . . . . 0.0 110.182 175.417 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 95.1 m-85 -156.68 150.22 24.52 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.433 -0.792 . . . . 0.0 109.971 -178.873 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.48 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 59.6 ttt180 -91.93 145.13 24.79 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.807 -1.183 . . . . 0.0 110.327 178.771 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.486 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 74.9 m -129.98 140.02 50.97 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.583 -0.698 . . . . 0.0 109.718 -176.156 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.576 ' CD2' HG22 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -128.74 128.32 43.79 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.858 -1.152 . . . . 0.0 111.324 178.184 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.529 ' CG2' ' OG ' ' A' ' 60' ' ' SER . 4.3 t -104.95 131.42 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.283 -0.886 . . . . 0.0 110.695 -178.108 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.466 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 33.4 m -115.91 168.16 7.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 O-C-N 121.962 -0.461 . . . . 0.0 109.963 179.427 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.458 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 2.5 tm-20 -101.11 115.31 30.19 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.305 -0.872 . . . . 0.0 109.409 178.538 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.517 HD21 ' CD1' ' A' ' 36' ' ' LEU . 9.8 tp -79.15 125.33 83.74 Favored Pre-proline 0 C--N 1.295 -1.804 0 O-C-N 121.617 -0.677 . . . . 0.0 109.868 -176.543 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.467 ' HG3' ' O ' ' A' ' 9' ' ' THR . 27.7 Cg_endo -67.5 -179.16 1.79 Allowed 'Trans proline' 0 C--N 1.309 -1.552 0 O-C-N 123.894 1.471 . . . . 0.0 110.826 -179.54 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.502 ' OD1' ' N ' ' A' ' 31' ' ' HIS . 32.3 p-10 -64.85 -40.02 94.5 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.322 -0.861 . . . . 0.0 110.952 -175.56 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.574 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.01 1.32 56.44 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.939 -1.101 . . . . 0.0 110.987 -174.037 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.574 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 98.7 mmm -112.17 -14.14 13.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.854 -1.154 . . . . 0.0 109.871 171.411 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.53 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 19.2 mt -69.93 -20.38 63.34 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.39 -0.818 . . . . 0.0 110.437 176.203 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -61.0 123.05 16.5 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.088 -1.007 . . . . 0.0 111.286 -171.276 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 48.92 54.72 13.29 Favored Glycine 0 N--CA 1.493 2.498 0 C-N-CA 120.339 -0.934 . . . . 0.0 111.015 169.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.517 ' CD1' HD21 ' A' ' 28' ' ' LEU . 6.4 tt -113.25 155.44 25.07 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.83 -1.394 . . . . 0.0 110.181 174.131 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 21.3 pt-20 -149.95 167.85 25.48 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.221 -0.924 . . . . 0.0 110.139 -178.207 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.543 ' CG2' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -68.09 155.27 39.92 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.212 -0.93 . . . . 0.0 109.754 177.539 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.56 -8.86 63.63 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.744 -1.343 . . . . 0.0 109.744 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.42 ' HB2' HG23 ' A' ' 51' ' ' VAL . . . -75.37 159.91 30.88 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.11 -1.229 . . . . 0.0 109.753 178.126 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.468 ' HB2' ' HB2' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -105.2 120.2 40.95 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.831 -1.168 . . . . 0.0 110.309 -179.416 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.581 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 1.6 t -109.95 132.51 58.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.328 -0.858 . . . . 0.0 109.193 172.74 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.467 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -92.38 119.95 32.42 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.145 -0.972 . . . . 0.0 109.337 172.59 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.575 ' CE1' HG12 ' A' ' 42' ' ' VAL . 0.4 OUTLIER -89.83 106.92 18.79 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.402 -0.811 . . . . 0.0 109.109 177.865 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.493 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.6 t-20 52.57 17.59 0.82 Allowed 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.39 -0.819 . . . . 0.0 110.503 -166.5 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.49 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 116.35 -4.81 19.77 Favored Glycine 0 N--CA 1.487 2.084 0 C-N-CA 119.64 -1.267 . . . . 0.0 110.831 170.219 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.525 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 17.3 t -90.08 109.84 20.87 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.345 -1.679 . . . . 0.0 109.084 174.491 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.444 ' HA ' ' HA ' ' A' ' 43' ' ' ALA . 27.5 p -77.68 124.89 28.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.996 -1.065 . . . . 0.0 110.691 -172.397 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.53 ' CB ' ' O4 ' ' A' ' 98' ' ' RBF . 0.2 OUTLIER -136.85 166.38 23.74 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.353 -0.842 . . . . 0.0 108.945 172.128 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.457 ' O ' ' OD1' ' A' ' 62' ' ' ASP . 54.9 m -103.13 154.18 19.56 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.574 -1.329 . . . . 0.0 111.146 -169.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.554 ' CG1' HG11 ' A' ' 59' ' ' VAL . 7.0 t -74.67 113.26 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.899 -0.5 . . . . 0.0 110.034 -179.294 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.579 ' CG2' ' N ' ' A' ' 62' ' ' ASP . 19.0 p -75.3 -43.59 50.21 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.365 -0.835 . . . . 0.0 109.57 176.209 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.433 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -158.36 150.53 21.77 Favored 'General case' 0 N--CA 1.491 1.621 0 C-N-CA 119.576 -0.85 . . . . 0.0 110.335 179.246 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.543 HD11 ' CG2' ' A' ' 38' ' ' THR . 2.5 mp -108.18 132.3 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.225 -0.922 . . . . 0.0 110.304 175.975 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.451 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 54.9 m-80 -108.26 66.24 0.65 Allowed 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.662 -0.649 . . . . 0.0 109.541 177.824 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.44 -119.36 5.79 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 108.794 -1.722 . . . . 0.0 108.794 -173.112 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.53 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -77.12 -17.71 58.46 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.016 -1.285 . . . . 0.0 109.009 176.084 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.613 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 9.1 m170 -77.57 160.09 28.82 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.312 -0.867 . . . . 0.0 110.419 -178.447 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.589 HG12 ' CE2' ' A' ' 61' ' ' PHE . 94.1 t -145.16 117.83 2.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 C-N-CA 119.379 -0.928 . . . . 0.0 110.879 175.423 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.529 ' OG ' ' CG2' ' A' ' 25' ' ' VAL . 19.6 m -81.92 125.3 30.58 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.529 -0.732 . . . . 0.0 109.592 175.953 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.589 ' CE2' HG12 ' A' ' 59' ' ' VAL . 82.9 m-85 -110.03 154.78 22.73 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.898 -1.127 . . . . 0.0 110.23 178.73 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.579 ' N ' ' CG2' ' A' ' 52' ' ' THR . 9.1 p-10 -89.54 148.18 23.53 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.132 -0.98 . . . . 0.0 111.265 -176.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.548 ' CD2' ' CD1' ' A' ' 68' ' ' LEU . 0.0 OUTLIER -159.16 102.2 1.6 Allowed 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.705 -0.622 . . . . 0.0 109.485 -175.363 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.486 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 54.5 ttm -59.98 140.16 56.93 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.892 -1.13 . . . . 0.0 109.47 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.473 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 22.0 tptm -60.05 -43.45 95.38 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.027 -1.046 . . . . 0.0 110.315 -174.472 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.68 -39.96 76.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.974 -1.079 . . . . 0.0 110.012 177.695 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.486 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 93.7 m -60.95 -38.39 85.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.996 -1.065 . . . . 0.0 109.294 173.135 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.548 ' CD1' ' CD2' ' A' ' 63' ' ' LEU . 7.1 tp -59.96 -45.71 91.8 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.325 -0.859 . . . . 0.0 109.746 178.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 76.5 ttt-85 -69.32 -39.67 78.07 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.428 -0.795 . . . . 0.0 110.438 177.739 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.467 HG21 HG22 ' A' ' 71' ' ' THR . 1.3 tt -64.65 -41.57 92.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.171 -0.955 . . . . 0.0 109.434 -176.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.473 HG22 ' O ' ' A' ' 67' ' ' THR . 42.0 p -85.25 -174.62 5.33 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 175.906 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.481 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 2.6 t30 -101.11 21.82 13.29 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 171.624 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.464 HD13 HD23 ' A' ' 63' ' ' LEU . 41.9 mt -69.99 -40.05 75.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.012 -1.055 . . . . 0.0 110.304 175.122 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.525 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -48.62 -22.29 2.6 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 -178.548 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.4 p-10 -66.11 -16.49 64.0 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.137 -1.213 . . . . 0.0 110.588 -174.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 94.7 mt -59.99 141.44 55.61 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.276 -0.89 . . . . 0.0 110.763 -176.232 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.484 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 95.1 mttt -140.0 139.77 36.1 Favored 'General case' 0 N--CA 1.493 1.678 0 CA-C-O 121.337 0.589 . . . . 0.0 109.444 174.202 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.576 ' CG2' HG13 ' A' ' 15' ' ' ILE . 16.4 t -60.51 152.45 5.39 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 120.788 -1.195 . . . . 0.0 110.383 -176.225 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.0 -15.56 57.66 Favored Glycine 0 N--CA 1.484 1.86 0 N-CA-C 108.811 -1.716 . . . . 0.0 108.811 -176.045 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 9.2 t0 -95.28 165.51 12.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.347 -1.09 . . . . 0.0 109.689 175.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.578 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.5 m95 -114.55 157.2 23.33 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.058 -1.027 . . . . 0.0 110.202 177.504 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.52 HG13 ' CB ' ' A' ' 10' ' ' ALA . 1.3 p -120.04 149.34 22.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.429 -0.795 . . . . 0.0 109.843 -179.18 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.484 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 0.2 OUTLIER -75.79 104.36 6.3 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.021 -1.049 . . . . 0.0 109.43 169.286 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.517 ' CG1' ' CE1' ' A' ' 44' ' ' HIS . 0.0 OUTLIER -106.21 137.76 34.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 120.459 -1.401 . . . . 0.0 111.392 -176.943 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -130.06 144.86 51.57 Favored 'General case' 0 N--CA 1.495 1.78 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.986 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . 0.441 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 34.0 ptt180 -81.45 133.67 35.44 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.261 -0.899 . . . . 0.0 111.024 -176.235 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.569 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -131.94 145.76 51.69 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.429 -0.794 . . . . 0.0 110.176 175.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -131.43 130.66 42.8 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.509 -0.744 . . . . 0.0 110.534 -176.538 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 38.1 mttt -60.09 -39.99 88.05 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.373 -0.829 . . . . 0.0 110.46 -179.174 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 51.7 p90 -153.01 159.94 42.95 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.198 -0.939 . . . . 0.0 110.54 -179.028 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 88.3 p -132.81 149.23 52.29 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.282 -0.886 . . . . 0.0 110.087 177.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 57.1 t0 -70.1 -50.89 36.3 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.194 -0.941 . . . . 0.0 110.373 -179.219 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.479 ' O ' ' HG3' ' A' ' 93' ' ' GLU . 19.4 pt-20 -167.02 68.09 0.09 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.179 -0.951 . . . . 0.0 111.145 -175.111 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.429 ' O ' ' C ' ' A' ' 95' ' ' GLY . 33.0 mm -59.97 -45.37 95.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 120.9 -1.125 . . . . 0.0 109.875 174.834 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 94' ' ' ILE . . . 40.89 69.56 0.49 Allowed Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 176.559 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 70.51 19.93 76.67 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.876 -1.29 . . . . 0.0 109.876 176.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 11.6 t-80 . . . . . 0 N--CA 1.492 1.626 0 O-C-N 121.182 -1.187 . . . . 0.0 110.09 178.596 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 75.2 mtm . . . . . 0 N--CA 1.495 1.776 0 CA-C-O 122.232 1.015 . . . . 0.0 109.977 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.59 ' CD1' ' O ' ' B' ' 2' ' ' PHE . 8.5 p90 -174.13 143.5 0.91 Allowed 'General case' 0 C--N 1.282 -2.361 0 CA-C-N 115.154 -0.93 . . . . 0.0 108.494 172.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.478 HG21 ' C ' ' B' ' 2' ' ' PHE . 71.7 p -135.65 -41.45 0.69 Allowed 'General case' 0 C--N 1.295 -1.795 0 O-C-N 120.904 -1.122 . . . . 0.0 108.633 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.483 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 49.72 22.78 4.43 Favored Glycine 0 N--CA 1.481 1.652 0 N-CA-C 108.466 -1.853 . . . . 0.0 108.466 -176.054 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.475 HG13 ' O ' ' B' ' 3' ' ' THR . 56.7 mt -84.67 120.28 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.238 -1.154 . . . . 0.0 110.092 -176.63 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.536 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.4 t -72.51 150.08 8.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.435 -0.791 . . . . 0.0 110.628 -175.45 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.433 ' OE1' ' HG2' ' B' ' 86' ' ' ARG . 18.2 pt20 -93.48 -23.61 18.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.508 -0.745 . . . . 0.0 110.834 179.264 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.536 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -150.62 173.87 30.09 Favored Glycine 0 N--CA 1.493 2.498 0 C-N-CA 119.396 -1.383 . . . . 0.0 109.911 -175.553 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.479 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 2.2 p -123.3 170.83 9.9 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.001 -1.293 . . . . 0.0 110.932 -177.386 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.521 ' CB ' HG13 ' B' ' 82' ' ' VAL . . . -139.33 149.54 44.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.592 -0.693 . . . . 0.0 109.165 -179.634 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 33.4 tttt -106.82 115.58 30.43 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.045 -1.034 . . . . 0.0 110.139 179.554 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.53 ' CG ' ' HA ' ' B' ' 78' ' ' VAL . 12.2 tp -58.84 127.09 30.47 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.013 -1.054 . . . . 0.0 108.721 173.351 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.605 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.6 p -129.83 -30.27 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.983 0 O-C-N 121.421 -0.8 . . . . 0.0 110.031 -177.783 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -145.14 140.46 28.0 Favored 'General case' 0 C--N 1.297 -1.676 0 C-N-CA 119.499 -0.881 . . . . 0.0 110.979 -179.46 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.574 HG13 ' CG2' ' B' ' 78' ' ' VAL . 13.9 mt -107.51 131.01 58.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 120.918 -1.114 . . . . 0.0 110.266 172.357 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.493 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 77.6 m-20 -108.63 114.94 29.15 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.451 -0.781 . . . . 0.0 109.919 174.728 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 87.1 tt0 -107.0 112.31 25.2 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.1 -1.0 . . . . 0.0 110.524 -176.04 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.468 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 6.1 mtmt -107.86 129.94 23.47 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.229 -0.919 . . . . 0.0 109.241 175.143 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -51.9 -24.44 18.9 Favored 'Trans proline' 0 C--N 1.303 -1.833 0 O-C-N 123.73 1.384 . . . . 0.0 110.187 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.554 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 10.6 m-80 -81.18 -40.03 24.54 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.206 -0.934 . . . . 0.0 110.127 175.411 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.554 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 95.2 m-85 -156.41 150.33 25.04 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.456 -0.778 . . . . 0.0 109.964 -178.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.471 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 59.6 ttt180 -91.95 145.07 24.83 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.884 -1.135 . . . . 0.0 110.327 178.754 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.493 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 78.3 m -130.02 139.98 50.94 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.677 -0.64 . . . . 0.0 109.757 -176.183 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.562 ' CD2' HG12 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -128.54 128.34 44.11 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.94 -1.1 . . . . 0.0 111.322 178.319 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.519 ' CG2' ' OG ' ' B' ' 60' ' ' SER . 4.3 t -104.94 131.65 53.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.384 -0.822 . . . . 0.0 110.638 -178.135 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.479 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 33.5 m -116.22 168.09 8.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.973 -0.455 . . . . 0.0 109.788 179.546 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.455 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 2.5 tm-20 -101.05 115.42 30.45 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.27 -0.894 . . . . 0.0 109.409 178.468 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.531 ' HB3' ' CD2' ' B' ' 33' ' ' LEU . 9.8 tp -79.2 125.3 83.68 Favored Pre-proline 0 C--N 1.296 -1.753 0 O-C-N 121.538 -0.727 . . . . 0.0 109.878 -176.546 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.467 ' HD2' HD11 ' B' ' 28' ' ' LEU . 27.9 Cg_endo -67.49 -179.23 1.83 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.788 1.415 . . . . 0.0 110.806 -179.538 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.493 ' OD1' ' N ' ' B' ' 31' ' ' HIS . 32.2 p-10 -64.85 -39.97 94.41 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.384 -0.823 . . . . 0.0 110.94 -175.49 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.576 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.99 1.25 56.51 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.886 -1.134 . . . . 0.0 110.954 -174.01 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.576 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 98.6 mmm -112.19 -14.12 13.42 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.902 -1.124 . . . . 0.0 109.881 171.479 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.541 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 19.6 mt -69.96 -20.31 63.33 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.398 -0.814 . . . . 0.0 110.484 176.17 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -61.03 123.0 16.37 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.117 -0.989 . . . . 0.0 111.263 -171.262 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 48.95 54.84 12.89 Favored Glycine 0 N--CA 1.493 2.448 0 O-C-N 121.208 -0.932 . . . . 0.0 110.927 169.675 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . 0.529 ' CD1' HD23 ' B' ' 28' ' ' LEU . 6.4 tt -113.34 155.52 25.03 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.728 -1.454 . . . . 0.0 110.091 174.15 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . . . . . . . . . 21.3 pt-20 -150.06 167.77 25.82 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.106 -0.996 . . . . 0.0 110.203 -178.211 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.53 ' CG2' HD11 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -67.99 155.15 40.1 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.309 -0.869 . . . . 0.0 109.811 177.55 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.62 -8.82 64.0 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.549 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.407 ' HB1' HG21 ' B' ' 51' ' ' VAL . . . -75.57 159.81 30.84 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.144 -1.21 . . . . 0.0 109.762 178.101 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.466 ' HB2' ' HB1' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -104.97 119.93 40.22 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.882 -1.136 . . . . 0.0 110.467 -179.357 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.572 ' HB ' ' CE1' ' B' ' 61' ' ' PHE . 1.6 t -109.94 132.6 57.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.424 -0.797 . . . . 0.0 109.219 172.754 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.47 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -92.34 120.04 32.49 Favored 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.133 -0.98 . . . . 0.0 109.407 172.532 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.578 ' CG ' HG23 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -89.85 107.03 18.86 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.382 -0.824 . . . . 0.0 109.074 177.832 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.493 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.6 t-20 52.5 17.63 0.81 Allowed 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.348 -0.845 . . . . 0.0 110.535 -166.558 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.49 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 116.26 -4.69 19.98 Favored Glycine 0 N--CA 1.488 2.127 0 C-N-CA 119.626 -1.273 . . . . 0.0 110.864 170.192 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.534 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 17.2 t -90.09 109.78 20.82 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.294 -1.709 . . . . 0.0 109.13 174.423 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . 0.449 ' HA ' ' HA ' ' B' ' 43' ' ' ALA . 27.6 p -77.6 124.93 28.57 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.937 -1.102 . . . . 0.0 110.742 -172.473 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.534 ' CD2' ' O ' ' B' ' 47' ' ' CYS . 0.2 OUTLIER -136.92 166.27 24.02 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.381 -0.825 . . . . 0.0 108.943 172.114 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 50' ' ' THR . . . . . 0.456 ' O ' ' OD1' ' B' ' 62' ' ' ASP . 55.5 m -102.94 154.33 19.33 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.633 -1.292 . . . . 0.0 111.201 -169.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.55 ' CG1' HG11 ' B' ' 59' ' ' VAL . 7.1 t -74.88 113.29 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 CA-C-O 121.249 0.547 . . . . 0.0 110.053 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.578 ' CG2' ' N ' ' B' ' 62' ' ' ASP . 19.0 p -75.29 -43.49 50.78 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.292 -0.88 . . . . 0.0 109.599 176.258 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.444 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -158.5 150.46 21.45 Favored 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.391 179.204 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.53 HD11 ' CG2' ' B' ' 38' ' ' THR . 2.5 mp -108.14 132.33 56.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.209 -0.932 . . . . 0.0 110.295 176.087 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.469 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 54.7 m-80 -108.33 66.19 0.64 Allowed 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 120.168 -0.613 . . . . 0.0 109.495 177.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.57 -119.31 5.74 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 -173.127 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.541 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -77.17 -17.85 58.26 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.965 -1.315 . . . . 0.0 108.946 176.112 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.605 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 9.1 m170 -77.49 160.02 28.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.468 -0.77 . . . . 0.0 110.436 -178.453 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.587 HG12 ' CE2' ' B' ' 61' ' ' PHE . 94.3 t -145.1 117.79 2.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 C-N-CA 119.329 -0.949 . . . . 0.0 110.874 175.527 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.519 ' OG ' ' CG2' ' B' ' 25' ' ' VAL . 19.7 m -82.03 125.36 30.72 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.618 -0.676 . . . . 0.0 109.622 176.037 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.587 ' CE2' HG12 ' B' ' 59' ' ' VAL . 83.0 m-85 -110.0 154.88 22.55 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 120.915 -1.116 . . . . 0.0 110.25 178.708 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.578 ' N ' ' CG2' ' B' ' 52' ' ' THR . 9.1 p-10 -89.57 148.29 23.46 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 120.984 -1.072 . . . . 0.0 111.192 -176.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.546 ' CD2' ' CD1' ' B' ' 68' ' ' LEU . 0.0 OUTLIER -159.22 102.11 1.59 Allowed 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 -175.361 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.484 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 54.5 ttm -59.99 140.15 56.95 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.968 -1.082 . . . . 0.0 109.476 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.471 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 22.0 tptm -60.04 -43.37 95.39 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.118 -0.989 . . . . 0.0 110.4 -174.456 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.67 -39.97 76.69 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.034 -1.041 . . . . 0.0 110.149 177.612 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.491 ' O ' HG22 ' B' ' 71' ' ' THR . 93.1 m -60.77 -38.6 85.81 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.97 -1.081 . . . . 0.0 109.329 173.002 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.546 ' CD1' ' CD2' ' B' ' 63' ' ' LEU . 7.1 tp -59.95 -45.45 92.59 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.324 -0.86 . . . . 0.0 109.89 178.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 76.5 ttt-85 -69.41 -39.63 77.8 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.526 -0.734 . . . . 0.0 110.451 177.66 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.484 HG23 HG22 ' B' ' 71' ' ' THR . 1.3 tt -64.72 -41.48 92.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.302 -0.873 . . . . 0.0 109.486 -176.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.491 HG22 ' O ' ' B' ' 67' ' ' THR . 40.7 p -85.1 -174.52 5.3 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.279 175.813 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.47 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 2.7 t30 -101.1 21.8 13.31 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 171.482 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.464 ' HB3' HD22 ' B' ' 63' ' ' LEU . 41.3 mt -70.06 -39.95 75.36 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.07 -1.019 . . . . 0.0 110.232 175.239 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.521 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -48.7 -22.36 2.72 Favored Glycine 0 N--CA 1.486 1.98 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -178.505 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.2 p-10 -65.93 -16.52 63.94 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.161 -1.199 . . . . 0.0 110.624 -174.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 94.2 mt -60.01 141.4 55.73 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.126 -0.984 . . . . 0.0 110.829 -176.217 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.486 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 95.1 mttt -139.96 139.82 36.18 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.734 -0.604 . . . . 0.0 109.397 174.196 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.574 ' CG2' HG13 ' B' ' 15' ' ' ILE . 16.4 t -60.55 152.46 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.989 -1.069 . . . . 0.0 110.357 -176.205 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.88 -15.25 58.19 Favored Glycine 0 N--CA 1.484 1.846 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 -176.088 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.481 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 9.1 t0 -95.44 165.32 12.42 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.402 -1.058 . . . . 0.0 109.706 175.768 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.6 m95 -114.46 157.24 23.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.147 -0.971 . . . . 0.0 110.288 177.441 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.578 HG23 ' CG ' ' B' ' 44' ' ' HIS . 1.3 p -120.06 149.34 22.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.688 -0.632 . . . . 0.0 109.871 -179.181 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.479 ' OD1' ' N ' ' A' ' 72' ' ' ASN . 0.2 OUTLIER -75.78 104.18 6.21 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.084 -1.01 . . . . 0.0 109.526 169.26 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.523 ' CG1' ' CE1' ' B' ' 44' ' ' HIS . 0.0 OUTLIER -106.09 137.83 34.41 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.459 -1.401 . . . . 0.0 111.38 -176.812 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -130.2 144.92 51.64 Favored 'General case' 0 N--CA 1.493 1.712 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.005 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . 0.443 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 34.1 ptt180 -81.53 133.72 35.42 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.206 -0.934 . . . . 0.0 110.93 -176.11 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.644 ' CB ' ' CZ ' ' A' ' 2' ' ' PHE . . . -131.93 145.78 51.71 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.355 -0.841 . . . . 0.0 110.08 175.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -131.57 130.4 42.19 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.519 -0.738 . . . . 0.0 110.553 -176.468 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 38.1 mttt -59.94 -40.03 87.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.432 -0.792 . . . . 0.0 110.402 -178.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 51.7 p90 -152.97 159.99 42.98 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.29 -0.881 . . . . 0.0 110.497 -178.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 91' ' ' SER . . . . . 0.518 ' HB2' ' CG1' ' B' ' 94' ' ' ILE . 88.4 p -132.96 149.13 52.26 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.366 -0.834 . . . . 0.0 110.098 177.836 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . 0.451 ' O ' ' HG2' ' B' ' 93' ' ' GLU . 57.1 t0 -70.03 -46.75 64.37 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.184 -0.948 . . . . 0.0 110.46 -179.183 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . 0.451 ' HG2' ' O ' ' B' ' 92' ' ' ASP . 78.0 mm-40 -153.97 47.61 0.63 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.233 -0.917 . . . . 0.0 110.307 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . 0.518 ' CG1' ' HB2' ' B' ' 91' ' ' SER . 36.6 mm -95.05 -34.66 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.454 -0.779 . . . . 0.0 110.528 177.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 93.16 -97.56 2.26 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 -176.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . 0.445 ' O ' ' HB3' ' B' ' 97' ' ' HIS . . . -94.78 -54.18 1.56 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 178.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . 0.445 ' HB3' ' O ' ' B' ' 96' ' ' GLY . 25.0 p-80 . . . . . 0 N--CA 1.492 1.643 0 O-C-N 121.244 -1.151 . . . . 0.0 110.167 -179.365 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.53 ' O4 ' ' CB ' ' A' ' 49' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.533 " O2'" ' C9 ' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.9 mtt . . . . . 0 N--CA 1.496 1.859 0 CA-C-O 121.138 0.495 . . . . 0.0 110.1 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.59 ' CZ ' ' HB2' ' B' ' 87' ' ' ALA . 6.4 p90 -170.06 156.18 5.88 Favored 'General case' 0 C--N 1.306 -1.29 0 O-C-N 121.108 -0.995 . . . . 0.0 108.985 175.098 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.504 ' CG2' ' O ' ' A' ' 2' ' ' PHE . 75.8 p -154.17 -41.73 0.09 Allowed 'General case' 0 C--N 1.292 -1.901 0 O-C-N 121.151 -0.968 . . . . 0.0 108.483 176.594 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.484 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 50.98 21.03 4.87 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 108.436 -1.866 . . . . 0.0 108.436 -176.148 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.473 HG13 ' HB ' ' A' ' 3' ' ' THR . 60.3 mt -81.85 130.71 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.281 -1.129 . . . . 0.0 109.82 -176.689 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.527 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.0 t -86.26 140.82 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.188 -0.945 . . . . 0.0 111.108 -169.789 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 27.8 mm100 -70.0 -36.32 75.04 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.793 -0.567 . . . . 0.0 110.686 177.254 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -155.24 169.11 33.19 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.029 -1.558 . . . . 0.0 110.187 -173.569 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.437 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 0.7 OUTLIER -108.91 172.39 6.87 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.081 -1.246 . . . . 0.0 111.104 -176.167 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.483 ' O ' ' HA ' ' A' ' 81' ' ' TRP . . . -139.46 148.54 42.87 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -178.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.588 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 20.8 tttt -106.42 117.01 32.92 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 120.993 -1.067 . . . . 0.0 110.149 178.759 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.526 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 12.0 tp -59.81 127.65 33.02 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 120.831 -1.168 . . . . 0.0 108.756 172.563 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.601 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -126.72 -30.85 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 C-N-CA 119.596 -0.842 . . . . 0.0 110.032 -178.215 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.13 142.56 27.48 Favored 'General case' 0 N--CA 1.494 1.762 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.361 -178.403 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.578 HG13 ' CG2' ' A' ' 78' ' ' VAL . 10.3 mt -109.46 133.78 53.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.186 -0.946 . . . . 0.0 110.191 172.92 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.483 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 83.8 m-20 -109.88 114.29 27.72 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.377 -0.827 . . . . 0.0 110.129 176.072 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.25 112.69 25.03 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.018 -1.051 . . . . 0.0 110.556 -177.284 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.469 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.0 OUTLIER -107.43 133.22 20.46 Favored Pre-proline 0 N--CA 1.492 1.661 0 O-C-N 121.186 -0.946 . . . . 0.0 109.372 174.915 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -51.99 -25.1 21.12 Favored 'Trans proline' 0 C--N 1.302 -1.869 0 O-C-N 123.859 1.452 . . . . 0.0 110.35 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.567 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 8.8 m-80 -86.2 -35.76 19.87 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.25 -0.906 . . . . 0.0 110.272 177.708 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.567 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 95.4 m-85 -157.17 150.24 23.71 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.407 -0.808 . . . . 0.0 110.244 -176.382 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.473 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 61.6 ttt180 -86.2 144.26 27.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.783 -1.198 . . . . 0.0 110.085 175.218 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.483 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 85.3 m -130.6 140.01 50.42 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.499 -0.751 . . . . 0.0 109.668 -175.676 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.583 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -130.98 141.27 50.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.776 -1.203 . . . . 0.0 111.546 -178.433 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.528 ' CG2' ' OG ' ' A' ' 60' ' ' SER . 12.8 t -120.98 135.05 62.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.118 -0.989 . . . . 0.0 110.656 -179.152 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.579 HG12 ' CE1' ' A' ' 61' ' ' PHE . 21.4 m -117.46 171.96 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.738 -0.601 . . . . 0.0 110.246 178.16 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.48 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 12.8 tt0 -106.3 116.87 32.67 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.922 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.582 ' CD2' ' CD2' ' A' ' 36' ' ' LEU . 9.6 tp -90.73 130.93 39.19 Favored Pre-proline 0 C--N 1.296 -1.747 0 O-C-N 121.203 -0.936 . . . . 0.0 110.521 -171.295 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.475 ' HD2' HD11 ' A' ' 28' ' ' LEU . 30.7 Cg_endo -68.05 176.91 4.84 Favored 'Trans proline' 0 C--N 1.308 -1.605 0 O-C-N 124.015 1.534 . . . . 0.0 111.053 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -60.55 -39.92 89.71 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.429 -0.795 . . . . 0.0 111.401 -175.187 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.578 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.89 0.03 57.29 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.8 -1.188 . . . . 0.0 110.755 -174.078 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.578 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.9 mmm -110.67 -16.14 13.69 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.95 -1.094 . . . . 0.0 109.638 169.793 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.538 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 29.6 mt -71.2 -24.86 62.3 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.313 -0.867 . . . . 0.0 109.863 174.386 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . 0.476 ' O ' ' N ' ' A' ' 36' ' ' LEU . 38.6 p-10 -71.16 162.25 29.74 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.467 -0.771 . . . . 0.0 110.94 -173.104 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.428 ' C ' ' O ' ' A' ' 34' ' ' ASP . . . 37.54 27.69 0.03 OUTLIER Glycine 0 N--CA 1.494 2.522 0 O-C-N 121.504 -0.747 . . . . 0.0 111.605 174.295 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.582 ' CD2' ' CD2' ' A' ' 28' ' ' LEU . 60.8 tp -101.21 158.45 16.02 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 120.537 -1.566 . . . . 0.0 110.919 179.025 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.422 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 21.5 pt-20 -160.04 161.09 33.9 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.566 -0.709 . . . . 0.0 109.428 177.49 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.541 ' CG2' ' HA ' ' A' ' 53' ' ' GLU . 0.0 OUTLIER -66.84 154.42 40.96 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.043 -1.035 . . . . 0.0 109.526 175.779 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.39 -9.45 61.43 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.257 -1.537 . . . . 0.0 109.257 -176.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.47 ' O ' HG21 ' A' ' 51' ' ' VAL . . . -69.87 153.21 43.6 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.135 -1.215 . . . . 0.0 109.627 177.935 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.471 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -97.35 104.53 16.56 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 120.966 -1.084 . . . . 0.0 109.906 178.117 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 1.6 t -87.87 137.54 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.239 -0.913 . . . . 0.0 109.027 174.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.45 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -102.96 120.12 40.06 Favored 'General case' 0 C--N 1.295 -1.781 0 O-C-N 120.865 -1.147 . . . . 0.0 109.535 170.167 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.582 ' CD2' HG23 ' A' ' 82' ' ' VAL . 1.2 m80 -87.45 101.02 13.19 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 176.12 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.0 t-20 58.55 8.88 0.95 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.575 -0.703 . . . . 0.0 111.399 -169.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.462 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 124.62 -3.19 8.73 Favored Glycine 0 N--CA 1.489 2.167 0 C-N-CA 119.674 -1.25 . . . . 0.0 110.617 174.344 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.526 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 19.7 t -90.34 107.39 19.12 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.334 -1.686 . . . . 0.0 109.2 174.623 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 23.5 p -78.12 125.55 29.51 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.127 -0.983 . . . . 0.0 110.768 -170.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.552 ' CD1' ' CD2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -142.57 160.16 40.83 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.508 -0.745 . . . . 0.0 109.592 176.051 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 27.6 m -99.51 149.15 23.53 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.715 -1.24 . . . . 0.0 111.378 -169.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.52 HG12 ' CG1' ' A' ' 59' ' ' VAL . 16.9 t -75.16 114.62 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.739 -0.6 . . . . 0.0 110.273 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.52 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 47.3 p -70.29 -40.0 74.55 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.299 -0.875 . . . . 0.0 109.947 174.214 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.541 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -162.78 154.5 18.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.344 -0.847 . . . . 0.0 110.23 -179.344 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.537 HD11 ' CG2' ' A' ' 38' ' ' THR . 5.5 mt -105.55 130.01 57.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.012 -1.055 . . . . 0.0 109.888 175.201 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.5 ' HB2' ' CB ' ' A' ' 58' ' ' HIS . 9.6 m-80 -101.66 61.94 0.91 Allowed 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.614 -0.678 . . . . 0.0 109.691 178.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.79 -114.72 4.16 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 108.743 -1.743 . . . . 0.0 108.743 -173.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.538 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.54 -19.97 51.72 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.024 -1.28 . . . . 0.0 108.807 174.374 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.601 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 9.3 m170 -75.29 160.04 30.79 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.459 -0.776 . . . . 0.0 110.116 -177.222 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.52 ' CG1' HG12 ' A' ' 51' ' ' VAL . 54.6 t -140.14 121.99 15.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 O-C-N 120.957 -1.089 . . . . 0.0 110.711 171.059 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.528 ' OG ' ' CG2' ' A' ' 25' ' ' VAL . 1.1 t -87.75 133.69 33.81 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.522 -0.736 . . . . 0.0 109.287 174.729 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.624 ' N ' ' CD1' ' A' ' 61' ' ' PHE . 1.3 p90 -126.85 154.07 44.85 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 121.43 -0.793 . . . . 0.0 110.225 178.554 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.52 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 31.4 p-10 -88.72 147.77 24.32 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.004 -1.06 . . . . 0.0 111.399 -170.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.588 ' CD2' ' CD1' ' A' ' 68' ' ' LEU . 0.0 OUTLIER -154.47 113.66 3.69 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 -176.186 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.514 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 56.9 ttm -69.96 140.61 53.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.794 -1.191 . . . . 0.0 109.449 -179.382 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.473 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 36.4 tptt -60.01 -49.23 78.5 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.995 -1.066 . . . . 0.0 110.299 -175.1 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -65.48 -40.01 92.62 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.901 -1.124 . . . . 0.0 110.129 178.162 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.514 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 60.8 m -62.76 -38.13 89.34 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.902 -1.124 . . . . 0.0 109.426 174.238 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.588 ' CD1' ' CD2' ' A' ' 63' ' ' LEU . 14.7 tp -60.05 -41.58 92.61 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.14 -0.975 . . . . 0.0 109.225 177.325 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.526 ' NH1' ' HB3' ' A' ' 69' ' ' ARG . 6.4 mmm180 -69.96 -38.85 76.24 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.466 -0.771 . . . . 0.0 110.433 174.012 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.471 HG23 ' O ' ' A' ' 67' ' ' THR . 1.1 tt -67.97 -40.43 83.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.327 -0.858 . . . . 0.0 109.412 -176.574 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.465 HG22 ' O ' ' A' ' 67' ' ' THR . 59.1 p -87.49 -171.56 3.51 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.339 0.59 . . . . 0.0 109.764 179.083 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.467 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 8.3 t30 -99.92 18.75 17.6 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.338 -0.852 . . . . 0.0 108.865 170.194 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.542 ' CD1' HD23 ' A' ' 63' ' ' LEU . 70.2 mt -68.33 -40.02 81.77 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.931 -1.106 . . . . 0.0 109.749 174.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.502 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -47.06 -22.55 1.3 Allowed Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 -179.702 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.3 p-10 -67.91 -17.18 64.39 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.975 -1.309 . . . . 0.0 110.419 -175.351 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 95.5 mt -63.51 142.11 58.51 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.223 -0.923 . . . . 0.0 110.917 -176.243 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.473 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 46.1 mttt -142.65 142.73 32.12 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.733 -0.604 . . . . 0.0 109.495 174.561 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.578 ' CG2' HG13 ' A' ' 15' ' ' ILE . 21.3 t -63.61 150.04 10.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.587 0 O-C-N 120.843 -1.16 . . . . 0.0 110.36 -176.707 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.78 -13.6 62.35 Favored Glycine 0 N--CA 1.483 1.797 0 N-CA-C 108.793 -1.723 . . . . 0.0 108.793 -175.21 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 44.9 t0 -95.2 166.31 11.97 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.267 -1.137 . . . . 0.0 109.55 176.1 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.588 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.8 m95 -117.22 159.04 23.28 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.006 -1.059 . . . . 0.0 110.118 176.563 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.582 HG23 ' CD2' ' A' ' 44' ' ' HIS . 1.0 OUTLIER -125.38 155.02 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.441 -0.787 . . . . 0.0 109.891 -179.124 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.522 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 0.3 OUTLIER -78.16 105.29 9.28 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.17 -0.956 . . . . 0.0 108.965 168.093 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.47 ' O ' HG12 ' A' ' 6' ' ' VAL . 0.1 OUTLIER -106.19 140.46 24.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 120.535 -1.353 . . . . 0.0 111.478 -176.312 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -134.27 157.09 47.19 Favored 'General case' 0 N--CA 1.496 1.855 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.948 -179.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 47.5 ptt85 -100.23 133.37 44.74 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.114 -0.991 . . . . 0.0 110.992 -176.232 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.561 ' HB1' ' CZ ' ' B' ' 2' ' ' PHE . . . -128.73 150.96 50.05 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.344 -0.848 . . . . 0.0 110.126 179.598 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -119.22 126.58 51.86 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.24 -0.913 . . . . 0.0 110.635 -178.704 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 28.3 mtpt -60.24 -40.01 88.73 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.507 -0.745 . . . . 0.0 110.965 -177.242 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . 0.407 ' CD1' ' C ' ' A' ' 90' ' ' PHE . 24.0 p90 -81.1 155.29 26.34 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.99 -1.069 . . . . 0.0 110.469 -177.387 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' SER . . . . . 0.422 ' HB3' ' HG3' ' A' ' 93' ' ' GLU . 53.1 m -72.08 129.93 39.69 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.359 -0.838 . . . . 0.0 110.742 -176.539 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.467 ' O ' ' HB2' ' A' ' 93' ' ' GLU . 56.7 t0 -70.07 -39.77 75.42 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.29 -0.881 . . . . 0.0 110.238 175.485 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.467 ' HB2' ' O ' ' A' ' 92' ' ' ASP . 98.5 mt-10 55.48 52.66 10.86 Favored 'General case' 0 N--CA 1.506 2.356 0 C-N-CA 119.887 -0.725 . . . . 0.0 110.498 177.568 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.436 HD13 ' OD1' ' A' ' 92' ' ' ASP . 30.5 mm -69.43 -40.08 79.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.295 -0.878 . . . . 0.0 110.231 175.279 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 56.21 74.74 0.29 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 -177.542 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.428 ' O ' ' CG2' ' A' ' 94' ' ' ILE . . . 73.61 170.12 19.66 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 -178.608 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 1.4 t-160 . . . . . 0 N--CA 1.492 1.668 0 O-C-N 121.253 -1.145 . . . . 0.0 110.19 178.866 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 53.9 ttm . . . . . 0 N--CA 1.493 1.712 0 CA-C-O 121.171 0.51 . . . . 0.0 110.261 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.569 ' CD1' ' C ' ' B' ' 2' ' ' PHE . 6.6 p90 -169.95 156.22 6.03 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 121.128 -0.982 . . . . 0.0 109.016 174.533 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.504 ' CG2' ' O ' ' B' ' 2' ' ' PHE . 75.6 p -154.16 -41.8 0.09 Allowed 'General case' 0 C--N 1.293 -1.851 0 O-C-N 121.084 -1.01 . . . . 0.0 108.517 176.58 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.462 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 51.24 20.76 5.17 Favored Glycine 0 N--CA 1.483 1.768 0 N-CA-C 108.408 -1.877 . . . . 0.0 108.408 -176.221 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.487 HG13 ' HB ' ' B' ' 3' ' ' THR . 59.7 mt -81.76 130.74 35.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.285 -1.126 . . . . 0.0 109.915 -176.63 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.534 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.0 t -86.21 140.74 15.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.19 -0.944 . . . . 0.0 111.11 -169.751 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 27.8 mm100 -69.98 -36.08 74.93 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.836 -0.54 . . . . 0.0 110.81 177.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.534 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -155.42 168.96 33.27 Favored Glycine 0 N--CA 1.495 2.631 0 C-N-CA 119.086 -1.53 . . . . 0.0 110.269 -173.563 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.44 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 0.7 OUTLIER -108.87 172.17 7.0 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.127 -1.219 . . . . 0.0 111.177 -176.128 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.488 ' O ' ' HA ' ' B' ' 81' ' ' TRP . . . -139.24 148.79 43.55 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 -179.145 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 20.8 tttt -106.59 117.11 33.18 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.091 -1.006 . . . . 0.0 110.055 178.787 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.519 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 12.0 tp -59.98 127.54 32.43 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.977 -1.077 . . . . 0.0 108.814 172.583 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.605 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -126.51 -31.0 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.837 0 O-C-N 121.312 -0.868 . . . . 0.0 110.061 -178.115 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.09 142.55 27.51 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.229 -0.988 . . . . 0.0 111.391 -178.358 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.579 HG13 ' CG2' ' B' ' 78' ' ' VAL . 10.3 mt -109.42 133.85 53.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.169 -0.957 . . . . 0.0 110.241 172.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.486 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.6 m-20 -110.0 114.44 27.98 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.387 -0.821 . . . . 0.0 110.077 176.059 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -100.24 112.66 24.99 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.101 -1.0 . . . . 0.0 110.612 -177.358 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.473 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.0 OUTLIER -107.47 133.3 20.44 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.27 -0.894 . . . . 0.0 109.4 174.904 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -52.12 -24.99 21.57 Favored 'Trans proline' 0 C--N 1.303 -1.855 0 O-C-N 123.873 1.46 . . . . 0.0 110.32 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.572 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 9.2 m-80 -86.12 -36.35 19.64 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.305 -0.872 . . . . 0.0 110.06 177.804 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.572 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 95.5 m-85 -156.71 150.27 24.52 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.43 -0.794 . . . . 0.0 110.296 -176.285 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.459 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 61.5 ttt180 -86.18 144.15 27.62 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.783 -1.198 . . . . 0.0 110.072 175.165 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.486 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 85.2 m -130.44 140.07 50.56 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.504 -0.747 . . . . 0.0 109.745 -175.76 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.585 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -130.92 141.29 50.28 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.859 -1.151 . . . . 0.0 111.505 -178.358 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.525 ' CG2' ' OG ' ' B' ' 60' ' ' SER . 12.6 t -120.9 135.21 61.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.313 -0.867 . . . . 0.0 110.648 -179.164 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.586 HG12 ' CE1' ' B' ' 61' ' ' PHE . 21.7 m -117.72 171.94 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.757 -0.589 . . . . 0.0 110.19 178.171 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.488 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 12.8 tt0 -106.19 116.82 32.59 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.583 ' CD2' ' CD2' ' B' ' 36' ' ' LEU . 9.5 tp -90.59 130.9 39.57 Favored Pre-proline 0 C--N 1.295 -1.773 0 O-C-N 121.16 -0.962 . . . . 0.0 110.547 -171.298 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.471 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 30.6 Cg_endo -68.13 176.92 4.89 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 O-C-N 123.98 1.516 . . . . 0.0 111.005 -179.505 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -60.51 -40.02 89.89 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.454 -0.779 . . . . 0.0 111.355 -175.143 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.574 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.87 0.06 57.27 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.738 -1.226 . . . . 0.0 110.707 -174.008 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.574 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.9 mmm -110.71 -16.03 13.7 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.848 -1.157 . . . . 0.0 109.665 169.765 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.545 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 29.4 mt -71.31 -24.92 62.22 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.298 -0.876 . . . . 0.0 109.779 174.408 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . 0.488 ' O ' ' N ' ' B' ' 36' ' ' LEU . 38.6 p-10 -71.11 162.18 29.86 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.443 -0.786 . . . . 0.0 110.955 -173.088 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' B' ' 34' ' ' ASP . . . 37.53 27.74 0.03 OUTLIER Glycine 0 N--CA 1.496 2.694 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.564 174.343 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . 0.583 ' CD2' ' CD2' ' B' ' 28' ' ' LEU . 60.8 tp -101.28 158.43 16.05 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.572 -1.546 . . . . 0.0 110.925 178.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.442 ' O ' ' HB1' ' B' ' 40' ' ' ALA . 21.5 pt-20 -159.97 161.17 34.09 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.561 -0.712 . . . . 0.0 109.421 177.525 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.544 ' CG2' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.97 154.43 41.14 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.007 -1.058 . . . . 0.0 109.49 175.794 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.38 -9.37 61.63 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -176.577 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.442 ' HB1' ' O ' ' B' ' 37' ' ' GLU . . . -70.01 152.98 43.79 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.265 -1.138 . . . . 0.0 109.612 177.885 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.468 ' OG ' ' O ' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -97.08 104.28 16.28 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.947 -1.096 . . . . 0.0 110.037 178.103 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.404 ' CG1' ' HD1' ' B' ' 44' ' ' HIS . 1.6 t -87.81 137.54 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.247 -0.908 . . . . 0.0 109.108 174.554 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.445 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -103.02 120.19 40.2 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 120.931 -1.106 . . . . 0.0 109.482 170.239 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.577 ' CD2' HG23 ' B' ' 82' ' ' VAL . 1.2 m80 -87.51 100.89 13.11 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.67 -0.812 . . . . 0.0 108.925 176.099 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.0 t-20 58.87 8.86 1.03 Allowed 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.5 -0.75 . . . . 0.0 111.256 -170.12 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.484 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 124.5 -2.9 8.82 Favored Glycine 0 N--CA 1.488 2.123 0 C-N-CA 119.699 -1.239 . . . . 0.0 110.601 174.173 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.517 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 19.7 t -90.44 107.33 19.09 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.3 -1.706 . . . . 0.0 109.266 174.492 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 23.3 p -78.05 125.55 29.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.128 -0.983 . . . . 0.0 110.774 -170.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.562 ' CD1' ' CD2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -142.59 160.08 41.0 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.596 -0.69 . . . . 0.0 109.632 176.05 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 27.7 m -99.25 149.3 23.25 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.676 -1.265 . . . . 0.0 111.357 -169.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.533 ' CG1' HG11 ' B' ' 59' ' ' VAL . 17.1 t -75.42 114.55 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.675 -0.641 . . . . 0.0 110.342 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.523 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 48.3 p -70.32 -39.96 74.46 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.178 -0.952 . . . . 0.0 109.865 174.433 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.531 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -162.74 154.6 18.26 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.388 -0.82 . . . . 0.0 110.214 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.544 HD11 ' CG2' ' B' ' 38' ' ' THR . 5.5 mt -105.63 129.9 57.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.12 -0.987 . . . . 0.0 109.925 175.215 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.505 ' HB2' ' CB ' ' B' ' 58' ' ' HIS . 9.6 m-80 -101.58 61.9 0.92 Allowed 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.658 -0.651 . . . . 0.0 109.748 178.867 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.78 -114.66 4.15 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 -173.655 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.545 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.41 -20.2 51.61 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.004 -1.292 . . . . 0.0 108.815 174.34 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.605 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 9.4 m170 -75.21 159.87 31.06 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.442 -0.786 . . . . 0.0 110.144 -177.203 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.533 HG11 ' CG1' ' B' ' 51' ' ' VAL . 54.7 t -140.04 122.16 16.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 C-N-CA 118.926 -1.11 . . . . 0.0 110.662 171.133 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.525 ' OG ' ' CG2' ' B' ' 25' ' ' VAL . 1.1 t -87.86 133.83 33.82 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.457 -0.777 . . . . 0.0 109.371 174.746 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.62 ' N ' ' CD1' ' B' ' 61' ' ' PHE . 1.3 p90 -126.98 154.07 45.05 Favored 'General case' 0 N--CA 1.498 1.929 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.109 178.681 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.523 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 31.1 p-10 -88.7 147.77 24.34 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.939 -1.1 . . . . 0.0 111.352 -170.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.583 ' CD2' ' CD1' ' B' ' 68' ' ' LEU . 0.0 OUTLIER -154.38 113.76 3.73 Favored 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 -176.309 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.505 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 56.8 ttm -70.05 140.53 52.82 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.744 -1.222 . . . . 0.0 109.402 -179.386 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.474 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 36.5 tptt -59.99 -49.1 78.99 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.023 -1.048 . . . . 0.0 110.347 -175.117 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 88.6 tt0 -65.54 -40.03 92.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.948 -1.095 . . . . 0.0 110.098 178.22 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.505 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 61.0 m -62.7 -38.23 89.6 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.905 -1.122 . . . . 0.0 109.426 174.242 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.583 ' CD1' ' CD2' ' B' ' 63' ' ' LEU . 14.7 tp -60.01 -41.46 92.21 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.292 -0.88 . . . . 0.0 109.264 177.312 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . 0.53 ' NH1' ' HB3' ' B' ' 69' ' ' ARG . 6.4 mmm180 -70.0 -38.99 76.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.558 -0.714 . . . . 0.0 110.386 174.03 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.466 HG23 HG22 ' B' ' 71' ' ' THR . 1.1 tt -67.88 -40.39 83.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.526 -176.641 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.466 HG22 HG23 ' B' ' 70' ' ' ILE . 59.2 p -87.37 -171.43 3.47 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-O 121.296 0.57 . . . . 0.0 109.863 178.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.501 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 8.4 t30 -99.92 18.74 17.62 Favored 'General case' 0 C--N 1.297 -1.703 0 O-C-N 121.384 -0.823 . . . . 0.0 108.814 170.195 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.538 ' CD1' HD23 ' B' ' 63' ' ' LEU . 69.4 mt -68.41 -39.98 81.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.023 -1.048 . . . . 0.0 109.716 174.811 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.5 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -47.02 -22.64 1.3 Allowed Glycine 0 N--CA 1.489 2.2 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -179.71 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.4 p-10 -67.94 -17.14 64.36 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.08 -1.247 . . . . 0.0 110.492 -175.321 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 95.5 mt -63.44 142.1 58.52 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.17 -0.956 . . . . 0.0 110.92 -176.334 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.477 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 46.1 mttt -142.84 142.84 31.91 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.71 -0.619 . . . . 0.0 109.391 174.507 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.579 ' CG2' HG13 ' B' ' 15' ' ' ILE . 21.5 t -63.61 149.99 10.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 120.903 -1.123 . . . . 0.0 110.422 -176.568 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.67 -13.34 62.8 Favored Glycine 0 N--CA 1.483 1.804 0 N-CA-C 108.885 -1.686 . . . . 0.0 108.885 -175.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 44.5 t0 -95.28 166.22 12.0 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.392 -1.064 . . . . 0.0 109.545 175.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.0 m95 -117.16 159.08 23.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.019 -1.051 . . . . 0.0 110.183 176.479 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.577 HG23 ' CD2' ' B' ' 44' ' ' HIS . 1.0 OUTLIER -125.45 155.15 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.5 -0.75 . . . . 0.0 109.936 -179.289 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.515 ' N ' HG21 ' B' ' 82' ' ' VAL . 0.3 OUTLIER -78.25 105.15 9.29 Favored 'General case' 0 C--N 1.297 -1.69 0 O-C-N 121.123 -0.986 . . . . 0.0 109.025 168.203 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.461 ' O ' HG11 ' B' ' 6' ' ' VAL . 0.1 OUTLIER -106.07 140.61 23.62 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 120.631 -1.293 . . . . 0.0 111.361 -176.047 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -134.54 157.06 47.52 Favored 'General case' 0 N--CA 1.495 1.785 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.888 -179.649 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 47.6 ptt85 -100.12 133.46 44.48 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.079 -1.013 . . . . 0.0 110.919 -176.12 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.59 ' HB2' ' CZ ' ' A' ' 2' ' ' PHE . . . -128.76 150.99 50.06 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.401 -0.812 . . . . 0.0 110.08 179.603 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -119.3 126.63 51.93 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.269 -0.894 . . . . 0.0 110.527 -178.697 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 28.3 mtpt -60.29 -40.09 89.23 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.416 -0.802 . . . . 0.0 110.918 -177.259 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . 0.406 ' CD1' ' C ' ' B' ' 90' ' ' PHE . 24.1 p90 -81.1 155.2 26.39 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.103 -0.998 . . . . 0.0 110.454 -177.364 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 91' ' ' SER . . . . . 0.454 ' HB3' ' HB ' ' B' ' 94' ' ' ILE . 53.2 m -72.03 129.92 39.69 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.289 -0.882 . . . . 0.0 110.795 -176.489 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 56.9 t0 -70.12 -46.4 64.87 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.254 -0.904 . . . . 0.0 110.454 175.529 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -140.38 52.54 1.65 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.914 -1.117 . . . . 0.0 110.909 -175.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . 0.454 ' HB ' ' HB3' ' B' ' 91' ' ' SER . 41.0 mt -130.6 2.35 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.162 -0.961 . . . . 0.0 110.203 176.38 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . -69.57 58.36 0.68 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.131 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' B' ' 94' ' ' ILE . . . 71.61 127.17 0.07 OUTLIER Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.288 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 35.8 m80 . . . . . 0 N--CA 1.491 1.583 0 O-C-N 121.207 -1.172 . . . . 0.0 110.184 -179.16 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.544 " O2'" ' C9 ' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.54 " O2'" ' C9 ' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 92.5 mmm . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.049 0.452 . . . . 0.0 110.042 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.583 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 6.1 p90 -167.86 148.35 5.11 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 121.056 -1.028 . . . . 0.0 109.033 174.648 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.548 ' CB ' HG12 ' A' ' 5' ' ' ILE . 4.9 p -146.22 -37.86 0.24 Allowed 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.108 -0.995 . . . . 0.0 109.008 178.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.48 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 46.39 26.28 2.35 Favored Glycine 0 N--CA 1.483 1.803 0 N-CA-C 108.494 -1.843 . . . . 0.0 108.494 -176.828 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.548 HG12 ' CB ' ' A' ' 3' ' ' THR . 27.7 mm -78.77 130.01 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.464 -1.021 . . . . 0.0 109.558 -178.914 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.535 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.2 t -93.17 140.37 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 120.934 -1.104 . . . . 0.0 111.09 -169.77 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -69.95 -35.11 74.24 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.778 -0.576 . . . . 0.0 111.072 176.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -156.24 172.97 34.14 Favored Glycine 0 N--CA 1.495 2.609 0 C-N-CA 118.747 -1.692 . . . . 0.0 110.513 -172.526 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.449 ' O ' ' HG3' ' A' ' 29' ' ' PRO . 12.6 p -117.75 172.35 7.43 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.031 -1.276 . . . . 0.0 111.017 -176.814 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.533 ' CB ' HG13 ' A' ' 82' ' ' VAL . . . -140.01 148.53 41.99 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.562 -0.711 . . . . 0.0 109.609 -178.726 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.581 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 37.6 tttt -107.18 115.3 29.93 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.047 -1.033 . . . . 0.0 110.321 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.532 ' HB3' ' HA ' ' A' ' 78' ' ' VAL . 11.3 tp -59.91 126.74 28.73 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.038 -1.039 . . . . 0.0 108.896 173.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.592 HG13 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -125.32 -29.32 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.838 0 C-N-CA 119.583 -0.847 . . . . 0.0 109.909 -179.417 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.93 142.4 24.37 Favored 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 118.942 -1.103 . . . . 0.0 111.523 179.735 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.574 HG12 ' CD2' ' A' ' 24' ' ' HIS . 12.0 mt -105.55 137.13 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.155 -0.966 . . . . 0.0 110.185 171.569 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.493 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 86.7 m-20 -112.95 115.99 29.28 Favored 'General case' 0 C--N 1.297 -1.703 0 O-C-N 121.344 -0.847 . . . . 0.0 109.937 173.512 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -105.9 115.24 29.9 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.897 -1.127 . . . . 0.0 110.799 -176.477 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.475 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 4.1 mtmt -110.4 127.58 26.77 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.121 -0.987 . . . . 0.0 108.935 171.703 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -52.27 -18.73 8.13 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.848 1.446 . . . . 0.0 110.812 -179.367 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.577 ' ND2' ' N ' ' A' ' 20' ' ' ASN . 0.3 OUTLIER -90.18 -35.84 15.13 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.139 -0.975 . . . . 0.0 108.741 177.077 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.501 ' CD2' ' HB2' ' A' ' 20' ' ' ASN . 81.9 m-85 -151.07 150.15 30.37 Favored 'General case' 0 N--CA 1.491 1.623 0 CA-C-O 121.192 0.52 . . . . 0.0 109.748 179.183 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.469 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 62.4 ttt180 -97.69 143.83 27.95 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.589 -1.32 . . . . 0.0 110.021 176.504 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.493 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 96.5 m -129.98 140.09 50.96 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.412 -0.805 . . . . 0.0 110.126 -173.304 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.574 ' CD2' HG12 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.22 135.77 48.5 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.984 -1.073 . . . . 0.0 111.207 179.216 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.512 ' HA ' ' HA ' ' A' ' 60' ' ' SER . 15.8 t -115.53 134.25 59.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.002 -1.061 . . . . 0.0 110.767 -178.276 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.445 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 29.5 m -119.67 170.02 9.88 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.062 -179.703 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.504 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 7.5 tt0 -103.55 116.97 33.36 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -179.383 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.469 HD21 ' O ' ' A' ' 32' ' ' MET . 8.9 tp -82.01 119.73 75.78 Favored Pre-proline 0 C--N 1.295 -1.798 0 O-C-N 121.502 -0.748 . . . . 0.0 109.815 -173.719 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.449 ' HG3' ' O ' ' A' ' 9' ' ' THR . 22.6 Cg_endo -65.33 179.22 1.66 Allowed 'Trans proline' 0 C--N 1.308 -1.554 0 O-C-N 123.85 1.447 . . . . 0.0 111.047 -179.378 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.417 ' OD1' ' C ' ' A' ' 30' ' ' ASP . 50.5 t0 -60.1 -41.28 92.18 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.415 -0.803 . . . . 0.0 111.098 -175.319 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.55 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.39 1.47 56.57 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.87 -1.144 . . . . 0.0 110.763 -174.156 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.55 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 96.4 mmm -111.07 -15.82 13.63 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.036 -1.04 . . . . 0.0 109.82 171.835 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.532 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 16.5 mt -68.18 -30.39 69.48 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.33 -0.856 . . . . 0.0 109.999 178.904 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 57.4 t0 -91.72 127.02 37.01 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.328 -0.858 . . . . 0.0 110.266 -179.648 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.28 -48.06 1.0 Allowed Glycine 0 N--CA 1.492 2.403 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 177.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.479 HD12 ' CG2' ' A' ' 42' ' ' VAL . 7.4 tt -70.02 145.81 51.49 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.141 -1.211 . . . . 0.0 110.664 -175.762 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.464 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 20.7 pt-20 -150.43 170.01 20.09 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.427 -0.796 . . . . 0.0 109.622 -179.512 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.528 ' CG2' HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -67.23 151.15 48.05 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.91 -1.119 . . . . 0.0 110.13 179.972 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.62 0.0 62.15 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 -176.226 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.464 ' HB1' ' O ' ' A' ' 37' ' ' GLU . . . -79.79 159.0 26.71 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.242 -1.152 . . . . 0.0 109.7 177.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.451 ' HB2' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -101.06 113.23 26.05 Favored 'General case' 0 N--CA 1.486 1.345 0 O-C-N 121.126 -0.984 . . . . 0.0 110.04 176.72 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.573 HG11 ' CE1' ' A' ' 44' ' ' HIS . 2.0 t -104.74 130.0 56.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.278 -0.889 . . . . 0.0 109.172 174.718 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.478 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -93.31 119.53 32.56 Favored 'General case' 0 C--N 1.297 -1.708 0 C-N-CA 119.146 -1.022 . . . . 0.0 109.149 172.257 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.573 ' CE1' HG11 ' A' ' 42' ' ' VAL . 0.3 OUTLIER -88.0 107.15 18.58 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 178.52 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.51 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.1 t-20 50.29 16.28 0.25 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.487 -0.758 . . . . 0.0 111.283 -166.457 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.494 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 120.92 0.85 11.75 Favored Glycine 0 N--CA 1.489 2.221 0 C-N-CA 119.444 -1.36 . . . . 0.0 111.164 171.292 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.524 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 34.8 t -98.71 108.46 21.15 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.137 -1.802 . . . . 0.0 109.492 175.082 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.501 ' SG ' ' C8 ' ' A' ' 98' ' ' RBF . 21.2 p -75.7 126.74 31.59 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.015 -1.053 . . . . 0.0 111.084 -171.116 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.526 ' CD1' ' HB3' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -141.35 162.74 34.76 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.505 -0.747 . . . . 0.0 109.466 172.712 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.418 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 55.0 m -102.47 152.88 20.61 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 120.637 -1.29 . . . . 0.0 111.074 -171.13 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.542 ' CG1' HG11 ' A' ' 59' ' ' VAL . 34.5 t -76.82 117.73 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.62 -0.675 . . . . 0.0 110.458 -177.934 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.542 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 41.2 p -70.21 -39.99 74.81 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.122 -0.986 . . . . 0.0 109.669 172.253 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.521 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 52.3 tp10 -164.72 156.12 15.26 Favored 'General case' 0 N--CA 1.492 1.642 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.819 -177.349 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.528 HD12 ' CG2' ' A' ' 38' ' ' THR . 8.8 mt -110.47 130.07 64.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.083 -1.011 . . . . 0.0 109.986 172.794 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.463 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 63.8 m-80 -104.7 65.62 0.76 Allowed 'General case' 0 C--N 1.297 -1.678 0 CA-C-O 121.532 0.682 . . . . 0.0 109.54 177.703 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.91 -115.09 4.24 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 -174.158 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.532 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.0 -21.08 44.04 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.121 -1.223 . . . . 0.0 109.162 176.609 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.592 ' CD2' HG13 ' A' ' 13' ' ' VAL . 9.5 m170 -77.05 159.38 29.91 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.186 -0.946 . . . . 0.0 109.791 -178.024 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.582 HG12 ' CE2' ' A' ' 61' ' ' PHE . 59.9 t -140.9 121.48 13.27 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 C-N-CA 119.078 -1.049 . . . . 0.0 110.522 171.707 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.512 ' HA ' ' HA ' ' A' ' 25' ' ' VAL . 1.2 t -84.35 135.35 34.33 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.434 -0.791 . . . . 0.0 109.264 175.885 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.582 ' CE2' HG12 ' A' ' 59' ' ' VAL . 58.9 m-85 -115.55 158.5 22.53 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.319 -0.863 . . . . 0.0 110.199 178.967 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.542 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 25.1 p-10 -92.12 147.47 22.91 Favored 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 122.106 0.955 . . . . 0.0 110.842 178.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.523 HD22 ' CD1' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -159.71 125.0 4.08 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 -176.864 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.518 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 56.1 ttm -84.85 146.44 27.31 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.931 -1.106 . . . . 0.0 109.434 -177.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.42 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 71.4 tttt -60.06 -49.13 78.88 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.014 -1.053 . . . . 0.0 109.99 -177.231 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 53.4 tp10 -69.59 -40.02 76.95 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.147 -0.97 . . . . 0.0 110.397 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.518 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 37.7 m -62.25 -38.66 90.11 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.823 -1.173 . . . . 0.0 109.085 174.427 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.528 ' CD1' ' HA2' ' A' ' 74' ' ' GLY . 1.0 OUTLIER -60.05 -47.37 86.16 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.233 -0.917 . . . . 0.0 109.709 177.419 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 74.9 ttt-85 -65.76 -40.05 91.65 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.467 -0.771 . . . . 0.0 110.481 178.192 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.503 HG21 ' N ' ' A' ' 71' ' ' THR . 1.4 tt -64.19 -41.28 91.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.234 -0.917 . . . . 0.0 109.093 -179.323 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.503 ' N ' HG21 ' A' ' 70' ' ' ILE . 20.1 p -89.72 -177.01 5.16 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 175.626 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.479 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 3.4 t30 -100.01 25.16 7.67 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.07 -1.019 . . . . 0.0 108.332 172.414 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.523 ' CD1' HD22 ' A' ' 63' ' ' LEU . 86.8 mt -67.66 -39.96 84.52 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.996 -1.065 . . . . 0.0 109.933 176.551 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.528 ' HA2' ' CD1' ' A' ' 68' ' ' LEU . . . -54.88 -23.98 32.41 Favored Glycine 0 N--CA 1.485 1.909 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -177.52 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 21.9 p-10 -64.12 -17.02 63.05 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.962 -1.317 . . . . 0.0 110.32 -175.335 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.52 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 96.0 mt -60.08 141.48 55.7 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.262 -0.898 . . . . 0.0 110.476 -177.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.472 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 59.8 mmtt -140.02 143.28 36.34 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-O 121.814 0.816 . . . . 0.0 110.4 175.807 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.564 ' CG2' HG13 ' A' ' 15' ' ' ILE . 35.9 t -63.08 149.51 10.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.252 -0.905 . . . . 0.0 110.235 -176.199 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.54 -13.79 63.05 Favored Glycine 0 N--CA 1.484 1.849 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 -175.338 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 46.3 t0 -96.23 163.13 13.22 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.346 -1.091 . . . . 0.0 109.587 176.167 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.581 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 13.7 m95 -113.89 162.15 16.73 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.062 -1.024 . . . . 0.0 110.201 176.52 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.533 HG13 ' CB ' ' A' ' 10' ' ' ALA . 1.6 p -130.8 140.24 49.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 O-C-N 121.514 -0.741 . . . . 0.0 110.16 -175.625 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.461 ' HB3' HG22 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -66.95 103.89 1.25 Allowed 'General case' 0 C--N 1.295 -1.795 0 O-C-N 121.095 -1.003 . . . . 0.0 109.46 169.07 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.474 HG13 ' ND1' ' A' ' 44' ' ' HIS . 0.1 OUTLIER -106.58 137.63 36.2 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.816 0 O-C-N 120.537 -1.352 . . . . 0.0 111.414 -178.885 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -132.73 131.66 41.46 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.072 179.703 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 75.9 ttt180 -72.18 139.2 48.11 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.151 -0.968 . . . . 0.0 110.972 -175.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.498 ' HB3' ' CZ ' ' B' ' 2' ' ' PHE . . . -132.55 150.03 52.22 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.436 -0.79 . . . . 0.0 109.814 176.654 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -117.12 141.83 47.77 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.28 -0.888 . . . . 0.0 111.152 -174.116 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.2 mmtt -60.2 -40.08 88.82 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.476 -0.765 . . . . 0.0 110.3 -179.603 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 44.3 p90 -118.77 162.56 18.24 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.235 -0.916 . . . . 0.0 110.206 -178.615 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' SER . . . . . 0.416 ' O ' ' HG2' ' A' ' 93' ' ' GLU . 12.9 m -105.17 131.27 52.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.278 -0.889 . . . . 0.0 110.593 -175.453 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.526 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 96.0 m-20 -61.6 -39.32 90.78 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.295 -0.878 . . . . 0.0 110.17 177.775 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.526 ' CG ' ' O ' ' A' ' 92' ' ' ASP . 8.4 pt-20 38.48 52.71 1.78 Allowed 'General case' 0 N--CA 1.512 2.674 0 CA-C-O 121.51 0.671 . . . . 0.0 110.208 -178.272 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 44.6 mm -70.0 -39.94 77.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.502 -0.749 . . . . 0.0 110.173 177.664 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 105.13 -94.3 0.99 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 -176.543 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.42 ' O ' ' HB2' ' A' ' 97' ' ' HIS . . . 84.49 -168.79 44.5 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 178.025 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . 0.42 ' HB2' ' O ' ' A' ' 96' ' ' GLY . 72.3 m-70 . . . . . 0 N--CA 1.491 1.593 0 O-C-N 121.386 -1.067 . . . . 0.0 110.283 -179.165 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 70.5 mtm . . . . . 0 N--CA 1.492 1.641 0 CA-C-O 121.252 0.549 . . . . 0.0 110.164 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' B' ' 2' ' ' PHE . 6.4 p90 -171.61 148.5 2.47 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 121.144 -0.973 . . . . 0.0 109.119 176.659 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.54 ' CB ' HG12 ' B' ' 5' ' ' ILE . 4.9 p -146.25 -37.76 0.24 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.187 -0.946 . . . . 0.0 109.029 178.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.494 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 46.19 26.43 2.24 Favored Glycine 0 N--CA 1.484 1.864 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 -176.832 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.54 HG12 ' CB ' ' B' ' 3' ' ' THR . 28.0 mm -78.85 129.95 36.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.523 -0.986 . . . . 0.0 109.581 -178.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.528 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.2 t -92.98 140.36 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 120.986 -1.071 . . . . 0.0 111.124 -169.765 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 -70.02 -34.73 73.66 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.715 -0.615 . . . . 0.0 111.137 176.826 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.528 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -156.56 172.81 34.33 Favored Glycine 0 N--CA 1.498 2.767 0 C-N-CA 118.814 -1.66 . . . . 0.0 110.599 -172.555 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.452 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 12.5 p -117.7 172.35 7.42 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.074 -1.251 . . . . 0.0 111.01 -176.763 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.529 ' CB ' HG11 ' B' ' 82' ' ' VAL . . . -139.95 148.68 42.3 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.654 -0.653 . . . . 0.0 109.518 -178.791 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 37.6 tttt -107.38 115.42 30.12 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.146 -0.971 . . . . 0.0 110.246 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.522 ' HB3' ' HA ' ' B' ' 78' ' ' VAL . 11.2 tp -60.03 126.67 28.44 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.058 -1.026 . . . . 0.0 108.956 173.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.587 HG13 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -125.14 -29.51 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.827 0 O-C-N 121.347 -0.846 . . . . 0.0 109.974 -179.366 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.88 142.27 24.29 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 119.089 -1.044 . . . . 0.0 111.52 179.819 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.574 HG12 ' CD2' ' B' ' 24' ' ' HIS . 11.8 mt -105.41 137.15 36.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.065 -1.022 . . . . 0.0 110.137 171.606 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.499 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 86.4 m-20 -113.09 115.99 29.18 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.398 -0.814 . . . . 0.0 109.854 173.536 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -105.83 115.24 29.9 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.895 -1.128 . . . . 0.0 110.754 -176.471 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.47 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 4.1 mtmt -110.45 127.67 26.62 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.188 -0.945 . . . . 0.0 108.925 171.636 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -52.34 -18.78 8.4 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.763 1.402 . . . . 0.0 110.744 -179.3 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.57 ' ND2' ' N ' ' B' ' 20' ' ' ASN . 0.3 OUTLIER -90.01 -36.22 15.06 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.174 -0.954 . . . . 0.0 108.659 177.044 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.499 ' CD2' ' HB2' ' B' ' 20' ' ' ASN . 81.7 m-85 -150.71 150.2 30.77 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.886 -0.509 . . . . 0.0 109.801 179.263 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.456 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 62.4 ttt180 -97.76 143.85 27.97 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.733 -1.229 . . . . 0.0 109.994 176.499 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.499 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 97.3 m -130.03 140.12 50.91 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.579 -0.7 . . . . 0.0 110.04 -173.335 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.574 ' CD2' HG12 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -129.99 135.94 48.86 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.045 -1.035 . . . . 0.0 111.186 179.179 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.53 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 15.7 t -115.54 134.44 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.09 -1.006 . . . . 0.0 110.687 -178.379 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.452 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 30.2 m -119.97 170.02 10.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 C-N-CA 120.46 -0.496 . . . . 0.0 109.957 -179.711 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.502 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 7.6 tt0 -103.51 117.13 33.74 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 121.455 -0.778 . . . . 0.0 108.968 -179.347 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.473 HD21 ' HA ' ' B' ' 33' ' ' LEU . 8.9 tp -82.05 119.77 75.86 Favored Pre-proline 0 C--N 1.294 -1.81 0 O-C-N 121.449 -0.782 . . . . 0.0 109.815 -173.678 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.474 ' HD2' ' HB2' ' B' ' 32' ' ' MET . 22.1 Cg_endo -65.42 179.08 1.75 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 O-C-N 123.829 1.437 . . . . 0.0 111.032 -179.327 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.419 ' OD1' ' C ' ' B' ' 30' ' ' ASP . 50.5 t0 -60.01 -41.26 91.78 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.413 -0.804 . . . . 0.0 111.134 -175.338 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.551 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.36 1.5 56.52 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.971 -1.08 . . . . 0.0 110.804 -174.236 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.551 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 96.4 mmm -110.97 -15.98 13.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.049 -1.032 . . . . 0.0 109.839 171.818 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.532 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 16.6 mt -68.01 -30.49 69.75 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.412 -0.805 . . . . 0.0 110.043 178.932 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -91.72 127.02 37.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.331 -0.856 . . . . 0.0 110.238 -179.635 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.3 -47.98 1.0 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 177.673 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . 0.443 HD11 HD23 ' B' ' 28' ' ' LEU . 7.4 tt -69.97 145.74 51.62 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.022 -1.281 . . . . 0.0 110.649 -175.758 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.476 ' O ' ' HB3' ' B' ' 40' ' ' ALA . 20.7 pt-20 -150.44 169.99 20.14 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.505 -0.747 . . . . 0.0 109.608 -179.529 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.524 ' CG2' ' HA ' ' B' ' 53' ' ' GLU . 0.0 OUTLIER -67.25 151.09 48.13 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.883 -1.136 . . . . 0.0 110.115 179.996 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.74 -0.09 62.4 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -176.211 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.476 ' HB3' ' O ' ' B' ' 37' ' ' GLU . . . -79.85 158.94 26.63 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.281 -1.129 . . . . 0.0 109.656 177.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.461 ' HB2' ' HB2' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -100.94 113.24 26.02 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.993 -1.067 . . . . 0.0 110.075 176.7 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.581 ' HB ' ' CE1' ' B' ' 61' ' ' PHE . 2.0 t -104.89 130.02 56.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 121.285 -0.884 . . . . 0.0 109.111 174.764 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.48 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -93.22 119.53 32.5 Favored 'General case' 0 C--N 1.298 -1.645 0 C-N-CA 119.085 -1.046 . . . . 0.0 109.278 172.155 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.567 ' CE1' HG11 ' B' ' 42' ' ' VAL . 0.3 OUTLIER -88.0 107.03 18.53 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.416 -0.802 . . . . 0.0 109.066 178.503 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.51 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.1 t-20 50.44 16.23 0.27 Allowed 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.469 -0.77 . . . . 0.0 111.222 -166.506 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.48 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 120.82 1.23 11.81 Favored Glycine 0 N--CA 1.49 2.298 0 C-N-CA 119.407 -1.378 . . . . 0.0 111.086 171.158 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.538 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 35.1 t -98.92 108.44 21.12 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.188 -1.772 . . . . 0.0 109.379 175.02 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . 0.507 ' SG ' ' C8 ' ' B' ' 99' ' ' RBF . 21.0 p -75.58 126.84 31.8 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.113 -0.992 . . . . 0.0 111.011 -171.172 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.538 ' CD2' ' O ' ' B' ' 47' ' ' CYS . 0.4 OUTLIER -141.44 162.74 34.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.458 -0.776 . . . . 0.0 109.461 172.637 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 50' ' ' THR . . . . . 0.43 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 55.0 m -102.44 152.97 20.5 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 120.612 -1.305 . . . . 0.0 111.037 -171.14 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.541 ' CG1' HG11 ' B' ' 59' ' ' VAL . 34.0 t -76.91 117.55 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.509 -0.745 . . . . 0.0 110.488 -177.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.539 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 40.9 p -70.02 -40.11 75.42 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.087 -1.008 . . . . 0.0 109.691 172.271 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.524 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 52.3 tp10 -164.68 156.14 15.39 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.252 -0.905 . . . . 0.0 110.838 -177.328 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.52 HD11 ' CG2' ' B' ' 38' ' ' THR . 9.0 mt -110.44 130.02 64.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.236 -0.915 . . . . 0.0 110.029 172.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.482 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 63.7 m-80 -104.74 65.45 0.75 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-O 121.445 0.641 . . . . 0.0 109.482 177.823 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.13 -115.04 4.21 Favored Glycine 0 N--CA 1.486 2.005 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 -174.213 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.532 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.01 -21.22 43.85 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.035 -1.273 . . . . 0.0 109.183 176.596 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.587 ' CD2' HG13 ' B' ' 13' ' ' VAL . 9.6 m170 -76.95 159.23 30.12 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.155 -0.966 . . . . 0.0 109.758 -178.036 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.584 HG12 ' CE2' ' B' ' 61' ' ' PHE . 59.5 t -140.83 121.52 13.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 C-N-CA 119.008 -1.077 . . . . 0.0 110.469 171.796 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.53 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 1.2 t -84.42 135.35 34.3 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.468 -0.77 . . . . 0.0 109.368 175.876 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.584 ' CE2' HG12 ' B' ' 59' ' ' VAL . 58.7 m-85 -115.47 158.72 22.15 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.287 -0.883 . . . . 0.0 110.165 179.012 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.539 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 25.1 p-10 -92.25 147.48 22.89 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.08 -1.013 . . . . 0.0 110.876 178.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.523 HD22 ' CD1' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.69 125.09 4.12 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -176.885 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.512 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 56.1 ttm -84.92 146.4 27.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.966 -1.084 . . . . 0.0 109.388 -177.811 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.421 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 71.3 tttt -60.03 -49.14 78.84 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.104 -0.998 . . . . 0.0 109.977 -177.205 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -69.6 -39.99 76.91 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.149 -0.969 . . . . 0.0 110.444 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.512 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 38.5 m -62.26 -38.83 90.8 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.935 -1.103 . . . . 0.0 108.98 174.449 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.518 ' CD1' ' HA2' ' B' ' 74' ' ' GLY . 1.0 OUTLIER -59.9 -47.28 86.43 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.436 -0.79 . . . . 0.0 109.8 177.398 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 74.9 ttt-85 -65.83 -39.99 91.36 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.54 -0.725 . . . . 0.0 110.513 178.173 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.496 HG23 ' N ' ' B' ' 71' ' ' THR . 1.3 tt -64.2 -41.19 91.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.285 -0.885 . . . . 0.0 109.13 -179.381 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.496 ' N ' HG23 ' B' ' 70' ' ' ILE . 20.4 p -89.7 -176.85 5.11 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 120.236 -0.586 . . . . 0.0 109.433 175.602 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.478 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 3.5 t30 -100.0 25.09 7.73 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.079 -1.013 . . . . 0.0 108.307 172.336 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.523 ' CD1' HD22 ' B' ' 63' ' ' LEU . 86.6 mt -67.69 -39.94 84.38 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.995 -1.066 . . . . 0.0 109.945 176.609 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.518 ' HA2' ' CD1' ' B' ' 68' ' ' LEU . . . -54.86 -23.95 32.12 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 110.321 -1.112 . . . . 0.0 110.321 -177.527 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 21.5 p-10 -64.1 -17.02 63.02 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.006 -1.29 . . . . 0.0 110.349 -175.381 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 96.1 mt -60.0 141.41 55.68 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.252 -0.905 . . . . 0.0 110.484 -177.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.472 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 59.8 mmtt -139.93 143.29 36.53 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 121.555 0.693 . . . . 0.0 110.446 175.771 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.565 ' CG2' HG13 ' B' ' 15' ' ' ILE . 36.5 t -63.19 149.47 10.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.22 -176.152 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.48 -13.53 63.64 Favored Glycine 0 N--CA 1.483 1.808 0 N-CA-C 108.818 -1.713 . . . . 0.0 108.818 -175.3 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 46.0 t0 -96.27 162.99 13.27 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.27 -1.135 . . . . 0.0 109.629 175.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 13.6 m95 -113.9 162.05 16.86 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.09 -1.007 . . . . 0.0 110.178 176.598 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.565 HG21 ' CG ' ' B' ' 44' ' ' HIS . 1.5 p -130.78 140.31 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.545 -0.722 . . . . 0.0 110.179 -175.78 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.447 ' OD1' ' N ' ' A' ' 72' ' ' ASN . 0.2 OUTLIER -66.87 103.78 1.21 Allowed 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.115 -0.991 . . . . 0.0 109.549 169.089 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.485 HG11 ' ND1' ' B' ' 44' ' ' HIS . 0.1 OUTLIER -106.48 137.92 34.58 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 120.589 -1.319 . . . . 0.0 111.28 -178.692 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . 0.44 ' HB2' HG22 ' B' ' 6' ' ' VAL . 84.3 tt0 -133.03 131.64 40.91 Favored 'General case' 0 N--CA 1.493 1.7 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.036 179.681 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 75.9 ttt180 -72.11 139.17 48.24 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.25 -0.906 . . . . 0.0 110.955 -175.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.579 ' HB2' ' CZ ' ' A' ' 2' ' ' PHE . . . -132.48 150.26 52.19 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.389 -0.82 . . . . 0.0 109.749 176.623 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -117.43 141.89 47.79 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.257 -0.902 . . . . 0.0 111.02 -174.099 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 20.2 mmtt -60.35 -39.93 88.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.369 -0.832 . . . . 0.0 110.287 -179.541 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 44.4 p90 -118.81 162.59 18.22 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.254 -0.904 . . . . 0.0 110.227 -178.741 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 91' ' ' SER . . . . . . . . . . . . . 12.9 m -105.12 131.37 52.7 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.265 -0.897 . . . . 0.0 110.643 -175.447 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -61.88 -39.95 93.7 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.335 -0.853 . . . . 0.0 110.36 177.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . 0.412 ' O ' ' HG3' ' B' ' 93' ' ' GLU . 21.5 pt-20 -159.17 53.61 0.4 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.095 -1.003 . . . . 0.0 110.491 -177.294 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . 0.446 HG21 ' O ' ' B' ' 94' ' ' ILE . 28.0 mt -124.22 13.9 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.256 -0.903 . . . . 0.0 110.25 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . -69.08 64.39 0.51 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -178.248 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . 0.413 ' O ' ' HB3' ' B' ' 97' ' ' HIS . . . 95.68 37.36 5.03 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 177.712 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . 0.413 ' HB3' ' O ' ' B' ' 96' ' ' GLY . 22.2 t-80 . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.197 -1.178 . . . . 0.0 110.156 179.43 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.501 ' C8 ' ' SG ' ' A' ' 48' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.507 ' C8 ' ' SG ' ' B' ' 48' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.474 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 76.6 mtm . . . . . 0 N--CA 1.493 1.701 0 CA-C-O 121.116 0.484 . . . . 0.0 110.139 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.584 ' CD1' ' O ' ' A' ' 2' ' ' PHE . 7.3 p90 -179.09 139.97 0.16 Allowed 'General case' 0 C--N 1.307 -1.253 0 O-C-N 121.328 -0.857 . . . . 0.0 108.974 178.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.512 ' CB ' HG12 ' A' ' 5' ' ' ILE . 11.1 p -130.85 -36.71 1.35 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 120.973 -1.079 . . . . 0.0 109.176 -176.54 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.484 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 55.12 20.31 20.19 Favored Glycine 0 N--CA 1.484 1.835 0 N-CA-C 108.689 -1.764 . . . . 0.0 108.689 -179.27 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.512 HG12 ' CB ' ' A' ' 3' ' ' THR . 32.1 mm -80.89 125.06 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.442 -1.034 . . . . 0.0 109.579 -176.701 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.523 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.9 t -82.93 143.53 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.014 -1.054 . . . . 0.0 111.408 -167.372 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . 0.433 ' HG2' ' HG3' ' A' ' 85' ' ' GLU . 89.5 mm-40 -70.02 -38.59 75.95 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.662 -0.649 . . . . 0.0 110.294 173.349 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.523 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -168.3 -176.52 38.76 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 119.404 -1.379 . . . . 0.0 109.816 -176.996 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.472 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 1.1 p -120.78 171.83 8.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.96 -1.317 . . . . 0.0 110.859 -177.431 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.537 ' CB ' HG13 ' A' ' 82' ' ' VAL . . . -140.3 149.92 43.38 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.556 -0.715 . . . . 0.0 109.531 -178.221 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.585 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 35.2 tttt -105.52 116.02 31.24 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 120.922 -1.111 . . . . 0.0 110.138 178.597 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.519 ' CG ' ' HA ' ' A' ' 78' ' ' VAL . 12.9 tp -59.83 128.48 37.14 Favored 'General case' 0 C--N 1.297 -1.703 0 O-C-N 120.863 -1.148 . . . . 0.0 108.69 172.558 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.629 ' CG1' ' CD2' ' A' ' 58' ' ' HIS . 1.6 p -129.41 -29.3 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.291 -177.839 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.68 142.36 26.66 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 118.948 -1.101 . . . . 0.0 111.534 179.368 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.578 HG13 ' CG2' ' A' ' 78' ' ' VAL . 10.9 mt -107.81 135.71 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.037 -1.039 . . . . 0.0 110.174 171.653 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.47 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 83.5 m-20 -110.14 114.56 28.15 Favored 'General case' 0 C--N 1.295 -1.769 0 O-C-N 121.308 -0.87 . . . . 0.0 110.272 173.909 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -101.91 109.6 21.38 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.175 -0.953 . . . . 0.0 110.421 -178.231 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.472 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.4 mtpt -103.87 134.54 19.67 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.056 -1.028 . . . . 0.0 109.424 175.272 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.58 -18.31 8.26 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 O-C-N 123.995 1.524 . . . . 0.0 110.802 -179.616 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.575 ' O ' ' CD1' ' A' ' 21' ' ' PHE . 0.3 OUTLIER -99.28 -32.77 11.03 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.143 -0.973 . . . . 0.0 109.138 -179.906 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.575 ' CD1' ' O ' ' A' ' 20' ' ' ASN . 56.3 m-85 -150.48 150.21 31.0 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.835 -0.54 . . . . 0.0 110.144 -175.747 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.461 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 56.1 ttt180 -94.02 143.33 26.45 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.639 -1.288 . . . . 0.0 110.055 173.14 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.47 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 44.5 m -129.99 139.22 51.09 Favored 'General case' 0 C--N 1.296 -1.743 0 O-C-N 121.564 -0.71 . . . . 0.0 109.818 -175.315 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.545 ' CD2' HG12 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.0 135.46 48.32 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.862 -1.149 . . . . 0.0 111.312 179.377 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.521 ' CG2' ' OG ' ' A' ' 60' ' ' SER . 4.8 t -117.47 131.91 68.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.085 -1.01 . . . . 0.0 110.731 -176.791 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.462 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 7.0 m -113.63 172.32 3.52 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.94 -0.475 . . . . 0.0 110.061 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.552 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 7.1 tt0 -105.34 117.27 33.59 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.427 -0.795 . . . . 0.0 108.948 178.567 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.519 ' HB3' ' CD2' ' A' ' 33' ' ' LEU . 9.0 tp -83.55 121.05 76.32 Favored Pre-proline 0 C--N 1.296 -1.751 0 O-C-N 121.632 -0.668 . . . . 0.0 109.943 -172.888 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.464 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 25.1 Cg_endo -66.27 176.0 4.4 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 O-C-N 123.9 1.474 . . . . 0.0 111.007 -179.372 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.441 ' HA ' HD12 ' A' ' 33' ' ' LEU . 51.2 t0 -60.07 -39.97 87.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.424 -0.798 . . . . 0.0 111.049 -175.177 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.578 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.08 0.35 57.18 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.939 -1.1 . . . . 0.0 110.785 -174.917 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.578 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 98.0 mmm -113.06 -11.03 13.4 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.959 -1.088 . . . . 0.0 110.053 172.328 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.53 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 15.7 mt -69.98 -32.32 70.46 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.304 -0.872 . . . . 0.0 109.923 177.629 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -79.91 139.91 36.92 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.512 -0.742 . . . . 0.0 111.009 -176.156 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.01 -38.43 3.17 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 120.024 -1.084 . . . . 0.0 110.645 171.786 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 64.7 tp -77.99 147.72 34.74 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.787 -1.42 . . . . 0.0 111.102 -174.015 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.464 ' O ' ' HB1' ' A' ' 40' ' ' ALA . 20.6 pt-20 -149.23 170.04 19.39 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.459 -0.775 . . . . 0.0 109.322 175.216 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.533 ' CG2' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -62.96 151.94 38.1 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.931 -1.106 . . . . 0.0 110.027 -178.688 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.24 -3.48 62.11 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -176.225 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.464 ' HB1' ' O ' ' A' ' 37' ' ' GLU . . . -77.1 158.72 30.3 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.242 -1.152 . . . . 0.0 109.491 176.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.47 ' HB2' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -100.97 110.05 22.04 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.901 -1.124 . . . . 0.0 110.045 178.567 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.583 HG13 ' CE1' ' A' ' 44' ' ' HIS . 2.0 t -98.99 129.94 48.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 121.212 -0.93 . . . . 0.0 109.155 174.782 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.478 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -95.51 119.95 34.9 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 119.244 -0.982 . . . . 0.0 109.227 172.093 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.583 ' CE1' HG13 ' A' ' 42' ' ' VAL . 0.6 OUTLIER -88.25 106.97 18.56 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 177.789 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.495 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 55.33 13.76 0.96 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.329 -0.857 . . . . 0.0 110.91 -167.326 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.485 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 117.56 -0.5 18.23 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 119.508 -1.329 . . . . 0.0 110.615 172.797 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.524 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 36.6 t -93.54 105.59 17.63 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.477 -1.602 . . . . 0.0 109.423 175.728 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 25.0 p -73.73 129.44 37.92 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.193 -0.942 . . . . 0.0 111.183 -170.747 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.536 ' CD1' ' HB3' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -145.39 160.57 41.36 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 172.841 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 21.3 m -96.3 152.95 18.1 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.534 -1.354 . . . . 0.0 111.175 -170.095 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.551 ' CG1' HG12 ' A' ' 59' ' ' VAL . 21.2 t -76.96 112.11 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.775 -0.578 . . . . 0.0 110.037 178.695 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.543 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 33.9 p -69.39 -40.05 77.61 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.119 -0.988 . . . . 0.0 109.556 173.757 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.511 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -160.59 156.13 25.21 Favored 'General case' 0 N--CA 1.49 1.557 0 C-N-CA 119.383 -0.927 . . . . 0.0 110.895 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.533 HD11 ' CG2' ' A' ' 38' ' ' THR . 7.8 mt -109.97 130.47 63.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.211 -0.931 . . . . 0.0 109.73 172.598 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.47 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 46.6 m-80 -104.45 65.03 0.76 Allowed 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 119.822 -0.751 . . . . 0.0 109.567 178.13 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.46 -114.91 4.42 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 -173.609 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.53 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.02 -19.74 47.0 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.078 -1.248 . . . . 0.0 109.119 176.645 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.629 ' CD2' ' CG1' ' A' ' 13' ' ' VAL . 9.8 m170 -76.61 159.0 30.66 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.256 -0.903 . . . . 0.0 110.061 -178.663 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.637 ' CG1' ' CZ ' ' A' ' 61' ' ' PHE . 54.0 t -141.45 122.52 12.97 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 O-C-N 121.01 -1.056 . . . . 0.0 111.029 173.655 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.521 ' OG ' ' CG2' ' A' ' 25' ' ' VAL . 17.4 m -91.83 127.48 37.31 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.655 -0.653 . . . . 0.0 109.897 179.581 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.637 ' CZ ' ' CG1' ' A' ' 59' ' ' VAL . 54.4 m-85 -111.59 160.81 16.85 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.869 -1.145 . . . . 0.0 110.243 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.543 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 38.1 p-10 -92.01 148.63 22.05 Favored 'General case' 0 N--CA 1.496 1.858 0 CA-C-O 122.065 0.936 . . . . 0.0 111.321 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.527 ' CD2' HD12 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -156.01 118.55 4.13 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 -177.304 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.508 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 74.3 mmm -73.0 142.73 47.74 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.937 -1.102 . . . . 0.0 109.514 179.088 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.474 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 38.5 tttp -60.0 -44.9 94.24 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.007 -1.058 . . . . 0.0 110.091 -177.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.449 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.6 tt0 -70.04 -39.95 75.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.01 -1.056 . . . . 0.0 110.105 179.109 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.508 ' HB ' ' HB2' ' A' ' 64' ' ' MET . 93.8 m -60.05 -39.37 85.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.923 -1.111 . . . . 0.0 109.286 172.31 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.535 ' CD1' ' HA2' ' A' ' 74' ' ' GLY . 9.3 tp -59.95 -44.95 94.07 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.199 -0.938 . . . . 0.0 109.348 -179.638 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 61.0 ttt180 -69.93 -39.92 75.83 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.517 -0.739 . . . . 0.0 110.686 175.528 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.452 HG23 HG22 ' A' ' 71' ' ' THR . 1.4 tt -66.85 -42.61 89.35 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 O-C-N 121.164 -0.96 . . . . 0.0 109.386 -176.289 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.472 HG22 ' O ' ' A' ' 67' ' ' THR . 43.6 p -84.74 -174.1 5.09 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 175.642 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.472 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 6.7 t30 -102.17 24.02 10.78 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 170.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.451 HD11 ' SG ' ' A' ' 47' ' ' CYS . 98.0 mt -69.98 -40.04 75.57 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.136 -0.978 . . . . 0.0 109.734 176.455 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.535 ' HA2' ' CD1' ' A' ' 68' ' ' LEU . . . -49.55 -22.91 4.24 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.381 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 25.6 p-10 -63.61 -19.33 64.76 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.014 -1.286 . . . . 0.0 110.357 -175.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.514 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.4 mt -61.33 140.43 58.0 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.148 -0.97 . . . . 0.0 110.962 -176.769 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.497 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 22.8 mttm -141.44 139.35 33.36 Favored 'General case' 0 C--N 1.296 -1.726 0 CA-C-O 121.479 0.657 . . . . 0.0 109.559 174.356 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.578 ' CG2' HG13 ' A' ' 15' ' ' ILE . 44.0 t -60.93 151.46 6.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 O-C-N 120.924 -1.11 . . . . 0.0 110.327 -176.338 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.97 -14.66 61.35 Favored Glycine 0 N--CA 1.482 1.746 0 N-CA-C 108.751 -1.739 . . . . 0.0 108.751 -175.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -98.16 167.12 11.07 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.31 -1.112 . . . . 0.0 109.626 175.311 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.585 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.5 m95 -115.37 156.72 25.02 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.104 -0.997 . . . . 0.0 110.134 177.092 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.537 HG13 ' CB ' ' A' ' 10' ' ' ALA . 0.9 OUTLIER -120.13 155.15 23.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 O-C-N 121.527 -0.733 . . . . 0.0 109.892 -178.124 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.516 ' N ' HG23 ' A' ' 82' ' ' VAL . 2.5 m-20 -80.02 106.75 12.27 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.21 -0.931 . . . . 0.0 108.988 168.793 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.472 ' CG2' ' C ' ' A' ' 9' ' ' THR . 0.0 OUTLIER -107.25 138.6 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.55 -1.344 . . . . 0.0 111.039 -175.223 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.433 ' HG3' ' HG2' ' A' ' 7' ' ' GLN . 86.4 tt0 -136.83 135.34 37.84 Favored 'General case' 0 N--CA 1.492 1.632 0 C-N-CA 120.381 -0.528 . . . . 0.0 109.752 -178.355 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -78.67 129.92 35.27 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.055 -1.028 . . . . 0.0 110.618 -176.212 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.505 ' HB2' ' CE2' ' B' ' 2' ' ' PHE . . . -121.13 145.6 47.64 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.401 -0.812 . . . . 0.0 110.199 178.298 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -128.12 141.17 51.57 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.799 -0.563 . . . . 0.0 110.352 -178.662 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 12.1 pttt -69.99 -21.01 63.27 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.234 -0.916 . . . . 0.0 110.008 177.469 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 39.9 p90 -141.15 160.33 40.33 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.05 -1.031 . . . . 0.0 110.119 174.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' SER . . . . . 0.46 ' OG ' ' HG3' ' A' ' 93' ' ' GLU . 74.4 p -140.25 149.94 43.48 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.305 -0.872 . . . . 0.0 110.282 176.556 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.416 ' O ' ' HB2' ' A' ' 93' ' ' GLU . 51.9 t0 -69.99 -39.98 75.57 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.267 -0.896 . . . . 0.0 110.185 178.331 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.46 ' HG3' ' OG ' ' A' ' 91' ' ' SER . 98.9 mt-10 51.85 54.76 10.36 Favored 'General case' 0 N--CA 1.504 2.269 0 O-C-N 121.164 -0.96 . . . . 0.0 109.919 176.413 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.432 ' O ' ' C ' ' A' ' 95' ' ' GLY . 40.6 mm -59.98 -41.27 85.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.366 -0.834 . . . . 0.0 109.862 178.268 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' A' ' 94' ' ' ILE . . . 41.28 57.86 3.01 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 178.647 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -86.99 -9.23 74.27 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 41.5 m80 . . . . . 0 N--CA 1.492 1.652 0 O-C-N 121.267 -1.137 . . . . 0.0 110.227 -179.501 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 60.2 ttm . . . . . 0 N--CA 1.494 1.738 0 CA-C-O 121.156 0.503 . . . . 0.0 110.24 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.589 ' CD1' ' O ' ' B' ' 2' ' ' PHE . 7.0 p90 -174.14 139.79 0.65 Allowed 'General case' 0 C--N 1.306 -1.314 0 O-C-N 121.173 -0.955 . . . . 0.0 108.961 174.259 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.527 ' CB ' HG12 ' B' ' 5' ' ' ILE . 11.0 p -130.89 -36.68 1.35 Allowed 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.016 -1.052 . . . . 0.0 109.17 -176.602 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.485 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 55.04 20.3 19.5 Favored Glycine 0 N--CA 1.484 1.872 0 N-CA-C 108.645 -1.782 . . . . 0.0 108.645 -179.252 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.527 HG12 ' CB ' ' B' ' 3' ' ' THR . 32.7 mm -80.81 125.07 39.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.412 -1.052 . . . . 0.0 109.505 -176.658 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.522 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.9 t -83.03 143.53 11.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 120.995 -1.066 . . . . 0.0 111.42 -167.406 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . 0.442 ' HG2' ' HG3' ' B' ' 85' ' ' GLU . 89.6 mm-40 -70.02 -38.31 75.86 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.694 -0.629 . . . . 0.0 110.371 173.437 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.522 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -168.6 -176.65 39.02 Favored Glycine 0 N--CA 1.494 2.556 0 C-N-CA 119.478 -1.344 . . . . 0.0 109.854 -177.013 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.48 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 1.1 p -120.73 171.83 8.32 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.039 -1.271 . . . . 0.0 110.918 -177.401 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.537 ' CB ' HG11 ' B' ' 82' ' ' VAL . . . -140.29 149.94 43.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.533 -0.729 . . . . 0.0 109.444 -178.18 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.587 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 35.3 tttt -105.51 116.13 31.42 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.057 -1.027 . . . . 0.0 110.087 178.531 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.526 ' CG ' ' HA ' ' B' ' 78' ' ' VAL . 12.9 tp -60.03 128.31 36.21 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.971 -1.081 . . . . 0.0 108.781 172.461 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.632 ' CG1' ' CD2' ' B' ' 58' ' ' HIS . 1.6 p -129.12 -29.53 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 C-N-CA 119.565 -0.854 . . . . 0.0 110.296 -177.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.57 142.33 26.74 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 119.072 -1.051 . . . . 0.0 111.501 179.454 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.57 HG13 ' CG2' ' B' ' 78' ' ' VAL . 10.9 mt -107.76 135.84 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.116 -0.99 . . . . 0.0 110.207 171.606 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.483 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.2 m-20 -110.33 114.69 28.35 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.443 -0.785 . . . . 0.0 110.184 173.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -101.91 109.53 21.29 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.099 -1.001 . . . . 0.0 110.443 -178.25 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.467 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.4 mtpt -103.88 134.6 19.63 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.218 -0.926 . . . . 0.0 109.546 175.196 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -52.73 -18.2 8.48 Favored 'Trans proline' 0 C--N 1.303 -1.868 0 O-C-N 123.952 1.501 . . . . 0.0 110.747 -179.461 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.574 ' O ' ' CD1' ' B' ' 21' ' ' PHE . 0.3 OUTLIER -99.04 -33.46 10.8 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.154 -0.966 . . . . 0.0 109.044 -179.966 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.574 ' CD1' ' O ' ' B' ' 20' ' ' ASN . 56.2 m-85 -149.96 150.31 31.64 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 120.327 -0.549 . . . . 0.0 110.176 -175.634 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.466 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 56.1 ttt180 -94.01 143.42 26.37 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.757 -1.214 . . . . 0.0 110.008 173.101 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.483 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 42.9 m -130.09 139.3 50.97 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.745 -0.597 . . . . 0.0 109.736 -175.367 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.55 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.02 135.64 48.5 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.984 -1.073 . . . . 0.0 111.227 179.347 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.53 ' HA ' ' HA ' ' B' ' 60' ' ' SER . 4.8 t -117.42 131.99 68.52 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.262 -0.899 . . . . 0.0 110.769 -176.822 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.473 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 7.2 m -113.79 172.24 3.62 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 O-C-N 121.909 -0.495 . . . . 0.0 110.025 179.234 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.555 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 7.0 tt0 -105.09 117.32 33.7 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.466 -0.771 . . . . 0.0 109.118 178.413 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.526 ' HB3' ' CD2' ' B' ' 33' ' ' LEU . 8.9 tp -83.51 120.99 76.35 Favored Pre-proline 0 C--N 1.295 -1.779 0 O-C-N 121.555 -0.716 . . . . 0.0 110.028 -172.944 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.454 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 25.6 Cg_endo -66.16 175.97 4.33 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 O-C-N 123.856 1.45 . . . . 0.0 111.005 -179.41 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.403 ' OD1' ' C ' ' B' ' 30' ' ' ASP . 51.3 t0 -60.02 -40.07 88.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.448 -0.783 . . . . 0.0 111.061 -175.27 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.583 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.02 0.34 57.16 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.884 -1.135 . . . . 0.0 110.851 -174.925 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.583 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 98.0 mmm -113.05 -11.2 13.39 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.105 -0.997 . . . . 0.0 110.053 172.377 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.543 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 15.8 mt -69.89 -32.21 70.41 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.35 -0.844 . . . . 0.0 110.022 177.628 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -80.11 139.96 36.64 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.545 -0.722 . . . . 0.0 110.927 -176.16 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.92 -38.4 3.17 Favored Glycine 0 N--CA 1.493 2.442 0 C-N-CA 119.965 -1.112 . . . . 0.0 110.581 171.799 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . 0.502 ' CD2' HD23 ' B' ' 28' ' ' LEU . 64.5 tp -77.97 147.68 34.8 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.93 -1.335 . . . . 0.0 111.146 -174.101 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.46 ' O ' ' HB1' ' B' ' 40' ' ' ALA . 20.6 pt-20 -149.13 170.03 19.35 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.466 -0.771 . . . . 0.0 109.323 175.269 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.534 ' CG2' HD12 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -62.99 151.79 38.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.932 -1.105 . . . . 0.0 110.071 -178.8 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.34 -3.51 62.37 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -176.159 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.46 ' HB1' ' O ' ' B' ' 37' ' ' GLU . . . -77.18 158.58 30.27 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.184 -1.186 . . . . 0.0 109.446 176.764 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.462 ' OG ' ' O ' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -100.65 109.84 21.93 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 120.904 -1.123 . . . . 0.0 110.14 178.537 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.572 HG11 ' CE1' ' B' ' 44' ' ' HIS . 2.0 t -99.0 129.9 48.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.284 -0.885 . . . . 0.0 109.171 174.713 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.475 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -95.44 120.01 34.94 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 119.204 -0.999 . . . . 0.0 109.199 172.06 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.572 ' CE1' HG11 ' B' ' 42' ' ' VAL . 0.6 OUTLIER -88.29 106.79 18.45 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.408 -0.807 . . . . 0.0 108.915 177.691 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.495 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 55.5 13.88 1.05 Allowed 'General case' 0 C--N 1.299 -1.597 0 O-C-N 121.333 -0.854 . . . . 0.0 110.888 -167.346 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.484 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 117.46 -0.32 18.44 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.513 -1.327 . . . . 0.0 110.612 172.671 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.519 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 36.7 t -93.66 105.59 17.62 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.536 -1.567 . . . . 0.0 109.439 175.67 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . 0.456 ' SG ' ' O ' ' A' ' 3' ' ' THR . 25.1 p -73.65 129.56 38.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.084 -1.01 . . . . 0.0 111.079 -170.707 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.519 ' CD2' ' O ' ' B' ' 47' ' ' CYS . 0.2 OUTLIER -145.61 160.54 41.52 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 172.714 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 21.3 m -96.14 153.05 18.0 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.703 -1.248 . . . . 0.0 111.181 -170.021 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.543 ' CG1' HG11 ' B' ' 59' ' ' VAL . 21.2 t -77.06 112.05 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.652 -0.655 . . . . 0.0 110.126 178.598 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.544 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 34.5 p -69.54 -39.91 77.18 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.168 -0.958 . . . . 0.0 109.462 173.986 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.511 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -160.64 156.1 25.05 Favored 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.861 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.534 HD12 ' CG2' ' B' ' 38' ' ' THR . 7.8 mt -110.01 130.42 63.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.259 -0.901 . . . . 0.0 109.728 172.651 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.482 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 46.6 m-80 -104.55 65.03 0.76 Allowed 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.575 178.151 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.61 -114.94 4.4 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 108.716 -1.754 . . . . 0.0 108.716 -173.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.543 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.03 -19.66 47.15 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.05 -1.265 . . . . 0.0 109.194 176.645 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.632 ' CD2' ' CG1' ' B' ' 13' ' ' VAL . 9.9 m170 -76.6 158.78 30.84 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.359 -0.838 . . . . 0.0 110.096 -178.698 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.645 ' CG1' ' CZ ' ' B' ' 61' ' ' PHE . 54.4 t -141.32 122.64 13.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.967 173.735 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.53 ' HA ' ' HA ' ' B' ' 25' ' ' VAL . 17.4 m -91.92 127.56 37.43 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.767 -0.583 . . . . 0.0 109.953 179.554 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.645 ' CZ ' ' CG1' ' B' ' 59' ' ' VAL . 54.4 m-85 -111.55 160.81 16.83 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.056 -1.027 . . . . 0.0 110.314 179.258 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.544 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 38.0 p-10 -92.0 148.66 22.03 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.135 -0.978 . . . . 0.0 111.269 179.805 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.524 ' CD2' HD11 ' B' ' 68' ' ' LEU . 0.0 OUTLIER -156.0 118.48 4.12 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -177.354 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.51 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 74.2 mmm -73.01 142.77 47.72 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.907 -1.12 . . . . 0.0 109.481 179.147 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.473 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 38.5 tttp -59.98 -44.92 94.17 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.091 -1.005 . . . . 0.0 110.075 -177.822 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . 0.454 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 86.6 tt0 -69.99 -40.06 75.52 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.047 -1.033 . . . . 0.0 110.062 179.196 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.51 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 94.2 m -59.96 -39.53 85.92 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.923 -1.111 . . . . 0.0 109.144 172.41 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.529 ' CD1' ' HA2' ' B' ' 74' ' ' GLY . 9.4 tp -60.07 -44.71 94.56 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.428 -0.795 . . . . 0.0 109.436 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 61.1 ttt180 -70.04 -39.92 75.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.498 -0.751 . . . . 0.0 110.673 175.372 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.484 HG22 HG23 ' B' ' 71' ' ' THR . 1.4 tt -66.77 -42.52 89.47 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.263 -0.898 . . . . 0.0 109.421 -176.368 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.484 HG23 HG22 ' B' ' 70' ' ' ILE . 43.8 p -84.74 -173.85 4.95 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 175.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.474 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 6.7 t30 -102.31 24.06 10.82 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 170.855 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.467 ' HB3' HD22 ' B' ' 63' ' ' LEU . 98.0 mt -69.99 -40.1 75.53 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.192 -0.942 . . . . 0.0 109.745 176.403 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.529 ' HA2' ' CD1' ' B' ' 68' ' ' LEU . . . -49.59 -22.91 4.31 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 -179.396 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 25.7 p-10 -63.55 -19.38 64.75 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.031 -1.276 . . . . 0.0 110.374 -175.934 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 97.5 mt -61.27 140.47 57.96 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.199 -0.938 . . . . 0.0 110.915 -176.786 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.498 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 22.8 mttm -141.39 139.38 33.47 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-O 121.336 0.589 . . . . 0.0 109.556 174.322 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.57 ' CG2' HG13 ' B' ' 15' ' ' ILE . 44.2 t -60.95 151.33 6.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 120.93 -1.107 . . . . 0.0 110.315 -176.345 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.96 -14.43 61.95 Favored Glycine 0 N--CA 1.482 1.751 0 N-CA-C 108.781 -1.727 . . . . 0.0 108.781 -175.41 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -98.2 167.09 11.08 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.362 -1.081 . . . . 0.0 109.6 175.207 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.587 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.4 m95 -115.42 156.71 25.09 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.177 -0.952 . . . . 0.0 110.13 177.073 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.537 HG11 ' CB ' ' B' ' 10' ' ' ALA . 0.9 OUTLIER -120.12 155.26 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.532 -0.73 . . . . 0.0 109.955 -178.206 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.469 ' ND2' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -80.05 106.43 12.06 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.243 -0.911 . . . . 0.0 109.03 168.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.48 ' CG2' ' C ' ' B' ' 9' ' ' THR . 0.0 OUTLIER -106.94 138.72 31.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 120.588 -1.32 . . . . 0.0 111.061 -175.145 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . 0.442 ' HG3' ' HG2' ' B' ' 7' ' ' GLN . 86.4 tt0 -137.02 135.36 37.51 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.836 -0.54 . . . . 0.0 109.765 -178.461 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -78.6 130.02 35.45 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.015 -1.053 . . . . 0.0 110.543 -176.155 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.579 ' HB2' ' CE2' ' A' ' 2' ' ' PHE . . . -121.11 145.66 47.57 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.525 -0.734 . . . . 0.0 110.144 178.248 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -128.23 141.14 51.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.625 -0.672 . . . . 0.0 110.322 -178.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 12.1 pttt -69.99 -20.95 63.27 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.287 -0.883 . . . . 0.0 110.028 177.527 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -141.22 160.3 40.39 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.103 -0.998 . . . . 0.0 110.107 174.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 91' ' ' SER . . . . . 0.434 ' HB2' HG12 ' B' ' 94' ' ' ILE . 74.6 p -140.16 149.97 43.64 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.297 -0.877 . . . . 0.0 110.304 176.547 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -70.07 -47.38 62.2 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.252 -0.905 . . . . 0.0 110.17 178.288 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . 0.471 ' O ' ' HG3' ' B' ' 93' ' ' GLU . 8.2 pt-20 -168.97 75.01 0.1 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.415 -0.803 . . . . 0.0 110.471 -176.853 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . 0.434 HG12 ' HB2' ' B' ' 91' ' ' SER . 23.7 mm -60.01 -44.74 95.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 120.964 -1.085 . . . . 0.0 109.855 176.651 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' B' ' 94' ' ' ILE . . . 41.39 57.96 3.04 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 178.163 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.28 -43.09 93.6 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.438 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 14.9 t60 . . . . . 0 N--CA 1.491 1.62 0 O-C-N 121.286 -1.126 . . . . 0.0 110.149 179.795 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.546 " C2'" ' HC9' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.545 " C2'" ' HC9' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.45 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 69.1 mtt . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.104 0.478 . . . . 0.0 110.211 . . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' PHE . . . . . 0.583 ' CD1' ' O ' ' B' ' 88' ' ' ALA . 0.3 OUTLIER -178.12 140.58 0.23 Allowed 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.2 -0.937 . . . . 0.0 109.234 175.582 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.503 ' O ' HG13 ' A' ' 5' ' ' ILE . 14.2 p -136.1 -32.62 0.86 Allowed 'General case' 0 C--N 1.295 -1.781 0 O-C-N 120.977 -1.077 . . . . 0.0 109.96 -174.783 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.415 ' C ' ' O ' ' A' ' 3' ' ' THR . . . 46.8 24.69 1.98 Allowed Glycine 0 N--CA 1.486 2.005 0 N-CA-C 108.847 -1.701 . . . . 0.0 108.847 -175.662 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . 0.515 ' CD1' HC82 ' B' ' 99' ' ' RBF . 30.0 mt -87.63 136.33 23.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.19 -1.183 . . . . 0.0 110.343 -176.976 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.531 ' CG1' ' O ' ' A' ' 8' ' ' GLY . 2.5 t -86.05 143.87 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.279 -0.888 . . . . 0.0 110.779 -175.417 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -70.0 -32.63 70.9 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.619 -0.676 . . . . 0.0 110.803 177.419 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.531 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -164.96 177.26 40.53 Favored Glycine 0 N--CA 1.494 2.564 0 C-N-CA 118.767 -1.682 . . . . 0.0 110.485 -174.237 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' THR . . . . . 0.506 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 2.9 p -116.34 167.89 10.62 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.131 -1.217 . . . . 0.0 110.886 -177.871 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . 0.492 ' O ' ' HA ' ' A' ' 81' ' ' TRP . . . -137.73 148.46 45.64 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 -176.009 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' LYS . . . . . 0.581 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 25.7 tttt -108.88 115.91 30.98 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.022 -1.049 . . . . 0.0 110.379 -179.333 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.517 HD22 ' N ' ' A' ' 78' ' ' VAL . 12.0 tp -58.7 127.37 31.86 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.077 -1.014 . . . . 0.0 108.89 174.284 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.593 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -125.11 -31.48 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 O-C-N 121.352 -0.843 . . . . 0.0 109.932 -179.679 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.54 144.05 28.23 Favored 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.327 -178.054 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.582 HG12 ' CD2' ' A' ' 24' ' ' HIS . 8.6 mt -108.1 130.08 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.214 -0.929 . . . . 0.0 110.181 172.265 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.483 ' CB ' ' HB ' ' A' ' 23' ' ' THR . 67.3 m-20 -105.66 114.24 28.29 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.318 -0.863 . . . . 0.0 109.768 172.895 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -106.59 108.88 20.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.975 -1.078 . . . . 0.0 110.856 -177.511 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' LYS . . . . . 0.464 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -104.26 128.65 26.63 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.198 -0.939 . . . . 0.0 108.888 173.052 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -50.33 -34.06 39.34 Favored 'Trans proline' 0 C--N 1.303 -1.861 0 O-C-N 123.753 1.396 . . . . 0.0 110.496 -179.601 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' ASN . . . . . 0.531 ' C ' ' CD2' ' A' ' 21' ' ' PHE . 12.4 m-80 -71.57 -39.86 70.32 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.201 -0.937 . . . . 0.0 110.039 175.559 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' PHE . . . . . 0.531 ' CD2' ' C ' ' A' ' 20' ' ' ASN . 89.2 m-85 -152.98 150.25 29.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.399 -0.813 . . . . 0.0 109.973 -179.411 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.459 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 62.6 ttt180 -93.27 144.95 24.82 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.732 -1.23 . . . . 0.0 110.124 177.046 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.483 ' HB ' ' CB ' ' A' ' 16' ' ' ASP . 56.8 m -130.31 141.56 50.59 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.48 -0.762 . . . . 0.0 110.09 -176.186 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.582 ' CD2' HG12 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -127.89 144.78 51.09 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 120.974 -1.079 . . . . 0.0 111.342 176.75 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.531 ' CG2' ' OG ' ' A' ' 60' ' ' SER . 4.3 t -124.63 133.55 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.183 -0.948 . . . . 0.0 110.703 -179.27 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.456 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 33.4 m -118.5 172.06 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.796 -0.565 . . . . 0.0 110.425 -179.96 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.457 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 12.9 tt0 -101.14 117.51 35.15 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.594 -0.691 . . . . 0.0 109.318 -179.551 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . 0.527 ' HB3' ' CD2' ' A' ' 33' ' ' LEU . 9.4 tp -82.0 121.26 78.91 Favored Pre-proline 0 C--N 1.297 -1.687 0 O-C-N 121.796 -0.565 . . . . 0.0 109.813 -175.302 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.477 ' HD2' ' HB2' ' A' ' 32' ' ' MET . 25.5 Cg_endo -66.23 179.47 1.95 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 O-C-N 123.863 1.454 . . . . 0.0 110.992 -179.42 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.456 ' HA ' HD12 ' A' ' 33' ' ' LEU . 96.0 m-20 -63.41 -40.0 96.0 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.368 -0.833 . . . . 0.0 111.067 -175.646 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' HIS . . . . . 0.414 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.42 1.09 56.97 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.922 -1.111 . . . . 0.0 111.067 -175.31 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' MET . . . . . 0.477 ' HB2' ' HD2' ' A' ' 29' ' ' PRO . 98.4 mmm -113.92 -13.95 12.51 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.998 -1.064 . . . . 0.0 109.801 172.254 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.536 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 14.0 mt -66.19 -39.85 89.99 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.289 -0.882 . . . . 0.0 109.784 176.57 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -77.19 132.35 38.72 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.496 -0.753 . . . . 0.0 110.586 -177.486 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.51 -43.06 1.87 Allowed Glycine 0 N--CA 1.492 2.391 0 C-N-CA 119.903 -1.141 . . . . 0.0 110.258 174.489 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' LEU . . . . . 0.485 HD12 ' CG2' ' A' ' 42' ' ' VAL . 5.7 tt -69.91 145.7 51.76 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.928 -1.337 . . . . 0.0 110.564 -174.94 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.466 ' O ' ' HB3' ' A' ' 40' ' ' ALA . 20.6 pt-20 -149.98 167.63 26.13 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.524 -0.735 . . . . 0.0 109.416 -179.555 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.534 ' CG2' HD13 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -67.95 149.94 49.13 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.85 -1.156 . . . . 0.0 110.201 -178.114 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.33 -3.61 62.03 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 -173.827 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' ALA . . . . . 0.466 ' HB3' ' O ' ' A' ' 37' ' ' GLU . . . -76.55 159.99 29.85 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.236 -1.155 . . . . 0.0 109.122 174.85 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' SER . . . . . 0.53 ' O ' ' CB ' ' A' ' 87' ' ' ALA . 1.1 p -104.21 117.88 35.3 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 118.72 -1.192 . . . . 0.0 109.897 177.184 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.571 ' CG1' ' CE1' ' A' ' 44' ' ' HIS . 0.9 OUTLIER -99.97 120.09 48.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.363 -0.836 . . . . 0.0 108.956 176.943 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.466 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -82.94 117.33 22.7 Favored 'General case' 0 C--N 1.298 -1.641 0 C-N-CA 119.262 -0.975 . . . . 0.0 109.241 174.495 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' HIS . . . . . 0.571 ' CE1' ' CG1' ' A' ' 42' ' ' VAL . 1.5 m80 -87.24 103.42 15.42 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 176.172 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.4 t-20 55.74 12.05 0.77 Allowed 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.548 -0.72 . . . . 0.0 111.335 -169.483 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.469 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 126.85 -6.13 7.39 Favored Glycine 0 N--CA 1.491 2.362 0 C-N-CA 119.605 -1.283 . . . . 0.0 110.825 173.324 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . 0.517 ' O ' ' CD2' ' A' ' 49' ' ' LEU . 44.8 t -93.31 103.64 15.87 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 120.509 -1.583 . . . . 0.0 109.67 176.038 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.453 ' SG ' ' O ' ' B' ' 3' ' ' THR . 16.0 p -72.18 121.91 20.13 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.096 -1.003 . . . . 0.0 110.737 -174.444 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' LEU . . . . . 0.637 ' CD1' ' CD1' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -132.04 160.57 35.53 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.364 -0.835 . . . . 0.0 109.341 173.704 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.404 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 37.2 m -97.72 152.52 19.03 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.439 -1.413 . . . . 0.0 111.436 -169.555 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . 0.532 ' CG1' HG12 ' A' ' 59' ' ' VAL . 19.4 t -81.02 114.62 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.917 -0.489 . . . . 0.0 110.396 -178.953 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' THR . . . . . 0.49 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 31.1 p -69.85 -40.08 76.02 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.294 -0.879 . . . . 0.0 109.705 174.416 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . 0.528 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.7 tt0 -161.38 155.64 22.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.437 -0.789 . . . . 0.0 109.909 179.686 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.534 HD13 ' CG2' ' A' ' 38' ' ' THR . 7.1 mt -105.15 128.99 58.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.966 -1.084 . . . . 0.0 109.574 174.613 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . 0.507 ' CB ' ' HB2' ' A' ' 58' ' ' HIS . 2.2 m-80 -100.6 62.6 1.05 Allowed 'General case' 0 C--N 1.298 -1.653 0 O-C-N 121.58 -0.7 . . . . 0.0 109.585 -179.014 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.04 -120.05 6.58 Favored Glycine 0 N--CA 1.487 2.054 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 -172.638 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.536 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -71.8 -20.22 61.88 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.931 -1.335 . . . . 0.0 108.981 175.094 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' HIS . . . . . 0.593 ' CD2' HG11 ' A' ' 13' ' ' VAL . 11.8 m170 -76.69 161.3 28.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.425 -0.797 . . . . 0.0 110.386 -176.748 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.532 HG12 ' CG1' ' A' ' 51' ' ' VAL . 54.5 t -140.02 125.52 20.9 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 C-N-CA 119.119 -1.032 . . . . 0.0 110.786 170.66 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' SER . . . . . 0.531 ' OG ' ' CG2' ' A' ' 25' ' ' VAL . 24.8 m -97.61 123.16 41.4 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.763 -0.586 . . . . 0.0 109.509 -179.551 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.637 ' CD1' ' CD1' ' A' ' 49' ' ' LEU . 10.1 p90 -118.32 159.67 22.99 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.822 -1.174 . . . . 0.0 110.72 -179.743 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.49 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 35.2 p-10 -93.37 156.56 16.72 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.089 -1.007 . . . . 0.0 111.532 -172.004 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' LEU . . . . . 0.564 ' CD2' ' CD1' ' A' ' 68' ' ' LEU . 0.1 OUTLIER -161.19 101.93 1.25 Allowed 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.705 -0.622 . . . . 0.0 109.607 -174.135 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' MET . . . . . 0.484 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 57.7 ttm -59.97 137.71 58.02 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.787 -1.195 . . . . 0.0 109.09 179.351 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.475 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 28.6 tttt -60.03 -45.91 91.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.977 -1.077 . . . . 0.0 110.614 -172.154 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.0 tp10 -66.15 -40.07 90.29 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.702 -1.248 . . . . 0.0 109.866 177.402 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' THR . . . . . 0.484 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 94.1 m -59.92 -40.01 87.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.087 -1.008 . . . . 0.0 109.573 172.683 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' LEU . . . . . 0.564 ' CD1' ' CD2' ' A' ' 63' ' ' LEU . 28.0 tp -60.02 -43.45 95.26 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.299 -0.876 . . . . 0.0 109.764 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 ttt85 -69.99 -39.09 76.12 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.326 -0.859 . . . . 0.0 110.352 177.765 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.534 ' CG2' HG22 ' A' ' 71' ' ' THR . 1.4 tt -64.78 -42.71 95.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.28 -0.887 . . . . 0.0 109.448 -176.816 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' THR . . . . . 0.534 HG22 ' CG2' ' A' ' 70' ' ' ILE . 30.5 p -81.99 -174.9 5.33 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 120.015 -0.674 . . . . 0.0 109.243 175.471 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.483 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 5.2 t30 -99.52 22.25 11.04 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.174 -0.954 . . . . 0.0 108.511 171.062 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' LEU . . . . . 0.526 ' CD1' HD23 ' A' ' 63' ' ' LEU . 70.6 mt -70.12 -39.97 75.12 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.946 -1.096 . . . . 0.0 109.816 175.602 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' GLY . . . . . 0.446 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -49.31 -21.67 3.03 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -177.943 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.2 p-10 -66.21 -16.46 64.01 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.068 -1.254 . . . . 0.0 110.562 -175.056 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' LEU . . . . . 0.503 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 96.1 mt -62.07 142.34 57.61 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.209 -0.932 . . . . 0.0 111.173 -175.116 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' LYS . . . . . 0.483 ' C ' ' CD2' ' A' ' 12' ' ' LEU . 86.6 mttt -141.48 141.16 33.65 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.647 -0.658 . . . . 0.0 109.558 172.642 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.55 ' CG2' HG13 ' A' ' 15' ' ' ILE . 16.7 t -59.52 151.72 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 120.711 -1.243 . . . . 0.0 110.297 -176.146 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.79 -13.55 60.64 Favored Glycine 0 N--CA 1.484 1.867 0 N-CA-C 108.948 -1.661 . . . . 0.0 108.948 -176.687 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 53.9 t0 -96.41 162.27 13.56 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.409 -1.054 . . . . 0.0 109.666 177.1 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 81' ' ' TRP . . . . . 0.581 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.0 m95 -113.21 153.33 28.51 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.141 -0.974 . . . . 0.0 110.42 177.369 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.482 HG13 ' HB2' ' A' ' 10' ' ' ALA . 0.8 OUTLIER -119.94 149.72 22.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.409 -0.807 . . . . 0.0 109.804 179.675 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 83' ' ' ASN . . . . . 0.515 ' HB3' ' CG2' ' A' ' 6' ' ' VAL . 0.2 OUTLIER -69.6 102.58 1.88 Allowed 'General case' 0 C--N 1.3 -1.556 0 O-C-N 120.952 -1.092 . . . . 0.0 109.012 167.8 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.506 ' CG2' ' C ' ' A' ' 9' ' ' THR . 0.1 OUTLIER -104.59 137.96 31.4 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 O-C-N 120.311 -1.493 . . . . 0.0 110.957 -178.772 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -135.83 138.42 42.51 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.923 -0.711 . . . . 0.0 110.235 -176.192 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 76.4 ttt180 -61.3 127.46 31.63 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.24 -0.912 . . . . 0.0 110.044 -179.916 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.53 ' CB ' ' O ' ' A' ' 41' ' ' SER . . . -129.24 153.46 47.76 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.257 -0.902 . . . . 0.0 109.957 179.937 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 88' ' ' ALA . . . . . 0.544 ' O ' ' CD1' ' B' ' 2' ' ' PHE . . . -143.14 158.05 43.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.388 -0.82 . . . . 0.0 110.825 -174.342 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . 0.46 ' HA ' ' CE1' ' B' ' 2' ' ' PHE . 32.0 mttt -64.5 -40.06 94.95 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.445 -0.784 . . . . 0.0 110.112 176.207 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -158.79 161.47 36.95 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.336 -0.852 . . . . 0.0 110.323 -178.395 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 91' ' ' SER . . . . . 0.45 ' CB ' ' HG3' ' A' ' 93' ' ' GLU . 72.7 m -129.89 133.19 46.72 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.431 -0.793 . . . . 0.0 110.149 177.801 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.456 ' O ' ' HB2' ' A' ' 93' ' ' GLU . 96.0 m-20 -60.12 -36.35 77.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.205 -0.934 . . . . 0.0 109.621 176.765 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.456 ' HB2' ' O ' ' A' ' 92' ' ' ASP . 93.7 mt-10 53.95 56.09 7.54 Favored 'General case' 0 N--CA 1.505 2.294 0 C-N-CA 119.472 -0.891 . . . . 0.0 110.167 172.494 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 94' ' ' ILE . . . . . 0.462 HG21 ' O ' ' A' ' 96' ' ' GLY . 40.6 mm -60.0 -40.53 83.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.298 -0.876 . . . . 0.0 109.893 177.652 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 65.47 -80.79 0.08 OUTLIER Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.769 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 96' ' ' GLY . . . . . 0.462 ' O ' HG21 ' A' ' 94' ' ' ILE . . . -99.87 -178.8 30.65 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.35 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 24.3 m-70 . . . . . 0 N--CA 1.492 1.626 0 O-C-N 121.171 -1.194 . . . . 0.0 110.115 178.667 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 26.1 ptp . . . . . 0 N--CA 1.493 1.719 0 CA-C-O 121.329 0.585 . . . . 0.0 110.221 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' B' B ' 2' ' ' PHE . . . . . 0.572 ' CD1' ' O ' ' B' ' 2' ' ' PHE . 0.3 OUTLIER -165.47 140.71 5.06 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.199 -0.938 . . . . 0.0 109.097 175.369 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 3' ' ' THR . . . . . 0.513 ' HB ' HG13 ' B' ' 5' ' ' ILE . 13.9 p -136.08 -32.64 0.86 Allowed 'General case' 0 C--N 1.294 -1.825 0 O-C-N 120.998 -1.064 . . . . 0.0 109.992 -174.783 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 4' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' B' ' 3' ' ' THR . . . 46.84 24.73 2.02 Favored Glycine 0 N--CA 1.486 2.028 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -175.639 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 5' ' ' ILE . . . . . 0.513 HG13 ' HB ' ' B' ' 3' ' ' THR . 29.8 mt -87.74 136.37 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.133 -1.216 . . . . 0.0 110.298 -176.964 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 6' ' ' VAL . . . . . 0.532 ' CG1' ' O ' ' B' ' 8' ' ' GLY . 2.5 t -86.11 143.86 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.27 -0.894 . . . . 0.0 110.723 -175.346 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -69.98 -32.52 70.78 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.601 -0.687 . . . . 0.0 110.88 177.382 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . 0.532 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -165.05 177.16 40.63 Favored Glycine 0 N--CA 1.496 2.641 0 C-N-CA 118.888 -1.625 . . . . 0.0 110.466 -174.184 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 9' ' ' THR . . . . . 0.508 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 3.0 p -116.3 167.82 10.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.105 -1.232 . . . . 0.0 110.953 -177.852 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 10' ' ' ALA . . . . . 0.497 ' O ' ' HA ' ' B' ' 81' ' ' TRP . . . -137.72 148.58 45.77 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -176.099 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 11' ' ' LYS . . . . . 0.581 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 25.9 tttt -108.96 116.08 31.31 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.148 -0.97 . . . . 0.0 110.249 -179.209 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . 0.51 HD21 ' N ' ' B' ' 78' ' ' VAL . 12.1 tp -58.97 127.29 31.46 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.124 -0.985 . . . . 0.0 108.976 174.257 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 13' ' ' VAL . . . . . 0.598 HG12 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -124.89 -31.67 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 C-N-CA 119.593 -0.843 . . . . 0.0 109.904 -179.638 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.35 143.98 28.41 Favored 'General case' 0 C--N 1.297 -1.675 0 C-N-CA 119.27 -0.972 . . . . 0.0 111.451 -178.019 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 15' ' ' ILE . . . . . 0.589 HG12 ' CD2' ' B' ' 24' ' ' HIS . 8.2 mt -108.02 130.18 60.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.264 -0.897 . . . . 0.0 110.232 172.246 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 16' ' ' ASP . . . . . 0.495 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 66.8 m-20 -105.94 114.31 28.38 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.369 -0.832 . . . . 0.0 109.724 172.994 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -106.57 108.82 20.52 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.912 -1.118 . . . . 0.0 110.938 -177.532 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 18' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -104.21 128.63 26.7 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.306 -0.871 . . . . 0.0 108.917 173.058 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -50.44 -34.03 40.09 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 O-C-N 123.789 1.415 . . . . 0.0 110.42 -179.508 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 20' ' ' ASN . . . . . 0.54 ' C ' ' CD2' ' B' ' 21' ' ' PHE . 12.4 m-80 -71.41 -40.25 70.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.131 -0.981 . . . . 0.0 109.985 175.524 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 21' ' ' PHE . . . . . 0.54 ' CD2' ' C ' ' B' ' 20' ' ' ASN . 89.3 m-85 -152.65 150.28 29.31 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.417 -0.802 . . . . 0.0 110.004 -179.327 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 22' ' ' ARG . . . . . 0.481 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 62.6 ttt180 -93.16 144.83 24.9 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.872 -1.143 . . . . 0.0 110.197 176.959 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 23' ' ' THR . . . . . 0.495 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 58.2 m -130.27 141.69 50.59 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.596 -0.69 . . . . 0.0 110.043 -176.305 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 24' ' ' HIS . . . . . 0.589 ' CD2' HG12 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -127.81 144.89 51.07 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.066 -1.021 . . . . 0.0 111.233 176.827 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 25' ' ' VAL . . . . . 0.531 ' CG2' ' OG ' ' B' ' 60' ' ' SER . 4.3 t -124.61 133.68 68.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.292 -0.88 . . . . 0.0 110.717 -179.293 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 26' ' ' VAL . . . . . 0.461 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 33.5 m -118.79 172.09 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 CA-C-O 121.27 0.557 . . . . 0.0 110.412 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 27' ' ' GLU . . . . . 0.457 ' HA ' ' CD2' ' B' ' 58' ' ' HIS . 13.1 tt0 -101.1 117.6 35.34 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.603 -0.686 . . . . 0.0 109.235 -179.473 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 28' ' ' LEU . . . . . 0.525 ' HB3' ' CD2' ' B' ' 33' ' ' LEU . 9.4 tp -82.01 121.27 78.89 Favored Pre-proline 0 C--N 1.297 -1.681 0 O-C-N 121.639 -0.663 . . . . 0.0 109.86 -175.401 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 29' ' ' PRO . . . . . 0.469 ' HG3' ' O ' ' B' ' 9' ' ' THR . 25.7 Cg_endo -66.24 179.59 1.9 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 123.913 1.48 . . . . 0.0 110.955 -179.399 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 30' ' ' ASP . . . . . 0.461 ' HA ' HD12 ' B' ' 33' ' ' LEU . 96.0 m-20 -63.48 -40.03 96.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.304 -0.873 . . . . 0.0 111.06 -175.662 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 31' ' ' HIS . . . . . 0.418 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.33 0.95 57.03 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.858 -1.151 . . . . 0.0 111.067 -175.253 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 32' ' ' MET . . . . . 0.469 ' O ' HD21 ' B' ' 28' ' ' LEU . 98.4 mmm -113.87 -13.93 12.54 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.945 -1.097 . . . . 0.0 109.799 172.305 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 33' ' ' LEU . . . . . 0.535 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 14.0 mt -66.15 -39.92 90.18 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.32 -0.862 . . . . 0.0 109.76 176.534 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -77.06 132.4 38.89 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.481 -0.762 . . . . 0.0 110.584 -177.487 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.37 -43.04 1.88 Allowed Glycine 0 N--CA 1.491 2.359 0 N-CA-C 110.306 -1.117 . . . . 0.0 110.306 174.512 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 36' ' ' LEU . . . . . 0.412 HD21 ' N ' ' B' ' 37' ' ' GLU . 5.7 tt -69.91 145.71 51.76 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.942 -1.328 . . . . 0.0 110.557 -174.949 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 37' ' ' GLU . . . . . 0.464 ' HA ' HD13 ' B' ' 54' ' ' ILE . 20.6 pt-20 -150.03 167.6 26.28 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.47 -0.769 . . . . 0.0 109.381 -179.56 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 38' ' ' THR . . . . . 0.54 ' CG2' HD12 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -67.92 149.81 49.33 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.864 -1.148 . . . . 0.0 110.237 -178.125 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.35 -3.46 62.61 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -173.813 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 40' ' ' ALA . . . . . 0.46 ' HB2' ' O ' ' B' ' 37' ' ' GLU . . . -76.74 160.04 29.66 Favored 'General case' 0 N--CA 1.486 1.375 0 O-C-N 121.218 -1.166 . . . . 0.0 109.129 174.742 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 41' ' ' SER . . . . . 0.527 ' O ' ' CB ' ' B' ' 87' ' ' ALA . 1.2 p -103.97 117.72 34.98 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 120.82 -1.175 . . . . 0.0 109.981 177.221 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 42' ' ' VAL . . . . . 0.581 HG12 ' CE1' ' B' ' 44' ' ' HIS . 0.9 OUTLIER -100.03 120.18 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.355 -0.841 . . . . 0.0 108.965 176.934 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 43' ' ' ALA . . . . . 0.474 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -82.89 117.28 22.63 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.247 -0.981 . . . . 0.0 109.316 174.474 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 44' ' ' HIS . . . . . 0.581 ' CE1' HG12 ' B' ' 42' ' ' VAL . 1.4 m80 -87.27 103.19 15.21 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.624 -0.831 . . . . 0.0 108.818 176.232 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.5 t-20 56.07 11.97 0.85 Allowed 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.677 -0.639 . . . . 0.0 111.239 -169.622 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 46' ' ' GLY . . . . . 0.469 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 126.73 -5.74 7.47 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 119.679 -1.248 . . . . 0.0 110.845 173.213 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 47' ' ' CYS . . . . . 0.521 ' O ' ' CD2' ' B' ' 49' ' ' LEU . 44.9 t -93.49 103.63 15.81 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.477 -1.602 . . . . 0.0 109.618 175.922 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 48' ' ' CYS . . . . . 0.459 ' SG ' ' O ' ' A' ' 3' ' ' THR . 14.8 p -72.14 122.07 20.37 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.117 -0.989 . . . . 0.0 110.617 -174.449 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 49' ' ' LEU . . . . . 0.638 ' CD1' ' CD1' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -132.21 160.53 35.86 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.461 -0.774 . . . . 0.0 109.283 173.568 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 50' ' ' THR . . . . . 0.411 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 37.5 m -97.53 152.59 18.86 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.42 -1.425 . . . . 0.0 111.464 -169.531 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 51' ' ' VAL . . . . . 0.537 ' CG1' HG13 ' B' ' 59' ' ' VAL . 20.0 t -81.18 114.76 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.795 -0.566 . . . . 0.0 110.389 -178.973 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 52' ' ' THR . . . . . 0.533 HG21 ' HB3' ' B' ' 62' ' ' ASP . 31.4 p -69.97 -40.03 75.63 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.152 -0.967 . . . . 0.0 109.739 174.575 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 53' ' ' GLU . . . . . 0.526 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.6 tt0 -161.49 155.63 22.38 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.416 -0.803 . . . . 0.0 109.804 179.634 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 54' ' ' ILE . . . . . 0.54 HD12 ' CG2' ' B' ' 38' ' ' THR . 7.1 mt -105.11 128.94 58.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.113 -0.992 . . . . 0.0 109.592 174.698 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 55' ' ' ASN . . . . . 0.501 ' CB ' ' HB2' ' B' ' 58' ' ' HIS . 2.2 m-80 -100.57 62.61 1.05 Allowed 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 119.878 -0.729 . . . . 0.0 109.55 -178.988 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.19 -120.08 6.51 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 108.657 -1.777 . . . . 0.0 108.657 -172.716 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 57' ' ' ASN . . . . . 0.535 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -71.8 -20.17 61.89 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 120.97 -1.312 . . . . 0.0 109.109 175.031 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 58' ' ' HIS . . . . . 0.598 ' CD2' HG12 ' B' ' 13' ' ' VAL . 11.8 m170 -76.68 161.22 28.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.421 -0.799 . . . . 0.0 110.432 -176.851 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 59' ' ' VAL . . . . . 0.537 HG13 ' CG1' ' B' ' 51' ' ' VAL . 54.8 t -140.04 125.53 20.82 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 C-N-CA 119.042 -1.063 . . . . 0.0 110.723 170.794 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 60' ' ' SER . . . . . 0.531 ' OG ' ' CG2' ' B' ' 25' ' ' VAL . 24.4 m -97.54 123.42 41.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.75 -0.594 . . . . 0.0 109.513 -179.573 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 61' ' ' PHE . . . . . 0.638 ' CD1' ' CD1' ' B' ' 49' ' ' LEU . 10.0 p90 -118.65 159.65 23.23 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 120.822 -1.174 . . . . 0.0 110.533 -179.655 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 62' ' ' ASP . . . . . 0.533 ' HB3' HG21 ' B' ' 52' ' ' THR . 35.2 p-10 -93.36 156.55 16.72 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.075 -1.016 . . . . 0.0 111.459 -171.99 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . 0.569 ' CD2' ' CD1' ' B' ' 68' ' ' LEU . 0.1 OUTLIER -161.11 102.12 1.26 Allowed 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 120.258 -0.577 . . . . 0.0 109.447 -174.235 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 64' ' ' MET . . . . . 0.486 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 57.6 ttm -60.07 137.64 58.05 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.707 -1.245 . . . . 0.0 109.068 179.266 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 65' ' ' LYS . . . . . 0.474 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 28.6 tttt -59.96 -45.93 91.06 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.91 -1.119 . . . . 0.0 110.63 -172.197 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 54.0 tp10 -66.21 -40.02 90.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.723 -1.236 . . . . 0.0 109.837 177.452 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 67' ' ' THR . . . . . 0.502 ' O ' HG22 ' B' ' 71' ' ' THR . 94.4 m -59.97 -40.03 87.69 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.036 -1.04 . . . . 0.0 109.512 172.657 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 68' ' ' LEU . . . . . 0.569 ' CD1' ' CD2' ' B' ' 63' ' ' LEU . 27.9 tp -60.05 -43.29 95.49 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.374 -0.829 . . . . 0.0 109.823 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 ttt85 -69.99 -39.26 76.02 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.318 -0.864 . . . . 0.0 110.364 177.751 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 70' ' ' ILE . . . . . 0.463 HG21 ' O ' ' B' ' 67' ' ' THR . 1.4 tt -64.56 -42.62 95.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.278 -0.889 . . . . 0.0 109.583 -176.903 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 71' ' ' THR . . . . . 0.502 HG22 ' O ' ' B' ' 67' ' ' THR . 30.5 p -82.06 -174.94 5.37 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.955 -0.698 . . . . 0.0 109.317 175.4 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 72' ' ' ASN . . . . . 0.472 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 5.2 t30 -99.38 22.17 11.03 Favored 'General case' 0 C--N 1.295 -1.77 0 O-C-N 121.141 -0.974 . . . . 0.0 108.534 171.074 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 73' ' ' LEU . . . . . 0.526 ' CD1' HD21 ' B' ' 63' ' ' LEU . 71.5 mt -70.03 -39.99 75.44 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.991 -1.068 . . . . 0.0 109.897 175.62 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 74' ' ' GLY . . . . . 0.454 ' HA2' HD13 ' B' ' 68' ' ' LEU . . . -49.38 -21.6 3.07 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 110.316 -1.113 . . . . 0.0 110.316 -177.954 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.2 p-10 -66.32 -16.31 63.94 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.127 -1.219 . . . . 0.0 110.525 -175.052 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 96.2 mt -62.26 142.36 57.76 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.291 -0.88 . . . . 0.0 111.189 -175.109 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . 0.485 ' C ' ' CD2' ' B' ' 12' ' ' LEU . 86.6 mttt -141.46 141.1 33.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.669 -0.645 . . . . 0.0 109.563 172.661 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 78' ' ' VAL . . . . . 0.535 ' CG2' HG13 ' B' ' 15' ' ' ILE . 16.7 t -59.42 151.63 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 120.812 -1.18 . . . . 0.0 110.245 -176.134 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.83 -13.44 60.98 Favored Glycine 0 N--CA 1.484 1.882 0 N-CA-C 108.887 -1.685 . . . . 0.0 108.887 -176.8 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 80' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 53.7 t0 -96.5 162.16 13.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.397 -1.061 . . . . 0.0 109.666 177.029 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 81' ' ' TRP . . . . . 0.581 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.0 m95 -113.13 153.32 28.42 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.103 -0.998 . . . . 0.0 110.372 177.532 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 82' ' ' VAL . . . . . 0.466 HG12 ' HB2' ' B' ' 10' ' ' ALA . 0.8 OUTLIER -120.01 149.75 22.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.553 -0.717 . . . . 0.0 109.858 179.553 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 83' ' ' ASN . . . . . 0.508 ' HB3' ' CG2' ' B' ' 6' ' ' VAL . 0.2 OUTLIER -69.53 102.41 1.82 Allowed 'General case' 0 C--N 1.298 -1.633 0 O-C-N 120.975 -1.078 . . . . 0.0 109.091 167.783 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . 0.508 ' CG2' ' C ' ' B' ' 9' ' ' THR . 0.1 OUTLIER -104.45 138.17 30.31 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 O-C-N 120.422 -1.424 . . . . 0.0 110.862 -178.611 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -136.12 138.38 41.98 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 119.982 -0.687 . . . . 0.0 110.234 -176.277 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 76.5 ttt180 -61.26 127.53 31.98 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.153 -0.967 . . . . 0.0 109.941 -179.8 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 87' ' ' ALA . . . . . 0.527 ' CB ' ' O ' ' B' ' 41' ' ' SER . . . -129.26 153.71 47.53 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.197 -0.939 . . . . 0.0 109.99 179.86 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 88' ' ' ALA . . . . . 0.583 ' O ' ' CD1' ' A' ' 2' ' ' PHE . . . -143.44 158.03 43.98 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.357 -0.839 . . . . 0.0 110.68 -174.179 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 89' ' ' LYS . . . . . 0.5 ' HA ' ' CE1' ' A' ' 2' ' ' PHE . 31.9 mttt -64.59 -39.98 94.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.495 -0.753 . . . . 0.0 110.063 176.221 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 41.5 p90 -158.87 161.52 36.85 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.238 -0.914 . . . . 0.0 110.396 -178.374 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 91' ' ' SER . . . . . . . . . . . . . 72.7 m -129.96 133.15 46.61 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.359 -0.838 . . . . 0.0 110.181 177.864 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -60.52 -45.61 93.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.146 -0.971 . . . . 0.0 109.76 176.906 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 93' ' ' GLU . . . . . 0.573 ' O ' ' CG ' ' B' ' 93' ' ' GLU . 5.0 tt0 -141.8 69.94 1.33 Allowed 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 122.201 1.0 . . . . 0.0 109.131 -177.956 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 94' ' ' ILE . . . . . 0.535 ' O ' ' CG2' ' B' ' 94' ' ' ILE . 21.7 mm 43.64 28.55 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.505 2.307 0 O-C-N 120.831 -1.168 . . . . 0.0 108.916 -176.324 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 95' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' B' ' 93' ' ' GLU . . . -65.46 80.44 0.08 OUTLIER Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 -174.888 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . 145.2 -176.17 24.37 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.744 -1.343 . . . . 0.0 109.744 176.806 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.582 0 O-C-N 121.297 -1.12 . . . . 0.0 110.273 178.393 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 98' ' ' RBF . . . . . 0.54 " C2'" ' HC9' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 99' ' ' RBF . . . . . 0.541 " C2'" ' HC9' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.887 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.3 t . . . . . 0 N--CA 1.495 1.804 0 CA-C-O 121.682 0.753 . . . . 0.0 111.026 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -59.98 -40.02 87.7 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.574 -0.704 . . . . 0.0 110.56 174.533 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.541 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -170.66 -176.95 40.37 Favored Glycine 0 N--CA 1.495 2.588 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.118 -174.634 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.48 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 21.4 p -117.58 169.83 9.24 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.872 -1.37 . . . . 0.0 111.13 -175.622 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 1.055 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -135.13 147.8 49.58 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.684 -0.635 . . . . 0.0 109.356 -179.033 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.576 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 34.0 tttt -103.57 115.74 31.07 Favored 'General case' 0 C--N 1.293 -1.856 0 O-C-N 121.046 -1.034 . . . . 0.0 110.269 -179.583 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 1.004 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.0 tp -59.87 126.45 27.62 Favored 'General case' 0 C--N 1.298 -1.653 0 O-C-N 120.892 -1.13 . . . . 0.0 108.823 172.736 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.094 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -126.91 -29.02 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 O-C-N 121.438 -0.789 . . . . 0.0 110.017 -179.094 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.04 141.91 26.88 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 119.058 -1.057 . . . . 0.0 111.606 -178.748 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.65 HG23 ' NE2' ' A' ' 24' ' ' HIS . 14.2 mt -109.08 130.52 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.052 -1.03 . . . . 0.0 110.206 170.786 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.504 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 81.6 m-20 -107.71 115.46 30.19 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.291 -0.88 . . . . 0.0 109.963 174.121 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -104.21 114.4 28.61 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.969 -1.082 . . . . 0.0 110.591 -176.412 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.0 OUTLIER -113.67 128.97 25.14 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.141 -0.974 . . . . 0.0 109.203 175.343 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.1 Cg_endo -52.37 -18.37 7.84 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 O-C-N 123.831 1.437 . . . . 0.0 110.944 -179.336 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.545 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 0.4 OUTLIER -92.3 -33.54 14.58 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.135 -0.978 . . . . 0.0 108.939 178.309 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.545 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 84.1 m-85 -156.16 150.24 25.33 Favored 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.358 0.599 . . . . 0.0 110.14 179.792 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.556 ' HD3' HD22 ' A' ' 68' ' ' LEU . 60.1 ttt180 -90.89 144.24 25.89 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 120.744 -1.223 . . . . 0.0 109.775 175.602 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.504 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 85.0 m -129.17 137.69 51.31 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.472 -0.767 . . . . 0.0 109.822 -177.09 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.65 ' NE2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.25 137.04 49.81 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 120.967 -1.083 . . . . 0.0 111.141 179.394 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.832 HG22 ' OG ' ' A' ' 60' ' ' SER . 15.6 t -119.05 134.91 61.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.037 -1.039 . . . . 0.0 110.641 -177.279 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.482 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 16.9 m -117.13 170.93 6.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 CA-C-O 121.088 0.47 . . . . 0.0 110.112 177.922 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.567 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 8.7 tt0 -107.42 116.58 32.18 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.507 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.3 tp -81.36 128.59 69.59 Favored Pre-proline 0 C--N 1.295 -1.766 0 O-C-N 121.307 -0.87 . . . . 0.0 109.978 -171.824 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.483 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 33.6 Cg_endo -68.0 176.83 4.9 Favored 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.903 1.475 . . . . 0.0 110.88 -179.376 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.556 ' HA ' HD12 ' A' ' 33' ' ' LEU . 96.0 m-20 -60.02 -40.02 87.85 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.255 -0.903 . . . . 0.0 111.261 -174.251 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.589 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.85 0.83 56.81 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.75 -1.219 . . . . 0.0 110.936 -173.912 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.589 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.9 mmm -113.23 -9.63 13.44 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 120.839 -1.163 . . . . 0.0 110.074 170.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.726 HD21 ' HB2' ' A' ' 57' ' ' ASN . 19.9 mt -70.02 -23.18 63.08 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.169 -0.957 . . . . 0.0 110.052 176.263 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -94.47 129.94 41.04 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.469 -0.769 . . . . 0.0 110.478 -177.769 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.98 -43.53 1.71 Allowed Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.909 -1.139 . . . . 0.0 110.396 174.126 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.906 HD23 ' N ' ' A' ' 37' ' ' GLU . 7.1 tt -69.94 149.16 48.07 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.836 -1.391 . . . . 0.0 110.855 -174.221 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.906 ' N ' HD23 ' A' ' 36' ' ' LEU . 19.3 pt-20 -150.42 170.02 20.06 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.512 -0.742 . . . . 0.0 109.682 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.874 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -65.82 153.51 41.7 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.024 -1.048 . . . . 0.0 110.235 179.779 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.41 -2.15 63.32 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -178.405 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.449 ' O ' ' HA ' ' A' ' 50' ' ' THR . . . -78.3 158.07 28.98 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.254 -1.145 . . . . 0.0 109.552 176.817 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.645 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.4 OUTLIER -100.31 107.74 19.61 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.026 -1.07 . . . . 0.0 109.876 175.653 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.666 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.1 t -93.65 133.23 35.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 121.321 -0.862 . . . . 0.0 108.896 173.305 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.508 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -97.98 120.0 37.59 Favored 'General case' 0 C--N 1.295 -1.763 0 C-N-CA 119.109 -1.036 . . . . 0.0 109.107 172.174 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.77 ' CD2' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -89.7 106.99 18.83 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 178.929 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 54.01 14.12 0.66 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.444 -0.785 . . . . 0.0 111.048 -168.569 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.505 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 117.87 2.83 16.37 Favored Glycine 0 N--CA 1.489 2.178 0 C-N-CA 119.527 -1.32 . . . . 0.0 110.798 172.559 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.762 ' O ' HD23 ' A' ' 49' ' ' LEU . 33.2 t -98.65 109.9 22.58 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.521 -1.576 . . . . 0.0 109.47 174.837 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.449 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 31.0 p -76.8 130.26 37.41 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.978 -1.076 . . . . 0.0 111.182 -170.251 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.961 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -146.54 161.23 40.93 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.573 -0.704 . . . . 0.0 109.333 173.123 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.449 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 22.9 m -100.81 153.02 19.82 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.587 -1.321 . . . . 0.0 111.105 -171.199 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.83 HG13 HG13 ' A' ' 59' ' ' VAL . 24.6 t -76.68 113.77 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.839 -0.538 . . . . 0.0 110.186 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.563 HG22 ' HB3' ' A' ' 62' ' ' ASP . 27.7 p -70.26 -41.55 73.3 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.24 -0.912 . . . . 0.0 109.518 174.146 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.57 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 20.4 pt-20 -160.12 160.09 32.59 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 119.543 -0.863 . . . . 0.0 110.813 176.785 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.874 HD11 ' N ' ' A' ' 38' ' ' THR . 8.9 mt -110.58 130.05 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.268 -0.895 . . . . 0.0 109.962 173.653 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.494 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 5.3 m120 -103.33 63.22 0.8 Allowed 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 120.071 -0.652 . . . . 0.0 109.509 179.25 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.36 -117.43 4.79 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 108.961 -1.655 . . . . 0.0 108.961 -173.612 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.726 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.1 OUTLIER -77.14 -20.63 55.29 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 120.965 -1.314 . . . . 0.0 108.803 175.45 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.094 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.1 m170 -75.56 158.7 32.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.28 -0.888 . . . . 0.0 110.141 -177.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.83 HG13 HG13 ' A' ' 51' ' ' VAL . 55.1 t -140.41 123.82 17.26 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 C-N-CA 119.143 -1.023 . . . . 0.0 110.674 171.478 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.832 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.1 t -89.82 134.17 34.33 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.391 -0.818 . . . . 0.0 109.381 175.505 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.961 ' HB3' HD12 ' A' ' 49' ' ' LEU . 89.1 m-85 -115.67 159.87 20.79 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.224 -0.922 . . . . 0.0 110.277 175.905 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.563 ' HB3' HG22 ' A' ' 52' ' ' THR . 28.3 p-10 -93.02 149.09 21.46 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.187 -0.945 . . . . 0.0 111.129 178.542 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.726 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -154.18 117.69 4.61 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -175.127 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.542 ' HB2' ' CB ' ' A' ' 67' ' ' THR . 54.1 mtp -70.33 139.38 52.0 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.911 -1.118 . . . . 0.0 109.981 179.149 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.499 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 45.0 tptt -59.93 -49.91 75.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.163 -0.961 . . . . 0.0 110.274 -179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.466 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.5 tt0 -64.97 -39.99 94.31 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.753 -1.217 . . . . 0.0 109.859 177.245 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.542 ' CB ' ' HB2' ' A' ' 64' ' ' MET . 85.5 m -59.87 -35.67 75.3 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.934 -1.104 . . . . 0.0 109.397 173.066 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.705 HD13 HD22 ' A' ' 63' ' ' LEU . 20.0 tp -62.84 -46.71 86.63 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.186 -0.946 . . . . 0.0 109.756 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 71.5 ttt-85 -69.98 -39.17 76.11 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.484 -0.76 . . . . 0.0 110.136 178.134 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.67 HG22 HG23 ' A' ' 71' ' ' THR . 1.1 tt -66.81 -40.02 84.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.366 -0.833 . . . . 0.0 109.337 -179.24 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.67 HG23 HG22 ' A' ' 70' ' ' ILE . 65.0 p -86.26 -173.65 4.66 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 174.244 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.4 t30 -104.18 25.04 10.53 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 170.196 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.726 ' HB3' HD21 ' A' ' 63' ' ' LEU . 87.9 mt -69.96 -40.0 75.69 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.027 -1.046 . . . . 0.0 110.008 177.298 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.531 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -47.7 -21.93 1.65 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.5 p-10 -67.11 -17.83 65.04 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.938 -1.33 . . . . 0.0 110.823 -174.221 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.0 mt -60.01 142.96 53.02 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.118 -0.989 . . . . 0.0 111.068 -175.603 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 1.004 ' C ' HD23 ' A' ' 12' ' ' LEU . 54.6 mttp -140.03 139.23 35.93 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.709 -0.619 . . . . 0.0 109.762 174.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.655 ' N ' HD23 ' A' ' 12' ' ' LEU . 15.8 t -61.02 153.08 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.862 -1.149 . . . . 0.0 110.351 -178.286 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.02 -15.03 58.99 Favored Glycine 0 N--CA 1.483 1.801 0 N-CA-C 108.716 -1.753 . . . . 0.0 108.716 -177.826 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.443 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 25.1 t0 -96.21 169.5 9.9 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.428 -1.042 . . . . 0.0 109.601 176.478 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.576 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.5 m95 -115.97 164.32 14.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.913 -1.117 . . . . 0.0 110.351 175.244 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.055 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.7 p -129.62 144.39 38.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.564 -0.71 . . . . 0.0 109.949 -176.518 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.887 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.6 m-20 -70.95 105.24 3.21 Favored 'General case' 0 C--N 1.293 -1.862 0 O-C-N 121.077 -1.014 . . . . 0.0 109.266 170.543 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.75 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -108.89 138.92 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 120.535 -1.353 . . . . 0.0 111.153 -176.063 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -137.15 147.02 45.68 Favored 'General case' 0 N--CA 1.495 1.82 0 C-N-CA 120.293 -0.563 . . . . 0.0 110.193 179.499 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 73.9 ttt-85 -85.22 130.65 34.56 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.232 -0.917 . . . . 0.0 111.309 -174.598 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.645 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.492 1.653 0 O-C-N 121.274 -0.891 . . . . 0.0 110.047 175.803 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 0.854 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.3 t . . . . . 0 N--CA 1.494 1.748 0 CA-C-O 121.646 0.736 . . . . 0.0 111.093 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -59.95 -39.91 87.18 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.59 -0.693 . . . . 0.0 110.62 174.534 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.542 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -170.88 -177.2 40.65 Favored Glycine 0 N--CA 1.495 2.616 0 C-N-CA 119.201 -1.476 . . . . 0.0 110.222 -174.534 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.487 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 21.4 p -117.48 169.8 9.24 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.896 -1.355 . . . . 0.0 111.207 -175.611 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.066 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -135.04 147.96 49.77 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 -179.066 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.585 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 34.0 tttt -103.78 115.84 31.22 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 121.15 -0.969 . . . . 0.0 110.16 -179.535 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 1.018 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.0 tp -59.99 126.31 27.05 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 120.96 -1.088 . . . . 0.0 108.843 172.776 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.1 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -126.67 -29.15 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.03 -179.087 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.02 141.83 26.82 Favored 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.25 -0.98 . . . . 0.0 111.568 -178.623 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.641 HG23 ' NE2' ' B' ' 24' ' ' HIS . 14.2 mt -108.96 130.64 61.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.046 -1.034 . . . . 0.0 110.232 170.778 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.516 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 81.0 m-20 -107.98 115.6 30.42 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.369 -0.832 . . . . 0.0 109.746 174.239 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -104.18 114.42 28.65 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.042 -1.037 . . . . 0.0 110.547 -176.48 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.459 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.0 OUTLIER -113.75 128.9 25.23 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.358 -0.839 . . . . 0.0 109.183 175.353 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 19' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 9.1 Cg_endo -52.37 -18.42 7.93 Favored 'Trans proline' 0 C--N 1.304 -1.809 0 O-C-N 123.858 1.451 . . . . 0.0 110.906 -179.326 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.548 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 0.4 OUTLIER -92.22 -33.9 14.49 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.06 -1.025 . . . . 0.0 108.769 178.413 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.548 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 84.2 m-85 -155.89 150.25 25.76 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.196 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 22' ' ' ARG . . . . . 0.551 ' HD3' HD22 ' B' ' 68' ' ' LEU . 60.0 ttt180 -90.87 144.14 26.0 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.909 -1.12 . . . . 0.0 109.797 175.639 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.516 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 82.7 m -129.14 137.74 51.37 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.539 -0.726 . . . . 0.0 109.826 -177.135 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.641 ' NE2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.18 136.94 49.8 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.029 -1.045 . . . . 0.0 111.054 179.573 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.831 HG22 ' OG ' ' B' ' 60' ' ' SER . 15.6 t -118.98 135.09 60.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.116 -0.99 . . . . 0.0 110.734 -177.404 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.491 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 17.2 m -117.42 170.91 6.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 C-N-CA 120.444 -0.502 . . . . 0.0 109.99 178.072 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.566 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 8.7 tt0 -107.36 116.53 32.1 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.594 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.497 ' HA ' HD12 ' B' ' 28' ' ' LEU . 9.3 tp -81.2 128.49 70.4 Favored Pre-proline 0 C--N 1.295 -1.781 0 O-C-N 121.228 -0.92 . . . . 0.0 110.05 -171.856 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.475 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 33.8 Cg_endo -67.99 176.82 4.9 Favored 'Trans proline' 0 C--N 1.308 -1.567 0 O-C-N 123.9 1.474 . . . . 0.0 110.87 -179.392 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.543 ' HA ' HD12 ' B' ' 33' ' ' LEU . 96.1 m-20 -60.02 -39.99 87.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.314 -0.866 . . . . 0.0 111.255 -174.211 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.596 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.82 0.84 56.78 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.733 -1.229 . . . . 0.0 110.974 -173.949 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.596 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.8 mmm -113.28 -9.57 13.41 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.824 -1.172 . . . . 0.0 110.143 170.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.707 HD21 ' HB2' ' B' ' 57' ' ' ASN . 20.0 mt -69.98 -23.33 63.14 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.232 -0.918 . . . . 0.0 109.994 176.189 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 94.3 m-20 -94.44 129.89 41.01 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.383 -0.823 . . . . 0.0 110.57 -177.76 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.96 -43.47 1.73 Allowed Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.885 -1.15 . . . . 0.0 110.48 174.249 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.917 HD23 ' N ' ' B' ' 37' ' ' GLU . 7.2 tt -70.09 149.15 47.92 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.926 -1.338 . . . . 0.0 110.81 -174.216 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 37' ' ' GLU . . . . . 0.917 ' N ' HD23 ' B' ' 36' ' ' LEU . 19.3 pt-20 -150.39 170.01 20.07 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.515 -0.741 . . . . 0.0 109.738 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 38' ' ' THR . . . . . 0.878 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -65.8 153.38 42.02 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.992 -1.068 . . . . 0.0 110.236 179.832 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.41 -2.06 63.62 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.453 ' O ' ' HA ' ' B' ' 50' ' ' THR . . . -78.42 157.89 28.87 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.259 -1.142 . . . . 0.0 109.558 176.713 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.639 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.4 OUTLIER -99.97 107.67 19.7 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.894 -1.128 . . . . 0.0 109.994 175.625 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.672 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.1 t -93.66 133.31 35.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.358 -0.839 . . . . 0.0 108.874 173.322 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 0.505 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -97.99 120.05 37.69 Favored 'General case' 0 C--N 1.296 -1.738 0 C-N-CA 119.162 -1.015 . . . . 0.0 109.055 172.184 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.76 ' CD2' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -89.75 106.78 18.69 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.427 -0.796 . . . . 0.0 108.994 178.876 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.751 HD22 ' HB2' ' A' ' 47' ' ' CYS . 0.9 OUTLIER 54.13 14.21 0.7 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.396 -0.815 . . . . 0.0 111.043 -168.537 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.505 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 117.65 3.21 16.58 Favored Glycine 0 N--CA 1.488 2.142 0 C-N-CA 119.545 -1.312 . . . . 0.0 110.823 172.452 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.76 ' O ' HD23 ' B' ' 49' ' ' LEU . 33.5 t -98.82 110.02 22.69 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.521 -1.576 . . . . 0.0 109.397 174.702 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 48' ' ' CYS . . . . . 0.449 ' O ' ' SG ' ' B' ' 48' ' ' CYS . 31.2 p -76.82 130.35 37.51 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.032 -1.043 . . . . 0.0 111.184 -170.32 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 1.011 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -146.7 161.17 41.15 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.62 -0.675 . . . . 0.0 109.304 173.105 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 50' ' ' THR . . . . . 0.453 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 22.9 m -100.69 153.13 19.69 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.722 -1.236 . . . . 0.0 111.06 -171.099 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.846 HG13 HG13 ' B' ' 59' ' ' VAL . 24.8 t -76.8 113.74 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.694 -0.629 . . . . 0.0 110.268 -179.55 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.574 HG22 ' HB3' ' B' ' 62' ' ' ASP . 28.0 p -70.25 -41.55 73.35 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.196 -0.94 . . . . 0.0 109.524 174.262 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.579 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 20.5 pt-20 -160.18 160.04 32.36 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.325 -0.859 . . . . 0.0 110.805 176.752 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.878 HD11 ' N ' ' B' ' 38' ' ' THR . 9.0 mt -110.52 130.02 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.307 -0.87 . . . . 0.0 109.945 173.773 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.511 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 5.3 m120 -103.33 63.13 0.79 Allowed 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 120.018 -0.673 . . . . 0.0 109.524 179.274 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.55 -117.53 4.79 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 108.884 -1.686 . . . . 0.0 108.884 -173.659 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.707 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -77.04 -20.79 55.47 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.1 -1.235 . . . . 0.0 108.814 175.471 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.1 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.2 m170 -75.33 158.51 32.69 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.423 -0.798 . . . . 0.0 110.223 -178.099 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.846 HG13 HG13 ' B' ' 51' ' ' VAL . 54.9 t -140.33 123.7 17.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 C-N-CA 119.126 -1.029 . . . . 0.0 110.677 171.593 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.831 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.1 t -89.76 134.31 34.24 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.448 -0.783 . . . . 0.0 109.406 175.501 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 1.011 ' HB3' HD12 ' B' ' 49' ' ' LEU . 89.2 m-85 -115.74 159.89 20.81 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.213 175.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.574 ' HB3' HG22 ' B' ' 52' ' ' THR . 28.3 p-10 -92.96 149.15 21.43 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.163 -0.961 . . . . 0.0 111.059 178.539 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.702 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -154.28 117.77 4.59 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -175.23 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.551 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 54.3 mtp -70.4 139.42 51.87 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.989 -1.07 . . . . 0.0 110.042 179.107 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.495 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 45.1 tptt -59.92 -49.88 75.95 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.188 -0.945 . . . . 0.0 110.328 -179.567 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 66' ' ' GLU . . . . . 0.478 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 86.5 tt0 -64.88 -40.0 94.43 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.868 -1.145 . . . . 0.0 109.953 177.17 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.551 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 85.0 m -60.05 -35.79 75.9 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.942 -1.099 . . . . 0.0 109.328 173.172 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.691 HD13 HD22 ' B' ' 63' ' ' LEU . 19.8 tp -62.61 -46.64 87.36 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.226 -0.921 . . . . 0.0 109.85 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 71.5 ttt-85 -70.07 -39.24 75.74 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.474 -0.766 . . . . 0.0 110.075 178.156 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.648 HG22 HG23 ' B' ' 71' ' ' THR . 1.1 tt -66.78 -40.04 85.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.466 -0.771 . . . . 0.0 109.302 -179.228 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.648 HG23 HG22 ' B' ' 70' ' ' ILE . 65.9 p -86.21 -173.53 4.6 Favored 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 120.035 -0.666 . . . . 0.0 109.324 174.265 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.489 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 4.4 t30 -104.32 25.21 10.41 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 170.244 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.702 ' HB3' HD21 ' B' ' 63' ' ' LEU . 87.6 mt -70.06 -39.97 75.36 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.02 -1.05 . . . . 0.0 109.985 177.223 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.515 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -47.92 -21.68 1.73 Allowed Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 -179.408 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.6 p-10 -67.18 -17.8 64.99 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.911 -1.347 . . . . 0.0 110.792 -174.279 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.507 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 97.0 mt -59.97 142.9 53.01 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.139 -0.976 . . . . 0.0 111.045 -175.596 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 1.018 ' C ' HD23 ' B' ' 12' ' ' LEU . 54.6 mttp -140.01 139.28 35.97 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.652 -0.655 . . . . 0.0 109.768 174.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.665 ' N ' HD23 ' B' ' 12' ' ' LEU . 15.9 t -61.13 153.06 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.964 -1.085 . . . . 0.0 110.322 -178.176 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.01 -14.82 59.54 Favored Glycine 0 N--CA 1.484 1.88 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.448 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 25.0 t0 -96.31 169.4 9.96 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.463 -1.022 . . . . 0.0 109.626 176.326 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.585 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.5 m95 -116.05 164.18 14.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.996 -1.065 . . . . 0.0 110.327 175.33 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 1.066 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.6 p -129.46 144.49 37.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.613 -0.679 . . . . 0.0 110.031 -176.659 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.854 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -70.91 105.08 3.14 Favored 'General case' 0 C--N 1.292 -1.892 0 O-C-N 121.164 -0.96 . . . . 0.0 109.301 170.512 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.719 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -108.84 138.93 33.52 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 120.614 -1.304 . . . . 0.0 111.099 -175.972 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -137.15 147.05 45.7 Favored 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.19 179.385 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 74.0 ttt-85 -85.16 130.7 34.56 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.175 -0.953 . . . . 0.0 111.278 -174.619 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.639 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.761 0 O-C-N 121.376 -0.827 . . . . 0.0 110.001 175.76 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.749 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.3 t . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 121.531 0.682 . . . . 0.0 110.061 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.508 ' OE1' ' NH1' ' A' ' 86' ' ' ARG . 97.2 mt-30 -70.24 -30.03 66.98 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.492 -0.755 . . . . 0.0 111.405 -178.495 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.53 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -148.44 176.13 27.39 Favored Glycine 0 N--CA 1.495 2.579 0 C-N-CA 118.687 -1.721 . . . . 0.0 110.271 -173.865 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.462 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 2.9 p -123.28 171.3 9.49 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.153 -1.204 . . . . 0.0 110.574 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 1.018 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -141.11 150.07 42.37 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.46 -0.775 . . . . 0.0 109.401 -175.837 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 26.3 tttt -111.53 116.23 30.52 Favored 'General case' 0 C--N 1.297 -1.704 0 O-C-N 121.059 -1.025 . . . . 0.0 110.334 179.875 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.877 HD23 ' C ' ' A' ' 77' ' ' LYS . 9.9 tp -58.43 124.78 20.74 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.013 -1.054 . . . . 0.0 108.931 173.1 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.058 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.0 OUTLIER -118.24 -29.29 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 O-C-N 121.359 -0.838 . . . . 0.0 109.597 178.751 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.43 149.96 27.37 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.057 -1.057 . . . . 0.0 111.639 -178.381 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.756 HG23 ' CD2' ' A' ' 24' ' ' HIS . 19.5 mt -112.09 132.24 61.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.158 -0.964 . . . . 0.0 109.998 172.846 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.518 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 86.3 m-20 -108.65 116.12 31.38 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.305 -0.872 . . . . 0.0 109.861 174.786 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -106.13 108.73 20.4 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.064 -1.023 . . . . 0.0 110.534 -176.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -102.14 128.55 28.24 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.069 -1.019 . . . . 0.0 108.924 172.66 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_endo -50.47 -29.61 24.86 Favored 'Trans proline' 0 C--N 1.303 -1.865 0 O-C-N 123.834 1.439 . . . . 0.0 110.453 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.49 ' HB3' ' CE2' ' A' ' 21' ' ' PHE . 12.8 m-80 -77.87 -39.99 41.54 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.181 -0.949 . . . . 0.0 110.021 176.069 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.49 ' CE2' ' HB3' ' A' ' 20' ' ' ASN . 51.0 m-85 -151.18 150.23 30.38 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.342 -0.849 . . . . 0.0 109.925 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.484 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 60.0 ttt180 -90.42 145.24 25.09 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.714 -1.241 . . . . 0.0 110.012 176.823 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.518 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 91.5 m -129.64 138.19 51.08 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.429 -0.794 . . . . 0.0 109.941 -177.251 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.756 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -128.99 136.44 50.34 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 120.91 -1.119 . . . . 0.0 111.085 178.934 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.784 HG22 ' CB ' ' A' ' 60' ' ' SER . 8.2 t -120.08 132.63 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.922 -1.111 . . . . 0.0 110.77 -176.55 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.774 HG13 ' CE1' ' A' ' 61' ' ' PHE . 23.2 m -116.9 173.31 4.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 CA-C-O 121.27 0.557 . . . . 0.0 110.341 178.575 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.674 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 9.9 tt0 -106.2 117.91 35.25 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.464 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.715 HD21 HD13 ' A' ' 36' ' ' LEU . 9.2 tp -85.54 125.69 68.71 Favored Pre-proline 0 C--N 1.299 -1.624 0 O-C-N 121.403 -0.81 . . . . 0.0 110.3 -171.209 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.482 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 22.2 Cg_endo -66.17 176.37 3.97 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.878 1.462 . . . . 0.0 111.245 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.477 ' HA ' HD12 ' A' ' 33' ' ' LEU . 47.8 t0 -60.06 -39.9 87.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.336 -0.853 . . . . 0.0 111.183 -175.421 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.61 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.03 0.0 57.35 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.844 -1.16 . . . . 0.0 110.663 -174.937 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.61 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.8 mmm -112.26 -12.34 13.61 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.958 -1.089 . . . . 0.0 109.704 171.502 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.583 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 17.9 mt -69.25 -36.89 77.63 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.4 -0.813 . . . . 0.0 110.069 175.787 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -82.7 138.9 33.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.438 -0.789 . . . . 0.0 110.778 -177.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.44 -40.73 2.83 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 110.194 -1.163 . . . . 0.0 110.194 174.553 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.805 HD23 ' N ' ' A' ' 37' ' ' GLU . 8.3 tt -73.28 145.93 45.72 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.053 -1.263 . . . . 0.0 110.631 -176.171 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.805 ' N ' HD23 ' A' ' 36' ' ' LEU . 20.9 pt-20 -150.35 167.0 28.33 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.488 -0.757 . . . . 0.0 109.687 179.765 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.783 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -65.2 152.18 44.28 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.033 -1.042 . . . . 0.0 110.237 -178.123 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.63 -3.87 62.28 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -176.18 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.621 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -77.32 155.42 32.01 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.141 -1.211 . . . . 0.0 109.467 176.336 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.579 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -96.82 104.36 16.36 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 119.036 -1.066 . . . . 0.0 109.82 176.831 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.668 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.1 t -86.06 132.0 33.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 O-C-N 121.24 -0.913 . . . . 0.0 109.139 174.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 1.075 ' HB3' ' CG ' ' A' ' 85' ' ' GLU . . . -98.78 120.29 38.98 Favored 'General case' 0 C--N 1.296 -1.742 0 C-N-CA 119.408 -0.917 . . . . 0.0 109.262 173.479 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.885 ' CD2' HG21 ' A' ' 82' ' ' VAL . 1.5 m80 -93.08 104.08 16.32 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.593 -0.692 . . . . 0.0 109.268 179.503 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.514 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.3 t-20 55.64 11.29 0.62 Allowed 'General case' 0 C--N 1.298 -1.633 0 O-C-N 121.622 -0.674 . . . . 0.0 111.094 -169.857 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.521 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.61 1.95 10.73 Favored Glycine 0 N--CA 1.488 2.166 0 C-N-CA 119.796 -1.193 . . . . 0.0 110.818 174.209 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.673 ' O ' HD23 ' A' ' 49' ' ' LEU . 8.6 t -97.22 113.26 24.85 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 120.361 -1.67 . . . . 0.0 109.545 175.494 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.408 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 26.4 p -79.86 124.25 28.48 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.119 -0.988 . . . . 0.0 111.191 -170.799 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.864 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -141.36 163.21 33.55 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.385 -0.822 . . . . 0.0 109.661 172.861 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.433 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 57.5 m -102.96 152.08 21.72 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.689 -1.257 . . . . 0.0 111.019 -172.122 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.916 HG13 HG13 ' A' ' 59' ' ' VAL . 14.0 t -78.38 114.69 19.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.751 -0.593 . . . . 0.0 110.272 -178.604 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.523 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 46.1 p -71.29 -44.51 65.07 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.194 -0.941 . . . . 0.0 109.868 175.644 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.561 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -158.33 153.89 26.17 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.199 -0.938 . . . . 0.0 110.336 178.126 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.783 HD11 ' N ' ' A' ' 38' ' ' THR . 8.0 mt -105.37 130.37 56.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.161 -0.962 . . . . 0.0 109.818 175.991 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.519 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 12.4 m-80 -102.4 64.25 0.9 Allowed 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.565 -0.71 . . . . 0.0 109.612 179.828 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.54 -113.08 3.93 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -173.029 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.583 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -80.05 -21.31 43.59 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.066 -1.255 . . . . 0.0 109.293 175.568 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.058 ' CE1' HG11 ' A' ' 13' ' ' VAL . 22.7 m-70 -74.88 159.53 31.76 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.352 -0.842 . . . . 0.0 110.102 -177.817 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.916 HG13 HG13 ' A' ' 51' ' ' VAL . 53.9 t -140.04 122.16 16.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 C-N-CA 119.023 -1.071 . . . . 0.0 110.916 172.162 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.784 ' CB ' HG22 ' A' ' 25' ' ' VAL . 60.2 p -91.06 129.09 37.09 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.724 -0.61 . . . . 0.0 109.689 177.772 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.864 ' HB2' HD12 ' A' ' 49' ' ' LEU . 1.3 p90 -123.14 156.89 34.12 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.964 -1.085 . . . . 0.0 110.61 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.523 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 32.6 p-10 -91.33 152.06 20.61 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.184 -0.948 . . . . 0.0 111.329 -172.658 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.821 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -155.72 111.84 3.1 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 -175.771 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.526 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 84.2 mmm -65.71 139.86 58.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.877 -1.14 . . . . 0.0 109.232 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.459 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 58.0 tptt -60.0 -44.41 94.56 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.958 -1.089 . . . . 0.0 109.981 -176.711 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.441 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.0 tt0 -69.01 -40.0 78.97 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.122 -0.986 . . . . 0.0 110.385 178.554 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.526 ' HB ' ' HB2' ' A' ' 64' ' ' MET . 89.9 m -60.98 -39.99 91.76 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.937 -1.102 . . . . 0.0 109.085 173.25 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.773 HD11 ' HA2' ' A' ' 74' ' ' GLY . 5.1 tp -60.01 -46.24 90.15 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.494 -0.753 . . . . 0.0 109.66 178.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 32.5 tpt180 -67.4 -40.11 85.58 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.548 -0.72 . . . . 0.0 110.519 177.587 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.788 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -69.96 -41.56 79.46 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.247 -0.908 . . . . 0.0 109.491 -176.457 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.788 HG23 HG22 ' A' ' 70' ' ' ILE . 61.1 p -84.65 -173.22 4.6 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 178.604 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.484 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.6 t30 -101.76 23.08 11.84 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 170.834 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.821 ' HB3' HD21 ' A' ' 63' ' ' LEU . 94.1 mt -70.04 -42.31 73.07 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.036 -1.04 . . . . 0.0 109.992 176.114 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.773 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -52.28 -18.93 5.31 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -178.029 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 23.7 p-10 -64.67 -18.32 64.86 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.085 -1.244 . . . . 0.0 110.469 -176.193 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 88.6 mt -59.97 143.23 52.23 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.257 -0.902 . . . . 0.0 110.836 -176.246 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 0.877 ' C ' HD23 ' A' ' 12' ' ' LEU . 54.6 mttt -142.58 141.25 31.96 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.734 -0.604 . . . . 0.0 109.597 175.658 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.623 ' N ' HD23 ' A' ' 12' ' ' LEU . 16.9 t -60.75 151.25 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 120.784 -1.198 . . . . 0.0 110.601 -174.51 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.65 -10.97 65.42 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -177.837 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 47.4 t0 -96.38 163.18 13.17 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.268 -1.137 . . . . 0.0 109.622 176.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.0 m95 -113.41 161.64 17.06 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.072 -1.018 . . . . 0.0 110.263 176.877 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.018 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.5 p -131.24 149.76 33.66 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 O-C-N 121.522 -0.736 . . . . 0.0 109.847 -176.324 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.749 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.6 m-20 -75.43 108.02 7.95 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 121.24 -0.912 . . . . 0.0 109.188 170.613 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.829 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.2 OUTLIER -111.71 145.11 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.52 -1.363 . . . . 0.0 111.501 -175.229 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 1.075 ' CG ' ' HB3' ' A' ' 43' ' ' ALA . 25.9 pt-20 -144.52 160.02 41.81 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.652 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.508 ' NH1' ' OE1' ' A' ' 7' ' ' GLN . 31.5 ptt-85 -98.27 132.91 43.36 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.024 -1.048 . . . . 0.0 110.979 -174.319 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.579 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.46 -0.775 . . . . 0.0 109.845 177.192 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 0.729 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.3 t . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.578 0.704 . . . . 0.0 110.003 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.514 ' OE1' ' NH1' ' B' ' 86' ' ' ARG . 97.2 mt-30 -70.2 -29.93 66.91 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.497 -0.752 . . . . 0.0 111.483 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.534 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -148.62 175.9 27.67 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 118.91 -1.614 . . . . 0.0 110.386 -173.766 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.472 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 2.9 p -123.25 171.17 9.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -1.164 . . . . 0.0 110.591 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.057 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -140.94 150.16 42.78 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.515 -0.741 . . . . 0.0 109.39 -175.872 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.587 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 26.4 tttt -111.62 116.44 30.81 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.122 -0.986 . . . . 0.0 110.275 179.797 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 0.882 HD23 ' C ' ' B' ' 77' ' ' LYS . 10.0 tp -58.65 124.87 21.16 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.136 -0.978 . . . . 0.0 108.911 173.133 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.044 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.0 OUTLIER -118.3 -29.08 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 C-N-CA 119.549 -0.86 . . . . 0.0 109.674 178.744 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.58 149.99 27.25 Favored 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 119.115 -1.034 . . . . 0.0 111.539 -178.416 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.759 HG23 ' CD2' ' B' ' 24' ' ' HIS . 19.5 mt -112.1 132.16 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.307 -0.87 . . . . 0.0 110.098 172.838 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.53 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 86.1 m-20 -108.71 116.23 31.59 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.386 -0.821 . . . . 0.0 109.776 174.888 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -106.21 108.54 20.1 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.001 -1.062 . . . . 0.0 110.537 -176.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -102.01 128.48 28.51 Favored Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.167 -0.958 . . . . 0.0 109.022 172.647 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 19' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.2 Cg_endo -50.49 -29.63 25.05 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 O-C-N 123.841 1.443 . . . . 0.0 110.465 -179.463 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.485 ' HB3' ' CE2' ' B' ' 21' ' ' PHE . 12.6 m-80 -77.7 -40.32 41.73 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.236 -0.915 . . . . 0.0 110.016 176.037 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.485 ' CE2' ' HB3' ' B' ' 20' ' ' ASN . 51.4 m-85 -150.94 150.19 30.53 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.409 -0.807 . . . . 0.0 109.9 -179.78 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 22' ' ' ARG . . . . . 0.474 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 60.0 ttt180 -90.43 145.12 25.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.74 -1.225 . . . . 0.0 110.063 176.841 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.53 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 92.0 m -129.49 138.36 51.34 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.569 -0.707 . . . . 0.0 109.843 -177.185 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.759 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -129.09 136.57 50.41 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.042 -1.037 . . . . 0.0 110.977 178.901 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.789 HG22 ' CB ' ' B' ' 60' ' ' SER . 8.5 t -120.04 132.78 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.119 -0.988 . . . . 0.0 110.711 -176.499 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.785 HG13 ' CE1' ' B' ' 61' ' ' PHE . 23.7 m -117.07 173.25 4.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.815 -0.553 . . . . 0.0 110.318 178.605 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.671 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 9.8 tt0 -105.98 117.89 35.19 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 -179.645 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.716 HD21 HD13 ' B' ' 36' ' ' LEU . 9.2 tp -85.58 125.67 68.68 Favored Pre-proline 0 C--N 1.298 -1.666 0 O-C-N 121.318 -0.864 . . . . 0.0 110.251 -171.226 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.485 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 22.1 Cg_endo -66.08 176.36 3.92 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 O-C-N 123.889 1.468 . . . . 0.0 111.196 -179.512 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.485 ' HA ' HD12 ' B' ' 33' ' ' LEU . 47.8 t0 -60.07 -39.98 87.93 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.338 -0.851 . . . . 0.0 111.135 -175.476 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.99 0.15 57.26 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.877 -1.139 . . . . 0.0 110.734 -174.928 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.597 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.7 mmm -112.33 -12.38 13.57 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.957 -1.09 . . . . 0.0 109.708 171.552 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.592 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 17.7 mt -69.28 -36.91 77.55 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.346 -0.847 . . . . 0.0 110.032 175.819 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 72.9 m-20 -82.71 138.96 33.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.438 -0.789 . . . . 0.0 110.8 -177.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.34 -40.61 2.86 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 174.621 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.801 HD23 ' N ' ' B' ' 37' ' ' GLU . 8.2 tt -73.37 145.95 45.53 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.997 -1.296 . . . . 0.0 110.556 -176.187 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 37' ' ' GLU . . . . . 0.801 ' N ' HD23 ' B' ' 36' ' ' LEU . 20.9 pt-20 -150.34 167.04 28.2 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.44 -0.787 . . . . 0.0 109.674 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 38' ' ' THR . . . . . 0.789 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -65.24 152.16 44.38 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.994 -1.066 . . . . 0.0 110.323 -178.156 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.62 -3.94 62.02 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -176.054 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.62 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -77.36 155.2 32.09 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.212 -1.17 . . . . 0.0 109.521 176.262 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.576 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -96.54 104.25 16.22 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.893 -1.13 . . . . 0.0 109.873 176.858 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.697 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.1 t -86.07 131.97 33.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.224 -0.923 . . . . 0.0 109.178 174.854 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 1.068 ' HB3' ' CG ' ' B' ' 85' ' ' GLU . . . -98.67 120.33 38.92 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 121.227 -0.921 . . . . 0.0 109.288 173.473 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.882 ' CD2' HG21 ' B' ' 82' ' ' VAL . 1.4 m80 -93.1 103.75 16.01 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.502 -0.749 . . . . 0.0 109.365 179.482 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.514 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.3 t-20 55.9 11.48 0.71 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.557 -0.714 . . . . 0.0 110.972 -169.946 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.521 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.41 2.24 10.84 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 119.755 -1.212 . . . . 0.0 110.8 174.048 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.685 ' O ' HD23 ' B' ' 49' ' ' LEU . 8.7 t -97.47 113.32 24.99 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 120.327 -1.69 . . . . 0.0 109.543 175.384 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 48' ' ' CYS . . . . . 0.41 ' O ' ' SG ' ' B' ' 48' ' ' CYS . 26.4 p -79.8 124.3 28.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.044 -1.035 . . . . 0.0 111.145 -170.723 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 0.897 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -141.51 163.34 33.2 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.538 -0.726 . . . . 0.0 109.618 172.77 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 50' ' ' THR . . . . . 0.44 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 57.4 m -102.92 152.18 21.59 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.78 -1.2 . . . . 0.0 110.991 -172.032 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.941 HG13 HG13 ' B' ' 59' ' ' VAL . 14.1 t -78.54 114.72 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.749 -0.594 . . . . 0.0 110.323 -178.644 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 47.0 p -71.32 -44.56 64.9 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.09 -1.006 . . . . 0.0 109.821 175.799 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.557 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -158.25 153.92 26.38 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.241 -0.912 . . . . 0.0 110.272 178.176 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.789 HD11 ' N ' ' B' ' 38' ' ' THR . 7.9 mt -105.34 130.32 56.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.117 -0.989 . . . . 0.0 109.825 176.028 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.531 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 12.3 m-80 -102.54 64.32 0.89 Allowed 'General case' 0 C--N 1.297 -1.675 0 C-N-CA 119.865 -0.734 . . . . 0.0 109.608 179.844 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.68 -113.0 3.88 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 108.659 -1.776 . . . . 0.0 108.659 -173.139 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.592 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -80.1 -21.53 43.19 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.045 -1.268 . . . . 0.0 109.225 175.609 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.044 ' CE1' HG11 ' B' ' 13' ' ' VAL . 22.9 m-70 -74.72 159.46 31.99 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.317 -0.864 . . . . 0.0 110.155 -177.83 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.941 HG13 HG13 ' B' ' 51' ' ' VAL . 54.5 t -140.06 122.19 16.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 C-N-CA 118.903 -1.119 . . . . 0.0 110.867 172.303 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.789 ' CB ' HG22 ' B' ' 25' ' ' VAL . 60.1 p -91.16 129.23 37.18 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.734 -0.604 . . . . 0.0 109.682 177.833 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.897 ' HB2' HD12 ' B' ' 49' ' ' LEU . 1.3 p90 -123.2 156.94 34.12 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.072 -1.018 . . . . 0.0 110.555 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 32.7 p-10 -91.28 152.22 20.58 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.097 -1.002 . . . . 0.0 111.224 -172.625 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.814 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -155.81 111.91 3.09 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -175.88 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.509 ' HB2' ' HB ' ' B' ' 67' ' ' THR . 84.1 mmm -65.8 139.82 58.35 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.871 -1.143 . . . . 0.0 109.186 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.457 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 57.9 tptt -60.03 -44.27 94.73 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.11 -0.994 . . . . 0.0 109.987 -176.685 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 66' ' ' GLU . . . . . 0.445 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 85.9 tt0 -69.15 -39.96 78.48 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.171 -0.955 . . . . 0.0 110.302 178.626 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.509 ' HB ' ' HB2' ' B' ' 64' ' ' MET . 90.5 m -61.05 -40.07 92.22 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.899 -1.126 . . . . 0.0 109.019 173.288 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.798 HD11 ' HA2' ' B' ' 74' ' ' GLY . 5.1 tp -59.94 -46.08 90.55 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.512 -0.742 . . . . 0.0 109.747 178.918 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 32.5 tpt180 -67.6 -39.98 84.75 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.612 -0.68 . . . . 0.0 110.506 177.585 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.775 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -70.0 -41.47 79.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 O-C-N 121.328 -0.858 . . . . 0.0 109.593 -176.544 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.775 HG23 HG22 ' B' ' 70' ' ' ILE . 60.2 p -84.65 -173.16 4.57 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 120.177 -0.609 . . . . 0.0 109.517 178.563 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.48 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 4.5 t30 -101.65 22.98 11.9 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 170.837 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.814 ' HB3' HD21 ' B' ' 63' ' ' LEU . 94.2 mt -69.96 -42.31 73.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.022 -1.049 . . . . 0.0 110.02 176.096 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.798 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -52.34 -18.82 5.31 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -178.025 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 23.7 p-10 -64.78 -18.29 64.95 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.054 -1.262 . . . . 0.0 110.436 -176.217 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.516 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 88.7 mt -59.99 143.24 52.27 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.23 -0.919 . . . . 0.0 110.844 -176.297 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 0.882 ' C ' HD23 ' B' ' 12' ' ' LEU . 54.6 mttt -142.61 141.22 31.91 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.652 -0.655 . . . . 0.0 109.62 175.723 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.619 ' N ' HD23 ' B' ' 12' ' ' LEU . 17.2 t -60.85 151.15 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 120.844 -1.16 . . . . 0.0 110.555 -174.408 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.68 -10.82 66.03 Favored Glycine 0 N--CA 1.487 2.07 0 N-CA-C 109.02 -1.632 . . . . 0.0 109.02 -177.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 47.0 t0 -96.45 163.11 13.19 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.348 -1.089 . . . . 0.0 109.695 176.761 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.587 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.0 m95 -113.38 161.58 17.1 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.056 -1.028 . . . . 0.0 110.284 176.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 1.057 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.5 p -131.27 149.92 33.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.575 -0.703 . . . . 0.0 109.801 -176.479 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.729 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -75.34 107.79 7.69 Favored 'General case' 0 C--N 1.294 -1.806 0 O-C-N 121.205 -0.934 . . . . 0.0 109.282 170.633 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.826 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.2 OUTLIER -111.65 145.2 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 120.522 -1.361 . . . . 0.0 111.501 -175.121 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 85' ' ' GLU . . . . . 1.068 ' CG ' ' HB3' ' B' ' 43' ' ' ALA . 25.9 pt-20 -144.6 159.98 41.91 Favored 'General case' 0 N--CA 1.494 1.773 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.691 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 86' ' ' ARG . . . . . 0.514 ' NH1' ' OE1' ' B' ' 7' ' ' GLN . 31.5 ptt-85 -98.1 132.88 43.25 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.869 -1.145 . . . . 0.0 110.963 -174.28 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.576 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.763 0 O-C-N 121.401 -0.812 . . . . 0.0 109.79 177.134 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.976 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.4 t . . . . . 0 N--CA 1.492 1.674 0 CA-C-O 121.537 0.684 . . . . 0.0 110.418 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -69.94 -33.65 72.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.51 -0.744 . . . . 0.0 111.051 178.703 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.515 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -155.66 172.85 33.77 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.871 -1.633 . . . . 0.0 109.909 -173.675 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.483 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 0.6 OUTLIER -115.2 168.8 9.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.143 -1.21 . . . . 0.0 110.48 -179.496 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 1.016 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -135.59 147.82 48.83 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.547 -0.721 . . . . 0.0 109.472 -179.142 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.577 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 29.1 tttt -105.98 115.86 30.96 Favored 'General case' 0 C--N 1.294 -1.829 0 O-C-N 121.121 -0.987 . . . . 0.0 110.247 178.835 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 1.029 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.1 tp -59.71 128.09 35.24 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 120.89 -1.131 . . . . 0.0 108.653 172.834 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.143 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.5 p -128.2 -31.52 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 C-N-CA 119.553 -0.859 . . . . 0.0 110.085 -177.719 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.91 144.71 30.35 Favored 'General case' 0 N--CA 1.495 1.786 0 C-N-CA 118.859 -1.136 . . . . 0.0 111.293 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.766 HG23 ' CD2' ' A' ' 24' ' ' HIS . 12.5 mt -109.44 132.99 56.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.245 -0.91 . . . . 0.0 110.351 173.177 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.499 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 79.8 m-20 -110.15 116.22 31.14 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.307 -0.871 . . . . 0.0 109.98 173.125 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -106.54 114.45 28.57 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.007 -1.058 . . . . 0.0 110.567 -178.216 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.456 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.7 mtmt -110.74 132.94 21.35 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.248 -0.907 . . . . 0.0 109.138 175.492 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -50.07 -34.54 38.83 Favored 'Trans proline' 0 C--N 1.301 -1.93 0 O-C-N 123.857 1.451 . . . . 0.0 110.692 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.465 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 12.3 m-80 -74.6 -39.71 62.02 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.149 -0.97 . . . . 0.0 110.076 177.304 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.465 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 96.1 m-85 -154.35 150.16 27.65 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.345 -0.847 . . . . 0.0 110.128 -178.471 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.492 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 59.5 ttt180 -91.71 146.29 23.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.751 -1.218 . . . . 0.0 110.121 176.684 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.499 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 90.4 m -130.0 140.04 50.95 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.408 -0.807 . . . . 0.0 109.927 -175.608 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.766 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -129.15 136.43 50.18 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.9 -1.125 . . . . 0.0 111.148 177.565 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.725 HG22 ' OG ' ' A' ' 60' ' ' SER . 5.8 t -115.78 132.46 65.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.075 -1.016 . . . . 0.0 110.7 -177.414 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.488 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 12.5 m -116.1 170.19 6.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-O 121.111 0.482 . . . . 0.0 110.124 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.502 ' HG2' HD22 ' A' ' 57' ' ' ASN . 2.7 tm-20 -101.55 117.8 35.65 Favored 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.322 -0.861 . . . . 0.0 109.23 179.068 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.597 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.3 tp -82.71 127.27 70.81 Favored Pre-proline 0 C--N 1.298 -1.661 0 O-C-N 121.485 -0.759 . . . . 0.0 110.003 -174.923 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.462 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 25.3 Cg_endo -66.5 -178.5 1.21 Allowed 'Trans proline' 0 C--N 1.308 -1.561 0 O-C-N 123.88 1.463 . . . . 0.0 111.008 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.502 ' OD1' ' N ' ' A' ' 30' ' ' ASP . 22.6 p-10 -65.66 -39.98 91.96 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.413 -0.804 . . . . 0.0 111.016 -177.18 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.604 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.0 0.36 57.15 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.905 -1.122 . . . . 0.0 110.924 -174.557 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.604 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.8 mmm -110.14 -16.02 13.88 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.949 -1.094 . . . . 0.0 109.692 171.645 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.597 ' HA ' HD23 ' A' ' 28' ' ' LEU . 13.4 mt -66.13 -32.04 73.25 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.515 -0.74 . . . . 0.0 110.41 178.163 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ASP . . . . . 0.419 ' OD1' ' N ' ' A' ' 35' ' ' GLY . 63.7 t0 -80.26 142.93 34.11 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.222 -0.924 . . . . 0.0 110.864 -176.7 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.419 ' N ' ' OD1' ' A' ' 34' ' ' ASP . . . 85.94 -31.77 3.92 Favored Glycine 0 N--CA 1.493 2.443 0 C-N-CA 119.99 -1.1 . . . . 0.0 111.096 170.702 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.552 HD23 ' CD2' ' A' ' 28' ' ' LEU . 57.7 tp -77.45 155.09 31.98 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.708 -1.466 . . . . 0.0 111.111 -173.839 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.454 ' C ' HD11 ' A' ' 54' ' ' ILE . 20.0 pt-20 -153.57 167.84 28.18 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.531 -0.731 . . . . 0.0 109.644 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.842 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -67.8 154.5 41.39 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.876 -1.14 . . . . 0.0 110.111 178.142 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.59 0.3 58.2 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -174.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.671 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -79.99 160.22 25.98 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.173 -1.193 . . . . 0.0 109.041 174.407 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.888 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 1.6 p -103.33 118.87 37.74 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 118.294 -1.362 . . . . 0.0 109.692 175.081 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.622 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.6 t -101.67 125.87 55.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 175.188 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -87.89 118.58 27.52 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 119.269 -0.972 . . . . 0.0 109.154 174.509 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.877 ' CD2' HG21 ' A' ' 82' ' ' VAL . 0.7 OUTLIER -91.43 106.08 18.24 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 176.378 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.564 HD22 ' HB2' ' B' ' 47' ' ' CYS . 0.8 OUTLIER 55.44 13.41 0.92 Allowed 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.452 -0.78 . . . . 0.0 111.257 -168.938 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.493 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.56 -6.25 10.63 Favored Glycine 0 N--CA 1.49 2.243 0 C-N-CA 119.459 -1.353 . . . . 0.0 110.999 171.25 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.816 ' O ' HD23 ' A' ' 49' ' ' LEU . 32.6 t -89.7 107.58 19.18 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.51 -1.583 . . . . 0.0 109.457 175.582 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.422 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 26.7 p -74.07 123.44 24.39 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.122 -0.986 . . . . 0.0 110.531 -174.13 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.829 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -138.96 156.53 47.17 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.405 -0.809 . . . . 0.0 109.411 175.196 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.442 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 26.8 m -94.76 156.42 16.39 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 120.489 -1.382 . . . . 0.0 111.315 -169.184 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.783 HG13 HG13 ' A' ' 59' ' ' VAL . 16.8 t -82.24 116.06 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.859 -0.525 . . . . 0.0 110.332 -178.055 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.575 HG22 ' HB3' ' A' ' 62' ' ' ASP . 59.8 p -69.85 -40.03 76.04 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.177 -0.952 . . . . 0.0 109.453 172.561 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.584 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 51.8 tp10 -162.55 156.29 20.69 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.221 -0.992 . . . . 0.0 110.839 -177.647 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.842 HD11 ' N ' ' A' ' 38' ' ' THR . 7.5 mt -109.98 130.03 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.087 -1.008 . . . . 0.0 109.545 170.699 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.515 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 14.1 m120 -104.2 62.94 0.74 Allowed 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.603 -0.686 . . . . 0.0 109.493 178.632 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.49 -114.77 4.1 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.809 -1.717 . . . . 0.0 108.809 -172.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.591 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -80.08 -19.72 46.81 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.042 -1.27 . . . . 0.0 109.038 175.967 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.143 ' CE1' HG11 ' A' ' 13' ' ' VAL . 23.7 m-70 -76.91 159.14 30.24 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.279 -0.888 . . . . 0.0 110.233 -177.73 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.783 HG13 HG13 ' A' ' 51' ' ' VAL . 54.0 t -140.42 120.34 12.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.027 -1.046 . . . . 0.0 110.948 173.403 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.725 ' OG ' HG22 ' A' ' 25' ' ' VAL . 21.3 m -86.02 128.72 34.92 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.57 -0.706 . . . . 0.0 109.729 177.257 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.829 ' HB3' HD12 ' A' ' 49' ' ' LEU . 60.2 m-85 -111.37 160.02 17.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.907 -1.12 . . . . 0.0 110.341 178.808 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.575 ' HB3' HG22 ' A' ' 52' ' ' THR . 31.8 p-10 -93.36 146.89 23.4 Favored 'General case' 0 N--CA 1.497 1.917 0 CA-C-O 122.099 0.952 . . . . 0.0 111.436 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.761 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -157.39 113.37 2.88 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.459 -176.967 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.505 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 57.0 ttm -69.27 142.39 54.15 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.847 -1.158 . . . . 0.0 109.572 179.116 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 47.6 tptt -60.05 -46.13 90.57 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.013 -1.054 . . . . 0.0 110.284 -175.732 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 87.8 tt0 -69.73 -40.09 76.43 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.92 -1.113 . . . . 0.0 110.201 179.358 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.505 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 86.5 m -60.29 -38.34 83.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.931 -1.106 . . . . 0.0 109.228 172.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.715 ' CD1' HD22 ' A' ' 63' ' ' LEU . 11.0 tp -60.05 -44.0 94.99 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.368 -0.832 . . . . 0.0 109.375 -179.618 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -68.11 -39.82 82.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.346 -0.846 . . . . 0.0 110.695 174.336 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.755 HG22 HG23 ' A' ' 71' ' ' THR . 1.4 tt -66.3 -41.64 89.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.275 -0.891 . . . . 0.0 109.626 -175.063 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.755 HG23 HG22 ' A' ' 70' ' ' ILE . 50.7 p -83.53 -168.58 2.17 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.709 -0.62 . . . . 0.0 109.606 177.679 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.496 ' CB ' ' H ' ' B' ' 83' ' ' ASN . 7.1 t30 -104.92 19.6 20.28 Favored 'General case' 0 C--N 1.293 -1.87 0 O-C-N 121.245 -0.909 . . . . 0.0 108.559 168.054 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.761 ' HB3' HD21 ' A' ' 63' ' ' LEU . 81.8 mt -69.98 -40.06 75.55 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.092 -1.005 . . . . 0.0 109.997 175.779 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.625 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -47.14 -22.68 1.43 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 178.208 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 22.2 p-10 -62.62 -16.25 55.69 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.959 -1.318 . . . . 0.0 110.391 -175.958 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.518 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 84.4 mt -63.07 146.21 53.75 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.252 -0.905 . . . . 0.0 111.037 -175.129 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 1.029 ' C ' HD23 ' A' ' 12' ' ' LEU . 96.6 mttt -149.21 138.17 21.29 Favored 'General case' 0 N--CA 1.493 1.698 0 CA-C-O 121.461 0.648 . . . . 0.0 109.684 174.182 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.72 HG23 HD11 ' A' ' 15' ' ' ILE . 17.5 t -61.52 151.86 6.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.843 -1.161 . . . . 0.0 110.51 -175.112 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.03 -14.51 60.38 Favored Glycine 0 N--CA 1.484 1.835 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 -175.279 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.428 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 25.7 t0 -97.82 168.4 10.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.267 -1.137 . . . . 0.0 109.625 176.22 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.577 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.2 m95 -116.64 169.12 9.59 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.079 -1.013 . . . . 0.0 110.045 177.112 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.016 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.5 p -136.34 147.98 27.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.329 -0.857 . . . . 0.0 109.965 -177.148 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.976 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.9 m-20 -73.11 104.36 4.16 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.078 -1.014 . . . . 0.0 109.197 170.06 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.832 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -107.96 140.26 27.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 120.786 -1.197 . . . . 0.0 111.183 -176.841 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.421 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.5 tt0 -142.19 140.83 32.49 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.783 -0.573 . . . . 0.0 110.235 -176.733 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 95.2 mtt180 -60.19 131.62 51.39 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.045 -1.035 . . . . 0.0 109.777 178.648 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.888 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.238 -0.914 . . . . 0.0 109.984 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 0.965 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.5 t . . . . . 0 N--CA 1.494 1.725 0 CA-C-O 121.548 0.69 . . . . 0.0 110.336 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -70.07 -33.5 72.01 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.525 -0.734 . . . . 0.0 111.096 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.531 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -155.79 172.71 33.84 Favored Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.029 -1.558 . . . . 0.0 110.025 -173.684 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.489 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 0.6 OUTLIER -115.18 168.67 9.74 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.203 -1.175 . . . . 0.0 110.537 -179.499 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.059 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -135.47 148.03 49.09 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.535 -0.728 . . . . 0.0 109.426 -179.245 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.573 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 29.1 tttt -106.13 115.92 31.05 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.163 -0.961 . . . . 0.0 110.191 178.876 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 1.028 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.1 tp -59.81 128.07 35.11 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.002 -1.061 . . . . 0.0 108.701 172.843 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.135 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.5 p -128.08 -31.68 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 C-N-CA 119.586 -0.845 . . . . 0.0 110.141 -177.745 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.74 144.65 30.47 Favored 'General case' 0 N--CA 1.493 1.687 0 C-N-CA 119.069 -1.052 . . . . 0.0 111.44 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.765 HG23 ' CD2' ' B' ' 24' ' ' HIS . 12.3 mt -109.27 133.03 55.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.19 -0.944 . . . . 0.0 110.479 173.125 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.513 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 79.6 m-20 -110.29 116.34 31.29 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.36 -0.837 . . . . 0.0 109.901 173.18 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -106.57 114.48 28.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.935 -1.103 . . . . 0.0 110.62 -178.269 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.453 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.7 mtmt -110.71 132.92 21.35 Favored Pre-proline 0 N--CA 1.493 1.719 0 O-C-N 121.297 -0.877 . . . . 0.0 109.192 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -50.19 -34.53 39.83 Favored 'Trans proline' 0 C--N 1.301 -1.927 0 O-C-N 123.8 1.421 . . . . 0.0 110.703 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.467 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 12.4 m-80 -74.5 -40.13 61.99 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.129 -0.982 . . . . 0.0 109.973 177.259 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.467 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 96.2 m-85 -153.89 150.2 28.13 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.371 -0.831 . . . . 0.0 110.182 -178.428 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 22' ' ' ARG . . . . . 0.488 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 59.5 ttt180 -91.65 146.22 23.96 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.899 -1.125 . . . . 0.0 110.159 176.595 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.513 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 91.2 m -129.93 140.0 51.02 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.416 -0.802 . . . . 0.0 110.023 -175.717 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.765 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -129.03 136.56 50.46 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.998 -1.064 . . . . 0.0 111.16 177.603 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.733 HG22 ' OG ' ' B' ' 60' ' ' SER . 5.7 t -115.76 132.49 65.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.185 -0.947 . . . . 0.0 110.755 -177.373 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.732 HG11 ' HE1' ' B' ' 44' ' ' HIS . 13.0 m -116.3 170.31 6.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.025 179.839 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.492 ' HG2' HD22 ' B' ' 57' ' ' ASN . 2.7 tm-20 -101.57 117.81 35.68 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 121.298 -0.876 . . . . 0.0 109.244 179.071 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.602 HD23 ' HA ' ' B' ' 33' ' ' LEU . 9.3 tp -82.65 127.28 70.9 Favored Pre-proline 0 C--N 1.299 -1.623 0 O-C-N 121.435 -0.791 . . . . 0.0 110.115 -174.958 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.464 ' HD2' ' HB2' ' B' ' 32' ' ' MET . 24.9 Cg_endo -66.55 -178.53 1.23 Allowed 'Trans proline' 0 C--N 1.307 -1.658 0 O-C-N 123.932 1.491 . . . . 0.0 110.917 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.49 ' OD1' ' N ' ' B' ' 30' ' ' ASP . 22.7 p-10 -65.56 -40.01 92.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.335 -0.853 . . . . 0.0 111.089 -177.271 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.592 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.02 0.38 57.14 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.913 -1.117 . . . . 0.0 110.983 -174.641 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.592 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.8 mmm -110.15 -15.98 13.88 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.978 -1.076 . . . . 0.0 109.756 171.593 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.604 HD21 ' HB2' ' B' ' 57' ' ' ASN . 13.5 mt -66.09 -32.08 73.33 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.462 -0.774 . . . . 0.0 110.453 178.071 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 34' ' ' ASP . . . . . 0.426 ' OD1' ' N ' ' B' ' 35' ' ' GLY . 63.7 t0 -80.2 142.93 34.23 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.282 -0.887 . . . . 0.0 110.894 -176.741 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 35' ' ' GLY . . . . . 0.426 ' N ' ' OD1' ' B' ' 34' ' ' ASP . . . 85.9 -31.91 3.88 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 119.92 -1.133 . . . . 0.0 111.092 170.726 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.55 HD23 ' CD2' ' B' ' 28' ' ' LEU . 57.8 tp -77.39 155.12 32.08 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.669 -1.489 . . . . 0.0 111.131 -173.824 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 37' ' ' GLU . . . . . 0.478 ' C ' HD11 ' B' ' 54' ' ' ILE . 20.0 pt-20 -153.57 167.92 27.89 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.558 -0.714 . . . . 0.0 109.665 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 38' ' ' THR . . . . . 0.849 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -67.96 154.51 41.46 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.953 -1.092 . . . . 0.0 110.157 178.15 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.65 0.31 58.52 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -174.924 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.674 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -80.07 159.96 25.96 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.202 -1.175 . . . . 0.0 109.074 174.271 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.913 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 1.6 p -102.86 118.83 37.7 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.559 -1.338 . . . . 0.0 109.818 175.076 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.696 HG12 ' CD2' ' B' ' 44' ' ' HIS . 1.6 t -101.88 125.98 55.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 175.198 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -87.99 118.62 27.67 Favored 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.196 -1.002 . . . . 0.0 109.155 174.532 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.732 ' HE1' HG11 ' B' ' 26' ' ' VAL . 3.7 m170 -91.39 105.9 18.11 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 176.374 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.529 HD22 ' HB2' ' A' ' 47' ' ' CYS . 0.8 OUTLIER 55.49 13.57 0.98 Allowed 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.423 -0.798 . . . . 0.0 111.266 -169.023 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.493 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.47 -6.1 10.73 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 119.379 -1.391 . . . . 0.0 110.961 171.081 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.819 ' O ' HD23 ' B' ' 49' ' ' LEU . 33.0 t -89.82 107.54 19.16 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.549 -1.559 . . . . 0.0 109.413 175.577 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 48' ' ' CYS . . . . . 0.417 ' O ' ' SG ' ' B' ' 48' ' ' CYS . 26.5 p -74.04 123.68 24.82 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.14 -0.975 . . . . 0.0 110.452 -174.129 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 0.838 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -139.15 156.54 47.05 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.42 -0.8 . . . . 0.0 109.344 175.141 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 50' ' ' THR . . . . . 0.446 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 26.8 m -94.63 156.44 16.42 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 120.608 -1.308 . . . . 0.0 111.266 -169.107 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.796 HG13 HG13 ' B' ' 59' ' ' VAL . 17.0 t -82.35 116.1 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.831 -0.543 . . . . 0.0 110.389 -178.151 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.566 HG22 ' HB3' ' B' ' 62' ' ' ASP . 60.1 p -69.85 -40.06 76.02 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.133 -0.98 . . . . 0.0 109.458 172.631 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.58 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 51.8 tp10 -162.58 156.25 20.58 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.384 -0.926 . . . . 0.0 110.827 -177.589 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.849 HD11 ' N ' ' B' ' 38' ' ' THR . 7.5 mt -110.0 129.98 63.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.14 -0.975 . . . . 0.0 109.535 170.789 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.529 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 14.1 m120 -104.2 62.85 0.74 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.624 -0.673 . . . . 0.0 109.539 178.672 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.6 -114.74 4.08 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 -172.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.604 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -80.06 -19.76 46.79 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.948 -1.325 . . . . 0.0 109.102 175.947 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.135 ' CE1' HG11 ' B' ' 13' ' ' VAL . 23.8 m-70 -76.91 158.97 30.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.337 -0.852 . . . . 0.0 110.263 -177.784 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.796 HG13 HG13 ' B' ' 51' ' ' VAL . 53.9 t -140.35 120.36 13.02 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 C-N-CA 119.104 -1.038 . . . . 0.0 110.921 173.542 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.733 ' OG ' HG22 ' B' ' 25' ' ' VAL . 21.8 m -85.99 128.83 34.93 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.648 -0.658 . . . . 0.0 109.751 177.293 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.838 ' HB3' HD12 ' B' ' 49' ' ' LEU . 60.4 m-85 -111.45 160.05 17.49 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.931 -1.106 . . . . 0.0 110.343 178.77 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.566 ' HB3' HG22 ' B' ' 52' ' ' THR . 31.6 p-10 -93.44 146.89 23.43 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.08 -1.012 . . . . 0.0 111.317 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.748 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -157.37 113.44 2.89 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 -177.033 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.514 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 56.9 ttm -69.25 142.37 54.19 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.877 -1.139 . . . . 0.0 109.61 179.012 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 47.6 tptt -59.91 -46.19 90.13 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.107 -0.995 . . . . 0.0 110.341 -175.771 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 87.8 tt0 -69.81 -40.04 76.18 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.971 -1.08 . . . . 0.0 110.123 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.514 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 87.1 m -60.29 -38.46 83.66 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.915 -1.115 . . . . 0.0 109.191 173.026 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.719 ' CD1' HD22 ' B' ' 63' ' ' LEU . 11.1 tp -60.04 -43.71 95.15 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.52 -0.738 . . . . 0.0 109.45 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -68.31 -39.81 81.91 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.304 -0.872 . . . . 0.0 110.598 174.314 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.743 HG22 HG23 ' B' ' 71' ' ' THR . 1.4 tt -66.38 -41.56 89.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.571 -174.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.743 HG23 HG22 ' B' ' 70' ' ' ILE . 51.3 p -83.51 -168.5 2.13 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.113 -0.635 . . . . 0.0 109.634 177.703 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.485 ' CB ' ' H ' ' A' ' 83' ' ' ASN . 7.2 t30 -104.93 19.59 20.29 Favored 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 168.042 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.748 ' HB3' HD21 ' B' ' 63' ' ' LEU . 81.5 mt -69.96 -40.07 75.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.005 -1.059 . . . . 0.0 109.931 175.817 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.61 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -47.28 -22.58 1.52 Allowed Glycine 0 N--CA 1.487 2.051 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 178.354 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 22.3 p-10 -62.64 -16.24 55.82 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.045 -1.268 . . . . 0.0 110.349 -175.917 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.516 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 84.2 mt -63.22 146.14 54.02 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.309 -0.87 . . . . 0.0 111.046 -175.085 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 1.028 ' C ' HD23 ' B' ' 12' ' ' LEU . 96.6 mttt -149.03 138.34 21.61 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.781 -0.575 . . . . 0.0 109.647 174.172 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.716 HG21 HG13 ' B' ' 15' ' ' ILE . 17.3 t -61.56 151.92 6.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.051 -1.031 . . . . 0.0 110.479 -175.127 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.89 -14.24 60.86 Favored Glycine 0 N--CA 1.483 1.777 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 -175.383 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 25.5 t0 -97.89 168.41 10.32 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.413 -1.051 . . . . 0.0 109.645 176.056 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.573 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.3 m95 -116.64 168.91 9.76 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.973 -1.079 . . . . 0.0 110.144 177.119 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 1.059 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.5 p -136.25 148.06 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.494 -0.754 . . . . 0.0 110.006 -177.295 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.965 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.8 m-20 -73.08 104.2 4.09 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.082 -1.011 . . . . 0.0 109.243 170.106 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.814 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -107.81 140.6 25.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 120.843 -1.161 . . . . 0.0 110.99 -176.664 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' B' B ' 85' ' ' GLU . . . . . 0.411 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.5 tt0 -142.49 140.81 32.0 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.762 -0.586 . . . . 0.0 110.183 -176.788 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 95.3 mtt180 -60.29 131.69 51.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.113 -0.992 . . . . 0.0 109.77 178.681 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.913 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.331 -0.856 . . . . 0.0 110.114 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.98 HG21 ' HB3' ' A' ' 83' ' ' ASN . 3.7 t . . . . . 0 N--CA 1.492 1.637 0 CA-C-O 121.683 0.754 . . . . 0.0 110.817 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 94.3 mm-40 -69.94 -33.2 71.81 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.603 -0.686 . . . . 0.0 110.556 175.92 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -168.87 174.52 43.45 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.104 -1.522 . . . . 0.0 109.87 -176.58 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.493 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 41.5 p -114.58 170.01 8.63 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.065 -1.256 . . . . 0.0 110.772 -177.598 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 1.033 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -135.53 149.93 49.6 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.572 -0.705 . . . . 0.0 109.577 -175.721 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.585 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.0 tttt -105.71 116.77 32.51 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.142 -0.974 . . . . 0.0 110.337 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 1.013 HD23 ' C ' ' A' ' 77' ' ' LYS . 11.5 tp -60.02 127.12 30.33 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 120.898 -1.126 . . . . 0.0 108.825 172.383 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.078 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.4 p -125.57 -31.45 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.876 0 O-C-N 121.405 -0.81 . . . . 0.0 109.983 -179.495 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.2 144.6 29.04 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.027 -1.069 . . . . 0.0 111.237 -179.243 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.776 HG23 ' CD2' ' A' ' 24' ' ' HIS . 13.4 mt -108.53 135.64 46.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.162 -0.961 . . . . 0.0 110.032 172.027 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.514 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 84.0 m-20 -109.35 114.88 28.93 Favored 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.289 -0.882 . . . . 0.0 109.867 174.732 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -105.67 114.25 28.3 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.994 -1.067 . . . . 0.0 110.587 -175.376 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.1 mtmt -111.46 127.78 26.37 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.18 -0.95 . . . . 0.0 108.993 174.285 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -50.99 -24.06 13.31 Favored 'Trans proline' 0 C--N 1.303 -1.859 0 O-C-N 123.824 1.434 . . . . 0.0 110.254 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.543 ' C ' ' CD2' ' A' ' 21' ' ' PHE . 11.4 m-80 -80.15 -42.5 23.33 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.251 -0.905 . . . . 0.0 109.985 175.243 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.543 ' CD2' ' C ' ' A' ' 20' ' ' ASN . 97.5 m-85 -153.97 150.32 28.18 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.4 -0.812 . . . . 0.0 109.977 -178.869 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.68 ' HD3' HD22 ' A' ' 68' ' ' LEU . 62.0 ttt180 -90.58 145.29 24.98 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.878 -1.139 . . . . 0.0 110.167 178.581 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.514 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 87.4 m -131.75 141.75 49.6 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.511 -0.743 . . . . 0.0 109.846 -175.409 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.776 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -131.03 143.91 51.07 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 120.97 -1.081 . . . . 0.0 111.475 -179.466 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.848 HG22 ' CB ' ' A' ' 60' ' ' SER . 6.6 t -125.34 133.94 68.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.128 -0.982 . . . . 0.0 110.975 -178.309 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.733 HG13 ' HE1' ' A' ' 61' ' ' PHE . 29.5 m -116.88 174.59 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 CA-C-O 121.24 0.543 . . . . 0.0 110.319 178.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.58 ' HG3' HD22 ' A' ' 57' ' ' ASN . 11.8 tt0 -104.59 118.46 36.65 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 177.7 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.831 HD13 ' HD2' ' A' ' 29' ' ' PRO 0.266 0.2 OUTLIER -87.32 123.08 70.41 Favored Pre-proline 0 C--N 1.297 -1.704 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -172.649 . . . . . . . . 4 4 . 1 . 004 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.831 ' HD2' HD13 ' A' ' 28' ' ' LEU . 17.8 Cg_endo -66.29 172.81 8.34 Favored 'Trans proline' 0 C--N 1.309 -1.51 0 O-C-N 123.551 1.29 . . . . 0.0 111.094 -178.266 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.509 ' HA ' HD12 ' A' ' 33' ' ' LEU . 96.0 m-20 -59.99 -40.05 87.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.568 -0.708 . . . . 0.0 111.196 -174.671 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.536 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.02 -0.0 57.35 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.672 -1.267 . . . . 0.0 110.659 -171.479 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.671 ' HB3' HD11 ' A' ' 28' ' ' LEU . 97.8 mmm -113.52 -14.87 12.65 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.908 -1.12 . . . . 0.0 109.715 169.128 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.532 ' N ' HD12 ' A' ' 28' ' ' LEU . 14.0 mt -62.32 -40.02 94.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.087 -1.008 . . . . 0.0 109.59 176.585 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -69.93 129.95 40.9 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.469 -0.769 . . . . 0.0 110.278 178.036 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.0 -44.25 1.66 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 176.961 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.796 ' CD2' HG21 ' A' ' 59' ' ' VAL . 66.0 tp -63.61 145.13 56.29 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.05 -1.265 . . . . 0.0 110.946 -176.442 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 21.6 pt-20 -153.09 160.02 42.87 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.507 -0.745 . . . . 0.0 109.316 175.755 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.738 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -62.81 148.76 45.98 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.93 -1.107 . . . . 0.0 110.058 -179.296 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.52 -6.45 68.94 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 -175.035 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 50' ' ' THR . . . -72.86 155.73 39.61 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.178 -1.189 . . . . 0.0 109.543 176.479 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.788 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -100.03 99.75 10.53 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 119.05 -1.06 . . . . 0.0 109.698 176.762 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.686 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.2 t -85.58 131.74 33.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.347 -0.846 . . . . 0.0 109.355 176.229 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.507 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -95.03 119.98 34.47 Favored 'General case' 0 C--N 1.294 -1.83 0 O-C-N 121.059 -1.025 . . . . 0.0 109.272 170.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.686 ' HE1' HG11 ' A' ' 42' ' ' VAL . 0.3 OUTLIER -89.51 108.2 19.52 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 176.579 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.697 HD22 ' HB2' ' B' ' 47' ' ' CYS . 0.9 OUTLIER 51.83 16.34 0.49 Allowed 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.235 -0.916 . . . . 0.0 111.056 -168.218 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.491 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 117.09 -1.53 19.33 Favored Glycine 0 N--CA 1.49 2.235 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.915 172.356 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.79 ' O ' HD23 ' A' ' 49' ' ' LEU . 18.9 t -93.84 107.13 19.05 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.505 -1.585 . . . . 0.0 109.304 174.621 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.437 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 32.1 p -75.19 130.01 38.45 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.003 -1.061 . . . . 0.0 111.019 -171.584 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.914 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -144.75 161.22 39.77 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.526 -0.734 . . . . 0.0 109.524 174.518 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.461 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 10.7 m -100.22 149.97 23.02 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.757 -1.214 . . . . 0.0 111.043 -171.012 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.813 HG13 HG13 ' A' ' 59' ' ' VAL . 36.7 t -80.03 115.33 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.773 -0.579 . . . . 0.0 110.432 -178.89 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.556 HG22 ' HB3' ' A' ' 62' ' ' ASP . 30.5 p -70.09 -39.99 75.22 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.175 -0.953 . . . . 0.0 109.871 175.378 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.652 ' HA ' HG21 ' A' ' 38' ' ' THR . 87.7 tt0 -161.3 154.2 20.88 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.262 -0.899 . . . . 0.0 110.333 179.059 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.738 HD11 ' N ' ' A' ' 38' ' ' THR . 5.8 mt -102.48 132.73 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.983 -1.073 . . . . 0.0 109.909 174.472 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.523 ' CB ' ' HB2' ' A' ' 58' ' ' HIS . 2.5 m-80 -103.89 65.25 0.81 Allowed 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.569 -0.707 . . . . 0.0 109.869 179.334 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.94 -118.55 5.69 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 108.719 -1.752 . . . . 0.0 108.719 -173.091 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.58 HD22 ' HG3' ' A' ' 27' ' ' GLU . 0.1 OUTLIER -75.02 -21.46 59.07 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 120.903 -1.351 . . . . 0.0 108.764 173.818 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.078 ' CE1' HG11 ' A' ' 13' ' ' VAL . 30.4 m-70 -72.89 159.96 32.9 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.242 -0.912 . . . . 0.0 110.17 -177.37 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.813 HG13 HG13 ' A' ' 51' ' ' VAL . 52.8 t -140.1 125.57 20.72 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 O-C-N 121.04 -1.037 . . . . 0.0 110.662 171.536 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.848 ' CB ' HG22 ' A' ' 25' ' ' VAL . 54.3 p -96.09 125.82 40.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.723 -0.611 . . . . 0.0 109.742 179.641 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.914 ' HB2' HD12 ' A' ' 49' ' ' LEU . 4.3 p90 -118.45 155.26 31.08 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.016 -1.052 . . . . 0.0 110.296 179.806 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.556 ' HB3' HG22 ' A' ' 52' ' ' THR . 35.1 p-10 -87.87 152.81 21.81 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.075 -1.016 . . . . 0.0 111.244 -173.229 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.75 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -157.96 114.36 2.84 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 -176.518 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.511 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 57.6 ttm -71.92 142.33 49.48 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.009 -1.057 . . . . 0.0 109.624 -178.84 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.471 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 71.3 tttt -59.98 -50.01 75.41 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.075 -1.016 . . . . 0.0 110.505 -175.285 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -65.58 -39.96 92.2 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.996 -1.065 . . . . 0.0 109.914 178.845 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.511 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 93.0 m -61.11 -40.04 92.27 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.978 -1.076 . . . . 0.0 109.289 174.05 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.68 HD22 ' HD3' ' A' ' 22' ' ' ARG . 18.0 tp -59.95 -43.01 95.28 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.319 -0.863 . . . . 0.0 109.466 178.368 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -67.64 -39.98 84.59 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.554 -0.716 . . . . 0.0 110.138 176.588 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.719 HG22 HG23 ' A' ' 71' ' ' THR . 1.2 tt -68.23 -40.02 82.04 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.357 -0.84 . . . . 0.0 109.301 -177.055 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.719 HG23 HG22 ' A' ' 70' ' ' ILE . 60.1 p -84.61 -172.73 4.33 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 120.261 -0.576 . . . . 0.0 109.483 177.779 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.478 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 5.9 t30 -102.32 22.45 13.33 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 169.527 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.75 ' HB3' HD21 ' A' ' 63' ' ' LEU . 88.2 mt -70.02 -39.92 75.51 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.01 -1.056 . . . . 0.0 109.757 174.794 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.449 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -44.56 -23.96 0.6 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.396 -1.082 . . . . 0.0 110.396 178.684 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 23.0 p-10 -69.97 -19.16 63.36 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.913 -1.346 . . . . 0.0 110.603 -174.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.519 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 98.4 mt -59.92 140.41 56.7 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.085 -1.01 . . . . 0.0 110.714 -176.682 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 1.013 ' C ' HD23 ' A' ' 12' ' ' LEU . 92.3 mttt -143.6 138.97 29.43 Favored 'General case' 0 C--N 1.297 -1.712 0 CA-C-O 121.427 0.632 . . . . 0.0 109.83 177.301 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.68 ' N ' HD23 ' A' ' 12' ' ' LEU . 16.4 t -60.33 152.2 5.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 120.983 -1.073 . . . . 0.0 110.48 -175.863 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.37 -14.46 59.43 Favored Glycine 0 N--CA 1.483 1.776 0 N-CA-C 108.906 -1.678 . . . . 0.0 108.906 -176.108 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 49.6 t0 -96.27 166.37 11.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.33 -1.1 . . . . 0.0 109.627 176.569 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.585 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.1 m95 -115.43 165.99 12.37 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.963 -1.086 . . . . 0.0 110.157 175.53 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.033 HG13 ' HB3' ' A' ' 10' ' ' ALA . 0.9 OUTLIER -129.96 158.4 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.339 -0.851 . . . . 0.0 110.081 -177.532 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.98 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.1 OUTLIER -80.0 107.5 12.83 Favored 'General case' 0 C--N 1.297 -1.674 0 O-C-N 121.006 -1.058 . . . . 0.0 109.14 167.029 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.736 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -108.85 138.13 37.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 120.596 -1.315 . . . . 0.0 111.194 -176.356 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -140.92 146.51 37.5 Favored 'General case' 0 N--CA 1.492 1.661 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.043 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 58.0 ttp180 -83.21 130.02 35.06 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.027 -1.045 . . . . 0.0 111.038 -176.41 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.788 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 110.031 174.61 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 1.004 HG21 ' HB3' ' B' ' 83' ' ' ASN . 3.7 t . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.532 0.682 . . . . 0.0 110.856 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 94.3 mm-40 -69.99 -32.97 71.44 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.735 -0.603 . . . . 0.0 110.635 175.876 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -169.13 174.4 43.61 Favored Glycine 0 N--CA 1.495 2.576 0 C-N-CA 119.175 -1.488 . . . . 0.0 109.935 -176.626 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.488 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 41.6 p -114.52 170.03 8.61 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.0 -1.294 . . . . 0.0 110.778 -177.475 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.051 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -135.61 150.04 49.54 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.614 -0.679 . . . . 0.0 109.523 -175.742 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.581 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 30.1 tttt -105.84 116.83 32.61 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.101 -0.999 . . . . 0.0 110.262 179.134 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 1.013 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.5 tp -60.0 127.13 30.36 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 120.96 -1.088 . . . . 0.0 108.9 172.334 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.062 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.4 p -125.53 -31.61 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.856 0 O-C-N 121.383 -0.823 . . . . 0.0 110.009 -179.479 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.02 144.59 29.25 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.273 -0.971 . . . . 0.0 111.351 -179.281 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.779 HG23 ' CD2' ' B' ' 24' ' ' HIS . 13.5 mt -108.58 135.67 46.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.217 -0.927 . . . . 0.0 109.994 172.058 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.526 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.6 m-20 -109.48 115.0 29.11 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 121.367 -0.833 . . . . 0.0 109.788 174.825 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -105.62 114.18 28.19 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.012 -1.055 . . . . 0.0 110.619 -175.388 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.44 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.0 OUTLIER -111.46 127.77 26.39 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.233 -0.917 . . . . 0.0 109.049 174.226 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 19' ' ' PRO . . . . . 0.431 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.2 Cg_endo -51.16 -23.97 13.96 Favored 'Trans proline' 0 C--N 1.303 -1.834 0 O-C-N 123.827 1.435 . . . . 0.0 110.238 -179.727 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.54 ' C ' ' CD2' ' B' ' 21' ' ' PHE . 11.2 m-80 -79.94 -43.0 22.91 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.106 -0.996 . . . . 0.0 109.884 175.15 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.54 ' CD2' ' C ' ' B' ' 20' ' ' ASN . 97.4 m-85 -153.69 150.37 28.5 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.54 -0.725 . . . . 0.0 109.993 -178.745 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 22' ' ' ARG . . . . . 0.685 ' HD3' HD22 ' B' ' 68' ' ' LEU . 62.1 ttt180 -90.54 145.2 25.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.934 -1.104 . . . . 0.0 110.108 178.65 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.526 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 87.0 m -131.63 141.84 49.72 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.541 -0.725 . . . . 0.0 109.852 -175.535 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.779 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -131.05 144.08 51.18 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 120.926 -1.109 . . . . 0.0 111.336 -179.431 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.857 HG22 ' CB ' ' B' ' 60' ' ' SER . 6.6 t -125.43 134.07 67.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.15 -0.969 . . . . 0.0 110.93 -178.271 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.749 HG13 ' HE1' ' B' ' 61' ' ' PHE . 30.3 m -117.14 174.59 3.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.812 -0.555 . . . . 0.0 110.304 179.102 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.604 ' HG3' HD22 ' B' ' 57' ' ' ASN . 12.0 tt0 -104.57 118.51 36.77 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 177.752 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.824 HD13 ' HD2' ' B' ' 29' ' ' PRO 0.266 0.2 OUTLIER -87.35 123.07 70.38 Favored Pre-proline 0 C--N 1.296 -1.728 0 O-C-N 121.403 -0.811 . . . . 0.0 108.968 -172.769 . . . . . . . . 4 4 . 1 . 004 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.824 ' HD2' HD13 ' B' ' 28' ' ' LEU . 18.1 Cg_endo -66.27 172.84 8.27 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 O-C-N 123.6 1.316 . . . . 0.0 111.114 -178.213 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.496 ' HA ' HD12 ' B' ' 33' ' ' LEU . 96.0 m-20 -60.07 -40.04 88.15 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.579 -0.701 . . . . 0.0 111.135 -174.647 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.534 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.94 -0.03 57.34 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.743 -1.223 . . . . 0.0 110.72 -171.514 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.649 ' HB3' HD11 ' B' ' 28' ' ' LEU . 98.0 mmm -113.48 -14.87 12.67 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.975 -1.078 . . . . 0.0 109.729 169.148 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.533 ' N ' HD12 ' B' ' 28' ' ' LEU . 14.0 mt -62.32 -39.93 94.66 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.071 -1.018 . . . . 0.0 109.652 176.572 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -70.02 130.07 41.16 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.486 -0.759 . . . . 0.0 110.29 177.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.88 -44.13 1.69 Allowed Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.179 -1.169 . . . . 0.0 110.179 176.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.797 ' CD2' HG21 ' B' ' 59' ' ' VAL . 66.4 tp -63.78 145.13 56.36 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.012 -1.287 . . . . 0.0 110.891 -176.441 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 37' ' ' GLU . . . . . . . . . . . . . 21.6 pt-20 -153.07 159.97 42.89 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.52 -0.737 . . . . 0.0 109.334 175.807 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 38' ' ' THR . . . . . 0.729 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -62.87 148.65 46.54 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.944 -1.098 . . . . 0.0 110.151 -179.303 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.67 -6.51 69.26 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 -174.909 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' B' ' 50' ' ' THR . . . -72.99 155.61 39.67 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.206 -1.173 . . . . 0.0 109.509 176.489 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.778 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -99.7 99.61 10.46 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 120.926 -1.109 . . . . 0.0 109.799 176.725 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.67 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.2 t -85.62 131.87 33.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.332 -0.855 . . . . 0.0 109.319 176.183 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -95.12 120.06 34.69 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.037 -1.039 . . . . 0.0 109.292 170.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.67 ' HE1' HG11 ' B' ' 42' ' ' VAL . 0.3 OUTLIER -89.58 107.97 19.39 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.32 -0.863 . . . . 0.0 108.916 176.639 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.71 HD22 ' HB2' ' A' ' 47' ' ' CYS . 0.9 OUTLIER 51.95 16.54 0.53 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.218 -0.926 . . . . 0.0 110.972 -168.204 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.491 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 116.92 -1.27 19.71 Favored Glycine 0 N--CA 1.489 2.227 0 C-N-CA 119.543 -1.313 . . . . 0.0 110.917 172.199 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.798 ' O ' HD23 ' B' ' 49' ' ' LEU . 18.9 t -93.99 107.07 19.01 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.49 -1.594 . . . . 0.0 109.316 174.56 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 48' ' ' CYS . . . . . 0.433 ' O ' ' SG ' ' B' ' 48' ' ' CYS . 32.1 p -75.04 129.99 38.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.037 -1.039 . . . . 0.0 111.089 -171.626 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 0.909 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -144.81 161.19 39.89 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.526 -0.734 . . . . 0.0 109.507 174.503 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 50' ' ' THR . . . . . 0.464 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 10.5 m -100.06 150.15 22.75 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.749 -1.219 . . . . 0.0 111.069 -171.024 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.823 HG13 HG13 ' B' ' 59' ' ' VAL . 37.7 t -80.27 115.36 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.639 -0.663 . . . . 0.0 110.434 -178.891 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.537 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 30.5 p -70.07 -39.98 75.32 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.14 -0.975 . . . . 0.0 109.91 175.474 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.629 ' HA ' HG21 ' B' ' 38' ' ' THR . 87.7 tt0 -161.36 154.25 20.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.267 -0.895 . . . . 0.0 110.297 179.079 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.729 HD11 ' N ' ' B' ' 38' ' ' THR . 5.8 mt -102.5 132.75 47.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.11 -0.994 . . . . 0.0 109.927 174.535 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.51 ' CB ' ' HB2' ' B' ' 58' ' ' HIS . 2.5 m-80 -104.04 65.36 0.8 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.528 -0.733 . . . . 0.0 109.758 179.415 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.02 -118.48 5.64 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.655 -1.778 . . . . 0.0 108.655 -173.224 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.604 HD22 ' HG3' ' B' ' 27' ' ' GLU . 0.1 OUTLIER -75.0 -21.66 59.0 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.928 -1.336 . . . . 0.0 108.777 173.796 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.062 ' CE1' HG11 ' B' ' 13' ' ' VAL . 30.4 m-70 -72.7 159.76 33.3 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.345 -0.847 . . . . 0.0 110.192 -177.411 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.823 HG13 HG13 ' B' ' 51' ' ' VAL . 53.1 t -140.03 125.52 20.87 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.093 -1.005 . . . . 0.0 110.748 171.56 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.857 ' CB ' HG22 ' B' ' 25' ' ' VAL . 54.4 p -96.04 126.06 41.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.651 -0.656 . . . . 0.0 109.818 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.909 ' HB2' HD12 ' B' ' 49' ' ' LEU . 4.3 p90 -118.6 155.2 31.37 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.963 -1.086 . . . . 0.0 110.344 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.537 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 34.9 p-10 -87.76 152.73 21.9 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.097 -1.002 . . . . 0.0 111.305 -173.226 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.752 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -157.79 114.53 2.91 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -176.662 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.519 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 57.7 ttm -72.08 142.41 49.22 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.931 -1.105 . . . . 0.0 109.574 -178.801 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.469 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 71.2 tttt -60.11 -49.91 75.77 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.988 -1.07 . . . . 0.0 110.441 -175.117 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -65.6 -40.02 92.2 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.969 -1.082 . . . . 0.0 109.906 178.803 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.519 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 93.1 m -61.2 -39.94 92.1 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.974 -1.079 . . . . 0.0 109.219 174.13 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.685 HD22 ' HD3' ' B' ' 22' ' ' ARG . 17.9 tp -59.98 -42.95 95.3 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.439 -0.788 . . . . 0.0 109.522 178.334 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -67.52 -39.99 85.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.581 -0.7 . . . . 0.0 110.269 176.476 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.71 HG22 HG23 ' B' ' 71' ' ' THR . 1.2 tt -68.19 -40.08 82.22 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 CA-C-O 121.904 0.859 . . . . 0.0 109.295 -177.115 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.71 HG23 HG22 ' B' ' 70' ' ' ILE . 59.2 p -84.52 -172.52 4.22 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 120.083 -0.647 . . . . 0.0 109.546 177.782 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.47 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 5.8 t30 -102.42 22.56 13.23 Favored 'General case' 0 C--N 1.296 -1.754 0 O-C-N 121.218 -0.927 . . . . 0.0 108.51 169.411 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.752 ' HB3' HD21 ' B' ' 63' ' ' LEU . 88.1 mt -70.09 -39.95 75.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.013 -1.054 . . . . 0.0 109.713 174.71 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.448 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -44.56 -23.82 0.58 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 178.687 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 23.2 p-10 -70.04 -19.07 63.31 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.932 -1.334 . . . . 0.0 110.648 -175.021 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.519 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.3 mt -60.03 140.41 56.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.121 -0.987 . . . . 0.0 110.67 -176.662 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 1.013 ' C ' HD23 ' B' ' 12' ' ' LEU . 92.2 mttt -143.6 139.05 29.46 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 121.363 0.601 . . . . 0.0 109.853 177.297 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.676 ' N ' HD23 ' B' ' 12' ' ' LEU . 16.5 t -60.56 152.24 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 120.937 -1.102 . . . . 0.0 110.42 -175.764 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.29 -14.22 59.89 Favored Glycine 0 N--CA 1.485 1.932 0 N-CA-C 108.927 -1.669 . . . . 0.0 108.927 -176.067 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.508 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 49.4 t0 -96.37 166.31 11.77 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.387 -1.066 . . . . 0.0 109.572 176.469 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.581 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.1 m95 -115.38 165.93 12.43 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.03 -1.044 . . . . 0.0 110.225 175.493 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 1.051 HG13 ' HB3' ' B' ' 10' ' ' ALA . 0.9 OUTLIER -129.95 158.5 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.387 -0.821 . . . . 0.0 110.081 -177.628 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 1.004 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.1 OUTLIER -79.96 107.29 12.63 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 120.987 -1.07 . . . . 0.0 109.179 167.043 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.722 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -108.67 138.34 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 120.668 -1.27 . . . . 0.0 111.061 -176.196 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -141.34 146.57 36.87 Favored 'General case' 0 N--CA 1.492 1.659 0 C-N-CA 120.397 -0.521 . . . . 0.0 109.933 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 58.0 ttp180 -83.07 129.97 35.08 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.027 -1.046 . . . . 0.0 110.996 -176.288 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.778 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.492 1.642 0 O-C-N 121.258 -0.901 . . . . 0.0 110.023 174.486 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.818 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.8 t . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 121.799 0.809 . . . . 0.0 111.047 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 30.3 mm100 -69.91 -36.25 75.23 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.716 -0.615 . . . . 0.0 110.836 178.033 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.537 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -154.36 170.78 32.84 Favored Glycine 0 N--CA 1.493 2.448 0 C-N-CA 119.156 -1.497 . . . . 0.0 109.986 -172.492 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.445 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 4.2 p -114.4 173.86 6.24 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.927 -1.337 . . . . 0.0 111.173 -175.337 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 1.061 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -142.2 149.8 40.16 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.676 -0.64 . . . . 0.0 109.347 -177.502 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.591 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 38.3 tttt -107.29 116.72 32.42 Favored 'General case' 0 C--N 1.295 -1.766 0 O-C-N 121.003 -1.061 . . . . 0.0 110.269 177.908 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 1.011 HD23 ' C ' ' A' ' 77' ' ' LYS . 11.9 tp -60.02 126.95 29.53 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.848 -1.157 . . . . 0.0 108.827 171.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.074 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.3 p -122.79 -31.65 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 O-C-N 121.395 -0.816 . . . . 0.0 109.881 -179.481 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.94 146.59 27.92 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 118.984 -1.086 . . . . 0.0 111.473 -179.324 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.852 HG23 ' CD2' ' A' ' 24' ' ' HIS . 7.6 mt -108.45 138.06 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.026 -1.046 . . . . 0.0 110.238 171.207 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.504 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.9 m-20 -109.22 115.72 30.55 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.196 -0.94 . . . . 0.0 109.765 171.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -104.56 112.27 25.28 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.019 -1.05 . . . . 0.0 110.379 -175.293 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.463 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 20.4 mmmt -115.64 129.27 25.28 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.17 -0.956 . . . . 0.0 109.125 177.33 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -51.03 -31.34 34.46 Favored 'Trans proline' 0 C--N 1.303 -1.841 0 O-C-N 123.775 1.408 . . . . 0.0 110.264 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 11.6 m-80 -74.42 -39.99 62.27 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.232 -0.917 . . . . 0.0 110.09 175.864 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 83.7 m-85 -156.35 150.46 25.27 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.328 -0.858 . . . . 0.0 110.308 -177.623 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.49 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 59.0 ttt180 -92.05 141.81 28.21 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.921 -1.112 . . . . 0.0 109.94 176.579 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.504 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.6 m -130.08 139.95 50.89 Favored 'General case' 0 C--N 1.294 -1.819 0 O-C-N 121.675 -0.641 . . . . 0.0 109.912 -173.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.852 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -131.12 141.41 50.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.905 -1.122 . . . . 0.0 111.068 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.763 HG22 ' CB ' ' A' ' 60' ' ' SER . 6.8 t -122.51 133.17 69.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.053 -1.03 . . . . 0.0 110.677 -178.823 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.825 HG13 ' CE1' ' A' ' 61' ' ' PHE . 30.1 m -116.19 173.33 3.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.808 -0.557 . . . . 0.0 110.22 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.626 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 8.4 tt0 -104.44 116.44 32.13 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.434 -0.791 . . . . 0.0 108.942 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.83 HD21 HD13 ' A' ' 36' ' ' LEU . 9.6 tp -83.55 124.35 75.56 Favored Pre-proline 0 C--N 1.298 -1.649 0 O-C-N 121.475 -0.766 . . . . 0.0 110.059 -173.159 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.481 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 26.2 Cg_endo -66.42 176.61 3.92 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 123.923 1.486 . . . . 0.0 111.104 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.487 ' HA ' HD12 ' A' ' 33' ' ' LEU . 47.4 t0 -60.09 -39.88 87.67 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.328 -0.858 . . . . 0.0 111.13 -175.467 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.596 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.64 0.06 57.19 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.756 -1.215 . . . . 0.0 110.576 -174.548 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.596 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.7 mmm -111.43 -14.1 13.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.037 -1.04 . . . . 0.0 109.813 170.291 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.582 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 17.5 mt -69.81 -39.97 76.21 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.271 -0.893 . . . . 0.0 110.308 177.648 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -78.06 129.37 35.15 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.919 . . . . 0.0 110.337 -178.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.88 -42.96 1.87 Allowed Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.865 -1.159 . . . . 0.0 110.374 174.883 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.83 HD13 HD21 ' A' ' 28' ' ' LEU . 7.1 tt -66.79 146.65 54.2 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.932 -1.334 . . . . 0.0 110.508 -175.012 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.689 ' N ' HD23 ' A' ' 36' ' ' LEU . 14.7 pt-20 -149.97 164.38 35.63 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.556 -0.715 . . . . 0.0 109.672 -178.73 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.803 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -66.5 150.06 49.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.99 -1.069 . . . . 0.0 109.949 179.335 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.7 -4.81 63.39 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -173.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.54 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -76.62 153.54 35.18 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.225 -1.162 . . . . 0.0 109.519 177.145 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.52 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -97.82 109.23 22.02 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 121.016 -1.052 . . . . 0.0 110.086 178.153 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.63 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.2 t -95.37 133.1 37.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.224 -0.923 . . . . 0.0 109.129 173.737 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.509 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -95.9 119.9 35.22 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.112 -0.993 . . . . 0.0 109.071 171.417 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.637 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.3 OUTLIER -88.81 104.85 17.3 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.433 -0.792 . . . . 0.0 108.884 177.636 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.5 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 54.82 12.86 0.64 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.361 -0.837 . . . . 0.0 111.258 -168.513 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.489 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.34 -1.22 11.46 Favored Glycine 0 N--CA 1.49 2.283 0 C-N-CA 119.603 -1.284 . . . . 0.0 110.769 172.804 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.839 ' O ' HD23 ' A' ' 49' ' ' LEU . 36.1 t -93.85 109.71 21.4 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 120.531 -1.57 . . . . 0.0 109.517 175.275 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.7 p -74.44 128.26 35.1 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.113 -0.992 . . . . 0.0 110.984 -171.748 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.947 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -144.3 159.18 43.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.506 -0.746 . . . . 0.0 109.421 174.177 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 65.3 m -102.34 151.26 22.46 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.718 -1.239 . . . . 0.0 111.148 -172.022 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.848 HG13 HG13 ' A' ' 59' ' ' VAL . 21.3 t -78.44 119.77 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.728 -0.608 . . . . 0.0 110.641 -177.329 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 43.2 p -73.25 -43.84 60.46 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.242 -0.911 . . . . 0.0 110.15 174.481 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.617 ' HA ' HG21 ' A' ' 38' ' ' THR . 86.4 tt0 -159.32 151.22 20.67 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.319 -0.863 . . . . 0.0 110.468 -178.244 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.803 HD11 ' N ' ' A' ' 38' ' ' THR . 6.3 mt -102.87 133.13 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.172 -0.955 . . . . 0.0 109.953 174.724 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.51 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 13.5 m120 -108.04 65.72 0.64 Allowed 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.492 -0.755 . . . . 0.0 109.703 178.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.93 -116.28 4.77 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -174.091 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.582 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -78.35 -20.89 50.38 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.02 -1.282 . . . . 0.0 109.059 175.028 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.074 ' CE1' HG11 ' A' ' 13' ' ' VAL . 24.5 m-70 -74.45 160.03 31.5 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.358 -0.839 . . . . 0.0 110.096 -177.109 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.848 HG13 HG13 ' A' ' 51' ' ' VAL . 54.9 t -140.37 122.88 16.14 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 O-C-N 121.006 -1.059 . . . . 0.0 110.808 171.117 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.763 ' CB ' HG22 ' A' ' 25' ' ' VAL . 3.0 m -89.46 128.96 36.02 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.643 -0.661 . . . . 0.0 109.586 177.162 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.947 ' HB2' HD12 ' A' ' 49' ' ' LEU . 3.1 p90 -123.23 155.5 37.01 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.026 -1.046 . . . . 0.0 110.082 178.643 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 29.6 p-10 -90.03 154.41 19.83 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.946 -1.096 . . . . 0.0 111.594 -170.377 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.801 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -158.85 123.96 4.23 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 -175.753 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.513 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 96.0 mtp -79.65 146.72 32.33 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.677 -1.264 . . . . 0.0 109.714 178.077 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.479 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 27.8 ttpt -60.01 -47.63 85.06 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.082 -1.011 . . . . 0.0 109.626 178.477 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.99 -40.03 75.55 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.214 -0.928 . . . . 0.0 110.833 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.62 ' O ' HG23 ' A' ' 71' ' ' THR . 23.6 m -65.51 -33.95 77.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.681 -1.262 . . . . 0.0 109.103 175.22 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.77 HD11 ' HA2' ' A' ' 74' ' ' GLY . 4.3 tp -60.04 -45.96 91.1 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.546 -0.721 . . . . 0.0 109.705 177.009 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 31.7 tpt180 -69.78 -40.05 76.27 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.304 -0.872 . . . . 0.0 110.54 178.477 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.805 HG22 HG23 ' A' ' 71' ' ' THR . 1.5 tt -63.94 -42.78 96.87 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 O-C-N 121.18 -0.95 . . . . 0.0 109.288 -178.681 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.805 HG23 HG22 ' A' ' 70' ' ' ILE . 20.9 p -83.59 -173.29 4.63 Favored 'General case' 0 C--N 1.298 -1.63 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 174.678 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 3.4 t30 -104.64 25.66 10.04 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 169.827 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.801 ' HB3' HD21 ' A' ' 63' ' ' LEU . 90.4 mt -68.07 -39.95 82.85 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.239 -0.913 . . . . 0.0 109.671 175.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.77 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -49.87 -23.7 5.51 Favored Glycine 0 N--CA 1.486 1.977 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.06 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 23.7 p-10 -64.52 -17.26 63.74 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.941 -1.329 . . . . 0.0 110.188 -176.202 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.518 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.7 mt -60.52 144.96 50.25 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.314 -0.866 . . . . 0.0 110.484 -178.454 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 1.011 ' C ' HD23 ' A' ' 12' ' ' LEU . 66.2 mttt -150.12 138.65 20.64 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 121.725 -0.609 . . . . 0.0 109.669 178.11 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.692 HG21 HG13 ' A' ' 15' ' ' ILE . 62.1 t -63.54 147.3 12.28 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 120.884 -1.135 . . . . 0.0 110.152 -175.516 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.98 -11.43 70.72 Favored Glycine 0 N--CA 1.483 1.805 0 N-CA-C 108.779 -1.729 . . . . 0.0 108.779 -172.876 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 41.7 t0 -100.88 162.25 13.03 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.392 -1.063 . . . . 0.0 109.722 176.408 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.591 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.4 m95 -114.09 159.9 19.52 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.144 -0.972 . . . . 0.0 109.976 177.268 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.061 HG13 ' HB3' ' A' ' 10' ' ' ALA . 0.9 OUTLIER -126.81 156.97 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.973 -177.516 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.818 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.4 m-20 -82.14 104.93 12.83 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.202 -0.936 . . . . 0.0 109.263 169.552 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.844 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -107.22 138.58 32.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 120.574 -1.329 . . . . 0.0 111.542 -175.564 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -131.63 147.55 52.53 Favored 'General case' 0 N--CA 1.494 1.738 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.994 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.489 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 38.2 ptt180 -87.92 131.77 34.47 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.135 -0.978 . . . . 0.0 110.627 -178.595 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.52 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.594 0 O-C-N 121.202 -0.936 . . . . 0.0 110.239 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 0.831 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.7 t . . . . . 0 N--CA 1.492 1.629 0 CA-C-O 121.737 0.78 . . . . 0.0 111.074 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 30.3 mm100 -69.94 -35.95 74.91 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.834 -0.541 . . . . 0.0 110.938 178.085 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.54 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -154.53 170.68 32.94 Favored Glycine 0 N--CA 1.495 2.596 0 C-N-CA 119.232 -1.461 . . . . 0.0 110.13 -172.526 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.447 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 4.2 p -114.43 173.82 6.27 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.992 -1.299 . . . . 0.0 111.246 -175.317 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.071 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -142.13 150.01 40.55 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -177.534 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 38.3 tttt -107.52 116.78 32.56 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.109 -0.994 . . . . 0.0 110.126 177.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 1.028 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.9 tp -60.06 126.82 28.99 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.872 -1.142 . . . . 0.0 108.916 171.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.053 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.3 p -122.68 -31.74 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.849 0 O-C-N 121.387 -0.821 . . . . 0.0 109.859 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.84 146.67 28.07 Favored 'General case' 0 N--CA 1.493 1.706 0 C-N-CA 119.16 -1.016 . . . . 0.0 111.474 -179.333 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.856 HG23 ' CD2' ' B' ' 24' ' ' HIS . 7.6 mt -108.47 138.06 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.067 -1.021 . . . . 0.0 110.291 171.152 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.515 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 78.1 m-20 -109.32 115.7 30.47 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.46 -0.775 . . . . 0.0 109.754 172.054 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -104.51 112.28 25.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.097 -1.002 . . . . 0.0 110.312 -175.253 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 20.1 mmmt -115.64 129.29 25.26 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.325 -0.859 . . . . 0.0 109.161 177.247 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 19' ' ' PRO . . . . . 0.426 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.4 Cg_endo -51.17 -31.25 35.46 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.721 1.379 . . . . 0.0 110.216 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.552 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 11.9 m-80 -74.42 -40.27 62.08 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.2 -0.937 . . . . 0.0 109.94 175.929 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.552 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 83.8 m-85 -156.07 150.4 25.64 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.289 -0.882 . . . . 0.0 110.357 -177.513 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 22' ' ' ARG . . . . . 0.496 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 58.8 ttt180 -91.97 141.69 28.35 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.989 -1.069 . . . . 0.0 110.016 176.525 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.515 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 94.6 m -129.95 139.98 51.0 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 121.67 -0.644 . . . . 0.0 109.951 -173.929 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.856 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -131.06 141.4 50.18 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.021 -1.049 . . . . 0.0 111.046 -179.586 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.768 HG22 ' CB ' ' B' ' 60' ' ' SER . 6.7 t -122.47 133.3 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.157 -0.964 . . . . 0.0 110.744 -178.91 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.831 HG13 ' HE1' ' B' ' 61' ' ' PHE . 30.7 m -116.37 173.26 4.07 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.766 -0.583 . . . . 0.0 110.101 178.94 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.627 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 8.4 tt0 -104.32 116.56 32.37 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 179.685 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.838 HD21 HD13 ' B' ' 36' ' ' LEU . 9.6 tp -83.57 124.32 75.56 Favored Pre-proline 0 C--N 1.299 -1.629 0 O-C-N 121.338 -0.851 . . . . 0.0 110.095 -173.164 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.476 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 26.0 Cg_endo -66.41 176.6 3.93 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 O-C-N 123.858 1.452 . . . . 0.0 111.104 -179.483 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.489 ' HA ' HD12 ' B' ' 33' ' ' LEU . 47.4 t0 -60.0 -40.03 87.78 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.341 -0.849 . . . . 0.0 111.104 -175.49 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.586 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.56 0.1 57.14 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.753 -1.217 . . . . 0.0 110.658 -174.57 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.586 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.7 mmm -111.43 -14.11 13.78 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.055 -1.028 . . . . 0.0 109.828 170.266 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.596 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 17.8 mt -69.7 -40.06 76.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.358 -0.839 . . . . 0.0 110.338 177.628 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 55.8 t0 -78.01 129.38 35.2 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.886 . . . . 0.0 110.432 -178.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.95 -43.08 1.85 Allowed Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.854 -1.165 . . . . 0.0 110.304 174.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.838 HD13 HD21 ' B' ' 28' ' ' LEU . 7.0 tt -66.81 146.68 54.17 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.866 -1.373 . . . . 0.0 110.533 -174.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 37' ' ' GLU . . . . . 0.681 ' N ' HD23 ' B' ' 36' ' ' LEU . 14.7 pt-20 -150.04 164.35 35.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.4 -0.812 . . . . 0.0 109.618 -178.664 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 38' ' ' THR . . . . . 0.795 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.49 149.94 49.7 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.031 -1.043 . . . . 0.0 109.962 179.369 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.85 -4.83 63.93 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 -174.048 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.542 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -76.63 153.35 35.32 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.293 -1.122 . . . . 0.0 109.592 177.024 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.523 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.1 OUTLIER -97.53 109.05 21.88 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 120.951 -1.093 . . . . 0.0 110.195 178.096 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.622 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.2 t -95.29 133.13 37.35 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 O-C-N 121.253 -0.904 . . . . 0.0 109.154 173.723 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 0.504 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -95.89 119.87 35.16 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 119.204 -0.999 . . . . 0.0 109.181 171.284 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.643 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.3 OUTLIER -88.79 104.66 17.11 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.302 -0.874 . . . . 0.0 108.966 177.696 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.5 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 55.01 12.88 0.67 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.54 -0.725 . . . . 0.0 111.291 -168.491 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.489 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.15 -0.79 11.63 Favored Glycine 0 N--CA 1.491 2.346 0 C-N-CA 119.662 -1.256 . . . . 0.0 110.75 172.687 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.844 ' O ' HD23 ' B' ' 49' ' ' LEU . 36.0 t -94.03 109.68 21.42 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.45 -1.617 . . . . 0.0 109.54 175.134 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 18.7 p -74.4 128.41 35.47 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.095 -1.003 . . . . 0.0 110.965 -171.717 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 0.943 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -144.5 159.1 43.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.541 -0.724 . . . . 0.0 109.387 174.129 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 64.9 m -102.22 151.38 22.28 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.705 -1.247 . . . . 0.0 111.112 -171.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.828 HG13 HG13 ' B' ' 59' ' ' VAL . 21.4 t -78.65 119.94 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.727 -0.608 . . . . 0.0 110.584 -177.27 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 43.3 p -73.32 -43.93 59.93 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.17 -0.956 . . . . 0.0 110.159 174.576 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.641 ' HA ' HG21 ' B' ' 38' ' ' THR . 86.5 tt0 -159.24 151.36 20.99 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.331 -0.856 . . . . 0.0 110.455 -178.312 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.795 HD11 ' N ' ' B' ' 38' ' ' THR . 6.3 mt -103.0 133.0 48.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.102 -0.999 . . . . 0.0 109.933 174.789 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.527 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 13.4 m120 -108.0 65.74 0.64 Allowed 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 119.972 -0.691 . . . . 0.0 109.679 179.014 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.08 -116.31 4.74 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 -174.22 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.596 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -78.31 -21.09 50.17 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 120.983 -1.304 . . . . 0.0 109.049 175.069 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.053 ' CE1' HG11 ' B' ' 13' ' ' VAL . 24.7 m-70 -74.17 159.77 32.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.474 -0.766 . . . . 0.0 110.252 -177.239 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.828 HG13 HG13 ' B' ' 51' ' ' VAL . 55.8 t -140.24 122.87 16.46 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 C-N-CA 119.094 -1.042 . . . . 0.0 110.877 171.177 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.768 ' CB ' HG22 ' B' ' 25' ' ' VAL . 3.0 m -89.61 128.97 36.12 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.751 -0.593 . . . . 0.0 109.556 177.304 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.943 ' HB2' HD12 ' B' ' 49' ' ' LEU . 3.1 p90 -123.21 155.56 36.88 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.113 -0.992 . . . . 0.0 110.07 178.71 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 29.7 p-10 -90.1 154.4 19.81 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.818 -1.176 . . . . 0.0 111.554 -170.273 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.77 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -158.78 124.04 4.3 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 -175.764 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.521 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 96.0 mtp -79.74 146.68 32.23 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.631 -1.293 . . . . 0.0 109.706 178.029 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.477 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 27.9 ttpt -60.07 -47.61 85.15 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.195 -0.941 . . . . 0.0 109.542 178.562 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.95 -40.01 75.71 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.186 -0.946 . . . . 0.0 110.896 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.638 ' O ' HG23 ' B' ' 71' ' ' THR . 23.7 m -65.48 -34.14 77.57 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.649 -1.282 . . . . 0.0 109.021 175.204 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.771 HD11 ' HA2' ' B' ' 74' ' ' GLY . 4.3 tp -60.04 -45.67 92.08 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.571 -0.706 . . . . 0.0 109.844 177.039 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 31.6 tpt180 -70.01 -39.99 75.5 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.278 -0.889 . . . . 0.0 110.498 178.401 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.798 HG22 HG23 ' B' ' 71' ' ' THR . 1.5 tt -63.85 -42.7 96.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.221 -0.924 . . . . 0.0 109.332 -178.795 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.798 HG23 HG22 ' B' ' 70' ' ' ILE . 21.3 p -83.71 -173.08 4.51 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 174.84 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.511 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 3.4 t30 -104.79 25.59 10.21 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 169.864 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.77 ' HB3' HD21 ' B' ' 63' ' ' LEU . 90.1 mt -68.07 -40.02 82.83 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.149 -0.97 . . . . 0.0 109.636 176.032 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.771 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -49.82 -23.74 5.46 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 -179.061 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 23.3 p-10 -64.46 -17.22 63.63 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.07 -1.253 . . . . 0.0 110.218 -176.227 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.519 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 97.7 mt -60.51 144.93 50.26 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.262 -0.899 . . . . 0.0 110.441 -178.47 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 1.028 ' C ' HD23 ' B' ' 12' ' ' LEU . 66.1 mttt -150.09 138.62 20.65 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.626 -0.671 . . . . 0.0 109.696 178.077 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.701 HG21 HG13 ' B' ' 15' ' ' ILE . 62.0 t -63.56 147.26 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.042 -1.036 . . . . 0.0 110.178 -175.513 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.0 -11.15 71.6 Favored Glycine 0 N--CA 1.484 1.85 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 -172.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 41.5 t0 -101.08 162.09 13.14 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.333 -1.098 . . . . 0.0 109.695 176.408 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.4 m95 -114.0 159.79 19.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.195 -0.941 . . . . 0.0 110.031 177.282 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 1.071 HG13 ' HB3' ' B' ' 10' ' ' ALA . 0.8 OUTLIER -126.77 157.12 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.402 -0.811 . . . . 0.0 109.896 -177.611 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.831 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.3 m-20 -82.17 104.86 12.81 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.277 -0.89 . . . . 0.0 109.29 169.601 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.843 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -107.13 138.77 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 120.665 -1.272 . . . . 0.0 111.453 -175.426 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -131.84 147.62 52.49 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.983 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 86' ' ' ARG . . . . . 0.489 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 38.2 ptt180 -87.89 131.84 34.42 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.166 -0.959 . . . . 0.0 110.568 -178.525 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.523 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.495 1.78 0 O-C-N 121.335 -0.853 . . . . 0.0 110.214 179.368 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.882 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.3 t . . . . . 0 N--CA 1.494 1.768 0 CA-C-O 121.791 0.805 . . . . 0.0 110.919 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 -70.04 -31.79 69.6 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.867 -0.521 . . . . 0.0 111.021 179.197 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.538 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -156.38 -177.97 30.06 Favored Glycine 0 N--CA 1.499 2.862 0 C-N-CA 118.541 -1.79 . . . . 0.0 110.795 -170.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.498 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.0 p -129.08 167.25 17.81 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.792 -1.417 . . . . 0.0 110.95 -178.435 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 1.039 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -139.97 149.84 43.75 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.597 -0.69 . . . . 0.0 109.201 -175.021 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.583 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 34.5 tttt -109.24 115.77 30.63 Favored 'General case' 0 C--N 1.294 -1.816 0 O-C-N 121.013 -1.055 . . . . 0.0 110.362 -179.12 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.995 HD23 ' C ' ' A' ' 77' ' ' LYS . 11.5 tp -59.98 127.68 33.08 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.916 -1.115 . . . . 0.0 108.863 172.622 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.114 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.6 p -127.01 -29.32 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 C-N-CA 119.6 -0.84 . . . . 0.0 109.932 -179.045 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.75 144.15 24.11 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 118.959 -1.096 . . . . 0.0 111.243 179.23 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.889 HG23 ' CD2' ' A' ' 24' ' ' HIS . 8.8 mt -107.9 141.03 24.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.187 -0.946 . . . . 0.0 110.233 174.702 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.511 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 79.7 m-20 -109.79 113.87 26.97 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.238 -0.914 . . . . 0.0 109.972 172.247 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -101.24 113.13 25.89 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.109 -0.995 . . . . 0.0 110.427 -178.099 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -109.77 134.4 20.64 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.197 -0.939 . . . . 0.0 109.499 176.005 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.64 -16.65 11.4 Favored 'Trans proline' 0 C--N 1.303 -1.854 0 O-C-N 123.973 1.512 . . . . 0.0 110.652 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.572 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 4.7 m120 -100.8 -26.57 13.73 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.129 -0.982 . . . . 0.0 110.035 179.23 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.572 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 92.9 m-85 -157.81 150.2 22.48 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.437 -0.789 . . . . 0.0 109.857 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.918 ' HD3' HD22 ' A' ' 68' ' ' LEU . 57.1 ttt180 -93.54 141.16 28.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.6 -1.312 . . . . 0.0 110.026 174.196 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.511 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.3 m -129.97 141.03 50.82 Favored 'General case' 0 C--N 1.294 -1.814 0 O-C-N 121.698 -0.626 . . . . 0.0 109.835 -173.703 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.889 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -129.98 143.6 50.88 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.012 -1.055 . . . . 0.0 111.612 -179.156 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.881 HG22 ' OG ' ' A' ' 60' ' ' SER . 6.4 t -123.34 132.88 70.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.11 -0.994 . . . . 0.0 110.613 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.801 HG13 ' CE1' ' A' ' 61' ' ' PHE . 26.0 m -114.9 174.48 2.93 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.326 178.509 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.684 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 12.8 tt0 -104.38 118.61 37.03 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.555 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.5 tp -81.21 122.57 81.52 Favored Pre-proline 0 C--N 1.297 -1.708 0 O-C-N 121.7 -0.625 . . . . 0.0 109.626 -174.75 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.489 ' HD2' HD12 ' A' ' 28' ' ' LEU . 18.3 Cg_endo -63.44 174.07 3.79 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 123.907 1.477 . . . . 0.0 110.572 -179.307 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.709 ' HA ' HD12 ' A' ' 33' ' ' LEU . 53.4 t0 -60.01 -39.47 85.91 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.412 -0.805 . . . . 0.0 110.611 -177.011 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.603 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.95 -0.1 57.39 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.843 -1.161 . . . . 0.0 110.894 -175.012 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.603 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 95.9 mmm -109.71 -11.73 14.7 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.87 -1.143 . . . . 0.0 109.824 170.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.709 HD12 ' HA ' ' A' ' 30' ' ' ASP . 15.3 mt -69.23 -40.1 78.13 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.323 -0.861 . . . . 0.0 110.312 179.225 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -79.98 123.89 28.21 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.349 -0.844 . . . . 0.0 110.527 -177.06 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.12 -47.09 1.08 Allowed Glycine 0 N--CA 1.492 2.377 0 C-N-CA 119.829 -1.177 . . . . 0.0 110.401 175.128 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.85 HD23 ' N ' ' A' ' 37' ' ' GLU . 8.2 tt -67.34 147.37 53.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.985 -1.303 . . . . 0.0 110.727 -175.068 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.85 ' N ' HD23 ' A' ' 36' ' ' LEU . 21.3 pt-20 -149.96 169.07 22.04 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.378 -0.826 . . . . 0.0 109.656 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.822 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -66.81 148.92 51.29 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.986 -1.071 . . . . 0.0 110.087 -179.985 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.9 -10.05 58.43 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 -175.539 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.432 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -71.25 157.87 37.37 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.245 -1.15 . . . . 0.0 109.272 174.706 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.893 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 1.6 p -105.34 116.82 32.59 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 118.533 -1.267 . . . . 0.0 109.754 176.012 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.619 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.6 t -99.63 126.38 53.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 121.333 -0.854 . . . . 0.0 109.006 175.353 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.512 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -88.31 119.53 28.81 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.234 -0.986 . . . . 0.0 109.089 173.374 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.738 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -89.75 105.43 17.8 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 119.729 -0.788 . . . . 0.0 108.939 177.955 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' B' ' 45' ' ' ASN . 0.8 OUTLIER 56.84 9.87 0.67 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.527 -0.733 . . . . 0.0 111.514 -170.316 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 126.57 -2.15 7.55 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.553 -1.308 . . . . 0.0 110.86 173.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.902 ' O ' HD23 ' A' ' 49' ' ' LEU . 50.2 t -98.63 104.86 16.93 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.521 -1.576 . . . . 0.0 109.756 176.236 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.404 ' HA ' ' HA ' ' A' ' 43' ' ' ALA . 25.5 p -71.36 128.91 37.44 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.176 -0.952 . . . . 0.0 110.727 -174.453 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.927 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -141.41 159.98 41.08 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.445 -0.785 . . . . 0.0 109.262 173.942 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.415 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 23.9 m -99.88 150.05 22.78 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 120.45 -1.406 . . . . 0.0 111.347 -170.252 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.779 HG13 HG13 ' A' ' 59' ' ' VAL . 34.9 t -76.25 116.44 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.941 -0.475 . . . . 0.0 110.318 -179.182 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.537 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 28.3 p -71.91 -39.96 69.15 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.365 -0.835 . . . . 0.0 109.789 174.186 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.573 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -163.27 152.9 15.21 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.272 -0.893 . . . . 0.0 110.362 -179.031 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.822 HD11 ' N ' ' A' ' 38' ' ' THR . 7.6 mt -105.52 132.14 53.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.193 -0.942 . . . . 0.0 109.965 175.915 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.509 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 26.6 m-80 -104.92 64.78 0.73 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.63 -0.669 . . . . 0.0 109.594 179.229 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.65 -116.95 5.3 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 -173.126 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.68 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.1 OUTLIER -77.0 -20.74 55.68 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.015 -1.285 . . . . 0.0 109.153 175.727 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.114 ' CE1' HG11 ' A' ' 13' ' ' VAL . 28.9 m-70 -75.64 159.98 30.59 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.33 -0.856 . . . . 0.0 110.192 -177.593 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.779 HG13 HG13 ' A' ' 51' ' ' VAL . 53.6 t -140.69 123.07 15.55 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 C-N-CA 119.133 -1.027 . . . . 0.0 110.74 173.208 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.881 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.3 t -90.71 134.61 34.29 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.48 -0.762 . . . . 0.0 109.416 177.329 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.927 ' HB2' HD12 ' A' ' 49' ' ' LEU . 2.7 p90 -126.75 151.17 48.56 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.366 -0.833 . . . . 0.0 110.318 176.911 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.537 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 38.2 p-10 -86.66 154.87 20.67 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.084 -1.01 . . . . 0.0 111.422 -171.762 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.835 HD22 HD13 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -161.9 100.42 1.12 Allowed 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.754 -0.591 . . . . 0.0 109.546 -175.49 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.471 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 33.0 ttp -60.68 140.06 57.63 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.883 -1.135 . . . . 0.0 109.52 -178.917 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.487 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 29.4 tptp -60.07 -48.31 82.23 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.891 -1.13 . . . . 0.0 110.473 -172.69 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -63.21 -39.99 96.19 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.714 -1.241 . . . . 0.0 109.806 177.411 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.471 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 55.2 m -60.05 -39.98 87.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.052 -1.03 . . . . 0.0 109.602 172.705 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.918 HD22 ' HD3' ' A' ' 22' ' ' ARG . 27.0 tp -61.64 -40.8 96.16 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.446 -0.784 . . . . 0.0 109.816 -179.592 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 15.5 ttm180 -69.92 -40.12 75.75 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.275 -0.891 . . . . 0.0 110.441 177.086 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.687 HG22 HG23 ' A' ' 71' ' ' THR . 1.2 tt -64.78 -44.58 96.42 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.285 -0.884 . . . . 0.0 109.602 -176.569 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.687 HG23 HG22 ' A' ' 70' ' ' ILE . 30.5 p -79.99 -174.98 4.73 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.561 -0.712 . . . . 0.0 109.25 175.258 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.514 ' HB2' ' N ' ' B' ' 83' ' ' ASN . 4.1 t30 -99.97 23.34 9.95 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.013 -1.054 . . . . 0.0 108.459 169.32 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.692 ' HB3' HD21 ' A' ' 63' ' ' LEU . 87.7 mt -69.18 -40.02 78.37 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.071 -1.018 . . . . 0.0 109.799 174.801 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.548 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -46.81 -22.44 1.15 Allowed Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.619 -0.993 . . . . 0.0 110.619 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.3 p-10 -68.98 -17.01 63.87 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.958 -1.319 . . . . 0.0 110.534 -174.668 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.503 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 98.4 mt -59.93 141.18 55.98 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.226 -0.921 . . . . 0.0 111.042 -176.858 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 0.995 ' C ' HD23 ' A' ' 12' ' ' LEU . 24.9 mttm -142.38 143.04 32.51 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.734 -0.604 . . . . 0.0 109.762 173.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.646 HG23 HD11 ' A' ' 15' ' ' ILE . 32.2 t -63.15 150.09 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.914 -1.116 . . . . 0.0 110.391 -177.209 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.46 -14.82 60.17 Favored Glycine 0 N--CA 1.485 1.916 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 -175.646 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.494 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 41.9 t0 -94.28 167.7 11.37 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.328 -1.101 . . . . 0.0 109.637 175.839 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.583 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.2 m95 -116.67 158.8 23.2 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.976 -1.077 . . . . 0.0 110.036 175.038 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.039 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.1 p -121.28 155.27 25.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.389 -0.82 . . . . 0.0 109.917 179.55 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.882 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -78.51 105.56 9.86 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 120.993 -1.067 . . . . 0.0 109.003 168.06 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.834 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -106.64 137.84 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 120.548 -1.345 . . . . 0.0 111.048 -176.96 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -138.98 140.09 38.11 Favored 'General case' 0 N--CA 1.492 1.629 0 C-N-CA 120.291 -0.564 . . . . 0.0 109.991 -177.319 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 53.0 ttt85 -60.06 127.05 29.97 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.155 -0.966 . . . . 0.0 110.293 -179.508 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.893 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.489 1.497 0 O-C-N 121.341 -0.849 . . . . 0.0 109.554 176.57 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 0.922 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.3 t . . . . . 0 N--CA 1.493 1.69 0 CA-C-O 121.773 0.797 . . . . 0.0 110.945 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 99.5 mt-30 -69.98 -31.72 69.55 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.785 -0.572 . . . . 0.0 111.025 179.27 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.549 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -156.49 -178.09 30.28 Favored Glycine 0 N--CA 1.499 2.895 0 C-N-CA 118.632 -1.747 . . . . 0.0 110.857 -170.872 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.503 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.0 p -129.03 167.13 17.94 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.913 -1.345 . . . . 0.0 111.028 -178.426 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.098 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -139.88 150.04 44.13 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 -175.179 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.579 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 34.5 tttt -109.3 115.81 30.68 Favored 'General case' 0 C--N 1.295 -1.772 0 O-C-N 121.028 -1.045 . . . . 0.0 110.294 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 1.012 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.5 tp -60.24 127.61 32.64 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 120.945 -1.097 . . . . 0.0 108.905 172.62 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.091 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.5 p -126.84 -29.38 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.874 0 O-C-N 121.345 -0.847 . . . . 0.0 110.034 -178.983 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.67 144.11 24.14 Favored 'General case' 0 C--N 1.297 -1.681 0 C-N-CA 119.225 -0.99 . . . . 0.0 111.243 179.224 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.89 HG23 ' CD2' ' B' ' 24' ' ' HIS . 8.9 mt -107.88 141.1 23.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.292 -0.88 . . . . 0.0 110.242 174.617 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.499 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 79.5 m-20 -109.92 113.98 27.15 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.364 -0.835 . . . . 0.0 109.961 172.243 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -101.22 113.08 25.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.155 -0.966 . . . . 0.0 110.444 -178.06 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.465 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.0 OUTLIER -109.87 134.36 20.68 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.311 -0.868 . . . . 0.0 109.442 176.043 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.71 -16.66 11.62 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 O-C-N 123.971 1.511 . . . . 0.0 110.662 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 4.7 m120 -100.51 -27.16 13.57 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.087 -1.008 . . . . 0.0 109.939 179.111 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 93.0 m-85 -157.37 150.33 23.44 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.416 -0.802 . . . . 0.0 109.814 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 22' ' ' ARG . . . . . 0.904 ' HD3' HD22 ' B' ' 68' ' ' LEU . 57.0 ttt180 -93.62 141.16 28.79 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.67 -1.269 . . . . 0.0 110.036 174.137 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.499 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 94.7 m -129.95 141.07 50.82 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.579 -0.701 . . . . 0.0 109.767 -173.683 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.89 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -129.93 143.78 50.98 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.989 -1.069 . . . . 0.0 111.472 -179.161 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.874 HG22 ' OG ' ' B' ' 60' ' ' SER . 6.4 t -123.38 132.93 70.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.161 -0.962 . . . . 0.0 110.709 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.81 HG13 ' HE1' ' B' ' 61' ' ' PHE . 26.7 m -115.08 174.44 3.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 121.688 -0.633 . . . . 0.0 110.226 178.677 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.681 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 12.8 tt0 -104.28 118.65 37.13 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.455 -0.778 . . . . 0.0 108.972 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.558 HD23 ' HA ' ' B' ' 33' ' ' LEU . 9.5 tp -81.13 122.58 81.69 Favored Pre-proline 0 C--N 1.296 -1.738 0 O-C-N 121.573 -0.704 . . . . 0.0 109.651 -174.818 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.496 ' HD2' HD12 ' B' ' 28' ' ' LEU . 18.2 Cg_endo -63.43 174.01 3.84 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.842 1.443 . . . . 0.0 110.564 -179.35 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.691 ' HA ' HD12 ' B' ' 33' ' ' LEU . 53.2 t0 -60.02 -39.46 85.93 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.501 -0.749 . . . . 0.0 110.56 -176.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.599 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.03 0.05 57.32 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.932 -1.105 . . . . 0.0 110.848 -174.974 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.599 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 95.8 mmm -109.73 -11.75 14.7 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.83 -1.169 . . . . 0.0 109.846 170.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.714 HD21 ' HB2' ' B' ' 57' ' ' ASN . 15.3 mt -69.26 -40.02 78.09 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.32 -0.863 . . . . 0.0 110.305 179.272 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -80.06 123.91 28.27 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.266 -0.896 . . . . 0.0 110.463 -177.054 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.11 -47.1 1.08 Allowed Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.784 -1.198 . . . . 0.0 110.391 175.116 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.851 HD23 ' N ' ' B' ' 37' ' ' GLU . 8.2 tt -67.26 147.3 53.19 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.001 -1.294 . . . . 0.0 110.805 -175.093 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 37' ' ' GLU . . . . . 0.851 ' N ' HD23 ' B' ' 36' ' ' LEU . 21.3 pt-20 -150.02 168.94 22.41 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.432 -0.792 . . . . 0.0 109.677 -179.617 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 38' ' ' THR . . . . . 0.824 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -66.77 148.86 51.37 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.95 -1.094 . . . . 0.0 110.106 -179.912 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.0 -10.09 58.78 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -175.509 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.445 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -71.33 157.76 37.53 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.17 -1.194 . . . . 0.0 109.102 174.669 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.913 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 1.7 p -105.02 116.44 31.96 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 118.844 -1.142 . . . . 0.0 109.968 175.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.623 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.5 t -99.9 126.4 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.472 -0.768 . . . . 0.0 108.971 175.432 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 0.509 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -88.23 119.43 28.63 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.094 -1.004 . . . . 0.0 109.16 173.401 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.748 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -89.7 105.26 17.68 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.369 -0.832 . . . . 0.0 109.019 177.934 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' A' ' 45' ' ' ASN . 0.8 OUTLIER 57.13 9.77 0.72 Allowed 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.515 -0.74 . . . . 0.0 111.464 -170.427 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 126.55 -1.93 7.55 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.504 -1.332 . . . . 0.0 110.84 173.877 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.888 ' O ' HD23 ' B' ' 49' ' ' LEU . 50.1 t -98.85 104.79 16.87 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.534 -1.568 . . . . 0.0 109.707 176.257 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 25.1 p -71.17 129.07 37.99 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.124 -0.985 . . . . 0.0 110.667 -174.489 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 0.952 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -141.65 159.85 41.37 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.348 -0.845 . . . . 0.0 109.239 173.857 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 50' ' ' THR . . . . . 0.42 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 23.7 m -99.69 150.02 22.72 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.588 -1.32 . . . . 0.0 111.412 -170.232 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.812 HG13 HG13 ' B' ' 59' ' ' VAL . 32.6 t -76.23 116.47 19.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.855 -0.528 . . . . 0.0 110.382 -179.225 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.536 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 28.6 p -71.92 -40.04 69.07 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.297 -0.877 . . . . 0.0 109.722 174.29 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.576 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -163.21 152.83 15.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.342 -0.849 . . . . 0.0 110.421 -178.946 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.824 HD11 ' N ' ' B' ' 38' ' ' THR . 7.6 mt -105.51 132.03 53.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.295 -0.878 . . . . 0.0 110.012 175.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.525 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 26.5 m-80 -104.87 64.82 0.73 Allowed 'General case' 0 C--N 1.297 -1.698 0 C-N-CA 120.048 -0.661 . . . . 0.0 109.562 179.285 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.72 -117.0 5.3 Favored Glycine 0 N--CA 1.487 2.063 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 -173.182 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.714 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -76.97 -20.9 55.54 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.076 -1.249 . . . . 0.0 109.164 175.73 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.091 ' CE1' HG11 ' B' ' 13' ' ' VAL . 29.1 m-70 -75.59 159.79 30.83 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.338 -0.851 . . . . 0.0 110.285 -177.683 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.812 HG13 HG13 ' B' ' 51' ' ' VAL . 56.7 t -140.46 123.1 16.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.76 173.361 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.874 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.3 t -90.67 134.67 34.24 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.481 -0.762 . . . . 0.0 109.54 177.278 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.952 ' HB2' HD12 ' B' ' 49' ' ' LEU . 2.7 p90 -126.93 151.05 49.0 Favored 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.314 176.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.536 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 38.2 p-10 -86.39 154.81 20.9 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.927 -1.108 . . . . 0.0 111.442 -171.702 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.85 HD22 HD13 ' B' ' 68' ' ' LEU . 0.0 OUTLIER -161.94 100.42 1.12 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.76 -0.588 . . . . 0.0 109.608 -175.614 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.486 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 33.0 ttp -60.67 139.99 57.64 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.836 -1.165 . . . . 0.0 109.53 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.485 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 29.5 tptp -59.94 -48.41 81.81 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.946 -1.096 . . . . 0.0 110.469 -172.69 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -63.24 -40.02 96.25 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.792 -1.193 . . . . 0.0 109.792 177.467 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.486 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 55.5 m -60.01 -39.88 87.36 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.188 -0.945 . . . . 0.0 109.657 172.691 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.904 HD22 ' HD3' ' B' ' 22' ' ' ARG . 27.1 tp -61.73 -40.66 95.84 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.504 -0.748 . . . . 0.0 109.892 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 15.6 ttm180 -69.96 -40.01 75.66 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.34 -0.85 . . . . 0.0 110.52 176.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.692 HG22 HG23 ' B' ' 71' ' ' THR . 1.2 tt -64.87 -44.47 96.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.296 -0.877 . . . . 0.0 109.623 -176.618 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.692 HG23 HG22 ' B' ' 70' ' ' ILE . 30.4 p -80.18 -174.89 4.76 Favored 'General case' 0 C--N 1.301 -1.538 0 C-N-CA 119.84 -0.744 . . . . 0.0 109.294 175.247 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.501 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 3.9 t30 -99.97 23.41 9.87 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.069 -1.02 . . . . 0.0 108.406 169.458 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.671 ' HB3' HD21 ' B' ' 63' ' ' LEU . 87.7 mt -69.25 -40.03 78.11 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.09 -1.006 . . . . 0.0 109.768 174.793 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.546 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -46.81 -22.38 1.14 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -179.365 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.3 p-10 -69.08 -16.9 63.79 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.905 -1.35 . . . . 0.0 110.488 -174.62 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.503 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.3 mt -60.1 141.29 56.04 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.229 -0.92 . . . . 0.0 111.06 -176.867 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 1.012 ' C ' HD23 ' B' ' 12' ' ' LEU . 24.9 mttm -142.47 143.07 32.42 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.725 -0.61 . . . . 0.0 109.694 174.073 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.663 HG23 HD11 ' B' ' 15' ' ' ILE . 32.7 t -63.19 150.05 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.924 -1.11 . . . . 0.0 110.317 -177.188 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.38 -14.7 60.4 Favored Glycine 0 N--CA 1.486 1.974 0 N-CA-C 108.777 -1.729 . . . . 0.0 108.777 -175.677 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.488 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 41.8 t0 -94.43 167.68 11.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.426 -1.044 . . . . 0.0 109.635 175.749 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.579 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.1 m95 -116.64 158.83 23.12 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.074 -1.016 . . . . 0.0 110.068 175.088 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 1.098 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.0 OUTLIER -121.32 155.33 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.419 -0.801 . . . . 0.0 109.887 179.457 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.922 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.2 OUTLIER -78.39 105.29 9.55 Favored 'General case' 0 C--N 1.297 -1.674 0 O-C-N 121.105 -0.997 . . . . 0.0 109.147 168.007 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.836 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -106.49 138.12 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 120.596 -1.315 . . . . 0.0 110.894 -176.821 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -139.29 140.21 37.55 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 120.268 -0.573 . . . . 0.0 109.914 -177.481 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 53.0 ttt85 -59.99 127.04 29.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.176 -0.953 . . . . 0.0 110.267 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.913 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.442 -0.786 . . . . 0.0 109.444 176.564 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.771 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.2 t . . . . . 0 N--CA 1.493 1.717 0 CA-C-O 121.529 0.68 . . . . 0.0 110.399 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -95.21 -22.06 18.06 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.493 -0.755 . . . . 0.0 110.75 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.529 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -144.43 175.59 24.1 Favored Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.081 -1.533 . . . . 0.0 109.968 -176.209 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.432 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.2 p -127.51 166.04 18.72 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.06 -1.259 . . . . 0.0 110.625 179.227 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 1.071 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -133.94 148.84 51.23 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.598 -0.689 . . . . 0.0 109.258 -178.681 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 23.5 tttt -107.66 116.89 32.76 Favored 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.113 -0.992 . . . . 0.0 110.147 179.353 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.996 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.2 tp -59.92 126.32 27.08 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 120.876 -1.14 . . . . 0.0 108.914 173.333 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.048 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.4 p -124.95 -30.8 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 C-N-CA 119.744 -0.782 . . . . 0.0 109.718 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.59 142.36 27.89 Favored 'General case' 0 N--CA 1.492 1.653 0 C-N-CA 119.214 -0.995 . . . . 0.0 111.127 -178.098 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.732 HG23 ' NE2' ' A' ' 24' ' ' HIS . 10.6 mt -108.62 130.19 61.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.113 -0.992 . . . . 0.0 110.314 172.4 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.502 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 74.1 m-20 -104.49 117.76 34.95 Favored 'General case' 0 C--N 1.295 -1.769 0 O-C-N 121.376 -0.827 . . . . 0.0 109.809 172.755 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -107.4 105.31 15.18 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.146 -0.971 . . . . 0.0 110.176 -177.518 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 2.1 mmmt -102.2 130.56 23.98 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.347 -0.846 . . . . 0.0 109.282 179.219 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -51.5 -19.43 7.12 Favored 'Trans proline' 0 C--N 1.303 -1.856 0 O-C-N 123.913 1.481 . . . . 0.0 110.573 -179.499 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.573 ' O ' ' CD1' ' A' ' 21' ' ' PHE . 0.4 OUTLIER -90.54 -38.37 13.24 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.169 -0.957 . . . . 0.0 109.102 177.268 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.573 ' CD1' ' O ' ' A' ' 20' ' ' ASN . 64.6 m-85 -153.15 150.18 28.8 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.833 -0.542 . . . . 0.0 110.148 -177.651 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.544 ' HD3' HD22 ' A' ' 68' ' ' LEU . 63.4 ttt180 -88.43 145.03 26.01 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.6 -1.313 . . . . 0.0 109.941 174.409 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.502 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 84.8 m -133.08 140.82 47.87 Favored 'General case' 0 C--N 1.296 -1.752 0 O-C-N 121.407 -0.808 . . . . 0.0 109.946 -174.173 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.732 ' NE2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.03 131.96 46.04 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.767 -1.208 . . . . 0.0 111.561 -179.669 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.612 HG22 ' CB ' ' A' ' 60' ' ' SER . 4.0 t -109.85 132.28 58.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.184 -0.947 . . . . 0.0 110.537 -178.941 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 15.5 m -117.44 169.85 7.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 120.359 -0.537 . . . . 0.0 110.343 -179.111 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.661 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 13.1 tt0 -103.22 118.31 36.5 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.215 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.513 ' CD2' ' O ' ' A' ' 32' ' ' MET . 9.5 tp -84.14 126.37 70.05 Favored Pre-proline 0 C--N 1.298 -1.667 0 O-C-N 121.327 -0.858 . . . . 0.0 109.759 -175.073 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.468 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 17.7 Cg_endo -64.27 176.84 2.37 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 123.903 1.475 . . . . 0.0 110.927 -179.192 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.412 ' HA ' HD12 ' A' ' 33' ' ' LEU . 77.4 m-20 -60.06 -39.94 87.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.427 -0.796 . . . . 0.0 110.997 -176.37 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.577 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.13 2.57 55.15 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.797 -1.19 . . . . 0.0 110.744 -174.457 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.577 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 89.1 mmm -113.07 -11.89 13.27 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.912 -1.118 . . . . 0.0 109.991 170.364 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.683 HD21 ' HB2' ' A' ' 57' ' ' ASN . 18.1 mt -69.97 -40.1 75.58 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.321 -0.862 . . . . 0.0 110.378 178.849 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -82.68 115.76 21.76 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.905 . . . . 0.0 110.505 -176.384 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.61 -52.75 0.69 Allowed Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.81 -1.186 . . . . 0.0 110.376 175.389 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.494 HD23 HD22 ' A' ' 28' ' ' LEU . 42.6 tp -61.52 151.34 33.23 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.955 -1.321 . . . . 0.0 110.851 -173.471 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.491 ' C ' HD11 ' A' ' 54' ' ' ILE . 20.9 pt-20 -149.95 168.33 24.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.468 -0.77 . . . . 0.0 109.484 178.854 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.91 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -66.09 152.84 43.82 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.885 -1.134 . . . . 0.0 109.982 -178.985 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.31 -4.72 66.31 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -176.348 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.514 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -77.26 156.64 31.27 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.291 -1.123 . . . . 0.0 109.668 176.941 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.612 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -100.61 108.24 20.09 Favored 'General case' 0 C--N 1.306 -1.286 0 O-C-N 121.103 -0.998 . . . . 0.0 110.087 178.629 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.588 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.2 t -94.24 129.45 44.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.224 -0.923 . . . . 0.0 109.125 174.203 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -93.33 119.54 32.59 Favored 'General case' 0 C--N 1.296 -1.724 0 C-N-CA 119.258 -0.977 . . . . 0.0 109.07 171.572 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.852 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.3 OUTLIER -89.17 102.6 15.26 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.64 -0.824 . . . . 0.0 108.94 178.463 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.499 ' HB3' ' HB3' ' B' ' 45' ' ' ASN . 1.7 t-20 58.22 11.49 1.58 Allowed 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.449 -0.782 . . . . 0.0 110.772 -169.882 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.512 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.16 -2.29 11.56 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.777 -1.201 . . . . 0.0 110.891 172.672 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.83 ' O ' HD23 ' A' ' 49' ' ' LEU . 43.0 t -92.16 109.17 20.53 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.39 -1.653 . . . . 0.0 109.389 174.352 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 15.8 p -74.89 128.43 35.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.099 -1.001 . . . . 0.0 110.844 -171.713 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.92 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -146.96 157.0 43.5 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.347 -0.846 . . . . 0.0 109.499 173.741 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.425 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 23.9 m -97.5 159.0 15.18 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.735 -1.228 . . . . 0.0 111.296 -170.6 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.965 HG22 ' CE1' ' A' ' 61' ' ' PHE . 22.4 t -83.26 116.63 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.832 -0.542 . . . . 0.0 110.43 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.54 HG22 ' HB3' ' A' ' 62' ' ' ASP . 39.4 p -70.0 -39.91 75.6 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.241 -0.912 . . . . 0.0 109.715 172.777 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.579 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.9 tt0 -160.95 154.83 22.5 Favored 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 119.357 -0.937 . . . . 0.0 111.204 -175.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.91 HD11 ' N ' ' A' ' 38' ' ' THR . 6.4 mt -110.06 129.99 64.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.091 -1.006 . . . . 0.0 110.044 169.497 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.488 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 27.7 m-80 -103.7 65.12 0.82 Allowed 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.592 -0.692 . . . . 0.0 109.514 176.648 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.49 -113.4 3.82 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.812 -1.715 . . . . 0.0 108.812 -173.263 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.683 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.1 OUTLIER -79.99 -21.07 44.09 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.05 -1.265 . . . . 0.0 109.168 175.405 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.048 ' CE1' HG11 ' A' ' 13' ' ' VAL . 17.9 m-70 -77.65 159.99 28.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.246 -0.909 . . . . 0.0 110.112 -176.488 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.668 ' CG1' HG13 ' A' ' 51' ' ' VAL . 97.7 t -144.4 115.43 2.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 C-N-CA 119.309 -0.957 . . . . 0.0 110.891 177.702 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.612 ' CB ' HG22 ' A' ' 25' ' ' VAL . 13.7 m -81.74 130.15 34.96 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.677 -0.639 . . . . 0.0 109.849 178.465 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.965 ' CE1' HG22 ' A' ' 51' ' ' VAL . 96.4 m-85 -115.19 159.98 20.28 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.952 -1.092 . . . . 0.0 110.235 178.037 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.54 ' HB3' HG22 ' A' ' 52' ' ' THR . 25.7 p-10 -95.2 147.81 23.07 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.163 -0.961 . . . . 0.0 111.335 -177.019 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.806 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -159.14 116.47 2.75 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.718 -0.614 . . . . 0.0 109.559 -175.729 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.48 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 57.9 ttm -75.27 146.97 40.63 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.863 -1.148 . . . . 0.0 109.852 179.251 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.477 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 39.0 ttpt -60.07 -49.75 76.4 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.078 -1.014 . . . . 0.0 110.305 -177.671 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -63.95 -42.46 97.3 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.895 -1.128 . . . . 0.0 110.17 178.574 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.48 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 69.4 m -60.31 -40.04 89.12 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.932 -1.105 . . . . 0.0 109.606 174.332 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.654 HD11 ' HA2' ' A' ' 74' ' ' GLY . 11.7 tp -59.99 -43.16 95.33 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.288 -0.882 . . . . 0.0 109.582 177.756 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 16.4 mmm180 -70.0 -40.07 75.52 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.57 -0.706 . . . . 0.0 110.608 177.613 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.87 HG22 HG23 ' A' ' 71' ' ' THR . 1.5 tt -66.15 -43.72 91.95 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.209 -0.932 . . . . 0.0 109.329 -177.169 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.87 HG23 HG22 ' A' ' 70' ' ' ILE . 32.9 p -84.7 -171.01 3.4 Favored 'General case' 0 C--N 1.297 -1.68 0 CA-C-O 121.361 0.601 . . . . 0.0 109.673 178.013 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.519 ' CB ' ' N ' ' B' ' 83' ' ' ASN . 1.6 t30 -103.2 21.84 15.14 Favored 'General case' 0 C--N 1.293 -1.862 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 170.477 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.806 ' HB3' HD21 ' A' ' 63' ' ' LEU . 91.5 mt -66.26 -40.0 89.84 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.939 -1.101 . . . . 0.0 109.787 173.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.654 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -49.79 -25.17 6.75 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -178.543 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 24.0 p-10 -65.99 -16.63 64.06 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.001 -1.294 . . . . 0.0 110.508 -174.816 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 96.2 mt -60.01 140.17 56.96 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.151 -0.968 . . . . 0.0 110.65 -176.805 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 0.996 ' C ' HD23 ' A' ' 12' ' ' LEU . 26.0 mttt -144.07 140.33 29.43 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-O 121.346 0.593 . . . . 0.0 109.688 176.01 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.686 ' N ' HD23 ' A' ' 12' ' ' LEU . 18.8 t -61.77 150.17 8.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 120.686 -1.259 . . . . 0.0 110.524 -173.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.61 -13.63 63.57 Favored Glycine 0 N--CA 1.482 1.733 0 N-CA-C 108.855 -1.698 . . . . 0.0 108.855 -176.463 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.434 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 34.8 t0 -95.36 169.94 9.72 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.324 -1.104 . . . . 0.0 109.459 175.673 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.3 m95 -117.47 168.31 10.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.908 -1.12 . . . . 0.0 110.245 175.785 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.071 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.4 p -130.17 153.05 38.37 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.491 -0.756 . . . . 0.0 109.696 179.369 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.771 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.2 m-20 -79.77 106.02 11.5 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 120.89 -1.131 . . . . 0.0 109.043 170.019 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.564 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -106.23 139.98 25.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 120.481 -1.387 . . . . 0.0 111.37 -175.042 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.421 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.5 tt0 -131.02 142.6 50.34 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.037 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 39.6 ttm180 -81.24 121.07 25.7 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 110.481 -178.753 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.612 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.23 -0.919 . . . . 0.0 110.124 176.57 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 0.789 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.2 t . . . . . 0 N--CA 1.493 1.691 0 CA-C-O 121.474 0.654 . . . . 0.0 110.398 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -95.35 -21.78 18.17 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.483 -0.76 . . . . 0.0 110.788 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.528 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -144.63 175.4 24.35 Favored Glycine 0 N--CA 1.493 2.459 0 C-N-CA 119.273 -1.441 . . . . 0.0 110.141 -176.251 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.426 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.1 p -127.45 166.09 18.58 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.118 -1.225 . . . . 0.0 110.589 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.054 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -133.9 148.98 51.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.631 -0.668 . . . . 0.0 109.254 -178.75 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.579 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 23.6 tttt -107.79 116.91 32.81 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.121 -0.987 . . . . 0.0 110.109 179.326 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 1.009 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.2 tp -59.96 126.3 27.02 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.963 -1.086 . . . . 0.0 108.98 173.308 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.027 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.4 p -124.93 -30.86 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 O-C-N 121.451 -0.781 . . . . 0.0 109.724 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.56 142.45 28.01 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.37 -0.932 . . . . 0.0 111.098 -178.135 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.748 HG23 ' NE2' ' B' ' 24' ' ' HIS . 10.7 mt -108.68 130.24 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.176 -0.952 . . . . 0.0 110.315 172.4 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.515 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 73.5 m-20 -104.71 117.88 35.18 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.287 -0.883 . . . . 0.0 109.662 172.892 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -107.4 105.37 15.26 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.105 -0.997 . . . . 0.0 110.157 -177.545 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.467 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 2.1 mmmt -102.23 130.5 24.08 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.427 -0.796 . . . . 0.0 109.276 179.189 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -51.55 -19.33 7.11 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 123.889 1.468 . . . . 0.0 110.606 -179.491 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.578 ' O ' ' CD1' ' B' ' 21' ' ' PHE . 0.4 OUTLIER -90.43 -38.94 12.95 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.176 -0.952 . . . . 0.0 108.941 177.272 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' B' ' 20' ' ' ASN . 64.8 m-85 -152.71 150.27 29.26 Favored 'General case' 0 N--CA 1.494 1.765 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.15 -177.562 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 22' ' ' ARG . . . . . 0.536 ' HD3' HD22 ' B' ' 68' ' ' LEU . 63.5 ttt180 -88.47 144.89 26.07 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.701 -1.249 . . . . 0.0 109.889 174.421 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.515 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 84.9 m -132.96 140.84 48.01 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.55 -0.719 . . . . 0.0 109.927 -174.213 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.748 ' NE2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -129.98 132.1 46.17 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.941 -1.099 . . . . 0.0 111.454 -179.654 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.621 HG22 ' CB ' ' B' ' 60' ' ' SER . 4.0 t -109.89 132.44 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.349 -0.844 . . . . 0.0 110.571 -178.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.505 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 16.0 m -117.61 169.78 7.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 CA-C-O 121.304 0.573 . . . . 0.0 110.215 -178.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.658 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 13.1 tt0 -103.09 118.48 36.89 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.102 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.519 ' CD2' ' O ' ' B' ' 32' ' ' MET . 9.5 tp -84.2 126.31 70.09 Favored Pre-proline 0 C--N 1.297 -1.711 0 O-C-N 121.254 -0.904 . . . . 0.0 109.749 -175.122 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.477 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 17.7 Cg_endo -64.27 176.8 2.39 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 O-C-N 123.865 1.455 . . . . 0.0 110.869 -179.191 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.419 ' HA ' HD12 ' B' ' 33' ' ' LEU . 77.3 m-20 -60.04 -40.0 87.88 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.413 -0.805 . . . . 0.0 111.007 -176.38 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.579 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.96 2.49 55.04 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.863 -1.148 . . . . 0.0 110.847 -174.552 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.579 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 89.2 mmm -113.06 -11.94 13.27 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.894 -1.129 . . . . 0.0 110.012 170.373 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.649 HD21 ' HB2' ' B' ' 57' ' ' ASN . 18.1 mt -69.96 -40.05 75.64 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.245 -0.91 . . . . 0.0 110.404 178.818 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -82.67 115.78 21.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.201 -0.937 . . . . 0.0 110.48 -176.396 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.62 -52.74 0.69 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.81 -1.185 . . . . 0.0 110.4 175.378 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.496 HD23 HD22 ' B' ' 28' ' ' LEU . 42.8 tp -61.65 151.42 33.61 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.919 -1.342 . . . . 0.0 110.795 -173.41 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 37' ' ' GLU . . . . . 0.507 ' C ' HD11 ' B' ' 54' ' ' ILE . 20.9 pt-20 -149.96 168.37 24.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.531 -0.731 . . . . 0.0 109.452 178.941 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 38' ' ' THR . . . . . 0.918 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.2 152.68 44.32 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.882 -1.136 . . . . 0.0 109.995 -178.921 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.52 -4.73 67.13 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 -176.388 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.511 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -77.4 156.48 31.15 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.299 -1.118 . . . . 0.0 109.616 176.941 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.624 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.1 OUTLIER -100.26 108.1 20.09 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.059 -1.026 . . . . 0.0 110.173 178.616 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.601 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.2 t -94.37 129.52 44.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.263 -0.898 . . . . 0.0 109.147 174.178 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 0.484 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -93.27 119.58 32.59 Favored 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 119.231 -0.988 . . . . 0.0 109.042 171.635 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.863 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.3 OUTLIER -89.21 102.55 15.21 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.319 -0.863 . . . . 0.0 108.946 178.434 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.499 ' HB3' ' HB3' ' A' ' 45' ' ' ASN . 1.8 t-20 58.38 11.47 1.66 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.511 -0.743 . . . . 0.0 110.68 -170.007 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.512 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.07 -2.13 11.65 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.888 172.662 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.83 ' O ' HD23 ' B' ' 49' ' ' LEU . 43.4 t -92.35 109.18 20.56 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.428 -1.631 . . . . 0.0 109.355 174.319 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 15.9 p -74.78 128.57 35.88 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.161 -0.962 . . . . 0.0 110.744 -171.736 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 0.904 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -147.2 156.85 43.31 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.448 -0.782 . . . . 0.0 109.477 173.649 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 50' ' ' THR . . . . . 0.427 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 23.8 m -97.26 159.09 15.12 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.737 -1.227 . . . . 0.0 111.281 -170.502 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.977 HG22 ' CE1' ' B' ' 61' ' ' PHE . 22.7 t -83.39 116.72 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.679 -0.638 . . . . 0.0 110.437 -178.524 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.561 HG22 ' HB3' ' B' ' 62' ' ' ASP . 39.8 p -70.01 -39.96 75.51 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.159 -0.963 . . . . 0.0 109.664 172.843 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.572 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.9 tt0 -160.93 154.76 22.43 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.409 -0.916 . . . . 0.0 111.172 -175.828 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.918 HD11 ' N ' ' B' ' 38' ' ' THR . 6.4 mt -109.97 129.99 63.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.115 -0.991 . . . . 0.0 110.03 169.525 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.493 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 27.6 m-80 -103.74 65.1 0.81 Allowed 'General case' 0 C--N 1.299 -1.615 0 C-N-CA 119.862 -0.735 . . . . 0.0 109.564 176.608 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.68 -113.43 3.81 Favored Glycine 0 N--CA 1.486 2.012 0 N-CA-C 108.715 -1.754 . . . . 0.0 108.715 -173.279 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.649 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -80.02 -21.1 43.93 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.061 -1.258 . . . . 0.0 109.152 175.45 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.027 ' CE1' HG11 ' B' ' 13' ' ' VAL . 17.6 m-70 -77.54 159.81 29.05 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.186 -0.947 . . . . 0.0 110.108 -176.535 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.647 ' CG1' HG13 ' B' ' 51' ' ' VAL . 97.1 t -144.31 115.47 2.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 C-N-CA 119.284 -0.967 . . . . 0.0 110.912 177.71 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.621 ' CB ' HG22 ' B' ' 25' ' ' VAL . 13.7 m -81.83 130.28 35.02 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.751 -0.593 . . . . 0.0 109.931 178.494 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.977 ' CE1' HG22 ' B' ' 51' ' ' VAL . 96.4 m-85 -115.27 160.02 20.29 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.977 -1.077 . . . . 0.0 110.275 178.107 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.561 ' HB3' HG22 ' B' ' 52' ' ' THR . 25.7 p-10 -95.2 147.77 23.11 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.012 -1.055 . . . . 0.0 111.273 -176.91 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.769 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.16 116.43 2.73 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.788 -0.57 . . . . 0.0 109.538 -175.744 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.476 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 58.0 ttm -75.25 146.99 40.66 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.867 -1.146 . . . . 0.0 109.851 179.275 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.476 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 39.0 ttpt -60.04 -49.88 75.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.041 -1.037 . . . . 0.0 110.249 -177.63 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -63.94 -42.4 97.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.888 -1.132 . . . . 0.0 110.241 178.64 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.476 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 71.3 m -60.27 -40.07 89.08 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.003 -1.061 . . . . 0.0 109.671 174.258 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.674 HD11 ' HA2' ' B' ' 74' ' ' GLY . 11.7 tp -59.94 -43.18 95.13 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.438 -0.789 . . . . 0.0 109.559 177.733 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 16.4 mmm180 -69.98 -39.93 75.65 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.562 -0.711 . . . . 0.0 110.665 177.618 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.85 HG22 HG23 ' B' ' 71' ' ' THR . 1.5 tt -66.22 -43.69 91.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 CA-C-O 121.922 0.868 . . . . 0.0 109.363 -177.195 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.85 HG23 HG22 ' B' ' 70' ' ' ILE . 33.0 p -84.6 -170.77 3.28 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 121.44 0.638 . . . . 0.0 109.708 177.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.533 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 1.6 t30 -103.39 21.82 15.31 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 170.531 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.769 ' HB3' HD21 ' B' ' 63' ' ' LEU . 91.7 mt -66.22 -40.02 89.99 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.917 -1.114 . . . . 0.0 109.736 173.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.674 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -49.78 -25.18 6.75 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 110.429 -1.068 . . . . 0.0 110.429 -178.496 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 24.2 p-10 -66.02 -16.64 64.08 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.995 -1.297 . . . . 0.0 110.433 -174.719 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.517 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 96.2 mt -59.98 140.21 56.91 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.155 -0.965 . . . . 0.0 110.639 -176.784 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 1.009 ' C ' HD23 ' B' ' 12' ' ' LEU . 26.0 mttt -144.13 140.4 29.39 Favored 'General case' 0 C--N 1.296 -1.737 0 O-C-N 121.796 -0.565 . . . . 0.0 109.675 175.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.692 ' N ' HD23 ' B' ' 12' ' ' LEU . 19.0 t -61.82 150.25 8.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 120.942 -1.099 . . . . 0.0 110.536 -173.864 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.47 -13.49 63.73 Favored Glycine 0 N--CA 1.483 1.778 0 N-CA-C 108.959 -1.656 . . . . 0.0 108.959 -176.407 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.442 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 34.4 t0 -95.35 169.95 9.71 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.366 -1.079 . . . . 0.0 109.51 175.55 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.579 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.3 m95 -117.52 168.19 10.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.951 -1.093 . . . . 0.0 110.261 175.823 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 1.054 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.4 p -130.15 153.14 38.49 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.465 -0.772 . . . . 0.0 109.63 179.307 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.789 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.1 m-20 -79.77 105.72 11.27 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 120.97 -1.081 . . . . 0.0 109.158 170.023 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.554 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -106.06 140.0 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.45 -1.406 . . . . 0.0 111.331 -174.873 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 85' ' ' GLU . . . . . 0.426 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.5 tt0 -131.01 142.69 50.35 Favored 'General case' 0 N--CA 1.492 1.675 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.059 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 39.5 ttm180 -81.31 121.2 25.9 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.36 -0.838 . . . . 0.0 110.351 -178.653 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.624 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.612 0 O-C-N 121.275 -0.891 . . . . 0.0 110.158 176.491 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.7 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.5 t . . . . . 0 N--CA 1.493 1.689 0 CA-C-O 121.676 0.75 . . . . 0.0 110.568 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -69.98 -33.6 72.27 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.669 -0.644 . . . . 0.0 110.708 -178.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.539 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -153.42 174.75 32.02 Favored Glycine 0 N--CA 1.495 2.585 0 C-N-CA 118.957 -1.592 . . . . 0.0 110.395 -172.645 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.497 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 17.9 p -120.61 169.0 10.78 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.991 -1.3 . . . . 0.0 111.008 -177.263 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 1.008 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -138.07 149.5 46.05 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.6 -0.687 . . . . 0.0 109.432 -175.337 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.58 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 19.1 tttt -106.47 117.3 33.7 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.076 -1.015 . . . . 0.0 110.216 179.088 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 1.037 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.0 tp -59.93 128.52 37.27 Favored 'General case' 0 C--N 1.298 -1.643 0 O-C-N 120.885 -1.135 . . . . 0.0 108.737 172.523 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.116 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.58 -28.81 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 O-C-N 121.369 -0.832 . . . . 0.0 110.055 -178.152 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.53 140.2 24.77 Favored 'General case' 0 N--CA 1.494 1.757 0 C-N-CA 119.14 -1.024 . . . . 0.0 111.385 -178.766 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.749 HG23 ' CD2' ' A' ' 24' ' ' HIS . 7.0 mt -107.01 133.16 52.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.002 -1.061 . . . . 0.0 110.043 169.845 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.494 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 86.9 m-20 -109.98 114.51 28.09 Favored 'General case' 0 C--N 1.294 -1.832 0 O-C-N 121.443 -0.786 . . . . 0.0 109.987 173.795 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -103.9 116.6 32.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.047 -1.033 . . . . 0.0 110.388 -177.016 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.405 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -111.67 135.1 21.13 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.298 -0.876 . . . . 0.0 109.344 178.205 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -51.8 -18.44 6.52 Favored 'Trans proline' 0 C--N 1.303 -1.829 0 O-C-N 123.906 1.477 . . . . 0.0 110.774 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.575 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 5.2 m120 -97.2 -32.6 11.85 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.027 -1.046 . . . . 0.0 110.423 178.59 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.575 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 83.2 m-85 -158.03 150.41 22.28 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.272 -0.893 . . . . 0.0 110.208 -177.394 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.493 ' HD3' HD22 ' A' ' 68' ' ' LEU . 65.8 ttt180 -90.72 144.11 26.06 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.7 -1.25 . . . . 0.0 110.03 176.648 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.494 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 96.8 m -129.84 139.96 51.1 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.607 -0.683 . . . . 0.0 109.746 -175.278 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.749 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.21 139.72 50.79 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.972 -1.08 . . . . 0.0 111.164 179.766 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.677 HG22 ' CB ' ' A' ' 60' ' ' SER . 4.0 t -120.51 132.52 69.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 O-C-N 121.051 -1.031 . . . . 0.0 110.468 -178.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.875 HG13 ' CE1' ' A' ' 61' ' ' PHE . 31.7 m -115.88 171.37 5.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.862 -0.524 . . . . 0.0 110.026 179.411 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.616 ' CG ' HD22 ' A' ' 57' ' ' ASN . 10.4 tt0 -108.54 115.7 30.59 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.523 HD22 HD23 ' A' ' 36' ' ' LEU . 8.7 tp -86.8 127.97 58.05 Favored Pre-proline 0 C--N 1.296 -1.725 0 O-C-N 121.206 -0.934 . . . . 0.0 110.285 -172.109 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.483 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 28.9 Cg_endo -66.72 177.1 3.68 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 O-C-N 123.941 1.496 . . . . 0.0 111.05 -179.401 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.534 ' HA ' HD12 ' A' ' 33' ' ' LEU . 95.9 m-20 -60.07 -40.06 88.21 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.23 -0.919 . . . . 0.0 111.083 -174.251 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.596 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.02 0.86 56.88 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.814 -1.178 . . . . 0.0 110.959 -174.655 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.596 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.8 mmm -112.59 -12.03 13.49 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.958 -1.089 . . . . 0.0 109.964 172.282 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.6 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 19.8 mt -70.07 -39.97 75.33 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.408 -0.807 . . . . 0.0 110.186 177.832 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -73.91 143.13 45.9 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.419 -0.801 . . . . 0.0 110.583 -178.147 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.5 -39.02 3.01 Favored Glycine 0 N--CA 1.492 2.409 0 C-N-CA 119.925 -1.131 . . . . 0.0 110.555 173.932 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.523 HD23 HD22 ' A' ' 28' ' ' LEU . 50.3 tp -77.54 147.93 35.5 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.896 -1.355 . . . . 0.0 110.892 -174.108 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.499 ' C ' HD11 ' A' ' 54' ' ' ILE . 21.3 pt-20 -149.07 166.58 28.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.409 -0.807 . . . . 0.0 109.511 177.947 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.843 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -64.99 147.78 52.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.825 -1.172 . . . . 0.0 109.862 179.376 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.94 -7.68 62.3 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -175.412 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.533 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -74.99 153.18 38.64 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.277 -1.131 . . . . 0.0 109.645 177.319 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.87 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.0 OUTLIER -96.58 110.12 22.59 Favored 'General case' 0 C--N 1.309 -1.19 0 O-C-N 120.76 -1.212 . . . . 0.0 109.955 175.474 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.657 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.0 t -92.91 130.09 42.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 173.321 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.574 ' HB3' ' CG ' ' A' ' 85' ' ' GLU . . . -93.47 119.69 32.85 Favored 'General case' 0 C--N 1.293 -1.848 0 C-N-CA 119.001 -1.079 . . . . 0.0 109.071 173.12 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.657 ' HE1' HG11 ' A' ' 42' ' ' VAL . 0.3 OUTLIER -90.31 106.02 18.21 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 177.727 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' B' ' 45' ' ' ASN . 0.9 OUTLIER 58.27 7.85 0.73 Allowed 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.341 -0.849 . . . . 0.0 111.547 -169.887 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.408 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 125.61 -3.2 8.13 Favored Glycine 0 N--CA 1.49 2.292 0 O-C-N 120.703 -1.248 . . . . 0.0 110.549 174.668 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.841 ' O ' HD23 ' A' ' 49' ' ' LEU . 32.6 t -94.37 108.26 20.17 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.59 -1.535 . . . . 0.0 109.812 176.857 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 19.5 p -70.29 128.54 36.57 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.163 -0.961 . . . . 0.0 110.895 -175.434 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.851 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -143.29 158.03 43.98 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.365 -0.834 . . . . 0.0 109.344 172.347 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 65.0 m -99.51 149.33 23.34 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.559 -1.338 . . . . 0.0 111.403 -170.242 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.917 HG13 HG13 ' A' ' 59' ' ' VAL . 20.4 t -76.88 114.74 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 CA-C-O 121.01 0.433 . . . . 0.0 110.406 -178.915 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.52 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 52.6 p -69.32 -40.07 77.84 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.184 -0.947 . . . . 0.0 109.602 173.781 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.566 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 89.3 tt0 -161.49 156.4 23.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.428 -0.795 . . . . 0.0 110.157 -178.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.843 HD11 ' N ' ' A' ' 38' ' ' THR . 8.2 mt -108.9 129.3 63.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.075 -1.015 . . . . 0.0 109.987 174.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.535 ' HB2' ' CB ' ' A' ' 58' ' ' HIS . 8.6 m-80 -102.39 62.95 0.87 Allowed 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.537 -0.727 . . . . 0.0 109.88 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.67 -117.99 5.33 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.768 -1.733 . . . . 0.0 108.768 -173.923 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.616 HD22 ' CG ' ' A' ' 27' ' ' GLU . 0.1 OUTLIER -74.9 -19.87 59.95 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 120.902 -1.352 . . . . 0.0 108.768 174.216 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.116 ' CD2' HG11 ' A' ' 13' ' ' VAL . 10.3 m170 -75.61 159.77 30.84 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.424 -0.798 . . . . 0.0 110.129 -177.177 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.917 HG13 HG13 ' A' ' 51' ' ' VAL . 53.6 t -140.55 123.0 15.81 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 121.039 -1.038 . . . . 0.0 110.641 171.092 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.677 ' CB ' HG22 ' A' ' 25' ' ' VAL . 17.0 m -89.65 128.72 36.11 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.609 -0.682 . . . . 0.0 109.478 177.682 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.875 ' CE1' HG13 ' A' ' 26' ' ' VAL . 2.4 p90 -124.14 152.38 42.86 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.98 -1.075 . . . . 0.0 110.182 179.002 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.52 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 33.1 p-10 -89.38 156.12 18.9 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 120.986 -1.071 . . . . 0.0 111.708 -171.216 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.923 HD22 HD13 ' A' ' 68' ' ' LEU . 0.2 OUTLIER -160.64 101.4 1.33 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.691 -0.631 . . . . 0.0 109.613 -173.416 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.503 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 57.2 ttm -61.53 139.56 58.23 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.57 -1.331 . . . . 0.0 109.174 178.491 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.477 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 78.7 tttt -59.96 -47.87 84.01 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.723 -1.236 . . . . 0.0 110.38 -173.574 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -64.49 -39.95 94.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.876 -1.14 . . . . 0.0 109.87 177.825 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.503 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 94.6 m -61.38 -39.93 92.45 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.898 -1.126 . . . . 0.0 109.526 173.13 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.923 HD13 HD22 ' A' ' 63' ' ' LEU . 16.3 tp -59.99 -41.14 91.42 Favored 'General case' 0 C--N 1.3 -1.587 0 O-C-N 121.352 -0.843 . . . . 0.0 109.269 178.378 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -67.02 -39.99 87.17 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.475 -0.766 . . . . 0.0 110.491 173.827 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.797 HG22 HG23 ' A' ' 71' ' ' THR . 0.8 OUTLIER -65.64 -43.39 93.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.139 -0.975 . . . . 0.0 109.359 -175.538 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.797 HG23 HG22 ' A' ' 70' ' ' ILE . 24.7 p -84.25 -174.43 5.27 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 175.035 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.4 t30 -101.45 23.48 11.02 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 171.704 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.681 HD13 HD21 ' A' ' 63' ' ' LEU . 91.6 mt -70.05 -39.96 75.4 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.132 -0.98 . . . . 0.0 110.009 176.049 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.547 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -47.53 -22.56 1.74 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 -178.816 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.508 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.3 p-10 -68.69 -17.15 64.02 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.066 -1.255 . . . . 0.0 110.612 -174.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.508 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 89.3 mt -62.38 143.04 57.49 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.243 -0.911 . . . . 0.0 110.909 -177.627 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 1.037 ' C ' HD23 ' A' ' 12' ' ' LEU . 89.8 mttt -141.5 144.61 34.43 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 109.327 -0.619 . . . . 0.0 109.327 174.789 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.687 HG21 HG13 ' A' ' 15' ' ' ILE . 47.3 t -64.95 147.28 12.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 120.752 -1.217 . . . . 0.0 110.07 -176.86 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.55 -14.14 62.14 Favored Glycine 0 N--CA 1.483 1.807 0 N-CA-C 108.616 -1.794 . . . . 0.0 108.616 -173.039 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 39.6 t0 -96.09 166.85 11.55 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.387 -1.067 . . . . 0.0 109.504 175.648 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.58 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.2 m95 -117.64 166.92 11.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.044 -1.035 . . . . 0.0 110.199 177.311 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.008 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.3 p -132.39 156.57 42.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.382 -0.824 . . . . 0.0 109.984 -178.294 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.7 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.2 m-20 -79.53 105.63 10.97 Favored 'General case' 0 C--N 1.296 -1.752 0 O-C-N 121.03 -1.044 . . . . 0.0 109.097 169.096 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.979 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -110.24 141.92 24.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 120.382 -1.449 . . . . 0.0 110.873 -176.56 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.574 ' CG ' ' HB3' ' A' ' 43' ' ' ALA . 19.9 pt-20 -149.06 153.83 38.41 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 119.748 -0.781 . . . . 0.0 110.162 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 63.1 ttt180 -68.2 130.03 41.7 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.228 -0.92 . . . . 0.0 110.385 -178.065 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.87 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.489 1.516 0 O-C-N 121.371 -0.831 . . . . 0.0 109.489 176.494 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 0.693 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.5 t . . . . . 0 N--CA 1.493 1.714 0 CA-C-O 121.731 0.777 . . . . 0.0 110.527 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 88.2 mt-30 -69.97 -33.37 71.99 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.672 -0.642 . . . . 0.0 110.792 -178.888 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.542 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -153.62 174.52 32.2 Favored Glycine 0 N--CA 1.498 2.767 0 C-N-CA 119.073 -1.537 . . . . 0.0 110.441 -172.583 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.499 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 18.1 p -120.49 168.85 10.9 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.049 -1.265 . . . . 0.0 111.053 -177.254 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.049 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -137.96 149.64 46.32 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.549 -0.719 . . . . 0.0 109.396 -175.477 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.575 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 19.1 tttt -106.54 117.37 33.86 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.105 -0.997 . . . . 0.0 110.194 179.102 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 1.047 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.0 tp -60.02 128.38 36.55 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.0 -1.063 . . . . 0.0 108.818 172.532 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.117 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.45 -28.84 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.926 0 C-N-CA 119.684 -0.806 . . . . 0.0 110.136 -178.148 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.46 140.22 24.86 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.304 -0.958 . . . . 0.0 111.459 -178.929 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.754 HG23 ' CD2' ' B' ' 24' ' ' HIS . 6.7 mt -106.87 133.12 52.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.922 -1.111 . . . . 0.0 110.145 169.837 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.508 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 86.9 m-20 -110.04 114.53 28.13 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.555 -0.716 . . . . 0.0 110.026 173.82 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -103.85 116.52 32.44 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.096 -1.002 . . . . 0.0 110.379 -176.931 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.41 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -111.59 134.99 21.11 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.285 -0.884 . . . . 0.0 109.35 178.208 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_endo -51.85 -18.44 6.62 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 O-C-N 123.861 1.453 . . . . 0.0 110.734 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.573 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 5.3 m120 -96.91 -33.32 11.65 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.095 -1.003 . . . . 0.0 110.263 178.62 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.573 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 83.7 m-85 -157.52 150.43 23.25 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.293 -0.879 . . . . 0.0 110.215 -177.243 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 22' ' ' ARG . . . . . 0.503 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 65.9 ttt180 -90.61 144.06 26.13 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.926 -1.109 . . . . 0.0 110.074 176.569 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.508 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 96.0 m -129.77 140.03 51.15 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.684 -0.635 . . . . 0.0 109.728 -175.33 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.754 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.18 139.77 50.82 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.007 -1.058 . . . . 0.0 111.118 179.802 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.669 HG22 ' CB ' ' B' ' 60' ' ' SER . 3.9 t -120.51 132.55 69.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.197 -0.939 . . . . 0.0 110.436 -178.871 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.858 HG13 ' CE1' ' B' ' 61' ' ' PHE . 32.4 m -116.03 171.38 5.1 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 121.691 -0.631 . . . . 0.0 109.922 179.462 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.606 ' CG ' HD22 ' B' ' 57' ' ' ASN . 10.4 tt0 -108.48 115.71 30.62 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 -179.537 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.531 HD22 HD23 ' B' ' 36' ' ' LEU . 8.7 tp -86.69 127.94 58.41 Favored Pre-proline 0 C--N 1.296 -1.732 0 O-C-N 121.148 -0.97 . . . . 0.0 110.28 -172.098 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.495 ' HD2' HD12 ' B' ' 28' ' ' LEU . 29.1 Cg_endo -66.79 177.12 3.71 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 O-C-N 123.924 1.486 . . . . 0.0 111.056 -179.435 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.517 ' HA ' HD12 ' B' ' 33' ' ' LEU . 96.1 m-20 -60.09 -39.95 87.9 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.273 -0.892 . . . . 0.0 111.159 -174.233 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.603 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.05 0.73 56.97 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.79 -1.194 . . . . 0.0 110.862 -174.671 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.603 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.7 mmm -112.58 -11.86 13.52 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.981 -1.074 . . . . 0.0 109.971 172.255 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.591 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 19.9 mt -70.14 -39.9 75.12 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.354 -0.841 . . . . 0.0 110.185 177.783 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -73.98 143.11 45.75 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.499 -0.751 . . . . 0.0 110.532 -178.083 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.51 -39.01 3.01 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 119.954 -1.117 . . . . 0.0 110.505 173.904 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.531 HD23 HD22 ' B' ' 28' ' ' LEU . 50.5 tp -77.47 147.91 35.66 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.86 -1.377 . . . . 0.0 110.826 -174.056 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 37' ' ' GLU . . . . . 0.489 ' C ' HD11 ' B' ' 54' ' ' ILE . 21.4 pt-20 -149.12 166.59 28.31 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.454 -0.779 . . . . 0.0 109.5 177.85 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 38' ' ' THR . . . . . 0.844 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -64.98 147.7 52.96 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.85 -1.156 . . . . 0.0 109.942 179.366 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.06 -7.76 62.43 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -175.393 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.537 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -75.02 152.89 38.67 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.336 -1.096 . . . . 0.0 109.64 177.254 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.875 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.0 OUTLIER -96.09 110.03 22.35 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 120.882 -1.137 . . . . 0.0 110.059 175.39 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.65 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.0 t -93.08 130.01 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 173.301 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 0.581 ' HB3' ' CG ' ' B' ' 85' ' ' GLU . . . -93.38 119.67 32.77 Favored 'General case' 0 C--N 1.295 -1.789 0 C-N-CA 118.993 -1.083 . . . . 0.0 109.167 173.075 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.65 ' HE1' HG11 ' B' ' 42' ' ' VAL . 0.3 OUTLIER -90.26 105.62 17.93 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 177.712 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.0 t-20 58.81 7.77 0.83 Allowed 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.375 -0.828 . . . . 0.0 111.379 -170.08 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.408 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 125.45 -2.82 8.22 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.749 -1.215 . . . . 0.0 110.638 174.57 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.849 ' O ' HD23 ' B' ' 49' ' ' LEU . 32.7 t -94.56 108.08 20.05 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.597 -1.531 . . . . 0.0 109.867 176.732 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 18.2 p -70.07 128.68 37.14 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.133 -0.979 . . . . 0.0 110.842 -175.414 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 0.867 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -143.42 158.08 43.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.335 -0.853 . . . . 0.0 109.263 172.239 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 65.1 m -99.46 149.42 23.22 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.523 -1.361 . . . . 0.0 111.411 -170.191 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.935 HG13 HG13 ' B' ' 59' ' ' VAL . 20.7 t -77.19 114.82 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.839 -0.538 . . . . 0.0 110.434 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.53 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 53.7 p -69.38 -40.02 77.66 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.176 -0.953 . . . . 0.0 109.601 173.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.566 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 89.3 tt0 -161.51 156.38 23.38 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.77 -0.772 . . . . 0.0 110.128 -178.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.844 HD11 ' N ' ' B' ' 38' ' ' THR . 8.3 mt -108.85 129.16 63.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.096 -1.003 . . . . 0.0 110.088 175.05 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.542 ' HB2' ' CB ' ' B' ' 58' ' ' HIS . 8.5 m-80 -102.45 63.12 0.86 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.626 -0.671 . . . . 0.0 109.782 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.67 -118.0 5.34 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.695 -1.762 . . . . 0.0 108.695 -173.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.606 HD22 ' CG ' ' B' ' 27' ' ' GLU . 0.1 OUTLIER -74.87 -20.01 59.92 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 120.988 -1.301 . . . . 0.0 108.78 174.249 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.117 ' CD2' HG11 ' B' ' 13' ' ' VAL . 10.3 m170 -75.52 159.59 31.11 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.469 -0.769 . . . . 0.0 110.234 -177.219 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.935 HG13 HG13 ' B' ' 51' ' ' VAL . 54.3 t -140.46 123.09 16.15 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 O-C-N 121.063 -1.023 . . . . 0.0 110.55 171.247 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.669 ' CB ' HG22 ' B' ' 25' ' ' VAL . 17.4 m -89.69 128.78 36.14 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.586 -0.696 . . . . 0.0 109.519 177.675 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.867 ' HB2' HD12 ' B' ' 49' ' ' LEU . 2.4 p90 -124.21 152.37 43.0 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.965 -1.085 . . . . 0.0 110.186 178.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.53 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 33.0 p-10 -89.32 156.09 18.94 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 120.834 -1.166 . . . . 0.0 111.588 -171.119 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.944 HD22 HD13 ' B' ' 68' ' ' LEU . 0.2 OUTLIER -160.66 101.52 1.32 Allowed 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.696 -0.628 . . . . 0.0 109.656 -173.526 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.494 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 57.1 ttm -61.59 139.45 58.27 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.612 -1.305 . . . . 0.0 109.163 178.527 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.48 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 78.6 tttt -59.94 -47.81 84.26 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.86 -1.15 . . . . 0.0 110.384 -173.506 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -64.5 -40.0 94.83 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.943 -1.098 . . . . 0.0 109.843 177.814 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.494 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 94.2 m -61.24 -40.08 92.7 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.96 -1.087 . . . . 0.0 109.564 173.117 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.944 HD13 HD22 ' B' ' 63' ' ' LEU . 16.3 tp -59.92 -41.08 90.94 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.339 -0.851 . . . . 0.0 109.35 178.352 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -67.04 -40.07 87.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.415 -0.803 . . . . 0.0 110.449 173.829 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.791 HG22 HG23 ' B' ' 71' ' ' THR . 0.8 OUTLIER -65.51 -43.32 94.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.24 -0.913 . . . . 0.0 109.426 -175.599 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.791 HG23 HG22 ' B' ' 70' ' ' ILE . 25.1 p -84.36 -174.17 5.13 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.006 -0.678 . . . . 0.0 109.195 175.171 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.528 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 4.1 t30 -101.62 23.47 11.17 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 171.708 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.698 HD13 HD21 ' B' ' 63' ' ' LEU . 91.6 mt -70.04 -39.99 75.39 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.133 -0.979 . . . . 0.0 109.996 176.013 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.54 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -47.42 -22.7 1.69 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -178.856 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.4 p-10 -68.65 -17.08 64.03 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.057 -1.261 . . . . 0.0 110.647 -174.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 89.5 mt -62.32 143.08 57.39 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.2 -0.937 . . . . 0.0 110.912 -177.702 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 1.047 ' C ' HD23 ' B' ' 12' ' ' LEU . 89.8 mttt -141.64 144.58 34.23 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 174.785 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.696 HG21 HG13 ' B' ' 15' ' ' ILE . 47.2 t -64.9 147.31 12.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.885 -1.134 . . . . 0.0 110.062 -176.858 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.49 -14.07 62.23 Favored Glycine 0 N--CA 1.484 1.875 0 N-CA-C 108.67 -1.772 . . . . 0.0 108.67 -173.072 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 39.2 t0 -96.12 166.76 11.6 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.472 -1.016 . . . . 0.0 109.483 175.564 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.575 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.3 m95 -117.64 166.84 11.93 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.057 -1.027 . . . . 0.0 110.136 177.388 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 1.049 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.3 p -132.36 156.66 42.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.429 -0.794 . . . . 0.0 109.963 -178.427 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.693 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.1 m-20 -79.44 105.53 10.82 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.116 -0.99 . . . . 0.0 109.203 169.117 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.947 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -110.2 142.21 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 120.419 -1.425 . . . . 0.0 110.765 -176.399 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 85' ' ' GLU . . . . . 0.581 ' CG ' ' HB3' ' B' ' 43' ' ' ALA . 19.9 pt-20 -149.38 153.84 38.0 Favored 'General case' 0 N--CA 1.492 1.64 0 C-N-CA 119.779 -0.768 . . . . 0.0 110.05 179.249 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 63.2 ttt180 -68.14 129.97 41.51 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.181 -0.95 . . . . 0.0 110.432 -178.045 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.875 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.411 -0.806 . . . . 0.0 109.502 176.509 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.885 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.0 t . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.704 0.764 . . . . 0.0 110.835 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -70.06 -34.83 73.71 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.86 -0.525 . . . . 0.0 111.036 178.356 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.544 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -154.76 174.44 33.05 Favored Glycine 0 N--CA 1.496 2.641 0 C-N-CA 118.933 -1.603 . . . . 0.0 110.191 -172.1 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.441 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.3 p -119.99 170.45 9.26 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.944 -1.327 . . . . 0.0 111.2 -176.14 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 1.018 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -139.46 150.1 44.79 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -178.005 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 21.6 tttt -108.9 117.68 34.83 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.045 -1.034 . . . . 0.0 110.375 -179.552 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 1.023 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.0 tp -59.41 128.85 39.15 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.892 -1.13 . . . . 0.0 108.947 173.531 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.119 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.99 -28.82 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 C-N-CA 119.512 -0.875 . . . . 0.0 110.101 -178.802 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.93 140.56 23.5 Favored 'General case' 0 N--CA 1.493 1.696 0 C-N-CA 119.089 -1.045 . . . . 0.0 111.445 -178.375 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.744 HG23 ' CD2' ' A' ' 24' ' ' HIS . 14.1 mt -109.96 133.39 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.116 -0.99 . . . . 0.0 110.279 172.656 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.498 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 76.6 m-20 -108.54 116.12 31.37 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.335 -0.853 . . . . 0.0 109.883 172.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -107.64 115.33 29.95 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.948 -1.095 . . . . 0.0 110.735 -175.473 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.48 130.27 24.45 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.21 -0.931 . . . . 0.0 109.209 176.822 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -52.1 -19.79 9.51 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.792 1.417 . . . . 0.0 110.275 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.57 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 0.5 OUTLIER -83.54 -42.57 16.67 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.186 -0.946 . . . . 0.0 108.991 176.554 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.57 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 89.5 m-85 -156.98 150.32 24.14 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-O 121.307 0.575 . . . . 0.0 110.044 -177.674 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.484 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 60.2 ttt180 -89.49 143.59 26.7 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.898 -1.126 . . . . 0.0 110.116 177.673 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.498 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.3 m -128.74 135.04 48.67 Favored 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.548 -0.72 . . . . 0.0 109.827 -176.358 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.744 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -127.78 141.36 51.6 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.813 -1.18 . . . . 0.0 111.594 -179.449 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.885 HG22 ' OG ' ' A' ' 60' ' ' SER . 6.3 t -123.26 133.48 69.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.172 -0.955 . . . . 0.0 110.667 -179.397 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.669 HG13 ' HE2' ' A' ' 61' ' ' PHE . 36.0 m -117.66 172.47 5.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-O 121.233 0.539 . . . . 0.0 110.274 179.533 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.535 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 7.2 tt0 -100.22 116.96 33.44 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.313 -0.867 . . . . 0.0 109.071 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.657 ' HG ' HD23 ' A' ' 36' ' ' LEU 0.256 0.1 OUTLIER -86.81 114.82 59.99 Favored Pre-proline 0 C--N 1.295 -1.777 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -176.818 . . . . . . . . 4 4 . 1 . 009 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.57 ' HD2' HD13 ' A' ' 28' ' ' LEU . 18.9 Cg_endo -63.3 174.48 3.33 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.779 1.41 . . . . 0.0 111.187 -178.299 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.574 ' HA ' HD12 ' A' ' 33' ' ' LEU . 1.9 p30 -63.22 -35.54 80.65 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.452 -0.78 . . . . 0.0 111.269 -174.219 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.527 ' N ' ' OD1' ' A' ' 30' ' ' ASP . 0.0 OUTLIER -91.0 -0.19 57.69 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.728 -1.232 . . . . 0.0 111.057 -173.551 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.646 ' HB3' HD11 ' A' ' 28' ' ' LEU . 96.2 mmm -114.48 -14.32 12.15 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 120.925 -1.109 . . . . 0.0 109.815 168.89 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.655 HD21 ' HA ' ' A' ' 57' ' ' ASN . 12.4 mt -64.3 -40.04 95.14 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.163 -0.961 . . . . 0.0 109.932 177.653 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -63.98 131.53 47.93 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.32 -0.862 . . . . 0.0 110.484 -178.104 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.39 -39.26 3.08 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 175.149 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.657 HD23 ' HG ' ' A' ' 28' ' ' LEU . 60.8 tp -62.38 144.52 55.7 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.963 -1.316 . . . . 0.0 110.85 -175.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.467 ' C ' HD11 ' A' ' 54' ' ' ILE . 19.2 pt-20 -151.49 164.78 36.02 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.728 -0.607 . . . . 0.0 109.452 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.8 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -66.92 150.48 49.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.849 -1.157 . . . . 0.0 109.763 178.376 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.63 -0.06 62.0 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 -174.572 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.438 ' CB ' ' O ' ' A' ' 37' ' ' GLU . . . -75.38 158.99 31.92 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.228 -1.16 . . . . 0.0 109.279 175.358 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.692 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.6 OUTLIER -100.39 110.89 23.12 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 118.854 -1.138 . . . . 0.0 109.829 176.025 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.664 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.8 t -100.1 125.67 53.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.457 -0.777 . . . . 0.0 109.041 175.688 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.48 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -92.0 119.78 32.03 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 119.041 -1.064 . . . . 0.0 109.242 172.401 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.688 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.6 OUTLIER -87.98 103.02 15.3 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 177.922 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.5 t-20 57.16 11.17 0.98 Allowed 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.455 -0.778 . . . . 0.0 111.141 -170.474 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 123.84 -0.21 9.17 Favored Glycine 0 N--CA 1.489 2.233 0 C-N-CA 119.584 -1.293 . . . . 0.0 110.605 174.621 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.834 ' O ' HD23 ' A' ' 49' ' ' LEU . 16.7 t -98.74 105.39 17.53 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.41 -1.641 . . . . 0.0 109.535 175.604 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.409 ' HA ' ' HA ' ' A' ' 43' ' ' ALA . 15.9 p -74.05 129.0 36.99 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.983 -1.073 . . . . 0.0 110.855 -172.368 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.864 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -142.95 160.84 39.59 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.377 -0.827 . . . . 0.0 109.605 173.739 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 6.6 m -100.43 148.1 25.12 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.552 -1.342 . . . . 0.0 111.237 -170.09 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.948 HG13 HG13 ' A' ' 59' ' ' VAL . 21.0 t -76.21 115.32 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.892 -0.505 . . . . 0.0 110.475 -179.361 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.534 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 30.4 p -70.46 -40.02 73.93 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.247 -0.908 . . . . 0.0 109.789 173.656 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.57 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -162.64 154.49 18.36 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.288 -0.882 . . . . 0.0 110.313 -179.479 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.8 HD11 ' N ' ' A' ' 38' ' ' THR . 7.6 mt -105.72 130.52 57.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.159 -0.963 . . . . 0.0 110.088 176.367 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.5 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 4.7 m-80 -102.51 64.39 0.9 Allowed 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.61 -0.681 . . . . 0.0 109.822 179.027 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.2 -119.5 5.9 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.774 -1.73 . . . . 0.0 108.774 -173.75 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.655 ' HA ' HD21 ' A' ' 33' ' ' LEU . 0.1 OUTLIER -73.12 -22.1 60.61 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 120.878 -1.366 . . . . 0.0 108.643 174.315 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.119 ' CD2' HG11 ' A' ' 13' ' ' VAL . 12.3 m80 -74.02 159.97 31.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.283 -0.885 . . . . 0.0 110.431 -176.579 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.948 HG13 HG13 ' A' ' 51' ' ' VAL . 51.4 t -139.98 125.38 20.77 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 121.084 -1.01 . . . . 0.0 110.706 170.526 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.885 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.7 t -91.6 135.08 34.13 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.444 -0.785 . . . . 0.0 109.274 175.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.864 ' HB2' HD12 ' A' ' 49' ' ' LEU . 8.8 p90 -128.35 154.39 46.02 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 121.304 -0.872 . . . . 0.0 110.483 177.141 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.534 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 28.9 p-10 -89.67 150.85 22.16 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.157 -0.965 . . . . 0.0 111.332 -171.616 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.7 HD21 HD13 ' A' ' 73' ' ' LEU . 0.0 OUTLIER -155.6 117.6 4.09 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -176.079 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.54 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 52.6 mtt -68.46 142.33 55.37 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.786 -1.196 . . . . 0.0 109.518 177.425 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.475 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 86.0 tttt -59.97 -44.59 94.36 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 120.991 -1.068 . . . . 0.0 109.715 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 52.5 tp10 -70.04 -39.93 75.43 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.189 -0.944 . . . . 0.0 110.235 178.415 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.54 ' HB ' ' HB2' ' A' ' 64' ' ' MET . 89.5 m -61.41 -37.81 84.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.795 -1.191 . . . . 0.0 109.084 172.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.581 ' CD1' HD22 ' A' ' 63' ' ' LEU . 7.1 tp -60.07 -44.32 94.84 Favored 'General case' 0 C--N 1.297 -1.69 0 O-C-N 121.143 -0.973 . . . . 0.0 109.193 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 52.0 ttt85 -70.08 -39.91 75.3 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.456 -0.777 . . . . 0.0 110.52 175.501 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.863 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -62.72 -41.38 92.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.176 -0.953 . . . . 0.0 109.072 -177.719 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.863 HG23 HG22 ' A' ' 70' ' ' ILE . 31.2 p -88.93 -176.76 5.29 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 175.765 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.481 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 2.4 t30 -100.18 25.08 7.87 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 172.112 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.7 HD13 HD21 ' A' ' 63' ' ' LEU . 55.7 mt -69.85 -39.99 76.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.941 -1.099 . . . . 0.0 109.861 174.556 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.541 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -48.12 -22.76 2.38 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 -179.034 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.0 p-10 -64.89 -17.38 64.26 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.151 -1.205 . . . . 0.0 110.5 -176.369 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 90.3 mt -62.06 144.02 55.8 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.299 -0.875 . . . . 0.0 110.889 -176.724 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 1.023 ' C ' HD23 ' A' ' 12' ' ' LEU . 35.0 mttp -143.83 143.86 31.51 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.747 -0.596 . . . . 0.0 109.41 174.13 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.67 ' N ' HD23 ' A' ' 12' ' ' LEU . 14.9 t -61.77 150.06 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 120.637 -1.289 . . . . 0.0 110.107 -176.722 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.35 -12.15 61.48 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 108.927 -1.669 . . . . 0.0 108.927 -176.361 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 48.7 t0 -95.77 166.27 11.89 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.312 -1.111 . . . . 0.0 109.496 176.236 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.6 m95 -117.43 156.63 27.62 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.987 -1.071 . . . . 0.0 110.524 178.728 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.018 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.1 p -120.05 150.88 22.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.516 -0.74 . . . . 0.0 109.874 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.885 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.3 OUTLIER -76.82 106.28 8.4 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.072 -1.018 . . . . 0.0 108.951 168.966 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.67 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -105.97 138.52 30.89 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 120.425 -1.422 . . . . 0.0 111.5 -175.223 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.431 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.8 tt0 -133.3 140.67 47.58 Favored 'General case' 0 N--CA 1.496 1.829 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.178 -179.318 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 71.6 ttt-85 -80.31 134.17 36.04 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.195 -0.94 . . . . 0.0 111.148 -175.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.692 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.734 0 O-C-N 121.409 -0.807 . . . . 0.0 110.28 179.361 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 0.874 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.0 t . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 121.739 0.78 . . . . 0.0 110.798 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -70.01 -34.71 73.65 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.79 -0.569 . . . . 0.0 111.063 178.342 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.542 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -154.96 174.33 33.2 Favored Glycine 0 N--CA 1.495 2.58 0 C-N-CA 118.902 -1.618 . . . . 0.0 110.248 -172.03 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.446 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.5 p -119.9 170.42 9.27 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.892 -1.358 . . . . 0.0 111.173 -176.016 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.067 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -139.53 150.17 44.78 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -178.157 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.57 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 21.6 tttt -108.82 117.83 35.22 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.115 -0.991 . . . . 0.0 110.346 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 1.006 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.0 tp -59.68 128.74 38.47 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 120.936 -1.102 . . . . 0.0 109.019 173.521 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.132 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.81 -28.9 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 O-C-N 121.33 -0.856 . . . . 0.0 110.139 -178.719 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.91 140.66 23.59 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.294 -0.962 . . . . 0.0 111.401 -178.371 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.766 HG23 ' CD2' ' B' ' 24' ' ' HIS . 14.1 mt -109.99 133.38 55.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.177 -0.952 . . . . 0.0 110.244 172.695 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.509 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 76.2 m-20 -108.61 116.23 31.58 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.344 -0.847 . . . . 0.0 109.706 173.01 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 99.9 mt-10 -107.72 115.37 30.03 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.917 -1.114 . . . . 0.0 110.717 -175.569 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.413 ' HA ' ' HD2' ' B' ' 19' ' ' PRO . 0.0 OUTLIER -115.55 130.27 24.46 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.269 -0.894 . . . . 0.0 109.294 176.82 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 19' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.7 Cg_endo -52.32 -19.77 10.13 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.731 1.385 . . . . 0.0 110.21 -179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.569 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 0.5 OUTLIER -83.28 -43.16 16.34 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.26 -0.9 . . . . 0.0 108.867 176.508 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.569 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 89.6 m-85 -156.54 150.36 24.87 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.813 -0.555 . . . . 0.0 110.028 -177.535 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 22' ' ' ARG . . . . . 0.481 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 60.2 ttt180 -89.37 143.52 26.76 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.942 -1.098 . . . . 0.0 110.152 177.585 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.509 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 94.3 m -128.64 135.04 48.77 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.648 -0.657 . . . . 0.0 109.89 -176.517 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.766 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -127.61 141.54 51.6 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.824 -1.173 . . . . 0.0 111.534 -179.466 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.882 HG22 ' OG ' ' B' ' 60' ' ' SER . 6.2 t -123.32 133.63 68.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.189 -0.945 . . . . 0.0 110.654 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.677 HG13 ' HE2' ' B' ' 61' ' ' PHE . 35.2 m -118.03 172.29 5.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.798 -0.564 . . . . 0.0 110.227 179.581 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.525 ' CB ' ' HB3' ' B' ' 11' ' ' LYS . 7.2 tt0 -99.99 117.06 33.47 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.321 -0.862 . . . . 0.0 109.058 179.184 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.678 HD11 ' HB3' ' B' ' 32' ' ' MET 0.255 0.1 OUTLIER -86.83 114.84 60.1 Favored Pre-proline 0 C--N 1.296 -1.723 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 -176.922 . . . . . . . . 4 4 . 1 . 009 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.6 ' HD2' HD13 ' B' ' 28' ' ' LEU . 19.0 Cg_endo -63.3 174.6 3.23 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.744 1.392 . . . . 0.0 111.267 -178.306 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.584 ' HA ' HD12 ' B' ' 33' ' ' LEU . 1.9 p30 -63.35 -35.56 80.81 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.484 -0.76 . . . . 0.0 111.169 -174.206 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.521 ' N ' ' OD1' ' B' ' 30' ' ' ASP . 0.0 OUTLIER -91.05 -0.02 57.64 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.738 -1.226 . . . . 0.0 110.997 -173.51 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.678 ' HB3' HD11 ' B' ' 28' ' ' LEU . 96.2 mmm -114.48 -14.34 12.15 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 120.881 -1.137 . . . . 0.0 109.806 168.83 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.649 HD21 ' HA ' ' B' ' 57' ' ' ASN . 12.4 mt -64.35 -39.96 94.93 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.184 -0.948 . . . . 0.0 109.989 177.642 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -64.02 131.51 47.82 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.307 -0.87 . . . . 0.0 110.497 -178.123 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.47 -39.31 3.07 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.329 -1.109 . . . . 0.0 110.329 175.207 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.664 HD23 ' HG ' ' B' ' 28' ' ' LEU . 60.7 tp -62.37 144.57 55.62 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.872 -1.37 . . . . 0.0 110.883 -175.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 37' ' ' GLU . . . . . 0.455 ' C ' HD11 ' B' ' 54' ' ' ILE . 19.2 pt-20 -151.57 164.78 36.09 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.658 -0.651 . . . . 0.0 109.36 -179.629 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 38' ' ' THR . . . . . 0.799 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.92 150.48 49.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.784 -1.198 . . . . 0.0 109.827 178.332 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.61 -0.01 62.03 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -174.535 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.435 ' CB ' ' O ' ' B' ' 37' ' ' GLU . . . -75.51 158.97 31.82 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.191 -1.182 . . . . 0.0 109.23 175.293 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.684 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.7 OUTLIER -100.21 110.64 22.9 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.977 -1.077 . . . . 0.0 109.901 176.018 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.648 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.8 t -99.95 125.69 53.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.427 -0.796 . . . . 0.0 109.081 175.627 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -91.98 119.73 31.97 Favored 'General case' 0 C--N 1.297 -1.712 0 C-N-CA 119.056 -1.058 . . . . 0.0 109.274 172.349 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.684 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.6 OUTLIER -87.94 102.95 15.22 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.417 -0.802 . . . . 0.0 108.968 177.887 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.6 t-20 57.32 11.11 1.04 Allowed 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.439 -0.788 . . . . 0.0 111.113 -170.537 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 123.77 0.2 9.17 Favored Glycine 0 N--CA 1.489 2.225 0 C-N-CA 119.653 -1.261 . . . . 0.0 110.609 174.509 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.826 ' O ' HD23 ' B' ' 49' ' ' LEU . 16.9 t -98.99 105.49 17.64 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.465 -1.609 . . . . 0.0 109.464 175.488 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 48' ' ' CYS . . . . . 0.411 ' HA ' ' HA ' ' B' ' 43' ' ' ALA . 15.9 p -74.06 129.02 37.03 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.012 -1.055 . . . . 0.0 110.802 -172.39 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 0.883 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -143.05 160.79 39.71 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.396 -0.815 . . . . 0.0 109.484 173.751 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 6.6 m -100.27 148.22 24.89 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 120.647 -1.283 . . . . 0.0 111.255 -170.128 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.981 HG13 HG13 ' B' ' 59' ' ' VAL . 21.2 t -76.46 115.24 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.716 -0.615 . . . . 0.0 110.479 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.536 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 30.3 p -70.39 -40.01 74.2 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.213 -0.929 . . . . 0.0 109.818 173.722 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.569 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -162.63 154.48 18.37 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.406 -0.809 . . . . 0.0 110.265 -179.525 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.799 HD11 ' N ' ' B' ' 38' ' ' THR . 7.6 mt -105.6 130.46 56.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.11 -0.994 . . . . 0.0 110.173 176.323 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.511 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 4.6 m-80 -102.53 64.41 0.89 Allowed 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.659 -0.651 . . . . 0.0 109.737 179.082 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.32 -119.52 5.87 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 108.739 -1.744 . . . . 0.0 108.739 -173.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.649 ' HA ' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -73.08 -22.09 60.65 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.894 -1.357 . . . . 0.0 108.753 174.216 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.132 ' CD2' HG11 ' B' ' 13' ' ' VAL . 12.4 m80 -74.07 160.05 31.81 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.257 -0.902 . . . . 0.0 110.421 -176.588 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.981 HG13 HG13 ' B' ' 51' ' ' VAL . 50.7 t -140.14 125.35 20.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 C-N-CA 119.107 -1.037 . . . . 0.0 110.595 170.692 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.882 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.7 t -91.57 135.25 34.0 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.5 -0.75 . . . . 0.0 109.284 175.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.883 ' HB2' HD12 ' B' ' 49' ' ' LEU . 8.7 p90 -128.46 154.46 46.05 Favored 'General case' 0 N--CA 1.496 1.828 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.417 177.099 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.536 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 29.2 p-10 -89.75 150.83 22.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.059 -1.026 . . . . 0.0 111.246 -171.554 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.68 HD21 HD13 ' B' ' 73' ' ' LEU . 0.0 OUTLIER -155.57 117.6 4.09 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -176.125 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.535 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 52.9 mtt -68.38 142.32 55.47 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.889 -1.132 . . . . 0.0 109.463 177.538 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.474 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 86.0 tttt -60.06 -44.54 94.64 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.072 -1.017 . . . . 0.0 109.635 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 52.5 tp10 -69.99 -39.92 75.62 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.148 -0.97 . . . . 0.0 110.328 178.415 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.535 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 89.2 m -61.38 -38.04 85.59 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.776 -1.203 . . . . 0.0 108.99 172.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.591 ' CD1' HD22 ' B' ' 63' ' ' LEU . 7.0 tp -59.99 -44.23 94.66 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.235 -0.916 . . . . 0.0 109.289 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 52.0 ttt85 -70.03 -39.93 75.48 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.38 -0.825 . . . . 0.0 110.563 175.429 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.828 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -62.73 -41.28 91.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 CA-C-O 121.917 0.865 . . . . 0.0 109.07 -177.743 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.828 HG23 HG22 ' B' ' 70' ' ' ILE . 31.5 p -89.0 -176.63 5.23 Favored 'General case' 0 C--N 1.3 -1.565 0 C-N-CA 120.2 -0.6 . . . . 0.0 109.394 175.859 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.48 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 2.3 t30 -100.17 25.11 7.83 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 172.144 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.68 HD13 HD21 ' B' ' 63' ' ' LEU . 54.8 mt -69.89 -40.0 75.92 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.894 -1.129 . . . . 0.0 109.848 174.569 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.527 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -48.16 -22.63 2.36 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 -179.021 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.5 p-10 -64.89 -17.51 64.39 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.189 -1.183 . . . . 0.0 110.438 -176.392 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 90.2 mt -62.08 143.95 55.93 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.256 -0.902 . . . . 0.0 110.871 -176.601 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 1.006 ' C ' HD23 ' B' ' 12' ' ' LEU . 35.0 mttp -143.76 143.95 31.6 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.637 -0.664 . . . . 0.0 109.395 174.123 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.662 ' N ' HD23 ' B' ' 12' ' ' LEU . 15.3 t -61.78 150.05 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.666 -1.271 . . . . 0.0 110.057 -176.634 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.2 -11.95 61.67 Favored Glycine 0 N--CA 1.484 1.868 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -176.39 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 48.5 t0 -95.81 166.25 11.9 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.386 -1.067 . . . . 0.0 109.458 176.051 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.57 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.6 m95 -117.4 156.62 27.6 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.051 -1.03 . . . . 0.0 110.516 178.759 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 1.067 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.1 p -120.14 150.94 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.569 -0.707 . . . . 0.0 109.807 179.683 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.874 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.3 OUTLIER -76.79 106.14 8.29 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.037 -1.039 . . . . 0.0 109.014 168.971 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.665 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -105.9 138.71 29.91 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 120.476 -1.39 . . . . 0.0 111.454 -175.118 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 85' ' ' GLU . . . . . 0.435 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.7 tt0 -133.42 140.69 47.46 Favored 'General case' 0 N--CA 1.495 1.824 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.191 -179.364 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 71.7 ttt-85 -80.33 134.29 36.04 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.16 -0.962 . . . . 0.0 111.029 -175.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.684 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.744 0 O-C-N 121.267 -0.896 . . . . 0.0 110.271 179.372 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.903 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.7 t . . . . . 0 N--CA 1.493 1.725 0 CA-C-O 121.332 0.587 . . . . 0.0 110.287 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -81.23 -26.29 35.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.427 -0.796 . . . . 0.0 110.891 -179.063 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.533 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -153.92 176.71 31.74 Favored Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.288 -1.434 . . . . 0.0 109.922 -176.086 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.472 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 18.4 p -123.34 170.01 10.75 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.942 -1.328 . . . . 0.0 110.839 -178.444 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 1.041 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -137.36 149.89 47.31 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.557 -0.715 . . . . 0.0 109.65 -177.076 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.583 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 36.9 tttt -104.07 117.86 35.28 Favored 'General case' 0 C--N 1.296 -1.731 0 O-C-N 120.901 -1.124 . . . . 0.0 110.355 178.673 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 1.021 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.1 tp -61.44 126.14 26.29 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.861 -1.15 . . . . 0.0 108.749 171.482 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.101 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.5 p -127.38 -28.86 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.934 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.004 -178.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -148.76 141.02 24.06 Favored 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 118.964 -1.094 . . . . 0.0 111.225 178.824 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.852 HG23 ' CD2' ' A' ' 24' ' ' HIS . 13.6 mt -105.54 138.22 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.007 -1.058 . . . . 0.0 110.062 171.372 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.509 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 83.7 m-20 -110.83 114.66 28.18 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.25 -0.906 . . . . 0.0 109.932 173.789 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -103.35 112.65 25.63 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.017 -1.052 . . . . 0.0 110.374 -178.008 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.456 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 19.7 mtmt -107.02 132.77 20.65 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.296 -0.877 . . . . 0.0 109.282 177.338 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.9 Cg_endo -51.84 -18.9 7.2 Favored 'Trans proline' 0 C--N 1.303 -1.851 0 O-C-N 123.879 1.462 . . . . 0.0 110.745 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.57 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 7.8 m-80 -95.77 -33.06 12.42 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.125 -0.984 . . . . 0.0 110.204 178.298 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.57 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 98.2 m-85 -157.46 150.29 23.23 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.363 -0.836 . . . . 0.0 110.318 -177.92 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -87.76 145.88 25.91 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.898 -1.126 . . . . 0.0 110.108 177.318 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.509 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 92.5 m -133.89 145.37 49.56 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.455 -0.778 . . . . 0.0 109.748 -176.418 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.852 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.4 OUTLIER -135.35 135.27 40.59 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.781 -1.199 . . . . 0.0 111.476 -177.879 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.634 HG22 ' CB ' ' A' ' 60' ' ' SER . 9.7 t -114.43 132.77 62.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.092 -1.005 . . . . 0.0 110.814 -179.127 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.442 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 17.4 m -118.11 170.92 6.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 CA-C-O 121.177 0.513 . . . . 0.0 110.106 179.217 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.658 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 13.5 tt0 -102.64 118.92 37.91 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.329 -0.857 . . . . 0.0 109.096 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.5 ' HB3' ' CD2' ' A' ' 33' ' ' LEU . 10.2 tp -83.59 123.77 76.1 Favored Pre-proline 0 C--N 1.3 -1.567 0 C-N-CA 119.969 -0.692 . . . . 0.0 109.739 -175.345 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.486 ' HD2' HD12 ' A' ' 28' ' ' LEU . 25.9 Cg_endo -66.18 175.31 4.97 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 O-C-N 123.843 1.444 . . . . 0.0 111.035 -179.298 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.402 ' HA ' HD12 ' A' ' 33' ' ' LEU . 57.8 t0 -59.86 -39.77 86.34 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.387 -0.821 . . . . 0.0 110.831 -175.714 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.602 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -88.76 1.08 55.82 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.941 -1.1 . . . . 0.0 110.633 -175.004 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.602 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 93.5 mmm -112.17 -14.16 13.42 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.989 -1.069 . . . . 0.0 109.916 170.683 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.589 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 19.6 mt -69.96 -39.92 75.72 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.454 -0.779 . . . . 0.0 110.516 178.422 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -82.26 113.57 20.16 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.281 -0.887 . . . . 0.0 110.437 -176.67 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.8 -52.62 0.7 Allowed Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.835 -1.174 . . . . 0.0 110.415 175.467 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.635 HD11 ' CG2' ' A' ' 42' ' ' VAL . 5.1 tt -66.37 152.21 45.51 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.93 -1.335 . . . . 0.0 110.756 -173.396 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.524 ' C ' HD11 ' A' ' 54' ' ' ILE . 11.3 pt-20 -150.76 169.96 20.39 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.477 -0.764 . . . . 0.0 109.752 -177.271 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.828 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -65.43 158.4 26.84 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.951 -1.093 . . . . 0.0 110.38 -178.27 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 71.51 2.71 51.1 Favored Glycine 0 N--CA 1.495 2.57 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 -178.229 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.559 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -82.52 163.73 21.35 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.227 -1.161 . . . . 0.0 109.768 177.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.784 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 1.0 OUTLIER -104.52 112.77 25.97 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.982 -1.074 . . . . 0.0 109.985 176.491 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.635 ' CG2' HD11 ' A' ' 36' ' ' LEU . 2.0 t -102.83 130.96 52.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.377 -0.827 . . . . 0.0 108.931 173.866 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.501 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -91.45 120.05 31.95 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.214 -0.995 . . . . 0.0 109.092 172.272 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.667 ' CD2' HG21 ' A' ' 82' ' ' VAL . 0.3 OUTLIER -90.3 107.9 19.43 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 177.112 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' B' ' 45' ' ' ASN . 0.9 OUTLIER 52.98 13.09 0.33 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.47 -0.769 . . . . 0.0 111.688 -167.149 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 121.22 -2.59 11.48 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.441 -1.362 . . . . 0.0 110.855 172.257 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.789 ' O ' HD23 ' A' ' 49' ' ' LEU . 35.5 t -94.25 109.0 20.84 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.402 -1.646 . . . . 0.0 109.448 174.829 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.3 p -76.99 124.65 28.08 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.105 -0.997 . . . . 0.0 110.836 -172.443 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.882 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -140.02 159.98 40.95 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.507 -0.745 . . . . 0.0 109.145 173.805 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.474 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 28.5 m -97.03 160.84 14.11 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.654 -1.278 . . . . 0.0 111.179 -170.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.756 HG22 ' CE1' ' A' ' 61' ' ' PHE . 18.8 t -84.69 116.39 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.854 -0.529 . . . . 0.0 110.372 -177.376 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.552 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 77.4 p -70.02 -40.02 75.47 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.252 -0.905 . . . . 0.0 109.667 173.793 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.552 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 54.4 tp10 -164.86 157.9 16.77 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.576 -176.364 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.828 HD11 ' N ' ' A' ' 38' ' ' THR . 8.7 mt -110.44 129.93 64.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.173 -0.954 . . . . 0.0 109.807 172.608 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.522 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 29.0 m-80 -102.35 64.05 0.9 Allowed 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.738 -0.601 . . . . 0.0 109.474 179.037 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.87 -114.28 4.3 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -172.18 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.589 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -78.82 -22.43 46.21 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 120.94 -1.33 . . . . 0.0 109.3 175.314 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.101 ' CE1' HG11 ' A' ' 13' ' ' VAL . 23.9 m-70 -74.43 159.94 31.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.271 -0.893 . . . . 0.0 110.052 -177.489 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.713 HG13 HG13 ' A' ' 51' ' ' VAL . 78.4 t -140.0 120.04 13.38 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 O-C-N 121.103 -0.998 . . . . 0.0 110.693 173.317 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.634 ' CB ' HG22 ' A' ' 25' ' ' VAL . 6.5 t -83.13 138.02 33.84 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.424 -0.798 . . . . 0.0 109.531 176.055 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.882 ' HB3' HD12 ' A' ' 49' ' ' LEU . 87.0 m-85 -120.2 160.52 22.75 Favored 'General case' 0 C--N 1.295 -1.788 0 O-C-N 121.336 -0.853 . . . . 0.0 110.543 177.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.552 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 32.9 p-10 -95.46 148.2 22.73 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.247 -0.908 . . . . 0.0 111.1 179.21 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.745 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -157.23 121.92 4.43 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -176.762 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.506 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 26.8 ttt -82.19 141.87 32.66 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.983 -1.073 . . . . 0.0 109.669 -178.141 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.484 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 83.3 tttt -60.0 -48.26 82.44 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.094 -1.003 . . . . 0.0 110.611 -173.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.2 tp10 -68.08 -40.06 82.77 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 120.793 -1.192 . . . . 0.0 109.94 179.014 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.506 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 87.4 m -60.01 -39.02 84.37 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.976 -1.078 . . . . 0.0 109.257 173.007 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.775 HD11 ' HA2' ' A' ' 74' ' ' GLY . 2.0 tp -59.98 -45.38 92.9 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.23 -0.919 . . . . 0.0 109.706 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -67.05 -39.96 87.04 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.329 -0.857 . . . . 0.0 110.363 176.929 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.708 HG22 HG23 ' A' ' 71' ' ' THR . 1.1 tt -66.04 -40.14 86.43 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.294 -0.879 . . . . 0.0 109.258 -176.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.708 HG23 HG22 ' A' ' 70' ' ' ILE . 52.3 p -84.92 -169.77 2.81 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 121.362 0.601 . . . . 0.0 109.524 175.28 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.475 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 7.1 t30 -105.97 22.92 14.83 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 170.445 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.745 ' HB3' HD21 ' A' ' 63' ' ' LEU . 88.5 mt -69.95 -40.03 75.69 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.199 -0.938 . . . . 0.0 110.219 178.289 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.775 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -50.16 -21.6 4.21 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -177.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.4 p-10 -69.19 -17.45 63.8 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.98 -1.306 . . . . 0.0 110.753 -173.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.513 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 95.9 mt -60.01 141.02 56.38 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.105 -0.997 . . . . 0.0 110.709 -176.818 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 1.021 ' C ' HD23 ' A' ' 12' ' ' LEU . 66.4 mttm -140.0 139.07 35.94 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 121.514 0.674 . . . . 0.0 109.88 175.651 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.665 ' N ' HD23 ' A' ' 12' ' ' LEU . 22.0 t -61.08 152.77 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 120.906 -1.122 . . . . 0.0 110.376 -176.393 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.83 -16.08 57.61 Favored Glycine 0 N--CA 1.482 1.725 0 N-CA-C 108.729 -1.748 . . . . 0.0 108.729 -176.181 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.9 t0 -97.39 169.72 9.56 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.344 -1.091 . . . . 0.0 109.544 175.645 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.583 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.2 m95 -117.26 166.57 12.12 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.03 -1.044 . . . . 0.0 110.045 177.306 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.041 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.3 p -128.69 157.47 41.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.283 -0.886 . . . . 0.0 110.03 -177.798 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.903 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.2 m-20 -83.54 104.71 13.89 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.177 -0.952 . . . . 0.0 109.083 170.821 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.703 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -107.54 139.27 30.0 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.781 0 O-C-N 120.444 -1.41 . . . . 0.0 111.287 -174.826 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.456 ' HB2' HG22 ' A' ' 6' ' ' VAL . 85.2 tt0 -139.58 138.48 36.25 Favored 'General case' 0 N--CA 1.492 1.674 0 C-N-CA 120.355 -0.538 . . . . 0.0 109.837 -178.612 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.489 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 39.0 ptt180 -73.02 137.72 45.55 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.983 -1.073 . . . . 0.0 110.664 -174.151 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.784 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.254 -0.904 . . . . 0.0 109.923 173.788 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 0.859 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.7 t . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.398 0.618 . . . . 0.0 110.291 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 17.4 pt20 -81.43 -25.96 35.74 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.38 -0.825 . . . . 0.0 110.887 -178.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.536 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -154.09 176.58 31.92 Favored Glycine 0 N--CA 1.494 2.559 0 C-N-CA 119.423 -1.37 . . . . 0.0 109.958 -176.1 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.468 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 18.4 p -123.32 170.05 10.69 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.951 -1.323 . . . . 0.0 110.838 -178.432 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.039 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -137.39 149.9 47.29 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.582 -0.699 . . . . 0.0 109.607 -177.143 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.574 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 36.9 tttt -104.13 117.98 35.55 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.961 -1.087 . . . . 0.0 110.304 178.615 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 1.019 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.1 tp -61.58 126.04 25.94 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.018 -1.051 . . . . 0.0 108.804 171.48 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.077 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.5 p -127.1 -29.12 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.979 0 O-C-N 121.371 -0.831 . . . . 0.0 110.054 -178.892 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -148.67 141.0 24.15 Favored 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 119.263 -0.975 . . . . 0.0 111.357 178.834 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.861 HG23 ' CD2' ' B' ' 24' ' ' HIS . 13.6 mt -105.6 138.32 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.996 -1.065 . . . . 0.0 110.082 171.373 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.525 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.6 m-20 -110.89 114.79 28.4 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.317 -0.865 . . . . 0.0 109.842 173.926 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -103.44 112.54 25.48 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.002 -1.061 . . . . 0.0 110.363 -177.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 19.6 mtmt -107.0 132.72 20.68 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.382 -0.823 . . . . 0.0 109.317 177.34 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -51.92 -18.79 7.3 Favored 'Trans proline' 0 C--N 1.304 -1.782 0 O-C-N 123.832 1.438 . . . . 0.0 110.716 -179.527 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.57 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 7.9 m-80 -95.64 -33.68 12.26 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.107 -0.996 . . . . 0.0 110.068 178.291 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.57 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 98.2 m-85 -157.0 150.29 24.09 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.352 -0.843 . . . . 0.0 110.412 -177.82 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -87.68 145.73 26.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.042 -1.036 . . . . 0.0 110.196 177.265 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.525 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 92.7 m -133.85 145.39 49.65 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.386 -0.821 . . . . 0.0 109.755 -176.483 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.861 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.4 OUTLIER -135.24 135.41 40.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.927 -1.108 . . . . 0.0 111.447 -177.804 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.65 HG22 ' CB ' ' B' ' 60' ' ' SER . 9.8 t -114.48 133.01 61.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 110.789 -179.119 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.449 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 17.7 m -118.45 170.85 7.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 CA-C-O 121.237 0.541 . . . . 0.0 109.988 179.357 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.655 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 13.5 tt0 -102.55 119.03 38.13 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.365 -0.834 . . . . 0.0 109.122 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.522 HD12 ' HA ' ' B' ' 28' ' ' LEU . 10.3 tp -83.68 123.75 75.94 Favored Pre-proline 0 C--N 1.299 -1.589 0 O-C-N 121.443 -0.786 . . . . 0.0 109.76 -175.358 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.496 ' HD2' HD12 ' B' ' 28' ' ' LEU . 25.8 Cg_endo -66.17 175.44 4.84 Favored 'Trans proline' 0 C--N 1.309 -1.538 0 O-C-N 123.851 1.448 . . . . 0.0 111.049 -179.221 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.411 ' HA ' HD12 ' B' ' 33' ' ' LEU . 58.0 t0 -60.07 -39.68 86.89 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.368 -0.833 . . . . 0.0 110.8 -175.655 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.607 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -88.78 1.08 55.83 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.819 -1.176 . . . . 0.0 110.695 -175.073 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.607 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 93.5 mmm -112.14 -14.13 13.44 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.961 -1.087 . . . . 0.0 109.92 170.628 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.594 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 19.7 mt -70.04 -39.91 75.46 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.366 -0.834 . . . . 0.0 110.511 178.442 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -82.2 113.56 20.12 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.296 -0.878 . . . . 0.0 110.436 -176.745 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.79 -52.64 0.7 Allowed Glycine 0 N--CA 1.491 2.335 0 C-N-CA 119.834 -1.174 . . . . 0.0 110.422 175.436 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.628 HD11 ' CG2' ' B' ' 42' ' ' VAL . 5.2 tt -66.39 152.2 45.57 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.916 -1.344 . . . . 0.0 110.807 -173.404 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 37' ' ' GLU . . . . . 0.503 ' C ' HD11 ' B' ' 54' ' ' ILE . 11.3 pt-20 -150.69 169.99 20.27 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.402 -0.811 . . . . 0.0 109.733 -177.249 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 38' ' ' THR . . . . . 0.835 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -65.41 158.36 26.9 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.958 -1.089 . . . . 0.0 110.425 -178.303 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 39' ' ' GLY . . . . . 0.403 ' N ' ' HB ' ' B' ' 51' ' ' VAL . . . 71.54 2.64 50.83 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.966 -1.253 . . . . 0.0 109.966 -178.233 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.558 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -82.54 163.47 21.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.226 -1.161 . . . . 0.0 109.817 177.854 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.784 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 1.0 OUTLIER -104.21 112.59 25.67 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.893 -1.129 . . . . 0.0 110.078 176.546 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.628 ' CG2' HD11 ' B' ' 36' ' ' LEU . 2.0 t -102.78 131.01 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.389 -0.819 . . . . 0.0 108.947 173.816 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 0.496 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -91.44 119.98 31.88 Favored 'General case' 0 C--N 1.296 -1.718 0 O-C-N 121.128 -0.983 . . . . 0.0 109.196 172.149 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.665 ' CD2' HG21 ' B' ' 82' ' ' VAL . 0.3 OUTLIER -90.23 107.55 19.2 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 177.138 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' A' ' 45' ' ' ASN . 0.9 OUTLIER 53.29 13.16 0.39 Allowed 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.445 -0.784 . . . . 0.0 111.515 -167.252 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 121.17 -2.44 11.54 Favored Glycine 0 N--CA 1.491 2.311 0 C-N-CA 119.474 -1.346 . . . . 0.0 110.784 172.14 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.782 ' O ' HD23 ' B' ' 49' ' ' LEU . 35.6 t -94.32 109.04 20.9 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.411 -1.64 . . . . 0.0 109.434 174.808 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 16.7 p -76.99 124.77 28.26 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.054 -1.029 . . . . 0.0 110.814 -172.436 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 0.853 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -140.21 159.96 41.02 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.553 -0.717 . . . . 0.0 109.086 173.773 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 50' ' ' THR . . . . . 0.48 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 28.5 m -96.79 160.95 14.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.686 -1.259 . . . . 0.0 111.214 -170.883 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.739 HG22 ' CE1' ' B' ' 61' ' ' PHE . 19.0 t -84.99 116.35 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.787 -0.57 . . . . 0.0 110.426 -177.42 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.542 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 77.3 p -69.96 -39.93 75.72 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.154 -0.966 . . . . 0.0 109.716 173.916 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.561 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 54.4 tp10 -164.94 157.8 16.46 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.589 -176.392 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.835 HD11 ' N ' ' B' ' 38' ' ' THR . 8.7 mt -110.32 129.89 64.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.194 -0.941 . . . . 0.0 109.854 172.667 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.531 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 28.7 m-80 -102.46 64.07 0.89 Allowed 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 120.103 -0.639 . . . . 0.0 109.42 179.101 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.02 -114.35 4.29 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 108.666 -1.774 . . . . 0.0 108.666 -172.282 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.594 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -78.65 -22.73 46.43 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.032 -1.275 . . . . 0.0 109.358 175.244 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.077 ' CE1' HG11 ' B' ' 13' ' ' VAL . 24.0 m-70 -74.21 159.8 32.02 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.386 -0.821 . . . . 0.0 110.097 -177.515 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.729 HG13 HG13 ' B' ' 51' ' ' VAL . 78.4 t -139.99 120.02 13.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 C-N-CA 119.017 -1.073 . . . . 0.0 110.574 173.505 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.65 ' CB ' HG22 ' B' ' 25' ' ' VAL . 6.4 t -83.16 137.98 33.84 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.426 -0.796 . . . . 0.0 109.578 176.044 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.853 ' HB3' HD12 ' B' ' 49' ' ' LEU . 86.4 m-85 -120.25 160.63 22.58 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.351 -0.843 . . . . 0.0 110.471 177.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.542 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 32.9 p-10 -95.48 148.24 22.69 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.113 -0.992 . . . . 0.0 110.945 179.388 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.717 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -157.21 121.93 4.44 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -176.829 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.512 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 26.9 ttt -82.21 141.87 32.64 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.067 -1.02 . . . . 0.0 109.722 -178.183 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.482 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 83.3 tttt -59.95 -48.39 81.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.066 -1.021 . . . . 0.0 110.53 -173.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 54.1 tp10 -68.0 -40.05 83.08 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.915 -1.116 . . . . 0.0 109.966 179.088 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.512 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 87.6 m -59.98 -39.1 84.54 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.004 -1.06 . . . . 0.0 109.278 173.017 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.775 HD11 ' HA2' ' B' ' 74' ' ' GLY . 2.0 tp -60.02 -45.2 93.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.314 -0.866 . . . . 0.0 109.734 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -67.06 -39.95 86.97 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.451 -0.781 . . . . 0.0 110.384 176.875 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.718 HG22 HG23 ' B' ' 71' ' ' THR . 1.2 tt -66.1 -40.11 86.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.289 -0.882 . . . . 0.0 109.212 -176.809 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.718 HG23 HG22 ' B' ' 70' ' ' ILE . 52.3 p -84.84 -169.43 2.64 Favored 'General case' 0 C--N 1.301 -1.543 0 C-N-CA 120.17 -0.612 . . . . 0.0 109.577 175.241 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.489 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 7.0 t30 -106.16 22.75 15.19 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 170.465 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.717 ' HB3' HD21 ' B' ' 63' ' ' LEU . 88.7 mt -69.91 -40.0 75.87 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.308 -0.87 . . . . 0.0 110.182 178.361 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.775 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -50.16 -21.67 4.27 Favored Glycine 0 N--CA 1.487 2.071 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -177.953 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.1 p-10 -69.22 -17.4 63.77 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.014 -1.286 . . . . 0.0 110.736 -173.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.507 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 95.8 mt -59.99 141.0 56.39 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.139 -0.975 . . . . 0.0 110.8 -176.921 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 1.019 ' C ' HD23 ' B' ' 12' ' ' LEU . 66.4 mttm -140.03 139.06 35.9 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 121.611 -0.681 . . . . 0.0 109.912 175.673 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.668 ' N ' HD23 ' B' ' 12' ' ' LEU . 22.1 t -61.11 152.76 5.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.036 -1.04 . . . . 0.0 110.43 -176.348 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.64 -15.83 57.95 Favored Glycine 0 N--CA 1.484 1.837 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 -176.072 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -97.49 169.63 9.6 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.345 -1.091 . . . . 0.0 109.582 175.502 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.574 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.3 m95 -117.23 166.52 12.16 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.104 -0.998 . . . . 0.0 110.05 177.389 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 1.039 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.3 p -128.65 157.54 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.41 -0.806 . . . . 0.0 110.054 -177.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.859 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.1 m-20 -83.48 104.53 13.7 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.307 -0.87 . . . . 0.0 109.263 170.775 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.686 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -107.38 139.55 28.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.468 -1.395 . . . . 0.0 111.17 -174.637 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 85' ' ' GLU . . . . . 0.456 ' HB2' HG22 ' B' ' 6' ' ' VAL . 85.2 tt0 -139.92 138.44 35.63 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 120.389 -0.525 . . . . 0.0 109.789 -178.645 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 86' ' ' ARG . . . . . 0.478 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 39.0 ptt180 -72.95 137.71 45.67 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.06 -1.025 . . . . 0.0 110.608 -174.09 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.784 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.162 -0.962 . . . . 0.0 109.825 173.764 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.655 HG21 ' HB3' ' A' ' 83' ' ' ASN . 3.4 t . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 121.624 0.726 . . . . 0.0 110.583 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 28.2 mm100 -98.48 -15.19 19.69 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.554 -0.716 . . . . 0.0 110.783 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.532 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -141.0 165.4 26.25 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.247 -1.454 . . . . 0.0 109.749 -177.595 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.488 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 0.7 OUTLIER -124.83 169.99 11.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.95 -1.324 . . . . 0.0 110.504 178.746 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 1.044 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -141.26 149.27 41.1 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.471 -0.768 . . . . 0.0 109.245 -176.525 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.579 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 32.1 tttt -109.65 114.13 27.48 Favored 'General case' 0 C--N 1.294 -1.839 0 O-C-N 121.091 -1.005 . . . . 0.0 110.175 178.852 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.994 HD23 ' C ' ' A' ' 77' ' ' LYS . 11.6 tp -59.69 127.86 34.11 Favored 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.061 -1.024 . . . . 0.0 108.903 175.137 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.102 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.5 p -128.31 -30.65 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.868 0 O-C-N 121.339 -0.851 . . . . 0.0 110.062 -178.682 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.35 141.97 30.08 Favored 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 119.088 -1.045 . . . . 0.0 111.284 -178.158 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.796 HD11 HG23 ' A' ' 78' ' ' VAL . 8.4 mt -110.04 132.89 57.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.098 -1.001 . . . . 0.0 110.362 172.964 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.514 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 88.5 m-20 -109.8 114.97 28.98 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.41 -0.806 . . . . 0.0 110.038 175.353 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -102.62 109.61 21.28 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.01 -1.056 . . . . 0.0 110.471 -177.402 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.3 OUTLIER -101.71 135.96 19.66 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.243 -0.91 . . . . 0.0 109.557 175.884 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -53.97 -16.92 9.83 Favored 'Trans proline' 0 C--N 1.302 -1.877 0 O-C-N 123.956 1.503 . . . . 0.0 110.853 -179.631 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.555 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 6.0 m-80 -102.7 -26.56 13.13 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.063 -1.023 . . . . 0.0 109.953 179.744 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.555 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 87.6 m-85 -156.69 150.24 24.52 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.428 -0.795 . . . . 0.0 109.919 -178.549 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.484 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 61.3 ttt180 -92.36 141.74 28.21 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.665 -1.272 . . . . 0.0 109.844 174.799 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.514 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 89.1 m -129.94 140.05 51.0 Favored 'General case' 0 C--N 1.295 -1.799 0 O-C-N 121.495 -0.753 . . . . 0.0 109.824 -172.677 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.717 ' NE2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -130.09 142.47 50.6 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 120.986 -1.071 . . . . 0.0 111.413 -179.286 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.826 HG22 ' CB ' ' A' ' 60' ' ' SER . 16.6 t -119.66 134.31 63.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.111 -0.993 . . . . 0.0 110.418 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.91 HG13 ' CE1' ' A' ' 61' ' ' PHE . 32.9 m -116.82 170.76 6.02 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 O-C-N 121.912 -0.492 . . . . 0.0 110.113 178.894 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.689 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 9.4 tt0 -102.65 116.64 33.0 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 179.401 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.499 HD23 ' HA ' ' A' ' 33' ' ' LEU . 8.7 tp -80.56 121.63 81.54 Favored Pre-proline 0 C--N 1.295 -1.771 0 O-C-N 121.493 -0.755 . . . . 0.0 109.653 -173.74 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.466 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 18.5 Cg_endo -63.42 178.84 1.07 Allowed 'Trans proline' 0 C--N 1.308 -1.583 0 O-C-N 123.874 1.46 . . . . 0.0 111.004 -179.112 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.527 ' HA ' HD12 ' A' ' 33' ' ' LEU . 88.3 m-20 -60.32 -39.91 88.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.373 -0.83 . . . . 0.0 111.102 -175.843 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.606 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.17 0.26 57.27 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.833 -1.167 . . . . 0.0 110.93 -175.553 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.606 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.1 mmm -109.12 -12.84 14.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.923 -1.11 . . . . 0.0 110.006 171.946 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.832 HD21 ' HB2' ' A' ' 57' ' ' ASN . 19.2 mt -68.8 -31.35 70.29 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.284 -0.885 . . . . 0.0 110.221 178.098 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 52.6 t0 -94.06 122.94 37.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.282 -0.886 . . . . 0.0 110.319 -178.315 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 111.42 -50.6 0.76 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 177.172 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.572 HD23 ' N ' ' A' ' 37' ' ' GLU . 6.7 tt -67.0 140.03 57.7 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.087 -1.243 . . . . 0.0 110.296 -176.952 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.572 ' N ' HD23 ' A' ' 36' ' ' LEU . 19.7 pt-20 -147.42 168.5 21.71 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.383 -0.823 . . . . 0.0 109.451 176.767 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.773 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -63.24 151.65 39.87 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.975 -1.078 . . . . 0.0 110.265 -175.885 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.52 -0.44 60.58 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -174.702 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.608 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -79.99 159.37 26.29 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.162 -1.199 . . . . 0.0 109.392 175.861 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.454 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.5 OUTLIER -103.19 117.54 34.77 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 118.849 -1.141 . . . . 0.0 110.155 177.068 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.642 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.6 t -102.37 128.28 55.21 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 121.335 -0.853 . . . . 0.0 108.907 172.476 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.51 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -92.88 119.68 32.44 Favored 'General case' 0 C--N 1.297 -1.689 0 C-N-CA 119.214 -0.995 . . . . 0.0 109.096 172.644 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.682 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -87.62 102.63 14.8 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 119.729 -0.789 . . . . 0.0 108.982 179.194 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.8 t-20 59.6 6.29 0.8 Allowed 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.685 -0.634 . . . . 0.0 111.681 -170.642 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.454 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 128.58 -1.04 6.42 Favored Glycine 0 N--CA 1.489 2.181 0 C-N-CA 119.525 -1.321 . . . . 0.0 110.655 174.352 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.677 ' O ' HD23 ' A' ' 49' ' ' LEU . 34.8 t -98.51 108.67 21.42 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.438 -1.624 . . . . 0.0 109.55 175.74 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 22.7 p -74.3 130.17 39.18 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.087 -1.008 . . . . 0.0 111.074 -171.351 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.841 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -147.02 153.82 40.48 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.429 -0.794 . . . . 0.0 109.356 173.901 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.424 HG22 ' N ' ' A' ' 51' ' ' VAL . 92.5 m -95.83 160.11 14.64 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.527 -1.358 . . . . 0.0 111.558 -169.118 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.925 HG13 HG13 ' A' ' 59' ' ' VAL . 15.8 t -82.08 114.72 23.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.847 -0.533 . . . . 0.0 110.358 -178.804 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.55 HG22 ' HB3' ' A' ' 62' ' ' ASP . 30.2 p -70.9 -39.94 72.47 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.322 -0.861 . . . . 0.0 109.977 175.137 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.571 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -166.19 154.2 10.47 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.31 -0.869 . . . . 0.0 110.177 179.677 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.773 HD11 ' N ' ' A' ' 38' ' ' THR . 9.8 mt -108.31 134.91 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.1 -1.0 . . . . 0.0 110.138 177.699 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.507 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 47.4 m-80 -108.81 66.23 0.63 Allowed 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.601 -0.687 . . . . 0.0 109.512 177.87 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.2 -116.84 5.11 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 -173.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.832 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.1 OUTLIER -78.43 -20.19 51.57 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.055 -1.262 . . . . 0.0 109.116 177.012 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.102 ' CE1' HG11 ' A' ' 13' ' ' VAL . 23.1 m-70 -76.61 158.92 30.72 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.241 -0.912 . . . . 0.0 110.044 -178.35 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.925 HG13 HG13 ' A' ' 51' ' ' VAL . 55.6 t -140.78 123.06 15.31 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 O-C-N 121.055 -1.028 . . . . 0.0 110.591 171.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.826 ' CB ' HG22 ' A' ' 25' ' ' VAL . 0.9 OUTLIER -87.5 133.32 33.78 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.47 -0.769 . . . . 0.0 109.13 175.264 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.91 ' CE1' HG13 ' A' ' 26' ' ' VAL . 1.8 p90 -125.96 156.01 40.46 Favored 'General case' 0 C--N 1.295 -1.79 0 O-C-N 121.378 -0.826 . . . . 0.0 110.185 178.038 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.55 ' HB3' HG22 ' A' ' 52' ' ' THR . 36.7 p-10 -90.78 151.16 21.31 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.089 -1.007 . . . . 0.0 111.398 -170.161 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.812 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -159.82 111.54 2.03 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 -175.574 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.525 ' HB2' ' CB ' ' A' ' 67' ' ' THR . 28.4 mtm -66.17 140.02 58.16 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.819 -1.176 . . . . 0.0 109.825 -179.848 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.498 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 49.3 tptt -60.11 -49.8 76.23 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.209 -0.932 . . . . 0.0 110.251 -178.411 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -65.2 -40.01 93.58 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.875 -1.141 . . . . 0.0 109.76 176.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.525 ' CB ' ' HB2' ' A' ' 64' ' ' MET . 94.3 m -60.05 -39.7 86.89 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.02 -1.05 . . . . 0.0 109.452 173.289 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.724 HD11 ' HA2' ' A' ' 74' ' ' GLY . 7.8 tp -59.95 -43.57 94.95 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.308 -0.87 . . . . 0.0 109.65 179.723 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -68.16 -40.01 82.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.38 -0.825 . . . . 0.0 110.579 176.042 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.853 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -64.9 -43.25 96.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.17 -0.956 . . . . 0.0 109.328 -177.108 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.853 HG23 HG22 ' A' ' 70' ' ' ILE . 29.9 p -86.68 -174.63 5.07 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.727 -0.608 . . . . 0.0 109.667 176.751 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.489 ' HB2' ' N ' ' B' ' 83' ' ' ASN . 6.1 t30 -98.78 22.59 9.87 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.167 -0.958 . . . . 0.0 108.686 171.469 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.812 ' HB3' HD21 ' A' ' 63' ' ' LEU . 91.8 mt -68.73 -39.98 80.12 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.095 -1.003 . . . . 0.0 109.975 176.907 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.724 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -50.44 -23.9 6.78 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -178.351 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.5 p-10 -62.12 -18.01 59.53 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.089 -1.242 . . . . 0.0 110.233 -175.764 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.9 mt -63.62 142.09 58.53 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.319 -0.863 . . . . 0.0 110.961 -177.69 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 0.994 ' C ' HD23 ' A' ' 12' ' ' LEU . 42.8 mttt -143.54 144.84 32.13 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-O 121.311 0.577 . . . . 0.0 109.731 175.106 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.796 HG23 HD11 ' A' ' 15' ' ' ILE . 21.9 t -64.52 149.93 10.7 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 120.843 -1.161 . . . . 0.0 110.479 -175.327 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.97 -13.63 60.78 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -175.144 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 46.6 t0 -94.61 163.3 13.44 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.337 -1.096 . . . . 0.0 109.585 176.021 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.579 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 13.9 m95 -113.28 154.79 26.23 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 120.964 -1.085 . . . . 0.0 110.155 175.829 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.044 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.4 p -119.99 153.03 22.82 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.437 -0.789 . . . . 0.0 109.852 -179.019 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.655 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.4 OUTLIER -77.73 107.34 10.16 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.171 -0.955 . . . . 0.0 109.02 168.475 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.758 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -109.4 138.85 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 120.474 -1.391 . . . . 0.0 111.364 -176.724 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.481 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.6 tt0 -131.49 139.59 49.35 Favored 'General case' 0 N--CA 1.494 1.749 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.131 -179.369 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -81.37 133.62 35.44 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.091 -1.006 . . . . 0.0 110.94 -175.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.454 ' O ' ' OG ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.736 0 O-C-N 121.28 -0.888 . . . . 0.0 110.639 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 0.653 HG21 ' HB3' ' B' ' 83' ' ' ASN . 3.4 t . . . . . 0 N--CA 1.489 1.491 0 CA-C-O 121.54 0.686 . . . . 0.0 110.583 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 28.2 mm100 -98.55 -14.83 19.77 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.54 -0.725 . . . . 0.0 110.854 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.529 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -141.28 165.14 26.42 Favored Glycine 0 N--CA 1.493 2.458 0 C-N-CA 119.338 -1.41 . . . . 0.0 109.868 -177.536 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.487 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 0.7 OUTLIER -124.74 169.99 11.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.123 -1.221 . . . . 0.0 110.556 178.821 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.023 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -141.31 149.34 41.1 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.507 -0.745 . . . . 0.0 109.235 -176.617 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 32.0 tttt -109.7 114.34 27.86 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.151 -0.968 . . . . 0.0 110.014 178.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 1.001 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.7 tp -60.02 127.78 33.57 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.104 -0.998 . . . . 0.0 108.939 175.106 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.091 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.5 p -127.96 -31.04 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 O-C-N 121.393 -0.817 . . . . 0.0 110.1 -178.651 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.08 141.9 30.32 Favored 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.328 -178.082 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.82 HD11 HG23 ' B' ' 78' ' ' VAL . 8.4 mt -109.91 132.96 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.128 -0.982 . . . . 0.0 110.377 172.917 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.519 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 88.2 m-20 -109.99 114.98 28.95 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.416 -0.803 . . . . 0.0 109.995 175.388 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -102.59 109.67 21.36 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.982 -1.074 . . . . 0.0 110.497 -177.399 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.3 OUTLIER -101.87 135.95 19.62 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.274 -0.892 . . . . 0.0 109.541 175.943 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.05 -16.85 9.97 Favored 'Trans proline' 0 C--N 1.303 -1.837 0 O-C-N 123.934 1.492 . . . . 0.0 110.856 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.547 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 6.0 m-80 -102.56 -26.98 13.03 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.107 -0.996 . . . . 0.0 109.874 179.706 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.547 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 87.5 m-85 -156.3 150.22 25.08 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.432 -0.793 . . . . 0.0 109.972 -178.426 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 22' ' ' ARG . . . . . 0.487 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 61.2 ttt180 -92.31 141.67 28.3 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.701 -1.25 . . . . 0.0 109.806 174.786 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.519 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 88.4 m -129.96 140.12 50.97 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 121.617 -0.677 . . . . 0.0 109.798 -172.715 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.729 ' NE2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -130.05 142.45 50.61 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 120.964 -1.085 . . . . 0.0 111.338 -179.158 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.835 HG22 ' CB ' ' B' ' 60' ' ' SER . 16.3 t -119.51 134.41 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.264 -0.898 . . . . 0.0 110.435 179.55 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.911 HG13 ' CE1' ' B' ' 61' ' ' PHE . 33.1 m -117.09 170.76 6.21 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 CA-C-O 121.263 0.554 . . . . 0.0 109.955 178.921 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.687 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 9.3 tt0 -102.56 116.68 33.08 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.345 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.498 ' HA ' HD12 ' B' ' 28' ' ' LEU . 8.7 tp -80.54 121.62 81.56 Favored Pre-proline 0 C--N 1.297 -1.703 0 O-C-N 121.433 -0.792 . . . . 0.0 109.716 -173.805 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.478 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 18.5 Cg_endo -63.4 178.86 1.06 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 O-C-N 123.91 1.479 . . . . 0.0 111.007 -179.09 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.516 ' HA ' HD12 ' B' ' 33' ' ' LEU . 88.1 m-20 -60.29 -39.98 88.85 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.356 -0.84 . . . . 0.0 111.118 -175.827 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.588 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.11 0.28 57.23 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.87 -1.144 . . . . 0.0 110.945 -175.609 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.588 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.1 mmm -109.16 -12.81 14.77 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.87 -1.144 . . . . 0.0 109.93 171.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.833 HD21 ' HB2' ' B' ' 57' ' ' ASN . 19.2 mt -68.88 -31.32 70.17 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.226 -0.921 . . . . 0.0 110.22 178.054 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -93.99 122.95 37.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.381 -0.824 . . . . 0.0 110.363 -178.38 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 111.43 -50.65 0.75 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.061 -1.215 . . . . 0.0 110.061 177.166 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.576 HD23 ' N ' ' B' ' 37' ' ' GLU . 6.7 tt -66.97 140.02 57.72 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.051 -1.264 . . . . 0.0 110.299 -176.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 37' ' ' GLU . . . . . 0.576 ' N ' HD23 ' B' ' 36' ' ' LEU . 19.7 pt-20 -147.38 168.55 21.54 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.401 -0.812 . . . . 0.0 109.41 176.673 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 38' ' ' THR . . . . . 0.783 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -63.33 151.51 40.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.995 -1.066 . . . . 0.0 110.382 -175.949 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.73 -0.48 61.32 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -174.658 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.607 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -80.07 159.34 26.18 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.141 -1.211 . . . . 0.0 109.382 175.816 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.451 ' OG ' ' O ' ' B' ' 87' ' ' ALA . 0.5 OUTLIER -102.99 117.33 34.36 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.782 -1.199 . . . . 0.0 110.309 177.03 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.635 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.7 t -102.27 128.43 54.93 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 121.357 -0.839 . . . . 0.0 108.868 172.5 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -92.97 119.74 32.55 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 119.227 -0.989 . . . . 0.0 108.988 172.617 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.684 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -87.72 102.45 14.65 Favored 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.54 -0.864 . . . . 0.0 109.098 179.106 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 59.84 6.38 0.89 Allowed 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.554 -0.716 . . . . 0.0 111.549 -170.688 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.454 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 128.38 -0.62 6.46 Favored Glycine 0 N--CA 1.489 2.218 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.714 174.228 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.694 ' O ' HD23 ' B' ' 49' ' ' LEU . 34.6 t -98.63 108.61 21.34 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.502 -1.587 . . . . 0.0 109.537 175.552 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 22.9 p -74.19 130.19 39.27 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.058 -1.026 . . . . 0.0 111.043 -171.429 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 0.856 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -147.11 153.92 40.5 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.527 -0.733 . . . . 0.0 109.359 173.726 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 50' ' ' THR . . . . . 0.421 HG22 ' N ' ' B' ' 51' ' ' VAL . 92.9 m -95.9 160.41 14.48 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 120.527 -1.358 . . . . 0.0 111.556 -169.085 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.946 HG13 HG13 ' B' ' 59' ' ' VAL . 16.1 t -82.44 114.65 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.84 -0.538 . . . . 0.0 110.433 -178.682 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.542 HG22 ' HB3' ' B' ' 62' ' ' ASP . 30.2 p -70.71 -40.03 73.07 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.272 -0.893 . . . . 0.0 109.918 175.339 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.574 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -166.21 154.11 10.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.202 -0.936 . . . . 0.0 110.208 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.783 HD11 ' N ' ' B' ' 38' ' ' THR . 9.8 mt -108.31 134.89 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.114 -0.991 . . . . 0.0 110.206 177.684 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.515 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 47.1 m-80 -108.84 66.14 0.63 Allowed 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.64 -0.662 . . . . 0.0 109.522 177.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.32 -116.81 5.08 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 108.861 -1.696 . . . . 0.0 108.861 -173.959 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.833 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -78.44 -20.29 51.35 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.075 -1.25 . . . . 0.0 109.151 177.054 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.091 ' CE1' HG11 ' B' ' 13' ' ' VAL . 23.1 m-70 -76.5 158.79 30.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.347 -0.846 . . . . 0.0 110.097 -178.375 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.946 HG13 HG13 ' B' ' 51' ' ' VAL . 55.8 t -140.76 123.15 15.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 C-N-CA 119.076 -1.05 . . . . 0.0 110.519 171.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.835 ' CB ' HG22 ' B' ' 25' ' ' VAL . 0.9 OUTLIER -87.52 133.3 33.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.441 -0.787 . . . . 0.0 109.204 175.225 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.911 ' CE1' HG13 ' B' ' 26' ' ' VAL . 1.8 p90 -125.98 155.99 40.53 Favored 'General case' 0 N--CA 1.494 1.773 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.177 178.033 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.542 ' HB3' HG22 ' B' ' 52' ' ' THR . 36.6 p-10 -90.67 151.19 21.37 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.0 -1.062 . . . . 0.0 111.381 -170.115 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.784 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.82 111.53 2.03 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -175.638 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.528 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 28.5 mtm -66.22 139.96 58.13 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.888 -1.133 . . . . 0.0 109.824 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.499 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 49.3 tptt -59.92 -49.87 76.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.131 -0.98 . . . . 0.0 110.3 -178.439 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -65.24 -39.99 93.42 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.913 -1.117 . . . . 0.0 109.765 176.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.528 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 94.5 m -60.01 -39.83 87.19 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.988 -1.07 . . . . 0.0 109.342 173.29 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.717 HD11 ' HA2' ' B' ' 74' ' ' GLY . 7.8 tp -59.94 -43.45 94.97 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.293 -0.879 . . . . 0.0 109.707 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 78.5 ttt180 -68.21 -40.08 82.21 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.293 -0.879 . . . . 0.0 110.603 175.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.831 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -64.75 -43.24 96.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.195 -0.941 . . . . 0.0 109.434 -177.213 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.831 HG23 HG22 ' B' ' 70' ' ' ILE . 30.0 p -86.65 -174.56 5.04 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 120.231 -0.588 . . . . 0.0 109.658 176.774 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.506 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 6.0 t30 -98.71 22.57 9.84 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.19 -0.944 . . . . 0.0 108.78 171.393 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.784 ' HB3' HD21 ' B' ' 63' ' ' LEU . 91.4 mt -68.71 -40.0 80.17 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.075 -1.015 . . . . 0.0 110.05 176.929 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.717 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -50.46 -23.87 6.78 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 -178.384 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.0 p-10 -62.1 -17.94 59.23 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.062 -1.258 . . . . 0.0 110.295 -175.909 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.513 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.1 mt -63.68 142.22 58.48 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.287 -0.883 . . . . 0.0 110.929 -177.746 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 1.001 ' C ' HD23 ' B' ' 12' ' ' LEU . 42.8 mttt -143.67 144.95 32.1 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.627 -0.671 . . . . 0.0 109.665 175.13 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.82 HG23 HD11 ' B' ' 15' ' ' ILE . 22.2 t -64.73 150.03 10.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 O-C-N 120.856 -1.153 . . . . 0.0 110.341 -175.182 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.8 -13.45 60.89 Favored Glycine 0 N--CA 1.484 1.84 0 N-CA-C 108.848 -1.701 . . . . 0.0 108.848 -175.16 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 46.2 t0 -94.62 163.23 13.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.319 -1.106 . . . . 0.0 109.59 175.832 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.584 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 13.9 m95 -113.31 154.73 26.37 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.97 -1.081 . . . . 0.0 110.215 175.782 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 1.023 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.4 p -119.98 153.1 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.579 -0.701 . . . . 0.0 109.881 -179.082 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.653 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.3 OUTLIER -77.72 107.27 10.09 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.178 -0.951 . . . . 0.0 109.018 168.569 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.765 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -109.32 138.96 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 120.462 -1.399 . . . . 0.0 111.211 -176.533 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 85' ' ' GLU . . . . . 0.465 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.7 tt0 -131.58 139.68 49.25 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.883 -0.511 . . . . 0.0 110.144 -179.569 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -81.35 133.69 35.46 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.117 -0.99 . . . . 0.0 110.916 -175.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.451 ' O ' ' OG ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.496 1.844 0 O-C-N 121.403 -0.81 . . . . 0.0 110.647 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.954 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.5 t . . . . . 0 N--CA 1.493 1.708 0 CA-C-O 121.557 0.694 . . . . 0.0 110.638 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 20.1 pt20 -89.64 -16.15 31.13 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.453 -0.779 . . . . 0.0 110.829 -178.426 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -158.45 177.12 35.25 Favored Glycine 0 N--CA 1.493 2.484 0 C-N-CA 119.129 -1.51 . . . . 0.0 110.083 -177.522 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.487 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 1.4 p -125.87 167.97 14.51 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.069 -1.254 . . . . 0.0 110.472 178.942 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 1.07 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -139.93 149.64 43.57 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.346 -0.846 . . . . 0.0 109.903 -174.283 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.585 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 31.2 tttt -106.26 116.01 31.21 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.126 -0.984 . . . . 0.0 110.169 179.255 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.998 HD23 ' C ' ' A' ' 77' ' ' LYS . 13.1 tp -59.93 128.03 34.84 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.793 -1.192 . . . . 0.0 108.582 171.676 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.145 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.7 p -131.34 -31.01 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 O-C-N 121.262 -0.898 . . . . 0.0 110.316 -176.869 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -144.34 139.68 28.65 Favored 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 118.936 -1.106 . . . . 0.0 111.39 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.736 HG23 ' CD2' ' A' ' 24' ' ' HIS . 9.9 mt -109.16 137.0 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.052 -1.03 . . . . 0.0 110.08 171.366 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.478 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 78.7 m-20 -111.86 114.35 27.25 Favored 'General case' 0 C--N 1.295 -1.79 0 O-C-N 121.415 -0.803 . . . . 0.0 110.182 173.028 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -105.04 118.61 36.97 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.033 -1.042 . . . . 0.0 110.492 -177.443 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.44 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.9 mtpp -118.26 140.18 27.74 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.256 -0.902 . . . . 0.0 109.779 178.876 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -55.1 -15.2 10.03 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 O-C-N 124.067 1.562 . . . . 0.0 110.964 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.568 ' O ' ' CD1' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -107.61 -25.25 11.42 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.999 -1.063 . . . . 0.0 109.308 -177.892 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.568 ' CD1' ' O ' ' A' ' 20' ' ' ASN . 75.8 m-85 -157.74 150.3 22.71 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.622 -0.674 . . . . 0.0 110.105 179.337 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.498 ' HD3' HD22 ' A' ' 68' ' ' LEU . 63.6 ttt180 -96.77 143.32 27.8 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 120.815 -1.178 . . . . 0.0 110.012 172.614 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.478 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 54.4 m -130.91 140.18 50.17 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.488 -0.758 . . . . 0.0 110.145 -173.414 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.736 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -130.14 143.86 51.03 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 120.94 -1.1 . . . . 0.0 111.604 178.805 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.859 HG22 ' OG ' ' A' ' 60' ' ' SER . 8.3 t -125.77 136.1 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.158 -0.964 . . . . 0.0 110.651 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 35.4 m -117.67 171.74 5.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 121.783 -0.573 . . . . 0.0 110.211 178.228 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.573 ' CG ' HD22 ' A' ' 57' ' ' ASN . 3.6 tt0 -104.25 117.31 33.92 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.218 -0.926 . . . . 0.0 109.247 -178.772 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.562 HD21 ' O ' ' A' ' 32' ' ' MET . 9.6 tp -82.81 125.87 74.4 Favored Pre-proline 0 C--N 1.299 -1.621 0 O-C-N 121.585 -0.697 . . . . 0.0 110.106 -173.641 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.54 ' HD2' HD12 ' A' ' 28' ' ' LEU . 28.2 Cg_endo -67.04 176.94 4.01 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 123.886 1.466 . . . . 0.0 111.069 -179.627 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.67 ' HA ' HD12 ' A' ' 33' ' ' LEU . 92.6 m-20 -60.03 -40.0 87.84 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.239 -0.913 . . . . 0.0 111.306 -174.938 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.595 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.99 0.64 56.99 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.751 -1.218 . . . . 0.0 110.907 -174.472 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.595 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.8 mmm -112.17 -8.57 13.99 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.875 -1.141 . . . . 0.0 110.006 170.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.696 HD21 ' HB2' ' A' ' 57' ' ' ASN . 16.0 mt -70.03 -40.01 75.42 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.224 -0.922 . . . . 0.0 109.915 177.065 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -81.74 128.81 34.38 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.594 -0.691 . . . . 0.0 110.486 -178.246 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.47 -46.18 1.21 Allowed Glycine 0 N--CA 1.493 2.445 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.256 174.795 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.7 HD23 ' N ' ' A' ' 37' ' ' GLU . 6.8 tt -69.7 148.84 48.71 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.93 -1.335 . . . . 0.0 110.445 -175.365 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.7 ' N ' HD23 ' A' ' 36' ' ' LEU . 21.3 pt-20 -150.62 170.02 20.16 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.367 -0.833 . . . . 0.0 109.397 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.717 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -70.06 151.15 45.84 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.058 -1.026 . . . . 0.0 110.228 -178.919 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.09 -3.3 66.2 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -174.183 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.453 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -77.99 161.48 27.46 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.27 -1.135 . . . . 0.0 109.661 177.612 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.476 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.6 OUTLIER -101.64 114.95 29.46 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.016 -1.052 . . . . 0.0 110.104 177.354 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.626 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.8 t -103.16 128.88 55.76 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.323 -0.861 . . . . 0.0 109.157 174.06 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -94.8 120.08 34.43 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.269 -0.972 . . . . 0.0 109.265 173.043 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.863 ' CD2' HG21 ' A' ' 82' ' ' VAL . 1.4 m80 -90.71 106.19 18.34 Favored 'General case' 0 C--N 1.301 -1.503 0 C-N-CA 119.676 -0.81 . . . . 0.0 109.054 177.568 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.494 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.8 t-20 53.92 14.81 0.72 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.338 -0.851 . . . . 0.0 110.925 -167.02 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.512 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 117.78 -0.5 17.73 Favored Glycine 0 N--CA 1.489 2.17 0 C-N-CA 119.623 -1.275 . . . . 0.0 110.978 170.559 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.833 ' O ' HD23 ' A' ' 49' ' ' LEU . 43.4 t -92.35 106.84 18.76 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.49 -1.594 . . . . 0.0 109.151 173.525 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.8 p -75.49 128.66 35.8 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.15 -0.969 . . . . 0.0 110.749 -170.874 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.833 HD23 ' O ' ' A' ' 47' ' ' CYS . 0.3 OUTLIER -143.14 159.66 41.88 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.442 -0.786 . . . . 0.0 109.714 175.296 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.421 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 28.9 m -100.16 149.82 23.14 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.576 -1.328 . . . . 0.0 111.409 -170.781 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.836 HG13 HG13 ' A' ' 59' ' ' VAL . 15.1 t -78.06 118.39 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 CA-C-O 121.155 0.502 . . . . 0.0 110.617 -178.002 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 42.9 p -73.89 -39.94 63.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.126 -0.984 . . . . 0.0 110.031 174.494 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.658 ' HA ' HG21 ' A' ' 38' ' ' THR . 86.6 tt0 -163.4 149.85 12.07 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.35 -0.844 . . . . 0.0 110.214 -178.007 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.717 HD11 ' N ' ' A' ' 38' ' ' THR . 5.7 mt -101.51 134.9 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.09 -1.007 . . . . 0.0 109.955 176.148 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.496 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 49.9 m-80 -110.45 65.78 0.62 Allowed 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.571 -0.705 . . . . 0.0 109.913 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.19 -118.68 4.99 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.879 -1.688 . . . . 0.0 108.879 -175.236 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.696 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.1 OUTLIER -78.62 -16.39 57.41 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 120.949 -1.324 . . . . 0.0 108.816 174.307 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.145 ' CD2' HG11 ' A' ' 13' ' ' VAL . 11.8 m170 -76.6 159.81 29.96 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.37 -0.831 . . . . 0.0 110.39 -178.192 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.836 HG13 HG13 ' A' ' 51' ' ' VAL . 52.2 t -140.3 127.02 22.42 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 O-C-N 121.02 -1.05 . . . . 0.0 110.596 170.036 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.859 ' OG ' HG22 ' A' ' 25' ' ' VAL . 2.7 t -95.8 136.74 35.83 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.474 -0.767 . . . . 0.0 109.564 178.382 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.807 ' HB2' HD12 ' A' ' 49' ' ' LEU . 2.0 p90 -128.06 157.78 39.76 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.864 173.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.533 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 25.0 p-10 -89.48 157.64 18.02 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.31 -0.869 . . . . 0.0 111.129 -171.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.746 HD22 ' CD1' ' A' ' 68' ' ' LEU . 0.1 OUTLIER -159.94 102.57 1.47 Allowed 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 120.035 -0.666 . . . . 0.0 109.461 -175.441 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.501 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 56.3 ttm -59.75 140.4 56.54 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.002 -1.062 . . . . 0.0 109.364 -179.557 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.457 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 39.4 ttpt -60.01 -43.32 95.31 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.022 -1.049 . . . . 0.0 110.285 -175.159 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.74 -39.99 76.43 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.02 -1.05 . . . . 0.0 110.067 178.279 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.501 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 92.2 m -60.56 -39.96 89.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.978 -1.076 . . . . 0.0 109.184 172.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.746 ' CD1' HD22 ' A' ' 63' ' ' LEU . 7.3 tp -59.94 -45.4 92.74 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.285 -0.885 . . . . 0.0 109.782 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 15.0 tpp180 -69.21 -39.59 78.51 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.529 -0.732 . . . . 0.0 110.47 177.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.857 HG22 HG23 ' A' ' 71' ' ' THR . 1.4 tt -63.68 -43.98 98.27 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.13 -0.982 . . . . 0.0 109.368 -177.47 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.857 HG23 HG22 ' A' ' 70' ' ' ILE . 37.8 p -83.55 -170.51 3.1 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.404 0.621 . . . . 0.0 109.703 178.611 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.5 t30 -103.28 22.63 13.79 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 170.187 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.72 ' HB3' HD21 ' A' ' 63' ' ' LEU . 89.4 mt -69.54 -41.23 76.22 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.158 -0.964 . . . . 0.0 109.999 176.731 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.73 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -51.01 -20.81 4.75 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 -178.163 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.1 p-10 -67.43 -18.5 65.12 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.927 -1.337 . . . . 0.0 110.673 -174.003 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.517 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 90.2 mt -60.89 142.86 55.92 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.166 -0.959 . . . . 0.0 110.983 -175.476 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 0.998 ' C ' HD23 ' A' ' 12' ' ' LEU . 98.7 mttt -140.34 139.53 35.43 Favored 'General case' 0 N--CA 1.493 1.695 0 CA-C-O 121.537 0.684 . . . . 0.0 109.955 173.905 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.706 ' N ' HD23 ' A' ' 12' ' ' LEU . 15.4 t -63.19 153.47 6.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 120.868 -1.145 . . . . 0.0 110.636 -174.45 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.0 -16.93 55.83 Favored Glycine 0 N--CA 1.485 1.928 0 N-CA-C 108.645 -1.782 . . . . 0.0 108.645 -175.134 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -95.14 170.09 9.64 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.402 -1.058 . . . . 0.0 109.743 175.845 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.585 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.5 m95 -116.97 169.51 9.35 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.965 -1.085 . . . . 0.0 110.17 176.013 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.07 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.4 p -134.09 155.63 39.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 121.438 -0.789 . . . . 0.0 109.808 -176.669 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.954 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.1 m-20 -79.57 109.12 13.66 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.006 -1.059 . . . . 0.0 109.134 168.668 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.783 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -110.78 138.59 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 120.43 -1.419 . . . . 0.0 111.275 -175.546 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -134.35 145.03 48.62 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.864 -0.522 . . . . 0.0 110.292 -177.244 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 36.1 ttm180 -83.49 130.65 35.02 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.311 -0.868 . . . . 0.0 111.027 -176.679 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.476 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.25 -0.906 . . . . 0.0 110.023 174.737 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 0.992 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.5 t . . . . . 0 N--CA 1.493 1.685 0 CA-C-O 121.477 0.656 . . . . 0.0 110.727 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 20.1 pt20 -89.72 -15.84 31.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.374 -0.828 . . . . 0.0 110.887 -178.418 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.525 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -158.8 177.0 35.59 Favored Glycine 0 N--CA 1.494 2.552 0 C-N-CA 119.143 -1.503 . . . . 0.0 110.113 -177.495 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.486 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 1.4 p -125.88 167.92 14.58 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.088 -1.243 . . . . 0.0 110.42 179.103 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.092 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -139.84 149.77 43.85 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.278 -0.889 . . . . 0.0 109.88 -174.399 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.583 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 31.2 tttt -106.35 116.04 31.25 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.081 -1.012 . . . . 0.0 110.141 179.201 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 0.998 HD23 ' C ' ' B' ' 77' ' ' LYS . 13.1 tp -60.06 128.03 34.82 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.828 -1.17 . . . . 0.0 108.671 171.634 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.145 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.7 p -131.41 -30.86 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.31 -176.711 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -144.46 139.8 28.55 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.12 -1.032 . . . . 0.0 111.348 179.913 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.742 HG23 ' CD2' ' B' ' 24' ' ' HIS . 10.3 mt -109.32 136.98 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.078 -1.013 . . . . 0.0 110.06 171.4 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.495 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 78.6 m-20 -111.97 114.5 27.44 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 121.44 -0.787 . . . . 0.0 110.159 173.039 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -104.96 118.74 37.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.188 -0.945 . . . . 0.0 110.493 -177.435 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.436 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.9 mtpp -118.39 140.3 27.99 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.29 -0.881 . . . . 0.0 109.771 178.838 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -55.39 -15.11 10.81 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 124.008 1.53 . . . . 0.0 110.967 -179.785 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.571 ' O ' ' CD1' ' B' ' 21' ' ' PHE . 0.0 OUTLIER -107.28 -25.9 11.28 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.01 -1.056 . . . . 0.0 109.214 -177.946 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.571 ' CD1' ' O ' ' B' ' 20' ' ' ASN . 75.3 m-85 -157.2 150.36 23.79 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.534 -0.729 . . . . 0.0 110.195 179.499 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 22' ' ' ARG . . . . . 0.478 ' HD3' HD22 ' B' ' 68' ' ' LEU . 63.7 ttt180 -96.8 143.21 27.93 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.914 -1.117 . . . . 0.0 109.944 172.616 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.495 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 54.0 m -130.76 140.21 50.29 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.638 -0.664 . . . . 0.0 110.134 -173.492 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.742 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -130.04 143.94 51.06 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.005 -1.06 . . . . 0.0 111.492 178.806 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.867 HG22 ' OG ' ' B' ' 60' ' ' SER . 8.2 t -125.7 136.3 61.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.317 -0.864 . . . . 0.0 110.764 179.869 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.469 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 35.6 m -117.91 171.78 5.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.744 -0.598 . . . . 0.0 110.126 178.355 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.578 ' CG ' HD22 ' B' ' 57' ' ' ASN . 3.6 tt0 -104.18 117.45 34.28 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.274 -0.891 . . . . 0.0 109.199 -178.786 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.55 HD21 ' O ' ' B' ' 32' ' ' MET . 9.6 tp -82.9 125.8 74.37 Favored Pre-proline 0 C--N 1.299 -1.613 0 O-C-N 121.545 -0.722 . . . . 0.0 110.129 -173.724 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.539 ' HD2' HD12 ' B' ' 28' ' ' LEU . 28.1 Cg_endo -67.01 176.96 3.97 Favored 'Trans proline' 0 C--N 1.31 -1.491 0 O-C-N 123.919 1.484 . . . . 0.0 110.934 -179.583 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.656 ' HA ' HD12 ' B' ' 33' ' ' LEU . 92.6 m-20 -60.01 -39.99 87.72 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.309 -0.869 . . . . 0.0 111.35 -174.938 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.584 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.01 0.63 57.0 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.761 -1.212 . . . . 0.0 110.844 -174.434 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.584 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.8 mmm -112.19 -8.58 13.98 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.856 -1.153 . . . . 0.0 110.006 170.891 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.715 HD21 ' HB2' ' B' ' 57' ' ' ASN . 16.0 mt -70.0 -40.04 75.52 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.268 -0.895 . . . . 0.0 109.888 177.07 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -81.7 128.93 34.49 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.597 -0.689 . . . . 0.0 110.508 -178.273 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.35 -46.15 1.21 Allowed Glycine 0 N--CA 1.492 2.414 0 C-N-CA 119.868 -1.158 . . . . 0.0 110.328 174.84 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.705 HD23 ' N ' ' B' ' 37' ' ' GLU . 6.8 tt -69.66 148.89 48.71 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.95 -1.324 . . . . 0.0 110.43 -175.402 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 37' ' ' GLU . . . . . 0.705 ' N ' HD23 ' B' ' 36' ' ' LEU . 21.4 pt-20 -150.68 169.95 20.36 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.347 -0.845 . . . . 0.0 109.51 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 38' ' ' THR . . . . . 0.72 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -69.99 151.12 45.94 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.038 -1.039 . . . . 0.0 110.252 -178.855 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.17 -3.5 65.96 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 -174.209 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.453 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -77.91 161.36 27.62 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.297 -1.119 . . . . 0.0 109.701 177.521 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.48 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.6 OUTLIER -101.43 114.82 29.17 Favored 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 119.096 -1.042 . . . . 0.0 110.18 177.35 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.644 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.8 t -103.12 129.01 55.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.379 -0.826 . . . . 0.0 109.141 174.068 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -94.87 120.05 34.45 Favored 'General case' 0 C--N 1.298 -1.651 0 C-N-CA 119.245 -0.982 . . . . 0.0 109.214 173.044 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.857 ' CD2' HG21 ' B' ' 82' ' ' VAL . 1.4 m80 -90.69 106.15 18.31 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.403 -0.811 . . . . 0.0 109.074 177.478 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.496 ' OD1' ' HB2' ' A' ' 47' ' ' CYS . 1.8 t-20 54.01 14.84 0.75 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.368 -0.833 . . . . 0.0 110.858 -167.157 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.512 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 117.66 -0.3 17.98 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.715 -1.231 . . . . 0.0 111.031 170.438 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.857 ' O ' HD23 ' B' ' 49' ' ' LEU . 43.1 t -92.38 106.9 18.8 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.411 -1.641 . . . . 0.0 109.134 173.395 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 17.8 p -75.45 128.75 36.04 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.097 -1.002 . . . . 0.0 110.684 -170.911 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 0.857 HD23 ' O ' ' B' ' 47' ' ' CYS . 0.3 OUTLIER -143.29 159.64 41.97 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.416 -0.803 . . . . 0.0 109.61 175.259 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 50' ' ' THR . . . . . 0.42 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 29.4 m -100.02 150.01 22.88 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.673 -1.267 . . . . 0.0 111.329 -170.74 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.816 HG13 HG13 ' B' ' 59' ' ' VAL . 15.4 t -78.38 118.46 25.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.827 -0.546 . . . . 0.0 110.607 -178.027 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.532 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 43.0 p -73.89 -40.01 63.49 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.201 -0.937 . . . . 0.0 110.037 174.629 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.666 ' HA ' HG21 ' B' ' 38' ' ' THR . 86.6 tt0 -163.32 149.83 12.19 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.336 -0.852 . . . . 0.0 110.206 -177.966 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.72 HD11 ' N ' ' B' ' 38' ' ' THR . 5.7 mt -101.52 134.79 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.096 -1.002 . . . . 0.0 109.993 176.148 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.515 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 49.7 m-80 -110.41 65.78 0.62 Allowed 'General case' 0 C--N 1.298 -1.634 0 C-N-CA 119.857 -0.737 . . . . 0.0 109.907 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.31 -118.75 4.99 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 108.809 -1.717 . . . . 0.0 108.809 -175.26 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.715 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -78.55 -16.54 57.32 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.969 -1.312 . . . . 0.0 108.901 174.302 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.145 ' CD2' HG11 ' B' ' 13' ' ' VAL . 11.8 m170 -76.51 159.63 30.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.491 -0.756 . . . . 0.0 110.347 -178.2 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.816 HG13 HG13 ' B' ' 51' ' ' VAL . 52.1 t -140.15 127.1 23.14 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 C-N-CA 119.042 -1.063 . . . . 0.0 110.554 170.054 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.867 ' OG ' HG22 ' B' ' 25' ' ' VAL . 2.7 t -95.81 136.85 35.69 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.575 -0.703 . . . . 0.0 109.616 178.307 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.81 ' HB2' HD12 ' B' ' 49' ' ' LEU . 2.0 p90 -128.11 157.63 40.2 Favored 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 119.054 -1.058 . . . . 0.0 110.876 174.065 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.532 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 25.3 p-10 -89.47 157.76 17.98 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.297 -0.877 . . . . 0.0 111.056 -171.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.749 HD22 ' CD1' ' B' ' 68' ' ' LEU . 0.1 OUTLIER -159.96 102.54 1.47 Allowed 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.958 -0.697 . . . . 0.0 109.445 -175.428 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.499 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 56.1 ttm -59.77 140.36 56.58 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.117 -0.989 . . . . 0.0 109.381 -179.501 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.456 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 39.4 ttpt -59.98 -43.38 95.15 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.042 -1.036 . . . . 0.0 110.242 -175.094 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.72 -40.04 76.47 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.049 -1.032 . . . . 0.0 110.083 178.297 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.499 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 92.2 m -60.58 -39.97 90.02 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.95 -1.094 . . . . 0.0 109.14 173.016 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.749 ' CD1' HD22 ' B' ' 63' ' ' LEU . 7.3 tp -60.0 -45.17 93.61 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.375 -0.828 . . . . 0.0 109.892 179.3 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 15.0 tpp180 -69.33 -39.41 78.21 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.547 -0.72 . . . . 0.0 110.493 177.912 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.852 HG22 HG23 ' B' ' 71' ' ' THR . 1.4 tt -63.85 -43.88 97.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.177 -0.952 . . . . 0.0 109.365 -177.427 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.852 HG23 HG22 ' B' ' 70' ' ' ILE . 37.3 p -83.44 -170.42 3.04 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 121.433 0.635 . . . . 0.0 109.805 178.529 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.492 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 4.3 t30 -103.33 22.58 13.91 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 170.176 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.704 ' HB3' HD21 ' B' ' 63' ' ' LEU . 89.3 mt -69.55 -41.16 76.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.228 -0.92 . . . . 0.0 110.091 176.689 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.731 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -51.01 -20.8 4.73 Favored Glycine 0 N--CA 1.487 2.099 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -178.23 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.1 p-10 -67.55 -18.41 65.01 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.998 -1.295 . . . . 0.0 110.706 -173.909 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.514 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 90.3 mt -60.92 142.82 56.07 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.077 -1.015 . . . . 0.0 110.947 -175.513 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 0.998 ' C ' HD23 ' B' ' 12' ' ' LEU . 98.7 mttt -140.32 139.74 35.49 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.682 -0.636 . . . . 0.0 109.854 173.914 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.714 HG23 HD11 ' B' ' 15' ' ' ILE . 16.2 t -63.4 153.45 7.01 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.12 -0.987 . . . . 0.0 110.625 -174.399 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.02 -16.68 56.48 Favored Glycine 0 N--CA 1.484 1.874 0 N-CA-C 108.687 -1.765 . . . . 0.0 108.687 -175.285 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 24.9 t0 -95.13 169.95 9.74 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.374 -1.074 . . . . 0.0 109.808 175.615 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.583 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.5 m95 -116.98 169.42 9.42 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.034 -1.041 . . . . 0.0 110.139 176.022 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 1.092 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.4 p -133.96 155.7 40.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.539 -0.726 . . . . 0.0 109.908 -176.824 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.992 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.0 m-20 -79.5 108.91 13.39 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.074 -1.016 . . . . 0.0 109.245 168.692 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.754 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -110.45 138.87 36.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 120.458 -1.401 . . . . 0.0 111.183 -175.393 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -134.73 145.08 48.13 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.856 -0.527 . . . . 0.0 110.128 -177.364 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 36.2 ttm180 -83.43 130.67 35.04 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.26 -0.9 . . . . 0.0 110.987 -176.675 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.48 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.493 1.715 0 O-C-N 121.279 -0.888 . . . . 0.0 109.965 174.666 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 1.025 HG21 ' HB3' ' A' ' 83' ' ' ASN . 4.0 t . . . . . 0 N--CA 1.493 1.696 0 CA-C-O 121.803 0.811 . . . . 0.0 111.3 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -69.99 -34.08 72.88 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.695 -0.628 . . . . 0.0 110.632 175.369 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -163.34 171.43 39.05 Favored Glycine 0 N--CA 1.494 2.555 0 C-N-CA 118.729 -1.7 . . . . 0.0 110.394 -174.518 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.497 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 11.7 p -112.81 168.35 9.75 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.031 -1.276 . . . . 0.0 110.699 -178.729 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 0.988 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -133.46 148.87 51.76 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -178.022 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.574 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 22.5 tttt -104.25 112.64 25.74 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 120.972 -1.08 . . . . 0.0 110.15 178.109 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.947 HD23 ' C ' ' A' ' 77' ' ' LYS . 10.9 tp -57.14 126.88 29.2 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 121.146 -0.971 . . . . 0.0 108.803 173.598 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.151 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.21 -31.35 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 O-C-N 121.349 -0.844 . . . . 0.0 110.046 -178.237 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -142.86 144.18 32.39 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.147 -1.021 . . . . 0.0 111.582 -179.454 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.687 HG13 HG21 ' A' ' 78' ' ' VAL . 8.1 mt -110.94 130.37 64.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 120.995 -1.065 . . . . 0.0 110.21 168.749 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.509 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 76.0 m-20 -108.86 115.49 30.19 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.364 -0.835 . . . . 0.0 109.889 172.331 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -103.91 110.28 22.35 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 120.888 -1.132 . . . . 0.0 110.495 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.9 OUTLIER -102.61 131.87 21.91 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.177 -0.952 . . . . 0.0 108.88 173.76 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -50.52 -34.21 41.43 Favored 'Trans proline' 0 C--N 1.302 -1.91 0 O-C-N 123.828 1.436 . . . . 0.0 110.383 -179.471 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.576 ' HB3' ' CE2' ' A' ' 21' ' ' PHE . 7.6 m120 -74.19 -39.33 63.25 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.244 -0.91 . . . . 0.0 110.32 175.899 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.576 ' CE2' ' HB3' ' A' ' 20' ' ' ASN . 49.9 m-85 -152.53 150.14 29.26 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.271 -0.893 . . . . 0.0 110.106 -176.882 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.438 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 50.7 ttt180 -88.73 144.96 25.91 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.914 -1.116 . . . . 0.0 109.999 175.065 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.509 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.8 m -130.07 140.06 50.89 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.437 -0.79 . . . . 0.0 110.099 -177.876 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.606 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -129.59 144.61 51.35 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.967 -1.083 . . . . 0.0 111.107 177.333 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.725 HG22 ' CB ' ' A' ' 60' ' ' SER . 6.9 t -124.06 133.37 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.034 -1.041 . . . . 0.0 110.508 179.229 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.912 HG13 ' CE1' ' A' ' 61' ' ' PHE . 13.1 m -112.88 172.31 3.26 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 121.737 -0.602 . . . . 0.0 109.954 177.403 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.585 ' CG ' HD22 ' A' ' 57' ' ' ASN . 8.1 tt0 -106.95 116.3 31.69 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.357 -0.839 . . . . 0.0 108.794 178.128 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.608 HD11 ' HB3' ' A' ' 32' ' ' MET . 9.2 tp -80.09 123.98 83.13 Favored Pre-proline 0 C--N 1.296 -1.753 0 O-C-N 121.548 -0.72 . . . . 0.0 109.977 -172.569 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.522 ' HD2' HD12 ' A' ' 28' ' ' LEU . 27.7 Cg_endo -66.35 -178.54 1.18 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 O-C-N 123.822 1.433 . . . . 0.0 110.977 -179.521 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.489 ' HA ' HD12 ' A' ' 33' ' ' LEU . 61.6 t0 -62.55 -40.97 98.52 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 111.027 -174.667 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.03 1.14 56.66 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.811 -1.181 . . . . 0.0 111.014 -174.664 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.608 ' HB3' HD11 ' A' ' 28' ' ' LEU . 99.4 mmm -108.56 -15.37 14.45 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.784 -1.198 . . . . 0.0 109.844 169.829 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.673 HD21 ' HB2' ' A' ' 57' ' ' ASN . 21.0 mt -69.51 -22.04 63.62 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.217 -0.927 . . . . 0.0 109.997 177.699 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -95.16 115.6 27.65 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.364 -0.835 . . . . 0.0 110.473 -178.59 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.34 -50.52 0.78 Allowed Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.764 -1.207 . . . . 0.0 110.556 173.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.83 HD23 ' N ' ' A' ' 37' ' ' GLU . 9.8 tt -60.98 159.33 11.67 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.886 -1.361 . . . . 0.0 111.123 -172.319 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.83 ' N ' HD23 ' A' ' 36' ' ' LEU . 22.0 pt-20 -157.52 163.46 38.39 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.998 HG23 HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -69.9 151.57 45.51 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.845 -1.159 . . . . 0.0 109.921 -177.474 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.09 -4.66 65.68 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 -172.859 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.413 ' O ' ' HA ' ' A' ' 50' ' ' THR . . . -74.33 160.12 31.48 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.293 -1.122 . . . . 0.0 109.683 176.828 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.84 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.7 OUTLIER -100.98 103.25 14.39 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.068 -1.02 . . . . 0.0 110.12 178.298 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.618 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.2 t -88.12 131.46 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.201 -0.937 . . . . 0.0 109.489 175.489 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.708 ' HB3' ' HB2' ' A' ' 85' ' ' GLU . . . -98.17 120.97 39.51 Favored 'General case' 0 C--N 1.296 -1.755 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.418 170.862 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.671 ' CG ' HG21 ' A' ' 82' ' ' VAL . 1.0 OUTLIER -88.74 105.83 17.96 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 119.583 -0.847 . . . . 0.0 108.987 177.525 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' B' ' 45' ' ' ASN . 0.9 OUTLIER 52.96 11.92 0.24 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.463 -0.773 . . . . 0.0 111.525 -166.482 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 127.73 -6.8 6.97 Favored Glycine 0 N--CA 1.489 2.233 0 C-N-CA 119.224 -1.465 . . . . 0.0 111.169 172.241 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.816 ' O ' HD23 ' A' ' 49' ' ' LEU . 13.8 t -92.49 105.99 18.06 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.192 -1.77 . . . . 0.0 109.471 177.027 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 16.2 p -75.24 129.52 37.6 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.14 -0.975 . . . . 0.0 111.122 -171.138 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.834 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -141.97 159.98 41.13 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.595 -0.691 . . . . 0.0 109.276 174.91 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.413 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 51.7 m -94.79 148.24 22.5 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.613 -1.305 . . . . 0.0 111.279 -170.91 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.658 HG13 HG13 ' A' ' 59' ' ' VAL . 19.3 t -77.27 122.03 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.651 -0.656 . . . . 0.0 110.265 178.849 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.522 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 19.3 p -77.54 -44.49 28.41 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.257 -0.902 . . . . 0.0 110.138 175.204 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.67 ' HA ' HG21 ' A' ' 38' ' ' THR . 86.1 tt0 -157.47 150.13 23.04 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.113 -0.992 . . . . 0.0 110.348 178.023 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.998 HD12 HG23 ' A' ' 38' ' ' THR . 1.4 mp -97.79 137.0 26.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.07 -1.019 . . . . 0.0 109.728 173.237 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.48 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 33.4 m-80 -110.03 70.43 0.72 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.595 -0.691 . . . . 0.0 109.698 178.147 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 72.04 -120.12 7.75 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 -172.999 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.673 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.1 OUTLIER -75.51 -21.17 58.21 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 120.995 -1.297 . . . . 0.0 109.04 175.543 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.151 ' CD2' HG11 ' A' ' 13' ' ' VAL . 10.7 m170 -72.41 160.48 32.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.28 -0.887 . . . . 0.0 110.234 -178.395 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.658 HG13 HG13 ' A' ' 51' ' ' VAL . 53.1 t -140.07 124.54 19.18 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 C-N-CA 119.127 -1.029 . . . . 0.0 110.536 170.679 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.725 ' CB ' HG22 ' A' ' 25' ' ' VAL . 53.1 p -95.08 128.56 42.01 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.476 -0.765 . . . . 0.0 109.553 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.912 ' CE1' HG13 ' A' ' 26' ' ' VAL . 1.8 p90 -124.01 157.35 34.65 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 120.995 -1.066 . . . . 0.0 110.254 -179.118 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.522 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 30.4 p-10 -93.27 152.79 18.96 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 122.09 0.947 . . . . 0.0 111.127 -172.794 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.752 ' CD2' HD12 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -152.21 120.03 6.15 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -175.894 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.51 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 63.5 tpp -77.16 139.58 39.96 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.983 -1.073 . . . . 0.0 109.848 -179.64 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.479 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 74.9 tttt -59.93 -49.85 76.07 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.12 -0.987 . . . . 0.0 110.578 -173.49 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.414 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 88.3 tt0 -66.27 -39.96 89.79 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.828 -1.17 . . . . 0.0 109.996 178.223 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.51 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 90.9 m -60.0 -39.57 86.21 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.002 -1.061 . . . . 0.0 109.197 173.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.752 HD12 ' CD2' ' A' ' 63' ' ' LEU . 2.1 tp -59.97 -45.28 93.18 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.319 -0.863 . . . . 0.0 109.852 179.339 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 tpt85 -69.39 -38.32 77.93 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.386 -0.821 . . . . 0.0 110.079 177.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.805 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -67.75 -39.9 82.84 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 O-C-N 121.333 -0.855 . . . . 0.0 109.191 -177.886 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.805 HG23 HG22 ' A' ' 70' ' ' ILE . 49.4 p -88.77 -176.41 5.22 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 175.572 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.467 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 8.8 t30 -98.22 21.18 11.26 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.244 -0.91 . . . . 0.0 108.903 173.87 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.713 ' HB3' HD21 ' A' ' 63' ' ' LEU . 34.4 mt -70.04 -39.99 75.42 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.912 -1.118 . . . . 0.0 110.444 179.609 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.729 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -52.54 -19.33 6.19 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -176.34 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 27.1 p-10 -69.98 -18.21 63.33 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.111 -1.229 . . . . 0.0 110.965 -174.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 85.5 mt -59.99 146.49 42.41 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.088 -1.008 . . . . 0.0 111.026 -174.54 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 0.947 ' C ' HD23 ' A' ' 12' ' ' LEU . 67.4 mttt -139.88 141.75 36.57 Favored 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 121.537 0.684 . . . . 0.0 109.906 176.68 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.687 HG21 HG13 ' A' ' 15' ' ' ILE . 46.2 t -66.44 150.06 11.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 120.888 -1.133 . . . . 0.0 110.466 -177.329 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.96 -14.99 60.46 Favored Glycine 0 N--CA 1.482 1.743 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 -174.714 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.478 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 13.9 t0 -96.65 168.27 10.62 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.409 -1.053 . . . . 0.0 109.576 174.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.574 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.4 m95 -115.83 156.09 26.71 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.04 -1.037 . . . . 0.0 110.304 177.72 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.988 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.1 p -120.07 150.0 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.262 -0.899 . . . . 0.0 110.1 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 1.025 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.4 OUTLIER -70.79 104.53 2.92 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.044 -1.035 . . . . 0.0 108.887 166.785 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.777 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -104.35 139.42 25.37 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 120.51 -1.369 . . . . 0.0 110.987 -176.839 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.922 ' HG3' HG22 ' A' ' 6' ' ' VAL . 85.2 mt-10 -125.47 146.62 49.56 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.918 -0.488 . . . . 0.0 110.15 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.533 ' HB3' ' CZ ' ' A' ' 86' ' ' ARG . 18.3 mtp-105 -90.26 114.77 26.87 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.513 -0.742 . . . . 0.0 110.033 177.494 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.84 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.061 -1.024 . . . . 0.0 110.524 -178.254 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 0.958 HG22 ' HG3' ' B' ' 85' ' ' GLU . 4.0 t . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.783 0.802 . . . . 0.0 111.367 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -70.05 -33.75 72.36 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.745 -0.597 . . . . 0.0 110.685 175.449 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.54 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -163.66 171.35 39.29 Favored Glycine 0 N--CA 1.495 2.628 0 C-N-CA 118.91 -1.614 . . . . 0.0 110.52 -174.52 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.498 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 11.7 p -112.9 168.29 9.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.06 -1.259 . . . . 0.0 110.739 -178.632 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.055 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -133.38 149.01 51.85 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 -178.017 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.568 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 22.7 tttt -104.36 112.79 25.97 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 120.982 -1.074 . . . . 0.0 110.047 178.115 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 0.964 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.0 tp -57.35 126.84 29.06 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.193 -0.942 . . . . 0.0 108.761 173.592 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.133 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.18 -31.24 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.784 0 O-C-N 121.339 -0.851 . . . . 0.0 110.089 -178.211 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -142.99 144.17 32.21 Favored 'General case' 0 N--CA 1.493 1.716 0 C-N-CA 119.234 -0.986 . . . . 0.0 111.553 -179.478 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.693 HG13 HG21 ' B' ' 78' ' ' VAL . 8.0 mt -110.85 130.47 64.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 120.992 -1.068 . . . . 0.0 110.193 168.836 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.518 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 75.5 m-20 -109.12 115.59 30.33 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.353 -0.842 . . . . 0.0 109.767 172.389 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -103.92 110.31 22.39 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.019 -1.05 . . . . 0.0 110.443 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.453 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.9 OUTLIER -102.7 131.92 21.82 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.347 -0.846 . . . . 0.0 108.874 173.763 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -50.62 -34.19 42.29 Favored 'Trans proline' 0 C--N 1.301 -1.95 0 O-C-N 123.825 1.434 . . . . 0.0 110.295 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.588 ' HB3' ' CE2' ' B' ' 21' ' ' PHE . 7.6 m120 -73.98 -39.96 63.31 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.224 -0.922 . . . . 0.0 110.165 175.905 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.588 ' CE2' ' HB3' ' B' ' 20' ' ' ASN . 49.4 m-85 -152.06 150.18 29.66 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.381 -0.824 . . . . 0.0 110.183 -176.757 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 22' ' ' ARG . . . . . 0.427 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 50.5 ttt180 -88.65 144.91 25.98 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.916 -1.115 . . . . 0.0 109.924 175.033 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.518 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 95.0 m -130.09 140.08 50.87 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.511 -0.743 . . . . 0.0 110.147 -178.003 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.605 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -129.57 144.58 51.33 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.095 -1.003 . . . . 0.0 110.994 177.476 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.73 HG22 ' CB ' ' B' ' 60' ' ' SER . 6.8 t -123.99 133.48 69.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.142 -0.974 . . . . 0.0 110.573 179.113 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.931 HG13 ' CE1' ' B' ' 61' ' ' PHE . 13.3 m -112.96 172.3 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.698 -0.626 . . . . 0.0 109.876 177.485 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.593 ' CG ' HD22 ' B' ' 57' ' ' ASN . 8.1 tt0 -106.86 116.24 31.58 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.444 -0.785 . . . . 0.0 108.923 177.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.605 HD11 ' HB3' ' B' ' 32' ' ' MET . 9.3 tp -80.01 123.98 83.26 Favored Pre-proline 0 C--N 1.296 -1.747 0 O-C-N 121.434 -0.791 . . . . 0.0 110.028 -172.587 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.526 ' HD2' HD12 ' B' ' 28' ' ' LEU . 27.7 Cg_endo -66.3 -178.42 1.13 Allowed 'Trans proline' 0 C--N 1.31 -1.489 0 O-C-N 123.831 1.437 . . . . 0.0 110.96 -179.523 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.478 ' HA ' HD12 ' B' ' 33' ' ' LEU . 61.7 t0 -62.67 -40.91 98.55 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.386 -0.821 . . . . 0.0 111.027 -174.698 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.595 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.01 1.11 56.68 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.867 -1.145 . . . . 0.0 111.01 -174.631 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.605 ' HB3' HD11 ' B' ' 28' ' ' LEU . 99.4 mmm -108.61 -15.25 14.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.752 -1.218 . . . . 0.0 109.813 169.84 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.696 HD21 ' HB2' ' B' ' 57' ' ' ASN . 20.8 mt -69.69 -21.93 63.47 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.269 -0.894 . . . . 0.0 109.982 177.722 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -95.22 115.68 27.75 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.348 -0.845 . . . . 0.0 110.408 -178.606 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.18 -50.43 0.78 Allowed Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.823 -1.179 . . . . 0.0 110.543 173.889 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.827 HD23 ' N ' ' B' ' 37' ' ' GLU . 9.8 tt -61.01 159.29 11.81 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.843 -1.386 . . . . 0.0 111.132 -172.362 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 37' ' ' GLU . . . . . 0.827 ' N ' HD23 ' B' ' 36' ' ' LEU . 21.9 pt-20 -157.51 163.36 38.51 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 38' ' ' THR . . . . . 1.049 HG23 HD12 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -69.85 151.59 45.53 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.862 -1.149 . . . . 0.0 109.965 -177.531 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.98 -4.47 66.05 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -172.865 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' B' ' 50' ' ' THR . . . -74.37 160.02 31.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.199 -1.177 . . . . 0.0 109.653 176.68 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.817 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.6 OUTLIER -100.82 103.12 14.32 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.969 -1.082 . . . . 0.0 110.139 178.291 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.634 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.2 t -88.1 131.59 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.284 -0.885 . . . . 0.0 109.486 175.432 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 0.705 ' HB3' ' HB2' ' B' ' 85' ' ' GLU . . . -98.25 121.0 39.64 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 120.961 -1.087 . . . . 0.0 109.441 170.716 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.668 ' CG ' HG21 ' B' ' 82' ' ' VAL . 1.0 OUTLIER -88.78 105.58 17.8 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.245 -0.91 . . . . 0.0 109.1 177.494 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' A' ' 45' ' ' ASN . 0.9 OUTLIER 53.23 11.94 0.28 Allowed 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.462 -0.774 . . . . 0.0 111.409 -166.565 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 127.55 -6.36 7.07 Favored Glycine 0 N--CA 1.49 2.251 0 C-N-CA 119.231 -1.461 . . . . 0.0 111.082 172.03 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.838 ' O ' HD23 ' B' ' 49' ' ' LEU . 13.9 t -92.66 106.04 18.09 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.059 -1.847 . . . . 0.0 109.439 176.825 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 16.1 p -75.21 129.57 37.7 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.086 -1.009 . . . . 0.0 111.145 -171.19 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 0.855 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -142.01 159.93 41.23 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 174.925 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 50' ' ' THR . . . . . 0.414 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 52.1 m -94.69 148.21 22.52 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.514 -1.366 . . . . 0.0 111.244 -170.879 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.67 HG13 HG13 ' B' ' 59' ' ' VAL . 18.6 t -77.23 122.06 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.647 -0.658 . . . . 0.0 110.281 178.796 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.519 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 19.7 p -77.66 -44.55 27.73 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.213 -0.93 . . . . 0.0 110.029 175.33 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.666 ' HA ' HG21 ' B' ' 38' ' ' THR . 86.3 tt0 -157.43 150.18 23.17 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.101 -0.999 . . . . 0.0 110.348 178.031 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 1.049 HD12 HG23 ' B' ' 38' ' ' THR . 1.4 mp -97.82 136.94 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.175 -0.953 . . . . 0.0 109.729 173.282 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.504 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 33.5 m-80 -109.95 70.29 0.72 Allowed 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.545 -0.722 . . . . 0.0 109.676 178.219 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 72.09 -120.11 7.71 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 108.713 -1.755 . . . . 0.0 108.713 -172.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.696 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -75.41 -21.28 58.35 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.054 -1.262 . . . . 0.0 109.12 175.468 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.133 ' CD2' HG11 ' B' ' 13' ' ' VAL . 10.8 m170 -72.43 160.27 32.61 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.407 -0.808 . . . . 0.0 110.362 -178.404 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.67 HG13 HG13 ' B' ' 51' ' ' VAL . 53.6 t -139.89 124.62 19.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 119.061 -1.056 . . . . 0.0 110.415 170.853 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.73 ' CB ' HG22 ' B' ' 25' ' ' VAL . 53.4 p -95.08 128.82 42.21 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.619 -0.675 . . . . 0.0 109.509 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.931 ' CE1' HG13 ' B' ' 26' ' ' VAL . 1.8 p90 -124.26 157.29 35.21 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.002 -1.061 . . . . 0.0 110.218 -179.148 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.519 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 30.5 p-10 -93.2 152.74 19.03 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.136 -0.978 . . . . 0.0 111.192 -172.753 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.752 ' CD2' HD12 ' B' ' 68' ' ' LEU . 0.0 OUTLIER -152.06 119.97 6.19 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 -175.883 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.511 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 63.6 tpp -77.19 139.57 39.93 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.976 -1.078 . . . . 0.0 109.845 -179.61 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.484 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 74.9 tttt -60.03 -49.73 76.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.166 -0.959 . . . . 0.0 110.492 -173.362 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 66' ' ' GLU . . . . . 0.424 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 88.4 tt0 -66.35 -40.0 89.53 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.794 -1.191 . . . . 0.0 109.946 178.326 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.511 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 90.3 m -60.05 -39.55 86.32 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.031 -1.043 . . . . 0.0 109.145 174.008 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.752 HD12 ' CD2' ' B' ' 63' ' ' LEU . 2.1 tp -60.01 -45.14 93.73 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.388 -0.82 . . . . 0.0 109.962 179.278 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 tpt85 -69.35 -38.52 78.14 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.409 -0.807 . . . . 0.0 110.079 177.909 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.771 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -67.55 -39.95 83.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 CA-C-O 121.73 0.776 . . . . 0.0 109.238 -178.032 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.771 HG23 HG22 ' B' ' 70' ' ' ILE . 49.6 p -88.74 -176.24 5.18 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 175.674 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.516 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 8.7 t30 -98.3 21.19 11.33 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 121.182 -0.948 . . . . 0.0 108.733 173.881 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.744 ' HB3' HD21 ' B' ' 63' ' ' LEU . 34.1 mt -70.01 -40.03 75.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.954 -1.091 . . . . 0.0 110.458 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.743 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -52.49 -19.31 6.09 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -176.324 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.504 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 27.2 p-10 -70.05 -18.25 63.28 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.083 -1.245 . . . . 0.0 110.946 -174.9 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.504 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 85.7 mt -59.95 146.43 42.45 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.188 -0.945 . . . . 0.0 111.012 -174.547 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 0.964 ' C ' HD23 ' B' ' 12' ' ' LEU . 67.4 mttt -139.89 141.78 36.54 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.626 -0.671 . . . . 0.0 109.888 176.658 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.693 HG21 HG13 ' B' ' 15' ' ' ILE . 46.2 t -66.49 150.01 11.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.04 -1.038 . . . . 0.0 110.498 -177.274 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.01 -14.94 60.65 Favored Glycine 0 N--CA 1.483 1.824 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -174.712 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 13.8 t0 -96.73 168.13 10.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.359 -1.083 . . . . 0.0 109.582 174.889 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.568 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.4 m95 -115.76 156.0 26.8 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.06 -1.025 . . . . 0.0 110.325 177.788 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 1.055 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.1 p -120.01 150.06 22.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.427 -0.795 . . . . 0.0 110.173 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.952 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.4 OUTLIER -70.68 104.32 2.81 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.001 -1.062 . . . . 0.0 109.053 166.705 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.773 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -104.22 139.59 24.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 120.464 -1.398 . . . . 0.0 110.905 -176.61 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' B' B ' 85' ' ' GLU . . . . . 0.958 ' HG3' HG22 ' B' ' 6' ' ' VAL . 85.0 mt-10 -125.73 146.57 49.7 Favored 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.193 0.521 . . . . 0.0 110.064 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 86' ' ' ARG . . . . . 0.539 ' HB3' ' CZ ' ' B' ' 86' ' ' ARG . 18.3 mtp-105 -90.26 114.84 26.95 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.35 -0.844 . . . . 0.0 109.957 177.566 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.817 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.624 0 O-C-N 121.256 -0.903 . . . . 0.0 110.57 -178.292 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.69 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.6 t . . . . . 0 N--CA 1.49 1.562 0 CA-C-O 121.836 0.827 . . . . 0.0 110.871 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -71.04 -33.09 69.98 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.866 -0.521 . . . . 0.0 111.182 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.533 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -150.35 171.92 30.2 Favored Glycine 0 N--CA 1.495 2.582 0 C-N-CA 119.054 -1.546 . . . . 0.0 110.133 -171.9 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.495 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 3.1 p -119.23 172.34 7.66 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.893 -1.357 . . . . 0.0 111.214 -176.453 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 1.013 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -142.64 150.0 39.66 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 -176.362 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.587 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.1 tttt -110.83 115.15 29.03 Favored 'General case' 0 C--N 1.295 -1.803 0 O-C-N 121.097 -1.002 . . . . 0.0 110.276 179.54 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.941 HD23 ' C ' ' A' ' 77' ' ' LYS . 10.9 tp -59.74 127.71 33.32 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.015 -1.053 . . . . 0.0 109.079 174.362 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.113 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -122.2 -28.9 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 C-N-CA 119.641 -0.824 . . . . 0.0 109.648 179.2 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.71 147.54 26.83 Favored 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 119.05 -1.06 . . . . 0.0 111.551 -179.155 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.839 HG23 ' CD2' ' A' ' 24' ' ' HIS . 11.7 mt -109.59 138.61 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.212 -0.93 . . . . 0.0 110.03 172.415 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.507 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.7 m-20 -109.58 114.62 28.4 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.283 -0.885 . . . . 0.0 109.924 173.52 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -100.35 112.15 24.47 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.13 -0.981 . . . . 0.0 110.369 -176.484 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.2 OUTLIER -112.76 132.76 22.12 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.203 -0.935 . . . . 0.0 108.94 175.492 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -49.57 -40.39 45.88 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 O-C-N 123.855 1.45 . . . . 0.0 110.754 -179.204 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.445 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 12.0 m-80 -70.59 -39.37 73.89 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.124 -0.985 . . . . 0.0 110.259 177.962 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.461 ' O ' ' HB2' ' A' ' 18' ' ' LYS . 95.7 m-85 -152.55 150.3 29.42 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.289 -0.882 . . . . 0.0 110.526 -174.978 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.603 ' HD3' HD22 ' A' ' 68' ' ' LEU . 60.7 ttt180 -91.28 143.54 26.54 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 120.835 -1.166 . . . . 0.0 109.909 175.006 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.507 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 97.1 m -129.57 140.77 51.12 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.597 -0.69 . . . . 0.0 109.738 -174.663 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.839 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -132.65 137.27 46.92 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 120.948 -1.095 . . . . 0.0 111.142 -177.95 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.836 HG22 ' OG ' ' A' ' 60' ' ' SER . 4.8 t -120.16 131.72 71.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.115 -0.991 . . . . 0.0 110.677 -178.379 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.863 HG13 ' CE1' ' A' ' 61' ' ' PHE . 18.9 m -111.9 175.74 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 CA-C-O 121.212 0.529 . . . . 0.0 110.265 178.007 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.569 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 7.9 tt0 -107.02 117.05 33.03 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.387 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.562 HD12 ' HD2' ' A' ' 29' ' ' PRO . 10.7 tp -80.45 126.74 77.97 Favored Pre-proline 0 C--N 1.296 -1.724 0 O-C-N 121.428 -0.795 . . . . 0.0 109.827 -173.53 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.562 ' HD2' HD12 ' A' ' 28' ' ' LEU . 18.7 Cg_endo -63.78 173.67 4.47 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.886 1.466 . . . . 0.0 110.654 -179.362 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.766 ' HA ' HD12 ' A' ' 33' ' ' LEU . 12.3 p-10 -59.99 -38.06 81.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.372 -0.83 . . . . 0.0 110.676 -176.159 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.589 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.18 0.06 57.37 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.959 -1.088 . . . . 0.0 110.947 -175.734 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.589 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 94.5 mmm -110.43 -12.01 14.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.854 -1.154 . . . . 0.0 109.948 170.176 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.944 HD21 ' HB2' ' A' ' 57' ' ' ASN . 15.8 mt -63.04 -31.38 72.5 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.299 -0.875 . . . . 0.0 110.15 176.817 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -93.23 139.99 30.02 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.339 -0.851 . . . . 0.0 110.536 -176.335 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.08 -41.42 2.34 Favored Glycine 0 N--CA 1.491 2.335 0 C-N-CA 119.892 -1.147 . . . . 0.0 110.387 174.878 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.76 HD23 ' N ' ' A' ' 37' ' ' GLU . 9.1 tt -76.1 149.28 37.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.926 -1.338 . . . . 0.0 111.054 -174.394 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.76 ' N ' HD23 ' A' ' 36' ' ' LEU . 15.8 pt-20 -151.59 169.25 22.56 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.464 -0.772 . . . . 0.0 109.58 177.289 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.926 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -61.32 151.64 31.47 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.936 -1.102 . . . . 0.0 109.876 179.107 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.73 -5.81 60.36 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -178.647 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.489 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -73.28 156.15 38.77 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.228 -1.16 . . . . 0.0 109.649 177.266 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.682 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -99.8 106.2 18.06 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.958 -1.089 . . . . 0.0 109.749 176.296 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.6 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.2 t -93.3 129.89 43.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 121.21 -0.931 . . . . 0.0 109.122 174.914 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.502 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -93.38 120.02 33.17 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.3 -0.96 . . . . 0.0 109.117 172.336 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.796 ' CD2' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -91.22 104.79 17.3 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.698 -0.801 . . . . 0.0 108.886 177.98 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.496 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.6 t-20 55.34 14.09 1.03 Allowed 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.314 -0.866 . . . . 0.0 110.896 -168.704 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 120.33 -5.16 12.12 Favored Glycine 0 N--CA 1.49 2.255 0 C-N-CA 119.58 -1.295 . . . . 0.0 110.919 172.132 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.848 ' O ' HD23 ' A' ' 49' ' ' LEU . 25.1 t -90.58 110.32 21.46 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.336 -1.685 . . . . 0.0 109.495 176.634 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.9 p -74.47 127.93 34.29 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.959 -1.088 . . . . 0.0 110.789 -171.47 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 1.008 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -143.21 160.06 41.16 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.323 -0.861 . . . . 0.0 109.707 174.825 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.459 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 3.6 m -102.22 151.56 22.06 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.773 -1.205 . . . . 0.0 111.083 -172.526 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.747 HG13 HG13 ' A' ' 59' ' ' VAL . 14.6 t -78.22 118.39 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.752 -0.593 . . . . 0.0 110.489 -177.341 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 43.9 p -72.32 -40.03 67.77 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.367 -0.833 . . . . 0.0 110.065 174.128 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.522 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -164.48 153.5 13.22 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.272 -0.893 . . . . 0.0 110.2 -176.956 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.926 HD11 ' N ' ' A' ' 38' ' ' THR . 6.8 mt -109.56 130.02 63.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.107 -0.996 . . . . 0.0 109.958 176.118 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.507 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 4.5 m-80 -102.56 63.28 0.86 Allowed 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.682 -0.636 . . . . 0.0 109.725 179.427 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.11 -114.06 4.06 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.781 -1.728 . . . . 0.0 108.781 -174.086 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.944 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.1 OUTLIER -78.53 -22.31 47.5 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 120.953 -1.322 . . . . 0.0 108.82 175.001 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.113 ' CD2' HG11 ' A' ' 13' ' ' VAL . 11.8 m80 -74.46 159.44 32.27 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.331 -0.856 . . . . 0.0 110.229 -177.651 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.747 HG13 HG13 ' A' ' 51' ' ' VAL . 54.1 t -141.62 122.58 12.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 C-N-CA 119.163 -1.015 . . . . 0.0 110.81 172.971 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.836 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.4 t -88.26 134.9 33.68 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.454 -0.779 . . . . 0.0 109.705 175.366 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 1.008 ' HB2' HD12 ' A' ' 49' ' ' LEU . 2.1 p90 -127.26 154.66 44.6 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.374 -0.829 . . . . 0.0 110.292 176.66 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 35.8 p-10 -88.95 152.29 21.8 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.149 -0.969 . . . . 0.0 111.329 -171.136 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.834 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -157.77 100.25 1.75 Allowed 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.598 -0.689 . . . . 0.0 109.369 -174.178 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.489 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 60.7 ttm -60.23 139.89 57.32 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.058 -1.026 . . . . 0.0 109.669 -177.307 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.494 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 5.1 ttpm? -59.94 -43.31 95.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.138 -0.977 . . . . 0.0 110.409 -175.36 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.33 -40.03 77.84 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.833 -1.167 . . . . 0.0 109.842 178.056 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.489 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 94.2 m -59.98 -37.64 80.24 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.05 -1.031 . . . . 0.0 109.474 172.231 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.712 HD11 ' HA2' ' A' ' 74' ' ' GLY . 14.2 tp -59.96 -45.81 91.45 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.273 -0.892 . . . . 0.0 109.428 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 55.2 ttt85 -69.96 -39.94 75.71 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.382 -0.824 . . . . 0.0 110.739 176.916 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.785 HG22 HG23 ' A' ' 71' ' ' THR . 1.5 tt -67.27 -42.82 88.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.233 -0.917 . . . . 0.0 109.445 -175.779 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.785 HG23 HG22 ' A' ' 70' ' ' ILE . 40.3 p -83.84 -173.87 4.96 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 174.678 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.496 ' HB3' ' HB2' ' B' ' 83' ' ' ASN . 3.1 t30 -102.71 23.63 11.77 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 169.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.834 ' HB3' HD21 ' A' ' 63' ' ' LEU . 86.9 mt -68.42 -40.07 81.36 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.089 -1.007 . . . . 0.0 110.015 176.768 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.712 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -47.88 -22.36 1.98 Allowed Glycine 0 N--CA 1.487 2.086 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.694 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.2 p-10 -62.83 -18.69 63.19 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.163 -1.198 . . . . 0.0 110.405 -176.303 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.513 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.8 mt -60.0 143.16 52.52 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.202 -0.936 . . . . 0.0 110.516 -177.752 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 0.941 ' C ' HD23 ' A' ' 12' ' ' LEU . 23.3 mttm -145.82 146.87 31.32 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.584 -0.698 . . . . 0.0 109.381 176.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.601 ' CG2' HG13 ' A' ' 15' ' ' ILE . 22.4 t -68.25 148.59 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.677 -1.265 . . . . 0.0 110.176 -175.625 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.14 -11.17 63.61 Favored Glycine 0 N--CA 1.483 1.813 0 N-CA-C 108.743 -1.743 . . . . 0.0 108.743 -174.167 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.494 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 45.5 t0 -95.68 162.63 13.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.344 -1.092 . . . . 0.0 109.694 176.785 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.587 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.0 m95 -114.76 149.35 37.07 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.124 -0.985 . . . . 0.0 110.005 176.778 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.013 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.2 p -115.21 153.79 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.498 -0.751 . . . . 0.0 109.971 -179.581 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.69 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.6 m-20 -78.19 106.11 9.87 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.143 -0.973 . . . . 0.0 109.125 168.607 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.875 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -108.4 139.88 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 120.665 -1.272 . . . . 0.0 111.177 -176.643 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.42 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.4 tt0 -136.92 144.02 43.23 Favored 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 120.217 -0.593 . . . . 0.0 110.201 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 66.5 ttp85 -79.58 129.92 34.91 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.279 -0.888 . . . . 0.0 111.011 -176.552 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.682 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.61 0 O-C-N 121.351 -0.843 . . . . 0.0 110.134 175.815 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 0.666 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.6 t . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 121.85 0.833 . . . . 0.0 110.921 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -71.11 -32.79 69.46 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.814 -0.554 . . . . 0.0 111.221 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.543 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -150.64 171.78 30.42 Favored Glycine 0 N--CA 1.495 2.63 0 C-N-CA 119.105 -1.522 . . . . 0.0 110.153 -171.876 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.499 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 3.1 p -119.23 172.26 7.72 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.937 -1.331 . . . . 0.0 111.238 -176.31 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.083 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -142.58 150.13 39.95 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 -176.417 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 30.1 tttt -110.9 115.25 29.19 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.102 -0.999 . . . . 0.0 110.224 179.585 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 0.929 HD23 ' C ' ' B' ' 77' ' ' LYS . 10.9 tp -59.95 127.68 33.08 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.085 -1.009 . . . . 0.0 109.068 174.41 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.127 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -122.03 -29.16 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.662 179.295 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.67 147.6 26.92 Favored 'General case' 0 N--CA 1.493 1.678 0 C-N-CA 119.188 -1.005 . . . . 0.0 111.473 -179.137 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.848 HG23 ' CD2' ' B' ' 24' ' ' HIS . 11.8 mt -109.59 138.71 35.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.305 -0.872 . . . . 0.0 110.041 172.404 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.506 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 77.4 m-20 -109.72 114.61 28.34 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 121.31 -0.869 . . . . 0.0 109.863 173.638 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.31 112.18 24.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.16 -0.963 . . . . 0.0 110.311 -176.449 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.2 OUTLIER -112.83 132.74 22.16 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.173 -0.954 . . . . 0.0 109.005 175.393 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -49.67 -40.35 46.85 Favored 'Trans proline' 0 C--N 1.303 -1.852 0 O-C-N 123.91 1.479 . . . . 0.0 110.705 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.438 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 12.1 m-80 -70.35 -40.07 74.3 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.141 -0.974 . . . . 0.0 110.108 177.897 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.461 ' O ' ' HB2' ' B' ' 18' ' ' LYS . 96.0 m-85 -152.03 150.36 29.87 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.314 -0.867 . . . . 0.0 110.542 -174.848 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 22' ' ' ARG . . . . . 0.614 ' HD3' HD22 ' B' ' 68' ' ' LEU . 60.6 ttt180 -91.31 143.42 26.66 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.893 -1.129 . . . . 0.0 109.965 174.959 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.506 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 97.2 m -129.41 140.69 51.25 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.659 -0.651 . . . . 0.0 109.718 -174.591 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.848 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -132.52 137.5 47.19 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.069 -1.019 . . . . 0.0 111.094 -178.088 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.845 HG22 ' OG ' ' B' ' 60' ' ' SER . 4.8 t -120.13 131.95 71.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.119 -0.988 . . . . 0.0 110.662 -178.379 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.866 HG13 ' CE1' ' B' ' 61' ' ' PHE . 19.0 m -112.24 175.64 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 121.751 -0.593 . . . . 0.0 110.171 178.067 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.575 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 7.9 tt0 -106.76 117.09 33.12 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 178.31 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.573 HD12 ' HD2' ' B' ' 29' ' ' PRO . 10.8 tp -80.42 126.67 78.22 Favored Pre-proline 0 C--N 1.295 -1.763 0 O-C-N 121.235 -0.916 . . . . 0.0 109.83 -173.554 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.573 ' HD2' HD12 ' B' ' 28' ' ' LEU . 18.6 Cg_endo -63.67 173.65 4.38 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 O-C-N 123.946 1.498 . . . . 0.0 110.699 -179.427 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.75 ' HA ' HD12 ' B' ' 33' ' ' LEU . 12.3 p-10 -59.97 -38.05 81.39 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 110.739 -176.265 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.585 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.16 -0.05 57.42 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.922 -1.112 . . . . 0.0 110.902 -175.72 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.585 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 94.6 mmm -110.35 -11.98 14.47 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.867 -1.146 . . . . 0.0 109.913 170.182 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.932 HD21 ' HB2' ' B' ' 57' ' ' ASN . 15.8 mt -63.0 -31.43 72.57 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.341 -0.849 . . . . 0.0 110.133 176.818 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -93.22 139.99 30.02 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.347 -0.846 . . . . 0.0 110.538 -176.277 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.06 -41.32 2.35 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 174.801 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.757 HD23 ' N ' ' B' ' 37' ' ' GLU . 9.0 tt -76.09 149.25 37.47 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.973 -1.31 . . . . 0.0 111.034 -174.399 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 37' ' ' GLU . . . . . 0.757 ' N ' HD23 ' B' ' 36' ' ' LEU . 15.8 pt-20 -151.52 169.3 22.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.52 -0.737 . . . . 0.0 109.645 177.194 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 38' ' ' THR . . . . . 0.93 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -61.34 151.66 31.52 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.026 -1.046 . . . . 0.0 109.969 179.059 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.79 -5.94 60.17 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 -178.599 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.5 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -73.26 155.96 38.98 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.24 -1.153 . . . . 0.0 109.668 177.234 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.689 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -99.52 106.05 18.02 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.86 -1.15 . . . . 0.0 109.87 176.252 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.617 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.2 t -93.3 130.01 42.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.311 -0.868 . . . . 0.0 109.071 174.932 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -93.31 120.02 33.11 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 119.274 -0.971 . . . . 0.0 109.225 172.241 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.783 ' CD2' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -91.22 104.67 17.2 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.578 -0.849 . . . . 0.0 108.939 177.977 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.697 HD22 ' HB2' ' A' ' 47' ' ' CYS . 0.8 OUTLIER 55.4 14.2 1.08 Allowed 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.378 -0.826 . . . . 0.0 110.864 -168.692 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 120.21 -4.92 12.34 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.622 -1.275 . . . . 0.0 110.916 171.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.862 ' O ' HD23 ' B' ' 49' ' ' LEU . 25.0 t -90.68 110.31 21.49 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.365 -1.668 . . . . 0.0 109.478 176.547 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 19.1 p -74.32 128.02 34.48 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.074 -1.016 . . . . 0.0 110.803 -171.556 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 1.0 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -143.36 159.98 41.38 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.41 -0.806 . . . . 0.0 109.709 174.78 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 50' ' ' THR . . . . . 0.469 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 3.6 m -102.07 151.66 21.89 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.803 -1.185 . . . . 0.0 111.019 -172.473 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.725 HG13 HG13 ' B' ' 59' ' ' VAL . 15.9 t -78.41 118.35 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.599 -0.688 . . . . 0.0 110.549 -177.39 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.53 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 43.9 p -72.26 -40.11 67.91 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.336 -0.853 . . . . 0.0 110.061 174.222 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.525 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -164.44 153.5 13.3 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.193 -0.942 . . . . 0.0 110.21 -176.956 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.93 HD11 ' N ' ' B' ' 38' ' ' THR . 6.9 mt -109.48 129.97 63.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.149 -0.97 . . . . 0.0 110.016 176.118 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.519 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 4.5 m-80 -102.68 63.3 0.85 Allowed 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.598 -0.689 . . . . 0.0 109.732 179.433 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.29 -114.11 4.05 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 108.758 -1.737 . . . . 0.0 108.758 -174.162 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.932 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -78.36 -22.57 47.76 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.01 -1.288 . . . . 0.0 108.903 174.89 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.127 ' CD2' HG11 ' B' ' 13' ' ' VAL . 12.0 m80 -74.27 159.23 32.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.475 -0.766 . . . . 0.0 110.249 -177.638 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.725 HG13 HG13 ' B' ' 51' ' ' VAL . 54.3 t -141.48 122.56 12.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.756 173.104 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.845 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.4 t -88.34 135.13 33.61 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.464 -0.772 . . . . 0.0 109.655 175.418 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 1.0 ' HB2' HD12 ' B' ' 49' ' ' LEU . 2.1 p90 -127.46 154.62 44.85 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.692 -0.803 . . . . 0.0 110.263 176.645 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.53 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 36.3 p-10 -88.89 152.29 21.83 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.035 -1.041 . . . . 0.0 111.275 -171.041 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.811 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -157.79 100.24 1.74 Allowed 'General case' 0 C--N 1.3 -1.562 0 C-N-CA 120.065 -0.654 . . . . 0.0 109.298 -174.186 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.495 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 60.8 ttm -60.14 139.84 57.28 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.066 -1.021 . . . . 0.0 109.737 -177.391 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.499 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 5.1 ttpm? -59.98 -43.28 95.23 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.131 -0.981 . . . . 0.0 110.399 -175.353 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.36 -40.01 77.74 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.914 -1.116 . . . . 0.0 109.883 178.044 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.495 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 94.4 m -60.01 -37.68 80.43 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.075 -1.015 . . . . 0.0 109.434 172.26 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.717 HD11 ' HA2' ' B' ' 74' ' ' GLY . 14.2 tp -60.01 -45.59 92.26 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.302 -0.874 . . . . 0.0 109.482 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 55.2 ttt85 -70.01 -40.03 75.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.465 -0.772 . . . . 0.0 110.732 176.85 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.769 HG22 HG23 ' B' ' 71' ' ' THR . 1.5 tt -67.2 -42.78 88.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.289 -0.882 . . . . 0.0 109.438 -175.802 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.769 HG23 HG22 ' B' ' 70' ' ' ILE . 40.2 p -83.84 -173.69 4.86 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 174.759 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.501 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 3.2 t30 -102.8 23.71 11.71 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.172 -1.048 . . . . 0.0 108.172 169.937 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.811 ' HB3' HD21 ' B' ' 63' ' ' LEU . 86.2 mt -68.6 -39.95 80.68 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.141 -0.975 . . . . 0.0 109.938 176.832 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.717 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -47.96 -22.28 2.02 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.646 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.3 p-10 -62.86 -18.69 63.27 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.092 -1.24 . . . . 0.0 110.434 -176.335 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.517 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.0 mt -60.02 143.26 52.31 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.269 -0.894 . . . . 0.0 110.496 -177.738 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 0.929 ' C ' HD23 ' B' ' 12' ' ' LEU . 23.3 mttm -145.99 146.71 31.1 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.681 -0.637 . . . . 0.0 109.351 177.02 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.585 ' CG2' HG13 ' B' ' 15' ' ' ILE . 22.1 t -68.05 148.69 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 120.865 -1.147 . . . . 0.0 110.303 -175.669 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 85.96 -10.94 63.83 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.86 -1.696 . . . . 0.0 108.86 -174.125 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.48 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 45.2 t0 -95.74 162.48 13.58 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.303 -1.116 . . . . 0.0 109.687 176.658 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.0 m95 -114.73 149.41 36.88 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.174 -0.954 . . . . 0.0 109.999 176.833 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 1.083 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.2 p -115.37 153.95 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.422 -0.799 . . . . 0.0 109.857 -179.574 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.666 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -78.27 106.09 9.94 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.138 -0.976 . . . . 0.0 109.197 168.616 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.898 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -108.36 140.04 28.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 120.726 -1.234 . . . . 0.0 111.014 -176.446 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' B' B ' 85' ' ' GLU . . . . . 0.413 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.5 tt0 -137.18 143.98 42.66 Favored 'General case' 0 N--CA 1.492 1.633 0 C-N-CA 120.282 -0.567 . . . . 0.0 110.205 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 66.5 ttp85 -79.36 130.03 35.04 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.219 -0.926 . . . . 0.0 110.946 -176.515 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.689 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.757 0 O-C-N 121.302 -0.874 . . . . 0.0 110.045 175.733 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.959 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.3 t . . . . . 0 N--CA 1.496 1.84 0 CA-C-O 121.781 0.801 . . . . 0.0 110.892 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 -69.43 -35.0 75.28 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.773 -0.579 . . . . 0.0 110.621 177.107 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.53 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -162.68 173.9 38.98 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 118.896 -1.621 . . . . 0.0 110.094 -174.114 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.464 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.5 p -114.69 174.76 5.8 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.154 -1.204 . . . . 0.0 110.836 -177.701 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 1.022 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -142.61 149.04 38.45 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.622 -0.674 . . . . 0.0 109.541 -177.718 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.0 tttt -103.95 118.62 37.1 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 120.95 -1.094 . . . . 0.0 110.2 178.134 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 1.02 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.2 tp -60.7 127.55 32.21 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 120.795 -1.191 . . . . 0.0 108.569 171.005 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.112 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.7 p -130.45 -31.17 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.874 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.229 -177.126 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -143.84 139.83 29.49 Favored 'General case' 0 C--N 1.296 -1.719 0 C-N-CA 119.079 -1.048 . . . . 0.0 111.272 -178.634 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.78 HG23 ' CD2' ' A' ' 24' ' ' HIS . 11.2 mt -110.02 130.81 62.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.034 -1.041 . . . . 0.0 110.198 171.201 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.508 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 81.6 m-20 -108.07 114.64 28.7 Favored 'General case' 0 C--N 1.294 -1.843 0 O-C-N 121.443 -0.786 . . . . 0.0 109.962 173.195 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.4 110.77 22.98 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.002 -1.061 . . . . 0.0 110.592 -176.85 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -110.29 128.12 25.89 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.133 -0.979 . . . . 0.0 108.917 174.09 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -50.61 -33.42 39.28 Favored 'Trans proline' 0 C--N 1.303 -1.851 0 O-C-N 123.767 1.404 . . . . 0.0 110.314 -179.73 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.474 ' C ' ' CD2' ' A' ' 21' ' ' PHE . 12.4 m-80 -72.27 -40.0 67.95 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.149 -0.97 . . . . 0.0 109.938 175.812 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.474 ' CD2' ' C ' ' A' ' 20' ' ' ASN . 91.0 m-85 -152.51 150.25 29.39 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.374 -0.829 . . . . 0.0 110.197 -178.4 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.486 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 57.5 ttt180 -88.31 139.95 29.97 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 120.734 -1.229 . . . . 0.0 109.7 173.074 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.508 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 95.0 m -124.97 131.73 53.38 Favored 'General case' 0 C--N 1.294 -1.847 0 O-C-N 121.597 -0.689 . . . . 0.0 109.901 -176.87 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.78 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -126.21 138.89 53.68 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.905 -1.122 . . . . 0.0 111.303 -179.7 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.767 HG22 ' CB ' ' A' ' 60' ' ' SER . 5.7 t -120.83 134.26 64.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.135 -0.978 . . . . 0.0 110.861 -176.98 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.814 HG13 ' CE1' ' A' ' 61' ' ' PHE . 35.9 m -114.79 172.17 4.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 O-C-N 121.804 -0.56 . . . . 0.0 110.09 178.243 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.56 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 9.2 tt0 -104.21 117.91 35.37 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.376 -0.827 . . . . 0.0 108.788 177.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.891 HD21 HD13 ' A' ' 36' ' ' LEU . 7.5 tp -85.83 127.93 60.48 Favored Pre-proline 0 C--N 1.297 -1.703 0 O-C-N 121.562 -0.711 . . . . 0.0 109.943 -171.128 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.479 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 20.6 Cg_endo -66.02 178.69 2.25 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.881 1.464 . . . . 0.0 110.743 -179.363 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.518 ' HA ' HD12 ' A' ' 33' ' ' LEU . 33.9 p-10 -62.65 -40.1 95.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.349 -0.844 . . . . 0.0 110.999 -175.542 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.606 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.93 -0.0 57.33 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.837 -1.164 . . . . 0.0 110.823 -174.367 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.606 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.0 mmm -108.11 -16.98 14.15 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.87 -1.144 . . . . 0.0 109.638 170.772 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.597 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 24.7 mt -66.2 -25.77 67.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.363 -0.835 . . . . 0.0 109.721 174.736 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -92.26 131.33 37.56 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.474 -0.766 . . . . 0.0 110.56 -178.094 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.79 -41.75 2.71 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 176.601 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.891 HD13 HD21 ' A' ' 28' ' ' LEU . 5.1 tt -70.84 148.2 48.09 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.076 -1.249 . . . . 0.0 110.335 -177.226 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.729 ' N ' HD23 ' A' ' 36' ' ' LEU . 19.9 pt-20 -156.75 166.36 33.61 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.322 -0.862 . . . . 0.0 109.599 -177.66 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.75 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -65.57 148.5 51.63 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.886 -1.134 . . . . 0.0 110.051 -178.886 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.67 -3.47 68.76 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.234 -1.546 . . . . 0.0 109.234 -174.369 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.463 ' CB ' ' O ' ' A' ' 37' ' ' GLU . . . -78.22 160.03 28.19 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.263 -1.14 . . . . 0.0 109.445 176.108 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.453 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -101.64 114.31 28.24 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 118.799 -1.16 . . . . 0.0 110.097 177.107 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.666 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.7 t -99.11 128.75 50.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.278 -0.889 . . . . 0.0 108.94 173.277 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.512 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -94.99 119.48 33.58 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 119.156 -1.017 . . . . 0.0 109.074 172.295 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.666 ' HE1' HG11 ' A' ' 42' ' ' VAL . 0.6 OUTLIER -87.32 103.14 15.19 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.415 -0.803 . . . . 0.0 108.958 178.41 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.498 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 57.83 8.9 0.77 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.441 -0.787 . . . . 0.0 111.309 -170.312 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.503 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 124.11 2.26 8.51 Favored Glycine 0 N--CA 1.489 2.168 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.858 174.846 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.803 ' O ' HD23 ' A' ' 49' ' ' LEU . 42.7 t -98.45 107.33 19.77 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.461 -1.611 . . . . 0.0 109.485 174.706 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 26.2 p -75.1 129.9 38.35 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.237 -0.914 . . . . 0.0 111.211 -170.961 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.975 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -145.27 160.63 41.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.443 -0.786 . . . . 0.0 109.637 173.552 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.41 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 57.9 m -100.95 151.17 22.08 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.737 -1.227 . . . . 0.0 110.923 -171.719 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.737 HG13 HG13 ' A' ' 59' ' ' VAL . 38.6 t -78.48 116.85 22.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.655 -0.653 . . . . 0.0 110.487 -178.358 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.532 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 37.7 p -70.03 -40.01 75.42 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.205 -0.934 . . . . 0.0 109.893 174.092 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.621 ' HA ' HG21 ' A' ' 38' ' ' THR . 86.5 tt0 -163.47 153.39 15.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.298 -0.876 . . . . 0.0 110.194 -177.676 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.75 HD11 ' N ' ' A' ' 38' ' ' THR . 5.9 mt -104.49 133.63 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.018 -1.051 . . . . 0.0 109.885 175.044 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.509 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 9.3 m120 -107.72 66.94 0.67 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.507 -0.745 . . . . 0.0 109.823 179.154 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.27 -116.06 4.83 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.816 -1.714 . . . . 0.0 108.816 -174.609 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.597 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -79.21 -19.13 51.53 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.055 -1.262 . . . . 0.0 108.764 174.545 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.112 ' CE1' HG11 ' A' ' 13' ' ' VAL . 25.5 m-70 -74.73 160.66 30.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.467 -0.77 . . . . 0.0 110.343 -178.236 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.737 HG13 HG13 ' A' ' 51' ' ' VAL . 62.9 t -141.25 123.21 14.27 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 O-C-N 121.229 -0.92 . . . . 0.0 110.433 171.904 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.767 ' CB ' HG22 ' A' ' 25' ' ' VAL . 13.3 m -91.32 130.53 37.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.573 -0.704 . . . . 0.0 109.535 178.283 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.975 ' HB2' HD12 ' A' ' 49' ' ' LEU . 4.0 p90 -124.69 153.66 42.0 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.096 -1.002 . . . . 0.0 110.333 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.532 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 27.2 p-10 -88.73 152.22 21.93 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.091 -1.006 . . . . 0.0 111.37 -170.92 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.866 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -155.73 114.33 3.46 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -176.128 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.513 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 7.1 ttp -71.64 140.0 49.52 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.803 -1.186 . . . . 0.0 109.685 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.5 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 37.5 ttpt -60.04 -46.03 90.86 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.075 -1.015 . . . . 0.0 110.532 -174.05 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -70.0 -40.05 75.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.659 -1.275 . . . . 0.0 110.003 178.522 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.513 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 33.4 m -61.88 -34.9 76.87 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.053 -1.029 . . . . 0.0 109.462 173.805 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.709 HD11 ' HA2' ' A' ' 74' ' ' GLY . 7.6 tp -59.96 -45.81 91.47 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.244 -0.91 . . . . 0.0 109.151 178.205 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 71.8 ttt-85 -66.46 -39.98 89.15 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.284 -0.885 . . . . 0.0 110.682 175.115 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.785 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -66.72 -44.24 89.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.173 -0.954 . . . . 0.0 109.584 -175.549 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.785 HG23 HG22 ' A' ' 70' ' ' ILE . 31.2 p -83.17 -175.13 5.68 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 120.199 -0.6 . . . . 0.0 109.437 175.5 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 3.7 t30 -99.48 23.59 9.21 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 171.216 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.866 ' HB3' HD21 ' A' ' 63' ' ' LEU . 90.9 mt -70.0 -39.96 75.55 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.12 -0.987 . . . . 0.0 110.117 176.928 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.709 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -53.75 -18.1 7.71 Favored Glycine 0 N--CA 1.486 1.987 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 -177.137 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.2 p-10 -69.99 -19.03 63.35 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.953 -1.322 . . . . 0.0 110.575 -175.567 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.518 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 87.9 mt -62.13 141.92 57.88 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.233 -0.917 . . . . 0.0 110.815 -176.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 1.02 ' C ' HD23 ' A' ' 12' ' ' LEU . 43.5 mtmt -141.49 141.74 33.62 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 121.63 -0.669 . . . . 0.0 109.776 174.32 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.733 HG23 HD11 ' A' ' 15' ' ' ILE . 16.6 t -60.32 152.6 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 120.926 -1.109 . . . . 0.0 110.451 -174.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.43 -15.9 57.45 Favored Glycine 0 N--CA 1.482 1.722 0 N-CA-C 108.762 -1.735 . . . . 0.0 108.762 -176.348 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 37.8 t0 -95.76 166.8 11.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.312 -1.111 . . . . 0.0 109.664 175.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.584 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.3 m95 -116.82 160.49 20.74 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.083 -1.011 . . . . 0.0 110.171 178.014 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.022 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.1 p -125.55 155.21 34.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.339 -0.851 . . . . 0.0 110.034 -177.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.959 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -79.97 105.04 10.96 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.964 -1.085 . . . . 0.0 109.059 168.229 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.81 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -105.56 138.01 32.68 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 O-C-N 120.546 -1.346 . . . . 0.0 111.118 -176.539 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -133.53 140.03 46.96 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 120.298 -0.561 . . . . 0.0 110.028 -178.023 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.537 ' NH1' ' HB2' ' A' ' 86' ' ' ARG . 26.7 ttm105 -78.31 126.91 31.45 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.258 -0.901 . . . . 0.0 110.701 -176.053 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.453 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.392 -0.817 . . . . 0.0 110.076 176.289 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 0.966 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.3 t . . . . . 0 N--CA 1.495 1.793 0 CA-C-O 121.719 0.771 . . . . 0.0 110.984 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 90.8 mm-40 -69.51 -34.74 74.72 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.685 -0.635 . . . . 0.0 110.665 177.167 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.524 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -163.03 173.72 39.26 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.065 -1.541 . . . . 0.0 110.177 -174.111 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.468 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.4 p -114.68 174.63 5.87 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.156 -1.203 . . . . 0.0 110.841 -177.543 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.044 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -142.45 149.24 39.0 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.704 -0.622 . . . . 0.0 109.462 -177.802 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.58 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 29.9 tttt -103.97 118.68 37.24 Favored 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.051 -1.03 . . . . 0.0 110.154 178.065 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 1.017 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.1 tp -60.86 127.42 31.5 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 120.952 -1.092 . . . . 0.0 108.624 170.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.128 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.7 p -130.2 -31.53 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.836 0 O-C-N 121.265 -0.897 . . . . 0.0 110.267 -177.008 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -143.7 139.89 29.75 Favored 'General case' 0 C--N 1.295 -1.772 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.311 -178.649 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.792 HG23 ' CD2' ' B' ' 24' ' ' HIS . 11.2 mt -109.92 130.84 62.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.048 -1.032 . . . . 0.0 110.149 171.259 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.522 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 81.2 m-20 -108.2 114.79 28.95 Favored 'General case' 0 C--N 1.296 -1.722 0 O-C-N 121.42 -0.8 . . . . 0.0 109.912 173.127 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.38 110.79 23.01 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.119 -0.988 . . . . 0.0 110.503 -176.825 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -110.34 128.1 25.91 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.158 -0.964 . . . . 0.0 109.016 173.971 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -50.8 -33.27 40.2 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 O-C-N 123.758 1.399 . . . . 0.0 110.253 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.471 ' C ' ' CD2' ' B' ' 21' ' ' PHE . 12.3 m-80 -72.32 -40.17 67.66 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.203 -0.935 . . . . 0.0 109.902 175.713 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.471 ' CD2' ' C ' ' B' ' 20' ' ' ASN . 91.1 m-85 -152.33 150.23 29.5 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.393 -0.817 . . . . 0.0 110.233 -178.423 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 22' ' ' ARG . . . . . 0.498 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 57.5 ttt180 -88.13 139.89 30.05 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.777 -1.202 . . . . 0.0 109.706 173.063 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.522 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 95.6 m -124.96 131.75 53.38 Favored 'General case' 0 C--N 1.295 -1.781 0 O-C-N 121.676 -0.64 . . . . 0.0 109.908 -176.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.792 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -126.18 138.97 53.7 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.011 -1.056 . . . . 0.0 111.241 -179.635 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.778 HG22 ' CB ' ' B' ' 60' ' ' SER . 5.7 t -120.78 134.44 64.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.224 -0.923 . . . . 0.0 110.834 -176.971 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.804 HG13 ' CE1' ' B' ' 61' ' ' PHE . 35.8 m -115.04 172.08 4.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.773 -0.579 . . . . 0.0 110.021 178.28 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.559 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 9.2 tt0 -104.1 118.05 35.73 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 177.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.87 HD21 HD13 ' B' ' 36' ' ' LEU . 7.5 tp -85.84 127.8 60.96 Favored Pre-proline 0 C--N 1.296 -1.735 0 O-C-N 121.338 -0.851 . . . . 0.0 110.0 -171.209 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.469 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 20.9 Cg_endo -65.95 178.63 2.25 Favored 'Trans proline' 0 C--N 1.308 -1.604 0 O-C-N 123.828 1.436 . . . . 0.0 110.799 -179.365 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.522 ' HA ' HD12 ' B' ' 33' ' ' LEU . 33.8 p-10 -62.74 -39.94 95.68 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.322 -0.861 . . . . 0.0 110.984 -175.47 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.0 0.0 57.34 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.851 -1.156 . . . . 0.0 110.797 -174.363 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.597 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.0 mmm -108.16 -16.87 14.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.84 -1.162 . . . . 0.0 109.62 170.833 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.588 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 24.6 mt -66.36 -25.69 66.92 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.369 -0.832 . . . . 0.0 109.714 174.739 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -92.28 131.31 37.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.48 -0.762 . . . . 0.0 110.525 -178.129 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.76 -41.64 2.72 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 176.542 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.87 HD13 HD21 ' B' ' 28' ' ' LEU . 5.1 tt -70.81 148.26 48.05 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.033 -1.275 . . . . 0.0 110.267 -177.222 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 37' ' ' GLU . . . . . 0.733 ' N ' HD23 ' B' ' 36' ' ' LEU . 19.9 pt-20 -156.8 166.39 33.51 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.366 -0.834 . . . . 0.0 109.576 -177.702 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 38' ' ' THR . . . . . 0.748 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -65.65 148.46 51.72 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.927 -1.108 . . . . 0.0 110.064 -178.886 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.59 -3.33 68.94 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.319 -1.512 . . . . 0.0 109.319 -174.272 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.466 ' CB ' ' O ' ' B' ' 37' ' ' GLU . . . -78.41 159.99 28.01 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.286 -1.126 . . . . 0.0 109.33 176.021 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.457 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -101.56 114.18 27.97 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 120.86 -1.15 . . . . 0.0 110.116 177.177 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.657 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.7 t -99.24 128.77 50.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.319 -0.863 . . . . 0.0 108.923 173.329 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 0.509 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -94.86 119.47 33.47 Favored 'General case' 0 C--N 1.297 -1.707 0 O-C-N 121.083 -1.011 . . . . 0.0 109.135 172.294 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.657 ' HE1' HG11 ' B' ' 42' ' ' VAL . 0.6 OUTLIER -87.42 102.99 15.08 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.376 -0.828 . . . . 0.0 108.975 178.403 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.498 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 58.12 8.9 0.85 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.49 -0.756 . . . . 0.0 111.25 -170.459 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.503 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 123.87 2.73 8.57 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.789 -1.196 . . . . 0.0 110.802 174.709 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.82 ' O ' HD23 ' B' ' 49' ' ' LEU . 42.7 t -98.62 107.26 19.66 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 120.378 -1.66 . . . . 0.0 109.44 174.535 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 26.2 p -74.97 130.04 38.68 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.114 -0.991 . . . . 0.0 111.142 -171.026 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 0.957 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -145.43 160.41 41.62 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.484 -0.76 . . . . 0.0 109.717 173.462 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 50' ' ' THR . . . . . 0.423 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 57.7 m -100.7 151.35 21.76 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.781 -1.199 . . . . 0.0 110.982 -171.798 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.734 HG13 HG13 ' B' ' 59' ' ' VAL . 38.2 t -78.67 116.92 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.644 -0.66 . . . . 0.0 110.472 -178.358 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.519 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 38.8 p -70.07 -40.06 75.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.201 -0.937 . . . . 0.0 109.884 174.224 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.614 ' HA ' HG21 ' B' ' 38' ' ' THR . 86.5 tt0 -163.36 153.44 15.6 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.341 -0.849 . . . . 0.0 110.226 -177.683 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.748 HD11 ' N ' ' B' ' 38' ' ' THR . 5.9 mt -104.52 133.65 48.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.151 -0.968 . . . . 0.0 109.937 174.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.52 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 9.2 m120 -107.82 66.99 0.67 Allowed 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.572 -0.705 . . . . 0.0 109.762 179.194 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.41 -116.08 4.81 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 108.743 -1.743 . . . . 0.0 108.743 -174.733 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.588 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -79.18 -19.22 51.42 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 120.974 -1.309 . . . . 0.0 108.832 174.478 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.128 ' CE1' HG11 ' B' ' 13' ' ' VAL . 25.2 m-70 -74.65 160.53 30.69 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.443 -0.785 . . . . 0.0 110.361 -178.301 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.734 HG13 HG13 ' B' ' 51' ' ' VAL . 62.9 t -141.06 123.22 14.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 O-C-N 121.208 -0.932 . . . . 0.0 110.453 171.972 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.778 ' CB ' HG22 ' B' ' 25' ' ' VAL . 13.4 m -91.43 130.87 37.21 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.632 -0.667 . . . . 0.0 109.553 178.314 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.957 ' HB2' HD12 ' B' ' 49' ' ' LEU . 3.9 p90 -124.96 153.43 42.76 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.188 -0.945 . . . . 0.0 110.255 -179.721 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.519 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 27.4 p-10 -88.58 152.21 21.99 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.976 -1.077 . . . . 0.0 111.466 -170.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.831 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -155.71 114.4 3.48 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 -176.154 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.512 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 7.1 ttp -71.62 139.97 49.54 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.867 -1.146 . . . . 0.0 109.799 -178.076 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.501 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 37.5 ttpt -60.06 -45.98 91.06 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.128 -0.982 . . . . 0.0 110.477 -173.959 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -70.06 -39.98 75.36 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.806 -1.184 . . . . 0.0 110.023 178.591 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.512 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 34.4 m -61.94 -34.98 77.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.035 -1.041 . . . . 0.0 109.342 173.789 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.702 HD11 ' HA2' ' B' ' 74' ' ' GLY . 7.6 tp -60.05 -45.47 92.74 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.312 -0.867 . . . . 0.0 109.243 178.26 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 71.8 ttt-85 -66.7 -39.96 88.27 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.356 -0.84 . . . . 0.0 110.652 175.051 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.768 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -66.71 -44.23 89.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.144 -0.973 . . . . 0.0 109.595 -175.602 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.768 HG23 HG22 ' B' ' 70' ' ' ILE . 31.2 p -83.05 -175.02 5.63 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 120.114 -0.634 . . . . 0.0 109.477 175.518 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.492 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 3.7 t30 -99.56 23.68 9.16 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 171.125 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.831 ' HB3' HD21 ' B' ' 63' ' ' LEU . 90.7 mt -70.05 -39.96 75.4 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.123 -0.985 . . . . 0.0 110.089 176.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.702 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -53.79 -18.0 7.7 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 -177.11 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.4 p-10 -70.06 -18.99 63.3 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.039 -1.271 . . . . 0.0 110.578 -175.556 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.511 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 88.1 mt -62.14 141.89 57.91 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.231 -0.918 . . . . 0.0 110.828 -177.025 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 1.017 ' C ' HD23 ' B' ' 12' ' ' LEU . 43.4 mtmt -141.52 141.72 33.58 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.666 -0.646 . . . . 0.0 109.787 174.321 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.744 HG23 HD11 ' B' ' 15' ' ' ILE . 16.7 t -60.31 152.51 5.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.957 -1.09 . . . . 0.0 110.43 -174.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.38 -15.59 58.16 Favored Glycine 0 N--CA 1.484 1.846 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -176.415 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 38.0 t0 -95.97 166.68 11.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.422 -1.046 . . . . 0.0 109.655 175.855 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.58 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.4 m95 -116.76 160.53 20.66 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.15 -0.968 . . . . 0.0 110.176 178.076 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 1.044 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.1 p -125.56 155.35 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.407 -0.808 . . . . 0.0 109.979 -178.056 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.966 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.2 OUTLIER -80.01 104.89 10.89 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.093 -1.004 . . . . 0.0 109.003 168.296 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.809 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -105.54 138.18 31.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 120.559 -1.338 . . . . 0.0 111.075 -176.491 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -133.71 140.08 46.79 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 120.335 -0.546 . . . . 0.0 110.05 -178.103 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 86' ' ' ARG . . . . . 0.538 ' NH1' ' HB2' ' B' ' 86' ' ' ARG . 26.8 ttm105 -78.34 126.92 31.46 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.213 -0.929 . . . . 0.0 110.642 -176.014 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.457 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.766 0 O-C-N 121.334 -0.854 . . . . 0.0 110.015 176.286 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.979 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.7 t . . . . . 0 N--CA 1.493 1.707 0 CA-C-O 121.726 0.774 . . . . 0.0 110.784 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 79.2 mm-40 -69.97 -34.84 73.91 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.64 -0.663 . . . . 0.0 110.843 178.275 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.528 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -158.28 179.19 34.15 Favored Glycine 0 N--CA 1.494 2.527 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.235 -173.167 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.47 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 1.0 OUTLIER -118.54 170.0 9.32 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.117 -1.226 . . . . 0.0 110.956 -177.962 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 1.13 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -136.55 149.7 48.23 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.667 -0.646 . . . . 0.0 109.448 -179.237 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 39.6 tttt -110.57 117.87 34.69 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.024 -1.048 . . . . 0.0 110.455 -179.44 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.98 HD23 ' C ' ' A' ' 77' ' ' LYS . 10.9 tp -60.04 126.26 26.83 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.882 -1.136 . . . . 0.0 108.979 172.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.068 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.4 p -125.76 -31.67 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 O-C-N 121.471 -0.768 . . . . 0.0 109.545 179.252 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.09 143.12 30.24 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.453 -0.899 . . . . 0.0 111.103 -179.648 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.759 HG23 ' CD2' ' A' ' 24' ' ' HIS . 18.0 mt -106.71 134.98 46.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.038 -1.039 . . . . 0.0 110.0 171.027 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.515 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 56.0 m-20 -107.53 115.81 30.83 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.274 -0.891 . . . . 0.0 109.851 174.067 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -107.06 111.88 24.55 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.057 -1.027 . . . . 0.0 110.467 -176.448 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 8.2 mtmm -109.09 131.28 21.9 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.217 -0.927 . . . . 0.0 109.262 175.686 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -51.13 -22.88 11.69 Favored 'Trans proline' 0 C--N 1.304 -1.78 0 O-C-N 123.954 1.502 . . . . 0.0 111.052 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.582 ' O ' ' CD1' ' A' ' 21' ' ' PHE . 7.4 m-80 -92.78 -33.61 14.21 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.085 -1.009 . . . . 0.0 109.983 177.833 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.582 ' CD1' ' O ' ' A' ' 20' ' ' ASN . 36.3 m-85 -148.2 150.17 33.27 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.488 -0.758 . . . . 0.0 110.026 -177.516 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.68 ' HD3' HD22 ' A' ' 68' ' ' LEU . 60.4 ttt180 -95.76 143.5 26.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.668 -1.27 . . . . 0.0 109.964 173.739 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.515 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 56.3 m -132.61 145.65 51.27 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.494 -0.754 . . . . 0.0 109.955 -176.095 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.759 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -134.2 134.06 41.64 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.943 -1.098 . . . . 0.0 111.327 -179.666 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.732 HG22 ' CB ' ' A' ' 60' ' ' SER . 5.3 t -113.62 132.75 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.071 -1.018 . . . . 0.0 110.856 -177.32 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.546 HG22 ' HE2' ' A' ' 61' ' ' PHE . 12.9 m -118.79 170.93 7.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 CA-C-O 121.317 0.579 . . . . 0.0 110.331 -179.17 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.563 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 15.3 tt0 -100.08 116.65 32.6 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 177.789 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.879 HD13 ' HD2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -86.15 118.5 70.51 Favored Pre-proline 0 C--N 1.295 -1.798 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -175.36 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.879 ' HD2' HD13 ' A' ' 28' ' ' LEU . 19.6 Cg_endo -63.25 170.78 7.34 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 O-C-N 123.801 1.422 . . . . 0.0 110.976 -178.527 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.603 ' HA ' HD12 ' A' ' 33' ' ' LEU . 34.1 p-10 -61.26 -35.85 78.42 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.477 -0.765 . . . . 0.0 110.83 -175.713 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.602 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.69 -0.49 57.71 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.828 -1.17 . . . . 0.0 110.874 -173.486 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.604 ' HB3' HD11 ' A' ' 28' ' ' LEU . 99.9 mmm -116.69 -11.17 11.01 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.984 -1.072 . . . . 0.0 109.933 169.499 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.603 HD12 ' HA ' ' A' ' 30' ' ' ASP . 13.2 mt -65.67 -37.95 87.93 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.07 -1.019 . . . . 0.0 109.599 175.168 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -69.04 132.25 46.34 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.486 -0.759 . . . . 0.0 110.746 -177.402 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.12 -40.12 2.8 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 173.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 59.1 tp -69.2 145.44 53.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.03 -1.277 . . . . 0.0 110.688 -175.262 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.518 ' C ' HD11 ' A' ' 54' ' ' ILE . 16.8 pt-20 -148.01 169.1 20.64 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.591 -0.693 . . . . 0.0 109.408 177.445 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.844 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -64.53 148.56 50.45 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.9 -1.125 . . . . 0.0 109.83 178.291 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.42 -4.66 62.85 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -176.45 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -74.45 159.13 32.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.257 -1.143 . . . . 0.0 109.499 176.568 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.462 ' HB2' ' HB3' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -100.51 117.42 34.63 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 118.909 -1.116 . . . . 0.0 109.885 176.642 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.614 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.1 t -105.97 126.25 61.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.333 -0.855 . . . . 0.0 109.079 175.262 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -89.72 118.62 29.46 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.185 -1.006 . . . . 0.0 109.191 172.282 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.736 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -88.8 100.99 13.58 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 177.054 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.491 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 59.59 8.79 1.35 Allowed 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.486 -0.759 . . . . 0.0 111.143 -168.514 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.49 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 128.76 -12.69 6.18 Favored Glycine 0 N--CA 1.489 2.197 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.8 174.167 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.765 ' O ' HD23 ' A' ' 49' ' ' LEU . 42.8 t -85.97 110.05 19.2 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.356 -1.673 . . . . 0.0 109.779 179.196 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 19.6 p -77.65 113.4 15.46 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.304 -0.872 . . . . 0.0 110.984 -172.376 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.931 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -130.33 161.18 31.86 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.436 -0.79 . . . . 0.0 109.119 172.628 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 57.2 m -103.93 155.08 18.93 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.492 -1.38 . . . . 0.0 111.356 -168.972 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.756 HG13 HG13 ' A' ' 59' ' ' VAL . 21.2 t -77.44 112.79 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.677 -0.64 . . . . 0.0 110.379 -179.51 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.625 HG22 ' HB3' ' A' ' 62' ' ' ASP . 17.6 p -69.95 -40.0 75.72 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.211 -0.931 . . . . 0.0 109.493 172.193 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.404 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.0 tt0 -158.46 153.9 25.96 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 119.322 -0.951 . . . . 0.0 110.845 -177.846 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.844 HD11 ' N ' ' A' ' 38' ' ' THR . 13.6 mt -110.37 130.06 64.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.181 -0.95 . . . . 0.0 109.887 172.713 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.491 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 9.7 m-80 -103.73 63.67 0.78 Allowed 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.542 -0.724 . . . . 0.0 109.723 178.899 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.69 -112.51 3.55 Favored Glycine 0 N--CA 1.487 2.07 0 N-CA-C 108.691 -1.764 . . . . 0.0 108.691 -173.608 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.539 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -80.1 -22.49 42.14 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.988 -1.301 . . . . 0.0 108.846 174.201 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.068 ' CE1' HG11 ' A' ' 13' ' ' VAL . 18.6 m-70 -74.58 158.69 33.27 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.123 -0.985 . . . . 0.0 110.218 -176.211 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.756 HG13 HG13 ' A' ' 51' ' ' VAL . 80.2 t -141.31 119.68 9.72 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 C-N-CA 119.312 -0.955 . . . . 0.0 110.923 175.693 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.732 ' CB ' HG22 ' A' ' 25' ' ' VAL . 15.9 m -88.65 126.21 35.19 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.627 -0.671 . . . . 0.0 109.739 178.672 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.931 ' HB3' HD12 ' A' ' 49' ' ' LEU . 98.0 m-85 -109.9 156.53 20.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.788 -1.195 . . . . 0.0 110.396 179.52 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.625 ' HB3' HG22 ' A' ' 52' ' ' THR . 19.8 p-10 -89.8 148.22 23.34 Favored 'General case' 0 N--CA 1.494 1.738 0 CA-C-O 122.045 0.926 . . . . 0.0 110.878 178.856 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.823 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -155.53 116.6 3.91 Favored 'General case' 0 C--N 1.296 -1.759 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -176.483 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.534 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 93.2 mmm -69.97 141.72 52.96 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 119.109 -1.037 . . . . 0.0 109.518 179.738 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.421 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 46.8 tttp -60.0 -45.15 93.69 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.103 -0.998 . . . . 0.0 110.195 -176.849 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.457 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.4 tt0 -69.44 -40.04 77.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.984 -1.072 . . . . 0.0 110.283 177.642 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.534 ' HB ' ' HB2' ' A' ' 64' ' ' MET . 89.8 m -61.69 -39.38 91.24 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.927 -1.108 . . . . 0.0 109.278 174.091 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.68 HD22 ' HD3' ' A' ' 22' ' ' ARG . 7.7 tp -60.09 -43.57 95.42 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.325 -0.86 . . . . 0.0 109.364 178.022 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 92.6 mtt180 -69.86 -39.97 76.05 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.545 -0.722 . . . . 0.0 110.692 176.03 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.772 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -69.94 -41.61 79.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.246 -0.909 . . . . 0.0 109.404 -176.078 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.772 HG23 HG22 ' A' ' 70' ' ' ILE . 65.3 p -83.59 -173.94 5.0 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 178.072 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 3.0 t30 -100.73 22.62 11.68 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 170.883 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.823 ' HB3' HD21 ' A' ' 63' ' ' LEU . 96.6 mt -69.91 -40.2 75.75 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.013 -1.054 . . . . 0.0 110.053 174.653 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.604 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -52.99 -24.27 19.48 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 -176.095 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 25.9 p-10 -64.98 -19.67 66.1 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.043 -1.269 . . . . 0.0 110.634 -174.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.52 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 95.8 mt -60.01 140.25 56.9 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.216 -0.928 . . . . 0.0 110.923 -177.056 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 0.98 ' C ' HD23 ' A' ' 12' ' ' LEU . 75.9 mttt -140.92 144.1 35.0 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 173.606 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.617 ' N ' HD23 ' A' ' 12' ' ' LEU . 12.0 t -59.32 152.0 4.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 120.731 -1.231 . . . . 0.0 110.304 -173.538 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.15 -15.81 57.27 Favored Glycine 0 N--CA 1.484 1.847 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 -177.37 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 52.7 t0 -93.41 164.58 13.15 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.284 -1.127 . . . . 0.0 109.684 176.104 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.584 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.3 m95 -115.4 168.15 10.24 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.062 -1.023 . . . . 0.0 110.253 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.13 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.5 p -131.97 155.56 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.518 -0.739 . . . . 0.0 110.039 -178.878 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.979 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.6 m-20 -80.57 109.86 15.49 Favored 'General case' 0 C--N 1.296 -1.75 0 O-C-N 121.007 -1.058 . . . . 0.0 109.12 167.725 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.605 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -109.76 138.62 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.577 -1.327 . . . . 0.0 111.232 -175.301 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -137.02 138.53 40.57 Favored 'General case' 0 N--CA 1.494 1.741 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.801 -178.925 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 83.9 mtm180 -78.41 142.33 37.67 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.958 -1.089 . . . . 0.0 110.951 -176.14 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.462 ' HB3' ' HB2' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.492 1.663 0 O-C-N 121.387 -0.82 . . . . 0.0 110.133 176.876 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 0.954 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.7 t . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.658 0.742 . . . . 0.0 110.78 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 79.3 mm-40 -70.05 -34.63 73.46 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.79 -0.569 . . . . 0.0 110.842 178.284 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.53 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -158.56 179.01 34.53 Favored Glycine 0 N--CA 1.494 2.553 0 C-N-CA 119.048 -1.548 . . . . 0.0 110.227 -173.101 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.469 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 1.0 OUTLIER -118.45 170.03 9.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.094 -1.239 . . . . 0.0 110.976 -177.851 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.121 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -136.55 149.85 48.31 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.671 -0.643 . . . . 0.0 109.381 -179.329 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 39.8 tttt -110.65 117.98 34.96 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.048 -1.033 . . . . 0.0 110.39 -179.439 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 0.979 HD23 ' C ' ' B' ' 77' ' ' LYS . 10.9 tp -60.33 126.13 26.32 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.037 -1.039 . . . . 0.0 109.085 172.977 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.05 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.4 p -125.65 -31.54 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 O-C-N 121.442 -0.786 . . . . 0.0 109.684 179.488 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.23 143.15 30.11 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 119.516 -0.874 . . . . 0.0 111.092 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.759 HG23 ' CD2' ' B' ' 24' ' ' HIS . 17.8 mt -106.67 134.88 47.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.005 -1.06 . . . . 0.0 110.03 171.046 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.53 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 55.7 m-20 -107.54 115.88 30.94 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.28 -0.888 . . . . 0.0 109.898 174.079 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -107.05 111.78 24.41 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.035 -1.04 . . . . 0.0 110.428 -176.342 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.456 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 8.2 mtmm -109.02 131.27 21.9 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.259 -0.901 . . . . 0.0 109.288 175.623 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -51.11 -23.02 11.86 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 O-C-N 123.868 1.457 . . . . 0.0 111.061 -179.209 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.571 ' O ' ' CD1' ' B' ' 21' ' ' PHE . 7.4 m-80 -92.46 -34.22 14.2 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.065 -1.022 . . . . 0.0 109.879 177.827 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.571 ' CD1' ' O ' ' B' ' 20' ' ' ASN . 36.3 m-85 -147.7 150.23 33.93 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.431 -0.793 . . . . 0.0 110.026 -177.36 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 22' ' ' ARG . . . . . 0.671 ' HD3' HD22 ' B' ' 68' ' ' LEU . 60.3 ttt180 -95.74 143.53 26.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.756 -1.215 . . . . 0.0 110.058 173.559 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.53 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 55.9 m -132.59 145.61 51.24 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.503 -0.748 . . . . 0.0 110.029 -176.135 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.759 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -134.04 134.09 41.98 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.085 -1.009 . . . . 0.0 111.197 -179.517 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.736 HG22 ' CB ' ' B' ' 60' ' ' SER . 5.4 t -113.68 133.0 61.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.207 -0.933 . . . . 0.0 110.778 -177.41 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.536 HG22 ' HE2' ' B' ' 61' ' ' PHE . 13.2 m -119.05 170.94 7.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-O 121.232 0.539 . . . . 0.0 110.268 -179.067 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.558 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 15.3 tt0 -100.03 116.71 32.71 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 177.714 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.923 HD13 ' HD2' ' B' ' 29' ' ' PRO . 0.0 OUTLIER -86.11 118.35 70.28 Favored Pre-proline 0 C--N 1.295 -1.804 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 -175.422 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.923 ' HD2' HD13 ' B' ' 28' ' ' LEU . 19.5 Cg_endo -63.13 170.75 7.22 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 O-C-N 123.802 1.422 . . . . 0.0 110.96 -178.525 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.617 ' HA ' HD12 ' B' ' 33' ' ' LEU . 34.1 p-10 -61.28 -35.74 78.15 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.47 -0.769 . . . . 0.0 110.873 -175.741 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.595 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.74 -0.48 57.72 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.783 -1.198 . . . . 0.0 110.839 -173.487 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.595 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.9 mmm -116.64 -11.22 11.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.857 -1.152 . . . . 0.0 109.984 169.509 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.617 HD12 ' HA ' ' B' ' 30' ' ' ASP . 13.2 mt -65.68 -38.02 88.1 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.013 -1.054 . . . . 0.0 109.626 175.165 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -68.99 132.27 46.39 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.549 -0.719 . . . . 0.0 110.792 -177.404 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.1 -40.16 2.8 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 110.346 -1.102 . . . . 0.0 110.346 174.061 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 59.0 tp -69.13 145.49 53.3 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.045 -1.268 . . . . 0.0 110.726 -175.302 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 37' ' ' GLU . . . . . 0.496 ' C ' HD11 ' B' ' 54' ' ' ILE . 16.8 pt-20 -147.98 169.1 20.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.506 -0.746 . . . . 0.0 109.423 177.473 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 38' ' ' THR . . . . . 0.843 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -64.66 148.48 50.89 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.939 -1.101 . . . . 0.0 109.859 178.298 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.57 -4.67 63.44 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -176.464 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -74.49 158.98 32.86 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.121 -1.223 . . . . 0.0 109.492 176.474 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.45 ' HB2' ' HB3' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -100.37 117.21 34.09 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 120.94 -1.1 . . . . 0.0 110.029 176.584 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.636 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.1 t -105.96 126.28 61.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.383 -0.823 . . . . 0.0 109.105 175.316 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 0.513 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -89.7 118.64 29.46 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 119.133 -1.027 . . . . 0.0 109.114 172.351 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.742 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -88.77 100.72 13.36 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 176.994 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.491 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 59.88 8.79 1.49 Allowed 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.53 -0.731 . . . . 0.0 110.987 -168.642 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.49 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 128.68 -12.65 6.21 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.583 -1.294 . . . . 0.0 110.818 174.151 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.757 ' O ' HD23 ' B' ' 49' ' ' LEU . 41.7 t -85.97 109.94 19.12 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.259 -1.73 . . . . 0.0 109.757 179.151 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 19.4 p -77.54 113.44 15.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.227 -0.92 . . . . 0.0 110.969 -172.465 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 0.947 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -130.46 161.1 32.17 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.355 -0.841 . . . . 0.0 109.129 172.521 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 57.5 m -103.76 155.2 18.78 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.545 -1.347 . . . . 0.0 111.277 -168.841 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.78 HG13 HG13 ' B' ' 59' ' ' VAL . 21.2 t -77.62 112.79 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.606 -0.683 . . . . 0.0 110.415 -179.525 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.632 HG22 ' HB3' ' B' ' 62' ' ' ASP . 17.7 p -69.93 -40.05 75.77 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.16 -0.963 . . . . 0.0 109.512 172.339 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.411 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.0 tt0 -158.5 153.74 25.61 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.757 -177.753 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.843 HD11 ' N ' ' B' ' 38' ' ' THR . 13.7 mt -110.23 130.03 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.205 -0.934 . . . . 0.0 109.908 172.738 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.501 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 9.6 m-80 -103.73 63.64 0.78 Allowed 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.943 -0.703 . . . . 0.0 109.692 178.939 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.77 -112.5 3.55 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 108.638 -1.785 . . . . 0.0 108.638 -173.625 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.532 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -80.07 -22.64 42.04 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.865 -1.373 . . . . 0.0 108.873 174.206 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.05 ' CE1' HG11 ' B' ' 13' ' ' VAL . 18.8 m-70 -74.42 158.53 33.72 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.175 -0.953 . . . . 0.0 110.263 -176.278 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.78 HG13 HG13 ' B' ' 51' ' ' VAL . 79.9 t -141.26 119.72 9.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 C-N-CA 119.158 -1.017 . . . . 0.0 110.817 175.86 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.736 ' CB ' HG22 ' B' ' 25' ' ' VAL . 15.9 m -88.69 126.4 35.29 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.617 -0.677 . . . . 0.0 109.73 178.679 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.947 ' HB3' HD12 ' B' ' 49' ' ' LEU . 98.0 m-85 -110.08 156.49 20.49 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.867 -1.146 . . . . 0.0 110.374 179.554 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.632 ' HB3' HG22 ' B' ' 52' ' ' THR . 19.8 p-10 -89.72 148.2 23.41 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.209 -0.932 . . . . 0.0 110.9 178.888 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.805 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -155.51 116.72 3.94 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -176.585 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.517 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 93.1 mmm -70.04 141.67 52.84 Favored 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 119.119 -1.032 . . . . 0.0 109.552 179.683 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.416 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 46.8 tttp -60.06 -45.08 94.05 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.172 -0.955 . . . . 0.0 110.119 -176.7 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 66' ' ' GLU . . . . . 0.463 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 86.5 tt0 -69.38 -40.0 77.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.102 -0.999 . . . . 0.0 110.333 177.647 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.517 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 89.2 m -61.73 -39.6 92.13 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.959 -1.088 . . . . 0.0 109.16 174.148 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.671 HD22 ' HD3' ' B' ' 22' ' ' ARG . 7.7 tp -59.98 -43.41 95.15 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.562 -0.711 . . . . 0.0 109.47 178.077 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 92.7 mtt180 -69.96 -39.98 75.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.449 -0.782 . . . . 0.0 110.67 175.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.77 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -70.06 -41.35 79.17 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.278 -0.889 . . . . 0.0 109.52 -176.131 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.77 HG23 HG22 ' B' ' 70' ' ' ILE . 65.5 p -83.56 -173.81 4.93 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 177.983 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.53 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 3.1 t30 -100.78 22.66 11.68 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 170.827 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.805 ' HB3' HD21 ' B' ' 63' ' ' LEU . 96.9 mt -69.96 -40.09 75.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.116 -0.99 . . . . 0.0 110.071 174.665 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.597 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -53.01 -24.34 19.93 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 110.409 -1.077 . . . . 0.0 110.409 -176.127 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.1 p-10 -64.97 -19.65 66.09 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.116 -1.226 . . . . 0.0 110.632 -174.869 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.521 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 95.8 mt -60.02 140.19 56.95 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.187 -0.946 . . . . 0.0 110.901 -177.065 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 0.979 ' C ' HD23 ' B' ' 12' ' ' LEU . 76.0 mttt -140.92 144.1 34.99 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 173.607 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.618 ' N ' HD23 ' B' ' 12' ' ' LEU . 12.1 t -59.34 151.95 4.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 120.76 -1.213 . . . . 0.0 110.335 -173.519 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.18 -15.72 57.54 Favored Glycine 0 N--CA 1.484 1.847 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 -177.396 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 52.6 t0 -93.47 164.4 13.21 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.432 -1.04 . . . . 0.0 109.675 176.043 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.2 m95 -115.28 168.16 10.21 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.132 -0.98 . . . . 0.0 110.373 178.312 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 1.121 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.5 p -132.04 155.55 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.547 -0.721 . . . . 0.0 109.965 -178.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.954 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -80.4 109.67 15.12 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.009 -1.057 . . . . 0.0 109.174 167.729 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.589 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -109.45 138.95 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 120.66 -1.275 . . . . 0.0 111.138 -175.233 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -137.48 138.51 39.8 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.894 -0.504 . . . . 0.0 109.724 -179.056 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 83.9 mtm180 -78.35 142.44 37.68 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.042 -1.036 . . . . 0.0 110.917 -176.062 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.45 ' HB3' ' HB2' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.493 1.685 0 O-C-N 121.359 -0.838 . . . . 0.0 110.103 176.824 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.834 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.4 t . . . . . 0 N--CA 1.494 1.736 0 CA-C-O 121.508 0.671 . . . . 0.0 110.611 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.425 ' OE1' ' HG2' ' A' ' 86' ' ' ARG . 18.2 pt20 -93.34 -23.81 18.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.55 -0.719 . . . . 0.0 110.787 179.266 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.538 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -150.52 173.99 29.98 Favored Glycine 0 N--CA 1.493 2.487 0 C-N-CA 119.328 -1.415 . . . . 0.0 109.758 -175.485 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.478 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 2.2 p -123.37 170.83 9.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.845 -1.386 . . . . 0.0 110.981 -177.436 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 1.014 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -139.33 149.46 44.22 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.562 -0.711 . . . . 0.0 109.259 -179.649 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.575 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 33.3 tttt -106.73 115.43 30.19 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 120.908 -1.12 . . . . 0.0 110.254 179.535 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 1.014 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.2 tp -58.55 127.19 30.91 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 120.82 -1.175 . . . . 0.0 108.688 173.329 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.145 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.6 p -130.05 -30.14 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.898 0 O-C-N 121.345 -0.847 . . . . 0.0 109.946 -177.844 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -145.1 140.44 28.04 Favored 'General case' 0 N--CA 1.494 1.735 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.974 -179.439 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.778 HG23 ' CD2' ' A' ' 24' ' ' HIS . 13.9 mt -107.53 131.11 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 120.991 -1.068 . . . . 0.0 110.185 172.339 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.512 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.7 m-20 -108.53 114.87 29.04 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.384 -0.823 . . . . 0.0 109.873 174.692 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -107.11 112.38 25.27 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.002 -1.061 . . . . 0.0 110.522 -176.129 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 6.1 mtmt -107.94 129.93 23.48 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.219 -0.926 . . . . 0.0 109.177 175.24 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_endo -51.85 -24.47 18.73 Favored 'Trans proline' 0 C--N 1.303 -1.864 0 O-C-N 123.779 1.41 . . . . 0.0 110.279 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 7.8 m120 -81.2 -39.74 24.95 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.24 -0.913 . . . . 0.0 110.182 175.417 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 95.1 m-85 -156.68 150.22 24.52 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.433 -0.792 . . . . 0.0 109.971 -178.873 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.493 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 59.6 ttt180 -91.93 145.13 24.79 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.807 -1.183 . . . . 0.0 110.327 178.771 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.512 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 74.9 m -129.98 140.02 50.97 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.583 -0.698 . . . . 0.0 109.718 -176.156 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.778 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -128.74 128.32 43.79 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.858 -1.152 . . . . 0.0 111.324 178.184 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.823 HG22 ' OG ' ' A' ' 60' ' ' SER . 4.3 t -104.95 131.42 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.283 -0.886 . . . . 0.0 110.695 -178.108 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.495 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 33.4 m -115.91 168.16 7.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 O-C-N 121.962 -0.461 . . . . 0.0 109.963 179.427 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.526 ' OE2' ' ND2' ' A' ' 57' ' ' ASN . 2.5 tm-20 -101.11 115.31 30.19 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.305 -0.872 . . . . 0.0 109.409 178.538 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.785 HD21 HD13 ' A' ' 36' ' ' LEU . 9.8 tp -79.15 125.33 83.74 Favored Pre-proline 0 C--N 1.295 -1.804 0 O-C-N 121.617 -0.677 . . . . 0.0 109.868 -176.543 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.536 ' HD2' HD12 ' A' ' 28' ' ' LEU . 27.7 Cg_endo -67.5 -179.16 1.79 Allowed 'Trans proline' 0 C--N 1.309 -1.552 0 O-C-N 123.894 1.471 . . . . 0.0 110.826 -179.54 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 31' ' ' HIS . 32.3 p-10 -64.85 -40.02 94.5 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.322 -0.861 . . . . 0.0 110.952 -175.56 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.01 1.32 56.44 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.939 -1.101 . . . . 0.0 110.987 -174.037 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.597 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 98.7 mmm -112.17 -14.14 13.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.854 -1.154 . . . . 0.0 109.871 171.411 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.581 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 19.2 mt -69.93 -20.38 63.34 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.39 -0.818 . . . . 0.0 110.437 176.203 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -61.0 123.05 16.5 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.088 -1.007 . . . . 0.0 111.286 -171.276 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 48.92 54.72 13.29 Favored Glycine 0 N--CA 1.493 2.498 0 C-N-CA 120.339 -0.934 . . . . 0.0 111.015 169.749 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.802 HD23 ' N ' ' A' ' 37' ' ' GLU . 6.4 tt -113.25 155.44 25.07 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.83 -1.394 . . . . 0.0 110.181 174.131 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.802 ' N ' HD23 ' A' ' 36' ' ' LEU . 21.3 pt-20 -149.95 167.85 25.48 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.221 -0.924 . . . . 0.0 110.139 -178.207 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' THR . . . . . 1.038 HG23 HD12 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -68.09 155.27 39.92 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.212 -0.93 . . . . 0.0 109.754 177.539 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.56 -8.86 63.63 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.744 -1.343 . . . . 0.0 109.744 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.669 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -75.37 159.91 30.88 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.11 -1.229 . . . . 0.0 109.753 178.126 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.45 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -105.2 120.2 40.95 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.831 -1.168 . . . . 0.0 110.309 -179.416 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.573 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.6 t -109.95 132.51 58.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.328 -0.858 . . . . 0.0 109.193 172.74 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.51 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -92.38 119.95 32.42 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.145 -0.972 . . . . 0.0 109.337 172.59 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.786 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -89.83 106.92 18.79 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.402 -0.811 . . . . 0.0 109.109 177.865 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.644 ' ND2' ' HB2' ' B' ' 47' ' ' CYS . 0.9 OUTLIER 52.57 17.59 0.82 Allowed 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.39 -0.819 . . . . 0.0 110.503 -166.5 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.506 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 116.35 -4.81 19.77 Favored Glycine 0 N--CA 1.487 2.084 0 C-N-CA 119.64 -1.267 . . . . 0.0 110.831 170.219 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.758 ' O ' HD23 ' A' ' 49' ' ' LEU . 17.3 t -90.08 109.84 20.87 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.345 -1.679 . . . . 0.0 109.084 174.491 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.436 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 27.5 p -77.68 124.89 28.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.996 -1.065 . . . . 0.0 110.691 -172.397 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.967 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -136.85 166.38 23.74 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.353 -0.842 . . . . 0.0 108.945 172.128 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.457 ' O ' ' OD1' ' A' ' 62' ' ' ASP . 54.9 m -103.13 154.18 19.56 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.574 -1.329 . . . . 0.0 111.146 -169.959 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.82 HG13 HG13 ' A' ' 59' ' ' VAL . 7.0 t -74.67 113.26 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.899 -0.5 . . . . 0.0 110.034 -179.294 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.616 HG22 ' HB3' ' A' ' 62' ' ' ASP . 19.0 p -75.3 -43.59 50.21 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.365 -0.835 . . . . 0.0 109.57 176.209 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.463 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -158.36 150.53 21.77 Favored 'General case' 0 N--CA 1.491 1.621 0 C-N-CA 119.576 -0.85 . . . . 0.0 110.335 179.246 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 1.038 HD12 HG23 ' A' ' 38' ' ' THR . 2.5 mp -108.18 132.3 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.225 -0.922 . . . . 0.0 110.304 175.975 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.485 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 54.9 m-80 -108.26 66.24 0.65 Allowed 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.662 -0.649 . . . . 0.0 109.541 177.824 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.44 -119.36 5.79 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 108.794 -1.722 . . . . 0.0 108.794 -173.112 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.581 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -77.12 -17.71 58.46 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.016 -1.285 . . . . 0.0 109.009 176.084 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.145 ' CE1' HG11 ' A' ' 13' ' ' VAL . 20.8 m-70 -77.57 160.09 28.82 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.312 -0.867 . . . . 0.0 110.419 -178.447 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.82 HG13 HG13 ' A' ' 51' ' ' VAL . 94.1 t -145.16 117.83 2.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 C-N-CA 119.379 -0.928 . . . . 0.0 110.879 175.423 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.823 ' OG ' HG22 ' A' ' 25' ' ' VAL . 19.6 m -81.92 125.3 30.58 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.529 -0.732 . . . . 0.0 109.592 175.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.967 ' HB3' HD12 ' A' ' 49' ' ' LEU . 82.9 m-85 -110.03 154.78 22.73 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.898 -1.127 . . . . 0.0 110.23 178.73 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.616 ' HB3' HG22 ' A' ' 52' ' ' THR . 9.1 p-10 -89.54 148.18 23.53 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.132 -0.98 . . . . 0.0 111.265 -176.922 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.703 ' CD2' HD12 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -159.16 102.2 1.6 Allowed 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.705 -0.622 . . . . 0.0 109.485 -175.363 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.498 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 54.5 ttm -59.98 140.16 56.93 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.892 -1.13 . . . . 0.0 109.47 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.483 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 22.0 tptm -60.05 -43.45 95.38 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.027 -1.046 . . . . 0.0 110.315 -174.472 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.68 -39.96 76.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.974 -1.079 . . . . 0.0 110.012 177.695 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.498 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 93.7 m -60.95 -38.39 85.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.996 -1.065 . . . . 0.0 109.294 173.135 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.703 HD12 ' CD2' ' A' ' 63' ' ' LEU . 7.1 tp -59.96 -45.71 91.8 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.325 -0.859 . . . . 0.0 109.746 178.926 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 76.5 ttt-85 -69.32 -39.67 78.07 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.428 -0.795 . . . . 0.0 110.438 177.739 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.772 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -64.65 -41.57 92.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.171 -0.955 . . . . 0.0 109.434 -176.948 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.772 HG23 HG22 ' A' ' 70' ' ' ILE . 42.0 p -85.25 -174.62 5.33 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 175.906 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.481 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 2.6 t30 -101.11 21.82 13.29 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 171.624 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.691 ' HB3' HD21 ' A' ' 63' ' ' LEU . 41.9 mt -69.99 -40.05 75.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.012 -1.055 . . . . 0.0 110.304 175.122 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.664 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -48.62 -22.29 2.6 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 -178.548 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.4 p-10 -66.11 -16.49 64.0 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.137 -1.213 . . . . 0.0 110.588 -174.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 94.7 mt -59.99 141.44 55.61 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.276 -0.89 . . . . 0.0 110.763 -176.232 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 1.014 ' C ' HD23 ' A' ' 12' ' ' LEU . 95.1 mttt -140.0 139.77 36.1 Favored 'General case' 0 N--CA 1.493 1.678 0 CA-C-O 121.337 0.589 . . . . 0.0 109.444 174.202 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.72 HG23 HD11 ' A' ' 15' ' ' ILE . 16.4 t -60.51 152.45 5.39 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 120.788 -1.195 . . . . 0.0 110.383 -176.225 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.0 -15.56 57.66 Favored Glycine 0 N--CA 1.484 1.86 0 N-CA-C 108.811 -1.716 . . . . 0.0 108.811 -176.045 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 9.2 t0 -95.28 165.51 12.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.347 -1.09 . . . . 0.0 109.689 175.93 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.575 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.5 m95 -114.55 157.2 23.33 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.058 -1.027 . . . . 0.0 110.202 177.504 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.014 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.3 p -120.04 149.34 22.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.429 -0.795 . . . . 0.0 109.843 -179.18 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.834 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -75.79 104.36 6.3 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.021 -1.049 . . . . 0.0 109.43 169.286 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.67 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -106.21 137.76 34.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 120.459 -1.401 . . . . 0.0 111.392 -176.943 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.421 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.5 tt0 -130.06 144.86 51.57 Favored 'General case' 0 N--CA 1.495 1.78 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.986 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.458 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 34.0 ptt180 -81.45 133.67 35.44 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.261 -0.899 . . . . 0.0 111.024 -176.235 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.45 ' O ' ' OG ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.492 1.672 0 O-C-N 121.429 -0.794 . . . . 0.0 110.176 175.864 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 0.835 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.4 t . . . . . 0 N--CA 1.494 1.734 0 CA-C-O 121.544 0.688 . . . . 0.0 110.628 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.424 ' OE1' ' HG2' ' B' ' 86' ' ' ARG . 18.2 pt20 -93.48 -23.61 18.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.508 -0.745 . . . . 0.0 110.834 179.264 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.536 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -150.62 173.87 30.09 Favored Glycine 0 N--CA 1.493 2.498 0 C-N-CA 119.396 -1.383 . . . . 0.0 109.911 -175.553 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.479 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 2.2 p -123.3 170.83 9.9 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.001 -1.293 . . . . 0.0 110.932 -177.386 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.055 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -139.33 149.54 44.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.592 -0.693 . . . . 0.0 109.165 -179.634 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.58 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 33.4 tttt -106.82 115.58 30.43 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.045 -1.034 . . . . 0.0 110.139 179.554 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 1.014 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.2 tp -58.84 127.09 30.47 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.013 -1.054 . . . . 0.0 108.721 173.351 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.154 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.6 p -129.83 -30.27 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.983 0 O-C-N 121.421 -0.8 . . . . 0.0 110.031 -177.783 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -145.14 140.46 28.0 Favored 'General case' 0 C--N 1.297 -1.676 0 C-N-CA 119.499 -0.881 . . . . 0.0 110.979 -179.46 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.784 HG23 ' CD2' ' B' ' 24' ' ' HIS . 13.9 mt -107.51 131.01 58.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 120.918 -1.114 . . . . 0.0 110.266 172.357 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.52 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 77.6 m-20 -108.63 114.94 29.15 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.451 -0.781 . . . . 0.0 109.919 174.728 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 87.1 tt0 -107.0 112.31 25.2 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.1 -1.0 . . . . 0.0 110.524 -176.04 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 6.1 mtmt -107.86 129.94 23.47 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.229 -0.919 . . . . 0.0 109.241 175.143 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 19' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.5 Cg_endo -51.9 -24.44 18.9 Favored 'Trans proline' 0 C--N 1.303 -1.833 0 O-C-N 123.73 1.384 . . . . 0.0 110.187 -179.861 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.554 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 7.7 m120 -81.18 -40.03 24.54 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.206 -0.934 . . . . 0.0 110.127 175.411 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.554 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 95.2 m-85 -156.41 150.33 25.04 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.456 -0.778 . . . . 0.0 109.964 -178.87 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 22' ' ' ARG . . . . . 0.485 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 59.6 ttt180 -91.95 145.07 24.83 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.884 -1.135 . . . . 0.0 110.327 178.754 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.52 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 78.3 m -130.02 139.98 50.94 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.677 -0.64 . . . . 0.0 109.757 -176.183 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.784 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -128.54 128.34 44.11 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.94 -1.1 . . . . 0.0 111.322 178.319 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.803 HG22 ' OG ' ' B' ' 60' ' ' SER . 4.3 t -104.94 131.65 53.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.384 -0.822 . . . . 0.0 110.638 -178.135 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.504 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 33.5 m -116.22 168.09 8.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.973 -0.455 . . . . 0.0 109.788 179.546 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.528 ' OE2' ' ND2' ' B' ' 57' ' ' ASN . 2.5 tm-20 -101.05 115.42 30.45 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.27 -0.894 . . . . 0.0 109.409 178.468 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.763 HD21 HD13 ' B' ' 36' ' ' LEU . 9.8 tp -79.2 125.3 83.68 Favored Pre-proline 0 C--N 1.296 -1.753 0 O-C-N 121.538 -0.727 . . . . 0.0 109.878 -176.546 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.541 ' HD2' HD12 ' B' ' 28' ' ' LEU . 27.9 Cg_endo -67.49 -179.23 1.83 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.788 1.415 . . . . 0.0 110.806 -179.538 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' B' ' 31' ' ' HIS . 32.2 p-10 -64.85 -39.97 94.41 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.384 -0.823 . . . . 0.0 110.94 -175.49 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.6 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.99 1.25 56.51 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.886 -1.134 . . . . 0.0 110.954 -174.01 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.6 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 98.6 mmm -112.19 -14.12 13.42 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.902 -1.124 . . . . 0.0 109.881 171.479 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.586 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 19.6 mt -69.96 -20.31 63.33 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.398 -0.814 . . . . 0.0 110.484 176.17 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -61.03 123.0 16.37 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.117 -0.989 . . . . 0.0 111.263 -171.262 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 48.95 54.84 12.89 Favored Glycine 0 N--CA 1.493 2.448 0 O-C-N 121.208 -0.932 . . . . 0.0 110.927 169.675 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.793 HD23 ' N ' ' B' ' 37' ' ' GLU . 6.4 tt -113.34 155.52 25.03 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.728 -1.454 . . . . 0.0 110.091 174.15 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 37' ' ' GLU . . . . . 0.793 ' N ' HD23 ' B' ' 36' ' ' LEU . 21.3 pt-20 -150.06 167.77 25.82 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.106 -0.996 . . . . 0.0 110.203 -178.211 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 38' ' ' THR . . . . . 0.998 HG23 HD12 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -67.99 155.15 40.1 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.309 -0.869 . . . . 0.0 109.811 177.55 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.62 -8.82 64.0 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.549 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.679 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -75.57 159.81 30.84 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.144 -1.21 . . . . 0.0 109.762 178.101 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.436 ' OG ' ' O ' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -104.97 119.93 40.22 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.882 -1.136 . . . . 0.0 110.467 -179.357 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.565 ' HB ' ' CE1' ' B' ' 61' ' ' PHE . 1.6 t -109.94 132.6 57.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.424 -0.797 . . . . 0.0 109.219 172.754 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 0.511 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -92.34 120.04 32.49 Favored 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.133 -0.98 . . . . 0.0 109.407 172.532 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.783 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -89.85 107.03 18.86 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.382 -0.824 . . . . 0.0 109.074 177.832 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.611 ' ND2' ' HB2' ' A' ' 47' ' ' CYS . 0.8 OUTLIER 52.5 17.63 0.81 Allowed 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.348 -0.845 . . . . 0.0 110.535 -166.558 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.506 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 116.26 -4.69 19.98 Favored Glycine 0 N--CA 1.488 2.127 0 C-N-CA 119.626 -1.273 . . . . 0.0 110.864 170.192 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.747 ' O ' HD23 ' B' ' 49' ' ' LEU . 17.2 t -90.09 109.78 20.82 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.294 -1.709 . . . . 0.0 109.13 174.423 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 48' ' ' CYS . . . . . 0.442 ' O ' ' SG ' ' B' ' 48' ' ' CYS . 27.6 p -77.6 124.93 28.57 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.937 -1.102 . . . . 0.0 110.742 -172.473 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 0.974 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -136.92 166.27 24.02 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.381 -0.825 . . . . 0.0 108.943 172.114 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 50' ' ' THR . . . . . 0.456 ' O ' ' OD1' ' B' ' 62' ' ' ASP . 55.5 m -102.94 154.33 19.33 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.633 -1.292 . . . . 0.0 111.201 -169.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.819 HG13 HG13 ' B' ' 59' ' ' VAL . 7.1 t -74.88 113.29 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 CA-C-O 121.249 0.547 . . . . 0.0 110.053 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.595 HG22 ' HB3' ' B' ' 62' ' ' ASP . 19.0 p -75.29 -43.49 50.78 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.292 -0.88 . . . . 0.0 109.599 176.258 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.478 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -158.5 150.46 21.45 Favored 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.391 179.204 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.998 HD12 HG23 ' B' ' 38' ' ' THR . 2.5 mp -108.14 132.33 56.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.209 -0.932 . . . . 0.0 110.295 176.087 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.502 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 54.7 m-80 -108.33 66.19 0.64 Allowed 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 120.168 -0.613 . . . . 0.0 109.495 177.938 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.57 -119.31 5.74 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 -173.127 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.586 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -77.17 -17.85 58.26 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.965 -1.315 . . . . 0.0 108.946 176.112 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.154 ' CE1' HG11 ' B' ' 13' ' ' VAL . 20.7 m-70 -77.49 160.02 28.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.468 -0.77 . . . . 0.0 110.436 -178.453 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.819 HG13 HG13 ' B' ' 51' ' ' VAL . 94.3 t -145.1 117.79 2.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 C-N-CA 119.329 -0.949 . . . . 0.0 110.874 175.527 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.803 ' OG ' HG22 ' B' ' 25' ' ' VAL . 19.7 m -82.03 125.36 30.72 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.618 -0.676 . . . . 0.0 109.622 176.037 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.974 ' HB3' HD12 ' B' ' 49' ' ' LEU . 83.0 m-85 -110.0 154.88 22.55 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 120.915 -1.116 . . . . 0.0 110.25 178.708 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.595 ' HB3' HG22 ' B' ' 52' ' ' THR . 9.1 p-10 -89.57 148.29 23.46 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 120.984 -1.072 . . . . 0.0 111.192 -176.905 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.718 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.22 102.11 1.59 Allowed 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 -175.361 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.502 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 54.5 ttm -59.99 140.15 56.95 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.968 -1.082 . . . . 0.0 109.476 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.482 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 22.0 tptm -60.04 -43.37 95.39 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.118 -0.989 . . . . 0.0 110.4 -174.456 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.67 -39.97 76.69 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.034 -1.041 . . . . 0.0 110.149 177.612 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.502 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 93.1 m -60.77 -38.6 85.81 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.97 -1.081 . . . . 0.0 109.329 173.002 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.701 HD12 ' CD2' ' B' ' 63' ' ' LEU . 7.1 tp -59.95 -45.45 92.59 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.324 -0.86 . . . . 0.0 109.89 178.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 76.5 ttt-85 -69.41 -39.63 77.8 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.526 -0.734 . . . . 0.0 110.451 177.66 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.741 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -64.72 -41.48 92.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.302 -0.873 . . . . 0.0 109.486 -176.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.741 HG23 HG22 ' B' ' 70' ' ' ILE . 40.7 p -85.1 -174.52 5.3 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.279 175.813 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.47 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 2.7 t30 -101.1 21.8 13.31 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 171.482 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.718 ' HB3' HD21 ' B' ' 63' ' ' LEU . 41.3 mt -70.06 -39.95 75.36 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.07 -1.019 . . . . 0.0 110.232 175.239 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.659 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -48.7 -22.36 2.72 Favored Glycine 0 N--CA 1.486 1.98 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -178.505 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.2 p-10 -65.93 -16.52 63.94 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.161 -1.199 . . . . 0.0 110.624 -174.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 94.2 mt -60.01 141.4 55.73 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.126 -0.984 . . . . 0.0 110.829 -176.217 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 1.014 ' C ' HD23 ' B' ' 12' ' ' LEU . 95.1 mttt -139.96 139.82 36.18 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.734 -0.604 . . . . 0.0 109.397 174.196 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.733 HG23 HD11 ' B' ' 15' ' ' ILE . 16.4 t -60.55 152.46 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.989 -1.069 . . . . 0.0 110.357 -176.205 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.88 -15.25 58.19 Favored Glycine 0 N--CA 1.484 1.846 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 -176.088 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.481 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 9.1 t0 -95.44 165.32 12.42 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.402 -1.058 . . . . 0.0 109.706 175.768 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.58 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.6 m95 -114.46 157.24 23.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.147 -0.971 . . . . 0.0 110.288 177.441 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 1.055 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.3 p -120.06 149.34 22.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.688 -0.632 . . . . 0.0 109.871 -179.181 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.835 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.2 OUTLIER -75.78 104.18 6.21 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.084 -1.01 . . . . 0.0 109.526 169.26 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.676 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -106.09 137.83 34.41 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.459 -1.401 . . . . 0.0 111.38 -176.812 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' B' B ' 85' ' ' GLU . . . . . 0.418 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.4 tt0 -130.2 144.92 51.64 Favored 'General case' 0 N--CA 1.493 1.712 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.005 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 86' ' ' ARG . . . . . 0.461 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 34.1 ptt180 -81.53 133.72 35.42 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.206 -0.934 . . . . 0.0 110.93 -176.11 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.436 ' O ' ' OG ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.746 0 O-C-N 121.355 -0.841 . . . . 0.0 110.08 175.87 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.846 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.0 t . . . . . 0 N--CA 1.493 1.699 0 CA-C-O 121.83 0.824 . . . . 0.0 111.108 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 27.8 mm100 -70.0 -36.32 75.04 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.793 -0.567 . . . . 0.0 110.686 177.254 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -155.24 169.11 33.19 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.029 -1.558 . . . . 0.0 110.187 -173.569 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.437 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 0.7 OUTLIER -108.91 172.39 6.87 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.081 -1.246 . . . . 0.0 111.104 -176.167 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 1.039 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -139.46 148.54 42.87 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -178.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 20.8 tttt -106.42 117.01 32.92 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 120.993 -1.067 . . . . 0.0 110.149 178.759 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.992 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.0 tp -59.81 127.65 33.02 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 120.831 -1.168 . . . . 0.0 108.756 172.563 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.08 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.5 p -126.72 -30.85 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 C-N-CA 119.596 -0.842 . . . . 0.0 110.032 -178.215 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.13 142.56 27.48 Favored 'General case' 0 N--CA 1.494 1.762 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.361 -178.403 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.726 HG23 ' NE2' ' A' ' 24' ' ' HIS . 10.3 mt -109.46 133.78 53.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.186 -0.946 . . . . 0.0 110.191 172.92 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.515 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 83.8 m-20 -109.88 114.29 27.72 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.377 -0.827 . . . . 0.0 110.129 176.072 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.25 112.69 25.03 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.018 -1.051 . . . . 0.0 110.556 -177.284 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.0 OUTLIER -107.43 133.22 20.46 Favored Pre-proline 0 N--CA 1.492 1.661 0 O-C-N 121.186 -0.946 . . . . 0.0 109.372 174.915 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -51.99 -25.1 21.12 Favored 'Trans proline' 0 C--N 1.302 -1.869 0 O-C-N 123.859 1.452 . . . . 0.0 110.35 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.567 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 8.8 m-80 -86.2 -35.76 19.87 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.25 -0.906 . . . . 0.0 110.272 177.708 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.567 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 95.4 m-85 -157.17 150.24 23.71 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.407 -0.808 . . . . 0.0 110.244 -176.382 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.795 ' HD3' HD22 ' A' ' 68' ' ' LEU . 61.6 ttt180 -86.2 144.26 27.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.783 -1.198 . . . . 0.0 110.085 175.218 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.515 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 85.3 m -130.6 140.01 50.42 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.499 -0.751 . . . . 0.0 109.668 -175.676 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.726 ' NE2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.98 141.27 50.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.776 -1.203 . . . . 0.0 111.546 -178.433 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.843 HG22 ' OG ' ' A' ' 60' ' ' SER . 12.8 t -120.98 135.05 62.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.118 -0.989 . . . . 0.0 110.656 -179.152 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.879 HG13 ' CE1' ' A' ' 61' ' ' PHE . 21.4 m -117.46 171.96 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.738 -0.601 . . . . 0.0 110.246 178.16 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.572 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 12.8 tt0 -106.3 116.87 32.67 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.922 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.884 ' CD2' HD22 ' A' ' 36' ' ' LEU . 9.6 tp -90.73 130.93 39.19 Favored Pre-proline 0 C--N 1.296 -1.747 0 O-C-N 121.203 -0.936 . . . . 0.0 110.521 -171.295 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.472 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 30.7 Cg_endo -68.05 176.91 4.84 Favored 'Trans proline' 0 C--N 1.308 -1.605 0 O-C-N 124.015 1.534 . . . . 0.0 111.053 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -60.55 -39.92 89.71 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.429 -0.795 . . . . 0.0 111.401 -175.187 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.602 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.89 0.03 57.29 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.8 -1.188 . . . . 0.0 110.755 -174.078 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.602 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.9 mmm -110.67 -16.14 13.69 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.95 -1.094 . . . . 0.0 109.638 169.793 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.597 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 29.6 mt -71.2 -24.86 62.3 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.313 -0.867 . . . . 0.0 109.863 174.386 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ASP . . . . . 0.476 ' O ' ' N ' ' A' ' 36' ' ' LEU . 38.6 p-10 -71.16 162.25 29.74 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.467 -0.771 . . . . 0.0 110.94 -173.104 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.428 ' C ' ' O ' ' A' ' 34' ' ' ASP . . . 37.54 27.69 0.03 OUTLIER Glycine 0 N--CA 1.494 2.522 0 O-C-N 121.504 -0.747 . . . . 0.0 111.605 174.295 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.884 HD22 ' CD2' ' A' ' 28' ' ' LEU . 60.8 tp -101.21 158.45 16.02 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 120.537 -1.566 . . . . 0.0 110.919 179.025 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 21.5 pt-20 -160.04 161.09 33.9 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.566 -0.709 . . . . 0.0 109.428 177.49 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.817 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -66.84 154.42 40.96 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.043 -1.035 . . . . 0.0 109.526 175.779 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.39 -9.45 61.43 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.257 -1.537 . . . . 0.0 109.257 -176.631 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.505 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -69.87 153.21 43.6 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.135 -1.215 . . . . 0.0 109.627 177.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.529 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -97.35 104.53 16.56 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 120.966 -1.084 . . . . 0.0 109.906 178.117 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.414 ' CG1' ' HD1' ' A' ' 44' ' ' HIS . 1.6 t -87.87 137.54 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.239 -0.913 . . . . 0.0 109.027 174.526 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.484 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -102.96 120.12 40.06 Favored 'General case' 0 C--N 1.295 -1.781 0 O-C-N 120.865 -1.147 . . . . 0.0 109.535 170.167 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.806 ' CD2' HG21 ' A' ' 82' ' ' VAL . 1.2 m80 -87.45 101.02 13.19 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 176.12 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.0 t-20 58.55 8.88 0.95 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.575 -0.703 . . . . 0.0 111.399 -169.94 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 124.62 -3.19 8.73 Favored Glycine 0 N--CA 1.489 2.167 0 C-N-CA 119.674 -1.25 . . . . 0.0 110.617 174.344 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.815 ' O ' HD23 ' A' ' 49' ' ' LEU . 19.7 t -90.34 107.39 19.12 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.334 -1.686 . . . . 0.0 109.2 174.623 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 23.5 p -78.12 125.55 29.51 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.127 -0.983 . . . . 0.0 110.768 -170.817 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.941 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -142.57 160.16 40.83 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.508 -0.745 . . . . 0.0 109.592 176.051 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 27.6 m -99.51 149.15 23.53 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.715 -1.24 . . . . 0.0 111.378 -169.954 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.96 HG13 HG13 ' A' ' 59' ' ' VAL . 16.9 t -75.16 114.62 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.739 -0.6 . . . . 0.0 110.273 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.527 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 47.3 p -70.29 -40.0 74.55 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.299 -0.875 . . . . 0.0 109.947 174.214 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.587 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -162.78 154.5 18.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.344 -0.847 . . . . 0.0 110.23 -179.344 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.817 HD11 ' N ' ' A' ' 38' ' ' THR . 5.5 mt -105.55 130.01 57.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.012 -1.055 . . . . 0.0 109.888 175.201 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.524 ' HB2' ' CB ' ' A' ' 58' ' ' HIS . 9.6 m-80 -101.66 61.94 0.91 Allowed 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.614 -0.678 . . . . 0.0 109.691 178.858 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.79 -114.72 4.16 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 108.743 -1.743 . . . . 0.0 108.743 -173.687 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.597 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -78.54 -19.97 51.72 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.024 -1.28 . . . . 0.0 108.807 174.374 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.08 ' CE1' HG11 ' A' ' 13' ' ' VAL . 18.9 m-70 -75.29 160.04 30.79 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.459 -0.776 . . . . 0.0 110.116 -177.222 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.96 HG13 HG13 ' A' ' 51' ' ' VAL . 54.6 t -140.14 121.99 15.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 O-C-N 120.957 -1.089 . . . . 0.0 110.711 171.059 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.843 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.1 t -87.75 133.69 33.81 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.522 -0.736 . . . . 0.0 109.287 174.729 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.941 ' HB2' HD12 ' A' ' 49' ' ' LEU . 1.3 p90 -126.85 154.07 44.85 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 121.43 -0.793 . . . . 0.0 110.225 178.554 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.527 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 31.4 p-10 -88.72 147.77 24.32 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.004 -1.06 . . . . 0.0 111.399 -170.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.822 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -154.47 113.66 3.69 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 -176.186 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.527 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 56.9 ttm -69.96 140.61 53.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.794 -1.191 . . . . 0.0 109.449 -179.382 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.484 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 36.4 tptt -60.01 -49.23 78.5 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.995 -1.066 . . . . 0.0 110.299 -175.1 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.41 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 88.6 tt0 -65.48 -40.01 92.62 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.901 -1.124 . . . . 0.0 110.129 178.162 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.527 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 60.8 m -62.76 -38.13 89.34 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.902 -1.124 . . . . 0.0 109.426 174.238 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.795 HD22 ' HD3' ' A' ' 22' ' ' ARG . 14.7 tp -60.05 -41.58 92.61 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.14 -0.975 . . . . 0.0 109.225 177.325 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.525 ' NH1' ' HB3' ' A' ' 69' ' ' ARG . 6.4 mmm180 -69.96 -38.85 76.24 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.466 -0.771 . . . . 0.0 110.433 174.012 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.828 HG22 HG23 ' A' ' 71' ' ' THR . 1.1 tt -67.97 -40.43 83.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.327 -0.858 . . . . 0.0 109.412 -176.574 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.828 HG23 HG22 ' A' ' 70' ' ' ILE . 59.1 p -87.49 -171.56 3.51 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.339 0.59 . . . . 0.0 109.764 179.083 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.467 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 8.3 t30 -99.92 18.75 17.6 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.338 -0.852 . . . . 0.0 108.865 170.194 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.822 ' HB3' HD21 ' A' ' 63' ' ' LEU . 70.2 mt -68.33 -40.02 81.77 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.931 -1.106 . . . . 0.0 109.749 174.829 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.515 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -47.06 -22.55 1.3 Allowed Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 -179.702 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.3 p-10 -67.91 -17.18 64.39 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.975 -1.309 . . . . 0.0 110.419 -175.351 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 95.5 mt -63.51 142.11 58.51 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.223 -0.923 . . . . 0.0 110.917 -176.243 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 0.992 ' C ' HD23 ' A' ' 12' ' ' LEU . 46.1 mttt -142.65 142.73 32.12 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.733 -0.604 . . . . 0.0 109.495 174.561 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.697 HG23 HD11 ' A' ' 15' ' ' ILE . 21.3 t -63.61 150.04 10.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.587 0 O-C-N 120.843 -1.16 . . . . 0.0 110.36 -176.707 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.78 -13.6 62.35 Favored Glycine 0 N--CA 1.483 1.797 0 N-CA-C 108.793 -1.723 . . . . 0.0 108.793 -175.21 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 44.9 t0 -95.2 166.31 11.97 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.267 -1.137 . . . . 0.0 109.55 176.1 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.8 m95 -117.22 159.04 23.28 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.006 -1.059 . . . . 0.0 110.118 176.563 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.039 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.0 OUTLIER -125.38 155.02 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.441 -0.787 . . . . 0.0 109.891 -179.124 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.846 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.3 OUTLIER -78.16 105.29 9.28 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.17 -0.956 . . . . 0.0 108.965 168.093 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.846 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -106.19 140.46 24.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 120.535 -1.353 . . . . 0.0 111.478 -176.312 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.43 ' HB3' ' HB3' ' A' ' 43' ' ' ALA . 86.5 tt0 -134.27 157.09 47.19 Favored 'General case' 0 N--CA 1.496 1.855 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.948 -179.557 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 47.5 ptt85 -100.23 133.37 44.74 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.114 -0.991 . . . . 0.0 110.992 -176.232 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.529 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.492 1.665 0 O-C-N 121.344 -0.848 . . . . 0.0 110.126 179.598 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 0.826 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.0 t . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.701 0.762 . . . . 0.0 111.11 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 27.8 mm100 -69.98 -36.08 74.93 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.836 -0.54 . . . . 0.0 110.81 177.194 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.534 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -155.42 168.96 33.27 Favored Glycine 0 N--CA 1.495 2.631 0 C-N-CA 119.086 -1.53 . . . . 0.0 110.269 -173.563 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.44 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 0.7 OUTLIER -108.87 172.17 7.0 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.127 -1.219 . . . . 0.0 111.177 -176.128 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.06 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -139.24 148.79 43.55 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 -179.145 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.583 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 20.8 tttt -106.59 117.11 33.18 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.091 -1.006 . . . . 0.0 110.055 178.787 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 1.008 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.0 tp -59.98 127.54 32.43 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.977 -1.077 . . . . 0.0 108.814 172.583 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.08 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.5 p -126.51 -31.0 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.837 0 O-C-N 121.312 -0.868 . . . . 0.0 110.061 -178.115 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.09 142.55 27.51 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.229 -0.988 . . . . 0.0 111.391 -178.358 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.739 HG23 ' NE2' ' B' ' 24' ' ' HIS . 10.3 mt -109.42 133.85 53.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.169 -0.957 . . . . 0.0 110.241 172.893 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.511 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.6 m-20 -110.0 114.44 27.98 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.387 -0.821 . . . . 0.0 110.077 176.059 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -100.24 112.66 24.99 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.101 -1.0 . . . . 0.0 110.612 -177.358 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.0 OUTLIER -107.47 133.3 20.44 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.27 -0.894 . . . . 0.0 109.4 174.904 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -52.12 -24.99 21.57 Favored 'Trans proline' 0 C--N 1.303 -1.855 0 O-C-N 123.873 1.46 . . . . 0.0 110.32 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.572 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 9.2 m-80 -86.12 -36.35 19.64 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.305 -0.872 . . . . 0.0 110.06 177.804 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.572 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 95.5 m-85 -156.71 150.27 24.52 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.43 -0.794 . . . . 0.0 110.296 -176.285 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 22' ' ' ARG . . . . . 0.793 ' HD3' HD22 ' B' ' 68' ' ' LEU . 61.5 ttt180 -86.18 144.15 27.62 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.783 -1.198 . . . . 0.0 110.072 175.165 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.511 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 85.2 m -130.44 140.07 50.56 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.504 -0.747 . . . . 0.0 109.745 -175.76 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.739 ' NE2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.92 141.29 50.28 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.859 -1.151 . . . . 0.0 111.505 -178.358 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.841 HG22 ' OG ' ' B' ' 60' ' ' SER . 12.6 t -120.9 135.21 61.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.313 -0.867 . . . . 0.0 110.648 -179.164 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.892 HG13 ' CE1' ' B' ' 61' ' ' PHE . 21.7 m -117.72 171.94 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.757 -0.589 . . . . 0.0 110.19 178.171 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.582 ' HG3' HD22 ' B' ' 57' ' ' ASN . 12.8 tt0 -106.19 116.82 32.59 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.854 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.887 ' CD2' HD22 ' B' ' 36' ' ' LEU . 9.5 tp -90.59 130.9 39.57 Favored Pre-proline 0 C--N 1.295 -1.773 0 O-C-N 121.16 -0.962 . . . . 0.0 110.547 -171.298 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.481 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 30.6 Cg_endo -68.13 176.92 4.89 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 O-C-N 123.98 1.516 . . . . 0.0 111.005 -179.505 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -60.51 -40.02 89.89 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.454 -0.779 . . . . 0.0 111.355 -175.143 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.87 0.06 57.27 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.738 -1.226 . . . . 0.0 110.707 -174.008 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.597 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.9 mmm -110.71 -16.03 13.7 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.848 -1.157 . . . . 0.0 109.665 169.765 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.607 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 29.4 mt -71.31 -24.92 62.22 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.298 -0.876 . . . . 0.0 109.779 174.408 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 34' ' ' ASP . . . . . 0.488 ' O ' ' N ' ' B' ' 36' ' ' LEU . 38.6 p-10 -71.11 162.18 29.86 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.443 -0.786 . . . . 0.0 110.955 -173.088 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 35' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' B' ' 34' ' ' ASP . . . 37.53 27.74 0.03 OUTLIER Glycine 0 N--CA 1.496 2.694 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.564 174.343 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.887 HD22 ' CD2' ' B' ' 28' ' ' LEU . 60.8 tp -101.28 158.43 16.05 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.572 -1.546 . . . . 0.0 110.925 178.975 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 37' ' ' GLU . . . . . . . . . . . . . 21.5 pt-20 -159.97 161.17 34.09 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.561 -0.712 . . . . 0.0 109.421 177.525 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 38' ' ' THR . . . . . 0.817 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.97 154.43 41.14 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.007 -1.058 . . . . 0.0 109.49 175.794 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.38 -9.37 61.63 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -176.577 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.517 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -70.01 152.98 43.79 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.265 -1.138 . . . . 0.0 109.612 177.885 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.536 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -97.08 104.28 16.28 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.947 -1.096 . . . . 0.0 110.037 178.103 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.424 HG12 ' HD1' ' B' ' 44' ' ' HIS . 1.6 t -87.81 137.54 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.247 -0.908 . . . . 0.0 109.108 174.554 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 0.479 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -103.02 120.19 40.2 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 120.931 -1.106 . . . . 0.0 109.482 170.239 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.821 ' CD2' HG21 ' B' ' 82' ' ' VAL . 1.2 m80 -87.51 100.89 13.11 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.67 -0.812 . . . . 0.0 108.925 176.099 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.0 t-20 58.87 8.86 1.03 Allowed 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.5 -0.75 . . . . 0.0 111.256 -170.12 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 124.5 -2.9 8.82 Favored Glycine 0 N--CA 1.488 2.123 0 C-N-CA 119.699 -1.239 . . . . 0.0 110.601 174.173 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.813 ' O ' HD23 ' B' ' 49' ' ' LEU . 19.7 t -90.44 107.33 19.09 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.3 -1.706 . . . . 0.0 109.266 174.492 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 23.3 p -78.05 125.55 29.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.128 -0.983 . . . . 0.0 110.774 -170.761 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 0.939 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -142.59 160.08 41.0 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.596 -0.69 . . . . 0.0 109.632 176.05 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 27.7 m -99.25 149.3 23.25 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.676 -1.265 . . . . 0.0 111.357 -169.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.982 HG13 HG13 ' B' ' 59' ' ' VAL . 17.1 t -75.42 114.55 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.675 -0.641 . . . . 0.0 110.342 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.528 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 48.3 p -70.32 -39.96 74.46 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.178 -0.952 . . . . 0.0 109.865 174.433 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.574 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -162.74 154.6 18.26 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.388 -0.82 . . . . 0.0 110.214 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.817 HD11 ' N ' ' B' ' 38' ' ' THR . 5.5 mt -105.63 129.9 57.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.12 -0.987 . . . . 0.0 109.925 175.215 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.53 ' HB2' ' CB ' ' B' ' 58' ' ' HIS . 9.6 m-80 -101.58 61.9 0.92 Allowed 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.658 -0.651 . . . . 0.0 109.748 178.867 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.78 -114.66 4.15 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 -173.655 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.607 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -78.41 -20.2 51.61 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.004 -1.292 . . . . 0.0 108.815 174.34 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.08 ' CE1' HG11 ' B' ' 13' ' ' VAL . 19.1 m-70 -75.21 159.87 31.06 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.442 -0.786 . . . . 0.0 110.144 -177.203 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.982 HG13 HG13 ' B' ' 51' ' ' VAL . 54.7 t -140.04 122.16 16.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 C-N-CA 118.926 -1.11 . . . . 0.0 110.662 171.133 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.841 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.1 t -87.86 133.83 33.82 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.457 -0.777 . . . . 0.0 109.371 174.746 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.939 ' HB2' HD12 ' B' ' 49' ' ' LEU . 1.3 p90 -126.98 154.07 45.05 Favored 'General case' 0 N--CA 1.498 1.929 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.109 178.681 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.528 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 31.1 p-10 -88.7 147.77 24.34 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.939 -1.1 . . . . 0.0 111.352 -170.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.793 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -154.38 113.76 3.73 Favored 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 -176.309 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.531 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 56.8 ttm -70.05 140.53 52.82 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.744 -1.222 . . . . 0.0 109.402 -179.386 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.483 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 36.5 tptt -59.99 -49.1 78.99 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.023 -1.048 . . . . 0.0 110.347 -175.117 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 66' ' ' GLU . . . . . 0.411 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 88.6 tt0 -65.54 -40.03 92.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.948 -1.095 . . . . 0.0 110.098 178.22 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.531 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 61.0 m -62.7 -38.23 89.6 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.905 -1.122 . . . . 0.0 109.426 174.242 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.793 HD22 ' HD3' ' B' ' 22' ' ' ARG . 14.7 tp -60.01 -41.46 92.21 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.292 -0.88 . . . . 0.0 109.264 177.312 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 69' ' ' ARG . . . . . 0.529 ' NH1' ' HB3' ' B' ' 69' ' ' ARG . 6.4 mmm180 -70.0 -38.99 76.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.558 -0.714 . . . . 0.0 110.386 174.03 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.811 HG22 HG23 ' B' ' 71' ' ' THR . 1.1 tt -67.88 -40.39 83.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.526 -176.641 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.811 HG23 HG22 ' B' ' 70' ' ' ILE . 59.2 p -87.37 -171.43 3.47 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-O 121.296 0.57 . . . . 0.0 109.863 178.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.524 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 8.4 t30 -99.92 18.74 17.62 Favored 'General case' 0 C--N 1.297 -1.703 0 O-C-N 121.384 -0.823 . . . . 0.0 108.814 170.195 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.793 ' HB3' HD21 ' B' ' 63' ' ' LEU . 69.4 mt -68.41 -39.98 81.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.023 -1.048 . . . . 0.0 109.716 174.811 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.513 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -47.02 -22.64 1.3 Allowed Glycine 0 N--CA 1.489 2.2 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -179.71 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.4 p-10 -67.94 -17.14 64.36 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.08 -1.247 . . . . 0.0 110.492 -175.321 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 95.5 mt -63.44 142.1 58.52 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.17 -0.956 . . . . 0.0 110.92 -176.334 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 1.008 ' C ' HD23 ' B' ' 12' ' ' LEU . 46.1 mttt -142.84 142.84 31.91 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.71 -0.619 . . . . 0.0 109.391 174.507 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.718 HG23 HD11 ' B' ' 15' ' ' ILE . 21.5 t -63.61 149.99 10.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 120.903 -1.123 . . . . 0.0 110.422 -176.568 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.67 -13.34 62.8 Favored Glycine 0 N--CA 1.483 1.804 0 N-CA-C 108.885 -1.686 . . . . 0.0 108.885 -175.194 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 44.5 t0 -95.28 166.22 12.0 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.392 -1.064 . . . . 0.0 109.545 175.923 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.583 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.0 m95 -117.16 159.08 23.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.019 -1.051 . . . . 0.0 110.183 176.479 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 1.06 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.0 OUTLIER -125.45 155.15 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.5 -0.75 . . . . 0.0 109.936 -179.289 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.826 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.3 OUTLIER -78.25 105.15 9.29 Favored 'General case' 0 C--N 1.297 -1.69 0 O-C-N 121.123 -0.986 . . . . 0.0 109.025 168.203 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.856 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -106.07 140.61 23.62 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 120.631 -1.293 . . . . 0.0 111.361 -176.047 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' B' B ' 85' ' ' GLU . . . . . 0.431 ' HB3' ' HB3' ' B' ' 43' ' ' ALA . 86.4 tt0 -134.54 157.06 47.52 Favored 'General case' 0 N--CA 1.495 1.785 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.888 -179.649 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 47.6 ptt85 -100.12 133.46 44.48 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.079 -1.013 . . . . 0.0 110.919 -176.12 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.536 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.767 0 O-C-N 121.401 -0.812 . . . . 0.0 110.08 179.603 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.843 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.2 t . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 121.743 0.783 . . . . 0.0 111.09 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -69.95 -35.11 74.24 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.778 -0.576 . . . . 0.0 111.072 176.848 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -156.24 172.97 34.14 Favored Glycine 0 N--CA 1.495 2.609 0 C-N-CA 118.747 -1.692 . . . . 0.0 110.513 -172.526 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.458 ' O ' ' HG3' ' A' ' 29' ' ' PRO . 12.6 p -117.75 172.35 7.43 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.031 -1.276 . . . . 0.0 111.017 -176.814 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 1.041 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -140.01 148.53 41.99 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.562 -0.711 . . . . 0.0 109.609 -178.726 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.579 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 37.6 tttt -107.18 115.3 29.93 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.047 -1.033 . . . . 0.0 110.321 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.998 HD23 ' C ' ' A' ' 77' ' ' LYS . 11.3 tp -59.91 126.74 28.73 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.038 -1.039 . . . . 0.0 108.896 173.945 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.042 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -125.32 -29.32 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.838 0 C-N-CA 119.583 -0.847 . . . . 0.0 109.909 -179.417 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.93 142.4 24.37 Favored 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 118.942 -1.103 . . . . 0.0 111.523 179.735 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.782 HG23 ' CD2' ' A' ' 24' ' ' HIS . 12.0 mt -105.55 137.13 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.155 -0.966 . . . . 0.0 110.185 171.569 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.519 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 86.7 m-20 -112.95 115.99 29.28 Favored 'General case' 0 C--N 1.297 -1.703 0 O-C-N 121.344 -0.847 . . . . 0.0 109.937 173.512 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -105.9 115.24 29.9 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.897 -1.127 . . . . 0.0 110.799 -176.477 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.465 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 4.1 mtmt -110.4 127.58 26.77 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.121 -0.987 . . . . 0.0 108.935 171.703 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -52.27 -18.73 8.13 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.848 1.446 . . . . 0.0 110.812 -179.367 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.518 ' HB2' ' CD2' ' A' ' 21' ' ' PHE . 0.4 OUTLIER -90.18 -35.84 15.13 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.139 -0.975 . . . . 0.0 108.741 177.077 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.518 ' CD2' ' HB2' ' A' ' 20' ' ' ASN . 81.9 m-85 -151.07 150.15 30.37 Favored 'General case' 0 N--CA 1.491 1.623 0 CA-C-O 121.192 0.52 . . . . 0.0 109.748 179.183 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.48 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 62.4 ttt180 -97.69 143.83 27.95 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.589 -1.32 . . . . 0.0 110.021 176.504 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.519 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 96.5 m -129.98 140.09 50.96 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.412 -0.805 . . . . 0.0 110.126 -173.304 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.782 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.22 135.77 48.5 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.984 -1.073 . . . . 0.0 111.207 179.216 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.759 HG22 ' OG ' ' A' ' 60' ' ' SER . 15.8 t -115.53 134.25 59.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.002 -1.061 . . . . 0.0 110.767 -178.276 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 29.5 m -119.67 170.02 9.88 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.062 -179.703 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.535 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 7.5 tt0 -103.55 116.97 33.36 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -179.383 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.545 HD23 ' HA ' ' A' ' 33' ' ' LEU . 8.9 tp -82.01 119.73 75.78 Favored Pre-proline 0 C--N 1.295 -1.798 0 O-C-N 121.502 -0.748 . . . . 0.0 109.815 -173.719 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.458 ' HG3' ' O ' ' A' ' 9' ' ' THR . 22.6 Cg_endo -65.33 179.22 1.66 Allowed 'Trans proline' 0 C--N 1.308 -1.554 0 O-C-N 123.85 1.447 . . . . 0.0 111.047 -179.378 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.417 ' OD1' ' C ' ' A' ' 30' ' ' ASP . 50.5 t0 -60.1 -41.28 92.18 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.415 -0.803 . . . . 0.0 111.098 -175.319 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.57 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.39 1.47 56.57 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.87 -1.144 . . . . 0.0 110.763 -174.156 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.57 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 96.4 mmm -111.07 -15.82 13.63 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.036 -1.04 . . . . 0.0 109.82 171.835 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.613 HD21 ' HB2' ' A' ' 57' ' ' ASN . 16.5 mt -68.18 -30.39 69.48 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.33 -0.856 . . . . 0.0 109.999 178.904 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 57.4 t0 -91.72 127.02 37.01 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.328 -0.858 . . . . 0.0 110.266 -179.648 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.28 -48.06 1.0 Allowed Glycine 0 N--CA 1.492 2.403 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 177.712 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.788 HD23 ' N ' ' A' ' 37' ' ' GLU . 7.4 tt -70.02 145.81 51.49 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.141 -1.211 . . . . 0.0 110.664 -175.762 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.788 ' N ' HD23 ' A' ' 36' ' ' LEU . 20.7 pt-20 -150.43 170.01 20.09 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.427 -0.796 . . . . 0.0 109.622 -179.512 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.825 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -67.23 151.15 48.05 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.91 -1.119 . . . . 0.0 110.13 179.972 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.62 0.0 62.15 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 -176.226 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.452 ' O ' ' HA ' ' A' ' 50' ' ' THR . . . -79.79 159.0 26.71 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.242 -1.152 . . . . 0.0 109.7 177.894 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.552 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -101.06 113.23 26.05 Favored 'General case' 0 N--CA 1.486 1.345 0 O-C-N 121.126 -0.984 . . . . 0.0 110.04 176.72 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.611 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.0 t -104.74 130.0 56.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.278 -0.889 . . . . 0.0 109.172 174.718 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.516 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -93.31 119.53 32.56 Favored 'General case' 0 C--N 1.297 -1.708 0 C-N-CA 119.146 -1.022 . . . . 0.0 109.149 172.257 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.736 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.3 OUTLIER -88.0 107.15 18.58 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 178.52 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.51 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.1 t-20 50.29 16.28 0.25 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.487 -0.758 . . . . 0.0 111.283 -166.457 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.493 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 120.92 0.85 11.75 Favored Glycine 0 N--CA 1.489 2.221 0 C-N-CA 119.444 -1.36 . . . . 0.0 111.164 171.292 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.785 ' O ' HD23 ' A' ' 49' ' ' LEU . 34.8 t -98.71 108.46 21.15 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.137 -1.802 . . . . 0.0 109.492 175.082 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 21.2 p -75.7 126.74 31.59 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.015 -1.053 . . . . 0.0 111.084 -171.116 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.96 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -141.35 162.74 34.76 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.505 -0.747 . . . . 0.0 109.466 172.712 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.452 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 55.0 m -102.47 152.88 20.61 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 120.637 -1.29 . . . . 0.0 111.074 -171.13 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.896 HG22 ' CE1' ' A' ' 61' ' ' PHE . 34.5 t -76.82 117.73 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.62 -0.675 . . . . 0.0 110.458 -177.934 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.685 HG22 ' HB3' ' A' ' 62' ' ' ASP . 41.2 p -70.21 -39.99 74.81 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.122 -0.986 . . . . 0.0 109.669 172.253 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.572 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 52.3 tp10 -164.72 156.12 15.26 Favored 'General case' 0 N--CA 1.492 1.642 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.819 -177.349 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.825 HD11 ' N ' ' A' ' 38' ' ' THR . 8.8 mt -110.47 130.07 64.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.083 -1.011 . . . . 0.0 109.986 172.794 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.499 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 63.8 m-80 -104.7 65.62 0.76 Allowed 'General case' 0 C--N 1.297 -1.678 0 CA-C-O 121.532 0.682 . . . . 0.0 109.54 177.703 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.91 -115.09 4.24 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 -174.158 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.613 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.1 OUTLIER -80.0 -21.08 44.04 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.121 -1.223 . . . . 0.0 109.162 176.609 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.042 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.5 m170 -77.05 159.38 29.91 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.186 -0.946 . . . . 0.0 109.791 -178.024 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.815 HG13 HG13 ' A' ' 51' ' ' VAL . 59.9 t -140.9 121.48 13.27 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 C-N-CA 119.078 -1.049 . . . . 0.0 110.522 171.707 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.759 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.2 t -84.35 135.35 34.33 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.434 -0.791 . . . . 0.0 109.264 175.885 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.96 ' HB3' HD12 ' A' ' 49' ' ' LEU . 58.9 m-85 -115.55 158.5 22.53 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.319 -0.863 . . . . 0.0 110.199 178.967 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.685 ' HB3' HG22 ' A' ' 52' ' ' THR . 25.1 p-10 -92.12 147.47 22.91 Favored 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 122.106 0.955 . . . . 0.0 110.842 178.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.833 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -159.71 125.0 4.08 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 -176.864 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.536 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 56.1 ttm -84.85 146.44 27.31 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.931 -1.106 . . . . 0.0 109.434 -177.84 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.43 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 71.4 tttt -60.06 -49.13 78.88 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.014 -1.053 . . . . 0.0 109.99 -177.231 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 53.4 tp10 -69.59 -40.02 76.95 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.147 -0.97 . . . . 0.0 110.397 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.537 ' O ' HG23 ' A' ' 71' ' ' THR . 37.7 m -62.25 -38.66 90.11 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.823 -1.173 . . . . 0.0 109.085 174.427 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.802 HD11 ' HA2' ' A' ' 74' ' ' GLY . 1.0 OUTLIER -60.05 -47.37 86.16 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.233 -0.917 . . . . 0.0 109.709 177.419 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 74.9 ttt-85 -65.76 -40.05 91.65 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.467 -0.771 . . . . 0.0 110.481 178.192 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.878 HG22 HG23 ' A' ' 71' ' ' THR . 1.4 tt -64.19 -41.28 91.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.234 -0.917 . . . . 0.0 109.093 -179.323 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.878 HG23 HG22 ' A' ' 70' ' ' ILE . 20.1 p -89.72 -177.01 5.16 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 175.626 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.499 ' N ' ' OD1' ' B' ' 83' ' ' ASN . 3.4 t30 -100.01 25.16 7.67 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.07 -1.019 . . . . 0.0 108.332 172.414 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.833 ' HB3' HD21 ' A' ' 63' ' ' LEU . 86.8 mt -67.66 -39.96 84.52 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.996 -1.065 . . . . 0.0 109.933 176.551 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.802 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -54.88 -23.98 32.41 Favored Glycine 0 N--CA 1.485 1.909 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -177.52 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 21.9 p-10 -64.12 -17.02 63.05 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.962 -1.317 . . . . 0.0 110.32 -175.335 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.52 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 96.0 mt -60.08 141.48 55.7 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.262 -0.898 . . . . 0.0 110.476 -177.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 0.998 ' C ' HD23 ' A' ' 12' ' ' LEU . 59.8 mmtt -140.02 143.28 36.34 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-O 121.814 0.816 . . . . 0.0 110.4 175.807 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.596 ' CG2' HG13 ' A' ' 15' ' ' ILE . 35.9 t -63.08 149.51 10.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.252 -0.905 . . . . 0.0 110.235 -176.199 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.54 -13.79 63.05 Favored Glycine 0 N--CA 1.484 1.849 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 -175.338 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 46.3 t0 -96.23 163.13 13.22 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.346 -1.091 . . . . 0.0 109.587 176.167 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.579 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 13.7 m95 -113.89 162.15 16.73 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.062 -1.024 . . . . 0.0 110.201 176.52 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.041 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.6 p -130.8 140.24 49.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 O-C-N 121.514 -0.741 . . . . 0.0 110.16 -175.625 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.843 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -66.95 103.89 1.25 Allowed 'General case' 0 C--N 1.295 -1.795 0 O-C-N 121.095 -1.003 . . . . 0.0 109.46 169.07 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.732 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -106.58 137.63 36.2 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.816 0 O-C-N 120.537 -1.352 . . . . 0.0 111.414 -178.885 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.54 ' HB2' HG22 ' A' ' 6' ' ' VAL . 84.3 tt0 -132.73 131.66 41.46 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.072 179.703 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 75.9 ttt180 -72.18 139.2 48.11 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.151 -0.968 . . . . 0.0 110.972 -175.895 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.552 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.493 1.716 0 O-C-N 121.436 -0.79 . . . . 0.0 109.814 176.654 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 0.851 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.2 t . . . . . 0 N--CA 1.495 1.793 0 CA-C-O 121.731 0.777 . . . . 0.0 111.124 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 -70.02 -34.73 73.66 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.715 -0.615 . . . . 0.0 111.137 176.826 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.528 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -156.56 172.81 34.33 Favored Glycine 0 N--CA 1.498 2.767 0 C-N-CA 118.814 -1.66 . . . . 0.0 110.599 -172.555 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.453 ' O ' ' HG3' ' B' ' 29' ' ' PRO . 12.5 p -117.7 172.35 7.42 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.074 -1.251 . . . . 0.0 111.01 -176.763 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.048 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -139.95 148.68 42.3 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.654 -0.653 . . . . 0.0 109.518 -178.791 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 37.6 tttt -107.38 115.42 30.12 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.146 -0.971 . . . . 0.0 110.246 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 1.011 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.2 tp -60.03 126.67 28.44 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.058 -1.026 . . . . 0.0 108.956 173.923 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.057 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -125.14 -29.51 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.827 0 O-C-N 121.347 -0.846 . . . . 0.0 109.974 -179.366 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.88 142.27 24.29 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 119.089 -1.044 . . . . 0.0 111.52 179.819 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.789 HG23 ' CD2' ' B' ' 24' ' ' HIS . 11.8 mt -105.41 137.15 36.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.065 -1.022 . . . . 0.0 110.137 171.606 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.524 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 86.4 m-20 -113.09 115.99 29.18 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.398 -0.814 . . . . 0.0 109.854 173.536 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -105.83 115.24 29.9 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.895 -1.128 . . . . 0.0 110.754 -176.471 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 4.1 mtmt -110.45 127.67 26.62 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.188 -0.945 . . . . 0.0 108.925 171.636 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -52.34 -18.78 8.4 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.763 1.402 . . . . 0.0 110.744 -179.3 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.515 ' HB2' ' CD2' ' B' ' 21' ' ' PHE . 0.4 OUTLIER -90.01 -36.22 15.06 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.174 -0.954 . . . . 0.0 108.659 177.044 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.515 ' CD2' ' HB2' ' B' ' 20' ' ' ASN . 81.7 m-85 -150.71 150.2 30.77 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.886 -0.509 . . . . 0.0 109.801 179.263 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 22' ' ' ARG . . . . . 0.466 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 62.4 ttt180 -97.76 143.85 27.97 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.733 -1.229 . . . . 0.0 109.994 176.499 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.524 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 97.3 m -130.03 140.12 50.91 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.579 -0.7 . . . . 0.0 110.04 -173.335 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.789 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -129.99 135.94 48.86 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.045 -1.035 . . . . 0.0 111.186 179.179 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.754 HG22 ' OG ' ' B' ' 60' ' ' SER . 15.7 t -115.54 134.44 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.09 -1.006 . . . . 0.0 110.687 -178.379 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 30.2 m -119.97 170.02 10.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 C-N-CA 120.46 -0.496 . . . . 0.0 109.957 -179.711 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.525 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 7.6 tt0 -103.51 117.13 33.74 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 121.455 -0.778 . . . . 0.0 108.968 -179.347 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.552 HD23 ' HA ' ' B' ' 33' ' ' LEU . 8.9 tp -82.05 119.77 75.86 Favored Pre-proline 0 C--N 1.294 -1.81 0 O-C-N 121.449 -0.782 . . . . 0.0 109.815 -173.678 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.468 ' HD2' ' HB2' ' B' ' 32' ' ' MET . 22.1 Cg_endo -65.42 179.08 1.75 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 O-C-N 123.829 1.437 . . . . 0.0 111.032 -179.327 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.419 ' OD1' ' C ' ' B' ' 30' ' ' ASP . 50.5 t0 -60.01 -41.26 91.78 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.413 -0.804 . . . . 0.0 111.134 -175.338 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.57 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.36 1.5 56.52 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.971 -1.08 . . . . 0.0 110.804 -174.236 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.57 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 96.4 mmm -110.97 -15.98 13.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.049 -1.032 . . . . 0.0 109.839 171.818 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.633 HD21 ' HB2' ' B' ' 57' ' ' ASN . 16.6 mt -68.01 -30.49 69.75 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.412 -0.805 . . . . 0.0 110.043 178.932 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -91.72 127.02 37.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.331 -0.856 . . . . 0.0 110.238 -179.635 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.3 -47.98 1.0 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 177.673 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.778 HD23 ' N ' ' B' ' 37' ' ' GLU . 7.4 tt -69.97 145.74 51.62 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.022 -1.281 . . . . 0.0 110.649 -175.758 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 37' ' ' GLU . . . . . 0.778 ' N ' HD23 ' B' ' 36' ' ' LEU . 20.7 pt-20 -150.44 169.99 20.14 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.505 -0.747 . . . . 0.0 109.608 -179.529 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 38' ' ' THR . . . . . 0.834 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -67.25 151.09 48.13 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.883 -1.136 . . . . 0.0 110.115 179.996 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.74 -0.09 62.4 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -176.211 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.458 ' O ' ' HA ' ' B' ' 50' ' ' THR . . . -79.85 158.94 26.63 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.281 -1.129 . . . . 0.0 109.656 177.939 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.551 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -100.94 113.24 26.02 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.993 -1.067 . . . . 0.0 110.075 176.7 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.597 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.0 t -104.89 130.02 56.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 121.285 -0.884 . . . . 0.0 109.111 174.764 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 0.519 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -93.22 119.53 32.5 Favored 'General case' 0 C--N 1.298 -1.645 0 C-N-CA 119.085 -1.046 . . . . 0.0 109.278 172.155 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.731 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.3 OUTLIER -88.0 107.03 18.53 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.416 -0.802 . . . . 0.0 109.066 178.503 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.51 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.1 t-20 50.44 16.23 0.27 Allowed 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.469 -0.77 . . . . 0.0 111.222 -166.506 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.493 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 120.82 1.23 11.81 Favored Glycine 0 N--CA 1.49 2.298 0 C-N-CA 119.407 -1.378 . . . . 0.0 111.086 171.158 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.779 ' O ' HD23 ' B' ' 49' ' ' LEU . 35.1 t -98.92 108.44 21.12 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.188 -1.772 . . . . 0.0 109.379 175.02 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 21.0 p -75.58 126.84 31.8 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.113 -0.992 . . . . 0.0 111.011 -171.172 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 0.983 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -141.44 162.74 34.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.458 -0.776 . . . . 0.0 109.461 172.637 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 50' ' ' THR . . . . . 0.458 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 55.0 m -102.44 152.97 20.5 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 120.612 -1.305 . . . . 0.0 111.037 -171.14 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.905 HG22 ' CE1' ' B' ' 61' ' ' PHE . 34.0 t -76.91 117.55 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.509 -0.745 . . . . 0.0 110.488 -177.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.676 HG22 ' HB3' ' B' ' 62' ' ' ASP . 40.9 p -70.02 -40.11 75.42 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.087 -1.008 . . . . 0.0 109.691 172.271 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.576 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 52.3 tp10 -164.68 156.14 15.39 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.252 -0.905 . . . . 0.0 110.838 -177.328 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.834 HD11 ' N ' ' B' ' 38' ' ' THR . 9.0 mt -110.44 130.02 64.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.236 -0.915 . . . . 0.0 110.029 172.844 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.52 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 63.7 m-80 -104.74 65.45 0.75 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-O 121.445 0.641 . . . . 0.0 109.482 177.823 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.13 -115.04 4.21 Favored Glycine 0 N--CA 1.486 2.005 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 -174.213 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.633 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -80.01 -21.22 43.85 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.035 -1.273 . . . . 0.0 109.183 176.596 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.057 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.6 m170 -76.95 159.23 30.12 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.155 -0.966 . . . . 0.0 109.758 -178.036 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.81 HG13 HG13 ' B' ' 51' ' ' VAL . 59.5 t -140.83 121.52 13.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 C-N-CA 119.008 -1.077 . . . . 0.0 110.469 171.796 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.754 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.2 t -84.42 135.35 34.3 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.468 -0.77 . . . . 0.0 109.368 175.876 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.983 ' HB3' HD12 ' B' ' 49' ' ' LEU . 58.7 m-85 -115.47 158.72 22.15 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.287 -0.883 . . . . 0.0 110.165 179.012 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.676 ' HB3' HG22 ' B' ' 52' ' ' THR . 25.1 p-10 -92.25 147.48 22.89 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.08 -1.013 . . . . 0.0 110.876 178.925 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.8 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.69 125.09 4.12 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -176.885 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.533 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 56.1 ttm -84.92 146.4 27.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.966 -1.084 . . . . 0.0 109.388 -177.811 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.428 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 71.3 tttt -60.03 -49.14 78.84 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.104 -0.998 . . . . 0.0 109.977 -177.205 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -69.6 -39.99 76.91 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.149 -0.969 . . . . 0.0 110.444 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.554 ' O ' HG23 ' B' ' 71' ' ' THR . 38.5 m -62.26 -38.83 90.8 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.935 -1.103 . . . . 0.0 108.98 174.449 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.827 HD11 ' HA2' ' B' ' 74' ' ' GLY . 1.0 OUTLIER -59.9 -47.28 86.43 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.436 -0.79 . . . . 0.0 109.8 177.398 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 74.9 ttt-85 -65.83 -39.99 91.36 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.54 -0.725 . . . . 0.0 110.513 178.173 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.885 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -64.2 -41.19 91.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.285 -0.885 . . . . 0.0 109.13 -179.381 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.885 HG23 HG22 ' B' ' 70' ' ' ILE . 20.4 p -89.7 -176.85 5.11 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 120.236 -0.586 . . . . 0.0 109.433 175.602 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.527 ' CB ' ' H ' ' A' ' 83' ' ' ASN . 3.5 t30 -100.0 25.09 7.73 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.079 -1.013 . . . . 0.0 108.307 172.336 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.8 ' HB3' HD21 ' B' ' 63' ' ' LEU . 86.6 mt -67.69 -39.94 84.38 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.995 -1.066 . . . . 0.0 109.945 176.609 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.827 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -54.86 -23.95 32.12 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 110.321 -1.112 . . . . 0.0 110.321 -177.527 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 21.5 p-10 -64.1 -17.02 63.02 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.006 -1.29 . . . . 0.0 110.349 -175.381 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 96.1 mt -60.0 141.41 55.68 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.252 -0.905 . . . . 0.0 110.484 -177.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 1.011 ' C ' HD23 ' B' ' 12' ' ' LEU . 59.8 mmtt -139.93 143.29 36.53 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 121.555 0.693 . . . . 0.0 110.446 175.771 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.598 ' N ' HD23 ' B' ' 12' ' ' LEU . 36.5 t -63.19 149.47 10.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.22 -176.152 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.48 -13.53 63.64 Favored Glycine 0 N--CA 1.483 1.808 0 N-CA-C 108.818 -1.713 . . . . 0.0 108.818 -175.3 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 46.0 t0 -96.27 162.99 13.27 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.27 -1.135 . . . . 0.0 109.629 175.985 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 13.6 m95 -113.9 162.05 16.86 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.09 -1.007 . . . . 0.0 110.178 176.598 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 1.048 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.5 p -130.78 140.31 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.545 -0.722 . . . . 0.0 110.179 -175.78 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.851 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.2 OUTLIER -66.87 103.78 1.21 Allowed 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.115 -0.991 . . . . 0.0 109.549 169.089 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.746 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -106.48 137.92 34.58 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 120.589 -1.319 . . . . 0.0 111.28 -178.692 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 85' ' ' GLU . . . . . 0.541 ' HB2' HG22 ' B' ' 6' ' ' VAL . 84.3 tt0 -133.03 131.64 40.91 Favored 'General case' 0 N--CA 1.493 1.7 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.036 179.681 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 75.9 ttt180 -72.11 139.17 48.24 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.25 -0.906 . . . . 0.0 110.955 -175.849 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.551 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.496 1.847 0 O-C-N 121.389 -0.82 . . . . 0.0 109.749 176.623 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.852 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.9 t . . . . . 0 N--CA 1.493 1.697 0 CA-C-O 121.656 0.741 . . . . 0.0 111.408 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLN . . . . . 0.463 ' HG2' ' HG3' ' A' ' 85' ' ' GLU . 89.5 mm-40 -70.02 -38.59 75.95 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.662 -0.649 . . . . 0.0 110.294 173.349 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.523 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -168.3 -176.52 38.76 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 119.404 -1.379 . . . . 0.0 109.816 -176.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.472 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 1.1 p -120.78 171.83 8.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.96 -1.317 . . . . 0.0 110.859 -177.431 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 1.072 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -140.3 149.92 43.38 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.556 -0.715 . . . . 0.0 109.531 -178.221 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 35.2 tttt -105.52 116.02 31.24 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 120.922 -1.111 . . . . 0.0 110.138 178.597 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 1.025 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.9 tp -59.83 128.48 37.14 Favored 'General case' 0 C--N 1.297 -1.703 0 O-C-N 120.863 -1.148 . . . . 0.0 108.69 172.558 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.12 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.6 p -129.41 -29.3 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.291 -177.839 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.68 142.36 26.66 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 118.948 -1.101 . . . . 0.0 111.534 179.368 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.825 HG23 ' CD2' ' A' ' 24' ' ' HIS . 10.9 mt -107.81 135.71 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.037 -1.039 . . . . 0.0 110.174 171.653 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.494 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 83.5 m-20 -110.14 114.56 28.15 Favored 'General case' 0 C--N 1.295 -1.769 0 O-C-N 121.308 -0.87 . . . . 0.0 110.272 173.909 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -101.91 109.6 21.38 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.175 -0.953 . . . . 0.0 110.421 -178.231 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.4 mtpt -103.87 134.54 19.67 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.056 -1.028 . . . . 0.0 109.424 175.272 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.58 -18.31 8.26 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 O-C-N 123.995 1.524 . . . . 0.0 110.802 -179.616 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.581 ' HB2' ' CD2' ' A' ' 21' ' ' PHE . 0.4 OUTLIER -99.28 -32.77 11.03 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.143 -0.973 . . . . 0.0 109.138 -179.906 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.581 ' CD2' ' HB2' ' A' ' 20' ' ' ASN . 56.3 m-85 -150.48 150.21 31.0 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.835 -0.54 . . . . 0.0 110.144 -175.747 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.475 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 56.1 ttt180 -94.02 143.33 26.45 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.639 -1.288 . . . . 0.0 110.055 173.14 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.494 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 44.5 m -129.99 139.22 51.09 Favored 'General case' 0 C--N 1.296 -1.743 0 O-C-N 121.564 -0.71 . . . . 0.0 109.818 -175.315 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.825 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.0 135.46 48.32 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.862 -1.149 . . . . 0.0 111.312 179.377 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.765 HG22 ' CB ' ' A' ' 60' ' ' SER . 4.8 t -117.47 131.91 68.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.085 -1.01 . . . . 0.0 110.731 -176.791 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.578 HG22 ' HE2' ' A' ' 61' ' ' PHE . 7.0 m -113.63 172.32 3.52 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.94 -0.475 . . . . 0.0 110.061 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.544 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 7.1 tt0 -105.34 117.27 33.59 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.427 -0.795 . . . . 0.0 108.948 178.567 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.565 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.0 tp -83.55 121.05 76.32 Favored Pre-proline 0 C--N 1.296 -1.751 0 O-C-N 121.632 -0.668 . . . . 0.0 109.943 -172.888 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.473 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 25.1 Cg_endo -66.27 176.0 4.4 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 O-C-N 123.9 1.474 . . . . 0.0 111.007 -179.372 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.55 ' HA ' HD12 ' A' ' 33' ' ' LEU . 51.2 t0 -60.07 -39.97 87.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.424 -0.798 . . . . 0.0 111.049 -175.177 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.599 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.08 0.35 57.18 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.939 -1.1 . . . . 0.0 110.785 -174.917 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.599 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 98.0 mmm -113.06 -11.03 13.4 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.959 -1.088 . . . . 0.0 110.053 172.328 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.586 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 15.7 mt -69.98 -32.32 70.46 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.304 -0.872 . . . . 0.0 109.923 177.629 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -79.91 139.91 36.92 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.512 -0.742 . . . . 0.0 111.009 -176.156 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.01 -38.43 3.17 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 120.024 -1.084 . . . . 0.0 110.645 171.786 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.47 HD23 ' CD2' ' A' ' 28' ' ' LEU . 64.7 tp -77.99 147.72 34.74 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.787 -1.42 . . . . 0.0 111.102 -174.015 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.512 ' C ' HD11 ' A' ' 54' ' ' ILE . 20.6 pt-20 -149.23 170.04 19.39 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.459 -0.775 . . . . 0.0 109.322 175.216 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.856 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -62.96 151.94 38.1 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.931 -1.106 . . . . 0.0 110.027 -178.688 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.24 -3.48 62.11 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -176.225 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.464 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -77.1 158.72 30.3 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.242 -1.152 . . . . 0.0 109.491 176.802 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.557 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -100.97 110.05 22.04 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.901 -1.124 . . . . 0.0 110.045 178.567 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.673 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.0 t -98.99 129.94 48.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 121.212 -0.93 . . . . 0.0 109.155 174.782 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.516 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -95.51 119.95 34.9 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 119.244 -0.982 . . . . 0.0 109.227 172.093 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.673 ' HE1' HG11 ' A' ' 42' ' ' VAL . 0.6 OUTLIER -88.25 106.97 18.56 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 177.789 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.495 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 55.33 13.76 0.96 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.329 -0.857 . . . . 0.0 110.91 -167.326 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 117.56 -0.5 18.23 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 119.508 -1.329 . . . . 0.0 110.615 172.797 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.78 ' O ' HD23 ' A' ' 49' ' ' LEU . 36.6 t -93.54 105.59 17.63 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.477 -1.602 . . . . 0.0 109.423 175.728 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 25.0 p -73.73 129.44 37.92 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.193 -0.942 . . . . 0.0 111.183 -170.747 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.992 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -145.39 160.57 41.36 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 172.841 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 21.3 m -96.3 152.95 18.1 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.534 -1.354 . . . . 0.0 111.175 -170.095 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.784 HG13 HG13 ' A' ' 59' ' ' VAL . 21.2 t -76.96 112.11 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.775 -0.578 . . . . 0.0 110.037 178.695 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.575 HG22 ' HB3' ' A' ' 62' ' ' ASP . 33.9 p -69.39 -40.05 77.61 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.119 -0.988 . . . . 0.0 109.556 173.757 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.567 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -160.59 156.13 25.21 Favored 'General case' 0 N--CA 1.49 1.557 0 C-N-CA 119.383 -0.927 . . . . 0.0 110.895 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.856 HD11 ' N ' ' A' ' 38' ' ' THR . 7.8 mt -109.97 130.47 63.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.211 -0.931 . . . . 0.0 109.73 172.598 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.508 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 46.6 m-80 -104.45 65.03 0.76 Allowed 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 119.822 -0.751 . . . . 0.0 109.567 178.13 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.46 -114.91 4.42 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 -173.609 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.586 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -80.02 -19.74 47.0 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.078 -1.248 . . . . 0.0 109.119 176.645 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.12 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.8 m170 -76.61 159.0 30.66 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.256 -0.903 . . . . 0.0 110.061 -178.663 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.784 HG13 HG13 ' A' ' 51' ' ' VAL . 54.0 t -141.45 122.52 12.97 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 O-C-N 121.01 -1.056 . . . . 0.0 111.029 173.655 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.765 ' CB ' HG22 ' A' ' 25' ' ' VAL . 17.4 m -91.83 127.48 37.31 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.655 -0.653 . . . . 0.0 109.897 179.581 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.992 ' HB3' HD12 ' A' ' 49' ' ' LEU . 54.4 m-85 -111.59 160.81 16.85 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.869 -1.145 . . . . 0.0 110.243 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.575 ' HB3' HG22 ' A' ' 52' ' ' THR . 38.1 p-10 -92.01 148.63 22.05 Favored 'General case' 0 N--CA 1.496 1.858 0 CA-C-O 122.065 0.936 . . . . 0.0 111.321 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 0.713 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -156.01 118.55 4.13 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 -177.304 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.532 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 74.3 mmm -73.0 142.73 47.74 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.937 -1.102 . . . . 0.0 109.514 179.088 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.487 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 38.5 tttp -60.0 -44.9 94.24 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.007 -1.058 . . . . 0.0 110.091 -177.862 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.47 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.6 tt0 -70.04 -39.95 75.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.01 -1.056 . . . . 0.0 110.105 179.109 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.532 ' HB ' ' HB2' ' A' ' 64' ' ' MET . 93.8 m -60.05 -39.37 85.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.923 -1.111 . . . . 0.0 109.286 172.31 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 0.745 HD11 ' HA2' ' A' ' 74' ' ' GLY . 9.3 tp -59.95 -44.95 94.07 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.199 -0.938 . . . . 0.0 109.348 -179.638 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 61.0 ttt180 -69.93 -39.92 75.83 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.517 -0.739 . . . . 0.0 110.686 175.528 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.81 HG22 HG23 ' A' ' 71' ' ' THR . 1.4 tt -66.85 -42.61 89.35 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 O-C-N 121.164 -0.96 . . . . 0.0 109.386 -176.289 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.81 HG23 HG22 ' A' ' 70' ' ' ILE . 43.6 p -84.74 -174.1 5.09 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 175.642 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.472 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 6.7 t30 -102.17 24.02 10.78 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 170.898 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.755 HD11 ' SG ' ' A' ' 47' ' ' CYS . 98.0 mt -69.98 -40.04 75.57 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.136 -0.978 . . . . 0.0 109.734 176.455 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.745 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -49.55 -22.91 4.24 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.381 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 25.6 p-10 -63.61 -19.33 64.76 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.014 -1.286 . . . . 0.0 110.357 -175.907 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.514 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.4 mt -61.33 140.43 58.0 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.148 -0.97 . . . . 0.0 110.962 -176.769 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 1.025 ' C ' HD23 ' A' ' 12' ' ' LEU . 22.8 mttm -141.44 139.35 33.36 Favored 'General case' 0 C--N 1.296 -1.726 0 CA-C-O 121.479 0.657 . . . . 0.0 109.559 174.356 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.703 ' N ' HD23 ' A' ' 12' ' ' LEU . 44.0 t -60.93 151.46 6.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 O-C-N 120.924 -1.11 . . . . 0.0 110.327 -176.338 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.97 -14.66 61.35 Favored Glycine 0 N--CA 1.482 1.746 0 N-CA-C 108.751 -1.739 . . . . 0.0 108.751 -175.333 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -98.16 167.12 11.07 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.31 -1.112 . . . . 0.0 109.626 175.311 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.584 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.5 m95 -115.37 156.72 25.02 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.104 -0.997 . . . . 0.0 110.134 177.092 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.072 HG13 ' HB3' ' A' ' 10' ' ' ALA . 0.9 OUTLIER -120.13 155.15 23.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 O-C-N 121.527 -0.733 . . . . 0.0 109.892 -178.124 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 0.852 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.5 m-20 -80.02 106.75 12.27 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.21 -0.931 . . . . 0.0 108.988 168.793 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.716 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -107.25 138.6 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.55 -1.344 . . . . 0.0 111.039 -175.223 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.463 ' HG3' ' HG2' ' A' ' 7' ' ' GLN . 86.4 tt0 -136.83 135.34 37.84 Favored 'General case' 0 N--CA 1.492 1.632 0 C-N-CA 120.381 -0.528 . . . . 0.0 109.752 -178.355 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -78.67 129.92 35.27 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.055 -1.028 . . . . 0.0 110.618 -176.212 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.557 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.567 0 O-C-N 121.401 -0.812 . . . . 0.0 110.199 178.298 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 0.809 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.9 t . . . . . 0 N--CA 1.493 1.725 0 CA-C-O 121.681 0.753 . . . . 0.0 111.42 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 7' ' ' GLN . . . . . 0.47 ' HG2' ' HG3' ' B' ' 85' ' ' GLU . 89.6 mm-40 -70.02 -38.31 75.86 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.694 -0.629 . . . . 0.0 110.371 173.437 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.522 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -168.6 -176.65 39.02 Favored Glycine 0 N--CA 1.494 2.556 0 C-N-CA 119.478 -1.344 . . . . 0.0 109.854 -177.013 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.48 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 1.1 p -120.73 171.83 8.32 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.039 -1.271 . . . . 0.0 110.918 -177.401 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.066 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -140.29 149.94 43.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.533 -0.729 . . . . 0.0 109.444 -178.18 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.581 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 35.3 tttt -105.51 116.13 31.42 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.057 -1.027 . . . . 0.0 110.087 178.531 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 1.024 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.9 tp -60.03 128.31 36.21 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.971 -1.081 . . . . 0.0 108.781 172.461 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.12 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.6 p -129.12 -29.53 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 C-N-CA 119.565 -0.854 . . . . 0.0 110.296 -177.729 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.57 142.33 26.74 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 119.072 -1.051 . . . . 0.0 111.501 179.454 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.828 HG23 ' CD2' ' B' ' 24' ' ' HIS . 10.9 mt -107.76 135.84 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.116 -0.99 . . . . 0.0 110.207 171.606 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.504 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.2 m-20 -110.33 114.69 28.35 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.443 -0.785 . . . . 0.0 110.184 173.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -101.91 109.53 21.29 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.099 -1.001 . . . . 0.0 110.443 -178.25 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.4 mtpt -103.88 134.6 19.63 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.218 -0.926 . . . . 0.0 109.546 175.196 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -52.73 -18.2 8.48 Favored 'Trans proline' 0 C--N 1.303 -1.868 0 O-C-N 123.952 1.501 . . . . 0.0 110.747 -179.461 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.583 ' HB2' ' CD2' ' B' ' 21' ' ' PHE . 0.4 OUTLIER -99.04 -33.46 10.8 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.154 -0.966 . . . . 0.0 109.044 -179.966 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.583 ' CD2' ' HB2' ' B' ' 20' ' ' ASN . 56.2 m-85 -149.96 150.31 31.64 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 120.327 -0.549 . . . . 0.0 110.176 -175.634 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 22' ' ' ARG . . . . . 0.473 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 56.1 ttt180 -94.01 143.42 26.37 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.757 -1.214 . . . . 0.0 110.008 173.101 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.504 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 42.9 m -130.09 139.3 50.97 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.745 -0.597 . . . . 0.0 109.736 -175.367 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.828 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.02 135.64 48.5 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.984 -1.073 . . . . 0.0 111.227 179.347 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.764 HG22 ' CB ' ' B' ' 60' ' ' SER . 4.8 t -117.42 131.99 68.52 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.262 -0.899 . . . . 0.0 110.769 -176.822 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.585 HG22 ' HE2' ' B' ' 61' ' ' PHE . 7.2 m -113.79 172.24 3.62 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 O-C-N 121.909 -0.495 . . . . 0.0 110.025 179.234 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.669 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 7.0 tt0 -105.09 117.32 33.7 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.466 -0.771 . . . . 0.0 109.118 178.413 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.552 HD23 ' HA ' ' B' ' 33' ' ' LEU . 8.9 tp -83.51 120.99 76.35 Favored Pre-proline 0 C--N 1.295 -1.779 0 O-C-N 121.555 -0.716 . . . . 0.0 110.028 -172.944 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.465 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 25.6 Cg_endo -66.16 175.97 4.33 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 O-C-N 123.856 1.45 . . . . 0.0 111.005 -179.41 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.529 ' HA ' HD12 ' B' ' 33' ' ' LEU . 51.3 t0 -60.02 -40.07 88.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.448 -0.783 . . . . 0.0 111.061 -175.27 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.605 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.02 0.34 57.16 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.884 -1.135 . . . . 0.0 110.851 -174.925 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.605 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 98.0 mmm -113.05 -11.2 13.39 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.105 -0.997 . . . . 0.0 110.053 172.377 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.59 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 15.8 mt -69.89 -32.21 70.41 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.35 -0.844 . . . . 0.0 110.022 177.628 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -80.11 139.96 36.64 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.545 -0.722 . . . . 0.0 110.927 -176.16 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.92 -38.4 3.17 Favored Glycine 0 N--CA 1.493 2.442 0 C-N-CA 119.965 -1.112 . . . . 0.0 110.581 171.799 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.478 HD23 ' CD2' ' B' ' 28' ' ' LEU . 64.5 tp -77.97 147.68 34.8 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.93 -1.335 . . . . 0.0 111.146 -174.101 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 37' ' ' GLU . . . . . 0.491 ' C ' HD11 ' B' ' 54' ' ' ILE . 20.6 pt-20 -149.13 170.03 19.35 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.466 -0.771 . . . . 0.0 109.323 175.269 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 38' ' ' THR . . . . . 0.863 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -62.99 151.79 38.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.932 -1.105 . . . . 0.0 110.071 -178.8 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.34 -3.51 62.37 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -176.159 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.457 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -77.18 158.58 30.27 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.184 -1.186 . . . . 0.0 109.446 176.764 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.565 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -100.65 109.84 21.93 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 120.904 -1.123 . . . . 0.0 110.14 178.537 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.657 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.0 t -99.0 129.9 48.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.284 -0.885 . . . . 0.0 109.171 174.713 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 0.514 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -95.44 120.01 34.94 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 119.204 -0.999 . . . . 0.0 109.199 172.06 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.657 ' HE1' HG11 ' B' ' 42' ' ' VAL . 0.6 OUTLIER -88.29 106.79 18.45 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.408 -0.807 . . . . 0.0 108.915 177.691 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.641 HD22 ' HB2' ' A' ' 47' ' ' CYS . 0.9 OUTLIER 55.5 13.88 1.05 Allowed 'General case' 0 C--N 1.299 -1.597 0 O-C-N 121.333 -0.854 . . . . 0.0 110.888 -167.346 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 117.46 -0.32 18.44 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.513 -1.327 . . . . 0.0 110.612 172.671 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.797 ' O ' HD23 ' B' ' 49' ' ' LEU . 36.7 t -93.66 105.59 17.62 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.536 -1.567 . . . . 0.0 109.439 175.67 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 25.1 p -73.65 129.56 38.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.084 -1.01 . . . . 0.0 111.079 -170.707 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 1.009 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -145.61 160.54 41.52 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 172.714 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 21.3 m -96.14 153.05 18.0 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.703 -1.248 . . . . 0.0 111.181 -170.021 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.79 HG13 HG13 ' B' ' 59' ' ' VAL . 21.2 t -77.06 112.05 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.652 -0.655 . . . . 0.0 110.126 178.598 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.552 HG22 ' HB3' ' B' ' 62' ' ' ASP . 34.5 p -69.54 -39.91 77.18 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.168 -0.958 . . . . 0.0 109.462 173.986 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.568 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -160.64 156.1 25.05 Favored 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.861 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.863 HD11 ' N ' ' B' ' 38' ' ' THR . 7.8 mt -110.01 130.42 63.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.259 -0.901 . . . . 0.0 109.728 172.651 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.524 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 46.6 m-80 -104.55 65.03 0.76 Allowed 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.575 178.151 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.61 -114.94 4.4 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 108.716 -1.754 . . . . 0.0 108.716 -173.69 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.59 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -80.03 -19.66 47.15 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.05 -1.265 . . . . 0.0 109.194 176.645 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.12 ' CE1' HG11 ' B' ' 13' ' ' VAL . 24.3 m-70 -76.6 158.78 30.84 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.359 -0.838 . . . . 0.0 110.096 -178.698 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.79 HG13 HG13 ' B' ' 51' ' ' VAL . 54.4 t -141.32 122.64 13.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.967 173.735 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.764 ' CB ' HG22 ' B' ' 25' ' ' VAL . 17.4 m -91.92 127.56 37.43 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.767 -0.583 . . . . 0.0 109.953 179.554 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 1.009 ' HB3' HD12 ' B' ' 49' ' ' LEU . 54.4 m-85 -111.55 160.81 16.83 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.056 -1.027 . . . . 0.0 110.314 179.258 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.552 ' HB3' HG22 ' B' ' 52' ' ' THR . 38.0 p-10 -92.0 148.66 22.03 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.135 -0.978 . . . . 0.0 111.269 179.805 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 0.745 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -156.0 118.48 4.12 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -177.354 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.528 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 74.2 mmm -73.01 142.77 47.72 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.907 -1.12 . . . . 0.0 109.481 179.147 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.484 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 38.5 tttp -59.98 -44.92 94.17 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.091 -1.005 . . . . 0.0 110.075 -177.822 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 66' ' ' GLU . . . . . 0.478 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 86.6 tt0 -69.99 -40.06 75.52 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.047 -1.033 . . . . 0.0 110.062 179.196 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.528 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 94.2 m -59.96 -39.53 85.92 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.923 -1.111 . . . . 0.0 109.144 172.41 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 0.754 HD11 ' HA2' ' B' ' 74' ' ' GLY . 9.4 tp -60.07 -44.71 94.56 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.428 -0.795 . . . . 0.0 109.436 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 61.1 ttt180 -70.04 -39.92 75.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.498 -0.751 . . . . 0.0 110.673 175.372 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.791 HG22 HG23 ' B' ' 71' ' ' THR . 1.4 tt -66.77 -42.52 89.47 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.263 -0.898 . . . . 0.0 109.421 -176.368 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.791 HG23 HG22 ' B' ' 70' ' ' ILE . 43.8 p -84.74 -173.85 4.95 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 175.682 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.48 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 6.7 t30 -102.31 24.06 10.82 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 170.855 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.751 HD11 ' SG ' ' B' ' 47' ' ' CYS . 98.0 mt -69.99 -40.1 75.53 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.192 -0.942 . . . . 0.0 109.745 176.403 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.754 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -49.59 -22.91 4.31 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 -179.396 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 25.7 p-10 -63.55 -19.38 64.75 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.031 -1.276 . . . . 0.0 110.374 -175.934 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 97.5 mt -61.27 140.47 57.96 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.199 -0.938 . . . . 0.0 110.915 -176.786 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 1.024 ' C ' HD23 ' B' ' 12' ' ' LEU . 22.8 mttm -141.39 139.38 33.47 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-O 121.336 0.589 . . . . 0.0 109.556 174.322 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.703 ' N ' HD23 ' B' ' 12' ' ' LEU . 44.2 t -60.95 151.33 6.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 120.93 -1.107 . . . . 0.0 110.315 -176.345 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.96 -14.43 61.95 Favored Glycine 0 N--CA 1.482 1.751 0 N-CA-C 108.781 -1.727 . . . . 0.0 108.781 -175.41 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -98.2 167.09 11.08 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.362 -1.081 . . . . 0.0 109.6 175.207 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.581 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.4 m95 -115.42 156.71 25.09 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.177 -0.952 . . . . 0.0 110.13 177.073 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 1.066 HG13 ' HB3' ' B' ' 10' ' ' ALA . 0.9 OUTLIER -120.12 155.26 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.532 -0.73 . . . . 0.0 109.955 -178.206 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 0.809 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -80.05 106.43 12.06 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.243 -0.911 . . . . 0.0 109.03 168.866 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.702 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -106.94 138.72 31.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 120.588 -1.32 . . . . 0.0 111.061 -175.145 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' B' B ' 85' ' ' GLU . . . . . 0.47 ' HG3' ' HG2' ' B' ' 7' ' ' GLN . 86.4 tt0 -137.02 135.36 37.51 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.836 -0.54 . . . . 0.0 109.765 -178.461 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -78.6 130.02 35.45 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.015 -1.053 . . . . 0.0 110.543 -176.155 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.565 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.493 1.704 0 O-C-N 121.525 -0.734 . . . . 0.0 110.144 178.248 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 1.031 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.5 t . . . . . 0 N--CA 1.495 1.779 0 CA-C-O 121.55 0.691 . . . . 0.0 110.779 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -70.0 -32.63 70.9 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.619 -0.676 . . . . 0.0 110.803 177.419 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.531 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -164.96 177.26 40.53 Favored Glycine 0 N--CA 1.494 2.564 0 C-N-CA 118.767 -1.682 . . . . 0.0 110.485 -174.237 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 9' ' ' THR . . . . . 0.506 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 2.9 p -116.34 167.89 10.62 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.131 -1.217 . . . . 0.0 110.886 -177.871 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 10' ' ' ALA . . . . . 1.055 ' HB2' HG21 ' A' ' 84' ' ' VAL . . . -137.73 148.46 45.64 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 -176.009 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 11' ' ' LYS . . . . . 0.577 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 25.7 tttt -108.88 115.91 30.98 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.022 -1.049 . . . . 0.0 110.379 -179.333 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.994 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.0 tp -58.7 127.37 31.86 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.077 -1.014 . . . . 0.0 108.89 174.284 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.051 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.4 p -125.11 -31.48 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 O-C-N 121.352 -0.843 . . . . 0.0 109.932 -179.679 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.54 144.05 28.23 Favored 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.327 -178.054 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.584 HG12 ' CD2' ' A' ' 24' ' ' HIS . 8.6 mt -108.1 130.08 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.214 -0.929 . . . . 0.0 110.181 172.265 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.507 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 67.3 m-20 -105.66 114.24 28.29 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.318 -0.863 . . . . 0.0 109.768 172.895 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -106.59 108.88 20.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.975 -1.078 . . . . 0.0 110.856 -177.511 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 18' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -104.26 128.65 26.63 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.198 -0.939 . . . . 0.0 108.888 173.052 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -50.33 -34.06 39.34 Favored 'Trans proline' 0 C--N 1.303 -1.861 0 O-C-N 123.753 1.396 . . . . 0.0 110.496 -179.601 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 20' ' ' ASN . . . . . 0.531 ' C ' ' CD2' ' A' ' 21' ' ' PHE . 8.8 m120 -71.57 -39.86 70.32 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.201 -0.937 . . . . 0.0 110.039 175.559 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 21' ' ' PHE . . . . . 0.531 ' CD2' ' C ' ' A' ' 20' ' ' ASN . 89.2 m-85 -152.98 150.25 29.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.399 -0.813 . . . . 0.0 109.973 -179.411 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 22' ' ' ARG . . . . . 0.738 ' HD3' HD22 ' A' ' 68' ' ' LEU . 62.6 ttt180 -93.27 144.95 24.82 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.732 -1.23 . . . . 0.0 110.124 177.046 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.507 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 56.8 m -130.31 141.56 50.59 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.48 -0.762 . . . . 0.0 110.09 -176.186 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.607 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -127.89 144.78 51.09 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 120.974 -1.079 . . . . 0.0 111.342 176.75 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.763 HG22 ' CB ' ' A' ' 60' ' ' SER . 4.3 t -124.63 133.55 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.183 -0.948 . . . . 0.0 110.703 -179.27 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.592 HG13 ' HE2' ' A' ' 61' ' ' PHE . 33.4 m -118.5 172.06 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.796 -0.565 . . . . 0.0 110.425 -179.96 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.6 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 12.9 tt0 -101.14 117.51 35.15 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.594 -0.691 . . . . 0.0 109.318 -179.551 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.628 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.4 tp -82.0 121.26 78.91 Favored Pre-proline 0 C--N 1.297 -1.687 0 O-C-N 121.796 -0.565 . . . . 0.0 109.813 -175.302 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.49 ' HD2' HD12 ' A' ' 28' ' ' LEU . 25.5 Cg_endo -66.23 179.47 1.95 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 O-C-N 123.863 1.454 . . . . 0.0 110.992 -179.42 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.511 ' HA ' HD12 ' A' ' 33' ' ' LEU . 96.0 m-20 -63.41 -40.0 96.0 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.368 -0.833 . . . . 0.0 111.067 -175.646 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 31' ' ' HIS . . . . . 0.434 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.42 1.09 56.97 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.922 -1.111 . . . . 0.0 111.067 -175.31 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 32' ' ' MET . . . . . 0.474 ' HB2' ' HD2' ' A' ' 29' ' ' PRO . 98.4 mmm -113.92 -13.95 12.51 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.998 -1.064 . . . . 0.0 109.801 172.254 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.628 ' HA ' HD23 ' A' ' 28' ' ' LEU . 14.0 mt -66.19 -39.85 89.99 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.289 -0.882 . . . . 0.0 109.784 176.57 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -77.19 132.35 38.72 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.496 -0.753 . . . . 0.0 110.586 -177.486 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.51 -43.06 1.87 Allowed Glycine 0 N--CA 1.492 2.391 0 C-N-CA 119.903 -1.141 . . . . 0.0 110.258 174.489 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 36' ' ' LEU . . . . . 0.597 HD23 ' N ' ' A' ' 37' ' ' GLU . 5.7 tt -69.91 145.7 51.76 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.928 -1.337 . . . . 0.0 110.564 -174.94 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.597 ' N ' HD23 ' A' ' 36' ' ' LEU . 20.6 pt-20 -149.98 167.63 26.13 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.524 -0.735 . . . . 0.0 109.416 -179.555 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.822 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -67.95 149.94 49.13 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.85 -1.156 . . . . 0.0 110.201 -178.114 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.33 -3.61 62.03 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 -173.827 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 40' ' ' ALA . . . . . 0.538 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -76.55 159.99 29.85 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.236 -1.155 . . . . 0.0 109.122 174.85 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 41' ' ' SER . . . . . 0.903 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 1.1 p -104.21 117.88 35.3 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 118.72 -1.192 . . . . 0.0 109.897 177.184 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.626 HG11 ' HE1' ' A' ' 44' ' ' HIS . 0.9 OUTLIER -99.97 120.09 48.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.363 -0.836 . . . . 0.0 108.956 176.943 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -82.94 117.33 22.7 Favored 'General case' 0 C--N 1.298 -1.641 0 C-N-CA 119.262 -0.975 . . . . 0.0 109.241 174.495 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 44' ' ' HIS . . . . . 0.651 ' CD2' HG21 ' A' ' 82' ' ' VAL . 1.5 m80 -87.24 103.42 15.42 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 176.172 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' B' ' 45' ' ' ASN . 0.9 OUTLIER 55.74 12.05 0.77 Allowed 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.548 -0.72 . . . . 0.0 111.335 -169.483 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.49 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 126.85 -6.13 7.39 Favored Glycine 0 N--CA 1.491 2.362 0 C-N-CA 119.605 -1.283 . . . . 0.0 110.825 173.324 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 47' ' ' CYS . . . . . 0.896 ' O ' HD23 ' A' ' 49' ' ' LEU . 44.8 t -93.31 103.64 15.87 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 120.509 -1.583 . . . . 0.0 109.67 176.038 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 16.0 p -72.18 121.91 20.13 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.096 -1.003 . . . . 0.0 110.737 -174.444 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 49' ' ' LEU . . . . . 0.896 HD23 ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -132.04 160.57 35.53 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.364 -0.835 . . . . 0.0 109.341 173.704 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.433 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 37.2 m -97.72 152.52 19.03 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.439 -1.413 . . . . 0.0 111.436 -169.555 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 51' ' ' VAL . . . . . 0.878 HG13 HG13 ' A' ' 59' ' ' VAL . 19.4 t -81.02 114.62 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.917 -0.489 . . . . 0.0 110.396 -178.953 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 52' ' ' THR . . . . . 0.488 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 31.1 p -69.85 -40.08 76.02 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.294 -0.879 . . . . 0.0 109.705 174.416 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 53' ' ' GLU . . . . . 0.564 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.7 tt0 -161.38 155.64 22.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.437 -0.789 . . . . 0.0 109.909 179.686 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.822 HD11 ' N ' ' A' ' 38' ' ' THR . 7.1 mt -105.15 128.99 58.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.966 -1.084 . . . . 0.0 109.574 174.613 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 55' ' ' ASN . . . . . 0.53 ' CB ' ' HB2' ' A' ' 58' ' ' HIS . 2.2 m-80 -100.6 62.6 1.05 Allowed 'General case' 0 C--N 1.298 -1.653 0 O-C-N 121.58 -0.7 . . . . 0.0 109.585 -179.014 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.04 -120.05 6.58 Favored Glycine 0 N--CA 1.487 2.054 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 -172.638 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.577 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -71.8 -20.22 61.88 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.931 -1.335 . . . . 0.0 108.981 175.094 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 58' ' ' HIS . . . . . 1.051 ' CE1' HG11 ' A' ' 13' ' ' VAL . 28.3 m-70 -76.69 161.3 28.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.425 -0.797 . . . . 0.0 110.386 -176.748 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.878 HG13 HG13 ' A' ' 51' ' ' VAL . 54.5 t -140.02 125.52 20.9 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 C-N-CA 119.119 -1.032 . . . . 0.0 110.786 170.66 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 60' ' ' SER . . . . . 0.763 ' CB ' HG22 ' A' ' 25' ' ' VAL . 24.8 m -97.61 123.16 41.4 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.763 -0.586 . . . . 0.0 109.509 -179.551 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.818 ' HB2' HD12 ' A' ' 49' ' ' LEU . 10.1 p90 -118.32 159.67 22.99 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.822 -1.174 . . . . 0.0 110.72 -179.743 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 62' ' ' ASP . . . . . 0.488 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 35.2 p-10 -93.37 156.56 16.72 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.089 -1.007 . . . . 0.0 111.532 -172.004 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 63' ' ' LEU . . . . . 1.062 HD22 HD13 ' A' ' 68' ' ' LEU . 0.1 OUTLIER -161.19 101.93 1.25 Allowed 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.705 -0.622 . . . . 0.0 109.607 -174.135 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 64' ' ' MET . . . . . 0.494 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 57.7 ttm -59.97 137.71 58.02 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.787 -1.195 . . . . 0.0 109.09 179.351 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 28.6 tttt -60.03 -45.91 91.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.977 -1.077 . . . . 0.0 110.614 -172.154 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.0 tp10 -66.15 -40.07 90.29 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.702 -1.248 . . . . 0.0 109.866 177.402 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 67' ' ' THR . . . . . 0.494 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 94.1 m -59.92 -40.01 87.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.087 -1.008 . . . . 0.0 109.573 172.683 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 68' ' ' LEU . . . . . 1.062 HD13 HD22 ' A' ' 63' ' ' LEU . 28.0 tp -60.02 -43.45 95.26 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.299 -0.876 . . . . 0.0 109.764 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 ttt85 -69.99 -39.09 76.12 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.326 -0.859 . . . . 0.0 110.352 177.765 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.709 HG22 HG23 ' A' ' 71' ' ' THR . 1.4 tt -64.78 -42.71 95.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.28 -0.887 . . . . 0.0 109.448 -176.816 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 71' ' ' THR . . . . . 0.709 HG23 HG22 ' A' ' 70' ' ' ILE . 30.5 p -81.99 -174.9 5.33 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 120.015 -0.674 . . . . 0.0 109.243 175.471 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.538 ' CB ' ' H ' ' B' ' 83' ' ' ASN . 5.2 t30 -99.52 22.25 11.04 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.174 -0.954 . . . . 0.0 108.511 171.062 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 73' ' ' LEU . . . . . 0.719 HD13 HD21 ' A' ' 63' ' ' LEU . 70.6 mt -70.12 -39.97 75.12 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.946 -1.096 . . . . 0.0 109.816 175.602 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 74' ' ' GLY . . . . . 0.428 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -49.31 -21.67 3.03 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -177.943 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 75' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.2 p-10 -66.21 -16.46 64.01 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.068 -1.254 . . . . 0.0 110.562 -175.056 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 76' ' ' LEU . . . . . 0.503 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 96.1 mt -62.07 142.34 57.61 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.209 -0.932 . . . . 0.0 111.173 -175.116 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 77' ' ' LYS . . . . . 0.994 ' C ' HD23 ' A' ' 12' ' ' LEU . 86.6 mttt -141.48 141.16 33.65 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.647 -0.658 . . . . 0.0 109.558 172.642 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.705 ' N ' HD23 ' A' ' 12' ' ' LEU . 16.7 t -59.52 151.72 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 120.711 -1.243 . . . . 0.0 110.297 -176.146 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.79 -13.55 60.64 Favored Glycine 0 N--CA 1.484 1.867 0 N-CA-C 108.948 -1.661 . . . . 0.0 108.948 -176.687 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 53.9 t0 -96.41 162.27 13.56 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.409 -1.054 . . . . 0.0 109.666 177.1 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 81' ' ' TRP . . . . . 0.577 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.0 m95 -113.21 153.33 28.51 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.141 -0.974 . . . . 0.0 110.42 177.369 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.043 HG13 ' HB3' ' A' ' 10' ' ' ALA . 0.8 OUTLIER -119.94 149.72 22.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.409 -0.807 . . . . 0.0 109.804 179.675 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 83' ' ' ASN . . . . . 1.031 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -69.6 102.58 1.88 Allowed 'General case' 0 C--N 1.3 -1.556 0 O-C-N 120.952 -1.092 . . . . 0.0 109.012 167.8 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 1.055 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -104.59 137.96 31.4 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 O-C-N 120.311 -1.493 . . . . 0.0 110.957 -178.772 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.445 ' HB2' HG22 ' A' ' 6' ' ' VAL . 85.9 tt0 -135.83 138.42 42.51 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.923 -0.711 . . . . 0.0 110.235 -176.192 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 76.4 ttt180 -61.3 127.46 31.63 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.24 -0.912 . . . . 0.0 110.044 -179.916 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.903 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.572 0 O-C-N 121.257 -0.902 . . . . 0.0 109.957 179.937 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 6' ' ' VAL . . . . . 1.039 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.5 t . . . . . 0 N--CA 1.494 1.736 0 CA-C-O 121.608 0.718 . . . . 0.0 110.723 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -69.98 -32.52 70.78 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.601 -0.687 . . . . 0.0 110.88 177.382 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 8' ' ' GLY . . . . . 0.532 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -165.05 177.16 40.63 Favored Glycine 0 N--CA 1.496 2.641 0 C-N-CA 118.888 -1.625 . . . . 0.0 110.466 -174.184 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 9' ' ' THR . . . . . 0.508 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 3.0 p -116.3 167.82 10.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.105 -1.232 . . . . 0.0 110.953 -177.852 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 10' ' ' ALA . . . . . 1.044 ' HB2' HG21 ' B' ' 84' ' ' VAL . . . -137.72 148.58 45.77 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -176.099 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 11' ' ' LYS . . . . . 0.576 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 25.9 tttt -108.96 116.08 31.31 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.148 -0.97 . . . . 0.0 110.249 -179.209 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 12' ' ' LEU . . . . . 1.005 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.1 tp -58.97 127.29 31.46 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.124 -0.985 . . . . 0.0 108.976 174.257 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 13' ' ' VAL . . . . . 1.033 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.4 p -124.89 -31.67 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 C-N-CA 119.593 -0.843 . . . . 0.0 109.904 -179.638 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.35 143.98 28.41 Favored 'General case' 0 C--N 1.297 -1.675 0 C-N-CA 119.27 -0.972 . . . . 0.0 111.451 -178.019 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 15' ' ' ILE . . . . . 0.59 HG12 ' CD2' ' B' ' 24' ' ' HIS . 8.2 mt -108.02 130.18 60.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.264 -0.897 . . . . 0.0 110.232 172.246 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 16' ' ' ASP . . . . . 0.519 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 66.8 m-20 -105.94 114.31 28.38 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.369 -0.832 . . . . 0.0 109.724 172.994 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -106.57 108.82 20.52 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.912 -1.118 . . . . 0.0 110.938 -177.532 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 18' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -104.21 128.63 26.7 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.306 -0.871 . . . . 0.0 108.917 173.058 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 19' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.0 Cg_endo -50.44 -34.03 40.09 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 O-C-N 123.789 1.415 . . . . 0.0 110.42 -179.508 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 20' ' ' ASN . . . . . 0.54 ' C ' ' CD2' ' B' ' 21' ' ' PHE . 8.8 m120 -71.41 -40.25 70.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.131 -0.981 . . . . 0.0 109.985 175.524 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 21' ' ' PHE . . . . . 0.54 ' CD2' ' C ' ' B' ' 20' ' ' ASN . 89.3 m-85 -152.65 150.28 29.31 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.417 -0.802 . . . . 0.0 110.004 -179.327 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 22' ' ' ARG . . . . . 0.746 ' HD3' HD22 ' B' ' 68' ' ' LEU . 62.6 ttt180 -93.16 144.83 24.9 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.872 -1.143 . . . . 0.0 110.197 176.959 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 23' ' ' THR . . . . . 0.519 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 58.2 m -130.27 141.69 50.59 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.596 -0.69 . . . . 0.0 110.043 -176.305 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 24' ' ' HIS . . . . . 0.605 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -127.81 144.89 51.07 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.066 -1.021 . . . . 0.0 111.233 176.827 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 25' ' ' VAL . . . . . 0.769 HG22 ' CB ' ' B' ' 60' ' ' SER . 4.3 t -124.61 133.68 68.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.292 -0.88 . . . . 0.0 110.717 -179.293 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 26' ' ' VAL . . . . . 0.592 HG13 ' HE2' ' B' ' 61' ' ' PHE . 33.5 m -118.79 172.09 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 CA-C-O 121.27 0.557 . . . . 0.0 110.412 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 27' ' ' GLU . . . . . 0.605 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 13.1 tt0 -101.1 117.6 35.34 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.603 -0.686 . . . . 0.0 109.235 -179.473 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 28' ' ' LEU . . . . . 0.62 HD23 ' HA ' ' B' ' 33' ' ' LEU . 9.4 tp -82.01 121.27 78.89 Favored Pre-proline 0 C--N 1.297 -1.681 0 O-C-N 121.639 -0.663 . . . . 0.0 109.86 -175.401 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 29' ' ' PRO . . . . . 0.48 ' HD2' HD12 ' B' ' 28' ' ' LEU . 25.7 Cg_endo -66.24 179.59 1.9 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 123.913 1.48 . . . . 0.0 110.955 -179.399 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 30' ' ' ASP . . . . . 0.5 ' HA ' HD12 ' B' ' 33' ' ' LEU . 96.0 m-20 -63.48 -40.03 96.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.304 -0.873 . . . . 0.0 111.06 -175.662 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 31' ' ' HIS . . . . . 0.439 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.33 0.95 57.03 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.858 -1.151 . . . . 0.0 111.067 -175.253 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 32' ' ' MET . . . . . 0.455 ' HB2' ' HD2' ' B' ' 29' ' ' PRO . 98.4 mmm -113.87 -13.93 12.54 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.945 -1.097 . . . . 0.0 109.799 172.305 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 33' ' ' LEU . . . . . 0.62 ' HA ' HD23 ' B' ' 28' ' ' LEU . 14.0 mt -66.15 -39.92 90.18 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.32 -0.862 . . . . 0.0 109.76 176.534 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -77.06 132.4 38.89 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.481 -0.762 . . . . 0.0 110.584 -177.487 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.37 -43.04 1.88 Allowed Glycine 0 N--CA 1.491 2.359 0 N-CA-C 110.306 -1.117 . . . . 0.0 110.306 174.512 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 36' ' ' LEU . . . . . 0.595 HD23 ' N ' ' B' ' 37' ' ' GLU . 5.7 tt -69.91 145.71 51.76 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.942 -1.328 . . . . 0.0 110.557 -174.949 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 37' ' ' GLU . . . . . 0.595 ' N ' HD23 ' B' ' 36' ' ' LEU . 20.6 pt-20 -150.03 167.6 26.28 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.47 -0.769 . . . . 0.0 109.381 -179.56 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 38' ' ' THR . . . . . 0.815 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -67.92 149.81 49.33 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.864 -1.148 . . . . 0.0 110.237 -178.125 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.35 -3.46 62.61 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -173.813 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 40' ' ' ALA . . . . . 0.536 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -76.74 160.04 29.66 Favored 'General case' 0 N--CA 1.486 1.375 0 O-C-N 121.218 -1.166 . . . . 0.0 109.129 174.742 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 41' ' ' SER . . . . . 0.926 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 1.2 p -103.97 117.72 34.98 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 120.82 -1.175 . . . . 0.0 109.981 177.221 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 42' ' ' VAL . . . . . 0.597 HG11 ' HE1' ' B' ' 44' ' ' HIS . 0.9 OUTLIER -100.03 120.18 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.355 -0.841 . . . . 0.0 108.965 176.934 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 43' ' ' ALA . . . . . 0.508 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -82.89 117.28 22.63 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.247 -0.981 . . . . 0.0 109.316 174.474 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 44' ' ' HIS . . . . . 0.651 ' CD2' HG21 ' B' ' 82' ' ' VAL . 1.4 m80 -87.27 103.19 15.21 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.624 -0.831 . . . . 0.0 108.818 176.232 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' A' ' 45' ' ' ASN . 0.9 OUTLIER 56.07 11.97 0.85 Allowed 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.677 -0.639 . . . . 0.0 111.239 -169.622 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 46' ' ' GLY . . . . . 0.49 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 126.73 -5.74 7.47 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 119.679 -1.248 . . . . 0.0 110.845 173.213 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 47' ' ' CYS . . . . . 0.874 ' O ' HD23 ' B' ' 49' ' ' LEU . 44.9 t -93.49 103.63 15.81 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.477 -1.602 . . . . 0.0 109.618 175.922 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 14.8 p -72.14 122.07 20.37 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.117 -0.989 . . . . 0.0 110.617 -174.449 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 49' ' ' LEU . . . . . 0.874 HD23 ' O ' ' B' ' 47' ' ' CYS . 0.2 OUTLIER -132.21 160.53 35.86 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.461 -0.774 . . . . 0.0 109.283 173.568 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 50' ' ' THR . . . . . 0.444 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 37.5 m -97.53 152.59 18.86 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.42 -1.425 . . . . 0.0 111.464 -169.531 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 51' ' ' VAL . . . . . 0.907 HG13 HG13 ' B' ' 59' ' ' VAL . 20.0 t -81.18 114.76 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.795 -0.566 . . . . 0.0 110.389 -178.973 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 52' ' ' THR . . . . . 0.48 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 31.4 p -69.97 -40.03 75.63 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.152 -0.967 . . . . 0.0 109.739 174.575 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 53' ' ' GLU . . . . . 0.565 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.6 tt0 -161.49 155.63 22.38 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.416 -0.803 . . . . 0.0 109.804 179.634 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 54' ' ' ILE . . . . . 0.815 HD11 ' N ' ' B' ' 38' ' ' THR . 7.1 mt -105.11 128.94 58.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.113 -0.992 . . . . 0.0 109.592 174.698 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 55' ' ' ASN . . . . . 0.525 ' HB2' ' CB ' ' B' ' 58' ' ' HIS . 2.2 m-80 -100.57 62.61 1.05 Allowed 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 119.878 -0.729 . . . . 0.0 109.55 -178.988 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.19 -120.08 6.51 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 108.657 -1.777 . . . . 0.0 108.657 -172.716 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 57' ' ' ASN . . . . . 0.588 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -71.8 -20.17 61.89 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 120.97 -1.312 . . . . 0.0 109.109 175.031 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 58' ' ' HIS . . . . . 1.033 ' CE1' HG11 ' B' ' 13' ' ' VAL . 28.3 m-70 -76.68 161.22 28.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.421 -0.799 . . . . 0.0 110.432 -176.851 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 59' ' ' VAL . . . . . 0.907 HG13 HG13 ' B' ' 51' ' ' VAL . 54.8 t -140.04 125.53 20.82 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 C-N-CA 119.042 -1.063 . . . . 0.0 110.723 170.794 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 60' ' ' SER . . . . . 0.769 ' CB ' HG22 ' B' ' 25' ' ' VAL . 24.4 m -97.54 123.42 41.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.75 -0.594 . . . . 0.0 109.513 -179.573 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 61' ' ' PHE . . . . . 0.837 ' HB2' HD12 ' B' ' 49' ' ' LEU . 10.0 p90 -118.65 159.65 23.23 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 120.822 -1.174 . . . . 0.0 110.533 -179.655 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 62' ' ' ASP . . . . . 0.48 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 35.2 p-10 -93.36 156.55 16.72 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.075 -1.016 . . . . 0.0 111.459 -171.99 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 63' ' ' LEU . . . . . 1.085 HD22 HD13 ' B' ' 68' ' ' LEU . 0.1 OUTLIER -161.11 102.12 1.26 Allowed 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 120.258 -0.577 . . . . 0.0 109.447 -174.235 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 64' ' ' MET . . . . . 0.498 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 57.6 ttm -60.07 137.64 58.05 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.707 -1.245 . . . . 0.0 109.068 179.266 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 65' ' ' LYS . . . . . 0.484 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 28.6 tttt -59.96 -45.93 91.06 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.91 -1.119 . . . . 0.0 110.63 -172.197 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 54.0 tp10 -66.21 -40.02 90.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.723 -1.236 . . . . 0.0 109.837 177.452 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 67' ' ' THR . . . . . 0.498 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 94.4 m -59.97 -40.03 87.69 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.036 -1.04 . . . . 0.0 109.512 172.657 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 68' ' ' LEU . . . . . 1.085 HD13 HD22 ' B' ' 63' ' ' LEU . 27.9 tp -60.05 -43.29 95.49 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.374 -0.829 . . . . 0.0 109.823 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 ttt85 -69.99 -39.26 76.02 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.318 -0.864 . . . . 0.0 110.364 177.751 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 70' ' ' ILE . . . . . 0.707 HG22 HG23 ' B' ' 71' ' ' THR . 1.4 tt -64.56 -42.62 95.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.278 -0.889 . . . . 0.0 109.583 -176.903 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 71' ' ' THR . . . . . 0.707 HG23 HG22 ' B' ' 70' ' ' ILE . 30.5 p -82.06 -174.94 5.37 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.955 -0.698 . . . . 0.0 109.317 175.4 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 72' ' ' ASN . . . . . 0.52 ' CB ' ' H ' ' A' ' 83' ' ' ASN . 5.2 t30 -99.38 22.17 11.03 Favored 'General case' 0 C--N 1.295 -1.77 0 O-C-N 121.141 -0.974 . . . . 0.0 108.534 171.074 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 73' ' ' LEU . . . . . 0.728 HD13 HD21 ' B' ' 63' ' ' LEU . 71.5 mt -70.03 -39.99 75.44 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.991 -1.068 . . . . 0.0 109.897 175.62 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 74' ' ' GLY . . . . . 0.435 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -49.38 -21.6 3.07 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 110.316 -1.113 . . . . 0.0 110.316 -177.954 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.2 p-10 -66.32 -16.31 63.94 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.127 -1.219 . . . . 0.0 110.525 -175.052 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 96.2 mt -62.26 142.36 57.76 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.291 -0.88 . . . . 0.0 111.189 -175.109 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 77' ' ' LYS . . . . . 1.005 ' C ' HD23 ' B' ' 12' ' ' LEU . 86.6 mttt -141.46 141.1 33.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.669 -0.645 . . . . 0.0 109.563 172.661 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 78' ' ' VAL . . . . . 0.714 ' N ' HD23 ' B' ' 12' ' ' LEU . 16.7 t -59.42 151.63 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 120.812 -1.18 . . . . 0.0 110.245 -176.134 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.83 -13.44 60.98 Favored Glycine 0 N--CA 1.484 1.882 0 N-CA-C 108.887 -1.685 . . . . 0.0 108.887 -176.8 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 80' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 53.7 t0 -96.5 162.16 13.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.397 -1.061 . . . . 0.0 109.666 177.029 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 81' ' ' TRP . . . . . 0.576 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.0 m95 -113.13 153.32 28.42 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.103 -0.998 . . . . 0.0 110.372 177.532 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 82' ' ' VAL . . . . . 0.99 HG13 ' HB3' ' B' ' 10' ' ' ALA . 0.8 OUTLIER -120.01 149.75 22.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.553 -0.717 . . . . 0.0 109.858 179.553 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 83' ' ' ASN . . . . . 1.039 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.2 OUTLIER -69.53 102.41 1.82 Allowed 'General case' 0 C--N 1.298 -1.633 0 O-C-N 120.975 -1.078 . . . . 0.0 109.091 167.783 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 1.044 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -104.45 138.17 30.31 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 O-C-N 120.422 -1.424 . . . . 0.0 110.862 -178.611 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' B' B ' 85' ' ' GLU . . . . . 0.438 ' HB2' HG22 ' B' ' 6' ' ' VAL . 85.9 tt0 -136.12 138.38 41.98 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 119.982 -0.687 . . . . 0.0 110.234 -176.277 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 76.5 ttt180 -61.26 127.53 31.98 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.153 -0.967 . . . . 0.0 109.941 -179.8 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 87' ' ' ALA . . . . . 0.926 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.197 -0.939 . . . . 0.0 109.99 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.475 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 32.7 mtt . . . . . 0 N--CA 1.494 1.743 0 CA-C-O 121.063 0.458 . . . . 0.0 110.135 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 1.066 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 8.2 p90 179.98 139.5 0.13 Allowed 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 -178.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.561 ' CB ' HG12 ' A' ' 5' ' ' ILE . 14.7 p -126.42 -35.32 2.39 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 120.927 -1.108 . . . . 0.0 109.678 -175.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.53 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 58.38 17.27 31.6 Favored Glycine 0 N--CA 1.485 1.95 0 N-CA-C 108.986 -1.646 . . . . 0.0 108.986 -179.286 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.574 HD11 ' C9 ' ' B' ' 99' ' ' RBF . 19.2 mm -88.94 134.43 28.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.382 -1.07 . . . . 0.0 109.693 -175.714 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.887 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.3 t -103.5 139.96 23.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 120.969 -1.082 . . . . 0.0 111.026 -168.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -59.98 -40.02 87.7 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.574 -0.704 . . . . 0.0 110.56 174.533 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.541 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -170.66 -176.95 40.37 Favored Glycine 0 N--CA 1.495 2.588 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.118 -174.634 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.48 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 21.4 p -117.58 169.83 9.24 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.872 -1.37 . . . . 0.0 111.13 -175.622 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.055 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -135.13 147.8 49.58 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.684 -0.635 . . . . 0.0 109.356 -179.033 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.576 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 34.0 tttt -103.57 115.74 31.07 Favored 'General case' 0 C--N 1.293 -1.856 0 O-C-N 121.046 -1.034 . . . . 0.0 110.269 -179.583 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 1.004 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.0 tp -59.87 126.45 27.62 Favored 'General case' 0 C--N 1.298 -1.653 0 O-C-N 120.892 -1.13 . . . . 0.0 108.823 172.736 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.094 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -126.91 -29.02 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 O-C-N 121.438 -0.789 . . . . 0.0 110.017 -179.094 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.04 141.91 26.88 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 119.058 -1.057 . . . . 0.0 111.606 -178.748 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.65 HG23 ' NE2' ' A' ' 24' ' ' HIS . 14.2 mt -109.08 130.52 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.052 -1.03 . . . . 0.0 110.206 170.786 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.504 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 81.6 m-20 -107.71 115.46 30.19 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.291 -0.88 . . . . 0.0 109.963 174.121 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -104.21 114.4 28.61 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.969 -1.082 . . . . 0.0 110.591 -176.412 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.0 OUTLIER -113.67 128.97 25.14 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.141 -0.974 . . . . 0.0 109.203 175.343 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.1 Cg_endo -52.37 -18.37 7.84 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 O-C-N 123.831 1.437 . . . . 0.0 110.944 -179.336 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.545 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 0.4 OUTLIER -92.3 -33.54 14.58 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.135 -0.978 . . . . 0.0 108.939 178.309 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.545 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 84.1 m-85 -156.16 150.24 25.33 Favored 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.358 0.599 . . . . 0.0 110.14 179.792 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.556 ' HD3' HD22 ' A' ' 68' ' ' LEU . 60.1 ttt180 -90.89 144.24 25.89 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 120.744 -1.223 . . . . 0.0 109.775 175.602 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.504 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 85.0 m -129.17 137.69 51.31 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.472 -0.767 . . . . 0.0 109.822 -177.09 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.65 ' NE2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.25 137.04 49.81 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 120.967 -1.083 . . . . 0.0 111.141 179.394 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.832 HG22 ' OG ' ' A' ' 60' ' ' SER . 15.6 t -119.05 134.91 61.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.037 -1.039 . . . . 0.0 110.641 -177.279 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.482 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 16.9 m -117.13 170.93 6.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 CA-C-O 121.088 0.47 . . . . 0.0 110.112 177.922 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.567 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 8.7 tt0 -107.42 116.58 32.18 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.507 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.3 tp -81.36 128.59 69.59 Favored Pre-proline 0 C--N 1.295 -1.766 0 O-C-N 121.307 -0.87 . . . . 0.0 109.978 -171.824 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.483 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 33.6 Cg_endo -68.0 176.83 4.9 Favored 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.903 1.475 . . . . 0.0 110.88 -179.376 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.556 ' HA ' HD12 ' A' ' 33' ' ' LEU . 96.0 m-20 -60.02 -40.02 87.85 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.255 -0.903 . . . . 0.0 111.261 -174.251 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.589 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.85 0.83 56.81 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.75 -1.219 . . . . 0.0 110.936 -173.912 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.589 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.9 mmm -113.23 -9.63 13.44 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 120.839 -1.163 . . . . 0.0 110.074 170.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.726 HD21 ' HB2' ' A' ' 57' ' ' ASN . 19.9 mt -70.02 -23.18 63.08 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.169 -0.957 . . . . 0.0 110.052 176.263 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -94.47 129.94 41.04 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.469 -0.769 . . . . 0.0 110.478 -177.769 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.98 -43.53 1.71 Allowed Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.909 -1.139 . . . . 0.0 110.396 174.126 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.906 HD23 ' N ' ' A' ' 37' ' ' GLU . 7.1 tt -69.94 149.16 48.07 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.836 -1.391 . . . . 0.0 110.855 -174.221 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.906 ' N ' HD23 ' A' ' 36' ' ' LEU . 19.3 pt-20 -150.42 170.02 20.06 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.512 -0.742 . . . . 0.0 109.682 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.874 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -65.82 153.51 41.7 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.024 -1.048 . . . . 0.0 110.235 179.779 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.41 -2.15 63.32 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -178.405 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.449 ' O ' ' HA ' ' A' ' 50' ' ' THR . . . -78.3 158.07 28.98 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.254 -1.145 . . . . 0.0 109.552 176.817 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.645 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.4 OUTLIER -100.31 107.74 19.61 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.026 -1.07 . . . . 0.0 109.876 175.653 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.666 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.1 t -93.65 133.23 35.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 121.321 -0.862 . . . . 0.0 108.896 173.305 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.508 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -97.98 120.0 37.59 Favored 'General case' 0 C--N 1.295 -1.763 0 C-N-CA 119.109 -1.036 . . . . 0.0 109.107 172.174 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.77 ' CD2' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -89.7 106.99 18.83 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 178.929 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 54.01 14.12 0.66 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.444 -0.785 . . . . 0.0 111.048 -168.569 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.51 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 117.87 2.83 16.37 Favored Glycine 0 N--CA 1.489 2.178 0 C-N-CA 119.527 -1.32 . . . . 0.0 110.798 172.559 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.762 ' O ' HD23 ' A' ' 49' ' ' LEU . 33.2 t -98.65 109.9 22.58 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.521 -1.576 . . . . 0.0 109.47 174.837 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.455 ' SG ' ' C7 ' ' A' ' 98' ' ' RBF . 31.0 p -76.8 130.26 37.41 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.978 -1.076 . . . . 0.0 111.182 -170.251 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.961 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -146.54 161.23 40.93 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.573 -0.704 . . . . 0.0 109.333 173.123 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.449 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 22.9 m -100.81 153.02 19.82 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.587 -1.321 . . . . 0.0 111.105 -171.199 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.83 HG13 HG13 ' A' ' 59' ' ' VAL . 24.6 t -76.68 113.77 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.839 -0.538 . . . . 0.0 110.186 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.563 HG22 ' HB3' ' A' ' 62' ' ' ASP . 27.7 p -70.26 -41.55 73.3 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.24 -0.912 . . . . 0.0 109.518 174.146 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.57 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 20.4 pt-20 -160.12 160.09 32.59 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 119.543 -0.863 . . . . 0.0 110.813 176.785 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.874 HD11 ' N ' ' A' ' 38' ' ' THR . 8.9 mt -110.58 130.05 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.268 -0.895 . . . . 0.0 109.962 173.653 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.494 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 5.3 m120 -103.33 63.22 0.8 Allowed 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 120.071 -0.652 . . . . 0.0 109.509 179.25 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.36 -117.43 4.79 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 108.961 -1.655 . . . . 0.0 108.961 -173.612 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.726 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.1 OUTLIER -77.14 -20.63 55.29 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 120.965 -1.314 . . . . 0.0 108.803 175.45 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.094 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.1 m170 -75.56 158.7 32.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.28 -0.888 . . . . 0.0 110.141 -177.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.83 HG13 HG13 ' A' ' 51' ' ' VAL . 55.1 t -140.41 123.82 17.26 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 C-N-CA 119.143 -1.023 . . . . 0.0 110.674 171.478 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.832 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.1 t -89.82 134.17 34.33 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.391 -0.818 . . . . 0.0 109.381 175.505 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.961 ' HB3' HD12 ' A' ' 49' ' ' LEU . 89.1 m-85 -115.67 159.87 20.79 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.224 -0.922 . . . . 0.0 110.277 175.905 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.563 ' HB3' HG22 ' A' ' 52' ' ' THR . 28.3 p-10 -93.02 149.09 21.46 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.187 -0.945 . . . . 0.0 111.129 178.542 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.726 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -154.18 117.69 4.61 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -175.127 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.542 ' HB2' ' CB ' ' A' ' 67' ' ' THR . 54.1 mtp -70.33 139.38 52.0 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.911 -1.118 . . . . 0.0 109.981 179.149 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.499 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 45.0 tptt -59.93 -49.91 75.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.163 -0.961 . . . . 0.0 110.274 -179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.466 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.5 tt0 -64.97 -39.99 94.31 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.753 -1.217 . . . . 0.0 109.859 177.245 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.542 ' CB ' ' HB2' ' A' ' 64' ' ' MET . 85.5 m -59.87 -35.67 75.3 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.934 -1.104 . . . . 0.0 109.397 173.066 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.705 HD13 HD22 ' A' ' 63' ' ' LEU . 20.0 tp -62.84 -46.71 86.63 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.186 -0.946 . . . . 0.0 109.756 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 71.5 ttt-85 -69.98 -39.17 76.11 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.484 -0.76 . . . . 0.0 110.136 178.134 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.67 HG22 HG23 ' A' ' 71' ' ' THR . 1.1 tt -66.81 -40.02 84.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.366 -0.833 . . . . 0.0 109.337 -179.24 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.67 HG23 HG22 ' A' ' 70' ' ' ILE . 65.0 p -86.26 -173.65 4.66 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 174.244 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.4 t30 -104.18 25.04 10.53 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 170.196 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.726 ' HB3' HD21 ' A' ' 63' ' ' LEU . 87.9 mt -69.96 -40.0 75.69 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.027 -1.046 . . . . 0.0 110.008 177.298 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.531 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -47.7 -21.93 1.65 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.5 p-10 -67.11 -17.83 65.04 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.938 -1.33 . . . . 0.0 110.823 -174.221 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.0 mt -60.01 142.96 53.02 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.118 -0.989 . . . . 0.0 111.068 -175.603 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 1.004 ' C ' HD23 ' A' ' 12' ' ' LEU . 54.6 mttp -140.03 139.23 35.93 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.709 -0.619 . . . . 0.0 109.762 174.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.655 ' N ' HD23 ' A' ' 12' ' ' LEU . 15.8 t -61.02 153.08 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.862 -1.149 . . . . 0.0 110.351 -178.286 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.02 -15.03 58.99 Favored Glycine 0 N--CA 1.483 1.801 0 N-CA-C 108.716 -1.753 . . . . 0.0 108.716 -177.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.443 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 25.1 t0 -96.21 169.5 9.9 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.428 -1.042 . . . . 0.0 109.601 176.478 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.576 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.5 m95 -115.97 164.32 14.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.913 -1.117 . . . . 0.0 110.351 175.244 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.055 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.7 p -129.62 144.39 38.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.564 -0.71 . . . . 0.0 109.949 -176.518 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.887 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.6 m-20 -70.95 105.24 3.21 Favored 'General case' 0 C--N 1.293 -1.862 0 O-C-N 121.077 -1.014 . . . . 0.0 109.266 170.543 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.75 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -108.89 138.92 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 120.535 -1.353 . . . . 0.0 111.153 -176.063 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -137.15 147.02 45.68 Favored 'General case' 0 N--CA 1.495 1.82 0 C-N-CA 120.293 -0.563 . . . . 0.0 110.193 179.499 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 73.9 ttt-85 -85.22 130.65 34.56 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.232 -0.917 . . . . 0.0 111.309 -174.598 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.92 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -122.58 149.65 43.67 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.274 -0.891 . . . . 0.0 110.047 175.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -114.67 136.91 52.54 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.287 -0.883 . . . . 0.0 110.935 -178.222 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 23.6 mmtp -60.01 -40.06 87.93 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.375 -0.828 . . . . 0.0 110.15 -179.248 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 52.7 p90 -146.33 154.6 41.85 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.312 -0.868 . . . . 0.0 110.389 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 52.7 m -139.97 149.99 43.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.324 -0.86 . . . . 0.0 110.386 179.501 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -62.38 -43.17 99.45 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.277 -0.89 . . . . 0.0 110.209 176.607 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.468 ' O ' ' HB ' ' A' ' 94' ' ' ILE . 12.9 pt-20 -158.87 55.77 0.43 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.063 -1.023 . . . . 0.0 110.848 -179.14 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.731 HG22 ' O ' ' A' ' 94' ' ' ILE . 16.1 mm 53.1 22.85 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 C-N-CA 119.069 -1.052 . . . . 0.0 108.839 177.236 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -67.08 60.07 0.22 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -179.435 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' A' ' 94' ' ' ILE . . . -147.0 122.11 1.53 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.448 ' OXT' ' ND1' ' A' ' 97' ' ' HIS . 31.7 p80 . . . . . 0 N--CA 1.492 1.644 0 O-C-N 121.247 -1.149 . . . . 0.0 110.168 179.027 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 1' ' ' MET . . . . . 0.461 ' O ' ' HB3' ' B' ' 2' ' ' PHE . 96.8 mmm . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 121.077 0.465 . . . . 0.0 110.088 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.92 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 8.2 p90 -179.9 139.57 0.13 Allowed 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.71 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.552 ' CB ' HG12 ' B' ' 5' ' ' ILE . 14.7 p -126.48 -35.4 2.37 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 120.94 -1.1 . . . . 0.0 109.67 -176.055 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.51 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 58.3 17.41 31.58 Favored Glycine 0 N--CA 1.485 1.943 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -179.242 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 0.552 HG12 ' CB ' ' B' ' 3' ' ' THR . 18.8 mm -88.88 134.32 28.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.335 -1.097 . . . . 0.0 109.68 -175.808 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.854 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.3 t -103.46 140.05 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 120.958 -1.089 . . . . 0.0 111.093 -169.008 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -59.95 -39.91 87.18 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.59 -0.693 . . . . 0.0 110.62 174.534 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.542 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -170.88 -177.2 40.65 Favored Glycine 0 N--CA 1.495 2.616 0 C-N-CA 119.201 -1.476 . . . . 0.0 110.222 -174.534 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.487 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 21.4 p -117.48 169.8 9.24 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.896 -1.355 . . . . 0.0 111.207 -175.611 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.066 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -135.04 147.96 49.77 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 -179.066 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.585 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 34.0 tttt -103.78 115.84 31.22 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 121.15 -0.969 . . . . 0.0 110.16 -179.535 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 1.018 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.0 tp -59.99 126.31 27.05 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 120.96 -1.088 . . . . 0.0 108.843 172.776 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.1 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -126.67 -29.15 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.03 -179.087 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.02 141.83 26.82 Favored 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.25 -0.98 . . . . 0.0 111.568 -178.623 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.641 HG23 ' NE2' ' B' ' 24' ' ' HIS . 14.2 mt -108.96 130.64 61.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.046 -1.034 . . . . 0.0 110.232 170.778 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.516 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 81.0 m-20 -107.98 115.6 30.42 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.369 -0.832 . . . . 0.0 109.746 174.239 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -104.18 114.42 28.65 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.042 -1.037 . . . . 0.0 110.547 -176.48 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.459 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.0 OUTLIER -113.75 128.9 25.23 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.358 -0.839 . . . . 0.0 109.183 175.353 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 9.1 Cg_endo -52.37 -18.42 7.93 Favored 'Trans proline' 0 C--N 1.304 -1.809 0 O-C-N 123.858 1.451 . . . . 0.0 110.906 -179.326 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.548 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 0.4 OUTLIER -92.22 -33.9 14.49 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.06 -1.025 . . . . 0.0 108.769 178.413 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.548 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 84.2 m-85 -155.89 150.25 25.76 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.196 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.551 ' HD3' HD22 ' B' ' 68' ' ' LEU . 60.0 ttt180 -90.87 144.14 26.0 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.909 -1.12 . . . . 0.0 109.797 175.639 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.516 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 82.7 m -129.14 137.74 51.37 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.539 -0.726 . . . . 0.0 109.826 -177.135 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.641 ' NE2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.18 136.94 49.8 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.029 -1.045 . . . . 0.0 111.054 179.573 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.831 HG22 ' OG ' ' B' ' 60' ' ' SER . 15.6 t -118.98 135.09 60.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.116 -0.99 . . . . 0.0 110.734 -177.404 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.491 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 17.2 m -117.42 170.91 6.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 C-N-CA 120.444 -0.502 . . . . 0.0 109.99 178.072 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.566 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 8.7 tt0 -107.36 116.53 32.1 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.594 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.497 ' HA ' HD12 ' B' ' 28' ' ' LEU . 9.3 tp -81.2 128.49 70.4 Favored Pre-proline 0 C--N 1.295 -1.781 0 O-C-N 121.228 -0.92 . . . . 0.0 110.05 -171.856 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.475 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 33.8 Cg_endo -67.99 176.82 4.9 Favored 'Trans proline' 0 C--N 1.308 -1.567 0 O-C-N 123.9 1.474 . . . . 0.0 110.87 -179.392 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.543 ' HA ' HD12 ' B' ' 33' ' ' LEU . 96.1 m-20 -60.02 -39.99 87.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.314 -0.866 . . . . 0.0 111.255 -174.211 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.596 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.82 0.84 56.78 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.733 -1.229 . . . . 0.0 110.974 -173.949 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.596 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.8 mmm -113.28 -9.57 13.41 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.824 -1.172 . . . . 0.0 110.143 170.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.707 HD21 ' HB2' ' B' ' 57' ' ' ASN . 20.0 mt -69.98 -23.33 63.14 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.232 -0.918 . . . . 0.0 109.994 176.189 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 94.3 m-20 -94.44 129.89 41.01 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.383 -0.823 . . . . 0.0 110.57 -177.76 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.96 -43.47 1.73 Allowed Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.885 -1.15 . . . . 0.0 110.48 174.249 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.917 HD23 ' N ' ' B' ' 37' ' ' GLU . 7.2 tt -70.09 149.15 47.92 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.926 -1.338 . . . . 0.0 110.81 -174.216 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 37' ' ' GLU . . . . . 0.917 ' N ' HD23 ' B' ' 36' ' ' LEU . 19.3 pt-20 -150.39 170.01 20.07 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.515 -0.741 . . . . 0.0 109.738 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.878 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -65.8 153.38 42.02 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.992 -1.068 . . . . 0.0 110.236 179.832 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.41 -2.06 63.62 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.453 ' O ' ' HA ' ' B' ' 50' ' ' THR . . . -78.42 157.89 28.87 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.259 -1.142 . . . . 0.0 109.558 176.713 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.639 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.4 OUTLIER -99.97 107.67 19.7 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.894 -1.128 . . . . 0.0 109.994 175.625 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.672 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.1 t -93.66 133.31 35.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.358 -0.839 . . . . 0.0 108.874 173.322 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.505 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -97.99 120.05 37.69 Favored 'General case' 0 C--N 1.296 -1.738 0 C-N-CA 119.162 -1.015 . . . . 0.0 109.055 172.184 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.76 ' CD2' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -89.75 106.78 18.69 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.427 -0.796 . . . . 0.0 108.994 178.876 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.751 HD22 ' HB2' ' A' ' 47' ' ' CYS . 0.9 OUTLIER 54.13 14.21 0.7 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.396 -0.815 . . . . 0.0 111.043 -168.537 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.53 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 117.65 3.21 16.58 Favored Glycine 0 N--CA 1.488 2.142 0 C-N-CA 119.545 -1.312 . . . . 0.0 110.823 172.452 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.76 ' O ' HD23 ' B' ' 49' ' ' LEU . 33.5 t -98.82 110.02 22.69 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.521 -1.576 . . . . 0.0 109.397 174.702 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 48' ' ' CYS . . . . . 0.456 ' SG ' ' C7 ' ' B' ' 99' ' ' RBF . 31.2 p -76.82 130.35 37.51 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.032 -1.043 . . . . 0.0 111.184 -170.32 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 1.011 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -146.7 161.17 41.15 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.62 -0.675 . . . . 0.0 109.304 173.105 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 50' ' ' THR . . . . . 0.453 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 22.9 m -100.69 153.13 19.69 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.722 -1.236 . . . . 0.0 111.06 -171.099 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.846 HG13 HG13 ' B' ' 59' ' ' VAL . 24.8 t -76.8 113.74 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.694 -0.629 . . . . 0.0 110.268 -179.55 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.574 HG22 ' HB3' ' B' ' 62' ' ' ASP . 28.0 p -70.25 -41.55 73.35 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.196 -0.94 . . . . 0.0 109.524 174.262 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.579 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 20.5 pt-20 -160.18 160.04 32.36 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.325 -0.859 . . . . 0.0 110.805 176.752 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.878 HD11 ' N ' ' B' ' 38' ' ' THR . 9.0 mt -110.52 130.02 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.307 -0.87 . . . . 0.0 109.945 173.773 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.511 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 5.3 m120 -103.33 63.13 0.79 Allowed 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 120.018 -0.673 . . . . 0.0 109.524 179.274 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.55 -117.53 4.79 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 108.884 -1.686 . . . . 0.0 108.884 -173.659 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.707 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -77.04 -20.79 55.47 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.1 -1.235 . . . . 0.0 108.814 175.471 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.1 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.2 m170 -75.33 158.51 32.69 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.423 -0.798 . . . . 0.0 110.223 -178.099 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.846 HG13 HG13 ' B' ' 51' ' ' VAL . 54.9 t -140.33 123.7 17.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 C-N-CA 119.126 -1.029 . . . . 0.0 110.677 171.593 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.831 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.1 t -89.76 134.31 34.24 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.448 -0.783 . . . . 0.0 109.406 175.501 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 1.011 ' HB3' HD12 ' B' ' 49' ' ' LEU . 89.2 m-85 -115.74 159.89 20.81 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.213 175.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.574 ' HB3' HG22 ' B' ' 52' ' ' THR . 28.3 p-10 -92.96 149.15 21.43 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.163 -0.961 . . . . 0.0 111.059 178.539 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.702 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -154.28 117.77 4.59 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -175.23 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.551 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 54.3 mtp -70.4 139.42 51.87 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.989 -1.07 . . . . 0.0 110.042 179.107 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.495 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 45.1 tptt -59.92 -49.88 75.95 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.188 -0.945 . . . . 0.0 110.328 -179.567 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 66' ' ' GLU . . . . . 0.478 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 86.5 tt0 -64.88 -40.0 94.43 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.868 -1.145 . . . . 0.0 109.953 177.17 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.551 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 85.0 m -60.05 -35.79 75.9 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.942 -1.099 . . . . 0.0 109.328 173.172 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.691 HD13 HD22 ' B' ' 63' ' ' LEU . 19.8 tp -62.61 -46.64 87.36 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.226 -0.921 . . . . 0.0 109.85 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 71.5 ttt-85 -70.07 -39.24 75.74 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.474 -0.766 . . . . 0.0 110.075 178.156 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.648 HG22 HG23 ' B' ' 71' ' ' THR . 1.1 tt -66.78 -40.04 85.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.466 -0.771 . . . . 0.0 109.302 -179.228 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.648 HG23 HG22 ' B' ' 70' ' ' ILE . 65.9 p -86.21 -173.53 4.6 Favored 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 120.035 -0.666 . . . . 0.0 109.324 174.265 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.489 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 4.4 t30 -104.32 25.21 10.41 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 170.244 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.702 ' HB3' HD21 ' B' ' 63' ' ' LEU . 87.6 mt -70.06 -39.97 75.36 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.02 -1.05 . . . . 0.0 109.985 177.223 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.515 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -47.92 -21.68 1.73 Allowed Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 -179.408 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.6 p-10 -67.18 -17.8 64.99 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.911 -1.347 . . . . 0.0 110.792 -174.279 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.507 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 97.0 mt -59.97 142.9 53.01 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.139 -0.976 . . . . 0.0 111.045 -175.596 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 1.018 ' C ' HD23 ' B' ' 12' ' ' LEU . 54.6 mttp -140.01 139.28 35.97 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.652 -0.655 . . . . 0.0 109.768 174.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.665 ' N ' HD23 ' B' ' 12' ' ' LEU . 15.9 t -61.13 153.06 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.964 -1.085 . . . . 0.0 110.322 -178.176 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.01 -14.82 59.54 Favored Glycine 0 N--CA 1.484 1.88 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.448 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 25.0 t0 -96.31 169.4 9.96 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.463 -1.022 . . . . 0.0 109.626 176.326 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.585 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.5 m95 -116.05 164.18 14.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.996 -1.065 . . . . 0.0 110.327 175.33 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.066 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.6 p -129.46 144.49 37.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.613 -0.679 . . . . 0.0 110.031 -176.659 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.854 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -70.91 105.08 3.14 Favored 'General case' 0 C--N 1.292 -1.892 0 O-C-N 121.164 -0.96 . . . . 0.0 109.301 170.512 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.719 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -108.84 138.93 33.52 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 120.614 -1.304 . . . . 0.0 111.099 -175.972 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -137.15 147.05 45.7 Favored 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.19 179.385 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 74.0 ttt-85 -85.16 130.7 34.56 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.175 -0.953 . . . . 0.0 111.278 -174.619 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 1.066 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -122.71 149.81 43.57 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.376 -0.827 . . . . 0.0 110.001 175.76 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -114.92 136.82 52.69 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.287 -0.883 . . . . 0.0 110.869 -177.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 23.7 mmtp -59.98 -40.03 87.74 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.404 -0.81 . . . . 0.0 110.174 -179.179 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 52.8 p90 -146.31 154.56 41.82 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.266 -0.896 . . . . 0.0 110.389 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 91' ' ' SER . . . . . . . . . . . . . 53.1 m -140.02 149.97 43.84 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.43 -0.794 . . . . 0.0 110.402 179.415 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 92' ' ' ASP . . . . . 0.461 ' O ' ' HB2' ' B' ' 93' ' ' GLU . 96.0 m-20 -62.07 -39.98 94.27 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.214 -0.929 . . . . 0.0 110.02 176.538 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 93' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' B' ' 92' ' ' ASP . 98.9 mt-10 55.87 54.55 7.97 Favored 'General case' 0 N--CA 1.506 2.375 0 C-N-CA 120.102 -0.639 . . . . 0.0 110.549 176.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 94' ' ' ILE . . . . . . . . . . . . . 27.1 mm -60.03 -39.97 81.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.312 -0.868 . . . . 0.0 109.829 175.125 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 139.88 -69.36 0.47 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 179.039 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . 51.81 -141.91 22.66 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 179.461 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 70.5 t60 . . . . . 0 N--CA 1.492 1.643 0 O-C-N 121.247 -1.149 . . . . 0.0 110.203 -179.56 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 0.514 " O5'" HG21 ' A' ' 70' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 0.574 ' C9 ' HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.417 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 74.0 mtm . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.383 0.611 . . . . 0.0 110.61 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.881 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 5.0 p90 -176.32 139.98 0.37 Allowed 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 174.288 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.519 ' HB ' HG12 ' A' ' 5' ' ' ILE . 17.1 p -130.06 -39.56 1.37 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.873 -1.142 . . . . 0.0 108.833 -178.143 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.521 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 55.09 20.1 18.94 Favored Glycine 0 N--CA 1.482 1.753 0 N-CA-C 108.602 -1.799 . . . . 0.0 108.602 -178.776 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.519 HG12 ' HB ' ' A' ' 3' ' ' THR . 36.7 mm -81.16 114.37 22.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.317 -1.108 . . . . 0.0 110.106 -175.399 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.749 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.3 t -79.43 131.61 33.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.252 -0.905 . . . . 0.0 110.061 -176.635 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.508 ' OE1' ' NH1' ' A' ' 86' ' ' ARG . 97.2 mt-30 -70.24 -30.03 66.98 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.492 -0.755 . . . . 0.0 111.405 -178.495 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.53 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -148.44 176.13 27.39 Favored Glycine 0 N--CA 1.495 2.579 0 C-N-CA 118.687 -1.721 . . . . 0.0 110.271 -173.865 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.462 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 2.9 p -123.28 171.3 9.49 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.153 -1.204 . . . . 0.0 110.574 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.018 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -141.11 150.07 42.37 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.46 -0.775 . . . . 0.0 109.401 -175.837 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 26.3 tttt -111.53 116.23 30.52 Favored 'General case' 0 C--N 1.297 -1.704 0 O-C-N 121.059 -1.025 . . . . 0.0 110.334 179.875 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.877 HD23 ' C ' ' A' ' 77' ' ' LYS . 9.9 tp -58.43 124.78 20.74 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.013 -1.054 . . . . 0.0 108.931 173.1 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.058 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.0 OUTLIER -118.24 -29.29 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 O-C-N 121.359 -0.838 . . . . 0.0 109.597 178.751 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.43 149.96 27.37 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.057 -1.057 . . . . 0.0 111.639 -178.381 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.756 HG23 ' CD2' ' A' ' 24' ' ' HIS . 19.5 mt -112.09 132.24 61.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.158 -0.964 . . . . 0.0 109.998 172.846 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.518 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 86.3 m-20 -108.65 116.12 31.38 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.305 -0.872 . . . . 0.0 109.861 174.786 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -106.13 108.73 20.4 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.064 -1.023 . . . . 0.0 110.534 -176.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -102.14 128.55 28.24 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.069 -1.019 . . . . 0.0 108.924 172.66 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_endo -50.47 -29.61 24.86 Favored 'Trans proline' 0 C--N 1.303 -1.865 0 O-C-N 123.834 1.439 . . . . 0.0 110.453 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.49 ' HB3' ' CE2' ' A' ' 21' ' ' PHE . 12.8 m-80 -77.87 -39.99 41.54 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.181 -0.949 . . . . 0.0 110.021 176.069 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.49 ' CE2' ' HB3' ' A' ' 20' ' ' ASN . 51.0 m-85 -151.18 150.23 30.38 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.342 -0.849 . . . . 0.0 109.925 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.484 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 60.0 ttt180 -90.42 145.24 25.09 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.714 -1.241 . . . . 0.0 110.012 176.823 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.518 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 91.5 m -129.64 138.19 51.08 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.429 -0.794 . . . . 0.0 109.941 -177.251 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.756 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -128.99 136.44 50.34 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 120.91 -1.119 . . . . 0.0 111.085 178.934 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.784 HG22 ' CB ' ' A' ' 60' ' ' SER . 8.2 t -120.08 132.63 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.922 -1.111 . . . . 0.0 110.77 -176.55 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.774 HG13 ' CE1' ' A' ' 61' ' ' PHE . 23.2 m -116.9 173.31 4.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 CA-C-O 121.27 0.557 . . . . 0.0 110.341 178.575 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.674 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 9.9 tt0 -106.2 117.91 35.25 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.464 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.715 HD21 HD13 ' A' ' 36' ' ' LEU . 9.2 tp -85.54 125.69 68.71 Favored Pre-proline 0 C--N 1.299 -1.624 0 O-C-N 121.403 -0.81 . . . . 0.0 110.3 -171.209 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.482 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 22.2 Cg_endo -66.17 176.37 3.97 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.878 1.462 . . . . 0.0 111.245 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.477 ' HA ' HD12 ' A' ' 33' ' ' LEU . 47.8 t0 -60.06 -39.9 87.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.336 -0.853 . . . . 0.0 111.183 -175.421 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.61 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.03 0.0 57.35 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.844 -1.16 . . . . 0.0 110.663 -174.937 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.61 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.8 mmm -112.26 -12.34 13.61 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.958 -1.089 . . . . 0.0 109.704 171.502 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.583 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 17.9 mt -69.25 -36.89 77.63 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.4 -0.813 . . . . 0.0 110.069 175.787 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -82.7 138.9 33.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.438 -0.789 . . . . 0.0 110.778 -177.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.44 -40.73 2.83 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 110.194 -1.163 . . . . 0.0 110.194 174.553 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.805 HD23 ' N ' ' A' ' 37' ' ' GLU . 8.3 tt -73.28 145.93 45.72 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.053 -1.263 . . . . 0.0 110.631 -176.171 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.805 ' N ' HD23 ' A' ' 36' ' ' LEU . 20.9 pt-20 -150.35 167.0 28.33 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.488 -0.757 . . . . 0.0 109.687 179.765 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.783 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -65.2 152.18 44.28 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.033 -1.042 . . . . 0.0 110.237 -178.123 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.63 -3.87 62.28 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -176.18 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.621 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -77.32 155.42 32.01 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.141 -1.211 . . . . 0.0 109.467 176.336 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.579 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -96.82 104.36 16.36 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 119.036 -1.066 . . . . 0.0 109.82 176.831 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.668 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.1 t -86.06 132.0 33.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 O-C-N 121.24 -0.913 . . . . 0.0 109.139 174.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 1.075 ' HB3' ' CG ' ' A' ' 85' ' ' GLU . . . -98.78 120.29 38.98 Favored 'General case' 0 C--N 1.296 -1.742 0 C-N-CA 119.408 -0.917 . . . . 0.0 109.262 173.479 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.885 ' CD2' HG21 ' A' ' 82' ' ' VAL . 1.5 m80 -93.08 104.08 16.32 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.593 -0.692 . . . . 0.0 109.268 179.503 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.514 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.3 t-20 55.64 11.29 0.62 Allowed 'General case' 0 C--N 1.298 -1.633 0 O-C-N 121.622 -0.674 . . . . 0.0 111.094 -169.857 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.521 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.61 1.95 10.73 Favored Glycine 0 N--CA 1.488 2.166 0 C-N-CA 119.796 -1.193 . . . . 0.0 110.818 174.209 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.673 ' O ' HD23 ' A' ' 49' ' ' LEU . 8.6 t -97.22 113.26 24.85 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 120.361 -1.67 . . . . 0.0 109.545 175.494 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.408 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 26.4 p -79.86 124.25 28.48 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.119 -0.988 . . . . 0.0 111.191 -170.799 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.864 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -141.36 163.21 33.55 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.385 -0.822 . . . . 0.0 109.661 172.861 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.433 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 57.5 m -102.96 152.08 21.72 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.689 -1.257 . . . . 0.0 111.019 -172.122 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.916 HG13 HG13 ' A' ' 59' ' ' VAL . 14.0 t -78.38 114.69 19.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.751 -0.593 . . . . 0.0 110.272 -178.604 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.523 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 46.1 p -71.29 -44.51 65.07 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.194 -0.941 . . . . 0.0 109.868 175.644 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.561 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -158.33 153.89 26.17 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.199 -0.938 . . . . 0.0 110.336 178.126 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.783 HD11 ' N ' ' A' ' 38' ' ' THR . 8.0 mt -105.37 130.37 56.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.161 -0.962 . . . . 0.0 109.818 175.991 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.519 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 12.4 m-80 -102.4 64.25 0.9 Allowed 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.565 -0.71 . . . . 0.0 109.612 179.828 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.54 -113.08 3.93 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -173.029 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.583 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -80.05 -21.31 43.59 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.066 -1.255 . . . . 0.0 109.293 175.568 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.058 ' CE1' HG11 ' A' ' 13' ' ' VAL . 22.7 m-70 -74.88 159.53 31.76 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.352 -0.842 . . . . 0.0 110.102 -177.817 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.916 HG13 HG13 ' A' ' 51' ' ' VAL . 53.9 t -140.04 122.16 16.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 C-N-CA 119.023 -1.071 . . . . 0.0 110.916 172.162 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.784 ' CB ' HG22 ' A' ' 25' ' ' VAL . 60.2 p -91.06 129.09 37.09 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.724 -0.61 . . . . 0.0 109.689 177.772 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.864 ' HB2' HD12 ' A' ' 49' ' ' LEU . 1.3 p90 -123.14 156.89 34.12 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.964 -1.085 . . . . 0.0 110.61 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.523 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 32.6 p-10 -91.33 152.06 20.61 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.184 -0.948 . . . . 0.0 111.329 -172.658 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.821 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -155.72 111.84 3.1 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 -175.771 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.526 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 84.2 mmm -65.71 139.86 58.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.877 -1.14 . . . . 0.0 109.232 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.459 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 58.0 tptt -60.0 -44.41 94.56 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.958 -1.089 . . . . 0.0 109.981 -176.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.441 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.0 tt0 -69.01 -40.0 78.97 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.122 -0.986 . . . . 0.0 110.385 178.554 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.526 ' HB ' ' HB2' ' A' ' 64' ' ' MET . 89.9 m -60.98 -39.99 91.76 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.937 -1.102 . . . . 0.0 109.085 173.25 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.773 HD11 ' HA2' ' A' ' 74' ' ' GLY . 5.1 tp -60.01 -46.24 90.15 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.494 -0.753 . . . . 0.0 109.66 178.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 32.5 tpt180 -67.4 -40.11 85.58 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.548 -0.72 . . . . 0.0 110.519 177.587 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.788 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -69.96 -41.56 79.46 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.247 -0.908 . . . . 0.0 109.491 -176.457 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.788 HG23 HG22 ' A' ' 70' ' ' ILE . 61.1 p -84.65 -173.22 4.6 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 178.604 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.484 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.6 t30 -101.76 23.08 11.84 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 170.834 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.821 ' HB3' HD21 ' A' ' 63' ' ' LEU . 94.1 mt -70.04 -42.31 73.07 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.036 -1.04 . . . . 0.0 109.992 176.114 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.773 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -52.28 -18.93 5.31 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -178.029 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 23.7 p-10 -64.67 -18.32 64.86 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.085 -1.244 . . . . 0.0 110.469 -176.193 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 88.6 mt -59.97 143.23 52.23 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.257 -0.902 . . . . 0.0 110.836 -176.246 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 0.877 ' C ' HD23 ' A' ' 12' ' ' LEU . 54.6 mttt -142.58 141.25 31.96 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.734 -0.604 . . . . 0.0 109.597 175.658 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.623 ' N ' HD23 ' A' ' 12' ' ' LEU . 16.9 t -60.75 151.25 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 120.784 -1.198 . . . . 0.0 110.601 -174.51 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.65 -10.97 65.42 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -177.837 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 47.4 t0 -96.38 163.18 13.17 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.268 -1.137 . . . . 0.0 109.622 176.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.0 m95 -113.41 161.64 17.06 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.072 -1.018 . . . . 0.0 110.263 176.877 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.018 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.5 p -131.24 149.76 33.66 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 O-C-N 121.522 -0.736 . . . . 0.0 109.847 -176.324 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.749 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.6 m-20 -75.43 108.02 7.95 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 121.24 -0.912 . . . . 0.0 109.188 170.613 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.829 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.2 OUTLIER -111.71 145.11 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.52 -1.363 . . . . 0.0 111.501 -175.229 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 1.075 ' CG ' ' HB3' ' A' ' 43' ' ' ALA . 25.9 pt-20 -144.52 160.02 41.81 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.652 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.508 ' NH1' ' OE1' ' A' ' 7' ' ' GLN . 31.5 ptt-85 -98.27 132.91 43.36 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.024 -1.048 . . . . 0.0 110.979 -174.319 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.885 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -124.25 148.14 47.57 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.46 -0.775 . . . . 0.0 109.845 177.192 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -139.18 153.38 47.91 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.428 -0.795 . . . . 0.0 110.642 -177.355 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 17.2 mttp -60.06 -39.99 87.92 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.358 -0.839 . . . . 0.0 109.925 175.45 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.2 p90 -130.82 158.3 40.55 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.393 -0.817 . . . . 0.0 109.952 178.403 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 19.1 t -150.09 165.64 32.19 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.273 -0.892 . . . . 0.0 110.265 -179.307 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.526 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 96.0 m-20 -59.95 -40.07 87.73 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.228 -0.92 . . . . 0.0 110.14 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.526 ' CG ' ' O ' ' A' ' 92' ' ' ASP . 11.2 pt-20 38.59 51.32 1.69 Allowed 'General case' 0 N--CA 1.512 2.651 0 CA-C-O 121.64 0.733 . . . . 0.0 110.337 178.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 40.8 mm -68.25 -40.07 82.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.333 -0.855 . . . . 0.0 110.08 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 45.96 65.6 1.97 Allowed Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 179.296 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -69.28 -157.31 1.39 Allowed Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 178.575 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 22.5 p80 . . . . . 0 N--CA 1.492 1.633 0 O-C-N 121.187 -1.184 . . . . 0.0 110.242 -179.291 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 1' ' ' MET . . . . . 0.443 ' O ' ' HB3' ' B' ' 2' ' ' PHE . 82.5 mtp . . . . . 0 N--CA 1.495 1.801 0 CA-C-O 121.294 0.568 . . . . 0.0 110.642 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.885 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 5.3 p90 -178.5 140.01 0.19 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 174.186 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.544 ' HB ' HG12 ' B' ' 5' ' ' ILE . 17.0 p -129.98 -39.71 1.38 Allowed 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.854 -1.154 . . . . 0.0 108.776 -178.099 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.492 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 55.2 20.01 19.38 Favored Glycine 0 N--CA 1.483 1.791 0 N-CA-C 108.515 -1.834 . . . . 0.0 108.515 -178.703 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 0.544 HG12 ' HB ' ' B' ' 3' ' ' THR . 37.3 mm -81.15 114.38 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.351 -1.088 . . . . 0.0 109.969 -175.268 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.729 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.3 t -79.54 131.68 33.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.362 -0.836 . . . . 0.0 110.003 -176.655 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.514 ' OE1' ' NH1' ' B' ' 86' ' ' ARG . 97.2 mt-30 -70.2 -29.93 66.91 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.497 -0.752 . . . . 0.0 111.483 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.534 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -148.62 175.9 27.67 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 118.91 -1.614 . . . . 0.0 110.386 -173.766 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.472 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 2.9 p -123.25 171.17 9.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -1.164 . . . . 0.0 110.591 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.057 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -140.94 150.16 42.78 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.515 -0.741 . . . . 0.0 109.39 -175.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.587 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 26.4 tttt -111.62 116.44 30.81 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.122 -0.986 . . . . 0.0 110.275 179.797 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 0.882 HD23 ' C ' ' B' ' 77' ' ' LYS . 10.0 tp -58.65 124.87 21.16 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.136 -0.978 . . . . 0.0 108.911 173.133 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.044 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.0 OUTLIER -118.3 -29.08 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 C-N-CA 119.549 -0.86 . . . . 0.0 109.674 178.744 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.58 149.99 27.25 Favored 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 119.115 -1.034 . . . . 0.0 111.539 -178.416 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.759 HG23 ' CD2' ' B' ' 24' ' ' HIS . 19.5 mt -112.1 132.16 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.307 -0.87 . . . . 0.0 110.098 172.838 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.53 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 86.1 m-20 -108.71 116.23 31.59 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.386 -0.821 . . . . 0.0 109.776 174.888 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -106.21 108.54 20.1 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.001 -1.062 . . . . 0.0 110.537 -176.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -102.01 128.48 28.51 Favored Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.167 -0.958 . . . . 0.0 109.022 172.647 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.2 Cg_endo -50.49 -29.63 25.05 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 O-C-N 123.841 1.443 . . . . 0.0 110.465 -179.463 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.485 ' HB3' ' CE2' ' B' ' 21' ' ' PHE . 12.6 m-80 -77.7 -40.32 41.73 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.236 -0.915 . . . . 0.0 110.016 176.037 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.485 ' CE2' ' HB3' ' B' ' 20' ' ' ASN . 51.4 m-85 -150.94 150.19 30.53 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.409 -0.807 . . . . 0.0 109.9 -179.78 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.474 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 60.0 ttt180 -90.43 145.12 25.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.74 -1.225 . . . . 0.0 110.063 176.841 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.53 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 92.0 m -129.49 138.36 51.34 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.569 -0.707 . . . . 0.0 109.843 -177.185 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.759 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -129.09 136.57 50.41 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.042 -1.037 . . . . 0.0 110.977 178.901 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.789 HG22 ' CB ' ' B' ' 60' ' ' SER . 8.5 t -120.04 132.78 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.119 -0.988 . . . . 0.0 110.711 -176.499 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.785 HG13 ' CE1' ' B' ' 61' ' ' PHE . 23.7 m -117.07 173.25 4.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.815 -0.553 . . . . 0.0 110.318 178.605 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.671 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 9.8 tt0 -105.98 117.89 35.19 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 -179.645 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.716 HD21 HD13 ' B' ' 36' ' ' LEU . 9.2 tp -85.58 125.67 68.68 Favored Pre-proline 0 C--N 1.298 -1.666 0 O-C-N 121.318 -0.864 . . . . 0.0 110.251 -171.226 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.485 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 22.1 Cg_endo -66.08 176.36 3.92 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 O-C-N 123.889 1.468 . . . . 0.0 111.196 -179.512 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.485 ' HA ' HD12 ' B' ' 33' ' ' LEU . 47.8 t0 -60.07 -39.98 87.93 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.338 -0.851 . . . . 0.0 111.135 -175.476 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.99 0.15 57.26 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.877 -1.139 . . . . 0.0 110.734 -174.928 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.597 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.7 mmm -112.33 -12.38 13.57 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.957 -1.09 . . . . 0.0 109.708 171.552 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.592 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 17.7 mt -69.28 -36.91 77.55 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.346 -0.847 . . . . 0.0 110.032 175.819 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 72.9 m-20 -82.71 138.96 33.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.438 -0.789 . . . . 0.0 110.8 -177.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.34 -40.61 2.86 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 174.621 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.801 HD23 ' N ' ' B' ' 37' ' ' GLU . 8.2 tt -73.37 145.95 45.53 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.997 -1.296 . . . . 0.0 110.556 -176.187 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 37' ' ' GLU . . . . . 0.801 ' N ' HD23 ' B' ' 36' ' ' LEU . 20.9 pt-20 -150.34 167.04 28.2 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.44 -0.787 . . . . 0.0 109.674 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.789 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -65.24 152.16 44.38 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.994 -1.066 . . . . 0.0 110.323 -178.156 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.62 -3.94 62.02 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -176.054 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.62 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -77.36 155.2 32.09 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.212 -1.17 . . . . 0.0 109.521 176.262 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.576 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -96.54 104.25 16.22 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.893 -1.13 . . . . 0.0 109.873 176.858 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.697 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.1 t -86.07 131.97 33.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.224 -0.923 . . . . 0.0 109.178 174.854 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 1.068 ' HB3' ' CG ' ' B' ' 85' ' ' GLU . . . -98.67 120.33 38.92 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 121.227 -0.921 . . . . 0.0 109.288 173.473 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.882 ' CD2' HG21 ' B' ' 82' ' ' VAL . 1.4 m80 -93.1 103.75 16.01 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.502 -0.749 . . . . 0.0 109.365 179.482 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.514 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.3 t-20 55.9 11.48 0.71 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.557 -0.714 . . . . 0.0 110.972 -169.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.521 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 121.41 2.24 10.84 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 119.755 -1.212 . . . . 0.0 110.8 174.048 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.685 ' O ' HD23 ' B' ' 49' ' ' LEU . 8.7 t -97.47 113.32 24.99 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 120.327 -1.69 . . . . 0.0 109.543 175.384 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 48' ' ' CYS . . . . . 0.41 ' O ' ' SG ' ' B' ' 48' ' ' CYS . 26.4 p -79.8 124.3 28.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.044 -1.035 . . . . 0.0 111.145 -170.723 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 0.897 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -141.51 163.34 33.2 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.538 -0.726 . . . . 0.0 109.618 172.77 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 50' ' ' THR . . . . . 0.44 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 57.4 m -102.92 152.18 21.59 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.78 -1.2 . . . . 0.0 110.991 -172.032 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.941 HG13 HG13 ' B' ' 59' ' ' VAL . 14.1 t -78.54 114.72 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.749 -0.594 . . . . 0.0 110.323 -178.644 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 47.0 p -71.32 -44.56 64.9 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.09 -1.006 . . . . 0.0 109.821 175.799 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.557 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -158.25 153.92 26.38 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.241 -0.912 . . . . 0.0 110.272 178.176 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.789 HD11 ' N ' ' B' ' 38' ' ' THR . 7.9 mt -105.34 130.32 56.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.117 -0.989 . . . . 0.0 109.825 176.028 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.531 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 12.3 m-80 -102.54 64.32 0.89 Allowed 'General case' 0 C--N 1.297 -1.675 0 C-N-CA 119.865 -0.734 . . . . 0.0 109.608 179.844 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.68 -113.0 3.88 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 108.659 -1.776 . . . . 0.0 108.659 -173.139 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.592 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -80.1 -21.53 43.19 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.045 -1.268 . . . . 0.0 109.225 175.609 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.044 ' CE1' HG11 ' B' ' 13' ' ' VAL . 22.9 m-70 -74.72 159.46 31.99 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.317 -0.864 . . . . 0.0 110.155 -177.83 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.941 HG13 HG13 ' B' ' 51' ' ' VAL . 54.5 t -140.06 122.19 16.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 C-N-CA 118.903 -1.119 . . . . 0.0 110.867 172.303 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.789 ' CB ' HG22 ' B' ' 25' ' ' VAL . 60.1 p -91.16 129.23 37.18 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.734 -0.604 . . . . 0.0 109.682 177.833 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.897 ' HB2' HD12 ' B' ' 49' ' ' LEU . 1.3 p90 -123.2 156.94 34.12 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.072 -1.018 . . . . 0.0 110.555 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 32.7 p-10 -91.28 152.22 20.58 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.097 -1.002 . . . . 0.0 111.224 -172.625 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.814 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -155.81 111.91 3.09 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -175.88 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.509 ' HB2' ' HB ' ' B' ' 67' ' ' THR . 84.1 mmm -65.8 139.82 58.35 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.871 -1.143 . . . . 0.0 109.186 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.457 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 57.9 tptt -60.03 -44.27 94.73 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.11 -0.994 . . . . 0.0 109.987 -176.685 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 66' ' ' GLU . . . . . 0.445 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 85.9 tt0 -69.15 -39.96 78.48 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.171 -0.955 . . . . 0.0 110.302 178.626 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.509 ' HB ' ' HB2' ' B' ' 64' ' ' MET . 90.5 m -61.05 -40.07 92.22 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.899 -1.126 . . . . 0.0 109.019 173.288 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.798 HD11 ' HA2' ' B' ' 74' ' ' GLY . 5.1 tp -59.94 -46.08 90.55 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.512 -0.742 . . . . 0.0 109.747 178.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 32.5 tpt180 -67.6 -39.98 84.75 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.612 -0.68 . . . . 0.0 110.506 177.585 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.775 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -70.0 -41.47 79.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 O-C-N 121.328 -0.858 . . . . 0.0 109.593 -176.544 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.775 HG23 HG22 ' B' ' 70' ' ' ILE . 60.2 p -84.65 -173.16 4.57 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 120.177 -0.609 . . . . 0.0 109.517 178.563 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.48 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 4.5 t30 -101.65 22.98 11.9 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 170.837 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.814 ' HB3' HD21 ' B' ' 63' ' ' LEU . 94.2 mt -69.96 -42.31 73.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.022 -1.049 . . . . 0.0 110.02 176.096 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.798 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -52.34 -18.82 5.31 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -178.025 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 23.7 p-10 -64.78 -18.29 64.95 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.054 -1.262 . . . . 0.0 110.436 -176.217 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.516 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 88.7 mt -59.99 143.24 52.27 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.23 -0.919 . . . . 0.0 110.844 -176.297 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 0.882 ' C ' HD23 ' B' ' 12' ' ' LEU . 54.6 mttt -142.61 141.22 31.91 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.652 -0.655 . . . . 0.0 109.62 175.723 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.619 ' N ' HD23 ' B' ' 12' ' ' LEU . 17.2 t -60.85 151.15 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 120.844 -1.16 . . . . 0.0 110.555 -174.408 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.68 -10.82 66.03 Favored Glycine 0 N--CA 1.487 2.07 0 N-CA-C 109.02 -1.632 . . . . 0.0 109.02 -177.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 47.0 t0 -96.45 163.11 13.19 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.348 -1.089 . . . . 0.0 109.695 176.761 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.587 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.0 m95 -113.38 161.58 17.1 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.056 -1.028 . . . . 0.0 110.284 176.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.057 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.5 p -131.27 149.92 33.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.575 -0.703 . . . . 0.0 109.801 -176.479 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.729 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -75.34 107.79 7.69 Favored 'General case' 0 C--N 1.294 -1.806 0 O-C-N 121.205 -0.934 . . . . 0.0 109.282 170.633 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.826 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.2 OUTLIER -111.65 145.2 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 120.522 -1.361 . . . . 0.0 111.501 -175.121 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 85' ' ' GLU . . . . . 1.068 ' CG ' ' HB3' ' B' ' 43' ' ' ALA . 25.9 pt-20 -144.6 159.98 41.91 Favored 'General case' 0 N--CA 1.494 1.773 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.691 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 86' ' ' ARG . . . . . 0.514 ' NH1' ' OE1' ' B' ' 7' ' ' GLN . 31.5 ptt-85 -98.1 132.88 43.25 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.869 -1.145 . . . . 0.0 110.963 -174.28 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 0.881 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -124.24 148.14 47.56 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.401 -0.812 . . . . 0.0 109.79 177.134 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -139.32 153.29 47.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.457 -0.777 . . . . 0.0 110.58 -177.309 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 17.1 mttp -60.02 -40.01 87.82 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.427 -0.796 . . . . 0.0 109.977 175.455 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 53.1 p90 -130.82 158.34 40.44 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.322 -0.861 . . . . 0.0 109.942 178.425 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 91' ' ' SER . . . . . 0.401 ' HB3' ' HG2' ' B' ' 93' ' ' GLU . 19.3 t -150.08 165.8 31.7 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.266 -0.896 . . . . 0.0 110.259 -179.353 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -60.05 -39.6 86.52 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.908 . . . . 0.0 110.078 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 93' ' ' GLU . . . . . 0.401 ' HG2' ' HB3' ' B' ' 91' ' ' SER . 74.8 mm-40 48.06 54.33 10.3 Favored 'General case' 0 N--CA 1.506 2.335 0 O-C-N 121.249 -0.907 . . . . 0.0 110.045 177.431 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 94' ' ' ILE . . . . . . . . . . . . . 26.7 mm -60.24 -39.89 82.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.419 -0.801 . . . . 0.0 110.009 178.716 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 54.55 73.53 0.41 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.331 -1.507 . . . . 0.0 109.331 -179.043 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 96' ' ' GLY . . . . . 0.406 ' O ' ' C ' ' B' ' 97' ' ' HIS . . . 129.75 50.02 0.12 Allowed Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 -177.476 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 97' ' ' HIS . . . . . 0.406 ' C ' ' O ' ' B' ' 96' ' ' GLY . 74.9 t60 . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.293 -1.122 . . . . 0.0 110.204 -178.601 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 0.559 " C2'" ' HC9' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 0.554 " C2'" ' HC9' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.483 ' HA ' ' O ' ' B' ' 89' ' ' LYS . 72.2 mtm . . . . . 0 N--CA 1.495 1.788 0 CA-C-O 121.357 0.598 . . . . 0.0 110.34 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.755 ' HE2' ' HB1' ' B' ' 87' ' ' ALA . 0.7 OUTLIER -173.22 137.84 0.7 Allowed 'General case' 0 C--N 1.306 -1.322 0 O-C-N 121.318 -0.864 . . . . 0.0 109.008 177.698 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.515 ' O ' HG13 ' A' ' 5' ' ' ILE . 25.8 p -133.72 -31.78 1.16 Allowed 'General case' 0 C--N 1.297 -1.676 0 O-C-N 120.989 -1.069 . . . . 0.0 110.135 -173.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 3' ' ' THR . . . 45.79 25.1 1.44 Allowed Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.056 -1.618 . . . . 0.0 109.056 -174.687 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.872 HD11 ' C8M' ' B' ' 99' ' ' RBF . 57.7 mt -84.01 139.98 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.046 -1.267 . . . . 0.0 110.556 -177.287 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.976 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.4 t -94.39 138.62 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.423 -0.798 . . . . 0.0 110.418 -176.195 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -69.94 -33.65 72.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.51 -0.744 . . . . 0.0 111.051 178.703 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.515 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -155.66 172.85 33.77 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.871 -1.633 . . . . 0.0 109.909 -173.675 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.483 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 0.6 OUTLIER -115.2 168.8 9.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.143 -1.21 . . . . 0.0 110.48 -179.496 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.016 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -135.59 147.82 48.83 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.547 -0.721 . . . . 0.0 109.472 -179.142 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.577 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 29.1 tttt -105.98 115.86 30.96 Favored 'General case' 0 C--N 1.294 -1.829 0 O-C-N 121.121 -0.987 . . . . 0.0 110.247 178.835 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 1.029 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.1 tp -59.71 128.09 35.24 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 120.89 -1.131 . . . . 0.0 108.653 172.834 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.143 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.5 p -128.2 -31.52 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 C-N-CA 119.553 -0.859 . . . . 0.0 110.085 -177.719 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.91 144.71 30.35 Favored 'General case' 0 N--CA 1.495 1.786 0 C-N-CA 118.859 -1.136 . . . . 0.0 111.293 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.766 HG23 ' CD2' ' A' ' 24' ' ' HIS . 12.5 mt -109.44 132.99 56.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.245 -0.91 . . . . 0.0 110.351 173.177 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.499 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 79.8 m-20 -110.15 116.22 31.14 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.307 -0.871 . . . . 0.0 109.98 173.125 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -106.54 114.45 28.57 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.007 -1.058 . . . . 0.0 110.567 -178.216 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.456 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.7 mtmt -110.74 132.94 21.35 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.248 -0.907 . . . . 0.0 109.138 175.492 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -50.07 -34.54 38.83 Favored 'Trans proline' 0 C--N 1.301 -1.93 0 O-C-N 123.857 1.451 . . . . 0.0 110.692 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.465 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 12.3 m-80 -74.6 -39.71 62.02 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.149 -0.97 . . . . 0.0 110.076 177.304 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.465 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 96.1 m-85 -154.35 150.16 27.65 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.345 -0.847 . . . . 0.0 110.128 -178.471 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.492 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 59.5 ttt180 -91.71 146.29 23.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.751 -1.218 . . . . 0.0 110.121 176.684 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.499 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 90.4 m -130.0 140.04 50.95 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.408 -0.807 . . . . 0.0 109.927 -175.608 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.766 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -129.15 136.43 50.18 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.9 -1.125 . . . . 0.0 111.148 177.565 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.725 HG22 ' OG ' ' A' ' 60' ' ' SER . 5.8 t -115.78 132.46 65.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.075 -1.016 . . . . 0.0 110.7 -177.414 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.488 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 12.5 m -116.1 170.19 6.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-O 121.111 0.482 . . . . 0.0 110.124 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.502 ' HG2' HD22 ' A' ' 57' ' ' ASN . 2.7 tm-20 -101.55 117.8 35.65 Favored 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.322 -0.861 . . . . 0.0 109.23 179.068 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.597 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.3 tp -82.71 127.27 70.81 Favored Pre-proline 0 C--N 1.298 -1.661 0 O-C-N 121.485 -0.759 . . . . 0.0 110.003 -174.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.462 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 25.3 Cg_endo -66.5 -178.5 1.21 Allowed 'Trans proline' 0 C--N 1.308 -1.561 0 O-C-N 123.88 1.463 . . . . 0.0 111.008 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.502 ' OD1' ' N ' ' A' ' 30' ' ' ASP . 22.6 p-10 -65.66 -39.98 91.96 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.413 -0.804 . . . . 0.0 111.016 -177.18 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.604 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.0 0.36 57.15 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.905 -1.122 . . . . 0.0 110.924 -174.557 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.604 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.8 mmm -110.14 -16.02 13.88 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.949 -1.094 . . . . 0.0 109.692 171.645 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.597 ' HA ' HD23 ' A' ' 28' ' ' LEU . 13.4 mt -66.13 -32.04 73.25 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.515 -0.74 . . . . 0.0 110.41 178.163 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ASP . . . . . 0.419 ' OD1' ' N ' ' A' ' 35' ' ' GLY . 63.7 t0 -80.26 142.93 34.11 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.222 -0.924 . . . . 0.0 110.864 -176.7 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.419 ' N ' ' OD1' ' A' ' 34' ' ' ASP . . . 85.94 -31.77 3.92 Favored Glycine 0 N--CA 1.493 2.443 0 C-N-CA 119.99 -1.1 . . . . 0.0 111.096 170.702 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.552 HD23 ' CD2' ' A' ' 28' ' ' LEU . 57.7 tp -77.45 155.09 31.98 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.708 -1.466 . . . . 0.0 111.111 -173.839 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.454 ' C ' HD11 ' A' ' 54' ' ' ILE . 20.0 pt-20 -153.57 167.84 28.18 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.531 -0.731 . . . . 0.0 109.644 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.842 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -67.8 154.5 41.39 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.876 -1.14 . . . . 0.0 110.111 178.142 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.59 0.3 58.2 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -174.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.671 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -79.99 160.22 25.98 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.173 -1.193 . . . . 0.0 109.041 174.407 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.888 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 1.6 p -103.33 118.87 37.74 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 118.294 -1.362 . . . . 0.0 109.692 175.081 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.622 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.6 t -101.67 125.87 55.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 175.188 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -87.89 118.58 27.52 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 119.269 -0.972 . . . . 0.0 109.154 174.509 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.877 ' CD2' HG21 ' A' ' 82' ' ' VAL . 0.7 OUTLIER -91.43 106.08 18.24 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 176.378 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.564 HD22 ' HB2' ' B' ' 47' ' ' CYS . 0.8 OUTLIER 55.44 13.41 0.92 Allowed 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.452 -0.78 . . . . 0.0 111.257 -168.938 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.493 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.56 -6.25 10.63 Favored Glycine 0 N--CA 1.49 2.243 0 C-N-CA 119.459 -1.353 . . . . 0.0 110.999 171.25 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.816 ' O ' HD23 ' A' ' 49' ' ' LEU . 32.6 t -89.7 107.58 19.18 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.51 -1.583 . . . . 0.0 109.457 175.582 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.44 ' SG ' ' O ' ' B' ' 3' ' ' THR . 26.7 p -74.07 123.44 24.39 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.122 -0.986 . . . . 0.0 110.531 -174.13 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.829 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -138.96 156.53 47.17 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.405 -0.809 . . . . 0.0 109.411 175.196 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.442 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 26.8 m -94.76 156.42 16.39 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 120.489 -1.382 . . . . 0.0 111.315 -169.184 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.783 HG13 HG13 ' A' ' 59' ' ' VAL . 16.8 t -82.24 116.06 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.859 -0.525 . . . . 0.0 110.332 -178.055 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.575 HG22 ' HB3' ' A' ' 62' ' ' ASP . 59.8 p -69.85 -40.03 76.04 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.177 -0.952 . . . . 0.0 109.453 172.561 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.584 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 51.8 tp10 -162.55 156.29 20.69 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.221 -0.992 . . . . 0.0 110.839 -177.647 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.842 HD11 ' N ' ' A' ' 38' ' ' THR . 7.5 mt -109.98 130.03 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.087 -1.008 . . . . 0.0 109.545 170.699 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.515 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 14.1 m120 -104.2 62.94 0.74 Allowed 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.603 -0.686 . . . . 0.0 109.493 178.632 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.49 -114.77 4.1 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.809 -1.717 . . . . 0.0 108.809 -172.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.591 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -80.08 -19.72 46.81 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.042 -1.27 . . . . 0.0 109.038 175.967 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.143 ' CE1' HG11 ' A' ' 13' ' ' VAL . 23.7 m-70 -76.91 159.14 30.24 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.279 -0.888 . . . . 0.0 110.233 -177.73 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.783 HG13 HG13 ' A' ' 51' ' ' VAL . 54.0 t -140.42 120.34 12.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.027 -1.046 . . . . 0.0 110.948 173.403 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.725 ' OG ' HG22 ' A' ' 25' ' ' VAL . 21.3 m -86.02 128.72 34.92 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.57 -0.706 . . . . 0.0 109.729 177.257 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.829 ' HB3' HD12 ' A' ' 49' ' ' LEU . 60.2 m-85 -111.37 160.02 17.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.907 -1.12 . . . . 0.0 110.341 178.808 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.575 ' HB3' HG22 ' A' ' 52' ' ' THR . 31.8 p-10 -93.36 146.89 23.4 Favored 'General case' 0 N--CA 1.497 1.917 0 CA-C-O 122.099 0.952 . . . . 0.0 111.436 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.761 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -157.39 113.37 2.88 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.459 -176.967 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.505 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 57.0 ttm -69.27 142.39 54.15 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.847 -1.158 . . . . 0.0 109.572 179.116 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 47.6 tptt -60.05 -46.13 90.57 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.013 -1.054 . . . . 0.0 110.284 -175.732 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 87.8 tt0 -69.73 -40.09 76.43 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.92 -1.113 . . . . 0.0 110.201 179.358 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.505 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 86.5 m -60.29 -38.34 83.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.931 -1.106 . . . . 0.0 109.228 172.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.715 ' CD1' HD22 ' A' ' 63' ' ' LEU . 11.0 tp -60.05 -44.0 94.99 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.368 -0.832 . . . . 0.0 109.375 -179.618 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -68.11 -39.82 82.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.346 -0.846 . . . . 0.0 110.695 174.336 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.755 HG22 HG23 ' A' ' 71' ' ' THR . 1.4 tt -66.3 -41.64 89.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.275 -0.891 . . . . 0.0 109.626 -175.063 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.755 HG23 HG22 ' A' ' 70' ' ' ILE . 50.7 p -83.53 -168.58 2.17 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.709 -0.62 . . . . 0.0 109.606 177.679 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.496 ' CB ' ' H ' ' B' ' 83' ' ' ASN . 7.1 t30 -104.92 19.6 20.28 Favored 'General case' 0 C--N 1.293 -1.87 0 O-C-N 121.245 -0.909 . . . . 0.0 108.559 168.054 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.761 ' HB3' HD21 ' A' ' 63' ' ' LEU . 81.8 mt -69.98 -40.06 75.55 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.092 -1.005 . . . . 0.0 109.997 175.779 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.625 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -47.14 -22.68 1.43 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 178.208 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 22.2 p-10 -62.62 -16.25 55.69 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.959 -1.318 . . . . 0.0 110.391 -175.958 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.518 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 84.4 mt -63.07 146.21 53.75 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.252 -0.905 . . . . 0.0 111.037 -175.129 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 1.029 ' C ' HD23 ' A' ' 12' ' ' LEU . 96.6 mttt -149.21 138.17 21.29 Favored 'General case' 0 N--CA 1.493 1.698 0 CA-C-O 121.461 0.648 . . . . 0.0 109.684 174.182 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.72 HG23 HD11 ' A' ' 15' ' ' ILE . 17.5 t -61.52 151.86 6.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.843 -1.161 . . . . 0.0 110.51 -175.112 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.03 -14.51 60.38 Favored Glycine 0 N--CA 1.484 1.835 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 -175.279 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.428 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 25.7 t0 -97.82 168.4 10.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.267 -1.137 . . . . 0.0 109.625 176.22 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.577 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.2 m95 -116.64 169.12 9.59 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.079 -1.013 . . . . 0.0 110.045 177.112 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.016 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.5 p -136.34 147.98 27.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.329 -0.857 . . . . 0.0 109.965 -177.148 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.976 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.9 m-20 -73.11 104.36 4.16 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.078 -1.014 . . . . 0.0 109.197 170.06 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.832 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -107.96 140.26 27.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 120.786 -1.197 . . . . 0.0 111.183 -176.841 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.421 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.5 tt0 -142.19 140.83 32.49 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.783 -0.573 . . . . 0.0 110.235 -176.733 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 95.2 mtt180 -60.19 131.62 51.39 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.045 -1.035 . . . . 0.0 109.777 178.648 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.888 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . -126.02 148.87 49.19 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.238 -0.914 . . . . 0.0 109.984 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.55 ' O ' ' CD1' ' B' ' 2' ' ' PHE . . . -147.13 156.36 42.93 Favored 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 120.005 -0.678 . . . . 0.0 110.883 -177.025 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.509 ' HA ' ' CD1' ' B' ' 2' ' ' PHE . 35.1 mttt -60.01 -40.0 87.73 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.559 -0.713 . . . . 0.0 110.139 175.597 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -129.8 160.96 31.88 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.326 -0.859 . . . . 0.0 110.138 -177.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 77.3 p -59.72 139.15 57.48 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.24 -0.912 . . . . 0.0 110.718 -174.216 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.528 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 95.6 m-20 -106.31 -6.9 18.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.466 -0.772 . . . . 0.0 110.088 176.143 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.528 ' CG ' ' O ' ' A' ' 92' ' ' ASP . 17.0 pt-20 38.92 52.85 1.99 Allowed 'General case' 0 N--CA 1.509 2.498 0 O-C-N 121.603 -0.685 . . . . 0.0 110.893 176.858 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 42.2 mm -59.98 -48.91 85.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.007 -1.058 . . . . 0.0 109.74 172.375 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 91.96 -48.96 2.75 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 177.166 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 154.65 -176.08 32.54 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.302 -1.117 . . . . 0.0 110.223 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 28.3 ptm . . . . . 0 N--CA 1.491 1.618 0 CA-C-O 121.178 0.513 . . . . 0.0 110.218 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.749 ' HE2' ' HB1' ' A' ' 87' ' ' ALA . 0.8 OUTLIER -166.07 137.78 3.79 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.187 -0.946 . . . . 0.0 109.145 175.935 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.519 ' O ' HG13 ' B' ' 5' ' ' ILE . 25.8 p -133.53 -31.95 1.18 Allowed 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.039 -1.038 . . . . 0.0 110.194 -174.111 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' B' ' 3' ' ' THR . . . 45.97 24.97 1.52 Allowed Glycine 0 N--CA 1.488 2.13 0 N-CA-C 109.038 -1.625 . . . . 0.0 109.038 -174.664 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 0.843 HD11 ' C8M' ' A' ' 98' ' ' RBF . 57.5 mt -83.93 140.0 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.11 -1.23 . . . . 0.0 110.597 -177.306 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.965 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.5 t -94.35 138.71 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.402 -0.812 . . . . 0.0 110.336 -176.19 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -70.07 -33.5 72.01 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.525 -0.734 . . . . 0.0 111.096 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.531 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -155.79 172.71 33.84 Favored Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.029 -1.558 . . . . 0.0 110.025 -173.684 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.489 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 0.6 OUTLIER -115.18 168.67 9.74 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.203 -1.175 . . . . 0.0 110.537 -179.499 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.059 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -135.47 148.03 49.09 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.535 -0.728 . . . . 0.0 109.426 -179.245 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.573 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 29.1 tttt -106.13 115.92 31.05 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.163 -0.961 . . . . 0.0 110.191 178.876 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 1.028 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.1 tp -59.81 128.07 35.11 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.002 -1.061 . . . . 0.0 108.701 172.843 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.135 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.5 p -128.08 -31.68 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 C-N-CA 119.586 -0.845 . . . . 0.0 110.141 -177.745 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.74 144.65 30.47 Favored 'General case' 0 N--CA 1.493 1.687 0 C-N-CA 119.069 -1.052 . . . . 0.0 111.44 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.765 HG23 ' CD2' ' B' ' 24' ' ' HIS . 12.3 mt -109.27 133.03 55.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.19 -0.944 . . . . 0.0 110.479 173.125 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.513 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 79.6 m-20 -110.29 116.34 31.29 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.36 -0.837 . . . . 0.0 109.901 173.18 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -106.57 114.48 28.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.935 -1.103 . . . . 0.0 110.62 -178.269 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.453 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.7 mtmt -110.71 132.92 21.35 Favored Pre-proline 0 N--CA 1.493 1.719 0 O-C-N 121.297 -0.877 . . . . 0.0 109.192 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -50.19 -34.53 39.83 Favored 'Trans proline' 0 C--N 1.301 -1.927 0 O-C-N 123.8 1.421 . . . . 0.0 110.703 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.467 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 12.4 m-80 -74.5 -40.13 61.99 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.129 -0.982 . . . . 0.0 109.973 177.259 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.467 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 96.2 m-85 -153.89 150.2 28.13 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.371 -0.831 . . . . 0.0 110.182 -178.428 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.488 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 59.5 ttt180 -91.65 146.22 23.96 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.899 -1.125 . . . . 0.0 110.159 176.595 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.513 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 91.2 m -129.93 140.0 51.02 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.416 -0.802 . . . . 0.0 110.023 -175.717 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.765 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -129.03 136.56 50.46 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.998 -1.064 . . . . 0.0 111.16 177.603 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.733 HG22 ' OG ' ' B' ' 60' ' ' SER . 5.7 t -115.76 132.49 65.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.185 -0.947 . . . . 0.0 110.755 -177.373 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.732 HG11 ' HE1' ' B' ' 44' ' ' HIS . 13.0 m -116.3 170.31 6.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.025 179.839 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.492 ' HG2' HD22 ' B' ' 57' ' ' ASN . 2.7 tm-20 -101.57 117.81 35.68 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 121.298 -0.876 . . . . 0.0 109.244 179.071 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.602 HD23 ' HA ' ' B' ' 33' ' ' LEU . 9.3 tp -82.65 127.28 70.9 Favored Pre-proline 0 C--N 1.299 -1.623 0 O-C-N 121.435 -0.791 . . . . 0.0 110.115 -174.958 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.464 ' HD2' ' HB2' ' B' ' 32' ' ' MET . 24.9 Cg_endo -66.55 -178.53 1.23 Allowed 'Trans proline' 0 C--N 1.307 -1.658 0 O-C-N 123.932 1.491 . . . . 0.0 110.917 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.49 ' OD1' ' N ' ' B' ' 30' ' ' ASP . 22.7 p-10 -65.56 -40.01 92.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.335 -0.853 . . . . 0.0 111.089 -177.271 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.592 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.02 0.38 57.14 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.913 -1.117 . . . . 0.0 110.983 -174.641 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.592 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.8 mmm -110.15 -15.98 13.88 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.978 -1.076 . . . . 0.0 109.756 171.593 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.604 HD21 ' HB2' ' B' ' 57' ' ' ASN . 13.5 mt -66.09 -32.08 73.33 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.462 -0.774 . . . . 0.0 110.453 178.071 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 34' ' ' ASP . . . . . 0.426 ' OD1' ' N ' ' B' ' 35' ' ' GLY . 63.7 t0 -80.2 142.93 34.23 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.282 -0.887 . . . . 0.0 110.894 -176.741 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 35' ' ' GLY . . . . . 0.426 ' N ' ' OD1' ' B' ' 34' ' ' ASP . . . 85.9 -31.91 3.88 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 119.92 -1.133 . . . . 0.0 111.092 170.726 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.55 HD23 ' CD2' ' B' ' 28' ' ' LEU . 57.8 tp -77.39 155.12 32.08 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.669 -1.489 . . . . 0.0 111.131 -173.824 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 37' ' ' GLU . . . . . 0.478 ' C ' HD11 ' B' ' 54' ' ' ILE . 20.0 pt-20 -153.57 167.92 27.89 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.558 -0.714 . . . . 0.0 109.665 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.849 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -67.96 154.51 41.46 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.953 -1.092 . . . . 0.0 110.157 178.15 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.65 0.31 58.52 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -174.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.674 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -80.07 159.96 25.96 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.202 -1.175 . . . . 0.0 109.074 174.271 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.913 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 1.6 p -102.86 118.83 37.7 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.559 -1.338 . . . . 0.0 109.818 175.076 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.696 HG12 ' CD2' ' B' ' 44' ' ' HIS . 1.6 t -101.88 125.98 55.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 175.198 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -87.99 118.62 27.67 Favored 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.196 -1.002 . . . . 0.0 109.155 174.532 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.732 ' HE1' HG11 ' B' ' 26' ' ' VAL . 3.7 m170 -91.39 105.9 18.11 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 176.374 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.529 HD22 ' HB2' ' A' ' 47' ' ' CYS . 0.8 OUTLIER 55.49 13.57 0.98 Allowed 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.423 -0.798 . . . . 0.0 111.266 -169.023 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.493 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.47 -6.1 10.73 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 119.379 -1.391 . . . . 0.0 110.961 171.081 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.819 ' O ' HD23 ' B' ' 49' ' ' LEU . 33.0 t -89.82 107.54 19.16 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.549 -1.559 . . . . 0.0 109.413 175.577 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 48' ' ' CYS . . . . . 0.457 ' SG ' ' O ' ' A' ' 3' ' ' THR . 26.5 p -74.04 123.68 24.82 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.14 -0.975 . . . . 0.0 110.452 -174.129 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 0.838 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -139.15 156.54 47.05 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.42 -0.8 . . . . 0.0 109.344 175.141 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 50' ' ' THR . . . . . 0.446 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 26.8 m -94.63 156.44 16.42 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 120.608 -1.308 . . . . 0.0 111.266 -169.107 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.796 HG13 HG13 ' B' ' 59' ' ' VAL . 17.0 t -82.35 116.1 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.831 -0.543 . . . . 0.0 110.389 -178.151 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.566 HG22 ' HB3' ' B' ' 62' ' ' ASP . 60.1 p -69.85 -40.06 76.02 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.133 -0.98 . . . . 0.0 109.458 172.631 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.58 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 51.8 tp10 -162.58 156.25 20.58 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.384 -0.926 . . . . 0.0 110.827 -177.589 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.849 HD11 ' N ' ' B' ' 38' ' ' THR . 7.5 mt -110.0 129.98 63.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.14 -0.975 . . . . 0.0 109.535 170.789 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.529 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 14.1 m120 -104.2 62.85 0.74 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.624 -0.673 . . . . 0.0 109.539 178.672 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.6 -114.74 4.08 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 -172.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.604 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -80.06 -19.76 46.79 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.948 -1.325 . . . . 0.0 109.102 175.947 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.135 ' CE1' HG11 ' B' ' 13' ' ' VAL . 23.8 m-70 -76.91 158.97 30.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.337 -0.852 . . . . 0.0 110.263 -177.784 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.796 HG13 HG13 ' B' ' 51' ' ' VAL . 53.9 t -140.35 120.36 13.02 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 C-N-CA 119.104 -1.038 . . . . 0.0 110.921 173.542 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.733 ' OG ' HG22 ' B' ' 25' ' ' VAL . 21.8 m -85.99 128.83 34.93 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.648 -0.658 . . . . 0.0 109.751 177.293 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.838 ' HB3' HD12 ' B' ' 49' ' ' LEU . 60.4 m-85 -111.45 160.05 17.49 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.931 -1.106 . . . . 0.0 110.343 178.77 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.566 ' HB3' HG22 ' B' ' 52' ' ' THR . 31.6 p-10 -93.44 146.89 23.43 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.08 -1.012 . . . . 0.0 111.317 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.748 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -157.37 113.44 2.89 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 -177.033 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.514 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 56.9 ttm -69.25 142.37 54.19 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.877 -1.139 . . . . 0.0 109.61 179.012 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 47.6 tptt -59.91 -46.19 90.13 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.107 -0.995 . . . . 0.0 110.341 -175.771 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 87.8 tt0 -69.81 -40.04 76.18 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.971 -1.08 . . . . 0.0 110.123 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.514 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 87.1 m -60.29 -38.46 83.66 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.915 -1.115 . . . . 0.0 109.191 173.026 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.719 ' CD1' HD22 ' B' ' 63' ' ' LEU . 11.1 tp -60.04 -43.71 95.15 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.52 -0.738 . . . . 0.0 109.45 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -68.31 -39.81 81.91 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.304 -0.872 . . . . 0.0 110.598 174.314 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.743 HG22 HG23 ' B' ' 71' ' ' THR . 1.4 tt -66.38 -41.56 89.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.571 -174.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.743 HG23 HG22 ' B' ' 70' ' ' ILE . 51.3 p -83.51 -168.5 2.13 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.113 -0.635 . . . . 0.0 109.634 177.703 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.485 ' CB ' ' H ' ' A' ' 83' ' ' ASN . 7.2 t30 -104.93 19.59 20.29 Favored 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 168.042 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.748 ' HB3' HD21 ' B' ' 63' ' ' LEU . 81.5 mt -69.96 -40.07 75.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.005 -1.059 . . . . 0.0 109.931 175.817 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.61 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -47.28 -22.58 1.52 Allowed Glycine 0 N--CA 1.487 2.051 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 178.354 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 22.3 p-10 -62.64 -16.24 55.82 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.045 -1.268 . . . . 0.0 110.349 -175.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.516 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 84.2 mt -63.22 146.14 54.02 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.309 -0.87 . . . . 0.0 111.046 -175.085 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 1.028 ' C ' HD23 ' B' ' 12' ' ' LEU . 96.6 mttt -149.03 138.34 21.61 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.781 -0.575 . . . . 0.0 109.647 174.172 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.716 HG21 HG13 ' B' ' 15' ' ' ILE . 17.3 t -61.56 151.92 6.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.051 -1.031 . . . . 0.0 110.479 -175.127 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.89 -14.24 60.86 Favored Glycine 0 N--CA 1.483 1.777 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 -175.383 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 25.5 t0 -97.89 168.41 10.32 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.413 -1.051 . . . . 0.0 109.645 176.056 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.573 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.3 m95 -116.64 168.91 9.76 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.973 -1.079 . . . . 0.0 110.144 177.119 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.059 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.5 p -136.25 148.06 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.494 -0.754 . . . . 0.0 110.006 -177.295 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.965 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.8 m-20 -73.08 104.2 4.09 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.082 -1.011 . . . . 0.0 109.243 170.106 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.814 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -107.81 140.6 25.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 120.843 -1.161 . . . . 0.0 110.99 -176.664 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' B' B ' 85' ' ' GLU . . . . . 0.411 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.5 tt0 -142.49 140.81 32.0 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.762 -0.586 . . . . 0.0 110.183 -176.788 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 95.3 mtt180 -60.29 131.69 51.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.113 -0.992 . . . . 0.0 109.77 178.681 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 0.913 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . -126.0 149.09 49.07 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.331 -0.856 . . . . 0.0 110.114 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 88' ' ' ALA . . . . . 0.584 ' O ' ' CD1' ' A' ' 2' ' ' PHE . . . -147.5 156.08 42.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.513 -0.742 . . . . 0.0 110.79 -176.66 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 89' ' ' LYS . . . . . 0.537 ' HA ' ' CD1' ' A' ' 2' ' ' PHE . 35.1 mttt -59.96 -40.03 87.65 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.614 -0.679 . . . . 0.0 110.185 175.64 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -129.74 160.93 31.88 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.26 -0.9 . . . . 0.0 110.087 -177.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 91' ' ' SER . . . . . 0.897 ' OG ' HD11 ' B' ' 94' ' ' ILE . 77.3 p -59.72 139.28 57.38 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.19 -0.943 . . . . 0.0 110.672 -174.247 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -106.53 -11.92 15.76 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.347 -0.845 . . . . 0.0 110.084 176.215 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -113.93 54.11 0.76 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.242 -0.911 . . . . 0.0 110.135 -178.016 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 94' ' ' ILE . . . . . 0.897 HD11 ' OG ' ' B' ' 91' ' ' SER . 23.0 mm -60.03 -39.97 81.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.338 -0.851 . . . . 0.0 110.078 178.311 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 49.8 70.85 0.71 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 -176.293 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . 160.39 -179.97 35.56 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 -179.151 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 38.5 m-70 . . . . . 0 N--CA 1.493 1.68 0 O-C-N 121.214 -1.168 . . . . 0.0 110.249 179.603 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 0.843 ' C8M' HD11 ' B' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 0.872 ' C8M' HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.457 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 25.0 ptp . . . . . 0 N--CA 1.494 1.728 0 CA-C-O 121.227 0.537 . . . . 0.0 110.29 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.937 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 5.6 p90 -179.33 138.73 0.14 Allowed 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 179.091 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.482 ' HB ' ' CD1' ' A' ' 5' ' ' ILE . 20.8 p -125.76 -36.61 2.39 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 120.838 -1.164 . . . . 0.0 110.234 -173.617 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.493 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 57.6 17.7 27.86 Favored Glycine 0 N--CA 1.486 2.011 0 N-CA-C 108.849 -1.7 . . . . 0.0 108.849 -177.155 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 1.026 HD11 HC81 ' B' ' 99' ' ' RBF . 26.5 mt -88.6 117.04 31.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.289 -1.124 . . . . 0.0 109.533 -177.376 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.98 HG21 ' HB3' ' A' ' 83' ' ' ASN . 3.7 t -86.94 144.05 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.116 -0.99 . . . . 0.0 110.817 -172.793 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 94.3 mm-40 -69.94 -33.2 71.81 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.603 -0.686 . . . . 0.0 110.556 175.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -168.87 174.52 43.45 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.104 -1.522 . . . . 0.0 109.87 -176.58 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.493 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 41.5 p -114.58 170.01 8.63 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.065 -1.256 . . . . 0.0 110.772 -177.598 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.033 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -135.53 149.93 49.6 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.572 -0.705 . . . . 0.0 109.577 -175.721 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.585 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.0 tttt -105.71 116.77 32.51 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.142 -0.974 . . . . 0.0 110.337 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 1.013 HD23 ' C ' ' A' ' 77' ' ' LYS . 11.5 tp -60.02 127.12 30.33 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 120.898 -1.126 . . . . 0.0 108.825 172.383 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.078 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.4 p -125.57 -31.45 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.876 0 O-C-N 121.405 -0.81 . . . . 0.0 109.983 -179.495 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.2 144.6 29.04 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.027 -1.069 . . . . 0.0 111.237 -179.243 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.776 HG23 ' CD2' ' A' ' 24' ' ' HIS . 13.4 mt -108.53 135.64 46.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.162 -0.961 . . . . 0.0 110.032 172.027 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.514 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 84.0 m-20 -109.35 114.88 28.93 Favored 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.289 -0.882 . . . . 0.0 109.867 174.732 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -105.67 114.25 28.3 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.994 -1.067 . . . . 0.0 110.587 -175.376 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.1 mtmt -111.46 127.78 26.37 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.18 -0.95 . . . . 0.0 108.993 174.285 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -50.99 -24.06 13.31 Favored 'Trans proline' 0 C--N 1.303 -1.859 0 O-C-N 123.824 1.434 . . . . 0.0 110.254 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.543 ' C ' ' CD2' ' A' ' 21' ' ' PHE . 11.4 m-80 -80.15 -42.5 23.33 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.251 -0.905 . . . . 0.0 109.985 175.243 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.543 ' CD2' ' C ' ' A' ' 20' ' ' ASN . 97.5 m-85 -153.97 150.32 28.18 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.4 -0.812 . . . . 0.0 109.977 -178.869 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.68 ' HD3' HD22 ' A' ' 68' ' ' LEU . 62.0 ttt180 -90.58 145.29 24.98 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.878 -1.139 . . . . 0.0 110.167 178.581 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.514 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 87.4 m -131.75 141.75 49.6 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.511 -0.743 . . . . 0.0 109.846 -175.409 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.776 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -131.03 143.91 51.07 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 120.97 -1.081 . . . . 0.0 111.475 -179.466 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.848 HG22 ' CB ' ' A' ' 60' ' ' SER . 6.6 t -125.34 133.94 68.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.128 -0.982 . . . . 0.0 110.975 -178.309 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.733 HG13 ' HE1' ' A' ' 61' ' ' PHE . 29.5 m -116.88 174.59 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 CA-C-O 121.24 0.543 . . . . 0.0 110.319 178.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.58 ' HG3' HD22 ' A' ' 57' ' ' ASN . 11.8 tt0 -104.59 118.46 36.65 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 177.7 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.831 HD13 ' HD2' ' A' ' 29' ' ' PRO 0.266 0.2 OUTLIER -87.32 123.08 70.41 Favored Pre-proline 0 C--N 1.297 -1.704 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -172.649 . . . . . . . . 4 4 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.831 ' HD2' HD13 ' A' ' 28' ' ' LEU . 17.8 Cg_endo -66.29 172.81 8.34 Favored 'Trans proline' 0 C--N 1.309 -1.51 0 O-C-N 123.551 1.29 . . . . 0.0 111.094 -178.266 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.509 ' HA ' HD12 ' A' ' 33' ' ' LEU . 96.0 m-20 -59.99 -40.05 87.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.568 -0.708 . . . . 0.0 111.196 -174.671 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.536 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.02 -0.0 57.35 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.672 -1.267 . . . . 0.0 110.659 -171.479 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.671 ' HB3' HD11 ' A' ' 28' ' ' LEU . 97.8 mmm -113.52 -14.87 12.65 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.908 -1.12 . . . . 0.0 109.715 169.128 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.532 ' N ' HD12 ' A' ' 28' ' ' LEU . 14.0 mt -62.32 -40.02 94.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.087 -1.008 . . . . 0.0 109.59 176.585 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -69.93 129.95 40.9 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.469 -0.769 . . . . 0.0 110.278 178.036 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.0 -44.25 1.66 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 176.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.796 ' CD2' HG21 ' A' ' 59' ' ' VAL . 66.0 tp -63.61 145.13 56.29 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.05 -1.265 . . . . 0.0 110.946 -176.442 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 21.6 pt-20 -153.09 160.02 42.87 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.507 -0.745 . . . . 0.0 109.316 175.755 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.738 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -62.81 148.76 45.98 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.93 -1.107 . . . . 0.0 110.058 -179.296 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.52 -6.45 68.94 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 -175.035 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 50' ' ' THR . . . -72.86 155.73 39.61 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.178 -1.189 . . . . 0.0 109.543 176.479 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.788 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -100.03 99.75 10.53 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 119.05 -1.06 . . . . 0.0 109.698 176.762 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.686 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.2 t -85.58 131.74 33.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.347 -0.846 . . . . 0.0 109.355 176.229 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.507 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -95.03 119.98 34.47 Favored 'General case' 0 C--N 1.294 -1.83 0 O-C-N 121.059 -1.025 . . . . 0.0 109.272 170.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.686 ' HE1' HG11 ' A' ' 42' ' ' VAL . 0.3 OUTLIER -89.51 108.2 19.52 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 176.579 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.697 HD22 ' HB2' ' B' ' 47' ' ' CYS . 0.9 OUTLIER 51.83 16.34 0.49 Allowed 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.235 -0.916 . . . . 0.0 111.056 -168.218 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.491 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 117.09 -1.53 19.33 Favored Glycine 0 N--CA 1.49 2.235 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.915 172.356 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.79 ' O ' HD23 ' A' ' 49' ' ' LEU . 18.9 t -93.84 107.13 19.05 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.505 -1.585 . . . . 0.0 109.304 174.621 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.437 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 32.1 p -75.19 130.01 38.45 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.003 -1.061 . . . . 0.0 111.019 -171.584 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.914 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -144.75 161.22 39.77 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.526 -0.734 . . . . 0.0 109.524 174.518 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.461 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 10.7 m -100.22 149.97 23.02 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.757 -1.214 . . . . 0.0 111.043 -171.012 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.813 HG13 HG13 ' A' ' 59' ' ' VAL . 36.7 t -80.03 115.33 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.773 -0.579 . . . . 0.0 110.432 -178.89 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.556 HG22 ' HB3' ' A' ' 62' ' ' ASP . 30.5 p -70.09 -39.99 75.22 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.175 -0.953 . . . . 0.0 109.871 175.378 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.652 ' HA ' HG21 ' A' ' 38' ' ' THR . 87.7 tt0 -161.3 154.2 20.88 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.262 -0.899 . . . . 0.0 110.333 179.059 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.738 HD11 ' N ' ' A' ' 38' ' ' THR . 5.8 mt -102.48 132.73 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.983 -1.073 . . . . 0.0 109.909 174.472 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.523 ' CB ' ' HB2' ' A' ' 58' ' ' HIS . 2.5 m-80 -103.89 65.25 0.81 Allowed 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.569 -0.707 . . . . 0.0 109.869 179.334 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.94 -118.55 5.69 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 108.719 -1.752 . . . . 0.0 108.719 -173.091 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.58 HD22 ' HG3' ' A' ' 27' ' ' GLU . 0.1 OUTLIER -75.02 -21.46 59.07 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 120.903 -1.351 . . . . 0.0 108.764 173.818 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.078 ' CE1' HG11 ' A' ' 13' ' ' VAL . 30.4 m-70 -72.89 159.96 32.9 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.242 -0.912 . . . . 0.0 110.17 -177.37 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.813 HG13 HG13 ' A' ' 51' ' ' VAL . 52.8 t -140.1 125.57 20.72 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 O-C-N 121.04 -1.037 . . . . 0.0 110.662 171.536 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.848 ' CB ' HG22 ' A' ' 25' ' ' VAL . 54.3 p -96.09 125.82 40.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.723 -0.611 . . . . 0.0 109.742 179.641 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.914 ' HB2' HD12 ' A' ' 49' ' ' LEU . 4.3 p90 -118.45 155.26 31.08 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.016 -1.052 . . . . 0.0 110.296 179.806 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.556 ' HB3' HG22 ' A' ' 52' ' ' THR . 35.1 p-10 -87.87 152.81 21.81 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.075 -1.016 . . . . 0.0 111.244 -173.229 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.75 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -157.96 114.36 2.84 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 -176.518 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.511 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 57.6 ttm -71.92 142.33 49.48 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.009 -1.057 . . . . 0.0 109.624 -178.84 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.471 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 71.3 tttt -59.98 -50.01 75.41 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.075 -1.016 . . . . 0.0 110.505 -175.285 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -65.58 -39.96 92.2 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.996 -1.065 . . . . 0.0 109.914 178.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.511 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 93.0 m -61.11 -40.04 92.27 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.978 -1.076 . . . . 0.0 109.289 174.05 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.68 HD22 ' HD3' ' A' ' 22' ' ' ARG . 18.0 tp -59.95 -43.01 95.28 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.319 -0.863 . . . . 0.0 109.466 178.368 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -67.64 -39.98 84.59 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.554 -0.716 . . . . 0.0 110.138 176.588 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.719 HG22 HG23 ' A' ' 71' ' ' THR . 1.2 tt -68.23 -40.02 82.04 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.357 -0.84 . . . . 0.0 109.301 -177.055 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.719 HG23 HG22 ' A' ' 70' ' ' ILE . 60.1 p -84.61 -172.73 4.33 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 120.261 -0.576 . . . . 0.0 109.483 177.779 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.478 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 5.9 t30 -102.32 22.45 13.33 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 169.527 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.75 ' HB3' HD21 ' A' ' 63' ' ' LEU . 88.2 mt -70.02 -39.92 75.51 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.01 -1.056 . . . . 0.0 109.757 174.794 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.449 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -44.56 -23.96 0.6 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.396 -1.082 . . . . 0.0 110.396 178.684 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 23.0 p-10 -69.97 -19.16 63.36 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.913 -1.346 . . . . 0.0 110.603 -174.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.519 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 98.4 mt -59.92 140.41 56.7 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.085 -1.01 . . . . 0.0 110.714 -176.682 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 1.013 ' C ' HD23 ' A' ' 12' ' ' LEU . 92.3 mttt -143.6 138.97 29.43 Favored 'General case' 0 C--N 1.297 -1.712 0 CA-C-O 121.427 0.632 . . . . 0.0 109.83 177.301 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.68 ' N ' HD23 ' A' ' 12' ' ' LEU . 16.4 t -60.33 152.2 5.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 120.983 -1.073 . . . . 0.0 110.48 -175.863 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.37 -14.46 59.43 Favored Glycine 0 N--CA 1.483 1.776 0 N-CA-C 108.906 -1.678 . . . . 0.0 108.906 -176.108 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 49.6 t0 -96.27 166.37 11.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.33 -1.1 . . . . 0.0 109.627 176.569 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.585 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.1 m95 -115.43 165.99 12.37 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.963 -1.086 . . . . 0.0 110.157 175.53 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.033 HG13 ' HB3' ' A' ' 10' ' ' ALA . 0.9 OUTLIER -129.96 158.4 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.339 -0.851 . . . . 0.0 110.081 -177.532 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.98 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.1 OUTLIER -80.0 107.5 12.83 Favored 'General case' 0 C--N 1.297 -1.674 0 O-C-N 121.006 -1.058 . . . . 0.0 109.14 167.029 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.736 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -108.85 138.13 37.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 120.596 -1.315 . . . . 0.0 111.194 -176.356 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -140.92 146.51 37.5 Favored 'General case' 0 N--CA 1.492 1.661 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.043 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 58.0 ttp180 -83.21 130.02 35.06 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.027 -1.045 . . . . 0.0 111.038 -176.41 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.9 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -118.01 146.15 44.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 110.031 174.61 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -123.64 138.34 54.56 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.614 -0.679 . . . . 0.0 110.648 -176.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 9.2 mttm -60.07 -39.94 87.78 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.333 -0.854 . . . . 0.0 110.005 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -142.95 156.0 44.8 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.236 -0.915 . . . . 0.0 110.28 178.414 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 58.7 m -126.82 129.95 49.28 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 109.988 177.253 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -64.78 -45.96 84.11 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.168 -0.958 . . . . 0.0 110.496 -179.665 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -95.72 44.96 1.08 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.07 -1.018 . . . . 0.0 111.101 -171.163 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 20.4 mm -60.64 -40.98 86.4 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 O-C-N 121.268 -0.895 . . . . 0.0 110.132 170.439 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 113.72 -102.05 1.2 Allowed Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 179.279 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.557 ' O ' ' CG ' ' A' ' 97' ' ' HIS . . . 79.99 -178.92 53.58 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -177.361 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.557 ' CG ' ' O ' ' A' ' 96' ' ' GLY . 1.5 m170 . . . . . 0 N--CA 1.493 1.687 0 O-C-N 121.218 -1.166 . . . . 0.0 110.203 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 1' ' ' MET . . . . . 0.424 ' O ' ' HB3' ' B' ' 2' ' ' PHE . 57.2 ttm . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 121.282 0.563 . . . . 0.0 110.199 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.9 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 5.4 p90 -176.92 138.55 0.26 Allowed 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.236 -0.915 . . . . 0.0 108.766 176.464 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.485 ' HB ' ' CD1' ' B' ' 5' ' ' ILE . 21.0 p -125.69 -36.67 2.4 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 120.846 -1.159 . . . . 0.0 110.183 -173.594 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.486 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 57.58 17.82 28.18 Favored Glycine 0 N--CA 1.486 1.969 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 -177.116 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 0.962 HD11 HC81 ' A' ' 98' ' ' RBF . 25.9 mt -88.75 117.02 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.362 -1.081 . . . . 0.0 109.587 -177.412 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 1.004 HG21 ' HB3' ' B' ' 83' ' ' ASN . 3.7 t -86.78 144.05 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.121 -0.987 . . . . 0.0 110.856 -172.739 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 94.3 mm-40 -69.99 -32.97 71.44 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.735 -0.603 . . . . 0.0 110.635 175.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -169.13 174.4 43.61 Favored Glycine 0 N--CA 1.495 2.576 0 C-N-CA 119.175 -1.488 . . . . 0.0 109.935 -176.626 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.488 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 41.6 p -114.52 170.03 8.61 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.0 -1.294 . . . . 0.0 110.778 -177.475 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.051 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -135.61 150.04 49.54 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.614 -0.679 . . . . 0.0 109.523 -175.742 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.581 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 30.1 tttt -105.84 116.83 32.61 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.101 -0.999 . . . . 0.0 110.262 179.134 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 1.013 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.5 tp -60.0 127.13 30.36 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 120.96 -1.088 . . . . 0.0 108.9 172.334 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.062 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.4 p -125.53 -31.61 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.856 0 O-C-N 121.383 -0.823 . . . . 0.0 110.009 -179.479 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.02 144.59 29.25 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.273 -0.971 . . . . 0.0 111.351 -179.281 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.779 HG23 ' CD2' ' B' ' 24' ' ' HIS . 13.5 mt -108.58 135.67 46.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.217 -0.927 . . . . 0.0 109.994 172.058 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.526 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.6 m-20 -109.48 115.0 29.11 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 121.367 -0.833 . . . . 0.0 109.788 174.825 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -105.62 114.18 28.19 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.012 -1.055 . . . . 0.0 110.619 -175.388 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.44 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.0 OUTLIER -111.46 127.77 26.39 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.233 -0.917 . . . . 0.0 109.049 174.226 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.431 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.2 Cg_endo -51.16 -23.97 13.96 Favored 'Trans proline' 0 C--N 1.303 -1.834 0 O-C-N 123.827 1.435 . . . . 0.0 110.238 -179.727 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.54 ' C ' ' CD2' ' B' ' 21' ' ' PHE . 11.2 m-80 -79.94 -43.0 22.91 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.106 -0.996 . . . . 0.0 109.884 175.15 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.54 ' CD2' ' C ' ' B' ' 20' ' ' ASN . 97.4 m-85 -153.69 150.37 28.5 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.54 -0.725 . . . . 0.0 109.993 -178.745 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.685 ' HD3' HD22 ' B' ' 68' ' ' LEU . 62.1 ttt180 -90.54 145.2 25.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.934 -1.104 . . . . 0.0 110.108 178.65 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.526 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 87.0 m -131.63 141.84 49.72 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.541 -0.725 . . . . 0.0 109.852 -175.535 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.779 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -131.05 144.08 51.18 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 120.926 -1.109 . . . . 0.0 111.336 -179.431 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.857 HG22 ' CB ' ' B' ' 60' ' ' SER . 6.6 t -125.43 134.07 67.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.15 -0.969 . . . . 0.0 110.93 -178.271 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.749 HG13 ' HE1' ' B' ' 61' ' ' PHE . 30.3 m -117.14 174.59 3.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.812 -0.555 . . . . 0.0 110.304 179.102 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.604 ' HG3' HD22 ' B' ' 57' ' ' ASN . 12.0 tt0 -104.57 118.51 36.77 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 177.752 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.824 HD13 ' HD2' ' B' ' 29' ' ' PRO 0.266 0.2 OUTLIER -87.35 123.07 70.38 Favored Pre-proline 0 C--N 1.296 -1.728 0 O-C-N 121.403 -0.811 . . . . 0.0 108.968 -172.769 . . . . . . . . 4 4 . 1 . 004 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.824 ' HD2' HD13 ' B' ' 28' ' ' LEU . 18.1 Cg_endo -66.27 172.84 8.27 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 O-C-N 123.6 1.316 . . . . 0.0 111.114 -178.213 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.496 ' HA ' HD12 ' B' ' 33' ' ' LEU . 96.0 m-20 -60.07 -40.04 88.15 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.579 -0.701 . . . . 0.0 111.135 -174.647 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.534 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.94 -0.03 57.34 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.743 -1.223 . . . . 0.0 110.72 -171.514 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.649 ' HB3' HD11 ' B' ' 28' ' ' LEU . 98.0 mmm -113.48 -14.87 12.67 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.975 -1.078 . . . . 0.0 109.729 169.148 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.533 ' N ' HD12 ' B' ' 28' ' ' LEU . 14.0 mt -62.32 -39.93 94.66 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.071 -1.018 . . . . 0.0 109.652 176.572 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -70.02 130.07 41.16 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.486 -0.759 . . . . 0.0 110.29 177.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.88 -44.13 1.69 Allowed Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.179 -1.169 . . . . 0.0 110.179 176.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.797 ' CD2' HG21 ' B' ' 59' ' ' VAL . 66.4 tp -63.78 145.13 56.36 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.012 -1.287 . . . . 0.0 110.891 -176.441 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 37' ' ' GLU . . . . . . . . . . . . . 21.6 pt-20 -153.07 159.97 42.89 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.52 -0.737 . . . . 0.0 109.334 175.807 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.729 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -62.87 148.65 46.54 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.944 -1.098 . . . . 0.0 110.151 -179.303 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.67 -6.51 69.26 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 -174.909 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' B' ' 50' ' ' THR . . . -72.99 155.61 39.67 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.206 -1.173 . . . . 0.0 109.509 176.489 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.778 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -99.7 99.61 10.46 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 120.926 -1.109 . . . . 0.0 109.799 176.725 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.67 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.2 t -85.62 131.87 33.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.332 -0.855 . . . . 0.0 109.319 176.183 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -95.12 120.06 34.69 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.037 -1.039 . . . . 0.0 109.292 170.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.67 ' HE1' HG11 ' B' ' 42' ' ' VAL . 0.3 OUTLIER -89.58 107.97 19.39 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.32 -0.863 . . . . 0.0 108.916 176.639 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.71 HD22 ' HB2' ' A' ' 47' ' ' CYS . 0.9 OUTLIER 51.95 16.54 0.53 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.218 -0.926 . . . . 0.0 110.972 -168.204 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.493 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 116.92 -1.27 19.71 Favored Glycine 0 N--CA 1.489 2.227 0 C-N-CA 119.543 -1.313 . . . . 0.0 110.917 172.199 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.798 ' O ' HD23 ' B' ' 49' ' ' LEU . 18.9 t -93.99 107.07 19.01 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.49 -1.594 . . . . 0.0 109.316 174.56 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 48' ' ' CYS . . . . . 0.442 ' SG ' ' O ' ' A' ' 3' ' ' THR . 32.1 p -75.04 129.99 38.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.037 -1.039 . . . . 0.0 111.089 -171.626 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 0.909 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -144.81 161.19 39.89 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.526 -0.734 . . . . 0.0 109.507 174.503 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 50' ' ' THR . . . . . 0.464 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 10.5 m -100.06 150.15 22.75 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.749 -1.219 . . . . 0.0 111.069 -171.024 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.823 HG13 HG13 ' B' ' 59' ' ' VAL . 37.7 t -80.27 115.36 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.639 -0.663 . . . . 0.0 110.434 -178.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.537 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 30.5 p -70.07 -39.98 75.32 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.14 -0.975 . . . . 0.0 109.91 175.474 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.629 ' HA ' HG21 ' B' ' 38' ' ' THR . 87.7 tt0 -161.36 154.25 20.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.267 -0.895 . . . . 0.0 110.297 179.079 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.729 HD11 ' N ' ' B' ' 38' ' ' THR . 5.8 mt -102.5 132.75 47.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.11 -0.994 . . . . 0.0 109.927 174.535 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.51 ' CB ' ' HB2' ' B' ' 58' ' ' HIS . 2.5 m-80 -104.04 65.36 0.8 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.528 -0.733 . . . . 0.0 109.758 179.415 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.02 -118.48 5.64 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.655 -1.778 . . . . 0.0 108.655 -173.224 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.604 HD22 ' HG3' ' B' ' 27' ' ' GLU . 0.1 OUTLIER -75.0 -21.66 59.0 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.928 -1.336 . . . . 0.0 108.777 173.796 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.062 ' CE1' HG11 ' B' ' 13' ' ' VAL . 30.4 m-70 -72.7 159.76 33.3 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.345 -0.847 . . . . 0.0 110.192 -177.411 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.823 HG13 HG13 ' B' ' 51' ' ' VAL . 53.1 t -140.03 125.52 20.87 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.093 -1.005 . . . . 0.0 110.748 171.56 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.857 ' CB ' HG22 ' B' ' 25' ' ' VAL . 54.4 p -96.04 126.06 41.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.651 -0.656 . . . . 0.0 109.818 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.909 ' HB2' HD12 ' B' ' 49' ' ' LEU . 4.3 p90 -118.6 155.2 31.37 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.963 -1.086 . . . . 0.0 110.344 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.537 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 34.9 p-10 -87.76 152.73 21.9 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.097 -1.002 . . . . 0.0 111.305 -173.226 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.752 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -157.79 114.53 2.91 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -176.662 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.519 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 57.7 ttm -72.08 142.41 49.22 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.931 -1.105 . . . . 0.0 109.574 -178.801 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.469 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 71.2 tttt -60.11 -49.91 75.77 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.988 -1.07 . . . . 0.0 110.441 -175.117 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -65.6 -40.02 92.2 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.969 -1.082 . . . . 0.0 109.906 178.803 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.519 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 93.1 m -61.2 -39.94 92.1 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.974 -1.079 . . . . 0.0 109.219 174.13 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.685 HD22 ' HD3' ' B' ' 22' ' ' ARG . 17.9 tp -59.98 -42.95 95.3 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.439 -0.788 . . . . 0.0 109.522 178.334 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -67.52 -39.99 85.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.581 -0.7 . . . . 0.0 110.269 176.476 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.71 HG22 HG23 ' B' ' 71' ' ' THR . 1.2 tt -68.19 -40.08 82.22 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 CA-C-O 121.904 0.859 . . . . 0.0 109.295 -177.115 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.71 HG23 HG22 ' B' ' 70' ' ' ILE . 59.2 p -84.52 -172.52 4.22 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 120.083 -0.647 . . . . 0.0 109.546 177.782 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.47 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 5.8 t30 -102.42 22.56 13.23 Favored 'General case' 0 C--N 1.296 -1.754 0 O-C-N 121.218 -0.927 . . . . 0.0 108.51 169.411 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.752 ' HB3' HD21 ' B' ' 63' ' ' LEU . 88.1 mt -70.09 -39.95 75.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.013 -1.054 . . . . 0.0 109.713 174.71 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.448 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -44.56 -23.82 0.58 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 178.687 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 23.2 p-10 -70.04 -19.07 63.31 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.932 -1.334 . . . . 0.0 110.648 -175.021 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.519 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.3 mt -60.03 140.41 56.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.121 -0.987 . . . . 0.0 110.67 -176.662 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 1.013 ' C ' HD23 ' B' ' 12' ' ' LEU . 92.2 mttt -143.6 139.05 29.46 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 121.363 0.601 . . . . 0.0 109.853 177.297 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.676 ' N ' HD23 ' B' ' 12' ' ' LEU . 16.5 t -60.56 152.24 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 120.937 -1.102 . . . . 0.0 110.42 -175.764 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.29 -14.22 59.89 Favored Glycine 0 N--CA 1.485 1.932 0 N-CA-C 108.927 -1.669 . . . . 0.0 108.927 -176.067 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.508 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 49.4 t0 -96.37 166.31 11.77 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.387 -1.066 . . . . 0.0 109.572 176.469 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.581 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.1 m95 -115.38 165.93 12.43 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.03 -1.044 . . . . 0.0 110.225 175.493 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.051 HG13 ' HB3' ' B' ' 10' ' ' ALA . 0.9 OUTLIER -129.95 158.5 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.387 -0.821 . . . . 0.0 110.081 -177.628 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 1.004 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.1 OUTLIER -79.96 107.29 12.63 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 120.987 -1.07 . . . . 0.0 109.179 167.043 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.722 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -108.67 138.34 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 120.668 -1.27 . . . . 0.0 111.061 -176.196 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -141.34 146.57 36.87 Favored 'General case' 0 N--CA 1.492 1.659 0 C-N-CA 120.397 -0.521 . . . . 0.0 109.933 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 58.0 ttp180 -83.07 129.97 35.08 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.027 -1.046 . . . . 0.0 110.996 -176.288 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 0.937 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -117.97 146.29 44.1 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.258 -0.901 . . . . 0.0 110.023 174.486 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -123.78 138.37 54.52 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.499 -0.751 . . . . 0.0 110.636 -176.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 9.3 mttm -60.08 -39.94 87.86 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.392 -0.818 . . . . 0.0 110.042 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -142.96 156.06 44.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.315 -0.866 . . . . 0.0 110.246 178.365 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 91' ' ' SER . . . . . 0.806 ' OG ' HD12 ' B' ' 94' ' ' ILE . 58.8 m -126.83 129.92 49.22 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.349 -0.844 . . . . 0.0 110.011 177.215 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 92' ' ' ASP . . . . . 0.466 ' O ' ' HB3' ' B' ' 93' ' ' GLU . 54.4 t0 -64.75 -43.46 93.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.267 -0.895 . . . . 0.0 110.387 -179.651 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 93' ' ' GLU . . . . . 0.466 ' HB3' ' O ' ' B' ' 92' ' ' ASP . 7.3 pt-20 -179.58 48.58 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.69 -0.631 . . . . 0.0 109.899 -175.274 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 94' ' ' ILE . . . . . 0.806 HD12 ' OG ' ' B' ' 91' ' ' SER . 58.6 mt -70.44 -44.24 77.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.498 -0.751 . . . . 0.0 110.767 -176.129 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 95' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' B' ' 94' ' ' ILE . . . 41.34 61.55 2.06 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 -176.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -103.8 -92.7 2.25 Favored Glycine 0 N--CA 1.492 2.407 0 O-C-N 121.069 -1.254 . . . . 0.0 110.014 -176.372 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 24.1 p80 . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.192 -1.181 . . . . 0.0 110.253 -178.078 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 0.962 HC81 HD11 ' B' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 1.026 HC81 HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 95.4 mtp . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.132 0.491 . . . . 0.0 110.097 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.913 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 7.5 p90 -173.38 153.04 2.3 Favored 'General case' 0 C--N 1.307 -1.275 0 O-C-N 121.129 -0.982 . . . . 0.0 108.899 177.67 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.523 HG23 ' C ' ' A' ' 2' ' ' PHE . 20.9 p -150.49 -39.16 0.13 Allowed 'General case' 0 C--N 1.296 -1.747 0 O-C-N 120.966 -1.084 . . . . 0.0 109.017 175.579 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.46 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 48.25 24.04 3.28 Favored Glycine 0 N--CA 1.484 1.862 0 N-CA-C 108.272 -1.931 . . . . 0.0 108.272 -175.369 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.651 HD11 ' C8M' ' B' ' 99' ' ' RBF . 65.7 mt -81.49 134.45 27.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.371 -1.076 . . . . 0.0 109.857 -176.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.818 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.8 t -87.86 139.63 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.106 -0.996 . . . . 0.0 111.047 -169.791 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 30.3 mm100 -69.91 -36.25 75.23 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.716 -0.615 . . . . 0.0 110.836 178.033 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.537 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -154.36 170.78 32.84 Favored Glycine 0 N--CA 1.493 2.448 0 C-N-CA 119.156 -1.497 . . . . 0.0 109.986 -172.492 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.445 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 4.2 p -114.4 173.86 6.24 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.927 -1.337 . . . . 0.0 111.173 -175.337 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.061 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -142.2 149.8 40.16 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.676 -0.64 . . . . 0.0 109.347 -177.502 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.591 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 38.3 tttt -107.29 116.72 32.42 Favored 'General case' 0 C--N 1.295 -1.766 0 O-C-N 121.003 -1.061 . . . . 0.0 110.269 177.908 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 1.011 HD23 ' C ' ' A' ' 77' ' ' LYS . 11.9 tp -60.02 126.95 29.53 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.848 -1.157 . . . . 0.0 108.827 171.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.074 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.3 p -122.79 -31.65 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 O-C-N 121.395 -0.816 . . . . 0.0 109.881 -179.481 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.94 146.59 27.92 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 118.984 -1.086 . . . . 0.0 111.473 -179.324 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.852 HG23 ' CD2' ' A' ' 24' ' ' HIS . 7.6 mt -108.45 138.06 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.026 -1.046 . . . . 0.0 110.238 171.207 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.504 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.9 m-20 -109.22 115.72 30.55 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.196 -0.94 . . . . 0.0 109.765 171.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -104.56 112.27 25.28 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.019 -1.05 . . . . 0.0 110.379 -175.293 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.463 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 20.4 mmmt -115.64 129.27 25.28 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.17 -0.956 . . . . 0.0 109.125 177.33 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -51.03 -31.34 34.46 Favored 'Trans proline' 0 C--N 1.303 -1.841 0 O-C-N 123.775 1.408 . . . . 0.0 110.264 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 11.6 m-80 -74.42 -39.99 62.27 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.232 -0.917 . . . . 0.0 110.09 175.864 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 83.7 m-85 -156.35 150.46 25.27 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.328 -0.858 . . . . 0.0 110.308 -177.623 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.49 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 59.0 ttt180 -92.05 141.81 28.21 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.921 -1.112 . . . . 0.0 109.94 176.579 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.504 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.6 m -130.08 139.95 50.89 Favored 'General case' 0 C--N 1.294 -1.819 0 O-C-N 121.675 -0.641 . . . . 0.0 109.912 -173.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.852 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -131.12 141.41 50.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.905 -1.122 . . . . 0.0 111.068 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.763 HG22 ' CB ' ' A' ' 60' ' ' SER . 6.8 t -122.51 133.17 69.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.053 -1.03 . . . . 0.0 110.677 -178.823 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.825 HG13 ' CE1' ' A' ' 61' ' ' PHE . 30.1 m -116.19 173.33 3.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.808 -0.557 . . . . 0.0 110.22 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.626 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 8.4 tt0 -104.44 116.44 32.13 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.434 -0.791 . . . . 0.0 108.942 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.83 HD21 HD13 ' A' ' 36' ' ' LEU . 9.6 tp -83.55 124.35 75.56 Favored Pre-proline 0 C--N 1.298 -1.649 0 O-C-N 121.475 -0.766 . . . . 0.0 110.059 -173.159 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.481 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 26.2 Cg_endo -66.42 176.61 3.92 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 123.923 1.486 . . . . 0.0 111.104 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.487 ' HA ' HD12 ' A' ' 33' ' ' LEU . 47.4 t0 -60.09 -39.88 87.67 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.328 -0.858 . . . . 0.0 111.13 -175.467 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.596 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.64 0.06 57.19 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.756 -1.215 . . . . 0.0 110.576 -174.548 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.596 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.7 mmm -111.43 -14.1 13.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.037 -1.04 . . . . 0.0 109.813 170.291 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.582 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 17.5 mt -69.81 -39.97 76.21 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.271 -0.893 . . . . 0.0 110.308 177.648 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -78.06 129.37 35.15 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.919 . . . . 0.0 110.337 -178.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.88 -42.96 1.87 Allowed Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.865 -1.159 . . . . 0.0 110.374 174.883 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.83 HD13 HD21 ' A' ' 28' ' ' LEU . 7.1 tt -66.79 146.65 54.2 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.932 -1.334 . . . . 0.0 110.508 -175.012 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.689 ' N ' HD23 ' A' ' 36' ' ' LEU . 14.7 pt-20 -149.97 164.38 35.63 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.556 -0.715 . . . . 0.0 109.672 -178.73 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.803 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -66.5 150.06 49.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.99 -1.069 . . . . 0.0 109.949 179.335 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.7 -4.81 63.39 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -173.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.54 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -76.62 153.54 35.18 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.225 -1.162 . . . . 0.0 109.519 177.145 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.52 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -97.82 109.23 22.02 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 121.016 -1.052 . . . . 0.0 110.086 178.153 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.63 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.2 t -95.37 133.1 37.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.224 -0.923 . . . . 0.0 109.129 173.737 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.509 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -95.9 119.9 35.22 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.112 -0.993 . . . . 0.0 109.071 171.417 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.637 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.3 OUTLIER -88.81 104.85 17.3 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.433 -0.792 . . . . 0.0 108.884 177.636 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.5 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 54.82 12.86 0.64 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.361 -0.837 . . . . 0.0 111.258 -168.513 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.489 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.34 -1.22 11.46 Favored Glycine 0 N--CA 1.49 2.283 0 C-N-CA 119.603 -1.284 . . . . 0.0 110.769 172.804 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.839 ' O ' HD23 ' A' ' 49' ' ' LEU . 36.1 t -93.85 109.71 21.4 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 120.531 -1.57 . . . . 0.0 109.517 175.275 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.7 p -74.44 128.26 35.1 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.113 -0.992 . . . . 0.0 110.984 -171.748 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.947 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -144.3 159.18 43.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.506 -0.746 . . . . 0.0 109.421 174.177 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 65.3 m -102.34 151.26 22.46 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.718 -1.239 . . . . 0.0 111.148 -172.022 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.848 HG13 HG13 ' A' ' 59' ' ' VAL . 21.3 t -78.44 119.77 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.728 -0.608 . . . . 0.0 110.641 -177.329 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 43.2 p -73.25 -43.84 60.46 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.242 -0.911 . . . . 0.0 110.15 174.481 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.617 ' HA ' HG21 ' A' ' 38' ' ' THR . 86.4 tt0 -159.32 151.22 20.67 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.319 -0.863 . . . . 0.0 110.468 -178.244 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.803 HD11 ' N ' ' A' ' 38' ' ' THR . 6.3 mt -102.87 133.13 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.172 -0.955 . . . . 0.0 109.953 174.724 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.51 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 13.5 m120 -108.04 65.72 0.64 Allowed 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.492 -0.755 . . . . 0.0 109.703 178.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.93 -116.28 4.77 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -174.091 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.582 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -78.35 -20.89 50.38 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.02 -1.282 . . . . 0.0 109.059 175.028 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.074 ' CE1' HG11 ' A' ' 13' ' ' VAL . 24.5 m-70 -74.45 160.03 31.5 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.358 -0.839 . . . . 0.0 110.096 -177.109 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.848 HG13 HG13 ' A' ' 51' ' ' VAL . 54.9 t -140.37 122.88 16.14 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 O-C-N 121.006 -1.059 . . . . 0.0 110.808 171.117 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.763 ' CB ' HG22 ' A' ' 25' ' ' VAL . 3.0 m -89.46 128.96 36.02 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.643 -0.661 . . . . 0.0 109.586 177.162 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.947 ' HB2' HD12 ' A' ' 49' ' ' LEU . 3.1 p90 -123.23 155.5 37.01 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.026 -1.046 . . . . 0.0 110.082 178.643 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 29.6 p-10 -90.03 154.41 19.83 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.946 -1.096 . . . . 0.0 111.594 -170.377 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.801 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -158.85 123.96 4.23 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 -175.753 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.513 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 96.0 mtp -79.65 146.72 32.33 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.677 -1.264 . . . . 0.0 109.714 178.077 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.479 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 27.8 ttpt -60.01 -47.63 85.06 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.082 -1.011 . . . . 0.0 109.626 178.477 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.99 -40.03 75.55 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.214 -0.928 . . . . 0.0 110.833 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.62 ' O ' HG23 ' A' ' 71' ' ' THR . 23.6 m -65.51 -33.95 77.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.681 -1.262 . . . . 0.0 109.103 175.22 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.77 HD11 ' HA2' ' A' ' 74' ' ' GLY . 4.3 tp -60.04 -45.96 91.1 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.546 -0.721 . . . . 0.0 109.705 177.009 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 31.7 tpt180 -69.78 -40.05 76.27 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.304 -0.872 . . . . 0.0 110.54 178.477 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.805 HG22 HG23 ' A' ' 71' ' ' THR . 1.5 tt -63.94 -42.78 96.87 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 O-C-N 121.18 -0.95 . . . . 0.0 109.288 -178.681 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.805 HG23 HG22 ' A' ' 70' ' ' ILE . 20.9 p -83.59 -173.29 4.63 Favored 'General case' 0 C--N 1.298 -1.63 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 174.678 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 3.4 t30 -104.64 25.66 10.04 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 169.827 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.801 ' HB3' HD21 ' A' ' 63' ' ' LEU . 90.4 mt -68.07 -39.95 82.85 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.239 -0.913 . . . . 0.0 109.671 175.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.77 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -49.87 -23.7 5.51 Favored Glycine 0 N--CA 1.486 1.977 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.06 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 23.7 p-10 -64.52 -17.26 63.74 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.941 -1.329 . . . . 0.0 110.188 -176.202 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.518 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.7 mt -60.52 144.96 50.25 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.314 -0.866 . . . . 0.0 110.484 -178.454 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 1.011 ' C ' HD23 ' A' ' 12' ' ' LEU . 66.2 mttt -150.12 138.65 20.64 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 121.725 -0.609 . . . . 0.0 109.669 178.11 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.692 HG21 HG13 ' A' ' 15' ' ' ILE . 62.1 t -63.54 147.3 12.28 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 120.884 -1.135 . . . . 0.0 110.152 -175.516 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.98 -11.43 70.72 Favored Glycine 0 N--CA 1.483 1.805 0 N-CA-C 108.779 -1.729 . . . . 0.0 108.779 -172.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 41.7 t0 -100.88 162.25 13.03 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.392 -1.063 . . . . 0.0 109.722 176.408 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.591 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.4 m95 -114.09 159.9 19.52 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.144 -0.972 . . . . 0.0 109.976 177.268 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.061 HG13 ' HB3' ' A' ' 10' ' ' ALA . 0.9 OUTLIER -126.81 156.97 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.973 -177.516 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.818 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.4 m-20 -82.14 104.93 12.83 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.202 -0.936 . . . . 0.0 109.263 169.552 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.844 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -107.22 138.58 32.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 120.574 -1.329 . . . . 0.0 111.542 -175.564 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -131.63 147.55 52.53 Favored 'General case' 0 N--CA 1.494 1.738 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.994 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.489 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 38.2 ptt180 -87.92 131.77 34.47 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.135 -0.978 . . . . 0.0 110.627 -178.595 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.793 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -126.98 145.86 50.55 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.202 -0.936 . . . . 0.0 110.239 179.405 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -136.35 154.21 50.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.71 -0.619 . . . . 0.0 110.549 -178.098 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 28.7 mtpt -59.99 -39.99 87.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.266 -0.896 . . . . 0.0 110.301 179.033 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 42.9 p90 -132.74 161.55 33.74 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.266 -0.896 . . . . 0.0 110.221 -178.291 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 61.1 m -118.26 142.79 47.12 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.285 -0.884 . . . . 0.0 110.552 -176.568 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.455 ' O ' ' HB2' ' A' ' 93' ' ' GLU . 96.1 m-20 -61.86 -39.56 92.31 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.505 -0.747 . . . . 0.0 110.312 179.353 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.455 ' HB2' ' O ' ' A' ' 92' ' ' ASP . 96.6 mt-10 55.5 50.39 14.73 Favored 'General case' 0 N--CA 1.507 2.402 0 O-C-N 121.289 -0.882 . . . . 0.0 110.301 -179.307 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 61.1 mt -64.56 -41.15 91.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.548 -0.72 . . . . 0.0 110.254 178.391 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 127.71 -84.33 0.33 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -178.118 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 83.9 -170.45 47.7 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 177.688 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.46 ' CG ' ' OXT' ' A' ' 97' ' ' HIS . 83.2 t60 . . . . . 0 N--CA 1.492 1.653 0 O-C-N 121.305 -1.115 . . . . 0.0 110.151 -179.346 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 1' ' ' MET . . . . . 0.465 ' O ' ' HG3' ' B' ' 1' ' ' MET . 28.1 ptm . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 121.163 0.506 . . . . 0.0 110.056 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.793 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 7.8 p90 -172.79 153.03 2.59 Favored 'General case' 0 C--N 1.306 -1.291 0 O-C-N 121.211 -0.931 . . . . 0.0 108.856 177.588 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.515 ' HB ' ' CD1' ' B' ' 5' ' ' ILE . 20.7 p -150.46 -39.08 0.13 Allowed 'General case' 0 C--N 1.296 -1.747 0 O-C-N 120.916 -1.115 . . . . 0.0 109.133 175.472 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.444 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 48.45 23.8 3.35 Favored Glycine 0 N--CA 1.484 1.878 0 N-CA-C 108.278 -1.929 . . . . 0.0 108.278 -175.487 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 0.548 HD11 ' C8M' ' A' ' 98' ' ' RBF . 66.1 mt -81.47 134.47 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.451 -1.029 . . . . 0.0 109.824 -176.67 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.831 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.7 t -87.91 139.58 17.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.022 -1.049 . . . . 0.0 111.074 -169.794 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 30.3 mm100 -69.94 -35.95 74.91 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.834 -0.541 . . . . 0.0 110.938 178.085 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.54 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -154.53 170.68 32.94 Favored Glycine 0 N--CA 1.495 2.596 0 C-N-CA 119.232 -1.461 . . . . 0.0 110.13 -172.526 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.447 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 4.2 p -114.43 173.82 6.27 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.992 -1.299 . . . . 0.0 111.246 -175.317 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.071 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -142.13 150.01 40.55 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -177.534 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 38.3 tttt -107.52 116.78 32.56 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.109 -0.994 . . . . 0.0 110.126 177.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 1.028 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.9 tp -60.06 126.82 28.99 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.872 -1.142 . . . . 0.0 108.916 171.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.053 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.3 p -122.68 -31.74 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.849 0 O-C-N 121.387 -0.821 . . . . 0.0 109.859 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.84 146.67 28.07 Favored 'General case' 0 N--CA 1.493 1.706 0 C-N-CA 119.16 -1.016 . . . . 0.0 111.474 -179.333 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.856 HG23 ' CD2' ' B' ' 24' ' ' HIS . 7.6 mt -108.47 138.06 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.067 -1.021 . . . . 0.0 110.291 171.152 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.515 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 78.1 m-20 -109.32 115.7 30.47 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.46 -0.775 . . . . 0.0 109.754 172.054 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -104.51 112.28 25.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.097 -1.002 . . . . 0.0 110.312 -175.253 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 20.1 mmmt -115.64 129.29 25.26 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.325 -0.859 . . . . 0.0 109.161 177.247 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.426 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.4 Cg_endo -51.17 -31.25 35.46 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.721 1.379 . . . . 0.0 110.216 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.552 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 11.9 m-80 -74.42 -40.27 62.08 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.2 -0.937 . . . . 0.0 109.94 175.929 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.552 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 83.8 m-85 -156.07 150.4 25.64 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.289 -0.882 . . . . 0.0 110.357 -177.513 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.496 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 58.8 ttt180 -91.97 141.69 28.35 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.989 -1.069 . . . . 0.0 110.016 176.525 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.515 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 94.6 m -129.95 139.98 51.0 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 121.67 -0.644 . . . . 0.0 109.951 -173.929 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.856 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -131.06 141.4 50.18 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.021 -1.049 . . . . 0.0 111.046 -179.586 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.768 HG22 ' CB ' ' B' ' 60' ' ' SER . 6.7 t -122.47 133.3 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.157 -0.964 . . . . 0.0 110.744 -178.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.831 HG13 ' HE1' ' B' ' 61' ' ' PHE . 30.7 m -116.37 173.26 4.07 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.766 -0.583 . . . . 0.0 110.101 178.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.627 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 8.4 tt0 -104.32 116.56 32.37 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 179.685 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.838 HD21 HD13 ' B' ' 36' ' ' LEU . 9.6 tp -83.57 124.32 75.56 Favored Pre-proline 0 C--N 1.299 -1.629 0 O-C-N 121.338 -0.851 . . . . 0.0 110.095 -173.164 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.476 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 26.0 Cg_endo -66.41 176.6 3.93 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 O-C-N 123.858 1.452 . . . . 0.0 111.104 -179.483 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.489 ' HA ' HD12 ' B' ' 33' ' ' LEU . 47.4 t0 -60.0 -40.03 87.78 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.341 -0.849 . . . . 0.0 111.104 -175.49 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.586 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.56 0.1 57.14 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.753 -1.217 . . . . 0.0 110.658 -174.57 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.586 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.7 mmm -111.43 -14.11 13.78 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.055 -1.028 . . . . 0.0 109.828 170.266 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.596 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 17.8 mt -69.7 -40.06 76.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.358 -0.839 . . . . 0.0 110.338 177.628 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 55.8 t0 -78.01 129.38 35.2 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.886 . . . . 0.0 110.432 -178.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.95 -43.08 1.85 Allowed Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.854 -1.165 . . . . 0.0 110.304 174.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.838 HD13 HD21 ' B' ' 28' ' ' LEU . 7.0 tt -66.81 146.68 54.17 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.866 -1.373 . . . . 0.0 110.533 -174.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 37' ' ' GLU . . . . . 0.681 ' N ' HD23 ' B' ' 36' ' ' LEU . 14.7 pt-20 -150.04 164.35 35.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.4 -0.812 . . . . 0.0 109.618 -178.664 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.795 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.49 149.94 49.7 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.031 -1.043 . . . . 0.0 109.962 179.369 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.85 -4.83 63.93 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 -174.048 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.542 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -76.63 153.35 35.32 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.293 -1.122 . . . . 0.0 109.592 177.024 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.523 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.1 OUTLIER -97.53 109.05 21.88 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 120.951 -1.093 . . . . 0.0 110.195 178.096 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.622 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.2 t -95.29 133.13 37.35 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 O-C-N 121.253 -0.904 . . . . 0.0 109.154 173.723 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.504 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -95.89 119.87 35.16 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 119.204 -0.999 . . . . 0.0 109.181 171.284 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.643 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.3 OUTLIER -88.79 104.66 17.11 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.302 -0.874 . . . . 0.0 108.966 177.696 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.5 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 55.01 12.88 0.67 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.54 -0.725 . . . . 0.0 111.291 -168.491 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.489 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.15 -0.79 11.63 Favored Glycine 0 N--CA 1.491 2.346 0 C-N-CA 119.662 -1.256 . . . . 0.0 110.75 172.687 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.844 ' O ' HD23 ' B' ' 49' ' ' LEU . 36.0 t -94.03 109.68 21.42 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.45 -1.617 . . . . 0.0 109.54 175.134 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 18.7 p -74.4 128.41 35.47 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.095 -1.003 . . . . 0.0 110.965 -171.717 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 0.943 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -144.5 159.1 43.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.541 -0.724 . . . . 0.0 109.387 174.129 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 64.9 m -102.22 151.38 22.28 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.705 -1.247 . . . . 0.0 111.112 -171.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.828 HG13 HG13 ' B' ' 59' ' ' VAL . 21.4 t -78.65 119.94 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.727 -0.608 . . . . 0.0 110.584 -177.27 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 43.3 p -73.32 -43.93 59.93 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.17 -0.956 . . . . 0.0 110.159 174.576 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.641 ' HA ' HG21 ' B' ' 38' ' ' THR . 86.5 tt0 -159.24 151.36 20.99 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.331 -0.856 . . . . 0.0 110.455 -178.312 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.795 HD11 ' N ' ' B' ' 38' ' ' THR . 6.3 mt -103.0 133.0 48.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.102 -0.999 . . . . 0.0 109.933 174.789 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.527 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 13.4 m120 -108.0 65.74 0.64 Allowed 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 119.972 -0.691 . . . . 0.0 109.679 179.014 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.08 -116.31 4.74 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 -174.22 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.596 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -78.31 -21.09 50.17 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 120.983 -1.304 . . . . 0.0 109.049 175.069 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.053 ' CE1' HG11 ' B' ' 13' ' ' VAL . 24.7 m-70 -74.17 159.77 32.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.474 -0.766 . . . . 0.0 110.252 -177.239 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.828 HG13 HG13 ' B' ' 51' ' ' VAL . 55.8 t -140.24 122.87 16.46 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 C-N-CA 119.094 -1.042 . . . . 0.0 110.877 171.177 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.768 ' CB ' HG22 ' B' ' 25' ' ' VAL . 3.0 m -89.61 128.97 36.12 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.751 -0.593 . . . . 0.0 109.556 177.304 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.943 ' HB2' HD12 ' B' ' 49' ' ' LEU . 3.1 p90 -123.21 155.56 36.88 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.113 -0.992 . . . . 0.0 110.07 178.71 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 29.7 p-10 -90.1 154.4 19.81 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.818 -1.176 . . . . 0.0 111.554 -170.273 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.77 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -158.78 124.04 4.3 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 -175.764 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.521 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 96.0 mtp -79.74 146.68 32.23 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.631 -1.293 . . . . 0.0 109.706 178.029 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.477 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 27.9 ttpt -60.07 -47.61 85.15 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.195 -0.941 . . . . 0.0 109.542 178.562 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.95 -40.01 75.71 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.186 -0.946 . . . . 0.0 110.896 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.638 ' O ' HG23 ' B' ' 71' ' ' THR . 23.7 m -65.48 -34.14 77.57 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.649 -1.282 . . . . 0.0 109.021 175.204 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.771 HD11 ' HA2' ' B' ' 74' ' ' GLY . 4.3 tp -60.04 -45.67 92.08 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.571 -0.706 . . . . 0.0 109.844 177.039 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 31.6 tpt180 -70.01 -39.99 75.5 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.278 -0.889 . . . . 0.0 110.498 178.401 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.798 HG22 HG23 ' B' ' 71' ' ' THR . 1.5 tt -63.85 -42.7 96.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.221 -0.924 . . . . 0.0 109.332 -178.795 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.798 HG23 HG22 ' B' ' 70' ' ' ILE . 21.3 p -83.71 -173.08 4.51 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 174.84 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.511 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 3.4 t30 -104.79 25.59 10.21 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 169.864 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.77 ' HB3' HD21 ' B' ' 63' ' ' LEU . 90.1 mt -68.07 -40.02 82.83 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.149 -0.97 . . . . 0.0 109.636 176.032 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.771 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -49.82 -23.74 5.46 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 -179.061 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 23.3 p-10 -64.46 -17.22 63.63 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.07 -1.253 . . . . 0.0 110.218 -176.227 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.519 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 97.7 mt -60.51 144.93 50.26 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.262 -0.899 . . . . 0.0 110.441 -178.47 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 1.028 ' C ' HD23 ' B' ' 12' ' ' LEU . 66.1 mttt -150.09 138.62 20.65 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.626 -0.671 . . . . 0.0 109.696 178.077 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.701 HG21 HG13 ' B' ' 15' ' ' ILE . 62.0 t -63.56 147.26 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.042 -1.036 . . . . 0.0 110.178 -175.513 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.0 -11.15 71.6 Favored Glycine 0 N--CA 1.484 1.85 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 -172.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 41.5 t0 -101.08 162.09 13.14 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.333 -1.098 . . . . 0.0 109.695 176.408 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.4 m95 -114.0 159.79 19.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.195 -0.941 . . . . 0.0 110.031 177.282 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.071 HG13 ' HB3' ' B' ' 10' ' ' ALA . 0.8 OUTLIER -126.77 157.12 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.402 -0.811 . . . . 0.0 109.896 -177.611 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.831 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.3 m-20 -82.17 104.86 12.81 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.277 -0.89 . . . . 0.0 109.29 169.601 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.843 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -107.13 138.77 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 120.665 -1.272 . . . . 0.0 111.453 -175.426 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -131.84 147.62 52.49 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.983 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 86' ' ' ARG . . . . . 0.489 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 38.2 ptt180 -87.89 131.84 34.42 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.166 -0.959 . . . . 0.0 110.568 -178.525 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 0.913 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -127.0 145.74 50.6 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.335 -0.853 . . . . 0.0 110.214 179.368 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 88' ' ' ALA . . . . . 0.403 ' N ' ' CE2' ' A' ' 2' ' ' PHE . . . -136.38 154.2 50.89 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.689 -0.632 . . . . 0.0 110.54 -178.171 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 28.7 mtpt -59.99 -40.0 87.66 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.293 -0.879 . . . . 0.0 110.225 179.189 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 43.0 p90 -132.75 161.43 34.07 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.209 -0.932 . . . . 0.0 110.23 -178.185 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 91' ' ' SER . . . . . . . . . . . . . 61.0 m -118.2 142.84 47.04 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.307 -0.871 . . . . 0.0 110.553 -176.581 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -62.11 -39.98 94.35 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.36 -0.838 . . . . 0.0 110.278 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 93' ' ' GLU . . . . . 0.447 ' O ' ' HB ' ' B' ' 94' ' ' ILE . 18.6 pt-20 -138.79 56.44 1.7 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.321 -0.862 . . . . 0.0 110.362 -177.653 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 94' ' ' ILE . . . . . 0.704 HG22 ' O ' ' B' ' 94' ' ' ILE . 16.0 mm 53.37 21.86 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.196 0 O-C-N 121.242 -0.911 . . . . 0.0 109.199 179.027 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.15 65.9 1.55 Allowed Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 178.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -76.82 146.52 32.53 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 58.6 m-70 . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.282 -1.128 . . . . 0.0 110.212 -178.849 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 0.548 ' C8M' HD11 ' B' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 0.651 ' C8M' HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 98.6 mmm . . . . . 0 N--CA 1.492 1.641 0 CA-C-O 121.154 0.502 . . . . 0.0 109.973 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.768 ' HE2' ' HB1' ' B' ' 87' ' ' ALA . 1.3 p90 -169.9 132.09 1.1 Allowed 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.17 -0.956 . . . . 0.0 109.311 179.589 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.523 ' O ' HG13 ' A' ' 5' ' ' ILE . 34.7 p -128.8 -31.23 2.2 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.061 -1.024 . . . . 0.0 110.212 -178.196 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' B' ' 46' ' ' GLY . . . 45.8 24.44 1.27 Allowed Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 -174.1 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.965 HD11 ' C8M' ' B' ' 99' ' ' RBF . 53.0 mt -85.25 144.21 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 120.979 -1.306 . . . . 0.0 110.533 -177.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.882 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.3 t -88.87 144.47 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.345 -0.847 . . . . 0.0 110.919 -175.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 -70.04 -31.79 69.6 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.867 -0.521 . . . . 0.0 111.021 179.197 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.538 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -156.38 -177.97 30.06 Favored Glycine 0 N--CA 1.499 2.862 0 C-N-CA 118.541 -1.79 . . . . 0.0 110.795 -170.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.498 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.0 p -129.08 167.25 17.81 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.792 -1.417 . . . . 0.0 110.95 -178.435 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.039 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -139.97 149.84 43.75 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.597 -0.69 . . . . 0.0 109.201 -175.021 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.583 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 34.5 tttt -109.24 115.77 30.63 Favored 'General case' 0 C--N 1.294 -1.816 0 O-C-N 121.013 -1.055 . . . . 0.0 110.362 -179.12 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.995 HD23 ' C ' ' A' ' 77' ' ' LYS . 11.5 tp -59.98 127.68 33.08 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.916 -1.115 . . . . 0.0 108.863 172.622 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.114 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.6 p -127.01 -29.32 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 C-N-CA 119.6 -0.84 . . . . 0.0 109.932 -179.045 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.75 144.15 24.11 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 118.959 -1.096 . . . . 0.0 111.243 179.23 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.889 HG23 ' CD2' ' A' ' 24' ' ' HIS . 8.8 mt -107.9 141.03 24.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.187 -0.946 . . . . 0.0 110.233 174.702 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.511 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 79.7 m-20 -109.79 113.87 26.97 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.238 -0.914 . . . . 0.0 109.972 172.247 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -101.24 113.13 25.89 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.109 -0.995 . . . . 0.0 110.427 -178.099 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -109.77 134.4 20.64 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.197 -0.939 . . . . 0.0 109.499 176.005 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.64 -16.65 11.4 Favored 'Trans proline' 0 C--N 1.303 -1.854 0 O-C-N 123.973 1.512 . . . . 0.0 110.652 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.572 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 4.7 m120 -100.8 -26.57 13.73 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.129 -0.982 . . . . 0.0 110.035 179.23 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.572 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 92.9 m-85 -157.81 150.2 22.48 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.437 -0.789 . . . . 0.0 109.857 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.918 ' HD3' HD22 ' A' ' 68' ' ' LEU . 57.1 ttt180 -93.54 141.16 28.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.6 -1.312 . . . . 0.0 110.026 174.196 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.511 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.3 m -129.97 141.03 50.82 Favored 'General case' 0 C--N 1.294 -1.814 0 O-C-N 121.698 -0.626 . . . . 0.0 109.835 -173.703 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.889 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -129.98 143.6 50.88 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.012 -1.055 . . . . 0.0 111.612 -179.156 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.881 HG22 ' OG ' ' A' ' 60' ' ' SER . 6.4 t -123.34 132.88 70.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.11 -0.994 . . . . 0.0 110.613 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.801 HG13 ' CE1' ' A' ' 61' ' ' PHE . 26.0 m -114.9 174.48 2.93 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.326 178.509 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.684 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 12.8 tt0 -104.38 118.61 37.03 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.555 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.5 tp -81.21 122.57 81.52 Favored Pre-proline 0 C--N 1.297 -1.708 0 O-C-N 121.7 -0.625 . . . . 0.0 109.626 -174.75 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.489 ' HD2' HD12 ' A' ' 28' ' ' LEU . 18.3 Cg_endo -63.44 174.07 3.79 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 123.907 1.477 . . . . 0.0 110.572 -179.307 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.709 ' HA ' HD12 ' A' ' 33' ' ' LEU . 53.4 t0 -60.01 -39.47 85.91 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.412 -0.805 . . . . 0.0 110.611 -177.011 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.603 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.95 -0.1 57.39 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.843 -1.161 . . . . 0.0 110.894 -175.012 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.603 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 95.9 mmm -109.71 -11.73 14.7 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.87 -1.143 . . . . 0.0 109.824 170.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.709 HD12 ' HA ' ' A' ' 30' ' ' ASP . 15.3 mt -69.23 -40.1 78.13 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.323 -0.861 . . . . 0.0 110.312 179.225 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -79.98 123.89 28.21 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.349 -0.844 . . . . 0.0 110.527 -177.06 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.12 -47.09 1.08 Allowed Glycine 0 N--CA 1.492 2.377 0 C-N-CA 119.829 -1.177 . . . . 0.0 110.401 175.128 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.85 HD23 ' N ' ' A' ' 37' ' ' GLU . 8.2 tt -67.34 147.37 53.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.985 -1.303 . . . . 0.0 110.727 -175.068 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.85 ' N ' HD23 ' A' ' 36' ' ' LEU . 21.3 pt-20 -149.96 169.07 22.04 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.378 -0.826 . . . . 0.0 109.656 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.822 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -66.81 148.92 51.29 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.986 -1.071 . . . . 0.0 110.087 -179.985 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.9 -10.05 58.43 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 -175.539 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.432 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -71.25 157.87 37.37 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.245 -1.15 . . . . 0.0 109.272 174.706 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.893 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 1.6 p -105.34 116.82 32.59 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 118.533 -1.267 . . . . 0.0 109.754 176.012 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.619 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.6 t -99.63 126.38 53.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 121.333 -0.854 . . . . 0.0 109.006 175.353 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.512 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -88.31 119.53 28.81 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.234 -0.986 . . . . 0.0 109.089 173.374 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.738 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -89.75 105.43 17.8 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 119.729 -0.788 . . . . 0.0 108.939 177.955 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' B' ' 45' ' ' ASN . 0.8 OUTLIER 56.84 9.87 0.67 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.527 -0.733 . . . . 0.0 111.514 -170.316 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' B' ' 4' ' ' GLY . . . 126.57 -2.15 7.55 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.553 -1.308 . . . . 0.0 110.86 173.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.902 ' O ' HD23 ' A' ' 49' ' ' LEU . 50.2 t -98.63 104.86 16.93 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.521 -1.576 . . . . 0.0 109.756 176.236 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.54 ' SG ' HC72 ' A' ' 98' ' ' RBF . 25.5 p -71.36 128.91 37.44 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.176 -0.952 . . . . 0.0 110.727 -174.453 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.927 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -141.41 159.98 41.08 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.445 -0.785 . . . . 0.0 109.262 173.942 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.415 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 23.9 m -99.88 150.05 22.78 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 120.45 -1.406 . . . . 0.0 111.347 -170.252 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.779 HG13 HG13 ' A' ' 59' ' ' VAL . 34.9 t -76.25 116.44 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.941 -0.475 . . . . 0.0 110.318 -179.182 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.537 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 28.3 p -71.91 -39.96 69.15 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.365 -0.835 . . . . 0.0 109.789 174.186 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.573 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -163.27 152.9 15.21 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.272 -0.893 . . . . 0.0 110.362 -179.031 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.822 HD11 ' N ' ' A' ' 38' ' ' THR . 7.6 mt -105.52 132.14 53.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.193 -0.942 . . . . 0.0 109.965 175.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.509 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 26.6 m-80 -104.92 64.78 0.73 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.63 -0.669 . . . . 0.0 109.594 179.229 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.65 -116.95 5.3 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 -173.126 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.68 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.1 OUTLIER -77.0 -20.74 55.68 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.015 -1.285 . . . . 0.0 109.153 175.727 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.114 ' CE1' HG11 ' A' ' 13' ' ' VAL . 28.9 m-70 -75.64 159.98 30.59 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.33 -0.856 . . . . 0.0 110.192 -177.593 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.779 HG13 HG13 ' A' ' 51' ' ' VAL . 53.6 t -140.69 123.07 15.55 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 C-N-CA 119.133 -1.027 . . . . 0.0 110.74 173.208 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.881 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.3 t -90.71 134.61 34.29 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.48 -0.762 . . . . 0.0 109.416 177.329 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.927 ' HB2' HD12 ' A' ' 49' ' ' LEU . 2.7 p90 -126.75 151.17 48.56 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.366 -0.833 . . . . 0.0 110.318 176.911 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.537 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 38.2 p-10 -86.66 154.87 20.67 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.084 -1.01 . . . . 0.0 111.422 -171.762 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.835 HD22 HD13 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -161.9 100.42 1.12 Allowed 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.754 -0.591 . . . . 0.0 109.546 -175.49 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.471 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 33.0 ttp -60.68 140.06 57.63 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.883 -1.135 . . . . 0.0 109.52 -178.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.487 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 29.4 tptp -60.07 -48.31 82.23 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.891 -1.13 . . . . 0.0 110.473 -172.69 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -63.21 -39.99 96.19 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.714 -1.241 . . . . 0.0 109.806 177.411 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.492 HG21 ' O2 ' ' A' ' 98' ' ' RBF . 55.2 m -60.05 -39.98 87.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.052 -1.03 . . . . 0.0 109.602 172.705 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.918 HD22 ' HD3' ' A' ' 22' ' ' ARG . 27.0 tp -61.64 -40.8 96.16 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.446 -0.784 . . . . 0.0 109.816 -179.592 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 15.5 ttm180 -69.92 -40.12 75.75 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.275 -0.891 . . . . 0.0 110.441 177.086 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.687 HG22 HG23 ' A' ' 71' ' ' THR . 1.2 tt -64.78 -44.58 96.42 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.285 -0.884 . . . . 0.0 109.602 -176.569 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.687 HG23 HG22 ' A' ' 70' ' ' ILE . 30.5 p -79.99 -174.98 4.73 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.561 -0.712 . . . . 0.0 109.25 175.258 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.514 ' HB2' ' N ' ' B' ' 83' ' ' ASN . 4.1 t30 -99.97 23.34 9.95 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.013 -1.054 . . . . 0.0 108.459 169.32 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.692 ' HB3' HD21 ' A' ' 63' ' ' LEU . 87.7 mt -69.18 -40.02 78.37 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.071 -1.018 . . . . 0.0 109.799 174.801 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.548 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -46.81 -22.44 1.15 Allowed Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.619 -0.993 . . . . 0.0 110.619 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.3 p-10 -68.98 -17.01 63.87 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.958 -1.319 . . . . 0.0 110.534 -174.668 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.503 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 98.4 mt -59.93 141.18 55.98 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.226 -0.921 . . . . 0.0 111.042 -176.858 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 0.995 ' C ' HD23 ' A' ' 12' ' ' LEU . 24.9 mttm -142.38 143.04 32.51 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.734 -0.604 . . . . 0.0 109.762 173.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.646 HG23 HD11 ' A' ' 15' ' ' ILE . 32.2 t -63.15 150.09 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.914 -1.116 . . . . 0.0 110.391 -177.209 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.46 -14.82 60.17 Favored Glycine 0 N--CA 1.485 1.916 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 -175.646 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.494 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 41.9 t0 -94.28 167.7 11.37 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.328 -1.101 . . . . 0.0 109.637 175.839 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.583 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.2 m95 -116.67 158.8 23.2 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.976 -1.077 . . . . 0.0 110.036 175.038 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.039 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.1 p -121.28 155.27 25.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.389 -0.82 . . . . 0.0 109.917 179.55 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.882 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -78.51 105.56 9.86 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 120.993 -1.067 . . . . 0.0 109.003 168.06 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.834 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -106.64 137.84 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 120.548 -1.345 . . . . 0.0 111.048 -176.96 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -138.98 140.09 38.11 Favored 'General case' 0 N--CA 1.492 1.629 0 C-N-CA 120.291 -0.564 . . . . 0.0 109.991 -177.319 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 53.0 ttt85 -60.06 127.05 29.97 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.155 -0.966 . . . . 0.0 110.293 -179.508 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.893 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . -121.62 148.38 44.61 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.341 -0.849 . . . . 0.0 109.554 176.57 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.551 ' O ' ' CD1' ' B' ' 2' ' ' PHE . . . -132.72 147.56 52.33 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.255 -0.903 . . . . 0.0 111.401 -174.067 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.541 ' HA ' ' CE1' ' B' ' 2' ' ' PHE . 10.3 pttt -71.87 -16.93 62.15 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.362 -0.836 . . . . 0.0 109.672 171.784 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 44.4 p90 -122.31 161.55 23.14 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.43 -0.794 . . . . 0.0 110.081 178.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.53 ' HB2' ' CG1' ' A' ' 94' ' ' ILE . 53.3 m -60.0 130.58 47.41 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.229 -0.919 . . . . 0.0 110.498 -176.124 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -69.48 -35.43 75.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.398 -0.814 . . . . 0.0 110.145 178.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -88.29 44.96 1.24 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.154 -0.966 . . . . 0.0 110.272 -179.777 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.633 HG22 ' O ' ' A' ' 94' ' ' ILE . 15.1 mm -130.19 4.74 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.622 -0.674 . . . . 0.0 110.253 175.268 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -58.55 82.41 0.01 OUTLIER Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -178.528 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.51 ' N ' ' O ' ' A' ' 94' ' ' ILE . . . 179.98 175.92 47.01 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.346 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.252 -1.146 . . . . 0.0 110.14 179.784 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 1' ' ' MET . . . . . 0.463 ' O ' ' HG3' ' B' ' 1' ' ' MET . 8.7 ptt? . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 121.239 0.542 . . . . 0.0 110.38 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.78 ' HE2' ' HB1' ' A' ' 87' ' ' ALA . 1.4 p90 -168.42 132.16 1.55 Allowed 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.274 -0.891 . . . . 0.0 109.122 175.551 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.523 ' O ' HG13 ' B' ' 5' ' ' ILE . 34.7 p -128.84 -31.35 2.18 Favored 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.059 -1.026 . . . . 0.0 110.226 -178.305 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' A' ' 46' ' ' GLY . . . 45.85 24.53 1.32 Allowed Glycine 0 N--CA 1.487 2.06 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -174.114 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 0.948 HD11 ' C8M' ' A' ' 98' ' ' RBF . 53.0 mt -85.25 144.29 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 120.98 -1.306 . . . . 0.0 110.588 -178.062 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.922 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.3 t -88.99 144.41 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.365 -0.834 . . . . 0.0 110.945 -175.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 99.5 mt-30 -69.98 -31.72 69.55 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.785 -0.572 . . . . 0.0 111.025 179.27 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.549 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -156.49 -178.09 30.28 Favored Glycine 0 N--CA 1.499 2.895 0 C-N-CA 118.632 -1.747 . . . . 0.0 110.857 -170.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.503 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.0 p -129.03 167.13 17.94 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.913 -1.345 . . . . 0.0 111.028 -178.426 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.098 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -139.88 150.04 44.13 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 -175.179 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.579 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 34.5 tttt -109.3 115.81 30.68 Favored 'General case' 0 C--N 1.295 -1.772 0 O-C-N 121.028 -1.045 . . . . 0.0 110.294 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 1.012 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.5 tp -60.24 127.61 32.64 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 120.945 -1.097 . . . . 0.0 108.905 172.62 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.091 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.5 p -126.84 -29.38 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.874 0 O-C-N 121.345 -0.847 . . . . 0.0 110.034 -178.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.67 144.11 24.14 Favored 'General case' 0 C--N 1.297 -1.681 0 C-N-CA 119.225 -0.99 . . . . 0.0 111.243 179.224 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.89 HG23 ' CD2' ' B' ' 24' ' ' HIS . 8.9 mt -107.88 141.1 23.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.292 -0.88 . . . . 0.0 110.242 174.617 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.499 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 79.5 m-20 -109.92 113.98 27.15 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.364 -0.835 . . . . 0.0 109.961 172.243 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -101.22 113.08 25.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.155 -0.966 . . . . 0.0 110.444 -178.06 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.465 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.0 OUTLIER -109.87 134.36 20.68 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.311 -0.868 . . . . 0.0 109.442 176.043 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.71 -16.66 11.62 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 O-C-N 123.971 1.511 . . . . 0.0 110.662 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 4.7 m120 -100.51 -27.16 13.57 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.087 -1.008 . . . . 0.0 109.939 179.111 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 93.0 m-85 -157.37 150.33 23.44 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.416 -0.802 . . . . 0.0 109.814 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.904 ' HD3' HD22 ' B' ' 68' ' ' LEU . 57.0 ttt180 -93.62 141.16 28.79 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.67 -1.269 . . . . 0.0 110.036 174.137 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.499 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 94.7 m -129.95 141.07 50.82 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.579 -0.701 . . . . 0.0 109.767 -173.683 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.89 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -129.93 143.78 50.98 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.989 -1.069 . . . . 0.0 111.472 -179.161 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.874 HG22 ' OG ' ' B' ' 60' ' ' SER . 6.4 t -123.38 132.93 70.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.161 -0.962 . . . . 0.0 110.709 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.81 HG13 ' HE1' ' B' ' 61' ' ' PHE . 26.7 m -115.08 174.44 3.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 121.688 -0.633 . . . . 0.0 110.226 178.677 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.681 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 12.8 tt0 -104.28 118.65 37.13 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.455 -0.778 . . . . 0.0 108.972 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.558 HD23 ' HA ' ' B' ' 33' ' ' LEU . 9.5 tp -81.13 122.58 81.69 Favored Pre-proline 0 C--N 1.296 -1.738 0 O-C-N 121.573 -0.704 . . . . 0.0 109.651 -174.818 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.496 ' HD2' HD12 ' B' ' 28' ' ' LEU . 18.2 Cg_endo -63.43 174.01 3.84 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.842 1.443 . . . . 0.0 110.564 -179.35 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.691 ' HA ' HD12 ' B' ' 33' ' ' LEU . 53.2 t0 -60.02 -39.46 85.93 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.501 -0.749 . . . . 0.0 110.56 -176.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.599 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.03 0.05 57.32 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.932 -1.105 . . . . 0.0 110.848 -174.974 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.599 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 95.8 mmm -109.73 -11.75 14.7 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.83 -1.169 . . . . 0.0 109.846 170.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.714 HD21 ' HB2' ' B' ' 57' ' ' ASN . 15.3 mt -69.26 -40.02 78.09 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.32 -0.863 . . . . 0.0 110.305 179.272 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -80.06 123.91 28.27 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.266 -0.896 . . . . 0.0 110.463 -177.054 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.11 -47.1 1.08 Allowed Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.784 -1.198 . . . . 0.0 110.391 175.116 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.851 HD23 ' N ' ' B' ' 37' ' ' GLU . 8.2 tt -67.26 147.3 53.19 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.001 -1.294 . . . . 0.0 110.805 -175.093 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 37' ' ' GLU . . . . . 0.851 ' N ' HD23 ' B' ' 36' ' ' LEU . 21.3 pt-20 -150.02 168.94 22.41 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.432 -0.792 . . . . 0.0 109.677 -179.617 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.824 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -66.77 148.86 51.37 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.95 -1.094 . . . . 0.0 110.106 -179.912 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.0 -10.09 58.78 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -175.509 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.445 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -71.33 157.76 37.53 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.17 -1.194 . . . . 0.0 109.102 174.669 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.913 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 1.7 p -105.02 116.44 31.96 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 118.844 -1.142 . . . . 0.0 109.968 175.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.623 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.5 t -99.9 126.4 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.472 -0.768 . . . . 0.0 108.971 175.432 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.509 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -88.23 119.43 28.63 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.094 -1.004 . . . . 0.0 109.16 173.401 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.748 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -89.7 105.26 17.68 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.369 -0.832 . . . . 0.0 109.019 177.934 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' A' ' 45' ' ' ASN . 0.8 OUTLIER 57.13 9.77 0.72 Allowed 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.515 -0.74 . . . . 0.0 111.464 -170.427 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 4' ' ' GLY . . . 126.55 -1.93 7.55 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.504 -1.332 . . . . 0.0 110.84 173.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.888 ' O ' HD23 ' B' ' 49' ' ' LEU . 50.1 t -98.85 104.79 16.87 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.534 -1.568 . . . . 0.0 109.707 176.257 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 48' ' ' CYS . . . . . 0.537 ' SG ' HC72 ' B' ' 99' ' ' RBF . 25.1 p -71.17 129.07 37.99 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.124 -0.985 . . . . 0.0 110.667 -174.489 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 0.952 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -141.65 159.85 41.37 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.348 -0.845 . . . . 0.0 109.239 173.857 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 50' ' ' THR . . . . . 0.42 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 23.7 m -99.69 150.02 22.72 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.588 -1.32 . . . . 0.0 111.412 -170.232 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.812 HG13 HG13 ' B' ' 59' ' ' VAL . 32.6 t -76.23 116.47 19.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.855 -0.528 . . . . 0.0 110.382 -179.225 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.536 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 28.6 p -71.92 -40.04 69.07 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.297 -0.877 . . . . 0.0 109.722 174.29 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.576 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -163.21 152.83 15.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.342 -0.849 . . . . 0.0 110.421 -178.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.824 HD11 ' N ' ' B' ' 38' ' ' THR . 7.6 mt -105.51 132.03 53.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.295 -0.878 . . . . 0.0 110.012 175.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.525 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 26.5 m-80 -104.87 64.82 0.73 Allowed 'General case' 0 C--N 1.297 -1.698 0 C-N-CA 120.048 -0.661 . . . . 0.0 109.562 179.285 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.72 -117.0 5.3 Favored Glycine 0 N--CA 1.487 2.063 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 -173.182 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.714 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -76.97 -20.9 55.54 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.076 -1.249 . . . . 0.0 109.164 175.73 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.091 ' CE1' HG11 ' B' ' 13' ' ' VAL . 29.1 m-70 -75.59 159.79 30.83 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.338 -0.851 . . . . 0.0 110.285 -177.683 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.812 HG13 HG13 ' B' ' 51' ' ' VAL . 56.7 t -140.46 123.1 16.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.76 173.361 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.874 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.3 t -90.67 134.67 34.24 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.481 -0.762 . . . . 0.0 109.54 177.278 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.952 ' HB2' HD12 ' B' ' 49' ' ' LEU . 2.7 p90 -126.93 151.05 49.0 Favored 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.314 176.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.536 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 38.2 p-10 -86.39 154.81 20.9 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.927 -1.108 . . . . 0.0 111.442 -171.702 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.85 HD22 HD13 ' B' ' 68' ' ' LEU . 0.0 OUTLIER -161.94 100.42 1.12 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.76 -0.588 . . . . 0.0 109.608 -175.614 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.486 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 33.0 ttp -60.67 139.99 57.64 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.836 -1.165 . . . . 0.0 109.53 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.485 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 29.5 tptp -59.94 -48.41 81.81 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.946 -1.096 . . . . 0.0 110.469 -172.69 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -63.24 -40.02 96.25 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.792 -1.193 . . . . 0.0 109.792 177.467 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.502 HG23 " O4'" ' B' ' 99' ' ' RBF . 55.5 m -60.01 -39.88 87.36 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.188 -0.945 . . . . 0.0 109.657 172.691 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.904 HD22 ' HD3' ' B' ' 22' ' ' ARG . 27.1 tp -61.73 -40.66 95.84 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.504 -0.748 . . . . 0.0 109.892 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 15.6 ttm180 -69.96 -40.01 75.66 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.34 -0.85 . . . . 0.0 110.52 176.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.692 HG22 HG23 ' B' ' 71' ' ' THR . 1.2 tt -64.87 -44.47 96.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.296 -0.877 . . . . 0.0 109.623 -176.618 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.692 HG23 HG22 ' B' ' 70' ' ' ILE . 30.4 p -80.18 -174.89 4.76 Favored 'General case' 0 C--N 1.301 -1.538 0 C-N-CA 119.84 -0.744 . . . . 0.0 109.294 175.247 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.501 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 3.9 t30 -99.97 23.41 9.87 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.069 -1.02 . . . . 0.0 108.406 169.458 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.671 ' HB3' HD21 ' B' ' 63' ' ' LEU . 87.7 mt -69.25 -40.03 78.11 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.09 -1.006 . . . . 0.0 109.768 174.793 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.546 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -46.81 -22.38 1.14 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -179.365 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.3 p-10 -69.08 -16.9 63.79 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.905 -1.35 . . . . 0.0 110.488 -174.62 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.503 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.3 mt -60.1 141.29 56.04 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.229 -0.92 . . . . 0.0 111.06 -176.867 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 1.012 ' C ' HD23 ' B' ' 12' ' ' LEU . 24.9 mttm -142.47 143.07 32.42 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.725 -0.61 . . . . 0.0 109.694 174.073 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.663 HG23 HD11 ' B' ' 15' ' ' ILE . 32.7 t -63.19 150.05 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.924 -1.11 . . . . 0.0 110.317 -177.188 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.38 -14.7 60.4 Favored Glycine 0 N--CA 1.486 1.974 0 N-CA-C 108.777 -1.729 . . . . 0.0 108.777 -175.677 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.488 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 41.8 t0 -94.43 167.68 11.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.426 -1.044 . . . . 0.0 109.635 175.749 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.579 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.1 m95 -116.64 158.83 23.12 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.074 -1.016 . . . . 0.0 110.068 175.088 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.098 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.0 OUTLIER -121.32 155.33 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.419 -0.801 . . . . 0.0 109.887 179.457 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.922 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.2 OUTLIER -78.39 105.29 9.55 Favored 'General case' 0 C--N 1.297 -1.674 0 O-C-N 121.105 -0.997 . . . . 0.0 109.147 168.007 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.836 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -106.49 138.12 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 120.596 -1.315 . . . . 0.0 110.894 -176.821 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -139.29 140.21 37.55 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 120.268 -0.573 . . . . 0.0 109.914 -177.481 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 53.0 ttt85 -59.99 127.04 29.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.176 -0.953 . . . . 0.0 110.267 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 0.913 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . -121.28 148.95 43.62 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.442 -0.786 . . . . 0.0 109.444 176.564 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 88' ' ' ALA . . . . . 0.558 ' O ' ' CD1' ' A' ' 2' ' ' PHE . . . -133.3 147.47 51.89 Favored 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.454 -0.899 . . . . 0.0 111.331 -174.287 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 89' ' ' LYS . . . . . 0.535 ' HA ' ' CE1' ' A' ' 2' ' ' PHE . 10.3 pttt -71.76 -16.93 62.22 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.42 -0.8 . . . . 0.0 109.657 171.839 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 44.4 p90 -122.4 161.62 23.13 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.475 -0.766 . . . . 0.0 110.009 179.092 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 91' ' ' SER . . . . . 0.527 ' HB3' ' CG1' ' B' ' 94' ' ' ILE . 53.8 m -60.07 130.48 46.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.232 -0.918 . . . . 0.0 110.522 -176.096 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 92' ' ' ASP . . . . . 0.473 ' O ' ' HG3' ' B' ' 93' ' ' GLU . 96.0 m-20 -69.88 -40.1 75.88 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.419 -0.801 . . . . 0.0 110.39 178.733 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 93' ' ' GLU . . . . . 0.473 ' HG3' ' O ' ' B' ' 92' ' ' ASP . 98.8 mt-10 -153.95 54.15 0.71 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.221 -0.925 . . . . 0.0 110.149 -176.051 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 94' ' ' ILE . . . . . 0.656 HG22 ' O ' ' B' ' 94' ' ' ILE . 21.5 mm -101.04 6.58 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.309 -0.869 . . . . 0.0 110.354 179.54 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . -49.97 90.48 0.01 OUTLIER Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 -178.763 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 96' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' B' ' 94' ' ' ILE . . . 80.52 12.47 82.94 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 178.011 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 97' ' ' HIS . . . . . 0.452 ' HB3' ' HA ' ' B' ' 94' ' ' ILE . 83.5 t60 . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.076 -1.249 . . . . 0.0 110.135 178.225 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 0.948 ' C8M' HD11 ' B' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 0.965 ' C8M' HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 96.0 mmm . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 121.192 0.52 . . . . 0.0 110.255 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.963 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 12.8 p90 -176.41 154.87 1.36 Allowed 'General case' 0 C--N 1.306 -1.309 0 O-C-N 121.252 -0.905 . . . . 0.0 109.027 179.085 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.572 HG23 ' C ' ' A' ' 2' ' ' PHE . 71.8 p -151.79 -40.26 0.11 Allowed 'General case' 0 C--N 1.297 -1.715 0 O-C-N 120.915 -1.116 . . . . 0.0 109.174 178.348 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 45.65 24.81 1.27 Allowed Glycine 0 N--CA 1.483 1.796 0 N-CA-C 108.57 -1.812 . . . . 0.0 108.57 -174.224 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.81 HD11 HC82 ' B' ' 99' ' ' RBF . 95.3 mt -76.88 138.61 20.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.228 -1.16 . . . . 0.0 110.296 -176.181 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.771 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.2 t -97.97 147.66 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.353 -0.842 . . . . 0.0 110.399 -175.029 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -95.21 -22.06 18.06 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.493 -0.755 . . . . 0.0 110.75 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.529 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -144.43 175.59 24.1 Favored Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.081 -1.533 . . . . 0.0 109.968 -176.209 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.432 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.2 p -127.51 166.04 18.72 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.06 -1.259 . . . . 0.0 110.625 179.227 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.071 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -133.94 148.84 51.23 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.598 -0.689 . . . . 0.0 109.258 -178.681 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 23.5 tttt -107.66 116.89 32.76 Favored 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.113 -0.992 . . . . 0.0 110.147 179.353 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.996 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.2 tp -59.92 126.32 27.08 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 120.876 -1.14 . . . . 0.0 108.914 173.333 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.048 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.4 p -124.95 -30.8 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 C-N-CA 119.744 -0.782 . . . . 0.0 109.718 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.59 142.36 27.89 Favored 'General case' 0 N--CA 1.492 1.653 0 C-N-CA 119.214 -0.995 . . . . 0.0 111.127 -178.098 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.732 HG23 ' NE2' ' A' ' 24' ' ' HIS . 10.6 mt -108.62 130.19 61.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.113 -0.992 . . . . 0.0 110.314 172.4 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.502 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 74.1 m-20 -104.49 117.76 34.95 Favored 'General case' 0 C--N 1.295 -1.769 0 O-C-N 121.376 -0.827 . . . . 0.0 109.809 172.755 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -107.4 105.31 15.18 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.146 -0.971 . . . . 0.0 110.176 -177.518 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 2.1 mmmt -102.2 130.56 23.98 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.347 -0.846 . . . . 0.0 109.282 179.219 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -51.5 -19.43 7.12 Favored 'Trans proline' 0 C--N 1.303 -1.856 0 O-C-N 123.913 1.481 . . . . 0.0 110.573 -179.499 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.573 ' O ' ' CD1' ' A' ' 21' ' ' PHE . 0.4 OUTLIER -90.54 -38.37 13.24 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.169 -0.957 . . . . 0.0 109.102 177.268 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.573 ' CD1' ' O ' ' A' ' 20' ' ' ASN . 64.6 m-85 -153.15 150.18 28.8 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.833 -0.542 . . . . 0.0 110.148 -177.651 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.544 ' HD3' HD22 ' A' ' 68' ' ' LEU . 63.4 ttt180 -88.43 145.03 26.01 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.6 -1.313 . . . . 0.0 109.941 174.409 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.502 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 84.8 m -133.08 140.82 47.87 Favored 'General case' 0 C--N 1.296 -1.752 0 O-C-N 121.407 -0.808 . . . . 0.0 109.946 -174.173 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.732 ' NE2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.03 131.96 46.04 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.767 -1.208 . . . . 0.0 111.561 -179.669 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.612 HG22 ' CB ' ' A' ' 60' ' ' SER . 4.0 t -109.85 132.28 58.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.184 -0.947 . . . . 0.0 110.537 -178.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 15.5 m -117.44 169.85 7.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 120.359 -0.537 . . . . 0.0 110.343 -179.111 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.661 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 13.1 tt0 -103.22 118.31 36.5 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.215 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.513 ' CD2' ' O ' ' A' ' 32' ' ' MET . 9.5 tp -84.14 126.37 70.05 Favored Pre-proline 0 C--N 1.298 -1.667 0 O-C-N 121.327 -0.858 . . . . 0.0 109.759 -175.073 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.468 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 17.7 Cg_endo -64.27 176.84 2.37 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 123.903 1.475 . . . . 0.0 110.927 -179.192 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.412 ' HA ' HD12 ' A' ' 33' ' ' LEU . 77.4 m-20 -60.06 -39.94 87.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.427 -0.796 . . . . 0.0 110.997 -176.37 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.577 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.13 2.57 55.15 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.797 -1.19 . . . . 0.0 110.744 -174.457 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.577 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 89.1 mmm -113.07 -11.89 13.27 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.912 -1.118 . . . . 0.0 109.991 170.364 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.683 HD21 ' HB2' ' A' ' 57' ' ' ASN . 18.1 mt -69.97 -40.1 75.58 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.321 -0.862 . . . . 0.0 110.378 178.849 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -82.68 115.76 21.76 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.905 . . . . 0.0 110.505 -176.384 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.61 -52.75 0.69 Allowed Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.81 -1.186 . . . . 0.0 110.376 175.389 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.494 HD23 HD22 ' A' ' 28' ' ' LEU . 42.6 tp -61.52 151.34 33.23 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.955 -1.321 . . . . 0.0 110.851 -173.471 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.491 ' C ' HD11 ' A' ' 54' ' ' ILE . 20.9 pt-20 -149.95 168.33 24.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.468 -0.77 . . . . 0.0 109.484 178.854 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.91 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -66.09 152.84 43.82 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.885 -1.134 . . . . 0.0 109.982 -178.985 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.31 -4.72 66.31 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -176.348 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.514 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -77.26 156.64 31.27 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.291 -1.123 . . . . 0.0 109.668 176.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.612 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -100.61 108.24 20.09 Favored 'General case' 0 C--N 1.306 -1.286 0 O-C-N 121.103 -0.998 . . . . 0.0 110.087 178.629 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.588 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.2 t -94.24 129.45 44.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.224 -0.923 . . . . 0.0 109.125 174.203 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -93.33 119.54 32.59 Favored 'General case' 0 C--N 1.296 -1.724 0 C-N-CA 119.258 -0.977 . . . . 0.0 109.07 171.572 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.852 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.3 OUTLIER -89.17 102.6 15.26 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.64 -0.824 . . . . 0.0 108.94 178.463 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.499 ' HB3' ' HB3' ' B' ' 45' ' ' ASN . 1.7 t-20 58.22 11.49 1.58 Allowed 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.449 -0.782 . . . . 0.0 110.772 -169.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.512 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.16 -2.29 11.56 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.777 -1.201 . . . . 0.0 110.891 172.672 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.83 ' O ' HD23 ' A' ' 49' ' ' LEU . 43.0 t -92.16 109.17 20.53 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.39 -1.653 . . . . 0.0 109.389 174.352 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 15.8 p -74.89 128.43 35.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.099 -1.001 . . . . 0.0 110.844 -171.713 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.92 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -146.96 157.0 43.5 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.347 -0.846 . . . . 0.0 109.499 173.741 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.425 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 23.9 m -97.5 159.0 15.18 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.735 -1.228 . . . . 0.0 111.296 -170.6 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.965 HG22 ' CE1' ' A' ' 61' ' ' PHE . 22.4 t -83.26 116.63 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.832 -0.542 . . . . 0.0 110.43 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.54 HG22 ' HB3' ' A' ' 62' ' ' ASP . 39.4 p -70.0 -39.91 75.6 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.241 -0.912 . . . . 0.0 109.715 172.777 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.579 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.9 tt0 -160.95 154.83 22.5 Favored 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 119.357 -0.937 . . . . 0.0 111.204 -175.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.91 HD11 ' N ' ' A' ' 38' ' ' THR . 6.4 mt -110.06 129.99 64.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.091 -1.006 . . . . 0.0 110.044 169.497 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.488 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 27.7 m-80 -103.7 65.12 0.82 Allowed 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.592 -0.692 . . . . 0.0 109.514 176.648 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.49 -113.4 3.82 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.812 -1.715 . . . . 0.0 108.812 -173.263 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.683 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.1 OUTLIER -79.99 -21.07 44.09 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.05 -1.265 . . . . 0.0 109.168 175.405 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.048 ' CE1' HG11 ' A' ' 13' ' ' VAL . 17.9 m-70 -77.65 159.99 28.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.246 -0.909 . . . . 0.0 110.112 -176.488 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.668 ' CG1' HG13 ' A' ' 51' ' ' VAL . 97.7 t -144.4 115.43 2.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 C-N-CA 119.309 -0.957 . . . . 0.0 110.891 177.702 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.612 ' CB ' HG22 ' A' ' 25' ' ' VAL . 13.7 m -81.74 130.15 34.96 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.677 -0.639 . . . . 0.0 109.849 178.465 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.965 ' CE1' HG22 ' A' ' 51' ' ' VAL . 96.4 m-85 -115.19 159.98 20.28 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.952 -1.092 . . . . 0.0 110.235 178.037 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.54 ' HB3' HG22 ' A' ' 52' ' ' THR . 25.7 p-10 -95.2 147.81 23.07 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.163 -0.961 . . . . 0.0 111.335 -177.019 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.806 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -159.14 116.47 2.75 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.718 -0.614 . . . . 0.0 109.559 -175.729 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.48 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 57.9 ttm -75.27 146.97 40.63 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.863 -1.148 . . . . 0.0 109.852 179.251 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.477 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 39.0 ttpt -60.07 -49.75 76.4 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.078 -1.014 . . . . 0.0 110.305 -177.671 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -63.95 -42.46 97.3 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.895 -1.128 . . . . 0.0 110.17 178.574 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.923 HG23 " O4'" ' A' ' 98' ' ' RBF . 69.4 m -60.31 -40.04 89.12 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.932 -1.105 . . . . 0.0 109.606 174.332 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.654 HD11 ' HA2' ' A' ' 74' ' ' GLY . 11.7 tp -59.99 -43.16 95.33 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.288 -0.882 . . . . 0.0 109.582 177.756 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 16.4 mmm180 -70.0 -40.07 75.52 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.57 -0.706 . . . . 0.0 110.608 177.613 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.87 HG22 HG23 ' A' ' 71' ' ' THR . 1.5 tt -66.15 -43.72 91.95 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.209 -0.932 . . . . 0.0 109.329 -177.169 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.87 HG23 HG22 ' A' ' 70' ' ' ILE . 32.9 p -84.7 -171.01 3.4 Favored 'General case' 0 C--N 1.297 -1.68 0 CA-C-O 121.361 0.601 . . . . 0.0 109.673 178.013 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.519 ' CB ' ' N ' ' B' ' 83' ' ' ASN . 1.6 t30 -103.2 21.84 15.14 Favored 'General case' 0 C--N 1.293 -1.862 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 170.477 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.806 ' HB3' HD21 ' A' ' 63' ' ' LEU . 91.5 mt -66.26 -40.0 89.84 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.939 -1.101 . . . . 0.0 109.787 173.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.654 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -49.79 -25.17 6.75 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -178.543 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 24.0 p-10 -65.99 -16.63 64.06 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.001 -1.294 . . . . 0.0 110.508 -174.816 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 96.2 mt -60.01 140.17 56.96 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.151 -0.968 . . . . 0.0 110.65 -176.805 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 0.996 ' C ' HD23 ' A' ' 12' ' ' LEU . 26.0 mttt -144.07 140.33 29.43 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-O 121.346 0.593 . . . . 0.0 109.688 176.01 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.686 ' N ' HD23 ' A' ' 12' ' ' LEU . 18.8 t -61.77 150.17 8.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 120.686 -1.259 . . . . 0.0 110.524 -173.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.61 -13.63 63.57 Favored Glycine 0 N--CA 1.482 1.733 0 N-CA-C 108.855 -1.698 . . . . 0.0 108.855 -176.463 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.434 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 34.8 t0 -95.36 169.94 9.72 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.324 -1.104 . . . . 0.0 109.459 175.673 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.3 m95 -117.47 168.31 10.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.908 -1.12 . . . . 0.0 110.245 175.785 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.071 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.4 p -130.17 153.05 38.37 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.491 -0.756 . . . . 0.0 109.696 179.369 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.771 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.2 m-20 -79.77 106.02 11.5 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 120.89 -1.131 . . . . 0.0 109.043 170.019 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.564 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -106.23 139.98 25.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 120.481 -1.387 . . . . 0.0 111.37 -175.042 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.421 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.5 tt0 -131.02 142.6 50.34 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.037 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 39.6 ttm180 -81.24 121.07 25.7 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 110.481 -178.753 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.939 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -118.04 144.49 45.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.23 -0.919 . . . . 0.0 110.124 176.57 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -126.21 142.13 51.65 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-O 121.48 0.657 . . . . 0.0 110.687 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 28.2 mmtp -60.52 -38.83 85.64 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.531 -0.73 . . . . 0.0 110.157 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.456 ' CD1' ' N ' ' A' ' 90' ' ' PHE . 33.2 p90 -132.44 157.13 45.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.288 -0.882 . . . . 0.0 110.314 -178.702 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.494 ' HB2' HG12 ' A' ' 94' ' ' ILE . 87.7 p -85.84 156.95 20.34 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.34 -0.85 . . . . 0.0 110.319 -179.129 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.499 ' O ' ' HG3' ' A' ' 93' ' ' GLU . 95.9 m-20 -70.97 -56.14 6.82 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.195 -0.941 . . . . 0.0 110.363 179.306 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.499 ' HG3' ' O ' ' A' ' 92' ' ' ASP . 98.8 mt-10 -154.97 59.95 0.66 Allowed 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.206 -0.934 . . . . 0.0 111.052 -172.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.494 HG12 ' HB2' ' A' ' 91' ' ' SER . 26.0 mm -64.26 -39.96 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.855 -1.153 . . . . 0.0 109.631 173.651 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 100.51 -47.59 1.24 Allowed Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 178.688 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 68.83 -155.09 53.51 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 34.6 p80 . . . . . 0 N--CA 1.491 1.593 0 O-C-N 121.242 -1.152 . . . . 0.0 110.184 179.73 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 99.4 mtp . . . . . 0 N--CA 1.496 1.87 0 CA-C-O 122.378 1.085 . . . . 0.0 109.676 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.939 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 13.5 p90 -174.68 154.85 2.06 Favored 'General case' 0 C--N 1.281 -2.373 0 CA-C-N 115.283 -0.871 . . . . 0.0 108.88 179.369 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.567 HG23 ' C ' ' B' ' 2' ' ' PHE . 72.4 p -151.74 -40.32 0.11 Allowed 'General case' 0 C--N 1.295 -1.788 0 O-C-N 120.967 -1.083 . . . . 0.0 109.226 178.405 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.45 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 45.74 24.68 1.29 Allowed Glycine 0 N--CA 1.484 1.837 0 N-CA-C 108.616 -1.794 . . . . 0.0 108.616 -174.225 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 0.769 HD11 HC82 ' A' ' 98' ' ' RBF . 95.6 mt -76.92 138.58 20.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.209 -1.171 . . . . 0.0 110.334 -176.104 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.789 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.2 t -97.87 147.76 6.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.314 -0.866 . . . . 0.0 110.398 -174.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -95.35 -21.78 18.17 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.483 -0.76 . . . . 0.0 110.788 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.528 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -144.63 175.4 24.35 Favored Glycine 0 N--CA 1.493 2.459 0 C-N-CA 119.273 -1.441 . . . . 0.0 110.141 -176.251 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.426 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.1 p -127.45 166.09 18.58 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.118 -1.225 . . . . 0.0 110.589 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.054 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -133.9 148.98 51.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.631 -0.668 . . . . 0.0 109.254 -178.75 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.579 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 23.6 tttt -107.79 116.91 32.81 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.121 -0.987 . . . . 0.0 110.109 179.326 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 1.009 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.2 tp -59.96 126.3 27.02 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.963 -1.086 . . . . 0.0 108.98 173.308 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.027 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.4 p -124.93 -30.86 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 O-C-N 121.451 -0.781 . . . . 0.0 109.724 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.56 142.45 28.01 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.37 -0.932 . . . . 0.0 111.098 -178.135 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.748 HG23 ' NE2' ' B' ' 24' ' ' HIS . 10.7 mt -108.68 130.24 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.176 -0.952 . . . . 0.0 110.315 172.4 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.515 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 73.5 m-20 -104.71 117.88 35.18 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.287 -0.883 . . . . 0.0 109.662 172.892 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -107.4 105.37 15.26 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.105 -0.997 . . . . 0.0 110.157 -177.545 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.467 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 2.1 mmmt -102.23 130.5 24.08 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.427 -0.796 . . . . 0.0 109.276 179.189 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -51.55 -19.33 7.11 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 123.889 1.468 . . . . 0.0 110.606 -179.491 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.578 ' O ' ' CD1' ' B' ' 21' ' ' PHE . 0.4 OUTLIER -90.43 -38.94 12.95 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.176 -0.952 . . . . 0.0 108.941 177.272 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' B' ' 20' ' ' ASN . 64.8 m-85 -152.71 150.27 29.26 Favored 'General case' 0 N--CA 1.494 1.765 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.15 -177.562 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.536 ' HD3' HD22 ' B' ' 68' ' ' LEU . 63.5 ttt180 -88.47 144.89 26.07 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.701 -1.249 . . . . 0.0 109.889 174.421 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.515 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 84.9 m -132.96 140.84 48.01 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.55 -0.719 . . . . 0.0 109.927 -174.213 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.748 ' NE2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -129.98 132.1 46.17 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.941 -1.099 . . . . 0.0 111.454 -179.654 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.621 HG22 ' CB ' ' B' ' 60' ' ' SER . 4.0 t -109.89 132.44 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.349 -0.844 . . . . 0.0 110.571 -178.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.505 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 16.0 m -117.61 169.78 7.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 CA-C-O 121.304 0.573 . . . . 0.0 110.215 -178.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.658 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 13.1 tt0 -103.09 118.48 36.89 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.102 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.519 ' CD2' ' O ' ' B' ' 32' ' ' MET . 9.5 tp -84.2 126.31 70.09 Favored Pre-proline 0 C--N 1.297 -1.711 0 O-C-N 121.254 -0.904 . . . . 0.0 109.749 -175.122 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.477 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 17.7 Cg_endo -64.27 176.8 2.39 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 O-C-N 123.865 1.455 . . . . 0.0 110.869 -179.191 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.419 ' HA ' HD12 ' B' ' 33' ' ' LEU . 77.3 m-20 -60.04 -40.0 87.88 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.413 -0.805 . . . . 0.0 111.007 -176.38 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.579 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.96 2.49 55.04 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.863 -1.148 . . . . 0.0 110.847 -174.552 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.579 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 89.2 mmm -113.06 -11.94 13.27 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.894 -1.129 . . . . 0.0 110.012 170.373 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.649 HD21 ' HB2' ' B' ' 57' ' ' ASN . 18.1 mt -69.96 -40.05 75.64 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.245 -0.91 . . . . 0.0 110.404 178.818 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -82.67 115.78 21.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.201 -0.937 . . . . 0.0 110.48 -176.396 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.62 -52.74 0.69 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.81 -1.185 . . . . 0.0 110.4 175.378 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.496 HD23 HD22 ' B' ' 28' ' ' LEU . 42.8 tp -61.65 151.42 33.61 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.919 -1.342 . . . . 0.0 110.795 -173.41 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 37' ' ' GLU . . . . . 0.507 ' C ' HD11 ' B' ' 54' ' ' ILE . 20.9 pt-20 -149.96 168.37 24.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.531 -0.731 . . . . 0.0 109.452 178.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.918 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.2 152.68 44.32 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.882 -1.136 . . . . 0.0 109.995 -178.921 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.52 -4.73 67.13 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 -176.388 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.511 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -77.4 156.48 31.15 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.299 -1.118 . . . . 0.0 109.616 176.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.624 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.1 OUTLIER -100.26 108.1 20.09 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.059 -1.026 . . . . 0.0 110.173 178.616 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.601 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.2 t -94.37 129.52 44.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.263 -0.898 . . . . 0.0 109.147 174.178 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.484 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -93.27 119.58 32.59 Favored 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 119.231 -0.988 . . . . 0.0 109.042 171.635 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.863 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.3 OUTLIER -89.21 102.55 15.21 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.319 -0.863 . . . . 0.0 108.946 178.434 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.499 ' HB3' ' HB3' ' A' ' 45' ' ' ASN . 1.8 t-20 58.38 11.47 1.66 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.511 -0.743 . . . . 0.0 110.68 -170.007 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.512 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.07 -2.13 11.65 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.888 172.662 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.83 ' O ' HD23 ' B' ' 49' ' ' LEU . 43.4 t -92.35 109.18 20.56 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.428 -1.631 . . . . 0.0 109.355 174.319 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 15.9 p -74.78 128.57 35.88 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.161 -0.962 . . . . 0.0 110.744 -171.736 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 0.904 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -147.2 156.85 43.31 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.448 -0.782 . . . . 0.0 109.477 173.649 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 50' ' ' THR . . . . . 0.427 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 23.8 m -97.26 159.09 15.12 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.737 -1.227 . . . . 0.0 111.281 -170.502 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.977 HG22 ' CE1' ' B' ' 61' ' ' PHE . 22.7 t -83.39 116.72 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.679 -0.638 . . . . 0.0 110.437 -178.524 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.561 HG22 ' HB3' ' B' ' 62' ' ' ASP . 39.8 p -70.01 -39.96 75.51 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.159 -0.963 . . . . 0.0 109.664 172.843 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.572 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.9 tt0 -160.93 154.76 22.43 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.409 -0.916 . . . . 0.0 111.172 -175.828 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.918 HD11 ' N ' ' B' ' 38' ' ' THR . 6.4 mt -109.97 129.99 63.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.115 -0.991 . . . . 0.0 110.03 169.525 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.493 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 27.6 m-80 -103.74 65.1 0.81 Allowed 'General case' 0 C--N 1.299 -1.615 0 C-N-CA 119.862 -0.735 . . . . 0.0 109.564 176.608 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.68 -113.43 3.81 Favored Glycine 0 N--CA 1.486 2.012 0 N-CA-C 108.715 -1.754 . . . . 0.0 108.715 -173.279 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.649 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -80.02 -21.1 43.93 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.061 -1.258 . . . . 0.0 109.152 175.45 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.027 ' CE1' HG11 ' B' ' 13' ' ' VAL . 17.6 m-70 -77.54 159.81 29.05 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.186 -0.947 . . . . 0.0 110.108 -176.535 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.647 ' CG1' HG13 ' B' ' 51' ' ' VAL . 97.1 t -144.31 115.47 2.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 C-N-CA 119.284 -0.967 . . . . 0.0 110.912 177.71 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.621 ' CB ' HG22 ' B' ' 25' ' ' VAL . 13.7 m -81.83 130.28 35.02 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.751 -0.593 . . . . 0.0 109.931 178.494 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.977 ' CE1' HG22 ' B' ' 51' ' ' VAL . 96.4 m-85 -115.27 160.02 20.29 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.977 -1.077 . . . . 0.0 110.275 178.107 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.561 ' HB3' HG22 ' B' ' 52' ' ' THR . 25.7 p-10 -95.2 147.77 23.11 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.012 -1.055 . . . . 0.0 111.273 -176.91 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.769 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.16 116.43 2.73 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.788 -0.57 . . . . 0.0 109.538 -175.744 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.476 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 58.0 ttm -75.25 146.99 40.66 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.867 -1.146 . . . . 0.0 109.851 179.275 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.476 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 39.0 ttpt -60.04 -49.88 75.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.041 -1.037 . . . . 0.0 110.249 -177.63 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -63.94 -42.4 97.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.888 -1.132 . . . . 0.0 110.241 178.64 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.895 HG23 " O4'" ' B' ' 99' ' ' RBF . 71.3 m -60.27 -40.07 89.08 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.003 -1.061 . . . . 0.0 109.671 174.258 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.674 HD11 ' HA2' ' B' ' 74' ' ' GLY . 11.7 tp -59.94 -43.18 95.13 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.438 -0.789 . . . . 0.0 109.559 177.733 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 16.4 mmm180 -69.98 -39.93 75.65 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.562 -0.711 . . . . 0.0 110.665 177.618 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.85 HG22 HG23 ' B' ' 71' ' ' THR . 1.5 tt -66.22 -43.69 91.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 CA-C-O 121.922 0.868 . . . . 0.0 109.363 -177.195 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.85 HG23 HG22 ' B' ' 70' ' ' ILE . 33.0 p -84.6 -170.77 3.28 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 121.44 0.638 . . . . 0.0 109.708 177.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.533 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 1.6 t30 -103.39 21.82 15.31 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 170.531 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.769 ' HB3' HD21 ' B' ' 63' ' ' LEU . 91.7 mt -66.22 -40.02 89.99 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.917 -1.114 . . . . 0.0 109.736 173.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.674 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -49.78 -25.18 6.75 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 110.429 -1.068 . . . . 0.0 110.429 -178.496 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 24.2 p-10 -66.02 -16.64 64.08 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.995 -1.297 . . . . 0.0 110.433 -174.719 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.517 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 96.2 mt -59.98 140.21 56.91 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.155 -0.965 . . . . 0.0 110.639 -176.784 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 1.009 ' C ' HD23 ' B' ' 12' ' ' LEU . 26.0 mttt -144.13 140.4 29.39 Favored 'General case' 0 C--N 1.296 -1.737 0 O-C-N 121.796 -0.565 . . . . 0.0 109.675 175.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.692 ' N ' HD23 ' B' ' 12' ' ' LEU . 19.0 t -61.82 150.25 8.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 120.942 -1.099 . . . . 0.0 110.536 -173.864 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.47 -13.49 63.73 Favored Glycine 0 N--CA 1.483 1.778 0 N-CA-C 108.959 -1.656 . . . . 0.0 108.959 -176.407 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.442 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 34.4 t0 -95.35 169.95 9.71 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.366 -1.079 . . . . 0.0 109.51 175.55 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.579 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.3 m95 -117.52 168.19 10.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.951 -1.093 . . . . 0.0 110.261 175.823 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.054 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.4 p -130.15 153.14 38.49 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.465 -0.772 . . . . 0.0 109.63 179.307 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.789 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.1 m-20 -79.77 105.72 11.27 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 120.97 -1.081 . . . . 0.0 109.158 170.023 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.554 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -106.06 140.0 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.45 -1.406 . . . . 0.0 111.331 -174.873 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 85' ' ' GLU . . . . . 0.426 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.5 tt0 -131.01 142.69 50.35 Favored 'General case' 0 N--CA 1.492 1.675 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.059 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 39.5 ttm180 -81.31 121.2 25.9 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.36 -0.838 . . . . 0.0 110.351 -178.653 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 0.963 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -117.97 144.63 45.35 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.275 -0.891 . . . . 0.0 110.158 176.491 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -126.41 142.05 51.67 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.644 -0.66 . . . . 0.0 110.663 -177.423 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 28.2 mmtp -60.5 -38.89 85.81 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.481 -0.762 . . . . 0.0 110.102 179.112 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 90' ' ' PHE . . . . . 0.454 ' CD1' ' N ' ' B' ' 90' ' ' PHE . 33.2 p90 -132.39 157.09 45.43 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.241 -0.912 . . . . 0.0 110.357 -178.715 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 91' ' ' SER . . . . . 0.789 ' CB ' HD12 ' B' ' 94' ' ' ILE . 87.4 p -85.84 156.78 20.41 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.247 -0.908 . . . . 0.0 110.32 -179.114 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 92' ' ' ASP . . . . . 0.467 ' O ' ' HB3' ' B' ' 93' ' ' GLU . 96.0 m-20 -70.39 -44.33 68.21 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.138 -0.976 . . . . 0.0 110.229 179.171 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 93' ' ' GLU . . . . . 0.525 ' O ' ' CG ' ' B' ' 93' ' ' GLU . 4.8 pt-20 -177.28 54.09 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.336 -0.853 . . . . 0.0 110.489 176.287 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 94' ' ' ILE . . . . . 0.789 HD12 ' CB ' ' B' ' 91' ' ' SER . 57.1 mt -62.29 -40.03 86.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.083 -1.01 . . . . 0.0 110.034 178.7 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 89.53 -41.4 3.01 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.135 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 96' ' ' GLY . . . . . 0.526 ' H ' HG22 ' B' ' 94' ' ' ILE . . . 95.95 -0.03 62.29 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.646 -1.381 . . . . 0.0 109.646 -178.7 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 1.5 t-80 . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.122 -1.222 . . . . 0.0 110.192 179.559 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 0.923 " O4'" HG23 ' A' ' 67' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 0.895 " O4'" HG23 ' B' ' 67' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 59.8 ttm . . . . . 0 N--CA 1.496 1.826 0 CA-C-O 121.376 0.607 . . . . 0.0 110.344 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.628 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 5.2 p90 -166.0 141.2 4.74 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.407 -0.808 . . . . 0.0 109.231 174.161 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.503 ' O ' HG13 ' A' ' 5' ' ' ILE . 26.4 p -140.95 -34.94 0.49 Allowed 'General case' 0 C--N 1.296 -1.755 0 O-C-N 121.091 -1.006 . . . . 0.0 110.095 -175.06 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.424 ' O ' ' O ' ' B' ' 46' ' ' GLY . . . 44.81 24.99 0.82 Allowed Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.031 -1.627 . . . . 0.0 109.031 -173.679 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.785 HD11 ' C8M' ' B' ' 99' ' ' RBF . 51.7 mt -83.21 135.59 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.103 -1.234 . . . . 0.0 110.288 -176.734 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.7 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.5 t -83.09 139.24 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.375 -0.828 . . . . 0.0 110.568 -176.018 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -69.98 -33.6 72.27 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.669 -0.644 . . . . 0.0 110.708 -178.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.539 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -153.42 174.75 32.02 Favored Glycine 0 N--CA 1.495 2.585 0 C-N-CA 118.957 -1.592 . . . . 0.0 110.395 -172.645 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.497 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 17.9 p -120.61 169.0 10.78 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.991 -1.3 . . . . 0.0 111.008 -177.263 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.008 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -138.07 149.5 46.05 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.6 -0.687 . . . . 0.0 109.432 -175.337 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.58 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 19.1 tttt -106.47 117.3 33.7 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.076 -1.015 . . . . 0.0 110.216 179.088 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 1.037 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.0 tp -59.93 128.52 37.27 Favored 'General case' 0 C--N 1.298 -1.643 0 O-C-N 120.885 -1.135 . . . . 0.0 108.737 172.523 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.116 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.58 -28.81 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 O-C-N 121.369 -0.832 . . . . 0.0 110.055 -178.152 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.53 140.2 24.77 Favored 'General case' 0 N--CA 1.494 1.757 0 C-N-CA 119.14 -1.024 . . . . 0.0 111.385 -178.766 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.749 HG23 ' CD2' ' A' ' 24' ' ' HIS . 7.0 mt -107.01 133.16 52.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.002 -1.061 . . . . 0.0 110.043 169.845 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.494 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 86.9 m-20 -109.98 114.51 28.09 Favored 'General case' 0 C--N 1.294 -1.832 0 O-C-N 121.443 -0.786 . . . . 0.0 109.987 173.795 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -103.9 116.6 32.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.047 -1.033 . . . . 0.0 110.388 -177.016 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.405 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -111.67 135.1 21.13 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.298 -0.876 . . . . 0.0 109.344 178.205 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -51.8 -18.44 6.52 Favored 'Trans proline' 0 C--N 1.303 -1.829 0 O-C-N 123.906 1.477 . . . . 0.0 110.774 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.575 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 5.2 m120 -97.2 -32.6 11.85 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.027 -1.046 . . . . 0.0 110.423 178.59 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.575 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 83.2 m-85 -158.03 150.41 22.28 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.272 -0.893 . . . . 0.0 110.208 -177.394 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.493 ' HD3' HD22 ' A' ' 68' ' ' LEU . 65.8 ttt180 -90.72 144.11 26.06 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.7 -1.25 . . . . 0.0 110.03 176.648 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.494 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 96.8 m -129.84 139.96 51.1 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.607 -0.683 . . . . 0.0 109.746 -175.278 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.749 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.21 139.72 50.79 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.972 -1.08 . . . . 0.0 111.164 179.766 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.677 HG22 ' CB ' ' A' ' 60' ' ' SER . 4.0 t -120.51 132.52 69.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 O-C-N 121.051 -1.031 . . . . 0.0 110.468 -178.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.875 HG13 ' CE1' ' A' ' 61' ' ' PHE . 31.7 m -115.88 171.37 5.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.862 -0.524 . . . . 0.0 110.026 179.411 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.616 ' CG ' HD22 ' A' ' 57' ' ' ASN . 10.4 tt0 -108.54 115.7 30.59 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.523 HD22 HD23 ' A' ' 36' ' ' LEU . 8.7 tp -86.8 127.97 58.05 Favored Pre-proline 0 C--N 1.296 -1.725 0 O-C-N 121.206 -0.934 . . . . 0.0 110.285 -172.109 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.483 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 28.9 Cg_endo -66.72 177.1 3.68 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 O-C-N 123.941 1.496 . . . . 0.0 111.05 -179.401 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.534 ' HA ' HD12 ' A' ' 33' ' ' LEU . 95.9 m-20 -60.07 -40.06 88.21 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.23 -0.919 . . . . 0.0 111.083 -174.251 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.596 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.02 0.86 56.88 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.814 -1.178 . . . . 0.0 110.959 -174.655 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.596 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.8 mmm -112.59 -12.03 13.49 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.958 -1.089 . . . . 0.0 109.964 172.282 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.6 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 19.8 mt -70.07 -39.97 75.33 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.408 -0.807 . . . . 0.0 110.186 177.832 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -73.91 143.13 45.9 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.419 -0.801 . . . . 0.0 110.583 -178.147 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.5 -39.02 3.01 Favored Glycine 0 N--CA 1.492 2.409 0 C-N-CA 119.925 -1.131 . . . . 0.0 110.555 173.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.523 HD23 HD22 ' A' ' 28' ' ' LEU . 50.3 tp -77.54 147.93 35.5 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.896 -1.355 . . . . 0.0 110.892 -174.108 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.499 ' C ' HD11 ' A' ' 54' ' ' ILE . 21.3 pt-20 -149.07 166.58 28.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.409 -0.807 . . . . 0.0 109.511 177.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.843 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -64.99 147.78 52.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.825 -1.172 . . . . 0.0 109.862 179.376 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.94 -7.68 62.3 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -175.412 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.533 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -74.99 153.18 38.64 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.277 -1.131 . . . . 0.0 109.645 177.319 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.87 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.0 OUTLIER -96.58 110.12 22.59 Favored 'General case' 0 C--N 1.309 -1.19 0 O-C-N 120.76 -1.212 . . . . 0.0 109.955 175.474 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.657 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.0 t -92.91 130.09 42.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 173.321 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.574 ' HB3' ' CG ' ' A' ' 85' ' ' GLU . . . -93.47 119.69 32.85 Favored 'General case' 0 C--N 1.293 -1.848 0 C-N-CA 119.001 -1.079 . . . . 0.0 109.071 173.12 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.657 ' HE1' HG11 ' A' ' 42' ' ' VAL . 0.3 OUTLIER -90.31 106.02 18.21 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 177.727 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' B' ' 45' ' ' ASN . 0.9 OUTLIER 58.27 7.85 0.73 Allowed 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.341 -0.849 . . . . 0.0 111.547 -169.887 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.408 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 125.61 -3.2 8.13 Favored Glycine 0 N--CA 1.49 2.292 0 O-C-N 120.703 -1.248 . . . . 0.0 110.549 174.668 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.841 ' O ' HD23 ' A' ' 49' ' ' LEU . 32.6 t -94.37 108.26 20.17 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.59 -1.535 . . . . 0.0 109.812 176.857 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 19.5 p -70.29 128.54 36.57 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.163 -0.961 . . . . 0.0 110.895 -175.434 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.851 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -143.29 158.03 43.98 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.365 -0.834 . . . . 0.0 109.344 172.347 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 65.0 m -99.51 149.33 23.34 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.559 -1.338 . . . . 0.0 111.403 -170.242 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.917 HG13 HG13 ' A' ' 59' ' ' VAL . 20.4 t -76.88 114.74 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 CA-C-O 121.01 0.433 . . . . 0.0 110.406 -178.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.52 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 52.6 p -69.32 -40.07 77.84 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.184 -0.947 . . . . 0.0 109.602 173.781 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.566 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 89.3 tt0 -161.49 156.4 23.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.428 -0.795 . . . . 0.0 110.157 -178.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.843 HD11 ' N ' ' A' ' 38' ' ' THR . 8.2 mt -108.9 129.3 63.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.075 -1.015 . . . . 0.0 109.987 174.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.535 ' HB2' ' CB ' ' A' ' 58' ' ' HIS . 8.6 m-80 -102.39 62.95 0.87 Allowed 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.537 -0.727 . . . . 0.0 109.88 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.67 -117.99 5.33 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.768 -1.733 . . . . 0.0 108.768 -173.923 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.616 HD22 ' CG ' ' A' ' 27' ' ' GLU . 0.1 OUTLIER -74.9 -19.87 59.95 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 120.902 -1.352 . . . . 0.0 108.768 174.216 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.116 ' CD2' HG11 ' A' ' 13' ' ' VAL . 10.3 m170 -75.61 159.77 30.84 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.424 -0.798 . . . . 0.0 110.129 -177.177 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.917 HG13 HG13 ' A' ' 51' ' ' VAL . 53.6 t -140.55 123.0 15.81 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 121.039 -1.038 . . . . 0.0 110.641 171.092 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.677 ' CB ' HG22 ' A' ' 25' ' ' VAL . 17.0 m -89.65 128.72 36.11 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.609 -0.682 . . . . 0.0 109.478 177.682 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.875 ' CE1' HG13 ' A' ' 26' ' ' VAL . 2.4 p90 -124.14 152.38 42.86 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.98 -1.075 . . . . 0.0 110.182 179.002 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.52 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 33.1 p-10 -89.38 156.12 18.9 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 120.986 -1.071 . . . . 0.0 111.708 -171.216 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.923 HD22 HD13 ' A' ' 68' ' ' LEU . 0.2 OUTLIER -160.64 101.4 1.33 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.691 -0.631 . . . . 0.0 109.613 -173.416 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.503 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 57.2 ttm -61.53 139.56 58.23 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.57 -1.331 . . . . 0.0 109.174 178.491 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.477 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 78.7 tttt -59.96 -47.87 84.01 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.723 -1.236 . . . . 0.0 110.38 -173.574 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -64.49 -39.95 94.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.876 -1.14 . . . . 0.0 109.87 177.825 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.503 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 94.6 m -61.38 -39.93 92.45 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.898 -1.126 . . . . 0.0 109.526 173.13 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.923 HD13 HD22 ' A' ' 63' ' ' LEU . 16.3 tp -59.99 -41.14 91.42 Favored 'General case' 0 C--N 1.3 -1.587 0 O-C-N 121.352 -0.843 . . . . 0.0 109.269 178.378 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -67.02 -39.99 87.17 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.475 -0.766 . . . . 0.0 110.491 173.827 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.797 HG22 HG23 ' A' ' 71' ' ' THR . 0.8 OUTLIER -65.64 -43.39 93.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.139 -0.975 . . . . 0.0 109.359 -175.538 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.797 HG23 HG22 ' A' ' 70' ' ' ILE . 24.7 p -84.25 -174.43 5.27 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 175.035 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.4 t30 -101.45 23.48 11.02 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 171.704 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.681 HD13 HD21 ' A' ' 63' ' ' LEU . 91.6 mt -70.05 -39.96 75.4 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.132 -0.98 . . . . 0.0 110.009 176.049 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.547 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -47.53 -22.56 1.74 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 -178.816 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.508 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.3 p-10 -68.69 -17.15 64.02 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.066 -1.255 . . . . 0.0 110.612 -174.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.508 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 89.3 mt -62.38 143.04 57.49 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.243 -0.911 . . . . 0.0 110.909 -177.627 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 1.037 ' C ' HD23 ' A' ' 12' ' ' LEU . 89.8 mttt -141.5 144.61 34.43 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 109.327 -0.619 . . . . 0.0 109.327 174.789 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.687 HG21 HG13 ' A' ' 15' ' ' ILE . 47.3 t -64.95 147.28 12.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 120.752 -1.217 . . . . 0.0 110.07 -176.86 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.55 -14.14 62.14 Favored Glycine 0 N--CA 1.483 1.807 0 N-CA-C 108.616 -1.794 . . . . 0.0 108.616 -173.039 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 39.6 t0 -96.09 166.85 11.55 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.387 -1.067 . . . . 0.0 109.504 175.648 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.58 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.2 m95 -117.64 166.92 11.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.044 -1.035 . . . . 0.0 110.199 177.311 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.008 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.3 p -132.39 156.57 42.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.382 -0.824 . . . . 0.0 109.984 -178.294 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.7 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.2 m-20 -79.53 105.63 10.97 Favored 'General case' 0 C--N 1.296 -1.752 0 O-C-N 121.03 -1.044 . . . . 0.0 109.097 169.096 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.979 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -110.24 141.92 24.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 120.382 -1.449 . . . . 0.0 110.873 -176.56 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.574 ' CG ' ' HB3' ' A' ' 43' ' ' ALA . 19.9 pt-20 -149.06 153.83 38.41 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 119.748 -0.781 . . . . 0.0 110.162 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 63.1 ttt180 -68.2 130.03 41.7 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.228 -0.92 . . . . 0.0 110.385 -178.065 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.87 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . -128.97 148.24 50.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.371 -0.831 . . . . 0.0 109.489 176.494 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.751 ' HB2' ' O ' ' A' ' 87' ' ' ALA . . . 164.61 31.32 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.457 -0.777 . . . . 0.0 111.367 178.756 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.58 ' HB3' ' CD1' ' B' ' 2' ' ' PHE . 0.0 OUTLIER 50.68 28.41 3.53 Favored 'General case' 0 N--CA 1.511 2.609 0 O-C-N 120.923 -1.11 . . . . 0.0 109.835 -179.52 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.432 ' CD2' ' O ' ' A' ' 91' ' ' SER . 42.8 p90 -88.87 165.81 14.39 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.122 -0.986 . . . . 0.0 110.198 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.526 ' HB2' ' CG1' ' A' ' 94' ' ' ILE . 84.7 p -68.73 149.22 49.29 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.061 -1.024 . . . . 0.0 110.309 -175.237 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.502 ' O ' ' HG3' ' A' ' 93' ' ' GLU . 96.1 m-20 -69.58 -45.23 69.15 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.145 -0.972 . . . . 0.0 110.505 -178.565 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.502 ' HG3' ' O ' ' A' ' 92' ' ' ASP . 43.6 mt-10 -155.04 54.04 0.64 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.0 -1.062 . . . . 0.0 110.68 179.361 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.526 ' CG1' ' HB2' ' A' ' 91' ' ' SER . 35.1 mm -97.02 -13.45 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.16 -0.962 . . . . 0.0 110.346 176.799 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 113.3 -83.85 0.34 Allowed Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -178.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 64.88 -168.11 29.05 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 178.958 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.702 0 O-C-N 121.303 -1.116 . . . . 0.0 110.172 179.865 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 67.5 mtt . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 121.097 0.475 . . . . 0.0 110.065 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.616 ' CZ ' ' HA ' ' A' ' 88' ' ' ALA . 5.4 p90 -158.52 141.02 14.31 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.11 -0.994 . . . . 0.0 109.068 170.598 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.508 ' O ' HG13 ' B' ' 5' ' ' ILE . 26.3 p -140.95 -35.09 0.48 Allowed 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.14 -0.975 . . . . 0.0 110.046 -175.059 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.436 ' C ' ' O ' ' B' ' 3' ' ' THR . . . 44.92 24.99 0.85 Allowed Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -173.658 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 0.811 HD11 ' C8M' ' A' ' 98' ' ' RBF . 51.8 mt -83.29 135.6 24.48 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.09 -1.241 . . . . 0.0 110.268 -176.706 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.693 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.5 t -83.12 139.25 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.313 -0.867 . . . . 0.0 110.527 -175.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 88.2 mt-30 -69.97 -33.37 71.99 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.672 -0.642 . . . . 0.0 110.792 -178.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.542 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -153.62 174.52 32.2 Favored Glycine 0 N--CA 1.498 2.767 0 C-N-CA 119.073 -1.537 . . . . 0.0 110.441 -172.583 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.499 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 18.1 p -120.49 168.85 10.9 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.049 -1.265 . . . . 0.0 111.053 -177.254 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.049 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -137.96 149.64 46.32 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.549 -0.719 . . . . 0.0 109.396 -175.477 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.575 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 19.1 tttt -106.54 117.37 33.86 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.105 -0.997 . . . . 0.0 110.194 179.102 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 1.047 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.0 tp -60.02 128.38 36.55 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.0 -1.063 . . . . 0.0 108.818 172.532 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.117 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.45 -28.84 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.926 0 C-N-CA 119.684 -0.806 . . . . 0.0 110.136 -178.148 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.46 140.22 24.86 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.304 -0.958 . . . . 0.0 111.459 -178.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.754 HG23 ' CD2' ' B' ' 24' ' ' HIS . 6.7 mt -106.87 133.12 52.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.922 -1.111 . . . . 0.0 110.145 169.837 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.508 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 86.9 m-20 -110.04 114.53 28.13 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.555 -0.716 . . . . 0.0 110.026 173.82 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -103.85 116.52 32.44 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.096 -1.002 . . . . 0.0 110.379 -176.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.41 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -111.59 134.99 21.11 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.285 -0.884 . . . . 0.0 109.35 178.208 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_endo -51.85 -18.44 6.62 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 O-C-N 123.861 1.453 . . . . 0.0 110.734 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.573 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 5.3 m120 -96.91 -33.32 11.65 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.095 -1.003 . . . . 0.0 110.263 178.62 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.573 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 83.7 m-85 -157.52 150.43 23.25 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.293 -0.879 . . . . 0.0 110.215 -177.243 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.503 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 65.9 ttt180 -90.61 144.06 26.13 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.926 -1.109 . . . . 0.0 110.074 176.569 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.508 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 96.0 m -129.77 140.03 51.15 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.684 -0.635 . . . . 0.0 109.728 -175.33 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.754 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.18 139.77 50.82 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.007 -1.058 . . . . 0.0 111.118 179.802 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.669 HG22 ' CB ' ' B' ' 60' ' ' SER . 3.9 t -120.51 132.55 69.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.197 -0.939 . . . . 0.0 110.436 -178.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.858 HG13 ' CE1' ' B' ' 61' ' ' PHE . 32.4 m -116.03 171.38 5.1 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 121.691 -0.631 . . . . 0.0 109.922 179.462 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.606 ' CG ' HD22 ' B' ' 57' ' ' ASN . 10.4 tt0 -108.48 115.71 30.62 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 -179.537 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.531 HD22 HD23 ' B' ' 36' ' ' LEU . 8.7 tp -86.69 127.94 58.41 Favored Pre-proline 0 C--N 1.296 -1.732 0 O-C-N 121.148 -0.97 . . . . 0.0 110.28 -172.098 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.495 ' HD2' HD12 ' B' ' 28' ' ' LEU . 29.1 Cg_endo -66.79 177.12 3.71 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 O-C-N 123.924 1.486 . . . . 0.0 111.056 -179.435 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.517 ' HA ' HD12 ' B' ' 33' ' ' LEU . 96.1 m-20 -60.09 -39.95 87.9 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.273 -0.892 . . . . 0.0 111.159 -174.233 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.603 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.05 0.73 56.97 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.79 -1.194 . . . . 0.0 110.862 -174.671 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.603 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.7 mmm -112.58 -11.86 13.52 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.981 -1.074 . . . . 0.0 109.971 172.255 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.591 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 19.9 mt -70.14 -39.9 75.12 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.354 -0.841 . . . . 0.0 110.185 177.783 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -73.98 143.11 45.75 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.499 -0.751 . . . . 0.0 110.532 -178.083 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.51 -39.01 3.01 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 119.954 -1.117 . . . . 0.0 110.505 173.904 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.531 HD23 HD22 ' B' ' 28' ' ' LEU . 50.5 tp -77.47 147.91 35.66 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.86 -1.377 . . . . 0.0 110.826 -174.056 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 37' ' ' GLU . . . . . 0.489 ' C ' HD11 ' B' ' 54' ' ' ILE . 21.4 pt-20 -149.12 166.59 28.31 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.454 -0.779 . . . . 0.0 109.5 177.85 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.844 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -64.98 147.7 52.96 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.85 -1.156 . . . . 0.0 109.942 179.366 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.06 -7.76 62.43 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -175.393 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.537 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -75.02 152.89 38.67 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.336 -1.096 . . . . 0.0 109.64 177.254 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.875 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.0 OUTLIER -96.09 110.03 22.35 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 120.882 -1.137 . . . . 0.0 110.059 175.39 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.65 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.0 t -93.08 130.01 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 173.301 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.581 ' HB3' ' CG ' ' B' ' 85' ' ' GLU . . . -93.38 119.67 32.77 Favored 'General case' 0 C--N 1.295 -1.789 0 C-N-CA 118.993 -1.083 . . . . 0.0 109.167 173.075 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.65 ' HE1' HG11 ' B' ' 42' ' ' VAL . 0.3 OUTLIER -90.26 105.62 17.93 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 177.712 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.0 t-20 58.81 7.77 0.83 Allowed 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.375 -0.828 . . . . 0.0 111.379 -170.08 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.424 ' O ' ' O ' ' A' ' 4' ' ' GLY . . . 125.45 -2.82 8.22 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.749 -1.215 . . . . 0.0 110.638 174.57 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.849 ' O ' HD23 ' B' ' 49' ' ' LEU . 32.7 t -94.56 108.08 20.05 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.597 -1.531 . . . . 0.0 109.867 176.732 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 18.2 p -70.07 128.68 37.14 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.133 -0.979 . . . . 0.0 110.842 -175.414 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 0.867 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -143.42 158.08 43.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.335 -0.853 . . . . 0.0 109.263 172.239 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 65.1 m -99.46 149.42 23.22 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.523 -1.361 . . . . 0.0 111.411 -170.191 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.935 HG13 HG13 ' B' ' 59' ' ' VAL . 20.7 t -77.19 114.82 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.839 -0.538 . . . . 0.0 110.434 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.53 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 53.7 p -69.38 -40.02 77.66 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.176 -0.953 . . . . 0.0 109.601 173.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.566 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 89.3 tt0 -161.51 156.38 23.38 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.77 -0.772 . . . . 0.0 110.128 -178.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.844 HD11 ' N ' ' B' ' 38' ' ' THR . 8.3 mt -108.85 129.16 63.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.096 -1.003 . . . . 0.0 110.088 175.05 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.542 ' HB2' ' CB ' ' B' ' 58' ' ' HIS . 8.5 m-80 -102.45 63.12 0.86 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.626 -0.671 . . . . 0.0 109.782 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.67 -118.0 5.34 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.695 -1.762 . . . . 0.0 108.695 -173.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.606 HD22 ' CG ' ' B' ' 27' ' ' GLU . 0.1 OUTLIER -74.87 -20.01 59.92 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 120.988 -1.301 . . . . 0.0 108.78 174.249 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.117 ' CD2' HG11 ' B' ' 13' ' ' VAL . 10.3 m170 -75.52 159.59 31.11 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.469 -0.769 . . . . 0.0 110.234 -177.219 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.935 HG13 HG13 ' B' ' 51' ' ' VAL . 54.3 t -140.46 123.09 16.15 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 O-C-N 121.063 -1.023 . . . . 0.0 110.55 171.247 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.669 ' CB ' HG22 ' B' ' 25' ' ' VAL . 17.4 m -89.69 128.78 36.14 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.586 -0.696 . . . . 0.0 109.519 177.675 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.867 ' HB2' HD12 ' B' ' 49' ' ' LEU . 2.4 p90 -124.21 152.37 43.0 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.965 -1.085 . . . . 0.0 110.186 178.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.53 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 33.0 p-10 -89.32 156.09 18.94 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 120.834 -1.166 . . . . 0.0 111.588 -171.119 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.944 HD22 HD13 ' B' ' 68' ' ' LEU . 0.2 OUTLIER -160.66 101.52 1.32 Allowed 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.696 -0.628 . . . . 0.0 109.656 -173.526 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.494 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 57.1 ttm -61.59 139.45 58.27 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.612 -1.305 . . . . 0.0 109.163 178.527 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.48 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 78.6 tttt -59.94 -47.81 84.26 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.86 -1.15 . . . . 0.0 110.384 -173.506 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -64.5 -40.0 94.83 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.943 -1.098 . . . . 0.0 109.843 177.814 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.494 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 94.2 m -61.24 -40.08 92.7 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.96 -1.087 . . . . 0.0 109.564 173.117 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.944 HD13 HD22 ' B' ' 63' ' ' LEU . 16.3 tp -59.92 -41.08 90.94 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.339 -0.851 . . . . 0.0 109.35 178.352 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -67.04 -40.07 87.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.415 -0.803 . . . . 0.0 110.449 173.829 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.791 HG22 HG23 ' B' ' 71' ' ' THR . 0.8 OUTLIER -65.51 -43.32 94.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.24 -0.913 . . . . 0.0 109.426 -175.599 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.791 HG23 HG22 ' B' ' 70' ' ' ILE . 25.1 p -84.36 -174.17 5.13 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.006 -0.678 . . . . 0.0 109.195 175.171 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.528 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 4.1 t30 -101.62 23.47 11.17 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 171.708 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.698 HD13 HD21 ' B' ' 63' ' ' LEU . 91.6 mt -70.04 -39.99 75.39 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.133 -0.979 . . . . 0.0 109.996 176.013 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.54 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -47.42 -22.7 1.69 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -178.856 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.4 p-10 -68.65 -17.08 64.03 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.057 -1.261 . . . . 0.0 110.647 -174.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 89.5 mt -62.32 143.08 57.39 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.2 -0.937 . . . . 0.0 110.912 -177.702 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 1.047 ' C ' HD23 ' B' ' 12' ' ' LEU . 89.8 mttt -141.64 144.58 34.23 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 174.785 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.696 HG21 HG13 ' B' ' 15' ' ' ILE . 47.2 t -64.9 147.31 12.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.885 -1.134 . . . . 0.0 110.062 -176.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.49 -14.07 62.23 Favored Glycine 0 N--CA 1.484 1.875 0 N-CA-C 108.67 -1.772 . . . . 0.0 108.67 -173.072 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 39.2 t0 -96.12 166.76 11.6 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.472 -1.016 . . . . 0.0 109.483 175.564 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.575 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.3 m95 -117.64 166.84 11.93 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.057 -1.027 . . . . 0.0 110.136 177.388 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.049 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.3 p -132.36 156.66 42.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.429 -0.794 . . . . 0.0 109.963 -178.427 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.693 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.1 m-20 -79.44 105.53 10.82 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.116 -0.99 . . . . 0.0 109.203 169.117 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.947 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -110.2 142.21 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 120.419 -1.425 . . . . 0.0 110.765 -176.399 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 85' ' ' GLU . . . . . 0.581 ' CG ' ' HB3' ' B' ' 43' ' ' ALA . 19.9 pt-20 -149.38 153.84 38.0 Favored 'General case' 0 N--CA 1.492 1.64 0 C-N-CA 119.779 -0.768 . . . . 0.0 110.05 179.249 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 63.2 ttt180 -68.14 129.97 41.51 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.181 -0.95 . . . . 0.0 110.432 -178.045 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 0.875 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . -128.68 148.55 50.83 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.411 -0.806 . . . . 0.0 109.502 176.509 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 88' ' ' ALA . . . . . 0.763 ' HB2' ' O ' ' B' ' 87' ' ' ALA . . . 164.23 31.3 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.158 0 O-C-N 121.418 -0.801 . . . . 0.0 111.346 178.586 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 89' ' ' LYS . . . . . 0.519 ' O ' ' CG ' ' B' ' 89' ' ' LYS . 0.0 OUTLIER 50.75 28.39 3.58 Favored 'General case' 0 N--CA 1.51 2.537 0 O-C-N 120.951 -1.093 . . . . 0.0 109.892 -179.561 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 90' ' ' PHE . . . . . 0.44 ' CD2' ' O ' ' B' ' 91' ' ' SER . 42.9 p90 -89.0 165.71 14.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.079 -1.013 . . . . 0.0 110.147 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 91' ' ' SER . . . . . 0.44 ' O ' ' CD2' ' B' ' 90' ' ' PHE . 84.6 p -68.59 149.03 49.65 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.057 -1.027 . . . . 0.0 110.383 -175.25 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 92' ' ' ASP . . . . . 0.429 ' O ' ' HB3' ' B' ' 93' ' ' GLU . 95.9 m-20 -69.61 -47.41 63.58 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.145 -0.972 . . . . 0.0 110.397 -178.508 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 93' ' ' GLU . . . . . 0.478 ' O ' ' HG3' ' B' ' 93' ' ' GLU . 21.5 pt-20 -175.92 46.68 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.341 0 CA-C-O 121.751 0.786 . . . . 0.0 110.161 -178.153 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 94' ' ' ILE . . . . . . . . . . . . . 22.1 mm -65.35 -40.01 87.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.584 -0.698 . . . . 0.0 110.166 178.297 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 115.82 -71.91 0.26 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.358 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -132.54 148.51 19.23 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.456 -1.457 . . . . 0.0 109.456 179.151 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 78.0 t60 . . . . . 0 N--CA 1.493 1.68 0 O-C-N 121.264 -1.139 . . . . 0.0 110.208 -179.378 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 0.811 ' C8M' HD11 ' B' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 0.785 ' C8M' HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 29.6 mtp . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.033 0.444 . . . . 0.0 110.081 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 1.081 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 3.9 p90 -169.78 155.17 5.69 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.127 -0.983 . . . . 0.0 108.559 174.523 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.556 HG23 ' C ' ' A' ' 2' ' ' PHE . 30.0 p -150.72 -38.75 0.13 Allowed 'General case' 0 C--N 1.295 -1.771 0 O-C-N 120.942 -1.099 . . . . 0.0 109.284 175.658 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.464 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 48.48 23.98 3.51 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 108.277 -1.929 . . . . 0.0 108.277 -175.309 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.554 HD11 HC82 ' B' ' 99' ' ' RBF . 79.1 mt -79.28 125.44 38.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.437 -1.037 . . . . 0.0 109.732 -178.079 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.885 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.0 t -84.36 139.44 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.191 -0.943 . . . . 0.0 110.835 -170.524 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -70.06 -34.83 73.71 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.86 -0.525 . . . . 0.0 111.036 178.356 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.544 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -154.76 174.44 33.05 Favored Glycine 0 N--CA 1.496 2.641 0 C-N-CA 118.933 -1.603 . . . . 0.0 110.191 -172.1 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.441 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.3 p -119.99 170.45 9.26 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.944 -1.327 . . . . 0.0 111.2 -176.14 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.018 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -139.46 150.1 44.79 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -178.005 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 21.6 tttt -108.9 117.68 34.83 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.045 -1.034 . . . . 0.0 110.375 -179.552 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 1.023 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.0 tp -59.41 128.85 39.15 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.892 -1.13 . . . . 0.0 108.947 173.531 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.119 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.99 -28.82 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 C-N-CA 119.512 -0.875 . . . . 0.0 110.101 -178.802 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.93 140.56 23.5 Favored 'General case' 0 N--CA 1.493 1.696 0 C-N-CA 119.089 -1.045 . . . . 0.0 111.445 -178.375 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.744 HG23 ' CD2' ' A' ' 24' ' ' HIS . 14.1 mt -109.96 133.39 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.116 -0.99 . . . . 0.0 110.279 172.656 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.498 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 76.6 m-20 -108.54 116.12 31.37 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.335 -0.853 . . . . 0.0 109.883 172.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -107.64 115.33 29.95 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.948 -1.095 . . . . 0.0 110.735 -175.473 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.48 130.27 24.45 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.21 -0.931 . . . . 0.0 109.209 176.822 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -52.1 -19.79 9.51 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.792 1.417 . . . . 0.0 110.275 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.57 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 0.5 OUTLIER -83.54 -42.57 16.67 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.186 -0.946 . . . . 0.0 108.991 176.554 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.57 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 89.5 m-85 -156.98 150.32 24.14 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-O 121.307 0.575 . . . . 0.0 110.044 -177.674 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.484 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 60.2 ttt180 -89.49 143.59 26.7 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.898 -1.126 . . . . 0.0 110.116 177.673 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.498 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.3 m -128.74 135.04 48.67 Favored 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.548 -0.72 . . . . 0.0 109.827 -176.358 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.744 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -127.78 141.36 51.6 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.813 -1.18 . . . . 0.0 111.594 -179.449 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.885 HG22 ' OG ' ' A' ' 60' ' ' SER . 6.3 t -123.26 133.48 69.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.172 -0.955 . . . . 0.0 110.667 -179.397 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.669 HG13 ' HE2' ' A' ' 61' ' ' PHE . 36.0 m -117.66 172.47 5.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-O 121.233 0.539 . . . . 0.0 110.274 179.533 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.535 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 7.2 tt0 -100.22 116.96 33.44 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.313 -0.867 . . . . 0.0 109.071 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.657 ' HG ' HD23 ' A' ' 36' ' ' LEU 0.256 0.1 OUTLIER -86.81 114.82 59.99 Favored Pre-proline 0 C--N 1.295 -1.777 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -176.818 . . . . . . . . 4 4 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.57 ' HD2' HD13 ' A' ' 28' ' ' LEU . 18.9 Cg_endo -63.3 174.48 3.33 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.779 1.41 . . . . 0.0 111.187 -178.299 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.574 ' HA ' HD12 ' A' ' 33' ' ' LEU . 1.9 p30 -63.22 -35.54 80.65 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.452 -0.78 . . . . 0.0 111.269 -174.219 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.527 ' N ' ' OD1' ' A' ' 30' ' ' ASP . 0.0 OUTLIER -91.0 -0.19 57.69 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.728 -1.232 . . . . 0.0 111.057 -173.551 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.646 ' HB3' HD11 ' A' ' 28' ' ' LEU . 96.2 mmm -114.48 -14.32 12.15 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 120.925 -1.109 . . . . 0.0 109.815 168.89 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.655 HD21 ' HA ' ' A' ' 57' ' ' ASN . 12.4 mt -64.3 -40.04 95.14 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.163 -0.961 . . . . 0.0 109.932 177.653 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -63.98 131.53 47.93 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.32 -0.862 . . . . 0.0 110.484 -178.104 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.39 -39.26 3.08 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 175.149 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.657 HD23 ' HG ' ' A' ' 28' ' ' LEU . 60.8 tp -62.38 144.52 55.7 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.963 -1.316 . . . . 0.0 110.85 -175.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.467 ' C ' HD11 ' A' ' 54' ' ' ILE . 19.2 pt-20 -151.49 164.78 36.02 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.728 -0.607 . . . . 0.0 109.452 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.8 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -66.92 150.48 49.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.849 -1.157 . . . . 0.0 109.763 178.376 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.63 -0.06 62.0 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 -174.572 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.438 ' CB ' ' O ' ' A' ' 37' ' ' GLU . . . -75.38 158.99 31.92 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.228 -1.16 . . . . 0.0 109.279 175.358 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.692 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.6 OUTLIER -100.39 110.89 23.12 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 118.854 -1.138 . . . . 0.0 109.829 176.025 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.664 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.8 t -100.1 125.67 53.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.457 -0.777 . . . . 0.0 109.041 175.688 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.48 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -92.0 119.78 32.03 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 119.041 -1.064 . . . . 0.0 109.242 172.401 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.688 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.6 OUTLIER -87.98 103.02 15.3 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 177.922 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.5 t-20 57.16 11.17 0.98 Allowed 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.455 -0.778 . . . . 0.0 111.141 -170.474 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.471 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 123.84 -0.21 9.17 Favored Glycine 0 N--CA 1.489 2.233 0 C-N-CA 119.584 -1.293 . . . . 0.0 110.605 174.621 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.834 ' O ' HD23 ' A' ' 49' ' ' LEU . 16.7 t -98.74 105.39 17.53 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.41 -1.641 . . . . 0.0 109.535 175.604 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.409 ' HA ' ' HA ' ' A' ' 43' ' ' ALA . 15.9 p -74.05 129.0 36.99 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.983 -1.073 . . . . 0.0 110.855 -172.368 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.864 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -142.95 160.84 39.59 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.377 -0.827 . . . . 0.0 109.605 173.739 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 6.6 m -100.43 148.1 25.12 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.552 -1.342 . . . . 0.0 111.237 -170.09 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.948 HG13 HG13 ' A' ' 59' ' ' VAL . 21.0 t -76.21 115.32 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.892 -0.505 . . . . 0.0 110.475 -179.361 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.534 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 30.4 p -70.46 -40.02 73.93 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.247 -0.908 . . . . 0.0 109.789 173.656 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.57 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -162.64 154.49 18.36 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.288 -0.882 . . . . 0.0 110.313 -179.479 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.8 HD11 ' N ' ' A' ' 38' ' ' THR . 7.6 mt -105.72 130.52 57.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.159 -0.963 . . . . 0.0 110.088 176.367 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.5 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 4.7 m-80 -102.51 64.39 0.9 Allowed 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.61 -0.681 . . . . 0.0 109.822 179.027 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.2 -119.5 5.9 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.774 -1.73 . . . . 0.0 108.774 -173.75 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.655 ' HA ' HD21 ' A' ' 33' ' ' LEU . 0.1 OUTLIER -73.12 -22.1 60.61 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 120.878 -1.366 . . . . 0.0 108.643 174.315 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.119 ' CD2' HG11 ' A' ' 13' ' ' VAL . 12.3 m80 -74.02 159.97 31.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.283 -0.885 . . . . 0.0 110.431 -176.579 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.948 HG13 HG13 ' A' ' 51' ' ' VAL . 51.4 t -139.98 125.38 20.77 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 121.084 -1.01 . . . . 0.0 110.706 170.526 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.885 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.7 t -91.6 135.08 34.13 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.444 -0.785 . . . . 0.0 109.274 175.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.864 ' HB2' HD12 ' A' ' 49' ' ' LEU . 8.8 p90 -128.35 154.39 46.02 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 121.304 -0.872 . . . . 0.0 110.483 177.141 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.534 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 28.9 p-10 -89.67 150.85 22.16 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.157 -0.965 . . . . 0.0 111.332 -171.616 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.7 HD21 HD13 ' A' ' 73' ' ' LEU . 0.0 OUTLIER -155.6 117.6 4.09 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -176.079 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.54 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 52.6 mtt -68.46 142.33 55.37 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.786 -1.196 . . . . 0.0 109.518 177.425 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.475 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 86.0 tttt -59.97 -44.59 94.36 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 120.991 -1.068 . . . . 0.0 109.715 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 52.5 tp10 -70.04 -39.93 75.43 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.189 -0.944 . . . . 0.0 110.235 178.415 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.54 ' HB ' ' HB2' ' A' ' 64' ' ' MET . 89.5 m -61.41 -37.81 84.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.795 -1.191 . . . . 0.0 109.084 172.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.581 ' CD1' HD22 ' A' ' 63' ' ' LEU . 7.1 tp -60.07 -44.32 94.84 Favored 'General case' 0 C--N 1.297 -1.69 0 O-C-N 121.143 -0.973 . . . . 0.0 109.193 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 52.0 ttt85 -70.08 -39.91 75.3 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.456 -0.777 . . . . 0.0 110.52 175.501 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.863 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -62.72 -41.38 92.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.176 -0.953 . . . . 0.0 109.072 -177.719 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.863 HG23 HG22 ' A' ' 70' ' ' ILE . 31.2 p -88.93 -176.76 5.29 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 175.765 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.481 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 2.4 t30 -100.18 25.08 7.87 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 172.112 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.7 HD13 HD21 ' A' ' 63' ' ' LEU . 55.7 mt -69.85 -39.99 76.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.941 -1.099 . . . . 0.0 109.861 174.556 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.541 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -48.12 -22.76 2.38 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 -179.034 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.0 p-10 -64.89 -17.38 64.26 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.151 -1.205 . . . . 0.0 110.5 -176.369 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 90.3 mt -62.06 144.02 55.8 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.299 -0.875 . . . . 0.0 110.889 -176.724 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 1.023 ' C ' HD23 ' A' ' 12' ' ' LEU . 35.0 mttp -143.83 143.86 31.51 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.747 -0.596 . . . . 0.0 109.41 174.13 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.67 ' N ' HD23 ' A' ' 12' ' ' LEU . 14.9 t -61.77 150.06 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 120.637 -1.289 . . . . 0.0 110.107 -176.722 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.35 -12.15 61.48 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 108.927 -1.669 . . . . 0.0 108.927 -176.361 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 48.7 t0 -95.77 166.27 11.89 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.312 -1.111 . . . . 0.0 109.496 176.236 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.6 m95 -117.43 156.63 27.62 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.987 -1.071 . . . . 0.0 110.524 178.728 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.018 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.1 p -120.05 150.88 22.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.516 -0.74 . . . . 0.0 109.874 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.885 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.3 OUTLIER -76.82 106.28 8.4 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.072 -1.018 . . . . 0.0 108.951 168.966 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.67 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -105.97 138.52 30.89 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 120.425 -1.422 . . . . 0.0 111.5 -175.223 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.431 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.8 tt0 -133.3 140.67 47.58 Favored 'General case' 0 N--CA 1.496 1.829 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.178 -179.318 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 71.6 ttt-85 -80.31 134.17 36.04 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.195 -0.94 . . . . 0.0 111.148 -175.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 1.059 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -132.15 150.76 52.08 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.409 -0.807 . . . . 0.0 110.28 179.361 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -124.58 156.13 37.93 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.213 -0.929 . . . . 0.0 111.239 -175.019 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 16.3 mmtp -59.96 -46.97 87.69 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.993 -1.067 . . . . 0.0 110.68 -175.684 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 42.6 p90 -158.62 160.04 36.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.075 -1.016 . . . . 0.0 110.467 178.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.427 ' HB3' ' CG1' ' A' ' 94' ' ' ILE . 16.8 m -154.51 115.43 4.0 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.468 -0.77 . . . . 0.0 110.229 177.646 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.49 ' O ' ' HG3' ' A' ' 93' ' ' GLU . 96.0 m-20 -69.76 -38.29 76.7 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.214 -0.929 . . . . 0.0 110.331 179.007 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.49 ' HG3' ' O ' ' A' ' 92' ' ' ASP . 93.0 mt-10 -156.38 53.07 0.54 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.369 -0.832 . . . . 0.0 110.16 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.427 ' CG1' ' HB3' ' A' ' 91' ' ' SER . 46.0 mm -92.88 -50.83 12.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.286 -0.884 . . . . 0.0 110.31 -179.548 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 90.83 -43.06 2.86 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.46 ' O ' ' HB2' ' A' ' 97' ' ' HIS . . . 141.11 78.57 0.05 OUTLIER Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.554 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.46 ' HB2' ' O ' ' A' ' 96' ' ' GLY . 72.4 t60 . . . . . 0 N--CA 1.492 1.668 0 O-C-N 121.365 -1.079 . . . . 0.0 110.079 178.411 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 72.1 mtm . . . . . 0 N--CA 1.494 1.756 0 CA-C-O 121.143 0.497 . . . . 0.0 110.071 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 1.059 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 4.1 p90 -175.33 155.37 1.85 Allowed 'General case' 0 C--N 1.305 -1.358 0 O-C-N 121.216 -0.928 . . . . 0.0 108.715 177.669 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.546 HG23 ' C ' ' B' ' 2' ' ' PHE . 29.9 p -150.71 -38.76 0.13 Allowed 'General case' 0 C--N 1.294 -1.812 0 O-C-N 120.939 -1.101 . . . . 0.0 109.267 175.628 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 48.48 23.98 3.52 Favored Glycine 0 N--CA 1.483 1.794 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 -175.301 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 0.538 ' CD1' ' HB ' ' B' ' 3' ' ' THR . 79.0 mt -79.25 125.44 38.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.515 -0.991 . . . . 0.0 109.764 -178.111 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.874 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.0 t -84.35 139.38 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.18 -0.95 . . . . 0.0 110.798 -170.51 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -70.01 -34.71 73.65 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.79 -0.569 . . . . 0.0 111.063 178.342 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.542 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -154.96 174.33 33.2 Favored Glycine 0 N--CA 1.495 2.58 0 C-N-CA 118.902 -1.618 . . . . 0.0 110.248 -172.03 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.446 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.5 p -119.9 170.42 9.27 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.892 -1.358 . . . . 0.0 111.173 -176.016 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.067 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -139.53 150.17 44.78 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -178.157 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.57 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 21.6 tttt -108.82 117.83 35.22 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.115 -0.991 . . . . 0.0 110.346 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 1.006 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.0 tp -59.68 128.74 38.47 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 120.936 -1.102 . . . . 0.0 109.019 173.521 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.132 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.81 -28.9 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 O-C-N 121.33 -0.856 . . . . 0.0 110.139 -178.719 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.91 140.66 23.59 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.294 -0.962 . . . . 0.0 111.401 -178.371 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.766 HG23 ' CD2' ' B' ' 24' ' ' HIS . 14.1 mt -109.99 133.38 55.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.177 -0.952 . . . . 0.0 110.244 172.695 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.509 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 76.2 m-20 -108.61 116.23 31.58 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.344 -0.847 . . . . 0.0 109.706 173.01 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 99.9 mt-10 -107.72 115.37 30.03 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.917 -1.114 . . . . 0.0 110.717 -175.569 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.413 ' HA ' ' HD2' ' B' ' 19' ' ' PRO . 0.0 OUTLIER -115.55 130.27 24.46 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.269 -0.894 . . . . 0.0 109.294 176.82 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.7 Cg_endo -52.32 -19.77 10.13 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.731 1.385 . . . . 0.0 110.21 -179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.569 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 0.5 OUTLIER -83.28 -43.16 16.34 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.26 -0.9 . . . . 0.0 108.867 176.508 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.569 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 89.6 m-85 -156.54 150.36 24.87 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.813 -0.555 . . . . 0.0 110.028 -177.535 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.481 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 60.2 ttt180 -89.37 143.52 26.76 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.942 -1.098 . . . . 0.0 110.152 177.585 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.509 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 94.3 m -128.64 135.04 48.77 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.648 -0.657 . . . . 0.0 109.89 -176.517 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.766 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -127.61 141.54 51.6 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.824 -1.173 . . . . 0.0 111.534 -179.466 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.882 HG22 ' OG ' ' B' ' 60' ' ' SER . 6.2 t -123.32 133.63 68.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.189 -0.945 . . . . 0.0 110.654 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.677 HG13 ' HE2' ' B' ' 61' ' ' PHE . 35.2 m -118.03 172.29 5.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.798 -0.564 . . . . 0.0 110.227 179.581 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.525 ' CB ' ' HB3' ' B' ' 11' ' ' LYS . 7.2 tt0 -99.99 117.06 33.47 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.321 -0.862 . . . . 0.0 109.058 179.184 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.678 HD11 ' HB3' ' B' ' 32' ' ' MET 0.255 0.1 OUTLIER -86.83 114.84 60.1 Favored Pre-proline 0 C--N 1.296 -1.723 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 -176.922 . . . . . . . . 4 4 . 1 . 009 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.6 ' HD2' HD13 ' B' ' 28' ' ' LEU . 19.0 Cg_endo -63.3 174.6 3.23 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.744 1.392 . . . . 0.0 111.267 -178.306 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.584 ' HA ' HD12 ' B' ' 33' ' ' LEU . 1.9 p30 -63.35 -35.56 80.81 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.484 -0.76 . . . . 0.0 111.169 -174.206 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.521 ' N ' ' OD1' ' B' ' 30' ' ' ASP . 0.0 OUTLIER -91.05 -0.02 57.64 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.738 -1.226 . . . . 0.0 110.997 -173.51 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.678 ' HB3' HD11 ' B' ' 28' ' ' LEU . 96.2 mmm -114.48 -14.34 12.15 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 120.881 -1.137 . . . . 0.0 109.806 168.83 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.649 HD21 ' HA ' ' B' ' 57' ' ' ASN . 12.4 mt -64.35 -39.96 94.93 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.184 -0.948 . . . . 0.0 109.989 177.642 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -64.02 131.51 47.82 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.307 -0.87 . . . . 0.0 110.497 -178.123 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.47 -39.31 3.07 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.329 -1.109 . . . . 0.0 110.329 175.207 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.664 HD23 ' HG ' ' B' ' 28' ' ' LEU . 60.7 tp -62.37 144.57 55.62 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.872 -1.37 . . . . 0.0 110.883 -175.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 37' ' ' GLU . . . . . 0.455 ' C ' HD11 ' B' ' 54' ' ' ILE . 19.2 pt-20 -151.57 164.78 36.09 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.658 -0.651 . . . . 0.0 109.36 -179.629 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.799 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.92 150.48 49.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.784 -1.198 . . . . 0.0 109.827 178.332 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.61 -0.01 62.03 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -174.535 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.435 ' CB ' ' O ' ' B' ' 37' ' ' GLU . . . -75.51 158.97 31.82 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.191 -1.182 . . . . 0.0 109.23 175.293 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.684 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.7 OUTLIER -100.21 110.64 22.9 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.977 -1.077 . . . . 0.0 109.901 176.018 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.648 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.8 t -99.95 125.69 53.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.427 -0.796 . . . . 0.0 109.081 175.627 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -91.98 119.73 31.97 Favored 'General case' 0 C--N 1.297 -1.712 0 C-N-CA 119.056 -1.058 . . . . 0.0 109.274 172.349 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.684 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.6 OUTLIER -87.94 102.95 15.22 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.417 -0.802 . . . . 0.0 108.968 177.887 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.6 t-20 57.32 11.11 1.04 Allowed 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.439 -0.788 . . . . 0.0 111.113 -170.537 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.464 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 123.77 0.2 9.17 Favored Glycine 0 N--CA 1.489 2.225 0 C-N-CA 119.653 -1.261 . . . . 0.0 110.609 174.509 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.826 ' O ' HD23 ' B' ' 49' ' ' LEU . 16.9 t -98.99 105.49 17.64 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.465 -1.609 . . . . 0.0 109.464 175.488 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 48' ' ' CYS . . . . . 0.411 ' HA ' ' HA ' ' B' ' 43' ' ' ALA . 15.9 p -74.06 129.02 37.03 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.012 -1.055 . . . . 0.0 110.802 -172.39 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 0.883 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -143.05 160.79 39.71 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.396 -0.815 . . . . 0.0 109.484 173.751 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 6.6 m -100.27 148.22 24.89 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 120.647 -1.283 . . . . 0.0 111.255 -170.128 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.981 HG13 HG13 ' B' ' 59' ' ' VAL . 21.2 t -76.46 115.24 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.716 -0.615 . . . . 0.0 110.479 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.536 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 30.3 p -70.39 -40.01 74.2 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.213 -0.929 . . . . 0.0 109.818 173.722 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.569 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -162.63 154.48 18.37 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.406 -0.809 . . . . 0.0 110.265 -179.525 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.799 HD11 ' N ' ' B' ' 38' ' ' THR . 7.6 mt -105.6 130.46 56.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.11 -0.994 . . . . 0.0 110.173 176.323 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.511 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 4.6 m-80 -102.53 64.41 0.89 Allowed 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.659 -0.651 . . . . 0.0 109.737 179.082 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.32 -119.52 5.87 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 108.739 -1.744 . . . . 0.0 108.739 -173.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.649 ' HA ' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -73.08 -22.09 60.65 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.894 -1.357 . . . . 0.0 108.753 174.216 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.132 ' CD2' HG11 ' B' ' 13' ' ' VAL . 12.4 m80 -74.07 160.05 31.81 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.257 -0.902 . . . . 0.0 110.421 -176.588 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.981 HG13 HG13 ' B' ' 51' ' ' VAL . 50.7 t -140.14 125.35 20.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 C-N-CA 119.107 -1.037 . . . . 0.0 110.595 170.692 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.882 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.7 t -91.57 135.25 34.0 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.5 -0.75 . . . . 0.0 109.284 175.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.883 ' HB2' HD12 ' B' ' 49' ' ' LEU . 8.7 p90 -128.46 154.46 46.05 Favored 'General case' 0 N--CA 1.496 1.828 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.417 177.099 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.536 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 29.2 p-10 -89.75 150.83 22.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.059 -1.026 . . . . 0.0 111.246 -171.554 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.68 HD21 HD13 ' B' ' 73' ' ' LEU . 0.0 OUTLIER -155.57 117.6 4.09 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -176.125 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.535 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 52.9 mtt -68.38 142.32 55.47 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.889 -1.132 . . . . 0.0 109.463 177.538 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.474 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 86.0 tttt -60.06 -44.54 94.64 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.072 -1.017 . . . . 0.0 109.635 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 52.5 tp10 -69.99 -39.92 75.62 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.148 -0.97 . . . . 0.0 110.328 178.415 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.535 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 89.2 m -61.38 -38.04 85.59 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.776 -1.203 . . . . 0.0 108.99 172.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.591 ' CD1' HD22 ' B' ' 63' ' ' LEU . 7.0 tp -59.99 -44.23 94.66 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.235 -0.916 . . . . 0.0 109.289 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 52.0 ttt85 -70.03 -39.93 75.48 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.38 -0.825 . . . . 0.0 110.563 175.429 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.828 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -62.73 -41.28 91.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 CA-C-O 121.917 0.865 . . . . 0.0 109.07 -177.743 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.828 HG23 HG22 ' B' ' 70' ' ' ILE . 31.5 p -89.0 -176.63 5.23 Favored 'General case' 0 C--N 1.3 -1.565 0 C-N-CA 120.2 -0.6 . . . . 0.0 109.394 175.859 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.48 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 2.3 t30 -100.17 25.11 7.83 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 172.144 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.68 HD13 HD21 ' B' ' 63' ' ' LEU . 54.8 mt -69.89 -40.0 75.92 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.894 -1.129 . . . . 0.0 109.848 174.569 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.527 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -48.16 -22.63 2.36 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 -179.021 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.5 p-10 -64.89 -17.51 64.39 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.189 -1.183 . . . . 0.0 110.438 -176.392 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 90.2 mt -62.08 143.95 55.93 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.256 -0.902 . . . . 0.0 110.871 -176.601 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 1.006 ' C ' HD23 ' B' ' 12' ' ' LEU . 35.0 mttp -143.76 143.95 31.6 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.637 -0.664 . . . . 0.0 109.395 174.123 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.662 ' N ' HD23 ' B' ' 12' ' ' LEU . 15.3 t -61.78 150.05 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.666 -1.271 . . . . 0.0 110.057 -176.634 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.2 -11.95 61.67 Favored Glycine 0 N--CA 1.484 1.868 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -176.39 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 48.5 t0 -95.81 166.25 11.9 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.386 -1.067 . . . . 0.0 109.458 176.051 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.57 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.6 m95 -117.4 156.62 27.6 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.051 -1.03 . . . . 0.0 110.516 178.759 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.067 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.1 p -120.14 150.94 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.569 -0.707 . . . . 0.0 109.807 179.683 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.874 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.3 OUTLIER -76.79 106.14 8.29 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.037 -1.039 . . . . 0.0 109.014 168.971 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.665 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -105.9 138.71 29.91 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 120.476 -1.39 . . . . 0.0 111.454 -175.118 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 85' ' ' GLU . . . . . 0.435 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.7 tt0 -133.42 140.69 47.46 Favored 'General case' 0 N--CA 1.495 1.824 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.191 -179.364 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 71.7 ttt-85 -80.33 134.29 36.04 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.16 -0.962 . . . . 0.0 111.029 -175.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 1.081 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -132.15 150.93 52.04 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.267 -0.896 . . . . 0.0 110.271 179.372 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -124.88 156.09 38.46 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.241 -0.912 . . . . 0.0 111.104 -174.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 16.3 mmtp -59.99 -46.93 87.85 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.917 -1.115 . . . . 0.0 110.663 -175.667 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 43.0 p90 -158.73 160.01 35.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.099 -1.001 . . . . 0.0 110.451 178.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 91' ' ' SER . . . . . 0.721 ' CB ' HD11 ' B' ' 94' ' ' ILE . 17.1 m -154.48 115.43 4.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.433 -0.792 . . . . 0.0 110.246 177.697 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -69.94 -40.25 75.59 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.279 -0.888 . . . . 0.0 110.326 179.071 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -114.54 54.32 0.77 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.182 -0.948 . . . . 0.0 111.02 -174.728 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 94' ' ' ILE . . . . . 0.721 HD11 ' CB ' ' B' ' 91' ' ' SER . 24.6 mm -60.02 -39.98 81.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.132 -0.98 . . . . 0.0 110.111 173.569 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 98.86 -55.37 1.0 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 178.361 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -98.55 174.24 28.0 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.802 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 56.5 p-80 . . . . . 0 N--CA 1.491 1.614 0 O-C-N 121.27 -1.135 . . . . 0.0 110.124 179.397 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 0.541 " C2'" ' HC9' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 0.554 HC82 HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.454 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 77.8 mtm . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.212 0.529 . . . . 0.0 110.069 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 1.044 ' CZ ' ' HB1' ' B' ' 87' ' ' ALA . 10.6 p90 -179.6 143.44 0.19 Allowed 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.304 -0.872 . . . . 0.0 109.221 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.5 ' HB ' ' CD1' ' A' ' 5' ' ' ILE . 72.1 p -138.5 -40.82 0.5 Allowed 'General case' 0 C--N 1.298 -1.642 0 O-C-N 120.945 -1.097 . . . . 0.0 108.976 -177.4 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.489 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 44.99 25.59 1.01 Allowed Glycine 0 N--CA 1.485 1.92 0 N-CA-C 108.598 -1.801 . . . . 0.0 108.598 -173.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.999 HD11 ' C8M' ' B' ' 99' ' ' RBF . 94.5 mt -77.26 130.55 36.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.166 -1.196 . . . . 0.0 110.374 -176.221 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.903 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.7 t -89.06 139.97 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.54 -0.725 . . . . 0.0 110.287 -175.072 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -81.23 -26.29 35.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.427 -0.796 . . . . 0.0 110.891 -179.063 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.533 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -153.92 176.71 31.74 Favored Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.288 -1.434 . . . . 0.0 109.922 -176.086 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.472 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 18.4 p -123.34 170.01 10.75 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.942 -1.328 . . . . 0.0 110.839 -178.444 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.041 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -137.36 149.89 47.31 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.557 -0.715 . . . . 0.0 109.65 -177.076 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.583 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 36.9 tttt -104.07 117.86 35.28 Favored 'General case' 0 C--N 1.296 -1.731 0 O-C-N 120.901 -1.124 . . . . 0.0 110.355 178.673 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 1.021 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.1 tp -61.44 126.14 26.29 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.861 -1.15 . . . . 0.0 108.749 171.482 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.101 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.5 p -127.38 -28.86 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.934 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.004 -178.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -148.76 141.02 24.06 Favored 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 118.964 -1.094 . . . . 0.0 111.225 178.824 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.852 HG23 ' CD2' ' A' ' 24' ' ' HIS . 13.6 mt -105.54 138.22 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.007 -1.058 . . . . 0.0 110.062 171.372 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.509 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 83.7 m-20 -110.83 114.66 28.18 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.25 -0.906 . . . . 0.0 109.932 173.789 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -103.35 112.65 25.63 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.017 -1.052 . . . . 0.0 110.374 -178.008 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.456 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 19.7 mtmt -107.02 132.77 20.65 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.296 -0.877 . . . . 0.0 109.282 177.338 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.9 Cg_endo -51.84 -18.9 7.2 Favored 'Trans proline' 0 C--N 1.303 -1.851 0 O-C-N 123.879 1.462 . . . . 0.0 110.745 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.57 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 7.8 m-80 -95.77 -33.06 12.42 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.125 -0.984 . . . . 0.0 110.204 178.298 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.57 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 98.2 m-85 -157.46 150.29 23.23 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.363 -0.836 . . . . 0.0 110.318 -177.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -87.76 145.88 25.91 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.898 -1.126 . . . . 0.0 110.108 177.318 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.509 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 92.5 m -133.89 145.37 49.56 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.455 -0.778 . . . . 0.0 109.748 -176.418 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.852 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.4 OUTLIER -135.35 135.27 40.59 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.781 -1.199 . . . . 0.0 111.476 -177.879 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.634 HG22 ' CB ' ' A' ' 60' ' ' SER . 9.7 t -114.43 132.77 62.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.092 -1.005 . . . . 0.0 110.814 -179.127 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.442 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 17.4 m -118.11 170.92 6.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 CA-C-O 121.177 0.513 . . . . 0.0 110.106 179.217 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.658 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 13.5 tt0 -102.64 118.92 37.91 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.329 -0.857 . . . . 0.0 109.096 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.5 ' HB3' ' CD2' ' A' ' 33' ' ' LEU . 10.2 tp -83.59 123.77 76.1 Favored Pre-proline 0 C--N 1.3 -1.567 0 C-N-CA 119.969 -0.692 . . . . 0.0 109.739 -175.345 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.486 ' HD2' HD12 ' A' ' 28' ' ' LEU . 25.9 Cg_endo -66.18 175.31 4.97 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 O-C-N 123.843 1.444 . . . . 0.0 111.035 -179.298 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.402 ' HA ' HD12 ' A' ' 33' ' ' LEU . 57.8 t0 -59.86 -39.77 86.34 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.387 -0.821 . . . . 0.0 110.831 -175.714 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.602 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -88.76 1.08 55.82 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.941 -1.1 . . . . 0.0 110.633 -175.004 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.602 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 93.5 mmm -112.17 -14.16 13.42 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.989 -1.069 . . . . 0.0 109.916 170.683 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.589 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 19.6 mt -69.96 -39.92 75.72 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.454 -0.779 . . . . 0.0 110.516 178.422 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -82.26 113.57 20.16 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.281 -0.887 . . . . 0.0 110.437 -176.67 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.8 -52.62 0.7 Allowed Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.835 -1.174 . . . . 0.0 110.415 175.467 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.635 HD11 ' CG2' ' A' ' 42' ' ' VAL . 5.1 tt -66.37 152.21 45.51 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.93 -1.335 . . . . 0.0 110.756 -173.396 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.524 ' C ' HD11 ' A' ' 54' ' ' ILE . 11.3 pt-20 -150.76 169.96 20.39 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.477 -0.764 . . . . 0.0 109.752 -177.271 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.828 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -65.43 158.4 26.84 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.951 -1.093 . . . . 0.0 110.38 -178.27 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 71.51 2.71 51.1 Favored Glycine 0 N--CA 1.495 2.57 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 -178.229 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.559 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -82.52 163.73 21.35 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.227 -1.161 . . . . 0.0 109.768 177.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.784 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 1.0 OUTLIER -104.52 112.77 25.97 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.982 -1.074 . . . . 0.0 109.985 176.491 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.635 ' CG2' HD11 ' A' ' 36' ' ' LEU . 2.0 t -102.83 130.96 52.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.377 -0.827 . . . . 0.0 108.931 173.866 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.501 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -91.45 120.05 31.95 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.214 -0.995 . . . . 0.0 109.092 172.272 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.667 ' CD2' HG21 ' A' ' 82' ' ' VAL . 0.3 OUTLIER -90.3 107.9 19.43 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 177.112 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' B' ' 45' ' ' ASN . 0.9 OUTLIER 52.98 13.09 0.33 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.47 -0.769 . . . . 0.0 111.688 -167.149 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.446 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 121.22 -2.59 11.48 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.441 -1.362 . . . . 0.0 110.855 172.257 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.789 ' O ' HD23 ' A' ' 49' ' ' LEU . 35.5 t -94.25 109.0 20.84 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.402 -1.646 . . . . 0.0 109.448 174.829 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.52 ' SG ' ' C8 ' ' A' ' 98' ' ' RBF . 17.3 p -76.99 124.65 28.08 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.105 -0.997 . . . . 0.0 110.836 -172.443 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.882 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -140.02 159.98 40.95 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.507 -0.745 . . . . 0.0 109.145 173.805 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.474 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 28.5 m -97.03 160.84 14.11 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.654 -1.278 . . . . 0.0 111.179 -170.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.756 HG22 ' CE1' ' A' ' 61' ' ' PHE . 18.8 t -84.69 116.39 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.854 -0.529 . . . . 0.0 110.372 -177.376 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.552 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 77.4 p -70.02 -40.02 75.47 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.252 -0.905 . . . . 0.0 109.667 173.793 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.552 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 54.4 tp10 -164.86 157.9 16.77 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.576 -176.364 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.828 HD11 ' N ' ' A' ' 38' ' ' THR . 8.7 mt -110.44 129.93 64.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.173 -0.954 . . . . 0.0 109.807 172.608 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.522 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 29.0 m-80 -102.35 64.05 0.9 Allowed 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.738 -0.601 . . . . 0.0 109.474 179.037 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.87 -114.28 4.3 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -172.18 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.589 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -78.82 -22.43 46.21 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 120.94 -1.33 . . . . 0.0 109.3 175.314 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.101 ' CE1' HG11 ' A' ' 13' ' ' VAL . 23.9 m-70 -74.43 159.94 31.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.271 -0.893 . . . . 0.0 110.052 -177.489 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.713 HG13 HG13 ' A' ' 51' ' ' VAL . 78.4 t -140.0 120.04 13.38 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 O-C-N 121.103 -0.998 . . . . 0.0 110.693 173.317 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.634 ' CB ' HG22 ' A' ' 25' ' ' VAL . 6.5 t -83.13 138.02 33.84 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.424 -0.798 . . . . 0.0 109.531 176.055 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.882 ' HB3' HD12 ' A' ' 49' ' ' LEU . 87.0 m-85 -120.2 160.52 22.75 Favored 'General case' 0 C--N 1.295 -1.788 0 O-C-N 121.336 -0.853 . . . . 0.0 110.543 177.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.552 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 32.9 p-10 -95.46 148.2 22.73 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.247 -0.908 . . . . 0.0 111.1 179.21 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.745 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -157.23 121.92 4.43 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -176.762 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.506 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 26.8 ttt -82.19 141.87 32.66 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.983 -1.073 . . . . 0.0 109.669 -178.141 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.484 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 83.3 tttt -60.0 -48.26 82.44 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.094 -1.003 . . . . 0.0 110.611 -173.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.2 tp10 -68.08 -40.06 82.77 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 120.793 -1.192 . . . . 0.0 109.94 179.014 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.566 HG23 HC3' ' A' ' 98' ' ' RBF . 87.4 m -60.01 -39.02 84.37 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.976 -1.078 . . . . 0.0 109.257 173.007 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.775 HD11 ' HA2' ' A' ' 74' ' ' GLY . 2.0 tp -59.98 -45.38 92.9 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.23 -0.919 . . . . 0.0 109.706 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -67.05 -39.96 87.04 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.329 -0.857 . . . . 0.0 110.363 176.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.708 HG22 HG23 ' A' ' 71' ' ' THR . 1.1 tt -66.04 -40.14 86.43 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.294 -0.879 . . . . 0.0 109.258 -176.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.708 HG23 HG22 ' A' ' 70' ' ' ILE . 52.3 p -84.92 -169.77 2.81 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 121.362 0.601 . . . . 0.0 109.524 175.28 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.475 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 7.1 t30 -105.97 22.92 14.83 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 170.445 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.745 ' HB3' HD21 ' A' ' 63' ' ' LEU . 88.5 mt -69.95 -40.03 75.69 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.199 -0.938 . . . . 0.0 110.219 178.289 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.775 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -50.16 -21.6 4.21 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -177.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.4 p-10 -69.19 -17.45 63.8 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.98 -1.306 . . . . 0.0 110.753 -173.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.513 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 95.9 mt -60.01 141.02 56.38 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.105 -0.997 . . . . 0.0 110.709 -176.818 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 1.021 ' C ' HD23 ' A' ' 12' ' ' LEU . 66.4 mttm -140.0 139.07 35.94 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 121.514 0.674 . . . . 0.0 109.88 175.651 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.665 ' N ' HD23 ' A' ' 12' ' ' LEU . 22.0 t -61.08 152.77 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 120.906 -1.122 . . . . 0.0 110.376 -176.393 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.83 -16.08 57.61 Favored Glycine 0 N--CA 1.482 1.725 0 N-CA-C 108.729 -1.748 . . . . 0.0 108.729 -176.181 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.9 t0 -97.39 169.72 9.56 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.344 -1.091 . . . . 0.0 109.544 175.645 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.583 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.2 m95 -117.26 166.57 12.12 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.03 -1.044 . . . . 0.0 110.045 177.306 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.041 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.3 p -128.69 157.47 41.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.283 -0.886 . . . . 0.0 110.03 -177.798 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.903 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.2 m-20 -83.54 104.71 13.89 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.177 -0.952 . . . . 0.0 109.083 170.821 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.703 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -107.54 139.27 30.0 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.781 0 O-C-N 120.444 -1.41 . . . . 0.0 111.287 -174.826 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.456 ' HB2' HG22 ' A' ' 6' ' ' VAL . 85.2 tt0 -139.58 138.48 36.25 Favored 'General case' 0 N--CA 1.492 1.674 0 C-N-CA 120.355 -0.538 . . . . 0.0 109.837 -178.612 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.489 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 39.0 ptt180 -73.02 137.72 45.55 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.983 -1.073 . . . . 0.0 110.664 -174.151 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.976 ' HB1' ' CZ ' ' B' ' 2' ' ' PHE . . . -128.09 144.18 51.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -0.904 . . . . 0.0 109.923 173.788 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -132.32 148.71 52.44 Favored 'General case' 0 N--CA 1.491 1.622 0 C-N-CA 120.023 -0.671 . . . . 0.0 111.25 -173.335 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 30.9 mtpt -60.54 -40.0 89.95 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.427 -0.796 . . . . 0.0 109.836 174.011 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.5 p90 -145.79 159.07 43.72 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.354 -0.841 . . . . 0.0 110.243 -179.445 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 58.5 m -133.29 143.85 49.32 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.261 -0.899 . . . . 0.0 110.298 178.415 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -68.88 -38.8 79.92 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.164 -0.96 . . . . 0.0 110.436 179.361 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 50.71 56.6 7.73 Favored 'General case' 0 N--CA 1.507 2.41 0 C-N-CA 119.834 -0.747 . . . . 0.0 110.373 177.163 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.548 ' O ' ' N ' ' A' ' 96' ' ' GLY . 29.8 mm -60.06 -43.75 93.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.142 -0.974 . . . . 0.0 110.219 177.244 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -49.85 88.26 0.01 OUTLIER Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.976 -1.25 . . . . 0.0 109.976 -171.042 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 94' ' ' ILE . . . -171.14 -179.81 42.51 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 5.4 m-70 . . . . . 0 N--CA 1.491 1.612 0 O-C-N 121.287 -1.125 . . . . 0.0 110.192 -179.647 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 96.8 mtp . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.091 0.472 . . . . 0.0 110.093 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.976 ' CZ ' ' HB1' ' A' ' 87' ' ' ALA . 10.9 p90 -172.49 143.35 1.36 Allowed 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.183 -0.948 . . . . 0.0 109.18 174.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.508 ' HB ' ' CD1' ' B' ' 5' ' ' ILE . 72.8 p -138.57 -40.78 0.5 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 120.95 -1.093 . . . . 0.0 109.0 -177.458 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.446 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 45.24 25.25 1.1 Allowed Glycine 0 N--CA 1.485 1.907 0 N-CA-C 108.623 -1.791 . . . . 0.0 108.623 -174.057 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 1.055 HD11 HC81 ' A' ' 98' ' ' RBF . 94.4 mt -77.38 130.6 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.209 -1.171 . . . . 0.0 110.422 -176.041 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.859 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.7 t -89.08 140.05 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.454 -0.779 . . . . 0.0 110.291 -175.012 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 17.4 pt20 -81.43 -25.96 35.74 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.38 -0.825 . . . . 0.0 110.887 -178.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.536 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -154.09 176.58 31.92 Favored Glycine 0 N--CA 1.494 2.559 0 C-N-CA 119.423 -1.37 . . . . 0.0 109.958 -176.1 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.468 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 18.4 p -123.32 170.05 10.69 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.951 -1.323 . . . . 0.0 110.838 -178.432 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.039 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -137.39 149.9 47.29 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.582 -0.699 . . . . 0.0 109.607 -177.143 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.574 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 36.9 tttt -104.13 117.98 35.55 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.961 -1.087 . . . . 0.0 110.304 178.615 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 1.019 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.1 tp -61.58 126.04 25.94 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.018 -1.051 . . . . 0.0 108.804 171.48 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.077 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.5 p -127.1 -29.12 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.979 0 O-C-N 121.371 -0.831 . . . . 0.0 110.054 -178.892 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -148.67 141.0 24.15 Favored 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 119.263 -0.975 . . . . 0.0 111.357 178.834 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.861 HG23 ' CD2' ' B' ' 24' ' ' HIS . 13.6 mt -105.6 138.32 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.996 -1.065 . . . . 0.0 110.082 171.373 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.525 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.6 m-20 -110.89 114.79 28.4 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.317 -0.865 . . . . 0.0 109.842 173.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -103.44 112.54 25.48 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.002 -1.061 . . . . 0.0 110.363 -177.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 19.6 mtmt -107.0 132.72 20.68 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.382 -0.823 . . . . 0.0 109.317 177.34 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -51.92 -18.79 7.3 Favored 'Trans proline' 0 C--N 1.304 -1.782 0 O-C-N 123.832 1.438 . . . . 0.0 110.716 -179.527 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.57 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 7.9 m-80 -95.64 -33.68 12.26 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.107 -0.996 . . . . 0.0 110.068 178.291 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.57 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 98.2 m-85 -157.0 150.29 24.09 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.352 -0.843 . . . . 0.0 110.412 -177.82 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -87.68 145.73 26.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.042 -1.036 . . . . 0.0 110.196 177.265 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.525 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 92.7 m -133.85 145.39 49.65 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.386 -0.821 . . . . 0.0 109.755 -176.483 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.861 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.4 OUTLIER -135.24 135.41 40.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.927 -1.108 . . . . 0.0 111.447 -177.804 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.65 HG22 ' CB ' ' B' ' 60' ' ' SER . 9.8 t -114.48 133.01 61.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 110.789 -179.119 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.449 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 17.7 m -118.45 170.85 7.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 CA-C-O 121.237 0.541 . . . . 0.0 109.988 179.357 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.655 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 13.5 tt0 -102.55 119.03 38.13 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.365 -0.834 . . . . 0.0 109.122 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.522 HD12 ' HA ' ' B' ' 28' ' ' LEU . 10.3 tp -83.68 123.75 75.94 Favored Pre-proline 0 C--N 1.299 -1.589 0 O-C-N 121.443 -0.786 . . . . 0.0 109.76 -175.358 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.496 ' HD2' HD12 ' B' ' 28' ' ' LEU . 25.8 Cg_endo -66.17 175.44 4.84 Favored 'Trans proline' 0 C--N 1.309 -1.538 0 O-C-N 123.851 1.448 . . . . 0.0 111.049 -179.221 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.411 ' HA ' HD12 ' B' ' 33' ' ' LEU . 58.0 t0 -60.07 -39.68 86.89 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.368 -0.833 . . . . 0.0 110.8 -175.655 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.607 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -88.78 1.08 55.83 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.819 -1.176 . . . . 0.0 110.695 -175.073 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.607 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 93.5 mmm -112.14 -14.13 13.44 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.961 -1.087 . . . . 0.0 109.92 170.628 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.594 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 19.7 mt -70.04 -39.91 75.46 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.366 -0.834 . . . . 0.0 110.511 178.442 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -82.2 113.56 20.12 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.296 -0.878 . . . . 0.0 110.436 -176.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.79 -52.64 0.7 Allowed Glycine 0 N--CA 1.491 2.335 0 C-N-CA 119.834 -1.174 . . . . 0.0 110.422 175.436 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.628 HD11 ' CG2' ' B' ' 42' ' ' VAL . 5.2 tt -66.39 152.2 45.57 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.916 -1.344 . . . . 0.0 110.807 -173.404 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 37' ' ' GLU . . . . . 0.503 ' C ' HD11 ' B' ' 54' ' ' ILE . 11.3 pt-20 -150.69 169.99 20.27 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.402 -0.811 . . . . 0.0 109.733 -177.249 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.835 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -65.41 158.36 26.9 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.958 -1.089 . . . . 0.0 110.425 -178.303 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 39' ' ' GLY . . . . . 0.403 ' N ' ' HB ' ' B' ' 51' ' ' VAL . . . 71.54 2.64 50.83 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.966 -1.253 . . . . 0.0 109.966 -178.233 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.558 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -82.54 163.47 21.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.226 -1.161 . . . . 0.0 109.817 177.854 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.784 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 1.0 OUTLIER -104.21 112.59 25.67 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.893 -1.129 . . . . 0.0 110.078 176.546 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.628 ' CG2' HD11 ' B' ' 36' ' ' LEU . 2.0 t -102.78 131.01 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.389 -0.819 . . . . 0.0 108.947 173.816 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.496 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -91.44 119.98 31.88 Favored 'General case' 0 C--N 1.296 -1.718 0 O-C-N 121.128 -0.983 . . . . 0.0 109.196 172.149 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.665 ' CD2' HG21 ' B' ' 82' ' ' VAL . 0.3 OUTLIER -90.23 107.55 19.2 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 177.138 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' A' ' 45' ' ' ASN . 0.9 OUTLIER 53.29 13.16 0.39 Allowed 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.445 -0.784 . . . . 0.0 111.515 -167.252 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.489 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 121.17 -2.44 11.54 Favored Glycine 0 N--CA 1.491 2.311 0 C-N-CA 119.474 -1.346 . . . . 0.0 110.784 172.14 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.782 ' O ' HD23 ' B' ' 49' ' ' LEU . 35.6 t -94.32 109.04 20.9 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.411 -1.64 . . . . 0.0 109.434 174.808 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 48' ' ' CYS . . . . . 0.513 ' SG ' ' C8 ' ' B' ' 99' ' ' RBF . 16.7 p -76.99 124.77 28.26 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.054 -1.029 . . . . 0.0 110.814 -172.436 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 0.853 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -140.21 159.96 41.02 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.553 -0.717 . . . . 0.0 109.086 173.773 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 50' ' ' THR . . . . . 0.48 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 28.5 m -96.79 160.95 14.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.686 -1.259 . . . . 0.0 111.214 -170.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.739 HG22 ' CE1' ' B' ' 61' ' ' PHE . 19.0 t -84.99 116.35 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.787 -0.57 . . . . 0.0 110.426 -177.42 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.542 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 77.3 p -69.96 -39.93 75.72 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.154 -0.966 . . . . 0.0 109.716 173.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.561 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 54.4 tp10 -164.94 157.8 16.46 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.589 -176.392 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.835 HD11 ' N ' ' B' ' 38' ' ' THR . 8.7 mt -110.32 129.89 64.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.194 -0.941 . . . . 0.0 109.854 172.667 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.531 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 28.7 m-80 -102.46 64.07 0.89 Allowed 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 120.103 -0.639 . . . . 0.0 109.42 179.101 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.02 -114.35 4.29 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 108.666 -1.774 . . . . 0.0 108.666 -172.282 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.594 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -78.65 -22.73 46.43 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.032 -1.275 . . . . 0.0 109.358 175.244 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.077 ' CE1' HG11 ' B' ' 13' ' ' VAL . 24.0 m-70 -74.21 159.8 32.02 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.386 -0.821 . . . . 0.0 110.097 -177.515 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.729 HG13 HG13 ' B' ' 51' ' ' VAL . 78.4 t -139.99 120.02 13.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 C-N-CA 119.017 -1.073 . . . . 0.0 110.574 173.505 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.65 ' CB ' HG22 ' B' ' 25' ' ' VAL . 6.4 t -83.16 137.98 33.84 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.426 -0.796 . . . . 0.0 109.578 176.044 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.853 ' HB3' HD12 ' B' ' 49' ' ' LEU . 86.4 m-85 -120.25 160.63 22.58 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.351 -0.843 . . . . 0.0 110.471 177.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.542 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 32.9 p-10 -95.48 148.24 22.69 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.113 -0.992 . . . . 0.0 110.945 179.388 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.717 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -157.21 121.93 4.44 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -176.829 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.512 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 26.9 ttt -82.21 141.87 32.64 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.067 -1.02 . . . . 0.0 109.722 -178.183 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.482 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 83.3 tttt -59.95 -48.39 81.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.066 -1.021 . . . . 0.0 110.53 -173.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 54.1 tp10 -68.0 -40.05 83.08 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.915 -1.116 . . . . 0.0 109.966 179.088 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.556 HG23 HC3' ' B' ' 99' ' ' RBF . 87.6 m -59.98 -39.1 84.54 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.004 -1.06 . . . . 0.0 109.278 173.017 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.775 HD11 ' HA2' ' B' ' 74' ' ' GLY . 2.0 tp -60.02 -45.2 93.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.314 -0.866 . . . . 0.0 109.734 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -67.06 -39.95 86.97 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.451 -0.781 . . . . 0.0 110.384 176.875 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.718 HG22 HG23 ' B' ' 71' ' ' THR . 1.2 tt -66.1 -40.11 86.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.289 -0.882 . . . . 0.0 109.212 -176.809 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.718 HG23 HG22 ' B' ' 70' ' ' ILE . 52.3 p -84.84 -169.43 2.64 Favored 'General case' 0 C--N 1.301 -1.543 0 C-N-CA 120.17 -0.612 . . . . 0.0 109.577 175.241 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.489 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 7.0 t30 -106.16 22.75 15.19 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 170.465 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.717 ' HB3' HD21 ' B' ' 63' ' ' LEU . 88.7 mt -69.91 -40.0 75.87 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.308 -0.87 . . . . 0.0 110.182 178.361 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.775 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -50.16 -21.67 4.27 Favored Glycine 0 N--CA 1.487 2.071 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -177.953 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.1 p-10 -69.22 -17.4 63.77 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.014 -1.286 . . . . 0.0 110.736 -173.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.507 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 95.8 mt -59.99 141.0 56.39 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.139 -0.975 . . . . 0.0 110.8 -176.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 1.019 ' C ' HD23 ' B' ' 12' ' ' LEU . 66.4 mttm -140.03 139.06 35.9 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 121.611 -0.681 . . . . 0.0 109.912 175.673 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.668 ' N ' HD23 ' B' ' 12' ' ' LEU . 22.1 t -61.11 152.76 5.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.036 -1.04 . . . . 0.0 110.43 -176.348 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.64 -15.83 57.95 Favored Glycine 0 N--CA 1.484 1.837 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 -176.072 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -97.49 169.63 9.6 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.345 -1.091 . . . . 0.0 109.582 175.502 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.574 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.3 m95 -117.23 166.52 12.16 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.104 -0.998 . . . . 0.0 110.05 177.389 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.039 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.3 p -128.65 157.54 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.41 -0.806 . . . . 0.0 110.054 -177.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.859 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.1 m-20 -83.48 104.53 13.7 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.307 -0.87 . . . . 0.0 109.263 170.775 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.686 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -107.38 139.55 28.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.468 -1.395 . . . . 0.0 111.17 -174.637 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 85' ' ' GLU . . . . . 0.456 ' HB2' HG22 ' B' ' 6' ' ' VAL . 85.2 tt0 -139.92 138.44 35.63 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 120.389 -0.525 . . . . 0.0 109.789 -178.645 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 86' ' ' ARG . . . . . 0.478 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 39.0 ptt180 -72.95 137.71 45.67 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.06 -1.025 . . . . 0.0 110.608 -174.09 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 1.044 ' HB1' ' CZ ' ' A' ' 2' ' ' PHE . . . -128.01 144.31 51.1 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.162 -0.962 . . . . 0.0 109.825 173.764 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -132.56 148.74 52.38 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.501 -0.75 . . . . 0.0 111.126 -173.334 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 30.9 mtpt -60.61 -39.9 89.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.349 -0.845 . . . . 0.0 109.923 174.007 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 53.5 p90 -145.83 159.15 43.61 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.282 -0.886 . . . . 0.0 110.332 -179.565 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 91' ' ' SER . . . . . 0.508 ' HB3' ' CG1' ' B' ' 94' ' ' ILE . 58.6 m -133.45 143.79 49.07 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.211 -0.931 . . . . 0.0 110.238 178.545 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -69.15 -44.71 71.74 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.119 -0.988 . . . . 0.0 110.661 179.47 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 82.5 mm-40 -146.66 52.18 1.11 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.76 -1.212 . . . . 0.0 111.128 -176.241 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 94' ' ' ILE . . . . . 0.508 ' CG1' ' HB3' ' B' ' 91' ' ' SER . 46.1 mm -104.87 -57.01 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.132 -0.98 . . . . 0.0 110.121 174.276 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 95' ' ' GLY . . . . . 0.414 ' C ' ' O ' ' B' ' 94' ' ' ILE . . . 40.03 68.38 0.56 Allowed Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.034 -1.226 . . . . 0.0 110.034 177.196 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . 167.63 -153.01 22.06 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.601 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 83.7 t60 . . . . . 0 N--CA 1.492 1.636 0 O-C-N 121.216 -1.167 . . . . 0.0 110.158 -179.554 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 1.055 HC81 HD11 ' B' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 0.999 ' C8M' HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.495 ' N ' ' HA ' ' B' ' 89' ' ' LYS . 98.2 mtp . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 121.272 0.558 . . . . 0.0 110.292 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.923 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 4.6 p90 -170.04 156.43 6.02 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 175.14 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.58 HG23 ' C ' ' A' ' 2' ' ' PHE . 62.0 p -152.3 -40.83 0.11 Allowed 'General case' 0 C--N 1.293 -1.873 0 O-C-N 120.852 -1.155 . . . . 0.0 108.87 174.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' B' ' 46' ' ' GLY . . . 47.51 23.98 2.39 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 108.162 -1.975 . . . . 0.0 108.162 -174.64 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.556 HD11 ' C8M' ' B' ' 99' ' ' RBF . 71.1 mt -81.91 119.77 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.32 -1.106 . . . . 0.0 109.715 -176.945 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.655 HG21 ' HB3' ' A' ' 83' ' ' ASN . 3.4 t -75.15 149.16 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.362 -0.836 . . . . 0.0 110.583 -173.929 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 28.2 mm100 -98.48 -15.19 19.69 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.554 -0.716 . . . . 0.0 110.783 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.532 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -141.0 165.4 26.25 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.247 -1.454 . . . . 0.0 109.749 -177.595 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.488 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 0.7 OUTLIER -124.83 169.99 11.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.95 -1.324 . . . . 0.0 110.504 178.746 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.044 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -141.26 149.27 41.1 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.471 -0.768 . . . . 0.0 109.245 -176.525 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.579 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 32.1 tttt -109.65 114.13 27.48 Favored 'General case' 0 C--N 1.294 -1.839 0 O-C-N 121.091 -1.005 . . . . 0.0 110.175 178.852 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.994 HD23 ' C ' ' A' ' 77' ' ' LYS . 11.6 tp -59.69 127.86 34.11 Favored 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.061 -1.024 . . . . 0.0 108.903 175.137 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.102 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.5 p -128.31 -30.65 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.868 0 O-C-N 121.339 -0.851 . . . . 0.0 110.062 -178.682 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.35 141.97 30.08 Favored 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 119.088 -1.045 . . . . 0.0 111.284 -178.158 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.796 HD11 HG23 ' A' ' 78' ' ' VAL . 8.4 mt -110.04 132.89 57.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.098 -1.001 . . . . 0.0 110.362 172.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.514 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 88.5 m-20 -109.8 114.97 28.98 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.41 -0.806 . . . . 0.0 110.038 175.353 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -102.62 109.61 21.28 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.01 -1.056 . . . . 0.0 110.471 -177.402 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.3 OUTLIER -101.71 135.96 19.66 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.243 -0.91 . . . . 0.0 109.557 175.884 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -53.97 -16.92 9.83 Favored 'Trans proline' 0 C--N 1.302 -1.877 0 O-C-N 123.956 1.503 . . . . 0.0 110.853 -179.631 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.555 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 6.0 m-80 -102.7 -26.56 13.13 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.063 -1.023 . . . . 0.0 109.953 179.744 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.555 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 87.6 m-85 -156.69 150.24 24.52 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.428 -0.795 . . . . 0.0 109.919 -178.549 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.484 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 61.3 ttt180 -92.36 141.74 28.21 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.665 -1.272 . . . . 0.0 109.844 174.799 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.514 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 89.1 m -129.94 140.05 51.0 Favored 'General case' 0 C--N 1.295 -1.799 0 O-C-N 121.495 -0.753 . . . . 0.0 109.824 -172.677 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.717 ' NE2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -130.09 142.47 50.6 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 120.986 -1.071 . . . . 0.0 111.413 -179.286 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.826 HG22 ' CB ' ' A' ' 60' ' ' SER . 16.6 t -119.66 134.31 63.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.111 -0.993 . . . . 0.0 110.418 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.91 HG13 ' CE1' ' A' ' 61' ' ' PHE . 32.9 m -116.82 170.76 6.02 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 O-C-N 121.912 -0.492 . . . . 0.0 110.113 178.894 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.689 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 9.4 tt0 -102.65 116.64 33.0 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 179.401 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.499 HD23 ' HA ' ' A' ' 33' ' ' LEU . 8.7 tp -80.56 121.63 81.54 Favored Pre-proline 0 C--N 1.295 -1.771 0 O-C-N 121.493 -0.755 . . . . 0.0 109.653 -173.74 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.466 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 18.5 Cg_endo -63.42 178.84 1.07 Allowed 'Trans proline' 0 C--N 1.308 -1.583 0 O-C-N 123.874 1.46 . . . . 0.0 111.004 -179.112 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.527 ' HA ' HD12 ' A' ' 33' ' ' LEU . 88.3 m-20 -60.32 -39.91 88.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.373 -0.83 . . . . 0.0 111.102 -175.843 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.606 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.17 0.26 57.27 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.833 -1.167 . . . . 0.0 110.93 -175.553 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.606 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.1 mmm -109.12 -12.84 14.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.923 -1.11 . . . . 0.0 110.006 171.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.832 HD21 ' HB2' ' A' ' 57' ' ' ASN . 19.2 mt -68.8 -31.35 70.29 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.284 -0.885 . . . . 0.0 110.221 178.098 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 52.6 t0 -94.06 122.94 37.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.282 -0.886 . . . . 0.0 110.319 -178.315 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 111.42 -50.6 0.76 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 177.172 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.572 HD23 ' N ' ' A' ' 37' ' ' GLU . 6.7 tt -67.0 140.03 57.7 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.087 -1.243 . . . . 0.0 110.296 -176.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.572 ' N ' HD23 ' A' ' 36' ' ' LEU . 19.7 pt-20 -147.42 168.5 21.71 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.383 -0.823 . . . . 0.0 109.451 176.767 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.773 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -63.24 151.65 39.87 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.975 -1.078 . . . . 0.0 110.265 -175.885 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.52 -0.44 60.58 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -174.702 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.608 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -79.99 159.37 26.29 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.162 -1.199 . . . . 0.0 109.392 175.861 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.456 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.5 OUTLIER -103.19 117.54 34.77 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 118.849 -1.141 . . . . 0.0 110.155 177.068 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.642 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.6 t -102.37 128.28 55.21 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 121.335 -0.853 . . . . 0.0 108.907 172.476 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.51 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -92.88 119.68 32.44 Favored 'General case' 0 C--N 1.297 -1.689 0 C-N-CA 119.214 -0.995 . . . . 0.0 109.096 172.644 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.682 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -87.62 102.63 14.8 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 119.729 -0.789 . . . . 0.0 108.982 179.194 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.8 t-20 59.6 6.29 0.8 Allowed 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.685 -0.634 . . . . 0.0 111.681 -170.642 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.454 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 128.58 -1.04 6.42 Favored Glycine 0 N--CA 1.489 2.181 0 C-N-CA 119.525 -1.321 . . . . 0.0 110.655 174.352 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.677 ' O ' HD23 ' A' ' 49' ' ' LEU . 34.8 t -98.51 108.67 21.42 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.438 -1.624 . . . . 0.0 109.55 175.74 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 22.7 p -74.3 130.17 39.18 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.087 -1.008 . . . . 0.0 111.074 -171.351 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.841 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -147.02 153.82 40.48 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.429 -0.794 . . . . 0.0 109.356 173.901 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.424 HG22 ' N ' ' A' ' 51' ' ' VAL . 92.5 m -95.83 160.11 14.64 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.527 -1.358 . . . . 0.0 111.558 -169.118 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.925 HG13 HG13 ' A' ' 59' ' ' VAL . 15.8 t -82.08 114.72 23.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.847 -0.533 . . . . 0.0 110.358 -178.804 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.55 HG22 ' HB3' ' A' ' 62' ' ' ASP . 30.2 p -70.9 -39.94 72.47 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.322 -0.861 . . . . 0.0 109.977 175.137 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.571 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -166.19 154.2 10.47 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.31 -0.869 . . . . 0.0 110.177 179.677 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.773 HD11 ' N ' ' A' ' 38' ' ' THR . 9.8 mt -108.31 134.91 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.1 -1.0 . . . . 0.0 110.138 177.699 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.507 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 47.4 m-80 -108.81 66.23 0.63 Allowed 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.601 -0.687 . . . . 0.0 109.512 177.87 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.2 -116.84 5.11 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 -173.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.832 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.1 OUTLIER -78.43 -20.19 51.57 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.055 -1.262 . . . . 0.0 109.116 177.012 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.102 ' CE1' HG11 ' A' ' 13' ' ' VAL . 23.1 m-70 -76.61 158.92 30.72 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.241 -0.912 . . . . 0.0 110.044 -178.35 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.925 HG13 HG13 ' A' ' 51' ' ' VAL . 55.6 t -140.78 123.06 15.31 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 O-C-N 121.055 -1.028 . . . . 0.0 110.591 171.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.826 ' CB ' HG22 ' A' ' 25' ' ' VAL . 0.9 OUTLIER -87.5 133.32 33.78 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.47 -0.769 . . . . 0.0 109.13 175.264 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.91 ' CE1' HG13 ' A' ' 26' ' ' VAL . 1.8 p90 -125.96 156.01 40.46 Favored 'General case' 0 C--N 1.295 -1.79 0 O-C-N 121.378 -0.826 . . . . 0.0 110.185 178.038 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.55 ' HB3' HG22 ' A' ' 52' ' ' THR . 36.7 p-10 -90.78 151.16 21.31 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.089 -1.007 . . . . 0.0 111.398 -170.161 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.812 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -159.82 111.54 2.03 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 -175.574 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.525 ' HB2' ' CB ' ' A' ' 67' ' ' THR . 28.4 mtm -66.17 140.02 58.16 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.819 -1.176 . . . . 0.0 109.825 -179.848 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.498 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 49.3 tptt -60.11 -49.8 76.23 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.209 -0.932 . . . . 0.0 110.251 -178.411 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -65.2 -40.01 93.58 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.875 -1.141 . . . . 0.0 109.76 176.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.525 ' CB ' ' HB2' ' A' ' 64' ' ' MET . 94.3 m -60.05 -39.7 86.89 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.02 -1.05 . . . . 0.0 109.452 173.289 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.724 HD11 ' HA2' ' A' ' 74' ' ' GLY . 7.8 tp -59.95 -43.57 94.95 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.308 -0.87 . . . . 0.0 109.65 179.723 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -68.16 -40.01 82.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.38 -0.825 . . . . 0.0 110.579 176.042 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.853 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -64.9 -43.25 96.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.17 -0.956 . . . . 0.0 109.328 -177.108 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.853 HG23 HG22 ' A' ' 70' ' ' ILE . 29.9 p -86.68 -174.63 5.07 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.727 -0.608 . . . . 0.0 109.667 176.751 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.489 ' HB2' ' N ' ' B' ' 83' ' ' ASN . 6.1 t30 -98.78 22.59 9.87 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.167 -0.958 . . . . 0.0 108.686 171.469 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.812 ' HB3' HD21 ' A' ' 63' ' ' LEU . 91.8 mt -68.73 -39.98 80.12 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.095 -1.003 . . . . 0.0 109.975 176.907 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.724 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -50.44 -23.9 6.78 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -178.351 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.5 p-10 -62.12 -18.01 59.53 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.089 -1.242 . . . . 0.0 110.233 -175.764 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.9 mt -63.62 142.09 58.53 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.319 -0.863 . . . . 0.0 110.961 -177.69 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 0.994 ' C ' HD23 ' A' ' 12' ' ' LEU . 42.8 mttt -143.54 144.84 32.13 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-O 121.311 0.577 . . . . 0.0 109.731 175.106 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.796 HG23 HD11 ' A' ' 15' ' ' ILE . 21.9 t -64.52 149.93 10.7 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 120.843 -1.161 . . . . 0.0 110.479 -175.327 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.97 -13.63 60.78 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -175.144 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 46.6 t0 -94.61 163.3 13.44 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.337 -1.096 . . . . 0.0 109.585 176.021 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.579 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 13.9 m95 -113.28 154.79 26.23 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 120.964 -1.085 . . . . 0.0 110.155 175.829 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.044 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.4 p -119.99 153.03 22.82 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.437 -0.789 . . . . 0.0 109.852 -179.019 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.655 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.4 OUTLIER -77.73 107.34 10.16 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.171 -0.955 . . . . 0.0 109.02 168.475 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.758 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -109.4 138.85 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 120.474 -1.391 . . . . 0.0 111.364 -176.724 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.481 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.6 tt0 -131.49 139.59 49.35 Favored 'General case' 0 N--CA 1.494 1.749 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.131 -179.369 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -81.37 133.62 35.44 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.091 -1.006 . . . . 0.0 110.94 -175.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.901 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -130.69 147.31 52.35 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.28 -0.888 . . . . 0.0 110.639 179.809 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.885 ' HB1' ' CE2' ' A' ' 90' ' ' PHE . . . -151.19 9.07 0.55 Allowed 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.49 -0.756 . . . . 0.0 111.981 -178.168 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.622 ' HG3' ' CE2' ' B' ' 2' ' ' PHE . 20.7 mttm 60.02 19.83 8.96 Favored 'General case' 0 N--CA 1.513 2.698 0 O-C-N 121.373 -0.829 . . . . 0.0 110.781 175.029 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.885 ' CE2' ' HB1' ' A' ' 88' ' ' ALA . 9.6 p90 -154.09 159.65 41.6 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.905 -1.122 . . . . 0.0 110.591 172.68 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.536 ' HB3' ' CG1' ' A' ' 94' ' ' ILE . 56.7 m -141.78 150.18 41.37 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.493 -0.754 . . . . 0.0 109.831 175.89 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.496 ' O ' ' HG3' ' A' ' 93' ' ' GLU . 51.8 t0 -69.87 -45.93 66.62 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.107 -0.996 . . . . 0.0 110.313 -178.886 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.496 ' HG3' ' O ' ' A' ' 92' ' ' ASP . 94.0 mt-10 -157.35 53.96 0.49 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.338 -0.852 . . . . 0.0 110.444 179.198 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.536 ' CG1' ' HB3' ' A' ' 91' ' ' SER . 48.4 mm -98.95 -37.77 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.138 -0.976 . . . . 0.0 110.456 178.661 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 47.11 67.66 1.4 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 -178.635 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' A' ' 97' ' ' HIS . . . -178.59 -170.01 40.07 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -178.911 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.493 ' CB ' ' O ' ' A' ' 96' ' ' GLY . 0.9 OUTLIER . . . . . 0 N--CA 1.493 1.723 0 O-C-N 121.188 -1.184 . . . . 0.0 110.139 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 98.1 mtp . . . . . 0 N--CA 1.492 1.655 0 CA-C-O 121.062 0.458 . . . . 0.0 110.139 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.901 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 4.6 p90 -165.77 156.24 13.12 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.075 -1.016 . . . . 0.0 108.406 172.725 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.594 HG23 ' C ' ' B' ' 2' ' ' PHE . 60.7 p -152.2 -40.9 0.11 Allowed 'General case' 0 C--N 1.292 -1.912 0 O-C-N 120.91 -1.119 . . . . 0.0 108.818 175.01 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.448 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 47.39 24.13 2.33 Favored Glycine 0 N--CA 1.481 1.692 0 N-CA-C 108.213 -1.955 . . . . 0.0 108.213 -174.52 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 0.519 HD11 ' C8M' ' A' ' 98' ' ' RBF . 70.8 mt -82.01 119.77 32.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.287 -1.125 . . . . 0.0 109.689 -176.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.653 HG21 ' HB3' ' B' ' 83' ' ' ASN . 3.4 t -75.1 149.17 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.352 -0.843 . . . . 0.0 110.583 -173.889 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 28.2 mm100 -98.55 -14.83 19.77 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.54 -0.725 . . . . 0.0 110.854 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.529 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -141.28 165.14 26.42 Favored Glycine 0 N--CA 1.493 2.458 0 C-N-CA 119.338 -1.41 . . . . 0.0 109.868 -177.536 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.487 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 0.7 OUTLIER -124.74 169.99 11.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.123 -1.221 . . . . 0.0 110.556 178.821 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.023 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -141.31 149.34 41.1 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.507 -0.745 . . . . 0.0 109.235 -176.617 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 32.0 tttt -109.7 114.34 27.86 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.151 -0.968 . . . . 0.0 110.014 178.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 1.001 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.7 tp -60.02 127.78 33.57 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.104 -0.998 . . . . 0.0 108.939 175.106 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.091 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.5 p -127.96 -31.04 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 O-C-N 121.393 -0.817 . . . . 0.0 110.1 -178.651 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.08 141.9 30.32 Favored 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.328 -178.082 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.82 HD11 HG23 ' B' ' 78' ' ' VAL . 8.4 mt -109.91 132.96 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.128 -0.982 . . . . 0.0 110.377 172.917 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.519 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 88.2 m-20 -109.99 114.98 28.95 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.416 -0.803 . . . . 0.0 109.995 175.388 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -102.59 109.67 21.36 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.982 -1.074 . . . . 0.0 110.497 -177.399 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.3 OUTLIER -101.87 135.95 19.62 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.274 -0.892 . . . . 0.0 109.541 175.943 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.05 -16.85 9.97 Favored 'Trans proline' 0 C--N 1.303 -1.837 0 O-C-N 123.934 1.492 . . . . 0.0 110.856 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.547 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 6.0 m-80 -102.56 -26.98 13.03 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.107 -0.996 . . . . 0.0 109.874 179.706 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.547 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 87.5 m-85 -156.3 150.22 25.08 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.432 -0.793 . . . . 0.0 109.972 -178.426 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.487 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 61.2 ttt180 -92.31 141.67 28.3 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.701 -1.25 . . . . 0.0 109.806 174.786 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.519 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 88.4 m -129.96 140.12 50.97 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 121.617 -0.677 . . . . 0.0 109.798 -172.715 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.729 ' NE2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -130.05 142.45 50.61 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 120.964 -1.085 . . . . 0.0 111.338 -179.158 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.835 HG22 ' CB ' ' B' ' 60' ' ' SER . 16.3 t -119.51 134.41 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.264 -0.898 . . . . 0.0 110.435 179.55 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.911 HG13 ' CE1' ' B' ' 61' ' ' PHE . 33.1 m -117.09 170.76 6.21 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 CA-C-O 121.263 0.554 . . . . 0.0 109.955 178.921 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.687 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 9.3 tt0 -102.56 116.68 33.08 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.345 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.498 ' HA ' HD12 ' B' ' 28' ' ' LEU . 8.7 tp -80.54 121.62 81.56 Favored Pre-proline 0 C--N 1.297 -1.703 0 O-C-N 121.433 -0.792 . . . . 0.0 109.716 -173.805 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.478 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 18.5 Cg_endo -63.4 178.86 1.06 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 O-C-N 123.91 1.479 . . . . 0.0 111.007 -179.09 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.516 ' HA ' HD12 ' B' ' 33' ' ' LEU . 88.1 m-20 -60.29 -39.98 88.85 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.356 -0.84 . . . . 0.0 111.118 -175.827 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.588 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.11 0.28 57.23 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.87 -1.144 . . . . 0.0 110.945 -175.609 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.588 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.1 mmm -109.16 -12.81 14.77 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.87 -1.144 . . . . 0.0 109.93 171.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.833 HD21 ' HB2' ' B' ' 57' ' ' ASN . 19.2 mt -68.88 -31.32 70.17 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.226 -0.921 . . . . 0.0 110.22 178.054 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -93.99 122.95 37.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.381 -0.824 . . . . 0.0 110.363 -178.38 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 111.43 -50.65 0.75 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.061 -1.215 . . . . 0.0 110.061 177.166 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.576 HD23 ' N ' ' B' ' 37' ' ' GLU . 6.7 tt -66.97 140.02 57.72 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.051 -1.264 . . . . 0.0 110.299 -176.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 37' ' ' GLU . . . . . 0.576 ' N ' HD23 ' B' ' 36' ' ' LEU . 19.7 pt-20 -147.38 168.55 21.54 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.401 -0.812 . . . . 0.0 109.41 176.673 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.783 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -63.33 151.51 40.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.995 -1.066 . . . . 0.0 110.382 -175.949 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.73 -0.48 61.32 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -174.658 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.607 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -80.07 159.34 26.18 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.141 -1.211 . . . . 0.0 109.382 175.816 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.498 ' HG ' ' HZ ' ' A' ' 2' ' ' PHE . 0.5 OUTLIER -102.99 117.33 34.36 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.782 -1.199 . . . . 0.0 110.309 177.03 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.635 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.7 t -102.27 128.43 54.93 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 121.357 -0.839 . . . . 0.0 108.868 172.5 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -92.97 119.74 32.55 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 119.227 -0.989 . . . . 0.0 108.988 172.617 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.684 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -87.72 102.45 14.65 Favored 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.54 -0.864 . . . . 0.0 109.098 179.106 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 59.84 6.38 0.89 Allowed 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.554 -0.716 . . . . 0.0 111.549 -170.688 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' A' ' 4' ' ' GLY . . . 128.38 -0.62 6.46 Favored Glycine 0 N--CA 1.489 2.218 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.714 174.228 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.694 ' O ' HD23 ' B' ' 49' ' ' LEU . 34.6 t -98.63 108.61 21.34 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.502 -1.587 . . . . 0.0 109.537 175.552 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 22.9 p -74.19 130.19 39.27 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.058 -1.026 . . . . 0.0 111.043 -171.429 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 0.856 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -147.11 153.92 40.5 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.527 -0.733 . . . . 0.0 109.359 173.726 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 50' ' ' THR . . . . . 0.421 HG22 ' N ' ' B' ' 51' ' ' VAL . 92.9 m -95.9 160.41 14.48 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 120.527 -1.358 . . . . 0.0 111.556 -169.085 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.946 HG13 HG13 ' B' ' 59' ' ' VAL . 16.1 t -82.44 114.65 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.84 -0.538 . . . . 0.0 110.433 -178.682 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.542 HG22 ' HB3' ' B' ' 62' ' ' ASP . 30.2 p -70.71 -40.03 73.07 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.272 -0.893 . . . . 0.0 109.918 175.339 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.574 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -166.21 154.11 10.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.202 -0.936 . . . . 0.0 110.208 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.783 HD11 ' N ' ' B' ' 38' ' ' THR . 9.8 mt -108.31 134.89 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.114 -0.991 . . . . 0.0 110.206 177.684 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.515 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 47.1 m-80 -108.84 66.14 0.63 Allowed 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.64 -0.662 . . . . 0.0 109.522 177.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.32 -116.81 5.08 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 108.861 -1.696 . . . . 0.0 108.861 -173.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.833 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -78.44 -20.29 51.35 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.075 -1.25 . . . . 0.0 109.151 177.054 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.091 ' CE1' HG11 ' B' ' 13' ' ' VAL . 23.1 m-70 -76.5 158.79 30.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.347 -0.846 . . . . 0.0 110.097 -178.375 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.946 HG13 HG13 ' B' ' 51' ' ' VAL . 55.8 t -140.76 123.15 15.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 C-N-CA 119.076 -1.05 . . . . 0.0 110.519 171.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.835 ' CB ' HG22 ' B' ' 25' ' ' VAL . 0.9 OUTLIER -87.52 133.3 33.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.441 -0.787 . . . . 0.0 109.204 175.225 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.911 ' CE1' HG13 ' B' ' 26' ' ' VAL . 1.8 p90 -125.98 155.99 40.53 Favored 'General case' 0 N--CA 1.494 1.773 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.177 178.033 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.542 ' HB3' HG22 ' B' ' 52' ' ' THR . 36.6 p-10 -90.67 151.19 21.37 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.0 -1.062 . . . . 0.0 111.381 -170.115 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.784 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.82 111.53 2.03 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -175.638 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.528 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 28.5 mtm -66.22 139.96 58.13 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.888 -1.133 . . . . 0.0 109.824 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.499 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 49.3 tptt -59.92 -49.87 76.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.131 -0.98 . . . . 0.0 110.3 -178.439 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -65.24 -39.99 93.42 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.913 -1.117 . . . . 0.0 109.765 176.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.528 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 94.5 m -60.01 -39.83 87.19 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.988 -1.07 . . . . 0.0 109.342 173.29 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.717 HD11 ' HA2' ' B' ' 74' ' ' GLY . 7.8 tp -59.94 -43.45 94.97 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.293 -0.879 . . . . 0.0 109.707 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 78.5 ttt180 -68.21 -40.08 82.21 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.293 -0.879 . . . . 0.0 110.603 175.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.831 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -64.75 -43.24 96.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.195 -0.941 . . . . 0.0 109.434 -177.213 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.831 HG23 HG22 ' B' ' 70' ' ' ILE . 30.0 p -86.65 -174.56 5.04 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 120.231 -0.588 . . . . 0.0 109.658 176.774 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.506 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 6.0 t30 -98.71 22.57 9.84 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.19 -0.944 . . . . 0.0 108.78 171.393 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.784 ' HB3' HD21 ' B' ' 63' ' ' LEU . 91.4 mt -68.71 -40.0 80.17 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.075 -1.015 . . . . 0.0 110.05 176.929 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.717 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -50.46 -23.87 6.78 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 -178.384 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.0 p-10 -62.1 -17.94 59.23 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.062 -1.258 . . . . 0.0 110.295 -175.909 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.513 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.1 mt -63.68 142.22 58.48 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.287 -0.883 . . . . 0.0 110.929 -177.746 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 1.001 ' C ' HD23 ' B' ' 12' ' ' LEU . 42.8 mttt -143.67 144.95 32.1 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.627 -0.671 . . . . 0.0 109.665 175.13 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.82 HG23 HD11 ' B' ' 15' ' ' ILE . 22.2 t -64.73 150.03 10.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 O-C-N 120.856 -1.153 . . . . 0.0 110.341 -175.182 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.8 -13.45 60.89 Favored Glycine 0 N--CA 1.484 1.84 0 N-CA-C 108.848 -1.701 . . . . 0.0 108.848 -175.16 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 46.2 t0 -94.62 163.23 13.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.319 -1.106 . . . . 0.0 109.59 175.832 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.584 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 13.9 m95 -113.31 154.73 26.37 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.97 -1.081 . . . . 0.0 110.215 175.782 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.023 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.4 p -119.98 153.1 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.579 -0.701 . . . . 0.0 109.881 -179.082 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.653 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.3 OUTLIER -77.72 107.27 10.09 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.178 -0.951 . . . . 0.0 109.018 168.569 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.765 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -109.32 138.96 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 120.462 -1.399 . . . . 0.0 111.211 -176.533 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 85' ' ' GLU . . . . . 0.465 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.7 tt0 -131.58 139.68 49.25 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.883 -0.511 . . . . 0.0 110.144 -179.569 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -81.35 133.69 35.46 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.117 -0.99 . . . . 0.0 110.916 -175.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 0.923 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -130.85 147.19 52.47 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.403 -0.81 . . . . 0.0 110.647 179.814 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 88' ' ' ALA . . . . . 0.883 ' HB1' ' CE2' ' B' ' 90' ' ' PHE . . . -151.22 8.96 0.55 Allowed 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.39 -0.819 . . . . 0.0 112.067 -178.066 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 89' ' ' LYS . . . . . 0.592 ' HG3' ' CE2' ' A' ' 2' ' ' PHE . 20.6 mttm 59.96 19.98 9.03 Favored 'General case' 0 N--CA 1.512 2.66 0 O-C-N 121.334 -0.854 . . . . 0.0 110.732 175.015 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 90' ' ' PHE . . . . . 0.883 ' CE2' ' HB1' ' B' ' 88' ' ' ALA . 9.7 p90 -154.1 159.68 41.6 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.872 -1.143 . . . . 0.0 110.685 172.536 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 91' ' ' SER . . . . . 0.525 ' HB3' HG12 ' B' ' 94' ' ' ILE . 56.4 m -141.8 150.28 41.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.476 -0.765 . . . . 0.0 109.787 175.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -69.94 -50.29 43.47 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.081 -1.012 . . . . 0.0 110.388 -178.842 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 93' ' ' GLU . . . . . 0.435 ' O ' ' HG3' ' B' ' 93' ' ' GLU . 16.6 pt-20 -160.51 63.46 0.32 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.037 -1.039 . . . . 0.0 111.441 -175.589 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 94' ' ' ILE . . . . . 0.787 HG21 ' OXT' ' B' ' 97' ' ' HIS . 20.2 mm -60.04 -42.96 91.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 120.92 -1.113 . . . . 0.0 109.995 174.745 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 114.67 -102.02 1.13 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.489 -1.445 . . . . 0.0 109.489 -177.706 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -67.28 -41.62 91.41 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -178.887 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 97' ' ' HIS . . . . . 0.787 ' OXT' HG21 ' B' ' 94' ' ' ILE . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 O-C-N 121.236 -1.155 . . . . 0.0 110.291 -178.064 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 0.538 " O2'" ' C9 ' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 0.556 ' C8M' HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.422 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 73.0 mtm . . . . . 0 N--CA 1.493 1.724 0 CA-C-O 121.274 0.559 . . . . 0.0 110.12 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 1.003 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 5.0 p90 -176.83 147.59 0.61 Allowed 'General case' 0 C--N 1.306 -1.322 0 O-C-N 121.148 -0.97 . . . . 0.0 108.815 179.413 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.55 ' CB ' HG12 ' A' ' 5' ' ' ILE . 6.0 p -141.05 -37.98 0.43 Allowed 'General case' 0 C--N 1.296 -1.723 0 O-C-N 120.891 -1.131 . . . . 0.0 109.223 -179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.461 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 47.64 24.64 2.89 Favored Glycine 0 N--CA 1.485 1.918 0 N-CA-C 108.541 -1.824 . . . . 0.0 108.541 -176.214 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.55 HG12 ' CB ' ' A' ' 3' ' ' THR . 48.4 mm -80.48 124.64 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.294 -1.121 . . . . 0.0 110.032 -175.906 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.954 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.5 t -84.22 141.82 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.367 -0.833 . . . . 0.0 110.638 -172.606 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 20.1 pt20 -89.64 -16.15 31.13 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.453 -0.779 . . . . 0.0 110.829 -178.426 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -158.45 177.12 35.25 Favored Glycine 0 N--CA 1.493 2.484 0 C-N-CA 119.129 -1.51 . . . . 0.0 110.083 -177.522 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.487 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 1.4 p -125.87 167.97 14.51 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.069 -1.254 . . . . 0.0 110.472 178.942 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.07 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -139.93 149.64 43.57 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.346 -0.846 . . . . 0.0 109.903 -174.283 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.585 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 31.2 tttt -106.26 116.01 31.21 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.126 -0.984 . . . . 0.0 110.169 179.255 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.998 HD23 ' C ' ' A' ' 77' ' ' LYS . 13.1 tp -59.93 128.03 34.84 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.793 -1.192 . . . . 0.0 108.582 171.676 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.145 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.7 p -131.34 -31.01 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 O-C-N 121.262 -0.898 . . . . 0.0 110.316 -176.869 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -144.34 139.68 28.65 Favored 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 118.936 -1.106 . . . . 0.0 111.39 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.736 HG23 ' CD2' ' A' ' 24' ' ' HIS . 9.9 mt -109.16 137.0 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.052 -1.03 . . . . 0.0 110.08 171.366 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.478 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 78.7 m-20 -111.86 114.35 27.25 Favored 'General case' 0 C--N 1.295 -1.79 0 O-C-N 121.415 -0.803 . . . . 0.0 110.182 173.028 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -105.04 118.61 36.97 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.033 -1.042 . . . . 0.0 110.492 -177.443 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.44 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.9 mtpp -118.26 140.18 27.74 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.256 -0.902 . . . . 0.0 109.779 178.876 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -55.1 -15.2 10.03 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 O-C-N 124.067 1.562 . . . . 0.0 110.964 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.568 ' O ' ' CD1' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -107.61 -25.25 11.42 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.999 -1.063 . . . . 0.0 109.308 -177.892 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.568 ' CD1' ' O ' ' A' ' 20' ' ' ASN . 75.8 m-85 -157.74 150.3 22.71 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.622 -0.674 . . . . 0.0 110.105 179.337 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.498 ' HD3' HD22 ' A' ' 68' ' ' LEU . 63.6 ttt180 -96.77 143.32 27.8 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 120.815 -1.178 . . . . 0.0 110.012 172.614 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.478 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 54.4 m -130.91 140.18 50.17 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.488 -0.758 . . . . 0.0 110.145 -173.414 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.736 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -130.14 143.86 51.03 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 120.94 -1.1 . . . . 0.0 111.604 178.805 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.859 HG22 ' OG ' ' A' ' 60' ' ' SER . 8.3 t -125.77 136.1 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.158 -0.964 . . . . 0.0 110.651 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 35.4 m -117.67 171.74 5.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 121.783 -0.573 . . . . 0.0 110.211 178.228 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.573 ' CG ' HD22 ' A' ' 57' ' ' ASN . 3.6 tt0 -104.25 117.31 33.92 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.218 -0.926 . . . . 0.0 109.247 -178.772 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.562 HD21 ' O ' ' A' ' 32' ' ' MET . 9.6 tp -82.81 125.87 74.4 Favored Pre-proline 0 C--N 1.299 -1.621 0 O-C-N 121.585 -0.697 . . . . 0.0 110.106 -173.641 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.54 ' HD2' HD12 ' A' ' 28' ' ' LEU . 28.2 Cg_endo -67.04 176.94 4.01 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 123.886 1.466 . . . . 0.0 111.069 -179.627 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.67 ' HA ' HD12 ' A' ' 33' ' ' LEU . 92.6 m-20 -60.03 -40.0 87.84 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.239 -0.913 . . . . 0.0 111.306 -174.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.595 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.99 0.64 56.99 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.751 -1.218 . . . . 0.0 110.907 -174.472 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.595 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.8 mmm -112.17 -8.57 13.99 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.875 -1.141 . . . . 0.0 110.006 170.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.696 HD21 ' HB2' ' A' ' 57' ' ' ASN . 16.0 mt -70.03 -40.01 75.42 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.224 -0.922 . . . . 0.0 109.915 177.065 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -81.74 128.81 34.38 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.594 -0.691 . . . . 0.0 110.486 -178.246 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.47 -46.18 1.21 Allowed Glycine 0 N--CA 1.493 2.445 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.256 174.795 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.7 HD23 ' N ' ' A' ' 37' ' ' GLU . 6.8 tt -69.7 148.84 48.71 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.93 -1.335 . . . . 0.0 110.445 -175.365 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.7 ' N ' HD23 ' A' ' 36' ' ' LEU . 21.3 pt-20 -150.62 170.02 20.16 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.367 -0.833 . . . . 0.0 109.397 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.717 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -70.06 151.15 45.84 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.058 -1.026 . . . . 0.0 110.228 -178.919 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.09 -3.3 66.2 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -174.183 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.453 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -77.99 161.48 27.46 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.27 -1.135 . . . . 0.0 109.661 177.612 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.476 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.6 OUTLIER -101.64 114.95 29.46 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.016 -1.052 . . . . 0.0 110.104 177.354 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.626 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.8 t -103.16 128.88 55.76 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.323 -0.861 . . . . 0.0 109.157 174.06 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -94.8 120.08 34.43 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.269 -0.972 . . . . 0.0 109.265 173.043 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.863 ' CD2' HG21 ' A' ' 82' ' ' VAL . 1.4 m80 -90.71 106.19 18.34 Favored 'General case' 0 C--N 1.301 -1.503 0 C-N-CA 119.676 -0.81 . . . . 0.0 109.054 177.568 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.494 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.8 t-20 53.92 14.81 0.72 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.338 -0.851 . . . . 0.0 110.925 -167.02 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.512 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 117.78 -0.5 17.73 Favored Glycine 0 N--CA 1.489 2.17 0 C-N-CA 119.623 -1.275 . . . . 0.0 110.978 170.559 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.833 ' O ' HD23 ' A' ' 49' ' ' LEU . 43.4 t -92.35 106.84 18.76 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.49 -1.594 . . . . 0.0 109.151 173.525 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.8 p -75.49 128.66 35.8 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.15 -0.969 . . . . 0.0 110.749 -170.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.833 HD23 ' O ' ' A' ' 47' ' ' CYS . 0.3 OUTLIER -143.14 159.66 41.88 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.442 -0.786 . . . . 0.0 109.714 175.296 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.421 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 28.9 m -100.16 149.82 23.14 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.576 -1.328 . . . . 0.0 111.409 -170.781 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.836 HG13 HG13 ' A' ' 59' ' ' VAL . 15.1 t -78.06 118.39 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 CA-C-O 121.155 0.502 . . . . 0.0 110.617 -178.002 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 42.9 p -73.89 -39.94 63.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.126 -0.984 . . . . 0.0 110.031 174.494 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.658 ' HA ' HG21 ' A' ' 38' ' ' THR . 86.6 tt0 -163.4 149.85 12.07 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.35 -0.844 . . . . 0.0 110.214 -178.007 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.717 HD11 ' N ' ' A' ' 38' ' ' THR . 5.7 mt -101.51 134.9 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.09 -1.007 . . . . 0.0 109.955 176.148 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.496 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 49.9 m-80 -110.45 65.78 0.62 Allowed 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.571 -0.705 . . . . 0.0 109.913 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.19 -118.68 4.99 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.879 -1.688 . . . . 0.0 108.879 -175.236 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.696 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.1 OUTLIER -78.62 -16.39 57.41 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 120.949 -1.324 . . . . 0.0 108.816 174.307 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.145 ' CD2' HG11 ' A' ' 13' ' ' VAL . 11.8 m170 -76.6 159.81 29.96 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.37 -0.831 . . . . 0.0 110.39 -178.192 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.836 HG13 HG13 ' A' ' 51' ' ' VAL . 52.2 t -140.3 127.02 22.42 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 O-C-N 121.02 -1.05 . . . . 0.0 110.596 170.036 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.859 ' OG ' HG22 ' A' ' 25' ' ' VAL . 2.7 t -95.8 136.74 35.83 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.474 -0.767 . . . . 0.0 109.564 178.382 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.807 ' HB2' HD12 ' A' ' 49' ' ' LEU . 2.0 p90 -128.06 157.78 39.76 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.864 173.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.533 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 25.0 p-10 -89.48 157.64 18.02 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.31 -0.869 . . . . 0.0 111.129 -171.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.746 HD22 ' CD1' ' A' ' 68' ' ' LEU . 0.1 OUTLIER -159.94 102.57 1.47 Allowed 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 120.035 -0.666 . . . . 0.0 109.461 -175.441 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.501 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 56.3 ttm -59.75 140.4 56.54 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.002 -1.062 . . . . 0.0 109.364 -179.557 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.457 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 39.4 ttpt -60.01 -43.32 95.31 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.022 -1.049 . . . . 0.0 110.285 -175.159 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.74 -39.99 76.43 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.02 -1.05 . . . . 0.0 110.067 178.279 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.501 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 92.2 m -60.56 -39.96 89.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.978 -1.076 . . . . 0.0 109.184 172.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.746 ' CD1' HD22 ' A' ' 63' ' ' LEU . 7.3 tp -59.94 -45.4 92.74 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.285 -0.885 . . . . 0.0 109.782 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 15.0 tpp180 -69.21 -39.59 78.51 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.529 -0.732 . . . . 0.0 110.47 177.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.857 HG22 HG23 ' A' ' 71' ' ' THR . 1.4 tt -63.68 -43.98 98.27 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.13 -0.982 . . . . 0.0 109.368 -177.47 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.857 HG23 HG22 ' A' ' 70' ' ' ILE . 37.8 p -83.55 -170.51 3.1 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.404 0.621 . . . . 0.0 109.703 178.611 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.5 t30 -103.28 22.63 13.79 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 170.187 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.72 ' HB3' HD21 ' A' ' 63' ' ' LEU . 89.4 mt -69.54 -41.23 76.22 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.158 -0.964 . . . . 0.0 109.999 176.731 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.73 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -51.01 -20.81 4.75 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 -178.163 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.1 p-10 -67.43 -18.5 65.12 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.927 -1.337 . . . . 0.0 110.673 -174.003 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.517 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 90.2 mt -60.89 142.86 55.92 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.166 -0.959 . . . . 0.0 110.983 -175.476 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 0.998 ' C ' HD23 ' A' ' 12' ' ' LEU . 98.7 mttt -140.34 139.53 35.43 Favored 'General case' 0 N--CA 1.493 1.695 0 CA-C-O 121.537 0.684 . . . . 0.0 109.955 173.905 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.706 ' N ' HD23 ' A' ' 12' ' ' LEU . 15.4 t -63.19 153.47 6.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 120.868 -1.145 . . . . 0.0 110.636 -174.45 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.0 -16.93 55.83 Favored Glycine 0 N--CA 1.485 1.928 0 N-CA-C 108.645 -1.782 . . . . 0.0 108.645 -175.134 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -95.14 170.09 9.64 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.402 -1.058 . . . . 0.0 109.743 175.845 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.585 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.5 m95 -116.97 169.51 9.35 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.965 -1.085 . . . . 0.0 110.17 176.013 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.07 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.4 p -134.09 155.63 39.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 121.438 -0.789 . . . . 0.0 109.808 -176.669 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.954 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.1 m-20 -79.57 109.12 13.66 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.006 -1.059 . . . . 0.0 109.134 168.668 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.783 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -110.78 138.59 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 120.43 -1.419 . . . . 0.0 111.275 -175.546 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -134.35 145.03 48.62 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.864 -0.522 . . . . 0.0 110.292 -177.244 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 36.1 ttm180 -83.49 130.65 35.02 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.311 -0.868 . . . . 0.0 111.027 -176.679 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.995 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -127.66 148.19 50.38 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.25 -0.906 . . . . 0.0 110.023 174.737 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -123.69 141.62 51.84 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.423 -0.798 . . . . 0.0 110.873 -175.723 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 15.9 mttp -60.0 -40.03 87.8 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.471 -0.768 . . . . 0.0 110.84 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -159.05 160.0 35.33 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.998 -1.064 . . . . 0.0 111.07 -177.033 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.633 ' CB ' HD12 ' A' ' 94' ' ' ILE . 79.7 p -154.65 161.42 41.58 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.415 -0.803 . . . . 0.0 109.715 173.293 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.509 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 96.0 m-20 -69.96 -40.35 75.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.081 -1.012 . . . . 0.0 110.698 -178.626 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.509 ' CG ' ' O ' ' A' ' 92' ' ' ASP . 59.1 mt-10 -158.11 60.04 0.46 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.949 -1.095 . . . . 0.0 111.323 -172.426 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.794 HG22 ' O ' ' A' ' 94' ' ' ILE . 96.7 mt -92.99 25.91 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 120.649 -1.282 . . . . 0.0 109.422 170.613 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 94' ' ' ILE . . . -39.25 -24.7 0.04 OUTLIER Glycine 0 N--CA 1.496 2.643 0 C-N-CA 120.322 -0.942 . . . . 0.0 111.42 -175.196 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 94' ' ' ILE . . . 94.24 171.56 38.27 Favored Glycine 0 N--CA 1.491 2.342 0 O-C-N 120.476 -1.602 . . . . 0.0 109.399 -179.366 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.411 ' ND1' ' N ' ' A' ' 97' ' ' HIS . 30.5 p-80 . . . . . 0 N--CA 1.492 1.633 0 O-C-N 121.289 -1.124 . . . . 0.0 110.161 -179.415 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 58.2 mtm . . . . . 0 N--CA 1.492 1.663 0 CA-C-O 121.115 0.483 . . . . 0.0 110.413 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.995 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 5.1 p90 -166.62 147.39 6.08 Favored 'General case' 0 C--N 1.306 -1.308 0 O-C-N 121.184 -0.947 . . . . 0.0 108.653 173.419 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.55 ' CB ' HG12 ' B' ' 5' ' ' ILE . 6.0 p -141.15 -37.96 0.42 Allowed 'General case' 0 C--N 1.298 -1.667 0 O-C-N 120.789 -1.194 . . . . 0.0 109.21 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.407 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 47.67 24.58 2.9 Favored Glycine 0 N--CA 1.485 1.949 0 N-CA-C 108.515 -1.834 . . . . 0.0 108.515 -176.32 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 0.55 HG12 ' CB ' ' B' ' 3' ' ' THR . 48.3 mm -80.46 124.6 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.357 -1.084 . . . . 0.0 110.056 -175.906 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.992 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.5 t -84.11 141.8 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.367 -0.833 . . . . 0.0 110.727 -172.634 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 20.1 pt20 -89.72 -15.84 31.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.374 -0.828 . . . . 0.0 110.887 -178.418 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.525 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -158.8 177.0 35.59 Favored Glycine 0 N--CA 1.494 2.552 0 C-N-CA 119.143 -1.503 . . . . 0.0 110.113 -177.495 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.486 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 1.4 p -125.88 167.92 14.58 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.088 -1.243 . . . . 0.0 110.42 179.103 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.092 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -139.84 149.77 43.85 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.278 -0.889 . . . . 0.0 109.88 -174.399 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.583 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 31.2 tttt -106.35 116.04 31.25 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.081 -1.012 . . . . 0.0 110.141 179.201 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 0.998 HD23 ' C ' ' B' ' 77' ' ' LYS . 13.1 tp -60.06 128.03 34.82 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.828 -1.17 . . . . 0.0 108.671 171.634 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.145 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.7 p -131.41 -30.86 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.31 -176.711 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -144.46 139.8 28.55 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.12 -1.032 . . . . 0.0 111.348 179.913 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.742 HG23 ' CD2' ' B' ' 24' ' ' HIS . 10.3 mt -109.32 136.98 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.078 -1.013 . . . . 0.0 110.06 171.4 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.495 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 78.6 m-20 -111.97 114.5 27.44 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 121.44 -0.787 . . . . 0.0 110.159 173.039 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -104.96 118.74 37.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.188 -0.945 . . . . 0.0 110.493 -177.435 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.436 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.9 mtpp -118.39 140.3 27.99 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.29 -0.881 . . . . 0.0 109.771 178.838 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -55.39 -15.11 10.81 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 124.008 1.53 . . . . 0.0 110.967 -179.785 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.571 ' O ' ' CD1' ' B' ' 21' ' ' PHE . 0.0 OUTLIER -107.28 -25.9 11.28 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.01 -1.056 . . . . 0.0 109.214 -177.946 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.571 ' CD1' ' O ' ' B' ' 20' ' ' ASN . 75.3 m-85 -157.2 150.36 23.79 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.534 -0.729 . . . . 0.0 110.195 179.499 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.478 ' HD3' HD22 ' B' ' 68' ' ' LEU . 63.7 ttt180 -96.8 143.21 27.93 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.914 -1.117 . . . . 0.0 109.944 172.616 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.495 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 54.0 m -130.76 140.21 50.29 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.638 -0.664 . . . . 0.0 110.134 -173.492 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.742 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -130.04 143.94 51.06 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.005 -1.06 . . . . 0.0 111.492 178.806 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.867 HG22 ' OG ' ' B' ' 60' ' ' SER . 8.2 t -125.7 136.3 61.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.317 -0.864 . . . . 0.0 110.764 179.869 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.469 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 35.6 m -117.91 171.78 5.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.744 -0.598 . . . . 0.0 110.126 178.355 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.578 ' CG ' HD22 ' B' ' 57' ' ' ASN . 3.6 tt0 -104.18 117.45 34.28 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.274 -0.891 . . . . 0.0 109.199 -178.786 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.55 HD21 ' O ' ' B' ' 32' ' ' MET . 9.6 tp -82.9 125.8 74.37 Favored Pre-proline 0 C--N 1.299 -1.613 0 O-C-N 121.545 -0.722 . . . . 0.0 110.129 -173.724 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.539 ' HD2' HD12 ' B' ' 28' ' ' LEU . 28.1 Cg_endo -67.01 176.96 3.97 Favored 'Trans proline' 0 C--N 1.31 -1.491 0 O-C-N 123.919 1.484 . . . . 0.0 110.934 -179.583 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.656 ' HA ' HD12 ' B' ' 33' ' ' LEU . 92.6 m-20 -60.01 -39.99 87.72 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.309 -0.869 . . . . 0.0 111.35 -174.938 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.584 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.01 0.63 57.0 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.761 -1.212 . . . . 0.0 110.844 -174.434 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.584 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.8 mmm -112.19 -8.58 13.98 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.856 -1.153 . . . . 0.0 110.006 170.891 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.715 HD21 ' HB2' ' B' ' 57' ' ' ASN . 16.0 mt -70.0 -40.04 75.52 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.268 -0.895 . . . . 0.0 109.888 177.07 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -81.7 128.93 34.49 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.597 -0.689 . . . . 0.0 110.508 -178.273 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.35 -46.15 1.21 Allowed Glycine 0 N--CA 1.492 2.414 0 C-N-CA 119.868 -1.158 . . . . 0.0 110.328 174.84 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.705 HD23 ' N ' ' B' ' 37' ' ' GLU . 6.8 tt -69.66 148.89 48.71 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.95 -1.324 . . . . 0.0 110.43 -175.402 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 37' ' ' GLU . . . . . 0.705 ' N ' HD23 ' B' ' 36' ' ' LEU . 21.4 pt-20 -150.68 169.95 20.36 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.347 -0.845 . . . . 0.0 109.51 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.72 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -69.99 151.12 45.94 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.038 -1.039 . . . . 0.0 110.252 -178.855 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.17 -3.5 65.96 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 -174.209 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.453 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -77.91 161.36 27.62 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.297 -1.119 . . . . 0.0 109.701 177.521 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.48 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.6 OUTLIER -101.43 114.82 29.17 Favored 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 119.096 -1.042 . . . . 0.0 110.18 177.35 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.644 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.8 t -103.12 129.01 55.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.379 -0.826 . . . . 0.0 109.141 174.068 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -94.87 120.05 34.45 Favored 'General case' 0 C--N 1.298 -1.651 0 C-N-CA 119.245 -0.982 . . . . 0.0 109.214 173.044 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.857 ' CD2' HG21 ' B' ' 82' ' ' VAL . 1.4 m80 -90.69 106.15 18.31 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.403 -0.811 . . . . 0.0 109.074 177.478 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.496 ' OD1' ' HB2' ' A' ' 47' ' ' CYS . 1.8 t-20 54.01 14.84 0.75 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.368 -0.833 . . . . 0.0 110.858 -167.157 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.512 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 117.66 -0.3 17.98 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.715 -1.231 . . . . 0.0 111.031 170.438 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.857 ' O ' HD23 ' B' ' 49' ' ' LEU . 43.1 t -92.38 106.9 18.8 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.411 -1.641 . . . . 0.0 109.134 173.395 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 17.8 p -75.45 128.75 36.04 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.097 -1.002 . . . . 0.0 110.684 -170.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 0.857 HD23 ' O ' ' B' ' 47' ' ' CYS . 0.3 OUTLIER -143.29 159.64 41.97 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.416 -0.803 . . . . 0.0 109.61 175.259 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 50' ' ' THR . . . . . 0.42 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 29.4 m -100.02 150.01 22.88 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.673 -1.267 . . . . 0.0 111.329 -170.74 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.816 HG13 HG13 ' B' ' 59' ' ' VAL . 15.4 t -78.38 118.46 25.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.827 -0.546 . . . . 0.0 110.607 -178.027 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.532 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 43.0 p -73.89 -40.01 63.49 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.201 -0.937 . . . . 0.0 110.037 174.629 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.666 ' HA ' HG21 ' B' ' 38' ' ' THR . 86.6 tt0 -163.32 149.83 12.19 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.336 -0.852 . . . . 0.0 110.206 -177.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.72 HD11 ' N ' ' B' ' 38' ' ' THR . 5.7 mt -101.52 134.79 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.096 -1.002 . . . . 0.0 109.993 176.148 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.515 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 49.7 m-80 -110.41 65.78 0.62 Allowed 'General case' 0 C--N 1.298 -1.634 0 C-N-CA 119.857 -0.737 . . . . 0.0 109.907 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.31 -118.75 4.99 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 108.809 -1.717 . . . . 0.0 108.809 -175.26 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.715 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -78.55 -16.54 57.32 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.969 -1.312 . . . . 0.0 108.901 174.302 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.145 ' CD2' HG11 ' B' ' 13' ' ' VAL . 11.8 m170 -76.51 159.63 30.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.491 -0.756 . . . . 0.0 110.347 -178.2 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.816 HG13 HG13 ' B' ' 51' ' ' VAL . 52.1 t -140.15 127.1 23.14 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 C-N-CA 119.042 -1.063 . . . . 0.0 110.554 170.054 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.867 ' OG ' HG22 ' B' ' 25' ' ' VAL . 2.7 t -95.81 136.85 35.69 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.575 -0.703 . . . . 0.0 109.616 178.307 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.81 ' HB2' HD12 ' B' ' 49' ' ' LEU . 2.0 p90 -128.11 157.63 40.2 Favored 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 119.054 -1.058 . . . . 0.0 110.876 174.065 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.532 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 25.3 p-10 -89.47 157.76 17.98 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.297 -0.877 . . . . 0.0 111.056 -171.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.749 HD22 ' CD1' ' B' ' 68' ' ' LEU . 0.1 OUTLIER -159.96 102.54 1.47 Allowed 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.958 -0.697 . . . . 0.0 109.445 -175.428 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.499 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 56.1 ttm -59.77 140.36 56.58 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.117 -0.989 . . . . 0.0 109.381 -179.501 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.456 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 39.4 ttpt -59.98 -43.38 95.15 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.042 -1.036 . . . . 0.0 110.242 -175.094 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.72 -40.04 76.47 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.049 -1.032 . . . . 0.0 110.083 178.297 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.499 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 92.2 m -60.58 -39.97 90.02 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.95 -1.094 . . . . 0.0 109.14 173.016 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.749 ' CD1' HD22 ' B' ' 63' ' ' LEU . 7.3 tp -60.0 -45.17 93.61 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.375 -0.828 . . . . 0.0 109.892 179.3 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 15.0 tpp180 -69.33 -39.41 78.21 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.547 -0.72 . . . . 0.0 110.493 177.912 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.852 HG22 HG23 ' B' ' 71' ' ' THR . 1.4 tt -63.85 -43.88 97.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.177 -0.952 . . . . 0.0 109.365 -177.427 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.852 HG23 HG22 ' B' ' 70' ' ' ILE . 37.3 p -83.44 -170.42 3.04 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 121.433 0.635 . . . . 0.0 109.805 178.529 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.492 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 4.3 t30 -103.33 22.58 13.91 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 170.176 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.704 ' HB3' HD21 ' B' ' 63' ' ' LEU . 89.3 mt -69.55 -41.16 76.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.228 -0.92 . . . . 0.0 110.091 176.689 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.731 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -51.01 -20.8 4.73 Favored Glycine 0 N--CA 1.487 2.099 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -178.23 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.1 p-10 -67.55 -18.41 65.01 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.998 -1.295 . . . . 0.0 110.706 -173.909 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.514 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 90.3 mt -60.92 142.82 56.07 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.077 -1.015 . . . . 0.0 110.947 -175.513 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 0.998 ' C ' HD23 ' B' ' 12' ' ' LEU . 98.7 mttt -140.32 139.74 35.49 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.682 -0.636 . . . . 0.0 109.854 173.914 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.714 HG23 HD11 ' B' ' 15' ' ' ILE . 16.2 t -63.4 153.45 7.01 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.12 -0.987 . . . . 0.0 110.625 -174.399 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.02 -16.68 56.48 Favored Glycine 0 N--CA 1.484 1.874 0 N-CA-C 108.687 -1.765 . . . . 0.0 108.687 -175.285 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 24.9 t0 -95.13 169.95 9.74 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.374 -1.074 . . . . 0.0 109.808 175.615 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.583 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.5 m95 -116.98 169.42 9.42 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.034 -1.041 . . . . 0.0 110.139 176.022 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.092 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.4 p -133.96 155.7 40.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.539 -0.726 . . . . 0.0 109.908 -176.824 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.992 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.0 m-20 -79.5 108.91 13.39 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.074 -1.016 . . . . 0.0 109.245 168.692 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.754 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -110.45 138.87 36.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 120.458 -1.401 . . . . 0.0 111.183 -175.393 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -134.73 145.08 48.13 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.856 -0.527 . . . . 0.0 110.128 -177.364 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 36.2 ttm180 -83.43 130.67 35.04 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.26 -0.9 . . . . 0.0 110.987 -176.675 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 1.003 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -127.68 148.29 50.39 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.279 -0.888 . . . . 0.0 109.965 174.666 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -123.88 141.7 51.79 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.305 -0.872 . . . . 0.0 110.779 -175.748 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 16.0 mttp -59.96 -40.04 87.67 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.414 -0.804 . . . . 0.0 110.863 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -159.07 160.01 35.28 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.033 -1.042 . . . . 0.0 111.02 -177.039 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 91' ' ' SER . . . . . 0.504 ' OG ' HG13 ' B' ' 94' ' ' ILE . 79.6 p -154.5 161.66 41.55 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.373 -0.829 . . . . 0.0 109.727 173.256 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -69.74 -33.34 72.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.955 -1.091 . . . . 0.0 110.491 -178.705 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 93' ' ' GLU . . . . . 0.571 ' O ' ' CG ' ' B' ' 93' ' ' GLU . 10.8 tt0 -114.74 57.7 0.71 Allowed 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 122.349 1.071 . . . . 0.0 109.465 -178.881 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 94' ' ' ILE . . . . . 0.512 ' O ' ' N ' ' B' ' 96' ' ' GLY . 66.1 mt -65.99 -40.0 86.13 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 120.539 -1.351 . . . . 0.0 110.341 -178.803 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 95' ' ' GLY . . . . . 0.439 ' C ' ' O ' ' B' ' 94' ' ' ILE . . . -39.91 93.86 0.01 OUTLIER Glycine 0 N--CA 1.494 2.538 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 -172.488 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 96' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' B' ' 94' ' ' ILE . . . -148.31 146.29 15.71 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 177.642 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 97' ' ' HIS . . . . . 0.417 ' C ' ' O ' ' B' ' 96' ' ' GLY . 40.0 m-70 . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.25 -1.147 . . . . 0.0 110.351 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 0.563 " C2'" ' HC9' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 0.556 " C2'" ' HC9' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 43.3 tpp . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 121.345 0.593 . . . . 0.0 110.41 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.951 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 13.4 p90 -174.89 143.82 0.75 Allowed 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.237 -0.915 . . . . 0.0 109.262 175.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.553 ' CB ' HG12 ' A' ' 5' ' ' ILE . 5.6 p -139.96 -40.27 0.44 Allowed 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.019 -1.051 . . . . 0.0 108.509 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.494 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 44.1 26.6 0.91 Allowed Glycine 0 N--CA 1.486 2.029 0 N-CA-C 108.685 -1.766 . . . . 0.0 108.685 -174.841 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.569 HD11 HC81 ' B' ' 99' ' ' RBF . 40.3 mm -79.1 124.33 37.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.445 -1.032 . . . . 0.0 109.52 -178.074 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 1.025 HG21 ' HB3' ' A' ' 83' ' ' ASN . 4.0 t -85.58 145.25 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.033 -1.042 . . . . 0.0 111.3 -168.544 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -69.99 -34.08 72.88 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.695 -0.628 . . . . 0.0 110.632 175.369 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -163.34 171.43 39.05 Favored Glycine 0 N--CA 1.494 2.555 0 C-N-CA 118.729 -1.7 . . . . 0.0 110.394 -174.518 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.497 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 11.7 p -112.81 168.35 9.75 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.031 -1.276 . . . . 0.0 110.699 -178.729 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.988 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -133.46 148.87 51.76 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -178.022 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.574 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 22.5 tttt -104.25 112.64 25.74 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 120.972 -1.08 . . . . 0.0 110.15 178.109 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.947 HD23 ' C ' ' A' ' 77' ' ' LYS . 10.9 tp -57.14 126.88 29.2 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 121.146 -0.971 . . . . 0.0 108.803 173.598 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.151 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.21 -31.35 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 O-C-N 121.349 -0.844 . . . . 0.0 110.046 -178.237 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -142.86 144.18 32.39 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.147 -1.021 . . . . 0.0 111.582 -179.454 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.687 HG13 HG21 ' A' ' 78' ' ' VAL . 8.1 mt -110.94 130.37 64.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 120.995 -1.065 . . . . 0.0 110.21 168.749 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.509 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 76.0 m-20 -108.86 115.49 30.19 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.364 -0.835 . . . . 0.0 109.889 172.331 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -103.91 110.28 22.35 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 120.888 -1.132 . . . . 0.0 110.495 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.9 OUTLIER -102.61 131.87 21.91 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.177 -0.952 . . . . 0.0 108.88 173.76 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -50.52 -34.21 41.43 Favored 'Trans proline' 0 C--N 1.302 -1.91 0 O-C-N 123.828 1.436 . . . . 0.0 110.383 -179.471 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.576 ' HB3' ' CE2' ' A' ' 21' ' ' PHE . 7.6 m120 -74.19 -39.33 63.25 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.244 -0.91 . . . . 0.0 110.32 175.899 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.576 ' CE2' ' HB3' ' A' ' 20' ' ' ASN . 49.9 m-85 -152.53 150.14 29.26 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.271 -0.893 . . . . 0.0 110.106 -176.882 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.438 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 50.7 ttt180 -88.73 144.96 25.91 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.914 -1.116 . . . . 0.0 109.999 175.065 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.509 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.8 m -130.07 140.06 50.89 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.437 -0.79 . . . . 0.0 110.099 -177.876 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.606 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -129.59 144.61 51.35 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.967 -1.083 . . . . 0.0 111.107 177.333 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.725 HG22 ' CB ' ' A' ' 60' ' ' SER . 6.9 t -124.06 133.37 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.034 -1.041 . . . . 0.0 110.508 179.229 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.912 HG13 ' CE1' ' A' ' 61' ' ' PHE . 13.1 m -112.88 172.31 3.26 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 121.737 -0.602 . . . . 0.0 109.954 177.403 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.585 ' CG ' HD22 ' A' ' 57' ' ' ASN . 8.1 tt0 -106.95 116.3 31.69 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.357 -0.839 . . . . 0.0 108.794 178.128 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.608 HD11 ' HB3' ' A' ' 32' ' ' MET . 9.2 tp -80.09 123.98 83.13 Favored Pre-proline 0 C--N 1.296 -1.753 0 O-C-N 121.548 -0.72 . . . . 0.0 109.977 -172.569 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.522 ' HD2' HD12 ' A' ' 28' ' ' LEU . 27.7 Cg_endo -66.35 -178.54 1.18 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 O-C-N 123.822 1.433 . . . . 0.0 110.977 -179.521 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.489 ' HA ' HD12 ' A' ' 33' ' ' LEU . 61.6 t0 -62.55 -40.97 98.52 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 111.027 -174.667 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.03 1.14 56.66 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.811 -1.181 . . . . 0.0 111.014 -174.664 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.608 ' HB3' HD11 ' A' ' 28' ' ' LEU . 99.4 mmm -108.56 -15.37 14.45 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.784 -1.198 . . . . 0.0 109.844 169.829 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.673 HD21 ' HB2' ' A' ' 57' ' ' ASN . 21.0 mt -69.51 -22.04 63.62 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.217 -0.927 . . . . 0.0 109.997 177.699 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -95.16 115.6 27.65 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.364 -0.835 . . . . 0.0 110.473 -178.59 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.34 -50.52 0.78 Allowed Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.764 -1.207 . . . . 0.0 110.556 173.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.83 HD23 ' N ' ' A' ' 37' ' ' GLU . 9.8 tt -60.98 159.33 11.67 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.886 -1.361 . . . . 0.0 111.123 -172.319 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.83 ' N ' HD23 ' A' ' 36' ' ' LEU . 22.0 pt-20 -157.52 163.46 38.39 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.998 HG23 HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -69.9 151.57 45.51 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.845 -1.159 . . . . 0.0 109.921 -177.474 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.09 -4.66 65.68 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 -172.859 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.413 ' O ' ' HA ' ' A' ' 50' ' ' THR . . . -74.33 160.12 31.48 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.293 -1.122 . . . . 0.0 109.683 176.828 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.84 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.7 OUTLIER -100.98 103.25 14.39 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.068 -1.02 . . . . 0.0 110.12 178.298 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.618 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.2 t -88.12 131.46 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.201 -0.937 . . . . 0.0 109.489 175.489 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.708 ' HB3' ' HB2' ' A' ' 85' ' ' GLU . . . -98.17 120.97 39.51 Favored 'General case' 0 C--N 1.296 -1.755 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.418 170.862 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.671 ' CG ' HG21 ' A' ' 82' ' ' VAL . 1.0 OUTLIER -88.74 105.83 17.96 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 119.583 -0.847 . . . . 0.0 108.987 177.525 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' B' ' 45' ' ' ASN . 0.9 OUTLIER 52.96 11.92 0.24 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.463 -0.773 . . . . 0.0 111.525 -166.482 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.47 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 127.73 -6.8 6.97 Favored Glycine 0 N--CA 1.489 2.233 0 C-N-CA 119.224 -1.465 . . . . 0.0 111.169 172.241 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.816 ' O ' HD23 ' A' ' 49' ' ' LEU . 13.8 t -92.49 105.99 18.06 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.192 -1.77 . . . . 0.0 109.471 177.027 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.516 ' SG ' ' C8 ' ' A' ' 98' ' ' RBF . 16.2 p -75.24 129.52 37.6 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.14 -0.975 . . . . 0.0 111.122 -171.138 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.834 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -141.97 159.98 41.13 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.595 -0.691 . . . . 0.0 109.276 174.91 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.413 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 51.7 m -94.79 148.24 22.5 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.613 -1.305 . . . . 0.0 111.279 -170.91 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.658 HG13 HG13 ' A' ' 59' ' ' VAL . 19.3 t -77.27 122.03 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.651 -0.656 . . . . 0.0 110.265 178.849 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.522 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 19.3 p -77.54 -44.49 28.41 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.257 -0.902 . . . . 0.0 110.138 175.204 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.67 ' HA ' HG21 ' A' ' 38' ' ' THR . 86.1 tt0 -157.47 150.13 23.04 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.113 -0.992 . . . . 0.0 110.348 178.023 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.998 HD12 HG23 ' A' ' 38' ' ' THR . 1.4 mp -97.79 137.0 26.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.07 -1.019 . . . . 0.0 109.728 173.237 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.48 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 33.4 m-80 -110.03 70.43 0.72 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.595 -0.691 . . . . 0.0 109.698 178.147 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 72.04 -120.12 7.75 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 -172.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.673 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.1 OUTLIER -75.51 -21.17 58.21 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 120.995 -1.297 . . . . 0.0 109.04 175.543 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.151 ' CD2' HG11 ' A' ' 13' ' ' VAL . 10.7 m170 -72.41 160.48 32.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.28 -0.887 . . . . 0.0 110.234 -178.395 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.658 HG13 HG13 ' A' ' 51' ' ' VAL . 53.1 t -140.07 124.54 19.18 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 C-N-CA 119.127 -1.029 . . . . 0.0 110.536 170.679 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.725 ' CB ' HG22 ' A' ' 25' ' ' VAL . 53.1 p -95.08 128.56 42.01 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.476 -0.765 . . . . 0.0 109.553 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.912 ' CE1' HG13 ' A' ' 26' ' ' VAL . 1.8 p90 -124.01 157.35 34.65 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 120.995 -1.066 . . . . 0.0 110.254 -179.118 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.522 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 30.4 p-10 -93.27 152.79 18.96 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 122.09 0.947 . . . . 0.0 111.127 -172.794 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.752 ' CD2' HD12 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -152.21 120.03 6.15 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -175.894 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.51 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 63.5 tpp -77.16 139.58 39.96 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.983 -1.073 . . . . 0.0 109.848 -179.64 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.479 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 74.9 tttt -59.93 -49.85 76.07 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.12 -0.987 . . . . 0.0 110.578 -173.49 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.414 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 88.3 tt0 -66.27 -39.96 89.79 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.828 -1.17 . . . . 0.0 109.996 178.223 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.699 HG23 HC3' ' A' ' 98' ' ' RBF . 90.9 m -60.0 -39.57 86.21 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.002 -1.061 . . . . 0.0 109.197 173.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.752 HD12 ' CD2' ' A' ' 63' ' ' LEU . 2.1 tp -59.97 -45.28 93.18 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.319 -0.863 . . . . 0.0 109.852 179.339 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 tpt85 -69.39 -38.32 77.93 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.386 -0.821 . . . . 0.0 110.079 177.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.805 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -67.75 -39.9 82.84 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 O-C-N 121.333 -0.855 . . . . 0.0 109.191 -177.886 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.805 HG23 HG22 ' A' ' 70' ' ' ILE . 49.4 p -88.77 -176.41 5.22 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 175.572 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.467 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 8.8 t30 -98.22 21.18 11.26 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.244 -0.91 . . . . 0.0 108.903 173.87 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.713 ' HB3' HD21 ' A' ' 63' ' ' LEU . 34.4 mt -70.04 -39.99 75.42 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.912 -1.118 . . . . 0.0 110.444 179.609 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.729 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -52.54 -19.33 6.19 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -176.34 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 27.1 p-10 -69.98 -18.21 63.33 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.111 -1.229 . . . . 0.0 110.965 -174.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 85.5 mt -59.99 146.49 42.41 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.088 -1.008 . . . . 0.0 111.026 -174.54 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 0.947 ' C ' HD23 ' A' ' 12' ' ' LEU . 67.4 mttt -139.88 141.75 36.57 Favored 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 121.537 0.684 . . . . 0.0 109.906 176.68 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.687 HG21 HG13 ' A' ' 15' ' ' ILE . 46.2 t -66.44 150.06 11.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 120.888 -1.133 . . . . 0.0 110.466 -177.329 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.96 -14.99 60.46 Favored Glycine 0 N--CA 1.482 1.743 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 -174.714 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.478 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 13.9 t0 -96.65 168.27 10.62 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.409 -1.053 . . . . 0.0 109.576 174.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.574 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.4 m95 -115.83 156.09 26.71 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.04 -1.037 . . . . 0.0 110.304 177.72 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.988 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.1 p -120.07 150.0 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.262 -0.899 . . . . 0.0 110.1 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 1.025 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.4 OUTLIER -70.79 104.53 2.92 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.044 -1.035 . . . . 0.0 108.887 166.785 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.777 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -104.35 139.42 25.37 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 120.51 -1.369 . . . . 0.0 110.987 -176.839 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.922 ' HG3' HG22 ' A' ' 6' ' ' VAL . 85.2 mt-10 -125.47 146.62 49.56 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.918 -0.488 . . . . 0.0 110.15 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.533 ' HB3' ' CZ ' ' A' ' 86' ' ' ARG . 18.3 mtp-105 -90.26 114.77 26.87 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.513 -0.742 . . . . 0.0 110.033 177.494 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.87 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -114.42 147.43 39.25 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.061 -1.024 . . . . 0.0 110.524 -178.254 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -131.45 148.54 52.65 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.609 -0.682 . . . . 0.0 110.862 -176.284 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -59.98 -39.95 87.48 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.435 -0.79 . . . . 0.0 110.185 176.531 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 52.8 p90 -132.36 160.09 37.32 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.279 -0.888 . . . . 0.0 110.253 179.716 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.408 ' OG ' ' CG1' ' A' ' 94' ' ' ILE . 2.6 p -119.07 135.29 54.71 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.228 -0.92 . . . . 0.0 110.366 -177.746 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 71.7 m-20 -69.83 -40.1 76.05 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.365 -0.834 . . . . 0.0 111.008 -176.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -147.29 71.09 1.2 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.932 -1.105 . . . . 0.0 110.573 -174.448 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.426 ' O ' ' C ' ' A' ' 95' ' ' GLY . 25.5 mm -60.07 -41.06 85.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.191 -0.943 . . . . 0.0 109.725 175.768 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 94' ' ' ILE . . . 40.18 69.99 0.41 Allowed Glycine 0 N--CA 1.494 2.52 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 174.858 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -109.65 115.08 4.1 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 178.526 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 46.7 p-80 . . . . . 0 N--CA 1.493 1.706 0 O-C-N 121.3 -1.117 . . . . 0.0 110.128 178.873 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 38.3 mtm . . . . . 0 N--CA 1.495 1.797 0 CA-C-O 121.258 0.551 . . . . 0.0 110.177 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.87 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 13.4 p90 -171.72 143.83 1.74 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.11 -0.994 . . . . 0.0 109.248 174.715 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.562 ' CB ' HG12 ' B' ' 5' ' ' ILE . 5.6 p -139.99 -40.28 0.44 Allowed 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.067 -1.021 . . . . 0.0 108.452 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 44.32 26.33 0.94 Allowed Glycine 0 N--CA 1.486 2.004 0 N-CA-C 108.642 -1.783 . . . . 0.0 108.642 -174.935 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 0.563 HD11 HC81 ' A' ' 98' ' ' RBF . 40.0 mm -79.1 124.37 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.342 -1.093 . . . . 0.0 109.533 -177.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.958 HG22 ' HG3' ' B' ' 85' ' ' GLU . 4.0 t -85.59 145.25 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.059 -1.025 . . . . 0.0 111.367 -168.56 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -70.05 -33.75 72.36 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.745 -0.597 . . . . 0.0 110.685 175.449 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.54 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -163.66 171.35 39.29 Favored Glycine 0 N--CA 1.495 2.628 0 C-N-CA 118.91 -1.614 . . . . 0.0 110.52 -174.52 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.498 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 11.7 p -112.9 168.29 9.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.06 -1.259 . . . . 0.0 110.739 -178.632 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.055 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -133.38 149.01 51.85 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 -178.017 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.568 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 22.7 tttt -104.36 112.79 25.97 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 120.982 -1.074 . . . . 0.0 110.047 178.115 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 0.964 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.0 tp -57.35 126.84 29.06 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.193 -0.942 . . . . 0.0 108.761 173.592 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.133 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.18 -31.24 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.784 0 O-C-N 121.339 -0.851 . . . . 0.0 110.089 -178.211 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -142.99 144.17 32.21 Favored 'General case' 0 N--CA 1.493 1.716 0 C-N-CA 119.234 -0.986 . . . . 0.0 111.553 -179.478 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.693 HG13 HG21 ' B' ' 78' ' ' VAL . 8.0 mt -110.85 130.47 64.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 120.992 -1.068 . . . . 0.0 110.193 168.836 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.518 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 75.5 m-20 -109.12 115.59 30.33 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.353 -0.842 . . . . 0.0 109.767 172.389 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -103.92 110.31 22.39 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.019 -1.05 . . . . 0.0 110.443 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.453 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.9 OUTLIER -102.7 131.92 21.82 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.347 -0.846 . . . . 0.0 108.874 173.763 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -50.62 -34.19 42.29 Favored 'Trans proline' 0 C--N 1.301 -1.95 0 O-C-N 123.825 1.434 . . . . 0.0 110.295 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.588 ' HB3' ' CE2' ' B' ' 21' ' ' PHE . 7.6 m120 -73.98 -39.96 63.31 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.224 -0.922 . . . . 0.0 110.165 175.905 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.588 ' CE2' ' HB3' ' B' ' 20' ' ' ASN . 49.4 m-85 -152.06 150.18 29.66 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.381 -0.824 . . . . 0.0 110.183 -176.757 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.427 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 50.5 ttt180 -88.65 144.91 25.98 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.916 -1.115 . . . . 0.0 109.924 175.033 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.518 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 95.0 m -130.09 140.08 50.87 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.511 -0.743 . . . . 0.0 110.147 -178.003 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.605 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -129.57 144.58 51.33 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.095 -1.003 . . . . 0.0 110.994 177.476 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.73 HG22 ' CB ' ' B' ' 60' ' ' SER . 6.8 t -123.99 133.48 69.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.142 -0.974 . . . . 0.0 110.573 179.113 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.931 HG13 ' CE1' ' B' ' 61' ' ' PHE . 13.3 m -112.96 172.3 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.698 -0.626 . . . . 0.0 109.876 177.485 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.593 ' CG ' HD22 ' B' ' 57' ' ' ASN . 8.1 tt0 -106.86 116.24 31.58 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.444 -0.785 . . . . 0.0 108.923 177.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.605 HD11 ' HB3' ' B' ' 32' ' ' MET . 9.3 tp -80.01 123.98 83.26 Favored Pre-proline 0 C--N 1.296 -1.747 0 O-C-N 121.434 -0.791 . . . . 0.0 110.028 -172.587 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.526 ' HD2' HD12 ' B' ' 28' ' ' LEU . 27.7 Cg_endo -66.3 -178.42 1.13 Allowed 'Trans proline' 0 C--N 1.31 -1.489 0 O-C-N 123.831 1.437 . . . . 0.0 110.96 -179.523 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.478 ' HA ' HD12 ' B' ' 33' ' ' LEU . 61.7 t0 -62.67 -40.91 98.55 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.386 -0.821 . . . . 0.0 111.027 -174.698 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.595 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.01 1.11 56.68 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.867 -1.145 . . . . 0.0 111.01 -174.631 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.605 ' HB3' HD11 ' B' ' 28' ' ' LEU . 99.4 mmm -108.61 -15.25 14.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.752 -1.218 . . . . 0.0 109.813 169.84 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.696 HD21 ' HB2' ' B' ' 57' ' ' ASN . 20.8 mt -69.69 -21.93 63.47 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.269 -0.894 . . . . 0.0 109.982 177.722 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -95.22 115.68 27.75 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.348 -0.845 . . . . 0.0 110.408 -178.606 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.18 -50.43 0.78 Allowed Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.823 -1.179 . . . . 0.0 110.543 173.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.827 HD23 ' N ' ' B' ' 37' ' ' GLU . 9.8 tt -61.01 159.29 11.81 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.843 -1.386 . . . . 0.0 111.132 -172.362 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 37' ' ' GLU . . . . . 0.827 ' N ' HD23 ' B' ' 36' ' ' LEU . 21.9 pt-20 -157.51 163.36 38.51 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 38' ' ' THR . . . . . 1.049 HG23 HD12 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -69.85 151.59 45.53 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.862 -1.149 . . . . 0.0 109.965 -177.531 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.98 -4.47 66.05 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -172.865 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' B' ' 50' ' ' THR . . . -74.37 160.02 31.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.199 -1.177 . . . . 0.0 109.653 176.68 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.817 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.6 OUTLIER -100.82 103.12 14.32 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.969 -1.082 . . . . 0.0 110.139 178.291 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.634 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.2 t -88.1 131.59 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.284 -0.885 . . . . 0.0 109.486 175.432 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.705 ' HB3' ' HB2' ' B' ' 85' ' ' GLU . . . -98.25 121.0 39.64 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 120.961 -1.087 . . . . 0.0 109.441 170.716 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.668 ' CG ' HG21 ' B' ' 82' ' ' VAL . 1.0 OUTLIER -88.78 105.58 17.8 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.245 -0.91 . . . . 0.0 109.1 177.494 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' A' ' 45' ' ' ASN . 0.9 OUTLIER 53.23 11.94 0.28 Allowed 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.462 -0.774 . . . . 0.0 111.409 -166.565 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.494 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 127.55 -6.36 7.07 Favored Glycine 0 N--CA 1.49 2.251 0 C-N-CA 119.231 -1.461 . . . . 0.0 111.082 172.03 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.838 ' O ' HD23 ' B' ' 49' ' ' LEU . 13.9 t -92.66 106.04 18.09 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.059 -1.847 . . . . 0.0 109.439 176.825 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 48' ' ' CYS . . . . . 0.519 ' SG ' ' C8 ' ' B' ' 99' ' ' RBF . 16.1 p -75.21 129.57 37.7 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.086 -1.009 . . . . 0.0 111.145 -171.19 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 0.855 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -142.01 159.93 41.23 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 174.925 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 50' ' ' THR . . . . . 0.414 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 52.1 m -94.69 148.21 22.52 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.514 -1.366 . . . . 0.0 111.244 -170.879 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.67 HG13 HG13 ' B' ' 59' ' ' VAL . 18.6 t -77.23 122.06 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.647 -0.658 . . . . 0.0 110.281 178.796 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.519 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 19.7 p -77.66 -44.55 27.73 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.213 -0.93 . . . . 0.0 110.029 175.33 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.666 ' HA ' HG21 ' B' ' 38' ' ' THR . 86.3 tt0 -157.43 150.18 23.17 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.101 -0.999 . . . . 0.0 110.348 178.031 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 1.049 HD12 HG23 ' B' ' 38' ' ' THR . 1.4 mp -97.82 136.94 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.175 -0.953 . . . . 0.0 109.729 173.282 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.504 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 33.5 m-80 -109.95 70.29 0.72 Allowed 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.545 -0.722 . . . . 0.0 109.676 178.219 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 72.09 -120.11 7.71 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 108.713 -1.755 . . . . 0.0 108.713 -172.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.696 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -75.41 -21.28 58.35 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.054 -1.262 . . . . 0.0 109.12 175.468 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.133 ' CD2' HG11 ' B' ' 13' ' ' VAL . 10.8 m170 -72.43 160.27 32.61 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.407 -0.808 . . . . 0.0 110.362 -178.404 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.67 HG13 HG13 ' B' ' 51' ' ' VAL . 53.6 t -139.89 124.62 19.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 119.061 -1.056 . . . . 0.0 110.415 170.853 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.73 ' CB ' HG22 ' B' ' 25' ' ' VAL . 53.4 p -95.08 128.82 42.21 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.619 -0.675 . . . . 0.0 109.509 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.931 ' CE1' HG13 ' B' ' 26' ' ' VAL . 1.8 p90 -124.26 157.29 35.21 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.002 -1.061 . . . . 0.0 110.218 -179.148 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.519 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 30.5 p-10 -93.2 152.74 19.03 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.136 -0.978 . . . . 0.0 111.192 -172.753 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.752 ' CD2' HD12 ' B' ' 68' ' ' LEU . 0.0 OUTLIER -152.06 119.97 6.19 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 -175.883 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.511 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 63.6 tpp -77.19 139.57 39.93 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.976 -1.078 . . . . 0.0 109.845 -179.61 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.484 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 74.9 tttt -60.03 -49.73 76.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.166 -0.959 . . . . 0.0 110.492 -173.362 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 66' ' ' GLU . . . . . 0.424 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 88.4 tt0 -66.35 -40.0 89.53 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.794 -1.191 . . . . 0.0 109.946 178.326 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.677 HG23 HC3' ' B' ' 99' ' ' RBF . 90.3 m -60.05 -39.55 86.32 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.031 -1.043 . . . . 0.0 109.145 174.008 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.752 HD12 ' CD2' ' B' ' 63' ' ' LEU . 2.1 tp -60.01 -45.14 93.73 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.388 -0.82 . . . . 0.0 109.962 179.278 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 tpt85 -69.35 -38.52 78.14 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.409 -0.807 . . . . 0.0 110.079 177.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.771 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -67.55 -39.95 83.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 CA-C-O 121.73 0.776 . . . . 0.0 109.238 -178.032 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.771 HG23 HG22 ' B' ' 70' ' ' ILE . 49.6 p -88.74 -176.24 5.18 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 175.674 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.516 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 8.7 t30 -98.3 21.19 11.33 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 121.182 -0.948 . . . . 0.0 108.733 173.881 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.744 ' HB3' HD21 ' B' ' 63' ' ' LEU . 34.1 mt -70.01 -40.03 75.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.954 -1.091 . . . . 0.0 110.458 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.743 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -52.49 -19.31 6.09 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -176.324 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.504 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 27.2 p-10 -70.05 -18.25 63.28 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.083 -1.245 . . . . 0.0 110.946 -174.9 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.504 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 85.7 mt -59.95 146.43 42.45 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.188 -0.945 . . . . 0.0 111.012 -174.547 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 0.964 ' C ' HD23 ' B' ' 12' ' ' LEU . 67.4 mttt -139.89 141.78 36.54 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.626 -0.671 . . . . 0.0 109.888 176.658 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.693 HG21 HG13 ' B' ' 15' ' ' ILE . 46.2 t -66.49 150.01 11.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.04 -1.038 . . . . 0.0 110.498 -177.274 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.01 -14.94 60.65 Favored Glycine 0 N--CA 1.483 1.824 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -174.712 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 13.8 t0 -96.73 168.13 10.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.359 -1.083 . . . . 0.0 109.582 174.889 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.568 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.4 m95 -115.76 156.0 26.8 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.06 -1.025 . . . . 0.0 110.325 177.788 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.055 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.1 p -120.01 150.06 22.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.427 -0.795 . . . . 0.0 110.173 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.952 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.4 OUTLIER -70.68 104.32 2.81 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.001 -1.062 . . . . 0.0 109.053 166.705 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.773 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -104.22 139.59 24.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 120.464 -1.398 . . . . 0.0 110.905 -176.61 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' B' B ' 85' ' ' GLU . . . . . 0.958 ' HG3' HG22 ' B' ' 6' ' ' VAL . 85.0 mt-10 -125.73 146.57 49.7 Favored 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.193 0.521 . . . . 0.0 110.064 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 86' ' ' ARG . . . . . 0.539 ' HB3' ' CZ ' ' B' ' 86' ' ' ARG . 18.3 mtp-105 -90.26 114.84 26.95 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.35 -0.844 . . . . 0.0 109.957 177.566 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 0.951 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -114.48 147.58 39.12 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.256 -0.903 . . . . 0.0 110.57 -178.292 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -131.57 148.65 52.63 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.584 -0.697 . . . . 0.0 110.683 -176.174 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -60.06 -40.01 88.02 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.435 -0.79 . . . . 0.0 110.142 176.49 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -132.41 160.14 37.24 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.329 -0.857 . . . . 0.0 110.171 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 91' ' ' SER . . . . . 0.529 ' OG ' ' CG1' ' B' ' 94' ' ' ILE . 2.6 p -119.04 135.36 54.67 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.258 -0.901 . . . . 0.0 110.382 -177.673 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -69.93 -40.01 75.77 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.41 -0.807 . . . . 0.0 111.025 -176.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 77.1 mm-40 -143.34 68.82 1.29 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.005 -1.059 . . . . 0.0 110.537 -174.251 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 94' ' ' ILE . . . . . 0.529 ' CG1' ' OG ' ' B' ' 91' ' ' SER . 21.1 mm -59.97 -40.0 81.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.266 -0.896 . . . . 0.0 109.644 175.629 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 47.32 60.96 4.85 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.064 -1.215 . . . . 0.0 110.064 177.261 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -59.94 -40.05 96.38 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.064 -1.614 . . . . 0.0 109.064 176.663 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 17.6 t60 . . . . . 0 N--CA 1.491 1.613 0 O-C-N 121.331 -1.1 . . . . 0.0 110.122 177.581 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 0.699 HC3' HG23 ' A' ' 67' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 0.677 HC3' HG23 ' B' ' 67' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 17.9 mmm . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.292 0.568 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.928 ' CZ ' ' HB1' ' B' ' 87' ' ' ALA . 8.1 p90 -166.25 155.93 11.84 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.166 -0.959 . . . . 0.0 108.614 172.291 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.587 HG23 ' C ' ' A' ' 2' ' ' PHE . 40.3 p -155.77 -39.31 0.08 Allowed 'General case' 0 C--N 1.295 -1.802 0 O-C-N 120.902 -1.124 . . . . 0.0 109.131 177.044 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.463 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 45.25 25.25 1.11 Allowed Glycine 0 N--CA 1.484 1.845 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 -173.574 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.488 HG13 ' O ' ' A' ' 3' ' ' THR . 91.4 mt -77.92 135.57 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.323 -1.104 . . . . 0.0 109.777 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.69 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.6 t -91.42 137.77 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.097 -1.002 . . . . 0.0 110.871 -170.439 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -71.04 -33.09 69.98 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.866 -0.521 . . . . 0.0 111.182 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.533 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -150.35 171.92 30.2 Favored Glycine 0 N--CA 1.495 2.582 0 C-N-CA 119.054 -1.546 . . . . 0.0 110.133 -171.9 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.495 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 3.1 p -119.23 172.34 7.66 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.893 -1.357 . . . . 0.0 111.214 -176.453 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.013 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -142.64 150.0 39.66 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 -176.362 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.587 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.1 tttt -110.83 115.15 29.03 Favored 'General case' 0 C--N 1.295 -1.803 0 O-C-N 121.097 -1.002 . . . . 0.0 110.276 179.54 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.941 HD23 ' C ' ' A' ' 77' ' ' LYS . 10.9 tp -59.74 127.71 33.32 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.015 -1.053 . . . . 0.0 109.079 174.362 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.113 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -122.2 -28.9 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 C-N-CA 119.641 -0.824 . . . . 0.0 109.648 179.2 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.71 147.54 26.83 Favored 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 119.05 -1.06 . . . . 0.0 111.551 -179.155 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.839 HG23 ' CD2' ' A' ' 24' ' ' HIS . 11.7 mt -109.59 138.61 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.212 -0.93 . . . . 0.0 110.03 172.415 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.507 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.7 m-20 -109.58 114.62 28.4 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.283 -0.885 . . . . 0.0 109.924 173.52 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -100.35 112.15 24.47 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.13 -0.981 . . . . 0.0 110.369 -176.484 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.2 OUTLIER -112.76 132.76 22.12 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.203 -0.935 . . . . 0.0 108.94 175.492 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -49.57 -40.39 45.88 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 O-C-N 123.855 1.45 . . . . 0.0 110.754 -179.204 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.445 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 12.0 m-80 -70.59 -39.37 73.89 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.124 -0.985 . . . . 0.0 110.259 177.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.461 ' O ' ' HB2' ' A' ' 18' ' ' LYS . 95.7 m-85 -152.55 150.3 29.42 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.289 -0.882 . . . . 0.0 110.526 -174.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.603 ' HD3' HD22 ' A' ' 68' ' ' LEU . 60.7 ttt180 -91.28 143.54 26.54 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 120.835 -1.166 . . . . 0.0 109.909 175.006 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.507 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 97.1 m -129.57 140.77 51.12 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.597 -0.69 . . . . 0.0 109.738 -174.663 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.839 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -132.65 137.27 46.92 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 120.948 -1.095 . . . . 0.0 111.142 -177.95 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.836 HG22 ' OG ' ' A' ' 60' ' ' SER . 4.8 t -120.16 131.72 71.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.115 -0.991 . . . . 0.0 110.677 -178.379 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.863 HG13 ' CE1' ' A' ' 61' ' ' PHE . 18.9 m -111.9 175.74 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 CA-C-O 121.212 0.529 . . . . 0.0 110.265 178.007 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.569 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 7.9 tt0 -107.02 117.05 33.03 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.387 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.562 HD12 ' HD2' ' A' ' 29' ' ' PRO . 10.7 tp -80.45 126.74 77.97 Favored Pre-proline 0 C--N 1.296 -1.724 0 O-C-N 121.428 -0.795 . . . . 0.0 109.827 -173.53 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.562 ' HD2' HD12 ' A' ' 28' ' ' LEU . 18.7 Cg_endo -63.78 173.67 4.47 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.886 1.466 . . . . 0.0 110.654 -179.362 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.766 ' HA ' HD12 ' A' ' 33' ' ' LEU . 12.3 p-10 -59.99 -38.06 81.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.372 -0.83 . . . . 0.0 110.676 -176.159 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.589 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.18 0.06 57.37 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.959 -1.088 . . . . 0.0 110.947 -175.734 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.589 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 94.5 mmm -110.43 -12.01 14.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.854 -1.154 . . . . 0.0 109.948 170.176 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.944 HD21 ' HB2' ' A' ' 57' ' ' ASN . 15.8 mt -63.04 -31.38 72.5 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.299 -0.875 . . . . 0.0 110.15 176.817 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -93.23 139.99 30.02 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.339 -0.851 . . . . 0.0 110.536 -176.335 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.08 -41.42 2.34 Favored Glycine 0 N--CA 1.491 2.335 0 C-N-CA 119.892 -1.147 . . . . 0.0 110.387 174.878 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.76 HD23 ' N ' ' A' ' 37' ' ' GLU . 9.1 tt -76.1 149.28 37.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.926 -1.338 . . . . 0.0 111.054 -174.394 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.76 ' N ' HD23 ' A' ' 36' ' ' LEU . 15.8 pt-20 -151.59 169.25 22.56 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.464 -0.772 . . . . 0.0 109.58 177.289 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.926 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -61.32 151.64 31.47 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.936 -1.102 . . . . 0.0 109.876 179.107 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.73 -5.81 60.36 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -178.647 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.489 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -73.28 156.15 38.77 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.228 -1.16 . . . . 0.0 109.649 177.266 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.682 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -99.8 106.2 18.06 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.958 -1.089 . . . . 0.0 109.749 176.296 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.6 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.2 t -93.3 129.89 43.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 121.21 -0.931 . . . . 0.0 109.122 174.914 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.502 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -93.38 120.02 33.17 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.3 -0.96 . . . . 0.0 109.117 172.336 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.796 ' CD2' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -91.22 104.79 17.3 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.698 -0.801 . . . . 0.0 108.886 177.98 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.496 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.6 t-20 55.34 14.09 1.03 Allowed 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.314 -0.866 . . . . 0.0 110.896 -168.704 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.457 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 120.33 -5.16 12.12 Favored Glycine 0 N--CA 1.49 2.255 0 C-N-CA 119.58 -1.295 . . . . 0.0 110.919 172.132 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.848 ' O ' HD23 ' A' ' 49' ' ' LEU . 25.1 t -90.58 110.32 21.46 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.336 -1.685 . . . . 0.0 109.495 176.634 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.9 p -74.47 127.93 34.29 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.959 -1.088 . . . . 0.0 110.789 -171.47 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 1.008 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -143.21 160.06 41.16 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.323 -0.861 . . . . 0.0 109.707 174.825 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.459 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 3.6 m -102.22 151.56 22.06 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.773 -1.205 . . . . 0.0 111.083 -172.526 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.747 HG13 HG13 ' A' ' 59' ' ' VAL . 14.6 t -78.22 118.39 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.752 -0.593 . . . . 0.0 110.489 -177.341 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 43.9 p -72.32 -40.03 67.77 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.367 -0.833 . . . . 0.0 110.065 174.128 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.522 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -164.48 153.5 13.22 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.272 -0.893 . . . . 0.0 110.2 -176.956 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.926 HD11 ' N ' ' A' ' 38' ' ' THR . 6.8 mt -109.56 130.02 63.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.107 -0.996 . . . . 0.0 109.958 176.118 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.507 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 4.5 m-80 -102.56 63.28 0.86 Allowed 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.682 -0.636 . . . . 0.0 109.725 179.427 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.11 -114.06 4.06 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.781 -1.728 . . . . 0.0 108.781 -174.086 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.944 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.1 OUTLIER -78.53 -22.31 47.5 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 120.953 -1.322 . . . . 0.0 108.82 175.001 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.113 ' CD2' HG11 ' A' ' 13' ' ' VAL . 11.8 m80 -74.46 159.44 32.27 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.331 -0.856 . . . . 0.0 110.229 -177.651 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.747 HG13 HG13 ' A' ' 51' ' ' VAL . 54.1 t -141.62 122.58 12.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 C-N-CA 119.163 -1.015 . . . . 0.0 110.81 172.971 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.836 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.4 t -88.26 134.9 33.68 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.454 -0.779 . . . . 0.0 109.705 175.366 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 1.008 ' HB2' HD12 ' A' ' 49' ' ' LEU . 2.1 p90 -127.26 154.66 44.6 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.374 -0.829 . . . . 0.0 110.292 176.66 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 35.8 p-10 -88.95 152.29 21.8 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.149 -0.969 . . . . 0.0 111.329 -171.136 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.834 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -157.77 100.25 1.75 Allowed 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.598 -0.689 . . . . 0.0 109.369 -174.178 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.489 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 60.7 ttm -60.23 139.89 57.32 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.058 -1.026 . . . . 0.0 109.669 -177.307 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.494 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 5.1 ttpm? -59.94 -43.31 95.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.138 -0.977 . . . . 0.0 110.409 -175.36 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.33 -40.03 77.84 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.833 -1.167 . . . . 0.0 109.842 178.056 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.64 HG21 ' O2 ' ' A' ' 98' ' ' RBF . 94.2 m -59.98 -37.64 80.24 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.05 -1.031 . . . . 0.0 109.474 172.231 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.712 HD11 ' HA2' ' A' ' 74' ' ' GLY . 14.2 tp -59.96 -45.81 91.45 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.273 -0.892 . . . . 0.0 109.428 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 55.2 ttt85 -69.96 -39.94 75.71 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.382 -0.824 . . . . 0.0 110.739 176.916 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.785 HG22 HG23 ' A' ' 71' ' ' THR . 1.5 tt -67.27 -42.82 88.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.233 -0.917 . . . . 0.0 109.445 -175.779 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.785 HG23 HG22 ' A' ' 70' ' ' ILE . 40.3 p -83.84 -173.87 4.96 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 174.678 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.496 ' HB3' ' HB2' ' B' ' 83' ' ' ASN . 3.1 t30 -102.71 23.63 11.77 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 169.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.834 ' HB3' HD21 ' A' ' 63' ' ' LEU . 86.9 mt -68.42 -40.07 81.36 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.089 -1.007 . . . . 0.0 110.015 176.768 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.712 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -47.88 -22.36 1.98 Allowed Glycine 0 N--CA 1.487 2.086 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.694 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.2 p-10 -62.83 -18.69 63.19 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.163 -1.198 . . . . 0.0 110.405 -176.303 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.513 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.8 mt -60.0 143.16 52.52 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.202 -0.936 . . . . 0.0 110.516 -177.752 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 0.941 ' C ' HD23 ' A' ' 12' ' ' LEU . 23.3 mttm -145.82 146.87 31.32 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.584 -0.698 . . . . 0.0 109.381 176.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.601 ' CG2' HG13 ' A' ' 15' ' ' ILE . 22.4 t -68.25 148.59 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.677 -1.265 . . . . 0.0 110.176 -175.625 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.14 -11.17 63.61 Favored Glycine 0 N--CA 1.483 1.813 0 N-CA-C 108.743 -1.743 . . . . 0.0 108.743 -174.167 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.494 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 45.5 t0 -95.68 162.63 13.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.344 -1.092 . . . . 0.0 109.694 176.785 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.587 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.0 m95 -114.76 149.35 37.07 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.124 -0.985 . . . . 0.0 110.005 176.778 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.013 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.2 p -115.21 153.79 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.498 -0.751 . . . . 0.0 109.971 -179.581 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.69 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.6 m-20 -78.19 106.11 9.87 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.143 -0.973 . . . . 0.0 109.125 168.607 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.875 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -108.4 139.88 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 120.665 -1.272 . . . . 0.0 111.177 -176.643 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.42 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.4 tt0 -136.92 144.02 43.23 Favored 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 120.217 -0.593 . . . . 0.0 110.201 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 66.5 ttp85 -79.58 129.92 34.91 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.279 -0.888 . . . . 0.0 111.011 -176.552 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.824 ' HB1' ' CZ ' ' B' ' 2' ' ' PHE . . . -125.76 145.92 49.99 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.351 -0.843 . . . . 0.0 110.134 175.815 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -136.37 142.9 43.79 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.668 -0.645 . . . . 0.0 110.457 -177.443 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 26.9 mttt -60.03 -39.9 87.48 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.252 -0.905 . . . . 0.0 109.948 179.774 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -137.83 156.41 47.96 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.364 -0.835 . . . . 0.0 110.04 177.656 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 48.2 m -133.65 147.18 51.42 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.27 -0.894 . . . . 0.0 110.005 176.243 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.462 ' O ' ' HB2' ' A' ' 93' ' ' GLU . 53.2 t0 -60.05 -37.9 81.2 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.194 -0.941 . . . . 0.0 109.697 177.61 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.462 ' HB2' ' O ' ' A' ' 92' ' ' ASP . 62.7 mm-40 55.93 50.01 14.76 Favored 'General case' 0 N--CA 1.507 2.402 0 O-C-N 121.574 -0.704 . . . . 0.0 110.512 178.363 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 56.9 mt -60.9 -44.48 97.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.27 -0.894 . . . . 0.0 109.498 172.514 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 79.96 -91.44 1.31 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 178.386 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -169.41 171.06 43.0 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.525 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 . . . . . 0 N--CA 1.491 1.596 0 O-C-N 121.208 -1.172 . . . . 0.0 110.204 -179.556 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 92.3 mmm . . . . . 0 N--CA 1.492 1.645 0 CA-C-O 121.286 0.565 . . . . 0.0 110.487 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.824 ' CZ ' ' HB1' ' A' ' 87' ' ' ALA . 8.4 p90 -168.38 155.87 7.97 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 174.826 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.58 HG23 ' C ' ' B' ' 2' ' ' PHE . 40.3 p -155.65 -39.26 0.08 Allowed 'General case' 0 C--N 1.295 -1.795 0 O-C-N 120.85 -1.156 . . . . 0.0 109.174 177.078 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 45.5 24.95 1.2 Allowed Glycine 0 N--CA 1.484 1.86 0 N-CA-C 108.503 -1.839 . . . . 0.0 108.503 -173.69 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 0.485 HG13 ' O ' ' B' ' 3' ' ' THR . 91.5 mt -77.91 135.51 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.388 -1.066 . . . . 0.0 109.75 -179.517 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.666 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.6 t -91.37 137.76 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.051 -1.031 . . . . 0.0 110.921 -170.45 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -71.11 -32.79 69.46 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.814 -0.554 . . . . 0.0 111.221 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.543 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -150.64 171.78 30.42 Favored Glycine 0 N--CA 1.495 2.63 0 C-N-CA 119.105 -1.522 . . . . 0.0 110.153 -171.876 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.499 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 3.1 p -119.23 172.26 7.72 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.937 -1.331 . . . . 0.0 111.238 -176.31 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.083 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -142.58 150.13 39.95 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 -176.417 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 30.1 tttt -110.9 115.25 29.19 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.102 -0.999 . . . . 0.0 110.224 179.585 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 0.929 HD23 ' C ' ' B' ' 77' ' ' LYS . 10.9 tp -59.95 127.68 33.08 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.085 -1.009 . . . . 0.0 109.068 174.41 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.127 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -122.03 -29.16 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.662 179.295 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.67 147.6 26.92 Favored 'General case' 0 N--CA 1.493 1.678 0 C-N-CA 119.188 -1.005 . . . . 0.0 111.473 -179.137 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.848 HG23 ' CD2' ' B' ' 24' ' ' HIS . 11.8 mt -109.59 138.71 35.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.305 -0.872 . . . . 0.0 110.041 172.404 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.506 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 77.4 m-20 -109.72 114.61 28.34 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 121.31 -0.869 . . . . 0.0 109.863 173.638 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.31 112.18 24.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.16 -0.963 . . . . 0.0 110.311 -176.449 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.2 OUTLIER -112.83 132.74 22.16 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.173 -0.954 . . . . 0.0 109.005 175.393 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -49.67 -40.35 46.85 Favored 'Trans proline' 0 C--N 1.303 -1.852 0 O-C-N 123.91 1.479 . . . . 0.0 110.705 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.438 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 12.1 m-80 -70.35 -40.07 74.3 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.141 -0.974 . . . . 0.0 110.108 177.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.461 ' O ' ' HB2' ' B' ' 18' ' ' LYS . 96.0 m-85 -152.03 150.36 29.87 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.314 -0.867 . . . . 0.0 110.542 -174.848 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.614 ' HD3' HD22 ' B' ' 68' ' ' LEU . 60.6 ttt180 -91.31 143.42 26.66 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.893 -1.129 . . . . 0.0 109.965 174.959 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.506 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 97.2 m -129.41 140.69 51.25 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.659 -0.651 . . . . 0.0 109.718 -174.591 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.848 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -132.52 137.5 47.19 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.069 -1.019 . . . . 0.0 111.094 -178.088 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.845 HG22 ' OG ' ' B' ' 60' ' ' SER . 4.8 t -120.13 131.95 71.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.119 -0.988 . . . . 0.0 110.662 -178.379 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.866 HG13 ' CE1' ' B' ' 61' ' ' PHE . 19.0 m -112.24 175.64 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 121.751 -0.593 . . . . 0.0 110.171 178.067 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.575 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 7.9 tt0 -106.76 117.09 33.12 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 178.31 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.573 HD12 ' HD2' ' B' ' 29' ' ' PRO . 10.8 tp -80.42 126.67 78.22 Favored Pre-proline 0 C--N 1.295 -1.763 0 O-C-N 121.235 -0.916 . . . . 0.0 109.83 -173.554 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.573 ' HD2' HD12 ' B' ' 28' ' ' LEU . 18.6 Cg_endo -63.67 173.65 4.38 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 O-C-N 123.946 1.498 . . . . 0.0 110.699 -179.427 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.75 ' HA ' HD12 ' B' ' 33' ' ' LEU . 12.3 p-10 -59.97 -38.05 81.39 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 110.739 -176.265 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.585 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.16 -0.05 57.42 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.922 -1.112 . . . . 0.0 110.902 -175.72 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.585 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 94.6 mmm -110.35 -11.98 14.47 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.867 -1.146 . . . . 0.0 109.913 170.182 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.932 HD21 ' HB2' ' B' ' 57' ' ' ASN . 15.8 mt -63.0 -31.43 72.57 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.341 -0.849 . . . . 0.0 110.133 176.818 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -93.22 139.99 30.02 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.347 -0.846 . . . . 0.0 110.538 -176.277 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.06 -41.32 2.35 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 174.801 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.757 HD23 ' N ' ' B' ' 37' ' ' GLU . 9.0 tt -76.09 149.25 37.47 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.973 -1.31 . . . . 0.0 111.034 -174.399 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 37' ' ' GLU . . . . . 0.757 ' N ' HD23 ' B' ' 36' ' ' LEU . 15.8 pt-20 -151.52 169.3 22.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.52 -0.737 . . . . 0.0 109.645 177.194 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.93 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -61.34 151.66 31.52 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.026 -1.046 . . . . 0.0 109.969 179.059 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.79 -5.94 60.17 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 -178.599 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.5 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -73.26 155.96 38.98 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.24 -1.153 . . . . 0.0 109.668 177.234 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.689 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -99.52 106.05 18.02 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.86 -1.15 . . . . 0.0 109.87 176.252 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.617 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.2 t -93.3 130.01 42.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.311 -0.868 . . . . 0.0 109.071 174.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -93.31 120.02 33.11 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 119.274 -0.971 . . . . 0.0 109.225 172.241 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.783 ' CD2' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -91.22 104.67 17.2 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.578 -0.849 . . . . 0.0 108.939 177.977 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.697 HD22 ' HB2' ' A' ' 47' ' ' CYS . 0.8 OUTLIER 55.4 14.2 1.08 Allowed 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.378 -0.826 . . . . 0.0 110.864 -168.692 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.463 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 120.21 -4.92 12.34 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.622 -1.275 . . . . 0.0 110.916 171.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.862 ' O ' HD23 ' B' ' 49' ' ' LEU . 25.0 t -90.68 110.31 21.49 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.365 -1.668 . . . . 0.0 109.478 176.547 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 19.1 p -74.32 128.02 34.48 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.074 -1.016 . . . . 0.0 110.803 -171.556 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 1.0 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -143.36 159.98 41.38 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.41 -0.806 . . . . 0.0 109.709 174.78 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 50' ' ' THR . . . . . 0.469 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 3.6 m -102.07 151.66 21.89 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.803 -1.185 . . . . 0.0 111.019 -172.473 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.725 HG13 HG13 ' B' ' 59' ' ' VAL . 15.9 t -78.41 118.35 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.599 -0.688 . . . . 0.0 110.549 -177.39 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.53 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 43.9 p -72.26 -40.11 67.91 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.336 -0.853 . . . . 0.0 110.061 174.222 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.525 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -164.44 153.5 13.3 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.193 -0.942 . . . . 0.0 110.21 -176.956 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.93 HD11 ' N ' ' B' ' 38' ' ' THR . 6.9 mt -109.48 129.97 63.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.149 -0.97 . . . . 0.0 110.016 176.118 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.519 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 4.5 m-80 -102.68 63.3 0.85 Allowed 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.598 -0.689 . . . . 0.0 109.732 179.433 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.29 -114.11 4.05 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 108.758 -1.737 . . . . 0.0 108.758 -174.162 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.932 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -78.36 -22.57 47.76 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.01 -1.288 . . . . 0.0 108.903 174.89 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.127 ' CD2' HG11 ' B' ' 13' ' ' VAL . 12.0 m80 -74.27 159.23 32.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.475 -0.766 . . . . 0.0 110.249 -177.638 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.725 HG13 HG13 ' B' ' 51' ' ' VAL . 54.3 t -141.48 122.56 12.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.756 173.104 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.845 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.4 t -88.34 135.13 33.61 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.464 -0.772 . . . . 0.0 109.655 175.418 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 1.0 ' HB2' HD12 ' B' ' 49' ' ' LEU . 2.1 p90 -127.46 154.62 44.85 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.692 -0.803 . . . . 0.0 110.263 176.645 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.53 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 36.3 p-10 -88.89 152.29 21.83 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.035 -1.041 . . . . 0.0 111.275 -171.041 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.811 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -157.79 100.24 1.74 Allowed 'General case' 0 C--N 1.3 -1.562 0 C-N-CA 120.065 -0.654 . . . . 0.0 109.298 -174.186 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.495 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 60.8 ttm -60.14 139.84 57.28 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.066 -1.021 . . . . 0.0 109.737 -177.391 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.499 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 5.1 ttpm? -59.98 -43.28 95.23 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.131 -0.981 . . . . 0.0 110.399 -175.353 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.36 -40.01 77.74 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.914 -1.116 . . . . 0.0 109.883 178.044 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.644 HG21 ' O2 ' ' B' ' 99' ' ' RBF . 94.4 m -60.01 -37.68 80.43 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.075 -1.015 . . . . 0.0 109.434 172.26 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.717 HD11 ' HA2' ' B' ' 74' ' ' GLY . 14.2 tp -60.01 -45.59 92.26 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.302 -0.874 . . . . 0.0 109.482 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 55.2 ttt85 -70.01 -40.03 75.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.465 -0.772 . . . . 0.0 110.732 176.85 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.769 HG22 HG23 ' B' ' 71' ' ' THR . 1.5 tt -67.2 -42.78 88.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.289 -0.882 . . . . 0.0 109.438 -175.802 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.769 HG23 HG22 ' B' ' 70' ' ' ILE . 40.2 p -83.84 -173.69 4.86 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 174.759 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.501 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 3.2 t30 -102.8 23.71 11.71 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.172 -1.048 . . . . 0.0 108.172 169.937 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.811 ' HB3' HD21 ' B' ' 63' ' ' LEU . 86.2 mt -68.6 -39.95 80.68 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.141 -0.975 . . . . 0.0 109.938 176.832 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.717 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -47.96 -22.28 2.02 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.646 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.3 p-10 -62.86 -18.69 63.27 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.092 -1.24 . . . . 0.0 110.434 -176.335 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.517 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.0 mt -60.02 143.26 52.31 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.269 -0.894 . . . . 0.0 110.496 -177.738 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 0.929 ' C ' HD23 ' B' ' 12' ' ' LEU . 23.3 mttm -145.99 146.71 31.1 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.681 -0.637 . . . . 0.0 109.351 177.02 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.585 ' CG2' HG13 ' B' ' 15' ' ' ILE . 22.1 t -68.05 148.69 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 120.865 -1.147 . . . . 0.0 110.303 -175.669 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 85.96 -10.94 63.83 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.86 -1.696 . . . . 0.0 108.86 -174.125 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.48 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 45.2 t0 -95.74 162.48 13.58 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.303 -1.116 . . . . 0.0 109.687 176.658 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.0 m95 -114.73 149.41 36.88 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.174 -0.954 . . . . 0.0 109.999 176.833 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.083 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.2 p -115.37 153.95 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.422 -0.799 . . . . 0.0 109.857 -179.574 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.666 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -78.27 106.09 9.94 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.138 -0.976 . . . . 0.0 109.197 168.616 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.898 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -108.36 140.04 28.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 120.726 -1.234 . . . . 0.0 111.014 -176.446 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 85' ' ' GLU . . . . . 0.413 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.5 tt0 -137.18 143.98 42.66 Favored 'General case' 0 N--CA 1.492 1.633 0 C-N-CA 120.282 -0.567 . . . . 0.0 110.205 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 66.5 ttp85 -79.36 130.03 35.04 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.219 -0.926 . . . . 0.0 110.946 -176.515 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 0.928 ' HB1' ' CZ ' ' A' ' 2' ' ' PHE . . . -125.87 145.95 50.03 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.302 -0.874 . . . . 0.0 110.045 175.733 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 88' ' ' ALA . . . . . 0.413 ' N ' ' CE2' ' A' ' 2' ' ' PHE . . . -136.41 142.86 43.72 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.586 -0.696 . . . . 0.0 110.508 -177.5 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 26.8 mttt -59.98 -40.05 87.82 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.899 179.839 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -137.8 156.5 47.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.377 -0.827 . . . . 0.0 109.949 177.681 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 91' ' ' SER . . . . . 0.622 ' H ' HD11 ' B' ' 94' ' ' ILE . 48.4 m -133.62 147.24 51.46 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.344 -0.848 . . . . 0.0 110.001 176.266 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 52.9 t0 -60.09 -40.03 88.17 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.137 -0.977 . . . . 0.0 109.693 177.679 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 -109.34 51.73 0.74 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.172 -0.955 . . . . 0.0 110.707 -177.827 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 94' ' ' ILE . . . . . 0.622 HD11 ' H ' ' B' ' 91' ' ' SER . 59.0 mt -59.98 -41.96 87.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.217 -0.927 . . . . 0.0 109.54 174.725 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 57.83 75.44 0.26 Allowed Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 175.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . 174.37 179.97 45.33 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 178.094 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 93.8 m-70 . . . . . 0 N--CA 1.491 1.61 0 O-C-N 121.331 -1.1 . . . . 0.0 110.143 179.618 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 0.64 ' O2 ' HG21 ' A' ' 67' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 0.644 ' O2 ' HG21 ' B' ' 67' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.457 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 98.2 mtp . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 121.238 0.542 . . . . 0.0 110.227 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.948 ' CZ ' ' HB1' ' B' ' 87' ' ' ALA . 6.3 p90 -178.26 140.0 0.21 Allowed 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.293 -0.879 . . . . 0.0 108.846 177.642 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.559 ' CB ' HG12 ' A' ' 5' ' ' ILE . 9.9 p -130.99 -36.91 1.31 Allowed 'General case' 0 C--N 1.3 -1.566 0 O-C-N 120.816 -1.177 . . . . 0.0 109.133 -177.11 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.5 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 52.61 22.03 10.53 Favored Glycine 0 N--CA 1.485 1.901 0 N-CA-C 108.584 -1.806 . . . . 0.0 108.584 -178.33 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.559 HG12 ' CB ' ' A' ' 3' ' ' THR . 32.8 mm -80.43 122.82 36.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.429 -1.041 . . . . 0.0 109.789 -176.897 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.959 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.3 t -82.66 142.84 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.184 -0.947 . . . . 0.0 110.892 -171.702 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 -69.43 -35.0 75.28 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.773 -0.579 . . . . 0.0 110.621 177.107 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.53 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -162.68 173.9 38.98 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 118.896 -1.621 . . . . 0.0 110.094 -174.114 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.464 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.5 p -114.69 174.76 5.8 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.154 -1.204 . . . . 0.0 110.836 -177.701 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.022 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -142.61 149.04 38.45 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.622 -0.674 . . . . 0.0 109.541 -177.718 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.0 tttt -103.95 118.62 37.1 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 120.95 -1.094 . . . . 0.0 110.2 178.134 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 1.02 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.2 tp -60.7 127.55 32.21 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 120.795 -1.191 . . . . 0.0 108.569 171.005 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.112 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.7 p -130.45 -31.17 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.874 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.229 -177.126 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -143.84 139.83 29.49 Favored 'General case' 0 C--N 1.296 -1.719 0 C-N-CA 119.079 -1.048 . . . . 0.0 111.272 -178.634 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.78 HG23 ' CD2' ' A' ' 24' ' ' HIS . 11.2 mt -110.02 130.81 62.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.034 -1.041 . . . . 0.0 110.198 171.201 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.508 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 81.6 m-20 -108.07 114.64 28.7 Favored 'General case' 0 C--N 1.294 -1.843 0 O-C-N 121.443 -0.786 . . . . 0.0 109.962 173.195 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.4 110.77 22.98 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.002 -1.061 . . . . 0.0 110.592 -176.85 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -110.29 128.12 25.89 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.133 -0.979 . . . . 0.0 108.917 174.09 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -50.61 -33.42 39.28 Favored 'Trans proline' 0 C--N 1.303 -1.851 0 O-C-N 123.767 1.404 . . . . 0.0 110.314 -179.73 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.474 ' C ' ' CD2' ' A' ' 21' ' ' PHE . 12.4 m-80 -72.27 -40.0 67.95 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.149 -0.97 . . . . 0.0 109.938 175.812 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.474 ' CD2' ' C ' ' A' ' 20' ' ' ASN . 91.0 m-85 -152.51 150.25 29.39 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.374 -0.829 . . . . 0.0 110.197 -178.4 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.486 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 57.5 ttt180 -88.31 139.95 29.97 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 120.734 -1.229 . . . . 0.0 109.7 173.074 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.508 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 95.0 m -124.97 131.73 53.38 Favored 'General case' 0 C--N 1.294 -1.847 0 O-C-N 121.597 -0.689 . . . . 0.0 109.901 -176.87 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.78 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -126.21 138.89 53.68 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.905 -1.122 . . . . 0.0 111.303 -179.7 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.767 HG22 ' CB ' ' A' ' 60' ' ' SER . 5.7 t -120.83 134.26 64.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.135 -0.978 . . . . 0.0 110.861 -176.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.814 HG13 ' CE1' ' A' ' 61' ' ' PHE . 35.9 m -114.79 172.17 4.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 O-C-N 121.804 -0.56 . . . . 0.0 110.09 178.243 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.56 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 9.2 tt0 -104.21 117.91 35.37 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.376 -0.827 . . . . 0.0 108.788 177.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.891 HD21 HD13 ' A' ' 36' ' ' LEU . 7.5 tp -85.83 127.93 60.48 Favored Pre-proline 0 C--N 1.297 -1.703 0 O-C-N 121.562 -0.711 . . . . 0.0 109.943 -171.128 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.479 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 20.6 Cg_endo -66.02 178.69 2.25 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.881 1.464 . . . . 0.0 110.743 -179.363 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.518 ' HA ' HD12 ' A' ' 33' ' ' LEU . 33.9 p-10 -62.65 -40.1 95.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.349 -0.844 . . . . 0.0 110.999 -175.542 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.606 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.93 -0.0 57.33 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.837 -1.164 . . . . 0.0 110.823 -174.367 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.606 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.0 mmm -108.11 -16.98 14.15 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.87 -1.144 . . . . 0.0 109.638 170.772 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.597 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 24.7 mt -66.2 -25.77 67.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.363 -0.835 . . . . 0.0 109.721 174.736 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -92.26 131.33 37.56 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.474 -0.766 . . . . 0.0 110.56 -178.094 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.79 -41.75 2.71 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 176.601 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.891 HD13 HD21 ' A' ' 28' ' ' LEU . 5.1 tt -70.84 148.2 48.09 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.076 -1.249 . . . . 0.0 110.335 -177.226 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.729 ' N ' HD23 ' A' ' 36' ' ' LEU . 19.9 pt-20 -156.75 166.36 33.61 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.322 -0.862 . . . . 0.0 109.599 -177.66 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.75 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -65.57 148.5 51.63 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.886 -1.134 . . . . 0.0 110.051 -178.886 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.67 -3.47 68.76 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.234 -1.546 . . . . 0.0 109.234 -174.369 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.463 ' CB ' ' O ' ' A' ' 37' ' ' GLU . . . -78.22 160.03 28.19 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.263 -1.14 . . . . 0.0 109.445 176.108 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.453 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -101.64 114.31 28.24 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 118.799 -1.16 . . . . 0.0 110.097 177.107 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.666 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.7 t -99.11 128.75 50.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.278 -0.889 . . . . 0.0 108.94 173.277 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.512 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -94.99 119.48 33.58 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 119.156 -1.017 . . . . 0.0 109.074 172.295 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.666 ' HE1' HG11 ' A' ' 42' ' ' VAL . 0.6 OUTLIER -87.32 103.14 15.19 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.415 -0.803 . . . . 0.0 108.958 178.41 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.498 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 57.83 8.9 0.77 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.441 -0.787 . . . . 0.0 111.309 -170.312 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.503 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 124.11 2.26 8.51 Favored Glycine 0 N--CA 1.489 2.168 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.858 174.846 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.803 ' O ' HD23 ' A' ' 49' ' ' LEU . 42.7 t -98.45 107.33 19.77 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.461 -1.611 . . . . 0.0 109.485 174.706 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.504 ' SG ' ' C7 ' ' A' ' 98' ' ' RBF . 26.2 p -75.1 129.9 38.35 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.237 -0.914 . . . . 0.0 111.211 -170.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.975 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -145.27 160.63 41.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.443 -0.786 . . . . 0.0 109.637 173.552 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.41 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 57.9 m -100.95 151.17 22.08 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.737 -1.227 . . . . 0.0 110.923 -171.719 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.737 HG13 HG13 ' A' ' 59' ' ' VAL . 38.6 t -78.48 116.85 22.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.655 -0.653 . . . . 0.0 110.487 -178.358 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.532 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 37.7 p -70.03 -40.01 75.42 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.205 -0.934 . . . . 0.0 109.893 174.092 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.621 ' HA ' HG21 ' A' ' 38' ' ' THR . 86.5 tt0 -163.47 153.39 15.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.298 -0.876 . . . . 0.0 110.194 -177.676 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.75 HD11 ' N ' ' A' ' 38' ' ' THR . 5.9 mt -104.49 133.63 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.018 -1.051 . . . . 0.0 109.885 175.044 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.509 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 9.3 m120 -107.72 66.94 0.67 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.507 -0.745 . . . . 0.0 109.823 179.154 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.27 -116.06 4.83 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.816 -1.714 . . . . 0.0 108.816 -174.609 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.597 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -79.21 -19.13 51.53 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.055 -1.262 . . . . 0.0 108.764 174.545 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.112 ' CE1' HG11 ' A' ' 13' ' ' VAL . 25.5 m-70 -74.73 160.66 30.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.467 -0.77 . . . . 0.0 110.343 -178.236 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.737 HG13 HG13 ' A' ' 51' ' ' VAL . 62.9 t -141.25 123.21 14.27 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 O-C-N 121.229 -0.92 . . . . 0.0 110.433 171.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.767 ' CB ' HG22 ' A' ' 25' ' ' VAL . 13.3 m -91.32 130.53 37.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.573 -0.704 . . . . 0.0 109.535 178.283 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.975 ' HB2' HD12 ' A' ' 49' ' ' LEU . 4.0 p90 -124.69 153.66 42.0 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.096 -1.002 . . . . 0.0 110.333 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.532 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 27.2 p-10 -88.73 152.22 21.93 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.091 -1.006 . . . . 0.0 111.37 -170.92 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.866 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -155.73 114.33 3.46 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -176.128 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.513 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 7.1 ttp -71.64 140.0 49.52 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.803 -1.186 . . . . 0.0 109.685 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.5 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 37.5 ttpt -60.04 -46.03 90.86 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.075 -1.015 . . . . 0.0 110.532 -174.05 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -70.0 -40.05 75.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.659 -1.275 . . . . 0.0 110.003 178.522 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.513 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 33.4 m -61.88 -34.9 76.87 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.053 -1.029 . . . . 0.0 109.462 173.805 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.709 HD11 ' HA2' ' A' ' 74' ' ' GLY . 7.6 tp -59.96 -45.81 91.47 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.244 -0.91 . . . . 0.0 109.151 178.205 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 71.8 ttt-85 -66.46 -39.98 89.15 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.284 -0.885 . . . . 0.0 110.682 175.115 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.785 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -66.72 -44.24 89.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.173 -0.954 . . . . 0.0 109.584 -175.549 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.785 HG23 HG22 ' A' ' 70' ' ' ILE . 31.2 p -83.17 -175.13 5.68 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 120.199 -0.6 . . . . 0.0 109.437 175.5 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 3.7 t30 -99.48 23.59 9.21 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 171.216 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.866 ' HB3' HD21 ' A' ' 63' ' ' LEU . 90.9 mt -70.0 -39.96 75.55 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.12 -0.987 . . . . 0.0 110.117 176.928 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.709 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -53.75 -18.1 7.71 Favored Glycine 0 N--CA 1.486 1.987 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 -177.137 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.2 p-10 -69.99 -19.03 63.35 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.953 -1.322 . . . . 0.0 110.575 -175.567 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.518 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 87.9 mt -62.13 141.92 57.88 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.233 -0.917 . . . . 0.0 110.815 -176.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 1.02 ' C ' HD23 ' A' ' 12' ' ' LEU . 43.5 mtmt -141.49 141.74 33.62 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 121.63 -0.669 . . . . 0.0 109.776 174.32 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.733 HG23 HD11 ' A' ' 15' ' ' ILE . 16.6 t -60.32 152.6 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 120.926 -1.109 . . . . 0.0 110.451 -174.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.43 -15.9 57.45 Favored Glycine 0 N--CA 1.482 1.722 0 N-CA-C 108.762 -1.735 . . . . 0.0 108.762 -176.348 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 37.8 t0 -95.76 166.8 11.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.312 -1.111 . . . . 0.0 109.664 175.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.584 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.3 m95 -116.82 160.49 20.74 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.083 -1.011 . . . . 0.0 110.171 178.014 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.022 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.1 p -125.55 155.21 34.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.339 -0.851 . . . . 0.0 110.034 -177.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.959 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -79.97 105.04 10.96 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.964 -1.085 . . . . 0.0 109.059 168.229 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.81 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -105.56 138.01 32.68 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 O-C-N 120.546 -1.346 . . . . 0.0 111.118 -176.539 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -133.53 140.03 46.96 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 120.298 -0.561 . . . . 0.0 110.028 -178.023 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.537 ' NH1' ' HB2' ' A' ' 86' ' ' ARG . 26.7 ttm105 -78.31 126.91 31.45 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.258 -0.901 . . . . 0.0 110.701 -176.053 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.93 ' HB1' ' CZ ' ' B' ' 2' ' ' PHE . . . -120.51 144.3 48.1 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.392 -0.817 . . . . 0.0 110.076 176.289 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -137.37 157.8 45.8 Favored 'General case' 0 N--CA 1.49 1.533 0 CA-C-O 121.515 0.674 . . . . 0.0 110.727 -176.302 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 40.0 mmtt -66.17 -39.96 90.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.387 -0.82 . . . . 0.0 110.576 179.798 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 45.7 p90 -108.77 161.45 15.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.085 -1.009 . . . . 0.0 110.499 -175.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 58.4 m -119.93 144.86 47.21 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.438 -0.789 . . . . 0.0 110.323 -178.527 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.42 ' O ' ' OD1' ' A' ' 92' ' ' ASP . 55.0 t0 -69.9 -24.64 63.43 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.41 -0.806 . . . . 0.0 110.696 -178.74 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -92.85 43.19 1.12 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.736 -1.228 . . . . 0.0 110.856 -172.856 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 57.9 mt -61.44 -45.85 97.78 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 O-C-N 121.35 -0.843 . . . . 0.0 109.765 170.55 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 149.08 -91.44 0.14 Allowed Glycine 0 N--CA 1.488 2.158 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -178.211 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 86.27 -9.94 68.25 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 178.645 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 44.1 m80 . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.202 -1.175 . . . . 0.0 110.174 -178.539 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 1' ' ' MET . . . . . 0.445 ' O ' ' HB3' ' B' ' 2' ' ' PHE . 67.6 mtt . . . . . 0 N--CA 1.492 1.675 0 CA-C-O 121.254 0.549 . . . . 0.0 110.261 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.93 ' CZ ' ' HB1' ' A' ' 87' ' ' ALA . 6.4 p90 -177.94 139.99 0.23 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.304 -0.872 . . . . 0.0 108.748 176.5 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.558 ' CB ' HG12 ' B' ' 5' ' ' ILE . 9.6 p -130.97 -36.88 1.32 Allowed 'General case' 0 C--N 1.301 -1.533 0 O-C-N 120.824 -1.173 . . . . 0.0 109.174 -177.174 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.483 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 52.59 22.01 10.43 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.608 -1.797 . . . . 0.0 108.608 -178.335 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 0.558 HG12 ' CB ' ' B' ' 3' ' ' THR . 32.9 mm -80.42 122.75 36.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.356 -1.085 . . . . 0.0 109.833 -176.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.966 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.3 t -82.56 142.89 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.166 -0.959 . . . . 0.0 110.984 -171.724 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 90.8 mm-40 -69.51 -34.74 74.72 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.685 -0.635 . . . . 0.0 110.665 177.167 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.524 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -163.03 173.72 39.26 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.065 -1.541 . . . . 0.0 110.177 -174.111 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.468 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.4 p -114.68 174.63 5.87 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.156 -1.203 . . . . 0.0 110.841 -177.543 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.044 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -142.45 149.24 39.0 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.704 -0.622 . . . . 0.0 109.462 -177.802 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.58 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 29.9 tttt -103.97 118.68 37.24 Favored 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.051 -1.03 . . . . 0.0 110.154 178.065 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 1.017 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.1 tp -60.86 127.42 31.5 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 120.952 -1.092 . . . . 0.0 108.624 170.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.128 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.7 p -130.2 -31.53 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.836 0 O-C-N 121.265 -0.897 . . . . 0.0 110.267 -177.008 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -143.7 139.89 29.75 Favored 'General case' 0 C--N 1.295 -1.772 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.311 -178.649 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.792 HG23 ' CD2' ' B' ' 24' ' ' HIS . 11.2 mt -109.92 130.84 62.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.048 -1.032 . . . . 0.0 110.149 171.259 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.522 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 81.2 m-20 -108.2 114.79 28.95 Favored 'General case' 0 C--N 1.296 -1.722 0 O-C-N 121.42 -0.8 . . . . 0.0 109.912 173.127 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.38 110.79 23.01 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.119 -0.988 . . . . 0.0 110.503 -176.825 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -110.34 128.1 25.91 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.158 -0.964 . . . . 0.0 109.016 173.971 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -50.8 -33.27 40.2 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 O-C-N 123.758 1.399 . . . . 0.0 110.253 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.471 ' C ' ' CD2' ' B' ' 21' ' ' PHE . 12.3 m-80 -72.32 -40.17 67.66 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.203 -0.935 . . . . 0.0 109.902 175.713 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.471 ' CD2' ' C ' ' B' ' 20' ' ' ASN . 91.1 m-85 -152.33 150.23 29.5 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.393 -0.817 . . . . 0.0 110.233 -178.423 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.498 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 57.5 ttt180 -88.13 139.89 30.05 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.777 -1.202 . . . . 0.0 109.706 173.063 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.522 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 95.6 m -124.96 131.75 53.38 Favored 'General case' 0 C--N 1.295 -1.781 0 O-C-N 121.676 -0.64 . . . . 0.0 109.908 -176.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.792 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -126.18 138.97 53.7 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.011 -1.056 . . . . 0.0 111.241 -179.635 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.778 HG22 ' CB ' ' B' ' 60' ' ' SER . 5.7 t -120.78 134.44 64.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.224 -0.923 . . . . 0.0 110.834 -176.971 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.804 HG13 ' CE1' ' B' ' 61' ' ' PHE . 35.8 m -115.04 172.08 4.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.773 -0.579 . . . . 0.0 110.021 178.28 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.559 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 9.2 tt0 -104.1 118.05 35.73 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 177.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.87 HD21 HD13 ' B' ' 36' ' ' LEU . 7.5 tp -85.84 127.8 60.96 Favored Pre-proline 0 C--N 1.296 -1.735 0 O-C-N 121.338 -0.851 . . . . 0.0 110.0 -171.209 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.469 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 20.9 Cg_endo -65.95 178.63 2.25 Favored 'Trans proline' 0 C--N 1.308 -1.604 0 O-C-N 123.828 1.436 . . . . 0.0 110.799 -179.365 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.522 ' HA ' HD12 ' B' ' 33' ' ' LEU . 33.8 p-10 -62.74 -39.94 95.68 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.322 -0.861 . . . . 0.0 110.984 -175.47 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.0 0.0 57.34 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.851 -1.156 . . . . 0.0 110.797 -174.363 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.597 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.0 mmm -108.16 -16.87 14.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.84 -1.162 . . . . 0.0 109.62 170.833 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.588 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 24.6 mt -66.36 -25.69 66.92 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.369 -0.832 . . . . 0.0 109.714 174.739 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -92.28 131.31 37.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.48 -0.762 . . . . 0.0 110.525 -178.129 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.76 -41.64 2.72 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 176.542 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.87 HD13 HD21 ' B' ' 28' ' ' LEU . 5.1 tt -70.81 148.26 48.05 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.033 -1.275 . . . . 0.0 110.267 -177.222 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 37' ' ' GLU . . . . . 0.733 ' N ' HD23 ' B' ' 36' ' ' LEU . 19.9 pt-20 -156.8 166.39 33.51 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.366 -0.834 . . . . 0.0 109.576 -177.702 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.748 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -65.65 148.46 51.72 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.927 -1.108 . . . . 0.0 110.064 -178.886 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.59 -3.33 68.94 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.319 -1.512 . . . . 0.0 109.319 -174.272 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.466 ' CB ' ' O ' ' B' ' 37' ' ' GLU . . . -78.41 159.99 28.01 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.286 -1.126 . . . . 0.0 109.33 176.021 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.457 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -101.56 114.18 27.97 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 120.86 -1.15 . . . . 0.0 110.116 177.177 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.657 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.7 t -99.24 128.77 50.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.319 -0.863 . . . . 0.0 108.923 173.329 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.509 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -94.86 119.47 33.47 Favored 'General case' 0 C--N 1.297 -1.707 0 O-C-N 121.083 -1.011 . . . . 0.0 109.135 172.294 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.657 ' HE1' HG11 ' B' ' 42' ' ' VAL . 0.6 OUTLIER -87.42 102.99 15.08 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.376 -0.828 . . . . 0.0 108.975 178.403 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.498 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 58.12 8.9 0.85 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.49 -0.756 . . . . 0.0 111.25 -170.459 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.503 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 123.87 2.73 8.57 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.789 -1.196 . . . . 0.0 110.802 174.709 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.82 ' O ' HD23 ' B' ' 49' ' ' LEU . 42.7 t -98.62 107.26 19.66 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 120.378 -1.66 . . . . 0.0 109.44 174.535 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 48' ' ' CYS . . . . . 0.513 ' SG ' ' C7 ' ' B' ' 99' ' ' RBF . 26.2 p -74.97 130.04 38.68 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.114 -0.991 . . . . 0.0 111.142 -171.026 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 0.957 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -145.43 160.41 41.62 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.484 -0.76 . . . . 0.0 109.717 173.462 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 50' ' ' THR . . . . . 0.423 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 57.7 m -100.7 151.35 21.76 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.781 -1.199 . . . . 0.0 110.982 -171.798 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.734 HG13 HG13 ' B' ' 59' ' ' VAL . 38.2 t -78.67 116.92 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.644 -0.66 . . . . 0.0 110.472 -178.358 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.519 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 38.8 p -70.07 -40.06 75.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.201 -0.937 . . . . 0.0 109.884 174.224 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.614 ' HA ' HG21 ' B' ' 38' ' ' THR . 86.5 tt0 -163.36 153.44 15.6 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.341 -0.849 . . . . 0.0 110.226 -177.683 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.748 HD11 ' N ' ' B' ' 38' ' ' THR . 5.9 mt -104.52 133.65 48.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.151 -0.968 . . . . 0.0 109.937 174.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.52 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 9.2 m120 -107.82 66.99 0.67 Allowed 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.572 -0.705 . . . . 0.0 109.762 179.194 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.41 -116.08 4.81 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 108.743 -1.743 . . . . 0.0 108.743 -174.733 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.588 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -79.18 -19.22 51.42 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 120.974 -1.309 . . . . 0.0 108.832 174.478 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.128 ' CE1' HG11 ' B' ' 13' ' ' VAL . 25.2 m-70 -74.65 160.53 30.69 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.443 -0.785 . . . . 0.0 110.361 -178.301 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.734 HG13 HG13 ' B' ' 51' ' ' VAL . 62.9 t -141.06 123.22 14.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 O-C-N 121.208 -0.932 . . . . 0.0 110.453 171.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.778 ' CB ' HG22 ' B' ' 25' ' ' VAL . 13.4 m -91.43 130.87 37.21 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.632 -0.667 . . . . 0.0 109.553 178.314 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.957 ' HB2' HD12 ' B' ' 49' ' ' LEU . 3.9 p90 -124.96 153.43 42.76 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.188 -0.945 . . . . 0.0 110.255 -179.721 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.519 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 27.4 p-10 -88.58 152.21 21.99 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.976 -1.077 . . . . 0.0 111.466 -170.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.831 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -155.71 114.4 3.48 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 -176.154 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.512 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 7.1 ttp -71.62 139.97 49.54 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.867 -1.146 . . . . 0.0 109.799 -178.076 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.501 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 37.5 ttpt -60.06 -45.98 91.06 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.128 -0.982 . . . . 0.0 110.477 -173.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -70.06 -39.98 75.36 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.806 -1.184 . . . . 0.0 110.023 178.591 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.512 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 34.4 m -61.94 -34.98 77.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.035 -1.041 . . . . 0.0 109.342 173.789 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.702 HD11 ' HA2' ' B' ' 74' ' ' GLY . 7.6 tp -60.05 -45.47 92.74 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.312 -0.867 . . . . 0.0 109.243 178.26 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 71.8 ttt-85 -66.7 -39.96 88.27 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.356 -0.84 . . . . 0.0 110.652 175.051 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.768 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -66.71 -44.23 89.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.144 -0.973 . . . . 0.0 109.595 -175.602 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.768 HG23 HG22 ' B' ' 70' ' ' ILE . 31.2 p -83.05 -175.02 5.63 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 120.114 -0.634 . . . . 0.0 109.477 175.518 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.492 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 3.7 t30 -99.56 23.68 9.16 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 171.125 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.831 ' HB3' HD21 ' B' ' 63' ' ' LEU . 90.7 mt -70.05 -39.96 75.4 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.123 -0.985 . . . . 0.0 110.089 176.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.702 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -53.79 -18.0 7.7 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 -177.11 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.4 p-10 -70.06 -18.99 63.3 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.039 -1.271 . . . . 0.0 110.578 -175.556 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.511 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 88.1 mt -62.14 141.89 57.91 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.231 -0.918 . . . . 0.0 110.828 -177.025 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 1.017 ' C ' HD23 ' B' ' 12' ' ' LEU . 43.4 mtmt -141.52 141.72 33.58 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.666 -0.646 . . . . 0.0 109.787 174.321 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.744 HG23 HD11 ' B' ' 15' ' ' ILE . 16.7 t -60.31 152.51 5.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.957 -1.09 . . . . 0.0 110.43 -174.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.38 -15.59 58.16 Favored Glycine 0 N--CA 1.484 1.846 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -176.415 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 38.0 t0 -95.97 166.68 11.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.422 -1.046 . . . . 0.0 109.655 175.855 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.58 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.4 m95 -116.76 160.53 20.66 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.15 -0.968 . . . . 0.0 110.176 178.076 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.044 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.1 p -125.56 155.35 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.407 -0.808 . . . . 0.0 109.979 -178.056 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.966 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.2 OUTLIER -80.01 104.89 10.89 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.093 -1.004 . . . . 0.0 109.003 168.296 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.809 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -105.54 138.18 31.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 120.559 -1.338 . . . . 0.0 111.075 -176.491 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -133.71 140.08 46.79 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 120.335 -0.546 . . . . 0.0 110.05 -178.103 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 86' ' ' ARG . . . . . 0.538 ' NH1' ' HB2' ' B' ' 86' ' ' ARG . 26.8 ttm105 -78.34 126.92 31.46 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.213 -0.929 . . . . 0.0 110.642 -176.014 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 0.948 ' HB1' ' CZ ' ' A' ' 2' ' ' PHE . . . -120.39 144.16 48.06 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.334 -0.854 . . . . 0.0 110.015 176.286 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -137.25 157.89 45.63 Favored 'General case' 0 N--CA 1.49 1.574 0 CA-C-O 121.438 0.637 . . . . 0.0 110.774 -176.473 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 40.0 mmtt -66.26 -39.96 89.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.395 -0.816 . . . . 0.0 110.555 179.799 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 45.8 p90 -108.77 161.53 15.02 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.158 -0.964 . . . . 0.0 110.543 -176.005 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 91' ' ' SER . . . . . . . . . . . . . 58.8 m -119.94 144.94 47.19 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.381 -0.824 . . . . 0.0 110.351 -178.567 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 92' ' ' ASP . . . . . 0.428 ' O ' ' OD1' ' B' ' 92' ' ' ASP . 55.3 t0 -70.02 -21.19 63.22 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.366 -0.834 . . . . 0.0 110.515 -178.658 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -117.02 55.9 0.82 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.489 -0.757 . . . . 0.0 110.268 -176.077 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 94' ' ' ILE . . . . . 0.432 ' O ' ' C ' ' B' ' 95' ' ' GLY . 38.7 mm -59.97 -44.72 95.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.276 -0.89 . . . . 0.0 109.64 177.776 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 95' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' B' ' 94' ' ' ILE . . . 40.34 65.87 0.91 Allowed Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 177.175 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . 120.32 -126.09 6.52 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.481 -1.447 . . . . 0.0 109.481 -178.65 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 28.0 p80 . . . . . 0 N--CA 1.49 1.573 0 O-C-N 121.203 -1.174 . . . . 0.0 110.266 -179.18 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 0.528 " O2'" ' C9 ' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 0.53 " O2'" ' C9 ' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 76.5 mtm . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 121.157 0.503 . . . . 0.0 110.325 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.932 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 10.2 p90 -171.05 143.92 2.04 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.182 -0.949 . . . . 0.0 109.202 177.396 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.555 ' CB ' HG12 ' A' ' 5' ' ' ILE . 6.7 p -140.99 -37.37 0.44 Allowed 'General case' 0 C--N 1.299 -1.604 0 O-C-N 120.984 -1.073 . . . . 0.0 109.087 -178.236 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.501 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 45.99 25.97 1.9 Allowed Glycine 0 N--CA 1.484 1.885 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -176.295 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.555 HG12 ' CB ' ' A' ' 3' ' ' THR . 41.3 mm -76.61 122.8 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.396 -1.061 . . . . 0.0 109.865 -177.294 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.979 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.7 t -86.17 139.05 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.256 -0.903 . . . . 0.0 110.784 -170.432 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 79.2 mm-40 -69.97 -34.84 73.91 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.64 -0.663 . . . . 0.0 110.843 178.275 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.528 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -158.28 179.19 34.15 Favored Glycine 0 N--CA 1.494 2.527 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.235 -173.167 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.47 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 1.0 OUTLIER -118.54 170.0 9.32 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.117 -1.226 . . . . 0.0 110.956 -177.962 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.13 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -136.55 149.7 48.23 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.667 -0.646 . . . . 0.0 109.448 -179.237 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 39.6 tttt -110.57 117.87 34.69 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.024 -1.048 . . . . 0.0 110.455 -179.44 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.98 HD23 ' C ' ' A' ' 77' ' ' LYS . 10.9 tp -60.04 126.26 26.83 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.882 -1.136 . . . . 0.0 108.979 172.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.068 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.4 p -125.76 -31.67 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 O-C-N 121.471 -0.768 . . . . 0.0 109.545 179.252 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.09 143.12 30.24 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.453 -0.899 . . . . 0.0 111.103 -179.648 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.759 HG23 ' CD2' ' A' ' 24' ' ' HIS . 18.0 mt -106.71 134.98 46.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.038 -1.039 . . . . 0.0 110.0 171.027 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.515 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 56.0 m-20 -107.53 115.81 30.83 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.274 -0.891 . . . . 0.0 109.851 174.067 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -107.06 111.88 24.55 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.057 -1.027 . . . . 0.0 110.467 -176.448 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 8.2 mtmm -109.09 131.28 21.9 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.217 -0.927 . . . . 0.0 109.262 175.686 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -51.13 -22.88 11.69 Favored 'Trans proline' 0 C--N 1.304 -1.78 0 O-C-N 123.954 1.502 . . . . 0.0 111.052 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.582 ' O ' ' CD1' ' A' ' 21' ' ' PHE . 7.4 m-80 -92.78 -33.61 14.21 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.085 -1.009 . . . . 0.0 109.983 177.833 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.582 ' CD1' ' O ' ' A' ' 20' ' ' ASN . 36.3 m-85 -148.2 150.17 33.27 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.488 -0.758 . . . . 0.0 110.026 -177.516 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.68 ' HD3' HD22 ' A' ' 68' ' ' LEU . 60.4 ttt180 -95.76 143.5 26.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.668 -1.27 . . . . 0.0 109.964 173.739 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.515 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 56.3 m -132.61 145.65 51.27 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.494 -0.754 . . . . 0.0 109.955 -176.095 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.759 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -134.2 134.06 41.64 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.943 -1.098 . . . . 0.0 111.327 -179.666 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.732 HG22 ' CB ' ' A' ' 60' ' ' SER . 5.3 t -113.62 132.75 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.071 -1.018 . . . . 0.0 110.856 -177.32 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.546 HG22 ' HE2' ' A' ' 61' ' ' PHE . 12.9 m -118.79 170.93 7.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 CA-C-O 121.317 0.579 . . . . 0.0 110.331 -179.17 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.563 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 15.3 tt0 -100.08 116.65 32.6 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 177.789 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.879 HD13 ' HD2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -86.15 118.5 70.51 Favored Pre-proline 0 C--N 1.295 -1.798 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -175.36 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.879 ' HD2' HD13 ' A' ' 28' ' ' LEU . 19.6 Cg_endo -63.25 170.78 7.34 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 O-C-N 123.801 1.422 . . . . 0.0 110.976 -178.527 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.603 ' HA ' HD12 ' A' ' 33' ' ' LEU . 34.1 p-10 -61.26 -35.85 78.42 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.477 -0.765 . . . . 0.0 110.83 -175.713 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.602 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.69 -0.49 57.71 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.828 -1.17 . . . . 0.0 110.874 -173.486 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.604 ' HB3' HD11 ' A' ' 28' ' ' LEU . 99.9 mmm -116.69 -11.17 11.01 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.984 -1.072 . . . . 0.0 109.933 169.499 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.603 HD12 ' HA ' ' A' ' 30' ' ' ASP . 13.2 mt -65.67 -37.95 87.93 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.07 -1.019 . . . . 0.0 109.599 175.168 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -69.04 132.25 46.34 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.486 -0.759 . . . . 0.0 110.746 -177.402 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.12 -40.12 2.8 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 173.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 59.1 tp -69.2 145.44 53.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.03 -1.277 . . . . 0.0 110.688 -175.262 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.518 ' C ' HD11 ' A' ' 54' ' ' ILE . 16.8 pt-20 -148.01 169.1 20.64 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.591 -0.693 . . . . 0.0 109.408 177.445 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.844 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -64.53 148.56 50.45 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.9 -1.125 . . . . 0.0 109.83 178.291 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.42 -4.66 62.85 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -176.45 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -74.45 159.13 32.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.257 -1.143 . . . . 0.0 109.499 176.568 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.47 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -100.51 117.42 34.63 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 118.909 -1.116 . . . . 0.0 109.885 176.642 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.614 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.1 t -105.97 126.25 61.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.333 -0.855 . . . . 0.0 109.079 175.262 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -89.72 118.62 29.46 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.185 -1.006 . . . . 0.0 109.191 172.282 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.736 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -88.8 100.99 13.58 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 177.054 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.491 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 59.59 8.79 1.35 Allowed 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.486 -0.759 . . . . 0.0 111.143 -168.514 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.49 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 128.76 -12.69 6.18 Favored Glycine 0 N--CA 1.489 2.197 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.8 174.167 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.765 ' O ' HD23 ' A' ' 49' ' ' LEU . 42.8 t -85.97 110.05 19.2 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.356 -1.673 . . . . 0.0 109.779 179.196 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.477 ' O ' ' C5A' ' A' ' 98' ' ' RBF . 19.6 p -77.65 113.4 15.46 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.304 -0.872 . . . . 0.0 110.984 -172.376 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.931 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -130.33 161.18 31.86 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.436 -0.79 . . . . 0.0 109.119 172.628 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 57.2 m -103.93 155.08 18.93 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.492 -1.38 . . . . 0.0 111.356 -168.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.756 HG13 HG13 ' A' ' 59' ' ' VAL . 21.2 t -77.44 112.79 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.677 -0.64 . . . . 0.0 110.379 -179.51 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.625 HG22 ' HB3' ' A' ' 62' ' ' ASP . 17.6 p -69.95 -40.0 75.72 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.211 -0.931 . . . . 0.0 109.493 172.193 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.404 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.0 tt0 -158.46 153.9 25.96 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 119.322 -0.951 . . . . 0.0 110.845 -177.846 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.844 HD11 ' N ' ' A' ' 38' ' ' THR . 13.6 mt -110.37 130.06 64.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.181 -0.95 . . . . 0.0 109.887 172.713 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.491 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 9.7 m-80 -103.73 63.67 0.78 Allowed 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.542 -0.724 . . . . 0.0 109.723 178.899 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.69 -112.51 3.55 Favored Glycine 0 N--CA 1.487 2.07 0 N-CA-C 108.691 -1.764 . . . . 0.0 108.691 -173.608 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.539 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -80.1 -22.49 42.14 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.988 -1.301 . . . . 0.0 108.846 174.201 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.068 ' CE1' HG11 ' A' ' 13' ' ' VAL . 18.6 m-70 -74.58 158.69 33.27 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.123 -0.985 . . . . 0.0 110.218 -176.211 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.756 HG13 HG13 ' A' ' 51' ' ' VAL . 80.2 t -141.31 119.68 9.72 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 C-N-CA 119.312 -0.955 . . . . 0.0 110.923 175.693 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.732 ' CB ' HG22 ' A' ' 25' ' ' VAL . 15.9 m -88.65 126.21 35.19 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.627 -0.671 . . . . 0.0 109.739 178.672 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.931 ' HB3' HD12 ' A' ' 49' ' ' LEU . 98.0 m-85 -109.9 156.53 20.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.788 -1.195 . . . . 0.0 110.396 179.52 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.625 ' HB3' HG22 ' A' ' 52' ' ' THR . 19.8 p-10 -89.8 148.22 23.34 Favored 'General case' 0 N--CA 1.494 1.738 0 CA-C-O 122.045 0.926 . . . . 0.0 110.878 178.856 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.823 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -155.53 116.6 3.91 Favored 'General case' 0 C--N 1.296 -1.759 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -176.483 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.534 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 93.2 mmm -69.97 141.72 52.96 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 119.109 -1.037 . . . . 0.0 109.518 179.738 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.421 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 46.8 tttp -60.0 -45.15 93.69 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.103 -0.998 . . . . 0.0 110.195 -176.849 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.457 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.4 tt0 -69.44 -40.04 77.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.984 -1.072 . . . . 0.0 110.283 177.642 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.534 ' HB ' ' HB2' ' A' ' 64' ' ' MET . 89.8 m -61.69 -39.38 91.24 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.927 -1.108 . . . . 0.0 109.278 174.091 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.68 HD22 ' HD3' ' A' ' 22' ' ' ARG . 7.7 tp -60.09 -43.57 95.42 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.325 -0.86 . . . . 0.0 109.364 178.022 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 92.6 mtt180 -69.86 -39.97 76.05 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.545 -0.722 . . . . 0.0 110.692 176.03 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.772 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -69.94 -41.61 79.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.246 -0.909 . . . . 0.0 109.404 -176.078 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.772 HG23 HG22 ' A' ' 70' ' ' ILE . 65.3 p -83.59 -173.94 5.0 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 178.072 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 3.0 t30 -100.73 22.62 11.68 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 170.883 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.823 ' HB3' HD21 ' A' ' 63' ' ' LEU . 96.6 mt -69.91 -40.2 75.75 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.013 -1.054 . . . . 0.0 110.053 174.653 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.604 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -52.99 -24.27 19.48 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 -176.095 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 25.9 p-10 -64.98 -19.67 66.1 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.043 -1.269 . . . . 0.0 110.634 -174.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.52 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 95.8 mt -60.01 140.25 56.9 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.216 -0.928 . . . . 0.0 110.923 -177.056 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 0.98 ' C ' HD23 ' A' ' 12' ' ' LEU . 75.9 mttt -140.92 144.1 35.0 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 173.606 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.617 ' N ' HD23 ' A' ' 12' ' ' LEU . 12.0 t -59.32 152.0 4.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 120.731 -1.231 . . . . 0.0 110.304 -173.538 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.15 -15.81 57.27 Favored Glycine 0 N--CA 1.484 1.847 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 -177.37 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 52.7 t0 -93.41 164.58 13.15 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.284 -1.127 . . . . 0.0 109.684 176.104 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.584 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.3 m95 -115.4 168.15 10.24 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.062 -1.023 . . . . 0.0 110.253 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.13 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.5 p -131.97 155.56 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.518 -0.739 . . . . 0.0 110.039 -178.878 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.979 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.6 m-20 -80.57 109.86 15.49 Favored 'General case' 0 C--N 1.296 -1.75 0 O-C-N 121.007 -1.058 . . . . 0.0 109.12 167.725 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.605 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -109.76 138.62 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.577 -1.327 . . . . 0.0 111.232 -175.301 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -137.02 138.53 40.57 Favored 'General case' 0 N--CA 1.494 1.741 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.801 -178.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 83.9 mtm180 -78.41 142.33 37.67 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.958 -1.089 . . . . 0.0 110.951 -176.14 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.802 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -134.43 148.04 50.55 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.387 -0.82 . . . . 0.0 110.133 176.876 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -136.28 148.36 47.96 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.668 -0.645 . . . . 0.0 110.638 -177.307 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.427 ' HE2' ' CE2' ' A' ' 90' ' ' PHE . 0.7 OUTLIER -70.0 -31.14 68.67 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.338 -0.851 . . . . 0.0 110.623 177.966 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.541 ' CD1' ' C ' ' A' ' 90' ' ' PHE . 7.6 p90 -143.11 160.0 41.22 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.908 -1.12 . . . . 0.0 110.343 173.578 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.418 ' O ' HG12 ' A' ' 94' ' ' ILE . 15.2 t -154.4 150.05 27.49 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.316 -0.865 . . . . 0.0 110.56 179.334 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -68.28 -40.01 81.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.354 -0.842 . . . . 0.0 110.226 176.371 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -104.42 50.19 0.8 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.377 -0.827 . . . . 0.0 110.582 -173.408 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.418 HG12 ' O ' ' A' ' 91' ' ' SER . 22.9 mm -59.98 -40.1 82.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.449 -0.782 . . . . 0.0 110.002 175.12 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 110.16 -51.59 0.69 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 177.444 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 66.33 -142.61 43.01 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 71.4 m80 . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.206 -1.173 . . . . 0.0 110.198 -177.833 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 92.9 mmm . . . . . 0 N--CA 1.492 1.642 0 CA-C-O 121.24 0.543 . . . . 0.0 110.219 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.802 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 10.3 p90 -171.52 144.04 1.86 Allowed 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.351 -0.843 . . . . 0.0 109.139 177.504 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.56 ' CB ' HG12 ' B' ' 5' ' ' ILE . 6.7 p -141.03 -37.41 0.44 Allowed 'General case' 0 C--N 1.298 -1.667 0 O-C-N 120.998 -1.064 . . . . 0.0 109.061 -178.198 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 46.29 25.66 2.01 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 -176.406 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 0.56 HG12 ' CB ' ' B' ' 3' ' ' THR . 41.6 mm -76.66 122.79 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.463 -1.021 . . . . 0.0 109.795 -177.051 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.954 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.7 t -86.14 139.07 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.225 -0.922 . . . . 0.0 110.78 -170.431 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 79.3 mm-40 -70.05 -34.63 73.46 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.79 -0.569 . . . . 0.0 110.842 178.284 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.53 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -158.56 179.01 34.53 Favored Glycine 0 N--CA 1.494 2.553 0 C-N-CA 119.048 -1.548 . . . . 0.0 110.227 -173.101 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.469 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 1.0 OUTLIER -118.45 170.03 9.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.094 -1.239 . . . . 0.0 110.976 -177.851 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.121 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -136.55 149.85 48.31 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.671 -0.643 . . . . 0.0 109.381 -179.329 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 39.8 tttt -110.65 117.98 34.96 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.048 -1.033 . . . . 0.0 110.39 -179.439 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 0.979 HD23 ' C ' ' B' ' 77' ' ' LYS . 10.9 tp -60.33 126.13 26.32 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.037 -1.039 . . . . 0.0 109.085 172.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.05 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.4 p -125.65 -31.54 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 O-C-N 121.442 -0.786 . . . . 0.0 109.684 179.488 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.23 143.15 30.11 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 119.516 -0.874 . . . . 0.0 111.092 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.759 HG23 ' CD2' ' B' ' 24' ' ' HIS . 17.8 mt -106.67 134.88 47.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.005 -1.06 . . . . 0.0 110.03 171.046 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.53 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 55.7 m-20 -107.54 115.88 30.94 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.28 -0.888 . . . . 0.0 109.898 174.079 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -107.05 111.78 24.41 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.035 -1.04 . . . . 0.0 110.428 -176.342 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.456 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 8.2 mtmm -109.02 131.27 21.9 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.259 -0.901 . . . . 0.0 109.288 175.623 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -51.11 -23.02 11.86 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 O-C-N 123.868 1.457 . . . . 0.0 111.061 -179.209 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.571 ' O ' ' CD1' ' B' ' 21' ' ' PHE . 7.4 m-80 -92.46 -34.22 14.2 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.065 -1.022 . . . . 0.0 109.879 177.827 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.571 ' CD1' ' O ' ' B' ' 20' ' ' ASN . 36.3 m-85 -147.7 150.23 33.93 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.431 -0.793 . . . . 0.0 110.026 -177.36 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.671 ' HD3' HD22 ' B' ' 68' ' ' LEU . 60.3 ttt180 -95.74 143.53 26.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.756 -1.215 . . . . 0.0 110.058 173.559 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.53 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 55.9 m -132.59 145.61 51.24 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.503 -0.748 . . . . 0.0 110.029 -176.135 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.759 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -134.04 134.09 41.98 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.085 -1.009 . . . . 0.0 111.197 -179.517 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.736 HG22 ' CB ' ' B' ' 60' ' ' SER . 5.4 t -113.68 133.0 61.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.207 -0.933 . . . . 0.0 110.778 -177.41 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.536 HG22 ' HE2' ' B' ' 61' ' ' PHE . 13.2 m -119.05 170.94 7.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-O 121.232 0.539 . . . . 0.0 110.268 -179.067 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.558 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 15.3 tt0 -100.03 116.71 32.71 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 177.714 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.923 HD13 ' HD2' ' B' ' 29' ' ' PRO . 0.0 OUTLIER -86.11 118.35 70.28 Favored Pre-proline 0 C--N 1.295 -1.804 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 -175.422 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.923 ' HD2' HD13 ' B' ' 28' ' ' LEU . 19.5 Cg_endo -63.13 170.75 7.22 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 O-C-N 123.802 1.422 . . . . 0.0 110.96 -178.525 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.617 ' HA ' HD12 ' B' ' 33' ' ' LEU . 34.1 p-10 -61.28 -35.74 78.15 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.47 -0.769 . . . . 0.0 110.873 -175.741 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.595 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.74 -0.48 57.72 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.783 -1.198 . . . . 0.0 110.839 -173.487 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.595 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.9 mmm -116.64 -11.22 11.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.857 -1.152 . . . . 0.0 109.984 169.509 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.617 HD12 ' HA ' ' B' ' 30' ' ' ASP . 13.2 mt -65.68 -38.02 88.1 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.013 -1.054 . . . . 0.0 109.626 175.165 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -68.99 132.27 46.39 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.549 -0.719 . . . . 0.0 110.792 -177.404 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.1 -40.16 2.8 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 110.346 -1.102 . . . . 0.0 110.346 174.061 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 59.0 tp -69.13 145.49 53.3 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.045 -1.268 . . . . 0.0 110.726 -175.302 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 37' ' ' GLU . . . . . 0.496 ' C ' HD11 ' B' ' 54' ' ' ILE . 16.8 pt-20 -147.98 169.1 20.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.506 -0.746 . . . . 0.0 109.423 177.473 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.843 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -64.66 148.48 50.89 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.939 -1.101 . . . . 0.0 109.859 178.298 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.57 -4.67 63.44 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -176.464 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -74.49 158.98 32.86 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.121 -1.223 . . . . 0.0 109.492 176.474 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.469 ' OG ' ' O ' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -100.37 117.21 34.09 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 120.94 -1.1 . . . . 0.0 110.029 176.584 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.636 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.1 t -105.96 126.28 61.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.383 -0.823 . . . . 0.0 109.105 175.316 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.513 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -89.7 118.64 29.46 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 119.133 -1.027 . . . . 0.0 109.114 172.351 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.742 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -88.77 100.72 13.36 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 176.994 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.491 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 59.88 8.79 1.49 Allowed 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.53 -0.731 . . . . 0.0 110.987 -168.642 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.501 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 128.68 -12.65 6.21 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.583 -1.294 . . . . 0.0 110.818 174.151 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.757 ' O ' HD23 ' B' ' 49' ' ' LEU . 41.7 t -85.97 109.94 19.12 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.259 -1.73 . . . . 0.0 109.757 179.151 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 48' ' ' CYS . . . . . 0.476 ' O ' ' C5A' ' B' ' 99' ' ' RBF . 19.4 p -77.54 113.44 15.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.227 -0.92 . . . . 0.0 110.969 -172.465 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 0.947 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -130.46 161.1 32.17 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.355 -0.841 . . . . 0.0 109.129 172.521 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 57.5 m -103.76 155.2 18.78 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.545 -1.347 . . . . 0.0 111.277 -168.841 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.78 HG13 HG13 ' B' ' 59' ' ' VAL . 21.2 t -77.62 112.79 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.606 -0.683 . . . . 0.0 110.415 -179.525 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.632 HG22 ' HB3' ' B' ' 62' ' ' ASP . 17.7 p -69.93 -40.05 75.77 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.16 -0.963 . . . . 0.0 109.512 172.339 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.411 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.0 tt0 -158.5 153.74 25.61 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.757 -177.753 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.843 HD11 ' N ' ' B' ' 38' ' ' THR . 13.7 mt -110.23 130.03 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.205 -0.934 . . . . 0.0 109.908 172.738 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.501 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 9.6 m-80 -103.73 63.64 0.78 Allowed 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.943 -0.703 . . . . 0.0 109.692 178.939 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.77 -112.5 3.55 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 108.638 -1.785 . . . . 0.0 108.638 -173.625 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.532 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -80.07 -22.64 42.04 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.865 -1.373 . . . . 0.0 108.873 174.206 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.05 ' CE1' HG11 ' B' ' 13' ' ' VAL . 18.8 m-70 -74.42 158.53 33.72 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.175 -0.953 . . . . 0.0 110.263 -176.278 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.78 HG13 HG13 ' B' ' 51' ' ' VAL . 79.9 t -141.26 119.72 9.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 C-N-CA 119.158 -1.017 . . . . 0.0 110.817 175.86 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.736 ' CB ' HG22 ' B' ' 25' ' ' VAL . 15.9 m -88.69 126.4 35.29 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.617 -0.677 . . . . 0.0 109.73 178.679 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.947 ' HB3' HD12 ' B' ' 49' ' ' LEU . 98.0 m-85 -110.08 156.49 20.49 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.867 -1.146 . . . . 0.0 110.374 179.554 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.632 ' HB3' HG22 ' B' ' 52' ' ' THR . 19.8 p-10 -89.72 148.2 23.41 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.209 -0.932 . . . . 0.0 110.9 178.888 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.805 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -155.51 116.72 3.94 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -176.585 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.517 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 93.1 mmm -70.04 141.67 52.84 Favored 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 119.119 -1.032 . . . . 0.0 109.552 179.683 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.416 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 46.8 tttp -60.06 -45.08 94.05 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.172 -0.955 . . . . 0.0 110.119 -176.7 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 66' ' ' GLU . . . . . 0.463 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 86.5 tt0 -69.38 -40.0 77.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.102 -0.999 . . . . 0.0 110.333 177.647 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.517 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 89.2 m -61.73 -39.6 92.13 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.959 -1.088 . . . . 0.0 109.16 174.148 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.671 HD22 ' HD3' ' B' ' 22' ' ' ARG . 7.7 tp -59.98 -43.41 95.15 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.562 -0.711 . . . . 0.0 109.47 178.077 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 92.7 mtt180 -69.96 -39.98 75.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.449 -0.782 . . . . 0.0 110.67 175.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.77 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -70.06 -41.35 79.17 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.278 -0.889 . . . . 0.0 109.52 -176.131 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.77 HG23 HG22 ' B' ' 70' ' ' ILE . 65.5 p -83.56 -173.81 4.93 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 177.983 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.53 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 3.1 t30 -100.78 22.66 11.68 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 170.827 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.805 ' HB3' HD21 ' B' ' 63' ' ' LEU . 96.9 mt -69.96 -40.09 75.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.116 -0.99 . . . . 0.0 110.071 174.665 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.597 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -53.01 -24.34 19.93 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 110.409 -1.077 . . . . 0.0 110.409 -176.127 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.1 p-10 -64.97 -19.65 66.09 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.116 -1.226 . . . . 0.0 110.632 -174.869 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.521 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 95.8 mt -60.02 140.19 56.95 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.187 -0.946 . . . . 0.0 110.901 -177.065 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 0.979 ' C ' HD23 ' B' ' 12' ' ' LEU . 76.0 mttt -140.92 144.1 34.99 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 173.607 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.618 ' N ' HD23 ' B' ' 12' ' ' LEU . 12.1 t -59.34 151.95 4.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 120.76 -1.213 . . . . 0.0 110.335 -173.519 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.18 -15.72 57.54 Favored Glycine 0 N--CA 1.484 1.847 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 -177.396 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 52.6 t0 -93.47 164.4 13.21 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.432 -1.04 . . . . 0.0 109.675 176.043 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.2 m95 -115.28 168.16 10.21 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.132 -0.98 . . . . 0.0 110.373 178.312 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.121 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.5 p -132.04 155.55 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.547 -0.721 . . . . 0.0 109.965 -178.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.954 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -80.4 109.67 15.12 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.009 -1.057 . . . . 0.0 109.174 167.729 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.589 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -109.45 138.95 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 120.66 -1.275 . . . . 0.0 111.138 -175.233 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -137.48 138.51 39.8 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.894 -0.504 . . . . 0.0 109.724 -179.056 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 83.9 mtm180 -78.35 142.44 37.68 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.042 -1.036 . . . . 0.0 110.917 -176.062 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 0.932 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -134.49 148.07 50.49 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.359 -0.838 . . . . 0.0 110.103 176.824 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -136.29 148.39 47.95 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.562 -0.711 . . . . 0.0 110.644 -177.344 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 89' ' ' LYS . . . . . 0.417 ' HE2' ' CE2' ' B' ' 90' ' ' PHE . 0.7 OUTLIER -70.01 -31.11 68.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.3 -0.875 . . . . 0.0 110.654 177.947 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' B' B ' 90' ' ' PHE . . . . . 0.541 ' CD1' ' C ' ' B' ' 90' ' ' PHE . 7.6 p90 -143.06 159.98 41.25 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.86 -1.15 . . . . 0.0 110.404 173.621 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 91' ' ' SER . . . . . . . . . . . . . 15.8 t -154.46 150.08 27.46 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.399 -0.813 . . . . 0.0 110.528 179.351 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 92' ' ' ASP . . . . . 0.497 ' O ' ' CG ' ' B' ' 93' ' ' GLU . 93.6 m-20 -68.32 -35.04 77.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.408 -0.807 . . . . 0.0 110.286 176.352 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 93' ' ' GLU . . . . . 0.497 ' CG ' ' O ' ' B' ' 92' ' ' ASP . 12.8 pt-20 36.21 52.82 0.92 Allowed 'General case' 0 N--CA 1.515 2.814 0 O-C-N 121.617 -0.677 . . . . 0.0 110.774 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 94' ' ' ILE . . . . . . . . . . . . . 48.1 mm -69.91 -40.13 78.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.304 -0.873 . . . . 0.0 110.399 -179.444 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 89.33 -44.84 3.09 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 178.513 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -116.36 -170.89 15.85 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 -179.292 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 84.6 m-70 . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.363 -1.081 . . . . 0.0 110.292 179.615 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 0.559 " C2'" ' HC9' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 0.561 " C2'" ' HC9' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.464 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 26.4 ptm . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.105 0.478 . . . . 0.0 110.168 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.972 ' CZ ' ' HB1' ' B' ' 87' ' ' ALA . 8.0 p90 -179.27 143.62 0.21 Allowed 'General case' 0 C--N 1.307 -1.26 0 O-C-N 121.231 -0.918 . . . . 0.0 108.733 176.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.509 ' O ' HG13 ' A' ' 5' ' ' ILE . 73.7 p -135.72 -41.48 0.69 Allowed 'General case' 0 C--N 1.293 -1.853 0 O-C-N 120.959 -1.088 . . . . 0.0 108.55 179.721 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.476 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 49.67 22.77 4.34 Favored Glycine 0 N--CA 1.482 1.718 0 N-CA-C 108.454 -1.858 . . . . 0.0 108.454 -175.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.532 HD11 HC82 ' B' ' 99' ' ' RBF . 57.2 mt -84.59 120.26 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.208 -1.172 . . . . 0.0 110.116 -176.647 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.834 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.4 t -72.55 149.97 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.292 -0.88 . . . . 0.0 110.611 -175.426 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.425 ' OE1' ' HG2' ' A' ' 86' ' ' ARG . 18.2 pt20 -93.34 -23.81 18.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.55 -0.719 . . . . 0.0 110.787 179.266 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.538 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -150.52 173.99 29.98 Favored Glycine 0 N--CA 1.493 2.487 0 C-N-CA 119.328 -1.415 . . . . 0.0 109.758 -175.485 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.478 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 2.2 p -123.37 170.83 9.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.845 -1.386 . . . . 0.0 110.981 -177.436 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.014 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -139.33 149.46 44.22 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.562 -0.711 . . . . 0.0 109.259 -179.649 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.575 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 33.3 tttt -106.73 115.43 30.19 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 120.908 -1.12 . . . . 0.0 110.254 179.535 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 1.014 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.2 tp -58.55 127.19 30.91 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 120.82 -1.175 . . . . 0.0 108.688 173.329 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.145 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.6 p -130.05 -30.14 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.898 0 O-C-N 121.345 -0.847 . . . . 0.0 109.946 -177.844 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -145.1 140.44 28.04 Favored 'General case' 0 N--CA 1.494 1.735 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.974 -179.439 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.778 HG23 ' CD2' ' A' ' 24' ' ' HIS . 13.9 mt -107.53 131.11 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 120.991 -1.068 . . . . 0.0 110.185 172.339 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.512 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.7 m-20 -108.53 114.87 29.04 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.384 -0.823 . . . . 0.0 109.873 174.692 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -107.11 112.38 25.27 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.002 -1.061 . . . . 0.0 110.522 -176.129 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 6.1 mtmt -107.94 129.93 23.48 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.219 -0.926 . . . . 0.0 109.177 175.24 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_endo -51.85 -24.47 18.73 Favored 'Trans proline' 0 C--N 1.303 -1.864 0 O-C-N 123.779 1.41 . . . . 0.0 110.279 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 7.8 m120 -81.2 -39.74 24.95 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.24 -0.913 . . . . 0.0 110.182 175.417 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 95.1 m-85 -156.68 150.22 24.52 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.433 -0.792 . . . . 0.0 109.971 -178.873 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.493 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 59.6 ttt180 -91.93 145.13 24.79 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.807 -1.183 . . . . 0.0 110.327 178.771 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.512 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 74.9 m -129.98 140.02 50.97 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.583 -0.698 . . . . 0.0 109.718 -176.156 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.778 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -128.74 128.32 43.79 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.858 -1.152 . . . . 0.0 111.324 178.184 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.823 HG22 ' OG ' ' A' ' 60' ' ' SER . 4.3 t -104.95 131.42 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.283 -0.886 . . . . 0.0 110.695 -178.108 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.495 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 33.4 m -115.91 168.16 7.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 O-C-N 121.962 -0.461 . . . . 0.0 109.963 179.427 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.526 ' OE2' ' ND2' ' A' ' 57' ' ' ASN . 2.5 tm-20 -101.11 115.31 30.19 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.305 -0.872 . . . . 0.0 109.409 178.538 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.785 HD21 HD13 ' A' ' 36' ' ' LEU . 9.8 tp -79.15 125.33 83.74 Favored Pre-proline 0 C--N 1.295 -1.804 0 O-C-N 121.617 -0.677 . . . . 0.0 109.868 -176.543 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.536 ' HD2' HD12 ' A' ' 28' ' ' LEU . 27.7 Cg_endo -67.5 -179.16 1.79 Allowed 'Trans proline' 0 C--N 1.309 -1.552 0 O-C-N 123.894 1.471 . . . . 0.0 110.826 -179.54 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 31' ' ' HIS . 32.3 p-10 -64.85 -40.02 94.5 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.322 -0.861 . . . . 0.0 110.952 -175.56 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.01 1.32 56.44 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.939 -1.101 . . . . 0.0 110.987 -174.037 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.597 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 98.7 mmm -112.17 -14.14 13.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.854 -1.154 . . . . 0.0 109.871 171.411 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.581 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 19.2 mt -69.93 -20.38 63.34 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.39 -0.818 . . . . 0.0 110.437 176.203 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -61.0 123.05 16.5 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.088 -1.007 . . . . 0.0 111.286 -171.276 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 48.92 54.72 13.29 Favored Glycine 0 N--CA 1.493 2.498 0 C-N-CA 120.339 -0.934 . . . . 0.0 111.015 169.749 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.802 HD23 ' N ' ' A' ' 37' ' ' GLU . 6.4 tt -113.25 155.44 25.07 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.83 -1.394 . . . . 0.0 110.181 174.131 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.802 ' N ' HD23 ' A' ' 36' ' ' LEU . 21.3 pt-20 -149.95 167.85 25.48 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.221 -0.924 . . . . 0.0 110.139 -178.207 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' THR . . . . . 1.038 HG23 HD12 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -68.09 155.27 39.92 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.212 -0.93 . . . . 0.0 109.754 177.539 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.56 -8.86 63.63 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.744 -1.343 . . . . 0.0 109.744 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.669 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -75.37 159.91 30.88 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.11 -1.229 . . . . 0.0 109.753 178.126 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.45 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -105.2 120.2 40.95 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.831 -1.168 . . . . 0.0 110.309 -179.416 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.573 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.6 t -109.95 132.51 58.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.328 -0.858 . . . . 0.0 109.193 172.74 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.51 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -92.38 119.95 32.42 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.145 -0.972 . . . . 0.0 109.337 172.59 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.786 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -89.83 106.92 18.79 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.402 -0.811 . . . . 0.0 109.109 177.865 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.644 ' ND2' ' HB2' ' B' ' 47' ' ' CYS . 0.9 OUTLIER 52.57 17.59 0.82 Allowed 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.39 -0.819 . . . . 0.0 110.503 -166.5 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.506 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 116.35 -4.81 19.77 Favored Glycine 0 N--CA 1.487 2.084 0 C-N-CA 119.64 -1.267 . . . . 0.0 110.831 170.219 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.758 ' O ' HD23 ' A' ' 49' ' ' LEU . 17.3 t -90.08 109.84 20.87 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.345 -1.679 . . . . 0.0 109.084 174.491 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.436 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 27.5 p -77.68 124.89 28.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.996 -1.065 . . . . 0.0 110.691 -172.397 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.967 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -136.85 166.38 23.74 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.353 -0.842 . . . . 0.0 108.945 172.128 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.457 ' O ' ' OD1' ' A' ' 62' ' ' ASP . 54.9 m -103.13 154.18 19.56 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.574 -1.329 . . . . 0.0 111.146 -169.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.82 HG13 HG13 ' A' ' 59' ' ' VAL . 7.0 t -74.67 113.26 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.899 -0.5 . . . . 0.0 110.034 -179.294 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.616 HG22 ' HB3' ' A' ' 62' ' ' ASP . 19.0 p -75.3 -43.59 50.21 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.365 -0.835 . . . . 0.0 109.57 176.209 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.463 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -158.36 150.53 21.77 Favored 'General case' 0 N--CA 1.491 1.621 0 C-N-CA 119.576 -0.85 . . . . 0.0 110.335 179.246 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 1.038 HD12 HG23 ' A' ' 38' ' ' THR . 2.5 mp -108.18 132.3 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.225 -0.922 . . . . 0.0 110.304 175.975 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.485 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 54.9 m-80 -108.26 66.24 0.65 Allowed 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.662 -0.649 . . . . 0.0 109.541 177.824 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.44 -119.36 5.79 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 108.794 -1.722 . . . . 0.0 108.794 -173.112 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.581 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -77.12 -17.71 58.46 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.016 -1.285 . . . . 0.0 109.009 176.084 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.145 ' CE1' HG11 ' A' ' 13' ' ' VAL . 20.8 m-70 -77.57 160.09 28.82 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.312 -0.867 . . . . 0.0 110.419 -178.447 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.82 HG13 HG13 ' A' ' 51' ' ' VAL . 94.1 t -145.16 117.83 2.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 C-N-CA 119.379 -0.928 . . . . 0.0 110.879 175.423 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.823 ' OG ' HG22 ' A' ' 25' ' ' VAL . 19.6 m -81.92 125.3 30.58 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.529 -0.732 . . . . 0.0 109.592 175.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.967 ' HB3' HD12 ' A' ' 49' ' ' LEU . 82.9 m-85 -110.03 154.78 22.73 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.898 -1.127 . . . . 0.0 110.23 178.73 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.616 ' HB3' HG22 ' A' ' 52' ' ' THR . 9.1 p-10 -89.54 148.18 23.53 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.132 -0.98 . . . . 0.0 111.265 -176.922 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.703 ' CD2' HD12 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -159.16 102.2 1.6 Allowed 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.705 -0.622 . . . . 0.0 109.485 -175.363 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.498 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 54.5 ttm -59.98 140.16 56.93 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.892 -1.13 . . . . 0.0 109.47 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.483 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 22.0 tptm -60.05 -43.45 95.38 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.027 -1.046 . . . . 0.0 110.315 -174.472 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.68 -39.96 76.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.974 -1.079 . . . . 0.0 110.012 177.695 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.566 HG21 ' O2 ' ' A' ' 98' ' ' RBF . 93.7 m -60.95 -38.39 85.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.996 -1.065 . . . . 0.0 109.294 173.135 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.703 HD12 ' CD2' ' A' ' 63' ' ' LEU . 7.1 tp -59.96 -45.71 91.8 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.325 -0.859 . . . . 0.0 109.746 178.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 76.5 ttt-85 -69.32 -39.67 78.07 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.428 -0.795 . . . . 0.0 110.438 177.739 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.772 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -64.65 -41.57 92.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.171 -0.955 . . . . 0.0 109.434 -176.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.772 HG23 HG22 ' A' ' 70' ' ' ILE . 42.0 p -85.25 -174.62 5.33 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 175.906 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.481 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 2.6 t30 -101.11 21.82 13.29 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 171.624 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.691 ' HB3' HD21 ' A' ' 63' ' ' LEU . 41.9 mt -69.99 -40.05 75.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.012 -1.055 . . . . 0.0 110.304 175.122 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.664 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -48.62 -22.29 2.6 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 -178.548 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.4 p-10 -66.11 -16.49 64.0 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.137 -1.213 . . . . 0.0 110.588 -174.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 94.7 mt -59.99 141.44 55.61 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.276 -0.89 . . . . 0.0 110.763 -176.232 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 1.014 ' C ' HD23 ' A' ' 12' ' ' LEU . 95.1 mttt -140.0 139.77 36.1 Favored 'General case' 0 N--CA 1.493 1.678 0 CA-C-O 121.337 0.589 . . . . 0.0 109.444 174.202 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.72 HG23 HD11 ' A' ' 15' ' ' ILE . 16.4 t -60.51 152.45 5.39 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 120.788 -1.195 . . . . 0.0 110.383 -176.225 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.0 -15.56 57.66 Favored Glycine 0 N--CA 1.484 1.86 0 N-CA-C 108.811 -1.716 . . . . 0.0 108.811 -176.045 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 9.2 t0 -95.28 165.51 12.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.347 -1.09 . . . . 0.0 109.689 175.93 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.575 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.5 m95 -114.55 157.2 23.33 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.058 -1.027 . . . . 0.0 110.202 177.504 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.014 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.3 p -120.04 149.34 22.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.429 -0.795 . . . . 0.0 109.843 -179.18 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.834 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -75.79 104.36 6.3 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.021 -1.049 . . . . 0.0 109.43 169.286 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.67 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -106.21 137.76 34.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 120.459 -1.401 . . . . 0.0 111.392 -176.943 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.421 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.5 tt0 -130.06 144.86 51.57 Favored 'General case' 0 N--CA 1.495 1.78 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.986 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.458 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 34.0 ptt180 -81.45 133.67 35.44 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.261 -0.899 . . . . 0.0 111.024 -176.235 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.864 ' HB1' ' CZ ' ' B' ' 2' ' ' PHE . . . -131.94 145.76 51.69 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.429 -0.794 . . . . 0.0 110.176 175.864 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -131.43 130.66 42.8 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.509 -0.744 . . . . 0.0 110.534 -176.538 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 38.1 mttt -60.09 -39.99 88.05 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.373 -0.829 . . . . 0.0 110.46 -179.174 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 51.7 p90 -153.01 159.94 42.95 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.198 -0.939 . . . . 0.0 110.54 -179.028 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 88.3 p -132.81 149.23 52.29 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.282 -0.886 . . . . 0.0 110.087 177.86 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 57.1 t0 -70.1 -50.89 36.3 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.194 -0.941 . . . . 0.0 110.373 -179.219 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.48 ' O ' ' HG3' ' A' ' 93' ' ' GLU . 19.4 pt-20 -167.02 68.09 0.09 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.179 -0.951 . . . . 0.0 111.145 -175.111 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.578 HG22 ' H ' ' A' ' 97' ' ' HIS . 33.0 mm -59.97 -45.37 95.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 120.9 -1.125 . . . . 0.0 109.875 174.834 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 94' ' ' ILE . . . 40.89 69.56 0.49 Allowed Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 176.559 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 70.51 19.93 76.67 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.876 -1.29 . . . . 0.0 109.876 176.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.578 ' H ' HG22 ' A' ' 94' ' ' ILE . 11.6 t-80 . . . . . 0 N--CA 1.492 1.626 0 O-C-N 121.182 -1.187 . . . . 0.0 110.09 178.596 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 75.2 mtm . . . . . 0 N--CA 1.495 1.776 0 CA-C-O 122.232 1.015 . . . . 0.0 109.977 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.864 ' CZ ' ' HB1' ' A' ' 87' ' ' ALA . 8.5 p90 -174.13 143.5 0.91 Allowed 'General case' 0 C--N 1.282 -2.361 0 CA-C-N 115.154 -0.93 . . . . 0.0 108.494 172.92 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.501 ' O ' HG13 ' B' ' 5' ' ' ILE . 71.7 p -135.65 -41.45 0.69 Allowed 'General case' 0 C--N 1.295 -1.795 0 O-C-N 120.904 -1.122 . . . . 0.0 108.633 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.488 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 49.72 22.78 4.43 Favored Glycine 0 N--CA 1.481 1.652 0 N-CA-C 108.466 -1.853 . . . . 0.0 108.466 -176.054 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 0.55 HG23 " O4'" ' A' ' 98' ' ' RBF . 56.7 mt -84.67 120.28 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.238 -1.154 . . . . 0.0 110.092 -176.63 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.835 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.4 t -72.51 150.08 8.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.435 -0.791 . . . . 0.0 110.628 -175.45 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.424 ' OE1' ' HG2' ' B' ' 86' ' ' ARG . 18.2 pt20 -93.48 -23.61 18.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.508 -0.745 . . . . 0.0 110.834 179.264 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.536 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -150.62 173.87 30.09 Favored Glycine 0 N--CA 1.493 2.498 0 C-N-CA 119.396 -1.383 . . . . 0.0 109.911 -175.553 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.479 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 2.2 p -123.3 170.83 9.9 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.001 -1.293 . . . . 0.0 110.932 -177.386 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.055 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -139.33 149.54 44.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.592 -0.693 . . . . 0.0 109.165 -179.634 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.58 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 33.4 tttt -106.82 115.58 30.43 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.045 -1.034 . . . . 0.0 110.139 179.554 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 1.014 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.2 tp -58.84 127.09 30.47 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.013 -1.054 . . . . 0.0 108.721 173.351 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.154 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.6 p -129.83 -30.27 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.983 0 O-C-N 121.421 -0.8 . . . . 0.0 110.031 -177.783 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -145.14 140.46 28.0 Favored 'General case' 0 C--N 1.297 -1.676 0 C-N-CA 119.499 -0.881 . . . . 0.0 110.979 -179.46 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.784 HG23 ' CD2' ' B' ' 24' ' ' HIS . 13.9 mt -107.51 131.01 58.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 120.918 -1.114 . . . . 0.0 110.266 172.357 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.52 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 77.6 m-20 -108.63 114.94 29.15 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.451 -0.781 . . . . 0.0 109.919 174.728 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 87.1 tt0 -107.0 112.31 25.2 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.1 -1.0 . . . . 0.0 110.524 -176.04 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 6.1 mtmt -107.86 129.94 23.47 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.229 -0.919 . . . . 0.0 109.241 175.143 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.5 Cg_endo -51.9 -24.44 18.9 Favored 'Trans proline' 0 C--N 1.303 -1.833 0 O-C-N 123.73 1.384 . . . . 0.0 110.187 -179.861 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.554 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 7.7 m120 -81.18 -40.03 24.54 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.206 -0.934 . . . . 0.0 110.127 175.411 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.554 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 95.2 m-85 -156.41 150.33 25.04 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.456 -0.778 . . . . 0.0 109.964 -178.87 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.485 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 59.6 ttt180 -91.95 145.07 24.83 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.884 -1.135 . . . . 0.0 110.327 178.754 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.52 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 78.3 m -130.02 139.98 50.94 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.677 -0.64 . . . . 0.0 109.757 -176.183 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.784 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -128.54 128.34 44.11 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.94 -1.1 . . . . 0.0 111.322 178.319 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.803 HG22 ' OG ' ' B' ' 60' ' ' SER . 4.3 t -104.94 131.65 53.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.384 -0.822 . . . . 0.0 110.638 -178.135 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.504 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 33.5 m -116.22 168.09 8.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.973 -0.455 . . . . 0.0 109.788 179.546 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.528 ' OE2' ' ND2' ' B' ' 57' ' ' ASN . 2.5 tm-20 -101.05 115.42 30.45 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.27 -0.894 . . . . 0.0 109.409 178.468 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.763 HD21 HD13 ' B' ' 36' ' ' LEU . 9.8 tp -79.2 125.3 83.68 Favored Pre-proline 0 C--N 1.296 -1.753 0 O-C-N 121.538 -0.727 . . . . 0.0 109.878 -176.546 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.541 ' HD2' HD12 ' B' ' 28' ' ' LEU . 27.9 Cg_endo -67.49 -179.23 1.83 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.788 1.415 . . . . 0.0 110.806 -179.538 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' B' ' 31' ' ' HIS . 32.2 p-10 -64.85 -39.97 94.41 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.384 -0.823 . . . . 0.0 110.94 -175.49 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.6 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.99 1.25 56.51 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.886 -1.134 . . . . 0.0 110.954 -174.01 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.6 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 98.6 mmm -112.19 -14.12 13.42 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.902 -1.124 . . . . 0.0 109.881 171.479 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.586 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 19.6 mt -69.96 -20.31 63.33 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.398 -0.814 . . . . 0.0 110.484 176.17 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -61.03 123.0 16.37 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.117 -0.989 . . . . 0.0 111.263 -171.262 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 48.95 54.84 12.89 Favored Glycine 0 N--CA 1.493 2.448 0 O-C-N 121.208 -0.932 . . . . 0.0 110.927 169.675 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.793 HD23 ' N ' ' B' ' 37' ' ' GLU . 6.4 tt -113.34 155.52 25.03 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.728 -1.454 . . . . 0.0 110.091 174.15 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 37' ' ' GLU . . . . . 0.793 ' N ' HD23 ' B' ' 36' ' ' LEU . 21.3 pt-20 -150.06 167.77 25.82 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.106 -0.996 . . . . 0.0 110.203 -178.211 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.998 HG23 HD12 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -67.99 155.15 40.1 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.309 -0.869 . . . . 0.0 109.811 177.55 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.62 -8.82 64.0 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.549 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.679 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -75.57 159.81 30.84 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.144 -1.21 . . . . 0.0 109.762 178.101 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.436 ' OG ' ' O ' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -104.97 119.93 40.22 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.882 -1.136 . . . . 0.0 110.467 -179.357 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.565 ' HB ' ' CE1' ' B' ' 61' ' ' PHE . 1.6 t -109.94 132.6 57.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.424 -0.797 . . . . 0.0 109.219 172.754 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.511 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -92.34 120.04 32.49 Favored 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.133 -0.98 . . . . 0.0 109.407 172.532 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.783 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -89.85 107.03 18.86 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.382 -0.824 . . . . 0.0 109.074 177.832 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.611 ' ND2' ' HB2' ' A' ' 47' ' ' CYS . 0.8 OUTLIER 52.5 17.63 0.81 Allowed 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.348 -0.845 . . . . 0.0 110.535 -166.558 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.506 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 116.26 -4.69 19.98 Favored Glycine 0 N--CA 1.488 2.127 0 C-N-CA 119.626 -1.273 . . . . 0.0 110.864 170.192 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.747 ' O ' HD23 ' B' ' 49' ' ' LEU . 17.2 t -90.09 109.78 20.82 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.294 -1.709 . . . . 0.0 109.13 174.423 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 48' ' ' CYS . . . . . 0.442 ' O ' ' SG ' ' B' ' 48' ' ' CYS . 27.6 p -77.6 124.93 28.57 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.937 -1.102 . . . . 0.0 110.742 -172.473 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 0.974 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -136.92 166.27 24.02 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.381 -0.825 . . . . 0.0 108.943 172.114 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 50' ' ' THR . . . . . 0.456 ' O ' ' OD1' ' B' ' 62' ' ' ASP . 55.5 m -102.94 154.33 19.33 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.633 -1.292 . . . . 0.0 111.201 -169.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.819 HG13 HG13 ' B' ' 59' ' ' VAL . 7.1 t -74.88 113.29 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 CA-C-O 121.249 0.547 . . . . 0.0 110.053 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.595 HG22 ' HB3' ' B' ' 62' ' ' ASP . 19.0 p -75.29 -43.49 50.78 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.292 -0.88 . . . . 0.0 109.599 176.258 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.478 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -158.5 150.46 21.45 Favored 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.391 179.204 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.998 HD12 HG23 ' B' ' 38' ' ' THR . 2.5 mp -108.14 132.33 56.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.209 -0.932 . . . . 0.0 110.295 176.087 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.502 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 54.7 m-80 -108.33 66.19 0.64 Allowed 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 120.168 -0.613 . . . . 0.0 109.495 177.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.57 -119.31 5.74 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 -173.127 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.586 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -77.17 -17.85 58.26 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.965 -1.315 . . . . 0.0 108.946 176.112 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.154 ' CE1' HG11 ' B' ' 13' ' ' VAL . 20.7 m-70 -77.49 160.02 28.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.468 -0.77 . . . . 0.0 110.436 -178.453 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.819 HG13 HG13 ' B' ' 51' ' ' VAL . 94.3 t -145.1 117.79 2.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 C-N-CA 119.329 -0.949 . . . . 0.0 110.874 175.527 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.803 ' OG ' HG22 ' B' ' 25' ' ' VAL . 19.7 m -82.03 125.36 30.72 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.618 -0.676 . . . . 0.0 109.622 176.037 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.974 ' HB3' HD12 ' B' ' 49' ' ' LEU . 83.0 m-85 -110.0 154.88 22.55 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 120.915 -1.116 . . . . 0.0 110.25 178.708 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.595 ' HB3' HG22 ' B' ' 52' ' ' THR . 9.1 p-10 -89.57 148.29 23.46 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 120.984 -1.072 . . . . 0.0 111.192 -176.905 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.718 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.22 102.11 1.59 Allowed 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 -175.361 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.502 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 54.5 ttm -59.99 140.15 56.95 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.968 -1.082 . . . . 0.0 109.476 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.482 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 22.0 tptm -60.04 -43.37 95.39 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.118 -0.989 . . . . 0.0 110.4 -174.456 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.67 -39.97 76.69 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.034 -1.041 . . . . 0.0 110.149 177.612 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.567 HG21 ' O2 ' ' B' ' 99' ' ' RBF . 93.1 m -60.77 -38.6 85.81 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.97 -1.081 . . . . 0.0 109.329 173.002 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.701 HD12 ' CD2' ' B' ' 63' ' ' LEU . 7.1 tp -59.95 -45.45 92.59 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.324 -0.86 . . . . 0.0 109.89 178.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 76.5 ttt-85 -69.41 -39.63 77.8 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.526 -0.734 . . . . 0.0 110.451 177.66 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.741 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -64.72 -41.48 92.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.302 -0.873 . . . . 0.0 109.486 -176.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.741 HG23 HG22 ' B' ' 70' ' ' ILE . 40.7 p -85.1 -174.52 5.3 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.279 175.813 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.47 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 2.7 t30 -101.1 21.8 13.31 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 171.482 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.718 ' HB3' HD21 ' B' ' 63' ' ' LEU . 41.3 mt -70.06 -39.95 75.36 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.07 -1.019 . . . . 0.0 110.232 175.239 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.659 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -48.7 -22.36 2.72 Favored Glycine 0 N--CA 1.486 1.98 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -178.505 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.2 p-10 -65.93 -16.52 63.94 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.161 -1.199 . . . . 0.0 110.624 -174.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 94.2 mt -60.01 141.4 55.73 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.126 -0.984 . . . . 0.0 110.829 -176.217 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 1.014 ' C ' HD23 ' B' ' 12' ' ' LEU . 95.1 mttt -139.96 139.82 36.18 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.734 -0.604 . . . . 0.0 109.397 174.196 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.733 HG23 HD11 ' B' ' 15' ' ' ILE . 16.4 t -60.55 152.46 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.989 -1.069 . . . . 0.0 110.357 -176.205 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.88 -15.25 58.19 Favored Glycine 0 N--CA 1.484 1.846 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 -176.088 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.481 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 9.1 t0 -95.44 165.32 12.42 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.402 -1.058 . . . . 0.0 109.706 175.768 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.58 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.6 m95 -114.46 157.24 23.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.147 -0.971 . . . . 0.0 110.288 177.441 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.055 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.3 p -120.06 149.34 22.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.688 -0.632 . . . . 0.0 109.871 -179.181 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.835 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.2 OUTLIER -75.78 104.18 6.21 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.084 -1.01 . . . . 0.0 109.526 169.26 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.676 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -106.09 137.83 34.41 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.459 -1.401 . . . . 0.0 111.38 -176.812 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 85' ' ' GLU . . . . . 0.418 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.4 tt0 -130.2 144.92 51.64 Favored 'General case' 0 N--CA 1.493 1.712 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.005 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 86' ' ' ARG . . . . . 0.461 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 34.1 ptt180 -81.53 133.72 35.42 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.206 -0.934 . . . . 0.0 110.93 -176.11 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 0.972 ' HB1' ' CZ ' ' A' ' 2' ' ' PHE . . . -131.93 145.78 51.71 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.355 -0.841 . . . . 0.0 110.08 175.87 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -131.57 130.4 42.19 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.519 -0.738 . . . . 0.0 110.553 -176.468 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 38.1 mttt -59.94 -40.03 87.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.432 -0.792 . . . . 0.0 110.402 -178.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 51.7 p90 -152.97 159.99 42.98 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.29 -0.881 . . . . 0.0 110.497 -178.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 91' ' ' SER . . . . . 0.535 ' HB2' ' CG1' ' B' ' 94' ' ' ILE . 88.4 p -132.96 149.13 52.26 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.366 -0.834 . . . . 0.0 110.098 177.836 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 92' ' ' ASP . . . . . 0.438 ' O ' ' HG2' ' B' ' 93' ' ' GLU . 57.1 t0 -70.03 -46.75 64.37 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.184 -0.948 . . . . 0.0 110.46 -179.183 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 93' ' ' GLU . . . . . 0.438 ' HG2' ' O ' ' B' ' 92' ' ' ASP . 78.0 mm-40 -153.97 47.61 0.63 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.233 -0.917 . . . . 0.0 110.307 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 94' ' ' ILE . . . . . 0.535 ' CG1' ' HB2' ' B' ' 91' ' ' SER . 36.6 mm -95.05 -34.66 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.454 -0.779 . . . . 0.0 110.528 177.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 93.16 -97.56 2.26 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 -176.833 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 96' ' ' GLY . . . . . 0.437 ' O ' ' HB3' ' B' ' 97' ' ' HIS . . . -94.78 -54.18 1.56 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 178.864 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 97' ' ' HIS . . . . . 0.437 ' HB3' ' O ' ' B' ' 96' ' ' GLY . 25.0 p-80 . . . . . 0 N--CA 1.492 1.643 0 O-C-N 121.244 -1.151 . . . . 0.0 110.167 -179.365 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 0.566 ' O2 ' HG21 ' A' ' 67' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 0.567 ' O2 ' HG21 ' B' ' 67' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.552 ' CE ' HD13 ' B' ' 94' ' ' ILE . 63.9 mtt . . . . . 0 N--CA 1.496 1.859 0 CA-C-O 121.138 0.495 . . . . 0.0 110.1 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 1.001 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 6.4 p90 -170.06 156.18 5.88 Favored 'General case' 0 C--N 1.306 -1.29 0 O-C-N 121.108 -0.995 . . . . 0.0 108.985 175.098 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.613 HG23 ' C ' ' A' ' 2' ' ' PHE . 75.8 p -154.17 -41.73 0.09 Allowed 'General case' 0 C--N 1.292 -1.901 0 O-C-N 121.151 -0.968 . . . . 0.0 108.483 176.594 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.477 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 50.98 21.03 4.87 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 108.436 -1.866 . . . . 0.0 108.436 -176.148 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.57 HD11 ' C8M' ' B' ' 99' ' ' RBF . 60.3 mt -81.85 130.71 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.281 -1.129 . . . . 0.0 109.82 -176.689 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.846 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.0 t -86.26 140.82 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.188 -0.945 . . . . 0.0 111.108 -169.789 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 27.8 mm100 -70.0 -36.32 75.04 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.793 -0.567 . . . . 0.0 110.686 177.254 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -155.24 169.11 33.19 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.029 -1.558 . . . . 0.0 110.187 -173.569 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.437 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 0.7 OUTLIER -108.91 172.39 6.87 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.081 -1.246 . . . . 0.0 111.104 -176.167 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.039 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -139.46 148.54 42.87 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -178.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 20.8 tttt -106.42 117.01 32.92 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 120.993 -1.067 . . . . 0.0 110.149 178.759 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.992 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.0 tp -59.81 127.65 33.02 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 120.831 -1.168 . . . . 0.0 108.756 172.563 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.08 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.5 p -126.72 -30.85 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 C-N-CA 119.596 -0.842 . . . . 0.0 110.032 -178.215 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.13 142.56 27.48 Favored 'General case' 0 N--CA 1.494 1.762 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.361 -178.403 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.726 HG23 ' NE2' ' A' ' 24' ' ' HIS . 10.3 mt -109.46 133.78 53.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.186 -0.946 . . . . 0.0 110.191 172.92 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.515 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 83.8 m-20 -109.88 114.29 27.72 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.377 -0.827 . . . . 0.0 110.129 176.072 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.25 112.69 25.03 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.018 -1.051 . . . . 0.0 110.556 -177.284 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.0 OUTLIER -107.43 133.22 20.46 Favored Pre-proline 0 N--CA 1.492 1.661 0 O-C-N 121.186 -0.946 . . . . 0.0 109.372 174.915 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -51.99 -25.1 21.12 Favored 'Trans proline' 0 C--N 1.302 -1.869 0 O-C-N 123.859 1.452 . . . . 0.0 110.35 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.567 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 8.8 m-80 -86.2 -35.76 19.87 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.25 -0.906 . . . . 0.0 110.272 177.708 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.567 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 95.4 m-85 -157.17 150.24 23.71 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.407 -0.808 . . . . 0.0 110.244 -176.382 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.795 ' HD3' HD22 ' A' ' 68' ' ' LEU . 61.6 ttt180 -86.2 144.26 27.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.783 -1.198 . . . . 0.0 110.085 175.218 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.515 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 85.3 m -130.6 140.01 50.42 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.499 -0.751 . . . . 0.0 109.668 -175.676 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.726 ' NE2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.98 141.27 50.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.776 -1.203 . . . . 0.0 111.546 -178.433 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.843 HG22 ' OG ' ' A' ' 60' ' ' SER . 12.8 t -120.98 135.05 62.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.118 -0.989 . . . . 0.0 110.656 -179.152 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.879 HG13 ' CE1' ' A' ' 61' ' ' PHE . 21.4 m -117.46 171.96 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.738 -0.601 . . . . 0.0 110.246 178.16 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.572 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 12.8 tt0 -106.3 116.87 32.67 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.922 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.884 ' CD2' HD22 ' A' ' 36' ' ' LEU . 9.6 tp -90.73 130.93 39.19 Favored Pre-proline 0 C--N 1.296 -1.747 0 O-C-N 121.203 -0.936 . . . . 0.0 110.521 -171.295 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.472 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 30.7 Cg_endo -68.05 176.91 4.84 Favored 'Trans proline' 0 C--N 1.308 -1.605 0 O-C-N 124.015 1.534 . . . . 0.0 111.053 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -60.55 -39.92 89.71 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.429 -0.795 . . . . 0.0 111.401 -175.187 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.602 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.89 0.03 57.29 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.8 -1.188 . . . . 0.0 110.755 -174.078 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.602 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.9 mmm -110.67 -16.14 13.69 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.95 -1.094 . . . . 0.0 109.638 169.793 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.597 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 29.6 mt -71.2 -24.86 62.3 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.313 -0.867 . . . . 0.0 109.863 174.386 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ASP . . . . . 0.476 ' O ' ' N ' ' A' ' 36' ' ' LEU . 38.6 p-10 -71.16 162.25 29.74 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.467 -0.771 . . . . 0.0 110.94 -173.104 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.428 ' C ' ' O ' ' A' ' 34' ' ' ASP . . . 37.54 27.69 0.03 OUTLIER Glycine 0 N--CA 1.494 2.522 0 O-C-N 121.504 -0.747 . . . . 0.0 111.605 174.295 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.884 HD22 ' CD2' ' A' ' 28' ' ' LEU . 60.8 tp -101.21 158.45 16.02 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 120.537 -1.566 . . . . 0.0 110.919 179.025 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 21.5 pt-20 -160.04 161.09 33.9 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.566 -0.709 . . . . 0.0 109.428 177.49 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.817 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -66.84 154.42 40.96 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.043 -1.035 . . . . 0.0 109.526 175.779 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.39 -9.45 61.43 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.257 -1.537 . . . . 0.0 109.257 -176.631 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.505 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -69.87 153.21 43.6 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.135 -1.215 . . . . 0.0 109.627 177.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.529 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -97.35 104.53 16.56 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 120.966 -1.084 . . . . 0.0 109.906 178.117 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.414 ' CG1' ' HD1' ' A' ' 44' ' ' HIS . 1.6 t -87.87 137.54 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.239 -0.913 . . . . 0.0 109.027 174.526 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.484 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -102.96 120.12 40.06 Favored 'General case' 0 C--N 1.295 -1.781 0 O-C-N 120.865 -1.147 . . . . 0.0 109.535 170.167 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.806 ' CD2' HG21 ' A' ' 82' ' ' VAL . 1.2 m80 -87.45 101.02 13.19 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 176.12 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.0 t-20 58.55 8.88 0.95 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.575 -0.703 . . . . 0.0 111.399 -169.94 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.449 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 124.62 -3.19 8.73 Favored Glycine 0 N--CA 1.489 2.167 0 C-N-CA 119.674 -1.25 . . . . 0.0 110.617 174.344 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.815 ' O ' HD23 ' A' ' 49' ' ' LEU . 19.7 t -90.34 107.39 19.12 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.334 -1.686 . . . . 0.0 109.2 174.623 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 23.5 p -78.12 125.55 29.51 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.127 -0.983 . . . . 0.0 110.768 -170.817 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.941 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -142.57 160.16 40.83 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.508 -0.745 . . . . 0.0 109.592 176.051 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 27.6 m -99.51 149.15 23.53 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.715 -1.24 . . . . 0.0 111.378 -169.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.96 HG13 HG13 ' A' ' 59' ' ' VAL . 16.9 t -75.16 114.62 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.739 -0.6 . . . . 0.0 110.273 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.527 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 47.3 p -70.29 -40.0 74.55 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.299 -0.875 . . . . 0.0 109.947 174.214 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.587 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -162.78 154.5 18.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.344 -0.847 . . . . 0.0 110.23 -179.344 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.817 HD11 ' N ' ' A' ' 38' ' ' THR . 5.5 mt -105.55 130.01 57.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.012 -1.055 . . . . 0.0 109.888 175.201 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.524 ' HB2' ' CB ' ' A' ' 58' ' ' HIS . 9.6 m-80 -101.66 61.94 0.91 Allowed 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.614 -0.678 . . . . 0.0 109.691 178.858 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.79 -114.72 4.16 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 108.743 -1.743 . . . . 0.0 108.743 -173.687 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.597 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -78.54 -19.97 51.72 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.024 -1.28 . . . . 0.0 108.807 174.374 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.08 ' CE1' HG11 ' A' ' 13' ' ' VAL . 18.9 m-70 -75.29 160.04 30.79 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.459 -0.776 . . . . 0.0 110.116 -177.222 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.96 HG13 HG13 ' A' ' 51' ' ' VAL . 54.6 t -140.14 121.99 15.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 O-C-N 120.957 -1.089 . . . . 0.0 110.711 171.059 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.843 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.1 t -87.75 133.69 33.81 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.522 -0.736 . . . . 0.0 109.287 174.729 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.941 ' HB2' HD12 ' A' ' 49' ' ' LEU . 1.3 p90 -126.85 154.07 44.85 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 121.43 -0.793 . . . . 0.0 110.225 178.554 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.527 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 31.4 p-10 -88.72 147.77 24.32 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.004 -1.06 . . . . 0.0 111.399 -170.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.822 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -154.47 113.66 3.69 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 -176.186 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.527 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 56.9 ttm -69.96 140.61 53.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.794 -1.191 . . . . 0.0 109.449 -179.382 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.484 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 36.4 tptt -60.01 -49.23 78.5 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.995 -1.066 . . . . 0.0 110.299 -175.1 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.41 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 88.6 tt0 -65.48 -40.01 92.62 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.901 -1.124 . . . . 0.0 110.129 178.162 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.527 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 60.8 m -62.76 -38.13 89.34 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.902 -1.124 . . . . 0.0 109.426 174.238 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.795 HD22 ' HD3' ' A' ' 22' ' ' ARG . 14.7 tp -60.05 -41.58 92.61 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.14 -0.975 . . . . 0.0 109.225 177.325 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.525 ' NH1' ' HB3' ' A' ' 69' ' ' ARG . 6.4 mmm180 -69.96 -38.85 76.24 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.466 -0.771 . . . . 0.0 110.433 174.012 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.828 HG22 HG23 ' A' ' 71' ' ' THR . 1.1 tt -67.97 -40.43 83.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.327 -0.858 . . . . 0.0 109.412 -176.574 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.828 HG23 HG22 ' A' ' 70' ' ' ILE . 59.1 p -87.49 -171.56 3.51 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.339 0.59 . . . . 0.0 109.764 179.083 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.467 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 8.3 t30 -99.92 18.75 17.6 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.338 -0.852 . . . . 0.0 108.865 170.194 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.822 ' HB3' HD21 ' A' ' 63' ' ' LEU . 70.2 mt -68.33 -40.02 81.77 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.931 -1.106 . . . . 0.0 109.749 174.829 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.515 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -47.06 -22.55 1.3 Allowed Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 -179.702 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.3 p-10 -67.91 -17.18 64.39 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.975 -1.309 . . . . 0.0 110.419 -175.351 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 95.5 mt -63.51 142.11 58.51 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.223 -0.923 . . . . 0.0 110.917 -176.243 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 0.992 ' C ' HD23 ' A' ' 12' ' ' LEU . 46.1 mttt -142.65 142.73 32.12 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.733 -0.604 . . . . 0.0 109.495 174.561 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.697 HG23 HD11 ' A' ' 15' ' ' ILE . 21.3 t -63.61 150.04 10.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.587 0 O-C-N 120.843 -1.16 . . . . 0.0 110.36 -176.707 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.78 -13.6 62.35 Favored Glycine 0 N--CA 1.483 1.797 0 N-CA-C 108.793 -1.723 . . . . 0.0 108.793 -175.21 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 44.9 t0 -95.2 166.31 11.97 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.267 -1.137 . . . . 0.0 109.55 176.1 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.8 m95 -117.22 159.04 23.28 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.006 -1.059 . . . . 0.0 110.118 176.563 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.039 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.0 OUTLIER -125.38 155.02 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.441 -0.787 . . . . 0.0 109.891 -179.124 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.846 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.3 OUTLIER -78.16 105.29 9.28 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.17 -0.956 . . . . 0.0 108.965 168.093 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.846 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -106.19 140.46 24.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 120.535 -1.353 . . . . 0.0 111.478 -176.312 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.43 ' HB3' ' HB3' ' A' ' 43' ' ' ALA . 86.5 tt0 -134.27 157.09 47.19 Favored 'General case' 0 N--CA 1.496 1.855 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.948 -179.557 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 47.5 ptt85 -100.23 133.37 44.74 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.114 -0.991 . . . . 0.0 110.992 -176.232 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.918 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -128.73 150.96 50.05 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.344 -0.848 . . . . 0.0 110.126 179.598 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -119.22 126.58 51.86 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.24 -0.913 . . . . 0.0 110.635 -178.704 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 28.3 mtpt -60.24 -40.01 88.73 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.507 -0.745 . . . . 0.0 110.965 -177.242 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' PHE . . . . . 0.407 ' CD1' ' C ' ' A' ' 90' ' ' PHE . 24.0 p90 -81.1 155.29 26.34 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.99 -1.069 . . . . 0.0 110.469 -177.387 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.454 ' HB3' ' HG3' ' A' ' 93' ' ' GLU . 53.1 m -72.08 129.93 39.69 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.359 -0.838 . . . . 0.0 110.742 -176.539 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.454 ' O ' ' HB2' ' A' ' 93' ' ' GLU . 56.7 t0 -70.07 -39.77 75.42 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.29 -0.881 . . . . 0.0 110.238 175.485 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.454 ' HB2' ' O ' ' A' ' 92' ' ' ASP . 98.5 mt-10 55.48 52.66 10.86 Favored 'General case' 0 N--CA 1.506 2.356 0 C-N-CA 119.887 -0.725 . . . . 0.0 110.498 177.568 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.808 HG22 ' O ' ' A' ' 96' ' ' GLY . 30.5 mm -69.43 -40.08 79.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.295 -0.878 . . . . 0.0 110.231 175.279 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 56.21 74.74 0.29 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 -177.542 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.808 ' O ' HG22 ' A' ' 94' ' ' ILE . . . 73.61 170.12 19.66 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 -178.608 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 1.4 t-160 . . . . . 0 N--CA 1.492 1.668 0 O-C-N 121.253 -1.145 . . . . 0.0 110.19 178.866 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 53.9 ttm . . . . . 0 N--CA 1.493 1.712 0 CA-C-O 121.171 0.51 . . . . 0.0 110.261 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.918 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 6.6 p90 -169.95 156.22 6.03 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 121.128 -0.982 . . . . 0.0 109.016 174.533 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.608 HG23 ' C ' ' B' ' 2' ' ' PHE . 75.6 p -154.16 -41.8 0.09 Allowed 'General case' 0 C--N 1.293 -1.851 0 O-C-N 121.084 -1.01 . . . . 0.0 108.517 176.58 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.449 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 51.24 20.76 5.17 Favored Glycine 0 N--CA 1.483 1.768 0 N-CA-C 108.408 -1.877 . . . . 0.0 108.408 -176.221 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 0.545 HD11 ' C8M' ' A' ' 98' ' ' RBF . 59.7 mt -81.76 130.74 35.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.285 -1.126 . . . . 0.0 109.915 -176.63 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.826 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.0 t -86.21 140.74 15.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.19 -0.944 . . . . 0.0 111.11 -169.751 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 27.8 mm100 -69.98 -36.08 74.93 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.836 -0.54 . . . . 0.0 110.81 177.194 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.534 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -155.42 168.96 33.27 Favored Glycine 0 N--CA 1.495 2.631 0 C-N-CA 119.086 -1.53 . . . . 0.0 110.269 -173.563 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.44 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 0.7 OUTLIER -108.87 172.17 7.0 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.127 -1.219 . . . . 0.0 111.177 -176.128 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.06 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -139.24 148.79 43.55 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 -179.145 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.583 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 20.8 tttt -106.59 117.11 33.18 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.091 -1.006 . . . . 0.0 110.055 178.787 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 1.008 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.0 tp -59.98 127.54 32.43 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.977 -1.077 . . . . 0.0 108.814 172.583 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.08 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.5 p -126.51 -31.0 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.837 0 O-C-N 121.312 -0.868 . . . . 0.0 110.061 -178.115 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.09 142.55 27.51 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.229 -0.988 . . . . 0.0 111.391 -178.358 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.739 HG23 ' NE2' ' B' ' 24' ' ' HIS . 10.3 mt -109.42 133.85 53.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.169 -0.957 . . . . 0.0 110.241 172.893 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.511 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.6 m-20 -110.0 114.44 27.98 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.387 -0.821 . . . . 0.0 110.077 176.059 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -100.24 112.66 24.99 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.101 -1.0 . . . . 0.0 110.612 -177.358 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.0 OUTLIER -107.47 133.3 20.44 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.27 -0.894 . . . . 0.0 109.4 174.904 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -52.12 -24.99 21.57 Favored 'Trans proline' 0 C--N 1.303 -1.855 0 O-C-N 123.873 1.46 . . . . 0.0 110.32 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.572 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 9.2 m-80 -86.12 -36.35 19.64 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.305 -0.872 . . . . 0.0 110.06 177.804 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.572 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 95.5 m-85 -156.71 150.27 24.52 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.43 -0.794 . . . . 0.0 110.296 -176.285 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.793 ' HD3' HD22 ' B' ' 68' ' ' LEU . 61.5 ttt180 -86.18 144.15 27.62 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.783 -1.198 . . . . 0.0 110.072 175.165 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.511 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 85.2 m -130.44 140.07 50.56 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.504 -0.747 . . . . 0.0 109.745 -175.76 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.739 ' NE2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.92 141.29 50.28 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.859 -1.151 . . . . 0.0 111.505 -178.358 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.841 HG22 ' OG ' ' B' ' 60' ' ' SER . 12.6 t -120.9 135.21 61.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.313 -0.867 . . . . 0.0 110.648 -179.164 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.892 HG13 ' CE1' ' B' ' 61' ' ' PHE . 21.7 m -117.72 171.94 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.757 -0.589 . . . . 0.0 110.19 178.171 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.582 ' HG3' HD22 ' B' ' 57' ' ' ASN . 12.8 tt0 -106.19 116.82 32.59 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.854 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.887 ' CD2' HD22 ' B' ' 36' ' ' LEU . 9.5 tp -90.59 130.9 39.57 Favored Pre-proline 0 C--N 1.295 -1.773 0 O-C-N 121.16 -0.962 . . . . 0.0 110.547 -171.298 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.481 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 30.6 Cg_endo -68.13 176.92 4.89 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 O-C-N 123.98 1.516 . . . . 0.0 111.005 -179.505 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -60.51 -40.02 89.89 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.454 -0.779 . . . . 0.0 111.355 -175.143 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.87 0.06 57.27 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.738 -1.226 . . . . 0.0 110.707 -174.008 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.597 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.9 mmm -110.71 -16.03 13.7 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.848 -1.157 . . . . 0.0 109.665 169.765 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.607 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 29.4 mt -71.31 -24.92 62.22 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.298 -0.876 . . . . 0.0 109.779 174.408 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 34' ' ' ASP . . . . . 0.488 ' O ' ' N ' ' B' ' 36' ' ' LEU . 38.6 p-10 -71.11 162.18 29.86 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.443 -0.786 . . . . 0.0 110.955 -173.088 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 35' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' B' ' 34' ' ' ASP . . . 37.53 27.74 0.03 OUTLIER Glycine 0 N--CA 1.496 2.694 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.564 174.343 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.887 HD22 ' CD2' ' B' ' 28' ' ' LEU . 60.8 tp -101.28 158.43 16.05 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.572 -1.546 . . . . 0.0 110.925 178.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 37' ' ' GLU . . . . . . . . . . . . . 21.5 pt-20 -159.97 161.17 34.09 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.561 -0.712 . . . . 0.0 109.421 177.525 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.817 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.97 154.43 41.14 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.007 -1.058 . . . . 0.0 109.49 175.794 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.38 -9.37 61.63 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -176.577 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.517 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -70.01 152.98 43.79 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.265 -1.138 . . . . 0.0 109.612 177.885 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.536 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -97.08 104.28 16.28 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.947 -1.096 . . . . 0.0 110.037 178.103 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.424 HG12 ' HD1' ' B' ' 44' ' ' HIS . 1.6 t -87.81 137.54 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.247 -0.908 . . . . 0.0 109.108 174.554 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.479 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -103.02 120.19 40.2 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 120.931 -1.106 . . . . 0.0 109.482 170.239 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.821 ' CD2' HG21 ' B' ' 82' ' ' VAL . 1.2 m80 -87.51 100.89 13.11 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.67 -0.812 . . . . 0.0 108.925 176.099 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.0 t-20 58.87 8.86 1.03 Allowed 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.5 -0.75 . . . . 0.0 111.256 -170.12 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.477 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 124.5 -2.9 8.82 Favored Glycine 0 N--CA 1.488 2.123 0 C-N-CA 119.699 -1.239 . . . . 0.0 110.601 174.173 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.813 ' O ' HD23 ' B' ' 49' ' ' LEU . 19.7 t -90.44 107.33 19.09 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.3 -1.706 . . . . 0.0 109.266 174.492 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 23.3 p -78.05 125.55 29.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.128 -0.983 . . . . 0.0 110.774 -170.761 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 0.939 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -142.59 160.08 41.0 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.596 -0.69 . . . . 0.0 109.632 176.05 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 27.7 m -99.25 149.3 23.25 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.676 -1.265 . . . . 0.0 111.357 -169.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.982 HG13 HG13 ' B' ' 59' ' ' VAL . 17.1 t -75.42 114.55 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.675 -0.641 . . . . 0.0 110.342 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.528 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 48.3 p -70.32 -39.96 74.46 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.178 -0.952 . . . . 0.0 109.865 174.433 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.574 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -162.74 154.6 18.26 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.388 -0.82 . . . . 0.0 110.214 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.817 HD11 ' N ' ' B' ' 38' ' ' THR . 5.5 mt -105.63 129.9 57.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.12 -0.987 . . . . 0.0 109.925 175.215 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.53 ' HB2' ' CB ' ' B' ' 58' ' ' HIS . 9.6 m-80 -101.58 61.9 0.92 Allowed 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.658 -0.651 . . . . 0.0 109.748 178.867 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.78 -114.66 4.15 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 -173.655 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.607 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -78.41 -20.2 51.61 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.004 -1.292 . . . . 0.0 108.815 174.34 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.08 ' CE1' HG11 ' B' ' 13' ' ' VAL . 19.1 m-70 -75.21 159.87 31.06 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.442 -0.786 . . . . 0.0 110.144 -177.203 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.982 HG13 HG13 ' B' ' 51' ' ' VAL . 54.7 t -140.04 122.16 16.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 C-N-CA 118.926 -1.11 . . . . 0.0 110.662 171.133 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.841 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.1 t -87.86 133.83 33.82 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.457 -0.777 . . . . 0.0 109.371 174.746 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.939 ' HB2' HD12 ' B' ' 49' ' ' LEU . 1.3 p90 -126.98 154.07 45.05 Favored 'General case' 0 N--CA 1.498 1.929 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.109 178.681 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.528 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 31.1 p-10 -88.7 147.77 24.34 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.939 -1.1 . . . . 0.0 111.352 -170.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.793 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -154.38 113.76 3.73 Favored 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 -176.309 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.531 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 56.8 ttm -70.05 140.53 52.82 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.744 -1.222 . . . . 0.0 109.402 -179.386 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.483 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 36.5 tptt -59.99 -49.1 78.99 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.023 -1.048 . . . . 0.0 110.347 -175.117 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 66' ' ' GLU . . . . . 0.411 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 88.6 tt0 -65.54 -40.03 92.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.948 -1.095 . . . . 0.0 110.098 178.22 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.531 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 61.0 m -62.7 -38.23 89.6 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.905 -1.122 . . . . 0.0 109.426 174.242 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.793 HD22 ' HD3' ' B' ' 22' ' ' ARG . 14.7 tp -60.01 -41.46 92.21 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.292 -0.88 . . . . 0.0 109.264 177.312 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 69' ' ' ARG . . . . . 0.529 ' NH1' ' HB3' ' B' ' 69' ' ' ARG . 6.4 mmm180 -70.0 -38.99 76.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.558 -0.714 . . . . 0.0 110.386 174.03 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.811 HG22 HG23 ' B' ' 71' ' ' THR . 1.1 tt -67.88 -40.39 83.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.526 -176.641 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.811 HG23 HG22 ' B' ' 70' ' ' ILE . 59.2 p -87.37 -171.43 3.47 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-O 121.296 0.57 . . . . 0.0 109.863 178.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.524 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 8.4 t30 -99.92 18.74 17.62 Favored 'General case' 0 C--N 1.297 -1.703 0 O-C-N 121.384 -0.823 . . . . 0.0 108.814 170.195 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.793 ' HB3' HD21 ' B' ' 63' ' ' LEU . 69.4 mt -68.41 -39.98 81.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.023 -1.048 . . . . 0.0 109.716 174.811 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.513 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -47.02 -22.64 1.3 Allowed Glycine 0 N--CA 1.489 2.2 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -179.71 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.4 p-10 -67.94 -17.14 64.36 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.08 -1.247 . . . . 0.0 110.492 -175.321 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 95.5 mt -63.44 142.1 58.52 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.17 -0.956 . . . . 0.0 110.92 -176.334 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 1.008 ' C ' HD23 ' B' ' 12' ' ' LEU . 46.1 mttt -142.84 142.84 31.91 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.71 -0.619 . . . . 0.0 109.391 174.507 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.718 HG23 HD11 ' B' ' 15' ' ' ILE . 21.5 t -63.61 149.99 10.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 120.903 -1.123 . . . . 0.0 110.422 -176.568 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.67 -13.34 62.8 Favored Glycine 0 N--CA 1.483 1.804 0 N-CA-C 108.885 -1.686 . . . . 0.0 108.885 -175.194 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 44.5 t0 -95.28 166.22 12.0 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.392 -1.064 . . . . 0.0 109.545 175.923 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.583 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.0 m95 -117.16 159.08 23.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.019 -1.051 . . . . 0.0 110.183 176.479 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.06 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.0 OUTLIER -125.45 155.15 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.5 -0.75 . . . . 0.0 109.936 -179.289 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.826 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.3 OUTLIER -78.25 105.15 9.29 Favored 'General case' 0 C--N 1.297 -1.69 0 O-C-N 121.123 -0.986 . . . . 0.0 109.025 168.203 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.856 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -106.07 140.61 23.62 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 120.631 -1.293 . . . . 0.0 111.361 -176.047 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' B' B ' 85' ' ' GLU . . . . . 0.431 ' HB3' ' HB3' ' B' ' 43' ' ' ALA . 86.4 tt0 -134.54 157.06 47.52 Favored 'General case' 0 N--CA 1.495 1.785 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.888 -179.649 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 47.6 ptt85 -100.12 133.46 44.48 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.079 -1.013 . . . . 0.0 110.919 -176.12 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 1.001 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -128.76 150.99 50.06 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.401 -0.812 . . . . 0.0 110.08 179.603 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -119.3 126.63 51.93 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.269 -0.894 . . . . 0.0 110.527 -178.697 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 28.3 mtpt -60.29 -40.09 89.23 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.416 -0.802 . . . . 0.0 110.918 -177.259 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 90' ' ' PHE . . . . . 0.406 ' CD1' ' C ' ' B' ' 90' ' ' PHE . 24.1 p90 -81.1 155.2 26.39 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.103 -0.998 . . . . 0.0 110.454 -177.364 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 91' ' ' SER . . . . . 0.482 ' HB3' ' HB ' ' B' ' 94' ' ' ILE . 53.2 m -72.03 129.92 39.69 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.289 -0.882 . . . . 0.0 110.795 -176.489 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 56.9 t0 -70.12 -46.4 64.87 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.254 -0.904 . . . . 0.0 110.454 175.529 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -140.38 52.54 1.65 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.914 -1.117 . . . . 0.0 110.909 -175.734 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 94' ' ' ILE . . . . . 0.552 HD13 ' CE ' ' A' ' 1' ' ' MET . 41.0 mt -130.6 2.35 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.162 -0.961 . . . . 0.0 110.203 176.38 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . -69.57 58.36 0.68 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.131 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 96' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' B' ' 94' ' ' ILE . . . 71.61 127.17 0.07 OUTLIER Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.288 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 35.8 m80 . . . . . 0 N--CA 1.491 1.583 0 O-C-N 121.207 -1.172 . . . . 0.0 110.184 -179.16 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 0.545 ' C8M' HD11 ' B' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 0.57 ' C8M' HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 92.5 mmm . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.049 0.452 . . . . 0.0 110.042 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 1.031 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 6.1 p90 -167.86 148.35 5.11 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 121.056 -1.028 . . . . 0.0 109.033 174.648 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.585 ' CB ' HG12 ' A' ' 5' ' ' ILE . 4.9 p -146.22 -37.86 0.24 Allowed 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.108 -0.995 . . . . 0.0 109.008 178.91 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.482 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 46.39 26.28 2.35 Favored Glycine 0 N--CA 1.483 1.803 0 N-CA-C 108.494 -1.843 . . . . 0.0 108.494 -176.828 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.585 HG12 ' CB ' ' A' ' 3' ' ' THR . 27.7 mm -78.77 130.01 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.464 -1.021 . . . . 0.0 109.558 -178.914 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.843 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.2 t -93.17 140.37 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 120.934 -1.104 . . . . 0.0 111.09 -169.77 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -69.95 -35.11 74.24 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.778 -0.576 . . . . 0.0 111.072 176.848 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -156.24 172.97 34.14 Favored Glycine 0 N--CA 1.495 2.609 0 C-N-CA 118.747 -1.692 . . . . 0.0 110.513 -172.526 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.458 ' O ' ' HG3' ' A' ' 29' ' ' PRO . 12.6 p -117.75 172.35 7.43 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.031 -1.276 . . . . 0.0 111.017 -176.814 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.041 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -140.01 148.53 41.99 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.562 -0.711 . . . . 0.0 109.609 -178.726 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.579 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 37.6 tttt -107.18 115.3 29.93 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.047 -1.033 . . . . 0.0 110.321 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.998 HD23 ' C ' ' A' ' 77' ' ' LYS . 11.3 tp -59.91 126.74 28.73 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.038 -1.039 . . . . 0.0 108.896 173.945 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.042 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -125.32 -29.32 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.838 0 C-N-CA 119.583 -0.847 . . . . 0.0 109.909 -179.417 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.93 142.4 24.37 Favored 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 118.942 -1.103 . . . . 0.0 111.523 179.735 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.782 HG23 ' CD2' ' A' ' 24' ' ' HIS . 12.0 mt -105.55 137.13 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.155 -0.966 . . . . 0.0 110.185 171.569 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.519 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 86.7 m-20 -112.95 115.99 29.28 Favored 'General case' 0 C--N 1.297 -1.703 0 O-C-N 121.344 -0.847 . . . . 0.0 109.937 173.512 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -105.9 115.24 29.9 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.897 -1.127 . . . . 0.0 110.799 -176.477 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.465 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 4.1 mtmt -110.4 127.58 26.77 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.121 -0.987 . . . . 0.0 108.935 171.703 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -52.27 -18.73 8.13 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.848 1.446 . . . . 0.0 110.812 -179.367 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.518 ' HB2' ' CD2' ' A' ' 21' ' ' PHE . 0.4 OUTLIER -90.18 -35.84 15.13 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.139 -0.975 . . . . 0.0 108.741 177.077 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.518 ' CD2' ' HB2' ' A' ' 20' ' ' ASN . 81.9 m-85 -151.07 150.15 30.37 Favored 'General case' 0 N--CA 1.491 1.623 0 CA-C-O 121.192 0.52 . . . . 0.0 109.748 179.183 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.48 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 62.4 ttt180 -97.69 143.83 27.95 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.589 -1.32 . . . . 0.0 110.021 176.504 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.519 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 96.5 m -129.98 140.09 50.96 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.412 -0.805 . . . . 0.0 110.126 -173.304 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.782 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.22 135.77 48.5 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.984 -1.073 . . . . 0.0 111.207 179.216 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.759 HG22 ' OG ' ' A' ' 60' ' ' SER . 15.8 t -115.53 134.25 59.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.002 -1.061 . . . . 0.0 110.767 -178.276 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 29.5 m -119.67 170.02 9.88 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.062 -179.703 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.535 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 7.5 tt0 -103.55 116.97 33.36 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -179.383 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.545 HD23 ' HA ' ' A' ' 33' ' ' LEU . 8.9 tp -82.01 119.73 75.78 Favored Pre-proline 0 C--N 1.295 -1.798 0 O-C-N 121.502 -0.748 . . . . 0.0 109.815 -173.719 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.458 ' HG3' ' O ' ' A' ' 9' ' ' THR . 22.6 Cg_endo -65.33 179.22 1.66 Allowed 'Trans proline' 0 C--N 1.308 -1.554 0 O-C-N 123.85 1.447 . . . . 0.0 111.047 -179.378 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.417 ' OD1' ' C ' ' A' ' 30' ' ' ASP . 50.5 t0 -60.1 -41.28 92.18 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.415 -0.803 . . . . 0.0 111.098 -175.319 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.57 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.39 1.47 56.57 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.87 -1.144 . . . . 0.0 110.763 -174.156 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.57 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 96.4 mmm -111.07 -15.82 13.63 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.036 -1.04 . . . . 0.0 109.82 171.835 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.613 HD21 ' HB2' ' A' ' 57' ' ' ASN . 16.5 mt -68.18 -30.39 69.48 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.33 -0.856 . . . . 0.0 109.999 178.904 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 57.4 t0 -91.72 127.02 37.01 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.328 -0.858 . . . . 0.0 110.266 -179.648 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.28 -48.06 1.0 Allowed Glycine 0 N--CA 1.492 2.403 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 177.712 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.788 HD23 ' N ' ' A' ' 37' ' ' GLU . 7.4 tt -70.02 145.81 51.49 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.141 -1.211 . . . . 0.0 110.664 -175.762 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.788 ' N ' HD23 ' A' ' 36' ' ' LEU . 20.7 pt-20 -150.43 170.01 20.09 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.427 -0.796 . . . . 0.0 109.622 -179.512 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.825 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -67.23 151.15 48.05 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.91 -1.119 . . . . 0.0 110.13 179.972 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.62 0.0 62.15 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 -176.226 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.452 ' O ' ' HA ' ' A' ' 50' ' ' THR . . . -79.79 159.0 26.71 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.242 -1.152 . . . . 0.0 109.7 177.894 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.552 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -101.06 113.23 26.05 Favored 'General case' 0 N--CA 1.486 1.345 0 O-C-N 121.126 -0.984 . . . . 0.0 110.04 176.72 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.611 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.0 t -104.74 130.0 56.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.278 -0.889 . . . . 0.0 109.172 174.718 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.516 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -93.31 119.53 32.56 Favored 'General case' 0 C--N 1.297 -1.708 0 C-N-CA 119.146 -1.022 . . . . 0.0 109.149 172.257 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.736 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.3 OUTLIER -88.0 107.15 18.58 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 178.52 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.51 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.1 t-20 50.29 16.28 0.25 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.487 -0.758 . . . . 0.0 111.283 -166.457 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.501 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 120.92 0.85 11.75 Favored Glycine 0 N--CA 1.489 2.221 0 C-N-CA 119.444 -1.36 . . . . 0.0 111.164 171.292 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.785 ' O ' HD23 ' A' ' 49' ' ' LEU . 34.8 t -98.71 108.46 21.15 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.137 -1.802 . . . . 0.0 109.492 175.082 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.501 ' SG ' ' C8 ' ' A' ' 98' ' ' RBF . 21.2 p -75.7 126.74 31.59 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.015 -1.053 . . . . 0.0 111.084 -171.116 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.96 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -141.35 162.74 34.76 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.505 -0.747 . . . . 0.0 109.466 172.712 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.452 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 55.0 m -102.47 152.88 20.61 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 120.637 -1.29 . . . . 0.0 111.074 -171.13 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.896 HG22 ' CE1' ' A' ' 61' ' ' PHE . 34.5 t -76.82 117.73 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.62 -0.675 . . . . 0.0 110.458 -177.934 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.685 HG22 ' HB3' ' A' ' 62' ' ' ASP . 41.2 p -70.21 -39.99 74.81 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.122 -0.986 . . . . 0.0 109.669 172.253 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.572 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 52.3 tp10 -164.72 156.12 15.26 Favored 'General case' 0 N--CA 1.492 1.642 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.819 -177.349 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.825 HD11 ' N ' ' A' ' 38' ' ' THR . 8.8 mt -110.47 130.07 64.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.083 -1.011 . . . . 0.0 109.986 172.794 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.499 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 63.8 m-80 -104.7 65.62 0.76 Allowed 'General case' 0 C--N 1.297 -1.678 0 CA-C-O 121.532 0.682 . . . . 0.0 109.54 177.703 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.91 -115.09 4.24 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 -174.158 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.613 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.1 OUTLIER -80.0 -21.08 44.04 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.121 -1.223 . . . . 0.0 109.162 176.609 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.042 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.5 m170 -77.05 159.38 29.91 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.186 -0.946 . . . . 0.0 109.791 -178.024 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.815 HG13 HG13 ' A' ' 51' ' ' VAL . 59.9 t -140.9 121.48 13.27 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 C-N-CA 119.078 -1.049 . . . . 0.0 110.522 171.707 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.759 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.2 t -84.35 135.35 34.33 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.434 -0.791 . . . . 0.0 109.264 175.885 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.96 ' HB3' HD12 ' A' ' 49' ' ' LEU . 58.9 m-85 -115.55 158.5 22.53 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.319 -0.863 . . . . 0.0 110.199 178.967 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.685 ' HB3' HG22 ' A' ' 52' ' ' THR . 25.1 p-10 -92.12 147.47 22.91 Favored 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 122.106 0.955 . . . . 0.0 110.842 178.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.833 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -159.71 125.0 4.08 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 -176.864 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.536 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 56.1 ttm -84.85 146.44 27.31 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.931 -1.106 . . . . 0.0 109.434 -177.84 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.43 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 71.4 tttt -60.06 -49.13 78.88 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.014 -1.053 . . . . 0.0 109.99 -177.231 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 53.4 tp10 -69.59 -40.02 76.95 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.147 -0.97 . . . . 0.0 110.397 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.537 ' O ' HG23 ' A' ' 71' ' ' THR . 37.7 m -62.25 -38.66 90.11 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.823 -1.173 . . . . 0.0 109.085 174.427 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.802 HD11 ' HA2' ' A' ' 74' ' ' GLY . 1.0 OUTLIER -60.05 -47.37 86.16 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.233 -0.917 . . . . 0.0 109.709 177.419 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 74.9 ttt-85 -65.76 -40.05 91.65 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.467 -0.771 . . . . 0.0 110.481 178.192 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.878 HG22 HG23 ' A' ' 71' ' ' THR . 1.4 tt -64.19 -41.28 91.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.234 -0.917 . . . . 0.0 109.093 -179.323 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.878 HG23 HG22 ' A' ' 70' ' ' ILE . 20.1 p -89.72 -177.01 5.16 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 175.626 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.499 ' N ' ' OD1' ' B' ' 83' ' ' ASN . 3.4 t30 -100.01 25.16 7.67 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.07 -1.019 . . . . 0.0 108.332 172.414 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.833 ' HB3' HD21 ' A' ' 63' ' ' LEU . 86.8 mt -67.66 -39.96 84.52 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.996 -1.065 . . . . 0.0 109.933 176.551 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.802 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -54.88 -23.98 32.41 Favored Glycine 0 N--CA 1.485 1.909 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -177.52 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 21.9 p-10 -64.12 -17.02 63.05 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.962 -1.317 . . . . 0.0 110.32 -175.335 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.52 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 96.0 mt -60.08 141.48 55.7 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.262 -0.898 . . . . 0.0 110.476 -177.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 0.998 ' C ' HD23 ' A' ' 12' ' ' LEU . 59.8 mmtt -140.02 143.28 36.34 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-O 121.814 0.816 . . . . 0.0 110.4 175.807 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.596 ' CG2' HG13 ' A' ' 15' ' ' ILE . 35.9 t -63.08 149.51 10.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.252 -0.905 . . . . 0.0 110.235 -176.199 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.54 -13.79 63.05 Favored Glycine 0 N--CA 1.484 1.849 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 -175.338 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 46.3 t0 -96.23 163.13 13.22 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.346 -1.091 . . . . 0.0 109.587 176.167 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.579 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 13.7 m95 -113.89 162.15 16.73 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.062 -1.024 . . . . 0.0 110.201 176.52 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.041 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.6 p -130.8 140.24 49.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 O-C-N 121.514 -0.741 . . . . 0.0 110.16 -175.625 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.843 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -66.95 103.89 1.25 Allowed 'General case' 0 C--N 1.295 -1.795 0 O-C-N 121.095 -1.003 . . . . 0.0 109.46 169.07 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.732 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -106.58 137.63 36.2 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.816 0 O-C-N 120.537 -1.352 . . . . 0.0 111.414 -178.885 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.54 ' HB2' HG22 ' A' ' 6' ' ' VAL . 84.3 tt0 -132.73 131.66 41.46 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.072 179.703 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 75.9 ttt180 -72.18 139.2 48.11 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.151 -0.968 . . . . 0.0 110.972 -175.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.924 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -132.55 150.03 52.22 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.436 -0.79 . . . . 0.0 109.814 176.654 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -117.12 141.83 47.77 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.28 -0.888 . . . . 0.0 111.152 -174.116 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.2 mmtt -60.2 -40.08 88.82 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.476 -0.765 . . . . 0.0 110.3 -179.603 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 44.3 p90 -118.77 162.56 18.24 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.235 -0.916 . . . . 0.0 110.206 -178.615 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.419 ' O ' ' HG2' ' A' ' 93' ' ' GLU . 12.9 m -105.17 131.27 52.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.278 -0.889 . . . . 0.0 110.593 -175.453 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.526 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 96.0 m-20 -61.6 -39.32 90.78 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.295 -0.878 . . . . 0.0 110.17 177.775 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.526 ' CG ' ' O ' ' A' ' 92' ' ' ASP . 8.4 pt-20 38.48 52.71 1.78 Allowed 'General case' 0 N--CA 1.512 2.674 0 CA-C-O 121.51 0.671 . . . . 0.0 110.208 -178.272 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.42 HG12 ' HB3' ' A' ' 92' ' ' ASP . 44.6 mm -70.0 -39.94 77.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.502 -0.749 . . . . 0.0 110.173 177.664 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 105.13 -94.3 0.99 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 -176.543 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.414 ' O ' ' HB2' ' A' ' 97' ' ' HIS . . . 84.49 -168.79 44.5 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 178.025 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' HIS . . . . . 0.414 ' HB2' ' O ' ' A' ' 96' ' ' GLY . 72.3 m-70 . . . . . 0 N--CA 1.491 1.593 0 O-C-N 121.386 -1.067 . . . . 0.0 110.283 -179.165 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 70.5 mtm . . . . . 0 N--CA 1.492 1.641 0 CA-C-O 121.252 0.549 . . . . 0.0 110.164 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.924 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 6.4 p90 -171.61 148.5 2.47 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 121.144 -0.973 . . . . 0.0 109.119 176.659 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.574 ' CB ' HG12 ' B' ' 5' ' ' ILE . 4.9 p -146.25 -37.76 0.24 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.187 -0.946 . . . . 0.0 109.029 178.963 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.501 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 46.19 26.43 2.24 Favored Glycine 0 N--CA 1.484 1.864 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 -176.832 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 0.574 HG12 ' CB ' ' B' ' 3' ' ' THR . 28.0 mm -78.85 129.95 36.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.523 -0.986 . . . . 0.0 109.581 -178.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.851 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.2 t -92.98 140.36 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 120.986 -1.071 . . . . 0.0 111.124 -169.765 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 -70.02 -34.73 73.66 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.715 -0.615 . . . . 0.0 111.137 176.826 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.528 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -156.56 172.81 34.33 Favored Glycine 0 N--CA 1.498 2.767 0 C-N-CA 118.814 -1.66 . . . . 0.0 110.599 -172.555 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.453 ' O ' ' HG3' ' B' ' 29' ' ' PRO . 12.5 p -117.7 172.35 7.42 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.074 -1.251 . . . . 0.0 111.01 -176.763 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.048 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -139.95 148.68 42.3 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.654 -0.653 . . . . 0.0 109.518 -178.791 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 37.6 tttt -107.38 115.42 30.12 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.146 -0.971 . . . . 0.0 110.246 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 1.011 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.2 tp -60.03 126.67 28.44 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.058 -1.026 . . . . 0.0 108.956 173.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.057 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -125.14 -29.51 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.827 0 O-C-N 121.347 -0.846 . . . . 0.0 109.974 -179.366 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.88 142.27 24.29 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 119.089 -1.044 . . . . 0.0 111.52 179.819 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.789 HG23 ' CD2' ' B' ' 24' ' ' HIS . 11.8 mt -105.41 137.15 36.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.065 -1.022 . . . . 0.0 110.137 171.606 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.524 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 86.4 m-20 -113.09 115.99 29.18 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.398 -0.814 . . . . 0.0 109.854 173.536 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -105.83 115.24 29.9 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.895 -1.128 . . . . 0.0 110.754 -176.471 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 4.1 mtmt -110.45 127.67 26.62 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.188 -0.945 . . . . 0.0 108.925 171.636 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -52.34 -18.78 8.4 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.763 1.402 . . . . 0.0 110.744 -179.3 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.515 ' HB2' ' CD2' ' B' ' 21' ' ' PHE . 0.4 OUTLIER -90.01 -36.22 15.06 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.174 -0.954 . . . . 0.0 108.659 177.044 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.515 ' CD2' ' HB2' ' B' ' 20' ' ' ASN . 81.7 m-85 -150.71 150.2 30.77 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.886 -0.509 . . . . 0.0 109.801 179.263 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.466 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 62.4 ttt180 -97.76 143.85 27.97 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.733 -1.229 . . . . 0.0 109.994 176.499 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.524 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 97.3 m -130.03 140.12 50.91 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.579 -0.7 . . . . 0.0 110.04 -173.335 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.789 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -129.99 135.94 48.86 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.045 -1.035 . . . . 0.0 111.186 179.179 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.754 HG22 ' OG ' ' B' ' 60' ' ' SER . 15.7 t -115.54 134.44 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.09 -1.006 . . . . 0.0 110.687 -178.379 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 30.2 m -119.97 170.02 10.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 C-N-CA 120.46 -0.496 . . . . 0.0 109.957 -179.711 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.525 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 7.6 tt0 -103.51 117.13 33.74 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 121.455 -0.778 . . . . 0.0 108.968 -179.347 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.552 HD23 ' HA ' ' B' ' 33' ' ' LEU . 8.9 tp -82.05 119.77 75.86 Favored Pre-proline 0 C--N 1.294 -1.81 0 O-C-N 121.449 -0.782 . . . . 0.0 109.815 -173.678 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.468 ' HD2' ' HB2' ' B' ' 32' ' ' MET . 22.1 Cg_endo -65.42 179.08 1.75 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 O-C-N 123.829 1.437 . . . . 0.0 111.032 -179.327 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.419 ' OD1' ' C ' ' B' ' 30' ' ' ASP . 50.5 t0 -60.01 -41.26 91.78 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.413 -0.804 . . . . 0.0 111.134 -175.338 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.57 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.36 1.5 56.52 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.971 -1.08 . . . . 0.0 110.804 -174.236 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.57 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 96.4 mmm -110.97 -15.98 13.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.049 -1.032 . . . . 0.0 109.839 171.818 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.633 HD21 ' HB2' ' B' ' 57' ' ' ASN . 16.6 mt -68.01 -30.49 69.75 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.412 -0.805 . . . . 0.0 110.043 178.932 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -91.72 127.02 37.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.331 -0.856 . . . . 0.0 110.238 -179.635 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.3 -47.98 1.0 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 177.673 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.778 HD23 ' N ' ' B' ' 37' ' ' GLU . 7.4 tt -69.97 145.74 51.62 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.022 -1.281 . . . . 0.0 110.649 -175.758 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 37' ' ' GLU . . . . . 0.778 ' N ' HD23 ' B' ' 36' ' ' LEU . 20.7 pt-20 -150.44 169.99 20.14 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.505 -0.747 . . . . 0.0 109.608 -179.529 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.834 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -67.25 151.09 48.13 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.883 -1.136 . . . . 0.0 110.115 179.996 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.74 -0.09 62.4 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -176.211 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.458 ' O ' ' HA ' ' B' ' 50' ' ' THR . . . -79.85 158.94 26.63 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.281 -1.129 . . . . 0.0 109.656 177.939 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.551 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -100.94 113.24 26.02 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.993 -1.067 . . . . 0.0 110.075 176.7 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.597 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.0 t -104.89 130.02 56.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 121.285 -0.884 . . . . 0.0 109.111 174.764 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.519 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -93.22 119.53 32.5 Favored 'General case' 0 C--N 1.298 -1.645 0 C-N-CA 119.085 -1.046 . . . . 0.0 109.278 172.155 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.731 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.3 OUTLIER -88.0 107.03 18.53 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.416 -0.802 . . . . 0.0 109.066 178.503 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.51 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.1 t-20 50.44 16.23 0.27 Allowed 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.469 -0.77 . . . . 0.0 111.222 -166.506 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.493 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 120.82 1.23 11.81 Favored Glycine 0 N--CA 1.49 2.298 0 C-N-CA 119.407 -1.378 . . . . 0.0 111.086 171.158 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.779 ' O ' HD23 ' B' ' 49' ' ' LEU . 35.1 t -98.92 108.44 21.12 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.188 -1.772 . . . . 0.0 109.379 175.02 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 48' ' ' CYS . . . . . 0.507 ' SG ' ' C8 ' ' B' ' 99' ' ' RBF . 21.0 p -75.58 126.84 31.8 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.113 -0.992 . . . . 0.0 111.011 -171.172 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 0.983 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -141.44 162.74 34.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.458 -0.776 . . . . 0.0 109.461 172.637 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 50' ' ' THR . . . . . 0.458 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 55.0 m -102.44 152.97 20.5 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 120.612 -1.305 . . . . 0.0 111.037 -171.14 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.905 HG22 ' CE1' ' B' ' 61' ' ' PHE . 34.0 t -76.91 117.55 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.509 -0.745 . . . . 0.0 110.488 -177.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.676 HG22 ' HB3' ' B' ' 62' ' ' ASP . 40.9 p -70.02 -40.11 75.42 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.087 -1.008 . . . . 0.0 109.691 172.271 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.576 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 52.3 tp10 -164.68 156.14 15.39 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.252 -0.905 . . . . 0.0 110.838 -177.328 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.834 HD11 ' N ' ' B' ' 38' ' ' THR . 9.0 mt -110.44 130.02 64.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.236 -0.915 . . . . 0.0 110.029 172.844 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.52 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 63.7 m-80 -104.74 65.45 0.75 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-O 121.445 0.641 . . . . 0.0 109.482 177.823 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.13 -115.04 4.21 Favored Glycine 0 N--CA 1.486 2.005 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 -174.213 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.633 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.1 OUTLIER -80.01 -21.22 43.85 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.035 -1.273 . . . . 0.0 109.183 176.596 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.057 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.6 m170 -76.95 159.23 30.12 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.155 -0.966 . . . . 0.0 109.758 -178.036 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.81 HG13 HG13 ' B' ' 51' ' ' VAL . 59.5 t -140.83 121.52 13.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 C-N-CA 119.008 -1.077 . . . . 0.0 110.469 171.796 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.754 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.2 t -84.42 135.35 34.3 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.468 -0.77 . . . . 0.0 109.368 175.876 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.983 ' HB3' HD12 ' B' ' 49' ' ' LEU . 58.7 m-85 -115.47 158.72 22.15 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.287 -0.883 . . . . 0.0 110.165 179.012 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.676 ' HB3' HG22 ' B' ' 52' ' ' THR . 25.1 p-10 -92.25 147.48 22.89 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.08 -1.013 . . . . 0.0 110.876 178.925 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.8 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.69 125.09 4.12 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -176.885 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.533 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 56.1 ttm -84.92 146.4 27.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.966 -1.084 . . . . 0.0 109.388 -177.811 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.428 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 71.3 tttt -60.03 -49.14 78.84 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.104 -0.998 . . . . 0.0 109.977 -177.205 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -69.6 -39.99 76.91 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.149 -0.969 . . . . 0.0 110.444 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.554 ' O ' HG23 ' B' ' 71' ' ' THR . 38.5 m -62.26 -38.83 90.8 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.935 -1.103 . . . . 0.0 108.98 174.449 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.827 HD11 ' HA2' ' B' ' 74' ' ' GLY . 1.0 OUTLIER -59.9 -47.28 86.43 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.436 -0.79 . . . . 0.0 109.8 177.398 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 74.9 ttt-85 -65.83 -39.99 91.36 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.54 -0.725 . . . . 0.0 110.513 178.173 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.885 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -64.2 -41.19 91.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.285 -0.885 . . . . 0.0 109.13 -179.381 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.885 HG23 HG22 ' B' ' 70' ' ' ILE . 20.4 p -89.7 -176.85 5.11 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 120.236 -0.586 . . . . 0.0 109.433 175.602 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.527 ' CB ' ' H ' ' A' ' 83' ' ' ASN . 3.5 t30 -100.0 25.09 7.73 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.079 -1.013 . . . . 0.0 108.307 172.336 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.8 ' HB3' HD21 ' B' ' 63' ' ' LEU . 86.6 mt -67.69 -39.94 84.38 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.995 -1.066 . . . . 0.0 109.945 176.609 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.827 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -54.86 -23.95 32.12 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 110.321 -1.112 . . . . 0.0 110.321 -177.527 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 21.5 p-10 -64.1 -17.02 63.02 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.006 -1.29 . . . . 0.0 110.349 -175.381 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 96.1 mt -60.0 141.41 55.68 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.252 -0.905 . . . . 0.0 110.484 -177.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 1.011 ' C ' HD23 ' B' ' 12' ' ' LEU . 59.8 mmtt -139.93 143.29 36.53 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 121.555 0.693 . . . . 0.0 110.446 175.771 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.598 ' N ' HD23 ' B' ' 12' ' ' LEU . 36.5 t -63.19 149.47 10.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.22 -176.152 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.48 -13.53 63.64 Favored Glycine 0 N--CA 1.483 1.808 0 N-CA-C 108.818 -1.713 . . . . 0.0 108.818 -175.3 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 46.0 t0 -96.27 162.99 13.27 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.27 -1.135 . . . . 0.0 109.629 175.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 13.6 m95 -113.9 162.05 16.86 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.09 -1.007 . . . . 0.0 110.178 176.598 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.048 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.5 p -130.78 140.31 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.545 -0.722 . . . . 0.0 110.179 -175.78 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.851 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.2 OUTLIER -66.87 103.78 1.21 Allowed 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.115 -0.991 . . . . 0.0 109.549 169.089 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.746 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -106.48 137.92 34.58 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 120.589 -1.319 . . . . 0.0 111.28 -178.692 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 85' ' ' GLU . . . . . 0.541 ' HB2' HG22 ' B' ' 6' ' ' VAL . 84.3 tt0 -133.03 131.64 40.91 Favored 'General case' 0 N--CA 1.493 1.7 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.036 179.681 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 75.9 ttt180 -72.11 139.17 48.24 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.25 -0.906 . . . . 0.0 110.955 -175.849 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 1.031 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -132.48 150.26 52.19 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.389 -0.82 . . . . 0.0 109.749 176.623 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -117.43 141.89 47.79 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.257 -0.902 . . . . 0.0 111.02 -174.099 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 20.2 mmtt -60.35 -39.93 88.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.369 -0.832 . . . . 0.0 110.287 -179.541 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 44.4 p90 -118.81 162.59 18.22 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.254 -0.904 . . . . 0.0 110.227 -178.741 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 91' ' ' SER . . . . . 0.415 ' OG ' HD12 ' B' ' 94' ' ' ILE . 12.9 m -105.12 131.37 52.7 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.265 -0.897 . . . . 0.0 110.643 -175.447 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -61.88 -39.95 93.7 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.335 -0.853 . . . . 0.0 110.36 177.89 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 93' ' ' GLU . . . . . 0.413 ' O ' ' HG3' ' B' ' 93' ' ' GLU . 21.5 pt-20 -159.17 53.61 0.4 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.095 -1.003 . . . . 0.0 110.491 -177.294 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 94' ' ' ILE . . . . . 0.415 HD12 ' OG ' ' B' ' 91' ' ' SER . 28.0 mt -124.22 13.9 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.256 -0.903 . . . . 0.0 110.25 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . -69.08 64.39 0.51 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -178.248 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 96' ' ' GLY . . . . . 0.42 ' O ' ' HB3' ' B' ' 97' ' ' HIS . . . 95.68 37.36 5.03 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 177.712 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 97' ' ' HIS . . . . . 0.42 ' HB3' ' O ' ' B' ' 96' ' ' GLY . 22.2 t-80 . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.197 -1.178 . . . . 0.0 110.156 179.43 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 0.501 ' C8 ' ' SG ' ' A' ' 48' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 0.507 ' C8 ' ' SG ' ' B' ' 48' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.473 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 76.6 mtm . . . . . 0 N--CA 1.493 1.701 0 CA-C-O 121.116 0.484 . . . . 0.0 110.139 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.972 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 7.3 p90 -179.09 139.97 0.16 Allowed 'General case' 0 C--N 1.307 -1.253 0 O-C-N 121.328 -0.857 . . . . 0.0 108.974 178.903 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.541 ' CB ' HG12 ' A' ' 5' ' ' ILE . 11.1 p -130.85 -36.71 1.35 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 120.973 -1.079 . . . . 0.0 109.176 -176.54 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.508 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 55.12 20.31 20.19 Favored Glycine 0 N--CA 1.484 1.835 0 N-CA-C 108.689 -1.764 . . . . 0.0 108.689 -179.27 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.557 HD11 ' C9 ' ' B' ' 99' ' ' RBF . 32.1 mm -80.89 125.06 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.442 -1.034 . . . . 0.0 109.579 -176.701 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.852 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.9 t -82.93 143.53 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.014 -1.054 . . . . 0.0 111.408 -167.372 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.463 ' HG2' ' HG3' ' A' ' 85' ' ' GLU . 89.5 mm-40 -70.02 -38.59 75.95 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.662 -0.649 . . . . 0.0 110.294 173.349 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.523 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -168.3 -176.52 38.76 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 119.404 -1.379 . . . . 0.0 109.816 -176.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.472 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 1.1 p -120.78 171.83 8.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.96 -1.317 . . . . 0.0 110.859 -177.431 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.072 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -140.3 149.92 43.38 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.556 -0.715 . . . . 0.0 109.531 -178.221 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 35.2 tttt -105.52 116.02 31.24 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 120.922 -1.111 . . . . 0.0 110.138 178.597 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 1.025 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.9 tp -59.83 128.48 37.14 Favored 'General case' 0 C--N 1.297 -1.703 0 O-C-N 120.863 -1.148 . . . . 0.0 108.69 172.558 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.12 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.6 p -129.41 -29.3 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.291 -177.839 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.68 142.36 26.66 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 118.948 -1.101 . . . . 0.0 111.534 179.368 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.825 HG23 ' CD2' ' A' ' 24' ' ' HIS . 10.9 mt -107.81 135.71 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.037 -1.039 . . . . 0.0 110.174 171.653 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.494 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 83.5 m-20 -110.14 114.56 28.15 Favored 'General case' 0 C--N 1.295 -1.769 0 O-C-N 121.308 -0.87 . . . . 0.0 110.272 173.909 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -101.91 109.6 21.38 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.175 -0.953 . . . . 0.0 110.421 -178.231 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.4 mtpt -103.87 134.54 19.67 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.056 -1.028 . . . . 0.0 109.424 175.272 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.58 -18.31 8.26 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 O-C-N 123.995 1.524 . . . . 0.0 110.802 -179.616 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.581 ' HB2' ' CD2' ' A' ' 21' ' ' PHE . 0.4 OUTLIER -99.28 -32.77 11.03 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.143 -0.973 . . . . 0.0 109.138 -179.906 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.581 ' CD2' ' HB2' ' A' ' 20' ' ' ASN . 56.3 m-85 -150.48 150.21 31.0 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.835 -0.54 . . . . 0.0 110.144 -175.747 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.475 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 56.1 ttt180 -94.02 143.33 26.45 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.639 -1.288 . . . . 0.0 110.055 173.14 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.494 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 44.5 m -129.99 139.22 51.09 Favored 'General case' 0 C--N 1.296 -1.743 0 O-C-N 121.564 -0.71 . . . . 0.0 109.818 -175.315 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.825 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.0 135.46 48.32 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.862 -1.149 . . . . 0.0 111.312 179.377 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.765 HG22 ' CB ' ' A' ' 60' ' ' SER . 4.8 t -117.47 131.91 68.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.085 -1.01 . . . . 0.0 110.731 -176.791 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.578 HG22 ' HE2' ' A' ' 61' ' ' PHE . 7.0 m -113.63 172.32 3.52 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.94 -0.475 . . . . 0.0 110.061 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.544 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 7.1 tt0 -105.34 117.27 33.59 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.427 -0.795 . . . . 0.0 108.948 178.567 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.565 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.0 tp -83.55 121.05 76.32 Favored Pre-proline 0 C--N 1.296 -1.751 0 O-C-N 121.632 -0.668 . . . . 0.0 109.943 -172.888 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.473 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 25.1 Cg_endo -66.27 176.0 4.4 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 O-C-N 123.9 1.474 . . . . 0.0 111.007 -179.372 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.55 ' HA ' HD12 ' A' ' 33' ' ' LEU . 51.2 t0 -60.07 -39.97 87.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.424 -0.798 . . . . 0.0 111.049 -175.177 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.599 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.08 0.35 57.18 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.939 -1.1 . . . . 0.0 110.785 -174.917 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.599 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 98.0 mmm -113.06 -11.03 13.4 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.959 -1.088 . . . . 0.0 110.053 172.328 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.586 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 15.7 mt -69.98 -32.32 70.46 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.304 -0.872 . . . . 0.0 109.923 177.629 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -79.91 139.91 36.92 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.512 -0.742 . . . . 0.0 111.009 -176.156 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.01 -38.43 3.17 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 120.024 -1.084 . . . . 0.0 110.645 171.786 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.47 HD23 ' CD2' ' A' ' 28' ' ' LEU . 64.7 tp -77.99 147.72 34.74 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.787 -1.42 . . . . 0.0 111.102 -174.015 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.512 ' C ' HD11 ' A' ' 54' ' ' ILE . 20.6 pt-20 -149.23 170.04 19.39 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.459 -0.775 . . . . 0.0 109.322 175.216 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.856 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -62.96 151.94 38.1 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.931 -1.106 . . . . 0.0 110.027 -178.688 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.24 -3.48 62.11 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -176.225 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.464 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -77.1 158.72 30.3 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.242 -1.152 . . . . 0.0 109.491 176.802 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.557 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -100.97 110.05 22.04 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.901 -1.124 . . . . 0.0 110.045 178.567 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.673 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.0 t -98.99 129.94 48.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 121.212 -0.93 . . . . 0.0 109.155 174.782 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.516 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -95.51 119.95 34.9 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 119.244 -0.982 . . . . 0.0 109.227 172.093 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.673 ' HE1' HG11 ' A' ' 42' ' ' VAL . 0.6 OUTLIER -88.25 106.97 18.56 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 177.789 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.495 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 55.33 13.76 0.96 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.329 -0.857 . . . . 0.0 110.91 -167.326 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.51 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 117.56 -0.5 18.23 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 119.508 -1.329 . . . . 0.0 110.615 172.797 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.78 ' O ' HD23 ' A' ' 49' ' ' LEU . 36.6 t -93.54 105.59 17.63 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.477 -1.602 . . . . 0.0 109.423 175.728 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 25.0 p -73.73 129.44 37.92 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.193 -0.942 . . . . 0.0 111.183 -170.747 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.992 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -145.39 160.57 41.36 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 172.841 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 21.3 m -96.3 152.95 18.1 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.534 -1.354 . . . . 0.0 111.175 -170.095 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.784 HG13 HG13 ' A' ' 59' ' ' VAL . 21.2 t -76.96 112.11 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.775 -0.578 . . . . 0.0 110.037 178.695 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.575 HG22 ' HB3' ' A' ' 62' ' ' ASP . 33.9 p -69.39 -40.05 77.61 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.119 -0.988 . . . . 0.0 109.556 173.757 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.567 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -160.59 156.13 25.21 Favored 'General case' 0 N--CA 1.49 1.557 0 C-N-CA 119.383 -0.927 . . . . 0.0 110.895 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.856 HD11 ' N ' ' A' ' 38' ' ' THR . 7.8 mt -109.97 130.47 63.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.211 -0.931 . . . . 0.0 109.73 172.598 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.508 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 46.6 m-80 -104.45 65.03 0.76 Allowed 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 119.822 -0.751 . . . . 0.0 109.567 178.13 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.46 -114.91 4.42 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 -173.609 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.586 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -80.02 -19.74 47.0 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.078 -1.248 . . . . 0.0 109.119 176.645 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.12 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.8 m170 -76.61 159.0 30.66 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.256 -0.903 . . . . 0.0 110.061 -178.663 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.784 HG13 HG13 ' A' ' 51' ' ' VAL . 54.0 t -141.45 122.52 12.97 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 O-C-N 121.01 -1.056 . . . . 0.0 111.029 173.655 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.765 ' CB ' HG22 ' A' ' 25' ' ' VAL . 17.4 m -91.83 127.48 37.31 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.655 -0.653 . . . . 0.0 109.897 179.581 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.992 ' HB3' HD12 ' A' ' 49' ' ' LEU . 54.4 m-85 -111.59 160.81 16.85 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.869 -1.145 . . . . 0.0 110.243 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.575 ' HB3' HG22 ' A' ' 52' ' ' THR . 38.1 p-10 -92.01 148.63 22.05 Favored 'General case' 0 N--CA 1.496 1.858 0 CA-C-O 122.065 0.936 . . . . 0.0 111.321 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 0.713 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -156.01 118.55 4.13 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 -177.304 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.532 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 74.3 mmm -73.0 142.73 47.74 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.937 -1.102 . . . . 0.0 109.514 179.088 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.487 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 38.5 tttp -60.0 -44.9 94.24 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.007 -1.058 . . . . 0.0 110.091 -177.862 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.47 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.6 tt0 -70.04 -39.95 75.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.01 -1.056 . . . . 0.0 110.105 179.109 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.628 HG21 ' O2 ' ' A' ' 98' ' ' RBF . 93.8 m -60.05 -39.37 85.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.923 -1.111 . . . . 0.0 109.286 172.31 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 0.745 HD11 ' HA2' ' A' ' 74' ' ' GLY . 9.3 tp -59.95 -44.95 94.07 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.199 -0.938 . . . . 0.0 109.348 -179.638 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 61.0 ttt180 -69.93 -39.92 75.83 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.517 -0.739 . . . . 0.0 110.686 175.528 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.81 HG22 HG23 ' A' ' 71' ' ' THR . 1.4 tt -66.85 -42.61 89.35 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 O-C-N 121.164 -0.96 . . . . 0.0 109.386 -176.289 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.81 HG23 HG22 ' A' ' 70' ' ' ILE . 43.6 p -84.74 -174.1 5.09 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 175.642 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.472 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 6.7 t30 -102.17 24.02 10.78 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 170.898 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.755 HD11 ' SG ' ' A' ' 47' ' ' CYS . 98.0 mt -69.98 -40.04 75.57 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.136 -0.978 . . . . 0.0 109.734 176.455 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.745 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -49.55 -22.91 4.24 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.381 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 25.6 p-10 -63.61 -19.33 64.76 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.014 -1.286 . . . . 0.0 110.357 -175.907 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.514 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.4 mt -61.33 140.43 58.0 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.148 -0.97 . . . . 0.0 110.962 -176.769 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 1.025 ' C ' HD23 ' A' ' 12' ' ' LEU . 22.8 mttm -141.44 139.35 33.36 Favored 'General case' 0 C--N 1.296 -1.726 0 CA-C-O 121.479 0.657 . . . . 0.0 109.559 174.356 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.703 ' N ' HD23 ' A' ' 12' ' ' LEU . 44.0 t -60.93 151.46 6.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 O-C-N 120.924 -1.11 . . . . 0.0 110.327 -176.338 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.97 -14.66 61.35 Favored Glycine 0 N--CA 1.482 1.746 0 N-CA-C 108.751 -1.739 . . . . 0.0 108.751 -175.333 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -98.16 167.12 11.07 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.31 -1.112 . . . . 0.0 109.626 175.311 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.584 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.5 m95 -115.37 156.72 25.02 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.104 -0.997 . . . . 0.0 110.134 177.092 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.072 HG13 ' HB3' ' A' ' 10' ' ' ALA . 0.9 OUTLIER -120.13 155.15 23.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 O-C-N 121.527 -0.733 . . . . 0.0 109.892 -178.124 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 0.852 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.5 m-20 -80.02 106.75 12.27 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.21 -0.931 . . . . 0.0 108.988 168.793 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.716 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -107.25 138.6 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.55 -1.344 . . . . 0.0 111.039 -175.223 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.463 ' HG3' ' HG2' ' A' ' 7' ' ' GLN . 86.4 tt0 -136.83 135.34 37.84 Favored 'General case' 0 N--CA 1.492 1.632 0 C-N-CA 120.381 -0.528 . . . . 0.0 109.752 -178.355 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -78.67 129.92 35.27 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.055 -1.028 . . . . 0.0 110.618 -176.212 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.908 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -121.13 145.6 47.64 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.401 -0.812 . . . . 0.0 110.199 178.298 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -128.12 141.17 51.57 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.799 -0.563 . . . . 0.0 110.352 -178.662 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 12.1 pttt -69.99 -21.01 63.27 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.234 -0.916 . . . . 0.0 110.008 177.469 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 39.9 p90 -141.15 160.33 40.33 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.05 -1.031 . . . . 0.0 110.119 174.764 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.464 ' OG ' ' HG3' ' A' ' 93' ' ' GLU . 74.4 p -140.25 149.94 43.48 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.305 -0.872 . . . . 0.0 110.282 176.556 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.403 ' O ' ' HB2' ' A' ' 93' ' ' GLU . 51.9 t0 -69.99 -39.98 75.57 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.267 -0.896 . . . . 0.0 110.185 178.331 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.464 ' HG3' ' OG ' ' A' ' 91' ' ' SER . 98.9 mt-10 51.85 54.76 10.36 Favored 'General case' 0 N--CA 1.504 2.269 0 O-C-N 121.164 -0.96 . . . . 0.0 109.919 176.413 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.432 ' O ' ' C ' ' A' ' 95' ' ' GLY . 40.6 mm -59.98 -41.27 85.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.366 -0.834 . . . . 0.0 109.862 178.268 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' A' ' 94' ' ' ILE . . . 41.28 57.86 3.01 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 178.647 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -86.99 -9.23 74.27 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.81 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 41.5 m80 . . . . . 0 N--CA 1.492 1.652 0 O-C-N 121.267 -1.137 . . . . 0.0 110.227 -179.501 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 1' ' ' MET . . . . . 0.4 ' HG2' ' N ' ' B' ' 2' ' ' PHE . 60.2 ttm . . . . . 0 N--CA 1.494 1.738 0 CA-C-O 121.156 0.503 . . . . 0.0 110.24 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.908 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 7.0 p90 -174.14 139.79 0.65 Allowed 'General case' 0 C--N 1.306 -1.314 0 O-C-N 121.173 -0.955 . . . . 0.0 108.961 174.259 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.555 ' CB ' HG12 ' B' ' 5' ' ' ILE . 11.0 p -130.89 -36.68 1.35 Allowed 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.016 -1.052 . . . . 0.0 109.17 -176.602 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.51 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 55.04 20.3 19.5 Favored Glycine 0 N--CA 1.484 1.872 0 N-CA-C 108.645 -1.782 . . . . 0.0 108.645 -179.252 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 0.555 HG12 ' CB ' ' B' ' 3' ' ' THR . 32.7 mm -80.81 125.07 39.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.412 -1.052 . . . . 0.0 109.505 -176.658 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 0.809 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.9 t -83.03 143.53 11.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 120.995 -1.066 . . . . 0.0 111.42 -167.406 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 7' ' ' GLN . . . . . 0.47 ' HG2' ' HG3' ' B' ' 85' ' ' GLU . 89.6 mm-40 -70.02 -38.31 75.86 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.694 -0.629 . . . . 0.0 110.371 173.437 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.522 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -168.6 -176.65 39.02 Favored Glycine 0 N--CA 1.494 2.556 0 C-N-CA 119.478 -1.344 . . . . 0.0 109.854 -177.013 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.48 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 1.1 p -120.73 171.83 8.32 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.039 -1.271 . . . . 0.0 110.918 -177.401 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.066 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -140.29 149.94 43.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.533 -0.729 . . . . 0.0 109.444 -178.18 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.581 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 35.3 tttt -105.51 116.13 31.42 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.057 -1.027 . . . . 0.0 110.087 178.531 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 1.024 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.9 tp -60.03 128.31 36.21 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.971 -1.081 . . . . 0.0 108.781 172.461 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.12 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.6 p -129.12 -29.53 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 C-N-CA 119.565 -0.854 . . . . 0.0 110.296 -177.729 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.57 142.33 26.74 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 119.072 -1.051 . . . . 0.0 111.501 179.454 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.828 HG23 ' CD2' ' B' ' 24' ' ' HIS . 10.9 mt -107.76 135.84 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.116 -0.99 . . . . 0.0 110.207 171.606 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.504 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.2 m-20 -110.33 114.69 28.35 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.443 -0.785 . . . . 0.0 110.184 173.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -101.91 109.53 21.29 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.099 -1.001 . . . . 0.0 110.443 -178.25 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.4 mtpt -103.88 134.6 19.63 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.218 -0.926 . . . . 0.0 109.546 175.196 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -52.73 -18.2 8.48 Favored 'Trans proline' 0 C--N 1.303 -1.868 0 O-C-N 123.952 1.501 . . . . 0.0 110.747 -179.461 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.583 ' HB2' ' CD2' ' B' ' 21' ' ' PHE . 0.4 OUTLIER -99.04 -33.46 10.8 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.154 -0.966 . . . . 0.0 109.044 -179.966 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.583 ' CD2' ' HB2' ' B' ' 20' ' ' ASN . 56.2 m-85 -149.96 150.31 31.64 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 120.327 -0.549 . . . . 0.0 110.176 -175.634 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.473 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 56.1 ttt180 -94.01 143.42 26.37 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.757 -1.214 . . . . 0.0 110.008 173.101 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.504 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 42.9 m -130.09 139.3 50.97 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.745 -0.597 . . . . 0.0 109.736 -175.367 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.828 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.02 135.64 48.5 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.984 -1.073 . . . . 0.0 111.227 179.347 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.764 HG22 ' CB ' ' B' ' 60' ' ' SER . 4.8 t -117.42 131.99 68.52 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.262 -0.899 . . . . 0.0 110.769 -176.822 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.585 HG22 ' HE2' ' B' ' 61' ' ' PHE . 7.2 m -113.79 172.24 3.62 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 O-C-N 121.909 -0.495 . . . . 0.0 110.025 179.234 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.669 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 7.0 tt0 -105.09 117.32 33.7 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.466 -0.771 . . . . 0.0 109.118 178.413 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.552 HD23 ' HA ' ' B' ' 33' ' ' LEU . 8.9 tp -83.51 120.99 76.35 Favored Pre-proline 0 C--N 1.295 -1.779 0 O-C-N 121.555 -0.716 . . . . 0.0 110.028 -172.944 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.465 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 25.6 Cg_endo -66.16 175.97 4.33 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 O-C-N 123.856 1.45 . . . . 0.0 111.005 -179.41 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.529 ' HA ' HD12 ' B' ' 33' ' ' LEU . 51.3 t0 -60.02 -40.07 88.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.448 -0.783 . . . . 0.0 111.061 -175.27 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.605 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.02 0.34 57.16 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.884 -1.135 . . . . 0.0 110.851 -174.925 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.605 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 98.0 mmm -113.05 -11.2 13.39 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.105 -0.997 . . . . 0.0 110.053 172.377 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.59 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 15.8 mt -69.89 -32.21 70.41 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.35 -0.844 . . . . 0.0 110.022 177.628 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -80.11 139.96 36.64 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.545 -0.722 . . . . 0.0 110.927 -176.16 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.92 -38.4 3.17 Favored Glycine 0 N--CA 1.493 2.442 0 C-N-CA 119.965 -1.112 . . . . 0.0 110.581 171.799 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.478 HD23 ' CD2' ' B' ' 28' ' ' LEU . 64.5 tp -77.97 147.68 34.8 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.93 -1.335 . . . . 0.0 111.146 -174.101 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 37' ' ' GLU . . . . . 0.491 ' C ' HD11 ' B' ' 54' ' ' ILE . 20.6 pt-20 -149.13 170.03 19.35 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.466 -0.771 . . . . 0.0 109.323 175.269 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.863 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -62.99 151.79 38.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.932 -1.105 . . . . 0.0 110.071 -178.8 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.34 -3.51 62.37 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -176.159 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.457 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -77.18 158.58 30.27 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.184 -1.186 . . . . 0.0 109.446 176.764 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.565 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -100.65 109.84 21.93 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 120.904 -1.123 . . . . 0.0 110.14 178.537 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.657 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.0 t -99.0 129.9 48.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.284 -0.885 . . . . 0.0 109.171 174.713 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.514 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -95.44 120.01 34.94 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 119.204 -0.999 . . . . 0.0 109.199 172.06 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.657 ' HE1' HG11 ' B' ' 42' ' ' VAL . 0.6 OUTLIER -88.29 106.79 18.45 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.408 -0.807 . . . . 0.0 108.915 177.691 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.641 HD22 ' HB2' ' A' ' 47' ' ' CYS . 0.9 OUTLIER 55.5 13.88 1.05 Allowed 'General case' 0 C--N 1.299 -1.597 0 O-C-N 121.333 -0.854 . . . . 0.0 110.888 -167.346 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.508 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 117.46 -0.32 18.44 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.513 -1.327 . . . . 0.0 110.612 172.671 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.797 ' O ' HD23 ' B' ' 49' ' ' LEU . 36.7 t -93.66 105.59 17.62 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.536 -1.567 . . . . 0.0 109.439 175.67 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 25.1 p -73.65 129.56 38.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.084 -1.01 . . . . 0.0 111.079 -170.707 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 1.009 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -145.61 160.54 41.52 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 172.714 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 21.3 m -96.14 153.05 18.0 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.703 -1.248 . . . . 0.0 111.181 -170.021 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.79 HG13 HG13 ' B' ' 59' ' ' VAL . 21.2 t -77.06 112.05 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.652 -0.655 . . . . 0.0 110.126 178.598 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.552 HG22 ' HB3' ' B' ' 62' ' ' ASP . 34.5 p -69.54 -39.91 77.18 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.168 -0.958 . . . . 0.0 109.462 173.986 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.568 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -160.64 156.1 25.05 Favored 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.861 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.863 HD11 ' N ' ' B' ' 38' ' ' THR . 7.8 mt -110.01 130.42 63.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.259 -0.901 . . . . 0.0 109.728 172.651 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.524 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 46.6 m-80 -104.55 65.03 0.76 Allowed 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.575 178.151 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.61 -114.94 4.4 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 108.716 -1.754 . . . . 0.0 108.716 -173.69 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.59 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -80.03 -19.66 47.15 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.05 -1.265 . . . . 0.0 109.194 176.645 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.12 ' CE1' HG11 ' B' ' 13' ' ' VAL . 24.3 m-70 -76.6 158.78 30.84 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.359 -0.838 . . . . 0.0 110.096 -178.698 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.79 HG13 HG13 ' B' ' 51' ' ' VAL . 54.4 t -141.32 122.64 13.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.967 173.735 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.764 ' CB ' HG22 ' B' ' 25' ' ' VAL . 17.4 m -91.92 127.56 37.43 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.767 -0.583 . . . . 0.0 109.953 179.554 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 1.009 ' HB3' HD12 ' B' ' 49' ' ' LEU . 54.4 m-85 -111.55 160.81 16.83 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.056 -1.027 . . . . 0.0 110.314 179.258 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.552 ' HB3' HG22 ' B' ' 52' ' ' THR . 38.0 p-10 -92.0 148.66 22.03 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.135 -0.978 . . . . 0.0 111.269 179.805 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 0.745 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -156.0 118.48 4.12 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -177.354 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.528 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 74.2 mmm -73.01 142.77 47.72 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.907 -1.12 . . . . 0.0 109.481 179.147 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.484 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 38.5 tttp -59.98 -44.92 94.17 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.091 -1.005 . . . . 0.0 110.075 -177.822 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 66' ' ' GLU . . . . . 0.478 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 86.6 tt0 -69.99 -40.06 75.52 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.047 -1.033 . . . . 0.0 110.062 179.196 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.632 HG21 ' O2 ' ' B' ' 99' ' ' RBF . 94.2 m -59.96 -39.53 85.92 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.923 -1.111 . . . . 0.0 109.144 172.41 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 0.754 HD11 ' HA2' ' B' ' 74' ' ' GLY . 9.4 tp -60.07 -44.71 94.56 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.428 -0.795 . . . . 0.0 109.436 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 61.1 ttt180 -70.04 -39.92 75.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.498 -0.751 . . . . 0.0 110.673 175.372 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.791 HG22 HG23 ' B' ' 71' ' ' THR . 1.4 tt -66.77 -42.52 89.47 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.263 -0.898 . . . . 0.0 109.421 -176.368 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.791 HG23 HG22 ' B' ' 70' ' ' ILE . 43.8 p -84.74 -173.85 4.95 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 175.682 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.48 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 6.7 t30 -102.31 24.06 10.82 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 170.855 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.751 HD11 ' SG ' ' B' ' 47' ' ' CYS . 98.0 mt -69.99 -40.1 75.53 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.192 -0.942 . . . . 0.0 109.745 176.403 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.754 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -49.59 -22.91 4.31 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 -179.396 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 25.7 p-10 -63.55 -19.38 64.75 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.031 -1.276 . . . . 0.0 110.374 -175.934 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 97.5 mt -61.27 140.47 57.96 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.199 -0.938 . . . . 0.0 110.915 -176.786 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 1.024 ' C ' HD23 ' B' ' 12' ' ' LEU . 22.8 mttm -141.39 139.38 33.47 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-O 121.336 0.589 . . . . 0.0 109.556 174.322 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.703 ' N ' HD23 ' B' ' 12' ' ' LEU . 44.2 t -60.95 151.33 6.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 120.93 -1.107 . . . . 0.0 110.315 -176.345 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.96 -14.43 61.95 Favored Glycine 0 N--CA 1.482 1.751 0 N-CA-C 108.781 -1.727 . . . . 0.0 108.781 -175.41 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -98.2 167.09 11.08 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.362 -1.081 . . . . 0.0 109.6 175.207 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.581 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.4 m95 -115.42 156.71 25.09 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.177 -0.952 . . . . 0.0 110.13 177.073 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 1.066 HG13 ' HB3' ' B' ' 10' ' ' ALA . 0.9 OUTLIER -120.12 155.26 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.532 -0.73 . . . . 0.0 109.955 -178.206 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 0.809 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -80.05 106.43 12.06 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.243 -0.911 . . . . 0.0 109.03 168.866 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.702 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -106.94 138.72 31.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 120.588 -1.32 . . . . 0.0 111.061 -175.145 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' B' B ' 85' ' ' GLU . . . . . 0.47 ' HG3' ' HG2' ' B' ' 7' ' ' GLN . 86.4 tt0 -137.02 135.36 37.51 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.836 -0.54 . . . . 0.0 109.765 -178.461 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -78.6 130.02 35.45 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.015 -1.053 . . . . 0.0 110.543 -176.155 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 0.972 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -121.11 145.66 47.57 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.525 -0.734 . . . . 0.0 110.144 178.248 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -128.23 141.14 51.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.625 -0.672 . . . . 0.0 110.322 -178.712 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 12.1 pttt -69.99 -20.95 63.27 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.287 -0.883 . . . . 0.0 110.028 177.527 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -141.22 160.3 40.39 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.103 -0.998 . . . . 0.0 110.107 174.767 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 91' ' ' SER . . . . . 0.459 ' HB2' HG12 ' B' ' 94' ' ' ILE . 74.6 p -140.16 149.97 43.64 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.297 -0.877 . . . . 0.0 110.304 176.547 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -70.07 -47.38 62.2 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.252 -0.905 . . . . 0.0 110.17 178.288 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 93' ' ' GLU . . . . . 0.47 ' O ' ' HG3' ' B' ' 93' ' ' GLU . 8.2 pt-20 -168.97 75.01 0.1 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.415 -0.803 . . . . 0.0 110.471 -176.853 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 94' ' ' ILE . . . . . 0.459 HG12 ' HB2' ' B' ' 91' ' ' SER . 23.7 mm -60.01 -44.74 95.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 120.964 -1.085 . . . . 0.0 109.855 176.651 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 95' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' B' ' 94' ' ' ILE . . . 41.39 57.96 3.04 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 178.163 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.28 -43.09 93.6 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.438 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 14.9 t60 . . . . . 0 N--CA 1.491 1.62 0 O-C-N 121.286 -1.126 . . . . 0.0 110.149 179.795 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 0.628 ' O2 ' HG21 ' A' ' 67' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 0.632 ' O2 ' HG21 ' B' ' 67' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.45 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 69.1 mtt . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.104 0.478 . . . . 0.0 110.211 . . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 2' ' ' PHE . . . . . 0.817 ' HE2' ' HB1' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -178.12 140.58 0.23 Allowed 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.2 -0.937 . . . . 0.0 109.234 175.582 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.536 ' O ' HG13 ' A' ' 5' ' ' ILE . 14.2 p -136.1 -32.62 0.86 Allowed 'General case' 0 C--N 1.295 -1.781 0 O-C-N 120.977 -1.077 . . . . 0.0 109.96 -174.783 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.415 ' C ' ' O ' ' A' ' 3' ' ' THR . . . 46.8 24.69 1.98 Allowed Glycine 0 N--CA 1.486 2.005 0 N-CA-C 108.847 -1.701 . . . . 0.0 108.847 -175.662 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 5' ' ' ILE . . . . . 0.595 HD11 ' C8M' ' B' ' 99' ' ' RBF . 30.0 mt -87.63 136.33 23.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.19 -1.183 . . . . 0.0 110.343 -176.976 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 1.031 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.5 t -86.05 143.87 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.279 -0.888 . . . . 0.0 110.779 -175.417 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -70.0 -32.63 70.9 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.619 -0.676 . . . . 0.0 110.803 177.419 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.531 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -164.96 177.26 40.53 Favored Glycine 0 N--CA 1.494 2.564 0 C-N-CA 118.767 -1.682 . . . . 0.0 110.485 -174.237 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 9' ' ' THR . . . . . 0.506 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 2.9 p -116.34 167.89 10.62 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.131 -1.217 . . . . 0.0 110.886 -177.871 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 1.055 ' HB2' HG21 ' A' ' 84' ' ' VAL . . . -137.73 148.46 45.64 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 -176.009 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 11' ' ' LYS . . . . . 0.577 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 25.7 tttt -108.88 115.91 30.98 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.022 -1.049 . . . . 0.0 110.379 -179.333 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.994 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.0 tp -58.7 127.37 31.86 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.077 -1.014 . . . . 0.0 108.89 174.284 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.051 HG11 ' CE1' ' A' ' 58' ' ' HIS . 1.4 p -125.11 -31.48 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 O-C-N 121.352 -0.843 . . . . 0.0 109.932 -179.679 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.54 144.05 28.23 Favored 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.327 -178.054 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.584 HG12 ' CD2' ' A' ' 24' ' ' HIS . 8.6 mt -108.1 130.08 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.214 -0.929 . . . . 0.0 110.181 172.265 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.507 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 67.3 m-20 -105.66 114.24 28.29 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.318 -0.863 . . . . 0.0 109.768 172.895 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -106.59 108.88 20.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.975 -1.078 . . . . 0.0 110.856 -177.511 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 18' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -104.26 128.65 26.63 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.198 -0.939 . . . . 0.0 108.888 173.052 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -50.33 -34.06 39.34 Favored 'Trans proline' 0 C--N 1.303 -1.861 0 O-C-N 123.753 1.396 . . . . 0.0 110.496 -179.601 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 20' ' ' ASN . . . . . 0.531 ' C ' ' CD2' ' A' ' 21' ' ' PHE . 8.8 m120 -71.57 -39.86 70.32 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.201 -0.937 . . . . 0.0 110.039 175.559 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 21' ' ' PHE . . . . . 0.531 ' CD2' ' C ' ' A' ' 20' ' ' ASN . 89.2 m-85 -152.98 150.25 29.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.399 -0.813 . . . . 0.0 109.973 -179.411 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.738 ' HD3' HD22 ' A' ' 68' ' ' LEU . 62.6 ttt180 -93.27 144.95 24.82 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.732 -1.23 . . . . 0.0 110.124 177.046 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.507 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 56.8 m -130.31 141.56 50.59 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.48 -0.762 . . . . 0.0 110.09 -176.186 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.607 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -127.89 144.78 51.09 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 120.974 -1.079 . . . . 0.0 111.342 176.75 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.763 HG22 ' CB ' ' A' ' 60' ' ' SER . 4.3 t -124.63 133.55 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.183 -0.948 . . . . 0.0 110.703 -179.27 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.592 HG13 ' HE2' ' A' ' 61' ' ' PHE . 33.4 m -118.5 172.06 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.796 -0.565 . . . . 0.0 110.425 -179.96 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.6 ' HG3' ' CE1' ' A' ' 58' ' ' HIS . 12.9 tt0 -101.14 117.51 35.15 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.594 -0.691 . . . . 0.0 109.318 -179.551 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.628 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.4 tp -82.0 121.26 78.91 Favored Pre-proline 0 C--N 1.297 -1.687 0 O-C-N 121.796 -0.565 . . . . 0.0 109.813 -175.302 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.49 ' HD2' HD12 ' A' ' 28' ' ' LEU . 25.5 Cg_endo -66.23 179.47 1.95 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 O-C-N 123.863 1.454 . . . . 0.0 110.992 -179.42 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.511 ' HA ' HD12 ' A' ' 33' ' ' LEU . 96.0 m-20 -63.41 -40.0 96.0 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.368 -0.833 . . . . 0.0 111.067 -175.646 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 31' ' ' HIS . . . . . 0.434 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.42 1.09 56.97 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.922 -1.111 . . . . 0.0 111.067 -175.31 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 32' ' ' MET . . . . . 0.474 ' HB2' ' HD2' ' A' ' 29' ' ' PRO . 98.4 mmm -113.92 -13.95 12.51 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.998 -1.064 . . . . 0.0 109.801 172.254 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.628 ' HA ' HD23 ' A' ' 28' ' ' LEU . 14.0 mt -66.19 -39.85 89.99 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.289 -0.882 . . . . 0.0 109.784 176.57 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -77.19 132.35 38.72 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.496 -0.753 . . . . 0.0 110.586 -177.486 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.51 -43.06 1.87 Allowed Glycine 0 N--CA 1.492 2.391 0 C-N-CA 119.903 -1.141 . . . . 0.0 110.258 174.489 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 36' ' ' LEU . . . . . 0.597 HD23 ' N ' ' A' ' 37' ' ' GLU . 5.7 tt -69.91 145.7 51.76 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.928 -1.337 . . . . 0.0 110.564 -174.94 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.597 ' N ' HD23 ' A' ' 36' ' ' LEU . 20.6 pt-20 -149.98 167.63 26.13 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.524 -0.735 . . . . 0.0 109.416 -179.555 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.822 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -67.95 149.94 49.13 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.85 -1.156 . . . . 0.0 110.201 -178.114 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.33 -3.61 62.03 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 -173.827 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 40' ' ' ALA . . . . . 0.538 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -76.55 159.99 29.85 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.236 -1.155 . . . . 0.0 109.122 174.85 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 41' ' ' SER . . . . . 0.903 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 1.1 p -104.21 117.88 35.3 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 118.72 -1.192 . . . . 0.0 109.897 177.184 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.626 HG11 ' HE1' ' A' ' 44' ' ' HIS . 0.9 OUTLIER -99.97 120.09 48.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.363 -0.836 . . . . 0.0 108.956 176.943 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -82.94 117.33 22.7 Favored 'General case' 0 C--N 1.298 -1.641 0 C-N-CA 119.262 -0.975 . . . . 0.0 109.241 174.495 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 44' ' ' HIS . . . . . 0.651 ' CD2' HG21 ' A' ' 82' ' ' VAL . 1.5 m80 -87.24 103.42 15.42 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 176.172 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' B' ' 45' ' ' ASN . 0.9 OUTLIER 55.74 12.05 0.77 Allowed 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.548 -0.72 . . . . 0.0 111.335 -169.483 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.49 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 126.85 -6.13 7.39 Favored Glycine 0 N--CA 1.491 2.362 0 C-N-CA 119.605 -1.283 . . . . 0.0 110.825 173.324 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 47' ' ' CYS . . . . . 0.896 ' O ' HD23 ' A' ' 49' ' ' LEU . 44.8 t -93.31 103.64 15.87 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 120.509 -1.583 . . . . 0.0 109.67 176.038 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.419 ' SG ' ' O ' ' B' ' 3' ' ' THR . 16.0 p -72.18 121.91 20.13 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.096 -1.003 . . . . 0.0 110.737 -174.444 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 49' ' ' LEU . . . . . 0.896 HD23 ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -132.04 160.57 35.53 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.364 -0.835 . . . . 0.0 109.341 173.704 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.433 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 37.2 m -97.72 152.52 19.03 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.439 -1.413 . . . . 0.0 111.436 -169.555 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 51' ' ' VAL . . . . . 0.878 HG13 HG13 ' A' ' 59' ' ' VAL . 19.4 t -81.02 114.62 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.917 -0.489 . . . . 0.0 110.396 -178.953 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 52' ' ' THR . . . . . 0.488 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 31.1 p -69.85 -40.08 76.02 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.294 -0.879 . . . . 0.0 109.705 174.416 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 53' ' ' GLU . . . . . 0.564 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.7 tt0 -161.38 155.64 22.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.437 -0.789 . . . . 0.0 109.909 179.686 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.822 HD11 ' N ' ' A' ' 38' ' ' THR . 7.1 mt -105.15 128.99 58.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.966 -1.084 . . . . 0.0 109.574 174.613 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 55' ' ' ASN . . . . . 0.53 ' CB ' ' HB2' ' A' ' 58' ' ' HIS . 2.2 m-80 -100.6 62.6 1.05 Allowed 'General case' 0 C--N 1.298 -1.653 0 O-C-N 121.58 -0.7 . . . . 0.0 109.585 -179.014 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.04 -120.05 6.58 Favored Glycine 0 N--CA 1.487 2.054 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 -172.638 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.577 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.1 OUTLIER -71.8 -20.22 61.88 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.931 -1.335 . . . . 0.0 108.981 175.094 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 58' ' ' HIS . . . . . 1.051 ' CE1' HG11 ' A' ' 13' ' ' VAL . 28.3 m-70 -76.69 161.3 28.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.425 -0.797 . . . . 0.0 110.386 -176.748 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.878 HG13 HG13 ' A' ' 51' ' ' VAL . 54.5 t -140.02 125.52 20.9 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 C-N-CA 119.119 -1.032 . . . . 0.0 110.786 170.66 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 60' ' ' SER . . . . . 0.763 ' CB ' HG22 ' A' ' 25' ' ' VAL . 24.8 m -97.61 123.16 41.4 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.763 -0.586 . . . . 0.0 109.509 -179.551 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.818 ' HB2' HD12 ' A' ' 49' ' ' LEU . 10.1 p90 -118.32 159.67 22.99 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.822 -1.174 . . . . 0.0 110.72 -179.743 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.488 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 35.2 p-10 -93.37 156.56 16.72 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.089 -1.007 . . . . 0.0 111.532 -172.004 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 63' ' ' LEU . . . . . 1.062 HD22 HD13 ' A' ' 68' ' ' LEU . 0.1 OUTLIER -161.19 101.93 1.25 Allowed 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.705 -0.622 . . . . 0.0 109.607 -174.135 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 64' ' ' MET . . . . . 0.494 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 57.7 ttm -59.97 137.71 58.02 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.787 -1.195 . . . . 0.0 109.09 179.351 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 28.6 tttt -60.03 -45.91 91.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.977 -1.077 . . . . 0.0 110.614 -172.154 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.0 tp10 -66.15 -40.07 90.29 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.702 -1.248 . . . . 0.0 109.866 177.402 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 67' ' ' THR . . . . . 0.494 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 94.1 m -59.92 -40.01 87.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.087 -1.008 . . . . 0.0 109.573 172.683 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 68' ' ' LEU . . . . . 1.062 HD13 HD22 ' A' ' 63' ' ' LEU . 28.0 tp -60.02 -43.45 95.26 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.299 -0.876 . . . . 0.0 109.764 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 ttt85 -69.99 -39.09 76.12 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.326 -0.859 . . . . 0.0 110.352 177.765 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.709 HG22 HG23 ' A' ' 71' ' ' THR . 1.4 tt -64.78 -42.71 95.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.28 -0.887 . . . . 0.0 109.448 -176.816 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 71' ' ' THR . . . . . 0.709 HG23 HG22 ' A' ' 70' ' ' ILE . 30.5 p -81.99 -174.9 5.33 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 120.015 -0.674 . . . . 0.0 109.243 175.471 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.538 ' CB ' ' H ' ' B' ' 83' ' ' ASN . 5.2 t30 -99.52 22.25 11.04 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.174 -0.954 . . . . 0.0 108.511 171.062 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 73' ' ' LEU . . . . . 0.719 HD13 HD21 ' A' ' 63' ' ' LEU . 70.6 mt -70.12 -39.97 75.12 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.946 -1.096 . . . . 0.0 109.816 175.602 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 74' ' ' GLY . . . . . 0.428 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -49.31 -21.67 3.03 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -177.943 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 75' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.2 p-10 -66.21 -16.46 64.01 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.068 -1.254 . . . . 0.0 110.562 -175.056 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 76' ' ' LEU . . . . . 0.503 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 96.1 mt -62.07 142.34 57.61 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.209 -0.932 . . . . 0.0 111.173 -175.116 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 77' ' ' LYS . . . . . 0.994 ' C ' HD23 ' A' ' 12' ' ' LEU . 86.6 mttt -141.48 141.16 33.65 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.647 -0.658 . . . . 0.0 109.558 172.642 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.705 ' N ' HD23 ' A' ' 12' ' ' LEU . 16.7 t -59.52 151.72 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 120.711 -1.243 . . . . 0.0 110.297 -176.146 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.79 -13.55 60.64 Favored Glycine 0 N--CA 1.484 1.867 0 N-CA-C 108.948 -1.661 . . . . 0.0 108.948 -176.687 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 53.9 t0 -96.41 162.27 13.56 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.409 -1.054 . . . . 0.0 109.666 177.1 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 81' ' ' TRP . . . . . 0.577 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.0 m95 -113.21 153.33 28.51 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.141 -0.974 . . . . 0.0 110.42 177.369 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.043 HG13 ' HB3' ' A' ' 10' ' ' ALA . 0.8 OUTLIER -119.94 149.72 22.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.409 -0.807 . . . . 0.0 109.804 179.675 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 83' ' ' ASN . . . . . 1.031 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -69.6 102.58 1.88 Allowed 'General case' 0 C--N 1.3 -1.556 0 O-C-N 120.952 -1.092 . . . . 0.0 109.012 167.8 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 1.055 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -104.59 137.96 31.4 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 O-C-N 120.311 -1.493 . . . . 0.0 110.957 -178.772 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.445 ' HB2' HG22 ' A' ' 6' ' ' VAL . 85.9 tt0 -135.83 138.42 42.51 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.923 -0.711 . . . . 0.0 110.235 -176.192 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 76.4 ttt180 -61.3 127.46 31.63 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.24 -0.912 . . . . 0.0 110.044 -179.916 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.903 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . -129.24 153.46 47.76 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.257 -0.902 . . . . 0.0 109.957 179.937 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 88' ' ' ALA . . . . . 0.544 ' O ' ' CD1' ' B' ' 2' ' ' PHE . . . -143.14 158.05 43.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.388 -0.82 . . . . 0.0 110.825 -174.342 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.467 ' HA ' ' CE1' ' B' ' 2' ' ' PHE . 32.0 mttt -64.5 -40.06 94.95 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.445 -0.784 . . . . 0.0 110.112 176.207 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -158.79 161.47 36.95 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.336 -0.852 . . . . 0.0 110.323 -178.395 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.467 ' CB ' ' HG3' ' A' ' 93' ' ' GLU . 72.7 m -129.89 133.19 46.72 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.431 -0.793 . . . . 0.0 110.149 177.801 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.446 ' O ' ' HB2' ' A' ' 93' ' ' GLU . 96.0 m-20 -60.12 -36.35 77.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.205 -0.934 . . . . 0.0 109.621 176.765 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.467 ' HG3' ' CB ' ' A' ' 91' ' ' SER . 93.7 mt-10 53.95 56.09 7.54 Favored 'General case' 0 N--CA 1.505 2.294 0 C-N-CA 119.472 -0.891 . . . . 0.0 110.167 172.494 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 94' ' ' ILE . . . . . 0.756 HG22 ' O ' ' A' ' 96' ' ' GLY . 40.6 mm -60.0 -40.53 83.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.298 -0.876 . . . . 0.0 109.893 177.652 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 65.47 -80.79 0.08 OUTLIER Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.769 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 96' ' ' GLY . . . . . 0.756 ' O ' HG22 ' A' ' 94' ' ' ILE . . . -99.87 -178.8 30.65 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.35 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 24.3 m-70 . . . . . 0 N--CA 1.492 1.626 0 O-C-N 121.171 -1.194 . . . . 0.0 110.115 178.667 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 26.1 ptp . . . . . 0 N--CA 1.493 1.719 0 CA-C-O 121.329 0.585 . . . . 0.0 110.221 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' B' B ' 2' ' ' PHE . . . . . 0.825 ' HE2' ' HB1' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -165.47 140.71 5.06 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.199 -0.938 . . . . 0.0 109.097 175.369 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 3' ' ' THR . . . . . 0.529 ' O ' HG13 ' B' ' 5' ' ' ILE . 13.9 p -136.08 -32.64 0.86 Allowed 'General case' 0 C--N 1.294 -1.825 0 O-C-N 120.998 -1.064 . . . . 0.0 109.992 -174.783 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 4' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' B' ' 3' ' ' THR . . . 46.84 24.73 2.02 Favored Glycine 0 N--CA 1.486 2.028 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -175.639 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 5' ' ' ILE . . . . . 0.544 HD11 ' C8M' ' A' ' 98' ' ' RBF . 29.8 mt -87.74 136.37 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.133 -1.216 . . . . 0.0 110.298 -176.964 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 6' ' ' VAL . . . . . 1.039 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.5 t -86.11 143.86 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.27 -0.894 . . . . 0.0 110.723 -175.346 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -69.98 -32.52 70.78 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.601 -0.687 . . . . 0.0 110.88 177.382 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 8' ' ' GLY . . . . . 0.532 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -165.05 177.16 40.63 Favored Glycine 0 N--CA 1.496 2.641 0 C-N-CA 118.888 -1.625 . . . . 0.0 110.466 -174.184 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 9' ' ' THR . . . . . 0.508 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 3.0 p -116.3 167.82 10.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.105 -1.232 . . . . 0.0 110.953 -177.852 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 10' ' ' ALA . . . . . 1.044 ' HB2' HG21 ' B' ' 84' ' ' VAL . . . -137.72 148.58 45.77 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -176.099 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 11' ' ' LYS . . . . . 0.576 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 25.9 tttt -108.96 116.08 31.31 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.148 -0.97 . . . . 0.0 110.249 -179.209 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 12' ' ' LEU . . . . . 1.005 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.1 tp -58.97 127.29 31.46 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.124 -0.985 . . . . 0.0 108.976 174.257 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 13' ' ' VAL . . . . . 1.033 HG11 ' CE1' ' B' ' 58' ' ' HIS . 1.4 p -124.89 -31.67 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 C-N-CA 119.593 -0.843 . . . . 0.0 109.904 -179.638 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.35 143.98 28.41 Favored 'General case' 0 C--N 1.297 -1.675 0 C-N-CA 119.27 -0.972 . . . . 0.0 111.451 -178.019 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 15' ' ' ILE . . . . . 0.59 HG12 ' CD2' ' B' ' 24' ' ' HIS . 8.2 mt -108.02 130.18 60.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.264 -0.897 . . . . 0.0 110.232 172.246 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 16' ' ' ASP . . . . . 0.519 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 66.8 m-20 -105.94 114.31 28.38 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.369 -0.832 . . . . 0.0 109.724 172.994 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -106.57 108.82 20.52 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.912 -1.118 . . . . 0.0 110.938 -177.532 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 18' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -104.21 128.63 26.7 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.306 -0.871 . . . . 0.0 108.917 173.058 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 19' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.0 Cg_endo -50.44 -34.03 40.09 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 O-C-N 123.789 1.415 . . . . 0.0 110.42 -179.508 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 20' ' ' ASN . . . . . 0.54 ' C ' ' CD2' ' B' ' 21' ' ' PHE . 8.8 m120 -71.41 -40.25 70.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.131 -0.981 . . . . 0.0 109.985 175.524 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 21' ' ' PHE . . . . . 0.54 ' CD2' ' C ' ' B' ' 20' ' ' ASN . 89.3 m-85 -152.65 150.28 29.31 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.417 -0.802 . . . . 0.0 110.004 -179.327 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 22' ' ' ARG . . . . . 0.746 ' HD3' HD22 ' B' ' 68' ' ' LEU . 62.6 ttt180 -93.16 144.83 24.9 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.872 -1.143 . . . . 0.0 110.197 176.959 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 23' ' ' THR . . . . . 0.519 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 58.2 m -130.27 141.69 50.59 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.596 -0.69 . . . . 0.0 110.043 -176.305 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 24' ' ' HIS . . . . . 0.605 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -127.81 144.89 51.07 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.066 -1.021 . . . . 0.0 111.233 176.827 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 25' ' ' VAL . . . . . 0.769 HG22 ' CB ' ' B' ' 60' ' ' SER . 4.3 t -124.61 133.68 68.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.292 -0.88 . . . . 0.0 110.717 -179.293 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 26' ' ' VAL . . . . . 0.592 HG13 ' HE2' ' B' ' 61' ' ' PHE . 33.5 m -118.79 172.09 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 CA-C-O 121.27 0.557 . . . . 0.0 110.412 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 27' ' ' GLU . . . . . 0.605 ' HG3' ' CE1' ' B' ' 58' ' ' HIS . 13.1 tt0 -101.1 117.6 35.34 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.603 -0.686 . . . . 0.0 109.235 -179.473 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 28' ' ' LEU . . . . . 0.62 HD23 ' HA ' ' B' ' 33' ' ' LEU . 9.4 tp -82.01 121.27 78.89 Favored Pre-proline 0 C--N 1.297 -1.681 0 O-C-N 121.639 -0.663 . . . . 0.0 109.86 -175.401 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 29' ' ' PRO . . . . . 0.48 ' HD2' HD12 ' B' ' 28' ' ' LEU . 25.7 Cg_endo -66.24 179.59 1.9 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 123.913 1.48 . . . . 0.0 110.955 -179.399 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 30' ' ' ASP . . . . . 0.5 ' HA ' HD12 ' B' ' 33' ' ' LEU . 96.0 m-20 -63.48 -40.03 96.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.304 -0.873 . . . . 0.0 111.06 -175.662 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 31' ' ' HIS . . . . . 0.439 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.33 0.95 57.03 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.858 -1.151 . . . . 0.0 111.067 -175.253 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 32' ' ' MET . . . . . 0.455 ' HB2' ' HD2' ' B' ' 29' ' ' PRO . 98.4 mmm -113.87 -13.93 12.54 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.945 -1.097 . . . . 0.0 109.799 172.305 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 33' ' ' LEU . . . . . 0.62 ' HA ' HD23 ' B' ' 28' ' ' LEU . 14.0 mt -66.15 -39.92 90.18 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.32 -0.862 . . . . 0.0 109.76 176.534 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -77.06 132.4 38.89 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.481 -0.762 . . . . 0.0 110.584 -177.487 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.37 -43.04 1.88 Allowed Glycine 0 N--CA 1.491 2.359 0 N-CA-C 110.306 -1.117 . . . . 0.0 110.306 174.512 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 36' ' ' LEU . . . . . 0.595 HD23 ' N ' ' B' ' 37' ' ' GLU . 5.7 tt -69.91 145.71 51.76 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.942 -1.328 . . . . 0.0 110.557 -174.949 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 37' ' ' GLU . . . . . 0.595 ' N ' HD23 ' B' ' 36' ' ' LEU . 20.6 pt-20 -150.03 167.6 26.28 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.47 -0.769 . . . . 0.0 109.381 -179.56 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 38' ' ' THR . . . . . 0.815 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -67.92 149.81 49.33 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.864 -1.148 . . . . 0.0 110.237 -178.125 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.35 -3.46 62.61 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -173.813 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 40' ' ' ALA . . . . . 0.536 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -76.74 160.04 29.66 Favored 'General case' 0 N--CA 1.486 1.375 0 O-C-N 121.218 -1.166 . . . . 0.0 109.129 174.742 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 41' ' ' SER . . . . . 0.926 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 1.2 p -103.97 117.72 34.98 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 120.82 -1.175 . . . . 0.0 109.981 177.221 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 42' ' ' VAL . . . . . 0.597 HG11 ' HE1' ' B' ' 44' ' ' HIS . 0.9 OUTLIER -100.03 120.18 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.355 -0.841 . . . . 0.0 108.965 176.934 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 43' ' ' ALA . . . . . 0.508 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -82.89 117.28 22.63 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.247 -0.981 . . . . 0.0 109.316 174.474 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 44' ' ' HIS . . . . . 0.651 ' CD2' HG21 ' B' ' 82' ' ' VAL . 1.4 m80 -87.27 103.19 15.21 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.624 -0.831 . . . . 0.0 108.818 176.232 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' A' ' 45' ' ' ASN . 0.9 OUTLIER 56.07 11.97 0.85 Allowed 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.677 -0.639 . . . . 0.0 111.239 -169.622 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 46' ' ' GLY . . . . . 0.49 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 126.73 -5.74 7.47 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 119.679 -1.248 . . . . 0.0 110.845 173.213 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 47' ' ' CYS . . . . . 0.874 ' O ' HD23 ' B' ' 49' ' ' LEU . 44.9 t -93.49 103.63 15.81 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.477 -1.602 . . . . 0.0 109.618 175.922 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 48' ' ' CYS . . . . . 0.436 ' SG ' ' O ' ' A' ' 3' ' ' THR . 14.8 p -72.14 122.07 20.37 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.117 -0.989 . . . . 0.0 110.617 -174.449 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 49' ' ' LEU . . . . . 0.874 HD23 ' O ' ' B' ' 47' ' ' CYS . 0.2 OUTLIER -132.21 160.53 35.86 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.461 -0.774 . . . . 0.0 109.283 173.568 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 50' ' ' THR . . . . . 0.444 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 37.5 m -97.53 152.59 18.86 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.42 -1.425 . . . . 0.0 111.464 -169.531 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 51' ' ' VAL . . . . . 0.907 HG13 HG13 ' B' ' 59' ' ' VAL . 20.0 t -81.18 114.76 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.795 -0.566 . . . . 0.0 110.389 -178.973 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 52' ' ' THR . . . . . 0.48 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 31.4 p -69.97 -40.03 75.63 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.152 -0.967 . . . . 0.0 109.739 174.575 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 53' ' ' GLU . . . . . 0.565 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.6 tt0 -161.49 155.63 22.38 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.416 -0.803 . . . . 0.0 109.804 179.634 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 54' ' ' ILE . . . . . 0.815 HD11 ' N ' ' B' ' 38' ' ' THR . 7.1 mt -105.11 128.94 58.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.113 -0.992 . . . . 0.0 109.592 174.698 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 55' ' ' ASN . . . . . 0.525 ' HB2' ' CB ' ' B' ' 58' ' ' HIS . 2.2 m-80 -100.57 62.61 1.05 Allowed 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 119.878 -0.729 . . . . 0.0 109.55 -178.988 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.19 -120.08 6.51 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 108.657 -1.777 . . . . 0.0 108.657 -172.716 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 57' ' ' ASN . . . . . 0.588 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.1 OUTLIER -71.8 -20.17 61.89 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 120.97 -1.312 . . . . 0.0 109.109 175.031 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 58' ' ' HIS . . . . . 1.033 ' CE1' HG11 ' B' ' 13' ' ' VAL . 28.3 m-70 -76.68 161.22 28.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.421 -0.799 . . . . 0.0 110.432 -176.851 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 59' ' ' VAL . . . . . 0.907 HG13 HG13 ' B' ' 51' ' ' VAL . 54.8 t -140.04 125.53 20.82 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 C-N-CA 119.042 -1.063 . . . . 0.0 110.723 170.794 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 60' ' ' SER . . . . . 0.769 ' CB ' HG22 ' B' ' 25' ' ' VAL . 24.4 m -97.54 123.42 41.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.75 -0.594 . . . . 0.0 109.513 -179.573 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 61' ' ' PHE . . . . . 0.837 ' HB2' HD12 ' B' ' 49' ' ' LEU . 10.0 p90 -118.65 159.65 23.23 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 120.822 -1.174 . . . . 0.0 110.533 -179.655 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 62' ' ' ASP . . . . . 0.48 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 35.2 p-10 -93.36 156.55 16.72 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.075 -1.016 . . . . 0.0 111.459 -171.99 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 63' ' ' LEU . . . . . 1.085 HD22 HD13 ' B' ' 68' ' ' LEU . 0.1 OUTLIER -161.11 102.12 1.26 Allowed 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 120.258 -0.577 . . . . 0.0 109.447 -174.235 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 64' ' ' MET . . . . . 0.498 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 57.6 ttm -60.07 137.64 58.05 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.707 -1.245 . . . . 0.0 109.068 179.266 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 65' ' ' LYS . . . . . 0.484 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 28.6 tttt -59.96 -45.93 91.06 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.91 -1.119 . . . . 0.0 110.63 -172.197 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 54.0 tp10 -66.21 -40.02 90.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.723 -1.236 . . . . 0.0 109.837 177.452 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 67' ' ' THR . . . . . 0.498 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 94.4 m -59.97 -40.03 87.69 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.036 -1.04 . . . . 0.0 109.512 172.657 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 68' ' ' LEU . . . . . 1.085 HD13 HD22 ' B' ' 63' ' ' LEU . 27.9 tp -60.05 -43.29 95.49 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.374 -0.829 . . . . 0.0 109.823 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 ttt85 -69.99 -39.26 76.02 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.318 -0.864 . . . . 0.0 110.364 177.751 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 70' ' ' ILE . . . . . 0.707 HG22 HG23 ' B' ' 71' ' ' THR . 1.4 tt -64.56 -42.62 95.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.278 -0.889 . . . . 0.0 109.583 -176.903 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 71' ' ' THR . . . . . 0.707 HG23 HG22 ' B' ' 70' ' ' ILE . 30.5 p -82.06 -174.94 5.37 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.955 -0.698 . . . . 0.0 109.317 175.4 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 72' ' ' ASN . . . . . 0.52 ' CB ' ' H ' ' A' ' 83' ' ' ASN . 5.2 t30 -99.38 22.17 11.03 Favored 'General case' 0 C--N 1.295 -1.77 0 O-C-N 121.141 -0.974 . . . . 0.0 108.534 171.074 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 73' ' ' LEU . . . . . 0.728 HD13 HD21 ' B' ' 63' ' ' LEU . 71.5 mt -70.03 -39.99 75.44 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.991 -1.068 . . . . 0.0 109.897 175.62 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 74' ' ' GLY . . . . . 0.435 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -49.38 -21.6 3.07 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 110.316 -1.113 . . . . 0.0 110.316 -177.954 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.2 p-10 -66.32 -16.31 63.94 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.127 -1.219 . . . . 0.0 110.525 -175.052 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 96.2 mt -62.26 142.36 57.76 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.291 -0.88 . . . . 0.0 111.189 -175.109 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 77' ' ' LYS . . . . . 1.005 ' C ' HD23 ' B' ' 12' ' ' LEU . 86.6 mttt -141.46 141.1 33.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.669 -0.645 . . . . 0.0 109.563 172.661 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 78' ' ' VAL . . . . . 0.714 ' N ' HD23 ' B' ' 12' ' ' LEU . 16.7 t -59.42 151.63 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 120.812 -1.18 . . . . 0.0 110.245 -176.134 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.83 -13.44 60.98 Favored Glycine 0 N--CA 1.484 1.882 0 N-CA-C 108.887 -1.685 . . . . 0.0 108.887 -176.8 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 80' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 53.7 t0 -96.5 162.16 13.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.397 -1.061 . . . . 0.0 109.666 177.029 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 81' ' ' TRP . . . . . 0.576 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.0 m95 -113.13 153.32 28.42 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.103 -0.998 . . . . 0.0 110.372 177.532 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 82' ' ' VAL . . . . . 0.99 HG13 ' HB3' ' B' ' 10' ' ' ALA . 0.8 OUTLIER -120.01 149.75 22.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.553 -0.717 . . . . 0.0 109.858 179.553 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 83' ' ' ASN . . . . . 1.039 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.2 OUTLIER -69.53 102.41 1.82 Allowed 'General case' 0 C--N 1.298 -1.633 0 O-C-N 120.975 -1.078 . . . . 0.0 109.091 167.783 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 1.044 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -104.45 138.17 30.31 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 O-C-N 120.422 -1.424 . . . . 0.0 110.862 -178.611 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' B' B ' 85' ' ' GLU . . . . . 0.438 ' HB2' HG22 ' B' ' 6' ' ' VAL . 85.9 tt0 -136.12 138.38 41.98 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 119.982 -0.687 . . . . 0.0 110.234 -176.277 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 76.5 ttt180 -61.26 127.53 31.98 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.153 -0.967 . . . . 0.0 109.941 -179.8 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 87' ' ' ALA . . . . . 0.926 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . -129.26 153.71 47.53 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.197 -0.939 . . . . 0.0 109.99 179.86 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 88' ' ' ALA . . . . . 0.583 ' O ' ' CD1' ' A' ' 2' ' ' PHE . . . -143.44 158.03 43.98 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.357 -0.839 . . . . 0.0 110.68 -174.179 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 89' ' ' LYS . . . . . 0.509 ' HA ' ' CE1' ' A' ' 2' ' ' PHE . 31.9 mttt -64.59 -39.98 94.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.495 -0.753 . . . . 0.0 110.063 176.221 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 41.5 p90 -158.87 161.52 36.85 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.238 -0.914 . . . . 0.0 110.396 -178.374 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 91' ' ' SER . . . . . . . . . . . . . 72.7 m -129.96 133.15 46.61 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.359 -0.838 . . . . 0.0 110.181 177.864 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -60.52 -45.61 93.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.146 -0.971 . . . . 0.0 109.76 176.906 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 93' ' ' GLU . . . . . 0.573 ' O ' ' CG ' ' B' ' 93' ' ' GLU . 5.0 tt0 -141.8 69.94 1.33 Allowed 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 122.201 1.0 . . . . 0.0 109.131 -177.956 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 94' ' ' ILE . . . . . 0.788 HG22 ' O ' ' B' ' 94' ' ' ILE . 21.7 mm 43.64 28.55 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.505 2.307 0 O-C-N 120.831 -1.168 . . . . 0.0 108.916 -176.324 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 95' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' B' ' 93' ' ' GLU . . . -65.46 80.44 0.08 OUTLIER Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 -174.888 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 96' ' ' GLY . . . . . 0.405 ' O ' ' HB2' ' B' ' 97' ' ' HIS . . . 145.2 -176.17 24.37 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.744 -1.343 . . . . 0.0 109.744 176.806 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 97' ' ' HIS . . . . . 0.405 ' HB2' ' O ' ' B' ' 96' ' ' GLY . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.582 0 O-C-N 121.297 -1.12 . . . . 0.0 110.273 178.393 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 98' ' ' RBF . . . . . 0.551 " C2'" ' HC9' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 99' ' ' RBF . . . . . 0.595 ' C8M' HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.887 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.3 t . . . . . 0 N--CA 1.495 1.804 0 CA-C-O 121.682 0.753 . . . . 0.0 111.026 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -59.98 -40.02 87.7 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.574 -0.704 . . . . 0.0 110.56 174.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.541 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -170.66 -176.95 40.37 Favored Glycine 0 N--CA 1.495 2.588 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.118 -174.634 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.48 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 21.4 p -117.58 169.83 9.24 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.872 -1.37 . . . . 0.0 111.13 -175.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 1.055 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -135.13 147.8 49.58 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.684 -0.635 . . . . 0.0 109.356 -179.033 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.576 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 34.0 tttt -103.57 115.74 31.07 Favored 'General case' 0 C--N 1.293 -1.856 0 O-C-N 121.046 -1.034 . . . . 0.0 110.269 -179.583 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 1.004 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.0 tp -59.87 126.45 27.62 Favored 'General case' 0 C--N 1.298 -1.653 0 O-C-N 120.892 -1.13 . . . . 0.0 108.823 172.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.094 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -126.91 -29.02 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 O-C-N 121.438 -0.789 . . . . 0.0 110.017 -179.094 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.04 141.91 26.88 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 119.058 -1.057 . . . . 0.0 111.606 -178.748 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.65 HG23 ' NE2' ' A' ' 24' ' ' HIS . 14.2 mt -109.08 130.52 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.052 -1.03 . . . . 0.0 110.206 170.786 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.504 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 81.6 m-20 -107.71 115.46 30.19 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.291 -0.88 . . . . 0.0 109.963 174.121 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -104.21 114.4 28.61 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.969 -1.082 . . . . 0.0 110.591 -176.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.0 OUTLIER -113.67 128.97 25.14 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.141 -0.974 . . . . 0.0 109.203 175.343 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.1 Cg_endo -52.37 -18.37 7.84 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 O-C-N 123.831 1.437 . . . . 0.0 110.944 -179.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.587 ' ND2' ' N ' ' A' ' 20' ' ' ASN . 0.3 OUTLIER -92.3 -33.54 14.58 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.135 -0.978 . . . . 0.0 108.939 178.309 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.545 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 84.1 m-85 -156.16 150.24 25.33 Favored 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.358 0.599 . . . . 0.0 110.14 179.792 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.556 ' HD3' HD22 ' A' ' 68' ' ' LEU . 60.1 ttt180 -90.89 144.24 25.89 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 120.744 -1.223 . . . . 0.0 109.775 175.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.504 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 85.0 m -129.17 137.69 51.31 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.472 -0.767 . . . . 0.0 109.822 -177.09 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.65 ' NE2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.25 137.04 49.81 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 120.967 -1.083 . . . . 0.0 111.141 179.394 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.832 HG22 ' OG ' ' A' ' 60' ' ' SER . 15.6 t -119.05 134.91 61.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.037 -1.039 . . . . 0.0 110.641 -177.279 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.482 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 16.9 m -117.13 170.93 6.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 CA-C-O 121.088 0.47 . . . . 0.0 110.112 177.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.567 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 8.7 tt0 -107.42 116.58 32.18 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.507 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.3 tp -81.36 128.59 69.59 Favored Pre-proline 0 C--N 1.295 -1.766 0 O-C-N 121.307 -0.87 . . . . 0.0 109.978 -171.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.483 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 33.6 Cg_endo -68.0 176.83 4.9 Favored 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.903 1.475 . . . . 0.0 110.88 -179.376 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.556 ' HA ' HD12 ' A' ' 33' ' ' LEU . 96.0 m-20 -60.02 -40.02 87.85 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.255 -0.903 . . . . 0.0 111.261 -174.251 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.589 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.85 0.83 56.81 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.75 -1.219 . . . . 0.0 110.936 -173.912 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.589 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.9 mmm -113.23 -9.63 13.44 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 120.839 -1.163 . . . . 0.0 110.074 170.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.726 HD21 ' HB2' ' A' ' 57' ' ' ASN . 19.9 mt -70.02 -23.18 63.08 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.169 -0.957 . . . . 0.0 110.052 176.263 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -94.47 129.94 41.04 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.469 -0.769 . . . . 0.0 110.478 -177.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.98 -43.53 1.71 Allowed Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.909 -1.139 . . . . 0.0 110.396 174.126 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.906 HD23 ' N ' ' A' ' 37' ' ' GLU . 7.1 tt -69.94 149.16 48.07 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.836 -1.391 . . . . 0.0 110.855 -174.221 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.906 ' N ' HD23 ' A' ' 36' ' ' LEU . 19.3 pt-20 -150.42 170.02 20.06 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.512 -0.742 . . . . 0.0 109.682 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.874 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -65.82 153.51 41.7 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.024 -1.048 . . . . 0.0 110.235 179.779 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.41 -2.15 63.32 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -178.405 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.449 ' O ' ' HA ' ' A' ' 50' ' ' THR . . . -78.3 158.07 28.98 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.254 -1.145 . . . . 0.0 109.552 176.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.645 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.4 OUTLIER -100.31 107.74 19.61 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.026 -1.07 . . . . 0.0 109.876 175.653 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.666 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.1 t -93.65 133.23 35.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 121.321 -0.862 . . . . 0.0 108.896 173.305 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.508 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -97.98 120.0 37.59 Favored 'General case' 0 C--N 1.295 -1.763 0 C-N-CA 119.109 -1.036 . . . . 0.0 109.107 172.174 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.77 ' CD2' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -89.7 106.99 18.83 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 178.929 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 54.01 14.12 0.66 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.444 -0.785 . . . . 0.0 111.048 -168.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.505 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 117.87 2.83 16.37 Favored Glycine 0 N--CA 1.489 2.178 0 C-N-CA 119.527 -1.32 . . . . 0.0 110.798 172.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.762 ' O ' HD23 ' A' ' 49' ' ' LEU . 33.2 t -98.65 109.9 22.58 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.521 -1.576 . . . . 0.0 109.47 174.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.449 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 31.0 p -76.8 130.26 37.41 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.978 -1.076 . . . . 0.0 111.182 -170.251 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.961 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -146.54 161.23 40.93 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.573 -0.704 . . . . 0.0 109.333 173.123 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.449 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 22.9 m -100.81 153.02 19.82 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.587 -1.321 . . . . 0.0 111.105 -171.199 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.83 HG13 HG13 ' A' ' 59' ' ' VAL . 24.6 t -76.68 113.77 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.839 -0.538 . . . . 0.0 110.186 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.563 HG22 ' HB3' ' A' ' 62' ' ' ASP . 27.7 p -70.26 -41.55 73.3 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.24 -0.912 . . . . 0.0 109.518 174.146 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.57 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 20.4 pt-20 -160.12 160.09 32.59 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 119.543 -0.863 . . . . 0.0 110.813 176.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.874 HD11 ' N ' ' A' ' 38' ' ' THR . 8.9 mt -110.58 130.05 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.268 -0.895 . . . . 0.0 109.962 173.653 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.494 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 3.2 m-80 -103.33 63.22 0.8 Allowed 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 120.071 -0.652 . . . . 0.0 109.509 179.25 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.36 -117.43 4.79 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 108.961 -1.655 . . . . 0.0 108.961 -173.612 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.726 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -77.14 -20.63 55.29 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 120.965 -1.314 . . . . 0.0 108.803 175.45 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.094 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.1 m170 -75.56 158.7 32.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.28 -0.888 . . . . 0.0 110.141 -177.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.83 HG13 HG13 ' A' ' 51' ' ' VAL . 55.1 t -140.41 123.82 17.26 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 C-N-CA 119.143 -1.023 . . . . 0.0 110.674 171.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.832 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.1 t -89.82 134.17 34.33 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.391 -0.818 . . . . 0.0 109.381 175.505 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.961 ' HB3' HD12 ' A' ' 49' ' ' LEU . 89.1 m-85 -115.67 159.87 20.79 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.224 -0.922 . . . . 0.0 110.277 175.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.563 ' HB3' HG22 ' A' ' 52' ' ' THR . 28.3 p-10 -93.02 149.09 21.46 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.187 -0.945 . . . . 0.0 111.129 178.542 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.726 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -154.18 117.69 4.61 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -175.127 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.542 ' HB2' ' CB ' ' A' ' 67' ' ' THR . 54.1 mtp -70.33 139.38 52.0 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.911 -1.118 . . . . 0.0 109.981 179.149 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.499 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 45.0 tptt -59.93 -49.91 75.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.163 -0.961 . . . . 0.0 110.274 -179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.466 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.5 tt0 -64.97 -39.99 94.31 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.753 -1.217 . . . . 0.0 109.859 177.245 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.542 ' CB ' ' HB2' ' A' ' 64' ' ' MET . 85.5 m -59.87 -35.67 75.3 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.934 -1.104 . . . . 0.0 109.397 173.066 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.705 HD13 HD22 ' A' ' 63' ' ' LEU . 20.0 tp -62.84 -46.71 86.63 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.186 -0.946 . . . . 0.0 109.756 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 71.5 ttt-85 -69.98 -39.17 76.11 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.484 -0.76 . . . . 0.0 110.136 178.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.67 HG22 HG23 ' A' ' 71' ' ' THR . 1.1 tt -66.81 -40.02 84.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.366 -0.833 . . . . 0.0 109.337 -179.24 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.67 HG23 HG22 ' A' ' 70' ' ' ILE . 65.0 p -86.26 -173.65 4.66 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 174.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.4 t30 -104.18 25.04 10.53 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 170.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.726 ' HB3' HD21 ' A' ' 63' ' ' LEU . 87.9 mt -69.96 -40.0 75.69 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.027 -1.046 . . . . 0.0 110.008 177.298 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.531 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -47.7 -21.93 1.65 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.5 p-10 -67.11 -17.83 65.04 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.938 -1.33 . . . . 0.0 110.823 -174.221 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.0 mt -60.01 142.96 53.02 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.118 -0.989 . . . . 0.0 111.068 -175.603 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 1.004 ' C ' HD23 ' A' ' 12' ' ' LEU . 54.6 mttp -140.03 139.23 35.93 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.709 -0.619 . . . . 0.0 109.762 174.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.655 ' N ' HD23 ' A' ' 12' ' ' LEU . 15.8 t -61.02 153.08 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.862 -1.149 . . . . 0.0 110.351 -178.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.02 -15.03 58.99 Favored Glycine 0 N--CA 1.483 1.801 0 N-CA-C 108.716 -1.753 . . . . 0.0 108.716 -177.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.443 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 25.1 t0 -96.21 169.5 9.9 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.428 -1.042 . . . . 0.0 109.601 176.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.576 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.5 m95 -115.97 164.32 14.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.913 -1.117 . . . . 0.0 110.351 175.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.055 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.7 p -129.62 144.39 38.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.564 -0.71 . . . . 0.0 109.949 -176.518 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.887 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.6 m-20 -70.95 105.24 3.21 Favored 'General case' 0 C--N 1.293 -1.862 0 O-C-N 121.077 -1.014 . . . . 0.0 109.266 170.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.75 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -108.89 138.92 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 120.535 -1.353 . . . . 0.0 111.153 -176.063 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -137.15 147.02 45.68 Favored 'General case' 0 N--CA 1.495 1.82 0 C-N-CA 120.293 -0.563 . . . . 0.0 110.193 179.499 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 73.9 ttt-85 -85.22 130.65 34.56 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.232 -0.917 . . . . 0.0 111.309 -174.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.645 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.492 1.653 0 O-C-N 121.274 -0.891 . . . . 0.0 110.047 175.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 0.854 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.3 t . . . . . 0 N--CA 1.494 1.748 0 CA-C-O 121.646 0.736 . . . . 0.0 111.093 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -59.95 -39.91 87.18 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.59 -0.693 . . . . 0.0 110.62 174.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.542 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -170.88 -177.2 40.65 Favored Glycine 0 N--CA 1.495 2.616 0 C-N-CA 119.201 -1.476 . . . . 0.0 110.222 -174.534 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.487 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 21.4 p -117.48 169.8 9.24 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.896 -1.355 . . . . 0.0 111.207 -175.611 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.066 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -135.04 147.96 49.77 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 -179.066 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.585 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 34.0 tttt -103.78 115.84 31.22 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 121.15 -0.969 . . . . 0.0 110.16 -179.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 1.018 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.0 tp -59.99 126.31 27.05 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 120.96 -1.088 . . . . 0.0 108.843 172.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.1 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -126.67 -29.15 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.03 -179.087 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.02 141.83 26.82 Favored 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.25 -0.98 . . . . 0.0 111.568 -178.623 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.641 HG23 ' NE2' ' B' ' 24' ' ' HIS . 14.2 mt -108.96 130.64 61.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.046 -1.034 . . . . 0.0 110.232 170.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.516 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 81.0 m-20 -107.98 115.6 30.42 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.369 -0.832 . . . . 0.0 109.746 174.239 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -104.18 114.42 28.65 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.042 -1.037 . . . . 0.0 110.547 -176.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.459 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.0 OUTLIER -113.75 128.9 25.23 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.358 -0.839 . . . . 0.0 109.183 175.353 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 9.1 Cg_endo -52.37 -18.42 7.93 Favored 'Trans proline' 0 C--N 1.304 -1.809 0 O-C-N 123.858 1.451 . . . . 0.0 110.906 -179.326 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.564 ' ND2' ' N ' ' B' ' 20' ' ' ASN . 0.3 OUTLIER -92.22 -33.9 14.49 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.06 -1.025 . . . . 0.0 108.769 178.413 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.548 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 84.2 m-85 -155.89 150.25 25.76 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.196 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . 0.551 ' HD3' HD22 ' B' ' 68' ' ' LEU . 60.0 ttt180 -90.87 144.14 26.0 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.909 -1.12 . . . . 0.0 109.797 175.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.516 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 82.7 m -129.14 137.74 51.37 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.539 -0.726 . . . . 0.0 109.826 -177.135 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.641 ' NE2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.18 136.94 49.8 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.029 -1.045 . . . . 0.0 111.054 179.573 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.831 HG22 ' OG ' ' B' ' 60' ' ' SER . 15.6 t -118.98 135.09 60.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.116 -0.99 . . . . 0.0 110.734 -177.404 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.491 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 17.2 m -117.42 170.91 6.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 C-N-CA 120.444 -0.502 . . . . 0.0 109.99 178.072 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.566 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 8.7 tt0 -107.36 116.53 32.1 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.594 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.497 ' HA ' HD12 ' B' ' 28' ' ' LEU . 9.3 tp -81.2 128.49 70.4 Favored Pre-proline 0 C--N 1.295 -1.781 0 O-C-N 121.228 -0.92 . . . . 0.0 110.05 -171.856 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.475 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 33.8 Cg_endo -67.99 176.82 4.9 Favored 'Trans proline' 0 C--N 1.308 -1.567 0 O-C-N 123.9 1.474 . . . . 0.0 110.87 -179.392 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.543 ' HA ' HD12 ' B' ' 33' ' ' LEU . 96.1 m-20 -60.02 -39.99 87.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.314 -0.866 . . . . 0.0 111.255 -174.211 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.596 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.82 0.84 56.78 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.733 -1.229 . . . . 0.0 110.974 -173.949 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.596 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.8 mmm -113.28 -9.57 13.41 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.824 -1.172 . . . . 0.0 110.143 170.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.707 HD21 ' HB2' ' B' ' 57' ' ' ASN . 20.0 mt -69.98 -23.33 63.14 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.232 -0.918 . . . . 0.0 109.994 176.189 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 94.3 m-20 -94.44 129.89 41.01 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.383 -0.823 . . . . 0.0 110.57 -177.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.96 -43.47 1.73 Allowed Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.885 -1.15 . . . . 0.0 110.48 174.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.917 HD23 ' N ' ' B' ' 37' ' ' GLU . 7.2 tt -70.09 149.15 47.92 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.926 -1.338 . . . . 0.0 110.81 -174.216 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . 0.917 ' N ' HD23 ' B' ' 36' ' ' LEU . 19.3 pt-20 -150.39 170.01 20.07 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.515 -0.741 . . . . 0.0 109.738 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 0.878 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -65.8 153.38 42.02 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.992 -1.068 . . . . 0.0 110.236 179.832 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.41 -2.06 63.62 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.453 ' O ' ' HA ' ' B' ' 50' ' ' THR . . . -78.42 157.89 28.87 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.259 -1.142 . . . . 0.0 109.558 176.713 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.639 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.4 OUTLIER -99.97 107.67 19.7 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.894 -1.128 . . . . 0.0 109.994 175.625 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.672 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.1 t -93.66 133.31 35.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.358 -0.839 . . . . 0.0 108.874 173.322 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 0.505 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -97.99 120.05 37.69 Favored 'General case' 0 C--N 1.296 -1.738 0 C-N-CA 119.162 -1.015 . . . . 0.0 109.055 172.184 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.76 ' CD2' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -89.75 106.78 18.69 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.427 -0.796 . . . . 0.0 108.994 178.876 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 54.13 14.21 0.7 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.396 -0.815 . . . . 0.0 111.043 -168.537 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.505 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 117.65 3.21 16.58 Favored Glycine 0 N--CA 1.488 2.142 0 C-N-CA 119.545 -1.312 . . . . 0.0 110.823 172.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.76 ' O ' HD23 ' B' ' 49' ' ' LEU . 33.5 t -98.82 110.02 22.69 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.521 -1.576 . . . . 0.0 109.397 174.702 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . 0.449 ' O ' ' SG ' ' B' ' 48' ' ' CYS . 31.2 p -76.82 130.35 37.51 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.032 -1.043 . . . . 0.0 111.184 -170.32 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 1.011 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -146.7 161.17 41.15 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.62 -0.675 . . . . 0.0 109.304 173.105 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . 0.453 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 22.9 m -100.69 153.13 19.69 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.722 -1.236 . . . . 0.0 111.06 -171.099 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.846 HG13 HG13 ' B' ' 59' ' ' VAL . 24.8 t -76.8 113.74 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.694 -0.629 . . . . 0.0 110.268 -179.55 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.574 HG22 ' HB3' ' B' ' 62' ' ' ASP . 28.0 p -70.25 -41.55 73.35 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.196 -0.94 . . . . 0.0 109.524 174.262 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.579 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 20.5 pt-20 -160.18 160.04 32.36 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.325 -0.859 . . . . 0.0 110.805 176.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.878 HD11 ' N ' ' B' ' 38' ' ' THR . 9.0 mt -110.52 130.02 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.307 -0.87 . . . . 0.0 109.945 173.773 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.511 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 3.2 m-80 -103.33 63.13 0.79 Allowed 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 120.018 -0.673 . . . . 0.0 109.524 179.274 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.55 -117.53 4.79 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 108.884 -1.686 . . . . 0.0 108.884 -173.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.707 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -77.04 -20.79 55.47 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.1 -1.235 . . . . 0.0 108.814 175.471 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.1 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.2 m170 -75.33 158.51 32.69 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.423 -0.798 . . . . 0.0 110.223 -178.099 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.846 HG13 HG13 ' B' ' 51' ' ' VAL . 54.9 t -140.33 123.7 17.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 C-N-CA 119.126 -1.029 . . . . 0.0 110.677 171.593 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.831 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.1 t -89.76 134.31 34.24 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.448 -0.783 . . . . 0.0 109.406 175.501 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 1.011 ' HB3' HD12 ' B' ' 49' ' ' LEU . 89.2 m-85 -115.74 159.89 20.81 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.213 175.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.574 ' HB3' HG22 ' B' ' 52' ' ' THR . 28.3 p-10 -92.96 149.15 21.43 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.163 -0.961 . . . . 0.0 111.059 178.539 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.702 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -154.28 117.77 4.59 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -175.23 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.551 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 54.3 mtp -70.4 139.42 51.87 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.989 -1.07 . . . . 0.0 110.042 179.107 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.495 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 45.1 tptt -59.92 -49.88 75.95 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.188 -0.945 . . . . 0.0 110.328 -179.567 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . 0.478 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 86.5 tt0 -64.88 -40.0 94.43 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.868 -1.145 . . . . 0.0 109.953 177.17 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.551 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 85.0 m -60.05 -35.79 75.9 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.942 -1.099 . . . . 0.0 109.328 173.172 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.691 HD13 HD22 ' B' ' 63' ' ' LEU . 19.8 tp -62.61 -46.64 87.36 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.226 -0.921 . . . . 0.0 109.85 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 71.5 ttt-85 -70.07 -39.24 75.74 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.474 -0.766 . . . . 0.0 110.075 178.156 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.648 HG22 HG23 ' B' ' 71' ' ' THR . 1.1 tt -66.78 -40.04 85.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.466 -0.771 . . . . 0.0 109.302 -179.228 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.648 HG23 HG22 ' B' ' 70' ' ' ILE . 65.9 p -86.21 -173.53 4.6 Favored 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 120.035 -0.666 . . . . 0.0 109.324 174.265 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.489 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 4.4 t30 -104.32 25.21 10.41 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 170.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.702 ' HB3' HD21 ' B' ' 63' ' ' LEU . 87.6 mt -70.06 -39.97 75.36 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.02 -1.05 . . . . 0.0 109.985 177.223 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.515 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -47.92 -21.68 1.73 Allowed Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 -179.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.6 p-10 -67.18 -17.8 64.99 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.911 -1.347 . . . . 0.0 110.792 -174.279 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.507 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 97.0 mt -59.97 142.9 53.01 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.139 -0.976 . . . . 0.0 111.045 -175.596 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 1.018 ' C ' HD23 ' B' ' 12' ' ' LEU . 54.6 mttp -140.01 139.28 35.97 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.652 -0.655 . . . . 0.0 109.768 174.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.665 ' N ' HD23 ' B' ' 12' ' ' LEU . 15.9 t -61.13 153.06 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.964 -1.085 . . . . 0.0 110.322 -178.176 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.01 -14.82 59.54 Favored Glycine 0 N--CA 1.484 1.88 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.448 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 25.0 t0 -96.31 169.4 9.96 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.463 -1.022 . . . . 0.0 109.626 176.326 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.585 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.5 m95 -116.05 164.18 14.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.996 -1.065 . . . . 0.0 110.327 175.33 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 1.066 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.6 p -129.46 144.49 37.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.613 -0.679 . . . . 0.0 110.031 -176.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.854 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -70.91 105.08 3.14 Favored 'General case' 0 C--N 1.292 -1.892 0 O-C-N 121.164 -0.96 . . . . 0.0 109.301 170.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.719 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -108.84 138.93 33.52 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 120.614 -1.304 . . . . 0.0 111.099 -175.972 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -137.15 147.05 45.7 Favored 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.19 179.385 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 74.0 ttt-85 -85.16 130.7 34.56 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.175 -0.953 . . . . 0.0 111.278 -174.619 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.639 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.761 0 O-C-N 121.376 -0.827 . . . . 0.0 110.001 175.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.749 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.3 t . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 121.531 0.682 . . . . 0.0 110.061 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.508 ' OE1' ' NH1' ' A' ' 86' ' ' ARG . 97.2 mt-30 -70.24 -30.03 66.98 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.492 -0.755 . . . . 0.0 111.405 -178.495 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.53 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -148.44 176.13 27.39 Favored Glycine 0 N--CA 1.495 2.579 0 C-N-CA 118.687 -1.721 . . . . 0.0 110.271 -173.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.462 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 2.9 p -123.28 171.3 9.49 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.153 -1.204 . . . . 0.0 110.574 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 1.018 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -141.11 150.07 42.37 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.46 -0.775 . . . . 0.0 109.401 -175.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 26.3 tttt -111.53 116.23 30.52 Favored 'General case' 0 C--N 1.297 -1.704 0 O-C-N 121.059 -1.025 . . . . 0.0 110.334 179.875 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.877 HD23 ' C ' ' A' ' 77' ' ' LYS . 9.9 tp -58.43 124.78 20.74 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.013 -1.054 . . . . 0.0 108.931 173.1 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.119 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.0 OUTLIER -118.24 -29.29 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 O-C-N 121.359 -0.838 . . . . 0.0 109.597 178.751 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.43 149.96 27.37 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.057 -1.057 . . . . 0.0 111.639 -178.381 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.756 HG23 ' CD2' ' A' ' 24' ' ' HIS . 19.5 mt -112.09 132.24 61.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.158 -0.964 . . . . 0.0 109.998 172.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.518 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 86.3 m-20 -108.65 116.12 31.38 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.305 -0.872 . . . . 0.0 109.861 174.786 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -106.13 108.73 20.4 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.064 -1.023 . . . . 0.0 110.534 -176.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -102.14 128.55 28.24 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.069 -1.019 . . . . 0.0 108.924 172.66 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_endo -50.47 -29.61 24.86 Favored 'Trans proline' 0 C--N 1.303 -1.865 0 O-C-N 123.834 1.439 . . . . 0.0 110.453 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.49 ' HB3' ' CE2' ' A' ' 21' ' ' PHE . 12.8 m-80 -77.87 -39.99 41.54 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.181 -0.949 . . . . 0.0 110.021 176.069 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.49 ' CE2' ' HB3' ' A' ' 20' ' ' ASN . 51.0 m-85 -151.18 150.23 30.38 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.342 -0.849 . . . . 0.0 109.925 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.484 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 60.0 ttt180 -90.42 145.24 25.09 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.714 -1.241 . . . . 0.0 110.012 176.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.518 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 91.5 m -129.64 138.19 51.08 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.429 -0.794 . . . . 0.0 109.941 -177.251 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.756 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -128.99 136.44 50.34 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 120.91 -1.119 . . . . 0.0 111.085 178.934 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.784 HG22 ' CB ' ' A' ' 60' ' ' SER . 8.2 t -120.08 132.63 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.922 -1.111 . . . . 0.0 110.77 -176.55 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.774 HG13 ' CE1' ' A' ' 61' ' ' PHE . 23.2 m -116.9 173.31 4.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 CA-C-O 121.27 0.557 . . . . 0.0 110.341 178.575 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.548 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 9.9 tt0 -106.2 117.91 35.25 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.464 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.715 HD21 HD13 ' A' ' 36' ' ' LEU . 9.2 tp -85.54 125.69 68.71 Favored Pre-proline 0 C--N 1.299 -1.624 0 O-C-N 121.403 -0.81 . . . . 0.0 110.3 -171.209 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.482 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 22.2 Cg_endo -66.17 176.37 3.97 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.878 1.462 . . . . 0.0 111.245 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.477 ' HA ' HD12 ' A' ' 33' ' ' LEU . 47.8 t0 -60.06 -39.9 87.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.336 -0.853 . . . . 0.0 111.183 -175.421 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.61 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.03 0.0 57.35 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.844 -1.16 . . . . 0.0 110.663 -174.937 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.61 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.8 mmm -112.26 -12.34 13.61 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.958 -1.089 . . . . 0.0 109.704 171.502 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.583 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 17.9 mt -69.25 -36.89 77.63 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.4 -0.813 . . . . 0.0 110.069 175.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -82.7 138.9 33.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.438 -0.789 . . . . 0.0 110.778 -177.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.44 -40.73 2.83 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 110.194 -1.163 . . . . 0.0 110.194 174.553 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.805 HD23 ' N ' ' A' ' 37' ' ' GLU . 8.3 tt -73.28 145.93 45.72 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.053 -1.263 . . . . 0.0 110.631 -176.171 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.805 ' N ' HD23 ' A' ' 36' ' ' LEU . 20.9 pt-20 -150.35 167.0 28.33 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.488 -0.757 . . . . 0.0 109.687 179.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.783 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -65.2 152.18 44.28 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.033 -1.042 . . . . 0.0 110.237 -178.123 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.63 -3.87 62.28 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -176.18 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.621 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -77.32 155.42 32.01 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.141 -1.211 . . . . 0.0 109.467 176.336 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.579 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -96.82 104.36 16.36 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 119.036 -1.066 . . . . 0.0 109.82 176.831 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.668 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.1 t -86.06 132.0 33.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 O-C-N 121.24 -0.913 . . . . 0.0 109.139 174.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 1.075 ' HB3' ' CG ' ' A' ' 85' ' ' GLU . . . -98.78 120.29 38.98 Favored 'General case' 0 C--N 1.296 -1.742 0 C-N-CA 119.408 -0.917 . . . . 0.0 109.262 173.479 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.885 ' CD2' HG21 ' A' ' 82' ' ' VAL . 1.5 m80 -93.08 104.08 16.32 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.593 -0.692 . . . . 0.0 109.268 179.503 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.514 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.3 t-20 55.64 11.29 0.62 Allowed 'General case' 0 C--N 1.298 -1.633 0 O-C-N 121.622 -0.674 . . . . 0.0 111.094 -169.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.521 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.61 1.95 10.73 Favored Glycine 0 N--CA 1.488 2.166 0 C-N-CA 119.796 -1.193 . . . . 0.0 110.818 174.209 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.673 ' O ' HD23 ' A' ' 49' ' ' LEU . 8.6 t -97.22 113.26 24.85 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 120.361 -1.67 . . . . 0.0 109.545 175.494 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.408 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 26.4 p -79.86 124.25 28.48 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.119 -0.988 . . . . 0.0 111.191 -170.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.864 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -141.36 163.21 33.55 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.385 -0.822 . . . . 0.0 109.661 172.861 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.433 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 57.5 m -102.96 152.08 21.72 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.689 -1.257 . . . . 0.0 111.019 -172.122 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.916 HG13 HG13 ' A' ' 59' ' ' VAL . 14.0 t -78.38 114.69 19.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.751 -0.593 . . . . 0.0 110.272 -178.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.523 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 46.1 p -71.29 -44.51 65.07 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.194 -0.941 . . . . 0.0 109.868 175.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.561 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -158.33 153.89 26.17 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.199 -0.938 . . . . 0.0 110.336 178.126 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.783 HD11 ' N ' ' A' ' 38' ' ' THR . 8.0 mt -105.37 130.37 56.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.161 -0.962 . . . . 0.0 109.818 175.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.519 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 12.4 m-80 -102.4 64.25 0.9 Allowed 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.565 -0.71 . . . . 0.0 109.612 179.828 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.54 -113.08 3.93 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -173.029 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.583 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.05 -21.31 43.59 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.066 -1.255 . . . . 0.0 109.293 175.568 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.119 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.8 m170 -74.88 159.53 31.76 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.352 -0.842 . . . . 0.0 110.102 -177.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.916 HG13 HG13 ' A' ' 51' ' ' VAL . 53.9 t -140.04 122.16 16.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 C-N-CA 119.023 -1.071 . . . . 0.0 110.916 172.162 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.784 ' CB ' HG22 ' A' ' 25' ' ' VAL . 60.2 p -91.06 129.09 37.09 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.724 -0.61 . . . . 0.0 109.689 177.772 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.864 ' HB2' HD12 ' A' ' 49' ' ' LEU . 1.3 p90 -123.14 156.89 34.12 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.964 -1.085 . . . . 0.0 110.61 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.523 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 32.6 p-10 -91.33 152.06 20.61 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.184 -0.948 . . . . 0.0 111.329 -172.658 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.821 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -155.72 111.84 3.1 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 -175.771 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.526 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 84.2 mmm -65.71 139.86 58.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.877 -1.14 . . . . 0.0 109.232 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.459 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 58.0 tptt -60.0 -44.41 94.56 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.958 -1.089 . . . . 0.0 109.981 -176.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.441 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.0 tt0 -69.01 -40.0 78.97 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.122 -0.986 . . . . 0.0 110.385 178.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.526 ' HB ' ' HB2' ' A' ' 64' ' ' MET . 89.9 m -60.98 -39.99 91.76 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.937 -1.102 . . . . 0.0 109.085 173.25 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.773 HD11 ' HA2' ' A' ' 74' ' ' GLY . 5.1 tp -60.01 -46.24 90.15 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.494 -0.753 . . . . 0.0 109.66 178.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 32.5 tpt180 -67.4 -40.11 85.58 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.548 -0.72 . . . . 0.0 110.519 177.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.788 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -69.96 -41.56 79.46 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.247 -0.908 . . . . 0.0 109.491 -176.457 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.788 HG23 HG22 ' A' ' 70' ' ' ILE . 61.1 p -84.65 -173.22 4.6 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 178.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.484 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.6 t30 -101.76 23.08 11.84 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 170.834 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.821 ' HB3' HD21 ' A' ' 63' ' ' LEU . 94.1 mt -70.04 -42.31 73.07 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.036 -1.04 . . . . 0.0 109.992 176.114 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.773 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -52.28 -18.93 5.31 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -178.029 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 23.7 p-10 -64.67 -18.32 64.86 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.085 -1.244 . . . . 0.0 110.469 -176.193 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 88.6 mt -59.97 143.23 52.23 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.257 -0.902 . . . . 0.0 110.836 -176.246 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 0.877 ' C ' HD23 ' A' ' 12' ' ' LEU . 54.6 mttt -142.58 141.25 31.96 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.734 -0.604 . . . . 0.0 109.597 175.658 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.623 ' N ' HD23 ' A' ' 12' ' ' LEU . 16.9 t -60.75 151.25 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 120.784 -1.198 . . . . 0.0 110.601 -174.51 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.65 -10.97 65.42 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -177.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 47.4 t0 -96.38 163.18 13.17 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.268 -1.137 . . . . 0.0 109.622 176.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.0 m95 -113.41 161.64 17.06 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.072 -1.018 . . . . 0.0 110.263 176.877 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.018 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.5 p -131.24 149.76 33.66 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 O-C-N 121.522 -0.736 . . . . 0.0 109.847 -176.324 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.749 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.6 m-20 -75.43 108.02 7.95 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 121.24 -0.912 . . . . 0.0 109.188 170.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.829 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.2 OUTLIER -111.71 145.11 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.52 -1.363 . . . . 0.0 111.501 -175.229 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 1.075 ' CG ' ' HB3' ' A' ' 43' ' ' ALA . 25.9 pt-20 -144.52 160.02 41.81 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.652 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.508 ' NH1' ' OE1' ' A' ' 7' ' ' GLN . 31.5 ptt-85 -98.27 132.91 43.36 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.024 -1.048 . . . . 0.0 110.979 -174.319 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.579 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.562 0 O-C-N 121.46 -0.775 . . . . 0.0 109.845 177.192 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 0.729 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.3 t . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.578 0.704 . . . . 0.0 110.003 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.514 ' OE1' ' NH1' ' B' ' 86' ' ' ARG . 97.2 mt-30 -70.2 -29.93 66.91 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.497 -0.752 . . . . 0.0 111.483 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.534 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -148.62 175.9 27.67 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 118.91 -1.614 . . . . 0.0 110.386 -173.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.472 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 2.9 p -123.25 171.17 9.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -1.164 . . . . 0.0 110.591 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.057 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -140.94 150.16 42.78 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.515 -0.741 . . . . 0.0 109.39 -175.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.587 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 26.4 tttt -111.62 116.44 30.81 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.122 -0.986 . . . . 0.0 110.275 179.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 0.882 HD23 ' C ' ' B' ' 77' ' ' LYS . 10.0 tp -58.65 124.87 21.16 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.136 -0.978 . . . . 0.0 108.911 173.133 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.124 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.0 OUTLIER -118.3 -29.08 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 C-N-CA 119.549 -0.86 . . . . 0.0 109.674 178.744 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.58 149.99 27.25 Favored 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 119.115 -1.034 . . . . 0.0 111.539 -178.416 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.759 HG23 ' CD2' ' B' ' 24' ' ' HIS . 19.5 mt -112.1 132.16 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.307 -0.87 . . . . 0.0 110.098 172.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.53 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 86.1 m-20 -108.71 116.23 31.59 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.386 -0.821 . . . . 0.0 109.776 174.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -106.21 108.54 20.1 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.001 -1.062 . . . . 0.0 110.537 -176.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -102.01 128.48 28.51 Favored Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.167 -0.958 . . . . 0.0 109.022 172.647 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.2 Cg_endo -50.49 -29.63 25.05 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 O-C-N 123.841 1.443 . . . . 0.0 110.465 -179.463 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.485 ' HB3' ' CE2' ' B' ' 21' ' ' PHE . 12.6 m-80 -77.7 -40.32 41.73 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.236 -0.915 . . . . 0.0 110.016 176.037 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.485 ' CE2' ' HB3' ' B' ' 20' ' ' ASN . 51.4 m-85 -150.94 150.19 30.53 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.409 -0.807 . . . . 0.0 109.9 -179.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . 0.474 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 60.0 ttt180 -90.43 145.12 25.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.74 -1.225 . . . . 0.0 110.063 176.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.53 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 92.0 m -129.49 138.36 51.34 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.569 -0.707 . . . . 0.0 109.843 -177.185 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.759 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -129.09 136.57 50.41 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.042 -1.037 . . . . 0.0 110.977 178.901 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.789 HG22 ' CB ' ' B' ' 60' ' ' SER . 8.5 t -120.04 132.78 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.119 -0.988 . . . . 0.0 110.711 -176.499 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.785 HG13 ' CE1' ' B' ' 61' ' ' PHE . 23.7 m -117.07 173.25 4.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.815 -0.553 . . . . 0.0 110.318 178.605 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.55 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 9.8 tt0 -105.98 117.89 35.19 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 -179.645 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.716 HD21 HD13 ' B' ' 36' ' ' LEU . 9.2 tp -85.58 125.67 68.68 Favored Pre-proline 0 C--N 1.298 -1.666 0 O-C-N 121.318 -0.864 . . . . 0.0 110.251 -171.226 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.485 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 22.1 Cg_endo -66.08 176.36 3.92 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 O-C-N 123.889 1.468 . . . . 0.0 111.196 -179.512 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.485 ' HA ' HD12 ' B' ' 33' ' ' LEU . 47.8 t0 -60.07 -39.98 87.93 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.338 -0.851 . . . . 0.0 111.135 -175.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.99 0.15 57.26 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.877 -1.139 . . . . 0.0 110.734 -174.928 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.597 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.7 mmm -112.33 -12.38 13.57 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.957 -1.09 . . . . 0.0 109.708 171.552 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.592 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 17.7 mt -69.28 -36.91 77.55 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.346 -0.847 . . . . 0.0 110.032 175.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 72.9 m-20 -82.71 138.96 33.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.438 -0.789 . . . . 0.0 110.8 -177.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.34 -40.61 2.86 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 174.621 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.801 HD23 ' N ' ' B' ' 37' ' ' GLU . 8.2 tt -73.37 145.95 45.53 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.997 -1.296 . . . . 0.0 110.556 -176.187 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . 0.801 ' N ' HD23 ' B' ' 36' ' ' LEU . 20.9 pt-20 -150.34 167.04 28.2 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.44 -0.787 . . . . 0.0 109.674 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 0.789 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -65.24 152.16 44.38 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.994 -1.066 . . . . 0.0 110.323 -178.156 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.62 -3.94 62.02 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -176.054 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.62 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -77.36 155.2 32.09 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.212 -1.17 . . . . 0.0 109.521 176.262 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.576 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -96.54 104.25 16.22 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.893 -1.13 . . . . 0.0 109.873 176.858 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.697 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.1 t -86.07 131.97 33.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.224 -0.923 . . . . 0.0 109.178 174.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 1.068 ' HB3' ' CG ' ' B' ' 85' ' ' GLU . . . -98.67 120.33 38.92 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 121.227 -0.921 . . . . 0.0 109.288 173.473 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.882 ' CD2' HG21 ' B' ' 82' ' ' VAL . 1.4 m80 -93.1 103.75 16.01 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.502 -0.749 . . . . 0.0 109.365 179.482 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.514 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.3 t-20 55.9 11.48 0.71 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.557 -0.714 . . . . 0.0 110.972 -169.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.521 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.41 2.24 10.84 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 119.755 -1.212 . . . . 0.0 110.8 174.048 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.685 ' O ' HD23 ' B' ' 49' ' ' LEU . 8.7 t -97.47 113.32 24.99 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 120.327 -1.69 . . . . 0.0 109.543 175.384 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . 0.41 ' O ' ' SG ' ' B' ' 48' ' ' CYS . 26.4 p -79.8 124.3 28.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.044 -1.035 . . . . 0.0 111.145 -170.723 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 0.897 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -141.51 163.34 33.2 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.538 -0.726 . . . . 0.0 109.618 172.77 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . 0.44 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 57.4 m -102.92 152.18 21.59 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.78 -1.2 . . . . 0.0 110.991 -172.032 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.941 HG13 HG13 ' B' ' 59' ' ' VAL . 14.1 t -78.54 114.72 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.749 -0.594 . . . . 0.0 110.323 -178.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 47.0 p -71.32 -44.56 64.9 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.09 -1.006 . . . . 0.0 109.821 175.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.557 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -158.25 153.92 26.38 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.241 -0.912 . . . . 0.0 110.272 178.176 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.789 HD11 ' N ' ' B' ' 38' ' ' THR . 7.9 mt -105.34 130.32 56.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.117 -0.989 . . . . 0.0 109.825 176.028 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.531 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 12.3 m-80 -102.54 64.32 0.89 Allowed 'General case' 0 C--N 1.297 -1.675 0 C-N-CA 119.865 -0.734 . . . . 0.0 109.608 179.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.68 -113.0 3.88 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 108.659 -1.776 . . . . 0.0 108.659 -173.139 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.592 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.1 -21.53 43.19 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.045 -1.268 . . . . 0.0 109.225 175.609 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.124 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.9 m170 -74.72 159.46 31.99 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.317 -0.864 . . . . 0.0 110.155 -177.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.941 HG13 HG13 ' B' ' 51' ' ' VAL . 54.5 t -140.06 122.19 16.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 C-N-CA 118.903 -1.119 . . . . 0.0 110.867 172.303 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.789 ' CB ' HG22 ' B' ' 25' ' ' VAL . 60.1 p -91.16 129.23 37.18 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.734 -0.604 . . . . 0.0 109.682 177.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.897 ' HB2' HD12 ' B' ' 49' ' ' LEU . 1.3 p90 -123.2 156.94 34.12 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.072 -1.018 . . . . 0.0 110.555 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 32.7 p-10 -91.28 152.22 20.58 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.097 -1.002 . . . . 0.0 111.224 -172.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.814 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -155.81 111.91 3.09 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -175.88 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.509 ' HB2' ' HB ' ' B' ' 67' ' ' THR . 84.1 mmm -65.8 139.82 58.35 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.871 -1.143 . . . . 0.0 109.186 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.457 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 57.9 tptt -60.03 -44.27 94.73 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.11 -0.994 . . . . 0.0 109.987 -176.685 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . 0.445 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 85.9 tt0 -69.15 -39.96 78.48 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.171 -0.955 . . . . 0.0 110.302 178.626 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.509 ' HB ' ' HB2' ' B' ' 64' ' ' MET . 90.5 m -61.05 -40.07 92.22 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.899 -1.126 . . . . 0.0 109.019 173.288 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.798 HD11 ' HA2' ' B' ' 74' ' ' GLY . 5.1 tp -59.94 -46.08 90.55 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.512 -0.742 . . . . 0.0 109.747 178.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 32.5 tpt180 -67.6 -39.98 84.75 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.612 -0.68 . . . . 0.0 110.506 177.585 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.775 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -70.0 -41.47 79.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 O-C-N 121.328 -0.858 . . . . 0.0 109.593 -176.544 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.775 HG23 HG22 ' B' ' 70' ' ' ILE . 60.2 p -84.65 -173.16 4.57 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 120.177 -0.609 . . . . 0.0 109.517 178.563 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.48 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 4.5 t30 -101.65 22.98 11.9 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 170.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.814 ' HB3' HD21 ' B' ' 63' ' ' LEU . 94.2 mt -69.96 -42.31 73.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.022 -1.049 . . . . 0.0 110.02 176.096 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.798 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -52.34 -18.82 5.31 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -178.025 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 23.7 p-10 -64.78 -18.29 64.95 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.054 -1.262 . . . . 0.0 110.436 -176.217 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.516 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 88.7 mt -59.99 143.24 52.27 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.23 -0.919 . . . . 0.0 110.844 -176.297 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 0.882 ' C ' HD23 ' B' ' 12' ' ' LEU . 54.6 mttt -142.61 141.22 31.91 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.652 -0.655 . . . . 0.0 109.62 175.723 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.619 ' N ' HD23 ' B' ' 12' ' ' LEU . 17.2 t -60.85 151.15 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 120.844 -1.16 . . . . 0.0 110.555 -174.408 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.68 -10.82 66.03 Favored Glycine 0 N--CA 1.487 2.07 0 N-CA-C 109.02 -1.632 . . . . 0.0 109.02 -177.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 47.0 t0 -96.45 163.11 13.19 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.348 -1.089 . . . . 0.0 109.695 176.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.587 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.0 m95 -113.38 161.58 17.1 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.056 -1.028 . . . . 0.0 110.284 176.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 1.057 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.5 p -131.27 149.92 33.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.575 -0.703 . . . . 0.0 109.801 -176.479 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.729 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -75.34 107.79 7.69 Favored 'General case' 0 C--N 1.294 -1.806 0 O-C-N 121.205 -0.934 . . . . 0.0 109.282 170.633 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.826 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.2 OUTLIER -111.65 145.2 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 120.522 -1.361 . . . . 0.0 111.501 -175.121 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . 1.068 ' CG ' ' HB3' ' B' ' 43' ' ' ALA . 25.9 pt-20 -144.6 159.98 41.91 Favored 'General case' 0 N--CA 1.494 1.773 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.691 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . 0.514 ' NH1' ' OE1' ' B' ' 7' ' ' GLN . 31.5 ptt-85 -98.1 132.88 43.25 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.869 -1.145 . . . . 0.0 110.963 -174.28 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.576 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.763 0 O-C-N 121.401 -0.812 . . . . 0.0 109.79 177.134 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.976 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.4 t . . . . . 0 N--CA 1.492 1.674 0 CA-C-O 121.537 0.684 . . . . 0.0 110.418 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -69.94 -33.65 72.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.51 -0.744 . . . . 0.0 111.051 178.703 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.515 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -155.66 172.85 33.77 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.871 -1.633 . . . . 0.0 109.909 -173.675 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.483 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 0.6 OUTLIER -115.2 168.8 9.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.143 -1.21 . . . . 0.0 110.48 -179.496 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 1.016 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -135.59 147.82 48.83 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.547 -0.721 . . . . 0.0 109.472 -179.142 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.577 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 29.1 tttt -105.98 115.86 30.96 Favored 'General case' 0 C--N 1.294 -1.829 0 O-C-N 121.121 -0.987 . . . . 0.0 110.247 178.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 1.029 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.1 tp -59.71 128.09 35.24 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 120.89 -1.131 . . . . 0.0 108.653 172.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.114 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -128.2 -31.52 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 C-N-CA 119.553 -0.859 . . . . 0.0 110.085 -177.719 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.91 144.71 30.35 Favored 'General case' 0 N--CA 1.495 1.786 0 C-N-CA 118.859 -1.136 . . . . 0.0 111.293 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.766 HG23 ' CD2' ' A' ' 24' ' ' HIS . 12.5 mt -109.44 132.99 56.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.245 -0.91 . . . . 0.0 110.351 173.177 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.499 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 79.8 m-20 -110.15 116.22 31.14 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.307 -0.871 . . . . 0.0 109.98 173.125 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -106.54 114.45 28.57 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.007 -1.058 . . . . 0.0 110.567 -178.216 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.456 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.7 mtmt -110.74 132.94 21.35 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.248 -0.907 . . . . 0.0 109.138 175.492 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -50.07 -34.54 38.83 Favored 'Trans proline' 0 C--N 1.301 -1.93 0 O-C-N 123.857 1.451 . . . . 0.0 110.692 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.465 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 12.3 m-80 -74.6 -39.71 62.02 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.149 -0.97 . . . . 0.0 110.076 177.304 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.465 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 96.1 m-85 -154.35 150.16 27.65 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.345 -0.847 . . . . 0.0 110.128 -178.471 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.492 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 59.5 ttt180 -91.71 146.29 23.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.751 -1.218 . . . . 0.0 110.121 176.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.499 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 90.4 m -130.0 140.04 50.95 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.408 -0.807 . . . . 0.0 109.927 -175.608 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.766 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -129.15 136.43 50.18 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.9 -1.125 . . . . 0.0 111.148 177.565 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.725 HG22 ' OG ' ' A' ' 60' ' ' SER . 5.8 t -115.78 132.46 65.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.075 -1.016 . . . . 0.0 110.7 -177.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.488 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 12.5 m -116.1 170.19 6.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-O 121.111 0.482 . . . . 0.0 110.124 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.468 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 2.7 tm-20 -101.55 117.8 35.65 Favored 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.322 -0.861 . . . . 0.0 109.23 179.068 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.597 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.3 tp -82.71 127.27 70.81 Favored Pre-proline 0 C--N 1.298 -1.661 0 O-C-N 121.485 -0.759 . . . . 0.0 110.003 -174.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.462 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 25.3 Cg_endo -66.5 -178.5 1.21 Allowed 'Trans proline' 0 C--N 1.308 -1.561 0 O-C-N 123.88 1.463 . . . . 0.0 111.008 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.502 ' OD1' ' N ' ' A' ' 30' ' ' ASP . 22.6 p-10 -65.66 -39.98 91.96 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.413 -0.804 . . . . 0.0 111.016 -177.18 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.604 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.0 0.36 57.15 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.905 -1.122 . . . . 0.0 110.924 -174.557 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.604 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.8 mmm -110.14 -16.02 13.88 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.949 -1.094 . . . . 0.0 109.692 171.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.597 ' HA ' HD23 ' A' ' 28' ' ' LEU . 13.4 mt -66.13 -32.04 73.25 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.515 -0.74 . . . . 0.0 110.41 178.163 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . 0.419 ' OD1' ' N ' ' A' ' 35' ' ' GLY . 63.7 t0 -80.26 142.93 34.11 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.222 -0.924 . . . . 0.0 110.864 -176.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.419 ' N ' ' OD1' ' A' ' 34' ' ' ASP . . . 85.94 -31.77 3.92 Favored Glycine 0 N--CA 1.493 2.443 0 C-N-CA 119.99 -1.1 . . . . 0.0 111.096 170.702 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.552 HD23 ' CD2' ' A' ' 28' ' ' LEU . 57.7 tp -77.45 155.09 31.98 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.708 -1.466 . . . . 0.0 111.111 -173.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.454 ' C ' HD11 ' A' ' 54' ' ' ILE . 20.0 pt-20 -153.57 167.84 28.18 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.531 -0.731 . . . . 0.0 109.644 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.842 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -67.8 154.5 41.39 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.876 -1.14 . . . . 0.0 110.111 178.142 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.59 0.3 58.2 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -174.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.671 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -79.99 160.22 25.98 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.173 -1.193 . . . . 0.0 109.041 174.407 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.888 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 1.6 p -103.33 118.87 37.74 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 118.294 -1.362 . . . . 0.0 109.692 175.081 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.622 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.6 t -101.67 125.87 55.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 175.188 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -87.89 118.58 27.52 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 119.269 -0.972 . . . . 0.0 109.154 174.509 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.877 ' CD2' HG21 ' A' ' 82' ' ' VAL . 0.7 OUTLIER -91.43 106.08 18.24 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 176.378 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.489 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.6 t-20 55.44 13.41 0.92 Allowed 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.452 -0.78 . . . . 0.0 111.257 -168.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.493 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.56 -6.25 10.63 Favored Glycine 0 N--CA 1.49 2.243 0 C-N-CA 119.459 -1.353 . . . . 0.0 110.999 171.25 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.816 ' O ' HD23 ' A' ' 49' ' ' LEU . 32.6 t -89.7 107.58 19.18 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.51 -1.583 . . . . 0.0 109.457 175.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.422 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 26.7 p -74.07 123.44 24.39 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.122 -0.986 . . . . 0.0 110.531 -174.13 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.829 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -138.96 156.53 47.17 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.405 -0.809 . . . . 0.0 109.411 175.196 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.442 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 26.8 m -94.76 156.42 16.39 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 120.489 -1.382 . . . . 0.0 111.315 -169.184 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.783 HG13 HG13 ' A' ' 59' ' ' VAL . 16.8 t -82.24 116.06 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.859 -0.525 . . . . 0.0 110.332 -178.055 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.575 HG22 ' HB3' ' A' ' 62' ' ' ASP . 59.8 p -69.85 -40.03 76.04 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.177 -0.952 . . . . 0.0 109.453 172.561 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.584 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 51.8 tp10 -162.55 156.29 20.69 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.221 -0.992 . . . . 0.0 110.839 -177.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.842 HD11 ' N ' ' A' ' 38' ' ' THR . 7.5 mt -109.98 130.03 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.087 -1.008 . . . . 0.0 109.545 170.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.515 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 46.5 m-80 -104.2 62.94 0.74 Allowed 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.603 -0.686 . . . . 0.0 109.493 178.632 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.49 -114.77 4.1 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.809 -1.717 . . . . 0.0 108.809 -172.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.591 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.08 -19.72 46.81 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.042 -1.27 . . . . 0.0 109.038 175.967 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.114 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.7 m170 -76.91 159.14 30.24 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.279 -0.888 . . . . 0.0 110.233 -177.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.783 HG13 HG13 ' A' ' 51' ' ' VAL . 54.0 t -140.42 120.34 12.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.027 -1.046 . . . . 0.0 110.948 173.403 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.725 ' OG ' HG22 ' A' ' 25' ' ' VAL . 21.3 m -86.02 128.72 34.92 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.57 -0.706 . . . . 0.0 109.729 177.257 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.829 ' HB3' HD12 ' A' ' 49' ' ' LEU . 60.2 m-85 -111.37 160.02 17.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.907 -1.12 . . . . 0.0 110.341 178.808 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.575 ' HB3' HG22 ' A' ' 52' ' ' THR . 31.8 p-10 -93.36 146.89 23.4 Favored 'General case' 0 N--CA 1.497 1.917 0 CA-C-O 122.099 0.952 . . . . 0.0 111.436 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.761 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -157.39 113.37 2.88 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.459 -176.967 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.505 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 57.0 ttm -69.27 142.39 54.15 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.847 -1.158 . . . . 0.0 109.572 179.116 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 47.6 tptt -60.05 -46.13 90.57 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.013 -1.054 . . . . 0.0 110.284 -175.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 87.8 tt0 -69.73 -40.09 76.43 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.92 -1.113 . . . . 0.0 110.201 179.358 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.505 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 86.5 m -60.29 -38.34 83.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.931 -1.106 . . . . 0.0 109.228 172.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.715 ' CD1' HD22 ' A' ' 63' ' ' LEU . 11.0 tp -60.05 -44.0 94.99 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.368 -0.832 . . . . 0.0 109.375 -179.618 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -68.11 -39.82 82.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.346 -0.846 . . . . 0.0 110.695 174.336 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.755 HG22 HG23 ' A' ' 71' ' ' THR . 1.4 tt -66.3 -41.64 89.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.275 -0.891 . . . . 0.0 109.626 -175.063 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.755 HG23 HG22 ' A' ' 70' ' ' ILE . 50.7 p -83.53 -168.58 2.17 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.709 -0.62 . . . . 0.0 109.606 177.679 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.496 ' CB ' ' H ' ' B' ' 83' ' ' ASN . 7.1 t30 -104.92 19.6 20.28 Favored 'General case' 0 C--N 1.293 -1.87 0 O-C-N 121.245 -0.909 . . . . 0.0 108.559 168.054 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.761 ' HB3' HD21 ' A' ' 63' ' ' LEU . 81.8 mt -69.98 -40.06 75.55 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.092 -1.005 . . . . 0.0 109.997 175.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.625 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -47.14 -22.68 1.43 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 178.208 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 22.2 p-10 -62.62 -16.25 55.69 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.959 -1.318 . . . . 0.0 110.391 -175.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.518 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 84.4 mt -63.07 146.21 53.75 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.252 -0.905 . . . . 0.0 111.037 -175.129 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 1.029 ' C ' HD23 ' A' ' 12' ' ' LEU . 96.6 mttt -149.21 138.17 21.29 Favored 'General case' 0 N--CA 1.493 1.698 0 CA-C-O 121.461 0.648 . . . . 0.0 109.684 174.182 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.72 HG23 HD11 ' A' ' 15' ' ' ILE . 17.5 t -61.52 151.86 6.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.843 -1.161 . . . . 0.0 110.51 -175.112 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.03 -14.51 60.38 Favored Glycine 0 N--CA 1.484 1.835 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 -175.279 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.428 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 25.7 t0 -97.82 168.4 10.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.267 -1.137 . . . . 0.0 109.625 176.22 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.577 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.2 m95 -116.64 169.12 9.59 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.079 -1.013 . . . . 0.0 110.045 177.112 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.016 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.5 p -136.34 147.98 27.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.329 -0.857 . . . . 0.0 109.965 -177.148 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.976 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.9 m-20 -73.11 104.36 4.16 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.078 -1.014 . . . . 0.0 109.197 170.06 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.832 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -107.96 140.26 27.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 120.786 -1.197 . . . . 0.0 111.183 -176.841 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.421 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.5 tt0 -142.19 140.83 32.49 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.783 -0.573 . . . . 0.0 110.235 -176.733 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 95.2 mtt180 -60.19 131.62 51.39 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.045 -1.035 . . . . 0.0 109.777 178.648 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.888 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.238 -0.914 . . . . 0.0 109.984 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 0.965 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.5 t . . . . . 0 N--CA 1.494 1.725 0 CA-C-O 121.548 0.69 . . . . 0.0 110.336 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -70.07 -33.5 72.01 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.525 -0.734 . . . . 0.0 111.096 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.531 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -155.79 172.71 33.84 Favored Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.029 -1.558 . . . . 0.0 110.025 -173.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.489 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 0.6 OUTLIER -115.18 168.67 9.74 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.203 -1.175 . . . . 0.0 110.537 -179.499 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.059 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -135.47 148.03 49.09 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.535 -0.728 . . . . 0.0 109.426 -179.245 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.573 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 29.1 tttt -106.13 115.92 31.05 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.163 -0.961 . . . . 0.0 110.191 178.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 1.028 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.1 tp -59.81 128.07 35.11 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.002 -1.061 . . . . 0.0 108.701 172.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.118 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -128.08 -31.68 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 C-N-CA 119.586 -0.845 . . . . 0.0 110.141 -177.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.74 144.65 30.47 Favored 'General case' 0 N--CA 1.493 1.687 0 C-N-CA 119.069 -1.052 . . . . 0.0 111.44 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.765 HG23 ' CD2' ' B' ' 24' ' ' HIS . 12.3 mt -109.27 133.03 55.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.19 -0.944 . . . . 0.0 110.479 173.125 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.513 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 79.6 m-20 -110.29 116.34 31.29 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.36 -0.837 . . . . 0.0 109.901 173.18 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -106.57 114.48 28.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.935 -1.103 . . . . 0.0 110.62 -178.269 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.453 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.7 mtmt -110.71 132.92 21.35 Favored Pre-proline 0 N--CA 1.493 1.719 0 O-C-N 121.297 -0.877 . . . . 0.0 109.192 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -50.19 -34.53 39.83 Favored 'Trans proline' 0 C--N 1.301 -1.927 0 O-C-N 123.8 1.421 . . . . 0.0 110.703 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.467 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 12.4 m-80 -74.5 -40.13 61.99 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.129 -0.982 . . . . 0.0 109.973 177.259 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.467 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 96.2 m-85 -153.89 150.2 28.13 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.371 -0.831 . . . . 0.0 110.182 -178.428 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . 0.488 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 59.5 ttt180 -91.65 146.22 23.96 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.899 -1.125 . . . . 0.0 110.159 176.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.513 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 91.2 m -129.93 140.0 51.02 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.416 -0.802 . . . . 0.0 110.023 -175.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.765 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -129.03 136.56 50.46 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.998 -1.064 . . . . 0.0 111.16 177.603 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.733 HG22 ' OG ' ' B' ' 60' ' ' SER . 5.7 t -115.76 132.49 65.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.185 -0.947 . . . . 0.0 110.755 -177.373 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.49 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 13.0 m -116.3 170.31 6.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.025 179.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.462 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 2.7 tm-20 -101.57 117.81 35.68 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 121.298 -0.876 . . . . 0.0 109.244 179.071 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.602 HD23 ' HA ' ' B' ' 33' ' ' LEU . 9.3 tp -82.65 127.28 70.9 Favored Pre-proline 0 C--N 1.299 -1.623 0 O-C-N 121.435 -0.791 . . . . 0.0 110.115 -174.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.464 ' HD2' ' HB2' ' B' ' 32' ' ' MET . 24.9 Cg_endo -66.55 -178.53 1.23 Allowed 'Trans proline' 0 C--N 1.307 -1.658 0 O-C-N 123.932 1.491 . . . . 0.0 110.917 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.49 ' OD1' ' N ' ' B' ' 30' ' ' ASP . 22.7 p-10 -65.56 -40.01 92.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.335 -0.853 . . . . 0.0 111.089 -177.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.592 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.02 0.38 57.14 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.913 -1.117 . . . . 0.0 110.983 -174.641 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.592 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.8 mmm -110.15 -15.98 13.88 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.978 -1.076 . . . . 0.0 109.756 171.593 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.604 HD21 ' HB2' ' B' ' 57' ' ' ASN . 13.5 mt -66.09 -32.08 73.33 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.462 -0.774 . . . . 0.0 110.453 178.071 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . 0.426 ' OD1' ' N ' ' B' ' 35' ' ' GLY . 63.7 t0 -80.2 142.93 34.23 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.282 -0.887 . . . . 0.0 110.894 -176.741 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . 0.426 ' N ' ' OD1' ' B' ' 34' ' ' ASP . . . 85.9 -31.91 3.88 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 119.92 -1.133 . . . . 0.0 111.092 170.726 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.55 HD23 ' CD2' ' B' ' 28' ' ' LEU . 57.8 tp -77.39 155.12 32.08 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.669 -1.489 . . . . 0.0 111.131 -173.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . 0.478 ' C ' HD11 ' B' ' 54' ' ' ILE . 20.0 pt-20 -153.57 167.92 27.89 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.558 -0.714 . . . . 0.0 109.665 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 0.849 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -67.96 154.51 41.46 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.953 -1.092 . . . . 0.0 110.157 178.15 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.65 0.31 58.52 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -174.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.674 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -80.07 159.96 25.96 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.202 -1.175 . . . . 0.0 109.074 174.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.913 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 1.6 p -102.86 118.83 37.7 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.559 -1.338 . . . . 0.0 109.818 175.076 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.647 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.6 t -101.88 125.98 55.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 175.198 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -87.99 118.62 27.67 Favored 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.196 -1.002 . . . . 0.0 109.155 174.532 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.874 ' CD2' HG21 ' B' ' 82' ' ' VAL . 0.7 OUTLIER -91.39 105.9 18.11 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 176.374 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.489 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.6 t-20 55.49 13.57 0.98 Allowed 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.423 -0.798 . . . . 0.0 111.266 -169.023 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.493 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.47 -6.1 10.73 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 119.379 -1.391 . . . . 0.0 110.961 171.081 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.819 ' O ' HD23 ' B' ' 49' ' ' LEU . 33.0 t -89.82 107.54 19.16 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.549 -1.559 . . . . 0.0 109.413 175.577 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . 0.417 ' O ' ' SG ' ' B' ' 48' ' ' CYS . 26.5 p -74.04 123.68 24.82 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.14 -0.975 . . . . 0.0 110.452 -174.129 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 0.838 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -139.15 156.54 47.05 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.42 -0.8 . . . . 0.0 109.344 175.141 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . 0.446 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 26.8 m -94.63 156.44 16.42 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 120.608 -1.308 . . . . 0.0 111.266 -169.107 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.796 HG13 HG13 ' B' ' 59' ' ' VAL . 17.0 t -82.35 116.1 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.831 -0.543 . . . . 0.0 110.389 -178.151 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.566 HG22 ' HB3' ' B' ' 62' ' ' ASP . 60.1 p -69.85 -40.06 76.02 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.133 -0.98 . . . . 0.0 109.458 172.631 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.58 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 51.8 tp10 -162.58 156.25 20.58 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.384 -0.926 . . . . 0.0 110.827 -177.589 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.849 HD11 ' N ' ' B' ' 38' ' ' THR . 7.5 mt -110.0 129.98 63.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.14 -0.975 . . . . 0.0 109.535 170.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.529 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 46.5 m-80 -104.2 62.85 0.74 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.624 -0.673 . . . . 0.0 109.539 178.672 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.6 -114.74 4.08 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 -172.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.604 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.06 -19.76 46.79 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.948 -1.325 . . . . 0.0 109.102 175.947 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.118 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.7 m170 -76.91 158.97 30.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.337 -0.852 . . . . 0.0 110.263 -177.784 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.796 HG13 HG13 ' B' ' 51' ' ' VAL . 53.9 t -140.35 120.36 13.02 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 C-N-CA 119.104 -1.038 . . . . 0.0 110.921 173.542 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.733 ' OG ' HG22 ' B' ' 25' ' ' VAL . 21.8 m -85.99 128.83 34.93 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.648 -0.658 . . . . 0.0 109.751 177.293 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.838 ' HB3' HD12 ' B' ' 49' ' ' LEU . 60.4 m-85 -111.45 160.05 17.49 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.931 -1.106 . . . . 0.0 110.343 178.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.566 ' HB3' HG22 ' B' ' 52' ' ' THR . 31.6 p-10 -93.44 146.89 23.43 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.08 -1.012 . . . . 0.0 111.317 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.748 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -157.37 113.44 2.89 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 -177.033 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.514 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 56.9 ttm -69.25 142.37 54.19 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.877 -1.139 . . . . 0.0 109.61 179.012 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 47.6 tptt -59.91 -46.19 90.13 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.107 -0.995 . . . . 0.0 110.341 -175.771 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 87.8 tt0 -69.81 -40.04 76.18 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.971 -1.08 . . . . 0.0 110.123 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.514 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 87.1 m -60.29 -38.46 83.66 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.915 -1.115 . . . . 0.0 109.191 173.026 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.719 ' CD1' HD22 ' B' ' 63' ' ' LEU . 11.1 tp -60.04 -43.71 95.15 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.52 -0.738 . . . . 0.0 109.45 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -68.31 -39.81 81.91 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.304 -0.872 . . . . 0.0 110.598 174.314 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.743 HG22 HG23 ' B' ' 71' ' ' THR . 1.4 tt -66.38 -41.56 89.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.571 -174.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.743 HG23 HG22 ' B' ' 70' ' ' ILE . 51.3 p -83.51 -168.5 2.13 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.113 -0.635 . . . . 0.0 109.634 177.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.485 ' CB ' ' H ' ' A' ' 83' ' ' ASN . 7.2 t30 -104.93 19.59 20.29 Favored 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 168.042 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.748 ' HB3' HD21 ' B' ' 63' ' ' LEU . 81.5 mt -69.96 -40.07 75.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.005 -1.059 . . . . 0.0 109.931 175.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.61 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -47.28 -22.58 1.52 Allowed Glycine 0 N--CA 1.487 2.051 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 178.354 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 22.3 p-10 -62.64 -16.24 55.82 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.045 -1.268 . . . . 0.0 110.349 -175.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.516 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 84.2 mt -63.22 146.14 54.02 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.309 -0.87 . . . . 0.0 111.046 -175.085 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 1.028 ' C ' HD23 ' B' ' 12' ' ' LEU . 96.6 mttt -149.03 138.34 21.61 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.781 -0.575 . . . . 0.0 109.647 174.172 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.716 HG21 HG13 ' B' ' 15' ' ' ILE . 17.3 t -61.56 151.92 6.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.051 -1.031 . . . . 0.0 110.479 -175.127 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.89 -14.24 60.86 Favored Glycine 0 N--CA 1.483 1.777 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 -175.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 25.5 t0 -97.89 168.41 10.32 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.413 -1.051 . . . . 0.0 109.645 176.056 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.573 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.3 m95 -116.64 168.91 9.76 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.973 -1.079 . . . . 0.0 110.144 177.119 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 1.059 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.5 p -136.25 148.06 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.494 -0.754 . . . . 0.0 110.006 -177.295 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.965 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.8 m-20 -73.08 104.2 4.09 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.082 -1.011 . . . . 0.0 109.243 170.106 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.814 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -107.81 140.6 25.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 120.843 -1.161 . . . . 0.0 110.99 -176.664 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . 0.411 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.5 tt0 -142.49 140.81 32.0 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.762 -0.586 . . . . 0.0 110.183 -176.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 95.3 mtt180 -60.29 131.69 51.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.113 -0.992 . . . . 0.0 109.77 178.681 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.913 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.331 -0.856 . . . . 0.0 110.114 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.98 HG21 ' HB3' ' A' ' 83' ' ' ASN . 3.7 t . . . . . 0 N--CA 1.492 1.637 0 CA-C-O 121.683 0.754 . . . . 0.0 110.817 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 94.3 mm-40 -69.94 -33.2 71.81 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.603 -0.686 . . . . 0.0 110.556 175.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -168.87 174.52 43.45 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.104 -1.522 . . . . 0.0 109.87 -176.58 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.493 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 41.5 p -114.58 170.01 8.63 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.065 -1.256 . . . . 0.0 110.772 -177.598 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 1.033 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -135.53 149.93 49.6 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.572 -0.705 . . . . 0.0 109.577 -175.721 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.585 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.0 tttt -105.71 116.77 32.51 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.142 -0.974 . . . . 0.0 110.337 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 1.013 HD23 ' C ' ' A' ' 77' ' ' LYS . 11.5 tp -60.02 127.12 30.33 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 120.898 -1.126 . . . . 0.0 108.825 172.383 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.139 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -125.57 -31.45 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.876 0 O-C-N 121.405 -0.81 . . . . 0.0 109.983 -179.495 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.2 144.6 29.04 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.027 -1.069 . . . . 0.0 111.237 -179.243 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.776 HG23 ' CD2' ' A' ' 24' ' ' HIS . 13.4 mt -108.53 135.64 46.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.162 -0.961 . . . . 0.0 110.032 172.027 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.514 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 84.0 m-20 -109.35 114.88 28.93 Favored 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.289 -0.882 . . . . 0.0 109.867 174.732 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -105.67 114.25 28.3 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.994 -1.067 . . . . 0.0 110.587 -175.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.1 mtmt -111.46 127.78 26.37 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.18 -0.95 . . . . 0.0 108.993 174.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -50.99 -24.06 13.31 Favored 'Trans proline' 0 C--N 1.303 -1.859 0 O-C-N 123.824 1.434 . . . . 0.0 110.254 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.543 ' C ' ' CD2' ' A' ' 21' ' ' PHE . 11.4 m-80 -80.15 -42.5 23.33 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.251 -0.905 . . . . 0.0 109.985 175.243 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.543 ' CD2' ' C ' ' A' ' 20' ' ' ASN . 97.5 m-85 -153.97 150.32 28.18 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.4 -0.812 . . . . 0.0 109.977 -178.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.68 ' HD3' HD22 ' A' ' 68' ' ' LEU . 62.0 ttt180 -90.58 145.29 24.98 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.878 -1.139 . . . . 0.0 110.167 178.581 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.514 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 87.4 m -131.75 141.75 49.6 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.511 -0.743 . . . . 0.0 109.846 -175.409 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.776 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -131.03 143.91 51.07 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 120.97 -1.081 . . . . 0.0 111.475 -179.466 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.848 HG22 ' CB ' ' A' ' 60' ' ' SER . 6.6 t -125.34 133.94 68.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.128 -0.982 . . . . 0.0 110.975 -178.309 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.733 HG13 ' HE1' ' A' ' 61' ' ' PHE . 29.5 m -116.88 174.59 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 CA-C-O 121.24 0.543 . . . . 0.0 110.319 178.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.509 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 11.8 tt0 -104.59 118.46 36.65 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 177.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.831 HD13 ' HD2' ' A' ' 29' ' ' PRO 0.266 0.2 OUTLIER -87.32 123.08 70.41 Favored Pre-proline 0 C--N 1.297 -1.704 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -172.649 . . . . . . . . 4 4 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.831 ' HD2' HD13 ' A' ' 28' ' ' LEU . 17.8 Cg_endo -66.29 172.81 8.34 Favored 'Trans proline' 0 C--N 1.309 -1.51 0 O-C-N 123.551 1.29 . . . . 0.0 111.094 -178.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.509 ' HA ' HD12 ' A' ' 33' ' ' LEU . 96.0 m-20 -59.99 -40.05 87.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.568 -0.708 . . . . 0.0 111.196 -174.671 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.536 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.02 -0.0 57.35 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.672 -1.267 . . . . 0.0 110.659 -171.479 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.671 ' HB3' HD11 ' A' ' 28' ' ' LEU . 97.8 mmm -113.52 -14.87 12.65 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.908 -1.12 . . . . 0.0 109.715 169.128 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.532 ' N ' HD12 ' A' ' 28' ' ' LEU . 14.0 mt -62.32 -40.02 94.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.087 -1.008 . . . . 0.0 109.59 176.585 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -69.93 129.95 40.9 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.469 -0.769 . . . . 0.0 110.278 178.036 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.0 -44.25 1.66 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 176.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.796 ' CD2' HG21 ' A' ' 59' ' ' VAL . 66.0 tp -63.61 145.13 56.29 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.05 -1.265 . . . . 0.0 110.946 -176.442 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 21.6 pt-20 -153.09 160.02 42.87 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.507 -0.745 . . . . 0.0 109.316 175.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.738 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -62.81 148.76 45.98 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.93 -1.107 . . . . 0.0 110.058 -179.296 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.52 -6.45 68.94 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 -175.035 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 50' ' ' THR . . . -72.86 155.73 39.61 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.178 -1.189 . . . . 0.0 109.543 176.479 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.788 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -100.03 99.75 10.53 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 119.05 -1.06 . . . . 0.0 109.698 176.762 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.686 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.2 t -85.58 131.74 33.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.347 -0.846 . . . . 0.0 109.355 176.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.507 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -95.03 119.98 34.47 Favored 'General case' 0 C--N 1.294 -1.83 0 O-C-N 121.059 -1.025 . . . . 0.0 109.272 170.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.686 ' HE1' HG11 ' A' ' 42' ' ' VAL . 0.3 OUTLIER -89.51 108.2 19.52 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 176.579 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.491 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.0 t-20 51.83 16.34 0.49 Allowed 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.235 -0.916 . . . . 0.0 111.056 -168.218 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.491 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 117.09 -1.53 19.33 Favored Glycine 0 N--CA 1.49 2.235 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.915 172.356 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.79 ' O ' HD23 ' A' ' 49' ' ' LEU . 18.9 t -93.84 107.13 19.05 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.505 -1.585 . . . . 0.0 109.304 174.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.437 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 32.1 p -75.19 130.01 38.45 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.003 -1.061 . . . . 0.0 111.019 -171.584 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.914 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -144.75 161.22 39.77 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.526 -0.734 . . . . 0.0 109.524 174.518 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.461 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 10.7 m -100.22 149.97 23.02 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.757 -1.214 . . . . 0.0 111.043 -171.012 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.813 HG13 HG13 ' A' ' 59' ' ' VAL . 36.7 t -80.03 115.33 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.773 -0.579 . . . . 0.0 110.432 -178.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.556 HG22 ' HB3' ' A' ' 62' ' ' ASP . 30.5 p -70.09 -39.99 75.22 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.175 -0.953 . . . . 0.0 109.871 175.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.652 ' HA ' HG21 ' A' ' 38' ' ' THR . 87.7 tt0 -161.3 154.2 20.88 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.262 -0.899 . . . . 0.0 110.333 179.059 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.738 HD11 ' N ' ' A' ' 38' ' ' THR . 5.8 mt -102.48 132.73 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.983 -1.073 . . . . 0.0 109.909 174.472 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.523 ' CB ' ' HB2' ' A' ' 58' ' ' HIS . 2.5 m-80 -103.89 65.25 0.81 Allowed 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.569 -0.707 . . . . 0.0 109.869 179.334 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.94 -118.55 5.69 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 108.719 -1.752 . . . . 0.0 108.719 -173.091 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.518 ' O ' ' HB2' ' A' ' 28' ' ' LEU . 0.0 OUTLIER -75.02 -21.46 59.07 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 120.903 -1.351 . . . . 0.0 108.764 173.818 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.139 ' CD2' HG11 ' A' ' 13' ' ' VAL . 12.8 m170 -72.89 159.96 32.9 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.242 -0.912 . . . . 0.0 110.17 -177.37 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.813 HG13 HG13 ' A' ' 51' ' ' VAL . 52.8 t -140.1 125.57 20.72 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 O-C-N 121.04 -1.037 . . . . 0.0 110.662 171.536 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.848 ' CB ' HG22 ' A' ' 25' ' ' VAL . 54.3 p -96.09 125.82 40.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.723 -0.611 . . . . 0.0 109.742 179.641 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.914 ' HB2' HD12 ' A' ' 49' ' ' LEU . 4.3 p90 -118.45 155.26 31.08 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.016 -1.052 . . . . 0.0 110.296 179.806 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.556 ' HB3' HG22 ' A' ' 52' ' ' THR . 35.1 p-10 -87.87 152.81 21.81 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.075 -1.016 . . . . 0.0 111.244 -173.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.75 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -157.96 114.36 2.84 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 -176.518 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.511 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 57.6 ttm -71.92 142.33 49.48 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.009 -1.057 . . . . 0.0 109.624 -178.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.471 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 71.3 tttt -59.98 -50.01 75.41 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.075 -1.016 . . . . 0.0 110.505 -175.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -65.58 -39.96 92.2 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.996 -1.065 . . . . 0.0 109.914 178.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.511 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 93.0 m -61.11 -40.04 92.27 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.978 -1.076 . . . . 0.0 109.289 174.05 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.68 HD22 ' HD3' ' A' ' 22' ' ' ARG . 18.0 tp -59.95 -43.01 95.28 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.319 -0.863 . . . . 0.0 109.466 178.368 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -67.64 -39.98 84.59 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.554 -0.716 . . . . 0.0 110.138 176.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.719 HG22 HG23 ' A' ' 71' ' ' THR . 1.2 tt -68.23 -40.02 82.04 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.357 -0.84 . . . . 0.0 109.301 -177.055 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.719 HG23 HG22 ' A' ' 70' ' ' ILE . 60.1 p -84.61 -172.73 4.33 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 120.261 -0.576 . . . . 0.0 109.483 177.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.478 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 5.9 t30 -102.32 22.45 13.33 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 169.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.75 ' HB3' HD21 ' A' ' 63' ' ' LEU . 88.2 mt -70.02 -39.92 75.51 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.01 -1.056 . . . . 0.0 109.757 174.794 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.449 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -44.56 -23.96 0.6 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.396 -1.082 . . . . 0.0 110.396 178.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 23.0 p-10 -69.97 -19.16 63.36 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.913 -1.346 . . . . 0.0 110.603 -174.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.519 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 98.4 mt -59.92 140.41 56.7 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.085 -1.01 . . . . 0.0 110.714 -176.682 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 1.013 ' C ' HD23 ' A' ' 12' ' ' LEU . 92.3 mttt -143.6 138.97 29.43 Favored 'General case' 0 C--N 1.297 -1.712 0 CA-C-O 121.427 0.632 . . . . 0.0 109.83 177.301 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.68 ' N ' HD23 ' A' ' 12' ' ' LEU . 16.4 t -60.33 152.2 5.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 120.983 -1.073 . . . . 0.0 110.48 -175.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.37 -14.46 59.43 Favored Glycine 0 N--CA 1.483 1.776 0 N-CA-C 108.906 -1.678 . . . . 0.0 108.906 -176.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 49.6 t0 -96.27 166.37 11.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.33 -1.1 . . . . 0.0 109.627 176.569 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.585 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.1 m95 -115.43 165.99 12.37 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.963 -1.086 . . . . 0.0 110.157 175.53 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.033 HG13 ' HB3' ' A' ' 10' ' ' ALA . 0.9 OUTLIER -129.96 158.4 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.339 -0.851 . . . . 0.0 110.081 -177.532 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.98 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.1 OUTLIER -80.0 107.5 12.83 Favored 'General case' 0 C--N 1.297 -1.674 0 O-C-N 121.006 -1.058 . . . . 0.0 109.14 167.029 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.736 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -108.85 138.13 37.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 120.596 -1.315 . . . . 0.0 111.194 -176.356 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -140.92 146.51 37.5 Favored 'General case' 0 N--CA 1.492 1.661 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.043 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 58.0 ttp180 -83.21 130.02 35.06 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.027 -1.045 . . . . 0.0 111.038 -176.41 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.788 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 110.031 174.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 1.004 HG21 ' HB3' ' B' ' 83' ' ' ASN . 3.7 t . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.532 0.682 . . . . 0.0 110.856 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 94.3 mm-40 -69.99 -32.97 71.44 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.735 -0.603 . . . . 0.0 110.635 175.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -169.13 174.4 43.61 Favored Glycine 0 N--CA 1.495 2.576 0 C-N-CA 119.175 -1.488 . . . . 0.0 109.935 -176.626 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.488 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 41.6 p -114.52 170.03 8.61 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.0 -1.294 . . . . 0.0 110.778 -177.475 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.051 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -135.61 150.04 49.54 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.614 -0.679 . . . . 0.0 109.523 -175.742 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.581 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 30.1 tttt -105.84 116.83 32.61 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.101 -0.999 . . . . 0.0 110.262 179.134 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 1.013 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.5 tp -60.0 127.13 30.36 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 120.96 -1.088 . . . . 0.0 108.9 172.334 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.142 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -125.53 -31.61 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.856 0 O-C-N 121.383 -0.823 . . . . 0.0 110.009 -179.479 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.02 144.59 29.25 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.273 -0.971 . . . . 0.0 111.351 -179.281 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.779 HG23 ' CD2' ' B' ' 24' ' ' HIS . 13.5 mt -108.58 135.67 46.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.217 -0.927 . . . . 0.0 109.994 172.058 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.526 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.6 m-20 -109.48 115.0 29.11 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 121.367 -0.833 . . . . 0.0 109.788 174.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -105.62 114.18 28.19 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.012 -1.055 . . . . 0.0 110.619 -175.388 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.44 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.0 OUTLIER -111.46 127.77 26.39 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.233 -0.917 . . . . 0.0 109.049 174.226 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . 0.431 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.2 Cg_endo -51.16 -23.97 13.96 Favored 'Trans proline' 0 C--N 1.303 -1.834 0 O-C-N 123.827 1.435 . . . . 0.0 110.238 -179.727 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.54 ' C ' ' CD2' ' B' ' 21' ' ' PHE . 11.2 m-80 -79.94 -43.0 22.91 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.106 -0.996 . . . . 0.0 109.884 175.15 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.54 ' CD2' ' C ' ' B' ' 20' ' ' ASN . 97.4 m-85 -153.69 150.37 28.5 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.54 -0.725 . . . . 0.0 109.993 -178.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . 0.685 ' HD3' HD22 ' B' ' 68' ' ' LEU . 62.1 ttt180 -90.54 145.2 25.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.934 -1.104 . . . . 0.0 110.108 178.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.526 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 87.0 m -131.63 141.84 49.72 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.541 -0.725 . . . . 0.0 109.852 -175.535 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.779 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -131.05 144.08 51.18 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 120.926 -1.109 . . . . 0.0 111.336 -179.431 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.857 HG22 ' CB ' ' B' ' 60' ' ' SER . 6.6 t -125.43 134.07 67.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.15 -0.969 . . . . 0.0 110.93 -178.271 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.749 HG13 ' HE1' ' B' ' 61' ' ' PHE . 30.3 m -117.14 174.59 3.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.812 -0.555 . . . . 0.0 110.304 179.102 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.515 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 12.0 tt0 -104.57 118.51 36.77 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 177.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.824 HD13 ' HD2' ' B' ' 29' ' ' PRO 0.266 0.2 OUTLIER -87.35 123.07 70.38 Favored Pre-proline 0 C--N 1.296 -1.728 0 O-C-N 121.403 -0.811 . . . . 0.0 108.968 -172.769 . . . . . . . . 4 4 . 1 . 004 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.824 ' HD2' HD13 ' B' ' 28' ' ' LEU . 18.1 Cg_endo -66.27 172.84 8.27 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 O-C-N 123.6 1.316 . . . . 0.0 111.114 -178.213 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.496 ' HA ' HD12 ' B' ' 33' ' ' LEU . 96.0 m-20 -60.07 -40.04 88.15 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.579 -0.701 . . . . 0.0 111.135 -174.647 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.534 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.94 -0.03 57.34 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.743 -1.223 . . . . 0.0 110.72 -171.514 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.649 ' HB3' HD11 ' B' ' 28' ' ' LEU . 98.0 mmm -113.48 -14.87 12.67 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.975 -1.078 . . . . 0.0 109.729 169.148 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.533 ' N ' HD12 ' B' ' 28' ' ' LEU . 14.0 mt -62.32 -39.93 94.66 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.071 -1.018 . . . . 0.0 109.652 176.572 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -70.02 130.07 41.16 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.486 -0.759 . . . . 0.0 110.29 177.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.88 -44.13 1.69 Allowed Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.179 -1.169 . . . . 0.0 110.179 176.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.797 ' CD2' HG21 ' B' ' 59' ' ' VAL . 66.4 tp -63.78 145.13 56.36 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.012 -1.287 . . . . 0.0 110.891 -176.441 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . . . . . . . . . 21.6 pt-20 -153.07 159.97 42.89 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.52 -0.737 . . . . 0.0 109.334 175.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 0.729 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -62.87 148.65 46.54 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.944 -1.098 . . . . 0.0 110.151 -179.303 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.67 -6.51 69.26 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 -174.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' B' ' 50' ' ' THR . . . -72.99 155.61 39.67 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.206 -1.173 . . . . 0.0 109.509 176.489 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.778 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -99.7 99.61 10.46 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 120.926 -1.109 . . . . 0.0 109.799 176.725 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.67 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.2 t -85.62 131.87 33.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.332 -0.855 . . . . 0.0 109.319 176.183 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -95.12 120.06 34.69 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.037 -1.039 . . . . 0.0 109.292 170.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.67 ' HE1' HG11 ' B' ' 42' ' ' VAL . 0.3 OUTLIER -89.58 107.97 19.39 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.32 -0.863 . . . . 0.0 108.916 176.639 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.491 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.0 t-20 51.95 16.54 0.53 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.218 -0.926 . . . . 0.0 110.972 -168.204 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.491 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 116.92 -1.27 19.71 Favored Glycine 0 N--CA 1.489 2.227 0 C-N-CA 119.543 -1.313 . . . . 0.0 110.917 172.199 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.798 ' O ' HD23 ' B' ' 49' ' ' LEU . 18.9 t -93.99 107.07 19.01 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.49 -1.594 . . . . 0.0 109.316 174.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . 0.433 ' O ' ' SG ' ' B' ' 48' ' ' CYS . 32.1 p -75.04 129.99 38.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.037 -1.039 . . . . 0.0 111.089 -171.626 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 0.909 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -144.81 161.19 39.89 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.526 -0.734 . . . . 0.0 109.507 174.503 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . 0.464 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 10.5 m -100.06 150.15 22.75 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.749 -1.219 . . . . 0.0 111.069 -171.024 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.823 HG13 HG13 ' B' ' 59' ' ' VAL . 37.7 t -80.27 115.36 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.639 -0.663 . . . . 0.0 110.434 -178.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.537 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 30.5 p -70.07 -39.98 75.32 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.14 -0.975 . . . . 0.0 109.91 175.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.629 ' HA ' HG21 ' B' ' 38' ' ' THR . 87.7 tt0 -161.36 154.25 20.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.267 -0.895 . . . . 0.0 110.297 179.079 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.729 HD11 ' N ' ' B' ' 38' ' ' THR . 5.8 mt -102.5 132.75 47.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.11 -0.994 . . . . 0.0 109.927 174.535 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.51 ' CB ' ' HB2' ' B' ' 58' ' ' HIS . 2.5 m-80 -104.04 65.36 0.8 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.528 -0.733 . . . . 0.0 109.758 179.415 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.02 -118.48 5.64 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.655 -1.778 . . . . 0.0 108.655 -173.224 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.52 ' O ' ' HB2' ' B' ' 28' ' ' LEU . 0.0 OUTLIER -75.0 -21.66 59.0 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.928 -1.336 . . . . 0.0 108.777 173.796 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.142 ' CD2' HG11 ' B' ' 13' ' ' VAL . 12.8 m170 -72.7 159.76 33.3 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.345 -0.847 . . . . 0.0 110.192 -177.411 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.823 HG13 HG13 ' B' ' 51' ' ' VAL . 53.1 t -140.03 125.52 20.87 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.093 -1.005 . . . . 0.0 110.748 171.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.857 ' CB ' HG22 ' B' ' 25' ' ' VAL . 54.4 p -96.04 126.06 41.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.651 -0.656 . . . . 0.0 109.818 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.909 ' HB2' HD12 ' B' ' 49' ' ' LEU . 4.3 p90 -118.6 155.2 31.37 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.963 -1.086 . . . . 0.0 110.344 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.537 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 34.9 p-10 -87.76 152.73 21.9 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.097 -1.002 . . . . 0.0 111.305 -173.226 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.752 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -157.79 114.53 2.91 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -176.662 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.519 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 57.7 ttm -72.08 142.41 49.22 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.931 -1.105 . . . . 0.0 109.574 -178.801 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.469 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 71.2 tttt -60.11 -49.91 75.77 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.988 -1.07 . . . . 0.0 110.441 -175.117 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -65.6 -40.02 92.2 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.969 -1.082 . . . . 0.0 109.906 178.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.519 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 93.1 m -61.2 -39.94 92.1 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.974 -1.079 . . . . 0.0 109.219 174.13 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.685 HD22 ' HD3' ' B' ' 22' ' ' ARG . 17.9 tp -59.98 -42.95 95.3 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.439 -0.788 . . . . 0.0 109.522 178.334 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -67.52 -39.99 85.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.581 -0.7 . . . . 0.0 110.269 176.476 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.71 HG22 HG23 ' B' ' 71' ' ' THR . 1.2 tt -68.19 -40.08 82.22 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 CA-C-O 121.904 0.859 . . . . 0.0 109.295 -177.115 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.71 HG23 HG22 ' B' ' 70' ' ' ILE . 59.2 p -84.52 -172.52 4.22 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 120.083 -0.647 . . . . 0.0 109.546 177.782 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.47 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 5.8 t30 -102.42 22.56 13.23 Favored 'General case' 0 C--N 1.296 -1.754 0 O-C-N 121.218 -0.927 . . . . 0.0 108.51 169.411 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.752 ' HB3' HD21 ' B' ' 63' ' ' LEU . 88.1 mt -70.09 -39.95 75.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.013 -1.054 . . . . 0.0 109.713 174.71 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.448 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -44.56 -23.82 0.58 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 178.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 23.2 p-10 -70.04 -19.07 63.31 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.932 -1.334 . . . . 0.0 110.648 -175.021 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.519 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.3 mt -60.03 140.41 56.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.121 -0.987 . . . . 0.0 110.67 -176.662 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 1.013 ' C ' HD23 ' B' ' 12' ' ' LEU . 92.2 mttt -143.6 139.05 29.46 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 121.363 0.601 . . . . 0.0 109.853 177.297 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.676 ' N ' HD23 ' B' ' 12' ' ' LEU . 16.5 t -60.56 152.24 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 120.937 -1.102 . . . . 0.0 110.42 -175.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.29 -14.22 59.89 Favored Glycine 0 N--CA 1.485 1.932 0 N-CA-C 108.927 -1.669 . . . . 0.0 108.927 -176.067 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.508 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 49.4 t0 -96.37 166.31 11.77 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.387 -1.066 . . . . 0.0 109.572 176.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.581 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.1 m95 -115.38 165.93 12.43 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.03 -1.044 . . . . 0.0 110.225 175.493 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 1.051 HG13 ' HB3' ' B' ' 10' ' ' ALA . 0.9 OUTLIER -129.95 158.5 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.387 -0.821 . . . . 0.0 110.081 -177.628 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 1.004 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.1 OUTLIER -79.96 107.29 12.63 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 120.987 -1.07 . . . . 0.0 109.179 167.043 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.722 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -108.67 138.34 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 120.668 -1.27 . . . . 0.0 111.061 -176.196 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -141.34 146.57 36.87 Favored 'General case' 0 N--CA 1.492 1.659 0 C-N-CA 120.397 -0.521 . . . . 0.0 109.933 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 58.0 ttp180 -83.07 129.97 35.08 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.027 -1.046 . . . . 0.0 110.996 -176.288 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.778 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.492 1.642 0 O-C-N 121.258 -0.901 . . . . 0.0 110.023 174.486 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.818 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.8 t . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 121.799 0.809 . . . . 0.0 111.047 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 30.3 mm100 -69.91 -36.25 75.23 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.716 -0.615 . . . . 0.0 110.836 178.033 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.537 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -154.36 170.78 32.84 Favored Glycine 0 N--CA 1.493 2.448 0 C-N-CA 119.156 -1.497 . . . . 0.0 109.986 -172.492 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.445 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 4.2 p -114.4 173.86 6.24 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.927 -1.337 . . . . 0.0 111.173 -175.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 1.061 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -142.2 149.8 40.16 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.676 -0.64 . . . . 0.0 109.347 -177.502 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.591 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 38.3 tttt -107.29 116.72 32.42 Favored 'General case' 0 C--N 1.295 -1.766 0 O-C-N 121.003 -1.061 . . . . 0.0 110.269 177.908 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 1.011 HD23 ' C ' ' A' ' 77' ' ' LYS . 11.9 tp -60.02 126.95 29.53 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.848 -1.157 . . . . 0.0 108.827 171.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.123 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.3 p -122.79 -31.65 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 O-C-N 121.395 -0.816 . . . . 0.0 109.881 -179.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.94 146.59 27.92 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 118.984 -1.086 . . . . 0.0 111.473 -179.324 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.852 HG23 ' CD2' ' A' ' 24' ' ' HIS . 7.6 mt -108.45 138.06 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.026 -1.046 . . . . 0.0 110.238 171.207 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.504 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.9 m-20 -109.22 115.72 30.55 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.196 -0.94 . . . . 0.0 109.765 171.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -104.56 112.27 25.28 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.019 -1.05 . . . . 0.0 110.379 -175.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.463 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 20.4 mmmt -115.64 129.27 25.28 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.17 -0.956 . . . . 0.0 109.125 177.33 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -51.03 -31.34 34.46 Favored 'Trans proline' 0 C--N 1.303 -1.841 0 O-C-N 123.775 1.408 . . . . 0.0 110.264 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 11.6 m-80 -74.42 -39.99 62.27 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.232 -0.917 . . . . 0.0 110.09 175.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 83.7 m-85 -156.35 150.46 25.27 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.328 -0.858 . . . . 0.0 110.308 -177.623 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.49 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 59.0 ttt180 -92.05 141.81 28.21 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.921 -1.112 . . . . 0.0 109.94 176.579 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.504 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.6 m -130.08 139.95 50.89 Favored 'General case' 0 C--N 1.294 -1.819 0 O-C-N 121.675 -0.641 . . . . 0.0 109.912 -173.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.852 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -131.12 141.41 50.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.905 -1.122 . . . . 0.0 111.068 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.763 HG22 ' CB ' ' A' ' 60' ' ' SER . 6.8 t -122.51 133.17 69.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.053 -1.03 . . . . 0.0 110.677 -178.823 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.825 HG13 ' CE1' ' A' ' 61' ' ' PHE . 30.1 m -116.19 173.33 3.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.808 -0.557 . . . . 0.0 110.22 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.512 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 8.4 tt0 -104.44 116.44 32.13 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.434 -0.791 . . . . 0.0 108.942 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.83 HD21 HD13 ' A' ' 36' ' ' LEU . 9.6 tp -83.55 124.35 75.56 Favored Pre-proline 0 C--N 1.298 -1.649 0 O-C-N 121.475 -0.766 . . . . 0.0 110.059 -173.159 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.481 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 26.2 Cg_endo -66.42 176.61 3.92 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 123.923 1.486 . . . . 0.0 111.104 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.487 ' HA ' HD12 ' A' ' 33' ' ' LEU . 47.4 t0 -60.09 -39.88 87.67 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.328 -0.858 . . . . 0.0 111.13 -175.467 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.596 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.64 0.06 57.19 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.756 -1.215 . . . . 0.0 110.576 -174.548 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.596 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.7 mmm -111.43 -14.1 13.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.037 -1.04 . . . . 0.0 109.813 170.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.582 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 17.5 mt -69.81 -39.97 76.21 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.271 -0.893 . . . . 0.0 110.308 177.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -78.06 129.37 35.15 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.919 . . . . 0.0 110.337 -178.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.88 -42.96 1.87 Allowed Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.865 -1.159 . . . . 0.0 110.374 174.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.83 HD13 HD21 ' A' ' 28' ' ' LEU . 7.1 tt -66.79 146.65 54.2 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.932 -1.334 . . . . 0.0 110.508 -175.012 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.689 ' N ' HD23 ' A' ' 36' ' ' LEU . 14.7 pt-20 -149.97 164.38 35.63 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.556 -0.715 . . . . 0.0 109.672 -178.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.803 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -66.5 150.06 49.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.99 -1.069 . . . . 0.0 109.949 179.335 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.7 -4.81 63.39 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -173.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.54 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -76.62 153.54 35.18 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.225 -1.162 . . . . 0.0 109.519 177.145 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.52 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -97.82 109.23 22.02 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 121.016 -1.052 . . . . 0.0 110.086 178.153 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.63 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.2 t -95.37 133.1 37.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.224 -0.923 . . . . 0.0 109.129 173.737 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.509 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -95.9 119.9 35.22 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.112 -0.993 . . . . 0.0 109.071 171.417 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.637 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.3 OUTLIER -88.81 104.85 17.3 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.433 -0.792 . . . . 0.0 108.884 177.636 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.5 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 54.82 12.86 0.64 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.361 -0.837 . . . . 0.0 111.258 -168.513 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.489 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.34 -1.22 11.46 Favored Glycine 0 N--CA 1.49 2.283 0 C-N-CA 119.603 -1.284 . . . . 0.0 110.769 172.804 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.839 ' O ' HD23 ' A' ' 49' ' ' LEU . 36.1 t -93.85 109.71 21.4 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 120.531 -1.57 . . . . 0.0 109.517 175.275 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.7 p -74.44 128.26 35.1 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.113 -0.992 . . . . 0.0 110.984 -171.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.947 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -144.3 159.18 43.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.506 -0.746 . . . . 0.0 109.421 174.177 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 65.3 m -102.34 151.26 22.46 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.718 -1.239 . . . . 0.0 111.148 -172.022 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.848 HG13 HG13 ' A' ' 59' ' ' VAL . 21.3 t -78.44 119.77 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.728 -0.608 . . . . 0.0 110.641 -177.329 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 43.2 p -73.25 -43.84 60.46 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.242 -0.911 . . . . 0.0 110.15 174.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.617 ' HA ' HG21 ' A' ' 38' ' ' THR . 86.4 tt0 -159.32 151.22 20.67 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.319 -0.863 . . . . 0.0 110.468 -178.244 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.803 HD11 ' N ' ' A' ' 38' ' ' THR . 6.3 mt -102.87 133.13 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.172 -0.955 . . . . 0.0 109.953 174.724 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.51 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 44.9 m-80 -108.04 65.72 0.64 Allowed 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.492 -0.755 . . . . 0.0 109.703 178.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.93 -116.28 4.77 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -174.091 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.582 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.35 -20.89 50.38 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.02 -1.282 . . . . 0.0 109.059 175.028 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.123 ' CD2' HG11 ' A' ' 13' ' ' VAL . 10.4 m170 -74.45 160.03 31.5 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.358 -0.839 . . . . 0.0 110.096 -177.109 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.848 HG13 HG13 ' A' ' 51' ' ' VAL . 54.9 t -140.37 122.88 16.14 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 O-C-N 121.006 -1.059 . . . . 0.0 110.808 171.117 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.763 ' CB ' HG22 ' A' ' 25' ' ' VAL . 3.0 m -89.46 128.96 36.02 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.643 -0.661 . . . . 0.0 109.586 177.162 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.947 ' HB2' HD12 ' A' ' 49' ' ' LEU . 3.1 p90 -123.23 155.5 37.01 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.026 -1.046 . . . . 0.0 110.082 178.643 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 29.6 p-10 -90.03 154.41 19.83 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.946 -1.096 . . . . 0.0 111.594 -170.377 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.801 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -158.85 123.96 4.23 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 -175.753 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.513 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 96.0 mtp -79.65 146.72 32.33 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.677 -1.264 . . . . 0.0 109.714 178.077 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.479 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 27.8 ttpt -60.01 -47.63 85.06 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.082 -1.011 . . . . 0.0 109.626 178.477 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.99 -40.03 75.55 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.214 -0.928 . . . . 0.0 110.833 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.62 ' O ' HG23 ' A' ' 71' ' ' THR . 23.6 m -65.51 -33.95 77.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.681 -1.262 . . . . 0.0 109.103 175.22 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.77 HD11 ' HA2' ' A' ' 74' ' ' GLY . 4.3 tp -60.04 -45.96 91.1 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.546 -0.721 . . . . 0.0 109.705 177.009 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 31.7 tpt180 -69.78 -40.05 76.27 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.304 -0.872 . . . . 0.0 110.54 178.477 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.805 HG22 HG23 ' A' ' 71' ' ' THR . 1.5 tt -63.94 -42.78 96.87 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 O-C-N 121.18 -0.95 . . . . 0.0 109.288 -178.681 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.805 HG23 HG22 ' A' ' 70' ' ' ILE . 20.9 p -83.59 -173.29 4.63 Favored 'General case' 0 C--N 1.298 -1.63 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 174.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 3.4 t30 -104.64 25.66 10.04 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 169.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.801 ' HB3' HD21 ' A' ' 63' ' ' LEU . 90.4 mt -68.07 -39.95 82.85 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.239 -0.913 . . . . 0.0 109.671 175.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.77 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -49.87 -23.7 5.51 Favored Glycine 0 N--CA 1.486 1.977 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.06 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 23.7 p-10 -64.52 -17.26 63.74 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.941 -1.329 . . . . 0.0 110.188 -176.202 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.518 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.7 mt -60.52 144.96 50.25 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.314 -0.866 . . . . 0.0 110.484 -178.454 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 1.011 ' C ' HD23 ' A' ' 12' ' ' LEU . 66.2 mttt -150.12 138.65 20.64 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 121.725 -0.609 . . . . 0.0 109.669 178.11 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.692 HG21 HG13 ' A' ' 15' ' ' ILE . 62.1 t -63.54 147.3 12.28 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 120.884 -1.135 . . . . 0.0 110.152 -175.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.98 -11.43 70.72 Favored Glycine 0 N--CA 1.483 1.805 0 N-CA-C 108.779 -1.729 . . . . 0.0 108.779 -172.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 41.7 t0 -100.88 162.25 13.03 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.392 -1.063 . . . . 0.0 109.722 176.408 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.591 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.4 m95 -114.09 159.9 19.52 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.144 -0.972 . . . . 0.0 109.976 177.268 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.061 HG13 ' HB3' ' A' ' 10' ' ' ALA . 0.9 OUTLIER -126.81 156.97 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.973 -177.516 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.818 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.4 m-20 -82.14 104.93 12.83 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.202 -0.936 . . . . 0.0 109.263 169.552 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.844 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -107.22 138.58 32.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 120.574 -1.329 . . . . 0.0 111.542 -175.564 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -131.63 147.55 52.53 Favored 'General case' 0 N--CA 1.494 1.738 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.994 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.489 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 38.2 ptt180 -87.92 131.77 34.47 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.135 -0.978 . . . . 0.0 110.627 -178.595 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.52 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.594 0 O-C-N 121.202 -0.936 . . . . 0.0 110.239 179.405 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 0.831 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.7 t . . . . . 0 N--CA 1.492 1.629 0 CA-C-O 121.737 0.78 . . . . 0.0 111.074 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 30.3 mm100 -69.94 -35.95 74.91 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.834 -0.541 . . . . 0.0 110.938 178.085 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.54 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -154.53 170.68 32.94 Favored Glycine 0 N--CA 1.495 2.596 0 C-N-CA 119.232 -1.461 . . . . 0.0 110.13 -172.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.447 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 4.2 p -114.43 173.82 6.27 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.992 -1.299 . . . . 0.0 111.246 -175.317 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.071 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -142.13 150.01 40.55 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -177.534 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 38.3 tttt -107.52 116.78 32.56 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.109 -0.994 . . . . 0.0 110.126 177.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 1.028 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.9 tp -60.06 126.82 28.99 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.872 -1.142 . . . . 0.0 108.916 171.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.123 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.3 p -122.68 -31.74 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.849 0 O-C-N 121.387 -0.821 . . . . 0.0 109.859 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.84 146.67 28.07 Favored 'General case' 0 N--CA 1.493 1.706 0 C-N-CA 119.16 -1.016 . . . . 0.0 111.474 -179.333 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.856 HG23 ' CD2' ' B' ' 24' ' ' HIS . 7.6 mt -108.47 138.06 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.067 -1.021 . . . . 0.0 110.291 171.152 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.515 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 78.1 m-20 -109.32 115.7 30.47 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.46 -0.775 . . . . 0.0 109.754 172.054 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -104.51 112.28 25.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.097 -1.002 . . . . 0.0 110.312 -175.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 20.1 mmmt -115.64 129.29 25.26 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.325 -0.859 . . . . 0.0 109.161 177.247 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . 0.426 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.4 Cg_endo -51.17 -31.25 35.46 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.721 1.379 . . . . 0.0 110.216 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.552 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 11.9 m-80 -74.42 -40.27 62.08 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.2 -0.937 . . . . 0.0 109.94 175.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.552 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 83.8 m-85 -156.07 150.4 25.64 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.289 -0.882 . . . . 0.0 110.357 -177.513 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . 0.496 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 58.8 ttt180 -91.97 141.69 28.35 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.989 -1.069 . . . . 0.0 110.016 176.525 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.515 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 94.6 m -129.95 139.98 51.0 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 121.67 -0.644 . . . . 0.0 109.951 -173.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.856 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -131.06 141.4 50.18 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.021 -1.049 . . . . 0.0 111.046 -179.586 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.768 HG22 ' CB ' ' B' ' 60' ' ' SER . 6.7 t -122.47 133.3 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.157 -0.964 . . . . 0.0 110.744 -178.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.831 HG13 ' HE1' ' B' ' 61' ' ' PHE . 30.7 m -116.37 173.26 4.07 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.766 -0.583 . . . . 0.0 110.101 178.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.504 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 8.4 tt0 -104.32 116.56 32.37 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 179.685 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.838 HD21 HD13 ' B' ' 36' ' ' LEU . 9.6 tp -83.57 124.32 75.56 Favored Pre-proline 0 C--N 1.299 -1.629 0 O-C-N 121.338 -0.851 . . . . 0.0 110.095 -173.164 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.476 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 26.0 Cg_endo -66.41 176.6 3.93 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 O-C-N 123.858 1.452 . . . . 0.0 111.104 -179.483 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.489 ' HA ' HD12 ' B' ' 33' ' ' LEU . 47.4 t0 -60.0 -40.03 87.78 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.341 -0.849 . . . . 0.0 111.104 -175.49 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.586 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.56 0.1 57.14 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.753 -1.217 . . . . 0.0 110.658 -174.57 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.586 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.7 mmm -111.43 -14.11 13.78 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.055 -1.028 . . . . 0.0 109.828 170.266 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.596 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 17.8 mt -69.7 -40.06 76.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.358 -0.839 . . . . 0.0 110.338 177.628 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 55.8 t0 -78.01 129.38 35.2 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.886 . . . . 0.0 110.432 -178.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.95 -43.08 1.85 Allowed Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.854 -1.165 . . . . 0.0 110.304 174.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.838 HD13 HD21 ' B' ' 28' ' ' LEU . 7.0 tt -66.81 146.68 54.17 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.866 -1.373 . . . . 0.0 110.533 -174.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . 0.681 ' N ' HD23 ' B' ' 36' ' ' LEU . 14.7 pt-20 -150.04 164.35 35.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.4 -0.812 . . . . 0.0 109.618 -178.664 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 0.795 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.49 149.94 49.7 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.031 -1.043 . . . . 0.0 109.962 179.369 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.85 -4.83 63.93 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 -174.048 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.542 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -76.63 153.35 35.32 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.293 -1.122 . . . . 0.0 109.592 177.024 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.523 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.1 OUTLIER -97.53 109.05 21.88 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 120.951 -1.093 . . . . 0.0 110.195 178.096 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.622 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.2 t -95.29 133.13 37.35 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 O-C-N 121.253 -0.904 . . . . 0.0 109.154 173.723 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 0.504 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -95.89 119.87 35.16 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 119.204 -0.999 . . . . 0.0 109.181 171.284 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.643 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.3 OUTLIER -88.79 104.66 17.11 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.302 -0.874 . . . . 0.0 108.966 177.696 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.5 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 55.01 12.88 0.67 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.54 -0.725 . . . . 0.0 111.291 -168.491 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.489 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.15 -0.79 11.63 Favored Glycine 0 N--CA 1.491 2.346 0 C-N-CA 119.662 -1.256 . . . . 0.0 110.75 172.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.844 ' O ' HD23 ' B' ' 49' ' ' LEU . 36.0 t -94.03 109.68 21.42 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.45 -1.617 . . . . 0.0 109.54 175.134 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 18.7 p -74.4 128.41 35.47 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.095 -1.003 . . . . 0.0 110.965 -171.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 0.943 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -144.5 159.1 43.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.541 -0.724 . . . . 0.0 109.387 174.129 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 64.9 m -102.22 151.38 22.28 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.705 -1.247 . . . . 0.0 111.112 -171.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.828 HG13 HG13 ' B' ' 59' ' ' VAL . 21.4 t -78.65 119.94 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.727 -0.608 . . . . 0.0 110.584 -177.27 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 43.3 p -73.32 -43.93 59.93 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.17 -0.956 . . . . 0.0 110.159 174.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.641 ' HA ' HG21 ' B' ' 38' ' ' THR . 86.5 tt0 -159.24 151.36 20.99 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.331 -0.856 . . . . 0.0 110.455 -178.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.795 HD11 ' N ' ' B' ' 38' ' ' THR . 6.3 mt -103.0 133.0 48.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.102 -0.999 . . . . 0.0 109.933 174.789 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.527 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 44.8 m-80 -108.0 65.74 0.64 Allowed 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 119.972 -0.691 . . . . 0.0 109.679 179.014 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.08 -116.31 4.74 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 -174.22 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.596 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.31 -21.09 50.17 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 120.983 -1.304 . . . . 0.0 109.049 175.069 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.123 ' CD2' HG11 ' B' ' 13' ' ' VAL . 10.6 m170 -74.17 159.77 32.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.474 -0.766 . . . . 0.0 110.252 -177.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.828 HG13 HG13 ' B' ' 51' ' ' VAL . 55.8 t -140.24 122.87 16.46 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 C-N-CA 119.094 -1.042 . . . . 0.0 110.877 171.177 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.768 ' CB ' HG22 ' B' ' 25' ' ' VAL . 3.0 m -89.61 128.97 36.12 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.751 -0.593 . . . . 0.0 109.556 177.304 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.943 ' HB2' HD12 ' B' ' 49' ' ' LEU . 3.1 p90 -123.21 155.56 36.88 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.113 -0.992 . . . . 0.0 110.07 178.71 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 29.7 p-10 -90.1 154.4 19.81 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.818 -1.176 . . . . 0.0 111.554 -170.273 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.77 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -158.78 124.04 4.3 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 -175.764 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.521 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 96.0 mtp -79.74 146.68 32.23 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.631 -1.293 . . . . 0.0 109.706 178.029 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.477 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 27.9 ttpt -60.07 -47.61 85.15 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.195 -0.941 . . . . 0.0 109.542 178.562 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.95 -40.01 75.71 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.186 -0.946 . . . . 0.0 110.896 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.638 ' O ' HG23 ' B' ' 71' ' ' THR . 23.7 m -65.48 -34.14 77.57 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.649 -1.282 . . . . 0.0 109.021 175.204 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.771 HD11 ' HA2' ' B' ' 74' ' ' GLY . 4.3 tp -60.04 -45.67 92.08 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.571 -0.706 . . . . 0.0 109.844 177.039 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 31.6 tpt180 -70.01 -39.99 75.5 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.278 -0.889 . . . . 0.0 110.498 178.401 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.798 HG22 HG23 ' B' ' 71' ' ' THR . 1.5 tt -63.85 -42.7 96.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.221 -0.924 . . . . 0.0 109.332 -178.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.798 HG23 HG22 ' B' ' 70' ' ' ILE . 21.3 p -83.71 -173.08 4.51 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 174.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.511 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 3.4 t30 -104.79 25.59 10.21 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 169.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.77 ' HB3' HD21 ' B' ' 63' ' ' LEU . 90.1 mt -68.07 -40.02 82.83 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.149 -0.97 . . . . 0.0 109.636 176.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.771 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -49.82 -23.74 5.46 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 -179.061 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 23.3 p-10 -64.46 -17.22 63.63 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.07 -1.253 . . . . 0.0 110.218 -176.227 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.519 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 97.7 mt -60.51 144.93 50.26 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.262 -0.899 . . . . 0.0 110.441 -178.47 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 1.028 ' C ' HD23 ' B' ' 12' ' ' LEU . 66.1 mttt -150.09 138.62 20.65 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.626 -0.671 . . . . 0.0 109.696 178.077 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.701 HG21 HG13 ' B' ' 15' ' ' ILE . 62.0 t -63.56 147.26 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.042 -1.036 . . . . 0.0 110.178 -175.513 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.0 -11.15 71.6 Favored Glycine 0 N--CA 1.484 1.85 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 -172.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 41.5 t0 -101.08 162.09 13.14 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.333 -1.098 . . . . 0.0 109.695 176.408 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.4 m95 -114.0 159.79 19.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.195 -0.941 . . . . 0.0 110.031 177.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 1.071 HG13 ' HB3' ' B' ' 10' ' ' ALA . 0.8 OUTLIER -126.77 157.12 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.402 -0.811 . . . . 0.0 109.896 -177.611 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.831 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.3 m-20 -82.17 104.86 12.81 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.277 -0.89 . . . . 0.0 109.29 169.601 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.843 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -107.13 138.77 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 120.665 -1.272 . . . . 0.0 111.453 -175.426 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -131.84 147.62 52.49 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.983 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . 0.489 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 38.2 ptt180 -87.89 131.84 34.42 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.166 -0.959 . . . . 0.0 110.568 -178.525 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.523 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.495 1.78 0 O-C-N 121.335 -0.853 . . . . 0.0 110.214 179.368 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.882 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.3 t . . . . . 0 N--CA 1.494 1.768 0 CA-C-O 121.791 0.805 . . . . 0.0 110.919 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 -70.04 -31.79 69.6 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.867 -0.521 . . . . 0.0 111.021 179.197 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.538 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -156.38 -177.97 30.06 Favored Glycine 0 N--CA 1.499 2.862 0 C-N-CA 118.541 -1.79 . . . . 0.0 110.795 -170.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.498 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.0 p -129.08 167.25 17.81 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.792 -1.417 . . . . 0.0 110.95 -178.435 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 1.039 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -139.97 149.84 43.75 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.597 -0.69 . . . . 0.0 109.201 -175.021 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.583 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 34.5 tttt -109.24 115.77 30.63 Favored 'General case' 0 C--N 1.294 -1.816 0 O-C-N 121.013 -1.055 . . . . 0.0 110.362 -179.12 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.995 HD23 ' C ' ' A' ' 77' ' ' LYS . 11.5 tp -59.98 127.68 33.08 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.916 -1.115 . . . . 0.0 108.863 172.622 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.117 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.6 p -127.01 -29.32 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 C-N-CA 119.6 -0.84 . . . . 0.0 109.932 -179.045 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.75 144.15 24.11 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 118.959 -1.096 . . . . 0.0 111.243 179.23 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.889 HG23 ' CD2' ' A' ' 24' ' ' HIS . 8.8 mt -107.9 141.03 24.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.187 -0.946 . . . . 0.0 110.233 174.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.511 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 79.7 m-20 -109.79 113.87 26.97 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.238 -0.914 . . . . 0.0 109.972 172.247 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -101.24 113.13 25.89 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.109 -0.995 . . . . 0.0 110.427 -178.099 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -109.77 134.4 20.64 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.197 -0.939 . . . . 0.0 109.499 176.005 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.64 -16.65 11.4 Favored 'Trans proline' 0 C--N 1.303 -1.854 0 O-C-N 123.973 1.512 . . . . 0.0 110.652 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.572 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 4.9 m-80 -100.8 -26.57 13.73 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.129 -0.982 . . . . 0.0 110.035 179.23 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.572 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 92.9 m-85 -157.81 150.2 22.48 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.437 -0.789 . . . . 0.0 109.857 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.918 ' HD3' HD22 ' A' ' 68' ' ' LEU . 57.1 ttt180 -93.54 141.16 28.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.6 -1.312 . . . . 0.0 110.026 174.196 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.511 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.3 m -129.97 141.03 50.82 Favored 'General case' 0 C--N 1.294 -1.814 0 O-C-N 121.698 -0.626 . . . . 0.0 109.835 -173.703 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.889 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -129.98 143.6 50.88 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.012 -1.055 . . . . 0.0 111.612 -179.156 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.881 HG22 ' OG ' ' A' ' 60' ' ' SER . 6.4 t -123.34 132.88 70.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.11 -0.994 . . . . 0.0 110.613 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.801 HG13 ' CE1' ' A' ' 61' ' ' PHE . 26.0 m -114.9 174.48 2.93 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.326 178.509 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.535 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 12.8 tt0 -104.38 118.61 37.03 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.555 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.5 tp -81.21 122.57 81.52 Favored Pre-proline 0 C--N 1.297 -1.708 0 O-C-N 121.7 -0.625 . . . . 0.0 109.626 -174.75 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.489 ' HD2' HD12 ' A' ' 28' ' ' LEU . 18.3 Cg_endo -63.44 174.07 3.79 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 123.907 1.477 . . . . 0.0 110.572 -179.307 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.709 ' HA ' HD12 ' A' ' 33' ' ' LEU . 53.4 t0 -60.01 -39.47 85.91 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.412 -0.805 . . . . 0.0 110.611 -177.011 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.603 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.95 -0.1 57.39 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.843 -1.161 . . . . 0.0 110.894 -175.012 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.603 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 95.9 mmm -109.71 -11.73 14.7 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.87 -1.143 . . . . 0.0 109.824 170.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.709 HD12 ' HA ' ' A' ' 30' ' ' ASP . 15.3 mt -69.23 -40.1 78.13 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.323 -0.861 . . . . 0.0 110.312 179.225 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -79.98 123.89 28.21 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.349 -0.844 . . . . 0.0 110.527 -177.06 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.12 -47.09 1.08 Allowed Glycine 0 N--CA 1.492 2.377 0 C-N-CA 119.829 -1.177 . . . . 0.0 110.401 175.128 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.85 HD23 ' N ' ' A' ' 37' ' ' GLU . 8.2 tt -67.34 147.37 53.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.985 -1.303 . . . . 0.0 110.727 -175.068 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.85 ' N ' HD23 ' A' ' 36' ' ' LEU . 21.3 pt-20 -149.96 169.07 22.04 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.378 -0.826 . . . . 0.0 109.656 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.822 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -66.81 148.92 51.29 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.986 -1.071 . . . . 0.0 110.087 -179.985 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.9 -10.05 58.43 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 -175.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.432 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -71.25 157.87 37.37 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.245 -1.15 . . . . 0.0 109.272 174.706 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.893 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 1.6 p -105.34 116.82 32.59 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 118.533 -1.267 . . . . 0.0 109.754 176.012 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.619 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.6 t -99.63 126.38 53.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 121.333 -0.854 . . . . 0.0 109.006 175.353 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.512 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -88.31 119.53 28.81 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.234 -0.986 . . . . 0.0 109.089 173.374 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.738 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -89.75 105.43 17.8 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 119.729 -0.788 . . . . 0.0 108.939 177.955 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.8 t-20 56.84 9.87 0.67 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.527 -0.733 . . . . 0.0 111.514 -170.316 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 126.57 -2.15 7.55 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.553 -1.308 . . . . 0.0 110.86 173.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.902 ' O ' HD23 ' A' ' 49' ' ' LEU . 50.2 t -98.63 104.86 16.93 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.521 -1.576 . . . . 0.0 109.756 176.236 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.404 ' HA ' ' HA ' ' A' ' 43' ' ' ALA . 25.5 p -71.36 128.91 37.44 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.176 -0.952 . . . . 0.0 110.727 -174.453 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.927 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -141.41 159.98 41.08 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.445 -0.785 . . . . 0.0 109.262 173.942 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.415 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 23.9 m -99.88 150.05 22.78 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 120.45 -1.406 . . . . 0.0 111.347 -170.252 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.779 HG13 HG13 ' A' ' 59' ' ' VAL . 34.9 t -76.25 116.44 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.941 -0.475 . . . . 0.0 110.318 -179.182 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.537 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 28.3 p -71.91 -39.96 69.15 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.365 -0.835 . . . . 0.0 109.789 174.186 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.573 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -163.27 152.9 15.21 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.272 -0.893 . . . . 0.0 110.362 -179.031 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.822 HD11 ' N ' ' A' ' 38' ' ' THR . 7.6 mt -105.52 132.14 53.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.193 -0.942 . . . . 0.0 109.965 175.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.509 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 26.6 m-80 -104.92 64.78 0.73 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.63 -0.669 . . . . 0.0 109.594 179.229 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.65 -116.95 5.3 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 -173.126 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.68 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -77.0 -20.74 55.68 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.015 -1.285 . . . . 0.0 109.153 175.727 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.117 ' CD2' HG11 ' A' ' 13' ' ' VAL . 11.2 m80 -75.64 159.98 30.59 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.33 -0.856 . . . . 0.0 110.192 -177.593 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.779 HG13 HG13 ' A' ' 51' ' ' VAL . 53.6 t -140.69 123.07 15.55 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 C-N-CA 119.133 -1.027 . . . . 0.0 110.74 173.208 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.881 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.3 t -90.71 134.61 34.29 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.48 -0.762 . . . . 0.0 109.416 177.329 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.927 ' HB2' HD12 ' A' ' 49' ' ' LEU . 2.7 p90 -126.75 151.17 48.56 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.366 -0.833 . . . . 0.0 110.318 176.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.537 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 38.2 p-10 -86.66 154.87 20.67 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.084 -1.01 . . . . 0.0 111.422 -171.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.835 HD22 HD13 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -161.9 100.42 1.12 Allowed 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.754 -0.591 . . . . 0.0 109.546 -175.49 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.471 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 33.0 ttp -60.68 140.06 57.63 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.883 -1.135 . . . . 0.0 109.52 -178.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.487 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 29.4 tptp -60.07 -48.31 82.23 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.891 -1.13 . . . . 0.0 110.473 -172.69 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -63.21 -39.99 96.19 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.714 -1.241 . . . . 0.0 109.806 177.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.471 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 55.2 m -60.05 -39.98 87.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.052 -1.03 . . . . 0.0 109.602 172.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.918 HD22 ' HD3' ' A' ' 22' ' ' ARG . 27.0 tp -61.64 -40.8 96.16 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.446 -0.784 . . . . 0.0 109.816 -179.592 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 15.5 ttm180 -69.92 -40.12 75.75 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.275 -0.891 . . . . 0.0 110.441 177.086 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.687 HG22 HG23 ' A' ' 71' ' ' THR . 1.2 tt -64.78 -44.58 96.42 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.285 -0.884 . . . . 0.0 109.602 -176.569 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.687 HG23 HG22 ' A' ' 70' ' ' ILE . 30.5 p -79.99 -174.98 4.73 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.561 -0.712 . . . . 0.0 109.25 175.258 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.514 ' HB2' ' N ' ' B' ' 83' ' ' ASN . 4.1 t30 -99.97 23.34 9.95 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.013 -1.054 . . . . 0.0 108.459 169.32 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.692 ' HB3' HD21 ' A' ' 63' ' ' LEU . 87.7 mt -69.18 -40.02 78.37 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.071 -1.018 . . . . 0.0 109.799 174.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.548 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -46.81 -22.44 1.15 Allowed Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.619 -0.993 . . . . 0.0 110.619 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.3 p-10 -68.98 -17.01 63.87 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.958 -1.319 . . . . 0.0 110.534 -174.668 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.503 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 98.4 mt -59.93 141.18 55.98 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.226 -0.921 . . . . 0.0 111.042 -176.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 0.995 ' C ' HD23 ' A' ' 12' ' ' LEU . 24.9 mttm -142.38 143.04 32.51 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.734 -0.604 . . . . 0.0 109.762 173.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.646 HG23 HD11 ' A' ' 15' ' ' ILE . 32.2 t -63.15 150.09 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.914 -1.116 . . . . 0.0 110.391 -177.209 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.46 -14.82 60.17 Favored Glycine 0 N--CA 1.485 1.916 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 -175.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.494 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 41.9 t0 -94.28 167.7 11.37 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.328 -1.101 . . . . 0.0 109.637 175.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.583 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.2 m95 -116.67 158.8 23.2 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.976 -1.077 . . . . 0.0 110.036 175.038 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.039 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.1 p -121.28 155.27 25.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.389 -0.82 . . . . 0.0 109.917 179.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.882 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -78.51 105.56 9.86 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 120.993 -1.067 . . . . 0.0 109.003 168.06 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.834 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -106.64 137.84 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 120.548 -1.345 . . . . 0.0 111.048 -176.96 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -138.98 140.09 38.11 Favored 'General case' 0 N--CA 1.492 1.629 0 C-N-CA 120.291 -0.564 . . . . 0.0 109.991 -177.319 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 53.0 ttt85 -60.06 127.05 29.97 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.155 -0.966 . . . . 0.0 110.293 -179.508 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.893 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.489 1.497 0 O-C-N 121.341 -0.849 . . . . 0.0 109.554 176.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 0.922 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.3 t . . . . . 0 N--CA 1.493 1.69 0 CA-C-O 121.773 0.797 . . . . 0.0 110.945 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 99.5 mt-30 -69.98 -31.72 69.55 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.785 -0.572 . . . . 0.0 111.025 179.27 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.549 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -156.49 -178.09 30.28 Favored Glycine 0 N--CA 1.499 2.895 0 C-N-CA 118.632 -1.747 . . . . 0.0 110.857 -170.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.503 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.0 p -129.03 167.13 17.94 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.913 -1.345 . . . . 0.0 111.028 -178.426 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.098 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -139.88 150.04 44.13 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 -175.179 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.579 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 34.5 tttt -109.3 115.81 30.68 Favored 'General case' 0 C--N 1.295 -1.772 0 O-C-N 121.028 -1.045 . . . . 0.0 110.294 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 1.012 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.5 tp -60.24 127.61 32.64 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 120.945 -1.097 . . . . 0.0 108.905 172.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.123 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -126.84 -29.38 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.874 0 O-C-N 121.345 -0.847 . . . . 0.0 110.034 -178.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.67 144.11 24.14 Favored 'General case' 0 C--N 1.297 -1.681 0 C-N-CA 119.225 -0.99 . . . . 0.0 111.243 179.224 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.89 HG23 ' CD2' ' B' ' 24' ' ' HIS . 8.9 mt -107.88 141.1 23.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.292 -0.88 . . . . 0.0 110.242 174.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.499 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 79.5 m-20 -109.92 113.98 27.15 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.364 -0.835 . . . . 0.0 109.961 172.243 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -101.22 113.08 25.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.155 -0.966 . . . . 0.0 110.444 -178.06 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.465 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.0 OUTLIER -109.87 134.36 20.68 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.311 -0.868 . . . . 0.0 109.442 176.043 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.71 -16.66 11.62 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 O-C-N 123.971 1.511 . . . . 0.0 110.662 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 4.8 m-80 -100.51 -27.16 13.57 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.087 -1.008 . . . . 0.0 109.939 179.111 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 93.0 m-85 -157.37 150.33 23.44 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.416 -0.802 . . . . 0.0 109.814 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . 0.904 ' HD3' HD22 ' B' ' 68' ' ' LEU . 57.0 ttt180 -93.62 141.16 28.79 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.67 -1.269 . . . . 0.0 110.036 174.137 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.499 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 94.7 m -129.95 141.07 50.82 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.579 -0.701 . . . . 0.0 109.767 -173.683 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.89 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -129.93 143.78 50.98 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.989 -1.069 . . . . 0.0 111.472 -179.161 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.874 HG22 ' OG ' ' B' ' 60' ' ' SER . 6.4 t -123.38 132.93 70.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.161 -0.962 . . . . 0.0 110.709 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.81 HG13 ' HE1' ' B' ' 61' ' ' PHE . 26.7 m -115.08 174.44 3.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 121.688 -0.633 . . . . 0.0 110.226 178.677 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.518 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 12.8 tt0 -104.28 118.65 37.13 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.455 -0.778 . . . . 0.0 108.972 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.558 HD23 ' HA ' ' B' ' 33' ' ' LEU . 9.5 tp -81.13 122.58 81.69 Favored Pre-proline 0 C--N 1.296 -1.738 0 O-C-N 121.573 -0.704 . . . . 0.0 109.651 -174.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.496 ' HD2' HD12 ' B' ' 28' ' ' LEU . 18.2 Cg_endo -63.43 174.01 3.84 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.842 1.443 . . . . 0.0 110.564 -179.35 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.691 ' HA ' HD12 ' B' ' 33' ' ' LEU . 53.2 t0 -60.02 -39.46 85.93 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.501 -0.749 . . . . 0.0 110.56 -176.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.599 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.03 0.05 57.32 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.932 -1.105 . . . . 0.0 110.848 -174.974 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.599 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 95.8 mmm -109.73 -11.75 14.7 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.83 -1.169 . . . . 0.0 109.846 170.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.714 HD21 ' HB2' ' B' ' 57' ' ' ASN . 15.3 mt -69.26 -40.02 78.09 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.32 -0.863 . . . . 0.0 110.305 179.272 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -80.06 123.91 28.27 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.266 -0.896 . . . . 0.0 110.463 -177.054 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.11 -47.1 1.08 Allowed Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.784 -1.198 . . . . 0.0 110.391 175.116 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.851 HD23 ' N ' ' B' ' 37' ' ' GLU . 8.2 tt -67.26 147.3 53.19 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.001 -1.294 . . . . 0.0 110.805 -175.093 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . 0.851 ' N ' HD23 ' B' ' 36' ' ' LEU . 21.3 pt-20 -150.02 168.94 22.41 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.432 -0.792 . . . . 0.0 109.677 -179.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 0.824 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -66.77 148.86 51.37 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.95 -1.094 . . . . 0.0 110.106 -179.912 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.0 -10.09 58.78 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -175.509 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.445 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -71.33 157.76 37.53 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.17 -1.194 . . . . 0.0 109.102 174.669 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.913 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 1.7 p -105.02 116.44 31.96 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 118.844 -1.142 . . . . 0.0 109.968 175.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.623 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.5 t -99.9 126.4 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.472 -0.768 . . . . 0.0 108.971 175.432 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 0.509 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -88.23 119.43 28.63 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.094 -1.004 . . . . 0.0 109.16 173.401 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.748 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -89.7 105.26 17.68 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.369 -0.832 . . . . 0.0 109.019 177.934 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.8 t-20 57.13 9.77 0.72 Allowed 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.515 -0.74 . . . . 0.0 111.464 -170.427 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 126.55 -1.93 7.55 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.504 -1.332 . . . . 0.0 110.84 173.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.888 ' O ' HD23 ' B' ' 49' ' ' LEU . 50.1 t -98.85 104.79 16.87 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.534 -1.568 . . . . 0.0 109.707 176.257 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 25.1 p -71.17 129.07 37.99 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.124 -0.985 . . . . 0.0 110.667 -174.489 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 0.952 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -141.65 159.85 41.37 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.348 -0.845 . . . . 0.0 109.239 173.857 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . 0.42 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 23.7 m -99.69 150.02 22.72 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.588 -1.32 . . . . 0.0 111.412 -170.232 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.812 HG13 HG13 ' B' ' 59' ' ' VAL . 32.6 t -76.23 116.47 19.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.855 -0.528 . . . . 0.0 110.382 -179.225 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.536 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 28.6 p -71.92 -40.04 69.07 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.297 -0.877 . . . . 0.0 109.722 174.29 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.576 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -163.21 152.83 15.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.342 -0.849 . . . . 0.0 110.421 -178.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.824 HD11 ' N ' ' B' ' 38' ' ' THR . 7.6 mt -105.51 132.03 53.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.295 -0.878 . . . . 0.0 110.012 175.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.525 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 26.5 m-80 -104.87 64.82 0.73 Allowed 'General case' 0 C--N 1.297 -1.698 0 C-N-CA 120.048 -0.661 . . . . 0.0 109.562 179.285 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.72 -117.0 5.3 Favored Glycine 0 N--CA 1.487 2.063 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 -173.182 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.714 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -76.97 -20.9 55.54 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.076 -1.249 . . . . 0.0 109.164 175.73 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.123 ' CD2' HG11 ' B' ' 13' ' ' VAL . 11.2 m80 -75.59 159.79 30.83 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.338 -0.851 . . . . 0.0 110.285 -177.683 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.812 HG13 HG13 ' B' ' 51' ' ' VAL . 56.7 t -140.46 123.1 16.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.76 173.361 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.874 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.3 t -90.67 134.67 34.24 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.481 -0.762 . . . . 0.0 109.54 177.278 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.952 ' HB2' HD12 ' B' ' 49' ' ' LEU . 2.7 p90 -126.93 151.05 49.0 Favored 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.314 176.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.536 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 38.2 p-10 -86.39 154.81 20.9 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.927 -1.108 . . . . 0.0 111.442 -171.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.85 HD22 HD13 ' B' ' 68' ' ' LEU . 0.0 OUTLIER -161.94 100.42 1.12 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.76 -0.588 . . . . 0.0 109.608 -175.614 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.486 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 33.0 ttp -60.67 139.99 57.64 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.836 -1.165 . . . . 0.0 109.53 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.485 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 29.5 tptp -59.94 -48.41 81.81 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.946 -1.096 . . . . 0.0 110.469 -172.69 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -63.24 -40.02 96.25 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.792 -1.193 . . . . 0.0 109.792 177.467 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.486 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 55.5 m -60.01 -39.88 87.36 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.188 -0.945 . . . . 0.0 109.657 172.691 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.904 HD22 ' HD3' ' B' ' 22' ' ' ARG . 27.1 tp -61.73 -40.66 95.84 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.504 -0.748 . . . . 0.0 109.892 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 15.6 ttm180 -69.96 -40.01 75.66 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.34 -0.85 . . . . 0.0 110.52 176.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.692 HG22 HG23 ' B' ' 71' ' ' THR . 1.2 tt -64.87 -44.47 96.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.296 -0.877 . . . . 0.0 109.623 -176.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.692 HG23 HG22 ' B' ' 70' ' ' ILE . 30.4 p -80.18 -174.89 4.76 Favored 'General case' 0 C--N 1.301 -1.538 0 C-N-CA 119.84 -0.744 . . . . 0.0 109.294 175.247 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.501 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 3.9 t30 -99.97 23.41 9.87 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.069 -1.02 . . . . 0.0 108.406 169.458 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.671 ' HB3' HD21 ' B' ' 63' ' ' LEU . 87.7 mt -69.25 -40.03 78.11 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.09 -1.006 . . . . 0.0 109.768 174.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.546 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -46.81 -22.38 1.14 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -179.365 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.3 p-10 -69.08 -16.9 63.79 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.905 -1.35 . . . . 0.0 110.488 -174.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.503 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.3 mt -60.1 141.29 56.04 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.229 -0.92 . . . . 0.0 111.06 -176.867 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 1.012 ' C ' HD23 ' B' ' 12' ' ' LEU . 24.9 mttm -142.47 143.07 32.42 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.725 -0.61 . . . . 0.0 109.694 174.073 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.663 HG23 HD11 ' B' ' 15' ' ' ILE . 32.7 t -63.19 150.05 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.924 -1.11 . . . . 0.0 110.317 -177.188 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.38 -14.7 60.4 Favored Glycine 0 N--CA 1.486 1.974 0 N-CA-C 108.777 -1.729 . . . . 0.0 108.777 -175.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.488 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 41.8 t0 -94.43 167.68 11.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.426 -1.044 . . . . 0.0 109.635 175.749 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.579 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.1 m95 -116.64 158.83 23.12 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.074 -1.016 . . . . 0.0 110.068 175.088 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 1.098 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.0 OUTLIER -121.32 155.33 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.419 -0.801 . . . . 0.0 109.887 179.457 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.922 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.2 OUTLIER -78.39 105.29 9.55 Favored 'General case' 0 C--N 1.297 -1.674 0 O-C-N 121.105 -0.997 . . . . 0.0 109.147 168.007 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.836 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -106.49 138.12 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 120.596 -1.315 . . . . 0.0 110.894 -176.821 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -139.29 140.21 37.55 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 120.268 -0.573 . . . . 0.0 109.914 -177.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 53.0 ttt85 -59.99 127.04 29.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.176 -0.953 . . . . 0.0 110.267 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.913 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.442 -0.786 . . . . 0.0 109.444 176.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.771 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.2 t . . . . . 0 N--CA 1.493 1.717 0 CA-C-O 121.529 0.68 . . . . 0.0 110.399 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -95.21 -22.06 18.06 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.493 -0.755 . . . . 0.0 110.75 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.529 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -144.43 175.59 24.1 Favored Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.081 -1.533 . . . . 0.0 109.968 -176.209 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.432 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.2 p -127.51 166.04 18.72 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.06 -1.259 . . . . 0.0 110.625 179.227 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 1.071 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -133.94 148.84 51.23 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.598 -0.689 . . . . 0.0 109.258 -178.681 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 23.5 tttt -107.66 116.89 32.76 Favored 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.113 -0.992 . . . . 0.0 110.147 179.353 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.996 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.2 tp -59.92 126.32 27.08 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 120.876 -1.14 . . . . 0.0 108.914 173.333 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.07 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -124.95 -30.8 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 C-N-CA 119.744 -0.782 . . . . 0.0 109.718 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.59 142.36 27.89 Favored 'General case' 0 N--CA 1.492 1.653 0 C-N-CA 119.214 -0.995 . . . . 0.0 111.127 -178.098 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.732 HG23 ' NE2' ' A' ' 24' ' ' HIS . 10.6 mt -108.62 130.19 61.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.113 -0.992 . . . . 0.0 110.314 172.4 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.502 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 74.1 m-20 -104.49 117.76 34.95 Favored 'General case' 0 C--N 1.295 -1.769 0 O-C-N 121.376 -0.827 . . . . 0.0 109.809 172.755 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -107.4 105.31 15.18 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.146 -0.971 . . . . 0.0 110.176 -177.518 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 2.1 mmmt -102.2 130.56 23.98 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.347 -0.846 . . . . 0.0 109.282 179.219 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -51.5 -19.43 7.12 Favored 'Trans proline' 0 C--N 1.303 -1.856 0 O-C-N 123.913 1.481 . . . . 0.0 110.573 -179.499 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.573 ' O ' ' CD1' ' A' ' 21' ' ' PHE . 0.3 OUTLIER -90.54 -38.37 13.24 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.169 -0.957 . . . . 0.0 109.102 177.268 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.573 ' CD1' ' O ' ' A' ' 20' ' ' ASN . 64.6 m-85 -153.15 150.18 28.8 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.833 -0.542 . . . . 0.0 110.148 -177.651 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.544 ' HD3' HD22 ' A' ' 68' ' ' LEU . 63.4 ttt180 -88.43 145.03 26.01 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.6 -1.313 . . . . 0.0 109.941 174.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.502 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 84.8 m -133.08 140.82 47.87 Favored 'General case' 0 C--N 1.296 -1.752 0 O-C-N 121.407 -0.808 . . . . 0.0 109.946 -174.173 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.732 ' NE2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.03 131.96 46.04 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.767 -1.208 . . . . 0.0 111.561 -179.669 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.612 HG22 ' CB ' ' A' ' 60' ' ' SER . 4.0 t -109.85 132.28 58.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.184 -0.947 . . . . 0.0 110.537 -178.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 15.5 m -117.44 169.85 7.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 120.359 -0.537 . . . . 0.0 110.343 -179.111 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.535 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 13.1 tt0 -103.22 118.31 36.5 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.215 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.513 ' CD2' ' O ' ' A' ' 32' ' ' MET . 9.5 tp -84.14 126.37 70.05 Favored Pre-proline 0 C--N 1.298 -1.667 0 O-C-N 121.327 -0.858 . . . . 0.0 109.759 -175.073 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.468 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 17.7 Cg_endo -64.27 176.84 2.37 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 123.903 1.475 . . . . 0.0 110.927 -179.192 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.412 ' HA ' HD12 ' A' ' 33' ' ' LEU . 77.4 m-20 -60.06 -39.94 87.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.427 -0.796 . . . . 0.0 110.997 -176.37 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.577 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.13 2.57 55.15 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.797 -1.19 . . . . 0.0 110.744 -174.457 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.577 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 89.1 mmm -113.07 -11.89 13.27 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.912 -1.118 . . . . 0.0 109.991 170.364 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.683 HD21 ' HB2' ' A' ' 57' ' ' ASN . 18.1 mt -69.97 -40.1 75.58 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.321 -0.862 . . . . 0.0 110.378 178.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -82.68 115.76 21.76 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.905 . . . . 0.0 110.505 -176.384 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.61 -52.75 0.69 Allowed Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.81 -1.186 . . . . 0.0 110.376 175.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.494 HD23 HD22 ' A' ' 28' ' ' LEU . 42.6 tp -61.52 151.34 33.23 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.955 -1.321 . . . . 0.0 110.851 -173.471 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.491 ' C ' HD11 ' A' ' 54' ' ' ILE . 20.9 pt-20 -149.95 168.33 24.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.468 -0.77 . . . . 0.0 109.484 178.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.91 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -66.09 152.84 43.82 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.885 -1.134 . . . . 0.0 109.982 -178.985 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.31 -4.72 66.31 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -176.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.514 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -77.26 156.64 31.27 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.291 -1.123 . . . . 0.0 109.668 176.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.612 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -100.61 108.24 20.09 Favored 'General case' 0 C--N 1.306 -1.286 0 O-C-N 121.103 -0.998 . . . . 0.0 110.087 178.629 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.588 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.2 t -94.24 129.45 44.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.224 -0.923 . . . . 0.0 109.125 174.203 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -93.33 119.54 32.59 Favored 'General case' 0 C--N 1.296 -1.724 0 C-N-CA 119.258 -0.977 . . . . 0.0 109.07 171.572 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.852 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.3 OUTLIER -89.17 102.6 15.26 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.64 -0.824 . . . . 0.0 108.94 178.463 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.499 ' HB3' ' HB3' ' B' ' 45' ' ' ASN . 1.7 t-20 58.22 11.49 1.58 Allowed 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.449 -0.782 . . . . 0.0 110.772 -169.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.512 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.16 -2.29 11.56 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.777 -1.201 . . . . 0.0 110.891 172.672 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.83 ' O ' HD23 ' A' ' 49' ' ' LEU . 43.0 t -92.16 109.17 20.53 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.39 -1.653 . . . . 0.0 109.389 174.352 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 15.8 p -74.89 128.43 35.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.099 -1.001 . . . . 0.0 110.844 -171.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.92 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -146.96 157.0 43.5 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.347 -0.846 . . . . 0.0 109.499 173.741 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.425 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 23.9 m -97.5 159.0 15.18 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.735 -1.228 . . . . 0.0 111.296 -170.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.965 HG22 ' CE1' ' A' ' 61' ' ' PHE . 22.4 t -83.26 116.63 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.832 -0.542 . . . . 0.0 110.43 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.54 HG22 ' HB3' ' A' ' 62' ' ' ASP . 39.4 p -70.0 -39.91 75.6 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.241 -0.912 . . . . 0.0 109.715 172.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.579 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.9 tt0 -160.95 154.83 22.5 Favored 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 119.357 -0.937 . . . . 0.0 111.204 -175.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.91 HD11 ' N ' ' A' ' 38' ' ' THR . 6.4 mt -110.06 129.99 64.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.091 -1.006 . . . . 0.0 110.044 169.497 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.488 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 27.7 m-80 -103.7 65.12 0.82 Allowed 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.592 -0.692 . . . . 0.0 109.514 176.648 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.49 -113.4 3.82 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.812 -1.715 . . . . 0.0 108.812 -173.263 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.683 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -79.99 -21.07 44.09 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.05 -1.265 . . . . 0.0 109.168 175.405 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.07 ' CD2' HG11 ' A' ' 13' ' ' VAL . 8.5 m170 -77.65 159.99 28.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.246 -0.909 . . . . 0.0 110.112 -176.488 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.668 ' CG1' HG13 ' A' ' 51' ' ' VAL . 97.7 t -144.4 115.43 2.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 C-N-CA 119.309 -0.957 . . . . 0.0 110.891 177.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.612 ' CB ' HG22 ' A' ' 25' ' ' VAL . 13.7 m -81.74 130.15 34.96 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.677 -0.639 . . . . 0.0 109.849 178.465 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.965 ' CE1' HG22 ' A' ' 51' ' ' VAL . 96.4 m-85 -115.19 159.98 20.28 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.952 -1.092 . . . . 0.0 110.235 178.037 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.54 ' HB3' HG22 ' A' ' 52' ' ' THR . 25.7 p-10 -95.2 147.81 23.07 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.163 -0.961 . . . . 0.0 111.335 -177.019 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.806 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -159.14 116.47 2.75 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.718 -0.614 . . . . 0.0 109.559 -175.729 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.48 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 57.9 ttm -75.27 146.97 40.63 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.863 -1.148 . . . . 0.0 109.852 179.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.477 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 39.0 ttpt -60.07 -49.75 76.4 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.078 -1.014 . . . . 0.0 110.305 -177.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -63.95 -42.46 97.3 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.895 -1.128 . . . . 0.0 110.17 178.574 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.48 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 69.4 m -60.31 -40.04 89.12 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.932 -1.105 . . . . 0.0 109.606 174.332 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.654 HD11 ' HA2' ' A' ' 74' ' ' GLY . 11.7 tp -59.99 -43.16 95.33 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.288 -0.882 . . . . 0.0 109.582 177.756 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 16.4 mmm180 -70.0 -40.07 75.52 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.57 -0.706 . . . . 0.0 110.608 177.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.87 HG22 HG23 ' A' ' 71' ' ' THR . 1.5 tt -66.15 -43.72 91.95 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.209 -0.932 . . . . 0.0 109.329 -177.169 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.87 HG23 HG22 ' A' ' 70' ' ' ILE . 32.9 p -84.7 -171.01 3.4 Favored 'General case' 0 C--N 1.297 -1.68 0 CA-C-O 121.361 0.601 . . . . 0.0 109.673 178.013 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.519 ' CB ' ' N ' ' B' ' 83' ' ' ASN . 1.6 t30 -103.2 21.84 15.14 Favored 'General case' 0 C--N 1.293 -1.862 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 170.477 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.806 ' HB3' HD21 ' A' ' 63' ' ' LEU . 91.5 mt -66.26 -40.0 89.84 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.939 -1.101 . . . . 0.0 109.787 173.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.654 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -49.79 -25.17 6.75 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -178.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 24.0 p-10 -65.99 -16.63 64.06 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.001 -1.294 . . . . 0.0 110.508 -174.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 96.2 mt -60.01 140.17 56.96 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.151 -0.968 . . . . 0.0 110.65 -176.805 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 0.996 ' C ' HD23 ' A' ' 12' ' ' LEU . 26.0 mttt -144.07 140.33 29.43 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-O 121.346 0.593 . . . . 0.0 109.688 176.01 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.686 ' N ' HD23 ' A' ' 12' ' ' LEU . 18.8 t -61.77 150.17 8.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 120.686 -1.259 . . . . 0.0 110.524 -173.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.61 -13.63 63.57 Favored Glycine 0 N--CA 1.482 1.733 0 N-CA-C 108.855 -1.698 . . . . 0.0 108.855 -176.463 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.434 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 34.8 t0 -95.36 169.94 9.72 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.324 -1.104 . . . . 0.0 109.459 175.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.3 m95 -117.47 168.31 10.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.908 -1.12 . . . . 0.0 110.245 175.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.071 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.4 p -130.17 153.05 38.37 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.491 -0.756 . . . . 0.0 109.696 179.369 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.771 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.2 m-20 -79.77 106.02 11.5 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 120.89 -1.131 . . . . 0.0 109.043 170.019 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.564 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -106.23 139.98 25.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 120.481 -1.387 . . . . 0.0 111.37 -175.042 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.421 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.5 tt0 -131.02 142.6 50.34 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.037 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 39.6 ttm180 -81.24 121.07 25.7 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 110.481 -178.753 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.612 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.571 0 O-C-N 121.23 -0.919 . . . . 0.0 110.124 176.57 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 0.789 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.2 t . . . . . 0 N--CA 1.493 1.691 0 CA-C-O 121.474 0.654 . . . . 0.0 110.398 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -95.35 -21.78 18.17 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.483 -0.76 . . . . 0.0 110.788 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.528 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -144.63 175.4 24.35 Favored Glycine 0 N--CA 1.493 2.459 0 C-N-CA 119.273 -1.441 . . . . 0.0 110.141 -176.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.426 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.1 p -127.45 166.09 18.58 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.118 -1.225 . . . . 0.0 110.589 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.054 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -133.9 148.98 51.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.631 -0.668 . . . . 0.0 109.254 -178.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.579 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 23.6 tttt -107.79 116.91 32.81 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.121 -0.987 . . . . 0.0 110.109 179.326 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 1.009 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.2 tp -59.96 126.3 27.02 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.963 -1.086 . . . . 0.0 108.98 173.308 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.062 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -124.93 -30.86 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 O-C-N 121.451 -0.781 . . . . 0.0 109.724 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.56 142.45 28.01 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.37 -0.932 . . . . 0.0 111.098 -178.135 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.748 HG23 ' NE2' ' B' ' 24' ' ' HIS . 10.7 mt -108.68 130.24 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.176 -0.952 . . . . 0.0 110.315 172.4 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.515 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 73.5 m-20 -104.71 117.88 35.18 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.287 -0.883 . . . . 0.0 109.662 172.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -107.4 105.37 15.26 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.105 -0.997 . . . . 0.0 110.157 -177.545 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.467 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 2.1 mmmt -102.23 130.5 24.08 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.427 -0.796 . . . . 0.0 109.276 179.189 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -51.55 -19.33 7.11 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 123.889 1.468 . . . . 0.0 110.606 -179.491 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.587 ' ND2' ' N ' ' B' ' 20' ' ' ASN . 0.3 OUTLIER -90.43 -38.94 12.95 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.176 -0.952 . . . . 0.0 108.941 177.272 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' B' ' 20' ' ' ASN . 64.8 m-85 -152.71 150.27 29.26 Favored 'General case' 0 N--CA 1.494 1.765 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.15 -177.562 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . 0.536 ' HD3' HD22 ' B' ' 68' ' ' LEU . 63.5 ttt180 -88.47 144.89 26.07 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.701 -1.249 . . . . 0.0 109.889 174.421 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.515 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 84.9 m -132.96 140.84 48.01 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.55 -0.719 . . . . 0.0 109.927 -174.213 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.748 ' NE2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -129.98 132.1 46.17 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.941 -1.099 . . . . 0.0 111.454 -179.654 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.621 HG22 ' CB ' ' B' ' 60' ' ' SER . 4.0 t -109.89 132.44 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.349 -0.844 . . . . 0.0 110.571 -178.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.505 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 16.0 m -117.61 169.78 7.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 CA-C-O 121.304 0.573 . . . . 0.0 110.215 -178.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.529 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 13.1 tt0 -103.09 118.48 36.89 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.102 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.519 ' CD2' ' O ' ' B' ' 32' ' ' MET . 9.5 tp -84.2 126.31 70.09 Favored Pre-proline 0 C--N 1.297 -1.711 0 O-C-N 121.254 -0.904 . . . . 0.0 109.749 -175.122 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.477 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 17.7 Cg_endo -64.27 176.8 2.39 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 O-C-N 123.865 1.455 . . . . 0.0 110.869 -179.191 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.419 ' HA ' HD12 ' B' ' 33' ' ' LEU . 77.3 m-20 -60.04 -40.0 87.88 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.413 -0.805 . . . . 0.0 111.007 -176.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.579 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.96 2.49 55.04 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.863 -1.148 . . . . 0.0 110.847 -174.552 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.579 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 89.2 mmm -113.06 -11.94 13.27 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.894 -1.129 . . . . 0.0 110.012 170.373 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.649 HD21 ' HB2' ' B' ' 57' ' ' ASN . 18.1 mt -69.96 -40.05 75.64 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.245 -0.91 . . . . 0.0 110.404 178.818 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -82.67 115.78 21.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.201 -0.937 . . . . 0.0 110.48 -176.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.62 -52.74 0.69 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.81 -1.185 . . . . 0.0 110.4 175.378 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.496 HD23 HD22 ' B' ' 28' ' ' LEU . 42.8 tp -61.65 151.42 33.61 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.919 -1.342 . . . . 0.0 110.795 -173.41 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . 0.507 ' C ' HD11 ' B' ' 54' ' ' ILE . 20.9 pt-20 -149.96 168.37 24.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.531 -0.731 . . . . 0.0 109.452 178.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 0.918 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.2 152.68 44.32 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.882 -1.136 . . . . 0.0 109.995 -178.921 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.52 -4.73 67.13 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 -176.388 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.511 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -77.4 156.48 31.15 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.299 -1.118 . . . . 0.0 109.616 176.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.624 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.1 OUTLIER -100.26 108.1 20.09 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.059 -1.026 . . . . 0.0 110.173 178.616 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.601 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.2 t -94.37 129.52 44.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.263 -0.898 . . . . 0.0 109.147 174.178 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 0.484 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -93.27 119.58 32.59 Favored 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 119.231 -0.988 . . . . 0.0 109.042 171.635 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.863 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.3 OUTLIER -89.21 102.55 15.21 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.319 -0.863 . . . . 0.0 108.946 178.434 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.499 ' HB3' ' HB3' ' A' ' 45' ' ' ASN . 1.8 t-20 58.38 11.47 1.66 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.511 -0.743 . . . . 0.0 110.68 -170.007 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.512 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.07 -2.13 11.65 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.888 172.662 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.83 ' O ' HD23 ' B' ' 49' ' ' LEU . 43.4 t -92.35 109.18 20.56 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.428 -1.631 . . . . 0.0 109.355 174.319 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 15.9 p -74.78 128.57 35.88 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.161 -0.962 . . . . 0.0 110.744 -171.736 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 0.904 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -147.2 156.85 43.31 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.448 -0.782 . . . . 0.0 109.477 173.649 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . 0.427 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 23.8 m -97.26 159.09 15.12 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.737 -1.227 . . . . 0.0 111.281 -170.502 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.977 HG22 ' CE1' ' B' ' 61' ' ' PHE . 22.7 t -83.39 116.72 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.679 -0.638 . . . . 0.0 110.437 -178.524 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.561 HG22 ' HB3' ' B' ' 62' ' ' ASP . 39.8 p -70.01 -39.96 75.51 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.159 -0.963 . . . . 0.0 109.664 172.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.572 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.9 tt0 -160.93 154.76 22.43 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.409 -0.916 . . . . 0.0 111.172 -175.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.918 HD11 ' N ' ' B' ' 38' ' ' THR . 6.4 mt -109.97 129.99 63.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.115 -0.991 . . . . 0.0 110.03 169.525 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.493 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 27.6 m-80 -103.74 65.1 0.81 Allowed 'General case' 0 C--N 1.299 -1.615 0 C-N-CA 119.862 -0.735 . . . . 0.0 109.564 176.608 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.68 -113.43 3.81 Favored Glycine 0 N--CA 1.486 2.012 0 N-CA-C 108.715 -1.754 . . . . 0.0 108.715 -173.279 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.649 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.02 -21.1 43.93 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.061 -1.258 . . . . 0.0 109.152 175.45 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.062 ' CD2' HG11 ' B' ' 13' ' ' VAL . 8.5 m170 -77.54 159.81 29.05 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.186 -0.947 . . . . 0.0 110.108 -176.535 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.647 ' CG1' HG13 ' B' ' 51' ' ' VAL . 97.1 t -144.31 115.47 2.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 C-N-CA 119.284 -0.967 . . . . 0.0 110.912 177.71 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.621 ' CB ' HG22 ' B' ' 25' ' ' VAL . 13.7 m -81.83 130.28 35.02 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.751 -0.593 . . . . 0.0 109.931 178.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.977 ' CE1' HG22 ' B' ' 51' ' ' VAL . 96.4 m-85 -115.27 160.02 20.29 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.977 -1.077 . . . . 0.0 110.275 178.107 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.561 ' HB3' HG22 ' B' ' 52' ' ' THR . 25.7 p-10 -95.2 147.77 23.11 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.012 -1.055 . . . . 0.0 111.273 -176.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.769 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.16 116.43 2.73 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.788 -0.57 . . . . 0.0 109.538 -175.744 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.476 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 58.0 ttm -75.25 146.99 40.66 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.867 -1.146 . . . . 0.0 109.851 179.275 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.476 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 39.0 ttpt -60.04 -49.88 75.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.041 -1.037 . . . . 0.0 110.249 -177.63 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -63.94 -42.4 97.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.888 -1.132 . . . . 0.0 110.241 178.64 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.476 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 71.3 m -60.27 -40.07 89.08 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.003 -1.061 . . . . 0.0 109.671 174.258 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.674 HD11 ' HA2' ' B' ' 74' ' ' GLY . 11.7 tp -59.94 -43.18 95.13 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.438 -0.789 . . . . 0.0 109.559 177.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 16.4 mmm180 -69.98 -39.93 75.65 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.562 -0.711 . . . . 0.0 110.665 177.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.85 HG22 HG23 ' B' ' 71' ' ' THR . 1.5 tt -66.22 -43.69 91.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 CA-C-O 121.922 0.868 . . . . 0.0 109.363 -177.195 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.85 HG23 HG22 ' B' ' 70' ' ' ILE . 33.0 p -84.6 -170.77 3.28 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 121.44 0.638 . . . . 0.0 109.708 177.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.533 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 1.6 t30 -103.39 21.82 15.31 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 170.531 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.769 ' HB3' HD21 ' B' ' 63' ' ' LEU . 91.7 mt -66.22 -40.02 89.99 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.917 -1.114 . . . . 0.0 109.736 173.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.674 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -49.78 -25.18 6.75 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 110.429 -1.068 . . . . 0.0 110.429 -178.496 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 24.2 p-10 -66.02 -16.64 64.08 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.995 -1.297 . . . . 0.0 110.433 -174.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.517 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 96.2 mt -59.98 140.21 56.91 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.155 -0.965 . . . . 0.0 110.639 -176.784 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 1.009 ' C ' HD23 ' B' ' 12' ' ' LEU . 26.0 mttt -144.13 140.4 29.39 Favored 'General case' 0 C--N 1.296 -1.737 0 O-C-N 121.796 -0.565 . . . . 0.0 109.675 175.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.692 ' N ' HD23 ' B' ' 12' ' ' LEU . 19.0 t -61.82 150.25 8.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 120.942 -1.099 . . . . 0.0 110.536 -173.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.47 -13.49 63.73 Favored Glycine 0 N--CA 1.483 1.778 0 N-CA-C 108.959 -1.656 . . . . 0.0 108.959 -176.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.442 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 34.4 t0 -95.35 169.95 9.71 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.366 -1.079 . . . . 0.0 109.51 175.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.579 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.3 m95 -117.52 168.19 10.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.951 -1.093 . . . . 0.0 110.261 175.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 1.054 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.4 p -130.15 153.14 38.49 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.465 -0.772 . . . . 0.0 109.63 179.307 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.789 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.1 m-20 -79.77 105.72 11.27 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 120.97 -1.081 . . . . 0.0 109.158 170.023 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.554 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -106.06 140.0 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.45 -1.406 . . . . 0.0 111.331 -174.873 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . 0.426 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.5 tt0 -131.01 142.69 50.35 Favored 'General case' 0 N--CA 1.492 1.675 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.059 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 39.5 ttm180 -81.31 121.2 25.9 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.36 -0.838 . . . . 0.0 110.351 -178.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.624 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.612 0 O-C-N 121.275 -0.891 . . . . 0.0 110.158 176.491 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.7 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.5 t . . . . . 0 N--CA 1.493 1.689 0 CA-C-O 121.676 0.75 . . . . 0.0 110.568 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -69.98 -33.6 72.27 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.669 -0.644 . . . . 0.0 110.708 -178.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.539 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -153.42 174.75 32.02 Favored Glycine 0 N--CA 1.495 2.585 0 C-N-CA 118.957 -1.592 . . . . 0.0 110.395 -172.645 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.497 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 17.9 p -120.61 169.0 10.78 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.991 -1.3 . . . . 0.0 111.008 -177.263 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 1.008 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -138.07 149.5 46.05 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.6 -0.687 . . . . 0.0 109.432 -175.337 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.58 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 19.1 tttt -106.47 117.3 33.7 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.076 -1.015 . . . . 0.0 110.216 179.088 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 1.037 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.0 tp -59.93 128.52 37.27 Favored 'General case' 0 C--N 1.298 -1.643 0 O-C-N 120.885 -1.135 . . . . 0.0 108.737 172.523 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.116 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.58 -28.81 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 O-C-N 121.369 -0.832 . . . . 0.0 110.055 -178.152 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.53 140.2 24.77 Favored 'General case' 0 N--CA 1.494 1.757 0 C-N-CA 119.14 -1.024 . . . . 0.0 111.385 -178.766 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.749 HG23 ' CD2' ' A' ' 24' ' ' HIS . 7.0 mt -107.01 133.16 52.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.002 -1.061 . . . . 0.0 110.043 169.845 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.494 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 86.9 m-20 -109.98 114.51 28.09 Favored 'General case' 0 C--N 1.294 -1.832 0 O-C-N 121.443 -0.786 . . . . 0.0 109.987 173.795 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -103.9 116.6 32.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.047 -1.033 . . . . 0.0 110.388 -177.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.405 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -111.67 135.1 21.13 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.298 -0.876 . . . . 0.0 109.344 178.205 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -51.8 -18.44 6.52 Favored 'Trans proline' 0 C--N 1.303 -1.829 0 O-C-N 123.906 1.477 . . . . 0.0 110.774 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.575 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 4.9 m-80 -97.2 -32.6 11.85 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.027 -1.046 . . . . 0.0 110.423 178.59 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.575 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 83.2 m-85 -158.03 150.41 22.28 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.272 -0.893 . . . . 0.0 110.208 -177.394 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.493 ' HD3' HD22 ' A' ' 68' ' ' LEU . 65.8 ttt180 -90.72 144.11 26.06 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.7 -1.25 . . . . 0.0 110.03 176.648 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.494 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 96.8 m -129.84 139.96 51.1 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.607 -0.683 . . . . 0.0 109.746 -175.278 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.749 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.21 139.72 50.79 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.972 -1.08 . . . . 0.0 111.164 179.766 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.677 HG22 ' CB ' ' A' ' 60' ' ' SER . 4.0 t -120.51 132.52 69.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 O-C-N 121.051 -1.031 . . . . 0.0 110.468 -178.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.875 HG13 ' CE1' ' A' ' 61' ' ' PHE . 31.7 m -115.88 171.37 5.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.862 -0.524 . . . . 0.0 110.026 179.411 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.556 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 10.4 tt0 -108.54 115.7 30.59 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.523 HD22 HD23 ' A' ' 36' ' ' LEU . 8.7 tp -86.8 127.97 58.05 Favored Pre-proline 0 C--N 1.296 -1.725 0 O-C-N 121.206 -0.934 . . . . 0.0 110.285 -172.109 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.483 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 28.9 Cg_endo -66.72 177.1 3.68 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 O-C-N 123.941 1.496 . . . . 0.0 111.05 -179.401 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.534 ' HA ' HD12 ' A' ' 33' ' ' LEU . 95.9 m-20 -60.07 -40.06 88.21 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.23 -0.919 . . . . 0.0 111.083 -174.251 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.596 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.02 0.86 56.88 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.814 -1.178 . . . . 0.0 110.959 -174.655 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.596 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.8 mmm -112.59 -12.03 13.49 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.958 -1.089 . . . . 0.0 109.964 172.282 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.6 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 19.8 mt -70.07 -39.97 75.33 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.408 -0.807 . . . . 0.0 110.186 177.832 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -73.91 143.13 45.9 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.419 -0.801 . . . . 0.0 110.583 -178.147 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.5 -39.02 3.01 Favored Glycine 0 N--CA 1.492 2.409 0 C-N-CA 119.925 -1.131 . . . . 0.0 110.555 173.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.523 HD23 HD22 ' A' ' 28' ' ' LEU . 50.3 tp -77.54 147.93 35.5 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.896 -1.355 . . . . 0.0 110.892 -174.108 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.499 ' C ' HD11 ' A' ' 54' ' ' ILE . 21.3 pt-20 -149.07 166.58 28.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.409 -0.807 . . . . 0.0 109.511 177.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.843 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -64.99 147.78 52.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.825 -1.172 . . . . 0.0 109.862 179.376 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.94 -7.68 62.3 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -175.412 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.533 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -74.99 153.18 38.64 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.277 -1.131 . . . . 0.0 109.645 177.319 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.87 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.0 OUTLIER -96.58 110.12 22.59 Favored 'General case' 0 C--N 1.309 -1.19 0 O-C-N 120.76 -1.212 . . . . 0.0 109.955 175.474 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.657 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.0 t -92.91 130.09 42.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 173.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.574 ' HB3' ' CG ' ' A' ' 85' ' ' GLU . . . -93.47 119.69 32.85 Favored 'General case' 0 C--N 1.293 -1.848 0 C-N-CA 119.001 -1.079 . . . . 0.0 109.071 173.12 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.657 ' HE1' HG11 ' A' ' 42' ' ' VAL . 0.3 OUTLIER -90.31 106.02 18.21 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 177.727 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.0 t-20 58.27 7.85 0.73 Allowed 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.341 -0.849 . . . . 0.0 111.547 -169.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.408 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 125.61 -3.2 8.13 Favored Glycine 0 N--CA 1.49 2.292 0 O-C-N 120.703 -1.248 . . . . 0.0 110.549 174.668 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.841 ' O ' HD23 ' A' ' 49' ' ' LEU . 32.6 t -94.37 108.26 20.17 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.59 -1.535 . . . . 0.0 109.812 176.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 19.5 p -70.29 128.54 36.57 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.163 -0.961 . . . . 0.0 110.895 -175.434 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.851 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -143.29 158.03 43.98 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.365 -0.834 . . . . 0.0 109.344 172.347 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 65.0 m -99.51 149.33 23.34 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.559 -1.338 . . . . 0.0 111.403 -170.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.917 HG13 HG13 ' A' ' 59' ' ' VAL . 20.4 t -76.88 114.74 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 CA-C-O 121.01 0.433 . . . . 0.0 110.406 -178.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.52 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 52.6 p -69.32 -40.07 77.84 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.184 -0.947 . . . . 0.0 109.602 173.781 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.566 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 89.3 tt0 -161.49 156.4 23.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.428 -0.795 . . . . 0.0 110.157 -178.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.843 HD11 ' N ' ' A' ' 38' ' ' THR . 8.2 mt -108.9 129.3 63.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.075 -1.015 . . . . 0.0 109.987 174.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.535 ' HB2' ' CB ' ' A' ' 58' ' ' HIS . 8.6 m-80 -102.39 62.95 0.87 Allowed 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.537 -0.727 . . . . 0.0 109.88 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.67 -117.99 5.33 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.768 -1.733 . . . . 0.0 108.768 -173.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.6 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -74.9 -19.87 59.95 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 120.902 -1.352 . . . . 0.0 108.768 174.216 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.116 ' CD2' HG11 ' A' ' 13' ' ' VAL . 10.3 m170 -75.61 159.77 30.84 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.424 -0.798 . . . . 0.0 110.129 -177.177 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.917 HG13 HG13 ' A' ' 51' ' ' VAL . 53.6 t -140.55 123.0 15.81 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 121.039 -1.038 . . . . 0.0 110.641 171.092 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.677 ' CB ' HG22 ' A' ' 25' ' ' VAL . 17.0 m -89.65 128.72 36.11 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.609 -0.682 . . . . 0.0 109.478 177.682 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.875 ' CE1' HG13 ' A' ' 26' ' ' VAL . 2.4 p90 -124.14 152.38 42.86 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.98 -1.075 . . . . 0.0 110.182 179.002 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.52 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 33.1 p-10 -89.38 156.12 18.9 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 120.986 -1.071 . . . . 0.0 111.708 -171.216 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.923 HD22 HD13 ' A' ' 68' ' ' LEU . 0.2 OUTLIER -160.64 101.4 1.33 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.691 -0.631 . . . . 0.0 109.613 -173.416 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.503 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 57.2 ttm -61.53 139.56 58.23 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.57 -1.331 . . . . 0.0 109.174 178.491 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.477 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 78.7 tttt -59.96 -47.87 84.01 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.723 -1.236 . . . . 0.0 110.38 -173.574 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -64.49 -39.95 94.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.876 -1.14 . . . . 0.0 109.87 177.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.503 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 94.6 m -61.38 -39.93 92.45 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.898 -1.126 . . . . 0.0 109.526 173.13 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.923 HD13 HD22 ' A' ' 63' ' ' LEU . 16.3 tp -59.99 -41.14 91.42 Favored 'General case' 0 C--N 1.3 -1.587 0 O-C-N 121.352 -0.843 . . . . 0.0 109.269 178.378 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -67.02 -39.99 87.17 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.475 -0.766 . . . . 0.0 110.491 173.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.797 HG22 HG23 ' A' ' 71' ' ' THR . 0.8 OUTLIER -65.64 -43.39 93.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.139 -0.975 . . . . 0.0 109.359 -175.538 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.797 HG23 HG22 ' A' ' 70' ' ' ILE . 24.7 p -84.25 -174.43 5.27 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 175.035 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.4 t30 -101.45 23.48 11.02 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 171.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.681 HD13 HD21 ' A' ' 63' ' ' LEU . 91.6 mt -70.05 -39.96 75.4 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.132 -0.98 . . . . 0.0 110.009 176.049 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.547 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -47.53 -22.56 1.74 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 -178.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.508 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.3 p-10 -68.69 -17.15 64.02 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.066 -1.255 . . . . 0.0 110.612 -174.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.508 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 89.3 mt -62.38 143.04 57.49 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.243 -0.911 . . . . 0.0 110.909 -177.627 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 1.037 ' C ' HD23 ' A' ' 12' ' ' LEU . 89.8 mttt -141.5 144.61 34.43 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 109.327 -0.619 . . . . 0.0 109.327 174.789 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.687 HG21 HG13 ' A' ' 15' ' ' ILE . 47.3 t -64.95 147.28 12.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 120.752 -1.217 . . . . 0.0 110.07 -176.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.55 -14.14 62.14 Favored Glycine 0 N--CA 1.483 1.807 0 N-CA-C 108.616 -1.794 . . . . 0.0 108.616 -173.039 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 39.6 t0 -96.09 166.85 11.55 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.387 -1.067 . . . . 0.0 109.504 175.648 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.58 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.2 m95 -117.64 166.92 11.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.044 -1.035 . . . . 0.0 110.199 177.311 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.008 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.3 p -132.39 156.57 42.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.382 -0.824 . . . . 0.0 109.984 -178.294 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.7 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.2 m-20 -79.53 105.63 10.97 Favored 'General case' 0 C--N 1.296 -1.752 0 O-C-N 121.03 -1.044 . . . . 0.0 109.097 169.096 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.979 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -110.24 141.92 24.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 120.382 -1.449 . . . . 0.0 110.873 -176.56 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.574 ' CG ' ' HB3' ' A' ' 43' ' ' ALA . 19.9 pt-20 -149.06 153.83 38.41 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 119.748 -0.781 . . . . 0.0 110.162 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 63.1 ttt180 -68.2 130.03 41.7 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.228 -0.92 . . . . 0.0 110.385 -178.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.87 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.489 1.516 0 O-C-N 121.371 -0.831 . . . . 0.0 109.489 176.494 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 0.693 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.5 t . . . . . 0 N--CA 1.493 1.714 0 CA-C-O 121.731 0.777 . . . . 0.0 110.527 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 88.2 mt-30 -69.97 -33.37 71.99 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.672 -0.642 . . . . 0.0 110.792 -178.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.542 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -153.62 174.52 32.2 Favored Glycine 0 N--CA 1.498 2.767 0 C-N-CA 119.073 -1.537 . . . . 0.0 110.441 -172.583 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.499 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 18.1 p -120.49 168.85 10.9 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.049 -1.265 . . . . 0.0 111.053 -177.254 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.049 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -137.96 149.64 46.32 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.549 -0.719 . . . . 0.0 109.396 -175.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.575 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 19.1 tttt -106.54 117.37 33.86 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.105 -0.997 . . . . 0.0 110.194 179.102 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 1.047 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.0 tp -60.02 128.38 36.55 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.0 -1.063 . . . . 0.0 108.818 172.532 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.117 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.45 -28.84 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.926 0 C-N-CA 119.684 -0.806 . . . . 0.0 110.136 -178.148 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.46 140.22 24.86 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.304 -0.958 . . . . 0.0 111.459 -178.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.754 HG23 ' CD2' ' B' ' 24' ' ' HIS . 6.7 mt -106.87 133.12 52.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.922 -1.111 . . . . 0.0 110.145 169.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.508 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 86.9 m-20 -110.04 114.53 28.13 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.555 -0.716 . . . . 0.0 110.026 173.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -103.85 116.52 32.44 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.096 -1.002 . . . . 0.0 110.379 -176.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.41 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -111.59 134.99 21.11 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.285 -0.884 . . . . 0.0 109.35 178.208 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_endo -51.85 -18.44 6.62 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 O-C-N 123.861 1.453 . . . . 0.0 110.734 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.573 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 4.9 m-80 -96.91 -33.32 11.65 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.095 -1.003 . . . . 0.0 110.263 178.62 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.573 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 83.7 m-85 -157.52 150.43 23.25 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.293 -0.879 . . . . 0.0 110.215 -177.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . 0.503 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 65.9 ttt180 -90.61 144.06 26.13 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.926 -1.109 . . . . 0.0 110.074 176.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.508 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 96.0 m -129.77 140.03 51.15 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.684 -0.635 . . . . 0.0 109.728 -175.33 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.754 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.18 139.77 50.82 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.007 -1.058 . . . . 0.0 111.118 179.802 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.669 HG22 ' CB ' ' B' ' 60' ' ' SER . 3.9 t -120.51 132.55 69.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.197 -0.939 . . . . 0.0 110.436 -178.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.858 HG13 ' CE1' ' B' ' 61' ' ' PHE . 32.4 m -116.03 171.38 5.1 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 121.691 -0.631 . . . . 0.0 109.922 179.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.564 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 10.4 tt0 -108.48 115.71 30.62 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 -179.537 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.531 HD22 HD23 ' B' ' 36' ' ' LEU . 8.7 tp -86.69 127.94 58.41 Favored Pre-proline 0 C--N 1.296 -1.732 0 O-C-N 121.148 -0.97 . . . . 0.0 110.28 -172.098 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.495 ' HD2' HD12 ' B' ' 28' ' ' LEU . 29.1 Cg_endo -66.79 177.12 3.71 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 O-C-N 123.924 1.486 . . . . 0.0 111.056 -179.435 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.517 ' HA ' HD12 ' B' ' 33' ' ' LEU . 96.1 m-20 -60.09 -39.95 87.9 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.273 -0.892 . . . . 0.0 111.159 -174.233 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.603 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.05 0.73 56.97 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.79 -1.194 . . . . 0.0 110.862 -174.671 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.603 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.7 mmm -112.58 -11.86 13.52 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.981 -1.074 . . . . 0.0 109.971 172.255 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.591 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 19.9 mt -70.14 -39.9 75.12 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.354 -0.841 . . . . 0.0 110.185 177.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -73.98 143.11 45.75 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.499 -0.751 . . . . 0.0 110.532 -178.083 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.51 -39.01 3.01 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 119.954 -1.117 . . . . 0.0 110.505 173.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.531 HD23 HD22 ' B' ' 28' ' ' LEU . 50.5 tp -77.47 147.91 35.66 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.86 -1.377 . . . . 0.0 110.826 -174.056 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . 0.489 ' C ' HD11 ' B' ' 54' ' ' ILE . 21.4 pt-20 -149.12 166.59 28.31 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.454 -0.779 . . . . 0.0 109.5 177.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 0.844 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -64.98 147.7 52.96 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.85 -1.156 . . . . 0.0 109.942 179.366 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.06 -7.76 62.43 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -175.393 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.537 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -75.02 152.89 38.67 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.336 -1.096 . . . . 0.0 109.64 177.254 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.875 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.0 OUTLIER -96.09 110.03 22.35 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 120.882 -1.137 . . . . 0.0 110.059 175.39 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.65 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.0 t -93.08 130.01 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 173.301 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 0.581 ' HB3' ' CG ' ' B' ' 85' ' ' GLU . . . -93.38 119.67 32.77 Favored 'General case' 0 C--N 1.295 -1.789 0 C-N-CA 118.993 -1.083 . . . . 0.0 109.167 173.075 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.65 ' HE1' HG11 ' B' ' 42' ' ' VAL . 0.3 OUTLIER -90.26 105.62 17.93 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 177.712 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.0 t-20 58.81 7.77 0.83 Allowed 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.375 -0.828 . . . . 0.0 111.379 -170.08 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.408 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 125.45 -2.82 8.22 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.749 -1.215 . . . . 0.0 110.638 174.57 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.849 ' O ' HD23 ' B' ' 49' ' ' LEU . 32.7 t -94.56 108.08 20.05 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.597 -1.531 . . . . 0.0 109.867 176.732 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 18.2 p -70.07 128.68 37.14 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.133 -0.979 . . . . 0.0 110.842 -175.414 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 0.867 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -143.42 158.08 43.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.335 -0.853 . . . . 0.0 109.263 172.239 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 65.1 m -99.46 149.42 23.22 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.523 -1.361 . . . . 0.0 111.411 -170.191 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.935 HG13 HG13 ' B' ' 59' ' ' VAL . 20.7 t -77.19 114.82 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.839 -0.538 . . . . 0.0 110.434 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.53 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 53.7 p -69.38 -40.02 77.66 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.176 -0.953 . . . . 0.0 109.601 173.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.566 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 89.3 tt0 -161.51 156.38 23.38 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.77 -0.772 . . . . 0.0 110.128 -178.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.844 HD11 ' N ' ' B' ' 38' ' ' THR . 8.3 mt -108.85 129.16 63.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.096 -1.003 . . . . 0.0 110.088 175.05 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.542 ' HB2' ' CB ' ' B' ' 58' ' ' HIS . 8.5 m-80 -102.45 63.12 0.86 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.626 -0.671 . . . . 0.0 109.782 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.67 -118.0 5.34 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.695 -1.762 . . . . 0.0 108.695 -173.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.591 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -74.87 -20.01 59.92 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 120.988 -1.301 . . . . 0.0 108.78 174.249 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.117 ' CD2' HG11 ' B' ' 13' ' ' VAL . 10.3 m170 -75.52 159.59 31.11 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.469 -0.769 . . . . 0.0 110.234 -177.219 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.935 HG13 HG13 ' B' ' 51' ' ' VAL . 54.3 t -140.46 123.09 16.15 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 O-C-N 121.063 -1.023 . . . . 0.0 110.55 171.247 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.669 ' CB ' HG22 ' B' ' 25' ' ' VAL . 17.4 m -89.69 128.78 36.14 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.586 -0.696 . . . . 0.0 109.519 177.675 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.867 ' HB2' HD12 ' B' ' 49' ' ' LEU . 2.4 p90 -124.21 152.37 43.0 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.965 -1.085 . . . . 0.0 110.186 178.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.53 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 33.0 p-10 -89.32 156.09 18.94 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 120.834 -1.166 . . . . 0.0 111.588 -171.119 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.944 HD22 HD13 ' B' ' 68' ' ' LEU . 0.2 OUTLIER -160.66 101.52 1.32 Allowed 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.696 -0.628 . . . . 0.0 109.656 -173.526 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.494 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 57.1 ttm -61.59 139.45 58.27 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.612 -1.305 . . . . 0.0 109.163 178.527 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.48 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 78.6 tttt -59.94 -47.81 84.26 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.86 -1.15 . . . . 0.0 110.384 -173.506 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -64.5 -40.0 94.83 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.943 -1.098 . . . . 0.0 109.843 177.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.494 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 94.2 m -61.24 -40.08 92.7 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.96 -1.087 . . . . 0.0 109.564 173.117 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.944 HD13 HD22 ' B' ' 63' ' ' LEU . 16.3 tp -59.92 -41.08 90.94 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.339 -0.851 . . . . 0.0 109.35 178.352 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -67.04 -40.07 87.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.415 -0.803 . . . . 0.0 110.449 173.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.791 HG22 HG23 ' B' ' 71' ' ' THR . 0.8 OUTLIER -65.51 -43.32 94.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.24 -0.913 . . . . 0.0 109.426 -175.599 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.791 HG23 HG22 ' B' ' 70' ' ' ILE . 25.1 p -84.36 -174.17 5.13 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.006 -0.678 . . . . 0.0 109.195 175.171 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.528 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 4.1 t30 -101.62 23.47 11.17 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 171.708 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.698 HD13 HD21 ' B' ' 63' ' ' LEU . 91.6 mt -70.04 -39.99 75.39 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.133 -0.979 . . . . 0.0 109.996 176.013 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.54 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -47.42 -22.7 1.69 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -178.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.4 p-10 -68.65 -17.08 64.03 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.057 -1.261 . . . . 0.0 110.647 -174.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 89.5 mt -62.32 143.08 57.39 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.2 -0.937 . . . . 0.0 110.912 -177.702 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 1.047 ' C ' HD23 ' B' ' 12' ' ' LEU . 89.8 mttt -141.64 144.58 34.23 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 174.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.696 HG21 HG13 ' B' ' 15' ' ' ILE . 47.2 t -64.9 147.31 12.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.885 -1.134 . . . . 0.0 110.062 -176.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.49 -14.07 62.23 Favored Glycine 0 N--CA 1.484 1.875 0 N-CA-C 108.67 -1.772 . . . . 0.0 108.67 -173.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 39.2 t0 -96.12 166.76 11.6 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.472 -1.016 . . . . 0.0 109.483 175.564 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.575 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.3 m95 -117.64 166.84 11.93 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.057 -1.027 . . . . 0.0 110.136 177.388 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 1.049 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.3 p -132.36 156.66 42.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.429 -0.794 . . . . 0.0 109.963 -178.427 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.693 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.1 m-20 -79.44 105.53 10.82 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.116 -0.99 . . . . 0.0 109.203 169.117 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.947 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -110.2 142.21 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 120.419 -1.425 . . . . 0.0 110.765 -176.399 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . 0.581 ' CG ' ' HB3' ' B' ' 43' ' ' ALA . 19.9 pt-20 -149.38 153.84 38.0 Favored 'General case' 0 N--CA 1.492 1.64 0 C-N-CA 119.779 -0.768 . . . . 0.0 110.05 179.249 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 63.2 ttt180 -68.14 129.97 41.51 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.181 -0.95 . . . . 0.0 110.432 -178.045 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.875 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.411 -0.806 . . . . 0.0 109.502 176.509 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.885 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.0 t . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.704 0.764 . . . . 0.0 110.835 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -70.06 -34.83 73.71 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.86 -0.525 . . . . 0.0 111.036 178.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.544 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -154.76 174.44 33.05 Favored Glycine 0 N--CA 1.496 2.641 0 C-N-CA 118.933 -1.603 . . . . 0.0 110.191 -172.1 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.441 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.3 p -119.99 170.45 9.26 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.944 -1.327 . . . . 0.0 111.2 -176.14 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 1.018 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -139.46 150.1 44.79 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -178.005 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 21.6 tttt -108.9 117.68 34.83 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.045 -1.034 . . . . 0.0 110.375 -179.552 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 1.023 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.0 tp -59.41 128.85 39.15 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.892 -1.13 . . . . 0.0 108.947 173.531 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.119 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.99 -28.82 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 C-N-CA 119.512 -0.875 . . . . 0.0 110.101 -178.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.93 140.56 23.5 Favored 'General case' 0 N--CA 1.493 1.696 0 C-N-CA 119.089 -1.045 . . . . 0.0 111.445 -178.375 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.744 HG23 ' CD2' ' A' ' 24' ' ' HIS . 14.1 mt -109.96 133.39 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.116 -0.99 . . . . 0.0 110.279 172.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.498 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 76.6 m-20 -108.54 116.12 31.37 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.335 -0.853 . . . . 0.0 109.883 172.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -107.64 115.33 29.95 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.948 -1.095 . . . . 0.0 110.735 -175.473 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.48 130.27 24.45 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.21 -0.931 . . . . 0.0 109.209 176.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -52.1 -19.79 9.51 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.792 1.417 . . . . 0.0 110.275 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.574 ' ND2' ' N ' ' A' ' 20' ' ' ASN . 0.4 OUTLIER -83.54 -42.57 16.67 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.186 -0.946 . . . . 0.0 108.991 176.554 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.57 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 89.5 m-85 -156.98 150.32 24.14 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-O 121.307 0.575 . . . . 0.0 110.044 -177.674 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.484 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 60.2 ttt180 -89.49 143.59 26.7 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.898 -1.126 . . . . 0.0 110.116 177.673 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.498 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.3 m -128.74 135.04 48.67 Favored 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.548 -0.72 . . . . 0.0 109.827 -176.358 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.744 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -127.78 141.36 51.6 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.813 -1.18 . . . . 0.0 111.594 -179.449 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.885 HG22 ' OG ' ' A' ' 60' ' ' SER . 6.3 t -123.26 133.48 69.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.172 -0.955 . . . . 0.0 110.667 -179.397 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.669 HG13 ' HE2' ' A' ' 61' ' ' PHE . 36.0 m -117.66 172.47 5.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-O 121.233 0.539 . . . . 0.0 110.274 179.533 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.535 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 7.2 tt0 -100.22 116.96 33.44 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.313 -0.867 . . . . 0.0 109.071 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.657 ' HG ' HD23 ' A' ' 36' ' ' LEU 0.256 0.1 OUTLIER -86.81 114.82 59.99 Favored Pre-proline 0 C--N 1.295 -1.777 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -176.818 . . . . . . . . 4 4 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.57 ' HD2' HD13 ' A' ' 28' ' ' LEU . 18.9 Cg_endo -63.3 174.48 3.33 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.779 1.41 . . . . 0.0 111.187 -178.299 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.574 ' HA ' HD12 ' A' ' 33' ' ' LEU . 1.9 p30 -63.22 -35.54 80.65 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.452 -0.78 . . . . 0.0 111.269 -174.219 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.527 ' N ' ' OD1' ' A' ' 30' ' ' ASP . 0.0 OUTLIER -91.0 -0.19 57.69 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.728 -1.232 . . . . 0.0 111.057 -173.551 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.646 ' HB3' HD11 ' A' ' 28' ' ' LEU . 96.2 mmm -114.48 -14.32 12.15 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 120.925 -1.109 . . . . 0.0 109.815 168.89 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.655 HD21 ' HA ' ' A' ' 57' ' ' ASN . 12.4 mt -64.3 -40.04 95.14 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.163 -0.961 . . . . 0.0 109.932 177.653 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -63.98 131.53 47.93 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.32 -0.862 . . . . 0.0 110.484 -178.104 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.39 -39.26 3.08 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 175.149 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.657 HD23 ' HG ' ' A' ' 28' ' ' LEU . 60.8 tp -62.38 144.52 55.7 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.963 -1.316 . . . . 0.0 110.85 -175.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.467 ' C ' HD11 ' A' ' 54' ' ' ILE . 19.2 pt-20 -151.49 164.78 36.02 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.728 -0.607 . . . . 0.0 109.452 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.8 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -66.92 150.48 49.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.849 -1.157 . . . . 0.0 109.763 178.376 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.63 -0.06 62.0 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 -174.572 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.438 ' CB ' ' O ' ' A' ' 37' ' ' GLU . . . -75.38 158.99 31.92 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.228 -1.16 . . . . 0.0 109.279 175.358 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.692 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.6 OUTLIER -100.39 110.89 23.12 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 118.854 -1.138 . . . . 0.0 109.829 176.025 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.664 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.8 t -100.1 125.67 53.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.457 -0.777 . . . . 0.0 109.041 175.688 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.48 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -92.0 119.78 32.03 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 119.041 -1.064 . . . . 0.0 109.242 172.401 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.688 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.6 OUTLIER -87.98 103.02 15.3 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 177.922 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.5 t-20 57.16 11.17 0.98 Allowed 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.455 -0.778 . . . . 0.0 111.141 -170.474 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 123.84 -0.21 9.17 Favored Glycine 0 N--CA 1.489 2.233 0 C-N-CA 119.584 -1.293 . . . . 0.0 110.605 174.621 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.834 ' O ' HD23 ' A' ' 49' ' ' LEU . 16.7 t -98.74 105.39 17.53 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.41 -1.641 . . . . 0.0 109.535 175.604 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.409 ' HA ' ' HA ' ' A' ' 43' ' ' ALA . 15.9 p -74.05 129.0 36.99 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.983 -1.073 . . . . 0.0 110.855 -172.368 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.864 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -142.95 160.84 39.59 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.377 -0.827 . . . . 0.0 109.605 173.739 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 6.6 m -100.43 148.1 25.12 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.552 -1.342 . . . . 0.0 111.237 -170.09 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.948 HG13 HG13 ' A' ' 59' ' ' VAL . 21.0 t -76.21 115.32 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.892 -0.505 . . . . 0.0 110.475 -179.361 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.534 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 30.4 p -70.46 -40.02 73.93 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.247 -0.908 . . . . 0.0 109.789 173.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.57 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -162.64 154.49 18.36 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.288 -0.882 . . . . 0.0 110.313 -179.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.8 HD11 ' N ' ' A' ' 38' ' ' THR . 7.6 mt -105.72 130.52 57.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.159 -0.963 . . . . 0.0 110.088 176.367 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.5 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 4.7 m-80 -102.51 64.39 0.9 Allowed 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.61 -0.681 . . . . 0.0 109.822 179.027 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.2 -119.5 5.9 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.774 -1.73 . . . . 0.0 108.774 -173.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.655 ' HA ' HD21 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -73.12 -22.1 60.61 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 120.878 -1.366 . . . . 0.0 108.643 174.315 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.119 ' CD2' HG11 ' A' ' 13' ' ' VAL . 12.3 m80 -74.02 159.97 31.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.283 -0.885 . . . . 0.0 110.431 -176.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.948 HG13 HG13 ' A' ' 51' ' ' VAL . 51.4 t -139.98 125.38 20.77 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 121.084 -1.01 . . . . 0.0 110.706 170.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.885 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.7 t -91.6 135.08 34.13 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.444 -0.785 . . . . 0.0 109.274 175.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.864 ' HB2' HD12 ' A' ' 49' ' ' LEU . 8.8 p90 -128.35 154.39 46.02 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 121.304 -0.872 . . . . 0.0 110.483 177.141 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.534 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 28.9 p-10 -89.67 150.85 22.16 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.157 -0.965 . . . . 0.0 111.332 -171.616 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.7 HD21 HD13 ' A' ' 73' ' ' LEU . 0.0 OUTLIER -155.6 117.6 4.09 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -176.079 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.54 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 52.6 mtt -68.46 142.33 55.37 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.786 -1.196 . . . . 0.0 109.518 177.425 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.475 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 86.0 tttt -59.97 -44.59 94.36 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 120.991 -1.068 . . . . 0.0 109.715 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 52.5 tp10 -70.04 -39.93 75.43 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.189 -0.944 . . . . 0.0 110.235 178.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.54 ' HB ' ' HB2' ' A' ' 64' ' ' MET . 89.5 m -61.41 -37.81 84.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.795 -1.191 . . . . 0.0 109.084 172.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.581 ' CD1' HD22 ' A' ' 63' ' ' LEU . 7.1 tp -60.07 -44.32 94.84 Favored 'General case' 0 C--N 1.297 -1.69 0 O-C-N 121.143 -0.973 . . . . 0.0 109.193 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 52.0 ttt85 -70.08 -39.91 75.3 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.456 -0.777 . . . . 0.0 110.52 175.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.863 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -62.72 -41.38 92.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.176 -0.953 . . . . 0.0 109.072 -177.719 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.863 HG23 HG22 ' A' ' 70' ' ' ILE . 31.2 p -88.93 -176.76 5.29 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 175.765 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.481 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 2.4 t30 -100.18 25.08 7.87 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 172.112 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.7 HD13 HD21 ' A' ' 63' ' ' LEU . 55.7 mt -69.85 -39.99 76.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.941 -1.099 . . . . 0.0 109.861 174.556 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.541 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -48.12 -22.76 2.38 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 -179.034 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.0 p-10 -64.89 -17.38 64.26 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.151 -1.205 . . . . 0.0 110.5 -176.369 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 90.3 mt -62.06 144.02 55.8 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.299 -0.875 . . . . 0.0 110.889 -176.724 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 1.023 ' C ' HD23 ' A' ' 12' ' ' LEU . 35.0 mttp -143.83 143.86 31.51 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.747 -0.596 . . . . 0.0 109.41 174.13 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.67 ' N ' HD23 ' A' ' 12' ' ' LEU . 14.9 t -61.77 150.06 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 120.637 -1.289 . . . . 0.0 110.107 -176.722 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.35 -12.15 61.48 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 108.927 -1.669 . . . . 0.0 108.927 -176.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 48.7 t0 -95.77 166.27 11.89 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.312 -1.111 . . . . 0.0 109.496 176.236 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.6 m95 -117.43 156.63 27.62 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.987 -1.071 . . . . 0.0 110.524 178.728 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.018 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.1 p -120.05 150.88 22.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.516 -0.74 . . . . 0.0 109.874 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.885 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.3 OUTLIER -76.82 106.28 8.4 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.072 -1.018 . . . . 0.0 108.951 168.966 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.67 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -105.97 138.52 30.89 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 120.425 -1.422 . . . . 0.0 111.5 -175.223 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.431 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.8 tt0 -133.3 140.67 47.58 Favored 'General case' 0 N--CA 1.496 1.829 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.178 -179.318 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 71.6 ttt-85 -80.31 134.17 36.04 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.195 -0.94 . . . . 0.0 111.148 -175.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.692 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.734 0 O-C-N 121.409 -0.807 . . . . 0.0 110.28 179.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 0.874 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.0 t . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 121.739 0.78 . . . . 0.0 110.798 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -70.01 -34.71 73.65 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.79 -0.569 . . . . 0.0 111.063 178.342 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.542 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -154.96 174.33 33.2 Favored Glycine 0 N--CA 1.495 2.58 0 C-N-CA 118.902 -1.618 . . . . 0.0 110.248 -172.03 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.446 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.5 p -119.9 170.42 9.27 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.892 -1.358 . . . . 0.0 111.173 -176.016 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.067 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -139.53 150.17 44.78 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -178.157 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.57 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 21.6 tttt -108.82 117.83 35.22 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.115 -0.991 . . . . 0.0 110.346 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 1.006 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.0 tp -59.68 128.74 38.47 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 120.936 -1.102 . . . . 0.0 109.019 173.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.132 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.81 -28.9 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 O-C-N 121.33 -0.856 . . . . 0.0 110.139 -178.719 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.91 140.66 23.59 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.294 -0.962 . . . . 0.0 111.401 -178.371 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.766 HG23 ' CD2' ' B' ' 24' ' ' HIS . 14.1 mt -109.99 133.38 55.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.177 -0.952 . . . . 0.0 110.244 172.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.509 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 76.2 m-20 -108.61 116.23 31.58 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.344 -0.847 . . . . 0.0 109.706 173.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 99.9 mt-10 -107.72 115.37 30.03 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.917 -1.114 . . . . 0.0 110.717 -175.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.413 ' HA ' ' HD2' ' B' ' 19' ' ' PRO . 0.0 OUTLIER -115.55 130.27 24.46 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.269 -0.894 . . . . 0.0 109.294 176.82 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.7 Cg_endo -52.32 -19.77 10.13 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.731 1.385 . . . . 0.0 110.21 -179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.569 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 0.4 OUTLIER -83.28 -43.16 16.34 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.26 -0.9 . . . . 0.0 108.867 176.508 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.569 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 89.6 m-85 -156.54 150.36 24.87 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.813 -0.555 . . . . 0.0 110.028 -177.535 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . 0.481 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 60.2 ttt180 -89.37 143.52 26.76 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.942 -1.098 . . . . 0.0 110.152 177.585 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.509 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 94.3 m -128.64 135.04 48.77 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.648 -0.657 . . . . 0.0 109.89 -176.517 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.766 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -127.61 141.54 51.6 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.824 -1.173 . . . . 0.0 111.534 -179.466 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.882 HG22 ' OG ' ' B' ' 60' ' ' SER . 6.2 t -123.32 133.63 68.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.189 -0.945 . . . . 0.0 110.654 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.677 HG13 ' HE2' ' B' ' 61' ' ' PHE . 35.2 m -118.03 172.29 5.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.798 -0.564 . . . . 0.0 110.227 179.581 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.525 ' CB ' ' HB3' ' B' ' 11' ' ' LYS . 7.2 tt0 -99.99 117.06 33.47 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.321 -0.862 . . . . 0.0 109.058 179.184 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.678 HD11 ' HB3' ' B' ' 32' ' ' MET 0.255 0.1 OUTLIER -86.83 114.84 60.1 Favored Pre-proline 0 C--N 1.296 -1.723 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 -176.922 . . . . . . . . 4 4 . 1 . 009 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.6 ' HD2' HD13 ' B' ' 28' ' ' LEU . 19.0 Cg_endo -63.3 174.6 3.23 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.744 1.392 . . . . 0.0 111.267 -178.306 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.584 ' HA ' HD12 ' B' ' 33' ' ' LEU . 1.9 p30 -63.35 -35.56 80.81 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.484 -0.76 . . . . 0.0 111.169 -174.206 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.521 ' N ' ' OD1' ' B' ' 30' ' ' ASP . 0.0 OUTLIER -91.05 -0.02 57.64 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.738 -1.226 . . . . 0.0 110.997 -173.51 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.678 ' HB3' HD11 ' B' ' 28' ' ' LEU . 96.2 mmm -114.48 -14.34 12.15 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 120.881 -1.137 . . . . 0.0 109.806 168.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.649 HD21 ' HA ' ' B' ' 57' ' ' ASN . 12.4 mt -64.35 -39.96 94.93 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.184 -0.948 . . . . 0.0 109.989 177.642 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -64.02 131.51 47.82 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.307 -0.87 . . . . 0.0 110.497 -178.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.47 -39.31 3.07 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.329 -1.109 . . . . 0.0 110.329 175.207 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.664 HD23 ' HG ' ' B' ' 28' ' ' LEU . 60.7 tp -62.37 144.57 55.62 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.872 -1.37 . . . . 0.0 110.883 -175.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . 0.455 ' C ' HD11 ' B' ' 54' ' ' ILE . 19.2 pt-20 -151.57 164.78 36.09 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.658 -0.651 . . . . 0.0 109.36 -179.629 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 0.799 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.92 150.48 49.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.784 -1.198 . . . . 0.0 109.827 178.332 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.61 -0.01 62.03 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -174.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.435 ' CB ' ' O ' ' B' ' 37' ' ' GLU . . . -75.51 158.97 31.82 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.191 -1.182 . . . . 0.0 109.23 175.293 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.684 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.7 OUTLIER -100.21 110.64 22.9 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.977 -1.077 . . . . 0.0 109.901 176.018 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.648 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.8 t -99.95 125.69 53.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.427 -0.796 . . . . 0.0 109.081 175.627 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -91.98 119.73 31.97 Favored 'General case' 0 C--N 1.297 -1.712 0 C-N-CA 119.056 -1.058 . . . . 0.0 109.274 172.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.684 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.6 OUTLIER -87.94 102.95 15.22 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.417 -0.802 . . . . 0.0 108.968 177.887 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.6 t-20 57.32 11.11 1.04 Allowed 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.439 -0.788 . . . . 0.0 111.113 -170.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 123.77 0.2 9.17 Favored Glycine 0 N--CA 1.489 2.225 0 C-N-CA 119.653 -1.261 . . . . 0.0 110.609 174.509 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.826 ' O ' HD23 ' B' ' 49' ' ' LEU . 16.9 t -98.99 105.49 17.64 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.465 -1.609 . . . . 0.0 109.464 175.488 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . 0.411 ' HA ' ' HA ' ' B' ' 43' ' ' ALA . 15.9 p -74.06 129.02 37.03 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.012 -1.055 . . . . 0.0 110.802 -172.39 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 0.883 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -143.05 160.79 39.71 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.396 -0.815 . . . . 0.0 109.484 173.751 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 6.6 m -100.27 148.22 24.89 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 120.647 -1.283 . . . . 0.0 111.255 -170.128 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.981 HG13 HG13 ' B' ' 59' ' ' VAL . 21.2 t -76.46 115.24 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.716 -0.615 . . . . 0.0 110.479 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.536 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 30.3 p -70.39 -40.01 74.2 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.213 -0.929 . . . . 0.0 109.818 173.722 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.569 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -162.63 154.48 18.37 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.406 -0.809 . . . . 0.0 110.265 -179.525 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.799 HD11 ' N ' ' B' ' 38' ' ' THR . 7.6 mt -105.6 130.46 56.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.11 -0.994 . . . . 0.0 110.173 176.323 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.511 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 4.6 m-80 -102.53 64.41 0.89 Allowed 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.659 -0.651 . . . . 0.0 109.737 179.082 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.32 -119.52 5.87 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 108.739 -1.744 . . . . 0.0 108.739 -173.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.649 ' HA ' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -73.08 -22.09 60.65 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.894 -1.357 . . . . 0.0 108.753 174.216 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.132 ' CD2' HG11 ' B' ' 13' ' ' VAL . 12.4 m80 -74.07 160.05 31.81 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.257 -0.902 . . . . 0.0 110.421 -176.588 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.981 HG13 HG13 ' B' ' 51' ' ' VAL . 50.7 t -140.14 125.35 20.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 C-N-CA 119.107 -1.037 . . . . 0.0 110.595 170.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.882 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.7 t -91.57 135.25 34.0 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.5 -0.75 . . . . 0.0 109.284 175.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.883 ' HB2' HD12 ' B' ' 49' ' ' LEU . 8.7 p90 -128.46 154.46 46.05 Favored 'General case' 0 N--CA 1.496 1.828 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.417 177.099 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.536 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 29.2 p-10 -89.75 150.83 22.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.059 -1.026 . . . . 0.0 111.246 -171.554 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.68 HD21 HD13 ' B' ' 73' ' ' LEU . 0.0 OUTLIER -155.57 117.6 4.09 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -176.125 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.535 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 52.9 mtt -68.38 142.32 55.47 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.889 -1.132 . . . . 0.0 109.463 177.538 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.474 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 86.0 tttt -60.06 -44.54 94.64 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.072 -1.017 . . . . 0.0 109.635 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 52.5 tp10 -69.99 -39.92 75.62 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.148 -0.97 . . . . 0.0 110.328 178.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.535 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 89.2 m -61.38 -38.04 85.59 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.776 -1.203 . . . . 0.0 108.99 172.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.591 ' CD1' HD22 ' B' ' 63' ' ' LEU . 7.0 tp -59.99 -44.23 94.66 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.235 -0.916 . . . . 0.0 109.289 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 52.0 ttt85 -70.03 -39.93 75.48 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.38 -0.825 . . . . 0.0 110.563 175.429 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.828 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -62.73 -41.28 91.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 CA-C-O 121.917 0.865 . . . . 0.0 109.07 -177.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.828 HG23 HG22 ' B' ' 70' ' ' ILE . 31.5 p -89.0 -176.63 5.23 Favored 'General case' 0 C--N 1.3 -1.565 0 C-N-CA 120.2 -0.6 . . . . 0.0 109.394 175.859 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.48 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 2.3 t30 -100.17 25.11 7.83 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 172.144 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.68 HD13 HD21 ' B' ' 63' ' ' LEU . 54.8 mt -69.89 -40.0 75.92 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.894 -1.129 . . . . 0.0 109.848 174.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.527 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -48.16 -22.63 2.36 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 -179.021 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.5 p-10 -64.89 -17.51 64.39 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.189 -1.183 . . . . 0.0 110.438 -176.392 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 90.2 mt -62.08 143.95 55.93 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.256 -0.902 . . . . 0.0 110.871 -176.601 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 1.006 ' C ' HD23 ' B' ' 12' ' ' LEU . 35.0 mttp -143.76 143.95 31.6 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.637 -0.664 . . . . 0.0 109.395 174.123 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.662 ' N ' HD23 ' B' ' 12' ' ' LEU . 15.3 t -61.78 150.05 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.666 -1.271 . . . . 0.0 110.057 -176.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.2 -11.95 61.67 Favored Glycine 0 N--CA 1.484 1.868 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -176.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 48.5 t0 -95.81 166.25 11.9 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.386 -1.067 . . . . 0.0 109.458 176.051 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.57 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.6 m95 -117.4 156.62 27.6 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.051 -1.03 . . . . 0.0 110.516 178.759 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 1.067 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.1 p -120.14 150.94 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.569 -0.707 . . . . 0.0 109.807 179.683 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.874 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.3 OUTLIER -76.79 106.14 8.29 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.037 -1.039 . . . . 0.0 109.014 168.971 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.665 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -105.9 138.71 29.91 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 120.476 -1.39 . . . . 0.0 111.454 -175.118 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . 0.435 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.7 tt0 -133.42 140.69 47.46 Favored 'General case' 0 N--CA 1.495 1.824 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.191 -179.364 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 71.7 ttt-85 -80.33 134.29 36.04 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.16 -0.962 . . . . 0.0 111.029 -175.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.684 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.744 0 O-C-N 121.267 -0.896 . . . . 0.0 110.271 179.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.903 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.7 t . . . . . 0 N--CA 1.493 1.725 0 CA-C-O 121.332 0.587 . . . . 0.0 110.287 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -81.23 -26.29 35.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.427 -0.796 . . . . 0.0 110.891 -179.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.533 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -153.92 176.71 31.74 Favored Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.288 -1.434 . . . . 0.0 109.922 -176.086 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.472 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 18.4 p -123.34 170.01 10.75 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.942 -1.328 . . . . 0.0 110.839 -178.444 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 1.041 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -137.36 149.89 47.31 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.557 -0.715 . . . . 0.0 109.65 -177.076 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.583 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 36.9 tttt -104.07 117.86 35.28 Favored 'General case' 0 C--N 1.296 -1.731 0 O-C-N 120.901 -1.124 . . . . 0.0 110.355 178.673 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 1.021 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.1 tp -61.44 126.14 26.29 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.861 -1.15 . . . . 0.0 108.749 171.482 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.067 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.38 -28.86 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.934 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.004 -178.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -148.76 141.02 24.06 Favored 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 118.964 -1.094 . . . . 0.0 111.225 178.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.852 HG23 ' CD2' ' A' ' 24' ' ' HIS . 13.6 mt -105.54 138.22 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.007 -1.058 . . . . 0.0 110.062 171.372 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.509 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 83.7 m-20 -110.83 114.66 28.18 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.25 -0.906 . . . . 0.0 109.932 173.789 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -103.35 112.65 25.63 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.017 -1.052 . . . . 0.0 110.374 -178.008 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.456 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 19.7 mtmt -107.02 132.77 20.65 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.296 -0.877 . . . . 0.0 109.282 177.338 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.9 Cg_endo -51.84 -18.9 7.2 Favored 'Trans proline' 0 C--N 1.303 -1.851 0 O-C-N 123.879 1.462 . . . . 0.0 110.745 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.57 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 7.8 m-80 -95.77 -33.06 12.42 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.125 -0.984 . . . . 0.0 110.204 178.298 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.57 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 98.2 m-85 -157.46 150.29 23.23 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.363 -0.836 . . . . 0.0 110.318 -177.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -87.76 145.88 25.91 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.898 -1.126 . . . . 0.0 110.108 177.318 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.509 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 92.5 m -133.89 145.37 49.56 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.455 -0.778 . . . . 0.0 109.748 -176.418 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.852 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.4 OUTLIER -135.35 135.27 40.59 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.781 -1.199 . . . . 0.0 111.476 -177.879 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.634 HG22 ' CB ' ' A' ' 60' ' ' SER . 9.7 t -114.43 132.77 62.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.092 -1.005 . . . . 0.0 110.814 -179.127 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.442 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 17.4 m -118.11 170.92 6.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 CA-C-O 121.177 0.513 . . . . 0.0 110.106 179.217 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.529 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 13.5 tt0 -102.64 118.92 37.91 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.329 -0.857 . . . . 0.0 109.096 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.5 ' HB3' ' CD2' ' A' ' 33' ' ' LEU . 10.2 tp -83.59 123.77 76.1 Favored Pre-proline 0 C--N 1.3 -1.567 0 C-N-CA 119.969 -0.692 . . . . 0.0 109.739 -175.345 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.486 ' HD2' HD12 ' A' ' 28' ' ' LEU . 25.9 Cg_endo -66.18 175.31 4.97 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 O-C-N 123.843 1.444 . . . . 0.0 111.035 -179.298 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.402 ' HA ' HD12 ' A' ' 33' ' ' LEU . 57.8 t0 -59.86 -39.77 86.34 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.387 -0.821 . . . . 0.0 110.831 -175.714 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.602 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -88.76 1.08 55.82 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.941 -1.1 . . . . 0.0 110.633 -175.004 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.602 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 93.5 mmm -112.17 -14.16 13.42 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.989 -1.069 . . . . 0.0 109.916 170.683 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.589 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 19.6 mt -69.96 -39.92 75.72 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.454 -0.779 . . . . 0.0 110.516 178.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -82.26 113.57 20.16 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.281 -0.887 . . . . 0.0 110.437 -176.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.8 -52.62 0.7 Allowed Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.835 -1.174 . . . . 0.0 110.415 175.467 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.635 HD11 ' CG2' ' A' ' 42' ' ' VAL . 5.1 tt -66.37 152.21 45.51 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.93 -1.335 . . . . 0.0 110.756 -173.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.524 ' C ' HD11 ' A' ' 54' ' ' ILE . 11.3 pt-20 -150.76 169.96 20.39 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.477 -0.764 . . . . 0.0 109.752 -177.271 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.828 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -65.43 158.4 26.84 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.951 -1.093 . . . . 0.0 110.38 -178.27 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 71.51 2.71 51.1 Favored Glycine 0 N--CA 1.495 2.57 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 -178.229 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.559 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -82.52 163.73 21.35 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.227 -1.161 . . . . 0.0 109.768 177.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.784 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 1.0 OUTLIER -104.52 112.77 25.97 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.982 -1.074 . . . . 0.0 109.985 176.491 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.635 ' CG2' HD11 ' A' ' 36' ' ' LEU . 2.0 t -102.83 130.96 52.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.377 -0.827 . . . . 0.0 108.931 173.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.501 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -91.45 120.05 31.95 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.214 -0.995 . . . . 0.0 109.092 172.272 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.667 ' CD2' HG21 ' A' ' 82' ' ' VAL . 0.3 OUTLIER -90.3 107.9 19.43 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 177.112 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.1 t-20 52.98 13.09 0.33 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.47 -0.769 . . . . 0.0 111.688 -167.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 121.22 -2.59 11.48 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.441 -1.362 . . . . 0.0 110.855 172.257 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.789 ' O ' HD23 ' A' ' 49' ' ' LEU . 35.5 t -94.25 109.0 20.84 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.402 -1.646 . . . . 0.0 109.448 174.829 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.3 p -76.99 124.65 28.08 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.105 -0.997 . . . . 0.0 110.836 -172.443 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.882 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -140.02 159.98 40.95 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.507 -0.745 . . . . 0.0 109.145 173.805 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.474 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 28.5 m -97.03 160.84 14.11 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.654 -1.278 . . . . 0.0 111.179 -170.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.756 HG22 ' CE1' ' A' ' 61' ' ' PHE . 18.8 t -84.69 116.39 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.854 -0.529 . . . . 0.0 110.372 -177.376 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.552 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 77.4 p -70.02 -40.02 75.47 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.252 -0.905 . . . . 0.0 109.667 173.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.552 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 54.4 tp10 -164.86 157.9 16.77 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.576 -176.364 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.828 HD11 ' N ' ' A' ' 38' ' ' THR . 8.7 mt -110.44 129.93 64.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.173 -0.954 . . . . 0.0 109.807 172.608 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.522 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 29.0 m-80 -102.35 64.05 0.9 Allowed 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.738 -0.601 . . . . 0.0 109.474 179.037 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.87 -114.28 4.3 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -172.18 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.589 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.82 -22.43 46.21 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 120.94 -1.33 . . . . 0.0 109.3 175.314 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.067 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.4 m170 -74.43 159.94 31.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.271 -0.893 . . . . 0.0 110.052 -177.489 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.713 HG13 HG13 ' A' ' 51' ' ' VAL . 78.4 t -140.0 120.04 13.38 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 O-C-N 121.103 -0.998 . . . . 0.0 110.693 173.317 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.634 ' CB ' HG22 ' A' ' 25' ' ' VAL . 6.5 t -83.13 138.02 33.84 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.424 -0.798 . . . . 0.0 109.531 176.055 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.882 ' HB3' HD12 ' A' ' 49' ' ' LEU . 87.0 m-85 -120.2 160.52 22.75 Favored 'General case' 0 C--N 1.295 -1.788 0 O-C-N 121.336 -0.853 . . . . 0.0 110.543 177.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.552 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 32.9 p-10 -95.46 148.2 22.73 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.247 -0.908 . . . . 0.0 111.1 179.21 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.745 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -157.23 121.92 4.43 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -176.762 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.506 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 26.8 ttt -82.19 141.87 32.66 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.983 -1.073 . . . . 0.0 109.669 -178.141 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.484 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 83.3 tttt -60.0 -48.26 82.44 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.094 -1.003 . . . . 0.0 110.611 -173.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.2 tp10 -68.08 -40.06 82.77 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 120.793 -1.192 . . . . 0.0 109.94 179.014 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.506 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 87.4 m -60.01 -39.02 84.37 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.976 -1.078 . . . . 0.0 109.257 173.007 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.775 HD11 ' HA2' ' A' ' 74' ' ' GLY . 2.0 tp -59.98 -45.38 92.9 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.23 -0.919 . . . . 0.0 109.706 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -67.05 -39.96 87.04 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.329 -0.857 . . . . 0.0 110.363 176.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.708 HG22 HG23 ' A' ' 71' ' ' THR . 1.1 tt -66.04 -40.14 86.43 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.294 -0.879 . . . . 0.0 109.258 -176.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.708 HG23 HG22 ' A' ' 70' ' ' ILE . 52.3 p -84.92 -169.77 2.81 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 121.362 0.601 . . . . 0.0 109.524 175.28 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.475 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 7.1 t30 -105.97 22.92 14.83 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 170.445 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.745 ' HB3' HD21 ' A' ' 63' ' ' LEU . 88.5 mt -69.95 -40.03 75.69 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.199 -0.938 . . . . 0.0 110.219 178.289 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.775 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -50.16 -21.6 4.21 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -177.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.4 p-10 -69.19 -17.45 63.8 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.98 -1.306 . . . . 0.0 110.753 -173.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.513 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 95.9 mt -60.01 141.02 56.38 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.105 -0.997 . . . . 0.0 110.709 -176.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 1.021 ' C ' HD23 ' A' ' 12' ' ' LEU . 66.4 mttm -140.0 139.07 35.94 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 121.514 0.674 . . . . 0.0 109.88 175.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.665 ' N ' HD23 ' A' ' 12' ' ' LEU . 22.0 t -61.08 152.77 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 120.906 -1.122 . . . . 0.0 110.376 -176.393 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.83 -16.08 57.61 Favored Glycine 0 N--CA 1.482 1.725 0 N-CA-C 108.729 -1.748 . . . . 0.0 108.729 -176.181 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.9 t0 -97.39 169.72 9.56 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.344 -1.091 . . . . 0.0 109.544 175.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.583 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.2 m95 -117.26 166.57 12.12 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.03 -1.044 . . . . 0.0 110.045 177.306 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.041 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.3 p -128.69 157.47 41.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.283 -0.886 . . . . 0.0 110.03 -177.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.903 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.2 m-20 -83.54 104.71 13.89 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.177 -0.952 . . . . 0.0 109.083 170.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.703 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -107.54 139.27 30.0 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.781 0 O-C-N 120.444 -1.41 . . . . 0.0 111.287 -174.826 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.456 ' HB2' HG22 ' A' ' 6' ' ' VAL . 85.2 tt0 -139.58 138.48 36.25 Favored 'General case' 0 N--CA 1.492 1.674 0 C-N-CA 120.355 -0.538 . . . . 0.0 109.837 -178.612 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.489 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 39.0 ptt180 -73.02 137.72 45.55 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.983 -1.073 . . . . 0.0 110.664 -174.151 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.784 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.254 -0.904 . . . . 0.0 109.923 173.788 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 0.859 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.7 t . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.398 0.618 . . . . 0.0 110.291 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -81.43 -25.96 35.74 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.38 -0.825 . . . . 0.0 110.887 -178.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.536 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -154.09 176.58 31.92 Favored Glycine 0 N--CA 1.494 2.559 0 C-N-CA 119.423 -1.37 . . . . 0.0 109.958 -176.1 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.468 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 18.4 p -123.32 170.05 10.69 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.951 -1.323 . . . . 0.0 110.838 -178.432 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.039 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -137.39 149.9 47.29 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.582 -0.699 . . . . 0.0 109.607 -177.143 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.574 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 36.9 tttt -104.13 117.98 35.55 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.961 -1.087 . . . . 0.0 110.304 178.615 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 1.019 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.1 tp -61.58 126.04 25.94 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.018 -1.051 . . . . 0.0 108.804 171.48 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.064 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.1 -29.12 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.979 0 O-C-N 121.371 -0.831 . . . . 0.0 110.054 -178.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -148.67 141.0 24.15 Favored 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 119.263 -0.975 . . . . 0.0 111.357 178.834 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.861 HG23 ' CD2' ' B' ' 24' ' ' HIS . 13.6 mt -105.6 138.32 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.996 -1.065 . . . . 0.0 110.082 171.373 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.525 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.6 m-20 -110.89 114.79 28.4 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.317 -0.865 . . . . 0.0 109.842 173.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -103.44 112.54 25.48 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.002 -1.061 . . . . 0.0 110.363 -177.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 19.6 mtmt -107.0 132.72 20.68 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.382 -0.823 . . . . 0.0 109.317 177.34 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -51.92 -18.79 7.3 Favored 'Trans proline' 0 C--N 1.304 -1.782 0 O-C-N 123.832 1.438 . . . . 0.0 110.716 -179.527 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.57 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 7.9 m-80 -95.64 -33.68 12.26 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.107 -0.996 . . . . 0.0 110.068 178.291 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.57 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 98.2 m-85 -157.0 150.29 24.09 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.352 -0.843 . . . . 0.0 110.412 -177.82 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -87.68 145.73 26.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.042 -1.036 . . . . 0.0 110.196 177.265 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.525 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 92.7 m -133.85 145.39 49.65 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.386 -0.821 . . . . 0.0 109.755 -176.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.861 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.4 OUTLIER -135.24 135.41 40.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.927 -1.108 . . . . 0.0 111.447 -177.804 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.65 HG22 ' CB ' ' B' ' 60' ' ' SER . 9.8 t -114.48 133.01 61.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 110.789 -179.119 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.449 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 17.7 m -118.45 170.85 7.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 CA-C-O 121.237 0.541 . . . . 0.0 109.988 179.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.528 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 13.5 tt0 -102.55 119.03 38.13 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.365 -0.834 . . . . 0.0 109.122 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.522 HD12 ' HA ' ' B' ' 28' ' ' LEU . 10.3 tp -83.68 123.75 75.94 Favored Pre-proline 0 C--N 1.299 -1.589 0 O-C-N 121.443 -0.786 . . . . 0.0 109.76 -175.358 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.496 ' HD2' HD12 ' B' ' 28' ' ' LEU . 25.8 Cg_endo -66.17 175.44 4.84 Favored 'Trans proline' 0 C--N 1.309 -1.538 0 O-C-N 123.851 1.448 . . . . 0.0 111.049 -179.221 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.411 ' HA ' HD12 ' B' ' 33' ' ' LEU . 58.0 t0 -60.07 -39.68 86.89 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.368 -0.833 . . . . 0.0 110.8 -175.655 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.607 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -88.78 1.08 55.83 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.819 -1.176 . . . . 0.0 110.695 -175.073 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.607 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 93.5 mmm -112.14 -14.13 13.44 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.961 -1.087 . . . . 0.0 109.92 170.628 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.594 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 19.7 mt -70.04 -39.91 75.46 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.366 -0.834 . . . . 0.0 110.511 178.442 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -82.2 113.56 20.12 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.296 -0.878 . . . . 0.0 110.436 -176.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.79 -52.64 0.7 Allowed Glycine 0 N--CA 1.491 2.335 0 C-N-CA 119.834 -1.174 . . . . 0.0 110.422 175.436 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.628 HD11 ' CG2' ' B' ' 42' ' ' VAL . 5.2 tt -66.39 152.2 45.57 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.916 -1.344 . . . . 0.0 110.807 -173.404 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . 0.503 ' C ' HD11 ' B' ' 54' ' ' ILE . 11.3 pt-20 -150.69 169.99 20.27 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.402 -0.811 . . . . 0.0 109.733 -177.249 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 0.835 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -65.41 158.36 26.9 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.958 -1.089 . . . . 0.0 110.425 -178.303 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . 0.403 ' N ' ' HB ' ' B' ' 51' ' ' VAL . . . 71.54 2.64 50.83 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.966 -1.253 . . . . 0.0 109.966 -178.233 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.558 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -82.54 163.47 21.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.226 -1.161 . . . . 0.0 109.817 177.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.784 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 1.0 OUTLIER -104.21 112.59 25.67 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.893 -1.129 . . . . 0.0 110.078 176.546 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.628 ' CG2' HD11 ' B' ' 36' ' ' LEU . 2.0 t -102.78 131.01 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.389 -0.819 . . . . 0.0 108.947 173.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 0.496 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -91.44 119.98 31.88 Favored 'General case' 0 C--N 1.296 -1.718 0 O-C-N 121.128 -0.983 . . . . 0.0 109.196 172.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.665 ' CD2' HG21 ' B' ' 82' ' ' VAL . 0.3 OUTLIER -90.23 107.55 19.2 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 177.138 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.1 t-20 53.29 13.16 0.39 Allowed 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.445 -0.784 . . . . 0.0 111.515 -167.252 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 121.17 -2.44 11.54 Favored Glycine 0 N--CA 1.491 2.311 0 C-N-CA 119.474 -1.346 . . . . 0.0 110.784 172.14 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.782 ' O ' HD23 ' B' ' 49' ' ' LEU . 35.6 t -94.32 109.04 20.9 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.411 -1.64 . . . . 0.0 109.434 174.808 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 16.7 p -76.99 124.77 28.26 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.054 -1.029 . . . . 0.0 110.814 -172.436 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 0.853 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -140.21 159.96 41.02 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.553 -0.717 . . . . 0.0 109.086 173.773 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . 0.48 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 28.5 m -96.79 160.95 14.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.686 -1.259 . . . . 0.0 111.214 -170.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.739 HG22 ' CE1' ' B' ' 61' ' ' PHE . 19.0 t -84.99 116.35 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.787 -0.57 . . . . 0.0 110.426 -177.42 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.542 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 77.3 p -69.96 -39.93 75.72 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.154 -0.966 . . . . 0.0 109.716 173.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.561 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 54.4 tp10 -164.94 157.8 16.46 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.589 -176.392 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.835 HD11 ' N ' ' B' ' 38' ' ' THR . 8.7 mt -110.32 129.89 64.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.194 -0.941 . . . . 0.0 109.854 172.667 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.531 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 28.7 m-80 -102.46 64.07 0.89 Allowed 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 120.103 -0.639 . . . . 0.0 109.42 179.101 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.02 -114.35 4.29 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 108.666 -1.774 . . . . 0.0 108.666 -172.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.594 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.65 -22.73 46.43 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.032 -1.275 . . . . 0.0 109.358 175.244 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.064 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.5 m170 -74.21 159.8 32.02 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.386 -0.821 . . . . 0.0 110.097 -177.515 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.729 HG13 HG13 ' B' ' 51' ' ' VAL . 78.4 t -139.99 120.02 13.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 C-N-CA 119.017 -1.073 . . . . 0.0 110.574 173.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.65 ' CB ' HG22 ' B' ' 25' ' ' VAL . 6.4 t -83.16 137.98 33.84 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.426 -0.796 . . . . 0.0 109.578 176.044 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.853 ' HB3' HD12 ' B' ' 49' ' ' LEU . 86.4 m-85 -120.25 160.63 22.58 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.351 -0.843 . . . . 0.0 110.471 177.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.542 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 32.9 p-10 -95.48 148.24 22.69 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.113 -0.992 . . . . 0.0 110.945 179.388 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.717 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -157.21 121.93 4.44 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -176.829 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.512 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 26.9 ttt -82.21 141.87 32.64 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.067 -1.02 . . . . 0.0 109.722 -178.183 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.482 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 83.3 tttt -59.95 -48.39 81.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.066 -1.021 . . . . 0.0 110.53 -173.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 54.1 tp10 -68.0 -40.05 83.08 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.915 -1.116 . . . . 0.0 109.966 179.088 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.512 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 87.6 m -59.98 -39.1 84.54 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.004 -1.06 . . . . 0.0 109.278 173.017 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.775 HD11 ' HA2' ' B' ' 74' ' ' GLY . 2.0 tp -60.02 -45.2 93.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.314 -0.866 . . . . 0.0 109.734 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -67.06 -39.95 86.97 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.451 -0.781 . . . . 0.0 110.384 176.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.718 HG22 HG23 ' B' ' 71' ' ' THR . 1.2 tt -66.1 -40.11 86.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.289 -0.882 . . . . 0.0 109.212 -176.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.718 HG23 HG22 ' B' ' 70' ' ' ILE . 52.3 p -84.84 -169.43 2.64 Favored 'General case' 0 C--N 1.301 -1.543 0 C-N-CA 120.17 -0.612 . . . . 0.0 109.577 175.241 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.489 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 7.0 t30 -106.16 22.75 15.19 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 170.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.717 ' HB3' HD21 ' B' ' 63' ' ' LEU . 88.7 mt -69.91 -40.0 75.87 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.308 -0.87 . . . . 0.0 110.182 178.361 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.775 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -50.16 -21.67 4.27 Favored Glycine 0 N--CA 1.487 2.071 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -177.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.1 p-10 -69.22 -17.4 63.77 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.014 -1.286 . . . . 0.0 110.736 -173.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.507 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 95.8 mt -59.99 141.0 56.39 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.139 -0.975 . . . . 0.0 110.8 -176.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 1.019 ' C ' HD23 ' B' ' 12' ' ' LEU . 66.4 mttm -140.03 139.06 35.9 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 121.611 -0.681 . . . . 0.0 109.912 175.673 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.668 ' N ' HD23 ' B' ' 12' ' ' LEU . 22.1 t -61.11 152.76 5.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.036 -1.04 . . . . 0.0 110.43 -176.348 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.64 -15.83 57.95 Favored Glycine 0 N--CA 1.484 1.837 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 -176.072 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -97.49 169.63 9.6 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.345 -1.091 . . . . 0.0 109.582 175.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.574 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.3 m95 -117.23 166.52 12.16 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.104 -0.998 . . . . 0.0 110.05 177.389 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 1.039 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.3 p -128.65 157.54 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.41 -0.806 . . . . 0.0 110.054 -177.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.859 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.1 m-20 -83.48 104.53 13.7 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.307 -0.87 . . . . 0.0 109.263 170.775 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.686 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -107.38 139.55 28.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.468 -1.395 . . . . 0.0 111.17 -174.637 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . 0.456 ' HB2' HG22 ' B' ' 6' ' ' VAL . 85.2 tt0 -139.92 138.44 35.63 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 120.389 -0.525 . . . . 0.0 109.789 -178.645 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . 0.478 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 39.0 ptt180 -72.95 137.71 45.67 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.06 -1.025 . . . . 0.0 110.608 -174.09 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.784 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.162 -0.962 . . . . 0.0 109.825 173.764 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.655 HG21 ' HB3' ' A' ' 83' ' ' ASN . 3.4 t . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 121.624 0.726 . . . . 0.0 110.583 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 28.2 mm100 -98.48 -15.19 19.69 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.554 -0.716 . . . . 0.0 110.783 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.532 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -141.0 165.4 26.25 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.247 -1.454 . . . . 0.0 109.749 -177.595 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.488 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 0.7 OUTLIER -124.83 169.99 11.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.95 -1.324 . . . . 0.0 110.504 178.746 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 1.044 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -141.26 149.27 41.1 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.471 -0.768 . . . . 0.0 109.245 -176.525 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.579 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 32.1 tttt -109.65 114.13 27.48 Favored 'General case' 0 C--N 1.294 -1.839 0 O-C-N 121.091 -1.005 . . . . 0.0 110.175 178.852 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.994 HD23 ' C ' ' A' ' 77' ' ' LYS . 11.6 tp -59.69 127.86 34.11 Favored 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.061 -1.024 . . . . 0.0 108.903 175.137 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.072 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -128.31 -30.65 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.868 0 O-C-N 121.339 -0.851 . . . . 0.0 110.062 -178.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.35 141.97 30.08 Favored 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 119.088 -1.045 . . . . 0.0 111.284 -178.158 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.796 HD11 HG23 ' A' ' 78' ' ' VAL . 8.4 mt -110.04 132.89 57.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.098 -1.001 . . . . 0.0 110.362 172.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.514 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 88.5 m-20 -109.8 114.97 28.98 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.41 -0.806 . . . . 0.0 110.038 175.353 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -102.62 109.61 21.28 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.01 -1.056 . . . . 0.0 110.471 -177.402 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.3 OUTLIER -101.71 135.96 19.66 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.243 -0.91 . . . . 0.0 109.557 175.884 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -53.97 -16.92 9.83 Favored 'Trans proline' 0 C--N 1.302 -1.877 0 O-C-N 123.956 1.503 . . . . 0.0 110.853 -179.631 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.555 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 6.0 m-80 -102.7 -26.56 13.13 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.063 -1.023 . . . . 0.0 109.953 179.744 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.555 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 87.6 m-85 -156.69 150.24 24.52 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.428 -0.795 . . . . 0.0 109.919 -178.549 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.484 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 61.3 ttt180 -92.36 141.74 28.21 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.665 -1.272 . . . . 0.0 109.844 174.799 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.514 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 89.1 m -129.94 140.05 51.0 Favored 'General case' 0 C--N 1.295 -1.799 0 O-C-N 121.495 -0.753 . . . . 0.0 109.824 -172.677 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.717 ' NE2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -130.09 142.47 50.6 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 120.986 -1.071 . . . . 0.0 111.413 -179.286 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.826 HG22 ' CB ' ' A' ' 60' ' ' SER . 16.6 t -119.66 134.31 63.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.111 -0.993 . . . . 0.0 110.418 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.91 HG13 ' CE1' ' A' ' 61' ' ' PHE . 32.9 m -116.82 170.76 6.02 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 O-C-N 121.912 -0.492 . . . . 0.0 110.113 178.894 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.539 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 9.4 tt0 -102.65 116.64 33.0 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 179.401 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.499 HD23 ' HA ' ' A' ' 33' ' ' LEU . 8.7 tp -80.56 121.63 81.54 Favored Pre-proline 0 C--N 1.295 -1.771 0 O-C-N 121.493 -0.755 . . . . 0.0 109.653 -173.74 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.466 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 18.5 Cg_endo -63.42 178.84 1.07 Allowed 'Trans proline' 0 C--N 1.308 -1.583 0 O-C-N 123.874 1.46 . . . . 0.0 111.004 -179.112 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.527 ' HA ' HD12 ' A' ' 33' ' ' LEU . 88.3 m-20 -60.32 -39.91 88.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.373 -0.83 . . . . 0.0 111.102 -175.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.606 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.17 0.26 57.27 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.833 -1.167 . . . . 0.0 110.93 -175.553 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.606 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.1 mmm -109.12 -12.84 14.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.923 -1.11 . . . . 0.0 110.006 171.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.832 HD21 ' HB2' ' A' ' 57' ' ' ASN . 19.2 mt -68.8 -31.35 70.29 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.284 -0.885 . . . . 0.0 110.221 178.098 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 52.6 t0 -94.06 122.94 37.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.282 -0.886 . . . . 0.0 110.319 -178.315 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 111.42 -50.6 0.76 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 177.172 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.572 HD23 ' N ' ' A' ' 37' ' ' GLU . 6.7 tt -67.0 140.03 57.7 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.087 -1.243 . . . . 0.0 110.296 -176.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.572 ' N ' HD23 ' A' ' 36' ' ' LEU . 19.7 pt-20 -147.42 168.5 21.71 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.383 -0.823 . . . . 0.0 109.451 176.767 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.773 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -63.24 151.65 39.87 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.975 -1.078 . . . . 0.0 110.265 -175.885 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.52 -0.44 60.58 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -174.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.608 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -79.99 159.37 26.29 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.162 -1.199 . . . . 0.0 109.392 175.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.454 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.5 OUTLIER -103.19 117.54 34.77 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 118.849 -1.141 . . . . 0.0 110.155 177.068 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.642 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.6 t -102.37 128.28 55.21 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 121.335 -0.853 . . . . 0.0 108.907 172.476 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.51 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -92.88 119.68 32.44 Favored 'General case' 0 C--N 1.297 -1.689 0 C-N-CA 119.214 -0.995 . . . . 0.0 109.096 172.644 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.682 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -87.62 102.63 14.8 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 119.729 -0.789 . . . . 0.0 108.982 179.194 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.8 t-20 59.6 6.29 0.8 Allowed 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.685 -0.634 . . . . 0.0 111.681 -170.642 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.454 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 128.58 -1.04 6.42 Favored Glycine 0 N--CA 1.489 2.181 0 C-N-CA 119.525 -1.321 . . . . 0.0 110.655 174.352 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.677 ' O ' HD23 ' A' ' 49' ' ' LEU . 34.8 t -98.51 108.67 21.42 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.438 -1.624 . . . . 0.0 109.55 175.74 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 22.7 p -74.3 130.17 39.18 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.087 -1.008 . . . . 0.0 111.074 -171.351 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.841 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -147.02 153.82 40.48 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.429 -0.794 . . . . 0.0 109.356 173.901 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.424 HG22 ' N ' ' A' ' 51' ' ' VAL . 92.5 m -95.83 160.11 14.64 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.527 -1.358 . . . . 0.0 111.558 -169.118 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.925 HG13 HG13 ' A' ' 59' ' ' VAL . 15.8 t -82.08 114.72 23.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.847 -0.533 . . . . 0.0 110.358 -178.804 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.55 HG22 ' HB3' ' A' ' 62' ' ' ASP . 30.2 p -70.9 -39.94 72.47 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.322 -0.861 . . . . 0.0 109.977 175.137 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.571 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -166.19 154.2 10.47 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.31 -0.869 . . . . 0.0 110.177 179.677 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.773 HD11 ' N ' ' A' ' 38' ' ' THR . 9.8 mt -108.31 134.91 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.1 -1.0 . . . . 0.0 110.138 177.699 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.507 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 47.4 m-80 -108.81 66.23 0.63 Allowed 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.601 -0.687 . . . . 0.0 109.512 177.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.2 -116.84 5.11 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 -173.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.832 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.43 -20.19 51.57 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.055 -1.262 . . . . 0.0 109.116 177.012 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.072 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.9 m170 -76.61 158.92 30.72 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.241 -0.912 . . . . 0.0 110.044 -178.35 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.925 HG13 HG13 ' A' ' 51' ' ' VAL . 55.6 t -140.78 123.06 15.31 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 O-C-N 121.055 -1.028 . . . . 0.0 110.591 171.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.826 ' CB ' HG22 ' A' ' 25' ' ' VAL . 0.9 OUTLIER -87.5 133.32 33.78 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.47 -0.769 . . . . 0.0 109.13 175.264 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.91 ' CE1' HG13 ' A' ' 26' ' ' VAL . 1.8 p90 -125.96 156.01 40.46 Favored 'General case' 0 C--N 1.295 -1.79 0 O-C-N 121.378 -0.826 . . . . 0.0 110.185 178.038 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.55 ' HB3' HG22 ' A' ' 52' ' ' THR . 36.7 p-10 -90.78 151.16 21.31 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.089 -1.007 . . . . 0.0 111.398 -170.161 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.812 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -159.82 111.54 2.03 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 -175.574 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.525 ' HB2' ' CB ' ' A' ' 67' ' ' THR . 28.4 mtm -66.17 140.02 58.16 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.819 -1.176 . . . . 0.0 109.825 -179.848 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.498 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 49.3 tptt -60.11 -49.8 76.23 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.209 -0.932 . . . . 0.0 110.251 -178.411 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -65.2 -40.01 93.58 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.875 -1.141 . . . . 0.0 109.76 176.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.525 ' CB ' ' HB2' ' A' ' 64' ' ' MET . 94.3 m -60.05 -39.7 86.89 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.02 -1.05 . . . . 0.0 109.452 173.289 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.724 HD11 ' HA2' ' A' ' 74' ' ' GLY . 7.8 tp -59.95 -43.57 94.95 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.308 -0.87 . . . . 0.0 109.65 179.723 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -68.16 -40.01 82.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.38 -0.825 . . . . 0.0 110.579 176.042 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.853 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -64.9 -43.25 96.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.17 -0.956 . . . . 0.0 109.328 -177.108 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.853 HG23 HG22 ' A' ' 70' ' ' ILE . 29.9 p -86.68 -174.63 5.07 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.727 -0.608 . . . . 0.0 109.667 176.751 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.489 ' HB2' ' N ' ' B' ' 83' ' ' ASN . 6.1 t30 -98.78 22.59 9.87 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.167 -0.958 . . . . 0.0 108.686 171.469 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.812 ' HB3' HD21 ' A' ' 63' ' ' LEU . 91.8 mt -68.73 -39.98 80.12 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.095 -1.003 . . . . 0.0 109.975 176.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.724 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -50.44 -23.9 6.78 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -178.351 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.5 p-10 -62.12 -18.01 59.53 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.089 -1.242 . . . . 0.0 110.233 -175.764 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.9 mt -63.62 142.09 58.53 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.319 -0.863 . . . . 0.0 110.961 -177.69 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 0.994 ' C ' HD23 ' A' ' 12' ' ' LEU . 42.8 mttt -143.54 144.84 32.13 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-O 121.311 0.577 . . . . 0.0 109.731 175.106 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.796 HG23 HD11 ' A' ' 15' ' ' ILE . 21.9 t -64.52 149.93 10.7 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 120.843 -1.161 . . . . 0.0 110.479 -175.327 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.97 -13.63 60.78 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -175.144 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 46.6 t0 -94.61 163.3 13.44 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.337 -1.096 . . . . 0.0 109.585 176.021 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.579 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 13.9 m95 -113.28 154.79 26.23 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 120.964 -1.085 . . . . 0.0 110.155 175.829 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.044 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.4 p -119.99 153.03 22.82 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.437 -0.789 . . . . 0.0 109.852 -179.019 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.655 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.4 OUTLIER -77.73 107.34 10.16 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.171 -0.955 . . . . 0.0 109.02 168.475 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.758 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -109.4 138.85 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 120.474 -1.391 . . . . 0.0 111.364 -176.724 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.481 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.6 tt0 -131.49 139.59 49.35 Favored 'General case' 0 N--CA 1.494 1.749 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.131 -179.369 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -81.37 133.62 35.44 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.091 -1.006 . . . . 0.0 110.94 -175.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.454 ' O ' ' OG ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.736 0 O-C-N 121.28 -0.888 . . . . 0.0 110.639 179.809 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 0.653 HG21 ' HB3' ' B' ' 83' ' ' ASN . 3.4 t . . . . . 0 N--CA 1.489 1.491 0 CA-C-O 121.54 0.686 . . . . 0.0 110.583 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 28.2 mm100 -98.55 -14.83 19.77 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.54 -0.725 . . . . 0.0 110.854 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.529 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -141.28 165.14 26.42 Favored Glycine 0 N--CA 1.493 2.458 0 C-N-CA 119.338 -1.41 . . . . 0.0 109.868 -177.536 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.487 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 0.7 OUTLIER -124.74 169.99 11.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.123 -1.221 . . . . 0.0 110.556 178.821 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.023 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -141.31 149.34 41.1 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.507 -0.745 . . . . 0.0 109.235 -176.617 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 32.0 tttt -109.7 114.34 27.86 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.151 -0.968 . . . . 0.0 110.014 178.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 1.001 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.7 tp -60.02 127.78 33.57 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.104 -0.998 . . . . 0.0 108.939 175.106 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.084 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.96 -31.04 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 O-C-N 121.393 -0.817 . . . . 0.0 110.1 -178.651 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.08 141.9 30.32 Favored 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.328 -178.082 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.82 HD11 HG23 ' B' ' 78' ' ' VAL . 8.4 mt -109.91 132.96 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.128 -0.982 . . . . 0.0 110.377 172.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.519 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 88.2 m-20 -109.99 114.98 28.95 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.416 -0.803 . . . . 0.0 109.995 175.388 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -102.59 109.67 21.36 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.982 -1.074 . . . . 0.0 110.497 -177.399 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.3 OUTLIER -101.87 135.95 19.62 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.274 -0.892 . . . . 0.0 109.541 175.943 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.05 -16.85 9.97 Favored 'Trans proline' 0 C--N 1.303 -1.837 0 O-C-N 123.934 1.492 . . . . 0.0 110.856 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.547 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 6.0 m-80 -102.56 -26.98 13.03 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.107 -0.996 . . . . 0.0 109.874 179.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.547 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 87.5 m-85 -156.3 150.22 25.08 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.432 -0.793 . . . . 0.0 109.972 -178.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . 0.487 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 61.2 ttt180 -92.31 141.67 28.3 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.701 -1.25 . . . . 0.0 109.806 174.786 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.519 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 88.4 m -129.96 140.12 50.97 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 121.617 -0.677 . . . . 0.0 109.798 -172.715 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.729 ' NE2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -130.05 142.45 50.61 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 120.964 -1.085 . . . . 0.0 111.338 -179.158 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.835 HG22 ' CB ' ' B' ' 60' ' ' SER . 16.3 t -119.51 134.41 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.264 -0.898 . . . . 0.0 110.435 179.55 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.911 HG13 ' CE1' ' B' ' 61' ' ' PHE . 33.1 m -117.09 170.76 6.21 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 CA-C-O 121.263 0.554 . . . . 0.0 109.955 178.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.522 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 9.3 tt0 -102.56 116.68 33.08 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.345 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.498 ' HA ' HD12 ' B' ' 28' ' ' LEU . 8.7 tp -80.54 121.62 81.56 Favored Pre-proline 0 C--N 1.297 -1.703 0 O-C-N 121.433 -0.792 . . . . 0.0 109.716 -173.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.478 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 18.5 Cg_endo -63.4 178.86 1.06 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 O-C-N 123.91 1.479 . . . . 0.0 111.007 -179.09 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.516 ' HA ' HD12 ' B' ' 33' ' ' LEU . 88.1 m-20 -60.29 -39.98 88.85 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.356 -0.84 . . . . 0.0 111.118 -175.827 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.588 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.11 0.28 57.23 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.87 -1.144 . . . . 0.0 110.945 -175.609 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.588 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.1 mmm -109.16 -12.81 14.77 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.87 -1.144 . . . . 0.0 109.93 171.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.833 HD21 ' HB2' ' B' ' 57' ' ' ASN . 19.2 mt -68.88 -31.32 70.17 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.226 -0.921 . . . . 0.0 110.22 178.054 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -93.99 122.95 37.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.381 -0.824 . . . . 0.0 110.363 -178.38 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 111.43 -50.65 0.75 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.061 -1.215 . . . . 0.0 110.061 177.166 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.576 HD23 ' N ' ' B' ' 37' ' ' GLU . 6.7 tt -66.97 140.02 57.72 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.051 -1.264 . . . . 0.0 110.299 -176.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . 0.576 ' N ' HD23 ' B' ' 36' ' ' LEU . 19.7 pt-20 -147.38 168.55 21.54 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.401 -0.812 . . . . 0.0 109.41 176.673 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 0.783 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -63.33 151.51 40.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.995 -1.066 . . . . 0.0 110.382 -175.949 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.73 -0.48 61.32 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -174.658 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.607 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -80.07 159.34 26.18 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.141 -1.211 . . . . 0.0 109.382 175.816 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.451 ' OG ' ' O ' ' B' ' 87' ' ' ALA . 0.5 OUTLIER -102.99 117.33 34.36 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.782 -1.199 . . . . 0.0 110.309 177.03 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.635 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.7 t -102.27 128.43 54.93 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 121.357 -0.839 . . . . 0.0 108.868 172.5 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -92.97 119.74 32.55 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 119.227 -0.989 . . . . 0.0 108.988 172.617 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.684 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -87.72 102.45 14.65 Favored 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.54 -0.864 . . . . 0.0 109.098 179.106 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 59.84 6.38 0.89 Allowed 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.554 -0.716 . . . . 0.0 111.549 -170.688 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.454 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 128.38 -0.62 6.46 Favored Glycine 0 N--CA 1.489 2.218 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.714 174.228 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.694 ' O ' HD23 ' B' ' 49' ' ' LEU . 34.6 t -98.63 108.61 21.34 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.502 -1.587 . . . . 0.0 109.537 175.552 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 22.9 p -74.19 130.19 39.27 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.058 -1.026 . . . . 0.0 111.043 -171.429 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 0.856 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -147.11 153.92 40.5 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.527 -0.733 . . . . 0.0 109.359 173.726 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . 0.421 HG22 ' N ' ' B' ' 51' ' ' VAL . 92.9 m -95.9 160.41 14.48 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 120.527 -1.358 . . . . 0.0 111.556 -169.085 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.946 HG13 HG13 ' B' ' 59' ' ' VAL . 16.1 t -82.44 114.65 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.84 -0.538 . . . . 0.0 110.433 -178.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.542 HG22 ' HB3' ' B' ' 62' ' ' ASP . 30.2 p -70.71 -40.03 73.07 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.272 -0.893 . . . . 0.0 109.918 175.339 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.574 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -166.21 154.11 10.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.202 -0.936 . . . . 0.0 110.208 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.783 HD11 ' N ' ' B' ' 38' ' ' THR . 9.8 mt -108.31 134.89 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.114 -0.991 . . . . 0.0 110.206 177.684 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.515 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 47.1 m-80 -108.84 66.14 0.63 Allowed 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.64 -0.662 . . . . 0.0 109.522 177.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.32 -116.81 5.08 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 108.861 -1.696 . . . . 0.0 108.861 -173.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.833 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.44 -20.29 51.35 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.075 -1.25 . . . . 0.0 109.151 177.054 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.084 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.9 m170 -76.5 158.79 30.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.347 -0.846 . . . . 0.0 110.097 -178.375 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.946 HG13 HG13 ' B' ' 51' ' ' VAL . 55.8 t -140.76 123.15 15.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 C-N-CA 119.076 -1.05 . . . . 0.0 110.519 171.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.835 ' CB ' HG22 ' B' ' 25' ' ' VAL . 0.9 OUTLIER -87.52 133.3 33.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.441 -0.787 . . . . 0.0 109.204 175.225 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.911 ' CE1' HG13 ' B' ' 26' ' ' VAL . 1.8 p90 -125.98 155.99 40.53 Favored 'General case' 0 N--CA 1.494 1.773 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.177 178.033 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.542 ' HB3' HG22 ' B' ' 52' ' ' THR . 36.6 p-10 -90.67 151.19 21.37 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.0 -1.062 . . . . 0.0 111.381 -170.115 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.784 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.82 111.53 2.03 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -175.638 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.528 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 28.5 mtm -66.22 139.96 58.13 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.888 -1.133 . . . . 0.0 109.824 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.499 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 49.3 tptt -59.92 -49.87 76.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.131 -0.98 . . . . 0.0 110.3 -178.439 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -65.24 -39.99 93.42 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.913 -1.117 . . . . 0.0 109.765 176.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.528 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 94.5 m -60.01 -39.83 87.19 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.988 -1.07 . . . . 0.0 109.342 173.29 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.717 HD11 ' HA2' ' B' ' 74' ' ' GLY . 7.8 tp -59.94 -43.45 94.97 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.293 -0.879 . . . . 0.0 109.707 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 78.5 ttt180 -68.21 -40.08 82.21 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.293 -0.879 . . . . 0.0 110.603 175.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.831 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -64.75 -43.24 96.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.195 -0.941 . . . . 0.0 109.434 -177.213 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.831 HG23 HG22 ' B' ' 70' ' ' ILE . 30.0 p -86.65 -174.56 5.04 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 120.231 -0.588 . . . . 0.0 109.658 176.774 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.506 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 6.0 t30 -98.71 22.57 9.84 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.19 -0.944 . . . . 0.0 108.78 171.393 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.784 ' HB3' HD21 ' B' ' 63' ' ' LEU . 91.4 mt -68.71 -40.0 80.17 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.075 -1.015 . . . . 0.0 110.05 176.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.717 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -50.46 -23.87 6.78 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 -178.384 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.0 p-10 -62.1 -17.94 59.23 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.062 -1.258 . . . . 0.0 110.295 -175.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.513 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.1 mt -63.68 142.22 58.48 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.287 -0.883 . . . . 0.0 110.929 -177.746 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 1.001 ' C ' HD23 ' B' ' 12' ' ' LEU . 42.8 mttt -143.67 144.95 32.1 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.627 -0.671 . . . . 0.0 109.665 175.13 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.82 HG23 HD11 ' B' ' 15' ' ' ILE . 22.2 t -64.73 150.03 10.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 O-C-N 120.856 -1.153 . . . . 0.0 110.341 -175.182 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.8 -13.45 60.89 Favored Glycine 0 N--CA 1.484 1.84 0 N-CA-C 108.848 -1.701 . . . . 0.0 108.848 -175.16 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 46.2 t0 -94.62 163.23 13.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.319 -1.106 . . . . 0.0 109.59 175.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.584 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 13.9 m95 -113.31 154.73 26.37 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.97 -1.081 . . . . 0.0 110.215 175.782 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 1.023 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.4 p -119.98 153.1 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.579 -0.701 . . . . 0.0 109.881 -179.082 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.653 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.3 OUTLIER -77.72 107.27 10.09 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.178 -0.951 . . . . 0.0 109.018 168.569 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.765 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -109.32 138.96 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 120.462 -1.399 . . . . 0.0 111.211 -176.533 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . 0.465 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.7 tt0 -131.58 139.68 49.25 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.883 -0.511 . . . . 0.0 110.144 -179.569 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -81.35 133.69 35.46 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.117 -0.99 . . . . 0.0 110.916 -175.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.451 ' O ' ' OG ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.496 1.844 0 O-C-N 121.403 -0.81 . . . . 0.0 110.647 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.954 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.5 t . . . . . 0 N--CA 1.493 1.708 0 CA-C-O 121.557 0.694 . . . . 0.0 110.638 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 20.1 pt20 -89.64 -16.15 31.13 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.453 -0.779 . . . . 0.0 110.829 -178.426 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -158.45 177.12 35.25 Favored Glycine 0 N--CA 1.493 2.484 0 C-N-CA 119.129 -1.51 . . . . 0.0 110.083 -177.522 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.487 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 1.4 p -125.87 167.97 14.51 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.069 -1.254 . . . . 0.0 110.472 178.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 1.07 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -139.93 149.64 43.57 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.346 -0.846 . . . . 0.0 109.903 -174.283 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.585 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 31.2 tttt -106.26 116.01 31.21 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.126 -0.984 . . . . 0.0 110.169 179.255 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.998 HD23 ' C ' ' A' ' 77' ' ' LYS . 13.1 tp -59.93 128.03 34.84 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.793 -1.192 . . . . 0.0 108.582 171.676 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.145 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.7 p -131.34 -31.01 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 O-C-N 121.262 -0.898 . . . . 0.0 110.316 -176.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -144.34 139.68 28.65 Favored 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 118.936 -1.106 . . . . 0.0 111.39 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.736 HG23 ' CD2' ' A' ' 24' ' ' HIS . 9.9 mt -109.16 137.0 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.052 -1.03 . . . . 0.0 110.08 171.366 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.478 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 78.7 m-20 -111.86 114.35 27.25 Favored 'General case' 0 C--N 1.295 -1.79 0 O-C-N 121.415 -0.803 . . . . 0.0 110.182 173.028 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -105.04 118.61 36.97 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.033 -1.042 . . . . 0.0 110.492 -177.443 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.44 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.9 mtpp -118.26 140.18 27.74 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.256 -0.902 . . . . 0.0 109.779 178.876 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -55.1 -15.2 10.03 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 O-C-N 124.067 1.562 . . . . 0.0 110.964 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.586 ' ND2' ' N ' ' A' ' 20' ' ' ASN . 0.1 OUTLIER -107.61 -25.25 11.42 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.999 -1.063 . . . . 0.0 109.308 -177.892 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.568 ' CD1' ' O ' ' A' ' 20' ' ' ASN . 75.8 m-85 -157.74 150.3 22.71 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.622 -0.674 . . . . 0.0 110.105 179.337 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.498 ' HD3' HD22 ' A' ' 68' ' ' LEU . 63.6 ttt180 -96.77 143.32 27.8 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 120.815 -1.178 . . . . 0.0 110.012 172.614 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.478 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 54.4 m -130.91 140.18 50.17 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.488 -0.758 . . . . 0.0 110.145 -173.414 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.736 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -130.14 143.86 51.03 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 120.94 -1.1 . . . . 0.0 111.604 178.805 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.859 HG22 ' OG ' ' A' ' 60' ' ' SER . 8.3 t -125.77 136.1 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.158 -0.964 . . . . 0.0 110.651 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 35.4 m -117.67 171.74 5.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 121.783 -0.573 . . . . 0.0 110.211 178.228 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.561 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 3.6 tt0 -104.25 117.31 33.92 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.218 -0.926 . . . . 0.0 109.247 -178.772 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.562 HD21 ' O ' ' A' ' 32' ' ' MET . 9.6 tp -82.81 125.87 74.4 Favored Pre-proline 0 C--N 1.299 -1.621 0 O-C-N 121.585 -0.697 . . . . 0.0 110.106 -173.641 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.54 ' HD2' HD12 ' A' ' 28' ' ' LEU . 28.2 Cg_endo -67.04 176.94 4.01 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 123.886 1.466 . . . . 0.0 111.069 -179.627 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.67 ' HA ' HD12 ' A' ' 33' ' ' LEU . 92.6 m-20 -60.03 -40.0 87.84 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.239 -0.913 . . . . 0.0 111.306 -174.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.595 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.99 0.64 56.99 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.751 -1.218 . . . . 0.0 110.907 -174.472 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.595 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.8 mmm -112.17 -8.57 13.99 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.875 -1.141 . . . . 0.0 110.006 170.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.696 HD21 ' HB2' ' A' ' 57' ' ' ASN . 16.0 mt -70.03 -40.01 75.42 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.224 -0.922 . . . . 0.0 109.915 177.065 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -81.74 128.81 34.38 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.594 -0.691 . . . . 0.0 110.486 -178.246 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.47 -46.18 1.21 Allowed Glycine 0 N--CA 1.493 2.445 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.256 174.795 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.7 HD23 ' N ' ' A' ' 37' ' ' GLU . 6.8 tt -69.7 148.84 48.71 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.93 -1.335 . . . . 0.0 110.445 -175.365 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.7 ' N ' HD23 ' A' ' 36' ' ' LEU . 21.3 pt-20 -150.62 170.02 20.16 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.367 -0.833 . . . . 0.0 109.397 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.717 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -70.06 151.15 45.84 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.058 -1.026 . . . . 0.0 110.228 -178.919 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.09 -3.3 66.2 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -174.183 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.453 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -77.99 161.48 27.46 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.27 -1.135 . . . . 0.0 109.661 177.612 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.476 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.6 OUTLIER -101.64 114.95 29.46 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.016 -1.052 . . . . 0.0 110.104 177.354 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.626 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.8 t -103.16 128.88 55.76 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.323 -0.861 . . . . 0.0 109.157 174.06 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -94.8 120.08 34.43 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.269 -0.972 . . . . 0.0 109.265 173.043 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.863 ' CD2' HG21 ' A' ' 82' ' ' VAL . 1.4 m80 -90.71 106.19 18.34 Favored 'General case' 0 C--N 1.301 -1.503 0 C-N-CA 119.676 -0.81 . . . . 0.0 109.054 177.568 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.494 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.8 t-20 53.92 14.81 0.72 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.338 -0.851 . . . . 0.0 110.925 -167.02 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.512 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 117.78 -0.5 17.73 Favored Glycine 0 N--CA 1.489 2.17 0 C-N-CA 119.623 -1.275 . . . . 0.0 110.978 170.559 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.833 ' O ' HD23 ' A' ' 49' ' ' LEU . 43.4 t -92.35 106.84 18.76 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.49 -1.594 . . . . 0.0 109.151 173.525 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.8 p -75.49 128.66 35.8 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.15 -0.969 . . . . 0.0 110.749 -170.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.833 HD23 ' O ' ' A' ' 47' ' ' CYS . 0.3 OUTLIER -143.14 159.66 41.88 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.442 -0.786 . . . . 0.0 109.714 175.296 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.421 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 28.9 m -100.16 149.82 23.14 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.576 -1.328 . . . . 0.0 111.409 -170.781 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.836 HG13 HG13 ' A' ' 59' ' ' VAL . 15.1 t -78.06 118.39 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 CA-C-O 121.155 0.502 . . . . 0.0 110.617 -178.002 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 42.9 p -73.89 -39.94 63.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.126 -0.984 . . . . 0.0 110.031 174.494 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.658 ' HA ' HG21 ' A' ' 38' ' ' THR . 86.6 tt0 -163.4 149.85 12.07 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.35 -0.844 . . . . 0.0 110.214 -178.007 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.717 HD11 ' N ' ' A' ' 38' ' ' THR . 5.7 mt -101.51 134.9 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.09 -1.007 . . . . 0.0 109.955 176.148 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.496 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 49.9 m-80 -110.45 65.78 0.62 Allowed 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.571 -0.705 . . . . 0.0 109.913 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.19 -118.68 4.99 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.879 -1.688 . . . . 0.0 108.879 -175.236 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.696 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.62 -16.39 57.41 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 120.949 -1.324 . . . . 0.0 108.816 174.307 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.145 ' CD2' HG11 ' A' ' 13' ' ' VAL . 11.8 m170 -76.6 159.81 29.96 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.37 -0.831 . . . . 0.0 110.39 -178.192 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.836 HG13 HG13 ' A' ' 51' ' ' VAL . 52.2 t -140.3 127.02 22.42 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 O-C-N 121.02 -1.05 . . . . 0.0 110.596 170.036 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.859 ' OG ' HG22 ' A' ' 25' ' ' VAL . 2.7 t -95.8 136.74 35.83 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.474 -0.767 . . . . 0.0 109.564 178.382 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.807 ' HB2' HD12 ' A' ' 49' ' ' LEU . 2.0 p90 -128.06 157.78 39.76 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.864 173.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.533 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 25.0 p-10 -89.48 157.64 18.02 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.31 -0.869 . . . . 0.0 111.129 -171.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.746 HD22 ' CD1' ' A' ' 68' ' ' LEU . 0.1 OUTLIER -159.94 102.57 1.47 Allowed 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 120.035 -0.666 . . . . 0.0 109.461 -175.441 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.501 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 56.3 ttm -59.75 140.4 56.54 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.002 -1.062 . . . . 0.0 109.364 -179.557 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.457 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 39.4 ttpt -60.01 -43.32 95.31 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.022 -1.049 . . . . 0.0 110.285 -175.159 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.74 -39.99 76.43 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.02 -1.05 . . . . 0.0 110.067 178.279 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.501 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 92.2 m -60.56 -39.96 89.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.978 -1.076 . . . . 0.0 109.184 172.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.746 ' CD1' HD22 ' A' ' 63' ' ' LEU . 7.3 tp -59.94 -45.4 92.74 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.285 -0.885 . . . . 0.0 109.782 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 15.0 tpp180 -69.21 -39.59 78.51 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.529 -0.732 . . . . 0.0 110.47 177.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.857 HG22 HG23 ' A' ' 71' ' ' THR . 1.4 tt -63.68 -43.98 98.27 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.13 -0.982 . . . . 0.0 109.368 -177.47 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.857 HG23 HG22 ' A' ' 70' ' ' ILE . 37.8 p -83.55 -170.51 3.1 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.404 0.621 . . . . 0.0 109.703 178.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.5 t30 -103.28 22.63 13.79 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 170.187 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.72 ' HB3' HD21 ' A' ' 63' ' ' LEU . 89.4 mt -69.54 -41.23 76.22 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.158 -0.964 . . . . 0.0 109.999 176.731 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.73 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -51.01 -20.81 4.75 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 -178.163 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.1 p-10 -67.43 -18.5 65.12 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.927 -1.337 . . . . 0.0 110.673 -174.003 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.517 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 90.2 mt -60.89 142.86 55.92 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.166 -0.959 . . . . 0.0 110.983 -175.476 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 0.998 ' C ' HD23 ' A' ' 12' ' ' LEU . 98.7 mttt -140.34 139.53 35.43 Favored 'General case' 0 N--CA 1.493 1.695 0 CA-C-O 121.537 0.684 . . . . 0.0 109.955 173.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.706 ' N ' HD23 ' A' ' 12' ' ' LEU . 15.4 t -63.19 153.47 6.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 120.868 -1.145 . . . . 0.0 110.636 -174.45 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.0 -16.93 55.83 Favored Glycine 0 N--CA 1.485 1.928 0 N-CA-C 108.645 -1.782 . . . . 0.0 108.645 -175.134 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -95.14 170.09 9.64 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.402 -1.058 . . . . 0.0 109.743 175.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.585 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.5 m95 -116.97 169.51 9.35 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.965 -1.085 . . . . 0.0 110.17 176.013 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.07 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.4 p -134.09 155.63 39.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 121.438 -0.789 . . . . 0.0 109.808 -176.669 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.954 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.1 m-20 -79.57 109.12 13.66 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.006 -1.059 . . . . 0.0 109.134 168.668 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.783 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -110.78 138.59 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 120.43 -1.419 . . . . 0.0 111.275 -175.546 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -134.35 145.03 48.62 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.864 -0.522 . . . . 0.0 110.292 -177.244 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 36.1 ttm180 -83.49 130.65 35.02 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.311 -0.868 . . . . 0.0 111.027 -176.679 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.476 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.25 -0.906 . . . . 0.0 110.023 174.737 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 0.992 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.5 t . . . . . 0 N--CA 1.493 1.685 0 CA-C-O 121.477 0.656 . . . . 0.0 110.727 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 20.1 pt20 -89.72 -15.84 31.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.374 -0.828 . . . . 0.0 110.887 -178.418 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.525 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -158.8 177.0 35.59 Favored Glycine 0 N--CA 1.494 2.552 0 C-N-CA 119.143 -1.503 . . . . 0.0 110.113 -177.495 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.486 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 1.4 p -125.88 167.92 14.58 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.088 -1.243 . . . . 0.0 110.42 179.103 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.092 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -139.84 149.77 43.85 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.278 -0.889 . . . . 0.0 109.88 -174.399 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.583 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 31.2 tttt -106.35 116.04 31.25 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.081 -1.012 . . . . 0.0 110.141 179.201 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 0.998 HD23 ' C ' ' B' ' 77' ' ' LYS . 13.1 tp -60.06 128.03 34.82 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.828 -1.17 . . . . 0.0 108.671 171.634 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.145 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.7 p -131.41 -30.86 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.31 -176.711 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -144.46 139.8 28.55 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.12 -1.032 . . . . 0.0 111.348 179.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.742 HG23 ' CD2' ' B' ' 24' ' ' HIS . 10.3 mt -109.32 136.98 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.078 -1.013 . . . . 0.0 110.06 171.4 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.495 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 78.6 m-20 -111.97 114.5 27.44 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 121.44 -0.787 . . . . 0.0 110.159 173.039 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -104.96 118.74 37.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.188 -0.945 . . . . 0.0 110.493 -177.435 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.436 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.9 mtpp -118.39 140.3 27.99 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.29 -0.881 . . . . 0.0 109.771 178.838 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -55.39 -15.11 10.81 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 124.008 1.53 . . . . 0.0 110.967 -179.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.571 ' O ' ' CD1' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -107.28 -25.9 11.28 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.01 -1.056 . . . . 0.0 109.214 -177.946 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.571 ' CD1' ' O ' ' B' ' 20' ' ' ASN . 75.3 m-85 -157.2 150.36 23.79 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.534 -0.729 . . . . 0.0 110.195 179.499 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . 0.478 ' HD3' HD22 ' B' ' 68' ' ' LEU . 63.7 ttt180 -96.8 143.21 27.93 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.914 -1.117 . . . . 0.0 109.944 172.616 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.495 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 54.0 m -130.76 140.21 50.29 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.638 -0.664 . . . . 0.0 110.134 -173.492 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.742 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -130.04 143.94 51.06 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.005 -1.06 . . . . 0.0 111.492 178.806 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.867 HG22 ' OG ' ' B' ' 60' ' ' SER . 8.2 t -125.7 136.3 61.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.317 -0.864 . . . . 0.0 110.764 179.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.469 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 35.6 m -117.91 171.78 5.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.744 -0.598 . . . . 0.0 110.126 178.355 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.567 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 3.6 tt0 -104.18 117.45 34.28 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.274 -0.891 . . . . 0.0 109.199 -178.786 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.55 HD21 ' O ' ' B' ' 32' ' ' MET . 9.6 tp -82.9 125.8 74.37 Favored Pre-proline 0 C--N 1.299 -1.613 0 O-C-N 121.545 -0.722 . . . . 0.0 110.129 -173.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.539 ' HD2' HD12 ' B' ' 28' ' ' LEU . 28.1 Cg_endo -67.01 176.96 3.97 Favored 'Trans proline' 0 C--N 1.31 -1.491 0 O-C-N 123.919 1.484 . . . . 0.0 110.934 -179.583 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.656 ' HA ' HD12 ' B' ' 33' ' ' LEU . 92.6 m-20 -60.01 -39.99 87.72 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.309 -0.869 . . . . 0.0 111.35 -174.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.584 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.01 0.63 57.0 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.761 -1.212 . . . . 0.0 110.844 -174.434 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.584 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.8 mmm -112.19 -8.58 13.98 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.856 -1.153 . . . . 0.0 110.006 170.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.715 HD21 ' HB2' ' B' ' 57' ' ' ASN . 16.0 mt -70.0 -40.04 75.52 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.268 -0.895 . . . . 0.0 109.888 177.07 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -81.7 128.93 34.49 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.597 -0.689 . . . . 0.0 110.508 -178.273 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.35 -46.15 1.21 Allowed Glycine 0 N--CA 1.492 2.414 0 C-N-CA 119.868 -1.158 . . . . 0.0 110.328 174.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.705 HD23 ' N ' ' B' ' 37' ' ' GLU . 6.8 tt -69.66 148.89 48.71 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.95 -1.324 . . . . 0.0 110.43 -175.402 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . 0.705 ' N ' HD23 ' B' ' 36' ' ' LEU . 21.4 pt-20 -150.68 169.95 20.36 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.347 -0.845 . . . . 0.0 109.51 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 0.72 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -69.99 151.12 45.94 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.038 -1.039 . . . . 0.0 110.252 -178.855 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.17 -3.5 65.96 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 -174.209 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.453 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -77.91 161.36 27.62 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.297 -1.119 . . . . 0.0 109.701 177.521 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.48 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.6 OUTLIER -101.43 114.82 29.17 Favored 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 119.096 -1.042 . . . . 0.0 110.18 177.35 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.644 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.8 t -103.12 129.01 55.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.379 -0.826 . . . . 0.0 109.141 174.068 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -94.87 120.05 34.45 Favored 'General case' 0 C--N 1.298 -1.651 0 C-N-CA 119.245 -0.982 . . . . 0.0 109.214 173.044 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.857 ' CD2' HG21 ' B' ' 82' ' ' VAL . 1.4 m80 -90.69 106.15 18.31 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.403 -0.811 . . . . 0.0 109.074 177.478 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.496 ' OD1' ' HB2' ' A' ' 47' ' ' CYS . 1.8 t-20 54.01 14.84 0.75 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.368 -0.833 . . . . 0.0 110.858 -167.157 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.512 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 117.66 -0.3 17.98 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.715 -1.231 . . . . 0.0 111.031 170.438 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.857 ' O ' HD23 ' B' ' 49' ' ' LEU . 43.1 t -92.38 106.9 18.8 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.411 -1.641 . . . . 0.0 109.134 173.395 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 17.8 p -75.45 128.75 36.04 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.097 -1.002 . . . . 0.0 110.684 -170.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 0.857 HD23 ' O ' ' B' ' 47' ' ' CYS . 0.3 OUTLIER -143.29 159.64 41.97 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.416 -0.803 . . . . 0.0 109.61 175.259 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . 0.42 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 29.4 m -100.02 150.01 22.88 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.673 -1.267 . . . . 0.0 111.329 -170.74 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.816 HG13 HG13 ' B' ' 59' ' ' VAL . 15.4 t -78.38 118.46 25.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.827 -0.546 . . . . 0.0 110.607 -178.027 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.532 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 43.0 p -73.89 -40.01 63.49 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.201 -0.937 . . . . 0.0 110.037 174.629 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.666 ' HA ' HG21 ' B' ' 38' ' ' THR . 86.6 tt0 -163.32 149.83 12.19 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.336 -0.852 . . . . 0.0 110.206 -177.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.72 HD11 ' N ' ' B' ' 38' ' ' THR . 5.7 mt -101.52 134.79 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.096 -1.002 . . . . 0.0 109.993 176.148 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.515 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 49.7 m-80 -110.41 65.78 0.62 Allowed 'General case' 0 C--N 1.298 -1.634 0 C-N-CA 119.857 -0.737 . . . . 0.0 109.907 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.31 -118.75 4.99 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 108.809 -1.717 . . . . 0.0 108.809 -175.26 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.715 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.55 -16.54 57.32 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.969 -1.312 . . . . 0.0 108.901 174.302 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.145 ' CD2' HG11 ' B' ' 13' ' ' VAL . 11.8 m170 -76.51 159.63 30.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.491 -0.756 . . . . 0.0 110.347 -178.2 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.816 HG13 HG13 ' B' ' 51' ' ' VAL . 52.1 t -140.15 127.1 23.14 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 C-N-CA 119.042 -1.063 . . . . 0.0 110.554 170.054 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.867 ' OG ' HG22 ' B' ' 25' ' ' VAL . 2.7 t -95.81 136.85 35.69 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.575 -0.703 . . . . 0.0 109.616 178.307 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.81 ' HB2' HD12 ' B' ' 49' ' ' LEU . 2.0 p90 -128.11 157.63 40.2 Favored 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 119.054 -1.058 . . . . 0.0 110.876 174.065 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.532 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 25.3 p-10 -89.47 157.76 17.98 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.297 -0.877 . . . . 0.0 111.056 -171.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.749 HD22 ' CD1' ' B' ' 68' ' ' LEU . 0.1 OUTLIER -159.96 102.54 1.47 Allowed 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.958 -0.697 . . . . 0.0 109.445 -175.428 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.499 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 56.1 ttm -59.77 140.36 56.58 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.117 -0.989 . . . . 0.0 109.381 -179.501 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.456 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 39.4 ttpt -59.98 -43.38 95.15 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.042 -1.036 . . . . 0.0 110.242 -175.094 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.72 -40.04 76.47 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.049 -1.032 . . . . 0.0 110.083 178.297 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.499 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 92.2 m -60.58 -39.97 90.02 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.95 -1.094 . . . . 0.0 109.14 173.016 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.749 ' CD1' HD22 ' B' ' 63' ' ' LEU . 7.3 tp -60.0 -45.17 93.61 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.375 -0.828 . . . . 0.0 109.892 179.3 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 15.0 tpp180 -69.33 -39.41 78.21 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.547 -0.72 . . . . 0.0 110.493 177.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.852 HG22 HG23 ' B' ' 71' ' ' THR . 1.4 tt -63.85 -43.88 97.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.177 -0.952 . . . . 0.0 109.365 -177.427 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.852 HG23 HG22 ' B' ' 70' ' ' ILE . 37.3 p -83.44 -170.42 3.04 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 121.433 0.635 . . . . 0.0 109.805 178.529 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.492 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 4.3 t30 -103.33 22.58 13.91 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 170.176 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.704 ' HB3' HD21 ' B' ' 63' ' ' LEU . 89.3 mt -69.55 -41.16 76.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.228 -0.92 . . . . 0.0 110.091 176.689 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.731 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -51.01 -20.8 4.73 Favored Glycine 0 N--CA 1.487 2.099 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -178.23 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.1 p-10 -67.55 -18.41 65.01 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.998 -1.295 . . . . 0.0 110.706 -173.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.514 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 90.3 mt -60.92 142.82 56.07 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.077 -1.015 . . . . 0.0 110.947 -175.513 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 0.998 ' C ' HD23 ' B' ' 12' ' ' LEU . 98.7 mttt -140.32 139.74 35.49 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.682 -0.636 . . . . 0.0 109.854 173.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.714 HG23 HD11 ' B' ' 15' ' ' ILE . 16.2 t -63.4 153.45 7.01 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.12 -0.987 . . . . 0.0 110.625 -174.399 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.02 -16.68 56.48 Favored Glycine 0 N--CA 1.484 1.874 0 N-CA-C 108.687 -1.765 . . . . 0.0 108.687 -175.285 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 24.9 t0 -95.13 169.95 9.74 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.374 -1.074 . . . . 0.0 109.808 175.615 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.583 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.5 m95 -116.98 169.42 9.42 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.034 -1.041 . . . . 0.0 110.139 176.022 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 1.092 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.4 p -133.96 155.7 40.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.539 -0.726 . . . . 0.0 109.908 -176.824 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.992 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.0 m-20 -79.5 108.91 13.39 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.074 -1.016 . . . . 0.0 109.245 168.692 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.754 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -110.45 138.87 36.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 120.458 -1.401 . . . . 0.0 111.183 -175.393 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -134.73 145.08 48.13 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.856 -0.527 . . . . 0.0 110.128 -177.364 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 36.2 ttm180 -83.43 130.67 35.04 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.26 -0.9 . . . . 0.0 110.987 -176.675 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.48 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.493 1.715 0 O-C-N 121.279 -0.888 . . . . 0.0 109.965 174.666 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 1.025 HG21 ' HB3' ' A' ' 83' ' ' ASN . 4.0 t . . . . . 0 N--CA 1.493 1.696 0 CA-C-O 121.803 0.811 . . . . 0.0 111.3 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -69.99 -34.08 72.88 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.695 -0.628 . . . . 0.0 110.632 175.369 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -163.34 171.43 39.05 Favored Glycine 0 N--CA 1.494 2.555 0 C-N-CA 118.729 -1.7 . . . . 0.0 110.394 -174.518 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.497 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 11.7 p -112.81 168.35 9.75 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.031 -1.276 . . . . 0.0 110.699 -178.729 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 0.988 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -133.46 148.87 51.76 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -178.022 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.574 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 22.5 tttt -104.25 112.64 25.74 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 120.972 -1.08 . . . . 0.0 110.15 178.109 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.947 HD23 ' C ' ' A' ' 77' ' ' LYS . 10.9 tp -57.14 126.88 29.2 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 121.146 -0.971 . . . . 0.0 108.803 173.598 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.151 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.21 -31.35 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 O-C-N 121.349 -0.844 . . . . 0.0 110.046 -178.237 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -142.86 144.18 32.39 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.147 -1.021 . . . . 0.0 111.582 -179.454 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.687 HG13 HG21 ' A' ' 78' ' ' VAL . 8.1 mt -110.94 130.37 64.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 120.995 -1.065 . . . . 0.0 110.21 168.749 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.509 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 76.0 m-20 -108.86 115.49 30.19 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.364 -0.835 . . . . 0.0 109.889 172.331 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -103.91 110.28 22.35 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 120.888 -1.132 . . . . 0.0 110.495 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.9 OUTLIER -102.61 131.87 21.91 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.177 -0.952 . . . . 0.0 108.88 173.76 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -50.52 -34.21 41.43 Favored 'Trans proline' 0 C--N 1.302 -1.91 0 O-C-N 123.828 1.436 . . . . 0.0 110.383 -179.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.576 ' HB3' ' CE2' ' A' ' 21' ' ' PHE . 10.4 m-80 -74.19 -39.33 63.25 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.244 -0.91 . . . . 0.0 110.32 175.899 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.576 ' CE2' ' HB3' ' A' ' 20' ' ' ASN . 49.9 m-85 -152.53 150.14 29.26 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.271 -0.893 . . . . 0.0 110.106 -176.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.438 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 50.7 ttt180 -88.73 144.96 25.91 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.914 -1.116 . . . . 0.0 109.999 175.065 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.509 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.8 m -130.07 140.06 50.89 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.437 -0.79 . . . . 0.0 110.099 -177.876 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.606 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -129.59 144.61 51.35 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.967 -1.083 . . . . 0.0 111.107 177.333 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.725 HG22 ' CB ' ' A' ' 60' ' ' SER . 6.9 t -124.06 133.37 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.034 -1.041 . . . . 0.0 110.508 179.229 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.912 HG13 ' CE1' ' A' ' 61' ' ' PHE . 13.1 m -112.88 172.31 3.26 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 121.737 -0.602 . . . . 0.0 109.954 177.403 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.567 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 8.1 tt0 -106.95 116.3 31.69 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.357 -0.839 . . . . 0.0 108.794 178.128 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.608 HD11 ' HB3' ' A' ' 32' ' ' MET . 9.2 tp -80.09 123.98 83.13 Favored Pre-proline 0 C--N 1.296 -1.753 0 O-C-N 121.548 -0.72 . . . . 0.0 109.977 -172.569 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.522 ' HD2' HD12 ' A' ' 28' ' ' LEU . 27.7 Cg_endo -66.35 -178.54 1.18 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 O-C-N 123.822 1.433 . . . . 0.0 110.977 -179.521 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.489 ' HA ' HD12 ' A' ' 33' ' ' LEU . 61.6 t0 -62.55 -40.97 98.52 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 111.027 -174.667 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.03 1.14 56.66 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.811 -1.181 . . . . 0.0 111.014 -174.664 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.608 ' HB3' HD11 ' A' ' 28' ' ' LEU . 99.4 mmm -108.56 -15.37 14.45 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.784 -1.198 . . . . 0.0 109.844 169.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.673 HD21 ' HB2' ' A' ' 57' ' ' ASN . 21.0 mt -69.51 -22.04 63.62 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.217 -0.927 . . . . 0.0 109.997 177.699 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -95.16 115.6 27.65 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.364 -0.835 . . . . 0.0 110.473 -178.59 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.34 -50.52 0.78 Allowed Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.764 -1.207 . . . . 0.0 110.556 173.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.83 HD23 ' N ' ' A' ' 37' ' ' GLU . 9.8 tt -60.98 159.33 11.67 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.886 -1.361 . . . . 0.0 111.123 -172.319 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.83 ' N ' HD23 ' A' ' 36' ' ' LEU . 22.0 pt-20 -157.52 163.46 38.39 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.998 HG23 HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -69.9 151.57 45.51 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.845 -1.159 . . . . 0.0 109.921 -177.474 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.09 -4.66 65.68 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 -172.859 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.413 ' O ' ' HA ' ' A' ' 50' ' ' THR . . . -74.33 160.12 31.48 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.293 -1.122 . . . . 0.0 109.683 176.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.84 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.7 OUTLIER -100.98 103.25 14.39 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.068 -1.02 . . . . 0.0 110.12 178.298 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.618 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.2 t -88.12 131.46 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.201 -0.937 . . . . 0.0 109.489 175.489 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.708 ' HB3' ' HB2' ' A' ' 85' ' ' GLU . . . -98.17 120.97 39.51 Favored 'General case' 0 C--N 1.296 -1.755 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.418 170.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.671 ' CG ' HG21 ' A' ' 82' ' ' VAL . 1.0 OUTLIER -88.74 105.83 17.96 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 119.583 -0.847 . . . . 0.0 108.987 177.525 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.1 t-20 52.96 11.92 0.24 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.463 -0.773 . . . . 0.0 111.525 -166.482 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 127.73 -6.8 6.97 Favored Glycine 0 N--CA 1.489 2.233 0 C-N-CA 119.224 -1.465 . . . . 0.0 111.169 172.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.816 ' O ' HD23 ' A' ' 49' ' ' LEU . 13.8 t -92.49 105.99 18.06 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.192 -1.77 . . . . 0.0 109.471 177.027 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 16.2 p -75.24 129.52 37.6 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.14 -0.975 . . . . 0.0 111.122 -171.138 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.834 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -141.97 159.98 41.13 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.595 -0.691 . . . . 0.0 109.276 174.91 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.413 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 51.7 m -94.79 148.24 22.5 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.613 -1.305 . . . . 0.0 111.279 -170.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.658 HG13 HG13 ' A' ' 59' ' ' VAL . 19.3 t -77.27 122.03 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.651 -0.656 . . . . 0.0 110.265 178.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.522 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 19.3 p -77.54 -44.49 28.41 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.257 -0.902 . . . . 0.0 110.138 175.204 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.67 ' HA ' HG21 ' A' ' 38' ' ' THR . 86.1 tt0 -157.47 150.13 23.04 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.113 -0.992 . . . . 0.0 110.348 178.023 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.998 HD12 HG23 ' A' ' 38' ' ' THR . 1.4 mp -97.79 137.0 26.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.07 -1.019 . . . . 0.0 109.728 173.237 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.48 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 33.4 m-80 -110.03 70.43 0.72 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.595 -0.691 . . . . 0.0 109.698 178.147 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 72.04 -120.12 7.75 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 -172.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.673 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -75.51 -21.17 58.21 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 120.995 -1.297 . . . . 0.0 109.04 175.543 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.151 ' CD2' HG11 ' A' ' 13' ' ' VAL . 10.7 m170 -72.41 160.48 32.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.28 -0.887 . . . . 0.0 110.234 -178.395 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.658 HG13 HG13 ' A' ' 51' ' ' VAL . 53.1 t -140.07 124.54 19.18 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 C-N-CA 119.127 -1.029 . . . . 0.0 110.536 170.679 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.725 ' CB ' HG22 ' A' ' 25' ' ' VAL . 53.1 p -95.08 128.56 42.01 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.476 -0.765 . . . . 0.0 109.553 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.912 ' CE1' HG13 ' A' ' 26' ' ' VAL . 1.8 p90 -124.01 157.35 34.65 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 120.995 -1.066 . . . . 0.0 110.254 -179.118 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.522 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 30.4 p-10 -93.27 152.79 18.96 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 122.09 0.947 . . . . 0.0 111.127 -172.794 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.752 ' CD2' HD12 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -152.21 120.03 6.15 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -175.894 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.51 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 63.5 tpp -77.16 139.58 39.96 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.983 -1.073 . . . . 0.0 109.848 -179.64 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.479 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 74.9 tttt -59.93 -49.85 76.07 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.12 -0.987 . . . . 0.0 110.578 -173.49 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.414 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 88.3 tt0 -66.27 -39.96 89.79 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.828 -1.17 . . . . 0.0 109.996 178.223 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.51 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 90.9 m -60.0 -39.57 86.21 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.002 -1.061 . . . . 0.0 109.197 173.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.752 HD12 ' CD2' ' A' ' 63' ' ' LEU . 2.1 tp -59.97 -45.28 93.18 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.319 -0.863 . . . . 0.0 109.852 179.339 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 tpt85 -69.39 -38.32 77.93 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.386 -0.821 . . . . 0.0 110.079 177.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.805 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -67.75 -39.9 82.84 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 O-C-N 121.333 -0.855 . . . . 0.0 109.191 -177.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.805 HG23 HG22 ' A' ' 70' ' ' ILE . 49.4 p -88.77 -176.41 5.22 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 175.572 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.467 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 8.8 t30 -98.22 21.18 11.26 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.244 -0.91 . . . . 0.0 108.903 173.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.713 ' HB3' HD21 ' A' ' 63' ' ' LEU . 34.4 mt -70.04 -39.99 75.42 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.912 -1.118 . . . . 0.0 110.444 179.609 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.729 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -52.54 -19.33 6.19 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -176.34 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 27.1 p-10 -69.98 -18.21 63.33 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.111 -1.229 . . . . 0.0 110.965 -174.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 85.5 mt -59.99 146.49 42.41 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.088 -1.008 . . . . 0.0 111.026 -174.54 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 0.947 ' C ' HD23 ' A' ' 12' ' ' LEU . 67.4 mttt -139.88 141.75 36.57 Favored 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 121.537 0.684 . . . . 0.0 109.906 176.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.687 HG21 HG13 ' A' ' 15' ' ' ILE . 46.2 t -66.44 150.06 11.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 120.888 -1.133 . . . . 0.0 110.466 -177.329 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.96 -14.99 60.46 Favored Glycine 0 N--CA 1.482 1.743 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 -174.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.478 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 13.9 t0 -96.65 168.27 10.62 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.409 -1.053 . . . . 0.0 109.576 174.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.574 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.4 m95 -115.83 156.09 26.71 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.04 -1.037 . . . . 0.0 110.304 177.72 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.988 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.1 p -120.07 150.0 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.262 -0.899 . . . . 0.0 110.1 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 1.025 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.4 OUTLIER -70.79 104.53 2.92 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.044 -1.035 . . . . 0.0 108.887 166.785 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.777 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -104.35 139.42 25.37 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 120.51 -1.369 . . . . 0.0 110.987 -176.839 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.922 ' HG3' HG22 ' A' ' 6' ' ' VAL . 85.2 mt-10 -125.47 146.62 49.56 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.918 -0.488 . . . . 0.0 110.15 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.533 ' HB3' ' CZ ' ' A' ' 86' ' ' ARG . 18.3 mtp-105 -90.26 114.77 26.87 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.513 -0.742 . . . . 0.0 110.033 177.494 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.84 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.492 1.631 0 O-C-N 121.061 -1.024 . . . . 0.0 110.524 -178.254 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 0.958 HG22 ' HG3' ' B' ' 85' ' ' GLU . 4.0 t . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 121.783 0.802 . . . . 0.0 111.367 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -70.05 -33.75 72.36 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.745 -0.597 . . . . 0.0 110.685 175.449 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.54 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -163.66 171.35 39.29 Favored Glycine 0 N--CA 1.495 2.628 0 C-N-CA 118.91 -1.614 . . . . 0.0 110.52 -174.52 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.498 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 11.7 p -112.9 168.29 9.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.06 -1.259 . . . . 0.0 110.739 -178.632 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.055 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -133.38 149.01 51.85 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 -178.017 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.568 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 22.7 tttt -104.36 112.79 25.97 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 120.982 -1.074 . . . . 0.0 110.047 178.115 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 0.964 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.0 tp -57.35 126.84 29.06 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.193 -0.942 . . . . 0.0 108.761 173.592 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.133 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.18 -31.24 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.784 0 O-C-N 121.339 -0.851 . . . . 0.0 110.089 -178.211 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -142.99 144.17 32.21 Favored 'General case' 0 N--CA 1.493 1.716 0 C-N-CA 119.234 -0.986 . . . . 0.0 111.553 -179.478 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.693 HG13 HG21 ' B' ' 78' ' ' VAL . 8.0 mt -110.85 130.47 64.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 120.992 -1.068 . . . . 0.0 110.193 168.836 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.518 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 75.5 m-20 -109.12 115.59 30.33 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.353 -0.842 . . . . 0.0 109.767 172.389 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -103.92 110.31 22.39 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.019 -1.05 . . . . 0.0 110.443 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.453 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.9 OUTLIER -102.7 131.92 21.82 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.347 -0.846 . . . . 0.0 108.874 173.763 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -50.62 -34.19 42.29 Favored 'Trans proline' 0 C--N 1.301 -1.95 0 O-C-N 123.825 1.434 . . . . 0.0 110.295 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.588 ' HB3' ' CE2' ' B' ' 21' ' ' PHE . 10.5 m-80 -73.98 -39.96 63.31 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.224 -0.922 . . . . 0.0 110.165 175.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.588 ' CE2' ' HB3' ' B' ' 20' ' ' ASN . 49.4 m-85 -152.06 150.18 29.66 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.381 -0.824 . . . . 0.0 110.183 -176.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . 0.427 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 50.5 ttt180 -88.65 144.91 25.98 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.916 -1.115 . . . . 0.0 109.924 175.033 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.518 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 95.0 m -130.09 140.08 50.87 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.511 -0.743 . . . . 0.0 110.147 -178.003 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.605 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -129.57 144.58 51.33 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.095 -1.003 . . . . 0.0 110.994 177.476 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.73 HG22 ' CB ' ' B' ' 60' ' ' SER . 6.8 t -123.99 133.48 69.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.142 -0.974 . . . . 0.0 110.573 179.113 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.931 HG13 ' CE1' ' B' ' 61' ' ' PHE . 13.3 m -112.96 172.3 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.698 -0.626 . . . . 0.0 109.876 177.485 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.571 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 8.1 tt0 -106.86 116.24 31.58 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.444 -0.785 . . . . 0.0 108.923 177.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.605 HD11 ' HB3' ' B' ' 32' ' ' MET . 9.3 tp -80.01 123.98 83.26 Favored Pre-proline 0 C--N 1.296 -1.747 0 O-C-N 121.434 -0.791 . . . . 0.0 110.028 -172.587 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.526 ' HD2' HD12 ' B' ' 28' ' ' LEU . 27.7 Cg_endo -66.3 -178.42 1.13 Allowed 'Trans proline' 0 C--N 1.31 -1.489 0 O-C-N 123.831 1.437 . . . . 0.0 110.96 -179.523 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.478 ' HA ' HD12 ' B' ' 33' ' ' LEU . 61.7 t0 -62.67 -40.91 98.55 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.386 -0.821 . . . . 0.0 111.027 -174.698 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.595 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.01 1.11 56.68 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.867 -1.145 . . . . 0.0 111.01 -174.631 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.605 ' HB3' HD11 ' B' ' 28' ' ' LEU . 99.4 mmm -108.61 -15.25 14.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.752 -1.218 . . . . 0.0 109.813 169.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.696 HD21 ' HB2' ' B' ' 57' ' ' ASN . 20.8 mt -69.69 -21.93 63.47 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.269 -0.894 . . . . 0.0 109.982 177.722 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -95.22 115.68 27.75 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.348 -0.845 . . . . 0.0 110.408 -178.606 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.18 -50.43 0.78 Allowed Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.823 -1.179 . . . . 0.0 110.543 173.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.827 HD23 ' N ' ' B' ' 37' ' ' GLU . 9.8 tt -61.01 159.29 11.81 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.843 -1.386 . . . . 0.0 111.132 -172.362 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . 0.827 ' N ' HD23 ' B' ' 36' ' ' LEU . 21.9 pt-20 -157.51 163.36 38.51 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 1.049 HG23 HD12 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -69.85 151.59 45.53 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.862 -1.149 . . . . 0.0 109.965 -177.531 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.98 -4.47 66.05 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -172.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' B' ' 50' ' ' THR . . . -74.37 160.02 31.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.199 -1.177 . . . . 0.0 109.653 176.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.817 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.6 OUTLIER -100.82 103.12 14.32 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.969 -1.082 . . . . 0.0 110.139 178.291 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.634 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.2 t -88.1 131.59 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.284 -0.885 . . . . 0.0 109.486 175.432 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 0.705 ' HB3' ' HB2' ' B' ' 85' ' ' GLU . . . -98.25 121.0 39.64 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 120.961 -1.087 . . . . 0.0 109.441 170.716 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.668 ' CG ' HG21 ' B' ' 82' ' ' VAL . 1.0 OUTLIER -88.78 105.58 17.8 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.245 -0.91 . . . . 0.0 109.1 177.494 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.1 t-20 53.23 11.94 0.28 Allowed 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.462 -0.774 . . . . 0.0 111.409 -166.565 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 127.55 -6.36 7.07 Favored Glycine 0 N--CA 1.49 2.251 0 C-N-CA 119.231 -1.461 . . . . 0.0 111.082 172.03 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.838 ' O ' HD23 ' B' ' 49' ' ' LEU . 13.9 t -92.66 106.04 18.09 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.059 -1.847 . . . . 0.0 109.439 176.825 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 16.1 p -75.21 129.57 37.7 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.086 -1.009 . . . . 0.0 111.145 -171.19 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 0.855 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -142.01 159.93 41.23 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 174.925 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . 0.414 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 52.1 m -94.69 148.21 22.52 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.514 -1.366 . . . . 0.0 111.244 -170.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.67 HG13 HG13 ' B' ' 59' ' ' VAL . 18.6 t -77.23 122.06 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.647 -0.658 . . . . 0.0 110.281 178.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.519 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 19.7 p -77.66 -44.55 27.73 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.213 -0.93 . . . . 0.0 110.029 175.33 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.666 ' HA ' HG21 ' B' ' 38' ' ' THR . 86.3 tt0 -157.43 150.18 23.17 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.101 -0.999 . . . . 0.0 110.348 178.031 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 1.049 HD12 HG23 ' B' ' 38' ' ' THR . 1.4 mp -97.82 136.94 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.175 -0.953 . . . . 0.0 109.729 173.282 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.504 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 33.5 m-80 -109.95 70.29 0.72 Allowed 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.545 -0.722 . . . . 0.0 109.676 178.219 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 72.09 -120.11 7.71 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 108.713 -1.755 . . . . 0.0 108.713 -172.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.696 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -75.41 -21.28 58.35 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.054 -1.262 . . . . 0.0 109.12 175.468 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.133 ' CD2' HG11 ' B' ' 13' ' ' VAL . 10.8 m170 -72.43 160.27 32.61 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.407 -0.808 . . . . 0.0 110.362 -178.404 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.67 HG13 HG13 ' B' ' 51' ' ' VAL . 53.6 t -139.89 124.62 19.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 119.061 -1.056 . . . . 0.0 110.415 170.853 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.73 ' CB ' HG22 ' B' ' 25' ' ' VAL . 53.4 p -95.08 128.82 42.21 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.619 -0.675 . . . . 0.0 109.509 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.931 ' CE1' HG13 ' B' ' 26' ' ' VAL . 1.8 p90 -124.26 157.29 35.21 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.002 -1.061 . . . . 0.0 110.218 -179.148 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.519 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 30.5 p-10 -93.2 152.74 19.03 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.136 -0.978 . . . . 0.0 111.192 -172.753 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.752 ' CD2' HD12 ' B' ' 68' ' ' LEU . 0.0 OUTLIER -152.06 119.97 6.19 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 -175.883 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.511 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 63.6 tpp -77.19 139.57 39.93 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.976 -1.078 . . . . 0.0 109.845 -179.61 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.484 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 74.9 tttt -60.03 -49.73 76.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.166 -0.959 . . . . 0.0 110.492 -173.362 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . 0.424 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 88.4 tt0 -66.35 -40.0 89.53 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.794 -1.191 . . . . 0.0 109.946 178.326 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.511 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 90.3 m -60.05 -39.55 86.32 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.031 -1.043 . . . . 0.0 109.145 174.008 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.752 HD12 ' CD2' ' B' ' 63' ' ' LEU . 2.1 tp -60.01 -45.14 93.73 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.388 -0.82 . . . . 0.0 109.962 179.278 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 tpt85 -69.35 -38.52 78.14 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.409 -0.807 . . . . 0.0 110.079 177.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.771 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -67.55 -39.95 83.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 CA-C-O 121.73 0.776 . . . . 0.0 109.238 -178.032 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.771 HG23 HG22 ' B' ' 70' ' ' ILE . 49.6 p -88.74 -176.24 5.18 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 175.674 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.516 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 8.7 t30 -98.3 21.19 11.33 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 121.182 -0.948 . . . . 0.0 108.733 173.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.744 ' HB3' HD21 ' B' ' 63' ' ' LEU . 34.1 mt -70.01 -40.03 75.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.954 -1.091 . . . . 0.0 110.458 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.743 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -52.49 -19.31 6.09 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -176.324 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.504 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 27.2 p-10 -70.05 -18.25 63.28 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.083 -1.245 . . . . 0.0 110.946 -174.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.504 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 85.7 mt -59.95 146.43 42.45 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.188 -0.945 . . . . 0.0 111.012 -174.547 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 0.964 ' C ' HD23 ' B' ' 12' ' ' LEU . 67.4 mttt -139.89 141.78 36.54 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.626 -0.671 . . . . 0.0 109.888 176.658 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.693 HG21 HG13 ' B' ' 15' ' ' ILE . 46.2 t -66.49 150.01 11.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.04 -1.038 . . . . 0.0 110.498 -177.274 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.01 -14.94 60.65 Favored Glycine 0 N--CA 1.483 1.824 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -174.712 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 13.8 t0 -96.73 168.13 10.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.359 -1.083 . . . . 0.0 109.582 174.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.568 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.4 m95 -115.76 156.0 26.8 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.06 -1.025 . . . . 0.0 110.325 177.788 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 1.055 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.1 p -120.01 150.06 22.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.427 -0.795 . . . . 0.0 110.173 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.952 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.4 OUTLIER -70.68 104.32 2.81 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.001 -1.062 . . . . 0.0 109.053 166.705 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.773 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -104.22 139.59 24.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 120.464 -1.398 . . . . 0.0 110.905 -176.61 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . 0.958 ' HG3' HG22 ' B' ' 6' ' ' VAL . 85.0 mt-10 -125.73 146.57 49.7 Favored 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.193 0.521 . . . . 0.0 110.064 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . 0.539 ' HB3' ' CZ ' ' B' ' 86' ' ' ARG . 18.3 mtp-105 -90.26 114.84 26.95 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.35 -0.844 . . . . 0.0 109.957 177.566 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.817 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.624 0 O-C-N 121.256 -0.903 . . . . 0.0 110.57 -178.292 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.69 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.6 t . . . . . 0 N--CA 1.49 1.562 0 CA-C-O 121.836 0.827 . . . . 0.0 110.871 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -71.04 -33.09 69.98 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.866 -0.521 . . . . 0.0 111.182 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.533 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -150.35 171.92 30.2 Favored Glycine 0 N--CA 1.495 2.582 0 C-N-CA 119.054 -1.546 . . . . 0.0 110.133 -171.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.495 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 3.1 p -119.23 172.34 7.66 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.893 -1.357 . . . . 0.0 111.214 -176.453 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 1.013 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -142.64 150.0 39.66 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 -176.362 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.587 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.1 tttt -110.83 115.15 29.03 Favored 'General case' 0 C--N 1.295 -1.803 0 O-C-N 121.097 -1.002 . . . . 0.0 110.276 179.54 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.941 HD23 ' C ' ' A' ' 77' ' ' LYS . 10.9 tp -59.74 127.71 33.32 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.015 -1.053 . . . . 0.0 109.079 174.362 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.113 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -122.2 -28.9 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 C-N-CA 119.641 -0.824 . . . . 0.0 109.648 179.2 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.71 147.54 26.83 Favored 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 119.05 -1.06 . . . . 0.0 111.551 -179.155 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.839 HG23 ' CD2' ' A' ' 24' ' ' HIS . 11.7 mt -109.59 138.61 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.212 -0.93 . . . . 0.0 110.03 172.415 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.507 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.7 m-20 -109.58 114.62 28.4 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.283 -0.885 . . . . 0.0 109.924 173.52 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -100.35 112.15 24.47 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.13 -0.981 . . . . 0.0 110.369 -176.484 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.2 OUTLIER -112.76 132.76 22.12 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.203 -0.935 . . . . 0.0 108.94 175.492 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -49.57 -40.39 45.88 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 O-C-N 123.855 1.45 . . . . 0.0 110.754 -179.204 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.445 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 12.0 m-80 -70.59 -39.37 73.89 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.124 -0.985 . . . . 0.0 110.259 177.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.461 ' O ' ' HB2' ' A' ' 18' ' ' LYS . 95.7 m-85 -152.55 150.3 29.42 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.289 -0.882 . . . . 0.0 110.526 -174.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.603 ' HD3' HD22 ' A' ' 68' ' ' LEU . 60.7 ttt180 -91.28 143.54 26.54 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 120.835 -1.166 . . . . 0.0 109.909 175.006 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.507 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 97.1 m -129.57 140.77 51.12 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.597 -0.69 . . . . 0.0 109.738 -174.663 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.839 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -132.65 137.27 46.92 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 120.948 -1.095 . . . . 0.0 111.142 -177.95 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.836 HG22 ' OG ' ' A' ' 60' ' ' SER . 4.8 t -120.16 131.72 71.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.115 -0.991 . . . . 0.0 110.677 -178.379 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.863 HG13 ' CE1' ' A' ' 61' ' ' PHE . 18.9 m -111.9 175.74 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 CA-C-O 121.212 0.529 . . . . 0.0 110.265 178.007 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.569 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 7.9 tt0 -107.02 117.05 33.03 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.387 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.562 HD12 ' HD2' ' A' ' 29' ' ' PRO . 10.7 tp -80.45 126.74 77.97 Favored Pre-proline 0 C--N 1.296 -1.724 0 O-C-N 121.428 -0.795 . . . . 0.0 109.827 -173.53 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.562 ' HD2' HD12 ' A' ' 28' ' ' LEU . 18.7 Cg_endo -63.78 173.67 4.47 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.886 1.466 . . . . 0.0 110.654 -179.362 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.766 ' HA ' HD12 ' A' ' 33' ' ' LEU . 12.3 p-10 -59.99 -38.06 81.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.372 -0.83 . . . . 0.0 110.676 -176.159 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.589 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.18 0.06 57.37 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.959 -1.088 . . . . 0.0 110.947 -175.734 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.589 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 94.5 mmm -110.43 -12.01 14.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.854 -1.154 . . . . 0.0 109.948 170.176 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.944 HD21 ' HB2' ' A' ' 57' ' ' ASN . 15.8 mt -63.04 -31.38 72.5 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.299 -0.875 . . . . 0.0 110.15 176.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -93.23 139.99 30.02 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.339 -0.851 . . . . 0.0 110.536 -176.335 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.08 -41.42 2.34 Favored Glycine 0 N--CA 1.491 2.335 0 C-N-CA 119.892 -1.147 . . . . 0.0 110.387 174.878 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.76 HD23 ' N ' ' A' ' 37' ' ' GLU . 9.1 tt -76.1 149.28 37.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.926 -1.338 . . . . 0.0 111.054 -174.394 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.76 ' N ' HD23 ' A' ' 36' ' ' LEU . 15.8 pt-20 -151.59 169.25 22.56 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.464 -0.772 . . . . 0.0 109.58 177.289 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.926 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -61.32 151.64 31.47 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.936 -1.102 . . . . 0.0 109.876 179.107 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.73 -5.81 60.36 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -178.647 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.489 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -73.28 156.15 38.77 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.228 -1.16 . . . . 0.0 109.649 177.266 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.682 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -99.8 106.2 18.06 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.958 -1.089 . . . . 0.0 109.749 176.296 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.6 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.2 t -93.3 129.89 43.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 121.21 -0.931 . . . . 0.0 109.122 174.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.502 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -93.38 120.02 33.17 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.3 -0.96 . . . . 0.0 109.117 172.336 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.796 ' CD2' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -91.22 104.79 17.3 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.698 -0.801 . . . . 0.0 108.886 177.98 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.496 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.6 t-20 55.34 14.09 1.03 Allowed 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.314 -0.866 . . . . 0.0 110.896 -168.704 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 120.33 -5.16 12.12 Favored Glycine 0 N--CA 1.49 2.255 0 C-N-CA 119.58 -1.295 . . . . 0.0 110.919 172.132 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.848 ' O ' HD23 ' A' ' 49' ' ' LEU . 25.1 t -90.58 110.32 21.46 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.336 -1.685 . . . . 0.0 109.495 176.634 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.9 p -74.47 127.93 34.29 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.959 -1.088 . . . . 0.0 110.789 -171.47 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 1.008 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -143.21 160.06 41.16 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.323 -0.861 . . . . 0.0 109.707 174.825 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.459 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 3.6 m -102.22 151.56 22.06 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.773 -1.205 . . . . 0.0 111.083 -172.526 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.747 HG13 HG13 ' A' ' 59' ' ' VAL . 14.6 t -78.22 118.39 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.752 -0.593 . . . . 0.0 110.489 -177.341 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 43.9 p -72.32 -40.03 67.77 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.367 -0.833 . . . . 0.0 110.065 174.128 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.522 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -164.48 153.5 13.22 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.272 -0.893 . . . . 0.0 110.2 -176.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.926 HD11 ' N ' ' A' ' 38' ' ' THR . 6.8 mt -109.56 130.02 63.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.107 -0.996 . . . . 0.0 109.958 176.118 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.507 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 4.5 m-80 -102.56 63.28 0.86 Allowed 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.682 -0.636 . . . . 0.0 109.725 179.427 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.11 -114.06 4.06 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.781 -1.728 . . . . 0.0 108.781 -174.086 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.944 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.53 -22.31 47.5 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 120.953 -1.322 . . . . 0.0 108.82 175.001 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.113 ' CD2' HG11 ' A' ' 13' ' ' VAL . 11.8 m80 -74.46 159.44 32.27 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.331 -0.856 . . . . 0.0 110.229 -177.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.747 HG13 HG13 ' A' ' 51' ' ' VAL . 54.1 t -141.62 122.58 12.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 C-N-CA 119.163 -1.015 . . . . 0.0 110.81 172.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.836 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.4 t -88.26 134.9 33.68 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.454 -0.779 . . . . 0.0 109.705 175.366 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 1.008 ' HB2' HD12 ' A' ' 49' ' ' LEU . 2.1 p90 -127.26 154.66 44.6 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.374 -0.829 . . . . 0.0 110.292 176.66 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 35.8 p-10 -88.95 152.29 21.8 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.149 -0.969 . . . . 0.0 111.329 -171.136 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.834 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -157.77 100.25 1.75 Allowed 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.598 -0.689 . . . . 0.0 109.369 -174.178 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.489 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 60.7 ttm -60.23 139.89 57.32 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.058 -1.026 . . . . 0.0 109.669 -177.307 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.494 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 5.1 ttpm? -59.94 -43.31 95.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.138 -0.977 . . . . 0.0 110.409 -175.36 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.33 -40.03 77.84 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.833 -1.167 . . . . 0.0 109.842 178.056 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.489 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 94.2 m -59.98 -37.64 80.24 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.05 -1.031 . . . . 0.0 109.474 172.231 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.712 HD11 ' HA2' ' A' ' 74' ' ' GLY . 14.2 tp -59.96 -45.81 91.45 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.273 -0.892 . . . . 0.0 109.428 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 55.2 ttt85 -69.96 -39.94 75.71 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.382 -0.824 . . . . 0.0 110.739 176.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.785 HG22 HG23 ' A' ' 71' ' ' THR . 1.5 tt -67.27 -42.82 88.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.233 -0.917 . . . . 0.0 109.445 -175.779 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.785 HG23 HG22 ' A' ' 70' ' ' ILE . 40.3 p -83.84 -173.87 4.96 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 174.678 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.496 ' HB3' ' HB2' ' B' ' 83' ' ' ASN . 3.1 t30 -102.71 23.63 11.77 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 169.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.834 ' HB3' HD21 ' A' ' 63' ' ' LEU . 86.9 mt -68.42 -40.07 81.36 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.089 -1.007 . . . . 0.0 110.015 176.768 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.712 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -47.88 -22.36 1.98 Allowed Glycine 0 N--CA 1.487 2.086 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.694 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.2 p-10 -62.83 -18.69 63.19 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.163 -1.198 . . . . 0.0 110.405 -176.303 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.513 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.8 mt -60.0 143.16 52.52 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.202 -0.936 . . . . 0.0 110.516 -177.752 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 0.941 ' C ' HD23 ' A' ' 12' ' ' LEU . 23.3 mttm -145.82 146.87 31.32 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.584 -0.698 . . . . 0.0 109.381 176.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.601 ' CG2' HG13 ' A' ' 15' ' ' ILE . 22.4 t -68.25 148.59 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.677 -1.265 . . . . 0.0 110.176 -175.625 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.14 -11.17 63.61 Favored Glycine 0 N--CA 1.483 1.813 0 N-CA-C 108.743 -1.743 . . . . 0.0 108.743 -174.167 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.494 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 45.5 t0 -95.68 162.63 13.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.344 -1.092 . . . . 0.0 109.694 176.785 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.587 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.0 m95 -114.76 149.35 37.07 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.124 -0.985 . . . . 0.0 110.005 176.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.013 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.2 p -115.21 153.79 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.498 -0.751 . . . . 0.0 109.971 -179.581 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.69 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.6 m-20 -78.19 106.11 9.87 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.143 -0.973 . . . . 0.0 109.125 168.607 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.875 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -108.4 139.88 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 120.665 -1.272 . . . . 0.0 111.177 -176.643 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.42 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.4 tt0 -136.92 144.02 43.23 Favored 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 120.217 -0.593 . . . . 0.0 110.201 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 66.5 ttp85 -79.58 129.92 34.91 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.279 -0.888 . . . . 0.0 111.011 -176.552 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.682 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.61 0 O-C-N 121.351 -0.843 . . . . 0.0 110.134 175.815 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 0.666 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.6 t . . . . . 0 N--CA 1.49 1.539 0 CA-C-O 121.85 0.833 . . . . 0.0 110.921 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -71.11 -32.79 69.46 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.814 -0.554 . . . . 0.0 111.221 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.543 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -150.64 171.78 30.42 Favored Glycine 0 N--CA 1.495 2.63 0 C-N-CA 119.105 -1.522 . . . . 0.0 110.153 -171.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.499 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 3.1 p -119.23 172.26 7.72 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.937 -1.331 . . . . 0.0 111.238 -176.31 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.083 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -142.58 150.13 39.95 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 -176.417 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 30.1 tttt -110.9 115.25 29.19 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.102 -0.999 . . . . 0.0 110.224 179.585 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 0.929 HD23 ' C ' ' B' ' 77' ' ' LYS . 10.9 tp -59.95 127.68 33.08 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.085 -1.009 . . . . 0.0 109.068 174.41 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.127 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -122.03 -29.16 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.662 179.295 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.67 147.6 26.92 Favored 'General case' 0 N--CA 1.493 1.678 0 C-N-CA 119.188 -1.005 . . . . 0.0 111.473 -179.137 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.848 HG23 ' CD2' ' B' ' 24' ' ' HIS . 11.8 mt -109.59 138.71 35.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.305 -0.872 . . . . 0.0 110.041 172.404 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.506 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 77.4 m-20 -109.72 114.61 28.34 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 121.31 -0.869 . . . . 0.0 109.863 173.638 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.31 112.18 24.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.16 -0.963 . . . . 0.0 110.311 -176.449 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.2 OUTLIER -112.83 132.74 22.16 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.173 -0.954 . . . . 0.0 109.005 175.393 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -49.67 -40.35 46.85 Favored 'Trans proline' 0 C--N 1.303 -1.852 0 O-C-N 123.91 1.479 . . . . 0.0 110.705 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.438 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 12.1 m-80 -70.35 -40.07 74.3 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.141 -0.974 . . . . 0.0 110.108 177.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.461 ' O ' ' HB2' ' B' ' 18' ' ' LYS . 96.0 m-85 -152.03 150.36 29.87 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.314 -0.867 . . . . 0.0 110.542 -174.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . 0.614 ' HD3' HD22 ' B' ' 68' ' ' LEU . 60.6 ttt180 -91.31 143.42 26.66 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.893 -1.129 . . . . 0.0 109.965 174.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.506 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 97.2 m -129.41 140.69 51.25 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.659 -0.651 . . . . 0.0 109.718 -174.591 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.848 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -132.52 137.5 47.19 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.069 -1.019 . . . . 0.0 111.094 -178.088 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.845 HG22 ' OG ' ' B' ' 60' ' ' SER . 4.8 t -120.13 131.95 71.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.119 -0.988 . . . . 0.0 110.662 -178.379 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.866 HG13 ' CE1' ' B' ' 61' ' ' PHE . 19.0 m -112.24 175.64 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 121.751 -0.593 . . . . 0.0 110.171 178.067 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.575 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 7.9 tt0 -106.76 117.09 33.12 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 178.31 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.573 HD12 ' HD2' ' B' ' 29' ' ' PRO . 10.8 tp -80.42 126.67 78.22 Favored Pre-proline 0 C--N 1.295 -1.763 0 O-C-N 121.235 -0.916 . . . . 0.0 109.83 -173.554 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.573 ' HD2' HD12 ' B' ' 28' ' ' LEU . 18.6 Cg_endo -63.67 173.65 4.38 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 O-C-N 123.946 1.498 . . . . 0.0 110.699 -179.427 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.75 ' HA ' HD12 ' B' ' 33' ' ' LEU . 12.3 p-10 -59.97 -38.05 81.39 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 110.739 -176.265 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.585 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.16 -0.05 57.42 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.922 -1.112 . . . . 0.0 110.902 -175.72 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.585 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 94.6 mmm -110.35 -11.98 14.47 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.867 -1.146 . . . . 0.0 109.913 170.182 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.932 HD21 ' HB2' ' B' ' 57' ' ' ASN . 15.8 mt -63.0 -31.43 72.57 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.341 -0.849 . . . . 0.0 110.133 176.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -93.22 139.99 30.02 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.347 -0.846 . . . . 0.0 110.538 -176.277 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.06 -41.32 2.35 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 174.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.757 HD23 ' N ' ' B' ' 37' ' ' GLU . 9.0 tt -76.09 149.25 37.47 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.973 -1.31 . . . . 0.0 111.034 -174.399 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . 0.757 ' N ' HD23 ' B' ' 36' ' ' LEU . 15.8 pt-20 -151.52 169.3 22.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.52 -0.737 . . . . 0.0 109.645 177.194 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 0.93 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -61.34 151.66 31.52 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.026 -1.046 . . . . 0.0 109.969 179.059 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.79 -5.94 60.17 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 -178.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.5 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -73.26 155.96 38.98 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.24 -1.153 . . . . 0.0 109.668 177.234 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.689 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -99.52 106.05 18.02 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.86 -1.15 . . . . 0.0 109.87 176.252 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.617 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.2 t -93.3 130.01 42.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.311 -0.868 . . . . 0.0 109.071 174.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -93.31 120.02 33.11 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 119.274 -0.971 . . . . 0.0 109.225 172.241 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.783 ' CD2' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -91.22 104.67 17.2 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.578 -0.849 . . . . 0.0 108.939 177.977 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.496 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.6 t-20 55.4 14.2 1.08 Allowed 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.378 -0.826 . . . . 0.0 110.864 -168.692 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 120.21 -4.92 12.34 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.622 -1.275 . . . . 0.0 110.916 171.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.862 ' O ' HD23 ' B' ' 49' ' ' LEU . 25.0 t -90.68 110.31 21.49 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.365 -1.668 . . . . 0.0 109.478 176.547 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 19.1 p -74.32 128.02 34.48 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.074 -1.016 . . . . 0.0 110.803 -171.556 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 1.0 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -143.36 159.98 41.38 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.41 -0.806 . . . . 0.0 109.709 174.78 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . 0.469 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 3.6 m -102.07 151.66 21.89 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.803 -1.185 . . . . 0.0 111.019 -172.473 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.725 HG13 HG13 ' B' ' 59' ' ' VAL . 15.9 t -78.41 118.35 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.599 -0.688 . . . . 0.0 110.549 -177.39 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.53 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 43.9 p -72.26 -40.11 67.91 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.336 -0.853 . . . . 0.0 110.061 174.222 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.525 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -164.44 153.5 13.3 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.193 -0.942 . . . . 0.0 110.21 -176.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.93 HD11 ' N ' ' B' ' 38' ' ' THR . 6.9 mt -109.48 129.97 63.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.149 -0.97 . . . . 0.0 110.016 176.118 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.519 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 4.5 m-80 -102.68 63.3 0.85 Allowed 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.598 -0.689 . . . . 0.0 109.732 179.433 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.29 -114.11 4.05 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 108.758 -1.737 . . . . 0.0 108.758 -174.162 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.932 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.36 -22.57 47.76 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.01 -1.288 . . . . 0.0 108.903 174.89 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.127 ' CD2' HG11 ' B' ' 13' ' ' VAL . 12.0 m80 -74.27 159.23 32.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.475 -0.766 . . . . 0.0 110.249 -177.638 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.725 HG13 HG13 ' B' ' 51' ' ' VAL . 54.3 t -141.48 122.56 12.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.756 173.104 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.845 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.4 t -88.34 135.13 33.61 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.464 -0.772 . . . . 0.0 109.655 175.418 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 1.0 ' HB2' HD12 ' B' ' 49' ' ' LEU . 2.1 p90 -127.46 154.62 44.85 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.692 -0.803 . . . . 0.0 110.263 176.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.53 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 36.3 p-10 -88.89 152.29 21.83 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.035 -1.041 . . . . 0.0 111.275 -171.041 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.811 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -157.79 100.24 1.74 Allowed 'General case' 0 C--N 1.3 -1.562 0 C-N-CA 120.065 -0.654 . . . . 0.0 109.298 -174.186 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.495 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 60.8 ttm -60.14 139.84 57.28 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.066 -1.021 . . . . 0.0 109.737 -177.391 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.499 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 5.1 ttpm? -59.98 -43.28 95.23 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.131 -0.981 . . . . 0.0 110.399 -175.353 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.36 -40.01 77.74 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.914 -1.116 . . . . 0.0 109.883 178.044 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.495 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 94.4 m -60.01 -37.68 80.43 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.075 -1.015 . . . . 0.0 109.434 172.26 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.717 HD11 ' HA2' ' B' ' 74' ' ' GLY . 14.2 tp -60.01 -45.59 92.26 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.302 -0.874 . . . . 0.0 109.482 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 55.2 ttt85 -70.01 -40.03 75.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.465 -0.772 . . . . 0.0 110.732 176.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.769 HG22 HG23 ' B' ' 71' ' ' THR . 1.5 tt -67.2 -42.78 88.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.289 -0.882 . . . . 0.0 109.438 -175.802 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.769 HG23 HG22 ' B' ' 70' ' ' ILE . 40.2 p -83.84 -173.69 4.86 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 174.759 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.501 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 3.2 t30 -102.8 23.71 11.71 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.172 -1.048 . . . . 0.0 108.172 169.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.811 ' HB3' HD21 ' B' ' 63' ' ' LEU . 86.2 mt -68.6 -39.95 80.68 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.141 -0.975 . . . . 0.0 109.938 176.832 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.717 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -47.96 -22.28 2.02 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.646 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.3 p-10 -62.86 -18.69 63.27 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.092 -1.24 . . . . 0.0 110.434 -176.335 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.517 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.0 mt -60.02 143.26 52.31 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.269 -0.894 . . . . 0.0 110.496 -177.738 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 0.929 ' C ' HD23 ' B' ' 12' ' ' LEU . 23.3 mttm -145.99 146.71 31.1 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.681 -0.637 . . . . 0.0 109.351 177.02 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.585 ' CG2' HG13 ' B' ' 15' ' ' ILE . 22.1 t -68.05 148.69 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 120.865 -1.147 . . . . 0.0 110.303 -175.669 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 85.96 -10.94 63.83 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.86 -1.696 . . . . 0.0 108.86 -174.125 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.48 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 45.2 t0 -95.74 162.48 13.58 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.303 -1.116 . . . . 0.0 109.687 176.658 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.0 m95 -114.73 149.41 36.88 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.174 -0.954 . . . . 0.0 109.999 176.833 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 1.083 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.2 p -115.37 153.95 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.422 -0.799 . . . . 0.0 109.857 -179.574 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.666 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -78.27 106.09 9.94 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.138 -0.976 . . . . 0.0 109.197 168.616 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.898 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -108.36 140.04 28.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 120.726 -1.234 . . . . 0.0 111.014 -176.446 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . 0.413 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.5 tt0 -137.18 143.98 42.66 Favored 'General case' 0 N--CA 1.492 1.633 0 C-N-CA 120.282 -0.567 . . . . 0.0 110.205 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 66.5 ttp85 -79.36 130.03 35.04 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.219 -0.926 . . . . 0.0 110.946 -176.515 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.689 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.757 0 O-C-N 121.302 -0.874 . . . . 0.0 110.045 175.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.959 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.3 t . . . . . 0 N--CA 1.496 1.84 0 CA-C-O 121.781 0.801 . . . . 0.0 110.892 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 -69.43 -35.0 75.28 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.773 -0.579 . . . . 0.0 110.621 177.107 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.53 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -162.68 173.9 38.98 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 118.896 -1.621 . . . . 0.0 110.094 -174.114 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.464 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.5 p -114.69 174.76 5.8 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.154 -1.204 . . . . 0.0 110.836 -177.701 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 1.022 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -142.61 149.04 38.45 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.622 -0.674 . . . . 0.0 109.541 -177.718 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.0 tttt -103.95 118.62 37.1 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 120.95 -1.094 . . . . 0.0 110.2 178.134 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 1.02 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.2 tp -60.7 127.55 32.21 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 120.795 -1.191 . . . . 0.0 108.569 171.005 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.153 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.7 p -130.45 -31.17 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.874 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.229 -177.126 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -143.84 139.83 29.49 Favored 'General case' 0 C--N 1.296 -1.719 0 C-N-CA 119.079 -1.048 . . . . 0.0 111.272 -178.634 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.78 HG23 ' CD2' ' A' ' 24' ' ' HIS . 11.2 mt -110.02 130.81 62.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.034 -1.041 . . . . 0.0 110.198 171.201 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.508 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 81.6 m-20 -108.07 114.64 28.7 Favored 'General case' 0 C--N 1.294 -1.843 0 O-C-N 121.443 -0.786 . . . . 0.0 109.962 173.195 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.4 110.77 22.98 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.002 -1.061 . . . . 0.0 110.592 -176.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -110.29 128.12 25.89 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.133 -0.979 . . . . 0.0 108.917 174.09 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -50.61 -33.42 39.28 Favored 'Trans proline' 0 C--N 1.303 -1.851 0 O-C-N 123.767 1.404 . . . . 0.0 110.314 -179.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.474 ' C ' ' CD2' ' A' ' 21' ' ' PHE . 12.4 m-80 -72.27 -40.0 67.95 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.149 -0.97 . . . . 0.0 109.938 175.812 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.474 ' CD2' ' C ' ' A' ' 20' ' ' ASN . 91.0 m-85 -152.51 150.25 29.39 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.374 -0.829 . . . . 0.0 110.197 -178.4 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.486 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 57.5 ttt180 -88.31 139.95 29.97 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 120.734 -1.229 . . . . 0.0 109.7 173.074 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.508 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 95.0 m -124.97 131.73 53.38 Favored 'General case' 0 C--N 1.294 -1.847 0 O-C-N 121.597 -0.689 . . . . 0.0 109.901 -176.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.78 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -126.21 138.89 53.68 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.905 -1.122 . . . . 0.0 111.303 -179.7 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.767 HG22 ' CB ' ' A' ' 60' ' ' SER . 5.7 t -120.83 134.26 64.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.135 -0.978 . . . . 0.0 110.861 -176.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.814 HG13 ' CE1' ' A' ' 61' ' ' PHE . 35.9 m -114.79 172.17 4.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 O-C-N 121.804 -0.56 . . . . 0.0 110.09 178.243 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.472 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 9.2 tt0 -104.21 117.91 35.37 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.376 -0.827 . . . . 0.0 108.788 177.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.891 HD21 HD13 ' A' ' 36' ' ' LEU . 7.5 tp -85.83 127.93 60.48 Favored Pre-proline 0 C--N 1.297 -1.703 0 O-C-N 121.562 -0.711 . . . . 0.0 109.943 -171.128 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.479 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 20.6 Cg_endo -66.02 178.69 2.25 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.881 1.464 . . . . 0.0 110.743 -179.363 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.518 ' HA ' HD12 ' A' ' 33' ' ' LEU . 33.9 p-10 -62.65 -40.1 95.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.349 -0.844 . . . . 0.0 110.999 -175.542 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.606 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.93 -0.0 57.33 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.837 -1.164 . . . . 0.0 110.823 -174.367 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.606 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.0 mmm -108.11 -16.98 14.15 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.87 -1.144 . . . . 0.0 109.638 170.772 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.597 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 24.7 mt -66.2 -25.77 67.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.363 -0.835 . . . . 0.0 109.721 174.736 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -92.26 131.33 37.56 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.474 -0.766 . . . . 0.0 110.56 -178.094 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.79 -41.75 2.71 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 176.601 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.891 HD13 HD21 ' A' ' 28' ' ' LEU . 5.1 tt -70.84 148.2 48.09 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.076 -1.249 . . . . 0.0 110.335 -177.226 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.729 ' N ' HD23 ' A' ' 36' ' ' LEU . 19.9 pt-20 -156.75 166.36 33.61 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.322 -0.862 . . . . 0.0 109.599 -177.66 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.75 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -65.57 148.5 51.63 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.886 -1.134 . . . . 0.0 110.051 -178.886 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.67 -3.47 68.76 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.234 -1.546 . . . . 0.0 109.234 -174.369 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.463 ' CB ' ' O ' ' A' ' 37' ' ' GLU . . . -78.22 160.03 28.19 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.263 -1.14 . . . . 0.0 109.445 176.108 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.453 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -101.64 114.31 28.24 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 118.799 -1.16 . . . . 0.0 110.097 177.107 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.666 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.7 t -99.11 128.75 50.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.278 -0.889 . . . . 0.0 108.94 173.277 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.512 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -94.99 119.48 33.58 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 119.156 -1.017 . . . . 0.0 109.074 172.295 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.666 ' HE1' HG11 ' A' ' 42' ' ' VAL . 0.6 OUTLIER -87.32 103.14 15.19 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.415 -0.803 . . . . 0.0 108.958 178.41 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.498 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 57.83 8.9 0.77 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.441 -0.787 . . . . 0.0 111.309 -170.312 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.503 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 124.11 2.26 8.51 Favored Glycine 0 N--CA 1.489 2.168 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.858 174.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.803 ' O ' HD23 ' A' ' 49' ' ' LEU . 42.7 t -98.45 107.33 19.77 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.461 -1.611 . . . . 0.0 109.485 174.706 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 26.2 p -75.1 129.9 38.35 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.237 -0.914 . . . . 0.0 111.211 -170.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.975 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -145.27 160.63 41.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.443 -0.786 . . . . 0.0 109.637 173.552 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.41 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 57.9 m -100.95 151.17 22.08 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.737 -1.227 . . . . 0.0 110.923 -171.719 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.737 HG13 HG13 ' A' ' 59' ' ' VAL . 38.6 t -78.48 116.85 22.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.655 -0.653 . . . . 0.0 110.487 -178.358 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.532 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 37.7 p -70.03 -40.01 75.42 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.205 -0.934 . . . . 0.0 109.893 174.092 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.621 ' HA ' HG21 ' A' ' 38' ' ' THR . 86.5 tt0 -163.47 153.39 15.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.298 -0.876 . . . . 0.0 110.194 -177.676 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.75 HD11 ' N ' ' A' ' 38' ' ' THR . 5.9 mt -104.49 133.63 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.018 -1.051 . . . . 0.0 109.885 175.044 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.509 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 31.4 m-80 -107.72 66.94 0.67 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.507 -0.745 . . . . 0.0 109.823 179.154 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.27 -116.06 4.83 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.816 -1.714 . . . . 0.0 108.816 -174.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.597 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -79.21 -19.13 51.53 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.055 -1.262 . . . . 0.0 108.764 174.545 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.153 ' CD2' HG11 ' A' ' 13' ' ' VAL . 11.2 m170 -74.73 160.66 30.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.467 -0.77 . . . . 0.0 110.343 -178.236 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.737 HG13 HG13 ' A' ' 51' ' ' VAL . 62.9 t -141.25 123.21 14.27 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 O-C-N 121.229 -0.92 . . . . 0.0 110.433 171.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.767 ' CB ' HG22 ' A' ' 25' ' ' VAL . 13.3 m -91.32 130.53 37.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.573 -0.704 . . . . 0.0 109.535 178.283 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.975 ' HB2' HD12 ' A' ' 49' ' ' LEU . 4.0 p90 -124.69 153.66 42.0 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.096 -1.002 . . . . 0.0 110.333 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.532 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 27.2 p-10 -88.73 152.22 21.93 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.091 -1.006 . . . . 0.0 111.37 -170.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.866 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -155.73 114.33 3.46 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -176.128 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.513 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 7.1 ttp -71.64 140.0 49.52 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.803 -1.186 . . . . 0.0 109.685 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.5 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 37.5 ttpt -60.04 -46.03 90.86 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.075 -1.015 . . . . 0.0 110.532 -174.05 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -70.0 -40.05 75.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.659 -1.275 . . . . 0.0 110.003 178.522 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.513 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 33.4 m -61.88 -34.9 76.87 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.053 -1.029 . . . . 0.0 109.462 173.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.709 HD11 ' HA2' ' A' ' 74' ' ' GLY . 7.6 tp -59.96 -45.81 91.47 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.244 -0.91 . . . . 0.0 109.151 178.205 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 71.8 ttt-85 -66.46 -39.98 89.15 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.284 -0.885 . . . . 0.0 110.682 175.115 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.785 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -66.72 -44.24 89.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.173 -0.954 . . . . 0.0 109.584 -175.549 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.785 HG23 HG22 ' A' ' 70' ' ' ILE . 31.2 p -83.17 -175.13 5.68 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 120.199 -0.6 . . . . 0.0 109.437 175.5 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 3.7 t30 -99.48 23.59 9.21 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 171.216 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.866 ' HB3' HD21 ' A' ' 63' ' ' LEU . 90.9 mt -70.0 -39.96 75.55 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.12 -0.987 . . . . 0.0 110.117 176.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.709 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -53.75 -18.1 7.71 Favored Glycine 0 N--CA 1.486 1.987 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 -177.137 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.2 p-10 -69.99 -19.03 63.35 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.953 -1.322 . . . . 0.0 110.575 -175.567 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.518 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 87.9 mt -62.13 141.92 57.88 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.233 -0.917 . . . . 0.0 110.815 -176.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 1.02 ' C ' HD23 ' A' ' 12' ' ' LEU . 43.5 mtmt -141.49 141.74 33.62 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 121.63 -0.669 . . . . 0.0 109.776 174.32 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.733 HG23 HD11 ' A' ' 15' ' ' ILE . 16.6 t -60.32 152.6 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 120.926 -1.109 . . . . 0.0 110.451 -174.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.43 -15.9 57.45 Favored Glycine 0 N--CA 1.482 1.722 0 N-CA-C 108.762 -1.735 . . . . 0.0 108.762 -176.348 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 37.8 t0 -95.76 166.8 11.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.312 -1.111 . . . . 0.0 109.664 175.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.584 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.3 m95 -116.82 160.49 20.74 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.083 -1.011 . . . . 0.0 110.171 178.014 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.022 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.1 p -125.55 155.21 34.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.339 -0.851 . . . . 0.0 110.034 -177.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.959 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -79.97 105.04 10.96 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.964 -1.085 . . . . 0.0 109.059 168.229 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.81 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -105.56 138.01 32.68 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 O-C-N 120.546 -1.346 . . . . 0.0 111.118 -176.539 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -133.53 140.03 46.96 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 120.298 -0.561 . . . . 0.0 110.028 -178.023 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.537 ' NH1' ' HB2' ' A' ' 86' ' ' ARG . 26.7 ttm105 -78.31 126.91 31.45 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.258 -0.901 . . . . 0.0 110.701 -176.053 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.453 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.587 0 O-C-N 121.392 -0.817 . . . . 0.0 110.076 176.289 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 0.966 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.3 t . . . . . 0 N--CA 1.495 1.793 0 CA-C-O 121.719 0.771 . . . . 0.0 110.984 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 90.8 mm-40 -69.51 -34.74 74.72 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.685 -0.635 . . . . 0.0 110.665 177.167 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.524 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -163.03 173.72 39.26 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.065 -1.541 . . . . 0.0 110.177 -174.111 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.468 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.4 p -114.68 174.63 5.87 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.156 -1.203 . . . . 0.0 110.841 -177.543 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.044 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -142.45 149.24 39.0 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.704 -0.622 . . . . 0.0 109.462 -177.802 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.58 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 29.9 tttt -103.97 118.68 37.24 Favored 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.051 -1.03 . . . . 0.0 110.154 178.065 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 1.017 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.1 tp -60.86 127.42 31.5 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 120.952 -1.092 . . . . 0.0 108.624 170.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.14 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.7 p -130.2 -31.53 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.836 0 O-C-N 121.265 -0.897 . . . . 0.0 110.267 -177.008 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -143.7 139.89 29.75 Favored 'General case' 0 C--N 1.295 -1.772 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.311 -178.649 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.792 HG23 ' CD2' ' B' ' 24' ' ' HIS . 11.2 mt -109.92 130.84 62.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.048 -1.032 . . . . 0.0 110.149 171.259 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.522 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 81.2 m-20 -108.2 114.79 28.95 Favored 'General case' 0 C--N 1.296 -1.722 0 O-C-N 121.42 -0.8 . . . . 0.0 109.912 173.127 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.38 110.79 23.01 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.119 -0.988 . . . . 0.0 110.503 -176.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -110.34 128.1 25.91 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.158 -0.964 . . . . 0.0 109.016 173.971 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -50.8 -33.27 40.2 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 O-C-N 123.758 1.399 . . . . 0.0 110.253 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.471 ' C ' ' CD2' ' B' ' 21' ' ' PHE . 12.3 m-80 -72.32 -40.17 67.66 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.203 -0.935 . . . . 0.0 109.902 175.713 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.471 ' CD2' ' C ' ' B' ' 20' ' ' ASN . 91.1 m-85 -152.33 150.23 29.5 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.393 -0.817 . . . . 0.0 110.233 -178.423 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . 0.498 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 57.5 ttt180 -88.13 139.89 30.05 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.777 -1.202 . . . . 0.0 109.706 173.063 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.522 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 95.6 m -124.96 131.75 53.38 Favored 'General case' 0 C--N 1.295 -1.781 0 O-C-N 121.676 -0.64 . . . . 0.0 109.908 -176.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.792 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -126.18 138.97 53.7 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.011 -1.056 . . . . 0.0 111.241 -179.635 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.778 HG22 ' CB ' ' B' ' 60' ' ' SER . 5.7 t -120.78 134.44 64.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.224 -0.923 . . . . 0.0 110.834 -176.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.804 HG13 ' CE1' ' B' ' 61' ' ' PHE . 35.8 m -115.04 172.08 4.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.773 -0.579 . . . . 0.0 110.021 178.28 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.475 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 9.2 tt0 -104.1 118.05 35.73 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 177.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.87 HD21 HD13 ' B' ' 36' ' ' LEU . 7.5 tp -85.84 127.8 60.96 Favored Pre-proline 0 C--N 1.296 -1.735 0 O-C-N 121.338 -0.851 . . . . 0.0 110.0 -171.209 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.469 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 20.9 Cg_endo -65.95 178.63 2.25 Favored 'Trans proline' 0 C--N 1.308 -1.604 0 O-C-N 123.828 1.436 . . . . 0.0 110.799 -179.365 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.522 ' HA ' HD12 ' B' ' 33' ' ' LEU . 33.8 p-10 -62.74 -39.94 95.68 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.322 -0.861 . . . . 0.0 110.984 -175.47 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.0 0.0 57.34 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.851 -1.156 . . . . 0.0 110.797 -174.363 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.597 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.0 mmm -108.16 -16.87 14.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.84 -1.162 . . . . 0.0 109.62 170.833 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.588 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 24.6 mt -66.36 -25.69 66.92 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.369 -0.832 . . . . 0.0 109.714 174.739 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -92.28 131.31 37.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.48 -0.762 . . . . 0.0 110.525 -178.129 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.76 -41.64 2.72 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 176.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.87 HD13 HD21 ' B' ' 28' ' ' LEU . 5.1 tt -70.81 148.26 48.05 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.033 -1.275 . . . . 0.0 110.267 -177.222 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . 0.733 ' N ' HD23 ' B' ' 36' ' ' LEU . 19.9 pt-20 -156.8 166.39 33.51 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.366 -0.834 . . . . 0.0 109.576 -177.702 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 0.748 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -65.65 148.46 51.72 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.927 -1.108 . . . . 0.0 110.064 -178.886 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.59 -3.33 68.94 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.319 -1.512 . . . . 0.0 109.319 -174.272 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.466 ' CB ' ' O ' ' B' ' 37' ' ' GLU . . . -78.41 159.99 28.01 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.286 -1.126 . . . . 0.0 109.33 176.021 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.457 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -101.56 114.18 27.97 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 120.86 -1.15 . . . . 0.0 110.116 177.177 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.657 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.7 t -99.24 128.77 50.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.319 -0.863 . . . . 0.0 108.923 173.329 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 0.509 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -94.86 119.47 33.47 Favored 'General case' 0 C--N 1.297 -1.707 0 O-C-N 121.083 -1.011 . . . . 0.0 109.135 172.294 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.657 ' HE1' HG11 ' B' ' 42' ' ' VAL . 0.6 OUTLIER -87.42 102.99 15.08 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.376 -0.828 . . . . 0.0 108.975 178.403 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.498 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 58.12 8.9 0.85 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.49 -0.756 . . . . 0.0 111.25 -170.459 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.503 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 123.87 2.73 8.57 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.789 -1.196 . . . . 0.0 110.802 174.709 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.82 ' O ' HD23 ' B' ' 49' ' ' LEU . 42.7 t -98.62 107.26 19.66 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 120.378 -1.66 . . . . 0.0 109.44 174.535 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 26.2 p -74.97 130.04 38.68 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.114 -0.991 . . . . 0.0 111.142 -171.026 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 0.957 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -145.43 160.41 41.62 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.484 -0.76 . . . . 0.0 109.717 173.462 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . 0.423 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 57.7 m -100.7 151.35 21.76 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.781 -1.199 . . . . 0.0 110.982 -171.798 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.734 HG13 HG13 ' B' ' 59' ' ' VAL . 38.2 t -78.67 116.92 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.644 -0.66 . . . . 0.0 110.472 -178.358 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.519 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 38.8 p -70.07 -40.06 75.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.201 -0.937 . . . . 0.0 109.884 174.224 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.614 ' HA ' HG21 ' B' ' 38' ' ' THR . 86.5 tt0 -163.36 153.44 15.6 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.341 -0.849 . . . . 0.0 110.226 -177.683 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.748 HD11 ' N ' ' B' ' 38' ' ' THR . 5.9 mt -104.52 133.65 48.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.151 -0.968 . . . . 0.0 109.937 174.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.52 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 31.3 m-80 -107.82 66.99 0.67 Allowed 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.572 -0.705 . . . . 0.0 109.762 179.194 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.41 -116.08 4.81 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 108.743 -1.743 . . . . 0.0 108.743 -174.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.588 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -79.18 -19.22 51.42 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 120.974 -1.309 . . . . 0.0 108.832 174.478 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.14 ' CD2' HG11 ' B' ' 13' ' ' VAL . 11.1 m170 -74.65 160.53 30.69 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.443 -0.785 . . . . 0.0 110.361 -178.301 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.734 HG13 HG13 ' B' ' 51' ' ' VAL . 62.9 t -141.06 123.22 14.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 O-C-N 121.208 -0.932 . . . . 0.0 110.453 171.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.778 ' CB ' HG22 ' B' ' 25' ' ' VAL . 13.4 m -91.43 130.87 37.21 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.632 -0.667 . . . . 0.0 109.553 178.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.957 ' HB2' HD12 ' B' ' 49' ' ' LEU . 3.9 p90 -124.96 153.43 42.76 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.188 -0.945 . . . . 0.0 110.255 -179.721 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.519 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 27.4 p-10 -88.58 152.21 21.99 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.976 -1.077 . . . . 0.0 111.466 -170.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.831 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -155.71 114.4 3.48 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 -176.154 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.512 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 7.1 ttp -71.62 139.97 49.54 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.867 -1.146 . . . . 0.0 109.799 -178.076 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.501 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 37.5 ttpt -60.06 -45.98 91.06 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.128 -0.982 . . . . 0.0 110.477 -173.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -70.06 -39.98 75.36 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.806 -1.184 . . . . 0.0 110.023 178.591 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.512 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 34.4 m -61.94 -34.98 77.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.035 -1.041 . . . . 0.0 109.342 173.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.702 HD11 ' HA2' ' B' ' 74' ' ' GLY . 7.6 tp -60.05 -45.47 92.74 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.312 -0.867 . . . . 0.0 109.243 178.26 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 71.8 ttt-85 -66.7 -39.96 88.27 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.356 -0.84 . . . . 0.0 110.652 175.051 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.768 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -66.71 -44.23 89.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.144 -0.973 . . . . 0.0 109.595 -175.602 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.768 HG23 HG22 ' B' ' 70' ' ' ILE . 31.2 p -83.05 -175.02 5.63 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 120.114 -0.634 . . . . 0.0 109.477 175.518 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.492 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 3.7 t30 -99.56 23.68 9.16 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 171.125 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.831 ' HB3' HD21 ' B' ' 63' ' ' LEU . 90.7 mt -70.05 -39.96 75.4 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.123 -0.985 . . . . 0.0 110.089 176.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.702 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -53.79 -18.0 7.7 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 -177.11 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.4 p-10 -70.06 -18.99 63.3 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.039 -1.271 . . . . 0.0 110.578 -175.556 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.511 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 88.1 mt -62.14 141.89 57.91 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.231 -0.918 . . . . 0.0 110.828 -177.025 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 1.017 ' C ' HD23 ' B' ' 12' ' ' LEU . 43.4 mtmt -141.52 141.72 33.58 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.666 -0.646 . . . . 0.0 109.787 174.321 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.744 HG23 HD11 ' B' ' 15' ' ' ILE . 16.7 t -60.31 152.51 5.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.957 -1.09 . . . . 0.0 110.43 -174.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.38 -15.59 58.16 Favored Glycine 0 N--CA 1.484 1.846 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -176.415 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 38.0 t0 -95.97 166.68 11.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.422 -1.046 . . . . 0.0 109.655 175.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.58 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.4 m95 -116.76 160.53 20.66 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.15 -0.968 . . . . 0.0 110.176 178.076 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 1.044 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.1 p -125.56 155.35 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.407 -0.808 . . . . 0.0 109.979 -178.056 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.966 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.2 OUTLIER -80.01 104.89 10.89 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.093 -1.004 . . . . 0.0 109.003 168.296 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.809 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -105.54 138.18 31.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 120.559 -1.338 . . . . 0.0 111.075 -176.491 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -133.71 140.08 46.79 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 120.335 -0.546 . . . . 0.0 110.05 -178.103 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . 0.538 ' NH1' ' HB2' ' B' ' 86' ' ' ARG . 26.8 ttm105 -78.34 126.92 31.46 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.213 -0.929 . . . . 0.0 110.642 -176.014 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.457 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.766 0 O-C-N 121.334 -0.854 . . . . 0.0 110.015 176.286 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.979 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.7 t . . . . . 0 N--CA 1.493 1.707 0 CA-C-O 121.726 0.774 . . . . 0.0 110.784 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 79.2 mm-40 -69.97 -34.84 73.91 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.64 -0.663 . . . . 0.0 110.843 178.275 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.528 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -158.28 179.19 34.15 Favored Glycine 0 N--CA 1.494 2.527 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.235 -173.167 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.47 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 1.0 OUTLIER -118.54 170.0 9.32 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.117 -1.226 . . . . 0.0 110.956 -177.962 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 1.13 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -136.55 149.7 48.23 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.667 -0.646 . . . . 0.0 109.448 -179.237 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 39.6 tttt -110.57 117.87 34.69 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.024 -1.048 . . . . 0.0 110.455 -179.44 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.98 HD23 ' C ' ' A' ' 77' ' ' LYS . 10.9 tp -60.04 126.26 26.83 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.882 -1.136 . . . . 0.0 108.979 172.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.064 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -125.76 -31.67 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 O-C-N 121.471 -0.768 . . . . 0.0 109.545 179.252 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.09 143.12 30.24 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.453 -0.899 . . . . 0.0 111.103 -179.648 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.759 HG23 ' CD2' ' A' ' 24' ' ' HIS . 18.0 mt -106.71 134.98 46.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.038 -1.039 . . . . 0.0 110.0 171.027 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.515 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 56.0 m-20 -107.53 115.81 30.83 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.274 -0.891 . . . . 0.0 109.851 174.067 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -107.06 111.88 24.55 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.057 -1.027 . . . . 0.0 110.467 -176.448 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 8.2 mtmm -109.09 131.28 21.9 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.217 -0.927 . . . . 0.0 109.262 175.686 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -51.13 -22.88 11.69 Favored 'Trans proline' 0 C--N 1.304 -1.78 0 O-C-N 123.954 1.502 . . . . 0.0 111.052 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.582 ' O ' ' CD1' ' A' ' 21' ' ' PHE . 7.4 m-80 -92.78 -33.61 14.21 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.085 -1.009 . . . . 0.0 109.983 177.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.582 ' CD1' ' O ' ' A' ' 20' ' ' ASN . 36.3 m-85 -148.2 150.17 33.27 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.488 -0.758 . . . . 0.0 110.026 -177.516 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.68 ' HD3' HD22 ' A' ' 68' ' ' LEU . 60.4 ttt180 -95.76 143.5 26.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.668 -1.27 . . . . 0.0 109.964 173.739 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.515 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 56.3 m -132.61 145.65 51.27 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.494 -0.754 . . . . 0.0 109.955 -176.095 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.759 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -134.2 134.06 41.64 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.943 -1.098 . . . . 0.0 111.327 -179.666 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.732 HG22 ' CB ' ' A' ' 60' ' ' SER . 5.3 t -113.62 132.75 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.071 -1.018 . . . . 0.0 110.856 -177.32 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.546 HG22 ' HE2' ' A' ' 61' ' ' PHE . 12.9 m -118.79 170.93 7.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 CA-C-O 121.317 0.579 . . . . 0.0 110.331 -179.17 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.497 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 15.3 tt0 -100.08 116.65 32.6 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 177.789 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.879 HD13 ' HD2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -86.15 118.5 70.51 Favored Pre-proline 0 C--N 1.295 -1.798 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -175.36 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.879 ' HD2' HD13 ' A' ' 28' ' ' LEU . 19.6 Cg_endo -63.25 170.78 7.34 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 O-C-N 123.801 1.422 . . . . 0.0 110.976 -178.527 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.603 ' HA ' HD12 ' A' ' 33' ' ' LEU . 34.1 p-10 -61.26 -35.85 78.42 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.477 -0.765 . . . . 0.0 110.83 -175.713 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.602 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.69 -0.49 57.71 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.828 -1.17 . . . . 0.0 110.874 -173.486 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.604 ' HB3' HD11 ' A' ' 28' ' ' LEU . 99.9 mmm -116.69 -11.17 11.01 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.984 -1.072 . . . . 0.0 109.933 169.499 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.603 HD12 ' HA ' ' A' ' 30' ' ' ASP . 13.2 mt -65.67 -37.95 87.93 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.07 -1.019 . . . . 0.0 109.599 175.168 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -69.04 132.25 46.34 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.486 -0.759 . . . . 0.0 110.746 -177.402 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.12 -40.12 2.8 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 173.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 59.1 tp -69.2 145.44 53.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.03 -1.277 . . . . 0.0 110.688 -175.262 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.518 ' C ' HD11 ' A' ' 54' ' ' ILE . 16.8 pt-20 -148.01 169.1 20.64 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.591 -0.693 . . . . 0.0 109.408 177.445 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.844 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -64.53 148.56 50.45 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.9 -1.125 . . . . 0.0 109.83 178.291 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.42 -4.66 62.85 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -176.45 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -74.45 159.13 32.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.257 -1.143 . . . . 0.0 109.499 176.568 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.462 ' HB2' ' HB3' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -100.51 117.42 34.63 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 118.909 -1.116 . . . . 0.0 109.885 176.642 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.614 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.1 t -105.97 126.25 61.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.333 -0.855 . . . . 0.0 109.079 175.262 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -89.72 118.62 29.46 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.185 -1.006 . . . . 0.0 109.191 172.282 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.736 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -88.8 100.99 13.58 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 177.054 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.491 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 59.59 8.79 1.35 Allowed 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.486 -0.759 . . . . 0.0 111.143 -168.514 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.49 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 128.76 -12.69 6.18 Favored Glycine 0 N--CA 1.489 2.197 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.8 174.167 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.765 ' O ' HD23 ' A' ' 49' ' ' LEU . 42.8 t -85.97 110.05 19.2 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.356 -1.673 . . . . 0.0 109.779 179.196 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 19.6 p -77.65 113.4 15.46 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.304 -0.872 . . . . 0.0 110.984 -172.376 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.931 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -130.33 161.18 31.86 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.436 -0.79 . . . . 0.0 109.119 172.628 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 57.2 m -103.93 155.08 18.93 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.492 -1.38 . . . . 0.0 111.356 -168.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.756 HG13 HG13 ' A' ' 59' ' ' VAL . 21.2 t -77.44 112.79 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.677 -0.64 . . . . 0.0 110.379 -179.51 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.625 HG22 ' HB3' ' A' ' 62' ' ' ASP . 17.6 p -69.95 -40.0 75.72 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.211 -0.931 . . . . 0.0 109.493 172.193 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.404 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.0 tt0 -158.46 153.9 25.96 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 119.322 -0.951 . . . . 0.0 110.845 -177.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.844 HD11 ' N ' ' A' ' 38' ' ' THR . 13.6 mt -110.37 130.06 64.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.181 -0.95 . . . . 0.0 109.887 172.713 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.491 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 9.7 m-80 -103.73 63.67 0.78 Allowed 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.542 -0.724 . . . . 0.0 109.723 178.899 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.69 -112.51 3.55 Favored Glycine 0 N--CA 1.487 2.07 0 N-CA-C 108.691 -1.764 . . . . 0.0 108.691 -173.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.539 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.1 -22.49 42.14 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.988 -1.301 . . . . 0.0 108.846 174.201 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.064 ' CD2' HG11 ' A' ' 13' ' ' VAL . 8.9 m170 -74.58 158.69 33.27 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.123 -0.985 . . . . 0.0 110.218 -176.211 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.756 HG13 HG13 ' A' ' 51' ' ' VAL . 80.2 t -141.31 119.68 9.72 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 C-N-CA 119.312 -0.955 . . . . 0.0 110.923 175.693 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.732 ' CB ' HG22 ' A' ' 25' ' ' VAL . 15.9 m -88.65 126.21 35.19 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.627 -0.671 . . . . 0.0 109.739 178.672 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.931 ' HB3' HD12 ' A' ' 49' ' ' LEU . 98.0 m-85 -109.9 156.53 20.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.788 -1.195 . . . . 0.0 110.396 179.52 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.625 ' HB3' HG22 ' A' ' 52' ' ' THR . 19.8 p-10 -89.8 148.22 23.34 Favored 'General case' 0 N--CA 1.494 1.738 0 CA-C-O 122.045 0.926 . . . . 0.0 110.878 178.856 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.823 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -155.53 116.6 3.91 Favored 'General case' 0 C--N 1.296 -1.759 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -176.483 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.534 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 93.2 mmm -69.97 141.72 52.96 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 119.109 -1.037 . . . . 0.0 109.518 179.738 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.421 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 46.8 tttp -60.0 -45.15 93.69 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.103 -0.998 . . . . 0.0 110.195 -176.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.457 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.4 tt0 -69.44 -40.04 77.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.984 -1.072 . . . . 0.0 110.283 177.642 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.534 ' HB ' ' HB2' ' A' ' 64' ' ' MET . 89.8 m -61.69 -39.38 91.24 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.927 -1.108 . . . . 0.0 109.278 174.091 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.68 HD22 ' HD3' ' A' ' 22' ' ' ARG . 7.7 tp -60.09 -43.57 95.42 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.325 -0.86 . . . . 0.0 109.364 178.022 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 92.6 mtt180 -69.86 -39.97 76.05 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.545 -0.722 . . . . 0.0 110.692 176.03 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.772 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -69.94 -41.61 79.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.246 -0.909 . . . . 0.0 109.404 -176.078 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.772 HG23 HG22 ' A' ' 70' ' ' ILE . 65.3 p -83.59 -173.94 5.0 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 178.072 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 3.0 t30 -100.73 22.62 11.68 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 170.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.823 ' HB3' HD21 ' A' ' 63' ' ' LEU . 96.6 mt -69.91 -40.2 75.75 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.013 -1.054 . . . . 0.0 110.053 174.653 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.604 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -52.99 -24.27 19.48 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 -176.095 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 25.9 p-10 -64.98 -19.67 66.1 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.043 -1.269 . . . . 0.0 110.634 -174.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.52 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 95.8 mt -60.01 140.25 56.9 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.216 -0.928 . . . . 0.0 110.923 -177.056 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 0.98 ' C ' HD23 ' A' ' 12' ' ' LEU . 75.9 mttt -140.92 144.1 35.0 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 173.606 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.617 ' N ' HD23 ' A' ' 12' ' ' LEU . 12.0 t -59.32 152.0 4.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 120.731 -1.231 . . . . 0.0 110.304 -173.538 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.15 -15.81 57.27 Favored Glycine 0 N--CA 1.484 1.847 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 -177.37 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 52.7 t0 -93.41 164.58 13.15 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.284 -1.127 . . . . 0.0 109.684 176.104 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.584 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.3 m95 -115.4 168.15 10.24 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.062 -1.023 . . . . 0.0 110.253 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.13 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.5 p -131.97 155.56 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.518 -0.739 . . . . 0.0 110.039 -178.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.979 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.6 m-20 -80.57 109.86 15.49 Favored 'General case' 0 C--N 1.296 -1.75 0 O-C-N 121.007 -1.058 . . . . 0.0 109.12 167.725 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.605 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -109.76 138.62 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.577 -1.327 . . . . 0.0 111.232 -175.301 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -137.02 138.53 40.57 Favored 'General case' 0 N--CA 1.494 1.741 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.801 -178.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 83.9 mtm180 -78.41 142.33 37.67 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.958 -1.089 . . . . 0.0 110.951 -176.14 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.462 ' HB3' ' HB2' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.492 1.663 0 O-C-N 121.387 -0.82 . . . . 0.0 110.133 176.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 0.954 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.7 t . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.658 0.742 . . . . 0.0 110.78 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 79.3 mm-40 -70.05 -34.63 73.46 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.79 -0.569 . . . . 0.0 110.842 178.284 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.53 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -158.56 179.01 34.53 Favored Glycine 0 N--CA 1.494 2.553 0 C-N-CA 119.048 -1.548 . . . . 0.0 110.227 -173.101 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.469 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 1.0 OUTLIER -118.45 170.03 9.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.094 -1.239 . . . . 0.0 110.976 -177.851 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.121 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -136.55 149.85 48.31 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.671 -0.643 . . . . 0.0 109.381 -179.329 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 39.8 tttt -110.65 117.98 34.96 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.048 -1.033 . . . . 0.0 110.39 -179.439 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 0.979 HD23 ' C ' ' B' ' 77' ' ' LYS . 10.9 tp -60.33 126.13 26.32 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.037 -1.039 . . . . 0.0 109.085 172.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.062 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -125.65 -31.54 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 O-C-N 121.442 -0.786 . . . . 0.0 109.684 179.488 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.23 143.15 30.11 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 119.516 -0.874 . . . . 0.0 111.092 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.759 HG23 ' CD2' ' B' ' 24' ' ' HIS . 17.8 mt -106.67 134.88 47.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.005 -1.06 . . . . 0.0 110.03 171.046 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.53 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 55.7 m-20 -107.54 115.88 30.94 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.28 -0.888 . . . . 0.0 109.898 174.079 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -107.05 111.78 24.41 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.035 -1.04 . . . . 0.0 110.428 -176.342 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.456 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 8.2 mtmm -109.02 131.27 21.9 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.259 -0.901 . . . . 0.0 109.288 175.623 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -51.11 -23.02 11.86 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 O-C-N 123.868 1.457 . . . . 0.0 111.061 -179.209 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.571 ' O ' ' CD1' ' B' ' 21' ' ' PHE . 7.4 m-80 -92.46 -34.22 14.2 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.065 -1.022 . . . . 0.0 109.879 177.827 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.571 ' CD1' ' O ' ' B' ' 20' ' ' ASN . 36.3 m-85 -147.7 150.23 33.93 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.431 -0.793 . . . . 0.0 110.026 -177.36 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . 0.671 ' HD3' HD22 ' B' ' 68' ' ' LEU . 60.3 ttt180 -95.74 143.53 26.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.756 -1.215 . . . . 0.0 110.058 173.559 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.53 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 55.9 m -132.59 145.61 51.24 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.503 -0.748 . . . . 0.0 110.029 -176.135 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.759 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -134.04 134.09 41.98 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.085 -1.009 . . . . 0.0 111.197 -179.517 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.736 HG22 ' CB ' ' B' ' 60' ' ' SER . 5.4 t -113.68 133.0 61.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.207 -0.933 . . . . 0.0 110.778 -177.41 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.536 HG22 ' HE2' ' B' ' 61' ' ' PHE . 13.2 m -119.05 170.94 7.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-O 121.232 0.539 . . . . 0.0 110.268 -179.067 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.51 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 15.3 tt0 -100.03 116.71 32.71 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 177.714 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.923 HD13 ' HD2' ' B' ' 29' ' ' PRO . 0.0 OUTLIER -86.11 118.35 70.28 Favored Pre-proline 0 C--N 1.295 -1.804 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 -175.422 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.923 ' HD2' HD13 ' B' ' 28' ' ' LEU . 19.5 Cg_endo -63.13 170.75 7.22 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 O-C-N 123.802 1.422 . . . . 0.0 110.96 -178.525 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.617 ' HA ' HD12 ' B' ' 33' ' ' LEU . 34.1 p-10 -61.28 -35.74 78.15 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.47 -0.769 . . . . 0.0 110.873 -175.741 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.595 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.74 -0.48 57.72 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.783 -1.198 . . . . 0.0 110.839 -173.487 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.595 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.9 mmm -116.64 -11.22 11.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.857 -1.152 . . . . 0.0 109.984 169.509 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.617 HD12 ' HA ' ' B' ' 30' ' ' ASP . 13.2 mt -65.68 -38.02 88.1 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.013 -1.054 . . . . 0.0 109.626 175.165 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -68.99 132.27 46.39 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.549 -0.719 . . . . 0.0 110.792 -177.404 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.1 -40.16 2.8 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 110.346 -1.102 . . . . 0.0 110.346 174.061 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 59.0 tp -69.13 145.49 53.3 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.045 -1.268 . . . . 0.0 110.726 -175.302 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . 0.496 ' C ' HD11 ' B' ' 54' ' ' ILE . 16.8 pt-20 -147.98 169.1 20.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.506 -0.746 . . . . 0.0 109.423 177.473 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 0.843 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -64.66 148.48 50.89 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.939 -1.101 . . . . 0.0 109.859 178.298 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.57 -4.67 63.44 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -176.464 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -74.49 158.98 32.86 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.121 -1.223 . . . . 0.0 109.492 176.474 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.45 ' HB2' ' HB3' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -100.37 117.21 34.09 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 120.94 -1.1 . . . . 0.0 110.029 176.584 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.636 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.1 t -105.96 126.28 61.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.383 -0.823 . . . . 0.0 109.105 175.316 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 0.513 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -89.7 118.64 29.46 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 119.133 -1.027 . . . . 0.0 109.114 172.351 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.742 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -88.77 100.72 13.36 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 176.994 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.491 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 59.88 8.79 1.49 Allowed 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.53 -0.731 . . . . 0.0 110.987 -168.642 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.49 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 128.68 -12.65 6.21 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.583 -1.294 . . . . 0.0 110.818 174.151 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.757 ' O ' HD23 ' B' ' 49' ' ' LEU . 41.7 t -85.97 109.94 19.12 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.259 -1.73 . . . . 0.0 109.757 179.151 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 19.4 p -77.54 113.44 15.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.227 -0.92 . . . . 0.0 110.969 -172.465 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 0.947 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -130.46 161.1 32.17 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.355 -0.841 . . . . 0.0 109.129 172.521 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 57.5 m -103.76 155.2 18.78 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.545 -1.347 . . . . 0.0 111.277 -168.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.78 HG13 HG13 ' B' ' 59' ' ' VAL . 21.2 t -77.62 112.79 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.606 -0.683 . . . . 0.0 110.415 -179.525 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.632 HG22 ' HB3' ' B' ' 62' ' ' ASP . 17.7 p -69.93 -40.05 75.77 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.16 -0.963 . . . . 0.0 109.512 172.339 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.411 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.0 tt0 -158.5 153.74 25.61 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.757 -177.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.843 HD11 ' N ' ' B' ' 38' ' ' THR . 13.7 mt -110.23 130.03 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.205 -0.934 . . . . 0.0 109.908 172.738 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.501 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 9.6 m-80 -103.73 63.64 0.78 Allowed 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.943 -0.703 . . . . 0.0 109.692 178.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.77 -112.5 3.55 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 108.638 -1.785 . . . . 0.0 108.638 -173.625 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.532 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.07 -22.64 42.04 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.865 -1.373 . . . . 0.0 108.873 174.206 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.062 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.0 m170 -74.42 158.53 33.72 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.175 -0.953 . . . . 0.0 110.263 -176.278 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.78 HG13 HG13 ' B' ' 51' ' ' VAL . 79.9 t -141.26 119.72 9.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 C-N-CA 119.158 -1.017 . . . . 0.0 110.817 175.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.736 ' CB ' HG22 ' B' ' 25' ' ' VAL . 15.9 m -88.69 126.4 35.29 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.617 -0.677 . . . . 0.0 109.73 178.679 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.947 ' HB3' HD12 ' B' ' 49' ' ' LEU . 98.0 m-85 -110.08 156.49 20.49 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.867 -1.146 . . . . 0.0 110.374 179.554 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.632 ' HB3' HG22 ' B' ' 52' ' ' THR . 19.8 p-10 -89.72 148.2 23.41 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.209 -0.932 . . . . 0.0 110.9 178.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.805 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -155.51 116.72 3.94 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -176.585 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.517 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 93.1 mmm -70.04 141.67 52.84 Favored 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 119.119 -1.032 . . . . 0.0 109.552 179.683 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.416 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 46.8 tttp -60.06 -45.08 94.05 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.172 -0.955 . . . . 0.0 110.119 -176.7 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . 0.463 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 86.5 tt0 -69.38 -40.0 77.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.102 -0.999 . . . . 0.0 110.333 177.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.517 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 89.2 m -61.73 -39.6 92.13 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.959 -1.088 . . . . 0.0 109.16 174.148 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.671 HD22 ' HD3' ' B' ' 22' ' ' ARG . 7.7 tp -59.98 -43.41 95.15 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.562 -0.711 . . . . 0.0 109.47 178.077 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 92.7 mtt180 -69.96 -39.98 75.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.449 -0.782 . . . . 0.0 110.67 175.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.77 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -70.06 -41.35 79.17 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.278 -0.889 . . . . 0.0 109.52 -176.131 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.77 HG23 HG22 ' B' ' 70' ' ' ILE . 65.5 p -83.56 -173.81 4.93 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 177.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.53 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 3.1 t30 -100.78 22.66 11.68 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 170.827 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.805 ' HB3' HD21 ' B' ' 63' ' ' LEU . 96.9 mt -69.96 -40.09 75.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.116 -0.99 . . . . 0.0 110.071 174.665 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.597 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -53.01 -24.34 19.93 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 110.409 -1.077 . . . . 0.0 110.409 -176.127 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.1 p-10 -64.97 -19.65 66.09 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.116 -1.226 . . . . 0.0 110.632 -174.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.521 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 95.8 mt -60.02 140.19 56.95 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.187 -0.946 . . . . 0.0 110.901 -177.065 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 0.979 ' C ' HD23 ' B' ' 12' ' ' LEU . 76.0 mttt -140.92 144.1 34.99 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 173.607 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.618 ' N ' HD23 ' B' ' 12' ' ' LEU . 12.1 t -59.34 151.95 4.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 120.76 -1.213 . . . . 0.0 110.335 -173.519 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.18 -15.72 57.54 Favored Glycine 0 N--CA 1.484 1.847 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 -177.396 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 52.6 t0 -93.47 164.4 13.21 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.432 -1.04 . . . . 0.0 109.675 176.043 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.2 m95 -115.28 168.16 10.21 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.132 -0.98 . . . . 0.0 110.373 178.312 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 1.121 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.5 p -132.04 155.55 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.547 -0.721 . . . . 0.0 109.965 -178.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.954 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -80.4 109.67 15.12 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.009 -1.057 . . . . 0.0 109.174 167.729 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.589 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -109.45 138.95 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 120.66 -1.275 . . . . 0.0 111.138 -175.233 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -137.48 138.51 39.8 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.894 -0.504 . . . . 0.0 109.724 -179.056 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 83.9 mtm180 -78.35 142.44 37.68 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.042 -1.036 . . . . 0.0 110.917 -176.062 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.45 ' HB3' ' HB2' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.493 1.685 0 O-C-N 121.359 -0.838 . . . . 0.0 110.103 176.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.834 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.4 t . . . . . 0 N--CA 1.494 1.736 0 CA-C-O 121.508 0.671 . . . . 0.0 110.611 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.425 ' OE1' ' HG2' ' A' ' 86' ' ' ARG . 18.2 pt20 -93.34 -23.81 18.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.55 -0.719 . . . . 0.0 110.787 179.266 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.538 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -150.52 173.99 29.98 Favored Glycine 0 N--CA 1.493 2.487 0 C-N-CA 119.328 -1.415 . . . . 0.0 109.758 -175.485 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.478 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 2.2 p -123.37 170.83 9.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.845 -1.386 . . . . 0.0 110.981 -177.436 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 1.014 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -139.33 149.46 44.22 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.562 -0.711 . . . . 0.0 109.259 -179.649 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.575 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 33.3 tttt -106.73 115.43 30.19 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 120.908 -1.12 . . . . 0.0 110.254 179.535 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 1.014 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.2 tp -58.55 127.19 30.91 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 120.82 -1.175 . . . . 0.0 108.688 173.329 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.09 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.6 p -130.05 -30.14 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.898 0 O-C-N 121.345 -0.847 . . . . 0.0 109.946 -177.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -145.1 140.44 28.04 Favored 'General case' 0 N--CA 1.494 1.735 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.974 -179.439 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.778 HG23 ' CD2' ' A' ' 24' ' ' HIS . 13.9 mt -107.53 131.11 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 120.991 -1.068 . . . . 0.0 110.185 172.339 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.512 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.7 m-20 -108.53 114.87 29.04 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.384 -0.823 . . . . 0.0 109.873 174.692 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -107.11 112.38 25.27 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.002 -1.061 . . . . 0.0 110.522 -176.129 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 6.1 mtmt -107.94 129.93 23.48 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.219 -0.926 . . . . 0.0 109.177 175.24 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_endo -51.85 -24.47 18.73 Favored 'Trans proline' 0 C--N 1.303 -1.864 0 O-C-N 123.779 1.41 . . . . 0.0 110.279 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 10.7 m-80 -81.2 -39.74 24.95 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.24 -0.913 . . . . 0.0 110.182 175.417 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 95.1 m-85 -156.68 150.22 24.52 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.433 -0.792 . . . . 0.0 109.971 -178.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.493 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 59.6 ttt180 -91.93 145.13 24.79 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.807 -1.183 . . . . 0.0 110.327 178.771 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.512 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 74.9 m -129.98 140.02 50.97 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.583 -0.698 . . . . 0.0 109.718 -176.156 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.778 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -128.74 128.32 43.79 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.858 -1.152 . . . . 0.0 111.324 178.184 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.823 HG22 ' OG ' ' A' ' 60' ' ' SER . 4.3 t -104.95 131.42 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.283 -0.886 . . . . 0.0 110.695 -178.108 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.495 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 33.4 m -115.91 168.16 7.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 O-C-N 121.962 -0.461 . . . . 0.0 109.963 179.427 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.511 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 2.5 tm-20 -101.11 115.31 30.19 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.305 -0.872 . . . . 0.0 109.409 178.538 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.785 HD21 HD13 ' A' ' 36' ' ' LEU . 9.8 tp -79.15 125.33 83.74 Favored Pre-proline 0 C--N 1.295 -1.804 0 O-C-N 121.617 -0.677 . . . . 0.0 109.868 -176.543 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.536 ' HD2' HD12 ' A' ' 28' ' ' LEU . 27.7 Cg_endo -67.5 -179.16 1.79 Allowed 'Trans proline' 0 C--N 1.309 -1.552 0 O-C-N 123.894 1.471 . . . . 0.0 110.826 -179.54 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 31' ' ' HIS . 32.3 p-10 -64.85 -40.02 94.5 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.322 -0.861 . . . . 0.0 110.952 -175.56 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.01 1.32 56.44 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.939 -1.101 . . . . 0.0 110.987 -174.037 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.597 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 98.7 mmm -112.17 -14.14 13.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.854 -1.154 . . . . 0.0 109.871 171.411 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.581 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 19.2 mt -69.93 -20.38 63.34 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.39 -0.818 . . . . 0.0 110.437 176.203 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -61.0 123.05 16.5 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.088 -1.007 . . . . 0.0 111.286 -171.276 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 48.92 54.72 13.29 Favored Glycine 0 N--CA 1.493 2.498 0 C-N-CA 120.339 -0.934 . . . . 0.0 111.015 169.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.802 HD23 ' N ' ' A' ' 37' ' ' GLU . 6.4 tt -113.25 155.44 25.07 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.83 -1.394 . . . . 0.0 110.181 174.131 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.802 ' N ' HD23 ' A' ' 36' ' ' LEU . 21.3 pt-20 -149.95 167.85 25.48 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.221 -0.924 . . . . 0.0 110.139 -178.207 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 1.038 HG23 HD12 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -68.09 155.27 39.92 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.212 -0.93 . . . . 0.0 109.754 177.539 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.56 -8.86 63.63 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.744 -1.343 . . . . 0.0 109.744 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.669 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -75.37 159.91 30.88 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.11 -1.229 . . . . 0.0 109.753 178.126 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.45 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -105.2 120.2 40.95 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.831 -1.168 . . . . 0.0 110.309 -179.416 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.573 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.6 t -109.95 132.51 58.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.328 -0.858 . . . . 0.0 109.193 172.74 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.51 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -92.38 119.95 32.42 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.145 -0.972 . . . . 0.0 109.337 172.59 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.786 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -89.83 106.92 18.79 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.402 -0.811 . . . . 0.0 109.109 177.865 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.493 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.6 t-20 52.57 17.59 0.82 Allowed 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.39 -0.819 . . . . 0.0 110.503 -166.5 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.506 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 116.35 -4.81 19.77 Favored Glycine 0 N--CA 1.487 2.084 0 C-N-CA 119.64 -1.267 . . . . 0.0 110.831 170.219 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.758 ' O ' HD23 ' A' ' 49' ' ' LEU . 17.3 t -90.08 109.84 20.87 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.345 -1.679 . . . . 0.0 109.084 174.491 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.436 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 27.5 p -77.68 124.89 28.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.996 -1.065 . . . . 0.0 110.691 -172.397 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.967 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -136.85 166.38 23.74 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.353 -0.842 . . . . 0.0 108.945 172.128 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.457 ' O ' ' OD1' ' A' ' 62' ' ' ASP . 54.9 m -103.13 154.18 19.56 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.574 -1.329 . . . . 0.0 111.146 -169.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.82 HG13 HG13 ' A' ' 59' ' ' VAL . 7.0 t -74.67 113.26 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.899 -0.5 . . . . 0.0 110.034 -179.294 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.616 HG22 ' HB3' ' A' ' 62' ' ' ASP . 19.0 p -75.3 -43.59 50.21 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.365 -0.835 . . . . 0.0 109.57 176.209 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.463 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -158.36 150.53 21.77 Favored 'General case' 0 N--CA 1.491 1.621 0 C-N-CA 119.576 -0.85 . . . . 0.0 110.335 179.246 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 1.038 HD12 HG23 ' A' ' 38' ' ' THR . 2.5 mp -108.18 132.3 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.225 -0.922 . . . . 0.0 110.304 175.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.485 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 54.9 m-80 -108.26 66.24 0.65 Allowed 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.662 -0.649 . . . . 0.0 109.541 177.824 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.44 -119.36 5.79 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 108.794 -1.722 . . . . 0.0 108.794 -173.112 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.581 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -77.12 -17.71 58.46 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.016 -1.285 . . . . 0.0 109.009 176.084 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.09 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.1 m170 -77.57 160.09 28.82 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.312 -0.867 . . . . 0.0 110.419 -178.447 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.82 HG13 HG13 ' A' ' 51' ' ' VAL . 94.1 t -145.16 117.83 2.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 C-N-CA 119.379 -0.928 . . . . 0.0 110.879 175.423 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.823 ' OG ' HG22 ' A' ' 25' ' ' VAL . 19.6 m -81.92 125.3 30.58 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.529 -0.732 . . . . 0.0 109.592 175.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.967 ' HB3' HD12 ' A' ' 49' ' ' LEU . 82.9 m-85 -110.03 154.78 22.73 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.898 -1.127 . . . . 0.0 110.23 178.73 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.616 ' HB3' HG22 ' A' ' 52' ' ' THR . 9.1 p-10 -89.54 148.18 23.53 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.132 -0.98 . . . . 0.0 111.265 -176.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.703 ' CD2' HD12 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -159.16 102.2 1.6 Allowed 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.705 -0.622 . . . . 0.0 109.485 -175.363 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.498 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 54.5 ttm -59.98 140.16 56.93 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.892 -1.13 . . . . 0.0 109.47 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.483 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 22.0 tptm -60.05 -43.45 95.38 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.027 -1.046 . . . . 0.0 110.315 -174.472 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.68 -39.96 76.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.974 -1.079 . . . . 0.0 110.012 177.695 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.498 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 93.7 m -60.95 -38.39 85.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.996 -1.065 . . . . 0.0 109.294 173.135 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.703 HD12 ' CD2' ' A' ' 63' ' ' LEU . 7.1 tp -59.96 -45.71 91.8 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.325 -0.859 . . . . 0.0 109.746 178.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 76.5 ttt-85 -69.32 -39.67 78.07 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.428 -0.795 . . . . 0.0 110.438 177.739 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.772 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -64.65 -41.57 92.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.171 -0.955 . . . . 0.0 109.434 -176.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.772 HG23 HG22 ' A' ' 70' ' ' ILE . 42.0 p -85.25 -174.62 5.33 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 175.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.481 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 2.6 t30 -101.11 21.82 13.29 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 171.624 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.691 ' HB3' HD21 ' A' ' 63' ' ' LEU . 41.9 mt -69.99 -40.05 75.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.012 -1.055 . . . . 0.0 110.304 175.122 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.664 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -48.62 -22.29 2.6 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 -178.548 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.4 p-10 -66.11 -16.49 64.0 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.137 -1.213 . . . . 0.0 110.588 -174.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 94.7 mt -59.99 141.44 55.61 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.276 -0.89 . . . . 0.0 110.763 -176.232 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 1.014 ' C ' HD23 ' A' ' 12' ' ' LEU . 95.1 mttt -140.0 139.77 36.1 Favored 'General case' 0 N--CA 1.493 1.678 0 CA-C-O 121.337 0.589 . . . . 0.0 109.444 174.202 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.72 HG23 HD11 ' A' ' 15' ' ' ILE . 16.4 t -60.51 152.45 5.39 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 120.788 -1.195 . . . . 0.0 110.383 -176.225 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.0 -15.56 57.66 Favored Glycine 0 N--CA 1.484 1.86 0 N-CA-C 108.811 -1.716 . . . . 0.0 108.811 -176.045 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 9.2 t0 -95.28 165.51 12.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.347 -1.09 . . . . 0.0 109.689 175.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.575 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.5 m95 -114.55 157.2 23.33 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.058 -1.027 . . . . 0.0 110.202 177.504 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.014 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.3 p -120.04 149.34 22.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.429 -0.795 . . . . 0.0 109.843 -179.18 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.834 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -75.79 104.36 6.3 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.021 -1.049 . . . . 0.0 109.43 169.286 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.67 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -106.21 137.76 34.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 120.459 -1.401 . . . . 0.0 111.392 -176.943 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.421 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.5 tt0 -130.06 144.86 51.57 Favored 'General case' 0 N--CA 1.495 1.78 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.986 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.458 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 34.0 ptt180 -81.45 133.67 35.44 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.261 -0.899 . . . . 0.0 111.024 -176.235 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.45 ' O ' ' OG ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.492 1.672 0 O-C-N 121.429 -0.794 . . . . 0.0 110.176 175.864 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 0.835 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.4 t . . . . . 0 N--CA 1.494 1.734 0 CA-C-O 121.544 0.688 . . . . 0.0 110.628 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.424 ' OE1' ' HG2' ' B' ' 86' ' ' ARG . 18.2 pt20 -93.48 -23.61 18.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.508 -0.745 . . . . 0.0 110.834 179.264 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.536 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -150.62 173.87 30.09 Favored Glycine 0 N--CA 1.493 2.498 0 C-N-CA 119.396 -1.383 . . . . 0.0 109.911 -175.553 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.479 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 2.2 p -123.3 170.83 9.9 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.001 -1.293 . . . . 0.0 110.932 -177.386 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.055 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -139.33 149.54 44.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.592 -0.693 . . . . 0.0 109.165 -179.634 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.58 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 33.4 tttt -106.82 115.58 30.43 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.045 -1.034 . . . . 0.0 110.139 179.554 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 1.014 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.2 tp -58.84 127.09 30.47 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.013 -1.054 . . . . 0.0 108.721 173.351 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.114 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.6 p -129.83 -30.27 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.983 0 O-C-N 121.421 -0.8 . . . . 0.0 110.031 -177.783 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -145.14 140.46 28.0 Favored 'General case' 0 C--N 1.297 -1.676 0 C-N-CA 119.499 -0.881 . . . . 0.0 110.979 -179.46 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.784 HG23 ' CD2' ' B' ' 24' ' ' HIS . 13.9 mt -107.51 131.01 58.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 120.918 -1.114 . . . . 0.0 110.266 172.357 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.52 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 77.6 m-20 -108.63 114.94 29.15 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.451 -0.781 . . . . 0.0 109.919 174.728 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 87.1 tt0 -107.0 112.31 25.2 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.1 -1.0 . . . . 0.0 110.524 -176.04 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 6.1 mtmt -107.86 129.94 23.47 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.229 -0.919 . . . . 0.0 109.241 175.143 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.5 Cg_endo -51.9 -24.44 18.9 Favored 'Trans proline' 0 C--N 1.303 -1.833 0 O-C-N 123.73 1.384 . . . . 0.0 110.187 -179.861 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.554 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 10.6 m-80 -81.18 -40.03 24.54 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.206 -0.934 . . . . 0.0 110.127 175.411 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.554 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 95.2 m-85 -156.41 150.33 25.04 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.456 -0.778 . . . . 0.0 109.964 -178.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . 0.485 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 59.6 ttt180 -91.95 145.07 24.83 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.884 -1.135 . . . . 0.0 110.327 178.754 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.52 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 78.3 m -130.02 139.98 50.94 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.677 -0.64 . . . . 0.0 109.757 -176.183 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.784 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -128.54 128.34 44.11 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.94 -1.1 . . . . 0.0 111.322 178.319 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.803 HG22 ' OG ' ' B' ' 60' ' ' SER . 4.3 t -104.94 131.65 53.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.384 -0.822 . . . . 0.0 110.638 -178.135 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.504 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 33.5 m -116.22 168.09 8.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.973 -0.455 . . . . 0.0 109.788 179.546 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.513 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 2.5 tm-20 -101.05 115.42 30.45 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.27 -0.894 . . . . 0.0 109.409 178.468 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.763 HD21 HD13 ' B' ' 36' ' ' LEU . 9.8 tp -79.2 125.3 83.68 Favored Pre-proline 0 C--N 1.296 -1.753 0 O-C-N 121.538 -0.727 . . . . 0.0 109.878 -176.546 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.541 ' HD2' HD12 ' B' ' 28' ' ' LEU . 27.9 Cg_endo -67.49 -179.23 1.83 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.788 1.415 . . . . 0.0 110.806 -179.538 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' B' ' 31' ' ' HIS . 32.2 p-10 -64.85 -39.97 94.41 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.384 -0.823 . . . . 0.0 110.94 -175.49 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.6 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.99 1.25 56.51 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.886 -1.134 . . . . 0.0 110.954 -174.01 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.6 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 98.6 mmm -112.19 -14.12 13.42 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.902 -1.124 . . . . 0.0 109.881 171.479 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.586 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 19.6 mt -69.96 -20.31 63.33 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.398 -0.814 . . . . 0.0 110.484 176.17 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -61.03 123.0 16.37 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.117 -0.989 . . . . 0.0 111.263 -171.262 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 48.95 54.84 12.89 Favored Glycine 0 N--CA 1.493 2.448 0 O-C-N 121.208 -0.932 . . . . 0.0 110.927 169.675 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.793 HD23 ' N ' ' B' ' 37' ' ' GLU . 6.4 tt -113.34 155.52 25.03 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.728 -1.454 . . . . 0.0 110.091 174.15 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . 0.793 ' N ' HD23 ' B' ' 36' ' ' LEU . 21.3 pt-20 -150.06 167.77 25.82 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.106 -0.996 . . . . 0.0 110.203 -178.211 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 0.998 HG23 HD12 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -67.99 155.15 40.1 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.309 -0.869 . . . . 0.0 109.811 177.55 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.62 -8.82 64.0 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.549 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.679 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -75.57 159.81 30.84 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.144 -1.21 . . . . 0.0 109.762 178.101 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.436 ' OG ' ' O ' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -104.97 119.93 40.22 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.882 -1.136 . . . . 0.0 110.467 -179.357 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.565 ' HB ' ' CE1' ' B' ' 61' ' ' PHE . 1.6 t -109.94 132.6 57.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.424 -0.797 . . . . 0.0 109.219 172.754 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 0.511 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -92.34 120.04 32.49 Favored 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.133 -0.98 . . . . 0.0 109.407 172.532 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.783 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -89.85 107.03 18.86 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.382 -0.824 . . . . 0.0 109.074 177.832 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.493 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.6 t-20 52.5 17.63 0.81 Allowed 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.348 -0.845 . . . . 0.0 110.535 -166.558 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.506 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 116.26 -4.69 19.98 Favored Glycine 0 N--CA 1.488 2.127 0 C-N-CA 119.626 -1.273 . . . . 0.0 110.864 170.192 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.747 ' O ' HD23 ' B' ' 49' ' ' LEU . 17.2 t -90.09 109.78 20.82 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.294 -1.709 . . . . 0.0 109.13 174.423 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . 0.442 ' O ' ' SG ' ' B' ' 48' ' ' CYS . 27.6 p -77.6 124.93 28.57 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.937 -1.102 . . . . 0.0 110.742 -172.473 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 0.974 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -136.92 166.27 24.02 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.381 -0.825 . . . . 0.0 108.943 172.114 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . 0.456 ' O ' ' OD1' ' B' ' 62' ' ' ASP . 55.5 m -102.94 154.33 19.33 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.633 -1.292 . . . . 0.0 111.201 -169.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.819 HG13 HG13 ' B' ' 59' ' ' VAL . 7.1 t -74.88 113.29 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 CA-C-O 121.249 0.547 . . . . 0.0 110.053 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.595 HG22 ' HB3' ' B' ' 62' ' ' ASP . 19.0 p -75.29 -43.49 50.78 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.292 -0.88 . . . . 0.0 109.599 176.258 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.478 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -158.5 150.46 21.45 Favored 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.391 179.204 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.998 HD12 HG23 ' B' ' 38' ' ' THR . 2.5 mp -108.14 132.33 56.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.209 -0.932 . . . . 0.0 110.295 176.087 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.502 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 54.7 m-80 -108.33 66.19 0.64 Allowed 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 120.168 -0.613 . . . . 0.0 109.495 177.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.57 -119.31 5.74 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 -173.127 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.586 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -77.17 -17.85 58.26 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.965 -1.315 . . . . 0.0 108.946 176.112 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.114 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.1 m170 -77.49 160.02 28.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.468 -0.77 . . . . 0.0 110.436 -178.453 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.819 HG13 HG13 ' B' ' 51' ' ' VAL . 94.3 t -145.1 117.79 2.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 C-N-CA 119.329 -0.949 . . . . 0.0 110.874 175.527 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.803 ' OG ' HG22 ' B' ' 25' ' ' VAL . 19.7 m -82.03 125.36 30.72 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.618 -0.676 . . . . 0.0 109.622 176.037 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.974 ' HB3' HD12 ' B' ' 49' ' ' LEU . 83.0 m-85 -110.0 154.88 22.55 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 120.915 -1.116 . . . . 0.0 110.25 178.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.595 ' HB3' HG22 ' B' ' 52' ' ' THR . 9.1 p-10 -89.57 148.29 23.46 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 120.984 -1.072 . . . . 0.0 111.192 -176.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.718 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.22 102.11 1.59 Allowed 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 -175.361 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.502 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 54.5 ttm -59.99 140.15 56.95 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.968 -1.082 . . . . 0.0 109.476 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.482 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 22.0 tptm -60.04 -43.37 95.39 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.118 -0.989 . . . . 0.0 110.4 -174.456 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.67 -39.97 76.69 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.034 -1.041 . . . . 0.0 110.149 177.612 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.502 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 93.1 m -60.77 -38.6 85.81 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.97 -1.081 . . . . 0.0 109.329 173.002 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.701 HD12 ' CD2' ' B' ' 63' ' ' LEU . 7.1 tp -59.95 -45.45 92.59 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.324 -0.86 . . . . 0.0 109.89 178.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 76.5 ttt-85 -69.41 -39.63 77.8 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.526 -0.734 . . . . 0.0 110.451 177.66 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.741 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -64.72 -41.48 92.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.302 -0.873 . . . . 0.0 109.486 -176.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.741 HG23 HG22 ' B' ' 70' ' ' ILE . 40.7 p -85.1 -174.52 5.3 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.279 175.813 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.47 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 2.7 t30 -101.1 21.8 13.31 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 171.482 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.718 ' HB3' HD21 ' B' ' 63' ' ' LEU . 41.3 mt -70.06 -39.95 75.36 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.07 -1.019 . . . . 0.0 110.232 175.239 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.659 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -48.7 -22.36 2.72 Favored Glycine 0 N--CA 1.486 1.98 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -178.505 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.2 p-10 -65.93 -16.52 63.94 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.161 -1.199 . . . . 0.0 110.624 -174.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 94.2 mt -60.01 141.4 55.73 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.126 -0.984 . . . . 0.0 110.829 -176.217 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 1.014 ' C ' HD23 ' B' ' 12' ' ' LEU . 95.1 mttt -139.96 139.82 36.18 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.734 -0.604 . . . . 0.0 109.397 174.196 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.733 HG23 HD11 ' B' ' 15' ' ' ILE . 16.4 t -60.55 152.46 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.989 -1.069 . . . . 0.0 110.357 -176.205 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.88 -15.25 58.19 Favored Glycine 0 N--CA 1.484 1.846 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 -176.088 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.481 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 9.1 t0 -95.44 165.32 12.42 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.402 -1.058 . . . . 0.0 109.706 175.768 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.58 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.6 m95 -114.46 157.24 23.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.147 -0.971 . . . . 0.0 110.288 177.441 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 1.055 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.3 p -120.06 149.34 22.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.688 -0.632 . . . . 0.0 109.871 -179.181 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.835 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.2 OUTLIER -75.78 104.18 6.21 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.084 -1.01 . . . . 0.0 109.526 169.26 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.676 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -106.09 137.83 34.41 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.459 -1.401 . . . . 0.0 111.38 -176.812 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . 0.418 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.4 tt0 -130.2 144.92 51.64 Favored 'General case' 0 N--CA 1.493 1.712 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.005 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . 0.461 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 34.1 ptt180 -81.53 133.72 35.42 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.206 -0.934 . . . . 0.0 110.93 -176.11 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.436 ' O ' ' OG ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.746 0 O-C-N 121.355 -0.841 . . . . 0.0 110.08 175.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.846 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.0 t . . . . . 0 N--CA 1.493 1.699 0 CA-C-O 121.83 0.824 . . . . 0.0 111.108 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 27.8 mm100 -70.0 -36.32 75.04 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.793 -0.567 . . . . 0.0 110.686 177.254 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -155.24 169.11 33.19 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.029 -1.558 . . . . 0.0 110.187 -173.569 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.437 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 0.7 OUTLIER -108.91 172.39 6.87 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.081 -1.246 . . . . 0.0 111.104 -176.167 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 1.039 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -139.46 148.54 42.87 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -178.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 20.8 tttt -106.42 117.01 32.92 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 120.993 -1.067 . . . . 0.0 110.149 178.759 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.992 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.0 tp -59.81 127.65 33.02 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 120.831 -1.168 . . . . 0.0 108.756 172.563 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.118 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -126.72 -30.85 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 C-N-CA 119.596 -0.842 . . . . 0.0 110.032 -178.215 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.13 142.56 27.48 Favored 'General case' 0 N--CA 1.494 1.762 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.361 -178.403 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.726 HG23 ' NE2' ' A' ' 24' ' ' HIS . 10.3 mt -109.46 133.78 53.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.186 -0.946 . . . . 0.0 110.191 172.92 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.515 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 83.8 m-20 -109.88 114.29 27.72 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.377 -0.827 . . . . 0.0 110.129 176.072 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.25 112.69 25.03 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.018 -1.051 . . . . 0.0 110.556 -177.284 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.0 OUTLIER -107.43 133.22 20.46 Favored Pre-proline 0 N--CA 1.492 1.661 0 O-C-N 121.186 -0.946 . . . . 0.0 109.372 174.915 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -51.99 -25.1 21.12 Favored 'Trans proline' 0 C--N 1.302 -1.869 0 O-C-N 123.859 1.452 . . . . 0.0 110.35 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.567 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 8.8 m-80 -86.2 -35.76 19.87 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.25 -0.906 . . . . 0.0 110.272 177.708 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.567 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 95.4 m-85 -157.17 150.24 23.71 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.407 -0.808 . . . . 0.0 110.244 -176.382 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.795 ' HD3' HD22 ' A' ' 68' ' ' LEU . 61.6 ttt180 -86.2 144.26 27.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.783 -1.198 . . . . 0.0 110.085 175.218 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.515 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 85.3 m -130.6 140.01 50.42 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.499 -0.751 . . . . 0.0 109.668 -175.676 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.726 ' NE2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.98 141.27 50.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.776 -1.203 . . . . 0.0 111.546 -178.433 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.843 HG22 ' OG ' ' A' ' 60' ' ' SER . 12.8 t -120.98 135.05 62.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.118 -0.989 . . . . 0.0 110.656 -179.152 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.879 HG13 ' CE1' ' A' ' 61' ' ' PHE . 21.4 m -117.46 171.96 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.738 -0.601 . . . . 0.0 110.246 178.16 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.493 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 12.8 tt0 -106.3 116.87 32.67 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.922 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.884 ' CD2' HD22 ' A' ' 36' ' ' LEU . 9.6 tp -90.73 130.93 39.19 Favored Pre-proline 0 C--N 1.296 -1.747 0 O-C-N 121.203 -0.936 . . . . 0.0 110.521 -171.295 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.472 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 30.7 Cg_endo -68.05 176.91 4.84 Favored 'Trans proline' 0 C--N 1.308 -1.605 0 O-C-N 124.015 1.534 . . . . 0.0 111.053 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -60.55 -39.92 89.71 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.429 -0.795 . . . . 0.0 111.401 -175.187 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.602 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.89 0.03 57.29 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.8 -1.188 . . . . 0.0 110.755 -174.078 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.602 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.9 mmm -110.67 -16.14 13.69 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.95 -1.094 . . . . 0.0 109.638 169.793 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.597 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 29.6 mt -71.2 -24.86 62.3 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.313 -0.867 . . . . 0.0 109.863 174.386 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . 0.476 ' O ' ' N ' ' A' ' 36' ' ' LEU . 38.6 p-10 -71.16 162.25 29.74 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.467 -0.771 . . . . 0.0 110.94 -173.104 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.428 ' C ' ' O ' ' A' ' 34' ' ' ASP . . . 37.54 27.69 0.03 OUTLIER Glycine 0 N--CA 1.494 2.522 0 O-C-N 121.504 -0.747 . . . . 0.0 111.605 174.295 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.884 HD22 ' CD2' ' A' ' 28' ' ' LEU . 60.8 tp -101.21 158.45 16.02 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 120.537 -1.566 . . . . 0.0 110.919 179.025 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 21.5 pt-20 -160.04 161.09 33.9 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.566 -0.709 . . . . 0.0 109.428 177.49 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.817 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -66.84 154.42 40.96 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.043 -1.035 . . . . 0.0 109.526 175.779 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.39 -9.45 61.43 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.257 -1.537 . . . . 0.0 109.257 -176.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.505 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -69.87 153.21 43.6 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.135 -1.215 . . . . 0.0 109.627 177.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.529 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -97.35 104.53 16.56 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 120.966 -1.084 . . . . 0.0 109.906 178.117 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.414 ' CG1' ' HD1' ' A' ' 44' ' ' HIS . 1.6 t -87.87 137.54 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.239 -0.913 . . . . 0.0 109.027 174.526 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.484 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -102.96 120.12 40.06 Favored 'General case' 0 C--N 1.295 -1.781 0 O-C-N 120.865 -1.147 . . . . 0.0 109.535 170.167 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.806 ' CD2' HG21 ' A' ' 82' ' ' VAL . 1.2 m80 -87.45 101.02 13.19 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 176.12 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.0 t-20 58.55 8.88 0.95 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.575 -0.703 . . . . 0.0 111.399 -169.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 124.62 -3.19 8.73 Favored Glycine 0 N--CA 1.489 2.167 0 C-N-CA 119.674 -1.25 . . . . 0.0 110.617 174.344 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.815 ' O ' HD23 ' A' ' 49' ' ' LEU . 19.7 t -90.34 107.39 19.12 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.334 -1.686 . . . . 0.0 109.2 174.623 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 23.5 p -78.12 125.55 29.51 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.127 -0.983 . . . . 0.0 110.768 -170.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.941 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -142.57 160.16 40.83 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.508 -0.745 . . . . 0.0 109.592 176.051 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 27.6 m -99.51 149.15 23.53 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.715 -1.24 . . . . 0.0 111.378 -169.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.96 HG13 HG13 ' A' ' 59' ' ' VAL . 16.9 t -75.16 114.62 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.739 -0.6 . . . . 0.0 110.273 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.527 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 47.3 p -70.29 -40.0 74.55 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.299 -0.875 . . . . 0.0 109.947 174.214 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.587 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -162.78 154.5 18.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.344 -0.847 . . . . 0.0 110.23 -179.344 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.817 HD11 ' N ' ' A' ' 38' ' ' THR . 5.5 mt -105.55 130.01 57.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.012 -1.055 . . . . 0.0 109.888 175.201 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.524 ' HB2' ' CB ' ' A' ' 58' ' ' HIS . 9.6 m-80 -101.66 61.94 0.91 Allowed 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.614 -0.678 . . . . 0.0 109.691 178.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.79 -114.72 4.16 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 108.743 -1.743 . . . . 0.0 108.743 -173.687 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.597 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.54 -19.97 51.72 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.024 -1.28 . . . . 0.0 108.807 174.374 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.118 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.3 m170 -75.29 160.04 30.79 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.459 -0.776 . . . . 0.0 110.116 -177.222 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.96 HG13 HG13 ' A' ' 51' ' ' VAL . 54.6 t -140.14 121.99 15.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 O-C-N 120.957 -1.089 . . . . 0.0 110.711 171.059 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.843 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.1 t -87.75 133.69 33.81 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.522 -0.736 . . . . 0.0 109.287 174.729 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.941 ' HB2' HD12 ' A' ' 49' ' ' LEU . 1.3 p90 -126.85 154.07 44.85 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 121.43 -0.793 . . . . 0.0 110.225 178.554 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.527 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 31.4 p-10 -88.72 147.77 24.32 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.004 -1.06 . . . . 0.0 111.399 -170.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.822 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -154.47 113.66 3.69 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 -176.186 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.527 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 56.9 ttm -69.96 140.61 53.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.794 -1.191 . . . . 0.0 109.449 -179.382 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.484 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 36.4 tptt -60.01 -49.23 78.5 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.995 -1.066 . . . . 0.0 110.299 -175.1 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.41 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 88.6 tt0 -65.48 -40.01 92.62 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.901 -1.124 . . . . 0.0 110.129 178.162 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.527 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 60.8 m -62.76 -38.13 89.34 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.902 -1.124 . . . . 0.0 109.426 174.238 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.795 HD22 ' HD3' ' A' ' 22' ' ' ARG . 14.7 tp -60.05 -41.58 92.61 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.14 -0.975 . . . . 0.0 109.225 177.325 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.525 ' NH1' ' HB3' ' A' ' 69' ' ' ARG . 6.4 mmm180 -69.96 -38.85 76.24 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.466 -0.771 . . . . 0.0 110.433 174.012 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.828 HG22 HG23 ' A' ' 71' ' ' THR . 1.1 tt -67.97 -40.43 83.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.327 -0.858 . . . . 0.0 109.412 -176.574 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.828 HG23 HG22 ' A' ' 70' ' ' ILE . 59.1 p -87.49 -171.56 3.51 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.339 0.59 . . . . 0.0 109.764 179.083 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.467 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 8.3 t30 -99.92 18.75 17.6 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.338 -0.852 . . . . 0.0 108.865 170.194 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.822 ' HB3' HD21 ' A' ' 63' ' ' LEU . 70.2 mt -68.33 -40.02 81.77 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.931 -1.106 . . . . 0.0 109.749 174.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.515 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -47.06 -22.55 1.3 Allowed Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 -179.702 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.3 p-10 -67.91 -17.18 64.39 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.975 -1.309 . . . . 0.0 110.419 -175.351 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 95.5 mt -63.51 142.11 58.51 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.223 -0.923 . . . . 0.0 110.917 -176.243 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 0.992 ' C ' HD23 ' A' ' 12' ' ' LEU . 46.1 mttt -142.65 142.73 32.12 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.733 -0.604 . . . . 0.0 109.495 174.561 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.697 HG23 HD11 ' A' ' 15' ' ' ILE . 21.3 t -63.61 150.04 10.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.587 0 O-C-N 120.843 -1.16 . . . . 0.0 110.36 -176.707 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.78 -13.6 62.35 Favored Glycine 0 N--CA 1.483 1.797 0 N-CA-C 108.793 -1.723 . . . . 0.0 108.793 -175.21 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 44.9 t0 -95.2 166.31 11.97 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.267 -1.137 . . . . 0.0 109.55 176.1 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.8 m95 -117.22 159.04 23.28 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.006 -1.059 . . . . 0.0 110.118 176.563 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.039 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.0 OUTLIER -125.38 155.02 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.441 -0.787 . . . . 0.0 109.891 -179.124 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.846 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.3 OUTLIER -78.16 105.29 9.28 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.17 -0.956 . . . . 0.0 108.965 168.093 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.846 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -106.19 140.46 24.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 120.535 -1.353 . . . . 0.0 111.478 -176.312 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.43 ' HB3' ' HB3' ' A' ' 43' ' ' ALA . 86.5 tt0 -134.27 157.09 47.19 Favored 'General case' 0 N--CA 1.496 1.855 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.948 -179.557 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 47.5 ptt85 -100.23 133.37 44.74 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.114 -0.991 . . . . 0.0 110.992 -176.232 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.529 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.492 1.665 0 O-C-N 121.344 -0.848 . . . . 0.0 110.126 179.598 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 0.826 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.0 t . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.701 0.762 . . . . 0.0 111.11 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 27.8 mm100 -69.98 -36.08 74.93 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.836 -0.54 . . . . 0.0 110.81 177.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.534 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -155.42 168.96 33.27 Favored Glycine 0 N--CA 1.495 2.631 0 C-N-CA 119.086 -1.53 . . . . 0.0 110.269 -173.563 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.44 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 0.7 OUTLIER -108.87 172.17 7.0 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.127 -1.219 . . . . 0.0 111.177 -176.128 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.06 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -139.24 148.79 43.55 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 -179.145 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.583 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 20.8 tttt -106.59 117.11 33.18 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.091 -1.006 . . . . 0.0 110.055 178.787 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 1.008 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.0 tp -59.98 127.54 32.43 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.977 -1.077 . . . . 0.0 108.814 172.583 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.112 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -126.51 -31.0 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.837 0 O-C-N 121.312 -0.868 . . . . 0.0 110.061 -178.115 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.09 142.55 27.51 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.229 -0.988 . . . . 0.0 111.391 -178.358 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.739 HG23 ' NE2' ' B' ' 24' ' ' HIS . 10.3 mt -109.42 133.85 53.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.169 -0.957 . . . . 0.0 110.241 172.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.511 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.6 m-20 -110.0 114.44 27.98 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.387 -0.821 . . . . 0.0 110.077 176.059 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -100.24 112.66 24.99 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.101 -1.0 . . . . 0.0 110.612 -177.358 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.0 OUTLIER -107.47 133.3 20.44 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.27 -0.894 . . . . 0.0 109.4 174.904 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -52.12 -24.99 21.57 Favored 'Trans proline' 0 C--N 1.303 -1.855 0 O-C-N 123.873 1.46 . . . . 0.0 110.32 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.572 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 9.2 m-80 -86.12 -36.35 19.64 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.305 -0.872 . . . . 0.0 110.06 177.804 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.572 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 95.5 m-85 -156.71 150.27 24.52 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.43 -0.794 . . . . 0.0 110.296 -176.285 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . 0.793 ' HD3' HD22 ' B' ' 68' ' ' LEU . 61.5 ttt180 -86.18 144.15 27.62 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.783 -1.198 . . . . 0.0 110.072 175.165 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.511 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 85.2 m -130.44 140.07 50.56 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.504 -0.747 . . . . 0.0 109.745 -175.76 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.739 ' NE2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.92 141.29 50.28 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.859 -1.151 . . . . 0.0 111.505 -178.358 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.841 HG22 ' OG ' ' B' ' 60' ' ' SER . 12.6 t -120.9 135.21 61.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.313 -0.867 . . . . 0.0 110.648 -179.164 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.892 HG13 ' CE1' ' B' ' 61' ' ' PHE . 21.7 m -117.72 171.94 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.757 -0.589 . . . . 0.0 110.19 178.171 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.481 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 12.8 tt0 -106.19 116.82 32.59 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.887 ' CD2' HD22 ' B' ' 36' ' ' LEU . 9.5 tp -90.59 130.9 39.57 Favored Pre-proline 0 C--N 1.295 -1.773 0 O-C-N 121.16 -0.962 . . . . 0.0 110.547 -171.298 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.481 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 30.6 Cg_endo -68.13 176.92 4.89 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 O-C-N 123.98 1.516 . . . . 0.0 111.005 -179.505 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -60.51 -40.02 89.89 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.454 -0.779 . . . . 0.0 111.355 -175.143 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.87 0.06 57.27 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.738 -1.226 . . . . 0.0 110.707 -174.008 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.597 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.9 mmm -110.71 -16.03 13.7 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.848 -1.157 . . . . 0.0 109.665 169.765 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.607 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 29.4 mt -71.31 -24.92 62.22 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.298 -0.876 . . . . 0.0 109.779 174.408 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . 0.488 ' O ' ' N ' ' B' ' 36' ' ' LEU . 38.6 p-10 -71.11 162.18 29.86 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.443 -0.786 . . . . 0.0 110.955 -173.088 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' B' ' 34' ' ' ASP . . . 37.53 27.74 0.03 OUTLIER Glycine 0 N--CA 1.496 2.694 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.564 174.343 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.887 HD22 ' CD2' ' B' ' 28' ' ' LEU . 60.8 tp -101.28 158.43 16.05 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.572 -1.546 . . . . 0.0 110.925 178.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . . . . . . . . . 21.5 pt-20 -159.97 161.17 34.09 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.561 -0.712 . . . . 0.0 109.421 177.525 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 0.817 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.97 154.43 41.14 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.007 -1.058 . . . . 0.0 109.49 175.794 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.38 -9.37 61.63 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -176.577 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.517 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -70.01 152.98 43.79 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.265 -1.138 . . . . 0.0 109.612 177.885 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.536 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -97.08 104.28 16.28 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.947 -1.096 . . . . 0.0 110.037 178.103 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.424 HG12 ' HD1' ' B' ' 44' ' ' HIS . 1.6 t -87.81 137.54 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.247 -0.908 . . . . 0.0 109.108 174.554 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 0.479 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -103.02 120.19 40.2 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 120.931 -1.106 . . . . 0.0 109.482 170.239 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.821 ' CD2' HG21 ' B' ' 82' ' ' VAL . 1.2 m80 -87.51 100.89 13.11 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.67 -0.812 . . . . 0.0 108.925 176.099 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.0 t-20 58.87 8.86 1.03 Allowed 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.5 -0.75 . . . . 0.0 111.256 -170.12 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 124.5 -2.9 8.82 Favored Glycine 0 N--CA 1.488 2.123 0 C-N-CA 119.699 -1.239 . . . . 0.0 110.601 174.173 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.813 ' O ' HD23 ' B' ' 49' ' ' LEU . 19.7 t -90.44 107.33 19.09 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.3 -1.706 . . . . 0.0 109.266 174.492 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 23.3 p -78.05 125.55 29.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.128 -0.983 . . . . 0.0 110.774 -170.761 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 0.939 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -142.59 160.08 41.0 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.596 -0.69 . . . . 0.0 109.632 176.05 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 27.7 m -99.25 149.3 23.25 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.676 -1.265 . . . . 0.0 111.357 -169.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.982 HG13 HG13 ' B' ' 59' ' ' VAL . 17.1 t -75.42 114.55 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.675 -0.641 . . . . 0.0 110.342 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.528 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 48.3 p -70.32 -39.96 74.46 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.178 -0.952 . . . . 0.0 109.865 174.433 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.574 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -162.74 154.6 18.26 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.388 -0.82 . . . . 0.0 110.214 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.817 HD11 ' N ' ' B' ' 38' ' ' THR . 5.5 mt -105.63 129.9 57.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.12 -0.987 . . . . 0.0 109.925 175.215 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.53 ' HB2' ' CB ' ' B' ' 58' ' ' HIS . 9.6 m-80 -101.58 61.9 0.92 Allowed 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.658 -0.651 . . . . 0.0 109.748 178.867 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.78 -114.66 4.15 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 -173.655 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.607 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.41 -20.2 51.61 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.004 -1.292 . . . . 0.0 108.815 174.34 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.112 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.4 m170 -75.21 159.87 31.06 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.442 -0.786 . . . . 0.0 110.144 -177.203 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.982 HG13 HG13 ' B' ' 51' ' ' VAL . 54.7 t -140.04 122.16 16.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 C-N-CA 118.926 -1.11 . . . . 0.0 110.662 171.133 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.841 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.1 t -87.86 133.83 33.82 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.457 -0.777 . . . . 0.0 109.371 174.746 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.939 ' HB2' HD12 ' B' ' 49' ' ' LEU . 1.3 p90 -126.98 154.07 45.05 Favored 'General case' 0 N--CA 1.498 1.929 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.109 178.681 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.528 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 31.1 p-10 -88.7 147.77 24.34 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.939 -1.1 . . . . 0.0 111.352 -170.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.793 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -154.38 113.76 3.73 Favored 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 -176.309 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.531 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 56.8 ttm -70.05 140.53 52.82 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.744 -1.222 . . . . 0.0 109.402 -179.386 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.483 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 36.5 tptt -59.99 -49.1 78.99 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.023 -1.048 . . . . 0.0 110.347 -175.117 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . 0.411 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 88.6 tt0 -65.54 -40.03 92.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.948 -1.095 . . . . 0.0 110.098 178.22 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.531 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 61.0 m -62.7 -38.23 89.6 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.905 -1.122 . . . . 0.0 109.426 174.242 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.793 HD22 ' HD3' ' B' ' 22' ' ' ARG . 14.7 tp -60.01 -41.46 92.21 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.292 -0.88 . . . . 0.0 109.264 177.312 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . 0.529 ' NH1' ' HB3' ' B' ' 69' ' ' ARG . 6.4 mmm180 -70.0 -38.99 76.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.558 -0.714 . . . . 0.0 110.386 174.03 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.811 HG22 HG23 ' B' ' 71' ' ' THR . 1.1 tt -67.88 -40.39 83.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.526 -176.641 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.811 HG23 HG22 ' B' ' 70' ' ' ILE . 59.2 p -87.37 -171.43 3.47 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-O 121.296 0.57 . . . . 0.0 109.863 178.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.524 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 8.4 t30 -99.92 18.74 17.62 Favored 'General case' 0 C--N 1.297 -1.703 0 O-C-N 121.384 -0.823 . . . . 0.0 108.814 170.195 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.793 ' HB3' HD21 ' B' ' 63' ' ' LEU . 69.4 mt -68.41 -39.98 81.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.023 -1.048 . . . . 0.0 109.716 174.811 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.513 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -47.02 -22.64 1.3 Allowed Glycine 0 N--CA 1.489 2.2 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -179.71 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.4 p-10 -67.94 -17.14 64.36 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.08 -1.247 . . . . 0.0 110.492 -175.321 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 95.5 mt -63.44 142.1 58.52 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.17 -0.956 . . . . 0.0 110.92 -176.334 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 1.008 ' C ' HD23 ' B' ' 12' ' ' LEU . 46.1 mttt -142.84 142.84 31.91 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.71 -0.619 . . . . 0.0 109.391 174.507 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.718 HG23 HD11 ' B' ' 15' ' ' ILE . 21.5 t -63.61 149.99 10.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 120.903 -1.123 . . . . 0.0 110.422 -176.568 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.67 -13.34 62.8 Favored Glycine 0 N--CA 1.483 1.804 0 N-CA-C 108.885 -1.686 . . . . 0.0 108.885 -175.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 44.5 t0 -95.28 166.22 12.0 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.392 -1.064 . . . . 0.0 109.545 175.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.583 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.0 m95 -117.16 159.08 23.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.019 -1.051 . . . . 0.0 110.183 176.479 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 1.06 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.0 OUTLIER -125.45 155.15 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.5 -0.75 . . . . 0.0 109.936 -179.289 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.826 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.3 OUTLIER -78.25 105.15 9.29 Favored 'General case' 0 C--N 1.297 -1.69 0 O-C-N 121.123 -0.986 . . . . 0.0 109.025 168.203 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.856 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -106.07 140.61 23.62 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 120.631 -1.293 . . . . 0.0 111.361 -176.047 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . 0.431 ' HB3' ' HB3' ' B' ' 43' ' ' ALA . 86.4 tt0 -134.54 157.06 47.52 Favored 'General case' 0 N--CA 1.495 1.785 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.888 -179.649 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 47.6 ptt85 -100.12 133.46 44.48 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.079 -1.013 . . . . 0.0 110.919 -176.12 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.536 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.494 1.767 0 O-C-N 121.401 -0.812 . . . . 0.0 110.08 179.603 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.843 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.2 t . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 121.743 0.783 . . . . 0.0 111.09 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -69.95 -35.11 74.24 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.778 -0.576 . . . . 0.0 111.072 176.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -156.24 172.97 34.14 Favored Glycine 0 N--CA 1.495 2.609 0 C-N-CA 118.747 -1.692 . . . . 0.0 110.513 -172.526 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.458 ' O ' ' HG3' ' A' ' 29' ' ' PRO . 12.6 p -117.75 172.35 7.43 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.031 -1.276 . . . . 0.0 111.017 -176.814 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 1.041 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -140.01 148.53 41.99 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.562 -0.711 . . . . 0.0 109.609 -178.726 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.579 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 37.6 tttt -107.18 115.3 29.93 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.047 -1.033 . . . . 0.0 110.321 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.998 HD23 ' C ' ' A' ' 77' ' ' LYS . 11.3 tp -59.91 126.74 28.73 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.038 -1.039 . . . . 0.0 108.896 173.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.042 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -125.32 -29.32 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.838 0 C-N-CA 119.583 -0.847 . . . . 0.0 109.909 -179.417 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.93 142.4 24.37 Favored 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 118.942 -1.103 . . . . 0.0 111.523 179.735 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.782 HG23 ' CD2' ' A' ' 24' ' ' HIS . 12.0 mt -105.55 137.13 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.155 -0.966 . . . . 0.0 110.185 171.569 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.519 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 86.7 m-20 -112.95 115.99 29.28 Favored 'General case' 0 C--N 1.297 -1.703 0 O-C-N 121.344 -0.847 . . . . 0.0 109.937 173.512 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -105.9 115.24 29.9 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.897 -1.127 . . . . 0.0 110.799 -176.477 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.465 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 4.1 mtmt -110.4 127.58 26.77 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.121 -0.987 . . . . 0.0 108.935 171.703 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -52.27 -18.73 8.13 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.848 1.446 . . . . 0.0 110.812 -179.367 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.577 ' ND2' ' N ' ' A' ' 20' ' ' ASN . 0.3 OUTLIER -90.18 -35.84 15.13 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.139 -0.975 . . . . 0.0 108.741 177.077 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.518 ' CD2' ' HB2' ' A' ' 20' ' ' ASN . 81.9 m-85 -151.07 150.15 30.37 Favored 'General case' 0 N--CA 1.491 1.623 0 CA-C-O 121.192 0.52 . . . . 0.0 109.748 179.183 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.48 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 62.4 ttt180 -97.69 143.83 27.95 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.589 -1.32 . . . . 0.0 110.021 176.504 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.519 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 96.5 m -129.98 140.09 50.96 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.412 -0.805 . . . . 0.0 110.126 -173.304 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.782 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.22 135.77 48.5 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.984 -1.073 . . . . 0.0 111.207 179.216 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.759 HG22 ' OG ' ' A' ' 60' ' ' SER . 15.8 t -115.53 134.25 59.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.002 -1.061 . . . . 0.0 110.767 -178.276 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 29.5 m -119.67 170.02 9.88 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.062 -179.703 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.535 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 7.5 tt0 -103.55 116.97 33.36 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -179.383 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.545 HD23 ' HA ' ' A' ' 33' ' ' LEU . 8.9 tp -82.01 119.73 75.78 Favored Pre-proline 0 C--N 1.295 -1.798 0 O-C-N 121.502 -0.748 . . . . 0.0 109.815 -173.719 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.458 ' HG3' ' O ' ' A' ' 9' ' ' THR . 22.6 Cg_endo -65.33 179.22 1.66 Allowed 'Trans proline' 0 C--N 1.308 -1.554 0 O-C-N 123.85 1.447 . . . . 0.0 111.047 -179.378 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.417 ' OD1' ' C ' ' A' ' 30' ' ' ASP . 50.5 t0 -60.1 -41.28 92.18 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.415 -0.803 . . . . 0.0 111.098 -175.319 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.57 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.39 1.47 56.57 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.87 -1.144 . . . . 0.0 110.763 -174.156 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.57 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 96.4 mmm -111.07 -15.82 13.63 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.036 -1.04 . . . . 0.0 109.82 171.835 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.613 HD21 ' HB2' ' A' ' 57' ' ' ASN . 16.5 mt -68.18 -30.39 69.48 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.33 -0.856 . . . . 0.0 109.999 178.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 57.4 t0 -91.72 127.02 37.01 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.328 -0.858 . . . . 0.0 110.266 -179.648 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.28 -48.06 1.0 Allowed Glycine 0 N--CA 1.492 2.403 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 177.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.788 HD23 ' N ' ' A' ' 37' ' ' GLU . 7.4 tt -70.02 145.81 51.49 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.141 -1.211 . . . . 0.0 110.664 -175.762 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.788 ' N ' HD23 ' A' ' 36' ' ' LEU . 20.7 pt-20 -150.43 170.01 20.09 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.427 -0.796 . . . . 0.0 109.622 -179.512 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.825 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -67.23 151.15 48.05 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.91 -1.119 . . . . 0.0 110.13 179.972 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.62 0.0 62.15 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 -176.226 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.452 ' O ' ' HA ' ' A' ' 50' ' ' THR . . . -79.79 159.0 26.71 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.242 -1.152 . . . . 0.0 109.7 177.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.552 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -101.06 113.23 26.05 Favored 'General case' 0 N--CA 1.486 1.345 0 O-C-N 121.126 -0.984 . . . . 0.0 110.04 176.72 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.611 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.0 t -104.74 130.0 56.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.278 -0.889 . . . . 0.0 109.172 174.718 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.516 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -93.31 119.53 32.56 Favored 'General case' 0 C--N 1.297 -1.708 0 C-N-CA 119.146 -1.022 . . . . 0.0 109.149 172.257 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.736 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.3 OUTLIER -88.0 107.15 18.58 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 178.52 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.51 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.1 t-20 50.29 16.28 0.25 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.487 -0.758 . . . . 0.0 111.283 -166.457 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.493 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 120.92 0.85 11.75 Favored Glycine 0 N--CA 1.489 2.221 0 C-N-CA 119.444 -1.36 . . . . 0.0 111.164 171.292 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.785 ' O ' HD23 ' A' ' 49' ' ' LEU . 34.8 t -98.71 108.46 21.15 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.137 -1.802 . . . . 0.0 109.492 175.082 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 21.2 p -75.7 126.74 31.59 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.015 -1.053 . . . . 0.0 111.084 -171.116 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.96 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -141.35 162.74 34.76 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.505 -0.747 . . . . 0.0 109.466 172.712 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.452 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 55.0 m -102.47 152.88 20.61 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 120.637 -1.29 . . . . 0.0 111.074 -171.13 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.896 HG22 ' CE1' ' A' ' 61' ' ' PHE . 34.5 t -76.82 117.73 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.62 -0.675 . . . . 0.0 110.458 -177.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.685 HG22 ' HB3' ' A' ' 62' ' ' ASP . 41.2 p -70.21 -39.99 74.81 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.122 -0.986 . . . . 0.0 109.669 172.253 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.572 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 52.3 tp10 -164.72 156.12 15.26 Favored 'General case' 0 N--CA 1.492 1.642 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.819 -177.349 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.825 HD11 ' N ' ' A' ' 38' ' ' THR . 8.8 mt -110.47 130.07 64.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.083 -1.011 . . . . 0.0 109.986 172.794 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.499 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 63.8 m-80 -104.7 65.62 0.76 Allowed 'General case' 0 C--N 1.297 -1.678 0 CA-C-O 121.532 0.682 . . . . 0.0 109.54 177.703 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.91 -115.09 4.24 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 -174.158 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.613 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.0 -21.08 44.04 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.121 -1.223 . . . . 0.0 109.162 176.609 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.042 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.5 m170 -77.05 159.38 29.91 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.186 -0.946 . . . . 0.0 109.791 -178.024 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.815 HG13 HG13 ' A' ' 51' ' ' VAL . 59.9 t -140.9 121.48 13.27 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 C-N-CA 119.078 -1.049 . . . . 0.0 110.522 171.707 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.759 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.2 t -84.35 135.35 34.33 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.434 -0.791 . . . . 0.0 109.264 175.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.96 ' HB3' HD12 ' A' ' 49' ' ' LEU . 58.9 m-85 -115.55 158.5 22.53 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.319 -0.863 . . . . 0.0 110.199 178.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.685 ' HB3' HG22 ' A' ' 52' ' ' THR . 25.1 p-10 -92.12 147.47 22.91 Favored 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 122.106 0.955 . . . . 0.0 110.842 178.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.833 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -159.71 125.0 4.08 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 -176.864 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.536 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 56.1 ttm -84.85 146.44 27.31 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.931 -1.106 . . . . 0.0 109.434 -177.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.43 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 71.4 tttt -60.06 -49.13 78.88 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.014 -1.053 . . . . 0.0 109.99 -177.231 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 53.4 tp10 -69.59 -40.02 76.95 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.147 -0.97 . . . . 0.0 110.397 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.537 ' O ' HG23 ' A' ' 71' ' ' THR . 37.7 m -62.25 -38.66 90.11 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.823 -1.173 . . . . 0.0 109.085 174.427 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.802 HD11 ' HA2' ' A' ' 74' ' ' GLY . 1.0 OUTLIER -60.05 -47.37 86.16 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.233 -0.917 . . . . 0.0 109.709 177.419 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 74.9 ttt-85 -65.76 -40.05 91.65 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.467 -0.771 . . . . 0.0 110.481 178.192 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.878 HG22 HG23 ' A' ' 71' ' ' THR . 1.4 tt -64.19 -41.28 91.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.234 -0.917 . . . . 0.0 109.093 -179.323 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.878 HG23 HG22 ' A' ' 70' ' ' ILE . 20.1 p -89.72 -177.01 5.16 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 175.626 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.499 ' N ' ' OD1' ' B' ' 83' ' ' ASN . 3.4 t30 -100.01 25.16 7.67 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.07 -1.019 . . . . 0.0 108.332 172.414 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.833 ' HB3' HD21 ' A' ' 63' ' ' LEU . 86.8 mt -67.66 -39.96 84.52 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.996 -1.065 . . . . 0.0 109.933 176.551 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.802 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -54.88 -23.98 32.41 Favored Glycine 0 N--CA 1.485 1.909 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -177.52 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 21.9 p-10 -64.12 -17.02 63.05 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.962 -1.317 . . . . 0.0 110.32 -175.335 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.52 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 96.0 mt -60.08 141.48 55.7 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.262 -0.898 . . . . 0.0 110.476 -177.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 0.998 ' C ' HD23 ' A' ' 12' ' ' LEU . 59.8 mmtt -140.02 143.28 36.34 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-O 121.814 0.816 . . . . 0.0 110.4 175.807 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.596 ' CG2' HG13 ' A' ' 15' ' ' ILE . 35.9 t -63.08 149.51 10.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.252 -0.905 . . . . 0.0 110.235 -176.199 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.54 -13.79 63.05 Favored Glycine 0 N--CA 1.484 1.849 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 -175.338 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 46.3 t0 -96.23 163.13 13.22 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.346 -1.091 . . . . 0.0 109.587 176.167 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.579 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 13.7 m95 -113.89 162.15 16.73 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.062 -1.024 . . . . 0.0 110.201 176.52 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.041 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.6 p -130.8 140.24 49.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 O-C-N 121.514 -0.741 . . . . 0.0 110.16 -175.625 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.843 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -66.95 103.89 1.25 Allowed 'General case' 0 C--N 1.295 -1.795 0 O-C-N 121.095 -1.003 . . . . 0.0 109.46 169.07 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.732 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -106.58 137.63 36.2 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.816 0 O-C-N 120.537 -1.352 . . . . 0.0 111.414 -178.885 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.54 ' HB2' HG22 ' A' ' 6' ' ' VAL . 84.3 tt0 -132.73 131.66 41.46 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.072 179.703 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 75.9 ttt180 -72.18 139.2 48.11 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.151 -0.968 . . . . 0.0 110.972 -175.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.552 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.493 1.716 0 O-C-N 121.436 -0.79 . . . . 0.0 109.814 176.654 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 0.851 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.2 t . . . . . 0 N--CA 1.495 1.793 0 CA-C-O 121.731 0.777 . . . . 0.0 111.124 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 -70.02 -34.73 73.66 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.715 -0.615 . . . . 0.0 111.137 176.826 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.528 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -156.56 172.81 34.33 Favored Glycine 0 N--CA 1.498 2.767 0 C-N-CA 118.814 -1.66 . . . . 0.0 110.599 -172.555 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.453 ' O ' ' HG3' ' B' ' 29' ' ' PRO . 12.5 p -117.7 172.35 7.42 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.074 -1.251 . . . . 0.0 111.01 -176.763 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.048 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -139.95 148.68 42.3 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.654 -0.653 . . . . 0.0 109.518 -178.791 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 37.6 tttt -107.38 115.42 30.12 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.146 -0.971 . . . . 0.0 110.246 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 1.011 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.2 tp -60.03 126.67 28.44 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.058 -1.026 . . . . 0.0 108.956 173.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.057 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -125.14 -29.51 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.827 0 O-C-N 121.347 -0.846 . . . . 0.0 109.974 -179.366 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.88 142.27 24.29 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 119.089 -1.044 . . . . 0.0 111.52 179.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.789 HG23 ' CD2' ' B' ' 24' ' ' HIS . 11.8 mt -105.41 137.15 36.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.065 -1.022 . . . . 0.0 110.137 171.606 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.524 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 86.4 m-20 -113.09 115.99 29.18 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.398 -0.814 . . . . 0.0 109.854 173.536 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -105.83 115.24 29.9 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.895 -1.128 . . . . 0.0 110.754 -176.471 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 4.1 mtmt -110.45 127.67 26.62 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.188 -0.945 . . . . 0.0 108.925 171.636 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -52.34 -18.78 8.4 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.763 1.402 . . . . 0.0 110.744 -179.3 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.57 ' ND2' ' N ' ' B' ' 20' ' ' ASN . 0.3 OUTLIER -90.01 -36.22 15.06 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.174 -0.954 . . . . 0.0 108.659 177.044 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.515 ' CD2' ' HB2' ' B' ' 20' ' ' ASN . 81.7 m-85 -150.71 150.2 30.77 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.886 -0.509 . . . . 0.0 109.801 179.263 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . 0.466 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 62.4 ttt180 -97.76 143.85 27.97 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.733 -1.229 . . . . 0.0 109.994 176.499 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.524 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 97.3 m -130.03 140.12 50.91 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.579 -0.7 . . . . 0.0 110.04 -173.335 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.789 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -129.99 135.94 48.86 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.045 -1.035 . . . . 0.0 111.186 179.179 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.754 HG22 ' OG ' ' B' ' 60' ' ' SER . 15.7 t -115.54 134.44 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.09 -1.006 . . . . 0.0 110.687 -178.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 30.2 m -119.97 170.02 10.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 C-N-CA 120.46 -0.496 . . . . 0.0 109.957 -179.711 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.525 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 7.6 tt0 -103.51 117.13 33.74 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 121.455 -0.778 . . . . 0.0 108.968 -179.347 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.552 HD23 ' HA ' ' B' ' 33' ' ' LEU . 8.9 tp -82.05 119.77 75.86 Favored Pre-proline 0 C--N 1.294 -1.81 0 O-C-N 121.449 -0.782 . . . . 0.0 109.815 -173.678 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.468 ' HD2' ' HB2' ' B' ' 32' ' ' MET . 22.1 Cg_endo -65.42 179.08 1.75 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 O-C-N 123.829 1.437 . . . . 0.0 111.032 -179.327 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.419 ' OD1' ' C ' ' B' ' 30' ' ' ASP . 50.5 t0 -60.01 -41.26 91.78 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.413 -0.804 . . . . 0.0 111.134 -175.338 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.57 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.36 1.5 56.52 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.971 -1.08 . . . . 0.0 110.804 -174.236 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.57 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 96.4 mmm -110.97 -15.98 13.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.049 -1.032 . . . . 0.0 109.839 171.818 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.633 HD21 ' HB2' ' B' ' 57' ' ' ASN . 16.6 mt -68.01 -30.49 69.75 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.412 -0.805 . . . . 0.0 110.043 178.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -91.72 127.02 37.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.331 -0.856 . . . . 0.0 110.238 -179.635 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.3 -47.98 1.0 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 177.673 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.778 HD23 ' N ' ' B' ' 37' ' ' GLU . 7.4 tt -69.97 145.74 51.62 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.022 -1.281 . . . . 0.0 110.649 -175.758 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . 0.778 ' N ' HD23 ' B' ' 36' ' ' LEU . 20.7 pt-20 -150.44 169.99 20.14 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.505 -0.747 . . . . 0.0 109.608 -179.529 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 0.834 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -67.25 151.09 48.13 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.883 -1.136 . . . . 0.0 110.115 179.996 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.74 -0.09 62.4 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -176.211 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.458 ' O ' ' HA ' ' B' ' 50' ' ' THR . . . -79.85 158.94 26.63 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.281 -1.129 . . . . 0.0 109.656 177.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.551 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -100.94 113.24 26.02 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.993 -1.067 . . . . 0.0 110.075 176.7 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.597 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.0 t -104.89 130.02 56.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 121.285 -0.884 . . . . 0.0 109.111 174.764 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 0.519 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -93.22 119.53 32.5 Favored 'General case' 0 C--N 1.298 -1.645 0 C-N-CA 119.085 -1.046 . . . . 0.0 109.278 172.155 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.731 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.3 OUTLIER -88.0 107.03 18.53 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.416 -0.802 . . . . 0.0 109.066 178.503 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.51 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.1 t-20 50.44 16.23 0.27 Allowed 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.469 -0.77 . . . . 0.0 111.222 -166.506 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.493 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 120.82 1.23 11.81 Favored Glycine 0 N--CA 1.49 2.298 0 C-N-CA 119.407 -1.378 . . . . 0.0 111.086 171.158 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.779 ' O ' HD23 ' B' ' 49' ' ' LEU . 35.1 t -98.92 108.44 21.12 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.188 -1.772 . . . . 0.0 109.379 175.02 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 21.0 p -75.58 126.84 31.8 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.113 -0.992 . . . . 0.0 111.011 -171.172 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 0.983 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -141.44 162.74 34.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.458 -0.776 . . . . 0.0 109.461 172.637 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . 0.458 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 55.0 m -102.44 152.97 20.5 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 120.612 -1.305 . . . . 0.0 111.037 -171.14 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.905 HG22 ' CE1' ' B' ' 61' ' ' PHE . 34.0 t -76.91 117.55 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.509 -0.745 . . . . 0.0 110.488 -177.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.676 HG22 ' HB3' ' B' ' 62' ' ' ASP . 40.9 p -70.02 -40.11 75.42 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.087 -1.008 . . . . 0.0 109.691 172.271 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.576 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 52.3 tp10 -164.68 156.14 15.39 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.252 -0.905 . . . . 0.0 110.838 -177.328 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.834 HD11 ' N ' ' B' ' 38' ' ' THR . 9.0 mt -110.44 130.02 64.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.236 -0.915 . . . . 0.0 110.029 172.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.52 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 63.7 m-80 -104.74 65.45 0.75 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-O 121.445 0.641 . . . . 0.0 109.482 177.823 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.13 -115.04 4.21 Favored Glycine 0 N--CA 1.486 2.005 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 -174.213 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.633 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.01 -21.22 43.85 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.035 -1.273 . . . . 0.0 109.183 176.596 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.057 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.6 m170 -76.95 159.23 30.12 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.155 -0.966 . . . . 0.0 109.758 -178.036 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.81 HG13 HG13 ' B' ' 51' ' ' VAL . 59.5 t -140.83 121.52 13.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 C-N-CA 119.008 -1.077 . . . . 0.0 110.469 171.796 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.754 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.2 t -84.42 135.35 34.3 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.468 -0.77 . . . . 0.0 109.368 175.876 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.983 ' HB3' HD12 ' B' ' 49' ' ' LEU . 58.7 m-85 -115.47 158.72 22.15 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.287 -0.883 . . . . 0.0 110.165 179.012 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.676 ' HB3' HG22 ' B' ' 52' ' ' THR . 25.1 p-10 -92.25 147.48 22.89 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.08 -1.013 . . . . 0.0 110.876 178.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.8 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.69 125.09 4.12 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -176.885 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.533 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 56.1 ttm -84.92 146.4 27.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.966 -1.084 . . . . 0.0 109.388 -177.811 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.428 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 71.3 tttt -60.03 -49.14 78.84 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.104 -0.998 . . . . 0.0 109.977 -177.205 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -69.6 -39.99 76.91 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.149 -0.969 . . . . 0.0 110.444 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.554 ' O ' HG23 ' B' ' 71' ' ' THR . 38.5 m -62.26 -38.83 90.8 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.935 -1.103 . . . . 0.0 108.98 174.449 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.827 HD11 ' HA2' ' B' ' 74' ' ' GLY . 1.0 OUTLIER -59.9 -47.28 86.43 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.436 -0.79 . . . . 0.0 109.8 177.398 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 74.9 ttt-85 -65.83 -39.99 91.36 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.54 -0.725 . . . . 0.0 110.513 178.173 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.885 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -64.2 -41.19 91.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.285 -0.885 . . . . 0.0 109.13 -179.381 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.885 HG23 HG22 ' B' ' 70' ' ' ILE . 20.4 p -89.7 -176.85 5.11 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 120.236 -0.586 . . . . 0.0 109.433 175.602 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.527 ' CB ' ' H ' ' A' ' 83' ' ' ASN . 3.5 t30 -100.0 25.09 7.73 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.079 -1.013 . . . . 0.0 108.307 172.336 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.8 ' HB3' HD21 ' B' ' 63' ' ' LEU . 86.6 mt -67.69 -39.94 84.38 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.995 -1.066 . . . . 0.0 109.945 176.609 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.827 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -54.86 -23.95 32.12 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 110.321 -1.112 . . . . 0.0 110.321 -177.527 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 21.5 p-10 -64.1 -17.02 63.02 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.006 -1.29 . . . . 0.0 110.349 -175.381 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 96.1 mt -60.0 141.41 55.68 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.252 -0.905 . . . . 0.0 110.484 -177.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 1.011 ' C ' HD23 ' B' ' 12' ' ' LEU . 59.8 mmtt -139.93 143.29 36.53 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 121.555 0.693 . . . . 0.0 110.446 175.771 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.598 ' N ' HD23 ' B' ' 12' ' ' LEU . 36.5 t -63.19 149.47 10.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.22 -176.152 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.48 -13.53 63.64 Favored Glycine 0 N--CA 1.483 1.808 0 N-CA-C 108.818 -1.713 . . . . 0.0 108.818 -175.3 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 46.0 t0 -96.27 162.99 13.27 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.27 -1.135 . . . . 0.0 109.629 175.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 13.6 m95 -113.9 162.05 16.86 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.09 -1.007 . . . . 0.0 110.178 176.598 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 1.048 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.5 p -130.78 140.31 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.545 -0.722 . . . . 0.0 110.179 -175.78 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.851 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.2 OUTLIER -66.87 103.78 1.21 Allowed 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.115 -0.991 . . . . 0.0 109.549 169.089 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.746 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -106.48 137.92 34.58 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 120.589 -1.319 . . . . 0.0 111.28 -178.692 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . 0.541 ' HB2' HG22 ' B' ' 6' ' ' VAL . 84.3 tt0 -133.03 131.64 40.91 Favored 'General case' 0 N--CA 1.493 1.7 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.036 179.681 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 75.9 ttt180 -72.11 139.17 48.24 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.25 -0.906 . . . . 0.0 110.955 -175.849 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.551 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.496 1.847 0 O-C-N 121.389 -0.82 . . . . 0.0 109.749 176.623 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.852 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.9 t . . . . . 0 N--CA 1.493 1.697 0 CA-C-O 121.656 0.741 . . . . 0.0 111.408 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . 0.463 ' HG2' ' HG3' ' A' ' 85' ' ' GLU . 89.5 mm-40 -70.02 -38.59 75.95 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.662 -0.649 . . . . 0.0 110.294 173.349 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.523 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -168.3 -176.52 38.76 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 119.404 -1.379 . . . . 0.0 109.816 -176.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.472 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 1.1 p -120.78 171.83 8.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.96 -1.317 . . . . 0.0 110.859 -177.431 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 1.072 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -140.3 149.92 43.38 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.556 -0.715 . . . . 0.0 109.531 -178.221 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 35.2 tttt -105.52 116.02 31.24 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 120.922 -1.111 . . . . 0.0 110.138 178.597 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 1.025 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.9 tp -59.83 128.48 37.14 Favored 'General case' 0 C--N 1.297 -1.703 0 O-C-N 120.863 -1.148 . . . . 0.0 108.69 172.558 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.12 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.6 p -129.41 -29.3 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.291 -177.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.68 142.36 26.66 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 118.948 -1.101 . . . . 0.0 111.534 179.368 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.825 HG23 ' CD2' ' A' ' 24' ' ' HIS . 10.9 mt -107.81 135.71 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.037 -1.039 . . . . 0.0 110.174 171.653 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.494 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 83.5 m-20 -110.14 114.56 28.15 Favored 'General case' 0 C--N 1.295 -1.769 0 O-C-N 121.308 -0.87 . . . . 0.0 110.272 173.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -101.91 109.6 21.38 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.175 -0.953 . . . . 0.0 110.421 -178.231 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.4 mtpt -103.87 134.54 19.67 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.056 -1.028 . . . . 0.0 109.424 175.272 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.58 -18.31 8.26 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 O-C-N 123.995 1.524 . . . . 0.0 110.802 -179.616 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.581 ' HB2' ' CD2' ' A' ' 21' ' ' PHE . 0.3 OUTLIER -99.28 -32.77 11.03 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.143 -0.973 . . . . 0.0 109.138 -179.906 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.581 ' CD2' ' HB2' ' A' ' 20' ' ' ASN . 56.3 m-85 -150.48 150.21 31.0 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.835 -0.54 . . . . 0.0 110.144 -175.747 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.475 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 56.1 ttt180 -94.02 143.33 26.45 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.639 -1.288 . . . . 0.0 110.055 173.14 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.494 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 44.5 m -129.99 139.22 51.09 Favored 'General case' 0 C--N 1.296 -1.743 0 O-C-N 121.564 -0.71 . . . . 0.0 109.818 -175.315 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.825 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.0 135.46 48.32 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.862 -1.149 . . . . 0.0 111.312 179.377 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.765 HG22 ' CB ' ' A' ' 60' ' ' SER . 4.8 t -117.47 131.91 68.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.085 -1.01 . . . . 0.0 110.731 -176.791 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.578 HG22 ' HE2' ' A' ' 61' ' ' PHE . 7.0 m -113.63 172.32 3.52 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.94 -0.475 . . . . 0.0 110.061 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.544 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 7.1 tt0 -105.34 117.27 33.59 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.427 -0.795 . . . . 0.0 108.948 178.567 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.565 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.0 tp -83.55 121.05 76.32 Favored Pre-proline 0 C--N 1.296 -1.751 0 O-C-N 121.632 -0.668 . . . . 0.0 109.943 -172.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.473 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 25.1 Cg_endo -66.27 176.0 4.4 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 O-C-N 123.9 1.474 . . . . 0.0 111.007 -179.372 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.55 ' HA ' HD12 ' A' ' 33' ' ' LEU . 51.2 t0 -60.07 -39.97 87.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.424 -0.798 . . . . 0.0 111.049 -175.177 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.599 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.08 0.35 57.18 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.939 -1.1 . . . . 0.0 110.785 -174.917 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.599 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 98.0 mmm -113.06 -11.03 13.4 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.959 -1.088 . . . . 0.0 110.053 172.328 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.586 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 15.7 mt -69.98 -32.32 70.46 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.304 -0.872 . . . . 0.0 109.923 177.629 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -79.91 139.91 36.92 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.512 -0.742 . . . . 0.0 111.009 -176.156 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.01 -38.43 3.17 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 120.024 -1.084 . . . . 0.0 110.645 171.786 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.47 HD23 ' CD2' ' A' ' 28' ' ' LEU . 64.7 tp -77.99 147.72 34.74 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.787 -1.42 . . . . 0.0 111.102 -174.015 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.512 ' C ' HD11 ' A' ' 54' ' ' ILE . 20.6 pt-20 -149.23 170.04 19.39 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.459 -0.775 . . . . 0.0 109.322 175.216 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.856 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -62.96 151.94 38.1 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.931 -1.106 . . . . 0.0 110.027 -178.688 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.24 -3.48 62.11 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -176.225 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.464 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -77.1 158.72 30.3 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.242 -1.152 . . . . 0.0 109.491 176.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.557 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -100.97 110.05 22.04 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.901 -1.124 . . . . 0.0 110.045 178.567 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.673 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.0 t -98.99 129.94 48.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 121.212 -0.93 . . . . 0.0 109.155 174.782 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.516 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -95.51 119.95 34.9 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 119.244 -0.982 . . . . 0.0 109.227 172.093 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.673 ' HE1' HG11 ' A' ' 42' ' ' VAL . 0.6 OUTLIER -88.25 106.97 18.56 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 177.789 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.495 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 55.33 13.76 0.96 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.329 -0.857 . . . . 0.0 110.91 -167.326 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 117.56 -0.5 18.23 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 119.508 -1.329 . . . . 0.0 110.615 172.797 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.78 ' O ' HD23 ' A' ' 49' ' ' LEU . 36.6 t -93.54 105.59 17.63 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.477 -1.602 . . . . 0.0 109.423 175.728 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 25.0 p -73.73 129.44 37.92 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.193 -0.942 . . . . 0.0 111.183 -170.747 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.992 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -145.39 160.57 41.36 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 172.841 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 21.3 m -96.3 152.95 18.1 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.534 -1.354 . . . . 0.0 111.175 -170.095 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.784 HG13 HG13 ' A' ' 59' ' ' VAL . 21.2 t -76.96 112.11 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.775 -0.578 . . . . 0.0 110.037 178.695 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.575 HG22 ' HB3' ' A' ' 62' ' ' ASP . 33.9 p -69.39 -40.05 77.61 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.119 -0.988 . . . . 0.0 109.556 173.757 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.567 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -160.59 156.13 25.21 Favored 'General case' 0 N--CA 1.49 1.557 0 C-N-CA 119.383 -0.927 . . . . 0.0 110.895 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.856 HD11 ' N ' ' A' ' 38' ' ' THR . 7.8 mt -109.97 130.47 63.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.211 -0.931 . . . . 0.0 109.73 172.598 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.508 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 46.6 m-80 -104.45 65.03 0.76 Allowed 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 119.822 -0.751 . . . . 0.0 109.567 178.13 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.46 -114.91 4.42 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 -173.609 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.586 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.02 -19.74 47.0 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.078 -1.248 . . . . 0.0 109.119 176.645 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.12 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.8 m170 -76.61 159.0 30.66 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.256 -0.903 . . . . 0.0 110.061 -178.663 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.784 HG13 HG13 ' A' ' 51' ' ' VAL . 54.0 t -141.45 122.52 12.97 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 O-C-N 121.01 -1.056 . . . . 0.0 111.029 173.655 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.765 ' CB ' HG22 ' A' ' 25' ' ' VAL . 17.4 m -91.83 127.48 37.31 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.655 -0.653 . . . . 0.0 109.897 179.581 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.992 ' HB3' HD12 ' A' ' 49' ' ' LEU . 54.4 m-85 -111.59 160.81 16.85 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.869 -1.145 . . . . 0.0 110.243 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.575 ' HB3' HG22 ' A' ' 52' ' ' THR . 38.1 p-10 -92.01 148.63 22.05 Favored 'General case' 0 N--CA 1.496 1.858 0 CA-C-O 122.065 0.936 . . . . 0.0 111.321 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 0.713 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -156.01 118.55 4.13 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 -177.304 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.532 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 74.3 mmm -73.0 142.73 47.74 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.937 -1.102 . . . . 0.0 109.514 179.088 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.487 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 38.5 tttp -60.0 -44.9 94.24 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.007 -1.058 . . . . 0.0 110.091 -177.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.47 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.6 tt0 -70.04 -39.95 75.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.01 -1.056 . . . . 0.0 110.105 179.109 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.532 ' HB ' ' HB2' ' A' ' 64' ' ' MET . 93.8 m -60.05 -39.37 85.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.923 -1.111 . . . . 0.0 109.286 172.31 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 0.745 HD11 ' HA2' ' A' ' 74' ' ' GLY . 9.3 tp -59.95 -44.95 94.07 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.199 -0.938 . . . . 0.0 109.348 -179.638 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 61.0 ttt180 -69.93 -39.92 75.83 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.517 -0.739 . . . . 0.0 110.686 175.528 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.81 HG22 HG23 ' A' ' 71' ' ' THR . 1.4 tt -66.85 -42.61 89.35 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 O-C-N 121.164 -0.96 . . . . 0.0 109.386 -176.289 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.81 HG23 HG22 ' A' ' 70' ' ' ILE . 43.6 p -84.74 -174.1 5.09 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 175.642 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.472 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 6.7 t30 -102.17 24.02 10.78 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 170.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.755 HD11 ' SG ' ' A' ' 47' ' ' CYS . 98.0 mt -69.98 -40.04 75.57 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.136 -0.978 . . . . 0.0 109.734 176.455 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.745 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -49.55 -22.91 4.24 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.381 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 25.6 p-10 -63.61 -19.33 64.76 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.014 -1.286 . . . . 0.0 110.357 -175.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.514 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.4 mt -61.33 140.43 58.0 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.148 -0.97 . . . . 0.0 110.962 -176.769 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 1.025 ' C ' HD23 ' A' ' 12' ' ' LEU . 22.8 mttm -141.44 139.35 33.36 Favored 'General case' 0 C--N 1.296 -1.726 0 CA-C-O 121.479 0.657 . . . . 0.0 109.559 174.356 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.703 ' N ' HD23 ' A' ' 12' ' ' LEU . 44.0 t -60.93 151.46 6.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 O-C-N 120.924 -1.11 . . . . 0.0 110.327 -176.338 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.97 -14.66 61.35 Favored Glycine 0 N--CA 1.482 1.746 0 N-CA-C 108.751 -1.739 . . . . 0.0 108.751 -175.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -98.16 167.12 11.07 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.31 -1.112 . . . . 0.0 109.626 175.311 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.584 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.5 m95 -115.37 156.72 25.02 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.104 -0.997 . . . . 0.0 110.134 177.092 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.072 HG13 ' HB3' ' A' ' 10' ' ' ALA . 0.9 OUTLIER -120.13 155.15 23.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 O-C-N 121.527 -0.733 . . . . 0.0 109.892 -178.124 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 0.852 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.5 m-20 -80.02 106.75 12.27 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.21 -0.931 . . . . 0.0 108.988 168.793 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.716 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -107.25 138.6 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.55 -1.344 . . . . 0.0 111.039 -175.223 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.463 ' HG3' ' HG2' ' A' ' 7' ' ' GLN . 86.4 tt0 -136.83 135.34 37.84 Favored 'General case' 0 N--CA 1.492 1.632 0 C-N-CA 120.381 -0.528 . . . . 0.0 109.752 -178.355 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -78.67 129.92 35.27 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.055 -1.028 . . . . 0.0 110.618 -176.212 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.557 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.567 0 O-C-N 121.401 -0.812 . . . . 0.0 110.199 178.298 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 0.809 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.9 t . . . . . 0 N--CA 1.493 1.725 0 CA-C-O 121.681 0.753 . . . . 0.0 111.42 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . 0.47 ' HG2' ' HG3' ' B' ' 85' ' ' GLU . 89.6 mm-40 -70.02 -38.31 75.86 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.694 -0.629 . . . . 0.0 110.371 173.437 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.522 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -168.6 -176.65 39.02 Favored Glycine 0 N--CA 1.494 2.556 0 C-N-CA 119.478 -1.344 . . . . 0.0 109.854 -177.013 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.48 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 1.1 p -120.73 171.83 8.32 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.039 -1.271 . . . . 0.0 110.918 -177.401 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.066 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -140.29 149.94 43.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.533 -0.729 . . . . 0.0 109.444 -178.18 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.581 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 35.3 tttt -105.51 116.13 31.42 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.057 -1.027 . . . . 0.0 110.087 178.531 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 1.024 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.9 tp -60.03 128.31 36.21 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.971 -1.081 . . . . 0.0 108.781 172.461 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.128 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.6 p -129.12 -29.53 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 C-N-CA 119.565 -0.854 . . . . 0.0 110.296 -177.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.57 142.33 26.74 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 119.072 -1.051 . . . . 0.0 111.501 179.454 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.828 HG23 ' CD2' ' B' ' 24' ' ' HIS . 10.9 mt -107.76 135.84 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.116 -0.99 . . . . 0.0 110.207 171.606 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.504 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.2 m-20 -110.33 114.69 28.35 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.443 -0.785 . . . . 0.0 110.184 173.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -101.91 109.53 21.29 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.099 -1.001 . . . . 0.0 110.443 -178.25 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.4 mtpt -103.88 134.6 19.63 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.218 -0.926 . . . . 0.0 109.546 175.196 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -52.73 -18.2 8.48 Favored 'Trans proline' 0 C--N 1.303 -1.868 0 O-C-N 123.952 1.501 . . . . 0.0 110.747 -179.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.583 ' HB2' ' CD2' ' B' ' 21' ' ' PHE . 0.3 OUTLIER -99.04 -33.46 10.8 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.154 -0.966 . . . . 0.0 109.044 -179.966 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.583 ' CD2' ' HB2' ' B' ' 20' ' ' ASN . 56.2 m-85 -149.96 150.31 31.64 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 120.327 -0.549 . . . . 0.0 110.176 -175.634 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . 0.473 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 56.1 ttt180 -94.01 143.42 26.37 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.757 -1.214 . . . . 0.0 110.008 173.101 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.504 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 42.9 m -130.09 139.3 50.97 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.745 -0.597 . . . . 0.0 109.736 -175.367 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.828 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.02 135.64 48.5 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.984 -1.073 . . . . 0.0 111.227 179.347 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.764 HG22 ' CB ' ' B' ' 60' ' ' SER . 4.8 t -117.42 131.99 68.52 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.262 -0.899 . . . . 0.0 110.769 -176.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.585 HG22 ' HE2' ' B' ' 61' ' ' PHE . 7.2 m -113.79 172.24 3.62 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 O-C-N 121.909 -0.495 . . . . 0.0 110.025 179.234 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.549 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 7.0 tt0 -105.09 117.32 33.7 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.466 -0.771 . . . . 0.0 109.118 178.413 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.552 HD23 ' HA ' ' B' ' 33' ' ' LEU . 8.9 tp -83.51 120.99 76.35 Favored Pre-proline 0 C--N 1.295 -1.779 0 O-C-N 121.555 -0.716 . . . . 0.0 110.028 -172.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.465 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 25.6 Cg_endo -66.16 175.97 4.33 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 O-C-N 123.856 1.45 . . . . 0.0 111.005 -179.41 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.529 ' HA ' HD12 ' B' ' 33' ' ' LEU . 51.3 t0 -60.02 -40.07 88.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.448 -0.783 . . . . 0.0 111.061 -175.27 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.605 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.02 0.34 57.16 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.884 -1.135 . . . . 0.0 110.851 -174.925 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.605 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 98.0 mmm -113.05 -11.2 13.39 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.105 -0.997 . . . . 0.0 110.053 172.377 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.59 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 15.8 mt -69.89 -32.21 70.41 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.35 -0.844 . . . . 0.0 110.022 177.628 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -80.11 139.96 36.64 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.545 -0.722 . . . . 0.0 110.927 -176.16 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.92 -38.4 3.17 Favored Glycine 0 N--CA 1.493 2.442 0 C-N-CA 119.965 -1.112 . . . . 0.0 110.581 171.799 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.478 HD23 ' CD2' ' B' ' 28' ' ' LEU . 64.5 tp -77.97 147.68 34.8 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.93 -1.335 . . . . 0.0 111.146 -174.101 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . 0.491 ' C ' HD11 ' B' ' 54' ' ' ILE . 20.6 pt-20 -149.13 170.03 19.35 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.466 -0.771 . . . . 0.0 109.323 175.269 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 0.863 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -62.99 151.79 38.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.932 -1.105 . . . . 0.0 110.071 -178.8 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.34 -3.51 62.37 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -176.159 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.457 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -77.18 158.58 30.27 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.184 -1.186 . . . . 0.0 109.446 176.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.565 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -100.65 109.84 21.93 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 120.904 -1.123 . . . . 0.0 110.14 178.537 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.657 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.0 t -99.0 129.9 48.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.284 -0.885 . . . . 0.0 109.171 174.713 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 0.514 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -95.44 120.01 34.94 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 119.204 -0.999 . . . . 0.0 109.199 172.06 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.657 ' HE1' HG11 ' B' ' 42' ' ' VAL . 0.6 OUTLIER -88.29 106.79 18.45 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.408 -0.807 . . . . 0.0 108.915 177.691 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.495 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 55.5 13.88 1.05 Allowed 'General case' 0 C--N 1.299 -1.597 0 O-C-N 121.333 -0.854 . . . . 0.0 110.888 -167.346 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . . . . . . . . . . . 117.46 -0.32 18.44 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.513 -1.327 . . . . 0.0 110.612 172.671 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.797 ' O ' HD23 ' B' ' 49' ' ' LEU . 36.7 t -93.66 105.59 17.62 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.536 -1.567 . . . . 0.0 109.439 175.67 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 25.1 p -73.65 129.56 38.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.084 -1.01 . . . . 0.0 111.079 -170.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 1.009 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -145.61 160.54 41.52 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 172.714 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 21.3 m -96.14 153.05 18.0 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.703 -1.248 . . . . 0.0 111.181 -170.021 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.79 HG13 HG13 ' B' ' 59' ' ' VAL . 21.2 t -77.06 112.05 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.652 -0.655 . . . . 0.0 110.126 178.598 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.552 HG22 ' HB3' ' B' ' 62' ' ' ASP . 34.5 p -69.54 -39.91 77.18 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.168 -0.958 . . . . 0.0 109.462 173.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.568 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -160.64 156.1 25.05 Favored 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.861 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.863 HD11 ' N ' ' B' ' 38' ' ' THR . 7.8 mt -110.01 130.42 63.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.259 -0.901 . . . . 0.0 109.728 172.651 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.524 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 46.6 m-80 -104.55 65.03 0.76 Allowed 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.575 178.151 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.61 -114.94 4.4 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 108.716 -1.754 . . . . 0.0 108.716 -173.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.59 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.03 -19.66 47.15 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.05 -1.265 . . . . 0.0 109.194 176.645 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.128 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.9 m170 -76.6 158.78 30.84 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.359 -0.838 . . . . 0.0 110.096 -178.698 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.79 HG13 HG13 ' B' ' 51' ' ' VAL . 54.4 t -141.32 122.64 13.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.967 173.735 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.764 ' CB ' HG22 ' B' ' 25' ' ' VAL . 17.4 m -91.92 127.56 37.43 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.767 -0.583 . . . . 0.0 109.953 179.554 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 1.009 ' HB3' HD12 ' B' ' 49' ' ' LEU . 54.4 m-85 -111.55 160.81 16.83 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.056 -1.027 . . . . 0.0 110.314 179.258 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.552 ' HB3' HG22 ' B' ' 52' ' ' THR . 38.0 p-10 -92.0 148.66 22.03 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.135 -0.978 . . . . 0.0 111.269 179.805 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 0.745 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -156.0 118.48 4.12 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -177.354 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.528 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 74.2 mmm -73.01 142.77 47.72 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.907 -1.12 . . . . 0.0 109.481 179.147 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.484 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 38.5 tttp -59.98 -44.92 94.17 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.091 -1.005 . . . . 0.0 110.075 -177.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . 0.478 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 86.6 tt0 -69.99 -40.06 75.52 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.047 -1.033 . . . . 0.0 110.062 179.196 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.528 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 94.2 m -59.96 -39.53 85.92 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.923 -1.111 . . . . 0.0 109.144 172.41 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 0.754 HD11 ' HA2' ' B' ' 74' ' ' GLY . 9.4 tp -60.07 -44.71 94.56 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.428 -0.795 . . . . 0.0 109.436 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 61.1 ttt180 -70.04 -39.92 75.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.498 -0.751 . . . . 0.0 110.673 175.372 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.791 HG22 HG23 ' B' ' 71' ' ' THR . 1.4 tt -66.77 -42.52 89.47 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.263 -0.898 . . . . 0.0 109.421 -176.368 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.791 HG23 HG22 ' B' ' 70' ' ' ILE . 43.8 p -84.74 -173.85 4.95 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 175.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.48 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 6.7 t30 -102.31 24.06 10.82 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 170.855 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.751 HD11 ' SG ' ' B' ' 47' ' ' CYS . 98.0 mt -69.99 -40.1 75.53 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.192 -0.942 . . . . 0.0 109.745 176.403 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.754 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -49.59 -22.91 4.31 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 -179.396 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 25.7 p-10 -63.55 -19.38 64.75 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.031 -1.276 . . . . 0.0 110.374 -175.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 97.5 mt -61.27 140.47 57.96 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.199 -0.938 . . . . 0.0 110.915 -176.786 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 1.024 ' C ' HD23 ' B' ' 12' ' ' LEU . 22.8 mttm -141.39 139.38 33.47 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-O 121.336 0.589 . . . . 0.0 109.556 174.322 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.703 ' N ' HD23 ' B' ' 12' ' ' LEU . 44.2 t -60.95 151.33 6.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 120.93 -1.107 . . . . 0.0 110.315 -176.345 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.96 -14.43 61.95 Favored Glycine 0 N--CA 1.482 1.751 0 N-CA-C 108.781 -1.727 . . . . 0.0 108.781 -175.41 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -98.2 167.09 11.08 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.362 -1.081 . . . . 0.0 109.6 175.207 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.581 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.4 m95 -115.42 156.71 25.09 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.177 -0.952 . . . . 0.0 110.13 177.073 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 1.066 HG13 ' HB3' ' B' ' 10' ' ' ALA . 0.9 OUTLIER -120.12 155.26 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.532 -0.73 . . . . 0.0 109.955 -178.206 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 0.809 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -80.05 106.43 12.06 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.243 -0.911 . . . . 0.0 109.03 168.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.702 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -106.94 138.72 31.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 120.588 -1.32 . . . . 0.0 111.061 -175.145 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . 0.47 ' HG3' ' HG2' ' B' ' 7' ' ' GLN . 86.4 tt0 -137.02 135.36 37.51 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.836 -0.54 . . . . 0.0 109.765 -178.461 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -78.6 130.02 35.45 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.015 -1.053 . . . . 0.0 110.543 -176.155 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.565 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.493 1.704 0 O-C-N 121.525 -0.734 . . . . 0.0 110.144 178.248 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 1.031 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.5 t . . . . . 0 N--CA 1.495 1.779 0 CA-C-O 121.55 0.691 . . . . 0.0 110.779 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -70.0 -32.63 70.9 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.619 -0.676 . . . . 0.0 110.803 177.419 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.531 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -164.96 177.26 40.53 Favored Glycine 0 N--CA 1.494 2.564 0 C-N-CA 118.767 -1.682 . . . . 0.0 110.485 -174.237 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . 0.506 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 2.9 p -116.34 167.89 10.62 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.131 -1.217 . . . . 0.0 110.886 -177.871 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' ALA . . . . . 1.055 ' HB2' HG21 ' A' ' 84' ' ' VAL . . . -137.73 148.46 45.64 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 -176.009 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' LYS . . . . . 0.577 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 25.7 tttt -108.88 115.91 30.98 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.022 -1.049 . . . . 0.0 110.379 -179.333 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.994 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.0 tp -58.7 127.37 31.86 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.077 -1.014 . . . . 0.0 108.89 174.284 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.086 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -125.11 -31.48 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 O-C-N 121.352 -0.843 . . . . 0.0 109.932 -179.679 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.54 144.05 28.23 Favored 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.327 -178.054 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.584 HG12 ' CD2' ' A' ' 24' ' ' HIS . 8.6 mt -108.1 130.08 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.214 -0.929 . . . . 0.0 110.181 172.265 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.507 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 67.3 m-20 -105.66 114.24 28.29 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.318 -0.863 . . . . 0.0 109.768 172.895 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -106.59 108.88 20.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.975 -1.078 . . . . 0.0 110.856 -177.511 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -104.26 128.65 26.63 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.198 -0.939 . . . . 0.0 108.888 173.052 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -50.33 -34.06 39.34 Favored 'Trans proline' 0 C--N 1.303 -1.861 0 O-C-N 123.753 1.396 . . . . 0.0 110.496 -179.601 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' ASN . . . . . 0.531 ' C ' ' CD2' ' A' ' 21' ' ' PHE . 12.4 m-80 -71.57 -39.86 70.32 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.201 -0.937 . . . . 0.0 110.039 175.559 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' PHE . . . . . 0.531 ' CD2' ' C ' ' A' ' 20' ' ' ASN . 89.2 m-85 -152.98 150.25 29.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.399 -0.813 . . . . 0.0 109.973 -179.411 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' ARG . . . . . 0.738 ' HD3' HD22 ' A' ' 68' ' ' LEU . 62.6 ttt180 -93.27 144.95 24.82 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.732 -1.23 . . . . 0.0 110.124 177.046 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.507 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 56.8 m -130.31 141.56 50.59 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.48 -0.762 . . . . 0.0 110.09 -176.186 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.607 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -127.89 144.78 51.09 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 120.974 -1.079 . . . . 0.0 111.342 176.75 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.763 HG22 ' CB ' ' A' ' 60' ' ' SER . 4.3 t -124.63 133.55 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.183 -0.948 . . . . 0.0 110.703 -179.27 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.592 HG13 ' HE2' ' A' ' 61' ' ' PHE . 33.4 m -118.5 172.06 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.796 -0.565 . . . . 0.0 110.425 -179.96 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.514 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 12.9 tt0 -101.14 117.51 35.15 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.594 -0.691 . . . . 0.0 109.318 -179.551 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.628 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.4 tp -82.0 121.26 78.91 Favored Pre-proline 0 C--N 1.297 -1.687 0 O-C-N 121.796 -0.565 . . . . 0.0 109.813 -175.302 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.49 ' HD2' HD12 ' A' ' 28' ' ' LEU . 25.5 Cg_endo -66.23 179.47 1.95 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 O-C-N 123.863 1.454 . . . . 0.0 110.992 -179.42 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.511 ' HA ' HD12 ' A' ' 33' ' ' LEU . 96.0 m-20 -63.41 -40.0 96.0 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.368 -0.833 . . . . 0.0 111.067 -175.646 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' HIS . . . . . 0.434 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.42 1.09 56.97 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.922 -1.111 . . . . 0.0 111.067 -175.31 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' MET . . . . . 0.474 ' HB2' ' HD2' ' A' ' 29' ' ' PRO . 98.4 mmm -113.92 -13.95 12.51 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.998 -1.064 . . . . 0.0 109.801 172.254 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.628 ' HA ' HD23 ' A' ' 28' ' ' LEU . 14.0 mt -66.19 -39.85 89.99 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.289 -0.882 . . . . 0.0 109.784 176.57 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -77.19 132.35 38.72 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.496 -0.753 . . . . 0.0 110.586 -177.486 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.51 -43.06 1.87 Allowed Glycine 0 N--CA 1.492 2.391 0 C-N-CA 119.903 -1.141 . . . . 0.0 110.258 174.489 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' LEU . . . . . 0.597 HD23 ' N ' ' A' ' 37' ' ' GLU . 5.7 tt -69.91 145.7 51.76 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.928 -1.337 . . . . 0.0 110.564 -174.94 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.597 ' N ' HD23 ' A' ' 36' ' ' LEU . 20.6 pt-20 -149.98 167.63 26.13 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.524 -0.735 . . . . 0.0 109.416 -179.555 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.822 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -67.95 149.94 49.13 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.85 -1.156 . . . . 0.0 110.201 -178.114 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.33 -3.61 62.03 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 -173.827 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' ALA . . . . . 0.538 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -76.55 159.99 29.85 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.236 -1.155 . . . . 0.0 109.122 174.85 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' SER . . . . . 0.903 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 1.1 p -104.21 117.88 35.3 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 118.72 -1.192 . . . . 0.0 109.897 177.184 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.626 HG11 ' HE1' ' A' ' 44' ' ' HIS . 0.9 OUTLIER -99.97 120.09 48.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.363 -0.836 . . . . 0.0 108.956 176.943 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -82.94 117.33 22.7 Favored 'General case' 0 C--N 1.298 -1.641 0 C-N-CA 119.262 -0.975 . . . . 0.0 109.241 174.495 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' HIS . . . . . 0.651 ' CD2' HG21 ' A' ' 82' ' ' VAL . 1.5 m80 -87.24 103.42 15.42 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 176.172 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.4 t-20 55.74 12.05 0.77 Allowed 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.548 -0.72 . . . . 0.0 111.335 -169.483 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.49 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 126.85 -6.13 7.39 Favored Glycine 0 N--CA 1.491 2.362 0 C-N-CA 119.605 -1.283 . . . . 0.0 110.825 173.324 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . 0.896 ' O ' HD23 ' A' ' 49' ' ' LEU . 44.8 t -93.31 103.64 15.87 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 120.509 -1.583 . . . . 0.0 109.67 176.038 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 16.0 p -72.18 121.91 20.13 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.096 -1.003 . . . . 0.0 110.737 -174.444 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' LEU . . . . . 0.896 HD23 ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -132.04 160.57 35.53 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.364 -0.835 . . . . 0.0 109.341 173.704 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.433 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 37.2 m -97.72 152.52 19.03 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.439 -1.413 . . . . 0.0 111.436 -169.555 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . 0.878 HG13 HG13 ' A' ' 59' ' ' VAL . 19.4 t -81.02 114.62 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.917 -0.489 . . . . 0.0 110.396 -178.953 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 52' ' ' THR . . . . . 0.488 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 31.1 p -69.85 -40.08 76.02 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.294 -0.879 . . . . 0.0 109.705 174.416 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 53' ' ' GLU . . . . . 0.564 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.7 tt0 -161.38 155.64 22.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.437 -0.789 . . . . 0.0 109.909 179.686 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.822 HD11 ' N ' ' A' ' 38' ' ' THR . 7.1 mt -105.15 128.99 58.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.966 -1.084 . . . . 0.0 109.574 174.613 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 55' ' ' ASN . . . . . 0.53 ' CB ' ' HB2' ' A' ' 58' ' ' HIS . 2.2 m-80 -100.6 62.6 1.05 Allowed 'General case' 0 C--N 1.298 -1.653 0 O-C-N 121.58 -0.7 . . . . 0.0 109.585 -179.014 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.04 -120.05 6.58 Favored Glycine 0 N--CA 1.487 2.054 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 -172.638 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.577 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -71.8 -20.22 61.88 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.931 -1.335 . . . . 0.0 108.981 175.094 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' HIS . . . . . 1.086 ' CD2' HG11 ' A' ' 13' ' ' VAL . 11.8 m170 -76.69 161.3 28.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.425 -0.797 . . . . 0.0 110.386 -176.748 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.878 HG13 HG13 ' A' ' 51' ' ' VAL . 54.5 t -140.02 125.52 20.9 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 C-N-CA 119.119 -1.032 . . . . 0.0 110.786 170.66 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . 0.763 ' CB ' HG22 ' A' ' 25' ' ' VAL . 24.8 m -97.61 123.16 41.4 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.763 -0.586 . . . . 0.0 109.509 -179.551 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.818 ' HB2' HD12 ' A' ' 49' ' ' LEU . 10.1 p90 -118.32 159.67 22.99 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.822 -1.174 . . . . 0.0 110.72 -179.743 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' ASP . . . . . 0.488 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 35.2 p-10 -93.37 156.56 16.72 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.089 -1.007 . . . . 0.0 111.532 -172.004 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' LEU . . . . . 1.062 HD22 HD13 ' A' ' 68' ' ' LEU . 0.1 OUTLIER -161.19 101.93 1.25 Allowed 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.705 -0.622 . . . . 0.0 109.607 -174.135 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' MET . . . . . 0.494 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 57.7 ttm -59.97 137.71 58.02 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.787 -1.195 . . . . 0.0 109.09 179.351 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 28.6 tttt -60.03 -45.91 91.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.977 -1.077 . . . . 0.0 110.614 -172.154 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.0 tp10 -66.15 -40.07 90.29 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.702 -1.248 . . . . 0.0 109.866 177.402 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' THR . . . . . 0.494 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 94.1 m -59.92 -40.01 87.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.087 -1.008 . . . . 0.0 109.573 172.683 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' LEU . . . . . 1.062 HD13 HD22 ' A' ' 63' ' ' LEU . 28.0 tp -60.02 -43.45 95.26 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.299 -0.876 . . . . 0.0 109.764 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 ttt85 -69.99 -39.09 76.12 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.326 -0.859 . . . . 0.0 110.352 177.765 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.709 HG22 HG23 ' A' ' 71' ' ' THR . 1.4 tt -64.78 -42.71 95.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.28 -0.887 . . . . 0.0 109.448 -176.816 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' THR . . . . . 0.709 HG23 HG22 ' A' ' 70' ' ' ILE . 30.5 p -81.99 -174.9 5.33 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 120.015 -0.674 . . . . 0.0 109.243 175.471 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.538 ' CB ' ' H ' ' B' ' 83' ' ' ASN . 5.2 t30 -99.52 22.25 11.04 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.174 -0.954 . . . . 0.0 108.511 171.062 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' LEU . . . . . 0.719 HD13 HD21 ' A' ' 63' ' ' LEU . 70.6 mt -70.12 -39.97 75.12 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.946 -1.096 . . . . 0.0 109.816 175.602 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 74' ' ' GLY . . . . . 0.428 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -49.31 -21.67 3.03 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -177.943 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 75' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.2 p-10 -66.21 -16.46 64.01 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.068 -1.254 . . . . 0.0 110.562 -175.056 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 76' ' ' LEU . . . . . 0.503 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 96.1 mt -62.07 142.34 57.61 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.209 -0.932 . . . . 0.0 111.173 -175.116 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 77' ' ' LYS . . . . . 0.994 ' C ' HD23 ' A' ' 12' ' ' LEU . 86.6 mttt -141.48 141.16 33.65 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.647 -0.658 . . . . 0.0 109.558 172.642 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.705 ' N ' HD23 ' A' ' 12' ' ' LEU . 16.7 t -59.52 151.72 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 120.711 -1.243 . . . . 0.0 110.297 -176.146 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.79 -13.55 60.64 Favored Glycine 0 N--CA 1.484 1.867 0 N-CA-C 108.948 -1.661 . . . . 0.0 108.948 -176.687 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 53.9 t0 -96.41 162.27 13.56 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.409 -1.054 . . . . 0.0 109.666 177.1 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 81' ' ' TRP . . . . . 0.577 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.0 m95 -113.21 153.33 28.51 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.141 -0.974 . . . . 0.0 110.42 177.369 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.043 HG13 ' HB3' ' A' ' 10' ' ' ALA . 0.8 OUTLIER -119.94 149.72 22.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.409 -0.807 . . . . 0.0 109.804 179.675 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 83' ' ' ASN . . . . . 1.031 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -69.6 102.58 1.88 Allowed 'General case' 0 C--N 1.3 -1.556 0 O-C-N 120.952 -1.092 . . . . 0.0 109.012 167.8 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 1.055 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -104.59 137.96 31.4 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 O-C-N 120.311 -1.493 . . . . 0.0 110.957 -178.772 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.445 ' HB2' HG22 ' A' ' 6' ' ' VAL . 85.9 tt0 -135.83 138.42 42.51 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.923 -0.711 . . . . 0.0 110.235 -176.192 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 76.4 ttt180 -61.3 127.46 31.63 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.24 -0.912 . . . . 0.0 110.044 -179.916 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.903 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.49 1.572 0 O-C-N 121.257 -0.902 . . . . 0.0 109.957 179.937 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 6' ' ' VAL . . . . . 1.039 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.5 t . . . . . 0 N--CA 1.494 1.736 0 CA-C-O 121.608 0.718 . . . . 0.0 110.723 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -69.98 -32.52 70.78 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.601 -0.687 . . . . 0.0 110.88 177.382 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 8' ' ' GLY . . . . . 0.532 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -165.05 177.16 40.63 Favored Glycine 0 N--CA 1.496 2.641 0 C-N-CA 118.888 -1.625 . . . . 0.0 110.466 -174.184 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 9' ' ' THR . . . . . 0.508 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 3.0 p -116.3 167.82 10.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.105 -1.232 . . . . 0.0 110.953 -177.852 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 10' ' ' ALA . . . . . 1.044 ' HB2' HG21 ' B' ' 84' ' ' VAL . . . -137.72 148.58 45.77 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -176.099 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 11' ' ' LYS . . . . . 0.576 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 25.9 tttt -108.96 116.08 31.31 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.148 -0.97 . . . . 0.0 110.249 -179.209 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 12' ' ' LEU . . . . . 1.005 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.1 tp -58.97 127.29 31.46 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.124 -0.985 . . . . 0.0 108.976 174.257 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 13' ' ' VAL . . . . . 1.092 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -124.89 -31.67 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 C-N-CA 119.593 -0.843 . . . . 0.0 109.904 -179.638 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.35 143.98 28.41 Favored 'General case' 0 C--N 1.297 -1.675 0 C-N-CA 119.27 -0.972 . . . . 0.0 111.451 -178.019 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 15' ' ' ILE . . . . . 0.59 HG12 ' CD2' ' B' ' 24' ' ' HIS . 8.2 mt -108.02 130.18 60.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.264 -0.897 . . . . 0.0 110.232 172.246 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 16' ' ' ASP . . . . . 0.519 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 66.8 m-20 -105.94 114.31 28.38 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.369 -0.832 . . . . 0.0 109.724 172.994 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -106.57 108.82 20.52 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.912 -1.118 . . . . 0.0 110.938 -177.532 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 18' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -104.21 128.63 26.7 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.306 -0.871 . . . . 0.0 108.917 173.058 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 19' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.0 Cg_endo -50.44 -34.03 40.09 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 O-C-N 123.789 1.415 . . . . 0.0 110.42 -179.508 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 20' ' ' ASN . . . . . 0.54 ' C ' ' CD2' ' B' ' 21' ' ' PHE . 12.4 m-80 -71.41 -40.25 70.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.131 -0.981 . . . . 0.0 109.985 175.524 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 21' ' ' PHE . . . . . 0.54 ' CD2' ' C ' ' B' ' 20' ' ' ASN . 89.3 m-85 -152.65 150.28 29.31 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.417 -0.802 . . . . 0.0 110.004 -179.327 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 22' ' ' ARG . . . . . 0.746 ' HD3' HD22 ' B' ' 68' ' ' LEU . 62.6 ttt180 -93.16 144.83 24.9 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.872 -1.143 . . . . 0.0 110.197 176.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 23' ' ' THR . . . . . 0.519 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 58.2 m -130.27 141.69 50.59 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.596 -0.69 . . . . 0.0 110.043 -176.305 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 24' ' ' HIS . . . . . 0.605 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -127.81 144.89 51.07 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.066 -1.021 . . . . 0.0 111.233 176.827 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 25' ' ' VAL . . . . . 0.769 HG22 ' CB ' ' B' ' 60' ' ' SER . 4.3 t -124.61 133.68 68.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.292 -0.88 . . . . 0.0 110.717 -179.293 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 26' ' ' VAL . . . . . 0.592 HG13 ' HE2' ' B' ' 61' ' ' PHE . 33.5 m -118.79 172.09 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 CA-C-O 121.27 0.557 . . . . 0.0 110.412 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 27' ' ' GLU . . . . . 0.511 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 13.1 tt0 -101.1 117.6 35.34 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.603 -0.686 . . . . 0.0 109.235 -179.473 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 28' ' ' LEU . . . . . 0.62 HD23 ' HA ' ' B' ' 33' ' ' LEU . 9.4 tp -82.01 121.27 78.89 Favored Pre-proline 0 C--N 1.297 -1.681 0 O-C-N 121.639 -0.663 . . . . 0.0 109.86 -175.401 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 29' ' ' PRO . . . . . 0.48 ' HD2' HD12 ' B' ' 28' ' ' LEU . 25.7 Cg_endo -66.24 179.59 1.9 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 123.913 1.48 . . . . 0.0 110.955 -179.399 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 30' ' ' ASP . . . . . 0.5 ' HA ' HD12 ' B' ' 33' ' ' LEU . 96.0 m-20 -63.48 -40.03 96.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.304 -0.873 . . . . 0.0 111.06 -175.662 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 31' ' ' HIS . . . . . 0.439 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.33 0.95 57.03 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.858 -1.151 . . . . 0.0 111.067 -175.253 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 32' ' ' MET . . . . . 0.455 ' HB2' ' HD2' ' B' ' 29' ' ' PRO . 98.4 mmm -113.87 -13.93 12.54 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.945 -1.097 . . . . 0.0 109.799 172.305 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 33' ' ' LEU . . . . . 0.62 ' HA ' HD23 ' B' ' 28' ' ' LEU . 14.0 mt -66.15 -39.92 90.18 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.32 -0.862 . . . . 0.0 109.76 176.534 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -77.06 132.4 38.89 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.481 -0.762 . . . . 0.0 110.584 -177.487 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.37 -43.04 1.88 Allowed Glycine 0 N--CA 1.491 2.359 0 N-CA-C 110.306 -1.117 . . . . 0.0 110.306 174.512 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 36' ' ' LEU . . . . . 0.595 HD23 ' N ' ' B' ' 37' ' ' GLU . 5.7 tt -69.91 145.71 51.76 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.942 -1.328 . . . . 0.0 110.557 -174.949 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 37' ' ' GLU . . . . . 0.595 ' N ' HD23 ' B' ' 36' ' ' LEU . 20.6 pt-20 -150.03 167.6 26.28 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.47 -0.769 . . . . 0.0 109.381 -179.56 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 38' ' ' THR . . . . . 0.815 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -67.92 149.81 49.33 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.864 -1.148 . . . . 0.0 110.237 -178.125 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.35 -3.46 62.61 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -173.813 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 40' ' ' ALA . . . . . 0.536 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -76.74 160.04 29.66 Favored 'General case' 0 N--CA 1.486 1.375 0 O-C-N 121.218 -1.166 . . . . 0.0 109.129 174.742 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 41' ' ' SER . . . . . 0.926 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 1.2 p -103.97 117.72 34.98 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 120.82 -1.175 . . . . 0.0 109.981 177.221 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 42' ' ' VAL . . . . . 0.597 HG11 ' HE1' ' B' ' 44' ' ' HIS . 0.9 OUTLIER -100.03 120.18 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.355 -0.841 . . . . 0.0 108.965 176.934 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 43' ' ' ALA . . . . . 0.508 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -82.89 117.28 22.63 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.247 -0.981 . . . . 0.0 109.316 174.474 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 44' ' ' HIS . . . . . 0.651 ' CD2' HG21 ' B' ' 82' ' ' VAL . 1.4 m80 -87.27 103.19 15.21 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.624 -0.831 . . . . 0.0 108.818 176.232 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.5 t-20 56.07 11.97 0.85 Allowed 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.677 -0.639 . . . . 0.0 111.239 -169.622 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 46' ' ' GLY . . . . . 0.49 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 126.73 -5.74 7.47 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 119.679 -1.248 . . . . 0.0 110.845 173.213 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 47' ' ' CYS . . . . . 0.874 ' O ' HD23 ' B' ' 49' ' ' LEU . 44.9 t -93.49 103.63 15.81 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.477 -1.602 . . . . 0.0 109.618 175.922 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 14.8 p -72.14 122.07 20.37 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.117 -0.989 . . . . 0.0 110.617 -174.449 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 49' ' ' LEU . . . . . 0.874 HD23 ' O ' ' B' ' 47' ' ' CYS . 0.2 OUTLIER -132.21 160.53 35.86 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.461 -0.774 . . . . 0.0 109.283 173.568 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 50' ' ' THR . . . . . 0.444 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 37.5 m -97.53 152.59 18.86 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.42 -1.425 . . . . 0.0 111.464 -169.531 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 51' ' ' VAL . . . . . 0.907 HG13 HG13 ' B' ' 59' ' ' VAL . 20.0 t -81.18 114.76 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.795 -0.566 . . . . 0.0 110.389 -178.973 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 52' ' ' THR . . . . . 0.48 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 31.4 p -69.97 -40.03 75.63 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.152 -0.967 . . . . 0.0 109.739 174.575 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 53' ' ' GLU . . . . . 0.565 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.6 tt0 -161.49 155.63 22.38 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.416 -0.803 . . . . 0.0 109.804 179.634 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 54' ' ' ILE . . . . . 0.815 HD11 ' N ' ' B' ' 38' ' ' THR . 7.1 mt -105.11 128.94 58.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.113 -0.992 . . . . 0.0 109.592 174.698 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 55' ' ' ASN . . . . . 0.525 ' HB2' ' CB ' ' B' ' 58' ' ' HIS . 2.2 m-80 -100.57 62.61 1.05 Allowed 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 119.878 -0.729 . . . . 0.0 109.55 -178.988 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.19 -120.08 6.51 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 108.657 -1.777 . . . . 0.0 108.657 -172.716 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 57' ' ' ASN . . . . . 0.588 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -71.8 -20.17 61.89 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 120.97 -1.312 . . . . 0.0 109.109 175.031 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 58' ' ' HIS . . . . . 1.092 ' CD2' HG11 ' B' ' 13' ' ' VAL . 11.8 m170 -76.68 161.22 28.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.421 -0.799 . . . . 0.0 110.432 -176.851 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 59' ' ' VAL . . . . . 0.907 HG13 HG13 ' B' ' 51' ' ' VAL . 54.8 t -140.04 125.53 20.82 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 C-N-CA 119.042 -1.063 . . . . 0.0 110.723 170.794 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 60' ' ' SER . . . . . 0.769 ' CB ' HG22 ' B' ' 25' ' ' VAL . 24.4 m -97.54 123.42 41.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.75 -0.594 . . . . 0.0 109.513 -179.573 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 61' ' ' PHE . . . . . 0.837 ' HB2' HD12 ' B' ' 49' ' ' LEU . 10.0 p90 -118.65 159.65 23.23 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 120.822 -1.174 . . . . 0.0 110.533 -179.655 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 62' ' ' ASP . . . . . 0.48 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 35.2 p-10 -93.36 156.55 16.72 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.075 -1.016 . . . . 0.0 111.459 -171.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 63' ' ' LEU . . . . . 1.085 HD22 HD13 ' B' ' 68' ' ' LEU . 0.1 OUTLIER -161.11 102.12 1.26 Allowed 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 120.258 -0.577 . . . . 0.0 109.447 -174.235 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 64' ' ' MET . . . . . 0.498 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 57.6 ttm -60.07 137.64 58.05 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.707 -1.245 . . . . 0.0 109.068 179.266 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 65' ' ' LYS . . . . . 0.484 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 28.6 tttt -59.96 -45.93 91.06 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.91 -1.119 . . . . 0.0 110.63 -172.197 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 54.0 tp10 -66.21 -40.02 90.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.723 -1.236 . . . . 0.0 109.837 177.452 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 67' ' ' THR . . . . . 0.498 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 94.4 m -59.97 -40.03 87.69 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.036 -1.04 . . . . 0.0 109.512 172.657 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 68' ' ' LEU . . . . . 1.085 HD13 HD22 ' B' ' 63' ' ' LEU . 27.9 tp -60.05 -43.29 95.49 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.374 -0.829 . . . . 0.0 109.823 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 ttt85 -69.99 -39.26 76.02 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.318 -0.864 . . . . 0.0 110.364 177.751 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 70' ' ' ILE . . . . . 0.707 HG22 HG23 ' B' ' 71' ' ' THR . 1.4 tt -64.56 -42.62 95.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.278 -0.889 . . . . 0.0 109.583 -176.903 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 71' ' ' THR . . . . . 0.707 HG23 HG22 ' B' ' 70' ' ' ILE . 30.5 p -82.06 -174.94 5.37 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.955 -0.698 . . . . 0.0 109.317 175.4 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 72' ' ' ASN . . . . . 0.52 ' CB ' ' H ' ' A' ' 83' ' ' ASN . 5.2 t30 -99.38 22.17 11.03 Favored 'General case' 0 C--N 1.295 -1.77 0 O-C-N 121.141 -0.974 . . . . 0.0 108.534 171.074 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 73' ' ' LEU . . . . . 0.728 HD13 HD21 ' B' ' 63' ' ' LEU . 71.5 mt -70.03 -39.99 75.44 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.991 -1.068 . . . . 0.0 109.897 175.62 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 74' ' ' GLY . . . . . 0.435 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -49.38 -21.6 3.07 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 110.316 -1.113 . . . . 0.0 110.316 -177.954 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.2 p-10 -66.32 -16.31 63.94 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.127 -1.219 . . . . 0.0 110.525 -175.052 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 96.2 mt -62.26 142.36 57.76 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.291 -0.88 . . . . 0.0 111.189 -175.109 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 77' ' ' LYS . . . . . 1.005 ' C ' HD23 ' B' ' 12' ' ' LEU . 86.6 mttt -141.46 141.1 33.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.669 -0.645 . . . . 0.0 109.563 172.661 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 78' ' ' VAL . . . . . 0.714 ' N ' HD23 ' B' ' 12' ' ' LEU . 16.7 t -59.42 151.63 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 120.812 -1.18 . . . . 0.0 110.245 -176.134 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.83 -13.44 60.98 Favored Glycine 0 N--CA 1.484 1.882 0 N-CA-C 108.887 -1.685 . . . . 0.0 108.887 -176.8 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 80' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 53.7 t0 -96.5 162.16 13.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.397 -1.061 . . . . 0.0 109.666 177.029 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 81' ' ' TRP . . . . . 0.576 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.0 m95 -113.13 153.32 28.42 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.103 -0.998 . . . . 0.0 110.372 177.532 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 82' ' ' VAL . . . . . 0.99 HG13 ' HB3' ' B' ' 10' ' ' ALA . 0.8 OUTLIER -120.01 149.75 22.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.553 -0.717 . . . . 0.0 109.858 179.553 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 83' ' ' ASN . . . . . 1.039 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.2 OUTLIER -69.53 102.41 1.82 Allowed 'General case' 0 C--N 1.298 -1.633 0 O-C-N 120.975 -1.078 . . . . 0.0 109.091 167.783 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 1.044 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -104.45 138.17 30.31 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 O-C-N 120.422 -1.424 . . . . 0.0 110.862 -178.611 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' B' B ' 85' ' ' GLU . . . . . 0.438 ' HB2' HG22 ' B' ' 6' ' ' VAL . 85.9 tt0 -136.12 138.38 41.98 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 119.982 -0.687 . . . . 0.0 110.234 -176.277 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 76.5 ttt180 -61.26 127.53 31.98 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.153 -0.967 . . . . 0.0 109.941 -179.8 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 87' ' ' ALA . . . . . 0.926 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.197 -0.939 . . . . 0.0 109.99 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.475 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 32.7 mtt . . . . . 0 N--CA 1.494 1.743 0 CA-C-O 121.063 0.458 . . . . 0.0 110.135 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 1.066 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 8.2 p90 179.98 139.5 0.13 Allowed 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 -178.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.561 ' CB ' HG12 ' A' ' 5' ' ' ILE . 14.7 p -126.42 -35.32 2.39 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 120.927 -1.108 . . . . 0.0 109.678 -175.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.53 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 58.38 17.27 31.6 Favored Glycine 0 N--CA 1.485 1.95 0 N-CA-C 108.986 -1.646 . . . . 0.0 108.986 -179.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.574 HD11 ' C9 ' ' B' ' 99' ' ' RBF . 19.2 mm -88.94 134.43 28.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.382 -1.07 . . . . 0.0 109.693 -175.714 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.887 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.3 t -103.5 139.96 23.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 120.969 -1.082 . . . . 0.0 111.026 -168.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -59.98 -40.02 87.7 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.574 -0.704 . . . . 0.0 110.56 174.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.541 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -170.66 -176.95 40.37 Favored Glycine 0 N--CA 1.495 2.588 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.118 -174.634 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.48 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 21.4 p -117.58 169.83 9.24 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.872 -1.37 . . . . 0.0 111.13 -175.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.055 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -135.13 147.8 49.58 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.684 -0.635 . . . . 0.0 109.356 -179.033 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.576 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 34.0 tttt -103.57 115.74 31.07 Favored 'General case' 0 C--N 1.293 -1.856 0 O-C-N 121.046 -1.034 . . . . 0.0 110.269 -179.583 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 1.004 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.0 tp -59.87 126.45 27.62 Favored 'General case' 0 C--N 1.298 -1.653 0 O-C-N 120.892 -1.13 . . . . 0.0 108.823 172.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.094 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -126.91 -29.02 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.909 0 O-C-N 121.438 -0.789 . . . . 0.0 110.017 -179.094 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.04 141.91 26.88 Favored 'General case' 0 N--CA 1.495 1.801 0 C-N-CA 119.058 -1.057 . . . . 0.0 111.606 -178.748 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.65 HG23 ' NE2' ' A' ' 24' ' ' HIS . 14.2 mt -109.08 130.52 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.052 -1.03 . . . . 0.0 110.206 170.786 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.504 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 81.6 m-20 -107.71 115.46 30.19 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.291 -0.88 . . . . 0.0 109.963 174.121 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -104.21 114.4 28.61 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.969 -1.082 . . . . 0.0 110.591 -176.412 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.0 OUTLIER -113.67 128.97 25.14 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.141 -0.974 . . . . 0.0 109.203 175.343 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.1 Cg_endo -52.37 -18.37 7.84 Favored 'Trans proline' 0 C--N 1.304 -1.793 0 O-C-N 123.831 1.437 . . . . 0.0 110.944 -179.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.587 ' ND2' ' N ' ' A' ' 20' ' ' ASN . 0.3 OUTLIER -92.3 -33.54 14.58 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.135 -0.978 . . . . 0.0 108.939 178.309 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.545 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 84.1 m-85 -156.16 150.24 25.33 Favored 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.358 0.599 . . . . 0.0 110.14 179.792 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.556 ' HD3' HD22 ' A' ' 68' ' ' LEU . 60.1 ttt180 -90.89 144.24 25.89 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 120.744 -1.223 . . . . 0.0 109.775 175.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.504 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 85.0 m -129.17 137.69 51.31 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.472 -0.767 . . . . 0.0 109.822 -177.09 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.65 ' NE2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.25 137.04 49.81 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 120.967 -1.083 . . . . 0.0 111.141 179.394 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.832 HG22 ' OG ' ' A' ' 60' ' ' SER . 15.6 t -119.05 134.91 61.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.037 -1.039 . . . . 0.0 110.641 -177.279 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.482 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 16.9 m -117.13 170.93 6.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 CA-C-O 121.088 0.47 . . . . 0.0 110.112 177.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.567 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 8.7 tt0 -107.42 116.58 32.18 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 179.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.507 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.3 tp -81.36 128.59 69.59 Favored Pre-proline 0 C--N 1.295 -1.766 0 O-C-N 121.307 -0.87 . . . . 0.0 109.978 -171.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.483 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 33.6 Cg_endo -68.0 176.83 4.9 Favored 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.903 1.475 . . . . 0.0 110.88 -179.376 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.556 ' HA ' HD12 ' A' ' 33' ' ' LEU . 96.0 m-20 -60.02 -40.02 87.85 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.255 -0.903 . . . . 0.0 111.261 -174.251 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.589 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.85 0.83 56.81 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.75 -1.219 . . . . 0.0 110.936 -173.912 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.589 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.9 mmm -113.23 -9.63 13.44 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 120.839 -1.163 . . . . 0.0 110.074 170.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.726 HD21 ' HB2' ' A' ' 57' ' ' ASN . 19.9 mt -70.02 -23.18 63.08 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.169 -0.957 . . . . 0.0 110.052 176.263 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 94.5 m-20 -94.47 129.94 41.04 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.469 -0.769 . . . . 0.0 110.478 -177.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.98 -43.53 1.71 Allowed Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.909 -1.139 . . . . 0.0 110.396 174.126 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.906 HD23 ' N ' ' A' ' 37' ' ' GLU . 7.1 tt -69.94 149.16 48.07 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.836 -1.391 . . . . 0.0 110.855 -174.221 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.906 ' N ' HD23 ' A' ' 36' ' ' LEU . 19.3 pt-20 -150.42 170.02 20.06 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.512 -0.742 . . . . 0.0 109.682 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.874 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -65.82 153.51 41.7 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.024 -1.048 . . . . 0.0 110.235 179.779 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.41 -2.15 63.32 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 -178.405 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.449 ' O ' ' HA ' ' A' ' 50' ' ' THR . . . -78.3 158.07 28.98 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.254 -1.145 . . . . 0.0 109.552 176.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.645 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.4 OUTLIER -100.31 107.74 19.61 Favored 'General case' 0 N--CA 1.488 1.46 0 C-N-CA 119.026 -1.07 . . . . 0.0 109.876 175.653 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.666 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.1 t -93.65 133.23 35.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 121.321 -0.862 . . . . 0.0 108.896 173.305 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.508 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -97.98 120.0 37.59 Favored 'General case' 0 C--N 1.295 -1.763 0 C-N-CA 119.109 -1.036 . . . . 0.0 109.107 172.174 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.77 ' CD2' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -89.7 106.99 18.83 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 178.929 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 54.01 14.12 0.66 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.444 -0.785 . . . . 0.0 111.048 -168.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.51 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 117.87 2.83 16.37 Favored Glycine 0 N--CA 1.489 2.178 0 C-N-CA 119.527 -1.32 . . . . 0.0 110.798 172.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.762 ' O ' HD23 ' A' ' 49' ' ' LEU . 33.2 t -98.65 109.9 22.58 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.521 -1.576 . . . . 0.0 109.47 174.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.455 ' SG ' ' C7 ' ' A' ' 98' ' ' RBF . 31.0 p -76.8 130.26 37.41 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.978 -1.076 . . . . 0.0 111.182 -170.251 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.961 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -146.54 161.23 40.93 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.573 -0.704 . . . . 0.0 109.333 173.123 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.449 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 22.9 m -100.81 153.02 19.82 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 120.587 -1.321 . . . . 0.0 111.105 -171.199 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.83 HG13 HG13 ' A' ' 59' ' ' VAL . 24.6 t -76.68 113.77 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.839 -0.538 . . . . 0.0 110.186 -179.453 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.563 HG22 ' HB3' ' A' ' 62' ' ' ASP . 27.7 p -70.26 -41.55 73.3 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.24 -0.912 . . . . 0.0 109.518 174.146 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.57 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 20.4 pt-20 -160.12 160.09 32.59 Favored 'General case' 0 N--CA 1.49 1.529 0 C-N-CA 119.543 -0.863 . . . . 0.0 110.813 176.785 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.874 HD11 ' N ' ' A' ' 38' ' ' THR . 8.9 mt -110.58 130.05 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.268 -0.895 . . . . 0.0 109.962 173.653 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.494 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 3.2 m-80 -103.33 63.22 0.8 Allowed 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 120.071 -0.652 . . . . 0.0 109.509 179.25 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.36 -117.43 4.79 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 108.961 -1.655 . . . . 0.0 108.961 -173.612 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.726 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -77.14 -20.63 55.29 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 120.965 -1.314 . . . . 0.0 108.803 175.45 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.094 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.1 m170 -75.56 158.7 32.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.28 -0.888 . . . . 0.0 110.141 -177.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.83 HG13 HG13 ' A' ' 51' ' ' VAL . 55.1 t -140.41 123.82 17.26 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 C-N-CA 119.143 -1.023 . . . . 0.0 110.674 171.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.832 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.1 t -89.82 134.17 34.33 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.391 -0.818 . . . . 0.0 109.381 175.505 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.961 ' HB3' HD12 ' A' ' 49' ' ' LEU . 89.1 m-85 -115.67 159.87 20.79 Favored 'General case' 0 C--N 1.296 -1.723 0 O-C-N 121.224 -0.922 . . . . 0.0 110.277 175.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.563 ' HB3' HG22 ' A' ' 52' ' ' THR . 28.3 p-10 -93.02 149.09 21.46 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.187 -0.945 . . . . 0.0 111.129 178.542 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.726 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -154.18 117.69 4.61 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -175.127 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.542 ' HB2' ' CB ' ' A' ' 67' ' ' THR . 54.1 mtp -70.33 139.38 52.0 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.911 -1.118 . . . . 0.0 109.981 179.149 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.499 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 45.0 tptt -59.93 -49.91 75.82 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.163 -0.961 . . . . 0.0 110.274 -179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.466 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.5 tt0 -64.97 -39.99 94.31 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.753 -1.217 . . . . 0.0 109.859 177.245 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.542 ' CB ' ' HB2' ' A' ' 64' ' ' MET . 85.5 m -59.87 -35.67 75.3 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.934 -1.104 . . . . 0.0 109.397 173.066 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.705 HD13 HD22 ' A' ' 63' ' ' LEU . 20.0 tp -62.84 -46.71 86.63 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.186 -0.946 . . . . 0.0 109.756 -179.838 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 71.5 ttt-85 -69.98 -39.17 76.11 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.484 -0.76 . . . . 0.0 110.136 178.134 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.67 HG22 HG23 ' A' ' 71' ' ' THR . 1.1 tt -66.81 -40.02 84.95 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.366 -0.833 . . . . 0.0 109.337 -179.24 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.67 HG23 HG22 ' A' ' 70' ' ' ILE . 65.0 p -86.26 -173.65 4.66 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 174.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.4 t30 -104.18 25.04 10.53 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 170.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.726 ' HB3' HD21 ' A' ' 63' ' ' LEU . 87.9 mt -69.96 -40.0 75.69 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.027 -1.046 . . . . 0.0 110.008 177.298 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.531 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -47.7 -21.93 1.65 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 110.595 -1.002 . . . . 0.0 110.595 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.5 p-10 -67.11 -17.83 65.04 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.938 -1.33 . . . . 0.0 110.823 -174.221 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.0 mt -60.01 142.96 53.02 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.118 -0.989 . . . . 0.0 111.068 -175.603 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 1.004 ' C ' HD23 ' A' ' 12' ' ' LEU . 54.6 mttp -140.03 139.23 35.93 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.709 -0.619 . . . . 0.0 109.762 174.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.655 ' N ' HD23 ' A' ' 12' ' ' LEU . 15.8 t -61.02 153.08 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 120.862 -1.149 . . . . 0.0 110.351 -178.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.02 -15.03 58.99 Favored Glycine 0 N--CA 1.483 1.801 0 N-CA-C 108.716 -1.753 . . . . 0.0 108.716 -177.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.443 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 25.1 t0 -96.21 169.5 9.9 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.428 -1.042 . . . . 0.0 109.601 176.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.576 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.5 m95 -115.97 164.32 14.6 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.913 -1.117 . . . . 0.0 110.351 175.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.055 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.7 p -129.62 144.39 38.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.564 -0.71 . . . . 0.0 109.949 -176.518 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.887 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.6 m-20 -70.95 105.24 3.21 Favored 'General case' 0 C--N 1.293 -1.862 0 O-C-N 121.077 -1.014 . . . . 0.0 109.266 170.543 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.75 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -108.89 138.92 33.64 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 120.535 -1.353 . . . . 0.0 111.153 -176.063 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -137.15 147.02 45.68 Favored 'General case' 0 N--CA 1.495 1.82 0 C-N-CA 120.293 -0.563 . . . . 0.0 110.193 179.499 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 73.9 ttt-85 -85.22 130.65 34.56 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.232 -0.917 . . . . 0.0 111.309 -174.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.92 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -122.58 149.65 43.67 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.274 -0.891 . . . . 0.0 110.047 175.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -114.67 136.91 52.54 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.287 -0.883 . . . . 0.0 110.935 -178.222 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 23.6 mmtp -60.01 -40.06 87.93 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.375 -0.828 . . . . 0.0 110.15 -179.248 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 52.7 p90 -146.33 154.6 41.85 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.312 -0.868 . . . . 0.0 110.389 -179.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 52.7 m -139.97 149.99 43.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.324 -0.86 . . . . 0.0 110.386 179.501 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -62.38 -43.17 99.45 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.277 -0.89 . . . . 0.0 110.209 176.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.468 ' O ' ' HB ' ' A' ' 94' ' ' ILE . 12.9 pt-20 -158.87 55.77 0.43 Allowed 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.063 -1.023 . . . . 0.0 110.848 -179.14 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.731 HG22 ' O ' ' A' ' 94' ' ' ILE . 16.1 mm 53.1 22.85 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.264 0 C-N-CA 119.069 -1.052 . . . . 0.0 108.839 177.236 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -67.08 60.07 0.22 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -179.435 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' A' ' 94' ' ' ILE . . . -147.0 122.11 1.53 Allowed Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 179.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.448 ' OXT' ' ND1' ' A' ' 97' ' ' HIS . 31.7 p80 . . . . . 0 N--CA 1.492 1.644 0 O-C-N 121.247 -1.149 . . . . 0.0 110.168 179.027 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . 0.461 ' O ' ' HB3' ' B' ' 2' ' ' PHE . 96.8 mmm . . . . . 0 N--CA 1.491 1.625 0 CA-C-O 121.077 0.465 . . . . 0.0 110.088 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.92 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 8.2 p90 -179.9 139.57 0.13 Allowed 'General case' 0 C--N 1.306 -1.319 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 178.71 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.552 ' CB ' HG12 ' B' ' 5' ' ' ILE . 14.7 p -126.48 -35.4 2.37 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 120.94 -1.1 . . . . 0.0 109.67 -176.055 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.51 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 58.3 17.41 31.58 Favored Glycine 0 N--CA 1.485 1.943 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -179.242 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 0.552 HG12 ' CB ' ' B' ' 3' ' ' THR . 18.8 mm -88.88 134.32 28.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.335 -1.097 . . . . 0.0 109.68 -175.808 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.854 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.3 t -103.46 140.05 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 120.958 -1.089 . . . . 0.0 111.093 -169.008 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -59.95 -39.91 87.18 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.59 -0.693 . . . . 0.0 110.62 174.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.542 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -170.88 -177.2 40.65 Favored Glycine 0 N--CA 1.495 2.616 0 C-N-CA 119.201 -1.476 . . . . 0.0 110.222 -174.534 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.487 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 21.4 p -117.48 169.8 9.24 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.896 -1.355 . . . . 0.0 111.207 -175.611 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.066 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -135.04 147.96 49.77 Favored 'General case' 0 N--CA 1.495 1.791 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 -179.066 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.585 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 34.0 tttt -103.78 115.84 31.22 Favored 'General case' 0 C--N 1.296 -1.749 0 O-C-N 121.15 -0.969 . . . . 0.0 110.16 -179.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 1.018 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.0 tp -59.99 126.31 27.05 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 120.96 -1.088 . . . . 0.0 108.843 172.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.1 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -126.67 -29.15 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 C-N-CA 119.724 -0.79 . . . . 0.0 110.03 -179.087 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.02 141.83 26.82 Favored 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.25 -0.98 . . . . 0.0 111.568 -178.623 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.641 HG23 ' NE2' ' B' ' 24' ' ' HIS . 14.2 mt -108.96 130.64 61.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.046 -1.034 . . . . 0.0 110.232 170.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.516 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 81.0 m-20 -107.98 115.6 30.42 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.369 -0.832 . . . . 0.0 109.746 174.239 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -104.18 114.42 28.65 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.042 -1.037 . . . . 0.0 110.547 -176.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.459 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.0 OUTLIER -113.75 128.9 25.23 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.358 -0.839 . . . . 0.0 109.183 175.353 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 9.1 Cg_endo -52.37 -18.42 7.93 Favored 'Trans proline' 0 C--N 1.304 -1.809 0 O-C-N 123.858 1.451 . . . . 0.0 110.906 -179.326 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.564 ' ND2' ' N ' ' B' ' 20' ' ' ASN . 0.3 OUTLIER -92.22 -33.9 14.49 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.06 -1.025 . . . . 0.0 108.769 178.413 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.548 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 84.2 m-85 -155.89 150.25 25.76 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.196 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.551 ' HD3' HD22 ' B' ' 68' ' ' LEU . 60.0 ttt180 -90.87 144.14 26.0 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.909 -1.12 . . . . 0.0 109.797 175.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.516 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 82.7 m -129.14 137.74 51.37 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.539 -0.726 . . . . 0.0 109.826 -177.135 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.641 ' NE2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.18 136.94 49.8 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.029 -1.045 . . . . 0.0 111.054 179.573 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.831 HG22 ' OG ' ' B' ' 60' ' ' SER . 15.6 t -118.98 135.09 60.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.116 -0.99 . . . . 0.0 110.734 -177.404 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.491 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 17.2 m -117.42 170.91 6.35 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 C-N-CA 120.444 -0.502 . . . . 0.0 109.99 178.072 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.566 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 8.7 tt0 -107.36 116.53 32.1 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.594 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.497 ' HA ' HD12 ' B' ' 28' ' ' LEU . 9.3 tp -81.2 128.49 70.4 Favored Pre-proline 0 C--N 1.295 -1.781 0 O-C-N 121.228 -0.92 . . . . 0.0 110.05 -171.856 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.475 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 33.8 Cg_endo -67.99 176.82 4.9 Favored 'Trans proline' 0 C--N 1.308 -1.567 0 O-C-N 123.9 1.474 . . . . 0.0 110.87 -179.392 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.543 ' HA ' HD12 ' B' ' 33' ' ' LEU . 96.1 m-20 -60.02 -39.99 87.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.314 -0.866 . . . . 0.0 111.255 -174.211 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.596 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.82 0.84 56.78 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.733 -1.229 . . . . 0.0 110.974 -173.949 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.596 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.8 mmm -113.28 -9.57 13.41 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.824 -1.172 . . . . 0.0 110.143 170.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.707 HD21 ' HB2' ' B' ' 57' ' ' ASN . 20.0 mt -69.98 -23.33 63.14 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.232 -0.918 . . . . 0.0 109.994 176.189 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 94.3 m-20 -94.44 129.89 41.01 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.383 -0.823 . . . . 0.0 110.57 -177.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.96 -43.47 1.73 Allowed Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.885 -1.15 . . . . 0.0 110.48 174.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.917 HD23 ' N ' ' B' ' 37' ' ' GLU . 7.2 tt -70.09 149.15 47.92 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.926 -1.338 . . . . 0.0 110.81 -174.216 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . 0.917 ' N ' HD23 ' B' ' 36' ' ' LEU . 19.3 pt-20 -150.39 170.01 20.07 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.515 -0.741 . . . . 0.0 109.738 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.878 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -65.8 153.38 42.02 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.992 -1.068 . . . . 0.0 110.236 179.832 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 77.41 -2.06 63.62 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.658 -1.377 . . . . 0.0 109.658 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.453 ' O ' ' HA ' ' B' ' 50' ' ' THR . . . -78.42 157.89 28.87 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.259 -1.142 . . . . 0.0 109.558 176.713 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.639 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.4 OUTLIER -99.97 107.67 19.7 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.894 -1.128 . . . . 0.0 109.994 175.625 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.672 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.1 t -93.66 133.31 35.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.358 -0.839 . . . . 0.0 108.874 173.322 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.505 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -97.99 120.05 37.69 Favored 'General case' 0 C--N 1.296 -1.738 0 C-N-CA 119.162 -1.015 . . . . 0.0 109.055 172.184 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.76 ' CD2' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -89.75 106.78 18.69 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.427 -0.796 . . . . 0.0 108.994 178.876 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 54.13 14.21 0.7 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.396 -0.815 . . . . 0.0 111.043 -168.537 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.53 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 117.65 3.21 16.58 Favored Glycine 0 N--CA 1.488 2.142 0 C-N-CA 119.545 -1.312 . . . . 0.0 110.823 172.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.76 ' O ' HD23 ' B' ' 49' ' ' LEU . 33.5 t -98.82 110.02 22.69 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.521 -1.576 . . . . 0.0 109.397 174.702 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . 0.456 ' SG ' ' C7 ' ' B' ' 99' ' ' RBF . 31.2 p -76.82 130.35 37.51 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.032 -1.043 . . . . 0.0 111.184 -170.32 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 1.011 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -146.7 161.17 41.15 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.62 -0.675 . . . . 0.0 109.304 173.105 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . 0.453 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 22.9 m -100.69 153.13 19.69 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.722 -1.236 . . . . 0.0 111.06 -171.099 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.846 HG13 HG13 ' B' ' 59' ' ' VAL . 24.8 t -76.8 113.74 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.694 -0.629 . . . . 0.0 110.268 -179.55 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.574 HG22 ' HB3' ' B' ' 62' ' ' ASP . 28.0 p -70.25 -41.55 73.35 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.196 -0.94 . . . . 0.0 109.524 174.262 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.579 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 20.5 pt-20 -160.18 160.04 32.36 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.325 -0.859 . . . . 0.0 110.805 176.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.878 HD11 ' N ' ' B' ' 38' ' ' THR . 9.0 mt -110.52 130.02 64.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.307 -0.87 . . . . 0.0 109.945 173.773 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.511 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 3.2 m-80 -103.33 63.13 0.79 Allowed 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 120.018 -0.673 . . . . 0.0 109.524 179.274 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.55 -117.53 4.79 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 108.884 -1.686 . . . . 0.0 108.884 -173.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.707 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -77.04 -20.79 55.47 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.1 -1.235 . . . . 0.0 108.814 175.471 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.1 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.2 m170 -75.33 158.51 32.69 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.423 -0.798 . . . . 0.0 110.223 -178.099 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.846 HG13 HG13 ' B' ' 51' ' ' VAL . 54.9 t -140.33 123.7 17.32 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 C-N-CA 119.126 -1.029 . . . . 0.0 110.677 171.593 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.831 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.1 t -89.76 134.31 34.24 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.448 -0.783 . . . . 0.0 109.406 175.501 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 1.011 ' HB3' HD12 ' B' ' 49' ' ' LEU . 89.2 m-85 -115.74 159.89 20.81 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.213 175.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.574 ' HB3' HG22 ' B' ' 52' ' ' THR . 28.3 p-10 -92.96 149.15 21.43 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.163 -0.961 . . . . 0.0 111.059 178.539 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.702 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -154.28 117.77 4.59 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -175.23 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.551 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 54.3 mtp -70.4 139.42 51.87 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.989 -1.07 . . . . 0.0 110.042 179.107 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.495 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 45.1 tptt -59.92 -49.88 75.95 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.188 -0.945 . . . . 0.0 110.328 -179.567 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . 0.478 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 86.5 tt0 -64.88 -40.0 94.43 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.868 -1.145 . . . . 0.0 109.953 177.17 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.551 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 85.0 m -60.05 -35.79 75.9 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.942 -1.099 . . . . 0.0 109.328 173.172 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.691 HD13 HD22 ' B' ' 63' ' ' LEU . 19.8 tp -62.61 -46.64 87.36 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.226 -0.921 . . . . 0.0 109.85 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 71.5 ttt-85 -70.07 -39.24 75.74 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.474 -0.766 . . . . 0.0 110.075 178.156 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.648 HG22 HG23 ' B' ' 71' ' ' THR . 1.1 tt -66.78 -40.04 85.03 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.466 -0.771 . . . . 0.0 109.302 -179.228 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.648 HG23 HG22 ' B' ' 70' ' ' ILE . 65.9 p -86.21 -173.53 4.6 Favored 'General case' 0 C--N 1.299 -1.604 0 C-N-CA 120.035 -0.666 . . . . 0.0 109.324 174.265 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.489 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 4.4 t30 -104.32 25.21 10.41 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 170.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.702 ' HB3' HD21 ' B' ' 63' ' ' LEU . 87.6 mt -70.06 -39.97 75.36 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.02 -1.05 . . . . 0.0 109.985 177.223 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.515 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -47.92 -21.68 1.73 Allowed Glycine 0 N--CA 1.49 2.254 0 N-CA-C 110.594 -1.002 . . . . 0.0 110.594 -179.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.6 p-10 -67.18 -17.8 64.99 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 120.911 -1.347 . . . . 0.0 110.792 -174.279 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.507 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 97.0 mt -59.97 142.9 53.01 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.139 -0.976 . . . . 0.0 111.045 -175.596 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 1.018 ' C ' HD23 ' B' ' 12' ' ' LEU . 54.6 mttp -140.01 139.28 35.97 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.652 -0.655 . . . . 0.0 109.768 174.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.665 ' N ' HD23 ' B' ' 12' ' ' LEU . 15.9 t -61.13 153.06 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.964 -1.085 . . . . 0.0 110.322 -178.176 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.01 -14.82 59.54 Favored Glycine 0 N--CA 1.484 1.88 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.448 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 25.0 t0 -96.31 169.4 9.96 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.463 -1.022 . . . . 0.0 109.626 176.326 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.585 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.5 m95 -116.05 164.18 14.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.996 -1.065 . . . . 0.0 110.327 175.33 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.066 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.6 p -129.46 144.49 37.96 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.613 -0.679 . . . . 0.0 110.031 -176.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.854 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -70.91 105.08 3.14 Favored 'General case' 0 C--N 1.292 -1.892 0 O-C-N 121.164 -0.96 . . . . 0.0 109.301 170.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.719 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -108.84 138.93 33.52 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.901 0 O-C-N 120.614 -1.304 . . . . 0.0 111.099 -175.972 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 88.0 tt0 -137.15 147.05 45.7 Favored 'General case' 0 N--CA 1.495 1.778 0 C-N-CA 120.302 -0.559 . . . . 0.0 110.19 179.385 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 74.0 ttt-85 -85.16 130.7 34.56 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.175 -0.953 . . . . 0.0 111.278 -174.619 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 1.066 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -122.71 149.81 43.57 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.376 -0.827 . . . . 0.0 110.001 175.76 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -114.92 136.82 52.69 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.287 -0.883 . . . . 0.0 110.869 -177.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 23.7 mmtp -59.98 -40.03 87.74 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.404 -0.81 . . . . 0.0 110.174 -179.179 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 52.8 p90 -146.31 154.56 41.82 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.266 -0.896 . . . . 0.0 110.389 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . . . . . . . . . 53.1 m -140.02 149.97 43.84 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.43 -0.794 . . . . 0.0 110.402 179.415 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . 0.461 ' O ' ' HB2' ' B' ' 93' ' ' GLU . 96.0 m-20 -62.07 -39.98 94.27 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.214 -0.929 . . . . 0.0 110.02 176.538 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . 0.461 ' HB2' ' O ' ' B' ' 92' ' ' ASP . 98.9 mt-10 55.87 54.55 7.97 Favored 'General case' 0 N--CA 1.506 2.375 0 C-N-CA 120.102 -0.639 . . . . 0.0 110.549 176.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . . . . . . . . . 27.1 mm -60.03 -39.97 81.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.312 -0.868 . . . . 0.0 109.829 175.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 139.88 -69.36 0.47 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.522 -1.431 . . . . 0.0 109.522 179.039 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . 51.81 -141.91 22.66 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 179.461 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 70.5 t60 . . . . . 0 N--CA 1.492 1.643 0 O-C-N 121.247 -1.149 . . . . 0.0 110.203 -179.56 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 0.514 " O5'" HG21 ' A' ' 70' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 0.574 ' C9 ' HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.417 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 74.0 mtm . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.383 0.611 . . . . 0.0 110.61 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.881 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 5.0 p90 -176.32 139.98 0.37 Allowed 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 174.288 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.519 ' HB ' HG12 ' A' ' 5' ' ' ILE . 17.1 p -130.06 -39.56 1.37 Allowed 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.873 -1.142 . . . . 0.0 108.833 -178.143 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.521 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 55.09 20.1 18.94 Favored Glycine 0 N--CA 1.482 1.753 0 N-CA-C 108.602 -1.799 . . . . 0.0 108.602 -178.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.519 HG12 ' HB ' ' A' ' 3' ' ' THR . 36.7 mm -81.16 114.37 22.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.317 -1.108 . . . . 0.0 110.106 -175.399 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.749 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.3 t -79.43 131.61 33.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.252 -0.905 . . . . 0.0 110.061 -176.635 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.508 ' OE1' ' NH1' ' A' ' 86' ' ' ARG . 97.2 mt-30 -70.24 -30.03 66.98 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.492 -0.755 . . . . 0.0 111.405 -178.495 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.53 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -148.44 176.13 27.39 Favored Glycine 0 N--CA 1.495 2.579 0 C-N-CA 118.687 -1.721 . . . . 0.0 110.271 -173.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.462 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 2.9 p -123.28 171.3 9.49 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.153 -1.204 . . . . 0.0 110.574 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.018 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -141.11 150.07 42.37 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.46 -0.775 . . . . 0.0 109.401 -175.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 26.3 tttt -111.53 116.23 30.52 Favored 'General case' 0 C--N 1.297 -1.704 0 O-C-N 121.059 -1.025 . . . . 0.0 110.334 179.875 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.877 HD23 ' C ' ' A' ' 77' ' ' LYS . 9.9 tp -58.43 124.78 20.74 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.013 -1.054 . . . . 0.0 108.931 173.1 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.119 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.0 OUTLIER -118.24 -29.29 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 O-C-N 121.359 -0.838 . . . . 0.0 109.597 178.751 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.43 149.96 27.37 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.057 -1.057 . . . . 0.0 111.639 -178.381 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.756 HG23 ' CD2' ' A' ' 24' ' ' HIS . 19.5 mt -112.09 132.24 61.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.158 -0.964 . . . . 0.0 109.998 172.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.518 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 86.3 m-20 -108.65 116.12 31.38 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.305 -0.872 . . . . 0.0 109.861 174.786 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -106.13 108.73 20.4 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.064 -1.023 . . . . 0.0 110.534 -176.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -102.14 128.55 28.24 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.069 -1.019 . . . . 0.0 108.924 172.66 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_endo -50.47 -29.61 24.86 Favored 'Trans proline' 0 C--N 1.303 -1.865 0 O-C-N 123.834 1.439 . . . . 0.0 110.453 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.49 ' HB3' ' CE2' ' A' ' 21' ' ' PHE . 12.8 m-80 -77.87 -39.99 41.54 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.181 -0.949 . . . . 0.0 110.021 176.069 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.49 ' CE2' ' HB3' ' A' ' 20' ' ' ASN . 51.0 m-85 -151.18 150.23 30.38 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.342 -0.849 . . . . 0.0 109.925 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.484 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 60.0 ttt180 -90.42 145.24 25.09 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.714 -1.241 . . . . 0.0 110.012 176.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.518 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 91.5 m -129.64 138.19 51.08 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.429 -0.794 . . . . 0.0 109.941 -177.251 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.756 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -128.99 136.44 50.34 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 120.91 -1.119 . . . . 0.0 111.085 178.934 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.784 HG22 ' CB ' ' A' ' 60' ' ' SER . 8.2 t -120.08 132.63 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 120.922 -1.111 . . . . 0.0 110.77 -176.55 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.774 HG13 ' CE1' ' A' ' 61' ' ' PHE . 23.2 m -116.9 173.31 4.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 CA-C-O 121.27 0.557 . . . . 0.0 110.341 178.575 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.548 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 9.9 tt0 -106.2 117.91 35.25 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -179.464 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.715 HD21 HD13 ' A' ' 36' ' ' LEU . 9.2 tp -85.54 125.69 68.71 Favored Pre-proline 0 C--N 1.299 -1.624 0 O-C-N 121.403 -0.81 . . . . 0.0 110.3 -171.209 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.482 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 22.2 Cg_endo -66.17 176.37 3.97 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.878 1.462 . . . . 0.0 111.245 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.477 ' HA ' HD12 ' A' ' 33' ' ' LEU . 47.8 t0 -60.06 -39.9 87.6 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.336 -0.853 . . . . 0.0 111.183 -175.421 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.61 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.03 0.0 57.35 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.844 -1.16 . . . . 0.0 110.663 -174.937 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.61 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.8 mmm -112.26 -12.34 13.61 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.958 -1.089 . . . . 0.0 109.704 171.502 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.583 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 17.9 mt -69.25 -36.89 77.63 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.4 -0.813 . . . . 0.0 110.069 175.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -82.7 138.9 33.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.438 -0.789 . . . . 0.0 110.778 -177.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.44 -40.73 2.83 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 110.194 -1.163 . . . . 0.0 110.194 174.553 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.805 HD23 ' N ' ' A' ' 37' ' ' GLU . 8.3 tt -73.28 145.93 45.72 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.053 -1.263 . . . . 0.0 110.631 -176.171 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.805 ' N ' HD23 ' A' ' 36' ' ' LEU . 20.9 pt-20 -150.35 167.0 28.33 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.488 -0.757 . . . . 0.0 109.687 179.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.783 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -65.2 152.18 44.28 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.033 -1.042 . . . . 0.0 110.237 -178.123 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.63 -3.87 62.28 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -176.18 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.621 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -77.32 155.42 32.01 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.141 -1.211 . . . . 0.0 109.467 176.336 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.579 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -96.82 104.36 16.36 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 119.036 -1.066 . . . . 0.0 109.82 176.831 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.668 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.1 t -86.06 132.0 33.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 O-C-N 121.24 -0.913 . . . . 0.0 109.139 174.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 1.075 ' HB3' ' CG ' ' A' ' 85' ' ' GLU . . . -98.78 120.29 38.98 Favored 'General case' 0 C--N 1.296 -1.742 0 C-N-CA 119.408 -0.917 . . . . 0.0 109.262 173.479 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.885 ' CD2' HG21 ' A' ' 82' ' ' VAL . 1.5 m80 -93.08 104.08 16.32 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.593 -0.692 . . . . 0.0 109.268 179.503 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.514 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.3 t-20 55.64 11.29 0.62 Allowed 'General case' 0 C--N 1.298 -1.633 0 O-C-N 121.622 -0.674 . . . . 0.0 111.094 -169.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.521 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.61 1.95 10.73 Favored Glycine 0 N--CA 1.488 2.166 0 C-N-CA 119.796 -1.193 . . . . 0.0 110.818 174.209 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.673 ' O ' HD23 ' A' ' 49' ' ' LEU . 8.6 t -97.22 113.26 24.85 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 120.361 -1.67 . . . . 0.0 109.545 175.494 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.408 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 26.4 p -79.86 124.25 28.48 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.119 -0.988 . . . . 0.0 111.191 -170.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.864 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -141.36 163.21 33.55 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.385 -0.822 . . . . 0.0 109.661 172.861 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.433 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 57.5 m -102.96 152.08 21.72 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 120.689 -1.257 . . . . 0.0 111.019 -172.122 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.916 HG13 HG13 ' A' ' 59' ' ' VAL . 14.0 t -78.38 114.69 19.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.751 -0.593 . . . . 0.0 110.272 -178.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.523 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 46.1 p -71.29 -44.51 65.07 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.194 -0.941 . . . . 0.0 109.868 175.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.561 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -158.33 153.89 26.17 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.199 -0.938 . . . . 0.0 110.336 178.126 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.783 HD11 ' N ' ' A' ' 38' ' ' THR . 8.0 mt -105.37 130.37 56.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.161 -0.962 . . . . 0.0 109.818 175.991 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.519 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 12.4 m-80 -102.4 64.25 0.9 Allowed 'General case' 0 C--N 1.297 -1.715 0 O-C-N 121.565 -0.71 . . . . 0.0 109.612 179.828 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.54 -113.08 3.93 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -173.029 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.583 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.05 -21.31 43.59 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.066 -1.255 . . . . 0.0 109.293 175.568 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.119 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.8 m170 -74.88 159.53 31.76 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.352 -0.842 . . . . 0.0 110.102 -177.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.916 HG13 HG13 ' A' ' 51' ' ' VAL . 53.9 t -140.04 122.16 16.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 C-N-CA 119.023 -1.071 . . . . 0.0 110.916 172.162 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.784 ' CB ' HG22 ' A' ' 25' ' ' VAL . 60.2 p -91.06 129.09 37.09 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.724 -0.61 . . . . 0.0 109.689 177.772 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.864 ' HB2' HD12 ' A' ' 49' ' ' LEU . 1.3 p90 -123.14 156.89 34.12 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.964 -1.085 . . . . 0.0 110.61 -179.58 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.523 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 32.6 p-10 -91.33 152.06 20.61 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.184 -0.948 . . . . 0.0 111.329 -172.658 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.821 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -155.72 111.84 3.1 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 -175.771 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.526 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 84.2 mmm -65.71 139.86 58.41 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.877 -1.14 . . . . 0.0 109.232 179.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.459 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 58.0 tptt -60.0 -44.41 94.56 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.958 -1.089 . . . . 0.0 109.981 -176.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.441 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.0 tt0 -69.01 -40.0 78.97 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.122 -0.986 . . . . 0.0 110.385 178.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.526 ' HB ' ' HB2' ' A' ' 64' ' ' MET . 89.9 m -60.98 -39.99 91.76 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.937 -1.102 . . . . 0.0 109.085 173.25 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.773 HD11 ' HA2' ' A' ' 74' ' ' GLY . 5.1 tp -60.01 -46.24 90.15 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.494 -0.753 . . . . 0.0 109.66 178.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 32.5 tpt180 -67.4 -40.11 85.58 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.548 -0.72 . . . . 0.0 110.519 177.587 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.788 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -69.96 -41.56 79.46 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.247 -0.908 . . . . 0.0 109.491 -176.457 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.788 HG23 HG22 ' A' ' 70' ' ' ILE . 61.1 p -84.65 -173.22 4.6 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 178.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.484 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.6 t30 -101.76 23.08 11.84 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 170.834 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.821 ' HB3' HD21 ' A' ' 63' ' ' LEU . 94.1 mt -70.04 -42.31 73.07 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.036 -1.04 . . . . 0.0 109.992 176.114 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.773 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -52.28 -18.93 5.31 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -178.029 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 23.7 p-10 -64.67 -18.32 64.86 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.085 -1.244 . . . . 0.0 110.469 -176.193 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 88.6 mt -59.97 143.23 52.23 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.257 -0.902 . . . . 0.0 110.836 -176.246 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 0.877 ' C ' HD23 ' A' ' 12' ' ' LEU . 54.6 mttt -142.58 141.25 31.96 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.734 -0.604 . . . . 0.0 109.597 175.658 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.623 ' N ' HD23 ' A' ' 12' ' ' LEU . 16.9 t -60.75 151.25 6.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 120.784 -1.198 . . . . 0.0 110.601 -174.51 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.65 -10.97 65.42 Favored Glycine 0 N--CA 1.486 1.976 0 N-CA-C 109.03 -1.628 . . . . 0.0 109.03 -177.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 47.4 t0 -96.38 163.18 13.17 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.268 -1.137 . . . . 0.0 109.622 176.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.0 m95 -113.41 161.64 17.06 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.072 -1.018 . . . . 0.0 110.263 176.877 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.018 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.5 p -131.24 149.76 33.66 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 O-C-N 121.522 -0.736 . . . . 0.0 109.847 -176.324 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.749 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.6 m-20 -75.43 108.02 7.95 Favored 'General case' 0 C--N 1.294 -1.817 0 O-C-N 121.24 -0.912 . . . . 0.0 109.188 170.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.829 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.2 OUTLIER -111.71 145.11 18.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.52 -1.363 . . . . 0.0 111.501 -175.229 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 1.075 ' CG ' ' HB3' ' A' ' 43' ' ' ALA . 25.9 pt-20 -144.52 160.02 41.81 Favored 'General case' 0 N--CA 1.494 1.751 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.652 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.508 ' NH1' ' OE1' ' A' ' 7' ' ' GLN . 31.5 ptt-85 -98.27 132.91 43.36 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.024 -1.048 . . . . 0.0 110.979 -174.319 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.885 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -124.25 148.14 47.57 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.46 -0.775 . . . . 0.0 109.845 177.192 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -139.18 153.38 47.91 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.428 -0.795 . . . . 0.0 110.642 -177.355 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 17.2 mttp -60.06 -39.99 87.92 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.358 -0.839 . . . . 0.0 109.925 175.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.2 p90 -130.82 158.3 40.55 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.393 -0.817 . . . . 0.0 109.952 178.403 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 19.1 t -150.09 165.64 32.19 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.273 -0.892 . . . . 0.0 110.265 -179.307 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.526 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 96.0 m-20 -59.95 -40.07 87.73 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.228 -0.92 . . . . 0.0 110.14 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.526 ' CG ' ' O ' ' A' ' 92' ' ' ASP . 11.2 pt-20 38.59 51.32 1.69 Allowed 'General case' 0 N--CA 1.512 2.651 0 CA-C-O 121.64 0.733 . . . . 0.0 110.337 178.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 40.8 mm -68.25 -40.07 82.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.333 -0.855 . . . . 0.0 110.08 -179.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 45.96 65.6 1.97 Allowed Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.909 -1.276 . . . . 0.0 109.909 179.296 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -69.28 -157.31 1.39 Allowed Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 178.575 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 13.6 p-80 . . . . . 0 N--CA 1.492 1.633 0 O-C-N 121.187 -1.184 . . . . 0.0 110.242 -179.291 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . 0.443 ' O ' ' HB3' ' B' ' 2' ' ' PHE . 82.5 mtp . . . . . 0 N--CA 1.495 1.801 0 CA-C-O 121.294 0.568 . . . . 0.0 110.642 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.885 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 5.3 p90 -178.5 140.01 0.19 Allowed 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 174.186 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.544 ' HB ' HG12 ' B' ' 5' ' ' ILE . 17.0 p -129.98 -39.71 1.38 Allowed 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.854 -1.154 . . . . 0.0 108.776 -178.099 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.492 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 55.2 20.01 19.38 Favored Glycine 0 N--CA 1.483 1.791 0 N-CA-C 108.515 -1.834 . . . . 0.0 108.515 -178.703 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 0.544 HG12 ' HB ' ' B' ' 3' ' ' THR . 37.3 mm -81.15 114.38 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.351 -1.088 . . . . 0.0 109.969 -175.268 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.729 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.3 t -79.54 131.68 33.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.362 -0.836 . . . . 0.0 110.003 -176.655 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.514 ' OE1' ' NH1' ' B' ' 86' ' ' ARG . 97.2 mt-30 -70.2 -29.93 66.91 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.497 -0.752 . . . . 0.0 111.483 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.534 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -148.62 175.9 27.67 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 118.91 -1.614 . . . . 0.0 110.386 -173.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.472 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 2.9 p -123.25 171.17 9.57 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -1.164 . . . . 0.0 110.591 -179.77 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.057 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -140.94 150.16 42.78 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.515 -0.741 . . . . 0.0 109.39 -175.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.587 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 26.4 tttt -111.62 116.44 30.81 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.122 -0.986 . . . . 0.0 110.275 179.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 0.882 HD23 ' C ' ' B' ' 77' ' ' LYS . 10.0 tp -58.65 124.87 21.16 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.136 -0.978 . . . . 0.0 108.911 173.133 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.124 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.0 OUTLIER -118.3 -29.08 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 C-N-CA 119.549 -0.86 . . . . 0.0 109.674 178.744 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -154.58 149.99 27.25 Favored 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 119.115 -1.034 . . . . 0.0 111.539 -178.416 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.759 HG23 ' CD2' ' B' ' 24' ' ' HIS . 19.5 mt -112.1 132.16 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.307 -0.87 . . . . 0.0 110.098 172.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.53 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 86.1 m-20 -108.71 116.23 31.59 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.386 -0.821 . . . . 0.0 109.776 174.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -106.21 108.54 20.1 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.001 -1.062 . . . . 0.0 110.537 -176.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -102.01 128.48 28.51 Favored Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.167 -0.958 . . . . 0.0 109.022 172.647 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.2 Cg_endo -50.49 -29.63 25.05 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 O-C-N 123.841 1.443 . . . . 0.0 110.465 -179.463 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.485 ' HB3' ' CE2' ' B' ' 21' ' ' PHE . 12.6 m-80 -77.7 -40.32 41.73 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.236 -0.915 . . . . 0.0 110.016 176.037 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.485 ' CE2' ' HB3' ' B' ' 20' ' ' ASN . 51.4 m-85 -150.94 150.19 30.53 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.409 -0.807 . . . . 0.0 109.9 -179.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.474 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 60.0 ttt180 -90.43 145.12 25.17 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.74 -1.225 . . . . 0.0 110.063 176.841 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.53 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 92.0 m -129.49 138.36 51.34 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.569 -0.707 . . . . 0.0 109.843 -177.185 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.759 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -129.09 136.57 50.41 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.042 -1.037 . . . . 0.0 110.977 178.901 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.789 HG22 ' CB ' ' B' ' 60' ' ' SER . 8.5 t -120.04 132.78 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.119 -0.988 . . . . 0.0 110.711 -176.499 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.785 HG13 ' CE1' ' B' ' 61' ' ' PHE . 23.7 m -117.07 173.25 4.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.815 -0.553 . . . . 0.0 110.318 178.605 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.55 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 9.8 tt0 -105.98 117.89 35.19 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 -179.645 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.716 HD21 HD13 ' B' ' 36' ' ' LEU . 9.2 tp -85.58 125.67 68.68 Favored Pre-proline 0 C--N 1.298 -1.666 0 O-C-N 121.318 -0.864 . . . . 0.0 110.251 -171.226 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.485 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 22.1 Cg_endo -66.08 176.36 3.92 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 O-C-N 123.889 1.468 . . . . 0.0 111.196 -179.512 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.485 ' HA ' HD12 ' B' ' 33' ' ' LEU . 47.8 t0 -60.07 -39.98 87.93 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.338 -0.851 . . . . 0.0 111.135 -175.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.99 0.15 57.26 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.877 -1.139 . . . . 0.0 110.734 -174.928 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.597 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.7 mmm -112.33 -12.38 13.57 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.957 -1.09 . . . . 0.0 109.708 171.552 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.592 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 17.7 mt -69.28 -36.91 77.55 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.346 -0.847 . . . . 0.0 110.032 175.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 72.9 m-20 -82.71 138.96 33.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.438 -0.789 . . . . 0.0 110.8 -177.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.34 -40.61 2.86 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 174.621 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.801 HD23 ' N ' ' B' ' 37' ' ' GLU . 8.2 tt -73.37 145.95 45.53 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.997 -1.296 . . . . 0.0 110.556 -176.187 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . 0.801 ' N ' HD23 ' B' ' 36' ' ' LEU . 20.9 pt-20 -150.34 167.04 28.2 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.44 -0.787 . . . . 0.0 109.674 179.699 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.789 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -65.24 152.16 44.38 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.994 -1.066 . . . . 0.0 110.323 -178.156 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.62 -3.94 62.02 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -176.054 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.62 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -77.36 155.2 32.09 Favored 'General case' 0 N--CA 1.487 1.385 0 O-C-N 121.212 -1.17 . . . . 0.0 109.521 176.262 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.576 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -96.54 104.25 16.22 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.893 -1.13 . . . . 0.0 109.873 176.858 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.697 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.1 t -86.07 131.97 33.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.224 -0.923 . . . . 0.0 109.178 174.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 1.068 ' HB3' ' CG ' ' B' ' 85' ' ' GLU . . . -98.67 120.33 38.92 Favored 'General case' 0 C--N 1.297 -1.686 0 O-C-N 121.227 -0.921 . . . . 0.0 109.288 173.473 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.882 ' CD2' HG21 ' B' ' 82' ' ' VAL . 1.4 m80 -93.1 103.75 16.01 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.502 -0.749 . . . . 0.0 109.365 179.482 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.514 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.3 t-20 55.9 11.48 0.71 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.557 -0.714 . . . . 0.0 110.972 -169.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.521 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 121.41 2.24 10.84 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 119.755 -1.212 . . . . 0.0 110.8 174.048 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.685 ' O ' HD23 ' B' ' 49' ' ' LEU . 8.7 t -97.47 113.32 24.99 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 120.327 -1.69 . . . . 0.0 109.543 175.384 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . 0.41 ' O ' ' SG ' ' B' ' 48' ' ' CYS . 26.4 p -79.8 124.3 28.49 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.044 -1.035 . . . . 0.0 111.145 -170.723 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 0.897 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -141.51 163.34 33.2 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.538 -0.726 . . . . 0.0 109.618 172.77 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . 0.44 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 57.4 m -102.92 152.18 21.59 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 120.78 -1.2 . . . . 0.0 110.991 -172.032 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.941 HG13 HG13 ' B' ' 59' ' ' VAL . 14.1 t -78.54 114.72 19.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.749 -0.594 . . . . 0.0 110.323 -178.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 47.0 p -71.32 -44.56 64.9 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.09 -1.006 . . . . 0.0 109.821 175.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.557 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -158.25 153.92 26.38 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.241 -0.912 . . . . 0.0 110.272 178.176 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.789 HD11 ' N ' ' B' ' 38' ' ' THR . 7.9 mt -105.34 130.32 56.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.117 -0.989 . . . . 0.0 109.825 176.028 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.531 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 12.3 m-80 -102.54 64.32 0.89 Allowed 'General case' 0 C--N 1.297 -1.675 0 C-N-CA 119.865 -0.734 . . . . 0.0 109.608 179.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.68 -113.0 3.88 Favored Glycine 0 N--CA 1.487 2.062 0 N-CA-C 108.659 -1.776 . . . . 0.0 108.659 -173.139 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.592 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.1 -21.53 43.19 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.045 -1.268 . . . . 0.0 109.225 175.609 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.124 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.9 m170 -74.72 159.46 31.99 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.317 -0.864 . . . . 0.0 110.155 -177.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.941 HG13 HG13 ' B' ' 51' ' ' VAL . 54.5 t -140.06 122.19 16.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 C-N-CA 118.903 -1.119 . . . . 0.0 110.867 172.303 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.789 ' CB ' HG22 ' B' ' 25' ' ' VAL . 60.1 p -91.16 129.23 37.18 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.734 -0.604 . . . . 0.0 109.682 177.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.897 ' HB2' HD12 ' B' ' 49' ' ' LEU . 1.3 p90 -123.2 156.94 34.12 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.072 -1.018 . . . . 0.0 110.555 -179.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 32.7 p-10 -91.28 152.22 20.58 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.097 -1.002 . . . . 0.0 111.224 -172.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.814 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -155.81 111.91 3.09 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -175.88 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.509 ' HB2' ' HB ' ' B' ' 67' ' ' THR . 84.1 mmm -65.8 139.82 58.35 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.871 -1.143 . . . . 0.0 109.186 179.881 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.457 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 57.9 tptt -60.03 -44.27 94.73 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.11 -0.994 . . . . 0.0 109.987 -176.685 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . 0.445 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 85.9 tt0 -69.15 -39.96 78.48 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.171 -0.955 . . . . 0.0 110.302 178.626 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.509 ' HB ' ' HB2' ' B' ' 64' ' ' MET . 90.5 m -61.05 -40.07 92.22 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.899 -1.126 . . . . 0.0 109.019 173.288 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.798 HD11 ' HA2' ' B' ' 74' ' ' GLY . 5.1 tp -59.94 -46.08 90.55 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.512 -0.742 . . . . 0.0 109.747 178.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 32.5 tpt180 -67.6 -39.98 84.75 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.612 -0.68 . . . . 0.0 110.506 177.585 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.775 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -70.0 -41.47 79.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 O-C-N 121.328 -0.858 . . . . 0.0 109.593 -176.544 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.775 HG23 HG22 ' B' ' 70' ' ' ILE . 60.2 p -84.65 -173.16 4.57 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 120.177 -0.609 . . . . 0.0 109.517 178.563 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.48 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 4.5 t30 -101.65 22.98 11.9 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.291 -1.003 . . . . 0.0 108.291 170.837 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.814 ' HB3' HD21 ' B' ' 63' ' ' LEU . 94.2 mt -69.96 -42.31 73.36 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.022 -1.049 . . . . 0.0 110.02 176.096 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.798 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -52.34 -18.82 5.31 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 -178.025 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 23.7 p-10 -64.78 -18.29 64.95 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.054 -1.262 . . . . 0.0 110.436 -176.217 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.516 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 88.7 mt -59.99 143.24 52.27 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.23 -0.919 . . . . 0.0 110.844 -176.297 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 0.882 ' C ' HD23 ' B' ' 12' ' ' LEU . 54.6 mttt -142.61 141.22 31.91 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.652 -0.655 . . . . 0.0 109.62 175.723 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.619 ' N ' HD23 ' B' ' 12' ' ' LEU . 17.2 t -60.85 151.15 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 120.844 -1.16 . . . . 0.0 110.555 -174.408 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.68 -10.82 66.03 Favored Glycine 0 N--CA 1.487 2.07 0 N-CA-C 109.02 -1.632 . . . . 0.0 109.02 -177.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 47.0 t0 -96.45 163.11 13.19 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.348 -1.089 . . . . 0.0 109.695 176.761 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.587 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.0 m95 -113.38 161.58 17.1 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.056 -1.028 . . . . 0.0 110.284 176.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.057 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.5 p -131.27 149.92 33.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.575 -0.703 . . . . 0.0 109.801 -176.479 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.729 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -75.34 107.79 7.69 Favored 'General case' 0 C--N 1.294 -1.806 0 O-C-N 121.205 -0.934 . . . . 0.0 109.282 170.633 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.826 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.2 OUTLIER -111.65 145.2 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 120.522 -1.361 . . . . 0.0 111.501 -175.121 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . 1.068 ' CG ' ' HB3' ' B' ' 43' ' ' ALA . 25.9 pt-20 -144.6 159.98 41.91 Favored 'General case' 0 N--CA 1.494 1.773 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.691 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . 0.514 ' NH1' ' OE1' ' B' ' 7' ' ' GLN . 31.5 ptt-85 -98.1 132.88 43.25 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.869 -1.145 . . . . 0.0 110.963 -174.28 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 0.881 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -124.24 148.14 47.56 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.401 -0.812 . . . . 0.0 109.79 177.134 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -139.32 153.29 47.71 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.457 -0.777 . . . . 0.0 110.58 -177.309 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 17.1 mttp -60.02 -40.01 87.82 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.427 -0.796 . . . . 0.0 109.977 175.455 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 53.1 p90 -130.82 158.34 40.44 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.322 -0.861 . . . . 0.0 109.942 178.425 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . 0.401 ' HB3' ' HG2' ' B' ' 93' ' ' GLU . 19.3 t -150.08 165.8 31.7 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.266 -0.896 . . . . 0.0 110.259 -179.353 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -60.05 -39.6 86.52 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.248 -0.908 . . . . 0.0 110.078 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . 0.401 ' HG2' ' HB3' ' B' ' 91' ' ' SER . 74.8 mm-40 48.06 54.33 10.3 Favored 'General case' 0 N--CA 1.506 2.335 0 O-C-N 121.249 -0.907 . . . . 0.0 110.045 177.431 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . . . . . . . . . 26.7 mm -60.24 -39.89 82.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.419 -0.801 . . . . 0.0 110.009 178.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 54.55 73.53 0.41 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.331 -1.507 . . . . 0.0 109.331 -179.043 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . 0.406 ' O ' ' C ' ' B' ' 97' ' ' HIS . . . 129.75 50.02 0.12 Allowed Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 -177.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . 0.406 ' C ' ' O ' ' B' ' 96' ' ' GLY . 74.9 t60 . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.293 -1.122 . . . . 0.0 110.204 -178.601 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 0.559 " C2'" ' HC9' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 0.554 " C2'" ' HC9' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.483 ' HA ' ' O ' ' B' ' 89' ' ' LYS . 72.2 mtm . . . . . 0 N--CA 1.495 1.788 0 CA-C-O 121.357 0.598 . . . . 0.0 110.34 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.755 ' HE2' ' HB1' ' B' ' 87' ' ' ALA . 0.7 OUTLIER -173.22 137.84 0.7 Allowed 'General case' 0 C--N 1.306 -1.322 0 O-C-N 121.318 -0.864 . . . . 0.0 109.008 177.698 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.515 ' O ' HG13 ' A' ' 5' ' ' ILE . 25.8 p -133.72 -31.78 1.16 Allowed 'General case' 0 C--N 1.297 -1.676 0 O-C-N 120.989 -1.069 . . . . 0.0 110.135 -173.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 3' ' ' THR . . . 45.79 25.1 1.44 Allowed Glycine 0 N--CA 1.488 2.119 0 N-CA-C 109.056 -1.618 . . . . 0.0 109.056 -174.687 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.872 HD11 ' C8M' ' B' ' 99' ' ' RBF . 57.7 mt -84.01 139.98 16.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.046 -1.267 . . . . 0.0 110.556 -177.287 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.976 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.4 t -94.39 138.62 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.423 -0.798 . . . . 0.0 110.418 -176.195 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -69.94 -33.65 72.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.51 -0.744 . . . . 0.0 111.051 178.703 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.515 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -155.66 172.85 33.77 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.871 -1.633 . . . . 0.0 109.909 -173.675 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.483 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 0.6 OUTLIER -115.2 168.8 9.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.143 -1.21 . . . . 0.0 110.48 -179.496 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.016 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -135.59 147.82 48.83 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.547 -0.721 . . . . 0.0 109.472 -179.142 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.577 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 29.1 tttt -105.98 115.86 30.96 Favored 'General case' 0 C--N 1.294 -1.829 0 O-C-N 121.121 -0.987 . . . . 0.0 110.247 178.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 1.029 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.1 tp -59.71 128.09 35.24 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 120.89 -1.131 . . . . 0.0 108.653 172.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.114 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -128.2 -31.52 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 C-N-CA 119.553 -0.859 . . . . 0.0 110.085 -177.719 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.91 144.71 30.35 Favored 'General case' 0 N--CA 1.495 1.786 0 C-N-CA 118.859 -1.136 . . . . 0.0 111.293 179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.766 HG23 ' CD2' ' A' ' 24' ' ' HIS . 12.5 mt -109.44 132.99 56.08 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.245 -0.91 . . . . 0.0 110.351 173.177 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.499 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 79.8 m-20 -110.15 116.22 31.14 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.307 -0.871 . . . . 0.0 109.98 173.125 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -106.54 114.45 28.57 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.007 -1.058 . . . . 0.0 110.567 -178.216 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.456 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.7 mtmt -110.74 132.94 21.35 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.248 -0.907 . . . . 0.0 109.138 175.492 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -50.07 -34.54 38.83 Favored 'Trans proline' 0 C--N 1.301 -1.93 0 O-C-N 123.857 1.451 . . . . 0.0 110.692 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.465 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 12.3 m-80 -74.6 -39.71 62.02 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.149 -0.97 . . . . 0.0 110.076 177.304 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.465 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 96.1 m-85 -154.35 150.16 27.65 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.345 -0.847 . . . . 0.0 110.128 -178.471 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.492 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 59.5 ttt180 -91.71 146.29 23.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.751 -1.218 . . . . 0.0 110.121 176.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.499 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 90.4 m -130.0 140.04 50.95 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.408 -0.807 . . . . 0.0 109.927 -175.608 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.766 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -129.15 136.43 50.18 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.9 -1.125 . . . . 0.0 111.148 177.565 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.725 HG22 ' OG ' ' A' ' 60' ' ' SER . 5.8 t -115.78 132.46 65.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.075 -1.016 . . . . 0.0 110.7 -177.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.488 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 12.5 m -116.1 170.19 6.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 CA-C-O 121.111 0.482 . . . . 0.0 110.124 179.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.468 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 2.7 tm-20 -101.55 117.8 35.65 Favored 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.322 -0.861 . . . . 0.0 109.23 179.068 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.597 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.3 tp -82.71 127.27 70.81 Favored Pre-proline 0 C--N 1.298 -1.661 0 O-C-N 121.485 -0.759 . . . . 0.0 110.003 -174.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.462 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 25.3 Cg_endo -66.5 -178.5 1.21 Allowed 'Trans proline' 0 C--N 1.308 -1.561 0 O-C-N 123.88 1.463 . . . . 0.0 111.008 -179.657 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.502 ' OD1' ' N ' ' A' ' 30' ' ' ASP . 22.6 p-10 -65.66 -39.98 91.96 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.413 -0.804 . . . . 0.0 111.016 -177.18 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.604 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.0 0.36 57.15 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.905 -1.122 . . . . 0.0 110.924 -174.557 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.604 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.8 mmm -110.14 -16.02 13.88 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.949 -1.094 . . . . 0.0 109.692 171.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.597 ' HA ' HD23 ' A' ' 28' ' ' LEU . 13.4 mt -66.13 -32.04 73.25 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.515 -0.74 . . . . 0.0 110.41 178.163 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . 0.419 ' OD1' ' N ' ' A' ' 35' ' ' GLY . 63.7 t0 -80.26 142.93 34.11 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.222 -0.924 . . . . 0.0 110.864 -176.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.419 ' N ' ' OD1' ' A' ' 34' ' ' ASP . . . 85.94 -31.77 3.92 Favored Glycine 0 N--CA 1.493 2.443 0 C-N-CA 119.99 -1.1 . . . . 0.0 111.096 170.702 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.552 HD23 ' CD2' ' A' ' 28' ' ' LEU . 57.7 tp -77.45 155.09 31.98 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.708 -1.466 . . . . 0.0 111.111 -173.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.454 ' C ' HD11 ' A' ' 54' ' ' ILE . 20.0 pt-20 -153.57 167.84 28.18 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.531 -0.731 . . . . 0.0 109.644 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.842 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -67.8 154.5 41.39 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.876 -1.14 . . . . 0.0 110.111 178.142 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.59 0.3 58.2 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 -174.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.671 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -79.99 160.22 25.98 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.173 -1.193 . . . . 0.0 109.041 174.407 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.888 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 1.6 p -103.33 118.87 37.74 Favored 'General case' 0 N--CA 1.487 1.386 0 C-N-CA 118.294 -1.362 . . . . 0.0 109.692 175.081 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.622 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.6 t -101.67 125.87 55.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 175.188 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -87.89 118.58 27.52 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 119.269 -0.972 . . . . 0.0 109.154 174.509 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.877 ' CD2' HG21 ' A' ' 82' ' ' VAL . 0.7 OUTLIER -91.43 106.08 18.24 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 176.378 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.489 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.6 t-20 55.44 13.41 0.92 Allowed 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.452 -0.78 . . . . 0.0 111.257 -168.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.493 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.56 -6.25 10.63 Favored Glycine 0 N--CA 1.49 2.243 0 C-N-CA 119.459 -1.353 . . . . 0.0 110.999 171.25 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.816 ' O ' HD23 ' A' ' 49' ' ' LEU . 32.6 t -89.7 107.58 19.18 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.51 -1.583 . . . . 0.0 109.457 175.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.44 ' SG ' ' O ' ' B' ' 3' ' ' THR . 26.7 p -74.07 123.44 24.39 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.122 -0.986 . . . . 0.0 110.531 -174.13 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.829 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -138.96 156.53 47.17 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.405 -0.809 . . . . 0.0 109.411 175.196 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.442 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 26.8 m -94.76 156.42 16.39 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 120.489 -1.382 . . . . 0.0 111.315 -169.184 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.783 HG13 HG13 ' A' ' 59' ' ' VAL . 16.8 t -82.24 116.06 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.859 -0.525 . . . . 0.0 110.332 -178.055 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.575 HG22 ' HB3' ' A' ' 62' ' ' ASP . 59.8 p -69.85 -40.03 76.04 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.177 -0.952 . . . . 0.0 109.453 172.561 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.584 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 51.8 tp10 -162.55 156.29 20.69 Favored 'General case' 0 N--CA 1.491 1.594 0 C-N-CA 119.221 -0.992 . . . . 0.0 110.839 -177.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.842 HD11 ' N ' ' A' ' 38' ' ' THR . 7.5 mt -109.98 130.03 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.087 -1.008 . . . . 0.0 109.545 170.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.515 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 46.5 m-80 -104.2 62.94 0.74 Allowed 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.603 -0.686 . . . . 0.0 109.493 178.632 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.49 -114.77 4.1 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 108.809 -1.717 . . . . 0.0 108.809 -172.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.591 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.08 -19.72 46.81 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.042 -1.27 . . . . 0.0 109.038 175.967 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.114 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.7 m170 -76.91 159.14 30.24 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.279 -0.888 . . . . 0.0 110.233 -177.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.783 HG13 HG13 ' A' ' 51' ' ' VAL . 54.0 t -140.42 120.34 12.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.027 -1.046 . . . . 0.0 110.948 173.403 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.725 ' OG ' HG22 ' A' ' 25' ' ' VAL . 21.3 m -86.02 128.72 34.92 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.57 -0.706 . . . . 0.0 109.729 177.257 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.829 ' HB3' HD12 ' A' ' 49' ' ' LEU . 60.2 m-85 -111.37 160.02 17.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.907 -1.12 . . . . 0.0 110.341 178.808 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.575 ' HB3' HG22 ' A' ' 52' ' ' THR . 31.8 p-10 -93.36 146.89 23.4 Favored 'General case' 0 N--CA 1.497 1.917 0 CA-C-O 122.099 0.952 . . . . 0.0 111.436 179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.761 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -157.39 113.37 2.88 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.459 -176.967 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.505 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 57.0 ttm -69.27 142.39 54.15 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.847 -1.158 . . . . 0.0 109.572 179.116 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 47.6 tptt -60.05 -46.13 90.57 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.013 -1.054 . . . . 0.0 110.284 -175.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 87.8 tt0 -69.73 -40.09 76.43 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.92 -1.113 . . . . 0.0 110.201 179.358 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.505 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 86.5 m -60.29 -38.34 83.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.931 -1.106 . . . . 0.0 109.228 172.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.715 ' CD1' HD22 ' A' ' 63' ' ' LEU . 11.0 tp -60.05 -44.0 94.99 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.368 -0.832 . . . . 0.0 109.375 -179.618 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -68.11 -39.82 82.69 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.346 -0.846 . . . . 0.0 110.695 174.336 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.755 HG22 HG23 ' A' ' 71' ' ' THR . 1.4 tt -66.3 -41.64 89.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.275 -0.891 . . . . 0.0 109.626 -175.063 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.755 HG23 HG22 ' A' ' 70' ' ' ILE . 50.7 p -83.53 -168.58 2.17 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.709 -0.62 . . . . 0.0 109.606 177.679 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.496 ' CB ' ' H ' ' B' ' 83' ' ' ASN . 7.1 t30 -104.92 19.6 20.28 Favored 'General case' 0 C--N 1.293 -1.87 0 O-C-N 121.245 -0.909 . . . . 0.0 108.559 168.054 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.761 ' HB3' HD21 ' A' ' 63' ' ' LEU . 81.8 mt -69.98 -40.06 75.55 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.092 -1.005 . . . . 0.0 109.997 175.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.625 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -47.14 -22.68 1.43 Allowed Glycine 0 N--CA 1.487 2.052 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 178.208 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 22.2 p-10 -62.62 -16.25 55.69 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.959 -1.318 . . . . 0.0 110.391 -175.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.518 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 84.4 mt -63.07 146.21 53.75 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.252 -0.905 . . . . 0.0 111.037 -175.129 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 1.029 ' C ' HD23 ' A' ' 12' ' ' LEU . 96.6 mttt -149.21 138.17 21.29 Favored 'General case' 0 N--CA 1.493 1.698 0 CA-C-O 121.461 0.648 . . . . 0.0 109.684 174.182 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.72 HG23 HD11 ' A' ' 15' ' ' ILE . 17.5 t -61.52 151.86 6.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.843 -1.161 . . . . 0.0 110.51 -175.112 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.03 -14.51 60.38 Favored Glycine 0 N--CA 1.484 1.835 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 -175.279 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.428 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 25.7 t0 -97.82 168.4 10.34 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.267 -1.137 . . . . 0.0 109.625 176.22 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.577 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.2 m95 -116.64 169.12 9.59 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.079 -1.013 . . . . 0.0 110.045 177.112 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.016 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.5 p -136.34 147.98 27.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.329 -0.857 . . . . 0.0 109.965 -177.148 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.976 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.9 m-20 -73.11 104.36 4.16 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.078 -1.014 . . . . 0.0 109.197 170.06 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.832 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -107.96 140.26 27.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 120.786 -1.197 . . . . 0.0 111.183 -176.841 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.421 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.5 tt0 -142.19 140.83 32.49 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.783 -0.573 . . . . 0.0 110.235 -176.733 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 95.2 mtt180 -60.19 131.62 51.39 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.045 -1.035 . . . . 0.0 109.777 178.648 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.888 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . -126.02 148.87 49.19 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.238 -0.914 . . . . 0.0 109.984 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.55 ' O ' ' CD1' ' B' ' 2' ' ' PHE . . . -147.13 156.36 42.93 Favored 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 120.005 -0.678 . . . . 0.0 110.883 -177.025 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.509 ' HA ' ' CD1' ' B' ' 2' ' ' PHE . 35.1 mttt -60.01 -40.0 87.73 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.559 -0.713 . . . . 0.0 110.139 175.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 50.2 p90 -129.8 160.96 31.88 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.326 -0.859 . . . . 0.0 110.138 -177.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 77.3 p -59.72 139.15 57.48 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.24 -0.912 . . . . 0.0 110.718 -174.216 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.528 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 95.6 m-20 -106.31 -6.9 18.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.466 -0.772 . . . . 0.0 110.088 176.143 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.528 ' CG ' ' O ' ' A' ' 92' ' ' ASP . 17.0 pt-20 38.92 52.85 1.99 Allowed 'General case' 0 N--CA 1.509 2.498 0 O-C-N 121.603 -0.685 . . . . 0.0 110.893 176.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 42.2 mm -59.98 -48.91 85.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.007 -1.058 . . . . 0.0 109.74 172.375 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 91.96 -48.96 2.75 Favored Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 177.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 154.65 -176.08 32.54 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.569 0 O-C-N 121.302 -1.117 . . . . 0.0 110.223 179.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 28.3 ptm . . . . . 0 N--CA 1.491 1.618 0 CA-C-O 121.178 0.513 . . . . 0.0 110.218 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.749 ' HE2' ' HB1' ' A' ' 87' ' ' ALA . 0.8 OUTLIER -166.07 137.78 3.79 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.187 -0.946 . . . . 0.0 109.145 175.935 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.519 ' O ' HG13 ' B' ' 5' ' ' ILE . 25.8 p -133.53 -31.95 1.18 Allowed 'General case' 0 C--N 1.296 -1.739 0 O-C-N 121.039 -1.038 . . . . 0.0 110.194 -174.111 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' B' ' 3' ' ' THR . . . 45.97 24.97 1.52 Allowed Glycine 0 N--CA 1.488 2.13 0 N-CA-C 109.038 -1.625 . . . . 0.0 109.038 -174.664 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 0.843 HD11 ' C8M' ' A' ' 98' ' ' RBF . 57.5 mt -83.93 140.0 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.11 -1.23 . . . . 0.0 110.597 -177.306 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.965 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.5 t -94.35 138.71 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.402 -0.812 . . . . 0.0 110.336 -176.19 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 95.2 mm-40 -70.07 -33.5 72.01 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.525 -0.734 . . . . 0.0 111.096 178.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.531 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -155.79 172.71 33.84 Favored Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.029 -1.558 . . . . 0.0 110.025 -173.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.489 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 0.6 OUTLIER -115.18 168.67 9.74 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.203 -1.175 . . . . 0.0 110.537 -179.499 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.059 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -135.47 148.03 49.09 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.535 -0.728 . . . . 0.0 109.426 -179.245 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.573 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 29.1 tttt -106.13 115.92 31.05 Favored 'General case' 0 C--N 1.298 -1.673 0 O-C-N 121.163 -0.961 . . . . 0.0 110.191 178.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 1.028 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.1 tp -59.81 128.07 35.11 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.002 -1.061 . . . . 0.0 108.701 172.843 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.118 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -128.08 -31.68 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 C-N-CA 119.586 -0.845 . . . . 0.0 110.141 -177.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.74 144.65 30.47 Favored 'General case' 0 N--CA 1.493 1.687 0 C-N-CA 119.069 -1.052 . . . . 0.0 111.44 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.765 HG23 ' CD2' ' B' ' 24' ' ' HIS . 12.3 mt -109.27 133.03 55.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.19 -0.944 . . . . 0.0 110.479 173.125 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.513 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 79.6 m-20 -110.29 116.34 31.29 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.36 -0.837 . . . . 0.0 109.901 173.18 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -106.57 114.48 28.62 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.935 -1.103 . . . . 0.0 110.62 -178.269 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.453 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.7 mtmt -110.71 132.92 21.35 Favored Pre-proline 0 N--CA 1.493 1.719 0 O-C-N 121.297 -0.877 . . . . 0.0 109.192 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -50.19 -34.53 39.83 Favored 'Trans proline' 0 C--N 1.301 -1.927 0 O-C-N 123.8 1.421 . . . . 0.0 110.703 -179.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.467 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 12.4 m-80 -74.5 -40.13 61.99 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.129 -0.982 . . . . 0.0 109.973 177.259 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.467 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 96.2 m-85 -153.89 150.2 28.13 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.371 -0.831 . . . . 0.0 110.182 -178.428 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.488 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 59.5 ttt180 -91.65 146.22 23.96 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.899 -1.125 . . . . 0.0 110.159 176.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.513 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 91.2 m -129.93 140.0 51.02 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.416 -0.802 . . . . 0.0 110.023 -175.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.765 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -129.03 136.56 50.46 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.998 -1.064 . . . . 0.0 111.16 177.603 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.733 HG22 ' OG ' ' B' ' 60' ' ' SER . 5.7 t -115.76 132.49 65.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.185 -0.947 . . . . 0.0 110.755 -177.373 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.49 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 13.0 m -116.3 170.31 6.09 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.025 179.839 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.462 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 2.7 tm-20 -101.57 117.81 35.68 Favored 'General case' 0 C--N 1.306 -1.304 0 O-C-N 121.298 -0.876 . . . . 0.0 109.244 179.071 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.602 HD23 ' HA ' ' B' ' 33' ' ' LEU . 9.3 tp -82.65 127.28 70.9 Favored Pre-proline 0 C--N 1.299 -1.623 0 O-C-N 121.435 -0.791 . . . . 0.0 110.115 -174.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.464 ' HD2' ' HB2' ' B' ' 32' ' ' MET . 24.9 Cg_endo -66.55 -178.53 1.23 Allowed 'Trans proline' 0 C--N 1.307 -1.658 0 O-C-N 123.932 1.491 . . . . 0.0 110.917 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.49 ' OD1' ' N ' ' B' ' 30' ' ' ASP . 22.7 p-10 -65.56 -40.01 92.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.335 -0.853 . . . . 0.0 111.089 -177.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.592 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.02 0.38 57.14 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.913 -1.117 . . . . 0.0 110.983 -174.641 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.592 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.8 mmm -110.15 -15.98 13.88 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.978 -1.076 . . . . 0.0 109.756 171.593 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.604 HD21 ' HB2' ' B' ' 57' ' ' ASN . 13.5 mt -66.09 -32.08 73.33 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.462 -0.774 . . . . 0.0 110.453 178.071 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . 0.426 ' OD1' ' N ' ' B' ' 35' ' ' GLY . 63.7 t0 -80.2 142.93 34.23 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.282 -0.887 . . . . 0.0 110.894 -176.741 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . 0.426 ' N ' ' OD1' ' B' ' 34' ' ' ASP . . . 85.9 -31.91 3.88 Favored Glycine 0 N--CA 1.493 2.467 0 C-N-CA 119.92 -1.133 . . . . 0.0 111.092 170.726 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.55 HD23 ' CD2' ' B' ' 28' ' ' LEU . 57.8 tp -77.39 155.12 32.08 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.669 -1.489 . . . . 0.0 111.131 -173.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . 0.478 ' C ' HD11 ' B' ' 54' ' ' ILE . 20.0 pt-20 -153.57 167.92 27.89 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.558 -0.714 . . . . 0.0 109.665 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.849 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -67.96 154.51 41.46 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.953 -1.092 . . . . 0.0 110.157 178.15 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 74.65 0.31 58.52 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -174.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.674 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -80.07 159.96 25.96 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.202 -1.175 . . . . 0.0 109.074 174.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.913 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 1.6 p -102.86 118.83 37.7 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.559 -1.338 . . . . 0.0 109.818 175.076 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.647 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.6 t -101.88 125.98 55.92 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 175.198 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -87.99 118.62 27.67 Favored 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.196 -1.002 . . . . 0.0 109.155 174.532 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.874 ' CD2' HG21 ' B' ' 82' ' ' VAL . 0.7 OUTLIER -91.39 105.9 18.11 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 176.374 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.489 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.6 t-20 55.49 13.57 0.98 Allowed 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.423 -0.798 . . . . 0.0 111.266 -169.023 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.493 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.47 -6.1 10.73 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 119.379 -1.391 . . . . 0.0 110.961 171.081 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.819 ' O ' HD23 ' B' ' 49' ' ' LEU . 33.0 t -89.82 107.54 19.16 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.549 -1.559 . . . . 0.0 109.413 175.577 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . 0.457 ' SG ' ' O ' ' A' ' 3' ' ' THR . 26.5 p -74.04 123.68 24.82 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.14 -0.975 . . . . 0.0 110.452 -174.129 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 0.838 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -139.15 156.54 47.05 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.42 -0.8 . . . . 0.0 109.344 175.141 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . 0.446 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 26.8 m -94.63 156.44 16.42 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 120.608 -1.308 . . . . 0.0 111.266 -169.107 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.796 HG13 HG13 ' B' ' 59' ' ' VAL . 17.0 t -82.35 116.1 26.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.831 -0.543 . . . . 0.0 110.389 -178.151 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.566 HG22 ' HB3' ' B' ' 62' ' ' ASP . 60.1 p -69.85 -40.06 76.02 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.133 -0.98 . . . . 0.0 109.458 172.631 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.58 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 51.8 tp10 -162.58 156.25 20.58 Favored 'General case' 0 N--CA 1.489 1.495 0 C-N-CA 119.384 -0.926 . . . . 0.0 110.827 -177.589 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.849 HD11 ' N ' ' B' ' 38' ' ' THR . 7.5 mt -110.0 129.98 63.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.14 -0.975 . . . . 0.0 109.535 170.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.529 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 46.5 m-80 -104.2 62.85 0.74 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.624 -0.673 . . . . 0.0 109.539 178.672 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.6 -114.74 4.08 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 -172.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.604 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.06 -19.76 46.79 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.948 -1.325 . . . . 0.0 109.102 175.947 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.118 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.7 m170 -76.91 158.97 30.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.337 -0.852 . . . . 0.0 110.263 -177.784 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.796 HG13 HG13 ' B' ' 51' ' ' VAL . 53.9 t -140.35 120.36 13.02 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.581 0 C-N-CA 119.104 -1.038 . . . . 0.0 110.921 173.542 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.733 ' OG ' HG22 ' B' ' 25' ' ' VAL . 21.8 m -85.99 128.83 34.93 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.648 -0.658 . . . . 0.0 109.751 177.293 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.838 ' HB3' HD12 ' B' ' 49' ' ' LEU . 60.4 m-85 -111.45 160.05 17.49 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.931 -1.106 . . . . 0.0 110.343 178.77 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.566 ' HB3' HG22 ' B' ' 52' ' ' THR . 31.6 p-10 -93.44 146.89 23.43 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.08 -1.012 . . . . 0.0 111.317 179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.748 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -157.37 113.44 2.89 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 -177.033 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.514 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 56.9 ttm -69.25 142.37 54.19 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.877 -1.139 . . . . 0.0 109.61 179.012 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 47.6 tptt -59.91 -46.19 90.13 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.107 -0.995 . . . . 0.0 110.341 -175.771 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 87.8 tt0 -69.81 -40.04 76.18 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.971 -1.08 . . . . 0.0 110.123 179.462 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.514 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 87.1 m -60.29 -38.46 83.66 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.915 -1.115 . . . . 0.0 109.191 173.026 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.719 ' CD1' HD22 ' B' ' 63' ' ' LEU . 11.1 tp -60.04 -43.71 95.15 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.52 -0.738 . . . . 0.0 109.45 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 77.8 ttt-85 -68.31 -39.81 81.91 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.304 -0.872 . . . . 0.0 110.598 174.314 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.743 HG22 HG23 ' B' ' 71' ' ' THR . 1.4 tt -66.38 -41.56 89.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.571 -174.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.743 HG23 HG22 ' B' ' 70' ' ' ILE . 51.3 p -83.51 -168.5 2.13 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.113 -0.635 . . . . 0.0 109.634 177.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.485 ' CB ' ' H ' ' A' ' 83' ' ' ASN . 7.2 t30 -104.93 19.59 20.29 Favored 'General case' 0 C--N 1.293 -1.885 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 168.042 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.748 ' HB3' HD21 ' B' ' 63' ' ' LEU . 81.5 mt -69.96 -40.07 75.64 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.005 -1.059 . . . . 0.0 109.931 175.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.61 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -47.28 -22.58 1.52 Allowed Glycine 0 N--CA 1.487 2.051 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 178.354 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.516 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 22.3 p-10 -62.64 -16.24 55.82 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.045 -1.268 . . . . 0.0 110.349 -175.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.516 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 84.2 mt -63.22 146.14 54.02 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.309 -0.87 . . . . 0.0 111.046 -175.085 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 1.028 ' C ' HD23 ' B' ' 12' ' ' LEU . 96.6 mttt -149.03 138.34 21.61 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.781 -0.575 . . . . 0.0 109.647 174.172 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.716 HG21 HG13 ' B' ' 15' ' ' ILE . 17.3 t -61.56 151.92 6.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.051 -1.031 . . . . 0.0 110.479 -175.127 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.89 -14.24 60.86 Favored Glycine 0 N--CA 1.483 1.777 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 -175.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.441 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 25.5 t0 -97.89 168.41 10.32 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.413 -1.051 . . . . 0.0 109.645 176.056 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.573 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.3 m95 -116.64 168.91 9.76 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.973 -1.079 . . . . 0.0 110.144 177.119 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.059 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.5 p -136.25 148.06 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.494 -0.754 . . . . 0.0 110.006 -177.295 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.965 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.8 m-20 -73.08 104.2 4.09 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.082 -1.011 . . . . 0.0 109.243 170.106 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.814 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -107.81 140.6 25.59 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 120.843 -1.161 . . . . 0.0 110.99 -176.664 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . 0.411 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.5 tt0 -142.49 140.81 32.0 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.762 -0.586 . . . . 0.0 110.183 -176.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 95.3 mtt180 -60.29 131.69 51.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.113 -0.992 . . . . 0.0 109.77 178.681 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 0.913 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . -126.0 149.09 49.07 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.331 -0.856 . . . . 0.0 110.114 179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . 0.584 ' O ' ' CD1' ' A' ' 2' ' ' PHE . . . -147.5 156.08 42.5 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.513 -0.742 . . . . 0.0 110.79 -176.66 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . 0.537 ' HA ' ' CD1' ' A' ' 2' ' ' PHE . 35.1 mttt -59.96 -40.03 87.65 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.614 -0.679 . . . . 0.0 110.185 175.64 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -129.74 160.93 31.88 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.26 -0.9 . . . . 0.0 110.087 -177.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . 0.897 ' OG ' HD11 ' B' ' 94' ' ' ILE . 77.3 p -59.72 139.28 57.38 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.19 -0.943 . . . . 0.0 110.672 -174.247 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 95.4 m-20 -106.53 -11.92 15.76 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.347 -0.845 . . . . 0.0 110.084 176.215 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 99.0 mt-10 -113.93 54.11 0.76 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.242 -0.911 . . . . 0.0 110.135 -178.016 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . 0.897 HD11 ' OG ' ' B' ' 91' ' ' SER . 23.0 mm -60.03 -39.97 81.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.338 -0.851 . . . . 0.0 110.078 178.311 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 49.8 70.85 0.71 Allowed Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 -176.293 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . 160.39 -179.97 35.56 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 -179.151 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 38.5 m-70 . . . . . 0 N--CA 1.493 1.68 0 O-C-N 121.214 -1.168 . . . . 0.0 110.249 179.603 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 0.843 ' C8M' HD11 ' B' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 0.872 ' C8M' HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.457 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 25.0 ptp . . . . . 0 N--CA 1.494 1.728 0 CA-C-O 121.227 0.537 . . . . 0.0 110.29 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.937 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 5.6 p90 -179.33 138.73 0.14 Allowed 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 179.091 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.482 ' HB ' ' CD1' ' A' ' 5' ' ' ILE . 20.8 p -125.76 -36.61 2.39 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 120.838 -1.164 . . . . 0.0 110.234 -173.617 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.493 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 57.6 17.7 27.86 Favored Glycine 0 N--CA 1.486 2.011 0 N-CA-C 108.849 -1.7 . . . . 0.0 108.849 -177.155 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 1.026 HD11 HC81 ' B' ' 99' ' ' RBF . 26.5 mt -88.6 117.04 31.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.289 -1.124 . . . . 0.0 109.533 -177.376 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.98 HG21 ' HB3' ' A' ' 83' ' ' ASN . 3.7 t -86.94 144.05 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.116 -0.99 . . . . 0.0 110.817 -172.793 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 94.3 mm-40 -69.94 -33.2 71.81 Favored 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.603 -0.686 . . . . 0.0 110.556 175.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -168.87 174.52 43.45 Favored Glycine 0 N--CA 1.493 2.466 0 C-N-CA 119.104 -1.522 . . . . 0.0 109.87 -176.58 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.493 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 41.5 p -114.58 170.01 8.63 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.065 -1.256 . . . . 0.0 110.772 -177.598 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.033 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -135.53 149.93 49.6 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.572 -0.705 . . . . 0.0 109.577 -175.721 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.585 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.0 tttt -105.71 116.77 32.51 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 121.142 -0.974 . . . . 0.0 110.337 179.073 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 1.013 HD23 ' C ' ' A' ' 77' ' ' LYS . 11.5 tp -60.02 127.12 30.33 Favored 'General case' 0 C--N 1.297 -1.694 0 O-C-N 120.898 -1.126 . . . . 0.0 108.825 172.383 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.139 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -125.57 -31.45 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.876 0 O-C-N 121.405 -0.81 . . . . 0.0 109.983 -179.495 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.2 144.6 29.04 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.027 -1.069 . . . . 0.0 111.237 -179.243 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.776 HG23 ' CD2' ' A' ' 24' ' ' HIS . 13.4 mt -108.53 135.64 46.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.162 -0.961 . . . . 0.0 110.032 172.027 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.514 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 84.0 m-20 -109.35 114.88 28.93 Favored 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.289 -0.882 . . . . 0.0 109.867 174.732 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -105.67 114.25 28.3 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.994 -1.067 . . . . 0.0 110.587 -175.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.1 mtmt -111.46 127.78 26.37 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.18 -0.95 . . . . 0.0 108.993 174.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_endo -50.99 -24.06 13.31 Favored 'Trans proline' 0 C--N 1.303 -1.859 0 O-C-N 123.824 1.434 . . . . 0.0 110.254 -179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.543 ' C ' ' CD2' ' A' ' 21' ' ' PHE . 11.4 m-80 -80.15 -42.5 23.33 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.251 -0.905 . . . . 0.0 109.985 175.243 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.543 ' CD2' ' C ' ' A' ' 20' ' ' ASN . 97.5 m-85 -153.97 150.32 28.18 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.4 -0.812 . . . . 0.0 109.977 -178.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.68 ' HD3' HD22 ' A' ' 68' ' ' LEU . 62.0 ttt180 -90.58 145.29 24.98 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.878 -1.139 . . . . 0.0 110.167 178.581 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.514 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 87.4 m -131.75 141.75 49.6 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 121.511 -0.743 . . . . 0.0 109.846 -175.409 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.776 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -131.03 143.91 51.07 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 120.97 -1.081 . . . . 0.0 111.475 -179.466 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.848 HG22 ' CB ' ' A' ' 60' ' ' SER . 6.6 t -125.34 133.94 68.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.128 -0.982 . . . . 0.0 110.975 -178.309 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.733 HG13 ' HE1' ' A' ' 61' ' ' PHE . 29.5 m -116.88 174.59 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 CA-C-O 121.24 0.543 . . . . 0.0 110.319 178.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.509 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 11.8 tt0 -104.59 118.46 36.65 Favored 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 177.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.831 HD13 ' HD2' ' A' ' 29' ' ' PRO 0.266 0.2 OUTLIER -87.32 123.08 70.41 Favored Pre-proline 0 C--N 1.297 -1.704 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 -172.649 . . . . . . . . 4 4 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.831 ' HD2' HD13 ' A' ' 28' ' ' LEU . 17.8 Cg_endo -66.29 172.81 8.34 Favored 'Trans proline' 0 C--N 1.309 -1.51 0 O-C-N 123.551 1.29 . . . . 0.0 111.094 -178.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.509 ' HA ' HD12 ' A' ' 33' ' ' LEU . 96.0 m-20 -59.99 -40.05 87.83 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.568 -0.708 . . . . 0.0 111.196 -174.671 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.536 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.02 -0.0 57.35 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.672 -1.267 . . . . 0.0 110.659 -171.479 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.671 ' HB3' HD11 ' A' ' 28' ' ' LEU . 97.8 mmm -113.52 -14.87 12.65 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 120.908 -1.12 . . . . 0.0 109.715 169.128 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.532 ' N ' HD12 ' A' ' 28' ' ' LEU . 14.0 mt -62.32 -40.02 94.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.087 -1.008 . . . . 0.0 109.59 176.585 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -69.93 129.95 40.9 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.469 -0.769 . . . . 0.0 110.278 178.036 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.0 -44.25 1.66 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 176.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.796 ' CD2' HG21 ' A' ' 59' ' ' VAL . 66.0 tp -63.61 145.13 56.29 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.05 -1.265 . . . . 0.0 110.946 -176.442 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 21.6 pt-20 -153.09 160.02 42.87 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.507 -0.745 . . . . 0.0 109.316 175.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.738 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -62.81 148.76 45.98 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.93 -1.107 . . . . 0.0 110.058 -179.296 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.52 -6.45 68.94 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 -175.035 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 50' ' ' THR . . . -72.86 155.73 39.61 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.178 -1.189 . . . . 0.0 109.543 176.479 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.788 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -100.03 99.75 10.53 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 119.05 -1.06 . . . . 0.0 109.698 176.762 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.686 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.2 t -85.58 131.74 33.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 O-C-N 121.347 -0.846 . . . . 0.0 109.355 176.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.507 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -95.03 119.98 34.47 Favored 'General case' 0 C--N 1.294 -1.83 0 O-C-N 121.059 -1.025 . . . . 0.0 109.272 170.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.686 ' HE1' HG11 ' A' ' 42' ' ' VAL . 0.3 OUTLIER -89.51 108.2 19.52 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 176.579 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.491 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.0 t-20 51.83 16.34 0.49 Allowed 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.235 -0.916 . . . . 0.0 111.056 -168.218 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.491 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 117.09 -1.53 19.33 Favored Glycine 0 N--CA 1.49 2.235 0 C-N-CA 119.509 -1.329 . . . . 0.0 110.915 172.356 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.79 ' O ' HD23 ' A' ' 49' ' ' LEU . 18.9 t -93.84 107.13 19.05 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.505 -1.585 . . . . 0.0 109.304 174.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.437 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 32.1 p -75.19 130.01 38.45 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.003 -1.061 . . . . 0.0 111.019 -171.584 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.914 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -144.75 161.22 39.77 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.526 -0.734 . . . . 0.0 109.524 174.518 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.461 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 10.7 m -100.22 149.97 23.02 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 120.757 -1.214 . . . . 0.0 111.043 -171.012 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.813 HG13 HG13 ' A' ' 59' ' ' VAL . 36.7 t -80.03 115.33 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.773 -0.579 . . . . 0.0 110.432 -178.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.556 HG22 ' HB3' ' A' ' 62' ' ' ASP . 30.5 p -70.09 -39.99 75.22 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.175 -0.953 . . . . 0.0 109.871 175.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.652 ' HA ' HG21 ' A' ' 38' ' ' THR . 87.7 tt0 -161.3 154.2 20.88 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.262 -0.899 . . . . 0.0 110.333 179.059 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.738 HD11 ' N ' ' A' ' 38' ' ' THR . 5.8 mt -102.48 132.73 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.983 -1.073 . . . . 0.0 109.909 174.472 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.523 ' CB ' ' HB2' ' A' ' 58' ' ' HIS . 2.5 m-80 -103.89 65.25 0.81 Allowed 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.569 -0.707 . . . . 0.0 109.869 179.334 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.94 -118.55 5.69 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 108.719 -1.752 . . . . 0.0 108.719 -173.091 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.518 ' O ' ' HB2' ' A' ' 28' ' ' LEU . 0.0 OUTLIER -75.02 -21.46 59.07 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 120.903 -1.351 . . . . 0.0 108.764 173.818 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.139 ' CD2' HG11 ' A' ' 13' ' ' VAL . 12.8 m170 -72.89 159.96 32.9 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.242 -0.912 . . . . 0.0 110.17 -177.37 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.813 HG13 HG13 ' A' ' 51' ' ' VAL . 52.8 t -140.1 125.57 20.72 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 O-C-N 121.04 -1.037 . . . . 0.0 110.662 171.536 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.848 ' CB ' HG22 ' A' ' 25' ' ' VAL . 54.3 p -96.09 125.82 40.89 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.723 -0.611 . . . . 0.0 109.742 179.641 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.914 ' HB2' HD12 ' A' ' 49' ' ' LEU . 4.3 p90 -118.45 155.26 31.08 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.016 -1.052 . . . . 0.0 110.296 179.806 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.556 ' HB3' HG22 ' A' ' 52' ' ' THR . 35.1 p-10 -87.87 152.81 21.81 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.075 -1.016 . . . . 0.0 111.244 -173.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.75 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -157.96 114.36 2.84 Favored 'General case' 0 C--N 1.3 -1.586 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 -176.518 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.511 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 57.6 ttm -71.92 142.33 49.48 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.009 -1.057 . . . . 0.0 109.624 -178.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.471 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 71.3 tttt -59.98 -50.01 75.41 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.075 -1.016 . . . . 0.0 110.505 -175.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -65.58 -39.96 92.2 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.996 -1.065 . . . . 0.0 109.914 178.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.511 ' HB ' ' HB3' ' A' ' 64' ' ' MET . 93.0 m -61.11 -40.04 92.27 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.978 -1.076 . . . . 0.0 109.289 174.05 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.68 HD22 ' HD3' ' A' ' 22' ' ' ARG . 18.0 tp -59.95 -43.01 95.28 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.319 -0.863 . . . . 0.0 109.466 178.368 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -67.64 -39.98 84.59 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.554 -0.716 . . . . 0.0 110.138 176.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.719 HG22 HG23 ' A' ' 71' ' ' THR . 1.2 tt -68.23 -40.02 82.04 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.357 -0.84 . . . . 0.0 109.301 -177.055 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.719 HG23 HG22 ' A' ' 70' ' ' ILE . 60.1 p -84.61 -172.73 4.33 Favored 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 120.261 -0.576 . . . . 0.0 109.483 177.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.478 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 5.9 t30 -102.32 22.45 13.33 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 169.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.75 ' HB3' HD21 ' A' ' 63' ' ' LEU . 88.2 mt -70.02 -39.92 75.51 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.01 -1.056 . . . . 0.0 109.757 174.794 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.449 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -44.56 -23.96 0.6 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.396 -1.082 . . . . 0.0 110.396 178.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 23.0 p-10 -69.97 -19.16 63.36 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.913 -1.346 . . . . 0.0 110.603 -174.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.519 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 98.4 mt -59.92 140.41 56.7 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.085 -1.01 . . . . 0.0 110.714 -176.682 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 1.013 ' C ' HD23 ' A' ' 12' ' ' LEU . 92.3 mttt -143.6 138.97 29.43 Favored 'General case' 0 C--N 1.297 -1.712 0 CA-C-O 121.427 0.632 . . . . 0.0 109.83 177.301 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.68 ' N ' HD23 ' A' ' 12' ' ' LEU . 16.4 t -60.33 152.2 5.39 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 120.983 -1.073 . . . . 0.0 110.48 -175.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.37 -14.46 59.43 Favored Glycine 0 N--CA 1.483 1.776 0 N-CA-C 108.906 -1.678 . . . . 0.0 108.906 -176.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 49.6 t0 -96.27 166.37 11.76 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.33 -1.1 . . . . 0.0 109.627 176.569 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.585 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.1 m95 -115.43 165.99 12.37 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.963 -1.086 . . . . 0.0 110.157 175.53 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.033 HG13 ' HB3' ' A' ' 10' ' ' ALA . 0.9 OUTLIER -129.96 158.4 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.339 -0.851 . . . . 0.0 110.081 -177.532 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.98 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.1 OUTLIER -80.0 107.5 12.83 Favored 'General case' 0 C--N 1.297 -1.674 0 O-C-N 121.006 -1.058 . . . . 0.0 109.14 167.029 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.736 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -108.85 138.13 37.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 120.596 -1.315 . . . . 0.0 111.194 -176.356 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -140.92 146.51 37.5 Favored 'General case' 0 N--CA 1.492 1.661 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.043 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 58.0 ttp180 -83.21 130.02 35.06 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.027 -1.045 . . . . 0.0 111.038 -176.41 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.9 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -118.01 146.15 44.24 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.294 -0.879 . . . . 0.0 110.031 174.61 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -123.64 138.34 54.56 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.614 -0.679 . . . . 0.0 110.648 -176.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 9.2 mttm -60.07 -39.94 87.78 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.333 -0.854 . . . . 0.0 110.005 179.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -142.95 156.0 44.8 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.236 -0.915 . . . . 0.0 110.28 178.414 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 58.7 m -126.82 129.95 49.28 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.284 -0.885 . . . . 0.0 109.988 177.253 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -64.78 -45.96 84.11 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.168 -0.958 . . . . 0.0 110.496 -179.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -95.72 44.96 1.08 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.07 -1.018 . . . . 0.0 111.101 -171.163 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 20.4 mm -60.64 -40.98 86.4 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.772 0 O-C-N 121.268 -0.895 . . . . 0.0 110.132 170.439 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 113.72 -102.05 1.2 Allowed Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 179.279 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.557 ' O ' ' CG ' ' A' ' 97' ' ' HIS . . . 79.99 -178.92 53.58 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -177.361 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.557 ' CG ' ' O ' ' A' ' 96' ' ' GLY . 1.5 m170 . . . . . 0 N--CA 1.493 1.687 0 O-C-N 121.218 -1.166 . . . . 0.0 110.203 179.102 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . 0.424 ' O ' ' HB3' ' B' ' 2' ' ' PHE . 57.2 ttm . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 121.282 0.563 . . . . 0.0 110.199 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.9 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 5.4 p90 -176.92 138.55 0.26 Allowed 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.236 -0.915 . . . . 0.0 108.766 176.464 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.485 ' HB ' ' CD1' ' B' ' 5' ' ' ILE . 21.0 p -125.69 -36.67 2.4 Favored 'General case' 0 C--N 1.298 -1.637 0 O-C-N 120.846 -1.159 . . . . 0.0 110.183 -173.594 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.486 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 57.58 17.82 28.18 Favored Glycine 0 N--CA 1.486 1.969 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 -177.116 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 0.962 HD11 HC81 ' A' ' 98' ' ' RBF . 25.9 mt -88.75 117.02 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.362 -1.081 . . . . 0.0 109.587 -177.412 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 1.004 HG21 ' HB3' ' B' ' 83' ' ' ASN . 3.7 t -86.78 144.05 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.121 -0.987 . . . . 0.0 110.856 -172.739 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 94.3 mm-40 -69.99 -32.97 71.44 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.735 -0.603 . . . . 0.0 110.635 175.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -169.13 174.4 43.61 Favored Glycine 0 N--CA 1.495 2.576 0 C-N-CA 119.175 -1.488 . . . . 0.0 109.935 -176.626 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.488 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 41.6 p -114.52 170.03 8.61 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.0 -1.294 . . . . 0.0 110.778 -177.475 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.051 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -135.61 150.04 49.54 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.614 -0.679 . . . . 0.0 109.523 -175.742 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.581 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 30.1 tttt -105.84 116.83 32.61 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.101 -0.999 . . . . 0.0 110.262 179.134 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 1.013 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.5 tp -60.0 127.13 30.36 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 120.96 -1.088 . . . . 0.0 108.9 172.334 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.142 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -125.53 -31.61 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.856 0 O-C-N 121.383 -0.823 . . . . 0.0 110.009 -179.479 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.02 144.59 29.25 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.273 -0.971 . . . . 0.0 111.351 -179.281 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.779 HG23 ' CD2' ' B' ' 24' ' ' HIS . 13.5 mt -108.58 135.67 46.66 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.217 -0.927 . . . . 0.0 109.994 172.058 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.526 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.6 m-20 -109.48 115.0 29.11 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 121.367 -0.833 . . . . 0.0 109.788 174.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -105.62 114.18 28.19 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.012 -1.055 . . . . 0.0 110.619 -175.388 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.44 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.0 OUTLIER -111.46 127.77 26.39 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.233 -0.917 . . . . 0.0 109.049 174.226 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.431 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.2 Cg_endo -51.16 -23.97 13.96 Favored 'Trans proline' 0 C--N 1.303 -1.834 0 O-C-N 123.827 1.435 . . . . 0.0 110.238 -179.727 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.54 ' C ' ' CD2' ' B' ' 21' ' ' PHE . 11.2 m-80 -79.94 -43.0 22.91 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.106 -0.996 . . . . 0.0 109.884 175.15 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.54 ' CD2' ' C ' ' B' ' 20' ' ' ASN . 97.4 m-85 -153.69 150.37 28.5 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.54 -0.725 . . . . 0.0 109.993 -178.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.685 ' HD3' HD22 ' B' ' 68' ' ' LEU . 62.1 ttt180 -90.54 145.2 25.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 120.934 -1.104 . . . . 0.0 110.108 178.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.526 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 87.0 m -131.63 141.84 49.72 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.541 -0.725 . . . . 0.0 109.852 -175.535 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.779 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -131.05 144.08 51.18 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 120.926 -1.109 . . . . 0.0 111.336 -179.431 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.857 HG22 ' CB ' ' B' ' 60' ' ' SER . 6.6 t -125.43 134.07 67.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.15 -0.969 . . . . 0.0 110.93 -178.271 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.749 HG13 ' HE1' ' B' ' 61' ' ' PHE . 30.3 m -117.14 174.59 3.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.812 -0.555 . . . . 0.0 110.304 179.102 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.515 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 12.0 tt0 -104.57 118.51 36.77 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 177.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.824 HD13 ' HD2' ' B' ' 29' ' ' PRO 0.266 0.2 OUTLIER -87.35 123.07 70.38 Favored Pre-proline 0 C--N 1.296 -1.728 0 O-C-N 121.403 -0.811 . . . . 0.0 108.968 -172.769 . . . . . . . . 4 4 . 1 . 004 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.824 ' HD2' HD13 ' B' ' 28' ' ' LEU . 18.1 Cg_endo -66.27 172.84 8.27 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 O-C-N 123.6 1.316 . . . . 0.0 111.114 -178.213 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.496 ' HA ' HD12 ' B' ' 33' ' ' LEU . 96.0 m-20 -60.07 -40.04 88.15 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.579 -0.701 . . . . 0.0 111.135 -174.647 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.534 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.94 -0.03 57.34 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.743 -1.223 . . . . 0.0 110.72 -171.514 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.649 ' HB3' HD11 ' B' ' 28' ' ' LEU . 98.0 mmm -113.48 -14.87 12.67 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.975 -1.078 . . . . 0.0 109.729 169.148 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.533 ' N ' HD12 ' B' ' 28' ' ' LEU . 14.0 mt -62.32 -39.93 94.66 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.071 -1.018 . . . . 0.0 109.652 176.572 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -70.02 130.07 41.16 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.486 -0.759 . . . . 0.0 110.29 177.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.88 -44.13 1.69 Allowed Glycine 0 N--CA 1.491 2.338 0 N-CA-C 110.179 -1.169 . . . . 0.0 110.179 176.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.797 ' CD2' HG21 ' B' ' 59' ' ' VAL . 66.4 tp -63.78 145.13 56.36 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.012 -1.287 . . . . 0.0 110.891 -176.441 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . . . . . . . . . 21.6 pt-20 -153.07 159.97 42.89 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.52 -0.737 . . . . 0.0 109.334 175.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.729 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -62.87 148.65 46.54 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.944 -1.098 . . . . 0.0 110.151 -179.303 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.67 -6.51 69.26 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 -174.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' B' ' 50' ' ' THR . . . -72.99 155.61 39.67 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.206 -1.173 . . . . 0.0 109.509 176.489 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.778 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -99.7 99.61 10.46 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 120.926 -1.109 . . . . 0.0 109.799 176.725 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.67 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.2 t -85.62 131.87 33.3 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.332 -0.855 . . . . 0.0 109.319 176.183 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -95.12 120.06 34.69 Favored 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.037 -1.039 . . . . 0.0 109.292 170.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.67 ' HE1' HG11 ' B' ' 42' ' ' VAL . 0.3 OUTLIER -89.58 107.97 19.39 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.32 -0.863 . . . . 0.0 108.916 176.639 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.491 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.0 t-20 51.95 16.54 0.53 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.218 -0.926 . . . . 0.0 110.972 -168.204 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.493 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 116.92 -1.27 19.71 Favored Glycine 0 N--CA 1.489 2.227 0 C-N-CA 119.543 -1.313 . . . . 0.0 110.917 172.199 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.798 ' O ' HD23 ' B' ' 49' ' ' LEU . 18.9 t -93.99 107.07 19.01 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.49 -1.594 . . . . 0.0 109.316 174.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . 0.442 ' SG ' ' O ' ' A' ' 3' ' ' THR . 32.1 p -75.04 129.99 38.55 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.037 -1.039 . . . . 0.0 111.089 -171.626 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 0.909 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -144.81 161.19 39.89 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.526 -0.734 . . . . 0.0 109.507 174.503 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . 0.464 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 10.5 m -100.06 150.15 22.75 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 120.749 -1.219 . . . . 0.0 111.069 -171.024 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.823 HG13 HG13 ' B' ' 59' ' ' VAL . 37.7 t -80.27 115.36 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.639 -0.663 . . . . 0.0 110.434 -178.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.537 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 30.5 p -70.07 -39.98 75.32 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.14 -0.975 . . . . 0.0 109.91 175.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.629 ' HA ' HG21 ' B' ' 38' ' ' THR . 87.7 tt0 -161.36 154.25 20.82 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.267 -0.895 . . . . 0.0 110.297 179.079 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.729 HD11 ' N ' ' B' ' 38' ' ' THR . 5.8 mt -102.5 132.75 47.93 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.11 -0.994 . . . . 0.0 109.927 174.535 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.51 ' CB ' ' HB2' ' B' ' 58' ' ' HIS . 2.5 m-80 -104.04 65.36 0.8 Allowed 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.528 -0.733 . . . . 0.0 109.758 179.415 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.02 -118.48 5.64 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.655 -1.778 . . . . 0.0 108.655 -173.224 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.52 ' O ' ' HB2' ' B' ' 28' ' ' LEU . 0.0 OUTLIER -75.0 -21.66 59.0 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.928 -1.336 . . . . 0.0 108.777 173.796 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.142 ' CD2' HG11 ' B' ' 13' ' ' VAL . 12.8 m170 -72.7 159.76 33.3 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.345 -0.847 . . . . 0.0 110.192 -177.411 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.823 HG13 HG13 ' B' ' 51' ' ' VAL . 53.1 t -140.03 125.52 20.87 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.093 -1.005 . . . . 0.0 110.748 171.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.857 ' CB ' HG22 ' B' ' 25' ' ' VAL . 54.4 p -96.04 126.06 41.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.651 -0.656 . . . . 0.0 109.818 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.909 ' HB2' HD12 ' B' ' 49' ' ' LEU . 4.3 p90 -118.6 155.2 31.37 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.963 -1.086 . . . . 0.0 110.344 179.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.537 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 34.9 p-10 -87.76 152.73 21.9 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.097 -1.002 . . . . 0.0 111.305 -173.226 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.752 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -157.79 114.53 2.91 Favored 'General case' 0 C--N 1.299 -1.6 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -176.662 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.519 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 57.7 ttm -72.08 142.41 49.22 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 120.931 -1.105 . . . . 0.0 109.574 -178.801 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.469 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 71.2 tttt -60.11 -49.91 75.77 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.988 -1.07 . . . . 0.0 110.441 -175.117 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -65.6 -40.02 92.2 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.969 -1.082 . . . . 0.0 109.906 178.803 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.519 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 93.1 m -61.2 -39.94 92.1 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.974 -1.079 . . . . 0.0 109.219 174.13 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.685 HD22 ' HD3' ' B' ' 22' ' ' ARG . 17.9 tp -59.98 -42.95 95.3 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.439 -0.788 . . . . 0.0 109.522 178.334 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 31.6 mmt180 -67.52 -39.99 85.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.581 -0.7 . . . . 0.0 110.269 176.476 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.71 HG22 HG23 ' B' ' 71' ' ' THR . 1.2 tt -68.19 -40.08 82.22 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 CA-C-O 121.904 0.859 . . . . 0.0 109.295 -177.115 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.71 HG23 HG22 ' B' ' 70' ' ' ILE . 59.2 p -84.52 -172.52 4.22 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 120.083 -0.647 . . . . 0.0 109.546 177.782 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.47 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 5.8 t30 -102.42 22.56 13.23 Favored 'General case' 0 C--N 1.296 -1.754 0 O-C-N 121.218 -0.927 . . . . 0.0 108.51 169.411 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.752 ' HB3' HD21 ' B' ' 63' ' ' LEU . 88.1 mt -70.09 -39.95 75.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.013 -1.054 . . . . 0.0 109.713 174.71 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.448 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -44.56 -23.82 0.58 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 178.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 23.2 p-10 -70.04 -19.07 63.31 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.932 -1.334 . . . . 0.0 110.648 -175.021 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.519 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.3 mt -60.03 140.41 56.82 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.121 -0.987 . . . . 0.0 110.67 -176.662 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 1.013 ' C ' HD23 ' B' ' 12' ' ' LEU . 92.2 mttt -143.6 139.05 29.46 Favored 'General case' 0 C--N 1.297 -1.708 0 CA-C-O 121.363 0.601 . . . . 0.0 109.853 177.297 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.676 ' N ' HD23 ' B' ' 12' ' ' LEU . 16.5 t -60.56 152.24 5.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 120.937 -1.102 . . . . 0.0 110.42 -175.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.29 -14.22 59.89 Favored Glycine 0 N--CA 1.485 1.932 0 N-CA-C 108.927 -1.669 . . . . 0.0 108.927 -176.067 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.508 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 49.4 t0 -96.37 166.31 11.77 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.387 -1.066 . . . . 0.0 109.572 176.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.581 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.1 m95 -115.38 165.93 12.43 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.03 -1.044 . . . . 0.0 110.225 175.493 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.051 HG13 ' HB3' ' B' ' 10' ' ' ALA . 0.9 OUTLIER -129.95 158.5 42.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.387 -0.821 . . . . 0.0 110.081 -177.628 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 1.004 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.1 OUTLIER -79.96 107.29 12.63 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 120.987 -1.07 . . . . 0.0 109.179 167.043 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.722 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -108.67 138.34 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 120.668 -1.27 . . . . 0.0 111.061 -176.196 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 87.9 tt0 -141.34 146.57 36.87 Favored 'General case' 0 N--CA 1.492 1.659 0 C-N-CA 120.397 -0.521 . . . . 0.0 109.933 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 58.0 ttp180 -83.07 129.97 35.08 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.027 -1.046 . . . . 0.0 110.996 -176.288 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 0.937 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -117.97 146.29 44.1 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.258 -0.901 . . . . 0.0 110.023 174.486 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -123.78 138.37 54.52 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.499 -0.751 . . . . 0.0 110.636 -176.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 9.3 mttm -60.08 -39.94 87.86 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.392 -0.818 . . . . 0.0 110.042 179.312 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -142.96 156.06 44.81 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.315 -0.866 . . . . 0.0 110.246 178.365 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . 0.806 ' OG ' HD12 ' B' ' 94' ' ' ILE . 58.8 m -126.83 129.92 49.22 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.349 -0.844 . . . . 0.0 110.011 177.215 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . 0.466 ' O ' ' HB3' ' B' ' 93' ' ' GLU . 54.4 t0 -64.75 -43.46 93.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.267 -0.895 . . . . 0.0 110.387 -179.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . 0.466 ' HB3' ' O ' ' B' ' 92' ' ' ASP . 7.3 pt-20 -179.58 48.58 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.69 -0.631 . . . . 0.0 109.899 -175.274 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . 0.806 HD12 ' OG ' ' B' ' 91' ' ' SER . 58.6 mt -70.44 -44.24 77.39 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.498 -0.751 . . . . 0.0 110.767 -176.129 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' B' ' 94' ' ' ILE . . . 41.34 61.55 2.06 Favored Glycine 0 N--CA 1.495 2.59 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 -176.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -103.8 -92.7 2.25 Favored Glycine 0 N--CA 1.492 2.407 0 O-C-N 121.069 -1.254 . . . . 0.0 110.014 -176.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 24.1 p80 . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.192 -1.181 . . . . 0.0 110.253 -178.078 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 0.962 HC81 HD11 ' B' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 1.026 HC81 HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 95.4 mtp . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.132 0.491 . . . . 0.0 110.097 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.913 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 7.5 p90 -173.38 153.04 2.3 Favored 'General case' 0 C--N 1.307 -1.275 0 O-C-N 121.129 -0.982 . . . . 0.0 108.899 177.67 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.523 HG23 ' C ' ' A' ' 2' ' ' PHE . 20.9 p -150.49 -39.16 0.13 Allowed 'General case' 0 C--N 1.296 -1.747 0 O-C-N 120.966 -1.084 . . . . 0.0 109.017 175.579 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.46 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 48.25 24.04 3.28 Favored Glycine 0 N--CA 1.484 1.862 0 N-CA-C 108.272 -1.931 . . . . 0.0 108.272 -175.369 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.651 HD11 ' C8M' ' B' ' 99' ' ' RBF . 65.7 mt -81.49 134.45 27.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.371 -1.076 . . . . 0.0 109.857 -176.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.818 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.8 t -87.86 139.63 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.106 -0.996 . . . . 0.0 111.047 -169.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 30.3 mm100 -69.91 -36.25 75.23 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.716 -0.615 . . . . 0.0 110.836 178.033 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.537 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -154.36 170.78 32.84 Favored Glycine 0 N--CA 1.493 2.448 0 C-N-CA 119.156 -1.497 . . . . 0.0 109.986 -172.492 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.445 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 4.2 p -114.4 173.86 6.24 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.927 -1.337 . . . . 0.0 111.173 -175.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.061 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -142.2 149.8 40.16 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.676 -0.64 . . . . 0.0 109.347 -177.502 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.591 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 38.3 tttt -107.29 116.72 32.42 Favored 'General case' 0 C--N 1.295 -1.766 0 O-C-N 121.003 -1.061 . . . . 0.0 110.269 177.908 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 1.011 HD23 ' C ' ' A' ' 77' ' ' LYS . 11.9 tp -60.02 126.95 29.53 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 120.848 -1.157 . . . . 0.0 108.827 171.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.123 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.3 p -122.79 -31.65 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 O-C-N 121.395 -0.816 . . . . 0.0 109.881 -179.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.94 146.59 27.92 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 118.984 -1.086 . . . . 0.0 111.473 -179.324 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.852 HG23 ' CD2' ' A' ' 24' ' ' HIS . 7.6 mt -108.45 138.06 37.1 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.026 -1.046 . . . . 0.0 110.238 171.207 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.504 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.9 m-20 -109.22 115.72 30.55 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.196 -0.94 . . . . 0.0 109.765 171.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -104.56 112.27 25.28 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.019 -1.05 . . . . 0.0 110.379 -175.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.463 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 20.4 mmmt -115.64 129.27 25.28 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.17 -0.956 . . . . 0.0 109.125 177.33 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -51.03 -31.34 34.46 Favored 'Trans proline' 0 C--N 1.303 -1.841 0 O-C-N 123.775 1.408 . . . . 0.0 110.264 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 11.6 m-80 -74.42 -39.99 62.27 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.232 -0.917 . . . . 0.0 110.09 175.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 83.7 m-85 -156.35 150.46 25.27 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.328 -0.858 . . . . 0.0 110.308 -177.623 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.49 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 59.0 ttt180 -92.05 141.81 28.21 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.921 -1.112 . . . . 0.0 109.94 176.579 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.504 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.6 m -130.08 139.95 50.89 Favored 'General case' 0 C--N 1.294 -1.819 0 O-C-N 121.675 -0.641 . . . . 0.0 109.912 -173.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.852 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -131.12 141.41 50.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.905 -1.122 . . . . 0.0 111.068 -179.606 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.763 HG22 ' CB ' ' A' ' 60' ' ' SER . 6.8 t -122.51 133.17 69.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.053 -1.03 . . . . 0.0 110.677 -178.823 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.825 HG13 ' CE1' ' A' ' 61' ' ' PHE . 30.1 m -116.19 173.33 3.96 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.808 -0.557 . . . . 0.0 110.22 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.512 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 8.4 tt0 -104.44 116.44 32.13 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.434 -0.791 . . . . 0.0 108.942 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.83 HD21 HD13 ' A' ' 36' ' ' LEU . 9.6 tp -83.55 124.35 75.56 Favored Pre-proline 0 C--N 1.298 -1.649 0 O-C-N 121.475 -0.766 . . . . 0.0 110.059 -173.159 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.481 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 26.2 Cg_endo -66.42 176.61 3.92 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 123.923 1.486 . . . . 0.0 111.104 -179.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.487 ' HA ' HD12 ' A' ' 33' ' ' LEU . 47.4 t0 -60.09 -39.88 87.67 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.328 -0.858 . . . . 0.0 111.13 -175.467 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.596 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.64 0.06 57.19 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.756 -1.215 . . . . 0.0 110.576 -174.548 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.596 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.7 mmm -111.43 -14.1 13.78 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.037 -1.04 . . . . 0.0 109.813 170.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.582 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 17.5 mt -69.81 -39.97 76.21 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.271 -0.893 . . . . 0.0 110.308 177.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -78.06 129.37 35.15 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.23 -0.919 . . . . 0.0 110.337 -178.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.88 -42.96 1.87 Allowed Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.865 -1.159 . . . . 0.0 110.374 174.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.83 HD13 HD21 ' A' ' 28' ' ' LEU . 7.1 tt -66.79 146.65 54.2 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.932 -1.334 . . . . 0.0 110.508 -175.012 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.689 ' N ' HD23 ' A' ' 36' ' ' LEU . 14.7 pt-20 -149.97 164.38 35.63 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.556 -0.715 . . . . 0.0 109.672 -178.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.803 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -66.5 150.06 49.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 120.99 -1.069 . . . . 0.0 109.949 179.335 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.7 -4.81 63.39 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -173.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.54 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -76.62 153.54 35.18 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.225 -1.162 . . . . 0.0 109.519 177.145 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.52 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -97.82 109.23 22.02 Favored 'General case' 0 N--CA 1.485 1.283 0 O-C-N 121.016 -1.052 . . . . 0.0 110.086 178.153 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.63 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.2 t -95.37 133.1 37.56 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.224 -0.923 . . . . 0.0 109.129 173.737 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.509 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -95.9 119.9 35.22 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.112 -0.993 . . . . 0.0 109.071 171.417 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.637 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.3 OUTLIER -88.81 104.85 17.3 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.433 -0.792 . . . . 0.0 108.884 177.636 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.5 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 54.82 12.86 0.64 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.361 -0.837 . . . . 0.0 111.258 -168.513 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.489 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.34 -1.22 11.46 Favored Glycine 0 N--CA 1.49 2.283 0 C-N-CA 119.603 -1.284 . . . . 0.0 110.769 172.804 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.839 ' O ' HD23 ' A' ' 49' ' ' LEU . 36.1 t -93.85 109.71 21.4 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 120.531 -1.57 . . . . 0.0 109.517 175.275 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.7 p -74.44 128.26 35.1 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.113 -0.992 . . . . 0.0 110.984 -171.748 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.947 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -144.3 159.18 43.13 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.506 -0.746 . . . . 0.0 109.421 174.177 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 65.3 m -102.34 151.26 22.46 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.718 -1.239 . . . . 0.0 111.148 -172.022 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.848 HG13 HG13 ' A' ' 59' ' ' VAL . 21.3 t -78.44 119.77 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.728 -0.608 . . . . 0.0 110.641 -177.329 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 43.2 p -73.25 -43.84 60.46 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.242 -0.911 . . . . 0.0 110.15 174.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.617 ' HA ' HG21 ' A' ' 38' ' ' THR . 86.4 tt0 -159.32 151.22 20.67 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.319 -0.863 . . . . 0.0 110.468 -178.244 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.803 HD11 ' N ' ' A' ' 38' ' ' THR . 6.3 mt -102.87 133.13 47.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.172 -0.955 . . . . 0.0 109.953 174.724 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.51 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 44.9 m-80 -108.04 65.72 0.64 Allowed 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.492 -0.755 . . . . 0.0 109.703 178.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.93 -116.28 4.77 Favored Glycine 0 N--CA 1.489 2.17 0 N-CA-C 108.821 -1.712 . . . . 0.0 108.821 -174.091 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.582 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.35 -20.89 50.38 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.02 -1.282 . . . . 0.0 109.059 175.028 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.123 ' CD2' HG11 ' A' ' 13' ' ' VAL . 10.4 m170 -74.45 160.03 31.5 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.358 -0.839 . . . . 0.0 110.096 -177.109 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.848 HG13 HG13 ' A' ' 51' ' ' VAL . 54.9 t -140.37 122.88 16.14 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 O-C-N 121.006 -1.059 . . . . 0.0 110.808 171.117 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.763 ' CB ' HG22 ' A' ' 25' ' ' VAL . 3.0 m -89.46 128.96 36.02 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.643 -0.661 . . . . 0.0 109.586 177.162 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.947 ' HB2' HD12 ' A' ' 49' ' ' LEU . 3.1 p90 -123.23 155.5 37.01 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.026 -1.046 . . . . 0.0 110.082 178.643 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 29.6 p-10 -90.03 154.41 19.83 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.946 -1.096 . . . . 0.0 111.594 -170.377 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.801 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -158.85 123.96 4.23 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 109.014 -0.736 . . . . 0.0 109.014 -175.753 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.513 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 96.0 mtp -79.65 146.72 32.33 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.677 -1.264 . . . . 0.0 109.714 178.077 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.479 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 27.8 ttpt -60.01 -47.63 85.06 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.082 -1.011 . . . . 0.0 109.626 178.477 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.99 -40.03 75.55 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.214 -0.928 . . . . 0.0 110.833 179.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.62 ' O ' HG23 ' A' ' 71' ' ' THR . 23.6 m -65.51 -33.95 77.13 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 120.681 -1.262 . . . . 0.0 109.103 175.22 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.77 HD11 ' HA2' ' A' ' 74' ' ' GLY . 4.3 tp -60.04 -45.96 91.1 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.546 -0.721 . . . . 0.0 109.705 177.009 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 31.7 tpt180 -69.78 -40.05 76.27 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.304 -0.872 . . . . 0.0 110.54 178.477 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.805 HG22 HG23 ' A' ' 71' ' ' THR . 1.5 tt -63.94 -42.78 96.87 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.352 0 O-C-N 121.18 -0.95 . . . . 0.0 109.288 -178.681 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.805 HG23 HG22 ' A' ' 70' ' ' ILE . 20.9 p -83.59 -173.29 4.63 Favored 'General case' 0 C--N 1.298 -1.63 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 174.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 3.4 t30 -104.64 25.66 10.04 Favored 'General case' 0 C--N 1.294 -1.818 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 169.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.801 ' HB3' HD21 ' A' ' 63' ' ' LEU . 90.4 mt -68.07 -39.95 82.85 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.239 -0.913 . . . . 0.0 109.671 175.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.77 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -49.87 -23.7 5.51 Favored Glycine 0 N--CA 1.486 1.977 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.06 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 23.7 p-10 -64.52 -17.26 63.74 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.941 -1.329 . . . . 0.0 110.188 -176.202 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.518 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.7 mt -60.52 144.96 50.25 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.314 -0.866 . . . . 0.0 110.484 -178.454 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 1.011 ' C ' HD23 ' A' ' 12' ' ' LEU . 66.2 mttt -150.12 138.65 20.64 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 121.725 -0.609 . . . . 0.0 109.669 178.11 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.692 HG21 HG13 ' A' ' 15' ' ' ILE . 62.1 t -63.54 147.3 12.28 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 120.884 -1.135 . . . . 0.0 110.152 -175.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.98 -11.43 70.72 Favored Glycine 0 N--CA 1.483 1.805 0 N-CA-C 108.779 -1.729 . . . . 0.0 108.779 -172.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 41.7 t0 -100.88 162.25 13.03 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.392 -1.063 . . . . 0.0 109.722 176.408 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.591 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.4 m95 -114.09 159.9 19.52 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.144 -0.972 . . . . 0.0 109.976 177.268 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.061 HG13 ' HB3' ' A' ' 10' ' ' ALA . 0.9 OUTLIER -126.81 156.97 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.29 -0.881 . . . . 0.0 109.973 -177.516 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.818 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.4 m-20 -82.14 104.93 12.83 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.202 -0.936 . . . . 0.0 109.263 169.552 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.844 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -107.22 138.58 32.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 120.574 -1.329 . . . . 0.0 111.542 -175.564 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -131.63 147.55 52.53 Favored 'General case' 0 N--CA 1.494 1.738 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.994 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.489 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 38.2 ptt180 -87.92 131.77 34.47 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.135 -0.978 . . . . 0.0 110.627 -178.595 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.793 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -126.98 145.86 50.55 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.202 -0.936 . . . . 0.0 110.239 179.405 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -136.35 154.21 50.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.71 -0.619 . . . . 0.0 110.549 -178.098 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 28.7 mtpt -59.99 -39.99 87.61 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.266 -0.896 . . . . 0.0 110.301 179.033 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 42.9 p90 -132.74 161.55 33.74 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.266 -0.896 . . . . 0.0 110.221 -178.291 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 61.1 m -118.26 142.79 47.12 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.285 -0.884 . . . . 0.0 110.552 -176.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.455 ' O ' ' HB2' ' A' ' 93' ' ' GLU . 96.1 m-20 -61.86 -39.56 92.31 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.505 -0.747 . . . . 0.0 110.312 179.353 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.455 ' HB2' ' O ' ' A' ' 92' ' ' ASP . 96.6 mt-10 55.5 50.39 14.73 Favored 'General case' 0 N--CA 1.507 2.402 0 O-C-N 121.289 -0.882 . . . . 0.0 110.301 -179.307 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 61.1 mt -64.56 -41.15 91.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.548 -0.72 . . . . 0.0 110.254 178.391 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 127.71 -84.33 0.33 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.315 -1.514 . . . . 0.0 109.315 -178.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 83.9 -170.45 47.7 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 177.688 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.46 ' CG ' ' OXT' ' A' ' 97' ' ' HIS . 83.2 t60 . . . . . 0 N--CA 1.492 1.653 0 O-C-N 121.305 -1.115 . . . . 0.0 110.151 -179.346 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . 0.465 ' O ' ' HG3' ' B' ' 1' ' ' MET . 28.1 ptm . . . . . 0 N--CA 1.493 1.716 0 CA-C-O 121.163 0.506 . . . . 0.0 110.056 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.793 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 7.8 p90 -172.79 153.03 2.59 Favored 'General case' 0 C--N 1.306 -1.291 0 O-C-N 121.211 -0.931 . . . . 0.0 108.856 177.588 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.515 ' HB ' ' CD1' ' B' ' 5' ' ' ILE . 20.7 p -150.46 -39.08 0.13 Allowed 'General case' 0 C--N 1.296 -1.747 0 O-C-N 120.916 -1.115 . . . . 0.0 109.133 175.472 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.444 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 48.45 23.8 3.35 Favored Glycine 0 N--CA 1.484 1.878 0 N-CA-C 108.278 -1.929 . . . . 0.0 108.278 -175.487 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 0.548 HD11 ' C8M' ' A' ' 98' ' ' RBF . 66.1 mt -81.47 134.47 27.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.451 -1.029 . . . . 0.0 109.824 -176.67 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.831 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.7 t -87.91 139.58 17.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.022 -1.049 . . . . 0.0 111.074 -169.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 30.3 mm100 -69.94 -35.95 74.91 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.834 -0.541 . . . . 0.0 110.938 178.085 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.54 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -154.53 170.68 32.94 Favored Glycine 0 N--CA 1.495 2.596 0 C-N-CA 119.232 -1.461 . . . . 0.0 110.13 -172.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.447 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 4.2 p -114.43 173.82 6.27 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.992 -1.299 . . . . 0.0 111.246 -175.317 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.071 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -142.13 150.01 40.55 Favored 'General case' 0 N--CA 1.493 1.696 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 -177.534 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 38.3 tttt -107.52 116.78 32.56 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.109 -0.994 . . . . 0.0 110.126 177.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 1.028 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.9 tp -60.06 126.82 28.99 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.872 -1.142 . . . . 0.0 108.916 171.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.123 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.3 p -122.68 -31.74 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.849 0 O-C-N 121.387 -0.821 . . . . 0.0 109.859 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.84 146.67 28.07 Favored 'General case' 0 N--CA 1.493 1.706 0 C-N-CA 119.16 -1.016 . . . . 0.0 111.474 -179.333 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.856 HG23 ' CD2' ' B' ' 24' ' ' HIS . 7.6 mt -108.47 138.06 37.14 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.067 -1.021 . . . . 0.0 110.291 171.152 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.515 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 78.1 m-20 -109.32 115.7 30.47 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.46 -0.775 . . . . 0.0 109.754 172.054 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -104.51 112.28 25.28 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.097 -1.002 . . . . 0.0 110.312 -175.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 20.1 mmmt -115.64 129.29 25.26 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.325 -0.859 . . . . 0.0 109.161 177.247 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.426 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.4 Cg_endo -51.17 -31.25 35.46 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.721 1.379 . . . . 0.0 110.216 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.552 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 11.9 m-80 -74.42 -40.27 62.08 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.2 -0.937 . . . . 0.0 109.94 175.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.552 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 83.8 m-85 -156.07 150.4 25.64 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.289 -0.882 . . . . 0.0 110.357 -177.513 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.496 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 58.8 ttt180 -91.97 141.69 28.35 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.989 -1.069 . . . . 0.0 110.016 176.525 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.515 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 94.6 m -129.95 139.98 51.0 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 121.67 -0.644 . . . . 0.0 109.951 -173.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.856 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -131.06 141.4 50.18 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.021 -1.049 . . . . 0.0 111.046 -179.586 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.768 HG22 ' CB ' ' B' ' 60' ' ' SER . 6.7 t -122.47 133.3 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.157 -0.964 . . . . 0.0 110.744 -178.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.831 HG13 ' HE1' ' B' ' 61' ' ' PHE . 30.7 m -116.37 173.26 4.07 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.766 -0.583 . . . . 0.0 110.101 178.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.504 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 8.4 tt0 -104.32 116.56 32.37 Favored 'General case' 0 C--N 1.304 -1.388 0 N-CA-C 108.998 -0.742 . . . . 0.0 108.998 179.685 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.838 HD21 HD13 ' B' ' 36' ' ' LEU . 9.6 tp -83.57 124.32 75.56 Favored Pre-proline 0 C--N 1.299 -1.629 0 O-C-N 121.338 -0.851 . . . . 0.0 110.095 -173.164 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.476 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 26.0 Cg_endo -66.41 176.6 3.93 Favored 'Trans proline' 0 C--N 1.309 -1.513 0 O-C-N 123.858 1.452 . . . . 0.0 111.104 -179.483 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.489 ' HA ' HD12 ' B' ' 33' ' ' LEU . 47.4 t0 -60.0 -40.03 87.78 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.341 -0.849 . . . . 0.0 111.104 -175.49 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.586 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.56 0.1 57.14 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.753 -1.217 . . . . 0.0 110.658 -174.57 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.586 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.7 mmm -111.43 -14.11 13.78 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.055 -1.028 . . . . 0.0 109.828 170.266 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.596 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 17.8 mt -69.7 -40.06 76.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.358 -0.839 . . . . 0.0 110.338 177.628 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 55.8 t0 -78.01 129.38 35.2 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.282 -0.886 . . . . 0.0 110.432 -178.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.95 -43.08 1.85 Allowed Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.854 -1.165 . . . . 0.0 110.304 174.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.838 HD13 HD21 ' B' ' 28' ' ' LEU . 7.0 tt -66.81 146.68 54.17 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.866 -1.373 . . . . 0.0 110.533 -174.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . 0.681 ' N ' HD23 ' B' ' 36' ' ' LEU . 14.7 pt-20 -150.04 164.35 35.77 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.4 -0.812 . . . . 0.0 109.618 -178.664 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.795 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.49 149.94 49.7 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.031 -1.043 . . . . 0.0 109.962 179.369 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.85 -4.83 63.93 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 -174.048 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.542 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -76.63 153.35 35.32 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.293 -1.122 . . . . 0.0 109.592 177.024 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.523 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.1 OUTLIER -97.53 109.05 21.88 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 120.951 -1.093 . . . . 0.0 110.195 178.096 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.622 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.2 t -95.29 133.13 37.35 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.454 0 O-C-N 121.253 -0.904 . . . . 0.0 109.154 173.723 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.504 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -95.89 119.87 35.16 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 119.204 -0.999 . . . . 0.0 109.181 171.284 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.643 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.3 OUTLIER -88.79 104.66 17.11 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.302 -0.874 . . . . 0.0 108.966 177.696 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.5 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 55.01 12.88 0.67 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.54 -0.725 . . . . 0.0 111.291 -168.491 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.489 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.15 -0.79 11.63 Favored Glycine 0 N--CA 1.491 2.346 0 C-N-CA 119.662 -1.256 . . . . 0.0 110.75 172.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.844 ' O ' HD23 ' B' ' 49' ' ' LEU . 36.0 t -94.03 109.68 21.42 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.45 -1.617 . . . . 0.0 109.54 175.134 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 18.7 p -74.4 128.41 35.47 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.095 -1.003 . . . . 0.0 110.965 -171.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 0.943 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -144.5 159.1 43.32 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.541 -0.724 . . . . 0.0 109.387 174.129 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 64.9 m -102.22 151.38 22.28 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 120.705 -1.247 . . . . 0.0 111.112 -171.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.828 HG13 HG13 ' B' ' 59' ' ' VAL . 21.4 t -78.65 119.94 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.727 -0.608 . . . . 0.0 110.584 -177.27 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 43.3 p -73.32 -43.93 59.93 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.17 -0.956 . . . . 0.0 110.159 174.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.641 ' HA ' HG21 ' B' ' 38' ' ' THR . 86.5 tt0 -159.24 151.36 20.99 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.331 -0.856 . . . . 0.0 110.455 -178.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.795 HD11 ' N ' ' B' ' 38' ' ' THR . 6.3 mt -103.0 133.0 48.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.102 -0.999 . . . . 0.0 109.933 174.789 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.527 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 44.8 m-80 -108.0 65.74 0.64 Allowed 'General case' 0 C--N 1.299 -1.597 0 C-N-CA 119.972 -0.691 . . . . 0.0 109.679 179.014 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.08 -116.31 4.74 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 108.711 -1.756 . . . . 0.0 108.711 -174.22 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.596 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.31 -21.09 50.17 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 120.983 -1.304 . . . . 0.0 109.049 175.069 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.123 ' CD2' HG11 ' B' ' 13' ' ' VAL . 10.6 m170 -74.17 159.77 32.1 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.474 -0.766 . . . . 0.0 110.252 -177.239 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.828 HG13 HG13 ' B' ' 51' ' ' VAL . 55.8 t -140.24 122.87 16.46 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 C-N-CA 119.094 -1.042 . . . . 0.0 110.877 171.177 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.768 ' CB ' HG22 ' B' ' 25' ' ' VAL . 3.0 m -89.61 128.97 36.12 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.751 -0.593 . . . . 0.0 109.556 177.304 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.943 ' HB2' HD12 ' B' ' 49' ' ' LEU . 3.1 p90 -123.21 155.56 36.88 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.113 -0.992 . . . . 0.0 110.07 178.71 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 29.7 p-10 -90.1 154.4 19.81 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.818 -1.176 . . . . 0.0 111.554 -170.273 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.77 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -158.78 124.04 4.3 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 -175.764 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.521 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 96.0 mtp -79.74 146.68 32.23 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.631 -1.293 . . . . 0.0 109.706 178.029 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.477 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 27.9 ttpt -60.07 -47.61 85.15 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.195 -0.941 . . . . 0.0 109.542 178.562 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.95 -40.01 75.71 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.186 -0.946 . . . . 0.0 110.896 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.638 ' O ' HG23 ' B' ' 71' ' ' THR . 23.7 m -65.48 -34.14 77.57 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.649 -1.282 . . . . 0.0 109.021 175.204 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.771 HD11 ' HA2' ' B' ' 74' ' ' GLY . 4.3 tp -60.04 -45.67 92.08 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.571 -0.706 . . . . 0.0 109.844 177.039 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 31.6 tpt180 -70.01 -39.99 75.5 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.278 -0.889 . . . . 0.0 110.498 178.401 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.798 HG22 HG23 ' B' ' 71' ' ' THR . 1.5 tt -63.85 -42.7 96.72 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.221 -0.924 . . . . 0.0 109.332 -178.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.798 HG23 HG22 ' B' ' 70' ' ' ILE . 21.3 p -83.71 -173.08 4.51 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 109.16 -0.682 . . . . 0.0 109.16 174.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.511 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 3.4 t30 -104.79 25.59 10.21 Favored 'General case' 0 C--N 1.293 -1.865 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 169.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.77 ' HB3' HD21 ' B' ' 63' ' ' LEU . 90.1 mt -68.07 -40.02 82.83 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.149 -0.97 . . . . 0.0 109.636 176.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.771 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -49.82 -23.74 5.46 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 -179.061 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.519 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 23.3 p-10 -64.46 -17.22 63.63 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.07 -1.253 . . . . 0.0 110.218 -176.227 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.519 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 97.7 mt -60.51 144.93 50.26 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.262 -0.899 . . . . 0.0 110.441 -178.47 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 1.028 ' C ' HD23 ' B' ' 12' ' ' LEU . 66.1 mttt -150.09 138.62 20.65 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.626 -0.671 . . . . 0.0 109.696 178.077 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.701 HG21 HG13 ' B' ' 15' ' ' ILE . 62.0 t -63.56 147.26 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.042 -1.036 . . . . 0.0 110.178 -175.513 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.0 -11.15 71.6 Favored Glycine 0 N--CA 1.484 1.85 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 -172.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 41.5 t0 -101.08 162.09 13.14 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.333 -1.098 . . . . 0.0 109.695 176.408 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.4 m95 -114.0 159.79 19.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.195 -0.941 . . . . 0.0 110.031 177.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.071 HG13 ' HB3' ' B' ' 10' ' ' ALA . 0.8 OUTLIER -126.77 157.12 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.402 -0.811 . . . . 0.0 109.896 -177.611 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.831 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.3 m-20 -82.17 104.86 12.81 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.277 -0.89 . . . . 0.0 109.29 169.601 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.843 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -107.13 138.77 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 120.665 -1.272 . . . . 0.0 111.453 -175.426 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -131.84 147.62 52.49 Favored 'General case' 0 N--CA 1.492 1.666 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.983 179.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . 0.489 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 38.2 ptt180 -87.89 131.84 34.42 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.166 -0.959 . . . . 0.0 110.568 -178.525 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 0.913 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -127.0 145.74 50.6 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.335 -0.853 . . . . 0.0 110.214 179.368 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . 0.403 ' N ' ' CE2' ' A' ' 2' ' ' PHE . . . -136.38 154.2 50.89 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.689 -0.632 . . . . 0.0 110.54 -178.171 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 28.7 mtpt -59.99 -40.0 87.66 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.293 -0.879 . . . . 0.0 110.225 179.189 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 43.0 p90 -132.75 161.43 34.07 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.209 -0.932 . . . . 0.0 110.23 -178.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . . . . . . . . . 61.0 m -118.2 142.84 47.04 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.307 -0.871 . . . . 0.0 110.553 -176.581 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -62.11 -39.98 94.35 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.36 -0.838 . . . . 0.0 110.278 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . 0.447 ' O ' ' HB ' ' B' ' 94' ' ' ILE . 18.6 pt-20 -138.79 56.44 1.7 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.321 -0.862 . . . . 0.0 110.362 -177.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . 0.704 HG22 ' O ' ' B' ' 94' ' ' ILE . 16.0 mm 53.37 21.86 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.503 2.196 0 O-C-N 121.242 -0.911 . . . . 0.0 109.199 179.027 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . -73.15 65.9 1.55 Allowed Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 178.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -76.82 146.52 32.53 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.039 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 58.6 m-70 . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.282 -1.128 . . . . 0.0 110.212 -178.849 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 0.548 ' C8M' HD11 ' B' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 0.651 ' C8M' HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 98.6 mmm . . . . . 0 N--CA 1.492 1.641 0 CA-C-O 121.154 0.502 . . . . 0.0 109.973 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.768 ' HE2' ' HB1' ' B' ' 87' ' ' ALA . 1.3 p90 -169.9 132.09 1.1 Allowed 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.17 -0.956 . . . . 0.0 109.311 179.589 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.523 ' O ' HG13 ' A' ' 5' ' ' ILE . 34.7 p -128.8 -31.23 2.2 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.061 -1.024 . . . . 0.0 110.212 -178.196 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' B' ' 46' ' ' GLY . . . 45.8 24.44 1.27 Allowed Glycine 0 N--CA 1.487 2.061 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 -174.1 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.965 HD11 ' C8M' ' B' ' 99' ' ' RBF . 53.0 mt -85.25 144.21 10.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 120.979 -1.306 . . . . 0.0 110.533 -177.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.882 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.3 t -88.87 144.47 9.05 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 121.345 -0.847 . . . . 0.0 110.919 -175.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 99.4 mt-30 -70.04 -31.79 69.6 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.867 -0.521 . . . . 0.0 111.021 179.197 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.538 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -156.38 -177.97 30.06 Favored Glycine 0 N--CA 1.499 2.862 0 C-N-CA 118.541 -1.79 . . . . 0.0 110.795 -170.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.498 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.0 p -129.08 167.25 17.81 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.792 -1.417 . . . . 0.0 110.95 -178.435 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.039 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -139.97 149.84 43.75 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.597 -0.69 . . . . 0.0 109.201 -175.021 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.583 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 34.5 tttt -109.24 115.77 30.63 Favored 'General case' 0 C--N 1.294 -1.816 0 O-C-N 121.013 -1.055 . . . . 0.0 110.362 -179.12 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.995 HD23 ' C ' ' A' ' 77' ' ' LYS . 11.5 tp -59.98 127.68 33.08 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.916 -1.115 . . . . 0.0 108.863 172.622 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.117 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.6 p -127.01 -29.32 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.921 0 C-N-CA 119.6 -0.84 . . . . 0.0 109.932 -179.045 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.75 144.15 24.11 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 118.959 -1.096 . . . . 0.0 111.243 179.23 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.889 HG23 ' CD2' ' A' ' 24' ' ' HIS . 8.8 mt -107.9 141.03 24.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.187 -0.946 . . . . 0.0 110.233 174.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.511 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 79.7 m-20 -109.79 113.87 26.97 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.238 -0.914 . . . . 0.0 109.972 172.247 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -101.24 113.13 25.89 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.109 -0.995 . . . . 0.0 110.427 -178.099 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.0 OUTLIER -109.77 134.4 20.64 Favored Pre-proline 0 N--CA 1.49 1.525 0 O-C-N 121.197 -0.939 . . . . 0.0 109.499 176.005 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.64 -16.65 11.4 Favored 'Trans proline' 0 C--N 1.303 -1.854 0 O-C-N 123.973 1.512 . . . . 0.0 110.652 -179.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.572 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 4.9 m-80 -100.8 -26.57 13.73 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.129 -0.982 . . . . 0.0 110.035 179.23 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.572 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 92.9 m-85 -157.81 150.2 22.48 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.437 -0.789 . . . . 0.0 109.857 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.918 ' HD3' HD22 ' A' ' 68' ' ' LEU . 57.1 ttt180 -93.54 141.16 28.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.6 -1.312 . . . . 0.0 110.026 174.196 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.511 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.3 m -129.97 141.03 50.82 Favored 'General case' 0 C--N 1.294 -1.814 0 O-C-N 121.698 -0.626 . . . . 0.0 109.835 -173.703 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.889 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -129.98 143.6 50.88 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.012 -1.055 . . . . 0.0 111.612 -179.156 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.881 HG22 ' OG ' ' A' ' 60' ' ' SER . 6.4 t -123.34 132.88 70.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.11 -0.994 . . . . 0.0 110.613 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.801 HG13 ' CE1' ' A' ' 61' ' ' PHE . 26.0 m -114.9 174.48 2.93 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 C-N-CA 120.376 -0.529 . . . . 0.0 110.326 178.509 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.535 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 12.8 tt0 -104.38 118.61 37.03 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 179.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.555 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.5 tp -81.21 122.57 81.52 Favored Pre-proline 0 C--N 1.297 -1.708 0 O-C-N 121.7 -0.625 . . . . 0.0 109.626 -174.75 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.489 ' HD2' HD12 ' A' ' 28' ' ' LEU . 18.3 Cg_endo -63.44 174.07 3.79 Favored 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 123.907 1.477 . . . . 0.0 110.572 -179.307 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.709 ' HA ' HD12 ' A' ' 33' ' ' LEU . 53.4 t0 -60.01 -39.47 85.91 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.412 -0.805 . . . . 0.0 110.611 -177.011 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.603 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.95 -0.1 57.39 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.843 -1.161 . . . . 0.0 110.894 -175.012 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.603 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 95.9 mmm -109.71 -11.73 14.7 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 120.87 -1.143 . . . . 0.0 109.824 170.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.709 HD12 ' HA ' ' A' ' 30' ' ' ASP . 15.3 mt -69.23 -40.1 78.13 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.323 -0.861 . . . . 0.0 110.312 179.225 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 53.5 t0 -79.98 123.89 28.21 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.349 -0.844 . . . . 0.0 110.527 -177.06 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.12 -47.09 1.08 Allowed Glycine 0 N--CA 1.492 2.377 0 C-N-CA 119.829 -1.177 . . . . 0.0 110.401 175.128 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.85 HD23 ' N ' ' A' ' 37' ' ' GLU . 8.2 tt -67.34 147.37 53.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.985 -1.303 . . . . 0.0 110.727 -175.068 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.85 ' N ' HD23 ' A' ' 36' ' ' LEU . 21.3 pt-20 -149.96 169.07 22.04 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.378 -0.826 . . . . 0.0 109.656 -179.64 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.822 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -66.81 148.92 51.29 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.986 -1.071 . . . . 0.0 110.087 -179.985 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.9 -10.05 58.43 Favored Glycine 0 N--CA 1.492 2.377 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 -175.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.432 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -71.25 157.87 37.37 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.245 -1.15 . . . . 0.0 109.272 174.706 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.893 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 1.6 p -105.34 116.82 32.59 Favored 'General case' 0 C--N 1.307 -1.265 0 C-N-CA 118.533 -1.267 . . . . 0.0 109.754 176.012 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.619 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.6 t -99.63 126.38 53.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 121.333 -0.854 . . . . 0.0 109.006 175.353 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.512 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -88.31 119.53 28.81 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.234 -0.986 . . . . 0.0 109.089 173.374 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.738 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -89.75 105.43 17.8 Favored 'General case' 0 C--N 1.302 -1.485 0 C-N-CA 119.729 -0.788 . . . . 0.0 108.939 177.955 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.8 t-20 56.84 9.87 0.67 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.527 -0.733 . . . . 0.0 111.514 -170.316 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' B' ' 4' ' ' GLY . . . 126.57 -2.15 7.55 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.553 -1.308 . . . . 0.0 110.86 173.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.902 ' O ' HD23 ' A' ' 49' ' ' LEU . 50.2 t -98.63 104.86 16.93 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 120.521 -1.576 . . . . 0.0 109.756 176.236 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.54 ' SG ' HC72 ' A' ' 98' ' ' RBF . 25.5 p -71.36 128.91 37.44 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.176 -0.952 . . . . 0.0 110.727 -174.453 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.927 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -141.41 159.98 41.08 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.445 -0.785 . . . . 0.0 109.262 173.942 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.415 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 23.9 m -99.88 150.05 22.78 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 120.45 -1.406 . . . . 0.0 111.347 -170.252 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.779 HG13 HG13 ' A' ' 59' ' ' VAL . 34.9 t -76.25 116.44 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.941 -0.475 . . . . 0.0 110.318 -179.182 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.537 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 28.3 p -71.91 -39.96 69.15 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.365 -0.835 . . . . 0.0 109.789 174.186 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.573 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -163.27 152.9 15.21 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.272 -0.893 . . . . 0.0 110.362 -179.031 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.822 HD11 ' N ' ' A' ' 38' ' ' THR . 7.6 mt -105.52 132.14 53.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.193 -0.942 . . . . 0.0 109.965 175.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.509 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 26.6 m-80 -104.92 64.78 0.73 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.63 -0.669 . . . . 0.0 109.594 179.229 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.65 -116.95 5.3 Favored Glycine 0 N--CA 1.487 2.097 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 -173.126 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.68 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -77.0 -20.74 55.68 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.015 -1.285 . . . . 0.0 109.153 175.727 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.117 ' CD2' HG11 ' A' ' 13' ' ' VAL . 11.2 m80 -75.64 159.98 30.59 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.33 -0.856 . . . . 0.0 110.192 -177.593 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.779 HG13 HG13 ' A' ' 51' ' ' VAL . 53.6 t -140.69 123.07 15.55 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 C-N-CA 119.133 -1.027 . . . . 0.0 110.74 173.208 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.881 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.3 t -90.71 134.61 34.29 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.48 -0.762 . . . . 0.0 109.416 177.329 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.927 ' HB2' HD12 ' A' ' 49' ' ' LEU . 2.7 p90 -126.75 151.17 48.56 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.366 -0.833 . . . . 0.0 110.318 176.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.537 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 38.2 p-10 -86.66 154.87 20.67 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.084 -1.01 . . . . 0.0 111.422 -171.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.835 HD22 HD13 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -161.9 100.42 1.12 Allowed 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.754 -0.591 . . . . 0.0 109.546 -175.49 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.471 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 33.0 ttp -60.68 140.06 57.63 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.883 -1.135 . . . . 0.0 109.52 -178.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.487 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 29.4 tptp -60.07 -48.31 82.23 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.891 -1.13 . . . . 0.0 110.473 -172.69 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -63.21 -39.99 96.19 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.714 -1.241 . . . . 0.0 109.806 177.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.492 HG21 ' O2 ' ' A' ' 98' ' ' RBF . 55.2 m -60.05 -39.98 87.84 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.052 -1.03 . . . . 0.0 109.602 172.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.918 HD22 ' HD3' ' A' ' 22' ' ' ARG . 27.0 tp -61.64 -40.8 96.16 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.446 -0.784 . . . . 0.0 109.816 -179.592 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 15.5 ttm180 -69.92 -40.12 75.75 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.275 -0.891 . . . . 0.0 110.441 177.086 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.687 HG22 HG23 ' A' ' 71' ' ' THR . 1.2 tt -64.78 -44.58 96.42 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.285 -0.884 . . . . 0.0 109.602 -176.569 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.687 HG23 HG22 ' A' ' 70' ' ' ILE . 30.5 p -79.99 -174.98 4.73 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.561 -0.712 . . . . 0.0 109.25 175.258 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.514 ' HB2' ' N ' ' B' ' 83' ' ' ASN . 4.1 t30 -99.97 23.34 9.95 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.013 -1.054 . . . . 0.0 108.459 169.32 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.692 ' HB3' HD21 ' A' ' 63' ' ' LEU . 87.7 mt -69.18 -40.02 78.37 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.071 -1.018 . . . . 0.0 109.799 174.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.548 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -46.81 -22.44 1.15 Allowed Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.619 -0.993 . . . . 0.0 110.619 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.3 p-10 -68.98 -17.01 63.87 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 120.958 -1.319 . . . . 0.0 110.534 -174.668 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.503 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 98.4 mt -59.93 141.18 55.98 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.226 -0.921 . . . . 0.0 111.042 -176.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 0.995 ' C ' HD23 ' A' ' 12' ' ' LEU . 24.9 mttm -142.38 143.04 32.51 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.734 -0.604 . . . . 0.0 109.762 173.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.646 HG23 HD11 ' A' ' 15' ' ' ILE . 32.2 t -63.15 150.09 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.914 -1.116 . . . . 0.0 110.391 -177.209 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.46 -14.82 60.17 Favored Glycine 0 N--CA 1.485 1.916 0 N-CA-C 108.71 -1.756 . . . . 0.0 108.71 -175.646 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.494 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 41.9 t0 -94.28 167.7 11.37 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.328 -1.101 . . . . 0.0 109.637 175.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.583 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.2 m95 -116.67 158.8 23.2 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 120.976 -1.077 . . . . 0.0 110.036 175.038 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.039 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.1 p -121.28 155.27 25.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.389 -0.82 . . . . 0.0 109.917 179.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.882 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -78.51 105.56 9.86 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 120.993 -1.067 . . . . 0.0 109.003 168.06 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.834 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -106.64 137.84 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 120.548 -1.345 . . . . 0.0 111.048 -176.96 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -138.98 140.09 38.11 Favored 'General case' 0 N--CA 1.492 1.629 0 C-N-CA 120.291 -0.564 . . . . 0.0 109.991 -177.319 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 53.0 ttt85 -60.06 127.05 29.97 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.155 -0.966 . . . . 0.0 110.293 -179.508 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.893 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . -121.62 148.38 44.61 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.341 -0.849 . . . . 0.0 109.554 176.57 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.551 ' O ' ' CD1' ' B' ' 2' ' ' PHE . . . -132.72 147.56 52.33 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.255 -0.903 . . . . 0.0 111.401 -174.067 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.541 ' HA ' ' CE1' ' B' ' 2' ' ' PHE . 10.3 pttt -71.87 -16.93 62.15 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.362 -0.836 . . . . 0.0 109.672 171.784 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 44.4 p90 -122.31 161.55 23.14 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.43 -0.794 . . . . 0.0 110.081 178.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.53 ' HB2' ' CG1' ' A' ' 94' ' ' ILE . 53.3 m -60.0 130.58 47.41 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.229 -0.919 . . . . 0.0 110.498 -176.124 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -69.48 -35.43 75.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.398 -0.814 . . . . 0.0 110.145 178.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 81.5 mm-40 -88.29 44.96 1.24 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.154 -0.966 . . . . 0.0 110.272 -179.777 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.633 HG22 ' O ' ' A' ' 94' ' ' ILE . 15.1 mm -130.19 4.74 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.622 -0.674 . . . . 0.0 110.253 175.268 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -58.55 82.41 0.01 OUTLIER Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -178.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.51 ' N ' ' O ' ' A' ' 94' ' ' ILE . . . 179.98 175.92 47.01 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.538 -1.425 . . . . 0.0 109.538 179.346 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.252 -1.146 . . . . 0.0 110.14 179.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . 0.463 ' O ' ' HG3' ' B' ' 1' ' ' MET . 8.7 ptt? . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 121.239 0.542 . . . . 0.0 110.38 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.78 ' HE2' ' HB1' ' A' ' 87' ' ' ALA . 1.4 p90 -168.42 132.16 1.55 Allowed 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.274 -0.891 . . . . 0.0 109.122 175.551 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.523 ' O ' HG13 ' B' ' 5' ' ' ILE . 34.7 p -128.84 -31.35 2.18 Favored 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.059 -1.026 . . . . 0.0 110.226 -178.305 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' A' ' 46' ' ' GLY . . . 45.85 24.53 1.32 Allowed Glycine 0 N--CA 1.487 2.06 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -174.114 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 0.948 HD11 ' C8M' ' A' ' 98' ' ' RBF . 53.0 mt -85.25 144.29 9.94 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 120.98 -1.306 . . . . 0.0 110.588 -178.062 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.922 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.3 t -88.99 144.41 9.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.365 -0.834 . . . . 0.0 110.945 -175.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 99.5 mt-30 -69.98 -31.72 69.55 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.785 -0.572 . . . . 0.0 111.025 179.27 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.549 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -156.49 -178.09 30.28 Favored Glycine 0 N--CA 1.499 2.895 0 C-N-CA 118.632 -1.747 . . . . 0.0 110.857 -170.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.503 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.0 p -129.03 167.13 17.94 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.913 -1.345 . . . . 0.0 111.028 -178.426 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.098 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -139.88 150.04 44.13 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 -175.179 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.579 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 34.5 tttt -109.3 115.81 30.68 Favored 'General case' 0 C--N 1.295 -1.772 0 O-C-N 121.028 -1.045 . . . . 0.0 110.294 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 1.012 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.5 tp -60.24 127.61 32.64 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 120.945 -1.097 . . . . 0.0 108.905 172.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.123 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -126.84 -29.38 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.874 0 O-C-N 121.345 -0.847 . . . . 0.0 110.034 -178.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.67 144.11 24.14 Favored 'General case' 0 C--N 1.297 -1.681 0 C-N-CA 119.225 -0.99 . . . . 0.0 111.243 179.224 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.89 HG23 ' CD2' ' B' ' 24' ' ' HIS . 8.9 mt -107.88 141.1 23.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.292 -0.88 . . . . 0.0 110.242 174.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.499 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 79.5 m-20 -109.92 113.98 27.15 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.364 -0.835 . . . . 0.0 109.961 172.243 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -101.22 113.08 25.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.155 -0.966 . . . . 0.0 110.444 -178.06 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.465 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.0 OUTLIER -109.87 134.36 20.68 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.311 -0.868 . . . . 0.0 109.442 176.043 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.71 -16.66 11.62 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 O-C-N 123.971 1.511 . . . . 0.0 110.662 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 4.8 m-80 -100.51 -27.16 13.57 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.087 -1.008 . . . . 0.0 109.939 179.111 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 93.0 m-85 -157.37 150.33 23.44 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.416 -0.802 . . . . 0.0 109.814 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.904 ' HD3' HD22 ' B' ' 68' ' ' LEU . 57.0 ttt180 -93.62 141.16 28.79 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.67 -1.269 . . . . 0.0 110.036 174.137 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.499 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 94.7 m -129.95 141.07 50.82 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.579 -0.701 . . . . 0.0 109.767 -173.683 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.89 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -129.93 143.78 50.98 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 120.989 -1.069 . . . . 0.0 111.472 -179.161 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.874 HG22 ' OG ' ' B' ' 60' ' ' SER . 6.4 t -123.38 132.93 70.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.475 0 O-C-N 121.161 -0.962 . . . . 0.0 110.709 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.81 HG13 ' HE1' ' B' ' 61' ' ' PHE . 26.7 m -115.08 174.44 3.0 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 121.688 -0.633 . . . . 0.0 110.226 178.677 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.518 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 12.8 tt0 -104.28 118.65 37.13 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.455 -0.778 . . . . 0.0 108.972 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.558 HD23 ' HA ' ' B' ' 33' ' ' LEU . 9.5 tp -81.13 122.58 81.69 Favored Pre-proline 0 C--N 1.296 -1.738 0 O-C-N 121.573 -0.704 . . . . 0.0 109.651 -174.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.496 ' HD2' HD12 ' B' ' 28' ' ' LEU . 18.2 Cg_endo -63.43 174.01 3.84 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.842 1.443 . . . . 0.0 110.564 -179.35 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.691 ' HA ' HD12 ' B' ' 33' ' ' LEU . 53.2 t0 -60.02 -39.46 85.93 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.501 -0.749 . . . . 0.0 110.56 -176.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.599 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.03 0.05 57.32 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.932 -1.105 . . . . 0.0 110.848 -174.974 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.599 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 95.8 mmm -109.73 -11.75 14.7 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.83 -1.169 . . . . 0.0 109.846 170.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.714 HD21 ' HB2' ' B' ' 57' ' ' ASN . 15.3 mt -69.26 -40.02 78.09 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.32 -0.863 . . . . 0.0 110.305 179.272 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -80.06 123.91 28.27 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.266 -0.896 . . . . 0.0 110.463 -177.054 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.11 -47.1 1.08 Allowed Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.784 -1.198 . . . . 0.0 110.391 175.116 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.851 HD23 ' N ' ' B' ' 37' ' ' GLU . 8.2 tt -67.26 147.3 53.19 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.001 -1.294 . . . . 0.0 110.805 -175.093 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . 0.851 ' N ' HD23 ' B' ' 36' ' ' LEU . 21.3 pt-20 -150.02 168.94 22.41 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.432 -0.792 . . . . 0.0 109.677 -179.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.824 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -66.77 148.86 51.37 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.95 -1.094 . . . . 0.0 110.106 -179.912 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.0 -10.09 58.78 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -175.509 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.445 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -71.33 157.76 37.53 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.17 -1.194 . . . . 0.0 109.102 174.669 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.913 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 1.7 p -105.02 116.44 31.96 Favored 'General case' 0 C--N 1.298 -1.666 0 C-N-CA 118.844 -1.142 . . . . 0.0 109.968 175.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.623 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.5 t -99.9 126.4 53.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.472 -0.768 . . . . 0.0 108.971 175.432 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.509 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -88.23 119.43 28.63 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 121.094 -1.004 . . . . 0.0 109.16 173.401 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.748 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -89.7 105.26 17.68 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.369 -0.832 . . . . 0.0 109.019 177.934 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.8 t-20 57.13 9.77 0.72 Allowed 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.515 -0.74 . . . . 0.0 111.464 -170.427 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 4' ' ' GLY . . . 126.55 -1.93 7.55 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.504 -1.332 . . . . 0.0 110.84 173.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.888 ' O ' HD23 ' B' ' 49' ' ' LEU . 50.1 t -98.85 104.79 16.87 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.534 -1.568 . . . . 0.0 109.707 176.257 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . 0.537 ' SG ' HC72 ' B' ' 99' ' ' RBF . 25.1 p -71.17 129.07 37.99 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.124 -0.985 . . . . 0.0 110.667 -174.489 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 0.952 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -141.65 159.85 41.37 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.348 -0.845 . . . . 0.0 109.239 173.857 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . 0.42 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 23.7 m -99.69 150.02 22.72 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.588 -1.32 . . . . 0.0 111.412 -170.232 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.812 HG13 HG13 ' B' ' 59' ' ' VAL . 32.6 t -76.23 116.47 19.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.855 -0.528 . . . . 0.0 110.382 -179.225 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.536 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 28.6 p -71.92 -40.04 69.07 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.297 -0.877 . . . . 0.0 109.722 174.29 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.576 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -163.21 152.83 15.26 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.342 -0.849 . . . . 0.0 110.421 -178.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.824 HD11 ' N ' ' B' ' 38' ' ' THR . 7.6 mt -105.51 132.03 53.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.295 -0.878 . . . . 0.0 110.012 175.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.525 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 26.5 m-80 -104.87 64.82 0.73 Allowed 'General case' 0 C--N 1.297 -1.698 0 C-N-CA 120.048 -0.661 . . . . 0.0 109.562 179.285 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.72 -117.0 5.3 Favored Glycine 0 N--CA 1.487 2.063 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 -173.182 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.714 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -76.97 -20.9 55.54 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.076 -1.249 . . . . 0.0 109.164 175.73 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.123 ' CD2' HG11 ' B' ' 13' ' ' VAL . 11.2 m80 -75.59 159.79 30.83 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.338 -0.851 . . . . 0.0 110.285 -177.683 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.812 HG13 HG13 ' B' ' 51' ' ' VAL . 56.7 t -140.46 123.1 16.18 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 C-N-CA 119.088 -1.045 . . . . 0.0 110.76 173.361 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.874 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.3 t -90.67 134.67 34.24 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.481 -0.762 . . . . 0.0 109.54 177.278 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.952 ' HB2' HD12 ' B' ' 49' ' ' LEU . 2.7 p90 -126.93 151.05 49.0 Favored 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 119.556 -0.858 . . . . 0.0 110.314 176.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.536 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 38.2 p-10 -86.39 154.81 20.9 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.927 -1.108 . . . . 0.0 111.442 -171.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.85 HD22 HD13 ' B' ' 68' ' ' LEU . 0.0 OUTLIER -161.94 100.42 1.12 Allowed 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.76 -0.588 . . . . 0.0 109.608 -175.614 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.486 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 33.0 ttp -60.67 139.99 57.64 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.836 -1.165 . . . . 0.0 109.53 -178.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.485 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 29.5 tptp -59.94 -48.41 81.81 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.946 -1.096 . . . . 0.0 110.469 -172.69 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 87.2 tt0 -63.24 -40.02 96.25 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.792 -1.193 . . . . 0.0 109.792 177.467 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.502 HG23 " O4'" ' B' ' 99' ' ' RBF . 55.5 m -60.01 -39.88 87.36 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.188 -0.945 . . . . 0.0 109.657 172.691 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.904 HD22 ' HD3' ' B' ' 22' ' ' ARG . 27.1 tp -61.73 -40.66 95.84 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.504 -0.748 . . . . 0.0 109.892 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 15.6 ttm180 -69.96 -40.01 75.66 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.34 -0.85 . . . . 0.0 110.52 176.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.692 HG22 HG23 ' B' ' 71' ' ' THR . 1.2 tt -64.87 -44.47 96.25 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.296 -0.877 . . . . 0.0 109.623 -176.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.692 HG23 HG22 ' B' ' 70' ' ' ILE . 30.4 p -80.18 -174.89 4.76 Favored 'General case' 0 C--N 1.301 -1.538 0 C-N-CA 119.84 -0.744 . . . . 0.0 109.294 175.247 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.501 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 3.9 t30 -99.97 23.41 9.87 Favored 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.069 -1.02 . . . . 0.0 108.406 169.458 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.671 ' HB3' HD21 ' B' ' 63' ' ' LEU . 87.7 mt -69.25 -40.03 78.11 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.09 -1.006 . . . . 0.0 109.768 174.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.546 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -46.81 -22.38 1.14 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -179.365 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.3 p-10 -69.08 -16.9 63.79 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.905 -1.35 . . . . 0.0 110.488 -174.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.503 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.3 mt -60.1 141.29 56.04 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.229 -0.92 . . . . 0.0 111.06 -176.867 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 1.012 ' C ' HD23 ' B' ' 12' ' ' LEU . 24.9 mttm -142.47 143.07 32.42 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.725 -0.61 . . . . 0.0 109.694 174.073 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.663 HG23 HD11 ' B' ' 15' ' ' ILE . 32.7 t -63.19 150.05 9.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.924 -1.11 . . . . 0.0 110.317 -177.188 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.38 -14.7 60.4 Favored Glycine 0 N--CA 1.486 1.974 0 N-CA-C 108.777 -1.729 . . . . 0.0 108.777 -175.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.488 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 41.8 t0 -94.43 167.68 11.36 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.426 -1.044 . . . . 0.0 109.635 175.749 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.579 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.1 m95 -116.64 158.83 23.12 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.074 -1.016 . . . . 0.0 110.068 175.088 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.098 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.0 OUTLIER -121.32 155.33 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.419 -0.801 . . . . 0.0 109.887 179.457 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.922 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.2 OUTLIER -78.39 105.29 9.55 Favored 'General case' 0 C--N 1.297 -1.674 0 O-C-N 121.105 -0.997 . . . . 0.0 109.147 168.007 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.836 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -106.49 138.12 33.61 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 120.596 -1.315 . . . . 0.0 110.894 -176.821 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -139.29 140.21 37.55 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 120.268 -0.573 . . . . 0.0 109.914 -177.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 53.0 ttt85 -59.99 127.04 29.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.176 -0.953 . . . . 0.0 110.267 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 0.913 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . -121.28 148.95 43.62 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.442 -0.786 . . . . 0.0 109.444 176.564 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . 0.558 ' O ' ' CD1' ' A' ' 2' ' ' PHE . . . -133.3 147.47 51.89 Favored 'General case' 0 N--CA 1.492 1.639 0 C-N-CA 119.454 -0.899 . . . . 0.0 111.331 -174.287 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . 0.535 ' HA ' ' CE1' ' A' ' 2' ' ' PHE . 10.3 pttt -71.76 -16.93 62.22 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.42 -0.8 . . . . 0.0 109.657 171.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 44.4 p90 -122.4 161.62 23.13 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.475 -0.766 . . . . 0.0 110.009 179.092 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . 0.527 ' HB3' ' CG1' ' B' ' 94' ' ' ILE . 53.8 m -60.07 130.48 46.9 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.232 -0.918 . . . . 0.0 110.522 -176.096 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . 0.473 ' O ' ' HG3' ' B' ' 93' ' ' GLU . 96.0 m-20 -69.88 -40.1 75.88 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.419 -0.801 . . . . 0.0 110.39 178.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . 0.473 ' HG3' ' O ' ' B' ' 92' ' ' ASP . 98.8 mt-10 -153.95 54.15 0.71 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.221 -0.925 . . . . 0.0 110.149 -176.051 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . 0.656 HG22 ' O ' ' B' ' 94' ' ' ILE . 21.5 mm -101.04 6.58 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.309 -0.869 . . . . 0.0 110.354 179.54 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . -49.97 90.48 0.01 OUTLIER Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 -178.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' B' ' 94' ' ' ILE . . . 80.52 12.47 82.94 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 178.011 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . 0.452 ' HB3' ' HA ' ' B' ' 94' ' ' ILE . 83.5 t60 . . . . . 0 N--CA 1.491 1.578 0 O-C-N 121.076 -1.249 . . . . 0.0 110.135 178.225 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 0.948 ' C8M' HD11 ' B' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 0.965 ' C8M' HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 96.0 mmm . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 121.192 0.52 . . . . 0.0 110.255 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.963 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 12.8 p90 -176.41 154.87 1.36 Allowed 'General case' 0 C--N 1.306 -1.309 0 O-C-N 121.252 -0.905 . . . . 0.0 109.027 179.085 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.572 HG23 ' C ' ' A' ' 2' ' ' PHE . 71.8 p -151.79 -40.26 0.11 Allowed 'General case' 0 C--N 1.297 -1.715 0 O-C-N 120.915 -1.116 . . . . 0.0 109.174 178.348 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 45.65 24.81 1.27 Allowed Glycine 0 N--CA 1.483 1.796 0 N-CA-C 108.57 -1.812 . . . . 0.0 108.57 -174.224 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.81 HD11 HC82 ' B' ' 99' ' ' RBF . 95.3 mt -76.88 138.61 20.25 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.774 0 O-C-N 121.228 -1.16 . . . . 0.0 110.296 -176.181 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.771 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.2 t -97.97 147.66 6.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.353 -0.842 . . . . 0.0 110.399 -175.029 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -95.21 -22.06 18.06 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.493 -0.755 . . . . 0.0 110.75 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.529 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -144.43 175.59 24.1 Favored Glycine 0 N--CA 1.492 2.418 0 C-N-CA 119.081 -1.533 . . . . 0.0 109.968 -176.209 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.432 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.2 p -127.51 166.04 18.72 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.06 -1.259 . . . . 0.0 110.625 179.227 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.071 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -133.94 148.84 51.23 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.598 -0.689 . . . . 0.0 109.258 -178.681 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 23.5 tttt -107.66 116.89 32.76 Favored 'General case' 0 C--N 1.295 -1.78 0 O-C-N 121.113 -0.992 . . . . 0.0 110.147 179.353 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.996 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.2 tp -59.92 126.32 27.08 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 120.876 -1.14 . . . . 0.0 108.914 173.333 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.07 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -124.95 -30.8 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.29 -2.002 0 C-N-CA 119.744 -0.782 . . . . 0.0 109.718 179.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.59 142.36 27.89 Favored 'General case' 0 N--CA 1.492 1.653 0 C-N-CA 119.214 -0.995 . . . . 0.0 111.127 -178.098 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.732 HG23 ' NE2' ' A' ' 24' ' ' HIS . 10.6 mt -108.62 130.19 61.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.113 -0.992 . . . . 0.0 110.314 172.4 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.502 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 74.1 m-20 -104.49 117.76 34.95 Favored 'General case' 0 C--N 1.295 -1.769 0 O-C-N 121.376 -0.827 . . . . 0.0 109.809 172.755 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -107.4 105.31 15.18 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.146 -0.971 . . . . 0.0 110.176 -177.518 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 2.1 mmmt -102.2 130.56 23.98 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.347 -0.846 . . . . 0.0 109.282 179.219 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -51.5 -19.43 7.12 Favored 'Trans proline' 0 C--N 1.303 -1.856 0 O-C-N 123.913 1.481 . . . . 0.0 110.573 -179.499 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.573 ' O ' ' CD1' ' A' ' 21' ' ' PHE . 0.3 OUTLIER -90.54 -38.37 13.24 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.169 -0.957 . . . . 0.0 109.102 177.268 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.573 ' CD1' ' O ' ' A' ' 20' ' ' ASN . 64.6 m-85 -153.15 150.18 28.8 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.833 -0.542 . . . . 0.0 110.148 -177.651 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.544 ' HD3' HD22 ' A' ' 68' ' ' LEU . 63.4 ttt180 -88.43 145.03 26.01 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 120.6 -1.313 . . . . 0.0 109.941 174.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.502 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 84.8 m -133.08 140.82 47.87 Favored 'General case' 0 C--N 1.296 -1.752 0 O-C-N 121.407 -0.808 . . . . 0.0 109.946 -174.173 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.732 ' NE2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.03 131.96 46.04 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.767 -1.208 . . . . 0.0 111.561 -179.669 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.612 HG22 ' CB ' ' A' ' 60' ' ' SER . 4.0 t -109.85 132.28 58.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.184 -0.947 . . . . 0.0 110.537 -178.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 15.5 m -117.44 169.85 7.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 120.359 -0.537 . . . . 0.0 110.343 -179.111 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.535 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 13.1 tt0 -103.22 118.31 36.5 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.215 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.513 ' CD2' ' O ' ' A' ' 32' ' ' MET . 9.5 tp -84.14 126.37 70.05 Favored Pre-proline 0 C--N 1.298 -1.667 0 O-C-N 121.327 -0.858 . . . . 0.0 109.759 -175.073 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.468 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 17.7 Cg_endo -64.27 176.84 2.37 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 123.903 1.475 . . . . 0.0 110.927 -179.192 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.412 ' HA ' HD12 ' A' ' 33' ' ' LEU . 77.4 m-20 -60.06 -39.94 87.73 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.427 -0.796 . . . . 0.0 110.997 -176.37 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.577 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.13 2.57 55.15 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.797 -1.19 . . . . 0.0 110.744 -174.457 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.577 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 89.1 mmm -113.07 -11.89 13.27 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.912 -1.118 . . . . 0.0 109.991 170.364 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.683 HD21 ' HB2' ' A' ' 57' ' ' ASN . 18.1 mt -69.97 -40.1 75.58 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.321 -0.862 . . . . 0.0 110.378 178.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -82.68 115.76 21.76 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.253 -0.905 . . . . 0.0 110.505 -176.384 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.61 -52.75 0.69 Allowed Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.81 -1.186 . . . . 0.0 110.376 175.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.494 HD23 HD22 ' A' ' 28' ' ' LEU . 42.6 tp -61.52 151.34 33.23 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.955 -1.321 . . . . 0.0 110.851 -173.471 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.491 ' C ' HD11 ' A' ' 54' ' ' ILE . 20.9 pt-20 -149.95 168.33 24.12 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.468 -0.77 . . . . 0.0 109.484 178.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.91 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -66.09 152.84 43.82 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.885 -1.134 . . . . 0.0 109.982 -178.985 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.31 -4.72 66.31 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -176.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.514 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -77.26 156.64 31.27 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.291 -1.123 . . . . 0.0 109.668 176.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.612 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.1 OUTLIER -100.61 108.24 20.09 Favored 'General case' 0 C--N 1.306 -1.286 0 O-C-N 121.103 -0.998 . . . . 0.0 110.087 178.629 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.588 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.2 t -94.24 129.45 44.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.224 -0.923 . . . . 0.0 109.125 174.203 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -93.33 119.54 32.59 Favored 'General case' 0 C--N 1.296 -1.724 0 C-N-CA 119.258 -0.977 . . . . 0.0 109.07 171.572 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.852 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.3 OUTLIER -89.17 102.6 15.26 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.64 -0.824 . . . . 0.0 108.94 178.463 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.499 ' HB3' ' HB3' ' B' ' 45' ' ' ASN . 1.7 t-20 58.22 11.49 1.58 Allowed 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.449 -0.782 . . . . 0.0 110.772 -169.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.512 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 121.16 -2.29 11.56 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 119.777 -1.201 . . . . 0.0 110.891 172.672 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.83 ' O ' HD23 ' A' ' 49' ' ' LEU . 43.0 t -92.16 109.17 20.53 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.39 -1.653 . . . . 0.0 109.389 174.352 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 15.8 p -74.89 128.43 35.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.099 -1.001 . . . . 0.0 110.844 -171.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.92 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -146.96 157.0 43.5 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.347 -0.846 . . . . 0.0 109.499 173.741 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.425 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 23.9 m -97.5 159.0 15.18 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.735 -1.228 . . . . 0.0 111.296 -170.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.965 HG22 ' CE1' ' A' ' 61' ' ' PHE . 22.4 t -83.26 116.63 27.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.832 -0.542 . . . . 0.0 110.43 -178.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.54 HG22 ' HB3' ' A' ' 62' ' ' ASP . 39.4 p -70.0 -39.91 75.6 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.241 -0.912 . . . . 0.0 109.715 172.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.579 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.9 tt0 -160.95 154.83 22.5 Favored 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 119.357 -0.937 . . . . 0.0 111.204 -175.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.91 HD11 ' N ' ' A' ' 38' ' ' THR . 6.4 mt -110.06 129.99 64.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.091 -1.006 . . . . 0.0 110.044 169.497 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.488 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 27.7 m-80 -103.7 65.12 0.82 Allowed 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.592 -0.692 . . . . 0.0 109.514 176.648 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.49 -113.4 3.82 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 108.812 -1.715 . . . . 0.0 108.812 -173.263 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.683 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -79.99 -21.07 44.09 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.05 -1.265 . . . . 0.0 109.168 175.405 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.07 ' CD2' HG11 ' A' ' 13' ' ' VAL . 8.5 m170 -77.65 159.99 28.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.246 -0.909 . . . . 0.0 110.112 -176.488 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.668 ' CG1' HG13 ' A' ' 51' ' ' VAL . 97.7 t -144.4 115.43 2.23 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 C-N-CA 119.309 -0.957 . . . . 0.0 110.891 177.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.612 ' CB ' HG22 ' A' ' 25' ' ' VAL . 13.7 m -81.74 130.15 34.96 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.677 -0.639 . . . . 0.0 109.849 178.465 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.965 ' CE1' HG22 ' A' ' 51' ' ' VAL . 96.4 m-85 -115.19 159.98 20.28 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.952 -1.092 . . . . 0.0 110.235 178.037 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.54 ' HB3' HG22 ' A' ' 52' ' ' THR . 25.7 p-10 -95.2 147.81 23.07 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.163 -0.961 . . . . 0.0 111.335 -177.019 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.806 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -159.14 116.47 2.75 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.718 -0.614 . . . . 0.0 109.559 -175.729 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.48 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 57.9 ttm -75.27 146.97 40.63 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.863 -1.148 . . . . 0.0 109.852 179.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.477 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 39.0 ttpt -60.07 -49.75 76.4 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.078 -1.014 . . . . 0.0 110.305 -177.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -63.95 -42.46 97.3 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 120.895 -1.128 . . . . 0.0 110.17 178.574 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.923 HG23 " O4'" ' A' ' 98' ' ' RBF . 69.4 m -60.31 -40.04 89.12 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.932 -1.105 . . . . 0.0 109.606 174.332 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.654 HD11 ' HA2' ' A' ' 74' ' ' GLY . 11.7 tp -59.99 -43.16 95.33 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.288 -0.882 . . . . 0.0 109.582 177.756 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 16.4 mmm180 -70.0 -40.07 75.52 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.57 -0.706 . . . . 0.0 110.608 177.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.87 HG22 HG23 ' A' ' 71' ' ' THR . 1.5 tt -66.15 -43.72 91.95 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.209 -0.932 . . . . 0.0 109.329 -177.169 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.87 HG23 HG22 ' A' ' 70' ' ' ILE . 32.9 p -84.7 -171.01 3.4 Favored 'General case' 0 C--N 1.297 -1.68 0 CA-C-O 121.361 0.601 . . . . 0.0 109.673 178.013 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.519 ' CB ' ' N ' ' B' ' 83' ' ' ASN . 1.6 t30 -103.2 21.84 15.14 Favored 'General case' 0 C--N 1.293 -1.862 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 170.477 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.806 ' HB3' HD21 ' A' ' 63' ' ' LEU . 91.5 mt -66.26 -40.0 89.84 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.939 -1.101 . . . . 0.0 109.787 173.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.654 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -49.79 -25.17 6.75 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -178.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 24.0 p-10 -65.99 -16.63 64.06 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.001 -1.294 . . . . 0.0 110.508 -174.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 96.2 mt -60.01 140.17 56.96 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.151 -0.968 . . . . 0.0 110.65 -176.805 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 0.996 ' C ' HD23 ' A' ' 12' ' ' LEU . 26.0 mttt -144.07 140.33 29.43 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-O 121.346 0.593 . . . . 0.0 109.688 176.01 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.686 ' N ' HD23 ' A' ' 12' ' ' LEU . 18.8 t -61.77 150.17 8.27 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 120.686 -1.259 . . . . 0.0 110.524 -173.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.61 -13.63 63.57 Favored Glycine 0 N--CA 1.482 1.733 0 N-CA-C 108.855 -1.698 . . . . 0.0 108.855 -176.463 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.434 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 34.8 t0 -95.36 169.94 9.72 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.324 -1.104 . . . . 0.0 109.459 175.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.3 m95 -117.47 168.31 10.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.908 -1.12 . . . . 0.0 110.245 175.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.071 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.4 p -130.17 153.05 38.37 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.491 -0.756 . . . . 0.0 109.696 179.369 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.771 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.2 m-20 -79.77 106.02 11.5 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 120.89 -1.131 . . . . 0.0 109.043 170.019 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.564 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -106.23 139.98 25.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 120.481 -1.387 . . . . 0.0 111.37 -175.042 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.421 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.5 tt0 -131.02 142.6 50.34 Favored 'General case' 0 N--CA 1.492 1.644 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.037 179.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 39.6 ttm180 -81.24 121.07 25.7 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 110.481 -178.753 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.939 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -118.04 144.49 45.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.23 -0.919 . . . . 0.0 110.124 176.57 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -126.21 142.13 51.65 Favored 'General case' 0 N--CA 1.491 1.609 0 CA-C-O 121.48 0.657 . . . . 0.0 110.687 -177.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 28.2 mmtp -60.52 -38.83 85.64 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.531 -0.73 . . . . 0.0 110.157 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.456 ' CD1' ' N ' ' A' ' 90' ' ' PHE . 33.2 p90 -132.44 157.13 45.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.288 -0.882 . . . . 0.0 110.314 -178.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.494 ' HB2' HG12 ' A' ' 94' ' ' ILE . 87.7 p -85.84 156.95 20.34 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.34 -0.85 . . . . 0.0 110.319 -179.129 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.499 ' O ' ' HG3' ' A' ' 93' ' ' GLU . 95.9 m-20 -70.97 -56.14 6.82 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.195 -0.941 . . . . 0.0 110.363 179.306 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.499 ' HG3' ' O ' ' A' ' 92' ' ' ASP . 98.8 mt-10 -154.97 59.95 0.66 Allowed 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.206 -0.934 . . . . 0.0 111.052 -172.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.494 HG12 ' HB2' ' A' ' 91' ' ' SER . 26.0 mm -64.26 -39.96 87.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 120.855 -1.153 . . . . 0.0 109.631 173.651 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 100.51 -47.59 1.24 Allowed Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 178.688 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 68.83 -155.09 53.51 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 24.7 p-80 . . . . . 0 N--CA 1.491 1.593 0 O-C-N 121.242 -1.152 . . . . 0.0 110.184 179.73 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 99.4 mtp . . . . . 0 N--CA 1.496 1.87 0 CA-C-O 122.378 1.085 . . . . 0.0 109.676 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.939 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 13.5 p90 -174.68 154.85 2.06 Favored 'General case' 0 C--N 1.281 -2.373 0 CA-C-N 115.283 -0.871 . . . . 0.0 108.88 179.369 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.567 HG23 ' C ' ' B' ' 2' ' ' PHE . 72.4 p -151.74 -40.32 0.11 Allowed 'General case' 0 C--N 1.295 -1.788 0 O-C-N 120.967 -1.083 . . . . 0.0 109.226 178.405 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.45 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 45.74 24.68 1.29 Allowed Glycine 0 N--CA 1.484 1.837 0 N-CA-C 108.616 -1.794 . . . . 0.0 108.616 -174.225 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 0.769 HD11 HC82 ' A' ' 98' ' ' RBF . 95.6 mt -76.92 138.58 20.3 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.209 -1.171 . . . . 0.0 110.334 -176.104 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.789 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.2 t -97.87 147.76 6.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.314 -0.866 . . . . 0.0 110.398 -174.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 93.6 mt-30 -95.35 -21.78 18.17 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.483 -0.76 . . . . 0.0 110.788 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.528 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -144.63 175.4 24.35 Favored Glycine 0 N--CA 1.493 2.459 0 C-N-CA 119.273 -1.441 . . . . 0.0 110.141 -176.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.426 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.1 p -127.45 166.09 18.58 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.118 -1.225 . . . . 0.0 110.589 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.054 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -133.9 148.98 51.29 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.631 -0.668 . . . . 0.0 109.254 -178.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.579 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 23.6 tttt -107.79 116.91 32.81 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.121 -0.987 . . . . 0.0 110.109 179.326 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 1.009 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.2 tp -59.96 126.3 27.02 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.963 -1.086 . . . . 0.0 108.98 173.308 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.062 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -124.93 -30.86 1.15 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 O-C-N 121.451 -0.781 . . . . 0.0 109.724 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -146.56 142.45 28.01 Favored 'General case' 0 C--N 1.298 -1.667 0 C-N-CA 119.37 -0.932 . . . . 0.0 111.098 -178.135 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.748 HG23 ' NE2' ' B' ' 24' ' ' HIS . 10.7 mt -108.68 130.24 61.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.176 -0.952 . . . . 0.0 110.315 172.4 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.515 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 73.5 m-20 -104.71 117.88 35.18 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.287 -0.883 . . . . 0.0 109.662 172.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -107.4 105.37 15.26 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.105 -0.997 . . . . 0.0 110.157 -177.545 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.467 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 2.1 mmmt -102.23 130.5 24.08 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.427 -0.796 . . . . 0.0 109.276 179.189 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -51.55 -19.33 7.11 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 123.889 1.468 . . . . 0.0 110.606 -179.491 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.587 ' ND2' ' N ' ' B' ' 20' ' ' ASN . 0.3 OUTLIER -90.43 -38.94 12.95 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.176 -0.952 . . . . 0.0 108.941 177.272 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.578 ' CD1' ' O ' ' B' ' 20' ' ' ASN . 64.8 m-85 -152.71 150.27 29.26 Favored 'General case' 0 N--CA 1.494 1.765 0 C-N-CA 120.344 -0.542 . . . . 0.0 110.15 -177.562 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.536 ' HD3' HD22 ' B' ' 68' ' ' LEU . 63.5 ttt180 -88.47 144.89 26.07 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.701 -1.249 . . . . 0.0 109.889 174.421 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.515 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 84.9 m -132.96 140.84 48.01 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 121.55 -0.719 . . . . 0.0 109.927 -174.213 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.748 ' NE2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -129.98 132.1 46.17 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.941 -1.099 . . . . 0.0 111.454 -179.654 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.621 HG22 ' CB ' ' B' ' 60' ' ' SER . 4.0 t -109.89 132.44 58.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.349 -0.844 . . . . 0.0 110.571 -178.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.505 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 16.0 m -117.61 169.78 7.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.576 0 CA-C-O 121.304 0.573 . . . . 0.0 110.215 -178.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.529 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 13.1 tt0 -103.09 118.48 36.89 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.102 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.519 ' CD2' ' O ' ' B' ' 32' ' ' MET . 9.5 tp -84.2 126.31 70.09 Favored Pre-proline 0 C--N 1.297 -1.711 0 O-C-N 121.254 -0.904 . . . . 0.0 109.749 -175.122 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.477 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 17.7 Cg_endo -64.27 176.8 2.39 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 O-C-N 123.865 1.455 . . . . 0.0 110.869 -179.191 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.419 ' HA ' HD12 ' B' ' 33' ' ' LEU . 77.3 m-20 -60.04 -40.0 87.88 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.413 -0.805 . . . . 0.0 111.007 -176.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.579 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.96 2.49 55.04 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.863 -1.148 . . . . 0.0 110.847 -174.552 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.579 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 89.2 mmm -113.06 -11.94 13.27 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.894 -1.129 . . . . 0.0 110.012 170.373 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.649 HD21 ' HB2' ' B' ' 57' ' ' ASN . 18.1 mt -69.96 -40.05 75.64 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.245 -0.91 . . . . 0.0 110.404 178.818 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -82.67 115.78 21.76 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.201 -0.937 . . . . 0.0 110.48 -176.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.62 -52.74 0.69 Allowed Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.81 -1.185 . . . . 0.0 110.4 175.378 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.496 HD23 HD22 ' B' ' 28' ' ' LEU . 42.8 tp -61.65 151.42 33.61 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.919 -1.342 . . . . 0.0 110.795 -173.41 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . 0.507 ' C ' HD11 ' B' ' 54' ' ' ILE . 20.9 pt-20 -149.96 168.37 24.0 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.531 -0.731 . . . . 0.0 109.452 178.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.918 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.2 152.68 44.32 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.882 -1.136 . . . . 0.0 109.995 -178.921 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.52 -4.73 67.13 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 -176.388 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.511 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -77.4 156.48 31.15 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.299 -1.118 . . . . 0.0 109.616 176.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.624 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.1 OUTLIER -100.26 108.1 20.09 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.059 -1.026 . . . . 0.0 110.173 178.616 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.601 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.2 t -94.37 129.52 44.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.263 -0.898 . . . . 0.0 109.147 174.178 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.484 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -93.27 119.58 32.59 Favored 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 119.231 -0.988 . . . . 0.0 109.042 171.635 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.863 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.3 OUTLIER -89.21 102.55 15.21 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.319 -0.863 . . . . 0.0 108.946 178.434 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.499 ' HB3' ' HB3' ' A' ' 45' ' ' ASN . 1.8 t-20 58.38 11.47 1.66 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.511 -0.743 . . . . 0.0 110.68 -170.007 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.512 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 121.07 -2.13 11.65 Favored Glycine 0 N--CA 1.491 2.314 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.888 172.662 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.83 ' O ' HD23 ' B' ' 49' ' ' LEU . 43.4 t -92.35 109.18 20.56 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.428 -1.631 . . . . 0.0 109.355 174.319 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 15.9 p -74.78 128.57 35.88 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.161 -0.962 . . . . 0.0 110.744 -171.736 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 0.904 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -147.2 156.85 43.31 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.448 -0.782 . . . . 0.0 109.477 173.649 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . 0.427 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 23.8 m -97.26 159.09 15.12 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.737 -1.227 . . . . 0.0 111.281 -170.502 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.977 HG22 ' CE1' ' B' ' 61' ' ' PHE . 22.7 t -83.39 116.72 27.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.679 -0.638 . . . . 0.0 110.437 -178.524 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.561 HG22 ' HB3' ' B' ' 62' ' ' ASP . 39.8 p -70.01 -39.96 75.51 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.159 -0.963 . . . . 0.0 109.664 172.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.572 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.9 tt0 -160.93 154.76 22.43 Favored 'General case' 0 N--CA 1.491 1.585 0 C-N-CA 119.409 -0.916 . . . . 0.0 111.172 -175.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.918 HD11 ' N ' ' B' ' 38' ' ' THR . 6.4 mt -109.97 129.99 63.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.115 -0.991 . . . . 0.0 110.03 169.525 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.493 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 27.6 m-80 -103.74 65.1 0.81 Allowed 'General case' 0 C--N 1.299 -1.615 0 C-N-CA 119.862 -0.735 . . . . 0.0 109.564 176.608 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.68 -113.43 3.81 Favored Glycine 0 N--CA 1.486 2.012 0 N-CA-C 108.715 -1.754 . . . . 0.0 108.715 -173.279 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.649 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.02 -21.1 43.93 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.061 -1.258 . . . . 0.0 109.152 175.45 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.062 ' CD2' HG11 ' B' ' 13' ' ' VAL . 8.5 m170 -77.54 159.81 29.05 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.186 -0.947 . . . . 0.0 110.108 -176.535 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.647 ' CG1' HG13 ' B' ' 51' ' ' VAL . 97.1 t -144.31 115.47 2.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 C-N-CA 119.284 -0.967 . . . . 0.0 110.912 177.71 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.621 ' CB ' HG22 ' B' ' 25' ' ' VAL . 13.7 m -81.83 130.28 35.02 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.751 -0.593 . . . . 0.0 109.931 178.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.977 ' CE1' HG22 ' B' ' 51' ' ' VAL . 96.4 m-85 -115.27 160.02 20.29 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.977 -1.077 . . . . 0.0 110.275 178.107 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.561 ' HB3' HG22 ' B' ' 52' ' ' THR . 25.7 p-10 -95.2 147.77 23.11 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.012 -1.055 . . . . 0.0 111.273 -176.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.769 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.16 116.43 2.73 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.788 -0.57 . . . . 0.0 109.538 -175.744 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.476 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 58.0 ttm -75.25 146.99 40.66 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.867 -1.146 . . . . 0.0 109.851 179.275 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.476 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 39.0 ttpt -60.04 -49.88 75.9 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.041 -1.037 . . . . 0.0 110.249 -177.63 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -63.94 -42.4 97.35 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.888 -1.132 . . . . 0.0 110.241 178.64 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.895 HG23 " O4'" ' B' ' 99' ' ' RBF . 71.3 m -60.27 -40.07 89.08 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.003 -1.061 . . . . 0.0 109.671 174.258 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.674 HD11 ' HA2' ' B' ' 74' ' ' GLY . 11.7 tp -59.94 -43.18 95.13 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.438 -0.789 . . . . 0.0 109.559 177.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 16.4 mmm180 -69.98 -39.93 75.65 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.562 -0.711 . . . . 0.0 110.665 177.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.85 HG22 HG23 ' B' ' 71' ' ' THR . 1.5 tt -66.22 -43.69 91.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 CA-C-O 121.922 0.868 . . . . 0.0 109.363 -177.195 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.85 HG23 HG22 ' B' ' 70' ' ' ILE . 33.0 p -84.6 -170.77 3.28 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-O 121.44 0.638 . . . . 0.0 109.708 177.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.533 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 1.6 t30 -103.39 21.82 15.31 Favored 'General case' 0 C--N 1.295 -1.8 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 170.531 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.769 ' HB3' HD21 ' B' ' 63' ' ' LEU . 91.7 mt -66.22 -40.02 89.99 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.917 -1.114 . . . . 0.0 109.736 173.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.674 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -49.78 -25.18 6.75 Favored Glycine 0 N--CA 1.488 2.101 0 N-CA-C 110.429 -1.068 . . . . 0.0 110.429 -178.496 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 24.2 p-10 -66.02 -16.64 64.08 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.995 -1.297 . . . . 0.0 110.433 -174.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.517 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 96.2 mt -59.98 140.21 56.91 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.155 -0.965 . . . . 0.0 110.639 -176.784 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 1.009 ' C ' HD23 ' B' ' 12' ' ' LEU . 26.0 mttt -144.13 140.4 29.39 Favored 'General case' 0 C--N 1.296 -1.737 0 O-C-N 121.796 -0.565 . . . . 0.0 109.675 175.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.692 ' N ' HD23 ' B' ' 12' ' ' LEU . 19.0 t -61.82 150.25 8.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 120.942 -1.099 . . . . 0.0 110.536 -173.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.47 -13.49 63.73 Favored Glycine 0 N--CA 1.483 1.778 0 N-CA-C 108.959 -1.656 . . . . 0.0 108.959 -176.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.442 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 34.4 t0 -95.35 169.95 9.71 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.366 -1.079 . . . . 0.0 109.51 175.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.579 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.3 m95 -117.52 168.19 10.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.951 -1.093 . . . . 0.0 110.261 175.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.054 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.4 p -130.15 153.14 38.49 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.465 -0.772 . . . . 0.0 109.63 179.307 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.789 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.1 m-20 -79.77 105.72 11.27 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 120.97 -1.081 . . . . 0.0 109.158 170.023 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.554 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -106.06 140.0 25.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.45 -1.406 . . . . 0.0 111.331 -174.873 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . 0.426 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.5 tt0 -131.01 142.69 50.35 Favored 'General case' 0 N--CA 1.492 1.675 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.059 179.765 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 39.5 ttm180 -81.31 121.2 25.9 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.36 -0.838 . . . . 0.0 110.351 -178.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 0.963 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -117.97 144.63 45.35 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.275 -0.891 . . . . 0.0 110.158 176.491 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -126.41 142.05 51.67 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.644 -0.66 . . . . 0.0 110.663 -177.423 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 28.2 mmtp -60.5 -38.89 85.81 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.481 -0.762 . . . . 0.0 110.102 179.112 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . 0.454 ' CD1' ' N ' ' B' ' 90' ' ' PHE . 33.2 p90 -132.39 157.09 45.43 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.241 -0.912 . . . . 0.0 110.357 -178.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . 0.789 ' CB ' HD12 ' B' ' 94' ' ' ILE . 87.4 p -85.84 156.78 20.41 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.247 -0.908 . . . . 0.0 110.32 -179.114 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . 0.467 ' O ' ' HB3' ' B' ' 93' ' ' GLU . 96.0 m-20 -70.39 -44.33 68.21 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.138 -0.976 . . . . 0.0 110.229 179.171 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . 0.525 ' O ' ' CG ' ' B' ' 93' ' ' GLU . 4.8 pt-20 -177.28 54.09 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.336 -0.853 . . . . 0.0 110.489 176.287 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . 0.789 HD12 ' CB ' ' B' ' 91' ' ' SER . 57.1 mt -62.29 -40.03 86.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.083 -1.01 . . . . 0.0 110.034 178.7 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 89.53 -41.4 3.01 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 179.135 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . 0.526 ' H ' HG22 ' B' ' 94' ' ' ILE . . . 95.95 -0.03 62.29 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.646 -1.381 . . . . 0.0 109.646 -178.7 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 1.5 t-80 . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.122 -1.222 . . . . 0.0 110.192 179.559 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 0.923 " O4'" HG23 ' A' ' 67' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 0.895 " O4'" HG23 ' B' ' 67' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 59.8 ttm . . . . . 0 N--CA 1.496 1.826 0 CA-C-O 121.376 0.607 . . . . 0.0 110.344 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.628 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 5.2 p90 -166.0 141.2 4.74 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.407 -0.808 . . . . 0.0 109.231 174.161 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.503 ' O ' HG13 ' A' ' 5' ' ' ILE . 26.4 p -140.95 -34.94 0.49 Allowed 'General case' 0 C--N 1.296 -1.755 0 O-C-N 121.091 -1.006 . . . . 0.0 110.095 -175.06 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.424 ' O ' ' O ' ' B' ' 46' ' ' GLY . . . 44.81 24.99 0.82 Allowed Glycine 0 N--CA 1.488 2.109 0 N-CA-C 109.031 -1.627 . . . . 0.0 109.031 -173.679 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.785 HD11 ' C8M' ' B' ' 99' ' ' RBF . 51.7 mt -83.21 135.59 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.103 -1.234 . . . . 0.0 110.288 -176.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.7 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.5 t -83.09 139.24 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.375 -0.828 . . . . 0.0 110.568 -176.018 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -69.98 -33.6 72.27 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.669 -0.644 . . . . 0.0 110.708 -178.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.539 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -153.42 174.75 32.02 Favored Glycine 0 N--CA 1.495 2.585 0 C-N-CA 118.957 -1.592 . . . . 0.0 110.395 -172.645 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.497 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 17.9 p -120.61 169.0 10.78 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.991 -1.3 . . . . 0.0 111.008 -177.263 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.008 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -138.07 149.5 46.05 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.6 -0.687 . . . . 0.0 109.432 -175.337 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.58 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 19.1 tttt -106.47 117.3 33.7 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.076 -1.015 . . . . 0.0 110.216 179.088 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 1.037 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.0 tp -59.93 128.52 37.27 Favored 'General case' 0 C--N 1.298 -1.643 0 O-C-N 120.885 -1.135 . . . . 0.0 108.737 172.523 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.116 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.58 -28.81 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 O-C-N 121.369 -0.832 . . . . 0.0 110.055 -178.152 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.53 140.2 24.77 Favored 'General case' 0 N--CA 1.494 1.757 0 C-N-CA 119.14 -1.024 . . . . 0.0 111.385 -178.766 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.749 HG23 ' CD2' ' A' ' 24' ' ' HIS . 7.0 mt -107.01 133.16 52.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.002 -1.061 . . . . 0.0 110.043 169.845 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.494 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 86.9 m-20 -109.98 114.51 28.09 Favored 'General case' 0 C--N 1.294 -1.832 0 O-C-N 121.443 -0.786 . . . . 0.0 109.987 173.795 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -103.9 116.6 32.57 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.047 -1.033 . . . . 0.0 110.388 -177.016 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.405 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -111.67 135.1 21.13 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.298 -0.876 . . . . 0.0 109.344 178.205 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -51.8 -18.44 6.52 Favored 'Trans proline' 0 C--N 1.303 -1.829 0 O-C-N 123.906 1.477 . . . . 0.0 110.774 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.575 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 4.9 m-80 -97.2 -32.6 11.85 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.027 -1.046 . . . . 0.0 110.423 178.59 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.575 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 83.2 m-85 -158.03 150.41 22.28 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.272 -0.893 . . . . 0.0 110.208 -177.394 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.493 ' HD3' HD22 ' A' ' 68' ' ' LEU . 65.8 ttt180 -90.72 144.11 26.06 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.7 -1.25 . . . . 0.0 110.03 176.648 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.494 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 96.8 m -129.84 139.96 51.1 Favored 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.607 -0.683 . . . . 0.0 109.746 -175.278 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.749 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.21 139.72 50.79 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.972 -1.08 . . . . 0.0 111.164 179.766 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.677 HG22 ' CB ' ' A' ' 60' ' ' SER . 4.0 t -120.51 132.52 69.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 O-C-N 121.051 -1.031 . . . . 0.0 110.468 -178.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.875 HG13 ' CE1' ' A' ' 61' ' ' PHE . 31.7 m -115.88 171.37 5.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.862 -0.524 . . . . 0.0 110.026 179.411 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.556 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 10.4 tt0 -108.54 115.7 30.59 Favored 'General case' 0 C--N 1.304 -1.376 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.523 HD22 HD23 ' A' ' 36' ' ' LEU . 8.7 tp -86.8 127.97 58.05 Favored Pre-proline 0 C--N 1.296 -1.725 0 O-C-N 121.206 -0.934 . . . . 0.0 110.285 -172.109 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.483 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 28.9 Cg_endo -66.72 177.1 3.68 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 O-C-N 123.941 1.496 . . . . 0.0 111.05 -179.401 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.534 ' HA ' HD12 ' A' ' 33' ' ' LEU . 95.9 m-20 -60.07 -40.06 88.21 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.23 -0.919 . . . . 0.0 111.083 -174.251 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.596 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.02 0.86 56.88 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 120.814 -1.178 . . . . 0.0 110.959 -174.655 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.596 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.8 mmm -112.59 -12.03 13.49 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.958 -1.089 . . . . 0.0 109.964 172.282 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.6 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 19.8 mt -70.07 -39.97 75.33 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.408 -0.807 . . . . 0.0 110.186 177.832 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 88.3 m-20 -73.91 143.13 45.9 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.419 -0.801 . . . . 0.0 110.583 -178.147 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.5 -39.02 3.01 Favored Glycine 0 N--CA 1.492 2.409 0 C-N-CA 119.925 -1.131 . . . . 0.0 110.555 173.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.523 HD23 HD22 ' A' ' 28' ' ' LEU . 50.3 tp -77.54 147.93 35.5 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.896 -1.355 . . . . 0.0 110.892 -174.108 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.499 ' C ' HD11 ' A' ' 54' ' ' ILE . 21.3 pt-20 -149.07 166.58 28.3 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.409 -0.807 . . . . 0.0 109.511 177.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.843 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -64.99 147.78 52.84 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.825 -1.172 . . . . 0.0 109.862 179.376 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 81.94 -7.68 62.3 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.329 -1.508 . . . . 0.0 109.329 -175.412 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.533 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -74.99 153.18 38.64 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.277 -1.131 . . . . 0.0 109.645 177.319 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.87 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.0 OUTLIER -96.58 110.12 22.59 Favored 'General case' 0 C--N 1.309 -1.19 0 O-C-N 120.76 -1.212 . . . . 0.0 109.955 175.474 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.657 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.0 t -92.91 130.09 42.5 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 173.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.574 ' HB3' ' CG ' ' A' ' 85' ' ' GLU . . . -93.47 119.69 32.85 Favored 'General case' 0 C--N 1.293 -1.848 0 C-N-CA 119.001 -1.079 . . . . 0.0 109.071 173.12 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.657 ' HE1' HG11 ' A' ' 42' ' ' VAL . 0.3 OUTLIER -90.31 106.02 18.21 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 177.727 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.0 t-20 58.27 7.85 0.73 Allowed 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.341 -0.849 . . . . 0.0 111.547 -169.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.408 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 125.61 -3.2 8.13 Favored Glycine 0 N--CA 1.49 2.292 0 O-C-N 120.703 -1.248 . . . . 0.0 110.549 174.668 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.841 ' O ' HD23 ' A' ' 49' ' ' LEU . 32.6 t -94.37 108.26 20.17 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 120.59 -1.535 . . . . 0.0 109.812 176.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 19.5 p -70.29 128.54 36.57 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.163 -0.961 . . . . 0.0 110.895 -175.434 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.851 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -143.29 158.03 43.98 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.365 -0.834 . . . . 0.0 109.344 172.347 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 65.0 m -99.51 149.33 23.34 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 120.559 -1.338 . . . . 0.0 111.403 -170.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.917 HG13 HG13 ' A' ' 59' ' ' VAL . 20.4 t -76.88 114.74 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 CA-C-O 121.01 0.433 . . . . 0.0 110.406 -178.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.52 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 52.6 p -69.32 -40.07 77.84 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.184 -0.947 . . . . 0.0 109.602 173.781 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.566 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 89.3 tt0 -161.49 156.4 23.46 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.428 -0.795 . . . . 0.0 110.157 -178.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.843 HD11 ' N ' ' A' ' 38' ' ' THR . 8.2 mt -108.9 129.3 63.75 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.075 -1.015 . . . . 0.0 109.987 174.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.535 ' HB2' ' CB ' ' A' ' 58' ' ' HIS . 8.6 m-80 -102.39 62.95 0.87 Allowed 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.537 -0.727 . . . . 0.0 109.88 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.67 -117.99 5.33 Favored Glycine 0 N--CA 1.488 2.116 0 N-CA-C 108.768 -1.733 . . . . 0.0 108.768 -173.923 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.6 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -74.9 -19.87 59.95 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 120.902 -1.352 . . . . 0.0 108.768 174.216 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.116 ' CD2' HG11 ' A' ' 13' ' ' VAL . 10.3 m170 -75.61 159.77 30.84 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.424 -0.798 . . . . 0.0 110.129 -177.177 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.917 HG13 HG13 ' A' ' 51' ' ' VAL . 53.6 t -140.55 123.0 15.81 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 O-C-N 121.039 -1.038 . . . . 0.0 110.641 171.092 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.677 ' CB ' HG22 ' A' ' 25' ' ' VAL . 17.0 m -89.65 128.72 36.11 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.609 -0.682 . . . . 0.0 109.478 177.682 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.875 ' CE1' HG13 ' A' ' 26' ' ' VAL . 2.4 p90 -124.14 152.38 42.86 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.98 -1.075 . . . . 0.0 110.182 179.002 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.52 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 33.1 p-10 -89.38 156.12 18.9 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 120.986 -1.071 . . . . 0.0 111.708 -171.216 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.923 HD22 HD13 ' A' ' 68' ' ' LEU . 0.2 OUTLIER -160.64 101.4 1.33 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.691 -0.631 . . . . 0.0 109.613 -173.416 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.503 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 57.2 ttm -61.53 139.56 58.23 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.57 -1.331 . . . . 0.0 109.174 178.491 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.477 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 78.7 tttt -59.96 -47.87 84.01 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.723 -1.236 . . . . 0.0 110.38 -173.574 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.8 tt0 -64.49 -39.95 94.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.876 -1.14 . . . . 0.0 109.87 177.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.503 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 94.6 m -61.38 -39.93 92.45 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.898 -1.126 . . . . 0.0 109.526 173.13 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.923 HD13 HD22 ' A' ' 63' ' ' LEU . 16.3 tp -59.99 -41.14 91.42 Favored 'General case' 0 C--N 1.3 -1.587 0 O-C-N 121.352 -0.843 . . . . 0.0 109.269 178.378 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -67.02 -39.99 87.17 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.475 -0.766 . . . . 0.0 110.491 173.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.797 HG22 HG23 ' A' ' 71' ' ' THR . 0.8 OUTLIER -65.64 -43.39 93.89 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 O-C-N 121.139 -0.975 . . . . 0.0 109.359 -175.538 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.797 HG23 HG22 ' A' ' 70' ' ' ILE . 24.7 p -84.25 -174.43 5.27 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 109.215 -0.661 . . . . 0.0 109.215 175.035 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.4 t30 -101.45 23.48 11.02 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 108.25 -1.018 . . . . 0.0 108.25 171.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.681 HD13 HD21 ' A' ' 63' ' ' LEU . 91.6 mt -70.05 -39.96 75.4 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.132 -0.98 . . . . 0.0 110.009 176.049 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.547 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -47.53 -22.56 1.74 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 -178.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.508 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.3 p-10 -68.69 -17.15 64.02 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.066 -1.255 . . . . 0.0 110.612 -174.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.508 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 89.3 mt -62.38 143.04 57.49 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.243 -0.911 . . . . 0.0 110.909 -177.627 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 1.037 ' C ' HD23 ' A' ' 12' ' ' LEU . 89.8 mttt -141.5 144.61 34.43 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 109.327 -0.619 . . . . 0.0 109.327 174.789 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.687 HG21 HG13 ' A' ' 15' ' ' ILE . 47.3 t -64.95 147.28 12.68 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 120.752 -1.217 . . . . 0.0 110.07 -176.86 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.55 -14.14 62.14 Favored Glycine 0 N--CA 1.483 1.807 0 N-CA-C 108.616 -1.794 . . . . 0.0 108.616 -173.039 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 39.6 t0 -96.09 166.85 11.55 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.387 -1.067 . . . . 0.0 109.504 175.648 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.58 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.2 m95 -117.64 166.92 11.82 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.044 -1.035 . . . . 0.0 110.199 177.311 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.008 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.3 p -132.39 156.57 42.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.382 -0.824 . . . . 0.0 109.984 -178.294 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.7 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.2 m-20 -79.53 105.63 10.97 Favored 'General case' 0 C--N 1.296 -1.752 0 O-C-N 121.03 -1.044 . . . . 0.0 109.097 169.096 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.979 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -110.24 141.92 24.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 120.382 -1.449 . . . . 0.0 110.873 -176.56 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.574 ' CG ' ' HB3' ' A' ' 43' ' ' ALA . 19.9 pt-20 -149.06 153.83 38.41 Favored 'General case' 0 N--CA 1.494 1.734 0 C-N-CA 119.748 -0.781 . . . . 0.0 110.162 179.268 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 63.1 ttt180 -68.2 130.03 41.7 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.228 -0.92 . . . . 0.0 110.385 -178.065 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.87 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . -128.97 148.24 50.93 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.371 -0.831 . . . . 0.0 109.489 176.494 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.751 ' HB2' ' O ' ' A' ' 87' ' ' ALA . . . 164.61 31.32 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.457 -0.777 . . . . 0.0 111.367 178.756 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.58 ' HB3' ' CD1' ' B' ' 2' ' ' PHE . 0.0 OUTLIER 50.68 28.41 3.53 Favored 'General case' 0 N--CA 1.511 2.609 0 O-C-N 120.923 -1.11 . . . . 0.0 109.835 -179.52 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.432 ' CD2' ' O ' ' A' ' 91' ' ' SER . 42.8 p90 -88.87 165.81 14.39 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.122 -0.986 . . . . 0.0 110.198 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.526 ' HB2' ' CG1' ' A' ' 94' ' ' ILE . 84.7 p -68.73 149.22 49.29 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.061 -1.024 . . . . 0.0 110.309 -175.237 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.502 ' O ' ' HG3' ' A' ' 93' ' ' GLU . 96.1 m-20 -69.58 -45.23 69.15 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.145 -0.972 . . . . 0.0 110.505 -178.565 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.502 ' HG3' ' O ' ' A' ' 92' ' ' ASP . 43.6 mt-10 -155.04 54.04 0.64 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.0 -1.062 . . . . 0.0 110.68 179.361 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.526 ' CG1' ' HB2' ' A' ' 91' ' ' SER . 35.1 mm -97.02 -13.45 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.16 -0.962 . . . . 0.0 110.346 176.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 113.3 -83.85 0.34 Allowed Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -178.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 64.88 -168.11 29.05 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 178.958 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.52 ' N ' ' CD2' ' A' ' 97' ' ' HIS . 0.4 OUTLIER . . . . . 0 N--CA 1.493 1.702 0 O-C-N 121.303 -1.116 . . . . 0.0 110.172 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 67.5 mtt . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 121.097 0.475 . . . . 0.0 110.065 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.616 ' CZ ' ' HA ' ' A' ' 88' ' ' ALA . 5.4 p90 -158.52 141.02 14.31 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.11 -0.994 . . . . 0.0 109.068 170.598 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.508 ' O ' HG13 ' B' ' 5' ' ' ILE . 26.3 p -140.95 -35.09 0.48 Allowed 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.14 -0.975 . . . . 0.0 110.046 -175.059 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.436 ' C ' ' O ' ' B' ' 3' ' ' THR . . . 44.92 24.99 0.85 Allowed Glycine 0 N--CA 1.487 2.044 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -173.658 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 0.811 HD11 ' C8M' ' A' ' 98' ' ' RBF . 51.8 mt -83.29 135.6 24.48 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 O-C-N 121.09 -1.241 . . . . 0.0 110.268 -176.706 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.693 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.5 t -83.12 139.25 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.313 -0.867 . . . . 0.0 110.527 -175.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 88.2 mt-30 -69.97 -33.37 71.99 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.672 -0.642 . . . . 0.0 110.792 -178.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.542 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -153.62 174.52 32.2 Favored Glycine 0 N--CA 1.498 2.767 0 C-N-CA 119.073 -1.537 . . . . 0.0 110.441 -172.583 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.499 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 18.1 p -120.49 168.85 10.9 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.049 -1.265 . . . . 0.0 111.053 -177.254 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.049 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -137.96 149.64 46.32 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.549 -0.719 . . . . 0.0 109.396 -175.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.575 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 19.1 tttt -106.54 117.37 33.86 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 121.105 -0.997 . . . . 0.0 110.194 179.102 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 1.047 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.0 tp -60.02 128.38 36.55 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.0 -1.063 . . . . 0.0 108.818 172.532 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.117 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.45 -28.84 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.926 0 C-N-CA 119.684 -0.806 . . . . 0.0 110.136 -178.148 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.46 140.22 24.86 Favored 'General case' 0 C--N 1.296 -1.729 0 C-N-CA 119.304 -0.958 . . . . 0.0 111.459 -178.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.754 HG23 ' CD2' ' B' ' 24' ' ' HIS . 6.7 mt -106.87 133.12 52.39 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.922 -1.111 . . . . 0.0 110.145 169.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.508 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 86.9 m-20 -110.04 114.53 28.13 Favored 'General case' 0 C--N 1.295 -1.761 0 O-C-N 121.555 -0.716 . . . . 0.0 110.026 173.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.6 tt0 -103.85 116.52 32.44 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.096 -1.002 . . . . 0.0 110.379 -176.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.41 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -111.59 134.99 21.11 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.285 -0.884 . . . . 0.0 109.35 178.208 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_endo -51.85 -18.44 6.62 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 O-C-N 123.861 1.453 . . . . 0.0 110.734 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.573 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 4.9 m-80 -96.91 -33.32 11.65 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.095 -1.003 . . . . 0.0 110.263 178.62 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.573 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 83.7 m-85 -157.52 150.43 23.25 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.293 -0.879 . . . . 0.0 110.215 -177.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.503 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 65.9 ttt180 -90.61 144.06 26.13 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.926 -1.109 . . . . 0.0 110.074 176.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.508 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 96.0 m -129.77 140.03 51.15 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.684 -0.635 . . . . 0.0 109.728 -175.33 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.754 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.18 139.77 50.82 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.007 -1.058 . . . . 0.0 111.118 179.802 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.669 HG22 ' CB ' ' B' ' 60' ' ' SER . 3.9 t -120.51 132.55 69.8 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.197 -0.939 . . . . 0.0 110.436 -178.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.858 HG13 ' CE1' ' B' ' 61' ' ' PHE . 32.4 m -116.03 171.38 5.1 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 121.691 -0.631 . . . . 0.0 109.922 179.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.564 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 10.4 tt0 -108.48 115.71 30.62 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 -179.537 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.531 HD22 HD23 ' B' ' 36' ' ' LEU . 8.7 tp -86.69 127.94 58.41 Favored Pre-proline 0 C--N 1.296 -1.732 0 O-C-N 121.148 -0.97 . . . . 0.0 110.28 -172.098 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.495 ' HD2' HD12 ' B' ' 28' ' ' LEU . 29.1 Cg_endo -66.79 177.12 3.71 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 O-C-N 123.924 1.486 . . . . 0.0 111.056 -179.435 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.517 ' HA ' HD12 ' B' ' 33' ' ' LEU . 96.1 m-20 -60.09 -39.95 87.9 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.273 -0.892 . . . . 0.0 111.159 -174.233 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.603 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.05 0.73 56.97 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.79 -1.194 . . . . 0.0 110.862 -174.671 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.603 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.7 mmm -112.58 -11.86 13.52 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.981 -1.074 . . . . 0.0 109.971 172.255 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.591 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 19.9 mt -70.14 -39.9 75.12 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.354 -0.841 . . . . 0.0 110.185 177.783 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 88.2 m-20 -73.98 143.11 45.75 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.499 -0.751 . . . . 0.0 110.532 -178.083 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.51 -39.01 3.01 Favored Glycine 0 N--CA 1.491 2.358 0 C-N-CA 119.954 -1.117 . . . . 0.0 110.505 173.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.531 HD23 HD22 ' B' ' 28' ' ' LEU . 50.5 tp -77.47 147.91 35.66 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.86 -1.377 . . . . 0.0 110.826 -174.056 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . 0.489 ' C ' HD11 ' B' ' 54' ' ' ILE . 21.4 pt-20 -149.12 166.59 28.31 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.454 -0.779 . . . . 0.0 109.5 177.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.844 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -64.98 147.7 52.96 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 120.85 -1.156 . . . . 0.0 109.942 179.366 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 82.06 -7.76 62.43 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -175.393 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.537 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -75.02 152.89 38.67 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.336 -1.096 . . . . 0.0 109.64 177.254 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.875 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.0 OUTLIER -96.09 110.03 22.35 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 120.882 -1.137 . . . . 0.0 110.059 175.39 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.65 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.0 t -93.08 130.01 42.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 173.301 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.581 ' HB3' ' CG ' ' B' ' 85' ' ' GLU . . . -93.38 119.67 32.77 Favored 'General case' 0 C--N 1.295 -1.789 0 C-N-CA 118.993 -1.083 . . . . 0.0 109.167 173.075 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.65 ' HE1' HG11 ' B' ' 42' ' ' VAL . 0.3 OUTLIER -90.26 105.62 17.93 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.806 -0.813 . . . . 0.0 108.806 177.712 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.0 t-20 58.81 7.77 0.83 Allowed 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.375 -0.828 . . . . 0.0 111.379 -170.08 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.424 ' O ' ' O ' ' A' ' 4' ' ' GLY . . . 125.45 -2.82 8.22 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.749 -1.215 . . . . 0.0 110.638 174.57 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.849 ' O ' HD23 ' B' ' 49' ' ' LEU . 32.7 t -94.56 108.08 20.05 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.597 -1.531 . . . . 0.0 109.867 176.732 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 18.2 p -70.07 128.68 37.14 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.133 -0.979 . . . . 0.0 110.842 -175.414 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 0.867 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -143.42 158.08 43.94 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.335 -0.853 . . . . 0.0 109.263 172.239 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 65.1 m -99.46 149.42 23.22 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.523 -1.361 . . . . 0.0 111.411 -170.191 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.935 HG13 HG13 ' B' ' 59' ' ' VAL . 20.7 t -77.19 114.82 18.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.839 -0.538 . . . . 0.0 110.434 -178.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.53 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 53.7 p -69.38 -40.02 77.66 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.176 -0.953 . . . . 0.0 109.601 173.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.566 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 89.3 tt0 -161.51 156.38 23.38 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 119.77 -0.772 . . . . 0.0 110.128 -178.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.844 HD11 ' N ' ' B' ' 38' ' ' THR . 8.3 mt -108.85 129.16 63.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.096 -1.003 . . . . 0.0 110.088 175.05 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.542 ' HB2' ' CB ' ' B' ' 58' ' ' HIS . 8.5 m-80 -102.45 63.12 0.86 Allowed 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.626 -0.671 . . . . 0.0 109.782 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.67 -118.0 5.34 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.695 -1.762 . . . . 0.0 108.695 -173.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.591 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -74.87 -20.01 59.92 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 120.988 -1.301 . . . . 0.0 108.78 174.249 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.117 ' CD2' HG11 ' B' ' 13' ' ' VAL . 10.3 m170 -75.52 159.59 31.11 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.469 -0.769 . . . . 0.0 110.234 -177.219 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.935 HG13 HG13 ' B' ' 51' ' ' VAL . 54.3 t -140.46 123.09 16.15 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.62 0 O-C-N 121.063 -1.023 . . . . 0.0 110.55 171.247 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.669 ' CB ' HG22 ' B' ' 25' ' ' VAL . 17.4 m -89.69 128.78 36.14 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.586 -0.696 . . . . 0.0 109.519 177.675 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.867 ' HB2' HD12 ' B' ' 49' ' ' LEU . 2.4 p90 -124.21 152.37 43.0 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.965 -1.085 . . . . 0.0 110.186 178.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.53 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 33.0 p-10 -89.32 156.09 18.94 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 120.834 -1.166 . . . . 0.0 111.588 -171.119 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.944 HD22 HD13 ' B' ' 68' ' ' LEU . 0.2 OUTLIER -160.66 101.52 1.32 Allowed 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.696 -0.628 . . . . 0.0 109.656 -173.526 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.494 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 57.1 ttm -61.59 139.45 58.27 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.612 -1.305 . . . . 0.0 109.163 178.527 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.48 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 78.6 tttt -59.94 -47.81 84.26 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.86 -1.15 . . . . 0.0 110.384 -173.506 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -64.5 -40.0 94.83 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.943 -1.098 . . . . 0.0 109.843 177.814 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.494 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 94.2 m -61.24 -40.08 92.7 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.96 -1.087 . . . . 0.0 109.564 173.117 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.944 HD13 HD22 ' B' ' 63' ' ' LEU . 16.3 tp -59.92 -41.08 90.94 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.339 -0.851 . . . . 0.0 109.35 178.352 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 82.3 mtp180 -67.04 -40.07 87.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.415 -0.803 . . . . 0.0 110.449 173.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.791 HG22 HG23 ' B' ' 71' ' ' THR . 0.8 OUTLIER -65.51 -43.32 94.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.24 -0.913 . . . . 0.0 109.426 -175.599 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.791 HG23 HG22 ' B' ' 70' ' ' ILE . 25.1 p -84.36 -174.17 5.13 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 120.006 -0.678 . . . . 0.0 109.195 175.171 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.528 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 4.1 t30 -101.62 23.47 11.17 Favored 'General case' 0 C--N 1.294 -1.834 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 171.708 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.698 HD13 HD21 ' B' ' 63' ' ' LEU . 91.6 mt -70.04 -39.99 75.39 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.133 -0.979 . . . . 0.0 109.996 176.013 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.54 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -47.42 -22.7 1.69 Allowed Glycine 0 N--CA 1.489 2.223 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 -178.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.4 p-10 -68.65 -17.08 64.03 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.057 -1.261 . . . . 0.0 110.647 -174.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 89.5 mt -62.32 143.08 57.39 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.2 -0.937 . . . . 0.0 110.912 -177.702 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 1.047 ' C ' HD23 ' B' ' 12' ' ' LEU . 89.8 mttt -141.64 144.58 34.23 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 174.785 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.696 HG21 HG13 ' B' ' 15' ' ' ILE . 47.2 t -64.9 147.31 12.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.885 -1.134 . . . . 0.0 110.062 -176.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.49 -14.07 62.23 Favored Glycine 0 N--CA 1.484 1.875 0 N-CA-C 108.67 -1.772 . . . . 0.0 108.67 -173.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 39.2 t0 -96.12 166.76 11.6 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.472 -1.016 . . . . 0.0 109.483 175.564 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.575 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.3 m95 -117.64 166.84 11.93 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.057 -1.027 . . . . 0.0 110.136 177.388 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.049 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.3 p -132.36 156.66 42.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.429 -0.794 . . . . 0.0 109.963 -178.427 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.693 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.1 m-20 -79.44 105.53 10.82 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.116 -0.99 . . . . 0.0 109.203 169.117 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.947 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -110.2 142.21 23.32 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 120.419 -1.425 . . . . 0.0 110.765 -176.399 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . 0.581 ' CG ' ' HB3' ' B' ' 43' ' ' ALA . 19.9 pt-20 -149.38 153.84 38.0 Favored 'General case' 0 N--CA 1.492 1.64 0 C-N-CA 119.779 -0.768 . . . . 0.0 110.05 179.249 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 63.2 ttt180 -68.14 129.97 41.51 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.181 -0.95 . . . . 0.0 110.432 -178.045 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 0.875 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . -128.68 148.55 50.83 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.411 -0.806 . . . . 0.0 109.502 176.509 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . 0.763 ' HB2' ' O ' ' B' ' 87' ' ' ALA . . . 164.23 31.3 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.158 0 O-C-N 121.418 -0.801 . . . . 0.0 111.346 178.586 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . 0.519 ' O ' ' CG ' ' B' ' 89' ' ' LYS . 0.0 OUTLIER 50.75 28.39 3.58 Favored 'General case' 0 N--CA 1.51 2.537 0 O-C-N 120.951 -1.093 . . . . 0.0 109.892 -179.561 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . 0.44 ' CD2' ' O ' ' B' ' 91' ' ' SER . 42.9 p90 -89.0 165.71 14.37 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.079 -1.013 . . . . 0.0 110.147 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . 0.44 ' O ' ' CD2' ' B' ' 90' ' ' PHE . 84.6 p -68.59 149.03 49.65 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.057 -1.027 . . . . 0.0 110.383 -175.25 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . 0.429 ' O ' ' HB3' ' B' ' 93' ' ' GLU . 95.9 m-20 -69.61 -47.41 63.58 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.145 -0.972 . . . . 0.0 110.397 -178.508 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . 0.478 ' O ' ' HG3' ' B' ' 93' ' ' GLU . 21.5 pt-20 -175.92 46.68 0.01 OUTLIER 'General case' 0 C--N 1.305 -1.341 0 CA-C-O 121.751 0.786 . . . . 0.0 110.161 -178.153 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . . . . . . . . . 22.1 mm -65.35 -40.01 87.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.584 -0.698 . . . . 0.0 110.166 178.297 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 115.82 -71.91 0.26 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 -179.358 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -132.54 148.51 19.23 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.456 -1.457 . . . . 0.0 109.456 179.151 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 78.0 t60 . . . . . 0 N--CA 1.493 1.68 0 O-C-N 121.264 -1.139 . . . . 0.0 110.208 -179.378 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 0.811 ' C8M' HD11 ' B' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 0.785 ' C8M' HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 29.6 mtp . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.033 0.444 . . . . 0.0 110.081 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 1.081 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 3.9 p90 -169.78 155.17 5.69 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.127 -0.983 . . . . 0.0 108.559 174.523 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.556 HG23 ' C ' ' A' ' 2' ' ' PHE . 30.0 p -150.72 -38.75 0.13 Allowed 'General case' 0 C--N 1.295 -1.771 0 O-C-N 120.942 -1.099 . . . . 0.0 109.284 175.658 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.464 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 48.48 23.98 3.51 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 108.277 -1.929 . . . . 0.0 108.277 -175.309 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.554 HD11 HC82 ' B' ' 99' ' ' RBF . 79.1 mt -79.28 125.44 38.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.437 -1.037 . . . . 0.0 109.732 -178.079 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.885 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.0 t -84.36 139.44 17.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.191 -0.943 . . . . 0.0 110.835 -170.524 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -70.06 -34.83 73.71 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.86 -0.525 . . . . 0.0 111.036 178.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.544 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -154.76 174.44 33.05 Favored Glycine 0 N--CA 1.496 2.641 0 C-N-CA 118.933 -1.603 . . . . 0.0 110.191 -172.1 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.441 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.3 p -119.99 170.45 9.26 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.944 -1.327 . . . . 0.0 111.2 -176.14 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.018 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -139.46 150.1 44.79 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -178.005 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 21.6 tttt -108.9 117.68 34.83 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.045 -1.034 . . . . 0.0 110.375 -179.552 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 1.023 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.0 tp -59.41 128.85 39.15 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.892 -1.13 . . . . 0.0 108.947 173.531 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.119 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.99 -28.82 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 C-N-CA 119.512 -0.875 . . . . 0.0 110.101 -178.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.93 140.56 23.5 Favored 'General case' 0 N--CA 1.493 1.696 0 C-N-CA 119.089 -1.045 . . . . 0.0 111.445 -178.375 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.744 HG23 ' CD2' ' A' ' 24' ' ' HIS . 14.1 mt -109.96 133.39 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.116 -0.99 . . . . 0.0 110.279 172.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.498 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 76.6 m-20 -108.54 116.12 31.37 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.335 -0.853 . . . . 0.0 109.883 172.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -107.64 115.33 29.95 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.948 -1.095 . . . . 0.0 110.735 -175.473 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.48 130.27 24.45 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.21 -0.931 . . . . 0.0 109.209 176.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -52.1 -19.79 9.51 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 123.792 1.417 . . . . 0.0 110.275 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.574 ' ND2' ' N ' ' A' ' 20' ' ' ASN . 0.4 OUTLIER -83.54 -42.57 16.67 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.186 -0.946 . . . . 0.0 108.991 176.554 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.57 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 89.5 m-85 -156.98 150.32 24.14 Favored 'General case' 0 N--CA 1.491 1.617 0 CA-C-O 121.307 0.575 . . . . 0.0 110.044 -177.674 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.484 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 60.2 ttt180 -89.49 143.59 26.7 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.898 -1.126 . . . . 0.0 110.116 177.673 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.498 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.3 m -128.74 135.04 48.67 Favored 'General case' 0 C--N 1.296 -1.735 0 O-C-N 121.548 -0.72 . . . . 0.0 109.827 -176.358 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.744 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -127.78 141.36 51.6 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.813 -1.18 . . . . 0.0 111.594 -179.449 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.885 HG22 ' OG ' ' A' ' 60' ' ' SER . 6.3 t -123.26 133.48 69.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.172 -0.955 . . . . 0.0 110.667 -179.397 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.669 HG13 ' HE2' ' A' ' 61' ' ' PHE . 36.0 m -117.66 172.47 5.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-O 121.233 0.539 . . . . 0.0 110.274 179.533 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.535 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 7.2 tt0 -100.22 116.96 33.44 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.313 -0.867 . . . . 0.0 109.071 179.169 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.657 ' HG ' HD23 ' A' ' 36' ' ' LEU 0.256 0.1 OUTLIER -86.81 114.82 59.99 Favored Pre-proline 0 C--N 1.295 -1.777 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -176.818 . . . . . . . . 4 4 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.57 ' HD2' HD13 ' A' ' 28' ' ' LEU . 18.9 Cg_endo -63.3 174.48 3.33 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.779 1.41 . . . . 0.0 111.187 -178.299 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.574 ' HA ' HD12 ' A' ' 33' ' ' LEU . 1.9 p30 -63.22 -35.54 80.65 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.452 -0.78 . . . . 0.0 111.269 -174.219 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.527 ' N ' ' OD1' ' A' ' 30' ' ' ASP . 0.0 OUTLIER -91.0 -0.19 57.69 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.728 -1.232 . . . . 0.0 111.057 -173.551 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.646 ' HB3' HD11 ' A' ' 28' ' ' LEU . 96.2 mmm -114.48 -14.32 12.15 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 120.925 -1.109 . . . . 0.0 109.815 168.89 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.655 HD21 ' HA ' ' A' ' 57' ' ' ASN . 12.4 mt -64.3 -40.04 95.14 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.163 -0.961 . . . . 0.0 109.932 177.653 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -63.98 131.53 47.93 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.32 -0.862 . . . . 0.0 110.484 -178.104 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.39 -39.26 3.08 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 175.149 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.657 HD23 ' HG ' ' A' ' 28' ' ' LEU . 60.8 tp -62.38 144.52 55.7 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.963 -1.316 . . . . 0.0 110.85 -175.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.467 ' C ' HD11 ' A' ' 54' ' ' ILE . 19.2 pt-20 -151.49 164.78 36.02 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.728 -0.607 . . . . 0.0 109.452 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.8 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -66.92 150.48 49.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.849 -1.157 . . . . 0.0 109.763 178.376 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.63 -0.06 62.0 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 -174.572 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.438 ' CB ' ' O ' ' A' ' 37' ' ' GLU . . . -75.38 158.99 31.92 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.228 -1.16 . . . . 0.0 109.279 175.358 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.692 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.6 OUTLIER -100.39 110.89 23.12 Favored 'General case' 0 N--CA 1.486 1.346 0 C-N-CA 118.854 -1.138 . . . . 0.0 109.829 176.025 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.664 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.8 t -100.1 125.67 53.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.457 -0.777 . . . . 0.0 109.041 175.688 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.48 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -92.0 119.78 32.03 Favored 'General case' 0 C--N 1.297 -1.715 0 C-N-CA 119.041 -1.064 . . . . 0.0 109.242 172.401 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.688 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.6 OUTLIER -87.98 103.02 15.3 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 177.922 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.5 t-20 57.16 11.17 0.98 Allowed 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.455 -0.778 . . . . 0.0 111.141 -170.474 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.471 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 123.84 -0.21 9.17 Favored Glycine 0 N--CA 1.489 2.233 0 C-N-CA 119.584 -1.293 . . . . 0.0 110.605 174.621 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.834 ' O ' HD23 ' A' ' 49' ' ' LEU . 16.7 t -98.74 105.39 17.53 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.41 -1.641 . . . . 0.0 109.535 175.604 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.409 ' HA ' ' HA ' ' A' ' 43' ' ' ALA . 15.9 p -74.05 129.0 36.99 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.983 -1.073 . . . . 0.0 110.855 -172.368 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.864 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -142.95 160.84 39.59 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.377 -0.827 . . . . 0.0 109.605 173.739 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 6.6 m -100.43 148.1 25.12 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.552 -1.342 . . . . 0.0 111.237 -170.09 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.948 HG13 HG13 ' A' ' 59' ' ' VAL . 21.0 t -76.21 115.32 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.892 -0.505 . . . . 0.0 110.475 -179.361 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.534 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 30.4 p -70.46 -40.02 73.93 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.247 -0.908 . . . . 0.0 109.789 173.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.57 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -162.64 154.49 18.36 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.288 -0.882 . . . . 0.0 110.313 -179.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.8 HD11 ' N ' ' A' ' 38' ' ' THR . 7.6 mt -105.72 130.52 57.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.159 -0.963 . . . . 0.0 110.088 176.367 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.5 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 4.7 m-80 -102.51 64.39 0.9 Allowed 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.61 -0.681 . . . . 0.0 109.822 179.027 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.2 -119.5 5.9 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 108.774 -1.73 . . . . 0.0 108.774 -173.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.655 ' HA ' HD21 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -73.12 -22.1 60.61 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 120.878 -1.366 . . . . 0.0 108.643 174.315 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.119 ' CD2' HG11 ' A' ' 13' ' ' VAL . 12.3 m80 -74.02 159.97 31.95 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.283 -0.885 . . . . 0.0 110.431 -176.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.948 HG13 HG13 ' A' ' 51' ' ' VAL . 51.4 t -139.98 125.38 20.77 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 121.084 -1.01 . . . . 0.0 110.706 170.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.885 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.7 t -91.6 135.08 34.13 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.444 -0.785 . . . . 0.0 109.274 175.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.864 ' HB2' HD12 ' A' ' 49' ' ' LEU . 8.8 p90 -128.35 154.39 46.02 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 121.304 -0.872 . . . . 0.0 110.483 177.141 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.534 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 28.9 p-10 -89.67 150.85 22.16 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.157 -0.965 . . . . 0.0 111.332 -171.616 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.7 HD21 HD13 ' A' ' 73' ' ' LEU . 0.0 OUTLIER -155.6 117.6 4.09 Favored 'General case' 0 C--N 1.299 -1.614 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 -176.079 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.54 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 52.6 mtt -68.46 142.33 55.37 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.786 -1.196 . . . . 0.0 109.518 177.425 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.475 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 86.0 tttt -59.97 -44.59 94.36 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 120.991 -1.068 . . . . 0.0 109.715 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 52.5 tp10 -70.04 -39.93 75.43 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.189 -0.944 . . . . 0.0 110.235 178.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.54 ' HB ' ' HB2' ' A' ' 64' ' ' MET . 89.5 m -61.41 -37.81 84.83 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.795 -1.191 . . . . 0.0 109.084 172.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.581 ' CD1' HD22 ' A' ' 63' ' ' LEU . 7.1 tp -60.07 -44.32 94.84 Favored 'General case' 0 C--N 1.297 -1.69 0 O-C-N 121.143 -0.973 . . . . 0.0 109.193 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 52.0 ttt85 -70.08 -39.91 75.3 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.456 -0.777 . . . . 0.0 110.52 175.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.863 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -62.72 -41.38 92.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.176 -0.953 . . . . 0.0 109.072 -177.719 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.863 HG23 HG22 ' A' ' 70' ' ' ILE . 31.2 p -88.93 -176.76 5.29 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 175.765 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.481 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 2.4 t30 -100.18 25.08 7.87 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 172.112 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.7 HD13 HD21 ' A' ' 63' ' ' LEU . 55.7 mt -69.85 -39.99 76.05 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.941 -1.099 . . . . 0.0 109.861 174.556 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.541 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -48.12 -22.76 2.38 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 110.124 -1.19 . . . . 0.0 110.124 -179.034 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.0 p-10 -64.89 -17.38 64.26 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.151 -1.205 . . . . 0.0 110.5 -176.369 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 90.3 mt -62.06 144.02 55.8 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.299 -0.875 . . . . 0.0 110.889 -176.724 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 1.023 ' C ' HD23 ' A' ' 12' ' ' LEU . 35.0 mttp -143.83 143.86 31.51 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.747 -0.596 . . . . 0.0 109.41 174.13 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.67 ' N ' HD23 ' A' ' 12' ' ' LEU . 14.9 t -61.77 150.06 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 120.637 -1.289 . . . . 0.0 110.107 -176.722 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.35 -12.15 61.48 Favored Glycine 0 N--CA 1.483 1.78 0 N-CA-C 108.927 -1.669 . . . . 0.0 108.927 -176.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 48.7 t0 -95.77 166.27 11.89 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.312 -1.111 . . . . 0.0 109.496 176.236 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.6 m95 -117.43 156.63 27.62 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.987 -1.071 . . . . 0.0 110.524 178.728 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.018 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.1 p -120.05 150.88 22.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.516 -0.74 . . . . 0.0 109.874 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.885 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.3 OUTLIER -76.82 106.28 8.4 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.072 -1.018 . . . . 0.0 108.951 168.966 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.67 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -105.97 138.52 30.89 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 120.425 -1.422 . . . . 0.0 111.5 -175.223 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.431 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.8 tt0 -133.3 140.67 47.58 Favored 'General case' 0 N--CA 1.496 1.829 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.178 -179.318 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 71.6 ttt-85 -80.31 134.17 36.04 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.195 -0.94 . . . . 0.0 111.148 -175.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 1.059 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -132.15 150.76 52.08 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.409 -0.807 . . . . 0.0 110.28 179.361 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -124.58 156.13 37.93 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.213 -0.929 . . . . 0.0 111.239 -175.019 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 16.3 mmtp -59.96 -46.97 87.69 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.993 -1.067 . . . . 0.0 110.68 -175.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 42.6 p90 -158.62 160.04 36.09 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.075 -1.016 . . . . 0.0 110.467 178.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.427 ' HB3' ' CG1' ' A' ' 94' ' ' ILE . 16.8 m -154.51 115.43 4.0 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.468 -0.77 . . . . 0.0 110.229 177.646 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.49 ' O ' ' HG3' ' A' ' 93' ' ' GLU . 96.0 m-20 -69.76 -38.29 76.7 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.214 -0.929 . . . . 0.0 110.331 179.007 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.49 ' HG3' ' O ' ' A' ' 92' ' ' ASP . 93.0 mt-10 -156.38 53.07 0.54 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.369 -0.832 . . . . 0.0 110.16 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.427 ' CG1' ' HB3' ' A' ' 91' ' ' SER . 46.0 mm -92.88 -50.83 12.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.286 -0.884 . . . . 0.0 110.31 -179.548 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 90.83 -43.06 2.86 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.46 ' O ' ' HB2' ' A' ' 97' ' ' HIS . . . 141.11 78.57 0.05 OUTLIER Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 179.554 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.46 ' HB2' ' O ' ' A' ' 96' ' ' GLY . 72.4 t60 . . . . . 0 N--CA 1.492 1.668 0 O-C-N 121.365 -1.079 . . . . 0.0 110.079 178.411 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 72.1 mtm . . . . . 0 N--CA 1.494 1.756 0 CA-C-O 121.143 0.497 . . . . 0.0 110.071 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 1.059 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 4.1 p90 -175.33 155.37 1.85 Allowed 'General case' 0 C--N 1.305 -1.358 0 O-C-N 121.216 -0.928 . . . . 0.0 108.715 177.669 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.546 HG23 ' C ' ' B' ' 2' ' ' PHE . 29.9 p -150.71 -38.76 0.13 Allowed 'General case' 0 C--N 1.294 -1.812 0 O-C-N 120.939 -1.101 . . . . 0.0 109.267 175.628 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.471 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 48.48 23.98 3.52 Favored Glycine 0 N--CA 1.483 1.794 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 -175.301 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 0.538 ' CD1' ' HB ' ' B' ' 3' ' ' THR . 79.0 mt -79.25 125.44 38.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.515 -0.991 . . . . 0.0 109.764 -178.111 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.874 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.0 t -84.35 139.38 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.18 -0.95 . . . . 0.0 110.798 -170.51 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -70.01 -34.71 73.65 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.79 -0.569 . . . . 0.0 111.063 178.342 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.542 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -154.96 174.33 33.2 Favored Glycine 0 N--CA 1.495 2.58 0 C-N-CA 118.902 -1.618 . . . . 0.0 110.248 -172.03 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.446 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.5 p -119.9 170.42 9.27 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.892 -1.358 . . . . 0.0 111.173 -176.016 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.067 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -139.53 150.17 44.78 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -178.157 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.57 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 21.6 tttt -108.82 117.83 35.22 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.115 -0.991 . . . . 0.0 110.346 -179.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 1.006 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.0 tp -59.68 128.74 38.47 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 120.936 -1.102 . . . . 0.0 109.019 173.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.132 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.81 -28.9 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 O-C-N 121.33 -0.856 . . . . 0.0 110.139 -178.719 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -148.91 140.66 23.59 Favored 'General case' 0 C--N 1.297 -1.697 0 C-N-CA 119.294 -0.962 . . . . 0.0 111.401 -178.371 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.766 HG23 ' CD2' ' B' ' 24' ' ' HIS . 14.1 mt -109.99 133.38 55.52 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.177 -0.952 . . . . 0.0 110.244 172.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.509 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 76.2 m-20 -108.61 116.23 31.58 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.344 -0.847 . . . . 0.0 109.706 173.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 99.9 mt-10 -107.72 115.37 30.03 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.917 -1.114 . . . . 0.0 110.717 -175.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.413 ' HA ' ' HD2' ' B' ' 19' ' ' PRO . 0.0 OUTLIER -115.55 130.27 24.46 Favored Pre-proline 0 N--CA 1.493 1.712 0 O-C-N 121.269 -0.894 . . . . 0.0 109.294 176.82 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.7 Cg_endo -52.32 -19.77 10.13 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 123.731 1.385 . . . . 0.0 110.21 -179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.569 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 0.4 OUTLIER -83.28 -43.16 16.34 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.26 -0.9 . . . . 0.0 108.867 176.508 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.569 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 89.6 m-85 -156.54 150.36 24.87 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.813 -0.555 . . . . 0.0 110.028 -177.535 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.481 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 60.2 ttt180 -89.37 143.52 26.76 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.942 -1.098 . . . . 0.0 110.152 177.585 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.509 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 94.3 m -128.64 135.04 48.77 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.648 -0.657 . . . . 0.0 109.89 -176.517 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.766 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -127.61 141.54 51.6 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.824 -1.173 . . . . 0.0 111.534 -179.466 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.882 HG22 ' OG ' ' B' ' 60' ' ' SER . 6.2 t -123.32 133.63 68.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.189 -0.945 . . . . 0.0 110.654 -179.458 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.677 HG13 ' HE2' ' B' ' 61' ' ' PHE . 35.2 m -118.03 172.29 5.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.798 -0.564 . . . . 0.0 110.227 179.581 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.525 ' CB ' ' HB3' ' B' ' 11' ' ' LYS . 7.2 tt0 -99.99 117.06 33.47 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.321 -0.862 . . . . 0.0 109.058 179.184 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.678 HD11 ' HB3' ' B' ' 32' ' ' MET 0.255 0.1 OUTLIER -86.83 114.84 60.1 Favored Pre-proline 0 C--N 1.296 -1.723 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 -176.922 . . . . . . . . 4 4 . 1 . 009 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.6 ' HD2' HD13 ' B' ' 28' ' ' LEU . 19.0 Cg_endo -63.3 174.6 3.23 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.744 1.392 . . . . 0.0 111.267 -178.306 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.584 ' HA ' HD12 ' B' ' 33' ' ' LEU . 1.9 p30 -63.35 -35.56 80.81 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.484 -0.76 . . . . 0.0 111.169 -174.206 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.521 ' N ' ' OD1' ' B' ' 30' ' ' ASP . 0.0 OUTLIER -91.05 -0.02 57.64 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.738 -1.226 . . . . 0.0 110.997 -173.51 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.678 ' HB3' HD11 ' B' ' 28' ' ' LEU . 96.2 mmm -114.48 -14.34 12.15 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 120.881 -1.137 . . . . 0.0 109.806 168.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.649 HD21 ' HA ' ' B' ' 57' ' ' ASN . 12.4 mt -64.35 -39.96 94.93 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.184 -0.948 . . . . 0.0 109.989 177.642 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -64.02 131.51 47.82 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.307 -0.87 . . . . 0.0 110.497 -178.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.47 -39.31 3.07 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.329 -1.109 . . . . 0.0 110.329 175.207 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.664 HD23 ' HG ' ' B' ' 28' ' ' LEU . 60.7 tp -62.37 144.57 55.62 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.872 -1.37 . . . . 0.0 110.883 -175.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . 0.455 ' C ' HD11 ' B' ' 54' ' ' ILE . 19.2 pt-20 -151.57 164.78 36.09 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.658 -0.651 . . . . 0.0 109.36 -179.629 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.799 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.92 150.48 49.15 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.784 -1.198 . . . . 0.0 109.827 178.332 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.61 -0.01 62.03 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 -174.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.435 ' CB ' ' O ' ' B' ' 37' ' ' GLU . . . -75.51 158.97 31.82 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.191 -1.182 . . . . 0.0 109.23 175.293 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.684 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.7 OUTLIER -100.21 110.64 22.9 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.977 -1.077 . . . . 0.0 109.901 176.018 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.648 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.8 t -99.95 125.69 53.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.427 -0.796 . . . . 0.0 109.081 175.627 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -91.98 119.73 31.97 Favored 'General case' 0 C--N 1.297 -1.712 0 C-N-CA 119.056 -1.058 . . . . 0.0 109.274 172.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.684 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.6 OUTLIER -87.94 102.95 15.22 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.417 -0.802 . . . . 0.0 108.968 177.887 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.6 t-20 57.32 11.11 1.04 Allowed 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.439 -0.788 . . . . 0.0 111.113 -170.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.464 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 123.77 0.2 9.17 Favored Glycine 0 N--CA 1.489 2.225 0 C-N-CA 119.653 -1.261 . . . . 0.0 110.609 174.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.826 ' O ' HD23 ' B' ' 49' ' ' LEU . 16.9 t -98.99 105.49 17.64 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.465 -1.609 . . . . 0.0 109.464 175.488 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . 0.411 ' HA ' ' HA ' ' B' ' 43' ' ' ALA . 15.9 p -74.06 129.02 37.03 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.012 -1.055 . . . . 0.0 110.802 -172.39 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 0.883 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -143.05 160.79 39.71 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.396 -0.815 . . . . 0.0 109.484 173.751 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 6.6 m -100.27 148.22 24.89 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 120.647 -1.283 . . . . 0.0 111.255 -170.128 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.981 HG13 HG13 ' B' ' 59' ' ' VAL . 21.2 t -76.46 115.24 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.716 -0.615 . . . . 0.0 110.479 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.536 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 30.3 p -70.39 -40.01 74.2 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.213 -0.929 . . . . 0.0 109.818 173.722 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.569 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -162.63 154.48 18.37 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.406 -0.809 . . . . 0.0 110.265 -179.525 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.799 HD11 ' N ' ' B' ' 38' ' ' THR . 7.6 mt -105.6 130.46 56.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.11 -0.994 . . . . 0.0 110.173 176.323 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.511 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 4.6 m-80 -102.53 64.41 0.89 Allowed 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.659 -0.651 . . . . 0.0 109.737 179.082 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.32 -119.52 5.87 Favored Glycine 0 N--CA 1.488 2.166 0 N-CA-C 108.739 -1.744 . . . . 0.0 108.739 -173.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.649 ' HA ' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -73.08 -22.09 60.65 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.894 -1.357 . . . . 0.0 108.753 174.216 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.132 ' CD2' HG11 ' B' ' 13' ' ' VAL . 12.4 m80 -74.07 160.05 31.81 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.257 -0.902 . . . . 0.0 110.421 -176.588 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.981 HG13 HG13 ' B' ' 51' ' ' VAL . 50.7 t -140.14 125.35 20.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 C-N-CA 119.107 -1.037 . . . . 0.0 110.595 170.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.882 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.7 t -91.57 135.25 34.0 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.5 -0.75 . . . . 0.0 109.284 175.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.883 ' HB2' HD12 ' B' ' 49' ' ' LEU . 8.7 p90 -128.46 154.46 46.05 Favored 'General case' 0 N--CA 1.496 1.828 0 C-N-CA 119.338 -0.945 . . . . 0.0 110.417 177.099 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.536 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 29.2 p-10 -89.75 150.83 22.12 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.059 -1.026 . . . . 0.0 111.246 -171.554 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.68 HD21 HD13 ' B' ' 73' ' ' LEU . 0.0 OUTLIER -155.57 117.6 4.09 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -176.125 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.535 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 52.9 mtt -68.38 142.32 55.47 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.889 -1.132 . . . . 0.0 109.463 177.538 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.474 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 86.0 tttt -60.06 -44.54 94.64 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.072 -1.017 . . . . 0.0 109.635 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 52.5 tp10 -69.99 -39.92 75.62 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.148 -0.97 . . . . 0.0 110.328 178.415 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.535 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 89.2 m -61.38 -38.04 85.59 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.776 -1.203 . . . . 0.0 108.99 172.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.591 ' CD1' HD22 ' B' ' 63' ' ' LEU . 7.0 tp -59.99 -44.23 94.66 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.235 -0.916 . . . . 0.0 109.289 -179.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 52.0 ttt85 -70.03 -39.93 75.48 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.38 -0.825 . . . . 0.0 110.563 175.429 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.828 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -62.73 -41.28 91.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 CA-C-O 121.917 0.865 . . . . 0.0 109.07 -177.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.828 HG23 HG22 ' B' ' 70' ' ' ILE . 31.5 p -89.0 -176.63 5.23 Favored 'General case' 0 C--N 1.3 -1.565 0 C-N-CA 120.2 -0.6 . . . . 0.0 109.394 175.859 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.48 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 2.3 t30 -100.17 25.11 7.83 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 172.144 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.68 HD13 HD21 ' B' ' 63' ' ' LEU . 54.8 mt -69.89 -40.0 75.92 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.894 -1.129 . . . . 0.0 109.848 174.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.527 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -48.16 -22.63 2.36 Favored Glycine 0 N--CA 1.488 2.11 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 -179.021 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.5 p-10 -64.89 -17.51 64.39 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.189 -1.183 . . . . 0.0 110.438 -176.392 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 90.2 mt -62.08 143.95 55.93 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.256 -0.902 . . . . 0.0 110.871 -176.601 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 1.006 ' C ' HD23 ' B' ' 12' ' ' LEU . 35.0 mttp -143.76 143.95 31.6 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.637 -0.664 . . . . 0.0 109.395 174.123 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.662 ' N ' HD23 ' B' ' 12' ' ' LEU . 15.3 t -61.78 150.05 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.666 -1.271 . . . . 0.0 110.057 -176.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.2 -11.95 61.67 Favored Glycine 0 N--CA 1.484 1.868 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 -176.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 48.5 t0 -95.81 166.25 11.9 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.386 -1.067 . . . . 0.0 109.458 176.051 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.57 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.6 m95 -117.4 156.62 27.6 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.051 -1.03 . . . . 0.0 110.516 178.759 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.067 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.1 p -120.14 150.94 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.569 -0.707 . . . . 0.0 109.807 179.683 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.874 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.3 OUTLIER -76.79 106.14 8.29 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.037 -1.039 . . . . 0.0 109.014 168.971 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.665 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -105.9 138.71 29.91 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.952 0 O-C-N 120.476 -1.39 . . . . 0.0 111.454 -175.118 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . 0.435 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.7 tt0 -133.42 140.69 47.46 Favored 'General case' 0 N--CA 1.495 1.824 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.191 -179.364 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 71.7 ttt-85 -80.33 134.29 36.04 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.16 -0.962 . . . . 0.0 111.029 -175.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 1.081 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -132.15 150.93 52.04 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.267 -0.896 . . . . 0.0 110.271 179.372 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -124.88 156.09 38.46 Favored 'General case' 0 N--CA 1.5 2.038 0 O-C-N 121.241 -0.912 . . . . 0.0 111.104 -174.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 16.3 mmtp -59.99 -46.93 87.85 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.917 -1.115 . . . . 0.0 110.663 -175.667 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 43.0 p90 -158.73 160.01 35.89 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.099 -1.001 . . . . 0.0 110.451 178.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . 0.721 ' CB ' HD11 ' B' ' 94' ' ' ILE . 17.1 m -154.48 115.43 4.01 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.433 -0.792 . . . . 0.0 110.246 177.697 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -69.94 -40.25 75.59 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.279 -0.888 . . . . 0.0 110.326 179.071 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -114.54 54.32 0.77 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.182 -0.948 . . . . 0.0 111.02 -174.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . 0.721 HD11 ' CB ' ' B' ' 91' ' ' SER . 24.6 mm -60.02 -39.98 81.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.132 -0.98 . . . . 0.0 110.111 173.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 98.86 -55.37 1.0 Allowed Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 178.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -98.55 174.24 28.0 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 -179.802 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 56.5 p-80 . . . . . 0 N--CA 1.491 1.614 0 O-C-N 121.27 -1.135 . . . . 0.0 110.124 179.397 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 0.541 " C2'" ' HC9' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 0.554 HC82 HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.454 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 77.8 mtm . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.212 0.529 . . . . 0.0 110.069 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 1.044 ' CZ ' ' HB1' ' B' ' 87' ' ' ALA . 10.6 p90 -179.6 143.44 0.19 Allowed 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.304 -0.872 . . . . 0.0 109.221 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.5 ' HB ' ' CD1' ' A' ' 5' ' ' ILE . 72.1 p -138.5 -40.82 0.5 Allowed 'General case' 0 C--N 1.298 -1.642 0 O-C-N 120.945 -1.097 . . . . 0.0 108.976 -177.4 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.489 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 44.99 25.59 1.01 Allowed Glycine 0 N--CA 1.485 1.92 0 N-CA-C 108.598 -1.801 . . . . 0.0 108.598 -173.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.999 HD11 ' C8M' ' B' ' 99' ' ' RBF . 94.5 mt -77.26 130.55 36.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.166 -1.196 . . . . 0.0 110.374 -176.221 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.903 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.7 t -89.06 139.97 16.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.54 -0.725 . . . . 0.0 110.287 -175.072 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -81.23 -26.29 35.98 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.427 -0.796 . . . . 0.0 110.891 -179.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.533 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -153.92 176.71 31.74 Favored Glycine 0 N--CA 1.493 2.454 0 C-N-CA 119.288 -1.434 . . . . 0.0 109.922 -176.086 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.472 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 18.4 p -123.34 170.01 10.75 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.942 -1.328 . . . . 0.0 110.839 -178.444 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.041 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -137.36 149.89 47.31 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.557 -0.715 . . . . 0.0 109.65 -177.076 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.583 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 36.9 tttt -104.07 117.86 35.28 Favored 'General case' 0 C--N 1.296 -1.731 0 O-C-N 120.901 -1.124 . . . . 0.0 110.355 178.673 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 1.021 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.1 tp -61.44 126.14 26.29 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.861 -1.15 . . . . 0.0 108.749 171.482 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.067 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.38 -28.86 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.934 0 C-N-CA 119.59 -0.844 . . . . 0.0 110.004 -178.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -148.76 141.02 24.06 Favored 'General case' 0 N--CA 1.495 1.805 0 C-N-CA 118.964 -1.094 . . . . 0.0 111.225 178.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.852 HG23 ' CD2' ' A' ' 24' ' ' HIS . 13.6 mt -105.54 138.22 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.007 -1.058 . . . . 0.0 110.062 171.372 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.509 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 83.7 m-20 -110.83 114.66 28.18 Favored 'General case' 0 C--N 1.297 -1.683 0 O-C-N 121.25 -0.906 . . . . 0.0 109.932 173.789 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -103.35 112.65 25.63 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.017 -1.052 . . . . 0.0 110.374 -178.008 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.456 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 19.7 mtmt -107.02 132.77 20.65 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.296 -0.877 . . . . 0.0 109.282 177.338 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.9 Cg_endo -51.84 -18.9 7.2 Favored 'Trans proline' 0 C--N 1.303 -1.851 0 O-C-N 123.879 1.462 . . . . 0.0 110.745 -179.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.57 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 7.8 m-80 -95.77 -33.06 12.42 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.125 -0.984 . . . . 0.0 110.204 178.298 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.57 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 98.2 m-85 -157.46 150.29 23.23 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.363 -0.836 . . . . 0.0 110.318 -177.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -87.76 145.88 25.91 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 120.898 -1.126 . . . . 0.0 110.108 177.318 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.509 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 92.5 m -133.89 145.37 49.56 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.455 -0.778 . . . . 0.0 109.748 -176.418 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.852 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.4 OUTLIER -135.35 135.27 40.59 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.781 -1.199 . . . . 0.0 111.476 -177.879 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.634 HG22 ' CB ' ' A' ' 60' ' ' SER . 9.7 t -114.43 132.77 62.59 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.092 -1.005 . . . . 0.0 110.814 -179.127 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.442 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 17.4 m -118.11 170.92 6.91 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 CA-C-O 121.177 0.513 . . . . 0.0 110.106 179.217 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.529 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 13.5 tt0 -102.64 118.92 37.91 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.329 -0.857 . . . . 0.0 109.096 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.5 ' HB3' ' CD2' ' A' ' 33' ' ' LEU . 10.2 tp -83.59 123.77 76.1 Favored Pre-proline 0 C--N 1.3 -1.567 0 C-N-CA 119.969 -0.692 . . . . 0.0 109.739 -175.345 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.486 ' HD2' HD12 ' A' ' 28' ' ' LEU . 25.9 Cg_endo -66.18 175.31 4.97 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 O-C-N 123.843 1.444 . . . . 0.0 111.035 -179.298 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.402 ' HA ' HD12 ' A' ' 33' ' ' LEU . 57.8 t0 -59.86 -39.77 86.34 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.387 -0.821 . . . . 0.0 110.831 -175.714 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.602 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -88.76 1.08 55.82 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.941 -1.1 . . . . 0.0 110.633 -175.004 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.602 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 93.5 mmm -112.17 -14.16 13.42 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.989 -1.069 . . . . 0.0 109.916 170.683 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.589 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 19.6 mt -69.96 -39.92 75.72 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.454 -0.779 . . . . 0.0 110.516 178.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -82.26 113.57 20.16 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.281 -0.887 . . . . 0.0 110.437 -176.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.8 -52.62 0.7 Allowed Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.835 -1.174 . . . . 0.0 110.415 175.467 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.635 HD11 ' CG2' ' A' ' 42' ' ' VAL . 5.1 tt -66.37 152.21 45.51 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.93 -1.335 . . . . 0.0 110.756 -173.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.524 ' C ' HD11 ' A' ' 54' ' ' ILE . 11.3 pt-20 -150.76 169.96 20.39 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.477 -0.764 . . . . 0.0 109.752 -177.271 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.828 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -65.43 158.4 26.84 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.951 -1.093 . . . . 0.0 110.38 -178.27 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 71.51 2.71 51.1 Favored Glycine 0 N--CA 1.495 2.57 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 -178.229 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.559 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -82.52 163.73 21.35 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.227 -1.161 . . . . 0.0 109.768 177.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.784 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 1.0 OUTLIER -104.52 112.77 25.97 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 120.982 -1.074 . . . . 0.0 109.985 176.491 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.635 ' CG2' HD11 ' A' ' 36' ' ' LEU . 2.0 t -102.83 130.96 52.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 121.377 -0.827 . . . . 0.0 108.931 173.866 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.501 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -91.45 120.05 31.95 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.214 -0.995 . . . . 0.0 109.092 172.272 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.667 ' CD2' HG21 ' A' ' 82' ' ' VAL . 0.3 OUTLIER -90.3 107.9 19.43 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 177.112 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.1 t-20 52.98 13.09 0.33 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.47 -0.769 . . . . 0.0 111.688 -167.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.446 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 121.22 -2.59 11.48 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.441 -1.362 . . . . 0.0 110.855 172.257 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.789 ' O ' HD23 ' A' ' 49' ' ' LEU . 35.5 t -94.25 109.0 20.84 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.402 -1.646 . . . . 0.0 109.448 174.829 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.52 ' SG ' ' C8 ' ' A' ' 98' ' ' RBF . 17.3 p -76.99 124.65 28.08 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.105 -0.997 . . . . 0.0 110.836 -172.443 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.882 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -140.02 159.98 40.95 Favored 'General case' 0 C--N 1.301 -1.535 0 O-C-N 121.507 -0.745 . . . . 0.0 109.145 173.805 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.474 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 28.5 m -97.03 160.84 14.11 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 120.654 -1.278 . . . . 0.0 111.179 -170.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.756 HG22 ' CE1' ' A' ' 61' ' ' PHE . 18.8 t -84.69 116.39 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.854 -0.529 . . . . 0.0 110.372 -177.376 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.552 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 77.4 p -70.02 -40.02 75.47 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.252 -0.905 . . . . 0.0 109.667 173.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.552 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 54.4 tp10 -164.86 157.9 16.77 Favored 'General case' 0 N--CA 1.491 1.59 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.576 -176.364 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.828 HD11 ' N ' ' A' ' 38' ' ' THR . 8.7 mt -110.44 129.93 64.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.173 -0.954 . . . . 0.0 109.807 172.608 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.522 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 29.0 m-80 -102.35 64.05 0.9 Allowed 'General case' 0 C--N 1.297 -1.716 0 O-C-N 121.738 -0.601 . . . . 0.0 109.474 179.037 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.87 -114.28 4.3 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -172.18 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.589 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.82 -22.43 46.21 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 120.94 -1.33 . . . . 0.0 109.3 175.314 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.067 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.4 m170 -74.43 159.94 31.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.271 -0.893 . . . . 0.0 110.052 -177.489 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.713 HG13 HG13 ' A' ' 51' ' ' VAL . 78.4 t -140.0 120.04 13.38 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 O-C-N 121.103 -0.998 . . . . 0.0 110.693 173.317 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.634 ' CB ' HG22 ' A' ' 25' ' ' VAL . 6.5 t -83.13 138.02 33.84 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.424 -0.798 . . . . 0.0 109.531 176.055 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.882 ' HB3' HD12 ' A' ' 49' ' ' LEU . 87.0 m-85 -120.2 160.52 22.75 Favored 'General case' 0 C--N 1.295 -1.788 0 O-C-N 121.336 -0.853 . . . . 0.0 110.543 177.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.552 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 32.9 p-10 -95.46 148.2 22.73 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.247 -0.908 . . . . 0.0 111.1 179.21 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.745 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -157.23 121.92 4.43 Favored 'General case' 0 C--N 1.297 -1.691 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 -176.762 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.506 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 26.8 ttt -82.19 141.87 32.66 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.983 -1.073 . . . . 0.0 109.669 -178.141 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.484 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 83.3 tttt -60.0 -48.26 82.44 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.094 -1.003 . . . . 0.0 110.611 -173.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.2 tp10 -68.08 -40.06 82.77 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 120.793 -1.192 . . . . 0.0 109.94 179.014 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.566 HG23 HC3' ' A' ' 98' ' ' RBF . 87.4 m -60.01 -39.02 84.37 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.976 -1.078 . . . . 0.0 109.257 173.007 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.775 HD11 ' HA2' ' A' ' 74' ' ' GLY . 2.0 tp -59.98 -45.38 92.9 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.23 -0.919 . . . . 0.0 109.706 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.3 ttt180 -67.05 -39.96 87.04 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.329 -0.857 . . . . 0.0 110.363 176.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.708 HG22 HG23 ' A' ' 71' ' ' THR . 1.1 tt -66.04 -40.14 86.43 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 121.294 -0.879 . . . . 0.0 109.258 -176.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.708 HG23 HG22 ' A' ' 70' ' ' ILE . 52.3 p -84.92 -169.77 2.81 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-O 121.362 0.601 . . . . 0.0 109.524 175.28 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.475 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 7.1 t30 -105.97 22.92 14.83 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 170.445 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.745 ' HB3' HD21 ' A' ' 63' ' ' LEU . 88.5 mt -69.95 -40.03 75.69 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.199 -0.938 . . . . 0.0 110.219 178.289 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.775 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -50.16 -21.6 4.21 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 -177.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.4 p-10 -69.19 -17.45 63.8 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.98 -1.306 . . . . 0.0 110.753 -173.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.513 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 95.9 mt -60.01 141.02 56.38 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.105 -0.997 . . . . 0.0 110.709 -176.818 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 1.021 ' C ' HD23 ' A' ' 12' ' ' LEU . 66.4 mttm -140.0 139.07 35.94 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-O 121.514 0.674 . . . . 0.0 109.88 175.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.665 ' N ' HD23 ' A' ' 12' ' ' LEU . 22.0 t -61.08 152.77 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 120.906 -1.122 . . . . 0.0 110.376 -176.393 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.83 -16.08 57.61 Favored Glycine 0 N--CA 1.482 1.725 0 N-CA-C 108.729 -1.748 . . . . 0.0 108.729 -176.181 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.9 t0 -97.39 169.72 9.56 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.344 -1.091 . . . . 0.0 109.544 175.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.583 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.2 m95 -117.26 166.57 12.12 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.03 -1.044 . . . . 0.0 110.045 177.306 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.041 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.3 p -128.69 157.47 41.33 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.283 -0.886 . . . . 0.0 110.03 -177.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.903 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.2 m-20 -83.54 104.71 13.89 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.177 -0.952 . . . . 0.0 109.083 170.821 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.703 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -107.54 139.27 30.0 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.781 0 O-C-N 120.444 -1.41 . . . . 0.0 111.287 -174.826 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.456 ' HB2' HG22 ' A' ' 6' ' ' VAL . 85.2 tt0 -139.58 138.48 36.25 Favored 'General case' 0 N--CA 1.492 1.674 0 C-N-CA 120.355 -0.538 . . . . 0.0 109.837 -178.612 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.489 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 39.0 ptt180 -73.02 137.72 45.55 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.983 -1.073 . . . . 0.0 110.664 -174.151 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.976 ' HB1' ' CZ ' ' B' ' 2' ' ' PHE . . . -128.09 144.18 51.1 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.254 -0.904 . . . . 0.0 109.923 173.788 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -132.32 148.71 52.44 Favored 'General case' 0 N--CA 1.491 1.622 0 C-N-CA 120.023 -0.671 . . . . 0.0 111.25 -173.335 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 30.9 mtpt -60.54 -40.0 89.95 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.427 -0.796 . . . . 0.0 109.836 174.011 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 53.5 p90 -145.79 159.07 43.72 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.354 -0.841 . . . . 0.0 110.243 -179.445 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 58.5 m -133.29 143.85 49.32 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.261 -0.899 . . . . 0.0 110.298 178.415 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -68.88 -38.8 79.92 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.164 -0.96 . . . . 0.0 110.436 179.361 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 50.71 56.6 7.73 Favored 'General case' 0 N--CA 1.507 2.41 0 C-N-CA 119.834 -0.747 . . . . 0.0 110.373 177.163 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.548 ' O ' ' N ' ' A' ' 96' ' ' GLY . 29.8 mm -60.06 -43.75 93.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.142 -0.974 . . . . 0.0 110.219 177.244 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -49.85 88.26 0.01 OUTLIER Glycine 0 N--CA 1.491 2.358 0 N-CA-C 109.976 -1.25 . . . . 0.0 109.976 -171.042 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 94' ' ' ILE . . . -171.14 -179.81 42.51 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 5.4 m-70 . . . . . 0 N--CA 1.491 1.612 0 O-C-N 121.287 -1.125 . . . . 0.0 110.192 -179.647 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 96.8 mtp . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.091 0.472 . . . . 0.0 110.093 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.976 ' CZ ' ' HB1' ' A' ' 87' ' ' ALA . 10.9 p90 -172.49 143.35 1.36 Allowed 'General case' 0 C--N 1.305 -1.353 0 O-C-N 121.183 -0.948 . . . . 0.0 109.18 174.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.508 ' HB ' ' CD1' ' B' ' 5' ' ' ILE . 72.8 p -138.57 -40.78 0.5 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 120.95 -1.093 . . . . 0.0 109.0 -177.458 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.446 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 45.24 25.25 1.1 Allowed Glycine 0 N--CA 1.485 1.907 0 N-CA-C 108.623 -1.791 . . . . 0.0 108.623 -174.057 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 1.055 HD11 HC81 ' A' ' 98' ' ' RBF . 94.4 mt -77.38 130.6 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.209 -1.171 . . . . 0.0 110.422 -176.041 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.859 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.7 t -89.08 140.05 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.454 -0.779 . . . . 0.0 110.291 -175.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -81.43 -25.96 35.74 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.38 -0.825 . . . . 0.0 110.887 -178.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.536 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -154.09 176.58 31.92 Favored Glycine 0 N--CA 1.494 2.559 0 C-N-CA 119.423 -1.37 . . . . 0.0 109.958 -176.1 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.468 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 18.4 p -123.32 170.05 10.69 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.951 -1.323 . . . . 0.0 110.838 -178.432 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.039 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -137.39 149.9 47.29 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.582 -0.699 . . . . 0.0 109.607 -177.143 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.574 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 36.9 tttt -104.13 117.98 35.55 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.961 -1.087 . . . . 0.0 110.304 178.615 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 1.019 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.1 tp -61.58 126.04 25.94 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.018 -1.051 . . . . 0.0 108.804 171.48 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.064 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.1 -29.12 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.979 0 O-C-N 121.371 -0.831 . . . . 0.0 110.054 -178.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -148.67 141.0 24.15 Favored 'General case' 0 C--N 1.297 -1.688 0 C-N-CA 119.263 -0.975 . . . . 0.0 111.357 178.834 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.861 HG23 ' CD2' ' B' ' 24' ' ' HIS . 13.6 mt -105.6 138.32 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.996 -1.065 . . . . 0.0 110.082 171.373 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.525 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.6 m-20 -110.89 114.79 28.4 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.317 -0.865 . . . . 0.0 109.842 173.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -103.44 112.54 25.48 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.002 -1.061 . . . . 0.0 110.363 -177.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.454 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 19.6 mtmt -107.0 132.72 20.68 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.382 -0.823 . . . . 0.0 109.317 177.34 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -51.92 -18.79 7.3 Favored 'Trans proline' 0 C--N 1.304 -1.782 0 O-C-N 123.832 1.438 . . . . 0.0 110.716 -179.527 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.57 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 7.9 m-80 -95.64 -33.68 12.26 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.107 -0.996 . . . . 0.0 110.068 178.291 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.57 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 98.2 m-85 -157.0 150.29 24.09 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.352 -0.843 . . . . 0.0 110.412 -177.82 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -87.68 145.73 26.02 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.042 -1.036 . . . . 0.0 110.196 177.265 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.525 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 92.7 m -133.85 145.39 49.65 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.386 -0.821 . . . . 0.0 109.755 -176.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.861 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.4 OUTLIER -135.24 135.41 40.92 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.927 -1.108 . . . . 0.0 111.447 -177.804 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.65 HG22 ' CB ' ' B' ' 60' ' ' SER . 9.8 t -114.48 133.01 61.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.25 -0.906 . . . . 0.0 110.789 -179.119 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.449 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 17.7 m -118.45 170.85 7.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 CA-C-O 121.237 0.541 . . . . 0.0 109.988 179.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.528 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 13.5 tt0 -102.55 119.03 38.13 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.365 -0.834 . . . . 0.0 109.122 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.522 HD12 ' HA ' ' B' ' 28' ' ' LEU . 10.3 tp -83.68 123.75 75.94 Favored Pre-proline 0 C--N 1.299 -1.589 0 O-C-N 121.443 -0.786 . . . . 0.0 109.76 -175.358 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.496 ' HD2' HD12 ' B' ' 28' ' ' LEU . 25.8 Cg_endo -66.17 175.44 4.84 Favored 'Trans proline' 0 C--N 1.309 -1.538 0 O-C-N 123.851 1.448 . . . . 0.0 111.049 -179.221 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.411 ' HA ' HD12 ' B' ' 33' ' ' LEU . 58.0 t0 -60.07 -39.68 86.89 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.368 -0.833 . . . . 0.0 110.8 -175.655 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.607 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -88.78 1.08 55.83 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.819 -1.176 . . . . 0.0 110.695 -175.073 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.607 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 93.5 mmm -112.14 -14.13 13.44 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.961 -1.087 . . . . 0.0 109.92 170.628 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.594 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 19.7 mt -70.04 -39.91 75.46 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.366 -0.834 . . . . 0.0 110.511 178.442 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -82.2 113.56 20.12 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.296 -0.878 . . . . 0.0 110.436 -176.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 118.79 -52.64 0.7 Allowed Glycine 0 N--CA 1.491 2.335 0 C-N-CA 119.834 -1.174 . . . . 0.0 110.422 175.436 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.628 HD11 ' CG2' ' B' ' 42' ' ' VAL . 5.2 tt -66.39 152.2 45.57 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 120.916 -1.344 . . . . 0.0 110.807 -173.404 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . 0.503 ' C ' HD11 ' B' ' 54' ' ' ILE . 11.3 pt-20 -150.69 169.99 20.27 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.402 -0.811 . . . . 0.0 109.733 -177.249 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.835 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -65.41 158.36 26.9 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.958 -1.089 . . . . 0.0 110.425 -178.303 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . 0.403 ' N ' ' HB ' ' B' ' 51' ' ' VAL . . . 71.54 2.64 50.83 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.966 -1.253 . . . . 0.0 109.966 -178.233 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.558 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -82.54 163.47 21.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.226 -1.161 . . . . 0.0 109.817 177.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.784 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 1.0 OUTLIER -104.21 112.59 25.67 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.893 -1.129 . . . . 0.0 110.078 176.546 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.628 ' CG2' HD11 ' B' ' 36' ' ' LEU . 2.0 t -102.78 131.01 51.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.389 -0.819 . . . . 0.0 108.947 173.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.496 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -91.44 119.98 31.88 Favored 'General case' 0 C--N 1.296 -1.718 0 O-C-N 121.128 -0.983 . . . . 0.0 109.196 172.149 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.665 ' CD2' HG21 ' B' ' 82' ' ' VAL . 0.3 OUTLIER -90.23 107.55 19.2 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 177.138 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.1 t-20 53.29 13.16 0.39 Allowed 'General case' 0 C--N 1.298 -1.644 0 O-C-N 121.445 -0.784 . . . . 0.0 111.515 -167.252 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.489 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 121.17 -2.44 11.54 Favored Glycine 0 N--CA 1.491 2.311 0 C-N-CA 119.474 -1.346 . . . . 0.0 110.784 172.14 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.782 ' O ' HD23 ' B' ' 49' ' ' LEU . 35.6 t -94.32 109.04 20.9 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.411 -1.64 . . . . 0.0 109.434 174.808 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . 0.513 ' SG ' ' C8 ' ' B' ' 99' ' ' RBF . 16.7 p -76.99 124.77 28.26 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.054 -1.029 . . . . 0.0 110.814 -172.436 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 0.853 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -140.21 159.96 41.02 Favored 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.553 -0.717 . . . . 0.0 109.086 173.773 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . 0.48 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 28.5 m -96.79 160.95 14.08 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.686 -1.259 . . . . 0.0 111.214 -170.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.739 HG22 ' CE1' ' B' ' 61' ' ' PHE . 19.0 t -84.99 116.35 28.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.787 -0.57 . . . . 0.0 110.426 -177.42 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.542 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 77.3 p -69.96 -39.93 75.72 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.154 -0.966 . . . . 0.0 109.716 173.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.561 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 54.4 tp10 -164.94 157.8 16.46 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.546 -0.862 . . . . 0.0 110.589 -176.392 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.835 HD11 ' N ' ' B' ' 38' ' ' THR . 8.7 mt -110.32 129.89 64.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.194 -0.941 . . . . 0.0 109.854 172.667 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.531 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 28.7 m-80 -102.46 64.07 0.89 Allowed 'General case' 0 C--N 1.298 -1.657 0 C-N-CA 120.103 -0.639 . . . . 0.0 109.42 179.101 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.02 -114.35 4.29 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 108.666 -1.774 . . . . 0.0 108.666 -172.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.594 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.65 -22.73 46.43 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.032 -1.275 . . . . 0.0 109.358 175.244 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.064 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.5 m170 -74.21 159.8 32.02 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.386 -0.821 . . . . 0.0 110.097 -177.515 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.729 HG13 HG13 ' B' ' 51' ' ' VAL . 78.4 t -139.99 120.02 13.36 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 C-N-CA 119.017 -1.073 . . . . 0.0 110.574 173.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.65 ' CB ' HG22 ' B' ' 25' ' ' VAL . 6.4 t -83.16 137.98 33.84 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.426 -0.796 . . . . 0.0 109.578 176.044 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.853 ' HB3' HD12 ' B' ' 49' ' ' LEU . 86.4 m-85 -120.25 160.63 22.58 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.351 -0.843 . . . . 0.0 110.471 177.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.542 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 32.9 p-10 -95.48 148.24 22.69 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.113 -0.992 . . . . 0.0 110.945 179.388 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.717 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -157.21 121.93 4.44 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 109.227 -0.657 . . . . 0.0 109.227 -176.829 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.512 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 26.9 ttt -82.21 141.87 32.64 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.067 -1.02 . . . . 0.0 109.722 -178.183 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.482 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 83.3 tttt -59.95 -48.39 81.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.066 -1.021 . . . . 0.0 110.53 -173.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 54.1 tp10 -68.0 -40.05 83.08 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.915 -1.116 . . . . 0.0 109.966 179.088 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.556 HG23 HC3' ' B' ' 99' ' ' RBF . 87.6 m -59.98 -39.1 84.54 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.004 -1.06 . . . . 0.0 109.278 173.017 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.775 HD11 ' HA2' ' B' ' 74' ' ' GLY . 2.0 tp -60.02 -45.2 93.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.314 -0.866 . . . . 0.0 109.734 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -67.06 -39.95 86.97 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.451 -0.781 . . . . 0.0 110.384 176.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.718 HG22 HG23 ' B' ' 71' ' ' THR . 1.2 tt -66.1 -40.11 86.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.289 -0.882 . . . . 0.0 109.212 -176.809 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.718 HG23 HG22 ' B' ' 70' ' ' ILE . 52.3 p -84.84 -169.43 2.64 Favored 'General case' 0 C--N 1.301 -1.543 0 C-N-CA 120.17 -0.612 . . . . 0.0 109.577 175.241 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.489 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 7.0 t30 -106.16 22.75 15.19 Favored 'General case' 0 C--N 1.293 -1.876 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 170.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.717 ' HB3' HD21 ' B' ' 63' ' ' LEU . 88.7 mt -69.91 -40.0 75.87 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.308 -0.87 . . . . 0.0 110.182 178.361 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.775 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -50.16 -21.67 4.27 Favored Glycine 0 N--CA 1.487 2.071 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -177.953 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.1 p-10 -69.22 -17.4 63.77 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.014 -1.286 . . . . 0.0 110.736 -173.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.507 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 95.8 mt -59.99 141.0 56.39 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.139 -0.975 . . . . 0.0 110.8 -176.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 1.019 ' C ' HD23 ' B' ' 12' ' ' LEU . 66.4 mttm -140.03 139.06 35.9 Favored 'General case' 0 C--N 1.298 -1.634 0 O-C-N 121.611 -0.681 . . . . 0.0 109.912 175.673 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.668 ' N ' HD23 ' B' ' 12' ' ' LEU . 22.1 t -61.11 152.76 5.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.036 -1.04 . . . . 0.0 110.43 -176.348 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.64 -15.83 57.95 Favored Glycine 0 N--CA 1.484 1.837 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 -176.072 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 19.8 t0 -97.49 169.63 9.6 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.345 -1.091 . . . . 0.0 109.582 175.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.574 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.3 m95 -117.23 166.52 12.16 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.104 -0.998 . . . . 0.0 110.05 177.389 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.039 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.3 p -128.65 157.54 41.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.41 -0.806 . . . . 0.0 110.054 -177.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.859 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.1 m-20 -83.48 104.53 13.7 Favored 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.307 -0.87 . . . . 0.0 109.263 170.775 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.686 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -107.38 139.55 28.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 120.468 -1.395 . . . . 0.0 111.17 -174.637 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . 0.456 ' HB2' HG22 ' B' ' 6' ' ' VAL . 85.2 tt0 -139.92 138.44 35.63 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 120.389 -0.525 . . . . 0.0 109.789 -178.645 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . 0.478 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 39.0 ptt180 -72.95 137.71 45.67 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.06 -1.025 . . . . 0.0 110.608 -174.09 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 1.044 ' HB1' ' CZ ' ' A' ' 2' ' ' PHE . . . -128.01 144.31 51.1 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.162 -0.962 . . . . 0.0 109.825 173.764 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -132.56 148.74 52.38 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.501 -0.75 . . . . 0.0 111.126 -173.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 30.9 mtpt -60.61 -39.9 89.85 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.349 -0.845 . . . . 0.0 109.923 174.007 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 53.5 p90 -145.83 159.15 43.61 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.282 -0.886 . . . . 0.0 110.332 -179.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . 0.508 ' HB3' ' CG1' ' B' ' 94' ' ' ILE . 58.6 m -133.45 143.79 49.07 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.211 -0.931 . . . . 0.0 110.238 178.545 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -69.15 -44.71 71.74 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.119 -0.988 . . . . 0.0 110.661 179.47 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 82.5 mm-40 -146.66 52.18 1.11 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.76 -1.212 . . . . 0.0 111.128 -176.241 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . 0.508 ' CG1' ' HB3' ' B' ' 91' ' ' SER . 46.1 mm -104.87 -57.01 4.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.132 -0.98 . . . . 0.0 110.121 174.276 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . 0.414 ' C ' ' O ' ' B' ' 94' ' ' ILE . . . 40.03 68.38 0.56 Allowed Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.034 -1.226 . . . . 0.0 110.034 177.196 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . 167.63 -153.01 22.06 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 -179.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 83.7 t60 . . . . . 0 N--CA 1.492 1.636 0 O-C-N 121.216 -1.167 . . . . 0.0 110.158 -179.554 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 1.055 HC81 HD11 ' B' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 0.999 ' C8M' HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.495 ' N ' ' HA ' ' B' ' 89' ' ' LYS . 98.2 mtp . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 121.272 0.558 . . . . 0.0 110.292 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.923 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 4.6 p90 -170.04 156.43 6.02 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 175.14 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.58 HG23 ' C ' ' A' ' 2' ' ' PHE . 62.0 p -152.3 -40.83 0.11 Allowed 'General case' 0 C--N 1.293 -1.873 0 O-C-N 120.852 -1.155 . . . . 0.0 108.87 174.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' B' ' 46' ' ' GLY . . . 47.51 23.98 2.39 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 108.162 -1.975 . . . . 0.0 108.162 -174.64 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.556 HD11 ' C8M' ' B' ' 99' ' ' RBF . 71.1 mt -81.91 119.77 32.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.32 -1.106 . . . . 0.0 109.715 -176.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.655 HG21 ' HB3' ' A' ' 83' ' ' ASN . 3.4 t -75.15 149.16 7.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.362 -0.836 . . . . 0.0 110.583 -173.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 28.2 mm100 -98.48 -15.19 19.69 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.554 -0.716 . . . . 0.0 110.783 179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.532 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -141.0 165.4 26.25 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 119.247 -1.454 . . . . 0.0 109.749 -177.595 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.488 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 0.7 OUTLIER -124.83 169.99 11.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.95 -1.324 . . . . 0.0 110.504 178.746 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.044 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -141.26 149.27 41.1 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.471 -0.768 . . . . 0.0 109.245 -176.525 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.579 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 32.1 tttt -109.65 114.13 27.48 Favored 'General case' 0 C--N 1.294 -1.839 0 O-C-N 121.091 -1.005 . . . . 0.0 110.175 178.852 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.994 HD23 ' C ' ' A' ' 77' ' ' LYS . 11.6 tp -59.69 127.86 34.11 Favored 'General case' 0 C--N 1.298 -1.667 0 O-C-N 121.061 -1.024 . . . . 0.0 108.903 175.137 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.072 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -128.31 -30.65 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.868 0 O-C-N 121.339 -0.851 . . . . 0.0 110.062 -178.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.35 141.97 30.08 Favored 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 119.088 -1.045 . . . . 0.0 111.284 -178.158 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.796 HD11 HG23 ' A' ' 78' ' ' VAL . 8.4 mt -110.04 132.89 57.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.098 -1.001 . . . . 0.0 110.362 172.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.514 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 88.5 m-20 -109.8 114.97 28.98 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.41 -0.806 . . . . 0.0 110.038 175.353 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -102.62 109.61 21.28 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.01 -1.056 . . . . 0.0 110.471 -177.402 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.3 OUTLIER -101.71 135.96 19.66 Favored Pre-proline 0 N--CA 1.492 1.646 0 O-C-N 121.243 -0.91 . . . . 0.0 109.557 175.884 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -53.97 -16.92 9.83 Favored 'Trans proline' 0 C--N 1.302 -1.877 0 O-C-N 123.956 1.503 . . . . 0.0 110.853 -179.631 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.555 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 6.0 m-80 -102.7 -26.56 13.13 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.063 -1.023 . . . . 0.0 109.953 179.744 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.555 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 87.6 m-85 -156.69 150.24 24.52 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.428 -0.795 . . . . 0.0 109.919 -178.549 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.484 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 61.3 ttt180 -92.36 141.74 28.21 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.665 -1.272 . . . . 0.0 109.844 174.799 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.514 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 89.1 m -129.94 140.05 51.0 Favored 'General case' 0 C--N 1.295 -1.799 0 O-C-N 121.495 -0.753 . . . . 0.0 109.824 -172.677 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.717 ' NE2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -130.09 142.47 50.6 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 120.986 -1.071 . . . . 0.0 111.413 -179.286 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.826 HG22 ' CB ' ' A' ' 60' ' ' SER . 16.6 t -119.66 134.31 63.63 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.111 -0.993 . . . . 0.0 110.418 179.574 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.91 HG13 ' CE1' ' A' ' 61' ' ' PHE . 32.9 m -116.82 170.76 6.02 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 O-C-N 121.912 -0.492 . . . . 0.0 110.113 178.894 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.539 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 9.4 tt0 -102.65 116.64 33.0 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 108.82 -0.808 . . . . 0.0 108.82 179.401 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.499 HD23 ' HA ' ' A' ' 33' ' ' LEU . 8.7 tp -80.56 121.63 81.54 Favored Pre-proline 0 C--N 1.295 -1.771 0 O-C-N 121.493 -0.755 . . . . 0.0 109.653 -173.74 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.466 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 18.5 Cg_endo -63.42 178.84 1.07 Allowed 'Trans proline' 0 C--N 1.308 -1.583 0 O-C-N 123.874 1.46 . . . . 0.0 111.004 -179.112 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.527 ' HA ' HD12 ' A' ' 33' ' ' LEU . 88.3 m-20 -60.32 -39.91 88.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.373 -0.83 . . . . 0.0 111.102 -175.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.606 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.17 0.26 57.27 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.833 -1.167 . . . . 0.0 110.93 -175.553 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.606 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.1 mmm -109.12 -12.84 14.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.923 -1.11 . . . . 0.0 110.006 171.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.832 HD21 ' HB2' ' A' ' 57' ' ' ASN . 19.2 mt -68.8 -31.35 70.29 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.284 -0.885 . . . . 0.0 110.221 178.098 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 52.6 t0 -94.06 122.94 37.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.282 -0.886 . . . . 0.0 110.319 -178.315 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 111.42 -50.6 0.76 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 177.172 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.572 HD23 ' N ' ' A' ' 37' ' ' GLU . 6.7 tt -67.0 140.03 57.7 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.087 -1.243 . . . . 0.0 110.296 -176.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.572 ' N ' HD23 ' A' ' 36' ' ' LEU . 19.7 pt-20 -147.42 168.5 21.71 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.383 -0.823 . . . . 0.0 109.451 176.767 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.773 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -63.24 151.65 39.87 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 120.975 -1.078 . . . . 0.0 110.265 -175.885 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.52 -0.44 60.58 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 -174.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.608 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -79.99 159.37 26.29 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.162 -1.199 . . . . 0.0 109.392 175.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.456 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.5 OUTLIER -103.19 117.54 34.77 Favored 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 118.849 -1.141 . . . . 0.0 110.155 177.068 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.642 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.6 t -102.37 128.28 55.21 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.639 0 O-C-N 121.335 -0.853 . . . . 0.0 108.907 172.476 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.51 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -92.88 119.68 32.44 Favored 'General case' 0 C--N 1.297 -1.689 0 C-N-CA 119.214 -0.995 . . . . 0.0 109.096 172.644 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.682 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -87.62 102.63 14.8 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 119.729 -0.789 . . . . 0.0 108.982 179.194 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.8 t-20 59.6 6.29 0.8 Allowed 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.685 -0.634 . . . . 0.0 111.681 -170.642 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.454 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 128.58 -1.04 6.42 Favored Glycine 0 N--CA 1.489 2.181 0 C-N-CA 119.525 -1.321 . . . . 0.0 110.655 174.352 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.677 ' O ' HD23 ' A' ' 49' ' ' LEU . 34.8 t -98.51 108.67 21.42 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.438 -1.624 . . . . 0.0 109.55 175.74 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 22.7 p -74.3 130.17 39.18 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.087 -1.008 . . . . 0.0 111.074 -171.351 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.841 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -147.02 153.82 40.48 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.429 -0.794 . . . . 0.0 109.356 173.901 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.424 HG22 ' N ' ' A' ' 51' ' ' VAL . 92.5 m -95.83 160.11 14.64 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 120.527 -1.358 . . . . 0.0 111.558 -169.118 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.925 HG13 HG13 ' A' ' 59' ' ' VAL . 15.8 t -82.08 114.72 23.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.847 -0.533 . . . . 0.0 110.358 -178.804 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.55 HG22 ' HB3' ' A' ' 62' ' ' ASP . 30.2 p -70.9 -39.94 72.47 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.322 -0.861 . . . . 0.0 109.977 175.137 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.571 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -166.19 154.2 10.47 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.31 -0.869 . . . . 0.0 110.177 179.677 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.773 HD11 ' N ' ' A' ' 38' ' ' THR . 9.8 mt -108.31 134.91 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.1 -1.0 . . . . 0.0 110.138 177.699 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.507 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 47.4 m-80 -108.81 66.23 0.63 Allowed 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.601 -0.687 . . . . 0.0 109.512 177.87 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.2 -116.84 5.11 Favored Glycine 0 N--CA 1.487 2.091 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 -173.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.832 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.43 -20.19 51.57 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.055 -1.262 . . . . 0.0 109.116 177.012 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.072 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.9 m170 -76.61 158.92 30.72 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.241 -0.912 . . . . 0.0 110.044 -178.35 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.925 HG13 HG13 ' A' ' 51' ' ' VAL . 55.6 t -140.78 123.06 15.31 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 O-C-N 121.055 -1.028 . . . . 0.0 110.591 171.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.826 ' CB ' HG22 ' A' ' 25' ' ' VAL . 0.9 OUTLIER -87.5 133.32 33.78 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.47 -0.769 . . . . 0.0 109.13 175.264 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.91 ' CE1' HG13 ' A' ' 26' ' ' VAL . 1.8 p90 -125.96 156.01 40.46 Favored 'General case' 0 C--N 1.295 -1.79 0 O-C-N 121.378 -0.826 . . . . 0.0 110.185 178.038 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.55 ' HB3' HG22 ' A' ' 52' ' ' THR . 36.7 p-10 -90.78 151.16 21.31 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.089 -1.007 . . . . 0.0 111.398 -170.161 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.812 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -159.82 111.54 2.03 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 -175.574 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.525 ' HB2' ' CB ' ' A' ' 67' ' ' THR . 28.4 mtm -66.17 140.02 58.16 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.819 -1.176 . . . . 0.0 109.825 -179.848 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.498 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 49.3 tptt -60.11 -49.8 76.23 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.209 -0.932 . . . . 0.0 110.251 -178.411 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -65.2 -40.01 93.58 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.875 -1.141 . . . . 0.0 109.76 176.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.525 ' CB ' ' HB2' ' A' ' 64' ' ' MET . 94.3 m -60.05 -39.7 86.89 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.02 -1.05 . . . . 0.0 109.452 173.289 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.724 HD11 ' HA2' ' A' ' 74' ' ' GLY . 7.8 tp -59.95 -43.57 94.95 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.308 -0.87 . . . . 0.0 109.65 179.723 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -68.16 -40.01 82.45 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.38 -0.825 . . . . 0.0 110.579 176.042 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.853 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -64.9 -43.25 96.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.17 -0.956 . . . . 0.0 109.328 -177.108 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.853 HG23 HG22 ' A' ' 70' ' ' ILE . 29.9 p -86.68 -174.63 5.07 Favored 'General case' 0 C--N 1.299 -1.618 0 O-C-N 121.727 -0.608 . . . . 0.0 109.667 176.751 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.489 ' HB2' ' N ' ' B' ' 83' ' ' ASN . 6.1 t30 -98.78 22.59 9.87 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.167 -0.958 . . . . 0.0 108.686 171.469 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.812 ' HB3' HD21 ' A' ' 63' ' ' LEU . 91.8 mt -68.73 -39.98 80.12 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.095 -1.003 . . . . 0.0 109.975 176.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.724 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -50.44 -23.9 6.78 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -178.351 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.5 p-10 -62.12 -18.01 59.53 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.089 -1.242 . . . . 0.0 110.233 -175.764 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.9 mt -63.62 142.09 58.53 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.319 -0.863 . . . . 0.0 110.961 -177.69 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 0.994 ' C ' HD23 ' A' ' 12' ' ' LEU . 42.8 mttt -143.54 144.84 32.13 Favored 'General case' 0 N--CA 1.493 1.686 0 CA-C-O 121.311 0.577 . . . . 0.0 109.731 175.106 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.796 HG23 HD11 ' A' ' 15' ' ' ILE . 21.9 t -64.52 149.93 10.7 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 120.843 -1.161 . . . . 0.0 110.479 -175.327 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.97 -13.63 60.78 Favored Glycine 0 N--CA 1.484 1.842 0 N-CA-C 108.745 -1.742 . . . . 0.0 108.745 -175.144 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 46.6 t0 -94.61 163.3 13.44 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.337 -1.096 . . . . 0.0 109.585 176.021 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.579 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 13.9 m95 -113.28 154.79 26.23 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 120.964 -1.085 . . . . 0.0 110.155 175.829 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.044 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.4 p -119.99 153.03 22.82 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.437 -0.789 . . . . 0.0 109.852 -179.019 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.655 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.4 OUTLIER -77.73 107.34 10.16 Favored 'General case' 0 C--N 1.295 -1.794 0 O-C-N 121.171 -0.955 . . . . 0.0 109.02 168.475 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.758 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -109.4 138.85 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 120.474 -1.391 . . . . 0.0 111.364 -176.724 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.481 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.6 tt0 -131.49 139.59 49.35 Favored 'General case' 0 N--CA 1.494 1.749 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.131 -179.369 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -81.37 133.62 35.44 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.091 -1.006 . . . . 0.0 110.94 -175.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.901 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -130.69 147.31 52.35 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.28 -0.888 . . . . 0.0 110.639 179.809 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.885 ' HB1' ' CE2' ' A' ' 90' ' ' PHE . . . -151.19 9.07 0.55 Allowed 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.49 -0.756 . . . . 0.0 111.981 -178.168 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.622 ' HG3' ' CE2' ' B' ' 2' ' ' PHE . 20.7 mttm 60.02 19.83 8.96 Favored 'General case' 0 N--CA 1.513 2.698 0 O-C-N 121.373 -0.829 . . . . 0.0 110.781 175.029 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.885 ' CE2' ' HB1' ' A' ' 88' ' ' ALA . 9.6 p90 -154.09 159.65 41.6 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.905 -1.122 . . . . 0.0 110.591 172.68 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.536 ' HB3' ' CG1' ' A' ' 94' ' ' ILE . 56.7 m -141.78 150.18 41.37 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.493 -0.754 . . . . 0.0 109.831 175.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.496 ' O ' ' HG3' ' A' ' 93' ' ' GLU . 51.8 t0 -69.87 -45.93 66.62 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.107 -0.996 . . . . 0.0 110.313 -178.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.496 ' HG3' ' O ' ' A' ' 92' ' ' ASP . 94.0 mt-10 -157.35 53.96 0.49 Allowed 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.338 -0.852 . . . . 0.0 110.444 179.198 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.536 ' CG1' ' HB3' ' A' ' 91' ' ' SER . 48.4 mm -98.95 -37.77 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.138 -0.976 . . . . 0.0 110.456 178.661 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 47.11 67.66 1.4 Allowed Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 -178.635 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.493 ' O ' ' CB ' ' A' ' 97' ' ' HIS . . . -178.59 -170.01 40.07 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -178.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.493 ' CB ' ' O ' ' A' ' 96' ' ' GLY . 0.9 OUTLIER . . . . . 0 N--CA 1.493 1.723 0 O-C-N 121.188 -1.184 . . . . 0.0 110.139 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 98.1 mtp . . . . . 0 N--CA 1.492 1.655 0 CA-C-O 121.062 0.458 . . . . 0.0 110.139 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.901 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 4.6 p90 -165.77 156.24 13.12 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.075 -1.016 . . . . 0.0 108.406 172.725 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.594 HG23 ' C ' ' B' ' 2' ' ' PHE . 60.7 p -152.2 -40.9 0.11 Allowed 'General case' 0 C--N 1.292 -1.912 0 O-C-N 120.91 -1.119 . . . . 0.0 108.818 175.01 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.448 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 47.39 24.13 2.33 Favored Glycine 0 N--CA 1.481 1.692 0 N-CA-C 108.213 -1.955 . . . . 0.0 108.213 -174.52 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 0.519 HD11 ' C8M' ' A' ' 98' ' ' RBF . 70.8 mt -82.01 119.77 32.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.287 -1.125 . . . . 0.0 109.689 -176.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.653 HG21 ' HB3' ' B' ' 83' ' ' ASN . 3.4 t -75.1 149.17 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.352 -0.843 . . . . 0.0 110.583 -173.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 28.2 mm100 -98.55 -14.83 19.77 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.54 -0.725 . . . . 0.0 110.854 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.529 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -141.28 165.14 26.42 Favored Glycine 0 N--CA 1.493 2.458 0 C-N-CA 119.338 -1.41 . . . . 0.0 109.868 -177.536 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.487 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 0.7 OUTLIER -124.74 169.99 11.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.123 -1.221 . . . . 0.0 110.556 178.821 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.023 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -141.31 149.34 41.1 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.507 -0.745 . . . . 0.0 109.235 -176.617 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 32.0 tttt -109.7 114.34 27.86 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.151 -0.968 . . . . 0.0 110.014 178.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 1.001 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.7 tp -60.02 127.78 33.57 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.104 -0.998 . . . . 0.0 108.939 175.106 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.084 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.96 -31.04 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 O-C-N 121.393 -0.817 . . . . 0.0 110.1 -178.651 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -144.08 141.9 30.32 Favored 'General case' 0 N--CA 1.492 1.645 0 C-N-CA 119.397 -0.921 . . . . 0.0 111.328 -178.082 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.82 HD11 HG23 ' B' ' 78' ' ' VAL . 8.4 mt -109.91 132.96 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.128 -0.982 . . . . 0.0 110.377 172.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.519 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 88.2 m-20 -109.99 114.98 28.95 Favored 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.416 -0.803 . . . . 0.0 109.995 175.388 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -102.59 109.67 21.36 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.982 -1.074 . . . . 0.0 110.497 -177.399 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.3 OUTLIER -101.87 135.95 19.62 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.274 -0.892 . . . . 0.0 109.541 175.943 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.05 -16.85 9.97 Favored 'Trans proline' 0 C--N 1.303 -1.837 0 O-C-N 123.934 1.492 . . . . 0.0 110.856 -179.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.547 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 6.0 m-80 -102.56 -26.98 13.03 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.107 -0.996 . . . . 0.0 109.874 179.706 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.547 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 87.5 m-85 -156.3 150.22 25.08 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.432 -0.793 . . . . 0.0 109.972 -178.426 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.487 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 61.2 ttt180 -92.31 141.67 28.3 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 120.701 -1.25 . . . . 0.0 109.806 174.786 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.519 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 88.4 m -129.96 140.12 50.97 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 121.617 -0.677 . . . . 0.0 109.798 -172.715 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.729 ' NE2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -130.05 142.45 50.61 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 120.964 -1.085 . . . . 0.0 111.338 -179.158 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.835 HG22 ' CB ' ' B' ' 60' ' ' SER . 16.3 t -119.51 134.41 63.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.264 -0.898 . . . . 0.0 110.435 179.55 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.911 HG13 ' CE1' ' B' ' 61' ' ' PHE . 33.1 m -117.09 170.76 6.21 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 CA-C-O 121.263 0.554 . . . . 0.0 109.955 178.921 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.522 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 9.3 tt0 -102.56 116.68 33.08 Favored 'General case' 0 C--N 1.304 -1.378 0 N-CA-C 108.878 -0.786 . . . . 0.0 108.878 179.345 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.498 ' HA ' HD12 ' B' ' 28' ' ' LEU . 8.7 tp -80.54 121.62 81.56 Favored Pre-proline 0 C--N 1.297 -1.703 0 O-C-N 121.433 -0.792 . . . . 0.0 109.716 -173.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.478 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 18.5 Cg_endo -63.4 178.86 1.06 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 O-C-N 123.91 1.479 . . . . 0.0 111.007 -179.09 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.516 ' HA ' HD12 ' B' ' 33' ' ' LEU . 88.1 m-20 -60.29 -39.98 88.85 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.356 -0.84 . . . . 0.0 111.118 -175.827 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.588 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.11 0.28 57.23 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.87 -1.144 . . . . 0.0 110.945 -175.609 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.588 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.1 mmm -109.16 -12.81 14.77 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.87 -1.144 . . . . 0.0 109.93 171.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.833 HD21 ' HB2' ' B' ' 57' ' ' ASN . 19.2 mt -68.88 -31.32 70.17 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.226 -0.921 . . . . 0.0 110.22 178.054 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -93.99 122.95 37.02 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.381 -0.824 . . . . 0.0 110.363 -178.38 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 111.43 -50.65 0.75 Allowed Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.061 -1.215 . . . . 0.0 110.061 177.166 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.576 HD23 ' N ' ' B' ' 37' ' ' GLU . 6.7 tt -66.97 140.02 57.72 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.051 -1.264 . . . . 0.0 110.299 -176.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . 0.576 ' N ' HD23 ' B' ' 36' ' ' LEU . 19.7 pt-20 -147.38 168.55 21.54 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.401 -0.812 . . . . 0.0 109.41 176.673 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.783 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -63.33 151.51 40.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.995 -1.066 . . . . 0.0 110.382 -175.949 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.73 -0.48 61.32 Favored Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -174.658 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.607 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -80.07 159.34 26.18 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 121.141 -1.211 . . . . 0.0 109.382 175.816 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.498 ' HG ' ' HZ ' ' A' ' 2' ' ' PHE . 0.5 OUTLIER -102.99 117.33 34.36 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.782 -1.199 . . . . 0.0 110.309 177.03 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.635 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.7 t -102.27 128.43 54.93 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 121.357 -0.839 . . . . 0.0 108.868 172.5 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -92.97 119.74 32.55 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 119.227 -0.989 . . . . 0.0 108.988 172.617 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.684 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -87.72 102.45 14.65 Favored 'General case' 0 C--N 1.302 -1.49 0 C-N-CA 119.54 -0.864 . . . . 0.0 109.098 179.106 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 59.84 6.38 0.89 Allowed 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.554 -0.716 . . . . 0.0 111.549 -170.688 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' A' ' 4' ' ' GLY . . . 128.38 -0.62 6.46 Favored Glycine 0 N--CA 1.489 2.218 0 C-N-CA 119.568 -1.301 . . . . 0.0 110.714 174.228 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.694 ' O ' HD23 ' B' ' 49' ' ' LEU . 34.6 t -98.63 108.61 21.34 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.502 -1.587 . . . . 0.0 109.537 175.552 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 22.9 p -74.19 130.19 39.27 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.058 -1.026 . . . . 0.0 111.043 -171.429 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 0.856 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -147.11 153.92 40.5 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.527 -0.733 . . . . 0.0 109.359 173.726 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . 0.421 HG22 ' N ' ' B' ' 51' ' ' VAL . 92.9 m -95.9 160.41 14.48 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 120.527 -1.358 . . . . 0.0 111.556 -169.085 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.946 HG13 HG13 ' B' ' 59' ' ' VAL . 16.1 t -82.44 114.65 23.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.84 -0.538 . . . . 0.0 110.433 -178.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.542 HG22 ' HB3' ' B' ' 62' ' ' ASP . 30.2 p -70.71 -40.03 73.07 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.272 -0.893 . . . . 0.0 109.918 175.339 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.574 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -166.21 154.11 10.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.202 -0.936 . . . . 0.0 110.208 179.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.783 HD11 ' N ' ' B' ' 38' ' ' THR . 9.8 mt -108.31 134.89 48.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.114 -0.991 . . . . 0.0 110.206 177.684 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.515 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 47.1 m-80 -108.84 66.14 0.63 Allowed 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.64 -0.662 . . . . 0.0 109.522 177.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.32 -116.81 5.08 Favored Glycine 0 N--CA 1.488 2.111 0 N-CA-C 108.861 -1.696 . . . . 0.0 108.861 -173.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.833 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.44 -20.29 51.35 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 121.075 -1.25 . . . . 0.0 109.151 177.054 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.084 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.9 m170 -76.5 158.79 30.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.347 -0.846 . . . . 0.0 110.097 -178.375 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.946 HG13 HG13 ' B' ' 51' ' ' VAL . 55.8 t -140.76 123.15 15.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 C-N-CA 119.076 -1.05 . . . . 0.0 110.519 171.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.835 ' CB ' HG22 ' B' ' 25' ' ' VAL . 0.9 OUTLIER -87.52 133.3 33.79 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.441 -0.787 . . . . 0.0 109.204 175.225 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.911 ' CE1' HG13 ' B' ' 26' ' ' VAL . 1.8 p90 -125.98 155.99 40.53 Favored 'General case' 0 N--CA 1.494 1.773 0 C-N-CA 119.395 -0.922 . . . . 0.0 110.177 178.033 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.542 ' HB3' HG22 ' B' ' 52' ' ' THR . 36.6 p-10 -90.67 151.19 21.37 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.0 -1.062 . . . . 0.0 111.381 -170.115 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.784 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.82 111.53 2.03 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 -175.638 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.528 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 28.5 mtm -66.22 139.96 58.13 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.888 -1.133 . . . . 0.0 109.824 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.499 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 49.3 tptt -59.92 -49.87 76.01 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.131 -0.98 . . . . 0.0 110.3 -178.439 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -65.24 -39.99 93.42 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.913 -1.117 . . . . 0.0 109.765 176.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.528 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 94.5 m -60.01 -39.83 87.19 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.988 -1.07 . . . . 0.0 109.342 173.29 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.717 HD11 ' HA2' ' B' ' 74' ' ' GLY . 7.8 tp -59.94 -43.45 94.97 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.293 -0.879 . . . . 0.0 109.707 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 78.5 ttt180 -68.21 -40.08 82.21 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.293 -0.879 . . . . 0.0 110.603 175.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.831 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -64.75 -43.24 96.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.195 -0.941 . . . . 0.0 109.434 -177.213 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.831 HG23 HG22 ' B' ' 70' ' ' ILE . 30.0 p -86.65 -174.56 5.04 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 120.231 -0.588 . . . . 0.0 109.658 176.774 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.506 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 6.0 t30 -98.71 22.57 9.84 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 121.19 -0.944 . . . . 0.0 108.78 171.393 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.784 ' HB3' HD21 ' B' ' 63' ' ' LEU . 91.4 mt -68.71 -40.0 80.17 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.075 -1.015 . . . . 0.0 110.05 176.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.717 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -50.46 -23.87 6.78 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 -178.384 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.0 p-10 -62.1 -17.94 59.23 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.062 -1.258 . . . . 0.0 110.295 -175.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.513 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.1 mt -63.68 142.22 58.48 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.287 -0.883 . . . . 0.0 110.929 -177.746 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 1.001 ' C ' HD23 ' B' ' 12' ' ' LEU . 42.8 mttt -143.67 144.95 32.1 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.627 -0.671 . . . . 0.0 109.665 175.13 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.82 HG23 HD11 ' B' ' 15' ' ' ILE . 22.2 t -64.73 150.03 10.76 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 O-C-N 120.856 -1.153 . . . . 0.0 110.341 -175.182 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.8 -13.45 60.89 Favored Glycine 0 N--CA 1.484 1.84 0 N-CA-C 108.848 -1.701 . . . . 0.0 108.848 -175.16 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 46.2 t0 -94.62 163.23 13.47 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.319 -1.106 . . . . 0.0 109.59 175.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.584 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 13.9 m95 -113.31 154.73 26.37 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.97 -1.081 . . . . 0.0 110.215 175.782 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.023 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.4 p -119.98 153.1 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.579 -0.701 . . . . 0.0 109.881 -179.082 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.653 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.3 OUTLIER -77.72 107.27 10.09 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.178 -0.951 . . . . 0.0 109.018 168.569 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.765 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -109.32 138.96 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 120.462 -1.399 . . . . 0.0 111.211 -176.533 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . 0.465 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.7 tt0 -131.58 139.68 49.25 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.883 -0.511 . . . . 0.0 110.144 -179.569 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -81.35 133.69 35.46 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.117 -0.99 . . . . 0.0 110.916 -175.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 0.923 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -130.85 147.19 52.47 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.403 -0.81 . . . . 0.0 110.647 179.814 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . 0.883 ' HB1' ' CE2' ' B' ' 90' ' ' PHE . . . -151.22 8.96 0.55 Allowed 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.39 -0.819 . . . . 0.0 112.067 -178.066 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . 0.592 ' HG3' ' CE2' ' A' ' 2' ' ' PHE . 20.6 mttm 59.96 19.98 9.03 Favored 'General case' 0 N--CA 1.512 2.66 0 O-C-N 121.334 -0.854 . . . . 0.0 110.732 175.015 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . 0.883 ' CE2' ' HB1' ' B' ' 88' ' ' ALA . 9.7 p90 -154.1 159.68 41.6 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 120.872 -1.143 . . . . 0.0 110.685 172.536 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . 0.525 ' HB3' HG12 ' B' ' 94' ' ' ILE . 56.4 m -141.8 150.28 41.48 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.476 -0.765 . . . . 0.0 109.787 175.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 52.0 t0 -69.94 -50.29 43.47 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.081 -1.012 . . . . 0.0 110.388 -178.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . 0.435 ' O ' ' HG3' ' B' ' 93' ' ' GLU . 16.6 pt-20 -160.51 63.46 0.32 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.037 -1.039 . . . . 0.0 111.441 -175.589 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . 0.787 HG21 ' OXT' ' B' ' 97' ' ' HIS . 20.2 mm -60.04 -42.96 91.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 120.92 -1.113 . . . . 0.0 109.995 174.745 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 114.67 -102.02 1.13 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.489 -1.445 . . . . 0.0 109.489 -177.706 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -67.28 -41.62 91.41 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -178.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . 0.787 ' OXT' HG21 ' B' ' 94' ' ' ILE . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.588 0 O-C-N 121.236 -1.155 . . . . 0.0 110.291 -178.064 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 0.538 " O2'" ' C9 ' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 0.556 ' C8M' HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.422 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 73.0 mtm . . . . . 0 N--CA 1.493 1.724 0 CA-C-O 121.274 0.559 . . . . 0.0 110.12 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 1.003 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 5.0 p90 -176.83 147.59 0.61 Allowed 'General case' 0 C--N 1.306 -1.322 0 O-C-N 121.148 -0.97 . . . . 0.0 108.815 179.413 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.55 ' CB ' HG12 ' A' ' 5' ' ' ILE . 6.0 p -141.05 -37.98 0.43 Allowed 'General case' 0 C--N 1.296 -1.723 0 O-C-N 120.891 -1.131 . . . . 0.0 109.223 -179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.461 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 47.64 24.64 2.89 Favored Glycine 0 N--CA 1.485 1.918 0 N-CA-C 108.541 -1.824 . . . . 0.0 108.541 -176.214 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.55 HG12 ' CB ' ' A' ' 3' ' ' THR . 48.4 mm -80.48 124.64 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.294 -1.121 . . . . 0.0 110.032 -175.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.954 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.5 t -84.22 141.82 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.367 -0.833 . . . . 0.0 110.638 -172.606 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 20.1 pt20 -89.64 -16.15 31.13 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.453 -0.779 . . . . 0.0 110.829 -178.426 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -158.45 177.12 35.25 Favored Glycine 0 N--CA 1.493 2.484 0 C-N-CA 119.129 -1.51 . . . . 0.0 110.083 -177.522 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.487 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 1.4 p -125.87 167.97 14.51 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.069 -1.254 . . . . 0.0 110.472 178.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.07 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -139.93 149.64 43.57 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.346 -0.846 . . . . 0.0 109.903 -174.283 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.585 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 31.2 tttt -106.26 116.01 31.21 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.126 -0.984 . . . . 0.0 110.169 179.255 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.998 HD23 ' C ' ' A' ' 77' ' ' LYS . 13.1 tp -59.93 128.03 34.84 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.793 -1.192 . . . . 0.0 108.582 171.676 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.145 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.7 p -131.34 -31.01 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 O-C-N 121.262 -0.898 . . . . 0.0 110.316 -176.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -144.34 139.68 28.65 Favored 'General case' 0 N--CA 1.493 1.714 0 C-N-CA 118.936 -1.106 . . . . 0.0 111.39 179.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.736 HG23 ' CD2' ' A' ' 24' ' ' HIS . 9.9 mt -109.16 137.0 43.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.052 -1.03 . . . . 0.0 110.08 171.366 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.478 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 78.7 m-20 -111.86 114.35 27.25 Favored 'General case' 0 C--N 1.295 -1.79 0 O-C-N 121.415 -0.803 . . . . 0.0 110.182 173.028 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -105.04 118.61 36.97 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.033 -1.042 . . . . 0.0 110.492 -177.443 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.44 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.9 mtpp -118.26 140.18 27.74 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.256 -0.902 . . . . 0.0 109.779 178.876 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -55.1 -15.2 10.03 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 O-C-N 124.067 1.562 . . . . 0.0 110.964 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.586 ' ND2' ' N ' ' A' ' 20' ' ' ASN . 0.1 OUTLIER -107.61 -25.25 11.42 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 120.999 -1.063 . . . . 0.0 109.308 -177.892 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.568 ' CD1' ' O ' ' A' ' 20' ' ' ASN . 75.8 m-85 -157.74 150.3 22.71 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.622 -0.674 . . . . 0.0 110.105 179.337 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.498 ' HD3' HD22 ' A' ' 68' ' ' LEU . 63.6 ttt180 -96.77 143.32 27.8 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 120.815 -1.178 . . . . 0.0 110.012 172.614 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.478 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 54.4 m -130.91 140.18 50.17 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.488 -0.758 . . . . 0.0 110.145 -173.414 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.736 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -130.14 143.86 51.03 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 120.94 -1.1 . . . . 0.0 111.604 178.805 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.859 HG22 ' OG ' ' A' ' 60' ' ' SER . 8.3 t -125.77 136.1 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.158 -0.964 . . . . 0.0 110.651 -179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.457 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 35.4 m -117.67 171.74 5.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 121.783 -0.573 . . . . 0.0 110.211 178.228 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.561 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 3.6 tt0 -104.25 117.31 33.92 Favored 'General case' 0 C--N 1.304 -1.378 0 O-C-N 121.218 -0.926 . . . . 0.0 109.247 -178.772 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.562 HD21 ' O ' ' A' ' 32' ' ' MET . 9.6 tp -82.81 125.87 74.4 Favored Pre-proline 0 C--N 1.299 -1.621 0 O-C-N 121.585 -0.697 . . . . 0.0 110.106 -173.641 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.54 ' HD2' HD12 ' A' ' 28' ' ' LEU . 28.2 Cg_endo -67.04 176.94 4.01 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 123.886 1.466 . . . . 0.0 111.069 -179.627 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.67 ' HA ' HD12 ' A' ' 33' ' ' LEU . 92.6 m-20 -60.03 -40.0 87.84 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.239 -0.913 . . . . 0.0 111.306 -174.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.595 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.99 0.64 56.99 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 120.751 -1.218 . . . . 0.0 110.907 -174.472 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.595 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.8 mmm -112.17 -8.57 13.99 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.875 -1.141 . . . . 0.0 110.006 170.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.696 HD21 ' HB2' ' A' ' 57' ' ' ASN . 16.0 mt -70.03 -40.01 75.42 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.224 -0.922 . . . . 0.0 109.915 177.065 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -81.74 128.81 34.38 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.594 -0.691 . . . . 0.0 110.486 -178.246 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.47 -46.18 1.21 Allowed Glycine 0 N--CA 1.493 2.445 0 C-N-CA 119.852 -1.166 . . . . 0.0 110.256 174.795 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.7 HD23 ' N ' ' A' ' 37' ' ' GLU . 6.8 tt -69.7 148.84 48.71 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.93 -1.335 . . . . 0.0 110.445 -175.365 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.7 ' N ' HD23 ' A' ' 36' ' ' LEU . 21.3 pt-20 -150.62 170.02 20.16 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.367 -0.833 . . . . 0.0 109.397 179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.717 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -70.06 151.15 45.84 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.058 -1.026 . . . . 0.0 110.228 -178.919 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.09 -3.3 66.2 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 -174.183 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.453 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -77.99 161.48 27.46 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.27 -1.135 . . . . 0.0 109.661 177.612 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.476 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.6 OUTLIER -101.64 114.95 29.46 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.016 -1.052 . . . . 0.0 110.104 177.354 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.626 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.8 t -103.16 128.88 55.76 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.323 -0.861 . . . . 0.0 109.157 174.06 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -94.8 120.08 34.43 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.269 -0.972 . . . . 0.0 109.265 173.043 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.863 ' CD2' HG21 ' A' ' 82' ' ' VAL . 1.4 m80 -90.71 106.19 18.34 Favored 'General case' 0 C--N 1.301 -1.503 0 C-N-CA 119.676 -0.81 . . . . 0.0 109.054 177.568 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.494 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.8 t-20 53.92 14.81 0.72 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.338 -0.851 . . . . 0.0 110.925 -167.02 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.512 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 117.78 -0.5 17.73 Favored Glycine 0 N--CA 1.489 2.17 0 C-N-CA 119.623 -1.275 . . . . 0.0 110.978 170.559 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.833 ' O ' HD23 ' A' ' 49' ' ' LEU . 43.4 t -92.35 106.84 18.76 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.49 -1.594 . . . . 0.0 109.151 173.525 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 17.8 p -75.49 128.66 35.8 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.15 -0.969 . . . . 0.0 110.749 -170.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.833 HD23 ' O ' ' A' ' 47' ' ' CYS . 0.3 OUTLIER -143.14 159.66 41.88 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.442 -0.786 . . . . 0.0 109.714 175.296 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.421 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 28.9 m -100.16 149.82 23.14 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.576 -1.328 . . . . 0.0 111.409 -170.781 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.836 HG13 HG13 ' A' ' 59' ' ' VAL . 15.1 t -78.06 118.39 25.0 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 CA-C-O 121.155 0.502 . . . . 0.0 110.617 -178.002 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.533 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 42.9 p -73.89 -39.94 63.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.126 -0.984 . . . . 0.0 110.031 174.494 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.658 ' HA ' HG21 ' A' ' 38' ' ' THR . 86.6 tt0 -163.4 149.85 12.07 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.35 -0.844 . . . . 0.0 110.214 -178.007 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.717 HD11 ' N ' ' A' ' 38' ' ' THR . 5.7 mt -101.51 134.9 40.43 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 121.09 -1.007 . . . . 0.0 109.955 176.148 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.496 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 49.9 m-80 -110.45 65.78 0.62 Allowed 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.571 -0.705 . . . . 0.0 109.913 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.19 -118.68 4.99 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.879 -1.688 . . . . 0.0 108.879 -175.236 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.696 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.62 -16.39 57.41 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 120.949 -1.324 . . . . 0.0 108.816 174.307 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.145 ' CD2' HG11 ' A' ' 13' ' ' VAL . 11.8 m170 -76.6 159.81 29.96 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.37 -0.831 . . . . 0.0 110.39 -178.192 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.836 HG13 HG13 ' A' ' 51' ' ' VAL . 52.2 t -140.3 127.02 22.42 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.706 0 O-C-N 121.02 -1.05 . . . . 0.0 110.596 170.036 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.859 ' OG ' HG22 ' A' ' 25' ' ' VAL . 2.7 t -95.8 136.74 35.83 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.474 -0.767 . . . . 0.0 109.564 178.382 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.807 ' HB2' HD12 ' A' ' 49' ' ' LEU . 2.0 p90 -128.06 157.78 39.76 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.303 -0.959 . . . . 0.0 110.864 173.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.533 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 25.0 p-10 -89.48 157.64 18.02 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.31 -0.869 . . . . 0.0 111.129 -171.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.746 HD22 ' CD1' ' A' ' 68' ' ' LEU . 0.1 OUTLIER -159.94 102.57 1.47 Allowed 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 120.035 -0.666 . . . . 0.0 109.461 -175.441 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.501 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 56.3 ttm -59.75 140.4 56.54 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.002 -1.062 . . . . 0.0 109.364 -179.557 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.457 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 39.4 ttpt -60.01 -43.32 95.31 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.022 -1.049 . . . . 0.0 110.285 -175.159 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.74 -39.99 76.43 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.02 -1.05 . . . . 0.0 110.067 178.279 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.501 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 92.2 m -60.56 -39.96 89.9 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.978 -1.076 . . . . 0.0 109.184 172.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.746 ' CD1' HD22 ' A' ' 63' ' ' LEU . 7.3 tp -59.94 -45.4 92.74 Favored 'General case' 0 C--N 1.299 -1.611 0 O-C-N 121.285 -0.885 . . . . 0.0 109.782 179.326 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 15.0 tpp180 -69.21 -39.59 78.51 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.529 -0.732 . . . . 0.0 110.47 177.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.857 HG22 HG23 ' A' ' 71' ' ' THR . 1.4 tt -63.68 -43.98 98.27 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.13 -0.982 . . . . 0.0 109.368 -177.47 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.857 HG23 HG22 ' A' ' 70' ' ' ILE . 37.8 p -83.55 -170.51 3.1 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-O 121.404 0.621 . . . . 0.0 109.703 178.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 4.5 t30 -103.28 22.63 13.79 Favored 'General case' 0 C--N 1.295 -1.796 0 N-CA-C 108.287 -1.005 . . . . 0.0 108.287 170.187 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.72 ' HB3' HD21 ' A' ' 63' ' ' LEU . 89.4 mt -69.54 -41.23 76.22 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.158 -0.964 . . . . 0.0 109.999 176.731 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.73 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -51.01 -20.81 4.75 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 -178.163 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.1 p-10 -67.43 -18.5 65.12 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.927 -1.337 . . . . 0.0 110.673 -174.003 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.517 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 90.2 mt -60.89 142.86 55.92 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.166 -0.959 . . . . 0.0 110.983 -175.476 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 0.998 ' C ' HD23 ' A' ' 12' ' ' LEU . 98.7 mttt -140.34 139.53 35.43 Favored 'General case' 0 N--CA 1.493 1.695 0 CA-C-O 121.537 0.684 . . . . 0.0 109.955 173.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.706 ' N ' HD23 ' A' ' 12' ' ' LEU . 15.4 t -63.19 153.47 6.85 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 120.868 -1.145 . . . . 0.0 110.636 -174.45 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.0 -16.93 55.83 Favored Glycine 0 N--CA 1.485 1.928 0 N-CA-C 108.645 -1.782 . . . . 0.0 108.645 -175.134 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -95.14 170.09 9.64 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.402 -1.058 . . . . 0.0 109.743 175.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.585 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.5 m95 -116.97 169.51 9.35 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.965 -1.085 . . . . 0.0 110.17 176.013 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.07 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.4 p -134.09 155.63 39.76 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 O-C-N 121.438 -0.789 . . . . 0.0 109.808 -176.669 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.954 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.1 m-20 -79.57 109.12 13.66 Favored 'General case' 0 C--N 1.295 -1.763 0 O-C-N 121.006 -1.059 . . . . 0.0 109.134 168.668 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.783 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -110.78 138.59 38.24 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 120.43 -1.419 . . . . 0.0 111.275 -175.546 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -134.35 145.03 48.62 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.864 -0.522 . . . . 0.0 110.292 -177.244 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 36.1 ttm180 -83.49 130.65 35.02 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.311 -0.868 . . . . 0.0 111.027 -176.679 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.995 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -127.66 148.19 50.38 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.25 -0.906 . . . . 0.0 110.023 174.737 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -123.69 141.62 51.84 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.423 -0.798 . . . . 0.0 110.873 -175.723 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 15.9 mttp -60.0 -40.03 87.8 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.471 -0.768 . . . . 0.0 110.84 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 45.1 p90 -159.05 160.0 35.33 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.998 -1.064 . . . . 0.0 111.07 -177.033 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.633 ' CB ' HD12 ' A' ' 94' ' ' ILE . 79.7 p -154.65 161.42 41.58 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.415 -0.803 . . . . 0.0 109.715 173.293 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.509 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 96.0 m-20 -69.96 -40.35 75.45 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.081 -1.012 . . . . 0.0 110.698 -178.626 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.509 ' CG ' ' O ' ' A' ' 92' ' ' ASP . 59.1 mt-10 -158.11 60.04 0.46 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.949 -1.095 . . . . 0.0 111.323 -172.426 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.794 HG22 ' O ' ' A' ' 94' ' ' ILE . 96.7 mt -92.99 25.91 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 120.649 -1.282 . . . . 0.0 109.422 170.613 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.431 ' C ' ' O ' ' A' ' 94' ' ' ILE . . . -39.25 -24.7 0.04 OUTLIER Glycine 0 N--CA 1.496 2.643 0 C-N-CA 120.322 -0.942 . . . . 0.0 111.42 -175.196 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 94' ' ' ILE . . . 94.24 171.56 38.27 Favored Glycine 0 N--CA 1.491 2.342 0 O-C-N 120.476 -1.602 . . . . 0.0 109.399 -179.366 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.411 ' ND1' ' N ' ' A' ' 97' ' ' HIS . 30.5 p-80 . . . . . 0 N--CA 1.492 1.633 0 O-C-N 121.289 -1.124 . . . . 0.0 110.161 -179.415 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 58.2 mtm . . . . . 0 N--CA 1.492 1.663 0 CA-C-O 121.115 0.483 . . . . 0.0 110.413 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.995 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 5.1 p90 -166.62 147.39 6.08 Favored 'General case' 0 C--N 1.306 -1.308 0 O-C-N 121.184 -0.947 . . . . 0.0 108.653 173.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.55 ' CB ' HG12 ' B' ' 5' ' ' ILE . 6.0 p -141.15 -37.96 0.42 Allowed 'General case' 0 C--N 1.298 -1.667 0 O-C-N 120.789 -1.194 . . . . 0.0 109.21 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.407 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 47.67 24.58 2.9 Favored Glycine 0 N--CA 1.485 1.949 0 N-CA-C 108.515 -1.834 . . . . 0.0 108.515 -176.32 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 0.55 HG12 ' CB ' ' B' ' 3' ' ' THR . 48.3 mm -80.46 124.6 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.357 -1.084 . . . . 0.0 110.056 -175.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.992 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.5 t -84.11 141.8 14.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.367 -0.833 . . . . 0.0 110.727 -172.634 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 20.1 pt20 -89.72 -15.84 31.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.374 -0.828 . . . . 0.0 110.887 -178.418 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.525 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -158.8 177.0 35.59 Favored Glycine 0 N--CA 1.494 2.552 0 C-N-CA 119.143 -1.503 . . . . 0.0 110.113 -177.495 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.486 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 1.4 p -125.88 167.92 14.58 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.088 -1.243 . . . . 0.0 110.42 179.103 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.092 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -139.84 149.77 43.85 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.278 -0.889 . . . . 0.0 109.88 -174.399 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.583 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 31.2 tttt -106.35 116.04 31.25 Favored 'General case' 0 C--N 1.298 -1.654 0 O-C-N 121.081 -1.012 . . . . 0.0 110.141 179.201 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 0.998 HD23 ' C ' ' B' ' 77' ' ' LYS . 13.1 tp -60.06 128.03 34.82 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 120.828 -1.17 . . . . 0.0 108.671 171.634 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.145 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.7 p -131.41 -30.86 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 C-N-CA 119.44 -0.904 . . . . 0.0 110.31 -176.711 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -144.46 139.8 28.55 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.12 -1.032 . . . . 0.0 111.348 179.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.742 HG23 ' CD2' ' B' ' 24' ' ' HIS . 10.3 mt -109.32 136.98 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.078 -1.013 . . . . 0.0 110.06 171.4 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.495 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 78.6 m-20 -111.97 114.5 27.44 Favored 'General case' 0 C--N 1.298 -1.674 0 O-C-N 121.44 -0.787 . . . . 0.0 110.159 173.039 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -104.96 118.74 37.3 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.188 -0.945 . . . . 0.0 110.493 -177.435 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.436 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.9 mtpp -118.39 140.3 27.99 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.29 -0.881 . . . . 0.0 109.771 178.838 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -55.39 -15.11 10.81 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 124.008 1.53 . . . . 0.0 110.967 -179.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.571 ' O ' ' CD1' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -107.28 -25.9 11.28 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.01 -1.056 . . . . 0.0 109.214 -177.946 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.571 ' CD1' ' O ' ' B' ' 20' ' ' ASN . 75.3 m-85 -157.2 150.36 23.79 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.534 -0.729 . . . . 0.0 110.195 179.499 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.478 ' HD3' HD22 ' B' ' 68' ' ' LEU . 63.7 ttt180 -96.8 143.21 27.93 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 120.914 -1.117 . . . . 0.0 109.944 172.616 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.495 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 54.0 m -130.76 140.21 50.29 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.638 -0.664 . . . . 0.0 110.134 -173.492 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.742 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -130.04 143.94 51.06 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.005 -1.06 . . . . 0.0 111.492 178.806 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.867 HG22 ' OG ' ' B' ' 60' ' ' SER . 8.2 t -125.7 136.3 61.28 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.317 -0.864 . . . . 0.0 110.764 179.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.469 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 35.6 m -117.91 171.78 5.99 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.744 -0.598 . . . . 0.0 110.126 178.355 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.567 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 3.6 tt0 -104.18 117.45 34.28 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.274 -0.891 . . . . 0.0 109.199 -178.786 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.55 HD21 ' O ' ' B' ' 32' ' ' MET . 9.6 tp -82.9 125.8 74.37 Favored Pre-proline 0 C--N 1.299 -1.613 0 O-C-N 121.545 -0.722 . . . . 0.0 110.129 -173.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.539 ' HD2' HD12 ' B' ' 28' ' ' LEU . 28.1 Cg_endo -67.01 176.96 3.97 Favored 'Trans proline' 0 C--N 1.31 -1.491 0 O-C-N 123.919 1.484 . . . . 0.0 110.934 -179.583 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.656 ' HA ' HD12 ' B' ' 33' ' ' LEU . 92.6 m-20 -60.01 -39.99 87.72 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.309 -0.869 . . . . 0.0 111.35 -174.938 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.584 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.01 0.63 57.0 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.761 -1.212 . . . . 0.0 110.844 -174.434 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.584 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.8 mmm -112.19 -8.58 13.98 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.856 -1.153 . . . . 0.0 110.006 170.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.715 HD21 ' HB2' ' B' ' 57' ' ' ASN . 16.0 mt -70.0 -40.04 75.52 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.268 -0.895 . . . . 0.0 109.888 177.07 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -81.7 128.93 34.49 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.597 -0.689 . . . . 0.0 110.508 -178.273 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.35 -46.15 1.21 Allowed Glycine 0 N--CA 1.492 2.414 0 C-N-CA 119.868 -1.158 . . . . 0.0 110.328 174.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.705 HD23 ' N ' ' B' ' 37' ' ' GLU . 6.8 tt -69.66 148.89 48.71 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.95 -1.324 . . . . 0.0 110.43 -175.402 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . 0.705 ' N ' HD23 ' B' ' 36' ' ' LEU . 21.4 pt-20 -150.68 169.95 20.36 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.347 -0.845 . . . . 0.0 109.51 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.72 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -69.99 151.12 45.94 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.038 -1.039 . . . . 0.0 110.252 -178.855 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.17 -3.5 65.96 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 -174.209 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.453 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -77.91 161.36 27.62 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.297 -1.119 . . . . 0.0 109.701 177.521 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.48 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.6 OUTLIER -101.43 114.82 29.17 Favored 'General case' 0 N--CA 1.489 1.504 0 C-N-CA 119.096 -1.042 . . . . 0.0 110.18 177.35 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.644 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.8 t -103.12 129.01 55.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.379 -0.826 . . . . 0.0 109.141 174.068 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -94.87 120.05 34.45 Favored 'General case' 0 C--N 1.298 -1.651 0 C-N-CA 119.245 -0.982 . . . . 0.0 109.214 173.044 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.857 ' CD2' HG21 ' B' ' 82' ' ' VAL . 1.4 m80 -90.69 106.15 18.31 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.403 -0.811 . . . . 0.0 109.074 177.478 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.496 ' OD1' ' HB2' ' A' ' 47' ' ' CYS . 1.8 t-20 54.01 14.84 0.75 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.368 -0.833 . . . . 0.0 110.858 -167.157 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.512 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 117.66 -0.3 17.98 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.715 -1.231 . . . . 0.0 111.031 170.438 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.857 ' O ' HD23 ' B' ' 49' ' ' LEU . 43.1 t -92.38 106.9 18.8 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 120.411 -1.641 . . . . 0.0 109.134 173.395 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 17.8 p -75.45 128.75 36.04 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.097 -1.002 . . . . 0.0 110.684 -170.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 0.857 HD23 ' O ' ' B' ' 47' ' ' CYS . 0.3 OUTLIER -143.29 159.64 41.97 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.416 -0.803 . . . . 0.0 109.61 175.259 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . 0.42 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 29.4 m -100.02 150.01 22.88 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.673 -1.267 . . . . 0.0 111.329 -170.74 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.816 HG13 HG13 ' B' ' 59' ' ' VAL . 15.4 t -78.38 118.46 25.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.827 -0.546 . . . . 0.0 110.607 -178.027 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.532 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 43.0 p -73.89 -40.01 63.49 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.201 -0.937 . . . . 0.0 110.037 174.629 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.666 ' HA ' HG21 ' B' ' 38' ' ' THR . 86.6 tt0 -163.32 149.83 12.19 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.336 -0.852 . . . . 0.0 110.206 -177.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.72 HD11 ' N ' ' B' ' 38' ' ' THR . 5.7 mt -101.52 134.79 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.096 -1.002 . . . . 0.0 109.993 176.148 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.515 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 49.7 m-80 -110.41 65.78 0.62 Allowed 'General case' 0 C--N 1.298 -1.634 0 C-N-CA 119.857 -0.737 . . . . 0.0 109.907 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 78.31 -118.75 4.99 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 108.809 -1.717 . . . . 0.0 108.809 -175.26 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.715 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.55 -16.54 57.32 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.969 -1.312 . . . . 0.0 108.901 174.302 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.145 ' CD2' HG11 ' B' ' 13' ' ' VAL . 11.8 m170 -76.51 159.63 30.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.491 -0.756 . . . . 0.0 110.347 -178.2 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.816 HG13 HG13 ' B' ' 51' ' ' VAL . 52.1 t -140.15 127.1 23.14 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 C-N-CA 119.042 -1.063 . . . . 0.0 110.554 170.054 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.867 ' OG ' HG22 ' B' ' 25' ' ' VAL . 2.7 t -95.81 136.85 35.69 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.575 -0.703 . . . . 0.0 109.616 178.307 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.81 ' HB2' HD12 ' B' ' 49' ' ' LEU . 2.0 p90 -128.11 157.63 40.2 Favored 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 119.054 -1.058 . . . . 0.0 110.876 174.065 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.532 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 25.3 p-10 -89.47 157.76 17.98 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.297 -0.877 . . . . 0.0 111.056 -171.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.749 HD22 ' CD1' ' B' ' 68' ' ' LEU . 0.1 OUTLIER -159.96 102.54 1.47 Allowed 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.958 -0.697 . . . . 0.0 109.445 -175.428 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.499 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 56.1 ttm -59.77 140.36 56.58 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.117 -0.989 . . . . 0.0 109.381 -179.501 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.456 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 39.4 ttpt -59.98 -43.38 95.15 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.042 -1.036 . . . . 0.0 110.242 -175.094 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.72 -40.04 76.47 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.049 -1.032 . . . . 0.0 110.083 178.297 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.499 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 92.2 m -60.58 -39.97 90.02 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 120.95 -1.094 . . . . 0.0 109.14 173.016 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.749 ' CD1' HD22 ' B' ' 63' ' ' LEU . 7.3 tp -60.0 -45.17 93.61 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.375 -0.828 . . . . 0.0 109.892 179.3 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 15.0 tpp180 -69.33 -39.41 78.21 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.547 -0.72 . . . . 0.0 110.493 177.912 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.852 HG22 HG23 ' B' ' 71' ' ' THR . 1.4 tt -63.85 -43.88 97.96 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 121.177 -0.952 . . . . 0.0 109.365 -177.427 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.852 HG23 HG22 ' B' ' 70' ' ' ILE . 37.3 p -83.44 -170.42 3.04 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 121.433 0.635 . . . . 0.0 109.805 178.529 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.492 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 4.3 t30 -103.33 22.58 13.91 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 170.176 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.704 ' HB3' HD21 ' B' ' 63' ' ' LEU . 89.3 mt -69.55 -41.16 76.27 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.228 -0.92 . . . . 0.0 110.091 176.689 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.731 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -51.01 -20.8 4.73 Favored Glycine 0 N--CA 1.487 2.099 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -178.23 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.1 p-10 -67.55 -18.41 65.01 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.998 -1.295 . . . . 0.0 110.706 -173.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.514 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 90.3 mt -60.92 142.82 56.07 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.077 -1.015 . . . . 0.0 110.947 -175.513 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 0.998 ' C ' HD23 ' B' ' 12' ' ' LEU . 98.7 mttt -140.32 139.74 35.49 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.682 -0.636 . . . . 0.0 109.854 173.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.714 HG23 HD11 ' B' ' 15' ' ' ILE . 16.2 t -63.4 153.45 7.01 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.12 -0.987 . . . . 0.0 110.625 -174.399 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.02 -16.68 56.48 Favored Glycine 0 N--CA 1.484 1.874 0 N-CA-C 108.687 -1.765 . . . . 0.0 108.687 -175.285 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 24.9 t0 -95.13 169.95 9.74 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.374 -1.074 . . . . 0.0 109.808 175.615 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.583 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.5 m95 -116.98 169.42 9.42 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.034 -1.041 . . . . 0.0 110.139 176.022 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.092 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.4 p -133.96 155.7 40.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.539 -0.726 . . . . 0.0 109.908 -176.824 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.992 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.0 m-20 -79.5 108.91 13.39 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.074 -1.016 . . . . 0.0 109.245 168.692 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.754 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -110.45 138.87 36.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 120.458 -1.401 . . . . 0.0 111.183 -175.393 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -134.73 145.08 48.13 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.856 -0.527 . . . . 0.0 110.128 -177.364 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 36.2 ttm180 -83.43 130.67 35.04 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.26 -0.9 . . . . 0.0 110.987 -176.675 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 1.003 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -127.68 148.29 50.39 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.279 -0.888 . . . . 0.0 109.965 174.666 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -123.88 141.7 51.79 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.305 -0.872 . . . . 0.0 110.779 -175.748 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 16.0 mttp -59.96 -40.04 87.67 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.414 -0.804 . . . . 0.0 110.863 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -159.07 160.01 35.28 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.033 -1.042 . . . . 0.0 111.02 -177.039 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . 0.504 ' OG ' HG13 ' B' ' 94' ' ' ILE . 79.6 p -154.5 161.66 41.55 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.373 -0.829 . . . . 0.0 109.727 173.256 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -69.74 -33.34 72.32 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.955 -1.091 . . . . 0.0 110.491 -178.705 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . 0.571 ' O ' ' CG ' ' B' ' 93' ' ' GLU . 10.8 tt0 -114.74 57.7 0.71 Allowed 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 122.349 1.071 . . . . 0.0 109.465 -178.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . 0.512 ' O ' ' N ' ' B' ' 96' ' ' GLY . 66.1 mt -65.99 -40.0 86.13 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 120.539 -1.351 . . . . 0.0 110.341 -178.803 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . 0.439 ' C ' ' O ' ' B' ' 94' ' ' ILE . . . -39.91 93.86 0.01 OUTLIER Glycine 0 N--CA 1.494 2.538 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 -172.488 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . 0.512 ' N ' ' O ' ' B' ' 94' ' ' ILE . . . -148.31 146.29 15.71 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 177.642 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . 0.417 ' C ' ' O ' ' B' ' 96' ' ' GLY . 32.8 m80 . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.25 -1.147 . . . . 0.0 110.351 179.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 0.563 " C2'" ' HC9' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 0.556 " C2'" ' HC9' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 43.3 tpp . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 121.345 0.593 . . . . 0.0 110.41 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.951 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 13.4 p90 -174.89 143.82 0.75 Allowed 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.237 -0.915 . . . . 0.0 109.262 175.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.553 ' CB ' HG12 ' A' ' 5' ' ' ILE . 5.6 p -139.96 -40.27 0.44 Allowed 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.019 -1.051 . . . . 0.0 108.509 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.494 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 44.1 26.6 0.91 Allowed Glycine 0 N--CA 1.486 2.029 0 N-CA-C 108.685 -1.766 . . . . 0.0 108.685 -174.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.569 HD11 HC81 ' B' ' 99' ' ' RBF . 40.3 mm -79.1 124.33 37.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.445 -1.032 . . . . 0.0 109.52 -178.074 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 1.025 HG21 ' HB3' ' A' ' 83' ' ' ASN . 4.0 t -85.58 145.25 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.033 -1.042 . . . . 0.0 111.3 -168.544 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -69.99 -34.08 72.88 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.695 -0.628 . . . . 0.0 110.632 175.369 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -163.34 171.43 39.05 Favored Glycine 0 N--CA 1.494 2.555 0 C-N-CA 118.729 -1.7 . . . . 0.0 110.394 -174.518 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.497 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 11.7 p -112.81 168.35 9.75 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.031 -1.276 . . . . 0.0 110.699 -178.729 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.988 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -133.46 148.87 51.76 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 -178.022 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.574 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 22.5 tttt -104.25 112.64 25.74 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 120.972 -1.08 . . . . 0.0 110.15 178.109 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.947 HD23 ' C ' ' A' ' 77' ' ' LYS . 10.9 tp -57.14 126.88 29.2 Favored 'General case' 0 C--N 1.298 -1.656 0 O-C-N 121.146 -0.971 . . . . 0.0 108.803 173.598 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.151 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -127.21 -31.35 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 O-C-N 121.349 -0.844 . . . . 0.0 110.046 -178.237 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -142.86 144.18 32.39 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.147 -1.021 . . . . 0.0 111.582 -179.454 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.687 HG13 HG21 ' A' ' 78' ' ' VAL . 8.1 mt -110.94 130.37 64.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 120.995 -1.065 . . . . 0.0 110.21 168.749 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.509 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 76.0 m-20 -108.86 115.49 30.19 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.364 -0.835 . . . . 0.0 109.889 172.331 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -103.91 110.28 22.35 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 120.888 -1.132 . . . . 0.0 110.495 -179.718 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.9 OUTLIER -102.61 131.87 21.91 Favored Pre-proline 0 N--CA 1.489 1.501 0 O-C-N 121.177 -0.952 . . . . 0.0 108.88 173.76 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -50.52 -34.21 41.43 Favored 'Trans proline' 0 C--N 1.302 -1.91 0 O-C-N 123.828 1.436 . . . . 0.0 110.383 -179.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.576 ' HB3' ' CE2' ' A' ' 21' ' ' PHE . 10.4 m-80 -74.19 -39.33 63.25 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.244 -0.91 . . . . 0.0 110.32 175.899 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.576 ' CE2' ' HB3' ' A' ' 20' ' ' ASN . 49.9 m-85 -152.53 150.14 29.26 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.271 -0.893 . . . . 0.0 110.106 -176.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.438 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 50.7 ttt180 -88.73 144.96 25.91 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.914 -1.116 . . . . 0.0 109.999 175.065 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.509 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 94.8 m -130.07 140.06 50.89 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.437 -0.79 . . . . 0.0 110.099 -177.876 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.606 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -129.59 144.61 51.35 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.967 -1.083 . . . . 0.0 111.107 177.333 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.725 HG22 ' CB ' ' A' ' 60' ' ' SER . 6.9 t -124.06 133.37 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.034 -1.041 . . . . 0.0 110.508 179.229 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.912 HG13 ' CE1' ' A' ' 61' ' ' PHE . 13.1 m -112.88 172.31 3.26 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 O-C-N 121.737 -0.602 . . . . 0.0 109.954 177.403 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.567 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 8.1 tt0 -106.95 116.3 31.69 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.357 -0.839 . . . . 0.0 108.794 178.128 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.608 HD11 ' HB3' ' A' ' 32' ' ' MET . 9.2 tp -80.09 123.98 83.13 Favored Pre-proline 0 C--N 1.296 -1.753 0 O-C-N 121.548 -0.72 . . . . 0.0 109.977 -172.569 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.522 ' HD2' HD12 ' A' ' 28' ' ' LEU . 27.7 Cg_endo -66.35 -178.54 1.18 Allowed 'Trans proline' 0 C--N 1.309 -1.547 0 O-C-N 123.822 1.433 . . . . 0.0 110.977 -179.521 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.489 ' HA ' HD12 ' A' ' 33' ' ' LEU . 61.6 t0 -62.55 -40.97 98.52 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.239 -0.913 . . . . 0.0 111.027 -174.667 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.03 1.14 56.66 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.811 -1.181 . . . . 0.0 111.014 -174.664 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.608 ' HB3' HD11 ' A' ' 28' ' ' LEU . 99.4 mmm -108.56 -15.37 14.45 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.784 -1.198 . . . . 0.0 109.844 169.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.673 HD21 ' HB2' ' A' ' 57' ' ' ASN . 21.0 mt -69.51 -22.04 63.62 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.217 -0.927 . . . . 0.0 109.997 177.699 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -95.16 115.6 27.65 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.364 -0.835 . . . . 0.0 110.473 -178.59 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.34 -50.52 0.78 Allowed Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.764 -1.207 . . . . 0.0 110.556 173.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.83 HD23 ' N ' ' A' ' 37' ' ' GLU . 9.8 tt -60.98 159.33 11.67 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.886 -1.361 . . . . 0.0 111.123 -172.319 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.83 ' N ' HD23 ' A' ' 36' ' ' LEU . 22.0 pt-20 -157.52 163.46 38.39 Favored 'General case' 0 N--CA 1.489 1.485 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.998 HG23 HD12 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -69.9 151.57 45.51 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.845 -1.159 . . . . 0.0 109.921 -177.474 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 80.09 -4.66 65.68 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 -172.859 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.413 ' O ' ' HA ' ' A' ' 50' ' ' THR . . . -74.33 160.12 31.48 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.293 -1.122 . . . . 0.0 109.683 176.828 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.84 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.7 OUTLIER -100.98 103.25 14.39 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.068 -1.02 . . . . 0.0 110.12 178.298 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.618 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.2 t -88.12 131.46 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.201 -0.937 . . . . 0.0 109.489 175.489 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.708 ' HB3' ' HB2' ' A' ' 85' ' ' GLU . . . -98.17 120.97 39.51 Favored 'General case' 0 C--N 1.296 -1.755 0 C-N-CA 118.917 -1.113 . . . . 0.0 109.418 170.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.671 ' CG ' HG21 ' A' ' 82' ' ' VAL . 1.0 OUTLIER -88.74 105.83 17.96 Favored 'General case' 0 N--CA 1.49 1.558 0 C-N-CA 119.583 -0.847 . . . . 0.0 108.987 177.525 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.1 t-20 52.96 11.92 0.24 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.463 -0.773 . . . . 0.0 111.525 -166.482 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.47 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 127.73 -6.8 6.97 Favored Glycine 0 N--CA 1.489 2.233 0 C-N-CA 119.224 -1.465 . . . . 0.0 111.169 172.241 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.816 ' O ' HD23 ' A' ' 49' ' ' LEU . 13.8 t -92.49 105.99 18.06 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.192 -1.77 . . . . 0.0 109.471 177.027 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.516 ' SG ' ' C8 ' ' A' ' 98' ' ' RBF . 16.2 p -75.24 129.52 37.6 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.14 -0.975 . . . . 0.0 111.122 -171.138 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.834 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -141.97 159.98 41.13 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.595 -0.691 . . . . 0.0 109.276 174.91 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.413 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 51.7 m -94.79 148.24 22.5 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.613 -1.305 . . . . 0.0 111.279 -170.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.658 HG13 HG13 ' A' ' 59' ' ' VAL . 19.3 t -77.27 122.03 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.651 -0.656 . . . . 0.0 110.265 178.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.522 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 19.3 p -77.54 -44.49 28.41 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.257 -0.902 . . . . 0.0 110.138 175.204 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.67 ' HA ' HG21 ' A' ' 38' ' ' THR . 86.1 tt0 -157.47 150.13 23.04 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.113 -0.992 . . . . 0.0 110.348 178.023 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.998 HD12 HG23 ' A' ' 38' ' ' THR . 1.4 mp -97.79 137.0 26.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.07 -1.019 . . . . 0.0 109.728 173.237 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.48 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 33.4 m-80 -110.03 70.43 0.72 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.595 -0.691 . . . . 0.0 109.698 178.147 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 72.04 -120.12 7.75 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 -172.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.673 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -75.51 -21.17 58.21 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 120.995 -1.297 . . . . 0.0 109.04 175.543 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.151 ' CD2' HG11 ' A' ' 13' ' ' VAL . 10.7 m170 -72.41 160.48 32.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.28 -0.887 . . . . 0.0 110.234 -178.395 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.658 HG13 HG13 ' A' ' 51' ' ' VAL . 53.1 t -140.07 124.54 19.18 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 C-N-CA 119.127 -1.029 . . . . 0.0 110.536 170.679 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.725 ' CB ' HG22 ' A' ' 25' ' ' VAL . 53.1 p -95.08 128.56 42.01 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.476 -0.765 . . . . 0.0 109.553 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.912 ' CE1' HG13 ' A' ' 26' ' ' VAL . 1.8 p90 -124.01 157.35 34.65 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 120.995 -1.066 . . . . 0.0 110.254 -179.118 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.522 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 30.4 p-10 -93.27 152.79 18.96 Favored 'General case' 0 N--CA 1.493 1.69 0 CA-C-O 122.09 0.947 . . . . 0.0 111.127 -172.794 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.752 ' CD2' HD12 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -152.21 120.03 6.15 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -175.894 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.51 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 63.5 tpp -77.16 139.58 39.96 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.983 -1.073 . . . . 0.0 109.848 -179.64 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.479 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 74.9 tttt -59.93 -49.85 76.07 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.12 -0.987 . . . . 0.0 110.578 -173.49 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.414 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 88.3 tt0 -66.27 -39.96 89.79 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.828 -1.17 . . . . 0.0 109.996 178.223 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.699 HG23 HC3' ' A' ' 98' ' ' RBF . 90.9 m -60.0 -39.57 86.21 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.002 -1.061 . . . . 0.0 109.197 173.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.752 HD12 ' CD2' ' A' ' 63' ' ' LEU . 2.1 tp -59.97 -45.28 93.18 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.319 -0.863 . . . . 0.0 109.852 179.339 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 tpt85 -69.39 -38.32 77.93 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.386 -0.821 . . . . 0.0 110.079 177.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.805 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -67.75 -39.9 82.84 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.302 0 O-C-N 121.333 -0.855 . . . . 0.0 109.191 -177.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.805 HG23 HG22 ' A' ' 70' ' ' ILE . 49.4 p -88.77 -176.41 5.22 Favored 'General case' 0 C--N 1.3 -1.546 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 175.572 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.467 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 8.8 t30 -98.22 21.18 11.26 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 121.244 -0.91 . . . . 0.0 108.903 173.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.713 ' HB3' HD21 ' A' ' 63' ' ' LEU . 34.4 mt -70.04 -39.99 75.42 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.912 -1.118 . . . . 0.0 110.444 179.609 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.729 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -52.54 -19.33 6.19 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 -176.34 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 27.1 p-10 -69.98 -18.21 63.33 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.111 -1.229 . . . . 0.0 110.965 -174.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 85.5 mt -59.99 146.49 42.41 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.088 -1.008 . . . . 0.0 111.026 -174.54 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 0.947 ' C ' HD23 ' A' ' 12' ' ' LEU . 67.4 mttt -139.88 141.75 36.57 Favored 'General case' 0 N--CA 1.492 1.662 0 CA-C-O 121.537 0.684 . . . . 0.0 109.906 176.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.687 HG21 HG13 ' A' ' 15' ' ' ILE . 46.2 t -66.44 150.06 11.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 120.888 -1.133 . . . . 0.0 110.466 -177.329 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.96 -14.99 60.46 Favored Glycine 0 N--CA 1.482 1.743 0 N-CA-C 108.663 -1.775 . . . . 0.0 108.663 -174.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.478 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 13.9 t0 -96.65 168.27 10.62 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.409 -1.053 . . . . 0.0 109.576 174.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.574 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.4 m95 -115.83 156.09 26.71 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.04 -1.037 . . . . 0.0 110.304 177.72 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.988 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.1 p -120.07 150.0 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.262 -0.899 . . . . 0.0 110.1 179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 1.025 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.4 OUTLIER -70.79 104.53 2.92 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.044 -1.035 . . . . 0.0 108.887 166.785 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.777 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -104.35 139.42 25.37 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 120.51 -1.369 . . . . 0.0 110.987 -176.839 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.922 ' HG3' HG22 ' A' ' 6' ' ' VAL . 85.2 mt-10 -125.47 146.62 49.56 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.918 -0.488 . . . . 0.0 110.15 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.533 ' HB3' ' CZ ' ' A' ' 86' ' ' ARG . 18.3 mtp-105 -90.26 114.77 26.87 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.513 -0.742 . . . . 0.0 110.033 177.494 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.87 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -114.42 147.43 39.25 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.061 -1.024 . . . . 0.0 110.524 -178.254 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -131.45 148.54 52.65 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.609 -0.682 . . . . 0.0 110.862 -176.284 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -59.98 -39.95 87.48 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.435 -0.79 . . . . 0.0 110.185 176.531 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 52.8 p90 -132.36 160.09 37.32 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.279 -0.888 . . . . 0.0 110.253 179.716 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.408 ' OG ' ' CG1' ' A' ' 94' ' ' ILE . 2.6 p -119.07 135.29 54.71 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.228 -0.92 . . . . 0.0 110.366 -177.746 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 71.7 m-20 -69.83 -40.1 76.05 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.365 -0.834 . . . . 0.0 111.008 -176.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -147.29 71.09 1.2 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.932 -1.105 . . . . 0.0 110.573 -174.448 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.426 ' O ' ' C ' ' A' ' 95' ' ' GLY . 25.5 mm -60.07 -41.06 85.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.191 -0.943 . . . . 0.0 109.725 175.768 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 94' ' ' ILE . . . 40.18 69.99 0.41 Allowed Glycine 0 N--CA 1.494 2.52 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 174.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -109.65 115.08 4.1 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 178.526 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 46.7 p-80 . . . . . 0 N--CA 1.493 1.706 0 O-C-N 121.3 -1.117 . . . . 0.0 110.128 178.873 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 38.3 mtm . . . . . 0 N--CA 1.495 1.797 0 CA-C-O 121.258 0.551 . . . . 0.0 110.177 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.87 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 13.4 p90 -171.72 143.83 1.74 Allowed 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.11 -0.994 . . . . 0.0 109.248 174.715 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.562 ' CB ' HG12 ' B' ' 5' ' ' ILE . 5.6 p -139.99 -40.28 0.44 Allowed 'General case' 0 C--N 1.297 -1.696 0 O-C-N 121.067 -1.021 . . . . 0.0 108.452 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 44.32 26.33 0.94 Allowed Glycine 0 N--CA 1.486 2.004 0 N-CA-C 108.642 -1.783 . . . . 0.0 108.642 -174.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 0.563 HD11 HC81 ' A' ' 98' ' ' RBF . 40.0 mm -79.1 124.37 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.342 -1.093 . . . . 0.0 109.533 -177.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.958 HG22 ' HG3' ' B' ' 85' ' ' GLU . 4.0 t -85.59 145.25 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.059 -1.025 . . . . 0.0 111.367 -168.56 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 98.9 mt-30 -70.05 -33.75 72.36 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.745 -0.597 . . . . 0.0 110.685 175.449 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.54 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -163.66 171.35 39.29 Favored Glycine 0 N--CA 1.495 2.628 0 C-N-CA 118.91 -1.614 . . . . 0.0 110.52 -174.52 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.498 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 11.7 p -112.9 168.29 9.81 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.06 -1.259 . . . . 0.0 110.739 -178.632 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.055 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -133.38 149.01 51.85 Favored 'General case' 0 N--CA 1.491 1.613 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 -178.017 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.568 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 22.7 tttt -104.36 112.79 25.97 Favored 'General case' 0 C--N 1.296 -1.726 0 O-C-N 120.982 -1.074 . . . . 0.0 110.047 178.115 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 0.964 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.0 tp -57.35 126.84 29.06 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.193 -0.942 . . . . 0.0 108.761 173.592 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.133 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -127.18 -31.24 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.784 0 O-C-N 121.339 -0.851 . . . . 0.0 110.089 -178.211 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -142.99 144.17 32.21 Favored 'General case' 0 N--CA 1.493 1.716 0 C-N-CA 119.234 -0.986 . . . . 0.0 111.553 -179.478 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.693 HG13 HG21 ' B' ' 78' ' ' VAL . 8.0 mt -110.85 130.47 64.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 120.992 -1.068 . . . . 0.0 110.193 168.836 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.518 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 75.5 m-20 -109.12 115.59 30.33 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.353 -0.842 . . . . 0.0 109.767 172.389 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -103.92 110.31 22.39 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.019 -1.05 . . . . 0.0 110.443 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.453 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.9 OUTLIER -102.7 131.92 21.82 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.347 -0.846 . . . . 0.0 108.874 173.763 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -50.62 -34.19 42.29 Favored 'Trans proline' 0 C--N 1.301 -1.95 0 O-C-N 123.825 1.434 . . . . 0.0 110.295 -179.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.588 ' HB3' ' CE2' ' B' ' 21' ' ' PHE . 10.5 m-80 -73.98 -39.96 63.31 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.224 -0.922 . . . . 0.0 110.165 175.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.588 ' CE2' ' HB3' ' B' ' 20' ' ' ASN . 49.4 m-85 -152.06 150.18 29.66 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.381 -0.824 . . . . 0.0 110.183 -176.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.427 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 50.5 ttt180 -88.65 144.91 25.98 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 120.916 -1.115 . . . . 0.0 109.924 175.033 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.518 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 95.0 m -130.09 140.08 50.87 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.511 -0.743 . . . . 0.0 110.147 -178.003 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.605 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -129.57 144.58 51.33 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.095 -1.003 . . . . 0.0 110.994 177.476 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.73 HG22 ' CB ' ' B' ' 60' ' ' SER . 6.8 t -123.99 133.48 69.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.142 -0.974 . . . . 0.0 110.573 179.113 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.931 HG13 ' CE1' ' B' ' 61' ' ' PHE . 13.3 m -112.96 172.3 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.698 -0.626 . . . . 0.0 109.876 177.485 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.571 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 8.1 tt0 -106.86 116.24 31.58 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.444 -0.785 . . . . 0.0 108.923 177.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.605 HD11 ' HB3' ' B' ' 32' ' ' MET . 9.3 tp -80.01 123.98 83.26 Favored Pre-proline 0 C--N 1.296 -1.747 0 O-C-N 121.434 -0.791 . . . . 0.0 110.028 -172.587 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.526 ' HD2' HD12 ' B' ' 28' ' ' LEU . 27.7 Cg_endo -66.3 -178.42 1.13 Allowed 'Trans proline' 0 C--N 1.31 -1.489 0 O-C-N 123.831 1.437 . . . . 0.0 110.96 -179.523 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.478 ' HA ' HD12 ' B' ' 33' ' ' LEU . 61.7 t0 -62.67 -40.91 98.55 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.386 -0.821 . . . . 0.0 111.027 -174.698 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.595 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.01 1.11 56.68 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.867 -1.145 . . . . 0.0 111.01 -174.631 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.605 ' HB3' HD11 ' B' ' 28' ' ' LEU . 99.4 mmm -108.61 -15.25 14.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.752 -1.218 . . . . 0.0 109.813 169.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.696 HD21 ' HB2' ' B' ' 57' ' ' ASN . 20.8 mt -69.69 -21.93 63.47 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.269 -0.894 . . . . 0.0 109.982 177.722 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -95.22 115.68 27.75 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.348 -0.845 . . . . 0.0 110.408 -178.606 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 115.18 -50.43 0.78 Allowed Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.823 -1.179 . . . . 0.0 110.543 173.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.827 HD23 ' N ' ' B' ' 37' ' ' GLU . 9.8 tt -61.01 159.29 11.81 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.843 -1.386 . . . . 0.0 111.132 -172.362 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . 0.827 ' N ' HD23 ' B' ' 36' ' ' LEU . 21.9 pt-20 -157.51 163.36 38.51 Favored 'General case' 0 N--CA 1.49 1.528 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 1.049 HG23 HD12 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -69.85 151.59 45.53 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.862 -1.149 . . . . 0.0 109.965 -177.531 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.98 -4.47 66.05 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -172.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' B' ' 50' ' ' THR . . . -74.37 160.02 31.59 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.199 -1.177 . . . . 0.0 109.653 176.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.817 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.6 OUTLIER -100.82 103.12 14.32 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 120.969 -1.082 . . . . 0.0 110.139 178.291 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.634 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.2 t -88.1 131.59 35.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.284 -0.885 . . . . 0.0 109.486 175.432 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.705 ' HB3' ' HB2' ' B' ' 85' ' ' GLU . . . -98.25 121.0 39.64 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 120.961 -1.087 . . . . 0.0 109.441 170.716 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.668 ' CG ' HG21 ' B' ' 82' ' ' VAL . 1.0 OUTLIER -88.78 105.58 17.8 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.245 -0.91 . . . . 0.0 109.1 177.494 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.511 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.1 t-20 53.23 11.94 0.28 Allowed 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.462 -0.774 . . . . 0.0 111.409 -166.565 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.494 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 127.55 -6.36 7.07 Favored Glycine 0 N--CA 1.49 2.251 0 C-N-CA 119.231 -1.461 . . . . 0.0 111.082 172.03 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.838 ' O ' HD23 ' B' ' 49' ' ' LEU . 13.9 t -92.66 106.04 18.09 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.059 -1.847 . . . . 0.0 109.439 176.825 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . 0.519 ' SG ' ' C8 ' ' B' ' 99' ' ' RBF . 16.1 p -75.21 129.57 37.7 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.086 -1.009 . . . . 0.0 111.145 -171.19 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 0.855 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -142.01 159.93 41.23 Favored 'General case' 0 N--CA 1.492 1.653 0 N-CA-C 109.203 -0.666 . . . . 0.0 109.203 174.925 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . 0.414 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 52.1 m -94.69 148.21 22.52 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 120.514 -1.366 . . . . 0.0 111.244 -170.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.67 HG13 HG13 ' B' ' 59' ' ' VAL . 18.6 t -77.23 122.06 31.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.647 -0.658 . . . . 0.0 110.281 178.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.519 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 19.7 p -77.66 -44.55 27.73 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.213 -0.93 . . . . 0.0 110.029 175.33 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.666 ' HA ' HG21 ' B' ' 38' ' ' THR . 86.3 tt0 -157.43 150.18 23.17 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.101 -0.999 . . . . 0.0 110.348 178.031 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 1.049 HD12 HG23 ' B' ' 38' ' ' THR . 1.4 mp -97.82 136.94 26.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.175 -0.953 . . . . 0.0 109.729 173.282 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.504 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 33.5 m-80 -109.95 70.29 0.72 Allowed 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.545 -0.722 . . . . 0.0 109.676 178.219 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 72.09 -120.11 7.71 Favored Glycine 0 N--CA 1.489 2.176 0 N-CA-C 108.713 -1.755 . . . . 0.0 108.713 -172.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.696 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -75.41 -21.28 58.35 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.054 -1.262 . . . . 0.0 109.12 175.468 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.133 ' CD2' HG11 ' B' ' 13' ' ' VAL . 10.8 m170 -72.43 160.27 32.61 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.407 -0.808 . . . . 0.0 110.362 -178.404 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.67 HG13 HG13 ' B' ' 51' ' ' VAL . 53.6 t -139.89 124.62 19.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 C-N-CA 119.061 -1.056 . . . . 0.0 110.415 170.853 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.73 ' CB ' HG22 ' B' ' 25' ' ' VAL . 53.4 p -95.08 128.82 42.21 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.619 -0.675 . . . . 0.0 109.509 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.931 ' CE1' HG13 ' B' ' 26' ' ' VAL . 1.8 p90 -124.26 157.29 35.21 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.002 -1.061 . . . . 0.0 110.218 -179.148 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.519 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 30.5 p-10 -93.2 152.74 19.03 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.136 -0.978 . . . . 0.0 111.192 -172.753 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.752 ' CD2' HD12 ' B' ' 68' ' ' LEU . 0.0 OUTLIER -152.06 119.97 6.19 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 -175.883 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.511 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 63.6 tpp -77.19 139.57 39.93 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.976 -1.078 . . . . 0.0 109.845 -179.61 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.484 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 74.9 tttt -60.03 -49.73 76.53 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.166 -0.959 . . . . 0.0 110.492 -173.362 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . 0.424 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 88.4 tt0 -66.35 -40.0 89.53 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.794 -1.191 . . . . 0.0 109.946 178.326 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.677 HG23 HC3' ' B' ' 99' ' ' RBF . 90.3 m -60.05 -39.55 86.32 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.031 -1.043 . . . . 0.0 109.145 174.008 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.752 HD12 ' CD2' ' B' ' 63' ' ' LEU . 2.1 tp -60.01 -45.14 93.73 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.388 -0.82 . . . . 0.0 109.962 179.278 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 tpt85 -69.35 -38.52 78.14 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.409 -0.807 . . . . 0.0 110.079 177.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.771 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -67.55 -39.95 83.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.449 0 CA-C-O 121.73 0.776 . . . . 0.0 109.238 -178.032 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.771 HG23 HG22 ' B' ' 70' ' ' ILE . 49.6 p -88.74 -176.24 5.18 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 175.674 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.516 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 8.7 t30 -98.3 21.19 11.33 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 121.182 -0.948 . . . . 0.0 108.733 173.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.744 ' HB3' HD21 ' B' ' 63' ' ' LEU . 34.1 mt -70.01 -40.03 75.47 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.954 -1.091 . . . . 0.0 110.458 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.743 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -52.49 -19.31 6.09 Favored Glycine 0 N--CA 1.488 2.113 0 N-CA-C 110.281 -1.128 . . . . 0.0 110.281 -176.324 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.504 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 27.2 p-10 -70.05 -18.25 63.28 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.083 -1.245 . . . . 0.0 110.946 -174.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.504 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 85.7 mt -59.95 146.43 42.45 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.188 -0.945 . . . . 0.0 111.012 -174.547 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 0.964 ' C ' HD23 ' B' ' 12' ' ' LEU . 67.4 mttt -139.89 141.78 36.54 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.626 -0.671 . . . . 0.0 109.888 176.658 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.693 HG21 HG13 ' B' ' 15' ' ' ILE . 46.2 t -66.49 150.01 11.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.04 -1.038 . . . . 0.0 110.498 -177.274 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 90.01 -14.94 60.65 Favored Glycine 0 N--CA 1.483 1.824 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -174.712 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 13.8 t0 -96.73 168.13 10.7 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.359 -1.083 . . . . 0.0 109.582 174.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.568 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.4 m95 -115.76 156.0 26.8 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.06 -1.025 . . . . 0.0 110.325 177.788 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.055 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.1 p -120.01 150.06 22.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.427 -0.795 . . . . 0.0 110.173 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.952 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.4 OUTLIER -70.68 104.32 2.81 Favored 'General case' 0 C--N 1.296 -1.745 0 O-C-N 121.001 -1.062 . . . . 0.0 109.053 166.705 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.773 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -104.22 139.59 24.75 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 120.464 -1.398 . . . . 0.0 110.905 -176.61 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . 0.958 ' HG3' HG22 ' B' ' 6' ' ' VAL . 85.0 mt-10 -125.73 146.57 49.7 Favored 'General case' 0 N--CA 1.492 1.63 0 CA-C-O 121.193 0.521 . . . . 0.0 110.064 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . 0.539 ' HB3' ' CZ ' ' B' ' 86' ' ' ARG . 18.3 mtp-105 -90.26 114.84 26.95 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.35 -0.844 . . . . 0.0 109.957 177.566 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 0.951 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -114.48 147.58 39.12 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.256 -0.903 . . . . 0.0 110.57 -178.292 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -131.57 148.65 52.63 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.584 -0.697 . . . . 0.0 110.683 -176.174 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -60.06 -40.01 88.02 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.435 -0.79 . . . . 0.0 110.142 176.49 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -132.41 160.14 37.24 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.329 -0.857 . . . . 0.0 110.171 179.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . 0.529 ' OG ' ' CG1' ' B' ' 94' ' ' ILE . 2.6 p -119.04 135.36 54.67 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.258 -0.901 . . . . 0.0 110.382 -177.673 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 71.6 m-20 -69.93 -40.01 75.77 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.41 -0.807 . . . . 0.0 111.025 -176.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 77.1 mm-40 -143.34 68.82 1.29 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.005 -1.059 . . . . 0.0 110.537 -174.251 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . 0.529 ' CG1' ' OG ' ' B' ' 91' ' ' SER . 21.1 mm -59.97 -40.0 81.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.266 -0.896 . . . . 0.0 109.644 175.629 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 47.32 60.96 4.85 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 110.064 -1.215 . . . . 0.0 110.064 177.261 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -59.94 -40.05 96.38 Favored Glycine 0 N--CA 1.49 2.238 0 N-CA-C 109.064 -1.614 . . . . 0.0 109.064 176.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 17.6 t60 . . . . . 0 N--CA 1.491 1.613 0 O-C-N 121.331 -1.1 . . . . 0.0 110.122 177.581 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 0.699 HC3' HG23 ' A' ' 67' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 0.677 HC3' HG23 ' B' ' 67' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 17.9 mmm . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.292 0.568 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.928 ' CZ ' ' HB1' ' B' ' 87' ' ' ALA . 8.1 p90 -166.25 155.93 11.84 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.166 -0.959 . . . . 0.0 108.614 172.291 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.587 HG23 ' C ' ' A' ' 2' ' ' PHE . 40.3 p -155.77 -39.31 0.08 Allowed 'General case' 0 C--N 1.295 -1.802 0 O-C-N 120.902 -1.124 . . . . 0.0 109.131 177.044 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.463 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 45.25 25.25 1.11 Allowed Glycine 0 N--CA 1.484 1.845 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 -173.574 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.488 HG13 ' O ' ' A' ' 3' ' ' THR . 91.4 mt -77.92 135.57 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.323 -1.104 . . . . 0.0 109.777 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.69 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.6 t -91.42 137.77 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.097 -1.002 . . . . 0.0 110.871 -170.439 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -71.04 -33.09 69.98 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.866 -0.521 . . . . 0.0 111.182 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.533 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -150.35 171.92 30.2 Favored Glycine 0 N--CA 1.495 2.582 0 C-N-CA 119.054 -1.546 . . . . 0.0 110.133 -171.9 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.495 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 3.1 p -119.23 172.34 7.66 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.893 -1.357 . . . . 0.0 111.214 -176.453 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.013 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -142.64 150.0 39.66 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 -176.362 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.587 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.1 tttt -110.83 115.15 29.03 Favored 'General case' 0 C--N 1.295 -1.803 0 O-C-N 121.097 -1.002 . . . . 0.0 110.276 179.54 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.941 HD23 ' C ' ' A' ' 77' ' ' LYS . 10.9 tp -59.74 127.71 33.32 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.015 -1.053 . . . . 0.0 109.079 174.362 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.113 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -122.2 -28.9 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.865 0 C-N-CA 119.641 -0.824 . . . . 0.0 109.648 179.2 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.71 147.54 26.83 Favored 'General case' 0 N--CA 1.492 1.675 0 C-N-CA 119.05 -1.06 . . . . 0.0 111.551 -179.155 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.839 HG23 ' CD2' ' A' ' 24' ' ' HIS . 11.7 mt -109.59 138.61 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.212 -0.93 . . . . 0.0 110.03 172.415 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.507 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.7 m-20 -109.58 114.62 28.4 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.283 -0.885 . . . . 0.0 109.924 173.52 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -100.35 112.15 24.47 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.13 -0.981 . . . . 0.0 110.369 -176.484 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.2 OUTLIER -112.76 132.76 22.12 Favored Pre-proline 0 N--CA 1.491 1.61 0 O-C-N 121.203 -0.935 . . . . 0.0 108.94 175.492 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -49.57 -40.39 45.88 Favored 'Trans proline' 0 C--N 1.302 -1.886 0 O-C-N 123.855 1.45 . . . . 0.0 110.754 -179.204 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.445 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 12.0 m-80 -70.59 -39.37 73.89 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.124 -0.985 . . . . 0.0 110.259 177.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.461 ' O ' ' HB2' ' A' ' 18' ' ' LYS . 95.7 m-85 -152.55 150.3 29.42 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.289 -0.882 . . . . 0.0 110.526 -174.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.603 ' HD3' HD22 ' A' ' 68' ' ' LEU . 60.7 ttt180 -91.28 143.54 26.54 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 120.835 -1.166 . . . . 0.0 109.909 175.006 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.507 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 97.1 m -129.57 140.77 51.12 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.597 -0.69 . . . . 0.0 109.738 -174.663 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.839 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -132.65 137.27 46.92 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 120.948 -1.095 . . . . 0.0 111.142 -177.95 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.836 HG22 ' OG ' ' A' ' 60' ' ' SER . 4.8 t -120.16 131.72 71.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.115 -0.991 . . . . 0.0 110.677 -178.379 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.863 HG13 ' CE1' ' A' ' 61' ' ' PHE . 18.9 m -111.9 175.74 1.86 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.591 0 CA-C-O 121.212 0.529 . . . . 0.0 110.265 178.007 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.569 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 7.9 tt0 -107.02 117.05 33.03 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 178.387 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.562 HD12 ' HD2' ' A' ' 29' ' ' PRO . 10.7 tp -80.45 126.74 77.97 Favored Pre-proline 0 C--N 1.296 -1.724 0 O-C-N 121.428 -0.795 . . . . 0.0 109.827 -173.53 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.562 ' HD2' HD12 ' A' ' 28' ' ' LEU . 18.7 Cg_endo -63.78 173.67 4.47 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.886 1.466 . . . . 0.0 110.654 -179.362 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.766 ' HA ' HD12 ' A' ' 33' ' ' LEU . 12.3 p-10 -59.99 -38.06 81.51 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.372 -0.83 . . . . 0.0 110.676 -176.159 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.589 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.18 0.06 57.37 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.959 -1.088 . . . . 0.0 110.947 -175.734 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.589 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 94.5 mmm -110.43 -12.01 14.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.854 -1.154 . . . . 0.0 109.948 170.176 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.944 HD21 ' HB2' ' A' ' 57' ' ' ASN . 15.8 mt -63.04 -31.38 72.5 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.299 -0.875 . . . . 0.0 110.15 176.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -93.23 139.99 30.02 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.339 -0.851 . . . . 0.0 110.536 -176.335 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.08 -41.42 2.34 Favored Glycine 0 N--CA 1.491 2.335 0 C-N-CA 119.892 -1.147 . . . . 0.0 110.387 174.878 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.76 HD23 ' N ' ' A' ' 37' ' ' GLU . 9.1 tt -76.1 149.28 37.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.926 -1.338 . . . . 0.0 111.054 -174.394 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.76 ' N ' HD23 ' A' ' 36' ' ' LEU . 15.8 pt-20 -151.59 169.25 22.56 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.464 -0.772 . . . . 0.0 109.58 177.289 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.926 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -61.32 151.64 31.47 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.936 -1.102 . . . . 0.0 109.876 179.107 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.73 -5.81 60.36 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -178.647 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.489 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -73.28 156.15 38.77 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.228 -1.16 . . . . 0.0 109.649 177.266 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.682 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -99.8 106.2 18.06 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.958 -1.089 . . . . 0.0 109.749 176.296 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.6 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.2 t -93.3 129.89 43.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.534 0 O-C-N 121.21 -0.931 . . . . 0.0 109.122 174.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.502 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -93.38 120.02 33.17 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.3 -0.96 . . . . 0.0 109.117 172.336 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.796 ' CD2' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -91.22 104.79 17.3 Favored 'General case' 0 C--N 1.302 -1.479 0 C-N-CA 119.698 -0.801 . . . . 0.0 108.886 177.98 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.496 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.6 t-20 55.34 14.09 1.03 Allowed 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.314 -0.866 . . . . 0.0 110.896 -168.704 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.457 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 120.33 -5.16 12.12 Favored Glycine 0 N--CA 1.49 2.255 0 C-N-CA 119.58 -1.295 . . . . 0.0 110.919 172.132 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.848 ' O ' HD23 ' A' ' 49' ' ' LEU . 25.1 t -90.58 110.32 21.46 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.336 -1.685 . . . . 0.0 109.495 176.634 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.9 p -74.47 127.93 34.29 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.959 -1.088 . . . . 0.0 110.789 -171.47 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 1.008 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -143.21 160.06 41.16 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.323 -0.861 . . . . 0.0 109.707 174.825 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.459 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 3.6 m -102.22 151.56 22.06 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.773 -1.205 . . . . 0.0 111.083 -172.526 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.747 HG13 HG13 ' A' ' 59' ' ' VAL . 14.6 t -78.22 118.39 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.752 -0.593 . . . . 0.0 110.489 -177.341 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.526 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 43.9 p -72.32 -40.03 67.77 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.367 -0.833 . . . . 0.0 110.065 174.128 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.522 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -164.48 153.5 13.22 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.272 -0.893 . . . . 0.0 110.2 -176.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.926 HD11 ' N ' ' A' ' 38' ' ' THR . 6.8 mt -109.56 130.02 63.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.107 -0.996 . . . . 0.0 109.958 176.118 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.507 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 4.5 m-80 -102.56 63.28 0.86 Allowed 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.682 -0.636 . . . . 0.0 109.725 179.427 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.11 -114.06 4.06 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.781 -1.728 . . . . 0.0 108.781 -174.086 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.944 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.53 -22.31 47.5 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 120.953 -1.322 . . . . 0.0 108.82 175.001 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.113 ' CD2' HG11 ' A' ' 13' ' ' VAL . 11.8 m80 -74.46 159.44 32.27 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.331 -0.856 . . . . 0.0 110.229 -177.651 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.747 HG13 HG13 ' A' ' 51' ' ' VAL . 54.1 t -141.62 122.58 12.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 C-N-CA 119.163 -1.015 . . . . 0.0 110.81 172.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.836 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.4 t -88.26 134.9 33.68 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.454 -0.779 . . . . 0.0 109.705 175.366 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 1.008 ' HB2' HD12 ' A' ' 49' ' ' LEU . 2.1 p90 -127.26 154.66 44.6 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 121.374 -0.829 . . . . 0.0 110.292 176.66 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.526 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 35.8 p-10 -88.95 152.29 21.8 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.149 -0.969 . . . . 0.0 111.329 -171.136 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.834 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -157.77 100.25 1.75 Allowed 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.598 -0.689 . . . . 0.0 109.369 -174.178 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.489 ' HB3' ' HB ' ' A' ' 67' ' ' THR . 60.7 ttm -60.23 139.89 57.32 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.058 -1.026 . . . . 0.0 109.669 -177.307 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.494 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 5.1 ttpm? -59.94 -43.31 95.07 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.138 -0.977 . . . . 0.0 110.409 -175.36 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.33 -40.03 77.84 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.833 -1.167 . . . . 0.0 109.842 178.056 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.64 HG21 ' O2 ' ' A' ' 98' ' ' RBF . 94.2 m -59.98 -37.64 80.24 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.05 -1.031 . . . . 0.0 109.474 172.231 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.712 HD11 ' HA2' ' A' ' 74' ' ' GLY . 14.2 tp -59.96 -45.81 91.45 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.273 -0.892 . . . . 0.0 109.428 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 55.2 ttt85 -69.96 -39.94 75.71 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.382 -0.824 . . . . 0.0 110.739 176.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.785 HG22 HG23 ' A' ' 71' ' ' THR . 1.5 tt -67.27 -42.82 88.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.233 -0.917 . . . . 0.0 109.445 -175.779 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.785 HG23 HG22 ' A' ' 70' ' ' ILE . 40.3 p -83.84 -173.87 4.96 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 174.678 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.496 ' HB3' ' HB2' ' B' ' 83' ' ' ASN . 3.1 t30 -102.71 23.63 11.77 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 169.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.834 ' HB3' HD21 ' A' ' 63' ' ' LEU . 86.9 mt -68.42 -40.07 81.36 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.089 -1.007 . . . . 0.0 110.015 176.768 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.712 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -47.88 -22.36 1.98 Allowed Glycine 0 N--CA 1.487 2.086 0 N-CA-C 110.253 -1.139 . . . . 0.0 110.253 179.694 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.513 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.2 p-10 -62.83 -18.69 63.19 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.163 -1.198 . . . . 0.0 110.405 -176.303 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.513 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.8 mt -60.0 143.16 52.52 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.202 -0.936 . . . . 0.0 110.516 -177.752 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 0.941 ' C ' HD23 ' A' ' 12' ' ' LEU . 23.3 mttm -145.82 146.87 31.32 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.584 -0.698 . . . . 0.0 109.381 176.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.601 ' CG2' HG13 ' A' ' 15' ' ' ILE . 22.4 t -68.25 148.59 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.677 -1.265 . . . . 0.0 110.176 -175.625 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 86.14 -11.17 63.61 Favored Glycine 0 N--CA 1.483 1.813 0 N-CA-C 108.743 -1.743 . . . . 0.0 108.743 -174.167 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.494 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 45.5 t0 -95.68 162.63 13.53 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.344 -1.092 . . . . 0.0 109.694 176.785 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.587 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.0 m95 -114.76 149.35 37.07 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.124 -0.985 . . . . 0.0 110.005 176.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.013 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.2 p -115.21 153.79 16.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.498 -0.751 . . . . 0.0 109.971 -179.581 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.69 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.6 m-20 -78.19 106.11 9.87 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 121.143 -0.973 . . . . 0.0 109.125 168.607 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.875 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -108.4 139.88 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 120.665 -1.272 . . . . 0.0 111.177 -176.643 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.42 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.4 tt0 -136.92 144.02 43.23 Favored 'General case' 0 N--CA 1.493 1.676 0 C-N-CA 120.217 -0.593 . . . . 0.0 110.201 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 66.5 ttp85 -79.58 129.92 34.91 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.279 -0.888 . . . . 0.0 111.011 -176.552 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.824 ' HB1' ' CZ ' ' B' ' 2' ' ' PHE . . . -125.76 145.92 49.99 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.351 -0.843 . . . . 0.0 110.134 175.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -136.37 142.9 43.79 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.668 -0.645 . . . . 0.0 110.457 -177.443 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 26.9 mttt -60.03 -39.9 87.48 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.252 -0.905 . . . . 0.0 109.948 179.774 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -137.83 156.41 47.96 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.364 -0.835 . . . . 0.0 110.04 177.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 48.2 m -133.65 147.18 51.42 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.27 -0.894 . . . . 0.0 110.005 176.243 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.462 ' O ' ' HB2' ' A' ' 93' ' ' GLU . 53.2 t0 -60.05 -37.9 81.2 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.194 -0.941 . . . . 0.0 109.697 177.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.462 ' HB2' ' O ' ' A' ' 92' ' ' ASP . 62.7 mm-40 55.93 50.01 14.76 Favored 'General case' 0 N--CA 1.507 2.402 0 O-C-N 121.574 -0.704 . . . . 0.0 110.512 178.363 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 56.9 mt -60.9 -44.48 97.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.27 -0.894 . . . . 0.0 109.498 172.514 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 79.96 -91.44 1.31 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 178.386 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -169.41 171.06 43.0 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.45 -1.46 . . . . 0.0 109.45 -179.525 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 . . . . . 0 N--CA 1.491 1.596 0 O-C-N 121.208 -1.172 . . . . 0.0 110.204 -179.556 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 92.3 mmm . . . . . 0 N--CA 1.492 1.645 0 CA-C-O 121.286 0.565 . . . . 0.0 110.487 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.824 ' CZ ' ' HB1' ' A' ' 87' ' ' ALA . 8.4 p90 -168.38 155.87 7.97 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 174.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.58 HG23 ' C ' ' B' ' 2' ' ' PHE . 40.3 p -155.65 -39.26 0.08 Allowed 'General case' 0 C--N 1.295 -1.795 0 O-C-N 120.85 -1.156 . . . . 0.0 109.174 177.078 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.457 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 45.5 24.95 1.2 Allowed Glycine 0 N--CA 1.484 1.86 0 N-CA-C 108.503 -1.839 . . . . 0.0 108.503 -173.69 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 0.485 HG13 ' O ' ' B' ' 3' ' ' THR . 91.5 mt -77.91 135.51 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.388 -1.066 . . . . 0.0 109.75 -179.517 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.666 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.6 t -91.37 137.76 21.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.051 -1.031 . . . . 0.0 110.921 -170.45 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 96.5 mt-30 -71.11 -32.79 69.46 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.814 -0.554 . . . . 0.0 111.221 -179.989 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.543 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -150.64 171.78 30.42 Favored Glycine 0 N--CA 1.495 2.63 0 C-N-CA 119.105 -1.522 . . . . 0.0 110.153 -171.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.499 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 3.1 p -119.23 172.26 7.72 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.937 -1.331 . . . . 0.0 111.238 -176.31 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.083 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -142.58 150.13 39.95 Favored 'General case' 0 N--CA 1.492 1.628 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 -176.417 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 30.1 tttt -110.9 115.25 29.19 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.102 -0.999 . . . . 0.0 110.224 179.585 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 0.929 HD23 ' C ' ' B' ' 77' ' ' LYS . 10.9 tp -59.95 127.68 33.08 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.085 -1.009 . . . . 0.0 109.068 174.41 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.127 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -122.03 -29.16 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 C-N-CA 119.658 -0.817 . . . . 0.0 109.662 179.295 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -151.67 147.6 26.92 Favored 'General case' 0 N--CA 1.493 1.678 0 C-N-CA 119.188 -1.005 . . . . 0.0 111.473 -179.137 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.848 HG23 ' CD2' ' B' ' 24' ' ' HIS . 11.8 mt -109.59 138.71 35.79 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 121.305 -0.872 . . . . 0.0 110.041 172.404 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.506 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 77.4 m-20 -109.72 114.61 28.34 Favored 'General case' 0 C--N 1.298 -1.633 0 O-C-N 121.31 -0.869 . . . . 0.0 109.863 173.638 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.31 112.18 24.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.16 -0.963 . . . . 0.0 110.311 -176.449 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.2 OUTLIER -112.83 132.74 22.16 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.173 -0.954 . . . . 0.0 109.005 175.393 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -49.67 -40.35 46.85 Favored 'Trans proline' 0 C--N 1.303 -1.852 0 O-C-N 123.91 1.479 . . . . 0.0 110.705 -179.092 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.438 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 12.1 m-80 -70.35 -40.07 74.3 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.141 -0.974 . . . . 0.0 110.108 177.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.461 ' O ' ' HB2' ' B' ' 18' ' ' LYS . 96.0 m-85 -152.03 150.36 29.87 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.314 -0.867 . . . . 0.0 110.542 -174.848 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.614 ' HD3' HD22 ' B' ' 68' ' ' LEU . 60.6 ttt180 -91.31 143.42 26.66 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.893 -1.129 . . . . 0.0 109.965 174.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.506 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 97.2 m -129.41 140.69 51.25 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.659 -0.651 . . . . 0.0 109.718 -174.591 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.848 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -132.52 137.5 47.19 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.069 -1.019 . . . . 0.0 111.094 -178.088 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.845 HG22 ' OG ' ' B' ' 60' ' ' SER . 4.8 t -120.13 131.95 71.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.119 -0.988 . . . . 0.0 110.662 -178.379 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.866 HG13 ' CE1' ' B' ' 61' ' ' PHE . 19.0 m -112.24 175.64 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 121.751 -0.593 . . . . 0.0 110.171 178.067 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.575 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 7.9 tt0 -106.76 117.09 33.12 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 108.806 -0.812 . . . . 0.0 108.806 178.31 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.573 HD12 ' HD2' ' B' ' 29' ' ' PRO . 10.8 tp -80.42 126.67 78.22 Favored Pre-proline 0 C--N 1.295 -1.763 0 O-C-N 121.235 -0.916 . . . . 0.0 109.83 -173.554 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.573 ' HD2' HD12 ' B' ' 28' ' ' LEU . 18.6 Cg_endo -63.67 173.65 4.38 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 O-C-N 123.946 1.498 . . . . 0.0 110.699 -179.427 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.75 ' HA ' HD12 ' B' ' 33' ' ' LEU . 12.3 p-10 -59.97 -38.05 81.39 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.258 -0.901 . . . . 0.0 110.739 -176.265 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.585 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.16 -0.05 57.42 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.922 -1.112 . . . . 0.0 110.902 -175.72 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.585 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 94.6 mmm -110.35 -11.98 14.47 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.867 -1.146 . . . . 0.0 109.913 170.182 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.932 HD21 ' HB2' ' B' ' 57' ' ' ASN . 15.8 mt -63.0 -31.43 72.57 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.341 -0.849 . . . . 0.0 110.133 176.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 30.5 t0 -93.22 139.99 30.02 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.347 -0.846 . . . . 0.0 110.538 -176.277 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.06 -41.32 2.35 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 174.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.757 HD23 ' N ' ' B' ' 37' ' ' GLU . 9.0 tt -76.09 149.25 37.47 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.973 -1.31 . . . . 0.0 111.034 -174.399 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . 0.757 ' N ' HD23 ' B' ' 36' ' ' LEU . 15.8 pt-20 -151.52 169.3 22.4 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.52 -0.737 . . . . 0.0 109.645 177.194 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.93 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -61.34 151.66 31.52 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.026 -1.046 . . . . 0.0 109.969 179.059 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.79 -5.94 60.17 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 -178.599 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.5 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -73.26 155.96 38.98 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.24 -1.153 . . . . 0.0 109.668 177.234 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.689 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -99.52 106.05 18.02 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.86 -1.15 . . . . 0.0 109.87 176.252 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.617 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.2 t -93.3 130.01 42.95 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.311 -0.868 . . . . 0.0 109.071 174.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -93.31 120.02 33.11 Favored 'General case' 0 C--N 1.298 -1.64 0 C-N-CA 119.274 -0.971 . . . . 0.0 109.225 172.241 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.783 ' CD2' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -91.22 104.67 17.2 Favored 'General case' 0 C--N 1.301 -1.527 0 C-N-CA 119.578 -0.849 . . . . 0.0 108.939 177.977 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.496 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.6 t-20 55.4 14.2 1.08 Allowed 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.378 -0.826 . . . . 0.0 110.864 -168.692 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.463 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 120.21 -4.92 12.34 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.622 -1.275 . . . . 0.0 110.916 171.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.862 ' O ' HD23 ' B' ' 49' ' ' LEU . 25.0 t -90.68 110.31 21.49 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 120.365 -1.668 . . . . 0.0 109.478 176.547 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 19.1 p -74.32 128.02 34.48 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.074 -1.016 . . . . 0.0 110.803 -171.556 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 1.0 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -143.36 159.98 41.38 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.41 -0.806 . . . . 0.0 109.709 174.78 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . 0.469 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 3.6 m -102.07 151.66 21.89 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.803 -1.185 . . . . 0.0 111.019 -172.473 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.725 HG13 HG13 ' B' ' 59' ' ' VAL . 15.9 t -78.41 118.35 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.599 -0.688 . . . . 0.0 110.549 -177.39 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.53 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 43.9 p -72.26 -40.11 67.91 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.336 -0.853 . . . . 0.0 110.061 174.222 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.525 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -164.44 153.5 13.3 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.193 -0.942 . . . . 0.0 110.21 -176.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.93 HD11 ' N ' ' B' ' 38' ' ' THR . 6.9 mt -109.48 129.97 63.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.149 -0.97 . . . . 0.0 110.016 176.118 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.519 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 4.5 m-80 -102.68 63.3 0.85 Allowed 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.598 -0.689 . . . . 0.0 109.732 179.433 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.29 -114.11 4.05 Favored Glycine 0 N--CA 1.488 2.136 0 N-CA-C 108.758 -1.737 . . . . 0.0 108.758 -174.162 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.932 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.36 -22.57 47.76 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.01 -1.288 . . . . 0.0 108.903 174.89 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.127 ' CD2' HG11 ' B' ' 13' ' ' VAL . 12.0 m80 -74.27 159.23 32.73 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.475 -0.766 . . . . 0.0 110.249 -177.638 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.725 HG13 HG13 ' B' ' 51' ' ' VAL . 54.3 t -141.48 122.56 12.95 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.756 173.104 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.845 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.4 t -88.34 135.13 33.61 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.464 -0.772 . . . . 0.0 109.655 175.418 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 1.0 ' HB2' HD12 ' B' ' 49' ' ' LEU . 2.1 p90 -127.46 154.62 44.85 Favored 'General case' 0 N--CA 1.495 1.806 0 C-N-CA 119.692 -0.803 . . . . 0.0 110.263 176.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.53 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 36.3 p-10 -88.89 152.29 21.83 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.035 -1.041 . . . . 0.0 111.275 -171.041 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.811 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -157.79 100.24 1.74 Allowed 'General case' 0 C--N 1.3 -1.562 0 C-N-CA 120.065 -0.654 . . . . 0.0 109.298 -174.186 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.495 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 60.8 ttm -60.14 139.84 57.28 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.066 -1.021 . . . . 0.0 109.737 -177.391 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.499 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 5.1 ttpm? -59.98 -43.28 95.23 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.131 -0.981 . . . . 0.0 110.399 -175.353 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.36 -40.01 77.74 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.914 -1.116 . . . . 0.0 109.883 178.044 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.644 HG21 ' O2 ' ' B' ' 99' ' ' RBF . 94.4 m -60.01 -37.68 80.43 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.075 -1.015 . . . . 0.0 109.434 172.26 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.717 HD11 ' HA2' ' B' ' 74' ' ' GLY . 14.2 tp -60.01 -45.59 92.26 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.302 -0.874 . . . . 0.0 109.482 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 55.2 ttt85 -70.01 -40.03 75.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.465 -0.772 . . . . 0.0 110.732 176.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.769 HG22 HG23 ' B' ' 71' ' ' THR . 1.5 tt -67.2 -42.78 88.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.289 -0.882 . . . . 0.0 109.438 -175.802 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.769 HG23 HG22 ' B' ' 70' ' ' ILE . 40.2 p -83.84 -173.69 4.86 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 109.251 -0.648 . . . . 0.0 109.251 174.759 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.501 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 3.2 t30 -102.8 23.71 11.71 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 108.172 -1.048 . . . . 0.0 108.172 169.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.811 ' HB3' HD21 ' B' ' 63' ' ' LEU . 86.2 mt -68.6 -39.95 80.68 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.141 -0.975 . . . . 0.0 109.938 176.832 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.717 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -47.96 -22.28 2.02 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.646 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.3 p-10 -62.86 -18.69 63.27 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.092 -1.24 . . . . 0.0 110.434 -176.335 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.517 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 98.0 mt -60.02 143.26 52.31 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.269 -0.894 . . . . 0.0 110.496 -177.738 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 0.929 ' C ' HD23 ' B' ' 12' ' ' LEU . 23.3 mttm -145.99 146.71 31.1 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.681 -0.637 . . . . 0.0 109.351 177.02 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.585 ' CG2' HG13 ' B' ' 15' ' ' ILE . 22.1 t -68.05 148.69 11.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 120.865 -1.147 . . . . 0.0 110.303 -175.669 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 85.96 -10.94 63.83 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.86 -1.696 . . . . 0.0 108.86 -174.125 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.48 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 45.2 t0 -95.74 162.48 13.58 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.303 -1.116 . . . . 0.0 109.687 176.658 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.0 m95 -114.73 149.41 36.88 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.174 -0.954 . . . . 0.0 109.999 176.833 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.083 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.2 p -115.37 153.95 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.422 -0.799 . . . . 0.0 109.857 -179.574 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.666 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -78.27 106.09 9.94 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.138 -0.976 . . . . 0.0 109.197 168.616 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.898 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -108.36 140.04 28.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 120.726 -1.234 . . . . 0.0 111.014 -176.446 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . 0.413 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.5 tt0 -137.18 143.98 42.66 Favored 'General case' 0 N--CA 1.492 1.633 0 C-N-CA 120.282 -0.567 . . . . 0.0 110.205 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 66.5 ttp85 -79.36 130.03 35.04 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.219 -0.926 . . . . 0.0 110.946 -176.515 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 0.928 ' HB1' ' CZ ' ' A' ' 2' ' ' PHE . . . -125.87 145.95 50.03 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.302 -0.874 . . . . 0.0 110.045 175.733 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . 0.413 ' N ' ' CE2' ' A' ' 2' ' ' PHE . . . -136.41 142.86 43.72 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.586 -0.696 . . . . 0.0 110.508 -177.5 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 26.8 mttt -59.98 -40.05 87.82 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 109.899 179.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -137.8 156.5 47.89 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.377 -0.827 . . . . 0.0 109.949 177.681 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . 0.622 ' H ' HD11 ' B' ' 94' ' ' ILE . 48.4 m -133.62 147.24 51.46 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.344 -0.848 . . . . 0.0 110.001 176.266 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 52.9 t0 -60.09 -40.03 88.17 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.137 -0.977 . . . . 0.0 109.693 177.679 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 -109.34 51.73 0.74 Allowed 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.172 -0.955 . . . . 0.0 110.707 -177.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . 0.622 HD11 ' H ' ' B' ' 91' ' ' SER . 59.0 mt -59.98 -41.96 87.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.217 -0.927 . . . . 0.0 109.54 174.725 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 57.83 75.44 0.26 Allowed Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 175.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . 174.37 179.97 45.33 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 178.094 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 93.8 m-70 . . . . . 0 N--CA 1.491 1.61 0 O-C-N 121.331 -1.1 . . . . 0.0 110.143 179.618 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 0.64 ' O2 ' HG21 ' A' ' 67' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 0.644 ' O2 ' HG21 ' B' ' 67' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.457 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 98.2 mtp . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 121.238 0.542 . . . . 0.0 110.227 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.948 ' CZ ' ' HB1' ' B' ' 87' ' ' ALA . 6.3 p90 -178.26 140.0 0.21 Allowed 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.293 -0.879 . . . . 0.0 108.846 177.642 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.559 ' CB ' HG12 ' A' ' 5' ' ' ILE . 9.9 p -130.99 -36.91 1.31 Allowed 'General case' 0 C--N 1.3 -1.566 0 O-C-N 120.816 -1.177 . . . . 0.0 109.133 -177.11 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.5 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 52.61 22.03 10.53 Favored Glycine 0 N--CA 1.485 1.901 0 N-CA-C 108.584 -1.806 . . . . 0.0 108.584 -178.33 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.559 HG12 ' CB ' ' A' ' 3' ' ' THR . 32.8 mm -80.43 122.82 36.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.429 -1.041 . . . . 0.0 109.789 -176.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.959 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.3 t -82.66 142.84 13.07 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.184 -0.947 . . . . 0.0 110.892 -171.702 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 90.9 mm-40 -69.43 -35.0 75.28 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.773 -0.579 . . . . 0.0 110.621 177.107 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.53 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -162.68 173.9 38.98 Favored Glycine 0 N--CA 1.493 2.444 0 C-N-CA 118.896 -1.621 . . . . 0.0 110.094 -174.114 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.464 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 6.5 p -114.69 174.76 5.8 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.154 -1.204 . . . . 0.0 110.836 -177.701 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.022 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -142.61 149.04 38.45 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.622 -0.674 . . . . 0.0 109.541 -177.718 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 30.0 tttt -103.95 118.62 37.1 Favored 'General case' 0 C--N 1.295 -1.789 0 O-C-N 120.95 -1.094 . . . . 0.0 110.2 178.134 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 1.02 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.2 tp -60.7 127.55 32.21 Favored 'General case' 0 C--N 1.298 -1.642 0 O-C-N 120.795 -1.191 . . . . 0.0 108.569 171.005 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.153 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.7 p -130.45 -31.17 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.874 0 C-N-CA 119.5 -0.88 . . . . 0.0 110.229 -177.126 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -143.84 139.83 29.49 Favored 'General case' 0 C--N 1.296 -1.719 0 C-N-CA 119.079 -1.048 . . . . 0.0 111.272 -178.634 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.78 HG23 ' CD2' ' A' ' 24' ' ' HIS . 11.2 mt -110.02 130.81 62.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.034 -1.041 . . . . 0.0 110.198 171.201 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.508 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 81.6 m-20 -108.07 114.64 28.7 Favored 'General case' 0 C--N 1.294 -1.843 0 O-C-N 121.443 -0.786 . . . . 0.0 109.962 173.195 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.4 110.77 22.98 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.002 -1.061 . . . . 0.0 110.592 -176.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -110.29 128.12 25.89 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.133 -0.979 . . . . 0.0 108.917 174.09 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -50.61 -33.42 39.28 Favored 'Trans proline' 0 C--N 1.303 -1.851 0 O-C-N 123.767 1.404 . . . . 0.0 110.314 -179.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.474 ' C ' ' CD2' ' A' ' 21' ' ' PHE . 12.4 m-80 -72.27 -40.0 67.95 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.149 -0.97 . . . . 0.0 109.938 175.812 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.474 ' CD2' ' C ' ' A' ' 20' ' ' ASN . 91.0 m-85 -152.51 150.25 29.39 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.374 -0.829 . . . . 0.0 110.197 -178.4 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.486 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 57.5 ttt180 -88.31 139.95 29.97 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 120.734 -1.229 . . . . 0.0 109.7 173.074 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.508 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 95.0 m -124.97 131.73 53.38 Favored 'General case' 0 C--N 1.294 -1.847 0 O-C-N 121.597 -0.689 . . . . 0.0 109.901 -176.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.78 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.2 OUTLIER -126.21 138.89 53.68 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.905 -1.122 . . . . 0.0 111.303 -179.7 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.767 HG22 ' CB ' ' A' ' 60' ' ' SER . 5.7 t -120.83 134.26 64.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.135 -0.978 . . . . 0.0 110.861 -176.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.814 HG13 ' CE1' ' A' ' 61' ' ' PHE . 35.9 m -114.79 172.17 4.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 O-C-N 121.804 -0.56 . . . . 0.0 110.09 178.243 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.472 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 9.2 tt0 -104.21 117.91 35.37 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.376 -0.827 . . . . 0.0 108.788 177.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.891 HD21 HD13 ' A' ' 36' ' ' LEU . 7.5 tp -85.83 127.93 60.48 Favored Pre-proline 0 C--N 1.297 -1.703 0 O-C-N 121.562 -0.711 . . . . 0.0 109.943 -171.128 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.479 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 20.6 Cg_endo -66.02 178.69 2.25 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 O-C-N 123.881 1.464 . . . . 0.0 110.743 -179.363 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.518 ' HA ' HD12 ' A' ' 33' ' ' LEU . 33.9 p-10 -62.65 -40.1 95.99 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.349 -0.844 . . . . 0.0 110.999 -175.542 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.606 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.93 -0.0 57.33 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.837 -1.164 . . . . 0.0 110.823 -174.367 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.606 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 97.0 mmm -108.11 -16.98 14.15 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.87 -1.144 . . . . 0.0 109.638 170.772 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.597 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 24.7 mt -66.2 -25.77 67.08 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.363 -0.835 . . . . 0.0 109.721 174.736 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -92.26 131.33 37.56 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.474 -0.766 . . . . 0.0 110.56 -178.094 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.79 -41.75 2.71 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 176.601 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.891 HD13 HD21 ' A' ' 28' ' ' LEU . 5.1 tt -70.84 148.2 48.09 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.076 -1.249 . . . . 0.0 110.335 -177.226 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.729 ' N ' HD23 ' A' ' 36' ' ' LEU . 19.9 pt-20 -156.75 166.36 33.61 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.322 -0.862 . . . . 0.0 109.599 -177.66 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.75 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -65.57 148.5 51.63 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 120.886 -1.134 . . . . 0.0 110.051 -178.886 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.67 -3.47 68.76 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.234 -1.546 . . . . 0.0 109.234 -174.369 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.463 ' CB ' ' O ' ' A' ' 37' ' ' GLU . . . -78.22 160.03 28.19 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.263 -1.14 . . . . 0.0 109.445 176.108 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.453 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -101.64 114.31 28.24 Favored 'General case' 0 N--CA 1.485 1.281 0 C-N-CA 118.799 -1.16 . . . . 0.0 110.097 177.107 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.666 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.7 t -99.11 128.75 50.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.278 -0.889 . . . . 0.0 108.94 173.277 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.512 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -94.99 119.48 33.58 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 119.156 -1.017 . . . . 0.0 109.074 172.295 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.666 ' HE1' HG11 ' A' ' 42' ' ' VAL . 0.6 OUTLIER -87.32 103.14 15.19 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.415 -0.803 . . . . 0.0 108.958 178.41 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.498 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 57.83 8.9 0.77 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.441 -0.787 . . . . 0.0 111.309 -170.312 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.503 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 124.11 2.26 8.51 Favored Glycine 0 N--CA 1.489 2.168 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.858 174.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.803 ' O ' HD23 ' A' ' 49' ' ' LEU . 42.7 t -98.45 107.33 19.77 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 120.461 -1.611 . . . . 0.0 109.485 174.706 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.504 ' SG ' ' C7 ' ' A' ' 98' ' ' RBF . 26.2 p -75.1 129.9 38.35 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.237 -0.914 . . . . 0.0 111.211 -170.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.975 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -145.27 160.63 41.2 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.443 -0.786 . . . . 0.0 109.637 173.552 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.41 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 57.9 m -100.95 151.17 22.08 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 120.737 -1.227 . . . . 0.0 110.923 -171.719 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.737 HG13 HG13 ' A' ' 59' ' ' VAL . 38.6 t -78.48 116.85 22.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.655 -0.653 . . . . 0.0 110.487 -178.358 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.532 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 37.7 p -70.03 -40.01 75.42 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.205 -0.934 . . . . 0.0 109.893 174.092 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.621 ' HA ' HG21 ' A' ' 38' ' ' THR . 86.5 tt0 -163.47 153.39 15.32 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.298 -0.876 . . . . 0.0 110.194 -177.676 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.75 HD11 ' N ' ' A' ' 38' ' ' THR . 5.9 mt -104.49 133.63 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.018 -1.051 . . . . 0.0 109.885 175.044 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.509 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 31.4 m-80 -107.72 66.94 0.67 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.507 -0.745 . . . . 0.0 109.823 179.154 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.27 -116.06 4.83 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.816 -1.714 . . . . 0.0 108.816 -174.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.597 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -79.21 -19.13 51.53 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.055 -1.262 . . . . 0.0 108.764 174.545 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.153 ' CD2' HG11 ' A' ' 13' ' ' VAL . 11.2 m170 -74.73 160.66 30.46 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.467 -0.77 . . . . 0.0 110.343 -178.236 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.737 HG13 HG13 ' A' ' 51' ' ' VAL . 62.9 t -141.25 123.21 14.27 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 O-C-N 121.229 -0.92 . . . . 0.0 110.433 171.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.767 ' CB ' HG22 ' A' ' 25' ' ' VAL . 13.3 m -91.32 130.53 37.17 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.573 -0.704 . . . . 0.0 109.535 178.283 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.975 ' HB2' HD12 ' A' ' 49' ' ' LEU . 4.0 p90 -124.69 153.66 42.0 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.096 -1.002 . . . . 0.0 110.333 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.532 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 27.2 p-10 -88.73 152.22 21.93 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.091 -1.006 . . . . 0.0 111.37 -170.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.866 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.1 OUTLIER -155.73 114.33 3.46 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -176.128 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.513 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 7.1 ttp -71.64 140.0 49.52 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.803 -1.186 . . . . 0.0 109.685 -177.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.5 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 37.5 ttpt -60.04 -46.03 90.86 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.075 -1.015 . . . . 0.0 110.532 -174.05 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -70.0 -40.05 75.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.659 -1.275 . . . . 0.0 110.003 178.522 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.513 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 33.4 m -61.88 -34.9 76.87 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.053 -1.029 . . . . 0.0 109.462 173.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.709 HD11 ' HA2' ' A' ' 74' ' ' GLY . 7.6 tp -59.96 -45.81 91.47 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.244 -0.91 . . . . 0.0 109.151 178.205 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 71.8 ttt-85 -66.46 -39.98 89.15 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.284 -0.885 . . . . 0.0 110.682 175.115 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.785 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -66.72 -44.24 89.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.173 -0.954 . . . . 0.0 109.584 -175.549 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.785 HG23 HG22 ' A' ' 70' ' ' ILE . 31.2 p -83.17 -175.13 5.68 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 120.199 -0.6 . . . . 0.0 109.437 175.5 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.482 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 3.7 t30 -99.48 23.59 9.21 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 171.216 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.866 ' HB3' HD21 ' A' ' 63' ' ' LEU . 90.9 mt -70.0 -39.96 75.55 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.12 -0.987 . . . . 0.0 110.117 176.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.709 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -53.75 -18.1 7.71 Favored Glycine 0 N--CA 1.486 1.987 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 -177.137 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.2 p-10 -69.99 -19.03 63.35 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.953 -1.322 . . . . 0.0 110.575 -175.567 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.518 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 87.9 mt -62.13 141.92 57.88 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.233 -0.917 . . . . 0.0 110.815 -176.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 1.02 ' C ' HD23 ' A' ' 12' ' ' LEU . 43.5 mtmt -141.49 141.74 33.62 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 121.63 -0.669 . . . . 0.0 109.776 174.32 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.733 HG23 HD11 ' A' ' 15' ' ' ILE . 16.6 t -60.32 152.6 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 120.926 -1.109 . . . . 0.0 110.451 -174.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.43 -15.9 57.45 Favored Glycine 0 N--CA 1.482 1.722 0 N-CA-C 108.762 -1.735 . . . . 0.0 108.762 -176.348 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.468 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 37.8 t0 -95.76 166.8 11.64 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.312 -1.111 . . . . 0.0 109.664 175.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.584 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 16.3 m95 -116.82 160.49 20.74 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.083 -1.011 . . . . 0.0 110.171 178.014 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.022 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.1 p -125.55 155.21 34.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.339 -0.851 . . . . 0.0 110.034 -177.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.959 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -79.97 105.04 10.96 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 120.964 -1.085 . . . . 0.0 109.059 168.229 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.81 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -105.56 138.01 32.68 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 O-C-N 120.546 -1.346 . . . . 0.0 111.118 -176.539 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -133.53 140.03 46.96 Favored 'General case' 0 N--CA 1.493 1.704 0 C-N-CA 120.298 -0.561 . . . . 0.0 110.028 -178.023 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.537 ' NH1' ' HB2' ' A' ' 86' ' ' ARG . 26.7 ttm105 -78.31 126.91 31.45 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.258 -0.901 . . . . 0.0 110.701 -176.053 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.93 ' HB1' ' CZ ' ' B' ' 2' ' ' PHE . . . -120.51 144.3 48.1 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.392 -0.817 . . . . 0.0 110.076 176.289 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -137.37 157.8 45.8 Favored 'General case' 0 N--CA 1.49 1.533 0 CA-C-O 121.515 0.674 . . . . 0.0 110.727 -176.302 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 40.0 mmtt -66.17 -39.96 90.13 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.387 -0.82 . . . . 0.0 110.576 179.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 45.7 p90 -108.77 161.45 15.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.085 -1.009 . . . . 0.0 110.499 -175.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 58.4 m -119.93 144.86 47.21 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.438 -0.789 . . . . 0.0 110.323 -178.527 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.42 ' O ' ' OD1' ' A' ' 92' ' ' ASP . 55.0 t0 -69.9 -24.64 63.43 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.41 -0.806 . . . . 0.0 110.696 -178.74 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -92.85 43.19 1.12 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.736 -1.228 . . . . 0.0 110.856 -172.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . . . . . . . . . 57.9 mt -61.44 -45.85 97.78 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.738 0 O-C-N 121.35 -0.843 . . . . 0.0 109.765 170.55 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 149.08 -91.44 0.14 Allowed Glycine 0 N--CA 1.488 2.158 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 -178.211 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 86.27 -9.94 68.25 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 178.645 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 44.1 m80 . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.202 -1.175 . . . . 0.0 110.174 -178.539 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . 0.445 ' O ' ' HB3' ' B' ' 2' ' ' PHE . 67.6 mtt . . . . . 0 N--CA 1.492 1.675 0 CA-C-O 121.254 0.549 . . . . 0.0 110.261 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.93 ' CZ ' ' HB1' ' A' ' 87' ' ' ALA . 6.4 p90 -177.94 139.99 0.23 Allowed 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.304 -0.872 . . . . 0.0 108.748 176.5 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.558 ' CB ' HG12 ' B' ' 5' ' ' ILE . 9.6 p -130.97 -36.88 1.32 Allowed 'General case' 0 C--N 1.301 -1.533 0 O-C-N 120.824 -1.173 . . . . 0.0 109.174 -177.174 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.483 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 52.59 22.01 10.43 Favored Glycine 0 N--CA 1.485 1.959 0 N-CA-C 108.608 -1.797 . . . . 0.0 108.608 -178.335 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 0.558 HG12 ' CB ' ' B' ' 3' ' ' THR . 32.9 mm -80.42 122.75 36.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.356 -1.085 . . . . 0.0 109.833 -176.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.966 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.3 t -82.56 142.89 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.166 -0.959 . . . . 0.0 110.984 -171.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 90.8 mm-40 -69.51 -34.74 74.72 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.685 -0.635 . . . . 0.0 110.665 177.167 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.524 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -163.03 173.72 39.26 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.065 -1.541 . . . . 0.0 110.177 -174.111 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.468 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 6.4 p -114.68 174.63 5.87 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.156 -1.203 . . . . 0.0 110.841 -177.543 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.044 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -142.45 149.24 39.0 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.704 -0.622 . . . . 0.0 109.462 -177.802 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.58 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 29.9 tttt -103.97 118.68 37.24 Favored 'General case' 0 C--N 1.296 -1.725 0 O-C-N 121.051 -1.03 . . . . 0.0 110.154 178.065 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 1.017 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.1 tp -60.86 127.42 31.5 Favored 'General case' 0 C--N 1.297 -1.687 0 O-C-N 120.952 -1.092 . . . . 0.0 108.624 170.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.14 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.7 p -130.2 -31.53 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.836 0 O-C-N 121.265 -0.897 . . . . 0.0 110.267 -177.008 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -143.7 139.89 29.75 Favored 'General case' 0 C--N 1.295 -1.772 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.311 -178.649 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.792 HG23 ' CD2' ' B' ' 24' ' ' HIS . 11.2 mt -109.92 130.84 62.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.048 -1.032 . . . . 0.0 110.149 171.259 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.522 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 81.2 m-20 -108.2 114.79 28.95 Favored 'General case' 0 C--N 1.296 -1.722 0 O-C-N 121.42 -0.8 . . . . 0.0 109.912 173.127 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.38 110.79 23.01 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.119 -0.988 . . . . 0.0 110.503 -176.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.457 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -110.34 128.1 25.91 Favored Pre-proline 0 N--CA 1.492 1.629 0 O-C-N 121.158 -0.964 . . . . 0.0 109.016 173.971 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 7.9 Cg_endo -50.8 -33.27 40.2 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 O-C-N 123.758 1.399 . . . . 0.0 110.253 -179.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.471 ' C ' ' CD2' ' B' ' 21' ' ' PHE . 12.3 m-80 -72.32 -40.17 67.66 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.203 -0.935 . . . . 0.0 109.902 175.713 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.471 ' CD2' ' C ' ' B' ' 20' ' ' ASN . 91.1 m-85 -152.33 150.23 29.5 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.393 -0.817 . . . . 0.0 110.233 -178.423 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.498 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 57.5 ttt180 -88.13 139.89 30.05 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.777 -1.202 . . . . 0.0 109.706 173.063 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.522 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 95.6 m -124.96 131.75 53.38 Favored 'General case' 0 C--N 1.295 -1.781 0 O-C-N 121.676 -0.64 . . . . 0.0 109.908 -176.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.792 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.2 OUTLIER -126.18 138.97 53.7 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.011 -1.056 . . . . 0.0 111.241 -179.635 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.778 HG22 ' CB ' ' B' ' 60' ' ' SER . 5.7 t -120.78 134.44 64.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.224 -0.923 . . . . 0.0 110.834 -176.971 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.804 HG13 ' CE1' ' B' ' 61' ' ' PHE . 35.8 m -115.04 172.08 4.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 O-C-N 121.773 -0.579 . . . . 0.0 110.021 178.28 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.475 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 9.2 tt0 -104.1 118.05 35.73 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 177.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.87 HD21 HD13 ' B' ' 36' ' ' LEU . 7.5 tp -85.84 127.8 60.96 Favored Pre-proline 0 C--N 1.296 -1.735 0 O-C-N 121.338 -0.851 . . . . 0.0 110.0 -171.209 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.469 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 20.9 Cg_endo -65.95 178.63 2.25 Favored 'Trans proline' 0 C--N 1.308 -1.604 0 O-C-N 123.828 1.436 . . . . 0.0 110.799 -179.365 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.522 ' HA ' HD12 ' B' ' 33' ' ' LEU . 33.8 p-10 -62.74 -39.94 95.68 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.322 -0.861 . . . . 0.0 110.984 -175.47 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.0 0.0 57.34 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.851 -1.156 . . . . 0.0 110.797 -174.363 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.597 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 97.0 mmm -108.16 -16.87 14.16 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.84 -1.162 . . . . 0.0 109.62 170.833 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.588 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 24.6 mt -66.36 -25.69 66.92 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.369 -0.832 . . . . 0.0 109.714 174.739 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -92.28 131.31 37.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.48 -0.762 . . . . 0.0 110.525 -178.129 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.76 -41.64 2.72 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 176.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.87 HD13 HD21 ' B' ' 28' ' ' LEU . 5.1 tt -70.81 148.26 48.05 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.033 -1.275 . . . . 0.0 110.267 -177.222 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . 0.733 ' N ' HD23 ' B' ' 36' ' ' LEU . 19.9 pt-20 -156.8 166.39 33.51 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.366 -0.834 . . . . 0.0 109.576 -177.702 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.748 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -65.65 148.46 51.72 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 120.927 -1.108 . . . . 0.0 110.064 -178.886 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.59 -3.33 68.94 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.319 -1.512 . . . . 0.0 109.319 -174.272 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.466 ' CB ' ' O ' ' B' ' 37' ' ' GLU . . . -78.41 159.99 28.01 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.286 -1.126 . . . . 0.0 109.33 176.021 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.457 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -101.56 114.18 27.97 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 120.86 -1.15 . . . . 0.0 110.116 177.177 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.657 HG11 ' HE1' ' B' ' 44' ' ' HIS . 1.7 t -99.24 128.77 50.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.319 -0.863 . . . . 0.0 108.923 173.329 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.509 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -94.86 119.47 33.47 Favored 'General case' 0 C--N 1.297 -1.707 0 O-C-N 121.083 -1.011 . . . . 0.0 109.135 172.294 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.657 ' HE1' HG11 ' B' ' 42' ' ' VAL . 0.6 OUTLIER -87.42 102.99 15.08 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.376 -0.828 . . . . 0.0 108.975 178.403 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.498 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 58.12 8.9 0.85 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.49 -0.756 . . . . 0.0 111.25 -170.459 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.503 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 123.87 2.73 8.57 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.789 -1.196 . . . . 0.0 110.802 174.709 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.82 ' O ' HD23 ' B' ' 49' ' ' LEU . 42.7 t -98.62 107.26 19.66 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 120.378 -1.66 . . . . 0.0 109.44 174.535 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . 0.513 ' SG ' ' C7 ' ' B' ' 99' ' ' RBF . 26.2 p -74.97 130.04 38.68 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.114 -0.991 . . . . 0.0 111.142 -171.026 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 0.957 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -145.43 160.41 41.62 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.484 -0.76 . . . . 0.0 109.717 173.462 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . 0.423 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 57.7 m -100.7 151.35 21.76 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 120.781 -1.199 . . . . 0.0 110.982 -171.798 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.734 HG13 HG13 ' B' ' 59' ' ' VAL . 38.2 t -78.67 116.92 23.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.644 -0.66 . . . . 0.0 110.472 -178.358 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.519 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 38.8 p -70.07 -40.06 75.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.201 -0.937 . . . . 0.0 109.884 174.224 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.614 ' HA ' HG21 ' B' ' 38' ' ' THR . 86.5 tt0 -163.36 153.44 15.6 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.341 -0.849 . . . . 0.0 110.226 -177.683 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.748 HD11 ' N ' ' B' ' 38' ' ' THR . 5.9 mt -104.52 133.65 48.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.151 -0.968 . . . . 0.0 109.937 174.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.52 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 31.3 m-80 -107.82 66.99 0.67 Allowed 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.572 -0.705 . . . . 0.0 109.762 179.194 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.41 -116.08 4.81 Favored Glycine 0 N--CA 1.489 2.206 0 N-CA-C 108.743 -1.743 . . . . 0.0 108.743 -174.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.588 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -79.18 -19.22 51.42 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 120.974 -1.309 . . . . 0.0 108.832 174.478 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.14 ' CD2' HG11 ' B' ' 13' ' ' VAL . 11.1 m170 -74.65 160.53 30.69 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.443 -0.785 . . . . 0.0 110.361 -178.301 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.734 HG13 HG13 ' B' ' 51' ' ' VAL . 62.9 t -141.06 123.22 14.75 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 O-C-N 121.208 -0.932 . . . . 0.0 110.453 171.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.778 ' CB ' HG22 ' B' ' 25' ' ' VAL . 13.4 m -91.43 130.87 37.21 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.632 -0.667 . . . . 0.0 109.553 178.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.957 ' HB2' HD12 ' B' ' 49' ' ' LEU . 3.9 p90 -124.96 153.43 42.76 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.188 -0.945 . . . . 0.0 110.255 -179.721 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.519 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 27.4 p-10 -88.58 152.21 21.99 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.976 -1.077 . . . . 0.0 111.466 -170.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.831 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.1 OUTLIER -155.71 114.4 3.48 Favored 'General case' 0 C--N 1.299 -1.594 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 -176.154 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.512 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 7.1 ttp -71.62 139.97 49.54 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.867 -1.146 . . . . 0.0 109.799 -178.076 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.501 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 37.5 ttpt -60.06 -45.98 91.06 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.128 -0.982 . . . . 0.0 110.477 -173.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -70.06 -39.98 75.36 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 120.806 -1.184 . . . . 0.0 110.023 178.591 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.512 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 34.4 m -61.94 -34.98 77.09 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.035 -1.041 . . . . 0.0 109.342 173.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.702 HD11 ' HA2' ' B' ' 74' ' ' GLY . 7.6 tp -60.05 -45.47 92.74 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.312 -0.867 . . . . 0.0 109.243 178.26 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 71.8 ttt-85 -66.7 -39.96 88.27 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.356 -0.84 . . . . 0.0 110.652 175.051 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.768 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -66.71 -44.23 89.64 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.144 -0.973 . . . . 0.0 109.595 -175.602 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.768 HG23 HG22 ' B' ' 70' ' ' ILE . 31.2 p -83.05 -175.02 5.63 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 120.114 -0.634 . . . . 0.0 109.477 175.518 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.492 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 3.7 t30 -99.56 23.68 9.16 Favored 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 171.125 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.831 ' HB3' HD21 ' B' ' 63' ' ' LEU . 90.7 mt -70.05 -39.96 75.4 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.123 -0.985 . . . . 0.0 110.089 176.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.702 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -53.79 -18.0 7.7 Favored Glycine 0 N--CA 1.487 2.09 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 -177.11 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.4 p-10 -70.06 -18.99 63.3 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.039 -1.271 . . . . 0.0 110.578 -175.556 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.511 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 88.1 mt -62.14 141.89 57.91 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.231 -0.918 . . . . 0.0 110.828 -177.025 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 1.017 ' C ' HD23 ' B' ' 12' ' ' LEU . 43.4 mtmt -141.52 141.72 33.58 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.666 -0.646 . . . . 0.0 109.787 174.321 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.744 HG23 HD11 ' B' ' 15' ' ' ILE . 16.7 t -60.31 152.51 5.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 O-C-N 120.957 -1.09 . . . . 0.0 110.43 -174.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.38 -15.59 58.16 Favored Glycine 0 N--CA 1.484 1.846 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -176.415 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.473 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 38.0 t0 -95.97 166.68 11.66 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.422 -1.046 . . . . 0.0 109.655 175.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.58 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.4 m95 -116.76 160.53 20.66 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.15 -0.968 . . . . 0.0 110.176 178.076 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.044 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.1 p -125.56 155.35 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.407 -0.808 . . . . 0.0 109.979 -178.056 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.966 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.2 OUTLIER -80.01 104.89 10.89 Favored 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.093 -1.004 . . . . 0.0 109.003 168.296 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.809 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -105.54 138.18 31.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 120.559 -1.338 . . . . 0.0 111.075 -176.491 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.0 tt0 -133.71 140.08 46.79 Favored 'General case' 0 N--CA 1.492 1.662 0 C-N-CA 120.335 -0.546 . . . . 0.0 110.05 -178.103 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . 0.538 ' NH1' ' HB2' ' B' ' 86' ' ' ARG . 26.8 ttm105 -78.34 126.92 31.46 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.213 -0.929 . . . . 0.0 110.642 -176.014 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 0.948 ' HB1' ' CZ ' ' A' ' 2' ' ' PHE . . . -120.39 144.16 48.06 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.334 -0.854 . . . . 0.0 110.015 176.286 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -137.25 157.89 45.63 Favored 'General case' 0 N--CA 1.49 1.574 0 CA-C-O 121.438 0.637 . . . . 0.0 110.774 -176.473 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 40.0 mmtt -66.26 -39.96 89.82 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.395 -0.816 . . . . 0.0 110.555 179.799 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 45.8 p90 -108.77 161.53 15.02 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.158 -0.964 . . . . 0.0 110.543 -176.005 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . . . . . . . . . 58.8 m -119.94 144.94 47.19 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.381 -0.824 . . . . 0.0 110.351 -178.567 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . 0.428 ' O ' ' OD1' ' B' ' 92' ' ' ASP . 55.3 t0 -70.02 -21.19 63.22 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.366 -0.834 . . . . 0.0 110.515 -178.658 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 91.2 mt-10 -117.02 55.9 0.82 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.489 -0.757 . . . . 0.0 110.268 -176.077 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . 0.432 ' O ' ' C ' ' B' ' 95' ' ' GLY . 38.7 mm -59.97 -44.72 95.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.276 -0.89 . . . . 0.0 109.64 177.776 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' B' ' 94' ' ' ILE . . . 40.34 65.87 0.91 Allowed Glycine 0 N--CA 1.493 2.472 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 177.175 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . 120.32 -126.09 6.52 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.481 -1.447 . . . . 0.0 109.481 -178.65 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . 0.493 ' OXT' ' CD2' ' B' ' 97' ' ' HIS . 30.0 p-80 . . . . . 0 N--CA 1.49 1.573 0 O-C-N 121.203 -1.174 . . . . 0.0 110.266 -179.18 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 0.528 " O2'" ' C9 ' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 0.53 " O2'" ' C9 ' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 76.5 mtm . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 121.157 0.503 . . . . 0.0 110.325 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.932 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 10.2 p90 -171.05 143.92 2.04 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.182 -0.949 . . . . 0.0 109.202 177.396 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.555 ' CB ' HG12 ' A' ' 5' ' ' ILE . 6.7 p -140.99 -37.37 0.44 Allowed 'General case' 0 C--N 1.299 -1.604 0 O-C-N 120.984 -1.073 . . . . 0.0 109.087 -178.236 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.501 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 45.99 25.97 1.9 Allowed Glycine 0 N--CA 1.484 1.885 0 N-CA-C 108.635 -1.786 . . . . 0.0 108.635 -176.295 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.555 HG12 ' CB ' ' A' ' 3' ' ' THR . 41.3 mm -76.61 122.8 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.396 -1.061 . . . . 0.0 109.865 -177.294 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.979 HG21 ' HB3' ' A' ' 83' ' ' ASN . 1.7 t -86.17 139.05 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.256 -0.903 . . . . 0.0 110.784 -170.432 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 79.2 mm-40 -69.97 -34.84 73.91 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.64 -0.663 . . . . 0.0 110.843 178.275 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.528 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -158.28 179.19 34.15 Favored Glycine 0 N--CA 1.494 2.527 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.235 -173.167 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.47 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 1.0 OUTLIER -118.54 170.0 9.32 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.117 -1.226 . . . . 0.0 110.956 -177.962 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.13 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -136.55 149.7 48.23 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.667 -0.646 . . . . 0.0 109.448 -179.237 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 39.6 tttt -110.57 117.87 34.69 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.024 -1.048 . . . . 0.0 110.455 -179.44 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.98 HD23 ' C ' ' A' ' 77' ' ' LYS . 10.9 tp -60.04 126.26 26.83 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.882 -1.136 . . . . 0.0 108.979 172.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.064 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -125.76 -31.67 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 O-C-N 121.471 -0.768 . . . . 0.0 109.545 179.252 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.09 143.12 30.24 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.453 -0.899 . . . . 0.0 111.103 -179.648 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.759 HG23 ' CD2' ' A' ' 24' ' ' HIS . 18.0 mt -106.71 134.98 46.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.038 -1.039 . . . . 0.0 110.0 171.027 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.515 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 56.0 m-20 -107.53 115.81 30.83 Favored 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.274 -0.891 . . . . 0.0 109.851 174.067 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -107.06 111.88 24.55 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.057 -1.027 . . . . 0.0 110.467 -176.448 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 8.2 mtmm -109.09 131.28 21.9 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.217 -0.927 . . . . 0.0 109.262 175.686 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -51.13 -22.88 11.69 Favored 'Trans proline' 0 C--N 1.304 -1.78 0 O-C-N 123.954 1.502 . . . . 0.0 111.052 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.582 ' O ' ' CD1' ' A' ' 21' ' ' PHE . 7.4 m-80 -92.78 -33.61 14.21 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.085 -1.009 . . . . 0.0 109.983 177.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.582 ' CD1' ' O ' ' A' ' 20' ' ' ASN . 36.3 m-85 -148.2 150.17 33.27 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.488 -0.758 . . . . 0.0 110.026 -177.516 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.68 ' HD3' HD22 ' A' ' 68' ' ' LEU . 60.4 ttt180 -95.76 143.5 26.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.668 -1.27 . . . . 0.0 109.964 173.739 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.515 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 56.3 m -132.61 145.65 51.27 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.494 -0.754 . . . . 0.0 109.955 -176.095 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.759 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -134.2 134.06 41.64 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.943 -1.098 . . . . 0.0 111.327 -179.666 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.732 HG22 ' CB ' ' A' ' 60' ' ' SER . 5.3 t -113.62 132.75 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.071 -1.018 . . . . 0.0 110.856 -177.32 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.546 HG22 ' HE2' ' A' ' 61' ' ' PHE . 12.9 m -118.79 170.93 7.47 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 CA-C-O 121.317 0.579 . . . . 0.0 110.331 -179.17 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.497 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 15.3 tt0 -100.08 116.65 32.6 Favored 'General case' 0 C--N 1.301 -1.529 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 177.789 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.879 HD13 ' HD2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -86.15 118.5 70.51 Favored Pre-proline 0 C--N 1.295 -1.798 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 -175.36 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.879 ' HD2' HD13 ' A' ' 28' ' ' LEU . 19.6 Cg_endo -63.25 170.78 7.34 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 O-C-N 123.801 1.422 . . . . 0.0 110.976 -178.527 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.603 ' HA ' HD12 ' A' ' 33' ' ' LEU . 34.1 p-10 -61.26 -35.85 78.42 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.477 -0.765 . . . . 0.0 110.83 -175.713 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.602 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.69 -0.49 57.71 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.828 -1.17 . . . . 0.0 110.874 -173.486 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.604 ' HB3' HD11 ' A' ' 28' ' ' LEU . 99.9 mmm -116.69 -11.17 11.01 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.984 -1.072 . . . . 0.0 109.933 169.499 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.603 HD12 ' HA ' ' A' ' 30' ' ' ASP . 13.2 mt -65.67 -37.95 87.93 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.07 -1.019 . . . . 0.0 109.599 175.168 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -69.04 132.25 46.34 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.486 -0.759 . . . . 0.0 110.746 -177.402 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.12 -40.12 2.8 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 173.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . . . . . . . . . 59.1 tp -69.2 145.44 53.22 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.03 -1.277 . . . . 0.0 110.688 -175.262 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.518 ' C ' HD11 ' A' ' 54' ' ' ILE . 16.8 pt-20 -148.01 169.1 20.64 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.591 -0.693 . . . . 0.0 109.408 177.445 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.844 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -64.53 148.56 50.45 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.9 -1.125 . . . . 0.0 109.83 178.291 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.42 -4.66 62.85 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -176.45 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . . . . . . . . . . . -74.45 159.13 32.7 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.257 -1.143 . . . . 0.0 109.499 176.568 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.47 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -100.51 117.42 34.63 Favored 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 118.909 -1.116 . . . . 0.0 109.885 176.642 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.614 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.1 t -105.97 126.25 61.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.333 -0.855 . . . . 0.0 109.079 175.262 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -89.72 118.62 29.46 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 119.185 -1.006 . . . . 0.0 109.191 172.282 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.736 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -88.8 100.99 13.58 Favored 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 177.054 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.491 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 59.59 8.79 1.35 Allowed 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.486 -0.759 . . . . 0.0 111.143 -168.514 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.49 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 128.76 -12.69 6.18 Favored Glycine 0 N--CA 1.489 2.197 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.8 174.167 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.765 ' O ' HD23 ' A' ' 49' ' ' LEU . 42.8 t -85.97 110.05 19.2 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.356 -1.673 . . . . 0.0 109.779 179.196 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.477 ' O ' ' C5A' ' A' ' 98' ' ' RBF . 19.6 p -77.65 113.4 15.46 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.304 -0.872 . . . . 0.0 110.984 -172.376 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.931 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -130.33 161.18 31.86 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.436 -0.79 . . . . 0.0 109.119 172.628 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 57.2 m -103.93 155.08 18.93 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 120.492 -1.38 . . . . 0.0 111.356 -168.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.756 HG13 HG13 ' A' ' 59' ' ' VAL . 21.2 t -77.44 112.79 15.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.677 -0.64 . . . . 0.0 110.379 -179.51 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.625 HG22 ' HB3' ' A' ' 62' ' ' ASP . 17.6 p -69.95 -40.0 75.72 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.211 -0.931 . . . . 0.0 109.493 172.193 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.404 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.0 tt0 -158.46 153.9 25.96 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 119.322 -0.951 . . . . 0.0 110.845 -177.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.844 HD11 ' N ' ' A' ' 38' ' ' THR . 13.6 mt -110.37 130.06 64.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.181 -0.95 . . . . 0.0 109.887 172.713 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.491 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 9.7 m-80 -103.73 63.67 0.78 Allowed 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.542 -0.724 . . . . 0.0 109.723 178.899 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.69 -112.51 3.55 Favored Glycine 0 N--CA 1.487 2.07 0 N-CA-C 108.691 -1.764 . . . . 0.0 108.691 -173.608 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.539 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.1 -22.49 42.14 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.988 -1.301 . . . . 0.0 108.846 174.201 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.064 ' CD2' HG11 ' A' ' 13' ' ' VAL . 8.9 m170 -74.58 158.69 33.27 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.123 -0.985 . . . . 0.0 110.218 -176.211 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.756 HG13 HG13 ' A' ' 51' ' ' VAL . 80.2 t -141.31 119.68 9.72 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.671 0 C-N-CA 119.312 -0.955 . . . . 0.0 110.923 175.693 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.732 ' CB ' HG22 ' A' ' 25' ' ' VAL . 15.9 m -88.65 126.21 35.19 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.627 -0.671 . . . . 0.0 109.739 178.672 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.931 ' HB3' HD12 ' A' ' 49' ' ' LEU . 98.0 m-85 -109.9 156.53 20.3 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.788 -1.195 . . . . 0.0 110.396 179.52 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.625 ' HB3' HG22 ' A' ' 52' ' ' THR . 19.8 p-10 -89.8 148.22 23.34 Favored 'General case' 0 N--CA 1.494 1.738 0 CA-C-O 122.045 0.926 . . . . 0.0 110.878 178.856 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.823 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -155.53 116.6 3.91 Favored 'General case' 0 C--N 1.296 -1.759 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 -176.483 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.534 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 93.2 mmm -69.97 141.72 52.96 Favored 'General case' 0 N--CA 1.491 1.6 0 C-N-CA 119.109 -1.037 . . . . 0.0 109.518 179.738 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.421 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 46.8 tttp -60.0 -45.15 93.69 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.103 -0.998 . . . . 0.0 110.195 -176.849 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.457 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.4 tt0 -69.44 -40.04 77.45 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.984 -1.072 . . . . 0.0 110.283 177.642 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.534 ' HB ' ' HB2' ' A' ' 64' ' ' MET . 89.8 m -61.69 -39.38 91.24 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.927 -1.108 . . . . 0.0 109.278 174.091 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.68 HD22 ' HD3' ' A' ' 22' ' ' ARG . 7.7 tp -60.09 -43.57 95.42 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.325 -0.86 . . . . 0.0 109.364 178.022 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 92.6 mtt180 -69.86 -39.97 76.05 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.545 -0.722 . . . . 0.0 110.692 176.03 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.772 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -69.94 -41.61 79.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.246 -0.909 . . . . 0.0 109.404 -176.078 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.772 HG23 HG22 ' A' ' 70' ' ' ILE . 65.3 p -83.59 -173.94 5.0 Favored 'General case' 0 C--N 1.297 -1.684 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 178.072 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.485 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 3.0 t30 -100.73 22.62 11.68 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 170.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.823 ' HB3' HD21 ' A' ' 63' ' ' LEU . 96.6 mt -69.91 -40.2 75.75 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.013 -1.054 . . . . 0.0 110.053 174.653 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.604 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -52.99 -24.27 19.48 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 -176.095 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 25.9 p-10 -64.98 -19.67 66.1 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.043 -1.269 . . . . 0.0 110.634 -174.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.52 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 95.8 mt -60.01 140.25 56.9 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.216 -0.928 . . . . 0.0 110.923 -177.056 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 0.98 ' C ' HD23 ' A' ' 12' ' ' LEU . 75.9 mttt -140.92 144.1 35.0 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 173.606 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.617 ' N ' HD23 ' A' ' 12' ' ' LEU . 12.0 t -59.32 152.0 4.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 O-C-N 120.731 -1.231 . . . . 0.0 110.304 -173.538 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.15 -15.81 57.27 Favored Glycine 0 N--CA 1.484 1.847 0 N-CA-C 108.913 -1.675 . . . . 0.0 108.913 -177.37 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.518 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 52.7 t0 -93.41 164.58 13.15 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.284 -1.127 . . . . 0.0 109.684 176.104 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.584 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.3 m95 -115.4 168.15 10.24 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.062 -1.023 . . . . 0.0 110.253 178.355 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.13 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.5 p -131.97 155.56 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.518 -0.739 . . . . 0.0 110.039 -178.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.979 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.6 m-20 -80.57 109.86 15.49 Favored 'General case' 0 C--N 1.296 -1.75 0 O-C-N 121.007 -1.058 . . . . 0.0 109.12 167.725 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.605 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -109.76 138.62 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.577 -1.327 . . . . 0.0 111.232 -175.301 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -137.02 138.53 40.57 Favored 'General case' 0 N--CA 1.494 1.741 0 CA-C-N 116.055 -0.521 . . . . 0.0 109.801 -178.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 83.9 mtm180 -78.41 142.33 37.67 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.958 -1.089 . . . . 0.0 110.951 -176.14 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.802 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -134.43 148.04 50.55 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.387 -0.82 . . . . 0.0 110.133 176.876 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -136.28 148.36 47.96 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.668 -0.645 . . . . 0.0 110.638 -177.307 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.427 ' HE2' ' CE2' ' A' ' 90' ' ' PHE . 0.7 OUTLIER -70.0 -31.14 68.67 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.338 -0.851 . . . . 0.0 110.623 177.966 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.541 ' CD1' ' C ' ' A' ' 90' ' ' PHE . 7.6 p90 -143.11 160.0 41.22 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.908 -1.12 . . . . 0.0 110.343 173.578 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.418 ' O ' HG12 ' A' ' 94' ' ' ILE . 15.2 t -154.4 150.05 27.49 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.316 -0.865 . . . . 0.0 110.56 179.334 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 93.7 m-20 -68.28 -40.01 81.94 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.354 -0.842 . . . . 0.0 110.226 176.371 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -104.42 50.19 0.8 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.377 -0.827 . . . . 0.0 110.582 -173.408 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.418 HG12 ' O ' ' A' ' 91' ' ' SER . 22.9 mm -59.98 -40.1 82.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.449 -0.782 . . . . 0.0 110.002 175.12 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 110.16 -51.59 0.69 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 177.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 66.33 -142.61 43.01 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 89.7 m-70 . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.206 -1.173 . . . . 0.0 110.198 -177.833 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 92.9 mmm . . . . . 0 N--CA 1.492 1.642 0 CA-C-O 121.24 0.543 . . . . 0.0 110.219 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.802 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 10.3 p90 -171.52 144.04 1.86 Allowed 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.351 -0.843 . . . . 0.0 109.139 177.504 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.56 ' CB ' HG12 ' B' ' 5' ' ' ILE . 6.7 p -141.03 -37.41 0.44 Allowed 'General case' 0 C--N 1.298 -1.667 0 O-C-N 120.998 -1.064 . . . . 0.0 109.061 -178.198 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 46.29 25.66 2.01 Favored Glycine 0 N--CA 1.486 1.992 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 -176.406 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 0.56 HG12 ' CB ' ' B' ' 3' ' ' THR . 41.6 mm -76.66 122.79 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.463 -1.021 . . . . 0.0 109.795 -177.051 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.954 HG21 ' HB3' ' B' ' 83' ' ' ASN . 1.7 t -86.14 139.07 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.225 -0.922 . . . . 0.0 110.78 -170.431 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 79.3 mm-40 -70.05 -34.63 73.46 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.79 -0.569 . . . . 0.0 110.842 178.284 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.53 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -158.56 179.01 34.53 Favored Glycine 0 N--CA 1.494 2.553 0 C-N-CA 119.048 -1.548 . . . . 0.0 110.227 -173.101 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.469 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 1.0 OUTLIER -118.45 170.03 9.27 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.094 -1.239 . . . . 0.0 110.976 -177.851 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.121 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -136.55 149.85 48.31 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.671 -0.643 . . . . 0.0 109.381 -179.329 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 39.8 tttt -110.65 117.98 34.96 Favored 'General case' 0 C--N 1.298 -1.668 0 O-C-N 121.048 -1.033 . . . . 0.0 110.39 -179.439 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 0.979 HD23 ' C ' ' B' ' 77' ' ' LYS . 10.9 tp -60.33 126.13 26.32 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.037 -1.039 . . . . 0.0 109.085 172.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.062 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -125.65 -31.54 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 O-C-N 121.442 -0.786 . . . . 0.0 109.684 179.488 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -145.23 143.15 30.11 Favored 'General case' 0 C--N 1.298 -1.652 0 C-N-CA 119.516 -0.874 . . . . 0.0 111.092 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.759 HG23 ' CD2' ' B' ' 24' ' ' HIS . 17.8 mt -106.67 134.88 47.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.005 -1.06 . . . . 0.0 110.03 171.046 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.53 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 55.7 m-20 -107.54 115.88 30.94 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.28 -0.888 . . . . 0.0 109.898 174.079 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -107.05 111.78 24.41 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.035 -1.04 . . . . 0.0 110.428 -176.342 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.456 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 8.2 mtmm -109.02 131.27 21.9 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 121.259 -0.901 . . . . 0.0 109.288 175.623 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -51.11 -23.02 11.86 Favored 'Trans proline' 0 C--N 1.304 -1.767 0 O-C-N 123.868 1.457 . . . . 0.0 111.061 -179.209 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.571 ' O ' ' CD1' ' B' ' 21' ' ' PHE . 7.4 m-80 -92.46 -34.22 14.2 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.065 -1.022 . . . . 0.0 109.879 177.827 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.571 ' CD1' ' O ' ' B' ' 20' ' ' ASN . 36.3 m-85 -147.7 150.23 33.93 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.431 -0.793 . . . . 0.0 110.026 -177.36 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.671 ' HD3' HD22 ' B' ' 68' ' ' LEU . 60.3 ttt180 -95.74 143.53 26.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.756 -1.215 . . . . 0.0 110.058 173.559 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.53 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 55.9 m -132.59 145.61 51.24 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.503 -0.748 . . . . 0.0 110.029 -176.135 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.759 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -134.04 134.09 41.98 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.085 -1.009 . . . . 0.0 111.197 -179.517 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.736 HG22 ' CB ' ' B' ' 60' ' ' SER . 5.4 t -113.68 133.0 61.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.207 -0.933 . . . . 0.0 110.778 -177.41 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.536 HG22 ' HE2' ' B' ' 61' ' ' PHE . 13.2 m -119.05 170.94 7.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 CA-C-O 121.232 0.539 . . . . 0.0 110.268 -179.067 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.51 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 15.3 tt0 -100.03 116.71 32.71 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 177.714 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.923 HD13 ' HD2' ' B' ' 29' ' ' PRO . 0.0 OUTLIER -86.11 118.35 70.28 Favored Pre-proline 0 C--N 1.295 -1.804 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 -175.422 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.923 ' HD2' HD13 ' B' ' 28' ' ' LEU . 19.5 Cg_endo -63.13 170.75 7.22 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 O-C-N 123.802 1.422 . . . . 0.0 110.96 -178.525 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.617 ' HA ' HD12 ' B' ' 33' ' ' LEU . 34.1 p-10 -61.28 -35.74 78.15 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.47 -0.769 . . . . 0.0 110.873 -175.741 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.595 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.74 -0.48 57.72 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.783 -1.198 . . . . 0.0 110.839 -173.487 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.595 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.9 mmm -116.64 -11.22 11.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 120.857 -1.152 . . . . 0.0 109.984 169.509 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.617 HD12 ' HA ' ' B' ' 30' ' ' ASP . 13.2 mt -65.68 -38.02 88.1 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.013 -1.054 . . . . 0.0 109.626 175.165 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 84.0 m-20 -68.99 132.27 46.39 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.549 -0.719 . . . . 0.0 110.792 -177.404 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.1 -40.16 2.8 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 110.346 -1.102 . . . . 0.0 110.346 174.061 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . . . . . . . . . 59.0 tp -69.13 145.49 53.3 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.045 -1.268 . . . . 0.0 110.726 -175.302 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . 0.496 ' C ' HD11 ' B' ' 54' ' ' ILE . 16.8 pt-20 -147.98 169.1 20.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.506 -0.746 . . . . 0.0 109.423 177.473 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.843 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -64.66 148.48 50.89 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.939 -1.101 . . . . 0.0 109.859 178.298 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 79.57 -4.67 63.44 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -176.464 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . . . . . . . . . . . -74.49 158.98 32.86 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.121 -1.223 . . . . 0.0 109.492 176.474 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.469 ' OG ' ' O ' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -100.37 117.21 34.09 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 120.94 -1.1 . . . . 0.0 110.029 176.584 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.636 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.1 t -105.96 126.28 61.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 O-C-N 121.383 -0.823 . . . . 0.0 109.105 175.316 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.513 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -89.7 118.64 29.46 Favored 'General case' 0 C--N 1.298 -1.671 0 C-N-CA 119.133 -1.027 . . . . 0.0 109.114 172.351 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.742 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -88.77 100.72 13.36 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 176.994 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.491 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 59.88 8.79 1.49 Allowed 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.53 -0.731 . . . . 0.0 110.987 -168.642 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.501 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 128.68 -12.65 6.21 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.583 -1.294 . . . . 0.0 110.818 174.151 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.757 ' O ' HD23 ' B' ' 49' ' ' LEU . 41.7 t -85.97 109.94 19.12 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.259 -1.73 . . . . 0.0 109.757 179.151 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . 0.476 ' O ' ' C5A' ' B' ' 99' ' ' RBF . 19.4 p -77.54 113.44 15.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.227 -0.92 . . . . 0.0 110.969 -172.465 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 0.947 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -130.46 161.1 32.17 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.355 -0.841 . . . . 0.0 109.129 172.521 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 57.5 m -103.76 155.2 18.78 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.545 -1.347 . . . . 0.0 111.277 -168.841 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.78 HG13 HG13 ' B' ' 59' ' ' VAL . 21.2 t -77.62 112.79 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.606 -0.683 . . . . 0.0 110.415 -179.525 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.632 HG22 ' HB3' ' B' ' 62' ' ' ASP . 17.7 p -69.93 -40.05 75.77 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.16 -0.963 . . . . 0.0 109.512 172.339 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.411 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.0 tt0 -158.5 153.74 25.61 Favored 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 119.324 -0.95 . . . . 0.0 110.757 -177.753 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.843 HD11 ' N ' ' B' ' 38' ' ' THR . 13.7 mt -110.23 130.03 64.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.205 -0.934 . . . . 0.0 109.908 172.738 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.501 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 9.6 m-80 -103.73 63.64 0.78 Allowed 'General case' 0 C--N 1.299 -1.593 0 C-N-CA 119.943 -0.703 . . . . 0.0 109.692 178.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.77 -112.5 3.55 Favored Glycine 0 N--CA 1.487 2.079 0 N-CA-C 108.638 -1.785 . . . . 0.0 108.638 -173.625 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.532 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.07 -22.64 42.04 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 120.865 -1.373 . . . . 0.0 108.873 174.206 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.062 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.0 m170 -74.42 158.53 33.72 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.175 -0.953 . . . . 0.0 110.263 -176.278 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.78 HG13 HG13 ' B' ' 51' ' ' VAL . 79.9 t -141.26 119.72 9.89 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 C-N-CA 119.158 -1.017 . . . . 0.0 110.817 175.86 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.736 ' CB ' HG22 ' B' ' 25' ' ' VAL . 15.9 m -88.69 126.4 35.29 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.617 -0.677 . . . . 0.0 109.73 178.679 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.947 ' HB3' HD12 ' B' ' 49' ' ' LEU . 98.0 m-85 -110.08 156.49 20.49 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.867 -1.146 . . . . 0.0 110.374 179.554 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.632 ' HB3' HG22 ' B' ' 52' ' ' THR . 19.8 p-10 -89.72 148.2 23.41 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.209 -0.932 . . . . 0.0 110.9 178.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.805 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -155.51 116.72 3.94 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 -176.585 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.517 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 93.1 mmm -70.04 141.67 52.84 Favored 'General case' 0 N--CA 1.49 1.568 0 C-N-CA 119.119 -1.032 . . . . 0.0 109.552 179.683 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.416 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 46.8 tttp -60.06 -45.08 94.05 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.172 -0.955 . . . . 0.0 110.119 -176.7 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . 0.463 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 86.5 tt0 -69.38 -40.0 77.69 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.102 -0.999 . . . . 0.0 110.333 177.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.517 ' CB ' ' HB2' ' B' ' 64' ' ' MET . 89.2 m -61.73 -39.6 92.13 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.959 -1.088 . . . . 0.0 109.16 174.148 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.671 HD22 ' HD3' ' B' ' 22' ' ' ARG . 7.7 tp -59.98 -43.41 95.15 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.562 -0.711 . . . . 0.0 109.47 178.077 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 92.7 mtt180 -69.96 -39.98 75.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.449 -0.782 . . . . 0.0 110.67 175.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.77 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -70.06 -41.35 79.17 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.278 -0.889 . . . . 0.0 109.52 -176.131 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.77 HG23 HG22 ' B' ' 70' ' ' ILE . 65.5 p -83.56 -173.81 4.93 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 177.983 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.53 ' CB ' ' N ' ' A' ' 83' ' ' ASN . 3.1 t30 -100.78 22.66 11.68 Favored 'General case' 0 C--N 1.296 -1.743 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 170.827 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.805 ' HB3' HD21 ' B' ' 63' ' ' LEU . 96.9 mt -69.96 -40.09 75.63 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.116 -0.99 . . . . 0.0 110.071 174.665 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.597 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -53.01 -24.34 19.93 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 110.409 -1.077 . . . . 0.0 110.409 -176.127 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.521 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.1 p-10 -64.97 -19.65 66.09 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.116 -1.226 . . . . 0.0 110.632 -174.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.521 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 95.8 mt -60.02 140.19 56.95 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.187 -0.946 . . . . 0.0 110.901 -177.065 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 0.979 ' C ' HD23 ' B' ' 12' ' ' LEU . 76.0 mttt -140.92 144.1 34.99 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 173.607 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.618 ' N ' HD23 ' B' ' 12' ' ' LEU . 12.1 t -59.34 151.95 4.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 120.76 -1.213 . . . . 0.0 110.335 -173.519 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.18 -15.72 57.54 Favored Glycine 0 N--CA 1.484 1.847 0 N-CA-C 108.92 -1.672 . . . . 0.0 108.92 -177.396 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 52.6 t0 -93.47 164.4 13.21 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.432 -1.04 . . . . 0.0 109.675 176.043 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.2 m95 -115.28 168.16 10.21 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.132 -0.98 . . . . 0.0 110.373 178.312 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.121 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.5 p -132.04 155.55 41.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.547 -0.721 . . . . 0.0 109.965 -178.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.954 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -80.4 109.67 15.12 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.009 -1.057 . . . . 0.0 109.174 167.729 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.589 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -109.45 138.95 34.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 120.66 -1.275 . . . . 0.0 111.138 -175.233 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . . . . . . . . . 86.9 tt0 -137.48 138.51 39.8 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.894 -0.504 . . . . 0.0 109.724 -179.056 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 83.9 mtm180 -78.35 142.44 37.68 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.042 -1.036 . . . . 0.0 110.917 -176.062 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 0.932 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -134.49 148.07 50.49 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.359 -0.838 . . . . 0.0 110.103 176.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -136.29 148.39 47.95 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.562 -0.711 . . . . 0.0 110.644 -177.344 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . 0.417 ' HE2' ' CE2' ' B' ' 90' ' ' PHE . 0.7 OUTLIER -70.01 -31.11 68.62 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.3 -0.875 . . . . 0.0 110.654 177.947 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . 0.541 ' CD1' ' C ' ' B' ' 90' ' ' PHE . 7.6 p90 -143.06 159.98 41.25 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.86 -1.15 . . . . 0.0 110.404 173.621 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . . . . . . . . . 15.8 t -154.46 150.08 27.46 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.399 -0.813 . . . . 0.0 110.528 179.351 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . 0.497 ' O ' ' CG ' ' B' ' 93' ' ' GLU . 93.6 m-20 -68.32 -35.04 77.2 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.408 -0.807 . . . . 0.0 110.286 176.352 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . 0.497 ' CG ' ' O ' ' B' ' 92' ' ' ASP . 12.8 pt-20 36.21 52.82 0.92 Allowed 'General case' 0 N--CA 1.515 2.814 0 O-C-N 121.617 -0.677 . . . . 0.0 110.774 -179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . . . . . . . . . 48.1 mm -69.91 -40.13 78.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.304 -0.873 . . . . 0.0 110.399 -179.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 89.33 -44.84 3.09 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 178.513 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -116.36 -170.89 15.85 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 -179.292 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 84.6 m-70 . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.363 -1.081 . . . . 0.0 110.292 179.615 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 0.559 " C2'" ' HC9' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 0.561 " C2'" ' HC9' ' B' ' 99' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.464 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 26.4 ptm . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.105 0.478 . . . . 0.0 110.168 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.972 ' CZ ' ' HB1' ' B' ' 87' ' ' ALA . 8.0 p90 -179.27 143.62 0.21 Allowed 'General case' 0 C--N 1.307 -1.26 0 O-C-N 121.231 -0.918 . . . . 0.0 108.733 176.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.509 ' O ' HG13 ' A' ' 5' ' ' ILE . 73.7 p -135.72 -41.48 0.69 Allowed 'General case' 0 C--N 1.293 -1.853 0 O-C-N 120.959 -1.088 . . . . 0.0 108.55 179.721 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.476 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 49.67 22.77 4.34 Favored Glycine 0 N--CA 1.482 1.718 0 N-CA-C 108.454 -1.858 . . . . 0.0 108.454 -175.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.532 HD11 HC82 ' B' ' 99' ' ' RBF . 57.2 mt -84.59 120.26 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.208 -1.172 . . . . 0.0 110.116 -176.647 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.834 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.4 t -72.55 149.97 8.59 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.292 -0.88 . . . . 0.0 110.611 -175.426 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.425 ' OE1' ' HG2' ' A' ' 86' ' ' ARG . 18.2 pt20 -93.34 -23.81 18.33 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.55 -0.719 . . . . 0.0 110.787 179.266 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.538 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -150.52 173.99 29.98 Favored Glycine 0 N--CA 1.493 2.487 0 C-N-CA 119.328 -1.415 . . . . 0.0 109.758 -175.485 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.478 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 2.2 p -123.37 170.83 9.93 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.845 -1.386 . . . . 0.0 110.981 -177.436 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.014 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -139.33 149.46 44.22 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.562 -0.711 . . . . 0.0 109.259 -179.649 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.575 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 33.3 tttt -106.73 115.43 30.19 Favored 'General case' 0 C--N 1.296 -1.736 0 O-C-N 120.908 -1.12 . . . . 0.0 110.254 179.535 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 1.014 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.2 tp -58.55 127.19 30.91 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 120.82 -1.175 . . . . 0.0 108.688 173.329 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.09 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.6 p -130.05 -30.14 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.898 0 O-C-N 121.345 -0.847 . . . . 0.0 109.946 -177.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -145.1 140.44 28.04 Favored 'General case' 0 N--CA 1.494 1.735 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.974 -179.439 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.778 HG23 ' CD2' ' A' ' 24' ' ' HIS . 13.9 mt -107.53 131.11 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 120.991 -1.068 . . . . 0.0 110.185 172.339 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.512 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 77.7 m-20 -108.53 114.87 29.04 Favored 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.384 -0.823 . . . . 0.0 109.873 174.692 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -107.11 112.38 25.27 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.002 -1.061 . . . . 0.0 110.522 -176.129 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 6.1 mtmt -107.94 129.93 23.48 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.219 -0.926 . . . . 0.0 109.177 175.24 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.6 Cg_endo -51.85 -24.47 18.73 Favored 'Trans proline' 0 C--N 1.303 -1.864 0 O-C-N 123.779 1.41 . . . . 0.0 110.279 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.562 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 10.7 m-80 -81.2 -39.74 24.95 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.24 -0.913 . . . . 0.0 110.182 175.417 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.562 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 95.1 m-85 -156.68 150.22 24.52 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.433 -0.792 . . . . 0.0 109.971 -178.873 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.493 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 59.6 ttt180 -91.93 145.13 24.79 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.807 -1.183 . . . . 0.0 110.327 178.771 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.512 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 74.9 m -129.98 140.02 50.97 Favored 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.583 -0.698 . . . . 0.0 109.718 -176.156 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.778 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -128.74 128.32 43.79 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.858 -1.152 . . . . 0.0 111.324 178.184 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.823 HG22 ' OG ' ' A' ' 60' ' ' SER . 4.3 t -104.95 131.42 54.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.283 -0.886 . . . . 0.0 110.695 -178.108 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.495 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 33.4 m -115.91 168.16 7.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 O-C-N 121.962 -0.461 . . . . 0.0 109.963 179.427 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.511 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 2.5 tm-20 -101.11 115.31 30.19 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.305 -0.872 . . . . 0.0 109.409 178.538 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.785 HD21 HD13 ' A' ' 36' ' ' LEU . 9.8 tp -79.15 125.33 83.74 Favored Pre-proline 0 C--N 1.295 -1.804 0 O-C-N 121.617 -0.677 . . . . 0.0 109.868 -176.543 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.536 ' HD2' HD12 ' A' ' 28' ' ' LEU . 27.7 Cg_endo -67.5 -179.16 1.79 Allowed 'Trans proline' 0 C--N 1.309 -1.552 0 O-C-N 123.894 1.471 . . . . 0.0 110.826 -179.54 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 31' ' ' HIS . 32.3 p-10 -64.85 -40.02 94.5 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.322 -0.861 . . . . 0.0 110.952 -175.56 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.01 1.32 56.44 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.939 -1.101 . . . . 0.0 110.987 -174.037 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.597 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 98.7 mmm -112.17 -14.14 13.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.854 -1.154 . . . . 0.0 109.871 171.411 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.581 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 19.2 mt -69.93 -20.38 63.34 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.39 -0.818 . . . . 0.0 110.437 176.203 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -61.0 123.05 16.5 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.088 -1.007 . . . . 0.0 111.286 -171.276 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 48.92 54.72 13.29 Favored Glycine 0 N--CA 1.493 2.498 0 C-N-CA 120.339 -0.934 . . . . 0.0 111.015 169.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.802 HD23 ' N ' ' A' ' 37' ' ' GLU . 6.4 tt -113.25 155.44 25.07 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.83 -1.394 . . . . 0.0 110.181 174.131 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.802 ' N ' HD23 ' A' ' 36' ' ' LEU . 21.3 pt-20 -149.95 167.85 25.48 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.221 -0.924 . . . . 0.0 110.139 -178.207 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 1.038 HG23 HD12 ' A' ' 54' ' ' ILE . 0.1 OUTLIER -68.09 155.27 39.92 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.212 -0.93 . . . . 0.0 109.754 177.539 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.56 -8.86 63.63 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.744 -1.343 . . . . 0.0 109.744 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.669 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -75.37 159.91 30.88 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.11 -1.229 . . . . 0.0 109.753 178.126 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.45 ' OG ' ' O ' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -105.2 120.2 40.95 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.831 -1.168 . . . . 0.0 110.309 -179.416 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.573 HG11 ' HE1' ' A' ' 44' ' ' HIS . 1.6 t -109.95 132.51 58.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.328 -0.858 . . . . 0.0 109.193 172.74 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.51 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -92.38 119.95 32.42 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.145 -0.972 . . . . 0.0 109.337 172.59 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.786 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.4 OUTLIER -89.83 106.92 18.79 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.402 -0.811 . . . . 0.0 109.109 177.865 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.493 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.6 t-20 52.57 17.59 0.82 Allowed 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.39 -0.819 . . . . 0.0 110.503 -166.5 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.506 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 116.35 -4.81 19.77 Favored Glycine 0 N--CA 1.487 2.084 0 C-N-CA 119.64 -1.267 . . . . 0.0 110.831 170.219 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.758 ' O ' HD23 ' A' ' 49' ' ' LEU . 17.3 t -90.08 109.84 20.87 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.345 -1.679 . . . . 0.0 109.084 174.491 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.436 ' O ' ' SG ' ' A' ' 48' ' ' CYS . 27.5 p -77.68 124.89 28.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.996 -1.065 . . . . 0.0 110.691 -172.397 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.967 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -136.85 166.38 23.74 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.353 -0.842 . . . . 0.0 108.945 172.128 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.457 ' O ' ' OD1' ' A' ' 62' ' ' ASP . 54.9 m -103.13 154.18 19.56 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.574 -1.329 . . . . 0.0 111.146 -169.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.82 HG13 HG13 ' A' ' 59' ' ' VAL . 7.0 t -74.67 113.26 13.02 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.899 -0.5 . . . . 0.0 110.034 -179.294 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.616 HG22 ' HB3' ' A' ' 62' ' ' ASP . 19.0 p -75.3 -43.59 50.21 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.365 -0.835 . . . . 0.0 109.57 176.209 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.463 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -158.36 150.53 21.77 Favored 'General case' 0 N--CA 1.491 1.621 0 C-N-CA 119.576 -0.85 . . . . 0.0 110.335 179.246 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 1.038 HD12 HG23 ' A' ' 38' ' ' THR . 2.5 mp -108.18 132.3 56.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.225 -0.922 . . . . 0.0 110.304 175.975 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.485 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 54.9 m-80 -108.26 66.24 0.65 Allowed 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.662 -0.649 . . . . 0.0 109.541 177.824 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.44 -119.36 5.79 Favored Glycine 0 N--CA 1.488 2.124 0 N-CA-C 108.794 -1.722 . . . . 0.0 108.794 -173.112 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.581 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -77.12 -17.71 58.46 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.016 -1.285 . . . . 0.0 109.009 176.084 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.09 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.1 m170 -77.57 160.09 28.82 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.312 -0.867 . . . . 0.0 110.419 -178.447 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.82 HG13 HG13 ' A' ' 51' ' ' VAL . 94.1 t -145.16 117.83 2.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 C-N-CA 119.379 -0.928 . . . . 0.0 110.879 175.423 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.823 ' OG ' HG22 ' A' ' 25' ' ' VAL . 19.6 m -81.92 125.3 30.58 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.529 -0.732 . . . . 0.0 109.592 175.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.967 ' HB3' HD12 ' A' ' 49' ' ' LEU . 82.9 m-85 -110.03 154.78 22.73 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.898 -1.127 . . . . 0.0 110.23 178.73 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.616 ' HB3' HG22 ' A' ' 52' ' ' THR . 9.1 p-10 -89.54 148.18 23.53 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.132 -0.98 . . . . 0.0 111.265 -176.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.703 ' CD2' HD12 ' A' ' 68' ' ' LEU . 0.0 OUTLIER -159.16 102.2 1.6 Allowed 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.705 -0.622 . . . . 0.0 109.485 -175.363 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.498 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 54.5 ttm -59.98 140.16 56.93 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.892 -1.13 . . . . 0.0 109.47 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.483 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 22.0 tptm -60.05 -43.45 95.38 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.027 -1.046 . . . . 0.0 110.315 -174.472 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -69.68 -39.96 76.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.974 -1.079 . . . . 0.0 110.012 177.695 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.566 HG21 ' O2 ' ' A' ' 98' ' ' RBF . 93.7 m -60.95 -38.39 85.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.996 -1.065 . . . . 0.0 109.294 173.135 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.703 HD12 ' CD2' ' A' ' 63' ' ' LEU . 7.1 tp -59.96 -45.71 91.8 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.325 -0.859 . . . . 0.0 109.746 178.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 76.5 ttt-85 -69.32 -39.67 78.07 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.428 -0.795 . . . . 0.0 110.438 177.739 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.772 HG22 HG23 ' A' ' 71' ' ' THR . 1.3 tt -64.65 -41.57 92.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.171 -0.955 . . . . 0.0 109.434 -176.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.772 HG23 HG22 ' A' ' 70' ' ' ILE . 42.0 p -85.25 -174.62 5.33 Favored 'General case' 0 C--N 1.298 -1.631 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 175.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.481 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 2.6 t30 -101.11 21.82 13.29 Favored 'General case' 0 C--N 1.295 -1.77 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 171.624 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.691 ' HB3' HD21 ' A' ' 63' ' ' LEU . 41.9 mt -69.99 -40.05 75.56 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.012 -1.055 . . . . 0.0 110.304 175.122 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.664 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -48.62 -22.29 2.6 Favored Glycine 0 N--CA 1.487 2.094 0 N-CA-C 110.07 -1.212 . . . . 0.0 110.07 -178.548 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.4 p-10 -66.11 -16.49 64.0 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.137 -1.213 . . . . 0.0 110.588 -174.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 94.7 mt -59.99 141.44 55.61 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.276 -0.89 . . . . 0.0 110.763 -176.232 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 1.014 ' C ' HD23 ' A' ' 12' ' ' LEU . 95.1 mttt -140.0 139.77 36.1 Favored 'General case' 0 N--CA 1.493 1.678 0 CA-C-O 121.337 0.589 . . . . 0.0 109.444 174.202 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.72 HG23 HD11 ' A' ' 15' ' ' ILE . 16.4 t -60.51 152.45 5.39 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 120.788 -1.195 . . . . 0.0 110.383 -176.225 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.0 -15.56 57.66 Favored Glycine 0 N--CA 1.484 1.86 0 N-CA-C 108.811 -1.716 . . . . 0.0 108.811 -176.045 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.496 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 9.2 t0 -95.28 165.51 12.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.347 -1.09 . . . . 0.0 109.689 175.93 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.575 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.5 m95 -114.55 157.2 23.33 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.058 -1.027 . . . . 0.0 110.202 177.504 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.014 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.3 p -120.04 149.34 22.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.429 -0.795 . . . . 0.0 109.843 -179.18 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.834 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -75.79 104.36 6.3 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 121.021 -1.049 . . . . 0.0 109.43 169.286 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.67 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -106.21 137.76 34.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 120.459 -1.401 . . . . 0.0 111.392 -176.943 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.421 ' HB2' HG22 ' A' ' 6' ' ' VAL . 86.5 tt0 -130.06 144.86 51.57 Favored 'General case' 0 N--CA 1.495 1.78 0 CA-C-N 115.925 -0.579 . . . . 0.0 109.986 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.458 ' O ' ' HG3' ' A' ' 86' ' ' ARG . 34.0 ptt180 -81.45 133.67 35.44 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.261 -0.899 . . . . 0.0 111.024 -176.235 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.864 ' HB1' ' CZ ' ' B' ' 2' ' ' PHE . . . -131.94 145.76 51.69 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.429 -0.794 . . . . 0.0 110.176 175.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -131.43 130.66 42.8 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.509 -0.744 . . . . 0.0 110.534 -176.538 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 38.1 mttt -60.09 -39.99 88.05 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.373 -0.829 . . . . 0.0 110.46 -179.174 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 51.7 p90 -153.01 159.94 42.95 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.198 -0.939 . . . . 0.0 110.54 -179.028 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 88.3 p -132.81 149.23 52.29 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.282 -0.886 . . . . 0.0 110.087 177.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 57.1 t0 -70.1 -50.89 36.3 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.194 -0.941 . . . . 0.0 110.373 -179.219 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.48 ' O ' ' HG3' ' A' ' 93' ' ' GLU . 19.4 pt-20 -167.02 68.09 0.09 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.179 -0.951 . . . . 0.0 111.145 -175.111 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.578 HG22 ' H ' ' A' ' 97' ' ' HIS . 33.0 mm -59.97 -45.37 95.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 120.9 -1.125 . . . . 0.0 109.875 174.834 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' A' ' 94' ' ' ILE . . . 40.89 69.56 0.49 Allowed Glycine 0 N--CA 1.493 2.444 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 176.559 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . 70.51 19.93 76.67 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.876 -1.29 . . . . 0.0 109.876 176.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.578 ' H ' HG22 ' A' ' 94' ' ' ILE . 11.6 t-80 . . . . . 0 N--CA 1.492 1.626 0 O-C-N 121.182 -1.187 . . . . 0.0 110.09 178.596 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 75.2 mtm . . . . . 0 N--CA 1.495 1.776 0 CA-C-O 122.232 1.015 . . . . 0.0 109.977 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.864 ' CZ ' ' HB1' ' A' ' 87' ' ' ALA . 8.5 p90 -174.13 143.5 0.91 Allowed 'General case' 0 C--N 1.282 -2.361 0 CA-C-N 115.154 -0.93 . . . . 0.0 108.494 172.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.501 ' O ' HG13 ' B' ' 5' ' ' ILE . 71.7 p -135.65 -41.45 0.69 Allowed 'General case' 0 C--N 1.295 -1.795 0 O-C-N 120.904 -1.122 . . . . 0.0 108.633 179.735 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.488 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 49.72 22.78 4.43 Favored Glycine 0 N--CA 1.481 1.652 0 N-CA-C 108.466 -1.853 . . . . 0.0 108.466 -176.054 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 0.55 HG23 " O4'" ' A' ' 98' ' ' RBF . 56.7 mt -84.67 120.28 35.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.238 -1.154 . . . . 0.0 110.092 -176.63 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.835 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.4 t -72.51 150.08 8.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.435 -0.791 . . . . 0.0 110.628 -175.45 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.424 ' OE1' ' HG2' ' B' ' 86' ' ' ARG . 18.2 pt20 -93.48 -23.61 18.31 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.508 -0.745 . . . . 0.0 110.834 179.264 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.536 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -150.62 173.87 30.09 Favored Glycine 0 N--CA 1.493 2.498 0 C-N-CA 119.396 -1.383 . . . . 0.0 109.911 -175.553 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.479 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 2.2 p -123.3 170.83 9.9 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.001 -1.293 . . . . 0.0 110.932 -177.386 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.055 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -139.33 149.54 44.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.592 -0.693 . . . . 0.0 109.165 -179.634 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.58 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 33.4 tttt -106.82 115.58 30.43 Favored 'General case' 0 C--N 1.297 -1.709 0 O-C-N 121.045 -1.034 . . . . 0.0 110.139 179.554 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 1.014 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.2 tp -58.84 127.09 30.47 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.013 -1.054 . . . . 0.0 108.721 173.351 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.114 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.6 p -129.83 -30.27 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.983 0 O-C-N 121.421 -0.8 . . . . 0.0 110.031 -177.783 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -145.14 140.46 28.0 Favored 'General case' 0 C--N 1.297 -1.676 0 C-N-CA 119.499 -0.881 . . . . 0.0 110.979 -179.46 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.784 HG23 ' CD2' ' B' ' 24' ' ' HIS . 13.9 mt -107.51 131.01 58.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 120.918 -1.114 . . . . 0.0 110.266 172.357 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.52 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 77.6 m-20 -108.63 114.94 29.15 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.451 -0.781 . . . . 0.0 109.919 174.728 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 87.1 tt0 -107.0 112.31 25.2 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.1 -1.0 . . . . 0.0 110.524 -176.04 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.46 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 6.1 mtmt -107.86 129.94 23.47 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.229 -0.919 . . . . 0.0 109.241 175.143 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.5 Cg_endo -51.9 -24.44 18.9 Favored 'Trans proline' 0 C--N 1.303 -1.833 0 O-C-N 123.73 1.384 . . . . 0.0 110.187 -179.861 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.554 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 10.6 m-80 -81.18 -40.03 24.54 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.206 -0.934 . . . . 0.0 110.127 175.411 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.554 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 95.2 m-85 -156.41 150.33 25.04 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.456 -0.778 . . . . 0.0 109.964 -178.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.485 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 59.6 ttt180 -91.95 145.07 24.83 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.884 -1.135 . . . . 0.0 110.327 178.754 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.52 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 78.3 m -130.02 139.98 50.94 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.677 -0.64 . . . . 0.0 109.757 -176.183 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.784 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -128.54 128.34 44.11 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.94 -1.1 . . . . 0.0 111.322 178.319 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.803 HG22 ' OG ' ' B' ' 60' ' ' SER . 4.3 t -104.94 131.65 53.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.384 -0.822 . . . . 0.0 110.638 -178.135 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.504 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 33.5 m -116.22 168.09 8.29 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.973 -0.455 . . . . 0.0 109.788 179.546 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.513 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 2.5 tm-20 -101.05 115.42 30.45 Favored 'General case' 0 C--N 1.304 -1.385 0 O-C-N 121.27 -0.894 . . . . 0.0 109.409 178.468 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.763 HD21 HD13 ' B' ' 36' ' ' LEU . 9.8 tp -79.2 125.3 83.68 Favored Pre-proline 0 C--N 1.296 -1.753 0 O-C-N 121.538 -0.727 . . . . 0.0 109.878 -176.546 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.541 ' HD2' HD12 ' B' ' 28' ' ' LEU . 27.9 Cg_endo -67.49 -179.23 1.83 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 123.788 1.415 . . . . 0.0 110.806 -179.538 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' B' ' 31' ' ' HIS . 32.2 p-10 -64.85 -39.97 94.41 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.384 -0.823 . . . . 0.0 110.94 -175.49 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.6 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.99 1.25 56.51 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.886 -1.134 . . . . 0.0 110.954 -174.01 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.6 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 98.6 mmm -112.19 -14.12 13.42 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.902 -1.124 . . . . 0.0 109.881 171.479 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.586 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 19.6 mt -69.96 -20.31 63.33 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.398 -0.814 . . . . 0.0 110.484 176.17 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 58.7 t0 -61.03 123.0 16.37 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.117 -0.989 . . . . 0.0 111.263 -171.262 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 48.95 54.84 12.89 Favored Glycine 0 N--CA 1.493 2.448 0 O-C-N 121.208 -0.932 . . . . 0.0 110.927 169.675 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.793 HD23 ' N ' ' B' ' 37' ' ' GLU . 6.4 tt -113.34 155.52 25.03 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.728 -1.454 . . . . 0.0 110.091 174.15 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . 0.793 ' N ' HD23 ' B' ' 36' ' ' LEU . 21.3 pt-20 -150.06 167.77 25.82 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.106 -0.996 . . . . 0.0 110.203 -178.211 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.998 HG23 HD12 ' B' ' 54' ' ' ILE . 0.1 OUTLIER -67.99 155.15 40.1 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.309 -0.869 . . . . 0.0 109.811 177.55 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.62 -8.82 64.0 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.549 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.679 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -75.57 159.81 30.84 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.144 -1.21 . . . . 0.0 109.762 178.101 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.436 ' OG ' ' O ' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -104.97 119.93 40.22 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.882 -1.136 . . . . 0.0 110.467 -179.357 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.565 ' HB ' ' CE1' ' B' ' 61' ' ' PHE . 1.6 t -109.94 132.6 57.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.424 -0.797 . . . . 0.0 109.219 172.754 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.511 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -92.34 120.04 32.49 Favored 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.133 -0.98 . . . . 0.0 109.407 172.532 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.783 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.4 OUTLIER -89.85 107.03 18.86 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.382 -0.824 . . . . 0.0 109.074 177.832 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.493 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.6 t-20 52.5 17.63 0.81 Allowed 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.348 -0.845 . . . . 0.0 110.535 -166.558 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.506 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 116.26 -4.69 19.98 Favored Glycine 0 N--CA 1.488 2.127 0 C-N-CA 119.626 -1.273 . . . . 0.0 110.864 170.192 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.747 ' O ' HD23 ' B' ' 49' ' ' LEU . 17.2 t -90.09 109.78 20.82 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.294 -1.709 . . . . 0.0 109.13 174.423 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . 0.442 ' O ' ' SG ' ' B' ' 48' ' ' CYS . 27.6 p -77.6 124.93 28.57 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.937 -1.102 . . . . 0.0 110.742 -172.473 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 0.974 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -136.92 166.27 24.02 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.381 -0.825 . . . . 0.0 108.943 172.114 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . 0.456 ' O ' ' OD1' ' B' ' 62' ' ' ASP . 55.5 m -102.94 154.33 19.33 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.633 -1.292 . . . . 0.0 111.201 -169.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.819 HG13 HG13 ' B' ' 59' ' ' VAL . 7.1 t -74.88 113.29 13.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.462 0 CA-C-O 121.249 0.547 . . . . 0.0 110.053 -179.32 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.595 HG22 ' HB3' ' B' ' 62' ' ' ASP . 19.0 p -75.29 -43.49 50.78 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.292 -0.88 . . . . 0.0 109.599 176.258 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.478 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -158.5 150.46 21.45 Favored 'General case' 0 N--CA 1.49 1.531 0 C-N-CA 119.71 -0.796 . . . . 0.0 110.391 179.204 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.998 HD12 HG23 ' B' ' 38' ' ' THR . 2.5 mp -108.14 132.33 56.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.209 -0.932 . . . . 0.0 110.295 176.087 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.502 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 54.7 m-80 -108.33 66.19 0.64 Allowed 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 120.168 -0.613 . . . . 0.0 109.495 177.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.57 -119.31 5.74 Favored Glycine 0 N--CA 1.489 2.169 0 N-CA-C 108.785 -1.726 . . . . 0.0 108.785 -173.127 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.586 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -77.17 -17.85 58.26 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.965 -1.315 . . . . 0.0 108.946 176.112 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.114 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.1 m170 -77.49 160.02 28.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.468 -0.77 . . . . 0.0 110.436 -178.453 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.819 HG13 HG13 ' B' ' 51' ' ' VAL . 94.3 t -145.1 117.79 2.42 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 C-N-CA 119.329 -0.949 . . . . 0.0 110.874 175.527 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.803 ' OG ' HG22 ' B' ' 25' ' ' VAL . 19.7 m -82.03 125.36 30.72 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.618 -0.676 . . . . 0.0 109.622 176.037 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.974 ' HB3' HD12 ' B' ' 49' ' ' LEU . 83.0 m-85 -110.0 154.88 22.55 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 120.915 -1.116 . . . . 0.0 110.25 178.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.595 ' HB3' HG22 ' B' ' 52' ' ' THR . 9.1 p-10 -89.57 148.29 23.46 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 120.984 -1.072 . . . . 0.0 111.192 -176.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.718 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.22 102.11 1.59 Allowed 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 -175.361 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.502 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 54.5 ttm -59.99 140.15 56.95 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.968 -1.082 . . . . 0.0 109.476 -179.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.482 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 22.0 tptm -60.04 -43.37 95.39 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.118 -0.989 . . . . 0.0 110.4 -174.456 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -69.67 -39.97 76.69 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.034 -1.041 . . . . 0.0 110.149 177.612 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.567 HG21 ' O2 ' ' B' ' 99' ' ' RBF . 93.1 m -60.77 -38.6 85.81 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.97 -1.081 . . . . 0.0 109.329 173.002 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.701 HD12 ' CD2' ' B' ' 63' ' ' LEU . 7.1 tp -59.95 -45.45 92.59 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.324 -0.86 . . . . 0.0 109.89 178.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 76.5 ttt-85 -69.41 -39.63 77.8 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.526 -0.734 . . . . 0.0 110.451 177.66 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.741 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -64.72 -41.48 92.34 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.302 -0.873 . . . . 0.0 109.486 -176.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.741 HG23 HG22 ' B' ' 70' ' ' ILE . 40.7 p -85.1 -174.52 5.3 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.973 -0.691 . . . . 0.0 109.279 175.813 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.47 ' O ' ' OD1' ' B' ' 72' ' ' ASN . 2.7 t30 -101.1 21.8 13.31 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 171.482 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.718 ' HB3' HD21 ' B' ' 63' ' ' LEU . 41.3 mt -70.06 -39.95 75.36 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.07 -1.019 . . . . 0.0 110.232 175.239 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.659 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -48.7 -22.36 2.72 Favored Glycine 0 N--CA 1.486 1.98 0 N-CA-C 110.06 -1.216 . . . . 0.0 110.06 -178.505 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.2 p-10 -65.93 -16.52 63.94 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.161 -1.199 . . . . 0.0 110.624 -174.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 94.2 mt -60.01 141.4 55.73 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.126 -0.984 . . . . 0.0 110.829 -176.217 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 1.014 ' C ' HD23 ' B' ' 12' ' ' LEU . 95.1 mttt -139.96 139.82 36.18 Favored 'General case' 0 C--N 1.297 -1.682 0 O-C-N 121.734 -0.604 . . . . 0.0 109.397 174.196 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.733 HG23 HD11 ' B' ' 15' ' ' ILE . 16.4 t -60.55 152.46 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 120.989 -1.069 . . . . 0.0 110.357 -176.205 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.88 -15.25 58.19 Favored Glycine 0 N--CA 1.484 1.846 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 -176.088 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.481 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 9.1 t0 -95.44 165.32 12.42 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.402 -1.058 . . . . 0.0 109.706 175.768 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.58 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.6 m95 -114.46 157.24 23.19 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.147 -0.971 . . . . 0.0 110.288 177.441 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.055 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.3 p -120.06 149.34 22.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.688 -0.632 . . . . 0.0 109.871 -179.181 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.835 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.2 OUTLIER -75.78 104.18 6.21 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.084 -1.01 . . . . 0.0 109.526 169.26 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.676 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -106.09 137.83 34.41 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 120.459 -1.401 . . . . 0.0 111.38 -176.812 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . 0.418 ' HB2' HG22 ' B' ' 6' ' ' VAL . 86.4 tt0 -130.2 144.92 51.64 Favored 'General case' 0 N--CA 1.493 1.712 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.005 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . 0.461 ' O ' ' HG3' ' B' ' 86' ' ' ARG . 34.1 ptt180 -81.53 133.72 35.42 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.206 -0.934 . . . . 0.0 110.93 -176.11 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 0.972 ' HB1' ' CZ ' ' A' ' 2' ' ' PHE . . . -131.93 145.78 51.71 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.355 -0.841 . . . . 0.0 110.08 175.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -131.57 130.4 42.19 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.519 -0.738 . . . . 0.0 110.553 -176.468 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 38.1 mttt -59.94 -40.03 87.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.432 -0.792 . . . . 0.0 110.402 -178.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 51.7 p90 -152.97 159.99 42.98 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.29 -0.881 . . . . 0.0 110.497 -178.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . 0.535 ' HB2' ' CG1' ' B' ' 94' ' ' ILE . 88.4 p -132.96 149.13 52.26 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.366 -0.834 . . . . 0.0 110.098 177.836 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . 0.438 ' O ' ' HG2' ' B' ' 93' ' ' GLU . 57.1 t0 -70.03 -46.75 64.37 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.184 -0.948 . . . . 0.0 110.46 -179.183 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . 0.438 ' HG2' ' O ' ' B' ' 92' ' ' ASP . 78.0 mm-40 -153.97 47.61 0.63 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.233 -0.917 . . . . 0.0 110.307 -179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . 0.535 ' CG1' ' HB2' ' B' ' 91' ' ' SER . 36.6 mm -95.05 -34.66 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.454 -0.779 . . . . 0.0 110.528 177.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . 93.16 -97.56 2.26 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 -176.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . 0.437 ' O ' ' HB3' ' B' ' 97' ' ' HIS . . . -94.78 -54.18 1.56 Allowed Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 178.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . 0.437 ' HB3' ' O ' ' B' ' 96' ' ' GLY . 25.0 p-80 . . . . . 0 N--CA 1.492 1.643 0 O-C-N 121.244 -1.151 . . . . 0.0 110.167 -179.365 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 0.566 ' O2 ' HG21 ' A' ' 67' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 0.567 ' O2 ' HG21 ' B' ' 67' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.552 ' CE ' HD13 ' B' ' 94' ' ' ILE . 63.9 mtt . . . . . 0 N--CA 1.496 1.859 0 CA-C-O 121.138 0.495 . . . . 0.0 110.1 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 1.001 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 6.4 p90 -170.06 156.18 5.88 Favored 'General case' 0 C--N 1.306 -1.29 0 O-C-N 121.108 -0.995 . . . . 0.0 108.985 175.098 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.613 HG23 ' C ' ' A' ' 2' ' ' PHE . 75.8 p -154.17 -41.73 0.09 Allowed 'General case' 0 C--N 1.292 -1.901 0 O-C-N 121.151 -0.968 . . . . 0.0 108.483 176.594 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.477 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 50.98 21.03 4.87 Favored Glycine 0 N--CA 1.482 1.754 0 N-CA-C 108.436 -1.866 . . . . 0.0 108.436 -176.148 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.57 HD11 ' C8M' ' B' ' 99' ' ' RBF . 60.3 mt -81.85 130.71 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.281 -1.129 . . . . 0.0 109.82 -176.689 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.846 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.0 t -86.26 140.82 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.188 -0.945 . . . . 0.0 111.108 -169.789 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 27.8 mm100 -70.0 -36.32 75.04 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.793 -0.567 . . . . 0.0 110.686 177.254 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.527 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -155.24 169.11 33.19 Favored Glycine 0 N--CA 1.494 2.517 0 C-N-CA 119.029 -1.558 . . . . 0.0 110.187 -173.569 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.437 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 0.7 OUTLIER -108.91 172.39 6.87 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.081 -1.246 . . . . 0.0 111.104 -176.167 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.039 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -139.46 148.54 42.87 Favored 'General case' 0 N--CA 1.491 1.614 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -178.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.586 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 20.8 tttt -106.42 117.01 32.92 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 120.993 -1.067 . . . . 0.0 110.149 178.759 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.992 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.0 tp -59.81 127.65 33.02 Favored 'General case' 0 C--N 1.297 -1.705 0 O-C-N 120.831 -1.168 . . . . 0.0 108.756 172.563 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.118 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.5 p -126.72 -30.85 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 C-N-CA 119.596 -0.842 . . . . 0.0 110.032 -178.215 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.13 142.56 27.48 Favored 'General case' 0 N--CA 1.494 1.762 0 C-N-CA 119.157 -1.017 . . . . 0.0 111.361 -178.403 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.726 HG23 ' NE2' ' A' ' 24' ' ' HIS . 10.3 mt -109.46 133.78 53.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.186 -0.946 . . . . 0.0 110.191 172.92 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.515 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 83.8 m-20 -109.88 114.29 27.72 Favored 'General case' 0 C--N 1.299 -1.609 0 O-C-N 121.377 -0.827 . . . . 0.0 110.129 176.072 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -100.25 112.69 25.03 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.018 -1.051 . . . . 0.0 110.556 -177.284 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.0 OUTLIER -107.43 133.22 20.46 Favored Pre-proline 0 N--CA 1.492 1.661 0 O-C-N 121.186 -0.946 . . . . 0.0 109.372 174.915 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -51.99 -25.1 21.12 Favored 'Trans proline' 0 C--N 1.302 -1.869 0 O-C-N 123.859 1.452 . . . . 0.0 110.35 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.567 ' O ' ' CG ' ' A' ' 21' ' ' PHE . 8.8 m-80 -86.2 -35.76 19.87 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.25 -0.906 . . . . 0.0 110.272 177.708 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.567 ' CG ' ' O ' ' A' ' 20' ' ' ASN . 95.4 m-85 -157.17 150.24 23.71 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.407 -0.808 . . . . 0.0 110.244 -176.382 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.795 ' HD3' HD22 ' A' ' 68' ' ' LEU . 61.6 ttt180 -86.2 144.26 27.55 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.783 -1.198 . . . . 0.0 110.085 175.218 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.515 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 85.3 m -130.6 140.01 50.42 Favored 'General case' 0 C--N 1.296 -1.728 0 O-C-N 121.499 -0.751 . . . . 0.0 109.668 -175.676 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.726 ' NE2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.98 141.27 50.24 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.776 -1.203 . . . . 0.0 111.546 -178.433 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.843 HG22 ' OG ' ' A' ' 60' ' ' SER . 12.8 t -120.98 135.05 62.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.118 -0.989 . . . . 0.0 110.656 -179.152 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.879 HG13 ' CE1' ' A' ' 61' ' ' PHE . 21.4 m -117.46 171.96 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.738 -0.601 . . . . 0.0 110.246 178.16 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.493 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 12.8 tt0 -106.3 116.87 32.67 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 178.922 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.884 ' CD2' HD22 ' A' ' 36' ' ' LEU . 9.6 tp -90.73 130.93 39.19 Favored Pre-proline 0 C--N 1.296 -1.747 0 O-C-N 121.203 -0.936 . . . . 0.0 110.521 -171.295 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.472 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 30.7 Cg_endo -68.05 176.91 4.84 Favored 'Trans proline' 0 C--N 1.308 -1.605 0 O-C-N 124.015 1.534 . . . . 0.0 111.053 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -60.55 -39.92 89.71 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.429 -0.795 . . . . 0.0 111.401 -175.187 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.602 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -89.89 0.03 57.29 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.8 -1.188 . . . . 0.0 110.755 -174.078 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.602 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 99.9 mmm -110.67 -16.14 13.69 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.95 -1.094 . . . . 0.0 109.638 169.793 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.597 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 29.6 mt -71.2 -24.86 62.3 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.313 -0.867 . . . . 0.0 109.863 174.386 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . 0.476 ' O ' ' N ' ' A' ' 36' ' ' LEU . 38.6 p-10 -71.16 162.25 29.74 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.467 -0.771 . . . . 0.0 110.94 -173.104 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.428 ' C ' ' O ' ' A' ' 34' ' ' ASP . . . 37.54 27.69 0.03 OUTLIER Glycine 0 N--CA 1.494 2.522 0 O-C-N 121.504 -0.747 . . . . 0.0 111.605 174.295 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.884 HD22 ' CD2' ' A' ' 28' ' ' LEU . 60.8 tp -101.21 158.45 16.02 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 120.537 -1.566 . . . . 0.0 110.919 179.025 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 21.5 pt-20 -160.04 161.09 33.9 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.566 -0.709 . . . . 0.0 109.428 177.49 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.817 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -66.84 154.42 40.96 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.043 -1.035 . . . . 0.0 109.526 175.779 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.39 -9.45 61.43 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 109.257 -1.537 . . . . 0.0 109.257 -176.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.505 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -69.87 153.21 43.6 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.135 -1.215 . . . . 0.0 109.627 177.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.529 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -97.35 104.53 16.56 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 120.966 -1.084 . . . . 0.0 109.906 178.117 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.414 ' CG1' ' HD1' ' A' ' 44' ' ' HIS . 1.6 t -87.87 137.54 20.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.239 -0.913 . . . . 0.0 109.027 174.526 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.484 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -102.96 120.12 40.06 Favored 'General case' 0 C--N 1.295 -1.781 0 O-C-N 120.865 -1.147 . . . . 0.0 109.535 170.167 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.806 ' CD2' HG21 ' A' ' 82' ' ' VAL . 1.2 m80 -87.45 101.02 13.19 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 176.12 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.0 t-20 58.55 8.88 0.95 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.575 -0.703 . . . . 0.0 111.399 -169.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.449 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 124.62 -3.19 8.73 Favored Glycine 0 N--CA 1.489 2.167 0 C-N-CA 119.674 -1.25 . . . . 0.0 110.617 174.344 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.815 ' O ' HD23 ' A' ' 49' ' ' LEU . 19.7 t -90.34 107.39 19.12 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.334 -1.686 . . . . 0.0 109.2 174.623 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 23.5 p -78.12 125.55 29.51 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.127 -0.983 . . . . 0.0 110.768 -170.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.941 HD12 ' HB2' ' A' ' 61' ' ' PHE . 0.3 OUTLIER -142.57 160.16 40.83 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.508 -0.745 . . . . 0.0 109.592 176.051 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 27.6 m -99.51 149.15 23.53 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 120.715 -1.24 . . . . 0.0 111.378 -169.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.96 HG13 HG13 ' A' ' 59' ' ' VAL . 16.9 t -75.16 114.62 15.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.739 -0.6 . . . . 0.0 110.273 -179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.527 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 47.3 p -70.29 -40.0 74.55 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.299 -0.875 . . . . 0.0 109.947 174.214 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.587 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.5 tt0 -162.78 154.5 18.05 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.344 -0.847 . . . . 0.0 110.23 -179.344 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.817 HD11 ' N ' ' A' ' 38' ' ' THR . 5.5 mt -105.55 130.01 57.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.012 -1.055 . . . . 0.0 109.888 175.201 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.524 ' HB2' ' CB ' ' A' ' 58' ' ' HIS . 9.6 m-80 -101.66 61.94 0.91 Allowed 'General case' 0 C--N 1.298 -1.66 0 O-C-N 121.614 -0.678 . . . . 0.0 109.691 178.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.79 -114.72 4.16 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 108.743 -1.743 . . . . 0.0 108.743 -173.687 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.597 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -78.54 -19.97 51.72 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.024 -1.28 . . . . 0.0 108.807 174.374 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.118 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.3 m170 -75.29 160.04 30.79 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.459 -0.776 . . . . 0.0 110.116 -177.222 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.96 HG13 HG13 ' A' ' 51' ' ' VAL . 54.6 t -140.14 121.99 15.62 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.713 0 O-C-N 120.957 -1.089 . . . . 0.0 110.711 171.059 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.843 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.1 t -87.75 133.69 33.81 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.522 -0.736 . . . . 0.0 109.287 174.729 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.941 ' HB2' HD12 ' A' ' 49' ' ' LEU . 1.3 p90 -126.85 154.07 44.85 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 121.43 -0.793 . . . . 0.0 110.225 178.554 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.527 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 31.4 p-10 -88.72 147.77 24.32 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.004 -1.06 . . . . 0.0 111.399 -170.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.822 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -154.47 113.66 3.69 Favored 'General case' 0 C--N 1.298 -1.65 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 -176.186 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.527 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 56.9 ttm -69.96 140.61 53.01 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.794 -1.191 . . . . 0.0 109.449 -179.382 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.484 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 36.4 tptt -60.01 -49.23 78.5 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 120.995 -1.066 . . . . 0.0 110.299 -175.1 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.41 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 88.6 tt0 -65.48 -40.01 92.62 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.901 -1.124 . . . . 0.0 110.129 178.162 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.527 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 60.8 m -62.76 -38.13 89.34 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.902 -1.124 . . . . 0.0 109.426 174.238 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.795 HD22 ' HD3' ' A' ' 22' ' ' ARG . 14.7 tp -60.05 -41.58 92.61 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.14 -0.975 . . . . 0.0 109.225 177.325 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.525 ' NH1' ' HB3' ' A' ' 69' ' ' ARG . 6.4 mmm180 -69.96 -38.85 76.24 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.466 -0.771 . . . . 0.0 110.433 174.012 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.828 HG22 HG23 ' A' ' 71' ' ' THR . 1.1 tt -67.97 -40.43 83.29 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.327 -0.858 . . . . 0.0 109.412 -176.574 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.828 HG23 HG22 ' A' ' 70' ' ' ILE . 59.1 p -87.49 -171.56 3.51 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 121.339 0.59 . . . . 0.0 109.764 179.083 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.467 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 8.3 t30 -99.92 18.75 17.6 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.338 -0.852 . . . . 0.0 108.865 170.194 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.822 ' HB3' HD21 ' A' ' 63' ' ' LEU . 70.2 mt -68.33 -40.02 81.77 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.931 -1.106 . . . . 0.0 109.749 174.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.515 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -47.06 -22.55 1.3 Allowed Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 -179.702 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.3 p-10 -67.91 -17.18 64.39 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.975 -1.309 . . . . 0.0 110.419 -175.351 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.509 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 95.5 mt -63.51 142.11 58.51 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.223 -0.923 . . . . 0.0 110.917 -176.243 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 0.992 ' C ' HD23 ' A' ' 12' ' ' LEU . 46.1 mttt -142.65 142.73 32.12 Favored 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.733 -0.604 . . . . 0.0 109.495 174.561 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.697 HG23 HD11 ' A' ' 15' ' ' ILE . 21.3 t -63.61 150.04 10.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.587 0 O-C-N 120.843 -1.16 . . . . 0.0 110.36 -176.707 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.78 -13.6 62.35 Favored Glycine 0 N--CA 1.483 1.797 0 N-CA-C 108.793 -1.723 . . . . 0.0 108.793 -175.21 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 44.9 t0 -95.2 166.31 11.97 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.267 -1.137 . . . . 0.0 109.55 176.1 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.586 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.8 m95 -117.22 159.04 23.28 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.006 -1.059 . . . . 0.0 110.118 176.563 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.039 HG13 ' HB3' ' A' ' 10' ' ' ALA . 1.0 OUTLIER -125.38 155.02 34.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.441 -0.787 . . . . 0.0 109.891 -179.124 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.846 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.3 OUTLIER -78.16 105.29 9.28 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.17 -0.956 . . . . 0.0 108.965 168.093 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.846 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -106.19 140.46 24.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 120.535 -1.353 . . . . 0.0 111.478 -176.312 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.43 ' HB3' ' HB3' ' A' ' 43' ' ' ALA . 86.5 tt0 -134.27 157.09 47.19 Favored 'General case' 0 N--CA 1.496 1.855 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.948 -179.557 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 47.5 ptt85 -100.23 133.37 44.74 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.114 -0.991 . . . . 0.0 110.992 -176.232 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.918 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -128.73 150.96 50.05 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.344 -0.848 . . . . 0.0 110.126 179.598 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -119.22 126.58 51.86 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.24 -0.913 . . . . 0.0 110.635 -178.704 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 28.3 mtpt -60.24 -40.01 88.73 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.507 -0.745 . . . . 0.0 110.965 -177.242 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . 0.407 ' CD1' ' C ' ' A' ' 90' ' ' PHE . 24.0 p90 -81.1 155.29 26.34 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.99 -1.069 . . . . 0.0 110.469 -177.387 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.454 ' HB3' ' HG3' ' A' ' 93' ' ' GLU . 53.1 m -72.08 129.93 39.69 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.359 -0.838 . . . . 0.0 110.742 -176.539 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.454 ' O ' ' HB2' ' A' ' 93' ' ' GLU . 56.7 t0 -70.07 -39.77 75.42 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.29 -0.881 . . . . 0.0 110.238 175.485 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.454 ' HB2' ' O ' ' A' ' 92' ' ' ASP . 98.5 mt-10 55.48 52.66 10.86 Favored 'General case' 0 N--CA 1.506 2.356 0 C-N-CA 119.887 -0.725 . . . . 0.0 110.498 177.568 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.808 HG22 ' O ' ' A' ' 96' ' ' GLY . 30.5 mm -69.43 -40.08 79.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.295 -0.878 . . . . 0.0 110.231 175.279 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 56.21 74.74 0.29 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 -177.542 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.808 ' O ' HG22 ' A' ' 94' ' ' ILE . . . 73.61 170.12 19.66 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.252 -1.539 . . . . 0.0 109.252 -178.608 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 1.4 t-160 . . . . . 0 N--CA 1.492 1.668 0 O-C-N 121.253 -1.145 . . . . 0.0 110.19 178.866 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 53.9 ttm . . . . . 0 N--CA 1.493 1.712 0 CA-C-O 121.171 0.51 . . . . 0.0 110.261 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.918 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 6.6 p90 -169.95 156.22 6.03 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 121.128 -0.982 . . . . 0.0 109.016 174.533 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.608 HG23 ' C ' ' B' ' 2' ' ' PHE . 75.6 p -154.16 -41.8 0.09 Allowed 'General case' 0 C--N 1.293 -1.851 0 O-C-N 121.084 -1.01 . . . . 0.0 108.517 176.58 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.449 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 51.24 20.76 5.17 Favored Glycine 0 N--CA 1.483 1.768 0 N-CA-C 108.408 -1.877 . . . . 0.0 108.408 -176.221 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 0.545 HD11 ' C8M' ' A' ' 98' ' ' RBF . 59.7 mt -81.76 130.74 35.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.285 -1.126 . . . . 0.0 109.915 -176.63 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.826 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.0 t -86.21 140.74 15.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.19 -0.944 . . . . 0.0 111.11 -169.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 27.8 mm100 -69.98 -36.08 74.93 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.836 -0.54 . . . . 0.0 110.81 177.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.534 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -155.42 168.96 33.27 Favored Glycine 0 N--CA 1.495 2.631 0 C-N-CA 119.086 -1.53 . . . . 0.0 110.269 -173.563 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.44 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 0.7 OUTLIER -108.87 172.17 7.0 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.127 -1.219 . . . . 0.0 111.177 -176.128 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.06 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -139.24 148.79 43.55 Favored 'General case' 0 N--CA 1.493 1.712 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 -179.145 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.583 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 20.8 tttt -106.59 117.11 33.18 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.091 -1.006 . . . . 0.0 110.055 178.787 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 1.008 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.0 tp -59.98 127.54 32.43 Favored 'General case' 0 C--N 1.298 -1.645 0 O-C-N 120.977 -1.077 . . . . 0.0 108.814 172.583 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.112 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.5 p -126.51 -31.0 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.837 0 O-C-N 121.312 -0.868 . . . . 0.0 110.061 -178.115 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.09 142.55 27.51 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.229 -0.988 . . . . 0.0 111.391 -178.358 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.739 HG23 ' NE2' ' B' ' 24' ' ' HIS . 10.3 mt -109.42 133.85 53.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.169 -0.957 . . . . 0.0 110.241 172.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.511 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.6 m-20 -110.0 114.44 27.98 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.387 -0.821 . . . . 0.0 110.077 176.059 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.5 tt0 -100.24 112.66 24.99 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.101 -1.0 . . . . 0.0 110.612 -177.358 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.0 OUTLIER -107.47 133.3 20.44 Favored Pre-proline 0 N--CA 1.493 1.695 0 O-C-N 121.27 -0.894 . . . . 0.0 109.4 174.904 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -52.12 -24.99 21.57 Favored 'Trans proline' 0 C--N 1.303 -1.855 0 O-C-N 123.873 1.46 . . . . 0.0 110.32 -179.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.572 ' O ' ' CG ' ' B' ' 21' ' ' PHE . 9.2 m-80 -86.12 -36.35 19.64 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.305 -0.872 . . . . 0.0 110.06 177.804 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.572 ' CG ' ' O ' ' B' ' 20' ' ' ASN . 95.5 m-85 -156.71 150.27 24.52 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.43 -0.794 . . . . 0.0 110.296 -176.285 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.793 ' HD3' HD22 ' B' ' 68' ' ' LEU . 61.5 ttt180 -86.18 144.15 27.62 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.783 -1.198 . . . . 0.0 110.072 175.165 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.511 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 85.2 m -130.44 140.07 50.56 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.504 -0.747 . . . . 0.0 109.745 -175.76 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.739 ' NE2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.92 141.29 50.28 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.859 -1.151 . . . . 0.0 111.505 -178.358 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.841 HG22 ' OG ' ' B' ' 60' ' ' SER . 12.6 t -120.9 135.21 61.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.313 -0.867 . . . . 0.0 110.648 -179.164 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.892 HG13 ' CE1' ' B' ' 61' ' ' PHE . 21.7 m -117.72 171.94 5.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.757 -0.589 . . . . 0.0 110.19 178.171 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.481 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 12.8 tt0 -106.19 116.82 32.59 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 178.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.887 ' CD2' HD22 ' B' ' 36' ' ' LEU . 9.5 tp -90.59 130.9 39.57 Favored Pre-proline 0 C--N 1.295 -1.773 0 O-C-N 121.16 -0.962 . . . . 0.0 110.547 -171.298 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.481 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 30.6 Cg_endo -68.13 176.92 4.89 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 O-C-N 123.98 1.516 . . . . 0.0 111.005 -179.505 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -60.51 -40.02 89.89 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.454 -0.779 . . . . 0.0 111.355 -175.143 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.597 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -89.87 0.06 57.27 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.738 -1.226 . . . . 0.0 110.707 -174.008 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.597 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 99.9 mmm -110.71 -16.03 13.7 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.848 -1.157 . . . . 0.0 109.665 169.765 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.607 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 29.4 mt -71.31 -24.92 62.22 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.298 -0.876 . . . . 0.0 109.779 174.408 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . 0.488 ' O ' ' N ' ' B' ' 36' ' ' LEU . 38.6 p-10 -71.11 162.18 29.86 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.443 -0.786 . . . . 0.0 110.955 -173.088 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' B' ' 34' ' ' ASP . . . 37.53 27.74 0.03 OUTLIER Glycine 0 N--CA 1.496 2.694 0 C-N-CA 120.733 -0.746 . . . . 0.0 111.564 174.343 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.887 HD22 ' CD2' ' B' ' 28' ' ' LEU . 60.8 tp -101.28 158.43 16.05 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.572 -1.546 . . . . 0.0 110.925 178.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . . . . . . . . . 21.5 pt-20 -159.97 161.17 34.09 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.561 -0.712 . . . . 0.0 109.421 177.525 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.817 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -66.97 154.43 41.14 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.007 -1.058 . . . . 0.0 109.49 175.794 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 83.38 -9.37 61.63 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 109.353 -1.499 . . . . 0.0 109.353 -176.577 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.517 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -70.01 152.98 43.79 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.265 -1.138 . . . . 0.0 109.612 177.885 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.536 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -97.08 104.28 16.28 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 120.947 -1.096 . . . . 0.0 110.037 178.103 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.424 HG12 ' HD1' ' B' ' 44' ' ' HIS . 1.6 t -87.81 137.54 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.247 -0.908 . . . . 0.0 109.108 174.554 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.479 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -103.02 120.19 40.2 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 120.931 -1.106 . . . . 0.0 109.482 170.239 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.821 ' CD2' HG21 ' B' ' 82' ' ' VAL . 1.2 m80 -87.51 100.89 13.11 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 119.67 -0.812 . . . . 0.0 108.925 176.099 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.509 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.0 t-20 58.87 8.86 1.03 Allowed 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.5 -0.75 . . . . 0.0 111.256 -170.12 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.477 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 124.5 -2.9 8.82 Favored Glycine 0 N--CA 1.488 2.123 0 C-N-CA 119.699 -1.239 . . . . 0.0 110.601 174.173 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.813 ' O ' HD23 ' B' ' 49' ' ' LEU . 19.7 t -90.44 107.33 19.09 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.3 -1.706 . . . . 0.0 109.266 174.492 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 23.3 p -78.05 125.55 29.52 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.128 -0.983 . . . . 0.0 110.774 -170.761 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 0.939 HD12 ' HB2' ' B' ' 61' ' ' PHE . 0.3 OUTLIER -142.59 160.08 41.0 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.596 -0.69 . . . . 0.0 109.632 176.05 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 27.7 m -99.25 149.3 23.25 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 120.676 -1.265 . . . . 0.0 111.357 -169.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.982 HG13 HG13 ' B' ' 59' ' ' VAL . 17.1 t -75.42 114.55 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.675 -0.641 . . . . 0.0 110.342 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.528 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 48.3 p -70.32 -39.96 74.46 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.178 -0.952 . . . . 0.0 109.865 174.433 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.574 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.5 tt0 -162.74 154.6 18.26 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.388 -0.82 . . . . 0.0 110.214 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.817 HD11 ' N ' ' B' ' 38' ' ' THR . 5.5 mt -105.63 129.9 57.87 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.12 -0.987 . . . . 0.0 109.925 175.215 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.53 ' HB2' ' CB ' ' B' ' 58' ' ' HIS . 9.6 m-80 -101.58 61.9 0.92 Allowed 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.658 -0.651 . . . . 0.0 109.748 178.867 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.78 -114.66 4.15 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 -173.655 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.607 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -78.41 -20.2 51.61 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.004 -1.292 . . . . 0.0 108.815 174.34 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.112 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.4 m170 -75.21 159.87 31.06 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.442 -0.786 . . . . 0.0 110.144 -177.203 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.982 HG13 HG13 ' B' ' 51' ' ' VAL . 54.7 t -140.04 122.16 16.07 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.642 0 C-N-CA 118.926 -1.11 . . . . 0.0 110.662 171.133 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.841 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.1 t -87.86 133.83 33.82 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.457 -0.777 . . . . 0.0 109.371 174.746 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.939 ' HB2' HD12 ' B' ' 49' ' ' LEU . 1.3 p90 -126.98 154.07 45.05 Favored 'General case' 0 N--CA 1.498 1.929 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.109 178.681 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.528 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 31.1 p-10 -88.7 147.77 24.34 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.939 -1.1 . . . . 0.0 111.352 -170.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.793 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -154.38 113.76 3.73 Favored 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 109.099 -0.704 . . . . 0.0 109.099 -176.309 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.531 ' HB3' ' HB ' ' B' ' 67' ' ' THR . 56.8 ttm -70.05 140.53 52.82 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.744 -1.222 . . . . 0.0 109.402 -179.386 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.483 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 36.5 tptt -59.99 -49.1 78.99 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.023 -1.048 . . . . 0.0 110.347 -175.117 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . 0.411 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 88.6 tt0 -65.54 -40.03 92.41 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 120.948 -1.095 . . . . 0.0 110.098 178.22 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.531 ' HB ' ' HB3' ' B' ' 64' ' ' MET . 61.0 m -62.7 -38.23 89.6 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.905 -1.122 . . . . 0.0 109.426 174.242 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.793 HD22 ' HD3' ' B' ' 22' ' ' ARG . 14.7 tp -60.01 -41.46 92.21 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.292 -0.88 . . . . 0.0 109.264 177.312 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . 0.529 ' NH1' ' HB3' ' B' ' 69' ' ' ARG . 6.4 mmm180 -70.0 -38.99 76.15 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.558 -0.714 . . . . 0.0 110.386 174.03 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.811 HG22 HG23 ' B' ' 71' ' ' THR . 1.1 tt -67.88 -40.39 83.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.273 -0.892 . . . . 0.0 109.526 -176.641 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.811 HG23 HG22 ' B' ' 70' ' ' ILE . 59.2 p -87.37 -171.43 3.47 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-O 121.296 0.57 . . . . 0.0 109.863 178.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.524 ' HB2' ' N ' ' A' ' 83' ' ' ASN . 8.4 t30 -99.92 18.74 17.62 Favored 'General case' 0 C--N 1.297 -1.703 0 O-C-N 121.384 -0.823 . . . . 0.0 108.814 170.195 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.793 ' HB3' HD21 ' B' ' 63' ' ' LEU . 69.4 mt -68.41 -39.98 81.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.023 -1.048 . . . . 0.0 109.716 174.811 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.513 ' CA ' ' HG ' ' B' ' 68' ' ' LEU . . . -47.02 -22.64 1.3 Allowed Glycine 0 N--CA 1.489 2.2 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -179.71 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.4 p-10 -67.94 -17.14 64.36 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.08 -1.247 . . . . 0.0 110.492 -175.321 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.512 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 95.5 mt -63.44 142.1 58.52 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.17 -0.956 . . . . 0.0 110.92 -176.334 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 1.008 ' C ' HD23 ' B' ' 12' ' ' LEU . 46.1 mttt -142.84 142.84 31.91 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.71 -0.619 . . . . 0.0 109.391 174.507 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.718 HG23 HD11 ' B' ' 15' ' ' ILE . 21.5 t -63.61 149.99 10.09 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 120.903 -1.123 . . . . 0.0 110.422 -176.568 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 88.67 -13.34 62.8 Favored Glycine 0 N--CA 1.483 1.804 0 N-CA-C 108.885 -1.686 . . . . 0.0 108.885 -175.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.509 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 44.5 t0 -95.28 166.22 12.0 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.392 -1.064 . . . . 0.0 109.545 175.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.583 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 16.0 m95 -117.16 159.08 23.17 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.019 -1.051 . . . . 0.0 110.183 176.479 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.06 HG13 ' HB3' ' B' ' 10' ' ' ALA . 1.0 OUTLIER -125.45 155.15 34.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.5 -0.75 . . . . 0.0 109.936 -179.289 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.826 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.3 OUTLIER -78.25 105.15 9.29 Favored 'General case' 0 C--N 1.297 -1.69 0 O-C-N 121.123 -0.986 . . . . 0.0 109.025 168.203 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.856 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -106.07 140.61 23.62 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 120.631 -1.293 . . . . 0.0 111.361 -176.047 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . 0.431 ' HB3' ' HB3' ' B' ' 43' ' ' ALA . 86.4 tt0 -134.54 157.06 47.52 Favored 'General case' 0 N--CA 1.495 1.785 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.888 -179.649 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 47.6 ptt85 -100.12 133.46 44.48 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.079 -1.013 . . . . 0.0 110.919 -176.12 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 1.001 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -128.76 150.99 50.06 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.401 -0.812 . . . . 0.0 110.08 179.603 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -119.3 126.63 51.93 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.269 -0.894 . . . . 0.0 110.527 -178.697 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 28.3 mtpt -60.29 -40.09 89.23 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.416 -0.802 . . . . 0.0 110.918 -177.259 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . 0.406 ' CD1' ' C ' ' B' ' 90' ' ' PHE . 24.1 p90 -81.1 155.2 26.39 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.103 -0.998 . . . . 0.0 110.454 -177.364 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . 0.482 ' HB3' ' HB ' ' B' ' 94' ' ' ILE . 53.2 m -72.03 129.92 39.69 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.289 -0.882 . . . . 0.0 110.795 -176.489 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 56.9 t0 -70.12 -46.4 64.87 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.254 -0.904 . . . . 0.0 110.454 175.529 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 -140.38 52.54 1.65 Allowed 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.914 -1.117 . . . . 0.0 110.909 -175.734 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . 0.552 HD13 ' CE ' ' A' ' 1' ' ' MET . 41.0 mt -130.6 2.35 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.162 -0.961 . . . . 0.0 110.203 176.38 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . -69.57 58.36 0.68 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.131 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' B' ' 94' ' ' ILE . . . 71.61 127.17 0.07 OUTLIER Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.416 -1.474 . . . . 0.0 109.416 -179.288 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 35.8 m80 . . . . . 0 N--CA 1.491 1.583 0 O-C-N 121.207 -1.172 . . . . 0.0 110.184 -179.16 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 0.545 ' C8M' HD11 ' B' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 0.57 ' C8M' HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 92.5 mmm . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.049 0.452 . . . . 0.0 110.042 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 1.031 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 6.1 p90 -167.86 148.35 5.11 Favored 'General case' 0 C--N 1.306 -1.31 0 O-C-N 121.056 -1.028 . . . . 0.0 109.033 174.648 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.585 ' CB ' HG12 ' A' ' 5' ' ' ILE . 4.9 p -146.22 -37.86 0.24 Allowed 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.108 -0.995 . . . . 0.0 109.008 178.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.482 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 46.39 26.28 2.35 Favored Glycine 0 N--CA 1.483 1.803 0 N-CA-C 108.494 -1.843 . . . . 0.0 108.494 -176.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.585 HG12 ' CB ' ' A' ' 3' ' ' THR . 27.7 mm -78.77 130.01 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.464 -1.021 . . . . 0.0 109.558 -178.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.843 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.2 t -93.17 140.37 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.807 0 O-C-N 120.934 -1.104 . . . . 0.0 111.09 -169.77 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -69.95 -35.11 74.24 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.778 -0.576 . . . . 0.0 111.072 176.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.535 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -156.24 172.97 34.14 Favored Glycine 0 N--CA 1.495 2.609 0 C-N-CA 118.747 -1.692 . . . . 0.0 110.513 -172.526 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.458 ' O ' ' HG3' ' A' ' 29' ' ' PRO . 12.6 p -117.75 172.35 7.43 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.031 -1.276 . . . . 0.0 111.017 -176.814 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.041 ' HB3' ' CG1' ' A' ' 82' ' ' VAL . . . -140.01 148.53 41.99 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.562 -0.711 . . . . 0.0 109.609 -178.726 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.579 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 37.6 tttt -107.18 115.3 29.93 Favored 'General case' 0 C--N 1.295 -1.768 0 O-C-N 121.047 -1.033 . . . . 0.0 110.321 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.998 HD23 ' C ' ' A' ' 77' ' ' LYS . 11.3 tp -59.91 126.74 28.73 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 121.038 -1.039 . . . . 0.0 108.896 173.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.042 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -125.32 -29.32 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.838 0 C-N-CA 119.583 -0.847 . . . . 0.0 109.909 -179.417 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.93 142.4 24.37 Favored 'General case' 0 N--CA 1.495 1.783 0 C-N-CA 118.942 -1.103 . . . . 0.0 111.523 179.735 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.782 HG23 ' CD2' ' A' ' 24' ' ' HIS . 12.0 mt -105.55 137.13 36.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.155 -0.966 . . . . 0.0 110.185 171.569 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.519 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 86.7 m-20 -112.95 115.99 29.28 Favored 'General case' 0 C--N 1.297 -1.703 0 O-C-N 121.344 -0.847 . . . . 0.0 109.937 173.512 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -105.9 115.24 29.9 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.897 -1.127 . . . . 0.0 110.799 -176.477 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.465 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 4.1 mtmt -110.4 127.58 26.77 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.121 -0.987 . . . . 0.0 108.935 171.703 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -52.27 -18.73 8.13 Favored 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.848 1.446 . . . . 0.0 110.812 -179.367 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.577 ' ND2' ' N ' ' A' ' 20' ' ' ASN . 0.3 OUTLIER -90.18 -35.84 15.13 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.139 -0.975 . . . . 0.0 108.741 177.077 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.518 ' CD2' ' HB2' ' A' ' 20' ' ' ASN . 81.9 m-85 -151.07 150.15 30.37 Favored 'General case' 0 N--CA 1.491 1.623 0 CA-C-O 121.192 0.52 . . . . 0.0 109.748 179.183 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.48 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 62.4 ttt180 -97.69 143.83 27.95 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.589 -1.32 . . . . 0.0 110.021 176.504 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.519 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 96.5 m -129.98 140.09 50.96 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.412 -0.805 . . . . 0.0 110.126 -173.304 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.782 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.22 135.77 48.5 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.984 -1.073 . . . . 0.0 111.207 179.216 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.759 HG22 ' OG ' ' A' ' 60' ' ' SER . 15.8 t -115.53 134.25 59.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.002 -1.061 . . . . 0.0 110.767 -178.276 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.46 ' O ' ' HA ' ' A' ' 58' ' ' HIS . 29.5 m -119.67 170.02 9.88 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.608 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.062 -179.703 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.535 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 7.5 tt0 -103.55 116.97 33.36 Favored 'General case' 0 C--N 1.304 -1.39 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 -179.383 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.545 HD23 ' HA ' ' A' ' 33' ' ' LEU . 8.9 tp -82.01 119.73 75.78 Favored Pre-proline 0 C--N 1.295 -1.798 0 O-C-N 121.502 -0.748 . . . . 0.0 109.815 -173.719 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.458 ' HG3' ' O ' ' A' ' 9' ' ' THR . 22.6 Cg_endo -65.33 179.22 1.66 Allowed 'Trans proline' 0 C--N 1.308 -1.554 0 O-C-N 123.85 1.447 . . . . 0.0 111.047 -179.378 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.417 ' OD1' ' C ' ' A' ' 30' ' ' ASP . 50.5 t0 -60.1 -41.28 92.18 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.415 -0.803 . . . . 0.0 111.098 -175.319 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.57 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.39 1.47 56.57 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.87 -1.144 . . . . 0.0 110.763 -174.156 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.57 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 96.4 mmm -111.07 -15.82 13.63 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.036 -1.04 . . . . 0.0 109.82 171.835 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.613 HD21 ' HB2' ' A' ' 57' ' ' ASN . 16.5 mt -68.18 -30.39 69.48 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.33 -0.856 . . . . 0.0 109.999 178.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 57.4 t0 -91.72 127.02 37.01 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.328 -0.858 . . . . 0.0 110.266 -179.648 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.28 -48.06 1.0 Allowed Glycine 0 N--CA 1.492 2.403 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 177.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.788 HD23 ' N ' ' A' ' 37' ' ' GLU . 7.4 tt -70.02 145.81 51.49 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.141 -1.211 . . . . 0.0 110.664 -175.762 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.788 ' N ' HD23 ' A' ' 36' ' ' LEU . 20.7 pt-20 -150.43 170.01 20.09 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.427 -0.796 . . . . 0.0 109.622 -179.512 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.825 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -67.23 151.15 48.05 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.91 -1.119 . . . . 0.0 110.13 179.972 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.62 0.0 62.15 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 -176.226 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.452 ' O ' ' HA ' ' A' ' 50' ' ' THR . . . -79.79 159.0 26.71 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.242 -1.152 . . . . 0.0 109.7 177.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.552 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -101.06 113.23 26.05 Favored 'General case' 0 N--CA 1.486 1.345 0 O-C-N 121.126 -0.984 . . . . 0.0 110.04 176.72 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.611 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.0 t -104.74 130.0 56.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.556 0 O-C-N 121.278 -0.889 . . . . 0.0 109.172 174.718 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.516 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -93.31 119.53 32.56 Favored 'General case' 0 C--N 1.297 -1.708 0 C-N-CA 119.146 -1.022 . . . . 0.0 109.149 172.257 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.736 ' CG ' HG21 ' A' ' 82' ' ' VAL . 0.3 OUTLIER -88.0 107.15 18.58 Favored 'General case' 0 N--CA 1.489 1.481 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 178.52 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.51 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.1 t-20 50.29 16.28 0.25 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.487 -0.758 . . . . 0.0 111.283 -166.457 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.501 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 120.92 0.85 11.75 Favored Glycine 0 N--CA 1.489 2.221 0 C-N-CA 119.444 -1.36 . . . . 0.0 111.164 171.292 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.785 ' O ' HD23 ' A' ' 49' ' ' LEU . 34.8 t -98.71 108.46 21.15 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 120.137 -1.802 . . . . 0.0 109.492 175.082 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.501 ' SG ' ' C8 ' ' A' ' 98' ' ' RBF . 21.2 p -75.7 126.74 31.59 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.015 -1.053 . . . . 0.0 111.084 -171.116 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.96 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.4 OUTLIER -141.35 162.74 34.76 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.505 -0.747 . . . . 0.0 109.466 172.712 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.452 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 55.0 m -102.47 152.88 20.61 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 120.637 -1.29 . . . . 0.0 111.074 -171.13 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.896 HG22 ' CE1' ' A' ' 61' ' ' PHE . 34.5 t -76.82 117.73 22.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.62 -0.675 . . . . 0.0 110.458 -177.934 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.685 HG22 ' HB3' ' A' ' 62' ' ' ASP . 41.2 p -70.21 -39.99 74.81 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.122 -0.986 . . . . 0.0 109.669 172.253 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.572 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 52.3 tp10 -164.72 156.12 15.26 Favored 'General case' 0 N--CA 1.492 1.642 0 C-N-CA 119.398 -0.921 . . . . 0.0 110.819 -177.349 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.825 HD11 ' N ' ' A' ' 38' ' ' THR . 8.8 mt -110.47 130.07 64.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.083 -1.011 . . . . 0.0 109.986 172.794 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.499 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 63.8 m-80 -104.7 65.62 0.76 Allowed 'General case' 0 C--N 1.297 -1.678 0 CA-C-O 121.532 0.682 . . . . 0.0 109.54 177.703 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 76.91 -115.09 4.24 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 -174.158 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.613 ' HB2' HD21 ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.0 -21.08 44.04 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.121 -1.223 . . . . 0.0 109.162 176.609 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.042 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.5 m170 -77.05 159.38 29.91 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.186 -0.946 . . . . 0.0 109.791 -178.024 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.815 HG13 HG13 ' A' ' 51' ' ' VAL . 59.9 t -140.9 121.48 13.27 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 C-N-CA 119.078 -1.049 . . . . 0.0 110.522 171.707 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.759 ' OG ' HG22 ' A' ' 25' ' ' VAL . 1.2 t -84.35 135.35 34.33 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.434 -0.791 . . . . 0.0 109.264 175.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.96 ' HB3' HD12 ' A' ' 49' ' ' LEU . 58.9 m-85 -115.55 158.5 22.53 Favored 'General case' 0 C--N 1.297 -1.697 0 O-C-N 121.319 -0.863 . . . . 0.0 110.199 178.967 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.685 ' HB3' HG22 ' A' ' 52' ' ' THR . 25.1 p-10 -92.12 147.47 22.91 Favored 'General case' 0 N--CA 1.49 1.566 0 CA-C-O 122.106 0.955 . . . . 0.0 110.842 178.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.833 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -159.71 125.0 4.08 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 -176.864 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.536 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 56.1 ttm -84.85 146.44 27.31 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.931 -1.106 . . . . 0.0 109.434 -177.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.43 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 71.4 tttt -60.06 -49.13 78.88 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.014 -1.053 . . . . 0.0 109.99 -177.231 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 53.4 tp10 -69.59 -40.02 76.95 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.147 -0.97 . . . . 0.0 110.397 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.537 ' O ' HG23 ' A' ' 71' ' ' THR . 37.7 m -62.25 -38.66 90.11 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.823 -1.173 . . . . 0.0 109.085 174.427 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.802 HD11 ' HA2' ' A' ' 74' ' ' GLY . 1.0 OUTLIER -60.05 -47.37 86.16 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.233 -0.917 . . . . 0.0 109.709 177.419 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 74.9 ttt-85 -65.76 -40.05 91.65 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.467 -0.771 . . . . 0.0 110.481 178.192 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.878 HG22 HG23 ' A' ' 71' ' ' THR . 1.4 tt -64.19 -41.28 91.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.234 -0.917 . . . . 0.0 109.093 -179.323 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.878 HG23 HG22 ' A' ' 70' ' ' ILE . 20.1 p -89.72 -177.01 5.16 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 175.626 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.499 ' N ' ' OD1' ' B' ' 83' ' ' ASN . 3.4 t30 -100.01 25.16 7.67 Favored 'General case' 0 C--N 1.299 -1.622 0 O-C-N 121.07 -1.019 . . . . 0.0 108.332 172.414 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.833 ' HB3' HD21 ' A' ' 63' ' ' LEU . 86.8 mt -67.66 -39.96 84.52 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.996 -1.065 . . . . 0.0 109.933 176.551 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.802 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -54.88 -23.98 32.41 Favored Glycine 0 N--CA 1.485 1.909 0 N-CA-C 110.303 -1.119 . . . . 0.0 110.303 -177.52 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 21.9 p-10 -64.12 -17.02 63.05 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.962 -1.317 . . . . 0.0 110.32 -175.335 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.52 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 96.0 mt -60.08 141.48 55.7 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.262 -0.898 . . . . 0.0 110.476 -177.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 0.998 ' C ' HD23 ' A' ' 12' ' ' LEU . 59.8 mmtt -140.02 143.28 36.34 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-O 121.814 0.816 . . . . 0.0 110.4 175.807 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.596 ' CG2' HG13 ' A' ' 15' ' ' ILE . 35.9 t -63.08 149.51 10.28 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 O-C-N 121.252 -0.905 . . . . 0.0 110.235 -176.199 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.54 -13.79 63.05 Favored Glycine 0 N--CA 1.484 1.849 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 -175.338 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 46.3 t0 -96.23 163.13 13.22 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.346 -1.091 . . . . 0.0 109.587 176.167 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.579 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 13.7 m95 -113.89 162.15 16.73 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.062 -1.024 . . . . 0.0 110.201 176.52 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.041 ' CG1' ' HB3' ' A' ' 10' ' ' ALA . 1.6 p -130.8 140.24 49.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.543 0 O-C-N 121.514 -0.741 . . . . 0.0 110.16 -175.625 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.843 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -66.95 103.89 1.25 Allowed 'General case' 0 C--N 1.295 -1.795 0 O-C-N 121.095 -1.003 . . . . 0.0 109.46 169.07 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.732 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -106.58 137.63 36.2 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.816 0 O-C-N 120.537 -1.352 . . . . 0.0 111.414 -178.885 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.54 ' HB2' HG22 ' A' ' 6' ' ' VAL . 84.3 tt0 -132.73 131.66 41.46 Favored 'General case' 0 N--CA 1.494 1.77 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.072 179.703 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 75.9 ttt180 -72.18 139.2 48.11 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.151 -0.968 . . . . 0.0 110.972 -175.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.924 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -132.55 150.03 52.22 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.436 -0.79 . . . . 0.0 109.814 176.654 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -117.12 141.83 47.77 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.28 -0.888 . . . . 0.0 111.152 -174.116 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.2 mmtt -60.2 -40.08 88.82 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.476 -0.765 . . . . 0.0 110.3 -179.603 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 44.3 p90 -118.77 162.56 18.24 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.235 -0.916 . . . . 0.0 110.206 -178.615 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.419 ' O ' ' HG2' ' A' ' 93' ' ' GLU . 12.9 m -105.17 131.27 52.86 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.278 -0.889 . . . . 0.0 110.593 -175.453 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.526 ' O ' ' CG ' ' A' ' 93' ' ' GLU . 96.0 m-20 -61.6 -39.32 90.78 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.295 -0.878 . . . . 0.0 110.17 177.775 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.526 ' CG ' ' O ' ' A' ' 92' ' ' ASP . 8.4 pt-20 38.48 52.71 1.78 Allowed 'General case' 0 N--CA 1.512 2.674 0 CA-C-O 121.51 0.671 . . . . 0.0 110.208 -178.272 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.42 HG12 ' HB3' ' A' ' 92' ' ' ASP . 44.6 mm -70.0 -39.94 77.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.502 -0.749 . . . . 0.0 110.173 177.664 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 105.13 -94.3 0.99 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 -176.543 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.414 ' O ' ' HB2' ' A' ' 97' ' ' HIS . . . 84.49 -168.79 44.5 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 178.025 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . 0.414 ' HB2' ' O ' ' A' ' 96' ' ' GLY . 72.3 m-70 . . . . . 0 N--CA 1.491 1.593 0 O-C-N 121.386 -1.067 . . . . 0.0 110.283 -179.165 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 70.5 mtm . . . . . 0 N--CA 1.492 1.641 0 CA-C-O 121.252 0.549 . . . . 0.0 110.164 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.924 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 6.4 p90 -171.61 148.5 2.47 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 121.144 -0.973 . . . . 0.0 109.119 176.659 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.574 ' CB ' HG12 ' B' ' 5' ' ' ILE . 4.9 p -146.25 -37.76 0.24 Allowed 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.187 -0.946 . . . . 0.0 109.029 178.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.501 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 46.19 26.43 2.24 Favored Glycine 0 N--CA 1.484 1.864 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 -176.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 0.574 HG12 ' CB ' ' B' ' 3' ' ' THR . 28.0 mm -78.85 129.95 36.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.523 -0.986 . . . . 0.0 109.581 -178.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.851 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.2 t -92.98 140.36 16.44 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 120.986 -1.071 . . . . 0.0 111.124 -169.765 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 94.4 mm-40 -70.02 -34.73 73.66 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.715 -0.615 . . . . 0.0 111.137 176.826 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.528 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -156.56 172.81 34.33 Favored Glycine 0 N--CA 1.498 2.767 0 C-N-CA 118.814 -1.66 . . . . 0.0 110.599 -172.555 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.453 ' O ' ' HG3' ' B' ' 29' ' ' PRO . 12.5 p -117.7 172.35 7.42 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.074 -1.251 . . . . 0.0 111.01 -176.763 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.048 ' HB3' ' CG1' ' B' ' 82' ' ' VAL . . . -139.95 148.68 42.3 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.654 -0.653 . . . . 0.0 109.518 -178.791 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 37.6 tttt -107.38 115.42 30.12 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.146 -0.971 . . . . 0.0 110.246 179.829 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 1.011 HD23 ' C ' ' B' ' 77' ' ' LYS . 11.2 tp -60.03 126.67 28.44 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.058 -1.026 . . . . 0.0 108.956 173.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.057 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -125.14 -29.51 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.827 0 O-C-N 121.347 -0.846 . . . . 0.0 109.974 -179.366 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -149.88 142.27 24.29 Favored 'General case' 0 N--CA 1.493 1.688 0 C-N-CA 119.089 -1.044 . . . . 0.0 111.52 179.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.789 HG23 ' CD2' ' B' ' 24' ' ' HIS . 11.8 mt -105.41 137.15 36.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.065 -1.022 . . . . 0.0 110.137 171.606 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.524 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 86.4 m-20 -113.09 115.99 29.18 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.398 -0.814 . . . . 0.0 109.854 173.536 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 86.7 tt0 -105.83 115.24 29.9 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.895 -1.128 . . . . 0.0 110.754 -176.471 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 4.1 mtmt -110.45 127.67 26.62 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.188 -0.945 . . . . 0.0 108.925 171.636 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -52.34 -18.78 8.4 Favored 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.763 1.402 . . . . 0.0 110.744 -179.3 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.57 ' ND2' ' N ' ' B' ' 20' ' ' ASN . 0.3 OUTLIER -90.01 -36.22 15.06 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.174 -0.954 . . . . 0.0 108.659 177.044 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.515 ' CD2' ' HB2' ' B' ' 20' ' ' ASN . 81.7 m-85 -150.71 150.2 30.77 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.886 -0.509 . . . . 0.0 109.801 179.263 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.466 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 62.4 ttt180 -97.76 143.85 27.97 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.733 -1.229 . . . . 0.0 109.994 176.499 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.524 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 97.3 m -130.03 140.12 50.91 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.579 -0.7 . . . . 0.0 110.04 -173.335 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.789 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -129.99 135.94 48.86 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.045 -1.035 . . . . 0.0 111.186 179.179 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.754 HG22 ' OG ' ' B' ' 60' ' ' SER . 15.7 t -115.54 134.44 58.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.09 -1.006 . . . . 0.0 110.687 -178.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.47 ' O ' ' HA ' ' B' ' 58' ' ' HIS . 30.2 m -119.97 170.02 10.27 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 C-N-CA 120.46 -0.496 . . . . 0.0 109.957 -179.711 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.525 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 7.6 tt0 -103.51 117.13 33.74 Favored 'General case' 0 C--N 1.306 -1.299 0 O-C-N 121.455 -0.778 . . . . 0.0 108.968 -179.347 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.552 HD23 ' HA ' ' B' ' 33' ' ' LEU . 8.9 tp -82.05 119.77 75.86 Favored Pre-proline 0 C--N 1.294 -1.81 0 O-C-N 121.449 -0.782 . . . . 0.0 109.815 -173.678 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.468 ' HD2' ' HB2' ' B' ' 32' ' ' MET . 22.1 Cg_endo -65.42 179.08 1.75 Allowed 'Trans proline' 0 C--N 1.309 -1.52 0 O-C-N 123.829 1.437 . . . . 0.0 111.032 -179.327 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.419 ' OD1' ' C ' ' B' ' 30' ' ' ASP . 50.5 t0 -60.01 -41.26 91.78 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.413 -0.804 . . . . 0.0 111.134 -175.338 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.57 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.36 1.5 56.52 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.971 -1.08 . . . . 0.0 110.804 -174.236 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.57 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 96.4 mmm -110.97 -15.98 13.63 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.049 -1.032 . . . . 0.0 109.839 171.818 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.633 HD21 ' HB2' ' B' ' 57' ' ' ASN . 16.6 mt -68.01 -30.49 69.75 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.412 -0.805 . . . . 0.0 110.043 178.932 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -91.72 127.02 37.01 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.331 -0.856 . . . . 0.0 110.238 -179.635 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.3 -47.98 1.0 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 177.673 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.778 HD23 ' N ' ' B' ' 37' ' ' GLU . 7.4 tt -69.97 145.74 51.62 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.022 -1.281 . . . . 0.0 110.649 -175.758 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . 0.778 ' N ' HD23 ' B' ' 36' ' ' LEU . 20.7 pt-20 -150.44 169.99 20.14 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.505 -0.747 . . . . 0.0 109.608 -179.529 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.834 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -67.25 151.09 48.13 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.883 -1.136 . . . . 0.0 110.115 179.996 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 75.74 -0.09 62.4 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -176.211 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.458 ' O ' ' HA ' ' B' ' 50' ' ' THR . . . -79.85 158.94 26.63 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.281 -1.129 . . . . 0.0 109.656 177.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.551 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -100.94 113.24 26.02 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 120.993 -1.067 . . . . 0.0 110.075 176.7 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.597 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.0 t -104.89 130.02 56.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 O-C-N 121.285 -0.884 . . . . 0.0 109.111 174.764 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.519 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -93.22 119.53 32.5 Favored 'General case' 0 C--N 1.298 -1.645 0 C-N-CA 119.085 -1.046 . . . . 0.0 109.278 172.155 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.731 ' CG ' HG21 ' B' ' 82' ' ' VAL . 0.3 OUTLIER -88.0 107.03 18.53 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.416 -0.802 . . . . 0.0 109.066 178.503 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.51 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.1 t-20 50.44 16.23 0.27 Allowed 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.469 -0.77 . . . . 0.0 111.222 -166.506 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.493 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 120.82 1.23 11.81 Favored Glycine 0 N--CA 1.49 2.298 0 C-N-CA 119.407 -1.378 . . . . 0.0 111.086 171.158 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.779 ' O ' HD23 ' B' ' 49' ' ' LEU . 35.1 t -98.92 108.44 21.12 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 120.188 -1.772 . . . . 0.0 109.379 175.02 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . 0.507 ' SG ' ' C8 ' ' B' ' 99' ' ' RBF . 21.0 p -75.58 126.84 31.8 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.113 -0.992 . . . . 0.0 111.011 -171.172 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 0.983 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.4 OUTLIER -141.44 162.74 34.76 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.458 -0.776 . . . . 0.0 109.461 172.637 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . 0.458 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 55.0 m -102.44 152.97 20.5 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 120.612 -1.305 . . . . 0.0 111.037 -171.14 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.905 HG22 ' CE1' ' B' ' 61' ' ' PHE . 34.0 t -76.91 117.55 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.509 -0.745 . . . . 0.0 110.488 -177.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.676 HG22 ' HB3' ' B' ' 62' ' ' ASP . 40.9 p -70.02 -40.11 75.42 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.087 -1.008 . . . . 0.0 109.691 172.271 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.576 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 52.3 tp10 -164.68 156.14 15.39 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.252 -0.905 . . . . 0.0 110.838 -177.328 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.834 HD11 ' N ' ' B' ' 38' ' ' THR . 9.0 mt -110.44 130.02 64.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.236 -0.915 . . . . 0.0 110.029 172.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.52 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 63.7 m-80 -104.74 65.45 0.75 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-O 121.445 0.641 . . . . 0.0 109.482 177.823 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 77.13 -115.04 4.21 Favored Glycine 0 N--CA 1.486 2.005 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 -174.213 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.633 ' HB2' HD21 ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.01 -21.22 43.85 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.035 -1.273 . . . . 0.0 109.183 176.596 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.057 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.6 m170 -76.95 159.23 30.12 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.155 -0.966 . . . . 0.0 109.758 -178.036 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.81 HG13 HG13 ' B' ' 51' ' ' VAL . 59.5 t -140.83 121.52 13.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 C-N-CA 119.008 -1.077 . . . . 0.0 110.469 171.796 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.754 ' OG ' HG22 ' B' ' 25' ' ' VAL . 1.2 t -84.42 135.35 34.3 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.468 -0.77 . . . . 0.0 109.368 175.876 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.983 ' HB3' HD12 ' B' ' 49' ' ' LEU . 58.7 m-85 -115.47 158.72 22.15 Favored 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.287 -0.883 . . . . 0.0 110.165 179.012 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.676 ' HB3' HG22 ' B' ' 52' ' ' THR . 25.1 p-10 -92.25 147.48 22.89 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.08 -1.013 . . . . 0.0 110.876 178.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.8 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -159.69 125.09 4.12 Favored 'General case' 0 C--N 1.295 -1.79 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -176.885 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.533 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 56.1 ttm -84.92 146.4 27.28 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.966 -1.084 . . . . 0.0 109.388 -177.811 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.428 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 71.3 tttt -60.03 -49.14 78.84 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.104 -0.998 . . . . 0.0 109.977 -177.205 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 53.5 tp10 -69.6 -39.99 76.91 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.149 -0.969 . . . . 0.0 110.444 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.554 ' O ' HG23 ' B' ' 71' ' ' THR . 38.5 m -62.26 -38.83 90.8 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.935 -1.103 . . . . 0.0 108.98 174.449 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.827 HD11 ' HA2' ' B' ' 74' ' ' GLY . 1.0 OUTLIER -59.9 -47.28 86.43 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.436 -0.79 . . . . 0.0 109.8 177.398 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 74.9 ttt-85 -65.83 -39.99 91.36 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.54 -0.725 . . . . 0.0 110.513 178.173 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.885 HG22 HG23 ' B' ' 71' ' ' THR . 1.3 tt -64.2 -41.19 91.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.285 -0.885 . . . . 0.0 109.13 -179.381 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.885 HG23 HG22 ' B' ' 70' ' ' ILE . 20.4 p -89.7 -176.85 5.11 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 120.236 -0.586 . . . . 0.0 109.433 175.602 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.527 ' CB ' ' H ' ' A' ' 83' ' ' ASN . 3.5 t30 -100.0 25.09 7.73 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.079 -1.013 . . . . 0.0 108.307 172.336 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.8 ' HB3' HD21 ' B' ' 63' ' ' LEU . 86.6 mt -67.69 -39.94 84.38 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.995 -1.066 . . . . 0.0 109.945 176.609 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.827 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -54.86 -23.95 32.12 Favored Glycine 0 N--CA 1.485 1.914 0 N-CA-C 110.321 -1.112 . . . . 0.0 110.321 -177.527 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 21.5 p-10 -64.1 -17.02 63.02 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.006 -1.29 . . . . 0.0 110.349 -175.381 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 96.1 mt -60.0 141.41 55.68 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.252 -0.905 . . . . 0.0 110.484 -177.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 1.011 ' C ' HD23 ' B' ' 12' ' ' LEU . 59.8 mmtt -139.93 143.29 36.53 Favored 'General case' 0 C--N 1.296 -1.718 0 CA-C-O 121.555 0.693 . . . . 0.0 110.446 175.771 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.598 ' N ' HD23 ' B' ' 12' ' ' LEU . 36.5 t -63.19 149.47 10.38 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 C-N-CA 119.602 -0.839 . . . . 0.0 110.22 -176.152 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.48 -13.53 63.64 Favored Glycine 0 N--CA 1.483 1.808 0 N-CA-C 108.818 -1.713 . . . . 0.0 108.818 -175.3 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 46.0 t0 -96.27 162.99 13.27 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.27 -1.135 . . . . 0.0 109.629 175.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.582 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 13.6 m95 -113.9 162.05 16.86 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.09 -1.007 . . . . 0.0 110.178 176.598 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.048 ' CG1' ' HB3' ' B' ' 10' ' ' ALA . 1.5 p -130.78 140.31 49.02 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.545 -0.722 . . . . 0.0 110.179 -175.78 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.851 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.2 OUTLIER -66.87 103.78 1.21 Allowed 'General case' 0 C--N 1.296 -1.746 0 O-C-N 121.115 -0.991 . . . . 0.0 109.549 169.089 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.746 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -106.48 137.92 34.58 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 120.589 -1.319 . . . . 0.0 111.28 -178.692 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . 0.541 ' HB2' HG22 ' B' ' 6' ' ' VAL . 84.3 tt0 -133.03 131.64 40.91 Favored 'General case' 0 N--CA 1.493 1.7 0 CA-C-N 116.022 -0.536 . . . . 0.0 110.036 179.681 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 75.9 ttt180 -72.11 139.17 48.24 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.25 -0.906 . . . . 0.0 110.955 -175.849 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 1.031 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -132.48 150.26 52.19 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.389 -0.82 . . . . 0.0 109.749 176.623 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -117.43 141.89 47.79 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.257 -0.902 . . . . 0.0 111.02 -174.099 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 20.2 mmtt -60.35 -39.93 88.91 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.369 -0.832 . . . . 0.0 110.287 -179.541 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 44.4 p90 -118.81 162.59 18.22 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.254 -0.904 . . . . 0.0 110.227 -178.741 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . 0.415 ' OG ' HD12 ' B' ' 94' ' ' ILE . 12.9 m -105.12 131.37 52.7 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.265 -0.897 . . . . 0.0 110.643 -175.447 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 95.8 m-20 -61.88 -39.95 93.7 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.335 -0.853 . . . . 0.0 110.36 177.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . 0.413 ' O ' ' HG3' ' B' ' 93' ' ' GLU . 21.5 pt-20 -159.17 53.61 0.4 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.095 -1.003 . . . . 0.0 110.491 -177.294 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . 0.415 HD12 ' OG ' ' B' ' 91' ' ' SER . 28.0 mt -124.22 13.9 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.256 -0.903 . . . . 0.0 110.25 179.757 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . . . . . . . . . . . -69.08 64.39 0.51 Allowed Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -178.248 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . 0.42 ' O ' ' HB3' ' B' ' 97' ' ' HIS . . . 95.68 37.36 5.03 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.779 -1.329 . . . . 0.0 109.779 177.712 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . 0.42 ' HB3' ' O ' ' B' ' 96' ' ' GLY . 22.2 t-80 . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.197 -1.178 . . . . 0.0 110.156 179.43 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 0.501 ' C8 ' ' SG ' ' A' ' 48' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 0.507 ' C8 ' ' SG ' ' B' ' 48' ' ' CYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.473 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 76.6 mtm . . . . . 0 N--CA 1.493 1.701 0 CA-C-O 121.116 0.484 . . . . 0.0 110.139 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.972 ' CE2' ' HB1' ' B' ' 87' ' ' ALA . 7.3 p90 -179.09 139.97 0.16 Allowed 'General case' 0 C--N 1.307 -1.253 0 O-C-N 121.328 -0.857 . . . . 0.0 108.974 178.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.541 ' CB ' HG12 ' A' ' 5' ' ' ILE . 11.1 p -130.85 -36.71 1.35 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 120.973 -1.079 . . . . 0.0 109.176 -176.54 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.508 ' HA3' ' O ' ' B' ' 46' ' ' GLY . . . 55.12 20.31 20.19 Favored Glycine 0 N--CA 1.484 1.835 0 N-CA-C 108.689 -1.764 . . . . 0.0 108.689 -179.27 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.557 HD11 ' C9 ' ' B' ' 99' ' ' RBF . 32.1 mm -80.89 125.06 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.442 -1.034 . . . . 0.0 109.579 -176.701 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.852 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.9 t -82.93 143.53 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.014 -1.054 . . . . 0.0 111.408 -167.372 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.463 ' HG2' ' HG3' ' A' ' 85' ' ' GLU . 89.5 mm-40 -70.02 -38.59 75.95 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.662 -0.649 . . . . 0.0 110.294 173.349 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.523 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -168.3 -176.52 38.76 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 119.404 -1.379 . . . . 0.0 109.816 -176.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.472 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 1.1 p -120.78 171.83 8.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.96 -1.317 . . . . 0.0 110.859 -177.431 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.072 ' HB3' HG13 ' A' ' 82' ' ' VAL . . . -140.3 149.92 43.38 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.556 -0.715 . . . . 0.0 109.531 -178.221 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.584 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 35.2 tttt -105.52 116.02 31.24 Favored 'General case' 0 C--N 1.296 -1.753 0 O-C-N 120.922 -1.111 . . . . 0.0 110.138 178.597 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 1.025 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.9 tp -59.83 128.48 37.14 Favored 'General case' 0 C--N 1.297 -1.703 0 O-C-N 120.863 -1.148 . . . . 0.0 108.69 172.558 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.12 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.6 p -129.41 -29.3 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 C-N-CA 119.597 -0.841 . . . . 0.0 110.291 -177.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.68 142.36 26.66 Favored 'General case' 0 N--CA 1.495 1.79 0 C-N-CA 118.948 -1.101 . . . . 0.0 111.534 179.368 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.825 HG23 ' CD2' ' A' ' 24' ' ' HIS . 10.9 mt -107.81 135.71 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.037 -1.039 . . . . 0.0 110.174 171.653 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.494 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 83.5 m-20 -110.14 114.56 28.15 Favored 'General case' 0 C--N 1.295 -1.769 0 O-C-N 121.308 -0.87 . . . . 0.0 110.272 173.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -101.91 109.6 21.38 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.175 -0.953 . . . . 0.0 110.421 -178.231 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.462 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 1.4 mtpt -103.87 134.54 19.67 Favored Pre-proline 0 N--CA 1.492 1.657 0 O-C-N 121.056 -1.028 . . . . 0.0 109.424 175.272 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -52.58 -18.31 8.26 Favored 'Trans proline' 0 C--N 1.303 -1.843 0 O-C-N 123.995 1.524 . . . . 0.0 110.802 -179.616 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.581 ' HB2' ' CD2' ' A' ' 21' ' ' PHE . 0.3 OUTLIER -99.28 -32.77 11.03 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.143 -0.973 . . . . 0.0 109.138 -179.906 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.581 ' CD2' ' HB2' ' A' ' 20' ' ' ASN . 56.3 m-85 -150.48 150.21 31.0 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.835 -0.54 . . . . 0.0 110.144 -175.747 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.475 ' HB3' ' O ' ' A' ' 63' ' ' LEU . 56.1 ttt180 -94.02 143.33 26.45 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 120.639 -1.288 . . . . 0.0 110.055 173.14 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.494 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 44.5 m -129.99 139.22 51.09 Favored 'General case' 0 C--N 1.296 -1.743 0 O-C-N 121.564 -0.71 . . . . 0.0 109.818 -175.315 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.825 ' CD2' HG23 ' A' ' 15' ' ' ILE . 0.3 OUTLIER -130.0 135.46 48.32 Favored 'General case' 0 C--N 1.3 -1.563 0 O-C-N 120.862 -1.149 . . . . 0.0 111.312 179.377 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.765 HG22 ' CB ' ' A' ' 60' ' ' SER . 4.8 t -117.47 131.91 68.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.085 -1.01 . . . . 0.0 110.731 -176.791 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.578 HG22 ' HE2' ' A' ' 61' ' ' PHE . 7.0 m -113.63 172.32 3.52 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.94 -0.475 . . . . 0.0 110.061 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.544 ' HG3' ' CD2' ' A' ' 58' ' ' HIS . 7.1 tt0 -105.34 117.27 33.59 Favored 'General case' 0 C--N 1.304 -1.381 0 O-C-N 121.427 -0.795 . . . . 0.0 108.948 178.567 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.565 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.0 tp -83.55 121.05 76.32 Favored Pre-proline 0 C--N 1.296 -1.751 0 O-C-N 121.632 -0.668 . . . . 0.0 109.943 -172.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.473 ' O ' ' HG ' ' A' ' 33' ' ' LEU . 25.1 Cg_endo -66.27 176.0 4.4 Favored 'Trans proline' 0 C--N 1.309 -1.539 0 O-C-N 123.9 1.474 . . . . 0.0 111.007 -179.372 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.55 ' HA ' HD12 ' A' ' 33' ' ' LEU . 51.2 t0 -60.07 -39.97 87.9 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.424 -0.798 . . . . 0.0 111.049 -175.177 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.599 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.08 0.35 57.18 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.939 -1.1 . . . . 0.0 110.785 -174.917 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.599 ' HG2' ' CE1' ' A' ' 31' ' ' HIS . 98.0 mmm -113.06 -11.03 13.4 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.959 -1.088 . . . . 0.0 110.053 172.328 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.586 ' CD2' ' HA ' ' A' ' 57' ' ' ASN . 15.7 mt -69.98 -32.32 70.46 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.304 -0.872 . . . . 0.0 109.923 177.629 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -79.91 139.91 36.92 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.512 -0.742 . . . . 0.0 111.009 -176.156 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 93.01 -38.43 3.17 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 120.024 -1.084 . . . . 0.0 110.645 171.786 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.47 HD23 ' CD2' ' A' ' 28' ' ' LEU . 64.7 tp -77.99 147.72 34.74 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.787 -1.42 . . . . 0.0 111.102 -174.015 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.512 ' C ' HD11 ' A' ' 54' ' ' ILE . 20.6 pt-20 -149.23 170.04 19.39 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.459 -0.775 . . . . 0.0 109.322 175.216 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.856 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -62.96 151.94 38.1 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.931 -1.106 . . . . 0.0 110.027 -178.688 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.24 -3.48 62.11 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -176.225 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.464 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -77.1 158.72 30.3 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.242 -1.152 . . . . 0.0 109.491 176.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.557 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 0.2 OUTLIER -100.97 110.05 22.04 Favored 'General case' 0 N--CA 1.485 1.295 0 O-C-N 120.901 -1.124 . . . . 0.0 110.045 178.567 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.673 HG11 ' HE1' ' A' ' 44' ' ' HIS . 2.0 t -98.99 129.94 48.64 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 O-C-N 121.212 -0.93 . . . . 0.0 109.155 174.782 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.516 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -95.51 119.95 34.9 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 119.244 -0.982 . . . . 0.0 109.227 172.093 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.673 ' HE1' HG11 ' A' ' 42' ' ' VAL . 0.6 OUTLIER -88.25 106.97 18.56 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 177.789 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.495 ' O ' ' O ' ' B' ' 45' ' ' ASN . 1.9 t-20 55.33 13.76 0.96 Allowed 'General case' 0 C--N 1.299 -1.598 0 O-C-N 121.329 -0.857 . . . . 0.0 110.91 -167.326 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.51 ' O ' ' HA3' ' B' ' 4' ' ' GLY . . . 117.56 -0.5 18.23 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 119.508 -1.329 . . . . 0.0 110.615 172.797 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.78 ' O ' HD23 ' A' ' 49' ' ' LEU . 36.6 t -93.54 105.59 17.63 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.477 -1.602 . . . . 0.0 109.423 175.728 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 25.0 p -73.73 129.44 37.92 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.193 -0.942 . . . . 0.0 111.183 -170.747 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.992 HD12 ' HB3' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -145.39 160.57 41.36 Favored 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 172.841 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 21.3 m -96.3 152.95 18.1 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.534 -1.354 . . . . 0.0 111.175 -170.095 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.784 HG13 HG13 ' A' ' 59' ' ' VAL . 21.2 t -76.96 112.11 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.775 -0.578 . . . . 0.0 110.037 178.695 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.575 HG22 ' HB3' ' A' ' 62' ' ' ASP . 33.9 p -69.39 -40.05 77.61 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.119 -0.988 . . . . 0.0 109.556 173.757 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.567 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.4 tt0 -160.59 156.13 25.21 Favored 'General case' 0 N--CA 1.49 1.557 0 C-N-CA 119.383 -0.927 . . . . 0.0 110.895 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.856 HD11 ' N ' ' A' ' 38' ' ' THR . 7.8 mt -109.97 130.47 63.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.211 -0.931 . . . . 0.0 109.73 172.598 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.508 ' HB2' ' HB2' ' A' ' 58' ' ' HIS . 46.6 m-80 -104.45 65.03 0.76 Allowed 'General case' 0 C--N 1.296 -1.741 0 C-N-CA 119.822 -0.751 . . . . 0.0 109.567 178.13 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.46 -114.91 4.42 Favored Glycine 0 N--CA 1.487 2.1 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 -173.609 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.586 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -80.02 -19.74 47.0 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.078 -1.248 . . . . 0.0 109.119 176.645 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.12 ' CD2' HG11 ' A' ' 13' ' ' VAL . 9.8 m170 -76.61 159.0 30.66 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.256 -0.903 . . . . 0.0 110.061 -178.663 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.784 HG13 HG13 ' A' ' 51' ' ' VAL . 54.0 t -141.45 122.52 12.97 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 O-C-N 121.01 -1.056 . . . . 0.0 111.029 173.655 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.765 ' CB ' HG22 ' A' ' 25' ' ' VAL . 17.4 m -91.83 127.48 37.31 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.655 -0.653 . . . . 0.0 109.897 179.581 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.992 ' HB3' HD12 ' A' ' 49' ' ' LEU . 54.4 m-85 -111.59 160.81 16.85 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.869 -1.145 . . . . 0.0 110.243 179.224 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.575 ' HB3' HG22 ' A' ' 52' ' ' THR . 38.1 p-10 -92.01 148.63 22.05 Favored 'General case' 0 N--CA 1.496 1.858 0 CA-C-O 122.065 0.936 . . . . 0.0 111.321 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 0.713 HD21 ' HB3' ' A' ' 73' ' ' LEU . 0.0 OUTLIER -156.01 118.55 4.13 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 -177.304 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.532 ' HB2' ' HB ' ' A' ' 67' ' ' THR . 74.3 mmm -73.0 142.73 47.74 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.937 -1.102 . . . . 0.0 109.514 179.088 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.487 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 38.5 tttp -60.0 -44.9 94.24 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.007 -1.058 . . . . 0.0 110.091 -177.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.47 ' O ' ' HB ' ' A' ' 70' ' ' ILE . 86.6 tt0 -70.04 -39.95 75.44 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.01 -1.056 . . . . 0.0 110.105 179.109 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.628 HG21 ' O2 ' ' A' ' 98' ' ' RBF . 93.8 m -60.05 -39.37 85.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.923 -1.111 . . . . 0.0 109.286 172.31 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 0.745 HD11 ' HA2' ' A' ' 74' ' ' GLY . 9.3 tp -59.95 -44.95 94.07 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.199 -0.938 . . . . 0.0 109.348 -179.638 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 61.0 ttt180 -69.93 -39.92 75.83 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.517 -0.739 . . . . 0.0 110.686 175.528 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.81 HG22 HG23 ' A' ' 71' ' ' THR . 1.4 tt -66.85 -42.61 89.35 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.349 0 O-C-N 121.164 -0.96 . . . . 0.0 109.386 -176.289 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.81 HG23 HG22 ' A' ' 70' ' ' ILE . 43.6 p -84.74 -174.1 5.09 Favored 'General case' 0 C--N 1.297 -1.687 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 175.642 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.472 ' O ' ' OD1' ' A' ' 72' ' ' ASN . 6.7 t30 -102.17 24.02 10.78 Favored 'General case' 0 C--N 1.294 -1.806 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 170.898 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.755 HD11 ' SG ' ' A' ' 47' ' ' CYS . 98.0 mt -69.98 -40.04 75.57 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.136 -0.978 . . . . 0.0 109.734 176.455 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.745 ' HA2' HD11 ' A' ' 68' ' ' LEU . . . -49.55 -22.91 4.24 Favored Glycine 0 N--CA 1.487 2.047 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.381 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 25.6 p-10 -63.61 -19.33 64.76 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.014 -1.286 . . . . 0.0 110.357 -175.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.514 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 97.4 mt -61.33 140.43 58.0 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.148 -0.97 . . . . 0.0 110.962 -176.769 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 1.025 ' C ' HD23 ' A' ' 12' ' ' LEU . 22.8 mttm -141.44 139.35 33.36 Favored 'General case' 0 C--N 1.296 -1.726 0 CA-C-O 121.479 0.657 . . . . 0.0 109.559 174.356 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.703 ' N ' HD23 ' A' ' 12' ' ' LEU . 44.0 t -60.93 151.46 6.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 O-C-N 120.924 -1.11 . . . . 0.0 110.327 -176.338 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.97 -14.66 61.35 Favored Glycine 0 N--CA 1.482 1.746 0 N-CA-C 108.751 -1.739 . . . . 0.0 108.751 -175.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -98.16 167.12 11.07 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.31 -1.112 . . . . 0.0 109.626 175.311 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.584 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 15.5 m95 -115.37 156.72 25.02 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.104 -0.997 . . . . 0.0 110.134 177.092 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.072 HG13 ' HB3' ' A' ' 10' ' ' ALA . 0.9 OUTLIER -120.13 155.15 23.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 O-C-N 121.527 -0.733 . . . . 0.0 109.892 -178.124 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 0.852 ' HB3' HG21 ' A' ' 6' ' ' VAL . 2.5 m-20 -80.02 106.75 12.27 Favored 'General case' 0 C--N 1.297 -1.708 0 O-C-N 121.21 -0.931 . . . . 0.0 108.988 168.793 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.716 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.0 OUTLIER -107.25 138.6 32.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.55 -1.344 . . . . 0.0 111.039 -175.223 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.463 ' HG3' ' HG2' ' A' ' 7' ' ' GLN . 86.4 tt0 -136.83 135.34 37.84 Favored 'General case' 0 N--CA 1.492 1.632 0 C-N-CA 120.381 -0.528 . . . . 0.0 109.752 -178.355 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -78.67 129.92 35.27 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.055 -1.028 . . . . 0.0 110.618 -176.212 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.908 ' HB1' ' CE2' ' B' ' 2' ' ' PHE . . . -121.13 145.6 47.64 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.401 -0.812 . . . . 0.0 110.199 178.298 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . . . . . . . . . . . -128.12 141.17 51.57 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.799 -0.563 . . . . 0.0 110.352 -178.662 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 12.1 pttt -69.99 -21.01 63.27 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.234 -0.916 . . . . 0.0 110.008 177.469 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 39.9 p90 -141.15 160.33 40.33 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.05 -1.031 . . . . 0.0 110.119 174.764 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.464 ' OG ' ' HG3' ' A' ' 93' ' ' GLU . 74.4 p -140.25 149.94 43.48 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.305 -0.872 . . . . 0.0 110.282 176.556 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.403 ' O ' ' HB2' ' A' ' 93' ' ' GLU . 51.9 t0 -69.99 -39.98 75.57 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.267 -0.896 . . . . 0.0 110.185 178.331 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.464 ' HG3' ' OG ' ' A' ' 91' ' ' SER . 98.9 mt-10 51.85 54.76 10.36 Favored 'General case' 0 N--CA 1.504 2.269 0 O-C-N 121.164 -0.96 . . . . 0.0 109.919 176.413 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.432 ' O ' ' C ' ' A' ' 95' ' ' GLY . 40.6 mm -59.98 -41.27 85.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.366 -0.834 . . . . 0.0 109.862 178.268 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' A' ' 94' ' ' ILE . . . 41.28 57.86 3.01 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.91 -1.276 . . . . 0.0 109.91 178.647 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . . . . . . . . . . . -86.99 -9.23 74.27 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 179.81 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 41.5 m80 . . . . . 0 N--CA 1.492 1.652 0 O-C-N 121.267 -1.137 . . . . 0.0 110.227 -179.501 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . 0.4 ' HG2' ' N ' ' B' ' 2' ' ' PHE . 60.2 ttm . . . . . 0 N--CA 1.494 1.738 0 CA-C-O 121.156 0.503 . . . . 0.0 110.24 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.908 ' CE2' ' HB1' ' A' ' 87' ' ' ALA . 7.0 p90 -174.14 139.79 0.65 Allowed 'General case' 0 C--N 1.306 -1.314 0 O-C-N 121.173 -0.955 . . . . 0.0 108.961 174.259 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.555 ' CB ' HG12 ' B' ' 5' ' ' ILE . 11.0 p -130.89 -36.68 1.35 Allowed 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.016 -1.052 . . . . 0.0 109.17 -176.602 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.51 ' HA3' ' O ' ' A' ' 46' ' ' GLY . . . 55.04 20.3 19.5 Favored Glycine 0 N--CA 1.484 1.872 0 N-CA-C 108.645 -1.782 . . . . 0.0 108.645 -179.252 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 0.555 HG12 ' CB ' ' B' ' 3' ' ' THR . 32.7 mm -80.81 125.07 39.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.412 -1.052 . . . . 0.0 109.505 -176.658 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 0.809 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.9 t -83.03 143.53 11.81 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 120.995 -1.066 . . . . 0.0 111.42 -167.406 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . 0.47 ' HG2' ' HG3' ' B' ' 85' ' ' GLU . 89.6 mm-40 -70.02 -38.31 75.86 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.694 -0.629 . . . . 0.0 110.371 173.437 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.522 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -168.6 -176.65 39.02 Favored Glycine 0 N--CA 1.494 2.556 0 C-N-CA 119.478 -1.344 . . . . 0.0 109.854 -177.013 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.48 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 1.1 p -120.73 171.83 8.32 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.039 -1.271 . . . . 0.0 110.918 -177.401 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.066 ' HB3' HG13 ' B' ' 82' ' ' VAL . . . -140.29 149.94 43.42 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.533 -0.729 . . . . 0.0 109.444 -178.18 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.581 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 35.3 tttt -105.51 116.13 31.42 Favored 'General case' 0 C--N 1.296 -1.724 0 O-C-N 121.057 -1.027 . . . . 0.0 110.087 178.531 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 1.024 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.9 tp -60.03 128.31 36.21 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.971 -1.081 . . . . 0.0 108.781 172.461 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.128 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.6 p -129.12 -29.53 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 C-N-CA 119.565 -0.854 . . . . 0.0 110.296 -177.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.57 142.33 26.74 Favored 'General case' 0 N--CA 1.493 1.692 0 C-N-CA 119.072 -1.051 . . . . 0.0 111.501 179.454 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.828 HG23 ' CD2' ' B' ' 24' ' ' HIS . 10.9 mt -107.76 135.84 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.116 -0.99 . . . . 0.0 110.207 171.606 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.504 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 83.2 m-20 -110.33 114.69 28.35 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.443 -0.785 . . . . 0.0 110.184 173.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -101.91 109.53 21.29 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.099 -1.001 . . . . 0.0 110.443 -178.25 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.458 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 1.4 mtpt -103.88 134.6 19.63 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.218 -0.926 . . . . 0.0 109.546 175.196 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -52.73 -18.2 8.48 Favored 'Trans proline' 0 C--N 1.303 -1.868 0 O-C-N 123.952 1.501 . . . . 0.0 110.747 -179.461 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.583 ' HB2' ' CD2' ' B' ' 21' ' ' PHE . 0.3 OUTLIER -99.04 -33.46 10.8 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.154 -0.966 . . . . 0.0 109.044 -179.966 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.583 ' CD2' ' HB2' ' B' ' 20' ' ' ASN . 56.2 m-85 -149.96 150.31 31.64 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 120.327 -0.549 . . . . 0.0 110.176 -175.634 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.473 ' HB3' ' O ' ' B' ' 63' ' ' LEU . 56.1 ttt180 -94.01 143.42 26.37 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.757 -1.214 . . . . 0.0 110.008 173.101 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.504 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 42.9 m -130.09 139.3 50.97 Favored 'General case' 0 C--N 1.299 -1.629 0 O-C-N 121.745 -0.597 . . . . 0.0 109.736 -175.367 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.828 ' CD2' HG23 ' B' ' 15' ' ' ILE . 0.3 OUTLIER -130.02 135.64 48.5 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 120.984 -1.073 . . . . 0.0 111.227 179.347 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.764 HG22 ' CB ' ' B' ' 60' ' ' SER . 4.8 t -117.42 131.99 68.52 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.262 -0.899 . . . . 0.0 110.769 -176.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.585 HG22 ' HE2' ' B' ' 61' ' ' PHE . 7.2 m -113.79 172.24 3.62 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 O-C-N 121.909 -0.495 . . . . 0.0 110.025 179.234 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.549 ' HG3' ' CD2' ' B' ' 58' ' ' HIS . 7.0 tt0 -105.09 117.32 33.7 Favored 'General case' 0 C--N 1.305 -1.337 0 O-C-N 121.466 -0.771 . . . . 0.0 109.118 178.413 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.552 HD23 ' HA ' ' B' ' 33' ' ' LEU . 8.9 tp -83.51 120.99 76.35 Favored Pre-proline 0 C--N 1.295 -1.779 0 O-C-N 121.555 -0.716 . . . . 0.0 110.028 -172.944 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.465 ' O ' ' HG ' ' B' ' 33' ' ' LEU . 25.6 Cg_endo -66.16 175.97 4.33 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 O-C-N 123.856 1.45 . . . . 0.0 111.005 -179.41 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.529 ' HA ' HD12 ' B' ' 33' ' ' LEU . 51.3 t0 -60.02 -40.07 88.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.448 -0.783 . . . . 0.0 111.061 -175.27 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.605 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.02 0.34 57.16 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.884 -1.135 . . . . 0.0 110.851 -174.925 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.605 ' HG2' ' CE1' ' B' ' 31' ' ' HIS . 98.0 mmm -113.05 -11.2 13.39 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.105 -0.997 . . . . 0.0 110.053 172.377 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.59 ' CD2' ' HA ' ' B' ' 57' ' ' ASN . 15.8 mt -69.89 -32.21 70.41 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.35 -0.844 . . . . 0.0 110.022 177.628 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -80.11 139.96 36.64 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.545 -0.722 . . . . 0.0 110.927 -176.16 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 92.92 -38.4 3.17 Favored Glycine 0 N--CA 1.493 2.442 0 C-N-CA 119.965 -1.112 . . . . 0.0 110.581 171.799 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.478 HD23 ' CD2' ' B' ' 28' ' ' LEU . 64.5 tp -77.97 147.68 34.8 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.93 -1.335 . . . . 0.0 111.146 -174.101 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . 0.491 ' C ' HD11 ' B' ' 54' ' ' ILE . 20.6 pt-20 -149.13 170.03 19.35 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.466 -0.771 . . . . 0.0 109.323 175.269 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.863 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -62.99 151.79 38.66 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.932 -1.105 . . . . 0.0 110.071 -178.8 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.34 -3.51 62.37 Favored Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -176.159 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.457 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -77.18 158.58 30.27 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.184 -1.186 . . . . 0.0 109.446 176.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.565 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 0.2 OUTLIER -100.65 109.84 21.93 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 120.904 -1.123 . . . . 0.0 110.14 178.537 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.657 HG11 ' HE1' ' B' ' 44' ' ' HIS . 2.0 t -99.0 129.9 48.71 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.284 -0.885 . . . . 0.0 109.171 174.713 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.514 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -95.44 120.01 34.94 Favored 'General case' 0 C--N 1.298 -1.664 0 C-N-CA 119.204 -0.999 . . . . 0.0 109.199 172.06 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.657 ' HE1' HG11 ' B' ' 42' ' ' VAL . 0.6 OUTLIER -88.29 106.79 18.45 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.408 -0.807 . . . . 0.0 108.915 177.691 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.495 ' O ' ' O ' ' A' ' 45' ' ' ASN . 1.9 t-20 55.5 13.88 1.05 Allowed 'General case' 0 C--N 1.299 -1.597 0 O-C-N 121.333 -0.854 . . . . 0.0 110.888 -167.346 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.508 ' O ' ' HA3' ' A' ' 4' ' ' GLY . . . 117.46 -0.32 18.44 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.513 -1.327 . . . . 0.0 110.612 172.671 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.797 ' O ' HD23 ' B' ' 49' ' ' LEU . 36.7 t -93.66 105.59 17.62 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.536 -1.567 . . . . 0.0 109.439 175.67 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . . . . . . . . . 25.1 p -73.65 129.56 38.21 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.084 -1.01 . . . . 0.0 111.079 -170.707 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 1.009 HD12 ' HB3' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -145.61 160.54 41.52 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 172.714 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . . . . . . . . . 21.3 m -96.14 153.05 18.0 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.703 -1.248 . . . . 0.0 111.181 -170.021 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.79 HG13 HG13 ' B' ' 59' ' ' VAL . 21.2 t -77.06 112.05 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.652 -0.655 . . . . 0.0 110.126 178.598 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.552 HG22 ' HB3' ' B' ' 62' ' ' ASP . 34.5 p -69.54 -39.91 77.18 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.168 -0.958 . . . . 0.0 109.462 173.986 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.568 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.4 tt0 -160.64 156.1 25.05 Favored 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 119.45 -0.9 . . . . 0.0 110.861 -179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.863 HD11 ' N ' ' B' ' 38' ' ' THR . 7.8 mt -110.01 130.42 63.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.259 -0.901 . . . . 0.0 109.728 172.651 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.524 ' HB2' ' HB2' ' B' ' 58' ' ' HIS . 46.6 m-80 -104.55 65.03 0.76 Allowed 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.7 -0.8 . . . . 0.0 109.575 178.151 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 75.61 -114.94 4.4 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 108.716 -1.754 . . . . 0.0 108.716 -173.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.59 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -80.03 -19.66 47.15 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.05 -1.265 . . . . 0.0 109.194 176.645 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.128 ' CD2' HG11 ' B' ' 13' ' ' VAL . 9.9 m170 -76.6 158.78 30.84 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.359 -0.838 . . . . 0.0 110.096 -178.698 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.79 HG13 HG13 ' B' ' 51' ' ' VAL . 54.4 t -141.32 122.64 13.46 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 C-N-CA 119.02 -1.072 . . . . 0.0 110.967 173.735 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.764 ' CB ' HG22 ' B' ' 25' ' ' VAL . 17.4 m -91.92 127.56 37.43 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.767 -0.583 . . . . 0.0 109.953 179.554 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 1.009 ' HB3' HD12 ' B' ' 49' ' ' LEU . 54.4 m-85 -111.55 160.81 16.83 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.056 -1.027 . . . . 0.0 110.314 179.258 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.552 ' HB3' HG22 ' B' ' 52' ' ' THR . 38.0 p-10 -92.0 148.66 22.03 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.135 -0.978 . . . . 0.0 111.269 179.805 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 0.745 HD21 ' HB3' ' B' ' 73' ' ' LEU . 0.0 OUTLIER -156.0 118.48 4.12 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 -177.354 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.528 ' HB2' ' CB ' ' B' ' 67' ' ' THR . 74.2 mmm -73.01 142.77 47.72 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.907 -1.12 . . . . 0.0 109.481 179.147 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.484 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 38.5 tttp -59.98 -44.92 94.17 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.091 -1.005 . . . . 0.0 110.075 -177.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . 0.478 ' O ' ' HB ' ' B' ' 70' ' ' ILE . 86.6 tt0 -69.99 -40.06 75.52 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.047 -1.033 . . . . 0.0 110.062 179.196 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.632 HG21 ' O2 ' ' B' ' 99' ' ' RBF . 94.2 m -59.96 -39.53 85.92 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.923 -1.111 . . . . 0.0 109.144 172.41 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 0.754 HD11 ' HA2' ' B' ' 74' ' ' GLY . 9.4 tp -60.07 -44.71 94.56 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.428 -0.795 . . . . 0.0 109.436 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 61.1 ttt180 -70.04 -39.92 75.44 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.498 -0.751 . . . . 0.0 110.673 175.372 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.791 HG22 HG23 ' B' ' 71' ' ' THR . 1.4 tt -66.77 -42.52 89.47 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 O-C-N 121.263 -0.898 . . . . 0.0 109.421 -176.368 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.791 HG23 HG22 ' B' ' 70' ' ' ILE . 43.8 p -84.74 -173.85 4.95 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 175.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.48 ' HB3' ' HB2' ' A' ' 83' ' ' ASN . 6.7 t30 -102.31 24.06 10.82 Favored 'General case' 0 C--N 1.295 -1.783 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 170.855 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.751 HD11 ' SG ' ' B' ' 47' ' ' CYS . 98.0 mt -69.99 -40.1 75.53 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.192 -0.942 . . . . 0.0 109.745 176.403 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.754 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -49.59 -22.91 4.31 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 -179.396 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.515 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 25.7 p-10 -63.55 -19.38 64.75 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.031 -1.276 . . . . 0.0 110.374 -175.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.515 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 97.5 mt -61.27 140.47 57.96 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.199 -0.938 . . . . 0.0 110.915 -176.786 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 1.024 ' C ' HD23 ' B' ' 12' ' ' LEU . 22.8 mttm -141.39 139.38 33.47 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-O 121.336 0.589 . . . . 0.0 109.556 174.322 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.703 ' N ' HD23 ' B' ' 12' ' ' LEU . 44.2 t -60.95 151.33 6.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 120.93 -1.107 . . . . 0.0 110.315 -176.345 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 89.96 -14.43 61.95 Favored Glycine 0 N--CA 1.482 1.751 0 N-CA-C 108.781 -1.727 . . . . 0.0 108.781 -175.41 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -98.2 167.09 11.08 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.362 -1.081 . . . . 0.0 109.6 175.207 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.581 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 15.4 m95 -115.42 156.71 25.09 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.177 -0.952 . . . . 0.0 110.13 177.073 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 1.066 HG13 ' HB3' ' B' ' 10' ' ' ALA . 0.9 OUTLIER -120.12 155.26 23.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.532 -0.73 . . . . 0.0 109.955 -178.206 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 0.809 ' HB3' HG21 ' B' ' 6' ' ' VAL . 2.5 m-20 -80.05 106.43 12.06 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.243 -0.911 . . . . 0.0 109.03 168.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.702 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.0 OUTLIER -106.94 138.72 31.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.754 0 O-C-N 120.588 -1.32 . . . . 0.0 111.061 -175.145 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . 0.47 ' HG3' ' HG2' ' B' ' 7' ' ' GLN . 86.4 tt0 -137.02 135.36 37.51 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.836 -0.54 . . . . 0.0 109.765 -178.461 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 61.0 ttp180 -78.6 130.02 35.45 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.015 -1.053 . . . . 0.0 110.543 -176.155 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 0.972 ' HB1' ' CE2' ' A' ' 2' ' ' PHE . . . -121.11 145.66 47.57 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.525 -0.734 . . . . 0.0 110.144 178.248 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . . . . . . . . . . . -128.23 141.14 51.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.625 -0.672 . . . . 0.0 110.322 -178.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . . . . . . . . . 12.1 pttt -69.99 -20.95 63.27 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.287 -0.883 . . . . 0.0 110.028 177.527 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 40.2 p90 -141.22 160.3 40.39 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.103 -0.998 . . . . 0.0 110.107 174.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . 0.459 ' HB2' HG12 ' B' ' 94' ' ' ILE . 74.6 p -140.16 149.97 43.64 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.297 -0.877 . . . . 0.0 110.304 176.547 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -70.07 -47.38 62.2 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.252 -0.905 . . . . 0.0 110.17 178.288 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . 0.47 ' O ' ' HG3' ' B' ' 93' ' ' GLU . 8.2 pt-20 -168.97 75.01 0.1 Allowed 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.415 -0.803 . . . . 0.0 110.471 -176.853 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . 0.459 HG12 ' HB2' ' B' ' 91' ' ' SER . 23.7 mm -60.01 -44.74 95.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 120.964 -1.085 . . . . 0.0 109.855 176.651 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' B' ' 94' ' ' ILE . . . 41.39 57.96 3.04 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 178.163 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . . . . . . . . . . . -66.28 -43.09 93.6 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.438 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . . . . . . . . . 14.9 t60 . . . . . 0 N--CA 1.491 1.62 0 O-C-N 121.286 -1.126 . . . . 0.0 110.149 179.795 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 0.628 ' O2 ' HG21 ' A' ' 67' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 0.632 ' O2 ' HG21 ' B' ' 67' ' ' THR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.45 ' O ' ' HB3' ' A' ' 2' ' ' PHE . 69.1 mtt . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.104 0.478 . . . . 0.0 110.211 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' PHE . . . . . 0.817 ' HE2' ' HB1' ' B' ' 87' ' ' ALA . 0.3 OUTLIER -178.12 140.58 0.23 Allowed 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.2 -0.937 . . . . 0.0 109.234 175.582 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.536 ' O ' HG13 ' A' ' 5' ' ' ILE . 14.2 p -136.1 -32.62 0.86 Allowed 'General case' 0 C--N 1.295 -1.781 0 O-C-N 120.977 -1.077 . . . . 0.0 109.96 -174.783 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.415 ' C ' ' O ' ' A' ' 3' ' ' THR . . . 46.8 24.69 1.98 Allowed Glycine 0 N--CA 1.486 2.005 0 N-CA-C 108.847 -1.701 . . . . 0.0 108.847 -175.662 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . 0.595 HD11 ' C8M' ' B' ' 99' ' ' RBF . 30.0 mt -87.63 136.33 23.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.19 -1.183 . . . . 0.0 110.343 -176.976 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 1.031 HG21 ' HB3' ' A' ' 83' ' ' ASN . 2.5 t -86.05 143.87 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.279 -0.888 . . . . 0.0 110.779 -175.417 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -70.0 -32.63 70.9 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.619 -0.676 . . . . 0.0 110.803 177.419 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.531 ' O ' ' CG1' ' A' ' 6' ' ' VAL . . . -164.96 177.26 40.53 Favored Glycine 0 N--CA 1.494 2.564 0 C-N-CA 118.767 -1.682 . . . . 0.0 110.485 -174.237 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . 0.506 ' C ' ' CG2' ' A' ' 84' ' ' VAL . 2.9 p -116.34 167.89 10.62 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.131 -1.217 . . . . 0.0 110.886 -177.871 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 1.055 ' HB2' HG21 ' A' ' 84' ' ' VAL . . . -137.73 148.46 45.64 Favored 'General case' 0 N--CA 1.489 1.508 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 -176.009 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' LYS . . . . . 0.577 ' HB2' ' CE2' ' A' ' 81' ' ' TRP . 25.7 tttt -108.88 115.91 30.98 Favored 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.022 -1.049 . . . . 0.0 110.379 -179.333 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.994 HD23 ' C ' ' A' ' 77' ' ' LYS . 12.0 tp -58.7 127.37 31.86 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.077 -1.014 . . . . 0.0 108.89 174.284 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.086 HG11 ' CD2' ' A' ' 58' ' ' HIS . 1.4 p -125.11 -31.48 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 O-C-N 121.352 -0.843 . . . . 0.0 109.932 -179.679 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.54 144.05 28.23 Favored 'General case' 0 N--CA 1.493 1.702 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.327 -178.054 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.584 HG12 ' CD2' ' A' ' 24' ' ' HIS . 8.6 mt -108.1 130.08 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.214 -0.929 . . . . 0.0 110.181 172.265 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.507 ' HB2' ' HB ' ' A' ' 23' ' ' THR . 67.3 m-20 -105.66 114.24 28.29 Favored 'General case' 0 C--N 1.298 -1.67 0 O-C-N 121.318 -0.863 . . . . 0.0 109.768 172.895 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -106.59 108.88 20.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.975 -1.078 . . . . 0.0 110.856 -177.511 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' A' ' 21' ' ' PHE . 0.1 OUTLIER -104.26 128.65 26.63 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.198 -0.939 . . . . 0.0 108.888 173.052 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -50.33 -34.06 39.34 Favored 'Trans proline' 0 C--N 1.303 -1.861 0 O-C-N 123.753 1.396 . . . . 0.0 110.496 -179.601 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' ASN . . . . . 0.531 ' C ' ' CD2' ' A' ' 21' ' ' PHE . 12.4 m-80 -71.57 -39.86 70.32 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.201 -0.937 . . . . 0.0 110.039 175.559 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' PHE . . . . . 0.531 ' CD2' ' C ' ' A' ' 20' ' ' ASN . 89.2 m-85 -152.98 150.25 29.03 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.399 -0.813 . . . . 0.0 109.973 -179.411 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.738 ' HD3' HD22 ' A' ' 68' ' ' LEU . 62.6 ttt180 -93.27 144.95 24.82 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.732 -1.23 . . . . 0.0 110.124 177.046 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.507 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 56.8 m -130.31 141.56 50.59 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 121.48 -0.762 . . . . 0.0 110.09 -176.186 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.607 ' HB3' ' CZ ' ' A' ' 61' ' ' PHE . 0.2 OUTLIER -127.89 144.78 51.09 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 120.974 -1.079 . . . . 0.0 111.342 176.75 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.763 HG22 ' CB ' ' A' ' 60' ' ' SER . 4.3 t -124.63 133.55 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.183 -0.948 . . . . 0.0 110.703 -179.27 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.592 HG13 ' HE2' ' A' ' 61' ' ' PHE . 33.4 m -118.5 172.06 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.796 -0.565 . . . . 0.0 110.425 -179.96 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.514 ' HB3' ' HB3' ' A' ' 11' ' ' LYS . 12.9 tt0 -101.14 117.51 35.15 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.594 -0.691 . . . . 0.0 109.318 -179.551 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.628 HD23 ' HA ' ' A' ' 33' ' ' LEU . 9.4 tp -82.0 121.26 78.91 Favored Pre-proline 0 C--N 1.297 -1.687 0 O-C-N 121.796 -0.565 . . . . 0.0 109.813 -175.302 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.49 ' HD2' HD12 ' A' ' 28' ' ' LEU . 25.5 Cg_endo -66.23 179.47 1.95 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 O-C-N 123.863 1.454 . . . . 0.0 110.992 -179.42 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.511 ' HA ' HD12 ' A' ' 33' ' ' LEU . 96.0 m-20 -63.41 -40.0 96.0 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.368 -0.833 . . . . 0.0 111.067 -175.646 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' HIS . . . . . 0.434 ' CE1' ' HG2' ' A' ' 32' ' ' MET . 0.0 OUTLIER -90.42 1.09 56.97 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.922 -1.111 . . . . 0.0 111.067 -175.31 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' MET . . . . . 0.474 ' HB2' ' HD2' ' A' ' 29' ' ' PRO . 98.4 mmm -113.92 -13.95 12.51 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.998 -1.064 . . . . 0.0 109.801 172.254 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.628 ' HA ' HD23 ' A' ' 28' ' ' LEU . 14.0 mt -66.19 -39.85 89.99 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.289 -0.882 . . . . 0.0 109.784 176.57 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -77.19 132.35 38.72 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.496 -0.753 . . . . 0.0 110.586 -177.486 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.51 -43.06 1.87 Allowed Glycine 0 N--CA 1.492 2.391 0 C-N-CA 119.903 -1.141 . . . . 0.0 110.258 174.489 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' LEU . . . . . 0.597 HD23 ' N ' ' A' ' 37' ' ' GLU . 5.7 tt -69.91 145.7 51.76 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 120.928 -1.337 . . . . 0.0 110.564 -174.94 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.597 ' N ' HD23 ' A' ' 36' ' ' LEU . 20.6 pt-20 -149.98 167.63 26.13 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.524 -0.735 . . . . 0.0 109.416 -179.555 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.822 ' N ' HD11 ' A' ' 54' ' ' ILE . 0.0 OUTLIER -67.95 149.94 49.13 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.85 -1.156 . . . . 0.0 110.201 -178.114 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.33 -3.61 62.03 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 -173.827 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' ALA . . . . . 0.538 ' O ' HG23 ' A' ' 51' ' ' VAL . . . -76.55 159.99 29.85 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.236 -1.155 . . . . 0.0 109.122 174.85 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' SER . . . . . 0.903 ' O ' ' HB3' ' A' ' 87' ' ' ALA . 1.1 p -104.21 117.88 35.3 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 118.72 -1.192 . . . . 0.0 109.897 177.184 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.626 HG11 ' HE1' ' A' ' 44' ' ' HIS . 0.9 OUTLIER -99.97 120.09 48.91 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.363 -0.836 . . . . 0.0 108.956 176.943 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.5 ' HA ' ' O ' ' A' ' 47' ' ' CYS . . . -82.94 117.33 22.7 Favored 'General case' 0 C--N 1.298 -1.641 0 C-N-CA 119.262 -0.975 . . . . 0.0 109.241 174.495 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' HIS . . . . . 0.651 ' CD2' HG21 ' A' ' 82' ' ' VAL . 1.5 m80 -87.24 103.42 15.42 Favored 'General case' 0 C--N 1.3 -1.567 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 176.172 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' B' ' 45' ' ' ASN . 2.4 t-20 55.74 12.05 0.77 Allowed 'General case' 0 C--N 1.298 -1.664 0 O-C-N 121.548 -0.72 . . . . 0.0 111.335 -169.483 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.49 ' HA3' ' HA3' ' B' ' 46' ' ' GLY . . . 126.85 -6.13 7.39 Favored Glycine 0 N--CA 1.491 2.362 0 C-N-CA 119.605 -1.283 . . . . 0.0 110.825 173.324 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . 0.896 ' O ' HD23 ' A' ' 49' ' ' LEU . 44.8 t -93.31 103.64 15.87 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 120.509 -1.583 . . . . 0.0 109.67 176.038 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.419 ' SG ' ' O ' ' B' ' 3' ' ' THR . 16.0 p -72.18 121.91 20.13 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.096 -1.003 . . . . 0.0 110.737 -174.444 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' LEU . . . . . 0.896 HD23 ' O ' ' A' ' 47' ' ' CYS . 0.2 OUTLIER -132.04 160.57 35.53 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.364 -0.835 . . . . 0.0 109.341 173.704 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.433 ' HA ' ' O ' ' A' ' 40' ' ' ALA . 37.2 m -97.72 152.52 19.03 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 120.439 -1.413 . . . . 0.0 111.436 -169.555 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . 0.878 HG13 HG13 ' A' ' 59' ' ' VAL . 19.4 t -81.02 114.62 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.917 -0.489 . . . . 0.0 110.396 -178.953 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' THR . . . . . 0.488 ' CG2' ' HB3' ' A' ' 62' ' ' ASP . 31.1 p -69.85 -40.08 76.02 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.294 -0.879 . . . . 0.0 109.705 174.416 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . 0.564 ' HA ' ' CG2' ' A' ' 38' ' ' THR . 86.7 tt0 -161.38 155.64 22.66 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.437 -0.789 . . . . 0.0 109.909 179.686 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.822 HD11 ' N ' ' A' ' 38' ' ' THR . 7.1 mt -105.15 128.99 58.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.966 -1.084 . . . . 0.0 109.574 174.613 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . 0.53 ' CB ' ' HB2' ' A' ' 58' ' ' HIS . 2.2 m-80 -100.6 62.6 1.05 Allowed 'General case' 0 C--N 1.298 -1.653 0 O-C-N 121.58 -0.7 . . . . 0.0 109.585 -179.014 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.04 -120.05 6.58 Favored Glycine 0 N--CA 1.487 2.054 0 N-CA-C 108.769 -1.732 . . . . 0.0 108.769 -172.638 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.577 ' HA ' ' CD2' ' A' ' 33' ' ' LEU . 0.0 OUTLIER -71.8 -20.22 61.88 Favored 'General case' 0 C--N 1.303 -1.449 0 O-C-N 120.931 -1.335 . . . . 0.0 108.981 175.094 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' HIS . . . . . 1.086 ' CD2' HG11 ' A' ' 13' ' ' VAL . 11.8 m170 -76.69 161.3 28.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.425 -0.797 . . . . 0.0 110.386 -176.748 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.878 HG13 HG13 ' A' ' 51' ' ' VAL . 54.5 t -140.02 125.52 20.9 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 C-N-CA 119.119 -1.032 . . . . 0.0 110.786 170.66 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . 0.763 ' CB ' HG22 ' A' ' 25' ' ' VAL . 24.8 m -97.61 123.16 41.4 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.763 -0.586 . . . . 0.0 109.509 -179.551 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.818 ' HB2' HD12 ' A' ' 49' ' ' LEU . 10.1 p90 -118.32 159.67 22.99 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 120.822 -1.174 . . . . 0.0 110.72 -179.743 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.488 ' HB3' ' CG2' ' A' ' 52' ' ' THR . 35.2 p-10 -93.37 156.56 16.72 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.089 -1.007 . . . . 0.0 111.532 -172.004 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' LEU . . . . . 1.062 HD22 HD13 ' A' ' 68' ' ' LEU . 0.1 OUTLIER -161.19 101.93 1.25 Allowed 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.705 -0.622 . . . . 0.0 109.607 -174.135 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' MET . . . . . 0.494 ' HB3' ' CB ' ' A' ' 67' ' ' THR . 57.7 ttm -59.97 137.71 58.02 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.787 -1.195 . . . . 0.0 109.09 179.351 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.486 ' O ' ' HB3' ' A' ' 68' ' ' LEU . 28.6 tttt -60.03 -45.91 91.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.977 -1.077 . . . . 0.0 110.614 -172.154 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 54.0 tp10 -66.15 -40.07 90.29 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.702 -1.248 . . . . 0.0 109.866 177.402 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' THR . . . . . 0.494 ' CB ' ' HB3' ' A' ' 64' ' ' MET . 94.1 m -59.92 -40.01 87.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.087 -1.008 . . . . 0.0 109.573 172.683 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' LEU . . . . . 1.062 HD13 HD22 ' A' ' 63' ' ' LEU . 28.0 tp -60.02 -43.45 95.26 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.299 -0.876 . . . . 0.0 109.764 -179.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 ttt85 -69.99 -39.09 76.12 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.326 -0.859 . . . . 0.0 110.352 177.765 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.709 HG22 HG23 ' A' ' 71' ' ' THR . 1.4 tt -64.78 -42.71 95.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.28 -0.887 . . . . 0.0 109.448 -176.816 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' THR . . . . . 0.709 HG23 HG22 ' A' ' 70' ' ' ILE . 30.5 p -81.99 -174.9 5.33 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 120.015 -0.674 . . . . 0.0 109.243 175.471 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.538 ' CB ' ' H ' ' B' ' 83' ' ' ASN . 5.2 t30 -99.52 22.25 11.04 Favored 'General case' 0 C--N 1.296 -1.757 0 O-C-N 121.174 -0.954 . . . . 0.0 108.511 171.062 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' LEU . . . . . 0.719 HD13 HD21 ' A' ' 63' ' ' LEU . 70.6 mt -70.12 -39.97 75.12 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 120.946 -1.096 . . . . 0.0 109.816 175.602 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' GLY . . . . . 0.428 ' CA ' ' HG ' ' A' ' 68' ' ' LEU . . . -49.31 -21.67 3.03 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -177.943 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . 0.503 ' OD1' ' N ' ' A' ' 76' ' ' LEU . 26.2 p-10 -66.21 -16.46 64.01 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.068 -1.254 . . . . 0.0 110.562 -175.056 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' LEU . . . . . 0.503 ' N ' ' OD1' ' A' ' 75' ' ' ASP . 96.1 mt -62.07 142.34 57.61 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.209 -0.932 . . . . 0.0 111.173 -175.116 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' LYS . . . . . 0.994 ' C ' HD23 ' A' ' 12' ' ' LEU . 86.6 mttt -141.48 141.16 33.65 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.647 -0.658 . . . . 0.0 109.558 172.642 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.705 ' N ' HD23 ' A' ' 12' ' ' LEU . 16.7 t -59.52 151.72 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 120.711 -1.243 . . . . 0.0 110.297 -176.146 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.79 -13.55 60.64 Favored Glycine 0 N--CA 1.484 1.867 0 N-CA-C 108.948 -1.661 . . . . 0.0 108.948 -176.687 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.511 ' OD1' ' N ' ' A' ' 81' ' ' TRP . 53.9 t0 -96.41 162.27 13.56 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.409 -1.054 . . . . 0.0 109.666 177.1 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 81' ' ' TRP . . . . . 0.577 ' CE2' ' HB2' ' A' ' 11' ' ' LYS . 14.0 m95 -113.21 153.33 28.51 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.141 -0.974 . . . . 0.0 110.42 177.369 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.043 HG13 ' HB3' ' A' ' 10' ' ' ALA . 0.8 OUTLIER -119.94 149.72 22.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.409 -0.807 . . . . 0.0 109.804 179.675 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 83' ' ' ASN . . . . . 1.031 ' HB3' HG21 ' A' ' 6' ' ' VAL . 0.2 OUTLIER -69.6 102.58 1.88 Allowed 'General case' 0 C--N 1.3 -1.556 0 O-C-N 120.952 -1.092 . . . . 0.0 109.012 167.8 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 1.055 HG21 ' HB2' ' A' ' 10' ' ' ALA . 0.1 OUTLIER -104.59 137.96 31.4 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.807 0 O-C-N 120.311 -1.493 . . . . 0.0 110.957 -178.772 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.445 ' HB2' HG22 ' A' ' 6' ' ' VAL . 85.9 tt0 -135.83 138.42 42.51 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 119.923 -0.711 . . . . 0.0 110.235 -176.192 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 76.4 ttt180 -61.3 127.46 31.63 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.24 -0.912 . . . . 0.0 110.044 -179.916 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.903 ' HB3' ' O ' ' A' ' 41' ' ' SER . . . -129.24 153.46 47.76 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.257 -0.902 . . . . 0.0 109.957 179.937 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 88' ' ' ALA . . . . . 0.544 ' O ' ' CD1' ' B' ' 2' ' ' PHE . . . -143.14 158.05 43.96 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.388 -0.82 . . . . 0.0 110.825 -174.342 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.467 ' HA ' ' CE1' ' B' ' 2' ' ' PHE . 32.0 mttt -64.5 -40.06 94.95 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.445 -0.784 . . . . 0.0 110.112 176.207 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 90' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -158.79 161.47 36.95 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.336 -0.852 . . . . 0.0 110.323 -178.395 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.467 ' CB ' ' HG3' ' A' ' 93' ' ' GLU . 72.7 m -129.89 133.19 46.72 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.431 -0.793 . . . . 0.0 110.149 177.801 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.446 ' O ' ' HB2' ' A' ' 93' ' ' GLU . 96.0 m-20 -60.12 -36.35 77.28 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.205 -0.934 . . . . 0.0 109.621 176.765 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.467 ' HG3' ' CB ' ' A' ' 91' ' ' SER . 93.7 mt-10 53.95 56.09 7.54 Favored 'General case' 0 N--CA 1.505 2.294 0 C-N-CA 119.472 -0.891 . . . . 0.0 110.167 172.494 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 94' ' ' ILE . . . . . 0.756 HG22 ' O ' ' A' ' 96' ' ' GLY . 40.6 mm -60.0 -40.53 83.36 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.298 -0.876 . . . . 0.0 109.893 177.652 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 65.47 -80.79 0.08 OUTLIER Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.505 -1.438 . . . . 0.0 109.505 -179.769 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 96' ' ' GLY . . . . . 0.756 ' O ' HG22 ' A' ' 94' ' ' ILE . . . -99.87 -178.8 30.65 Favored Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 179.35 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 97' ' ' HIS . . . . . . . . . . . . . 24.3 m-70 . . . . . 0 N--CA 1.492 1.626 0 O-C-N 121.171 -1.194 . . . . 0.0 110.115 178.667 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' B' B ' 1' ' ' MET . . . . . . . . . . . . . 26.1 ptp . . . . . 0 N--CA 1.493 1.719 0 CA-C-O 121.329 0.585 . . . . 0.0 110.221 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' B' B ' 2' ' ' PHE . . . . . 0.825 ' HE2' ' HB1' ' A' ' 87' ' ' ALA . 0.3 OUTLIER -165.47 140.71 5.06 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 121.199 -0.938 . . . . 0.0 109.097 175.369 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 3' ' ' THR . . . . . 0.529 ' O ' HG13 ' B' ' 5' ' ' ILE . 13.9 p -136.08 -32.64 0.86 Allowed 'General case' 0 C--N 1.294 -1.825 0 O-C-N 120.998 -1.064 . . . . 0.0 109.992 -174.783 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 4' ' ' GLY . . . . . 0.409 ' C ' ' O ' ' B' ' 3' ' ' THR . . . 46.84 24.73 2.02 Favored Glycine 0 N--CA 1.486 2.028 0 N-CA-C 108.891 -1.684 . . . . 0.0 108.891 -175.639 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 5' ' ' ILE . . . . . 0.544 HD11 ' C8M' ' A' ' 98' ' ' RBF . 29.8 mt -87.74 136.37 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.133 -1.216 . . . . 0.0 110.298 -176.964 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 6' ' ' VAL . . . . . 1.039 HG21 ' HB3' ' B' ' 83' ' ' ASN . 2.5 t -86.11 143.86 10.63 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.27 -0.894 . . . . 0.0 110.723 -175.346 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 7' ' ' GLN . . . . . . . . . . . . . 96.4 mt-30 -69.98 -32.52 70.78 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.601 -0.687 . . . . 0.0 110.88 177.382 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . 0.532 ' O ' ' CG1' ' B' ' 6' ' ' VAL . . . -165.05 177.16 40.63 Favored Glycine 0 N--CA 1.496 2.641 0 C-N-CA 118.888 -1.625 . . . . 0.0 110.466 -174.184 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 9' ' ' THR . . . . . 0.508 ' C ' ' CG2' ' B' ' 84' ' ' VAL . 3.0 p -116.3 167.82 10.68 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.105 -1.232 . . . . 0.0 110.953 -177.852 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 10' ' ' ALA . . . . . 1.044 ' HB2' HG21 ' B' ' 84' ' ' VAL . . . -137.72 148.58 45.77 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -176.099 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 11' ' ' LYS . . . . . 0.576 ' HB2' ' CE2' ' B' ' 81' ' ' TRP . 25.9 tttt -108.96 116.08 31.31 Favored 'General case' 0 C--N 1.296 -1.76 0 O-C-N 121.148 -0.97 . . . . 0.0 110.249 -179.209 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . 1.005 HD23 ' C ' ' B' ' 77' ' ' LYS . 12.1 tp -58.97 127.29 31.46 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.124 -0.985 . . . . 0.0 108.976 174.257 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 13' ' ' VAL . . . . . 1.092 HG11 ' CD2' ' B' ' 58' ' ' HIS . 1.4 p -124.89 -31.67 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 C-N-CA 119.593 -0.843 . . . . 0.0 109.904 -179.638 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 14' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -147.35 143.98 28.41 Favored 'General case' 0 C--N 1.297 -1.675 0 C-N-CA 119.27 -0.972 . . . . 0.0 111.451 -178.019 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 15' ' ' ILE . . . . . 0.59 HG12 ' CD2' ' B' ' 24' ' ' HIS . 8.2 mt -108.02 130.18 60.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.264 -0.897 . . . . 0.0 110.232 172.246 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 16' ' ' ASP . . . . . 0.519 ' HB2' ' HB ' ' B' ' 23' ' ' THR . 66.8 m-20 -105.94 114.31 28.38 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.369 -0.832 . . . . 0.0 109.724 172.994 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 17' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -106.57 108.82 20.52 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.912 -1.118 . . . . 0.0 110.938 -177.532 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 18' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' B' ' 21' ' ' PHE . 0.1 OUTLIER -104.21 128.63 26.7 Favored Pre-proline 0 N--CA 1.493 1.678 0 O-C-N 121.306 -0.871 . . . . 0.0 108.917 173.058 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 19' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' B' ' 18' ' ' LYS . 8.0 Cg_endo -50.44 -34.03 40.09 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 O-C-N 123.789 1.415 . . . . 0.0 110.42 -179.508 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 20' ' ' ASN . . . . . 0.54 ' C ' ' CD2' ' B' ' 21' ' ' PHE . 12.4 m-80 -71.41 -40.25 70.6 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.131 -0.981 . . . . 0.0 109.985 175.524 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 21' ' ' PHE . . . . . 0.54 ' CD2' ' C ' ' B' ' 20' ' ' ASN . 89.3 m-85 -152.65 150.28 29.31 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.417 -0.802 . . . . 0.0 110.004 -179.327 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 22' ' ' ARG . . . . . 0.746 ' HD3' HD22 ' B' ' 68' ' ' LEU . 62.6 ttt180 -93.16 144.83 24.9 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.872 -1.143 . . . . 0.0 110.197 176.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 23' ' ' THR . . . . . 0.519 ' HB ' ' HB2' ' B' ' 16' ' ' ASP . 58.2 m -130.27 141.69 50.59 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.596 -0.69 . . . . 0.0 110.043 -176.305 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 24' ' ' HIS . . . . . 0.605 ' HB3' ' CZ ' ' B' ' 61' ' ' PHE . 0.2 OUTLIER -127.81 144.89 51.07 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.066 -1.021 . . . . 0.0 111.233 176.827 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 25' ' ' VAL . . . . . 0.769 HG22 ' CB ' ' B' ' 60' ' ' SER . 4.3 t -124.61 133.68 68.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.292 -0.88 . . . . 0.0 110.717 -179.293 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 26' ' ' VAL . . . . . 0.592 HG13 ' HE2' ' B' ' 61' ' ' PHE . 33.5 m -118.79 172.09 6.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 CA-C-O 121.27 0.557 . . . . 0.0 110.412 -179.942 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 27' ' ' GLU . . . . . 0.511 ' HB3' ' HB3' ' B' ' 11' ' ' LYS . 13.1 tt0 -101.1 117.6 35.34 Favored 'General case' 0 N--CA 1.485 1.312 0 O-C-N 121.603 -0.686 . . . . 0.0 109.235 -179.473 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 28' ' ' LEU . . . . . 0.62 HD23 ' HA ' ' B' ' 33' ' ' LEU . 9.4 tp -82.01 121.27 78.89 Favored Pre-proline 0 C--N 1.297 -1.681 0 O-C-N 121.639 -0.663 . . . . 0.0 109.86 -175.401 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 29' ' ' PRO . . . . . 0.48 ' HD2' HD12 ' B' ' 28' ' ' LEU . 25.7 Cg_endo -66.24 179.59 1.9 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 123.913 1.48 . . . . 0.0 110.955 -179.399 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 30' ' ' ASP . . . . . 0.5 ' HA ' HD12 ' B' ' 33' ' ' LEU . 96.0 m-20 -63.48 -40.03 96.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.304 -0.873 . . . . 0.0 111.06 -175.662 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 31' ' ' HIS . . . . . 0.439 ' CE1' ' HG2' ' B' ' 32' ' ' MET . 0.0 OUTLIER -90.33 0.95 57.03 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.858 -1.151 . . . . 0.0 111.067 -175.253 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 32' ' ' MET . . . . . 0.455 ' HB2' ' HD2' ' B' ' 29' ' ' PRO . 98.4 mmm -113.87 -13.93 12.54 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 120.945 -1.097 . . . . 0.0 109.799 172.305 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 33' ' ' LEU . . . . . 0.62 ' HA ' HD23 ' B' ' 28' ' ' LEU . 14.0 mt -66.15 -39.92 90.18 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.32 -0.862 . . . . 0.0 109.76 176.534 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 34' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -77.06 132.4 38.89 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.481 -0.762 . . . . 0.0 110.584 -177.487 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.37 -43.04 1.88 Allowed Glycine 0 N--CA 1.491 2.359 0 N-CA-C 110.306 -1.117 . . . . 0.0 110.306 174.512 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 36' ' ' LEU . . . . . 0.595 HD23 ' N ' ' B' ' 37' ' ' GLU . 5.7 tt -69.91 145.71 51.76 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.942 -1.328 . . . . 0.0 110.557 -174.949 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 37' ' ' GLU . . . . . 0.595 ' N ' HD23 ' B' ' 36' ' ' LEU . 20.6 pt-20 -150.03 167.6 26.28 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.47 -0.769 . . . . 0.0 109.381 -179.56 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 38' ' ' THR . . . . . 0.815 ' N ' HD11 ' B' ' 54' ' ' ILE . 0.0 OUTLIER -67.92 149.81 49.33 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.864 -1.148 . . . . 0.0 110.237 -178.125 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 39' ' ' GLY . . . . . . . . . . . . . . . 78.35 -3.46 62.61 Favored Glycine 0 N--CA 1.492 2.401 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -173.813 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 40' ' ' ALA . . . . . 0.536 ' O ' HG23 ' B' ' 51' ' ' VAL . . . -76.74 160.04 29.66 Favored 'General case' 0 N--CA 1.486 1.375 0 O-C-N 121.218 -1.166 . . . . 0.0 109.129 174.742 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 41' ' ' SER . . . . . 0.926 ' O ' ' HB3' ' B' ' 87' ' ' ALA . 1.2 p -103.97 117.72 34.98 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 120.82 -1.175 . . . . 0.0 109.981 177.221 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 42' ' ' VAL . . . . . 0.597 HG11 ' HE1' ' B' ' 44' ' ' HIS . 0.9 OUTLIER -100.03 120.18 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.355 -0.841 . . . . 0.0 108.965 176.934 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 43' ' ' ALA . . . . . 0.508 ' HA ' ' O ' ' B' ' 47' ' ' CYS . . . -82.89 117.28 22.63 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.247 -0.981 . . . . 0.0 109.316 174.474 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 44' ' ' HIS . . . . . 0.651 ' CD2' HG21 ' B' ' 82' ' ' VAL . 1.4 m80 -87.27 103.19 15.21 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.624 -0.831 . . . . 0.0 108.818 176.232 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 45' ' ' ASN . . . . . 0.501 ' O ' ' O ' ' A' ' 45' ' ' ASN . 2.5 t-20 56.07 11.97 0.85 Allowed 'General case' 0 C--N 1.297 -1.675 0 O-C-N 121.677 -0.639 . . . . 0.0 111.239 -169.622 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 46' ' ' GLY . . . . . 0.49 ' HA3' ' HA3' ' A' ' 46' ' ' GLY . . . 126.73 -5.74 7.47 Favored Glycine 0 N--CA 1.49 2.26 0 C-N-CA 119.679 -1.248 . . . . 0.0 110.845 173.213 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 47' ' ' CYS . . . . . 0.874 ' O ' HD23 ' B' ' 49' ' ' LEU . 44.9 t -93.49 103.63 15.81 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.477 -1.602 . . . . 0.0 109.618 175.922 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 48' ' ' CYS . . . . . 0.436 ' SG ' ' O ' ' A' ' 3' ' ' THR . 14.8 p -72.14 122.07 20.37 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.117 -0.989 . . . . 0.0 110.617 -174.449 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 49' ' ' LEU . . . . . 0.874 HD23 ' O ' ' B' ' 47' ' ' CYS . 0.2 OUTLIER -132.21 160.53 35.86 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.461 -0.774 . . . . 0.0 109.283 173.568 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 50' ' ' THR . . . . . 0.444 ' HA ' ' O ' ' B' ' 40' ' ' ALA . 37.5 m -97.53 152.59 18.86 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 120.42 -1.425 . . . . 0.0 111.464 -169.531 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 51' ' ' VAL . . . . . 0.907 HG13 HG13 ' B' ' 59' ' ' VAL . 20.0 t -81.18 114.76 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.795 -0.566 . . . . 0.0 110.389 -178.973 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 52' ' ' THR . . . . . 0.48 ' CG2' ' HB3' ' B' ' 62' ' ' ASP . 31.4 p -69.97 -40.03 75.63 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.152 -0.967 . . . . 0.0 109.739 174.575 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 53' ' ' GLU . . . . . 0.565 ' HA ' ' CG2' ' B' ' 38' ' ' THR . 86.6 tt0 -161.49 155.63 22.38 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.416 -0.803 . . . . 0.0 109.804 179.634 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 54' ' ' ILE . . . . . 0.815 HD11 ' N ' ' B' ' 38' ' ' THR . 7.1 mt -105.11 128.94 58.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.113 -0.992 . . . . 0.0 109.592 174.698 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 55' ' ' ASN . . . . . 0.525 ' HB2' ' CB ' ' B' ' 58' ' ' HIS . 2.2 m-80 -100.57 62.61 1.05 Allowed 'General case' 0 C--N 1.299 -1.608 0 C-N-CA 119.878 -0.729 . . . . 0.0 109.55 -178.988 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 56' ' ' GLY . . . . . . . . . . . . . . . 74.19 -120.08 6.51 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 108.657 -1.777 . . . . 0.0 108.657 -172.716 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 57' ' ' ASN . . . . . 0.588 ' HA ' ' CD2' ' B' ' 33' ' ' LEU . 0.0 OUTLIER -71.8 -20.17 61.89 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 120.97 -1.312 . . . . 0.0 109.109 175.031 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 58' ' ' HIS . . . . . 1.092 ' CD2' HG11 ' B' ' 13' ' ' VAL . 11.8 m170 -76.68 161.22 28.7 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.421 -0.799 . . . . 0.0 110.432 -176.851 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 59' ' ' VAL . . . . . 0.907 HG13 HG13 ' B' ' 51' ' ' VAL . 54.8 t -140.04 125.53 20.82 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 C-N-CA 119.042 -1.063 . . . . 0.0 110.723 170.794 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 60' ' ' SER . . . . . 0.769 ' CB ' HG22 ' B' ' 25' ' ' VAL . 24.4 m -97.54 123.42 41.41 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.75 -0.594 . . . . 0.0 109.513 -179.573 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 61' ' ' PHE . . . . . 0.837 ' HB2' HD12 ' B' ' 49' ' ' LEU . 10.0 p90 -118.65 159.65 23.23 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 120.822 -1.174 . . . . 0.0 110.533 -179.655 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 62' ' ' ASP . . . . . 0.48 ' HB3' ' CG2' ' B' ' 52' ' ' THR . 35.2 p-10 -93.36 156.55 16.72 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.075 -1.016 . . . . 0.0 111.459 -171.99 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . 1.085 HD22 HD13 ' B' ' 68' ' ' LEU . 0.1 OUTLIER -161.11 102.12 1.26 Allowed 'General case' 0 C--N 1.301 -1.501 0 C-N-CA 120.258 -0.577 . . . . 0.0 109.447 -174.235 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 64' ' ' MET . . . . . 0.498 ' HB3' ' CB ' ' B' ' 67' ' ' THR . 57.6 ttm -60.07 137.64 58.05 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 120.707 -1.245 . . . . 0.0 109.068 179.266 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 65' ' ' LYS . . . . . 0.484 ' O ' ' HB3' ' B' ' 68' ' ' LEU . 28.6 tttt -59.96 -45.93 91.06 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.91 -1.119 . . . . 0.0 110.63 -172.197 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 66' ' ' GLU . . . . . . . . . . . . . 54.0 tp10 -66.21 -40.02 90.04 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.723 -1.236 . . . . 0.0 109.837 177.452 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 67' ' ' THR . . . . . 0.498 ' CB ' ' HB3' ' B' ' 64' ' ' MET . 94.4 m -59.97 -40.03 87.69 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.036 -1.04 . . . . 0.0 109.512 172.657 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 68' ' ' LEU . . . . . 1.085 HD13 HD22 ' B' ' 63' ' ' LEU . 27.9 tp -60.05 -43.29 95.49 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.374 -0.829 . . . . 0.0 109.823 179.971 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 69' ' ' ARG . . . . . . . . . . . . . 51.2 ttt85 -69.99 -39.26 76.02 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.318 -0.864 . . . . 0.0 110.364 177.751 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 70' ' ' ILE . . . . . 0.707 HG22 HG23 ' B' ' 71' ' ' THR . 1.4 tt -64.56 -42.62 95.68 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.458 0 O-C-N 121.278 -0.889 . . . . 0.0 109.583 -176.903 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 71' ' ' THR . . . . . 0.707 HG23 HG22 ' B' ' 70' ' ' ILE . 30.5 p -82.06 -174.94 5.37 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 119.955 -0.698 . . . . 0.0 109.317 175.4 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 72' ' ' ASN . . . . . 0.52 ' CB ' ' H ' ' A' ' 83' ' ' ASN . 5.2 t30 -99.38 22.17 11.03 Favored 'General case' 0 C--N 1.295 -1.77 0 O-C-N 121.141 -0.974 . . . . 0.0 108.534 171.074 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 73' ' ' LEU . . . . . 0.728 HD13 HD21 ' B' ' 63' ' ' LEU . 71.5 mt -70.03 -39.99 75.44 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.991 -1.068 . . . . 0.0 109.897 175.62 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 74' ' ' GLY . . . . . 0.435 ' HA2' HD11 ' B' ' 68' ' ' LEU . . . -49.38 -21.6 3.07 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 110.316 -1.113 . . . . 0.0 110.316 -177.954 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 75' ' ' ASP . . . . . 0.506 ' OD1' ' N ' ' B' ' 76' ' ' LEU . 26.2 p-10 -66.32 -16.31 63.94 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.127 -1.219 . . . . 0.0 110.525 -175.052 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 76' ' ' LEU . . . . . 0.506 ' N ' ' OD1' ' B' ' 75' ' ' ASP . 96.2 mt -62.26 142.36 57.76 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.291 -0.88 . . . . 0.0 111.189 -175.109 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . 1.005 ' C ' HD23 ' B' ' 12' ' ' LEU . 86.6 mttt -141.46 141.1 33.68 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.669 -0.645 . . . . 0.0 109.563 172.661 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 78' ' ' VAL . . . . . 0.714 ' N ' HD23 ' B' ' 12' ' ' LEU . 16.7 t -59.42 151.63 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 120.812 -1.18 . . . . 0.0 110.245 -176.134 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . 87.83 -13.44 60.98 Favored Glycine 0 N--CA 1.484 1.882 0 N-CA-C 108.887 -1.685 . . . . 0.0 108.887 -176.8 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 80' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' B' ' 81' ' ' TRP . 53.7 t0 -96.5 162.16 13.59 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.397 -1.061 . . . . 0.0 109.666 177.029 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 81' ' ' TRP . . . . . 0.576 ' CE2' ' HB2' ' B' ' 11' ' ' LYS . 14.0 m95 -113.13 153.32 28.42 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.103 -0.998 . . . . 0.0 110.372 177.532 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 82' ' ' VAL . . . . . 0.99 HG13 ' HB3' ' B' ' 10' ' ' ALA . 0.8 OUTLIER -120.01 149.75 22.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.738 0 O-C-N 121.553 -0.717 . . . . 0.0 109.858 179.553 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 83' ' ' ASN . . . . . 1.039 ' HB3' HG21 ' B' ' 6' ' ' VAL . 0.2 OUTLIER -69.53 102.41 1.82 Allowed 'General case' 0 C--N 1.298 -1.633 0 O-C-N 120.975 -1.078 . . . . 0.0 109.091 167.783 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 1.044 HG21 ' HB2' ' B' ' 10' ' ' ALA . 0.1 OUTLIER -104.45 138.17 30.31 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 O-C-N 120.422 -1.424 . . . . 0.0 110.862 -178.611 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' B' B ' 85' ' ' GLU . . . . . 0.438 ' HB2' HG22 ' B' ' 6' ' ' VAL . 85.9 tt0 -136.12 138.38 41.98 Favored 'General case' 0 C--N 1.299 -1.599 0 C-N-CA 119.982 -0.687 . . . . 0.0 110.234 -176.277 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 86' ' ' ARG . . . . . . . . . . . . . 76.5 ttt180 -61.26 127.53 31.98 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.153 -0.967 . . . . 0.0 109.941 -179.8 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 87' ' ' ALA . . . . . 0.926 ' HB3' ' O ' ' B' ' 41' ' ' SER . . . -129.26 153.71 47.53 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.197 -0.939 . . . . 0.0 109.99 179.86 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 88' ' ' ALA . . . . . 0.583 ' O ' ' CD1' ' A' ' 2' ' ' PHE . . . -143.44 158.03 43.98 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.357 -0.839 . . . . 0.0 110.68 -174.179 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 89' ' ' LYS . . . . . 0.509 ' HA ' ' CE1' ' A' ' 2' ' ' PHE . 31.9 mttt -64.59 -39.98 94.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.495 -0.753 . . . . 0.0 110.063 176.221 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 90' ' ' PHE . . . . . . . . . . . . . 41.5 p90 -158.87 161.52 36.85 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.238 -0.914 . . . . 0.0 110.396 -178.374 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 91' ' ' SER . . . . . . . . . . . . . 72.7 m -129.96 133.15 46.61 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.359 -0.838 . . . . 0.0 110.181 177.864 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 92' ' ' ASP . . . . . . . . . . . . . 96.0 m-20 -60.52 -45.61 93.2 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.146 -0.971 . . . . 0.0 109.76 176.906 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 93' ' ' GLU . . . . . 0.573 ' O ' ' CG ' ' B' ' 93' ' ' GLU . 5.0 tt0 -141.8 69.94 1.33 Allowed 'General case' 0 C--N 1.305 -1.361 0 CA-C-O 122.201 1.0 . . . . 0.0 109.131 -177.956 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 94' ' ' ILE . . . . . 0.788 HG22 ' O ' ' B' ' 94' ' ' ILE . 21.7 mm 43.64 28.55 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.505 2.307 0 O-C-N 120.831 -1.168 . . . . 0.0 108.916 -176.324 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 95' ' ' GLY . . . . . 0.413 ' N ' ' O ' ' B' ' 93' ' ' GLU . . . -65.46 80.44 0.08 OUTLIER Glycine 0 N--CA 1.49 2.236 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 -174.888 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 96' ' ' GLY . . . . . 0.405 ' O ' ' HB2' ' B' ' 97' ' ' HIS . . . 145.2 -176.17 24.37 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.744 -1.343 . . . . 0.0 109.744 176.806 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 97' ' ' HIS . . . . . 0.405 ' HB2' ' O ' ' B' ' 96' ' ' GLY . 0.4 OUTLIER . . . . . 0 N--CA 1.491 1.582 0 O-C-N 121.297 -1.12 . . . . 0.0 110.273 178.393 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 98' ' ' RBF . . . . . 0.551 " C2'" ' HC9' ' A' ' 98' ' ' RBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 99' ' ' RBF . . . . . 0.595 ' C8M' HD11 ' A' ' 5' ' ' ILE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 stop_ save_